words,sentence_id,labels
Androgen,0,B-CHEMICAL
antagonistic,0,O
effect,0,O
of,0,O
estramustine,0,B-CHEMICAL
phosphate,0,I-CHEMICAL
(,0,O
EMP,0,B-CHEMICAL
),0,O
metabolites,0,O
on,0,O
wild-type,0,O
and,0,O
mutated,0,O
androgen,0,B-GENE-Y
receptor,0,I-GENE-Y
.,0,O
Estramustine,1,B-CHEMICAL
phosphate,1,I-CHEMICAL
is,1,O
used,1,O
frequently,1,O
",",1,O
alone,1,O
or,1,O
in,1,O
combination,1,O
with,1,O
other,1,O
antitumor,1,O
agents,1,O
",",1,O
for,1,O
the,1,O
treatment,1,O
of,1,O
hormone-refractory,1,O
prostate,1,O
cancer,1,O
.,1,O
Estramustine,2,B-CHEMICAL
phosphate,2,I-CHEMICAL
is,2,O
metabolically,2,O
activated,2,O
in,2,O
vivo,2,O
",",2,O
and,2,O
its,2,O
metabolites,2,O
",",2,O
estramustine,2,B-CHEMICAL
",",2,O
estromustine,2,B-CHEMICAL
",",2,O
estrone,2,B-CHEMICAL
",",2,O
and,2,O
beta-estradiol,2,B-CHEMICAL
inhibit,2,O
the,2,O
assembly,2,O
of,2,O
microtubules,2,O
[,2,O
for,2,O
review,2,O
see,2,O
:,2,O
Kreis,2,O
W,2,O
",",2,O
In,2,O
:,2,O
Concepts,2,O
",",2,O
Mechanisms,2,O
",",2,O
and,2,O
New,2,O
Targets,2,O
for,2,O
Chemotherapy,2,O
(,2,O
Ed,2,O
.,2,O
Muggia,3,O
FM,3,O
),3,O
",",3,O
pp,3,O
.,3,O
163-184,4,O
.,4,O
Kluwer,5,O
Academic,5,O
Publishers,5,O
",",5,O
Boston,5,O
",",5,O
1995,5,O
],5,O
.,5,O
We,6,O
investigated,6,O
",",6,O
by,6,O
displacement,6,O
of,6,O
[,6,B-CHEMICAL
3H,6,I-CHEMICAL
],6,I-CHEMICAL
methyltrienolone,6,I-CHEMICAL
in,6,O
the,6,O
presence,6,O
of,6,O
2.5,6,O
mM,6,O
of,6,O
triamcinolone,6,B-CHEMICAL
acetonide,6,I-CHEMICAL
",",6,O
the,6,O
binding,6,O
of,6,O
estramustine,6,B-CHEMICAL
phosphate,6,I-CHEMICAL
and,6,O
its,6,O
metabolites,6,O
",",6,O
estramustine,6,B-CHEMICAL
",",6,O
estromustine,6,B-CHEMICAL
",",6,O
estrone,6,B-CHEMICAL
",",6,O
and,6,O
beta-estradiol,6,B-CHEMICAL
",",6,O
as,6,O
well,6,O
as,6,O
other,6,O
antiandrogen,6,O
agents,6,O
including,6,O
alpha-estradiol,6,B-CHEMICAL
",",6,O
bicalutamide,6,B-CHEMICAL
",",6,O
and,6,O
hydroxyflutamide,6,B-CHEMICAL
",",6,O
to,6,O
the,6,O
mutated,6,O
androgen,6,B-GENE-Y
receptor,6,I-GENE-Y
(,6,O
m-AR,6,O
),6,O
in,6,O
LNCaP,6,O
cells,6,O
and,6,O
to,6,O
the,6,O
wild-type,6,O
androgen,6,B-GENE-Y
receptor,6,I-GENE-Y
in,6,O
wild-type,6,O
AR,6,B-GENE-Y
cDNA,6,O
expression,6,O
plasmid,6,O
(,6,O
w-pAR0,6,O
),6,O
cDNA-transfected,6,O
HeLa,6,O
cells,6,O
.,6,O
Analogous,7,O
to,7,O
the,7,O
antiandrogens,7,O
",",7,O
bicalutamide,7,B-CHEMICAL
and,7,O
hydroxyflutamide,7,B-CHEMICAL
",",7,O
binding,7,O
of,7,O
estramustine,7,B-CHEMICAL
phosphate,7,I-CHEMICAL
metabolites,7,O
to,7,O
the,7,O
androgen,7,B-CHEMICAL
receptor,7,I-GENE-Y
was,7,O
observed,7,O
.,7,O
The,8,O
EC50,8,O
values,8,O
(,8,O
in,8,O
microM,8,O
),8,O
were,8,O
:,8,O
estramustine,8,B-CHEMICAL
phosphate,8,I-CHEMICAL
",",8,O
>,8,O
10,8,O
;,8,O
estramustine,8,B-CHEMICAL
",",8,O
3.129,8,O
+/-,8,O
0.312,8,O
;,8,O
estromustine,8,B-CHEMICAL
;,8,O
2.612,8,O
+/-,8,O
0.584,8,O
;,8,O
estrone,8,B-CHEMICAL
",",8,O
0.800,8,O
+/-,8,O
0.090,8,O
;,8,O
alpha-estradiol,8,B-CHEMICAL
",",8,O
1.051,8,O
+/-,8,O
0.096,8,O
;,8,O
beta-estradiol,8,B-CHEMICAL
",",8,O
0.523,8,O
+/-,8,O
0.028,8,O
;,8,O
bicalutamide,8,B-CHEMICAL
",",8,O
4.920,8,O
+/-,8,O
0.361,8,O
;,8,O
and,8,O
hydroxyflutamide,8,B-CHEMICAL
",",8,O
0.254,8,O
+/-,8,O
0.012,8,O
.,8,O
The,9,O
transactivation,9,O
assay,9,O
demonstrated,9,O
that,9,O
",",9,O
analogous,9,O
to,9,O
bicalutamide,9,B-CHEMICAL
",",9,O
estramustine,9,B-CHEMICAL
could,9,O
not,9,O
induce,9,O
luciferase,9,O
activity,9,O
in,9,O
either,9,O
w-pAR0,9,O
or,9,O
m-pARL,9,O
transfected,9,O
HeLa,9,O
cells,9,O
.,9,O
In,10,O
contrast,10,O
",",10,O
a,10,O
strong,10,O
induction,10,O
of,10,O
the,10,O
reporter,10,O
activity,10,O
by,10,O
dihydrotestosterone,10,B-CHEMICAL
was,10,O
observed,10,O
.,10,O
Down-regulation,11,O
of,11,O
prostate-specific,11,B-GENE-Y
antigen,11,I-GENE-Y
(,11,O
PSA,11,B-GENE-Y
),11,O
expression,11,O
",",11,O
an,11,O
AR-target,11,B-GENE-Y
gene,11,O
",",11,O
by,11,O
estramustine,11,B-CHEMICAL
and,11,O
bicalutamide,11,B-CHEMICAL
was,11,O
accompanied,11,O
by,11,O
the,11,O
blockade,11,O
of,11,O
the,11,O
mutated,11,O
androgen,11,B-GENE-Y
receptor,11,I-GENE-Y
.,11,O
Exposure,12,O
of,12,O
LNCaP,12,O
cells,12,O
to,12,O
estramustine,12,B-CHEMICAL
for,12,O
24,12,O
hr,12,O
caused,12,O
transcriptional,12,O
inhibition,12,O
of,12,O
PSA,12,B-GENE-Y
in,12,O
a,12,O
concentration-dependent,12,O
manner,12,O
.,12,O
The,13,O
levels,13,O
of,13,O
PSA,13,B-GENE-Y
mRNA,13,O
decreased,13,O
56,13,O
and,13,O
90,13,O
%,13,O
when,13,O
LNCaP,13,O
cells,13,O
were,13,O
treated,13,O
with,13,O
5,13,O
and,13,O
10,13,O
microM,13,O
of,13,O
estramustine,13,B-CHEMICAL
",",13,O
respectively,13,O
(,13,O
IC50,13,O
=,13,O
10.97,13,O
+/-,13,O
1.68,13,O
microM,13,O
),13,O
.,13,O
Binding,14,O
of,14,O
hydroxyflutamide,14,B-CHEMICAL
to,14,O
m-AR,14,O
in,14,O
LNCaP,14,O
cells,14,O
resulted,14,O
in,14,O
a,14,O
concentration-dependent,14,O
stimulation,14,O
of,14,O
PSA,14,B-GENE-Y
expression,14,O
",",14,O
suggesting,14,O
that,14,O
hydroxyflutamide,14,B-CHEMICAL
acted,14,O
as,14,O
an,14,O
agonist,14,O
of,14,O
the,14,O
m-AR,14,O
.,14,O
Our,15,O
data,15,O
indicate,15,O
that,15,O
estramustine,15,B-CHEMICAL
phosphate,15,I-CHEMICAL
metabolites,15,O
perform,15,O
as,15,O
androgen,15,B-CHEMICAL
antagonists,15,O
of,15,O
AR,15,B-GENE-Y
",",15,O
an,15,O
additional,15,O
mechanism,15,O
involved,15,O
in,15,O
the,15,O
therapeutic,15,O
effect,15,O
of,15,O
estramustine,15,B-CHEMICAL
phosphate,15,I-CHEMICAL
in,15,O
patients,15,O
with,15,O
prostate,15,O
cancer,15,O
.,15,O
Static,16,O
Laue,16,O
diffraction,16,O
studies,16,O
on,16,O
acetylcholinesterase,16,B-GENE-Y
.,16,O
Acetylcholinesterase,17,B-GENE-Y
(,17,O
AChE,17,B-GENE-Y
),17,O
is,17,O
one,17,O
of,17,O
nature,17,O
's,17,O
fastest,17,O
enzymes,17,O
",",17,O
despite,17,O
the,17,O
fact,17,O
that,17,O
its,17,O
three-dimensional,17,O
structure,17,O
reveals,17,O
its,17,O
active,17,O
site,17,O
to,17,O
be,17,O
deeply,17,O
sequestered,17,O
within,17,O
the,17,O
molecule,17,O
.,17,O
This,18,O
raises,18,O
questions,18,O
with,18,O
respect,18,O
to,18,O
traffic,18,O
of,18,O
substrate,18,O
to,18,O
",",18,O
and,18,O
products,18,O
from,18,O
",",18,O
the,18,O
active,18,O
site,18,O
",",18,O
which,18,O
may,18,O
be,18,O
investigated,18,O
by,18,O
time-resolved,18,O
crystallography,18,O
.,18,O
In,19,O
order,19,O
to,19,O
address,19,O
one,19,O
aspect,19,O
of,19,O
the,19,O
feasibility,19,O
of,19,O
performing,19,O
time-resolved,19,O
studies,19,O
on,19,O
AChE,19,B-GENE-Y
",",19,O
a,19,O
data,19,O
set,19,O
has,19,O
been,19,O
collected,19,O
using,19,O
the,19,O
Laue,19,O
technique,19,O
on,19,O
a,19,O
trigonal,19,O
crystal,19,O
of,19,O
Torpedo,19,B-GENE-Y
californica,19,I-GENE-Y
AChE,19,I-GENE-Y
soaked,19,O
with,19,O
the,19,O
reversible,19,O
inhibitor,19,O
edrophonium,19,B-CHEMICAL
",",19,O
using,19,O
a,19,O
total,19,O
X-ray,19,O
exposure,19,O
time,19,O
of,19,O
24,19,O
ms.,19,O
Electron-density,19,O
maps,19,O
obtained,19,O
from,19,O
the,19,O
Laue,19,O
data,19,O
",",19,O
which,19,O
are,19,O
of,19,O
surprisingly,19,O
good,19,O
quality,19,O
compared,19,O
with,19,O
similar,19,O
maps,19,O
from,19,O
monochromatic,19,O
data,19,O
",",19,O
show,19,O
essentially,19,O
the,19,O
same,19,O
features,19,O
.,19,O
They,20,O
clearly,20,O
reveal,20,O
the,20,O
bound,20,O
ligand,20,O
",",20,O
as,20,O
well,20,O
as,20,O
a,20,O
structural,20,O
change,20,O
in,20,O
the,20,O
conformation,20,O
of,20,O
the,20,O
active-site,20,O
Ser200,20,O
induced,20,O
upon,20,O
binding,20,O
.,20,O
Synthesis,21,O
of,21,O
thrombin-inhibiting,21,B-GENE-Y
heparin,21,O
mimetics,21,O
without,21,O
side,21,O
effects,21,O
.,21,O
Unwanted,22,O
side,22,O
effects,22,O
of,22,O
pharmacologically,22,O
active,22,O
compounds,22,O
can,22,O
usually,22,O
be,22,O
eliminated,22,O
by,22,O
structural,22,O
modifications,22,O
.,22,O
But,23,O
the,23,O
complex,23,O
heterogeneous,23,O
structure,23,O
of,23,O
the,23,O
polysaccharide,23,O
heparin,23,O
has,23,O
limited,23,O
this,23,O
approach,23,O
to,23,O
fragmentation,23,O
",",23,O
leading,23,O
to,23,O
slightly,23,O
better-tolerated,23,O
heparin,23,O
preparations,23,O
of,23,O
low,23,O
molecular,23,O
mass,23,O
.,23,O
Despite,24,O
this,24,O
improvement,24,O
",",24,O
heparin-induced,24,O
thrombocytopaenia,24,O
(,24,O
HIT,24,O
),24,O
",",24,O
related,24,O
to,24,O
an,24,O
interaction,24,O
with,24,O
platelet,24,B-GENE-Y
factor,24,I-GENE-Y
4,24,I-GENE-Y
(,24,O
PF4,24,B-GENE-Y
),24,O
and,24,O
",",24,O
to,24,O
a,24,O
lesser,24,O
extent,24,O
",",24,O
haemorrhages,24,O
",",24,O
remain,24,O
significant,24,O
side,24,O
effects,24,O
of,24,O
heparinotherapy,24,O
.,24,O
Breakthroughs,25,O
in,25,O
oligosaccharide,25,O
chemistry,25,O
made,25,O
possible,25,O
the,25,O
total,25,O
synthesis,25,O
of,25,O
the,25,O
pentasaccharide,25,O
antithrombin-binding,25,B-GENE-Y
site,25,O
of,25,O
heparin,25,O
.,25,O
This,26,O
pentasaccharide,26,O
represents,26,O
a,26,O
new,26,O
family,26,O
of,26,O
potential,26,O
antithrombotic,26,O
drugs,26,O
",",26,O
devoid,26,O
of,26,O
thrombin,26,B-GENE-Y
inhibitory,26,O
properties,26,O
",",26,O
and,26,O
free,26,O
of,26,O
undesired,26,O
interactions,26,O
with,26,O
blood,26,O
and,26,O
vessel,26,O
components,26,O
.,26,O
To,27,O
obtain,27,O
more,27,O
potent,27,O
and,27,O
well-tolerated,27,O
antithrombotic,27,O
drugs,27,O
",",27,O
we,27,O
wished,27,O
to,27,O
synthesize,27,O
heparin,27,O
mimetics,27,O
able,27,O
to,27,O
inhibit,27,O
thrombin,27,B-GENE-Y
",",27,O
that,27,O
is,27,O
",",27,O
longer,27,O
oligosaccharides,27,O
.,27,O
Like,28,O
thrombin,28,B-GENE-Y
inhibition,28,O
",",28,O
undesired,28,O
interactions,28,O
are,28,O
directly,28,O
correlated,28,O
to,28,O
the,28,O
charge,28,O
and,28,O
the,28,O
size,28,O
of,28,O
the,28,O
molecules,28,O
",",28,O
so,28,O
we,28,O
had,28,O
to,28,O
design,28,O
structures,28,O
that,28,O
were,28,O
able,28,O
to,28,O
discriminate,28,O
between,28,O
thrombin,28,B-GENE-Y
and,28,O
other,28,O
proteins,28,O
",",28,O
particularly,28,O
PF4,28,B-GENE-Y
.,28,O
Here,29,O
we,29,O
describe,29,O
the,29,O
use,29,O
of,29,O
multistep,29,O
converging,29,O
synthesis,29,O
to,29,O
obtain,29,O
sulphated,29,O
oligosaccharides,29,O
that,29,O
meet,29,O
these,29,O
requirements,29,O
.,29,O
Selective,30,O
inhibition,30,O
of,30,O
cyclooxygenase,30,B-GENE-Y
2,30,I-GENE-Y
spares,30,O
renal,30,O
function,30,O
and,30,O
prostaglandin,30,B-CHEMICAL
synthesis,30,O
in,30,O
cirrhotic,30,O
rats,30,O
with,30,O
ascites,30,O
.,30,O
BACKGROUND,31,O
&,31,O
AIMS,31,O
:,31,O
The,31,O
critical,31,O
role,31,O
of,31,O
cyclooxygenase,31,B-GENE-N
(,31,O
COX,31,B-GENE-N
),31,O
products,31,O
in,31,O
maintenance,31,O
of,31,O
renal,31,O
function,31,O
in,31,O
cirrhosis,31,O
with,31,O
ascites,31,O
discourages,31,O
the,31,O
use,31,O
of,31,O
nonsteroidal,31,O
anti-inflammatory,31,O
drugs,31,O
in,31,O
this,31,O
disease,31,O
.,31,O
The,32,O
recent,32,O
development,32,O
of,32,O
selective,32,O
COX-2,32,B-GENE-Y
inhibitors,32,O
opens,32,O
new,32,O
avenues,32,O
for,32,O
the,32,O
use,32,O
of,32,O
these,32,O
compounds,32,O
in,32,O
decompensated,32,O
cirrhosis,32,O
.,32,O
The,33,O
current,33,O
study,33,O
evaluates,33,O
the,33,O
effects,33,O
of,33,O
a,33,O
selective,33,O
COX-2,33,B-GENE-Y
inhibitor,33,O
(,33,O
SC-236,33,B-CHEMICAL
),33,O
on,33,O
renal,33,O
function,33,O
in,33,O
cirrhotic,33,O
rats,33,O
with,33,O
ascites,33,O
.,33,O
METHODS,34,O
:,34,O
In,34,O
protocol,34,O
1,34,O
",",34,O
urine,34,O
volume,34,O
",",34,O
urinary,34,O
excretion,34,O
of,34,O
sodium,34,B-CHEMICAL
and,34,O
prostaglandins,34,B-CHEMICAL
",",34,O
glomerular,34,O
filtration,34,O
rate,34,O
",",34,O
and,34,O
renal,34,O
plasma,34,O
flow,34,O
were,34,O
measured,34,O
before,34,O
and,34,O
after,34,O
administration,34,O
of,34,O
SC-236,34,B-CHEMICAL
(,34,O
n,34,O
=,34,O
12,34,O
),34,O
or,34,O
ketorolac,34,B-CHEMICAL
(,34,O
n,34,O
=,34,O
10,34,O
),34,O
to,34,O
rats,34,O
with,34,O
cirrhosis,34,O
.,34,O
Protocol,35,O
2,35,O
was,35,O
aimed,35,O
at,35,O
assessing,35,O
the,35,O
effects,35,O
of,35,O
COX,35,B-GENE-N
inhibitors,35,O
on,35,O
renal,35,O
water,35,O
metabolism,35,O
in,35,O
28,35,O
cirrhotic,35,O
rats,35,O
.,35,O
RESULTS,36,O
:,36,O
Administration,36,O
of,36,O
SC-236,36,B-CHEMICAL
to,36,O
cirrhotic,36,O
animals,36,O
did,36,O
not,36,O
produce,36,O
significant,36,O
renal,36,O
effects,36,O
",",36,O
whereas,36,O
administration,36,O
of,36,O
the,36,O
nonselective,36,O
COX-1/COX-2,36,B-GENE-Y
inhibitor,36,O
",",36,O
ketorolac,36,B-CHEMICAL
",",36,O
resulted,36,O
in,36,O
a,36,O
marked,36,O
reduction,36,O
in,36,O
urine,36,O
volume,36,O
",",36,O
urinary,36,O
excretion,36,O
of,36,O
prostaglandins,36,B-CHEMICAL
",",36,O
and,36,O
glomerular,36,O
filtration,36,O
rate,36,O
and,36,O
in,36,O
a,36,O
significant,36,O
impairment,36,O
in,36,O
renal,36,O
water,36,O
metabolism,36,O
.,36,O
CONCLUSIONS,37,O
:,37,O
These,37,O
findings,37,O
indicate,37,O
that,37,O
SC-236,37,B-CHEMICAL
does,37,O
not,37,O
significantly,37,O
impair,37,O
renal,37,O
function,37,O
in,37,O
rats,37,O
with,37,O
cirrhosis,37,O
.,37,O
Inhibition,38,O
of,38,O
cPLA2,38,B-GENE-Y
translocation,38,O
and,38,O
leukotriene,38,B-CHEMICAL
C4,38,I-CHEMICAL
secretion,38,O
by,38,O
fluticasone,38,B-CHEMICAL
propionate,38,I-CHEMICAL
in,38,O
exogenously,38,O
activated,38,O
human,38,O
eosinophils,38,O
.,38,O
We,39,O
examined,39,O
the,39,O
effect,39,O
of,39,O
the,39,O
highly,39,O
lipophilic,39,O
corticosteroid,39,O
",",39,O
fluticasone,39,B-CHEMICAL
propionate,39,I-CHEMICAL
(,39,O
FP,39,B-CHEMICAL
),39,O
",",39,O
in,39,O
causing,39,O
(,39,O
1,39,O
),39,O
inhibition,39,O
of,39,O
nuclear,39,O
translocation,39,O
of,39,O
cytosolic,39,B-GENE-Y
phospholipase,39,I-GENE-Y
A2,39,I-GENE-Y
(,39,O
cPLA2,39,B-GENE-Y
),39,O
",",39,O
and,39,O
(,39,O
2,39,O
),39,O
blockade,39,O
of,39,O
leukotriene,39,B-CHEMICAL
C4,39,I-CHEMICAL
(,39,O
LTC4,39,B-CHEMICAL
),39,O
synthesis,39,O
in,39,O
isolated,39,O
human,39,O
eosinophils,39,O
in,39,O
vitro,39,O
.,39,O
Eosinophils,40,O
were,40,O
isolated,40,O
from,40,O
peripheral,40,O
blood,40,O
",",40,O
treated,40,O
with,40,O
either,40,O
buffer,40,O
or,40,O
10,40,O
(,40,O
-,40,O
),40,O
10,40,O
M,40,O
to,40,O
10,40,O
(,40,O
-,40,O
),40,O
6,40,O
M,40,O
FP,40,B-CHEMICAL
in,40,O
the,40,O
presence,40,O
of,40,O
10,40,O
pg/ml,40,O
human,40,B-GENE-Y
recombinant,40,I-GENE-Y
interleukin-5,40,I-GENE-Y
(,40,O
rhIL-5,40,B-GENE-Y
),40,O
and,40,O
activated,40,O
with,40,O
formyl-met-leu-phe,40,B-CHEMICAL
(,40,O
FMLP,40,B-CHEMICAL
),40,O
+,40,O
cytochalasin,40,B-CHEMICAL
B,40,I-CHEMICAL
(,40,O
CB,40,B-CHEMICAL
),40,O
.,40,O
At,41,O
24,41,O
h,41,O
",",41,O
stimulated,41,O
LTC4,41,B-CHEMICAL
secretion,41,O
from,41,O
eosinophils,41,O
was,41,O
unchanged,41,O
;,41,O
however,41,O
",",41,O
when,41,O
corrected,41,O
for,41,O
cell,41,O
viability,41,O
",",41,O
LTC4,41,B-CHEMICAL
secretion,41,O
decreased,41,O
from,41,O
"1,429",41,O
+/-,41,O
327,41,O
pg/10,41,O
(,41,O
6,41,O
),41,O
cells,41,O
to,41,O
762,41,O
+/-,41,O
113,41,O
pg/10,41,O
(,41,O
6,41,O
),41,O
cells,41,O
for,41,O
eosinophils,41,O
treated,41,O
for,41,O
48,41,O
h,41,O
with,41,O
>,41,O
/=,41,O
10,41,O
(,41,O
-,41,O
),41,O
8,41,O
M,41,O
FP,41,B-CHEMICAL
(,41,O
p,41,O
<,41,O
0.003,41,O
),41,O
.,41,O
FMLP/CB-stimulated,42,B-CHEMICAL
translocation,42,O
of,42,O
cPLA2,42,B-GENE-Y
to,42,O
the,42,O
nuclear,42,O
envelope,42,O
assessed,42,O
by,42,O
specific,42,O
immunohistochemical,42,O
staining,42,O
also,42,O
was,42,O
blocked,42,O
by,42,O
FP,42,B-CHEMICAL
.,42,O
By,43,O
contrast,43,O
",",43,O
membrane,43,O
expression,43,O
of,43,O
annexin-1,43,B-GENE-Y
",",43,O
which,43,O
was,43,O
not,43,O
minimal,43,O
at,43,O
30,43,O
min,43,O
",",43,O
was,43,O
substantial,43,O
at,43,O
48,43,O
h,43,O
for,43,O
eosinophils,43,O
treated,43,O
with,43,O
>,43,O
10,43,O
(,43,O
-,43,O
),43,O
10,43,O
M,43,O
FP,43,B-CHEMICAL
",",43,O
and,43,O
inhibition,43,O
of,43,O
LTC4,43,B-CHEMICAL
synthesis,43,O
was,43,O
reversed,43,O
by,43,O
exogenous,43,O
arachidonic,43,B-CHEMICAL
acid,43,I-CHEMICAL
(,43,O
AA,43,B-CHEMICAL
),43,O
.,43,O
We,44,O
find,44,O
that,44,O
FP,44,B-CHEMICAL
causes,44,O
a,44,O
decrease,44,O
in,44,O
stimulated,44,O
eosinophil,44,O
secretion,44,O
of,44,O
LTC4,44,B-CHEMICAL
that,44,O
is,44,O
regulated,44,O
by,44,O
phospholipase,44,B-GENE-Y
A2,44,I-GENE-Y
(,44,O
PLA2,44,B-GENE-Y
),44,O
.,44,O
Inhibition,45,O
of,45,O
LTC4,45,B-CHEMICAL
synthesis,45,O
precedes,45,O
the,45,O
global,45,O
cytotoxic,45,O
effects,45,O
of,45,O
FP,45,B-CHEMICAL
as,45,O
indicated,45,O
by,45,O
the,45,O
simultaneous,45,O
upregulation,45,O
of,45,O
annexin-1,45,B-GENE-Y
expression,45,O
.,45,O
Inhibited,46,O
stimulated,46,O
secretion,46,O
corresponds,46,O
to,46,O
inhibited,46,O
translocation,46,O
of,46,O
cPLA2,46,B-GENE-Y
to,46,O
the,46,O
nuclear,46,O
envelope,46,O
during,46,O
cellular,46,O
activation,46,O
.,46,O
Desipramine,47,B-CHEMICAL
treatment,47,O
decreases,47,O
3H-nisoxetine,47,B-CHEMICAL
binding,47,O
and,47,O
norepinephrine,47,B-CHEMICAL
transporter,47,I-GENE-Y
mRNA,47,O
in,47,O
SK-N-SHSY5Y,47,O
cells,47,O
.,47,O
The,48,O
antidepressant,48,O
desipramine,48,B-CHEMICAL
has,48,O
been,48,O
shown,48,O
to,48,O
decrease,48,O
synaptic,48,O
membrane,48,O
concentrations,48,O
of,48,O
the,48,O
norepinephrine,48,B-CHEMICAL
re-uptake,48,I-GENE-Y
transporter,48,I-GENE-Y
(,48,O
NET,48,B-GENE-Y
),48,O
in,48,O
vivo,48,O
and,48,O
in,48,O
vitro,48,O
",",48,O
on,48,O
both,48,O
an,48,O
acute,48,O
and,48,O
a,48,O
chronic,48,O
basis,48,O
.,48,O
The,49,O
possible,49,O
contribution,49,O
of,49,O
decreased,49,O
NET,49,B-GENE-Y
synthesis,49,O
to,49,O
the,49,O
chronic,49,O
downregulation,49,O
of,49,O
the,49,O
NETs,49,B-GENE-Y
has,49,O
not,49,O
been,49,O
definitively,49,O
established,49,O
.,49,O
In,50,O
this,50,O
study,50,O
",",50,O
we,50,O
treated,50,O
SK-N-SHSY5Y,50,O
cells,50,O
with,50,O
100,50,O
nM,50,O
desipramine,50,B-CHEMICAL
for,50,O
24,50,O
or,50,O
72,50,O
h,50,O
",",50,O
and,50,O
measured,50,O
3H-nisoxetine,50,B-CHEMICAL
binding,50,O
(,50,O
as,50,O
an,50,O
estimate,50,O
of,50,O
NETs,50,B-GENE-Y
),50,O
and,50,O
NET,50,B-GENE-Y
mRNA,50,O
by,50,O
quantitative,50,O
reverse,50,O
transcription,50,O
polymerase,50,O
chain,50,O
reaction,50,O
.,50,O
Similar,51,O
to,51,O
what,51,O
has,51,O
been,51,O
reported,51,O
previously,51,O
",",51,O
membrane,51,O
3H-nisoxetine,51,B-CHEMICAL
binding,51,O
was,51,O
significantly,51,O
decreased,51,O
at,51,O
both,51,O
24,51,O
and,51,O
72,51,O
h,51,O
(,51,O
approximately,51,O
50,51,O
%,51,O
at,51,O
both,51,O
time,51,O
points,51,O
),51,O
.,51,O
However,52,O
",",52,O
a,52,O
significant,52,O
decrease,52,O
(,52,O
64,52,O
+/-,52,O
8,52,O
%,52,O
of,52,O
paired,52,O
control,52,O
),52,O
of,52,O
NET,52,B-GENE-Y
mRNA,52,O
was,52,O
observed,52,O
only,52,O
at,52,O
the,52,O
72-h,52,O
time,52,O
point,52,O
.,52,O
We,53,O
conclude,53,O
that,53,O
decreased,53,O
NET,53,B-GENE-Y
synthesis,53,O
may,53,O
contribute,53,O
to,53,O
the,53,O
chronic,53,O
",",53,O
but,53,O
not,53,O
acute,53,O
",",53,O
effect,53,O
of,53,O
desipramine,53,B-CHEMICAL
to,53,O
downregulate,53,O
the,53,O
NET,53,B-GENE-Y
.,53,O
Inhibition,54,O
of,54,O
the,54,O
human,54,B-GENE-Y
ether-a-go-go-related,54,I-GENE-Y
gene,54,I-GENE-Y
(,54,I-GENE-Y
HERG,54,I-GENE-Y
),54,I-GENE-Y
potassium,54,I-GENE-Y
channel,54,I-GENE-Y
by,54,O
cisapride,54,B-CHEMICAL
:,54,O
affinity,54,O
for,54,O
open,54,O
and,54,O
inactivated,54,O
states,54,O
.,54,O
1,55,O
Cisapride,55,B-CHEMICAL
is,55,O
a,55,O
prokinetic,55,O
agent,55,O
which,55,O
has,55,O
been,55,O
associated,55,O
with,55,O
QT,55,O
prolongation,55,O
",",55,O
torsades,55,O
de,55,O
pointes,55,O
and,55,O
cardiac,55,O
arrest,55,O
.,55,O
The,56,O
cellular,56,O
mechanism,56,O
for,56,O
these,56,O
observations,56,O
is,56,O
high,56,O
affinity,56,O
blockade,56,O
of,56,O
IKr,56,B-GENE-N
(,56,O
encoded,56,O
by,56,O
HERG,56,B-GENE-Y
),56,O
.,56,O
2,57,O
In,57,O
a,57,O
chronic,57,O
transfection,57,O
model,57,O
using,57,O
CHO-K1,57,O
cells,57,O
",",57,O
cisapride,57,B-CHEMICAL
inhibited,57,O
HERG,57,B-GENE-Y
tail,57,O
currents,57,O
after,57,O
a,57,O
step,57,O
to,57,O
+25,57,O
mV,57,O
with,57,O
similar,57,O
potency,57,O
at,57,O
room,57,O
and,57,O
physiological,57,O
temperatures,57,O
(,57,O
IC50,57,O
16,57,O
.,57,O
4,58,O
nM,58,O
at,58,O
20-22,58,O
degrees,58,O
C,58,O
and,58,O
23.6,58,O
nM,58,O
at,58,O
37,58,O
degrees,58,O
C,58,O
),58,O
.,58,O
3,59,O
Channel,59,O
inhibition,59,O
exhibited,59,O
time-,59,O
",",59,O
voltage-,59,O
and,59,O
frequency-dependence,59,O
.,59,O
In,60,O
an,60,O
envelope,60,O
of,60,O
tails,60,O
test,60,O
",",60,O
channel,60,O
blockade,60,O
increased,60,O
from,60,O
27+/-8,60,O
%,60,O
after,60,O
a,60,O
120,60,O
ms,60,O
depolarizing,60,O
step,60,O
to,60,O
50+/-4,60,O
%,60,O
after,60,O
a,60,O
1.0,60,O
s,60,O
step,60,O
.,60,O
These,61,O
findings,61,O
suggested,61,O
affinity,61,O
for,61,O
open,61,O
and/or,61,O
inactivated,61,O
channel,61,O
states,61,O
.,61,O
4,62,O
Inactivation,62,O
was,62,O
significantly,62,O
accelerated,62,O
by,62,O
cisapride,62,B-CHEMICAL
in,62,O
a,62,O
concentration-dependent,62,O
manner,62,O
and,62,O
there,62,O
was,62,O
a,62,O
small,62,O
(,62,O
-7,62,O
mV,62,O
),62,O
shift,62,O
in,62,O
the,62,O
voltage,62,O
dependence,62,O
of,62,O
steady,62,O
state,62,O
inactivation,62,O
.,62,O
5,63,O
Channel,63,O
blockade,63,O
by,63,O
cisapride,63,B-CHEMICAL
was,63,O
modulated,63,O
by,63,O
[,63,O
K+,63,B-CHEMICAL
],63,O
o,63,O
",",63,O
with,63,O
a,63,O
26,63,O
%,63,O
reduction,63,O
in,63,O
the,63,O
potency,63,O
of,63,O
channel,63,O
blockade,63,O
when,63,O
[,63,O
K+,63,B-CHEMICAL
],63,O
o,63,O
was,63,O
increased,63,O
from,63,O
1,63,O
to,63,O
10,63,O
mM,63,O
.,63,O
6,64,O
In,64,O
conclusion,64,O
",",64,O
HERG,64,B-GENE-Y
channel,64,O
inhibition,64,O
by,64,O
cisapride,64,B-CHEMICAL
exhibits,64,O
features,64,O
consistent,64,O
with,64,O
open,64,O
and,64,O
inactivated,64,O
state,64,O
binding,64,O
and,64,O
is,64,O
sensitive,64,O
to,64,O
external,64,O
potassium,64,B-CHEMICAL
concentration,64,O
.,64,O
These,65,O
features,65,O
may,65,O
have,65,O
significant,65,O
clinical,65,O
implications,65,O
with,65,O
regard,65,O
to,65,O
the,65,O
mechanism,65,O
and,65,O
treatment,65,O
of,65,O
cisapride-induced,65,B-CHEMICAL
proarrhythmia,65,O
.,65,O
Comparison,66,O
of,66,O
the,66,O
novel,66,O
antipsychotic,66,O
ziprasidone,66,B-CHEMICAL
with,66,O
clozapine,66,B-CHEMICAL
and,66,O
olanzapine,66,B-CHEMICAL
:,66,O
inhibition,66,O
of,66,O
dorsal,66,O
raphe,66,O
cell,66,O
firing,66,O
and,66,O
the,66,O
role,66,O
of,66,O
5-HT1A,66,B-GENE-Y
receptor,66,I-GENE-Y
activation,66,O
.,66,O
Ziprasidone,67,B-CHEMICAL
is,67,O
a,67,O
novel,67,O
antipsychotic,67,O
agent,67,O
which,67,O
binds,67,O
with,67,O
high,67,O
affinity,67,O
to,67,O
5-HT1A,67,B-GENE-Y
receptors,67,I-GENE-Y
(,67,O
Ki,67,O
=,67,O
3.4,67,O
nM,67,O
),67,O
",",67,O
in,67,O
addition,67,O
to,67,O
5-HT1D,67,B-GENE-Y
",",67,O
5-HT2,67,B-GENE-Y
",",67,O
and,67,O
D2,67,B-GENE-Y
sites,67,O
.,67,O
While,68,O
it,68,O
is,68,O
an,68,O
antagonist,68,O
at,68,O
these,68,O
latter,68,O
receptors,68,O
",",68,O
ziprasidone,68,B-CHEMICAL
behaves,68,O
as,68,O
a,68,O
5-HT1A,68,B-GENE-Y
agonist,68,O
in,68,O
vitro,68,O
in,68,O
adenylate,68,B-GENE-N
cyclase,68,I-GENE-N
measurements,68,O
.,68,O
The,69,O
goal,69,O
of,69,O
the,69,O
present,69,O
study,69,O
was,69,O
to,69,O
examine,69,O
the,69,O
5-HT1A,69,B-GENE-Y
properties,69,O
of,69,O
ziprasidone,69,B-CHEMICAL
in,69,O
vivo,69,O
using,69,O
as,69,O
a,69,O
marker,69,O
of,69,O
central,69,O
5-HT1A,69,B-GENE-Y
activity,69,O
the,69,O
inhibition,69,O
of,69,O
firing,69,O
of,69,O
serotonin-containing,69,B-CHEMICAL
neurons,69,O
in,69,O
the,69,O
dorsal,69,O
raphe,69,O
nucleus,69,O
.,69,O
In,70,O
anesthetized,70,O
rats,70,O
",",70,O
ziprasidone,70,B-CHEMICAL
dose-dependently,70,O
slowed,70,O
raphe,70,O
unit,70,O
activity,70,O
(,70,O
ED50,70,O
=,70,O
300,70,O
micrograms/kg,70,O
i.v,70,O
.,70,O
),70,O
as,71,O
did,71,O
the,71,O
atypical,71,O
antipsychotics,71,O
clozapine,71,B-CHEMICAL
(,71,O
ED50,71,O
=,71,O
250,71,O
micrograms/kg,71,O
i.v,71,O
.,71,O
),71,O
and,72,O
olanzapine,72,B-CHEMICAL
(,72,O
ED50,72,O
=,72,O
1000,72,O
micrograms/kg,72,O
i.v,72,O
.,72,O
),72,O
.,72,O
Pretreatment,73,O
with,73,O
the,73,O
5-HT1A,73,B-GENE-Y
antagonist,73,O
"WAY-100,635",73,B-CHEMICAL
(,73,O
10,73,O
micrograms/kg,73,O
i.v,73,O
.,73,O
),73,O
prevented,74,O
the,74,O
ziprasidone-induced,74,B-CHEMICAL
inhibition,74,O
;,74,O
the,74,O
same,74,O
dose,74,O
of,74,O
"WAY-100,635",74,B-CHEMICAL
had,74,O
little,74,O
effect,74,O
on,74,O
the,74,O
inhibition,74,O
produced,74,O
by,74,O
clozapine,74,B-CHEMICAL
and,74,O
olanzapine,74,B-CHEMICAL
.,74,O
Because,75,O
all,75,O
three,75,O
agents,75,O
also,75,O
bind,75,O
to,75,O
alpha,75,B-GENE-N
1,75,I-GENE-N
receptors,75,I-GENE-N
",",75,O
antagonists,75,O
of,75,O
which,75,O
inhibit,75,O
serotonin,75,B-CHEMICAL
neuronal,75,O
firing,75,O
",",75,O
this,75,O
aspect,75,O
of,75,O
their,75,O
pharmacology,75,O
was,75,O
assessed,75,O
with,75,O
desipramine,75,B-CHEMICAL
(,75,O
DMI,75,B-CHEMICAL
),75,O
",",75,O
a,75,O
NE,75,B-CHEMICAL
re-uptake,75,O
blocker,75,O
previously,75,O
shown,75,O
to,75,O
reverse,75,O
the,75,O
effects,75,O
of,75,O
alpha,75,O
1,75,O
antagonists,75,O
on,75,O
raphe,75,O
unit,75,O
activity,75,O
.,75,O
DMI,76,B-CHEMICAL
(,76,O
5,76,O
mg/kg,76,O
i.v,76,O
.,76,O
),76,O
failed,77,O
to,77,O
reverse,77,O
the,77,O
inhibitory,77,O
effect,77,O
of,77,O
ziprasidone,77,B-CHEMICAL
but,77,O
produced,77,O
nearly,77,O
complete,77,O
reversal,77,O
of,77,O
that,77,O
of,77,O
clozapine,77,B-CHEMICAL
and,77,O
olanzapine,77,B-CHEMICAL
.,77,O
These,78,O
profiles,78,O
suggest,78,O
a,78,O
mechanism,78,O
of,78,O
action,78,O
for,78,O
each,78,O
agent,78,O
",",78,O
5-HT1A,78,B-GENE-Y
agonism,78,O
for,78,O
ziprasidone,78,B-CHEMICAL
and,78,O
alpha,78,O
1,78,O
antagonism,78,O
for,78,O
clozapine,78,B-CHEMICAL
and,78,O
olanzapine,78,B-CHEMICAL
.,78,O
The,79,O
5-HT1A,79,B-GENE-Y
agonist,79,O
activity,79,O
reported,79,O
here,79,O
clearly,79,O
distinguishes,79,O
ziprasidone,79,B-CHEMICAL
from,79,O
currently,79,O
available,79,O
antipsychotic,79,O
agents,79,O
and,79,O
suggests,79,O
that,79,O
this,79,O
property,79,O
may,79,O
play,79,O
a,79,O
significant,79,O
role,79,O
in,79,O
its,79,O
pharmacologic,79,O
actions,79,O
.,79,O
Reduction,80,O
of,80,O
oral,80,O
ethanol,80,B-CHEMICAL
self-administration,80,O
in,80,O
rats,80,O
by,80,O
monoamine,80,B-GENE-N
oxidase,80,I-GENE-N
inhibitors,80,O
.,80,O
Evidence,81,O
for,81,O
a,81,O
role,81,O
of,81,O
dopamine,81,B-CHEMICAL
and,81,O
serotonin,81,B-CHEMICAL
in,81,O
the,81,O
control,81,O
of,81,O
ethanol,81,B-CHEMICAL
intake,81,O
in,81,O
animals,81,O
suggests,81,O
that,81,O
monoamine,81,B-CHEMICAL
oxidase,81,I-GENE-N
(,81,O
MAO,81,B-GENE-N
),81,O
inhibitors,81,O
",",81,O
which,81,O
increase,81,O
the,81,O
synaptic,81,O
availability,81,O
of,81,O
serotonin,81,B-CHEMICAL
and,81,O
dopamine,81,B-CHEMICAL
by,81,O
blocking,81,O
their,81,O
metabolism,81,O
",",81,O
might,81,O
have,81,O
efficacy,81,O
in,81,O
the,81,O
treatment,81,O
of,81,O
alcohol,81,B-CHEMICAL
dependence,81,O
.,81,O
The,82,O
aim,82,O
of,82,O
the,82,O
present,82,O
study,82,O
was,82,O
",",82,O
therefore,82,O
",",82,O
to,82,O
evaluate,82,O
several,82,O
MAO,82,B-GENE-N
inhibitors,82,O
for,82,O
their,82,O
capacity,82,O
to,82,O
affect,82,O
ethanol,82,B-CHEMICAL
self-administration,82,O
in,82,O
rats,82,O
trained,82,O
to,82,O
self-administer,82,O
ethanol,82,B-CHEMICAL
(,82,O
10,82,O
%,82,O
v/v,82,O
),82,O
orally,82,O
in,82,O
a,82,O
free-choice,82,O
two-lever,82,O
operant,82,O
task,82,O
.,82,O
The,83,O
nonselective,83,O
and,83,O
irreversible,83,O
MAO,83,B-GENE-N
inhibitors,83,O
",",83,O
phenelzine,83,B-CHEMICAL
(,83,O
3-10,83,O
mg/kg,83,O
),83,O
",",83,O
tranylcypromine,83,B-CHEMICAL
(,83,O
1-3,83,O
mg/kg,83,O
),83,O
",",83,O
and,83,O
nialamide,83,B-CHEMICAL
(,83,O
30,83,O
mg/kg,83,O
),83,O
",",83,O
decreased,83,O
rates,83,O
of,83,O
responding,83,O
maintained,83,O
by,83,O
ethanol,83,B-CHEMICAL
reinforcement,83,O
.,83,O
The,84,O
reversible,84,O
MAO-A,84,B-GENE-Y
inhibitor,84,O
",",84,O
befloxatone,84,B-CHEMICAL
(,84,O
0.3-3,84,O
mg/kg,84,O
),84,O
",",84,O
and,84,O
the,84,O
irreversible,84,O
MAO-A,84,B-GENE-Y
inhibitor,84,O
",",84,O
clorgyline,84,B-CHEMICAL
(,84,O
10-30,84,O
mg/kg,84,O
),84,O
",",84,O
also,84,O
reduced,84,O
ethanol,84,B-CHEMICAL
self-administration,84,O
.,84,O
However,85,O
",",85,O
befloxatone-induced,85,B-CHEMICAL
effects,85,O
leveled,85,O
off,85,O
at,85,O
a,85,O
50,85,O
%,85,O
decrease,85,O
.,85,O
The,86,O
irreversible,86,O
MAO-B,86,B-GENE-Y
inhibitors,86,O
",",86,O
pargyline,86,B-CHEMICAL
(,86,O
30,86,O
mg/kg,86,O
),86,O
and,86,O
l-deprenyl,86,B-CHEMICAL
(,86,O
3-10,86,O
mg/kg,86,O
),86,O
also,86,O
decreased,86,O
responding,86,O
maintained,86,O
by,86,O
ethanol,86,B-CHEMICAL
reinforcement,86,O
;,86,O
these,86,O
results,86,O
are,86,O
consistent,86,O
with,86,O
previous,86,O
findings,86,O
that,86,O
both,86,O
drugs,86,O
decreased,86,O
ethanol,86,B-CHEMICAL
intake,86,O
in,86,O
mice,86,O
.,86,O
In,87,O
conclusion,87,O
",",87,O
the,87,O
present,87,O
results,87,O
showing,87,O
that,87,O
several,87,O
MAO,87,B-GENE-N
inhibitors,87,O
decreased,87,O
ethanol,87,B-CHEMICAL
self-administration,87,O
in,87,O
rats,87,O
are,87,O
consistent,87,O
with,87,O
previous,87,O
findings,87,O
that,87,O
synaptic,87,O
levels,87,O
of,87,O
serotonin,87,B-CHEMICAL
and,87,O
dopamine,87,B-CHEMICAL
play,87,O
a,87,O
critical,87,O
role,87,O
in,87,O
the,87,O
control,87,O
of,87,O
ethanol,87,B-CHEMICAL
self-administration,87,O
.,87,O
Decreased,88,O
intracellular,88,O
proteolysis,88,O
correlates,88,O
with,88,O
the,88,O
maintenance,88,O
of,88,O
a,88,O
specific,88,O
isoenzyme,88,O
of,88,O
cytochrome,88,B-GENE-N
P-450,88,I-GENE-N
.,88,O
The,89,O
rates,89,O
of,89,O
intracellular,89,O
protein,89,O
degradation,89,O
",",89,O
of,89,O
identically,89,O
labelled,89,O
populations,89,O
of,89,O
proteins,89,O
",",89,O
were,89,O
compared,89,O
in,89,O
hepatocytes,89,O
cultured,89,O
at,89,O
37,89,O
degrees,89,O
(,89,O
on,89,O
an,89,O
adsorbed,89,O
collagen,89,O
layer,89,O
),89,O
and,89,O
in,89,O
cells,89,O
preserved,89,O
on,89,O
gelatin,89,O
gels,89,O
at,89,O
10,89,O
degrees,89,O
C.,89,O
The,89,O
half-lives,89,O
of,89,O
the,89,O
long-lived,89,O
proteins,89,O
were,89,O
35.4+/-8.6,89,O
h,89,O
(,89,O
N=4,89,O
),89,O
and,89,O
692.9+/-216.9,89,O
h,89,O
(,89,O
N=4,89,O
),89,O
respectively,89,O
.,89,O
Proteolysis,90,O
was,90,O
substantially,90,O
decreased,90,O
at,90,O
10,90,O
degrees,90,O
C,90,O
but,90,O
the,90,O
rate,90,O
of,90,O
decrease,90,O
remained,90,O
constant,90,O
.,90,O
Hepatocytes,91,O
rapidly,91,O
removed,91,O
resorufin,91,B-CHEMICAL
from,91,O
the,91,O
culture,91,O
medium,91,O
.,91,O
The,92,O
resorufin,92,B-CHEMICAL
was,92,O
not,92,O
being,92,O
conjugated,92,O
or,92,O
accumulated,92,O
within,92,O
the,92,O
cells,92,O
.,92,O
Dicumarol,93,B-CHEMICAL
",",93,O
a,93,O
potent,93,O
inhibitor,93,O
of,93,O
quinone,93,B-GENE-N
oxidoreductase,93,I-GENE-N
",",93,O
at,93,O
high,93,O
concentration,93,O
(,93,O
500,93,O
microm,93,O
),93,O
caused,93,O
only,93,O
a,93,O
72,93,O
%,93,O
decrease,93,O
in,93,O
the,93,O
utilization,93,O
of,93,O
resorufin,93,B-CHEMICAL
.,93,O
The,94,O
microsomal,94,O
detoxifying,94,O
enzyme,94,O
",",94,O
cytochrome,94,B-GENE-Y
P-450,94,I-GENE-Y
1A1,94,I-GENE-Y
remained,94,O
at,94,O
a,94,O
constant,94,O
level,94,O
in,94,O
the,94,O
preserved,94,O
hepatocyte,94,O
monolayers,94,O
.,94,O
The,95,O
results,95,O
of,95,O
this,95,O
study,95,O
strongly,95,O
favour,95,O
storing,95,O
hepatocytes,95,O
at,95,O
10,95,O
degrees,95,O
C,95,O
rather,95,O
than,95,O
at,95,O
4,95,O
degrees,95,O
or,95,O
37,95,O
degrees,95,O
C,95,O
.,95,O
A,96,O
novel,96,O
mutation,96,O
of,96,O
the,96,O
erythroid-specific,96,B-GENE-N
gamma-Aminolevulinate,96,B-CHEMICAL
synthase,96,I-GENE-N
gene,96,O
in,96,O
a,96,O
patient,96,O
with,96,O
non-inherited,96,O
pyridoxine-responsive,96,B-CHEMICAL
sideroblastic,96,O
anemia,96,O
.,96,O
A,97,O
novel,97,O
missense,97,O
mutation,97,O
",",97,O
G663A,97,B-GENE-N
",",97,O
in,97,O
exon,97,O
5,97,O
of,97,O
the,97,O
erythroid-specific,97,B-GENE-Y
delta-aminolevulinate,97,B-CHEMICAL
synthase,97,I-GENE-Y
gene,97,O
(,97,O
ALAS2,97,B-GENE-Y
),97,O
was,97,O
identified,97,O
in,97,O
a,97,O
Japanese,97,O
male,97,O
with,97,O
pyridoxine-responsive,97,B-CHEMICAL
sideroblastic,97,O
anemia,97,O
.,97,O
Activity,98,O
of,98,O
the,98,O
mutant,98,O
delta-aminolevulinate,98,B-GENE-Y
synthase,98,I-GENE-Y
protein,98,O
expressed,98,O
in,98,O
vitro,98,O
was,98,O
15.1,98,O
%,98,O
compared,98,O
with,98,O
the,98,O
normal,98,O
control,98,O
",",98,O
but,98,O
was,98,O
increased,98,O
up,98,O
to,98,O
34.5,98,O
%,98,O
by,98,O
the,98,O
addition,98,O
of,98,O
pyridoxal,98,B-CHEMICAL
5'-phosphate,98,I-CHEMICAL
",",98,O
consistent,98,O
with,98,O
the,98,O
clinical,98,O
response,98,O
of,98,O
the,98,O
patient,98,O
to,98,O
pyridoxine,98,B-CHEMICAL
treatment,98,O
.,98,O
The,99,O
same,99,O
mutation,99,O
was,99,O
also,99,O
detected,99,O
in,99,O
genomic,99,O
DNa,99,O
from,99,O
the,99,O
oral,99,O
mucosal,99,O
membrane,99,O
of,99,O
the,99,O
patiet,99,O
;,99,O
however,99,O
",",99,O
it,99,O
was,99,O
not,99,O
detected,99,O
in,99,O
other,99,O
family,99,O
member,99,O
.,99,O
These,100,O
findings,100,O
suggest,100,O
that,100,O
this,100,O
G663A,100,B-GENE-N
mutation,100,O
is,100,O
responsible,100,O
for,100,O
sideroblastic,100,O
anemia,100,O
in,100,O
the,100,O
proband,100,O
",",100,O
and,100,O
may,100,O
be,100,O
an,100,O
index,100,O
mutation,100,O
in,100,O
this,100,O
pedigree,100,O
.,100,O
Preferential,101,O
cerebrospinal,101,O
fluid,101,O
acetylcholinesterase,101,B-GENE-Y
inhibition,101,O
by,101,O
rivastigmine,101,B-CHEMICAL
in,101,O
humans,101,O
.,101,O
This,102,O
study,102,O
sought,102,O
to,102,O
examine,102,O
the,102,O
feasibility,102,O
of,102,O
prolonged,102,O
assessment,102,O
of,102,O
acetylcholinesterase,102,B-GENE-Y
(,102,O
AChE,102,B-GENE-Y
),102,O
activity,102,O
in,102,O
the,102,O
cerebrospinal,102,O
fluid,102,O
(,102,O
CSF,102,O
),102,O
of,102,O
volunteers,102,O
and,102,O
to,102,O
test,102,O
the,102,O
hypothesis,102,O
that,102,O
rivastigmine,102,B-CHEMICAL
(,102,O
ENA-713,102,B-CHEMICAL
;,102,O
Exelon,102,B-CHEMICAL
",",102,O
Novartis,102,O
Pharma,102,O
AG,102,O
",",102,O
Basel,102,O
",",102,O
Switzerland,102,O
),102,O
selectively,102,O
inhibits,102,O
AChE,102,B-GENE-Y
in,102,O
CSF,102,O
in,102,O
humans,102,O
at,102,O
a,102,O
dose,102,O
producing,102,O
minimal,102,O
inhibition,102,O
of,102,O
the,102,O
peripheral,102,O
enzyme,102,O
.,102,O
Lumbar,103,O
CSF,103,O
samples,103,O
were,103,O
collected,103,O
continuously,103,O
(,103,O
0.1,103,O
mL,103,O
x,103,O
min,103,O
(,103,O
-1,103,O
),103,O
),103,O
for,103,O
49,103,O
hours,103,O
from,103,O
eight,103,O
healthy,103,O
volunteers,103,O
who,103,O
took,103,O
either,103,O
placebo,103,O
or,103,O
a,103,O
single,103,O
oral,103,O
dose,103,O
of,103,O
rivastigmine,103,B-CHEMICAL
(,103,O
3,103,O
mg,103,O
),103,O
.,103,O
CSF,104,O
specimens,104,O
and,104,O
samples,104,O
of,104,O
blood,104,O
cells,104,O
and,104,O
blood,104,O
plasma,104,O
were,104,O
analyzed,104,O
at,104,O
intervals,104,O
for,104,O
rivastigmine,104,B-CHEMICAL
and,104,O
its,104,O
metabolite,104,O
NAP,104,B-CHEMICAL
226-90,104,I-CHEMICAL
(,104,O
[,104,B-CHEMICAL
-,104,I-CHEMICAL
],104,I-CHEMICAL
[,104,I-CHEMICAL
3-,104,I-CHEMICAL
(,104,I-CHEMICAL
[,104,I-CHEMICAL
1-dimethylaminolethyl,104,I-CHEMICAL
),104,I-CHEMICAL
-phenol,104,I-CHEMICAL
],104,I-CHEMICAL
),104,O
",",104,O
erythrocyte,104,O
AChE,104,B-GENE-Y
activity,104,O
",",104,O
CSF,104,O
AChE,104,B-GENE-Y
activity,104,O
",",104,O
and,104,O
plasma,104,O
and,104,O
CSF,104,O
butyrylcholinesterase,104,B-GENE-Y
(,104,O
BuChE,104,B-GENE-Y
),104,O
activity,104,O
.,104,O
Safety,105,O
evaluations,105,O
were,105,O
performed,105,O
23,105,O
hours,105,O
after,105,O
drug,105,O
dosing,105,O
and,105,O
at,105,O
the,105,O
end,105,O
of,105,O
the,105,O
study,105,O
.,105,O
Evaluable,106,O
data,106,O
were,106,O
obtained,106,O
from,106,O
six,106,O
subjects,106,O
.,106,O
The,107,O
mean,107,O
time,107,O
to,107,O
maximal,107,O
rivastigmine,107,B-CHEMICAL
plasma,107,O
concentration,107,O
(,107,O
tmax,107,O
),107,O
was,107,O
0.83,107,O
+/-,107,O
0.26,107,O
hours,107,O
",",107,O
the,107,O
mean,107,O
maximal,107,O
plasma,107,O
concentration,107,O
(,107,O
Cmax,107,O
),107,O
was,107,O
4.88,107,O
+/-,107,O
3.82,107,O
ng,107,O
x,107,O
mL,107,O
(,107,O
-1,107,O
),107,O
",",107,O
the,107,O
mean,107,O
plasma,107,O
area,107,O
under,107,O
the,107,O
concentration,107,O
versus,107,O
time,107,O
curve,107,O
(,107,O
AUC0-infinity,107,O
),107,O
was,107,O
7.43,107,O
+/-,107,O
4.74,107,O
ng,107,O
x,107,O
hr,107,O
x,107,O
mL,107,O
(,107,O
-1,107,O
),107,O
",",107,O
and,107,O
the,107,O
mean,107,O
plasma,107,O
t1/2,107,O
was,107,O
0.85,107,O
+/-,107,O
0.115,107,O
hours,107,O
.,107,O
The,108,O
concentration,108,O
of,108,O
rivastigmine,108,B-CHEMICAL
in,108,O
CSF,108,O
was,108,O
lower,108,O
than,108,O
the,108,O
quantification,108,O
limit,108,O
for,108,O
assay,108,O
(,108,O
0.65,108,O
ng,108,O
x,108,O
mL,108,O
(,108,O
-1,108,O
),108,O
),108,O
",",108,O
but,108,O
NAP,108,B-CHEMICAL
226-90,108,I-CHEMICAL
reached,108,O
a,108,O
mean,108,O
Cmax,108,O
of,108,O
3.14,108,O
+/-,108,O
0.57,108,O
ng,108,O
x,108,O
mL,108,O
(,108,O
-1,108,O
),108,O
.,108,O
Only,109,O
minimal,109,O
inhibition,109,O
of,109,O
erythrocyte,109,O
AChE,109,B-GENE-Y
activity,109,O
(,109,O
approximately,109,O
3,109,O
%,109,O
),109,O
was,109,O
observed,109,O
.,109,O
Inhibition,110,O
of,110,O
AChE,110,B-GENE-Y
in,110,O
the,110,O
CSF,110,O
after,110,O
rivastigmine,110,B-CHEMICAL
administration,110,O
was,110,O
significantly,110,O
greater,110,O
than,110,O
after,110,O
placebo,110,O
for,110,O
up,110,O
to,110,O
8.4,110,O
hours,110,O
after,110,O
the,110,O
dose,110,O
and,110,O
was,110,O
maximal,110,O
(,110,O
40,110,O
%,110,O
),110,O
at,110,O
2.4,110,O
hours,110,O
.,110,O
Plasma,111,O
BuChE,111,B-GENE-Y
activity,111,O
was,111,O
significantly,111,O
lower,111,O
after,111,O
rivastigmine,111,B-CHEMICAL
than,111,O
after,111,O
placebo,111,O
",",111,O
but,111,O
this,111,O
was,111,O
not,111,O
clinically,111,O
relevant,111,O
.,111,O
BuChE,112,B-GENE-Y
activity,112,O
in,112,O
CSF,112,O
was,112,O
significantly,112,O
lower,112,O
after,112,O
rivastigmine,112,B-CHEMICAL
than,112,O
after,112,O
placebo,112,O
for,112,O
up,112,O
to,112,O
3.6,112,O
hours,112,O
after,112,O
dosing,112,O
",",112,O
but,112,O
this,112,O
difference,112,O
was,112,O
not,112,O
sustained,112,O
.,112,O
This,113,O
study,113,O
confirms,113,O
the,113,O
feasibility,113,O
of,113,O
using,113,O
continuous,113,O
measurement,113,O
of,113,O
AChE,113,B-GENE-Y
activity,113,O
in,113,O
CSF,113,O
over,113,O
prolonged,113,O
periods,113,O
",",113,O
that,113,O
rivastigmine,113,B-CHEMICAL
markedly,113,O
inhibits,113,O
CSF,113,O
AChE,113,B-GENE-Y
after,113,O
a,113,O
single,113,O
oral,113,O
dose,113,O
of,113,O
3,113,O
mg,113,O
",",113,O
and,113,O
that,113,O
the,113,O
inhibition,113,O
of,113,O
central,113,O
AChE,113,B-GENE-Y
is,113,O
substantially,113,O
greater,113,O
than,113,O
that,113,O
of,113,O
peripheral,113,O
AChE,113,B-GENE-Y
or,113,O
BuChE,113,B-GENE-Y
.,113,O
Identification,114,O
of,114,O
amino,114,B-CHEMICAL
acids,114,I-CHEMICAL
in,114,O
the,114,O
factor,114,B-GENE-N
XI,114,I-GENE-N
apple,114,I-GENE-N
3,114,I-GENE-N
domain,114,I-GENE-N
required,114,O
for,114,O
activation,114,O
of,114,O
factor,114,B-GENE-Y
IX,114,I-GENE-Y
.,114,O
Activated,115,B-GENE-Y
coagulation,115,I-GENE-Y
factor,115,I-GENE-Y
XI,115,I-GENE-Y
(,115,O
factor,115,B-GENE-Y
XIa,115,I-GENE-Y
),115,O
proteolytically,115,O
cleaves,115,O
its,115,O
substrate,115,O
",",115,O
factor,115,B-GENE-Y
IX,115,I-GENE-Y
",",115,O
in,115,O
an,115,O
interaction,115,O
requiring,115,O
the,115,O
factor,115,B-GENE-N
XI,115,I-GENE-N
A3,115,I-GENE-N
domain,115,I-GENE-N
(,115,O
Sun,115,O
",",115,O
Y.,115,O
",",115,O
and,115,O
Gailani,115,O
",",115,O
D.,115,O
(,115,O
1996,115,O
),115,O
J.,115,O
Biol,115,O
.,115,O
Chem,116,O
.,116,O
271,117,O
",",117,O
29023-29028,117,O
),117,O
.,117,O
To,118,O
identify,118,O
key,118,O
amino,118,B-CHEMICAL
acids,118,I-CHEMICAL
involved,118,O
in,118,O
factor,118,B-GENE-Y
IX,118,I-GENE-Y
activation,118,O
",",118,O
recombinant,118,O
factor,118,B-GENE-Y
XIa,118,I-GENE-Y
proteins,118,O
containing,118,O
alanine,118,B-CHEMICAL
substitutions,118,O
for,118,O
wild-type,118,O
sequence,118,O
were,118,O
expressed,118,O
in,118,O
293,118,O
fibroblasts,118,O
and,118,O
tested,118,O
in,118,O
a,118,O
plasma,118,O
clotting,118,O
assay,118,O
.,118,O
Substitutions,119,O
for,119,O
Ile,119,O
(,119,O
183,119,O
),119,O
-Val,119,O
(,119,O
191,119,O
),119,O
and,119,O
Ser,119,O
(,119,O
195,119,O
),119,O
-Ile,119,O
(,119,O
197,119,O
),119,O
at,119,O
the,119,O
N,119,B-CHEMICAL
terminus,119,O
and,119,O
for,119,O
Ser,119,O
(,119,O
258,119,O
),119,O
-Ser,119,O
(,119,O
264,119,O
),119,O
at,119,O
the,119,O
C,119,B-CHEMICAL
terminus,119,O
of,119,O
the,119,O
A3,119,B-GENE-N
domain,119,I-GENE-N
markedly,119,O
decreased,119,O
factor,119,B-GENE-Y
XI,119,I-GENE-Y
coagulant,119,O
activity,119,O
.,119,O
The,120,O
plasma,120,B-GENE-N
protease,120,I-GENE-N
prekallikrein,120,B-GENE-Y
is,120,O
structurally,120,O
homologous,120,O
to,120,O
factor,120,B-GENE-Y
XI,120,I-GENE-Y
",",120,O
but,120,O
activated,120,O
factor,120,B-GENE-Y
IX,120,I-GENE-Y
poorly,120,O
.,120,O
A,121,O
chimeric,121,O
factor,121,B-GENE-Y
XIa,121,I-GENE-Y
molecule,121,O
with,121,O
the,121,O
A3,121,B-GENE-N
domain,121,I-GENE-N
replaced,121,O
with,121,O
A3,121,O
from,121,O
prekallikrein,121,B-GENE-Y
(,121,O
FXI/PKA3,121,B-GENE-Y
),121,O
activated,121,B-GENE-Y
factor,121,I-GENE-Y
IX,121,I-GENE-Y
with,121,O
a,121,O
K,121,O
(,121,O
m,121,O
),121,O
35-fold,121,O
greater,121,O
than,121,O
that,121,O
of,121,O
wild-type,121,O
factor,121,B-GENE-Y
XI,121,I-GENE-Y
.,121,O
FXI/PKA3,122,B-GENE-Y
was,122,O
used,122,O
as,122,O
a,122,O
template,122,O
for,122,O
a,122,O
series,122,O
of,122,O
proteins,122,O
in,122,O
which,122,O
prekallikrein,122,B-GENE-Y
A3,122,O
sequence,122,O
was,122,O
replaced,122,O
with,122,O
factor,122,B-GENE-Y
XI,122,I-GENE-Y
sequence,122,O
to,122,O
restore,122,O
factor,122,B-GENE-Y
IX,122,I-GENE-Y
activation,122,O
.,122,O
Clotting,123,O
and,123,O
kinetics,123,O
studies,123,O
using,123,O
these,123,O
chimeras,123,O
confirmed,123,O
the,123,O
results,123,O
obtained,123,O
with,123,O
alanine,123,B-CHEMICAL
mutants,123,O
.,123,O
Amino,124,B-CHEMICAL
acids,124,I-CHEMICAL
between,124,O
Ile,124,O
(,124,O
183,124,O
),124,O
and,124,O
Val,124,O
(,124,O
191,124,O
),124,O
are,124,O
necessary,124,O
for,124,O
proper,124,O
factor,124,B-GENE-Y
IX,124,I-GENE-Y
activation,124,O
",",124,O
but,124,O
additional,124,O
sequence,124,O
between,124,O
Ser,124,O
(,124,O
195,124,O
),124,O
and,124,O
Ile,124,O
(,124,O
197,124,O
),124,O
or,124,O
between,124,O
Phe,124,O
(,124,O
260,124,O
),124,O
and,124,O
Ser,124,O
(,124,O
265,124,O
),124,O
is,124,O
required,124,O
for,124,O
complete,124,O
restoration,124,O
of,124,O
activation,124,O
.,124,O
Agonist,125,O
and,125,O
antagonist,125,O
actions,125,O
of,125,O
yohimbine,125,B-CHEMICAL
as,125,O
compared,125,O
to,125,O
fluparoxan,125,B-CHEMICAL
at,125,O
alpha,125,B-GENE-N
(,125,I-GENE-N
2,125,I-GENE-N
),125,I-GENE-N
-adrenergic,125,I-GENE-N
receptors,125,I-GENE-N
(,125,B-GENE-N
AR,125,I-GENE-N
),125,I-GENE-N
s,125,I-GENE-N
",",125,O
serotonin,125,B-CHEMICAL
(,125,B-GENE-Y
5-HT,125,I-GENE-Y
),125,I-GENE-Y
(,125,I-GENE-Y
1A,125,I-GENE-Y
),125,I-GENE-Y
",",125,O
5-HT,125,B-GENE-Y
(,125,I-GENE-Y
1B,125,I-GENE-Y
),125,I-GENE-Y
",",125,O
5-HT,125,B-GENE-Y
(,125,I-GENE-Y
1D,125,I-GENE-Y
),125,I-GENE-Y
and,125,O
dopamine,125,B-GENE-N
D,125,I-GENE-N
(,125,I-GENE-N
2,125,I-GENE-N
),125,I-GENE-N
and,125,I-GENE-N
D,125,I-GENE-N
(,125,I-GENE-N
3,125,I-GENE-N
),125,I-GENE-N
receptors,125,I-GENE-N
.,125,O
Significance,126,O
for,126,O
the,126,O
modulation,126,O
of,126,O
frontocortical,126,O
monoaminergic,126,O
transmission,126,O
and,126,O
depressive,126,O
states,126,O
.,126,O
Herein,127,O
",",127,O
we,127,O
evaluate,127,O
the,127,O
interaction,127,O
of,127,O
the,127,O
alpha,127,B-GENE-N
(,127,I-GENE-N
2,127,I-GENE-N
),127,I-GENE-N
-AR,127,I-GENE-N
antagonist,127,I-GENE-N
",",127,O
yohimbine,127,B-CHEMICAL
",",127,O
as,127,O
compared,127,O
to,127,O
fluparoxan,127,B-CHEMICAL
",",127,O
at,127,O
multiple,127,O
monoaminergic,127,B-GENE-N
receptors,127,I-GENE-N
and,127,O
examine,127,O
their,127,O
roles,127,O
in,127,O
the,127,O
modulation,127,O
of,127,O
adrenergic,127,O
",",127,O
dopaminergic,127,O
and,127,O
serotonergic,127,O
transmission,127,O
in,127,O
freely-moving,127,O
rats,127,O
.,127,O
Yohimbine,128,B-CHEMICAL
displays,128,O
marked,128,O
affinity,128,O
at,128,O
human,128,B-GENE-N
(,128,I-GENE-N
h,128,I-GENE-N
),128,I-GENE-N
alpha,128,I-GENE-N
(,128,I-GENE-N
2A,128,I-GENE-N
),128,I-GENE-N
-,128,I-GENE-N
",",128,I-GENE-N
halpha,128,I-GENE-N
(,128,I-GENE-N
2B,128,I-GENE-N
),128,I-GENE-N
-,128,I-GENE-N
and,128,I-GENE-N
halpha,128,I-GENE-N
(,128,I-GENE-N
2C,128,I-GENE-N
),128,I-GENE-N
-ARs,128,I-GENE-N
",",128,O
significant,128,O
affinity,128,O
for,128,O
h5-HT,128,B-GENE-Y
(,128,I-GENE-Y
1A,128,I-GENE-Y
),128,I-GENE-Y
",",128,O
h5-HT,128,B-GENE-Y
(,128,I-GENE-Y
1B,128,I-GENE-Y
),128,I-GENE-Y
",",128,O
h5-HT,128,B-GENE-Y
(,128,I-GENE-Y
1D,128,I-GENE-Y
),128,I-GENE-Y
",",128,O
and,128,O
hD,128,B-GENE-Y
(,128,I-GENE-Y
2,128,I-GENE-Y
),128,I-GENE-Y
receptors,128,I-GENE-Y
and,128,O
weak,128,O
affinity,128,O
for,128,O
hD,128,B-GENE-Y
(,128,I-GENE-Y
3,128,I-GENE-Y
),128,I-GENE-Y
receptors,128,I-GENE-Y
.,128,O
In,129,O
[,129,O
(,129,B-CHEMICAL
35,129,I-CHEMICAL
),129,I-CHEMICAL
S,129,I-CHEMICAL
],129,O
GTPgammaS,129,O
binding,129,O
protocols,129,O
",",129,O
yohimbine,129,B-CHEMICAL
exerts,129,O
antagonist,129,O
actions,129,O
at,129,O
halpha,129,B-GENE-Y
(,129,I-GENE-Y
2A,129,I-GENE-Y
),129,I-GENE-Y
-AR,129,I-GENE-Y
",",129,O
h5-HT,129,B-GENE-Y
(,129,I-GENE-Y
1B,129,I-GENE-Y
),129,I-GENE-Y
",",129,O
h5-HT,129,B-GENE-Y
(,129,I-GENE-Y
1D,129,I-GENE-Y
),129,I-GENE-Y
",",129,O
and,129,O
hD,129,B-GENE-Y
(,129,I-GENE-Y
2,129,I-GENE-Y
),129,I-GENE-Y
sites,129,O
",",129,O
yet,129,O
partial,129,O
agonist,129,O
actions,129,O
at,129,O
h5-HT,129,B-GENE-Y
(,129,I-GENE-Y
1A,129,I-GENE-Y
),129,I-GENE-Y
sites,129,O
.,129,O
In,130,O
vivo,130,O
",",130,O
agonist,130,O
actions,130,O
of,130,O
yohimbine,130,B-CHEMICAL
at,130,O
5-HT,130,B-GENE-Y
(,130,I-GENE-Y
1A,130,I-GENE-Y
),130,I-GENE-Y
sites,130,O
are,130,O
revealed,130,O
by,130,O
"WAY100,635-reversible",130,B-CHEMICAL
induction,130,O
of,130,O
hypothermia,130,O
in,130,O
the,130,O
rat,130,O
.,130,O
In,131,O
guinea,131,O
pigs,131,O
",",131,O
antagonist,131,O
actions,131,O
of,131,O
yohimbine,131,B-CHEMICAL
at,131,O
5-HT,131,B-GENE-Y
(,131,I-GENE-Y
1B,131,I-GENE-Y
),131,I-GENE-Y
receptors,131,O
are,131,O
revealed,131,O
by,131,O
blockade,131,O
of,131,O
hypothermia,131,O
evoked,131,O
by,131,O
the,131,O
5-HT,131,B-GENE-Y
(,131,I-GENE-Y
1B,131,I-GENE-Y
),131,I-GENE-Y
agonist,131,O
",",131,O
"GR46,611",131,B-CHEMICAL
.,131,O
In,132,O
distinction,132,O
to,132,O
yohimbine,132,B-CHEMICAL
",",132,O
fluparoxan,132,B-CHEMICAL
shows,132,O
only,132,O
modest,132,O
partial,132,O
agonist,132,O
actions,132,O
at,132,O
h5-HT,132,B-GENE-Y
(,132,I-GENE-Y
1A,132,I-GENE-Y
),132,I-GENE-Y
sites,132,O
versus,132,O
marked,132,O
antagonist,132,O
actions,132,O
at,132,O
halpha,132,B-GENE-N
(,132,I-GENE-N
2,132,I-GENE-N
),132,I-GENE-N
-ARs,132,I-GENE-N
.,132,O
While,133,O
fluparoxan,133,B-CHEMICAL
selectively,133,O
enhances,133,O
hippocampal,133,O
noradrenaline,133,B-CHEMICAL
(,133,O
NAD,133,B-CHEMICAL
),133,O
turnover,133,O
",",133,O
yohimbine,133,B-CHEMICAL
also,133,O
enhances,133,O
striatal,133,O
dopamine,133,B-CHEMICAL
(,133,O
DA,133,B-CHEMICAL
),133,O
turnover,133,O
and,133,O
suppresses,133,O
striatal,133,O
turnover,133,O
of,133,O
5-HT,133,B-CHEMICAL
.,133,O
Further,134,O
",",134,O
yohimbine,134,B-CHEMICAL
decreases,134,O
firing,134,O
of,134,O
serotonergic,134,O
neurones,134,O
in,134,O
raphe,134,O
nuclei,134,O
",",134,O
an,134,O
action,134,O
reversed,134,O
by,134,O
"WAY100,635",134,B-CHEMICAL
.,134,O
Fluparoxan,135,B-CHEMICAL
increases,135,O
extracellular,135,O
levels,135,O
of,135,O
DA,135,B-CHEMICAL
and,135,O
NAD,135,B-CHEMICAL
",",135,O
but,135,O
not,135,O
5-HT,135,B-CHEMICAL
",",135,O
in,135,O
frontal,135,O
cortex,135,O
.,135,O
In,136,O
analogy,136,O
",",136,O
yohimbine,136,B-CHEMICAL
enhances,136,O
FCX,136,O
levels,136,O
of,136,O
DA,136,B-CHEMICAL
and,136,O
NAD,136,B-CHEMICAL
",",136,O
yet,136,O
suppresses,136,O
those,136,O
of,136,O
5-HT,136,B-CHEMICAL
",",136,O
the,136,O
latter,136,O
effect,136,O
being,136,O
antagonized,136,O
by,136,O
"WAY100,635",136,B-CHEMICAL
.,136,O
The,137,O
induction,137,O
by,137,O
fluoxetine,137,O
of,137,O
FCX,137,O
levels,137,O
of,137,O
5-HT,137,B-CHEMICAL
",",137,O
DA,137,B-CHEMICAL
",",137,O
and,137,O
NAD,137,B-CHEMICAL
is,137,O
potentiated,137,O
by,137,O
fluparoxan,137,B-CHEMICAL
.,137,O
Yohimbine,138,B-CHEMICAL
likewise,138,O
facilitates,138,O
the,138,O
influence,138,O
of,138,O
fluoxetine,138,B-CHEMICAL
upon,138,O
DA,138,B-CHEMICAL
and,138,O
NAD,138,B-CHEMICAL
levels,138,O
",",138,O
but,138,O
not,138,O
those,138,O
of,138,O
5-HT,138,B-CHEMICAL
.,138,O
In,139,O
conclusion,139,O
",",139,O
the,139,O
alpha,139,B-GENE-N
(,139,I-GENE-N
2,139,I-GENE-N
),139,I-GENE-N
-AR,139,I-GENE-N
antagonist,139,O
properties,139,O
of,139,O
yohimbine,139,B-CHEMICAL
increase,139,O
DA,139,B-CHEMICAL
and,139,O
NAD,139,B-CHEMICAL
levels,139,O
both,139,O
alone,139,O
and,139,O
in,139,O
association,139,O
with,139,O
fluoxetine,139,O
.,139,O
However,140,O
",",140,O
in,140,O
contrast,140,O
to,140,O
the,140,O
selective,140,O
alpha,140,B-GENE-N
(,140,I-GENE-N
2,140,I-GENE-N
),140,I-GENE-N
-AR,140,I-GENE-N
antagonist,140,O
",",140,O
fluparoxan,140,B-CHEMICAL
",",140,O
the,140,O
5-HT,140,B-GENE-Y
(,140,I-GENE-Y
1A,140,I-GENE-Y
),140,I-GENE-Y
agonist,140,O
actions,140,O
of,140,O
yohimbine,140,B-CHEMICAL
suppress,140,O
5-HT,140,B-CHEMICAL
levels,140,O
alone,140,O
and,140,O
underlie,140,O
its,140,O
inability,140,O
to,140,O
augment,140,O
the,140,O
influence,140,O
of,140,O
fluoxetine,140,B-CHEMICAL
upon,140,O
5-HT,140,B-CHEMICAL
levels,140,O
.,140,O
The,141,O
antitussive,141,O
activity,141,O
of,141,O
delta-opioid,141,B-GENE-Y
receptor,141,I-GENE-Y
stimulation,141,O
in,141,O
guinea,141,O
pigs,141,O
.,141,O
In,142,O
this,142,O
study,142,O
",",142,O
the,142,O
activity,142,O
of,142,O
the,142,O
delta-opioid,142,B-GENE-Y
receptor,142,I-GENE-Y
subtype-selective,142,O
agonist,142,O
",",142,O
SB,142,B-CHEMICAL
227122,142,I-CHEMICAL
",",142,O
was,142,O
investigated,142,O
in,142,O
a,142,O
guinea,142,O
pig,142,O
model,142,O
of,142,O
citric,142,B-CHEMICAL
acid-induced,142,O
cough,142,O
.,142,O
Parenteral,143,O
administration,143,O
of,143,O
selective,143,O
agonists,143,O
of,143,O
the,143,O
delta-opioid,143,B-GENE-Y
receptor,143,I-GENE-Y
(,143,O
SB,143,B-CHEMICAL
227122,143,I-CHEMICAL
),143,O
",",143,O
mu-opioid,143,B-GENE-Y
receptor,143,I-GENE-Y
(,143,O
codeine,143,B-CHEMICAL
and,143,O
hydrocodone,143,B-CHEMICAL
),143,O
",",143,O
and,143,O
kappa-opioid,143,B-GENE-Y
receptor,143,I-GENE-Y
(,143,O
BRL,143,B-CHEMICAL
52974,143,I-CHEMICAL
),143,O
produced,143,O
dose-related,143,O
inhibition,143,O
of,143,O
citric,143,B-CHEMICAL
acid-induced,143,O
cough,143,O
with,143,O
ED,143,O
(,143,O
50,143,O
),143,O
values,143,O
of,143,O
7.3,143,O
",",143,O
5.2,143,O
",",143,O
5.1,143,O
",",143,O
and,143,O
5.3,143,O
mg/kg,143,O
",",143,O
respectively,143,O
.,143,O
The,144,O
nonselective,144,O
opioid,144,B-GENE-N
receptor,144,I-GENE-N
antagonist,144,O
",",144,O
naloxone,144,B-CHEMICAL
(,144,O
3,144,O
mg/kg,144,O
",",144,O
i.m,144,O
.,144,O
),145,O
",",145,O
attenuated,145,O
the,145,O
antitussive,145,O
effects,145,O
of,145,O
codeine,145,O
or,145,O
SB,145,I-CHEMICAL
227122,145,O
",",145,O
indicating,145,O
that,145,O
the,145,O
antitussive,145,O
activity,145,O
of,145,O
both,145,O
compounds,145,O
is,145,O
opioid,145,I-GENE-N
receptor-mediated,145,O
.,145,O
The,146,O
delta-receptor,146,O
antagonist,146,O
",",146,O
SB,146,I-CHEMICAL
244525,146,O
(,146,O
10,146,O
mg/kg,146,O
",",146,O
i.p,146,O
.,146,O
),147,O
",",147,O
inhibited,147,O
the,147,O
antitussive,147,O
effect,147,O
of,147,O
SB,147,I-CHEMICAL
227122,147,O
(,147,O
20,147,O
mg/kg,147,O
",",147,O
i.p,147,O
.,147,O
),147,O
.,147,O
In,148,O
contrast,148,O
",",148,O
combined,148,O
pretreatment,148,O
with,148,O
beta-funaltrexamine,148,O
(,148,I-GENE-Y
mu-receptor,148,O
antagonist,148,O
;,148,O
20,148,O
mg/kg,148,O
",",148,O
s.c.,148,O
),148,O
and,148,O
norbinaltorphimine,148,O
(,148,I-GENE-Y
kappa-receptor,148,O
antagonist,148,O
;,148,O
20,148,O
mg/kg,148,O
",",148,O
s.c.,148,O
),148,O
",",148,O
at,148,O
doses,148,O
that,148,O
inhibited,148,O
the,148,O
antitussive,148,O
activity,148,O
of,148,O
mu-,148,I-GENE-N
and,148,I-GENE-N
kappa-receptor,148,O
agonists,148,O
",",148,O
respectively,148,O
",",148,O
was,148,O
without,148,O
effect,148,O
on,148,O
the,148,O
antitussive,148,O
response,148,O
of,148,O
SB,148,I-CHEMICAL
227122,148,O
(,148,O
20,148,O
mg/kg,148,O
",",148,O
i.p,148,O
.,148,O
),148,O
.,148,O
The,149,O
sigma-receptor,149,O
antagonist,149,O
rimcazole,149,O
(,149,O
3,149,O
mg/kg,149,O
",",149,O
i.p,149,O
.,149,O
),149,O
inhibited,150,O
the,150,O
antitussive,150,O
effect,150,O
of,150,O
dextromethorphan,150,O
(,150,O
30,150,O
mg/kg,150,O
",",150,O
i.p,150,O
.,150,O
),151,O
",",151,O
a,151,O
sigma-receptor,151,O
agonist,151,O
",",151,O
but,151,O
not,151,O
that,151,O
of,151,B-CHEMICAL
SB,151,I-CHEMICAL
227122,151,O
.,151,O
These,152,O
studies,152,O
provide,152,O
compelling,152,O
evidence,152,O
that,152,O
the,152,O
antitussive,152,O
effects,152,O
of,152,B-CHEMICAL
SB,152,I-CHEMICAL
227122,152,O
in,152,O
this,152,O
guinea,152,O
pig,152,O
cough,152,O
model,152,O
are,152,O
mediated,152,O
by,152,O
agonist,152,O
activity,152,O
at,152,O
the,152,O
delta-opioid,152,I-GENE-Y
receptor,152,O
.,152,O
COX-2-specific,153,B-GENE-Y
inhibition,153,O
:,153,O
implications,153,O
for,153,O
clinical,153,O
practice,153,O
.,153,O
Although,154,O
conventional,154,O
nonsteroidal,154,O
anti-inflammatory,154,O
drugs,154,O
(,154,O
NSAIDs,154,O
),154,O
have,154,O
long,154,O
been,154,O
a,154,O
major,154,O
therapeutic,154,O
choice,154,O
for,154,O
the,154,O
management,154,O
of,154,O
arthritic,154,O
conditions,154,O
",",154,O
the,154,O
potential,154,O
adverse,154,O
effects,154,O
of,154,O
these,154,O
agents,154,O
sometimes,154,O
compromise,154,O
their,154,O
clinical,154,O
utility,154,O
.,154,O
New,155,O
modes,155,O
of,155,O
therapy,155,O
have,155,O
recently,155,O
been,155,O
introduced,155,O
",",155,O
and,155,O
data,155,O
on,155,O
the,155,O
cyclooxygenase-2,155,B-GENE-Y
(,155,O
COX-2,155,B-GENE-Y
),155,O
-specific,155,O
inhibitors,155,O
celecoxib,155,B-CHEMICAL
and,155,O
rofecoxib,155,B-CHEMICAL
suggest,155,O
that,155,O
these,155,O
agents,155,O
will,155,O
meet,155,O
the,155,O
need,155,O
for,155,O
safe,155,O
and,155,O
effective,155,O
therapeutic,155,O
alternatives,155,O
to,155,O
conventional,155,O
NSAIDs,155,O
.,155,O
Kinetics,156,O
of,156,O
inhibition,156,O
of,156,O
human,156,B-GENE-N
and,156,I-GENE-N
rat,156,I-GENE-N
dihydroorotate,156,I-GENE-N
dehydrogenase,156,I-GENE-N
by,156,O
atovaquone,156,B-CHEMICAL
",",156,O
lawsone,156,B-CHEMICAL
derivatives,156,O
",",156,O
brequinar,156,B-CHEMICAL
sodium,156,I-CHEMICAL
and,156,O
polyporic,156,B-CHEMICAL
acid,156,I-CHEMICAL
.,156,O
Mitochondrially-bound,157,O
dihydroorotate,157,B-GENE-Y
dehydrogenase,157,I-GENE-Y
(,157,O
EC,157,B-GENE-Y
1.3.99.11,157,I-GENE-Y
),157,O
catalyzes,157,O
the,157,O
fourth,157,O
sequential,157,O
step,157,O
in,157,O
the,157,O
de,157,O
novo,157,O
synthesis,157,O
of,157,O
uridine,157,B-CHEMICAL
monophosphate,157,I-CHEMICAL
.,157,O
The,158,O
enzyme,158,O
has,158,O
been,158,O
identified,158,O
as,158,O
or,158,O
surmised,158,O
to,158,O
be,158,O
the,158,O
pharmacological,158,O
target,158,O
for,158,O
isoxazol,158,B-CHEMICAL
",",158,O
triazine,158,B-CHEMICAL
",",158,O
cinchoninic,158,B-CHEMICAL
acid,158,I-CHEMICAL
and,158,O
(,158,B-CHEMICAL
naphtho,158,I-CHEMICAL
),158,I-CHEMICAL
quinone,158,I-CHEMICAL
derivatives,158,O
",",158,O
which,158,O
exerted,158,O
antiproliferative,158,O
",",158,O
immunosuppressive,158,O
",",158,O
and,158,O
antiparasitic,158,O
effects,158,O
.,158,O
Despite,159,O
this,159,O
broad,159,O
spectrum,159,O
of,159,O
biological,159,O
and,159,O
clinical,159,O
relevance,159,O
",",159,O
there,159,O
have,159,O
been,159,O
no,159,O
comparative,159,O
studies,159,O
on,159,O
drug-dihydroorotate,159,O
dehydrogenase,159,I-GENE-Y
interactions,159,O
.,159,O
Here,160,O
",",160,O
we,160,O
describe,160,O
a,160,O
study,160,O
of,160,O
the,160,O
inhibition,160,O
of,160,O
the,160,O
purified,160,O
recombinant,160,O
human,160,B-GENE-N
and,160,I-GENE-N
rat,160,I-GENE-N
dihydroorotate,160,I-GENE-N
dehydrogenase,160,I-GENE-N
by,160,O
ten,160,O
compounds,160,O
.,160,O
"1,4-Naphthoquinone",161,B-CHEMICAL
",",161,O
"5,8-hydroxy-naphthoquinone",161,B-CHEMICAL
and,161,O
the,161,O
natural,161,O
compounds,161,O
juglon,161,B-CHEMICAL
",",161,O
plumbagin,161,B-CHEMICAL
and,161,O
polyporic,161,B-CHEMICAL
acid,161,I-CHEMICAL
(,161,O
quinone,161,B-CHEMICAL
derivative,161,O
),161,O
were,161,O
found,161,O
to,161,O
function,161,O
as,161,O
alternative,161,O
electron,161,O
acceptors,161,O
with,161,O
10-30,161,O
%,161,O
of,161,O
control,161,O
enzyme,161,O
activity,161,O
.,161,O
The,162,O
human,162,O
and,162,O
rat,162,O
enzyme,162,O
activity,162,O
was,162,O
decreased,162,O
by,162,O
50,162,O
%,162,O
by,162,O
the,162,O
natural,162,O
compound,162,O
lawsone,162,B-CHEMICAL
(,162,O
>,162,O
500,162,O
and,162,O
49,162,O
microM,162,O
",",162,O
respectively,162,O
),162,O
and,162,O
by,162,O
the,162,O
derivatives,162,O
dichloroally-lawsone,162,B-CHEMICAL
(,162,O
67,162,O
and,162,O
10,162,O
nM,162,O
),162,O
",",162,O
lapachol,162,B-CHEMICAL
(,162,O
618,162,O
and,162,O
61,162,O
nM,162,O
),162,O
and,162,O
atovaquone,162,B-CHEMICAL
(,162,O
15,162,O
microM,162,O
and,162,O
698,162,O
nM,162,O
),162,O
.,162,O
With,163,O
respect,163,O
to,163,O
the,163,O
quinone,163,B-CHEMICAL
co-substrate,163,O
of,163,O
the,163,O
dihydroorotate,163,B-CHEMICAL
dehydrogenase,163,I-GENE-Y
",",163,O
atovaquone,163,B-CHEMICAL
(,163,O
Kic,163,O
=,163,O
2.7,163,O
microM,163,O
),163,O
and,163,O
dichloroally-lawsone,163,B-CHEMICAL
(,163,O
Kic,163,O
=,163,O
9.8,163,O
nM,163,O
),163,O
were,163,O
shown,163,O
to,163,O
be,163,O
competitive,163,O
inhibitors,163,O
of,163,O
human,163,B-GENE-Y
dihydroorotate,163,B-CHEMICAL
dehydrogenase,163,I-GENE-Y
.,163,O
Atovaquone,164,B-CHEMICAL
(,164,O
Kic,164,O
=,164,O
60,164,O
nM,164,O
),164,O
was,164,O
also,164,O
acompetitive,164,O
inhibitor,164,O
of,164,O
the,164,O
rat,164,O
enzyme,164,O
.,164,O
Dichloroally,165,B-CHEMICAL
],165,I-CHEMICAL
-lawsone,165,I-CHEMICAL
was,165,O
found,165,O
to,165,O
be,165,O
a,165,O
time-dependent,165,O
inhibitor,165,O
of,165,O
the,165,O
rat,165,O
enzyme,165,O
",",165,O
with,165,O
the,165,O
lowest,165,O
inhibition,165,O
constant,165,O
(,165,O
Ki,165,O
*,165,O
=,165,O
0.77,165,O
nM,165,O
),165,O
determined,165,O
so,165,O
far,165,O
for,165,O
mammalian,165,B-GENE-N
dihydroorotate,165,I-GENE-N
dehydrogenases,165,I-GENE-N
.,165,O
Another,166,O
inhibitor,166,O
",",166,O
brequinar,166,B-CHEMICAL
was,166,O
previously,166,O
reported,166,O
to,166,O
be,166,O
a,166,O
slow-binding,166,O
inhibitor,166,O
of,166,O
the,166,O
human,166,B-GENE-Y
dihydroorotate,166,I-GENE-Y
dehydrogenase,166,I-GENE-Y
[,166,O
W.,166,O
Knecht,166,O
",",166,O
M.,166,O
Loffler,166,O
",",166,O
Species-related,166,O
inhibition,166,O
of,166,O
human,166,B-GENE-N
and,166,I-GENE-N
rat,166,I-GENE-N
dihyroorotate,166,I-GENE-N
dehydrogenase,166,I-GENE-N
by,166,O
immunosuppressive,166,O
isoxazol,166,B-CHEMICAL
and,166,O
cinchoninic,166,B-CHEMICAL
acid,166,I-CHEMICAL
derivatives,166,O
",",166,O
Biochem,166,O
.,166,O
Pharmacol,167,O
.,167,O
56,168,O
(,168,O
1998,168,O
),168,O
1259-1264,168,O
],168,O
.,168,O
The,169,O
slow,169,O
binding,169,O
features,169,O
of,169,O
this,169,O
potent,169,O
inhibitor,169,O
(,169,O
Ki,169,O
*,169,O
=,169,O
1.8,169,O
nM,169,O
),169,O
with,169,O
the,169,O
human,169,O
enzyme,169,O
",",169,O
were,169,O
verified,169,O
and,169,O
seen,169,O
to,169,O
be,169,O
one,169,O
of,169,O
the,169,O
reasons,169,O
for,169,O
the,169,O
narrow,169,O
therapeutic,169,O
window,169,O
(,169,O
efficacy,169,O
versus,169,O
toxicity,169,O
),169,O
reported,169,O
from,169,O
clinical,169,O
trials,169,O
on,169,O
its,169,O
antiproliferative,169,O
and,169,O
immunosuppressive,169,O
action,169,O
.,169,O
With,170,O
respect,170,O
to,170,O
the,170,O
substrate,170,O
dihydroorotate,170,B-CHEMICAL
",",170,O
atovaquone,170,B-CHEMICAL
was,170,O
an,170,O
uncompetitive,170,O
inhibitor,170,O
of,170,O
human,170,B-GENE-Y
dihydroorotate,170,I-GENE-Y
dehydrogenase,170,I-GENE-Y
(,170,O
Kiu,170,O
=,170,O
11.6,170,O
microM,170,O
),170,O
and,170,O
a,170,O
non-competitive,170,O
inhibitor,170,O
of,170,O
the,170,O
rat,170,O
enzyme,170,O
(,170,O
Kiu,170,O
=,170,O
905/,170,O
Kic,170,O
=,170,O
"1,012",170,O
nM,170,O
),170,O
.,170,O
1.5,171,O
mM,171,O
polyporic,171,B-CHEMICAL
acid,171,I-CHEMICAL
",",171,O
a,171,O
natural,171,O
quinone,171,B-CHEMICAL
from,171,O
fungi,171,O
",",171,O
influenced,171,O
the,171,O
activity,171,O
of,171,O
the,171,O
human,171,O
enzyme,171,O
only,171,O
slightly,171,O
;,171,O
the,171,O
activity,171,O
of,171,O
the,171,O
rat,171,O
enzyme,171,O
was,171,O
decreased,171,O
by,171,O
30,171,O
%,171,O
.,171,O
Sodium,172,B-GENE-N
channel,172,I-GENE-N
blockers,172,O
identify,172,O
risk,172,O
for,172,O
sudden,172,O
death,172,O
in,172,O
patients,172,O
with,172,O
ST-segment,172,O
elevation,172,O
and,172,O
right,172,O
bundle,172,O
branch,172,O
block,172,O
but,172,O
structurally,172,O
normal,172,O
hearts,172,O
.,172,O
BACKGROUND,173,O
:,173,O
A,173,O
mutation,173,O
in,173,O
the,173,O
cardiac,173,B-GENE-N
sodium,173,B-CHEMICAL
channel,173,I-GENE-N
gene,173,O
(,173,O
SCN5A,173,B-GENE-Y
),173,O
has,173,O
been,173,O
described,173,O
in,173,O
patients,173,O
with,173,O
the,173,O
syndrome,173,O
of,173,O
right,173,O
bundle,173,O
branch,173,O
block,173,O
",",173,O
ST-segment,173,O
elevation,173,O
in,173,O
leads,173,O
V1,173,O
to,173,O
V3,173,O
",",173,O
and,173,O
sudden,173,O
death,173,O
(,173,O
Brugada,173,O
syndrome,173,O
),173,O
.,173,O
These,174,O
electrocardiographic,174,O
manifestations,174,O
are,174,O
transient,174,O
in,174,O
many,174,O
patients,174,O
with,174,O
the,174,O
syndrome,174,O
.,174,O
The,175,O
present,175,O
study,175,O
examined,175,O
arrhythmic,175,O
risk,175,O
in,175,O
patients,175,O
with,175,O
overt,175,O
and,175,O
concealed,175,O
forms,175,O
of,175,O
the,175,O
disease,175,O
and,175,O
the,175,O
effectiveness,175,O
of,175,O
sodium,175,B-CHEMICAL
channel,175,I-GENE-N
blockers,175,O
to,175,O
unmask,175,O
the,175,O
syndrome,175,O
and,175,O
",",175,O
thus,175,O
",",175,O
identify,175,O
patients,175,O
at,175,O
risk,175,O
.,175,O
METHODS,176,O
AND,176,O
RESULTS,176,O
:,176,O
The,176,O
effect,176,O
of,176,O
intravenous,176,O
ajmaline,176,B-CHEMICAL
(,176,O
1,176,O
mg/kg,176,O
),176,O
",",176,O
procainamide,176,B-CHEMICAL
(,176,O
10,176,O
mg/kg,176,O
),176,O
",",176,O
or,176,O
flecainide,176,B-CHEMICAL
(,176,O
2,176,O
mg/kg,176,O
),176,O
on,176,O
the,176,O
ECG,176,O
was,176,O
studied,176,O
in,176,O
34,176,O
patients,176,O
with,176,O
the,176,O
syndrome,176,O
and,176,O
transient,176,O
normalization,176,O
of,176,O
the,176,O
ECG,176,O
(,176,O
group,176,O
A,176,O
),176,O
",",176,O
11,176,O
members,176,O
of,176,O
3,176,O
families,176,O
in,176,O
whom,176,O
a,176,O
SCN5A,176,B-GENE-Y
mutation,176,O
was,176,O
associated,176,O
with,176,O
the,176,O
syndrome,176,O
and,176,O
8,176,O
members,176,O
in,176,O
whom,176,O
it,176,O
was,176,O
not,176,O
(,176,O
group,176,O
B,176,O
),176,O
",",176,O
and,176,O
53,176,O
control,176,O
subjects,176,O
(,176,O
group,176,O
C,176,O
),176,O
.,176,O
Ajmaline,177,B-CHEMICAL
",",177,O
procainamide,177,B-CHEMICAL
",",177,O
or,177,O
flecainide,177,B-CHEMICAL
administration,177,O
resulted,177,O
in,177,O
ST-segment,177,O
elevation,177,O
and,177,O
right,177,O
bundle,177,O
branch,177,O
block,177,O
in,177,O
all,177,O
patients,177,O
in,177,O
group,177,O
A,177,O
and,177,O
in,177,O
all,177,O
11,177,O
patients,177,O
with,177,O
the,177,O
mutation,177,O
in,177,O
group,177,O
B,177,O
.,177,O
A,178,O
similar,178,O
pattern,178,O
could,178,O
not,178,O
be,178,O
elicited,178,O
in,178,O
the,178,O
8,178,O
patients,178,O
in,178,O
group,178,O
B,178,O
who,178,O
lacked,178,O
the,178,O
mutation,178,O
or,178,O
in,178,O
any,178,O
person,178,O
in,178,O
group,178,O
C.,178,O
The,178,O
follow-up,178,O
period,178,O
(,178,O
37+/-33,178,O
months,178,O
),178,O
revealed,178,O
no,178,O
differences,178,O
in,178,O
the,178,O
incidence,178,O
of,178,O
arrhythmia,178,O
between,178,O
the,178,O
34,178,O
patients,178,O
in,178,O
whom,178,O
the,178,O
phenotypic,178,O
manifestation,178,O
of,178,O
the,178,O
syndrome,178,O
was,178,O
transient,178,O
and,178,O
the,178,O
24,178,O
patients,178,O
in,178,O
whom,178,O
it,178,O
was,178,O
persistent,178,O
(,178,O
log-rank,178,O
",",178,O
0.639,178,O
),178,O
.,178,O
CONCLUSIONS,179,O
:,179,O
The,179,O
data,179,O
demonstrated,179,O
a,179,O
similar,179,O
incidence,179,O
of,179,O
potentially,179,O
lethal,179,O
arrhythmias,179,O
in,179,O
patients,179,O
displaying,179,O
transient,179,O
versus,179,O
persistent,179,O
ST-segment,179,O
elevation,179,O
and,179,O
right,179,O
bundle,179,O
branch,179,O
block,179,O
",",179,O
as,179,O
well,179,O
as,179,O
the,179,O
effectiveness,179,O
of,179,O
sodium,179,B-CHEMICAL
channel,179,I-GENE-N
blockers,179,O
to,179,O
unmask,179,O
the,179,O
syndrome,179,O
and,179,O
",",179,O
thus,179,O
",",179,O
identify,179,O
patients,179,O
at,179,O
risk,179,O
.,179,O
Determinants,180,O
of,180,O
voltage-dependent,180,O
inactivation,180,O
affect,180,O
Mibefradil,180,B-CHEMICAL
block,180,O
of,180,O
calcium,180,B-GENE-N
channels,180,I-GENE-N
.,180,O
The,181,O
voltage,181,B-GENE-N
gated,181,I-GENE-N
calcium,181,B-CHEMICAL
channel,181,I-GENE-N
family,181,O
is,181,O
a,181,O
major,181,O
target,181,O
for,181,O
a,181,O
range,181,O
of,181,O
therapeutic,181,O
drugs,181,O
.,181,O
Mibefradil,182,B-CHEMICAL
(,182,O
Ro,182,B-CHEMICAL
40-5967,182,I-CHEMICAL
),182,O
belongs,182,O
to,182,O
a,182,O
new,182,O
chemical,182,O
class,182,O
of,182,O
these,182,O
molecules,182,O
which,182,O
differs,182,O
from,182,O
other,182,O
Ca2+,182,B-CHEMICAL
antagonists,182,O
by,182,O
its,182,O
ability,182,O
to,182,O
potently,182,O
block,182,O
T-type,182,B-GENE-N
Ca2+,182,B-CHEMICAL
channels,182,I-GENE-N
.,182,O
However,183,O
",",183,O
this,183,O
molecule,183,O
has,183,O
also,183,O
been,183,O
shown,183,O
to,183,O
inhibit,183,O
other,183,O
Ca2+,183,B-CHEMICAL
channel,183,I-GENE-N
subtypes,183,O
.,183,O
To,184,O
further,184,O
analyze,184,O
the,184,O
mechanism,184,O
governing,184,O
the,184,O
Ca2+,184,B-CHEMICAL
channel-Mibefradil,184,O
interaction,184,O
",",184,O
we,184,O
examined,184,O
the,184,O
effect,184,O
of,184,O
Mibefradil,184,B-CHEMICAL
on,184,O
various,184,O
recombinant,184,O
Ca2+,184,B-GENE-N
channels,184,I-GENE-N
expressed,184,O
in,184,O
mammalian,184,O
cells,184,O
from,184,O
their,184,O
cloned,184,O
cDNAs,184,O
",",184,O
using,184,O
Ca2+,184,B-CHEMICAL
as,184,O
the,184,O
permeant,184,O
ion,184,O
at,184,O
physiological,184,O
concentration,184,O
.,184,O
Expression,185,O
of,185,O
alpha1A,185,O
",",185,O
alpha1C,185,O
",",185,O
and,185,O
alpha1E,185,O
in,185,O
tsA,185,O
201,185,O
cells,185,O
resulted,185,O
in,185,O
Ca2+,185,B-CHEMICAL
currents,185,O
with,185,O
functional,185,O
characteristics,185,O
closely,185,O
related,185,O
to,185,O
those,185,O
of,185,O
their,185,O
native,185,O
counterparts,185,O
.,185,O
Mibefradil,186,B-CHEMICAL
blocked,186,O
alpha1A,186,O
and,186,O
alpha1E,186,O
with,186,O
a,186,O
Kd,186,O
comparable,186,O
to,186,O
that,186,O
reported,186,O
for,186,O
T-type,186,B-GENE-N
channels,186,I-GENE-N
",",186,O
but,186,O
had,186,O
a,186,O
lower,186,O
affinity,186,O
(,186,O
approximately,186,O
30-fold,186,O
),186,O
for,186,O
alpha1C,186,O
.,186,O
For,187,O
each,187,O
channel,187,O
",",187,O
inhibition,187,O
by,187,O
Mibefradil,187,B-CHEMICAL
was,187,O
consistent,187,O
with,187,O
high-affinity,187,O
binding,187,O
to,187,O
the,187,O
inactivated,187,O
state,187,O
.,187,O
Modulation,188,O
of,188,O
the,188,O
voltage-dependent,188,O
inactivation,188,O
properties,188,O
by,188,O
the,188,O
nature,188,O
of,188,O
the,188,O
coexpressed,188,O
beta,188,O
subunit,188,O
or,188,O
the,188,O
alpha1,188,O
splice,188,O
variant,188,O
altered,188,O
block,188,O
at,188,O
the,188,O
Mibefradil,188,B-CHEMICAL
receptor,188,O
site,188,O
.,188,O
Therefore,189,O
",",189,O
we,189,O
conclude,189,O
that,189,O
the,189,O
tissue,189,O
and,189,O
sub-cellular,189,O
localization,189,O
of,189,O
calcium,189,B-CHEMICAL
channel,189,I-GENE-N
subunits,189,O
as,189,O
well,189,O
as,189,O
their,189,O
specific,189,O
associations,189,O
are,189,O
essential,189,O
parameters,189,O
to,189,O
understand,189,O
the,189,O
in,189,O
vivo,189,O
effects,189,O
of,189,O
Mibefradil,189,B-CHEMICAL
.,189,O
Use,190,O
of,190,O
tranexamic,190,B-CHEMICAL
acid,190,I-CHEMICAL
for,190,O
an,190,O
effective,190,O
blood,190,O
conservation,190,O
strategy,190,O
after,190,O
total,190,O
knee,190,O
arthroplasty,190,O
.,190,O
We,191,O
have,191,O
investigated,191,O
the,191,O
effect,191,O
of,191,O
treatment,191,O
with,191,O
tranexamic,191,B-CHEMICAL
acid,191,I-CHEMICAL
",",191,O
an,191,O
inhibitor,191,O
of,191,O
fibrinolysis,191,O
",",191,O
on,191,O
blood,191,O
loss,191,O
",",191,O
blood,191,O
transfusion,191,O
requirements,191,O
and,191,O
blood,191,O
coagulation,191,O
in,191,O
a,191,O
randomized,191,O
",",191,O
double-blind,191,O
",",191,O
placebo-controlled,191,O
study,191,O
of,191,O
42,191,O
patients,191,O
after,191,O
total,191,O
knee,191,O
arthroplasty,191,O
.,191,O
Tranexamic,192,B-CHEMICAL
acid,192,I-CHEMICAL
15,192,O
mg,192,O
kg-1,192,O
(,192,O
n,192,O
=,192,O
21,192,O
),192,O
or,192,O
an,192,O
equivalent,192,O
volume,192,O
of,192,O
normal,192,O
saline,192,O
(,192,O
n,192,O
=,192,O
21,192,O
),192,O
was,192,O
given,192,O
30,192,O
min,192,O
before,192,O
surgery,192,O
and,192,O
subsequently,192,O
every,192,O
8,192,O
h,192,O
for,192,O
3,192,O
days,192,O
.,192,O
Coagulation,193,O
and,193,O
fibrinolysis,193,O
values,193,O
",",193,O
blood,193,O
loss,193,O
and,193,O
blood,193,O
units,193,O
administered,193,O
were,193,O
measured,193,O
before,193,O
administration,193,O
of,193,O
tranexamic,193,B-CHEMICAL
acid,193,I-CHEMICAL
",",193,O
8,193,O
h,193,O
after,193,O
the,193,O
end,193,O
of,193,O
surgery,193,O
and,193,O
at,193,O
24,193,O
and,193,O
72,193,O
h,193,O
after,193,O
operation,193,O
.,193,O
Coagulation,194,O
profile,194,O
was,194,O
examined,194,O
(,194,O
bleeding,194,O
time,194,O
",",194,O
platelet,194,O
count,194,O
",",194,O
prothrombin,194,B-GENE-Y
time,194,O
(,194,O
PT,194,O
),194,O
",",194,O
activated,194,O
partial,194,O
thromboplastin,194,B-GENE-Y
time,194,O
(,194,O
aPTT,194,O
),194,O
",",194,O
plasminogen,194,B-GENE-Y
",",194,O
beta-thromboglobulin,194,B-GENE-Y
and,194,O
fibrinogen,194,B-GENE-N
),194,O
.,194,O
Fibrinolysis,195,O
was,195,O
evaluated,195,O
by,195,O
measurement,195,O
of,195,O
concentrations,195,O
of,195,O
D-dimer,195,O
and,195,O
fibrinogen,195,B-GENE-N
degradation,195,I-GENE-N
products,195,I-GENE-N
(,195,O
FDP,195,B-GENE-N
),195,O
.,195,O
Total,196,O
blood,196,O
loss,196,O
in,196,O
the,196,O
tranexamic,196,B-CHEMICAL
acid,196,I-CHEMICAL
group,196,O
was,196,O
678,196,O
(,196,O
SD,196,O
352,196,O
),196,O
ml,196,O
compared,196,O
with,196,O
1419,196,O
(,196,O
607,196,O
),196,O
ml,196,O
in,196,O
the,196,O
control,196,O
group,196,O
(,196,O
P,196,O
<,196,O
0.001,196,O
),196,O
",",196,O
and,196,O
occurred,196,O
primarily,196,O
during,196,O
the,196,O
first,196,O
24,196,O
h,196,O
after,196,O
surgery,196,O
.,196,O
Thirteen,197,O
patients,197,O
received,197,O
1-5,197,O
u.,197,O
of,197,O
packed,197,O
red,197,O
blood,197,O
cells,197,O
in,197,O
the,197,O
control,197,O
group,197,O
compared,197,O
with,197,O
two,197,O
patients,197,O
in,197,O
the,197,O
tranexamic,197,B-CHEMICAL
acid,197,I-CHEMICAL
group,197,O
",",197,O
who,197,O
received,197,O
3,197,O
u,197,O
.,197,O
(,198,O
P,198,O
<,198,O
0.001,198,O
),198,O
.,198,O
Postoperative,199,O
packed,199,O
cell,199,O
volume,199,O
values,199,O
were,199,O
higher,199,O
in,199,O
the,199,O
tranexamic,199,B-CHEMICAL
acid,199,I-CHEMICAL
group,199,O
despite,199,O
fewer,199,O
blood,199,O
transfusions,199,O
.,199,O
Postoperative,200,O
concentrations,200,O
of,200,O
plasminogen,200,B-GENE-Y
were,200,O
decreased,200,O
significantly,200,O
in,200,O
the,200,O
tranexamic,200,B-CHEMICAL
acid,200,I-CHEMICAL
group,200,O
(,200,O
P,200,O
<,200,O
0.001,200,O
),200,O
.,200,O
Platelet,201,O
count,201,O
",",201,O
PT,201,O
",",201,O
aPTT,201,O
",",201,O
bleeding,201,O
time,201,O
",",201,O
beta-thromboglobulin,201,B-GENE-Y
",",201,O
fibrinogen,201,B-GENE-N
and,201,O
FDP,201,B-GENE-N
concentrations,201,O
did,201,O
not,201,O
differ,201,O
between,201,O
groups,201,O
",",201,O
but,201,O
D-dimer,201,O
concentrations,201,O
were,201,O
increased,201,O
in,201,O
the,201,O
control,201,O
group,201,O
.,201,O
Thromboembolic,202,O
complications,202,O
occurred,202,O
in,202,O
two,202,O
patients,202,O
in,202,O
the,202,O
control,202,O
group,202,O
compared,202,O
with,202,O
none,202,O
in,202,O
the,202,O
tranexamic,202,B-CHEMICAL
acid,202,I-CHEMICAL
group,202,O
.,202,O
Correlations,203,O
between,203,O
serotonin,203,B-CHEMICAL
level,203,O
and,203,O
single-cell,203,O
firing,203,O
in,203,O
the,203,O
rat,203,O
's,203,O
nucleus,203,O
raphe,203,O
magnus,203,O
.,203,O
The,204,O
relation,204,O
between,204,O
serotonin,204,B-CHEMICAL
release,204,O
and,204,O
electrical,204,O
activity,204,O
was,204,O
examined,204,O
in,204,O
the,204,O
nucleus,204,O
raphe,204,O
magnus,204,O
of,204,O
rats,204,O
anesthetized,204,O
with,204,O
pentobarbital,204,B-CHEMICAL
.,204,O
Serotonin,205,B-CHEMICAL
levels,205,O
were,205,O
monitored,205,O
through,205,O
a,205,O
carbon-fiber,205,B-CHEMICAL
microelectrode,205,O
by,205,O
fast,205,O
cyclic,205,O
voltammetry,205,O
(,205,O
usually,205,O
at,205,O
1,205,O
Hz,205,O
),205,O
.,205,O
Single-cell,206,O
firing,206,O
was,206,O
recorded,206,O
through,206,O
the,206,O
same,206,O
microelectrode,206,O
",",206,O
except,206,O
during,206,O
the,206,O
voltammetry,206,O
waveform,206,O
and,206,O
associated,206,O
electrical,206,O
artifact,206,O
(,206,O
totaling,206,O
about,206,O
30,206,O
ms,206,O
),206,O
.,206,O
Multi-barrel,207,O
micropipettes,207,O
incorporating,207,O
the,207,O
voltammetry,207,O
electrode,207,O
were,207,O
used,207,O
for,207,O
iontophoresis,207,O
of,207,O
drugs,207,O
.,207,O
Cells,208,O
were,208,O
inhibited,208,O
",",208,O
excited,208,O
or,208,O
unaffected,208,O
by,208,O
noxious,208,O
mechanical,208,O
skin,208,O
stimulation,208,O
.,208,O
These,209,O
were,209,O
respectively,209,O
designated,209,O
as,209,O
off,209,O
(,209,O
M,209,O
),209,O
cells,209,O
",",209,O
on,209,O
(,209,O
M,209,O
),209,O
cells,209,O
and,209,O
neutral,209,O
(,209,O
M,209,O
),209,O
cells,209,O
",",209,O
M,209,O
denoting,209,O
mechanical,209,O
.,209,O
During,210,O
3,210,O
min,210,O
of,210,O
pinching,210,O
",",210,O
serotonin,210,B-CHEMICAL
slowly,210,O
rose,210,O
near,210,O
seven,210,O
of,210,O
14,210,O
on,210,O
(,210,O
M,210,O
),210,O
cells,210,O
and,210,O
26,210,O
of,210,O
46,210,O
off,210,O
(,210,O
M,210,O
),210,O
cells,210,O
;,210,O
it,210,O
fell,210,O
near,210,O
two,210,O
off,210,O
(,210,O
M,210,O
),210,O
cells,210,O
;,210,O
it,210,O
was,210,O
unchanged,210,O
near,210,O
all,210,O
other,210,O
cells,210,O
",",210,O
including,210,O
six,210,O
neutral,210,O
(,210,O
M,210,O
),210,O
cells,210,O
.,210,O
On,211,O
a,211,O
finer,211,O
spatiotemporal,211,O
scale,211,O
",",211,O
near,211,O
four,211,O
of,211,O
seven,211,O
on,211,O
(,211,O
M,211,O
),211,O
cells,211,O
",",211,O
10,211,O
of,211,O
14,211,O
off,211,O
(,211,O
M,211,O
),211,O
cells,211,O
and,211,O
0,211,O
of,211,O
four,211,O
neutral,211,O
(,211,O
M,211,O
),211,O
cells,211,O
",",211,O
average,211,O
serotonin,211,B-CHEMICAL
levels,211,O
fell,211,O
significantly,211,O
within,211,O
+/-,211,O
100,211,O
ms,211,O
of,211,O
spontaneous,211,O
spikes,211,O
.,211,O
Lower,212,O
serotonin,212,B-CHEMICAL
may,212,O
have,212,O
caused,212,O
the,212,O
higher,212,O
spike,212,O
probability,212,O
;,212,O
the,212,O
converse,212,O
is,212,O
theoretically,212,O
unlikely,212,O
",",212,O
since,212,O
delays,212,O
between,212,O
release,212,O
and,212,O
detection,212,O
are,212,O
estimated,212,O
to,212,O
exceed,212,O
100,212,O
ms,212,O
.,212,O
Increased,213,O
serotonin,213,B-CHEMICAL
and,213,O
decreased,213,O
firing,213,O
were,213,O
always,213,O
seen,213,O
following,213,O
iontophoresis,213,O
or,213,O
intravenous,213,O
injection,213,O
(,213,O
1,213,O
mg/kg,213,O
),213,O
of,213,O
the,213,O
serotonin,213,B-CHEMICAL
re-uptake,213,O
inhibitor,213,O
clomipramine,213,B-CHEMICAL
(,213,O
n,213,O
=,213,O
7,213,O
),213,O
.,213,O
Iontophoresis,214,O
of,214,O
+/-,214,B-CHEMICAL
propranolol,214,I-CHEMICAL
",",214,O
whose,214,O
serotonergic,214,O
actions,214,O
include,214,O
antagonism,214,O
and,214,O
partial,214,O
agonism,214,O
at,214,O
5-HT1,214,B-GENE-N
receptors,214,O
",",214,O
also,214,O
increased,214,O
serotonin,214,B-CHEMICAL
and,214,O
decreased,214,O
firing,214,O
(,214,O
n=4,214,O
),214,O
.,214,O
Methiothepin,215,B-CHEMICAL
(,215,O
intravenous,215,O
",",215,O
1,215,O
mg/kg,215,O
),215,O
",",215,O
whose,215,O
serotonergic,215,O
actions,215,O
include,215,O
5-HT1,215,B-GENE-N
and,215,O
5-HT2,215,B-GENE-N
antagonism,215,O
",",215,O
typically,215,O
raised,215,O
serotonin,215,B-CHEMICAL
levels,215,O
(,215,O
four,215,O
of,215,O
five,215,O
cells,215,O
),215,O
and,215,O
always,215,O
blocked,215,O
inhibition,215,O
by,215,O
clomipramine,215,B-CHEMICAL
(,215,O
n,215,O
=,215,O
3,215,O
),215,O
.,215,O
Iontophoresis,216,O
of,216,O
glutamate,216,B-CHEMICAL
always,216,O
lowered,216,O
serotonin,216,B-CHEMICAL
and,216,O
increased,216,O
firing,216,O
(,216,O
n,216,O
=,216,O
4,216,O
),216,O
.,216,O
Since,217,O
serotonin,217,B-CHEMICAL
levels,217,O
and,217,O
firing,217,O
were,217,O
usually,217,O
inversely,217,O
correlated,217,O
",",217,O
except,217,O
near,217,O
on,217,O
(,217,O
M,217,O
),217,O
cells,217,O
during,217,O
pinch,217,O
",",217,O
we,217,O
propose,217,O
that,217,O
serotonin,217,B-CHEMICAL
is,217,O
released,217,O
from,217,O
terminals,217,O
of,217,O
incoming,217,O
nociceptive,217,O
afferents,217,O
.,217,O
Prior,218,O
neuroanatomical,218,O
knowledge,218,O
favors,218,O
a,218,O
midbrain,218,O
origin,218,O
for,218,O
these,218,O
afferents,218,O
",",218,O
while,218,O
some,218,O
of,218,O
the,218,O
drug,218,O
findings,218,O
suggest,218,O
that,218,O
their,218,O
terminals,218,O
possess,218,O
inhibitory,218,O
serotonergic,218,O
autoreceptors,218,O
",",218,O
possibly,218,O
of,218,O
5-HT1b,218,B-GENE-Y
subtype,218,O
.,218,O
The,219,O
released,219,O
serotonin,219,B-CHEMICAL
could,219,O
contribute,219,O
to,219,O
the,219,O
inhibition,219,O
of,219,O
off,219,O
(,219,O
M,219,O
),219,O
cells,219,O
and,219,O
excitation,219,O
of,219,O
on,219,O
(,219,O
M,219,O
),219,O
cells,219,O
by,219,O
noxious,219,O
stimulation,219,O
",",219,O
since,219,O
inhibitory,219,O
5-HT1a,219,B-GENE-Y
receptors,219,O
and,219,O
excitatory,219,O
5-HT2,219,B-GENE-N
receptors,219,O
",",219,O
respectively,219,O
",",219,O
have,219,O
previously,219,O
been,219,O
shown,219,O
to,219,O
dominate,219,O
their,219,O
serotonergic,219,O
responses,219,O
.,219,O
The,220,O
Hsp90-specific,220,B-GENE-N
inhibitor,220,O
geldanamycin,220,B-CHEMICAL
selectively,220,O
disrupts,220,O
kinase-mediated,220,B-GENE-N
signaling,220,O
events,220,O
of,220,O
T-lymphocyte,220,O
activation,220,O
.,220,O
The,221,O
90-kDa,221,B-GENE-N
heat,221,I-GENE-N
shock,221,I-GENE-N
protein,221,I-GENE-N
(,221,O
Hsp90,221,B-GENE-N
),221,O
is,221,O
the,221,O
most,221,O
abundant,221,O
molecular,221,B-GENE-N
chaperone,221,I-GENE-N
of,221,O
eukaryotic,221,O
cells,221,O
.,221,O
Its,222,O
chaperone,222,O
function,222,O
in,222,O
folding,222,O
nascent,222,O
proteins,222,O
seems,222,O
to,222,O
be,222,O
restricted,222,O
to,222,O
a,222,O
subset,222,O
of,222,O
proteins,222,O
including,222,O
major,222,O
components,222,O
of,222,O
signal,222,O
transduction,222,O
pathways,222,O
(,222,O
eg,222,O
",",222,O
nuclear,222,B-GENE-N
hormone,222,I-GENE-N
receptors,222,I-GENE-N
",",222,O
transcription,222,O
factors,222,O
",",222,O
and,222,O
protein,222,B-GENE-N
kinases,222,I-GENE-N
),222,O
.,222,O
Improper,223,O
function,223,O
of,223,O
these,223,O
proteins,223,O
can,223,O
be,223,O
induced,223,O
by,223,O
selective,223,O
disruption,223,O
of,223,O
their,223,O
complexes,223,O
with,223,O
Hsp90,223,B-GENE-N
using,223,O
the,223,O
benzoquinonoid,223,B-CHEMICAL
ansamycin,223,I-CHEMICAL
geldanamycin,223,B-CHEMICAL
.,223,O
In,224,O
this,224,O
study,224,O
",",224,O
we,224,O
demonstrate,224,O
that,224,O
geldanamycin,224,B-CHEMICAL
treatment,224,O
blocks,224,O
interleukin,224,B-GENE-Y
(,224,I-GENE-Y
IL,224,I-GENE-Y
),224,I-GENE-Y
-2,224,I-GENE-Y
secretion,224,O
",",224,O
IL-2,224,B-GENE-N
receptor,224,I-GENE-N
expression,224,O
",",224,O
and,224,O
proliferation,224,O
of,224,O
stimulated,224,O
T-lymphocytes,224,O
.,224,O
Moreover,225,O
",",225,O
geldanamycin,225,B-CHEMICAL
decreases,225,O
the,225,O
amount,225,O
and,225,O
phosphorylation,225,O
of,225,O
Lck,225,B-GENE-Y
and,225,O
Raf-1,225,B-GENE-Y
kinases,225,B-GENE-N
and,225,O
prevents,225,O
activation,225,O
of,225,O
the,225,O
extracellular,225,B-GENE-Y
signal,225,I-GENE-Y
regulated,225,I-GENE-Y
kinase,225,I-GENE-Y
(,225,I-GENE-Y
ERK,225,I-GENE-Y
),225,I-GENE-Y
-2,225,I-GENE-Y
kinase,225,B-GENE-N
.,225,O
Geldanamycin,226,B-CHEMICAL
also,226,O
disrupts,226,O
the,226,O
T-cell,226,B-GENE-N
receptor-mediated,226,O
activation,226,O
of,226,O
nuclear,226,B-GENE-N
factor,226,I-GENE-N
of,226,I-GENE-N
activated,226,I-GENE-N
T-cells,226,I-GENE-N
(,226,O
NF-AT,226,B-GENE-N
),226,O
.,226,O
Treatment,227,O
with,227,O
geldanamycin,227,B-CHEMICAL
",",227,O
however,227,O
",",227,O
does,227,O
not,227,O
affect,227,O
the,227,O
activation,227,O
of,227,O
lysophosphatide,227,B-GENE-N
acyltransferase,227,I-GENE-N
",",227,O
which,227,O
is,227,O
a,227,O
plasma,227,O
membrane,227,O
enzyme,227,O
coupled,227,O
to,227,O
the,227,O
T-cell,227,B-GENE-N
receptor,227,I-GENE-N
after,227,O
T-cell,227,O
stimulation,227,O
.,227,O
Through,228,O
demonstrating,228,O
the,228,O
selective,228,O
inhibition,228,O
of,228,O
kinase-related,228,B-GENE-N
T-lymphocyte,228,O
responses,228,O
by,228,O
geldanamycin,228,B-CHEMICAL
",",228,O
our,228,O
results,228,O
emphasize,228,O
the,228,O
substantial,228,O
role,228,O
of,228,O
Hsp90-kinase,228,B-GENE-N
complexes,228,O
in,228,O
T-cell,228,O
activation,228,O
.,228,O
Carnitine,229,B-CHEMICAL
biosynthesis,229,O
.,229,O
Purification,230,O
of,230,O
gamma-butyrobetaine,230,B-GENE-Y
hydroxylase,230,I-GENE-Y
from,230,O
rat,230,O
liver,230,O
.,230,O
gamma-Butyrobetaine,231,B-CHEMICAL
hydroxylase,231,I-GENE-Y
catalyse,231,O
the,231,O
last,231,O
step,231,O
in,231,O
carnitine,231,B-CHEMICAL
biosynthesis,231,O
",",231,O
the,231,O
formation,231,O
of,231,O
L-carnitine,231,B-CHEMICAL
from,231,O
gamma-butyrobetaine,231,B-CHEMICAL
",",231,O
a,231,O
reaction,231,O
dependent,231,O
on,231,O
Fe2+,231,B-CHEMICAL
",",231,O
alpha-ketoglutarate,231,B-CHEMICAL
",",231,O
ascorbate,231,B-CHEMICAL
and,231,O
oxygen,231,B-CHEMICAL
.,231,O
Initial,232,O
attempts,232,O
to,232,O
purify,232,O
the,232,O
protein,232,O
from,232,O
rat,232,O
liver,232,O
showed,232,O
that,232,O
gamma-butyrobetaine,232,B-CHEMICAL
hydroxylase,232,I-GENE-Y
is,232,O
unstable,232,O
.,232,O
We,233,O
",",233,O
therefore,233,O
",",233,O
determined,233,O
the,233,O
influence,233,O
of,233,O
various,233,O
compounds,233,O
on,233,O
the,233,O
stability,233,O
of,233,O
gamma-butyrobetaine,233,B-CHEMICAL
hydroxylase,233,I-GENE-Y
at,233,O
different,233,O
storage,233,O
temperatures,233,O
.,233,O
The,234,O
enzyme,234,O
activity,234,O
was,234,O
best,234,O
conserved,234,O
by,234,O
storing,234,O
the,234,O
protein,234,O
at,234,O
4,234,O
degrees,234,O
C,234,O
in,234,O
the,234,O
presence,234,O
of,234,O
200,234,O
g/l,234,O
glycerol,234,B-CHEMICAL
and,234,O
10,234,O
mM,234,O
DTT,234,B-CHEMICAL
.,234,O
We,235,O
subsequently,235,O
purified,235,O
the,235,O
enzyme,235,O
from,235,O
rat,235,O
liver,235,O
to,235,O
apparent,235,O
homogeneity,235,O
by,235,O
liquid,235,O
chromatography,235,O
.,235,O
Aspirin,236,B-CHEMICAL
and,236,O
sodium,236,B-CHEMICAL
salicylate,236,I-CHEMICAL
inhibit,236,O
endothelin,236,O
ETA,236,B-GENE-Y
receptors,236,I-GENE-Y
by,236,O
an,236,O
allosteric,236,O
type,236,O
of,236,O
mechanism,236,O
.,236,O
Aspirin,237,B-CHEMICAL
is,237,O
a,237,O
commonly,237,O
used,237,O
drug,237,O
with,237,O
a,237,O
wide,237,O
pharmacological,237,O
spectrum,237,O
including,237,O
antiplatelet,237,O
",",237,O
anti-inflammatory,237,O
",",237,O
and,237,O
neuroprotective,237,O
actions,237,O
.,237,O
This,238,O
study,238,O
shows,238,O
that,238,O
aspirin,238,B-CHEMICAL
and,238,O
sodium,238,B-CHEMICAL
salicylate,238,I-CHEMICAL
",",238,O
its,238,O
major,238,O
blood,238,O
metabolite,238,O
",",238,O
reverse,238,O
contractile,238,O
actions,238,O
of,238,O
endothelin-1,238,B-GENE-N
(,238,O
ET-1,238,B-GENE-N
),238,O
in,238,O
isolated,238,O
rat,238,O
aorta,238,O
and,238,O
human,238,O
mammary,238,O
arteries,238,O
.,238,O
They,239,O
also,239,O
prevent,239,O
the,239,O
intracellular,239,O
Ca,239,B-CHEMICAL
(,239,I-CHEMICAL
2+,239,I-CHEMICAL
),239,I-CHEMICAL
mobilizing,239,O
action,239,O
of,239,O
ET-1,239,B-GENE-Y
in,239,O
cultured,239,O
endothelial,239,O
cells,239,O
but,239,O
not,239,O
those,239,O
of,239,O
neuromedin,239,B-GENE-Y
B,239,I-GENE-Y
or,239,O
UTP,239,O
.,239,O
Inhibition,240,O
of,240,O
the,240,O
actions,240,O
of,240,O
ET-1,240,B-GENE-Y
by,240,O
salicylates,240,B-CHEMICAL
is,240,O
apparently,240,O
competitive,240,O
.,240,O
Salicylates,241,B-CHEMICAL
inhibit,241,O
(,241,B-CHEMICAL
125,241,I-CHEMICAL
),241,I-CHEMICAL
I-ET-1,241,O
binding,241,O
to,241,O
recombinant,241,O
rat,241,B-GENE-Y
ETA,241,I-GENE-Y
receptors,241,I-GENE-Y
.,241,O
Salicylic,242,B-CHEMICAL
acid,242,I-CHEMICAL
promotes,242,O
dissociation,242,O
of,242,O
(,242,B-CHEMICAL
125,242,I-CHEMICAL
),242,I-CHEMICAL
I-ET-1,242,O
ETA,242,B-GENE-Y
receptor,242,I-GENE-Y
complexes,242,O
both,242,O
in,242,O
the,242,O
absence,242,O
and,242,O
the,242,O
presence,242,O
of,242,O
unlabeled,242,O
ET-1,242,B-GENE-Y
.,242,O
It,243,O
has,243,O
no,243,O
influence,243,O
on,243,O
the,243,O
rate,243,O
of,243,O
association,243,O
of,243,O
(,243,B-CHEMICAL
125,243,I-CHEMICAL
),243,I-CHEMICAL
I-ET-1,243,O
to,243,O
ETA,243,B-GENE-Y
receptors,243,I-GENE-Y
.,243,O
Salicylates,244,B-CHEMICAL
do,244,O
not,244,O
promote,244,O
dissociation,244,O
of,244,O
(,244,B-CHEMICAL
125,244,I-CHEMICAL
),244,I-CHEMICAL
I-ET-1,244,O
ETB,244,B-GENE-Y
receptor,244,I-GENE-Y
complexes,244,O
.,244,O
Salicylates,245,B-CHEMICAL
potentiate,245,O
relaxing,245,O
actions,245,O
of,245,O
receptor,245,O
antagonists,245,O
such,245,O
as,245,O
bosentan,245,B-CHEMICAL
.,245,O
It,246,O
is,246,O
concluded,246,O
that,246,O
salicylates,246,B-CHEMICAL
are,246,O
allosteric,246,O
inhibitors,246,O
of,246,O
ETA,246,B-GENE-Y
receptors,246,I-GENE-Y
.,246,O
The,247,O
results,247,O
also,247,O
suggest,247,O
that,247,O
:,247,O
1,247,O
),247,O
irreversible,247,O
ET-1,247,B-GENE-Y
binding,247,O
probably,247,O
limits,247,O
actions,247,O
of,247,O
receptor,247,O
antagonists,247,O
in,247,O
vivo,247,O
",",247,O
and,247,O
2,247,O
),247,O
an,247,O
association,247,O
of,247,O
salicylates,247,B-CHEMICAL
and,247,O
ETA,247,B-GENE-Y
receptor,247,I-GENE-Y
antagonists,247,O
should,247,O
be,247,O
used,247,O
to,247,O
evaluate,247,O
the,247,O
physiopathological,247,O
role,247,O
of,247,O
ET-1,247,B-GENE-Y
and,247,O
may,247,O
be,247,O
of,247,O
therapeutic,247,O
interest,247,O
in,247,O
the,247,O
treatment,247,O
of,247,O
ischemic,247,O
heart,247,O
disease,247,O
.,247,O
A,248,O
unique,248,O
cytosolic,248,O
activity,248,O
related,248,O
but,248,O
distinct,248,O
from,248,O
NQO1,248,B-GENE-N
catalyses,248,O
metabolic,248,O
activation,248,O
of,248,O
mitomycin,248,B-CHEMICAL
C.,248,O
Mitomycin,248,B-CHEMICAL
C,248,I-CHEMICAL
(,248,O
MMC,248,B-CHEMICAL
),248,O
is,248,O
a,248,O
prototype,248,O
bioreductive,248,O
drug,248,O
employed,248,O
to,248,O
treat,248,O
a,248,O
variety,248,O
of,248,O
cancers,248,O
including,248,O
head,248,O
and,248,O
neck,248,O
cancer,248,O
.,248,O
Among,249,O
the,249,O
various,249,O
enzymes,249,O
",",249,O
dicoumarol,249,B-CHEMICAL
inhibitable,249,O
cytosolic,249,O
NAD,249,B-CHEMICAL
(,249,I-CHEMICAL
P,249,I-CHEMICAL
),249,I-CHEMICAL
H,249,I-CHEMICAL
:,249,I-GENE-N
quinone,249,B-CHEMICAL
oxidoreductase1,249,I-GENE-N
(,249,O
NQO1,249,B-GENE-N
),249,O
was,249,O
shown,249,O
to,249,O
catalyse,249,O
bioreductive,249,O
activation,249,O
of,249,O
MMC,249,B-CHEMICAL
leading,249,O
to,249,O
cross-linking,249,O
of,249,O
the,249,O
DNA,249,O
and,249,O
cytotoxicity,249,O
.,249,O
However,250,O
",",250,O
the,250,O
role,250,O
of,250,O
NQO1,250,B-GENE-N
in,250,O
metabolic,250,O
activation,250,O
of,250,O
MMC,250,B-CHEMICAL
has,250,O
been,250,O
disputed,250,O
.,250,O
In,251,O
this,251,O
report,251,O
",",251,O
we,251,O
present,251,O
cellular,251,O
and,251,O
animal,251,O
models,251,O
to,251,O
demonstrate,251,O
that,251,O
NQO1,251,B-GENE-N
may,251,O
play,251,O
only,251,O
a,251,O
minor,251,O
role,251,O
in,251,O
metabolic,251,O
activation,251,O
of,251,O
MMC,251,B-CHEMICAL
.,251,O
We,252,O
further,252,O
demonstrate,252,O
that,252,O
bioreductive,252,O
activation,252,O
of,252,O
MMC,252,B-CHEMICAL
is,252,O
catalysed,252,O
by,252,O
a,252,O
unique,252,O
cytosolic,252,O
activity,252,O
which,252,O
is,252,O
related,252,O
but,252,O
distinct,252,O
from,252,O
NQO1,252,B-GENE-N
.,252,O
Chinese,253,O
hamster,253,O
ovary,253,O
(,253,O
CHO,253,O
),253,O
cells,253,O
were,253,O
developed,253,O
that,253,O
permanently,253,O
express,253,O
higher,253,O
levels,253,O
of,253,O
cDNA-derived,253,O
NQO1,253,B-GENE-N
.,253,O
These,254,O
cells,254,O
showed,254,O
significantly,254,O
increased,254,O
protection,254,O
against,254,O
menadione,254,B-CHEMICAL
toxicity,254,O
.,254,O
However,255,O
",",255,O
they,255,O
failed,255,O
to,255,O
demonstrate,255,O
higher,255,O
cytotoxicity,255,O
due,255,O
to,255,O
exposure,255,O
to,255,O
MMC,255,B-CHEMICAL
under,255,O
oxygen,255,B-CHEMICAL
(,255,O
normal,255,O
air,255,O
),255,O
or,255,O
hypoxia,255,O
",",255,O
as,255,O
compared,255,O
to,255,O
the,255,O
wild-type,255,O
control,255,O
CHO,255,O
cells,255,O
.,255,O
Disruption,256,O
of,256,O
the,256,O
NQO1,256,B-GENE-N
gene,256,O
by,256,O
homologous,256,O
recombination,256,O
generated,256,O
NQO1-/-,256,B-GENE-N
mice,256,O
that,256,O
do,256,O
not,256,O
express,256,O
the,256,O
NQO1,256,B-GENE-N
gene,256,O
resulting,256,O
in,256,O
the,256,O
loss,256,O
of,256,O
NQO1,256,B-GENE-N
protein,256,O
and,256,O
activity,256,O
.,256,O
The,257,O
cytosolic,257,O
fractions,257,O
from,257,O
liver,257,O
and,257,O
colon,257,O
tissues,257,O
of,257,O
NQO1-/-,257,B-GENE-N
mice,257,O
showed,257,O
similar,257,O
amounts,257,O
of,257,O
DNA,257,O
cross-linking,257,O
upon,257,O
exposure,257,O
to,257,O
MMC,257,B-CHEMICAL
",",257,O
as,257,O
observed,257,O
in,257,O
NQO1+/+,257,B-GENE-N
mice,257,O
.,257,O
The,258,O
unique,258,O
cytosolic,258,O
activity,258,O
that,258,O
activated,258,O
MMC,258,B-CHEMICAL
in,258,O
cytosolic,258,O
fractions,258,O
of,258,O
liver,258,O
and,258,O
colon,258,O
tissues,258,O
of,258,O
NQO1-/-,258,B-GENE-N
mice,258,O
was,258,O
designated,258,O
as,258,O
cytosolic,258,O
MMC,258,B-CHEMICAL
reductase,258,I-GENE-N
.,258,O
This,259,O
activity,259,O
",",259,O
like,259,O
NQO1,259,B-GENE-N
",",259,O
was,259,O
inhibited,259,O
by,259,O
dicoumarol,259,B-CHEMICAL
and,259,O
immunologically,259,O
related,259,O
to,259,O
NQO1,259,B-GENE-N
.,259,O
Troglitazone,260,B-CHEMICAL
reduces,260,O
plasminogen,260,B-GENE-Y
activator,260,I-GENE-Y
inhibitor-1,260,I-GENE-Y
expression,260,O
and,260,O
secretion,260,O
in,260,O
cultured,260,O
human,260,O
adipocytes,260,O
.,260,O
AIMS/HYPOTHESIS,261,O
:,261,O
Increased,261,O
plasma,261,B-GENE-Y
plasminogen,261,I-GENE-Y
activator,261,I-GENE-Y
inhibitor-1,261,I-GENE-Y
(,261,O
PAI-1,261,B-GENE-Y
),261,O
concentrations,261,O
are,261,O
characteristic,261,O
for,261,O
subjects,261,O
with,261,O
insulin,261,B-GENE-Y
resistance,261,O
and,261,O
could,261,O
contribute,261,O
to,261,O
the,261,O
increased,261,O
cardiovascular,261,O
risk,261,O
in,261,O
this,261,O
state,261,O
.,261,O
In,262,O
this,262,O
study,262,O
",",262,O
we,262,O
investigated,262,O
the,262,O
effect,262,O
of,262,O
troglitazone,262,B-CHEMICAL
",",262,O
a,262,O
ligand,262,O
of,262,O
the,262,O
nuclear,262,B-GENE-N
receptor,262,I-GENE-N
peroxisome,262,B-GENE-Y
proliferator,262,I-GENE-Y
activated,262,I-GENE-Y
receptor-gamma,262,I-GENE-Y
",",262,O
on,262,O
PAI-1,262,B-GENE-Y
expression,262,O
and,262,O
secretion,262,O
in,262,O
human,262,O
adipocytes,262,O
.,262,O
METHODS,263,O
:,263,O
We,263,O
used,263,O
two,263,O
models,263,O
:,263,O
in,263,O
vitro,263,O
differentiated,263,O
subcutaneous,263,O
and,263,O
omental,263,O
adipocytes,263,O
cultured,263,O
under,263,O
serum-free,263,O
conditions,263,O
and,263,O
isolated,263,O
subcutaneous,263,O
and,263,O
omental,263,O
fat,263,O
cells,263,O
kept,263,O
in,263,O
suspension,263,O
culture,263,O
.,263,O
Plasminogen,264,B-GENE-Y
activator,264,I-GENE-Y
inhibitor-1,264,I-GENE-Y
protein,264,O
was,264,O
measured,264,O
by,264,O
ELISA,264,O
",",264,O
PAI-1,264,B-GENE-Y
mRNA,264,O
by,264,O
a,264,O
semiquantitative,264,O
RT-PCR,264,O
technique,264,O
.,264,O
RESULTS,265,O
:,265,O
Exposure,265,O
of,265,O
in,265,O
vitro,265,O
differentiated,265,O
subcutaneous,265,O
adipocytes,265,O
from,265,O
young,265,O
normal-weight,265,O
females,265,O
to,265,O
1,265,O
microgram/ml,265,O
troglitazone,265,B-CHEMICAL
for,265,O
72,265,O
h,265,O
caused,265,O
a,265,O
reduction,265,O
of,265,O
both,265,O
PAI-1,265,B-GENE-Y
secretion,265,O
(,265,O
by,265,O
29,265,O
+/-,265,O
5,265,O
%,265,O
;,265,O
p,265,O
<,265,O
0.01,265,O
),265,O
and,265,O
PAI-1,265,B-GENE-Y
mRNA,265,O
expression,265,O
(,265,O
by,265,O
26,265,O
+/-,265,O
3,265,O
%,265,O
;,265,O
p,265,O
<,265,O
0.05,265,O
),265,O
.,265,O
In,266,O
cultures,266,O
from,266,O
severely,266,O
obese,266,O
subjects,266,O
",",266,O
troglitazone,266,B-CHEMICAL
induced,266,O
a,266,O
decrease,266,O
of,266,O
PAI-1,266,B-GENE-Y
antigen,266,O
secretion,266,O
from,266,O
newly,266,O
differentiated,266,O
omental,266,O
adipocytes,266,O
by,266,O
49,266,O
+/-,266,O
8,266,O
%,266,O
(,266,O
p,266,O
<,266,O
0.01,266,O
),266,O
and,266,O
from,266,O
subcutaneous,266,O
adipocytes,266,O
by,266,O
30,266,O
+/-,266,O
7,266,O
%,266,O
(,266,O
p,266,O
<,266,O
0.05,266,O
),266,O
.,266,O
Exposure,267,O
of,267,O
freshly,267,O
isolated,267,O
subcutaneous,267,O
and,267,O
omental,267,O
adipocytes,267,O
in,267,O
suspension,267,O
culture,267,O
to,267,O
troglitazone,267,B-CHEMICAL
induced,267,O
a,267,O
similar,267,O
reduction,267,O
of,267,O
PAI-1,267,B-GENE-Y
concentration,267,O
in,267,O
the,267,O
culture,267,O
medium,267,O
(,267,O
by,267,O
35,267,O
+/-,267,O
11,267,O
%,267,O
",",267,O
p,267,O
<,267,O
0.05,267,O
",",267,O
and,267,O
33,267,O
+/-,267,O
8,267,O
%,267,O
",",267,O
p,267,O
<,267,O
0.05,267,O
compared,267,O
with,267,O
control,267,O
",",267,O
respectively,267,O
),267,O
.,267,O
CONCLUSION/INTERPRETATION,268,O
:,268,O
This,268,O
study,268,O
provides,268,O
evidence,268,O
that,268,O
troglitazone,268,B-CHEMICAL
reduces,268,O
PAI-1,268,B-GENE-Y
production,268,O
in,268,O
human,268,O
adipocytes,268,O
",",268,O
probably,268,O
at,268,O
the,268,O
transcriptional,268,O
level,268,O
.,268,O
This,269,O
observation,269,O
could,269,O
point,269,O
to,269,O
a,269,O
new,269,O
beneficial,269,O
effect,269,O
of,269,O
troglitazone,269,B-CHEMICAL
",",269,O
particularly,269,O
in,269,O
obese,269,O
subjects,269,O
",",269,O
which,269,O
could,269,O
be,269,O
associated,269,O
with,269,O
a,269,O
reduced,269,O
cardiovascular,269,O
risk,269,O
.,269,O
Effect,270,O
of,270,O
JTH-601,270,O
",",270,O
a,270,O
novel,270,O
alpha,270,B-GENE-N
(,270,I-GENE-N
1,270,I-GENE-N
),270,I-GENE-N
-adrenoceptor,270,I-GENE-N
antagonist,270,O
",",270,O
on,270,O
prostate,270,O
function,270,O
in,270,O
dogs,270,O
.,270,O
We,271,O
examined,271,O
the,271,O
effect,271,O
of,271,O
JTH-601,271,B-CHEMICAL
(,271,O
3-,271,O
inverted,271,O
question,271,O
markN-,271,O
[,271,I-CHEMICAL
2-,271,I-CHEMICAL
(,271,I-CHEMICAL
4-hydroxy-2-isopropyl-5-methylphenoxy,271,I-CHEMICAL
),271,I-CHEMICAL
ethyl,271,I-CHEMICAL
],271,I-CHEMICAL
-N-methylaminom,271,I-CHEMICAL
ethyl,271,B-CHEMICAL
inverted,271,O
question,271,O
"mark-4-methoxy-2,5,6-trimethylphenol",271,O
hemifumarate,271,I-CHEMICAL
),271,O
",",271,O
a,271,O
new,271,O
alpha,271,B-GENE-N
(,271,I-GENE-N
1L,271,I-GENE-N
),271,I-GENE-N
-adrenoceptor,271,I-GENE-N
antagonist,271,O
",",271,O
on,271,O
prostatic,271,O
function,271,O
in,271,O
isolated,271,O
canine,271,O
prostate,271,O
and,271,O
in,271,O
anesthetized,271,O
dogs,271,O
.,271,O
In,272,O
the,272,O
contraction,272,O
study,272,O
",",272,O
phenylephrine,272,B-CHEMICAL
and,272,O
noradrenaline,272,B-CHEMICAL
produced,272,O
concentration-dependent,272,O
contractions,272,O
in,272,O
canine,272,O
prostate,272,O
and,272,O
carotid,272,O
artery,272,O
",",272,O
respectively,272,O
.,272,O
In,273,O
these,273,O
tissues,273,O
",",273,O
JTH-601,273,B-CHEMICAL
",",273,O
prazosin,273,B-CHEMICAL
(,273,O
a,273,O
non-selective,273,O
alpha,273,B-GENE-N
(,273,I-GENE-N
1,273,I-GENE-N
),273,I-GENE-N
-adrenoceptor,273,I-GENE-N
antagonist,273,O
),273,O
",",273,O
and,273,O
tamsulosin,273,B-CHEMICAL
(,273,O
an,273,O
alpha,273,B-GENE-Y
(,273,I-GENE-Y
1A,273,I-GENE-Y
),273,I-GENE-Y
-adrenoceptor,273,I-GENE-Y
antagonist,273,O
),273,O
competitively,273,O
antagonized,273,O
contraction,273,O
in,273,O
a,273,O
concentration-dependent,273,O
manner,273,O
.,273,O
The,274,O
pA,274,O
(,274,O
2,274,O
),274,O
(,274,O
pK,274,O
(,274,O
B,274,O
),274,O
),274,O
values,274,O
with,274,O
prostate,274,O
were,274,O
8.49+/-0.07,274,O
for,274,O
JTH-601,274,O
",",274,O
7.94+/-0.04,274,O
for,274,O
prazosin,274,B-CHEMICAL
and,274,O
9.42+/-0.22,274,O
for,274,O
tamsulosin,274,B-CHEMICAL
.,274,O
The,275,O
ratio,275,O
of,275,O
pA,275,O
(,275,O
2,275,O
),275,O
(,275,O
carotid,275,O
artery/prostate,275,O
),275,O
",",275,O
i.e,275,O
.,275,O
prostatic,276,O
selectivity,276,O
",",276,O
was,276,O
10.471,276,O
for,276,O
JTH-601,276,B-CHEMICAL
",",276,O
0.008,276,O
for,276,O
prazosin,276,B-CHEMICAL
and,276,O
0.371,276,O
for,276,O
tamsulosin,276,B-CHEMICAL
",",276,O
respectively,276,O
.,276,O
In,277,O
anesthetized,277,O
dogs,277,O
",",277,O
JTH-601,277,B-CHEMICAL
(,277,O
1,277,O
mg/kg,277,O
",",277,O
i.d,277,O
.,277,O
),277,O
significantly,278,O
decreased,278,O
urethral,278,O
pressure,278,O
by,278,O
15,278,O
%,278,O
without,278,O
affecting,278,O
blood,278,O
pressure,278,O
or,278,O
heart,278,O
rate,278,O
.,278,O
Tamsulosin,279,B-CHEMICAL
(,279,O
0.1,279,O
mg/kg,279,O
",",279,O
i.d,279,O
.,279,O
),279,O
decreased,280,O
urethral,280,O
pressure,280,O
to,280,O
the,280,O
same,280,O
extent,280,O
as,280,O
did,280,O
JTH-601,280,B-CHEMICAL
",",280,O
but,280,O
with,280,O
a,280,O
significant,280,O
effect,280,O
on,280,O
blood,280,O
pressure,280,O
and,280,O
heart,280,O
rate,280,O
.,280,O
JTH-601,281,B-CHEMICAL
showed,281,O
higher,281,O
selectivity,281,O
for,281,O
canine,281,O
prostate,281,O
both,281,O
in,281,O
vitro,281,O
and,281,O
in,281,O
vivo,281,O
.,281,O
In,282,O
prostate,282,O
",",282,O
an,282,O
important,282,O
role,282,O
of,282,O
the,282,O
alpha,282,B-GENE-N
(,282,I-GENE-N
1L,282,I-GENE-N
),282,I-GENE-N
-adrenoceptor,282,I-GENE-N
is,282,O
suggested,282,O
in,282,O
the,282,O
smooth,282,O
muscle,282,O
contraction,282,O
mediated,282,O
by,282,O
alpha,282,B-GENE-N
(,282,I-GENE-N
1,282,I-GENE-N
),282,I-GENE-N
-adrenoceptors,282,I-GENE-N
.,282,O
JTH-601,283,B-CHEMICAL
is,283,O
expected,283,O
to,283,O
be,283,O
an,283,O
effective,283,O
alpha,283,B-GENE-N
(,283,I-GENE-N
1,283,I-GENE-N
),283,I-GENE-N
-adrenoceptor,283,I-GENE-N
antagonist,283,O
for,283,O
the,283,O
treatment,283,O
of,283,O
urinary,283,O
outlet,283,O
obstruction,283,O
by,283,O
benign,283,O
prostatic,283,O
hypertrophy,283,O
with,283,O
a,283,O
minimum,283,O
effect,283,O
on,283,O
the,283,O
cardiovascular,283,O
system,283,O
.,283,O
Severe,284,O
impairment,284,O
of,284,O
salivation,284,O
in,284,O
Na+/K+/2Cl-,284,B-GENE-N
cotransporter,284,I-GENE-N
(,284,O
NKCC1,284,B-GENE-Y
),284,O
-deficient,284,O
mice,284,O
.,284,O
The,285,O
salivary,285,O
fluid,285,O
secretory,285,O
mechanism,285,O
is,285,O
thought,285,O
to,285,O
require,285,O
Na,285,B-GENE-N
(,285,I-GENE-N
+,285,I-GENE-N
),285,I-GENE-N
/K,285,I-GENE-N
(,285,I-GENE-N
+,285,I-GENE-N
),285,I-GENE-N
/2Cl,285,I-GENE-N
(,285,I-GENE-N
-,285,I-GENE-N
),285,I-GENE-N
cotransporter-mediated,285,O
Cl,285,B-CHEMICAL
(,285,I-CHEMICAL
-,285,I-CHEMICAL
),285,I-CHEMICAL
uptake,285,O
.,285,O
To,286,O
directly,286,O
test,286,O
this,286,O
possibility,286,O
we,286,O
studied,286,O
the,286,O
in,286,O
vivo,286,O
and,286,O
in,286,O
vitro,286,O
functioning,286,O
of,286,O
acinar,286,O
cells,286,O
from,286,O
the,286,O
parotid,286,O
glands,286,O
of,286,O
mice,286,O
with,286,O
targeted,286,O
disruption,286,O
of,286,O
Na,286,B-GENE-Y
(,286,I-GENE-Y
+,286,I-GENE-Y
),286,I-GENE-Y
/K,286,I-GENE-Y
(,286,I-GENE-Y
+,286,I-GENE-Y
),286,I-GENE-Y
/2Cl,286,I-GENE-Y
(,286,I-GENE-Y
-,286,I-GENE-Y
),286,I-GENE-Y
cotransporter,286,I-GENE-Y
isoform,286,I-GENE-Y
1,286,I-GENE-Y
(,286,O
Nkcc1,286,B-GENE-Y
),286,O
",",286,O
the,286,O
gene,286,O
encoding,286,O
the,286,O
salivary,286,O
Na,286,B-GENE-N
(,286,I-GENE-N
+,286,I-GENE-N
),286,I-GENE-N
/K,286,I-GENE-N
(,286,I-GENE-N
+,286,I-GENE-N
),286,I-GENE-N
/2Cl,286,I-GENE-N
(,286,I-GENE-N
-,286,I-GENE-N
),286,I-GENE-N
cotransporter,286,I-GENE-N
.,286,O
In,287,O
wild-type,287,O
mice,287,O
NKCC1,287,B-GENE-Y
was,287,O
localized,287,O
to,287,O
the,287,O
basolateral,287,O
membranes,287,O
of,287,O
parotid,287,O
acinar,287,O
cells,287,O
",",287,O
whereas,287,O
expression,287,O
was,287,O
not,287,O
detected,287,O
in,287,O
duct,287,O
cells,287,O
.,287,O
The,288,O
lack,288,O
of,288,O
functional,288,O
NKCC1,288,B-GENE-Y
resulted,288,O
in,288,O
a,288,O
dramatic,288,O
reduction,288,O
(,288,O
>,288,O
60,288,O
%,288,O
),288,O
in,288,O
the,288,O
volume,288,O
of,288,O
saliva,288,O
secreted,288,O
in,288,O
response,288,O
to,288,O
a,288,O
muscarinic,288,O
agonist,288,O
",",288,O
the,288,O
primary,288,O
in,288,O
situ,288,O
salivation,288,O
signal,288,O
.,288,O
Consistent,289,O
with,289,O
defective,289,O
Cl,289,B-CHEMICAL
(,289,I-CHEMICAL
-,289,I-CHEMICAL
),289,I-CHEMICAL
uptake,289,O
",",289,O
a,289,O
loss,289,O
of,289,O
bumetanide-sensitive,289,B-CHEMICAL
Cl,289,B-CHEMICAL
(,289,I-CHEMICAL
-,289,I-CHEMICAL
),289,I-CHEMICAL
influx,289,O
was,289,O
observed,289,O
in,289,O
parotid,289,O
acinar,289,O
cells,289,O
from,289,O
mice,289,O
lacking,289,O
NKCC1,289,B-GENE-Y
.,289,O
Cl,290,B-GENE-N
(,290,I-GENE-N
-,290,I-GENE-N
),290,I-GENE-N
/,290,I-GENE-N
HCO,290,I-GENE-N
(,290,I-GENE-N
3,290,I-GENE-N
),290,I-GENE-N
(,290,I-GENE-N
-,290,I-GENE-N
),290,I-GENE-N
exchanger,290,I-GENE-N
activity,290,O
was,290,O
increased,290,O
in,290,O
parotid,290,O
acinar,290,O
cells,290,O
isolated,290,O
from,290,O
knockout,290,O
mice,290,O
suggesting,290,O
that,290,O
the,290,O
residual,290,O
saliva,290,O
secreted,290,O
by,290,O
mice,290,O
lacking,290,O
NKCC1,290,B-GENE-Y
is,290,O
associated,290,O
with,290,O
anion,290,O
exchanger-dependent,290,O
Cl,290,B-CHEMICAL
(,290,I-CHEMICAL
-,290,I-CHEMICAL
),290,I-CHEMICAL
uptake,290,O
.,290,O
Indeed,291,O
",",291,O
expression,291,O
of,291,O
the,291,O
Cl,291,B-CHEMICAL
(,291,I-CHEMICAL
-,291,I-CHEMICAL
),291,I-CHEMICAL
/,291,I-GENE-N
HCO,291,B-CHEMICAL
(,291,I-CHEMICAL
3,291,I-CHEMICAL
),291,I-CHEMICAL
(,291,I-CHEMICAL
-,291,I-CHEMICAL
),291,I-CHEMICAL
exchanger,291,I-GENE-N
AE2,291,B-GENE-N
was,291,O
enhanced,291,O
suggesting,291,O
that,291,O
this,291,O
transporter,291,O
compensates,291,O
for,291,O
the,291,O
loss,291,O
of,291,O
functional,291,O
Na,291,B-CHEMICAL
(,291,I-CHEMICAL
+,291,I-CHEMICAL
),291,I-CHEMICAL
/K,291,I-GENE-N
(,291,I-CHEMICAL
+,291,I-CHEMICAL
),291,I-CHEMICAL
/2Cl,291,I-GENE-N
(,291,I-CHEMICAL
-,291,I-CHEMICAL
),291,I-CHEMICAL
cotransporter,291,I-GENE-N
.,291,O
Furthermore,292,O
",",292,O
the,292,O
ability,292,O
of,292,O
the,292,O
parotid,292,O
gland,292,O
to,292,O
conserve,292,O
NaCl,292,B-CHEMICAL
was,292,O
abolished,292,O
in,292,O
NKCC1-deficient,292,B-GENE-Y
mice,292,O
.,292,O
This,293,O
deficit,293,O
was,293,O
not,293,O
associated,293,O
with,293,O
changes,293,O
in,293,O
the,293,O
morphology,293,O
of,293,O
the,293,O
ducts,293,O
",",293,O
but,293,O
transcript,293,O
levels,293,O
for,293,O
the,293,O
alpha-,293,O
",",293,O
beta-,293,O
",",293,O
and,293,O
gamma-subunits,293,O
of,293,O
the,293,O
epithelial,293,O
Na,293,B-CHEMICAL
(,293,I-CHEMICAL
+,293,I-CHEMICAL
),293,I-CHEMICAL
channel,293,O
were,293,O
reduced,293,O
.,293,O
These,294,O
data,294,O
directly,294,O
demonstrate,294,O
that,294,O
NKCC1,294,B-GENE-Y
is,294,O
the,294,O
major,294,O
Cl,294,B-CHEMICAL
(,294,I-CHEMICAL
-,294,I-CHEMICAL
),294,I-CHEMICAL
uptake,294,O
mechanism,294,O
across,294,O
the,294,O
basolateral,294,O
membrane,294,O
of,294,O
acinar,294,O
cells,294,O
and,294,O
is,294,O
critical,294,O
for,294,O
driving,294,O
saliva,294,O
secretion,294,O
in,294,O
vivo,294,O
.,294,O
Evaluation,295,O
of,295,O
in,295,O
vivo,295,O
binding,295,O
properties,295,O
of,295,O
3H-NMPB,295,B-CHEMICAL
and,295,O
3H-QNB,295,B-CHEMICAL
in,295,O
mouse,295,O
brain,295,O
.,295,O
UNLABELLED,296,O
:,296,O
Apparent,296,O
muscarinic,296,B-GENE-N
acetylcholine,296,I-GENE-N
(,296,I-GENE-N
mAch,296,I-GENE-N
),296,I-GENE-N
receptor,296,I-GENE-N
occupancy,296,O
in,296,O
mouse,296,O
cerebral,296,O
cortex,296,O
",",296,O
hippocampus,296,O
",",296,O
and,296,O
striatum,296,O
by,296,O
scopolamine,296,B-CHEMICAL
",",296,O
an,296,O
antagonist,296,O
",",296,O
and,296,O
biperiden,296,B-CHEMICAL
",",296,O
a,296,O
relatively,296,O
selective,296,O
M1,296,B-GENE-Y
antagonist,296,O
",",296,O
was,296,O
estimated,296,O
with,296,O
competitive,296,O
binding,296,O
studies,296,O
using,296,O
two,296,O
different,296,O
radioligands,296,O
:,296,O
3H-N-methyl,296,B-CHEMICAL
piperidyl,296,I-CHEMICAL
benzilate,296,I-CHEMICAL
(,296,O
3H-NMPB,296,B-CHEMICAL
),296,O
and,296,O
3H-quinuclidinyl,296,B-CHEMICAL
benzilate,296,I-CHEMICAL
(,296,O
3H-QNB,296,B-CHEMICAL
),296,O
.,296,O
Both,297,O
radioligands,297,O
labeled,297,O
mAch,297,B-GENE-N
receptors,297,I-GENE-N
in,297,O
these,297,O
brain,297,O
regions,297,O
",",297,O
and,297,O
the,297,O
relative,297,O
regional,297,O
distributions,297,O
of,297,O
the,297,O
specific,297,O
binding,297,O
of,297,O
3H-NMPB,297,B-CHEMICAL
in,297,O
vivo,297,O
paralleled,297,O
the,297,O
distribution,297,O
of,297,O
mAch,297,B-GENE-N
receptors,297,I-GENE-N
.,297,O
3H-NMPB,298,B-CHEMICAL
binding,298,O
in,298,O
vivo,298,O
was,298,O
much,298,O
more,298,O
sensitive,298,O
to,298,O
direct,298,O
competitive,298,O
inhibition,298,O
by,298,O
scopolamine,298,B-CHEMICAL
than,298,O
was,298,O
3H-QNB,298,B-CHEMICAL
.,298,O
A,299,O
similar,299,O
discrepancy,299,O
in,299,O
sensitivity,299,O
to,299,O
competitors,299,O
between,299,O
3H-NMPB,299,B-CHEMICAL
and,299,O
3H-QNB,299,B-CHEMICAL
was,299,O
also,299,O
observed,299,O
when,299,O
biperiden,299,B-CHEMICAL
was,299,O
used,299,O
as,299,O
a,299,O
competitor,299,O
",",299,O
indicating,299,O
that,299,O
binding,299,O
to,299,O
different,299,O
subtypes,299,O
of,299,O
the,299,O
mAch,299,B-GENE-N
receptor,299,I-GENE-N
could,299,O
not,299,O
account,299,O
for,299,O
the,299,O
observed,299,O
differences,299,O
in,299,O
sensitivity,299,O
to,299,O
competition,299,O
.,299,O
An,300,O
in,300,O
vivo,300,O
saturation,300,O
study,300,O
suggested,300,O
that,300,O
the,300,O
apparent,300,O
association,300,O
rate,300,O
constant,300,O
(,300,O
k,300,O
on,300,O
),300,O
of,300,O
3H-QNB,300,B-CHEMICAL
binding,300,O
might,300,O
be,300,O
changed,300,O
by,300,O
ligand,300,O
concentration,300,O
.,300,O
The,301,O
heterogeneity,301,O
of,301,O
the,301,O
free,301,O
ligand,301,O
concentration,301,O
in,301,O
intact,301,O
brain,301,O
was,301,O
assessed,301,O
in,301,O
relation,301,O
to,301,O
the,301,O
ligand,301,O
concentration,301,O
dependency,301,O
of,301,O
the,301,O
apparent,301,O
association,301,O
rate,301,O
constant,301,O
(,301,O
k,301,O
on,301,O
),301,O
of,301,O
3H-QNB,301,B-CHEMICAL
binding,301,O
.,301,O
This,302,O
finding,302,O
",",302,O
together,302,O
with,302,O
the,302,O
more,302,O
favorable,302,O
accumulation,302,O
of,302,O
3H-NMPB,302,B-CHEMICAL
in,302,O
cerebral,302,O
cortex,302,O
",",302,O
hippocampus,302,O
",",302,O
and,302,O
striatum,302,O
",",302,O
leads,302,O
us,302,O
to,302,O
conclude,302,O
that,302,O
3H-NMPB,302,B-CHEMICAL
",",302,O
or,302,O
its,302,O
positron,302,O
emitting,302,O
counterpart,302,O
",",302,O
should,302,O
be,302,O
the,302,O
more,302,O
favorable,302,O
radiotracer,302,O
for,302,O
the,302,O
estimation,302,O
of,302,O
mAch,302,B-GENE-N
receptor,302,I-GENE-N
occupancy,302,O
by,302,O
cholinergic,302,O
drugs,302,O
in,302,O
the,302,O
brain,302,O
.,302,O
KEYWORDS,303,O
:,303,O
mAch,303,B-GENE-N
receptor,303,I-GENE-N
",",303,O
QNB,303,B-CHEMICAL
",",303,O
NMPB,303,B-CHEMICAL
",",303,O
in,303,O
vivo,303,O
",",303,O
mouse,303,O
.,303,O
Impaired,304,O
expression,304,O
of,304,O
the,304,O
uncoupling,304,B-GENE-Y
protein-3,304,I-GENE-Y
gene,304,O
in,304,O
skeletal,304,O
muscle,304,O
during,304,O
lactation,304,O
:,304,O
fibrates,304,O
and,304,O
troglitazone,304,B-CHEMICAL
reverse,304,O
lactation-induced,304,O
downregulation,304,O
of,304,O
the,304,O
uncoupling,304,B-GENE-Y
protein-3,304,I-GENE-Y
gene,304,O
.,304,O
The,305,O
expression,305,O
of,305,O
uncoupling,305,B-GENE-Y
protein,305,I-GENE-Y
(,305,I-GENE-Y
UCP,305,I-GENE-Y
),305,I-GENE-Y
-3,305,I-GENE-Y
mRNA,305,O
in,305,O
skeletal,305,O
muscle,305,O
is,305,O
dramatically,305,O
reduced,305,O
during,305,O
lactation,305,O
in,305,O
mice,305,O
.,305,O
The,306,O
reduction,306,O
in,306,O
UCP-3,306,B-GENE-Y
mRNA,306,O
levels,306,O
lowers,306,O
the,306,O
amount,306,O
of,306,O
the,306,O
UCP-3,306,B-GENE-Y
protein,306,O
in,306,O
skeletal,306,O
muscle,306,O
mitochondria,306,O
during,306,O
lactation,306,O
.,306,O
Spontaneous,307,O
or,307,O
abrupt,307,O
weaning,307,O
reverses,307,O
the,307,O
downregulation,307,O
of,307,O
the,307,O
UCP-3,307,B-GENE-Y
mRNA,307,O
but,307,O
not,307,O
the,307,O
reduction,307,O
in,307,O
UCP-3,307,B-GENE-Y
protein,307,O
levels,307,O
.,307,O
In,308,O
lactating,308,O
and,308,O
virgin,308,O
mice,308,O
",",308,O
however,308,O
",",308,O
fasting,308,O
increases,308,O
UCP-3,308,B-GENE-Y
mRNA,308,O
levels,308,O
.,308,O
Changes,309,O
in,309,O
UCP-3,309,B-GENE-Y
mRNA,309,O
occur,309,O
in,309,O
parallel,309,O
with,309,O
modifications,309,O
in,309,O
the,309,O
levels,309,O
of,309,O
free,309,O
fatty,309,B-CHEMICAL
acids,309,I-CHEMICAL
",",309,O
which,309,O
are,309,O
reduced,309,O
in,309,O
lactation,309,O
and,309,O
are,309,O
upregulated,309,O
due,309,O
to,309,O
weaning,309,O
or,309,O
fasting,309,O
.,309,O
Modifications,310,O
in,310,O
the,310,O
energy,310,O
nutritional,310,O
stress,310,O
of,310,O
lactating,310,O
dams,310,O
achieved,310,O
by,310,O
manipulating,310,O
litter,310,O
sizes,310,O
do,310,O
not,310,O
influence,310,O
UCP-3,310,B-GENE-Y
mRNA,310,O
levels,310,O
in,310,O
skeletal,310,O
muscle,310,O
.,310,O
Conversely,311,O
",",311,O
when,311,O
mice,311,O
are,311,O
fed,311,O
a,311,O
high-fat,311,O
diet,311,O
after,311,O
parturition,311,O
",",311,O
the,311,O
downregulation,311,O
of,311,O
UCP-3,311,B-GENE-Y
mRNA,311,O
and,311,O
UCP-3,311,B-GENE-Y
protein,311,O
levels,311,O
due,311,O
to,311,O
lactation,311,O
is,311,O
partially,311,O
reversed,311,O
",",311,O
as,311,O
is,311,O
the,311,O
reduction,311,O
in,311,O
serum,311,O
free,311,O
fatty,311,B-CHEMICAL
acid,311,I-CHEMICAL
levels,311,O
.,311,O
Treatment,312,O
of,312,O
lactating,312,O
mice,312,O
with,312,O
a,312,O
single,312,O
injection,312,O
of,312,O
bezafibrate,312,B-CHEMICAL
",",312,O
an,312,O
activator,312,O
of,312,O
the,312,O
peroxisome,312,B-GENE-N
proliferator-activated,312,I-GENE-N
receptor,312,I-GENE-N
(,312,O
PPAR,312,B-GENE-N
),312,O
",",312,O
raises,312,O
UCP-3,312,B-GENE-Y
mRNA,312,O
in,312,O
skeletal,312,O
muscle,312,O
to,312,O
levels,312,O
similar,312,O
to,312,O
those,312,O
in,312,O
virgin,312,O
mice,312,O
.,312,O
4-chloro-6-,313,B-CHEMICAL
[,313,I-CHEMICAL
(,313,I-CHEMICAL
"2,3-xylidine",313,I-CHEMICAL
),313,I-CHEMICAL
-pirimidinylthio,313,I-CHEMICAL
],313,I-CHEMICAL
acetic,313,I-CHEMICAL
acid,313,I-CHEMICAL
(,313,O
"WY-14,643",313,B-CHEMICAL
),313,O
",",313,O
a,313,O
specific,313,O
ligand,313,O
of,313,O
the,313,O
PPAR-alpha,313,B-GENE-Y
subtype,313,O
",",313,O
causes,313,O
the,313,O
most,313,O
dramatic,313,O
increase,313,O
in,313,O
UCP-3,313,B-GENE-Y
mRNA,313,O
",",313,O
whereas,313,O
troglitazone,313,B-CHEMICAL
",",313,O
a,313,O
specific,313,O
activator,313,O
of,313,O
PPAR-gamma,313,B-GENE-Y
",",313,O
also,313,O
significantly,313,O
increases,313,O
UCP-3,313,B-GENE-Y
mRNA,313,O
abundance,313,O
in,313,O
skeletal,313,O
muscle,313,O
of,313,O
lactating,313,O
mice,313,O
.,313,O
However,314,O
",",314,O
in,314,O
virgin,314,O
mice,314,O
",",314,O
bezafibrate,314,B-CHEMICAL
and,314,O
"WY-14,643",314,B-CHEMICAL
do,314,O
not,314,O
significantly,314,O
affect,314,O
UCP-3,314,B-GENE-Y
mRNA,314,O
expression,314,O
",",314,O
whereas,314,O
troglitazone,314,B-CHEMICAL
is,314,O
at,314,O
least,314,O
as,314,O
effective,314,O
as,314,O
it,314,O
is,314,O
in,314,O
lactating,314,O
dams,314,O
.,314,O
It,315,O
is,315,O
proposed,315,O
that,315,O
the,315,O
UCP-3,315,B-GENE-Y
gene,315,O
is,315,O
regulated,315,O
in,315,O
skeletal,315,O
muscle,315,O
during,315,O
lactation,315,O
in,315,O
response,315,O
to,315,O
changes,315,O
in,315,O
circulating,315,O
free,315,O
fatty,315,B-CHEMICAL
acids,315,I-CHEMICAL
by,315,O
mechanisms,315,O
involving,315,O
activation,315,O
of,315,O
PPARs,315,B-GENE-N
.,315,O
The,316,O
impaired,316,O
expression,316,O
of,316,O
the,316,O
UCP-3,316,B-GENE-Y
gene,316,O
is,316,O
consistent,316,O
with,316,O
the,316,O
involvement,316,O
of,316,O
UCP-3,316,B-GENE-Y
gene,316,O
regulation,316,O
in,316,O
the,316,O
reduction,316,O
of,316,O
the,316,O
use,316,O
of,316,O
fatty,316,B-CHEMICAL
acids,316,I-CHEMICAL
as,316,O
fuel,316,O
by,316,O
the,316,O
skeletal,316,O
muscle,316,O
and,316,O
in,316,O
impaired,316,O
adaptative,316,O
thermogenesis,316,O
",",316,O
both,316,O
of,316,O
which,316,O
are,316,O
major,316,O
metabolic,316,O
adaptations,316,O
that,316,O
occur,316,O
during,316,O
lactation,316,O
.,316,O
The,317,O
apoptosome,317,O
:,317,O
heart,317,O
and,317,O
soul,317,O
of,317,O
the,317,O
cell,317,O
death,317,O
machine,317,O
.,317,O
Apoptosis,318,O
is,318,O
a,318,O
fundamental,318,O
biologic,318,O
process,318,O
by,318,O
which,318,O
metazoan,318,O
cells,318,O
orchestrate,318,O
their,318,O
own,318,O
self-demise,318,O
.,318,O
Genetic,319,O
analyses,319,O
of,319,O
the,319,O
nematode,319,O
C,319,O
elegans,319,O
identified,319,O
three,319,O
core,319,O
components,319,O
of,319,O
the,319,O
suicide,319,O
apparatus,319,O
which,319,O
include,319,O
CED-3,319,B-GENE-Y
",",319,O
CED-4,319,B-GENE-Y
",",319,O
and,319,O
CED-9,319,B-GENE-Y
.,319,O
An,320,O
analogous,320,O
set,320,O
of,320,O
core,320,O
constituents,320,O
exists,320,O
in,320,O
mammalian,320,O
cells,320,O
and,320,O
includes,320,O
caspase-9,320,B-GENE-Y
",",320,O
Apaf-1,320,B-GENE-Y
",",320,O
and,320,O
bcl-2/xL,320,B-GENE-N
",",320,O
respectively,320,O
.,320,O
CED-3,321,B-GENE-Y
and,321,O
CED-4,321,B-GENE-Y
",",321,O
along,321,O
with,321,O
their,321,O
mammalian,321,O
counterparts,321,O
",",321,O
function,321,O
to,321,O
kill,321,O
cells,321,O
",",321,O
whereas,321,O
CED-9,321,B-GENE-Y
and,321,O
its,321,O
mammalian,321,O
equivalents,321,O
protect,321,O
cells,321,O
from,321,O
death,321,O
.,321,O
These,322,O
central,322,O
components,322,O
biochemically,322,O
intermingle,322,O
in,322,O
a,322,O
ternary,322,O
complex,322,O
recently,322,O
dubbed,322,O
the,322,O
``,322,O
apoptosome,322,O
.,322,O
'',322,O
The,323,O
C,323,O
elegans,323,O
protein,323,O
EGL-1,323,B-GENE-Y
and,323,O
its,323,O
mammalian,323,O
counterparts,323,O
",",323,O
pro-apoptotic,323,O
members,323,O
of,323,O
the,323,O
bcl-2,323,B-GENE-N
family,323,O
",",323,O
induce,323,O
cell,323,O
death,323,O
by,323,O
disrupting,323,O
apoptosome,323,O
interactions,323,O
.,323,O
Thus,324,O
",",324,O
EGL-1,324,B-GENE-Y
may,324,O
represent,324,O
a,324,O
primordial,324,O
signal,324,O
integrator,324,O
for,324,O
the,324,O
apoptosome,324,O
.,324,O
Various,325,O
biochemical,325,O
processes,325,O
including,325,O
oligomerization,325,O
",",325,O
adenosine,325,B-CHEMICAL
triphosphate,325,I-CHEMICAL
ATP/dATP,325,B-CHEMICAL
binding,325,O
",",325,O
and,325,O
cytochrome,325,B-GENE-Y
c,325,I-GENE-Y
interaction,325,O
play,325,O
a,325,O
role,325,O
in,325,O
regulating,325,O
the,325,O
ternary,325,O
death,325,O
complex,325,O
.,325,O
Recent,326,O
studies,326,O
suggest,326,O
that,326,O
cell,326,O
death,326,B-GENE-N
receptors,326,I-GENE-N
",",326,O
such,326,O
as,326,O
CD95,326,B-GENE-Y
",",326,O
may,326,O
amplify,326,O
their,326,O
suicide,326,O
signal,326,O
by,326,O
activating,326,O
the,326,O
apoptosome,326,O
.,326,O
These,327,O
mutual,327,O
associations,327,O
by,327,O
core,327,O
components,327,O
of,327,O
the,327,O
suicide,327,O
apparatus,327,O
provide,327,O
a,327,O
molecular,327,O
framework,327,O
in,327,O
which,327,O
diverse,327,O
death,327,O
signals,327,O
likely,327,O
interface,327,O
.,327,O
Understanding,328,O
the,328,O
apoptosome,328,O
and,328,O
its,328,O
cellular,328,O
connections,328,O
will,328,O
facilitate,328,O
the,328,O
design,328,O
of,328,O
novel,328,O
therapeutic,328,O
strategies,328,O
for,328,O
cancer,328,O
and,328,O
other,328,O
disease,328,O
states,328,O
in,328,O
which,328,O
apoptosis,328,O
plays,328,O
a,328,O
pivotal,328,O
role,328,O
.,328,O
Retigabine,329,B-CHEMICAL
",",329,O
a,329,O
novel,329,O
anti-convulsant,329,O
",",329,O
enhances,329,O
activation,329,O
of,329,O
KCNQ2/Q3,329,B-GENE-N
potassium,329,B-GENE-N
channels,329,I-GENE-N
.,329,O
Retigabine,330,B-CHEMICAL
[,330,O
N-,330,B-CHEMICAL
(,330,I-CHEMICAL
2-amino-4-,330,I-CHEMICAL
[,330,I-CHEMICAL
fluorobenzylamino,330,I-CHEMICAL
],330,I-CHEMICAL
-phenyl,330,I-CHEMICAL
),330,I-CHEMICAL
carbamic,330,I-CHEMICAL
acid,330,I-CHEMICAL
;,330,O
D-23129,330,B-CHEMICAL
],330,O
is,330,O
a,330,O
novel,330,O
anticonvulsant,330,O
",",330,O
unrelated,330,O
to,330,O
currently,330,O
available,330,O
antiepileptic,330,O
agents,330,O
",",330,O
with,330,O
activity,330,O
in,330,O
a,330,O
broad,330,O
range,330,O
of,330,O
seizure,330,O
models,330,O
.,330,O
In,331,O
the,331,O
present,331,O
study,331,O
",",331,O
we,331,O
sought,331,O
to,331,O
determine,331,O
whether,331,O
retigabine,331,O
could,331,O
enhance,331,O
current,331,O
through,331,O
M-like,331,O
currents,331,O
in,331,O
PC12,331,O
cells,331,O
and,331,O
KCNQ2/Q3,331,B-GENE-N
K,331,B-CHEMICAL
(,331,I-CHEMICAL
+,331,I-CHEMICAL
),331,I-CHEMICAL
channels,331,I-GENE-N
expressed,331,O
in,331,O
Chinese,331,O
hamster,331,O
ovary,331,O
cells,331,O
(,331,O
CHO-KCNQ2/Q3,331,O
),331,O
.,331,O
In,332,O
differentiated,332,O
PC12,332,O
cells,332,O
",",332,O
retigabine,332,O
enhanced,332,O
a,332,O
linopirdine-sensitive,332,B-CHEMICAL
current,332,O
.,332,O
The,333,O
effect,333,O
of,333,O
retigabine,333,B-CHEMICAL
was,333,O
associated,333,O
with,333,O
a,333,O
slowing,333,O
of,333,O
M-like,333,O
tail,333,O
current,333,O
deactivation,333,O
in,333,O
these,333,O
cells,333,O
.,333,O
Retigabine,334,B-CHEMICAL
(,334,O
0.1,334,O
to,334,O
10,334,O
microM,334,O
),334,O
induced,334,O
a,334,O
potassium,334,B-CHEMICAL
current,334,O
and,334,O
hyperpolarized,334,O
CHO,334,O
cells,334,O
expressing,334,O
KCNQ2/Q3,334,B-GENE-N
cells,334,O
but,334,O
not,334,O
in,334,O
wild-type,334,O
cells,334,O
.,334,O
Retigabine-induced,335,B-CHEMICAL
currents,335,O
in,335,O
CHO-KCNQ2/Q3,335,O
cells,335,O
were,335,O
inhibited,335,O
by,335,O
60.6,335,O
+/-,335,O
11,335,O
%,335,O
(,335,O
n,335,O
=,335,O
4,335,O
),335,O
by,335,O
the,335,O
KCNQ2/Q3,335,B-GENE-N
blocker,335,O
",",335,O
linopirdine,335,B-CHEMICAL
(,335,O
10,335,O
microM,335,O
),335,O
",",335,O
and,335,O
82.7,335,O
+/-,335,O
5.4,335,O
%,335,O
(,335,O
n,335,O
=,335,O
4,335,O
),335,O
by,335,O
BaCl,335,B-CHEMICAL
(,335,I-CHEMICAL
2,335,I-CHEMICAL
),335,I-CHEMICAL
(,335,O
10,335,O
mM,335,O
),335,O
.,335,O
The,336,O
mechanism,336,O
by,336,O
which,336,O
retigabine,336,B-CHEMICAL
enhanced,336,O
KCNQ2/Q3,336,B-GENE-N
currents,336,O
involved,336,O
large,336,O
",",336,O
drug-induced,336,O
",",336,O
leftward,336,O
shifts,336,O
in,336,O
the,336,O
voltage,336,O
dependence,336,O
of,336,O
channel,336,O
activation,336,O
(,336,O
-33.1,336,O
+/-,336,O
2.6,336,O
mV,336,O
",",336,O
n,336,O
=,336,O
4,336,O
",",336,O
by,336,O
10,336,O
microM,336,O
retigabine,336,B-CHEMICAL
),336,O
.,336,O
Retigabine,337,B-CHEMICAL
shifted,337,O
the,337,O
voltage,337,O
dependence,337,O
of,337,O
channel,337,O
activation,337,O
with,337,O
an,337,O
EC,337,O
(,337,O
50,337,O
),337,O
value,337,O
of,337,O
1.6,337,O
+/-,337,O
0.3,337,O
microM,337,O
(,337,O
slope,337,O
factor,337,O
was,337,O
1.2,337,O
+/-,337,O
0.1,337,O
",",337,O
n,337,O
=,337,O
4,337,O
to,337,O
5,337,O
cells,337,O
per,337,O
concentration,337,O
),337,O
.,337,O
Retigabine,338,B-CHEMICAL
(,338,O
0.1,338,O
to,338,O
10,338,O
microM,338,O
),338,O
also,338,O
slowed,338,O
the,338,O
rate,338,O
of,338,O
channel,338,O
deactivation,338,O
",",338,O
predominantly,338,O
by,338,O
increasing,338,O
the,338,O
contribution,338,O
of,338,O
a,338,O
slowly,338,O
deactivating,338,O
tail,338,O
current,338,O
component,338,O
.,338,O
Our,339,O
findings,339,O
identify,339,O
KCNQ2/Q3,339,B-GENE-N
channels,339,O
as,339,O
a,339,O
molecular,339,O
target,339,O
for,339,O
retigabine,339,B-CHEMICAL
and,339,O
suggest,339,O
that,339,O
activation,339,O
of,339,O
KCNQ2/Q3,339,B-GENE-N
channels,339,O
may,339,O
be,339,O
responsible,339,O
for,339,O
at,339,O
least,339,O
some,339,O
of,339,O
the,339,O
anticonvulsant,339,O
activity,339,O
of,339,O
this,339,O
agent,339,O
.,339,O
Serotonin,340,B-GENE-Y
transporter,340,I-GENE-Y
gene,340,O
regulatory,340,O
region,340,O
polymorphism,340,O
(,340,O
5-HTTLPR,340,B-GENE-Y
),340,O
",",340,O
[,340,B-CHEMICAL
3H,340,I-CHEMICAL
],340,I-CHEMICAL
paroxetine,340,I-CHEMICAL
binding,340,O
in,340,O
healthy,340,O
control,340,O
subjects,340,O
and,340,O
alcohol-dependent,340,O
patients,340,O
and,340,O
their,340,O
relationships,340,O
to,340,O
impulsivity,340,O
.,340,O
The,341,O
aim,341,O
of,341,O
this,341,O
study,341,O
was,341,O
to,341,O
investigate,341,O
[,341,B-CHEMICAL
3H,341,I-CHEMICAL
],341,I-CHEMICAL
paroxetine,341,I-CHEMICAL
binding,341,O
and,341,O
impulsivity,341,O
in,341,O
alcohol-dependent,341,B-CHEMICAL
and,341,O
age-matched,341,O
control,341,O
subjects,341,O
in,341,O
relation,341,O
to,341,O
a,341,O
5'-promoter,341,O
region,341,O
serotonin,341,B-CHEMICAL
transporter,341,I-GENE-Y
(,341,O
5-HTT,341,B-GENE-Y
),341,O
polymorphism,341,O
(,341,O
5-HTTLPR,341,B-GENE-Y
),341,O
.,341,O
Alcohol-dependent,342,O
subjects,342,O
were,342,O
hypothesized,342,O
to,342,O
show,342,O
a,342,O
decreased,342,O
number,342,O
of,342,O
bindings,342,O
sites,342,O
and,342,O
a,342,O
lower,342,O
dissociation,342,O
constant,342,O
.,342,O
5-HTTLPR,343,B-GENE-Y
S-genotype,343,O
carriers,343,O
in,343,O
both,343,O
alcohol-dependent,343,B-CHEMICAL
and,343,O
control,343,O
subjects,343,O
were,343,O
expected,343,O
to,343,O
show,343,O
significantly,343,O
fewer,343,O
binding,343,O
sites,343,O
and,343,O
a,343,O
lower,343,O
dissociation,343,O
constant,343,O
.,343,O
Influences,344,O
of,344,O
impulsive,344,O
traits,344,O
",",344,O
chronic,344,O
daily,344,O
alcohol,344,B-CHEMICAL
intake,344,O
",",344,O
duration,344,O
of,344,O
alcohol,344,B-CHEMICAL
dependence,344,O
",",344,O
age,344,O
of,344,O
onset,344,O
and,344,O
age,344,O
on,344,O
[,344,B-CHEMICAL
3H,344,I-CHEMICAL
],344,I-CHEMICAL
paroxetine,344,I-CHEMICAL
binding,344,O
were,344,O
also,344,O
investigated,344,O
.,344,O
Inpatients,345,O
meeting,345,O
DSM,345,O
IV,345,O
alcohol,345,B-CHEMICAL
dependence,345,O
criteria,345,O
and,345,O
of,345,O
German,345,O
descent,345,O
were,345,O
recruited,345,O
to,345,O
avoid,345,O
ethnic,345,O
stratification,345,O
effects,345,O
.,345,O
One,346,O
hundred,346,O
and,346,O
seventeen,346,O
control,346,O
subjects,346,O
of,346,O
similar,346,O
social,346,O
status,346,O
were,346,O
recruited,346,O
from,346,O
a,346,O
town,346,O
community,346,O
.,346,O
Blood,347,O
samples,347,O
were,347,O
taken,347,O
from,347,O
both,347,O
alcohol-dependent,347,B-CHEMICAL
and,347,O
control,347,O
subjects,347,O
to,347,O
determine,347,O
5-HTTLPR,347,B-GENE-Y
genotypes,347,O
using,347,O
PCR,347,O
of,347,O
lymphocyte,347,O
DNA,347,O
",",347,O
and,347,O
to,347,O
perform,347,O
platelet,347,O
[,347,B-CHEMICAL
3H,347,I-CHEMICAL
],347,I-CHEMICAL
paroxetine,347,I-CHEMICAL
binding,347,O
(,347,O
binding,347,O
capacity,347,O
:,347,O
B,347,O
(,347,O
max,347,O
),347,O
;,347,O
and,347,O
dissociation,347,O
constant,347,O
:,347,O
K,347,O
(,347,O
D,347,O
),347,O
),347,O
.,347,O
Impulsivity,348,O
was,348,O
assessed,348,O
using,348,O
the,348,O
Barratt,348,O
impulsiveness,348,O
scale,348,O
version,348,O
5,348,O
(,348,O
BIS-5,348,O
),348,O
in,348,O
alcohol-dependent,348,B-CHEMICAL
subjects,348,O
only,348,O
.,348,O
Alcohol-dependent,349,B-CHEMICAL
subjects,349,O
were,349,O
subdivided,349,O
into,349,O
low,349,O
or,349,O
high,349,O
impulsivity,349,O
groups,349,O
using,349,O
a,349,O
median-split,349,O
of,349,O
the,349,O
BIS-5,349,O
scale,349,O
.,349,O
The,350,O
control,350,O
group,350,O
was,350,O
slightly,350,O
older,350,O
than,350,O
the,350,O
alcohol-dependent,350,O
group,350,O
(,350,O
not,350,O
statistically,350,O
significant,350,O
),350,O
.,350,O
[,351,B-CHEMICAL
3H,351,I-CHEMICAL
],351,I-CHEMICAL
paroxetine,351,I-CHEMICAL
binding,351,O
was,351,O
investigated,351,O
in,351,O
72,351,O
control,351,O
subjects,351,O
and,351,O
72,351,O
patients,351,O
",",351,O
of,351,O
which,351,O
five,351,O
patients,351,O
met,351,O
type,351,O
2,351,O
alcohol,351,B-CHEMICAL
dependence,351,O
criteria,351,O
.,351,O
Genotyping,352,O
was,352,O
carried,352,O
out,352,O
in,352,O
all,352,O
patients,352,O
and,352,O
control,352,O
subjects,352,O
.,352,O
A,353,O
significant,353,O
influence,353,O
of,353,O
duration,353,O
of,353,O
alcohol,353,B-CHEMICAL
dependence,353,O
was,353,O
found,353,O
on,353,O
the,353,O
[,353,B-CHEMICAL
3H,353,I-CHEMICAL
],353,I-CHEMICAL
paroxetine,353,I-CHEMICAL
binding,353,O
K,353,O
(,353,O
D,353,O
),353,O
but,353,O
not,353,O
B,353,O
(,353,O
max,353,O
.,353,O
),353,O
Neither,354,O
alcohol-dependent,354,B-CHEMICAL
nor,354,O
control,354,O
subjects,354,O
showed,354,O
any,354,O
differences,354,O
in,354,O
B,354,O
(,354,O
max,354,O
),354,O
or,354,O
K,354,O
(,354,O
D,354,O
),354,O
.,354,O
S-allele,355,O
carriers,355,O
did,355,O
not,355,O
show,355,O
a,355,O
decreased,355,O
binding,355,O
or,355,O
lower,355,O
dissociation,355,O
constant,355,O
.,355,O
Furthermore,356,O
",",356,O
no,356,O
significant,356,O
interaction,356,O
between,356,O
B,356,O
(,356,O
max,356,O
),356,O
and,356,O
K,356,O
(,356,O
D,356,O
),356,O
with,356,O
either,356,O
5-HTTLPR,356,B-GENE-Y
genotype,356,O
or,356,O
impulsivity,356,O
was,356,O
revealed,356,O
.,356,O
This,357,O
was,357,O
the,357,O
first,357,O
study,357,O
to,357,O
investigate,357,O
platelet,357,O
[,357,B-CHEMICAL
3H,357,I-CHEMICAL
],357,I-CHEMICAL
paroxetine,357,I-CHEMICAL
binding,357,O
in,357,O
alcohol-dependent,357,B-CHEMICAL
and,357,O
age-matched,357,O
control,357,O
subjects,357,O
in,357,O
relation,357,O
to,357,O
the,357,O
5-HTTLPR,357,B-GENE-Y
genotype,357,O
.,357,O
No,358,O
differences,358,O
concerning,358,O
5-HTTLPR-alleles,358,B-GENE-Y
were,358,O
found,358,O
in,358,O
these,358,O
groups,358,O
Furthermore,358,O
",",358,O
no,358,O
significant,358,O
interaction,358,O
between,358,O
these,358,O
parameters,358,O
and,358,O
impulsivity,358,O
was,358,O
shown,358,O
in,358,O
alcohol-dependent,358,B-CHEMICAL
subjects,358,O
.,358,O
These,359,O
results,359,O
do,359,O
not,359,O
support,359,O
previous,359,O
results,359,O
of,359,O
altered,359,O
[,359,B-CHEMICAL
3H,359,I-CHEMICAL
],359,I-CHEMICAL
paroxetine,359,I-CHEMICAL
binding,359,O
sites,359,O
in,359,O
alcohol-dependent,359,O
subjects,359,O
or,359,O
5-HTTLPR,359,B-GENE-Y
S-allele,359,O
carriers,359,O
.,359,O
K,360,O
(,360,O
D,360,O
),360,O
might,360,O
be,360,O
influenced,360,O
by,360,O
duration,360,O
of,360,O
alcohol,360,B-CHEMICAL
dependence,360,O
",",360,O
but,360,O
not,360,O
sufficiently,360,O
to,360,O
yield,360,O
differences,360,O
between,360,O
alcohol-dependent,360,B-CHEMICAL
and,360,O
control,360,O
subjects,360,O
.,360,O
Arachidonic,361,B-CHEMICAL
acid,361,I-CHEMICAL
and,361,O
nonsteroidal,361,O
anti-inflammatory,361,O
drugs,361,O
induce,361,O
conformational,361,O
changes,361,O
in,361,O
the,361,O
human,361,B-GENE-Y
prostaglandin,361,I-GENE-Y
endoperoxide,361,I-GENE-Y
H2,361,I-GENE-Y
synthase-2,361,I-GENE-Y
(,361,O
cyclooxygenase-2,361,B-GENE-Y
),361,O
.,361,O
By,362,O
using,362,O
the,362,O
technique,362,O
of,362,O
site-directed,362,O
spin,362,O
labeling,362,O
combined,362,O
with,362,O
EPR,362,O
spectroscopy,362,O
",",362,O
we,362,O
have,362,O
observed,362,O
that,362,O
binding,362,O
of,362,O
arachidonic,362,B-CHEMICAL
acid,362,I-CHEMICAL
and,362,O
nonsteroidal,362,O
anti-inflammatory,362,O
drugs,362,O
induces,362,O
conformational,362,O
changes,362,O
in,362,O
the,362,O
human,362,B-GENE-N
prostaglandin,362,B-CHEMICAL
endoperoxide,362,I-CHEMICAL
H,362,I-CHEMICAL
(,362,I-CHEMICAL
2,362,I-CHEMICAL
),362,I-CHEMICAL
synthase,362,I-GENE-N
enzyme,362,I-GENE-N
(,362,O
PGHS-2,362,B-GENE-Y
),362,O
.,362,O
Line,363,O
shape,363,O
broadening,363,O
resulting,363,O
from,363,O
spin-spin,363,O
coupling,363,O
of,363,O
nitroxide,363,B-CHEMICAL
pairs,363,O
introduced,363,O
into,363,O
the,363,O
membrane-binding,363,O
helices,363,O
of,363,O
PGHS-2,363,B-GENE-Y
was,363,O
used,363,O
to,363,O
calculate,363,O
the,363,O
inter-helical,363,O
distances,363,O
and,363,O
changes,363,O
in,363,O
these,363,O
distances,363,O
that,363,O
occur,363,O
in,363,O
response,363,O
to,363,O
binding,363,O
various,363,O
ligands,363,O
.,363,O
The,364,O
inter-residue,364,O
distances,364,O
determined,364,O
for,364,O
the,364,O
PGHS-2,364,B-GENE-Y
holoenzyme,364,O
using,364,O
EPR,364,O
were,364,O
1-7.9,364,O
A,364,O
shorter,364,O
than,364,O
those,364,O
of,364,O
the,364,O
crystal,364,O
structure,364,O
of,364,O
the,364,O
PGHS-2,364,B-GENE-Y
holoenzyme,364,O
.,364,O
However,365,O
",",365,O
inter-helical,365,O
distances,365,O
calculated,365,O
and,365,O
determined,365,O
by,365,O
EPR,365,O
for,365,O
PGHS-2,365,B-GENE-Y
complexed,365,O
with,365,O
arachidonic,365,B-CHEMICAL
acid,365,I-CHEMICAL
",",365,O
flurbiprofen,365,B-CHEMICAL
",",365,O
and,365,O
SC-58125,365,B-CHEMICAL
were,365,O
in,365,O
close,365,O
agreement,365,O
with,365,O
those,365,O
obtained,365,O
from,365,O
the,365,O
cognate,365,O
crystal,365,O
structures,365,O
.,365,O
These,366,O
results,366,O
indicate,366,O
that,366,O
the,366,O
structure,366,O
of,366,O
the,366,O
solubilized,366,O
PGHS-2,366,B-GENE-Y
holoenzyme,366,O
measured,366,O
in,366,O
solution,366,O
differs,366,O
from,366,O
the,366,O
crystal,366,O
structure,366,O
of,366,O
PGHS-2,366,B-GENE-Y
holoenzyme,366,O
obtained,366,O
by,366,O
x-ray,366,O
analysis,366,O
.,366,O
Furthermore,367,O
",",367,O
binding,367,O
of,367,O
ligands,367,O
induces,367,O
a,367,O
conformational,367,O
change,367,O
in,367,O
the,367,O
holo-PGHS-2,367,O
",",367,O
converting,367,O
it,367,O
to,367,O
a,367,O
structure,367,O
similar,367,O
to,367,O
those,367,O
obtained,367,O
by,367,O
x-ray,367,O
analysis,367,O
.,367,O
Proteolysis,368,O
protection,368,O
assays,368,O
had,368,O
previously,368,O
provided,368,O
circumstantial,368,O
evidence,368,O
that,368,O
binding,368,O
of,368,O
heme,368,O
and,368,O
non-steroidal,368,O
anti-inflammatory,368,O
drugs,368,O
alters,368,O
the,368,O
conformation,368,O
of,368,O
PGHS,368,B-GENE-N
",",368,O
but,368,O
the,368,O
present,368,O
experiments,368,O
are,368,O
the,368,O
first,368,O
to,368,O
directly,368,O
measure,368,O
such,368,O
changes,368,O
.,368,O
The,369,O
finding,369,O
that,369,O
arachidonate,369,B-CHEMICAL
can,369,O
also,369,O
induce,369,O
a,369,O
conformational,369,O
change,369,O
in,369,O
PGHS-2,369,B-GENE-Y
was,369,O
unexpected,369,O
",",369,O
and,369,O
the,369,O
magnitude,369,O
of,369,O
changes,369,O
suggests,369,O
this,369,O
structural,369,O
flexibility,369,O
may,369,O
be,369,O
integral,369,O
to,369,O
the,369,O
cyclooxygenase,369,B-GENE-N
catalytic,369,O
mechanism,369,O
.,369,O
Suppression,370,O
of,370,O
NF-kappaB,370,B-GENE-N
activity,370,O
by,370,O
sulfasalazine,370,B-CHEMICAL
is,370,O
mediated,370,O
by,370,O
direct,370,O
inhibition,370,O
of,370,O
IkappaB,370,B-GENE-N
kinases,370,I-GENE-N
alpha,370,I-GENE-N
and,370,I-GENE-N
beta,370,I-GENE-N
.,370,O
BACKGROUND,371,O
&,371,O
AIMS,371,O
:,371,O
Activation,371,O
of,371,O
NF-kappaB/Rel,371,B-GENE-N
has,371,O
been,371,O
implicated,371,O
in,371,O
the,371,O
pathogenesis,371,O
of,371,O
inflammatory,371,O
bowel,371,O
disease,371,O
(,371,O
IBD,371,O
),371,O
.,371,O
Various,372,O
drugs,372,O
used,372,O
in,372,O
the,372,O
treatment,372,O
of,372,O
IBD,372,O
",",372,O
such,372,O
as,372,O
glucocorticoids,372,O
",",372,O
5-aminosalicylic,372,B-CHEMICAL
acid,372,I-CHEMICAL
",",372,O
and,372,O
sulfasalazine,372,B-CHEMICAL
",",372,O
interfere,372,O
with,372,O
NF-kappaB/Rel,372,B-GENE-N
signaling,372,O
.,372,O
The,373,O
aim,373,O
of,373,O
this,373,O
study,373,O
was,373,O
to,373,O
define,373,O
the,373,O
molecular,373,O
mechanism,373,O
by,373,O
which,373,O
sulfasalazine,373,B-CHEMICAL
inhibits,373,O
NF-kappaB,373,B-GENE-N
activation,373,O
.,373,O
METHODS,374,O
:,374,O
The,374,O
effects,374,O
of,374,O
sulfasalazine,374,B-CHEMICAL
and,374,O
its,374,O
moieties,374,O
on,374,O
NF-kappaB,374,B-GENE-N
signaling,374,O
were,374,O
evaluated,374,O
using,374,O
electromobility,374,O
shift,374,O
",",374,O
transfection,374,O
",",374,O
and,374,O
immune,374,O
complex,374,O
kinase,374,O
assays,374,O
.,374,O
The,375,O
direct,375,O
effect,375,O
of,375,O
sulfasalazine,375,B-CHEMICAL
on,375,O
IkappaB,375,B-GENE-N
kinase,375,I-GENE-N
(,375,O
IKK,375,B-GENE-N
),375,O
activity,375,O
was,375,O
investigated,375,O
using,375,O
purified,375,O
recombinant,375,O
IKK-alpha,375,B-GENE-N
and,375,I-GENE-N
-beta,375,I-GENE-N
proteins,375,O
.,375,O
RESULTS,376,O
:,376,O
NF-kappaB/Rel,376,B-GENE-N
activity,376,O
induced,376,O
by,376,O
tumor,376,B-GENE-Y
necrosis,376,I-GENE-Y
factor,376,I-GENE-Y
alpha,376,I-GENE-Y
",",376,O
12-O-tetradecanoylphorbol-13-acetate,376,B-CHEMICAL
",",376,O
or,376,O
overexpression,376,O
of,376,O
NF-kappaB-inducing,376,B-GENE-Y
kinase,376,I-GENE-Y
",",376,O
IKK-alpha,376,B-GENE-Y
",",376,O
IKK-beta,376,B-GENE-Y
",",376,O
or,376,O
constitutively,376,O
active,376,O
IKK-alpha,376,B-GENE-Y
and,376,O
IKK-beta,376,B-GENE-Y
mutants,376,O
was,376,O
inhibited,376,O
dose,376,O
dependently,376,O
by,376,O
sulfasalazine,376,B-CHEMICAL
.,376,O
Sulfasalazine,377,B-CHEMICAL
inhibited,377,O
tumor,377,B-GENE-Y
necrosis,377,I-GENE-Y
factor,377,I-GENE-Y
alpha-induced,377,O
activation,377,O
of,377,O
endogenous,377,O
IKK,377,B-GENE-N
in,377,O
Jurkat,377,O
T,377,O
cells,377,O
and,377,O
SW620,377,O
colon,377,O
cells,377,O
",",377,O
as,377,O
well,377,O
as,377,O
the,377,O
catalytic,377,O
activity,377,O
of,377,O
purified,377,O
IKK-alpha,377,B-GENE-Y
and,377,O
IKK-beta,377,B-GENE-Y
in,377,O
vitro,377,O
.,377,O
In,378,O
contrast,378,O
",",378,O
the,378,O
moieties,378,O
of,378,O
sulfasalazine,378,B-CHEMICAL
",",378,O
5-aminosalicylic,378,B-CHEMICAL
acid,378,I-CHEMICAL
",",378,O
and,378,O
sulfapyridine,378,B-CHEMICAL
or,378,O
4-aminosalicylic,378,B-CHEMICAL
acid,378,I-CHEMICAL
had,378,O
no,378,O
effect,378,O
.,378,O
Activation,379,O
of,379,O
extracellular,379,B-GENE-N
signal-related,379,I-GENE-N
kinase,379,I-GENE-N
(,379,I-GENE-N
ERK,379,I-GENE-N
),379,I-GENE-N
1,379,I-GENE-N
and,379,I-GENE-N
2,379,I-GENE-N
",",379,O
c-Jun-N-terminal,379,B-GENE-Y
kinase,379,I-GENE-Y
(,379,I-GENE-Y
JNK,379,I-GENE-Y
),379,I-GENE-Y
1,379,I-GENE-Y
",",379,O
and,379,O
p38,379,B-GENE-N
was,379,O
unaffected,379,O
by,379,O
sulfasalazine,379,B-CHEMICAL
.,379,O
The,380,O
decrease,380,O
in,380,O
substrate,380,O
phosphorylation,380,O
by,380,O
IKK-alpha,380,B-GENE-N
and,380,I-GENE-N
-beta,380,I-GENE-N
is,380,O
associated,380,O
with,380,O
a,380,O
decrease,380,O
in,380,O
autophosphorylation,380,O
of,380,O
IKKs,380,B-GENE-N
and,380,O
can,380,O
be,380,O
antagonized,380,O
by,380,O
excess,380,O
adenosine,380,B-CHEMICAL
triphosphate,380,I-CHEMICAL
.,380,O
CONCLUSIONS,381,O
:,381,O
These,381,O
data,381,O
identify,381,O
sulfasalazine,381,B-CHEMICAL
as,381,O
a,381,O
direct,381,O
inhibitor,381,O
of,381,O
IKK-alpha,381,B-GENE-N
and,381,I-GENE-N
-beta,381,I-GENE-N
by,381,O
antagonizing,381,O
adenosine,381,B-CHEMICAL
triphosphate,381,I-CHEMICAL
binding,381,O
.,381,O
The,382,O
suppression,382,O
of,382,O
NF-kappaB,382,B-GENE-N
activation,382,O
by,382,O
inhibition,382,O
of,382,O
the,382,O
IKKs,382,B-GENE-N
contributes,382,O
to,382,O
the,382,O
well-known,382,O
anti-inflammatory,382,O
and,382,O
immunosuppressive,382,O
effects,382,O
of,382,O
sulfasalazine,382,B-CHEMICAL
.,382,O
Biochemistry,383,O
of,383,O
cyclooxygenase,383,B-GENE-Y
(,383,I-GENE-Y
COX,383,I-GENE-Y
),383,I-GENE-Y
-2,383,I-GENE-Y
inhibitors,383,O
and,383,O
molecular,383,O
pathology,383,O
of,383,O
COX-2,383,B-GENE-Y
in,383,O
neoplasia,383,O
.,383,O
Several,384,O
types,384,O
of,384,O
human,384,O
tumors,384,O
overexpress,384,O
cyclooxygenase,384,B-GENE-Y
(,384,I-GENE-Y
COX,384,I-GENE-Y
),384,I-GENE-Y
-2,384,I-GENE-Y
but,384,O
not,384,O
COX-1,384,B-GENE-Y
",",384,O
and,384,O
gene,384,O
knockout,384,O
transfection,384,O
experiments,384,O
demonstrate,384,O
a,384,O
central,384,O
role,384,O
of,384,O
COX-2,384,B-GENE-Y
in,384,O
experimental,384,O
tumorigenesis,384,O
.,384,O
COX-2,385,B-GENE-Y
produces,385,O
prostaglandins,385,B-CHEMICAL
that,385,O
inhibit,385,O
apoptosis,385,O
and,385,O
stimulate,385,O
angiogenesis,385,O
and,385,O
invasiveness,385,O
.,385,O
Selective,386,O
COX-2,386,B-GENE-Y
inhibitors,386,O
reduce,386,O
prostaglandin,386,B-CHEMICAL
synthesis,386,O
",",386,O
restore,386,O
apoptosis,386,O
",",386,O
and,386,O
inhibit,386,O
cancer,386,O
cell,386,O
proliferation,386,O
.,386,O
In,387,O
animal,387,O
studies,387,O
they,387,O
limit,387,O
carcinogen-induced,387,O
tumorigenesis,387,O
.,387,O
In,388,O
contrast,388,O
",",388,O
aspirin-like,388,B-CHEMICAL
nonselective,388,O
NSAIDs,388,O
such,388,O
as,388,O
sulindac,388,B-CHEMICAL
and,388,O
indomethacin,388,B-CHEMICAL
inhibit,388,O
not,388,O
only,388,O
the,388,O
enzymatic,388,O
action,388,O
of,388,O
the,388,O
highly,388,O
inducible,388,O
",",388,O
proinflammatory,388,O
COX-2,388,B-GENE-Y
but,388,O
the,388,O
constitutively,388,O
expressed,388,O
",",388,O
cytoprotective,388,O
COX-1,388,B-GENE-Y
as,388,O
well,388,O
.,388,O
Consequently,389,O
",",389,O
nonselective,389,O
NSAIDs,389,O
can,389,O
cause,389,O
platelet,389,O
dysfunction,389,O
",",389,O
gastrointestinal,389,O
ulceration,389,O
",",389,O
and,389,O
kidney,389,O
damage,389,O
.,389,O
For,390,O
that,390,O
reason,390,O
",",390,O
selective,390,O
inhibition,390,O
of,390,O
COX-2,390,B-GENE-Y
to,390,O
treat,390,O
neoplastic,390,O
proliferation,390,O
is,390,O
preferable,390,O
to,390,O
nonselective,390,O
inhibition,390,O
.,390,O
Selective,391,O
COX-2,391,B-GENE-Y
inhibitors,391,O
",",391,O
such,391,O
as,391,O
meloxicam,391,B-CHEMICAL
",",391,O
celecoxib,391,B-CHEMICAL
(,391,O
SC-58635,391,B-CHEMICAL
),391,O
",",391,O
and,391,O
rofecoxib,391,B-CHEMICAL
(,391,O
MK-0966,391,B-CHEMICAL
),391,O
",",391,O
are,391,O
NSAIDs,391,O
that,391,O
have,391,O
been,391,O
modified,391,O
chemically,391,O
to,391,O
preferentially,391,O
inhibit,391,O
COX-2,391,B-GENE-Y
but,391,O
not,391,O
COX-1,391,B-GENE-Y
.,391,O
For,392,O
instance,392,O
",",392,O
meloxicam,392,B-CHEMICAL
inhibits,392,O
the,392,O
growth,392,O
of,392,O
cultured,392,O
colon,392,O
cancer,392,O
cells,392,O
(,392,O
HCA-7,392,O
and,392,O
Moser-S,392,O
),392,O
that,392,O
express,392,O
COX-2,392,B-GENE-Y
but,392,O
has,392,O
no,392,O
effect,392,O
on,392,O
HCT-116,392,O
tumor,392,O
cells,392,O
that,392,O
do,392,O
not,392,O
express,392,O
COX-2,392,B-GENE-Y
.,392,O
NS-398,393,B-CHEMICAL
induces,393,O
apoptosis,393,O
in,393,O
COX-2,393,B-GENE-Y
expressing,393,O
LNCaP,393,O
prostate,393,O
cancer,393,O
cells,393,O
and,393,O
",",393,O
surprisingly,393,O
",",393,O
in,393,O
colon,393,O
cancer,393,O
S/KS,393,O
cells,393,O
that,393,O
does,393,O
not,393,O
express,393,O
COX-2,393,B-GENE-Y
.,393,O
This,394,O
effect,394,O
may,394,O
due,394,O
to,394,O
induction,394,O
of,394,O
apoptosis,394,O
through,394,O
uncoupling,394,O
of,394,O
oxidative,394,O
phosphorylation,394,O
and,394,O
down-regulation,394,O
of,394,O
Bcl-2,394,B-GENE-Y
",",394,O
as,394,O
has,394,O
been,394,O
demonstrated,394,O
for,394,O
some,394,O
nonselective,394,O
NSAIDs,394,O
",",394,O
for,394,O
instance,394,O
",",394,O
flurbiprofen,394,B-CHEMICAL
.,394,O
COX-2,395,B-GENE-Y
mRNA,395,O
and,395,O
COX-2,395,B-GENE-Y
protein,395,O
is,395,O
constitutively,395,O
expressed,395,O
in,395,O
the,395,O
kidney,395,O
",",395,O
brain,395,O
",",395,O
spinal,395,O
cord,395,O
",",395,O
and,395,O
ductus,395,O
deferens,395,O
",",395,O
and,395,O
in,395,O
the,395,O
uterus,395,O
during,395,O
implantation,395,O
.,395,O
In,396,O
addition,396,O
",",396,O
COX-2,396,B-GENE-Y
is,396,O
constitutively,396,O
and,396,O
dominantly,396,O
expressed,396,O
in,396,O
the,396,O
pancreatic,396,O
islet,396,O
cells,396,O
.,396,O
These,397,O
findings,397,O
might,397,O
somewhat,397,O
limit,397,O
the,397,O
use,397,O
of,397,O
presently,397,O
available,397,O
selective,397,O
COX-2,397,B-GENE-Y
inhibitors,397,O
in,397,O
cancer,397,O
prevention,397,O
but,397,O
will,397,O
probably,397,O
not,397,O
deter,397,O
their,397,O
successful,397,O
application,397,O
for,397,O
the,397,O
treatment,397,O
of,397,O
human,397,O
cancers,397,O
.,397,O
The,398,O
aromatic-L-amino,398,B-GENE-Y
acid,398,I-GENE-Y
decarboxylase,398,I-GENE-Y
inhibitor,398,O
carbidopa,398,O
is,398,O
selectively,398,O
cytotoxic,398,O
to,398,O
human,398,O
pulmonary,398,O
carcinoid,398,O
and,398,O
small,398,O
cell,398,O
lung,398,O
carcinoma,398,O
cells,398,O
.,398,O
The,399,O
carcinoid,399,O
tumor,399,O
is,399,O
an,399,O
uncommon,399,O
neuroendocrine,399,O
neoplasm,399,O
the,399,O
hallmark,399,O
of,399,O
which,399,O
is,399,O
excessive,399,O
serotonin,399,B-CHEMICAL
production,399,O
.,399,O
In,400,O
studying,400,O
kinetics,400,O
of,400,O
tryptophan,400,B-CHEMICAL
hydroxylase,400,I-GENE-N
and,400,O
aromatic-L-amino,400,B-CHEMICAL
acid,400,I-CHEMICAL
decarboxylase,400,I-GENE-Y
(,400,O
AAAD,400,B-GENE-Y
),400,O
in,400,O
human,400,O
carcinoid,400,O
hepatic,400,O
metastases,400,O
and,400,O
adjacent,400,O
normal,400,O
liver,400,O
(,400,O
J,400,O
.,400,O
A.,401,O
Gilbert,401,O
et,401,O
al,401,O
",",401,O
Biochem,401,O
.,401,O
Pharmacol.,402,O
",",402,O
50,402,O
:,402,O
845-850,402,O
",",402,O
1995,402,O
),402,O
",",402,O
we,402,O
identified,402,O
one,402,O
significant,402,O
difference,402,O
:,402,O
the,402,O
Vmax,402,O
of,402,O
carcinoid,402,O
AAAD,402,B-GENE-Y
was,402,O
50-fold,402,O
higher,402,O
than,402,O
that,402,O
in,402,O
normal,402,O
liver,402,O
.,402,O
Here,403,O
",",403,O
we,403,O
report,403,O
Western,403,O
and,403,O
Northern,403,O
analyses,403,O
detecting,403,O
large,403,O
quantities,403,O
of,403,O
AAAD,403,B-GENE-Y
polypeptide,403,O
and,403,O
mRNA,403,O
in,403,O
human,403,O
carcinoid,403,O
primary,403,O
as,403,O
well,403,O
as,403,O
metastatic,403,O
tumors,403,O
compared,403,O
with,403,O
normal,403,O
surrounding,403,O
tissues,403,O
.,403,O
To,404,O
assess,404,O
the,404,O
feasibility,404,O
of,404,O
targeting,404,O
these,404,O
high,404,O
AAAD,404,B-GENE-Y
levels,404,O
for,404,O
chemotherapy,404,O
",",404,O
AAAD,404,B-GENE-Y
inhibitors,404,O
carbidopa,404,B-CHEMICAL
(,404,O
alpha-methyl-dopahydrazine,404,B-CHEMICAL
),404,O
",",404,O
alpha-monofluoromethyldopa,404,B-CHEMICAL
(,404,O
MFMD,404,B-CHEMICAL
),404,O
",",404,O
and,404,O
3-hydroxybenzylhydrazine,404,B-CHEMICAL
(,404,O
NSD-1015,404,B-CHEMICAL
),404,O
were,404,O
incubated,404,O
(,404,O
72,404,O
h,404,O
),404,O
with,404,O
NCI-H727,404,O
human,404,O
lung,404,O
carcinoid,404,O
cells,404,O
.,404,O
Carbidopa,405,B-CHEMICAL
and,405,O
MFMD,405,B-CHEMICAL
were,405,O
lethal,405,O
(,405,O
IC50,405,O
=,405,O
29,405,O
+/-,405,O
2,405,O
microM,405,O
and,405,O
56,405,O
+/-,405,O
6,405,O
microM,405,O
",",405,O
respectively,405,O
),405,O
;,405,O
NSD-1015,405,B-CHEMICAL
had,405,O
no,405,O
effect,405,O
on,405,O
proliferation,405,O
.,405,O
On,406,O
exposure,406,O
to,406,O
other,406,O
human,406,O
tumor,406,O
lines,406,O
",",406,O
carbidopa,406,B-CHEMICAL
was,406,O
lethal,406,O
only,406,O
to,406,O
NCI-H146,406,O
and,406,O
NCI-H209,406,O
small,406,O
cell,406,O
lung,406,O
carcinoma,406,O
(,406,O
SCLC,406,O
),406,O
lines,406,O
(,406,O
IC50,406,O
=,406,O
12,406,O
+/-,406,O
1,406,O
microM,406,O
and,406,O
22,406,O
+/-,406,O
5,406,O
microM,406,O
",",406,O
respectively,406,O
),406,O
.,406,O
Carbidopa,407,B-CHEMICAL
(,407,O
100,407,O
microM,407,O
),407,O
decreased,407,O
growth,407,O
of,407,O
(,407,O
but,407,O
did,407,O
not,407,O
kill,407,O
),407,O
SK-N-SH,407,O
neuroblastoma,407,O
and,407,O
A204,407,O
rhabdomyosarcoma,407,O
cells,407,O
and,407,O
did,407,O
not,407,O
affect,407,O
proliferation,407,O
of,407,O
DU,407,O
145,407,O
prostate,407,O
",",407,O
MCF7,407,O
breast,407,O
",",407,O
or,407,O
NCI-H460,407,O
large,407,O
cell,407,O
lung,407,O
carcinoma,407,O
lines,407,O
.,407,O
The,408,O
rank,408,O
order,408,O
of,408,O
lines,408,O
by,408,O
AAAD,408,B-GENE-Y
activity,408,O
was,408,O
NCI-H146,408,O
>,408,O
NCI-H209,408,O
>,408,O
SK-N-SH,408,O
>,408,O
NCI-H727,408,O
",",408,O
whereas,408,O
A204,408,O
",",408,O
DU,408,O
145,408,O
",",408,O
MCF7,408,O
",",408,O
and,408,O
NCI-H460,408,O
had,408,O
no,408,O
measurable,408,O
activity,408,O
.,408,O
For,409,O
lung,409,O
tumor,409,O
lines,409,O
(,409,O
carcinoid,409,O
",",409,O
two,409,O
SCLC,409,O
",",409,O
and,409,O
one,409,O
large,409,O
cell,409,O
lung,409,O
carcinoma,409,O
),409,O
",",409,O
AAAD,409,B-GENE-Y
activity,409,O
was,409,O
correlated,409,O
with,409,O
the,409,O
potency,409,O
of,409,O
carbidopa-induced,409,B-CHEMICAL
cytotoxicity,409,O
.,409,O
However,410,O
",",410,O
carcinoid,410,O
cell,410,O
death,410,O
was,410,O
not,410,O
solely,410,O
attributable,410,O
to,410,O
complete,410,O
inhibition,410,O
of,410,O
either,410,O
AAAD,410,B-GENE-Y
activity,410,O
or,410,O
the,410,O
serotonin,410,B-CHEMICAL
synthetic,410,O
pathway,410,O
.,410,O
In,411,O
further,411,O
evaluating,411,O
potential,411,O
applications,411,O
of,411,O
these,411,O
findings,411,O
with,411,O
carbidopa,411,B-CHEMICAL
",",411,O
we,411,O
determined,411,O
that,411,O
sublethal,411,O
doses,411,O
of,411,O
carbidopa,411,B-CHEMICAL
produced,411,O
additive,411,O
cytotoxic,411,O
effects,411,O
in,411,O
carcinoid,411,O
cells,411,O
in,411,O
combination,411,O
with,411,O
etoposide,411,O
and,411,O
cytotoxic,411,O
synergy,411,O
in,411,O
SCLC,411,O
cells,411,O
when,411,O
coincubated,411,O
with,411,O
topotecan,411,B-CHEMICAL
.,411,O
Hexahydrochromeno,412,B-CHEMICAL
[,412,I-CHEMICAL
"4,3-b",412,I-CHEMICAL
],412,I-CHEMICAL
pyrrole,412,I-CHEMICAL
derivatives,412,O
as,412,O
acetylcholinesterase,412,B-GENE-Y
inhibitors,412,O
.,412,O
In,413,O
a,413,O
search,413,O
for,413,O
less,413,O
flexible,413,O
analogues,413,O
of,413,O
caproctamine,413,B-CHEMICAL
(,413,O
1,413,O
),413,O
",",413,O
a,413,O
diamine,413,B-CHEMICAL
diamide,413,B-CHEMICAL
endowed,413,O
with,413,O
an,413,O
interesting,413,O
AChE,413,B-GENE-Y
affinity,413,O
profile,413,O
",",413,O
we,413,O
discovered,413,O
compound,413,O
2,413,O
",",413,O
in,413,O
which,413,O
the,413,O
terminal,413,O
2-methoxybenzyl,413,B-CHEMICAL
groups,413,O
of,413,O
1,413,O
have,413,O
been,413,O
incorporated,413,O
into,413,O
a,413,O
tricyclic,413,B-CHEMICAL
system,413,O
.,413,O
Since,414,O
this,414,O
compound,414,O
retains,414,O
good,414,O
AChE,414,B-GENE-Y
inhibitory,414,O
activity,414,O
and,414,O
its,414,O
hexahydrochromeno,414,B-CHEMICAL
[,414,I-CHEMICAL
"4,3-b",414,I-CHEMICAL
],414,I-CHEMICAL
pyrrole,414,I-CHEMICAL
moiety,414,O
is,414,O
reminiscent,414,O
of,414,O
the,414,O
hexahydropyrrolo,414,B-CHEMICAL
[,414,I-CHEMICAL
"2,3-b",414,I-CHEMICAL
],414,I-CHEMICAL
indole,414,I-CHEMICAL
of,414,I-CHEMICAL
physostigmine,414,I-CHEMICAL
(,414,O
3,414,O
),414,O
",",414,O
we,414,O
have,414,O
designed,414,O
and,414,O
synthesized,414,O
carbamates,414,B-CHEMICAL
4-6,414,O
",",414,O
and,414,O
their,414,O
biological,414,O
evaluation,414,O
has,414,O
been,414,O
assessed,414,O
in,414,O
vitro,414,O
against,414,O
human,414,B-GENE-Y
AChE,414,I-GENE-Y
and,414,O
BChE,414,B-GENE-Y
.,414,O
The,415,O
6-carbamate,415,B-CHEMICAL
4,415,O
was,415,O
almost,415,O
as,415,O
potent,415,O
as,415,O
physostigmine,415,B-CHEMICAL
and,415,O
was,415,O
60-,415,O
and,415,O
550-fold,415,O
more,415,O
potent,415,O
than,415,O
the,415,O
7-carbamate,415,O
5,415,O
and,415,O
the,415,O
8-carbamate,415,O
6,415,O
",",415,O
respectively,415,O
.,415,O
The,416,O
two,416,O
enantiomers,416,O
of,416,O
4,416,O
",",416,O
(,416,O
-,416,O
),416,O
-4,416,O
and,416,O
(,416,O
+,416,O
),416,O
-4,416,O
",",416,O
did,416,O
not,416,O
show,416,O
a,416,O
marked,416,O
enantioselectivity,416,O
.,416,O
Finally,417,O
",",417,O
a,417,O
similar,417,O
time-dependent,417,O
pattern,417,O
of,417,O
inhibition,417,O
of,417,O
AChE,417,B-GENE-Y
was,417,O
observed,417,O
for,417,O
3,417,O
and,417,O
4,417,O
.,417,O
Brugada,418,O
syndrome,418,O
without,418,O
mutation,418,O
of,418,O
the,418,O
cardiac,418,B-GENE-Y
sodium,418,B-CHEMICAL
channel,418,I-GENE-Y
gene,418,O
in,418,O
a,418,O
Taiwanese,418,O
patient,418,O
.,418,O
We,419,O
describe,419,O
a,419,O
45-year-old,419,O
Taiwanese,419,O
man,419,O
with,419,O
specific,419,O
features,419,O
of,419,O
Brugada,419,O
syndrome,419,O
but,419,O
no,419,O
clinical,419,O
features,419,O
of,419,O
structural,419,O
heart,419,O
disease,419,O
.,419,O
He,420,O
was,420,O
successfully,420,O
treated,420,O
with,420,O
an,420,O
implantable,420,O
cardioverter-defibrillator,420,O
.,420,O
His,421,O
electrocardiogram,421,O
(,421,O
ECG,421,O
),421,O
patterns,421,O
changed,421,O
intermittently,421,O
.,421,O
Alpha-adrenoceptor,422,B-GENE-N
stimulation,422,O
and,422,O
beta-adrenoceptor,422,B-GENE-N
blockade,422,O
augmented,422,O
the,422,O
characteristic,422,O
ST-segment,422,O
elevation,422,O
",",422,O
whereas,422,O
alpha-adrenoceptor,422,B-GENE-N
blockade,422,O
and,422,O
beta-adrenoceptor,422,B-GENE-N
stimulation,422,O
mitigated,422,O
the,422,O
ST-segment,422,O
elevation,422,O
.,422,O
Intravenous,423,O
procainamide,423,B-CHEMICAL
administration,423,O
did,423,O
not,423,O
aggravate,423,O
ST-segment,423,O
elevation,423,O
when,423,O
ECG,423,O
had,423,O
shown,423,O
coved,423,O
ST,423,O
elevation,423,O
in,423,O
the,423,O
right,423,O
precordial,423,O
leads,423,O
.,423,O
Molecular,424,O
study,424,O
did,424,O
not,424,O
reveal,424,O
the,424,O
same,424,O
mutations,424,O
in,424,O
the,424,O
cardiac,424,B-GENE-Y
sodium,424,I-GENE-Y
channel,424,I-GENE-Y
gene,424,O
(,424,O
SCN5A,424,B-GENE-Y
),424,O
as,424,O
previously,424,O
reported,424,O
in,424,O
Brugada,424,O
syndrome,424,O
.,424,O
This,425,O
case,425,O
demonstrates,425,O
the,425,O
genetic,425,O
heterogeneity,425,O
of,425,O
SCN5A,425,B-GENE-Y
in,425,O
Brugada,425,O
syndrome,425,O
.,425,O
Breakdown,426,O
of,426,O
Th,426,O
cell,426,O
immune,426,O
responses,426,O
and,426,O
steroidogenic,426,O
CYP11A1,426,B-GENE-Y
expression,426,O
in,426,O
CD4+,426,O
T,426,O
cells,426,O
in,426,O
a,426,O
murine,426,O
model,426,O
implanted,426,O
with,426,O
B16,426,O
melanoma,426,O
.,426,O
The,427,O
association,427,O
between,427,O
the,427,O
balance,427,O
of,427,O
Th1/Th2,427,O
cell,427,O
responses,427,O
and,427,O
CYP11A1,427,B-GENE-Y
expression,427,O
in,427,O
CD4+,427,O
T,427,O
cells,427,O
was,427,O
investigated,427,O
in,427,O
a,427,O
murine,427,O
model,427,O
implanted,427,O
with,427,O
highly,427,O
metastatic,427,O
B16F10,427,O
melanoma,427,O
cells,427,O
(,427,O
B16F10,427,O
mice,427,O
),427,O
.,427,O
When,428,O
2,428,O
x,428,O
10,428,O
(,428,O
5,428,O
),428,O
cells/mouse,428,O
of,428,O
B16F10,428,O
cells,428,O
were,428,O
inoculated,428,O
into,428,O
C57BL/6,428,O
mice,428,O
",",428,O
Th2,428,O
cell,428,O
responses,428,O
and,428,O
pulmonary,428,O
metastasis,428,O
were,428,O
increased,428,O
.,428,O
In,429,O
addition,429,O
",",429,O
corticosterone,429,B-CHEMICAL
levels,429,O
in,429,O
splenic,429,O
tissue,429,O
or,429,O
serum,429,O
and,429,O
CYP11A1,429,B-GENE-Y
mRNA,429,O
expression,429,O
(,429,O
mRNA,429,O
encoding,429,O
cholesterol,429,B-CHEMICAL
side-chain,429,I-GENE-Y
cleavage,429,I-GENE-Y
p450,429,I-GENE-Y
enzyme,429,I-GENE-Y
),429,O
in,429,O
CD4+,429,O
T,429,O
cells,429,O
were,429,O
increased,429,O
in,429,O
these,429,O
mice,429,O
.,429,O
When,430,O
the,430,O
anti-corticosterone,430,O
drug,430,O
aminoglutethimide,430,B-CHEMICAL
(,430,O
CYP11A1,430,B-GENE-Y
inhibitor,430,O
),430,O
was,430,O
administered,430,O
to,430,O
B16F10,430,O
mice,430,O
",",430,O
corticosterone,430,B-CHEMICAL
levels,430,O
in,430,O
splenic,430,O
tissue,430,O
or,430,O
serum,430,O
and,430,O
CYP11A1,430,B-GENE-Y
mRNA,430,O
expression,430,O
were,430,O
decreased,430,O
at,430,O
14,430,O
days,430,O
after,430,O
tumor,430,O
inoculation,430,O
.,430,O
In,431,O
addition,431,O
",",431,O
Th1,431,O
cell,431,O
responses,431,O
were,431,O
restored,431,O
and,431,O
pulmonary,431,O
metastasis,431,O
was,431,O
reduced,431,O
by,431,O
aminoglutethimide,431,B-CHEMICAL
.,431,O
These,432,O
results,432,O
indicated,432,O
that,432,O
the,432,O
breakdown,432,O
of,432,O
Th,432,O
cell,432,O
responses,432,O
and,432,O
increase,432,O
of,432,O
pulmonary,432,O
metastasis,432,O
were,432,O
due,432,O
to,432,O
an,432,O
increase,432,O
in,432,O
steroidogenic,432,O
CYP11A1,432,B-GENE-Y
mRNA,432,O
expression,432,O
in,432,O
CD4+,432,O
T,432,O
cells,432,O
.,432,O
Moreover,433,O
",",433,O
it,433,O
was,433,O
suggested,433,O
that,433,O
promotion,433,O
of,433,O
CYP11A1,433,B-GENE-Y
mRNA,433,O
expression,433,O
in,433,O
Th2,433,O
cells,433,O
was,433,O
partially,433,O
involved,433,O
due,433,O
to,433,O
an,433,O
increase,433,O
in,433,O
level,433,O
of,433,O
corticosterone,433,B-CHEMICAL
in,433,O
splenic,433,O
tissue,433,O
and,433,O
the,433,O
breakdown,433,O
of,433,O
Th,433,O
cell,433,O
responses,433,O
locally,433,O
in,433,O
the,433,O
splenic,433,O
tissue,433,O
",",433,O
which,433,O
then,433,O
affected,433,O
the,433,O
maintenance,433,O
of,433,O
Th2,433,O
cell,433,O
functions,433,O
in,433,O
the,433,O
microenvironment,433,O
of,433,O
tumor-bearing,433,O
mice,433,O
.,433,O
A,434,O
nonsense,434,O
mutation,434,O
in,434,O
the,434,O
NDUFS4,434,B-GENE-Y
gene,434,O
encoding,434,O
the,434,O
18,434,B-GENE-Y
kDa,434,I-GENE-Y
(,434,I-GENE-Y
AQDQ,434,I-GENE-Y
),434,I-GENE-Y
subunit,434,I-GENE-Y
of,434,I-GENE-Y
complex,434,I-GENE-Y
I,434,I-GENE-Y
abolishes,434,O
assembly,434,O
and,434,O
activity,434,O
of,434,O
the,434,O
complex,434,O
in,434,O
a,434,O
patient,434,O
with,434,O
Leigh-like,434,O
syndrome,434,O
.,434,O
Sequence,435,O
analysis,435,O
of,435,O
mitochondrial,435,O
and,435,O
nuclear,435,O
candidate,435,O
genes,435,O
of,435,O
complex,435,B-GENE-N
I,435,I-GENE-N
in,435,O
children,435,O
with,435,O
deficiency,435,O
of,435,O
this,435,O
complex,435,O
and,435,O
exhibiting,435,O
Leigh-like,435,O
syndrome,435,O
has,435,O
revealed,435,O
",",435,O
in,435,O
one,435,O
of,435,O
them,435,O
",",435,O
a,435,O
novel,435,O
mutation,435,O
in,435,O
the,435,O
NDUFS4,435,B-GENE-Y
gene,435,O
encoding,435,O
the,435,O
18,435,O
kDa,435,O
subunit,435,O
.,435,O
Phosphorylation,436,O
of,436,O
this,436,O
subunit,436,O
by,436,O
cAMP-dependent,436,B-GENE-N
protein,436,I-GENE-N
kinase,436,I-GENE-N
has,436,O
previously,436,O
been,436,O
found,436,O
to,436,O
activate,436,O
the,436,O
complex,436,O
.,436,O
The,437,O
present,437,O
mutation,437,O
consists,437,O
of,437,O
a,437,O
homozygous,437,O
G,437,O
--,437,O
>,437,O
A,437,O
transition,437,O
at,437,O
nucleotide,437,O
position,437,O
+44,437,O
of,437,O
the,437,O
coding,437,O
sequence,437,O
of,437,O
the,437,O
gene,437,O
",",437,O
resulting,437,O
in,437,O
the,437,O
change,437,O
of,437,O
a,437,O
tryptophan,437,B-CHEMICAL
codon,437,O
to,437,O
a,437,O
stop,437,O
codon,437,O
.,437,O
Such,438,O
mutation,438,O
causes,438,O
premature,438,O
termination,438,O
of,438,O
the,438,O
protein,438,O
after,438,O
only,438,O
14,438,O
amino,438,B-CHEMICAL
acids,438,I-CHEMICAL
of,438,O
the,438,O
putative,438,O
mitochondrial,438,O
targeting,438,O
peptide,438,O
.,438,O
Fibroblast,439,O
cultures,439,O
from,439,O
the,439,O
patient,439,O
exhibited,439,O
severe,439,O
reduction,439,O
of,439,O
the,439,O
rotenone-sensitive,439,O
NADH,439,B-CHEMICAL
--,439,I-GENE-N
>,439,I-GENE-N
UQ,439,I-GENE-N
oxidoreductase,439,I-GENE-N
activity,439,O
of,439,O
complex,439,B-GENE-N
I,439,I-GENE-N
",",439,O
which,439,O
was,439,O
insensitive,439,O
to,439,O
cAMP,439,B-CHEMICAL
stimulation,439,O
.,439,O
Two-dimensional,440,O
electrophoresis,440,O
showed,440,O
the,440,O
absence,440,O
of,440,O
detectable,440,O
normally,440,O
assembled,440,O
complex,440,B-GENE-N
I,440,I-GENE-N
in,440,O
the,440,O
inner,440,O
mitochondrial,440,O
membrane,440,O
.,440,O
These,441,O
findings,441,O
show,441,O
that,441,O
the,441,O
expression,441,O
of,441,O
the,441,O
NDUFS4,441,B-GENE-Y
gene,441,O
is,441,O
essential,441,O
for,441,O
the,441,O
assembly,441,O
of,441,O
a,441,O
functional,441,O
complex,441,B-GENE-N
I,441,I-GENE-N
.,441,O
Glucagon-like,442,B-GENE-Y
peptide,442,I-GENE-Y
(,442,I-GENE-Y
GLP,442,I-GENE-Y
),442,I-GENE-Y
-2,442,I-GENE-Y
reduces,442,O
chemotherapy-associated,442,O
mortality,442,O
and,442,O
enhances,442,O
cell,442,O
survival,442,O
in,442,O
cells,442,O
expressing,442,O
a,442,O
transfected,442,O
GLP-2,442,B-GENE-Y
receptor,442,I-GENE-Y
.,442,O
Chemotherapeutic,443,O
agents,443,O
produce,443,O
cytotoxicity,443,O
via,443,O
induction,443,O
of,443,O
apoptosis,443,O
and,443,O
cell,443,O
cycle,443,O
arrest,443,O
.,443,O
Rapidly,444,O
proliferating,444,O
cells,444,O
in,444,O
the,444,O
bone,444,O
marrow,444,O
and,444,O
intestinal,444,O
crypts,444,O
are,444,O
highly,444,O
susceptible,444,O
to,444,O
chemotherapy,444,O
",",444,O
and,444,O
damage,444,O
to,444,O
these,444,O
cellular,444,O
compartments,444,O
may,444,O
preclude,444,O
maximally,444,O
effective,444,O
chemotherapy,444,O
administration,444,O
.,444,O
Glucagon-like,445,B-GENE-Y
peptide,445,I-GENE-Y
(,445,I-GENE-Y
GLP,445,I-GENE-Y
),445,I-GENE-Y
-2,445,I-GENE-Y
is,445,O
an,445,O
enteroendocrine-derived,445,O
regulatory,445,O
peptide,445,O
that,445,O
inhibits,445,O
crypt,445,O
cell,445,O
apoptosis,445,O
after,445,O
administration,445,O
of,445,O
agents,445,O
that,445,O
damage,445,O
the,445,O
intestinal,445,O
epithelium,445,O
.,445,O
We,446,O
report,446,O
here,446,O
that,446,O
a,446,O
human,446,O
degradation-resistant,446,O
GLP-2,446,B-GENE-Y
analogue,446,O
",",446,O
h,446,O
[,446,O
Gly2,446,B-CHEMICAL
],446,O
-GLP-2,446,O
significantly,446,O
improves,446,O
survival,446,O
",",446,O
reduces,446,O
bacteremia,446,O
",",446,O
attenuates,446,O
epithelial,446,O
injury,446,O
",",446,O
and,446,O
inhibits,446,O
crypt,446,O
apoptosis,446,O
in,446,O
the,446,O
murine,446,O
gastrointestinal,446,O
tract,446,O
after,446,O
administration,446,O
of,446,O
topoisomerase,446,B-GENE-Y
I,446,I-GENE-Y
inhibitor,446,O
irinotecan,446,B-CHEMICAL
hydrochloride,446,I-CHEMICAL
or,446,O
the,446,O
antimetabolite,446,O
5-fluorouracil,446,B-CHEMICAL
.,446,O
h,447,O
[,447,O
Gly2,447,B-CHEMICAL
],447,O
-GLP-2,447,O
significantly,447,O
improved,447,O
survival,447,O
and,447,O
reduced,447,O
weight,447,O
loss,447,O
but,447,O
did,447,O
not,447,O
impair,447,O
chemotherapy,447,O
effectiveness,447,O
in,447,O
tumor-bearing,447,O
mice,447,O
treated,447,O
with,447,O
cyclical,447,O
irinotecan,447,O
.,447,O
Furthermore,448,O
",",448,O
h,448,O
[,448,O
Gly2,448,B-CHEMICAL
],448,O
-GLP-2,448,O
reduced,448,O
chemotherapy-induced,448,O
apoptosis,448,O
",",448,O
decreased,448,O
activation,448,O
of,448,O
caspase-8,448,B-GENE-N
and,448,I-GENE-N
-3,448,I-GENE-N
",",448,O
and,448,O
inhibited,448,O
poly,448,B-GENE-N
(,448,I-GENE-N
ADP-ribose,448,I-GENE-N
),448,I-GENE-N
polymerase,448,I-GENE-N
cleavage,448,O
in,448,O
heterologous,448,O
cells,448,O
transfected,448,O
with,448,O
the,448,O
GLP-2,448,B-GENE-Y
receptor,448,I-GENE-Y
.,448,O
These,449,O
observations,449,O
demonstrate,449,O
that,449,O
the,449,O
antiapoptotic,449,O
effects,449,O
of,449,O
GLP-2,449,B-GENE-Y
on,449,O
intestinal,449,O
crypt,449,O
cells,449,O
may,449,O
be,449,O
useful,449,O
for,449,O
the,449,O
attenuation,449,O
of,449,O
chemotherapy-induced,449,O
intestinal,449,O
mucositis,449,O
.,449,O
On,450,O
the,450,O
relationship,450,O
between,450,O
the,450,O
dopamine,450,B-GENE-N
transporter,450,I-GENE-N
and,450,O
the,450,O
reinforcing,450,O
effects,450,O
of,450,O
local,450,O
anesthetics,450,O
in,450,O
rhesus,450,O
monkeys,450,O
:,450,O
practical,450,O
and,450,O
theoretical,450,O
concerns,450,O
.,450,O
RATIONALE,451,O
:,451,O
Drugs,451,O
that,451,O
are,451,O
self-administered,451,O
appear,451,O
to,451,O
vary,451,O
in,451,O
their,451,O
potency,451,O
and,451,O
effectiveness,451,O
as,451,O
positive,451,O
reinforcers,451,O
.,451,O
Understanding,452,O
mechanisms,452,O
that,452,O
determine,452,O
relative,452,O
effectiveness,452,O
of,452,O
drugs,452,O
as,452,O
reinforcers,452,O
will,452,O
enhance,452,O
our,452,O
understanding,452,O
of,452,O
drug,452,O
abuse,452,O
.,452,O
OBJECTIVES,453,O
:,453,O
The,453,O
hypothesis,453,O
of,453,O
the,453,O
present,453,O
study,453,O
was,453,O
that,453,O
differences,453,O
among,453,O
dopamine,453,B-GENE-N
transporter,453,I-GENE-N
(,453,O
DAT,453,B-GENE-N
),453,O
ligands,453,O
in,453,O
potency,453,O
and,453,O
effectiveness,453,O
as,453,O
a,453,O
positive,453,O
reinforcers,453,O
were,453,O
related,453,O
to,453,O
potency,453,O
and,453,O
effectiveness,453,O
as,453,O
DA,453,B-CHEMICAL
uptake,453,O
inhibitors,453,O
.,453,O
Accordingly,454,O
",",454,O
self-administration,454,O
of,454,O
a,454,O
group,454,O
of,454,O
local,454,O
anesthetics,454,O
that,454,O
are,454,O
DAT,454,B-GENE-N
ligands,454,O
was,454,O
compared,454,O
to,454,O
their,454,O
effects,454,O
as,454,O
DA,454,B-CHEMICAL
uptake,454,O
blockers,454,O
in,454,O
vitro,454,O
in,454,O
brain,454,O
tissue,454,O
.,454,O
METHODS,455,O
:,455,O
Rhesus,455,O
monkeys,455,O
were,455,O
allowed,455,O
to,455,O
self-administer,455,O
cocaine,455,B-CHEMICAL
and,455,O
other,455,O
local,455,O
anesthetics,455,O
i.v,455,O
.,455,O
under,456,O
a,456,O
progressive-ratio,456,O
schedule,456,O
.,456,O
The,457,O
same,457,O
compounds,457,O
were,457,O
compared,457,O
in,457,O
standard,457,O
in,457,O
vitro,457,O
DA,457,B-CHEMICAL
uptake,457,O
assays,457,O
using,457,O
monkey,457,O
caudate,457,O
tissue,457,O
.,457,O
RESULTS,458,O
:,458,O
The,458,O
rank,458,O
order,458,O
of,458,O
both,458,O
potency,458,O
and,458,O
effectiveness,458,O
as,458,O
reinforcers,458,O
was,458,O
cocaine,458,B-CHEMICAL
>,458,O
dimethocaine,458,B-CHEMICAL
>,458,O
procaine,458,B-CHEMICAL
>,458,O
chloroprocaine,458,B-CHEMICAL
.,458,O
Tetracaine,459,B-CHEMICAL
did,459,O
not,459,O
maintain,459,O
self-administration,459,O
.,459,O
For,460,O
inhibiting,460,O
DA,460,B-CHEMICAL
uptake,460,O
",",460,O
the,460,O
potency,460,O
order,460,O
was,460,O
cocaine,460,B-CHEMICAL
>,460,O
dimethocaine,460,B-CHEMICAL
>,460,O
tetracaine,460,B-CHEMICAL
>,460,O
procaine,460,B-CHEMICAL
>,460,O
chloro-procaine,460,B-CHEMICAL
.,460,O
At,461,O
maximum,461,O
",",461,O
these,461,O
compounds,461,O
were,461,O
equally,461,O
effective,461,O
in,461,O
blocking,461,O
DA,461,B-CHEMICAL
uptake,461,O
.,461,O
Lidocaine,462,B-CHEMICAL
did,462,O
not,462,O
inhibit,462,O
DA,462,B-CHEMICAL
uptake,462,O
.,462,O
CONCLUSIONS,463,O
:,463,O
The,463,O
potency,463,O
of,463,O
local,463,O
anesthetics,463,O
as,463,O
positive,463,O
reinforcers,463,O
is,463,O
likely,463,O
related,463,O
to,463,O
their,463,O
potency,463,O
as,463,O
DA,463,B-CHEMICAL
uptake,463,O
inhibitors,463,O
.,463,O
Variation,464,O
in,464,O
their,464,O
effectiveness,464,O
as,464,O
positive,464,O
reinforcers,464,O
was,464,O
not,464,O
a,464,O
function,464,O
of,464,O
differences,464,O
in,464,O
effectiveness,464,O
as,464,O
DA,464,B-CHEMICAL
uptake,464,O
blockers,464,O
",",464,O
but,464,O
may,464,O
be,464,O
related,464,O
to,464,O
relative,464,O
potency,464,O
over,464,O
the,464,O
concentrations,464,O
that,464,O
are,464,O
achieved,464,O
in,464,O
vivo,464,O
.,464,O
Effects,465,O
at,465,O
sodium,465,B-GENE-N
channels,465,I-GENE-N
may,465,O
limit,465,O
the,465,O
reinforcing,465,O
effects,465,O
of,465,O
local,465,O
anesthetics,465,O
.,465,O
Contribution,466,O
of,466,O
the,466,O
Na+-K+-2Cl-,466,B-GENE-N
cotransporter,466,I-GENE-N
NKCC1,466,B-GENE-Y
to,466,O
Cl-,466,B-CHEMICAL
secretion,466,O
in,466,O
rat,466,O
OMCD,466,O
.,466,O
In,467,O
rat,467,O
kidney,467,O
the,467,O
``,467,O
secretory,467,O
'',467,O
isoform,467,O
of,467,O
the,467,O
Na+-K+-2Cl-,467,B-GENE-N
cotransporter,467,I-GENE-N
(,467,O
NKCC1,467,B-GENE-Y
),467,O
localizes,467,O
to,467,O
the,467,O
basolateral,467,O
membrane,467,O
of,467,O
the,467,O
alpha-intercalated,467,O
cell,467,O
.,467,O
The,468,O
purpose,468,O
of,468,O
this,468,O
study,468,O
was,468,O
to,468,O
determine,468,O
whether,468,O
rat,468,O
outer,468,O
medullary,468,O
collecting,468,O
duct,468,O
(,468,O
OMCD,468,O
),468,O
secretes,468,O
Cl-,468,B-CHEMICAL
and,468,O
whether,468,O
transepithelial,468,O
Cl-,468,B-CHEMICAL
transport,468,O
occurs,468,O
",",468,O
in,468,O
part,468,O
",",468,O
through,468,O
Cl-,468,B-CHEMICAL
uptake,468,O
across,468,O
the,468,O
basolateral,468,O
membrane,468,O
mediated,468,O
by,468,O
NKCC1,468,B-GENE-Y
in,468,O
series,468,O
with,468,O
Cl-,468,B-CHEMICAL
efflux,468,O
across,468,O
the,468,O
apical,468,O
membrane,468,O
.,468,O
OMCD,469,O
tubules,469,O
from,469,O
rats,469,O
treated,469,O
with,469,O
deoxycorticosterone,469,B-CHEMICAL
pivalate,469,I-CHEMICAL
were,469,O
perfused,469,O
in,469,O
vitro,469,O
in,469,O
symmetrical,469,O
HCO/CO2-buffered,469,B-CHEMICAL
solutions,469,O
.,469,O
Cl-,470,B-CHEMICAL
secretion,470,O
was,470,O
observed,470,O
in,470,O
this,470,O
segment,470,O
",",470,O
accompanied,470,O
by,470,O
a,470,O
lumen,470,O
positive,470,O
transepithelial,470,O
potential,470,O
.,470,O
Bumetanide,471,B-CHEMICAL
(,471,O
100,471,O
microM,471,O
),471,O
",",471,O
when,471,O
added,471,O
to,471,O
the,471,O
bath,471,O
",",471,O
reduced,471,O
Cl-,471,B-CHEMICAL
secretion,471,O
by,471,O
78,471,O
%,471,O
",",471,O
although,471,O
the,471,O
lumen,471,O
positive,471,O
transepithelial,471,O
potential,471,O
and,471,O
fluid,471,O
flux,471,O
were,471,O
unchanged,471,O
.,471,O
Bumetanide-sensitive,472,B-CHEMICAL
Cl-,472,B-CHEMICAL
secretion,472,O
was,472,O
dependent,472,O
on,472,O
extracellular,472,O
Na+,472,B-CHEMICAL
and,472,O
either,472,O
K+,472,B-CHEMICAL
or,472,O
NH,472,B-CHEMICAL
",",472,O
consistent,472,O
with,472,O
the,472,O
ion,472,O
dependency,472,O
of,472,O
NKCC1-mediated,472,B-GENE-Y
Cl-,472,B-CHEMICAL
transport,472,O
.,472,O
In,473,O
conclusion,473,O
",",473,O
OMCD,473,O
tubules,473,O
from,473,O
deoxycorticosterone,473,B-CHEMICAL
pivalate-treated,473,O
rats,473,O
secrete,473,O
Cl-,473,B-CHEMICAL
into,473,O
the,473,O
luminal,473,O
fluid,473,O
through,473,O
NKCC1-mediated,473,B-GENE-Y
Cl-,473,B-CHEMICAL
uptake,473,O
across,473,O
the,473,O
basolateral,473,O
membrane,473,O
in,473,O
series,473,O
with,473,O
Cl-,473,B-CHEMICAL
efflux,473,O
across,473,O
the,473,O
apical,473,O
membrane,473,O
.,473,O
The,474,O
physiological,474,O
role,474,O
of,474,O
NKCC1-mediated,474,B-GENE-Y
Cl-,474,B-CHEMICAL
uptake,474,O
remains,474,O
to,474,O
be,474,O
determined,474,O
.,474,O
However,475,O
",",475,O
the,475,O
role,475,O
of,475,O
NKCC1,475,B-GENE-Y
in,475,O
the,475,O
process,475,O
of,475,O
fluid,475,O
secretion,475,O
could,475,O
not,475,O
be,475,O
demonstrated,475,O
.,475,O
Evidence,476,O
for,476,O
genetic,476,O
heterogeneity,476,O
of,476,O
pseudohypoaldosteronism,476,O
type,476,O
1,476,O
:,476,O
identification,476,O
of,476,O
a,476,O
novel,476,O
mutation,476,O
in,476,O
the,476,O
human,476,B-GENE-Y
mineralocorticoid,476,I-GENE-Y
receptor,476,I-GENE-Y
in,476,O
one,476,O
sporadic,476,O
case,476,O
and,476,O
no,476,O
mutations,476,O
in,476,O
two,476,O
autosomal,476,O
dominant,476,O
kindreds,476,O
.,476,O
Pseudohypoaldosteronism,477,O
type,477,O
1,477,O
(,477,O
PHA1,477,O
),477,O
is,477,O
characterized,477,O
by,477,O
neonatal,477,O
salt,477,O
wasting,477,O
resistant,477,O
to,477,O
mineralocorticoids,477,O
.,477,O
There,478,O
are,478,O
2,478,O
forms,478,O
of,478,O
PHA1,478,O
:,478,O
the,478,O
autosomal,478,O
recessive,478,O
form,478,O
with,478,O
symptoms,478,O
persisting,478,O
into,478,O
adulthood,478,O
",",478,O
caused,478,O
by,478,O
mutations,478,O
in,478,O
the,478,O
amiloride-sensitive,478,B-GENE-N
luminal,478,I-GENE-N
sodium,478,I-GENE-N
channel,478,I-GENE-N
",",478,O
and,478,O
the,478,O
autosomal,478,O
dominant,478,O
or,478,O
sporadic,478,O
form,478,O
",",478,O
which,478,O
shows,478,O
milder,478,O
symptoms,478,O
that,478,O
remit,478,O
with,478,O
age,478,O
.,478,O
Mutations,479,O
in,479,O
the,479,O
gene,479,O
encoding,479,O
the,479,O
human,479,B-GENE-Y
mineralocorticoid,479,I-GENE-Y
receptor,479,I-GENE-Y
(,479,O
hMR,479,B-GENE-Y
),479,O
are,479,O
",",479,O
at,479,O
least,479,O
in,479,O
some,479,O
patients,479,O
",",479,O
responsible,479,O
for,479,O
the,479,O
latter,479,O
form,479,O
of,479,O
PHA1,479,O
.,479,O
We,480,O
here,480,O
report,480,O
the,480,O
results,480,O
of,480,O
a,480,O
genetic,480,O
study,480,O
in,480,O
a,480,O
sporadic,480,O
case,480,O
and,480,O
in,480,O
5,480,O
affected,480,O
patients,480,O
from,480,O
2,480,O
families,480,O
with,480,O
autosomal,480,O
dominant,480,O
PHA1,480,O
.,480,O
In,481,O
the,481,O
sporadic,481,O
case,481,O
we,481,O
identified,481,O
a,481,O
new,481,O
frameshift,481,O
mutation,481,O
",",481,O
Ins2871C,481,B-GENE-N
",",481,O
in,481,O
exon,481,O
9,481,O
of,481,O
the,481,O
hMR,481,B-GENE-Y
gene,481,O
.,481,O
Family,482,O
members,482,O
were,482,O
asymptomatic,482,O
and,482,O
had,482,O
no,482,O
mutation,482,O
.,482,O
This,483,O
mutation,483,O
is,483,O
the,483,O
first,483,O
described,483,O
in,483,O
exon,483,O
9,483,O
and,483,O
impairs,483,O
the,483,O
last,483,O
27,483,O
amino,483,B-CHEMICAL
acids,483,I-CHEMICAL
of,483,O
the,483,O
hormone-binding,483,B-GENE-N
domain,483,I-GENE-N
.,483,O
In,484,O
2,484,O
kindreds,484,O
with,484,O
autosomal,484,O
dominant,484,O
PHA1,484,O
we,484,O
found,484,O
no,484,O
mutation,484,O
of,484,O
the,484,O
hMR,484,B-GENE-Y
gene,484,O
.,484,O
Our,485,O
results,485,O
confirm,485,O
the,485,O
hypothesis,485,O
that,485,O
autosomal,485,O
dominant,485,O
or,485,O
sporadic,485,O
PHA1,485,O
is,485,O
a,485,O
genetically,485,O
heterogeneous,485,O
disease,485,O
involving,485,O
other,485,O
",",485,O
as,485,O
yet,485,O
unidentified,485,O
",",485,O
genes,485,O
.,485,O
The,486,O
broad-spectrum,486,O
anti-emetic,486,O
activity,486,O
of,486,O
AS-8112,486,B-CHEMICAL
",",486,O
a,486,O
novel,486,O
dopamine,486,B-GENE-N
D2,486,I-GENE-N
",",486,I-GENE-N
D3,486,I-GENE-N
and,486,O
5-HT3,486,B-GENE-Y
receptors,486,I-GENE-Y
antagonist,486,O
.,486,O
The,487,O
anti-emetic,487,O
and,487,O
pharmacological,487,O
profile,487,O
of,487,O
AS-8112,487,B-CHEMICAL
(,487,O
(,487,B-CHEMICAL
R,487,I-CHEMICAL
),487,I-CHEMICAL
-5-bromo-N-,487,I-CHEMICAL
(,487,I-CHEMICAL
"1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl",487,I-CHEMICAL
),487,I-CHEMICAL
-2-methoxy-6-methy,487,I-CHEMICAL
lamino-3-pyridinecarboxamide.2,487,I-CHEMICAL
fumarate,487,I-CHEMICAL
),487,O
",",487,O
a,487,O
novel,487,O
and,487,O
potent,487,O
dopamine,487,B-GENE-N
D2,487,I-GENE-N
",",487,I-GENE-N
D3,487,I-GENE-N
and,487,O
5-hydroxytryptamine-3,487,B-GENE-Y
(,487,I-GENE-Y
5-HT3,487,I-GENE-Y
),487,I-GENE-Y
receptors,487,I-GENE-Y
ligand,487,O
",",487,O
was,487,O
investigated,487,O
in,487,O
the,487,O
present,487,O
study,487,O
.,487,O
In,488,O
guinea-pig,488,O
isolated,488,O
colon,488,O
",",488,O
AS-8112,488,B-CHEMICAL
produced,488,O
a,488,O
rightward,488,O
shift,488,O
of,488,O
the,488,O
concentration-response,488,O
curves,488,O
of,488,O
2-methyl-5HT,488,B-CHEMICAL
",",488,O
a,488,O
5-HT3,488,B-GENE-Y
receptor,488,I-GENE-Y
agonist,488,O
(,488,O
pA2,488,O
value,488,O
of,488,O
7.04,488,O
),488,O
.,488,O
Other,489,O
5-HT3,489,B-GENE-Y
receptor,489,I-GENE-Y
antagonists,489,O
also,489,O
produced,489,O
such,489,O
a,489,O
shift,489,O
in,489,O
the,489,O
following,489,O
antagonistic-potency,489,O
order,489,O
:,489,O
granisetron,489,B-CHEMICAL
>,489,O
ondansetron=AS-8112,489,B-CHEMICAL
>,489,O
>,489,O
metoclopramide,489,B-CHEMICAL
.,489,O
In,490,O
mice,490,O
",",490,O
AS-8112,490,B-CHEMICAL
(,490,O
1.0,490,O
-,490,O
3.0,490,O
mg,490,O
kg,490,O
(,490,O
-1,490,O
),490,O
s.c.,490,O
),490,O
potently,490,O
inhibited,490,O
hypothermia,490,O
induced,490,O
by,490,O
the,490,O
dopamine,490,B-GENE-Y
D3,490,I-GENE-Y
receptor,490,I-GENE-Y
agonist,490,O
;,490,O
R,490,B-CHEMICAL
(,490,I-CHEMICAL
+,490,I-CHEMICAL
),490,I-CHEMICAL
-7-OH-DPAT,490,I-CHEMICAL
(,490,O
R,490,B-CHEMICAL
(,490,I-CHEMICAL
+,490,I-CHEMICAL
),490,I-CHEMICAL
-7-hydroxy-2-,490,I-CHEMICAL
(,490,I-CHEMICAL
N,490,I-CHEMICAL
",",490,I-CHEMICAL
N-di-n-propylamino,490,I-CHEMICAL
),490,I-CHEMICAL
tetraline,490,I-CHEMICAL
),490,O
(,490,O
0.3,490,O
mg,490,O
kg,490,O
(,490,O
-1,490,O
),490,O
s.c.,490,O
),490,O
.,490,O
Domperidone,491,B-CHEMICAL
and,491,O
haloperidol,491,B-CHEMICAL
",",491,O
which,491,O
have,491,O
affinity,491,O
for,491,O
dopamine,491,B-GENE-Y
D3,491,I-GENE-Y
receptor,491,I-GENE-Y
",",491,O
also,491,O
inhibited,491,O
R,491,B-CHEMICAL
(,491,I-CHEMICAL
+,491,I-CHEMICAL
),491,I-CHEMICAL
-7-OH-DPAT-induced,491,O
hypothermia,491,O
.,491,O
In,492,O
ferrets,492,O
or,492,O
dogs,492,O
",",492,O
AS-8112,492,B-CHEMICAL
dose-dependently,492,O
inhibited,492,O
emesis,492,O
induced,492,O
by,492,O
R,492,B-CHEMICAL
(,492,I-CHEMICAL
+,492,I-CHEMICAL
),492,I-CHEMICAL
-7-OH-DPAT,492,I-CHEMICAL
",",492,O
apomorphine,492,B-CHEMICAL
",",492,O
morphine,492,B-CHEMICAL
or,492,O
cisplatin,492,B-CHEMICAL
with,492,O
ID50,492,O
values,492,O
of,492,O
2.22,492,O
microg,492,O
kg,492,O
(,492,O
-1,492,O
),492,O
s.c.,492,O
",",492,O
10.5,492,O
microg,492,O
kg,492,O
(,492,O
-1,492,O
),492,O
s.c.,492,O
",",492,O
14.2,492,O
microg,492,O
kg,492,O
(,492,O
-1,492,O
),492,O
i.v,492,O
.,492,O
and,493,O
17.6,493,O
microg,493,O
kg,493,O
(,493,O
-1,493,O
),493,O
i.v.,493,O
",",493,O
respectively,493,O
.,493,O
Moreover,494,O
",",494,O
oral,494,O
administration,494,O
of,494,O
AS-8112,494,B-CHEMICAL
significantly,494,O
inhibited,494,O
emesis,494,O
induced,494,O
by,494,O
these,494,O
emetogens,494,O
.,494,O
AS-8112,495,B-CHEMICAL
(,495,O
0.3,495,O
mg,495,O
kg,495,O
(,495,O
-1,495,O
),495,O
i.v,495,O
.,495,O
),495,O
significantly,496,O
inhibited,496,O
emesis,496,O
induced,496,O
by,496,O
cyclophosphamide,496,B-CHEMICAL
and,496,O
doxorubicin,496,B-CHEMICAL
.,496,O
In,497,O
conclusion,497,O
",",497,O
AS-8112,497,B-CHEMICAL
is,497,O
a,497,O
potent,497,O
dopamine,497,B-GENE-N
D2,497,I-GENE-N
",",497,I-GENE-N
D3,497,I-GENE-N
and,497,O
5-HT3,497,B-GENE-Y
receptors,497,I-GENE-Y
antagonist,497,O
",",497,O
and,497,O
a,497,O
novel,497,O
anti-emetic,497,O
agent,497,O
with,497,O
a,497,O
broad-spectrum,497,O
of,497,O
anti-emetic,497,O
activity,497,O
.,497,O
These,498,O
results,498,O
suggest,498,O
that,498,O
this,498,O
compound,498,O
is,498,O
worthy,498,O
of,498,O
clinical,498,O
investigation,498,O
.,498,O
Heparin-binding,499,O
exosite,499,O
of,499,O
factor,499,B-GENE-Y
Xa,499,I-GENE-Y
.,499,O
Recent,500,O
studies,500,O
have,500,O
indicated,500,O
that,500,O
the,500,O
basic,500,O
residues,500,O
Arg,500,B-CHEMICAL
(,500,O
93,500,O
),500,O
",",500,O
Lys,500,B-CHEMICAL
(,500,O
96,500,O
),500,O
",",500,O
Arg,500,B-CHEMICAL
(,500,O
125,500,O
),500,O
",",500,O
Arg,500,B-CHEMICAL
(,500,O
165,500,O
),500,O
",",500,O
Lys,500,B-CHEMICAL
(,500,O
169,500,O
),500,O
",",500,O
Lys,500,B-CHEMICAL
(,500,O
236,500,O
),500,O
",",500,O
and,500,O
Arg,500,B-CHEMICAL
(,500,O
240,500,O
),500,O
(,500,O
chymotrypsin,500,B-GENE-N
numbering,500,O
),500,O
constitute,500,O
an,500,O
exosite,500,O
in,500,O
the,500,O
catalytic,500,O
domain,500,O
of,500,O
factor,500,B-GENE-Y
Xa,500,I-GENE-Y
that,500,O
can,500,O
effectively,500,O
bind,500,O
heparin,500,O
only,500,O
if,500,O
the,500,O
acidic,500,O
N-terminal,500,B-CHEMICAL
Gla,500,I-GENE-N
domain,500,I-GENE-N
of,500,O
the,500,O
proteinase,500,B-GENE-N
was,500,O
neutralized,500,O
by,500,O
physiological,500,O
levels,500,O
of,500,O
calcium,500,B-CHEMICAL
.,500,O
Binding,501,O
of,501,O
a,501,O
full-length,501,O
heparin,501,O
chain,501,O
to,501,O
this,501,O
site,501,O
of,501,O
factor,501,B-GENE-Y
Xa,501,I-GENE-Y
in,501,O
the,501,O
presence,501,O
of,501,O
calcium,501,B-CHEMICAL
makes,501,O
a,501,O
significant,501,O
contribution,501,O
to,501,O
acceleration,501,O
of,501,O
the,501,O
proteinase,501,B-GENE-N
inhibition,501,O
by,501,O
antithrombin,501,B-GENE-Y
through,501,O
a,501,O
ternary,501,O
complex,501,O
bridging,501,O
or,501,O
template,501,O
mechanism,501,O
.,501,O
Moreover,502,O
",",502,O
certain,502,O
basic,502,O
residues,502,O
of,502,O
this,502,O
site,502,O
",",502,O
particularly,502,O
Arg,502,B-CHEMICAL
(,502,O
165,502,O
),502,O
and,502,O
Lys,502,B-CHEMICAL
(,502,O
169,502,O
),502,O
",",502,O
play,502,O
a,502,O
key,502,O
role,502,O
in,502,O
factor,502,B-GENE-Y
Va,502,I-GENE-Y
and/or,502,O
prothrombin,502,B-GENE-Y
recognition,502,O
by,502,O
factor,502,B-GENE-Y
Xa,502,I-GENE-Y
in,502,O
the,502,O
prothrombinase,502,O
complex,502,O
.,502,O
This,503,O
article,503,O
reviews,503,O
recent,503,O
structural,503,O
",",503,O
mutagenesis,503,O
and,503,O
kinetic,503,O
data,503,O
that,503,O
lead,503,O
to,503,O
identification,503,O
of,503,O
this,503,O
exosite,503,O
and,503,O
discusses,503,O
how,503,O
the,503,O
binding,503,O
of,503,O
protein,503,O
or,503,O
polysaccharide,503,O
cofactors,503,O
to,503,O
this,503,O
site,503,O
of,503,O
factor,503,B-GENE-Y
Xa,503,I-GENE-Y
can,503,O
modulate,503,O
the,503,O
specificity,503,O
and,503,O
physiological,503,O
function,503,O
of,503,O
this,503,O
key,503,O
coagulant,503,O
enzyme,503,O
in,503,O
plasma,503,O
.,503,O
Rofecoxib,504,B-CHEMICAL
:,504,O
a,504,O
review,504,O
of,504,O
its,504,O
use,504,O
in,504,O
the,504,O
management,504,O
of,504,O
osteoarthritis,504,O
",",504,O
acute,504,O
pain,504,O
and,504,O
rheumatoid,504,O
arthritis,504,O
.,504,O
Rofecoxib,505,B-CHEMICAL
is,505,O
a,505,O
selective,505,O
cyclo-oxygenase,505,B-GENE-Y
(,505,I-GENE-Y
COX,505,I-GENE-Y
),505,I-GENE-Y
-2,505,I-GENE-Y
inhibitor,505,O
which,505,O
has,505,O
little,505,O
or,505,O
no,505,O
effect,505,O
on,505,O
the,505,O
COX-1,505,B-GENE-Y
isoenzyme,505,O
at,505,O
doses,505,O
up,505,O
to,505,O
1000,505,O
mg/day,505,O
.,505,O
Rofecoxib,506,B-CHEMICAL
has,506,O
greater,506,O
selectivity,506,O
for,506,O
COX-2,506,B-GENE-Y
than,506,O
celecoxib,506,B-CHEMICAL
",",506,O
meloxicam,506,B-CHEMICAL
",",506,O
diclofenac,506,B-CHEMICAL
and,506,O
indomethacin,506,B-CHEMICAL
.,506,O
In,507,O
well-controlled,507,O
clinical,507,O
trials,507,O
",",507,O
rofecoxib,507,B-CHEMICAL
12.5,507,O
to,507,O
500,507,O
mg/day,507,O
has,507,O
been,507,O
evaluated,507,O
for,507,O
its,507,O
efficacy,507,O
in,507,O
the,507,O
treatment,507,O
of,507,O
osteoarthritis,507,O
",",507,O
acute,507,O
pain,507,O
and,507,O
rheumatoid,507,O
arthritis,507,O
[,507,O
lower,507,O
dosages,507,O
(,507,O
5,507,O
to,507,O
125,507,O
mg/day,507,O
),507,O
were,507,O
generally,507,O
used,507,O
in,507,O
the,507,O
chronic,507,O
pain,507,O
indications,507,O
],507,O
.,507,O
In,508,O
the,508,O
treatment,508,O
of,508,O
patients,508,O
with,508,O
osteoarthritis,508,O
",",508,O
rofecoxib,508,B-CHEMICAL
was,508,O
more,508,O
effective,508,O
in,508,O
providing,508,O
symptomatic,508,O
relief,508,O
than,508,O
placebo,508,O
",",508,O
paracetamol,508,B-CHEMICAL
(,508,O
acetaminophen,508,B-CHEMICAL
),508,O
and,508,O
celecoxib,508,B-CHEMICAL
and,508,O
was,508,O
similar,508,O
in,508,O
efficacy,508,O
to,508,O
ibuprofen,508,B-CHEMICAL
",",508,O
diclofenac,508,B-CHEMICAL
",",508,O
naproxen,508,B-CHEMICAL
and,508,O
nabumetone,508,B-CHEMICAL
.,508,O
Overall,509,O
",",509,O
both,509,O
the,509,O
physician,509,O
's,509,O
assessment,509,O
of,509,O
disease,509,O
status,509,O
and,509,O
the,509,O
patient,509,O
's,509,O
assessment,509,O
of,509,O
response,509,O
to,509,O
therapy,509,O
tended,509,O
to,509,O
favour,509,O
rofecoxib,509,B-CHEMICAL
.,509,O
In,510,O
patients,510,O
with,510,O
postsurgical,510,O
dental,510,O
pain,510,O
",",510,O
pain,510,O
after,510,O
spinal,510,O
fusion,510,O
or,510,O
orthopaedic,510,O
surgery,510,O
",",510,O
or,510,O
primary,510,O
dysmenorrhoea,510,O
",",510,O
rofecoxib,510,B-CHEMICAL
provided,510,O
more,510,O
rapid,510,O
and,510,O
more,510,O
sustained,510,O
pain,510,O
relief,510,O
and,510,O
reduced,510,O
requirements,510,O
for,510,O
supplemental,510,O
morphine,510,O
use,510,O
after,510,O
surgery,510,O
than,510,O
placebo,510,O
.,510,O
Rofecoxib,511,B-CHEMICAL
was,511,O
more,511,O
efficacious,511,O
than,511,O
celecoxib,511,B-CHEMICAL
in,511,O
patients,511,O
with,511,O
acute,511,O
dental,511,O
pain,511,O
and,511,O
pain,511,O
after,511,O
spinal,511,O
fusion,511,O
surgery,511,O
",",511,O
although,511,O
celecoxib,511,B-CHEMICAL
may,511,O
have,511,O
been,511,O
used,511,O
at,511,O
a,511,O
subtherapeutic,511,O
dose,511,O
.,511,O
In,512,O
comparison,512,O
with,512,O
traditional,512,O
nonsteroidal,512,O
anti-inflammatory,512,O
drugs,512,O
(,512,O
NSAIDs,512,O
),512,O
ibuprofen,512,B-CHEMICAL
",",512,O
diclofenac,512,B-CHEMICAL
and,512,O
naproxen,512,B-CHEMICAL
sodium,512,I-CHEMICAL
",",512,O
rofecoxib,512,B-CHEMICAL
was,512,O
similar,512,O
in,512,O
efficacy,512,O
in,512,O
the,512,O
treatment,512,O
of,512,O
acute,512,O
pain,512,O
.,512,O
Although,513,O
naproxen,513,B-CHEMICAL
sodium,513,I-CHEMICAL
provided,513,O
more,513,O
rapid,513,O
pain,513,O
relief,513,O
than,513,O
rofecoxib,513,B-CHEMICAL
in,513,O
patients,513,O
with,513,O
primary,513,O
dysmenorrhoea,513,O
",",513,O
the,513,O
reverse,513,O
was,513,O
true,513,O
after,513,O
orthopaedic,513,O
surgery,513,O
:,513,O
rofecoxib,513,B-CHEMICAL
provided,513,O
more,513,O
rapid,513,O
pain,513,O
relief,513,O
and,513,O
less,513,O
supplemental,513,O
morphine,513,B-CHEMICAL
was,513,O
needed,513,O
.,513,O
Rofecoxib,514,B-CHEMICAL
was,514,O
as,514,O
effective,514,O
as,514,O
naproxen,514,B-CHEMICAL
in,514,O
providing,514,O
symptomatic,514,O
relief,514,O
for,514,O
over,514,O
8700,514,O
patients,514,O
with,514,O
rheumatoid,514,O
arthritis,514,O
.,514,O
Compared,515,O
with,515,O
traditional,515,O
NSAID,515,O
therapy,515,O
",",515,O
rofecoxib,515,B-CHEMICAL
had,515,O
a,515,O
significantly,515,O
lower,515,O
incidence,515,O
of,515,O
endoscopically,515,O
confirmed,515,O
gastroduodenal,515,O
ulceration,515,O
and,515,O
",",515,O
in,515,O
approximately,515,O
"13,000",515,O
patients,515,O
with,515,O
osteoarthritis,515,O
and,515,O
rheumatoid,515,O
arthritis,515,O
",",515,O
a,515,O
lower,515,O
incidence,515,O
of,515,O
gastrointestinal,515,O
(,515,O
GI,515,O
),515,O
adverse,515,O
events,515,O
.,515,O
Rofecoxib,516,B-CHEMICAL
was,516,O
generally,516,O
well,516,O
tolerated,516,O
in,516,O
all,516,O
indications,516,O
with,516,O
an,516,O
overall,516,O
tolerability,516,O
profile,516,O
similar,516,O
to,516,O
traditional,516,O
NSAIDs,516,O
.,516,O
The,517,O
most,517,O
common,517,O
adverse,517,O
events,517,O
in,517,O
rofecoxib,517,B-CHEMICAL
recipients,517,O
were,517,O
nausea,517,O
",",517,O
dizziness,517,O
and,517,O
headache,517,O
.,517,O
In,518,O
conclusion,518,O
",",518,O
rofecoxib,518,B-CHEMICAL
is,518,O
at,518,O
least,518,O
as,518,O
effective,518,O
as,518,O
traditional,518,O
NSAID,518,O
therapy,518,O
in,518,O
providing,518,O
pain,518,O
relief,518,O
for,518,O
both,518,O
chronic,518,O
and,518,O
acute,518,O
pain,518,O
conditions,518,O
.,518,O
Rofecoxib,519,B-CHEMICAL
provides,519,O
an,519,O
alternative,519,O
treatment,519,O
option,519,O
to,519,O
traditional,519,O
NSAID,519,O
therapy,519,O
in,519,O
the,519,O
management,519,O
of,519,O
symptomatic,519,O
pain,519,O
relief,519,O
in,519,O
patients,519,O
with,519,O
osteoarthritis,519,O
.,519,O
Initial,520,O
data,520,O
from,520,O
patients,520,O
with,520,O
primary,520,O
dysmenorrhoea,520,O
and,520,O
postoperative,520,O
pain,520,O
are,520,O
promising,520,O
and,520,O
further,520,O
trials,520,O
may,520,O
confirm,520,O
its,520,O
place,520,O
in,520,O
the,520,O
treatment,520,O
of,520,O
these,520,O
indications,520,O
.,520,O
Rofecoxib,521,B-CHEMICAL
has,521,O
also,521,O
shown,521,O
promising,521,O
results,521,O
in,521,O
patients,521,O
with,521,O
rheumatoid,521,O
arthritis,521,O
and,521,O
is,521,O
likely,521,O
to,521,O
become,521,O
a,521,O
valuable,521,O
addition,521,O
to,521,O
current,521,O
drug,521,O
therapy,521,O
for,521,O
this,521,O
patient,521,O
population,521,O
.,521,O
Importantly,522,O
",",522,O
rofecoxib,522,B-CHEMICAL
is,522,O
associated,522,O
with,522,O
a,522,O
lower,522,O
incidence,522,O
of,522,O
GI,522,O
adverse,522,O
events,522,O
than,522,O
traditional,522,O
NSAIDs,522,O
making,522,O
it,522,O
a,522,O
primary,522,O
treatment,522,O
option,522,O
in,522,O
patients,522,O
at,522,O
risk,522,O
of,522,O
developing,522,O
GI,522,O
complications,522,O
or,522,O
patients,522,O
with,522,O
chronic,522,O
conditions,522,O
requiring,522,O
long,522,O
term,522,O
treatment,522,O
.,522,O
Clinical,523,O
",",523,O
biochemical,523,O
and,523,O
molecular,523,O
genetic,523,O
data,523,O
in,523,O
five,523,O
children,523,O
with,523,O
Gitelman,523,O
's,523,O
syndrome,523,O
.,523,O
Gitelman,524,O
's,524,O
variant,524,O
of,524,O
Bartter,524,O
's,524,O
syndrome,524,O
",",524,O
inherited,524,O
hypokalemic,524,O
alkalosis,524,O
",",524,O
is,524,O
caused,524,O
by,524,O
mutation,524,O
in,524,O
the,524,O
thiazide-sensitive,524,B-GENE-Y
NaCl,524,I-GENE-Y
co-transporter,524,I-GENE-Y
(,524,O
NCCT,524,B-GENE-Y
),524,O
.,524,O
The,525,O
main,525,O
clinical,525,O
symptoms,525,O
are,525,O
:,525,O
muscular,525,O
weakness,525,O
",",525,O
carpopedal,525,O
spasm,525,O
",",525,O
constipation,525,O
and,525,O
short,525,O
stature,525,O
.,525,O
The,526,O
diagnosis,526,O
was,526,O
suspected,526,O
in,526,O
five,526,O
children,526,O
according,526,O
to,526,O
clinical,526,O
criteria,526,O
.,526,O
All,527,O
patients,527,O
exhibited,527,O
carpopedal,527,O
spasm,527,O
during,527,O
febrile,527,O
illness,527,O
",",527,O
three,527,O
patients,527,O
had,527,O
short,527,O
stature,527,O
.,527,O
Biochemical,528,O
features,528,O
were,528,O
:,528,O
metabolic,528,O
alkalosis,528,O
",",528,O
hypokalemia,528,O
",",528,O
hypomagnesemia,528,O
",",528,O
low,528,O
IGF-I,528,B-GENE-Y
levels,528,O
",",528,O
hyperkaliuria,528,O
",",528,O
hypernatriuria,528,O
",",528,O
hypocalciuria,528,O
and,528,O
normoprostaglandinuria,528,O
.,528,O
Three,529,O
patients,529,O
had,529,O
elevated,529,O
plasma,529,O
renin,529,B-GENE-Y
activity,529,O
and,529,O
hyperaldosteronism,529,O
.,529,O
Mutational,530,O
analysis,530,O
of,530,O
the,530,O
NCCT,530,B-GENE-Y
gene,530,O
confirmed,530,O
the,530,O
diagnosis,530,O
in,530,O
all,530,O
five,530,O
patients,530,O
.,530,O
Different,531,O
forms,531,O
of,531,O
therapy,531,O
",",531,O
potassium,531,B-CHEMICAL
and,531,O
magnesium,531,B-CHEMICAL
substitution,531,O
",",531,O
spironolactone,531,B-CHEMICAL
and,531,O
indomethacin,531,B-CHEMICAL
failed,531,O
to,531,O
fully,531,O
correct,531,O
hypokalemia,531,O
and,531,O
hypomagnesemia,531,O
",",531,O
but,531,O
markedly,531,O
improved,531,O
growth,531,O
velocity,531,O
and,531,O
normalized,531,O
IGF-I,531,B-GENE-Y
levels,531,O
in,531,O
the,531,O
three,531,O
patients,531,O
with,531,O
short,531,O
stature,531,O
.,531,O
During,532,O
therapy,532,O
",",532,O
clinical,532,O
symptoms,532,O
disappeared,532,O
.,532,O
We,533,O
conclude,533,O
that,533,O
Gitelman,533,O
's,533,O
syndrome,533,O
is,533,O
a,533,O
disorder,533,O
with,533,O
a,533,O
variable,533,O
symptom,533,O
profile,533,O
",",533,O
but,533,O
can,533,O
be,533,O
suspected,533,O
on,533,O
clinical,533,O
signs,533,O
already,533,O
in,533,O
early,533,O
childhood,533,O
.,533,O
The,534,O
early,534,O
diagnosis,534,O
is,534,O
essential,534,O
in,534,O
preventing,534,O
complications,534,O
.,534,O
Peroxisome,535,B-GENE-N
proliferator-activated,535,I-GENE-N
receptor,535,I-GENE-N
subtype-specific,535,O
regulation,535,O
of,535,O
hepatic,535,O
and,535,O
peripheral,535,O
gene,535,O
expression,535,O
in,535,O
the,535,O
Zucker,535,O
diabetic,535,O
fatty,535,O
rat,535,O
.,535,O
Fibrates,536,B-CHEMICAL
and,536,O
thiazolidinediones,536,B-CHEMICAL
are,536,O
used,536,O
clinically,536,O
to,536,O
treat,536,O
hypertriglyceridemia,536,O
and,536,O
hyperglycemia,536,O
",",536,O
respectively,536,O
.,536,O
Fibrates,537,B-CHEMICAL
bind,537,O
to,537,O
the,537,O
peroxisome,537,B-GENE-Y
proliferator-activated,537,I-GENE-Y
receptor,537,I-GENE-Y
(,537,I-GENE-Y
PPAR,537,I-GENE-Y
),537,I-GENE-Y
-alpha,537,I-GENE-Y
",",537,O
and,537,O
thiazolidinediones,537,B-CHEMICAL
are,537,O
ligands,537,O
of,537,O
PPAR-gamma,537,B-GENE-Y
.,537,O
These,538,O
intracellular,538,O
receptors,538,O
form,538,O
heterodimers,538,O
with,538,O
retinoid,538,B-CHEMICAL
X,538,I-GENE-N
receptor,538,I-GENE-N
to,538,O
modulate,538,O
gene,538,O
transcription,538,O
.,538,O
To,539,O
elucidate,539,O
the,539,O
target,539,O
genes,539,O
regulated,539,O
by,539,O
these,539,O
compounds,539,O
",",539,O
we,539,O
treated,539,O
Zucker,539,O
diabetic,539,O
fatty,539,O
rats,539,O
(,539,O
ZDF,539,O
),539,O
for,539,O
15,539,O
days,539,O
with,539,O
a,539,O
PPAR-alpha-specific,539,B-GENE-Y
compound,539,O
",",539,O
fenofibrate,539,B-CHEMICAL
",",539,O
a,539,O
PPAR-gamma-specific,539,B-GENE-Y
ligand,539,O
",",539,O
rosiglitazone,539,B-CHEMICAL
",",539,O
and,539,O
a,539,O
PPAR-alpha/-gamma,539,B-GENE-N
coagonist,539,O
",",539,O
GW2331,539,B-CHEMICAL
",",539,O
and,539,O
measured,539,O
the,539,O
levels,539,O
of,539,O
several,539,O
messenger,539,O
RNAs,539,O
(,539,O
mRNAs,539,O
),539,O
in,539,O
liver,539,O
by,539,O
real-time,539,O
polymerase,539,O
chain,539,O
reaction,539,O
.,539,O
All,540,O
3,540,O
compounds,540,O
decreased,540,O
serum,540,O
glucose,540,B-CHEMICAL
and,540,O
triglyceride,540,B-CHEMICAL
levels,540,O
.,540,O
Fenofibrate,541,B-CHEMICAL
and,541,O
GW2331,541,B-CHEMICAL
induced,541,O
expression,541,O
of,541,O
acyl-coenzyme,541,B-GENE-N
A,541,I-GENE-N
(,541,I-GENE-N
CoA,541,I-GENE-N
),541,I-GENE-N
oxidase,541,I-GENE-N
and,541,O
enoyl-CoA,541,B-GENE-Y
hydratase,541,I-GENE-Y
and,541,O
reduced,541,O
apolipoprotein,541,B-GENE-Y
C-III,541,I-GENE-Y
and,541,O
phosphoenolpyruvate,541,B-GENE-N
carboxykinase,541,I-GENE-N
mRNAs,541,O
.,541,O
Rosiglitazone,542,B-CHEMICAL
modestly,542,O
increased,542,O
apolipoprotein,542,B-GENE-Y
C-III,542,I-GENE-Y
mRNA,542,O
and,542,O
had,542,O
no,542,O
effect,542,O
on,542,O
expression,542,O
of,542,O
the,542,O
other,542,O
2,542,O
genes,542,O
in,542,O
the,542,O
liver,542,O
but,542,O
increased,542,O
the,542,O
expression,542,O
of,542,O
glucose,542,B-CHEMICAL
transporter,542,I-GENE-Y
4,542,I-GENE-Y
and,542,O
phosphoenolpyruvate,542,B-CHEMICAL
carboxykinase,542,I-GENE-N
in,542,O
adipose,542,O
tissue,542,O
.,542,O
We,543,O
identified,543,O
a,543,O
novel,543,O
target,543,O
in,543,O
liver,543,O
",",543,O
mitogen-activated,543,B-GENE-Y
phosphokinase,543,I-GENE-Y
phosphatase,543,I-GENE-Y
1,543,I-GENE-Y
",",543,O
whose,543,O
down-regulation,543,O
by,543,O
PPAR-alpha,543,B-GENE-Y
agonists,543,O
may,543,O
improve,543,O
insulin,543,B-GENE-N
sensitivity,543,O
in,543,O
that,543,O
tissue,543,O
by,543,O
prolonging,543,O
insulin,543,B-GENE-N
responses,543,O
.,543,O
The,544,O
results,544,O
of,544,O
these,544,O
studies,544,O
suggest,544,O
that,544,O
activation,544,O
of,544,O
PPAR-alpha,544,B-GENE-Y
as,544,O
well,544,O
as,544,O
PPAR-gamma,544,B-GENE-Y
in,544,O
therapy,544,O
for,544,O
type,544,O
2,544,O
diabetes,544,O
will,544,O
enhance,544,O
glucose,544,B-CHEMICAL
and,544,O
triglyceride,544,B-CHEMICAL
control,544,O
by,544,O
combining,544,O
actions,544,O
in,544,O
hepatic,544,O
and,544,O
peripheral,544,O
tissues,544,O
.,544,O
Serotonergic,545,O
effects,545,O
and,545,O
extracellular,545,O
brain,545,O
levels,545,O
of,545,O
eletriptan,545,B-CHEMICAL
",",545,O
zolmitriptan,545,B-CHEMICAL
and,545,O
sumatriptan,545,B-CHEMICAL
in,545,O
rat,545,O
brain,545,O
.,545,O
In,546,O
vivo,546,O
microdialysis,546,O
was,546,O
used,546,O
to,546,O
assess,546,O
the,546,O
central,546,O
serotonergic,546,O
effects,546,O
and,546,O
extracellular,546,O
brain,546,O
levels,546,O
of,546,O
the,546,O
5-HT,546,B-GENE-N
(,546,I-GENE-N
1B/1D,546,I-GENE-N
),546,I-GENE-N
receptor,546,O
agonists,546,O
eletriptan,546,B-CHEMICAL
",",546,O
zolmitriptan,546,B-CHEMICAL
and,546,O
sumatriptan,546,B-CHEMICAL
in,546,O
rats,546,O
after,546,O
intravenous,546,O
and,546,O
intracerebral,546,O
administration,546,O
",",546,O
while,546,O
their,546,O
binding,546,O
affinities,546,O
and,546,O
functional,546,O
potencies,546,O
were,546,O
determined,546,O
at,546,O
5-HT,546,B-GENE-Y
(,546,I-GENE-Y
1B,546,I-GENE-Y
),546,I-GENE-Y
",",546,O
5-HT,546,B-GENE-Y
(,546,I-GENE-Y
1D,546,I-GENE-Y
),546,I-GENE-Y
and,546,O
5-HT,546,B-GENE-Y
(,546,I-GENE-Y
1A,546,I-GENE-Y
),546,I-GENE-Y
receptors,546,O
.,546,O
In,547,O
vitro,547,O
studies,547,O
showed,547,O
that,547,O
all,547,O
three,547,O
triptans,547,B-CHEMICAL
are,547,O
high,547,O
affinity,547,O
",",547,O
full,547,O
agonists,547,O
at,547,O
5-HT,547,B-GENE-N
(,547,I-GENE-N
1B/1D,547,I-GENE-N
),547,I-GENE-N
receptors,547,O
",",547,O
but,547,O
that,547,O
sumatriptan,547,B-CHEMICAL
is,547,O
functionally,547,O
less,547,O
potent,547,O
as,547,O
a,547,O
5-HT,547,B-GENE-N
(,547,I-GENE-N
1B/1D,547,I-GENE-N
),547,I-GENE-N
agonist,547,O
than,547,O
zolmitriptan,547,B-CHEMICAL
and,547,O
eletriptan,547,B-CHEMICAL
.,547,O
Local,548,O
intracortical,548,O
perfusion,548,O
with,548,O
the,548,O
compounds,548,O
via,548,O
the,548,O
dialysis,548,O
probe,548,O
decreased,548,O
cortical,548,O
5-HT,548,B-CHEMICAL
(,548,O
5-hydroxytryptamine,548,B-CHEMICAL
",",548,O
serotonin,548,B-CHEMICAL
),548,O
release,548,O
with,548,O
ED,548,O
(,548,O
50,548,O
),548,O
values,548,O
of,548,O
approximately,548,O
0.1,548,O
microM,548,O
for,548,O
eletriptan,548,B-CHEMICAL
and,548,O
zolmitriptan,548,B-CHEMICAL
and,548,O
0.5,548,O
microM,548,O
for,548,O
sumatriptan,548,B-CHEMICAL
.,548,O
At,549,O
3.2,549,O
mg/kg,549,O
i.v.,549,O
",",549,O
both,549,O
eletriptan,549,B-CHEMICAL
and,549,O
zolmitriptan,549,B-CHEMICAL
decreased,549,O
5-HT,549,B-CHEMICAL
levels,549,O
by,549,O
about,549,O
35,549,O
%,549,O
",",549,O
while,549,O
sumatriptan,549,B-CHEMICAL
had,549,O
no,549,O
effect,549,O
",",549,O
despite,549,O
the,549,O
fact,549,O
that,549,O
maximal,549,O
sumatriptan,549,B-CHEMICAL
concentrations,549,O
in,549,O
cortical,549,O
dialysates,549,O
were,549,O
higher,549,O
(,549,O
8.8,549,O
nM,549,O
at,549,O
20,549,O
min,549,O
),549,O
than,549,O
those,549,O
of,549,O
zolmitriptan,549,B-CHEMICAL
(,549,O
5.9,549,O
nM,549,O
at,549,O
20,549,O
min,549,O
),549,O
and,549,O
eletriptan,549,B-CHEMICAL
(,549,O
2.6,549,O
nM,549,O
at,549,O
40,549,O
min,549,O
),549,O
.,549,O
The,550,O
observation,550,O
that,550,O
eletriptan,550,B-CHEMICAL
and,550,O
zolmitriptan,550,B-CHEMICAL
produce,550,O
almost,550,O
identical,550,O
central,550,O
serotonergic,550,O
effects,550,O
",",550,O
after,550,O
intracerebral,550,O
as,550,O
well,550,O
as,550,O
after,550,O
systemic,550,O
administration,550,O
",",550,O
is,550,O
in,550,O
agreement,550,O
with,550,O
their,550,O
comparable,550,O
functional,550,O
5-HT,550,B-GENE-N
(,550,I-GENE-N
1B/1D,550,I-GENE-N
),550,I-GENE-N
receptor,550,O
agonist,550,O
potencies,550,O
and,550,O
their,550,O
free,550,O
levels,550,O
in,550,O
cortical,550,O
dialysates,550,O
after,550,O
3.2,550,O
mg/kg,550,O
i.v,550,O
.,550,O
On,551,O
the,551,O
other,551,O
hand,551,O
",",551,O
the,551,O
lack,551,O
of,551,O
central,551,O
serotonergic,551,O
effects,551,O
of,551,O
3.2,551,O
mg/kg,551,O
i.v,551,O
.,551,O
sumatriptan,552,B-CHEMICAL
is,552,O
likely,552,O
due,552,O
to,552,O
its,552,O
weaker,552,O
functional,552,O
5-HT,552,B-GENE-N
(,552,I-GENE-N
1B/1D,552,I-GENE-N
),552,I-GENE-N
receptor,552,O
agonist,552,O
potency,552,O
than,552,O
eletriptan,552,B-CHEMICAL
and,552,O
zolmitriptan,552,B-CHEMICAL
",",552,O
rather,552,O
than,552,O
lower,552,O
brain,552,O
levels,552,O
",",552,O
consistent,552,O
with,552,O
sumatriptan,552,O
's,552,O
fivefold,552,O
lower,552,O
potency,552,O
after,552,O
intracerebral,552,O
administration,552,O
.,552,O
Urokinase,553,B-GENE-Y
plasminogen,553,I-GENE-Y
activator,553,I-GENE-Y
and,553,O
plasmin,553,B-GENE-Y
efficiently,553,O
convert,553,O
hemofiltrate,553,B-GENE-Y
CC,553,I-GENE-Y
chemokine,553,I-GENE-Y
1,553,I-GENE-Y
into,553,O
its,553,O
active,553,O
.,553,O
We,554,O
have,554,O
previously,554,O
isolated,554,O
from,554,O
human,554,O
hemofiltrate,554,O
an,554,O
N-terminally,554,B-CHEMICAL
truncated,554,O
form,554,O
of,554,O
the,554,O
hemofiltrate,554,B-GENE-Y
CC,554,I-GENE-Y
chemokine,554,I-GENE-Y
1,554,I-GENE-Y
(,554,O
HCC-1,554,B-GENE-Y
),554,O
",",554,O
and,554,O
characterized,554,O
HCC-1,554,B-GENE-Y
[,554,I-GENE-Y
9-74,554,I-GENE-Y
],554,I-GENE-Y
as,554,O
a,554,O
strong,554,O
agonist,554,O
of,554,O
CCR1,554,B-GENE-Y
",",554,O
CCR5,554,B-GENE-Y
",",554,O
and,554,O
to,554,O
a,554,O
lower,554,O
extent,554,O
CCR3,554,B-GENE-Y
.,554,O
In,555,O
this,555,O
study,555,O
",",555,O
we,555,O
show,555,O
that,555,O
conditioned,555,O
media,555,O
from,555,O
human,555,O
tumor,555,O
cell,555,O
lines,555,O
PC-3,555,O
and,555,O
143B,555,O
contain,555,O
proteolytic,555,O
activities,555,O
that,555,O
convert,555,O
HCC-1,555,B-GENE-Y
into,555,O
the,555,O
[,555,O
9-74,555,O
],555,O
form,555,O
.,555,O
This,556,O
activity,556,O
was,556,O
fully,556,O
inhibited,556,O
by,556,O
inhibitors,556,O
of,556,O
urokinase-type,556,B-GENE-Y
plasminogen,556,I-GENE-Y
activator,556,I-GENE-Y
(,556,O
uPA,556,B-GENE-Y
),556,O
",",556,O
including,556,O
PA,556,B-GENE-Y
inhibitor-1,556,I-GENE-Y
",",556,O
an,556,O
anti-uPA,556,O
mAb,556,O
",",556,O
and,556,O
amiloride,556,O
.,556,O
Pure,557,O
preparations,557,O
of,557,O
uPA,557,B-GENE-Y
processed,557,O
HCC-1,557,B-GENE-Y
with,557,O
high,557,O
efficiency,557,O
",",557,O
without,557,O
further,557,O
degrading,557,O
HCC-1,557,B-GENE-Y
[,557,I-GENE-Y
9-74,557,I-GENE-Y
],557,I-GENE-Y
.,557,O
Plasmin,558,B-GENE-Y
could,558,O
also,558,O
generate,558,O
HCC-1,558,B-GENE-Y
[,558,I-GENE-Y
9-74,558,I-GENE-Y
],558,I-GENE-Y
",",558,O
but,558,O
degraded,558,O
the,558,O
active,558,O
product,558,O
as,558,O
well,558,O
.,558,O
The,559,O
kinetics,559,O
of,559,O
HCC-1,559,B-GENE-Y
cleavage,559,O
by,559,O
uPA,559,B-GENE-Y
and,559,O
plasmin,559,B-GENE-Y
(,559,O
Michaelis,559,O
constant,559,O
",",559,O
K,559,O
(,559,O
m,559,O
),559,O
",",559,O
of,559,O
0.76,559,O
+/-,559,O
0.4,559,O
microM,559,O
for,559,O
uPA,559,B-GENE-Y
",",559,O
and,559,O
0.096,559,O
+/-,559,O
0.05,559,O
microM,559,O
for,559,O
plasmin,559,B-GENE-Y
;,559,O
catalytic,559,O
rate,559,O
constant,559,O
",",559,O
k,559,O
(,559,O
cat,559,O
),559,O
:,559,O
3.36,559,O
+/-,559,O
0.96,559,O
s,559,O
(,559,O
-1,559,O
),559,O
for,559,O
uPA,559,B-GENE-Y
and,559,O
6,559,O
+/-,559,O
3.6,559,O
s,559,O
(,559,O
-1,559,O
),559,O
for,559,O
plasmin,559,B-GENE-Y
),559,O
are,559,O
fully,559,O
compatible,559,O
with,559,O
a,559,O
role,559,O
in,559,O
vivo,559,O
.,559,O
The,560,O
activation,560,O
of,560,O
an,560,O
abundant,560,O
inactive,560,O
precursor,560,O
into,560,O
a,560,O
broad-spectrum,560,O
chemokine,560,O
by,560,O
uPA,560,B-GENE-Y
and,560,O
plasmin,560,B-GENE-Y
directly,560,O
links,560,O
the,560,O
production,560,O
of,560,O
uPA,560,B-GENE-Y
by,560,O
numerous,560,O
tumors,560,O
and,560,O
their,560,O
ability,560,O
to,560,O
recruit,560,O
mononuclear,560,O
leukocytes,560,O
",",560,O
without,560,O
the,560,O
need,560,O
for,560,O
the,560,O
transcriptional,560,O
activation,560,O
of,560,O
chemokine,560,B-GENE-N
genes,560,O
.,560,O
Cembranoid,561,B-CHEMICAL
and,561,O
long-chain,561,B-CHEMICAL
alkanol,561,I-CHEMICAL
sites,561,O
on,561,O
the,561,O
nicotinic,561,B-GENE-N
acetylcholine,561,I-GENE-N
receptor,561,I-GENE-N
and,561,O
their,561,O
allosteric,561,O
interaction,561,O
.,561,O
Long-chain,562,B-CHEMICAL
alkanols,562,I-CHEMICAL
are,562,O
general,562,O
anesthetics,562,O
which,562,O
can,562,O
also,562,O
act,562,O
as,562,O
uncharged,562,O
noncompetitive,562,O
inhibitors,562,O
of,562,O
the,562,O
peripheral,562,O
nicotinic,562,B-GENE-N
acetylcholine,562,B-CHEMICAL
receptor,562,I-GENE-N
(,562,O
AChR,562,B-GENE-N
),562,O
by,562,O
binding,562,O
to,562,O
one,562,O
or,562,O
more,562,O
specific,562,O
sites,562,O
on,562,O
the,562,O
AChR,562,B-GENE-N
.,562,O
Cembranoids,563,B-CHEMICAL
are,563,O
naturally,563,O
occurring,563,O
",",563,O
uncharged,563,O
noncompetitive,563,O
inhibitors,563,O
of,563,O
peripheral,563,O
and,563,O
neuronal,563,O
AChRs,563,B-GENE-N
",",563,O
which,563,O
have,563,O
no,563,O
demonstrable,563,O
general,563,O
anesthetic,563,O
activity,563,O
in,563,O
vivo,563,O
.,563,O
In,564,O
this,564,O
study,564,O
",",564,O
[,564,B-CHEMICAL
3H,564,I-CHEMICAL
],564,I-CHEMICAL
tenocyclidine,564,I-CHEMICAL
(,564,O
[,564,B-CHEMICAL
3H,564,I-CHEMICAL
],564,I-CHEMICAL
TCP,564,I-CHEMICAL
),564,O
",",564,O
an,564,O
analogue,564,O
of,564,O
the,564,O
cationic,564,O
noncompetitive,564,O
inhibitor,564,O
phencyclidine,564,B-CHEMICAL
(,564,O
PCP,564,B-CHEMICAL
),564,O
",",564,O
was,564,O
used,564,O
to,564,O
characterize,564,O
the,564,O
cembranoid,564,B-CHEMICAL
and,564,O
long-chain,564,B-CHEMICAL
alkanol,564,I-CHEMICAL
sites,564,O
on,564,O
the,564,O
desensitized,564,O
Torpedo,564,O
californica,564,O
AChR,564,B-GENE-N
and,564,O
to,564,O
investigate,564,O
if,564,O
these,564,O
sites,564,O
interact,564,O
.,564,O
These,565,O
studies,565,O
confirm,565,O
that,565,O
there,565,O
is,565,O
a,565,O
single,565,O
cembranoid,565,O
site,565,O
which,565,O
sterically,565,O
overlaps,565,O
the,565,O
[,565,B-CHEMICAL
3H,565,I-CHEMICAL
],565,I-CHEMICAL
TCP,565,I-CHEMICAL
channel,565,O
site,565,O
.,565,O
This,566,O
cembranoid,566,B-CHEMICAL
site,566,O
probably,566,O
also,566,O
overlaps,566,O
the,566,O
sites,566,O
for,566,O
the,566,O
cationic,566,O
noncompetitive,566,O
inhibitors,566,O
",",566,O
procaine,566,B-CHEMICAL
and,566,O
quinacrine,566,B-CHEMICAL
.,566,O
Evidence,567,O
is,567,O
also,567,O
presented,567,O
for,567,O
one,567,O
or,567,O
more,567,O
allosteric,567,O
cembranoid,567,O
sites,567,O
which,567,O
negatively,567,O
modulate,567,O
cembranoid,567,B-CHEMICAL
affinity,567,O
for,567,O
the,567,O
inhibitory,567,O
site,567,O
.,567,O
In,568,O
contrast,568,O
",",568,O
long-chain,568,B-CHEMICAL
alkanols,568,I-CHEMICAL
inhibit,568,O
[,568,B-CHEMICAL
3H,568,I-CHEMICAL
],568,I-CHEMICAL
TCP,568,I-CHEMICAL
binding,568,O
through,568,O
an,568,O
allosteric,568,O
mechanism,568,O
involving,568,O
two,568,O
or,568,O
more,568,O
alkanol,568,B-CHEMICAL
sites,568,O
which,568,O
display,568,O
positive,568,O
cooperativity,568,O
toward,568,O
each,568,O
other,568,O
.,568,O
Double,569,O
inhibitor,569,O
studies,569,O
show,569,O
that,569,O
the,569,O
cembranoid,569,B-CHEMICAL
inhibitory,569,O
site,569,O
and,569,O
the,569,O
alkanol,569,B-CHEMICAL
sites,569,O
are,569,O
not,569,O
independent,569,O
of,569,O
each,569,O
other,569,O
but,569,O
interfere,569,O
allosterically,569,O
with,569,O
each,569,O
other,569,O
's,569,O
inhibition,569,O
of,569,O
[,569,B-CHEMICAL
3H,569,I-CHEMICAL
],569,I-CHEMICAL
TCP,569,I-CHEMICAL
binding,569,O
.,569,O
The,570,O
simplest,570,O
models,570,O
consistent,570,O
with,570,O
the,570,O
observed,570,O
data,570,O
are,570,O
presented,570,O
and,570,O
discussed,570,O
.,570,O
Sulfasalazine,571,B-CHEMICAL
",",571,O
a,571,O
potent,571,O
suppressor,571,O
of,571,O
lymphoma,571,O
growth,571,O
by,571,O
inhibition,571,O
of,571,O
the,571,O
x,571,B-GENE-Y
(,571,I-GENE-Y
c,571,I-GENE-Y
),571,I-GENE-Y
-,571,I-GENE-Y
cystine,571,I-GENE-Y
transporter,571,I-GENE-Y
:,571,O
a,571,O
new,571,O
action,571,O
for,571,O
an,571,O
old,571,O
drug,571,O
.,571,O
Although,572,O
cyst,572,B-CHEMICAL
(,572,I-CHEMICAL
e,572,I-CHEMICAL
),572,I-CHEMICAL
ine,572,I-CHEMICAL
is,572,O
nutritionally,572,O
a,572,O
non-essential,572,B-CHEMICAL
amino,572,I-CHEMICAL
acid,572,I-CHEMICAL
",",572,O
lymphoid,572,O
cells,572,O
can,572,O
not,572,O
synthesize,572,O
it,572,O
",",572,O
rendering,572,O
their,572,O
growth,572,O
dependent,572,O
on,572,O
uptake,572,O
of,572,O
cyst,572,B-CHEMICAL
(,572,I-CHEMICAL
e,572,I-CHEMICAL
),572,I-CHEMICAL
ine,572,I-CHEMICAL
from,572,O
their,572,O
microenvironment,572,O
.,572,O
Accordingly,573,O
",",573,O
we,573,O
previously,573,O
suggested,573,O
that,573,O
the,573,O
x,573,B-GENE-Y
(,573,I-GENE-Y
c,573,I-GENE-Y
),573,I-GENE-Y
-,573,I-GENE-Y
plasma,573,I-GENE-Y
membrane,573,I-GENE-Y
cystine,573,B-CHEMICAL
transporter,573,I-GENE-Y
provided,573,O
a,573,O
target,573,O
for,573,O
lymphoid,573,O
cancer,573,O
therapy,573,O
.,573,O
Its,574,O
inhibition,574,O
could,574,O
lead,574,O
to,574,O
cyst,574,B-CHEMICAL
(,574,I-CHEMICAL
e,574,I-CHEMICAL
),574,I-CHEMICAL
ine,574,I-CHEMICAL
deficiency,574,O
in,574,O
lymphoma,574,O
cells,574,O
via,574,O
reduction,574,O
of,574,O
both,574,O
their,574,O
cystine,574,B-CHEMICAL
uptake,574,O
and,574,O
cysteine,574,B-CHEMICAL
supply,574,O
by,574,O
somatic,574,O
cells,574,O
.,574,O
In,575,O
this,575,O
study,575,O
",",575,O
using,575,O
rat,575,O
Nb2,575,O
lymphoma,575,O
cultures,575,O
",",575,O
drugs,575,O
were,575,O
screened,575,O
for,575,O
growth,575,O
arrest,575,O
based,575,O
on,575,O
x,575,B-GENE-Y
(,575,I-GENE-Y
c,575,I-GENE-Y
),575,I-GENE-Y
-,575,O
inhibition,575,O
.,575,O
Sulfasalazine,576,B-CHEMICAL
was,576,O
fortuitously,576,O
found,576,O
to,576,O
be,576,O
a,576,O
novel,576,O
",",576,O
potent,576,O
inhibitor,576,O
of,576,O
the,576,O
x,576,B-GENE-Y
(,576,I-GENE-Y
c,576,I-GENE-Y
),576,I-GENE-Y
-,576,I-GENE-Y
transporter,576,I-GENE-Y
.,576,O
It,577,O
showed,577,O
high,577,O
rat,577,O
lymphoma,577,O
growth-inhibitory,577,O
and,577,O
lytic,577,O
activity,577,O
in,577,O
vitro,577,O
(,577,O
IC50,577,O
=,577,O
0.16,577,O
mM,577,O
),577,O
",",577,O
based,577,O
specifically,577,O
on,577,O
inhibition,577,O
of,577,O
x,577,B-GENE-Y
(,577,I-GENE-Y
c,577,I-GENE-Y
),577,I-GENE-Y
--,577,O
mediated,577,O
cystine,577,B-CHEMICAL
uptake,577,O
",",577,O
in,577,O
contrast,577,O
to,577,O
its,577,O
colonic,577,O
metabolites,577,O
",",577,O
sulfapyridine,577,B-CHEMICAL
and,577,O
5-aminosalicylic,577,B-CHEMICAL
acid,577,I-CHEMICAL
.,577,O
Sulfasalazine,578,B-CHEMICAL
was,578,O
even,578,O
more,578,O
effective,578,O
against,578,O
human,578,O
non-Hodgkin,578,O
's,578,O
lymphoma,578,O
(,578,O
DoHH2,578,O
),578,O
cultures,578,O
.,578,O
In,579,O
rats,579,O
(,579,O
n,579,O
=,579,O
13,579,O
),579,O
",",579,O
sulfasalazine,579,B-CHEMICAL
(,579,O
i.p,579,O
.,579,O
),579,O
markedly,580,O
inhibited,580,O
growth,580,O
of,580,O
well-developed,580,O
",",580,O
rapidly,580,O
growing,580,O
rat,580,O
Nb2,580,O
lymphoma,580,O
transplants,580,O
without,580,O
apparent,580,O
side-effects,580,O
.,580,O
Reduced,581,O
",",581,O
macrophage-mediated,581,O
supply,581,O
of,581,O
cysteine,581,B-CHEMICAL
was,581,O
probably,581,O
involved,581,O
.,581,O
In,582,O
five,582,O
rats,582,O
",",582,O
90-100,582,O
%,582,O
tumor,582,O
growth,582,O
suppression,582,O
",",582,O
relative,582,O
to,582,O
controls,582,O
",",582,O
was,582,O
obtained,582,O
.,582,O
The,583,O
x,583,B-GENE-Y
(,583,I-GENE-Y
c,583,I-GENE-Y
),583,I-GENE-Y
-,583,I-GENE-Y
cystine,583,B-CHEMICAL
transporter,583,I-GENE-Y
represents,583,O
a,583,O
novel,583,O
target,583,O
for,583,O
sulfasalazine-like,583,B-CHEMICAL
drugs,583,O
with,583,O
high,583,O
potential,583,O
for,583,O
application,583,O
in,583,O
therapy,583,O
of,583,O
lymphoblastic,583,O
and,583,O
other,583,O
malignancies,583,O
dependent,583,O
on,583,O
extracellular,583,O
cyst,583,B-CHEMICAL
(,583,I-CHEMICAL
e,583,I-CHEMICAL
),583,I-CHEMICAL
ine,583,I-CHEMICAL
.,583,O
Advances,584,O
in,584,O
antihypertensive,584,O
combination,584,O
therapy,584,O
:,584,O
benefits,584,O
of,584,O
low-dose,584,O
thiazide,584,B-CHEMICAL
diuretics,584,O
in,584,O
conjunction,584,O
with,584,O
omapatrilat,584,B-CHEMICAL
",",584,O
a,584,O
vasopeptidase,584,B-GENE-N
inhibitor,584,O
.,584,O
The,585,O
preferred,585,O
initial,585,O
agents,585,O
for,585,O
the,585,O
treatment,585,O
of,585,O
high,585,O
blood,585,O
pressure,585,O
are,585,O
low-dose,585,O
thiazide,585,B-CHEMICAL
diuretics,585,O
",",585,O
beta,585,O
blockers,585,O
",",585,O
calcium,585,B-CHEMICAL
antagonists,585,O
",",585,O
and,585,O
angiotensin-converting,585,B-CHEMICAL
enzyme,585,I-GENE-Y
(,585,O
ACE,585,B-GENE-Y
),585,O
inhibitors,585,O
.,585,O
In,586,O
high-risk,586,O
patients,586,O
",",586,O
including,586,O
those,586,O
with,586,O
diabetes,586,O
",",586,O
renal,586,O
insufficiency,586,O
",",586,O
left,586,O
ventricular,586,O
dysfunction,586,O
",",586,O
and,586,O
atherosclerosis,586,O
",",586,O
ACE,586,B-GENE-Y
inhibitors,586,O
may,586,O
have,586,O
specific,586,O
benefit,586,O
in,586,O
reducing,586,O
cardiovascular,586,O
morbidity,586,O
and,586,O
mortality,586,O
.,586,O
Omapatrilat,587,B-CHEMICAL
",",587,O
the,587,O
prototypical,587,O
vasopeptidase,587,B-GENE-N
inhibitor,587,O
",",587,O
inhibits,587,O
not,587,O
only,587,O
ACE,587,B-GENE-Y
but,587,O
also,587,O
neutral,587,B-GENE-Y
endopeptidase,587,I-GENE-Y
.,587,O
Like,588,O
conventional,588,O
ACE,588,B-GENE-Y
inhibitors,588,O
",",588,O
omapatrilat,588,B-CHEMICAL
causes,588,O
extracellular,588,O
volume,588,O
reduction,588,O
and,588,O
vasodilatation,588,O
;,588,O
moreover,588,O
",",588,O
it,588,O
increases,588,O
levels,588,O
of,588,O
atrial,588,B-GENE-N
and,588,I-GENE-N
brain,588,I-GENE-N
natriuretic,588,I-GENE-N
peptides,588,I-GENE-N
and,588,O
bradykinin,588,B-GENE-Y
.,588,O
Effective,589,O
blood,589,O
pressure,589,O
control,589,O
",",589,O
especially,589,O
in,589,O
the,589,O
high-risk,589,O
patient,589,O
",",589,O
usually,589,O
necessitates,589,O
combination,589,O
therapy,589,O
.,589,O
A,590,O
recent,590,O
study,590,O
randomized,590,O
274,590,O
subjects,590,O
with,590,O
mild,590,O
to,590,O
severe,590,O
hypertension,590,O
(,590,O
stages,590,O
1-3,590,O
diastolic,590,O
blood,590,O
pressure,590,O
elevation,590,O
),590,O
and,590,O
confirmed,590,O
the,590,O
benefits,590,O
of,590,O
omapatrilat,590,B-CHEMICAL
combined,590,O
with,590,O
hydrochlorothiazide,590,B-CHEMICAL
in,590,O
patients,590,O
not,590,O
controlled,590,O
on,590,O
hydrochlorothiazide,590,B-CHEMICAL
alone,590,O
.,590,O
The,591,O
frequencies,591,O
of,591,O
adverse,591,O
events,591,O
",",591,O
serious,591,O
adverse,591,O
events,591,O
",",591,O
and,591,O
discontinuation,591,O
attributed,591,O
to,591,O
adverse,591,O
events,591,O
were,591,O
similar,591,O
for,591,O
omapatrilat,591,B-CHEMICAL
and,591,O
placebo,591,O
.,591,O
Furthermore,592,O
",",592,O
there,592,O
were,592,O
no,592,O
clinically,592,O
significant,592,O
changes,592,O
in,592,O
serum,592,O
creatinine,592,B-CHEMICAL
",",592,O
potassium,592,B-CHEMICAL
",",592,O
or,592,O
other,592,O
laboratory,592,O
parameters,592,O
.,592,O
Adding,593,O
omapatrilat,593,B-CHEMICAL
to,593,O
the,593,O
background,593,O
of,593,O
hydrochlorothiazide,593,B-CHEMICAL
treatment,593,O
produced,593,O
statistically,593,O
significant,593,O
additional,593,O
reductions,593,O
in,593,O
trough,593,O
diastolic,593,O
and,593,O
systolic,593,O
blood,593,O
pressures,593,O
at,593,O
weeks,593,O
4,593,O
and,593,O
8,593,O
.,593,O
Neonatal,594,O
red,594,O
blood,594,O
cells,594,O
:,594,O
amiloride-insensitive,594,B-CHEMICAL
Na+-H+,594,B-CHEMICAL
transport,594,O
isoform,594,O
would,594,O
express,594,O
Na+-Li+,594,B-CHEMICAL
exchange,594,O
.,594,O
Neonatal,595,O
red,595,O
cells,595,O
(,595,O
umbilical,595,O
cord,595,O
blood,595,O
),595,O
were,595,O
in,595,O
vitro,595,O
incubated,595,O
in,595,O
isotonic,595,O
media,595,O
(,595,O
thiocyanate,595,B-CHEMICAL
as,595,O
predominant,595,O
anion,595,O
),595,O
.,595,O
This,596,O
experimental,596,O
condition,596,O
was,596,O
selected,596,O
as,596,O
it,596,O
was,596,O
known,596,O
that,596,O
this,596,O
chaotropic,596,O
anion,596,O
induced,596,O
activation,596,O
of,596,O
Na+-H+,596,B-CHEMICAL
exchange,596,O
.,596,O
The,597,O
transport,597,O
amiloride-sensitive,597,B-CHEMICAL
mechanism,597,O
",",597,O
that,597,O
decreased,597,O
the,597,O
acidic,597,O
intracellular,597,O
pH,597,O
change,597,O
occurring,597,O
in,597,O
this,597,O
medium,597,O
",",597,O
would,597,O
correspond,597,O
to,597,O
Na+-H+,597,B-CHEMICAL
exchange,597,O
(,597,O
NHE1,597,B-GENE-Y
isoform,597,O
),597,O
.,597,O
However,598,O
",",598,O
the,598,O
Na+-Li+,598,B-CHEMICAL
exchange,598,O
",",598,O
also,598,O
determined,598,O
in,598,O
the,598,O
cells,598,O
in,598,O
the,598,O
above-mentioned,598,O
medium,598,O
was,598,O
not,598,O
affected,598,O
by,598,O
amiloride,598,B-CHEMICAL
.,598,O
The,599,O
present,599,O
data,599,O
suggest,599,O
that,599,O
an,599,O
amiloride,599,B-CHEMICAL
insensitive,599,O
Na+-H+,599,B-CHEMICAL
exchange,599,O
isoform,599,O
would,599,O
express,599,O
Na+-Li+,599,B-CHEMICAL
countertransport,599,O
in,599,O
these,599,O
cells,599,O
.,599,O
Aspirin,600,B-CHEMICAL
and,600,O
salicylate,600,B-CHEMICAL
bind,600,O
to,600,O
immunoglobulin,600,B-GENE-Y
heavy,600,I-GENE-Y
chain,600,I-GENE-Y
binding,600,I-GENE-Y
protein,600,I-GENE-Y
(,600,O
BiP,600,B-GENE-Y
),600,O
and,600,O
inhibit,600,O
its,600,O
ATPase,600,B-GENE-N
activity,600,O
in,600,O
human,600,O
fibroblasts,600,O
.,600,O
Salicylic,601,B-CHEMICAL
acid,601,I-CHEMICAL
(,601,O
SA,601,B-CHEMICAL
),601,O
",",601,O
an,601,O
endogenous,601,O
signaling,601,O
molecule,601,O
of,601,O
plants,601,O
",",601,O
possesses,601,O
anti-inflammatory,601,O
and,601,O
anti-neoplastic,601,O
actions,601,O
in,601,O
human,601,O
.,601,O
Its,602,O
derivative,602,O
",",602,O
aspirin,602,O
",",602,O
is,602,O
the,602,O
most,602,O
commonly,602,O
used,602,O
anti-inflammatory,602,O
and,602,O
analgesic,602,O
drug,602,O
.,602,O
Aspirin,603,B-CHEMICAL
and,603,O
sodium,603,B-CHEMICAL
salicylate,603,I-CHEMICAL
(,603,O
salicylates,603,B-CHEMICAL
),603,O
have,603,O
been,603,O
reported,603,O
to,603,O
have,603,O
multiple,603,O
pharmacological,603,O
actions,603,O
.,603,O
However,604,O
",",604,O
it,604,O
is,604,O
unclear,604,O
whether,604,O
they,604,O
bind,604,O
to,604,O
a,604,O
cellular,604,O
protein,604,O
.,604,O
Here,605,O
",",605,O
we,605,O
report,605,O
for,605,O
the,605,O
first,605,O
time,605,O
the,605,O
purification,605,O
from,605,O
human,605,O
fibroblasts,605,O
of,605,O
a,605,O
approximately,605,O
78,605,O
kDa,605,O
salicylate,605,B-GENE-N
binding,605,I-GENE-N
protein,605,I-GENE-N
with,605,O
sequence,605,O
identity,605,O
to,605,O
immunoglobulin,605,B-GENE-Y
heavy,605,I-GENE-Y
chain,605,I-GENE-Y
binding,605,I-GENE-Y
protein,605,I-GENE-Y
(,605,O
BiP,605,B-GENE-Y
),605,O
.,605,O
The,606,O
Kd,606,O
values,606,O
of,606,O
SA,606,B-CHEMICAL
binding,606,O
to,606,O
crude,606,O
extract,606,O
and,606,O
to,606,O
recombinant,606,O
BiP,606,B-GENE-Y
were,606,O
45.2,606,O
and,606,O
54.6,606,O
microM,606,O
",",606,O
respectively,606,O
.,606,O
BiP,607,B-GENE-Y
is,607,O
a,607,O
chaperone,607,B-GENE-N
protein,607,I-GENE-N
containing,607,O
a,607,O
polypeptide,607,O
binding,607,O
site,607,O
recognizing,607,O
specific,607,O
heptapeptide,607,B-GENE-N
sequence,607,I-GENE-N
and,607,O
an,607,O
ATP,607,B-CHEMICAL
binding,607,I-GENE-N
site,607,I-GENE-N
.,607,O
A,608,O
heptapeptide,608,O
with,608,O
the,608,O
specific,608,O
sequence,608,O
displaced,608,O
SA,608,B-CHEMICAL
binding,608,O
in,608,O
a,608,O
concentration-dependent,608,O
manner,608,O
whereas,608,O
a,608,O
control,608,O
heptapeptide,608,O
did,608,O
not,608,O
.,608,O
Salicylates,609,B-CHEMICAL
inhibited,609,O
ATPase,609,B-GENE-N
activity,609,O
stimulated,609,O
by,609,O
this,609,O
specific,609,O
heptapeptide,609,O
but,609,O
did,609,O
not,609,O
block,609,O
ATP,609,B-CHEMICAL
binding,609,O
or,609,O
induce,609,O
BiP,609,B-GENE-Y
expression,609,O
.,609,O
These,610,O
results,610,O
indicate,610,O
that,610,O
salicylates,610,B-CHEMICAL
bind,610,O
specifically,610,O
to,610,O
the,610,O
polypeptide,610,O
binding,610,O
site,610,O
of,610,O
BiP,610,B-GENE-Y
in,610,O
human,610,O
cells,610,O
that,610,O
may,610,O
interfere,610,O
with,610,O
folding,610,O
and,610,O
transport,610,O
of,610,O
proteins,610,O
important,610,O
in,610,O
inflammation,610,O
.,610,O
Compensatory,611,O
changes,611,O
in,611,O
enzymes,611,O
of,611,O
arginine,611,B-CHEMICAL
metabolism,611,O
during,611,O
renal,611,O
hypertrophy,611,O
in,611,O
mice,611,O
.,611,O
The,612,O
present,612,O
study,612,O
investigates,612,O
enzyme,612,O
activities,612,O
of,612,O
the,612,O
urea,612,O
cycle,612,O
",",612,O
transamidinase,612,B-GENE-Y
and,612,O
ornithine-proline,612,B-CHEMICAL
inter-conversion,612,O
in,612,O
the,612,O
hypertrophied,612,O
kidney,612,O
after,612,O
unilateral,612,O
nephrectomy,612,O
in,612,O
mice,612,O
.,612,O
Surgical,613,O
removal,613,O
of,613,O
the,613,O
left,613,O
kidney,613,O
in,613,O
mice,613,O
led,613,O
to,613,O
compensatory,613,O
enlargement,613,O
of,613,O
the,613,O
right,613,O
kidney,613,O
after,613,O
1,613,O
and,613,O
14,613,O
days,613,O
.,613,O
This,614,O
renal,614,O
growth,614,O
was,614,O
associated,614,O
with,614,O
an,614,O
increase,614,O
in,614,O
glomerular,614,O
volume,614,O
(,614,O
but,614,O
not,614,O
number,614,O
),614,O
and,614,O
enlargement,614,O
of,614,O
the,614,O
proximal,614,O
convoluted,614,O
tubules,614,O
.,614,O
The,615,O
total,615,O
renal,615,O
protein,615,O
content,615,O
increased,615,O
in,615,O
proportion,615,O
to,615,O
the,615,O
increase,615,O
in,615,O
kidney,615,O
weight,615,O
",",615,O
but,615,O
the,615,O
protein,615,O
per,615,O
gram,615,O
weight,615,O
of,615,O
kidney,615,O
did,615,O
not,615,O
change,615,O
.,615,O
The,616,O
specific,616,O
activity,616,O
of,616,O
only,616,O
ornithine,616,B-GENE-Y
aminotransferase,616,I-GENE-Y
(,616,O
OAT,616,B-GENE-Y
),616,O
",",616,O
the,616,O
rate-limiting,616,O
enzyme,616,O
in,616,O
the,616,O
conversion,616,O
of,616,O
ornithine,616,B-CHEMICAL
to,616,O
proline,616,B-CHEMICAL
",",616,O
increased,616,O
in,616,O
2,616,O
weeks,616,O
of,616,O
hypertrophy,616,O
.,616,O
The,617,O
specific,617,O
activity,617,O
of,617,O
all,617,O
other,617,O
enzymes,617,O
was,617,O
unchanged,617,O
.,617,O
However,618,O
",",618,O
the,618,O
total,618,O
enzyme,618,O
activity,618,O
per,618,O
kidney,618,O
of,618,O
all,618,O
the,618,O
enzymes,618,O
",",618,O
without,618,O
exception,618,O
",",618,O
was,618,O
elevated,618,O
in,618,O
the,618,O
hypertrophied,618,O
kidney,618,O
.,618,O
While,619,O
the,619,O
increase,619,O
in,619,O
total,619,O
OAT,619,B-GENE-Y
activity,619,O
was,619,O
much,619,O
more,619,O
than,619,O
the,619,O
increase,619,O
in,619,O
kidney,619,O
weight,619,O
",",619,O
all,619,O
other,619,O
enzymes,619,O
increased,619,O
more,619,O
or,619,O
less,619,O
in,619,O
proportion,619,O
to,619,O
the,619,O
increase,619,O
in,619,O
renal,619,O
mass,619,O
.,619,O
The,620,O
results,620,O
suggest,620,O
that,620,O
compensation,620,O
in,620,O
OAT,620,B-GENE-Y
activity,620,O
to,620,O
chronic,620,O
reduction,620,O
in,620,O
renal,620,O
mass,620,O
was,620,O
complete,620,O
",",620,O
but,620,O
only,620,O
partial,620,O
in,620,O
the,620,O
case,620,O
of,620,O
other,620,O
enzymes,620,O
.,620,O
Analgesia,621,O
and,621,O
COX-2,621,B-GENE-Y
inhibition,621,O
.,621,O
While,622,O
non-steroidal,622,O
anti-inflammatory,622,O
drugs,622,O
(,622,O
NSAIDs,622,O
),622,O
are,622,O
the,622,O
mainstay,622,O
of,622,O
therapy,622,O
for,622,O
the,622,O
management,622,O
of,622,O
acute,622,O
pain,622,O
and,622,O
rheumatoid,622,O
arthritis,622,O
",",622,O
toxicity,622,O
associated,622,O
with,622,O
chronic,622,O
administration,622,O
limits,622,O
their,622,O
benefit-to-risk,622,O
relationship,622,O
in,622,O
many,622,O
patients,622,O
.,622,O
A,623,O
series,623,O
of,623,O
studies,623,O
is,623,O
reviewed,623,O
that,623,O
assesses,623,O
the,623,O
relationship,623,O
between,623,O
cytokines,623,B-GENE-N
released,623,O
at,623,O
the,623,O
site,623,O
of,623,O
tissue,623,O
injury,623,O
and,623,O
NSAID,623,O
analgesia,623,O
",",623,O
and,623,O
the,623,O
in,623,O
vivo,623,O
selectivity,623,O
of,623,O
a,623,O
selective,623,O
cyclooxygenase,623,B-GENE-Y
(,623,I-GENE-Y
COX,623,I-GENE-Y
),623,I-GENE-Y
-2,623,I-GENE-Y
inhibitor,623,O
(,623,O
celecoxib,623,B-CHEMICAL
),623,O
in,623,O
comparison,623,O
to,623,O
a,623,O
dual,623,O
COX-1/COX-2,623,B-GENE-Y
inhibitor,623,O
(,623,O
ketorolac,623,B-CHEMICAL
),623,O
.,623,O
Three,624,O
replicate,624,O
studies,624,O
in,624,O
the,624,O
oral,624,O
surgery,624,O
model,624,O
of,624,O
acute,624,O
pain,624,O
used,624,O
submucosal,624,O
microdialysis,624,O
sample,624,O
collection,624,O
for,624,O
the,624,O
measurement,624,O
of,624,O
prostaglandin,624,B-CHEMICAL
E2,624,I-CHEMICAL
(,624,O
PGE2,624,B-CHEMICAL
;,624,O
a,624,O
product,624,O
of,624,O
both,624,O
COX-1,624,B-GENE-Y
and,624,O
COX-2,624,B-GENE-Y
),624,O
and,624,O
thromboxane,624,B-CHEMICAL
B2,624,I-CHEMICAL
(,624,O
as,624,O
a,624,O
biomarker,624,O
for,624,O
COX-1,624,B-GENE-Y
activity,624,O
),624,O
with,624,O
parallel,624,O
assessments,624,O
of,624,O
pain,624,O
.,624,O
The,625,O
time,625,O
course,625,O
of,625,O
PGE2,625,B-CHEMICAL
production,625,O
was,625,O
consistent,625,O
with,625,O
early,625,O
release,625,O
due,625,O
to,625,O
COX-1,625,B-GENE-Y
activity,625,O
followed,625,O
by,625,O
increased,625,O
production,625,O
2-3,625,O
hours,625,O
after,625,O
surgery,625,O
",",625,O
consistent,625,O
with,625,O
COX-2,625,B-GENE-Y
expression,625,O
.,625,O
Ketorolac,626,B-CHEMICAL
30,626,O
mg,626,O
at,626,O
pain,626,O
onset,626,O
suppressed,626,O
both,626,O
pain,626,O
and,626,O
peripheral,626,O
PGE2,626,B-CHEMICAL
levels,626,O
.,626,O
Ketorolac,627,B-CHEMICAL
1,627,O
mg,627,O
either,627,O
at,627,O
the,627,O
site,627,O
of,627,O
injury,627,O
or,627,O
intramuscularly,627,O
also,627,O
produced,627,O
analgesia,627,O
but,627,O
without,627,O
any,627,O
effect,627,O
on,627,O
peripheral,627,O
PGE2,627,B-CHEMICAL
levels,627,O
.,627,O
Celecoxib,628,B-CHEMICAL
selectively,628,O
suppressed,628,O
PGE2,628,B-CHEMICAL
but,628,O
not,628,O
TxB2,628,B-CHEMICAL
at,628,O
time,628,O
points,628,O
consistent,628,O
with,628,O
COX-2,628,B-GENE-Y
activity,628,O
",",628,O
while,628,O
producing,628,O
analgesia,628,O
.,628,O
These,629,O
studies,629,O
demonstrate,629,O
the,629,O
ability,629,O
to,629,O
assess,629,O
the,629,O
time,629,O
course,629,O
and,629,O
selective,629,O
effects,629,O
of,629,O
COX-2,629,B-GENE-Y
inhibitors,629,O
in,629,O
vivo,629,O
and,629,O
suggest,629,O
that,629,O
suppression,629,O
of,629,O
COX-2,629,B-GENE-Y
mediated,629,O
PGE2,629,B-CHEMICAL
is,629,O
temporally,629,O
related,629,O
to,629,O
NSAID,629,O
analgesia,629,O
.,629,O
[,630,B-CHEMICAL
3H,630,I-CHEMICAL
],630,I-CHEMICAL
dofetilide,630,I-CHEMICAL
binding,630,O
to,630,O
HERG,630,B-GENE-Y
transfected,630,O
membranes,630,O
:,630,O
a,630,O
potential,630,O
high,630,O
throughput,630,O
preclinical,630,O
screen,630,O
.,630,O
The,631,O
pharmacological,631,O
characteristics,631,O
of,631,O
[,631,B-CHEMICAL
3H,631,I-CHEMICAL
],631,I-CHEMICAL
dofetilide,631,I-CHEMICAL
binding,631,O
were,631,O
examined,631,O
in,631,O
membranes,631,O
prepared,631,O
from,631,O
human,631,O
embryonic,631,O
kidney,631,O
(,631,O
HEK293,631,O
),631,O
cells,631,O
stably,631,O
expressing,631,O
human,631,B-GENE-Y
ether-a-go-go,631,B-CHEMICAL
related,631,I-GENE-Y
gene,631,I-GENE-Y
(,631,I-GENE-Y
HERG,631,I-GENE-Y
),631,I-GENE-Y
K+,631,B-CHEMICAL
channels,631,I-GENE-Y
.,631,O
The,632,O
classIII,632,O
antiarrhythmic,632,O
compounds,632,O
dofetilide,632,B-CHEMICAL
",",632,O
clofilium,632,B-CHEMICAL
",",632,O
4'-,632,B-CHEMICAL
[,632,I-CHEMICAL
[,632,I-CHEMICAL
1-,632,I-CHEMICAL
[,632,I-CHEMICAL
2-,632,I-CHEMICAL
(,632,I-CHEMICAL
6-methyl-2-pyridyl,632,I-CHEMICAL
),632,I-CHEMICAL
ethyl,632,I-CHEMICAL
],632,I-CHEMICAL
-4-piperidyl,632,I-CHEMICAL
],632,I-CHEMICAL
carbonyl,632,I-CHEMICAL
],632,I-CHEMICAL
methanesulfonanilide,632,I-CHEMICAL
(,632,O
E-4031,632,B-CHEMICAL
),632,O
",",632,O
N-methyl-N-,632,B-CHEMICAL
[,632,I-CHEMICAL
2-,632,I-CHEMICAL
[,632,I-CHEMICAL
methyl-,632,I-CHEMICAL
(,632,I-CHEMICAL
1-methyl-1H-benzimidazol-2-yl,632,I-CHEMICAL
),632,I-CHEMICAL
amino,632,I-CHEMICAL
],632,I-CHEMICAL
ethyl,632,I-CHEMICAL
],632,I-CHEMICAL
-4-,632,I-CHEMICAL
[,632,I-CHEMICAL
(,632,I-CHEMICAL
methylsulfo,632,I-CHEMICAL
nyl,632,I-CHEMICAL
),632,I-CHEMICAL
amino,632,I-CHEMICAL
],632,I-CHEMICAL
benzene-sulfonamide,632,I-CHEMICAL
(,632,O
"WAY-123,398",632,B-CHEMICAL
),632,O
and,632,O
d-sotalol,632,B-CHEMICAL
all,632,O
inhibited,632,O
[,632,B-CHEMICAL
3H,632,I-CHEMICAL
],632,I-CHEMICAL
dofetilide,632,I-CHEMICAL
binding,632,O
.,632,O
In,633,O
addition,633,O
",",633,O
the,633,O
structurally,633,O
unrelated,633,O
compounds,633,O
pimozide,633,B-CHEMICAL
",",633,O
terfenadine,633,B-CHEMICAL
and,633,O
haloperidol,633,B-CHEMICAL
",",633,O
all,633,O
of,633,O
which,633,O
prolong,633,O
the,633,O
QT,633,O
interval,633,O
in,633,O
man,633,O
",",633,O
also,633,O
inhibited,633,O
binding,633,O
.,633,O
These,634,O
data,634,O
indicate,634,O
that,634,O
a,634,O
[,634,B-CHEMICAL
3H,634,I-CHEMICAL
],634,I-CHEMICAL
dofetilide,634,I-CHEMICAL
binding,634,O
assay,634,O
using,634,O
HERG,634,B-GENE-Y
membranes,634,O
may,634,O
help,634,O
identify,634,O
compounds,634,O
that,634,O
prolong,634,O
the,634,O
QT,634,O
interval,634,O
.,634,O
Effects,635,O
of,635,O
the,635,O
antidepressant/antipanic,635,O
drug,635,O
phenelzine,635,B-CHEMICAL
on,635,O
alanine,635,B-CHEMICAL
and,635,O
alanine,635,B-GENE-N
transaminase,635,I-GENE-N
in,635,O
rat,635,O
brain,635,O
.,635,O
1,636,O
.,636,O
Phenelzine,637,B-CHEMICAL
(,637,O
PLZ,637,B-CHEMICAL
),637,O
is,637,O
an,637,O
antidepressant,637,O
with,637,O
anxiolytic,637,O
properties,637,O
.,637,O
Acute,638,O
and,638,O
chronic,638,O
PLZ,638,B-CHEMICAL
administration,638,O
increase,638,O
brain,638,O
GABA,638,B-CHEMICAL
levels,638,O
",",638,O
an,638,O
effect,638,O
due,638,O
",",638,O
at,638,O
least,638,O
in,638,O
part,638,O
",",638,O
to,638,O
an,638,O
inhibition,638,O
of,638,O
the,638,O
activity,638,O
of,638,O
the,638,O
GABA,638,B-CHEMICAL
metabolizing,638,O
enzyme,638,O
",",638,O
GABA,638,B-GENE-Y
transaminase,638,I-GENE-Y
(,638,O
GABA-T,638,B-GENE-Y
),638,O
.,638,O
2,639,O
.,639,O
Previous,640,O
preliminary,640,O
reports,640,O
have,640,O
indicated,640,O
that,640,O
acute,640,O
PLZ,640,B-CHEMICAL
treatment,640,O
also,640,O
elevates,640,O
brain,640,O
alanine,640,B-CHEMICAL
levels,640,O
.,640,O
As,641,O
with,641,O
GABA,641,B-CHEMICAL
",",641,O
the,641,O
metabolism,641,O
of,641,O
alanine,641,B-CHEMICAL
involves,641,O
a,641,O
pyridoxal,641,B-GENE-N
phosphate-dependent,641,I-GENE-N
transaminase,641,I-GENE-N
.,641,O
3,642,O
.,642,O
In,643,O
the,643,O
study,643,O
reported,643,O
here,643,O
",",643,O
the,643,O
effects,643,O
of,643,O
acute,643,O
PLZ,643,B-CHEMICAL
treatment,643,O
on,643,O
the,643,O
levels,643,O
of,643,O
various,643,O
amino,643,B-CHEMICAL
acids,643,I-CHEMICAL
",",643,O
some,643,O
of,643,O
which,643,O
are,643,O
also,643,O
metabolized,643,O
by,643,O
pyridoxal,643,B-GENE-N
phosphate-dependent,643,I-GENE-N
transaminases,643,I-GENE-N
were,643,O
compared,643,O
in,643,O
rat,643,O
whole,643,O
brain,643,O
.,643,O
Of,644,O
the,644,O
6,644,O
amino,644,B-CHEMICAL
acids,644,I-CHEMICAL
investigated,644,O
",",644,O
only,644,O
GABA,644,B-CHEMICAL
and,644,O
alanine,644,B-CHEMICAL
levels,644,O
were,644,O
elevated,644,O
(,644,O
in,644,O
a,644,O
time-,644,O
and,644,O
dose-dependent,644,O
manner,644,O
),644,O
.,644,O
4,645,O
.,645,O
The,646,O
elevation,646,O
in,646,O
brain,646,O
alanine,646,B-CHEMICAL
levels,646,O
could,646,O
be,646,O
explained,646,O
",",646,O
at,646,O
least,646,O
in,646,O
part,646,O
",",646,O
by,646,O
a,646,O
time-,646,O
and,646,O
dose-dependent,646,O
inhibitory,646,O
effect,646,O
of,646,O
PLZ,646,B-CHEMICAL
on,646,O
alanine,646,B-GENE-N
transaminase,646,I-GENE-N
(,646,O
ALA-T,646,B-GENE-N
),646,O
",",646,O
although,646,O
as,646,O
with,646,O
GABA,646,B-CHEMICAL
the,646,O
increases,646,O
are,646,O
higher,646,O
than,646,O
expected,646,O
from,646,O
the,646,O
degree,646,O
of,646,O
enzyme,646,O
inhibition,646,O
produced,646,O
.,646,O
In,647,O
addition,647,O
",",647,O
we,647,O
also,647,O
showed,647,O
that,647,O
the,647,O
elevation,647,O
in,647,O
alanine,647,B-CHEMICAL
levels,647,O
and,647,O
the,647,O
inhibition,647,O
of,647,O
alanine,647,B-GENE-N
transaminase,647,I-GENE-N
in,647,O
the,647,O
brain,647,O
are,647,O
retained,647,O
after,647,O
14,647,O
days,647,O
of,647,O
PLZ,647,B-CHEMICAL
treatment,647,O
",",647,O
and,647,O
that,647,O
PLZ,647,B-CHEMICAL
produces,647,O
a,647,O
marked,647,O
increase,647,O
in,647,O
extracellular,647,O
levels,647,O
of,647,O
alanine,647,B-CHEMICAL
.,647,O
5,648,O
.,648,O
These,649,O
results,649,O
are,649,O
discussed,649,O
in,649,O
terms,649,O
of,649,O
their,649,O
relevance,649,O
to,649,O
synaptic,649,O
function,649,O
and,649,O
to,649,O
the,649,O
pharmacological,649,O
profile,649,O
of,649,O
PLZ,649,B-CHEMICAL
.,649,O
Nicotine-induced,650,B-CHEMICAL
contraction,650,O
in,650,O
the,650,O
rat,650,O
coronary,650,O
artery,650,O
:,650,O
possible,650,O
involvement,650,O
of,650,O
the,650,O
endothelium,650,O
",",650,O
reactive,650,O
oxygen,650,B-CHEMICAL
species,650,O
and,650,O
COX-1,650,B-GENE-Y
metabolites,650,O
.,650,O
Nicotine,651,B-CHEMICAL
caused,651,O
a,651,O
contraction,651,O
of,651,O
the,651,O
rat,651,O
coronary,651,O
artery,651,O
in,651,O
the,651,O
presence,651,O
of,651,O
Nomega-nitro-L-arginine,651,B-CHEMICAL
methyl,651,I-CHEMICAL
ester,651,I-CHEMICAL
(,651,O
L-NAME,651,B-CHEMICAL
),651,O
and,651,O
arachidonic,651,B-CHEMICAL
acid,651,I-CHEMICAL
",",651,O
and,651,O
did,651,O
not,651,O
in,651,O
the,651,O
absence,651,O
of,651,O
these,651,O
agents,651,O
.,651,O
The,652,O
present,652,O
experiments,652,O
were,652,O
undertaken,652,O
to,652,O
pharmacologically,652,O
characterize,652,O
the,652,O
nicotine-induced,652,B-CHEMICAL
contraction,652,O
in,652,O
ring,652,O
preparations,652,O
of,652,O
the,652,O
rat,652,O
coronary,652,O
artery,652,O
.,652,O
The,653,O
contraction,653,O
was,653,O
abolished,653,O
by,653,O
chemical,653,O
removal,653,O
of,653,O
endothelium,653,O
saponin,653,B-CHEMICAL
.,653,O
Oxygen,654,B-CHEMICAL
radical,654,O
scavengers,654,O
",",654,O
superoxide,654,B-GENE-N
dismutase,654,I-GENE-N
and,654,O
catalase,654,B-GENE-Y
",",654,O
significantly,654,O
attenuated,654,O
the,654,O
contraction,654,O
.,654,O
Cyclooxygenase-1,655,B-GENE-Y
(,655,O
COX-1,655,B-GENE-Y
),655,O
inhibitors,655,O
(,655,O
flurbiprofen,655,B-CHEMICAL
",",655,O
ketoprofen,655,B-CHEMICAL
and,655,O
ketrolack,655,B-CHEMICAL
),655,O
attenuated,655,O
the,655,O
nicotine-induced,655,B-CHEMICAL
contraction,655,O
in,655,O
a,655,O
concentration-dependent,655,O
manner,655,O
",",655,O
and,655,O
cyclooxygenase-2,655,B-GENE-Y
(,655,O
COX-2,655,B-GENE-Y
),655,O
inhibitors,655,O
at,655,O
high,655,O
concentrations,655,O
(,655,O
nimesulide,655,B-CHEMICAL
and,655,O
NS-389,655,B-CHEMICAL
),655,O
slightly,655,O
attenuated,655,O
the,655,O
contraction,655,O
.,655,O
A,656,O
TXA2,656,B-GENE-Y
synthetase,656,I-GENE-Y
inhibitor,656,O
(,656,O
OKY-046,656,B-CHEMICAL
),656,O
attenuated,656,O
the,656,O
contraction,656,O
to,656,O
a,656,O
small,656,O
extent,656,O
only,656,O
at,656,O
high,656,O
concentrations,656,O
.,656,O
A,657,O
TXA2,657,B-GENE-Y
receptor,657,I-GENE-Y
antagonist,657,O
(,657,O
S-1452,657,B-CHEMICAL
),657,O
attenuated,657,O
the,657,O
contraction,657,O
in,657,O
a,657,O
concentration-dependent,657,O
manner,657,O
.,657,O
A,658,O
nicotinic,658,B-GENE-N
receptor,658,I-GENE-N
antagonist,658,O
(,658,O
hexamethonium,658,B-CHEMICAL
),658,O
attenuated,658,O
the,658,O
contraction,658,O
in,658,O
part,658,O
and,658,O
an,658,O
alpha-adrenoceptor,658,B-GENE-N
antagonist,658,O
(,658,O
prazosin,658,B-CHEMICAL
),658,O
nearly,658,O
abolished,658,O
the,658,O
contraction,658,O
.,658,O
From,659,O
these,659,O
results,659,O
",",659,O
it,659,O
was,659,O
suggested,659,O
that,659,O
the,659,O
contraction,659,O
induced,659,O
by,659,O
nicotine,659,B-CHEMICAL
in,659,O
the,659,O
rat,659,O
coronary,659,O
artery,659,O
in,659,O
the,659,O
presence,659,O
of,659,O
L-NAME,659,B-CHEMICAL
and,659,O
arachidonic,659,B-CHEMICAL
acid,659,I-CHEMICAL
is,659,O
endothelium,659,O
dependent,659,O
",",659,O
and,659,O
involves,659,O
reactive,659,O
oxygen,659,B-CHEMICAL
species,659,O
and,659,O
endothelial,659,O
COX-1,659,B-GENE-Y
metabolites,659,O
of,659,O
arachidonic,659,B-CHEMICAL
acid,659,I-CHEMICAL
.,659,O
Part,660,O
of,660,O
the,660,O
contraction,660,O
is,660,O
probably,660,O
due,660,O
to,660,O
release,660,O
of,660,O
norepinephrine,660,B-CHEMICAL
.,660,O
Efficacy,661,O
and,661,O
safety,661,O
of,661,O
the,661,O
factor,661,B-GENE-Y
VIII/von,661,O
Willebrand,661,I-GENE-Y
factor,661,I-GENE-Y
concentrate,661,O
",",661,O
haemate-P/humate-P,661,O
:,661,O
ristocetin,661,B-CHEMICAL
cofactor,661,O
unit,661,O
dosing,661,O
in,661,O
patients,661,O
with,661,O
von,661,O
Willebrand,661,O
disease,661,O
.,661,O
The,662,O
present,662,O
study,662,O
was,662,O
initiated,662,O
to,662,O
evaluate,662,O
the,662,O
safety,662,O
and,662,O
efficacy,662,O
of,662,O
Haemate-P,662,O
(,662,O
Humate-P,662,O
in,662,O
North,662,O
America,662,O
),662,O
(,662,O
anti-hemophilic,662,O
FVIII/VWF,662,B-GENE-Y
complex,662,O
[,662,O
human,662,O
],662,O
dried,662,O
",",662,O
pasteurized,662,O
),662,O
dosed,662,O
in,662,O
ristocetin,662,B-CHEMICAL
cofactor,662,O
units,662,O
(,662,O
VWF,662,O
:,662,O
RCo,662,O
),662,O
in,662,O
the,662,O
treatment,662,O
of,662,O
von,662,O
Willebrand,662,O
disease,662,O
(,662,O
VWD,662,O
),662,O
patients,662,O
in,662,O
Canada,662,O
.,662,O
This,663,O
retrospective,663,O
data,663,O
collection,663,O
reviewed,663,O
the,663,O
medical,663,O
records,663,O
of,663,O
VWD,663,O
patients,663,O
treated,663,O
under,663,O
the,663,O
Canadian,663,O
Emergency,663,O
Drug,663,O
Release,663,O
Program,663,O
from,663,O
November,663,O
22,663,O
",",663,O
1991,663,O
",",663,O
to,663,O
April,663,O
30,663,O
",",663,O
1996,663,O
.,663,O
Data,664,O
collection,664,O
was,664,O
accomplished,664,O
by,664,O
on-site,664,O
retrieval,664,O
from,664,O
source,664,O
data,664,O
for,664,O
97,664,O
patients,664,O
.,664,O
Dosing,665,O
was,665,O
based,665,O
on,665,O
the,665,O
German,665,O
package,665,O
insert,665,O
",",665,O
which,665,O
lists,665,O
only,665,O
Factor,665,B-GENE-Y
VIII,665,I-GENE-Y
:,665,I-GENE-Y
C,665,I-GENE-Y
(,665,O
FVIII,665,B-GENE-Y
:,665,I-GENE-Y
C,665,I-GENE-Y
),665,O
units,665,O
",",665,O
which,665,O
were,665,O
converted,665,O
in,665,O
the,665,O
study,665,O
analysis,665,O
to,665,O
VWF,665,O
:,665,O
RCo,665,O
units,665,O
based,665,O
on,665,O
the,665,O
analysis,665,O
of,665,O
the,665,O
individual,665,O
manufactured,665,O
lots,665,O
of,665,O
product,665,O
used,665,O
in,665,O
these,665,O
patients,665,O
(,665,O
average,665,O
ratio,665,O
of,665,O
2.6,665,O
IU,665,O
VWF,665,O
:,665,O
RCo,665,O
per,665,O
IU,665,O
FVIII,665,B-GENE-Y
:,665,I-GENE-Y
C,665,I-GENE-Y
),665,O
.,665,O
Twenty,666,O
five,666,O
different,666,O
lots,666,O
of,666,O
Haemate-P/Humate-P,666,O
were,666,O
used,666,O
to,666,O
treat,666,O
437,666,O
different,666,O
events,666,O
in,666,O
the,666,O
97,666,O
study,666,O
patients,666,O
(,666,O
344,666,O
hemorrhagic,666,O
events,666,O
",",666,O
73,666,O
surgical,666,O
interventions,666,O
and,666,O
20,666,O
prophylactic,666,O
infusion,666,O
cycles,666,O
),666,O
.,666,O
Overall,667,O
",",667,O
the,667,O
median,667,O
dose,667,O
of,667,O
concentrate,667,O
per,667,O
infusion,667,O
used,667,O
to,667,O
treat,667,O
surgical,667,O
events,667,O
was,667,O
69.1,667,O
IU,667,O
VWF,667,O
:,667,O
RCo/kg,667,O
(,667,O
range,667,O
11.9-222.8,667,O
),667,O
;,667,O
bleeding,667,O
events,667,O
55.3,667,O
IU,667,O
VWF,667,O
:,667,O
RCo/kg,667,O
(,667,O
range,667,O
17.1-227.5,667,O
),667,O
and,667,O
prophylaxis,667,O
41.6,667,O
IU,667,O
VWF,667,O
:,667,O
RCo/kg,667,O
(,667,O
range,667,O
34.6-81.0,667,O
),667,O
.,667,O
Treatment,668,O
periods,668,O
varied,668,O
",",668,O
with,668,O
the,668,O
majority,668,O
of,668,O
events,668,O
treated,668,O
for,668,O
<,668,O
or,668,O
=,668,O
10,668,O
days,668,O
(,668,O
91,668,O
%,668,O
),668,O
.,668,O
Fifty,669,O
percent,669,O
of,669,O
events,669,O
that,669,O
were,669,O
treated,669,O
longer,669,O
than,669,O
10,669,O
days,669,O
were,669,O
given,669,O
for,669,O
prophylactic,669,O
reasons,669,O
.,669,O
Efficacy,670,O
was,670,O
determined,670,O
in,670,O
a,670,O
standardized,670,O
manner,670,O
by,670,O
the,670,O
physician,670,O
",",670,O
based,670,O
on,670,O
dosing,670,O
in,670,O
VWF,670,O
:,670,O
RCo,670,O
activity,670,O
.,670,O
An,671,O
overall,671,O
clinical,671,O
result,671,O
of,671,O
``,671,O
excellent,671,O
'',671,O
or,671,O
``,671,O
good,671,O
'',671,O
was,671,O
reported,671,O
in,671,O
97,671,O
%,671,O
(,671,O
424/437,671,O
),671,O
of,671,O
treatment,671,O
events,671,O
.,671,O
A,672,O
pediatric,672,O
sub-population,672,O
analysis,672,O
of,672,O
the,672,O
patient,672,O
population,672,O
reported,672,O
``,672,O
excellent/good,672,O
'',672,O
efficacy,672,O
in,672,O
100,672,O
%,672,O
(,672,O
17/17,672,O
),672,O
of,672,O
treatment,672,O
events,672,O
in,672,O
infants,672,O
",",672,O
95,672,O
%,672,O
(,672,O
155/164,672,O
),672,O
in,672,O
children,672,O
",",672,O
and,672,O
94,672,O
%,672,O
(,672,O
76/81,672,O
),672,O
in,672,O
adolescent,672,O
patients,672,O
.,672,O
Related,673,O
adverse,673,O
events,673,O
(,673,O
AEs,673,O
),673,O
were,673,O
observed,673,O
in,673,O
only,673,O
4,673,O
(,673,O
4,673,O
%,673,O
),673,O
patients,673,O
and,673,O
were,673,O
not,673,O
deemed,673,O
to,673,O
be,673,O
serious,673,O
.,673,O
The,674,O
findings,674,O
in,674,O
this,674,O
study,674,O
confirm,674,O
the,674,O
safety,674,O
and,674,O
efficacy,674,O
of,674,O
Haemate-P/Humate-P,674,O
using,674,O
VWF,674,B-GENE-Y
:,674,O
RCo,674,O
dosing,674,O
in,674,O
pediatric,674,O
and,674,O
adult,674,O
patients,674,O
with,674,O
various,674,O
types,674,O
of,674,O
VWD,674,O
.,674,O
Differential,675,O
binding,675,O
mode,675,O
of,675,O
diverse,675,O
cyclooxygenase,675,B-GENE-N
inhibitors,675,O
.,675,O
Non-steroidal,676,O
anti-inflammatory,676,O
drugs,676,O
(,676,O
NSAIDs,676,O
),676,O
are,676,O
competitive,676,O
inhibitors,676,O
of,676,O
cyclooxygenase,676,B-GENE-N
(,676,O
COX,676,B-GENE-N
),676,O
",",676,O
the,676,O
enzyme,676,O
that,676,O
mediates,676,O
biosynthesis,676,O
of,676,O
prostaglandins,676,B-CHEMICAL
and,676,O
thromboxanes,676,B-CHEMICAL
from,676,O
arachidonic,676,B-CHEMICAL
acid,676,I-CHEMICAL
.,676,O
There,677,O
are,677,O
at,677,O
least,677,O
two,677,O
different,677,O
isoforms,677,O
of,677,O
the,677,O
enzyme,677,O
known,677,O
as,677,O
COX-1,677,B-GENE-N
and,677,I-GENE-N
-2,677,I-GENE-N
.,677,O
Site,678,O
directed,678,O
mutagenesis,678,O
studies,678,O
suggest,678,O
that,678,O
non-selective,678,O
COX,678,B-GENE-N
inhibitors,678,O
of,678,O
diverse,678,O
chemical,678,O
families,678,O
exhibit,678,O
differential,678,O
binding,678,O
modes,678,O
to,678,O
the,678,O
two,678,O
isozymes,678,O
.,678,O
These,679,O
results,679,O
can,679,O
not,679,O
clearly,679,O
be,679,O
explained,679,O
from,679,O
the,679,O
sole,679,O
analysis,679,O
of,679,O
the,679,O
crystal,679,O
structures,679,O
of,679,O
COX,679,B-GENE-N
available,679,O
from,679,O
X-ray,679,O
diffraction,679,O
studies,679,O
.,679,O
With,680,O
the,680,O
aim,680,O
to,680,O
elucidate,680,O
the,680,O
structural,680,O
features,680,O
governing,680,O
the,680,O
differential,680,O
inhibitory,680,O
binding,680,O
behavior,680,O
of,680,O
these,680,O
inhibitors,680,O
",",680,O
molecular,680,O
modeling,680,O
studies,680,O
were,680,O
undertaken,680,O
to,680,O
generate,680,O
atomic,680,O
models,680,O
compatible,680,O
with,680,O
the,680,O
experimental,680,O
data,680,O
available,680,O
.,680,O
Accordingly,681,O
",",681,O
docking,681,O
of,681,O
different,681,O
COX,681,B-GENE-N
inhibitors,681,O
",",681,O
including,681,O
selective,681,O
and,681,O
non-selective,681,O
ligands,681,O
:,681,O
rofecoxib,681,B-CHEMICAL
",",681,O
ketoprofen,681,B-CHEMICAL
",",681,O
suprofen,681,B-CHEMICAL
",",681,O
carprofen,681,B-CHEMICAL
",",681,O
zomepirac,681,B-CHEMICAL
",",681,O
indomethacin,681,B-CHEMICAL
",",681,O
diclofenac,681,B-CHEMICAL
and,681,O
meclofenamic,681,B-CHEMICAL
acid,681,I-CHEMICAL
were,681,O
undertaken,681,O
using,681,O
the,681,O
AMBER,681,O
program,681,O
.,681,O
The,682,O
results,682,O
of,682,O
the,682,O
present,682,O
study,682,O
provide,682,O
new,682,O
insights,682,O
into,682,O
a,682,O
better,682,O
understanding,682,O
of,682,O
the,682,O
differential,682,O
binding,682,O
mode,682,O
of,682,O
diverse,682,O
families,682,O
of,682,O
COX,682,B-GENE-N
inhibitors,682,O
",",682,O
and,682,O
are,682,O
expected,682,O
to,682,O
contribute,682,O
to,682,O
the,682,O
design,682,O
of,682,O
new,682,O
selective,682,O
compounds,682,O
.,682,O
Pure,683,O
antiestrogens,683,O
and,683,O
breast,683,O
cancer,683,O
.,683,O
Tamoxifen,684,B-CHEMICAL
",",684,O
which,684,O
is,684,O
the,684,O
most,684,O
commonly,684,O
used,684,O
drug,684,O
for,684,O
treatment,684,O
of,684,O
breast,684,O
cancer,684,O
",",684,O
has,684,O
both,684,O
estrogen,684,B-CHEMICAL
agonist,684,O
and,684,O
antagonist,684,O
actions,684,O
.,684,O
Pure,685,O
antiestrogens,685,O
are,685,O
devoid,685,O
of,685,O
any,685,O
estrogen,685,B-CHEMICAL
agonist,685,O
effects,685,O
.,685,O
ICI,686,B-CHEMICAL
"182,780",686,I-CHEMICAL
(,686,O
fulvestrant,686,B-CHEMICAL
),686,O
(,686,O
Faslodex,686,B-CHEMICAL
),686,O
and,686,O
ICI,686,B-CHEMICAL
"164,384",686,I-CHEMICAL
are,686,O
competitive,686,O
inhibitors,686,O
of,686,O
estrogen,686,B-CHEMICAL
by,686,O
binding,686,O
to,686,O
the,686,O
estrogen,686,B-GENE-Y
receptor,686,I-GENE-Y
(,686,O
ER,686,B-GENE-Y
),686,O
.,686,O
Preclinical,687,O
and,687,O
clinical,687,O
studies,687,O
show,687,O
that,687,O
fulvestrant,687,B-CHEMICAL
and,687,O
ICI,687,B-CHEMICAL
"164,384",687,I-CHEMICAL
are,687,O
more,687,O
potent,687,O
than,687,O
tamoxifen,687,B-CHEMICAL
in,687,O
inhibiting,687,O
the,687,O
growth,687,O
of,687,O
breast,687,O
cancer,687,O
cells,687,O
.,687,O
They,688,O
are,688,O
devoid,688,O
of,688,O
any,688,O
estrogen-agonist,688,B-CHEMICAL
action,688,O
on,688,O
the,688,O
uterus,688,O
and,688,O
vagina,688,O
but,688,O
lack,688,O
the,688,O
beneficial,688,O
effects,688,O
of,688,O
tamoxifen,688,B-CHEMICAL
on,688,O
the,688,O
bone,688,O
and,688,O
serum,688,O
lipid,688,O
profile,688,O
.,688,O
Fulvestrant,689,B-CHEMICAL
is,689,O
the,689,O
first,689,O
pure,689,O
antiestrogen,689,B-CHEMICAL
to,689,O
complete,689,O
phase,689,O
III,689,O
clinical,689,O
trials,689,O
.,689,O
Such,690,O
studies,690,O
have,690,O
shown,690,O
that,690,O
fulvestrant,690,B-CHEMICAL
is,690,O
at,690,O
least,690,O
as,690,O
good,690,O
as,690,O
anastrozole,690,B-CHEMICAL
in,690,O
the,690,O
treatment,690,O
of,690,O
post-menopausal,690,O
women,690,O
with,690,O
advanced,690,O
breast,690,O
cancer,690,O
who,690,O
had,690,O
relapsed,690,O
or,690,O
progressed,690,O
on,690,O
prior,690,O
endocrine,690,O
therapy,690,O
.,690,O
The,691,O
drug,691,O
was,691,O
well,691,O
tolerated,691,O
and,691,O
only,691,O
minor,691,O
side-effects,691,O
were,691,O
reported,691,O
.,691,O
Its,692,O
potential,692,O
role,692,O
in,692,O
the,692,O
adjuvant,692,O
setting,692,O
will,692,O
be,692,O
determined,692,O
by,692,O
its,692,O
adverse,692,O
effects,692,O
on,692,O
bone,692,O
mass,692,O
and,692,O
serum,692,O
lipids,692,O
.,692,O
EM-800,693,B-CHEMICAL
and,693,O
EM-652,693,B-CHEMICAL
are,693,O
the,693,O
most,693,O
potent,693,O
pure,693,O
antiestrogens,693,O
and,693,O
EM-652,693,B-CHEMICAL
has,693,O
the,693,O
highest,693,O
affinity,693,O
of,693,O
all,693,O
antiestrogens,693,O
to,693,O
ER,693,B-GENE-Y
.,693,O
They,694,O
have,694,O
no,694,O
stimulatory,694,O
effects,694,O
on,694,O
the,694,O
uterus,694,O
or,694,O
vagina,694,O
.,694,O
It,695,O
seems,695,O
reasonable,695,O
to,695,O
expect,695,O
that,695,O
pure,695,O
antiestrogens,695,O
will,695,O
be,695,O
good,695,O
alternatives,695,O
to,695,O
tamoxifen,695,B-CHEMICAL
and,695,O
aromatase,695,O
inhibitors,695,O
in,695,O
the,695,O
treatment,695,O
of,695,O
breast,695,O
cancer,695,O
.,695,O
Hepatotoxicity,696,O
of,696,O
commonly,696,O
used,696,O
drugs,696,O
:,696,O
nonsteroidal,696,O
anti-inflammatory,696,O
drugs,696,O
",",696,O
antihypertensives,696,O
",",696,O
antidiabetic,696,O
agents,696,O
",",696,O
anticonvulsants,696,O
",",696,O
lipid-lowering,696,O
agents,696,O
",",696,O
psychotropic,696,O
drugs,696,O
.,696,O
Hepatotoxic,697,O
adverse,697,O
drug,697,O
reactions,697,O
have,697,O
contributed,697,O
to,697,O
the,697,O
decline,697,O
of,697,O
many,697,O
promising,697,O
therapies,697,O
",",697,O
even,697,O
among,697,O
mainstream,697,O
medication,697,O
classes,697,O
(,697,O
bromfenac,697,B-CHEMICAL
and,697,O
troglitazone,697,B-CHEMICAL
are,697,O
recent,697,O
examples,697,O
),697,O
.,697,O
The,698,O
spectrum,698,O
of,698,O
nonsteroidal,698,O
anti-inflammatory,698,O
drug-related,698,O
liver,698,O
toxicity,698,O
continues,698,O
to,698,O
expand,698,O
",",698,O
with,698,O
reports,698,O
in,698,O
children,698,O
",",698,O
interactive,698,O
toxicity,698,O
in,698,O
persons,698,O
with,698,O
hepatitis,698,O
C,698,O
",",698,O
and,698,O
recognition,698,O
of,698,O
the,698,O
toxicity,698,O
of,698,O
both,698,O
the,698,O
preferential,698,O
and,698,O
selective,698,O
cyclooxygenase-2,698,B-GENE-Y
inhibitors,698,O
.,698,O
Of,699,O
the,699,O
antihypertensive,699,O
agents,699,O
",",699,O
methyldopa,699,O
is,699,O
now,699,O
rarely,699,O
prescribed,699,O
and,699,O
adverse,699,O
effects,699,O
are,699,O
reported,699,O
infrequently,699,O
",",699,O
whereas,699,O
cases,699,O
of,699,O
liver,699,O
injury,699,O
associated,699,O
with,699,O
the,699,O
angiotensin,699,B-GENE-N
receptor,699,I-GENE-N
and,699,O
converting,699,B-GENE-Y
enzyme,699,I-GENE-Y
inhibitors,699,O
are,699,O
increasingly,699,O
reported,699,O
.,699,O
Of,700,O
the,700,O
antidiabetic,700,O
agents,700,O
",",700,O
acarbose,700,B-CHEMICAL
",",700,O
gliclazide,700,B-CHEMICAL
",",700,O
metformin,700,B-CHEMICAL
",",700,O
and,700,O
human,700,B-GENE-Y
insulin,700,I-GENE-Y
have,700,O
been,700,O
implicated,700,O
in,700,O
causing,700,O
liver,700,O
injury,700,O
.,700,O
To,701,O
date,701,O
",",701,O
the,701,O
newer,701,O
thiazolidinediones,701,B-CHEMICAL
do,701,O
not,701,O
appear,701,O
to,701,O
share,701,O
the,701,O
hepatotoxic,701,O
potential,701,O
of,701,O
troglitazone,701,B-CHEMICAL
",",701,O
although,701,O
a,701,O
few,701,O
reports,701,O
of,701,O
acute,701,O
hepatitis,701,O
have,701,O
accrued,701,O
.,701,O
Although,702,O
liver,702,O
injury,702,O
has,702,O
been,702,O
associated,702,O
with,702,O
the,702,O
``,702,O
statins,702,O
",",702,O
'',702,O
the,702,O
frequency,702,O
of,702,O
such,702,O
toxicity,702,O
is,702,O
lower,702,O
than,702,O
that,702,O
of,702,O
the,702,O
background,702,O
population,702,O
and,702,O
the,702,O
value,702,O
of,702,O
biochemical,702,O
monitoring,702,O
remains,702,O
unproved,702,O
.,702,O
Newer,703,O
concepts,703,O
in,703,O
anticonvulsant,703,O
hepatotoxicity,703,O
have,703,O
been,703,O
the,703,O
recognition,703,O
of,703,O
the,703,O
reactive,703,O
metabolite,703,O
syndrome,703,O
",",703,O
delineation,703,O
of,703,O
the,703,O
risk,703,O
factors,703,O
for,703,O
valproic,703,B-CHEMICAL
acid,703,I-CHEMICAL
toxicity,703,O
",",703,O
the,703,O
potential,703,O
role,703,O
of,703,O
carnitine,703,B-CHEMICAL
in,703,O
preventing,703,O
valproic,703,B-CHEMICAL
acid,703,I-CHEMICAL
hepatotoxicity,703,O
",",703,O
and,703,O
the,703,O
toxicity,703,O
of,703,O
second-line,703,O
antiepileptic,703,O
drugs,703,O
.,703,O
Liver,704,O
injury,704,O
associated,704,O
with,704,O
newer,704,O
psychotropic,704,O
agents,704,O
",",704,O
particularly,704,O
the,704,O
selective,704,O
serotonin,704,B-CHEMICAL
reuptake,704,O
inhibitors,704,O
",",704,O
is,704,O
also,704,O
discussed,704,O
.,704,O
The,705,O
focus,705,O
of,705,O
the,705,O
review,705,O
is,705,O
the,705,O
hepatotoxicity,705,O
of,705,O
commonly,705,O
used,705,O
drugs,705,O
with,705,O
particular,705,O
reference,705,O
to,705,O
recent,705,O
and,705,O
novel,705,O
reports,705,O
of,705,O
toxicity,705,O
.,705,O
Well-known,706,O
causes,706,O
of,706,O
liver,706,O
injury,706,O
such,706,O
as,706,O
chlorpromazine,706,B-CHEMICAL
",",706,O
phenytoin,706,B-CHEMICAL
",",706,O
and,706,O
methyldopa,706,B-CHEMICAL
are,706,O
not,706,O
discussed,706,O
.,706,O
Pharmacological,707,O
",",707,O
pharmacokinetic,707,O
and,707,O
clinical,707,O
properties,707,O
of,707,O
olopatadine,707,B-CHEMICAL
hydrochloride,707,I-CHEMICAL
",",707,O
a,707,O
new,707,O
antiallergic,707,O
drug,707,O
.,707,O
Olopatadine,708,B-CHEMICAL
hydrochloride,708,I-CHEMICAL
(,708,O
olopatadine,708,B-CHEMICAL
",",708,O
11-,708,B-CHEMICAL
[,708,I-CHEMICAL
(,708,I-CHEMICAL
Z,708,I-CHEMICAL
),708,I-CHEMICAL
-3-,708,I-CHEMICAL
(,708,I-CHEMICAL
dimethylamino,708,I-CHEMICAL
),708,I-CHEMICAL
propylidene,708,I-CHEMICAL
],708,I-CHEMICAL
"-6,11-dihydrodibenz",708,I-CHEMICAL
[,708,I-CHEMICAL
b,708,I-CHEMICAL
",",708,I-CHEMICAL
e,708,I-CHEMICAL
],708,I-CHEMICAL
oxepin-2-acetic,708,I-CHEMICAL
acid,708,I-CHEMICAL
monohydrochloride,708,I-CHEMICAL
),708,O
is,708,O
a,708,O
novel,708,O
antiallergic/histamine,708,O
H1-receptor,708,I-GENE-Y
antagonistic,708,O
drug,708,O
that,708,O
was,708,O
synthesized,708,O
and,708,O
evaluated,708,O
in,708,O
our,708,O
laboratories,708,O
.,708,O
Oral,709,O
administration,709,O
of,709,O
olopatadine,709,B-CHEMICAL
at,709,O
doses,709,O
of,709,O
0.03,709,O
mg/kg,709,O
or,709,O
higher,709,O
inhibited,709,O
the,709,O
symptoms,709,O
of,709,O
experimental,709,O
allergic,709,O
skin,709,O
responses,709,O
",",709,O
rhinoconjunctivitis,709,O
and,709,O
bronchial,709,O
asthma,709,O
in,709,O
sensitized,709,O
guinea,709,O
pigs,709,O
and,709,O
rats,709,O
.,709,O
Olopatadine,710,B-CHEMICAL
is,710,O
a,710,O
selective,710,O
histamine,710,B-GENE-Y
H1-receptor,710,I-GENE-Y
antagonist,710,O
possessing,710,O
inhibitory,710,O
effects,710,O
on,710,O
the,710,O
release,710,O
of,710,O
inflammatory,710,O
lipid,710,O
mediators,710,O
such,710,O
as,710,O
leukotriene,710,B-CHEMICAL
and,710,O
thromboxane,710,B-CHEMICAL
from,710,O
human,710,O
polymorphonuclear,710,O
leukocytes,710,O
and,710,O
eosinophils,710,O
.,710,O
Olopatadine,711,B-CHEMICAL
also,711,O
inhibited,711,O
the,711,O
tachykininergic,711,O
contraction,711,O
in,711,O
the,711,O
guinea,711,O
pig,711,O
bronchi,711,O
by,711,O
prejunctional,711,O
inhibition,711,O
of,711,O
peripheral,711,O
sensory,711,O
nerves,711,O
.,711,O
Olopatadine,712,B-CHEMICAL
exerted,712,O
no,712,O
significant,712,O
effects,712,O
on,712,O
action,712,O
potential,712,O
duration,712,O
in,712,O
isolated,712,O
guinea,712,O
pig,712,O
ventricular,712,O
myocytes,712,O
",",712,O
myocardium,712,O
and,712,O
human,712,B-GENE-Y
ether-a-go-go-related,712,I-GENE-Y
gene,712,I-GENE-Y
channel,712,I-GENE-Y
.,712,O
Olopatadine,713,B-CHEMICAL
was,713,O
highly,713,O
and,713,O
rapidly,713,O
absorbed,713,O
in,713,O
healthy,713,O
human,713,O
volunteers,713,O
.,713,O
The,714,O
urinary,714,O
excretion,714,O
of,714,O
olopatadine,714,B-CHEMICAL
accounted,714,O
for,714,O
not,714,O
less,714,O
than,714,O
58,714,O
%,714,O
and,714,O
the,714,O
contribution,714,O
of,714,O
metabolism,714,O
was,714,O
considerably,714,O
low,714,O
in,714,O
the,714,O
clearance,714,O
of,714,O
olopatadine,714,B-CHEMICAL
in,714,O
humans,714,O
.,714,O
Olopatadine,715,B-CHEMICAL
is,715,O
one,715,O
of,715,O
the,715,O
few,715,O
renal,715,O
clearance,715,O
drugs,715,O
in,715,O
antiallergic,715,O
drugs,715,O
.,715,O
Olopatadine,716,B-CHEMICAL
was,716,O
shown,716,O
to,716,O
be,716,O
useful,716,O
for,716,O
the,716,O
treatment,716,O
of,716,O
allergic,716,O
rhinitis,716,O
and,716,O
chronic,716,O
urticaria,716,O
in,716,O
double-blind,716,O
clinical,716,O
trials,716,O
.,716,O
Olopatadine,717,B-CHEMICAL
was,717,O
approved,717,O
in,717,O
Japan,717,O
for,717,O
the,717,O
treatment,717,O
of,717,O
allergic,717,O
rhinitis,717,O
",",717,O
chronic,717,O
urticaria,717,O
",",717,O
eczema,717,O
dermatitis,717,O
",",717,O
prurigo,717,O
",",717,O
pruritus,717,O
cutaneous,717,O
",",717,O
psoriasis,717,O
vulgaris,717,O
and,717,O
erythema,717,O
exsudativum,717,O
multiforme,717,O
in,717,O
December,717,O
",",717,O
2000,717,O
.,717,O
Ophthalmic,718,O
solution,718,O
of,718,O
olopatadine,718,B-CHEMICAL
was,718,O
also,718,O
approved,718,O
in,718,O
the,718,O
United,718,O
States,718,O
for,718,O
the,718,O
treatment,718,O
of,718,O
seasonal,718,O
allergic,718,O
conjunctivitis,718,O
in,718,O
December,718,O
",",718,O
1996,718,O
(,718,O
Appendix,718,O
:,718,O
also,718,O
in,718,O
the,718,O
European,718,O
Union,718,O
",",718,O
it,718,O
was,718,O
approved,718,O
in,718,O
February,718,O
2002,718,O
),718,O
.,718,O
Serotonin,719,B-CHEMICAL
transporter,719,I-GENE-Y
polymorphisms,719,O
and,719,O
measures,719,O
of,719,O
impulsivity,719,O
",",719,O
aggression,719,O
",",719,O
and,719,O
sensation,719,O
seeking,719,O
among,719,O
African-American,719,O
cocaine-dependent,719,B-CHEMICAL
individuals,719,O
.,719,O
Considerable,720,O
evidence,720,O
indicates,720,O
that,720,O
serotonergic,720,O
mechanisms,720,O
",",720,O
particularly,720,O
the,720,O
serotonin,720,B-CHEMICAL
transporter,720,I-GENE-Y
(,720,O
5HTT,720,B-GENE-Y
),720,O
",",720,O
may,720,O
mediate,720,O
central,720,O
effects,720,O
of,720,O
cocaine,720,B-CHEMICAL
and,720,O
may,720,O
also,720,O
be,720,O
involved,720,O
in,720,O
impulsive,720,O
and,720,O
aggressive,720,O
behavior,720,O
.,720,O
We,721,O
investigated,721,O
whether,721,O
polymorphisms,721,O
in,721,O
the,721,O
5HTT,721,B-GENE-Y
gene,721,O
were,721,O
related,721,O
to,721,O
traits,721,O
of,721,O
impulsivity,721,O
",",721,O
sensation,721,O
seeking,721,O
",",721,O
and,721,O
aggression,721,O
among,721,O
cocaine,721,B-CHEMICAL
abusers,721,O
.,721,O
Standardized,722,O
measures,722,O
of,722,O
these,722,O
personality,722,O
traits,722,O
were,722,O
obtained,722,O
in,722,O
a,722,O
sample,722,O
of,722,O
105,722,O
severely,722,O
affected,722,O
cocaine-dependent,722,B-CHEMICAL
African-American,722,O
subjects,722,O
and,722,O
44,722,O
African-American,722,O
controls,722,O
.,722,O
Two,723,O
polymorphisms,723,O
of,723,O
the,723,O
5HTT,723,B-GENE-Y
gene,723,O
were,723,O
examined,723,O
involving,723,O
the,723,O
5,723,O
',723,O
promoter,723,O
(,723,O
5HTTLPR,723,B-GENE-N
),723,O
region,723,O
and,723,O
a,723,O
17,723,O
base,723,O
pair,723,O
variable-number-tandem-repeat,723,B-GENE-N
(,723,O
VNTR,723,B-GENE-N
),723,O
marker,723,O
among,723,O
cocaine,723,B-CHEMICAL
patients,723,O
.,723,O
No,724,O
significant,724,O
relationships,724,O
were,724,O
observed,724,O
between,724,O
polymorphic,724,O
variants,724,O
of,724,O
the,724,O
5HTTLPR,724,B-GENE-N
and,724,O
VNTR,724,B-GENE-N
regions,724,O
and,724,O
scores,724,O
on,724,O
any,724,O
of,724,O
the,724,O
trait,724,O
measures,724,O
.,724,O
Similarly,725,O
",",725,O
demographic,725,O
variables,725,O
and,725,O
measures,725,O
of,725,O
severity,725,O
of,725,O
substance,725,O
use,725,O
and,725,O
depression,725,O
were,725,O
unrelated,725,O
to,725,O
allele,725,O
frequencies,725,O
or,725,O
genotype,725,O
distributions,725,O
of,725,O
the,725,O
variants,725,O
among,725,O
cocaine,725,B-CHEMICAL
patients,725,O
.,725,O
As,726,O
expected,726,O
",",726,O
cocaine,726,B-CHEMICAL
patients,726,O
scored,726,O
significantly,726,O
higher,726,O
on,726,O
total,726,O
scores,726,O
of,726,O
impulsivity,726,O
",",726,O
aggression,726,O
",",726,O
and,726,O
sensation,726,O
seeking,726,O
compared,726,O
to,726,O
controls,726,O
.,726,O
The,727,O
findings,727,O
do,727,O
not,727,O
seem,727,O
to,727,O
support,727,O
an,727,O
association,727,O
between,727,O
these,727,O
polymorphisms,727,O
in,727,O
the,727,O
5HTT,727,B-GENE-Y
gene,727,O
and,727,O
impulsive-aggressive,727,O
traits,727,O
among,727,O
cocaine-dependent,727,B-CHEMICAL
African-American,727,O
individuals,727,O
.,727,O
A,728,O
molecular,728,O
mechanism,728,O
of,728,O
action,728,O
of,728,O
theophylline,728,B-CHEMICAL
:,728,O
Induction,728,O
of,728,O
histone,728,B-GENE-N
deacetylase,728,I-GENE-N
activity,728,O
to,728,O
decrease,728,O
inflammatory,728,O
gene,728,O
expression,728,O
.,728,O
The,729,O
molecular,729,O
mechanism,729,O
for,729,O
the,729,O
anti-inflammatory,729,O
action,729,O
of,729,O
theophylline,729,B-CHEMICAL
is,729,O
currently,729,O
unknown,729,O
",",729,O
but,729,O
low-dose,729,O
theophylline,729,B-CHEMICAL
is,729,O
an,729,O
effective,729,O
add-on,729,O
therapy,729,O
to,729,O
corticosteroids,729,O
in,729,O
controlling,729,O
asthma,729,O
.,729,O
Corticosteroids,730,B-CHEMICAL
act,730,O
",",730,O
at,730,O
least,730,O
in,730,O
part,730,O
",",730,O
by,730,O
recruitment,730,O
of,730,O
histone,730,B-GENE-N
deacetylases,730,I-GENE-N
(,730,O
HDACs,730,B-GENE-N
),730,O
to,730,O
the,730,O
site,730,O
of,730,O
active,730,O
inflammatory,730,O
gene,730,O
transcription,730,O
.,730,O
They,731,O
thereby,731,O
inhibit,731,O
the,731,O
acetylation,731,O
of,731,O
core,731,O
histones,731,O
that,731,O
is,731,O
necessary,731,O
for,731,O
inflammatory,731,O
gene,731,O
transcription,731,O
.,731,O
We,732,O
show,732,O
both,732,O
in,732,O
vitro,732,O
and,732,O
in,732,O
vivo,732,O
that,732,O
low-dose,732,O
theophylline,732,B-CHEMICAL
enhances,732,O
HDAC,732,B-GENE-N
activity,732,O
in,732,O
epithelial,732,O
cells,732,O
and,732,O
macrophages,732,O
.,732,O
This,733,O
increased,733,O
HDAC,733,B-GENE-N
activity,733,O
is,733,O
then,733,O
available,733,O
for,733,O
corticosteroid,733,B-CHEMICAL
recruitment,733,O
and,733,O
predicts,733,O
a,733,O
cooperative,733,O
interaction,733,O
between,733,O
corticosteroids,733,B-CHEMICAL
and,733,O
theophylline,733,B-CHEMICAL
.,733,O
This,734,O
mechanism,734,O
occurs,734,O
at,734,O
therapeutic,734,O
concentrations,734,O
of,734,O
theophylline,734,B-CHEMICAL
and,734,O
is,734,O
dissociated,734,O
from,734,O
phosphodiesterase,734,B-GENE-N
inhibition,734,O
(,734,O
the,734,O
mechanism,734,O
of,734,O
bronchodilation,734,O
),734,O
or,734,O
the,734,O
blockade,734,O
of,734,O
adenosine,734,B-GENE-N
receptors,734,I-GENE-N
",",734,O
which,734,O
are,734,O
partially,734,O
responsible,734,O
for,734,O
its,734,O
side,734,O
effects,734,O
.,734,O
Thus,735,O
we,735,O
have,735,O
shown,735,O
that,735,O
low-dose,735,O
theophylline,735,B-CHEMICAL
exerts,735,O
an,735,O
anti-asthma,735,O
effect,735,O
through,735,O
increasing,735,O
activation,735,O
of,735,O
HDAC,735,B-GENE-N
which,735,O
is,735,O
subsequently,735,O
recruited,735,O
by,735,O
corticosteroids,735,B-CHEMICAL
to,735,O
suppress,735,O
inflammatory,735,O
genes,735,O
.,735,O
Interactions,736,O
of,736,O
rifamycin,736,B-CHEMICAL
SV,736,I-CHEMICAL
and,736,O
rifampicin,736,B-CHEMICAL
with,736,O
organic,736,O
anion,736,O
uptake,736,O
systems,736,O
of,736,O
human,736,O
liver,736,O
.,736,O
The,737,O
antibiotics,737,O
rifamycin,737,B-CHEMICAL
SV,737,I-CHEMICAL
and,737,O
rifampicin,737,B-CHEMICAL
substantially,737,O
reduce,737,O
sulfobromophthalein,737,B-CHEMICAL
(,737,O
BSP,737,B-CHEMICAL
),737,O
elimination,737,O
in,737,O
humans,737,O
.,737,O
In,738,O
rats,738,O
",",738,O
rifamycin,738,B-CHEMICAL
SV,738,I-CHEMICAL
and,738,O
rifampicin,738,B-CHEMICAL
were,738,O
shown,738,O
to,738,O
interfere,738,O
with,738,O
hepatic,738,O
organic,738,O
anion,738,O
uptake,738,O
by,738,O
inhibition,738,O
of,738,O
the,738,O
organic,738,B-GENE-N
anion,738,I-GENE-N
transporting,738,I-GENE-N
polypeptides,738,I-GENE-N
Oatp1,738,B-GENE-Y
and,738,O
Oatp2,738,B-GENE-Y
.,738,O
Therefore,739,O
",",739,O
we,739,O
investigated,739,O
the,739,O
effects,739,O
of,739,O
rifamycin,739,B-CHEMICAL
SV,739,I-CHEMICAL
and,739,O
rifampicin,739,B-CHEMICAL
on,739,O
the,739,O
OATPs,739,B-GENE-N
of,739,O
human,739,O
liver,739,O
and,739,O
determined,739,O
whether,739,O
rifampicin,739,B-CHEMICAL
is,739,O
a,739,O
substrate,739,O
of,739,O
1,739,O
or,739,O
several,739,O
of,739,O
these,739,O
carriers,739,O
.,739,O
In,740,O
complementary,740,O
RNA,740,O
(,740,O
cRNA,740,O
),740,O
-injected,740,O
Xenopus,740,O
laevis,740,O
oocytes,740,O
",",740,O
rifamycin,740,B-CHEMICAL
SV,740,I-CHEMICAL
(,740,O
10,740,O
micromol/L,740,O
),740,O
cis-inhibited,740,O
human,740,B-GENE-Y
organic,740,I-GENE-Y
anion,740,I-GENE-Y
transporting,740,I-GENE-Y
polypeptide,740,I-GENE-Y
C,740,I-GENE-Y
(,740,O
SLC21A6,740,B-GENE-Y
),740,O
(,740,O
OATP-C,740,B-GENE-Y
),740,O
",",740,O
human,740,B-GENE-Y
organic,740,I-GENE-Y
anion,740,I-GENE-Y
transporting,740,I-GENE-Y
polypeptide,740,I-GENE-Y
8,740,I-GENE-Y
(,740,O
SLC21A8,740,B-GENE-Y
),740,O
(,740,O
OATP8,740,B-GENE-Y
),740,O
",",740,O
human,740,B-GENE-Y
organic,740,I-GENE-Y
anion,740,I-GENE-Y
transporting,740,I-GENE-Y
polypeptide,740,I-GENE-Y
B,740,I-GENE-Y
(,740,O
SLC21A9,740,B-GENE-Y
),740,O
(,740,O
OATP-B,740,B-GENE-Y
),740,O
",",740,O
and,740,O
human,740,B-GENE-Y
organic,740,I-GENE-Y
anion,740,I-GENE-Y
transporting,740,I-GENE-Y
polypeptide,740,I-GENE-Y
A,740,I-GENE-Y
(,740,O
SLC21A3,740,B-GENE-Y
),740,O
(,740,O
OATP-A,740,B-GENE-Y
),740,O
mediated,740,O
BSP,740,O
uptake,740,O
by,740,O
69,740,O
%,740,O
",",740,O
79,740,O
%,740,O
",",740,O
89,740,O
%,740,O
",",740,O
and,740,O
57,740,O
%,740,O
",",740,O
respectively,740,O
",",740,O
as,740,O
compared,740,O
with,740,O
uptake,740,O
into,740,O
control,740,O
oocytes,740,O
.,740,O
In,741,O
the,741,O
presence,741,O
of,741,O
100,741,O
micromol/L,741,O
rifamycin,741,B-CHEMICAL
SV,741,I-CHEMICAL
",",741,O
BSP,741,B-CHEMICAL
uptake,741,O
was,741,O
almost,741,O
completely,741,O
abolished,741,O
.,741,O
Approximate,742,O
K,742,O
(,742,O
i,742,O
),742,O
values,742,O
were,742,O
2,742,O
micromol/L,742,O
for,742,O
OATP-C,742,B-GENE-Y
",",742,O
3,742,O
micromol/L,742,O
for,742,O
OATP8,742,B-GENE-Y
",",742,O
3,742,O
micromol/L,742,O
for,742,O
OATP-B,742,B-GENE-Y
and,742,O
11,742,O
micromol/L,742,O
for,742,O
OATP-A,742,B-GENE-Y
.,742,O
Rifampicin,743,B-CHEMICAL
(,743,O
10,743,O
micromol/L,743,O
),743,O
inhibited,743,O
OATP8-mediated,743,B-GENE-Y
BSP,743,B-CHEMICAL
uptake,743,O
by,743,O
50,743,O
%,743,O
",",743,O
whereas,743,O
inhibition,743,O
of,743,O
OATP-C-,743,B-GENE-Y
",",743,O
OATP-B-,743,B-GENE-Y
",",743,O
and,743,O
OATP-A-mediated,743,B-GENE-Y
BSP,743,B-CHEMICAL
transport,743,O
was,743,O
below,743,O
15,743,O
%,743,O
.,743,O
100,744,O
micromol/L,744,O
rifampicin,744,B-CHEMICAL
inhibited,744,O
OATP-C-,744,B-GENE-Y
and,744,O
OATP8-,744,B-GENE-Y
",",744,O
OATP-B-,744,B-GENE-Y
and,744,O
OATP-A-mediated,744,B-GENE-Y
BSP,744,B-CHEMICAL
uptake,744,O
by,744,O
66,744,O
%,744,O
",",744,O
96,744,O
%,744,O
",",744,O
25,744,O
%,744,O
",",744,O
and,744,O
49,744,O
%,744,O
",",744,O
respectively,744,O
.,744,O
The,745,O
corresponding,745,O
K,745,O
(,745,O
i,745,O
),745,O
values,745,O
were,745,O
17,745,O
micromol/L,745,O
for,745,O
OATP-C,745,B-GENE-Y
",",745,O
5,745,O
micromol/L,745,O
for,745,O
OATP8,745,B-GENE-Y
",",745,O
and,745,O
51,745,O
micromol/L,745,O
for,745,O
OATP-A,745,B-GENE-Y
.,745,O
Direct,746,O
transport,746,O
of,746,O
rifampicin,746,B-CHEMICAL
could,746,O
be,746,O
shown,746,O
for,746,O
OATP-C,746,B-GENE-Y
(,746,O
apparent,746,O
K,746,O
(,746,O
m,746,O
),746,O
value,746,O
13,746,O
micromol/L,746,O
),746,O
and,746,O
OATP8,746,B-GENE-Y
(,746,O
2.3,746,O
micromol/L,746,O
),746,O
.,746,O
In,747,O
conclusion,747,O
",",747,O
these,747,O
results,747,O
show,747,O
that,747,O
rifamycin,747,B-CHEMICAL
SV,747,I-CHEMICAL
and,747,O
rifampicin,747,B-CHEMICAL
interact,747,O
with,747,O
OATP-mediated,747,B-GENE-N
substrate,747,O
transport,747,O
to,747,O
different,747,O
extents,747,O
.,747,O
Inhibition,748,O
of,748,O
human,748,B-GENE-N
liver,748,I-GENE-N
OATPs,748,I-GENE-N
can,748,O
explain,748,O
the,748,O
previously,748,O
observed,748,O
effects,748,O
of,748,O
rifamycin,748,B-CHEMICAL
SV,748,I-CHEMICAL
and,748,O
rifampicin,748,B-CHEMICAL
on,748,O
hepatic,748,O
organic,748,O
anion,748,O
elimination,748,O
.,748,O
Metformin,749,B-CHEMICAL
increases,749,O
AMP-activated,749,B-GENE-N
protein,749,I-GENE-N
kinase,749,I-GENE-N
activity,749,O
in,749,O
skeletal,749,O
muscle,749,O
of,749,O
subjects,749,O
with,749,O
type,749,O
2,749,O
diabetes,749,O
.,749,O
Metformin,750,B-CHEMICAL
is,750,O
an,750,O
effective,750,O
hypoglycemic,750,O
drug,750,O
that,750,O
lowers,750,O
blood,750,O
glucose,750,B-CHEMICAL
concentrations,750,O
by,750,O
decreasing,750,O
hepatic,750,O
glucose,750,B-CHEMICAL
production,750,O
and,750,O
increasing,750,O
glucose,750,B-CHEMICAL
disposal,750,O
in,750,O
skeletal,750,O
muscle,750,O
;,750,O
however,750,O
",",750,O
the,750,O
molecular,750,O
site,750,O
of,750,O
metformin,750,B-CHEMICAL
action,750,O
is,750,O
not,750,O
well,750,O
understood,750,O
.,750,O
AMP-activated,751,B-GENE-N
protein,751,I-GENE-N
kinase,751,I-GENE-N
(,751,O
AMPK,751,B-GENE-N
),751,O
activity,751,O
increases,751,O
in,751,O
response,751,O
to,751,O
depletion,751,O
of,751,O
cellular,751,O
energy,751,O
stores,751,O
",",751,O
and,751,O
this,751,O
enzyme,751,O
has,751,O
been,751,O
implicated,751,O
in,751,O
the,751,O
stimulation,751,O
of,751,O
glucose,751,B-CHEMICAL
uptake,751,O
into,751,O
skeletal,751,O
muscle,751,O
and,751,O
the,751,O
inhibition,751,O
of,751,O
liver,751,O
gluconeogenesis,751,O
.,751,O
We,752,O
recently,752,O
reported,752,O
that,752,O
AMPK,752,B-GENE-N
is,752,O
activated,752,O
by,752,O
metformin,752,B-CHEMICAL
in,752,O
cultured,752,O
rat,752,O
hepatocytes,752,O
",",752,O
mediating,752,O
the,752,O
inhibitory,752,O
effects,752,O
of,752,O
the,752,O
drug,752,O
on,752,O
hepatic,752,O
glucose,752,B-CHEMICAL
production,752,O
.,752,O
In,753,O
the,753,O
present,753,O
study,753,O
",",753,O
we,753,O
evaluated,753,O
whether,753,O
therapeutic,753,O
doses,753,O
of,753,O
metformin,753,B-CHEMICAL
increase,753,O
AMPK,753,B-GENE-N
activity,753,O
in,753,O
vivo,753,O
in,753,O
subjects,753,O
with,753,O
type,753,O
2,753,O
diabetes,753,O
.,753,O
Metformin,754,B-CHEMICAL
treatment,754,O
for,754,O
10,754,O
weeks,754,O
significantly,754,O
increased,754,O
AMPK,754,B-GENE-Y
alpha2,754,I-GENE-Y
activity,754,O
in,754,O
the,754,O
skeletal,754,O
muscle,754,O
",",754,O
and,754,O
this,754,O
was,754,O
associated,754,O
with,754,O
increased,754,O
phosphorylation,754,O
of,754,O
AMPK,754,B-GENE-N
on,754,O
Thr172,754,O
and,754,O
decreased,754,O
acetyl-CoA,754,B-GENE-Y
carboxylase-2,754,I-GENE-Y
activity,754,O
.,754,O
The,755,O
increase,755,O
in,755,O
AMPK,755,B-GENE-Y
alpha2,755,I-GENE-Y
activity,755,O
was,755,O
likely,755,O
due,755,O
to,755,O
a,755,O
change,755,O
in,755,O
muscle,755,O
energy,755,O
status,755,O
because,755,O
ATP,755,B-CHEMICAL
and,755,O
phosphocreatine,755,B-CHEMICAL
concentrations,755,O
were,755,O
lower,755,O
after,755,O
metformin,755,B-CHEMICAL
treatment,755,O
.,755,O
Metformin-induced,756,B-CHEMICAL
increases,756,O
in,756,O
AMPK,756,B-GENE-N
activity,756,O
were,756,O
associated,756,O
with,756,O
higher,756,O
rates,756,O
of,756,O
glucose,756,B-CHEMICAL
disposal,756,O
and,756,O
muscle,756,O
glycogen,756,O
concentrations,756,O
.,756,O
These,757,O
findings,757,O
suggest,757,O
that,757,O
the,757,O
metabolic,757,O
effects,757,O
of,757,O
metformin,757,O
in,757,O
subjects,757,O
with,757,O
type,757,O
2,757,O
diabetes,757,O
may,757,O
be,757,O
mediated,757,O
by,757,O
the,757,O
activation,757,O
of,757,O
AMPK,757,B-GENE-Y
alpha2,757,I-GENE-Y
.,757,O
Thalidomide,758,B-CHEMICAL
prevents,758,O
alcoholic,758,B-CHEMICAL
liver,758,O
injury,758,O
in,758,O
rats,758,O
through,758,O
suppression,758,O
of,758,O
Kupffer,758,O
cell,758,O
sensitization,758,O
and,758,O
TNF-alpha,758,B-GENE-Y
production,758,O
.,758,O
BACKGROUND,759,O
&,759,O
AIMS,759,O
:,759,O
Sensitization,759,O
of,759,O
Kupffer,759,O
cells,759,O
(,759,O
KCs,759,O
),759,O
to,759,O
lipopolysaccharide,759,O
(,759,O
LPS,759,O
),759,O
and,759,O
overproduction,759,O
of,759,O
tumor,759,B-GENE-Y
necrosis,759,I-GENE-Y
factor,759,I-GENE-Y
(,759,I-GENE-Y
TNF,759,I-GENE-Y
),759,I-GENE-Y
alpha,759,I-GENE-Y
are,759,O
critical,759,O
for,759,O
progression,759,O
of,759,O
alcoholic,759,B-CHEMICAL
liver,759,O
injury,759,O
.,759,O
Thalidomide,760,B-CHEMICAL
has,760,O
been,760,O
shown,760,O
to,760,O
suppress,760,O
TNF-alpha,760,B-GENE-Y
production,760,O
from,760,O
macrophages,760,O
.,760,O
Accordingly,761,O
",",761,O
the,761,O
purpose,761,O
of,761,O
this,761,O
study,761,O
was,761,O
to,761,O
determine,761,O
whether,761,O
thalidomide,761,B-CHEMICAL
could,761,O
prevent,761,O
alcohol-induced,761,B-CHEMICAL
liver,761,O
injury,761,O
.,761,O
METHODS,762,O
:,762,O
Rats,762,O
were,762,O
given,762,O
ethanol,762,B-CHEMICAL
(,762,O
5,762,O
g/kg,762,O
body,762,O
wt,762,O
),762,O
and,762,O
thalidomide,762,B-CHEMICAL
(,762,O
5,762,O
mg/kg,762,O
),762,O
once,762,O
every,762,O
24,762,O
hours,762,O
intragastrically,762,O
.,762,O
To,763,O
assess,763,O
the,763,O
sensitization,763,O
of,763,O
Kupffer,763,O
cells,763,O
",",763,O
LPS,763,O
(,763,O
5,763,O
mg/kg,763,O
intravenously,763,O
),763,O
was,763,O
administered,763,O
and,763,O
liver,763,O
histology,763,O
was,763,O
evaluated,763,O
24,763,O
hours,763,O
later,763,O
.,763,O
KCs,764,O
were,764,O
isolated,764,O
after,764,O
4,764,O
weeks,764,O
of,764,O
ethanol,764,B-CHEMICAL
treatment,764,O
and,764,O
intracellular,764,O
Ca2+,764,B-CHEMICAL
(,764,O
[,764,O
Ca2+,764,B-CHEMICAL
],764,O
i,764,O
),764,O
was,764,O
measured,764,O
using,764,O
fura-2,764,O
",",764,O
whereas,764,O
TNF-alpha,764,B-GENE-Y
was,764,O
evaluated,764,O
by,764,O
reverse-transcription,764,O
polymerase,764,O
chain,764,O
reaction,764,O
and,764,O
enzyme-linked,764,O
immunosorbent,764,O
assay,764,O
.,764,O
CD14,765,B-GENE-Y
was,765,O
determined,765,O
by,765,O
Western,765,O
and,765,O
fluorescence,765,O
staining,765,O
.,765,O
RESULTS,766,O
:,766,O
Treatment,766,O
with,766,O
ethanol,766,B-CHEMICAL
for,766,O
8,766,O
weeks,766,O
caused,766,O
marked,766,O
steatosis,766,O
",",766,O
necrosis,766,O
",",766,O
and,766,O
inflammation,766,O
in,766,O
the,766,O
liver,766,O
.,766,O
These,767,O
pathologic,767,O
parameters,767,O
were,767,O
diminished,767,O
markedly,767,O
by,767,O
treatment,767,O
with,767,O
thalidomide,767,B-CHEMICAL
.,767,O
In,768,O
the,768,O
4-week,768,O
ethanol,768,B-CHEMICAL
group,768,O
",",768,O
the,768,O
LPS-induced,768,O
liver,768,O
damage,768,O
was,768,O
aggravated,768,O
and,768,O
KCs,768,O
were,768,O
sensitized,768,O
to,768,O
LPS,768,O
.,768,O
Coadministration,769,O
of,769,O
thalidomide,769,B-CHEMICAL
with,769,O
ethanol,769,B-CHEMICAL
prevented,769,O
the,769,O
KC,769,O
sensitization,769,O
completely,769,O
.,769,O
Furthermore,770,O
",",770,O
thalidomide,770,B-CHEMICAL
abolished,770,O
the,770,O
LPS-induced,770,O
increase,770,O
in,770,O
CD14,770,B-GENE-Y
expression,770,O
and,770,O
[,770,O
Ca2+,770,B-CHEMICAL
],770,O
i,770,O
elevation,770,O
in,770,O
KCs,770,O
.,770,O
Gut,771,O
permeability,771,O
was,771,O
increased,771,O
about,771,O
10-fold,771,O
after,771,O
4,771,O
weeks,771,O
of,771,O
ethanol,771,B-CHEMICAL
exposure,771,O
",",771,O
which,771,O
was,771,O
not,771,O
affected,771,O
by,771,O
thalidomide,771,B-CHEMICAL
.,771,O
Moreover,772,O
",",772,O
thalidomide,772,B-CHEMICAL
reduced,772,O
the,772,O
LPS-induced,772,O
TNF-alpha,772,B-GENE-Y
production,772,O
by,772,O
KCs,772,O
by,772,O
decreasing,772,O
TNF-alpha,772,B-GENE-Y
messenger,772,O
RNA,772,O
.,772,O
CONCLUSIONS,773,O
:,773,O
These,773,O
results,773,O
collectively,773,O
indicate,773,O
that,773,O
thalidomide,773,B-CHEMICAL
prevents,773,O
alcoholic,773,O
liver,773,O
injury,773,O
through,773,O
suppression,773,O
of,773,O
TNF-alpha,773,B-GENE-Y
production,773,O
and,773,O
abolishment,773,O
of,773,O
KC,773,O
sensitization,773,O
.,773,O
Identification,774,O
and,774,O
characterization,774,O
of,774,O
a,774,O
novel,774,O
flavin-containing,774,B-CHEMICAL
spermine,774,B-GENE-N
oxidase,774,I-GENE-N
of,774,O
mammalian,774,O
cell,774,O
origin,774,O
.,774,O
During,775,O
polyamine,775,B-CHEMICAL
catabolism,775,O
",",775,O
spermine,775,B-CHEMICAL
and,775,O
spermidine,775,B-CHEMICAL
are,775,O
first,775,O
acetylated,775,O
by,775,O
spermidine/spermine,775,B-GENE-Y
N,775,I-GENE-Y
(,775,I-GENE-Y
1,775,I-GENE-Y
),775,I-GENE-Y
-acetyltransferase,775,I-GENE-Y
(,775,O
SSAT,775,B-GENE-Y
),775,O
and,775,O
subsequently,775,O
oxidized,775,O
by,775,O
polyamine,775,B-CHEMICAL
oxidase,775,I-GENE-Y
(,775,O
PAO,775,B-GENE-Y
),775,O
to,775,O
produce,775,O
spermidine,775,B-CHEMICAL
and,775,O
putrescine,775,B-CHEMICAL
",",775,O
respectively,775,O
.,775,O
In,776,O
attempting,776,O
to,776,O
clone,776,O
the,776,O
PAO,776,B-GENE-Y
involved,776,O
in,776,O
this,776,O
back-conversion,776,O
pathway,776,O
",",776,O
we,776,O
encountered,776,O
an,776,O
oxidase,776,B-GENE-N
that,776,O
preferentially,776,O
cleaves,776,O
spermine,776,B-CHEMICAL
in,776,O
the,776,O
absence,776,O
of,776,O
prior,776,O
acetylation,776,O
by,776,O
SSAT,776,B-GENE-Y
.,776,O
A,777,O
BLAST,777,O
search,777,O
using,777,O
maize,777,B-GENE-Y
PAO,777,I-GENE-Y
sequences,777,O
identified,777,O
homologous,777,O
mammalian,777,O
cDNAs,777,O
derived,777,O
from,777,O
human,777,O
hepatoma,777,O
and,777,O
mouse,777,O
mammary,777,O
carcinoma,777,O
:,777,O
the,777,O
encoded,777,O
proteins,777,O
differed,777,O
by,777,O
20,777,O
amino,777,B-CHEMICAL
acids,777,I-CHEMICAL
.,777,O
When,778,O
either,778,O
cDNA,778,O
was,778,O
transiently,778,O
transfected,778,O
into,778,O
HEK-293,778,O
cells,778,O
",",778,O
intracellular,778,O
spermine,778,B-CHEMICAL
pools,778,O
decreased,778,O
by,778,O
75,778,O
%,778,O
while,778,O
spermidine,778,B-CHEMICAL
and,778,O
N,778,B-CHEMICAL
(,778,I-CHEMICAL
1,778,I-CHEMICAL
),778,I-CHEMICAL
-acetylspermidine,778,I-CHEMICAL
pools,778,O
increased,778,O
",",778,O
suggesting,778,O
that,778,O
spermine,778,B-CHEMICAL
was,778,O
selectively,778,O
and,778,O
directly,778,O
oxidized,778,O
by,778,O
the,778,O
enzyme,778,O
.,778,O
Substrate,779,O
specificity,779,O
using,779,O
lysates,779,O
of,779,O
oxidase-transfected,779,B-GENE-N
HEK-293,779,O
cells,779,O
revealed,779,O
that,779,O
the,779,O
newly,779,O
identified,779,O
oxidase,779,B-GENE-N
strongly,779,O
favoured,779,O
spermine,779,B-CHEMICAL
over,779,O
N,779,B-CHEMICAL
(,779,I-CHEMICAL
1,779,I-CHEMICAL
),779,I-CHEMICAL
-acetylspermine,779,I-CHEMICAL
and,779,O
that,779,O
it,779,O
failed,779,O
to,779,O
act,779,O
on,779,O
N,779,B-CHEMICAL
(,779,I-CHEMICAL
1,779,I-CHEMICAL
),779,I-CHEMICAL
-acetylspermidine,779,I-CHEMICAL
",",779,O
spermidine,779,B-CHEMICAL
or,779,O
the,779,O
preferred,779,O
PAO,779,B-GENE-Y
substrate,779,O
",",779,O
N,779,B-CHEMICAL
(,779,I-CHEMICAL
1,779,I-CHEMICAL
),779,I-CHEMICAL
",",779,I-CHEMICAL
N,779,I-CHEMICAL
(,779,I-CHEMICAL
12,779,I-CHEMICAL
),779,I-CHEMICAL
-diacetylspermine,779,I-CHEMICAL
.,779,O
The,780,O
PAO,780,B-GENE-Y
inhibitor,780,O
",",780,O
"MDL-72,527",780,B-CHEMICAL
",",780,O
only,780,O
partially,780,O
blocked,780,O
oxidation,780,O
of,780,O
spermine,780,B-CHEMICAL
while,780,O
a,780,O
previously,780,O
reported,780,O
PAO,780,B-GENE-Y
substrate,780,O
",",780,O
N,780,B-CHEMICAL
(,780,I-CHEMICAL
1,780,I-CHEMICAL
),780,I-CHEMICAL
-,780,I-CHEMICAL
(,780,I-CHEMICAL
n,780,I-CHEMICAL
-octanesulphonyl,780,I-CHEMICAL
),780,I-CHEMICAL
spermine,780,I-CHEMICAL
",",780,O
potently,780,O
inhibited,780,O
the,780,O
reaction,780,O
.,780,O
Overall,781,O
",",781,O
the,781,O
data,781,O
indicate,781,O
that,781,O
the,781,O
enzyme,781,O
represents,781,O
a,781,O
novel,781,O
mammalian,781,B-GENE-N
oxidase,781,I-GENE-N
which,781,O
",",781,O
on,781,O
the,781,O
basis,781,O
of,781,O
substrate,781,O
specificity,781,O
",",781,O
we,781,O
have,781,O
designated,781,O
spermine,781,B-CHEMICAL
oxidase,781,I-GENE-N
in,781,O
order,781,O
to,781,O
distinguish,781,O
it,781,O
from,781,O
the,781,O
PAO,781,B-GENE-N
involved,781,O
in,781,O
polyamine,781,B-CHEMICAL
back-conversion,781,O
.,781,O
The,782,O
identification,782,O
of,782,O
an,782,O
enzyme,782,O
capable,782,O
of,782,O
directly,782,O
oxidizing,782,O
spermine,782,B-CHEMICAL
to,782,O
spermidine,782,B-CHEMICAL
has,782,O
important,782,O
implications,782,O
for,782,O
understanding,782,O
polyamine,782,O
homoeostasis,782,O
and,782,O
for,782,O
interpreting,782,O
metabolic,782,O
and,782,O
cellular,782,O
responses,782,O
to,782,O
clinically,782,O
relevant,782,O
polyamine,782,B-CHEMICAL
analogues,782,O
and,782,O
inhibitors,782,O
.,782,O
Low,783,O
incidence,783,O
of,783,O
paradoxical,783,O
platelet,783,O
activation,783,O
by,783,O
glycoprotein,783,B-GENE-N
IIb/IIIa,783,I-GENE-N
inhibitors,783,O
.,783,O
The,784,O
human,784,B-GENE-N
platelet,784,I-GENE-N
antigen-1,784,I-GENE-N
(,784,O
HPA-1,784,B-GENE-N
",",784,O
Pl,784,B-GENE-N
(,784,I-GENE-N
A,784,I-GENE-N
),784,I-GENE-N
),784,O
polymorphism,784,O
has,784,O
been,784,O
proposed,784,O
to,784,O
influence,784,O
the,784,O
inhibitory,784,O
actions,784,O
of,784,O
abciximab,784,O
.,784,O
Thus,785,O
",",785,O
we,785,O
hypothesized,785,O
that,785,O
this,785,O
polymorphism,785,O
might,785,O
also,785,O
be,785,O
the,785,O
cause,785,O
for,785,O
paradoxical,785,O
activation,785,O
of,785,O
platelets,785,O
by,785,O
GPIIb/IIIa,785,B-GENE-N
inhibitors,785,O
.,785,O
The,786,O
effects,786,O
of,786,O
abciximab,786,O
(,786,O
1-10,786,O
microg/ml,786,O
),786,O
",",786,O
tirofiban,786,B-CHEMICAL
(,786,O
3-30,786,O
nM,786,O
),786,O
",",786,O
or,786,O
eptifibatide,786,B-CHEMICAL
(,786,O
0.3-3,786,O
microg/ml,786,O
),786,O
on,786,O
basal,786,O
and,786,O
ADP,786,B-CHEMICAL
(,786,O
3,786,O
microM,786,O
),786,O
-induced,786,O
CD62P,786,B-GENE-Y
externalization,786,O
were,786,O
measured,786,O
in,786,O
n=62,786,O
healthy,786,O
blood,786,O
donors,786,O
and,786,O
n=177,786,O
patients,786,O
with,786,O
stable,786,O
coronary,786,O
artery,786,O
disease,786,O
.,786,O
All,787,O
subjects,787,O
were,787,O
genotyped,787,O
for,787,O
the,787,O
human,787,B-GENE-N
platelet,787,I-GENE-N
antigen-1,787,I-GENE-N
(,787,O
HPA-1,787,B-GENE-N
",",787,O
Pl,787,B-GENE-N
(,787,I-GENE-N
A,787,I-GENE-N
),787,I-GENE-N
),787,O
polymorphism,787,O
by,787,O
GALIOS,787,O
(,787,O
R,787,O
),787,O
and,787,O
fluorescence,787,O
correlation,787,O
spectroscopy,787,O
.,787,O
Although,788,O
a,788,O
significant,788,O
platelet,788,O
hyperreactivity,788,O
was,788,O
observed,788,O
in,788,O
the,788,O
patients,788,O
",",788,O
the,788,O
HPA-1,788,B-GENE-N
genotype,788,O
did,788,O
not,788,O
influence,788,O
basal,788,O
or,788,O
ADP-induced,788,B-CHEMICAL
CD62P,788,B-GENE-Y
expression,788,O
.,788,O
A,789,O
moderate,789,O
(,789,O
twofold,789,O
),789,O
stimulation,789,O
of,789,O
CD62P,789,B-GENE-Y
expression,789,O
by,789,O
abciximab,789,O
but,789,O
not,789,O
by,789,O
tirofiban,789,B-CHEMICAL
or,789,O
eptifibatide,789,B-CHEMICAL
was,789,O
observed,789,O
in,789,O
one,789,O
patient,789,O
.,789,O
Interestingly,790,O
",",790,O
this,790,O
patient,790,O
carried,790,O
the,790,O
HPA-1,790,B-GENE-N
b/b,790,O
genotype,790,O
.,790,O
In,791,O
no,791,O
other,791,O
subject,791,O
any,791,O
activation,791,O
of,791,O
platelets,791,O
by,791,O
GP,791,B-GENE-N
IIb/IIIa,791,I-GENE-N
inhibitors,791,O
was,791,O
observed,791,O
and,791,O
there,791,O
were,791,O
no,791,O
statistically,791,O
significant,791,O
differences,791,O
between,791,O
HPA-1,791,B-GENE-N
genotypes,791,O
with,791,O
respect,791,O
to,791,O
the,791,O
effects,791,O
of,791,O
GP,791,B-GENE-N
IIb/IIIa,791,I-GENE-N
inhibitors,791,O
on,791,O
basal,791,O
or,791,O
ADP-stimulated,791,B-CHEMICAL
CD62P,791,B-GENE-Y
expression,791,O
.,791,O
It,792,O
is,792,O
concluded,792,O
that,792,O
paradoxical,792,O
platelet,792,O
activation,792,O
by,792,O
abciximab,792,O
is,792,O
a,792,O
rare,792,O
(,792,O
<,792,O
2,792,O
%,792,O
),792,O
phenomenon,792,O
.,792,O
HPA-1,793,B-GENE-N
b/b,793,O
genotype,793,O
might,793,O
be,793,O
a,793,O
contributing,793,O
factor,793,O
but,793,O
clearly,793,O
does,793,O
not,793,O
predict,793,O
platelet,793,O
activation,793,O
by,793,O
GP,793,B-GENE-N
IIb/IIIa,793,I-GENE-N
inhibitors,793,O
.,793,O
Toxic,794,O
",",794,O
halogenated,794,O
cysteine,794,B-CHEMICAL
S-conjugates,794,I-CHEMICAL
and,794,O
targeting,794,O
of,794,O
mitochondrial,794,O
enzymes,794,O
of,794,O
energy,794,O
metabolism,794,O
.,794,O
Several,795,O
haloalkenes,795,B-CHEMICAL
are,795,O
metabolized,795,O
in,795,O
part,795,O
to,795,O
nephrotoxic,795,O
cysteine,795,B-CHEMICAL
S-conjugates,795,I-CHEMICAL
;,795,O
for,795,O
example,795,O
",",795,O
trichloroethylene,795,B-CHEMICAL
and,795,O
tetrafluoroethylene,795,B-CHEMICAL
are,795,O
converted,795,O
to,795,O
S-,795,B-CHEMICAL
(,795,I-CHEMICAL
"1,2-dichlorovinyl",795,I-CHEMICAL
),795,I-CHEMICAL
-L-cysteine,795,I-CHEMICAL
(,795,O
DCVC,795,B-CHEMICAL
),795,O
and,795,O
S-,795,B-CHEMICAL
(,795,I-CHEMICAL
"1,1,2,2-tetrafluoroethyl",795,I-CHEMICAL
),795,I-CHEMICAL
-L-cysteine,795,I-CHEMICAL
(,795,O
TFEC,795,B-CHEMICAL
),795,O
",",795,O
respectively,795,O
.,795,O
Although,796,O
DCVC-induced,796,B-CHEMICAL
toxicity,796,O
has,796,O
been,796,O
investigated,796,O
since,796,O
the,796,O
1950s,796,O
",",796,O
the,796,O
toxicity,796,O
of,796,O
TFEC,796,B-CHEMICAL
and,796,O
other,796,O
haloalkene-derived,796,B-CHEMICAL
cysteine,796,I-CHEMICAL
S-conjugates,796,I-CHEMICAL
has,796,O
been,796,O
studied,796,O
more,796,O
recently,796,O
.,796,O
Some,797,O
segments,797,O
of,797,O
the,797,O
US,797,O
population,797,O
are,797,O
exposed,797,O
to,797,O
haloalkenes,797,B-CHEMICAL
either,797,O
through,797,O
drinking,797,O
water,797,O
or,797,O
in,797,O
the,797,O
workplace,797,O
.,797,O
Therefore,798,O
",",798,O
it,798,O
is,798,O
important,798,O
to,798,O
define,798,O
the,798,O
toxicological,798,O
consequences,798,O
of,798,O
such,798,O
exposures,798,O
.,798,O
Most,799,O
halogenated,799,O
cysteine,799,B-CHEMICAL
S-conjugates,799,I-CHEMICAL
are,799,O
metabolized,799,O
by,799,O
cysteine,799,B-CHEMICAL
S-conjugate,799,I-CHEMICAL
beta-lyases,799,B-GENE-N
to,799,O
pyruvate,799,B-CHEMICAL
",",799,O
ammonia,799,B-CHEMICAL
",",799,O
and,799,O
an,799,O
alpha-chloroenethiolate,799,B-CHEMICAL
(,799,O
with,799,O
DCVC,799,B-CHEMICAL
),799,O
or,799,O
an,799,O
alpha-difluoroalkylthiolate,799,B-CHEMICAL
(,799,O
with,799,O
TFEC,799,B-CHEMICAL
),799,O
that,799,O
may,799,O
eliminate,799,O
halide,799,B-CHEMICAL
to,799,O
give,799,O
a,799,O
thioacyl,799,B-CHEMICAL
halide,799,I-CHEMICAL
",",799,O
which,799,O
reacts,799,O
with,799,O
epsilon-amino,799,B-CHEMICAL
groups,799,O
of,799,O
lysine,799,B-CHEMICAL
residues,799,O
in,799,O
proteins,799,O
.,799,O
Nine,800,O
mammalian,800,O
pyridoxal,800,B-CHEMICAL
5'-phosphate,800,I-CHEMICAL
(,800,O
PLP,800,B-CHEMICAL
),800,O
-containing,800,O
enzymes,800,O
catalyze,800,O
cysteine,800,B-CHEMICAL
S-conjugate,800,I-CHEMICAL
beta-lyase,800,B-GENE-N
reactions,800,O
",",800,O
including,800,O
mitochondrial,800,B-GENE-Y
aspartate,800,I-GENE-Y
aminotransferase,800,I-GENE-Y
(,800,O
mitAspAT,800,B-GENE-Y
),800,O
",",800,O
and,800,O
mitochondrial,800,B-GENE-Y
branched-chain,800,I-GENE-Y
amino,800,I-GENE-Y
acid,800,I-GENE-Y
aminotransferase,800,I-GENE-Y
(,800,O
BCAT,800,B-GENE-Y
(,800,I-GENE-Y
m,800,I-GENE-Y
),800,I-GENE-Y
),800,O
.,800,O
Most,801,O
of,801,O
the,801,O
cysteine,801,B-CHEMICAL
S-conjugate,801,I-CHEMICAL
beta-lyases,801,B-GENE-N
are,801,O
syncatalytically,801,O
inactivated,801,O
.,801,O
TFEC-induced,802,B-CHEMICAL
toxicity,802,O
is,802,O
associated,802,O
with,802,O
covalent,802,O
modification,802,O
of,802,O
several,802,O
mitochondrial,802,O
enzymes,802,O
of,802,O
energy,802,O
metabolism,802,O
.,802,O
Interestingly,803,O
",",803,O
the,803,O
alpha-ketoglutarate-,803,B-CHEMICAL
and,803,I-GENE-N
branched-chain,803,B-CHEMICAL
alpha-keto,803,I-CHEMICAL
acid,803,I-CHEMICAL
dehydrogenase,803,I-GENE-N
complexes,803,I-GENE-N
(,803,O
KGDHC,803,B-GENE-N
and,803,O
BCDHC,803,B-GENE-N
),803,O
",",803,O
but,803,O
not,803,O
the,803,O
pyruvate,803,B-CHEMICAL
dehydrogenase,803,I-GENE-N
complex,803,I-GENE-N
(,803,O
PDHC,803,B-GENE-N
),803,O
",",803,O
are,803,O
susceptible,803,O
to,803,O
inactivation,803,O
.,803,O
mitAspAT,804,B-GENE-Y
and,804,O
BCAT,804,B-GENE-Y
(,804,I-GENE-Y
m,804,I-GENE-Y
),804,I-GENE-Y
may,804,O
form,804,O
metabolons,804,O
with,804,O
KGDHC,804,B-GENE-N
and,804,O
BCDHC,804,B-GENE-N
",",804,O
respectively,804,O
",",804,O
but,804,O
no,804,O
PLP,804,B-GENE-N
enzyme,804,I-GENE-N
is,804,O
known,804,O
to,804,O
associate,804,O
with,804,O
PDHC,804,B-GENE-N
.,804,O
Consequently,805,O
",",805,O
we,805,O
hypothesize,805,O
that,805,O
not,805,O
only,805,O
do,805,O
these,805,O
metabolons,805,O
facilitate,805,O
substrate,805,O
channeling,805,O
",",805,O
but,805,O
they,805,O
also,805,O
facilitate,805,O
toxicant,805,O
channeling,805,O
",",805,O
thereby,805,O
promoting,805,O
the,805,O
inactivation,805,O
of,805,O
proximate,805,O
mitochondrial,805,O
enzymes,805,O
and,805,O
the,805,O
induction,805,O
of,805,O
mitochondrial,805,O
dysfunction,805,O
.,805,O
A,806,O
heterozygote,806,O
phenotype,806,O
is,806,O
present,806,O
in,806,O
the,806,O
jvs,806,O
+/-,806,O
mutant,806,O
mouse,806,O
livers,806,O
.,806,O
The,807,O
juvenile,807,O
visceral,807,O
steatosis,807,O
(,807,O
jvs,807,O
),807,O
mouse,807,O
",",807,O
having,807,O
a,807,O
mutation,807,O
in,807,O
the,807,O
carnitine,807,B-CHEMICAL
transporter,807,O
gene,807,O
Octn2,807,B-GENE-Y
",",807,O
is,807,O
a,807,O
model,807,O
of,807,O
primary,807,O
systemic,807,O
carnitine,807,B-CHEMICAL
deficiency,807,O
in,807,O
humans,807,O
(,807,O
SCD,807,O
",",807,O
OMIM,807,O
212140,807,O
),807,O
.,807,O
Like,808,O
humans,808,O
with,808,O
SCD,808,O
",",808,O
homozygous,808,O
jvs,808,O
-/-,808,O
mice,808,O
have,808,O
hepatic,808,O
and,808,O
cardiac,808,O
steatoses,808,O
",",808,O
reduced,808,O
plasma,808,O
and,808,O
tissue,808,O
carnitines,808,B-CHEMICAL
",",808,O
and,808,O
increased,808,O
urinary,808,O
carnitine,808,B-CHEMICAL
clearance,808,O
.,808,O
Because,809,O
symptomatic,809,O
heterozygotes,809,O
have,809,O
been,809,O
reported,809,O
for,809,O
some,809,O
fatty,809,B-CHEMICAL
acid,809,I-CHEMICAL
oxidation,809,O
disorders,809,O
",",809,O
including,809,O
SCD,809,O
",",809,O
we,809,O
compared,809,O
the,809,O
jvs,809,O
heterozygotes,809,O
to,809,O
normal,809,O
control,809,O
mice,809,O
.,809,O
We,810,O
measured,810,O
the,810,O
free,810,O
and,810,O
esterified,810,O
carnitine,810,B-CHEMICAL
",",810,O
total,810,O
cholesterol,810,B-CHEMICAL
",",810,O
and,810,O
triglycerides,810,B-CHEMICAL
in,810,O
adult,810,O
liver,810,O
samples,810,O
",",810,O
myocardium,810,O
",",810,O
and,810,O
skeletal,810,O
muscle,810,O
.,810,O
Our,811,O
results,811,O
indicate,811,O
significant,811,O
differences,811,O
between,811,O
the,811,O
livers,811,O
of,811,O
nonfasting,811,O
adult,811,O
normal,811,O
(,811,O
n,811,O
=,811,O
8,811,O
),811,O
vs,811,O
jvs,811,O
heterozygotes,811,O
(,811,O
n,811,O
=,811,O
8,811,O
),811,O
(,811,O
means,811,O
+/-,811,O
SEM,811,O
",",811,O
p,811,O
<,811,O
0.01,811,O
),811,O
for,811,O
the,811,O
following,811,O
parameters,811,O
:,811,O
free,811,O
carnitine,811,B-CHEMICAL
",",811,O
2.28,811,O
+/-,811,O
0.36,811,O
nmol/mg,811,O
protein,811,O
vs,811,O
0.41,811,O
+/-,811,O
0.13,811,O
;,811,O
total,811,O
carnitine,811,B-CHEMICAL
",",811,O
3.48,811,O
+/-,811,O
0.36,811,O
vs,811,O
1.27,811,O
+/-,811,O
0.25,811,O
;,811,O
triglycerides,811,B-CHEMICAL
",",811,O
0.14,811,O
+/-,811,O
0.04,811,O
vs,811,O
0.39,811,O
+/-,811,O
0.02,811,O
;,811,O
and,811,O
total,811,O
cholesterol,811,B-CHEMICAL
",",811,O
0.21,811,O
+/-,811,O
0.02,811,O
vs,811,O
0.39,811,O
+/-,811,O
0.04,811,O
",",811,O
but,811,O
not,811,O
for,811,O
esterified,811,O
carnitine,811,B-CHEMICAL
",",811,O
1.18,811,O
+/-,811,O
0.17,811,O
vs,811,O
0.90,811,O
+/-,811,O
0.17,811,O
(,811,O
p,811,O
>,811,O
0.05,811,O
),811,O
.,811,O
There,812,O
is,812,O
also,812,O
a,812,O
negative,812,O
correlation,812,O
between,812,O
hepatic,812,O
free,812,O
carnitine,812,B-CHEMICAL
and,812,O
triglycerides,812,B-CHEMICAL
from,812,O
jvs,812,O
heterozygotes,812,O
(,812,O
p,812,O
<,812,O
0.05,812,O
),812,O
.,812,O
Similar,813,O
results,813,O
were,813,O
obtained,813,O
with,813,O
myocardium,813,O
and,813,O
skeletal,813,O
muscle,813,O
.,813,O
We,814,O
conclude,814,O
that,814,O
free,814,O
and,814,O
total,814,O
carnitine,814,B-CHEMICAL
levels,814,O
are,814,O
significantly,814,O
lower,814,O
in,814,O
the,814,O
heterozygote,814,O
mouse,814,O
liver,814,O
and,814,O
heart,814,O
while,814,O
triglyceride,814,B-CHEMICAL
and,814,O
total,814,O
cholesterol,814,B-CHEMICAL
levels,814,O
are,814,O
significantly,814,O
higher,814,O
.,814,O
We,815,O
speculate,815,O
that,815,O
in,815,O
situations,815,O
of,815,O
lipolytic,815,O
stress,815,O
",",815,O
some,815,O
SCD,815,O
heterozygotes,815,O
might,815,O
develop,815,O
clinical,815,O
symptoms,815,O
of,815,O
carnitine,815,B-CHEMICAL
deficiency,815,O
.,815,O
Organic,816,B-GENE-N
cation,816,I-GENE-N
transporter,816,I-GENE-N
mRNA,816,O
and,816,O
function,816,O
in,816,O
the,816,O
rat,816,O
superior,816,O
cervical,816,O
ganglion,816,O
.,816,O
Reuptake,817,O
of,817,O
extracellular,817,O
noradrenaline,817,B-CHEMICAL
(,817,O
NA,817,B-CHEMICAL
),817,O
into,817,O
superior,817,O
cervical,817,O
ganglion,817,O
(,817,O
SCG,817,O
),817,O
neurones,817,O
is,817,O
mediated,817,O
by,817,O
means,817,O
of,817,O
the,817,O
noradrenaline,817,B-CHEMICAL
transporter,817,I-GENE-Y
(,817,O
NAT,817,B-GENE-Y
",",817,O
uptake,817,O
1,817,O
),817,O
.,817,O
We,818,O
now,818,O
demonstrate,818,O
by,818,O
single-cell,818,O
RT-PCR,818,O
that,818,O
mRNA,818,O
of,818,O
the,818,O
organic,818,B-GENE-Y
cation,818,I-GENE-Y
transporter,818,I-GENE-Y
3,818,I-GENE-Y
(,818,O
OCT3,818,B-GENE-Y
",",818,O
uptake,818,O
2,818,O
),818,O
occurs,818,O
in,818,O
rat,818,O
SCG,818,O
neurones,818,O
as,818,O
well,818,O
.,818,O
Furthermore,819,O
",",819,O
our,819,O
RT-PCR,819,O
analyses,819,O
reveal,819,O
the,819,O
presence,819,O
of,819,O
mRNA,819,O
for,819,O
novel,819,B-GENE-N
organic,819,I-GENE-N
cation,819,I-GENE-N
transporters,819,I-GENE-N
1,819,I-GENE-N
and,819,I-GENE-N
2,819,I-GENE-N
(,819,O
OCTN1,819,B-GENE-Y
and,819,O
OCTN2,819,B-GENE-Y
),819,O
",",819,O
but,819,O
not,819,O
for,819,O
OCT1,819,B-GENE-Y
or,819,O
OCT2,819,B-GENE-Y
in,819,O
the,819,O
ganglion,819,O
.,819,O
Making,820,O
use,820,O
of,820,O
the,820,O
NAT,820,B-GENE-Y
as,820,O
a,820,O
powerful,820,O
",",820,O
neurone-specific,820,O
transporter,820,O
system,820,O
",",820,O
we,820,O
loaded,820,O
[,820,B-CHEMICAL
3H,820,I-CHEMICAL
],820,I-CHEMICAL
-N-methyl-4-phenylpyridinium,820,I-CHEMICAL
(,820,O
[,820,B-CHEMICAL
3H,820,I-CHEMICAL
],820,I-CHEMICAL
-MPP+,820,I-CHEMICAL
),820,O
into,820,O
cultured,820,O
rat,820,O
SCG,820,O
neurones,820,O
.,820,O
The,821,O
ensuing,821,O
radioactive,821,O
outflow,821,O
from,821,O
these,821,O
cultures,821,O
was,821,O
enhanced,821,O
by,821,O
desipramine,821,B-CHEMICAL
and,821,O
reserpine,821,B-CHEMICAL
",",821,O
but,821,O
reduced,821,O
(,821,O
in,821,O
the,821,O
presence,821,O
of,821,O
desipramine,821,B-CHEMICAL
),821,O
by,821,O
the,821,O
OCT3,821,B-GENE-Y
inhibitors,821,O
cyanine,821,O
863,821,O
",",821,O
oestradiol,821,B-CHEMICAL
and,821,O
corticosterone,821,B-CHEMICAL
.,821,O
In,822,O
contrast,822,O
",",822,O
cyanine,822,O
863,822,O
enhanced,822,O
the,822,O
radioactive,822,O
outflow,822,O
from,822,O
cultures,822,O
preloaded,822,O
with,822,O
[,822,B-CHEMICAL
3H,822,I-CHEMICAL
],822,I-CHEMICAL
-NA,822,I-CHEMICAL
.,822,O
Two,823,O
observations,823,O
suggest,823,O
that,823,O
a,823,O
depletion,823,O
of,823,O
storage,823,O
vesicles,823,O
by,823,O
cyanine,823,O
863,823,O
accounts,823,O
for,823,O
the,823,O
latter,823,O
phenomenon,823,O
:,823,O
first,823,O
",",823,O
the,823,O
primary,823,O
radioactive,823,O
product,823,O
isolated,823,O
from,823,O
supernatants,823,O
of,823,O
cultures,823,O
loaded,823,O
with,823,O
[,823,B-CHEMICAL
3H,823,I-CHEMICAL
],823,I-CHEMICAL
-NA,823,I-CHEMICAL
was,823,O
the,823,O
metabolite,823,O
[,823,B-CHEMICAL
3H,823,I-CHEMICAL
],823,I-CHEMICAL
-DHPG,823,I-CHEMICAL
;,823,O
and,823,O
second,823,O
",",823,O
inhibition,823,O
of,823,O
MAO,823,B-GENE-N
significantly,823,O
reduced,823,O
the,823,O
radioactive,823,O
outflow,823,O
in,823,O
response,823,O
to,823,O
cyanine,823,O
863,823,O
.,823,O
The,824,O
outflow,824,O
of,824,O
[,824,B-CHEMICAL
3H,824,I-CHEMICAL
],824,I-CHEMICAL
-MPP+,824,I-CHEMICAL
was,824,O
significantly,824,O
enhanced,824,O
by,824,O
MPP+,824,B-CHEMICAL
",",824,O
guanidine,824,B-CHEMICAL
",",824,O
choline,824,B-CHEMICAL
and,824,O
amantadine,824,B-CHEMICAL
as,824,O
potential,824,O
substrates,824,O
for,824,O
OCT-related,824,B-GENE-N
transmembrane,824,B-GENE-N
transporters,824,I-GENE-N
.,824,O
However,825,O
",",825,O
desipramine,825,B-CHEMICAL
at,825,O
a,825,O
low,825,O
concentration,825,O
essentially,825,O
blocked,825,O
the,825,O
radioactive,825,O
outflow,825,O
induced,825,O
by,825,O
all,825,O
of,825,O
these,825,O
substances,825,O
with,825,O
the,825,O
exception,825,O
of,825,O
MPP+,825,B-CHEMICAL
",",825,O
indicating,825,O
the,825,O
NAT,825,B-GENE-Y
and,825,O
not,825,O
an,825,O
OCT,825,B-GENE-N
as,825,O
their,825,O
primary,825,O
site,825,O
of,825,O
action,825,O
.,825,O
The,826,O
MPP+-induced,826,B-CHEMICAL
release,826,O
of,826,O
[,826,B-CHEMICAL
3H,826,I-CHEMICAL
],826,I-CHEMICAL
-MPP+,826,I-CHEMICAL
was,826,O
fully,826,O
prevented,826,O
by,826,O
a,826,O
combined,826,O
application,826,O
of,826,O
desipramine,826,B-CHEMICAL
and,826,O
cyanine,826,O
863,826,O
.,826,O
No,827,O
trans-stimulation,827,O
of,827,O
[,827,B-CHEMICAL
3H,827,I-CHEMICAL
],827,I-CHEMICAL
-MPP+,827,I-CHEMICAL
outflow,827,O
was,827,O
observed,827,O
by,827,O
the,827,O
OCTN1,827,B-GENE-Y
and,827,O
OCTN2,827,B-GENE-Y
substrate,827,O
carnitine,827,O
at,827,O
100,827,O
microM,827,O
.,827,O
Our,828,O
observations,828,O
indicate,828,O
an,828,O
OCT-mediated,828,B-GENE-N
transmembrane,828,O
transport,828,O
of,828,O
[,828,B-CHEMICAL
3H,828,I-CHEMICAL
],828,I-CHEMICAL
-MPP+,828,I-CHEMICAL
.,828,O
Amongst,829,O
the,829,O
three,829,O
OCTs,829,B-GENE-N
expressed,829,O
in,829,O
the,829,O
SCG,829,O
",",829,O
OCT3,829,B-GENE-Y
best,829,O
fits,829,O
the,829,O
profile,829,O
of,829,O
substrates,829,O
and,829,O
antagonists,829,O
that,829,O
cause,829,O
trans-stimulation,829,O
and,829,O
trans-inhibition,829,O
",",829,O
respectively,829,O
",",829,O
of,829,O
[,829,B-CHEMICAL
3H,829,I-CHEMICAL
],829,I-CHEMICAL
-MPP+,829,I-CHEMICAL
release,829,O
.,829,O
Neuroprotection,830,O
by,830,O
propargylamines,830,B-CHEMICAL
in,830,O
Parkinson,830,O
's,830,O
disease,830,O
:,830,O
suppression,830,O
of,830,O
apoptosis,830,O
and,830,O
induction,830,O
of,830,O
prosurvival,830,O
genes,830,O
.,830,O
In,831,O
Parkinson,831,O
's,831,O
disease,831,O
(,831,O
PD,831,O
),831,O
",",831,O
therapies,831,O
to,831,O
delay,831,O
or,831,O
suppress,831,O
the,831,O
progression,831,O
of,831,O
cell,831,O
death,831,O
in,831,O
nigrostriatal,831,O
dopamine,831,B-CHEMICAL
neurons,831,O
have,831,O
been,831,O
proposed,831,O
by,831,O
use,831,O
of,831,O
various,831,O
agents,831,O
.,831,O
An,832,O
inhibitor,832,O
of,832,O
type,832,B-GENE-Y
B,832,I-GENE-Y
monoamine,832,B-CHEMICAL
oxidase,832,I-GENE-Y
(,832,O
MAO-B,832,B-GENE-Y
),832,O
",",832,O
(,832,B-CHEMICAL
-,832,I-CHEMICAL
),832,I-CHEMICAL
deprenyl,832,I-CHEMICAL
(,832,O
selegiline,832,B-CHEMICAL
),832,O
",",832,O
was,832,O
reported,832,O
to,832,O
have,832,O
neuroprotective,832,O
activity,832,O
",",832,O
but,832,O
clinical,832,O
trials,832,O
failed,832,O
to,832,O
confirm,832,O
it,832,O
.,832,O
However,833,O
",",833,O
the,833,O
animal,833,O
and,833,O
cellular,833,O
models,833,O
of,833,O
PD,833,O
proved,833,O
that,833,O
selegiline,833,B-CHEMICAL
protects,833,O
neurons,833,O
from,833,O
cell,833,O
death,833,O
.,833,O
Among,834,O
selegiline-related,834,B-CHEMICAL
propargylamines,834,B-CHEMICAL
",",834,O
(,834,B-CHEMICAL
R,834,I-CHEMICAL
),834,I-CHEMICAL
(,834,I-CHEMICAL
+,834,I-CHEMICAL
),834,I-CHEMICAL
-N-propargyl-1-aminoindan,834,I-CHEMICAL
(,834,O
rasagiline,834,B-CHEMICAL
),834,O
was,834,O
the,834,O
most,834,O
effective,834,O
to,834,O
suppress,834,O
the,834,O
cell,834,O
death,834,O
in,834,O
in,834,O
vivo,834,O
and,834,O
in,834,O
vitro,834,O
experiments,834,O
.,834,O
In,835,O
this,835,O
paper,835,O
",",835,O
the,835,O
mechanism,835,O
of,835,O
the,835,O
neuroprotection,835,O
by,835,O
rasagiline,835,B-CHEMICAL
was,835,O
examined,835,O
using,835,O
human,835,O
dopaminergic,835,O
SH-SY5Y,835,O
cells,835,O
against,835,O
cell,835,O
death,835,O
induced,835,O
by,835,O
an,835,O
endogenous,835,O
dopaminergic,835,O
neurotoxin,835,O
N-methyl,835,B-CHEMICAL
(,835,I-CHEMICAL
R,835,I-CHEMICAL
),835,I-CHEMICAL
salsolinol,835,I-CHEMICAL
(,835,O
NM,835,B-CHEMICAL
(,835,I-CHEMICAL
R,835,I-CHEMICAL
),835,I-CHEMICAL
Sal,835,I-CHEMICAL
),835,O
.,835,O
NM,836,B-CHEMICAL
(,836,I-CHEMICAL
R,836,I-CHEMICAL
),836,I-CHEMICAL
Sal,836,I-CHEMICAL
induced,836,O
apoptosis,836,O
(,836,O
but,836,O
not,836,O
necrosis,836,O
),836,O
in,836,O
SH-SY5Y,836,O
cells,836,O
",",836,O
and,836,O
the,836,O
apoptotic,836,O
cascade,836,O
was,836,O
initiated,836,O
by,836,O
mitochondrial,836,O
permeability,836,O
transition,836,O
(,836,O
PT,836,O
),836,O
and,836,O
activated,836,O
by,836,O
stepwise,836,O
reactions,836,O
.,836,O
Rasagiline,837,B-CHEMICAL
prevented,837,O
the,837,O
PT,837,O
in,837,O
mitochondria,837,O
directly,837,O
and,837,O
also,837,O
indirectly,837,O
through,837,O
induction,837,O
of,837,O
antiapoptotic,837,O
Bcl-2,837,B-GENE-Y
and,837,O
a,837,O
neurotrophic,837,B-GENE-N
factor,837,I-GENE-N
",",837,O
glial,837,B-GENE-Y
cell,837,I-GENE-Y
line-derived,837,I-GENE-Y
neurotrophic,837,I-GENE-Y
factor,837,I-GENE-Y
(,837,O
GDNF,837,B-GENE-Y
),837,O
.,837,O
Long-term,838,O
administration,838,O
of,838,O
propargylamines,838,B-CHEMICAL
to,838,O
rats,838,O
increased,838,O
the,838,O
activities,838,O
of,838,O
antioxidative,838,O
enzymes,838,O
superoxide,838,B-CHEMICAL
dismutase,838,I-GENE-N
(,838,O
SOD,838,B-GENE-N
),838,O
and,838,O
catalase,838,B-GENE-Y
in,838,O
the,838,O
brain,838,O
regions,838,O
containing,838,O
dopamine,838,B-CHEMICAL
neurons,838,O
.,838,O
Rasagiline,839,B-CHEMICAL
and,839,O
related,839,O
propargylamines,839,B-CHEMICAL
may,839,O
rescue,839,O
degenerating,839,O
dopamine,839,B-CHEMICAL
neurons,839,O
through,839,O
inhibiting,839,O
death,839,O
signal,839,O
transduction,839,O
initiated,839,O
by,839,O
mitochondria,839,O
PT,839,O
.,839,O
Pharmacodynamics,840,O
and,840,O
pharmacokinetics,840,O
of,840,O
phenylbutazone,840,B-CHEMICAL
in,840,O
calves,840,O
.,840,O
Phenylbutazone,841,B-CHEMICAL
(,841,O
PBZ,841,B-CHEMICAL
),841,O
was,841,O
administered,841,O
to,841,O
six,841,O
calves,841,O
intravenously,841,O
(,841,O
i.v,841,O
.,841,O
),841,O
and,842,O
orally,842,O
at,842,O
a,842,O
dose,842,O
rate,842,O
of,842,O
4.4,842,O
mg/kg,842,O
in,842,O
a,842,O
three-period,842,O
cross-over,842,O
study,842,O
incorporating,842,O
a,842,O
placebo,842,O
treatment,842,O
to,842,O
establish,842,O
its,842,O
pharmacokinetic,842,O
and,842,O
pharmacodynamic,842,O
properties,842,O
.,842,O
Extravascular,843,O
distribution,843,O
was,843,O
determined,843,O
by,843,O
measuring,843,O
penetration,843,O
into,843,O
tissue,843,O
chamber,843,O
fluid,843,O
in,843,O
the,843,O
absence,843,O
of,843,O
stimulation,843,O
(,843,O
transudate,843,O
),843,O
and,843,O
after,843,O
stimulation,843,O
of,843,O
chamber,843,O
tissue,843,O
with,843,O
the,843,O
mild,843,O
irritant,843,O
carrageenan,843,O
(,843,O
exudate,843,O
),843,O
.,843,O
PBZ,844,B-CHEMICAL
pharmacokinetics,844,O
after,844,O
i.v,844,O
.,844,O
dosage,845,O
was,845,O
characterized,845,O
by,845,O
slow,845,O
clearance,845,O
(,845,O
1.29,845,O
mL/kg/h,845,O
),845,O
",",845,O
long-terminal,845,O
half-life,845,O
(,845,O
53.4,845,O
h,845,O
),845,O
",",845,O
low,845,O
distribution,845,O
volume,845,O
(,845,O
0.09,845,O
L/kg,845,O
),845,O
and,845,O
low,845,O
concentrations,845,O
in,845,O
plasma,845,O
of,845,O
the,845,O
metabolite,845,O
oxyphenbutazone,845,B-CHEMICAL
(,845,O
OPBZ,845,B-CHEMICAL
),845,O
",",845,O
confirming,845,O
previously,845,O
published,845,O
data,845,O
for,845,O
adult,845,O
cattle,845,O
.,845,O
After,846,O
oral,846,O
dosage,846,O
bioavailability,846,O
(,846,O
F,846,O
),846,O
was,846,O
66,846,O
%,846,O
.,846,O
Passage,847,O
into,847,O
exudate,847,O
was,847,O
slow,847,O
and,847,O
limited,847,O
",",847,O
and,847,O
penetration,847,O
into,847,O
transudate,847,O
was,847,O
even,847,O
slower,847,O
and,847,O
more,847,O
limited,847,O
;,847,O
area,847,O
under,847,O
curve,847,O
values,847,O
for,847,O
plasma,847,O
",",847,O
exudate,847,O
and,847,O
transudate,847,O
after,847,O
i.v,847,O
.,847,O
dosage,848,O
were,848,O
3604,848,O
",",848,O
1117,848,O
and,848,O
766,848,O
microg,848,O
h/mL,848,O
and,848,O
corresponding,848,O
values,848,O
after,848,O
oral,848,O
dosage,848,O
were,848,O
2435,848,O
",",848,O
647,848,O
and,848,O
486,848,O
microg,848,O
h/mL,848,O
.,848,O
These,849,O
concentrations,849,O
were,849,O
approximately,849,O
15-20,849,O
(,849,O
plasma,849,O
),849,O
and,849,O
nine,849,O
(,849,O
exudate,849,O
),849,O
times,849,O
greater,849,O
than,849,O
those,849,O
previously,849,O
reported,849,O
in,849,O
horses,849,O
(,849,O
receiving,849,O
the,849,O
same,849,O
dose,849,O
rate,849,O
of,849,O
PBZ,849,B-CHEMICAL
),849,O
.,849,O
In,850,O
the,850,O
horse,850,O
",",850,O
the,850,O
lower,850,O
concentrations,850,O
had,850,O
produced,850,O
marked,850,O
inhibition,850,O
of,850,O
eicosanoid,850,O
synthesis,850,O
and,850,O
suppressed,850,O
the,850,O
inflammatory,850,O
response,850,O
.,850,O
The,851,O
higher,851,O
concentrations,851,O
in,851,O
calves,851,O
were,851,O
insufficient,851,O
to,851,O
inhibit,851,O
significantly,851,O
exudate,851,O
prostaglandin,851,B-CHEMICAL
E2,851,I-CHEMICAL
(,851,O
PGE2,851,B-CHEMICAL
),851,O
",",851,O
leukotriene,851,B-CHEMICAL
B4,851,I-CHEMICAL
(,851,O
LTB4,851,B-CHEMICAL
),851,O
and,851,O
beta-glucuronidase,851,B-GENE-Y
concentrations,851,O
and,851,O
exudate,851,O
leucocyte,851,O
numbers,851,O
",",851,O
serum,851,O
thromboxane,851,B-CHEMICAL
B2,851,I-CHEMICAL
(,851,O
TxB2,851,B-CHEMICAL
),851,O
",",851,O
and,851,O
bradykinin-induced,851,B-GENE-Y
skin,851,O
swelling,851,O
.,851,O
These,852,O
differences,852,O
from,852,O
the,852,O
horse,852,O
might,852,O
be,852,O
the,852,O
result,852,O
of,852,O
:,852,O
(,852,O
a,852,O
),852,O
the,852,O
presence,852,O
in,852,O
equine,852,O
biological,852,O
fluids,852,O
of,852,O
higher,852,O
concentrations,852,O
than,852,O
in,852,O
calves,852,O
of,852,O
the,852,O
active,852,O
PBZ,852,B-CHEMICAL
metabolite,852,O
",",852,O
OPBZ,852,B-CHEMICAL
;,852,O
(,852,O
b,852,O
),852,O
a,852,O
greater,852,O
degree,852,O
of,852,O
binding,852,O
of,852,O
PBZ,852,B-CHEMICAL
to,852,O
plasma,852,O
protein,852,O
in,852,O
calves,852,O
;,852,O
(,852,O
c,852,O
),852,O
species,852,O
differences,852,O
in,852,O
the,852,O
sensitivity,852,O
to,852,O
PBZ,852,B-CHEMICAL
of,852,O
the,852,O
cyclo-oxygenase,852,B-GENE-N
(,852,O
COX,852,B-GENE-N
),852,O
isoenzymes,852,O
",",852,O
COX-1,852,B-GENE-Y
and,852,O
COX-2,852,B-GENE-Y
or,852,O
;,852,O
(,852,O
d,852,O
),852,O
a,852,O
combination,852,O
of,852,O
these,852,O
factors,852,O
.,852,O
To,853,O
achieve,853,O
clinical,853,O
efficacy,853,O
with,853,O
single,853,O
doses,853,O
of,853,O
PBZ,853,B-CHEMICAL
in,853,O
calves,853,O
",",853,O
higher,853,O
dosages,853,O
than,853,O
4.4,853,O
mg/kg,853,O
will,853,O
be,853,O
probably,853,O
required,853,O
.,853,O
Practical,854,O
asymmetric,854,O
synthesis,854,O
of,854,O
aprepitant,854,B-CHEMICAL
",",854,O
a,854,O
potent,854,O
human,854,O
NK-1,854,B-GENE-Y
receptor,854,I-GENE-Y
antagonist,854,O
",",854,O
via,854,O
a,854,O
stereoselective,854,O
Lewis,854,O
acid-catalyzed,854,O
trans,854,O
acetalization,854,O
reaction,854,O
.,854,O
A,855,O
streamlined,855,O
and,855,O
high-yielding,855,O
synthesis,855,O
of,855,O
aprepitant,855,B-CHEMICAL
(,855,O
1,855,O
),855,O
",",855,O
a,855,O
potent,855,O
substance,855,B-CHEMICAL
P,855,I-CHEMICAL
(,855,I-GENE-Y
SP,855,B-CHEMICAL
),855,I-GENE-Y
receptor,855,I-GENE-Y
antagonist,855,O
",",855,O
is,855,O
described,855,O
.,855,O
The,856,O
enantiopure,856,O
oxazinone,856,B-CHEMICAL
16,856,O
starting,856,O
material,856,O
was,856,O
synthesized,856,O
via,856,O
a,856,O
novel,856,O
crystallization-induced,856,O
dynamic,856,O
resolution,856,O
process,856,O
.,856,O
Conversion,857,O
of,857,O
16,857,O
to,857,O
the,857,O
penultimate,857,O
intermediate,857,O
cis-sec-amine,857,B-CHEMICAL
9,857,O
features,857,O
a,857,O
highly,857,O
stereoselective,857,O
Lewis,857,O
acid-catalyzed,857,O
trans,857,O
acetalization,857,O
of,857,O
chiral,857,B-CHEMICAL
alcohol,857,I-CHEMICAL
3,857,O
with,857,O
trichloroacetimidate,857,B-CHEMICAL
18,857,O
followed,857,O
by,857,O
inversion,857,O
of,857,O
the,857,O
adjacent,857,O
chiral,857,O
center,857,O
on,857,O
the,857,O
morpholine,857,B-CHEMICAL
ring,857,O
.,857,O
The,858,O
six-step,858,O
process,858,O
for,858,O
the,858,O
synthesis,858,O
of,858,O
9,858,O
was,858,O
accomplished,858,O
in,858,O
extremely,858,O
high,858,O
overall,858,O
yield,858,O
(,858,O
81,858,O
%,858,O
),858,O
and,858,O
with,858,O
only,858,O
two,858,O
isolations,858,O
.,858,O
Signaling,859,O
through,859,O
Gi,859,B-GENE-N
family,859,O
members,859,O
in,859,O
platelets,859,O
.,859,O
Redundancy,860,O
and,860,O
specificity,860,O
in,860,O
the,860,O
regulation,860,O
of,860,O
adenylyl,860,B-GENE-N
cyclase,860,I-GENE-N
and,860,O
other,860,O
effectors,860,O
.,860,O
Platelet,861,O
responses,861,O
at,861,O
sites,861,O
of,861,O
vascular,861,O
injury,861,O
are,861,O
regulated,861,O
by,861,O
intracellular,861,O
cAMP,861,B-CHEMICAL
levels,861,O
",",861,O
which,861,O
rise,861,O
rapidly,861,O
when,861,O
prostacyclin,861,B-CHEMICAL
(,861,O
PGI,861,B-CHEMICAL
(,861,I-CHEMICAL
2,861,I-CHEMICAL
),861,I-CHEMICAL
),861,O
is,861,O
released,861,O
from,861,O
endothelial,861,O
cells,861,O
.,861,O
Platelet,862,O
agonists,862,O
such,862,O
as,862,O
ADP,862,B-CHEMICAL
and,862,O
epinephrine,862,O
suppress,862,O
PGI,862,B-CHEMICAL
(,862,I-CHEMICAL
2,862,I-CHEMICAL
),862,I-CHEMICAL
-stimulated,862,O
cAMP,862,B-CHEMICAL
formation,862,O
by,862,O
activating,862,O
receptors,862,O
coupled,862,O
to,862,O
G,862,B-GENE-N
(,862,I-GENE-N
i,862,I-GENE-N
),862,I-GENE-N
family,862,O
members,862,O
",",862,O
four,862,O
of,862,O
which,862,O
are,862,O
present,862,O
in,862,O
platelets,862,O
.,862,O
To,863,O
address,863,O
questions,863,O
about,863,O
the,863,O
specificity,863,O
of,863,O
receptor,863,O
:,863,O
G,863,B-GENE-N
protein,863,I-GENE-N
coupling,863,O
",",863,O
the,863,O
regulation,863,O
of,863,O
cAMP,863,B-CHEMICAL
formation,863,O
in,863,O
vivo,863,O
and,863,O
the,863,O
contribution,863,O
of,863,O
G,863,B-GENE-N
(,863,I-GENE-N
i,863,I-GENE-N
),863,I-GENE-N
-mediated,863,O
pathways,863,O
that,863,O
do,863,O
not,863,O
involve,863,O
adenylyl,863,B-GENE-N
cyclase,863,I-GENE-N
",",863,O
we,863,O
studied,863,O
platelets,863,O
from,863,O
mice,863,O
that,863,O
lacked,863,O
the,863,O
alpha,863,O
subunits,863,O
of,863,O
one,863,O
or,863,O
more,863,O
of,863,O
the,863,O
three,863,O
most,863,O
abundantly,863,O
expressed,863,O
G,863,B-GENE-N
(,863,I-GENE-N
i,863,I-GENE-N
),863,I-GENE-N
family,863,O
members,863,O
and,863,O
compared,863,O
the,863,O
results,863,O
with,863,O
platelets,863,O
from,863,O
mice,863,O
that,863,O
lacked,863,O
the,863,O
PGI,863,B-GENE-Y
(,863,I-GENE-Y
2,863,I-GENE-Y
),863,I-GENE-Y
receptor,863,I-GENE-Y
",",863,O
IP,863,B-GENE-Y
.,863,O
As,864,O
reported,864,O
previously,864,O
",",864,O
loss,864,O
of,864,O
G,864,B-GENE-Y
(,864,I-GENE-Y
i2,864,I-GENE-Y
),864,I-GENE-Y
alpha,864,I-GENE-Y
or,864,O
G,864,B-GENE-Y
(,864,I-GENE-Y
z,864,I-GENE-Y
),864,I-GENE-Y
alpha,864,I-GENE-Y
inhibited,864,O
aggregation,864,O
in,864,O
response,864,O
to,864,O
ADP,864,B-CHEMICAL
and,864,O
epinephrine,864,B-CHEMICAL
",",864,O
respectively,864,O
",",864,O
producing,864,O
defects,864,O
that,864,O
could,864,O
not,864,O
be,864,O
reversed,864,O
by,864,O
adding,864,O
an,864,O
adenylyl,864,B-GENE-N
cyclase,864,I-GENE-N
inhibitor,864,O
.,864,O
Platelets,865,O
that,865,O
lacked,865,O
both,865,O
G,865,B-GENE-Y
(,865,I-GENE-Y
i2,865,I-GENE-Y
),865,I-GENE-Y
alpha,865,I-GENE-Y
and,865,O
G,865,B-GENE-Y
(,865,I-GENE-Y
z,865,I-GENE-Y
),865,I-GENE-Y
alpha,865,I-GENE-Y
showed,865,O
impaired,865,O
responses,865,O
to,865,O
both,865,O
agonists,865,O
",",865,O
but,865,O
the,865,O
impairment,865,O
was,865,O
no,865,O
greater,865,O
than,865,O
in,865,O
the,865,O
individual,865,O
knockouts,865,O
.,865,O
Loss,866,O
of,866,O
G,866,B-GENE-Y
(,866,I-GENE-Y
i3,866,I-GENE-Y
),866,I-GENE-Y
alpha,866,I-GENE-Y
had,866,O
no,866,O
effect,866,O
either,866,O
alone,866,O
or,866,O
in,866,O
combination,866,O
with,866,O
G,866,B-GENE-Y
(,866,I-GENE-Y
z,866,I-GENE-Y
),866,I-GENE-Y
alpha,866,I-GENE-Y
.,866,O
Loss,867,O
of,867,O
either,867,O
G,867,B-GENE-Y
(,867,I-GENE-Y
z,867,I-GENE-Y
),867,I-GENE-Y
alpha,867,I-GENE-Y
or,867,O
G,867,B-GENE-Y
(,867,I-GENE-Y
i2,867,I-GENE-Y
),867,I-GENE-Y
alpha,867,I-GENE-Y
impaired,867,O
the,867,O
ability,867,O
of,867,O
ADP,867,B-CHEMICAL
and,867,O
epinephrine,867,B-CHEMICAL
to,867,O
inhibit,867,O
PGI,867,B-CHEMICAL
(,867,I-CHEMICAL
2,867,I-CHEMICAL
),867,I-CHEMICAL
-stimulated,867,O
adenylyl,867,B-CHEMICAL
cyclase,867,I-GENE-N
activity,867,O
and,867,O
caused,867,O
a,867,O
40,867,O
%,867,O
-50,867,O
%,867,O
rise,867,O
in,867,O
basal,867,O
cAMP,867,B-CHEMICAL
levels,867,O
",",867,O
whereas,867,O
loss,867,O
of,867,O
G,867,B-GENE-Y
(,867,I-GENE-Y
i3,867,I-GENE-Y
),867,I-GENE-Y
alpha,867,I-GENE-Y
did,867,O
not,867,O
.,867,O
Conversely,868,O
",",868,O
deletion,868,O
of,868,O
IP,868,B-GENE-Y
abolished,868,O
responses,868,O
to,868,O
PGI,868,B-CHEMICAL
(,868,I-CHEMICAL
2,868,I-CHEMICAL
),868,I-CHEMICAL
and,868,O
caused,868,O
cAMP,868,B-CHEMICAL
levels,868,O
to,868,O
fall,868,O
by,868,O
30,868,O
%,868,O
",",868,O
effects,868,O
that,868,O
did,868,O
not,868,O
translate,868,O
into,868,O
enhanced,868,O
responsiveness,868,O
to,868,O
agonists,868,O
ex,868,O
vivo,868,O
.,868,O
From,869,O
these,869,O
results,869,O
we,869,O
conclude,869,O
that,869,O
1,869,O
),869,O
cAMP,869,B-CHEMICAL
levels,869,O
in,869,O
circulating,869,O
platelets,869,O
reflect,869,O
ongoing,869,O
signaling,869,O
through,869,O
G,869,B-GENE-N
(,869,I-GENE-N
i2,869,I-GENE-N
),869,I-GENE-N
",",869,O
G,869,B-GENE-N
(,869,I-GENE-N
z,869,I-GENE-N
),869,I-GENE-N
",",869,O
and,869,O
IP,869,B-GENE-Y
",",869,O
but,869,O
not,869,O
G,869,B-GENE-N
(,869,I-GENE-N
i3,869,I-GENE-N
),869,I-GENE-N
;,869,O
2,869,O
),869,O
platelet,869,O
epinephrine,869,B-CHEMICAL
(,869,B-GENE-Y
alpha,869,I-GENE-Y
(,869,I-GENE-Y
2A,869,I-GENE-Y
),869,I-GENE-Y
-adrenergic,869,I-GENE-Y
),869,O
and,869,O
ADP,869,B-CHEMICAL
(,869,O
P2Y12,869,B-GENE-Y
),869,O
receptors,869,O
display,869,O
strong,869,O
preferences,869,O
among,869,O
G,869,B-GENE-N
(,869,I-GENE-N
i,869,I-GENE-N
),869,I-GENE-N
family,869,O
members,869,O
with,869,O
little,869,O
evidence,869,O
of,869,O
redundancy,869,O
;,869,O
and,869,O
3,869,O
),869,O
these,869,O
receptor,869,O
preferences,869,O
do,869,O
not,869,O
extend,869,O
to,869,O
G,869,B-GENE-N
(,869,I-GENE-N
i3,869,I-GENE-N
),869,I-GENE-N
.,869,O
Finally,870,O
",",870,O
the,870,O
failure,870,O
of,870,O
ADP,870,B-CHEMICAL
and,870,O
epinephrine,870,B-CHEMICAL
to,870,O
inhibit,870,O
basal,870,O
",",870,O
as,870,O
opposed,870,O
to,870,O
PGI,870,B-CHEMICAL
(,870,I-CHEMICAL
2,870,I-CHEMICAL
),870,I-CHEMICAL
-stimulated,870,O
",",870,O
cAMP,870,B-CHEMICAL
formation,870,O
highlights,870,O
the,870,O
need,870,O
during,870,O
platelet,870,O
activation,870,O
for,870,O
G,870,B-GENE-N
(,870,I-GENE-N
i,870,I-GENE-N
),870,I-GENE-N
signaling,870,O
pathways,870,O
that,870,O
involve,870,O
effectors,870,O
other,870,O
than,870,O
adenylyl,870,B-GENE-N
cyclase,870,I-GENE-N
.,870,O
Effects,871,O
of,871,O
pentosan,871,O
polysulfate,871,O
sodium,871,B-CHEMICAL
on,871,O
the,871,O
estrogen-induced,871,B-CHEMICAL
pituitary,871,O
prolactinoma,871,O
in,871,O
Fischer,871,O
344,871,O
rats,871,O
.,871,O
The,872,O
development,872,O
of,872,O
estrogen-induced,872,B-CHEMICAL
pituitary,872,O
prolactinoma,872,O
in,872,O
Fischer,872,O
344,872,O
(,872,O
F344,872,O
),872,O
rats,872,O
is,872,O
associated,872,O
with,872,O
enhanced,872,O
neovascularization,872,O
.,872,O
This,873,O
type,873,O
of,873,O
tumor,873,O
is,873,O
a,873,O
rich,873,O
source,873,O
of,873,O
basic,873,B-GENE-Y
fibroblast,873,I-GENE-Y
growth,873,I-GENE-Y
factor,873,I-GENE-Y
(,873,O
bFGF,873,B-GENE-Y
),873,O
",",873,O
which,873,O
possesses,873,O
strong,873,O
mitogenic,873,O
and,873,O
angiogenic,873,O
properties,873,O
.,873,O
Pentosan,874,O
polysulfate,874,O
sodium,874,B-CHEMICAL
(,874,O
PPS,874,O
),874,O
has,874,O
been,874,O
shown,874,O
to,874,O
exert,874,O
antitumor,874,O
activity,874,O
by,874,O
antagonizing,874,O
the,874,O
binding,874,O
of,874,O
bFGF,874,B-GENE-Y
to,874,O
cell,874,O
surface,874,O
receptors,874,O
.,874,O
We,875,O
have,875,O
examined,875,O
the,875,O
effects,875,O
of,875,O
pentosan,875,O
on,875,O
tumor,875,O
growth,875,O
",",875,O
hyperprolactinemia,875,O
and,875,O
angiogenesis,875,O
in,875,O
diethylstilbestrol-induced,875,B-CHEMICAL
anterior,875,O
pituitary,875,O
adenoma,875,O
in,875,O
F344,875,O
rats,875,O
.,875,O
Chronic,876,O
treatment,876,O
with,876,O
PPS,876,O
did,876,O
not,876,O
cause,876,O
any,876,O
changes,876,O
in,876,O
the,876,O
pituitary,876,O
weight,876,O
and,876,O
serum,876,O
prolactin,876,O
concentration,876,O
in,876,O
comparison,876,O
with,876,O
untreated,876,O
animals,876,O
.,876,O
The,877,O
density,877,O
of,877,O
microvessels,877,O
identified,877,O
by,877,O
CD-31,877,O
was,877,O
also,877,O
not,877,O
affected,877,O
by,877,O
the,877,O
tested,877,O
drug,877,O
.,877,O
On,878,O
the,878,O
other,878,O
hand,878,O
",",878,O
pentosan,878,O
has,878,O
been,878,O
found,878,O
to,878,O
decrease,878,O
cell,878,O
proliferation,878,O
evaluated,878,O
by,878,O
a,878,O
number,878,O
of,878,O
PCNA-positive,878,O
stained,878,O
cell,878,O
nuclei,878,O
.,878,O
Moreover,879,O
",",879,O
the,879,O
TUNEL,879,O
method,879,O
has,879,O
revealed,879,O
an,879,O
increased,879,O
number,879,O
of,879,O
apoptotic,879,O
bodies,879,O
within,879,O
the,879,O
anterior,879,O
pituitary,879,O
after,879,O
treatment,879,O
with,879,O
PPS,879,O
.,879,O
Despite,880,O
the,880,O
antiproliferative,880,O
and,880,O
proapoptotic,880,O
activity,880,O
of,880,O
pentosan,880,O
",",880,O
the,880,O
drug,880,O
failed,880,O
to,880,O
inhibit,880,O
tumor,880,O
growth,880,O
.,880,O
This,881,O
fact,881,O
might,881,O
be,881,O
due,881,O
to,881,O
the,881,O
lack,881,O
of,881,O
antiangiogenic,881,O
activity,881,O
of,881,O
PPS,881,O
in,881,O
this,881,O
experimental,881,O
design,881,O
.,881,O
Localization,882,O
of,882,O
the,882,O
ammonium,882,B-CHEMICAL
transporter,882,I-GENE-N
proteins,882,I-GENE-N
RhBG,882,B-GENE-Y
and,882,O
RhCG,882,B-GENE-Y
in,882,O
mouse,882,O
kidney,882,O
.,882,O
Ammonia,883,B-CHEMICAL
is,883,O
both,883,O
produced,883,O
and,883,O
transported,883,O
by,883,O
renal,883,O
epithelial,883,O
cells,883,O
",",883,O
and,883,O
it,883,O
regulates,883,O
renal,883,O
ion,883,O
transport,883,O
.,883,O
Recent,884,O
studies,884,O
have,884,O
identified,884,O
a,884,O
family,884,O
of,884,O
putative,884,O
ammonium,884,B-CHEMICAL
transporters,884,I-GENE-N
;,884,O
mRNA,884,O
for,884,O
two,884,O
members,884,O
of,884,O
this,884,O
family,884,O
",",884,O
Rh,884,B-GENE-Y
B-glycoprotein,884,I-GENE-Y
(,884,O
RhBG,884,B-GENE-Y
),884,O
and,884,O
Rh,884,B-GENE-Y
C-glycoprotein,884,I-GENE-Y
(,884,O
RhCG,884,B-GENE-Y
),884,O
",",884,O
is,884,O
expressed,884,O
in,884,O
the,884,O
kidney,884,O
.,884,O
The,885,O
purpose,885,O
of,885,O
this,885,O
study,885,O
was,885,O
to,885,O
determine,885,O
the,885,O
cellular,885,O
location,885,O
of,885,O
RhBG,885,B-GENE-Y
and,885,O
RhCG,885,B-GENE-Y
protein,885,O
in,885,O
the,885,O
mouse,885,O
kidney,885,O
.,885,O
We,886,O
generated,886,O
RhBG-,886,B-GENE-Y
and,886,O
RhCG-specific,886,B-GENE-Y
anti-peptide,886,O
antibodies,886,O
.,886,O
Immunoblot,887,O
analysis,887,O
confirmed,887,O
that,887,O
both,887,O
proteins,887,O
were,887,O
expressed,887,O
in,887,O
the,887,O
mouse,887,O
kidney,887,O
.,887,O
RhBG,888,B-GENE-Y
localization,888,O
with,888,O
immunohistochemistry,888,O
revealed,888,O
discrete,888,O
basolateral,888,O
labeling,888,O
in,888,O
the,888,O
connecting,888,O
segment,888,O
(,888,O
CNT,888,O
),888,O
and,888,O
in,888,O
the,888,O
majority,888,O
of,888,O
initial,888,O
collecting,888,O
tubule,888,O
(,888,O
ICT,888,O
),888,O
and,888,O
cortical,888,O
collecting,888,O
duct,888,O
(,888,O
CCD,888,O
),888,O
cells,888,O
.,888,O
In,889,O
the,889,O
outer,889,O
medullary,889,O
collecting,889,O
duct,889,O
(,889,O
OMCD,889,O
),889,O
and,889,O
inner,889,O
medullary,889,O
collecting,889,O
duct,889,O
(,889,O
IMCD,889,O
),889,O
only,889,O
a,889,O
subpopulation,889,O
of,889,O
cells,889,O
exhibited,889,O
basolateral,889,O
immunoreactivity,889,O
.,889,O
Colocalization,890,O
of,890,O
RhBG,890,B-GENE-Y
with,890,O
carbonic,890,B-GENE-Y
anhydrase,890,I-GENE-Y
II,890,I-GENE-Y
",",890,O
the,890,O
thiazide-sensitive,890,B-CHEMICAL
transporter,890,O
",",890,O
and,890,O
the,890,O
anion,890,B-GENE-N
exchangers,890,I-GENE-N
AE1,890,B-GENE-Y
and,890,O
pendrin,890,B-GENE-Y
demonstrated,890,O
RhBG,890,B-GENE-Y
immunoreactivity,890,O
in,890,O
all,890,O
CNT,890,O
cells,890,O
and,890,O
all,890,O
CCD,890,O
and,890,O
ICT,890,O
principal,890,O
cells,890,O
.,890,O
In,891,O
the,891,O
ICT,891,O
and,891,O
CCD,891,O
",",891,O
basolateral,891,O
RhBG,891,B-GENE-Y
immunoreactivity,891,O
is,891,O
also,891,O
present,891,O
in,891,O
A-type,891,O
intercalated,891,O
cells,891,O
but,891,O
not,891,O
in,891,O
pendrin-positive,891,B-GENE-Y
CCD,891,O
intercalated,891,O
cells,891,O
.,891,O
In,892,O
the,892,O
OMCD,892,O
and,892,O
IMCD,892,O
",",892,O
only,892,O
intercalated,892,O
cells,892,O
exhibit,892,O
RhBG,892,B-GENE-Y
immunoreactivity,892,O
.,892,O
Immunoreactivity,893,O
for,893,O
a,893,O
second,893,O
putative,893,O
ammonium,893,B-CHEMICAL
transporter,893,I-GENE-N
",",893,O
RhCG,893,B-GENE-Y
",",893,O
was,893,O
present,893,O
in,893,O
the,893,O
apical,893,O
region,893,O
of,893,O
cells,893,O
with,893,O
almost,893,O
the,893,O
same,893,O
distribution,893,O
as,893,O
RhBG,893,B-GENE-Y
.,893,O
However,894,O
",",894,O
RhCG,894,B-GENE-Y
immunoreactivity,894,O
was,894,O
present,894,O
in,894,O
all,894,O
CCD,894,O
cells,894,O
",",894,O
and,894,O
it,894,O
was,894,O
present,894,O
in,894,O
outer,894,O
stripe,894,O
OMCD,894,O
principal,894,O
cells,894,O
",",894,O
in,894,O
addition,894,O
to,894,O
OMCD,894,O
and,894,O
IMCD,894,O
intercalated,894,O
cells,894,O
.,894,O
Thus,895,O
the,895,O
majority,895,O
of,895,O
RhBG,895,B-GENE-Y
and,895,O
RhCG,895,B-GENE-Y
protein,895,O
expression,895,O
is,895,O
present,895,O
in,895,O
the,895,O
same,895,O
epithelial,895,O
cell,895,O
types,895,O
in,895,O
the,895,O
CNT,895,O
and,895,O
collecting,895,O
duct,895,O
but,895,O
with,895,O
opposite,895,O
polarity,895,O
.,895,O
These,896,O
findings,896,O
suggest,896,O
that,896,O
RhBG,896,B-GENE-Y
and,896,O
RhCG,896,B-GENE-Y
may,896,O
play,896,O
important,896,O
and,896,O
cell-specific,896,O
roles,896,O
in,896,O
ammonium,896,B-CHEMICAL
transport,896,O
and,896,O
signaling,896,O
in,896,O
these,896,O
regions,896,O
of,896,O
the,896,O
kidney,896,O
.,896,O
Phosphodiesterase,897,B-GENE-Y
type,897,I-GENE-Y
5,897,I-GENE-Y
as,897,O
a,897,O
pharmacologic,897,O
target,897,O
in,897,O
erectile,897,O
dysfunction,897,O
.,897,O
The,898,O
scientific,898,O
rationale,898,O
of,898,O
pharmacologically,898,O
inhibiting,898,O
phosphodiesterase,898,B-GENE-Y
type,898,I-GENE-Y
5,898,I-GENE-Y
(,898,O
PDE5,898,B-GENE-Y
),898,O
in,898,O
the,898,O
treatment,898,O
of,898,O
erectile,898,O
dysfunction,898,O
(,898,O
ED,898,O
),898,O
is,898,O
reviewed,898,O
.,898,O
Published,899,O
literature,899,O
on,899,O
the,899,O
nitric,899,B-CHEMICAL
oxide-cyclic,899,O
guanosine,899,I-CHEMICAL
monophosphate,899,I-CHEMICAL
(,899,O
cGMP,899,B-CHEMICAL
),899,O
pathway,899,O
for,899,O
penile,899,O
erection,899,O
and,899,O
on,899,O
PDE5,899,B-GENE-Y
inhibition,899,O
using,899,O
sildenafil,899,O
as,899,O
the,899,O
model,899,O
for,899,O
pharmacologic,899,O
PDE5,899,B-GENE-Y
inhibition,899,O
are,899,O
assessed,899,O
.,899,O
The,900,O
key,900,O
second,900,O
messenger,900,O
in,900,O
the,900,O
mediation,900,O
of,900,O
penile,900,O
erection,900,O
is,900,O
cGMP,900,O
.,900,O
PDE5,901,B-GENE-Y
is,901,O
the,901,O
predominant,901,O
PDE,901,B-GENE-N
in,901,O
the,901,O
corpus,901,O
cavernosum,901,O
",",901,O
and,901,O
cGMP,901,B-CHEMICAL
is,901,O
its,901,O
primary,901,O
substrate,901,O
.,901,O
Therefore,902,O
",",902,O
in,902,O
men,902,O
with,902,O
ED,902,O
",",902,O
elevation,902,O
of,902,O
cGMP,902,B-CHEMICAL
in,902,O
corpus,902,O
cavernosal,902,O
tissue,902,O
via,902,O
selective,902,O
inhibition,902,O
of,902,O
cGMP-specific,902,B-CHEMICAL
PDE5,902,B-GENE-Y
is,902,O
a,902,O
means,902,O
of,902,O
improving,902,O
erectile,902,O
function,902,O
at,902,O
minimal,902,O
risk,902,O
of,902,O
adverse,902,O
events,902,O
.,902,O
This,903,O
approach,903,O
is,903,O
validated,903,O
by,903,O
the,903,O
clinical,903,O
efficacy,903,O
and,903,O
safety,903,O
of,903,O
sildenafil,903,B-CHEMICAL
",",903,O
the,903,O
pioneering,903,O
drug,903,O
for,903,O
selective,903,O
PDE5,903,B-GENE-Y
inhibitor,903,O
therapy,903,O
for,903,O
ED,903,O
.,903,O
Sildenafil,904,B-CHEMICAL
exhibits,904,O
inhibitory,904,O
potency,904,O
against,904,O
PDE5,904,B-GENE-Y
and,904,O
a,904,O
10-fold,904,O
lower,904,O
dose-related,904,O
inhibitory,904,O
potency,904,O
against,904,O
rod,904,O
outer,904,O
segment,904,O
PDE6,904,B-GENE-N
",",904,O
the,904,O
predominant,904,O
PDE,904,B-GENE-N
in,904,O
the,904,O
phototransduction,904,O
cascade,904,O
in,904,O
rods,904,O
.,904,O
Thus,905,O
",",905,O
its,905,O
pharmacologic,905,O
profile,905,O
is,905,O
predictable,905,O
",",905,O
with,905,O
close,905,O
correlation,905,O
between,905,O
pharmacodynamic,905,O
and,905,O
pharmacokinetic,905,O
properties,905,O
.,905,O
Clinically,906,O
",",906,O
sildenafil,906,B-CHEMICAL
improves,906,O
erectile,906,O
function,906,O
in,906,O
a,906,O
large,906,O
percentage,906,O
of,906,O
men,906,O
with,906,O
ED,906,O
.,906,O
The,907,O
most,907,O
common,907,O
adverse,907,O
events,907,O
are,907,O
due,907,O
to,907,O
PDE5,907,B-GENE-Y
inhibition,907,O
in,907,O
vascular,907,O
and,907,O
visceral,907,O
smooth,907,O
muscle,907,O
;,907,O
similar,907,O
adverse,907,O
events,907,O
are,907,O
expected,907,O
during,907,O
therapeutic,907,O
use,907,O
of,907,O
all,907,O
PDE5,907,B-GENE-Y
inhibitors,907,O
.,907,O
As,908,O
free,908,O
sildenafil,908,B-CHEMICAL
plasma,908,O
concentrations,908,O
approach,908,O
concentrations,908,O
sufficient,908,O
to,908,O
inhibit,908,O
retinal,908,O
PDE6,908,B-GENE-N
",",908,O
usually,908,O
at,908,O
higher,908,O
therapeutic,908,O
doses,908,O
",",908,O
transient,908,O
",",908,O
reversible,908,O
visual,908,O
adverse,908,O
events,908,O
can,908,O
occur,908,O
",",908,O
albeit,908,O
infrequently,908,O
.,908,O
Selective,909,O
inhibition,909,O
of,909,O
PDE5,909,B-GENE-Y
is,909,O
a,909,O
rational,909,O
therapeutic,909,O
approach,909,O
in,909,O
ED,909,O
",",909,O
as,909,O
proved,909,O
by,909,O
the,909,O
clinical,909,O
success,909,O
of,909,O
sildenafil,909,B-CHEMICAL
.,909,O
Study,910,O
of,910,O
the,910,O
nematode,910,O
putative,910,O
GABA,910,B-GENE-N
type-A,910,I-GENE-N
receptor,910,I-GENE-N
subunits,910,O
:,910,O
evidence,910,O
for,910,O
modulation,910,O
by,910,O
ivermectin,910,B-CHEMICAL
.,910,O
Two,911,O
alleles,911,O
of,911,O
the,911,O
HG1,911,B-GENE-Y
gene,911,O
",",911,O
which,911,O
encodes,911,O
a,911,O
putative,911,O
GABA,911,B-GENE-N
receptor,911,I-GENE-N
alpha/gamma,911,I-GENE-N
subunit,911,O
",",911,O
were,911,O
isolated,911,O
from,911,O
Haemonchus,911,O
contortus,911,O
.,911,O
These,912,O
two,912,O
alleles,912,O
were,912,O
shown,912,O
previously,912,O
to,912,O
be,912,O
associated,912,O
with,912,O
ivermectin,912,B-CHEMICAL
susceptibility,912,O
(,912,O
HG1A,912,B-GENE-Y
),912,O
and,912,O
resistance,912,O
(,912,O
HG1E,912,B-GENE-Y
),912,O
",",912,O
respectively,912,O
.,912,O
Sequence,913,O
analysis,913,O
indicates,913,O
that,913,O
they,913,O
differ,913,O
in,913,O
four,913,O
amino,913,B-CHEMICAL
acids,913,I-CHEMICAL
.,913,O
To,914,O
explore,914,O
the,914,O
functional,914,O
properties,914,O
of,914,O
the,914,O
two,914,O
alleles,914,O
",",914,O
a,914,O
full-length,914,O
cDNA,914,O
encoding,914,O
the,914,O
beta,914,O
subunit,914,O
",",914,O
a,914,O
key,914,O
functional,914,O
component,914,O
of,914,O
the,914,O
GABA,914,B-GENE-N
receptor,914,I-GENE-N
",",914,O
was,914,O
isolated,914,O
from,914,O
Caenorhabditis,914,O
elegans,914,O
(,914,O
gab-1,914,B-GENE-Y
",",914,O
corresponding,914,O
to,914,O
the,914,O
GenBank,914,B-GENE-Y
locus,914,I-GENE-Y
ZC482.1,914,I-GENE-Y
),914,O
and,914,O
coexpressed,914,O
in,914,O
Xenopus,914,O
oocytes,914,O
with,914,O
the,914,O
HG1,914,B-GENE-Y
alleles,914,O
.,914,O
When,915,O
gab-1,915,B-GENE-Y
was,915,O
coexpressed,915,O
with,915,O
either,915,O
the,915,O
HG1A,915,B-GENE-Y
allele,915,O
or,915,O
the,915,O
HG1E,915,B-GENE-Y
allele,915,O
in,915,O
Xenopus,915,O
oocytes,915,O
",",915,O
gamma-aminobutyric,915,B-GENE-N
acid,915,I-GENE-N
(,915,I-GENE-N
GABA,915,I-GENE-N
),915,I-GENE-N
-responsive,915,I-GENE-N
channels,915,I-GENE-N
with,915,O
different,915,O
sensitivity,915,O
to,915,O
the,915,O
agonist,915,O
were,915,O
formed,915,O
.,915,O
The,916,O
effects,916,O
of,916,O
ivermectin,916,B-CHEMICAL
on,916,O
the,916,O
hetero-oligomeric,916,O
receptors,916,O
were,916,O
determined,916,O
.,916,O
Application,917,O
of,917,O
ivermectin,917,B-CHEMICAL
alone,917,O
had,917,O
no,917,O
effect,917,O
on,917,O
the,917,O
receptors,917,O
.,917,O
However,918,O
",",918,O
when,918,O
coapplied,918,O
with,918,O
10,918,O
micro,918,O
m,918,O
GABA,918,B-CHEMICAL
",",918,O
ivermectin,918,B-CHEMICAL
potentiated,918,O
the,918,O
GABA-evoked,918,B-CHEMICAL
current,918,O
of,918,O
the,918,O
GAB-1/HG1A,918,B-GENE-Y
receptor,918,O
",",918,O
but,918,O
attenuated,918,O
the,918,O
GABA,918,B-CHEMICAL
response,918,O
of,918,O
the,918,O
GAB-1/HG1E,918,B-GENE-Y
receptor,918,O
.,918,O
We,919,O
demonstrated,919,O
that,919,O
the,919,O
coexpressed,919,O
HG1,919,B-GENE-Y
and,919,O
GAB-1,919,B-GENE-Y
receptors,919,O
are,919,O
GABA-responsive,919,B-CHEMICAL
",",919,O
and,919,O
provide,919,O
evidence,919,O
for,919,O
the,919,O
possible,919,O
involvement,919,O
of,919,O
GABA,919,B-CHEMICAL
receptors,919,I-GENE-N
in,919,O
the,919,O
mechanism,919,O
of,919,O
ivermectin,919,B-CHEMICAL
resistance,919,O
.,919,O
Yohimbine,920,B-CHEMICAL
dimers,920,O
exhibiting,920,O
selectivity,920,O
for,920,O
the,920,O
human,920,B-GENE-Y
alpha,920,I-GENE-Y
2C-adrenoceptor,920,I-GENE-Y
subtype,920,O
.,920,O
Yohimbine,921,B-CHEMICAL
is,921,O
a,921,O
potent,921,O
and,921,O
selective,921,O
alpha2-,921,B-GENE-N
versus,921,I-GENE-N
alpha1-adrenoceptor,921,I-GENE-N
antagonist,921,O
.,921,O
To,922,O
date,922,O
",",922,O
drugs,922,O
with,922,O
high,922,O
specificity,922,O
for,922,O
the,922,O
alpha2-adrenoceptor,922,B-GENE-N
show,922,O
marginal,922,O
selectivity,922,O
among,922,O
the,922,O
three,922,O
alpha2-adrenoceptor,922,B-GENE-N
subtypes,922,O
.,922,O
Initial,923,O
studies,923,O
showed,923,O
that,923,O
yohimbine,923,B-CHEMICAL
was,923,O
about,923,O
4-,923,O
and,923,O
15-fold,923,O
more,923,O
selective,923,O
for,923,O
the,923,O
human,923,B-GENE-Y
alpha2C-adrenoceptor,923,I-GENE-Y
in,923,O
comparison,923,O
with,923,O
the,923,O
alpha2A-,923,B-GENE-N
and,923,I-GENE-N
alpha2B-adrenoceptors,923,I-GENE-N
",",923,O
respectively,923,O
.,923,O
To,924,O
improve,924,O
on,924,O
this,924,O
alpha2-adrenoceptor,924,B-GENE-N
subtype,924,O
selectivity,924,O
",",924,O
a,924,O
series,924,O
of,924,O
yohimbine,924,B-CHEMICAL
dimers,924,O
(,924,O
varying,924,O
from,924,O
n,924,O
=,924,O
2,924,O
to,924,O
24,924,O
spacer,924,O
atoms,924,O
),924,O
were,924,O
prepared,924,O
and,924,O
evaluated,924,O
for,924,O
receptor,924,O
binding,924,O
on,924,O
human,924,B-GENE-N
alpha2-adrenoceptor,924,I-GENE-N
subtypes,924,O
expressed,924,O
in,924,O
Chinese,924,O
hamster,924,O
ovary,924,O
cells,924,O
.,924,O
Each,925,O
dimeric,925,O
analog,925,O
showed,925,O
higher,925,O
affinities,925,O
for,925,O
alpha2A-,925,B-GENE-N
and,925,I-GENE-N
alpha2C-adrenoceptor,925,I-GENE-N
versus,925,O
the,925,O
alpha2B-adrenoceptor,925,B-GENE-Y
;,925,O
and,925,O
yohimbine,925,B-CHEMICAL
dimers,925,O
with,925,O
spacers,925,O
of,925,O
n,925,O
=,925,O
2,925,O
",",925,O
3,925,O
",",925,O
4,925,O
",",925,O
18,925,O
",",925,O
and,925,O
24,925,O
exhibited,925,O
selectivity,925,O
for,925,O
the,925,O
alpha2C-adrenoceptor,925,B-GENE-Y
.,925,O
The,926,O
yohimbine,926,B-CHEMICAL
dimers,926,O
n,926,O
=,926,O
3,926,O
and,926,O
n,926,O
=,926,O
24,926,O
showed,926,O
the,926,O
highest,926,O
potency,926,O
and,926,O
selectivity,926,O
(,926,O
32-,926,O
and,926,O
82-fold,926,O
.,926,O
respectively,927,O
),927,O
for,927,O
the,927,O
alpha2C-adrenoceptor,927,B-GENE-Y
in,927,O
receptor,927,O
binding,927,O
and,927,O
in,927,O
functional,927,O
studies,927,O
(,927,O
42-,927,O
and,927,O
29-fold,927,O
",",927,O
respectively,927,O
),927,O
measuring,927,O
cAMP,927,B-CHEMICAL
changes,927,O
using,927,O
a,927,O
cell-based,927,O
luciferase,927,O
reporter,927,O
gene,927,O
assay,927,O
.,927,O
The,928,O
dimers,928,O
(,928,O
n,928,O
=,928,O
3,928,O
and,928,O
n,928,O
=,928,O
24,928,O
),928,O
had,928,O
high,928,O
selectivity,928,O
(,928,O
>,928,O
1000-fold,928,O
),928,O
for,928,O
the,928,O
alpha2C-adrenoceptor,928,B-GENE-Y
compared,928,O
with,928,O
the,928,O
three,928,O
alpha1-adrenoceptor,928,B-GENE-N
subtypes,928,O
.,928,O
These,929,O
findings,929,O
demonstrate,929,O
that,929,O
the,929,O
addition,929,O
of,929,O
spacer,929,O
linkages,929,O
to,929,O
bivalent,929,O
yohimbine,929,B-CHEMICAL
molecules,929,O
provides,929,O
a,929,O
successful,929,O
approach,929,O
to,929,O
the,929,O
development,929,O
of,929,O
ligands,929,O
that,929,O
are,929,O
potent,929,O
and,929,O
highly,929,O
selective,929,O
for,929,O
the,929,O
alpha2C-adrenoceptor,929,B-GENE-Y
.,929,O
Plasmacytoid,930,O
dendritic,930,O
cells,930,O
produce,930,O
cytokines,930,B-GENE-N
and,930,O
mature,930,O
in,930,O
response,930,O
to,930,O
the,930,O
TLR7,930,B-GENE-Y
agonists,930,O
",",930,O
imiquimod,930,B-CHEMICAL
and,930,O
resiquimod,930,B-CHEMICAL
.,930,O
The,931,O
immune,931,O
response,931,O
modifiers,931,O
",",931,O
imiquimod,931,B-CHEMICAL
and,931,O
resiquimod,931,B-CHEMICAL
",",931,O
are,931,O
TLR7,931,B-GENE-Y
agonists,931,O
that,931,O
induce,931,O
type,931,B-GENE-N
I,931,I-GENE-N
interferon,931,I-GENE-N
in,931,O
numerous,931,O
species,931,O
",",931,O
including,931,O
humans,931,O
.,931,O
Recently,932,O
",",932,O
it,932,O
was,932,O
shown,932,O
that,932,O
plasmacytoid,932,O
dendritic,932,O
cells,932,O
(,932,O
pDC,932,O
),932,O
are,932,O
the,932,O
primary,932,O
interferon-producing,932,B-GENE-N
cells,932,O
in,932,O
the,932,O
blood,932,O
in,932,O
response,932,O
to,932,O
viral,932,O
infections,932,O
.,932,O
Here,933,O
",",933,O
we,933,O
characterize,933,O
the,933,O
activation,933,O
of,933,O
human,933,O
pDC,933,O
with,933,O
the,933,O
TLR7,933,B-GENE-Y
agonists,933,O
imiquimod,933,B-CHEMICAL
and,933,O
resiquimod,933,B-CHEMICAL
.,933,O
Results,934,O
indicate,934,O
that,934,O
imiquimod,934,B-CHEMICAL
and,934,O
resiquimod,934,B-CHEMICAL
induce,934,O
IFN-alpha,934,B-GENE-N
and,934,O
IFN-omega,934,B-GENE-N
from,934,O
purified,934,O
pDC,934,O
",",934,O
and,934,O
pDC,934,O
are,934,O
the,934,O
principle,934,O
IFN-producing,934,B-GENE-N
cells,934,O
in,934,O
the,934,O
blood,934,O
.,934,O
Resiquimod-stimulated,935,B-CHEMICAL
pDC,935,O
also,935,O
produce,935,O
a,935,O
number,935,O
of,935,O
other,935,O
cytokines,935,B-GENE-N
including,935,O
TNF-alpha,935,B-GENE-Y
and,935,O
IP-10,935,B-GENE-Y
.,935,O
Resiquimod,936,B-CHEMICAL
enhances,936,O
co-stimulatory,936,O
marker,936,O
expression,936,O
",",936,O
CCR7,936,B-GENE-Y
expression,936,O
",",936,O
and,936,O
pDC,936,O
viability,936,O
.,936,O
Resiquimod,937,B-CHEMICAL
was,937,O
compared,937,O
throughout,937,O
the,937,O
study,937,O
to,937,O
the,937,O
pDC,937,O
survival,937,O
factors,937,O
",",937,O
IL-3,937,B-GENE-Y
and,937,O
IFN-alpha,937,B-GENE-N
;,937,O
resiquimod,937,B-CHEMICAL
more,937,O
effectively,937,O
matures,937,O
pDC,937,O
than,937,O
either,937,O
IL-3,937,B-GENE-Y
or,937,O
IFN-alpha,937,B-GENE-N
alone,937,O
.,937,O
These,938,O
results,938,O
demonstrate,938,O
that,938,O
imidazoquinoline,938,B-CHEMICAL
molecules,938,O
directly,938,O
induce,938,O
pDC,938,O
maturation,938,O
as,938,O
determined,938,O
by,938,O
cytokine,938,B-GENE-N
induction,938,O
",",938,O
CCR7,938,B-GENE-Y
and,938,O
co-stimulatory,938,O
marker,938,O
expression,938,O
and,938,O
prolonging,938,O
viability,938,O
.,938,O
Induction,939,O
of,939,O
heat,939,B-GENE-N
shock,939,I-GENE-N
proteins,939,I-GENE-N
(,939,O
HSPs,939,B-GENE-N
),939,O
by,939,O
sodium,939,B-CHEMICAL
arsenite,939,I-CHEMICAL
in,939,O
cultured,939,O
astrocytes,939,O
and,939,O
reduction,939,O
of,939,O
hydrogen,939,B-CHEMICAL
peroxide-induced,939,O
cell,939,O
death,939,O
.,939,O
Induction,940,O
of,940,O
heat,940,B-GENE-N
shock,940,I-GENE-N
proteins,940,I-GENE-N
(,940,O
HSPs,940,B-GENE-N
),940,O
protects,940,O
cells,940,O
from,940,O
oxidative,940,O
injury,940,O
.,940,O
Here,941,O
Hsp72,941,B-GENE-Y
",",941,O
Hsp27,941,B-GENE-Y
and,941,O
heme,941,B-GENE-Y
oxygenase-1,941,I-GENE-Y
(,941,O
HO-1,941,B-GENE-Y
),941,O
were,941,O
induced,941,O
in,941,O
cultured,941,O
rat,941,O
astrocytes,941,O
",",941,O
and,941,O
protection,941,O
against,941,O
oxidative,941,O
stress,941,O
was,941,O
investigated,941,O
.,941,O
Astrocytes,942,O
were,942,O
treated,942,O
with,942,O
sodium,942,B-CHEMICAL
arsenite,942,I-CHEMICAL
(,942,O
20-50,942,O
micro,942,O
m,942,O
),942,O
for,942,O
1,942,O
h,942,O
",",942,O
which,942,O
was,942,O
non-toxic,942,O
to,942,O
cells,942,O
",",942,O
24,942,O
h,942,O
later,942,O
they,942,O
were,942,O
exposed,942,O
to,942,O
400,942,O
micro,942,O
m,942,O
H2O2,942,B-CHEMICAL
for,942,O
1,942,O
h,942,O
",",942,O
and,942,O
cell,942,O
death,942,O
was,942,O
evaluated,942,O
at,942,O
different,942,O
time,942,O
points,942,O
.,942,O
Arsenite,943,B-CHEMICAL
triggered,943,O
strong,943,O
induction,943,O
of,943,O
HSPs,943,B-GENE-N
",",943,O
which,943,O
was,943,O
prevented,943,O
by,943,O
1,943,O
micro,943,O
g/mL,943,O
cycloheximide,943,B-CHEMICAL
(,943,O
CXH,943,B-CHEMICAL
),943,O
.,943,O
H2O2,944,B-CHEMICAL
caused,944,O
cell,944,O
loss,944,O
and,944,O
increased,944,O
cell,944,O
death,944,O
with,944,O
features,944,O
of,944,O
apoptosis,944,O
",",944,O
i.e,944,O
.,944,O
TdT-mediated,945,O
dUTP,945,O
nick-end,945,O
labelling,945,O
(,945,O
TUNEL,945,O
),945,O
reaction,945,O
and,945,O
caspase-3,945,B-GENE-Y
activation,945,O
.,945,O
These,946,O
features,946,O
were,946,O
abrogated,946,O
by,946,O
pre-treatment,946,O
with,946,O
arsenite,946,B-CHEMICAL
",",946,O
which,946,O
prevented,946,O
cell,946,O
loss,946,O
and,946,O
significantly,946,O
reduced,946,O
the,946,O
number,946,O
of,946,O
dead,946,O
cells,946,O
.,946,O
The,947,O
protective,947,O
effect,947,O
of,947,O
arsenite,947,B-CHEMICAL
was,947,O
not,947,O
detected,947,O
in,947,O
the,947,O
presence,947,O
of,947,O
CHX,947,B-CHEMICAL
.,947,O
Pre-treatment,948,O
with,948,O
arsenite,948,O
increased,948,O
protein,948,B-GENE-N
kinase,948,I-GENE-N
B,948,I-GENE-N
(,948,O
Akt,948,B-GENE-N
),948,O
and,948,O
extracellular,948,B-GENE-N
signal,948,I-GENE-N
regulated,948,I-GENE-N
kinase,948,I-GENE-N
1/2,948,I-GENE-N
(,948,O
ERK1/2,948,B-GENE-N
),948,O
phosphorylation,948,O
after,948,O
H2O2,948,B-CHEMICAL
.,948,O
However,949,O
",",949,O
while,949,O
Akt,949,B-GENE-N
phosphorylation,949,O
was,949,O
prevented,949,O
by,949,O
CHX,949,O
",",949,O
Erk1/2,949,B-GENE-N
phosphorylation,949,O
was,949,O
further,949,O
enhanced,949,O
by,949,O
CHX,949,B-CHEMICAL
.,949,O
The,950,O
results,950,O
show,950,O
that,950,O
transient,950,O
arsenite,950,B-CHEMICAL
pre-treatment,950,O
induces,950,O
Hsp72,950,B-GENE-Y
",",950,O
HO-1,950,B-GENE-Y
and,950,O
",",950,O
to,950,O
a,950,O
lesser,950,O
extent,950,O
",",950,O
Hsp27,950,B-GENE-Y
;,950,O
it,950,O
reduces,950,O
H2O2-induced,950,B-CHEMICAL
astrocyte,950,O
death,950,O
;,950,O
and,950,O
it,950,O
causes,950,O
selective,950,O
activation,950,O
of,950,O
Akt,950,B-GENE-N
following,950,O
H2O2,950,B-CHEMICAL
.,950,O
It,951,O
is,951,O
suggested,951,O
that,951,O
HSP,951,B-GENE-N
expression,951,O
at,951,O
the,951,O
time,951,O
of,951,O
H2O2,951,B-CHEMICAL
exposure,951,O
protects,951,O
astrocytes,951,O
from,951,O
oxidative,951,O
injury,951,O
and,951,O
apoptotic,951,O
cell,951,O
death,951,O
by,951,O
means,951,O
of,951,O
pro-survival,951,O
Akt,951,B-GENE-N
.,951,O
Investigation,952,O
of,952,O
bradykinin,952,B-GENE-N
metabolism,952,O
in,952,O
human,952,O
and,952,O
rat,952,O
plasma,952,O
in,952,O
the,952,O
presence,952,O
of,952,O
the,952,O
dual,952,O
ACE/NEP,952,B-GENE-N
inhibitors,952,O
GW660511X,952,B-CHEMICAL
and,952,O
omapatrilat,952,B-CHEMICAL
.,952,O
Several,953,O
studies,953,O
have,953,O
suggested,953,O
that,953,O
the,953,O
accumulation,953,O
of,953,O
bradykinin,953,B-GENE-Y
",",953,O
or,953,O
that,953,O
of,953,O
one,953,O
its,953,O
metabolites,953,O
BK1-8,953,O
",",953,O
is,953,O
involved,953,O
in,953,O
the,953,O
occurrence,953,O
of,953,O
side,953,O
effects,953,O
such,953,O
as,953,O
AE,953,O
associated,953,O
with,953,O
the,953,O
use,953,O
of,953,O
various,953,O
ACEi,953,B-GENE-Y
.,953,O
In,954,O
this,954,O
work,954,O
a,954,O
novel,954,O
approach,954,O
combining,954,O
HPLC-UV,954,O
on-line,954,O
with,954,O
oaTOF-MS,954,O
and,954,O
ICPMS,954,O
was,954,O
applied,954,O
to,954,O
investigate,954,O
in,954,O
human,954,O
and,954,O
rat,954,O
plasma,954,O
the,954,O
metabolism,954,O
of,954,O
labelled,954,O
BK,954,B-GENE-N
(,954,O
79/81,954,B-GENE-N
Br-Phe5,954,I-GENE-N
),954,O
BrBK,954,B-GENE-N
in,954,O
the,954,O
presence,954,O
of,954,O
two,954,O
new,954,O
dual,954,O
ACE/NEP,954,B-GENE-N
inhibitors,954,O
(,954,O
GW660511X,954,B-CHEMICAL
and,954,O
omapatrilat,954,B-CHEMICAL
),954,O
currently,954,O
under,954,O
clinical,954,O
trial,954,O
.,954,O
In,955,O
human,955,O
plasma,955,O
the,955,O
BrBK,955,B-GENE-Y
half-life,955,O
values,955,O
in,955,O
the,955,O
absence,955,O
or,955,O
in,955,O
the,955,O
presence,955,O
of,955,O
GW660511X,955,B-CHEMICAL
(,955,O
3.8,955,O
microM,955,O
),955,O
or,955,O
omapatrilat,955,B-CHEMICAL
(,955,O
32,955,O
nM,955,O
),955,O
were,955,O
38.7,955,O
+/-,955,O
2.4,955,O
",",955,O
51.2,955,O
+/-,955,O
4.7,955,O
and,955,O
114.7,955,O
+/-,955,O
9.3,955,O
min,955,O
",",955,O
respectively,955,O
and,955,O
BrBK,955,B-GENE-Y
was,955,O
degraded,955,O
into,955,O
BrBK1-8,955,B-GENE-Y
",",955,O
BrBK1-7,955,B-GENE-Y
",",955,O
BrBK1-5,955,B-GENE-Y
and,955,O
Br-Phe,955,B-GENE-Y
.,955,O
In,956,O
the,956,O
presence,956,O
of,956,O
inhibitors,956,O
",",956,O
however,956,O
",",956,O
the,956,O
levels,956,O
of,956,O
these,956,O
resultant,956,O
metabolites,956,O
were,956,O
different,956,O
.,956,O
Unlike,957,O
GW660511X,957,B-CHEMICAL
",",957,O
omapatrilat,957,B-CHEMICAL
abolished,957,O
the,957,O
production,957,O
of,957,O
BrBK1-5,957,B-GENE-Y
and,957,O
BrBK1-7,957,B-GENE-Y
",",957,O
suggesting,957,O
a,957,O
better,957,O
ACE,957,B-GENE-Y
inhibition,957,O
effect,957,O
over,957,O
GW660511X,957,B-CHEMICAL
as,957,O
no,957,O
NEP,957,B-GENE-Y
activity,957,O
was,957,O
found,957,O
.,957,O
In,958,O
addition,958,O
the,958,O
production,958,O
of,958,O
BrBK1-8,958,B-GENE-Y
was,958,O
enhanced,958,O
in,958,O
the,958,O
presence,958,O
of,958,O
these,958,O
inhibitors,958,O
with,958,O
a,958,O
greater,958,O
accumulation,958,O
being,958,O
observed,958,O
with,958,O
omapatrilat,958,B-CHEMICAL
.,958,O
The,959,O
production,959,O
of,959,O
Br-Phe5,959,B-GENE-Y
was,959,O
reduced,959,O
with,959,O
GW660511X,959,B-CHEMICAL
while,959,O
no,959,O
significant,959,O
change,959,O
was,959,O
observed,959,O
with,959,O
omapatrilat,959,B-CHEMICAL
after,959,O
4,959,O
h,959,O
of,959,O
incubation,959,O
.,959,O
In,960,O
rat,960,O
plasma,960,O
the,960,O
BrBK,960,B-CHEMICAL
half-life,960,O
values,960,O
in,960,O
the,960,O
absence,960,O
or,960,O
in,960,O
the,960,O
presence,960,O
of,960,O
GW660511X,960,B-CHEMICAL
(,960,O
530,960,O
nM,960,O
),960,O
or,960,O
omapatrilat,960,B-CHEMICAL
(,960,O
50,960,O
nM,960,O
),960,O
were,960,O
9.31,960,O
+/-,960,O
1.7,960,O
",",960,O
22.06,960,O
+/-,960,O
3.1,960,O
and,960,O
25.3,960,O
+/-,960,O
1.7,960,O
min,960,O
",",960,O
respectively,960,O
and,960,O
BrBK,960,B-CHEMICAL
was,960,O
degraded,960,O
into,960,O
BrBK1-8,960,B-GENE-Y
",",960,O
BrBK1-7,960,B-GENE-Y
",",960,O
BrBK1-5,960,B-GENE-Y
and,960,O
Br-Phe5,960,B-GENE-Y
plus,960,O
BrBK2-9,960,B-GENE-Y
",",960,O
BrBK4-8,960,B-GENE-Y
and,960,O
BrBK2-8,960,B-GENE-N
metabolites,960,O
not,960,O
found,960,O
in,960,O
human,960,O
plasma,960,O
.,960,O
GW660511X,961,B-CHEMICAL
and,961,O
omapatrilat,961,B-CHEMICAL
reduced,961,O
the,961,O
production,961,O
of,961,O
BrBK1-5,961,B-GENE-Y
and,961,O
BrBK1-7,961,B-GENE-Y
with,961,O
more,961,O
effect,961,O
being,961,O
observed,961,O
with,961,O
omapatrilat,961,B-CHEMICAL
.,961,O
GW660511X,962,B-CHEMICAL
and,962,O
omapatrilat,962,B-CHEMICAL
increased,962,O
the,962,O
production,962,O
of,962,O
both,962,O
BrBK1-8,962,B-GENE-N
and,962,O
Br-Phe5,962,B-GENE-N
but,962,O
not,962,O
that,962,O
of,962,O
BrBK4-8,962,B-GENE-N
and,962,O
BrBK2-8,962,B-GENE-N
.,962,O
This,963,O
study,963,O
shows,963,O
that,963,O
the,963,O
potency,963,O
of,963,O
GW660511X,963,B-CHEMICAL
in,963,O
comparison,963,O
with,963,O
omapatrilat,963,B-CHEMICAL
is,963,O
more,963,O
than,963,O
100-fold,963,O
lower,963,O
in,963,O
human,963,O
",",963,O
but,963,O
less,963,O
than,963,O
10-fold,963,O
lower,963,O
in,963,O
rat,963,O
plasma,963,O
",",963,O
suggesting,963,O
that,963,O
rat,963,O
may,963,O
not,963,O
be,963,O
a,963,O
suitable,963,O
in,963,O
vivo,963,O
model,963,O
for,963,O
the,963,O
evaluation,963,O
of,963,O
ACE/NEP,963,B-GENE-Y
inhibition,963,O
in,963,O
relation,963,O
to,963,O
effects,963,O
in,963,O
humans,963,O
.,963,O
Activity,964,O
of,964,O
opioid,964,O
ligands,964,O
in,964,O
cells,964,O
expressing,964,O
cloned,964,O
mu,964,B-GENE-Y
opioid,964,I-GENE-Y
receptors,964,I-GENE-Y
.,964,O
BACKGROUND,965,O
:,965,O
The,965,O
aim,965,O
of,965,O
the,965,O
present,965,O
study,965,O
was,965,O
to,965,O
describe,965,O
the,965,O
activity,965,O
of,965,O
a,965,O
set,965,O
of,965,O
opioid,965,O
drugs,965,O
",",965,O
including,965,O
partial,965,O
agonists,965,O
",",965,O
in,965,O
a,965,O
cell,965,O
system,965,O
expressing,965,O
only,965,O
mu,965,B-GENE-Y
opioid,965,I-GENE-Y
receptors,965,I-GENE-Y
.,965,O
Receptor,966,O
activation,966,O
was,966,O
assessed,966,O
by,966,O
measuring,966,O
the,966,O
inhibition,966,O
of,966,O
forskolin-stimulated,966,B-CHEMICAL
cyclic,966,B-CHEMICAL
adenosine,966,I-CHEMICAL
mono,966,I-CHEMICAL
phosphate,966,I-CHEMICAL
(,966,O
cAMP,966,B-CHEMICAL
),966,O
production,966,O
.,966,O
Efficacies,967,O
and,967,O
potencies,967,O
of,967,O
these,967,O
ligands,967,O
were,967,O
determined,967,O
relative,967,O
to,967,O
the,967,O
endogenous,967,O
ligand,967,O
beta-endorphin,967,B-GENE-Y
and,967,O
the,967,O
common,967,O
mu,967,O
agonist,967,O
",",967,O
morphine,967,B-CHEMICAL
.,967,O
RESULTS,968,O
:,968,O
Among,968,O
the,968,O
ligands,968,O
studied,968,O
naltrexone,968,B-CHEMICAL
",",968,O
WIN,968,B-CHEMICAL
"44,441",968,I-CHEMICAL
and,968,O
SKF,968,B-CHEMICAL
10047,968,I-CHEMICAL
",",968,O
were,968,O
classified,968,O
as,968,O
antagonists,968,O
",",968,O
while,968,O
the,968,O
remaining,968,O
ligands,968,O
were,968,O
agonists,968,O
.,968,O
Agonist,969,O
efficacy,969,O
was,969,O
assessed,969,O
by,969,O
determining,969,O
the,969,O
extent,969,O
of,969,O
inhibition,969,O
of,969,O
forskolin-stimulated,969,B-CHEMICAL
cAMP,969,B-CHEMICAL
production,969,O
.,969,O
The,970,O
rank,970,O
order,970,O
of,970,O
efficacy,970,O
of,970,O
the,970,O
agonists,970,O
was,970,O
fentanyl,970,B-CHEMICAL
=,970,O
hydromorphone,970,B-CHEMICAL
=,970,O
beta-endorphin,970,O
>,970,O
etorphine,970,B-CHEMICAL
=,970,O
lofentanil,970,B-CHEMICAL
=,970,O
butorphanol,970,B-CHEMICAL
=,970,O
morphine,970,B-CHEMICAL
=,970,O
nalbuphine,970,B-CHEMICAL
=,970,O
nalorphine,970,B-CHEMICAL
>,970,O
cyclazocine,970,B-CHEMICAL
=,970,O
dezocine,970,B-CHEMICAL
=,970,O
metazocine,970,B-CHEMICAL
>,970,O
or=,970,O
xorphanol,970,B-CHEMICAL
.,970,O
The,971,O
rank,971,O
order,971,O
of,971,O
potency,971,O
of,971,O
these,971,O
ligands,971,O
was,971,O
different,971,O
from,971,O
that,971,O
of,971,O
their,971,O
efficacies,971,O
;,971,O
etorphine,971,B-CHEMICAL
>,971,O
hydromorphone,971,B-CHEMICAL
>,971,O
dezocine,971,B-CHEMICAL
>,971,O
xorphanol,971,B-CHEMICAL
=,971,O
nalorphine,971,B-CHEMICAL
=,971,O
butorphanol,971,B-CHEMICAL
=,971,O
lofentanil,971,B-CHEMICAL
>,971,O
metazocine,971,B-CHEMICAL
>,971,O
nalbuphine,971,B-CHEMICAL
>,971,O
cyclazocine,971,B-CHEMICAL
>,971,O
fentanyl,971,B-CHEMICAL
>,971,O
morphine,971,B-CHEMICAL
>,971,O
>,971,O
>,971,O
>,971,O
beta-endorphin,971,O
.,971,O
CONCLUSION,972,O
:,972,O
These,972,O
results,972,O
elucidate,972,O
the,972,O
relative,972,O
activities,972,O
of,972,O
a,972,O
set,972,O
of,972,O
opioid,972,O
ligands,972,O
at,972,O
mu,972,B-GENE-Y
opioid,972,I-GENE-Y
receptor,972,I-GENE-Y
and,972,O
can,972,O
serve,972,O
as,972,O
the,972,O
initial,972,O
step,972,O
in,972,O
a,972,O
systematic,972,O
study,972,O
leading,972,O
to,972,O
understanding,972,O
of,972,O
the,972,O
mode,972,O
of,972,O
action,972,O
of,972,O
opioid,972,O
ligands,972,O
at,972,O
this,972,O
receptor,972,O
.,972,O
Furthermore,973,O
",",973,O
these,973,O
results,973,O
can,973,O
assist,973,O
in,973,O
understanding,973,O
the,973,O
physiological,973,O
effect,973,O
of,973,O
many,973,O
opioid,973,O
ligands,973,O
acting,973,O
through,973,O
mu,973,B-GENE-Y
opioid,973,I-GENE-Y
receptors,973,I-GENE-Y
.,973,O
Ventricular,974,O
tachyarrhythmias,974,O
in,974,O
a,974,O
canine,974,O
model,974,O
of,974,O
LQT3,974,O
:,974,O
arrhythmogenic,974,O
effects,974,O
of,974,O
sympathetic,974,O
activity,974,O
and,974,O
therapeutic,974,O
effects,974,O
of,974,O
mexiletine,974,B-CHEMICAL
.,974,O
The,975,O
ventricular,975,O
tachyarrhythmias,975,O
associated,975,O
with,975,O
the,975,O
LQT3,975,O
syndrome,975,O
are,975,O
typically,975,O
bradycardia-dependent,975,O
.,975,O
However,976,O
",",976,O
some,976,O
episodes,976,O
can,976,O
be,976,O
associated,976,O
with,976,O
exercise,976,O
or,976,O
emotional,976,O
stress,976,O
",",976,O
suggesting,976,O
a,976,O
different,976,O
arrhythmogenic,976,O
mechanism,976,O
when,976,O
sympathetic,976,O
activity,976,O
predominates,976,O
.,976,O
This,977,O
study,977,O
examined,977,O
the,977,O
potential,977,O
arrhythmogenic,977,O
mechanisms,977,O
during,977,O
periods,977,O
of,977,O
autonomically,977,O
mediated,977,O
transient,977,O
heart,977,O
rate,977,O
acceleration,977,O
in,977,O
a,977,O
canine,977,O
anthopleurin-A,977,B-GENE-Y
model,977,O
of,977,O
LQT3,977,O
syndrome,977,O
.,977,O
Using,978,O
plunge,978,O
needle,978,O
electrodes,978,O
",",978,O
transmural,978,O
unipolar,978,O
electrograms,978,O
of,978,O
the,978,O
left,978,O
ventricle,978,O
were,978,O
recorded,978,O
from,978,O
endocardial,978,O
(,978,O
Endo,978,O
),978,O
",",978,O
mid-myocardial,978,O
(,978,O
Mid,978,O
),978,O
and,978,O
epicardial,978,O
(,978,O
Epi,978,O
),978,O
sites,978,O
.,978,O
The,979,O
activation-recovery,979,O
interval,979,O
(,979,O
ARI,979,O
),979,O
was,979,O
measured,979,O
to,979,O
estimate,979,O
local,979,O
refractoriness,979,O
.,979,O
The,980,O
cardiac,980,O
cycle,980,O
length,980,O
was,980,O
gradually,980,O
shortened,980,O
by,980,O
cessation,980,O
of,980,O
vagal,980,O
stimulation,980,O
(,980,O
vagal,980,O
stimulation,980,O
protocol,980,O
(,980,O
VSP,980,O
),980,O
),980,O
",",980,O
and,980,O
intramural,980,O
electrograms,980,O
and,980,O
onset,980,O
mode,980,O
of,980,O
ventricular,980,O
tachyarrhythmias,980,O
were,980,O
analyzed,980,O
in,980,O
7,980,O
experiments,980,O
.,980,O
The,981,O
VSP,981,O
was,981,O
performed,981,O
8,981,O
times,981,O
before,981,O
and,981,O
5,981,O
times,981,O
after,981,O
administration,981,O
of,981,O
mexiletine,981,B-CHEMICAL
in,981,O
each,981,O
experiment,981,O
.,981,O
Before,982,O
mexiletine,982,B-CHEMICAL
",",982,O
vagal,982,O
stimulation,982,O
slowed,982,O
the,982,O
heart,982,O
rate,982,O
and,982,O
created,982,O
large,982,O
transmural,982,O
ARI,982,O
dispersion,982,O
because,982,O
of,982,O
a,982,O
greater,982,O
ARI,982,O
prolongation,982,O
at,982,O
Mid,982,O
rather,982,O
than,982,O
Epi/Endo,982,O
sites,982,O
.,982,O
After,983,O
cessation,983,O
of,983,O
vagal,983,O
stimulation,983,O
",",983,O
unipolar,983,O
electrograms,983,O
started,983,O
to,983,O
show,983,O
ARI,983,O
alternans,983,O
and,983,O
ventricular,983,O
premature,983,O
beats,983,O
developed,983,O
sporadically,983,O
.,983,O
Sustained,984,O
ventricular,984,O
tachyarrhythmias,984,O
were,984,O
induced,984,O
in,984,O
12,984,O
of,984,O
the,984,O
56,984,O
trials,984,O
of,984,O
the,984,O
VSP,984,O
.,984,O
Initiation,985,O
of,985,O
ventricular,985,O
tachyarrhythmias,985,O
was,985,O
associated,985,O
with,985,O
delayed,985,O
conduction,985,O
at,985,O
Mid/Endo,985,O
sites,985,O
.,985,O
Mexiletine,986,B-CHEMICAL
attenuated,986,O
transmural,986,O
ARI,986,O
dispersion,986,O
",",986,O
and,986,O
neither,986,O
ARI,986,O
alternans,986,O
nor,986,O
ventricular,986,O
tachyarrhythmias,986,O
was,986,O
observed,986,O
during,986,O
all,986,O
35,986,O
trials,986,O
of,986,O
the,986,O
VSP,986,O
after,986,O
mexiletine,986,B-CHEMICAL
administration,986,O
.,986,O
Heart,987,O
rate,987,O
acceleration,987,O
induced,987,O
by,987,O
an,987,O
abrupt,987,O
shift,987,O
to,987,O
a,987,O
state,987,O
of,987,O
predominant,987,O
sympathetic,987,O
activity,987,O
enhances,987,O
arrhythmias,987,O
in,987,O
this,987,O
LQT3,987,O
model,987,O
.,987,O
Mexiletine,988,B-CHEMICAL
homogenizes,988,O
ventricular,988,O
repolarization,988,O
",",988,O
suppresses,988,O
premature,988,O
complexes,988,O
and,988,O
was,988,O
antiarrhythmic,988,O
during,988,O
ventricular,988,O
tachyarrhythmias,988,O
induced,988,O
by,988,O
the,988,O
VSP,988,O
.,988,O
Butyrylcholinesterase,989,B-GENE-Y
:,989,O
an,989,O
important,989,O
new,989,O
target,989,O
in,989,O
Alzheimer,989,O
's,989,O
disease,989,O
therapy,989,O
.,989,O
Acetylcholinesterase,990,B-GENE-Y
(,990,O
AChE,990,B-GENE-Y
),990,O
predominates,990,O
in,990,O
the,990,O
healthy,990,O
brain,990,O
",",990,O
with,990,O
butyrylcholinesterase,990,B-GENE-Y
(,990,O
BuChE,990,B-GENE-Y
),990,O
considered,990,O
to,990,O
play,990,O
a,990,O
minor,990,O
role,990,O
in,990,O
regulating,990,O
brain,990,O
acetylcholine,990,B-CHEMICAL
(,990,O
ACh,990,B-CHEMICAL
),990,O
levels,990,O
.,990,O
However,991,O
",",991,O
BuChE,991,B-GENE-Y
activity,991,O
progressively,991,O
increases,991,O
in,991,O
patients,991,O
with,991,O
Alzheimer,991,O
's,991,O
disease,991,O
(,991,O
AD,991,O
),991,O
",",991,O
while,991,O
AChE,991,B-GENE-Y
activity,991,O
remains,991,O
unchanged,991,O
or,991,O
declines,991,O
.,991,O
Both,992,O
enzymes,992,O
therefore,992,O
represent,992,O
legitimate,992,O
therapeutic,992,O
targets,992,O
for,992,O
ameliorating,992,O
the,992,O
cholinergic,992,O
deficit,992,O
considered,992,O
to,992,O
be,992,O
responsible,992,O
for,992,O
the,992,O
declines,992,O
in,992,O
cognitive,992,O
",",992,O
behavioral,992,O
and,992,O
global,992,O
functioning,992,O
characteristic,992,O
of,992,O
AD,992,O
.,992,O
The,993,O
two,993,O
enzymes,993,O
differ,993,O
in,993,O
substrate,993,O
specificity,993,O
",",993,O
kinetics,993,O
and,993,O
activity,993,O
in,993,O
different,993,O
brain,993,O
regions,993,O
.,993,O
Experimental,994,O
evidence,994,O
from,994,O
the,994,O
use,994,O
of,994,O
agents,994,O
with,994,O
enhanced,994,O
selectivity,994,O
for,994,O
BuChE,994,B-GENE-Y
(,994,O
cymserine,994,B-CHEMICAL
analogues,994,O
",",994,O
MF-8622,994,B-CHEMICAL
),994,O
and,994,O
the,994,O
dual,994,O
inhibitor,994,O
of,994,O
both,994,O
AChE,994,B-GENE-Y
and,994,O
BuChE,994,B-GENE-Y
",",994,O
rivastigmine,994,B-CHEMICAL
",",994,O
indicates,994,O
potential,994,O
therapeutic,994,O
benefits,994,O
of,994,O
inhibiting,994,O
both,994,O
AChE,994,B-GENE-Y
and,994,O
BuChE,994,B-GENE-Y
in,994,O
AD,994,O
and,994,O
related,994,O
dementias,994,O
.,994,O
Recent,995,O
evidence,995,O
suggests,995,O
that,995,O
both,995,O
AChE,995,B-GENE-Y
and,995,O
BuChE,995,B-GENE-Y
may,995,O
have,995,O
roles,995,O
in,995,O
the,995,O
aetiology,995,O
and,995,O
progression,995,O
of,995,O
AD,995,O
beyond,995,O
regulation,995,O
of,995,O
synaptic,995,O
ACh,995,O
levels,995,O
.,995,O
The,996,O
development,996,O
of,996,O
specific,996,O
BuChE,996,B-GENE-Y
inhibitors,996,O
and,996,O
further,996,O
experience,996,O
with,996,O
the,996,O
dual,996,O
enzyme,996,O
inhibitor,996,O
rivastigmine,996,B-CHEMICAL
will,996,O
improve,996,O
understanding,996,O
of,996,O
the,996,O
aetiology,996,O
of,996,O
AD,996,O
and,996,O
should,996,O
lead,996,O
to,996,O
a,996,O
wider,996,O
variety,996,O
of,996,O
potent,996,O
treatment,996,O
options,996,O
.,996,O
A,997,O
low,997,O
toxicity,997,O
maintenance,997,O
regime,997,O
",",997,O
using,997,O
eicosapentaenoic,997,B-CHEMICAL
acid,997,I-CHEMICAL
and,997,O
readily,997,O
available,997,O
drugs,997,O
",",997,O
for,997,O
mantle,997,O
cell,997,O
lymphoma,997,O
and,997,O
other,997,O
malignancies,997,O
with,997,O
excess,997,O
cyclin,997,B-GENE-Y
D1,997,I-GENE-Y
levels,997,O
.,997,O
Mantle,998,O
cell,998,O
lymphoma,998,O
is,998,O
a,998,O
difficult,998,O
to,998,O
treat,998,O
non-Hodgkin,998,O
's,998,O
lymphoma,998,O
(,998,O
NHL,998,O
),998,O
whose,998,O
biochemistry,998,O
is,998,O
unusually,998,O
well,998,O
characterised,998,O
.,998,O
Almost,999,O
all,999,O
and,999,O
perhaps,999,O
all,999,O
patients,999,O
overexpress,999,O
the,999,O
cyclin,999,B-GENE-Y
D1,999,I-GENE-Y
protein,999,O
which,999,O
is,999,O
crucial,999,O
in,999,O
driving,999,O
cells,999,O
from,999,O
the,999,O
G1,999,O
to,999,O
the,999,O
S,999,O
phase,999,O
.,999,O
This,1000,O
overexpression,1000,O
may,1000,O
be,1000,O
responsible,1000,O
for,1000,O
the,1000,O
refractoriness,1000,O
.,1000,O
Despite,1001,O
this,1001,O
understanding,1001,O
",",1001,O
treatments,1001,O
for,1001,O
mantle,1001,O
cell,1001,O
lymphoma,1001,O
are,1001,O
based,1001,O
on,1001,O
standard,1001,O
NHL,1001,O
regimes,1001,O
of,1001,O
cyclophosphamide,1001,B-CHEMICAL
",",1001,O
doxorubicin,1001,B-CHEMICAL
",",1001,O
vincristine,1001,B-CHEMICAL
and,1001,O
prednisone,1001,B-CHEMICAL
",",1001,O
perhaps,1001,O
supplemented,1001,O
with,1001,O
the,1001,O
monoclonal,1001,O
antibody,1001,O
rituximab,1001,O
.,1001,O
There,1002,O
has,1002,O
never,1002,O
been,1002,O
any,1002,O
attempt,1002,O
to,1002,O
direct,1002,O
treatment,1002,O
to,1002,O
the,1002,O
cyclin,1002,B-GENE-Y
D1,1002,I-GENE-Y
mechanism,1002,O
or,1002,O
to,1002,O
angiogenesis,1002,O
which,1002,O
is,1002,O
now,1002,O
known,1002,O
to,1002,O
be,1002,O
important,1002,O
in,1002,O
all,1002,O
lymphomas,1002,O
.,1002,O
Both,1003,O
these,1003,O
targets,1003,O
lend,1003,O
themselves,1003,O
to,1003,O
long-term,1003,O
maintenance,1003,O
regimes,1003,O
of,1003,O
relatively,1003,O
low,1003,O
toxicity,1003,O
which,1003,O
can,1003,O
be,1003,O
used,1003,O
as,1003,O
adjuvants,1003,O
to,1003,O
standard,1003,O
therapy,1003,O
.,1003,O
Agents,1004,O
which,1004,O
have,1004,O
recently,1004,O
been,1004,O
shown,1004,O
to,1004,O
block,1004,O
cyclin,1004,B-GENE-Y
D1,1004,I-GENE-Y
translation,1004,O
by,1004,O
regulating,1004,O
calcium,1004,O
levels,1004,O
are,1004,O
the,1004,O
unsaturated,1004,B-CHEMICAL
essential,1004,I-CHEMICAL
fatty,1004,I-CHEMICAL
acid,1004,I-CHEMICAL
",",1004,O
eicosapentaenoic,1004,B-CHEMICAL
acid,1004,I-CHEMICAL
(,1004,O
EPA,1004,B-CHEMICAL
),1004,O
",",1004,O
the,1004,O
antidiabetic,1004,O
thiazolidinediones,1004,B-CHEMICAL
",",1004,O
and,1004,O
the,1004,O
antifungal,1004,O
agent,1004,O
",",1004,O
clotrimazole,1004,B-CHEMICAL
.,1004,O
Two,1005,O
types,1005,O
of,1005,O
agent,1005,O
which,1005,O
have,1005,O
been,1005,O
shown,1005,O
to,1005,O
inhibit,1005,O
angiogenesis,1005,O
are,1005,O
the,1005,O
teratogen,1005,O
",",1005,O
thalidomide,1005,B-CHEMICAL
",",1005,O
and,1005,O
the,1005,O
selective,1005,O
inhibitors,1005,O
of,1005,O
cyclo-oxygenase,1005,B-GENE-Y
2,1005,I-GENE-Y
(,1005,O
COX-2,1005,B-GENE-Y
),1005,O
.,1005,O
Retinoids,1006,B-CHEMICAL
exert,1006,O
synergistic,1006,O
effects,1006,O
with,1006,O
EPA,1006,B-CHEMICAL
and,1006,O
have,1006,O
been,1006,O
shown,1006,O
to,1006,O
inhibit,1006,O
both,1006,O
tumour,1006,O
growth,1006,O
and,1006,O
angiogenesis,1006,O
.,1006,O
The,1007,O
mechanisms,1007,O
of,1007,O
action,1007,O
of,1007,O
these,1007,O
various,1007,O
agents,1007,O
are,1007,O
discussed,1007,O
",",1007,O
and,1007,O
specific,1007,O
suggestions,1007,O
are,1007,O
made,1007,O
for,1007,O
low,1007,O
toxicity,1007,O
maintenance,1007,O
therapy,1007,O
of,1007,O
mantle,1007,O
cell,1007,O
lymphoma,1007,O
and,1007,O
of,1007,O
other,1007,O
tumours,1007,O
which,1007,O
overexpress,1007,O
cyclin,1007,B-GENE-Y
D1,1007,I-GENE-Y
.,1007,O
Angiotensin,1008,B-CHEMICAL
AT1,1008,I-GENE-Y
receptor,1008,I-GENE-Y
antagonist,1008,O
losartan,1008,B-CHEMICAL
and,1008,O
the,1008,O
defence,1008,O
reaction,1008,O
in,1008,O
the,1008,O
anaesthetised,1008,O
rat,1008,O
.,1008,O
Effect,1009,O
on,1009,O
the,1009,O
carotid,1009,O
chemoreflex,1009,O
.,1009,O
Modulation,1010,O
at,1010,O
the,1010,O
level,1010,O
of,1010,O
the,1010,O
nucleus,1010,O
tractus,1010,O
solitarii,1010,O
(,1010,O
NTS,1010,O
),1010,O
appears,1010,O
to,1010,O
be,1010,O
an,1010,O
effective,1010,O
way,1010,O
of,1010,O
controlling,1010,O
cardiovascular,1010,O
reflexes,1010,O
.,1010,O
Angiotensin,1011,B-GENE-Y
II,1011,I-GENE-Y
acting,1011,O
on,1011,O
angiotensin,1011,B-GENE-Y
AT1,1011,I-GENE-Y
receptors,1011,I-GENE-Y
at,1011,O
the,1011,O
central,1011,O
nervous,1011,O
system,1011,O
appears,1011,O
to,1011,O
have,1011,O
an,1011,O
important,1011,O
role,1011,O
in,1011,O
these,1011,O
modulatory,1011,O
processes,1011,O
.,1011,O
The,1012,O
hypothalamic,1012,O
defence,1012,O
area,1012,O
(,1012,O
HDA,1012,O
),1012,O
is,1012,O
a,1012,O
potential,1012,O
source,1012,O
of,1012,O
descending,1012,O
fibres,1012,O
containing,1012,O
angiotensin,1012,B-GENE-Y
II,1012,I-GENE-Y
that,1012,O
innervate,1012,O
the,1012,O
NTS,1012,O
.,1012,O
We,1013,O
investigated,1013,O
the,1013,O
effect,1013,O
of,1013,O
AT1,1013,B-GENE-Y
receptor,1013,I-GENE-Y
blockade,1013,O
in,1013,O
the,1013,O
NTS,1013,O
on,1013,O
the,1013,O
response,1013,O
to,1013,O
stimulation,1013,O
of,1013,O
HDA,1013,O
in,1013,O
anaesthetised,1013,O
rats,1013,O
treated,1013,O
with,1013,O
the,1013,O
neuromuscular,1013,O
blocking,1013,O
agent,1013,O
pancuronium,1013,B-CHEMICAL
bromide,1013,I-CHEMICAL
.,1013,O
The,1014,O
characteristic,1014,O
increase,1014,O
in,1014,O
heart,1014,O
rate,1014,O
",",1014,O
blood,1014,O
pressure,1014,O
and,1014,O
phrenic,1014,O
nerve,1014,O
activity,1014,O
evoked,1014,O
by,1014,O
electrical,1014,O
stimulation,1014,O
of,1014,O
HDA,1014,O
is,1014,O
decreased,1014,O
by,1014,O
the,1014,O
microinjection,1014,O
of,1014,O
the,1014,O
AT1,1014,B-GENE-Y
receptor,1014,I-GENE-Y
antagonist,1014,O
losartan,1014,O
into,1014,O
the,1014,O
NTS,1014,O
and,1014,O
the,1014,O
cardiovascular,1014,O
response,1014,O
to,1014,O
carotid,1014,O
body,1014,O
chemical,1014,O
stimulation,1014,O
is,1014,O
also,1014,O
reduced,1014,O
.,1014,O
These,1015,O
results,1015,O
support,1015,O
the,1015,O
hypothesis,1015,O
that,1015,O
AT1,1015,B-GENE-Y
receptors,1015,I-GENE-Y
in,1015,O
the,1015,O
NTS,1015,O
play,1015,O
a,1015,O
role,1015,O
in,1015,O
the,1015,O
modulation,1015,O
of,1015,O
cardiovascular,1015,O
reflexes,1015,O
",",1015,O
and,1015,O
modify,1015,O
the,1015,O
influence,1015,O
exerted,1015,O
on,1015,O
the,1015,O
processing,1015,O
of,1015,O
these,1015,O
reflexes,1015,O
by,1015,O
other,1015,O
areas,1015,O
of,1015,O
the,1015,O
central,1015,O
nervous,1015,O
system,1015,O
.,1015,O
Defective,1016,O
processing,1016,O
of,1016,O
the,1016,O
transforming,1016,B-GENE-Y
growth,1016,I-GENE-Y
factor-beta1,1016,I-GENE-Y
in,1016,O
azoxymethane-induced,1016,B-CHEMICAL
mouse,1016,O
colon,1016,O
tumors,1016,O
.,1016,O
High,1017,O
levels,1017,O
of,1017,O
the,1017,O
cell,1017,O
growth,1017,O
inhibitor,1017,O
transforming,1017,B-GENE-Y
growth,1017,I-GENE-Y
factor-beta1,1017,I-GENE-Y
(,1017,O
TGF-beta1,1017,B-GENE-Y
),1017,O
are,1017,O
often,1017,O
found,1017,O
in,1017,O
a,1017,O
variety,1017,O
of,1017,O
human,1017,O
cancers,1017,O
.,1017,O
However,1018,O
",",1018,O
the,1018,O
physiological,1018,O
significance,1018,O
of,1018,O
this,1018,O
overexpression,1018,O
depends,1018,O
on,1018,O
the,1018,O
availability,1018,O
of,1018,O
the,1018,O
biologically,1018,O
active,1018,O
form,1018,O
of,1018,O
TGF-beta1,1018,B-GENE-Y
within,1018,O
the,1018,O
extracellular,1018,O
matrix,1018,O
of,1018,O
the,1018,O
tumor,1018,O
microenvironment,1018,O
.,1018,O
To,1019,O
determine,1019,O
the,1019,O
expression,1019,O
and,1019,O
activation,1019,O
status,1019,O
of,1019,O
TGF-beta1,1019,B-GENE-Y
in,1019,O
chemically,1019,O
induced,1019,O
tumors,1019,O
",",1019,O
6-wk-old,1019,O
A/J,1019,O
mice,1019,O
were,1019,O
injected,1019,O
intraperitoneally,1019,O
with,1019,O
either,1019,O
azoxymethane,1019,B-CHEMICAL
(,1019,O
AOM,1019,B-CHEMICAL
),1019,O
(,1019,O
10,1019,O
mg/kg,1019,O
body,1019,O
weight,1019,O
",",1019,O
once,1019,O
a,1019,O
week,1019,O
for,1019,O
6,1019,O
wk,1019,O
),1019,O
or,1019,O
normal,1019,O
saline,1019,O
solution,1019,O
",",1019,O
and,1019,O
colon,1019,O
tumors,1019,O
were,1019,O
isolated,1019,O
24,1019,O
wk,1019,O
following,1019,O
the,1019,O
last,1019,O
injection,1019,O
.,1019,O
An,1020,O
enzyme-linked,1020,O
immunosorbent,1020,O
assay,1020,O
for,1020,O
TGF-beta1,1020,B-GENE-Y
revealed,1020,O
a,1020,O
significant,1020,O
increase,1020,O
(,1020,O
1.7-fold,1020,O
",",1020,O
P,1020,O
<,1020,O
0.05,1020,O
),1020,O
in,1020,O
total,1020,O
TGF-beta1,1020,B-GENE-Y
protein,1020,O
in,1020,O
tumors,1020,O
.,1020,O
Interestingly,1021,O
",",1021,O
while,1021,O
80,1021,O
%,1021,O
of,1021,O
the,1021,O
total,1021,O
TGF-beta1,1021,B-GENE-Y
in,1021,O
the,1021,O
control,1021,O
colon,1021,O
tissues,1021,O
was,1021,O
in,1021,O
the,1021,O
active,1021,O
form,1021,O
",",1021,O
only,1021,O
50,1021,O
%,1021,O
was,1021,O
found,1021,O
to,1021,O
be,1021,O
active,1021,O
in,1021,O
tumors,1021,O
.,1021,O
Together,1022,O
with,1022,O
our,1022,O
earlier,1022,O
observations,1022,O
that,1022,O
TGF-beta1,1022,B-GENE-Y
mRNA,1022,O
levels,1022,O
are,1022,O
unchanged,1022,O
in,1022,O
A/J,1022,O
tumors,1022,O
",",1022,O
these,1022,O
data,1022,O
further,1022,O
support,1022,O
a,1022,O
mechanism,1022,O
whereby,1022,O
elevated,1022,O
TGF-beta1,1022,B-GENE-Y
levels,1022,O
result,1022,O
from,1022,O
a,1022,O
defective,1022,O
activation,1022,O
and,1022,O
turnover,1022,O
of,1022,O
this,1022,O
protein,1022,O
.,1022,O
Because,1023,O
plasmin,1023,B-GENE-Y
is,1023,O
known,1023,O
to,1023,O
be,1023,O
a,1023,O
major,1023,O
activator,1023,O
of,1023,O
TGF-beta1,1023,B-GENE-Y
in,1023,O
vivo,1023,O
",",1023,O
we,1023,O
hypothesized,1023,O
that,1023,O
reduced,1023,O
plasmin,1023,B-GENE-Y
activity,1023,O
may,1023,O
be,1023,O
responsible,1023,O
for,1023,O
the,1023,O
observed,1023,O
dysregulation,1023,O
of,1023,O
TGF-beta1,1023,B-GENE-Y
processing,1023,O
in,1023,O
these,1023,O
behaviorally,1023,O
benign,1023,O
tumors,1023,O
.,1023,O
With,1024,O
a,1024,O
fluorogenic,1024,O
peptide,1024,O
substrate,1024,O
for,1024,O
serine,1024,B-CHEMICAL
proteases,1024,I-GENE-N
",",1024,O
a,1024,O
deficiency,1024,O
in,1024,O
plasmin,1024,B-GENE-Y
activity,1024,O
was,1024,O
found,1024,O
in,1024,O
the,1024,O
tumors,1024,O
.,1024,O
Furthermore,1025,O
",",1025,O
semiquantitative,1025,O
reverse,1025,O
transcription,1025,O
(,1025,O
RT,1025,O
),1025,O
-polymerase,1025,O
chain,1025,O
reaction,1025,O
(,1025,O
PCR,1025,O
),1025,O
analysis,1025,O
of,1025,O
a,1025,O
panel,1025,O
of,1025,O
genes,1025,O
involved,1025,O
in,1025,O
the,1025,O
plasminogen,1025,B-GENE-Y
activation,1025,O
system,1025,O
",",1025,O
including,1025,O
plasminogen,1025,B-GENE-Y
activator,1025,I-GENE-Y
inhibitor-1,1025,I-GENE-Y
(,1025,O
PAI-1,1025,B-GENE-Y
),1025,O
",",1025,O
urokinase-plasminogen,1025,B-GENE-Y
activator,1025,I-GENE-Y
(,1025,O
u-PA,1025,B-GENE-Y
),1025,O
",",1025,O
and,1025,O
urokinase-receptor,1025,B-GENE-Y
(,1025,O
u-PAR-1,1025,B-GENE-Y
),1025,O
",",1025,O
demonstrated,1025,O
a,1025,O
significant,1025,O
upregulation,1025,O
(,1025,O
approximately,1025,O
fourfold,1025,O
to,1025,O
sixfold,1025,O
",",1025,O
P,1025,O
<,1025,O
0.05,1025,O
),1025,O
in,1025,O
the,1025,O
expression,1025,O
of,1025,O
each,1025,O
of,1025,O
these,1025,O
genes,1025,O
in,1025,O
the,1025,O
tumor,1025,O
tissue,1025,O
.,1025,O
In,1026,O
addition,1026,O
",",1026,O
no,1026,O
significant,1026,O
changes,1026,O
were,1026,O
observed,1026,O
in,1026,O
the,1026,O
expression,1026,O
levels,1026,O
of,1026,O
thrombospondin-1,1026,B-GENE-Y
(,1026,O
TSP-1,1026,B-GENE-Y
),1026,O
and,1026,O
insulin-like,1026,B-GENE-Y
growth,1026,I-GENE-Y
factor,1026,I-GENE-Y
type,1026,I-GENE-Y
II,1026,I-GENE-Y
receptor,1026,I-GENE-Y
(,1026,O
IGF-IIR,1026,B-GENE-Y
),1026,O
",",1026,O
which,1026,O
also,1026,O
mediate,1026,O
the,1026,O
activation,1026,O
of,1026,O
latent,1026,O
TGF-beta1,1026,B-GENE-Y
.,1026,O
To,1027,O
gain,1027,O
further,1027,O
insight,1027,O
into,1027,O
the,1027,O
functionality,1027,O
of,1027,O
the,1027,O
TGF-beta1,1027,B-GENE-Y
pathway,1027,O
",",1027,O
cDNA,1027,O
microarrays,1027,O
were,1027,O
performed,1027,O
and,1027,O
the,1027,O
expression,1027,O
levels,1027,O
of,1027,O
a,1027,O
panel,1027,O
of,1027,O
21,1027,O
TGF-beta1-specific,1027,B-GENE-Y
target,1027,O
genes,1027,O
were,1027,O
determined,1027,O
in,1027,O
AOM-induced,1027,B-CHEMICAL
tumors,1027,O
that,1027,O
overexpress,1027,O
the,1027,O
ligand,1027,O
.,1027,O
A,1028,O
significant,1028,O
dysregulation,1028,O
in,1028,O
the,1028,O
expression,1028,O
of,1028,O
each,1028,O
of,1028,O
these,1028,O
targets,1028,O
was,1028,O
observed,1028,O
",",1028,O
providing,1028,O
evidence,1028,O
of,1028,O
aberrant,1028,O
TGF-beta1,1028,B-GENE-Y
signaling,1028,O
in,1028,O
tumors,1028,O
.,1028,O
Overall,1029,O
",",1029,O
the,1029,O
present,1029,O
study,1029,O
demonstrates,1029,O
a,1029,O
very,1029,O
low,1029,O
plasmin,1029,B-GENE-Y
activity,1029,O
in,1029,O
A/J,1029,O
colon,1029,O
tumors,1029,O
",",1029,O
possibly,1029,O
as,1029,O
a,1029,O
result,1029,O
of,1029,O
the,1029,O
potent,1029,O
inhibitory,1029,O
effect,1029,O
of,1029,O
PAI-1,1029,B-GENE-Y
on,1029,O
the,1029,O
plasminogen,1029,B-GENE-Y
activation,1029,O
cascade,1029,O
.,1029,O
The,1030,O
observed,1030,O
deficiency,1030,O
in,1030,O
plasmin,1030,B-GENE-Y
activity,1030,O
may,1030,O
not,1030,O
be,1030,O
sufficiently,1030,O
compensated,1030,O
for,1030,O
by,1030,O
other,1030,O
mechanisms,1030,O
of,1030,O
latent,1030,O
TGF-beta1,1030,B-GENE-Y
activation,1030,O
",",1030,O
including,1030,O
TSP-1,1030,B-GENE-Y
and,1030,O
IGF-IIR,1030,B-GENE-Y
",",1030,O
thereby,1030,O
resulting,1030,O
in,1030,O
a,1030,O
decreased,1030,O
fraction,1030,O
of,1030,O
the,1030,O
biologically,1030,O
active,1030,O
form,1030,O
of,1030,O
TGF-beta1,1030,B-GENE-Y
and,1030,O
subsequent,1030,O
aberration,1030,O
in,1030,O
TGF-beta1-specific,1030,B-GENE-Y
gene,1030,O
regulation,1030,O
in,1030,O
A/J,1030,O
tumors,1030,O
.,1030,O
Inhibition,1031,O
by,1031,O
pentosan,1031,O
polysulfate,1031,O
(,1031,O
PPS,1031,O
),1031,O
of,1031,O
heparin-binding,1031,B-GENE-N
growth,1031,I-GENE-N
factors,1031,I-GENE-N
released,1031,O
from,1031,O
tumor,1031,O
cells,1031,O
and,1031,O
blockage,1031,O
by,1031,O
PPS,1031,O
of,1031,O
tumor,1031,O
growth,1031,O
in,1031,O
animals,1031,O
.,1031,O
BACKGROUND,1032,O
:,1032,O
In,1032,O
a,1032,O
proliferating,1032,O
tumor,1032,O
",",1032,O
locally,1032,O
secreted,1032,O
polypeptide,1032,O
growth,1032,O
factors,1032,O
",",1032,O
which,1032,O
have,1032,O
autocrine,1032,O
and,1032,O
paracrine,1032,O
functions,1032,O
",",1032,O
induce,1032,O
vascularization,1032,O
essential,1032,O
for,1032,O
tumor,1032,O
growth,1032,O
and,1032,O
metastasis,1032,O
.,1032,O
These,1033,O
growth,1033,O
factors,1033,O
may,1033,O
serve,1033,O
as,1033,O
targets,1033,O
for,1033,O
tumor,1033,O
therapy,1033,O
.,1033,O
We,1034,O
have,1034,O
shown,1034,O
that,1034,O
the,1034,O
heparinoid,1034,O
pentosan,1034,O
polysulfate,1034,O
(,1034,O
PPS,1034,O
),1034,O
can,1034,O
block,1034,O
growth,1034,O
of,1034,O
subcutaneous,1034,O
human,1034,O
tumor,1034,O
xenografts,1034,O
in,1034,O
nude,1034,O
mice,1034,O
and,1034,O
angiogenesis,1034,O
induced,1034,O
by,1034,O
the,1034,O
heparin-binding,1034,O
",",1034,O
Kaposi,1034,B-GENE-N
's,1034,I-GENE-N
sarcoma-derived,1034,I-GENE-N
fibroblast,1034,I-GENE-N
growth,1034,I-GENE-N
factor,1034,I-GENE-N
(,1034,O
K-FGF,1034,B-GENE-N
),1034,O
.,1034,O
PURPOSE,1035,O
:,1035,O
The,1035,O
purpose,1035,O
of,1035,O
this,1035,O
study,1035,O
was,1035,O
to,1035,O
determine,1035,O
whether,1035,O
PPS,1035,O
might,1035,O
also,1035,O
interfere,1035,O
with,1035,O
stimulation,1035,O
of,1035,O
endothelial,1035,O
cells,1035,O
by,1035,O
other,1035,O
growth,1035,O
factors,1035,O
released,1035,O
from,1035,O
tumor,1035,O
cells,1035,O
and,1035,O
whether,1035,O
the,1035,O
promising,1035,O
antitumor,1035,O
effects,1035,O
of,1035,O
PPS,1035,O
extend,1035,O
to,1035,O
other,1035,O
human,1035,O
tumor,1035,O
cell,1035,O
lines,1035,O
.,1035,O
We,1036,O
studied,1036,O
the,1036,O
effects,1036,O
of,1036,O
PPS,1036,O
on,1036,O
stimulation,1036,O
by,1036,O
heparin-binding,1036,B-GENE-N
growth,1036,I-GENE-N
factors,1036,I-GENE-N
released,1036,O
from,1036,O
seven,1036,O
human,1036,O
tumor,1036,O
cell,1036,O
lines,1036,O
in,1036,O
vitro,1036,O
and,1036,O
on,1036,O
tumors,1036,O
growing,1036,O
from,1036,O
these,1036,O
cell,1036,O
lines,1036,O
in,1036,O
athymic,1036,O
nude,1036,O
mice,1036,O
.,1036,O
METHODS,1037,O
:,1037,O
Seven,1037,O
human,1037,O
cell,1037,O
lines,1037,O
established,1037,O
from,1037,O
breast,1037,O
",",1037,O
prostate,1037,O
",",1037,O
epidermoid,1037,O
",",1037,O
and,1037,O
lung,1037,O
carcinomas,1037,O
and,1037,O
rhabdomyosarcoma,1037,O
were,1037,O
used,1037,O
in,1037,O
in,1037,O
vivo,1037,O
as,1037,O
well,1037,O
as,1037,O
in,1037,O
vitro,1037,O
studies,1037,O
of,1037,O
the,1037,O
effects,1037,O
of,1037,O
PPS,1037,O
.,1037,O
We,1038,O
also,1038,O
studied,1038,O
in,1038,O
vitro,1038,O
the,1038,O
effects,1038,O
of,1038,O
PPS,1038,O
on,1038,O
growth,1038,O
factor-induced,1038,O
colony,1038,O
formation,1038,O
of,1038,O
normal,1038,O
rat,1038,O
kidney,1038,O
fibroblasts,1038,O
and,1038,O
human,1038,O
adrenal,1038,O
carcinoma,1038,O
cells,1038,O
.,1038,O
RESULTS,1039,O
:,1039,O
The,1039,O
tumor,1039,O
cell,1039,O
lines,1039,O
released,1039,O
growth,1039,O
factors,1039,O
into,1039,O
their,1039,O
media,1039,O
that,1039,O
stimulated,1039,O
growth,1039,O
of,1039,O
endothelial,1039,O
and,1039,O
epithelial,1039,O
cells,1039,O
as,1039,O
well,1039,O
as,1039,O
fibroblasts,1039,O
.,1039,O
Heparin-affinity,1040,O
chromatography,1040,O
showed,1040,O
that,1040,O
heparin-binding,1040,B-GENE-N
growth,1040,I-GENE-N
factors,1040,I-GENE-N
contributed,1040,O
substantially,1040,O
to,1040,O
this,1040,O
paracrine,1040,O
activity,1040,O
and,1040,O
that,1040,O
PPS,1040,O
inhibited,1040,O
this,1040,O
stimulus,1040,O
.,1040,O
Six,1041,O
of,1041,O
the,1041,O
seven,1041,O
tumor,1041,O
cell,1041,O
lines,1041,O
were,1041,O
resistant,1041,O
to,1041,O
PPS,1041,O
in,1041,O
soft-agar,1041,O
cloning,1041,O
assays,1041,O
and,1041,O
hence,1041,O
did,1041,O
not,1041,O
appear,1041,O
to,1041,O
depend,1041,O
on,1041,O
autocrine,1041,O
stimulation,1041,O
by,1041,O
the,1041,O
heparin-binding,1041,B-GENE-N
growth,1041,I-GENE-N
factors,1041,I-GENE-N
.,1041,O
In,1042,O
contrast,1042,O
to,1042,O
this,1042,O
in,1042,O
vitro,1042,O
resistance,1042,O
",",1042,O
subcutaneous,1042,O
growth,1042,O
of,1042,O
tumors,1042,O
from,1042,O
all,1042,O
cell,1042,O
lines,1042,O
in,1042,O
athymic,1042,O
nude,1042,O
mice,1042,O
was,1042,O
inhibited,1042,O
in,1042,O
a,1042,O
dose-dependent,1042,O
fashion,1042,O
by,1042,O
daily,1042,O
intraperitoneal,1042,O
injections,1042,O
of,1042,O
PPS,1042,O
.,1042,O
CONCLUSIONS,1043,O
:,1043,O
We,1043,O
conclude,1043,O
that,1043,O
heparin-binding,1043,B-GENE-N
growth,1043,I-GENE-N
factors,1043,I-GENE-N
contribute,1043,O
substantially,1043,O
to,1043,O
tumor,1043,O
growth,1043,O
in,1043,O
vivo,1043,O
and,1043,O
that,1043,O
PPS,1043,O
acts,1043,O
by,1043,O
blocking,1043,O
the,1043,O
paracrine,1043,O
effects,1043,O
of,1043,O
heparin-binding,1043,B-GENE-N
growth,1043,I-GENE-N
factors,1043,I-GENE-N
released,1043,O
from,1043,O
the,1043,O
tumor,1043,O
cells,1043,O
.,1043,O
IMPLICATION,1044,O
:,1044,O
PPS,1044,O
could,1044,O
become,1044,O
a,1044,O
novel,1044,O
treatment,1044,O
tool,1044,O
targeting,1044,O
tumor,1044,O
growth,1044,O
factors,1044,O
.,1044,O
Binding,1045,O
and,1045,O
GTPgammaS,1045,B-CHEMICAL
autoradiographic,1045,O
analysis,1045,O
of,1045,O
preproorphanin,1045,B-GENE-N
precursor,1045,I-GENE-N
peptide,1045,I-GENE-N
products,1045,O
at,1045,O
the,1045,O
ORL1,1045,B-GENE-Y
and,1045,O
opioid,1045,B-GENE-N
receptors,1045,I-GENE-N
.,1045,O
Utilizing,1046,O
agonist-stimulated,1046,O
GTPgammaS,1046,B-CHEMICAL
autoradiography,1046,O
",",1046,O
we,1046,O
analyzed,1046,O
the,1046,O
ability,1046,O
of,1046,O
preproorphanin,1046,B-GENE-N
FQ,1046,I-GENE-N
(,1046,I-GENE-N
ppOFQ,1046,I-GENE-N
),1046,I-GENE-N
peptides,1046,I-GENE-N
to,1046,O
stimulate,1046,O
[,1046,B-CHEMICAL
35S,1046,I-CHEMICAL
],1046,I-CHEMICAL
-GTPgammaS,1046,I-CHEMICAL
binding,1046,O
in,1046,O
adult,1046,O
rat,1046,O
brain,1046,O
.,1046,O
Orphanin,1047,B-GENE-Y
FQ,1047,I-GENE-Y
(,1047,O
OFQ,1047,B-GENE-Y
),1047,O
stimulated,1047,O
[,1047,B-CHEMICAL
35S,1047,I-CHEMICAL
],1047,I-CHEMICAL
-GTPgammaS,1047,I-CHEMICAL
binding,1047,O
in,1047,O
a,1047,O
pattern,1047,O
similar,1047,O
to,1047,O
that,1047,O
described,1047,O
for,1047,O
[,1047,O
125I,1047,B-CHEMICAL
],1047,O
-OFQ,1047,O
at,1047,O
the,1047,O
endogenous,1047,O
opioid,1047,B-GENE-Y
receptor-like,1047,I-GENE-Y
(,1047,I-GENE-Y
ORL1,1047,I-GENE-Y
),1047,I-GENE-Y
receptor,1047,I-GENE-Y
.,1047,O
The,1048,O
ppOFQ,1048,B-GENE-N
peptides,1048,O
nocistatin,1048,O
and,1048,O
orphanin,1048,B-GENE-Y
FQ2,1048,I-GENE-Y
(,1048,O
OFQ,1048,B-GENE-Y
II,1048,I-GENE-Y
(,1048,I-GENE-Y
1-17,1048,I-GENE-Y
),1048,I-GENE-Y
),1048,O
had,1048,O
no,1048,O
effect,1048,O
",",1048,O
suggesting,1048,O
that,1048,O
they,1048,O
do,1048,O
not,1048,O
mediate,1048,O
their,1048,O
reported,1048,O
analgesic,1048,O
effects,1048,O
via,1048,O
a,1048,O
G,1048,B-GENE-N
(,1048,I-GENE-N
i/o,1048,I-GENE-N
),1048,I-GENE-N
-coupled,1048,I-GENE-N
receptor,1048,I-GENE-N
(,1048,O
i.e,1048,O
.,1048,O
opioid,1049,O
or,1049,O
ORL1,1049,B-GENE-Y
),1049,O
.,1049,O
Unlike,1050,O
OFQ,1050,B-GENE-Y
II,1050,I-GENE-Y
(,1050,I-GENE-Y
1-17,1050,I-GENE-Y
),1050,I-GENE-Y
",",1050,O
high,1050,O
concentrations,1050,O
of,1050,O
its,1050,O
C-terminal,1050,B-CHEMICAL
extension,1050,O
",",1050,O
OFQ,1050,B-GENE-Y
II,1050,I-GENE-Y
(,1050,I-GENE-Y
1-28,1050,I-GENE-Y
),1050,I-GENE-Y
",",1050,O
stimulated,1050,O
[,1050,B-CHEMICAL
35S,1050,I-CHEMICAL
],1050,I-CHEMICAL
-GTPgammaS,1050,I-CHEMICAL
binding,1050,O
in,1050,O
a,1050,O
mu,1050,B-GENE-Y
(,1050,I-GENE-Y
mu,1050,I-GENE-Y
),1050,I-GENE-Y
opioid,1050,I-GENE-Y
receptor-like,1050,O
distribution,1050,O
and,1050,O
the,1050,O
effect,1050,O
was,1050,O
blocked,1050,O
by,1050,O
naloxone,1050,B-CHEMICAL
.,1050,O
To,1051,O
explore,1051,O
these,1051,O
observations,1051,O
",",1051,O
we,1051,O
evaluated,1051,O
the,1051,O
receptor,1051,O
binding,1051,O
profile,1051,O
of,1051,O
OFQ,1051,B-GENE-Y
II,1051,I-GENE-Y
(,1051,I-GENE-Y
1-28,1051,I-GENE-Y
),1051,I-GENE-Y
at,1051,O
the,1051,O
cloned,1051,O
ORL1,1051,B-GENE-Y
and,1051,O
mu,1051,B-GENE-Y
opioid,1051,I-GENE-Y
receptors,1051,I-GENE-Y
.,1051,O
OFQ,1052,B-GENE-Y
II,1052,I-GENE-Y
(,1052,I-GENE-Y
1-28,1052,I-GENE-Y
),1052,I-GENE-Y
had,1052,O
no,1052,O
specific,1052,O
binding,1052,O
at,1052,O
either,1052,O
ORL1,1052,B-GENE-Y
or,1052,O
mu,1052,B-GENE-Y
opioid,1052,I-GENE-Y
receptors,1052,I-GENE-Y
at,1052,O
concentrations,1052,O
up,1052,O
to,1052,O
50,1052,O
microM,1052,O
.,1052,O
This,1053,O
lack,1053,O
of,1053,O
affinity,1053,O
was,1053,O
not,1053,O
consistent,1053,O
with,1053,O
a,1053,O
mu-mediated,1053,O
effect,1053,O
",",1053,O
as,1053,O
suggested,1053,O
by,1053,O
preliminary,1053,O
observation,1053,O
using,1053,O
functional,1053,O
autoradiography,1053,O
in,1053,O
rat,1053,O
brain,1053,O
sections,1053,O
.,1053,O
Although,1054,O
behavioral,1054,O
studies,1054,O
suggest,1054,O
that,1054,O
OFQ,1054,B-GENE-Y
II,1054,I-GENE-Y
(,1054,I-GENE-Y
1-28,1054,I-GENE-Y
),1054,I-GENE-Y
possesses,1054,O
analgesic,1054,O
activity,1054,O
",",1054,O
this,1054,O
effect,1054,O
does,1054,O
not,1054,O
appear,1054,O
to,1054,O
be,1054,O
mediated,1054,O
via,1054,O
direct,1054,O
binding,1054,O
at,1054,O
the,1054,O
mu,1054,B-GENE-Y
opioid,1054,I-GENE-Y
receptor,1054,I-GENE-Y
.,1054,O
Taken,1055,O
together,1055,O
",",1055,O
these,1055,O
findings,1055,O
support,1055,O
the,1055,O
view,1055,O
that,1055,O
(,1055,O
1,1055,O
),1055,O
OFQ,1055,B-GENE-Y
is,1055,O
the,1055,O
only,1055,O
ppOFQ,1055,B-GENE-N
peptide,1055,O
that,1055,O
binds,1055,O
to,1055,O
and,1055,O
activates,1055,O
the,1055,O
ORL1,1055,B-GENE-N
receptor,1055,O
and,1055,O
(,1055,O
2,1055,O
),1055,O
OFQ,1055,B-GENE-Y
II,1055,I-GENE-Y
(,1055,I-GENE-Y
1-28,1055,I-GENE-Y
),1055,I-GENE-Y
does,1055,O
not,1055,O
bind,1055,O
or,1055,O
stimulate,1055,O
[,1055,B-CHEMICAL
35S,1055,I-CHEMICAL
],1055,I-CHEMICAL
-GTPgammaS,1055,I-CHEMICAL
binding,1055,O
in,1055,O
cells,1055,O
expressing,1055,O
the,1055,O
mu,1055,B-GENE-Y
opioid,1055,I-GENE-Y
receptor,1055,I-GENE-Y
.,1055,O
Tethered,1056,O
dimers,1056,O
as,1056,O
NAD,1056,B-CHEMICAL
synthetase,1056,I-GENE-N
inhibitors,1056,O
with,1056,O
antibacterial,1056,O
activity,1056,O
.,1056,O
The,1057,O
solution-phase,1057,O
parallel,1057,O
synthesis,1057,O
of,1057,O
tethered,1057,O
dimers,1057,O
was,1057,O
employed,1057,O
to,1057,O
identify,1057,O
lead,1057,O
inhibitors,1057,O
of,1057,O
bacterial,1057,B-GENE-N
NAD,1057,I-GENE-N
synthetase,1057,I-GENE-N
.,1057,O
Active,1058,O
dimers,1058,O
contained,1058,O
two,1058,O
aromatic,1058,O
end,1058,O
groups,1058,O
joined,1058,O
by,1058,O
a,1058,O
polymethylene,1058,O
linker,1058,O
",",1058,O
with,1058,O
one,1058,O
end,1058,O
group,1058,O
containing,1058,O
a,1058,O
permanent,1058,O
positive,1058,O
charge,1058,O
.,1058,O
Effective,1059,O
inhibitors,1059,O
of,1059,O
NAD,1059,B-GENE-N
synthetase,1059,I-GENE-N
also,1059,O
inhibited,1059,O
the,1059,O
growth,1059,O
of,1059,O
Gram-positive,1059,O
(,1059,O
but,1059,O
not,1059,O
Gram-negative,1059,O
),1059,O
bacteria,1059,O
",",1059,O
including,1059,O
antibiotic-resistant,1059,O
strains,1059,O
.,1059,O
The,1060,O
desmethyl,1060,O
precursors,1060,O
of,1060,O
active,1060,O
inhibitors,1060,O
lacked,1060,O
a,1060,O
permanent,1060,O
positive,1060,O
charge,1060,O
and,1060,O
were,1060,O
inactive,1060,O
as,1060,O
either,1060,O
enzyme,1060,O
inhibitors,1060,O
or,1060,O
antibacterial,1060,O
agents,1060,O
.,1060,O
Similarly,1061,O
",",1061,O
a,1061,O
close,1061,O
structural,1061,O
analogue,1061,O
of,1061,O
the,1061,O
most,1061,O
active,1061,O
inhibitors,1061,O
contained,1061,O
two,1061,O
additional,1061,O
ether,1061,O
oxygens,1061,B-CHEMICAL
in,1061,O
the,1061,O
tether,1061,O
and,1061,O
was,1061,O
inactive,1061,O
in,1061,O
both,1061,O
assays,1061,O
.,1061,O
These,1062,O
results,1062,O
are,1062,O
consistent,1062,O
with,1062,O
the,1062,O
premise,1062,O
that,1062,O
NAD,1062,B-GENE-N
synthetase,1062,I-GENE-N
inhibition,1062,O
is,1062,O
responsible,1062,O
for,1062,O
the,1062,O
antibacterial,1062,O
actions,1062,O
and,1062,O
support,1062,O
further,1062,O
studies,1062,O
on,1062,O
NAD,1062,B-CHEMICAL
synthetase,1062,I-GENE-N
as,1062,O
a,1062,O
new,1062,O
target,1062,O
for,1062,O
antibacterial,1062,O
agents,1062,O
.,1062,O
Blockade,1063,O
of,1063,O
LTC4,1063,B-CHEMICAL
synthesis,1063,O
caused,1063,O
by,1063,O
additive,1063,O
inhibition,1063,O
of,1063,O
gIV-PLA2,1063,B-GENE-N
phosphorylation,1063,O
:,1063,O
Effect,1063,O
of,1063,O
salmeterol,1063,B-CHEMICAL
and,1063,O
PDE4,1063,B-GENE-N
inhibition,1063,O
in,1063,O
human,1063,O
eosinophils,1063,O
.,1063,O
BACKGROUND,1064,O
:,1064,O
Prior,1064,O
investigations,1064,O
have,1064,O
demonstrated,1064,O
that,1064,O
beta,1064,B-GENE-Y
(,1064,I-GENE-Y
2,1064,I-GENE-Y
),1064,I-GENE-Y
-adrenoceptor,1064,I-GENE-Y
stimulation,1064,O
is,1064,O
ineffective,1064,O
in,1064,O
inhibiting,1064,O
synthesis,1064,O
of,1064,O
eicosanoids,1064,O
in,1064,O
human,1064,O
eosinophils,1064,O
.,1064,O
This,1065,O
effect,1065,O
has,1065,O
been,1065,O
postulated,1065,O
to,1065,O
relate,1065,O
to,1065,O
density,1065,O
or,1065,O
structural,1065,O
differences,1065,O
in,1065,O
the,1065,O
beta,1065,B-GENE-Y
(,1065,I-GENE-Y
2,1065,I-GENE-Y
),1065,I-GENE-Y
-adrenoceptor,1065,I-GENE-Y
or,1065,O
its,1065,O
coupled,1065,O
G-protein,1065,B-GENE-N
.,1065,O
However,1066,O
",",1066,O
recent,1066,O
reports,1066,O
indicate,1066,O
that,1066,O
cAMP-specific,1066,B-GENE-N
PDE4,1066,I-GENE-N
activity,1066,O
in,1066,O
eosinophils,1066,O
is,1066,O
10-fold,1066,O
that,1066,O
of,1066,O
other,1066,O
inflammatory,1066,O
cells,1066,O
.,1066,O
We,1067,O
postulated,1067,O
that,1067,O
selective,1067,O
blockade,1067,O
of,1067,O
PDE4,1067,B-GENE-N
in,1067,O
eosinophils,1067,O
would,1067,O
unmask,1067,O
the,1067,O
inhibitory,1067,O
effect,1067,O
of,1067,O
beta,1067,B-GENE-Y
(,1067,I-GENE-Y
2,1067,I-GENE-Y
),1067,I-GENE-Y
-adrenoceptor,1067,I-GENE-Y
stimulation,1067,O
and,1067,O
that,1067,O
this,1067,O
inhibition,1067,O
would,1067,O
result,1067,O
from,1067,O
decreased,1067,O
phosphor-ylation,1067,O
of,1067,O
cytosolic,1067,B-GENE-N
group,1067,I-GENE-N
IV-PLA,1067,I-GENE-N
(,1067,I-GENE-N
2,1067,I-GENE-N
),1067,I-GENE-N
(,1067,O
gIV-PLA,1067,B-GENE-N
(,1067,I-GENE-N
2,1067,I-GENE-N
),1067,I-GENE-N
),1067,O
.,1067,O
OBJECTIVE,1068,O
:,1068,O
To,1068,O
determine,1068,O
(,1068,O
a,1068,O
),1068,O
whether,1068,O
PDE4,1068,B-GENE-N
inhibition,1068,O
alone,1068,O
with,1068,O
rolipram,1068,B-CHEMICAL
blocked,1068,O
secretions,1068,O
of,1068,O
arachidonic,1068,B-CHEMICAL
acid,1068,I-CHEMICAL
(,1068,O
AA,1068,B-CHEMICAL
),1068,O
and,1068,O
leukotriene,1068,B-CHEMICAL
C,1068,I-CHEMICAL
(,1068,I-CHEMICAL
4,1068,I-CHEMICAL
),1068,I-CHEMICAL
(,1068,O
LTC,1068,B-CHEMICAL
(,1068,I-CHEMICAL
4,1068,I-CHEMICAL
),1068,I-CHEMICAL
),1068,O
caused,1068,O
by,1068,O
activation,1068,O
of,1068,O
eosinophils,1068,O
with,1068,O
formyl-met-leu-phe,1068,B-CHEMICAL
plus,1068,O
cytochalasin,1068,B-CHEMICAL
B,1068,I-CHEMICAL
(,1068,O
FMLP/B,1068,O
),1068,O
",",1068,O
(,1068,O
b,1068,O
),1068,O
to,1068,O
determine,1068,O
if,1068,O
PDE4,1068,B-GENE-N
inhibition,1068,O
plus,1068,O
beta,1068,B-GENE-Y
(,1068,I-GENE-Y
2,1068,I-GENE-Y
),1068,I-GENE-Y
-adrenoceptor,1068,I-GENE-Y
agonist,1068,O
act,1068,O
additively,1068,O
to,1068,O
augment,1068,O
endogenous,1068,O
cAMP,1068,B-CHEMICAL
concentration,1068,O
",",1068,O
and,1068,O
(,1068,O
c,1068,O
),1068,O
to,1068,O
determine,1068,O
the,1068,O
mechanism,1068,O
by,1068,O
which,1068,O
additive,1068,O
inhibition,1068,O
of,1068,O
AA,1068,B-CHEMICAL
and,1068,O
LTC,1068,B-CHEMICAL
(,1068,I-CHEMICAL
4,1068,I-CHEMICAL
),1068,I-CHEMICAL
synthesis,1068,O
is,1068,O
regulated,1068,O
by,1068,O
cAMP,1068,B-CHEMICAL
.,1068,O
METHODS,1069,O
:,1069,O
Human,1069,O
eosinophils,1069,O
were,1069,O
pretreated,1069,O
with,1069,O
buffer,1069,O
",",1069,O
salmeterol,1069,B-CHEMICAL
or,1069,O
rolipram,1069,B-CHEMICAL
(,1069,O
singly,1069,O
or,1069,O
combination,1069,O
),1069,O
before,1069,O
FMLP/B,1069,O
activation,1069,O
.,1069,O
Release,1070,O
of,1070,O
AA,1070,B-CHEMICAL
and,1070,O
LTC,1070,B-CHEMICAL
(,1070,I-CHEMICAL
4,1070,I-CHEMICAL
),1070,I-CHEMICAL
",",1070,O
intracellular,1070,O
cAMP,1070,B-CHEMICAL
concentration,1070,O
",",1070,O
and,1070,O
phosphorylation,1070,O
and,1070,O
activation,1070,O
of,1070,O
gIV-PLA,1070,B-GENE-N
(,1070,I-GENE-N
2,1070,I-GENE-N
),1070,I-GENE-N
were,1070,O
determined,1070,O
.,1070,O
RESULTS,1071,O
:,1071,O
Rolipram,1071,B-CHEMICAL
unmasked,1071,O
the,1071,O
inhibitory,1071,O
effect,1071,O
of,1071,O
beta,1071,B-GENE-N
(,1071,I-GENE-N
2,1071,I-GENE-N
),1071,I-GENE-N
-adrenoceptor,1071,I-GENE-N
stimulation,1071,O
with,1071,O
salmeterol,1071,B-CHEMICAL
and,1071,O
significantly,1071,O
attenuated,1071,O
the,1071,O
stimulated,1071,O
release,1071,O
of,1071,O
AA,1071,B-CHEMICAL
and,1071,O
subsequent,1071,O
LTC,1071,B-CHEMICAL
(,1071,I-CHEMICAL
4,1071,I-CHEMICAL
),1071,I-CHEMICAL
.,1071,O
Inhibition,1072,O
corresponded,1072,O
to,1072,O
increased,1072,O
cAMP,1072,B-CHEMICAL
production,1072,O
caused,1072,O
by,1072,O
rolipram,1072,B-CHEMICAL
alone,1072,O
or,1072,O
rolipram,1072,B-CHEMICAL
plus,1072,O
salmeterol,1072,B-CHEMICAL
and,1072,O
blocked,1072,O
proportionately,1072,O
the,1072,O
phosphorylation,1072,O
and,1072,O
activation,1072,O
of,1072,O
gIV-PLA,1072,B-GENE-N
(,1072,I-GENE-N
2,1072,I-GENE-N
),1072,I-GENE-N
in,1072,O
FMLP/B-activated,1072,O
eosinophils,1072,O
.,1072,O
CONCLUSIONS,1073,O
:,1073,O
Inhibition,1073,O
of,1073,O
PDE4,1073,B-GENE-N
by,1073,O
rolipram,1073,B-CHEMICAL
unmasks,1073,O
beta,1073,B-GENE-Y
(,1073,I-GENE-Y
2,1073,I-GENE-Y
),1073,I-GENE-Y
-adrenergic,1073,I-GENE-Y
blockade,1073,O
of,1073,O
LTC,1073,B-CHEMICAL
(,1073,I-CHEMICAL
4,1073,I-CHEMICAL
),1073,I-CHEMICAL
synthesis,1073,O
caused,1073,O
by,1073,O
FMLP/B,1073,O
.,1073,O
A,1074,O
phase,1074,O
1,1074,O
study,1074,O
of,1074,O
tazarotene,1074,B-CHEMICAL
in,1074,O
adults,1074,O
with,1074,O
advanced,1074,O
cancer,1074,O
.,1074,O
Tazarotene,1075,B-CHEMICAL
is,1075,O
an,1075,O
acetylenic,1075,B-CHEMICAL
retinoid,1075,I-CHEMICAL
which,1075,O
is,1075,O
metabolised,1075,O
to,1075,O
tazarotenic,1075,B-CHEMICAL
acid,1075,I-CHEMICAL
and,1075,O
which,1075,O
binds,1075,O
selectively,1075,O
to,1075,O
the,1075,O
retinoid,1075,B-CHEMICAL
receptors,1075,I-GENE-N
RARbeta,1075,B-GENE-Y
and,1075,O
RARgamma,1075,B-GENE-Y
.,1075,O
The,1076,O
safety,1076,O
",",1076,O
toxicity,1076,O
and,1076,O
pharmacokinetics,1076,O
of,1076,O
oral,1076,O
tazarotene,1076,B-CHEMICAL
were,1076,O
determined,1076,O
over,1076,O
12,1076,O
weeks,1076,O
of,1076,O
treatment,1076,O
in,1076,O
34,1076,O
patients,1076,O
with,1076,O
advanced,1076,O
cancer,1076,O
.,1076,O
Commonly,1077,O
seen,1077,O
toxicities,1077,O
were,1077,O
mucocutaneous,1077,O
symptoms,1077,O
",",1077,O
musculoskeletal,1077,O
pain,1077,O
and,1077,O
headache,1077,O
.,1077,O
Dose-limiting,1078,O
toxicities,1078,O
were,1078,O
hypercalcaemia,1078,O
",",1078,O
hypertriglyceridaemia,1078,O
and,1078,O
musculoskeletal,1078,O
pain,1078,O
.,1078,O
The,1079,O
maximum,1079,O
tolerated,1079,O
dose,1079,O
of,1079,O
tazarotene,1079,B-CHEMICAL
in,1079,O
this,1079,O
schedule,1079,O
is,1079,O
25.2,1079,O
mg,1079,O
day,1079,O
(,1079,O
-1,1079,O
),1079,O
.,1079,O
Plasma,1080,O
concentrations,1080,O
of,1080,O
tazarotenic,1080,B-CHEMICAL
acid,1080,I-CHEMICAL
were,1080,O
found,1080,O
to,1080,O
peak,1080,O
rapidly,1080,O
within,1080,O
1-3,1080,O
h,1080,O
of,1080,O
dosing,1080,O
and,1080,O
thereafter,1080,O
declined,1080,O
quickly,1080,O
.,1080,O
The,1081,O
C,1081,O
(,1081,O
max,1081,O
),1081,O
and,1081,O
AUC,1081,O
values,1081,O
on,1081,O
day,1081,O
0,1081,O
",",1081,O
and,1081,O
weeks,1081,O
2,1081,O
and,1081,O
4,1081,O
were,1081,O
similar,1081,O
indicating,1081,O
no,1081,O
drug,1081,O
accumulation,1081,O
.,1081,O
The,1082,O
dose-normalised,1082,O
C,1082,O
(,1082,O
max,1082,O
),1082,O
and,1082,O
AUC,1082,O
values,1082,O
at,1082,O
different,1082,O
dose,1082,O
levels,1082,O
and,1082,O
different,1082,O
study,1082,O
days,1082,O
appeared,1082,O
to,1082,O
be,1082,O
similar,1082,O
indicating,1082,O
linear,1082,O
pharmacokinetics,1082,O
.,1082,O
No,1083,O
objective,1083,O
responses,1083,O
were,1083,O
seen,1083,O
",",1083,O
although,1083,O
stable,1083,O
disease,1083,O
was,1083,O
seen,1083,O
in,1083,O
six,1083,O
out,1083,O
of,1083,O
eight,1083,O
evaluable,1083,O
patients,1083,O
receiving,1083,O
the,1083,O
three,1083,O
highest,1083,O
dose,1083,O
levels,1083,O
of,1083,O
tazarotene,1083,B-CHEMICAL
(,1083,O
16.8,1083,O
",",1083,O
25.2,1083,O
or,1083,O
33.4,1083,O
mg,1083,O
day,1083,O
(,1083,O
-1,1083,O
),1083,O
),1083,O
.,1083,O
We,1084,O
conclude,1084,O
that,1084,O
oral,1084,O
tazarotene,1084,B-CHEMICAL
is,1084,O
well,1084,O
tolerated,1084,O
when,1084,O
administered,1084,O
daily,1084,O
for,1084,O
12,1084,O
weeks,1084,O
",",1084,O
has,1084,O
a,1084,O
favourable,1084,O
toxicity,1084,O
profile,1084,O
compared,1084,O
with,1084,O
other,1084,O
retinoids,1084,B-CHEMICAL
and,1084,O
merits,1084,O
further,1084,O
investigation,1084,O
as,1084,O
an,1084,O
anticancer,1084,O
therapy,1084,O
.,1084,O
Anabolic,1085,O
effects,1085,O
of,1085,O
clenbuterol,1085,B-CHEMICAL
on,1085,O
skeletal,1085,O
muscle,1085,O
are,1085,O
mediated,1085,O
by,1085,O
beta,1085,B-GENE-Y
2-adrenoceptor,1085,I-GENE-Y
activation,1085,O
.,1085,O
The,1086,O
potent,1086,O
anabolic,1086,O
effects,1086,O
of,1086,O
the,1086,O
beta,1086,B-GENE-Y
2-adrenoceptor,1086,I-GENE-Y
agonist,1086,O
clenbuterol,1086,B-CHEMICAL
on,1086,O
skeletal,1086,O
muscle,1086,O
have,1086,O
been,1086,O
reported,1086,O
to,1086,O
be,1086,O
independent,1086,O
of,1086,O
actions,1086,O
on,1086,O
beta-adrenoceptors,1086,B-GENE-N
.,1086,O
In,1087,O
the,1087,O
present,1087,O
study,1087,O
clenbuterol,1087,B-CHEMICAL
",",1087,O
presented,1087,O
to,1087,O
rats,1087,O
in,1087,O
the,1087,O
diet,1087,O
(,1087,O
4,1087,O
mg/kg,1087,O
),1087,O
",",1087,O
caused,1087,O
significant,1087,O
increases,1087,O
in,1087,O
gastrocnemius,1087,O
muscle,1087,O
mass,1087,O
",",1087,O
protein,1087,O
",",1087,O
and,1087,O
RNA,1087,O
content,1087,O
and,1087,O
a,1087,O
decrease,1087,O
in,1087,O
epididymal,1087,O
fat,1087,O
pad,1087,O
mass,1087,O
.,1087,O
These,1088,O
effects,1088,O
were,1088,O
not,1088,O
mimicked,1088,O
by,1088,O
oral,1088,O
administration,1088,O
of,1088,O
the,1088,O
beta,1088,B-GENE-Y
2-adrenoceptor,1088,I-GENE-Y
agonist,1088,O
salbutamol,1088,B-CHEMICAL
even,1088,O
at,1088,O
high,1088,O
dose,1088,O
(,1088,O
52,1088,O
mg/kg,1088,O
diet,1088,O
),1088,O
",",1088,O
and,1088,O
the,1088,O
effects,1088,O
of,1088,O
clenbuterol,1088,B-CHEMICAL
were,1088,O
not,1088,O
inhibited,1088,O
by,1088,O
addition,1088,O
of,1088,O
DL-propranolol,1088,B-CHEMICAL
(,1088,O
200,1088,O
mg/kg,1088,O
diet,1088,O
),1088,O
.,1088,O
However,1089,O
",",1089,O
the,1089,O
selective,1089,O
beta,1089,O
2-antagonist,1089,O
"ICI-118,551",1089,B-CHEMICAL
(,1089,O
200,1089,O
mg/kg,1089,O
diet,1089,O
),1089,O
reversed,1089,O
the,1089,O
anabolic,1089,O
effects,1089,O
of,1089,O
clenbuterol,1089,B-CHEMICAL
",",1089,O
and,1089,O
a,1089,O
high,1089,O
dose,1089,O
of,1089,O
DL-propranolol,1089,B-CHEMICAL
(,1089,O
"1,000",1089,O
mg/kg,1089,O
diet,1089,O
),1089,O
also,1089,O
inhibited,1089,O
these,1089,O
actions,1089,O
of,1089,O
clenbuterol,1089,B-CHEMICAL
.,1089,O
Furthermore,1090,O
",",1090,O
continuous,1090,O
infusion,1090,O
of,1090,O
salbutamol,1090,B-CHEMICAL
(,1090,O
1.15,1090,O
mg.kg,1090,O
body,1090,O
wt-1.day-1,1090,O
),1090,O
via,1090,O
miniosmotic,1090,O
pumps,1090,O
did,1090,O
cause,1090,O
significant,1090,O
increases,1090,O
in,1090,O
muscle,1090,O
mass,1090,O
",",1090,O
protein,1090,O
",",1090,O
and,1090,O
RNA,1090,O
content,1090,O
.,1090,O
These,1091,O
results,1091,O
indicate,1091,O
that,1091,O
the,1091,O
anabolic,1091,O
effects,1091,O
of,1091,O
clenbuterol,1091,B-CHEMICAL
are,1091,O
dependent,1091,O
on,1091,O
interaction,1091,O
with,1091,O
the,1091,O
beta,1091,B-GENE-Y
2-adrenoceptor,1091,I-GENE-Y
.,1091,O
However,1092,O
",",1092,O
a,1092,O
long,1092,O
duration,1092,O
of,1092,O
action,1092,O
appears,1092,O
to,1092,O
be,1092,O
required,1092,O
to,1092,O
induce,1092,O
the,1092,O
anabolic,1092,O
effects,1092,O
of,1092,O
beta,1092,O
2-agonists,1092,O
.,1092,O
Evidence,1093,O
that,1093,O
an,1093,O
alpha,1093,B-GENE-Y
2A-adrenoceptor,1093,I-GENE-Y
subtype,1093,O
mediates,1093,O
antinociception,1093,O
in,1093,O
mice,1093,O
.,1093,O
In,1094,O
the,1094,O
hot-plate,1094,O
test,1094,O
in,1094,O
mice,1094,O
",",1094,O
the,1094,O
antinociceptive,1094,O
action,1094,O
of,1094,O
the,1094,O
alpha,1094,B-GENE-N
2-adrenoceptor,1094,I-GENE-N
agonist,1094,O
",",1094,O
UK,1094,B-CHEMICAL
"14,304",1094,I-CHEMICAL
",",1094,O
was,1094,O
abolished,1094,O
by,1094,O
the,1094,O
alpha,1094,B-GENE-N
2-adrenoceptor,1094,I-GENE-N
antagonist,1094,O
",",1094,O
idazoxan,1094,B-CHEMICAL
",",1094,O
the,1094,O
potent,1094,O
alpha,1094,B-GENE-Y
2A-adrenoceptor,1094,I-GENE-Y
antagonist,1094,O
",",1094,O
RX,1094,B-CHEMICAL
821002,1094,I-CHEMICAL
and,1094,O
the,1094,O
preferential,1094,O
alpha,1094,B-GENE-Y
2A-adrenoceptor,1094,I-GENE-Y
antagonist,1094,O
",",1094,O
BRL,1094,B-CHEMICAL
44408,1094,I-CHEMICAL
.,1094,O
In,1095,O
contrast,1095,O
",",1095,O
the,1095,O
preferential,1095,O
alpha,1095,B-GENE-N
2B-,1095,I-GENE-N
(,1095,I-GENE-N
and,1095,I-GENE-N
alpha,1095,I-GENE-N
2C,1095,I-GENE-N
),1095,I-GENE-N
-adrenoceptor,1095,I-GENE-N
ligands,1095,O
(,1095,O
'antagonists,1095,O
',1095,O
),1095,O
",",1095,O
ARC-239,1095,B-CHEMICAL
",",1095,O
BRL,1095,B-CHEMICAL
41992,1095,I-CHEMICAL
and,1095,O
prazosin,1095,B-CHEMICAL
were,1095,O
inactive,1095,O
.,1095,O
The,1096,O
preferential,1096,O
alpha,1096,B-GENE-Y
2A-adrenoceptor,1096,I-GENE-Y
partial,1096,O
agonist,1096,O
",",1096,O
guanfacine,1096,B-CHEMICAL
",",1096,O
partially,1096,O
inhibited,1096,O
UK,1096,B-CHEMICAL
"14,304-induced",1096,O
antinociception,1096,O
.,1096,O
Further,1097,O
",",1097,O
guanfacine,1097,B-CHEMICAL
BRL,1097,B-CHEMICAL
44408,1097,I-CHEMICAL
reversibly,1097,O
elicited,1097,O
submaximal,1097,O
antinociception,1097,O
.,1097,O
It,1098,O
is,1098,O
concluded,1098,O
that,1098,O
alpha,1098,B-GENE-Y
2A-adrenoceptors,1098,I-GENE-Y
mediate,1098,O
antinociception,1098,O
in,1098,O
mice,1098,O
.,1098,O
Crystal,1099,O
structure,1099,O
of,1099,O
serine,1099,B-GENE-Y
dehydratase,1099,I-GENE-Y
from,1099,O
rat,1099,O
liver,1099,O
.,1099,O
SDH,1100,B-GENE-Y
(,1100,B-GENE-Y
L-serine,1100,I-GENE-Y
dehydratase,1100,I-GENE-Y
",",1100,O
EC,1100,B-GENE-Y
4.3.1.17,1100,I-GENE-Y
),1100,O
catalyzes,1100,O
the,1100,O
pyridoxal,1100,B-CHEMICAL
5'-phosphate,1100,I-CHEMICAL
(,1100,O
PLP,1100,B-CHEMICAL
),1100,O
-dependent,1100,O
dehydration,1100,O
of,1100,O
L-serine,1100,B-CHEMICAL
to,1100,O
yield,1100,O
pyruvate,1100,B-CHEMICAL
and,1100,O
ammonia,1100,B-CHEMICAL
.,1100,O
Liver,1101,O
SDH,1101,B-GENE-Y
plays,1101,O
an,1101,O
important,1101,O
role,1101,O
in,1101,O
gluconeogenesis,1101,O
.,1101,O
Formation,1102,O
of,1102,O
pyruvate,1102,B-CHEMICAL
by,1102,O
SDH,1102,B-GENE-Y
is,1102,O
a,1102,O
two-step,1102,O
reaction,1102,O
in,1102,O
which,1102,O
the,1102,O
hydroxyl,1102,B-CHEMICAL
group,1102,O
of,1102,O
serine,1102,B-CHEMICAL
is,1102,O
cleaved,1102,O
to,1102,O
produce,1102,O
aminoacrylate,1102,B-CHEMICAL
",",1102,O
and,1102,O
then,1102,O
the,1102,O
aminoacrylate,1102,B-CHEMICAL
is,1102,O
deaminated,1102,O
by,1102,O
nonenzymatic,1102,O
hydrolysis,1102,O
to,1102,O
produce,1102,O
pyruvate,1102,B-CHEMICAL
.,1102,O
The,1103,O
crystal,1103,O
structure,1103,O
of,1103,O
rat,1103,B-GENE-Y
liver,1103,I-GENE-Y
apo-SDH,1103,I-GENE-Y
was,1103,O
determined,1103,O
by,1103,O
single,1103,O
isomorphous,1103,O
replacement,1103,O
at,1103,O
2.8,1103,O
A,1103,O
resolution,1103,O
.,1103,O
The,1104,O
holo-SDH,1104,B-GENE-Y
crystallized,1104,O
with,1104,O
O-methylserine,1104,B-CHEMICAL
(,1104,O
OMS,1104,B-CHEMICAL
),1104,O
was,1104,O
also,1104,O
determined,1104,O
at,1104,O
2.6,1104,O
A,1104,O
resolution,1104,O
by,1104,O
molecular,1104,O
replacement,1104,O
.,1104,O
SDH,1105,B-GENE-Y
is,1105,O
composed,1105,O
of,1105,O
two,1105,O
domains,1105,O
",",1105,O
and,1105,O
each,1105,O
domain,1105,O
has,1105,O
a,1105,O
typical,1105,O
alphabeta-open,1105,O
structure,1105,O
.,1105,O
The,1106,O
active,1106,O
site,1106,O
is,1106,O
located,1106,O
in,1106,O
the,1106,O
cleft,1106,O
between,1106,O
the,1106,O
two,1106,O
domains,1106,O
.,1106,O
The,1107,O
holo-SDH,1107,B-GENE-Y
contained,1107,O
PLP-OMS,1107,O
aldimine,1107,B-CHEMICAL
in,1107,O
the,1107,O
active,1107,O
site,1107,O
",",1107,O
indicating,1107,O
that,1107,O
OMS,1107,B-CHEMICAL
can,1107,O
form,1107,O
the,1107,O
Schiff,1107,B-CHEMICAL
base,1107,I-CHEMICAL
linkage,1107,O
with,1107,O
PLP,1107,B-CHEMICAL
",",1107,O
but,1107,O
the,1107,O
subsequent,1107,O
dehydration,1107,O
did,1107,O
not,1107,O
occur,1107,O
.,1107,O
Apo-SDH,1108,B-GENE-Y
forms,1108,O
a,1108,O
dimer,1108,O
by,1108,O
inserting,1108,O
the,1108,O
small,1108,O
domain,1108,O
into,1108,O
the,1108,O
catalytic,1108,O
cleft,1108,O
of,1108,O
the,1108,O
partner,1108,O
subunit,1108,O
so,1108,O
that,1108,O
the,1108,O
active,1108,O
site,1108,O
is,1108,O
closed,1108,O
.,1108,O
Holo-SDH,1109,B-GENE-Y
also,1109,O
forms,1109,O
a,1109,O
dimer,1109,O
by,1109,O
making,1109,O
contacts,1109,O
at,1109,O
the,1109,O
back,1109,O
of,1109,O
the,1109,O
clefts,1109,O
so,1109,O
that,1109,O
the,1109,O
dimerization,1109,O
does,1109,O
not,1109,O
close,1109,O
the,1109,O
catalytic,1109,O
cleft,1109,O
.,1109,O
The,1110,O
phosphate,1110,O
group,1110,O
of,1110,O
PLP,1110,B-CHEMICAL
is,1110,O
surrounded,1110,O
by,1110,O
a,1110,O
characteristic,1110,O
G-rich,1110,B-GENE-N
sequence,1110,I-GENE-N
(,1110,O
(,1110,O
168,1110,O
),1110,O
GGGGL,1110,B-CHEMICAL
(,1110,O
172,1110,O
),1110,O
),1110,O
and,1110,O
forms,1110,O
hydrogen,1110,B-CHEMICAL
bonds,1110,O
with,1110,O
the,1110,O
amide,1110,B-CHEMICAL
groups,1110,O
of,1110,O
those,1110,O
amino,1110,B-CHEMICAL
acid,1110,I-CHEMICAL
residues,1110,O
",",1110,O
suggesting,1110,O
that,1110,O
the,1110,O
phosphate,1110,B-CHEMICAL
group,1110,O
can,1110,O
be,1110,O
protonated,1110,O
.,1110,O
N,1111,O
(,1111,O
1,1111,O
),1111,O
of,1111,O
PLP,1111,B-CHEMICAL
participates,1111,O
in,1111,O
a,1111,O
hydrogen,1111,B-CHEMICAL
bond,1111,O
with,1111,O
Cys303,1111,O
",",1111,O
and,1111,O
similar,1111,O
hydrogen,1111,B-CHEMICAL
bonds,1111,O
with,1111,O
N,1111,O
(,1111,O
1,1111,O
),1111,O
participating,1111,O
are,1111,O
seen,1111,O
in,1111,O
other,1111,O
beta-elimination,1111,O
enzymes,1111,O
.,1111,O
These,1112,O
hydrogen,1112,B-CHEMICAL
bonding,1112,O
schemes,1112,O
indicate,1112,O
that,1112,O
N,1112,O
(,1112,O
1,1112,O
),1112,O
is,1112,O
not,1112,O
protonated,1112,O
",",1112,O
and,1112,O
thus,1112,O
",",1112,O
the,1112,O
pyridine,1112,B-CHEMICAL
ring,1112,O
can,1112,O
not,1112,O
take,1112,O
a,1112,O
quinone-like,1112,B-CHEMICAL
structure,1112,O
.,1112,O
These,1113,O
characteristics,1113,O
of,1113,O
the,1113,O
bound,1113,O
PLP,1113,B-CHEMICAL
suggest,1113,O
that,1113,O
SDH,1113,B-GENE-Y
catalysis,1113,O
is,1113,O
not,1113,O
facilitated,1113,O
by,1113,O
forming,1113,O
the,1113,O
resonance-stabilized,1113,O
structure,1113,O
of,1113,O
the,1113,O
PLP-Ser,1113,B-CHEMICAL
aldimine,1113,I-CHEMICAL
as,1113,O
seen,1113,O
in,1113,O
aminotransferases,1113,B-GENE-N
.,1113,O
A,1114,O
possible,1114,O
catalytic,1114,O
mechanism,1114,O
involves,1114,O
the,1114,O
phosphate,1114,B-CHEMICAL
group,1114,O
",",1114,O
surrounded,1114,O
by,1114,O
the,1114,O
characteristic,1114,O
sequence,1114,O
",",1114,O
acting,1114,O
as,1114,O
a,1114,O
general,1114,O
acid,1114,O
to,1114,O
donate,1114,O
a,1114,O
proton,1114,O
to,1114,O
the,1114,O
leaving,1114,O
hydroxyl,1114,B-CHEMICAL
group,1114,O
of,1114,O
serine,1114,B-CHEMICAL
.,1114,O
Epidermal,1115,B-GENE-Y
growth,1115,I-GENE-Y
factor,1115,I-GENE-Y
receptor,1115,I-GENE-Y
autocrine,1115,O
signaling,1115,O
in,1115,O
RIE-1,1115,O
cells,1115,O
transformed,1115,O
by,1115,O
the,1115,O
Ras,1115,B-GENE-N
oncogene,1115,O
enhances,1115,O
radiation,1115,O
resistance,1115,O
.,1115,O
Oncogenic,1116,O
forms,1116,O
of,1116,O
the,1116,O
small,1116,O
GTPase,1116,B-GENE-N
Ras,1116,B-GENE-N
increase,1116,O
the,1116,O
resistance,1116,O
of,1116,O
cells,1116,O
to,1116,O
killing,1116,O
by,1116,O
ionizing,1116,O
radiation,1116,O
(,1116,O
IR,1116,O
),1116,O
.,1116,O
Although,1117,O
not,1117,O
all,1117,O
of,1117,O
the,1117,O
signaling,1117,O
pathways,1117,O
for,1117,O
radioresistance,1117,O
are,1117,O
well,1117,O
defined,1117,O
",",1117,O
it,1117,O
is,1117,O
now,1117,O
clear,1117,O
that,1117,O
Ras-dependent,1117,B-GENE-N
signaling,1117,O
pathways,1117,O
involved,1117,O
in,1117,O
radioresistance,1117,O
include,1117,O
those,1117,O
mediated,1117,O
by,1117,O
phosphatidylinositol,1117,B-CHEMICAL
3'-kinase,1117,I-GENE-N
(,1117,O
PI3-K,1117,B-GENE-N
),1117,O
and,1117,O
Raf,1117,B-GENE-N
.,1117,O
Nevertheless,1118,O
",",1118,O
PI3-K,1118,B-GENE-N
and,1118,O
Raf,1118,B-GENE-N
together,1118,O
are,1118,O
not,1118,O
sufficient,1118,O
to,1118,O
reconstitute,1118,O
all,1118,O
of,1118,O
the,1118,O
resistance,1118,O
conferred,1118,O
by,1118,O
Ras,1118,B-GENE-N
",",1118,O
indicating,1118,O
that,1118,O
other,1118,O
effectors,1118,O
must,1118,O
also,1118,O
contribute,1118,O
.,1118,O
We,1119,O
show,1119,O
here,1119,O
that,1119,O
Ras-driven,1119,B-GENE-N
autocrine,1119,O
signaling,1119,O
through,1119,O
the,1119,O
epidermal,1119,B-GENE-Y
growth,1119,I-GENE-Y
factor,1119,I-GENE-Y
receptor,1119,I-GENE-Y
(,1119,O
EGFR,1119,B-GENE-Y
),1119,O
also,1119,O
contributes,1119,O
to,1119,O
radioresistance,1119,O
in,1119,O
Ras-transformed,1119,B-GENE-N
cells,1119,O
.,1119,O
Conditioned,1120,O
media,1120,O
(,1120,O
CM,1120,O
),1120,O
collected,1120,O
from,1120,O
RIE-1,1120,O
rat,1120,O
intestinal,1120,O
epithelial,1120,O
cells,1120,O
expressing,1120,O
oncogenic,1120,O
Ras,1120,B-GENE-N
increased,1120,O
the,1120,O
survival,1120,O
of,1120,O
irradiated,1120,O
cells,1120,O
.,1120,O
Ras-CM,1121,B-GENE-N
contains,1121,O
elevated,1121,O
levels,1121,O
of,1121,O
the,1121,O
EGFR,1121,B-GENE-Y
ligand,1121,O
transforming,1121,B-GENE-Y
growth,1121,I-GENE-Y
factor,1121,I-GENE-Y
alpha,1121,I-GENE-Y
(,1121,O
TGF-alpha,1121,B-GENE-Y
),1121,O
.,1121,O
Both,1122,O
Ras-CM,1122,B-GENE-N
and,1122,O
TGF-alpha,1122,B-GENE-Y
stimulated,1122,O
EGFR,1122,B-GENE-Y
phosphorylation,1122,O
",",1122,O
and,1122,O
exogenous,1122,O
TGF-alpha,1122,B-GENE-Y
mimicked,1122,O
the,1122,O
effects,1122,O
of,1122,O
Ras-CM,1122,B-GENE-N
to,1122,O
increase,1122,O
radioresistance,1122,O
.,1122,O
Blocking,1123,O
EGFR,1123,B-GENE-Y
signaling,1123,O
with,1123,O
the,1123,O
EGFR/HER-2,1123,B-GENE-Y
kinase,1123,O
inhibitor,1123,O
(,1123,O
KI,1123,O
),1123,O
GW572016,1123,B-CHEMICAL
decreased,1123,O
the,1123,O
postradiation,1123,O
survival,1123,O
of,1123,O
irradiated,1123,O
Ras-transformed,1123,B-GENE-N
cells,1123,O
and,1123,O
normal,1123,O
cells,1123,O
but,1123,O
had,1123,O
no,1123,O
effect,1123,O
on,1123,O
the,1123,O
survival,1123,O
of,1123,O
unirradiated,1123,O
cells,1123,O
.,1123,O
Ras-CM,1124,B-GENE-N
and,1124,O
TGF-alpha,1124,B-GENE-Y
also,1124,O
increase,1124,O
PI3-K,1124,B-GENE-N
activity,1124,O
downstream,1124,O
of,1124,O
the,1124,O
EGFR,1124,B-GENE-Y
and,1124,O
increase,1124,O
postradiation,1124,O
survival,1124,O
",",1124,O
both,1124,O
of,1124,O
which,1124,O
are,1124,O
abrogated,1124,O
by,1124,O
GW572016,1124,B-CHEMICAL
.,1124,O
Thus,1125,O
",",1125,O
Ras,1125,B-GENE-N
utilizes,1125,O
autocrine,1125,O
signaling,1125,O
through,1125,O
EGFR,1125,B-GENE-Y
to,1125,O
increase,1125,O
radioresistance,1125,O
",",1125,O
and,1125,O
the,1125,O
EGFR,1125,B-GENE-Y
KI,1125,O
GW572016,1125,B-CHEMICAL
acts,1125,O
as,1125,O
a,1125,O
radiosensitizer,1125,O
.,1125,O
The,1126,O
observation,1126,O
that,1126,O
Ras-transformed,1126,B-GENE-N
cells,1126,O
can,1126,O
be,1126,O
sensitized,1126,O
to,1126,O
killing,1126,O
by,1126,O
ionizing,1126,O
radiation,1126,O
with,1126,O
GW572016,1126,B-CHEMICAL
demonstrates,1126,O
that,1126,O
EGFR,1126,B-GENE-Y
KIs,1126,O
could,1126,O
potentially,1126,O
be,1126,O
used,1126,O
to,1126,O
radiosensitize,1126,O
tumors,1126,O
in,1126,O
which,1126,O
radioresistance,1126,O
is,1126,O
dependent,1126,O
on,1126,O
Ras-driven,1126,B-GENE-N
autocrine,1126,O
signaling,1126,O
through,1126,O
EGFR,1126,B-GENE-Y
.,1126,O
Characterization,1127,O
of,1127,O
beta,1127,B-GENE-Y
3-adrenoceptor-mediated,1127,O
relaxation,1127,O
in,1127,O
rat,1127,O
abdominal,1127,O
aorta,1127,O
smooth,1127,O
muscle,1127,O
.,1127,O
The,1128,O
present,1128,O
study,1128,O
was,1128,O
carried,1128,O
out,1128,O
to,1128,O
characterize,1128,O
beta-adrenoceptor,1128,B-GENE-N
subtypes,1128,O
mediating,1128,O
relaxation,1128,O
of,1128,O
rat,1128,O
abdominal,1128,O
aorta,1128,O
smooth,1128,O
muscle,1128,O
.,1128,O
(,1129,B-CHEMICAL
-,1129,I-CHEMICAL
),1129,I-CHEMICAL
-Isoprenaline,1129,I-CHEMICAL
and,1129,O
a,1129,O
nonconventional,1129,O
beta,1129,B-GENE-Y
(,1129,I-GENE-Y
3,1129,I-GENE-Y
),1129,I-GENE-Y
-adrenoceptor,1129,I-GENE-Y
agonist,1129,O
",",1129,O
(,1129,B-CHEMICAL
+/-,1129,I-CHEMICAL
),1129,I-CHEMICAL
-,1129,I-CHEMICAL
[,1129,I-CHEMICAL
4-,1129,I-CHEMICAL
[,1129,I-CHEMICAL
3-,1129,I-CHEMICAL
[,1129,I-CHEMICAL
(,1129,I-CHEMICAL
"1,1-dimethylethyl",1129,I-CHEMICAL
),1129,I-CHEMICAL
amino,1129,I-CHEMICAL
],1129,I-CHEMICAL
-2-hydroxypropoxy,1129,I-CHEMICAL
],1129,I-CHEMICAL
"-1,3-dihydro-2H-benzimida",1129,I-CHEMICAL
zol-2-one,1129,I-CHEMICAL
],1129,I-CHEMICAL
hydrochloride,1129,I-CHEMICAL
(,1129,O
(,1129,B-CHEMICAL
+/-,1129,I-CHEMICAL
),1129,I-CHEMICAL
-CGP12177A,1129,I-CHEMICAL
),1129,O
",",1129,O
induced,1129,O
concentration-dependent,1129,O
relaxation,1129,O
of,1129,O
(,1129,B-CHEMICAL
-,1129,I-CHEMICAL
),1129,I-CHEMICAL
-phenylephrine,1129,I-CHEMICAL
(,1129,O
0.3,1129,O
microM,1129,O
),1129,O
preconstricted,1129,O
spiral,1129,O
preparations,1129,O
.,1129,O
Pretreatment,1130,O
with,1130,O
a,1130,O
combination,1130,O
of,1130,O
(,1130,B-CHEMICAL
+/-,1130,I-CHEMICAL
),1130,I-CHEMICAL
-2-hydroxy-5-,1130,I-CHEMICAL
[,1130,I-CHEMICAL
2-,1130,I-CHEMICAL
[,1130,I-CHEMICAL
[,1130,I-CHEMICAL
2-hydroxy-3-,1130,I-CHEMICAL
[,1130,I-CHEMICAL
4-,1130,I-CHEMICAL
[,1130,I-CHEMICAL
1-methyl-4-,1130,I-CHEMICAL
(,1130,I-CHEMICAL
trifluoromethyl,1130,I-CHEMICAL
),1130,I-CHEMICAL
-1H-imidazol-2,1130,I-CHEMICAL
-yl,1130,I-CHEMICAL
],1130,I-CHEMICAL
phenoxy,1130,I-CHEMICAL
],1130,I-CHEMICAL
propyl,1130,I-CHEMICAL
],1130,I-CHEMICAL
amino,1130,I-CHEMICAL
],1130,I-CHEMICAL
ethoxy,1130,I-CHEMICAL
],1130,I-CHEMICAL
-benzamide,1130,I-CHEMICAL
methanesulfonate,1130,I-CHEMICAL
(,1130,O
CGP20712A,1130,B-CHEMICAL
",",1130,O
a,1130,O
selective,1130,O
beta,1130,B-GENE-Y
(,1130,I-GENE-Y
1,1130,I-GENE-Y
),1130,I-GENE-Y
-adrenoceptor,1130,I-GENE-Y
antagonist,1130,O
),1130,O
and,1130,O
(,1130,B-CHEMICAL
+/-,1130,I-CHEMICAL
),1130,I-CHEMICAL
-1-,1130,I-CHEMICAL
[,1130,I-CHEMICAL
"2,3-",1130,I-CHEMICAL
(,1130,I-CHEMICAL
dihydro-7-methyl-1H-inden-4-yl,1130,I-CHEMICAL
),1130,I-CHEMICAL
oxy,1130,I-CHEMICAL
],1130,I-CHEMICAL
-3-,1130,I-CHEMICAL
[,1130,I-CHEMICAL
(,1130,I-CHEMICAL
1-methylethyl,1130,I-CHEMICAL
),1130,I-CHEMICAL
amino,1130,I-CHEMICAL
],1130,I-CHEMICAL
-2-buta,1130,I-CHEMICAL
nol,1130,I-CHEMICAL
hydrochloride,1130,I-CHEMICAL
(,1130,O
"ICI-118,5511",1130,B-CHEMICAL
",",1130,O
a,1130,O
selective,1130,O
beta,1130,B-GENE-Y
(,1130,I-GENE-Y
2,1130,I-GENE-Y
),1130,I-GENE-Y
-adrenoceptor,1130,I-GENE-Y
antagonist,1130,O
),1130,O
(,1130,O
0.1,1130,O
microM,1130,O
for,1130,O
each,1130,O
),1130,O
produced,1130,O
a,1130,O
14-fold,1130,O
rightward,1130,O
shift,1130,O
of,1130,O
the,1130,O
concentration-response,1130,O
curve,1130,O
for,1130,O
(,1130,B-CHEMICAL
-,1130,I-CHEMICAL
),1130,I-CHEMICAL
-isoprenaline,1130,I-CHEMICAL
;,1130,O
however,1130,O
",",1130,O
the,1130,O
relaxation,1130,O
in,1130,O
response,1130,O
to,1130,O
(,1130,B-CHEMICAL
+/-,1130,I-CHEMICAL
),1130,I-CHEMICAL
-CGP12177A,1130,I-CHEMICAL
was,1130,O
unaffected,1130,O
by,1130,O
the,1130,O
blockade,1130,O
of,1130,O
beta,1130,B-GENE-N
(,1130,I-GENE-N
1,1130,I-GENE-N
),1130,I-GENE-N
-,1130,I-GENE-N
and,1130,I-GENE-N
beta,1130,I-GENE-N
(,1130,I-GENE-N
2,1130,I-GENE-N
),1130,I-GENE-N
-adrenoceptors,1130,I-GENE-N
.,1130,O
In,1131,O
the,1131,O
presence,1131,O
of,1131,O
CGP20712A,1131,B-CHEMICAL
and,1131,O
"ICI-118,551",1131,B-CHEMICAL
(,1131,O
0.1,1131,O
microM,1131,O
for,1131,O
each,1131,O
),1131,O
",",1131,O
the,1131,O
concentration-response,1131,O
curves,1131,O
for,1131,O
(,1131,B-CHEMICAL
-,1131,I-CHEMICAL
),1131,I-CHEMICAL
-isoprenaline,1131,I-CHEMICAL
and,1131,O
(,1131,B-CHEMICAL
+/-,1131,I-CHEMICAL
),1131,I-CHEMICAL
-CGP12177A,1131,I-CHEMICAL
were,1131,O
shifted,1131,O
to,1131,O
the,1131,O
right,1131,O
by,1131,O
a,1131,O
nonselective,1131,O
beta,1131,B-GENE-N
(,1131,I-GENE-N
1,1131,I-GENE-N
),1131,I-GENE-N
-,1131,I-GENE-N
",",1131,I-GENE-N
beta,1131,I-GENE-N
(,1131,I-GENE-N
2,1131,I-GENE-N
),1131,I-GENE-N
-,1131,I-GENE-N
and,1131,I-GENE-N
beta,1131,I-GENE-N
(,1131,I-GENE-N
3,1131,I-GENE-N
),1131,I-GENE-N
-adrenoceptor,1131,I-GENE-N
antagonist,1131,O
",",1131,O
(,1131,B-CHEMICAL
+/-,1131,I-CHEMICAL
),1131,I-CHEMICAL
-bupranolol,1131,I-CHEMICAL
(,1131,O
3,1131,O
and,1131,O
10,1131,O
microM,1131,O
),1131,O
.,1131,O
These,1132,O
results,1132,O
clearly,1132,O
suggest,1132,O
that,1132,O
beta,1132,B-GENE-Y
(,1132,I-GENE-Y
3,1132,I-GENE-Y
),1132,I-GENE-Y
-adrenoceptors,1132,I-GENE-Y
are,1132,O
involved,1132,O
in,1132,O
beta-adrenoceptor-mediated,1132,B-GENE-N
relaxation,1132,O
of,1132,O
rat,1132,O
abdominal,1132,O
aorta,1132,O
smooth,1132,O
muscle,1132,O
.,1132,O
Use,1133,O
of,1133,O
the,1133,O
norepinephrine,1133,B-GENE-Y
transporter,1133,I-GENE-Y
as,1133,O
a,1133,O
reporter,1133,O
gene,1133,O
for,1133,O
non-invasive,1133,O
imaging,1133,O
of,1133,O
genetically,1133,O
modified,1133,O
cells,1133,O
.,1133,O
BACKGROUND,1134,O
:,1134,O
The,1134,O
norepinephrine,1134,B-CHEMICAL
transporter,1134,I-GENE-Y
(,1134,O
NET,1134,B-GENE-Y
),1134,O
is,1134,O
a,1134,O
high-affinity,1134,O
transporter,1134,O
for,1134,O
catecholamines,1134,B-CHEMICAL
.,1134,O
Its,1135,O
expression,1135,O
is,1135,O
almost,1135,O
exclusively,1135,O
restricted,1135,O
to,1135,O
the,1135,O
sympathetic,1135,O
nervous,1135,O
system,1135,O
.,1135,O
In,1136,O
this,1136,O
study,1136,O
we,1136,O
evaluated,1136,O
whether,1136,O
the,1136,O
NET,1136,B-GENE-Y
can,1136,O
be,1136,O
used,1136,O
as,1136,O
a,1136,O
reporter,1136,O
gene,1136,O
for,1136,O
non-invasive,1136,O
imaging,1136,O
of,1136,O
genetically,1136,O
modified,1136,O
cells,1136,O
with,1136,O
radiolabeled,1136,O
probes,1136,O
.,1136,O
METHODS,1137,O
:,1137,O
Human,1137,O
A431,1137,O
",",1137,O
HT1080,1137,O
and,1137,O
murine,1137,O
CMS-5,1137,O
cells,1137,O
were,1137,O
retrovirally,1137,O
transduced,1137,O
with,1137,O
bovine,1137,B-GENE-Y
NET,1137,I-GENE-Y
cDNA,1137,O
.,1137,O
Transduced,1138,O
and,1138,O
parental,1138,O
cells,1138,O
were,1138,O
incubated,1138,O
in,1138,O
vitro,1138,O
with,1138,O
[,1138,B-CHEMICAL
(,1138,I-CHEMICAL
131,1138,I-CHEMICAL
),1138,I-CHEMICAL
I,1138,I-CHEMICAL
],1138,I-CHEMICAL
meta-iodobenzylguanidine,1138,I-CHEMICAL
(,1138,O
[,1138,B-CHEMICAL
(,1138,I-CHEMICAL
131,1138,I-CHEMICAL
),1138,I-CHEMICAL
I,1138,I-CHEMICAL
],1138,I-CHEMICAL
MIBG,1138,I-CHEMICAL
),1138,O
.,1138,O
The,1139,O
specificity,1139,O
of,1139,O
tracer,1139,O
uptake,1139,O
was,1139,O
determined,1139,O
by,1139,O
adding,1139,O
the,1139,O
NET,1139,B-GENE-Y
inhibitor,1139,O
imipramine,1139,B-CHEMICAL
.,1139,O
Rat,1140,O
PC12,1140,O
cells,1140,O
served,1140,O
as,1140,O
positive,1140,O
controls,1140,O
.,1140,O
Parental,1141,O
and,1141,O
A431NET,1141,O
cells,1141,O
were,1141,O
xenotransplanted,1141,O
into,1141,O
nude,1141,O
mice,1141,O
and,1141,O
tumor,1141,O
uptake,1141,O
of,1141,O
[,1141,B-CHEMICAL
(,1141,I-CHEMICAL
123,1141,I-CHEMICAL
),1141,I-CHEMICAL
I,1141,I-CHEMICAL
],1141,I-CHEMICAL
MIBG,1141,I-CHEMICAL
in,1141,O
vivo,1141,O
was,1141,O
determined,1141,O
after,1141,O
tracer,1141,O
administration,1141,O
.,1141,O
RESULTS,1142,O
:,1142,O
In,1142,O
vitro,1142,O
stably,1142,O
transduced,1142,O
cells,1142,O
showed,1142,O
a,1142,O
66-,1142,O
to,1142,O
120-fold,1142,O
higher,1142,O
[,1142,B-CHEMICAL
(,1142,I-CHEMICAL
131,1142,I-CHEMICAL
),1142,I-CHEMICAL
I,1142,I-CHEMICAL
],1142,I-CHEMICAL
MIBG,1142,I-CHEMICAL
uptake,1142,O
than,1142,O
parental,1142,O
cells,1142,O
.,1142,O
Incubation,1143,O
with,1143,O
imipramine,1143,B-CHEMICAL
reduced,1143,O
[,1143,B-CHEMICAL
(,1143,I-CHEMICAL
131,1143,I-CHEMICAL
),1143,I-CHEMICAL
I,1143,I-CHEMICAL
],1143,I-CHEMICAL
MIBG,1143,I-CHEMICAL
uptake,1143,O
of,1143,O
transduced,1143,O
cells,1143,O
to,1143,O
the,1143,O
level,1143,O
found,1143,O
in,1143,O
parental,1143,O
cells,1143,O
.,1143,O
More,1144,O
than,1144,O
70,1144,O
%,1144,O
of,1144,O
the,1144,O
initial,1144,O
radioactivity,1144,O
was,1144,O
retained,1144,O
in,1144,O
all,1144,O
transduced,1144,O
cell,1144,O
lines,1144,O
after,1144,O
2,1144,O
h,1144,O
incubation,1144,O
with,1144,O
tracer-free,1144,O
medium,1144,O
.,1144,O
[,1145,B-CHEMICAL
(,1145,I-CHEMICAL
131,1145,I-CHEMICAL
),1145,I-CHEMICAL
I,1145,I-CHEMICAL
],1145,I-CHEMICAL
MIBG,1145,I-CHEMICAL
uptake,1145,O
in,1145,O
PC12,1145,O
cells,1145,O
",",1145,O
which,1145,O
express,1145,O
the,1145,O
NET,1145,B-GENE-Y
endogenously,1145,O
",",1145,O
was,1145,O
20-,1145,O
to,1145,O
28-fold,1145,O
lower,1145,O
than,1145,O
in,1145,O
transduced,1145,O
cells,1145,O
.,1145,O
In,1146,O
vivo,1146,O
",",1146,O
A431NET,1146,O
tumors,1146,O
demonstrated,1146,O
a,1146,O
33-fold,1146,O
higher,1146,O
[,1146,B-CHEMICAL
(,1146,I-CHEMICAL
123,1146,I-CHEMICAL
),1146,I-CHEMICAL
I,1146,I-CHEMICAL
],1146,I-CHEMICAL
MIBG,1146,I-CHEMICAL
uptake,1146,O
than,1146,O
parental,1146,O
tumors,1146,O
.,1146,O
Gamma,1147,O
camera,1147,O
images,1147,O
24,1147,O
h,1147,O
after,1147,O
tracer,1147,O
injection,1147,O
showed,1147,O
no,1147,O
tracer,1147,O
uptake,1147,O
in,1147,O
parental,1147,O
A431,1147,O
tumors,1147,O
",",1147,O
but,1147,O
clear,1147,O
images,1147,O
of,1147,O
A431NET,1147,O
tumors,1147,O
.,1147,O
CONCLUSIONS,1148,O
:,1148,O
Transduction,1148,O
of,1148,O
tumor,1148,O
cells,1148,O
with,1148,O
NET,1148,B-GENE-Y
cDNA,1148,O
causes,1148,O
highly,1148,O
specific,1148,O
uptake,1148,O
and,1148,O
significant,1148,O
retention,1148,O
of,1148,O
catecholamine,1148,B-CHEMICAL
analogs,1148,O
in,1148,O
vitro,1148,O
and,1148,O
in,1148,O
vivo,1148,O
.,1148,O
These,1149,O
characteristics,1149,O
make,1149,O
the,1149,O
NET,1149,B-GENE-Y
suitable,1149,O
as,1149,O
a,1149,O
reporter,1149,O
gene,1149,O
for,1149,O
non-invasive,1149,O
monitoring,1149,O
of,1149,O
gene,1149,O
transfer,1149,O
.,1149,O
Comparative,1150,O
pharmacology,1150,O
of,1150,O
human,1150,B-GENE-N
beta-adrenergic,1150,I-GENE-N
receptor,1150,I-GENE-N
subtypes,1150,O
--,1150,O
characterization,1150,O
of,1150,O
stably,1150,O
transfected,1150,O
receptors,1150,O
in,1150,O
CHO,1150,O
cells,1150,O
.,1150,O
Although,1151,O
many,1151,O
beta1-receptor,1151,B-GENE-Y
antagonists,1151,O
and,1151,O
beta2-receptor,1151,B-GENE-Y
agonists,1151,O
have,1151,O
been,1151,O
used,1151,O
in,1151,O
pharmacotherapy,1151,O
for,1151,O
many,1151,O
years,1151,O
their,1151,O
pharmacological,1151,O
properties,1151,O
at,1151,O
all,1151,O
three,1151,O
known,1151,O
subtypes,1151,O
of,1151,O
beta-adrenergic,1151,B-GENE-N
receptors,1151,I-GENE-N
are,1151,O
not,1151,O
always,1151,O
well,1151,O
characterized,1151,O
.,1151,O
The,1152,O
aim,1152,O
of,1152,O
this,1152,O
study,1152,O
was,1152,O
",",1152,O
therefore,1152,O
",",1152,O
to,1152,O
provide,1152,O
comparative,1152,O
binding,1152,O
characteristics,1152,O
of,1152,O
agonists,1152,O
(,1152,O
epinephrine,1152,B-CHEMICAL
",",1152,O
norepinephrine,1152,B-CHEMICAL
",",1152,O
isoproterenol,1152,B-CHEMICAL
",",1152,O
fenoterol,1152,B-CHEMICAL
",",1152,O
salbutamol,1152,B-CHEMICAL
",",1152,O
salmeterol,1152,B-CHEMICAL
",",1152,O
terbutalin,1152,B-CHEMICAL
",",1152,O
formoterol,1152,B-CHEMICAL
",",1152,O
broxaterol,1152,B-CHEMICAL
),1152,O
and,1152,O
antagonists,1152,O
(,1152,O
propranolol,1152,B-CHEMICAL
",",1152,O
alprenolol,1152,B-CHEMICAL
",",1152,O
atenolol,1152,B-CHEMICAL
",",1152,O
metoprolol,1152,B-CHEMICAL
",",1152,O
bisoprolol,1152,B-CHEMICAL
",",1152,O
carvedilol,1152,B-CHEMICAL
",",1152,O
pindolol,1152,B-CHEMICAL
",",1152,O
BRL,1152,B-CHEMICAL
37344,1152,I-CHEMICAL
",",1152,O
CGP,1152,B-CHEMICAL
20712,1152,I-CHEMICAL
",",1152,O
SR,1152,B-CHEMICAL
59230A,1152,I-CHEMICAL
",",1152,O
CGP,1152,B-CHEMICAL
12177,1152,I-CHEMICAL
",",1152,O
ICI,1152,B-CHEMICAL
118551,1152,I-CHEMICAL
),1152,O
at,1152,O
all,1152,O
three,1152,O
subtypes,1152,O
of,1152,O
human,1152,B-GENE-N
beta-adrenergic,1152,I-GENE-N
receptors,1152,I-GENE-N
in,1152,O
an,1152,O
identical,1152,O
cellular,1152,O
background,1152,O
.,1152,O
We,1153,O
generated,1153,O
Chinese,1153,O
hamster,1153,O
ovary,1153,O
(,1153,O
CHO,1153,O
),1153,O
cells,1153,O
stably,1153,O
expressing,1153,O
the,1153,O
three,1153,O
beta-adrenergic,1153,B-GENE-N
receptor,1153,I-GENE-N
subtypes,1153,O
at,1153,O
comparable,1153,O
levels,1153,O
.,1153,O
We,1154,O
characterized,1154,O
these,1154,O
receptor,1154,O
subtypes,1154,O
and,1154,O
analyzed,1154,O
the,1154,O
affinity,1154,O
of,1154,O
routinely,1154,O
used,1154,O
drugs,1154,O
as,1154,O
well,1154,O
as,1154,O
experimental,1154,O
compounds,1154,O
in,1154,O
competition,1154,O
binding,1154,O
studies,1154,O
",",1154,O
using,1154,O
the,1154,O
non-selective,1154,O
antagonist,1154,O
125I-cyanopindolol,1154,B-CHEMICAL
as,1154,O
a,1154,O
radioligand,1154,O
.,1154,O
Furthermore,1155,O
",",1155,O
we,1155,O
analyzed,1155,O
the,1155,O
beta-receptor-mediated,1155,B-GENE-N
adenylyl,1155,B-CHEMICAL
cyclase,1155,I-GENE-N
activity,1155,O
in,1155,O
isolated,1155,O
membranes,1155,O
from,1155,O
these,1155,O
cell,1155,O
lines,1155,O
.,1155,O
The,1156,O
results,1156,O
from,1156,O
our,1156,O
experiments,1156,O
show,1156,O
that,1156,O
all,1156,O
compounds,1156,O
exhibit,1156,O
distinct,1156,O
patterns,1156,O
of,1156,O
selectivity,1156,O
and,1156,O
activity,1156,O
at,1156,O
the,1156,O
three,1156,O
beta-receptor,1156,B-GENE-N
subtypes,1156,O
.,1156,O
In,1157,O
particular,1157,O
",",1157,O
a,1157,O
number,1157,O
of,1157,O
beta2-,1157,B-GENE-N
or,1157,I-GENE-N
beta3-receptor,1157,I-GENE-N
agonists,1157,O
that,1157,O
are,1157,O
inverse,1157,O
agonists,1157,O
at,1157,O
the,1157,O
other,1157,O
subtypes,1157,O
were,1157,O
identified,1157,O
.,1157,O
In,1158,O
addition,1158,O
",",1158,O
beta1-receptor,1158,B-GENE-Y
antagonists,1158,O
with,1158,O
agonistic,1158,O
activity,1158,O
at,1158,O
beta2-,1158,B-GENE-N
and,1158,I-GENE-N
beta3-receptors,1158,I-GENE-N
were,1158,O
found,1158,O
.,1158,O
These,1159,O
specific,1159,O
mixtures,1159,O
of,1159,O
agonism,1159,O
",",1159,O
antagonism,1159,O
",",1159,O
and,1159,O
inverse,1159,O
agonism,1159,O
at,1159,O
different,1159,O
subtypes,1159,O
may,1159,O
have,1159,O
important,1159,O
implications,1159,O
for,1159,O
the,1159,O
therapeutic,1159,O
use,1159,O
of,1159,O
the,1159,O
respective,1159,O
compounds,1159,O
.,1159,O
Ocular,1160,O
hypotensive,1160,O
FP,1160,O
prostaglandin,1160,B-CHEMICAL
(,1160,O
PG,1160,B-CHEMICAL
),1160,O
analogs,1160,O
:,1160,O
PG,1160,B-GENE-N
receptor,1160,I-GENE-N
subtype,1160,O
binding,1160,O
affinities,1160,O
and,1160,O
selectivities,1160,O
",",1160,O
and,1160,O
agonist,1160,O
potencies,1160,O
at,1160,O
FP,1160,B-GENE-Y
and,1160,O
other,1160,O
PG,1160,B-GENE-N
receptors,1160,I-GENE-N
in,1160,O
cultured,1160,O
cells,1160,O
.,1160,O
Natural,1161,O
prostaglandins,1161,B-CHEMICAL
(,1161,O
PGs,1161,B-CHEMICAL
),1161,O
such,1161,O
as,1161,O
PGD2,1161,B-CHEMICAL
",",1161,O
PGE2,1161,B-CHEMICAL
",",1161,O
PGF2,1161,B-CHEMICAL
(,1161,I-CHEMICAL
2alpha,1161,I-CHEMICAL
),1161,I-CHEMICAL
",",1161,O
and,1161,O
PGI2,1161,B-CHEMICAL
exhibited,1161,O
the,1161,O
highest,1161,O
affinity,1161,O
for,1161,O
their,1161,O
respective,1161,O
cognate,1161,O
receptors,1161,O
",",1161,O
but,1161,O
were,1161,O
the,1161,O
least,1161,O
selective,1161,O
agents,1161,O
when,1161,O
tested,1161,O
in,1161,O
receptor,1161,O
binding,1161,O
assays,1161,O
.,1161,O
Travoprost,1162,B-CHEMICAL
acid,1162,I-CHEMICAL
(,1162,O
[,1162,B-CHEMICAL
+,1162,I-CHEMICAL
],1162,I-CHEMICAL
-fluprostenol,1162,I-CHEMICAL
),1162,O
was,1162,O
the,1162,O
most,1162,O
FP-receptor-selective,1162,B-GENE-Y
compound,1162,O
",",1162,O
exhibiting,1162,O
a,1162,O
high,1162,O
affinity,1162,O
(,1162,O
Ki,1162,O
=,1162,O
35,1162,O
+/-,1162,O
5,1162,O
nM,1162,O
),1162,O
for,1162,O
the,1162,O
FP,1162,B-GENE-Y
receptor,1162,I-GENE-Y
",",1162,O
and,1162,O
minimal,1162,O
affinity,1162,O
for,1162,O
DP,1162,B-GENE-N
(,1162,O
Ki,1162,O
=,1162,O
"52,000",1162,O
nM,1162,O
),1162,O
",",1162,O
EP1,1162,B-GENE-Y
(,1162,O
Ki,1162,O
=,1162,O
9540,1162,O
nM,1162,O
),1162,O
",",1162,O
EP3,1162,B-GENE-Y
(,1162,O
Ki,1162,O
=,1162,O
3501,1162,O
nM,1162,O
),1162,O
",",1162,O
EP4,1162,B-GENE-Y
(,1162,O
Ki,1162,O
=,1162,O
"41,000",1162,O
nM,1162,O
),1162,O
",",1162,O
IP,1162,B-GENE-Y
(,1162,O
Ki,1162,O
>,1162,O
"90,000",1162,O
nM,1162,O
),1162,O
",",1162,O
and,1162,O
TP,1162,B-GENE-Y
(,1162,O
Ki,1162,O
=,1162,O
"121,000",1162,O
nM,1162,O
),1162,O
receptors,1162,O
.,1162,O
Travoprost,1163,B-CHEMICAL
acid,1163,I-CHEMICAL
was,1163,O
the,1163,O
most,1163,O
potent,1163,O
PG,1163,B-CHEMICAL
analog,1163,O
tested,1163,O
in,1163,O
FP,1163,B-GENE-Y
receptor,1163,I-GENE-Y
functional,1163,O
phosphoinositide,1163,B-CHEMICAL
turnover,1163,O
assays,1163,O
in,1163,O
the,1163,O
following,1163,O
cell,1163,O
types,1163,O
:,1163,O
human,1163,O
ciliary,1163,O
muscle,1163,O
(,1163,O
EC50,1163,O
=,1163,O
1.4,1163,O
nM,1163,O
),1163,O
",",1163,O
human,1163,O
trabecular,1163,O
meshwork,1163,O
(,1163,O
EC50,1163,O
=,1163,O
3.6,1163,O
nM,1163,O
),1163,O
",",1163,O
and,1163,O
mouse,1163,O
fibroblasts,1163,O
and,1163,O
rat,1163,O
aortic,1163,O
smooth,1163,O
muscle,1163,O
cells,1163,O
(,1163,O
EC50,1163,O
=,1163,O
2.6,1163,O
nM,1163,O
),1163,O
.,1163,O
Although,1164,O
latanoprost,1164,B-CHEMICAL
acid,1164,I-CHEMICAL
exhibited,1164,O
a,1164,O
relatively,1164,O
high,1164,O
affinity,1164,O
for,1164,O
the,1164,O
FP,1164,B-GENE-Y
receptor,1164,I-GENE-Y
(,1164,O
Ki,1164,O
=,1164,O
98,1164,O
nM,1164,O
),1164,O
",",1164,O
it,1164,O
had,1164,O
significant,1164,O
functional,1164,O
activity,1164,O
at,1164,O
FP,1164,B-GENE-Y
(,1164,O
EC50,1164,O
=,1164,O
32-124,1164,O
nM,1164,O
),1164,O
and,1164,O
EP1,1164,B-GENE-Y
(,1164,O
EC50,1164,O
=,1164,O
119,1164,O
nM,1164,O
),1164,O
receptors,1164,O
.,1164,O
Bimatoprost,1165,B-CHEMICAL
acid,1165,I-CHEMICAL
was,1165,O
less,1165,O
selective,1165,O
",",1165,O
exhibiting,1165,O
a,1165,O
relatively,1165,O
high,1165,O
affinity,1165,O
for,1165,O
the,1165,O
FP,1165,B-GENE-Y
(,1165,O
Ki,1165,O
=,1165,O
83,1165,O
nM,1165,O
),1165,O
",",1165,O
EP1,1165,B-GENE-Y
(,1165,O
Ki,1165,O
=,1165,O
95,1165,O
nM,1165,O
),1165,O
",",1165,O
and,1165,O
EP3,1165,B-GENE-Y
(,1165,O
Ki,1165,O
=,1165,O
387,1165,O
nM,1165,O
),1165,O
receptors,1165,O
.,1165,O
Bimatoprost,1166,B-CHEMICAL
acid,1166,I-CHEMICAL
exhibited,1166,O
functional,1166,O
activity,1166,O
at,1166,O
the,1166,O
EP1,1166,B-GENE-N
(,1166,O
EC50,1166,O
=,1166,O
2.7,1166,O
nM,1166,O
),1166,O
and,1166,O
FP,1166,B-GENE-Y
(,1166,O
EC50,1166,O
=,1166,O
2.8-3.8,1166,O
nM,1166,O
in,1166,O
most,1166,O
cells,1166,O
),1166,O
receptors,1166,O
.,1166,O
Bimatoprost,1167,B-CHEMICAL
(,1167,O
nonhydrolyzed,1167,O
amide,1167,O
),1167,O
also,1167,O
behaved,1167,O
as,1167,O
an,1167,O
FP,1167,B-GENE-Y
agonist,1167,O
at,1167,O
the,1167,O
cloned,1167,O
human,1167,B-GENE-Y
FP,1167,I-GENE-Y
receptor,1167,I-GENE-Y
(,1167,O
EC50,1167,O
=,1167,O
681,1167,O
nM,1167,O
),1167,O
",",1167,O
in,1167,O
h-TM,1167,O
(,1167,O
EC50,1167,O
=,1167,O
3245,1167,O
nM,1167,O
),1167,O
and,1167,O
other,1167,O
cell,1167,O
types,1167,O
.,1167,O
Unoprostone,1168,B-CHEMICAL
and,1168,O
S-1033,1168,B-CHEMICAL
bound,1168,O
with,1168,O
low,1168,O
affinity,1168,O
(,1168,O
Ki,1168,O
=,1168,O
5.9,1168,O
microM,1168,O
to,1168,O
>,1168,O
22,1168,O
microM,1168,O
),1168,O
to,1168,O
the,1168,O
FP,1168,B-GENE-Y
receptor,1168,I-GENE-Y
",",1168,O
were,1168,O
not,1168,O
selective,1168,O
",",1168,O
but,1168,O
activated,1168,O
the,1168,O
FP,1168,B-GENE-Y
receptor,1168,I-GENE-Y
.,1168,O
In,1169,O
conclusion,1169,O
",",1169,O
travoprost,1169,B-CHEMICAL
acid,1169,I-CHEMICAL
has,1169,O
the,1169,O
highest,1169,O
affinity,1169,O
",",1169,O
the,1169,O
highest,1169,O
FP-receptor-selectivity,1169,B-GENE-Y
",",1169,O
and,1169,O
the,1169,O
highest,1169,O
potency,1169,O
at,1169,O
the,1169,O
FP,1169,B-GENE-Y
receptor,1169,I-GENE-Y
as,1169,O
compared,1169,O
to,1169,O
the,1169,O
other,1169,O
ocular,1169,O
hypotensive,1169,O
PG,1169,O
analogs,1169,O
known,1169,O
so,1169,O
far,1169,O
",",1169,O
including,1169,O
free,1169,B-CHEMICAL
acids,1169,I-CHEMICAL
of,1169,I-CHEMICAL
latanoprost,1169,I-CHEMICAL
",",1169,I-CHEMICAL
bimatoprost,1169,I-CHEMICAL
",",1169,I-CHEMICAL
and,1169,I-CHEMICAL
unoprostone,1169,I-CHEMICAL
isopropyl,1169,I-CHEMICAL
ester,1169,I-CHEMICAL
.,1169,O
Loss,1170,O
of,1170,O
beta-adrenoceptor,1170,B-GENE-N
response,1170,O
in,1170,O
myocytes,1170,O
overexpressing,1170,O
the,1170,O
Na+/Ca,1170,B-CHEMICAL
(,1170,I-CHEMICAL
2+,1170,I-CHEMICAL
),1170,I-CHEMICAL
-exchanger,1170,I-GENE-N
.,1170,O
Increased,1171,O
Na+/Ca,1171,B-GENE-N
(,1171,I-GENE-N
2+,1171,I-GENE-N
),1171,I-GENE-N
-exchanger,1171,I-GENE-N
(,1171,O
NCX,1171,B-GENE-N
),1171,O
and,1171,O
altered,1171,O
beta-adrenoceptor,1171,B-GENE-N
(,1171,O
betaAR,1171,B-GENE-N
),1171,O
responses,1171,O
are,1171,O
observed,1171,O
in,1171,O
failing,1171,O
human,1171,O
heart,1171,O
.,1171,O
To,1172,O
determine,1172,O
the,1172,O
possible,1172,O
interaction,1172,O
between,1172,O
these,1172,O
changes,1172,O
",",1172,O
we,1172,O
investigated,1172,O
the,1172,O
effect,1172,O
of,1172,O
NCX,1172,B-GENE-N
overexpression,1172,O
on,1172,O
responses,1172,O
to,1172,O
isoproterenol,1172,O
in,1172,O
adult,1172,O
rat,1172,O
ventricular,1172,O
myocytes,1172,O
.,1172,O
Responses,1173,O
to,1173,O
isoproterenol,1173,B-CHEMICAL
were,1173,O
largely,1173,O
mediated,1173,O
through,1173,O
the,1173,O
beta1AR,1173,B-GENE-Y
in,1173,O
control,1173,O
myocytes,1173,O
.,1173,O
Adenovirally-mediated,1174,O
overexpression,1174,O
of,1174,O
NCX,1174,B-GENE-N
",",1174,O
at,1174,O
levels,1174,O
",",1174,O
which,1174,O
did,1174,O
not,1174,O
alter,1174,O
basal,1174,O
contraction,1174,O
of,1174,O
myocytes,1174,O
",",1174,O
markedly,1174,O
depressed,1174,O
the,1174,O
isoproterenol,1174,B-CHEMICAL
concentration-response,1174,O
curve,1174,O
.,1174,O
Responses,1175,O
to,1175,O
isoproterenol,1175,B-CHEMICAL
could,1175,O
be,1175,O
restored,1175,O
to,1175,O
normal,1175,O
by,1175,O
beta2AR,1175,B-GENE-Y
blockade,1175,O
",",1175,O
suggesting,1175,O
a,1175,O
beta2AR-mediated,1175,B-GENE-Y
inhibition,1175,O
of,1175,O
beta1AR,1175,B-GENE-Y
signalling,1175,O
.,1175,O
Pertussis,1176,B-GENE-N
toxin,1176,I-GENE-N
normalised,1176,O
isoproterenol,1176,B-CHEMICAL
responses,1176,O
in,1176,O
NCX,1176,B-GENE-N
cells,1176,O
",",1176,O
indicating,1176,O
that,1176,O
beta2AR,1176,B-GENE-Y
effects,1176,O
were,1176,O
mediated,1176,O
by,1176,O
Gi,1176,B-GENE-N
.,1176,O
Negative-inotropic,1177,O
effects,1177,O
of,1177,O
high,1177,O
concentrations,1177,O
of,1177,O
ICI,1177,O
"118,551",1177,O
",",1177,O
previously,1177,O
shown,1177,O
to,1177,O
be,1177,O
due,1177,O
to,1177,O
beta2AR-Gi,1177,B-GENE-Y
coupling,1177,O
",",1177,O
were,1177,O
increased,1177,O
in,1177,O
NCX,1177,B-GENE-N
cells,1177,O
.,1177,O
We,1178,O
conclude,1178,O
that,1178,O
NCX,1178,B-GENE-N
upregulation,1178,O
can,1178,O
markedly,1178,O
alter,1178,O
the,1178,O
consequences,1178,O
of,1178,O
betaAR,1178,B-GENE-N
stimulation,1178,O
and,1178,O
that,1178,O
this,1178,O
may,1178,O
contribute,1178,O
to,1178,O
the,1178,O
alterations,1178,O
in,1178,O
betaAR,1178,B-GENE-N
response,1178,O
seen,1178,O
in,1178,O
failing,1178,O
human,1178,O
heart,1178,O
.,1178,O
Manipulation,1179,O
of,1179,O
kinetic,1179,O
profiles,1179,O
in,1179,O
2-aryl,1179,B-CHEMICAL
propionic,1179,I-CHEMICAL
acid,1179,I-CHEMICAL
cyclooxygenase,1179,B-GENE-N
inhibitors,1179,O
.,1179,O
The,1180,O
nonsteroidal,1180,O
anti-inflammatory,1180,O
drugs,1180,O
flurbiprofen,1180,B-CHEMICAL
and,1180,O
ibuprofen,1180,B-CHEMICAL
were,1180,O
modified,1180,O
in,1180,O
an,1180,O
attempt,1180,O
to,1180,O
alter,1180,O
the,1180,O
kinetics,1180,O
of,1180,O
inhibitor,1180,O
binding,1180,O
by,1180,O
COX-1,1180,B-GENE-Y
.,1180,O
Contrary,1181,O
to,1181,O
prior,1181,O
predictions,1181,O
",",1181,O
a,1181,O
halogen,1181,B-CHEMICAL
substituent,1181,O
is,1181,O
not,1181,O
sufficient,1181,O
to,1181,O
confer,1181,O
slow,1181,O
tight-binding,1181,O
behavior,1181,O
.,1181,O
Conversion,1182,O
of,1182,O
the,1182,O
carboxylate,1182,B-CHEMICAL
moiety,1182,O
of,1182,O
flurbiprofen,1182,B-CHEMICAL
to,1182,O
an,1182,O
ester,1182,B-CHEMICAL
or,1182,O
amide,1182,B-CHEMICAL
abolishes,1182,O
slow,1182,O
tight-binding,1182,O
behavior,1182,O
",",1182,O
regardless,1182,O
of,1182,O
halogenation,1182,O
state,1182,O
.,1182,O
Effects,1183,O
of,1183,O
the,1183,O
EGFR/HER2,1183,B-GENE-Y
kinase,1183,B-GENE-N
inhibitor,1183,O
GW572016,1183,B-CHEMICAL
on,1183,O
EGFR-,1183,B-GENE-Y
and,1183,O
HER2-overexpressing,1183,B-GENE-Y
breast,1183,O
cancer,1183,O
cell,1183,O
line,1183,O
proliferation,1183,O
",",1183,O
radiosensitization,1183,O
",",1183,O
and,1183,O
resistance,1183,O
.,1183,O
PURPOSE,1184,O
:,1184,O
Two,1184,O
members,1184,O
of,1184,O
the,1184,O
epidermal,1184,O
growth,1184,O
factor,1184,O
receptor,1184,O
family,1184,O
",",1184,O
EGFR,1184,B-GENE-Y
and,1184,O
HER2,1184,B-GENE-Y
",",1184,O
have,1184,O
been,1184,O
implicated,1184,O
in,1184,O
radioresistance,1184,O
in,1184,O
breast,1184,O
cancer,1184,O
and,1184,O
other,1184,O
malignancies,1184,O
.,1184,O
To,1185,O
gauge,1185,O
the,1185,O
potential,1185,O
clinical,1185,O
utility,1185,O
of,1185,O
targeting,1185,O
both,1185,O
EGFR,1185,B-GENE-Y
and,1185,O
HER2,1185,B-GENE-Y
to,1185,O
control,1185,O
growth,1185,O
and,1185,O
radiosensitize,1185,O
human,1185,O
breast,1185,O
cancers,1185,O
",",1185,O
we,1185,O
examined,1185,O
the,1185,O
effect,1185,O
of,1185,O
a,1185,O
dual,1185,O
EGFR/HER2,1185,B-GENE-Y
inhibitor,1185,O
",",1185,O
GW572016,1185,B-CHEMICAL
",",1185,O
on,1185,O
the,1185,O
proliferation,1185,O
and,1185,O
radiation,1185,O
response,1185,O
of,1185,O
either,1185,O
EGFR-,1185,B-GENE-Y
or,1185,O
HER2-overexpressing,1185,B-GENE-Y
human,1185,O
breast,1185,O
cancer,1185,O
cell,1185,O
lines,1185,O
.,1185,O
METHODS,1186,O
AND,1186,O
MATERIALS,1186,O
:,1186,O
Primary,1186,O
human,1186,O
breast,1186,O
cancer,1186,O
cell,1186,O
lines,1186,O
that,1186,O
endogenously,1186,O
overexpress,1186,O
EGFR,1186,B-GENE-Y
or,1186,O
HER2,1186,B-GENE-Y
and,1186,O
luminal,1186,O
mammary,1186,O
epithelial,1186,O
H16N2,1186,O
cells,1186,O
stably,1186,O
transfected,1186,O
with,1186,O
HER2,1186,B-GENE-Y
were,1186,O
evaluated,1186,O
for,1186,O
the,1186,O
effect,1186,O
of,1186,O
GW572016,1186,B-CHEMICAL
on,1186,O
inhibition,1186,O
of,1186,O
ligand-induced,1186,O
or,1186,O
constitutive,1186,B-GENE-N
receptor,1186,I-GENE-N
phosphorylation,1186,O
",",1186,O
proliferation,1186,O
",",1186,O
radiosensitization,1186,O
",",1186,O
and,1186,O
inhibition,1186,O
of,1186,O
downstream,1186,O
signaling,1186,O
.,1186,O
RESULTS,1187,O
:,1187,O
GW572016,1187,B-CHEMICAL
inhibited,1187,O
constitutive,1187,O
and/or,1187,O
ligand-induced,1187,O
EGFR,1187,B-GENE-Y
or,1187,O
HER2,1187,B-GENE-Y
tyrosine,1187,B-CHEMICAL
phosphorylation,1187,O
of,1187,O
all,1187,O
five,1187,O
cell,1187,O
lines,1187,O
",",1187,O
which,1187,O
correlated,1187,O
with,1187,O
the,1187,O
antiproliferative,1187,O
response,1187,O
in,1187,O
all,1187,O
but,1187,O
one,1187,O
cell,1187,O
line,1187,O
.,1187,O
GW572016,1188,B-CHEMICAL
radiosensitized,1188,O
EGFR-overexpressing,1188,B-GENE-Y
cell,1188,O
lines,1188,O
",",1188,O
but,1188,O
HER2-overexpressing,1188,B-GENE-Y
cells,1188,O
were,1188,O
unable,1188,O
to,1188,O
form,1188,O
colonies,1188,O
after,1188,O
brief,1188,O
exposure,1188,O
to,1188,O
GW572016,1188,B-CHEMICAL
even,1188,O
in,1188,O
the,1188,O
absence,1188,O
of,1188,O
radiation,1188,O
",",1188,O
and,1188,O
thus,1188,O
could,1188,O
not,1188,O
be,1188,O
evaluated,1188,O
for,1188,O
radiosensitization,1188,O
.,1188,O
One,1189,O
cell,1189,O
line,1189,O
was,1189,O
resistant,1189,O
to,1189,O
the,1189,O
antiproliferative,1189,O
and,1189,O
radiosensitizing,1189,O
effects,1189,O
of,1189,O
GW572016,1189,B-CHEMICAL
",",1189,O
despite,1189,O
receptor,1189,O
inhibition,1189,O
.,1189,O
Exploration,1190,O
of,1190,O
potential,1190,O
mechanisms,1190,O
of,1190,O
resistance,1190,O
in,1190,O
SUM185,1190,O
cells,1190,O
revealed,1190,O
failure,1190,O
of,1190,O
GW572016,1190,B-CHEMICAL
to,1190,O
inhibit,1190,O
downstream,1190,O
ERK,1190,B-GENE-N
and,1190,O
Akt,1190,B-GENE-N
activation,1190,O
",",1190,O
despite,1190,O
inhibition,1190,O
of,1190,O
HER2,1190,B-GENE-Y
phosphorylation,1190,O
.,1190,O
In,1191,O
contrast,1191,O
",",1191,O
sensitive,1191,O
HER2-overexpressing,1191,B-GENE-Y
cell,1191,O
lines,1191,O
demonstrated,1191,O
inhibition,1191,O
of,1191,O
both,1191,O
ERK,1191,B-GENE-N
and,1191,O
Akt,1191,B-GENE-N
phosphorylation,1191,O
.,1191,O
CONCLUSION,1192,O
:,1192,O
GW572016,1192,B-CHEMICAL
potently,1192,O
inhibits,1192,O
receptor,1192,O
phosphorylation,1192,O
in,1192,O
either,1192,O
EGFR-,1192,B-GENE-Y
or,1192,O
HER2-overexpressing,1192,B-GENE-Y
cell,1192,O
lines,1192,O
and,1192,O
has,1192,O
both,1192,O
antiproliferative,1192,O
and,1192,O
radiosensitizing,1192,O
effects,1192,O
.,1192,O
Resistance,1193,O
to,1193,O
GW572016,1193,B-CHEMICAL
was,1193,O
not,1193,O
due,1193,O
to,1193,O
a,1193,O
lack,1193,O
of,1193,O
receptor,1193,O
inhibition,1193,O
",",1193,O
but,1193,O
rather,1193,O
with,1193,O
a,1193,O
lack,1193,O
of,1193,O
inhibition,1193,O
of,1193,O
ERK,1193,B-GENE-N
and,1193,O
Akt,1193,B-GENE-N
",",1193,O
suggesting,1193,O
that,1193,O
measurement,1193,O
of,1193,O
inhibition,1193,O
of,1193,O
crucial,1193,O
signaling,1193,O
pathways,1193,O
may,1193,O
better,1193,O
predict,1193,O
response,1193,O
than,1193,O
inhibition,1193,O
of,1193,O
receptor,1193,O
phosphorylation,1193,O
.,1193,O
The,1194,O
SUM185,1194,O
cell,1194,O
line,1194,O
provides,1194,O
a,1194,O
valuable,1194,O
model,1194,O
for,1194,O
studying,1194,O
mechanisms,1194,O
of,1194,O
resistance,1194,O
of,1194,O
EGFR/HER2,1194,B-GENE-Y
inhibitor,1194,O
therapy,1194,O
.,1194,O
Aquaporin-1,1195,B-GENE-Y
deletion,1195,O
reduces,1195,O
osmotic,1195,O
water,1195,O
permeability,1195,O
and,1195,O
cerebrospinal,1195,O
fluid,1195,O
production,1195,O
.,1195,O
Aquaporin-1,1196,B-GENE-Y
(,1196,O
AQP1,1196,B-GENE-Y
),1196,O
is,1196,O
a,1196,O
water,1196,B-GENE-N
channel,1196,I-GENE-N
that,1196,O
is,1196,O
strongly,1196,O
expressed,1196,O
at,1196,O
the,1196,O
ventricular-facing,1196,O
surface,1196,O
of,1196,O
choroid,1196,O
plexus,1196,O
epithelium,1196,O
.,1196,O
Using,1197,O
wildtype,1197,O
and,1197,O
AQP1,1197,B-GENE-Y
null,1197,O
mice,1197,O
",",1197,O
we,1197,O
developed,1197,O
novel,1197,O
methods,1197,O
to,1197,O
compare,1197,O
the,1197,O
water,1197,O
permeability,1197,O
in,1197,O
isolated,1197,O
choroid,1197,O
plexus,1197,O
",",1197,O
and,1197,O
cerebrospinal,1197,O
fluid,1197,O
(,1197,O
CSF,1197,O
),1197,O
production,1197,O
in,1197,O
living,1197,O
mice,1197,O
.,1197,O
Osmotically-induced,1198,O
water,1198,O
transport,1198,O
was,1198,O
rapid,1198,O
in,1198,O
freshly,1198,O
isolated,1198,O
choroid,1198,O
plexus,1198,O
from,1198,O
wildtype,1198,O
mice,1198,O
as,1198,O
measured,1198,O
by,1198,O
a,1198,O
spatial-filtering,1198,O
optical,1198,O
method,1198,O
",",1198,O
and,1198,O
reduced,1198,O
by,1198,O
5-fold,1198,O
by,1198,O
AQP1,1198,B-GENE-Y
deletion,1198,O
.,1198,O
CSF,1199,O
production,1199,O
",",1199,O
an,1199,O
isosmolar,1199,O
fluid,1199,O
secretion,1199,O
process,1199,O
",",1199,O
was,1199,O
measured,1199,O
by,1199,O
a,1199,O
dye,1199,O
dilution,1199,O
method,1199,O
involving,1199,O
fluid,1199,O
collections,1199,O
using,1199,O
a,1199,O
second,1199,O
microneedle,1199,O
introduced,1199,O
into,1199,O
the,1199,O
cisterna,1199,O
magna,1199,O
.,1199,O
CSF,1200,O
production,1200,O
in,1200,O
wildtype,1200,O
mice,1200,O
was,1200,O
(,1200,O
in,1200,O
microl/min,1200,O
),1200,O
0.37,1200,O
+/-,1200,O
0.04,1200,O
microl/min,1200,O
(,1200,O
control,1200,O
),1200,O
",",1200,O
0.16,1200,O
+/-,1200,O
0.03,1200,O
microl/min,1200,O
(,1200,O
acetazolamide-treated,1200,B-CHEMICAL
),1200,O
and,1200,O
1.14,1200,O
+/-,1200,O
0.15,1200,O
microl/min,1200,O
(,1200,O
forskolin-treated,1200,B-CHEMICAL
),1200,O
",",1200,O
and,1200,O
reduced,1200,O
by,1200,O
up,1200,O
to,1200,O
25,1200,O
%,1200,O
in,1200,O
AQP1,1200,B-GENE-Y
null,1200,O
mice,1200,O
.,1200,O
The,1201,O
impaired,1201,O
CSF,1201,O
production,1201,O
in,1201,O
AQP1,1201,B-GENE-Y
null,1201,O
mice,1201,O
provides,1201,O
direct,1201,O
functional,1201,O
evidence,1201,O
for,1201,O
the,1201,O
involvement,1201,O
of,1201,O
AQP1,1201,B-GENE-Y
in,1201,O
CSF,1201,O
formation,1201,O
.,1201,O
Metformin,1202,B-CHEMICAL
",",1202,O
but,1202,O
not,1202,O
leptin,1202,O
",",1202,O
regulates,1202,O
AMP-activated,1202,B-GENE-N
protein,1202,I-GENE-N
kinase,1202,I-GENE-N
in,1202,O
pancreatic,1202,O
islets,1202,O
:,1202,O
impact,1202,O
on,1202,O
glucose-stimulated,1202,B-CHEMICAL
insulin,1202,B-GENE-N
secretion,1202,O
.,1202,O
Metformin,1203,B-CHEMICAL
",",1203,O
a,1203,O
drug,1203,O
widely,1203,O
used,1203,O
in,1203,O
the,1203,O
treatment,1203,O
of,1203,O
type,1203,O
2,1203,O
diabetes,1203,O
",",1203,O
has,1203,O
recently,1203,O
been,1203,O
shown,1203,O
to,1203,O
act,1203,O
on,1203,O
skeletal,1203,O
muscle,1203,O
and,1203,O
liver,1203,O
in,1203,O
part,1203,O
through,1203,O
the,1203,O
activation,1203,O
of,1203,O
AMP-activated,1203,B-CHEMICAL
protein,1203,I-GENE-N
kinase,1203,I-GENE-N
(,1203,O
AMPK,1203,B-GENE-N
),1203,O
.,1203,O
Whether,1204,O
metformin,1204,B-CHEMICAL
or,1204,O
the,1204,O
satiety,1204,O
factor,1204,O
leptin,1204,O
",",1204,O
which,1204,O
also,1204,O
stimulates,1204,O
AMPK,1204,B-GENE-N
in,1204,O
muscle,1204,O
",",1204,O
regulates,1204,O
this,1204,O
enzyme,1204,O
in,1204,O
pancreatic,1204,O
islets,1204,O
is,1204,O
unknown,1204,O
.,1204,O
We,1205,O
have,1205,O
recently,1205,O
shown,1205,O
that,1205,O
forced,1205,O
increases,1205,O
in,1205,O
AMPK,1205,B-GENE-N
activity,1205,O
inhibit,1205,O
insulin,1205,B-GENE-N
secretion,1205,O
from,1205,O
MIN6,1205,O
cells,1205,O
(,1205,O
da,1205,O
Silva,1205,O
Xavier,1205,O
G,1205,O
",",1205,O
Leclerc,1205,O
I,1205,O
",",1205,O
Varadi,1205,O
A,1205,O
",",1205,O
Tsuboi,1205,O
T,1205,O
",",1205,O
Moule,1205,O
SK,1205,O
",",1205,O
and,1205,O
Rutter,1205,O
GA.,1205,O
Biochem,1205,O
J,1205,O
371,1205,O
:,1205,O
761-774,1205,O
",",1205,O
2003,1205,O
),1205,O
.,1205,O
Here,1206,O
",",1206,O
we,1206,O
explore,1206,O
whether,1206,O
1,1206,O
),1206,O
glucose,1206,B-CHEMICAL
",",1206,O
metformin,1206,B-CHEMICAL
",",1206,O
or,1206,O
leptin,1206,O
regulates,1206,O
AMPK,1206,B-GENE-N
activity,1206,O
in,1206,O
isolated,1206,O
islets,1206,O
from,1206,O
rodent,1206,O
and,1206,O
human,1206,O
and,1206,O
2,1206,O
),1206,O
whether,1206,O
changes,1206,O
in,1206,O
AMPK,1206,B-GENE-N
activity,1206,O
modulate,1206,O
insulin,1206,B-GENE-Y
secretion,1206,O
from,1206,O
human,1206,O
islets,1206,O
.,1206,O
Increases,1207,O
in,1207,O
glucose,1207,B-CHEMICAL
concentration,1207,O
from,1207,O
0,1207,O
to,1207,O
3,1207,O
and,1207,O
from,1207,O
3,1207,O
to,1207,O
17,1207,O
mM,1207,O
inhibited,1207,O
AMPK,1207,B-GENE-N
activity,1207,O
in,1207,O
primary,1207,O
islets,1207,O
from,1207,O
mouse,1207,O
",",1207,O
rat,1207,O
",",1207,O
and,1207,O
human,1207,O
",",1207,O
confirming,1207,O
previous,1207,O
findings,1207,O
in,1207,O
insulinoma,1207,O
cells,1207,O
.,1207,O
Incubation,1208,O
with,1208,O
metformin,1208,B-CHEMICAL
(,1208,O
0.2-1,1208,O
mM,1208,O
),1208,O
activated,1208,O
AMPK,1208,B-GENE-N
in,1208,O
both,1208,O
human,1208,O
islets,1208,O
and,1208,O
MIN6,1208,O
beta-cells,1208,O
in,1208,O
parallel,1208,O
with,1208,O
an,1208,O
inhibition,1208,O
of,1208,O
insulin,1208,B-GENE-N
secretion,1208,O
",",1208,O
whereas,1208,O
leptin,1208,O
(,1208,O
10-100,1208,O
nM,1208,O
),1208,O
was,1208,O
without,1208,O
effect,1208,O
in,1208,O
MIN6,1208,O
cells,1208,O
.,1208,O
These,1209,O
studies,1209,O
demonstrate,1209,O
that,1209,O
AMPK,1209,B-GENE-N
activity,1209,O
is,1209,O
subject,1209,O
to,1209,O
regulation,1209,O
by,1209,O
both,1209,O
glucose,1209,B-CHEMICAL
and,1209,O
metformin,1209,B-CHEMICAL
in,1209,O
pancreatic,1209,O
islets,1209,O
and,1209,O
clonal,1209,O
beta-cells,1209,O
.,1209,O
The,1210,O
inhibitory,1210,O
effects,1210,O
of,1210,O
metformin,1210,B-CHEMICAL
on,1210,O
insulin,1210,B-GENE-N
secretion,1210,O
may,1210,O
therefore,1210,O
need,1210,O
to,1210,O
be,1210,O
considered,1210,O
with,1210,O
respect,1210,O
to,1210,O
the,1210,O
use,1210,O
of,1210,O
this,1210,O
drug,1210,O
for,1210,O
the,1210,O
treatment,1210,O
of,1210,O
type,1210,O
2,1210,O
diabetes,1210,O
.,1210,O
A,1211,O
novel,1211,O
retinoic,1211,B-GENE-N
acid-responsive,1211,I-GENE-N
element,1211,I-GENE-N
regulates,1211,O
retinoic,1211,B-CHEMICAL
acid-induced,1211,O
BLR1,1211,B-GENE-N
expression,1211,O
.,1211,O
The,1212,O
mechanism,1212,O
of,1212,O
action,1212,O
of,1212,O
retinoic,1212,B-CHEMICAL
acid,1212,I-CHEMICAL
(,1212,O
RA,1212,B-CHEMICAL
),1212,O
is,1212,O
of,1212,O
broad,1212,O
relevance,1212,O
to,1212,O
cell,1212,O
and,1212,O
developmental,1212,O
biology,1212,O
",",1212,O
nutrition,1212,O
",",1212,O
and,1212,O
cancer,1212,O
chemotherapy,1212,O
.,1212,O
RA,1213,B-CHEMICAL
is,1213,O
known,1213,O
to,1213,O
induce,1213,O
expression,1213,O
of,1213,O
the,1213,O
Burkitt,1213,B-GENE-Y
's,1213,I-GENE-Y
lymphoma,1213,I-GENE-Y
receptor,1213,I-GENE-Y
1,1213,I-GENE-Y
(,1213,O
BLR1,1213,B-GENE-Y
),1213,O
gene,1213,O
which,1213,O
propels,1213,O
RA-induced,1213,B-CHEMICAL
cell,1213,O
cycle,1213,O
arrest,1213,O
and,1213,O
differentiation,1213,O
of,1213,O
HL-60,1213,O
human,1213,O
myeloblastic,1213,O
leukemia,1213,O
cells,1213,O
",",1213,O
motivating,1213,O
the,1213,O
present,1213,O
analysis,1213,O
of,1213,O
transcriptional,1213,O
regulation,1213,O
of,1213,O
blr1,1213,B-GENE-Y
expression,1213,O
by,1213,O
RA,1213,B-CHEMICAL
.,1213,O
The,1214,O
RA-treated,1214,B-CHEMICAL
HL-60,1214,O
cells,1214,O
used,1214,O
here,1214,O
expressed,1214,O
all,1214,O
RA,1214,B-GENE-N
receptor,1214,I-GENE-N
(,1214,O
RAR,1214,B-GENE-N
),1214,O
and,1214,O
retinoid,1214,B-GENE-N
X,1214,I-GENE-N
receptor,1214,I-GENE-N
(,1214,O
RXR,1214,B-GENE-N
),1214,O
subtypes,1214,O
(,1214,O
as,1214,O
detected,1214,O
by,1214,O
Northern,1214,O
analysis,1214,O
),1214,O
except,1214,O
RXRgamma,1214,B-GENE-Y
.,1214,O
Treatment,1215,O
with,1215,O
RAR-,1215,B-GENE-N
and,1215,O
RXR-selective,1215,B-GENE-N
ligands,1215,O
showed,1215,O
that,1215,O
RARalpha,1215,B-GENE-Y
synergized,1215,O
with,1215,O
RXRalpha,1215,B-GENE-Y
to,1215,O
transcriptionally,1215,O
activate,1215,O
blr1,1215,B-GENE-Y
expression,1215,O
.,1215,O
A,1216,O
5'-flanking,1216,O
region,1216,O
capable,1216,O
of,1216,O
supporting,1216,O
RA-induced,1216,B-CHEMICAL
blr1,1216,B-GENE-Y
activation,1216,O
in,1216,O
HL-60,1216,O
cells,1216,O
was,1216,O
found,1216,O
to,1216,O
contain,1216,O
a,1216,O
205-bp,1216,O
sequence,1216,O
in,1216,O
the,1216,O
distal,1216,O
portion,1216,O
that,1216,O
was,1216,O
necessary,1216,O
for,1216,O
transcriptional,1216,O
activation,1216,O
by,1216,O
RA,1216,B-CHEMICAL
.,1216,O
Within,1217,O
this,1217,O
sequence,1217,O
DNase,1217,B-GENE-Y
I,1217,I-GENE-Y
footprinting,1217,O
revealed,1217,O
that,1217,O
RA,1217,B-CHEMICAL
induced,1217,O
binding,1217,O
of,1217,O
a,1217,O
nuclear,1217,B-GENE-N
protein,1217,I-GENE-N
complex,1217,I-GENE-N
to,1217,O
an,1217,O
element,1217,O
containing,1217,O
two,1217,O
GT,1217,B-GENE-N
boxes,1217,I-GENE-N
.,1217,O
Electromobility,1218,O
shift,1218,O
assays,1218,O
(,1218,O
EMSAs,1218,O
),1218,O
and,1218,O
supershift,1218,O
assays,1218,O
showed,1218,O
that,1218,O
this,1218,O
element,1218,O
bound,1218,O
recombinant,1218,O
RARalpha,1218,B-GENE-Y
and,1218,O
RXRalpha,1218,B-GENE-Y
.,1218,O
Without,1219,O
RA,1219,B-CHEMICAL
there,1219,O
was,1219,O
neither,1219,O
complex,1219,O
binding,1219,O
nor,1219,O
transcriptional,1219,O
activation,1219,O
.,1219,O
Both,1220,O
GT,1220,B-GENE-N
boxes,1220,I-GENE-N
were,1220,O
needed,1220,O
for,1220,O
binding,1220,O
the,1220,O
complex,1220,O
",",1220,O
and,1220,O
mutation,1220,O
of,1220,O
either,1220,O
GT,1220,B-GENE-N
box,1220,I-GENE-N
caused,1220,O
the,1220,O
loss,1220,O
of,1220,O
transcriptional,1220,O
activation,1220,O
by,1220,O
RA,1220,B-CHEMICAL
.,1220,O
The,1221,O
ability,1221,O
of,1221,O
this,1221,O
cis-acting,1221,O
RAR-RXR,1221,B-GENE-N
binding,1221,I-GENE-N
element,1221,I-GENE-N
to,1221,O
activate,1221,O
transcription,1221,O
in,1221,O
response,1221,O
to,1221,O
RA,1221,B-CHEMICAL
also,1221,O
depended,1221,O
on,1221,O
downstream,1221,O
sequences,1221,O
where,1221,O
an,1221,O
octamer,1221,B-GENE-Y
transcription,1221,I-GENE-Y
factor,1221,I-GENE-Y
1,1221,I-GENE-Y
(,1221,O
Oct1,1221,B-GENE-Y
),1221,O
site,1221,O
and,1221,O
a,1221,O
nuclear,1221,B-GENE-Y
factor,1221,I-GENE-Y
of,1221,I-GENE-Y
activated,1221,I-GENE-Y
T,1221,I-GENE-Y
cells,1221,I-GENE-Y
(,1221,O
NFATc,1221,B-GENE-Y
),1221,O
site,1221,O
between,1221,O
this,1221,O
element,1221,O
and,1221,O
the,1221,O
transcriptional,1221,O
start,1221,O
",",1221,O
as,1221,O
well,1221,O
as,1221,O
a,1221,O
cyclic,1221,B-CHEMICAL
AMP,1221,I-CHEMICAL
response,1221,I-GENE-N
element,1221,I-GENE-N
binding,1221,I-GENE-N
factor,1221,I-GENE-N
(,1221,O
CREB,1221,B-GENE-N
),1221,O
site,1221,O
between,1221,O
the,1221,O
transcriptional,1221,O
start,1221,O
and,1221,O
first,1221,O
exon,1221,O
of,1221,O
the,1221,O
blr1,1221,B-GENE-Y
gene,1221,O
",",1221,O
were,1221,O
necessary,1221,O
.,1221,O
Each,1222,O
of,1222,O
these,1222,O
sites,1222,O
bound,1222,O
its,1222,O
corresponding,1222,O
transcription,1222,O
factor,1222,O
.,1222,O
A,1223,O
transcription,1223,O
factor-transcription,1223,O
factor,1223,O
binding,1223,O
array,1223,O
analysis,1223,O
of,1223,O
nuclear,1223,O
lysate,1223,O
from,1223,O
RA-treated,1223,B-CHEMICAL
cells,1223,O
indicated,1223,O
several,1223,O
prominent,1223,O
RARalpha,1223,B-GENE-Y
binding,1223,O
partners,1223,O
;,1223,O
among,1223,O
these,1223,O
",",1223,O
Oct1,1223,B-GENE-Y
",",1223,O
NFATc3,1223,B-GENE-Y
",",1223,O
and,1223,O
CREB2,1223,B-GENE-Y
were,1223,O
identified,1223,O
by,1223,O
competition,1223,O
EMSA,1223,O
and,1223,O
supershift,1223,O
and,1223,O
chromatin,1223,O
immunoprecipitation,1223,O
assays,1223,O
as,1223,O
components,1223,O
of,1223,O
the,1223,O
complex,1223,O
.,1223,O
RA,1224,B-CHEMICAL
upregulated,1224,O
expression,1224,O
of,1224,O
these,1224,O
three,1224,O
factors,1224,O
.,1224,O
In,1225,O
sum,1225,O
the,1225,O
results,1225,O
of,1225,O
the,1225,O
present,1225,O
study,1225,O
indicate,1225,O
that,1225,O
RA-induced,1225,B-CHEMICAL
expression,1225,O
of,1225,O
blr1,1225,B-GENE-Y
expression,1225,O
depends,1225,O
on,1225,O
a,1225,O
novel,1225,O
RA,1225,B-GENE-N
response,1225,I-GENE-N
element,1225,I-GENE-N
.,1225,O
This,1226,O
cis-acting,1226,O
element,1226,O
approximately,1226,O
1,1226,O
kb,1226,O
upstream,1226,O
of,1226,O
the,1226,O
transcriptional,1226,O
start,1226,O
consists,1226,O
of,1226,O
two,1226,O
GT,1226,B-GENE-N
boxes,1226,I-GENE-N
that,1226,O
bind,1226,O
RAR,1226,B-GENE-N
and,1226,O
RXR,1226,B-GENE-N
in,1226,O
a,1226,O
nuclear,1226,B-GENE-N
protein,1226,I-GENE-N
complex,1226,I-GENE-N
that,1226,O
also,1226,O
contains,1226,O
Oct1,1226,B-GENE-Y
",",1226,O
NFATc3,1226,B-GENE-Y
",",1226,O
and,1226,O
CREB2,1226,B-GENE-Y
bound,1226,O
to,1226,O
their,1226,O
cognate,1226,O
downstream,1226,O
consensus,1226,O
binding,1226,O
sites,1226,O
.,1226,O
The,1227,O
persistent,1227,O
membrane,1227,O
retention,1227,O
of,1227,O
desipramine,1227,B-CHEMICAL
causes,1227,O
lasting,1227,O
inhibition,1227,O
of,1227,O
norepinephrine,1227,B-GENE-Y
transporter,1227,I-GENE-Y
function,1227,O
.,1227,O
The,1228,O
present,1228,O
study,1228,O
examined,1228,O
the,1228,O
potential,1228,O
membrane,1228,O
retention,1228,O
of,1228,O
desipramine,1228,B-CHEMICAL
(,1228,O
DMI,1228,B-CHEMICAL
),1228,O
following,1228,O
exposures,1228,O
of,1228,O
293-hNET,1228,O
cells,1228,O
to,1228,O
DMI,1228,B-CHEMICAL
",",1228,O
and,1228,O
its,1228,O
effect,1228,O
on,1228,O
[,1228,B-CHEMICAL
3H,1228,I-CHEMICAL
],1228,I-CHEMICAL
NE,1228,I-CHEMICAL
uptake,1228,O
.,1228,O
Incubation,1229,O
of,1229,O
cells,1229,O
with,1229,O
500,1229,O
nM,1229,O
DMI,1229,B-CHEMICAL
for,1229,O
1,1229,O
h,1229,O
or,1229,O
1,1229,O
day,1229,O
persistently,1229,O
inhibited,1229,O
the,1229,O
uptake,1229,O
of,1229,O
[,1229,B-CHEMICAL
3H,1229,I-CHEMICAL
],1229,I-CHEMICAL
NE,1229,I-CHEMICAL
up,1229,O
to,1229,O
7,1229,O
days,1229,O
",",1229,O
despite,1229,O
daily,1229,O
repeated,1229,O
washing,1229,O
of,1229,O
cells,1229,O
with,1229,O
drug-free,1229,O
medium,1229,O
.,1229,O
Uptake,1230,O
inhibition,1230,O
was,1230,O
paralleled,1230,O
by,1230,O
persistent,1230,O
retention,1230,O
of,1230,O
DMI,1230,B-CHEMICAL
associated,1230,O
with,1230,O
cells,1230,O
",",1230,O
as,1230,O
determined,1230,O
by,1230,O
HPLC,1230,O
and,1230,O
by,1230,O
radiotracer,1230,O
experiments,1230,O
using,1230,O
[,1230,B-CHEMICAL
3H,1230,I-CHEMICAL
],1230,I-CHEMICAL
DMI,1230,I-CHEMICAL
.,1230,O
[,1231,B-CHEMICAL
3H,1231,I-CHEMICAL
],1231,I-CHEMICAL
DMI,1231,I-CHEMICAL
trapped,1231,O
in,1231,O
membranes,1231,O
was,1231,O
displaceable,1231,O
by,1231,O
the,1231,O
structurally,1231,O
unrelated,1231,O
NET,1231,B-GENE-Y
inhibitor,1231,O
",",1231,O
nisoxetine,1231,B-CHEMICAL
",",1231,O
in,1231,O
a,1231,O
concentration-dependent,1231,O
manner,1231,O
",",1231,O
implying,1231,O
interaction,1231,O
of,1231,O
retained,1231,O
[,1231,B-CHEMICAL
3H,1231,I-CHEMICAL
],1231,I-CHEMICAL
DMI,1231,I-CHEMICAL
with,1231,O
the,1231,O
NET,1231,B-GENE-Y
.,1231,O
A,1232,O
similar,1232,O
cellular,1232,O
retention,1232,O
was,1232,O
observed,1232,O
following,1232,O
incubation,1232,O
of,1232,O
cells,1232,O
with,1232,O
nisoxetine,1232,B-CHEMICAL
.,1232,O
The,1233,O
results,1233,O
demonstrate,1233,O
that,1233,O
DMI,1233,B-CHEMICAL
and,1233,O
nisoxetine,1233,B-CHEMICAL
are,1233,O
persistently,1233,O
retained,1233,O
in,1233,O
cell,1233,O
membranes,1233,O
",",1233,O
at,1233,O
least,1233,O
partly,1233,O
in,1233,O
association,1233,O
with,1233,O
the,1233,O
NET,1233,B-GENE-Y
.,1233,O
The,1234,O
retention,1234,O
and,1234,O
slow,1234,O
diffusion,1234,O
of,1234,O
DMI,1234,B-CHEMICAL
and,1234,O
nisoxetine,1234,B-CHEMICAL
from,1234,O
membranes,1234,O
may,1234,O
contribute,1234,O
to,1234,O
their,1234,O
pharmacological,1234,O
and,1234,O
modulatory,1234,O
action,1234,O
on,1234,O
NET,1234,B-GENE-Y
.,1234,O
AT1-receptor,1235,B-GENE-Y
antagonism,1235,O
in,1235,O
hypertension,1235,O
:,1235,O
what,1235,O
has,1235,O
been,1235,O
learned,1235,O
with,1235,O
irbesartan,1235,B-CHEMICAL
?,1235,O
Irbesartan,1236,B-CHEMICAL
is,1236,O
a,1236,O
long-acting,1236,O
angiotensin,1236,B-CHEMICAL
II,1236,I-CHEMICAL
antagonist,1236,O
acting,1236,O
specifically,1236,O
at,1236,O
the,1236,O
level,1236,O
of,1236,O
the,1236,O
Type,1236,O
1-receptor,1236,O
subtype,1236,O
(,1236,O
AT1-receptor,1236,B-GENE-Y
),1236,O
.,1236,O
This,1237,O
compound,1237,O
lowers,1237,O
blood,1237,O
pressure,1237,O
dose-dependently,1237,O
in,1237,O
hypertensive,1237,O
patients,1237,O
and,1237,O
has,1237,O
a,1237,O
placebo-like,1237,O
tolerability,1237,O
.,1237,O
The,1238,O
antihypertensive,1238,O
efficacy,1238,O
of,1238,O
irbesartan,1238,B-CHEMICAL
is,1238,O
greatly,1238,O
enhanced,1238,O
by,1238,O
the,1238,O
coadministration,1238,O
of,1238,O
a,1238,O
diuretic,1238,O
",",1238,O
and,1238,O
fixed-dose,1238,O
combinations,1238,O
of,1238,O
irbesartan,1238,B-CHEMICAL
and,1238,O
hydrochlorothiazide,1238,B-CHEMICAL
are,1238,O
now,1238,O
available,1238,O
.,1238,O
Irbesartan-based,1239,B-CHEMICAL
treatment,1239,O
appears,1239,O
especially,1239,O
effective,1239,O
for,1239,O
high-risk,1239,O
patients,1239,O
",",1239,O
such,1239,O
as,1239,O
those,1239,O
with,1239,O
diabetes,1239,O
",",1239,O
renal,1239,O
disease,1239,O
and,1239,O
cardiac,1239,O
hypertrophy,1239,O
.,1239,O
In,1240,O
patients,1240,O
with,1240,O
Type,1240,O
2,1240,O
diabetes,1240,O
",",1240,O
irbesartan,1240,B-CHEMICAL
delays,1240,O
the,1240,O
development,1240,O
of,1240,O
nephropathy,1240,O
as,1240,O
well,1240,O
as,1240,O
the,1240,O
progression,1240,O
of,1240,O
renal,1240,O
failure,1240,O
.,1240,O
Irbesartan,1241,B-CHEMICAL
may,1241,O
have,1241,O
antiatherosclerotic,1241,O
properties,1241,O
beyond,1241,O
those,1241,O
expected,1241,O
from,1241,O
blood,1241,O
pressure,1241,O
lowering,1241,O
per,1241,O
se,1241,O
:,1241,O
this,1241,O
AT1-blocker,1241,B-GENE-Y
decreases,1241,O
the,1241,O
vascular,1241,O
oxidative,1241,O
stress,1241,O
and,1241,O
prevents,1241,O
the,1241,O
procoagulant,1241,O
as,1241,O
well,1241,O
as,1241,O
the,1241,O
pro-inflammatory,1241,O
effects,1241,O
of,1241,O
angiotensin,1241,B-CHEMICAL
II,1241,I-CHEMICAL
.,1241,O
Irbesartan,1242,O
given,1242,O
alone,1242,O
or,1242,O
in,1242,O
combination,1242,O
with,1242,O
a,1242,O
diuretic,1242,O
therefore,1242,O
represents,1242,O
a,1242,O
rational,1242,O
approach,1242,O
to,1242,O
treat,1242,O
hypertensive,1242,O
patients,1242,O
.,1242,O
Binding,1243,O
of,1243,O
(,1243,B-CHEMICAL
-,1243,I-CHEMICAL
),1243,I-CHEMICAL
-,1243,I-CHEMICAL
[,1243,I-CHEMICAL
3H,1243,I-CHEMICAL
],1243,I-CHEMICAL
-CGP12177,1243,I-CHEMICAL
at,1243,O
two,1243,O
sites,1243,O
in,1243,O
recombinant,1243,O
human,1243,B-GENE-Y
beta,1243,I-GENE-Y
1-adrenoceptors,1243,I-GENE-Y
and,1243,O
interaction,1243,O
with,1243,O
beta-blockers,1243,O
.,1243,O
To,1244,O
verify,1244,O
the,1244,O
hypothesis,1244,O
that,1244,O
the,1244,O
non-conventional,1244,O
partial,1244,O
agonist,1244,O
(,1244,B-CHEMICAL
-,1244,I-CHEMICAL
),1244,I-CHEMICAL
-CGP12177,1244,I-CHEMICAL
binds,1244,O
at,1244,O
two,1244,O
beta,1244,B-GENE-Y
(,1244,I-GENE-Y
1,1244,I-GENE-Y
),1244,I-GENE-Y
-adrenoceptor,1244,I-GENE-Y
sites,1244,O
",",1244,O
human,1244,B-GENE-Y
beta,1244,I-GENE-Y
(,1244,I-GENE-Y
1,1244,I-GENE-Y
),1244,I-GENE-Y
-adrenoceptors,1244,I-GENE-Y
",",1244,O
expressed,1244,O
in,1244,O
CHO,1244,O
cells,1244,O
",",1244,O
were,1244,O
labelled,1244,O
with,1244,O
(,1244,B-CHEMICAL
-,1244,I-CHEMICAL
),1244,I-CHEMICAL
-,1244,I-CHEMICAL
[,1244,I-CHEMICAL
(,1244,I-CHEMICAL
3,1244,I-CHEMICAL
),1244,I-CHEMICAL
H,1244,I-CHEMICAL
],1244,I-CHEMICAL
-CGP12177,1244,I-CHEMICAL
.,1244,O
We,1245,O
compared,1245,O
the,1245,O
binding,1245,O
affinity,1245,O
and,1245,O
antagonist,1245,O
potency,1245,O
of,1245,O
12,1245,O
clinically,1245,O
used,1245,O
beta-blockers,1245,O
against,1245,O
the,1245,O
cyclic,1245,B-CHEMICAL
AMP-enhancing,1245,O
effects,1245,O
of,1245,O
(,1245,B-CHEMICAL
-,1245,I-CHEMICAL
),1245,I-CHEMICAL
-isoprenaline,1245,I-CHEMICAL
and,1245,O
(,1245,B-CHEMICAL
-,1245,I-CHEMICAL
),1245,I-CHEMICAL
-CGP12177,1245,I-CHEMICAL
.,1245,O
(,1246,O
-,1246,O
),1246,O
-,1246,O
[,1246,O
(,1246,O
3,1246,O
),1246,O
H,1246,O
],1246,O
-CGP12177,1246,O
bound,1246,O
to,1246,O
a,1246,O
high,1246,O
affinity,1246,O
site,1246,O
(,1246,O
H,1246,O
;,1246,O
K,1246,O
(,1246,O
H,1246,O
),1246,O
=0.47,1246,O
nM,1246,O
),1246,O
and,1246,O
low,1246,O
affinity,1246,O
site,1246,O
(,1246,O
L,1246,O
),1246,O
;,1246,O
K,1246,O
(,1246,O
L,1246,O
),1246,O
=235,1246,O
nM,1246,O
),1246,O
.,1246,O
(,1247,O
-,1247,O
),1247,O
-,1247,O
[,1247,O
(,1247,O
3,1247,O
),1247,O
H,1247,O
],1247,O
-CGP12177,1247,O
dissociated,1247,O
from,1247,O
the,1247,O
beta,1247,I-GENE-Y
(,1247,I-GENE-Y
1,1247,I-GENE-Y
),1247,I-GENE-Y
-adrenoceptors,1247,O
with,1247,O
a,1247,O
fast,1247,O
component,1247,O
(,1247,O
k,1247,O
(,1247,O
off,1247,O
),1247,O
=0.45,1247,O
min,1247,O
(,1247,O
-1,1247,O
),1247,O
),1247,O
",",1247,O
consistent,1247,O
with,1247,O
the,1247,O
L-site,1247,O
",",1247,O
and,1247,O
a,1247,O
slow,1247,O
component,1247,O
(,1247,O
k,1247,O
(,1247,O
off,1247,O
),1247,O
=0.017-0.033,1247,O
min,1247,O
(,1247,O
-1,1247,O
),1247,O
),1247,O
",",1247,O
consistent,1247,O
with,1247,O
the,1247,O
H-site,1247,O
.,1247,O
(,1248,O
-,1248,O
),1248,O
-Isoprenaline,1248,O
and,1248,O
(,1248,I-CHEMICAL
-,1248,I-CHEMICAL
),1248,I-CHEMICAL
-CGP12177,1248,O
caused,1248,O
96-fold,1248,O
and,1248,O
12-fold,1248,O
maximal,1248,O
increases,1248,O
in,1248,O
cyclic,1248,I-CHEMICAL
AMP,1248,O
levels,1248,O
with,1248,O
-logEC,1248,O
(,1248,O
50,1248,O
),1248,O
M,1248,O
of,1248,O
8.2,1248,O
and,1248,O
7.6,1248,O
.,1248,O
(,1249,O
-,1249,O
),1249,O
-CGP12177,1249,O
antagonised,1249,O
the,1249,O
effects,1249,O
of,1249,O
(,1249,I-CHEMICAL
-,1249,I-CHEMICAL
),1249,I-CHEMICAL
-isoprenaline,1249,O
with,1249,O
a,1249,O
pK,1249,O
(,1249,O
B,1249,O
),1249,O
of,1249,O
9.9,1249,O
.,1249,O
The,1250,O
beta-blockers,1250,O
antagonised,1250,O
the,1250,O
effects,1250,O
of,1250,O
(,1250,I-CHEMICAL
-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-isoprenaline,1250,O
more,1250,O
than,1250,O
the,1250,O
effects,1250,O
of,1250,O
(,1250,I-CHEMICAL
-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-CGP12177,1250,O
with,1250,O
potency,1250,O
ratios,1250,O
:,1250,O
(,1250,I-CHEMICAL
-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-atenolol,1250,O
"1,000",1250,O
",",1250,O
(,1250,I-CHEMICAL
+/-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-metropolol,1250,O
676,1250,O
",",1250,O
(,1250,I-CHEMICAL
-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-pindolol,1250,O
631,1250,O
",",1250,O
(,1250,I-CHEMICAL
-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-timolol,1250,O
589,1250,O
",",1250,O
(,1250,I-CHEMICAL
+/-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-carvedilol,1250,O
204,1250,O
",",1250,O
(,1250,I-CHEMICAL
+/-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-oxprenolol,1250,O
138,1250,O
",",1250,O
(,1250,I-CHEMICAL
+/-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-sotalol,1250,O
132,1250,O
",",1250,O
(,1250,I-CHEMICAL
-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-propranolol,1250,O
120,1250,O
",",1250,O
(,1250,I-CHEMICAL
+/-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-bisoprolol,1250,O
95,1250,O
",",1250,O
(,1250,I-CHEMICAL
+/-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-alprenolol,1250,O
81,1250,O
",",1250,O
(,1250,I-CHEMICAL
+/-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-nadolol,1250,O
68,1250,O
and,1250,O
(,1250,I-CHEMICAL
-,1250,I-CHEMICAL
),1250,I-CHEMICAL
-bupranolol,1250,O
56,1250,O
.,1250,O
In,1251,O
intact,1251,O
cells,1251,O
the,1251,O
binding,1251,O
constants,1251,O
of,1251,O
beta-blockers,1251,O
",",1251,O
estimated,1251,O
from,1251,O
competition,1251,O
with,1251,O
3-5,1251,O
nM,1251,O
(,1251,I-CHEMICAL
-,1251,I-CHEMICAL
),1251,I-CHEMICAL
-,1251,I-CHEMICAL
[,1251,I-CHEMICAL
(,1251,I-CHEMICAL
3,1251,I-CHEMICAL
),1251,I-CHEMICAL
H,1251,I-CHEMICAL
],1251,I-CHEMICAL
-CGP12177,1251,O
(,1251,O
binding,1251,O
to,1251,O
the,1251,O
H-site,1251,O
),1251,O
",",1251,O
correlated,1251,O
with,1251,O
the,1251,O
corresponding,1251,O
affinities,1251,O
estimated,1251,O
from,1251,O
antagonism,1251,O
of,1251,O
the,1251,O
(,1251,I-CHEMICAL
-,1251,I-CHEMICAL
),1251,I-CHEMICAL
-isoprenaline,1251,O
effects,1251,O
.,1251,O
We,1252,O
conclude,1252,O
that,1252,O
(,1252,I-CHEMICAL
-,1252,I-CHEMICAL
),1252,I-CHEMICAL
-,1252,I-CHEMICAL
[,1252,I-CHEMICAL
(,1252,I-CHEMICAL
3,1252,I-CHEMICAL
),1252,I-CHEMICAL
H,1252,I-CHEMICAL
],1252,I-CHEMICAL
-CGP12177,1252,O
binds,1252,O
at,1252,O
two,1252,O
sites,1252,O
in,1252,O
the,1252,O
recombinant,1252,O
beta,1252,I-GENE-Y
(,1252,I-GENE-Y
1,1252,I-GENE-Y
),1252,I-GENE-Y
-adrenoceptor,1252,O
.,1252,O
(,1253,O
-,1253,O
),1253,O
-CGP12177,1253,O
is,1253,O
an,1253,O
antagonist,1253,O
of,1253,O
catecholamine,1253,O
effects,1253,O
through,1253,O
the,1253,O
H-site,1253,O
and,1253,O
a,1253,O
non-conventional,1253,O
partial,1253,O
agonist,1253,O
through,1253,O
the,1253,O
L-site,1253,O
.,1253,O
beta-blockers,1254,O
are,1254,O
more,1254,O
potent,1254,O
antagonists,1254,O
through,1254,O
the,1254,O
H-site,1254,O
than,1254,O
the,1254,O
L-site,1254,O
.,1254,O
Imiquimod,1255,B-CHEMICAL
",",1255,O
a,1255,O
Toll-like,1255,B-GENE-Y
receptor-7,1255,I-GENE-Y
agonist,1255,O
",",1255,O
induces,1255,O
perforin,1255,B-GENE-Y
in,1255,O
cytotoxic,1255,O
T,1255,O
lymphocytes,1255,O
in,1255,O
vitro,1255,O
.,1255,O
Imiquimod,1256,B-CHEMICAL
(,1256,O
IMQ,1256,B-CHEMICAL
),1256,O
",",1256,O
an,1256,O
activator,1256,O
of,1256,O
Toll-like,1256,B-GENE-Y
receptor-7,1256,I-GENE-Y
(,1256,O
TLR-7,1256,B-GENE-Y
),1256,O
",",1256,O
induces,1256,O
by,1256,O
several,1256,O
routes,1256,O
a,1256,O
profound,1256,O
anti-viral,1256,O
and,1256,O
anti-tumor,1256,O
effect,1256,O
in,1256,O
vivo,1256,O
.,1256,O
Physiologically,1257,O
",",1257,O
the,1257,O
immune,1257,O
system,1257,O
is,1257,O
using,1257,O
perforin-containing,1257,B-GENE-Y
granules,1257,O
of,1257,O
cytotoxic,1257,O
T,1257,O
lymphocytes,1257,O
(,1257,O
CTL,1257,O
),1257,O
towards,1257,O
the,1257,O
same,1257,O
biological,1257,O
purpose,1257,O
.,1257,O
This,1258,O
functional,1258,O
synergism,1258,O
prompted,1258,O
our,1258,O
current,1258,O
experiments,1258,O
addressing,1258,O
the,1258,O
question,1258,O
whether,1258,O
IMQ,1258,B-CHEMICAL
may,1258,O
influence,1258,O
perforin-release,1258,B-GENE-Y
and/or,1258,O
induce,1258,O
perforin,1258,B-GENE-Y
in,1258,O
CTLs,1258,O
in,1258,O
vitro,1258,O
.,1258,O
In,1259,O
peripheral,1259,O
lymphocytes,1259,O
of,1259,O
healthy,1259,O
and,1259,O
diseased,1259,O
subjects,1259,O
",",1259,O
IMQ,1259,B-CHEMICAL
induced,1259,O
a,1259,O
significant,1259,O
increase,1259,O
of,1259,O
perforin,1259,B-GENE-Y
(,1259,O
+,1259,O
),1259,O
CTLs,1259,O
within,1259,O
12h,1259,O
in,1259,O
all,1259,O
experiments,1259,O
performed,1259,O
.,1259,O
This,1260,O
effect,1260,O
was,1260,O
most,1260,O
pronounced,1260,O
in,1260,O
CTLs,1260,O
of,1260,O
patients,1260,O
suffering,1260,O
from,1260,O
atopic,1260,O
dermatitis,1260,O
",",1260,O
a,1260,O
model,1260,O
disorder,1260,O
for,1260,O
subnormal,1260,O
perforin,1260,B-GENE-Y
expression,1260,O
:,1260,O
as,1260,O
compared,1260,O
to,1260,O
perforin,1260,B-GENE-Y
(,1260,O
+,1260,O
),1260,O
CTLs,1260,O
detected,1260,O
at,1260,O
time,1260,O
point,1260,O
zero,1260,O
(,1260,O
100,1260,O
%,1260,O
),1260,O
",",1260,O
up,1260,O
to,1260,O
270,1260,O
%,1260,O
of,1260,O
perforin,1260,B-GENE-Y
(,1260,O
+,1260,O
),1260,O
CTLs,1260,O
were,1260,O
induced,1260,O
by,1260,O
2.5,1260,O
microg/ml,1260,O
[,1260,O
corrected,1260,O
],1260,O
IMQ,1260,B-CHEMICAL
.,1260,O
Perforin,1261,B-GENE-Y
release,1261,O
from,1261,O
peripheral,1261,O
blood,1261,O
CTLs,1261,O
after,1261,O
PMA/ionomycin-stimulation,1261,O
was,1261,O
not,1261,O
influenced,1261,O
significantly,1261,O
by,1261,O
IMQ,1261,B-CHEMICAL
.,1261,O
Thus,1262,O
",",1262,O
the,1262,O
biological,1262,O
activity,1262,O
of,1262,O
IMQ,1262,B-CHEMICAL
appears,1262,O
to,1262,O
exceed,1262,O
its,1262,O
previously,1262,O
known,1262,O
functions,1262,O
",",1262,O
inasmuch,1262,O
as,1262,O
it,1262,O
boosts,1262,O
up,1262,O
significantly,1262,O
the,1262,O
perforin-granule,1262,B-GENE-Y
system,1262,O
.,1262,O
Caffeine,1263,B-CHEMICAL
as,1263,O
a,1263,O
psychomotor,1263,O
stimulant,1263,O
:,1263,O
mechanism,1263,O
of,1263,O
action,1263,O
.,1263,O
The,1264,O
popularity,1264,O
of,1264,O
caffeine,1264,B-CHEMICAL
as,1264,O
a,1264,O
psychoactive,1264,O
drug,1264,O
is,1264,O
due,1264,O
to,1264,O
its,1264,O
stimulant,1264,O
properties,1264,O
",",1264,O
which,1264,O
depend,1264,O
on,1264,O
its,1264,O
ability,1264,O
to,1264,O
reduce,1264,O
adenosine,1264,B-CHEMICAL
transmission,1264,O
in,1264,O
the,1264,O
brain,1264,O
.,1264,O
Adenosine,1265,B-CHEMICAL
A,1265,I-GENE-N
(,1265,I-GENE-N
1,1265,I-GENE-N
),1265,I-GENE-N
and,1265,I-GENE-N
A,1265,I-GENE-N
(,1265,I-GENE-N
2A,1265,I-GENE-N
),1265,I-GENE-N
receptors,1265,I-GENE-N
are,1265,O
expressed,1265,O
in,1265,O
the,1265,O
basal,1265,O
ganglia,1265,O
",",1265,O
a,1265,O
group,1265,O
of,1265,O
structures,1265,O
involved,1265,O
in,1265,O
various,1265,O
aspects,1265,O
of,1265,O
motor,1265,O
control,1265,O
.,1265,O
Caffeine,1266,B-CHEMICAL
acts,1266,O
as,1266,O
an,1266,O
antagonist,1266,O
to,1266,O
both,1266,O
types,1266,O
of,1266,O
receptors,1266,O
.,1266,O
Increasing,1267,O
evidence,1267,O
indicates,1267,O
that,1267,O
the,1267,O
psychomotor,1267,O
stimulant,1267,O
effect,1267,O
of,1267,O
caffeine,1267,B-CHEMICAL
is,1267,O
generated,1267,O
by,1267,O
affecting,1267,O
a,1267,O
particular,1267,O
group,1267,O
of,1267,O
projection,1267,O
neurons,1267,O
located,1267,O
in,1267,O
the,1267,O
striatum,1267,O
",",1267,O
the,1267,O
main,1267,O
receiving,1267,O
area,1267,O
of,1267,O
the,1267,O
basal,1267,O
ganglia,1267,O
.,1267,O
These,1268,O
cells,1268,O
express,1268,O
high,1268,O
levels,1268,O
of,1268,O
adenosine,1268,B-CHEMICAL
A,1268,I-GENE-Y
(,1268,I-GENE-Y
2A,1268,I-GENE-Y
),1268,I-GENE-Y
receptors,1268,I-GENE-Y
",",1268,O
which,1268,O
are,1268,O
involved,1268,O
in,1268,O
various,1268,O
intracellular,1268,O
processes,1268,O
",",1268,O
including,1268,O
the,1268,O
expression,1268,O
of,1268,O
immediate,1268,O
early,1268,O
genes,1268,O
and,1268,O
regulation,1268,O
of,1268,O
the,1268,O
dopamine-,1268,B-CHEMICAL
and,1268,I-GENE-Y
cyclic,1268,B-CHEMICAL
AMP-regulated,1268,I-GENE-Y
32-kDa,1268,I-GENE-Y
phosphoprotein,1268,I-GENE-Y
DARPP-32,1268,B-GENE-Y
.,1268,O
The,1269,O
present,1269,O
review,1269,O
focuses,1269,O
on,1269,O
the,1269,O
effects,1269,O
of,1269,O
caffeine,1269,B-CHEMICAL
on,1269,O
striatal,1269,O
signal,1269,O
transduction,1269,O
and,1269,O
on,1269,O
their,1269,O
involvement,1269,O
in,1269,O
caffeine-mediated,1269,B-CHEMICAL
motor,1269,O
stimulation,1269,O
.,1269,O
Mesenteric,1270,O
artery,1270,O
remodeling,1270,O
and,1270,O
effects,1270,O
of,1270,O
imidapril,1270,B-CHEMICAL
and,1270,O
irbesartan,1270,B-CHEMICAL
on,1270,O
it,1270,O
in,1270,O
spontaneously,1270,O
hypertensive,1270,O
rats,1270,O
.,1270,O
AIM,1271,O
:,1271,O
To,1271,O
investigate,1271,O
the,1271,O
remodeling,1271,O
of,1271,O
mesenteric,1271,O
artery,1271,O
and,1271,O
the,1271,O
expression,1271,O
of,1271,O
TGF-beta1,1271,B-GENE-Y
",",1271,O
c-Jun,1271,B-GENE-Y
in,1271,O
mesenteric,1271,O
artery,1271,O
and,1271,O
effects,1271,O
of,1271,O
imidapril,1271,B-CHEMICAL
and,1271,O
irbesartan,1271,B-CHEMICAL
on,1271,O
the,1271,O
remodeling,1271,O
in,1271,O
spontaneously,1271,O
hypertensive,1271,O
rats,1271,O
(,1271,O
SHR,1271,O
),1271,O
.,1271,O
METHODS,1272,O
:,1272,O
Thirty,1272,O
SHR,1272,O
(,1272,O
male/female,1272,O
",",1272,O
21/9,1272,O
),1272,O
",",1272,O
aged,1272,O
13,1272,O
wk,1272,O
",",1272,O
were,1272,O
randomly,1272,O
divided,1272,O
into,1272,O
3,1272,O
groups,1272,O
(,1272,O
7,1272,O
male,1272,O
rats,1272,O
and,1272,O
3,1272,O
female,1272,O
rats,1272,O
each,1272,O
group,1272,O
),1272,O
:,1272,O
SHR,1272,O
group,1272,O
",",1272,O
imidapril,1272,B-CHEMICAL
group,1272,O
(,1272,O
imidapril,1272,B-CHEMICAL
3,1272,O
mg/kg.d,1272,O
was,1272,O
given,1272,O
in,1272,O
drinking,1272,O
water,1272,O
for,1272,O
14,1272,O
wk,1272,O
),1272,O
",",1272,O
and,1272,O
irbesartan,1272,B-CHEMICAL
group,1272,O
(,1272,O
irbesartan,1272,B-CHEMICAL
50,1272,O
mg/kg.d,1272,O
was,1272,O
given,1272,O
in,1272,O
drinking,1272,O
water,1272,O
foe,1272,O
14,1272,O
wk,1272,O
),1272,O
.,1272,O
Ten,1273,O
homogeneous,1273,O
Wistar,1273,O
Kyoto,1273,O
rats,1273,O
",",1273,O
5,1273,O
males,1273,O
and,1273,O
5,1273,O
females,1273,O
",",1273,O
weighing,1273,O
206+/-49,1273,O
g,1273,O
",",1273,O
were,1273,O
selected,1273,O
as,1273,O
normal,1273,O
control,1273,O
group,1273,O
(,1273,O
WKY,1273,O
group,1273,O
),1273,O
.,1273,O
Systolic,1274,O
pressure,1274,O
was,1274,O
measured,1274,O
on,1274,O
d,1274,O
1,1274,O
",",1274,O
2,1274,O
",",1274,O
4,1274,O
",",1274,O
6,1274,O
",",1274,O
8,1274,O
",",1274,O
10,1274,O
",",1274,O
12,1274,O
and,1274,O
14,1274,O
during,1274,O
the,1274,O
experiment,1274,O
and,1274,O
the,1274,O
rats,1274,O
were,1274,O
killed,1274,O
at,1274,O
the,1274,O
end,1274,O
of,1274,O
the,1274,O
experiment,1274,O
.,1274,O
Angiotensin,1275,B-GENE-Y
II,1275,I-GENE-Y
(,1275,O
Ang,1275,B-GENE-Y
II,1275,I-GENE-Y
),1275,O
level,1275,O
in,1275,O
plasma,1275,O
and,1275,O
mesenteric,1275,O
arteries,1275,O
was,1275,O
measured,1275,O
by,1275,O
radioimmunoassay,1275,O
.,1275,O
The,1276,O
morphology,1276,O
of,1276,O
the,1276,O
secondary,1276,O
branches,1276,O
of,1276,O
mesenteric,1276,O
artery,1276,O
were,1276,O
examined,1276,O
by,1276,O
light,1276,O
microscopy,1276,O
and,1276,O
electron,1276,O
microscopy,1276,O
.,1276,O
Reverse,1277,O
transcription,1277,O
polymerase,1277,O
chain,1277,O
reaction,1277,O
(,1277,O
RT-PCR,1277,O
),1277,O
was,1277,O
used,1277,O
to,1277,O
detect,1277,O
the,1277,O
expression,1277,O
of,1277,O
transforming,1277,B-GENE-Y
growth,1277,I-GENE-Y
factor,1277,I-GENE-Y
TGF-beta1,1277,B-GENE-Y
and,1277,O
c-Jun,1277,B-GENE-Y
mRNA,1277,O
.,1277,O
RESULTS,1278,O
:,1278,O
Compared,1278,O
with,1278,O
imidapril,1278,B-CHEMICAL
group,1278,O
and,1278,O
irbesartan,1278,B-CHEMICAL
group,1278,O
",",1278,O
the,1278,O
blood,1278,O
pressure,1278,O
was,1278,O
remarkably,1278,O
increased,1278,O
in,1278,O
SHR,1278,O
group,1278,O
.,1278,O
Ang,1279,B-CHEMICAL
II,1279,I-CHEMICAL
level,1279,O
in,1279,O
plasma,1279,O
and,1279,O
mesenteric,1279,O
arteries,1279,O
in,1279,O
SHR,1279,O
group,1279,O
was,1279,O
the,1279,O
same,1279,O
or,1279,O
lower,1279,O
than,1279,O
that,1279,O
in,1279,O
WKY,1279,O
group,1279,O
",",1279,O
and,1279,O
was,1279,O
higher,1279,O
in,1279,O
irbesartan,1279,B-CHEMICAL
group,1279,O
and,1279,O
lower,1279,O
in,1279,O
imidapril,1279,B-CHEMICAL
group,1279,O
.,1279,O
The,1280,O
remodeling,1280,O
of,1280,O
mesenteric,1280,O
arteries,1280,O
in,1280,O
SHR,1280,O
group,1280,O
was,1280,O
mostly,1280,O
obvious,1280,O
among,1280,O
the,1280,O
4,1280,O
groups,1280,O
.,1280,O
The,1281,O
ratio,1281,O
of,1281,O
TGF-beta1,1281,B-GENE-Y
absorbed,1281,O
light,1281,O
value,1281,O
to,1281,O
GAPDH,1281,B-GENE-Y
absorbed,1281,O
light,1281,O
value,1281,O
in,1281,O
the,1281,O
SHR,1281,O
group,1281,O
was,1281,O
0.887+/-0.019,1281,O
",",1281,O
which,1281,O
was,1281,O
significantly,1281,O
higher,1281,O
than,1281,O
that,1281,O
in,1281,O
WKY,1281,O
group,1281,O
",",1281,O
imidapril,1281,B-CHEMICAL
group,1281,O
",",1281,O
and,1281,O
irbesartan,1281,B-CHEMICAL
group,1281,O
with,1281,O
the,1281,O
ratios,1281,O
of,1281,O
0.780+/-0.018,1281,O
",",1281,O
0.803+/-0.005,1281,O
",",1281,O
and,1281,O
0.847+/-0.017,1281,O
",",1281,O
respectively,1281,O
(,1281,O
P,1281,O
<,1281,O
0.01,1281,O
),1281,O
.,1281,O
Ang,1282,B-GENE-Y
II,1282,I-GENE-Y
level,1282,O
in,1282,O
plasma,1282,O
and,1282,O
mesenteric,1282,O
arteries,1282,O
in,1282,O
imidapril,1282,B-CHEMICAL
group,1282,O
was,1282,O
significantly,1282,O
lower,1282,O
than,1282,O
that,1282,O
in,1282,O
irbesartan,1282,B-CHEMICAL
group,1282,O
(,1282,O
P,1282,O
<,1282,O
0.05,1282,O
),1282,O
.,1282,O
The,1283,O
c-Jun,1283,B-GENE-Y
absorbed,1283,O
light,1283,O
value/GAPDH,1283,O
absorbed,1283,O
light,1283,O
value,1283,O
of,1283,O
mesenteric,1283,O
arteries,1283,O
in,1283,O
the,1283,O
SHR,1283,O
group,1283,O
was,1283,O
0.850+/-0.015,1283,O
",",1283,O
which,1283,O
was,1283,O
significantly,1283,O
higher,1283,O
than,1283,O
that,1283,O
in,1283,O
the,1283,O
WKY,1283,O
",",1283,O
imidapril,1283,B-CHEMICAL
",",1283,O
and,1283,O
irbesartan,1283,B-CHEMICAL
groups,1283,O
(,1283,O
0.582+/-0.013,1283,O
",",1283,O
0.743+/-0.012,1283,O
",",1283,O
and,1283,O
0.789+/-0.013,1283,O
",",1283,O
respectively,1283,O
",",1283,O
P,1283,O
<,1283,O
0.01,1283,O
),1283,O
",",1283,O
and,1283,O
was,1283,O
significantly,1283,O
lower,1283,O
in,1283,O
imidapril,1283,B-CHEMICAL
group,1283,O
than,1283,O
in,1283,O
irbesartan,1283,B-CHEMICAL
group,1283,O
(,1283,O
P,1283,O
<,1283,O
0.05,1283,O
),1283,O
.,1283,O
CONCLUSION,1284,O
:,1284,O
Imidapril,1284,B-CHEMICAL
and,1284,O
irbesartan,1284,B-CHEMICAL
can,1284,O
not,1284,O
only,1284,O
control,1284,O
blood,1284,O
pressure,1284,O
but,1284,O
also,1284,O
inhibit,1284,O
mesenteric,1284,O
arteries,1284,O
remodeling,1284,O
and,1284,O
mRNA,1284,O
expression,1284,O
of,1284,O
TGF-beta1,1284,B-GENE-Y
",",1284,O
c-Jun,1284,B-GENE-Y
in,1284,O
SHR,1284,O
.,1284,O
Imidapril,1285,B-CHEMICAL
is,1285,O
more,1285,O
effective,1285,O
than,1285,O
irbesartan,1285,B-CHEMICAL
.,1285,O
Clinical,1286,O
assessment,1286,O
of,1286,O
norepinephrine,1286,B-GENE-Y
transporter,1286,I-GENE-Y
blockade,1286,O
through,1286,O
biochemical,1286,O
and,1286,O
pharmacological,1286,O
profiles,1286,O
.,1286,O
BACKGROUND,1287,O
:,1287,O
To,1287,O
assess,1287,O
the,1287,O
sensitivity,1287,O
of,1287,O
biochemical,1287,O
",",1287,O
physiological,1287,O
",",1287,O
and,1287,O
pharmacological,1287,O
markers,1287,O
of,1287,O
peripheral,1287,O
norepinephrine,1287,B-CHEMICAL
(,1287,I-GENE-Y
NE,1287,I-GENE-Y
),1287,I-GENE-Y
transporter,1287,I-GENE-Y
(,1287,O
NET,1287,B-GENE-Y
),1287,O
function,1287,O
",",1287,O
we,1287,O
chronically,1287,O
antagonized,1287,O
NET,1287,B-GENE-Y
by,1287,O
a,1287,O
range,1287,O
of,1287,O
doses,1287,O
of,1287,O
duloxetine,1287,B-CHEMICAL
[,1287,O
(,1287,B-CHEMICAL
+,1287,I-CHEMICAL
),1287,I-CHEMICAL
-N-methyl-3-,1287,I-CHEMICAL
(,1287,I-CHEMICAL
1-naphthalenyloxy,1287,I-CHEMICAL
),1287,I-CHEMICAL
-2,1287,I-CHEMICAL
thiophenepropanamine,1287,I-CHEMICAL
],1287,O
",",1287,O
which,1287,O
blocks,1287,O
the,1287,O
NE,1287,B-CHEMICAL
reuptake,1287,O
process,1287,O
.,1287,O
METHODS,1288,O
AND,1288,O
RESULTS,1288,O
:,1288,O
Duloxetine,1288,B-CHEMICAL
was,1288,O
administered,1288,O
in,1288,O
a,1288,O
randomized,1288,O
",",1288,O
placebo-controlled,1288,O
study,1288,O
in,1288,O
15,1288,O
healthy,1288,O
volunteers,1288,O
.,1288,O
Plasma,1289,O
from,1289,O
duloxetine-treated,1289,B-CHEMICAL
subjects,1289,O
(,1289,O
ex,1289,O
vivo,1289,O
effect,1289,O
),1289,O
dose-dependently,1289,O
decreased,1289,O
radioligand,1289,O
binding,1289,O
to,1289,O
human,1289,B-GENE-Y
NET,1289,I-GENE-Y
(,1289,O
maximum,1289,O
inhibition,1289,O
was,1289,O
60,1289,O
%,1289,O
),1289,O
(,1289,O
P=0.02,1289,O
),1289,O
.,1289,O
The,1290,O
dose,1290,O
of,1290,O
intravenous,1290,O
tyramine,1290,O
required,1290,O
to,1290,O
raise,1290,O
systolic,1290,O
blood,1290,O
pressure,1290,O
by,1290,O
30,1290,O
mm,1290,O
Hg,1290,O
(,1290,O
PD30,1290,O
),1290,O
increased,1290,O
dose-dependently,1290,O
with,1290,O
duloxetine,1290,O
and,1290,O
was,1290,O
significant,1290,O
at,1290,O
the,1290,O
end,1290,O
of,1290,O
the,1290,O
120-mg/d,1290,O
dosage,1290,O
(,1290,O
P,1290,O
<,1290,O
0.001,1290,O
),1290,O
.,1290,O
The,1291,O
plasma,1291,O
dihydoxyphenylglycol,1291,B-CHEMICAL
to,1291,O
NE,1291,B-CHEMICAL
(,1291,O
DHPG/NE,1291,B-CHEMICAL
),1291,O
ratio,1291,O
was,1291,O
reduced,1291,O
significantly,1291,O
at,1291,O
2,1291,O
weeks,1291,O
of,1291,O
treatment,1291,O
with,1291,O
80,1291,O
mg/d,1291,O
duloxetine,1291,B-CHEMICAL
(,1291,O
11.3,1291,O
at,1291,O
baseline,1291,O
",",1291,O
3.4,1291,O
at,1291,O
240,1291,O
mg/d,1291,O
",",1291,O
P,1291,O
<,1291,O
0.001,1291,O
),1291,O
.,1291,O
Plasma,1292,O
NE,1292,B-CHEMICAL
was,1292,O
significantly,1292,O
increased,1292,O
starting,1292,O
at,1292,O
120,1292,O
mg/d,1292,O
duloxetine,1292,B-CHEMICAL
.,1292,O
Urine,1293,O
results,1293,O
(,1293,O
corrected,1293,O
for,1293,O
24-hour,1293,O
creatinine,1293,B-CHEMICAL
excretion,1293,O
),1293,O
showed,1293,O
a,1293,O
dose-dependent,1293,O
change,1293,O
from,1293,O
the,1293,O
baseline,1293,O
urinary,1293,O
excretion,1293,O
for,1293,O
NE,1293,B-CHEMICAL
",",1293,O
DHPG,1293,B-CHEMICAL
",",1293,O
and,1293,O
the,1293,O
DHPG/NE,1293,B-CHEMICAL
ratio,1293,O
.,1293,O
The,1294,O
most,1294,O
sensitive,1294,O
measure,1294,O
",",1294,O
the,1294,O
DHPG/NE,1294,B-CHEMICAL
ratio,1294,O
",",1294,O
was,1294,O
significant,1294,O
at,1294,O
the,1294,O
80-mg,1294,O
dose,1294,O
.,1294,O
Urinary,1295,O
NE,1295,B-CHEMICAL
excretion,1295,O
was,1295,O
significantly,1295,O
raised,1295,O
after,1295,O
2,1295,O
weeks,1295,O
of,1295,O
treatment,1295,O
with,1295,O
80,1295,O
mg/d,1295,O
duloxetine,1295,B-CHEMICAL
(,1295,O
P,1295,O
<,1295,O
0.001,1295,O
),1295,O
",",1295,O
the,1295,O
lowest,1295,O
dose,1295,O
used,1295,O
in,1295,O
the,1295,O
study,1295,O
.,1295,O
CONCLUSIONS,1296,O
:,1296,O
These,1296,O
findings,1296,O
suggest,1296,O
that,1296,O
the,1296,O
degree,1296,O
of,1296,O
NET,1296,B-GENE-Y
blockade,1296,O
can,1296,O
be,1296,O
assessed,1296,O
with,1296,O
the,1296,O
plasma,1296,O
or,1296,O
urine,1296,O
DHPG/NE,1296,B-CHEMICAL
ratio,1296,O
and,1296,O
the,1296,O
pressor,1296,O
effect,1296,O
of,1296,O
tyramine,1296,O
.,1296,O
Also,1297,O
",",1297,O
the,1297,O
DHPG/NE,1297,B-CHEMICAL
ratio,1297,O
is,1297,O
more,1297,O
sensitive,1297,O
at,1297,O
the,1297,O
lower,1297,O
end,1297,O
of,1297,O
NET,1297,B-GENE-Y
inhibition,1297,O
",",1297,O
whereas,1297,O
tyramine,1297,O
exhibits,1297,O
a,1297,O
linear,1297,O
relation,1297,O
",",1297,O
with,1297,O
NET,1297,B-GENE-Y
inhibition,1297,O
commencing,1297,O
at,1297,O
a,1297,O
higher,1297,O
dose,1297,O
.,1297,O
Auranofin,1298,B-CHEMICAL
increases,1298,O
apoptosis,1298,O
and,1298,O
ischaemia-reperfusion,1298,O
injury,1298,O
in,1298,O
the,1298,O
rat,1298,O
isolated,1298,O
heart,1298,O
.,1298,O
Auranofin,1299,B-CHEMICAL
",",1299,O
an,1299,O
antirheumatic,1299,O
gold,1299,O
compound,1299,O
",",1299,O
is,1299,O
an,1299,O
inhibitor,1299,O
of,1299,O
selenocysteine,1299,B-CHEMICAL
enzymes,1299,I-GENE-N
",",1299,O
such,1299,O
as,1299,O
thioredoxin,1299,B-GENE-Y
reductase,1299,I-GENE-Y
and,1299,O
glutathione,1299,B-CHEMICAL
peroxidase,1299,I-GENE-N
.,1299,O
These,1300,O
enzymes,1300,O
play,1300,O
an,1300,O
important,1300,O
role,1300,O
in,1300,O
protecting,1300,O
cardiac,1300,O
tissue,1300,O
from,1300,O
oxidative,1300,O
stress,1300,O
generated,1300,O
during,1300,O
ischaemia-reperfusion,1300,O
.,1300,O
Auranofin,1301,B-CHEMICAL
(,1301,O
100,1301,O
mg/kg,1301,O
),1301,O
was,1301,O
administered,1301,O
to,1301,O
rats,1301,O
and,1301,O
their,1301,O
hearts,1301,O
were,1301,O
subjected,1301,O
to,1301,O
an,1301,O
in,1301,O
vitro,1301,O
model,1301,O
of,1301,O
ischaemia-reperfusion,1301,O
.,1301,O
The,1302,O
activity,1302,O
of,1302,O
thioredoxin,1302,B-GENE-Y
reductase,1302,I-GENE-Y
and,1302,O
glutathione,1302,B-CHEMICAL
peroxidase,1302,I-GENE-N
was,1302,O
determined,1302,O
in,1302,O
liver,1302,O
and,1302,O
heart,1302,O
tissues,1302,O
in,1302,O
an,1302,O
attempt,1302,O
to,1302,O
correlate,1302,O
enzymatic,1302,O
activity,1302,O
with,1302,O
heart,1302,O
recovery,1302,O
after,1302,O
ischaemia-reperfusion,1302,O
.,1302,O
There,1303,O
was,1303,O
significantly,1303,O
less,1303,O
thioredoxin,1303,B-GENE-Y
reductase,1303,I-GENE-Y
activity,1303,O
in,1303,O
rat,1303,O
liver,1303,O
extracts,1303,O
",",1303,O
whereas,1303,O
the,1303,O
level,1303,O
of,1303,O
glutathione,1303,B-CHEMICAL
activity,1303,O
remained,1303,O
unchanged,1303,O
",",1303,O
demonstrating,1303,O
that,1303,O
the,1303,O
dose,1303,O
of,1303,O
auranofin,1303,B-CHEMICAL
used,1303,O
was,1303,O
able,1303,O
to,1303,O
selectively,1303,O
inhibit,1303,O
one,1303,O
of,1303,O
these,1303,O
enzyme,1303,O
systems,1303,O
.,1303,O
Rats,1304,O
administered,1304,O
auranofin,1304,B-CHEMICAL
displayed,1304,O
significantly,1304,O
impaired,1304,O
recovery,1304,O
from,1304,O
ischaemic,1304,O
insult,1304,O
.,1304,O
The,1305,O
end,1305,O
diastolic,1305,O
pressure,1305,O
was,1305,O
increased,1305,O
",",1305,O
whereas,1305,O
the,1305,O
rate,1305,O
pressure,1305,O
product,1305,O
was,1305,O
significantly,1305,O
decreased,1305,O
.,1305,O
The,1306,O
level,1306,O
of,1306,O
postischaemic,1306,O
apoptosis,1306,O
was,1306,O
also,1306,O
assessed,1306,O
by,1306,O
examining,1306,O
caspase-3,1306,B-GENE-Y
activity,1306,O
in,1306,O
tissue,1306,O
homogenates,1306,O
.,1306,O
Auranofin,1307,B-CHEMICAL
significantly,1307,O
increased,1307,O
the,1307,O
degree,1307,O
of,1307,O
postischaemic,1307,O
apoptosis,1307,O
",",1307,O
leading,1307,O
to,1307,O
poor,1307,O
postischaemic,1307,O
recovery,1307,O
.,1307,O
Gallium,1308,B-CHEMICAL
and,1308,O
other,1308,O
main,1308,O
group,1308,O
metal,1308,O
compounds,1308,O
as,1308,O
antitumor,1308,O
agents,1308,O
.,1308,O
Gallium,1309,B-CHEMICAL
has,1309,O
been,1309,O
the,1309,O
second,1309,O
metal,1309,O
to,1309,O
show,1309,O
activity,1309,O
against,1309,O
malignant,1309,O
tumors,1309,O
in,1309,O
humans,1309,O
soon,1309,O
after,1309,O
the,1309,O
establishment,1309,O
of,1309,O
platinum,1309,B-CHEMICAL
drugs,1309,O
in,1309,O
routine,1309,O
clinical,1309,O
practice,1309,O
.,1309,O
It,1310,O
has,1310,O
the,1310,O
unique,1310,O
property,1310,O
of,1310,O
inhibiting,1310,O
tumor,1310,O
growth,1310,O
as,1310,O
a,1310,O
simple,1310,O
cation,1310,O
",",1310,O
mainly,1310,O
because,1310,O
of,1310,O
its,1310,O
close,1310,O
resemblance,1310,O
to,1310,O
ferric,1310,B-CHEMICAL
iron,1310,I-CHEMICAL
.,1310,O
Even,1311,O
though,1311,O
its,1311,O
inability,1311,O
to,1311,O
shift,1311,O
between,1311,O
the,1311,O
trivalent,1311,O
and,1311,O
a,1311,O
divalent,1311,O
oxidation,1311,O
state,1311,O
precludes,1311,O
that,1311,O
gallium,1311,B-CHEMICAL
behaves,1311,O
as,1311,O
an,1311,O
iron,1311,B-CHEMICAL
analogue,1311,O
in,1311,O
every,1311,O
respect,1311,O
",",1311,O
it,1311,O
strongly,1311,O
interferes,1311,O
with,1311,O
cellular,1311,O
acquisition,1311,O
of,1311,O
iron,1311,O
from,1311,O
blood,1311,O
by,1311,O
competitive,1311,O
interaction,1311,O
with,1311,O
transferrin,1311,B-GENE-Y
and,1311,O
transferrin,1311,B-GENE-N
receptor-mediated,1311,O
endocytosis,1311,O
.,1311,O
Furthermore,1312,O
",",1312,O
gallium,1312,B-CHEMICAL
also,1312,O
seems,1312,O
to,1312,O
affect,1312,O
intracellular,1312,O
availability,1312,O
of,1312,O
iron,1312,B-CHEMICAL
already,1312,O
taken,1312,O
up,1312,O
via,1312,O
this,1312,O
pathway,1312,O
",",1312,O
probably,1312,O
due,1312,O
to,1312,O
its,1312,O
inhibitory,1312,O
activity,1312,O
on,1312,O
vacuolar-type,1312,B-GENE-N
H,1312,I-GENE-N
(,1312,I-GENE-N
+,1312,I-GENE-N
),1312,I-GENE-N
-ATPases,1312,I-GENE-N
.,1312,O
Apart,1313,O
from,1313,O
the,1313,O
consequences,1313,O
of,1313,O
iron,1313,B-CHEMICAL
deprivation,1313,O
",",1313,O
gallium,1313,B-CHEMICAL
exerts,1313,O
cytotoxic,1313,O
effects,1313,O
by,1313,O
direct,1313,O
interaction,1313,O
with,1313,O
the,1313,O
iron-dependent,1313,B-CHEMICAL
enzyme,1313,O
ribonucleotide,1313,B-GENE-N
reductase,1313,I-GENE-N
",",1313,O
resulting,1313,O
in,1313,O
reduced,1313,O
dNTP,1313,O
pools,1313,O
and,1313,O
inhibition,1313,O
of,1313,O
DNA,1313,O
synthesis,1313,O
.,1313,O
Both,1314,O
the,1314,O
abundance,1314,O
of,1314,O
transferrin,1314,B-GENE-N
receptors,1314,I-GENE-N
and,1314,O
upregulation,1314,O
of,1314,O
ribonucleotide,1314,B-GENE-N
reductase,1314,I-GENE-N
render,1314,O
tumors,1314,O
susceptible,1314,O
to,1314,O
gallium-induced,1314,B-CHEMICAL
cytotoxicity,1314,O
.,1314,O
However,1315,O
",",1315,O
some,1315,O
experimental,1315,O
findings,1315,O
raise,1315,O
the,1315,O
question,1315,O
whether,1315,O
these,1315,O
effects,1315,O
resulting,1315,O
from,1315,O
the,1315,O
iron-mimicking,1315,B-CHEMICAL
properties,1315,O
of,1315,O
gallium,1315,B-CHEMICAL
are,1315,O
solely,1315,O
responsible,1315,O
for,1315,O
its,1315,O
antineoplastic,1315,O
activity,1315,O
or,1315,O
whether,1315,O
additional,1315,O
mechanisms,1315,O
are,1315,O
involved,1315,O
",",1315,O
such,1315,O
as,1315,O
antimitotic,1315,O
effects,1315,O
which,1315,O
result,1315,O
from,1315,O
its,1315,O
capability,1315,O
of,1315,O
inhibiting,1315,O
tubulin,1315,B-GENE-N
polymerization,1315,O
.,1315,O
The,1316,O
limitations,1316,O
experienced,1316,O
with,1316,O
gallium,1316,B-CHEMICAL
nitrate,1316,I-CHEMICAL
and,1316,O
gallium,1316,B-CHEMICAL
chloride,1316,I-CHEMICAL
",",1316,O
which,1316,O
call,1316,O
for,1316,O
a,1316,O
prolonged,1316,O
exposure,1316,O
to,1316,O
low,1316,O
steady-state,1316,O
gallium,1316,B-CHEMICAL
levels,1316,O
in,1316,O
blood,1316,O
in,1316,O
order,1316,O
to,1316,O
adequately,1316,O
exploit,1316,O
the,1316,O
affinity,1316,O
of,1316,O
gallium,1316,B-CHEMICAL
to,1316,O
tumor,1316,O
tissues,1316,O
and,1316,O
to,1316,O
avoid,1316,O
severe,1316,O
toxic,1316,O
effects,1316,O
",",1316,O
may,1316,O
be,1316,O
overcome,1316,O
by,1316,O
oral,1316,O
gallium,1316,B-CHEMICAL
complexes,1316,O
such,1316,O
as,1316,O
tris,1316,B-CHEMICAL
(,1316,I-CHEMICAL
3-hydroxy-2-methyl-4H-pyran-4-onato,1316,I-CHEMICAL
),1316,I-CHEMICAL
gallium,1316,I-CHEMICAL
(,1316,I-CHEMICAL
III,1316,I-CHEMICAL
),1316,I-CHEMICAL
(,1316,O
gallium,1316,B-CHEMICAL
maltolate,1316,I-CHEMICAL
),1316,O
or,1316,O
tris,1316,B-CHEMICAL
(,1316,I-CHEMICAL
8-quinolinolato,1316,I-CHEMICAL
),1316,I-CHEMICAL
gallium,1316,I-CHEMICAL
(,1316,I-CHEMICAL
III,1316,I-CHEMICAL
),1316,I-CHEMICAL
(,1316,O
KP46,1316,B-CHEMICAL
),1316,O
",",1316,O
which,1316,O
are,1316,O
currently,1316,O
being,1316,O
evaluated,1316,O
in,1316,O
clinical,1316,O
trials,1316,O
and,1316,O
show,1316,O
promise,1316,O
to,1316,O
initiate,1316,O
a,1316,O
revival,1316,O
of,1316,O
gallium,1316,B-CHEMICAL
in,1316,O
the,1316,O
clinical,1316,O
setting,1316,O
.,1316,O
These,1317,O
two,1317,O
investigational,1317,O
drugs,1317,O
",",1317,O
albeit,1317,O
differing,1317,O
in,1317,O
their,1317,O
complex,1317,O
stability,1317,O
",",1317,O
have,1317,O
both,1317,O
been,1317,O
developed,1317,O
with,1317,O
the,1317,O
intention,1317,O
of,1317,O
providing,1317,O
gallium,1317,B-CHEMICAL
in,1317,O
a,1317,O
form,1317,O
which,1317,O
allows,1317,O
sufficient,1317,O
intestinal,1317,O
absorption,1317,O
",",1317,O
but,1317,O
without,1317,O
altering,1317,O
its,1317,O
pharmacodynamic,1317,O
effects,1317,O
.,1317,O
Gallium,1318,B-CHEMICAL
complexes,1318,O
based,1318,O
on,1318,O
other,1318,O
rationales,1318,O
are,1318,O
scarce,1318,O
and,1318,O
",",1318,O
with,1318,O
regard,1318,O
to,1318,O
the,1318,O
well-known,1318,O
antineoplastic,1318,O
potential,1318,O
of,1318,O
this,1318,O
metal,1318,O
",",1318,O
noticeably,1318,O
under-explored,1318,O
.,1318,O
With,1319,O
the,1319,O
recent,1319,O
approval,1319,O
of,1319,O
arsenic,1319,O
trioxide,1319,B-CHEMICAL
for,1319,O
the,1319,O
second-line,1319,O
treatment,1319,O
of,1319,O
acute,1319,O
promyelocytic,1319,O
leukemia,1319,O
",",1319,O
the,1319,O
clinical,1319,O
revival,1319,O
of,1319,O
arsenic,1319,B-CHEMICAL
compounds,1319,O
",",1319,O
which,1319,O
have,1319,O
been,1319,O
the,1319,O
mainstay,1319,O
of,1319,O
antileukemic,1319,O
therapy,1319,O
before,1319,O
the,1319,O
age,1319,O
of,1319,O
modern,1319,O
cancer,1319,O
chemotherapy,1319,O
",",1319,O
has,1319,O
already,1319,O
begun,1319,O
.,1319,O
Currently,1320,O
",",1320,O
strong,1320,O
efforts,1320,O
are,1320,O
being,1320,O
made,1320,O
to,1320,O
explore,1320,O
the,1320,O
activity,1320,O
spectrum,1320,O
in,1320,O
other,1320,O
(,1320,O
less,1320,O
rare,1320,O
),1320,O
malignancies,1320,O
and,1320,O
to,1320,O
gain,1320,O
a,1320,O
deeper,1320,O
insight,1320,O
into,1320,O
the,1320,O
mode,1320,O
of,1320,O
action,1320,O
.,1320,O
Although,1321,O
this,1321,O
development,1321,O
is,1321,O
currently,1321,O
focusing,1321,O
on,1321,O
arsenic,1321,B-CHEMICAL
trioxide,1321,I-CHEMICAL
",",1321,O
it,1321,O
should,1321,O
be,1321,O
suited,1321,O
to,1321,O
stimulate,1321,O
investigations,1321,O
into,1321,O
the,1321,O
therapeutic,1321,O
potential,1321,O
of,1321,O
other,1321,O
arsenic,1321,B-CHEMICAL
compounds,1321,O
as,1321,O
well,1321,O
.,1321,O
The,1322,O
synaptic,1322,B-GENE-Y
vesicle,1322,I-GENE-Y
protein,1322,I-GENE-Y
SV2A,1322,I-GENE-Y
is,1322,O
the,1322,O
binding,1322,O
site,1322,O
for,1322,O
the,1322,O
antiepileptic,1322,O
drug,1322,O
levetiracetam,1322,B-CHEMICAL
.,1322,O
Here,1323,O
",",1323,O
we,1323,O
show,1323,O
that,1323,O
the,1323,O
synaptic,1323,B-GENE-Y
vesicle,1323,I-GENE-Y
protein,1323,I-GENE-Y
SV2A,1323,I-GENE-Y
is,1323,O
the,1323,O
brain,1323,O
binding,1323,O
site,1323,O
of,1323,O
levetiracetam,1323,B-CHEMICAL
(,1323,O
LEV,1323,B-CHEMICAL
),1323,O
",",1323,O
a,1323,O
new,1323,O
antiepileptic,1323,O
drug,1323,O
with,1323,O
a,1323,O
unique,1323,O
activity,1323,O
profile,1323,O
in,1323,O
animal,1323,O
models,1323,O
of,1323,O
seizure,1323,O
and,1323,O
epilepsy,1323,O
.,1323,O
The,1324,O
LEV-binding,1324,B-CHEMICAL
site,1324,O
is,1324,O
enriched,1324,O
in,1324,O
synaptic,1324,O
vesicles,1324,O
",",1324,O
and,1324,O
photoaffinity,1324,O
labeling,1324,O
of,1324,O
purified,1324,O
synaptic,1324,O
vesicles,1324,O
confirms,1324,O
that,1324,O
it,1324,O
has,1324,O
an,1324,O
apparent,1324,O
molecular,1324,O
mass,1324,O
of,1324,O
approximately,1324,O
90,1324,O
kDa,1324,O
.,1324,O
Brain,1325,O
membranes,1325,O
and,1325,O
purified,1325,O
synaptic,1325,O
vesicles,1325,O
from,1325,O
mice,1325,O
lacking,1325,O
SV2A,1325,B-GENE-Y
do,1325,O
not,1325,O
bind,1325,O
a,1325,O
tritiated,1325,O
LEV,1325,B-CHEMICAL
derivative,1325,O
",",1325,O
indicating,1325,O
that,1325,O
SV2A,1325,B-GENE-Y
is,1325,O
necessary,1325,O
for,1325,O
LEV,1325,B-CHEMICAL
binding,1325,O
.,1325,O
LEV,1326,B-CHEMICAL
and,1326,O
related,1326,O
compounds,1326,O
bind,1326,O
to,1326,O
SV2A,1326,B-GENE-Y
expressed,1326,O
in,1326,O
fibroblasts,1326,O
",",1326,O
indicating,1326,O
that,1326,O
SV2A,1326,B-GENE-Y
is,1326,O
sufficient,1326,O
for,1326,O
LEV,1326,B-CHEMICAL
binding,1326,O
.,1326,O
No,1327,O
binding,1327,O
was,1327,O
observed,1327,O
to,1327,O
the,1327,O
related,1327,O
isoforms,1327,O
SV2B,1327,B-GENE-Y
and,1327,O
SV2C,1327,B-GENE-Y
.,1327,O
Furthermore,1328,O
",",1328,O
there,1328,O
is,1328,O
a,1328,O
high,1328,O
degree,1328,O
of,1328,O
correlation,1328,O
between,1328,O
binding,1328,O
affinities,1328,O
of,1328,O
a,1328,O
series,1328,O
of,1328,O
LEV,1328,B-CHEMICAL
derivatives,1328,O
to,1328,O
SV2A,1328,B-GENE-Y
in,1328,O
fibroblasts,1328,O
and,1328,O
to,1328,O
the,1328,O
LEV-binding,1328,B-CHEMICAL
site,1328,O
in,1328,O
brain,1328,O
.,1328,O
Finally,1329,O
",",1329,O
there,1329,O
is,1329,O
a,1329,O
strong,1329,O
correlation,1329,O
between,1329,O
the,1329,O
affinity,1329,O
of,1329,O
a,1329,O
compound,1329,O
for,1329,O
SV2A,1329,B-GENE-Y
and,1329,O
its,1329,O
ability,1329,O
to,1329,O
protect,1329,O
against,1329,O
seizures,1329,O
in,1329,O
an,1329,O
audiogenic,1329,O
mouse,1329,O
animal,1329,O
model,1329,O
of,1329,O
epilepsy,1329,O
.,1329,O
These,1330,O
experimental,1330,O
results,1330,O
suggest,1330,O
that,1330,O
SV2A,1330,B-GENE-Y
is,1330,O
the,1330,O
binding,1330,O
site,1330,O
of,1330,O
LEV,1330,B-CHEMICAL
in,1330,O
the,1330,O
brain,1330,O
and,1330,O
that,1330,O
LEV,1330,B-CHEMICAL
acts,1330,O
by,1330,O
modulating,1330,O
the,1330,O
function,1330,O
of,1330,O
SV2A,1330,B-GENE-Y
",",1330,O
supporting,1330,O
previous,1330,O
indications,1330,O
that,1330,O
LEV,1330,B-CHEMICAL
possesses,1330,O
a,1330,O
mechanism,1330,O
of,1330,O
action,1330,O
distinct,1330,O
from,1330,O
that,1330,O
of,1330,O
other,1330,O
antiepileptic,1330,O
drugs,1330,O
.,1330,O
Further,1331,O
",",1331,O
these,1331,O
results,1331,O
indicate,1331,O
that,1331,O
proteins,1331,O
involved,1331,O
in,1331,O
vesicle,1331,O
exocytosis,1331,O
",",1331,O
and,1331,O
SV2,1331,B-GENE-N
in,1331,O
particular,1331,O
",",1331,O
are,1331,O
promising,1331,O
targets,1331,O
for,1331,O
the,1331,O
development,1331,O
of,1331,O
new,1331,O
CNS,1331,O
drug,1331,O
therapies,1331,O
.,1331,O
Electrophysiological,1332,O
properties,1332,O
of,1332,O
mouse,1332,O
horizontal,1332,O
cell,1332,O
GABAA,1332,B-GENE-N
receptors,1332,I-GENE-N
.,1332,O
GABA-induced,1333,B-CHEMICAL
currents,1333,O
have,1333,O
been,1333,O
characterized,1333,O
in,1333,O
isolated,1333,O
horizontal,1333,O
cells,1333,O
from,1333,O
lower,1333,O
vertebrates,1333,O
but,1333,O
not,1333,O
in,1333,O
mammalian,1333,O
horizontal,1333,O
cells,1333,O
.,1333,O
Therefore,1334,O
horizontal,1334,O
cells,1334,O
were,1334,O
isolated,1334,O
after,1334,O
enzymatical,1334,O
and,1334,O
mechanical,1334,O
dissociation,1334,O
of,1334,O
the,1334,O
adult,1334,O
mouse,1334,O
retina,1334,O
and,1334,O
visually,1334,O
identified,1334,O
.,1334,O
We,1335,O
recorded,1335,O
from,1335,O
horizontal,1335,O
cell,1335,O
bodies,1335,O
using,1335,O
the,1335,O
whole,1335,O
cell,1335,O
and,1335,O
outside-out,1335,O
configuration,1335,O
of,1335,O
the,1335,O
patch-clamp,1335,O
technique,1335,O
.,1335,O
Extracellular,1336,O
application,1336,O
of,1336,O
GABA,1336,B-CHEMICAL
induced,1336,O
inward,1336,O
currents,1336,O
carried,1336,O
by,1336,O
chloride,1336,B-CHEMICAL
ions,1336,O
.,1336,O
GABA-evoked,1337,B-CHEMICAL
currents,1337,O
were,1337,O
completely,1337,O
and,1337,O
reversibly,1337,O
blocked,1337,O
by,1337,O
the,1337,O
competitive,1337,O
GABAA,1337,B-GENE-N
receptor,1337,I-GENE-N
antagonist,1337,O
bicuculline,1337,B-CHEMICAL
(,1337,O
IC50,1337,O
=,1337,O
1.7,1337,O
microM,1337,O
),1337,O
",",1337,O
indicating,1337,O
expression,1337,O
of,1337,O
GABAA,1337,B-GENE-N
but,1337,O
not,1337,O
GABAC,1337,B-GENE-N
receptors,1337,I-GENE-N
.,1337,O
Their,1338,O
affinity,1338,O
for,1338,O
GABA,1338,B-CHEMICAL
was,1338,O
moderate,1338,O
(,1338,O
EC50,1338,O
=,1338,O
30,1338,O
microM,1338,O
),1338,O
",",1338,O
and,1338,O
the,1338,O
Hill,1338,O
coefficient,1338,O
was,1338,O
1.3,1338,O
",",1338,O
corresponding,1338,O
to,1338,O
two,1338,O
GABA,1338,B-GENE-N
binding,1338,I-GENE-N
sites,1338,I-GENE-N
.,1338,O
GABA,1339,B-CHEMICAL
responses,1339,O
were,1339,O
partially,1339,O
reduced,1339,O
by,1339,O
picrotoxin,1339,B-CHEMICAL
with,1339,O
differential,1339,O
effects,1339,O
on,1339,O
peak,1339,O
and,1339,O
steady-state,1339,O
current,1339,O
values,1339,O
.,1339,O
Zinc,1340,B-CHEMICAL
blocked,1340,O
the,1340,O
GABA,1340,B-CHEMICAL
response,1340,O
with,1340,O
an,1340,O
IC50,1340,O
value,1340,O
of,1340,O
7.3,1340,O
microM,1340,O
in,1340,O
a,1340,O
noncompetitive,1340,O
manner,1340,O
.,1340,O
Furthermore,1341,O
",",1341,O
GABA,1341,B-CHEMICAL
receptors,1341,I-GENE-N
of,1341,O
horizontal,1341,O
cells,1341,O
were,1341,O
modulated,1341,O
by,1341,O
extracellular,1341,O
application,1341,O
of,1341,O
diazepam,1341,B-CHEMICAL
",",1341,O
zolpidem,1341,B-CHEMICAL
",",1341,O
methyl,1341,B-CHEMICAL
"6,7-dimethoxy-4-ethyl-beta-carboxylate",1341,I-CHEMICAL
",",1341,O
pentobarbital,1341,B-CHEMICAL
",",1341,O
and,1341,O
alphaxalone,1341,B-CHEMICAL
",",1341,O
thus,1341,O
showing,1341,O
typical,1341,O
pharmacological,1341,O
properties,1341,O
of,1341,O
CNS,1341,O
GABAA,1341,B-GENE-N
receptors,1341,I-GENE-N
.,1341,O
GABA-evoked,1342,B-CHEMICAL
single-channel,1342,O
currents,1342,O
were,1342,O
characterized,1342,O
by,1342,O
a,1342,O
main,1342,O
conductance,1342,O
state,1342,O
of,1342,O
29.8,1342,O
pS,1342,O
and,1342,O
two,1342,O
subconductance,1342,O
states,1342,O
(,1342,O
20.2,1342,O
and,1342,O
10.8,1342,O
pS,1342,O
",",1342,O
respectively,1342,O
),1342,O
.,1342,O
Kinetic,1343,O
analysis,1343,O
of,1343,O
single-channel,1343,O
events,1343,O
within,1343,O
bursts,1343,O
revealed,1343,O
similar,1343,O
mean,1343,O
open,1343,O
and,1343,O
closed,1343,O
times,1343,O
for,1343,O
the,1343,O
main,1343,O
conductance,1343,O
and,1343,O
the,1343,O
20.2-pS,1343,O
subconductance,1343,O
state,1343,O
",",1343,O
resulting,1343,O
in,1343,O
open,1343,O
probabilities,1343,O
of,1343,O
44.6,1343,O
and,1343,O
42.7,1343,O
%,1343,O
",",1343,O
respectively,1343,O
.,1343,O
The,1344,O
ratio,1344,O
of,1344,O
open,1344,O
to,1344,O
closed,1344,O
times,1344,O
",",1344,O
however,1344,O
",",1344,O
was,1344,O
significantly,1344,O
different,1344,O
for,1344,O
the,1344,O
10.8-pS,1344,O
subconductance,1344,O
state,1344,O
with,1344,O
an,1344,O
open,1344,O
probability,1344,O
of,1344,O
57.2,1344,O
%,1344,O
.,1344,O
Decreased,1345,O
histamine,1345,B-CHEMICAL
H1,1345,I-GENE-Y
receptor,1345,I-GENE-Y
binding,1345,O
in,1345,O
the,1345,O
brain,1345,O
of,1345,O
depressed,1345,O
patients,1345,O
.,1345,O
The,1346,O
central,1346,O
histaminergic,1346,O
neuron,1346,O
system,1346,O
modulates,1346,O
the,1346,O
wakefulness,1346,O
",",1346,O
sleep-awake,1346,O
cycle,1346,O
",",1346,O
appetite,1346,O
control,1346,O
",",1346,O
learning,1346,O
and,1346,O
memory,1346,O
",",1346,O
and,1346,O
emotion,1346,O
.,1346,O
Previous,1347,O
studies,1347,O
have,1347,O
reported,1347,O
changes,1347,O
in,1347,O
neuronal,1347,O
histamine,1347,B-CHEMICAL
release,1347,O
and,1347,O
its,1347,O
metabolism,1347,O
under,1347,O
stress,1347,O
conditions,1347,O
in,1347,O
the,1347,O
mammalian,1347,O
brain,1347,O
.,1347,O
In,1348,O
this,1348,O
study,1348,O
",",1348,O
we,1348,O
examined,1348,O
",",1348,O
using,1348,O
positron,1348,O
emission,1348,O
tomography,1348,O
(,1348,O
PET,1348,O
),1348,O
and,1348,O
[,1348,B-CHEMICAL
(,1348,I-CHEMICAL
11,1348,I-CHEMICAL
),1348,I-CHEMICAL
C,1348,I-CHEMICAL
],1348,I-CHEMICAL
-doxepin,1348,I-CHEMICAL
",",1348,O
whether,1348,O
the,1348,O
histaminergic,1348,O
neuron,1348,O
system,1348,O
is,1348,O
involved,1348,O
in,1348,O
human,1348,O
depression,1348,O
.,1348,O
Cerebral,1349,O
histamine,1349,B-CHEMICAL
H1,1349,I-GENE-Y
receptor,1349,I-GENE-Y
(,1349,O
H,1349,B-GENE-Y
(,1349,I-GENE-Y
1,1349,I-GENE-Y
),1349,I-GENE-Y
R,1349,I-GENE-Y
),1349,O
binding,1349,O
was,1349,O
measured,1349,O
in,1349,O
10,1349,O
patients,1349,O
with,1349,O
major,1349,O
depression,1349,O
and,1349,O
in,1349,O
10,1349,O
normal,1349,O
age-matched,1349,O
subjects,1349,O
using,1349,O
PET,1349,O
and,1349,O
[,1349,B-CHEMICAL
(,1349,I-CHEMICAL
11,1349,I-CHEMICAL
),1349,I-CHEMICAL
C,1349,I-CHEMICAL
],1349,I-CHEMICAL
-doxepin,1349,I-CHEMICAL
.,1349,O
Data,1350,O
were,1350,O
calculated,1350,O
by,1350,O
a,1350,O
graphical,1350,O
analysis,1350,O
on,1350,O
voxel-by-voxel,1350,O
and,1350,O
ROI,1350,O
(,1350,O
region,1350,O
of,1350,O
interests,1350,O
),1350,O
basis,1350,O
.,1350,O
Binding,1351,O
potential,1351,O
(,1351,O
BP,1351,O
),1351,O
values,1351,O
for,1351,O
[,1351,B-CHEMICAL
(,1351,I-CHEMICAL
11,1351,I-CHEMICAL
),1351,I-CHEMICAL
C,1351,I-CHEMICAL
],1351,I-CHEMICAL
-doxepin,1351,I-CHEMICAL
binding,1351,O
in,1351,O
the,1351,O
frontal,1351,O
and,1351,O
prefrontal,1351,O
cortices,1351,O
",",1351,O
and,1351,O
cingulate,1351,O
gyrus,1351,O
were,1351,O
significantly,1351,O
lower,1351,O
in,1351,O
the,1351,O
depressed,1351,O
patients,1351,O
than,1351,O
those,1351,O
in,1351,O
the,1351,O
normal,1351,O
control,1351,O
subjects,1351,O
.,1351,O
There,1352,O
was,1352,O
no,1352,O
area,1352,O
of,1352,O
the,1352,O
brain,1352,O
where,1352,O
[,1352,B-CHEMICAL
(,1352,I-CHEMICAL
11,1352,I-CHEMICAL
),1352,I-CHEMICAL
C,1352,I-CHEMICAL
],1352,I-CHEMICAL
-doxepin,1352,I-CHEMICAL
binding,1352,O
was,1352,O
significantly,1352,O
higher,1352,O
in,1352,O
the,1352,O
depressed,1352,O
patients,1352,O
than,1352,O
in,1352,O
the,1352,O
controls,1352,O
.,1352,O
ROI-based,1353,O
analysis,1353,O
also,1353,O
revealed,1353,O
that,1353,O
BP,1353,O
values,1353,O
for,1353,O
[,1353,B-CHEMICAL
(,1353,I-CHEMICAL
11,1353,I-CHEMICAL
),1353,I-CHEMICAL
C,1353,I-CHEMICAL
],1353,I-CHEMICAL
-doxepin,1353,I-CHEMICAL
binding,1353,O
in,1353,O
the,1353,O
frontal,1353,O
cortex,1353,O
and,1353,O
cingulate,1353,O
gyrus,1353,O
decreased,1353,O
in,1353,O
proportion,1353,O
to,1353,O
self-rating,1353,O
depressive,1353,O
scales,1353,O
scores,1353,O
.,1353,O
The,1354,O
results,1354,O
of,1354,O
this,1354,O
study,1354,O
demonstrate,1354,O
that,1354,O
depressed,1354,O
patients,1354,O
have,1354,O
decreased,1354,O
brain,1354,O
H,1354,B-GENE-Y
(,1354,I-GENE-Y
1,1354,I-GENE-Y
),1354,I-GENE-Y
R,1354,I-GENE-Y
binding,1354,O
and,1354,O
that,1354,O
this,1354,O
decrease,1354,O
correlates,1354,O
with,1354,O
the,1354,O
severity,1354,O
of,1354,O
depression,1354,O
symptoms,1354,O
.,1354,O
It,1355,O
is,1355,O
therefore,1355,O
suggested,1355,O
that,1355,O
the,1355,O
histaminergic,1355,O
neuron,1355,O
system,1355,O
plays,1355,O
an,1355,O
important,1355,O
role,1355,O
in,1355,O
the,1355,O
pathophysiology,1355,O
of,1355,O
depression,1355,O
and,1355,O
that,1355,O
its,1355,O
modulation,1355,O
may,1355,O
prove,1355,O
to,1355,O
be,1355,O
useful,1355,O
in,1355,O
the,1355,O
treatment,1355,O
of,1355,O
depression,1355,O
.,1355,O
Central,1356,O
effects,1356,O
of,1356,O
fexofenadine,1356,B-CHEMICAL
and,1356,O
cetirizine,1356,B-CHEMICAL
:,1356,O
measurement,1356,O
of,1356,O
psychomotor,1356,O
performance,1356,O
",",1356,O
subjective,1356,O
sleepiness,1356,O
",",1356,O
and,1356,O
brain,1356,O
histamine,1356,B-GENE-Y
H1-receptor,1356,I-GENE-Y
occupancy,1356,O
using,1356,O
11C-doxepin,1356,B-CHEMICAL
positron,1356,O
emission,1356,O
tomography,1356,O
.,1356,O
Histamine,1357,B-GENE-Y
H1-receptor,1357,I-GENE-Y
(,1357,O
H1R,1357,B-GENE-Y
),1357,O
antagonists,1357,O
",",1357,O
or,1357,O
antihistamines,1357,B-CHEMICAL
",",1357,O
often,1357,O
induce,1357,O
sedative,1357,O
side,1357,O
effects,1357,O
when,1357,O
used,1357,O
for,1357,O
the,1357,O
treatment,1357,O
of,1357,O
allergic,1357,O
disorders,1357,O
.,1357,O
This,1358,O
study,1358,O
compared,1358,O
the,1358,O
sedative,1358,O
profiles,1358,O
of,1358,O
the,1358,O
second-generation,1358,O
antihistamines,1358,B-CHEMICAL
",",1358,O
fexofenadine,1358,B-CHEMICAL
and,1358,O
cetirizine,1358,B-CHEMICAL
",",1358,O
using,1358,O
3,1358,O
different,1358,O
criteria,1358,O
:,1358,O
subjective,1358,O
sleepiness,1358,O
evaluated,1358,O
by,1358,O
the,1358,O
Stanford,1358,O
Sleepiness,1358,O
Scale,1358,O
",",1358,O
objective,1358,O
psychomotor,1358,O
tests,1358,O
(,1358,O
simple,1358,O
and,1358,O
choice,1358,O
reaction,1358,O
time,1358,O
tests,1358,O
and,1358,O
visual,1358,O
discrimination,1358,O
tests,1358,O
at,1358,O
4,1358,O
different,1358,O
exposure,1358,O
durations,1358,O
),1358,O
",",1358,O
and,1358,O
measurement,1358,O
of,1358,O
histamine,1358,B-GENE-Y
H1-receptor,1358,I-GENE-Y
occupancy,1358,O
(,1358,O
H1RO,1358,O
),1358,O
in,1358,O
the,1358,O
brain,1358,O
.,1358,O
Subjective,1359,O
sleepiness,1359,O
and,1359,O
psychomotor,1359,O
performance,1359,O
were,1359,O
measured,1359,O
in,1359,O
20,1359,O
healthy,1359,O
Japanese,1359,O
volunteers,1359,O
at,1359,O
baseline,1359,O
and,1359,O
90,1359,O
min,1359,O
after,1359,O
administration,1359,O
of,1359,O
fexofenadine,1359,B-CHEMICAL
120,1359,O
mg,1359,O
or,1359,O
cetirizine,1359,B-CHEMICAL
20,1359,O
mg,1359,O
in,1359,O
a,1359,O
double-blind,1359,O
",",1359,O
placebo-controlled,1359,O
crossover,1359,O
study,1359,O
.,1359,O
Hydroxyzine,1360,B-CHEMICAL
30,1360,O
mg,1360,O
was,1360,O
included,1360,O
as,1360,O
a,1360,O
positive,1360,O
control,1360,O
.,1360,O
H1RO,1361,O
was,1361,O
measured,1361,O
using,1361,O
positron,1361,O
emission,1361,O
tomography,1361,O
(,1361,O
PET,1361,O
),1361,O
with,1361,O
(,1361,B-CHEMICAL
11,1361,I-CHEMICAL
),1361,I-CHEMICAL
C-doxepin,1361,I-CHEMICAL
in,1361,O
12,1361,O
of,1361,O
the,1361,O
20,1361,O
subjects,1361,O
",",1361,O
and,1361,O
a,1361,O
further,1361,O
11,1361,O
volunteers,1361,O
were,1361,O
recruited,1361,O
to,1361,O
act,1361,O
as,1361,O
controls,1361,O
.,1361,O
In,1362,O
psychomotor,1362,O
tests,1362,O
",",1362,O
fexofenadine,1362,B-CHEMICAL
was,1362,O
not,1362,O
significantly,1362,O
different,1362,O
from,1362,O
placebo,1362,O
and,1362,O
significantly,1362,O
less,1362,O
impairing,1362,O
than,1362,O
cetirizine,1362,B-CHEMICAL
on,1362,O
some,1362,O
tasks,1362,O
",",1362,O
as,1362,O
well,1362,O
as,1362,O
significantly,1362,O
less,1362,O
impairing,1362,O
than,1362,O
hydroxyzine,1362,B-CHEMICAL
on,1362,O
all,1362,O
tasks,1362,O
.,1362,O
For,1363,O
subjective,1363,O
sleepiness,1363,O
",",1363,O
fexofenadine,1363,B-CHEMICAL
was,1363,O
not,1363,O
significantly,1363,O
different,1363,O
from,1363,O
placebo,1363,O
",",1363,O
whereas,1363,O
cetirizine,1363,B-CHEMICAL
showed,1363,O
a,1363,O
trend,1363,O
toward,1363,O
increased,1363,O
sleepiness,1363,O
compared,1363,O
with,1363,O
fexofenadine,1363,B-CHEMICAL
and,1363,O
placebo,1363,O
.,1363,O
H1RO,1364,O
was,1364,O
negligible,1364,O
with,1364,O
fexofenadine,1364,B-CHEMICAL
(,1364,O
-0.1,1364,O
%,1364,O
),1364,O
but,1364,O
moderately,1364,O
high,1364,O
with,1364,O
cetirizine,1364,B-CHEMICAL
(,1364,O
26.0,1364,O
%,1364,O
),1364,O
.,1364,O
In,1365,O
conclusion,1365,O
",",1365,O
fexofenadine,1365,B-CHEMICAL
120,1365,O
mg,1365,O
is,1365,O
distinguishable,1365,O
from,1365,O
cetirizine,1365,B-CHEMICAL
20,1365,O
mg,1365,O
",",1365,O
as,1365,O
assessed,1365,O
by,1365,O
H1RO,1365,O
and,1365,O
psychomotor,1365,O
testing,1365,O
.,1365,O
A,1366,O
novel,1366,O
membrane,1366,O
sensor,1366,O
for,1366,O
histamine,1366,B-GENE-Y
H1-receptor,1366,I-GENE-Y
antagonist,1366,O
``,1366,O
fexofenadine,1366,B-CHEMICAL
'',1366,O
.,1366,O
The,1367,O
construction,1367,O
and,1367,O
general,1367,O
performance,1367,O
of,1367,O
thirteen,1367,O
new,1367,O
polymeric,1367,O
membrane,1367,O
sensors,1367,O
for,1367,O
the,1367,O
determination,1367,O
of,1367,O
fexofenadine,1367,B-CHEMICAL
hydrochloride,1367,I-CHEMICAL
based,1367,O
on,1367,O
its,1367,O
ion,1367,O
exchange,1367,O
with,1367,O
reineckate,1367,O
",",1367,O
tetraphenylborate,1367,B-CHEMICAL
and,1367,O
tetraiodomercurate,1367,B-CHEMICAL
have,1367,O
been,1367,O
studied,1367,O
.,1367,O
The,1368,O
effects,1368,O
of,1368,O
membrane,1368,O
composition,1368,O
",",1368,O
type,1368,O
of,1368,O
plasticizer,1368,O
",",1368,O
pH,1368,O
value,1368,O
of,1368,O
sample,1368,O
solution,1368,O
and,1368,O
concentration,1368,O
of,1368,O
the,1368,O
analyte,1368,O
in,1368,O
the,1368,O
sensor,1368,O
internal,1368,O
solution,1368,O
have,1368,O
been,1368,O
thoroughly,1368,O
investigated,1368,O
.,1368,O
The,1369,O
novel,1369,O
sensor,1369,O
based,1369,O
on,1369,O
reineckate,1369,O
exchanger,1369,O
shows,1369,O
a,1369,O
stable,1369,O
",",1369,O
potentiometric,1369,O
response,1369,O
for,1369,O
fexofenadine,1369,B-CHEMICAL
in,1369,O
the,1369,O
concentration,1369,O
range,1369,O
of,1369,O
1,1369,O
x,1369,O
10,1369,O
(,1369,O
-2,1369,O
),1369,O
-,1369,O
2.5,1369,O
x,1369,O
10,1369,O
(,1369,O
-6,1369,O
),1369,O
M,1369,O
at,1369,O
25,1369,O
degrees,1369,O
C,1369,O
that,1369,O
is,1369,O
independent,1369,O
of,1369,O
pH,1369,O
in,1369,O
the,1369,O
range,1369,O
of,1369,O
2.0,1369,O
-,1369,O
4.5,1369,O
.,1369,O
The,1370,O
sensor,1370,O
possesses,1370,O
a,1370,O
Nernstian,1370,O
cationic,1370,O
slope,1370,O
of,1370,O
62.3+/-0.7,1370,O
mV/concentration,1370,O
decade,1370,O
and,1370,O
a,1370,O
lower,1370,O
detection,1370,O
limit,1370,O
of,1370,O
1.3,1370,O
x,1370,O
10,1370,O
(,1370,O
-6,1370,O
),1370,O
M,1370,O
with,1370,O
a,1370,O
fast,1370,O
response,1370,O
time,1370,O
of,1370,O
20,1370,O
-,1370,O
40,1370,O
s.,1370,O
Selectivity,1370,O
coefficients,1370,O
for,1370,O
a,1370,O
number,1370,O
of,1370,O
interfering,1370,O
ions,1370,O
and,1370,O
excipients,1370,O
relative,1370,O
to,1370,O
fexofenadine,1370,B-CHEMICAL
were,1370,O
investigated,1370,O
.,1370,O
There,1371,O
is,1371,O
negligible,1371,O
interference,1371,O
from,1371,O
almost,1371,O
all,1371,O
studied,1371,O
cations,1371,O
",",1371,O
anions,1371,O
",",1371,O
and,1371,O
pharmaceutical,1371,O
excipients,1371,O
",",1371,O
however,1371,O
",",1371,O
citrizine,1371,B-CHEMICAL
that,1371,O
has,1371,O
a,1371,O
structure,1371,O
homologous,1371,O
to,1371,O
that,1371,O
of,1371,O
fexofenadine,1371,B-CHEMICAL
was,1371,O
found,1371,O
to,1371,O
interfere,1371,O
.,1371,O
The,1372,O
determination,1372,O
of,1372,O
fexofenadine,1372,B-CHEMICAL
in,1372,O
aqueous,1372,O
solution,1372,O
shows,1372,O
an,1372,O
average,1372,O
recovery,1372,O
of,1372,O
99.83,1372,O
%,1372,O
with,1372,O
a,1372,O
mean,1372,O
relative,1372,O
standard,1372,O
deviation,1372,O
(,1372,O
RSD,1372,O
),1372,O
of,1372,O
0.5,1372,O
%,1372,O
.,1372,O
Direct,1373,O
potentiometric,1373,O
determination,1373,O
of,1373,O
fexofenadine,1373,B-CHEMICAL
in,1373,O
tablets,1373,O
gave,1373,O
results,1373,O
that,1373,O
compare,1373,O
favorably,1373,O
with,1373,O
those,1373,O
obtained,1373,O
by,1373,O
standard,1373,O
spectrophotometric,1373,O
methods,1373,O
.,1373,O
Potentiometric,1374,O
titration,1374,O
of,1374,O
fexofenadine,1374,B-CHEMICAL
with,1374,O
phosphomolybdic,1374,B-CHEMICAL
acid,1374,I-CHEMICAL
as,1374,O
a,1374,O
titrant,1374,O
has,1374,O
been,1374,O
monitored,1374,O
with,1374,O
the,1374,O
proposed,1374,O
sensor,1374,O
as,1374,O
an,1374,O
end,1374,O
point,1374,O
indicator,1374,O
electrode,1374,O
.,1374,O
Thymidylate,1375,B-GENE-Y
synthase,1375,I-GENE-Y
:,1375,O
a,1375,O
critical,1375,O
target,1375,O
in,1375,O
cancer,1375,O
therapy,1375,O
?,1375,O
For,1376,O
the,1376,O
last,1376,O
four,1376,O
decades,1376,O
",",1376,O
synthesis,1376,O
and,1376,O
testing,1376,O
of,1376,O
potentially,1376,O
active,1376,O
drugs,1376,O
(,1376,O
e.g.,1376,O
",",1376,O
antimetabolites,1376,O
),1376,O
have,1376,O
focused,1376,O
on,1376,O
structural,1376,O
modification,1376,O
of,1376,O
existing,1376,O
metabolites,1376,O
as,1376,O
precursors,1376,O
of,1376,O
DNA,1376,O
and,1376,O
RNA,1376,O
synthesis,1376,O
.,1376,O
In,1377,O
recent,1377,O
years,1377,O
",",1377,O
the,1377,O
focus,1377,O
has,1377,O
shifted,1377,O
to,1377,O
synthesis,1377,O
of,1377,O
target-specific,1377,O
agents,1377,O
.,1377,O
Thus,1378,O
",",1378,O
the,1378,O
current,1378,O
emphasis,1378,O
of,1378,O
drug,1378,O
development,1378,O
is,1378,O
directed,1378,O
at,1378,O
inhibiting,1378,O
specific,1378,O
target,1378,O
(,1378,O
s,1378,O
),1378,O
expressed,1378,O
preferentially,1378,O
",",1378,O
if,1378,O
not,1378,O
exclusively,1378,O
",",1378,O
in,1378,O
tumor,1378,O
tissues,1378,O
",",1378,O
with,1378,O
the,1378,O
ultimate,1378,O
goal,1378,O
of,1378,O
improving,1378,O
the,1378,O
therapeutic,1378,O
efficacy,1378,O
and,1378,O
selectivity,1378,O
of,1378,O
these,1378,O
new,1378,O
agents,1378,O
.,1378,O
Preclinically,1379,O
",",1379,O
proof-of-principle,1379,O
studies,1379,O
were,1379,O
carried,1379,O
out,1379,O
in,1379,O
tumors,1379,O
with,1379,O
specific,1379,O
expression,1379,O
of,1379,O
the,1379,O
intended,1379,O
target,1379,O
.,1379,O
With,1380,O
the,1380,O
hope,1380,O
of,1380,O
translating,1380,O
preclinical,1380,O
findings,1380,O
to,1380,O
the,1380,O
design,1380,O
of,1380,O
implementation,1380,O
of,1380,O
clinical,1380,O
trials,1380,O
.,1380,O
Thymidylate,1381,B-GENE-Y
synthase,1381,I-GENE-Y
(,1381,O
TS,1381,B-GENE-Y
),1381,O
continues,1381,O
to,1381,O
be,1381,O
a,1381,O
critical,1381,O
target,1381,O
for,1381,O
5-fluorouracil,1381,B-CHEMICAL
(,1381,O
5-FU,1381,B-CHEMICAL
),1381,O
and,1381,O
its,1381,O
prodrugs,1381,O
",",1381,O
UFT/LV,1381,B-CHEMICAL
(,1381,O
Orzel,1381,B-CHEMICAL
),1381,O
",",1381,O
capecitabine,1381,B-CHEMICAL
(,1381,O
Xeloda,1381,B-CHEMICAL
),1381,O
",",1381,O
and,1381,O
S-1,1381,B-CHEMICAL
",",1381,O
primarily,1381,O
because,1381,O
this,1381,O
enzyme,1381,O
is,1381,O
essential,1381,O
for,1381,O
the,1381,O
synthesis,1381,O
of,1381,O
2-deoxythymidine-5-monophosphate,1381,B-CHEMICAL
",",1381,O
a,1381,O
precursor,1381,O
for,1381,O
DNA,1381,O
synthesis,1381,O
.,1381,O
While,1382,O
fluoropyrimidine,1382,B-CHEMICAL
antimetabolites,1382,O
have,1382,O
other,1382,O
sites,1382,O
of,1382,O
action,1382,O
",",1382,O
antifolates,1382,O
ZD1694,1382,B-CHEMICAL
(,1382,O
raltitrexed,1382,B-CHEMICAL
",",1382,O
Tomudex,1382,B-CHEMICAL
),1382,O
and,1382,O
AG337,1382,B-CHEMICAL
(,1382,O
Thymitag,1382,B-CHEMICAL
),1382,O
are,1382,O
more,1382,O
specific,1382,O
and,1382,O
potent,1382,O
TS,1382,B-GENE-Y
inhibitors,1382,O
.,1382,O
Thus,1383,O
",",1383,O
it,1383,O
is,1383,O
hoped,1383,O
that,1383,O
pronounced,1383,O
and,1383,O
sustained,1383,O
inhibition,1383,O
of,1383,O
this,1383,O
enzyme,1383,O
could,1383,O
result,1383,O
in,1383,O
downstream,1383,O
regulation,1383,O
of,1383,O
molecular,1383,O
markers,1383,O
associated,1383,O
with,1383,O
sensitivity,1383,O
and,1383,O
resistance,1383,O
to,1383,O
these,1383,O
agents,1383,O
.,1383,O
It,1384,O
is,1384,O
also,1384,O
critical,1384,O
to,1384,O
recognize,1384,O
that,1384,O
the,1384,O
degree,1384,O
and,1384,O
duration,1384,O
of,1384,O
inhibition,1384,O
of,1384,O
the,1384,O
target,1384,O
enzyme,1384,O
may,1384,O
depend,1384,O
on,1384,O
the,1384,O
expression,1384,O
level,1384,O
of,1384,O
the,1384,O
target,1384,O
enzyme,1384,O
",",1384,O
thymidylate,1384,B-GENE-Y
synthase,1384,I-GENE-Y
.,1384,O
Correlative,1385,O
studies,1385,O
in,1385,O
preclinical,1385,O
and,1385,O
clinical,1385,O
systems,1385,O
demonstrated,1385,O
a,1385,O
close,1385,O
relationship,1385,O
between,1385,O
the,1385,O
enzyme,1385,O
level,1385,O
(,1385,O
mRNA,1385,O
and,1385,O
protein,1385,O
),1385,O
and,1385,O
response,1385,O
to,1385,O
therapy,1385,O
of,1385,O
colorectal,1385,O
cancer,1385,O
patients,1385,O
treated,1385,O
with,1385,O
fluoropyrimidine,1385,B-CHEMICAL
or,1385,O
Tomudex,1385,B-CHEMICAL
.,1385,O
However,1386,O
",",1386,O
significant,1386,O
overlap,1386,O
was,1386,O
demonstrated,1386,O
between,1386,O
responders,1386,O
and,1386,O
non-responders,1386,O
.,1386,O
These,1387,O
data,1387,O
are,1387,O
consistent,1387,O
with,1387,O
the,1387,O
hypothesis,1387,O
that,1387,O
prediction,1387,O
of,1387,O
response,1387,O
to,1387,O
anticancer,1387,O
drugs,1387,O
is,1387,O
multifactorial,1387,O
",",1387,O
and,1387,O
TS,1387,B-GENE-Y
is,1387,O
one,1387,O
target,1387,O
.,1387,O
Clinically,1388,O
",",1388,O
although,1388,O
overall,1388,O
response,1388,O
of,1388,O
colorectal,1388,O
cancer,1388,O
patients,1388,O
to,1388,O
a,1388,O
variety,1388,O
of,1388,O
TS,1388,B-GENE-Y
inhibitors,1388,O
is,1388,O
similar,1388,O
",",1388,O
toxicity,1388,O
profiles,1388,O
are,1388,O
different,1388,O
.,1388,O
The,1389,O
availability,1389,O
of,1389,O
the,1389,O
5-FU,1389,B-CHEMICAL
prodrugs,1389,O
offers,1389,O
the,1389,O
possibility,1389,O
of,1389,O
greater,1389,O
therapeutic,1389,O
selectivity,1389,O
based,1389,O
on,1389,O
the,1389,O
demonstration,1389,O
that,1389,O
thymidine,1389,B-GENE-Y
phosphorylase,1389,I-GENE-Y
",",1389,O
the,1389,O
activating,1389,O
enzyme,1389,O
for,1389,O
5-FU,1389,B-CHEMICAL
",",1389,O
is,1389,O
expressed,1389,O
at,1389,O
a,1389,O
higher,1389,O
level,1389,O
in,1389,O
tumor,1389,O
tissue,1389,O
compared,1389,O
with,1389,O
normal,1389,O
tissue,1389,O
counterparts,1389,O
.,1389,O
It,1390,O
is,1390,O
likely,1390,O
that,1390,O
successful,1390,O
application,1390,O
of,1390,O
TS,1390,B-GENE-Y
inhibitors,1390,O
will,1390,O
not,1390,O
only,1390,O
be,1390,O
based,1390,O
on,1390,O
measurement,1390,O
of,1390,O
the,1390,O
TS,1390,B-GENE-Y
level,1390,O
in,1390,O
tumors,1390,O
vs.,1390,O
normal,1390,O
tissues,1390,O
",",1390,O
but,1390,O
on,1390,O
the,1390,O
delineation,1390,O
of,1390,O
the,1390,O
consequences,1390,O
of,1390,O
this,1390,O
inhibition,1390,O
on,1390,O
molecular,1390,O
markers,1390,O
associated,1390,O
with,1390,O
cellular,1390,O
proliferation,1390,O
",",1390,O
apoptosis,1390,O
and,1390,O
cell,1390,O
cycle,1390,O
regulation,1390,O
.,1390,O
[,1391,O
Pharmacological,1391,O
treatment,1391,O
of,1391,O
obesity,1391,O
],1391,O
.,1391,O
The,1392,O
pharmacological,1392,O
treatment,1392,O
of,1392,O
obesity,1392,O
should,1392,O
be,1392,O
considered,1392,O
when,1392,O
can,1392,O
not,1392,O
be,1392,O
achieved,1392,O
a,1392,O
10,1392,O
%,1392,O
weight,1392,O
loss,1392,O
with,1392,O
diet,1392,O
therapy,1392,O
and,1392,O
physical,1392,O
activity,1392,O
.,1392,O
The,1393,O
drugs,1393,O
effective,1393,O
in,1393,O
obesity,1393,O
treatment,1393,O
may,1393,O
act,1393,O
by,1393,O
different,1393,O
mechanisms,1393,O
such,1393,O
as,1393,O
reduction,1393,O
in,1393,O
food,1393,O
intake,1393,O
",",1393,O
inhibition,1393,O
of,1393,O
fat,1393,O
absorption,1393,O
",",1393,O
increase,1393,O
of,1393,O
thermogenesis,1393,O
and,1393,O
stimulation,1393,O
of,1393,O
adipocyte,1393,O
apoptosis,1393,O
.,1393,O
At,1394,O
present,1394,O
",",1394,O
we,1394,O
only,1394,O
have,1394,O
two,1394,O
marketed,1394,O
drugs,1394,O
for,1394,O
obesity,1394,O
treatment,1394,O
.,1394,O
Sibutramine,1395,B-CHEMICAL
is,1395,O
an,1395,O
inhibitor,1395,O
of,1395,O
norepinephrine,1395,B-CHEMICAL
",",1395,O
dopamine,1395,B-CHEMICAL
and,1395,O
serotonina,1395,O
reuptake,1395,O
which,1395,O
inhibits,1395,O
food,1395,O
intake,1395,O
and,1395,O
increases,1395,O
thermogenesis,1395,O
.,1395,O
Sibutramine,1396,B-CHEMICAL
administration,1396,O
for,1396,O
a,1396,O
year,1396,O
can,1396,O
induce,1396,O
a,1396,O
weight,1396,O
loss,1396,O
of,1396,O
4-7,1396,O
%,1396,O
.,1396,O
Its,1397,O
main,1397,O
side,1397,O
effects,1397,O
are,1397,O
hypertension,1397,O
",",1397,O
headache,1397,O
",",1397,O
insomnia,1397,O
and,1397,O
constipation,1397,O
.,1397,O
Orlistat,1398,B-CHEMICAL
is,1398,O
an,1398,O
inhibitor,1398,O
of,1398,O
pancreatic,1398,B-GENE-N
lipase,1398,I-GENE-N
which,1398,O
is,1398,O
able,1398,O
to,1398,O
block,1398,O
the,1398,O
absorption,1398,O
of,1398,O
30,1398,O
%,1398,O
of,1398,O
ingested,1398,O
fat,1398,O
.,1398,O
Its,1399,O
administration,1399,O
induces,1399,O
weight,1399,O
loss,1399,O
and,1399,O
reduction,1399,O
of,1399,O
ulterior,1399,O
weight,1399,O
regain,1399,O
.,1399,O
Also,1400,O
",",1400,O
this,1400,O
drug,1400,O
improves,1400,O
hypertension,1400,O
dyslipdaemia,1400,O
and,1400,O
helps,1400,O
to,1400,O
prevent,1400,O
diabetes,1400,O
in,1400,O
52,1400,O
%,1400,O
of,1400,O
cases,1400,O
when,1400,O
administered,1400,O
over,1400,O
four,1400,O
years,1400,O
.,1400,O
The,1401,O
increase,1401,O
in,1401,O
frequency,1401,O
of,1401,O
stools,1401,O
and,1401,O
interference,1401,O
with,1401,O
vitamin,1401,O
absorption,1401,O
are,1401,O
its,1401,O
main,1401,O
side,1401,O
effects,1401,O
.,1401,O
Glucagon-like,1402,B-GENE-Y
peptide,1402,I-GENE-Y
1,1402,I-GENE-Y
",",1402,O
which,1402,O
increases,1402,O
insulin,1402,B-GENE-Y
sensitivity,1402,O
and,1402,O
satiety,1402,O
",",1402,O
adiponectin,1402,B-GENE-Y
and,1402,O
PPAR-gamma,1402,B-GENE-Y
agonists,1402,O
which,1402,O
reduce,1402,O
insulin,1402,B-GENE-Y
resistance,1402,O
and,1402,O
modulates,1402,O
adipocyte,1402,O
generation,1402,O
are,1402,O
the,1402,O
basis,1402,O
for,1402,O
future,1402,O
therapeutic,1402,O
approaches,1402,O
of,1402,O
obesity,1402,O
.,1402,O
Phosphatase,1403,B-GENE-N
inhibitors,1403,O
induce,1403,O
PPAR-gamma,1403,B-GENE-Y
phosphorylation,1403,O
and,1403,O
UCP-1,1403,B-GENE-Y
expression,1403,O
leading,1403,O
to,1403,O
an,1403,O
increase,1403,O
in,1403,O
thermogenesis,1403,O
and,1403,O
reduction,1403,O
in,1403,O
appetite,1403,O
.,1403,O
Viability,1404,O
assessment,1404,O
in,1404,O
sandwich-cultured,1404,O
rat,1404,O
hepatocytes,1404,O
after,1404,O
xenobiotic,1404,O
exposure,1404,O
.,1404,O
Troglitazone,1405,B-CHEMICAL
",",1405,O
bosentan,1405,B-CHEMICAL
and,1405,O
glibenclamide,1405,B-CHEMICAL
inhibit,1405,O
the,1405,O
bile,1405,B-GENE-Y
salt,1405,I-GENE-Y
export,1405,I-GENE-Y
pump,1405,I-GENE-Y
(,1405,O
Bsep,1405,B-GENE-Y
),1405,O
which,1405,O
transports,1405,O
taurocholate,1405,B-CHEMICAL
into,1405,O
bile,1405,O
.,1405,O
Sandwich-cultured,1406,O
rat,1406,O
hepatocytes,1406,O
maintain,1406,O
functional,1406,O
sodium,1406,B-CHEMICAL
taurocholate,1406,I-CHEMICAL
co-transporting,1406,I-GENE-Y
polypeptide,1406,I-GENE-Y
and,1406,O
Bsep,1406,B-GENE-Y
transport,1406,O
proteins,1406,O
",",1406,O
and,1406,O
may,1406,O
be,1406,O
useful,1406,O
to,1406,O
study,1406,O
inhibition,1406,O
of,1406,O
transport,1406,O
by,1406,O
xenobiotics,1406,O
at,1406,O
concentrations,1406,O
below,1406,O
the,1406,O
lowest,1406,O
observable,1406,O
adverse,1406,O
effect,1406,O
level,1406,O
(,1406,O
LOAEL,1406,O
),1406,O
.,1406,O
The,1407,O
purpose,1407,O
of,1407,O
this,1407,O
study,1407,O
was,1407,O
to,1407,O
compare,1407,O
viability,1407,O
assessments,1407,O
determined,1407,O
with,1407,O
the,1407,O
neutral,1407,O
red,1407,O
",",1407,O
lactate,1407,B-GENE-N
dehydrogenase,1407,I-GENE-N
(,1407,O
LDH,1407,B-GENE-N
),1407,O
",",1407,O
alamar,1407,B-CHEMICAL
blue,1407,I-CHEMICAL
",",1407,O
3-,1407,B-CHEMICAL
[,1407,I-CHEMICAL
"4,5-dimethylthiazol-2-yl",1407,I-CHEMICAL
],1407,I-CHEMICAL
"-2,5-diphenyltetrazolium",1407,I-CHEMICAL
bromide,1407,I-CHEMICAL
(,1407,O
MTT,1407,B-CHEMICAL
),1407,O
and,1407,O
propidium,1407,B-CHEMICAL
iodide,1407,I-CHEMICAL
assays,1407,O
in,1407,O
sandwich-cultured,1407,O
rat,1407,O
hepatocytes,1407,O
following,1407,O
exposure,1407,O
to,1407,O
xenobiotics,1407,O
known,1407,O
to,1407,O
inhibit,1407,O
Bsep,1407,B-GENE-Y
",",1407,O
and,1407,O
to,1407,O
define,1407,O
the,1407,O
LOAEL,1407,O
for,1407,O
these,1407,O
xenobiotics,1407,O
in,1407,O
this,1407,O
system,1407,O
.,1407,O
The,1408,O
neutral,1408,O
red,1408,O
assay,1408,O
was,1408,O
not,1408,O
amenable,1408,O
to,1408,O
use,1408,O
in,1408,O
this,1408,O
model,1408,O
due,1408,O
to,1408,O
crystal,1408,O
formation,1408,O
on,1408,O
the,1408,O
collagen,1408,B-GENE-N
.,1408,O
Troglitazone,1409,B-CHEMICAL
decreased,1409,O
viability,1409,O
in,1409,O
every,1409,O
assay,1409,O
examined,1409,O
",",1409,O
with,1409,O
a,1409,O
LOAEL,1409,O
approximately,1409,O
100,1409,O
microM,1409,O
.,1409,O
Bosentan,1410,B-CHEMICAL
also,1410,O
decreased,1410,O
viability,1410,O
as,1410,O
measured,1410,O
by,1410,O
the,1410,O
LDH,1410,B-GENE-N
",",1410,O
MTT,1410,B-CHEMICAL
and,1410,O
propidium,1410,B-CHEMICAL
iodide,1410,I-CHEMICAL
assays,1410,O
",",1410,O
with,1410,O
a,1410,O
LOAEL,1410,O
approximately,1410,O
200,1410,O
microM,1410,O
;,1410,O
however,1410,O
",",1410,O
a,1410,O
significant,1410,O
decrease,1410,O
in,1410,O
viability,1410,O
was,1410,O
not,1410,O
observed,1410,O
with,1410,O
the,1410,O
alamar,1410,B-CHEMICAL
blue,1410,I-CHEMICAL
assay,1410,O
.,1410,O
Glibenclamide,1411,B-CHEMICAL
did,1411,O
not,1411,O
decrease,1411,O
viability,1411,O
with,1411,O
any,1411,O
assay,1411,O
at,1411,O
the,1411,O
xenobiotic,1411,O
concentrations,1411,O
examined,1411,O
in,1411,O
this,1411,O
study,1411,O
.,1411,O
Based,1412,O
on,1412,O
the,1412,O
results,1412,O
of,1412,O
this,1412,O
study,1412,O
",",1412,O
the,1412,O
LDH,1412,B-GENE-N
or,1412,O
propidium,1412,B-CHEMICAL
iodide,1412,I-CHEMICAL
assays,1412,O
would,1412,O
be,1412,O
the,1412,O
methods,1412,O
of,1412,O
choice,1412,O
to,1412,O
assess,1412,O
viability,1412,O
in,1412,O
sandwich-cultured,1412,O
rat,1412,O
hepatocytes,1412,O
after,1412,O
xenobiotic,1412,O
exposure,1412,O
.,1412,O
Valdecoxib,1413,B-CHEMICAL
:,1413,O
assessment,1413,O
of,1413,O
cyclooxygenase-2,1413,B-GENE-Y
potency,1413,O
and,1413,O
selectivity,1413,O
.,1413,O
The,1414,O
discovery,1414,O
of,1414,O
a,1414,O
second,1414,B-GENE-Y
isoform,1414,I-GENE-Y
of,1414,I-GENE-Y
cyclooxygenase,1414,I-GENE-Y
(,1414,O
COX,1414,B-GENE-N
),1414,O
led,1414,O
to,1414,O
the,1414,O
search,1414,O
for,1414,O
compounds,1414,O
that,1414,O
could,1414,O
selectively,1414,O
inhibit,1414,O
COX-2,1414,B-GENE-Y
in,1414,O
humans,1414,O
while,1414,O
sparing,1414,O
prostaglandin,1414,B-CHEMICAL
formation,1414,O
from,1414,O
COX-1,1414,B-GENE-Y
.,1414,O
Celecoxib,1415,B-CHEMICAL
and,1415,O
rofecoxib,1415,B-CHEMICAL
were,1415,O
among,1415,O
the,1415,O
molecules,1415,O
developed,1415,O
from,1415,O
these,1415,O
efforts,1415,O
.,1415,O
We,1416,O
report,1416,O
here,1416,O
the,1416,O
pharmacological,1416,O
properties,1416,O
of,1416,O
a,1416,O
third,1416,O
selective,1416,O
COX-2,1416,B-GENE-Y
inhibitor,1416,O
",",1416,O
valdecoxib,1416,B-CHEMICAL
",",1416,O
which,1416,O
is,1416,O
the,1416,O
most,1416,O
potent,1416,O
and,1416,O
in,1416,O
vitro,1416,O
selective,1416,O
of,1416,O
the,1416,O
marketed,1416,O
COX-2,1416,B-GENE-Y
inhibitors,1416,O
that,1416,O
we,1416,O
have,1416,O
studied,1416,O
.,1416,O
Recombinant,1417,O
human,1417,B-GENE-Y
COX-1,1417,I-GENE-Y
and,1417,O
COX-2,1417,B-GENE-Y
were,1417,O
used,1417,O
to,1417,O
screen,1417,O
for,1417,O
new,1417,O
highly,1417,O
potent,1417,O
and,1417,O
in,1417,O
vitro,1417,O
selective,1417,O
COX-2,1417,B-GENE-Y
inhibitors,1417,O
and,1417,O
compare,1417,O
kinetic,1417,O
mechanisms,1417,O
of,1417,O
binding,1417,O
and,1417,O
enzyme,1417,O
inhibition,1417,O
with,1417,O
other,1417,O
COX,1417,B-GENE-N
inhibitors,1417,O
.,1417,O
Valdecoxib,1418,B-CHEMICAL
potently,1418,O
inhibits,1418,O
recombinant,1418,O
COX-2,1418,B-GENE-Y
",",1418,O
with,1418,O
an,1418,O
IC,1418,O
(,1418,O
50,1418,O
),1418,O
of,1418,O
0.005,1418,O
microM,1418,O
;,1418,O
this,1418,O
compares,1418,O
with,1418,O
IC,1418,O
values,1418,O
of,1418,O
0.05,1418,O
microM,1418,O
for,1418,O
celecoxib,1418,B-CHEMICAL
",",1418,O
0.5,1418,O
microM,1418,O
for,1418,O
rofecoxib,1418,B-CHEMICAL
",",1418,O
and,1418,O
5,1418,O
microM,1418,O
for,1418,O
etoricoxib,1418,B-CHEMICAL
.,1418,O
Unique,1419,O
binding,1419,O
interactions,1419,O
of,1419,O
valdecoxib,1419,B-CHEMICAL
with,1419,O
COX-2,1419,B-GENE-Y
translate,1419,O
into,1419,O
a,1419,O
fast,1419,O
rate,1419,O
of,1419,O
inactivation,1419,O
of,1419,O
COX-2,1419,B-GENE-Y
(,1419,O
"110,000",1419,O
M/s,1419,O
compared,1419,O
with,1419,O
7000,1419,O
M/s,1419,O
for,1419,O
rofecoxib,1419,B-CHEMICAL
and,1419,O
80,1419,O
M/s,1419,O
for,1419,O
etoricoxib,1419,B-CHEMICAL
),1419,O
.,1419,O
The,1420,O
overall,1420,O
saturation,1420,O
binding,1420,O
affinity,1420,O
for,1420,O
COX-2,1420,B-GENE-Y
of,1420,O
valdecoxib,1420,B-CHEMICAL
is,1420,O
2.6,1420,O
nM,1420,O
(,1420,O
compared,1420,O
with,1420,O
1.6,1420,O
nM,1420,O
for,1420,O
celecoxib,1420,B-CHEMICAL
",",1420,O
51,1420,O
nM,1420,O
for,1420,O
rofecoxib,1420,B-CHEMICAL
",",1420,O
and,1420,O
260,1420,O
nM,1420,O
for,1420,O
etoricoxib,1420,B-CHEMICAL
),1420,O
",",1420,O
with,1420,O
a,1420,O
slow,1420,O
off-rate,1420,O
(,1420,O
t,1420,O
(,1420,O
1/2,1420,O
),1420,O
approximately,1420,O
98,1420,O
min,1420,O
),1420,O
.,1420,O
Valdecoxib,1421,B-CHEMICAL
inhibits,1421,O
COX-1,1421,B-GENE-Y
in,1421,O
a,1421,O
competitive,1421,O
fashion,1421,O
only,1421,O
at,1421,O
very,1421,O
high,1421,O
concentrations,1421,O
(,1421,O
IC,1421,O
(,1421,O
50,1421,O
),1421,O
=,1421,O
150,1421,O
microM,1421,O
),1421,O
.,1421,O
Collectively,1422,O
",",1422,O
these,1422,O
data,1422,O
provide,1422,O
a,1422,O
mechanistic,1422,O
basis,1422,O
for,1422,O
the,1422,O
potency,1422,O
and,1422,O
in,1422,O
vitro,1422,O
selectivity,1422,O
of,1422,O
valdecoxib,1422,B-CHEMICAL
for,1422,O
COX-2,1422,B-GENE-Y
.,1422,O
Valdecoxib,1423,B-CHEMICAL
showed,1423,O
similar,1423,O
activity,1423,O
in,1423,O
the,1423,O
human,1423,B-GENE-N
whole-blood,1423,I-GENE-N
COX,1423,I-GENE-N
assay,1423,O
(,1423,O
COX-2,1423,B-GENE-Y
IC,1423,O
(,1423,O
50,1423,O
),1423,O
=,1423,O
0.24,1423,O
microM,1423,O
;,1423,O
COX-1,1423,B-GENE-Y
IC,1423,O
(,1423,O
50,1423,O
),1423,O
=,1423,O
21.9,1423,O
microM,1423,O
),1423,O
.,1423,O
We,1424,O
also,1424,O
determined,1424,O
whether,1424,O
this,1424,O
in,1424,O
vitro,1424,O
potency,1424,O
and,1424,O
selectivity,1424,O
translated,1424,O
to,1424,O
significant,1424,O
potency,1424,O
in,1424,O
vivo,1424,O
.,1424,O
In,1425,O
rats,1425,O
",",1425,O
valdecoxib,1425,B-CHEMICAL
demonstrated,1425,O
marked,1425,O
potency,1425,O
in,1425,O
acute,1425,O
and,1425,O
chronic,1425,O
models,1425,O
of,1425,O
inflammation,1425,O
(,1425,O
air,1425,O
pouch,1425,O
ED,1425,O
(,1425,O
50,1425,O
),1425,O
=,1425,O
0.06,1425,O
mg/kg,1425,O
;,1425,O
paw,1425,O
edema,1425,O
ED,1425,O
(,1425,O
50,1425,O
),1425,O
=,1425,O
5.9,1425,O
mg/kg,1425,O
;,1425,O
adjuvant,1425,O
arthritis,1425,O
ED,1425,O
(,1425,O
50,1425,O
),1425,O
=,1425,O
0.03,1425,O
mg/kg,1425,O
),1425,O
.,1425,O
In,1426,O
these,1426,O
same,1426,O
animals,1426,O
",",1426,O
COX-1,1426,B-GENE-Y
was,1426,O
spared,1426,O
at,1426,O
doses,1426,O
greater,1426,O
than,1426,O
200,1426,O
mg/kg,1426,O
.,1426,O
These,1427,O
data,1427,O
provide,1427,O
a,1427,O
basis,1427,O
for,1427,O
the,1427,O
observed,1427,O
potent,1427,O
anti-inflammatory,1427,O
activity,1427,O
of,1427,O
valdecoxib,1427,B-CHEMICAL
in,1427,O
humans,1427,O
.,1427,O
An,1428,O
angiotensin,1428,B-CHEMICAL
II,1428,I-CHEMICAL
AT1,1428,I-GENE-Y
receptor,1428,I-GENE-Y
antagonist,1428,O
",",1428,O
telmisartan,1428,B-CHEMICAL
augments,1428,O
glucose,1428,B-CHEMICAL
uptake,1428,O
and,1428,O
GLUT4,1428,B-GENE-Y
protein,1428,O
expression,1428,O
in,1428,O
3T3-L1,1428,O
adipocytes,1428,O
.,1428,O
Evidence,1429,O
has,1429,O
accumulated,1429,O
that,1429,O
some,1429,O
of,1429,O
the,1429,O
angiotensin,1429,B-CHEMICAL
II,1429,I-CHEMICAL
AT1,1429,I-GENE-Y
receptor,1429,I-GENE-Y
antagonists,1429,O
have,1429,O
insulin-sensitizing,1429,B-GENE-N
property,1429,O
.,1429,O
We,1430,O
thus,1430,O
examined,1430,O
the,1430,O
effect,1430,O
of,1430,O
telmisartan,1430,B-CHEMICAL
on,1430,O
insulin,1430,B-GENE-N
action,1430,O
using,1430,O
3T3-L1,1430,O
adipocytes,1430,O
.,1430,O
With,1431,O
standard,1431,O
differentiation,1431,O
inducers,1431,O
",",1431,O
a,1431,O
higher,1431,O
dose,1431,O
of,1431,O
telmisartan,1431,B-CHEMICAL
effectively,1431,O
facilitated,1431,O
differentiation,1431,O
of,1431,O
3T3-L1,1431,O
preadipocytes,1431,O
.,1431,O
Treatment,1432,O
of,1432,O
both,1432,O
differentiating,1432,O
adipocytes,1432,O
and,1432,O
fully,1432,O
differentiated,1432,O
adipocytes,1432,O
with,1432,O
telmisartan,1432,B-CHEMICAL
caused,1432,O
a,1432,O
dose-dependent,1432,O
increase,1432,O
in,1432,O
mRNA,1432,O
levels,1432,O
for,1432,O
PPARgamma,1432,B-GENE-Y
target,1432,O
genes,1432,O
such,1432,O
as,1432,O
aP2,1432,B-GENE-Y
and,1432,O
adiponectin,1432,B-GENE-Y
.,1432,O
By,1433,O
contrast,1433,O
",",1433,O
telmisartan,1433,B-CHEMICAL
attenuated,1433,O
11beta-hydroxysteroid,1433,B-CHEMICAL
dehydrogenase,1433,I-GENE-Y
type,1433,I-GENE-Y
1,1433,I-GENE-Y
mRNA,1433,O
level,1433,O
in,1433,O
differentiated,1433,O
adipocytes,1433,O
.,1433,O
Of,1434,O
note,1434,O
",",1434,O
we,1434,O
demonstrated,1434,O
for,1434,O
the,1434,O
first,1434,O
time,1434,O
that,1434,O
telmisartan,1434,B-CHEMICAL
augmented,1434,O
GLUT4,1434,B-GENE-Y
protein,1434,O
expression,1434,O
and,1434,O
2-deoxy,1434,B-CHEMICAL
glucose,1434,I-CHEMICAL
uptake,1434,O
both,1434,O
in,1434,O
basal,1434,O
and,1434,O
insulin-stimulated,1434,B-GENE-N
state,1434,O
of,1434,O
adipocytes,1434,O
",",1434,O
which,1434,O
may,1434,O
contribute,1434,O
",",1434,O
at,1434,O
least,1434,O
partly,1434,O
",",1434,O
to,1434,O
its,1434,O
insulin-sensitizing,1434,B-GENE-N
ability,1434,O
.,1434,O
Pharmacogenetic,1435,O
differences,1435,O
in,1435,O
response,1435,O
to,1435,O
albuterol,1435,B-CHEMICAL
between,1435,O
Puerto,1435,O
Ricans,1435,O
and,1435,O
Mexicans,1435,O
with,1435,O
asthma,1435,O
.,1435,O
BACKGROUND,1436,O
:,1436,O
In,1436,O
the,1436,O
United,1436,O
States,1436,O
",",1436,O
Puerto,1436,O
Ricans,1436,O
and,1436,O
Mexicans,1436,O
have,1436,O
the,1436,O
highest,1436,O
and,1436,O
lowest,1436,O
asthma,1436,O
prevalence,1436,O
",",1436,O
morbidity,1436,O
",",1436,O
and,1436,O
mortality,1436,O
",",1436,O
respectively,1436,O
.,1436,O
Ethnic-specific,1437,O
differences,1437,O
in,1437,O
the,1437,O
response,1437,O
to,1437,O
drug,1437,O
treatment,1437,O
may,1437,O
contribute,1437,O
to,1437,O
differences,1437,O
in,1437,O
disease,1437,O
outcomes,1437,O
.,1437,O
Genetic,1438,O
variants,1438,O
at,1438,O
the,1438,O
beta,1438,B-GENE-Y
(,1438,I-GENE-Y
2,1438,I-GENE-Y
),1438,I-GENE-Y
-adrenergic,1438,I-GENE-Y
receptor,1438,I-GENE-Y
(,1438,O
beta,1438,B-GENE-Y
(,1438,I-GENE-Y
2,1438,I-GENE-Y
),1438,I-GENE-Y
AR,1438,I-GENE-Y
),1438,O
may,1438,O
modify,1438,O
asthma,1438,O
severity,1438,O
and,1438,O
albuterol,1438,B-CHEMICAL
responsiveness,1438,O
.,1438,O
We,1439,O
tested,1439,O
the,1439,O
association,1439,O
of,1439,O
beta,1439,B-GENE-Y
(,1439,I-GENE-Y
2,1439,I-GENE-Y
),1439,I-GENE-Y
AR,1439,I-GENE-Y
genotypes,1439,O
with,1439,O
asthma,1439,O
severity,1439,O
and,1439,O
bronchodilator,1439,O
response,1439,O
to,1439,O
albuterol,1439,B-CHEMICAL
in,1439,O
Puerto,1439,O
Ricans,1439,O
and,1439,O
Mexicans,1439,O
with,1439,O
asthma,1439,O
.,1439,O
METHODS,1440,O
:,1440,O
We,1440,O
used,1440,O
both,1440,O
family-based,1440,O
and,1440,O
cross-sectional,1440,O
tests,1440,O
of,1440,O
association,1440,O
with,1440,O
8,1440,O
beta,1440,B-GENE-Y
(,1440,I-GENE-Y
2,1440,I-GENE-Y
),1440,I-GENE-Y
AR,1440,I-GENE-Y
single,1440,O
nucleotide,1440,B-CHEMICAL
polymorphisms,1440,O
in,1440,O
684,1440,O
Puerto,1440,O
Rican,1440,O
and,1440,O
Mexican,1440,O
families,1440,O
.,1440,O
Regression,1441,O
analyses,1441,O
were,1441,O
used,1441,O
to,1441,O
determine,1441,O
the,1441,O
interaction,1441,O
between,1441,O
genotype,1441,O
",",1441,O
asthma,1441,O
severity,1441,O
",",1441,O
and,1441,O
bronchodilator,1441,O
drug,1441,O
responsiveness,1441,O
.,1441,O
RESULTS,1442,O
:,1442,O
Among,1442,O
Puerto,1442,O
Ricans,1442,O
with,1442,O
asthma,1442,O
",",1442,O
the,1442,O
arginine,1442,B-CHEMICAL
(,1442,O
Arg,1442,B-CHEMICAL
),1442,O
16,1442,O
allele,1442,O
was,1442,O
associated,1442,O
with,1442,O
greater,1442,O
bronchodilator,1442,O
response,1442,O
using,1442,O
both,1442,O
family-based,1442,O
and,1442,O
cross-sectional,1442,O
tests,1442,O
(,1442,O
p,1442,O
=,1442,O
0.00001-0.01,1442,O
),1442,O
.,1442,O
We,1443,O
found,1443,O
a,1443,O
strong,1443,O
interaction,1443,O
of,1443,O
baseline,1443,O
FEV,1443,O
(,1443,O
1,1443,O
),1443,O
with,1443,O
the,1443,O
Arg16Glycine,1443,B-GENE-N
(,1443,O
Gly,1443,B-CHEMICAL
),1443,O
polymorphism,1443,O
in,1443,O
predicting,1443,O
bronchodilator,1443,O
response,1443,O
.,1443,O
Among,1444,O
Puerto,1444,O
Ricans,1444,O
with,1444,O
asthma,1444,O
with,1444,O
baseline,1444,O
FEV,1444,O
(,1444,O
1,1444,O
),1444,O
<,1444,O
80,1444,O
%,1444,O
of,1444,O
predicted,1444,O
",",1444,O
but,1444,O
not,1444,O
in,1444,O
those,1444,O
with,1444,O
FEV,1444,O
(,1444,O
1,1444,O
),1444,O
>,1444,O
80,1444,O
%,1444,O
",",1444,O
there,1444,O
was,1444,O
a,1444,O
very,1444,O
strong,1444,O
association,1444,O
between,1444,O
the,1444,O
Arg16,1444,O
genotype,1444,O
and,1444,O
greater,1444,O
bronchodilator,1444,O
responsiveness,1444,O
.,1444,O
No,1445,O
association,1445,O
was,1445,O
observed,1445,O
between,1445,O
Arg16Gly,1445,B-GENE-N
genotypes,1445,O
and,1445,O
drug,1445,O
responsiveness,1445,O
among,1445,O
Mexicans,1445,O
with,1445,O
asthma,1445,O
.,1445,O
CONCLUSIONS,1446,O
:,1446,O
Ethnic-specific,1446,O
pharmacogenetic,1446,O
differences,1446,O
exist,1446,O
between,1446,O
Arg16Gly,1446,B-GENE-N
genotypes,1446,O
",",1446,O
asthma,1446,O
severity,1446,O
",",1446,O
and,1446,O
bronchodilator,1446,O
response,1446,O
in,1446,O
Puerto,1446,O
Ricans,1446,O
and,1446,O
Mexicans,1446,O
with,1446,O
asthma,1446,O
.,1446,O
These,1447,O
findings,1447,O
underscore,1447,O
the,1447,O
need,1447,O
for,1447,O
additional,1447,O
research,1447,O
on,1447,O
racial/ethnic,1447,O
differences,1447,O
in,1447,O
asthma,1447,O
morbidity,1447,O
and,1447,O
drug,1447,O
responsiveness,1447,O
.,1447,O
Tyrosinase,1448,B-GENE-Y
inhibitors,1448,O
from,1448,O
Rhododendron,1448,O
collettianum,1448,O
and,1448,O
their,1448,O
structure-activity,1448,O
relationship,1448,O
(,1448,O
SAR,1448,O
),1448,O
studies,1448,O
.,1448,O
A,1449,O
new,1449,O
coumarinolignoid,1449,B-CHEMICAL
8'-epi-cleomiscosin,1449,B-CHEMICAL
A,1449,I-CHEMICAL
(,1449,O
1,1449,O
),1449,O
together,1449,O
with,1449,O
the,1449,O
new,1449,O
glycoside,1449,O
8-O-beta-D-glucopyranosyl-6-hydroxy-2-methyl-4H-1-benzopyrane-4-one,1449,B-CHEMICAL
(,1449,O
2,1449,O
),1449,O
have,1449,O
been,1449,O
isolated,1449,O
from,1449,O
the,1449,O
aerial,1449,O
parts,1449,O
of,1449,O
Rhododendron,1449,O
collettianum,1449,O
and,1449,O
their,1449,O
structures,1449,O
determined,1449,O
on,1449,O
the,1449,O
basis,1449,O
of,1449,O
spectroscopic,1449,O
evidences,1449,O
.,1449,O
Tyrosinase,1450,B-GENE-Y
inhibition,1450,O
study,1450,O
of,1450,O
these,1450,O
compounds,1450,O
and,1450,O
their,1450,O
structure-activity,1450,O
relationship,1450,O
(,1450,O
SAR,1450,O
),1450,O
were,1450,O
also,1450,O
investigated,1450,O
.,1450,O
The,1451,O
compounds,1451,O
exhibited,1451,O
potent,1451,O
to,1451,O
mild,1451,O
inhibition,1451,O
activity,1451,O
against,1451,O
the,1451,O
enzyme,1451,O
.,1451,O
Especially,1452,O
",",1452,O
the,1452,O
compound,1452,O
1,1452,O
showed,1452,O
strong,1452,O
inhibition,1452,O
(,1452,O
IC50=1.33,1452,O
microM,1452,O
),1452,O
against,1452,O
the,1452,O
enzyme,1452,O
tyrosinase,1452,B-GENE-Y
",",1452,O
as,1452,O
compared,1452,O
to,1452,O
the,1452,O
standard,1452,O
tyrosinase,1452,O
inhibitors,1452,O
kojic,1452,B-CHEMICAL
acid,1452,I-CHEMICAL
(,1452,O
IC50=16.67,1452,O
microM,1452,O
),1452,O
and,1452,O
L-mimosine,1452,B-CHEMICAL
(,1452,O
IC50=3.68,1452,O
microM,1452,O
),1452,O
",",1452,O
indicating,1452,O
its,1452,O
potential,1452,O
used,1452,O
for,1452,O
the,1452,O
treatment,1452,O
of,1452,O
hyperpigmentation,1452,O
associated,1452,O
with,1452,O
the,1452,O
high,1452,O
production,1452,O
of,1452,O
melanocytes,1452,O
.,1452,O
In,1453,O
vivo,1453,O
activity,1453,O
of,1453,O
the,1453,O
potent,1453,O
oxytocin,1453,B-GENE-Y
antagonist,1453,O
on,1453,O
uterine,1453,O
activity,1453,O
in,1453,O
the,1453,O
rat,1453,O
.,1453,O
Oxytocin,1454,B-GENE-Y
antagonist,1454,O
(,1454,O
OTA,1454,O
),1454,O
",",1454,O
TT-235,1454,B-CHEMICAL
",",1454,O
was,1454,O
developed,1454,O
by,1454,O
our,1454,O
group,1454,O
and,1454,O
shown,1454,O
to,1454,O
inhibit,1454,O
either,1454,O
spontaneous,1454,O
or,1454,O
oxytocin-induced,1454,B-CHEMICAL
uterine,1454,O
contractions,1454,O
in,1454,O
primates,1454,O
.,1454,O
The,1455,O
purpose,1455,O
of,1455,O
the,1455,O
present,1455,O
study,1455,O
was,1455,O
to,1455,O
confirm,1455,O
the,1455,O
duration,1455,O
of,1455,O
TT-235,1455,B-CHEMICAL
to,1455,O
block,1455,O
oxytocin-induced,1455,B-GENE-Y
uterine,1455,O
contractions,1455,O
in,1455,O
estrous,1455,O
rats,1455,O
.,1455,O
In,1456,O
Experiment,1456,O
1,1456,O
",",1456,O
the,1456,O
time-response,1456,O
of,1456,O
the,1456,O
three,1456,O
OTAs,1456,O
on,1456,O
uterine,1456,O
contractility,1456,O
was,1456,O
examined,1456,O
.,1456,O
The,1457,O
rats,1457,O
were,1457,O
anesthetized,1457,O
and,1457,O
cannulas,1457,O
were,1457,O
placed,1457,O
in,1457,O
the,1457,O
jugular,1457,O
vein,1457,O
for,1457,O
infusing,1457,O
vehicle,1457,O
(,1457,O
sterile,1457,O
saline,1457,O
),1457,O
",",1457,O
Antag,1457,B-CHEMICAL
I,1457,I-CHEMICAL
",",1457,O
Antag,1457,B-CHEMICAL
II,1457,I-CHEMICAL
and,1457,O
TT-235,1457,B-CHEMICAL
.,1457,O
The,1458,O
uterine,1458,O
activity,1458,O
was,1458,O
monitored,1458,O
through,1458,O
a,1458,O
water-filled,1458,O
balloon-tipped,1458,O
cannula,1458,O
placed,1458,O
in,1458,O
the,1458,O
uterine,1458,O
horn,1458,O
.,1458,O
The,1459,O
uterine,1459,O
contractile,1459,O
activity,1459,O
was,1459,O
determined,1459,O
as,1459,O
the,1459,O
integrated,1459,O
area,1459,O
for,1459,O
10,1459,O
minutes,1459,O
.,1459,O
Each,1460,O
OTA,1460,O
was,1460,O
administered,1460,O
as,1460,O
a,1460,O
single,1460,O
bolus,1460,O
injection,1460,O
of,1460,O
5,1460,O
microg,1460,O
",",1460,O
followed,1460,O
by,1460,O
100,1460,O
mU,1460,O
of,1460,O
oxytocin,1460,B-GENE-Y
5,1460,O
minutes,1460,O
later,1460,O
",",1460,O
also,1460,O
done,1460,O
as,1460,O
a,1460,O
single,1460,O
bolus,1460,O
.,1460,O
Oxytocin,1461,B-GENE-Y
injection,1461,O
of,1461,O
the,1461,O
same,1461,O
dosage,1461,O
was,1461,O
repeated,1461,O
every,1461,O
hour,1461,O
for,1461,O
5,1461,O
hours,1461,O
.,1461,O
Experiment,1462,O
2,1462,O
determined,1462,O
the,1462,O
effect,1462,O
of,1462,O
the,1462,O
three,1462,O
OTAs,1462,O
on,1462,O
uterine,1462,O
oxytocin,1462,B-GENE-Y
receptor,1462,I-GENE-Y
number,1462,O
(,1462,O
Rn,1462,O
),1462,O
and,1462,O
binding,1462,O
affinity,1462,O
(,1462,O
Kd,1462,O
),1462,O
.,1462,O
Rats,1463,O
treated,1463,O
with,1463,O
either,1463,O
OTA,1463,O
or,1463,O
vehicle,1463,O
were,1463,O
sacrificed,1463,O
at,1463,O
0.5,1463,O
and,1463,O
4,1463,O
hours,1463,O
for,1463,O
receptor,1463,O
assay,1463,O
.,1463,O
In,1464,O
Experiment,1464,O
1,1464,O
",",1464,O
Antag,1464,B-CHEMICAL
I,1464,I-CHEMICAL
",",1464,O
Antag,1464,B-CHEMICAL
II,1464,I-CHEMICAL
and,1464,O
TT-235,1464,B-CHEMICAL
inhibited,1464,O
the,1464,O
integrated,1464,O
uterine,1464,O
response,1464,O
to,1464,O
oxytocin,1464,B-CHEMICAL
at,1464,O
5,1464,O
minutes,1464,O
by,1464,O
76,1464,O
%,1464,O
",",1464,O
77,1464,O
%,1464,O
and,1464,O
80,1464,O
%,1464,O
",",1464,O
respectively,1464,O
",",1464,O
compared,1464,O
to,1464,O
controls,1464,O
(,1464,O
p,1464,O
<,1464,O
0.05,1464,O
),1464,O
.,1464,O
Two,1465,O
hours,1465,O
after,1465,O
injecting,1465,O
Antag,1465,B-CHEMICAL
I,1465,I-CHEMICAL
",",1465,O
inhibition,1465,O
of,1465,O
uterine,1465,O
contractility,1465,O
was,1465,O
55,1465,O
%,1465,O
lower,1465,O
than,1465,O
controls,1465,O
(,1465,O
p,1465,O
<,1465,O
0.05,1465,O
),1465,O
.,1465,O
At,1466,O
3,1466,O
hours,1466,O
",",1466,O
uterine,1466,O
contractility,1466,O
was,1466,O
no,1466,O
longer,1466,O
affected,1466,O
in,1466,O
rats,1466,O
treated,1466,O
with,1466,O
Antag,1466,B-CHEMICAL
I,1466,I-CHEMICAL
compared,1466,O
with,1466,O
controls,1466,O
.,1466,O
The,1467,O
suppressive,1467,O
uterine,1467,O
activity,1467,O
with,1467,O
Antag,1467,B-CHEMICAL
II,1467,I-CHEMICAL
continued,1467,O
up,1467,O
to,1467,O
3,1467,O
hours,1467,O
.,1467,O
However,1468,O
",",1468,O
uterine,1468,O
contractility,1468,O
remained,1468,O
lower,1468,O
(,1468,O
53,1468,O
%,1468,O
),1468,O
in,1468,O
rats,1468,O
treated,1468,O
with,1468,O
TT-235,1468,B-CHEMICAL
5,1468,O
hours,1468,O
later,1468,O
.,1468,O
In,1469,O
Experiment,1469,O
2,1469,O
",",1469,O
TT-235,1469,B-CHEMICAL
induced,1469,O
a,1469,O
significant,1469,O
decrease,1469,O
(,1469,O
p,1469,O
<,1469,O
0.05,1469,O
),1469,O
in,1469,O
oxytocin,1469,B-GENE-Y
receptor,1469,I-GENE-Y
number,1469,O
and,1469,O
binding,1469,O
affinity,1469,O
at,1469,O
both,1469,O
0.5,1469,O
and,1469,O
4,1469,O
hours,1469,O
compared,1469,O
with,1469,O
controls,1469,O
.,1469,O
Antag,1470,B-CHEMICAL
I,1470,I-CHEMICAL
and,1470,O
Antag,1470,B-CHEMICAL
II,1470,I-CHEMICAL
did,1470,O
not,1470,O
alter,1470,O
oxytocin,1470,B-GENE-Y
receptor,1470,I-GENE-Y
number,1470,O
or,1470,O
binding,1470,O
affinity,1470,O
significantly,1470,O
at,1470,O
each,1470,O
time,1470,O
point,1470,O
studied,1470,O
compared,1470,O
with,1470,O
controls,1470,O
.,1470,O
In,1471,O
conclusion,1471,O
",",1471,O
TT-235,1471,B-CHEMICAL
may,1471,O
inhibit,1471,O
the,1471,O
uterine,1471,O
response,1471,O
to,1471,O
oxytocin,1471,B-GENE-Y
by,1471,O
decreasing,1471,O
oxytocin,1471,B-GENE-Y
receptor,1471,I-GENE-Y
numbers,1471,O
and,1471,O
oxytocin,1471,B-GENE-Y
binding,1471,O
affinity,1471,O
",",1471,O
which,1471,O
might,1471,O
explain,1471,O
the,1471,O
prolonged,1471,O
oxytocin,1471,B-GENE-Y
antagonist,1471,O
activity,1471,O
of,1471,O
TT-235,1471,B-CHEMICAL
.,1471,O
Preclinical,1472,O
pharmacology,1472,O
of,1472,O
lumiracoxib,1472,B-CHEMICAL
:,1472,O
a,1472,O
novel,1472,O
selective,1472,O
inhibitor,1472,O
of,1472,O
cyclooxygenase-2,1472,B-GENE-Y
.,1472,O
1,1473,O
.,1473,O
This,1474,O
manuscript,1474,O
presents,1474,O
the,1474,O
preclinical,1474,O
profile,1474,O
of,1474,O
lumiracoxib,1474,B-CHEMICAL
",",1474,O
a,1474,O
novel,1474,O
cyclooxygenase-2,1474,B-GENE-Y
(,1474,O
COX-2,1474,B-GENE-Y
),1474,O
selective,1474,O
inhibitor,1474,O
.,1474,O
2,1475,O
.,1475,O
Lumiracoxib,1476,B-CHEMICAL
inhibited,1476,O
purified,1476,O
COX-1,1476,B-GENE-Y
and,1476,O
COX-2,1476,B-GENE-Y
with,1476,O
K,1476,O
(,1476,O
i,1476,O
),1476,O
values,1476,O
of,1476,O
3,1476,O
and,1476,O
0.06,1476,O
microM,1476,O
",",1476,O
respectively,1476,O
.,1476,O
In,1477,O
cellular,1477,O
assays,1477,O
",",1477,O
lumiracoxib,1477,B-CHEMICAL
had,1477,O
an,1477,O
IC,1477,O
(,1477,O
50,1477,O
),1477,O
of,1477,O
0.14,1477,O
microM,1477,O
in,1477,O
COX-2-expressing,1477,B-GENE-Y
dermal,1477,O
fibroblasts,1477,O
",",1477,O
but,1477,O
caused,1477,O
no,1477,O
inhibition,1477,O
of,1477,O
COX-1,1477,B-GENE-Y
at,1477,O
concentrations,1477,O
up,1477,O
to,1477,O
30,1477,O
microM,1477,O
(,1477,O
HEK,1477,O
293,1477,O
cells,1477,O
transfected,1477,O
with,1477,O
human,1477,B-GENE-N
COX-1,1477,I-GENE-N
),1477,O
.,1477,O
3,1478,O
.,1478,O
In,1479,O
a,1479,O
human,1479,O
whole,1479,O
blood,1479,O
assay,1479,O
",",1479,O
IC,1479,O
(,1479,O
50,1479,O
),1479,O
values,1479,O
for,1479,O
lumiracoxib,1479,B-CHEMICAL
were,1479,O
0.13,1479,O
microM,1479,O
for,1479,O
COX-2,1479,B-GENE-Y
and,1479,O
67,1479,O
microM,1479,O
for,1479,O
COX-1,1479,B-GENE-Y
(,1479,O
COX-1/COX-2,1479,B-GENE-Y
selectivity,1479,O
ratio,1479,O
515,1479,O
),1479,O
.,1479,O
4,1480,O
.,1480,O
Lumiracoxib,1481,B-CHEMICAL
was,1481,O
rapidly,1481,O
absorbed,1481,O
following,1481,O
oral,1481,O
administration,1481,O
in,1481,O
rats,1481,O
with,1481,O
peak,1481,O
plasma,1481,O
levels,1481,O
being,1481,O
reached,1481,O
between,1481,O
0.5,1481,O
and,1481,O
1,1481,O
h.,1481,O
5,1481,O
.,1481,O
Ex,1482,O
vivo,1482,O
",",1482,O
lumiracoxib,1482,B-CHEMICAL
inhibited,1482,O
COX-1-derived,1482,B-GENE-Y
thromboxane,1482,B-CHEMICAL
B,1482,I-CHEMICAL
(,1482,I-CHEMICAL
2,1482,I-CHEMICAL
),1482,I-CHEMICAL
(,1482,O
TxB,1482,B-CHEMICAL
(,1482,I-CHEMICAL
2,1482,I-CHEMICAL
),1482,I-CHEMICAL
),1482,O
generation,1482,O
with,1482,O
an,1482,O
ID,1482,O
(,1482,O
50,1482,O
),1482,O
of,1482,O
33,1482,O
mg,1482,O
kg,1482,O
(,1482,O
-1,1482,O
),1482,O
",",1482,O
whereas,1482,O
COX-2-derived,1482,B-GENE-Y
production,1482,O
of,1482,O
prostaglandin,1482,B-CHEMICAL
E,1482,I-CHEMICAL
(,1482,I-CHEMICAL
2,1482,I-CHEMICAL
),1482,I-CHEMICAL
(,1482,O
PGE,1482,B-CHEMICAL
(,1482,I-CHEMICAL
2,1482,I-CHEMICAL
),1482,I-CHEMICAL
),1482,O
in,1482,O
the,1482,O
lipopolysaccharide-stimulated,1482,O
rat,1482,O
air,1482,O
pouch,1482,O
was,1482,O
inhibited,1482,O
with,1482,O
an,1482,O
ID,1482,O
(,1482,O
50,1482,O
),1482,O
value,1482,O
of,1482,O
0.24,1482,O
mg,1482,O
kg,1482,O
(,1482,O
-1,1482,O
),1482,O
.,1482,O
6,1483,O
.,1483,O
Efficacy,1484,O
of,1484,O
lumiracoxib,1484,B-CHEMICAL
in,1484,O
rat,1484,O
models,1484,O
of,1484,O
hyperalgesia,1484,O
",",1484,O
oedema,1484,O
",",1484,O
pyresis,1484,O
and,1484,O
arthritis,1484,O
was,1484,O
dose-dependent,1484,O
and,1484,O
similar,1484,O
to,1484,O
diclofenac,1484,B-CHEMICAL
.,1484,O
However,1485,O
",",1485,O
consistent,1485,O
with,1485,O
its,1485,O
low,1485,O
COX-1,1485,B-GENE-Y
inhibitory,1485,O
activity,1485,O
",",1485,O
lumiracoxib,1485,B-CHEMICAL
at,1485,O
a,1485,O
dose,1485,O
of,1485,O
100,1485,O
mg,1485,O
kg,1485,O
(,1485,O
-1,1485,O
),1485,O
orally,1485,O
caused,1485,O
no,1485,O
ulcers,1485,O
and,1485,O
was,1485,O
significantly,1485,O
less,1485,O
ulcerogenic,1485,O
than,1485,O
diclofenac,1485,B-CHEMICAL
(,1485,O
P,1485,O
<,1485,O
0.05,1485,O
),1485,O
.,1485,O
7,1486,O
.,1486,O
Lumiracoxib,1487,B-CHEMICAL
is,1487,O
a,1487,O
highly,1487,O
selective,1487,O
COX-2,1487,B-GENE-Y
inhibitor,1487,O
with,1487,O
anti-inflammatory,1487,O
",",1487,O
analgesic,1487,O
and,1487,O
antipyretic,1487,O
activities,1487,O
comparable,1487,O
with,1487,O
diclofenac,1487,B-CHEMICAL
",",1487,O
the,1487,O
reference,1487,O
NSAID,1487,O
",",1487,O
but,1487,O
with,1487,O
much,1487,O
improved,1487,O
gastrointestinal,1487,O
safety,1487,O
.,1487,O
Cloning,1488,O
",",1488,O
sequencing,1488,O
",",1488,O
structural,1488,O
and,1488,O
molecular,1488,O
biological,1488,O
characterization,1488,O
of,1488,O
placental,1488,B-GENE-Y
protein,1488,I-GENE-Y
20,1488,I-GENE-Y
(,1488,O
PP20,1488,B-GENE-Y
),1488,O
/human,1488,O
thiamin,1488,B-CHEMICAL
pyrophosphokinase,1488,I-GENE-Y
(,1488,O
hTPK,1488,B-GENE-Y
),1488,O
.,1488,O
Full-length,1489,O
cDNAs,1489,O
of,1489,O
placental,1489,B-GENE-Y
protein,1489,I-GENE-Y
20,1489,I-GENE-Y
(,1489,O
PP20,1489,B-GENE-Y
),1489,O
were,1489,O
cloned,1489,O
by,1489,O
screening,1489,O
a,1489,O
human,1489,O
placental,1489,O
cDNA,1489,O
library,1489,O
",",1489,O
which,1489,O
encode,1489,O
a,1489,O
243,1489,O
amino,1489,O
acid,1489,O
protein,1489,O
",",1489,O
identical,1489,O
to,1489,O
human,1489,B-GENE-Y
thiamin,1489,B-CHEMICAL
pyrophosphokinase,1489,I-GENE-Y
(,1489,O
hTPK,1489,B-GENE-Y
),1489,O
as,1489,O
confirmed,1489,O
by,1489,O
protein,1489,O
sequence,1489,O
analysis,1489,O
.,1489,O
Genomic,1490,O
alignment,1490,O
showed,1490,O
that,1490,O
the,1490,O
PP20/hTPK,1490,B-GENE-Y
gene,1490,O
contains,1490,O
9,1490,O
exons,1490,O
.,1490,O
It,1491,O
is,1491,O
abundantly,1491,O
expressed,1491,O
in,1491,O
placenta,1491,O
",",1491,O
as,1491,O
numerous,1491,O
EST,1491,O
clones,1491,O
were,1491,O
identified,1491,O
.,1491,O
As,1492,O
thiamine,1492,B-CHEMICAL
metabolism,1492,O
deficiencies,1492,O
have,1492,O
been,1492,O
seen,1492,O
in,1492,O
placental,1492,O
infarcts,1492,O
previously,1492,O
",",1492,O
these,1492,O
indicate,1492,O
that,1492,O
PP20/hTPK,1492,B-GENE-Y
may,1492,O
have,1492,O
a,1492,O
role,1492,O
in,1492,O
placental,1492,O
diseases,1492,O
.,1492,O
Analysis,1493,O
of,1493,O
the,1493,O
1kb,1493,O
promoter,1493,O
region,1493,O
showed,1493,O
numerous,1493,O
putative,1493,O
transcription,1493,O
factor,1493,O
binding,1493,O
sites,1493,O
",",1493,O
which,1493,O
might,1493,O
be,1493,O
responsible,1493,O
for,1493,O
the,1493,O
ubiquitous,1493,O
PP20/hTPK,1493,B-GENE-Y
expression,1493,O
.,1493,O
This,1494,O
may,1494,O
also,1494,O
be,1494,O
in,1494,O
accordance,1494,O
with,1494,O
the,1494,O
presence,1494,O
of,1494,O
the,1494,O
protein,1494,O
in,1494,O
tissues,1494,O
responsible,1494,O
for,1494,O
the,1494,O
regulation,1494,O
of,1494,O
the,1494,O
exquisite,1494,O
balance,1494,O
between,1494,O
cell,1494,O
division,1494,O
",",1494,O
differentiation,1494,O
and,1494,O
survival,1494,O
.,1494,O
TPK,1495,B-GENE-Y
activity,1495,O
of,1495,O
the,1495,O
purified,1495,O
and,1495,O
recombinant,1495,O
protein,1495,O
was,1495,O
proved,1495,O
by,1495,O
mass,1495,O
spectrometry,1495,O
with,1495,O
electrospray,1495,O
ionization,1495,O
.,1495,O
By,1496,O
Western,1496,O
blot,1496,O
",",1496,O
PP20/hTPK,1496,B-GENE-Y
was,1496,O
found,1496,O
in,1496,O
all,1496,O
human,1496,O
normal,1496,O
and,1496,O
tumorous,1496,O
adult,1496,O
and,1496,O
fetal,1496,O
tissues,1496,O
in,1496,O
nearly,1496,O
equal,1496,O
amounts,1496,O
",",1496,O
but,1496,O
not,1496,O
in,1496,O
sera,1496,O
.,1496,O
By,1497,O
immunohistochemical,1497,O
and,1497,O
immunofluorescent,1497,O
confocal,1497,O
imaging,1497,O
methods,1497,O
",",1497,O
diffuse,1497,O
labelling,1497,O
in,1497,O
the,1497,O
cytoplasm,1497,O
of,1497,O
the,1497,O
syncytiotrophoblasts,1497,O
and,1497,O
weak,1497,O
staining,1497,O
of,1497,O
the,1497,O
trophoblasts,1497,O
were,1497,O
observed,1497,O
",",1497,O
and,1497,O
the,1497,O
amount,1497,O
of,1497,O
PP20/hTPK,1497,B-GENE-Y
decreased,1497,O
from,1497,O
the,1497,O
first,1497,O
trimester,1497,O
to,1497,O
the,1497,O
end,1497,O
of,1497,O
gestation,1497,O
.,1497,O
A,1498,O
3D,1498,O
model,1498,O
of,1498,O
PP20/hTPK,1498,B-GENE-Y
was,1498,O
computed,1498,O
(,1498,O
PDB,1498,O
No,1498,O
.,1498,O
:,1499,O
1OLY,1499,O
),1499,O
by,1499,O
homology,1499,O
modelling,1499,O
.,1499,O
A,1500,O
high,1500,O
degree,1500,O
of,1500,O
structural,1500,O
homology,1500,O
showed,1500,O
that,1500,O
the,1500,O
thiamin,1500,O
binding,1500,O
site,1500,O
was,1500,O
highly,1500,O
similar,1500,O
to,1500,O
that,1500,O
of,1500,O
the,1500,O
mouse,1500,O
enzyme,1500,O
",",1500,O
but,1500,O
highly,1500,O
different,1500,O
from,1500,O
the,1500,O
bacterial,1500,O
ones,1500,O
.,1500,O
Comparison,1501,O
of,1501,O
the,1501,O
catalytic,1501,O
centre,1501,O
sequences,1501,O
revealed,1501,O
differences,1501,O
",",1501,O
raising,1501,O
the,1501,O
possibility,1501,O
of,1501,O
designing,1501,O
new,1501,O
drugs,1501,O
which,1501,O
specifically,1501,O
inhibit,1501,O
bacterial,1501,O
and,1501,O
fungal,1501,O
enzymes,1501,O
without,1501,O
affecting,1501,O
PP20/hTPK,1501,O
and,1501,O
offering,1501,O
the,1501,O
possibility,1501,O
for,1501,O
safe,1501,O
antimicrobial,1501,O
therapy,1501,O
during,1501,O
pregnancy,1501,O
.,1501,O
Safety,1502,O
and,1502,O
tolerability,1502,O
of,1502,O
denufosol,1502,B-CHEMICAL
tetrasodium,1502,I-CHEMICAL
inhalation,1502,O
solution,1502,O
",",1502,O
a,1502,O
novel,1502,O
P2Y2,1502,B-GENE-Y
receptor,1502,I-GENE-Y
agonist,1502,O
:,1502,O
results,1502,O
of,1502,O
a,1502,O
phase,1502,O
1/phase,1502,O
2,1502,O
multicenter,1502,O
study,1502,O
in,1502,O
mild,1502,O
to,1502,O
moderate,1502,O
cystic,1502,O
fibrosis,1502,O
.,1502,O
Denufosol,1503,B-CHEMICAL
tetrasodium,1503,I-CHEMICAL
(,1503,O
INS37217,1503,B-CHEMICAL
),1503,O
is,1503,O
a,1503,O
selective,1503,O
P2Y,1503,B-GENE-Y
(,1503,I-GENE-Y
2,1503,I-GENE-Y
),1503,I-GENE-Y
agonist,1503,O
that,1503,O
stimulates,1503,O
ciliary,1503,O
beat,1503,O
frequency,1503,O
and,1503,O
Cl,1503,B-CHEMICAL
(,1503,I-CHEMICAL
-,1503,I-CHEMICAL
),1503,I-CHEMICAL
secretion,1503,O
in,1503,O
normal,1503,O
and,1503,O
cystic,1503,O
fibrosis,1503,O
(,1503,O
CF,1503,O
),1503,O
airway,1503,O
epithelia,1503,O
",",1503,O
and,1503,O
is,1503,O
being,1503,O
investigated,1503,O
as,1503,O
an,1503,O
inhaled,1503,O
treatment,1503,O
for,1503,O
CF,1503,O
.,1503,O
The,1504,O
Cl,1504,B-CHEMICAL
(,1504,I-CHEMICAL
-,1504,I-CHEMICAL
),1504,I-CHEMICAL
secretory,1504,O
response,1504,O
is,1504,O
mediated,1504,O
via,1504,O
a,1504,O
non-CFTR,1504,O
pathway,1504,O
",",1504,O
and,1504,O
the,1504,O
driving,1504,O
force,1504,O
for,1504,O
Cl,1504,B-CHEMICAL
(,1504,I-CHEMICAL
-,1504,I-CHEMICAL
),1504,I-CHEMICAL
secretion,1504,O
is,1504,O
enhanced,1504,O
by,1504,O
the,1504,O
effect,1504,O
of,1504,O
P2Y,1504,B-GENE-Y
(,1504,I-GENE-Y
2,1504,I-GENE-Y
),1504,I-GENE-Y
activation,1504,O
to,1504,O
also,1504,O
inhibit,1504,O
epithelial,1504,O
Na,1504,B-CHEMICAL
(,1504,I-CHEMICAL
+,1504,I-CHEMICAL
),1504,I-CHEMICAL
transport,1504,O
.,1504,O
Denufosol,1505,B-CHEMICAL
is,1505,O
metabolically,1505,O
more,1505,O
stable,1505,O
and,1505,O
better,1505,O
tolerated,1505,O
",",1505,O
and,1505,O
may,1505,O
enhance,1505,O
mucociliary,1505,O
clearance,1505,O
for,1505,O
a,1505,O
longer,1505,O
period,1505,O
of,1505,O
time,1505,O
than,1505,O
previously,1505,O
investigated,1505,O
P2Y,1505,B-GENE-Y
(,1505,I-GENE-Y
2,1505,I-GENE-Y
),1505,I-GENE-Y
agonists,1505,O
.,1505,O
The,1506,O
goal,1506,O
of,1506,O
this,1506,O
phase,1506,O
1/phase,1506,O
2,1506,O
study,1506,O
was,1506,O
to,1506,O
assess,1506,O
the,1506,O
safety,1506,O
and,1506,O
tolerability,1506,O
of,1506,O
single,1506,O
and,1506,O
repeated,1506,O
doses,1506,O
of,1506,O
aerosolized,1506,O
denufosol,1506,B-CHEMICAL
in,1506,O
subjects,1506,O
with,1506,O
CF,1506,O
.,1506,O
The,1507,O
study,1507,O
was,1507,O
a,1507,O
double-blind,1507,O
",",1507,O
placebo-controlled,1507,O
",",1507,O
multicenter,1507,O
comparison,1507,O
of,1507,O
ascending,1507,O
single,1507,O
doses,1507,O
of,1507,O
denufosol,1507,B-CHEMICAL
(,1507,O
10,1507,O
",",1507,O
20,1507,O
",",1507,O
40,1507,O
",",1507,O
and,1507,O
60,1507,O
mg,1507,O
",",1507,O
administered,1507,O
by,1507,O
inhalation,1507,O
via,1507,O
the,1507,O
Pari,1507,O
LC,1507,O
Star,1507,O
nebulizer,1507,O
),1507,O
vs.,1507,O
placebo,1507,O
(,1507,O
normal,1507,O
saline,1507,O
),1507,O
",",1507,O
followed,1507,O
by,1507,O
a,1507,O
comparison,1507,O
of,1507,O
twice-daily,1507,O
administration,1507,O
of,1507,O
the,1507,O
maximum,1507,O
tolerated,1507,O
dose,1507,O
(,1507,O
MTD,1507,O
),1507,O
of,1507,O
denufosol,1507,B-CHEMICAL
or,1507,O
placebo,1507,O
for,1507,O
5,1507,O
days,1507,O
.,1507,O
Thirty-seven,1508,O
adult,1508,O
(,1508,O
18,1508,O
years,1508,O
of,1508,O
age,1508,O
or,1508,O
older,1508,O
),1508,O
and,1508,O
24,1508,O
pediatric,1508,O
(,1508,O
5-17,1508,O
years,1508,O
of,1508,O
age,1508,O
),1508,O
subjects,1508,O
with,1508,O
CF,1508,O
were,1508,O
evaluated,1508,O
in,1508,O
five,1508,O
cohorts,1508,O
.,1508,O
Subjects,1509,O
were,1509,O
randomized,1509,O
in,1509,O
a,1509,O
3:1,1509,O
ratio,1509,O
to,1509,O
receive,1509,O
either,1509,O
denufosol,1509,B-CHEMICAL
or,1509,O
placebo,1509,O
within,1509,O
each,1509,O
cohort,1509,O
.,1509,O
The,1510,O
percent,1510,O
of,1510,O
subjects,1510,O
experiencing,1510,O
adverse,1510,O
events,1510,O
was,1510,O
similar,1510,O
between,1510,O
the,1510,O
denufosol,1510,B-CHEMICAL
and,1510,O
placebo,1510,O
groups,1510,O
.,1510,O
The,1511,O
most,1511,O
common,1511,O
adverse,1511,O
event,1511,O
in,1511,O
subjects,1511,O
receiving,1511,O
denufosol,1511,B-CHEMICAL
was,1511,O
chest,1511,O
tightness,1511,O
in,1511,O
adult,1511,O
subjects,1511,O
(,1511,O
39,1511,O
%,1511,O
),1511,O
and,1511,O
cough,1511,O
in,1511,O
pediatric,1511,O
subjects,1511,O
(,1511,O
56,1511,O
%,1511,O
),1511,O
.,1511,O
Three,1512,O
(,1512,O
7,1512,O
%,1512,O
),1512,O
subjects,1512,O
receiving,1512,O
denufosol,1512,B-CHEMICAL
and,1512,O
one,1512,O
(,1512,O
7,1512,O
%,1512,O
),1512,O
subject,1512,O
receiving,1512,O
placebo,1512,O
experienced,1512,O
a,1512,O
serious,1512,O
adverse,1512,O
event,1512,O
.,1512,O
Forced,1513,O
expiratory,1513,O
volume,1513,O
in,1513,O
1,1513,O
sec,1513,O
(,1513,O
FEV,1513,O
(,1513,O
1,1513,O
),1513,O
),1513,O
profiles,1513,O
following,1513,O
dosing,1513,O
were,1513,O
similar,1513,O
across,1513,O
treatment,1513,O
groups,1513,O
",",1513,O
with,1513,O
some,1513,O
acute,1513,O
",",1513,O
reversible,1513,O
decline,1513,O
seen,1513,O
in,1513,O
both,1513,O
groups,1513,O
",",1513,O
most,1513,O
notably,1513,O
in,1513,O
subjects,1513,O
with,1513,O
lower,1513,O
lung,1513,O
function,1513,O
at,1513,O
baseline,1513,O
.,1513,O
In,1514,O
conclusion,1514,O
",",1514,O
doses,1514,O
up,1514,O
to,1514,O
60,1514,O
mg,1514,O
of,1514,O
denufosol,1514,B-CHEMICAL
inhalation,1514,O
solution,1514,O
were,1514,O
well-tolerated,1514,O
in,1514,O
most,1514,O
subjects,1514,O
.,1514,O
Some,1515,O
intolerability,1515,O
was,1515,O
noted,1515,O
among,1515,O
subjects,1515,O
with,1515,O
lower,1515,O
baseline,1515,O
lung,1515,O
function,1515,O
.,1515,O
Based,1516,O
on,1516,O
the,1516,O
results,1516,O
of,1516,O
this,1516,O
phase,1516,O
1/phase,1516,O
2,1516,O
study,1516,O
",",1516,O
the,1516,O
Therapeutics,1516,O
Development,1516,O
Network,1516,O
(,1516,O
TDN,1516,O
),1516,O
of,1516,O
the,1516,O
Cystic,1516,O
Fibrosis,1516,O
Foundation,1516,O
(,1516,O
CFF,1516,O
),1516,O
and,1516,O
Inspire,1516,O
Pharmaceuticals,1516,O
",",1516,O
Inc.,1516,O
",",1516,O
recently,1516,O
completed,1516,O
a,1516,O
multicenter,1516,O
",",1516,O
28-day,1516,O
",",1516,O
phase,1516,O
2,1516,O
safety,1516,O
and,1516,O
efficacy,1516,O
clinical,1516,O
trial,1516,O
of,1516,O
denufosol,1516,B-CHEMICAL
inhalation,1516,O
solution,1516,O
in,1516,O
CF,1516,O
subjects,1516,O
with,1516,O
mild,1516,O
lung,1516,O
disease,1516,O
.,1516,O
The,1517,O
dextromethorphan,1517,B-CHEMICAL
analog,1517,O
dimemorfan,1517,B-CHEMICAL
attenuates,1517,O
kainate-induced,1517,O
seizures,1517,O
via,1517,O
sigma1,1517,B-GENE-Y
receptor,1517,I-GENE-Y
activation,1517,O
:,1517,O
comparison,1517,O
with,1517,O
the,1517,O
effects,1517,O
of,1517,O
dextromethorphan,1517,B-CHEMICAL
.,1517,O
In,1518,O
a,1518,O
previous,1518,O
study,1518,O
",",1518,O
we,1518,O
demonstrated,1518,O
that,1518,O
a,1518,O
dextromethorphan,1518,B-CHEMICAL
analog,1518,O
",",1518,O
dimemorfan,1518,B-CHEMICAL
",",1518,O
has,1518,O
neuroprotective,1518,O
effects,1518,O
.,1518,O
Dextromethorphan,1519,B-CHEMICAL
and,1519,O
dimemorfan,1519,B-CHEMICAL
are,1519,O
high-affinity,1519,O
ligands,1519,O
at,1519,O
sigma1,1519,B-GENE-Y
receptors,1519,I-GENE-Y
.,1519,O
Dextromethorphan,1520,B-CHEMICAL
has,1520,O
moderate,1520,O
affinities,1520,O
for,1520,O
phencyclidine,1520,B-CHEMICAL
sites,1520,O
",",1520,O
while,1520,O
dimemorfan,1520,B-CHEMICAL
has,1520,O
very,1520,O
low,1520,O
affinities,1520,O
for,1520,O
such,1520,O
sites,1520,O
",",1520,O
suggesting,1520,O
that,1520,O
these,1520,O
sites,1520,O
are,1520,O
not,1520,O
essential,1520,O
for,1520,O
the,1520,O
anticonvulsant,1520,O
actions,1520,O
of,1520,O
dimemorfan,1520,B-CHEMICAL
.,1520,O
Kainate,1521,B-CHEMICAL
(,1521,O
KA,1521,B-CHEMICAL
),1521,O
administration,1521,O
(,1521,O
10,1521,O
mg,1521,O
kg,1521,O
(,1521,O
-1,1521,O
),1521,O
",",1521,O
i.p,1521,O
.,1521,O
),1521,O
produced,1522,O
robust,1522,O
convulsions,1522,O
lasting,1522,O
4-6,1522,O
h,1522,O
in,1522,O
rats,1522,O
.,1522,O
Pre-treatment,1523,O
with,1523,O
dimemorfan,1523,B-CHEMICAL
(,1523,O
12,1523,O
or,1523,O
24,1523,O
mg,1523,O
kg,1523,O
(,1523,O
-1,1523,O
),1523,O
),1523,O
reduced,1523,O
seizures,1523,O
in,1523,O
a,1523,O
dose-dependent,1523,O
manner,1523,O
.,1523,O
Dimemorfan,1524,B-CHEMICAL
pre-treatment,1524,O
also,1524,O
attenuated,1524,O
the,1524,O
KA-induced,1524,B-CHEMICAL
increases,1524,O
in,1524,O
c-fos/c-jun,1524,B-GENE-Y
expression,1524,O
",",1524,O
activator,1524,B-GENE-Y
protein,1524,I-GENE-Y
(,1524,I-GENE-Y
AP,1524,I-GENE-Y
),1524,I-GENE-Y
-1,1524,I-GENE-Y
DNA-binding,1524,O
activity,1524,O
",",1524,O
and,1524,O
loss,1524,O
of,1524,O
cells,1524,O
in,1524,O
the,1524,O
CA1,1524,O
and,1524,O
CA3,1524,O
fields,1524,O
of,1524,O
the,1524,O
hippocampus,1524,O
.,1524,O
These,1525,O
effects,1525,O
of,1525,O
dimemorfan,1525,B-CHEMICAL
were,1525,O
comparable,1525,O
to,1525,O
those,1525,O
of,1525,O
dextromethorphan,1525,B-CHEMICAL
.,1525,O
The,1526,O
anticonvulsant,1526,O
action,1526,O
of,1526,O
dextromethorphan,1526,B-CHEMICAL
or,1526,O
dimemorfan,1526,B-CHEMICAL
was,1526,O
significantly,1526,O
counteracted,1526,O
by,1526,O
a,1526,O
selective,1526,O
sigma1,1526,B-GENE-Y
receptor,1526,I-GENE-Y
antagonist,1526,O
BD,1526,B-CHEMICAL
1047,1526,I-CHEMICAL
",",1526,O
suggesting,1526,O
that,1526,O
the,1526,O
anticonvulsant,1526,O
action,1526,O
of,1526,O
dextromethorphan,1526,B-CHEMICAL
or,1526,O
dimemorfan,1526,B-CHEMICAL
is,1526,O
",",1526,O
at,1526,O
least,1526,O
in,1526,O
part,1526,O
",",1526,O
related,1526,O
to,1526,O
sigma1,1526,B-GENE-Y
receptor-activated,1526,O
modulation,1526,O
of,1526,O
AP-1,1526,B-GENE-Y
transcription,1526,O
factors,1526,O
.,1526,O
We,1527,O
asked,1527,O
whether,1527,O
dimemorfan,1527,B-CHEMICAL
produces,1527,O
the,1527,O
behavioral,1527,O
side,1527,O
effects,1527,O
seen,1527,O
with,1527,O
dextromethorphan,1527,B-CHEMICAL
or,1527,O
dextrorphan,1527,B-CHEMICAL
(,1527,O
a,1527,O
phencyclidine-like,1527,B-CHEMICAL
metabolite,1527,O
of,1527,O
dextromethorphan,1527,B-CHEMICAL
),1527,O
.,1527,O
Conditioned,1528,O
place,1528,O
preference,1528,O
and,1528,O
circling,1528,O
behaviors,1528,O
were,1528,O
significantly,1528,O
increased,1528,O
in,1528,O
mice,1528,O
treated,1528,O
with,1528,O
phencyclidine,1528,B-CHEMICAL
",",1528,O
dextrorphan,1528,B-CHEMICAL
or,1528,O
dextromethorphan,1528,B-CHEMICAL
",",1528,O
while,1528,O
mice,1528,O
treated,1528,O
with,1528,O
dimemorfan,1528,O
showed,1528,O
no,1528,O
behavioral,1528,O
side,1528,O
effects,1528,O
.,1528,O
Our,1529,O
results,1529,O
suggest,1529,O
that,1529,O
dimemorfan,1529,B-CHEMICAL
is,1529,O
equipotent,1529,O
to,1529,O
dextromethorphan,1529,B-CHEMICAL
in,1529,O
preventing,1529,O
KA-induced,1529,B-CHEMICAL
seizures,1529,O
",",1529,O
while,1529,O
it,1529,O
may,1529,O
lack,1529,O
behavioral,1529,O
effects,1529,O
",",1529,O
such,1529,O
as,1529,O
psychotomimetic,1529,O
reactions,1529,O
.,1529,O
Binding,1530,O
domains,1530,O
of,1530,O
the,1530,O
oxytocin,1530,B-GENE-Y
receptor,1530,I-GENE-Y
for,1530,O
the,1530,O
selective,1530,O
oxytocin,1530,B-GENE-Y
receptor,1530,I-GENE-Y
antagonist,1530,O
barusiban,1530,B-CHEMICAL
in,1530,O
comparison,1530,O
to,1530,O
the,1530,O
agonists,1530,O
oxytocin,1530,B-GENE-Y
and,1530,O
carbetocin,1530,B-CHEMICAL
.,1530,O
We,1531,O
have,1531,O
analyzed,1531,O
binding,1531,O
domains,1531,O
of,1531,O
the,1531,O
oxytocin,1531,B-GENE-Y
receptor,1531,I-GENE-Y
for,1531,O
barusiban,1531,B-CHEMICAL
",",1531,O
a,1531,O
highly,1531,O
selective,1531,O
oxytocin,1531,B-GENE-Y
receptor,1531,I-GENE-Y
antagonist,1531,O
",",1531,O
in,1531,O
comparison,1531,O
to,1531,O
the,1531,O
combined,1531,O
vasopressin,1531,B-GENE-N
V1A/oxytocin,1531,I-GENE-N
receptor,1531,I-GENE-N
antagonist,1531,O
atosiban,1531,B-CHEMICAL
and,1531,O
the,1531,O
agonists,1531,O
oxytocin,1531,B-GENE-Y
and,1531,O
carbetocin,1531,B-CHEMICAL
.,1531,O
For,1532,O
this,1532,O
purpose,1532,O
",",1532,O
chimeric,1532,O
'gain-in,1532,O
function,1532,O
',1532,O
oxytocin/vasopressin,1532,B-GENE-N
V2,1532,I-GENE-N
receptors,1532,I-GENE-N
were,1532,O
expressed,1532,O
in,1532,O
COS-7,1532,O
cells,1532,O
.,1532,O
These,1533,O
recombinant,1533,O
receptors,1533,O
have,1533,O
been,1533,O
produced,1533,O
by,1533,O
transfer,1533,O
of,1533,O
domains,1533,O
from,1533,O
the,1533,O
oxytocin,1533,B-GENE-Y
receptor,1533,I-GENE-Y
into,1533,O
the,1533,O
related,1533,O
vasopressin,1533,B-GENE-Y
V2,1533,I-GENE-Y
receptor,1533,I-GENE-Y
and,1533,O
have,1533,O
already,1533,O
been,1533,O
successfully,1533,O
employed,1533,O
for,1533,O
the,1533,O
identification,1533,O
of,1533,O
ligand,1533,O
binding,1533,O
domains,1533,O
at,1533,O
the,1533,O
oxytocin,1533,B-GENE-Y
receptor,1533,I-GENE-Y
(,1533,O
Postina,1533,O
",",1533,O
R.,1533,O
",",1533,O
Kojro,1533,O
",",1533,O
E.,1533,O
",",1533,O
Fahrenholz,1533,O
",",1533,O
F.,1533,O
",",1533,O
1996,1533,O
.,1533,O
Separate,1534,O
agonist,1534,O
and,1534,O
peptide,1534,O
antagonist,1534,O
binding,1534,O
sites,1534,O
of,1534,O
the,1534,O
oxytocin,1534,B-GENE-Y
receptor,1534,I-GENE-Y
defined,1534,O
by,1534,O
their,1534,O
transfer,1534,O
into,1534,O
the,1534,O
V2,1534,B-GENE-Y
vasopressin,1534,I-GENE-Y
receptor,1534,I-GENE-Y
.,1534,O
J.,1535,O
Biol,1535,O
.,1535,O
Chem,1536,O
.,1536,O
271,1537,O
",",1537,O
31593-31601,1537,O
),1537,O
.,1537,O
In,1538,O
displacement,1538,O
studies,1538,O
with,1538,O
10,1538,O
chimeric,1538,O
receptor,1538,O
constructs,1538,O
",",1538,O
the,1538,O
binding,1538,O
profile,1538,O
of,1538,O
barusiban,1538,B-CHEMICAL
was,1538,O
compared,1538,O
with,1538,O
the,1538,O
binding,1538,O
profiles,1538,O
of,1538,O
the,1538,O
ligands,1538,O
oxytocin,1538,B-GENE-Y
",",1538,O
[,1538,B-CHEMICAL
Arg8,1538,I-CHEMICAL
],1538,I-CHEMICAL
vasopressin,1538,B-GENE-Y
",",1538,O
carbetocin,1538,B-CHEMICAL
",",1538,O
and,1538,O
atosiban,1538,B-CHEMICAL
.,1538,O
The,1539,O
binding,1539,O
profiles,1539,O
for,1539,O
the,1539,O
agonists,1539,O
oxytocin,1539,B-GENE-Y
and,1539,O
carbetocin,1539,B-CHEMICAL
were,1539,O
found,1539,O
to,1539,O
be,1539,O
similar,1539,O
.,1539,O
For,1540,O
both,1540,O
agonists,1540,O
",",1540,O
important,1540,O
binding,1540,O
domains,1540,O
were,1540,O
the,1540,O
extracellular,1540,O
N-terminus,1540,B-CHEMICAL
(,1540,O
=E1,1540,O
),1540,O
and,1540,O
the,1540,O
extracellular,1540,O
loops,1540,O
E2,1540,O
and,1540,O
E3,1540,O
from,1540,O
the,1540,O
oxytocin,1540,B-CHEMICAL
receptor,1540,I-GENE-Y
.,1540,O
For,1541,O
the,1541,O
vasopressin,1541,B-CHEMICAL
V1A/oxytocin,1541,I-GENE-N
receptor,1541,I-GENE-N
antagonist,1541,O
atosiban,1541,B-CHEMICAL
",",1541,O
none,1541,O
of,1541,O
the,1541,O
receptor,1541,O
constructs,1541,O
were,1541,O
able,1541,O
to,1541,O
provide,1541,O
a,1541,O
binding,1541,O
with,1541,O
higher,1541,O
affinity,1541,O
than,1541,O
the,1541,O
starting,1541,O
vasopressin,1541,B-GENE-Y
V2,1541,I-GENE-Y
receptor,1541,I-GENE-Y
.,1541,O
In,1542,O
contrast,1542,O
",",1542,O
the,1542,O
binding,1542,O
of,1542,O
barusiban,1542,B-CHEMICAL
was,1542,O
significantly,1542,O
improved,1542,O
when,1542,O
the,1542,O
transmembrane,1542,O
domains,1542,O
1,1542,O
and,1542,O
2,1542,O
were,1542,O
transferred,1542,O
from,1542,O
the,1542,O
oxytocin,1542,B-CHEMICAL
receptor,1542,O
to,1542,O
the,1542,O
vasopressin,1542,B-GENE-Y
V2,1542,I-GENE-Y
receptor,1542,I-GENE-Y
.,1542,O
The,1543,O
binding,1543,O
domain,1543,O
of,1543,O
barusiban,1543,B-CHEMICAL
differs,1543,O
from,1543,O
the,1543,O
binding,1543,O
domain,1543,O
of,1543,O
the,1543,O
agonists,1543,O
and,1543,O
the,1543,O
nonselective,1543,O
oxytocin,1543,B-GENE-Y
receptor,1543,I-GENE-Y
antagonist,1543,O
d,1543,B-CHEMICAL
(,1543,I-CHEMICAL
CH2,1543,I-CHEMICAL
),1543,I-CHEMICAL
5,1543,I-CHEMICAL
[,1543,I-CHEMICAL
Tyr-,1543,I-CHEMICAL
(,1543,I-CHEMICAL
Me,1543,I-CHEMICAL
),1543,I-CHEMICAL
2,1543,I-CHEMICAL
",",1543,I-CHEMICAL
Thr4,1543,I-CHEMICAL
",",1543,I-CHEMICAL
Orn8,1543,I-CHEMICAL
",",1543,I-CHEMICAL
Tyr9,1543,I-CHEMICAL
],1543,I-CHEMICAL
vasotocin,1543,B-GENE-N
that,1543,O
has,1543,O
been,1543,O
used,1543,O
in,1543,O
previous,1543,O
studies,1543,O
.,1543,O
Overall,1544,O
",",1544,O
the,1544,O
data,1544,O
supported,1544,O
the,1544,O
concept,1544,O
of,1544,O
a,1544,O
central,1544,O
pocket,1544,O
site,1544,O
within,1544,O
the,1544,O
oxytocin,1544,B-GENE-Y
receptor,1544,I-GENE-Y
.,1544,O
Neonatal,1545,O
epileptic,1545,O
encephalopathy,1545,O
caused,1545,O
by,1545,O
mutations,1545,O
in,1545,O
the,1545,O
PNPO,1545,B-GENE-Y
gene,1545,O
encoding,1545,O
pyridox,1545,B-GENE-Y
(,1545,I-GENE-Y
am,1545,I-GENE-Y
),1545,I-GENE-Y
ine,1545,I-GENE-Y
5'-phosphate,1545,I-GENE-Y
oxidase,1545,I-GENE-Y
.,1545,O
In,1546,O
the,1546,O
mouse,1546,O
",",1546,O
neurotransmitter,1546,O
metabolism,1546,O
can,1546,O
be,1546,O
regulated,1546,O
by,1546,O
modulation,1546,O
of,1546,O
the,1546,O
synthesis,1546,O
of,1546,O
pyridoxal,1546,B-CHEMICAL
5'-phosphate,1546,I-CHEMICAL
and,1546,O
failure,1546,O
to,1546,O
maintain,1546,O
pyridoxal,1546,B-CHEMICAL
phosphate,1546,I-CHEMICAL
(,1546,O
PLP,1546,B-CHEMICAL
),1546,O
levels,1546,O
results,1546,O
in,1546,O
epilepsy,1546,O
.,1546,O
This,1547,O
study,1547,O
of,1547,O
five,1547,O
patients,1547,O
with,1547,O
neonatal,1547,O
epileptic,1547,O
encephalopathy,1547,O
suggests,1547,O
that,1547,O
the,1547,O
same,1547,O
is,1547,O
true,1547,O
in,1547,O
man,1547,O
.,1547,O
Cerebrospinal,1548,O
fluid,1548,O
and,1548,O
urine,1548,O
analyses,1548,O
indicated,1548,O
reduced,1548,O
activity,1548,O
of,1548,O
aromatic,1548,B-CHEMICAL
L-amino,1548,I-CHEMICAL
acid,1548,I-CHEMICAL
decarboxylase,1548,I-GENE-Y
and,1548,O
other,1548,O
PLP-dependent,1548,B-CHEMICAL
enzymes,1548,O
.,1548,O
Seizures,1549,O
ceased,1549,O
with,1549,O
the,1549,O
administration,1549,O
of,1549,O
PLP,1549,B-CHEMICAL
",",1549,O
having,1549,O
been,1549,O
resistant,1549,O
to,1549,O
treatment,1549,O
with,1549,O
pyridoxine,1549,O
",",1549,O
suggesting,1549,O
a,1549,O
defect,1549,O
of,1549,O
pyridox,1549,B-CHEMICAL
(,1549,I-CHEMICAL
am,1549,I-CHEMICAL
),1549,I-CHEMICAL
ine,1549,I-CHEMICAL
5'-phosphate,1549,I-CHEMICAL
oxidase,1549,I-GENE-Y
(,1549,O
PNPO,1549,B-GENE-Y
),1549,O
.,1549,O
Sequencing,1550,O
of,1550,O
the,1550,O
PNPO,1550,B-GENE-Y
gene,1550,O
identified,1550,O
homozygous,1550,O
missense,1550,O
",",1550,O
splice,1550,O
site,1550,O
and,1550,O
stop,1550,O
codon,1550,O
mutations,1550,O
.,1550,O
Expression,1551,O
studies,1551,O
in,1551,O
Chinese,1551,O
hamster,1551,O
ovary,1551,O
cells,1551,O
showed,1551,O
that,1551,O
the,1551,O
splice,1551,O
site,1551,O
(,1551,O
IVS3-1g,1551,O
>,1551,I-GENE-N
a,1551,I-GENE-N
),1551,O
and,1551,O
stop,1551,O
codon,1551,O
(,1551,O
X262Q,1551,O
),1551,O
mutations,1551,O
were,1551,O
null,1551,O
activity,1551,O
mutations,1551,O
and,1551,O
that,1551,O
the,1551,O
missense,1551,O
mutation,1551,O
(,1551,O
R229W,1551,B-GENE-N
),1551,O
markedly,1551,O
reduced,1551,O
pyridox,1551,B-CHEMICAL
(,1551,I-CHEMICAL
am,1551,I-CHEMICAL
),1551,I-CHEMICAL
ine,1551,I-CHEMICAL
phosphate,1551,I-CHEMICAL
oxidase,1551,I-GENE-Y
activity,1551,O
.,1551,O
Maintenance,1552,O
of,1552,O
optimal,1552,O
PLP,1552,B-CHEMICAL
levels,1552,O
in,1552,O
the,1552,O
brain,1552,O
may,1552,O
be,1552,O
important,1552,O
in,1552,O
many,1552,O
neurological,1552,O
disorders,1552,O
in,1552,O
which,1552,O
neurotransmitter,1552,O
metabolism,1552,O
is,1552,O
disturbed,1552,O
(,1552,O
either,1552,O
as,1552,O
a,1552,O
primary,1552,O
or,1552,O
as,1552,O
a,1552,O
secondary,1552,O
phenomenon,1552,O
),1552,O
.,1552,O
Effect,1553,O
of,1553,O
5-azacytidine,1553,B-CHEMICAL
and,1553,O
procainamide,1553,B-CHEMICAL
on,1553,O
CD3-zeta,1553,B-GENE-Y
chain,1553,I-GENE-Y
expression,1553,O
in,1553,O
Jurkat,1553,O
T,1553,O
cells,1553,O
.,1553,O
It,1554,O
has,1554,O
been,1554,O
observed,1554,O
that,1554,O
decrease,1554,O
of,1554,O
DNA,1554,B-GENE-Y
methyltransferase,1554,I-GENE-Y
1,1554,I-GENE-Y
(,1554,O
DNMT1,1554,B-GENE-Y
),1554,O
activity,1554,O
is,1554,O
associated,1554,O
with,1554,O
low,1554,O
content,1554,O
of,1554,O
the,1554,O
CD3-zeta,1554,B-GENE-Y
(,1554,I-GENE-Y
zeta,1554,I-GENE-Y
),1554,I-GENE-Y
chain,1554,I-GENE-Y
in,1554,O
T,1554,B-GENE-N
cell,1554,I-GENE-N
receptor,1554,I-GENE-N
(,1554,O
TCR,1554,B-GENE-N
),1554,O
/CD3,1554,O
complex,1554,O
of,1554,O
T,1554,O
cells,1554,O
in,1554,O
systemic,1554,O
lupus,1554,O
erythematosus,1554,O
(,1554,O
SLE,1554,O
),1554,O
patients,1554,O
.,1554,O
The,1555,O
CD3-zeta,1555,B-GENE-Y
chain,1555,I-GENE-Y
plays,1555,O
a,1555,O
pivotal,1555,O
role,1555,O
in,1555,O
intracellular,1555,O
signal,1555,O
transmission,1555,O
between,1555,O
TCR/CD3,1555,B-GENE-N
complex,1555,O
and,1555,O
nuclei,1555,O
.,1555,O
The,1556,O
compounds,1556,O
5'-azacytidine,1556,B-CHEMICAL
(,1556,O
AZC,1556,B-CHEMICAL
),1556,O
and,1556,O
procainamide,1556,B-CHEMICAL
(,1556,O
PCA,1556,B-CHEMICAL
),1556,O
belong,1556,O
to,1556,O
inhibitors,1556,O
of,1556,O
DNMT1,1556,B-GENE-Y
",",1556,O
whose,1556,O
low,1556,O
activity,1556,O
correlates,1556,O
with,1556,O
increase,1556,O
in,1556,O
transcription,1556,O
of,1556,O
various,1556,O
genes,1556,O
.,1556,O
Using,1557,O
the,1557,O
reverse-transcription,1557,O
and,1557,O
real-time,1557,O
quantitative,1557,O
PCR,1557,O
(,1557,O
RQ-PCR,1557,O
),1557,O
analysis,1557,O
",",1557,O
we,1557,O
indicated,1557,O
that,1557,O
AZC,1557,B-CHEMICAL
and,1557,O
PCA,1557,B-CHEMICAL
did,1557,O
not,1557,O
profoundly,1557,O
affect,1557,O
on,1557,O
CD3-zeta,1557,B-GENE-Y
chain,1557,I-GENE-Y
transcription,1557,O
in,1557,O
Jurkat,1557,O
T,1557,O
leukemia,1557,O
cells,1557,O
clone,1557,O
E6-1,1557,O
.,1557,O
However,1558,O
",",1558,O
the,1558,O
flowcytometric,1558,O
analysis,1558,O
revealed,1558,O
that,1558,O
AZC,1558,B-CHEMICAL
and,1558,O
PCA,1558,B-CHEMICAL
decreased,1558,O
intracellular,1558,O
contents,1558,O
of,1558,O
CD3-zeta,1558,B-GENE-Y
chain,1558,I-GENE-Y
in,1558,O
these,1558,O
cells,1558,O
in,1558,O
dose,1558,O
dependent,1558,O
manner,1558,O
.,1558,O
Our,1559,O
results,1559,O
suggest,1559,O
that,1559,O
decrease,1559,O
of,1559,O
DNMT1,1559,B-GENE-Y
activity,1559,O
may,1559,O
alter,1559,O
intracellular,1559,O
signal,1559,O
transmission,1559,O
without,1559,O
effect,1559,O
on,1559,O
transcription,1559,O
level,1559,O
of,1559,O
CD3-zeta,1559,B-GENE-Y
chain,1559,I-GENE-Y
.,1559,O
Changes,1560,O
in,1560,O
gene,1560,O
expression,1560,O
associated,1560,O
with,1560,O
loss,1560,O
of,1560,O
function,1560,O
of,1560,O
the,1560,O
NSDHL,1560,B-GENE-Y
sterol,1560,B-GENE-N
dehydrogenase,1560,I-GENE-N
in,1560,O
mouse,1560,O
embryonic,1560,O
fibroblasts,1560,O
.,1560,O
Seven,1561,O
human,1561,O
disorders,1561,O
of,1561,O
postsqualene,1561,O
cholesterol,1561,B-CHEMICAL
biosynthesis,1561,O
have,1561,O
been,1561,O
described,1561,O
.,1561,O
One,1562,O
of,1562,O
these,1562,O
",",1562,O
congenital,1562,O
hemidysplasia,1562,O
with,1562,O
ichthyosiform,1562,O
nevus,1562,O
and,1562,O
limb,1562,O
defects,1562,O
(,1562,O
CHILD,1562,O
),1562,O
syndrome,1562,O
",",1562,O
results,1562,O
from,1562,O
mutations,1562,O
in,1562,O
the,1562,O
X-linked,1562,O
gene,1562,O
NADH,1562,B-CHEMICAL
sterol,1562,B-CHEMICAL
dehydrogenase-like,1562,I-GENE-Y
(,1562,O
NSDHL,1562,B-GENE-Y
),1562,O
encoding,1562,O
a,1562,O
sterol,1562,B-CHEMICAL
dehydrogenase,1562,I-GENE-N
.,1562,O
A,1563,O
series,1563,O
of,1563,O
mutant,1563,O
alleles,1563,O
of,1563,O
the,1563,O
murine,1563,O
Nsdhl,1563,B-GENE-Y
gene,1563,O
are,1563,O
carried,1563,O
by,1563,O
bare,1563,O
patches,1563,O
(,1563,O
Bpa,1563,O
),1563,O
mice,1563,O
",",1563,O
with,1563,O
Bpa,1563,O
(,1563,O
1H,1563,O
),1563,O
representing,1563,O
a,1563,O
null,1563,O
allele,1563,O
.,1563,O
Heterozygous,1564,O
Bpa,1564,O
(,1564,O
1H,1564,O
),1564,O
females,1564,O
display,1564,O
skin,1564,O
and,1564,O
skeletal,1564,O
abnormalities,1564,O
in,1564,O
a,1564,O
distribution,1564,O
reflecting,1564,O
random,1564,O
X,1564,O
inactivation,1564,O
",",1564,O
whereas,1564,O
hemizygous,1564,O
male,1564,O
embryos,1564,O
die,1564,O
before,1564,O
embryonic,1564,O
day,1564,O
10.5,1564,O
.,1564,O
To,1565,O
investigate,1565,O
the,1565,O
molecular,1565,O
basis,1565,O
of,1565,O
defects,1565,O
associated,1565,O
with,1565,O
perturbations,1565,O
in,1565,O
cholesterol,1565,B-CHEMICAL
biosynthesis,1565,O
",",1565,O
microarray,1565,O
analysis,1565,O
was,1565,O
performed,1565,O
comparing,1565,O
gene,1565,O
expression,1565,O
in,1565,O
embryonic,1565,O
fibroblasts,1565,O
expressing,1565,O
the,1565,O
Bpa,1565,O
(,1565,O
1H,1565,O
),1565,O
allele,1565,O
versus,1565,O
wild-type,1565,O
(,1565,O
wt,1565,O
),1565,O
cells,1565,O
.,1565,O
Labeled,1566,O
cDNAs,1566,O
from,1566,O
cells,1566,O
grown,1566,O
in,1566,O
normal,1566,O
serum,1566,O
or,1566,O
lipid-depleted,1566,O
serum,1566,O
(,1566,O
LDS,1566,O
),1566,O
were,1566,O
hybridized,1566,O
to,1566,O
microarrays,1566,O
containing,1566,O
"22,000",1566,O
mouse,1566,O
genes,1566,O
.,1566,O
Among,1567,O
44,1567,O
genes,1567,O
that,1567,O
showed,1567,O
higher,1567,O
expression,1567,O
in,1567,O
the,1567,O
Bpa,1567,O
(,1567,O
1H,1567,O
),1567,O
versus,1567,O
wt,1567,O
cells,1567,O
grown,1567,O
in,1567,O
LDS,1567,O
",",1567,O
11,1567,O
function,1567,O
in,1567,O
cholesterol,1567,B-CHEMICAL
biosynthesis,1567,O
",",1567,O
7,1567,O
are,1567,O
involved,1567,O
in,1567,O
fatty,1567,B-CHEMICAL
acid,1567,I-CHEMICAL
synthesis,1567,O
",",1567,O
3,1567,O
(,1567,O
Srebp2,1567,B-GENE-Y
",",1567,O
Insig1,1567,B-GENE-Y
",",1567,O
and,1567,O
Orf11,1567,B-GENE-N
),1567,O
encode,1567,O
sterol-regulatory,1567,B-CHEMICAL
proteins,1567,O
",",1567,O
and,1567,O
2,1567,O
(,1567,O
Ldlr,1567,B-GENE-Y
and,1567,O
StarD4,1567,B-GENE-Y
),1567,O
are,1567,O
lipid,1567,O
transporters,1567,O
.,1567,O
Of,1568,O
the,1568,O
21,1568,O
remaining,1568,O
genes,1568,O
",",1568,O
16,1568,O
are,1568,O
known,1568,O
genes,1568,O
",",1568,O
some,1568,O
of,1568,O
which,1568,O
have,1568,O
been,1568,O
implicated,1568,O
previously,1568,O
in,1568,O
cholesterol,1568,B-CHEMICAL
homeostasis,1568,O
or,1568,O
lipid-mediated,1568,O
signaling,1568,O
",",1568,O
and,1568,O
5,1568,O
are,1568,O
uncharacterized,1568,O
cDNA,1568,O
clones,1568,O
.,1568,O
Rapid,1569,O
quantitation,1569,O
of,1569,O
plasma,1569,O
2'-deoxyuridine,1569,B-CHEMICAL
by,1569,O
high-performance,1569,O
liquid,1569,O
chromatography/atmospheric,1569,O
pressure,1569,O
chemical,1569,O
ionization,1569,O
mass,1569,O
spectrometry,1569,O
and,1569,O
its,1569,O
application,1569,O
to,1569,O
pharmacodynamic,1569,O
studies,1569,O
in,1569,O
cancer,1569,O
patients,1569,O
.,1569,O
A,1570,O
novel,1570,O
method,1570,O
employing,1570,O
high-performance,1570,O
liquid,1570,O
chromatograph-mass,1570,O
spectrometry,1570,O
(,1570,O
LC-MS,1570,O
),1570,O
has,1570,O
been,1570,O
developed,1570,O
and,1570,O
validated,1570,O
for,1570,O
the,1570,O
quantitation,1570,O
of,1570,O
plasma,1570,O
2'-deoxyuridine,1570,B-CHEMICAL
(,1570,O
UdR,1570,B-CHEMICAL
),1570,O
.,1570,O
It,1571,O
involves,1571,O
a,1571,O
plasma,1571,O
clean-up,1571,O
step,1571,O
with,1571,O
strong,1571,O
anion-exchange,1571,O
solid-phase,1571,O
extraction,1571,O
(,1571,O
SAX-SPE,1571,O
),1571,O
followed,1571,O
by,1571,O
HPLC,1571,O
separation,1571,O
and,1571,O
atmospheric,1571,O
pressure,1571,O
chemical,1571,O
ionization,1571,O
mass,1571,O
spectrometry,1571,O
detection,1571,O
(,1571,O
APCI-MS,1571,O
),1571,O
in,1571,O
a,1571,O
selected-ion,1571,O
monitoring,1571,O
(,1571,O
SIM,1571,O
),1571,O
mode,1571,O
.,1571,O
The,1572,O
ionization,1572,O
conditions,1572,O
were,1572,O
optimised,1572,O
in,1572,O
negative,1572,O
ion,1572,O
mode,1572,O
to,1572,O
give,1572,O
the,1572,O
best,1572,O
intensity,1572,O
of,1572,O
the,1572,O
dominant,1572,O
formate,1572,B-CHEMICAL
adduct,1572,O
[,1572,O
M+HCOO,1572,O
],1572,O
-,1572,O
at,1572,O
m/z,1572,O
273,1572,O
.,1572,O
Retention,1573,O
times,1573,O
were,1573,O
7.5,1573,O
and,1573,O
12.5,1573,O
min,1573,O
for,1573,O
2'-deoxyuridine,1573,B-CHEMICAL
and,1573,O
5-iodo-2'-deoxyuridine,1573,B-CHEMICAL
",",1573,O
an,1573,O
iodinated,1573,O
analogue,1573,O
internal,1573,O
standard,1573,O
(,1573,O
IS,1573,O
),1573,O
",",1573,O
respectively,1573,O
.,1573,O
Peak,1574,O
area,1574,O
ratios,1574,O
of,1574,O
2'-deoxyuridine,1574,B-CHEMICAL
to,1574,O
IS,1574,O
were,1574,O
used,1574,O
for,1574,O
regression,1574,O
analysis,1574,O
of,1574,O
the,1574,O
calibration,1574,O
curve,1574,O
.,1574,O
The,1575,O
latter,1575,O
was,1575,O
linear,1575,O
from,1575,O
5,1575,O
to,1575,O
400,1575,O
nmol/l,1575,O
using,1575,O
1,1575,O
ml,1575,O
sample,1575,O
volume,1575,O
of,1575,O
plasma,1575,O
.,1575,O
The,1576,O
average,1576,O
recovery,1576,O
was,1576,O
81.5,1576,O
%,1576,O
and,1576,O
78.6,1576,O
%,1576,O
for,1576,O
2'-deoxyuridine,1576,B-CHEMICAL
and,1576,O
5-iodo-deoxyuridine,1576,B-CHEMICAL
",",1576,O
respectively,1576,O
.,1576,O
The,1577,O
method,1577,O
provides,1577,O
sufficient,1577,O
sensitivity,1577,O
",",1577,O
precision,1577,O
",",1577,O
accuracy,1577,O
and,1577,O
selectivity,1577,O
for,1577,O
routine,1577,O
analysis,1577,O
of,1577,O
human,1577,O
plasma,1577,O
2'-deoxyuridine,1577,B-CHEMICAL
concentration,1577,O
with,1577,O
the,1577,O
lowest,1577,O
limit,1577,O
of,1577,O
quantitation,1577,O
(,1577,O
LLOQ,1577,O
),1577,O
of,1577,O
5,1577,O
nmol/l,1577,O
.,1577,O
Clinical,1578,O
studies,1578,O
in,1578,O
cancer,1578,O
patients,1578,O
treated,1578,O
with,1578,O
the,1578,O
new,1578,O
fluoropyrimidine,1578,B-CHEMICAL
analogue,1578,O
capecitabine,1578,B-CHEMICAL
(,1578,O
N4-pentoxycarbonyl-5'-5-fluorocytidine,1578,B-CHEMICAL
),1578,O
have,1578,O
shown,1578,O
that,1578,O
plasma,1578,O
2'-deoxyuridine,1578,B-CHEMICAL
was,1578,O
significantly,1578,O
elevated,1578,O
after,1578,O
1,1578,O
week,1578,O
of,1578,O
treatment,1578,O
",",1578,O
consistent,1578,O
with,1578,O
inhibition,1578,O
of,1578,O
thymidylate,1578,B-CHEMICAL
synthase,1578,I-GENE-Y
(,1578,O
TS,1578,B-GENE-Y
),1578,O
.,1578,O
These,1579,O
findings,1579,O
suggest,1579,O
that,1579,O
the,1579,O
mechanism,1579,O
of,1579,O
antiproliferative,1579,O
toxicity,1579,O
of,1579,O
capecitabine,1579,B-CHEMICAL
is,1579,O
at,1579,O
least,1579,O
partly,1579,O
due,1579,O
to,1579,O
TS,1579,B-GENE-Y
inhibitory,1579,O
activity,1579,O
of,1579,O
its,1579,O
active,1579,O
metabolite,1579,O
5-fluoro-2'-deoxyuridine,1579,B-CHEMICAL
monophosphate,1579,I-CHEMICAL
(,1579,O
FdUMP,1579,B-CHEMICAL
),1579,O
.,1579,O
Monitoring,1580,O
of,1580,O
plasma,1580,O
UdR,1580,B-CHEMICAL
concentrations,1580,O
have,1580,O
the,1580,O
potential,1580,O
to,1580,O
help,1580,O
clinicians,1580,O
to,1580,O
guide,1580,O
scheduling,1580,O
of,1580,O
capecitabine,1580,B-CHEMICAL
or,1580,O
other,1580,O
TS,1580,B-GENE-Y
inhibitors,1580,O
in,1580,O
clinical,1580,O
trials,1580,O
.,1580,O
Marked,1581,O
differences,1581,O
of,1581,O
plasma,1581,O
2'-deoxyuridine,1581,B-CHEMICAL
between,1581,O
human,1581,O
and,1581,O
rodents,1581,O
have,1581,O
also,1581,O
been,1581,O
confirmed,1581,O
.,1581,O
In,1582,O
conclusion,1582,O
",",1582,O
the,1582,O
LC-MS,1582,O
method,1582,O
developed,1582,O
is,1582,O
simple,1582,O
",",1582,O
highly,1582,O
selective,1582,O
and,1582,O
sensitive,1582,O
and,1582,O
permits,1582,O
pharmacodynamic,1582,O
studies,1582,O
of,1582,O
TS,1582,B-GENE-N
inhibitors,1582,O
in,1582,O
several,1582,O
species,1582,O
.,1582,O
Induction,1583,O
of,1583,O
heparin-binding,1583,B-GENE-Y
EGF-like,1583,I-GENE-Y
growth,1583,I-GENE-Y
factor,1583,I-GENE-Y
and,1583,O
activation,1583,O
of,1583,O
EGF,1583,B-GENE-Y
receptor,1583,I-GENE-Y
in,1583,O
imatinib,1583,B-CHEMICAL
mesylate-treated,1583,O
squamous,1583,O
carcinoma,1583,O
cells,1583,O
.,1583,O
Imatinib,1584,B-CHEMICAL
mesylate,1584,I-CHEMICAL
is,1584,O
a,1584,O
tyrosine,1584,B-CHEMICAL
kinase,1584,I-GENE-N
inhibitor,1584,O
of,1584,O
the,1584,O
ABL,1584,B-GENE-Y
",",1584,O
platelet-derived,1584,B-GENE-Y
growth,1584,I-GENE-Y
factor,1584,I-GENE-Y
receptor,1584,I-GENE-Y
(,1584,O
PDGFR,1584,B-GENE-Y
),1584,O
",",1584,O
and,1584,O
c-kit,1584,B-GENE-Y
kinases,1584,B-GENE-N
.,1584,O
Inhibition,1585,O
of,1585,O
BCR-ABL,1585,B-GENE-Y
and,1585,O
c-kit,1585,B-GENE-Y
accounts,1585,O
for,1585,O
its,1585,O
clinical,1585,O
activity,1585,O
in,1585,O
leukemia,1585,O
and,1585,O
sarcoma,1585,O
",",1585,O
respectively,1585,O
.,1585,O
In,1586,O
this,1586,O
report,1586,O
",",1586,O
we,1586,O
describe,1586,O
other,1586,O
cellular,1586,O
targets,1586,O
for,1586,O
imatinib,1586,B-CHEMICAL
.,1586,O
Treatment,1587,O
of,1587,O
head,1587,O
and,1587,O
neck,1587,O
squamous,1587,O
carcinoma,1587,O
cells,1587,O
with,1587,O
clinically,1587,O
relevant,1587,O
concentrations,1587,O
of,1587,O
imatinib-induced,1587,B-CHEMICAL
changes,1587,O
in,1587,O
cell,1587,O
morphology,1587,O
and,1587,O
growth,1587,O
similar,1587,O
to,1587,O
changes,1587,O
associated,1587,O
with,1587,O
epidermal,1587,B-GENE-Y
growth,1587,I-GENE-Y
factor,1587,I-GENE-Y
receptor,1587,I-GENE-Y
(,1587,O
EGFR,1587,B-GENE-Y
),1587,O
activation,1587,O
.,1587,O
Imatinib-induced,1588,B-CHEMICAL
changes,1588,O
were,1588,O
blocked,1588,O
with,1588,O
the,1588,O
EGFR,1588,B-GENE-Y
antagonist,1588,O
cetuximab,1588,O
",",1588,O
which,1588,O
suggested,1588,O
direct,1588,O
involvement,1588,O
of,1588,O
EGFR,1588,B-GENE-Y
in,1588,O
this,1588,O
process,1588,O
.,1588,O
Western,1589,O
blot,1589,O
analysis,1589,O
of,1589,O
cells,1589,O
incubated,1589,O
with,1589,O
imatinib,1589,B-CHEMICAL
demonstrated,1589,O
activation,1589,O
of,1589,O
EGFR,1589,B-GENE-Y
and,1589,O
downstream,1589,O
signaling,1589,O
that,1589,O
was,1589,O
reduced,1589,O
by,1589,O
inhibition,1589,O
of,1589,O
mitogen-activated,1589,B-GENE-Y
protein/extracellular,1589,I-GENE-Y
signal-regulated,1589,I-GENE-Y
kinase,1589,I-GENE-Y
kinase,1589,I-GENE-Y
1,1589,I-GENE-Y
(,1589,O
MEK1,1589,B-GENE-Y
),1589,O
and,1589,O
EGFR,1589,B-GENE-Y
",",1589,O
but,1589,O
not,1589,O
Her2/ErbB2,1589,B-GENE-Y
.,1589,O
An,1590,O
in,1590,O
vitro,1590,O
kinase,1590,B-GENE-N
assay,1590,O
showed,1590,O
that,1590,O
imatinib,1590,B-CHEMICAL
did,1590,O
not,1590,O
directly,1590,O
affect,1590,O
EGFR,1590,B-GENE-Y
kinase,1590,B-GENE-N
activity,1590,O
",",1590,O
suggesting,1590,O
involvement,1590,O
of,1590,O
EGFR-activating,1590,B-GENE-Y
molecules,1590,O
.,1590,O
Inhibitors,1591,O
and,1591,O
neutralizing,1591,O
antibodies,1591,O
against,1591,O
heparin-binding,1591,B-GENE-Y
epidermal,1591,I-GENE-Y
growth,1591,I-GENE-Y
factor-like,1591,I-GENE-Y
growth,1591,I-GENE-Y
factor,1591,I-GENE-Y
(,1591,O
HB-EGF,1591,B-GENE-Y
),1591,O
",",1591,O
and,1591,O
to,1591,O
a,1591,O
lesser,1591,O
extent,1591,O
transforming,1591,B-GENE-Y
growth,1591,I-GENE-Y
factor-alpha,1591,I-GENE-Y
",",1591,O
reduced,1591,O
imatinib-mediated,1591,B-CHEMICAL
mitogen,1591,B-GENE-N
activated,1591,I-GENE-N
protein,1591,I-GENE-N
kinase,1591,I-GENE-N
(,1591,O
MAPK,1591,B-GENE-N
),1591,O
activation,1591,O
.,1591,O
Imatinib,1592,B-CHEMICAL
stimulated,1592,O
the,1592,O
rapid,1592,O
release,1592,O
of,1592,O
soluble,1592,O
HB-EGF,1592,B-GENE-Y
and,1592,O
the,1592,O
subsequent,1592,O
induction,1592,O
of,1592,O
membrane-bound,1592,O
HB-EGF,1592,B-GENE-Y
",",1592,O
which,1592,O
correlated,1592,O
with,1592,O
biphasic,1592,O
MAPK,1592,B-GENE-N
activation,1592,O
.,1592,O
Together,1593,O
",",1593,O
these,1593,O
results,1593,O
suggested,1593,O
that,1593,O
imatinib,1593,B-CHEMICAL
affects,1593,O
EGFR,1593,B-GENE-Y
activation,1593,O
and,1593,O
signaling,1593,O
pathways,1593,O
through,1593,O
rapid,1593,O
release,1593,O
and,1593,O
increased,1593,O
expression,1593,O
of,1593,O
endogenous,1593,O
EGFR-activating,1593,B-GENE-Y
ligands,1593,O
.,1593,O
Although,1594,O
",",1594,O
imatinib,1594,B-CHEMICAL
primarily,1594,O
inhibits,1594,O
tyrosine,1594,B-GENE-N
kinases,1594,I-GENE-N
",",1594,O
it,1594,O
also,1594,O
stimulates,1594,O
the,1594,O
activity,1594,O
of,1594,O
EGFR,1594,B-GENE-Y
tyrosine,1594,B-CHEMICAL
kinase,1594,I-GENE-N
in,1594,O
head,1594,O
and,1594,O
neck,1594,O
squamous,1594,O
tumors,1594,O
.,1594,O
This,1595,O
finding,1595,O
demonstrates,1595,O
the,1595,O
need,1595,O
for,1595,O
careful,1595,O
use,1595,O
of,1595,O
this,1595,O
drug,1595,O
in,1595,O
cancer,1595,O
patients,1595,O
.,1595,O
Epithelioid,1596,O
gastrointestinal,1596,O
stromal,1596,O
tumor,1596,O
with,1596,O
PDGFRA,1596,B-GENE-Y
activating,1596,O
mutation,1596,O
and,1596,O
immunoreactivity,1596,O
.,1596,O
The,1597,O
authors,1597,O
report,1597,O
a,1597,O
unique,1597,O
case,1597,O
of,1597,O
an,1597,O
intra-abdominal,1597,O
",",1597,O
epithelioid,1597,O
mesenchymal,1597,O
tumor,1597,O
that,1597,O
had,1597,O
an,1597,O
activating,1597,O
mutation,1597,O
of,1597,O
PDGFRA,1597,B-GENE-Y
and,1597,O
a,1597,O
strong,1597,O
PDGFRA,1597,B-GENE-Y
immunoreactivity,1597,O
but,1597,O
lacked,1597,O
both,1597,O
c-kit,1597,B-GENE-Y
mutation,1597,O
and,1597,O
c-kit,1597,B-GENE-Y
protein,1597,O
(,1597,O
CD117,1597,B-GENE-Y
),1597,O
expression,1597,O
.,1597,O
IHC,1598,O
study,1598,O
showed,1598,O
that,1598,O
the,1598,O
tumor,1598,O
cells,1598,O
were,1598,O
diffusely,1598,O
and,1598,O
strongly,1598,O
positive,1598,O
for,1598,O
PDGFRA,1598,B-GENE-Y
",",1598,O
vimentin,1598,B-GENE-Y
",",1598,O
CD34,1598,B-GENE-Y
",",1598,O
and,1598,O
Bcl-2,1598,B-GENE-Y
but,1598,O
completely,1598,O
negative,1598,O
for,1598,O
CD117,1598,B-GENE-Y
as,1598,O
well,1598,O
as,1598,O
for,1598,O
muscle,1598,O
",",1598,O
epithelial,1598,O
",",1598,O
endothelial,1598,O
",",1598,O
endocrine,1598,O
",",1598,O
mesothelial,1598,O
",",1598,O
neural,1598,O
",",1598,O
and,1598,O
melanocytic,1598,O
cell,1598,O
markers,1598,O
.,1598,O
Molecular,1599,O
study,1599,O
revealed,1599,O
a,1599,O
mutation,1599,O
at,1599,O
the,1599,O
juxtamembrane,1599,O
domain,1599,O
of,1599,O
exon,1599,O
12,1599,O
in,1599,O
PDGFRA,1599,B-GENE-Y
gene,1599,O
with,1599,O
GTC,1599,B-GENE-N
to,1599,I-GENE-N
GAC,1599,I-GENE-N
transition,1599,O
at,1599,O
codon,1599,O
561,1599,O
(,1599,O
V561D,1599,B-GENE-N
),1599,O
",",1599,O
as,1599,O
shown,1599,O
in,1599,O
the,1599,O
previous,1599,O
mutational,1599,O
studies,1599,O
on,1599,O
gastrointestinal,1599,O
stromal,1599,O
tumor,1599,O
(,1599,O
GIST,1599,O
),1599,O
.,1599,O
This,1600,O
case,1600,O
likely,1600,O
represents,1600,O
an,1600,O
example,1600,O
of,1600,O
GIST,1600,O
with,1600,O
PDGFRA,1600,B-GENE-Y
activating,1600,O
mutation,1600,O
and,1600,O
PDGFRA,1600,B-GENE-Y
immunoreactivity,1600,O
without,1600,O
CD117,1600,B-GENE-Y
positivity,1600,O
",",1600,O
which,1600,O
has,1600,O
not,1600,O
been,1600,O
documented,1600,O
in,1600,O
the,1600,O
literature,1600,O
.,1600,O
STI,1601,B-CHEMICAL
571,1601,I-CHEMICAL
(,1601,O
imatinib,1601,B-CHEMICAL
mesylate,1601,I-CHEMICAL
[,1601,O
Gleevec,1601,B-CHEMICAL
],1601,O
),1601,O
might,1601,O
be,1601,O
an,1601,O
effective,1601,O
therapy,1601,O
in,1601,O
this,1601,O
case,1601,O
",",1601,O
since,1601,O
Gleevec,1601,B-CHEMICAL
targets,1601,O
both,1601,O
PDGFRA,1601,B-GENE-Y
and,1601,O
c-kit,1601,B-GENE-Y
oncoproteins,1601,O
.,1601,O
Genetic,1602,O
polymorphism,1602,O
and,1602,O
activities,1602,O
of,1602,O
human,1602,B-GENE-N
lung,1602,I-GENE-N
alcohol,1602,I-GENE-N
and,1602,I-GENE-N
aldehyde,1602,I-GENE-N
dehydrogenases,1602,I-GENE-N
:,1602,O
implications,1602,O
for,1602,O
ethanol,1602,B-CHEMICAL
metabolism,1602,O
and,1602,O
cytotoxicity,1602,O
.,1602,O
Alcohol,1603,B-CHEMICAL
dehydrogenase,1603,I-GENE-N
(,1603,O
ADH,1603,B-GENE-N
),1603,O
and,1603,O
aldehyde,1603,B-CHEMICAL
dehydrogenase,1603,I-GENE-N
(,1603,O
ALDH,1603,B-GENE-N
),1603,O
exhibit,1603,O
genetic,1603,O
polymorphism,1603,O
and,1603,O
tissue,1603,O
specificity,1603,O
.,1603,O
ADH,1604,B-GENE-N
and,1604,O
ALDH,1604,B-GENE-N
isozyme,1604,O
phenotypes,1604,O
from,1604,O
39,1604,O
surgical,1604,O
Chinese,1604,O
lung,1604,O
specimens,1604,O
were,1604,O
identified,1604,O
by,1604,O
agarose,1604,O
isoelectric,1604,O
focusing,1604,O
.,1604,O
The,1605,O
identity,1605,O
of,1605,O
the,1605,O
lung,1605,O
beta-ADHs,1605,B-GENE-N
was,1605,O
further,1605,O
demonstrated,1605,O
by,1605,O
their,1605,O
characteristic,1605,O
pH-activity,1605,O
profiles,1605,O
for,1605,O
ethanol,1605,B-CHEMICAL
oxidation,1605,O
",",1605,O
Km,1605,O
values,1605,O
for,1605,O
NAD,1605,O
and,1605,O
ethanol,1605,B-CHEMICAL
",",1605,O
and,1605,O
inhibition,1605,O
by,1605,O
4-methylpyrazole,1605,B-CHEMICAL
or,1605,O
"1,10-phenanthroline",1605,B-CHEMICAL
.,1605,O
The,1606,O
beta,1606,O
2,1606,O
allele,1606,O
",",1606,O
coding,1606,O
for,1606,O
beta,1606,O
2,1606,O
polypeptide,1606,B-CHEMICAL
",",1606,O
was,1606,O
found,1606,O
to,1606,O
be,1606,O
predominant,1606,O
in,1606,O
the,1606,O
lung,1606,O
specimens,1606,O
studied,1606,O
.,1606,O
The,1607,O
ADH,1607,B-GENE-N
activities,1607,O
in,1607,O
the,1607,O
lungs,1607,O
with,1607,O
the,1607,O
homozygous,1607,O
phenotype,1607,O
ADH2,1607,B-GENE-Y
2-2,1607,I-GENE-Y
(,1607,O
exhibiting,1607,O
beta,1607,O
2,1607,O
beta,1607,O
2,1607,O
),1607,O
and,1607,O
ADH2,1607,B-GENE-Y
1-1,1607,I-GENE-Y
(,1607,O
exhibiting,1607,O
beta,1607,O
1,1607,O
beta,1607,O
1,1607,O
),1607,O
and,1607,O
the,1607,O
heterozygous,1607,O
phenotype,1607,O
ADH2,1607,B-GENE-Y
2-1,1607,I-GENE-Y
(,1607,O
exhibiting,1607,O
beta,1607,O
2,1607,O
beta,1607,O
2,1607,O
",",1607,O
beta,1607,O
2,1607,O
beta,1607,O
1,1607,O
",",1607,O
and,1607,O
beta,1607,O
1,1607,O
beta,1607,O
1,1607,O
),1607,O
were,1607,O
determined,1607,O
to,1607,O
be,1607,O
999,1607,O
+/-,1607,O
77,1607,O
",",1607,O
48,1607,O
+/-,1607,O
17,1607,O
",",1607,O
and,1607,O
494,1607,O
+/-,1607,O
61,1607,O
nmol/min/g,1607,O
tissue,1607,O
",",1607,O
respectively,1607,O
.,1607,O
Fifty-one,1608,O
percent,1608,O
of,1608,O
the,1608,O
specimens,1608,O
studied,1608,O
lacked,1608,O
the,1608,O
ALDH2,1608,B-GENE-Y
activity,1608,O
band,1608,O
on,1608,O
the,1608,O
isoelectric,1608,O
focusing,1608,O
gels,1608,O
.,1608,O
The,1609,O
activities,1609,O
in,1609,O
the,1609,O
lung,1609,O
tissues,1609,O
with,1609,O
the,1609,O
ALDH2-active,1609,B-GENE-Y
phenotype,1609,O
and,1609,O
the,1609,O
inactive,1609,O
phenotype,1609,O
were,1609,O
determined,1609,O
to,1609,O
be,1609,O
30,1609,O
+/-,1609,O
3,1609,O
and,1609,O
17,1609,O
+/-,1609,O
1,1609,O
nmol/min/g,1609,O
tissue,1609,O
",",1609,O
respectively,1609,O
.,1609,O
These,1610,O
findings,1610,O
indicate,1610,O
that,1610,O
human,1610,O
pulmonary,1610,O
ethanol-metabolizing,1610,B-CHEMICAL
activities,1610,O
differ,1610,O
significantly,1610,O
with,1610,O
respect,1610,O
to,1610,O
genetic,1610,O
polymorphism,1610,O
at,1610,O
both,1610,O
the,1610,O
ADH2,1610,B-GENE-Y
and,1610,O
the,1610,O
ALDH2,1610,B-GENE-Y
loci,1610,O
.,1610,O
The,1611,O
results,1611,O
suggest,1611,O
that,1611,O
individuals,1611,O
with,1611,O
high,1611,O
Vmax,1611,O
beta,1611,B-GENE-Y
2-ADH,1611,I-GENE-Y
and,1611,O
deficient,1611,O
in,1611,O
low-Km,1611,O
mitochondrial,1611,O
ALDH2,1611,B-GENE-Y
",",1611,O
accounting,1611,O
for,1611,O
approximately,1611,O
45,1611,O
%,1611,O
of,1611,O
the,1611,O
Chinese,1611,O
population,1611,O
",",1611,O
may,1611,O
end,1611,O
up,1611,O
with,1611,O
acetaldehyde,1611,B-CHEMICAL
accumulation,1611,O
during,1611,O
alcohol,1611,B-CHEMICAL
consumption,1611,O
",",1611,O
rendering,1611,O
them,1611,O
vulnerable,1611,O
to,1611,O
tissue,1611,O
injury,1611,O
caused,1611,O
by,1611,O
this,1611,O
highly,1611,O
reactive,1611,O
and,1611,O
toxic,1611,O
metabolite,1611,O
.,1611,O
Simvastatin,1612,B-CHEMICAL
induces,1612,O
interleukin-18,1612,B-GENE-Y
production,1612,O
in,1612,O
human,1612,O
peripheral,1612,O
blood,1612,O
mononuclear,1612,O
cells,1612,O
.,1612,O
The,1613,O
effects,1613,O
of,1613,O
statins,1613,O
on,1613,O
immune,1613,O
response,1613,O
depend,1613,O
on,1613,O
the,1613,O
inhibition,1613,O
of,1613,O
3-hydroxy-3-methylglutaryl,1613,B-CHEMICAL
coenzyme-A,1613,I-CHEMICAL
(,1613,I-GENE-Y
HMG-CoA,1613,B-CHEMICAL
),1613,I-GENE-Y
reductase,1613,I-GENE-Y
and,1613,O
leukocyte,1613,B-GENE-Y
function-associated,1613,I-GENE-Y
antigen,1613,I-GENE-Y
(,1613,I-GENE-Y
LFA,1613,I-GENE-Y
),1613,I-GENE-Y
-1,1613,I-GENE-Y
",",1613,O
which,1613,O
is,1613,O
a,1613,O
ligand,1613,O
of,1613,O
intercellular,1613,B-GENE-Y
adhesion,1613,I-GENE-Y
molecule,1613,I-GENE-Y
(,1613,I-GENE-Y
ICAM,1613,I-GENE-Y
),1613,I-GENE-Y
-1,1613,I-GENE-Y
.,1613,O
Simvastatin,1614,B-CHEMICAL
",",1614,O
an,1614,O
HMG-CoA,1614,B-CHEMICAL
reductase,1614,I-GENE-Y
inhibitor,1614,O
with,1614,O
mild,1614,O
inhibition,1614,O
of,1614,O
LFA-1,1614,B-GENE-Y
",",1614,O
induced,1614,O
the,1614,O
production,1614,O
of,1614,O
interleukin,1614,B-GENE-Y
(,1614,I-GENE-Y
IL,1614,I-GENE-Y
),1614,I-GENE-Y
-18,1614,I-GENE-Y
",",1614,O
tumor,1614,B-GENE-Y
necrosis,1614,I-GENE-Y
factor,1614,I-GENE-Y
(,1614,I-GENE-Y
TNF,1614,I-GENE-Y
),1614,I-GENE-Y
-alpha,1614,I-GENE-Y
and,1614,O
interferon,1614,B-GENE-Y
(,1614,I-GENE-Y
IFN,1614,I-GENE-Y
),1614,I-GENE-Y
-gamma,1614,I-GENE-Y
in,1614,O
human,1614,O
peripheral,1614,O
blood,1614,O
mononuclear,1614,O
cells,1614,O
(,1614,O
PBMC,1614,O
),1614,O
.,1614,O
The,1615,O
IL-18,1615,B-GENE-Y
production,1615,O
is,1615,O
located,1615,O
upstream,1615,O
of,1615,O
the,1615,O
cytokine,1615,B-GENE-N
cascade,1615,O
activated,1615,O
by,1615,O
simvastatin,1615,B-CHEMICAL
.,1615,O
Moreover,1616,O
",",1616,O
simvastatin,1616,B-CHEMICAL
concentration-dependently,1616,O
inhibited,1616,O
the,1616,O
expression,1616,O
of,1616,O
ICAM-1,1616,B-GENE-Y
and,1616,O
induced,1616,O
the,1616,O
expression,1616,O
of,1616,O
CD40,1616,B-GENE-Y
on,1616,O
monocytes,1616,O
.,1616,O
In,1617,O
the,1617,O
presence,1617,O
of,1617,O
IL-18,1617,B-GENE-Y
",",1617,O
simvastatin,1617,B-CHEMICAL
suppressed,1617,O
the,1617,O
expression,1617,O
of,1617,O
ICAM-1,1617,B-GENE-Y
and,1617,O
CD40,1617,B-GENE-Y
as,1617,O
well,1617,O
as,1617,O
the,1617,O
production,1617,O
of,1617,O
IL-12,1617,B-GENE-N
",",1617,O
TNF-alpha,1617,B-GENE-Y
and,1617,O
IFN-gamma,1617,B-GENE-Y
in,1617,O
PBMC,1617,O
",",1617,O
contributing,1617,O
to,1617,O
the,1617,O
anti-inflammatory,1617,O
effect,1617,O
of,1617,O
simvastatin,1617,B-CHEMICAL
.,1617,O
The,1618,O
effects,1618,O
of,1618,O
simvastatin,1618,B-CHEMICAL
were,1618,O
abolished,1618,O
by,1618,O
the,1618,O
addition,1618,O
of,1618,O
the,1618,O
product,1618,O
of,1618,O
the,1618,O
HMG-CoA,1618,B-GENE-Y
reductase,1618,I-GENE-Y
",",1618,O
mevalonate,1618,B-CHEMICAL
",",1618,O
indicating,1618,O
the,1618,O
involvement,1618,O
of,1618,O
HMG-CoA,1618,B-CHEMICAL
reductase,1618,I-GENE-Y
in,1618,O
the,1618,O
action,1618,O
of,1618,O
simvastatin,1618,B-CHEMICAL
.,1618,O
COX-1,1619,B-GENE-Y
and,1619,O
COX-2,1619,B-GENE-Y
inhibition,1619,O
in,1619,O
horse,1619,O
blood,1619,O
by,1619,O
phenylbutazone,1619,B-CHEMICAL
",",1619,O
flunixin,1619,B-CHEMICAL
",",1619,O
carprofen,1619,B-CHEMICAL
and,1619,O
meloxicam,1619,B-CHEMICAL
:,1619,O
an,1619,O
in,1619,O
vitro,1619,O
analysis,1619,O
.,1619,O
We,1620,O
report,1620,O
on,1620,O
the,1620,O
inhibitory,1620,O
activity,1620,O
of,1620,O
the,1620,O
NSAIDs,1620,O
meloxicam,1620,B-CHEMICAL
",",1620,O
carprofen,1620,B-CHEMICAL
",",1620,O
phenylbutazone,1620,B-CHEMICAL
and,1620,O
flunixin,1620,B-CHEMICAL
",",1620,O
on,1620,O
blood,1620,O
cyclooxygenases,1620,B-GENE-N
in,1620,O
the,1620,O
horse,1620,O
using,1620,O
in,1620,O
vitro,1620,O
enzyme-linked,1620,O
assays,1620,O
.,1620,O
As,1621,O
expected,1621,O
",",1621,O
comparison,1621,O
of,1621,O
IC50,1621,O
indicated,1621,O
that,1621,O
meloxicam,1621,B-CHEMICAL
and,1621,O
carprofen,1621,B-CHEMICAL
are,1621,O
more,1621,O
selective,1621,O
inhibitors,1621,O
of,1621,O
COX-2,1621,B-GENE-Y
than,1621,O
phenylbutazone,1621,B-CHEMICAL
and,1621,O
flunixin,1621,B-CHEMICAL
;,1621,O
meloxicam,1621,B-CHEMICAL
was,1621,O
the,1621,O
most,1621,O
advantageous,1621,O
for,1621,O
horses,1621,O
of,1621,O
four,1621,O
NSAIDs,1621,O
examined,1621,O
.,1621,O
However,1622,O
at,1622,O
IC80,1622,O
",",1622,O
phenylbutazone,1622,B-CHEMICAL
(,1622,O
+134.4,1622,O
%,1622,O
),1622,O
and,1622,O
flunixin,1622,B-CHEMICAL
(,1622,O
+29.7,1622,O
%,1622,O
),1622,O
had,1622,O
greater,1622,O
COX-2,1622,B-GENE-Y
selectivity,1622,O
than,1622,O
at,1622,O
IC50,1622,O
",",1622,O
and,1622,O
meloxicam,1622,B-CHEMICAL
(,1622,O
-41.2,1622,O
%,1622,O
),1622,O
and,1622,O
carprofen,1622,B-CHEMICAL
(,1622,O
-12.9,1622,O
%,1622,O
),1622,O
had,1622,O
lower,1622,O
COX-2,1622,B-GENE-Y
selectivity,1622,O
than,1622,O
at,1622,O
IC50,1622,O
.,1622,O
We,1623,O
therefore,1623,O
propose,1623,O
that,1623,O
the,1623,O
selectivity,1623,O
of,1623,O
NSAIDs,1623,O
should,1623,O
be,1623,O
assessed,1623,O
at,1623,O
the,1623,O
80,1623,O
%,1623,O
as,1623,O
well,1623,O
as,1623,O
50,1623,O
%,1623,O
inhibition,1623,O
level,1623,O
.,1623,O
Carvedilol,1624,B-CHEMICAL
prevents,1624,O
cardiac,1624,O
hypertrophy,1624,O
and,1624,O
overexpression,1624,O
of,1624,O
hypoxia-inducible,1624,B-GENE-Y
factor-1alpha,1624,I-GENE-Y
and,1624,O
vascular,1624,B-GENE-Y
endothelial,1624,I-GENE-Y
growth,1624,I-GENE-Y
factor,1624,I-GENE-Y
in,1624,O
pressure-overloaded,1624,O
rat,1624,O
heart,1624,O
.,1624,O
The,1625,O
use,1625,O
of,1625,O
beta-blockers,1625,O
has,1625,O
emerged,1625,O
as,1625,O
a,1625,O
beneficial,1625,O
treatment,1625,O
for,1625,O
cardiac,1625,O
hypertrophy,1625,O
.,1625,O
Hypoxia-inducible,1626,B-GENE-Y
factor-1alpha,1626,I-GENE-Y
(,1626,O
HIF-1alpha,1626,B-GENE-Y
),1626,O
is,1626,O
tightly,1626,O
regulated,1626,O
in,1626,O
the,1626,O
ventricular,1626,O
myocardium,1626,O
.,1626,O
However,1627,O
",",1627,O
the,1627,O
expression,1627,O
of,1627,O
HIF-1alpha,1627,B-GENE-Y
in,1627,O
cardiac,1627,O
hypertrophy,1627,O
due,1627,O
to,1627,O
pressure,1627,O
overload,1627,O
and,1627,O
after,1627,O
treatment,1627,O
with,1627,O
beta-blocker,1627,O
is,1627,O
little,1627,O
known,1627,O
.,1627,O
To,1628,O
evaluate,1628,O
the,1628,O
effect,1628,O
of,1628,O
carvedilol,1628,B-CHEMICAL
on,1628,O
both,1628,O
myocardial,1628,O
HIF-1alpha,1628,B-GENE-Y
expression,1628,O
and,1628,O
cardiac,1628,O
hypertrophy,1628,O
",",1628,O
infra-renal,1628,O
aortic,1628,O
banding,1628,O
was,1628,O
performed,1628,O
for,1628,O
4,1628,O
weeks,1628,O
in,1628,O
adult,1628,O
Sprague-Dawley,1628,O
rats,1628,O
to,1628,O
induce,1628,O
cardiac,1628,O
hypertrophy,1628,O
.,1628,O
Carvedilol,1629,B-CHEMICAL
at,1629,O
50,1629,O
mg/kg,1629,O
body,1629,O
weight,1629,O
per,1629,O
day,1629,O
after,1629,O
surgery,1629,O
was,1629,O
given,1629,O
.,1629,O
Heart,1630,O
weight,1630,O
and,1630,O
the,1630,O
ratio,1630,O
of,1630,O
heart,1630,O
weight,1630,O
and,1630,O
body,1630,O
weight,1630,O
increased,1630,O
significantly,1630,O
after,1630,O
aortic,1630,O
banding,1630,O
for,1630,O
4,1630,O
weeks,1630,O
in,1630,O
the,1630,O
absence,1630,O
of,1630,O
drug,1630,O
treatment,1630,O
.,1630,O
Mean,1631,O
arterial,1631,O
pressure,1631,O
increased,1631,O
from,1631,O
80,1631,O
+/-,1631,O
9,1631,O
mmHg,1631,O
in,1631,O
the,1631,O
sham,1631,O
group,1631,O
to,1631,O
94,1631,O
+/-5,1631,O
mmHg,1631,O
(,1631,O
p,1631,O
<,1631,O
0.001,1631,O
),1631,O
in,1631,O
the,1631,O
banding,1631,O
group,1631,O
.,1631,O
Echocardiography,1632,O
showed,1632,O
concentric,1632,O
hypertrophy,1632,O
after,1632,O
aortic,1632,O
banding,1632,O
.,1632,O
Mean,1633,O
arterial,1633,O
pressure,1633,O
decreased,1633,O
after,1633,O
treatment,1633,O
with,1633,O
carvedilol,1633,B-CHEMICAL
.,1633,O
The,1634,O
increased,1634,O
wall,1634,O
thickness,1634,O
and,1634,O
heart,1634,O
weight,1634,O
was,1634,O
reversed,1634,O
to,1634,O
normal,1634,O
by,1634,O
carvedilol,1634,B-CHEMICAL
.,1634,O
Western,1635,O
blot,1635,O
showed,1635,O
that,1635,O
HIF-1alpha,1635,B-GENE-Y
",",1635,O
vascular,1635,B-GENE-Y
endothelial,1635,I-GENE-Y
growth,1635,I-GENE-Y
factor,1635,I-GENE-Y
(,1635,O
VEGF,1635,B-GENE-Y
),1635,O
and,1635,O
brain,1635,B-GENE-Y
natriuretic,1635,I-GENE-Y
peptide,1635,I-GENE-Y
(,1635,O
BNP,1635,B-GENE-Y
),1635,O
proteins,1635,O
were,1635,O
up-regulated,1635,O
and,1635,O
nerve,1635,B-GENE-Y
growth,1635,I-GENE-Y
factor-beta,1635,I-GENE-Y
(,1635,O
NGF-beta,1635,B-GENE-Y
),1635,O
down-regulated,1635,O
in,1635,O
the,1635,O
banding,1635,O
group,1635,O
.,1635,O
Treatment,1636,O
with,1636,O
valsartan,1636,B-CHEMICAL
",",1636,O
doxazosin,1636,B-CHEMICAL
",",1636,O
or,1636,O
N-acetylcysteine,1636,B-CHEMICAL
did,1636,O
not,1636,O
significantly,1636,O
affect,1636,O
HIF-1alpha,1636,B-GENE-Y
and,1636,O
VEGF,1636,B-GENE-Y
proteins,1636,O
expression,1636,O
in,1636,O
the,1636,O
banding,1636,O
groups,1636,O
.,1636,O
Real-time,1637,O
polymerase,1637,O
chain,1637,O
reaction,1637,O
showed,1637,O
that,1637,O
mRNA,1637,O
of,1637,O
HIF-1alpha,1637,B-GENE-Y
",",1637,O
VEGF,1637,B-GENE-Y
and,1637,O
BNP,1637,B-GENE-Y
increased,1637,O
and,1637,O
mRNA,1637,O
of,1637,O
NGF-beta,1637,B-GENE-Y
decreased,1637,O
in,1637,O
the,1637,O
banding,1637,O
group,1637,O
.,1637,O
Treatment,1638,O
with,1638,O
carvedilol,1638,B-CHEMICAL
reversed,1638,O
both,1638,O
protein,1638,O
and,1638,O
mRNA,1638,O
of,1638,O
HIF-1alpha,1638,B-GENE-Y
",",1638,O
VEGF,1638,B-GENE-Y
",",1638,O
BNP,1638,B-GENE-Y
",",1638,O
and,1638,O
NGF-beta,1638,B-GENE-Y
to,1638,O
the,1638,O
baseline,1638,O
values,1638,O
.,1638,O
Increased,1639,O
immunohistochemical,1639,O
labeling,1639,O
of,1639,O
HIF-1alpha,1639,B-GENE-Y
",",1639,O
VEGF,1639,B-GENE-Y
",",1639,O
and,1639,O
BNP,1639,B-GENE-Y
in,1639,O
the,1639,O
ventricular,1639,O
myocardium,1639,O
was,1639,O
observed,1639,O
in,1639,O
the,1639,O
banding,1639,O
group,1639,O
and,1639,O
carvedilol,1639,B-CHEMICAL
again,1639,O
normalized,1639,O
the,1639,O
labeling,1639,O
.,1639,O
In,1640,O
conclusion,1640,O
",",1640,O
HIF-1alpha,1640,B-GENE-Y
",",1640,O
VEGF,1640,B-GENE-Y
",",1640,O
and,1640,O
BNP,1640,B-GENE-Y
mRNA,1640,O
and,1640,O
protein,1640,O
expression,1640,O
were,1640,O
up-regulated,1640,O
",",1640,O
while,1640,O
NGF-beta,1640,B-GENE-Y
mRNA,1640,O
and,1640,O
protein,1640,O
was,1640,O
downregulated,1640,O
in,1640,O
the,1640,O
rat,1640,O
model,1640,O
of,1640,O
pressure-overloaded,1640,O
cardiac,1640,O
hypertrophy,1640,O
.,1640,O
Treatment,1641,O
with,1641,O
carvedilol,1641,B-CHEMICAL
is,1641,O
associated,1641,O
with,1641,O
a,1641,O
reversal,1641,O
of,1641,O
abnormal,1641,O
regulation,1641,O
of,1641,O
HIF-1alpha,1641,B-GENE-Y
",",1641,O
VEGF,1641,B-GENE-Y
",",1641,O
BNP,1641,B-GENE-Y
",",1641,O
and,1641,O
NGF-beta,1641,B-GENE-Y
in,1641,O
the,1641,O
hypertrophic,1641,O
myocardium,1641,O
.,1641,O
Imatinib,1642,B-CHEMICAL
resistance,1642,O
in,1642,O
gastrointestinal,1642,O
stromal,1642,O
tumors,1642,O
.,1642,O
Conventional,1643,O
chemotherapeutic,1643,O
drugs,1643,O
are,1643,O
ineffective,1643,O
in,1643,O
treatment,1643,O
of,1643,O
gastrointestinal,1643,O
stromal,1643,O
tumors,1643,O
(,1643,O
GISTs,1643,O
),1643,O
.,1643,O
Imatinib,1644,B-CHEMICAL
(,1644,O
STI571,1644,B-CHEMICAL
",",1644,O
Gleevec,1644,B-CHEMICAL
",",1644,O
Glivec,1644,B-CHEMICAL
;,1644,O
Novartis,1644,O
Pharmaceuticals,1644,O
",",1644,O
East,1644,O
Hanover,1644,O
",",1644,O
NJ,1644,O
),1644,O
",",1644,O
a,1644,O
selective,1644,O
inhibitor,1644,O
of,1644,O
KIT,1644,B-GENE-Y
",",1644,O
ABL,1644,B-GENE-Y
",",1644,O
BCR-ABL,1644,B-GENE-Y
",",1644,O
PDGFRA,1644,B-GENE-Y
",",1644,O
and,1644,O
PDGFRB,1644,B-GENE-Y
",",1644,I-GENE-Y
represents,1644,O
a,1644,O
new,1644,O
paradigm,1644,O
of,1644,O
targeted,1644,O
cancer,1644,O
therapy,1644,O
and,1644,O
has,1644,O
revolutionized,1644,O
the,1644,O
treatment,1644,O
of,1644,O
patients,1644,O
with,1644,O
chronic,1644,O
myelogenous,1644,O
leukemia,1644,O
and,1644,O
GISTs,1644,O
.,1644,O
Unfortunately,1645,O
",",1645,O
imatinib,1645,B-CHEMICAL
resistance,1645,O
has,1645,O
emerged,1645,O
.,1645,O
The,1646,O
reported,1646,O
mechanism,1646,O
of,1646,O
imatinib,1646,B-CHEMICAL
resistance,1646,O
in,1646,O
GISTs,1646,O
involves,1646,O
missense,1646,O
mutation,1646,O
in,1646,O
the,1646,O
kinase,1646,B-GENE-N
domain,1646,I-GENE-N
of,1646,O
KIT,1646,B-GENE-N
",",1646,I-GENE-N
including,1646,O
Thr670Ile,1646,B-GENE-N
",",1646,O
Tyr823Asp,1646,B-GENE-N
",",1646,O
and,1646,O
Val654Ala,1646,B-GENE-N
.,1646,O
The,1647,O
established,1647,O
mechanisms,1647,O
and,1647,O
potential,1647,O
mechanisms,1647,O
of,1647,O
imatinib,1647,B-CHEMICAL
resistance,1647,O
in,1647,O
GISTs,1647,O
",",1647,O
the,1647,O
imaging,1647,O
studies,1647,O
indicative,1647,O
of,1647,O
early,1647,O
development,1647,O
of,1647,O
imatinib,1647,B-CHEMICAL
resistance,1647,O
",",1647,O
and,1647,O
the,1647,O
management,1647,O
of,1647,O
imatinib-resistant,1647,B-CHEMICAL
GISTs,1647,O
are,1647,O
discussed,1647,O
.,1647,O
Evaluation,1648,O
of,1648,O
histamine,1648,B-GENE-N
H1-,1648,I-GENE-N
",",1648,I-GENE-N
H2-,1648,I-GENE-N
",",1648,I-GENE-N
and,1648,I-GENE-N
H3-receptor,1648,I-GENE-N
ligands,1648,O
at,1648,O
the,1648,O
human,1648,B-GENE-Y
histamine,1648,I-GENE-Y
H4,1648,I-GENE-Y
receptor,1648,I-GENE-Y
:,1648,O
identification,1648,O
of,1648,O
4-methylhistamine,1648,B-CHEMICAL
as,1648,O
the,1648,O
first,1648,O
potent,1648,O
and,1648,O
selective,1648,O
H4,1648,B-GENE-Y
receptor,1648,I-GENE-Y
agonist,1648,O
.,1648,O
The,1649,O
histamine,1649,B-CHEMICAL
H,1649,I-GENE-Y
(,1649,I-GENE-Y
4,1649,I-GENE-Y
),1649,I-GENE-Y
receptor,1649,I-GENE-Y
(,1649,O
H,1649,B-GENE-Y
(,1649,I-GENE-Y
4,1649,I-GENE-Y
),1649,I-GENE-Y
R,1649,I-GENE-Y
),1649,O
is,1649,O
involved,1649,O
in,1649,O
the,1649,O
chemotaxis,1649,O
of,1649,O
leukocytes,1649,O
and,1649,O
mast,1649,O
cells,1649,O
to,1649,O
sites,1649,O
of,1649,O
inflammation,1649,O
and,1649,O
is,1649,O
suggested,1649,O
to,1649,O
be,1649,O
a,1649,O
potential,1649,O
drug,1649,O
target,1649,O
for,1649,O
asthma,1649,O
and,1649,O
allergy,1649,O
.,1649,O
So,1650,O
far,1650,O
",",1650,O
selective,1650,O
H,1650,B-GENE-Y
(,1650,I-GENE-Y
4,1650,I-GENE-Y
),1650,I-GENE-Y
R,1650,I-GENE-Y
agonists,1650,O
have,1650,O
not,1650,O
been,1650,O
identified,1650,O
.,1650,O
In,1651,O
the,1651,O
present,1651,O
study,1651,O
",",1651,O
we,1651,O
therefore,1651,O
evaluated,1651,O
the,1651,O
human,1651,B-GENE-Y
H,1651,I-GENE-Y
(,1651,I-GENE-Y
4,1651,I-GENE-Y
),1651,I-GENE-Y
R,1651,I-GENE-Y
(,1651,O
hH,1651,B-GENE-Y
(,1651,I-GENE-Y
4,1651,I-GENE-Y
),1651,I-GENE-Y
R,1651,I-GENE-Y
),1651,O
for,1651,O
its,1651,O
interaction,1651,O
with,1651,O
various,1651,O
known,1651,O
histaminergic,1651,O
ligands,1651,O
.,1651,O
Almost,1652,O
all,1652,O
of,1652,O
the,1652,O
tested,1652,O
H,1652,B-GENE-Y
(,1652,I-GENE-Y
1,1652,I-GENE-Y
),1652,I-GENE-Y
R,1652,I-GENE-Y
and,1652,O
H,1652,B-GENE-Y
(,1652,I-GENE-Y
2,1652,I-GENE-Y
),1652,I-GENE-Y
R,1652,I-GENE-Y
antagonists,1652,O
",",1652,O
including,1652,O
several,1652,O
important,1652,O
therapeutics,1652,O
",",1652,O
displaced,1652,O
less,1652,O
than,1652,O
30,1652,O
%,1652,O
of,1652,O
specific,1652,O
[,1652,B-CHEMICAL
(,1652,I-CHEMICAL
3,1652,I-CHEMICAL
),1652,I-CHEMICAL
H,1652,I-CHEMICAL
],1652,I-CHEMICAL
histamine,1652,I-CHEMICAL
binding,1652,O
to,1652,O
the,1652,O
hH,1652,B-GENE-Y
(,1652,I-GENE-Y
4,1652,I-GENE-Y
),1652,I-GENE-Y
R,1652,I-GENE-Y
at,1652,O
concentrations,1652,O
up,1652,O
to,1652,O
10,1652,O
microM,1652,O
.,1652,O
Most,1653,O
of,1653,O
the,1653,O
tested,1653,O
H,1653,B-GENE-Y
(,1653,I-GENE-Y
2,1653,I-GENE-Y
),1653,I-GENE-Y
R,1653,I-GENE-Y
agonists,1653,O
and,1653,O
imidazole-based,1653,B-CHEMICAL
H,1653,B-GENE-Y
(,1653,I-GENE-Y
3,1653,I-GENE-Y
),1653,I-GENE-Y
R,1653,I-GENE-Y
ligands,1653,O
show,1653,O
micromolar-to-nanomolar,1653,O
range,1653,O
hH,1653,B-GENE-Y
(,1653,I-GENE-Y
4,1653,I-GENE-Y
),1653,I-GENE-Y
R,1653,I-GENE-Y
affinity,1653,O
",",1653,O
and,1653,O
these,1653,O
ligands,1653,O
exert,1653,O
different,1653,O
intrinsic,1653,O
hH,1653,B-GENE-Y
(,1653,I-GENE-Y
4,1653,I-GENE-Y
),1653,I-GENE-Y
R,1653,I-GENE-Y
activities,1653,O
",",1653,O
ranging,1653,O
from,1653,O
full,1653,O
agonists,1653,O
to,1653,O
inverse,1653,O
agonists,1653,O
.,1653,O
Interestingly,1654,O
",",1654,O
we,1654,O
identified,1654,O
4-methylhistamine,1654,B-CHEMICAL
as,1654,O
a,1654,O
high-affinity,1654,O
H,1654,B-GENE-Y
(,1654,I-GENE-Y
4,1654,I-GENE-Y
),1654,I-GENE-Y
R,1654,I-GENE-Y
ligand,1654,O
(,1654,O
K,1654,O
(,1654,O
i,1654,O
),1654,O
=,1654,O
50,1654,O
nM,1654,O
),1654,O
that,1654,O
has,1654,O
a,1654,O
>,1654,O
100-fold,1654,O
selectivity,1654,O
for,1654,O
the,1654,O
hH,1654,B-GENE-Y
(,1654,I-GENE-Y
4,1654,I-GENE-Y
),1654,I-GENE-Y
R,1654,I-GENE-Y
over,1654,O
the,1654,O
other,1654,O
histamine,1654,B-CHEMICAL
receptor,1654,I-GENE-N
subtypes,1654,O
.,1654,O
Moreover,1655,O
",",1655,O
4-methylhistamine,1655,B-CHEMICAL
potently,1655,O
activated,1655,O
the,1655,O
hH,1655,B-GENE-Y
(,1655,I-GENE-Y
4,1655,I-GENE-Y
),1655,I-GENE-Y
R,1655,I-GENE-Y
(,1655,O
pEC,1655,O
(,1655,O
50,1655,O
),1655,O
=,1655,O
7.4,1655,O
+/-,1655,O
0.1,1655,O
;,1655,O
alpha,1655,O
=,1655,O
1,1655,O
),1655,O
",",1655,O
and,1655,O
this,1655,O
response,1655,O
was,1655,O
competitively,1655,O
antagonized,1655,O
by,1655,O
the,1655,O
selective,1655,O
H,1655,B-GENE-Y
(,1655,I-GENE-Y
4,1655,I-GENE-Y
),1655,I-GENE-Y
R,1655,I-GENE-Y
antagonist,1655,O
JNJ,1655,B-CHEMICAL
7777120,1655,I-CHEMICAL
[,1655,O
1-,1655,B-CHEMICAL
[,1655,I-CHEMICAL
(,1655,I-CHEMICAL
5-chloro-1H-indol-2-yl,1655,I-CHEMICAL
),1655,I-CHEMICAL
-carbonyl,1655,I-CHEMICAL
],1655,I-CHEMICAL
-4-methylpiperazine,1655,I-CHEMICAL
],1655,O
(,1655,O
pA,1655,O
(,1655,O
2,1655,O
),1655,O
=,1655,O
7.8,1655,O
),1655,O
.,1655,O
The,1656,O
identification,1656,O
of,1656,O
4-methylhistamine,1656,B-CHEMICAL
as,1656,O
a,1656,O
potent,1656,O
H,1656,B-GENE-Y
(,1656,I-GENE-Y
4,1656,I-GENE-Y
),1656,I-GENE-Y
R,1656,I-GENE-Y
agonist,1656,O
is,1656,O
of,1656,O
major,1656,O
importance,1656,O
for,1656,O
future,1656,O
studies,1656,O
to,1656,O
unravel,1656,O
the,1656,O
physiological,1656,O
roles,1656,O
of,1656,O
the,1656,O
H,1656,B-GENE-Y
(,1656,I-GENE-Y
4,1656,I-GENE-Y
),1656,I-GENE-Y
R,1656,I-GENE-Y
.,1656,O
Novel,1657,O
agents,1657,O
that,1657,O
potentially,1657,O
inhibit,1657,O
irinotecan-induced,1657,B-CHEMICAL
diarrhea,1657,O
.,1657,O
Irinotecan,1658,B-CHEMICAL
(,1658,O
CPT-11,1658,B-CHEMICAL
",",1658,O
7-ethyl-10-,1658,B-CHEMICAL
[,1658,I-CHEMICAL
4-,1658,I-CHEMICAL
(,1658,I-CHEMICAL
1-piperidino,1658,I-CHEMICAL
),1658,I-CHEMICAL
-1-piperidino,1658,I-CHEMICAL
],1658,I-CHEMICAL
carbonyloxycamptothecin,1658,I-CHEMICAL
),1658,O
has,1658,O
exhibited,1658,O
clinical,1658,O
activities,1658,O
against,1658,O
a,1658,O
broad,1658,O
spectrum,1658,O
of,1658,O
carcinomas,1658,O
by,1658,O
inhibiting,1658,O
DNA,1658,B-GENE-Y
topoisomerase,1658,I-GENE-Y
I,1658,I-GENE-Y
(,1658,O
Topo,1658,B-GENE-Y
I,1658,I-GENE-Y
),1658,O
.,1658,O
However,1659,O
",",1659,O
severe,1659,O
and,1659,O
unpredictable,1659,O
dosing-limiting,1659,O
toxicities,1659,O
(,1659,O
mainly,1659,O
myelosuppression,1659,O
and,1659,O
severe,1659,O
diarrhea,1659,O
),1659,O
hinder,1659,O
its,1659,O
clinical,1659,O
use,1659,O
.,1659,O
The,1660,O
latter,1660,O
consists,1660,O
of,1660,O
early,1660,O
and,1660,O
late-onset,1660,O
diarrhea,1660,O
",",1660,O
occurring,1660,O
within,1660,O
24,1660,O
hr,1660,O
or,1660,O
>,1660,O
or,1660,O
=,1660,O
24,1660,O
hr,1660,O
after,1660,O
CPT-11,1660,B-CHEMICAL
administration,1660,O
",",1660,O
respectively,1660,O
.,1660,O
This,1661,O
review,1661,O
highlights,1661,O
novel,1661,O
agents,1661,O
potentially,1661,O
inhibiting,1661,O
CPT-11-induced,1661,B-CHEMICAL
diarrhea,1661,O
",",1661,O
which,1661,O
are,1661,O
designed,1661,O
and,1661,O
tested,1661,O
under,1661,O
guidance,1661,O
of,1661,O
disposition,1661,O
pathways,1661,O
and,1661,O
potential,1661,O
toxicity,1661,O
mechanisms,1661,O
.,1661,O
Early-onset,1662,O
diarrhea,1662,O
is,1662,O
observed,1662,O
immediately,1662,O
after,1662,O
CPT-11,1662,B-CHEMICAL
infusion,1662,O
and,1662,O
probably,1662,O
due,1662,O
to,1662,O
the,1662,O
inhibition,1662,O
of,1662,O
acetylcholinesterase,1662,B-GENE-Y
activity,1662,O
",",1662,O
which,1662,O
can,1662,O
be,1662,O
eliminated,1662,O
by,1662,O
administration,1662,O
of,1662,O
atropine,1662,B-CHEMICAL
.,1662,O
Late-onset,1663,O
diarrhea,1663,O
appears,1663,O
to,1663,O
be,1663,O
associated,1663,O
with,1663,O
intestinal,1663,O
exposure,1663,O
to,1663,O
SN-38,1663,B-CHEMICAL
(,1663,O
7-ethyl-10-hydroxycamptothecin,1663,B-CHEMICAL
),1663,O
",",1663,O
the,1663,O
major,1663,O
active,1663,O
metabolite,1663,O
of,1663,O
CPT-11,1663,B-CHEMICAL
",",1663,O
which,1663,O
may,1663,O
bind,1663,O
to,1663,O
Topo,1663,B-GENE-Y
I,1663,I-GENE-Y
and,1663,O
induce,1663,O
apoptosis,1663,O
of,1663,O
intestinal,1663,O
epithelia,1663,O
",",1663,O
leading,1663,O
to,1663,O
the,1663,O
disturbance,1663,O
in,1663,O
the,1663,O
absorptive,1663,O
and,1663,O
secretory,1663,O
functions,1663,O
of,1663,O
mucosa,1663,O
.,1663,O
CPT-11,1664,B-CHEMICAL
and,1664,O
SN-38,1664,B-CHEMICAL
may,1664,O
also,1664,O
stimulate,1664,O
the,1664,O
production,1664,O
of,1664,O
pro-inflammatory,1664,O
cytokines,1664,B-GENE-N
and,1664,O
prostaglandins,1664,B-CHEMICAL
(,1664,O
PGs,1664,B-CHEMICAL
),1664,O
",",1664,O
thus,1664,O
inducing,1664,O
the,1664,O
secretion,1664,O
of,1664,O
Na,1664,B-CHEMICAL
(,1664,I-CHEMICAL
+,1664,I-CHEMICAL
),1664,I-CHEMICAL
and,1664,O
Cl,1664,B-CHEMICAL
(,1664,I-CHEMICAL
-,1664,I-CHEMICAL
),1664,I-CHEMICAL
.,1664,O
Early,1665,O
treatment,1665,O
of,1665,O
severe,1665,O
late-onset,1665,O
diarrhea,1665,O
with,1665,O
oral,1665,O
high-dose,1665,O
loperamide,1665,B-CHEMICAL
has,1665,O
decreased,1665,O
patient,1665,O
morbidity,1665,O
.,1665,O
Extensive,1666,O
studies,1666,O
have,1666,O
been,1666,O
conducted,1666,O
to,1666,O
identify,1666,O
other,1666,O
potential,1666,O
agents,1666,O
to,1666,O
ameliorate,1666,O
diarrhea,1666,O
in,1666,O
preclinical,1666,O
and,1666,O
clinical,1666,O
models,1666,O
.,1666,O
These,1667,O
include,1667,O
intestinal,1667,O
alkalizing,1667,O
agents,1667,O
",",1667,O
oral,1667,O
antibiotics,1667,O
",",1667,O
enzyme,1667,O
inducers,1667,O
",",1667,O
P-glycoprotein,1667,B-GENE-N
(,1667,O
PgP,1667,B-GENE-N
),1667,O
inhibitors,1667,O
",",1667,O
cyclooxygenase-2,1667,B-GENE-Y
(,1667,O
COX-2,1667,B-GENE-Y
),1667,O
inhibitors,1667,O
",",1667,O
tumor,1667,B-GENE-Y
necrosis,1667,I-GENE-Y
factor-alpha,1667,I-GENE-Y
(,1667,O
TNF-alpha,1667,B-GENE-Y
),1667,O
inhibitors,1667,O
",",1667,O
or,1667,O
blockers,1667,O
of,1667,O
biliary,1667,O
excretion,1667,O
of,1667,O
SN-38,1667,B-CHEMICAL
.,1667,O
Further,1668,O
studies,1668,O
are,1668,O
needed,1668,O
to,1668,O
identify,1668,O
the,1668,O
molecular,1668,O
targets,1668,O
associated,1668,O
with,1668,O
CPT-11,1668,B-CHEMICAL
toxicity,1668,O
and,1668,O
safe,1668,O
and,1668,O
effective,1668,O
agents,1668,O
for,1668,O
alleviating,1668,O
CPT-11-induced,1668,B-CHEMICAL
diarrhea,1668,O
.,1668,O
Crystal,1669,O
structure,1669,O
of,1669,O
pyridoxal,1669,B-GENE-Y
kinase,1669,I-GENE-Y
in,1669,O
complex,1669,O
with,1669,O
roscovitine,1669,B-CHEMICAL
and,1669,O
derivatives,1669,O
.,1669,O
Pyridoxal,1670,B-GENE-Y
kinase,1670,I-GENE-Y
(,1670,O
PDXK,1670,B-GENE-Y
),1670,O
catalyzes,1670,O
the,1670,O
phosphorylation,1670,O
of,1670,O
pyridoxal,1670,B-CHEMICAL
",",1670,O
pyridoxamine,1670,B-CHEMICAL
",",1670,O
and,1670,O
pyridoxine,1670,B-CHEMICAL
in,1670,O
the,1670,O
presence,1670,O
of,1670,O
ATP,1670,B-CHEMICAL
and,1670,O
Zn2+,1670,B-CHEMICAL
.,1670,O
This,1671,O
constitutes,1671,O
an,1671,O
essential,1671,O
step,1671,O
in,1671,O
the,1671,O
synthesis,1671,O
of,1671,O
pyridoxal,1671,B-CHEMICAL
5'-phosphate,1671,I-CHEMICAL
(,1671,O
PLP,1671,B-CHEMICAL
),1671,O
",",1671,O
the,1671,O
active,1671,O
form,1671,O
of,1671,O
vitamin,1671,B-CHEMICAL
B6,1671,I-CHEMICAL
",",1671,O
a,1671,O
cofactor,1671,O
for,1671,O
over,1671,O
140,1671,O
enzymes,1671,O
.,1671,O
(,1672,B-CHEMICAL
R,1672,I-CHEMICAL
),1672,I-CHEMICAL
-Roscovitine,1672,I-CHEMICAL
(,1672,O
CYC202,1672,B-CHEMICAL
",",1672,O
Seliciclib,1672,B-CHEMICAL
),1672,O
is,1672,O
a,1672,O
relatively,1672,O
selective,1672,O
inhibitor,1672,O
of,1672,O
cyclin-dependent,1672,B-GENE-N
kinases,1672,I-GENE-N
(,1672,O
CDKs,1672,B-GENE-N
),1672,O
",",1672,O
currently,1672,O
evaluated,1672,O
for,1672,O
the,1672,O
treatment,1672,O
of,1672,O
cancers,1672,O
",",1672,O
neurodegenerative,1672,O
disorders,1672,O
",",1672,O
renal,1672,O
diseases,1672,O
",",1672,O
and,1672,O
several,1672,O
viral,1672,O
infections,1672,O
.,1672,O
Affinity,1673,O
chromatography,1673,O
investigations,1673,O
have,1673,O
shown,1673,O
that,1673,O
(,1673,B-CHEMICAL
R,1673,I-CHEMICAL
),1673,I-CHEMICAL
-roscovitine,1673,I-CHEMICAL
also,1673,O
interacts,1673,O
with,1673,O
PDXK,1673,B-GENE-Y
.,1673,O
To,1674,O
understand,1674,O
this,1674,O
interaction,1674,O
",",1674,O
we,1674,O
determined,1674,O
the,1674,O
crystal,1674,O
structure,1674,O
of,1674,O
PDXK,1674,B-GENE-Y
in,1674,O
complex,1674,O
with,1674,O
(,1674,B-CHEMICAL
R,1674,I-CHEMICAL
),1674,I-CHEMICAL
-roscovitine,1674,I-CHEMICAL
",",1674,O
N6-methyl-,1674,B-CHEMICAL
(,1674,I-CHEMICAL
R,1674,I-CHEMICAL
),1674,I-CHEMICAL
-roscovitine,1674,I-CHEMICAL
",",1674,O
and,1674,O
O6-,1674,B-CHEMICAL
(,1674,I-CHEMICAL
R,1674,I-CHEMICAL
),1674,I-CHEMICAL
-roscovitine,1674,I-CHEMICAL
",",1674,O
the,1674,O
two,1674,O
latter,1674,O
derivatives,1674,O
being,1674,O
designed,1674,O
to,1674,O
bind,1674,O
to,1674,O
PDXK,1674,B-GENE-Y
but,1674,O
not,1674,O
to,1674,O
CDKs,1674,B-GENE-N
.,1674,O
Structural,1675,O
analysis,1675,O
revealed,1675,O
that,1675,O
these,1675,O
three,1675,O
roscovitines,1675,B-CHEMICAL
bind,1675,O
similarly,1675,O
in,1675,O
the,1675,O
pyridoxal-binding,1675,B-CHEMICAL
site,1675,O
of,1675,O
PDXK,1675,B-GENE-Y
rather,1675,O
than,1675,O
in,1675,O
the,1675,O
anticipated,1675,O
ATP-binding,1675,B-CHEMICAL
site,1675,O
.,1675,O
The,1676,O
pyridoxal,1676,B-CHEMICAL
pocket,1676,O
has,1676,O
thus,1676,O
an,1676,O
unexpected,1676,O
ability,1676,O
to,1676,O
accommodate,1676,O
molecules,1676,O
different,1676,O
from,1676,O
and,1676,O
larger,1676,O
than,1676,O
pyridoxal,1676,B-CHEMICAL
.,1676,O
This,1677,O
work,1677,O
provides,1677,O
detailed,1677,O
structural,1677,O
information,1677,O
on,1677,O
the,1677,O
interactions,1677,O
between,1677,O
PDXK,1677,B-GENE-Y
and,1677,O
roscovitine,1677,B-CHEMICAL
and,1677,O
analogs,1677,O
.,1677,O
It,1678,O
could,1678,O
also,1678,O
aid,1678,O
in,1678,O
the,1678,O
design,1678,O
of,1678,O
roscovitine,1678,B-CHEMICAL
derivatives,1678,O
displaying,1678,O
strict,1678,O
selectivity,1678,O
for,1678,O
either,1678,O
PDXK,1678,B-GENE-Y
or,1678,O
CDKs,1678,B-GENE-N
.,1678,O
Gastric,1679,B-GENE-N
mucin,1679,I-GENE-N
secretion,1679,O
in,1679,O
response,1679,O
to,1679,O
beta-adrenergic,1679,B-GENE-N
G,1679,I-GENE-N
protein-coupled,1679,I-GENE-N
receptor,1679,I-GENE-N
activation,1679,O
is,1679,O
mediated,1679,O
by,1679,O
SRC,1679,B-GENE-Y
kinase-dependent,1679,B-GENE-N
epidermal,1679,B-GENE-Y
growth,1679,I-GENE-Y
factor,1679,I-GENE-Y
receptor,1679,I-GENE-Y
transactivation,1679,O
.,1679,O
In,1680,O
many,1680,O
systems,1680,O
",",1680,O
the,1680,O
integration,1680,O
of,1680,O
converging,1680,O
regulatory,1680,O
signals,1680,O
that,1680,O
relay,1680,O
on,1680,O
G,1680,B-GENE-N
protein-coupled,1680,I-GENE-N
receptor,1680,I-GENE-N
(,1680,O
GPCR,1680,B-GENE-N
),1680,O
activation,1680,O
into,1680,O
functional,1680,O
cellular,1680,O
pathways,1680,O
requires,1680,O
the,1680,O
involvement,1680,O
of,1680,O
receptor,1680,B-GENE-N
tyrosine,1680,B-CHEMICAL
kinase,1680,I-GENE-N
.,1680,O
In,1681,O
this,1681,O
report,1681,O
",",1681,O
we,1681,O
provide,1681,O
evidence,1681,O
that,1681,O
activation,1681,O
of,1681,O
GPCR,1681,B-GENE-N
by,1681,O
beta-adrenergic,1681,O
agonist,1681,O
leading,1681,O
to,1681,O
stimulation,1681,O
in,1681,O
gastric,1681,B-GENE-N
mucin,1681,I-GENE-N
secretion,1681,O
requires,1681,O
epidermal,1681,B-GENE-Y
growth,1681,I-GENE-Y
factor,1681,I-GENE-Y
receptor,1681,I-GENE-Y
(,1681,O
EGFR,1681,B-GENE-Y
),1681,O
participation,1681,O
.,1681,O
Using,1682,O
[,1682,B-CHEMICAL
(,1682,I-CHEMICAL
3,1682,I-CHEMICAL
),1682,I-CHEMICAL
H,1682,I-CHEMICAL
],1682,I-CHEMICAL
glucosamine-labeled,1682,O
gastric,1682,O
mucosal,1682,O
cells,1682,O
",",1682,O
we,1682,O
show,1682,O
that,1682,O
stimulatory,1682,O
effect,1682,O
of,1682,O
beta-adrenergic,1682,O
agonist,1682,O
",",1682,O
isoproterenol,1682,O
",",1682,O
on,1682,O
mucin,1682,B-GENE-N
secretion,1682,O
was,1682,O
inhibited,1682,O
by,1682,O
EGFR,1682,B-GENE-Y
kinase,1682,B-GENE-N
inhibitor,1682,O
",",1682,O
PD153035,1682,B-CHEMICAL
",",1682,O
as,1682,O
well,1682,O
as,1682,O
wortmannin,1682,B-CHEMICAL
",",1682,O
a,1682,O
specific,1682,O
inhibitor,1682,O
of,1682,O
PI3K,1682,B-GENE-N
.,1682,O
Both,1683,O
inhibitors,1683,O
",",1683,O
moreover,1683,O
",",1683,O
blunted,1683,O
the,1683,O
mucin,1683,B-GENE-N
secretory,1683,O
responses,1683,O
to,1683,O
beta-adrenergic,1683,O
agonist-generated,1683,O
second,1683,O
messenger,1683,O
",",1683,O
cAMP,1683,B-CHEMICAL
as,1683,O
well,1683,O
as,1683,O
adenylate,1683,B-CHEMICAL
cyclase,1683,I-GENE-N
activator,1683,O
",",1683,O
forskolin,1683,B-CHEMICAL
.,1683,O
The,1684,O
gastric,1684,B-GENE-N
mucin,1684,I-GENE-N
secretory,1684,O
responses,1684,O
to,1684,O
isoproterenol,1684,B-CHEMICAL
",",1684,O
furthermore,1684,O
",",1684,O
were,1684,O
inhibited,1684,O
by,1684,O
PP2,1684,B-CHEMICAL
",",1684,O
a,1684,O
selective,1684,O
inhibitor,1684,O
of,1684,O
tyrosine,1684,B-GENE-N
kinase,1684,I-GENE-N
Src,1684,B-GENE-Y
responsible,1684,O
for,1684,O
ligand-independent,1684,O
EGFR,1684,B-GENE-Y
autophosphorylation,1684,O
",",1684,O
but,1684,O
not,1684,O
by,1684,O
ERK,1684,B-GENE-N
inhibitor,1684,O
",",1684,O
PD98059,1684,B-CHEMICAL
.,1684,O
The,1685,O
inhibition,1685,O
of,1685,O
ERK,1685,B-GENE-N
",",1685,O
moreover,1685,O
",",1685,O
did,1685,O
not,1685,O
cause,1685,O
attenuation,1685,O
in,1685,O
mucin,1685,B-GENE-N
secretion,1685,O
in,1685,O
response,1685,O
to,1685,O
cAMP,1685,B-CHEMICAL
and,1685,O
forskolin,1685,B-CHEMICAL
.,1685,O
The,1686,O
findings,1686,O
underline,1686,O
the,1686,O
role,1686,O
of,1686,O
EGFR,1686,B-GENE-Y
as,1686,O
a,1686,O
convergence,1686,O
point,1686,O
in,1686,O
gastric,1686,B-GENE-N
mucin,1686,I-GENE-N
secretion,1686,O
triggered,1686,O
by,1686,O
beta-adrenergic,1686,B-GENE-N
GPCR,1686,I-GENE-N
activation,1686,O
",",1686,O
and,1686,O
demonstrate,1686,O
the,1686,O
requirement,1686,O
for,1686,O
Src,1686,B-GENE-Y
kinase,1686,B-GENE-N
in,1686,O
EGFR,1686,B-GENE-Y
transactivation,1686,O
.,1686,O
Losartan,1687,B-CHEMICAL
:,1687,O
a,1687,O
selective,1687,O
angiotensin,1687,B-GENE-Y
II,1687,I-GENE-Y
type,1687,I-GENE-Y
1,1687,I-GENE-Y
(,1687,I-GENE-Y
AT1,1687,I-GENE-Y
),1687,I-GENE-Y
receptor,1687,I-GENE-Y
antagonist,1687,O
for,1687,O
the,1687,O
treatment,1687,O
of,1687,O
heart,1687,O
failure,1687,O
.,1687,O
Losartan,1688,B-CHEMICAL
(,1688,O
COZAAR,1688,B-CHEMICAL
),1688,O
is,1688,O
the,1688,O
prototype,1688,O
of,1688,O
a,1688,O
new,1688,O
class,1688,O
of,1688,O
potent,1688,O
and,1688,O
selective,1688,O
angiotensin,1688,B-GENE-Y
II,1688,I-GENE-Y
(,1688,I-GENE-Y
AII,1688,I-GENE-Y
),1688,I-GENE-Y
type,1688,I-GENE-Y
1,1688,I-GENE-Y
(,1688,I-GENE-Y
AT,1688,I-GENE-Y
(,1688,I-GENE-Y
1,1688,I-GENE-Y
),1688,I-GENE-Y
),1688,I-GENE-Y
receptor,1688,I-GENE-Y
antagonists,1688,O
with,1688,O
the,1688,O
largest,1688,O
published,1688,O
preclinical,1688,O
and,1688,O
clinical,1688,O
data,1688,O
base,1688,O
.,1688,O
Since,1689,O
all,1689,O
of,1689,O
the,1689,O
AII,1689,B-GENE-Y
antagonists,1689,O
are,1689,O
selective,1689,O
for,1689,O
the,1689,O
AT,1689,B-GENE-Y
(,1689,I-GENE-Y
1,1689,I-GENE-Y
),1689,I-GENE-Y
receptor,1689,I-GENE-Y
",",1689,O
these,1689,O
drugs,1689,O
should,1689,O
exhibit,1689,O
similar,1689,O
cardiovascular,1689,O
effects,1689,O
.,1689,O
However,1690,O
",",1690,O
since,1690,O
the,1690,O
pharmacokinetic/pharmacodynamic,1690,O
profiles,1690,O
of,1690,O
these,1690,O
agents,1690,O
and,1690,O
their,1690,O
degree,1690,O
of,1690,O
affinity,1690,O
for,1690,O
the,1690,O
AT,1690,B-GENE-Y
(,1690,I-GENE-Y
1,1690,I-GENE-Y
),1690,I-GENE-Y
receptor,1690,I-GENE-Y
differ,1690,O
",",1690,O
it,1690,O
is,1690,O
likely,1690,O
that,1690,O
differences,1690,O
in,1690,O
clinical,1690,O
profiles,1690,O
between,1690,O
these,1690,O
drugs,1690,O
exist,1690,O
and,1690,O
will,1690,O
require,1690,O
investigation,1690,O
.,1690,O
Losartan,1691,B-CHEMICAL
(,1691,O
parent,1691,O
compound,1691,O
),1691,O
",",1691,O
has,1691,O
moderate,1691,O
affinity,1691,O
for,1691,O
the,1691,O
AT,1691,B-GENE-Y
(,1691,I-GENE-Y
1,1691,I-GENE-Y
),1691,I-GENE-Y
receptor,1691,I-GENE-Y
(,1691,O
competitive,1691,O
inhibition,1691,O
),1691,O
.,1691,O
Losartan,1692,B-CHEMICAL
is,1692,O
well-absorbed,1692,O
orally,1692,O
as,1692,O
an,1692,O
active,1692,O
drug,1692,O
and,1692,O
is,1692,O
rapidly,1692,O
converted,1692,O
via,1692,O
oxidation,1692,O
in,1692,O
the,1692,O
human,1692,O
liver,1692,O
to,1692,O
a,1692,O
more,1692,O
potent,1692,O
metabolite,1692,O
(,1692,O
designated,1692,O
E3174,1692,O
),1692,O
with,1692,O
an,1692,O
affinity,1692,O
20-,1692,O
to,1692,O
30-times,1692,O
greater,1692,O
for,1692,O
the,1692,O
AT,1692,B-GENE-Y
(,1692,I-GENE-Y
1,1692,I-GENE-Y
),1692,I-GENE-Y
receptor,1692,I-GENE-Y
(,1692,O
non-competitive,1692,O
inhibition,1692,O
),1692,O
.,1692,O
E3174,1693,O
has,1693,O
a,1693,O
half-life,1693,O
of,1693,O
6,1693,O
-,1693,O
9,1693,O
h,1693,O
;,1693,O
elimination,1693,O
is,1693,O
via,1693,O
renal,1693,O
and,1693,O
hepatic,1693,O
routes,1693,O
.,1693,O
Antihypertensive,1694,O
and,1694,O
",",1694,O
in,1694,O
heart,1694,O
failure,1694,O
patients,1694,O
",",1694,O
haemodynamic,1694,O
activity,1694,O
is,1694,O
observed,1694,O
over,1694,O
a,1694,O
24,1694,O
h,1694,O
period,1694,O
with,1694,O
once,1694,O
daily,1694,O
dosing,1694,O
.,1694,O
Over,1695,O
6,1695,O
million,1695,O
patients,1695,O
have,1695,O
been,1695,O
treated,1695,O
for,1695,O
hypertension,1695,O
with,1695,O
continued,1695,O
excellent,1695,O
tolerability,1695,O
.,1695,O
Clinical,1696,O
experience,1696,O
in,1696,O
heart,1696,O
failure,1696,O
is,1696,O
growing,1696,O
",",1696,O
and,1696,O
recent,1696,O
data,1696,O
suggest,1696,O
an,1696,O
improved,1696,O
survival,1696,O
with,1696,O
losartan,1696,B-CHEMICAL
versus,1696,O
captopril,1696,B-CHEMICAL
",",1696,O
a,1696,O
drug,1696,O
from,1696,O
the,1696,O
angiotensin-converting-enzyme,1696,B-CHEMICAL
inhibitor,1696,O
class,1696,O
with,1696,O
proven,1696,O
benefit,1696,O
in,1696,O
this,1696,O
population,1696,O
.,1696,O
The,1697,O
current,1697,O
comprehensive,1697,O
losartan,1697,B-CHEMICAL
clinical,1697,O
end-point,1697,O
programme,1697,O
(,1697,O
4,1697,O
large,1697,O
scale,1697,O
morbidity/mortality,1697,O
trials,1697,O
),1697,O
should,1697,O
provide,1697,O
evidence,1697,O
regarding,1697,O
the,1697,O
efficacy,1697,O
of,1697,O
direct,1697,O
blockade,1697,O
of,1697,O
the,1697,O
AT,1697,B-GENE-Y
(,1697,I-GENE-Y
1,1697,I-GENE-Y
),1697,I-GENE-Y
receptor,1697,I-GENE-Y
with,1697,O
losartan,1697,B-CHEMICAL
compared,1697,O
to,1697,O
standard,1697,O
therapy,1697,O
:,1697,O
1,1697,O
),1697,O
The,1697,O
Losartan,1697,B-CHEMICAL
Heart,1697,O
Failure,1697,O
Survival,1697,O
Study,1697,O
-,1697,O
ELITE,1697,O
II,1697,O
",",1697,O
2,1697,O
),1697,O
The,1697,O
Losartan,1697,B-CHEMICAL
Post-Myocardial,1697,O
Infarction,1697,O
Survival,1697,O
Study,1697,O
-,1697,O
OPTIMAAL,1697,O
",",1697,O
3,1697,O
),1697,O
The,1697,O
Losartan,1697,B-CHEMICAL
Hypertension,1697,O
Survival,1697,O
Study,1697,O
-,1697,O
LIFE,1697,O
and,1697,O
4,1697,O
),1697,O
The,1697,O
Losartan,1697,B-CHEMICAL
Renal,1697,O
Protection,1697,O
Study,1697,O
-,1697,O
RENAAL,1697,O
.,1697,O
Effect,1698,O
of,1698,O
amrinone,1698,B-CHEMICAL
on,1698,O
tumor,1698,B-GENE-Y
necrosis,1698,I-GENE-Y
factor,1698,I-GENE-Y
production,1698,O
in,1698,O
endotoxic,1698,O
shock,1698,O
.,1698,O
Tumor,1699,B-GENE-Y
necrosis,1699,I-GENE-Y
factor,1699,I-GENE-Y
(,1699,O
TNF,1699,B-GENE-Y
),1699,O
is,1699,O
a,1699,O
macrophage-derived,1699,O
mediator,1699,O
responsible,1699,O
for,1699,O
many,1699,O
of,1699,O
the,1699,O
pathophysiologic,1699,O
manifestations,1699,O
of,1699,O
endotoxic,1699,O
shock,1699,O
.,1699,O
We,1700,O
now,1700,O
demonstrate,1700,O
that,1700,O
amrinone,1700,B-CHEMICAL
",",1700,O
a,1700,O
noncatechol,1700,O
inotrope,1700,O
",",1700,O
strongly,1700,O
inhibits,1700,O
lipopolysaccharide,1700,O
(,1700,O
LPS,1700,O
),1700,O
-induced,1700,O
TNF,1700,B-GENE-Y
production,1700,O
at,1700,O
concentrations,1700,O
readily,1700,O
achieved,1700,O
in,1700,O
vivo,1700,O
.,1700,O
This,1701,O
inhibition,1701,O
is,1701,O
apparent,1701,O
in,1701,O
murine,1701,O
macrophages,1701,O
",",1701,O
in,1701,O
macrophage,1701,O
cell,1701,O
lines,1701,O
",",1701,O
in,1701,O
vivo,1701,O
",",1701,O
and,1701,O
in,1701,O
cell,1701,O
lines,1701,O
containing,1701,O
a,1701,O
reporter,1701,O
gene,1701,O
construct,1701,O
that,1701,O
substitutes,1701,O
the,1701,O
chloramphenicol,1701,O
acetyl,1701,O
transferase,1701,O
(,1701,O
CAT,1701,O
),1701,O
coding,1701,O
sequence,1701,O
for,1701,O
the,1701,O
TNF,1701,B-GENE-Y
coding,1701,O
sequence,1701,O
and,1701,O
introns,1701,O
.,1701,O
Inhibition,1702,O
by,1702,O
amrinone,1702,B-CHEMICAL
(,1702,O
like,1702,O
inhibition,1702,O
by,1702,O
pentoxifylline,1702,B-CHEMICAL
),1702,O
is,1702,O
manifested,1702,O
at,1702,O
the,1702,O
level,1702,O
of,1702,O
mRNA,1702,O
accumulation,1702,O
",",1702,O
in,1702,O
contrast,1702,O
to,1702,O
inhibition,1702,O
caused,1702,O
by,1702,O
dexamethasone,1702,B-CHEMICAL
.,1702,O
Combined,1703,O
application,1703,O
of,1703,O
dexamethasone,1703,B-CHEMICAL
and,1703,O
amrinone,1703,B-CHEMICAL
caused,1703,O
additive,1703,O
inhibition,1703,O
of,1703,O
TNF,1703,B-GENE-Y
biosynthesis,1703,O
in,1703,O
vitro,1703,O
.,1703,O
Furthermore,1704,O
",",1704,O
treatment,1704,O
of,1704,O
mice,1704,O
with,1704,O
amrinone,1704,B-CHEMICAL
immediately,1704,O
prior,1704,O
to,1704,O
endotoxin,1704,O
challenge,1704,O
led,1704,O
to,1704,O
significantly,1704,O
improved,1704,O
survival,1704,O
.,1704,O
These,1705,O
findings,1705,O
suggest,1705,O
that,1705,O
amrinone,1705,B-CHEMICAL
possesses,1705,O
antiinflammatory,1705,O
as,1705,O
well,1705,O
as,1705,O
inotropic,1705,O
properties,1705,O
that,1705,O
may,1705,O
make,1705,O
it,1705,O
an,1705,O
appropriate,1705,O
agent,1705,O
for,1705,O
use,1705,O
in,1705,O
septic,1705,O
shock,1705,O
or,1705,O
other,1705,O
serious,1705,O
bacterial,1705,O
infections,1705,O
.,1705,O
Abrupt,1706,O
removal,1706,O
of,1706,O
amrinone,1706,B-CHEMICAL
or,1706,O
pentoxifylline,1706,B-CHEMICAL
from,1706,O
the,1706,O
culture,1706,O
medium,1706,O
prior,1706,O
to,1706,O
LPS,1706,O
stimulation,1706,O
",",1706,O
however,1706,O
",",1706,O
caused,1706,O
significantly,1706,O
augmented,1706,O
TNF,1706,B-GENE-Y
production,1706,O
.,1706,O
Therefore,1707,O
",",1707,O
amrinone,1707,B-CHEMICAL
and,1707,O
other,1707,O
phosphodiesterase,1707,B-GENE-N
inhibitors,1707,O
may,1707,O
also,1707,O
enhance,1707,O
sensitivity,1707,O
to,1707,O
LPS,1707,O
during,1707,O
a,1707,O
period,1707,O
of,1707,O
time,1707,O
following,1707,O
discontinuation,1707,O
of,1707,O
therapy,1707,O
.,1707,O
Age-dependent,1708,O
changes,1708,O
of,1708,O
pyridoxal,1708,B-CHEMICAL
phosphate,1708,I-CHEMICAL
synthesizing,1708,O
enzymes,1708,O
immunoreactivities,1708,O
and,1708,O
activities,1708,O
in,1708,O
the,1708,O
gerbil,1708,O
hippocampal,1708,O
CA1,1708,O
region,1708,O
.,1708,O
In,1709,O
the,1709,O
present,1709,O
study,1709,O
",",1709,O
age-related,1709,O
changes,1709,O
of,1709,O
pyridoxal,1709,B-CHEMICAL
5'-phosphate,1709,I-CHEMICAL
(,1709,O
PLP,1709,B-CHEMICAL
),1709,O
synthesizing,1709,O
enzymes,1709,O
",",1709,O
pyridoxal,1709,B-CHEMICAL
kinase,1709,I-GENE-N
(,1709,O
PLK,1709,B-GENE-N
),1709,O
and,1709,O
pyridoxine,1709,B-CHEMICAL
5'-phosphate,1709,I-CHEMICAL
oxidase,1709,I-GENE-N
(,1709,O
PNPO,1709,B-GENE-N
),1709,O
",",1709,O
their,1709,O
protein,1709,O
contents,1709,O
and,1709,O
activities,1709,O
were,1709,O
examined,1709,O
in,1709,O
the,1709,O
gerbil,1709,O
hippocampus,1709,O
proper,1709,O
.,1709,O
Significant,1710,O
age-dependent,1710,O
changes,1710,O
in,1710,O
PLK,1710,B-GENE-N
and,1710,O
PNPO,1710,B-GENE-N
immunoreactivities,1710,O
were,1710,O
found,1710,O
in,1710,O
the,1710,O
CA1,1710,O
region,1710,O
",",1710,O
but,1710,O
not,1710,O
in,1710,O
the,1710,O
CA2/3,1710,O
region,1710,O
.,1710,O
In,1711,O
the,1711,O
postnatal,1711,O
month,1711,O
1,1711,O
(,1711,O
PM,1711,O
1,1711,O
),1711,O
group,1711,O
",",1711,O
PLK,1711,B-GENE-N
and,1711,O
PNPO,1711,B-GENE-N
immunoreactivities,1711,O
were,1711,O
detected,1711,O
mainly,1711,O
in,1711,O
the,1711,O
stratum,1711,O
pyramidale,1711,O
of,1711,O
the,1711,O
CA1,1711,O
region,1711,O
.,1711,O
PLK,1712,B-GENE-N
and,1712,O
PNPO,1712,B-GENE-N
immunoreactivities,1712,O
and,1712,O
their,1712,O
protein,1712,O
contents,1712,O
were,1712,O
highest,1712,O
in,1712,O
the,1712,O
PM,1712,O
6,1712,O
group,1712,O
",",1712,O
showing,1712,O
that,1712,O
many,1712,O
CA1,1712,O
pyramidal,1712,O
cells,1712,O
had,1712,O
strong,1712,O
PLK,1712,B-GENE-N
and,1712,O
PNPO,1712,B-GENE-N
immunoreactivities,1712,O
.,1712,O
Thereafter,1713,O
",",1713,O
PLK,1713,B-GENE-N
and,1713,O
PNPO,1713,B-GENE-N
immunoreactivities,1713,O
started,1713,O
to,1713,O
decrease,1713,O
and,1713,O
were,1713,O
very,1713,O
low,1713,O
at,1713,O
PM,1713,O
24,1713,O
.,1713,O
Alterations,1714,O
in,1714,O
the,1714,O
change,1714,O
patterns,1714,O
in,1714,O
protein,1714,O
contents,1714,O
and,1714,O
total,1714,O
activities,1714,O
of,1714,O
PLK,1714,B-GENE-N
and,1714,O
PNPO,1714,B-GENE-N
corresponded,1714,O
to,1714,O
the,1714,O
immunohistochemical,1714,O
data,1714,O
",",1714,O
but,1714,O
their,1714,O
specific,1714,O
activities,1714,O
were,1714,O
not,1714,O
altered,1714,O
in,1714,O
any,1714,O
experimental,1714,O
group,1714,O
.,1714,O
Based,1715,O
on,1715,O
double,1715,O
immunofluorescence,1715,O
study,1715,O
",",1715,O
PLK,1715,B-GENE-N
and,1715,O
PNPO,1715,B-GENE-N
immunoreactive,1715,O
cells,1715,O
in,1715,O
the,1715,O
strata,1715,O
oriens,1715,O
and,1715,O
radiatum,1715,O
were,1715,O
identified,1715,O
as,1715,O
GABAergic,1715,O
cells,1715,O
.,1715,O
Therefore,1716,O
",",1716,O
decreases,1716,O
of,1716,O
PLK,1716,B-GENE-N
and,1716,O
PNPO,1716,B-GENE-N
in,1716,O
the,1716,O
hippocampal,1716,O
CA1,1716,O
region,1716,O
of,1716,O
aged,1716,O
brains,1716,O
may,1716,O
be,1716,O
involved,1716,O
in,1716,O
aging,1716,O
processes,1716,O
related,1716,O
with,1716,O
gamma-aminobutyric,1716,B-CHEMICAL
acid,1716,I-CHEMICAL
(,1716,O
GABA,1716,B-CHEMICAL
),1716,O
function,1716,O
.,1716,O
Functional,1717,O
characteristics,1717,O
of,1717,O
H+,1717,B-CHEMICAL
-dependent,1717,O
nicotinate,1717,B-CHEMICAL
transport,1717,O
in,1717,O
primary,1717,O
cultures,1717,O
of,1717,O
astrocytes,1717,O
from,1717,O
rat,1717,O
cerebral,1717,O
cortex,1717,O
.,1717,O
In,1718,O
the,1718,O
present,1718,O
study,1718,O
",",1718,O
we,1718,O
report,1718,O
the,1718,O
characteristics,1718,O
of,1718,O
H,1718,B-CHEMICAL
(,1718,I-CHEMICAL
+,1718,I-CHEMICAL
),1718,I-CHEMICAL
-coupled,1718,O
nicotinate,1718,B-CHEMICAL
transport,1718,O
in,1718,O
primary,1718,O
cultures,1718,O
of,1718,O
astrocytes,1718,O
from,1718,O
rat,1718,O
cerebral,1718,O
cortex,1718,O
.,1718,O
The,1719,O
[,1719,B-CHEMICAL
(,1719,I-CHEMICAL
3,1719,I-CHEMICAL
),1719,I-CHEMICAL
H,1719,I-CHEMICAL
],1719,I-CHEMICAL
nicotinate,1719,I-CHEMICAL
transport,1719,O
in,1719,O
rat,1719,O
astrocytes,1719,O
increased,1719,O
up,1719,O
to,1719,O
a,1719,O
pH,1719,O
5.5,1719,O
.,1719,O
The,1720,O
nicotinic,1720,B-CHEMICAL
acid,1720,I-CHEMICAL
uptake,1720,O
at,1720,O
pH,1720,O
6.0,1720,O
was,1720,O
both,1720,O
energy-dependent,1720,O
and,1720,O
saturable,1720,O
with,1720,O
a,1720,O
Michaelis,1720,O
constant,1720,O
(,1720,O
K,1720,O
(,1720,O
t,1720,O
),1720,O
),1720,O
of,1720,O
2.8+/-0.4,1720,O
mM,1720,O
and,1720,O
the,1720,O
maximal,1720,O
uptake,1720,O
rate,1720,O
(,1720,O
V,1720,O
(,1720,O
max,1720,O
),1720,O
),1720,O
of,1720,O
31+/-3.2,1720,O
nmol/mg,1720,O
protein/10,1720,O
min,1720,O
.,1720,O
This,1721,O
process,1721,O
was,1721,O
reduced,1721,O
by,1721,O
a,1721,O
protonophore,1721,O
",",1721,O
carbonylcyanide,1721,B-CHEMICAL
p-trifluoromethoxyphenylhydrazone,1721,I-CHEMICAL
",",1721,O
and,1721,O
a,1721,O
typical,1721,O
monocarboxylate,1721,B-GENE-N
transporter,1721,I-GENE-N
(,1721,O
MCT,1721,B-GENE-N
),1721,O
inhibitor,1721,O
",",1721,O
alpha-cyano-4-hydroxycinnamic,1721,B-CHEMICAL
acid,1721,I-CHEMICAL
",",1721,O
suggesting,1721,O
that,1721,O
nicotinate,1721,B-CHEMICAL
uptake,1721,O
by,1721,O
rat,1721,O
astrocytes,1721,O
is,1721,O
mediated,1721,O
by,1721,O
H,1721,B-CHEMICAL
(,1721,I-CHEMICAL
+,1721,I-CHEMICAL
),1721,I-CHEMICAL
-coupled,1721,O
monocarboxylate,1721,B-GENE-N
transport,1721,I-GENE-N
system,1721,I-GENE-N
.,1721,O
[,1722,B-CHEMICAL
(,1722,I-CHEMICAL
3,1722,I-CHEMICAL
),1722,I-CHEMICAL
H,1722,I-CHEMICAL
],1722,I-CHEMICAL
Nicotinate,1722,I-CHEMICAL
transport,1722,O
in,1722,O
rat,1722,O
astrocytes,1722,O
was,1722,O
significantly,1722,O
inhibited,1722,O
by,1722,O
various,1722,O
monocarboxylic,1722,B-CHEMICAL
acids,1722,I-CHEMICAL
such,1722,O
as,1722,O
l-lactic,1722,B-CHEMICAL
acid,1722,I-CHEMICAL
and,1722,O
pyruvic,1722,B-CHEMICAL
acid,1722,I-CHEMICAL
with,1722,O
a,1722,O
relatively,1722,O
low,1722,O
affinity,1722,O
(,1722,O
K,1722,O
(,1722,O
i,1722,O
),1722,O
>,1722,O
10,1722,O
mM,1722,O
),1722,O
.,1722,O
On,1723,O
the,1723,O
other,1723,O
hand,1723,O
",",1723,O
the,1723,O
uptake,1723,O
process,1723,O
of,1723,O
l-lactic,1723,B-CHEMICAL
acid,1723,I-CHEMICAL
was,1723,O
also,1723,O
saturable,1723,O
with,1723,O
a,1723,O
high-affinity,1723,O
component,1723,O
(,1723,O
K,1723,O
(,1723,O
t,1723,O
),1723,O
=0.27,1723,O
mM,1723,O
),1723,O
and,1723,O
a,1723,O
low-affinity,1723,O
component,1723,O
(,1723,O
K,1723,O
(,1723,O
t,1723,O
),1723,O
=35.9,1723,O
mM,1723,O
),1723,O
.,1723,O
Reverse,1724,O
transcription-PCR,1724,O
and,1724,O
Western,1724,O
blot,1724,O
analyses,1724,O
revealed,1724,O
that,1724,O
three,1724,O
MCT,1724,B-GENE-N
subtypes,1724,O
",",1724,O
MCT1/Slc16a1,1724,B-GENE-Y
",",1724,O
MCT2/Slc16a7,1724,B-GENE-Y
",",1724,O
and,1724,O
MCT4/Slc16a3,1724,B-GENE-Y
",",1724,O
were,1724,O
expressed,1724,O
in,1724,O
these,1724,O
cells,1724,O
.,1724,O
Because,1725,O
l-lactate,1725,B-CHEMICAL
reduced,1725,O
to,1725,O
67,1725,O
%,1725,O
of,1725,O
the,1725,O
nicotinate,1725,B-CHEMICAL
uptake,1725,O
even,1725,O
at,1725,O
10mM,1725,O
",",1725,O
it,1725,O
is,1725,O
unlikely,1725,O
that,1725,O
nicotinate,1725,B-CHEMICAL
uptake,1725,O
in,1725,O
rat,1725,O
astrocytes,1725,O
is,1725,O
mediated,1725,O
by,1725,O
MCT1,1725,B-GENE-Y
and/or,1725,O
MCT2,1725,B-GENE-Y
.,1725,O
These,1726,O
results,1726,O
provide,1726,O
biochemical,1726,O
evidence,1726,O
of,1726,O
a,1726,O
H,1726,B-CHEMICAL
(,1726,I-CHEMICAL
+,1726,I-CHEMICAL
),1726,I-CHEMICAL
-coupled,1726,O
and,1726,O
saturable,1726,O
transport,1726,O
system,1726,O
",",1726,O
presumed,1726,O
to,1726,O
be,1726,O
a,1726,O
low-affinity,1726,B-GENE-N
monocarboxylate,1726,B-CHEMICAL
transporter,1726,I-GENE-N
MCT4,1726,B-GENE-Y
or,1726,O
other,1726,O
unknown,1726,O
H,1726,B-CHEMICAL
(,1726,I-CHEMICAL
+,1726,I-CHEMICAL
),1726,I-CHEMICAL
-coupled,1726,I-GENE-N
monocarboxylate,1726,B-CHEMICAL
transport,1726,I-GENE-N
system,1726,I-GENE-N
",",1726,O
for,1726,O
nicotinate,1726,B-CHEMICAL
in,1726,O
rat,1726,O
cerebrocortical,1726,O
astrocytes,1726,O
.,1726,O
A,1727,O
review,1727,O
of,1727,O
the,1727,O
structural,1727,O
and,1727,O
functional,1727,O
features,1727,O
of,1727,O
olmesartan,1727,B-CHEMICAL
medoxomil,1727,I-CHEMICAL
",",1727,O
an,1727,O
angiotensin,1727,B-GENE-N
receptor,1727,I-GENE-N
blocker,1727,O
.,1727,O
The,1728,O
angiotensin,1728,B-CHEMICAL
II,1728,I-CHEMICAL
(,1728,I-GENE-Y
A-II,1728,B-CHEMICAL
),1728,I-GENE-Y
type,1728,I-GENE-Y
1,1728,I-GENE-Y
(,1728,I-GENE-Y
AT1,1728,I-GENE-Y
),1728,I-GENE-Y
receptor-mediated,1728,O
effects,1728,O
of,1728,O
A-II,1728,B-CHEMICAL
play,1728,O
a,1728,O
key,1728,O
role,1728,O
in,1728,O
the,1728,O
pathophysiology,1728,O
of,1728,O
hypertension,1728,O
.,1728,O
Effective,1729,O
inhibition,1729,O
of,1729,O
A-II,1729,B-CHEMICAL
is,1729,O
provided,1729,O
by,1729,O
the,1729,O
latest,1729,O
class,1729,O
of,1729,O
antihypertensive,1729,O
medications,1729,O
",",1729,O
the,1729,O
AT1,1729,B-GENE-Y
receptor,1729,O
blockers,1729,O
(,1729,O
ARBs,1729,O
),1729,O
.,1729,O
These,1730,O
orally,1730,O
available,1730,O
agents,1730,O
were,1730,O
developed,1730,O
around,1730,O
a,1730,O
common,1730,O
imidazole-based,1730,O
structural,1730,O
core,1730,O
.,1730,O
The,1731,O
most,1731,O
recent,1731,O
member,1731,O
of,1731,O
this,1731,O
drug,1731,O
class,1731,O
to,1731,O
be,1731,O
approved,1731,O
by,1731,O
the,1731,O
Food,1731,O
and,1731,O
Drug,1731,O
Administration,1731,O
",",1731,O
olmesartan,1731,B-CHEMICAL
medoxomil,1731,I-CHEMICAL
",",1731,O
contains,1731,O
unique,1731,O
features,1731,O
that,1731,O
may,1731,O
explain,1731,O
its,1731,O
clinical,1731,O
efficacy,1731,O
.,1731,O
Key,1732,O
structural,1732,O
elements,1732,O
of,1732,O
olmesartan,1732,B-CHEMICAL
medoxomil,1732,I-CHEMICAL
include,1732,O
a,1732,O
hydroxyalkyl,1732,O
substituent,1732,O
at,1732,O
the,1732,O
imidazole,1732,O
4-position,1732,O
and,1732,O
a,1732,O
hydrolyzable,1732,O
ester,1732,O
group,1732,O
at,1732,O
the,1732,O
imidazole,1732,O
5-position,1732,O
.,1732,O
Inter-,1733,O
and,1733,O
intramolecular,1733,O
hydrogen,1733,O
bonding,1733,O
involving,1733,O
these,1733,O
groups,1733,O
may,1733,O
contribute,1733,O
to,1733,O
the,1733,O
potentiation,1733,O
of,1733,O
antagonist,1733,O
activity,1733,O
.,1733,O
After,1734,O
oral,1734,O
administration,1734,O
",",1734,O
olmesartan,1734,B-CHEMICAL
medoxomil,1734,I-CHEMICAL
is,1734,O
deesterified,1734,O
in,1734,O
the,1734,O
intestinal,1734,O
tract,1734,O
to,1734,O
produce,1734,O
the,1734,O
active,1734,O
metabolite,1734,O
olmesartan,1734,O
",",1734,O
which,1734,O
undergoes,1734,O
no,1734,O
additional,1734,O
metabolic,1734,O
change,1734,O
.,1734,O
The,1735,O
marked,1735,O
antihypertensive,1735,O
efficacy,1735,O
of,1735,O
olmesartan,1735,B-CHEMICAL
medoxomil,1735,I-CHEMICAL
may,1735,O
result,1735,O
from,1735,O
a,1735,O
unique,1735,O
pharmacological,1735,O
interaction,1735,O
of,1735,O
the,1735,O
drug,1735,O
with,1735,O
the,1735,O
AT1,1735,B-GENE-Y
receptor,1735,O
",",1735,O
resulting,1735,O
in,1735,O
a,1735,O
potent,1735,O
",",1735,O
long-lasting,1735,O
",",1735,O
dose-dependent,1735,O
blockade,1735,O
of,1735,O
A-II,1735,B-CHEMICAL
.,1735,O
This,1736,O
review,1736,O
article,1736,O
characterizes,1736,O
the,1736,O
structural,1736,O
features,1736,O
of,1736,O
olmesartan,1736,O
that,1736,O
may,1736,O
be,1736,O
responsible,1736,O
for,1736,O
its,1736,O
clinical,1736,O
efficacy,1736,O
.,1736,O
Inferential,1737,O
pharmacological,1737,O
studies,1737,O
compare,1737,O
and,1737,O
contrast,1737,O
the,1737,O
effects,1737,O
of,1737,O
olmesartan,1737,O
to,1737,O
those,1737,O
of,1737,O
other,1737,O
ARBs,1737,O
in,1737,O
comparable,1737,O
preclinical,1737,O
animal,1737,O
models,1737,O
.,1737,O
Effects,1738,O
of,1738,O
granulocyte,1738,B-GENE-Y
colony-stimulating,1738,I-GENE-Y
factor,1738,I-GENE-Y
(,1738,O
G-CSF,1738,B-GENE-Y
),1738,O
and,1738,O
neutrophil,1738,B-GENE-Y
elastase,1738,I-GENE-Y
inhibitor,1738,O
(,1738,O
ONO-5046,1738,B-CHEMICAL
),1738,O
on,1738,O
acid-induced,1738,O
lung,1738,O
injury,1738,O
in,1738,O
rats,1738,O
.,1738,O
It,1739,O
has,1739,O
been,1739,O
suggested,1739,O
that,1739,O
neutrophils,1739,O
play,1739,O
an,1739,O
important,1739,O
role,1739,O
in,1739,O
acid-aspirated,1739,O
lung,1739,O
injury,1739,O
.,1739,O
We,1740,O
examined,1740,O
the,1740,O
effects,1740,O
of,1740,O
the,1740,O
high,1740,O
dose,1740,O
of,1740,O
granulocyte-colony,1740,B-GENE-Y
stimulating,1740,I-GENE-Y
factor,1740,I-GENE-Y
(,1740,O
G-CSF,1740,B-GENE-Y
),1740,O
",",1740,O
which,1740,O
is,1740,O
capable,1740,O
of,1740,O
increasing,1740,O
peripheral,1740,O
neutrophils,1740,O
",",1740,O
and,1740,O
a,1740,O
specific,1740,O
neutrophil,1740,B-GENE-Y
elastase,1740,I-GENE-Y
inhibitor,1740,O
(,1740,O
ONO-5046,1740,B-CHEMICAL
),1740,O
on,1740,O
acid,1740,O
lung,1740,O
injury,1740,O
in,1740,O
rats,1740,O
.,1740,O
Animals,1741,O
were,1741,O
anesthetized,1741,O
and,1741,O
normal,1741,O
saline,1741,O
(,1741,O
NS,1741,O
",",1741,O
2,1741,O
mL,1741,O
kg,1741,O
(,1741,O
-1,1741,O
),1741,O
),1741,O
or,1741,O
hydrochloric,1741,B-CHEMICAL
acid,1741,I-CHEMICAL
(,1741,O
HCl,1741,B-CHEMICAL
",",1741,O
0.1,1741,O
N,1741,O
2,1741,O
mL,1741,O
kg,1741,O
(,1741,O
-1,1741,O
),1741,O
),1741,O
was,1741,O
then,1741,O
instilled,1741,O
into,1741,O
trachea,1741,O
.,1741,O
Thirty,1742,O
minutes,1742,O
before,1742,O
HCl,1742,B-CHEMICAL
instillation,1742,O
",",1742,O
G-CSF,1742,B-GENE-Y
(,1742,O
150,1742,O
microg,1742,O
kg,1742,O
(,1742,O
-1,1742,O
),1742,O
),1742,O
was,1742,O
injected,1742,O
subcutaneously,1742,O
or,1742,O
ONO-5046,1742,B-CHEMICAL
(,1742,O
10,1742,O
mg,1742,O
kg,1742,O
(,1742,O
-1,1742,O
),1742,O
h,1742,O
(,1742,O
-1,1742,O
),1742,O
),1742,O
was,1742,O
infused,1742,O
continuously,1742,O
into,1742,O
the,1742,O
right,1742,O
jugular,1742,O
vein,1742,O
.,1742,O
Animals,1743,O
were,1743,O
ventilated,1743,O
during,1743,O
the,1743,O
experiments,1743,O
.,1743,O
Five,1744,O
hours,1744,O
after,1744,O
HCl,1744,B-CHEMICAL
or,1744,O
NS,1744,O
instillation,1744,O
",",1744,O
bronchoalveolar,1744,O
lavage,1744,O
fluid,1744,O
(,1744,O
BALF,1744,O
),1744,O
and,1744,O
lung,1744,O
tissue,1744,O
samples,1744,O
were,1744,O
obtained,1744,O
.,1744,O
Total,1745,O
nuclear,1745,O
cell,1745,O
count,1745,O
",",1745,O
absorbance,1745,O
",",1745,O
albumin,1745,B-GENE-Y
",",1745,O
tumor,1745,B-GENE-Y
necrosis,1745,I-GENE-Y
factor,1745,I-GENE-Y
(,1745,I-GENE-Y
TNF,1745,I-GENE-Y
),1745,I-GENE-Y
-alpha,1745,I-GENE-Y
",",1745,O
interleukin,1745,B-GENE-Y
(,1745,I-GENE-Y
IL,1745,I-GENE-Y
),1745,I-GENE-Y
-6,1745,I-GENE-Y
",",1745,O
cytokine-induced,1745,B-GENE-N
neutrophil,1745,I-GENE-N
chemoattractant,1745,I-GENE-N
(,1745,O
CINC,1745,B-GENE-N
),1745,O
",",1745,O
neutrophil,1745,B-GENE-Y
elastase,1745,I-GENE-Y
in,1745,O
BALF,1745,O
",",1745,O
wet-to-dry,1745,O
(,1745,O
W/D,1745,O
),1745,O
ratio,1745,O
were,1745,O
measured,1745,O
.,1745,O
HCl,1746,B-CHEMICAL
aspiration,1746,O
markedly,1746,O
increased,1746,O
these,1746,O
values,1746,O
in,1746,O
BALF,1746,O
and,1746,O
W/D,1746,O
ratio,1746,O
.,1746,O
Both,1747,O
ONO-5046,1747,B-CHEMICAL
and,1747,O
G-CSF,1747,B-GENE-Y
attenuated,1747,O
the,1747,O
parameters,1747,O
increased,1747,O
by,1747,O
acid-induced,1747,O
lung,1747,O
injury,1747,O
in,1747,O
rats,1747,O
.,1747,O
The,1748,O
data,1748,O
suggests,1748,O
that,1748,O
neutrophils,1748,O
play,1748,O
an,1748,O
important,1748,O
role,1748,O
in,1748,O
acid-induced,1748,O
lung,1748,O
injury,1748,O
.,1748,O
However,1749,O
",",1749,O
high-dose,1749,O
G-CSF,1749,B-GENE-Y
does,1749,O
not,1749,O
exacerbate,1749,O
acid-aspirated,1749,O
lung,1749,O
injury,1749,O
in,1749,O
rats,1749,O
",",1749,O
although,1749,O
this,1749,O
agent,1749,O
causes,1749,O
an,1749,O
increase,1749,O
in,1749,O
peripheral,1749,O
neutrophils,1749,O
.,1749,O
Guidance,1750,O
on,1750,O
the,1750,O
use,1750,O
of,1750,O
miglustat,1750,B-CHEMICAL
for,1750,O
treating,1750,O
patients,1750,O
with,1750,O
type,1750,O
1,1750,O
Gaucher,1750,O
disease,1750,O
.,1750,O
Type,1751,O
1,1751,O
Gaucher,1751,O
disease,1751,O
(,1751,O
GD,1751,O
),1751,O
is,1751,O
a,1751,O
progressive,1751,O
lysosomal,1751,O
storage,1751,O
disorder,1751,O
due,1751,O
to,1751,O
an,1751,O
autosomal,1751,O
recessive,1751,O
deficiency,1751,O
of,1751,O
glucocerebrosidase,1751,B-GENE-Y
.,1751,O
Clinical,1752,O
manifestations,1752,O
include,1752,O
anemia,1752,O
",",1752,O
thrombocytopenia,1752,O
",",1752,O
hepatosplenomegaly,1752,O
",",1752,O
and,1752,O
bone,1752,O
and,1752,O
pulmonary,1752,O
disease,1752,O
.,1752,O
Intravenous,1753,O
enzyme,1753,O
replacement,1753,O
(,1753,O
ERT,1753,O
),1753,O
with,1753,O
imiglucerase,1753,O
is,1753,O
the,1753,O
accepted,1753,O
standard,1753,O
for,1753,O
treatment,1753,O
of,1753,O
symptomatic,1753,O
patients,1753,O
.,1753,O
More,1754,O
than,1754,O
"3,500",1754,O
patients,1754,O
worldwide,1754,O
have,1754,O
received,1754,O
ERT,1754,O
with,1754,O
well-documented,1754,O
beneficial,1754,O
effects,1754,O
on,1754,O
the,1754,O
hematological,1754,O
",",1754,O
visceral,1754,O
",",1754,O
skeletal,1754,O
",",1754,O
and,1754,O
pulmonary,1754,O
manifestations,1754,O
",",1754,O
and,1754,O
with,1754,O
resultant,1754,O
improvement,1754,O
in,1754,O
health-related,1754,O
quality,1754,O
of,1754,O
life,1754,O
.,1754,O
Miglustat,1755,B-CHEMICAL
",",1755,O
an,1755,O
imino,1755,B-CHEMICAL
sugar,1755,I-CHEMICAL
that,1755,O
reversibly,1755,O
inhibits,1755,O
glucosylceramide,1755,B-GENE-Y
synthase,1755,I-GENE-Y
and,1755,O
reduces,1755,O
intracellular,1755,O
substrate,1755,O
burden,1755,O
",",1755,O
is,1755,O
an,1755,O
oral,1755,O
treatment,1755,O
for,1755,O
patients,1755,O
with,1755,O
type,1755,O
1,1755,O
GD,1755,O
that,1755,O
was,1755,O
recently,1755,O
approved,1755,O
in,1755,O
the,1755,O
United,1755,O
States,1755,O
for,1755,O
symptomatic,1755,O
patients,1755,O
with,1755,O
mild,1755,O
to,1755,O
moderate,1755,O
clinical,1755,O
manifestations,1755,O
for,1755,O
whom,1755,O
ERT,1755,O
is,1755,O
not,1755,O
an,1755,O
option,1755,O
.,1755,O
Because,1756,O
responses,1756,O
to,1756,O
miglustat,1756,B-CHEMICAL
are,1756,O
slower,1756,O
and,1756,O
less,1756,O
robust,1756,O
than,1756,O
those,1756,O
observed,1756,O
with,1756,O
ERT,1756,O
",",1756,O
and,1756,O
because,1756,O
miglustat,1756,B-CHEMICAL
is,1756,O
associated,1756,O
with,1756,O
significant,1756,O
side,1756,O
effects,1756,O
",",1756,O
clinicians,1756,O
who,1756,O
care,1756,O
for,1756,O
patients,1756,O
with,1756,O
GD,1756,O
should,1756,O
become,1756,O
familiar,1756,O
with,1756,O
the,1756,O
limited,1756,O
indications,1756,O
for,1756,O
miglustat,1756,B-CHEMICAL
use,1756,O
and,1756,O
the,1756,O
circumstances,1756,O
when,1756,O
it,1756,O
may,1756,O
be,1756,O
prescribed,1756,O
appropriately,1756,O
.,1756,O
This,1757,O
review,1757,O
article,1757,O
and,1757,O
position,1757,O
statement,1757,O
represents,1757,O
the,1757,O
current,1757,O
opinion,1757,O
of,1757,O
American,1757,O
physicians,1757,O
with,1757,O
extensive,1757,O
expertise,1757,O
in,1757,O
GD,1757,O
regarding,1757,O
patient,1757,O
management,1757,O
in,1757,O
the,1757,O
context,1757,O
of,1757,O
the,1757,O
availability,1757,O
of,1757,O
standard,1757,O
imiglucerase,1757,O
treatment,1757,O
and,1757,O
the,1757,O
recent,1757,O
introduction,1757,O
of,1757,O
miglustat,1757,B-CHEMICAL
.,1757,O
Nicotinic-receptor,1758,B-GENE-N
potentiator,1758,O
drugs,1758,O
",",1758,O
huprine,1758,O
X,1758,O
and,1758,O
galantamine,1758,B-CHEMICAL
",",1758,O
increase,1758,O
ACh,1758,B-CHEMICAL
release,1758,O
by,1758,O
blocking,1758,O
AChE,1758,B-GENE-Y
activity,1758,O
but,1758,O
not,1758,O
acting,1758,O
on,1758,O
nicotinic,1758,B-GENE-N
receptors,1758,I-GENE-N
.,1758,O
The,1759,O
main,1759,O
goal,1759,O
of,1759,O
the,1759,O
present,1759,O
study,1759,O
was,1759,O
to,1759,O
analyse,1759,O
the,1759,O
effects,1759,O
of,1759,O
(,1759,O
+/-,1759,O
),1759,O
-huprine,1759,O
X,1759,O
(,1759,O
(,1759,O
+/-,1759,O
),1759,O
-HX,1759,O
),1759,O
and,1759,O
galantamine,1759,O
(,1759,O
GAL,1759,O
),1759,O
",",1759,O
with,1759,O
potentiating,1759,O
action,1759,O
on,1759,O
nicotinic,1759,B-GENE-N
receptors,1759,I-GENE-N
",",1759,O
and,1759,O
huperzine,1759,O
A,1759,O
(,1759,O
HPA,1759,O
),1759,O
",",1759,O
devoid,1759,O
of,1759,O
nicotinic,1759,O
activity,1759,O
",",1759,O
on,1759,O
[,1759,B-CHEMICAL
3H,1759,I-CHEMICAL
],1759,I-CHEMICAL
-acetylcholine,1759,I-CHEMICAL
(,1759,O
[,1759,B-CHEMICAL
3H,1759,I-CHEMICAL
],1759,I-CHEMICAL
-ACh,1759,I-CHEMICAL
),1759,O
release,1759,O
in,1759,O
striatal,1759,O
slices,1759,O
of,1759,O
rat,1759,O
brain,1759,O
.,1759,O
All,1760,O
compounds,1760,O
are,1760,O
non-covalent,1760,O
and,1760,O
reversible,1760,O
inhibitors,1760,O
of,1760,O
AChE,1760,B-GENE-Y
.,1760,O
Addition,1761,O
of,1761,O
(,1761,O
+/-,1761,O
),1761,O
-HX,1761,O
(,1761,O
0.01,1761,O
microM,1761,O
),1761,O
",",1761,O
GAL,1761,O
(,1761,O
10,1761,O
microM,1761,O
),1761,O
and,1761,O
HPA,1761,O
(,1761,O
0.1,1761,O
microM,1761,O
),1761,O
to,1761,O
the,1761,O
superfusion,1761,O
medium,1761,O
decreased,1761,O
the,1761,O
release,1761,O
of,1761,O
the,1761,O
ACh,1761,B-CHEMICAL
neurotransmitter,1761,O
to,1761,O
a,1761,O
similar,1761,O
extent,1761,O
:,1761,O
36,1761,O
%,1761,O
",",1761,O
30,1761,O
%,1761,O
and,1761,O
34,1761,O
%,1761,O
",",1761,O
respectively,1761,O
(,1761,O
P,1761,O
<,1761,O
0.01,1761,O
),1761,O
.,1761,O
This,1762,O
effect,1762,O
was,1762,O
reverted,1762,O
in,1762,O
the,1762,O
presence,1762,O
of,1762,O
atropine,1762,B-CHEMICAL
(,1762,O
ATR,1762,B-CHEMICAL
;,1762,O
0.1,1762,O
microM,1762,O
),1762,O
",",1762,O
which,1762,O
blocks,1762,O
the,1762,O
pre-synaptic,1762,O
muscarinic,1762,B-GENE-Y
M2,1762,I-GENE-Y
receptor,1762,I-GENE-Y
.,1762,O
After,1763,O
that,1763,O
",",1763,O
a,1763,O
wide,1763,O
range,1763,O
of,1763,O
concentrations,1763,O
of,1763,O
drugs,1763,O
",",1763,O
concomitantly,1763,O
with,1763,O
ATR,1763,B-CHEMICAL
(,1763,O
0.1,1763,O
microM,1763,O
),1763,O
",",1763,O
was,1763,O
studied,1763,O
in,1763,O
the,1763,O
presence,1763,O
of,1763,O
haloperidol,1763,B-CHEMICAL
(,1763,O
HAL,1763,B-CHEMICAL
;,1763,O
0.01,1763,O
microM,1763,O
),1763,O
",",1763,O
a,1763,O
dopamine,1763,B-GENE-Y
D2,1763,I-GENE-Y
antagonist,1763,O
.,1763,O
In,1764,O
these,1764,O
conditions,1764,O
",",1764,O
a,1764,O
dose-dependent,1764,O
increase,1764,O
of,1764,O
[,1764,B-CHEMICAL
3H,1764,I-CHEMICAL
],1764,I-CHEMICAL
-ACh,1764,I-CHEMICAL
release,1764,O
was,1764,O
observed,1764,O
in,1764,O
the,1764,O
presence,1764,O
of,1764,O
(,1764,O
+/-,1764,O
),1764,O
-HX,1764,O
",",1764,O
GAL,1764,O
and,1764,O
HPA,1764,O
.,1764,O
To,1765,O
test,1765,O
the,1765,O
role,1765,O
of,1765,O
nicotinic,1765,B-GENE-N
receptors,1765,I-GENE-N
in,1765,O
the,1765,O
drugs,1765,O
',1765,O
effects,1765,O
on,1765,O
[,1765,B-CHEMICAL
3H,1765,I-CHEMICAL
],1765,I-CHEMICAL
-ACh,1765,I-CHEMICAL
release,1765,O
",",1765,O
mecamylamine,1765,B-CHEMICAL
(,1765,O
MEC,1765,B-CHEMICAL
),1765,O
100,1765,O
microM,1765,O
was,1765,O
used,1765,O
to,1765,O
block,1765,O
such,1765,O
receptors,1765,O
.,1765,O
MEC,1766,B-CHEMICAL
alone,1766,O
significantly,1766,O
decreased,1766,O
neurotransmitter,1766,O
release,1766,O
by,1766,O
18,1766,O
%,1766,O
(,1766,O
P,1766,O
<,1766,O
0.05,1766,O
),1766,O
",",1766,O
but,1766,O
no,1766,O
change,1766,O
was,1766,O
obtained,1766,O
in,1766,O
the,1766,O
presence,1766,O
of,1766,O
both,1766,O
ATR,1766,B-CHEMICAL
and,1766,O
MEC,1766,B-CHEMICAL
.,1766,O
Under,1767,O
these,1767,O
conditions,1767,O
",",1767,O
(,1767,O
+/-,1767,O
),1767,O
-HX,1767,O
",",1767,O
GAL,1767,O
and,1767,O
HPA,1767,O
increased,1767,O
the,1767,O
release,1767,O
of,1767,O
[,1767,B-CHEMICAL
3H,1767,I-CHEMICAL
],1767,I-CHEMICAL
-ACh,1767,I-CHEMICAL
by,1767,O
37,1767,O
%,1767,O
",",1767,O
25,1767,O
%,1767,O
and,1767,O
38,1767,O
%,1767,O
",",1767,O
respectively,1767,O
(,1767,O
P,1767,O
<,1767,O
0.01,1767,O
),1767,O
.,1767,O
Taking,1768,O
into,1768,O
account,1768,O
all,1768,O
of,1768,O
these,1768,O
data,1768,O
",",1768,O
the,1768,O
present,1768,O
results,1768,O
suggest,1768,O
that,1768,O
the,1768,O
effects,1768,O
induced,1768,O
by,1768,O
(,1768,O
+/-,1768,O
),1768,O
-HX,1768,O
and,1768,O
GAL,1768,O
nicotinic-receptor,1768,B-GENE-N
potentiators,1768,O
seem,1768,O
to,1768,O
be,1768,O
mainly,1768,O
due,1768,O
to,1768,O
their,1768,O
ability,1768,O
in,1768,O
inhibiting,1768,O
acetylcholinesterase,1768,B-GENE-Y
activity,1768,O
",",1768,O
but,1768,O
not,1768,O
by,1768,O
interaction,1768,O
on,1768,O
the,1768,O
nicotinic,1768,B-GENE-N
receptors,1768,I-GENE-N
.,1768,O
Rat,1769,O
hepatic,1769,O
stellate,1769,O
cells,1769,O
become,1769,O
retinoid,1769,B-CHEMICAL
unresponsive,1769,O
during,1769,O
activation,1769,O
.,1769,O
Hepatic,1770,O
stellate,1770,O
cells,1770,O
(,1770,O
HSC,1770,O
),1770,O
play,1770,O
an,1770,O
essential,1770,O
role,1770,O
in,1770,O
fibrogenesis,1770,O
.,1770,O
Many,1771,O
stimuli,1771,O
cause,1771,O
HSC,1771,O
to,1771,O
activate,1771,O
",",1771,O
lose,1771,O
their,1771,O
Vitamin,1771,B-CHEMICAL
A,1771,I-CHEMICAL
and,1771,O
produce,1771,O
collagen,1771,B-GENE-N
.,1771,O
It,1772,O
is,1772,O
unclear,1772,O
whether,1772,O
Vitamin,1772,B-CHEMICAL
A,1772,I-CHEMICAL
loss,1772,O
causes,1772,O
activation,1772,O
",",1772,O
potentiates,1772,O
it,1772,O
or,1772,O
is,1772,O
simply,1772,O
an,1772,O
event,1772,O
in,1772,O
the,1772,O
cascade,1772,O
of,1772,O
activation,1772,O
changes,1772,O
.,1772,O
We,1773,O
determine,1773,O
if,1773,O
exogenous,1773,O
retinoids,1773,B-CHEMICAL
prevent,1773,O
the,1773,O
activation,1773,O
of,1773,O
freshly,1773,O
isolated,1773,O
rat,1773,O
HSC,1773,O
activated,1773,O
by,1773,O
plating,1773,O
on,1773,O
plastic,1773,O
.,1773,O
We,1774,O
also,1774,O
determine,1774,O
if,1774,O
retinoids,1774,B-CHEMICAL
:,1774,O
(,1774,O
1,1774,O
),1774,O
reverse,1774,O
HSC,1774,O
activation,1774,O
;,1774,O
(,1774,O
2,1774,O
),1774,O
maintain/restore,1774,O
HSC,1774,O
intracellular,1774,O
retinoid,1774,B-CHEMICAL
levels,1774,O
;,1774,O
(,1774,O
3,1774,O
),1774,O
maintain,1774,O
expression,1774,O
of,1774,O
HSC,1774,O
nuclear,1774,B-GENE-N
receptors,1774,I-GENE-N
for,1774,I-GENE-N
retinoic,1774,B-CHEMICAL
acid,1774,I-CHEMICAL
(,1774,O
RAR,1774,B-GENE-N
),1774,O
in,1774,O
HSC,1774,O
that,1774,O
are,1774,O
becoming,1774,O
activated,1774,O
or,1774,O
are,1774,O
chronically,1774,O
activated,1774,O
.,1774,O
Markers,1775,O
of,1775,O
activation,1775,O
in,1775,O
freshly,1775,O
isolated,1775,O
HSC,1775,O
were,1775,O
decreased,1775,O
by,1775,O
either,1775,O
retinol,1775,B-CHEMICAL
or,1775,O
retinoic,1775,B-CHEMICAL
acid,1775,I-CHEMICAL
without,1775,O
increases,1775,O
in,1775,O
HSC,1775,O
retinoid,1775,B-CHEMICAL
concentration,1775,O
.,1775,O
mRNA,1776,O
levels,1776,O
for,1776,O
RAR-alpha,1776,B-GENE-Y
",",1776,O
RAR-beta,1776,B-GENE-Y
and,1776,O
RAR-gamma,1776,B-GENE-Y
",",1776,O
the,1776,O
nuclear,1776,B-GENE-N
receptors,1776,I-GENE-N
for,1776,O
retinoic,1776,B-CHEMICAL
acid,1776,I-CHEMICAL
",",1776,O
decreased,1776,O
during,1776,O
activation,1776,O
of,1776,O
freshly,1776,O
isolated,1776,O
HSC,1776,O
even,1776,O
with,1776,O
retinoid,1776,B-CHEMICAL
supplementation,1776,O
.,1776,O
RAR-alpha,1777,B-GENE-Y
",",1777,O
RAR-beta,1777,B-GENE-Y
and,1777,O
RAR-gamma,1777,B-GENE-Y
mRNA,1777,O
and,1777,O
RAR-beta,1777,B-GENE-N
protein,1777,O
was,1777,O
undetectable,1777,O
in,1777,O
chronically,1777,O
activated,1777,O
HSC,1777,O
and,1777,O
remained,1777,O
absent,1777,O
after,1777,O
retinoic,1777,B-CHEMICAL
acid,1777,I-CHEMICAL
supplementation,1777,O
.,1777,O
Activation,1778,O
markers,1778,O
in,1778,O
chronically,1778,O
activated,1778,O
HSC,1778,O
were,1778,O
only,1778,O
slightly,1778,O
decreased,1778,O
after,1778,O
retinoid,1778,B-CHEMICAL
exposure,1778,O
.,1778,O
We,1779,O
conclude,1779,O
that,1779,O
exposure,1779,O
of,1779,O
HSC,1779,O
to,1779,O
extracellular,1779,O
retinoids,1779,B-CHEMICAL
diminishes,1779,O
some,1779,O
markers,1779,O
of,1779,O
activation,1779,O
but,1779,O
does,1779,O
not,1779,O
prevent,1779,O
HSC,1779,O
activation,1779,O
.,1779,O
Protein,1780,B-GENE-N
kinase,1780,I-GENE-N
C,1780,I-GENE-N
potentiates,1780,O
homologous,1780,O
desensitization,1780,O
of,1780,O
the,1780,O
beta2-adrenoceptor,1780,B-GENE-Y
in,1780,O
bovine,1780,O
tracheal,1780,O
smooth,1780,O
muscle,1780,O
.,1780,O
Preincubation,1781,O
(,1781,O
30,1781,O
min,1781,O
),1781,O
of,1781,O
bovine,1781,O
tracheal,1781,O
smooth,1781,O
muscle,1781,O
with,1781,O
various,1781,O
concentrations,1781,O
(,1781,O
0.1,1781,O
",",1781,O
1,1781,O
and,1781,O
10,1781,O
microM,1781,O
),1781,O
of,1781,O
fenoterol,1781,B-CHEMICAL
decreased,1781,O
isoprenaline-induced,1781,B-CHEMICAL
maximal,1781,O
relaxation,1781,O
(,1781,O
E,1781,O
(,1781,O
max,1781,O
),1781,O
),1781,O
of,1781,O
methacholine-contracted,1781,B-CHEMICAL
preparations,1781,O
in,1781,O
a,1781,O
concentration,1781,O
dependent,1781,O
fashion,1781,O
",",1781,O
indicating,1781,O
desensitization,1781,O
of,1781,O
the,1781,O
beta,1781,B-GENE-Y
(,1781,I-GENE-Y
2,1781,I-GENE-Y
),1781,I-GENE-Y
-adrenoceptor,1781,I-GENE-Y
.,1781,O
Preincubation,1782,O
with,1782,O
1,1782,O
microM,1782,O
of,1782,O
the,1782,O
protein,1782,B-GENE-N
kinase,1782,I-GENE-N
C,1782,I-GENE-N
(,1782,O
PKC,1782,B-GENE-N
),1782,O
activator,1782,O
phorbol,1782,B-CHEMICAL
12-myristate,1782,I-CHEMICAL
13-acetate,1782,I-CHEMICAL
(,1782,O
PMA,1782,B-CHEMICAL
),1782,O
caused,1782,O
a,1782,O
small,1782,O
but,1782,O
significant,1782,O
decrease,1782,O
in,1782,O
isoprenaline-induced,1782,B-CHEMICAL
E,1782,O
(,1782,O
max,1782,O
),1782,O
",",1782,O
indicating,1782,O
activated,1782,O
PKC-mediated,1782,B-GENE-N
heterologous,1782,O
beta,1782,B-GENE-Y
(,1782,I-GENE-Y
2,1782,I-GENE-Y
),1782,I-GENE-Y
-adrenoceptor,1782,I-GENE-Y
desensitization,1782,O
.,1782,O
To,1783,O
investigate,1783,O
the,1783,O
capacity,1783,O
of,1783,O
activated,1783,O
PKC,1783,B-GENE-N
to,1783,O
regulate,1783,O
homologous,1783,O
desensitization,1783,O
",",1783,O
we,1783,O
incubated,1783,O
the,1783,O
smooth,1783,O
muscle,1783,O
strips,1783,O
with,1783,O
the,1783,O
combination,1783,O
of,1783,O
both,1783,O
1,1783,O
microM,1783,O
PMA,1783,O
and,1783,O
1,1783,O
microM,1783,O
fenoterol,1783,B-CHEMICAL
.,1783,O
This,1784,O
combined,1784,O
treatment,1784,O
synergistically,1784,O
decreased,1784,O
the,1784,O
isoprenaline-induced,1784,B-CHEMICAL
maximal,1784,O
relaxation,1784,O
",",1784,O
as,1784,O
compared,1784,O
to,1784,O
the,1784,O
individual,1784,O
effects,1784,O
of,1784,O
PMA,1784,B-CHEMICAL
and,1784,O
fenoterol,1784,B-CHEMICAL
alone,1784,O
",",1784,O
indicating,1784,O
a,1784,O
common,1784,O
pathway,1784,O
for,1784,O
heterologous,1784,O
and,1784,O
homologous,1784,O
desensitization,1784,O
.,1784,O
Moreover,1785,O
",",1785,O
the,1785,O
specific,1785,O
PKC-inhibitor,1785,B-GENE-N
2-,1785,B-CHEMICAL
[,1785,I-CHEMICAL
1-,1785,I-CHEMICAL
(,1785,I-CHEMICAL
3-dimethylaminopropyl,1785,I-CHEMICAL
),1785,I-CHEMICAL
-1H-indol-3-yl,1785,I-CHEMICAL
],1785,I-CHEMICAL
-3-,1785,I-CHEMICAL
(,1785,I-CHEMICAL
1H-indol-3-yl,1785,I-CHEMICAL
),1785,I-CHEMICAL
maleimide,1785,I-CHEMICAL
(,1785,O
GF,1785,B-CHEMICAL
109203X,1785,I-CHEMICAL
),1785,O
markedly,1785,O
increased,1785,O
the,1785,O
potency,1785,O
and,1785,O
E,1785,O
(,1785,O
max,1785,O
),1785,O
of,1785,O
isoprenaline,1785,B-CHEMICAL
for,1785,O
all,1785,O
conditions,1785,O
used,1785,O
",",1785,O
including,1785,O
control,1785,O
conditions,1785,O
",",1785,O
and,1785,O
the,1785,O
synergistic,1785,O
effects,1785,O
of,1785,O
PMA,1785,B-CHEMICAL
and,1785,O
fenoterol,1785,B-CHEMICAL
were,1785,O
completely,1785,O
prevented,1785,O
.,1785,O
In,1786,O
conclusion,1786,O
",",1786,O
the,1786,O
present,1786,O
study,1786,O
demonstrates,1786,O
that,1786,O
homologous,1786,O
desensitization,1786,O
of,1786,O
the,1786,O
beta,1786,B-GENE-Y
(,1786,I-GENE-Y
2,1786,I-GENE-Y
),1786,I-GENE-Y
-adrenergic,1786,I-GENE-Y
receptor,1786,I-GENE-Y
can,1786,O
be,1786,O
enhanced,1786,O
by,1786,O
PKC,1786,B-GENE-N
activation,1786,O
.,1786,O
For,1787,O
the,1787,O
first,1787,O
time,1787,O
we,1787,O
have,1787,O
provided,1787,O
evidence,1787,O
that,1787,O
this,1787,O
concept,1787,O
is,1787,O
functionally,1787,O
operative,1787,O
in,1787,O
airway,1787,O
smooth,1787,O
muscle,1787,O
",",1787,O
and,1787,O
it,1787,O
may,1787,O
explain,1787,O
the,1787,O
reduced,1787,O
bronchodilator,1787,O
response,1787,O
to,1787,O
beta,1787,B-GENE-Y
(,1787,I-GENE-Y
2,1787,I-GENE-Y
),1787,I-GENE-Y
-adrenoceptor,1787,I-GENE-Y
agonists,1787,O
in,1787,O
patients,1787,O
with,1787,O
asthma,1787,O
during,1787,O
a,1787,O
severe,1787,O
exacerbation,1787,O
.,1787,O
Overview,1788,O
of,1788,O
monoclonal,1788,O
antibodies,1788,O
and,1788,O
small,1788,O
molecules,1788,O
targeting,1788,O
the,1788,O
epidermal,1788,B-GENE-Y
growth,1788,I-GENE-Y
factor,1788,I-GENE-Y
receptor,1788,I-GENE-Y
pathway,1788,O
in,1788,O
colorectal,1788,O
cancer,1788,O
.,1788,O
The,1789,O
epidermal,1789,B-GENE-Y
growth,1789,I-GENE-Y
factor,1789,I-GENE-Y
receptor,1789,I-GENE-Y
(,1789,O
EGFR,1789,B-GENE-Y
),1789,O
provides,1789,O
survival,1789,O
signals,1789,O
and,1789,O
is,1789,O
overexpressed,1789,O
in,1789,O
the,1789,O
majority,1789,O
of,1789,O
colorectal,1789,O
cancers,1789,O
.,1789,O
As,1790,O
more,1790,O
is,1790,O
learned,1790,O
about,1790,O
the,1790,O
molecular,1790,O
details,1790,O
of,1790,O
EGFR,1790,B-GENE-Y
signaling,1790,O
",",1790,O
antibodies,1790,O
can,1790,O
be,1790,O
designed,1790,O
to,1790,O
interfere,1790,O
with,1790,O
specific,1790,O
domains,1790,O
of,1790,O
the,1790,O
EGFR,1790,B-GENE-Y
molecule,1790,O
.,1790,O
In,1791,O
this,1791,O
review,1791,O
",",1791,O
we,1791,O
analyze,1791,O
preclinical,1791,O
and,1791,O
current,1791,O
clinical,1791,O
data,1791,O
on,1791,O
EGFR-targeting,1791,B-GENE-Y
molecules,1791,O
and,1791,O
their,1791,O
potential,1791,O
role,1791,O
in,1791,O
the,1791,O
treatment,1791,O
of,1791,O
colorectal,1791,O
cancer,1791,O
.,1791,O
Cetuximab,1792,O
binds,1792,O
to,1792,O
domain,1792,O
III,1792,O
of,1792,O
EGFR,1792,B-GENE-Y
and,1792,O
hinders,1792,O
ligand,1792,O
binding,1792,O
.,1792,O
It,1793,O
is,1793,O
now,1793,O
approved,1793,O
by,1793,O
the,1793,O
US,1793,O
Food,1793,O
and,1793,O
Drug,1793,O
Administration,1793,O
for,1793,O
metastatic,1793,O
colorectal,1793,O
cancer,1793,O
treatment,1793,O
.,1793,O
Panitumumab,1794,O
is,1794,O
another,1794,O
widely,1794,O
studied,1794,O
anti-EGFR,1794,O
antibody,1794,O
with,1794,O
similar,1794,O
properties,1794,O
.,1794,O
Bispecific,1795,O
antibodies,1795,O
are,1795,O
modified,1795,O
immunoglobulin,1795,B-GENE-N
molecules,1795,O
containing,1795,O
2,1795,O
different,1795,O
binding,1795,O
specificities,1795,O
.,1795,O
These,1796,O
antibodies,1796,O
can,1796,O
redirect,1796,O
the,1796,O
immune,1796,O
response,1796,O
against,1796,O
tumor,1796,O
cells,1796,O
by,1796,O
tethering,1796,O
effector,1796,O
cells,1796,O
such,1796,O
as,1796,O
CD3e-expressing,1796,B-GENE-Y
T,1796,O
cells,1796,O
or,1796,O
CD16-expressing,1796,B-GENE-N
natural,1796,O
killer,1796,O
cells,1796,O
and,1796,O
granulocytes,1796,O
to,1796,O
the,1796,O
surface,1796,O
of,1796,O
cancer,1796,O
cells,1796,O
.,1796,O
Tyrosine,1797,B-GENE-N
kinase,1797,I-GENE-N
inhibitors,1797,O
are,1797,O
quinazoline-derived,1797,B-CHEMICAL
",",1797,O
low,1797,O
molecular,1797,O
weight,1797,O
synthetic,1797,O
molecules,1797,O
that,1797,O
can,1797,O
block,1797,O
the,1797,O
intracellular,1797,O
tyrosine,1797,B-GENE-N
kinase,1797,I-GENE-N
domain,1797,I-GENE-N
of,1797,O
several,1797,O
receptors,1797,O
",",1797,O
including,1797,O
EGFR,1797,B-GENE-Y
",",1797,O
Erb2,1797,B-GENE-Y
",",1797,O
and,1797,O
vascular,1797,B-GENE-N
endothelial,1797,I-GENE-N
growth,1797,I-GENE-N
factor,1797,I-GENE-N
receptor,1797,I-GENE-N
",",1797,O
and,1797,O
thereby,1797,O
inhibit,1797,O
ligand-induced,1797,O
receptor,1797,O
phosphorylation,1797,O
and,1797,O
abrogate,1797,O
the,1797,O
biologic,1797,O
effect,1797,O
of,1797,O
EGFR,1797,B-GENE-Y
signaling,1797,O
.,1797,O
The,1798,O
presence,1798,O
of,1798,O
skin,1798,O
rash,1798,O
and,1798,O
EGFR,1798,B-GENE-Y
gene,1798,O
amplification,1798,O
have,1798,O
been,1798,O
advanced,1798,O
as,1798,O
possible,1798,O
predictors,1798,O
of,1798,O
clinical,1798,O
effectiveness,1798,O
of,1798,O
targeted,1798,O
anti-EGFR,1798,O
therapies,1798,O
.,1798,O
Isolation,1799,O
and,1799,O
function,1799,O
of,1799,O
the,1799,O
amino,1799,B-GENE-Y
acid,1799,I-GENE-Y
transporter,1799,I-GENE-Y
PAT1,1799,I-GENE-Y
(,1799,O
slc36a1,1799,B-GENE-Y
),1799,O
from,1799,O
rabbit,1799,O
and,1799,O
discrimination,1799,O
between,1799,O
transport,1799,O
via,1799,O
PAT1,1799,B-GENE-Y
and,1799,O
system,1799,B-GENE-N
IMINO,1799,I-GENE-N
in,1799,O
renal,1799,O
brush-border,1799,O
membrane,1799,O
vesicles,1799,O
.,1799,O
Reabsorption,1800,O
of,1800,O
amino,1800,B-CHEMICAL
acids,1800,I-CHEMICAL
is,1800,O
an,1800,O
important,1800,O
function,1800,O
of,1800,O
the,1800,O
renal,1800,O
proximal,1800,O
tubule,1800,O
.,1800,O
pH-dependent,1801,O
amino,1801,B-CHEMICAL
acid,1801,I-CHEMICAL
transport,1801,O
has,1801,O
been,1801,O
measured,1801,O
previously,1801,O
using,1801,O
rabbit,1801,O
renal,1801,O
brush-border,1801,O
membrane,1801,O
vesicles,1801,O
(,1801,O
BBMV,1801,O
),1801,O
.,1801,O
The,1802,O
purpose,1802,O
of,1802,O
this,1802,O
investigation,1802,O
was,1802,O
to,1802,O
determine,1802,O
whether,1802,O
this,1802,O
pH-dependent,1802,O
uptake,1802,O
represents,1802,O
H,1802,B-CHEMICAL
(,1802,I-CHEMICAL
+,1802,I-CHEMICAL
),1802,I-CHEMICAL
/amino,1802,O
acid,1802,I-CHEMICAL
cotransport,1802,O
via,1802,O
a,1802,O
PAT1-like,1802,B-GENE-Y
transport,1802,O
system,1802,O
.,1802,O
The,1803,O
rabbit,1803,B-GENE-Y
PAT1,1803,I-GENE-Y
cDNA,1803,O
was,1803,O
isolated,1803,O
(,1803,O
2296bp,1803,O
including,1803,O
both,1803,O
5,1803,O
',1803,O
and,1803,O
3,1803,O
',1803,O
untranslated,1803,O
regions,1803,O
and,1803,O
poly,1803,B-GENE-N
(,1803,I-GENE-N
A,1803,I-GENE-N
),1803,I-GENE-N
tail,1803,I-GENE-N
),1803,I-GENE-N
and,1803,O
the,1803,O
open,1803,B-GENE-N
reading,1803,I-GENE-N
frame,1803,I-GENE-N
codes,1803,O
for,1803,O
a,1803,O
protein,1803,O
of,1803,O
475,1803,O
amino,1803,B-CHEMICAL
acids,1803,I-CHEMICAL
(,1803,O
92,1803,O
%,1803,O
identity,1803,O
to,1803,O
human,1803,B-GENE-Y
PAT1,1803,I-GENE-Y
),1803,O
.,1803,O
Rabbit,1804,B-GENE-Y
PAT1,1804,I-GENE-Y
mRNA,1804,O
was,1804,O
found,1804,O
in,1804,O
all,1804,O
tissues,1804,O
investigated,1804,O
including,1804,O
kidney,1804,O
.,1804,O
When,1805,O
expressed,1805,O
heterologously,1805,O
in,1805,O
a,1805,O
mammalian,1805,O
cell,1805,O
line,1805,O
",",1805,O
rabbit,1805,B-GENE-Y
PAT1,1805,I-GENE-Y
mediates,1805,O
pH-dependent,1805,O
",",1805,O
Na,1805,B-CHEMICAL
(,1805,I-CHEMICAL
+,1805,I-CHEMICAL
),1805,I-CHEMICAL
-independent,1805,O
uptake,1805,O
of,1805,O
proline,1805,B-CHEMICAL
",",1805,O
glycine,1805,B-CHEMICAL
",",1805,O
l-alanine,1805,B-CHEMICAL
and,1805,O
alpha-,1805,B-CHEMICAL
(,1805,I-CHEMICAL
methylamino,1805,I-CHEMICAL
),1805,I-CHEMICAL
isobutyric,1805,I-CHEMICAL
acid,1805,I-CHEMICAL
.,1805,O
Proline,1806,B-CHEMICAL
uptake,1806,O
was,1806,O
maximal,1806,O
at,1806,O
pH,1806,O
5.0,1806,O
(,1806,O
K,1806,O
(,1806,O
m,1806,O
),1806,O
2.2+/-0.7,1806,O
mM,1806,O
),1806,O
.,1806,O
A,1807,O
transport,1807,O
system,1807,O
with,1807,O
identical,1807,O
characteristics,1807,O
(,1807,O
ion,1807,O
dependency,1807,O
",",1807,O
substrate,1807,O
specificity,1807,O
),1807,O
was,1807,O
detected,1807,O
in,1807,O
rabbit,1807,O
renal,1807,O
BBMV,1807,O
where,1807,O
an,1807,O
overshoot,1807,O
was,1807,O
observed,1807,O
in,1807,O
the,1807,O
absence,1807,O
of,1807,O
Na+,1807,B-CHEMICAL
but,1807,O
in,1807,O
the,1807,O
presence,1807,O
of,1807,O
an,1807,O
inwardly,1807,O
directed,1807,O
H+,1807,B-CHEMICAL
gradient,1807,O
.,1807,O
In,1808,O
the,1808,O
presence,1808,O
of,1808,O
Na+,1808,B-CHEMICAL
and,1808,O
under,1808,O
conditions,1808,O
in,1808,O
which,1808,O
PAT1,1808,B-GENE-Y
transport,1808,O
function,1808,O
was,1808,O
suppressed,1808,O
",",1808,O
a,1808,O
second,1808,O
proline,1808,B-CHEMICAL
uptake,1808,O
system,1808,O
was,1808,O
detected,1808,O
that,1808,O
exhibited,1808,O
functional,1808,O
characteristics,1808,O
similar,1808,O
to,1808,O
those,1808,O
of,1808,O
the,1808,O
IMINO,1808,B-GENE-N
system,1808,I-GENE-N
.,1808,O
The,1809,O
functional,1809,O
characteristics,1809,O
of,1809,O
rabbit,1809,B-GENE-Y
PAT1,1809,I-GENE-Y
in,1809,O
either,1809,O
mammalian,1809,O
cells,1809,O
or,1809,O
renal,1809,O
BBMV,1809,O
suggest,1809,O
that,1809,O
PAT1,1809,B-GENE-Y
is,1809,O
the,1809,O
low-affinity,1809,O
transporter,1809,O
of,1809,O
proline,1809,B-CHEMICAL
",",1809,O
glycine,1809,B-CHEMICAL
and,1809,O
hydroxyproline,1809,B-CHEMICAL
believed,1809,O
to,1809,O
be,1809,O
defective,1809,O
in,1809,O
patients,1809,O
with,1809,O
iminoglycinuria,1809,O
.,1809,O
Antidepressants,1810,O
suppress,1810,O
production,1810,O
of,1810,O
the,1810,O
Th1,1810,O
cytokine,1810,B-GENE-N
interferon-gamma,1810,B-GENE-Y
",",1810,O
independent,1810,O
of,1810,O
monoamine,1810,B-GENE-N
transporter,1810,I-GENE-N
blockade,1810,O
.,1810,O
In,1811,O
this,1811,O
study,1811,O
",",1811,O
antidepressants,1811,O
with,1811,O
selectivity,1811,O
for,1811,O
the,1811,O
noradrenaline,1811,B-GENE-Y
transporter,1811,I-GENE-Y
(,1811,O
reboxetine,1811,B-CHEMICAL
and,1811,O
desipramine,1811,B-CHEMICAL
),1811,O
",",1811,O
or,1811,O
the,1811,O
serotonin,1811,B-CHEMICAL
transporter,1811,I-GENE-Y
(,1811,O
fluoxetine,1811,B-CHEMICAL
and,1811,O
clomipramine,1811,B-CHEMICAL
),1811,O
were,1811,O
examined,1811,O
in,1811,O
terms,1811,O
of,1811,O
their,1811,O
ability,1811,O
to,1811,O
promote,1811,O
an,1811,O
anti-inflammatory,1811,O
cytokine,1811,B-GENE-N
phenotype,1811,O
in,1811,O
human,1811,O
blood,1811,O
.,1811,O
In,1812,O
addition,1812,O
",",1812,O
we,1812,O
examined,1812,O
the,1812,O
ability,1812,O
of,1812,O
trimipramine,1812,B-CHEMICAL
;,1812,O
a,1812,O
tricyclic,1812,B-CHEMICAL
antidepressant,1812,O
that,1812,O
is,1812,O
devoid,1812,O
of,1812,O
monoamine,1812,B-CHEMICAL
reuptake,1812,O
inhibitory,1812,O
properties,1812,O
on,1812,O
cytokine,1812,B-GENE-N
production,1812,O
.,1812,O
Lipopolysaccharide,1813,O
(,1813,O
LPS,1813,O
),1813,O
was,1813,O
used,1813,O
to,1813,O
stimulate,1813,O
monocyte-derived,1813,O
pro-inflammatory,1813,O
(,1813,O
IL-1beta,1813,B-GENE-Y
",",1813,O
TNF-alpha,1813,B-GENE-Y
",",1813,O
IL-12,1813,B-GENE-N
),1813,O
and,1813,O
anti-inflammatory,1813,O
(,1813,O
IL-10,1813,B-GENE-Y
),1813,O
cytokines,1813,B-GENE-N
",",1813,O
whilst,1813,O
concanavalin,1813,O
A,1813,O
(,1813,O
Con,1813,O
A,1813,O
),1813,O
was,1813,O
used,1813,O
to,1813,O
stimulate,1813,O
T-cell,1813,O
(,1813,O
Th,1813,O
(,1813,O
1,1813,O
),1813,O
:,1813,O
IFN-gamma,1813,B-GENE-Y
and,1813,O
Th,1813,O
(,1813,O
2/3,1813,O
),1813,O
:,1813,O
IL-10,1813,B-GENE-Y
),1813,O
cytokines,1813,B-GENE-N
.,1813,O
All,1814,O
of,1814,O
the,1814,O
antidepressants,1814,O
suppressed,1814,O
IFN-gamma,1814,B-GENE-Y
production,1814,O
in,1814,O
the,1814,O
10-50,1814,O
microM,1814,O
concentration,1814,O
range,1814,O
",",1814,O
irrespective,1814,O
of,1814,O
their,1814,O
preference,1814,O
for,1814,O
serotonin,1814,B-GENE-N
or,1814,I-GENE-N
noradrenaline,1814,I-GENE-N
transporters,1814,I-GENE-N
.,1814,O
This,1815,O
suppression,1815,O
of,1815,O
IFN-gamma,1815,B-GENE-Y
production,1815,O
was,1815,O
paralleled,1815,O
by,1815,O
reduced,1815,O
T-cell,1815,O
proliferation,1815,O
",",1815,O
therefore,1815,O
we,1815,O
suggest,1815,O
that,1815,O
the,1815,O
ability,1815,O
of,1815,O
antidepressants,1815,O
to,1815,O
suppress,1815,O
IFN-gamma,1815,B-GENE-Y
production,1815,O
may,1815,O
be,1815,O
related,1815,O
to,1815,O
their,1815,O
anti-proliferative,1815,O
properties,1815,O
.,1815,O
The,1816,O
fact,1816,O
that,1816,O
trimipramine,1816,B-CHEMICAL
also,1816,O
suppressed,1816,O
IFN-gamma,1816,B-GENE-Y
production,1816,O
and,1816,O
T-cell,1816,O
proliferation,1816,O
indicates,1816,O
that,1816,O
these,1816,O
immunomodulatory,1816,O
actions,1816,O
of,1816,O
antidepressants,1816,O
are,1816,O
most,1816,O
likely,1816,O
unrelated,1816,O
to,1816,O
inhibition,1816,O
of,1816,O
monoamine,1816,B-CHEMICAL
reuptake,1816,O
.,1816,O
Interestingly,1817,O
",",1817,O
exposure,1817,O
to,1817,O
a,1817,O
lower,1817,O
concentration,1817,O
(,1817,O
1,1817,O
microM,1817,O
),1817,O
of,1817,O
the,1817,O
antidepressants,1817,O
tended,1817,O
to,1817,O
increase,1817,O
T-cell-derived,1817,O
IL-10,1817,B-GENE-Y
production,1817,O
",",1817,O
with,1817,O
significant,1817,O
effects,1817,O
elicited,1817,O
by,1817,O
the,1817,O
noradrenaline,1817,B-CHEMICAL
reuptake,1817,O
inhibitors,1817,O
reboxetine,1817,B-CHEMICAL
and,1817,O
desipramine,1817,B-CHEMICAL
.,1817,O
In,1818,O
contrast,1818,O
to,1818,O
the,1818,O
robust,1818,O
actions,1818,O
of,1818,O
antidepressants,1818,O
on,1818,O
T-cell,1818,O
derived,1818,O
cytokine,1818,B-GENE-N
production,1818,O
",",1818,O
they,1818,O
failed,1818,O
to,1818,O
induce,1818,O
any,1818,O
consistent,1818,O
change,1818,O
in,1818,O
LPS-induced,1818,O
monocyte,1818,O
cytokine,1818,B-GENE-N
production,1818,O
.,1818,O
Overall,1819,O
",",1819,O
our,1819,O
results,1819,O
indicate,1819,O
that,1819,O
IFN-gamma,1819,B-GENE-Y
producing,1819,O
T-cells,1819,O
(,1819,O
Th,1819,O
(,1819,O
1,1819,O
),1819,O
cells,1819,O
),1819,O
are,1819,O
the,1819,O
major,1819,O
target,1819,O
for,1819,O
the,1819,O
immunomodulatory,1819,O
actions,1819,O
of,1819,O
antidepressants,1819,O
",",1819,O
and,1819,O
provide,1819,O
evidence,1819,O
questioning,1819,O
the,1819,O
relationship,1819,O
between,1819,O
the,1819,O
monoaminergic,1819,O
reuptake,1819,O
properties,1819,O
of,1819,O
antidepressants,1819,O
and,1819,O
their,1819,O
immunomodulatory,1819,O
effects,1819,O
.,1819,O
The,1820,O
potential,1820,O
clinical,1820,O
significance,1820,O
of,1820,O
the,1820,O
anti-inflammatory,1820,O
actions,1820,O
of,1820,O
antidepressants,1820,O
is,1820,O
discussed,1820,O
.,1820,O
Effect,1821,O
of,1821,O
cyproheptadine,1821,B-CHEMICAL
on,1821,O
serum,1821,O
leptin,1821,B-GENE-Y
levels,1821,O
.,1821,O
Leptin,1822,B-GENE-Y
is,1822,O
a,1822,O
167,1822,O
amino,1822,B-CHEMICAL
acid,1822,I-CHEMICAL
protein,1822,O
encoded,1822,O
by,1822,O
the,1822,O
obesity,1822,O
gene,1822,O
that,1822,O
is,1822,O
synthesized,1822,O
in,1822,O
adipose,1822,O
tissue,1822,O
and,1822,O
interacts,1822,O
with,1822,O
receptors,1822,O
in,1822,O
the,1822,O
hypothalamus,1822,O
linked,1822,O
to,1822,O
the,1822,O
regulation,1822,O
of,1822,O
appetite,1822,O
and,1822,O
metabolism,1822,O
.,1822,O
It,1823,O
is,1823,O
known,1823,O
to,1823,O
suppress,1823,O
appetite,1823,O
and,1823,O
increase,1823,O
energy,1823,O
expenditure,1823,O
.,1823,O
Cyproheptadine,1824,B-CHEMICAL
is,1824,O
a,1824,O
piperidine,1824,B-CHEMICAL
antihistamine,1824,B-CHEMICAL
that,1824,O
increases,1824,O
appetite,1824,O
through,1824,O
its,1824,O
antiserotonergic,1824,O
effect,1824,O
on,1824,O
5-HT2,1824,B-GENE-Y
receptors,1824,O
in,1824,O
the,1824,O
brain,1824,O
.,1824,O
Although,1825,O
both,1825,O
leptin,1825,B-GENE-Y
and,1825,O
cyproheptadine,1825,B-CHEMICAL
are,1825,O
effective,1825,O
in,1825,O
controlling,1825,O
appetite,1825,O
",",1825,O
their,1825,O
interaction,1825,O
has,1825,O
not,1825,O
been,1825,O
addressed,1825,O
in,1825,O
clinical,1825,O
studies,1825,O
.,1825,O
This,1826,O
study,1826,O
evaluated,1826,O
serum,1826,O
leptin,1826,O
concentrations,1826,O
in,1826,O
patients,1826,O
who,1826,O
received,1826,O
cyproheptadine,1826,B-CHEMICAL
to,1826,O
treat,1826,O
a,1826,O
variety,1826,O
of,1826,O
disorders,1826,O
.,1826,O
Sixteen,1827,O
patients,1827,O
aged,1827,O
7,1827,O
to,1827,O
71,1827,O
years,1827,O
(,1827,O
mean,1827,O
",",1827,O
26.25,1827,O
years,1827,O
),1827,O
were,1827,O
given,1827,O
cyproheptadine,1827,B-CHEMICAL
2,1827,O
to,1827,O
6,1827,O
mg/day,1827,O
for,1827,O
a,1827,O
minimum,1827,O
of,1827,O
7,1827,O
days,1827,O
.,1827,O
Body,1828,O
weight,1828,O
was,1828,O
measured,1828,O
and,1828,O
blood,1828,O
samples,1828,O
were,1828,O
obtained,1828,O
at,1828,O
baseline,1828,O
and,1828,O
after,1828,O
1,1828,O
week,1828,O
of,1828,O
treatment,1828,O
.,1828,O
Serum,1829,O
leptin,1829,B-GENE-Y
levels,1829,O
were,1829,O
determined,1829,O
by,1829,O
leptin,1829,B-GENE-Y
radioimmunoassay,1829,O
.,1829,O
The,1830,O
mean,1830,O
body,1830,O
weight,1830,O
at,1830,O
baseline,1830,O
(,1830,O
52.59,1830,O
kg,1830,O
),1830,O
did,1830,O
not,1830,O
differ,1830,O
significantly,1830,O
from,1830,O
that,1830,O
at,1830,O
1,1830,O
week,1830,O
after,1830,O
treatment,1830,O
(,1830,O
52.84,1830,O
kg,1830,O
;,1830,O
P,1830,O
>,1830,O
.05,1830,O
),1830,O
",",1830,O
but,1830,O
the,1830,O
mean,1830,O
leptin,1830,B-GENE-Y
level,1830,O
after,1830,O
1,1830,O
week,1830,O
of,1830,O
treatment,1830,O
with,1830,O
cyproheptadine,1830,B-CHEMICAL
(,1830,O
3.14,1830,O
ng/mL,1830,O
),1830,O
was,1830,O
14.2,1830,O
%,1830,O
higher,1830,O
than,1830,O
that,1830,O
at,1830,O
baseline,1830,O
(,1830,O
2.75,1830,O
ng/mL,1830,O
;,1830,O
P,1830,O
<,1830,O
.05,1830,O
),1830,O
.,1830,O
This,1831,O
increase,1831,O
may,1831,O
suggest,1831,O
that,1831,O
both,1831,O
leptin,1831,B-GENE-Y
and,1831,O
cyproheptadine,1831,B-CHEMICAL
may,1831,O
affect,1831,O
appetite,1831,O
via,1831,O
similar,1831,O
receptors,1831,O
and,1831,O
that,1831,O
cyproheptadine,1831,B-CHEMICAL
does,1831,O
not,1831,O
impair,1831,O
leptin,1831,O
activity,1831,O
through,1831,O
these,1831,O
receptors,1831,O
.,1831,O
Further,1832,O
study,1832,O
will,1832,O
be,1832,O
necessary,1832,O
to,1832,O
clarify,1832,O
this,1832,O
relationship,1832,O
.,1832,O
Comparison,1833,O
of,1833,O
captopril,1833,B-CHEMICAL
and,1833,O
enalapril,1833,B-CHEMICAL
to,1833,O
study,1833,O
the,1833,O
role,1833,O
of,1833,O
the,1833,O
sulfhydryl-group,1833,B-CHEMICAL
in,1833,O
improvement,1833,O
of,1833,O
endothelial,1833,O
dysfunction,1833,O
with,1833,O
ACE,1833,B-GENE-Y
inhibitors,1833,O
in,1833,O
high,1833,O
dieted,1833,O
methionine,1833,B-CHEMICAL
mice,1833,O
.,1833,O
To,1834,O
examine,1834,O
the,1834,O
role,1834,O
of,1834,O
sulfhydryl,1834,B-CHEMICAL
(,1834,O
-SH,1834,O
),1834,O
group,1834,O
in,1834,O
improvement,1834,O
of,1834,O
endothelial,1834,O
dysfunction,1834,O
with,1834,O
angiotensin-converting,1834,B-GENE-Y
enzyme,1834,I-GENE-Y
(,1834,O
ACE,1834,B-GENE-Y
),1834,O
inhibitors,1834,O
in,1834,O
experimental,1834,O
high,1834,O
dose,1834,O
of,1834,O
methionine,1834,B-CHEMICAL
dieted,1834,O
rats,1834,O
.,1834,O
We,1835,O
compared,1835,O
the,1835,O
effects,1835,O
of,1835,O
Captopril,1835,B-CHEMICAL
(,1835,O
an,1835,O
ACE,1835,B-GENE-Y
inhibitor,1835,O
with,1835,O
-SH,1835,O
group,1835,O
),1835,O
",",1835,O
enalapril,1835,B-CHEMICAL
(,1835,O
an,1835,O
ACE-inhibitor,1835,B-GENE-Y
without,1835,O
-SH,1835,O
group,1835,O
),1835,O
",",1835,O
N-acetylcysteine,1835,B-CHEMICAL
(,1835,O
only,1835,O
-SH,1835,O
group,1835,O
not,1835,O
ACE,1835,B-GENE-Y
inhibitor,1835,O
),1835,O
on,1835,O
endothelial,1835,O
dysfunction,1835,O
injured,1835,O
by,1835,O
methionine-induced,1835,B-CHEMICAL
hyperhomocysteinemia,1835,O
(,1835,O
HHcy,1835,O
),1835,O
in,1835,O
rats,1835,O
.,1835,O
Male,1836,O
Sprague-Dawley,1836,O
rats,1836,O
were,1836,O
divided,1836,O
randomly,1836,O
into,1836,O
seven,1836,O
groups,1836,O
:,1836,O
control,1836,O
group,1836,O
",",1836,O
L-methionine,1836,B-CHEMICAL
group,1836,O
",",1836,O
low,1836,O
dose,1836,O
Captopril,1836,B-CHEMICAL
(,1836,O
15,1836,O
mg/kg,1836,O
),1836,O
",",1836,O
middle,1836,O
dose,1836,O
Captopril,1836,B-CHEMICAL
(,1836,O
30,1836,O
mg/kg,1836,O
),1836,O
",",1836,O
high,1836,O
dose,1836,O
Captopril,1836,B-CHEMICAL
(,1836,O
45,1836,O
mg/kg,1836,O
),1836,O
",",1836,O
enalapril,1836,B-CHEMICAL
(,1836,O
20,1836,O
mg/kg,1836,O
),1836,O
",",1836,O
N-acetylcysteine,1836,B-CHEMICAL
(,1836,O
200,1836,O
mg/kg,1836,O
),1836,O
;,1836,O
control,1836,O
group,1836,O
were,1836,O
intragastric,1836,O
gavaged,1836,O
by,1836,O
water,1836,O
and,1836,O
others,1836,O
groups,1836,O
were,1836,O
intragastric,1836,O
gavaged,1836,O
by,1836,O
L-methionine,1836,B-CHEMICAL
and,1836,O
drugs,1836,O
in,1836,O
water,1836,O
one,1836,O
time,1836,O
every,1836,O
day,1836,O
.,1836,O
Acetylcholine,1837,B-CHEMICAL
(,1837,O
ACh,1837,B-CHEMICAL
),1837,O
-induced,1837,O
endothelium-dependent,1837,O
relaxation,1837,O
(,1837,O
EDR,1837,O
),1837,O
",",1837,O
sodium,1837,B-CHEMICAL
nitroprusside,1837,I-CHEMICAL
(,1837,O
SNP,1837,B-CHEMICAL
),1837,O
-induced,1837,O
endothelium-independent,1837,O
relaxation,1837,O
of,1837,O
aortic,1837,O
rings,1837,O
were,1837,O
examined,1837,O
.,1837,O
Paraoxonase1,1838,B-GENE-Y
(,1838,O
PON1,1838,B-GENE-Y
),1838,O
and,1838,O
ACE,1838,B-GENE-Y
activity,1838,O
",",1838,O
malondialdehyde,1838,B-CHEMICAL
(,1838,O
MDA,1838,B-CHEMICAL
),1838,O
",",1838,O
nitric,1838,B-CHEMICAL
oxide,1838,I-CHEMICAL
(,1838,O
NO,1838,B-CHEMICAL
),1838,O
",",1838,O
superoxide,1838,B-CHEMICAL
dismutase,1838,I-GENE-N
(,1838,O
SOD,1838,B-GENE-N
),1838,O
in,1838,O
serum,1838,O
were,1838,O
analyzed,1838,O
.,1838,O
It,1839,O
was,1839,O
found,1839,O
that,1839,O
a,1839,O
single,1839,O
intragastric,1839,O
gavage,1839,O
by,1839,O
L-methionine,1839,B-CHEMICAL
resulted,1839,O
in,1839,O
inhibition,1839,O
of,1839,O
endothelium-dependent,1839,O
relaxation,1839,O
",",1839,O
markedly,1839,O
increased,1839,O
the,1839,O
serum,1839,O
level,1839,O
of,1839,O
malondialdehyde,1839,B-CHEMICAL
and,1839,O
decreased,1839,O
the,1839,O
activity,1839,O
of,1839,O
PON1,1839,B-GENE-Y
and,1839,O
SOD,1839,B-GENE-N
",",1839,O
similarly,1839,O
decreased,1839,O
the,1839,O
level,1839,O
of,1839,O
NO,1839,B-CHEMICAL
in,1839,O
the,1839,O
serum,1839,O
;,1839,O
but,1839,O
had,1839,O
no,1839,O
effects,1839,O
on,1839,O
endothelium-independent,1839,O
relaxation,1839,O
and,1839,O
angiotensin-converting,1839,B-CHEMICAL
enzyme,1839,I-GENE-Y
activity,1839,O
compared,1839,O
with,1839,O
the,1839,O
control,1839,O
group,1839,O
.,1839,O
Given,1840,O
the,1840,O
treatment,1840,O
with,1840,O
three,1840,O
doses,1840,O
of,1840,O
Captopril,1840,B-CHEMICAL
(,1840,O
15,1840,O
approximately,1840,O
45,1840,O
mg/kg,1840,O
),1840,O
markedly,1840,O
attenuated,1840,O
inhibition,1840,O
of,1840,O
vasodilator,1840,O
responses,1840,O
to,1840,O
ACh,1840,B-CHEMICAL
",",1840,O
and,1840,O
eliminated,1840,O
the,1840,O
increased,1840,O
level,1840,O
of,1840,O
malondialdehyde,1840,B-CHEMICAL
",",1840,O
the,1840,O
decreased,1840,O
level,1840,O
of,1840,O
NO,1840,B-CHEMICAL
",",1840,O
activity,1840,O
of,1840,O
PON1,1840,B-GENE-Y
and,1840,O
SOD,1840,B-GENE-N
in,1840,O
serum,1840,O
by,1840,O
single,1840,O
intragastric,1840,O
gavaged,1840,O
L-methionine,1840,B-CHEMICAL
.,1840,O
However,1841,O
",",1841,O
there,1841,O
were,1841,O
some,1841,O
significant,1841,O
differences,1841,O
among,1841,O
Captopril,1841,B-CHEMICAL
(,1841,O
30,1841,O
mg/kg,1841,O
or,1841,O
45,1841,O
mg/kg,1841,O
),1841,O
",",1841,O
enalapril,1841,B-CHEMICAL
(,1841,O
20,1841,O
mg/kg,1841,O
),1841,O
",",1841,O
and,1841,O
N-acetylcysteine,1841,B-CHEMICAL
particular,1841,O
in,1841,O
the,1841,O
activity,1841,O
of,1841,O
PON1,1841,B-GENE-Y
and,1841,O
ACE,1841,B-GENE-Y
.,1841,O
These,1842,O
results,1842,O
suggested,1842,O
that,1842,O
Captopril,1842,B-CHEMICAL
can,1842,O
protect,1842,O
the,1842,O
vascular,1842,O
endothelium,1842,O
against,1842,O
the,1842,O
damages,1842,O
induced,1842,O
by,1842,O
L-methionine,1842,B-CHEMICAL
in,1842,O
rats,1842,O
",",1842,O
and,1842,O
the,1842,O
beneficial,1842,O
effects,1842,O
of,1842,O
Captopril,1842,B-CHEMICAL
may,1842,O
be,1842,O
related,1842,O
to,1842,O
attenuating,1842,O
the,1842,O
decrease,1842,O
in,1842,O
PON1,1842,B-GENE-Y
activity,1842,O
and,1842,O
NO,1842,B-CHEMICAL
levels,1842,O
.,1842,O
Furthermore,1843,O
",",1843,O
this,1843,O
protective,1843,O
effect,1843,O
may,1843,O
be,1843,O
concerned,1843,O
with,1843,O
the,1843,O
sulfhydryl,1843,B-CHEMICAL
group,1843,O
.,1843,O
Preclinical,1844,O
and,1844,O
clinical,1844,O
development,1844,O
of,1844,O
the,1844,O
oral,1844,O
multikinase,1844,O
inhibitor,1844,O
sorafenib,1844,B-CHEMICAL
in,1844,O
cancer,1844,O
treatment,1844,O
.,1844,O
Tumor,1845,O
survival,1845,O
",",1845,O
growth,1845,O
and,1845,O
metastasis,1845,O
depend,1845,O
on,1845,O
efficient,1845,O
tumor,1845,O
cell,1845,O
proliferation,1845,O
and,1845,O
tumor,1845,O
angiogenesis,1845,O
",",1845,O
and,1845,O
targeting,1845,O
both,1845,O
of,1845,O
these,1845,O
processes,1845,O
simultaneously,1845,O
could,1845,O
prove,1845,O
to,1845,O
be,1845,O
therapeutically,1845,O
relevant,1845,O
.,1845,O
The,1846,O
RAS/RAF,1846,B-GENE-N
signaling,1846,O
pathway,1846,O
is,1846,O
an,1846,O
important,1846,O
mediator,1846,O
of,1846,O
tumor,1846,O
cell,1846,O
proliferation,1846,O
",",1846,O
and,1846,O
angiogenesis,1846,O
and,1846,O
is,1846,O
often,1846,O
aberrantly,1846,O
activated,1846,O
in,1846,O
human,1846,O
tumors,1846,O
due,1846,O
to,1846,O
the,1846,O
presence,1846,O
of,1846,O
activated,1846,O
Ras,1846,B-GENE-N
or,1846,O
mutant,1846,O
B-Raf,1846,B-GENE-Y
",",1846,O
or,1846,O
elevation,1846,O
of,1846,O
growth,1846,B-GENE-N
factor,1846,I-GENE-N
receptors,1846,I-GENE-N
.,1846,O
Sorafenib,1847,B-CHEMICAL
",",1847,O
which,1847,O
belongs,1847,O
chemically,1847,O
to,1847,O
a,1847,O
class,1847,O
that,1847,O
can,1847,O
be,1847,O
described,1847,O
as,1847,O
bis-aryl,1847,B-CHEMICAL
ureas,1847,I-CHEMICAL
",",1847,O
was,1847,O
selected,1847,O
for,1847,O
further,1847,O
pharmacologic,1847,O
characterization,1847,O
based,1847,O
on,1847,O
potent,1847,O
inhibition,1847,O
of,1847,O
Raf-1,1847,B-GENE-Y
and,1847,O
its,1847,O
favorable,1847,O
kinase,1847,B-GENE-N
selectivity,1847,O
profile,1847,O
.,1847,O
Further,1848,O
characterization,1848,O
showed,1848,O
that,1848,O
sorafenib,1848,B-CHEMICAL
suppresses,1848,O
both,1848,O
wild-type,1848,O
and,1848,O
V599E,1848,B-GENE-N
mutant,1848,O
B-Raf,1848,B-GENE-Y
activity,1848,O
in,1848,O
vitro,1848,O
.,1848,O
In,1849,O
addition,1849,O
",",1849,O
sorafenib,1849,B-CHEMICAL
demonstrated,1849,O
significant,1849,O
activity,1849,O
against,1849,O
several,1849,O
receptor,1849,B-GENE-N
tyrosine,1849,I-GENE-N
kinases,1849,I-GENE-N
involved,1849,O
in,1849,O
neovascularization,1849,O
and,1849,O
tumor,1849,O
progression,1849,O
",",1849,O
including,1849,O
vascular-endothelial,1849,B-GENE-Y
growth,1849,I-GENE-Y
factor,1849,I-GENE-Y
(,1849,I-GENE-Y
VEGFR,1849,I-GENE-Y
),1849,I-GENE-Y
-2,1849,I-GENE-Y
",",1849,O
VEGFR-3,1849,B-GENE-Y
",",1849,O
platelet-derived,1849,B-GENE-Y
growth,1849,I-GENE-Y
factor,1849,I-GENE-Y
(,1849,I-GENE-Y
PDGFR,1849,I-GENE-Y
),1849,I-GENE-Y
-beta,1849,I-GENE-Y
Flt-3,1849,B-GENE-Y
",",1849,O
and,1849,O
c-KIT,1849,B-GENE-Y
.,1849,O
Preclinically,1850,O
",",1850,O
sorafenib,1850,B-CHEMICAL
showed,1850,O
broad-spectrum,1850,O
antitumor,1850,O
activity,1850,O
in,1850,O
colon,1850,O
",",1850,O
breast,1850,O
and,1850,O
non-small-cell,1850,O
lung,1850,O
cancer,1850,O
xenograft,1850,O
models,1850,O
.,1850,O
A,1851,O
total,1851,O
of,1851,O
four,1851,O
phase,1851,O
I,1851,O
studies,1851,O
using,1851,O
oral,1851,O
sorafenib,1851,B-CHEMICAL
as,1851,O
a,1851,O
single,1851,O
agent,1851,O
have,1851,O
been,1851,O
completed,1851,O
",",1851,O
and,1851,O
the,1851,O
compound,1851,O
showed,1851,O
a,1851,O
favorable,1851,O
safety,1851,O
profile,1851,O
with,1851,O
mild,1851,O
to,1851,O
moderate,1851,O
diarrhea,1851,O
being,1851,O
the,1851,O
most,1851,O
common,1851,O
treatment-related,1851,O
adverse,1851,O
event,1851,O
.,1851,O
The,1852,O
maximum,1852,O
tolerated,1852,O
dose,1852,O
was,1852,O
400,1852,O
mg,1852,O
b.i.d,1852,O
.,1852,O
continuous,1853,O
.,1853,O
Single-agent,1854,O
phase,1854,O
II,1854,O
trials,1854,O
reported,1854,O
so,1854,O
far,1854,O
demonstrated,1854,O
antitumor,1854,O
activity,1854,O
of,1854,O
sorafenib,1854,B-CHEMICAL
in,1854,O
patients,1854,O
with,1854,O
hepatocellular,1854,O
carcinoma,1854,O
",",1854,O
sarcoma,1854,O
and,1854,O
renal,1854,O
cell,1854,O
cancer,1854,O
(,1854,O
RCC,1854,O
),1854,O
.,1854,O
Based,1855,O
on,1855,O
phase,1855,O
II,1855,O
results,1855,O
in,1855,O
RCC,1855,O
patients,1855,O
",",1855,O
a,1855,O
placebo-controlled,1855,O
phase,1855,O
III,1855,O
study,1855,O
was,1855,O
performed,1855,O
",",1855,O
which,1855,O
randomized,1855,O
a,1855,O
total,1855,O
of,1855,O
905,1855,O
patients,1855,O
",",1855,O
most,1855,O
of,1855,O
whom,1855,O
were,1855,O
treated,1855,O
previously,1855,O
.,1855,O
The,1856,O
partial,1856,O
response,1856,O
rate,1856,O
was,1856,O
2,1856,O
%,1856,O
for,1856,O
sorafenib,1856,B-CHEMICAL
and,1856,O
0,1856,O
%,1856,O
for,1856,O
placebo,1856,O
.,1856,O
Stable,1857,O
disease,1857,O
was,1857,O
observed,1857,O
in,1857,O
78,1857,O
%,1857,O
and,1857,O
55,1857,O
%,1857,O
of,1857,O
patients,1857,O
on,1857,O
sorafenib,1857,B-CHEMICAL
and,1857,O
placebo,1857,O
",",1857,O
respectively,1857,O
.,1857,O
Sorafenib,1858,B-CHEMICAL
significantly,1858,O
prolonged,1858,O
median,1858,O
progression-free,1858,O
survival,1858,O
(,1858,O
24,1858,O
weeks,1858,O
),1858,O
compared,1858,O
with,1858,O
placebo,1858,O
(,1858,O
12,1858,O
weeks,1858,O
),1858,O
in,1858,O
all,1858,O
subsets,1858,O
of,1858,O
patients,1858,O
evaluated,1858,O
.,1858,O
Approval,1859,O
of,1859,O
sorafenib,1859,B-CHEMICAL
by,1859,O
the,1859,O
U.S.,1859,O
Food,1859,O
and,1859,O
Drug,1859,O
Administration,1859,O
for,1859,O
this,1859,O
indication,1859,O
is,1859,O
pending,1859,O
.,1859,O
A,1860,O
first-line,1860,O
phase,1860,O
III,1860,O
study,1860,O
in,1860,O
RCC,1860,O
as,1860,O
well,1860,O
as,1860,O
phase,1860,O
III,1860,O
studies,1860,O
in,1860,O
hepatocellular,1860,O
carcinoma,1860,O
and,1860,O
metastatic,1860,O
melanoma,1860,O
have,1860,O
been,1860,O
initiated,1860,O
.,1860,O
A,1861,O
selective,1861,O
retinoid,1861,B-GENE-N
X,1861,I-GENE-N
receptor,1861,I-GENE-N
agonist,1861,O
bexarotene,1861,B-CHEMICAL
(,1861,O
LGD1069,1861,B-CHEMICAL
",",1861,O
targretin,1861,B-CHEMICAL
),1861,O
inhibits,1861,O
angiogenesis,1861,O
and,1861,O
metastasis,1861,O
in,1861,O
solid,1861,O
tumours,1861,O
.,1861,O
The,1862,O
present,1862,O
study,1862,O
determined,1862,O
the,1862,O
influence,1862,O
of,1862,O
a,1862,O
retinoid,1862,B-CHEMICAL
X,1862,I-GENE-N
receptor,1862,I-GENE-N
agonist,1862,O
bexarotene,1862,B-CHEMICAL
on,1862,O
angiogenesis,1862,O
and,1862,O
metastasis,1862,O
in,1862,O
solid,1862,O
tumours,1862,O
.,1862,O
In,1863,O
the,1863,O
experimental,1863,O
lung,1863,O
metastasis,1863,O
xenograft,1863,O
models,1863,O
",",1863,O
treatment,1863,O
with,1863,O
bexarotene,1863,B-CHEMICAL
inhibited,1863,O
the,1863,O
development,1863,O
of,1863,O
the,1863,O
lung,1863,O
tumour,1863,O
nodule,1863,O
formation,1863,O
compared,1863,O
to,1863,O
control,1863,O
.,1863,O
In,1864,O
vivo,1864,O
angiogenesis,1864,O
assay,1864,O
utilising,1864,O
gelfoam,1864,O
sponges,1864,O
",",1864,O
bexarotene,1864,B-CHEMICAL
reduced,1864,O
angiogenesis,1864,O
in,1864,O
sponges,1864,O
containing,1864,O
vascular,1864,B-GENE-Y
endothelial,1864,I-GENE-Y
growth,1864,I-GENE-Y
factor,1864,I-GENE-Y
",",1864,O
epidermal,1864,B-GENE-Y
growth,1864,I-GENE-Y
factor,1864,I-GENE-Y
and,1864,O
basic,1864,O
fibroblast,1864,B-GENE-N
growth,1864,I-GENE-N
factor,1864,I-GENE-N
to,1864,O
various,1864,O
extent,1864,O
.,1864,O
To,1865,O
determine,1865,O
the,1865,O
basis,1865,O
of,1865,O
these,1865,O
observations,1865,O
",",1865,O
human,1865,O
breast,1865,O
and,1865,O
non-small-cell,1865,O
lung,1865,O
cancer,1865,O
cells,1865,O
were,1865,O
subjected,1865,O
to,1865,O
migration,1865,O
and,1865,O
invasion,1865,O
assays,1865,O
in,1865,O
the,1865,O
presence,1865,O
of,1865,O
bexarotene,1865,B-CHEMICAL
.,1865,O
Our,1866,O
data,1866,O
showed,1866,O
that,1866,O
bexarotene,1866,B-CHEMICAL
decrease,1866,O
migration,1866,O
and,1866,O
invasiveness,1866,O
of,1866,O
tumour,1866,O
cells,1866,O
in,1866,O
a,1866,O
dose-dependent,1866,O
manner,1866,O
.,1866,O
Furthermore,1867,O
",",1867,O
bexarotene,1867,B-CHEMICAL
inhibited,1867,O
angiogenesis,1867,O
by,1867,O
directly,1867,O
inhibiting,1867,O
human,1867,O
umbilical,1867,O
vein,1867,O
endothelial,1867,O
cell,1867,O
growth,1867,O
and,1867,O
indirectly,1867,O
inhibiting,1867,O
tumour,1867,O
cell-mediated,1867,O
migration,1867,O
of,1867,O
human,1867,O
umbilical,1867,O
vein,1867,O
endothelial,1867,O
cells,1867,O
through,1867,O
Matrigel,1867,O
matrix,1867,O
.,1867,O
Analysis,1868,O
of,1868,O
tumour-conditioned,1868,O
medium,1868,O
indicated,1868,O
that,1868,O
bexarotene,1868,B-CHEMICAL
decreased,1868,O
the,1868,O
secretion,1868,O
of,1868,O
angiogenic,1868,O
factors,1868,O
and,1868,O
matrix,1868,B-GENE-N
metalloproteinases,1868,I-GENE-N
and,1868,O
increased,1868,O
the,1868,O
tissue,1868,O
inhibitor,1868,O
of,1868,O
matrix,1868,B-GENE-N
metalloproteinases,1868,I-GENE-N
.,1868,O
The,1869,O
ability,1869,O
of,1869,O
bexarotene,1869,B-CHEMICAL
to,1869,O
inhibit,1869,O
angiogenesis,1869,O
and,1869,O
metastasis,1869,O
was,1869,O
dependent,1869,O
on,1869,O
activation,1869,O
of,1869,O
its,1869,O
heterodimerisation,1869,O
partner,1869,O
peroxisome,1869,B-GENE-Y
proliferator-activated,1869,I-GENE-Y
receptor,1869,I-GENE-Y
gamma,1869,I-GENE-Y
.,1869,O
Collectively,1870,O
",",1870,O
our,1870,O
results,1870,O
suggest,1870,O
a,1870,O
role,1870,O
of,1870,O
bexarotene,1870,B-CHEMICAL
in,1870,O
treatment,1870,O
of,1870,O
angiogenesis,1870,O
and,1870,O
metastasis,1870,O
in,1870,O
solid,1870,O
tumours,1870,O
.,1870,O
DRD2,1871,B-GENE-N
promoter,1871,I-GENE-N
region,1871,O
variation,1871,O
as,1871,O
a,1871,O
predictor,1871,O
of,1871,O
sustained,1871,O
response,1871,O
to,1871,O
antipsychotic,1871,O
medication,1871,O
in,1871,O
first-episode,1871,O
schizophrenia,1871,O
patients,1871,O
.,1871,O
OBJECTIVE,1872,O
:,1872,O
All,1872,O
antipsychotics,1872,O
act,1872,O
on,1872,O
the,1872,O
dopamine,1872,B-GENE-Y
D,1872,I-GENE-Y
(,1872,I-GENE-Y
2,1872,I-GENE-Y
),1872,I-GENE-Y
receptor,1872,I-GENE-Y
.,1872,O
The,1873,O
present,1873,O
study,1873,O
extends,1873,O
prior,1873,O
pharmacogenetic,1873,O
investigations,1873,O
of,1873,O
the,1873,O
D,1873,B-GENE-Y
(,1873,I-GENE-Y
2,1873,I-GENE-Y
),1873,I-GENE-Y
receptor,1873,I-GENE-Y
gene,1873,O
(,1873,O
DRD2,1873,B-GENE-Y
),1873,O
by,1873,O
examining,1873,O
",",1873,O
in,1873,O
first-episode,1873,O
schizophrenia,1873,O
patients,1873,O
",",1873,O
promoter,1873,O
region,1873,O
variation,1873,O
as,1873,O
a,1873,O
predictor,1873,O
of,1873,O
response,1873,O
time,1873,O
to,1873,O
two,1873,O
first-line,1873,O
atypical,1873,O
antipsychotics,1873,O
.,1873,O
METHOD,1874,O
:,1874,O
Patients,1874,O
experiencing,1874,O
their,1874,O
first,1874,O
episode,1874,O
of,1874,O
schizophrenia,1874,O
(,1874,O
N=61,1874,O
),1874,O
were,1874,O
genotyped,1874,O
for,1874,O
two,1874,O
DRD2,1874,B-GENE-N
promoter,1874,I-GENE-N
region,1874,O
polymorphisms,1874,O
(,1874,O
A-241G,1874,B-GENE-N
and,1874,O
-141C,1874,O
Ins/Del,1874,O
),1874,O
and,1874,O
were,1874,O
randomly,1874,O
assigned,1874,O
to,1874,O
receive,1874,O
16,1874,O
weeks,1874,O
of,1874,O
treatment,1874,O
with,1874,O
either,1874,O
risperidone,1874,B-CHEMICAL
or,1874,O
olanzapine,1874,B-CHEMICAL
.,1874,O
Time,1875,O
until,1875,O
sustained,1875,O
response,1875,O
(,1875,O
two,1875,O
consecutive,1875,O
ratings,1875,O
without,1875,O
significant,1875,O
positive,1875,O
symptoms,1875,O
),1875,O
for,1875,O
rare,1875,O
allele,1875,O
carriers,1875,O
versus,1875,O
wild,1875,O
types,1875,O
was,1875,O
examined,1875,O
by,1875,O
using,1875,O
Kaplan-Meier,1875,O
curves,1875,O
.,1875,O
RESULTS,1876,O
:,1876,O
Relative,1876,O
to,1876,O
wild,1876,O
type,1876,O
homozygotes,1876,O
",",1876,O
G,1876,O
carriers,1876,O
(,1876,O
A-241G,1876,B-GENE-N
),1876,O
exhibited,1876,O
a,1876,O
significantly,1876,O
faster,1876,O
time,1876,O
until,1876,O
response,1876,O
",",1876,O
whereas,1876,O
-141C,1876,O
Del,1876,O
carriers,1876,O
took,1876,O
a,1876,O
significantly,1876,O
longer,1876,O
time,1876,O
to,1876,O
respond,1876,O
.,1876,O
Diplotype,1877,O
analysis,1877,O
revealed,1877,O
similar,1877,O
results,1877,O
.,1877,O
CONCLUSIONS,1878,O
:,1878,O
These,1878,O
findings,1878,O
suggest,1878,O
that,1878,O
variation,1878,O
in,1878,O
the,1878,O
D,1878,B-GENE-Y
(,1878,I-GENE-Y
2,1878,I-GENE-Y
),1878,I-GENE-Y
receptor,1878,I-GENE-Y
gene,1878,O
can,1878,O
",",1878,O
in,1878,O
part,1878,O
",",1878,O
explain,1878,O
variation,1878,O
in,1878,O
the,1878,O
timing,1878,O
of,1878,O
clinical,1878,O
response,1878,O
to,1878,O
antipsychotics,1878,O
in,1878,O
patients,1878,O
with,1878,O
first-episode,1878,O
schizophrenia,1878,O
.,1878,O
Intrauterine,1879,O
pressure,1879,O
",",1879,O
ischemia,1879,O
markers,1879,O
",",1879,O
and,1879,O
experienced,1879,O
pain,1879,O
during,1879,O
administration,1879,O
of,1879,O
a,1879,O
vasopressin,1879,B-GENE-Y
V1a,1879,I-GENE-Y
receptor,1879,I-GENE-Y
antagonist,1879,O
in,1879,O
spontaneous,1879,O
and,1879,O
vasopressin-induced,1879,B-GENE-Y
dysmenorrhea,1879,O
.,1879,O
BACKGROUND,1880,O
:,1880,O
A,1880,O
model,1880,O
to,1880,O
study,1880,O
the,1880,O
effect,1880,O
of,1880,O
vasopressin,1880,B-GENE-Y
V1a,1880,I-GENE-Y
antagonist,1880,O
in,1880,O
dysmenorrhea,1880,O
.,1880,O
METHODS,1881,O
:,1881,O
A,1881,O
double-blind,1881,O
",",1881,O
randomized,1881,O
",",1881,O
placebo-controlled,1881,O
",",1881,O
cross-over,1881,O
trial,1881,O
was,1881,O
performed,1881,O
.,1881,O
Eight,1882,O
patients,1882,O
with,1882,O
primary,1882,O
dysmenorrhea,1882,O
and,1882,O
eight,1882,O
tuballigated,1882,O
",",1882,O
healthy,1882,O
subjects,1882,O
participated,1882,O
on,1882,O
days,1882,O
1-2,1882,O
of,1882,O
two,1882,O
consecutive,1882,O
menstruations,1882,O
.,1882,O
At,1883,O
each,1883,O
menstruation,1883,O
a,1883,O
bolus,1883,O
injection,1883,O
of,1883,O
10,1883,O
pmol/kg,1883,O
of,1883,O
vasopressin,1883,B-CHEMICAL
was,1883,O
administered,1883,O
before,1883,O
and,1883,O
during,1883,O
infusion,1883,O
of,1883,O
either,1883,O
300,1883,O
microg/min,1883,O
of,1883,O
atosiban,1883,B-CHEMICAL
or,1883,O
placebo,1883,O
.,1883,O
Intrauterine,1884,O
pressure,1884,O
was,1884,O
measured,1884,O
as,1884,O
area,1884,O
under,1884,O
the,1884,O
curve,1884,O
throughout,1884,O
the,1884,O
experiments,1884,O
.,1884,O
Ischemia,1885,O
markers,1885,O
in,1885,O
plasma,1885,O
and,1885,O
pain,1885,O
recorded,1885,O
by,1885,O
a,1885,O
visual,1885,O
analog,1885,O
scale,1885,O
were,1885,O
measured,1885,O
before,1885,O
and,1885,O
after,1885,O
each,1885,O
vasopressin,1885,B-GENE-Y
injection,1885,O
as,1885,O
well,1885,O
as,1885,O
before,1885,O
and,1885,O
after,1885,O
the,1885,O
start,1885,O
of,1885,O
either,1885,O
atosiban,1885,B-CHEMICAL
or,1885,O
placebo,1885,O
infusion,1885,O
.,1885,O
RESULTS,1886,O
:,1886,O
Vasopressin,1886,B-GENE-Y
injections,1886,O
elevated,1886,O
area,1886,O
under,1886,O
the,1886,O
curve,1886,O
in,1886,O
both,1886,O
healthy,1886,O
volunteers,1886,O
and,1886,O
dysmenorrhea,1886,O
subjects,1886,O
.,1886,O
The,1887,O
vasopressin-induced,1887,B-CHEMICAL
rise,1887,O
in,1887,O
area,1887,O
under,1887,O
the,1887,O
curve,1887,O
was,1887,O
lower,1887,O
during,1887,O
atosiban,1887,B-CHEMICAL
administration,1887,O
than,1887,O
during,1887,O
infusion,1887,O
of,1887,O
placebo,1887,O
in,1887,O
both,1887,O
groups,1887,O
.,1887,O
None,1888,O
of,1888,O
the,1888,O
ischemia,1888,O
markers,1888,O
differed,1888,O
between,1888,O
or,1888,O
within,1888,O
groups,1888,O
at,1888,O
vasopressin,1888,B-CHEMICAL
injections,1888,O
or,1888,O
atosiban/placebo,1888,B-CHEMICAL
infusions,1888,O
.,1888,O
In,1889,O
subjects,1889,O
with,1889,O
dysmenorrhea,1889,O
the,1889,O
increase,1889,O
in,1889,O
pain,1889,O
following,1889,O
the,1889,O
administration,1889,O
of,1889,O
vasopressin,1889,B-CHEMICAL
was,1889,O
significantly,1889,O
lower,1889,O
during,1889,O
atosiban,1889,B-CHEMICAL
than,1889,O
during,1889,O
placebo,1889,O
infusion,1889,O
.,1889,O
Healthy,1890,O
volunteers,1890,O
experienced,1890,O
only,1890,O
slight,1890,O
discomfort,1890,O
after,1890,O
the,1890,O
vasopressin,1890,B-CHEMICAL
injections,1890,O
.,1890,O
CONCLUSIONS,1891,O
:,1891,O
Atosiban,1891,B-CHEMICAL
reduces,1891,O
vasopressin-induced,1891,B-CHEMICAL
intrauterine,1891,O
pressure,1891,O
in,1891,O
both,1891,O
healthy,1891,O
volunteers,1891,O
and,1891,O
dysmenorrheics,1891,O
",",1891,O
and,1891,O
reported,1891,O
pain,1891,O
in,1891,O
subjects,1891,O
with,1891,O
dysmenorrhea,1891,O
.,1891,O
The,1892,O
ischemia,1892,O
markers,1892,O
are,1892,O
not,1892,O
a,1892,O
useful,1892,O
biomarker,1892,O
index,1892,O
in,1892,O
women,1892,O
with,1892,O
dysmenorrhea,1892,O
.,1892,O
The,1893,O
dysmenorrhea,1893,O
pain,1893,O
evoked,1893,O
by,1893,O
vasopressin,1893,B-CHEMICAL
correlated,1893,O
poorly,1893,O
with,1893,O
area,1893,O
under,1893,O
the,1893,O
curve,1893,O
",",1893,O
which,1893,O
may,1893,O
suggest,1893,O
that,1893,O
the,1893,O
effect,1893,O
is,1893,O
mediated,1893,O
by,1893,O
more,1893,O
than,1893,O
one,1893,O
V1a-like,1893,B-GENE-Y
receptor,1893,I-GENE-Y
.,1893,O
We,1894,O
conclude,1894,O
that,1894,O
this,1894,O
model,1894,O
with,1894,O
recordings,1894,O
in,1894,O
healthy,1894,O
women,1894,O
is,1894,O
useful,1894,O
in,1894,O
the,1894,O
evaluation,1894,O
of,1894,O
drug,1894,O
candidates,1894,O
for,1894,O
primary,1894,O
dysmenorrhea,1894,O
.,1894,O
Thymidylate,1895,B-CHEMICAL
synthase,1895,I-GENE-Y
expression,1895,O
in,1895,O
resectable,1895,O
and,1895,O
unresectable,1895,O
pancreatic,1895,O
cancer,1895,O
:,1895,O
role,1895,O
as,1895,O
predictive,1895,O
or,1895,O
prognostic,1895,O
marker,1895,O
?,1895,O
BACKGROUND,1896,O
AND,1896,O
AIMS,1896,O
:,1896,O
Thymidylate,1896,B-CHEMICAL
synthase,1896,I-GENE-Y
(,1896,O
TS,1896,B-GENE-Y
),1896,O
is,1896,O
an,1896,O
important,1896,O
enzyme,1896,O
for,1896,O
DNA,1896,O
synthesis,1896,O
and,1896,O
the,1896,O
target,1896,O
for,1896,O
5-fluorouracil,1896,B-CHEMICAL
(,1896,O
5-FU,1896,B-CHEMICAL
),1896,O
.,1896,O
Its,1897,O
expression,1897,O
may,1897,O
determine,1897,O
the,1897,O
outcome,1897,O
of,1897,O
patients,1897,O
with,1897,O
gastrointestinal,1897,O
cancers,1897,O
.,1897,O
We,1898,O
examined,1898,O
the,1898,O
prognostic,1898,O
and,1898,O
predictive,1898,O
value,1898,O
of,1898,O
TS-protein,1898,B-GENE-Y
expression,1898,O
in,1898,O
patients,1898,O
with,1898,O
ductal,1898,O
adenocarcinoma,1898,O
of,1898,O
the,1898,O
pancreas,1898,O
.,1898,O
METHODS,1899,O
:,1899,O
TS,1899,B-GENE-Y
expression,1899,O
from,1899,O
131,1899,O
patients,1899,O
with,1899,O
ductal,1899,O
adenocarcinoma,1899,O
of,1899,O
the,1899,O
pancreas,1899,O
was,1899,O
analyzed,1899,O
by,1899,O
immunohistochemistry,1899,O
in,1899,O
paraffin-embedded,1899,O
primary,1899,O
tumour,1899,O
specimens,1899,O
or,1899,O
biopsies,1899,O
.,1899,O
RESULTS,1900,O
:,1900,O
The,1900,O
median,1900,O
disease-specific,1900,O
survival,1900,O
among,1900,O
all,1900,O
patients,1900,O
(,1900,O
n=131,1900,O
),1900,O
was,1900,O
13,1900,O
months,1900,O
.,1900,O
The,1901,O
invasion,1901,O
depth,1901,O
",",1901,O
the,1901,O
presence,1901,O
of,1901,O
metastases,1901,O
",",1901,O
grading,1901,O
and,1901,O
Union,1901,O
Internationale,1901,O
Contre,1901,O
le,1901,O
Cancer,1901,O
[,1901,O
International,1901,O
Union,1901,O
Against,1901,O
Cancer,1901,O
],1901,O
(,1901,O
UICC,1901,O
),1901,O
stage,1901,O
were,1901,O
associated,1901,O
with,1901,O
survival,1901,O
.,1901,O
Among,1902,O
resected,1902,O
patients,1902,O
(,1902,O
n=98,1902,O
),1902,O
",",1902,O
a,1902,O
difference,1902,O
in,1902,O
median,1902,O
survival,1902,O
was,1902,O
seen,1902,O
in,1902,O
the,1902,O
group,1902,O
receiving,1902,O
postoperative,1902,O
adjuvant,1902,O
treatment,1902,O
(,1902,O
21.1,1902,O
months,1902,O
),1902,O
compared,1902,O
with,1902,O
the,1902,O
group,1902,O
treated,1902,O
by,1902,O
surgery,1902,O
alone,1902,O
(,1902,O
12.4,1902,O
months,1902,O
),1902,O
(,1902,O
p=0.025,1902,O
),1902,O
.,1902,O
Low-,1903,O
and,1903,O
high-TS,1903,O
immunoreactivity,1903,O
was,1903,O
present,1903,O
in,1903,O
74,1903,O
(,1903,O
56,1903,O
%,1903,O
),1903,O
and,1903,O
56,1903,O
(,1903,O
43,1903,O
%,1903,O
),1903,O
of,1903,O
the,1903,O
cancers,1903,O
",",1903,O
respectively,1903,O
.,1903,O
One,1904,O
sample,1904,O
was,1904,O
not,1904,O
evaluable,1904,O
.,1904,O
No,1905,O
difference,1905,O
in,1905,O
median,1905,O
survival,1905,O
was,1905,O
observed,1905,O
among,1905,O
low-,1905,O
and,1905,O
high-TS-expressing,1905,O
tumours,1905,O
.,1905,O
Among,1906,O
patients,1906,O
undergoing,1906,O
resection,1906,O
and,1906,O
receiving,1906,O
postoperative,1906,O
intra-arterial,1906,O
chemotherapy,1906,O
(,1906,O
n=23,1906,O
),1906,O
",",1906,O
a,1906,O
marked,1906,O
trend,1906,O
to,1906,O
a,1906,O
longer,1906,O
median,1906,O
survival,1906,O
was,1906,O
seen,1906,O
for,1906,O
the,1906,O
group,1906,O
with,1906,O
low-TS-expressing,1906,O
tumours,1906,O
compared,1906,O
with,1906,O
the,1906,O
corresponding,1906,O
high-TS,1906,O
group,1906,O
(,1906,O
25.0,1906,O
vs,1906,O
16.0,1906,O
months,1906,O
),1906,O
(,1906,O
p=0.3834,1906,O
),1906,O
.,1906,O
There,1907,O
was,1907,O
no,1907,O
difference,1907,O
in,1907,O
survival,1907,O
among,1907,O
all,1907,O
palliative,1907,O
treated,1907,O
patients,1907,O
with,1907,O
low-,1907,O
and,1907,O
high-TS-expressing,1907,O
tumours,1907,O
.,1907,O
CONCLUSION,1908,O
:,1908,O
Especially,1908,O
patients,1908,O
undergoing,1908,O
tumour,1908,O
resection,1908,O
with,1908,O
low-TS,1908,O
values,1908,O
seemed,1908,O
to,1908,O
have,1908,O
taken,1908,O
advantage,1908,O
from,1908,O
an,1908,O
intensified,1908,O
postoperative,1908,O
chemotherapeutic,1908,O
protocol,1908,O
.,1908,O
However,1909,O
due,1909,O
to,1909,O
the,1909,O
heterogeneous,1909,O
group,1909,O
of,1909,O
patients,1909,O
in,1909,O
the,1909,O
present,1909,O
report,1909,O
",",1909,O
larger,1909,O
trials,1909,O
of,1909,O
more,1909,O
homogenous,1909,O
patient,1909,O
populations,1909,O
will,1909,O
be,1909,O
necessary,1909,O
to,1909,O
confirm,1909,O
this,1909,O
hypothesis,1909,O
.,1909,O
Enzymatic,1910,O
and,1910,O
biochemical,1910,O
properties,1910,O
of,1910,O
a,1910,O
novel,1910,O
human,1910,B-GENE-Y
serine,1910,B-CHEMICAL
dehydratase,1910,I-GENE-Y
isoform,1910,O
.,1910,O
A,1911,O
cDNA,1911,O
clone,1911,O
similar,1911,O
to,1911,O
human,1911,B-GENE-Y
serine,1911,B-CHEMICAL
dehydratase,1911,I-GENE-Y
(,1911,O
SDH,1911,B-GENE-Y
),1911,O
is,1911,O
deposited,1911,O
in,1911,O
the,1911,O
GenBank/EMBL,1911,O
databases,1911,O
",",1911,O
but,1911,O
its,1911,O
structural,1911,O
and,1911,O
functional,1911,O
bases,1911,O
remain,1911,O
unknown,1911,O
.,1911,O
Despite,1912,O
the,1912,O
occurrence,1912,O
of,1912,O
mRNA,1912,O
",",1912,O
the,1912,O
expected,1912,O
protein,1912,O
level,1912,O
was,1912,O
found,1912,O
to,1912,O
be,1912,O
low,1912,O
in,1912,O
cultured,1912,O
cells,1912,O
.,1912,O
To,1913,O
learn,1913,O
about,1913,O
physicochemical,1913,O
properties,1913,O
of,1913,O
the,1913,O
protein,1913,O
",",1913,O
we,1913,O
expressed,1913,O
the,1913,O
cDNA,1913,O
in,1913,O
Escherichia,1913,O
coli,1913,O
",",1913,O
and,1913,O
compared,1913,O
the,1913,O
expressed,1913,O
protein,1913,O
with,1913,O
that,1913,O
of,1913,O
a,1913,O
hepatic,1913,O
SDH,1913,B-GENE-Y
.,1913,O
The,1914,O
purified,1914,O
protein,1914,O
showed,1914,O
l-serine,1914,B-CHEMICAL
and,1914,I-GENE-Y
l-threonine,1914,B-CHEMICAL
dehydratase,1914,I-GENE-Y
activity,1914,O
",",1914,O
demonstrating,1914,O
to,1914,O
be,1914,O
an,1914,O
isoform,1914,O
of,1914,O
SDH,1914,B-GENE-Y
.,1914,O
However,1915,O
",",1915,O
their,1915,O
Km,1915,O
and,1915,O
Vmax,1915,O
constants,1915,O
were,1915,O
different,1915,O
in,1915,O
a,1915,O
range,1915,O
of,1915,O
two-order,1915,O
.,1915,O
Removal,1916,O
of,1916,O
Pro128,1916,O
from,1916,O
the,1916,O
hepatic,1916,O
SDH,1916,B-GENE-Y
consisting,1916,O
of,1916,O
328,1916,O
residues,1916,O
",",1916,O
which,1916,O
is,1916,O
missing,1916,O
in,1916,O
the,1916,O
corresponding,1916,O
position,1916,O
of,1916,O
the,1916,O
isoform,1916,O
consisting,1916,O
of,1916,O
329,1916,O
residues,1916,O
",",1916,O
significantly,1916,O
changed,1916,O
the,1916,O
Michaelis,1916,O
constants,1916,O
and,1916,O
Kd,1916,O
value,1916,O
for,1916,O
pyridoxal,1916,B-CHEMICAL
5'-phosphate,1916,I-CHEMICAL
",",1916,O
whereas,1916,O
addition,1916,O
of,1916,O
a,1916,O
proline,1916,B-CHEMICAL
residue,1916,O
to,1916,O
the,1916,O
isoform,1916,O
was,1916,O
without,1916,O
effect,1916,O
.,1916,O
These,1917,O
findings,1917,O
suggest,1917,O
the,1917,O
difference,1917,O
in,1917,O
the,1917,O
structures,1917,O
of,1917,O
the,1917,O
active,1917,O
sites,1917,O
of,1917,O
the,1917,O
two,1917,O
enzymes,1917,O
.,1917,O
Another,1918,O
striking,1918,O
feature,1918,O
was,1918,O
that,1918,O
the,1918,O
expressed,1918,O
level,1918,O
of,1918,O
the,1918,O
isoform,1918,O
in,1918,O
E.,1918,O
coli,1918,O
was,1918,O
7-fold,1918,O
lower,1918,O
than,1918,O
that,1918,O
of,1918,O
the,1918,O
hepatic,1918,O
SDH,1918,B-GENE-Y
.,1918,O
Substitution,1919,O
of,1919,O
Val,1919,B-GENE-N
for,1919,I-GENE-N
Leu287,1919,I-GENE-N
in,1919,O
the,1919,O
isoform,1919,O
dramatically,1919,O
increased,1919,O
the,1919,O
protein,1919,O
level,1919,O
.,1919,O
The,1920,O
high,1920,O
yield,1920,O
of,1920,O
the,1920,O
mutated,1920,O
isoform,1920,O
was,1920,O
also,1920,O
confirmed,1920,O
by,1920,O
the,1920,O
in,1920,O
vitro,1920,O
transcription,1920,O
and,1920,O
translation,1920,O
experiment,1920,O
.,1920,O
The,1921,O
poor,1921,O
expression,1921,O
of,1921,O
the,1921,O
isoform,1921,O
could,1921,O
be,1921,O
explained,1921,O
by,1921,O
the,1921,O
more,1921,O
stable,1921,O
secondary,1921,O
structure,1921,O
of,1921,O
the,1921,O
mRNA,1921,O
than,1921,O
that,1921,O
of,1921,O
the,1921,O
hepatic,1921,O
SDH,1921,B-GENE-Y
mRNA,1921,O
.,1921,O
The,1922,O
present,1922,O
findings,1922,O
may,1922,O
provide,1922,O
a,1922,O
clue,1922,O
as,1922,O
to,1922,O
why,1922,O
the,1922,O
protein,1922,O
level,1922,O
in,1922,O
cultured,1922,O
cells,1922,O
is,1922,O
low,1922,O
.,1922,O
Multiple,1923,O
enzyme,1923,O
inhibitions,1923,O
by,1923,O
histamine,1923,B-GENE-Y
H3,1923,I-GENE-Y
receptor,1923,I-GENE-Y
antagonists,1923,O
as,1923,O
potential,1923,O
procognitive,1923,O
agents,1923,O
.,1923,O
Novel,1924,O
highly,1924,O
affine,1924,O
histamine,1924,B-CHEMICAL
H3,1924,I-GENE-Y
receptor,1924,I-GENE-Y
ligands,1924,O
with,1924,O
additional,1924,O
inhibitory,1924,O
effects,1924,O
on,1924,O
the,1924,O
main,1924,O
histamine,1924,B-CHEMICAL
metabolizing,1924,O
enzyme,1924,O
in,1924,O
the,1924,O
brain,1924,O
",",1924,O
N-methyltransferase,1924,B-CHEMICAL
",",1924,O
chemically,1924,O
show,1924,O
structural,1924,O
elements,1924,O
of,1924,O
the,1924,O
acetylcholinesterase,1924,B-GENE-Y
inhibitor,1924,O
tacrine,1924,B-CHEMICAL
.,1924,O
H3,1925,B-GENE-Y
receptor,1925,I-GENE-Y
antagonism,1925,O
",",1925,O
inhibition,1925,O
of,1925,O
metabolisation,1925,O
of,1925,O
neuronal,1925,O
histamine,1925,B-CHEMICAL
as,1925,O
well,1925,O
as,1925,O
inhibition,1925,O
of,1925,O
hydrolysis,1925,O
of,1925,O
acetylcholine,1925,B-CHEMICAL
are,1925,O
each,1925,O
one,1925,O
believed,1925,O
to,1925,O
improve,1925,O
reduced,1925,O
cognitive,1925,O
functions,1925,O
",",1925,O
which,1925,O
is,1925,O
useful,1925,O
for,1925,O
symptomatic,1925,O
treatment,1925,O
of,1925,O
Alzheimer,1925,O
's,1925,O
disease,1925,O
.,1925,O
Some,1926,O
of,1926,O
the,1926,O
new,1926,O
compounds,1926,O
proved,1926,O
in,1926,O
a,1926,O
slightly,1926,O
modified,1926,O
colorimetric,1926,O
Ellmann,1926,O
's,1926,O
assay,1926,O
to,1926,O
be,1926,O
potent,1926,O
inhibitors,1926,O
of,1926,O
acetylcholinesterase,1926,B-GENE-Y
and,1926,O
of,1926,O
butyrylcholinesterase,1926,B-GENE-Y
which,1926,O
is,1926,O
another,1926,O
catalytic,1926,O
enzyme,1926,O
hydrolysing,1926,O
acetylcholine,1926,B-CHEMICAL
.,1926,O
Some,1927,O
compounds,1927,O
with,1927,O
(,1927,O
sub,1927,O
),1927,O
nanomolar,1927,O
activities,1927,O
on,1927,O
the,1927,O
histamine-related,1927,B-CHEMICAL
targets,1927,O
are,1927,O
also,1927,O
active,1927,O
in,1927,O
the,1927,O
nanomolar,1927,O
concentration,1927,O
range,1927,O
on,1927,O
both,1927,O
cholinesterase,1927,B-GENE-N
targets,1927,O
being,1927,O
5-,1927,O
to,1927,O
40-times,1927,O
more,1927,O
potent,1927,O
than,1927,O
tacrine,1927,B-CHEMICAL
.,1927,O
Preliminary,1928,O
structure-activity,1928,O
relationships,1928,O
could,1928,O
already,1928,O
be,1928,O
drawn,1928,O
from,1928,O
the,1928,O
small,1928,O
number,1928,O
of,1928,O
compounds,1928,O
.,1928,O
The,1929,O
compounds,1929,O
acting,1929,O
as,1929,O
hybrid,1929,O
drugs,1929,O
simultaneously,1929,O
on,1929,O
four,1929,O
different,1929,O
targets,1929,O
to,1929,O
enhance,1929,O
cognitive,1929,O
functions,1929,O
via,1929,O
different,1929,O
pathways,1929,O
are,1929,O
promising,1929,O
lead,1929,O
structures,1929,O
for,1929,O
a,1929,O
new,1929,O
approach,1929,O
in,1929,O
the,1929,O
treatment,1929,O
of,1929,O
Alzheimer,1929,O
's,1929,O
disease,1929,O
.,1929,O
Chemotherapy,1930,O
and,1930,O
targeted,1930,O
therapy,1930,O
combinations,1930,O
in,1930,O
advanced,1930,O
melanoma,1930,O
.,1930,O
For,1931,O
three,1931,O
decades,1931,O
",",1931,O
clinical,1931,O
trials,1931,O
with,1931,O
chemotherapy,1931,O
in,1931,O
melanoma,1931,O
have,1931,O
failed,1931,O
to,1931,O
show,1931,O
superiority,1931,O
of,1931,O
any,1931,O
one,1931,O
regimen,1931,O
over,1931,O
another,1931,O
.,1931,O
Dacarbazine,1932,B-CHEMICAL
remains,1932,O
the,1932,O
only,1932,O
``,1932,O
standard,1932,O
'',1932,O
agent,1932,O
.,1932,O
With,1933,O
response,1933,O
rates,1933,O
of,1933,O
<,1933,O
10,1933,O
%,1933,O
and,1933,O
median,1933,O
progression-free,1933,O
survival,1933,O
of,1933,O
2,1933,O
months,1933,O
or,1933,O
less,1933,O
in,1933,O
contemporary,1933,O
trials,1933,O
",",1933,O
there,1933,O
is,1933,O
a,1933,O
need,1933,O
to,1933,O
improve,1933,O
systemic,1933,O
therapy,1933,O
.,1933,O
Combination,1934,O
chemotherapy,1934,O
is,1934,O
associated,1934,O
with,1934,O
higher,1934,O
response,1934,O
rates,1934,O
than,1934,O
single-agent,1934,O
therapy,1934,O
but,1934,O
this,1934,O
has,1934,O
not,1934,O
translated,1934,O
into,1934,O
improved,1934,O
survival,1934,O
.,1934,O
An,1935,O
increasing,1935,O
number,1935,O
of,1935,O
potential,1935,O
therapeutic,1935,O
targets,1935,O
have,1935,O
been,1935,O
identified,1935,O
.,1935,O
For,1936,O
some,1936,O
",",1936,O
pharmacologic,1936,O
inhibitors,1936,O
are,1936,O
available,1936,O
",",1936,O
including,1936,O
sorafenib,1936,B-CHEMICAL
for,1936,O
BRAF,1936,B-GENE-Y
",",1936,O
farnesyltransferase,1936,B-GENE-N
inhibitors,1936,O
for,1936,O
NRAS,1936,B-GENE-Y
",",1936,O
PD-0325901,1936,B-CHEMICAL
for,1936,O
mitogen-activated,1936,B-GENE-N
protein,1936,I-GENE-N
kinase/extracellular,1936,O
signal-regulated,1936,I-GENE-N
kinase,1936,I-GENE-N
kinase,1936,I-GENE-N
",",1936,O
rapamycin,1936,B-CHEMICAL
analogues,1936,O
for,1936,O
mammalian,1936,B-GENE-Y
target,1936,I-GENE-Y
of,1936,I-GENE-Y
rapamycin,1936,B-CHEMICAL
",",1936,O
and,1936,O
agents,1936,O
that,1936,O
inhibit,1936,O
either,1936,O
vascular,1936,B-GENE-Y
endothelial,1936,I-GENE-Y
growth,1936,I-GENE-Y
factor,1936,I-GENE-Y
or,1936,O
its,1936,O
receptors,1936,O
.,1936,O
Several,1937,O
multitargeted,1937,O
kinase,1937,B-GENE-N
inhibitors,1937,O
have,1937,O
potency,1937,O
against,1937,O
the,1937,O
fibroblast,1937,B-GENE-N
growth,1937,I-GENE-N
factor,1937,I-GENE-N
receptor,1937,I-GENE-N
",",1937,O
c-kit,1937,B-GENE-Y
",",1937,O
and,1937,O
platelet-derived,1937,B-GENE-N
growth,1937,I-GENE-N
factor,1937,I-GENE-N
receptor,1937,I-GENE-N
.,1937,O
Small-molecule,1938,O
inhibitors,1938,O
of,1938,O
c-met,1938,B-GENE-Y
and,1938,O
Akt,1938,B-GENE-N
are,1938,O
in,1938,O
preclinical,1938,O
development,1938,O
.,1938,O
Another,1939,O
class,1939,O
of,1939,O
agents,1939,O
indirectly,1939,O
affect,1939,O
aberrant,1939,O
signaling,1939,O
",",1939,O
including,1939,O
inhibitors,1939,O
of,1939,O
chaperones,1939,B-GENE-N
and,1939,O
proteasomes,1939,B-GENE-N
.,1939,O
Several,1940,O
targeted,1940,O
agents,1940,O
seem,1940,O
to,1940,O
enhance,1940,O
the,1940,O
cytotoxicity,1940,O
of,1940,O
chemotherapy,1940,O
in,1940,O
preclinical,1940,O
models,1940,O
.,1940,O
The,1941,O
mechanism,1941,O
by,1941,O
which,1941,O
signaling,1941,O
inhibition,1941,O
might,1941,O
synergize,1941,O
with,1941,O
chemotherapy,1941,O
requires,1941,O
more,1941,O
study,1941,O
so,1941,O
that,1941,O
rational,1941,O
combinations,1941,O
move,1941,O
forward,1941,O
.,1941,O
Very,1942,O
few,1942,O
targeted,1942,O
agents,1942,O
have,1942,O
been,1942,O
studied,1942,O
rigorously,1942,O
in,1942,O
this,1942,O
fashion,1942,O
.,1942,O
Lipid,1943,O
specific,1943,O
activation,1943,O
of,1943,O
the,1943,O
murine,1943,B-GENE-N
P4-ATPase,1943,I-GENE-N
Atp8a1,1943,B-GENE-Y
(,1943,O
ATPase,1943,B-GENE-Y
II,1943,I-GENE-Y
),1943,O
.,1943,O
The,1944,O
asymmetric,1944,O
transbilayer,1944,O
distribution,1944,O
of,1944,O
phosphatidylserine,1944,B-CHEMICAL
(,1944,O
PS,1944,B-CHEMICAL
),1944,O
in,1944,O
the,1944,O
mammalian,1944,O
plasma,1944,O
membrane,1944,O
and,1944,O
secretory,1944,O
vesicles,1944,O
is,1944,O
maintained,1944,O
",",1944,O
in,1944,O
part,1944,O
",",1944,O
by,1944,O
an,1944,O
ATP-dependent,1944,B-CHEMICAL
transporter,1944,O
.,1944,O
This,1945,O
aminophospholipid,1945,O
``,1945,O
flippase,1945,B-GENE-N
'',1945,O
selectively,1945,O
transports,1945,O
PS,1945,B-CHEMICAL
to,1945,O
the,1945,O
cytosolic,1945,O
leaflet,1945,O
of,1945,O
the,1945,O
bilayer,1945,O
and,1945,O
is,1945,O
sensitive,1945,O
to,1945,O
vanadate,1945,B-CHEMICAL
",",1945,O
Ca,1945,B-CHEMICAL
(,1945,I-CHEMICAL
2+,1945,I-CHEMICAL
),1945,I-CHEMICAL
",",1945,O
and,1945,O
modification,1945,O
by,1945,O
sulfhydryl,1945,B-CHEMICAL
reagents,1945,O
.,1945,O
Although,1946,O
the,1946,O
flippase,1946,B-GENE-N
has,1946,O
not,1946,O
been,1946,O
positively,1946,O
identified,1946,O
",",1946,O
a,1946,O
subfamily,1946,O
of,1946,O
P-type,1946,B-GENE-N
ATPases,1946,I-GENE-N
has,1946,O
been,1946,O
proposed,1946,O
to,1946,O
function,1946,O
as,1946,O
transporters,1946,O
of,1946,O
amphipaths,1946,O
",",1946,O
including,1946,O
PS,1946,O
and,1946,O
other,1946,O
phospholipids,1946,O
.,1946,O
A,1947,O
candidate,1947,O
PS,1947,B-GENE-Y
flippase,1947,I-GENE-Y
ATP8A1,1947,I-GENE-Y
(,1947,O
ATPase,1947,B-GENE-Y
II,1947,I-GENE-Y
),1947,O
",",1947,O
originally,1947,O
isolated,1947,O
from,1947,O
bovine,1947,O
secretory,1947,O
vesicles,1947,O
",",1947,O
is,1947,O
a,1947,O
member,1947,O
of,1947,O
this,1947,O
subfamily,1947,O
based,1947,O
on,1947,O
sequence,1947,O
homology,1947,O
to,1947,O
the,1947,O
founding,1947,O
member,1947,O
of,1947,O
the,1947,O
subfamily,1947,O
",",1947,O
the,1947,O
yeast,1947,B-GENE-Y
protein,1947,I-GENE-Y
Drs2,1947,I-GENE-Y
",",1947,O
which,1947,O
has,1947,O
been,1947,O
linked,1947,O
to,1947,O
ribosomal,1947,O
assembly,1947,O
",",1947,O
the,1947,O
formation,1947,O
of,1947,O
Golgi-coated,1947,O
vesicles,1947,O
",",1947,O
and,1947,O
the,1947,O
maintenance,1947,O
of,1947,O
PS,1947,O
asymmetry,1947,O
.,1947,O
To,1948,O
determine,1948,O
if,1948,O
ATP8A1,1948,B-GENE-Y
has,1948,O
biochemical,1948,O
characteristics,1948,O
consistent,1948,O
with,1948,O
a,1948,O
PS,1948,B-GENE-N
flippase,1948,I-GENE-N
",",1948,O
a,1948,O
murine,1948,O
homologue,1948,O
of,1948,O
this,1948,O
enzyme,1948,O
was,1948,O
expressed,1948,O
in,1948,O
insect,1948,O
cells,1948,O
and,1948,O
purified,1948,O
.,1948,O
The,1949,O
purified,1949,O
Atp8a1,1949,B-GENE-Y
is,1949,O
inactive,1949,O
in,1949,O
detergent,1949,O
micelles,1949,O
or,1949,O
in,1949,O
micelles,1949,O
containing,1949,O
phosphatidylcholine,1949,B-CHEMICAL
",",1949,O
phosphatidic,1949,B-CHEMICAL
acid,1949,I-CHEMICAL
",",1949,O
or,1949,O
phosphatidylinositol,1949,B-CHEMICAL
",",1949,O
is,1949,O
minimally,1949,O
activated,1949,O
by,1949,O
phosphatidylglycerol,1949,B-CHEMICAL
or,1949,O
phosphatidylethanolamine,1949,B-CHEMICAL
(,1949,O
PE,1949,B-CHEMICAL
),1949,O
",",1949,O
and,1949,O
is,1949,O
maximally,1949,O
activated,1949,O
by,1949,O
PS,1949,B-CHEMICAL
.,1949,O
The,1950,O
selectivity,1950,O
for,1950,O
PS,1950,B-CHEMICAL
is,1950,O
dependent,1950,O
upon,1950,O
multiple,1950,O
elements,1950,O
of,1950,O
the,1950,O
lipid,1950,O
structure,1950,O
.,1950,O
Similar,1951,O
to,1951,O
the,1951,O
plasma,1951,B-GENE-N
membrane,1951,I-GENE-N
PS,1951,B-CHEMICAL
transporter,1951,I-GENE-N
",",1951,O
Atp8a1,1951,B-GENE-Y
is,1951,O
activated,1951,O
only,1951,O
by,1951,O
the,1951,O
naturally,1951,O
occurring,1951,O
"sn-1,2-glycerol",1951,B-CHEMICAL
isomer,1951,O
of,1951,O
PS,1951,O
and,1951,O
not,1951,O
the,1951,O
"sn-2,3-glycerol",1951,B-CHEMICAL
stereoisomer,1951,O
.,1951,O
Both,1952,O
flippase,1952,B-GENE-N
and,1952,O
Atp8a1,1952,B-GENE-Y
activities,1952,O
are,1952,O
insensitive,1952,O
to,1952,O
the,1952,O
stereochemistry,1952,O
of,1952,O
the,1952,O
serine,1952,O
headgroup,1952,O
.,1952,O
Most,1953,O
modifications,1953,O
of,1953,O
the,1953,O
PS,1953,B-CHEMICAL
headgroup,1953,O
structure,1953,O
decrease,1953,O
recognition,1953,O
by,1953,O
the,1953,O
plasma,1953,O
membrane,1953,O
PS,1953,B-GENE-N
flippase,1953,I-GENE-N
.,1953,O
Activation,1954,O
of,1954,O
Atp8a1,1954,B-GENE-Y
is,1954,O
also,1954,O
reduced,1954,O
by,1954,O
these,1954,O
modifications,1954,O
;,1954,O
phosphatidylserine-O-methyl,1954,B-CHEMICAL
ester,1954,I-CHEMICAL
",",1954,O
lysophosphatidylserine,1954,B-CHEMICAL
",",1954,O
glycerophosphoserine,1954,B-CHEMICAL
",",1954,O
and,1954,O
phosphoserine,1954,B-CHEMICAL
",",1954,O
which,1954,O
are,1954,O
not,1954,O
transported,1954,O
by,1954,O
the,1954,O
plasma,1954,O
membrane,1954,O
flippase,1954,O
",",1954,O
do,1954,O
not,1954,O
activate,1954,O
Atp8a1,1954,B-GENE-Y
.,1954,O
Weakly,1955,O
translocated,1955,O
lipids,1955,O
(,1955,O
PE,1955,B-CHEMICAL
",",1955,O
phosphatidylhydroxypropionate,1955,B-CHEMICAL
",",1955,O
and,1955,O
phosphatidylhomoserine,1955,B-CHEMICAL
),1955,O
are,1955,O
also,1955,O
weak,1955,O
Atp8a1,1955,B-GENE-Y
activators,1955,O
.,1955,O
However,1956,O
",",1956,O
N-methyl-phosphatidylserine,1956,B-CHEMICAL
",",1956,O
which,1956,O
is,1956,O
transported,1956,O
by,1956,O
the,1956,O
plasma,1956,O
membrane,1956,O
flippase,1956,B-GENE-N
at,1956,O
a,1956,O
rate,1956,O
equivalent,1956,O
to,1956,O
PS,1956,B-CHEMICAL
",",1956,O
is,1956,O
incapable,1956,O
of,1956,O
activating,1956,O
Atp8a1,1956,B-GENE-Y
activity,1956,O
.,1956,O
These,1957,O
results,1957,O
indicate,1957,O
that,1957,O
the,1957,O
ATPase,1957,B-GENE-N
activity,1957,O
of,1957,O
the,1957,O
secretory,1957,O
granule,1957,O
Atp8a1,1957,B-GENE-Y
is,1957,O
activated,1957,O
by,1957,O
phospholipids,1957,O
binding,1957,O
to,1957,O
a,1957,O
specific,1957,O
site,1957,O
whose,1957,O
properties,1957,O
(,1957,O
PS,1957,B-CHEMICAL
selectivity,1957,O
",",1957,O
dependence,1957,O
upon,1957,O
glycerol,1957,B-CHEMICAL
but,1957,O
not,1957,O
serine,1957,B-CHEMICAL
",",1957,O
stereochemistry,1957,O
",",1957,O
and,1957,O
vanadate,1957,O
sensitivity,1957,O
),1957,O
are,1957,O
similar,1957,O
to,1957,O
",",1957,O
but,1957,O
distinct,1957,O
from,1957,O
",",1957,O
the,1957,O
properties,1957,O
of,1957,O
the,1957,O
substrate,1957,O
binding,1957,O
site,1957,O
of,1957,O
the,1957,O
plasma,1957,O
membrane,1957,O
flippase,1957,B-GENE-N
.,1957,O
Pneumocystis,1958,O
jiroveci,1958,O
pneumonia,1958,O
in,1958,O
a,1958,O
patient,1958,O
with,1958,O
rheumatoid,1958,O
arthritis,1958,O
as,1958,O
a,1958,O
complication,1958,O
of,1958,O
treatment,1958,O
with,1958,O
infliximab,1958,O
",",1958,O
anti-tumor,1958,O
necrosis,1958,I-GENE-Y
factor,1958,I-GENE-Y
alpha,1958,I-GENE-Y
neutralizing,1958,O
antibody,1958,O
.,1958,O
We,1959,O
report,1959,O
that,1959,O
a-63-year-old,1959,O
woman,1959,O
developed,1959,O
Pneumocystis,1959,O
jiroveci,1959,O
pneumonia,1959,O
(,1959,O
PCP,1959,O
),1959,O
as,1959,O
a,1959,O
complication,1959,O
from,1959,O
treatment,1959,O
with,1959,O
infliximab,1959,O
for,1959,O
rheumatoid,1959,O
arthritis,1959,O
.,1959,O
Although,1960,O
there,1960,O
was,1960,O
neither,1960,O
symptoms,1960,O
of,1960,O
dyspnea,1960,O
nor,1960,O
typical,1960,O
observations,1960,O
on,1960,O
a,1960,O
chest,1960,O
X-ray,1960,O
examination,1960,O
",",1960,O
low,1960,O
levels,1960,O
of,1960,O
oxygen,1960,B-CHEMICAL
saturation,1960,O
and,1960,O
findings,1960,O
of,1960,O
high-resolution,1960,O
chest,1960,O
computed,1960,O
tomographic,1960,O
scanning,1960,O
suggested,1960,O
a,1960,O
possibility,1960,O
of,1960,O
interstitial,1960,O
pneumonia,1960,O
.,1960,O
A,1961,O
polymerase,1961,O
chain,1961,O
reaction-based,1961,O
detection,1961,O
of,1961,O
Pneumocystis,1961,O
jiroveci,1961,O
in,1961,O
induced,1961,O
sputum,1961,O
allowed,1961,O
an,1961,O
early,1961,O
diagnosis,1961,O
of,1961,O
PCP,1961,O
and,1961,O
subsequent,1961,O
effective,1961,O
treatment,1961,O
.,1961,O
High-mannose-type,1962,O
glycan,1962,O
modifications,1962,O
of,1962,O
dihydrofolate,1962,B-CHEMICAL
reductase,1962,I-GENE-Y
using,1962,O
glycan-methotrexate,1962,O
conjugates,1962,O
.,1962,O
Various,1963,O
high-mannose-type,1963,O
glycan,1963,O
modifications,1963,O
of,1963,O
dihydrofolate,1963,B-CHEMICAL
reductase,1963,I-GENE-Y
(,1963,O
DHFR,1963,B-GENE-Y
),1963,O
were,1963,O
achieved,1963,O
by,1963,O
ligand-based,1963,O
approach,1963,O
using,1963,O
glycan-methotrexate,1963,O
(,1963,O
MTX,1963,B-CHEMICAL
),1963,O
conjugates,1963,O
as,1963,O
tight,1963,O
binding,1963,O
glycan,1963,O
bearing,1963,O
ligands,1963,O
for,1963,O
DHFR,1963,B-GENE-Y
.,1963,O
The,1964,O
resulting,1964,O
glycan-MTX,1964,O
conjugates,1964,O
and,1964,O
the,1964,O
corresponding,1964,O
artificial,1964,O
glycoproteins,1964,O
could,1964,O
be,1964,O
useful,1964,O
as,1964,O
oligosaccharide-,1964,O
and,1964,O
glycoprotein-probes,1964,O
to,1964,O
perform,1964,O
quantitative,1964,O
analysis,1964,O
of,1964,O
glycan,1964,B-GENE-N
recognizing,1964,I-GENE-N
protein,1964,I-GENE-N
such,1964,O
as,1964,O
lectins,1964,B-GENE-N
",",1964,O
glycosyltransferases,1964,B-GENE-N
or,1964,O
glycosidases,1964,B-GENE-N
.,1964,O
Moreover,1965,O
",",1965,O
artificial,1965,O
glycoproteins,1965,O
having,1965,O
two,1965,O
different,1965,O
high-mannose-type,1965,O
glycans,1965,O
were,1965,O
developed,1965,O
for,1965,O
the,1965,O
first,1965,O
time,1965,O
by,1965,O
a,1965,O
combination,1965,O
of,1965,O
two,1965,O
different,1965,O
types,1965,O
of,1965,O
glycan,1965,O
modification,1965,O
strategies,1965,O
.,1965,O
NMDA,1966,B-GENE-N
receptors,1966,I-GENE-N
are,1966,O
not,1966,O
alone,1966,O
:,1966,O
dynamic,1966,O
regulation,1966,O
of,1966,O
NMDA,1966,B-GENE-N
receptor,1966,I-GENE-N
structure,1966,O
and,1966,O
function,1966,O
by,1966,O
neuregulins,1966,B-GENE-N
and,1966,O
transient,1966,B-GENE-N
cholesterol-rich,1966,I-GENE-N
membrane,1966,I-GENE-N
domains,1966,I-GENE-N
leads,1966,O
to,1966,O
disease-specific,1966,O
nuances,1966,O
of,1966,O
glutamate-signalling,1966,B-CHEMICAL
.,1966,O
Glutamate,1967,B-CHEMICAL
receptors,1967,I-GENE-N
of,1967,O
the,1967,O
N-methyl-D-asparate,1967,B-CHEMICAL
(,1967,O
NMDA-,1967,B-CHEMICAL
),1967,O
subtype,1967,O
are,1967,O
tetrameric,1967,O
allosteric,1967,O
and,1967,O
ligand-gated,1967,B-GENE-N
calcium,1967,I-GENE-N
channels,1967,I-GENE-N
.,1967,O
They,1968,O
are,1968,O
modulated,1968,O
by,1968,O
a,1968,O
variety,1968,O
of,1968,O
endogenous,1968,O
ligands,1968,O
and,1968,O
ions,1968,O
and,1968,O
play,1968,O
a,1968,O
pivotal,1968,O
role,1968,O
in,1968,O
memory-related,1968,O
signal,1968,O
transduction,1968,O
due,1968,O
to,1968,O
a,1968,O
voltage-dependent,1968,O
block,1968,O
by,1968,O
magnesium,1968,B-CHEMICAL
",",1968,O
which,1968,O
makes,1968,O
them,1968,O
Hebbian,1968,O
coincidence,1968,O
detectors,1968,O
.,1968,O
On,1969,O
the,1969,O
structural,1969,O
level,1969,O
NMDA,1969,B-CHEMICAL
receptors,1969,I-GENE-N
have,1969,O
an,1969,O
enormous,1969,O
flexibility,1969,O
due,1969,O
to,1969,O
seven,1969,O
genes,1969,O
(,1969,O
NR1,1969,B-GENE-Y
",",1969,O
NR2A-D,1969,B-GENE-N
and,1969,O
NR3A-B,1969,B-GENE-N
),1969,O
",",1969,O
alternative,1969,O
splicing,1969,O
",",1969,O
RNA-editing,1969,O
and,1969,O
extensive,1969,O
posttranslational,1969,O
modifications,1969,O
",",1969,O
like,1969,O
phosphorylation,1969,O
and,1969,O
glycosylation,1969,O
.,1969,O
NMDA,1970,B-GENE-N
receptors,1970,I-GENE-N
are,1970,O
thought,1970,O
to,1970,O
be,1970,O
responsible,1970,O
for,1970,O
excitotoxicity,1970,O
and,1970,O
subsequent,1970,O
downstream,1970,O
events,1970,O
like,1970,O
neuroinflammation,1970,O
and,1970,O
apoptosis,1970,O
and,1970,O
thus,1970,O
have,1970,O
been,1970,O
implicated,1970,O
in,1970,O
many,1970,O
important,1970,O
human,1970,O
pathologies,1970,O
",",1970,O
ranging,1970,O
from,1970,O
amyotrophic,1970,O
lateral,1970,O
sclerosis,1970,O
",",1970,O
Alzheimer,1970,O
's,1970,O
and,1970,O
Parkinson,1970,O
',1970,O
disease,1970,O
",",1970,O
depression,1970,O
",",1970,O
epilepsy,1970,O
",",1970,O
trauma,1970,O
and,1970,O
stroke,1970,O
to,1970,O
schizophrenia,1970,O
.,1970,O
This,1971,O
fundamental,1971,O
significance,1971,O
of,1971,O
NMDA,1971,B-GENE-N
receptor-related,1971,O
excitotoxicity,1971,O
is,1971,O
discussed,1971,O
in,1971,O
the,1971,O
context,1971,O
of,1971,O
the,1971,O
developing,1971,O
clinical,1971,O
success,1971,O
of,1971,O
Memantine,1971,B-CHEMICAL
",",1971,O
but,1971,O
moreover,1971,O
set,1971,O
into,1971,O
relation,1971,O
to,1971,O
various,1971,O
proteomic,1971,O
and,1971,O
genetic,1971,O
markers,1971,O
of,1971,O
said,1971,O
diseases,1971,O
.,1971,O
The,1972,O
very,1972,O
complex,1972,O
localisational,1972,O
and,1972,O
functional,1972,O
regulation,1972,O
of,1972,O
NMDA,1972,B-CHEMICAL
receptors,1972,I-GENE-N
appears,1972,O
to,1972,O
be,1972,O
dependent,1972,O
on,1972,O
neuregulins,1972,B-GENE-N
and,1972,O
receptor,1972,B-GENE-N
tyrosine,1972,B-CHEMICAL
kinases,1972,I-GENE-N
in,1972,O
cholesterol-rich,1972,B-CHEMICAL
membrane,1972,O
domains,1972,O
(,1972,O
lipid,1972,O
rafts,1972,O
),1972,O
",",1972,O
calcium-related,1972,B-CHEMICAL
mitochondrial,1972,O
feedback-loops,1972,O
and,1972,O
subsynaptic,1972,O
structural,1972,O
elements,1972,O
like,1972,O
PSD-95,1972,B-GENE-Y
(,1972,O
post-synaptic,1972,B-GENE-Y
density,1972,I-GENE-Y
protein,1972,I-GENE-Y
of,1972,I-GENE-Y
95,1972,I-GENE-Y
kD,1972,I-GENE-Y
),1972,O
.,1972,O
The,1973,O
flexibility,1973,O
and,1973,O
multitude,1973,O
of,1973,O
interaction,1973,O
partners,1973,O
and,1973,O
possibilities,1973,O
of,1973,O
these,1973,O
highly,1973,O
dynamic,1973,O
molecular,1973,O
systems,1973,O
are,1973,O
discussed,1973,O
in,1973,O
terms,1973,O
of,1973,O
drug,1973,O
development,1973,O
strategies,1973,O
",",1973,O
in,1973,O
particular,1973,O
comparing,1973,O
high,1973,O
affinity,1973,O
and,1973,O
sub-type,1973,O
specific,1973,O
ligands,1973,O
to,1973,O
currently,1973,O
successful,1973,O
or,1973,O
promising,1973,O
therapies,1973,O
.,1973,O
Sorafenib,1974,B-CHEMICAL
:,1974,O
recent,1974,O
update,1974,O
on,1974,O
activity,1974,O
as,1974,O
a,1974,O
single,1974,O
agent,1974,O
and,1974,O
in,1974,O
combination,1974,O
with,1974,O
interferon-alpha2,1974,B-GENE-Y
in,1974,O
patients,1974,O
with,1974,O
advanced-stage,1974,O
renal,1974,O
cell,1974,O
carcinoma,1974,O
.,1974,O
Metastatic,1975,O
renal,1975,O
cell,1975,O
carcinoma,1975,O
does,1975,O
not,1975,O
respond,1975,O
favorably,1975,O
to,1975,O
conventional,1975,O
treatment,1975,O
strategies,1975,O
and,1975,O
is,1975,O
not,1975,O
very,1975,O
responsive,1975,O
to,1975,O
cytokine,1975,O
therapy,1975,O
.,1975,O
Therefore,1976,O
",",1976,O
novel,1976,O
targeted,1976,O
treatment,1976,O
approaches,1976,O
have,1976,O
been,1976,O
explored,1976,O
for,1976,O
patients,1976,O
with,1976,O
renal,1976,O
cancer,1976,O
who,1976,O
have,1976,O
chemotherapy-refractory,1976,O
disease,1976,O
.,1976,O
Sorafenib,1977,B-CHEMICAL
(,1977,O
BAY,1977,B-CHEMICAL
43-9006,1977,I-CHEMICAL
),1977,O
is,1977,O
a,1977,O
small-molecule,1977,O
inhibitor,1977,O
that,1977,O
has,1977,O
been,1977,O
shown,1977,O
to,1977,O
target,1977,O
members,1977,O
of,1977,O
multiple,1977,O
classes,1977,O
of,1977,O
tyrosine,1977,B-GENE-N
kinases,1977,I-GENE-N
that,1977,O
are,1977,O
known,1977,O
to,1977,O
be,1977,O
involved,1977,O
in,1977,O
tumor,1977,O
cell,1977,O
proliferation,1977,O
and,1977,O
tumor,1977,O
angiogenesis,1977,O
.,1977,O
These,1978,O
kinases,1978,B-GENE-N
include,1978,O
vascular,1978,B-GENE-Y
endothelial,1978,I-GENE-Y
growth,1978,I-GENE-Y
factor,1978,I-GENE-Y
receptor,1978,I-GENE-Y
(,1978,I-GENE-Y
VEGFR,1978,I-GENE-Y
),1978,I-GENE-Y
-1,1978,I-GENE-Y
",",1978,O
VEGFR-2,1978,B-GENE-Y
",",1978,O
VEGFR-3,1978,B-GENE-Y
",",1978,O
platelet-derived,1978,B-GENE-Y
growth,1978,I-GENE-Y
factor,1978,I-GENE-Y
receptor,1978,I-GENE-Y
",",1978,O
Flt-3,1978,B-GENE-Y
",",1978,O
c-kit,1978,B-GENE-Y
",",1978,O
and,1978,O
Raf,1978,B-GENE-Y
kinases,1978,B-GENE-N
.,1978,O
Based,1979,O
on,1979,O
the,1979,O
significant,1979,O
improvement,1979,O
in,1979,O
progression-free,1979,O
survival,1979,O
",",1979,O
sorafenib,1979,B-CHEMICAL
received,1979,O
Food,1979,O
and,1979,O
Drug,1979,O
Administration,1979,O
approval,1979,O
in,1979,O
December,1979,O
2005,1979,O
for,1979,O
the,1979,O
treatment,1979,O
of,1979,O
renal,1979,O
cell,1979,O
carcinoma,1979,O
.,1979,O
In,1980,O
combination,1980,O
studies,1980,O
",",1980,O
sorafenib,1980,B-CHEMICAL
with,1980,O
other,1980,O
antitumor,1980,O
agents,1980,O
has,1980,O
demonstrated,1980,O
significant,1980,O
clinical,1980,O
activity,1980,O
in,1980,O
patients,1980,O
with,1980,O
renal,1980,O
cell,1980,O
carcinoma,1980,O
.,1980,O
As,1981,O
discussed,1981,O
in,1981,O
this,1981,O
mini-review,1981,O
",",1981,O
the,1981,O
clinical,1981,O
potency,1981,O
of,1981,O
sorafenib,1981,B-CHEMICAL
as,1981,O
a,1981,O
single,1981,O
agent,1981,O
or,1981,O
in,1981,O
combination,1981,O
with,1981,O
other,1981,O
antitumor,1981,O
agents,1981,O
is,1981,O
being,1981,O
evaluated,1981,O
in,1981,O
several,1981,O
ongoing,1981,O
clinical,1981,O
trials,1981,O
in,1981,O
patients,1981,O
with,1981,O
renal,1981,O
carcinoma,1981,O
.,1981,O
Hydrogen,1982,B-CHEMICAL
sulfide,1982,I-CHEMICAL
inhibits,1982,O
nitric,1982,B-CHEMICAL
oxide,1982,I-CHEMICAL
production,1982,O
and,1982,O
nuclear,1982,B-GENE-N
factor-kappaB,1982,I-GENE-N
via,1982,O
heme,1982,B-GENE-Y
oxygenase-1,1982,I-GENE-Y
expression,1982,O
in,1982,O
RAW264.7,1982,O
macrophages,1982,O
stimulated,1982,O
with,1982,O
lipopolysaccharide,1982,O
.,1982,O
Hydrogen,1983,B-CHEMICAL
sulfide,1983,I-CHEMICAL
(,1983,O
H,1983,B-CHEMICAL
(,1983,I-CHEMICAL
2,1983,I-CHEMICAL
),1983,I-CHEMICAL
S,1983,I-CHEMICAL
),1983,O
",",1983,O
a,1983,O
regulatory,1983,O
gaseous,1983,O
molecule,1983,O
that,1983,O
is,1983,O
endogenously,1983,O
synthesized,1983,O
by,1983,O
cystathionine,1983,B-GENE-Y
gamma-lyase,1983,I-GENE-Y
(,1983,O
CSE,1983,B-GENE-Y
),1983,O
and/or,1983,O
cystathionine,1983,B-CHEMICAL
beta-synthase,1983,I-GENE-Y
(,1983,O
CBS,1983,B-GENE-Y
),1983,O
from,1983,O
L-cysteine,1983,B-CHEMICAL
(,1983,O
L-Cys,1983,B-CHEMICAL
),1983,O
metabolism,1983,O
",",1983,O
is,1983,O
a,1983,O
putative,1983,O
vasodilator,1983,O
",",1983,O
and,1983,O
its,1983,O
role,1983,O
in,1983,O
nitric,1983,B-CHEMICAL
oxide,1983,I-CHEMICAL
(,1983,O
NO,1983,B-CHEMICAL
),1983,O
production,1983,O
is,1983,O
unexplored,1983,O
.,1983,O
Here,1984,O
",",1984,O
we,1984,O
show,1984,O
that,1984,O
at,1984,O
noncytotoxic,1984,O
concentrations,1984,O
",",1984,O
H,1984,B-CHEMICAL
(,1984,I-CHEMICAL
2,1984,I-CHEMICAL
),1984,I-CHEMICAL
S,1984,I-CHEMICAL
was,1984,O
able,1984,O
to,1984,O
inhibit,1984,O
NO,1984,B-CHEMICAL
production,1984,O
and,1984,O
inducible,1984,B-GENE-Y
NO,1984,I-GENE-Y
synthase,1984,I-GENE-Y
(,1984,O
iNOS,1984,B-GENE-Y
),1984,O
expression,1984,O
via,1984,O
heme,1984,B-GENE-N
oxygenase,1984,I-GENE-N
(,1984,O
HO-1,1984,B-GENE-Y
),1984,O
expression,1984,O
in,1984,O
RAW264.7,1984,O
macrophages,1984,O
stimulated,1984,O
with,1984,O
lipopolysaccharide,1984,O
(,1984,O
LPS,1984,O
),1984,O
.,1984,O
Both,1985,O
H,1985,B-CHEMICAL
(,1985,I-CHEMICAL
2,1985,I-CHEMICAL
),1985,I-CHEMICAL
S,1985,I-CHEMICAL
solution,1985,O
prepared,1985,O
by,1985,O
bubbling,1985,O
pure,1985,O
H,1985,B-CHEMICAL
(,1985,I-CHEMICAL
2,1985,I-CHEMICAL
),1985,I-CHEMICAL
S,1985,I-CHEMICAL
gas,1985,O
and,1985,O
NaSH,1985,B-CHEMICAL
",",1985,O
a,1985,O
H,1985,B-CHEMICAL
(,1985,I-CHEMICAL
2,1985,I-CHEMICAL
),1985,I-CHEMICAL
S,1985,I-CHEMICAL
donor,1985,O
",",1985,O
dose,1985,O
dependently,1985,O
induced,1985,O
HO-1,1985,B-GENE-Y
expression,1985,O
through,1985,O
the,1985,O
activation,1985,O
of,1985,O
the,1985,O
extracellular,1985,B-GENE-N
signal-regulated,1985,I-GENE-N
kinase,1985,I-GENE-N
(,1985,O
ERK,1985,B-GENE-N
),1985,O
.,1985,O
Pretreatment,1986,O
with,1986,O
H,1986,B-CHEMICAL
(,1986,I-CHEMICAL
2,1986,I-CHEMICAL
),1986,I-CHEMICAL
S,1986,I-CHEMICAL
or,1986,O
NaHS,1986,B-CHEMICAL
significantly,1986,O
inhibited,1986,O
LPS-induced,1986,O
iNOS,1986,B-GENE-Y
expression,1986,O
and,1986,O
NO,1986,B-CHEMICAL
production,1986,O
.,1986,O
Moreover,1987,O
",",1987,O
NO,1987,B-CHEMICAL
production,1987,O
in,1987,O
LPS-stimulated,1987,O
macrophages,1987,O
that,1987,O
are,1987,O
expressing,1987,O
CSE,1987,B-GENE-Y
mRNA,1987,O
was,1987,O
significantly,1987,O
reduced,1987,O
by,1987,O
the,1987,O
addition,1987,O
of,1987,O
L-Cys,1987,B-CHEMICAL
",",1987,O
a,1987,O
substrate,1987,O
for,1987,O
H,1987,B-CHEMICAL
(,1987,I-CHEMICAL
2,1987,I-CHEMICAL
),1987,I-CHEMICAL
S,1987,I-CHEMICAL
",",1987,O
but,1987,O
enhanced,1987,O
by,1987,O
the,1987,O
selective,1987,O
CSE,1987,B-GENE-Y
inhibitor,1987,O
beta-cyano-L-alanine,1987,B-CHEMICAL
but,1987,O
not,1987,O
by,1987,O
the,1987,O
CBS,1987,B-GENE-Y
inhibitor,1987,O
aminooxyacetic,1987,B-CHEMICAL
acid,1987,I-CHEMICAL
.,1987,O
While,1988,O
either,1988,O
blockage,1988,O
of,1988,O
HO,1988,B-GENE-Y
activity,1988,O
by,1988,O
the,1988,O
HO,1988,B-GENE-Y
inhibitor,1988,O
",",1988,O
tin,1988,O
protoporphyrin,1988,O
IX,1988,O
",",1988,O
or,1988,O
down-regulation,1988,O
of,1988,O
HO-1,1988,B-GENE-Y
expression,1988,O
by,1988,O
HO-1,1988,B-GENE-Y
small,1988,O
interfering,1988,O
RNA,1988,O
(,1988,O
siRNA,1988,O
),1988,O
reversed,1988,O
the,1988,O
inhibitory,1988,O
effects,1988,O
of,1988,O
H,1988,B-CHEMICAL
(,1988,I-CHEMICAL
2,1988,I-CHEMICAL
),1988,I-CHEMICAL
S,1988,I-CHEMICAL
on,1988,O
iNOS,1988,B-GENE-Y
expression,1988,O
and,1988,O
NO,1988,B-CHEMICAL
production,1988,O
",",1988,O
HO-1,1988,B-GENE-Y
overexpression,1988,O
produced,1988,O
the,1988,O
same,1988,O
inhibitory,1988,O
effects,1988,O
of,1988,O
H,1988,B-CHEMICAL
(,1988,I-CHEMICAL
2,1988,I-CHEMICAL
),1988,I-CHEMICAL
S.,1988,O
In,1988,O
addition,1988,O
",",1988,O
LPS-induced,1988,O
nuclear,1988,O
factor,1988,O
(,1988,B-GENE-N
NF,1988,I-GENE-N
),1988,I-GENE-N
-kappaB,1988,I-GENE-N
activation,1988,O
was,1988,O
diminished,1988,O
in,1988,O
RAW264.7,1988,O
macrophages,1988,O
preincubated,1988,O
with,1988,O
H,1988,B-CHEMICAL
(,1988,I-CHEMICAL
2,1988,I-CHEMICAL
),1988,I-CHEMICAL
S.,1988,O
Interestingly,1988,O
",",1988,O
the,1988,O
inhibitory,1988,O
effect,1988,O
of,1988,O
H,1988,B-CHEMICAL
(,1988,I-CHEMICAL
2,1988,I-CHEMICAL
),1988,I-CHEMICAL
S,1988,I-CHEMICAL
on,1988,O
NF-kappaB,1988,B-GENE-N
activation,1988,O
was,1988,O
reversed,1988,O
by,1988,O
the,1988,O
transient,1988,O
transfection,1988,O
with,1988,O
HO-1,1988,B-GENE-Y
siRNA,1988,O
",",1988,O
but,1988,O
was,1988,O
mimicked,1988,O
by,1988,O
either,1988,O
HO-1,1988,B-GENE-Y
gene,1988,O
transfection,1988,O
or,1988,O
treatment,1988,O
with,1988,O
carbon,1988,B-CHEMICAL
monoxide,1988,I-CHEMICAL
(,1988,O
CO,1988,B-CHEMICAL
),1988,O
",",1988,O
an,1988,O
end,1988,O
product,1988,O
of,1988,O
HO-1,1988,B-GENE-Y
.,1988,O
CO,1989,B-CHEMICAL
treatment,1989,O
also,1989,O
inhibited,1989,O
LPS-induced,1989,O
NO,1989,B-CHEMICAL
production,1989,O
and,1989,O
iNOS,1989,B-GENE-Y
expression,1989,O
via,1989,O
its,1989,O
inactivation,1989,O
of,1989,O
NF-kappaB,1989,B-GENE-N
.,1989,O
Collectively,1990,O
",",1990,O
our,1990,O
results,1990,O
suggest,1990,O
that,1990,O
H,1990,B-CHEMICAL
(,1990,I-CHEMICAL
2,1990,I-CHEMICAL
),1990,I-CHEMICAL
S,1990,I-CHEMICAL
can,1990,O
inhibit,1990,O
NO,1990,B-CHEMICAL
production,1990,O
and,1990,O
NF-kappaB,1990,B-GENE-N
activation,1990,O
in,1990,O
LPS-stimulated,1990,O
macrophages,1990,O
through,1990,O
a,1990,O
mechanism,1990,O
that,1990,O
involves,1990,O
the,1990,O
action,1990,O
of,1990,O
HO-1/CO,1990,B-GENE-Y
.,1990,O
Effect,1991,O
of,1991,O
chronic,1991,O
renal,1991,O
failure,1991,O
on,1991,O
arginase,1991,B-GENE-N
and,1991,O
argininosuccinate,1991,B-GENE-Y
synthetase,1991,I-GENE-Y
expression,1991,O
.,1991,O
BACKGROUND,1992,O
:,1992,O
L-arginine,1992,B-CHEMICAL
(,1992,O
L-arg,1992,B-CHEMICAL
),1992,O
participates,1992,O
in,1992,O
numerous,1992,O
biological,1992,O
functions,1992,O
including,1992,O
urea,1992,B-CHEMICAL
and,1992,O
nitric,1992,B-CHEMICAL
oxide,1992,I-CHEMICAL
synthesis,1992,O
.,1992,O
Sources,1993,O
of,1993,O
L-arg,1993,B-CHEMICAL
include,1993,O
dietary,1993,O
proteins,1993,O
and,1993,O
endogenous,1993,O
synthesis,1993,O
by,1993,O
argininosuccinate,1993,B-CHEMICAL
synthetase,1993,I-GENE-Y
and,1993,O
argininosuccinate,1993,B-GENE-Y
lyase,1993,I-GENE-Y
.,1993,O
L-arg,1994,B-CHEMICAL
is,1994,O
converted,1994,O
to,1994,O
urea,1994,B-CHEMICAL
by,1994,O
arginase,1994,B-GENE-Y
I,1994,I-GENE-Y
in,1994,O
the,1994,O
liver,1994,O
and,1994,O
arginase,1994,B-GENE-Y
II,1994,I-GENE-Y
in,1994,O
the,1994,O
kidney,1994,O
.,1994,O
Normally,1995,O
",",1995,O
the,1995,O
liver,1995,O
fully,1995,O
consumes,1995,O
L-arg,1995,B-CHEMICAL
for,1995,O
urea,1995,B-CHEMICAL
generation,1995,O
and,1995,O
does,1995,O
not,1995,O
contribute,1995,O
to,1995,O
its,1995,O
circulating,1995,O
pool,1995,O
.,1995,O
Instead,1996,O
",",1996,O
much,1996,O
of,1996,O
the,1996,O
circulating,1996,O
L-arg,1996,B-CHEMICAL
is,1996,O
produced,1996,O
by,1996,O
the,1996,O
kidney,1996,O
.,1996,O
If,1997,O
true,1997,O
",",1997,O
plasma,1997,O
L-arg,1997,B-CHEMICAL
should,1997,O
be,1997,O
severely,1997,O
reduced,1997,O
in,1997,O
chronic,1997,O
renal,1997,O
failure,1997,O
(,1997,O
CRF,1997,O
),1997,O
;,1997,O
however,1997,O
",",1997,O
plasma,1997,O
L-arg,1997,B-CHEMICAL
is,1997,O
frequently,1997,O
unchanged,1997,O
in,1997,O
CRF,1997,O
.,1997,O
We,1998,O
hypothesized,1998,O
that,1998,O
preservation,1998,O
of,1998,O
plasma,1998,O
L-arg,1998,B-CHEMICAL
in,1998,O
CRF,1998,O
may,1998,O
be,1998,O
",",1998,O
partly,1998,O
",",1998,O
due,1998,O
to,1998,O
downregulation/inhibition,1998,O
of,1998,O
arginase,1998,B-GENE-N
.,1998,O
METHODS,1999,O
:,1999,O
Argininosuccinate,1999,B-GENE-Y
synthetase,1999,I-GENE-Y
",",1999,O
arginase,1999,B-GENE-N
I,1999,I-GENE-N
and,1999,I-GENE-N
II,1999,I-GENE-N
protein,1999,O
abundance,1999,O
and,1999,O
activity,1999,O
were,1999,O
measured,1999,O
in,1999,O
the,1999,O
liver,1999,O
and,1999,O
kidneys,1999,O
of,1999,O
rats,1999,O
6,1999,O
weeks,1999,O
after,1999,O
5/6,1999,O
nephrectomy,1999,O
or,1999,O
sham,1999,O
operation,1999,O
.,1999,O
In,2000,O
addition,2000,O
",",2000,O
arginase,2000,B-GENE-N
activity,2000,O
was,2000,O
measured,2000,O
in,2000,O
the,2000,O
presence,2000,O
of,2000,O
different,2000,O
urea,2000,B-CHEMICAL
concentrations,2000,O
to,2000,O
simulate,2000,O
azotemia,2000,O
in,2000,O
vitro,2000,O
.,2000,O
RESULTS,2001,O
:,2001,O
Arginases,2001,B-GENE-N
I,2001,I-GENE-N
and,2001,I-GENE-N
II,2001,I-GENE-N
protein,2001,O
abundance,2001,O
as,2001,O
well,2001,O
as,2001,O
arginase,2001,B-GENE-N
activity,2001,O
in,2001,O
the,2001,O
liver,2001,O
",",2001,O
measured,2001,O
in,2001,O
the,2001,O
physiological,2001,O
buffer,2001,O
",",2001,O
were,2001,O
similar,2001,O
among,2001,O
the,2001,O
CRF,2001,O
and,2001,O
control,2001,O
groups,2001,O
.,2001,O
However,2002,O
",",2002,O
in,2002,O
vitro,2002,O
experiments,2002,O
simulating,2002,O
a,2002,O
uremic,2002,O
milieu,2002,O
revealed,2002,O
a,2002,O
marked,2002,O
concentration-dependent,2002,O
inhibition,2002,O
of,2002,O
arginase,2002,B-GENE-N
activity,2002,O
by,2002,O
urea,2002,B-CHEMICAL
in,2002,O
the,2002,O
tissue,2002,O
lysates,2002,O
.,2002,O
CRF,2003,O
had,2003,O
no,2003,O
significant,2003,O
effect,2003,O
on,2003,O
argininosuccinate,2003,B-CHEMICAL
synthetase,2003,I-GENE-Y
abundance,2003,O
in,2003,O
the,2003,O
kidney,2003,O
",",2003,O
liver,2003,O
",",2003,O
spleen,2003,O
or,2003,O
intestine,2003,O
.,2003,O
CONCLUSIONS,2004,O
:,2004,O
Although,2004,O
CRF,2004,O
does,2004,O
not,2004,O
change,2004,O
the,2004,O
abundance,2004,O
or,2004,O
intrinsic,2004,O
properties,2004,O
of,2004,O
arginase,2004,B-GENE-N
",",2004,O
the,2004,O
inherent,2004,O
rise,2004,O
in,2004,O
urea,2004,B-CHEMICAL
concentration,2004,O
inhibits,2004,O
its,2004,O
enzymatic,2004,O
activity,2004,O
.,2004,O
The,2005,O
latter,2005,O
",",2005,O
in,2005,O
turn,2005,O
",",2005,O
attenuates,2005,O
L-arg,2005,B-CHEMICAL
catabolism,2005,O
and,2005,O
urea,2005,O
production,2005,O
and,2005,O
",",2005,O
thereby,2005,O
",",2005,O
mitigates,2005,O
the,2005,O
fall,2005,O
in,2005,O
plasma,2005,O
L-arg,2005,B-CHEMICAL
.,2005,O
Epratuzumab,2006,O
",",2006,O
a,2006,O
CD22-targeting,2006,B-GENE-Y
recombinant,2006,O
humanized,2006,O
antibody,2006,O
with,2006,O
a,2006,O
different,2006,O
mode,2006,O
of,2006,O
action,2006,O
from,2006,O
rituximab,2006,O
.,2006,O
Epratuzumab,2007,O
is,2007,O
a,2007,O
humanized,2007,O
anti-CD22,2007,O
monoclonal,2007,O
antibody,2007,O
currently,2007,O
in,2007,O
clinical,2007,O
trials,2007,O
for,2007,O
treatment,2007,O
of,2007,O
non-Hodgkin,2007,O
lymphoma,2007,O
(,2007,O
NHL,2007,O
),2007,O
and,2007,O
certain,2007,O
autoimmune,2007,O
diseases,2007,O
.,2007,O
Here,2008,O
we,2008,O
report,2008,O
the,2008,O
results,2008,O
of,2008,O
investigations,2008,O
of,2008,O
epratuzumab,2008,O
's,2008,O
mode,2008,O
of,2008,O
action,2008,O
in,2008,O
comparison,2008,O
to,2008,O
and,2008,O
in,2008,O
combination,2008,O
with,2008,O
the,2008,O
anti-CD20,2008,O
mAb,2008,O
",",2008,O
rituximab,2008,O
.,2008,O
In,2009,O
vitro,2009,O
cell,2009,O
growth,2009,O
inhibition,2009,O
",",2009,O
induction,2009,O
of,2009,O
apoptosis,2009,O
",",2009,O
and,2009,O
the,2009,O
ability,2009,O
of,2009,O
the,2009,O
mAbs,2009,O
to,2009,O
mediate,2009,O
complement-dependent,2009,B-GENE-N
cytotoxicity,2009,O
(,2009,O
CDC,2009,O
),2009,O
and,2009,O
antibody-dependent,2009,O
cellular,2009,O
cytotoxicity,2009,O
(,2009,O
ADCC,2009,O
),2009,O
were,2009,O
evaluated,2009,O
.,2009,O
We,2010,O
also,2010,O
investigated,2010,O
the,2010,O
potential,2010,O
activity,2010,O
of,2010,O
epratuzumab,2010,O
in,2010,O
the,2010,O
regulation,2010,O
of,2010,O
B-cell,2010,B-GENE-N
antigen,2010,I-GENE-N
receptor,2010,I-GENE-N
(,2010,O
BCR,2010,B-GENE-N
),2010,O
activation,2010,O
.,2010,O
Epratuzumab,2011,O
and,2011,O
rituximab,2011,O
displayed,2011,O
very,2011,O
distinct,2011,O
modes,2011,O
of,2011,O
action,2011,O
;,2011,O
epratuzumab,2011,O
acts,2011,O
as,2011,O
an,2011,O
immunomodulatory,2011,O
agent,2011,O
",",2011,O
while,2011,O
rituximab,2011,O
is,2011,O
an,2011,O
acutely,2011,O
cytotoxic,2011,O
therapeutic,2011,O
antibody,2011,O
.,2011,O
Epratuzumab,2012,O
has,2012,O
distinct,2012,O
effects,2012,O
on,2012,O
cell,2012,O
growth,2012,O
from,2012,O
rituximab,2012,O
.,2012,O
For,2013,O
example,2013,O
",",2013,O
rituximab+anti-human,2013,O
IgG,2013,B-GENE-N
Fcgamma,2013,I-GENE-N
yielded,2013,O
marked,2013,O
inhibition,2013,O
of,2013,O
proliferation,2013,O
in,2013,O
human,2013,O
NHL,2013,O
cell,2013,O
lines,2013,O
",",2013,O
while,2013,O
epratuzumab,2013,O
had,2013,O
little,2013,O
or,2013,O
no,2013,O
effect,2013,O
in,2013,O
this,2013,O
assay,2013,O
.,2013,O
However,2014,O
",",2014,O
when,2014,O
cells,2014,O
were,2014,O
immobilized,2014,O
and,2014,O
stimulated,2014,O
with,2014,O
anti-IgM,2014,O
",",2014,O
epratuzumab,2014,O
",",2014,O
but,2014,O
not,2014,O
rituximab,2014,O
",",2014,O
caused,2014,O
a,2014,O
significant,2014,O
antiproliferative,2014,O
effect,2014,O
.,2014,O
Unlike,2015,O
rituximab,2015,O
",",2015,O
no,2015,O
CDC,2015,O
could,2015,O
be,2015,O
detected,2015,O
",",2015,O
and,2015,O
ADCC,2015,O
was,2015,O
modest,2015,O
but,2015,O
significant,2015,O
with,2015,O
epratuzumab,2015,O
.,2015,O
Importantly,2016,O
",",2016,O
combining,2016,O
rituximab,2016,O
and,2016,O
epratuzumab,2016,O
did,2016,O
not,2016,O
decrease,2016,O
rituximab,2016,O
's,2016,O
ability,2016,O
to,2016,O
induce,2016,O
apoptosis,2016,O
",",2016,O
CDC,2016,O
",",2016,O
and,2016,O
ADCC,2016,O
.,2016,O
In,2017,O
fact,2017,O
",",2017,O
the,2017,O
combination,2017,O
is,2017,O
more,2017,O
effective,2017,O
than,2017,O
rituximab,2017,O
alone,2017,O
in,2017,O
inhibiting,2017,O
proliferation,2017,O
of,2017,O
Daudi,2017,O
Burkitt,2017,O
lymphoma,2017,O
cells,2017,O
in,2017,O
the,2017,O
presence,2017,O
of,2017,O
second,2017,O
antibody,2017,O
",",2017,O
and,2017,O
at,2017,O
least,2017,O
equally,2017,O
effective,2017,O
to,2017,O
rituximab,2017,O
in,2017,O
the,2017,O
absence,2017,O
of,2017,O
crosslinking,2017,O
.,2017,O
These,2018,O
observations,2018,O
suggest,2018,O
that,2018,O
it,2018,O
may,2018,O
be,2018,O
possible,2018,O
to,2018,O
enhance,2018,O
clinical,2018,O
efficacy,2018,O
by,2018,O
combination,2018,O
therapy,2018,O
comprised,2018,O
of,2018,O
anti-CD20,2018,O
and,2018,O
anti-CD22,2018,O
mAbs,2018,O
.,2018,O
Vasopressin,2019,B-GENE-Y
antagonists,2019,O
as,2019,O
aquaretic,2019,O
agents,2019,O
for,2019,O
the,2019,O
treatment,2019,O
of,2019,O
hyponatremia,2019,O
.,2019,O
Hyponatremia,2020,O
is,2020,O
the,2020,O
most,2020,O
frequent,2020,O
electrolyte,2020,O
disorder,2020,O
encountered,2020,O
in,2020,O
hospitalized,2020,O
patients,2020,O
.,2020,O
It,2021,O
is,2021,O
a,2021,O
state,2021,O
of,2021,O
relative,2021,O
water,2021,O
excess,2021,O
due,2021,O
to,2021,O
stimulated,2021,O
arginine,2021,B-CHEMICAL
vasopressin,2021,I-CHEMICAL
(,2021,O
AVP,2021,B-GENE-Y
),2021,O
and,2021,O
fluid,2021,O
intake,2021,O
greater,2021,O
than,2021,O
obligatory,2021,O
losses,2021,O
.,2021,O
This,2022,O
kind,2022,O
of,2022,O
hyponatremia,2022,O
occurs,2022,O
in,2022,O
the,2022,O
syndrome,2022,O
of,2022,O
inappropriate,2022,O
antidiuretic,2022,B-GENE-Y
hormone,2022,I-GENE-Y
secretion,2022,O
",",2022,O
congestive,2022,O
heart,2022,O
failure,2022,O
",",2022,O
and,2022,O
liver,2022,O
cirrhosis,2022,O
.,2022,O
Fluid,2023,O
restriction,2023,O
is,2023,O
the,2023,O
presently,2023,O
recommended,2023,O
treatment,2023,O
for,2023,O
hyponatremia,2023,O
.,2023,O
However,2024,O
",",2024,O
fluid,2024,O
restriction,2024,O
may,2024,O
be,2024,O
very,2024,O
difficult,2024,O
for,2024,O
patients,2024,O
to,2024,O
achieve,2024,O
",",2024,O
is,2024,O
slow,2024,O
to,2024,O
work,2024,O
",",2024,O
and,2024,O
does,2024,O
not,2024,O
allow,2024,O
a,2024,O
graded,2024,O
therapeutic,2024,O
approach,2024,O
.,2024,O
More,2025,O
efficient,2025,O
and,2025,O
specific,2025,O
treatments,2025,O
of,2025,O
hyponatremia,2025,O
are,2025,O
needed,2025,O
.,2025,O
In,2026,O
this,2026,O
respect,2026,O
",",2026,O
pharmacologic,2026,O
research,2026,O
has,2026,O
yielded,2026,O
a,2026,O
number,2026,O
of,2026,O
compounds,2026,O
exhibiting,2026,O
antagonistic,2026,O
qualities,2026,O
at,2026,O
the,2026,O
vasopressin,2026,B-GENE-Y
V2,2026,I-GENE-Y
receptor,2026,I-GENE-Y
.,2026,O
Among,2027,O
these,2027,O
agents,2027,O
",",2027,O
peptidic,2027,O
derivatives,2027,O
of,2027,O
AVP,2027,B-GENE-Y
turned,2027,O
out,2027,O
to,2027,O
have,2027,O
intrinsic,2027,O
antidiuretic,2027,O
properties,2027,O
in,2027,O
vivo,2027,O
when,2027,O
given,2027,O
over,2027,O
days,2027,O
or,2027,O
weeks,2027,O
.,2027,O
The,2028,O
development,2028,O
of,2028,O
such,2028,O
agents,2028,O
for,2028,O
use,2028,O
in,2028,O
patients,2028,O
has,2028,O
not,2028,O
been,2028,O
pursued,2028,O
.,2028,O
However,2029,O
",",2029,O
several,2029,O
promising,2029,O
nonpeptide,2029,O
",",2029,O
vasopressin,2029,B-GENE-N
receptor,2029,I-GENE-N
antagonists,2029,O
have,2029,O
been,2029,O
described,2029,O
;,2029,O
these,2029,O
agents,2029,O
are,2029,O
VPA-985,2029,B-CHEMICAL
(,2029,O
lixivaptan,2029,B-CHEMICAL
),2029,O
",",2029,O
YM-087,2029,B-CHEMICAL
(,2029,O
conivaptan,2029,B-CHEMICAL
),2029,O
",",2029,O
OPC-41061,2029,B-CHEMICAL
(,2029,O
tolvaptan,2029,B-CHEMICAL
),2029,O
",",2029,O
and,2029,O
SR-121463,2029,B-CHEMICAL
.,2029,O
Prospective,2030,O
",",2030,O
randomized,2030,O
",",2030,O
placebo-controlled,2030,O
trials,2030,O
performed,2030,O
with,2030,O
these,2030,O
agents,2030,O
found,2030,O
that,2030,O
they,2030,O
corrected,2030,O
hyponatremia,2030,O
efficiently,2030,O
and,2030,O
safely,2030,O
.,2030,O
Most,2031,O
of,2031,O
the,2031,O
studies,2031,O
were,2031,O
conducted,2031,O
over,2031,O
a,2031,O
4-,2031,O
to,2031,O
28-day,2031,O
period,2031,O
.,2031,O
Long-term,2032,O
studies,2032,O
will,2032,O
be,2032,O
needed,2032,O
in,2032,O
the,2032,O
future,2032,O
to,2032,O
address,2032,O
such,2032,O
issues,2032,O
as,2032,O
the,2032,O
eventual,2032,O
benefit,2032,O
to,2032,O
patients,2032,O
and,2032,O
the,2032,O
effects,2032,O
of,2032,O
vasopressin,2032,B-CHEMICAL
antagonists,2032,O
on,2032,O
morbidity,2032,O
and,2032,O
mortality,2032,O
of,2032,O
patients,2032,O
with,2032,O
hyponatremia,2032,O
.,2032,O
Sedation,2033,O
and,2033,O
histamine,2033,B-GENE-Y
H1-receptor,2033,I-GENE-Y
antagonism,2033,O
:,2033,O
studies,2033,O
in,2033,O
man,2033,O
with,2033,O
the,2033,O
enantiomers,2033,O
of,2033,O
chlorpheniramine,2033,B-CHEMICAL
and,2033,O
dimethindene,2033,B-CHEMICAL
.,2033,O
1,2034,O
.,2034,O
The,2035,O
effects,2035,O
of,2035,O
10,2035,O
mg,2035,O
(,2035,B-CHEMICAL
+,2035,I-CHEMICAL
),2035,I-CHEMICAL
-,2035,I-CHEMICAL
and,2035,I-CHEMICAL
(,2035,I-CHEMICAL
-,2035,I-CHEMICAL
),2035,I-CHEMICAL
-chlorpheniramine,2035,I-CHEMICAL
and,2035,O
5,2035,O
mg,2035,O
(,2035,B-CHEMICAL
+,2035,I-CHEMICAL
),2035,I-CHEMICAL
-,2035,I-CHEMICAL
and,2035,I-CHEMICAL
(,2035,I-CHEMICAL
-,2035,I-CHEMICAL
),2035,I-CHEMICAL
-dimethindene,2035,I-CHEMICAL
on,2035,O
daytime,2035,O
sleep,2035,O
latencies,2035,O
",",2035,O
digit,2035,O
symbol,2035,O
substitution,2035,O
and,2035,O
subjective,2035,O
assessments,2035,O
of,2035,O
mood,2035,O
and,2035,O
well-being,2035,O
were,2035,O
studied,2035,O
in,2035,O
6,2035,O
healthy,2035,O
young,2035,O
adult,2035,O
humans,2035,O
.,2035,O
Each,2036,O
subject,2036,O
also,2036,O
took,2036,O
5,2036,O
mg,2036,O
triprolidine,2036,B-CHEMICAL
hydrochloride,2036,I-CHEMICAL
as,2036,O
an,2036,O
active,2036,O
control,2036,O
and,2036,O
two,2036,O
placebos,2036,O
.,2036,O
2,2037,O
.,2037,O
Daytime,2038,O
sleep,2038,O
latencies,2038,O
were,2038,O
reduced,2038,O
with,2038,O
triprolidine,2038,B-CHEMICAL
",",2038,O
(,2038,B-CHEMICAL
+,2038,I-CHEMICAL
),2038,I-CHEMICAL
-chlorpheniramine,2038,I-CHEMICAL
and,2038,O
(,2038,B-CHEMICAL
-,2038,I-CHEMICAL
),2038,I-CHEMICAL
-dimethindene,2038,I-CHEMICAL
",",2038,O
and,2038,O
subjects,2038,O
also,2038,O
reported,2038,O
that,2038,O
they,2038,O
felt,2038,O
more,2038,O
sleepy,2038,O
after,2038,O
(,2038,B-CHEMICAL
+,2038,I-CHEMICAL
),2038,I-CHEMICAL
-chlorpheniramine,2038,I-CHEMICAL
and,2038,O
(,2038,B-CHEMICAL
-,2038,I-CHEMICAL
),2038,I-CHEMICAL
-dimethindene,2038,I-CHEMICAL
.,2038,O
Performance,2039,O
on,2039,O
digit,2039,O
symbol,2039,O
substitution,2039,O
was,2039,O
impaired,2039,O
with,2039,O
(,2039,B-CHEMICAL
+,2039,I-CHEMICAL
),2039,I-CHEMICAL
-chlorpheniramine,2039,I-CHEMICAL
.,2039,O
3,2040,O
.,2040,O
Changes,2041,O
in,2041,O
measures,2041,O
with,2041,O
(,2041,B-CHEMICAL
-,2041,I-CHEMICAL
),2041,I-CHEMICAL
-chlorpheniramine,2041,I-CHEMICAL
and,2041,O
(,2041,B-CHEMICAL
+,2041,I-CHEMICAL
),2041,I-CHEMICAL
-dimethindene,2041,I-CHEMICAL
were,2041,O
not,2041,O
different,2041,O
from,2041,O
changes,2041,O
with,2041,O
placebo,2041,O
.,2041,O
4,2042,O
.,2042,O
In,2043,O
the,2043,O
present,2043,O
study,2043,O
",",2043,O
changes,2043,O
in,2043,O
measures,2043,O
of,2043,O
drowsiness,2043,O
and,2043,O
performance,2043,O
were,2043,O
limited,2043,O
to,2043,O
the,2043,O
enantiomers,2043,O
with,2043,O
high,2043,O
affinity,2043,O
for,2043,O
the,2043,O
histamine,2043,B-GENE-Y
H1-receptor,2043,I-GENE-Y
.,2043,O
These,2044,O
findings,2044,O
strongly,2044,O
suggest,2044,O
that,2044,O
sedation,2044,O
can,2044,O
arise,2044,O
from,2044,O
H1-receptor,2044,B-GENE-Y
antagonism,2044,O
alone,2044,O
",",2044,O
and,2044,O
provide,2044,O
further,2044,O
support,2044,O
for,2044,O
the,2044,O
belief,2044,O
that,2044,O
the,2044,O
histaminergic,2044,O
system,2044,O
is,2044,O
concerned,2044,O
with,2044,O
the,2044,O
regulation,2044,O
of,2044,O
alertness,2044,O
in,2044,O
man,2044,O
.,2044,O
Anti-clastogenic,2045,O
effect,2045,O
of,2045,O
beta-glucan,2045,O
extracted,2045,O
from,2045,O
barley,2045,O
towards,2045,O
chemically,2045,O
induced,2045,O
DNA,2045,O
damage,2045,O
in,2045,O
rodent,2045,O
cells,2045,O
.,2045,O
beta-Glucan,2046,O
(,2046,O
BG,2046,O
),2046,O
was,2046,O
tested,2046,O
in,2046,O
vitro,2046,O
to,2046,O
determine,2046,O
its,2046,O
potential,2046,O
clastogenic,2046,O
and/or,2046,O
anti-clastogenic,2046,O
activity,2046,O
",",2046,O
and,2046,O
attempts,2046,O
were,2046,O
made,2046,O
to,2046,O
elucidate,2046,O
its,2046,O
possible,2046,O
mechanism,2046,O
of,2046,O
action,2046,O
by,2046,O
using,2046,O
combinations,2046,O
with,2046,O
an,2046,O
inhibitor,2046,O
of,2046,O
DNA,2046,B-GENE-N
polymerase,2046,I-GENE-N
.,2046,O
The,2047,O
study,2047,O
was,2047,O
carried,2047,O
out,2047,O
on,2047,O
cells,2047,O
deficient,2047,O
(,2047,O
CHO-k1,2047,O
),2047,O
and,2047,O
cells,2047,O
proficient,2047,O
(,2047,O
HTC,2047,O
),2047,O
in,2047,O
phases,2047,O
I,2047,O
and,2047,O
II,2047,O
enzymes,2047,O
",",2047,O
and,2047,O
the,2047,O
DNA,2047,O
damage,2047,O
was,2047,O
assessed,2047,O
by,2047,O
the,2047,O
chromosomal,2047,O
aberration,2047,O
assay,2047,O
.,2047,O
BG,2048,O
did,2048,O
not,2048,O
show,2048,O
a,2048,O
clastogenic,2048,O
effect,2048,O
",",2048,O
but,2048,O
was,2048,O
anti-clastogenic,2048,O
in,2048,O
both,2048,O
cell,2048,O
lines,2048,O
used,2048,O
",",2048,O
and,2048,O
at,2048,O
all,2048,O
concentrations,2048,O
tested,2048,O
(,2048,O
2.5,2048,O
",",2048,O
5,2048,O
and,2048,O
10,2048,O
microg/mL,2048,O
),2048,O
in,2048,O
combination,2048,O
with,2048,O
damage,2048,O
inducing,2048,O
agents,2048,O
(,2048,O
methylmethane,2048,B-CHEMICAL
sulfonate,2048,I-CHEMICAL
in,2048,O
cell,2048,O
line,2048,O
CHO-k1,2048,O
",",2048,O
and,2048,O
methylmethane,2048,B-CHEMICAL
sulfonate,2048,I-CHEMICAL
or,2048,O
2-aminoanthracene,2048,B-CHEMICAL
in,2048,O
cell,2048,O
line,2048,O
HTC,2048,O
),2048,O
.,2048,O
BG,2049,O
also,2049,O
showed,2049,O
a,2049,O
protective,2049,O
effect,2049,O
in,2049,O
the,2049,O
presence,2049,O
of,2049,O
a,2049,O
DNA,2049,B-GENE-Y
polymerase,2049,I-GENE-Y
beta,2049,I-GENE-Y
inhibitor,2049,O
(,2049,O
cytosine,2049,B-CHEMICAL
arabinoside-3-phosphate,2049,I-CHEMICAL
",",2049,O
Ara-C,2049,B-CHEMICAL
),2049,O
",",2049,O
demonstrating,2049,O
that,2049,O
BG,2049,O
does,2049,O
not,2049,O
act,2049,O
through,2049,O
an,2049,O
anti-mutagenic,2049,O
mechanism,2049,O
of,2049,O
action,2049,O
involving,2049,O
DNA,2049,B-GENE-Y
polymerase,2049,I-GENE-Y
beta,2049,I-GENE-Y
.,2049,O
Association,2050,O
of,2050,O
DRD2,2050,B-GENE-Y
polymorphisms,2050,O
and,2050,O
chlorpromazine-induced,2050,B-CHEMICAL
extrapyramidal,2050,O
syndrome,2050,O
in,2050,O
Chinese,2050,O
schizophrenic,2050,O
patients,2050,O
.,2050,O
AIM,2051,O
:,2051,O
Extrapyramidal,2051,O
syndrome,2051,O
(,2051,O
EPS,2051,O
),2051,O
is,2051,O
most,2051,O
commonly,2051,O
affected,2051,O
by,2051,O
typical,2051,O
antipsychotic,2051,O
drugs,2051,O
that,2051,O
have,2051,O
a,2051,O
high,2051,O
affinity,2051,O
with,2051,O
the,2051,O
D2,2051,B-GENE-Y
receptor,2051,I-GENE-Y
.,2051,O
Recently,2052,O
",",2052,O
many,2052,O
research,2052,O
groups,2052,O
have,2052,O
reported,2052,O
on,2052,O
the,2052,O
positive,2052,O
relationship,2052,O
between,2052,O
the,2052,O
genetic,2052,O
variations,2052,O
in,2052,O
the,2052,O
DRD2,2052,B-GENE-Y
gene,2052,O
and,2052,O
the,2052,O
therapeutic,2052,O
response,2052,O
in,2052,O
schizophrenia,2052,O
patients,2052,O
as,2052,O
a,2052,O
result,2052,O
of,2052,O
the,2052,O
role,2052,O
of,2052,O
variations,2052,O
in,2052,O
the,2052,O
receptor,2052,O
in,2052,O
modulating,2052,O
receptor,2052,O
expression,2052,O
.,2052,O
In,2053,O
this,2053,O
study,2053,O
",",2053,O
we,2053,O
evaluate,2053,O
the,2053,O
role,2053,O
DRD2,2053,B-GENE-Y
plays,2053,O
in,2053,O
chlorpromazine-induced,2053,B-CHEMICAL
EPS,2053,O
in,2053,O
schizophrenic,2053,O
patients,2053,O
.,2053,O
METHODS,2054,O
:,2054,O
We,2054,O
identified,2054,O
seven,2054,O
SNP,2054,O
(,2054,O
single,2054,O
nucleotide,2054,B-CHEMICAL
polymorphism,2054,O
),2054,O
(,2054,O
-141Cins,2054,O
>,2054,O
del,2054,O
",",2054,O
TaqIB,2054,O
",",2054,O
TaqID,2054,O
",",2054,O
Ser311Cys,2054,B-GENE-N
",",2054,O
rs6275,2054,O
",",2054,O
rs6277,2054,O
and,2054,O
TaqIA,2054,O
),2054,O
in,2054,O
the,2054,O
DRD2,2054,B-GENE-Y
gene,2054,O
in,2054,O
146,2054,O
schizophrenic,2054,O
inpatients,2054,O
(,2054,O
59,2054,O
with,2054,O
EPS,2054,O
and,2054,O
87,2054,O
without,2054,O
EPS,2054,O
according,2054,O
to,2054,O
the,2054,O
Simpson-Angus,2054,O
Scale,2054,O
),2054,O
treated,2054,O
with,2054,O
chlorpromazine,2054,B-CHEMICAL
after,2054,O
8,2054,O
weeks,2054,O
.,2054,O
The,2055,O
alleles,2055,O
of,2055,O
all,2055,O
loci,2055,O
were,2055,O
determined,2055,O
by,2055,O
PCR,2055,O
(,2055,O
polymerase,2055,O
chain,2055,O
reaction,2055,O
),2055,O
.,2055,O
RESULTS,2056,O
:,2056,O
Polymorphisms,2056,O
TaqID,2056,O
",",2056,O
Ser311Cys,2056,B-GENE-N
and,2056,O
rs6277,2056,O
were,2056,O
not,2056,O
polymorphic,2056,O
in,2056,O
the,2056,O
population,2056,O
recruited,2056,O
in,2056,O
the,2056,O
present,2056,O
study,2056,O
.,2056,O
No,2057,O
statistical,2057,O
significance,2057,O
was,2057,O
found,2057,O
in,2057,O
the,2057,O
allele,2057,O
distribution,2057,O
of,2057,O
-141Cins,2057,O
>,2057,O
del,2057,O
",",2057,O
TaqIB,2057,O
",",2057,O
rs6275,2057,O
and,2057,O
TaqIA,2057,O
or,2057,O
in,2057,O
the,2057,O
estimated,2057,O
haplotypes,2057,O
(,2057,O
constituted,2057,O
by,2057,O
TaqIB,2057,O
",",2057,O
rs6275,2057,O
and,2057,O
TaqIA,2057,O
),2057,O
in,2057,O
linkage,2057,O
disequilibrium,2057,O
between,2057,O
the,2057,O
two,2057,O
groups,2057,O
.,2057,O
CONCLUSION,2058,O
:,2058,O
Our,2058,O
results,2058,O
did,2058,O
not,2058,O
lend,2058,O
strong,2058,O
support,2058,O
to,2058,O
the,2058,O
view,2058,O
that,2058,O
the,2058,O
genetic,2058,O
variation,2058,O
of,2058,O
the,2058,O
DRD2,2058,B-GENE-Y
gene,2058,O
plays,2058,O
a,2058,O
major,2058,O
role,2058,O
in,2058,O
the,2058,O
individually,2058,O
variable,2058,O
adverse,2058,O
effect,2058,O
induced,2058,O
by,2058,O
chlorpromazine,2058,B-CHEMICAL
",",2058,O
at,2058,O
least,2058,O
in,2058,O
Chinese,2058,O
patients,2058,O
with,2058,O
schizophrenia,2058,O
.,2058,O
Our,2059,O
results,2059,O
confirmed,2059,O
a,2059,O
previous,2059,O
study,2059,O
on,2059,O
the,2059,O
relationship,2059,O
between,2059,O
DRD2,2059,B-GENE-Y
and,2059,O
EPS,2059,O
in,2059,O
Caucasians,2059,O
.,2059,O
Activity-dependent,2060,O
cleavage,2060,O
of,2060,O
brain,2060,O
glutamic,2060,B-GENE-Y
acid,2060,I-GENE-Y
decarboxylase,2060,I-GENE-Y
65,2060,I-GENE-Y
by,2060,O
calpain,2060,B-GENE-N
.,2060,O
Previously,2061,O
",",2061,O
we,2061,O
reported,2061,O
that,2061,O
l-glutamic,2061,B-CHEMICAL
acid,2061,I-CHEMICAL
decarboxylase,2061,I-GENE-Y
isoform,2061,I-GENE-Y
65,2061,I-GENE-Y
(,2061,O
GAD65,2061,B-GENE-Y
),2061,O
could,2061,O
be,2061,O
cleaved,2061,O
in,2061,O
vitro,2061,O
to,2061,O
release,2061,O
a,2061,O
stable,2061,O
truncated,2061,O
form,2061,O
which,2061,O
lacks,2061,O
amino,2061,B-CHEMICAL
acid,2061,I-CHEMICAL
1-69,2061,O
from,2061,O
the,2061,O
N-terminus,2061,B-CHEMICAL
",",2061,O
GAD65,2061,B-GENE-Y
(,2061,I-GENE-Y
Delta1-69,2061,I-GENE-Y
),2061,I-GENE-Y
.,2061,O
However,2062,O
",",2062,O
whether,2062,O
such,2062,O
a,2062,O
truncated,2062,O
form,2062,O
is,2062,O
also,2062,O
present,2062,O
under,2062,O
certain,2062,O
physiological,2062,O
conditions,2062,O
remains,2062,O
elusive,2062,O
.,2062,O
In,2063,O
the,2063,O
present,2063,O
study,2063,O
",",2063,O
we,2063,O
showed,2063,O
that,2063,O
",",2063,O
upon,2063,O
sustained,2063,O
neuronal,2063,O
stimulation,2063,O
",",2063,O
GAD65,2063,B-GENE-Y
could,2063,O
be,2063,O
cleaved,2063,O
into,2063,O
a,2063,O
truncated,2063,O
form,2063,O
in,2063,O
a,2063,O
rat,2063,O
synaptosomal,2063,O
preparation,2063,O
.,2063,O
This,2064,O
truncated,2064,O
form,2064,O
had,2064,O
similar,2064,O
electrophoretic,2064,O
mobility,2064,O
to,2064,O
purified,2064,O
recombinant,2064,O
human,2064,B-GENE-Y
GAD65,2064,I-GENE-Y
(,2064,I-GENE-Y
Delta1-69,2064,I-GENE-Y
),2064,O
.,2064,O
Furthermore,2065,O
",",2065,O
we,2065,O
demonstrated,2065,O
that,2065,O
this,2065,O
conversion,2065,O
was,2065,O
calcium,2065,B-CHEMICAL
dependent,2065,O
.,2065,O
Calcium-chelating,2066,B-CHEMICAL
reagents,2066,O
such,2066,O
as,2066,O
EDTA,2066,B-CHEMICAL
and,2066,O
"1,2-bis-",2066,B-CHEMICAL
(,2066,I-CHEMICAL
o-aminphenoxy,2066,I-CHEMICAL
),2066,I-CHEMICAL
-ethane-N,2066,I-CHEMICAL
",",2066,I-CHEMICAL
N,2066,I-CHEMICAL
",",2066,I-CHEMICAL
N,2066,I-CHEMICAL
',2066,I-CHEMICAL
",",2066,I-CHEMICAL
N'-tetra-acetic,2066,I-CHEMICAL
acid,2066,I-CHEMICAL
tetra-acetoxy-methyl,2066,I-CHEMICAL
ester,2066,I-CHEMICAL
prevented,2066,O
the,2066,O
cleavage,2066,O
of,2066,O
GAD65,2066,B-GENE-Y
.,2066,O
In,2067,O
addition,2067,O
",",2067,O
our,2067,O
data,2067,O
suggested,2067,O
that,2067,O
calpain,2067,B-GENE-N
",",2067,O
a,2067,O
calcium-dependent,2067,B-CHEMICAL
cysteine,2067,B-CHEMICAL
protease,2067,I-GENE-N
",",2067,O
is,2067,O
activated,2067,O
upon,2067,O
neuronal,2067,O
stimulation,2067,O
and,2067,O
could,2067,O
be,2067,O
responsible,2067,O
for,2067,O
the,2067,O
conversion,2067,O
of,2067,O
full-length,2067,O
GAD65,2067,B-GENE-Y
to,2067,O
truncated,2067,O
GAD65,2067,B-GENE-Y
in,2067,O
the,2067,O
brain,2067,O
.,2067,O
Moreover,2068,O
",",2068,O
calpain,2068,B-GENE-N
inhibitors,2068,O
such,2068,O
as,2068,O
calpain,2068,O
inhibitor,2068,O
I,2068,O
or,2068,O
calpastatin,2068,B-GENE-Y
could,2068,O
block,2068,O
the,2068,O
cleavage,2068,O
.,2068,O
Results,2069,O
of,2069,O
our,2069,O
in,2069,O
vitro,2069,O
cleavage,2069,O
assay,2069,O
using,2069,O
purified,2069,O
calpain,2069,B-GENE-N
and,2069,O
immunopurified,2069,O
rat,2069,B-GENE-Y
GAD65,2069,I-GENE-Y
also,2069,O
supported,2069,O
the,2069,O
idea,2069,O
that,2069,O
GAD65,2069,B-GENE-Y
could,2069,O
be,2069,O
directly,2069,O
cleaved,2069,O
by,2069,O
calpain,2069,B-GENE-N
.,2069,O
Therapeutic,2070,O
targets,2070,O
in,2070,O
melanoma,2070,O
:,2070,O
map,2070,B-GENE-N
kinase,2070,I-GENE-N
pathway,2070,O
.,2070,O
Recent,2071,O
progress,2071,O
in,2071,O
our,2071,O
understanding,2071,O
of,2071,O
the,2071,O
genetic,2071,O
alterations,2071,O
that,2071,O
occur,2071,O
in,2071,O
the,2071,O
pathogenesis,2071,O
of,2071,O
melanoma,2071,O
provides,2071,O
exciting,2071,O
opportunities,2071,O
for,2071,O
therapy,2071,O
.,2071,O
The,2072,O
most,2072,O
important,2072,O
signaling,2072,O
pathways,2072,O
in,2072,O
melanoma,2072,O
lie,2072,O
downstream,2072,O
of,2072,O
NRAS,2072,B-GENE-Y
:,2072,O
the,2072,O
RAS-BRAF-MAPK,2072,B-GENE-N
pathway,2072,O
.,2072,O
A,2073,O
great,2073,O
deal,2073,O
of,2073,O
attention,2073,O
has,2073,O
been,2073,O
focused,2073,O
on,2073,O
the,2073,O
high,2073,O
mutation,2073,O
rate,2073,O
in,2073,O
the,2073,O
BRAF,2073,B-GENE-Y
oncogene,2073,O
",",2073,O
which,2073,O
approaches,2073,O
60,2073,O
%,2073,O
",",2073,O
because,2073,O
BRAF,2073,B-GENE-Y
itself,2073,O
is,2073,O
an,2073,O
appealing,2073,O
drug,2073,O
substrate,2073,O
and,2073,O
because,2073,O
of,2073,O
the,2073,O
central,2073,O
contribution,2073,O
of,2073,O
BRAF,2073,B-GENE-Y
function,2073,O
to,2073,O
melanoma,2073,O
development,2073,O
that,2073,O
the,2073,O
mutation,2073,O
rate,2073,O
signifies,2073,O
.,2073,O
Agents,2074,O
that,2074,O
specifically,2074,O
target,2074,O
BRAF,2074,B-GENE-Y
",",2074,O
such,2074,O
as,2074,O
sorafenib,2074,B-CHEMICAL
",",2074,O
as,2074,O
well,2074,O
as,2074,O
new,2074,O
molecules,2074,O
that,2074,O
function,2074,O
both,2074,O
upstream,2074,O
and,2074,O
downstream,2074,O
of,2074,O
BRAF,2074,B-GENE-Y
",",2074,O
are,2074,O
being,2074,O
actively,2074,O
investigated,2074,O
.,2074,O
Reduction,2075,O
of,2075,O
cerebral,2075,O
infarct,2075,O
size,2075,O
by,2075,O
the,2075,O
AT1-receptor,2075,B-GENE-N
blocker,2075,O
candesartan,2075,B-CHEMICAL
",",2075,O
the,2075,O
HMG-CoA,2075,B-GENE-Y
reductase,2075,I-GENE-Y
inhibitor,2075,O
rosuvastatin,2075,B-CHEMICAL
and,2075,O
their,2075,O
combination,2075,O
.,2075,O
An,2076,O
experimental,2076,O
study,2076,O
in,2076,O
rats,2076,O
.,2076,O
Our,2077,O
purpose,2077,O
was,2077,O
to,2077,O
test,2077,O
the,2077,O
impact,2077,O
of,2077,O
single,2077,O
and/or,2077,O
combined,2077,O
treatment,2077,O
with,2077,O
the,2077,O
AT,2077,B-GENE-N
(,2077,I-GENE-N
1,2077,I-GENE-N
),2077,I-GENE-N
-receptor,2077,O
blocker,2077,O
candesartan,2077,B-CHEMICAL
and,2077,O
the,2077,O
HMG-CoA,2077,B-CHEMICAL
reductase,2077,I-GENE-Y
inhibitor,2077,O
rosuvastatin,2077,B-CHEMICAL
on,2077,O
infarct,2077,O
size,2077,O
and,2077,O
neuroscore,2077,O
in,2077,O
transient,2077,O
cerebral,2077,O
ischemia,2077,O
in,2077,O
rats,2077,O
.,2077,O
L-NAME,2078,B-CHEMICAL
was,2078,O
used,2078,O
to,2078,O
test,2078,O
whether,2078,O
any,2078,O
potential,2078,O
effect,2078,O
was,2078,O
due,2078,O
to,2078,O
activation,2078,O
of,2078,O
endothelial,2078,B-GENE-Y
nitric,2078,I-GENE-Y
oxide,2078,I-GENE-Y
synthase,2078,I-GENE-Y
(,2078,O
eNOS,2078,B-GENE-Y
),2078,O
.,2078,O
Therefore,2079,O
",",2079,O
the,2079,O
middle,2079,O
cerebral,2079,O
artery,2079,O
was,2079,O
occluded,2079,O
for,2079,O
1,2079,O
h,2079,O
(,2079,O
MCAO,2079,O
),2079,O
followed,2079,O
by,2079,O
7,2079,O
days,2079,O
reperfusion,2079,O
.,2079,O
Rats,2080,O
received,2080,O
candesartan,2080,B-CHEMICAL
2h,2080,O
before,2080,O
and,2080,O
daily,2080,O
after,2080,O
MCAO,2080,O
(,2080,O
pretreatment,2080,O
),2080,O
or,2080,O
daily,2080,O
after,2080,O
MCAO,2080,O
(,2080,O
posttreatment,2080,O
),2080,O
;,2080,O
rosuvastatin,2080,B-CHEMICAL
was,2080,O
given,2080,O
daily,2080,O
for,2080,O
7,2080,O
days,2080,O
before,2080,O
MCAO,2080,O
without,2080,O
or,2080,O
with,2080,O
candesartan,2080,B-CHEMICAL
pre-,2080,O
and,2080,O
posttreatment,2080,O
.,2080,O
In,2081,O
addition,2081,O
",",2081,O
candesartan,2081,B-CHEMICAL
and,2081,O
rosuvastatin,2081,B-CHEMICAL
were,2081,O
combined,2081,O
with,2081,O
L-NAME,2081,B-CHEMICAL
.,2081,O
Infarct,2082,O
size,2082,O
and,2082,O
neuroscore,2082,O
at,2082,O
day,2082,O
7,2082,O
were,2082,O
compared,2082,O
to,2082,O
those,2082,O
of,2082,O
controls,2082,O
.,2082,O
As,2083,O
result,2083,O
",",2083,O
compared,2083,O
to,2083,O
controls,2083,O
(,2083,O
109+/-12,2083,O
mm,2083,O
(,2083,O
3,2083,O
),2083,O
),2083,O
infarct,2083,O
size,2083,O
with,2083,O
candesartan,2083,B-CHEMICAL
(,2083,O
pretreatment,2083,O
:,2083,O
21+/-5,2083,O
mm,2083,O
(,2083,O
3,2083,O
),2083,O
;,2083,O
posttreatment,2083,O
:,2083,O
68+/-29,2083,O
mm,2083,O
(,2083,O
3,2083,O
),2083,O
;,2083,O
P,2083,O
<,2083,O
0.05,2083,O
),2083,O
or,2083,O
rosuvastatin,2083,B-CHEMICAL
(,2083,O
69+/-14,2083,O
mm,2083,O
(,2083,O
3,2083,O
),2083,O
;,2083,O
P,2083,O
<,2083,O
0.05,2083,O
),2083,O
was,2083,O
smaller,2083,O
.,2083,O
Combined,2084,O
treatment,2084,O
also,2084,O
reduced,2084,O
infarct,2084,O
size,2084,O
(,2084,O
pretreatment,2084,O
:,2084,O
37+/-15,2084,O
mm,2084,O
(,2084,O
3,2084,O
),2084,O
;,2084,O
posttreatment,2084,O
57+/-20mm,2084,O
(,2084,O
3,2084,O
),2084,O
;,2084,O
P,2084,O
<,2084,O
0.05,2084,O
),2084,O
;,2084,O
but,2084,O
there,2084,O
was,2084,O
no,2084,O
benefit,2084,O
of,2084,O
combined,2084,O
treatment,2084,O
over,2084,O
candesartan,2084,B-CHEMICAL
pretreatment,2084,O
alone,2084,O
.,2084,O
Compared,2085,O
to,2085,O
controls,2085,O
(,2085,O
2.08+/-0.28,2085,O
),2085,O
only,2085,O
candesartan,2085,B-CHEMICAL
pretreatment,2085,O
and,2085,O
combined,2085,O
treatment,2085,O
improved,2085,O
the,2085,O
neuroscore,2085,O
(,2085,O
0.97+/-0.05,2085,O
",",2085,O
1.10+/-0.33,2085,O
;,2085,O
P,2085,O
<,2085,O
0.05,2085,O
),2085,O
.,2085,O
L-NAME,2086,B-CHEMICAL
abolished,2086,O
the,2086,O
reduction,2086,O
in,2086,O
infarct,2086,O
size,2086,O
and,2086,O
improvement,2086,O
in,2086,O
neuroscore,2086,O
.,2086,O
In,2087,O
conclusion,2087,O
",",2087,O
both,2087,O
",",2087,O
candesartan,2087,B-CHEMICAL
or,2087,O
rosuvastatin,2087,B-CHEMICAL
treatment,2087,O
alone,2087,O
reduced,2087,O
infarct,2087,O
size,2087,O
in,2087,O
transient,2087,O
cerebral,2087,O
ischemia,2087,O
",",2087,O
and,2087,O
the,2087,O
best,2087,O
result,2087,O
was,2087,O
achieved,2087,O
with,2087,O
candesartan,2087,B-CHEMICAL
pretreatment,2087,O
.,2087,O
Combined,2088,O
treatment,2088,O
was,2088,O
superior,2088,O
to,2088,O
rosuvastatin,2088,B-CHEMICAL
alone,2088,O
",",2088,O
but,2088,O
not,2088,O
to,2088,O
candesartan,2088,B-CHEMICAL
.,2088,O
The,2089,O
therapeutic,2089,O
benefit,2089,O
of,2089,O
both,2089,O
agents,2089,O
was,2089,O
at,2089,O
least,2089,O
in,2089,O
parts,2089,O
mediated,2089,O
by,2089,O
eNOS-activation,2089,B-GENE-Y
.,2089,O
ABCA12,2090,B-GENE-Y
is,2090,O
the,2090,O
major,2090,O
harlequin,2090,O
ichthyosis,2090,O
gene,2090,O
.,2090,O
Harlequin,2091,O
ichthyosis,2091,O
(,2091,O
HI,2091,O
),2091,O
is,2091,O
the,2091,O
most,2091,O
severe,2091,O
form,2091,O
of,2091,O
autosomal-recessive,2091,O
",",2091,O
congenital,2091,O
ichthyosis,2091,O
.,2091,O
Affected,2092,O
infants,2092,O
have,2092,O
markedly,2092,O
impaired,2092,O
barrier,2092,O
function,2092,O
and,2092,O
are,2092,O
more,2092,O
susceptible,2092,O
to,2092,O
infection,2092,O
.,2092,O
Abnormalities,2093,O
in,2093,O
the,2093,O
localization,2093,O
of,2093,O
epidermal,2093,O
lipids,2093,O
as,2093,O
well,2093,O
as,2093,O
abnormal,2093,O
lamellar,2093,O
granule,2093,O
formation,2093,O
are,2093,O
features,2093,O
of,2093,O
HI,2093,O
skin,2093,O
.,2093,O
Previously,2094,O
",",2094,O
we,2094,O
and,2094,O
others,2094,O
have,2094,O
shown,2094,O
that,2094,O
mutations,2094,O
in,2094,O
the,2094,O
ABCA12,2094,B-GENE-Y
gene,2094,O
encoding,2094,O
an,2094,O
adenosine,2094,B-GENE-N
triphosphate-binding,2094,I-GENE-N
cassette,2094,I-GENE-N
(,2094,I-GENE-N
ABC,2094,I-GENE-N
),2094,I-GENE-N
transporter,2094,I-GENE-N
underlie,2094,O
the,2094,O
skin,2094,O
disease,2094,O
HI,2094,O
.,2094,O
In,2095,O
this,2095,O
study,2095,O
",",2095,O
we,2095,O
have,2095,O
sequenced,2095,O
the,2095,O
ABCA12,2095,B-GENE-Y
gene,2095,O
in,2095,O
an,2095,O
additional,2095,O
14,2095,O
patients,2095,O
and,2095,O
show,2095,O
that,2095,O
all,2095,O
contain,2095,O
mutations,2095,O
",",2095,O
with,2095,O
the,2095,O
majority,2095,O
being,2095,O
either,2095,O
nonsense,2095,O
substitution,2095,O
or,2095,O
frameshift,2095,O
mutations,2095,O
.,2095,O
Eleven,2096,O
HI,2096,O
patients,2096,O
had,2096,O
bi-allelic,2096,O
ABCA12,2096,B-GENE-Y
mutations,2096,O
",",2096,O
whereas,2096,O
in,2096,O
the,2096,O
remaining,2096,O
three,2096,O
HI,2096,O
patients,2096,O
in,2096,O
this,2096,O
study,2096,O
",",2096,O
ABCA12,2096,B-GENE-Y
mutations,2096,O
were,2096,O
detected,2096,O
on,2096,O
only,2096,O
one,2096,O
allele,2096,O
by,2096,O
sequencing,2096,O
.,2096,O
In,2097,O
addition,2097,O
",",2097,O
the,2097,O
one,2097,O
patient,2097,O
from,2097,O
the,2097,O
previous,2097,O
study,2097,O
where,2097,O
no,2097,O
sequence,2097,O
mutations,2097,O
were,2097,O
detected,2097,O
was,2097,O
screened,2097,O
for,2097,O
heterozygous,2097,O
deletions,2097,O
.,2097,O
A,2098,O
combination,2098,O
of,2098,O
oligonucleotide,2098,O
arrays,2098,O
",",2098,O
multiplex,2098,O
PCR,2098,O
analysis,2098,O
and,2098,O
single-nucleotide,2098,O
polymorphism,2098,O
genotyping,2098,O
revealed,2098,O
a,2098,O
heterozygous,2098,O
intragenic,2098,O
deletion,2098,O
in,2098,O
exon,2098,O
8,2098,O
.,2098,O
These,2099,O
mutation,2099,O
data,2099,O
establish,2099,O
ABCA12,2099,B-GENE-Y
as,2099,O
the,2099,O
major,2099,O
HI,2099,O
gene,2099,O
.,2099,O
Phosphorylation,2100,O
and,2100,O
up-regulation,2100,O
of,2100,O
diacylglycerol,2100,B-GENE-Y
kinase,2100,I-GENE-Y
gamma,2100,I-GENE-Y
via,2100,O
its,2100,O
interaction,2100,O
with,2100,O
protein,2100,B-GENE-Y
kinase,2100,I-GENE-Y
C,2100,I-GENE-Y
gamma,2100,I-GENE-Y
.,2100,O
Diacylglycerol,2101,B-CHEMICAL
(,2101,O
DAG,2101,B-CHEMICAL
),2101,O
acts,2101,O
as,2101,O
an,2101,O
allosteric,2101,O
activator,2101,O
of,2101,O
protein,2101,B-GENE-N
kinase,2101,I-GENE-N
C,2101,I-GENE-N
(,2101,O
PKC,2101,B-GENE-N
),2101,O
and,2101,O
is,2101,O
converted,2101,O
to,2101,O
phosphatidic,2101,B-CHEMICAL
acid,2101,I-CHEMICAL
by,2101,O
DAG,2101,B-GENE-N
kinase,2101,I-GENE-N
(,2101,O
DGK,2101,B-GENE-N
),2101,O
.,2101,O
Therefore,2102,O
",",2102,O
DGK,2102,B-GENE-N
is,2102,O
thought,2102,O
to,2102,O
be,2102,O
a,2102,O
negative,2102,O
regulator,2102,O
of,2102,O
PKC,2102,B-GENE-N
activation,2102,O
.,2102,O
Here,2103,O
we,2103,O
show,2103,O
molecular,2103,O
mechanisms,2103,O
of,2103,O
functional,2103,O
coupling,2103,O
of,2103,O
the,2103,O
two,2103,O
kinases,2103,B-GENE-N
.,2103,O
gammaPKC,2104,B-GENE-Y
directly,2104,O
associated,2104,O
with,2104,O
DGKgamma,2104,B-GENE-Y
through,2104,O
its,2104,O
accessory,2104,O
domain,2104,O
(,2104,O
AD,2104,O
),2104,O
",",2104,O
depending,2104,O
on,2104,O
Ca2+,2104,B-CHEMICAL
as,2104,O
well,2104,O
as,2104,O
phosphatidylserine/diolein,2104,B-CHEMICAL
in,2104,O
vitro,2104,O
.,2104,O
Mass,2105,O
spectrometric,2105,O
analysis,2105,O
and,2105,O
mutation,2105,O
studies,2105,O
revealed,2105,O
that,2105,O
gammaPKC,2105,B-GENE-Y
phosphorylated,2105,B-CHEMICAL
Ser-776,2105,O
and,2105,O
Ser-779,2105,B-CHEMICAL
in,2105,O
the,2105,O
AD,2105,O
of,2105,O
DGKgamma,2105,B-GENE-Y
.,2105,O
The,2106,O
phosphorylation,2106,O
by,2106,O
gammaPKC,2106,B-GENE-Y
resulted,2106,O
in,2106,O
activation,2106,O
of,2106,O
DGKgamma,2106,B-GENE-Y
because,2106,O
a,2106,O
DGKgamma,2106,B-GENE-Y
mutant,2106,O
in,2106,O
which,2106,O
Ser-776,2106,B-CHEMICAL
and,2106,O
Ser-779,2106,B-CHEMICAL
were,2106,O
substituted,2106,O
with,2106,O
glutamic,2106,B-CHEMICAL
acid,2106,I-CHEMICAL
to,2106,O
mimic,2106,O
phosphorylation,2106,O
exhibited,2106,O
significantly,2106,O
higher,2106,O
activity,2106,O
compared,2106,O
with,2106,O
wild,2106,O
type,2106,O
DGKgamma,2106,B-GENE-Y
and,2106,O
an,2106,O
unphosphorylatable,2106,O
DGKgamma,2106,B-GENE-Y
mutant,2106,O
.,2106,O
Importantly,2107,O
",",2107,O
the,2107,O
interaction,2107,O
of,2107,O
the,2107,O
two,2107,O
kinases,2107,B-GENE-N
and,2107,O
the,2107,O
phosphorylation,2107,O
of,2107,O
DGKgamma,2107,B-GENE-Y
by,2107,O
gammaPKC,2107,B-GENE-Y
could,2107,O
be,2107,O
confirmed,2107,O
in,2107,O
vivo,2107,O
",",2107,O
and,2107,O
overexpression,2107,O
of,2107,O
the,2107,O
AD,2107,O
of,2107,O
DGKgamma,2107,B-GENE-Y
inhibited,2107,O
re-translocation,2107,O
of,2107,O
gammaPKC,2107,B-GENE-Y
.,2107,O
These,2108,O
results,2108,O
demonstrate,2108,O
that,2108,O
localization,2108,O
and,2108,O
activation,2108,O
of,2108,O
the,2108,O
functionally,2108,O
correlated,2108,O
kinases,2108,B-GENE-N
",",2108,O
gammaPKC,2108,B-GENE-Y
and,2108,O
DGKgamma,2108,B-GENE-Y
",",2108,O
are,2108,O
spatio-temporally,2108,O
orchestrated,2108,O
by,2108,O
their,2108,O
direct,2108,O
association,2108,O
and,2108,O
phosphorylation,2108,O
",",2108,O
contributing,2108,O
to,2108,O
subtype-specific,2108,O
regulation,2108,O
of,2108,O
DGKgamma,2108,B-GENE-Y
and,2108,O
DAG,2108,O
signaling,2108,O
.,2108,O
Differences,2109,O
in,2109,O
conformational,2109,O
stability,2109,O
between,2109,O
native,2109,O
and,2109,O
phosphorylated,2109,B-GENE-Y
acetylcholinesterase,2109,I-GENE-Y
as,2109,O
evidenced,2109,O
by,2109,O
a,2109,O
monoclonal,2109,O
antibody,2109,O
.,2109,O
Monoclonal,2110,O
antibody,2110,O
25B1,2110,O
generated,2110,O
against,2110,O
diisopropyl,2110,B-CHEMICAL
phosphorofluoridate,2110,I-CHEMICAL
inhibited,2110,O
fetal,2110,O
bovine,2110,B-GENE-Y
serum,2110,I-GENE-Y
acetylcholinesterase,2110,I-GENE-Y
has,2110,O
been,2110,O
extensively,2110,O
characterized,2110,O
with,2110,O
respect,2110,O
to,2110,O
its,2110,O
anticholinesterase,2110,B-GENE-Y
properties,2110,O
.,2110,O
This,2111,O
antibody,2111,O
demonstrated,2111,O
considerably,2111,O
different,2111,O
properties,2111,O
from,2111,O
previously,2111,O
reported,2111,O
inhibitory,2111,O
antibodies,2111,O
raised,2111,O
against,2111,O
acetylcholinesterase,2111,B-GENE-Y
in,2111,O
terms,2111,O
of,2111,O
the,2111,O
degree,2111,O
of,2111,O
inhibition,2111,O
(,2111,O
greater,2111,O
than,2111,O
98,2111,O
%,2111,O
),2111,O
",",2111,O
the,2111,O
high,2111,O
degree,2111,O
of,2111,O
specificity,2111,O
",",2111,O
and,2111,O
the,2111,O
stability,2111,O
of,2111,O
the,2111,O
antigen-antibody,2111,O
complex,2111,O
.,2111,O
Monoclonal,2112,O
antibody,2112,O
25B1,2112,O
appears,2112,O
to,2112,O
be,2112,O
directed,2112,O
against,2112,O
a,2112,O
conformational,2112,O
epitope,2112,O
located,2112,O
in,2112,O
close,2112,O
proximity,2112,O
to,2112,O
the,2112,O
catalytic,2112,O
center,2112,O
of,2112,O
the,2112,O
enzyme,2112,O
and,2112,O
was,2112,O
found,2112,O
to,2112,O
be,2112,O
most,2112,O
suitable,2112,O
for,2112,O
studying,2112,O
the,2112,O
stabilization,2112,O
of,2112,O
the,2112,O
active,2112,O
site,2112,O
of,2112,O
acetylcholinesterase,2112,B-GENE-Y
against,2112,O
denaturation,2112,O
by,2112,O
heat,2112,O
or,2112,O
guanidine,2112,B-CHEMICAL
following,2112,O
phosphorylation,2112,O
by,2112,O
organophosphorus,2112,O
anticholinesterase,2112,B-GENE-Y
compounds,2112,O
.,2112,O
This,2113,O
approach,2113,O
allowed,2113,O
the,2113,O
determination,2113,O
of,2113,O
stability,2113,O
rank,2113,O
order,2113,O
of,2113,O
various,2113,O
phosphorylated,2113,B-GENE-N
acetylcholinesterases,2113,I-GENE-N
.,2113,O
Among,2114,O
all,2114,O
the,2114,O
organophosphates,2114,B-CHEMICAL
tested,2114,O
",",2114,O
the,2114,O
combination,2114,O
of,2114,O
a,2114,O
methyl,2114,O
group,2114,O
and,2114,O
a,2114,O
negatively,2114,O
charged,2114,O
oxygen,2114,B-CHEMICAL
attached,2114,O
to,2114,O
the,2114,O
P,2114,B-CHEMICAL
atom,2114,O
",",2114,O
CH3P,2114,B-CHEMICAL
(,2114,I-CHEMICAL
O,2114,I-CHEMICAL
),2114,I-CHEMICAL
(,2114,I-CHEMICAL
O-,2114,I-CHEMICAL
),2114,I-CHEMICAL
-AChE,2114,O
",",2114,O
conferred,2114,O
the,2114,O
greatest,2114,O
protection,2114,O
to,2114,O
the,2114,O
active,2114,O
site,2114,O
of,2114,O
aged,2114,O
or,2114,O
nonaged,2114,O
organophosphoryl,2114,B-CHEMICAL
conjugates,2114,O
of,2114,O
acetylcholinesterase,2114,B-GENE-Y
.,2114,O
Effects,2115,O
of,2115,O
folic,2115,B-CHEMICAL
acid,2115,I-CHEMICAL
deficiency,2115,O
and,2115,O
MTHFR,2115,B-GENE-Y
C677T,2115,B-GENE-N
polymorphism,2115,O
on,2115,O
spontaneous,2115,O
and,2115,O
radiation-induced,2115,O
micronuclei,2115,O
in,2115,O
human,2115,O
lymphocytes,2115,O
.,2115,O
Folic,2116,B-CHEMICAL
acid,2116,I-CHEMICAL
plays,2116,O
a,2116,O
key,2116,O
role,2116,O
in,2116,O
the,2116,O
maintenance,2116,O
of,2116,O
genomic,2116,O
stability,2116,O
",",2116,O
providing,2116,O
methyl,2116,O
groups,2116,O
for,2116,O
the,2116,O
conversion,2116,O
of,2116,O
uracil,2116,B-CHEMICAL
to,2116,O
thymine,2116,B-CHEMICAL
and,2116,O
for,2116,O
DNA,2116,O
methylation,2116,O
.,2116,O
Besides,2117,O
dietary,2117,O
habits,2117,O
",",2117,O
folic,2117,B-CHEMICAL
acid,2117,I-CHEMICAL
metabolism,2117,O
is,2117,O
influenced,2117,O
by,2117,O
genetic,2117,O
polymorphism,2117,O
.,2117,O
The,2118,O
C677T,2118,B-GENE-N
polymorphism,2118,O
of,2118,O
the,2118,O
methylene-tetrahydrofolate,2118,B-GENE-Y
reductase,2118,I-GENE-Y
(,2118,O
MTHFR,2118,B-GENE-Y
),2118,O
gene,2118,O
is,2118,O
associated,2118,O
with,2118,O
a,2118,O
reduction,2118,O
of,2118,O
catalytic,2118,O
activity,2118,O
and,2118,O
is,2118,O
suggested,2118,O
to,2118,O
modify,2118,O
cancer,2118,O
risk,2118,O
differently,2118,O
depending,2118,O
on,2118,O
folate,2118,B-CHEMICAL
status,2118,O
.,2118,O
In,2119,O
this,2119,O
work,2119,O
the,2119,O
effect,2119,O
of,2119,O
folic,2119,B-CHEMICAL
acid,2119,I-CHEMICAL
deficiency,2119,O
on,2119,O
genome,2119,O
stability,2119,O
and,2119,O
radiosensitivity,2119,O
has,2119,O
been,2119,O
investigated,2119,O
in,2119,O
cultured,2119,O
lymphocytes,2119,O
of,2119,O
12,2119,O
subjects,2119,O
with,2119,O
different,2119,O
MTHFR,2119,B-GENE-Y
genotype,2119,O
(,2119,O
four,2119,O
for,2119,O
each,2119,O
genotype,2119,O
),2119,O
.,2119,O
Cells,2120,O
were,2120,O
grown,2120,O
for,2120,O
9,2120,O
days,2120,O
with,2120,O
12,2120,O
",",2120,O
24,2120,O
and,2120,O
120,2120,O
nM,2120,O
folic,2120,B-CHEMICAL
acid,2120,I-CHEMICAL
and,2120,O
analyzed,2120,O
in,2120,O
a,2120,O
comprehensive,2120,O
micronucleus,2120,O
test,2120,O
coupled,2120,O
with,2120,O
centromere,2120,O
characterization,2120,O
by,2120,O
CREST,2120,O
immunostaining,2120,O
.,2120,O
In,2121,O
other,2121,O
experiments,2121,O
",",2121,O
cells,2121,O
were,2121,O
grown,2121,O
with,2121,O
various,2121,O
folic,2121,B-CHEMICAL
acid,2121,I-CHEMICAL
concentrations,2121,O
",",2121,O
irradiated,2121,O
with,2121,O
0.5,2121,O
Gy,2121,O
of,2121,O
gamma,2121,O
rays,2121,O
and,2121,O
analyzed,2121,O
in,2121,O
the,2121,O
micronucleus,2121,O
test,2121,O
.,2121,O
The,2122,O
results,2122,O
obtained,2122,O
indicate,2122,O
that,2122,O
folic,2122,B-CHEMICAL
acid,2122,I-CHEMICAL
deficiency,2122,O
induces,2122,O
to,2122,O
a,2122,O
comparable,2122,O
extent,2122,O
chromosome,2122,O
loss,2122,O
and,2122,O
breakage,2122,O
",",2122,O
irrespective,2122,O
of,2122,O
the,2122,O
MTHFR,2122,B-GENE-Y
genotype,2122,O
.,2122,O
The,2123,O
effect,2123,O
of,2123,O
folic,2123,B-CHEMICAL
acid,2123,I-CHEMICAL
was,2123,O
highly,2123,O
significant,2123,O
(,2123,O
P,2123,O
<,2123,O
0.001,2123,O
),2123,O
and,2123,O
explained,2123,O
>,2123,O
50,2123,O
%,2123,O
of,2123,O
variance,2123,O
of,2123,O
both,2123,O
types,2123,O
of,2123,O
micronuclei,2123,O
.,2123,O
Also,2124,O
nucleoplasmic,2124,O
bridges,2124,O
and,2124,O
buds,2124,O
were,2124,O
significantly,2124,O
increased,2124,O
under,2124,O
low,2124,O
folate,2124,B-CHEMICAL
supply,2124,O
;,2124,O
the,2124,O
increase,2124,O
in,2124,O
bridges,2124,O
was,2124,O
mainly,2124,O
observed,2124,O
in,2124,O
TT,2124,O
cells,2124,O
",",2124,O
highlighting,2124,O
a,2124,O
significant,2124,O
effect,2124,O
of,2124,O
the,2124,O
MTHFR,2124,B-GENE-Y
genotype,2124,O
(,2124,O
P,2124,O
=,2124,O
0.006,2124,O
),2124,O
on,2124,O
this,2124,O
biomarker,2124,O
.,2124,O
Folic,2125,B-CHEMICAL
acid,2125,I-CHEMICAL
concentration,2125,O
significantly,2125,O
affected,2125,O
radiation-induced,2125,O
micronuclei,2125,O
(,2125,O
P,2125,O
<,2125,O
0.001,2125,O
),2125,O
:,2125,O
the,2125,O
increased,2125,O
incidence,2125,O
of,2125,O
radiation-induced,2125,O
micronuclei,2125,O
with,2125,O
low,2125,O
folic,2125,B-CHEMICAL
acid,2125,I-CHEMICAL
was,2125,O
mainly,2125,O
accounted,2125,O
for,2125,O
by,2125,O
carriers,2125,O
of,2125,O
the,2125,O
variant,2125,O
MTHFR,2125,B-GENE-Y
allele,2125,O
(,2125,O
both,2125,O
homozygotes,2125,O
and,2125,O
heterozygotes,2125,O
),2125,O
",",2125,O
but,2125,O
the,2125,O
overall,2125,O
effect,2125,O
of,2125,O
genotype,2125,O
did,2125,O
not,2125,O
attain,2125,O
statistical,2125,O
significance,2125,O
.,2125,O
Treatment,2126,O
with,2126,O
ionizing,2126,O
radiations,2126,O
also,2126,O
increased,2126,O
the,2126,O
frequency,2126,O
of,2126,O
nucleoplasmic,2126,O
bridges,2126,O
.,2126,O
The,2127,O
effect,2127,O
of,2127,O
folic,2127,B-CHEMICAL
acid,2127,I-CHEMICAL
level,2127,O
on,2127,O
this,2127,O
end-point,2127,O
was,2127,O
modulated,2127,O
by,2127,O
the,2127,O
MTHFR,2127,B-GENE-Y
genotype,2127,O
(,2127,O
P,2127,O
for,2127,O
interaction,2127,O
=,2127,O
0.02,2127,O
),2127,O
",",2127,O
with,2127,O
TT,2127,O
cells,2127,O
grown,2127,O
at,2127,O
low,2127,O
folic,2127,B-CHEMICAL
acid,2127,I-CHEMICAL
concentration,2127,O
apparently,2127,O
resistant,2127,O
to,2127,O
the,2127,O
induction,2127,O
of,2127,O
radiation-induced,2127,O
bridges,2127,O
.,2127,O
Finally,2128,O
",",2128,O
the,2128,O
effect,2128,O
of,2128,O
in,2128,O
vitro,2128,O
folate,2128,B-CHEMICAL
deprivation,2128,O
on,2128,O
global,2128,O
DNA,2128,O
methylation,2128,O
was,2128,O
evaluated,2128,O
in,2128,O
lymphocytes,2128,O
of,2128,O
six,2128,O
homozygous,2128,O
subjects,2128,O
(,2128,O
three,2128,O
CC,2128,O
and,2128,O
three,2128,O
TT,2128,O
),2128,O
.,2128,O
The,2129,O
results,2129,O
obtained,2129,O
suggest,2129,O
that,2129,O
",",2129,O
under,2129,O
the,2129,O
conditions,2129,O
of,2129,O
this,2129,O
work,2129,O
",",2129,O
folic,2129,B-CHEMICAL
acid,2129,I-CHEMICAL
deprivation,2129,O
is,2129,O
associated,2129,O
with,2129,O
global,2129,O
DNA,2129,O
hypermethylation,2129,O
.,2129,O
Antifungal,2130,O
agents,2130,O
:,2130,O
mode,2130,O
of,2130,O
action,2130,O
in,2130,O
yeast,2130,O
cells,2130,O
.,2130,O
Different,2131,O
kinds,2131,O
of,2131,O
mycoses,2131,O
",",2131,O
especially,2131,O
invasive,2131,O
",",2131,O
have,2131,O
become,2131,O
an,2131,O
important,2131,O
public,2131,O
health,2131,O
problem,2131,O
as,2131,O
their,2131,O
incidence,2131,O
has,2131,O
increased,2131,O
dramatically,2131,O
in,2131,O
the,2131,O
last,2131,O
decades,2131,O
in,2131,O
relation,2131,O
to,2131,O
AIDS,2131,O
",",2131,O
hematological,2131,O
malignancies,2131,O
",",2131,O
transplant,2131,O
recipients,2131,O
and,2131,O
other,2131,O
immunosuppressed,2131,O
individuals,2131,O
.,2131,O
Management,2132,O
of,2132,O
fungal,2132,O
infections,2132,O
is,2132,O
markedly,2132,O
limited,2132,O
by,2132,O
problems,2132,O
of,2132,O
drug,2132,O
safety,2132,O
",",2132,O
resistance,2132,O
and,2132,O
effectiveness,2132,O
profile,2132,O
.,2132,O
Current,2133,O
therapy,2133,O
for,2133,O
invasive,2133,O
mycoses,2133,O
uses,2133,O
a,2133,O
relatively,2133,O
reduced,2133,O
number,2133,O
of,2133,O
antifungal,2133,O
drugs,2133,O
",",2133,O
such,2133,O
as,2133,O
amphotericin,2133,B-CHEMICAL
B,2133,I-CHEMICAL
",",2133,O
fluconazole,2133,B-CHEMICAL
and,2133,O
itraconazole,2133,B-CHEMICAL
.,2133,O
Other,2134,O
new,2134,O
antifungal,2134,O
agents,2134,O
from,2134,O
old,2134,O
and,2134,O
new,2134,O
chemical,2134,O
families,2134,O
",",2134,O
like,2134,O
voriconazole,2134,B-CHEMICAL
",",2134,O
posaconazole,2134,B-CHEMICAL
",",2134,O
ravuconazole,2134,B-CHEMICAL
",",2134,O
caspofungin,2134,B-CHEMICAL
and,2134,O
micafungin,2134,B-CHEMICAL
",",2134,O
have,2134,O
been,2134,O
introduced,2134,O
into,2134,O
the,2134,O
armamentarium,2134,O
for,2134,O
fungal,2134,O
infections,2134,O
management,2134,O
.,2134,O
This,2135,O
review,2135,O
is,2135,O
focused,2135,O
on,2135,O
the,2135,O
mode,2135,O
of,2135,O
action,2135,O
of,2135,O
those,2135,O
antifungal,2135,O
drugs,2135,O
used,2135,O
against,2135,O
pathogenic,2135,O
yeasts,2135,O
.,2135,O
The,2136,O
interaction,2136,O
of,2136,O
amphotericin,2136,B-CHEMICAL
B,2136,I-CHEMICAL
with,2136,O
ergosterol,2136,B-CHEMICAL
and,2136,O
other,2136,O
membrane,2136,O
sterols,2136,B-CHEMICAL
results,2136,O
in,2136,O
the,2136,O
production,2136,O
of,2136,O
aqueous,2136,O
pores,2136,O
of,2136,O
drug,2136,O
and,2136,O
the,2136,O
ergosterol,2136,B-CHEMICAL
biosynthetic,2136,O
pathway,2136,O
is,2136,O
the,2136,O
target,2136,O
of,2136,O
the,2136,O
allylamines,2136,B-CHEMICAL
",",2136,O
phenylmorpholines,2136,B-CHEMICAL
and,2136,O
azole,2136,B-CHEMICAL
antifungal,2136,O
agents,2136,O
.,2136,O
The,2137,O
main,2137,O
molecular,2137,O
target,2137,O
of,2137,O
azole,2137,B-CHEMICAL
antifungals,2137,O
is,2137,O
the,2137,O
cytochrome,2137,B-GENE-N
P-450,2137,I-GENE-N
protein,2137,O
Erg11p/Cyp51p,2137,B-GENE-N
.,2137,O
Echinocandins,2138,O
",",2138,O
a,2138,O
new,2138,O
class,2138,O
of,2138,O
antifungal,2138,O
drugs,2138,O
",",2138,O
are,2138,O
fungal,2138,O
secondary,2138,O
metabolites,2138,O
that,2138,O
act,2138,O
against,2138,O
beta-1-3-D-glucan,2138,O
synthesis,2138,O
.,2138,O
The,2139,O
phenylmorpholines,2139,B-CHEMICAL
",",2139,O
of,2139,O
which,2139,O
amorolfine,2139,B-CHEMICAL
is,2139,O
the,2139,O
sole,2139,O
representative,2139,O
in,2139,O
human,2139,O
therapy,2139,O
",",2139,O
affect,2139,O
two,2139,O
targets,2139,O
in,2139,O
the,2139,O
ergosterol,2139,O
pathway,2139,O
:,2139,O
Erg24p,2139,B-GENE-N
(,2139,O
delta,2139,B-GENE-N
14,2139,I-GENE-N
reductase,2139,I-GENE-N
),2139,O
and,2139,O
Erg2p,2139,B-GENE-N
(,2139,O
delta,2139,B-GENE-N
8-delta,2139,I-GENE-N
7,2139,I-GENE-N
isomerase,2139,I-GENE-N
),2139,O
.,2139,O
The,2140,O
sordarins,2140,B-CHEMICAL
group,2140,O
are,2140,O
protein,2140,O
synthesis,2140,O
inhibitors,2140,O
that,2140,O
work,2140,O
by,2140,O
blocking,2140,O
the,2140,O
function,2140,O
of,2140,O
fungal,2140,B-GENE-N
translation,2140,I-GENE-N
elongation,2140,I-GENE-N
factor,2140,I-GENE-N
2,2140,I-GENE-N
.,2140,O
Other,2141,O
protein,2141,O
inhibitors,2141,O
are,2141,O
zofimarin,2141,B-CHEMICAL
",",2141,O
BE31045,2141,B-CHEMICAL
",",2141,O
SCH57504,2141,B-CHEMICAL
",",2141,O
xylarin,2141,B-CHEMICAL
",",2141,O
hypoxysordarin,2141,B-CHEMICAL
and,2141,O
GR135402,2141,B-CHEMICAL
.,2141,O
In,2142,O
order,2142,O
to,2142,O
overcome,2142,O
the,2142,O
problems,2142,O
derived,2142,O
from,2142,O
the,2142,O
exploitation,2142,O
of,2142,O
azole,2142,B-CHEMICAL
drugs,2142,O
",",2142,O
macrolides,2142,O
and,2142,O
echinocandins,2142,B-CHEMICAL
",",2142,O
novel,2142,O
targets,2142,O
were,2142,O
explored,2142,O
.,2142,O
Proposed,2143,O
antifungal,2143,O
drugs,2143,O
have,2143,O
been,2143,O
developed,2143,O
against,2143,O
potential,2143,O
targets,2143,O
like,2143,O
the,2143,O
N-myristylation,2143,B-CHEMICAL
of,2143,O
fungal,2143,O
proteins,2143,O
",",2143,O
with,2143,O
inhibitors,2143,O
like,2143,O
myristate,2143,B-CHEMICAL
and,2143,O
histidine,2143,B-CHEMICAL
analogues,2143,O
or,2143,O
myristoylpeptide,2143,O
derivatives,2143,O
",",2143,O
aminobenzothiazoles,2143,B-CHEMICAL
",",2143,O
quinolines,2143,B-CHEMICAL
and,2143,O
benzofurans,2143,B-CHEMICAL
.,2143,O
Polymerization,2144,O
of,2144,O
cell,2144,O
wall,2144,O
carbohydrates,2144,O
from,2144,O
uridine,2144,B-CHEMICAL
di-phospho,2144,I-CHEMICAL
sugars,2144,I-CHEMICAL
is,2144,O
another,2144,O
potential,2144,O
target,2144,O
.,2144,O
D-myo-inositol,2145,B-CHEMICAL
1-phosphate,2145,I-CHEMICAL
as,2145,O
a,2145,O
surrogate,2145,O
of,2145,O
D-myo-inositol,2145,B-CHEMICAL
"1,4,5-tris",2145,I-CHEMICAL
phosphate,2145,I-CHEMICAL
to,2145,O
monitor,2145,O
G,2145,B-GENE-N
protein-coupled,2145,I-GENE-N
receptor,2145,I-GENE-N
activation,2145,O
.,2145,O
Phospholipase,2146,B-GENE-N
C,2146,I-GENE-N
beta,2146,I-GENE-N
(,2146,O
PLC-beta,2146,B-GENE-N
),2146,O
-coupled,2146,O
G,2146,B-GENE-N
protein-coupled,2146,I-GENE-N
receptor,2146,I-GENE-N
(,2146,O
GPCR,2146,B-GENE-N
),2146,O
activities,2146,O
traditionally,2146,O
are,2146,O
assessed,2146,O
by,2146,O
measuring,2146,O
Ca2+,2146,B-CHEMICAL
triggered,2146,O
by,2146,O
D-myo-inositol,2146,B-CHEMICAL
"1,4,5-trisphosphate",2146,I-CHEMICAL
(,2146,O
IP3,2146,B-CHEMICAL
),2146,O
",",2146,O
a,2146,O
PLC-beta,2146,B-GENE-N
hydrolysis,2146,O
product,2146,O
",",2146,O
or,2146,O
by,2146,O
measuring,2146,O
the,2146,O
production,2146,O
of,2146,O
inositol,2146,B-CHEMICAL
phosphate,2146,I-CHEMICAL
using,2146,O
cumbersome,2146,O
radioactive,2146,O
assays,2146,O
.,2146,O
A,2147,O
specific,2147,O
detection,2147,O
of,2147,O
IP3,2147,B-CHEMICAL
production,2147,O
was,2147,O
also,2147,O
established,2147,O
using,2147,O
IP3,2147,B-CHEMICAL
binding,2147,O
proteins,2147,O
.,2147,O
The,2148,O
short,2148,O
lifetime,2148,O
of,2148,O
IP3,2148,B-CHEMICAL
makes,2148,O
this,2148,O
detection,2148,O
very,2148,O
challenging,2148,O
in,2148,O
measuring,2148,O
GPCR,2148,B-GENE-N
responses,2148,O
.,2148,O
Indeed,2149,O
",",2149,O
this,2149,O
IP3,2149,B-CHEMICAL
rapidly,2149,O
enters,2149,O
the,2149,O
metabolic,2149,O
inositol,2149,B-CHEMICAL
phosphate,2149,I-CHEMICAL
cascade,2149,O
.,2149,O
It,2150,O
has,2150,O
been,2150,O
known,2150,O
for,2150,O
decades,2150,O
that,2150,O
lithium,2150,B-CHEMICAL
chloride,2150,I-CHEMICAL
(,2150,O
LiCl,2150,B-CHEMICAL
),2150,O
leads,2150,O
to,2150,O
D-myo-inositol,2150,B-CHEMICAL
1-phosphate,2150,I-CHEMICAL
accumulation,2150,O
on,2150,O
GPCR,2150,B-GENE-N
activation,2150,O
by,2150,O
inhibiting,2150,O
inositol,2150,B-GENE-N
monophosphatase,2150,I-GENE-N
",",2150,O
the,2150,O
final,2150,O
enzyme,2150,O
of,2150,O
the,2150,O
IP3,2150,B-CHEMICAL
metabolic,2150,O
cascade,2150,O
.,2150,O
We,2151,O
show,2151,O
here,2151,O
that,2151,O
IP1,2151,B-CHEMICAL
can,2151,O
be,2151,O
used,2151,O
as,2151,O
a,2151,O
surrogate,2151,O
of,2151,O
IP3,2151,B-CHEMICAL
to,2151,O
monitor,2151,O
GPCR,2151,B-GENE-N
activation,2151,O
.,2151,O
We,2152,O
developed,2152,O
a,2152,O
novel,2152,O
homogeneous,2152,O
time-resolved,2152,O
fluorescence,2152,O
(,2152,O
HTRF,2152,O
),2152,O
assay,2152,O
that,2152,O
correlates,2152,O
perfectly,2152,O
with,2152,O
existing,2152,O
methods,2152,O
and,2152,O
is,2152,O
easily,2152,O
amenable,2152,O
to,2152,O
high-throughput,2152,O
screening,2152,O
.,2152,O
The,2153,O
IP-One,2153,O
assay,2153,O
was,2153,O
validated,2153,O
on,2153,O
various,2153,O
GPCR,2153,B-GENE-N
models,2153,O
.,2153,O
It,2154,O
has,2154,O
the,2154,O
advantage,2154,O
over,2154,O
the,2154,O
traditional,2154,O
Ca2+,2154,B-CHEMICAL
assay,2154,O
of,2154,O
allowing,2154,O
the,2154,O
measurement,2154,O
of,2154,O
inverse,2154,O
agonist,2154,O
activity,2154,O
as,2154,O
well,2154,O
as,2154,O
the,2154,O
analysis,2154,O
of,2154,O
PLC-beta,2154,B-GENE-N
activity,2154,O
in,2154,O
any,2154,O
nontransfected,2154,O
primary,2154,O
cultures,2154,O
.,2154,O
Finally,2155,O
",",2155,O
the,2155,O
high,2155,O
assay,2155,O
specificity,2155,O
for,2155,O
D-myo-inositol,2155,B-CHEMICAL
1,2155,I-CHEMICAL
monophosphate,2155,I-CHEMICAL
(,2155,O
IP1,2155,B-CHEMICAL
(,2155,O
1,2155,O
),2155,O
),2155,O
opens,2155,O
new,2155,O
possibilities,2155,O
in,2155,O
developing,2155,O
selective,2155,O
assays,2155,O
to,2155,O
study,2155,O
the,2155,O
functional,2155,O
roles,2155,O
of,2155,O
the,2155,O
various,2155,O
isoforms,2155,O
of,2155,O
inositol,2155,B-CHEMICAL
phosphates,2155,I-CHEMICAL
.,2155,O
Non-enzymatic,2156,O
interactions,2156,O
of,2156,O
glyoxylate,2156,B-CHEMICAL
with,2156,O
lysine,2156,B-CHEMICAL
",",2156,O
arginine,2156,B-CHEMICAL
",",2156,O
and,2156,O
glucosamine,2156,B-CHEMICAL
:,2156,O
a,2156,O
study,2156,O
of,2156,O
advanced,2156,O
non-enzymatic,2156,O
glycation,2156,O
like,2156,O
compounds,2156,O
.,2156,O
Glyoxylate,2157,B-CHEMICAL
is,2157,O
a,2157,O
2,2157,O
carbon,2157,B-CHEMICAL
aldo,2157,I-CHEMICAL
acid,2157,I-CHEMICAL
that,2157,O
is,2157,O
formed,2157,O
in,2157,O
hepatic,2157,O
tissue,2157,O
from,2157,O
glycolate,2157,B-CHEMICAL
.,2157,O
Once,2158,O
formed,2158,O
",",2158,O
the,2158,O
molecule,2158,O
can,2158,O
be,2158,O
converted,2158,O
to,2158,O
glycine,2158,B-CHEMICAL
by,2158,O
alanine-glyoxylate,2158,B-CHEMICAL
aminotransferase,2158,I-GENE-Y
(,2158,O
AGAT,2158,B-GENE-Y
),2158,O
.,2158,O
In,2159,O
defects,2159,O
of,2159,O
AGAT,2159,B-GENE-Y
",",2159,O
glyoxylate,2159,B-CHEMICAL
is,2159,O
transformed,2159,O
to,2159,O
oxalate,2159,B-CHEMICAL
",",2159,O
resulting,2159,O
in,2159,O
high,2159,O
levels,2159,O
of,2159,O
oxalate,2159,B-CHEMICAL
in,2159,O
the,2159,O
body,2159,O
.,2159,O
The,2160,O
objective,2160,O
of,2160,O
this,2160,O
study,2160,O
was,2160,O
2-fold,2160,O
.,2160,O
First,2161,O
",",2161,O
it,2161,O
was,2161,O
to,2161,O
determine,2161,O
",",2161,O
if,2161,O
akin,2161,O
to,2161,O
D-glucose,2161,B-CHEMICAL
",",2161,O
D-fructose,2161,B-CHEMICAL
or,2161,O
DL-glyceraldehyde,2161,B-CHEMICAL
",",2161,O
glyoxylate,2161,B-CHEMICAL
was,2161,O
susceptible,2161,O
to,2161,O
non-enzymatic,2161,O
attack,2161,O
by,2161,O
amino,2161,B-CHEMICAL
containing,2161,O
molecules,2161,O
such,2161,O
as,2161,O
lysine,2161,B-CHEMICAL
",",2161,O
arginine,2161,B-CHEMICAL
or,2161,O
glucosamine,2161,B-CHEMICAL
.,2161,O
Second,2162,O
",",2162,O
if,2162,O
by,2162,O
virtue,2162,O
of,2162,O
its,2162,O
molecular,2162,O
structure,2162,O
and,2162,O
size,2162,O
",",2162,O
glyoxylate,2162,B-CHEMICAL
was,2162,O
as,2162,O
reactive,2162,O
a,2162,O
reagent,2162,O
in,2162,O
non-enzymatic,2162,O
reactions,2162,O
as,2162,O
DL-glyceraldehyde,2162,B-CHEMICAL
;,2162,O
i.e.,2162,O
",",2162,O
a,2162,O
glycose,2162,B-CHEMICAL
that,2162,O
we,2162,O
previously,2162,O
demonstrated,2162,O
to,2162,O
be,2162,O
a,2162,O
more,2162,O
effective,2162,O
glycating,2162,O
agent,2162,O
than,2162,O
D-glucose,2162,B-CHEMICAL
or,2162,O
D-fructose,2162,B-CHEMICAL
.,2162,O
Using,2163,O
capillary,2163,O
electrophoresis,2163,O
(,2163,O
CE,2163,O
),2163,O
",",2163,O
high,2163,O
performance,2163,O
liquid,2163,O
chromatography,2163,O
and,2163,O
UV,2163,O
and,2163,O
fluorescence,2163,O
spectroscopy,2163,O
",",2163,O
glyoxylate,2163,B-CHEMICAL
was,2163,O
found,2163,O
to,2163,O
be,2163,O
a,2163,O
highly,2163,O
reactive,2163,O
precursor,2163,O
of,2163,O
advanced,2163,O
glycation,2163,O
like,2163,O
end,2163,O
products,2163,O
(,2163,O
AGLEs,2163,O
),2163,O
and,2163,O
a,2163,O
more,2163,O
effective,2163,O
promoter,2163,O
of,2163,O
non-enzymatic,2163,O
end,2163,O
products,2163,O
than,2163,O
D-glucose,2163,B-CHEMICAL
",",2163,O
D-fructose,2163,B-CHEMICAL
or,2163,O
DL-glyceraldehyde,2163,B-CHEMICAL
.,2163,O
Cortisol,2164,B-CHEMICAL
metabolism,2164,O
in,2164,O
hypertension,2164,O
.,2164,O
Corticosteroids,2165,B-CHEMICAL
are,2165,O
critically,2165,O
involved,2165,O
in,2165,O
blood,2165,O
pressure,2165,O
regulation,2165,O
.,2165,O
Lack,2166,O
of,2166,O
adrenal,2166,O
steroids,2166,B-CHEMICAL
in,2166,O
Addison,2166,O
's,2166,O
disease,2166,O
causes,2166,O
life-threatening,2166,O
hypotension,2166,O
",",2166,O
whereas,2166,O
glucocorticoid,2166,O
excess,2166,O
in,2166,O
Cushing,2166,O
's,2166,O
syndrome,2166,O
invariably,2166,O
results,2166,O
in,2166,O
high,2166,O
blood,2166,O
pressure,2166,O
.,2166,O
At,2167,O
a,2167,O
pre-receptor,2167,O
level,2167,O
",",2167,O
glucocorticoid,2167,O
action,2167,O
is,2167,O
modulated,2167,O
by,2167,O
11beta-hydroxysteroid,2167,B-CHEMICAL
dehydrogenases,2167,I-GENE-N
(,2167,O
11beta-HSDs,2167,B-GENE-N
),2167,O
.,2167,O
11Beta-HSD1,2168,B-GENE-Y
activates,2168,O
cortisone,2168,B-CHEMICAL
to,2168,O
cortisol,2168,B-CHEMICAL
to,2168,O
facilitate,2168,O
glucocorticoid,2168,B-GENE-Y
receptor,2168,I-GENE-Y
(,2168,O
GR,2168,B-GENE-Y
),2168,O
-mediated,2168,O
action,2168,O
.,2168,O
By,2169,O
contrast,2169,O
",",2169,O
11beta-HSD2,2169,B-GENE-Y
plays,2169,O
a,2169,O
pivotal,2169,O
role,2169,O
in,2169,O
aldosterone,2169,B-CHEMICAL
target,2169,O
tissues,2169,O
where,2169,O
it,2169,O
catalyses,2169,O
the,2169,O
opposite,2169,O
reaction,2169,O
(,2169,O
i.e,2169,O
.,2169,O
inactivation,2170,O
of,2170,O
cortisol,2170,B-CHEMICAL
to,2170,O
cortisone,2170,B-CHEMICAL
),2170,O
to,2170,O
prevent,2170,O
activation,2170,O
of,2170,O
the,2170,O
mineralocorticoid,2170,B-GENE-Y
receptor,2170,I-GENE-Y
(,2170,O
MR,2170,B-GENE-Y
),2170,O
by,2170,O
cortisol,2170,B-CHEMICAL
.,2170,O
Mutations,2171,O
in,2171,O
the,2171,O
11beta-HSD2,2171,B-GENE-Y
gene,2171,O
cause,2171,O
a,2171,O
rare,2171,O
form,2171,O
of,2171,O
inherited,2171,O
hypertension,2171,O
",",2171,O
the,2171,O
syndrome,2171,O
of,2171,O
apparent,2171,O
mineralocorticoid,2171,O
excess,2171,O
(,2171,O
AME,2171,O
),2171,O
",",2171,O
in,2171,O
which,2171,O
cortisol,2171,B-CHEMICAL
activates,2171,O
the,2171,O
MR,2171,B-GENE-Y
resulting,2171,O
in,2171,O
severe,2171,O
hypertension,2171,O
and,2171,O
hypokalemia,2171,O
.,2171,O
Ingestion,2172,O
of,2172,O
competitive,2172,O
inhibitors,2172,O
of,2172,O
11beta-HSD2,2172,B-GENE-Y
such,2172,O
as,2172,O
liquorice,2172,O
and,2172,O
carbenoxolone,2172,B-CHEMICAL
result,2172,O
in,2172,O
a,2172,O
similar,2172,O
but,2172,O
milder,2172,O
clinical,2172,O
phenotype,2172,O
.,2172,O
Epidemiological,2173,O
data,2173,O
suggests,2173,O
that,2173,O
polymorphic,2173,O
variability,2173,O
in,2173,O
the,2173,O
HSD11B2,2173,B-GENE-Y
gene,2173,O
determines,2173,O
salt,2173,O
sensitivity,2173,O
in,2173,O
the,2173,O
general,2173,O
population,2173,O
",",2173,O
which,2173,O
is,2173,O
a,2173,O
key,2173,O
predisposing,2173,O
factor,2173,O
to,2173,O
adult,2173,O
onset,2173,O
hypertension,2173,O
in,2173,O
some,2173,O
patients,2173,O
.,2173,O
Extrarenal,2174,O
sites,2174,O
of,2174,O
glucocorticoid,2174,O
action,2174,O
and,2174,O
metabolism,2174,O
that,2174,O
might,2174,O
impact,2174,O
on,2174,O
blood,2174,O
pressure,2174,O
include,2174,O
the,2174,O
vasculature,2174,O
and,2174,O
the,2174,O
central,2174,O
nervous,2174,O
system,2174,O
.,2174,O
Intriguingly,2175,O
",",2175,O
increased,2175,O
exposure,2175,O
to,2175,O
glucocorticoids,2175,O
during,2175,O
fetal,2175,O
life,2175,O
promotes,2175,O
high,2175,O
blood,2175,O
pressure,2175,O
in,2175,O
adulthood,2175,O
suggesting,2175,O
an,2175,O
early,2175,O
programming,2175,O
effect,2175,O
.,2175,O
Thus,2176,O
",",2176,O
metabolism,2176,O
and,2176,O
action,2176,O
in,2176,O
many,2176,O
peripheral,2176,O
tissues,2176,O
might,2176,O
contribute,2176,O
to,2176,O
the,2176,O
pathophysiology,2176,O
of,2176,O
human,2176,O
hypertension,2176,O
.,2176,O
PPARgamma,2177,B-GENE-Y
controls,2177,O
CD1d,2177,B-GENE-Y
expression,2177,O
by,2177,O
turning,2177,O
on,2177,O
retinoic,2177,B-CHEMICAL
acid,2177,I-CHEMICAL
synthesis,2177,O
in,2177,O
developing,2177,O
human,2177,O
dendritic,2177,O
cells,2177,O
.,2177,O
Dendritic,2178,O
cells,2178,O
(,2178,O
DCs,2178,O
),2178,O
expressing,2178,O
CD1d,2178,B-GENE-Y
",",2178,O
a,2178,O
molecule,2178,O
responsible,2178,O
for,2178,O
lipid,2178,O
antigen,2178,O
presentation,2178,O
",",2178,O
are,2178,O
capable,2178,O
of,2178,O
enhancing,2178,O
natural,2178,O
killer,2178,O
T,2178,O
(,2178,O
iNKT,2178,O
),2178,O
cell,2178,O
proliferation,2178,O
.,2178,O
The,2179,O
signals,2179,O
controlling,2179,O
CD1,2179,B-GENE-N
expression,2179,O
and,2179,O
lipid,2179,O
antigen,2179,O
presentation,2179,O
are,2179,O
poorly,2179,O
defined,2179,O
.,2179,O
We,2180,O
have,2180,O
shown,2180,O
previously,2180,O
that,2180,O
stimulation,2180,O
of,2180,O
the,2180,O
lipid-activated,2180,B-GENE-N
transcription,2180,I-GENE-N
factor,2180,I-GENE-N
",",2180,O
peroxisome,2180,B-GENE-Y
proliferator-activated,2180,I-GENE-Y
receptor,2180,I-GENE-Y
(,2180,I-GENE-Y
PPAR,2180,I-GENE-Y
),2180,I-GENE-Y
gamma,2180,I-GENE-Y
",",2180,O
indirectly,2180,O
regulates,2180,O
CD1d,2180,B-GENE-Y
expression,2180,O
.,2180,O
Here,2181,O
we,2181,O
demonstrate,2181,O
that,2181,O
PPARgamma,2181,B-GENE-Y
",",2181,O
turns,2181,O
on,2181,O
retinoic,2181,B-CHEMICAL
acid,2181,I-CHEMICAL
synthesis,2181,O
by,2181,O
inducing,2181,O
the,2181,O
expression,2181,O
of,2181,O
retinol,2181,B-CHEMICAL
and,2181,O
retinal,2181,B-CHEMICAL
metabolizing,2181,O
enzymes,2181,O
such,2181,O
as,2181,O
retinol,2181,B-CHEMICAL
dehydrogenase,2181,I-GENE-Y
10,2181,I-GENE-Y
and,2181,O
retinaldehyde,2181,B-CHEMICAL
dehydrogenase,2181,I-GENE-Y
type,2181,I-GENE-Y
2,2181,I-GENE-Y
(,2181,O
RALDH2,2181,B-GENE-Y
),2181,O
.,2181,O
PPARgamma-regulated,2182,B-GENE-Y
expression,2182,O
of,2182,O
these,2182,O
enzymes,2182,O
leads,2182,O
to,2182,O
an,2182,O
increase,2182,O
in,2182,O
the,2182,O
intracellular,2182,O
generation,2182,O
of,2182,O
all-trans,2182,B-CHEMICAL
retinoic,2182,I-CHEMICAL
acid,2182,I-CHEMICAL
(,2182,O
ATRA,2182,B-CHEMICAL
),2182,O
from,2182,O
retinol,2182,B-CHEMICAL
.,2182,O
ATRA,2183,B-CHEMICAL
regulates,2183,O
gene,2183,O
expression,2183,O
via,2183,O
the,2183,O
activation,2183,O
of,2183,O
the,2183,O
retinoic,2183,B-GENE-Y
acid,2183,I-GENE-Y
receptor,2183,I-GENE-Y
(,2183,I-GENE-Y
RAR,2183,I-GENE-Y
),2183,I-GENE-Y
alpha,2183,I-GENE-Y
in,2183,O
human,2183,O
DCs,2183,O
",",2183,O
and,2183,O
RARalpha,2183,B-GENE-Y
acutely,2183,O
regulates,2183,O
CD1d,2183,B-GENE-Y
expression,2183,O
.,2183,O
The,2184,O
retinoic,2184,B-CHEMICAL
acid-induced,2184,O
elevated,2184,O
expression,2184,O
of,2184,O
CD1d,2184,B-GENE-Y
is,2184,O
coupled,2184,O
to,2184,O
enhanced,2184,O
iNKT,2184,O
cell,2184,O
activation,2184,O
.,2184,O
Furthermore,2185,O
",",2185,O
in,2185,O
vivo,2185,O
relevant,2185,O
lipids,2185,O
such,2185,O
as,2185,O
oxidized,2185,O
low-density,2185,O
lipoprotein,2185,O
can,2185,O
also,2185,O
elicit,2185,O
retinoid,2185,B-CHEMICAL
signaling,2185,O
leading,2185,O
to,2185,O
CD1d,2185,B-GENE-Y
up-regulation,2185,O
.,2185,O
These,2186,O
data,2186,O
show,2186,O
that,2186,O
regulation,2186,O
of,2186,O
retinoid,2186,B-CHEMICAL
metabolism,2186,O
and,2186,O
signaling,2186,O
is,2186,O
part,2186,O
of,2186,O
the,2186,O
PPARgamma-controlled,2186,B-GENE-Y
transcriptional,2186,O
events,2186,O
in,2186,O
DCs,2186,O
.,2186,O
The,2187,O
uncovered,2187,O
mechanisms,2187,O
allow,2187,O
the,2187,O
DCs,2187,O
to,2187,O
respond,2187,O
to,2187,O
altered,2187,O
lipid,2187,O
homeostasis,2187,O
by,2187,O
changing,2187,O
CD1,2187,B-GENE-N
gene,2187,O
expression,2187,O
.,2187,O
Ramelteon,2188,B-CHEMICAL
:,2188,O
a,2188,O
novel,2188,O
hypnotic,2188,O
lacking,2188,O
abuse,2188,O
liability,2188,O
and,2188,O
sedative,2188,O
adverse,2188,O
effects,2188,O
.,2188,O
CONTEXT,2189,O
:,2189,O
Ramelteon,2189,B-CHEMICAL
is,2189,O
a,2189,O
novel,2189,O
MT1,2189,B-GENE-Y
and,2189,O
MT2,2189,B-GENE-Y
melatonin,2189,I-GENE-Y
receptor,2189,I-GENE-Y
selective,2189,O
agonist,2189,O
recently,2189,O
approved,2189,O
for,2189,O
insomnia,2189,O
treatment,2189,O
.,2189,O
Most,2190,O
approved,2190,O
insomnia,2190,O
medications,2190,O
have,2190,O
potential,2190,O
for,2190,O
abuse,2190,O
and,2190,O
cause,2190,O
motor,2190,O
and,2190,O
cognitive,2190,O
impairment,2190,O
.,2190,O
OBJECTIVE,2191,O
:,2191,O
To,2191,O
evaluate,2191,O
the,2191,O
potential,2191,O
for,2191,O
abuse,2191,O
",",2191,O
subjective,2191,O
effects,2191,O
",",2191,O
and,2191,O
motor,2191,O
and,2191,O
cognitive-impairing,2191,O
effects,2191,O
of,2191,O
ramelteon,2191,B-CHEMICAL
compared,2191,O
with,2191,O
triazolam,2191,B-CHEMICAL
",",2191,O
a,2191,O
classic,2191,O
benzodiazepine,2191,B-CHEMICAL
sedative-hypnotic,2191,O
drug,2191,O
.,2191,O
DESIGN,2192,O
:,2192,O
In,2192,O
this,2192,O
double-blind,2192,O
crossover,2192,O
study,2192,O
",",2192,O
each,2192,O
participant,2192,O
received,2192,O
oral,2192,O
doses,2192,O
of,2192,O
ramelteon,2192,B-CHEMICAL
(,2192,O
16,2192,O
",",2192,O
80,2192,O
",",2192,O
or,2192,O
160,2192,O
mg,2192,O
),2192,O
",",2192,O
triazolam,2192,B-CHEMICAL
(,2192,O
0.25,2192,O
",",2192,O
0.5,2192,O
",",2192,O
or,2192,O
0.75,2192,O
mg,2192,O
),2192,O
",",2192,O
and,2192,O
placebo,2192,O
during,2192,O
approximately,2192,O
18,2192,O
days,2192,O
.,2192,O
All,2193,O
participants,2193,O
received,2193,O
each,2193,O
treatment,2193,O
on,2193,O
different,2193,O
days,2193,O
.,2193,O
Most,2194,O
outcome,2194,O
measures,2194,O
were,2194,O
assessed,2194,O
at,2194,O
0.5,2194,O
hours,2194,O
before,2194,O
drug,2194,O
administration,2194,O
and,2194,O
repeatedly,2194,O
up,2194,O
to,2194,O
24,2194,O
hours,2194,O
after,2194,O
drug,2194,O
administration,2194,O
.,2194,O
SETTING,2195,O
:,2195,O
Residential,2195,O
research,2195,O
facility,2195,O
.,2195,O
PARTICIPANTS,2196,O
:,2196,O
Fourteen,2196,O
adults,2196,O
with,2196,O
histories,2196,O
of,2196,O
sedative,2196,O
abuse,2196,O
.,2196,O
MAIN,2197,O
OUTCOME,2197,O
MEASURES,2197,O
:,2197,O
Subject-rated,2197,O
measures,2197,O
included,2197,O
items,2197,O
relevant,2197,O
to,2197,O
potential,2197,O
for,2197,O
abuse,2197,O
(,2197,O
eg,2197,O
",",2197,O
drug,2197,O
liking,2197,O
",",2197,O
street,2197,O
value,2197,O
",",2197,O
and,2197,O
pharmacological,2197,O
classification,2197,O
),2197,O
",",2197,O
as,2197,O
well,2197,O
as,2197,O
assessments,2197,O
of,2197,O
a,2197,O
broad,2197,O
range,2197,O
of,2197,O
stimulant,2197,O
and,2197,O
sedative,2197,O
subjective,2197,O
effects,2197,O
.,2197,O
Observer-rated,2198,O
measures,2198,O
included,2198,O
assessments,2198,O
of,2198,O
sedation,2198,O
and,2198,O
impairment,2198,O
.,2198,O
Motor,2199,O
and,2199,O
cognitive,2199,O
performance,2199,O
measures,2199,O
included,2199,O
psychomotor,2199,O
and,2199,O
memory,2199,O
tasks,2199,O
and,2199,O
a,2199,O
standing,2199,O
balance,2199,O
task,2199,O
.,2199,O
RESULTS,2200,O
:,2200,O
Compared,2200,O
with,2200,O
placebo,2200,O
",",2200,O
ramelteon,2200,B-CHEMICAL
(,2200,O
16,2200,O
",",2200,O
80,2200,O
",",2200,O
and,2200,O
160,2200,O
mg,2200,O
),2200,O
showed,2200,O
no,2200,O
significant,2200,O
effect,2200,O
on,2200,O
any,2200,O
of,2200,O
the,2200,O
subjective,2200,O
effect,2200,O
measures,2200,O
",",2200,O
including,2200,O
those,2200,O
related,2200,O
to,2200,O
potential,2200,O
for,2200,O
abuse,2200,O
.,2200,O
In,2201,O
the,2201,O
pharmacological,2201,O
classification,2201,O
",",2201,O
79,2201,O
%,2201,O
(,2201,O
11/14,2201,O
),2201,O
of,2201,O
subjects,2201,O
identified,2201,O
the,2201,O
highest,2201,O
dose,2201,O
of,2201,O
ramelteon,2201,B-CHEMICAL
as,2201,O
placebo,2201,O
.,2201,O
Similarly,2202,O
",",2202,O
compared,2202,O
with,2202,O
placebo,2202,O
",",2202,O
ramelteon,2202,B-CHEMICAL
had,2202,O
no,2202,O
effect,2202,O
at,2202,O
any,2202,O
dose,2202,O
on,2202,O
any,2202,O
observer-rated,2202,O
or,2202,O
motor,2202,O
and,2202,O
cognitive,2202,O
performance,2202,O
measure,2202,O
.,2202,O
In,2203,O
contrast,2203,O
",",2203,O
triazolam,2203,B-CHEMICAL
showed,2203,O
dose-related,2203,O
effects,2203,O
on,2203,O
a,2203,O
wide,2203,O
range,2203,O
of,2203,O
subject-rated,2203,O
",",2203,O
observer-rated,2203,O
",",2203,O
and,2203,O
motor,2203,O
and,2203,O
cognitive,2203,O
performance,2203,O
measures,2203,O
",",2203,O
consistent,2203,O
with,2203,O
its,2203,O
profile,2203,O
as,2203,O
a,2203,O
sedative,2203,O
drug,2203,O
with,2203,O
abuse,2203,O
liability,2203,O
.,2203,O
CONCLUSION,2204,O
:,2204,O
Ramelteon,2204,B-CHEMICAL
demonstrated,2204,O
no,2204,O
significant,2204,O
effects,2204,O
indicative,2204,O
of,2204,O
potential,2204,O
for,2204,O
abuse,2204,O
or,2204,O
motor,2204,O
and,2204,O
cognitive,2204,O
impairment,2204,O
at,2204,O
up,2204,O
to,2204,O
20,2204,O
times,2204,O
the,2204,O
recommended,2204,O
therapeutic,2204,O
dose,2204,O
and,2204,O
may,2204,O
represent,2204,O
a,2204,O
useful,2204,O
alternative,2204,O
to,2204,O
existing,2204,O
insomnia,2204,O
medications,2204,O
.,2204,O
Inhibition,2205,O
of,2205,O
cardiac,2205,O
voltage-gated,2205,B-GENE-N
sodium,2205,I-GENE-N
channels,2205,I-GENE-N
by,2205,O
grape,2205,O
polyphenols,2205,O
.,2205,O
BACKGROUND,2206,O
AND,2206,O
PURPOSE,2206,O
:,2206,O
The,2206,O
cardiovascular,2206,O
benefits,2206,O
of,2206,O
red,2206,O
wine,2206,O
consumption,2206,O
are,2206,O
often,2206,O
attributed,2206,O
to,2206,O
the,2206,O
antioxidant,2206,O
effects,2206,O
of,2206,O
its,2206,O
polyphenolic,2206,O
constituents,2206,O
",",2206,O
including,2206,O
quercetin,2206,B-CHEMICAL
",",2206,O
catechin,2206,B-CHEMICAL
and,2206,O
resveratrol,2206,B-CHEMICAL
.,2206,O
Inhibition,2207,O
of,2207,O
cardiac,2207,O
voltage-gated,2207,B-GENE-N
sodium,2207,I-GENE-N
channels,2207,I-GENE-N
(,2207,O
VGSCs,2207,B-GENE-N
),2207,O
is,2207,O
antiarrhythmic,2207,O
and,2207,O
cardioprotective,2207,O
.,2207,O
As,2208,O
polyphenols,2208,O
may,2208,O
also,2208,O
modulate,2208,O
ion,2208,O
channels,2208,O
",",2208,O
and,2208,O
possess,2208,O
structural,2208,O
similarities,2208,O
to,2208,O
several,2208,O
antiarrhythmic,2208,O
VGSC,2208,B-GENE-N
inhibitors,2208,O
",",2208,O
we,2208,O
hypothesised,2208,O
that,2208,O
VGSC,2208,B-GENE-N
inhibition,2208,O
may,2208,O
contribute,2208,O
to,2208,O
cardioprotection,2208,O
by,2208,O
these,2208,O
polyphenols,2208,O
.,2208,O
EXPERIMENTAL,2209,O
APPROACH,2209,O
:,2209,O
The,2209,O
whole-cell,2209,O
voltage-clamp,2209,O
technique,2209,O
was,2209,O
used,2209,O
to,2209,O
record,2209,O
peak,2209,O
and,2209,O
late,2209,O
VGSC,2209,B-GENE-N
currents,2209,O
(,2209,O
INa,2209,O
),2209,O
from,2209,O
recombinant,2209,O
human,2209,B-GENE-Y
heart,2209,I-GENE-Y
NaV1.5,2209,I-GENE-Y
channels,2209,O
expressed,2209,O
in,2209,O
tsA201,2209,O
cells,2209,O
.,2209,O
Right,2210,O
ventricular,2210,O
myocytes,2210,O
from,2210,O
rat,2210,O
heart,2210,O
were,2210,O
isolated,2210,O
and,2210,O
single,2210,O
myocytes,2210,O
were,2210,O
field-stimulated,2210,O
.,2210,O
Either,2211,O
calcium,2211,B-CHEMICAL
transients,2211,O
or,2211,O
contractility,2211,O
were,2211,O
measured,2211,O
using,2211,O
the,2211,O
calcium-sensitive,2211,B-CHEMICAL
dye,2211,O
Calcium-Green,2211,B-CHEMICAL
1AM,2211,O
or,2211,O
video,2211,O
edge,2211,O
detection,2211,O
",",2211,O
respectively,2211,O
.,2211,O
KEY,2212,O
RESULTS,2212,O
:,2212,O
The,2212,O
red,2212,O
grape,2212,O
polyphenols,2212,O
quercetin,2212,B-CHEMICAL
",",2212,O
catechin,2212,B-CHEMICAL
and,2212,O
resveratrol,2212,B-CHEMICAL
blocked,2212,O
peak,2212,O
INa,2212,O
with,2212,O
IC50s,2212,O
of,2212,O
19.4,2212,O
microM,2212,O
",",2212,O
76.8,2212,O
microM,2212,O
and,2212,O
77.3,2212,O
microM,2212,O
",",2212,O
respectively,2212,O
.,2212,O
In,2213,O
contrast,2213,O
to,2213,O
lidocaine,2213,B-CHEMICAL
",",2213,O
resveratrol,2213,B-CHEMICAL
did,2213,O
not,2213,O
exhibit,2213,O
any,2213,O
frequency-dependence,2213,O
of,2213,O
peak,2213,O
INa,2213,O
block,2213,O
.,2213,O
Late,2214,O
INa,2214,O
induced,2214,O
by,2214,O
the,2214,O
VGSC,2214,B-GENE-N
long,2214,O
QT,2214,O
mutant,2214,O
R1623Q,2214,B-GENE-N
was,2214,O
reduced,2214,O
by,2214,O
resveratrol,2214,B-CHEMICAL
and,2214,O
quercetin,2214,B-CHEMICAL
.,2214,O
Resveratrol,2215,B-CHEMICAL
and,2215,O
quercetin,2215,B-CHEMICAL
also,2215,O
blocked,2215,O
late,2215,O
INa,2215,O
induced,2215,O
by,2215,O
the,2215,O
toxin,2215,O
",",2215,O
ATX,2215,O
II,2215,O
",",2215,O
with,2215,O
IC50s,2215,O
of,2215,O
26.1,2215,O
microM,2215,O
and,2215,O
24.9,2215,O
microM,2215,O
",",2215,O
respectively,2215,O
.,2215,O
In,2216,O
field-stimulated,2216,O
myocytes,2216,O
",",2216,O
ATXII-induced,2216,O
increases,2216,O
in,2216,O
diastolic,2216,O
calcium,2216,B-CHEMICAL
were,2216,O
prevented,2216,O
and,2216,O
reversed,2216,O
by,2216,O
resveratrol,2216,B-CHEMICAL
.,2216,O
ATXII-induced,2217,O
contractile,2217,O
dysfunction,2217,O
was,2217,O
delayed,2217,O
and,2217,O
reduced,2217,O
by,2217,O
resveratrol,2217,B-CHEMICAL
.,2217,O
CONCLUSIONS,2218,O
AND,2218,O
IMPLICATIONS,2218,O
:,2218,O
Our,2218,O
results,2218,O
indicate,2218,O
that,2218,O
several,2218,O
red,2218,O
grape,2218,O
polyphenols,2218,O
inhibit,2218,O
cardiac,2218,O
VGSCs,2218,B-GENE-N
and,2218,O
that,2218,O
this,2218,O
effect,2218,O
may,2218,O
contribute,2218,O
to,2218,O
the,2218,O
documented,2218,O
cardioprotective,2218,O
efficacy,2218,O
of,2218,O
red,2218,O
grape,2218,O
products,2218,O
.,2218,O
Enhancement,2219,O
of,2219,O
radiosensitivity,2219,O
by,2219,O
topoisomerase,2219,B-GENE-Y
II,2219,I-GENE-Y
inhibitor,2219,O
",",2219,O
amrubicin,2219,B-CHEMICAL
and,2219,O
amrubicinol,2219,B-CHEMICAL
",",2219,O
in,2219,O
human,2219,O
lung,2219,O
adenocarcinoma,2219,O
A549,2219,O
cells,2219,O
and,2219,O
kinetics,2219,O
of,2219,O
apoptosis,2219,O
and,2219,O
necrosis,2219,O
induction,2219,O
.,2219,O
The,2220,O
effects,2220,O
of,2220,O
amrubicin,2220,B-CHEMICAL
(,2220,O
AMR,2220,B-CHEMICAL
),2220,O
and,2220,O
its,2220,O
active,2220,O
metabolite,2220,O
",",2220,O
amrubicinol,2220,B-CHEMICAL
(,2220,O
AMROH,2220,B-CHEMICAL
),2220,O
",",2220,O
on,2220,O
the,2220,O
sensitivity,2220,O
of,2220,O
human,2220,O
lung,2220,O
adenocarcinoma,2220,O
A549,2220,O
cells,2220,O
to,2220,O
ionizing,2220,O
radiation,2220,O
were,2220,O
investigated,2220,O
in,2220,O
vitro,2220,O
.,2220,O
Further,2221,O
",",2221,O
the,2221,O
kinetics,2221,O
of,2221,O
apoptosis,2221,O
and,2221,O
necrosis,2221,O
induction,2221,O
were,2221,O
also,2221,O
analyzed,2221,O
.,2221,O
The,2222,O
cytocidal,2222,O
effects,2222,O
of,2222,O
X-ray,2222,O
irradiation,2222,O
on,2222,O
A549,2222,O
cells,2222,O
resulted,2222,O
in,2222,O
a,2222,O
low,2222,O
level,2222,O
of,2222,O
radiosensitivity,2222,O
with,2222,O
a,2222,O
D0,2222,O
value,2222,O
of,2222,O
12,2222,O
Gy,2222,O
.,2222,O
The,2223,O
slopes,2223,O
of,2223,O
the,2223,O
survival,2223,O
curves,2223,O
in,2223,O
the,2223,O
exponential,2223,O
phase,2223,O
were,2223,O
plotted,2223,O
on,2223,O
semilogarithmic,2223,O
paper,2223,O
for,2223,O
radiation,2223,O
combined,2223,O
with,2223,O
AMR,2223,B-CHEMICAL
(,2223,O
2.5,2223,O
microg/ml,2223,O
),2223,O
and,2223,O
AMROH,2223,B-CHEMICAL
(,2223,O
0.02,2223,O
microg/ml,2223,O
),2223,O
treatment,2223,O
",",2223,O
and,2223,O
were,2223,O
shown,2223,O
to,2223,O
be,2223,O
approximately,2223,O
parallel,2223,O
to,2223,O
treatment,2223,O
with,2223,O
irradiation,2223,O
alone,2223,O
.,2223,O
The,2224,O
initial,2224,O
shoulder-shape,2224,O
portion,2224,O
of,2224,O
the,2224,O
survival,2224,O
curve,2224,O
for,2224,O
radiation,2224,O
alone,2224,O
",",2224,O
indicating,2224,O
the,2224,O
repair,2224,O
of,2224,O
sublethal,2224,O
damage,2224,O
",",2224,O
was,2224,O
reduced,2224,O
as,2224,O
compared,2224,O
to,2224,O
that,2224,O
for,2224,O
sequential,2224,O
combined,2224,O
treatment,2224,O
with,2224,O
AMR,2224,B-CHEMICAL
or,2224,O
AMROH,2224,B-CHEMICAL
.,2224,O
Sequential,2225,O
treatments,2225,O
with,2225,O
AMR,2225,B-CHEMICAL
or,2225,O
AMROH,2225,B-CHEMICAL
prior,2225,O
to,2225,O
ionizing,2225,O
radiation,2225,O
resulted,2225,O
in,2225,O
an,2225,O
additive,2225,O
radio-enhancement,2225,O
effect,2225,O
that,2225,O
reduced,2225,O
not,2225,O
only,2225,O
survival,2225,O
",",2225,O
but,2225,O
also,2225,O
the,2225,O
shoulder,2225,O
width,2225,O
.,2225,O
Fractionated,2226,O
irradiation,2226,O
with,2226,O
2,2226,O
Gy,2226,O
per,2226,O
fraction,2226,O
of,2226,O
A549,2226,O
cells,2226,O
was,2226,O
carried,2226,O
out,2226,O
in,2226,O
vitro,2226,O
similar,2226,O
to,2226,O
that,2226,O
commonly,2226,O
performed,2226,O
in,2226,O
clinical,2226,O
radiotherapy,2226,O
and,2226,O
the,2226,O
radio-resistance,2226,O
of,2226,O
the,2226,O
cells,2226,O
was,2226,O
shown,2226,O
to,2226,O
be,2226,O
inhibited,2226,O
by,2226,O
AMR,2226,B-CHEMICAL
and,2226,O
AMROH,2226,B-CHEMICAL
.,2226,O
Similar,2227,O
to,2227,O
AMR,2227,B-CHEMICAL
and,2227,O
AMROH,2227,B-CHEMICAL
",",2227,O
adriamycin,2227,B-CHEMICAL
and,2227,O
etoposide,2227,B-CHEMICAL
(,2227,O
VP-16,2227,B-CHEMICAL
),2227,O
are,2227,O
DNA,2227,B-GENE-Y
topoisomerase,2227,I-GENE-Y
II,2227,I-GENE-Y
inhibitors,2227,O
.,2227,O
The,2228,O
effects,2228,O
of,2228,O
these,2228,O
4,2228,O
agents,2228,O
on,2228,O
cells,2228,O
that,2228,O
received,2228,O
X-ray,2228,O
irradiation,2228,O
were,2228,O
compared,2228,O
and,2228,O
all,2228,O
of,2228,O
the,2228,O
agents,2228,O
exhibited,2228,O
comparable,2228,O
radio-enhancement,2228,O
effects,2228,O
.,2228,O
The,2229,O
induction,2229,O
of,2229,O
apoptosis,2229,O
was,2229,O
investigated,2229,O
at,2229,O
48,2229,O
and,2229,O
72,2229,O
h,2229,O
after,2229,O
administration,2229,O
of,2229,O
AMROH,2229,B-CHEMICAL
",",2229,O
radiation,2229,O
or,2229,O
combined,2229,O
treatment,2229,O
",",2229,O
and,2229,O
apoptosis,2229,O
was,2229,O
not,2229,O
significantly,2229,O
induced,2229,O
after,2229,O
any,2229,O
of,2229,O
the,2229,O
treatments,2229,O
.,2229,O
We,2230,O
also,2230,O
examined,2230,O
the,2230,O
induction,2230,O
of,2230,O
necrosis,2230,O
",",2230,O
and,2230,O
found,2230,O
that,2230,O
the,2230,O
incidence,2230,O
of,2230,O
necrosis,2230,O
following,2230,O
combined,2230,O
treatment,2230,O
was,2230,O
approximately,2230,O
2,2230,O
times,2230,O
higher,2230,O
than,2230,O
that,2230,O
with,2230,O
either,2230,O
of,2230,O
the,2230,O
single,2230,O
treatments,2230,O
.,2230,O
Interaction,2231,O
of,2231,O
nonsteroidal,2231,O
anti-inflammatory,2231,O
drugs,2231,O
(,2231,O
NSAID,2231,O
),2231,O
with,2231,O
Helicobacter,2231,O
pylori,2231,O
in,2231,O
the,2231,O
stomach,2231,O
of,2231,O
humans,2231,O
and,2231,O
experimental,2231,O
animals,2231,O
.,2231,O
Helicobacter,2232,O
pylori,2232,O
(,2232,O
H.,2232,O
pylori,2232,O
),2232,O
and,2232,O
non-steroidal,2232,O
anti-inflammatory,2232,O
drugs,2232,O
(,2232,O
NSAID,2232,O
),2232,O
are,2232,O
major,2232,O
pathogenic,2232,O
factors,2232,O
in,2232,O
peptic,2232,O
ulcer,2232,O
disease,2232,O
but,2232,O
whether,2232,O
these,2232,O
two,2232,O
factors,2232,O
exert,2232,O
synergistic,2232,O
or,2232,O
antagonistic,2232,O
action,2232,O
on,2232,O
the,2232,O
gastric,2232,O
mucosa,2232,O
has,2232,O
been,2232,O
a,2232,O
subject,2232,O
of,2232,O
controversy,2232,O
.,2232,O
The,2233,O
classic,2233,O
concept,2233,O
states,2233,O
that,2233,O
there,2233,O
is,2233,O
an,2233,O
increased,2233,O
ulcer,2233,O
occurrence,2233,O
and,2233,O
bleeding,2233,O
in,2233,O
patients,2233,O
with,2233,O
both,2233,O
H.,2233,O
pylori,2233,O
infection,2233,O
and,2233,O
NSAID,2233,O
use,2233,O
.,2233,O
However,2234,O
",",2234,O
the,2234,O
question,2234,O
whether,2234,O
the,2234,O
H.,2234,O
pylori,2234,O
eradication,2234,O
therapy,2234,O
in,2234,O
NSAID,2234,O
users,2234,O
reduces,2234,O
the,2234,O
occurrence,2234,O
of,2234,O
peptic,2234,O
ulcer,2234,O
has,2234,O
not,2234,O
been,2234,O
fully,2234,O
addressed,2234,O
.,2234,O
Studies,2235,O
on,2235,O
secondary,2235,O
prevention,2235,O
of,2235,O
NSAID-associated,2235,O
ulcers,2235,O
in,2235,O
H.,2235,O
pylori,2235,O
patients,2235,O
have,2235,O
indicated,2235,O
that,2235,O
H.,2235,O
pylori,2235,O
eradication,2235,O
results,2235,O
in,2235,O
impaired,2235,O
ulcer,2235,O
healing,2235,O
with,2235,O
an,2235,O
effect,2235,O
on,2235,O
the,2235,O
rate,2235,O
of,2235,O
peptic,2235,O
ulcer,2235,O
occurrence,2235,O
.,2235,O
On,2236,O
the,2236,O
other,2236,O
hand,2236,O
",",2236,O
the,2236,O
treatment,2236,O
of,2236,O
H.,2236,O
pylori,2236,O
in,2236,O
patients,2236,O
with,2236,O
no,2236,O
prior,2236,O
history,2236,O
of,2236,O
chronic,2236,O
NSAID,2236,O
therapy,2236,O
has,2236,O
been,2236,O
shown,2236,O
to,2236,O
decrease,2236,O
the,2236,O
risk,2236,O
of,2236,O
peptic,2236,O
ulcer,2236,O
.,2236,O
Studies,2237,O
in,2237,O
experimental,2237,O
animals,2237,O
revealed,2237,O
for,2237,O
instance,2237,O
",",2237,O
that,2237,O
the,2237,O
H.,2237,O
pylori,2237,O
infection,2237,O
augments,2237,O
the,2237,O
gastric,2237,O
mucosal,2237,O
damage,2237,O
induced,2237,O
by,2237,O
NSAID,2237,O
in,2237,O
Mongolian,2237,O
gerbils,2237,O
.,2237,O
In,2238,O
rats,2238,O
with,2238,O
preexisting,2238,O
chromic,2238,O
gastric,2238,O
ulcers,2238,O
",",2238,O
H.,2238,O
pylori,2238,O
infection,2238,O
attenuated,2238,O
significantly,2238,O
the,2238,O
aspirin-induced,2238,B-CHEMICAL
inhibition,2238,O
of,2238,O
ulcer,2238,O
healing,2238,O
and,2238,O
accompanying,2238,O
fall,2238,O
in,2238,O
the,2238,O
gastric,2238,O
blood,2238,O
flow,2238,O
at,2238,O
the,2238,O
margin,2238,O
of,2238,O
these,2238,O
ulcers,2238,O
",",2238,O
suggesting,2238,O
negative,2238,O
interaction,2238,O
between,2238,O
aspirin,2238,B-CHEMICAL
and,2238,O
H.,2238,O
pylori,2238,O
on,2238,O
ulcerogenesis,2238,O
.,2238,O
Accumulated,2239,O
evidence,2239,O
in,2239,O
humans,2239,O
and,2239,O
animals,2239,O
shows,2239,O
that,2239,O
both,2239,O
aspirin,2239,B-CHEMICAL
and,2239,O
H.,2239,O
pylori,2239,O
upregulate,2239,O
the,2239,O
expression,2239,O
of,2239,O
cyclooxygenase,2239,B-GENE-N
(,2239,I-GENE-N
COX,2239,I-GENE-N
),2239,I-GENE-N
-2,2239,I-GENE-N
both,2239,O
at,2239,O
mRNA,2239,O
and,2239,O
protein,2239,O
levels,2239,O
at,2239,O
the,2239,O
ulcer,2239,O
margin,2239,O
",",2239,O
but,2239,O
failed,2239,O
to,2239,O
influence,2239,O
significantly,2239,O
that,2239,O
of,2239,O
COX-1,2239,B-GENE-N
.,2239,O
It,2240,O
was,2240,O
",",2240,O
therefore,2240,O
",",2240,O
proposed,2240,O
that,2240,O
H.,2240,O
pylori,2240,O
may,2240,O
in,2240,O
fact,2240,O
",",2240,O
antagonize,2240,O
",",2240,O
aspirin-induced,2240,B-CHEMICAL
delay,2240,O
of,2240,O
ulcer,2240,O
healing,2240,O
due,2240,O
to,2240,O
suppression,2240,O
of,2240,O
acid,2240,O
secretion,2240,O
by,2240,O
the,2240,O
enhancement,2240,O
in,2240,O
PGE,2240,B-CHEMICAL
(,2240,I-CHEMICAL
2,2240,I-CHEMICAL
),2240,I-CHEMICAL
possibly,2240,O
derived,2240,O
from,2240,O
COX-2,2240,B-GENE-N
expression,2240,O
and,2240,O
activity,2240,O
and,2240,O
to,2240,O
the,2240,O
overexpression,2240,O
of,2240,O
growth,2240,O
factors,2240,O
such,2240,O
as,2240,O
TGF,2240,B-GENE-N
alpha,2240,I-GENE-N
and,2240,O
VEGF,2240,B-GENE-N
.,2240,O
The,2241,O
present,2241,O
review,2241,O
summarizes,2241,O
and,2241,O
further,2241,O
addresses,2241,O
the,2241,O
issue,2241,O
of,2241,O
the,2241,O
interaction,2241,O
between,2241,O
these,2241,O
two,2241,O
major,2241,O
ulcer,2241,O
risk,2241,O
factors,2241,O
determined,2241,O
in,2241,O
the,2241,O
stomach,2241,O
of,2241,O
humans,2241,O
and,2241,O
experimental,2241,O
animals,2241,O
.,2241,O
The,2242,O
effect,2242,O
of,2242,O
a,2242,O
novel,2242,O
transition,2242,O
state,2242,O
inhibitor,2242,O
of,2242,O
methylthioadenosine,2242,B-GENE-Y
phosphorylase,2242,I-GENE-Y
on,2242,O
pemetrexed,2242,B-CHEMICAL
activity,2242,O
.,2242,O
Pemetrexed,2243,O
is,2243,O
a,2243,O
new-generation,2243,O
antifolate,2243,O
inhibitor,2243,O
of,2243,O
thymidylate,2243,B-GENE-Y
synthase,2243,I-GENE-Y
(,2243,O
TS,2243,B-GENE-Y
),2243,O
and,2243,O
a,2243,O
weaker,2243,O
inhibitor,2243,O
of,2243,O
glycinamide,2243,B-CHEMICAL
ribonucleotide,2243,I-CHEMICAL
transformylase,2243,I-GENE-Y
(,2243,O
GARFT,2243,B-GENE-Y
),2243,O
required,2243,O
for,2243,O
de,2243,O
novo,2243,O
purine,2243,B-CHEMICAL
synthesis,2243,O
.,2243,O
Methylthioadenosine,2244,B-CHEMICAL
phosphorylase,2244,I-GENE-Y
(,2244,O
MTAP,2244,B-GENE-Y
),2244,O
salvages,2244,O
purines,2244,B-CHEMICAL
by,2244,O
releasing,2244,O
adenine,2244,B-CHEMICAL
from,2244,O
methylthioadenosine,2244,B-CHEMICAL
and,2244,O
is,2244,O
often,2244,O
deleted,2244,O
in,2244,O
mesothelioma,2244,O
.,2244,O
The,2245,O
current,2245,O
study,2245,O
addresses,2245,O
the,2245,O
effect,2245,O
of,2245,O
MTAP,2245,B-GENE-Y
on,2245,O
pemetrexed,2245,B-CHEMICAL
activity,2245,O
using,2245,O
a,2245,O
highly,2245,O
potent,2245,O
transition,2245,O
state,2245,O
inhibitor,2245,O
of,2245,O
MTAP,2245,B-GENE-Y
",",2245,O
MT-DADMe-Immucillin,2245,O
A,2245,O
(,2245,O
ImmA,2245,O
;,2245,O
K,2245,O
(,2245,O
i,2245,O
),2245,O
=,2245,O
86,2245,O
pmol/L,2245,O
),2245,O
in,2245,O
the,2245,O
MTAP,2245,B-GENE-Y
(,2245,O
+,2245,O
),2245,O
NCI-H28,2245,O
and,2245,O
MTAP,2245,B-GENE-Y
(,2245,O
-,2245,O
),2245,O
NCI-H2052,2245,O
mesothelioma,2245,O
cell,2245,O
lines,2245,O
.,2245,O
Based,2246,O
on,2246,O
selective,2246,O
nucleoside,2246,O
protection,2246,O
",",2246,O
TS,2246,B-GENE-Y
was,2246,O
found,2246,O
to,2246,O
be,2246,O
the,2246,O
primary,2246,O
pemetrexed,2246,B-CHEMICAL
target,2246,O
in,2246,O
both,2246,O
cell,2246,O
lines,2246,O
with,2246,O
GARFT,2246,B-GENE-Y
inhibition,2246,O
requiring,2246,O
20-,2246,O
to,2246,O
30-fold,2246,O
higher,2246,O
pemetrexed,2246,B-CHEMICAL
concentrations,2246,O
.,2246,O
ImmA,2247,O
had,2247,O
no,2247,O
effect,2247,O
on,2247,O
pemetrexed,2247,B-CHEMICAL
activity,2247,O
but,2247,O
",",2247,O
when,2247,O
thymidine,2247,B-CHEMICAL
was,2247,O
added,2247,O
",",2247,O
the,2247,O
pemetrexed,2247,B-CHEMICAL
IC,2247,O
(,2247,O
50,2247,O
),2247,O
decreased,2247,O
by,2247,O
a,2247,O
factor,2247,O
of,2247,O
approximately,2247,O
3,2247,O
in,2247,O
MTAP,2247,B-GENE-Y
(,2247,O
+,2247,O
),2247,O
H28,2247,O
cells,2247,O
with,2247,O
no,2247,O
effect,2247,O
in,2247,O
MTAP,2247,B-GENE-Y
(,2247,O
-,2247,O
),2247,O
H2052,2247,O
cells,2247,O
.,2247,O
Conversely,2248,O
",",2248,O
the,2248,O
transfection,2248,O
of,2248,O
MTAP,2248,B-GENE-Y
into,2248,O
H2052,2248,O
cells,2248,O
increased,2248,O
the,2248,O
pemetrexed,2248,B-CHEMICAL
IC,2248,O
(,2248,O
50,2248,O
),2248,O
by,2248,O
nearly,2248,O
3-fold,2248,O
but,2248,O
only,2248,O
in,2248,O
the,2248,O
presence,2248,O
of,2248,O
thymidine,2248,B-CHEMICAL
;,2248,O
this,2248,O
was,2248,O
reversed,2248,O
by,2248,O
ImmA,2248,O
.,2248,O
An,2249,O
MTAP-specific,2249,B-GENE-Y
short,2249,O
interfering,2249,O
RNA,2249,O
produced,2249,O
a,2249,O
2-fold,2249,O
decrease,2249,O
in,2249,O
pemetrexed,2249,B-CHEMICAL
IC,2249,O
(,2249,O
50,2249,O
),2249,O
in,2249,O
MTAP,2249,B-GENE-Y
(,2249,O
+,2249,O
),2249,O
HeLa,2249,O
cells,2249,O
in,2249,O
the,2249,O
presence,2249,O
of,2249,O
thymidine,2249,B-CHEMICAL
.,2249,O
These,2250,O
data,2250,O
indicate,2250,O
that,2250,O
suppression,2250,O
of,2250,O
constitutive,2250,O
MTAP,2250,B-GENE-Y
has,2250,O
no,2250,O
effect,2250,O
on,2250,O
pemetrexed,2250,B-CHEMICAL
activity,2250,O
when,2250,O
the,2250,O
primary,2250,O
target,2250,O
is,2250,O
TS,2250,B-GENE-Y
.,2250,O
There,2251,O
is,2251,O
a,2251,O
modest,2251,O
salutary,2251,O
effect,2251,O
when,2251,O
the,2251,O
pemetrexed,2251,B-CHEMICAL
target,2251,O
is,2251,O
GARFT,2251,B-GENE-Y
alone,2251,O
.,2251,O
Sulfonylureas,2252,B-CHEMICAL
and,2252,O
glinides,2252,B-CHEMICAL
exhibit,2252,O
peroxisome,2252,B-GENE-Y
proliferator-activated,2252,I-GENE-Y
receptor,2252,I-GENE-Y
gamma,2252,I-GENE-Y
activity,2252,O
:,2252,O
a,2252,O
combined,2252,O
virtual,2252,O
screening,2252,O
and,2252,O
biological,2252,O
assay,2252,O
approach,2252,O
.,2252,O
Most,2253,O
drugs,2253,O
currently,2253,O
employed,2253,O
in,2253,O
the,2253,O
treatment,2253,O
of,2253,O
type,2253,O
2,2253,O
diabetes,2253,O
either,2253,O
target,2253,O
the,2253,O
sulfonylurea,2253,B-GENE-N
receptor,2253,I-GENE-N
stimulating,2253,O
insulin,2253,B-GENE-Y
release,2253,O
(,2253,O
sulfonylureas,2253,B-CHEMICAL
",",2253,O
glinides,2253,B-CHEMICAL
),2253,O
",",2253,O
or,2253,O
target,2253,O
the,2253,O
peroxisome,2253,B-GENE-N
proliferator-activated,2253,I-GENE-N
receptor,2253,I-GENE-N
(,2253,O
PPARgamma,2253,B-GENE-Y
),2253,O
improving,2253,O
insulin,2253,B-GENE-Y
resistance,2253,O
(,2253,O
thiazolidinediones,2253,B-CHEMICAL
),2253,O
.,2253,O
Our,2254,O
work,2254,O
shows,2254,O
that,2254,O
sulfonylureas,2254,B-CHEMICAL
and,2254,O
glinides,2254,B-CHEMICAL
additionally,2254,O
bind,2254,O
to,2254,O
PPARgamma,2254,B-GENE-Y
and,2254,O
exhibit,2254,O
PPARgamma,2254,B-GENE-Y
agonistic,2254,O
activity,2254,O
.,2254,O
This,2255,O
activity,2255,O
was,2255,O
predicted,2255,O
in,2255,O
silico,2255,O
by,2255,O
virtual,2255,O
screening,2255,O
and,2255,O
confirmed,2255,O
in,2255,O
vitro,2255,O
in,2255,O
a,2255,O
binding,2255,O
assay,2255,O
",",2255,O
a,2255,O
transactivation,2255,O
assay,2255,O
",",2255,O
and,2255,O
by,2255,O
measuring,2255,O
the,2255,O
expression,2255,O
of,2255,O
PPARgamma,2255,B-GENE-Y
target,2255,O
genes,2255,O
.,2255,O
Among,2256,O
the,2256,O
measured,2256,O
compounds,2256,O
",",2256,O
gliquidone,2256,B-CHEMICAL
and,2256,O
glipizide,2256,B-CHEMICAL
(,2256,O
two,2256,O
sulfonylureas,2256,B-CHEMICAL
),2256,O
",",2256,O
as,2256,O
well,2256,O
as,2256,O
nateglinide,2256,B-CHEMICAL
(,2256,O
a,2256,O
glinide,2256,B-CHEMICAL
),2256,O
",",2256,O
exhibit,2256,O
PPARgamma,2256,B-GENE-Y
agonistic,2256,O
activity,2256,O
at,2256,O
concentrations,2256,O
comparable,2256,O
with,2256,O
those,2256,O
reached,2256,O
under,2256,O
pharmacological,2256,O
treatment,2256,O
.,2256,O
The,2257,O
most,2257,O
active,2257,O
of,2257,O
these,2257,O
compounds,2257,O
",",2257,O
gliquidone,2257,B-CHEMICAL
",",2257,O
is,2257,O
shown,2257,O
to,2257,O
be,2257,O
as,2257,O
potent,2257,O
as,2257,O
pioglitazone,2257,B-CHEMICAL
at,2257,O
inducing,2257,O
PPARgamma,2257,B-GENE-Y
target,2257,O
gene,2257,O
expression,2257,O
.,2257,O
This,2258,O
dual,2258,O
mode,2258,O
of,2258,O
action,2258,O
of,2258,O
sulfonylureas,2258,B-CHEMICAL
and,2258,O
glinides,2258,B-CHEMICAL
may,2258,O
open,2258,O
new,2258,O
perspectives,2258,O
for,2258,O
the,2258,O
molecular,2258,O
pharmacology,2258,O
of,2258,O
antidiabetic,2258,O
drugs,2258,O
",",2258,O
because,2258,O
it,2258,O
provides,2258,O
evidence,2258,O
that,2258,O
drugs,2258,O
can,2258,O
be,2258,O
designed,2258,O
that,2258,O
target,2258,O
both,2258,O
the,2258,O
sulfonylurea,2258,B-GENE-N
receptor,2258,I-GENE-N
and,2258,O
PPARgamma,2258,B-GENE-Y
.,2258,O
Targeting,2259,O
both,2259,O
receptors,2259,O
could,2259,O
increase,2259,O
pancreatic,2259,O
insulin,2259,B-GENE-Y
secretion,2259,O
and,2259,O
improve,2259,O
insulin,2259,B-GENE-Y
resistance,2259,O
.,2259,O
Glinides,2260,B-CHEMICAL
",",2260,O
sulfonylureas,2260,B-CHEMICAL
",",2260,O
and,2260,O
other,2260,O
acidified,2260,B-CHEMICAL
sulfonamides,2260,I-CHEMICAL
may,2260,O
be,2260,O
promising,2260,O
leads,2260,O
in,2260,O
the,2260,O
development,2260,O
of,2260,O
new,2260,O
PPARgamma,2260,B-GENE-Y
agonists,2260,O
.,2260,O
In,2261,O
addition,2261,O
",",2261,O
we,2261,O
provide,2261,O
a,2261,O
unified,2261,O
concept,2261,O
of,2261,O
the,2261,O
PPARgamma,2261,B-GENE-Y
binding,2261,O
ability,2261,O
of,2261,O
seemingly,2261,O
disparate,2261,O
compound,2261,O
classes,2261,O
.,2261,O
PGE,2262,B-CHEMICAL
(,2262,I-CHEMICAL
1,2262,I-CHEMICAL
),2262,I-CHEMICAL
stimulation,2262,O
of,2262,O
HEK293,2262,O
cells,2262,O
generates,2262,O
multiple,2262,O
contiguous,2262,O
domains,2262,O
with,2262,O
different,2262,O
[,2262,O
cAMP,2262,B-CHEMICAL
],2262,O
:,2262,O
role,2262,O
of,2262,O
compartmentalized,2262,O
phosphodiesterases,2262,O
.,2262,O
There,2263,O
is,2263,O
a,2263,O
growing,2263,O
appreciation,2263,O
that,2263,O
the,2263,O
cyclic,2263,B-CHEMICAL
adenosine,2263,I-CHEMICAL
monophosphate,2263,I-CHEMICAL
(,2263,O
cAMP,2263,B-CHEMICAL
),2263,O
-protein,2263,O
kinase,2263,I-GENE-N
A,2263,I-GENE-N
(,2263,O
PKA,2263,B-GENE-N
),2263,O
signaling,2263,O
pathway,2263,O
is,2263,O
organized,2263,O
to,2263,O
form,2263,O
transduction,2263,O
units,2263,O
that,2263,O
function,2263,O
to,2263,O
deliver,2263,O
specific,2263,O
messages,2263,O
.,2263,O
Such,2264,O
organization,2264,O
results,2264,O
in,2264,O
the,2264,O
local,2264,O
activation,2264,O
of,2264,O
PKA,2264,B-GENE-N
subsets,2264,O
through,2264,O
the,2264,O
generation,2264,O
of,2264,O
confined,2264,O
intracellular,2264,O
gradients,2264,O
of,2264,O
cAMP,2264,B-CHEMICAL
",",2264,O
but,2264,O
the,2264,O
mechanisms,2264,O
responsible,2264,O
for,2264,O
limiting,2264,O
the,2264,O
diffusion,2264,O
of,2264,O
cAMP,2264,B-CHEMICAL
largely,2264,O
remain,2264,O
to,2264,O
be,2264,O
clarified,2264,O
.,2264,O
In,2265,O
this,2265,O
study,2265,O
",",2265,O
by,2265,O
performing,2265,O
real-time,2265,O
imaging,2265,O
of,2265,O
cAMP,2265,B-CHEMICAL
",",2265,O
we,2265,O
show,2265,O
that,2265,O
prostaglandin,2265,B-CHEMICAL
1,2265,I-CHEMICAL
stimulation,2265,O
generates,2265,O
multiple,2265,O
contiguous,2265,O
",",2265,O
intracellular,2265,O
domains,2265,O
with,2265,O
different,2265,O
cAMP,2265,B-CHEMICAL
concentration,2265,O
in,2265,O
human,2265,O
embryonic,2265,O
kidney,2265,O
293,2265,O
cells,2265,O
.,2265,O
By,2266,O
using,2266,O
pharmacological,2266,O
and,2266,O
genetic,2266,O
manipulation,2266,O
of,2266,O
phosphodiesterases,2266,B-GENE-N
(,2266,O
PDEs,2266,B-GENE-N
),2266,O
",",2266,O
we,2266,O
demonstrate,2266,O
that,2266,O
compartmentalized,2266,O
PDE4B,2266,B-GENE-Y
and,2266,O
PDE4D,2266,B-GENE-Y
are,2266,O
responsible,2266,O
for,2266,O
selectively,2266,O
modulating,2266,O
the,2266,O
concentration,2266,O
of,2266,O
cAMP,2266,B-CHEMICAL
in,2266,O
individual,2266,O
subcellular,2266,O
compartments,2266,O
.,2266,O
We,2267,O
propose,2267,O
a,2267,O
model,2267,O
whereby,2267,O
compartmentalized,2267,O
PDEs,2267,B-GENE-N
",",2267,O
rather,2267,O
than,2267,O
representing,2267,O
an,2267,O
enzymatic,2267,O
barrier,2267,O
to,2267,O
cAMP,2267,B-CHEMICAL
diffusion,2267,O
",",2267,O
act,2267,O
as,2267,O
a,2267,O
sink,2267,O
to,2267,O
drain,2267,O
the,2267,O
second,2267,O
messenger,2267,O
from,2267,O
discrete,2267,O
locations,2267,O
",",2267,O
resulting,2267,O
in,2267,O
multiple,2267,O
and,2267,O
simultaneous,2267,O
domains,2267,O
with,2267,O
different,2267,O
cAMP,2267,B-CHEMICAL
concentrations,2267,O
irrespective,2267,O
of,2267,O
their,2267,O
distance,2267,O
from,2267,O
the,2267,O
site,2267,O
of,2267,O
cAMP,2267,B-CHEMICAL
synthesis,2267,O
.,2267,O
DNA,2268,B-GENE-Y
topoisomerase,2268,I-GENE-Y
IIalpha,2268,I-GENE-Y
(,2268,O
TOP2A,2268,B-GENE-Y
),2268,O
inhibitors,2268,O
up-regulate,2268,O
fatty,2268,B-CHEMICAL
acid,2268,I-CHEMICAL
synthase,2268,I-GENE-Y
gene,2268,O
expression,2268,O
in,2268,O
SK-Br3,2268,O
breast,2268,O
cancer,2268,O
cells,2268,O
:,2268,O
in,2268,O
vitro,2268,O
evidence,2268,O
for,2268,O
a,2268,O
'functional,2268,O
amplicon,2268,O
',2268,O
involving,2268,O
FAS,2268,B-GENE-Y
",",2268,O
Her-2/neu,2268,B-GENE-Y
and,2268,O
TOP2A,2268,B-GENE-Y
genes,2268,O
.,2268,O
Fatty,2269,B-CHEMICAL
acid,2269,I-CHEMICAL
synthase,2269,I-GENE-Y
(,2269,O
FAS,2269,B-GENE-Y
),2269,O
",",2269,O
the,2269,O
key,2269,O
metabolic,2269,O
multi-enzyme,2269,O
that,2269,O
is,2269,O
responsible,2269,O
for,2269,O
the,2269,O
terminal,2269,O
catalytic,2269,O
step,2269,O
in,2269,O
the,2269,O
de,2269,O
novo,2269,O
fatty,2269,O
acid,2269,O
biosynthesis,2269,O
",",2269,O
plays,2269,O
an,2269,O
active,2269,O
role,2269,O
in,2269,O
the,2269,O
development,2269,O
",",2269,O
maintenance,2269,O
",",2269,O
and,2269,O
enhancement,2269,O
of,2269,O
the,2269,O
malignant,2269,O
phenotype,2269,O
in,2269,O
a,2269,O
subset,2269,O
of,2269,O
breast,2269,O
carcinomas,2269,O
.,2269,O
We,2270,O
recently,2270,O
described,2270,O
that,2270,O
a,2270,O
molecular,2270,O
bi-directional,2270,O
cross-talk,2270,O
between,2270,O
FAS,2270,B-GENE-Y
and,2270,O
the,2270,O
Her-2/neu,2270,B-GENE-Y
(,2270,O
erbB-2,2270,B-GENE-Y
),2270,O
oncogene,2270,O
is,2270,O
taking,2270,O
place,2270,O
at,2270,O
the,2270,O
level,2270,O
of,2270,O
transcription,2270,O
",",2270,O
translation,2270,O
",",2270,O
and,2270,O
activity,2270,O
in,2270,O
breast,2270,O
cancer,2270,O
cells,2270,O
.,2270,O
Because,2271,O
Her-2/neu,2271,B-GENE-Y
has,2271,O
been,2271,O
linked,2271,O
with,2271,O
altered,2271,O
sensitivity,2271,O
to,2271,O
cytotoxic,2271,O
drugs,2271,O
",",2271,O
we,2271,O
envisioned,2271,O
that,2271,O
FAS,2271,B-GENE-Y
gene,2271,O
expression,2271,O
may,2271,O
represent,2271,O
a,2271,O
novel,2271,O
predictive,2271,O
molecular,2271,O
factor,2271,O
for,2271,O
breast,2271,O
cancer,2271,O
response,2271,O
to,2271,O
chemotherapy,2271,O
in,2271,O
a,2271,O
Her-2/neu-related,2271,B-GENE-Y
manner,2271,O
.,2271,O
We,2272,O
herein,2272,O
evaluated,2272,O
whether,2272,O
chemotherapy-induced,2272,O
cell,2272,O
damage,2272,O
acts,2272,O
in,2272,O
an,2272,O
epigenetic,2272,O
fashion,2272,O
by,2272,O
inducing,2272,O
changes,2272,O
in,2272,O
the,2272,O
transcriptional,2272,O
activation,2272,O
of,2272,O
FAS,2272,B-GENE-Y
gene,2272,O
in,2272,O
breast,2272,O
cancer,2272,O
cells,2272,O
.,2272,O
To,2273,O
evaluate,2273,O
this,2273,O
option,2273,O
",",2273,O
FAS-,2273,B-GENE-Y
and,2273,O
Her-2/neu-overexpressing,2273,B-GENE-Y
SK-Br3,2273,O
breast,2273,O
cancer,2273,O
cells,2273,O
were,2273,O
transiently,2273,O
transfected,2273,O
with,2273,O
a,2273,O
FAS,2273,B-GENE-N
promoter-reporter,2273,O
construct,2273,O
(,2273,O
FAS-Luciferase,2273,B-GENE-Y
),2273,O
harboring,2273,O
all,2273,O
the,2273,O
elements,2273,O
necessary,2273,O
for,2273,O
high,2273,O
level,2273,O
expression,2273,O
in,2273,O
cancer,2273,O
cells,2273,O
.,2273,O
SK-Br3,2274,O
cells,2274,O
cultured,2274,O
in,2274,O
the,2274,O
presence,2274,O
of,2274,O
topoisomerase,2274,B-GENE-Y
IIalpha,2274,I-GENE-Y
(,2274,O
TOP2A,2274,B-GENE-Y
),2274,O
inhibitors,2274,O
doxorubicin,2274,B-CHEMICAL
and,2274,O
etopoxide,2274,B-CHEMICAL
(,2274,O
VP-16,2274,B-CHEMICAL
),2274,O
demonstrated,2274,O
a,2274,O
2-,2274,O
to,2274,O
3-fold,2274,O
increase,2274,O
in,2274,O
FAS,2274,B-GENE-N
promoter,2274,I-GENE-N
activity,2274,O
when,2274,O
compared,2274,O
with,2274,O
control,2274,O
cells,2274,O
growing,2274,O
in,2274,O
drug-free,2274,O
culture,2274,O
conditions,2274,O
.,2274,O
We,2275,O
failed,2275,O
to,2275,O
observe,2275,O
any,2275,O
significant,2275,O
activation,2275,O
of,2275,O
FAS,2275,B-GENE-N
promoter,2275,I-GENE-N
following,2275,O
exposure,2275,O
to,2275,O
the,2275,O
anti-metabolite,2275,O
5-fluorouracil,2275,B-CHEMICAL
",",2275,O
the,2275,O
alkylating,2275,O
drug,2275,O
cisplatin,2275,B-CHEMICAL
",",2275,O
or,2275,O
the,2275,O
microtubule,2275,O
interfering-agents,2275,O
paclitaxel,2275,B-CHEMICAL
and,2275,O
vincristine,2275,B-CHEMICAL
.,2275,O
Moreover,2276,O
",",2276,O
the,2276,O
up-regulatory,2276,O
effects,2276,O
of,2276,O
TOP2A,2276,B-GENE-Y
inhibitors,2276,O
on,2276,O
the,2276,O
transcriptional,2276,O
activation,2276,O
of,2276,O
FAS,2276,B-GENE-Y
gene,2276,O
expression,2276,O
were,2276,O
not,2276,O
significantly,2276,O
decreased,2276,O
when,2276,O
the,2276,O
FAS,2276,B-GENE-N
promoter,2276,I-GENE-N
was,2276,O
damaged,2276,O
at,2276,O
the,2276,O
sterol,2276,B-GENE-N
regulatory,2276,I-GENE-N
element,2276,I-GENE-N
binding,2276,I-GENE-N
protein,2276,I-GENE-N
(,2276,O
SREBP,2276,B-GENE-N
),2276,O
-binding,2276,O
site,2276,O
.,2276,O
Considering,2277,O
that,2277,O
FAS,2277,B-GENE-Y
inhibition,2277,O
produces,2277,O
profound,2277,O
inhibition,2277,O
of,2277,O
DNA,2277,O
replication,2277,O
and,2277,O
S-phase,2277,O
progression,2277,O
in,2277,O
cancer,2277,O
cells,2277,O
",",2277,O
we,2277,O
finally,2277,O
asked,2277,O
whether,2277,O
a,2277,O
cross-talk,2277,O
between,2277,O
TOP2A,2277,B-GENE-Y
and,2277,O
FAS,2277,B-GENE-Y
could,2277,O
exhibit,2277,O
a,2277,O
Her-2/neu-related,2277,B-GENE-Y
bi-directional,2277,O
nature,2277,O
.,2277,O
TOP2A,2278,B-GENE-Y
protein,2278,O
levels,2278,O
were,2278,O
decreased,2278,O
during,2278,O
treatment,2278,O
with,2278,O
the,2278,O
anti-Her-2/neu,2278,O
antibody,2278,O
trastuzumab,2278,O
while,2278,O
",",2278,O
concomitantly,2278,O
",",2278,O
FAS,2278,B-GENE-N
promoter,2278,I-GENE-N
activity,2278,O
and,2278,O
FAS,2278,B-GENE-Y
protein,2278,O
expression,2278,O
were,2278,O
significantly,2278,O
reduced,2278,O
.,2278,O
Of,2279,O
note,2279,O
",",2279,O
when,2279,O
the,2279,O
expression,2279,O
levels,2279,O
of,2279,O
TOP2A,2279,B-GENE-Y
protein,2279,O
were,2279,O
analyzed,2279,O
following,2279,O
exposure,2279,O
of,2279,O
SK-Br3,2279,O
cells,2279,O
to,2279,O
increasing,2279,O
concentrations,2279,O
of,2279,O
the,2279,O
novel,2279,O
slow-binding,2279,O
FAS,2279,B-GENE-Y
inhibitor,2279,O
C75,2279,O
",",2279,O
a,2279,O
dose-dependent,2279,O
reduction,2279,O
in,2279,O
TOP2A,2279,B-GENE-Y
expression,2279,O
was,2279,O
observed,2279,O
.,2279,O
Although,2280,O
FAS,2280,B-GENE-Y
gene,2280,O
is,2280,O
not,2280,O
physically,2280,O
located,2280,O
in,2280,O
the,2280,O
Her-2/neu-TOP2A,2280,B-GENE-Y
amplicon,2280,O
",",2280,O
our,2280,O
present,2280,O
findings,2280,O
strongly,2280,O
suggest,2280,O
that,2280,O
a,2280,O
tight,2280,O
functional,2280,O
association,2280,O
between,2280,O
FAS,2280,B-GENE-Y
",",2280,O
Her-2/neu,2280,B-GENE-Y
and,2280,O
TOP2A,2280,B-GENE-Y
genes,2280,O
is,2280,O
taking,2280,O
place,2280,O
in,2280,O
a,2280,O
subset,2280,O
of,2280,O
breast,2280,O
carcinoma,2280,O
cells,2280,O
.,2280,O
Mifepristone,2281,B-CHEMICAL
alters,2281,O
expression,2281,O
of,2281,O
endometrial,2281,O
steroid,2281,B-GENE-N
receptors,2281,I-GENE-N
and,2281,O
their,2281,O
cofactors,2281,O
in,2281,O
new,2281,O
users,2281,O
of,2281,O
medroxyprogesterone,2281,B-CHEMICAL
acetate,2281,I-CHEMICAL
.,2281,O
OBJECTIVE,2282,O
:,2282,O
To,2282,O
evaluate,2282,O
the,2282,O
effect,2282,O
of,2282,O
mifepristone,2282,O
on,2282,O
the,2282,O
expression,2282,O
of,2282,O
endometrial,2282,O
steroid,2282,B-CHEMICAL
receptors,2282,I-GENE-N
and,2282,O
their,2282,O
co-factors,2282,O
in,2282,O
depot,2282,O
medroxyprogesterone,2282,B-CHEMICAL
acetate,2282,I-CHEMICAL
(,2282,O
DMPA,2282,O
),2282,O
users,2282,O
.,2282,O
DESIGN,2283,O
:,2283,O
A,2283,O
prospective,2283,O
",",2283,O
randomized,2283,O
",",2283,O
placebo-controlled,2283,O
trial,2283,O
.,2283,O
SETTING,2284,O
:,2284,O
Reproductive,2284,O
research,2284,O
center,2284,O
.,2284,O
PATIENT,2285,O
(,2285,O
S,2285,O
),2285,O
:,2285,O
Fifty,2285,O
healthy,2285,O
women,2285,O
with,2285,O
regular,2285,O
menstrual,2285,O
cycle,2285,O
.,2285,O
INTERVENTION,2286,O
(,2286,O
S,2286,O
),2286,O
:,2286,O
One,2286,O
hundred,2286,O
fifty,2286,O
milligrams,2286,O
of,2286,O
DMPA,2286,O
were,2286,O
given,2286,O
every,2286,O
3,2286,O
months,2286,O
.,2286,O
Two,2287,O
pills,2287,O
(,2287,O
25,2287,O
mg,2287,O
each,2287,O
),2287,O
of,2287,O
placebo,2287,O
or,2287,O
mifepristone,2287,B-CHEMICAL
were,2287,O
administered,2287,O
every,2287,O
14,2287,O
days,2287,O
during,2287,O
the,2287,O
DMPA,2287,O
therapy,2287,O
.,2287,O
Four,2288,O
endometrial,2288,O
biopsy,2288,O
specimens,2288,O
were,2288,O
obtained,2288,O
from,2288,O
each,2288,O
patient,2288,O
.,2288,O
MAIN,2289,O
OUTCOME,2289,O
MEASURE,2289,O
(,2289,O
S,2289,O
),2289,O
:,2289,O
The,2289,O
expression,2289,O
of,2289,O
estrogen,2289,B-CHEMICAL
receptor,2289,I-GENE-N
subtypes,2289,I-GENE-N
alpha,2289,I-GENE-N
and,2289,I-GENE-N
beta,2289,I-GENE-N
(,2289,O
ERalpha,2289,B-GENE-Y
and,2289,O
ERbeta,2289,B-GENE-Y
),2289,O
",",2289,O
progesterone,2289,B-CHEMICAL
receptors,2289,I-GENE-N
A,2289,I-GENE-N
and,2289,I-GENE-N
B,2289,I-GENE-N
(,2289,O
PRAB,2289,B-GENE-N
and,2289,O
PRB,2289,B-GENE-Y
),2289,O
",",2289,O
and,2289,O
androgen,2289,B-CHEMICAL
receptor,2289,I-GENE-N
messenger,2289,O
RNA,2289,O
and,2289,O
protein,2289,O
was,2289,O
detected,2289,O
by,2289,O
real-time,2289,O
polymerase,2289,O
chain,2289,O
reaction,2289,O
and,2289,O
immunohistochemistry,2289,O
",",2289,O
respectively,2289,O
.,2289,O
Steroid,2290,B-GENE-Y
receptor,2290,I-GENE-Y
coactivator,2290,I-GENE-Y
1,2290,I-GENE-Y
(,2290,O
SRC-1,2290,B-GENE-Y
),2290,O
",",2290,O
silencing,2290,O
mediator,2290,O
for,2290,O
retinoid,2290,B-GENE-N
and,2290,I-GENE-N
thyroid-hormone,2290,I-GENE-N
receptors,2290,I-GENE-N
",",2290,O
and,2290,O
cell,2290,O
proliferation,2290,O
were,2290,O
evaluated,2290,O
by,2290,O
immunohistochemistry,2290,O
.,2290,O
RESULT,2291,O
(,2291,O
S,2291,O
),2291,O
:,2291,O
The,2291,O
expression,2291,O
of,2291,O
endometrial,2291,O
ERalpha,2291,B-GENE-Y
",",2291,O
PRAB,2291,B-GENE-N
",",2291,O
PRB,2291,B-GENE-Y
",",2291,O
and,2291,O
SRC-1,2291,B-GENE-Y
was,2291,O
increased,2291,O
significantly,2291,O
after,2291,O
1,2291,O
week,2291,O
of,2291,O
mifepristone,2291,B-CHEMICAL
",",2291,O
but,2291,O
the,2291,O
increase,2291,O
was,2291,O
no,2291,O
longer,2291,O
seen,2291,O
after,2291,O
10,2291,O
weeks,2291,O
.,2291,O
A,2292,O
positive,2292,O
correlation,2292,O
between,2292,O
endometrial,2292,O
ERalpha,2292,B-GENE-Y
",",2292,O
PRAB,2292,B-GENE-N
",",2292,O
PRB,2292,B-GENE-Y
",",2292,O
and,2292,O
SRC-1,2292,B-GENE-Y
production,2292,O
and,2292,O
proliferation,2292,O
was,2292,O
demonstrated,2292,O
.,2292,O
CONCLUSION,2293,O
(,2293,O
S,2293,O
),2293,O
:,2293,O
Short-term,2293,O
exposure,2293,O
of,2293,O
mifepristone,2293,B-CHEMICAL
in,2293,O
new,2293,O
starters,2293,O
of,2293,O
DMPA,2293,O
increases,2293,O
the,2293,O
expression,2293,O
of,2293,O
endometrial,2293,O
ERalpha,2293,B-GENE-Y
",",2293,O
PRAB,2293,B-GENE-N
",",2293,O
PRB,2293,B-GENE-Y
",",2293,O
and,2293,O
SRC-1,2293,B-GENE-Y
and,2293,O
promotes,2293,O
cell,2293,O
proliferation,2293,O
.,2293,O
Prolonged,2294,O
exposure,2294,O
to,2294,O
mifepristone,2294,B-CHEMICAL
does,2294,O
not,2294,O
alter,2294,O
the,2294,O
suppression,2294,O
of,2294,O
these,2294,O
receptors,2294,O
that,2294,O
are,2294,O
caused,2294,O
by,2294,O
DMPA,2294,O
and,2294,O
continues,2294,O
to,2294,O
result,2294,O
in,2294,O
endometrial,2294,O
atrophy,2294,O
.,2294,O
Characterization,2295,O
of,2295,O
the,2295,O
molecular,2295,O
mechanisms,2295,O
involved,2295,O
in,2295,O
the,2295,O
increased,2295,O
insulin,2295,B-GENE-N
secretion,2295,O
in,2295,O
rats,2295,O
with,2295,O
acute,2295,O
liver,2295,O
failure,2295,O
.,2295,O
To,2296,O
investigate,2296,O
the,2296,O
mechanism,2296,O
of,2296,O
hyperinsulinaemia,2296,O
in,2296,O
rats,2296,O
with,2296,O
acute,2296,O
liver,2296,O
failure,2296,O
induced,2296,O
by,2296,O
the,2296,O
administration,2296,O
of,2296,O
d-galactosamine,2296,B-CHEMICAL
(,2296,O
GalN,2296,B-CHEMICAL
),2296,O
",",2296,O
we,2296,O
focused,2296,O
on,2296,O
the,2296,O
role,2296,O
of,2296,O
polyprimidine,2296,B-GENE-Y
tract-binding,2296,I-GENE-Y
protein,2296,I-GENE-Y
(,2296,O
PTB,2296,B-GENE-Y
),2296,O
in,2296,O
islet,2296,O
insulin,2296,B-GENE-N
synthesis,2296,O
.,2296,O
Recent,2297,O
reports,2297,O
indicate,2297,O
that,2297,O
PTB,2297,B-GENE-Y
binds,2297,O
and,2297,O
stabilizes,2297,O
mRNA,2297,O
encoding,2297,O
insulin,2297,B-GENE-N
and,2297,O
insulin,2297,B-GENE-N
secretory,2297,I-GENE-N
granule,2297,I-GENE-N
proteins,2297,I-GENE-N
",",2297,O
including,2297,O
islet,2297,B-GENE-Y
cell,2297,I-GENE-Y
autoantigen,2297,I-GENE-Y
512,2297,I-GENE-Y
(,2297,O
ICA512,2297,B-GENE-Y
),2297,O
",",2297,O
prohormone,2297,B-GENE-N
convertase,2297,I-GENE-N
1/3,2297,I-GENE-N
(,2297,O
PC1/3,2297,B-GENE-N
),2297,O
",",2297,O
and,2297,O
PC2,2297,B-GENE-Y
.,2297,O
In,2298,O
the,2298,O
present,2298,O
study,2298,O
",",2298,O
glucose-stimulated,2298,B-CHEMICAL
insulin,2298,B-GENE-N
secretion,2298,O
was,2298,O
significantly,2298,O
increased,2298,O
in,2298,O
GalN-treated,2298,B-CHEMICAL
rats,2298,O
compared,2298,O
to,2298,O
controls,2298,O
.,2298,O
Levels,2299,O
of,2299,O
mRNA,2299,O
encoding,2299,O
insulin,2299,B-GENE-Y
1,2299,I-GENE-Y
",",2299,O
ICA512,2299,B-GENE-Y
",",2299,O
and,2299,O
PC1/3,2299,B-GENE-N
were,2299,O
increased,2299,O
in,2299,O
the,2299,O
pancreatic,2299,O
islets,2299,O
of,2299,O
GalN-treated,2299,B-CHEMICAL
rats,2299,O
.,2299,O
This,2300,O
mRNA,2300,O
level,2300,O
elevation,2300,O
was,2300,O
not,2300,O
prevented,2300,O
by,2300,O
pretreatment,2300,O
with,2300,O
actinomycin,2300,B-CHEMICAL
D.,2300,O
When,2300,O
the,2300,O
PTB-binding,2300,B-GENE-N
site,2300,I-GENE-N
in,2300,O
insulin,2300,B-GENE-Y
1,2300,I-GENE-Y
mRNA,2300,O
was,2300,O
incubated,2300,O
with,2300,O
the,2300,O
islet,2300,O
cytosolic,2300,O
fraction,2300,O
",",2300,O
the,2300,O
RNA-protein,2300,O
complex,2300,O
level,2300,O
was,2300,O
increased,2300,O
in,2300,O
the,2300,O
cytosolic,2300,O
fraction,2300,O
obtained,2300,O
from,2300,O
GalN-treated,2300,B-CHEMICAL
rats,2300,O
compared,2300,O
to,2300,O
the,2300,O
level,2300,O
in,2300,O
control,2300,O
rats,2300,O
.,2300,O
The,2301,O
cytosolic,2301,O
fraction,2301,O
obtained,2301,O
from,2301,O
pancreatic,2301,O
islets,2301,O
obtained,2301,O
from,2301,O
GalN-treated,2301,B-CHEMICAL
rats,2301,O
had,2301,O
an,2301,O
increased,2301,O
PTB,2301,B-GENE-Y
level,2301,O
compared,2301,O
to,2301,O
the,2301,O
levels,2301,O
obtained,2301,O
from,2301,O
the,2301,O
pancreatic,2301,O
islets,2301,O
of,2301,O
control,2301,O
rats,2301,O
.,2301,O
These,2302,O
findings,2302,O
suggest,2302,O
that,2302,O
",",2302,O
in,2302,O
rats,2302,O
with,2302,O
acute,2302,O
liver,2302,O
failure,2302,O
",",2302,O
cytosolic,2302,O
PTB,2302,B-GENE-Y
binds,2302,O
and,2302,O
stabilizes,2302,O
mRNA,2302,O
encoding,2302,O
insulin,2302,B-GENE-N
and,2302,O
its,2302,O
secretory,2302,B-GENE-N
granule,2302,I-GENE-N
proteins,2302,I-GENE-N
.,2302,O
Cysteinyl,2303,B-GENE-Y
leukotriene,2303,I-GENE-Y
receptor,2303,I-GENE-Y
1,2303,I-GENE-Y
is,2303,O
involved,2303,O
in,2303,O
N-methyl-D-aspartate-mediated,2303,B-CHEMICAL
neuronal,2303,O
injury,2303,O
in,2303,O
mice,2303,O
.,2303,O
AIM,2304,O
:,2304,O
To,2304,O
determine,2304,O
whether,2304,O
cysteinyl,2304,B-CHEMICAL
leukotriene,2304,I-CHEMICAL
receptor,2304,I-GENE-Y
1,2304,I-GENE-Y
(,2304,O
CysLT1,2304,B-GENE-Y
receptor,2304,I-GENE-Y
),2304,O
is,2304,O
involved,2304,O
in,2304,O
N-methyl-D-aspartate,2304,B-CHEMICAL
(,2304,O
NMDA,2304,B-CHEMICAL
),2304,O
-induced,2304,O
excitotoxic,2304,O
injury,2304,O
in,2304,O
the,2304,O
mouse,2304,O
brain,2304,O
.,2304,O
METHODS,2305,O
:,2305,O
Brain,2305,O
injury,2305,O
was,2305,O
induced,2305,O
by,2305,O
NMDA,2305,B-CHEMICAL
microinjection,2305,O
(,2305,O
50-150,2305,O
nmol,2305,O
in,2305,O
0.5,2305,O
microL,2305,O
),2305,O
into,2305,O
the,2305,O
cerebral,2305,O
cortex,2305,O
.,2305,O
The,2306,O
changes,2306,O
in,2306,O
CysLT1,2306,B-GENE-Y
receptor,2306,I-GENE-Y
expression,2306,O
24,2306,O
h,2306,O
after,2306,O
NMDA,2306,B-CHEMICAL
injection,2306,O
and,2306,O
the,2306,O
effects,2306,O
of,2306,O
a,2306,O
CysLT1,2306,B-GENE-Y
receptor,2306,I-GENE-Y
antagonist,2306,O
",",2306,O
pranlukast,2306,B-CHEMICAL
(,2306,O
0.01,2306,O
and,2306,O
0.1,2306,O
mg/kg,2306,O
),2306,O
",",2306,O
an,2306,O
NMDA,2306,B-CHEMICAL
receptor,2306,I-GENE-N
antagonist,2306,O
",",2306,O
ketamine,2306,B-CHEMICAL
(,2306,O
30,2306,O
mg/kg,2306,O
),2306,O
",",2306,O
and,2306,O
an,2306,O
antioxidant,2306,O
",",2306,O
edaravone,2306,B-CHEMICAL
(,2306,O
9,2306,O
mg/kg,2306,O
),2306,O
were,2306,O
observed,2306,O
.,2306,O
RESULTS,2307,O
:,2307,O
In,2307,O
the,2307,O
NMDA-injured,2307,B-CHEMICAL
brain,2307,O
",",2307,O
the,2307,O
CysLT1,2307,B-GENE-Y
receptor,2307,I-GENE-Y
mRNA,2307,O
",",2307,O
and,2307,O
protein,2307,O
expression,2307,O
were,2307,O
upregulated,2307,O
",",2307,O
and,2307,O
the,2307,O
receptor,2307,O
was,2307,O
mainly,2307,O
localized,2307,O
in,2307,O
the,2307,O
neurons,2307,O
and,2307,O
not,2307,O
in,2307,O
the,2307,O
astrocytes,2307,O
.,2307,O
Pranlukast,2308,B-CHEMICAL
",",2308,O
ketamine,2308,B-CHEMICAL
and,2308,O
edaravone,2308,B-CHEMICAL
decreased,2308,O
NMDA-induced,2308,B-CHEMICAL
injury,2308,O
;,2308,O
pranlukast,2308,B-CHEMICAL
(,2308,O
0.1,2308,O
mg/kg,2308,O
),2308,O
and,2308,O
ketamine,2308,B-CHEMICAL
inhibited,2308,O
the,2308,O
upregulated,2308,O
expression,2308,O
of,2308,O
the,2308,O
CysLT1,2308,B-GENE-Y
receptor,2308,I-GENE-Y
.,2308,O
CONCLUSION,2309,O
:,2309,O
CysLT1,2309,B-GENE-Y
receptor,2309,I-GENE-Y
expression,2309,O
in,2309,O
neurons,2309,O
is,2309,O
upregulated,2309,O
after,2309,O
NMDA,2309,B-CHEMICAL
injection,2309,O
",",2309,O
and,2309,O
NMDA-induced,2309,B-CHEMICAL
responses,2309,O
are,2309,O
inhibited,2309,O
by,2309,O
CysLT1,2309,B-GENE-Y
receptor,2309,I-GENE-Y
antagonists,2309,O
",",2309,O
indicating,2309,O
that,2309,O
the,2309,O
increased,2309,O
CysLT1,2309,B-GENE-Y
receptor,2309,I-GENE-Y
is,2309,O
involved,2309,O
in,2309,O
NMDA,2309,B-CHEMICAL
excitotoxicity,2309,O
.,2309,O
Bcl-2,2310,B-GENE-Y
phosphorylation,2310,O
has,2310,O
pathological,2310,O
significance,2310,O
in,2310,O
human,2310,O
breast,2310,O
cancer,2310,O
.,2310,O
The,2311,O
anti-apoptotic,2311,O
molecule,2311,O
",",2311,O
Bcl-2,2311,B-GENE-Y
",",2311,O
is,2311,O
well,2311,O
known,2311,O
to,2311,O
play,2311,O
an,2311,O
important,2311,O
role,2311,O
in,2311,O
the,2311,O
chemoresistance,2311,O
of,2311,O
breast,2311,O
cancer,2311,O
.,2311,O
We,2312,O
have,2312,O
previously,2312,O
demonstrated,2312,O
that,2312,O
phosphorylation,2312,O
of,2312,O
Fas-associated,2312,B-GENE-Y
death,2312,I-GENE-Y
domain-containing,2312,I-GENE-Y
protein,2312,I-GENE-Y
(,2312,O
FADD,2312,B-GENE-Y
),2312,O
at,2312,O
194,2312,O
serine,2312,B-CHEMICAL
through,2312,O
c-jun,2312,B-GENE-N
NH2-terminal,2312,B-CHEMICAL
kinase,2312,I-GENE-N
(,2312,O
JNK,2312,B-GENE-N
),2312,O
activation,2312,O
sensitizes,2312,O
breast,2312,O
cancer,2312,O
cells,2312,O
to,2312,O
chemotherapy,2312,O
through,2312,O
accelerating,2312,O
cell,2312,O
cycle,2312,O
arrest,2312,O
at,2312,O
G2/M,2312,O
",",2312,O
and,2312,O
that,2312,O
Bcl-2,2312,B-GENE-Y
phosphorylation,2312,O
downstream,2312,O
of,2312,O
JNK/FADD,2312,B-GENE-N
plays,2312,O
an,2312,O
important,2312,O
role,2312,O
in,2312,O
cell,2312,O
growth,2312,O
suppression,2312,O
by,2312,O
paclitaxel,2312,B-CHEMICAL
.,2312,O
In,2313,O
this,2313,O
study,2313,O
",",2313,O
the,2313,O
clinicopathological,2313,O
association,2313,O
of,2313,O
phosphorylated,2313,B-GENE-Y
Bcl-2,2313,I-GENE-Y
(,2313,O
P-Bcl-2,2313,B-GENE-Y
),2313,O
with,2313,O
estrogen,2313,B-CHEMICAL
",",2313,I-GENE-N
progesterone,2313,B-CHEMICAL
",",2313,I-GENE-N
c-erbB-2,2313,I-GENE-N
receptors,2313,I-GENE-N
",",2313,O
p53,2313,B-GENE-Y
expressions,2313,O
and,2313,O
phosphorylated,2313,B-GENE-Y
FADD/JNK,2313,O
(,2313,O
P-FADD/JNK,2313,B-GENE-Y
),2313,O
was,2313,O
analyzed,2313,O
immunohistochemically,2313,O
using,2313,O
107,2313,O
human,2313,O
breast,2313,O
cancer,2313,O
specimens,2313,O
.,2313,O
Expression,2314,O
of,2314,O
P-Bcl-2,2314,B-GENE-Y
was,2314,O
found,2314,O
to,2314,O
significantly,2314,O
correlate,2314,O
with,2314,O
lymphatic,2314,O
invasion,2314,O
",",2314,O
lymph,2314,O
node,2314,O
metastasis,2314,O
",",2314,O
but,2314,O
not,2314,O
histological,2314,O
differentiation,2314,O
",",2314,O
tumor,2314,O
grade,2314,O
or,2314,O
vascular,2314,O
and,2314,O
fatty,2314,O
invasion,2314,O
.,2314,O
The,2315,O
positivity,2315,O
of,2315,O
P-Bcl-2,2315,B-GENE-Y
was,2315,O
also,2315,O
significantly,2315,O
correlated,2315,O
to,2315,O
that,2315,O
of,2315,O
P-FADD/JNK,2315,B-GENE-Y
.,2315,O
Thus,2316,O
",",2316,O
P-Bcl-2,2316,B-GENE-Y
as,2316,O
well,2316,O
as,2316,O
the,2316,O
P-FADD/JNK,2316,B-GENE-Y
parameter,2316,O
might,2316,O
be,2316,O
useful,2316,O
markers,2316,O
for,2316,O
cancer,2316,O
progression,2316,O
",",2316,O
independent,2316,O
of,2316,O
the,2316,O
hormone,2316,O
receptor,2316,O
status,2316,O
",",2316,O
in,2316,O
human,2316,O
breast,2316,O
cancers,2316,O
.,2316,O
Studies,2317,O
on,2317,O
the,2317,O
mechanism,2317,O
of,2317,O
arterial,2317,O
vasodilation,2317,O
produced,2317,O
by,2317,O
the,2317,O
novel,2317,O
antihypertensive,2317,O
agent,2317,O
",",2317,O
carvedilol,2317,B-CHEMICAL
.,2317,O
The,2318,O
mechanism,2318,O
(,2318,O
s,2318,O
),2318,O
responsible,2318,O
for,2318,O
arterial,2318,O
vasodilation,2318,O
observed,2318,O
following,2318,O
acute,2318,O
administration,2318,O
of,2318,O
racemic,2318,B-CHEMICAL
carvedilol,2318,I-CHEMICAL
",",2318,O
a,2318,O
novel,2318,O
vasodilator/beta,2318,O
adrenoceptor,2318,I-GENE-N
antagonist,2318,O
",",2318,O
has,2318,O
been,2318,O
investigated,2318,O
in,2318,O
rats,2318,O
.,2318,O
In,2319,O
conscious,2319,O
spontaneously,2319,O
hypertensive,2319,O
rats,2319,O
",",2319,O
carvedilol,2319,B-CHEMICAL
(,2319,O
0.03-3.0,2319,O
mg/kg,2319,O
",",2319,O
iv,2319,O
),2319,O
produced,2319,O
a,2319,O
dose-dependent,2319,O
reduction,2319,O
in,2319,O
blood,2319,O
pressure,2319,O
with,2319,O
no,2319,O
significant,2319,O
effect,2319,O
on,2319,O
heart,2319,O
rate,2319,O
.,2319,O
Because,2320,O
cardiac,2320,O
output,2320,O
was,2320,O
relatively,2320,O
unaffected,2320,O
",",2320,O
the,2320,O
antihypertensive,2320,O
response,2320,O
of,2320,O
carvedilol,2320,B-CHEMICAL
was,2320,O
associated,2320,O
with,2320,O
a,2320,O
dose-dependent,2320,O
reduction,2320,O
in,2320,O
total,2320,O
peripheral,2320,O
vascular,2320,O
resistance,2320,O
.,2320,O
Submaximal,2321,O
antihypertensive,2321,O
doses,2321,O
of,2321,O
carvedilol,2321,B-CHEMICAL
were,2321,O
chosen,2321,O
for,2321,O
mechanism,2321,O
of,2321,O
action,2321,O
studies,2321,O
in,2321,O
pithed,2321,O
rats,2321,O
.,2321,O
Carvedilol,2322,B-CHEMICAL
(,2322,O
0.3,2322,O
mg/kg,2322,O
",",2322,O
iv,2322,O
),2322,O
produced,2322,O
a,2322,O
significant,2322,O
inhibition,2322,O
of,2322,O
the,2322,O
beta,2322,B-GENE-Y
1,2322,I-GENE-Y
adrenoceptor,2322,I-GENE-Y
mediated,2322,O
positive,2322,O
chronotropic,2322,O
response,2322,O
to,2322,O
isoproterenol,2322,B-CHEMICAL
.,2322,O
This,2323,O
same,2323,O
dose,2323,O
of,2323,O
carvedilol,2323,B-CHEMICAL
also,2323,O
inhibited,2323,O
",",2323,O
but,2323,O
to,2323,O
a,2323,O
lesser,2323,O
degree,2323,O
",",2323,O
the,2323,O
beta,2323,B-GENE-Y
2,2323,I-GENE-Y
adrenoceptor,2323,I-GENE-Y
mediated,2323,O
vasodepressor,2323,O
response,2323,O
to,2323,O
salbutamol,2323,B-CHEMICAL
in,2323,O
pithed,2323,O
rats,2323,O
whose,2323,O
blood,2323,O
pressure,2323,O
was,2323,O
elevated,2323,O
by,2323,O
a,2323,O
constant,2323,O
intravenous,2323,O
infusion,2323,O
of,2323,O
angiotensin,2323,B-GENE-Y
II,2323,I-GENE-Y
.,2323,O
Thus,2324,O
",",2324,O
carvedilol,2324,B-CHEMICAL
blocks,2324,O
both,2324,O
beta,2324,B-GENE-N
1,2324,I-GENE-N
and,2324,I-GENE-N
beta,2324,I-GENE-N
2,2324,I-GENE-N
adrenoceptors,2324,I-GENE-N
at,2324,O
antihypertensive,2324,O
doses,2324,O
",",2324,O
with,2324,O
modest,2324,O
selectivity,2324,O
being,2324,O
observed,2324,O
for,2324,O
the,2324,O
beta,2324,B-GENE-Y
1,2324,I-GENE-Y
adrenoceptor,2324,I-GENE-Y
subtype,2324,O
.,2324,O
Carvedilol,2325,B-CHEMICAL
produced,2325,O
significant,2325,O
inhibition,2325,O
of,2325,O
the,2325,O
alpha,2325,B-GENE-N
1,2325,I-GENE-N
adrenoceptor,2325,I-GENE-N
mediated,2325,O
pressor,2325,O
response,2325,O
to,2325,O
cirazoline,2325,B-CHEMICAL
in,2325,O
the,2325,O
pithed,2325,O
rat,2325,O
",",2325,O
but,2325,O
had,2325,O
no,2325,O
effect,2325,O
on,2325,O
the,2325,O
alpha,2325,B-GENE-Y
2,2325,I-GENE-Y
adrenoceptor,2325,I-GENE-Y
mediated,2325,O
pressor,2325,O
response,2325,O
to,2325,O
B-HT,2325,B-CHEMICAL
933,2325,I-CHEMICAL
",",2325,O
suggesting,2325,O
that,2325,O
carvedilol,2325,B-CHEMICAL
is,2325,O
also,2325,O
an,2325,O
alpha,2325,B-GENE-N
1,2325,I-GENE-N
adrenoceptor,2325,I-GENE-N
antagonist,2325,O
at,2325,O
antihypertensive,2325,O
doses,2325,O
.,2325,O
Carvedilol,2326,B-CHEMICAL
had,2326,O
no,2326,O
effect,2326,O
on,2326,O
the,2326,O
pressor,2326,O
response,2326,O
elicited,2326,O
by,2326,O
angiotensin,2326,B-GENE-Y
II,2326,I-GENE-Y
",",2326,O
indicating,2326,O
a,2326,O
lack,2326,O
of,2326,O
nonspecific,2326,O
vasodilator,2326,O
activity,2326,O
.,2326,O
The,2327,O
vasopressor,2327,O
response,2327,O
to,2327,O
the,2327,O
calcium,2327,B-CHEMICAL
channel,2327,I-GENE-N
activator,2327,O
",",2327,O
BAY-K-8644,2327,B-CHEMICAL
",",2327,O
which,2327,O
is,2327,O
mediated,2327,O
through,2327,O
the,2327,O
opening,2327,O
of,2327,O
voltage,2327,B-GENE-N
dependent,2327,I-GENE-N
calcium,2327,B-CHEMICAL
channels,2327,I-GENE-N
and,2327,O
the,2327,O
subsequent,2327,O
translocation,2327,O
of,2327,O
extracellular,2327,O
calcium,2327,B-CHEMICAL
",",2327,O
was,2327,O
significantly,2327,O
inhibited,2327,O
by,2327,O
carvedilol,2327,B-CHEMICAL
(,2327,O
1,2327,O
mg/kg,2327,O
",",2327,O
iv,2327,O
),2327,O
",",2327,O
suggesting,2327,O
that,2327,O
carvedilol,2327,B-CHEMICAL
is,2327,O
also,2327,O
a,2327,O
calcium,2327,B-GENE-N
channel,2327,I-GENE-N
antagonist,2327,O
",",2327,O
consistent,2327,O
with,2327,O
our,2327,O
previous,2327,O
in,2327,O
vitro,2327,O
studies,2327,O
.,2327,O
In,2328,O
anesthetized,2328,O
spontaneously,2328,O
hypertensive,2328,O
rats,2328,O
",",2328,O
the,2328,O
antihypertensive,2328,O
activity,2328,O
of,2328,O
carvedilol,2328,B-CHEMICAL
was,2328,O
nearly,2328,O
abolished,2328,O
by,2328,O
combined,2328,O
pretreatment,2328,O
of,2328,O
the,2328,O
rats,2328,O
with,2328,O
high,2328,O
doses,2328,O
of,2328,O
the,2328,O
alpha,2328,B-GENE-N
1,2328,I-GENE-N
adrenoceptor,2328,I-GENE-N
antagonist,2328,O
",",2328,O
prazosin,2328,B-CHEMICAL
(,2328,O
1,2328,O
mg/kg,2328,O
",",2328,O
iv,2328,O
),2328,O
",",2328,O
and,2328,O
the,2328,O
nonselective,2328,O
beta,2328,B-GENE-N
adrenoceptor,2328,I-GENE-N
antagonist,2328,O
",",2328,O
propranolol,2328,B-CHEMICAL
(,2328,O
3,2328,O
mg/kg,2328,O
",",2328,O
iv,2328,O
),2328,O
",",2328,O
suggesting,2328,O
that,2328,O
the,2328,O
majority,2328,O
of,2328,O
the,2328,O
antihypertensive,2328,O
response,2328,O
produced,2328,O
by,2328,O
carvedilol,2328,B-CHEMICAL
may,2328,O
be,2328,O
accounted,2328,O
for,2328,O
by,2328,O
blockade,2328,O
of,2328,O
beta,2328,B-GENE-N
and,2328,I-GENE-N
alpha,2328,I-GENE-N
1,2328,I-GENE-N
adrenoceptors,2328,I-GENE-N
.,2328,O
We,2329,O
therefore,2329,O
conclude,2329,O
that,2329,O
carvedilol,2329,B-CHEMICAL
",",2329,O
at,2329,O
antihypertensive,2329,O
doses,2329,O
",",2329,O
is,2329,O
an,2329,O
antagonist,2329,O
of,2329,O
beta,2329,B-GENE-N
1,2329,I-GENE-N
",",2329,I-GENE-N
beta,2329,I-GENE-N
2,2329,I-GENE-N
",",2329,I-GENE-N
and,2329,I-GENE-N
alpha,2329,I-GENE-N
1,2329,I-GENE-N
adrenoceptors,2329,I-GENE-N
",",2329,O
and,2329,O
also,2329,O
of,2329,O
calcium,2329,B-GENE-N
channels,2329,I-GENE-N
in,2329,O
vascular,2329,O
smooth,2329,O
muscle,2329,O
.,2329,O
(,2330,O
ABSTRACT,2330,O
TRUNCATED,2330,O
AT,2330,O
400,2330,O
WORDS,2330,O
),2330,O
Clinical,2331,O
",",2331,O
biochemical,2331,O
and,2331,O
molecular,2331,O
diagnosis,2331,O
of,2331,O
a,2331,O
compound,2331,O
homozygote,2331,O
for,2331,O
the,2331,O
254,2331,O
bp,2331,O
deletion-8,2331,O
bp,2331,O
insertion,2331,O
of,2331,O
the,2331,O
APRT,2331,B-GENE-Y
gene,2331,O
suffering,2331,O
from,2331,O
severe,2331,O
renal,2331,O
failure,2331,O
.,2331,O
OBJECTIVE,2332,O
:,2332,O
To,2332,O
determine,2332,O
the,2332,O
type,2332,O
of,2332,O
mutation,2332,O
in,2332,O
a,2332,O
patient,2332,O
with,2332,O
clinical,2332,O
diagnosis,2332,O
of,2332,O
suspected,2332,O
APRT,2332,B-GENE-Y
deficiency,2332,O
.,2332,O
DESIGN,2333,O
AND,2333,O
METHODS,2333,O
:,2333,O
A,2333,O
51-year-old,2333,O
male,2333,O
patient,2333,O
",",2333,O
with,2333,O
a,2333,O
clinical,2333,O
history,2333,O
of,2333,O
two,2333,O
prior,2333,O
episodes,2333,O
of,2333,O
renal,2333,O
colic,2333,O
with,2333,O
urinary,2333,O
stone,2333,O
excretion,2333,O
(,2333,O
reported,2333,O
as,2333,O
uric,2333,B-CHEMICAL
acid,2333,I-CHEMICAL
stones,2333,O
in,2333,O
the,2333,O
first,2333,O
episode,2333,O
and,2333,O
as,2333,O
calcium,2333,B-CHEMICAL
oxalate,2333,I-CHEMICAL
stones,2333,O
in,2333,O
the,2333,O
second,2333,O
),2333,O
",",2333,O
was,2333,O
admitted,2333,O
to,2333,O
the,2333,O
hospital,2333,O
with,2333,O
severe,2333,O
non-oliguric,2333,O
renal,2333,O
failure,2333,O
(,2333,O
1.06,2333,O
mmol/L,2333,O
serum,2333,O
creatinine,2333,B-CHEMICAL
),2333,O
",",2333,O
severe,2333,O
hyponatremia,2333,O
(,2333,O
114,2333,O
mmol/L,2333,O
Na,2333,B-CHEMICAL
(,2333,I-CHEMICAL
+,2333,I-CHEMICAL
),2333,I-CHEMICAL
),2333,O
",",2333,O
metabolic,2333,O
acidosis,2333,O
(,2333,O
14,2333,O
mmol/L,2333,O
HCO,2333,B-CHEMICAL
(,2333,I-CHEMICAL
3,2333,I-CHEMICAL
),2333,I-CHEMICAL
(,2333,I-CHEMICAL
-,2333,I-CHEMICAL
),2333,I-CHEMICAL
),2333,O
and,2333,O
uricemia,2333,O
in,2333,O
the,2333,O
normal,2333,O
range,2333,O
.,2333,O
Abnormalities,2334,O
at,2334,O
renal,2334,O
scan,2334,O
and,2334,O
persistency,2334,O
of,2334,O
severe,2334,O
renal,2334,O
failure,2334,O
required,2334,O
to,2334,O
start,2334,O
haemodialysis,2334,O
.,2334,O
Results,2335,O
of,2335,O
renal,2335,O
biopsy,2335,O
prompted,2335,O
us,2335,O
to,2335,O
undertake,2335,O
a,2335,O
biochemical,2335,O
and,2335,O
molecular,2335,O
biological,2335,O
evaluation,2335,O
of,2335,O
the,2335,O
patient,2335,O
for,2335,O
suspected,2335,O
adenine,2335,B-CHEMICAL
phosphoribosyltransferase,2335,I-GENE-Y
(,2335,O
APRT,2335,B-GENE-Y
),2335,O
deficiency,2335,O
.,2335,O
RESULTS,2336,O
:,2336,O
HPLC,2336,O
analysis,2336,O
of,2336,O
serum,2336,O
and,2336,O
urine,2336,O
",",2336,O
for,2336,O
determining,2336,O
purine,2336,B-CHEMICAL
derivative,2336,O
profile,2336,O
",",2336,O
showed,2336,O
the,2336,O
pathological,2336,O
presence,2336,O
of,2336,O
adenine,2336,B-CHEMICAL
in,2336,O
both,2336,O
biological,2336,O
fluids,2336,O
(,2336,O
3.57,2336,O
micromol/L,2336,O
and,2336,O
7.11,2336,O
micromol/mmol,2336,O
creatinine,2336,B-CHEMICAL
in,2336,O
serum,2336,O
and,2336,O
urine,2336,O
",",2336,O
respectively,2336,O
;,2336,O
not,2336,O
detectable,2336,O
in,2336,O
both,2336,O
fluids,2336,O
in,2336,O
healthy,2336,O
controls,2336,O
),2336,O
.,2336,O
APRT,2337,B-GENE-Y
assay,2337,O
in,2337,O
a,2337,O
sample,2337,O
of,2337,O
patient,2337,O
hemolysate,2337,O
showed,2337,O
no,2337,O
detectable,2337,O
activity,2337,O
of,2337,O
the,2337,O
enzyme,2337,O
(,2337,O
25.56+/-9.55,2337,O
U/L,2337,O
red,2337,O
blood,2337,O
cells,2337,O
in,2337,O
control,2337,O
healthy,2337,O
subjects,2337,O
),2337,O
.,2337,O
Molecular,2338,O
biological,2338,O
analysis,2338,O
of,2338,O
the,2338,O
amplified,2338,O
APRT,2338,B-GENE-Y
gene,2338,O
revealed,2338,O
that,2338,O
the,2338,O
patient,2338,O
harboured,2338,O
in,2338,O
exon,2338,O
3,2338,O
a,2338,O
homozygous,2338,O
254,2338,O
bp,2338,O
deletion-8,2338,O
bp,2338,O
insertion,2338,O
",",2338,O
previously,2338,O
described,2338,O
only,2338,O
once,2338,O
in,2338,O
a,2338,O
compound,2338,O
heterozygote,2338,O
.,2338,O
Analysis,2339,O
of,2339,O
the,2339,O
patient,2339,O
family,2339,O
showed,2339,O
that,2339,O
heterozygotes,2339,O
for,2339,O
this,2339,O
APRT,2339,B-GENE-Y
gene,2339,O
mutation,2339,O
",",2339,O
in,2339,O
spite,2339,O
of,2339,O
a,2339,O
69,2339,O
%,2339,O
lower,2339,O
APRT,2339,B-GENE-Y
enzymatic,2339,O
activity,2339,O
than,2339,O
that,2339,O
of,2339,O
healthy,2339,O
subjects,2339,O
",",2339,O
had,2339,O
no,2339,O
detectable,2339,O
adenine,2339,B-CHEMICAL
concentrations,2339,O
in,2339,O
both,2339,O
serum,2339,O
and,2339,O
urine,2339,O
.,2339,O
CONCLUSIONS,2340,O
:,2340,O
Results,2340,O
of,2340,O
the,2340,O
first,2340,O
patient,2340,O
harbouring,2340,O
the,2340,O
homozygous,2340,O
254,2340,O
bp,2340,O
deletion-8,2340,O
bp,2340,O
insertion,2340,O
of,2340,O
the,2340,O
APRT,2340,B-GENE-Y
gene,2340,O
strongly,2340,O
indicated,2340,O
that,2340,O
definitive,2340,O
diagnosis,2340,O
of,2340,O
APRT,2340,B-GENE-Y
deficiency,2340,O
(,2340,O
often,2340,O
under,2340,O
or,2340,O
misdiagnosed,2340,O
),2340,O
would,2340,O
require,2340,O
a,2340,O
combined,2340,O
clinical,2340,O
",",2340,O
biochemical,2340,O
and,2340,O
molecular,2340,O
biological,2340,O
evaluation,2340,O
.,2340,O
Phospholipase,2341,B-GENE-Y
Cgamma1,2341,I-GENE-Y
negatively,2341,O
regulates,2341,O
growth,2341,B-GENE-Y
hormone,2341,I-GENE-Y
signalling,2341,O
by,2341,O
forming,2341,O
a,2341,O
ternary,2341,O
complex,2341,O
with,2341,O
Jak2,2341,B-GENE-Y
and,2341,O
protein,2341,B-GENE-Y
tyrosine,2341,B-CHEMICAL
phosphatase-1B,2341,I-GENE-Y
.,2341,O
Growth,2342,B-GENE-Y
hormone,2342,I-GENE-Y
binds,2342,O
to,2342,O
its,2342,O
membrane,2342,O
receptor,2342,O
(,2342,O
GHR,2342,B-GENE-Y
),2342,O
",",2342,O
whereby,2342,O
it,2342,O
regulates,2342,O
many,2342,O
cellular,2342,O
functions,2342,O
",",2342,O
including,2342,O
proliferation,2342,O
",",2342,O
differentiation,2342,O
and,2342,O
chemotaxis,2342,O
.,2342,O
However,2343,O
",",2343,O
although,2343,O
the,2343,O
activation,2343,O
of,2343,O
growth,2343,B-GENE-Y
hormone-mediated,2343,O
signalling,2343,O
is,2343,O
well,2343,O
understood,2343,O
",",2343,O
the,2343,O
precise,2343,O
mechanism,2343,O
responsible,2343,O
for,2343,O
its,2343,O
regulation,2343,O
has,2343,O
not,2343,O
been,2343,O
elucidated,2343,O
.,2343,O
Here,2344,O
",",2344,O
we,2344,O
demonstrate,2344,O
that,2344,O
phospholipase,2344,B-GENE-Y
Cgamma1,2344,I-GENE-Y
(,2344,O
PLCgamma1,2344,B-GENE-Y
),2344,O
modulates,2344,O
the,2344,O
action,2344,O
of,2344,O
growth,2344,B-GENE-Y
hormone-mediated,2344,O
signalling,2344,O
by,2344,O
interacting,2344,O
with,2344,O
tyrosine,2344,B-CHEMICAL
kinase,2344,I-GENE-Y
Jak2,2344,I-GENE-Y
(,2344,O
janus,2344,B-GENE-Y
kinase,2344,I-GENE-Y
2,2344,I-GENE-Y
),2344,O
in,2344,O
a,2344,O
growth,2344,B-GENE-Y
hormone-dependent,2344,O
manner,2344,O
.,2344,O
In,2345,O
the,2345,O
absence,2345,O
of,2345,O
PLCgamma1,2345,B-GENE-Y
(,2345,O
PLCgamma1,2345,B-GENE-Y
(,2345,O
-/-,2345,O
),2345,O
),2345,O
",",2345,O
growth,2345,B-GENE-Y
hormone-induced,2345,O
JAK2,2345,B-GENE-Y
and,2345,O
STAT5,2345,B-GENE-Y
phosphorylation,2345,O
significantly,2345,O
increased,2345,O
in,2345,O
mouse,2345,O
embryonic,2345,O
fibroblasts,2345,O
(,2345,O
MEFs,2345,O
),2345,O
.,2345,O
Furthermore,2346,O
",",2346,O
the,2346,O
re-expression,2346,O
of,2346,O
PLCgamma1,2346,B-GENE-Y
reduced,2346,O
growth,2346,B-GENE-Y
hormone-induced,2346,O
Jak2,2346,B-GENE-Y
activation,2346,O
.,2346,O
Growth,2347,B-GENE-Y
hormone-induced,2347,O
Jak2,2347,B-GENE-Y
phosphorylation,2347,O
was,2347,O
enhanced,2347,O
by,2347,O
siRNA-specific,2347,O
knockdown,2347,O
of,2347,O
PLCgamma1,2347,B-GENE-Y
.,2347,O
Interestingly,2348,O
",",2348,O
PLCgamma1,2348,B-GENE-Y
physically,2348,O
linked,2348,O
Jak2,2348,B-GENE-Y
and,2348,O
protein,2348,B-GENE-N
tyrosine,2348,I-GENE-N
phosphatase-1B,2348,I-GENE-N
(,2348,O
PTP-1B,2348,B-GENE-N
),2348,O
by,2348,O
binding,2348,O
to,2348,O
both,2348,O
using,2348,O
different,2348,O
domains,2348,O
",",2348,O
and,2348,O
this,2348,O
process,2348,O
was,2348,O
implicated,2348,O
in,2348,O
the,2348,O
modulation,2348,O
of,2348,O
cytokine,2348,B-GENE-N
signalling,2348,O
through,2348,O
Jak2,2348,B-GENE-Y
.,2348,O
In,2349,O
addition,2349,O
",",2349,O
in,2349,O
PLCgamma1,2349,B-GENE-Y
(,2349,O
-/-,2349,O
),2349,O
MEFs,2349,O
",",2349,O
growth,2349,B-GENE-Y
hormone-dependent,2349,O
c-Fos,2349,B-GENE-Y
activation,2349,O
was,2349,O
upregulated,2349,O
and,2349,O
growth,2349,B-GENE-Y
hormone-induced,2349,O
proliferation,2349,O
was,2349,O
potentiated,2349,O
.,2349,O
These,2350,O
results,2350,O
suggest,2350,O
that,2350,O
PLCgamma1,2350,B-GENE-Y
has,2350,O
a,2350,O
key,2350,O
function,2350,O
in,2350,O
the,2350,O
regulation,2350,O
of,2350,O
growth,2350,B-GENE-Y
hormone-mediated,2350,O
signalling,2350,O
by,2350,O
negatively,2350,O
regulating,2350,O
Jak2,2350,B-GENE-Y
activation,2350,O
.,2350,O
Increased,2351,O
responsiveness,2351,O
of,2351,O
rat,2351,O
colonic,2351,O
splanchnic,2351,O
afferents,2351,O
to,2351,O
5-HT,2351,B-CHEMICAL
after,2351,O
inflammation,2351,O
and,2351,O
recovery,2351,O
.,2351,O
5-Hydroxytryptamine,2352,B-CHEMICAL
(,2352,O
5-HT,2352,B-CHEMICAL
),2352,O
activates,2352,O
colonic,2352,O
splanchnic,2352,O
afferents,2352,O
",",2352,O
a,2352,O
mechanism,2352,O
by,2352,O
which,2352,O
it,2352,O
has,2352,O
been,2352,O
implicated,2352,O
in,2352,O
generating,2352,O
symptoms,2352,O
in,2352,O
postinfectious,2352,O
and,2352,O
postinflammatory,2352,O
states,2352,O
in,2352,O
humans,2352,O
.,2352,O
Here,2353,O
we,2353,O
compared,2353,O
mechanisms,2353,O
of,2353,O
colonic,2353,O
afferent,2353,O
activation,2353,O
by,2353,O
5-HT,2353,B-CHEMICAL
and,2353,O
mechanical,2353,O
stimuli,2353,O
in,2353,O
normal,2353,O
and,2353,O
inflamed,2353,O
rat,2353,O
colon,2353,O
",",2353,O
and,2353,O
after,2353,O
recovery,2353,O
from,2353,O
inflammation,2353,O
.,2353,O
Colonic,2354,O
inflammation,2354,O
was,2354,O
induced,2354,O
in,2354,O
rats,2354,O
by,2354,O
dextran,2354,B-CHEMICAL
sulphate,2354,I-CHEMICAL
sodium,2354,I-CHEMICAL
.,2354,O
Single-fibre,2355,O
recordings,2355,O
of,2355,O
colonic,2355,O
lumbar,2355,O
splanchnic,2355,O
afferents,2355,O
revealed,2355,O
that,2355,O
58,2355,O
%,2355,O
of,2355,O
endings,2355,O
responded,2355,O
to,2355,O
5-HT,2355,B-CHEMICAL
(,2355,O
10,2355,O
(,2355,O
-4,2355,O
),2355,O
m,2355,O
),2355,O
in,2355,O
controls,2355,O
",",2355,O
88,2355,O
%,2355,O
in,2355,O
acute,2355,O
inflammation,2355,O
(,2355,O
P,2355,O
<,2355,O
0.05,2355,O
),2355,O
and,2355,O
75,2355,O
%,2355,O
after,2355,O
21,2355,O
days,2355,O
recovery,2355,O
(,2355,O
P,2355,O
<,2355,O
0.05,2355,O
versus,2355,O
control,2355,O
),2355,O
.,2355,O
Maximal,2356,O
responses,2356,O
to,2356,O
5-HT,2356,B-CHEMICAL
were,2356,O
also,2356,O
larger,2356,O
",",2356,O
and,2356,O
the,2356,O
estimated,2356,O
EC50,2356,O
was,2356,O
reduced,2356,O
from,2356,O
3.2,2356,O
x,2356,O
10,2356,O
(,2356,O
-6,2356,O
),2356,O
to,2356,O
8,2356,O
x,2356,O
10,2356,O
(,2356,O
-7,2356,O
),2356,O
m,2356,O
in,2356,O
acute,2356,O
inflammation,2356,O
and,2356,O
recovered,2356,O
to,2356,O
2,2356,O
x,2356,O
10,2356,O
(,2356,O
-6,2356,O
),2356,O
m,2356,O
after,2356,O
recovery,2356,O
.,2356,O
Responsiveness,2357,O
to,2357,O
mechanical,2357,O
stimulation,2357,O
was,2357,O
unaffected,2357,O
.,2357,O
5-HT3,2358,B-GENE-Y
receptor,2358,I-GENE-Y
antagonism,2358,O
with,2358,O
alosetron,2358,B-CHEMICAL
reduced,2358,O
responses,2358,O
to,2358,O
5-HT,2358,B-CHEMICAL
in,2358,O
controls,2358,O
but,2358,O
not,2358,O
during,2358,O
inflammation,2358,O
.,2358,O
Responses,2359,O
to,2359,O
the,2359,O
mast,2359,O
cell,2359,O
degranulator,2359,O
48/80,2359,O
mimicked,2359,O
those,2359,O
to,2359,O
5-HT,2359,B-CHEMICAL
in,2359,O
inflamed,2359,O
tissue,2359,O
but,2359,O
not,2359,O
in,2359,O
controls,2359,O
",",2359,O
and,2359,O
more,2359,O
5-HT-containing,2359,B-CHEMICAL
mast,2359,O
cells,2359,O
were,2359,O
seen,2359,O
close,2359,O
to,2359,O
calcitonin,2359,B-GENE-N
gene-related,2359,I-GENE-N
peptide-containing,2359,O
fibres,2359,O
in,2359,O
inflamed,2359,O
serosa,2359,O
.,2359,O
We,2360,O
conclude,2360,O
that,2360,O
colonic,2360,O
serosal,2360,O
and,2360,O
mesenteric,2360,O
endings,2360,O
exhibit,2360,O
increased,2360,O
sensitivity,2360,O
to,2360,O
5-HT,2360,B-CHEMICAL
in,2360,O
inflammation,2360,O
",",2360,O
with,2360,O
both,2360,O
an,2360,O
increase,2360,O
in,2360,O
proportion,2360,O
of,2360,O
responders,2360,O
and,2360,O
an,2360,O
increase,2360,O
in,2360,O
sensitivity,2360,O
",",2360,O
which,2360,O
is,2360,O
maintained,2360,O
after,2360,O
healing,2360,O
of,2360,O
inflammation,2360,O
.,2360,O
This,2361,O
is,2361,O
associated,2361,O
with,2361,O
alterations,2361,O
in,2361,O
the,2361,O
roles,2361,O
of,2361,O
5-HT3,2361,B-GENE-Y
receptors,2361,I-GENE-Y
and,2361,O
mast,2361,O
cells,2361,O
.,2361,O
The,2362,O
role,2362,O
of,2362,O
extranuclear,2362,O
signaling,2362,O
actions,2362,O
of,2362,O
progesterone,2362,B-GENE-Y
receptor,2362,I-GENE-Y
in,2362,O
mediating,2362,O
progesterone,2362,B-CHEMICAL
regulation,2362,O
of,2362,O
gene,2362,O
expression,2362,O
and,2362,O
the,2362,O
cell,2362,O
cycle,2362,O
.,2362,O
Human,2363,B-GENE-Y
progesterone,2363,B-CHEMICAL
receptor,2363,I-GENE-Y
(,2363,O
PR,2363,B-GENE-Y
),2363,O
contains,2363,O
a,2363,O
motif,2363,O
that,2363,O
interacts,2363,O
with,2363,O
the,2363,O
SH3,2363,B-GENE-N
domain,2363,I-GENE-N
of,2363,O
Src,2363,B-GENE-Y
and,2363,O
mediates,2363,O
rapid,2363,O
activation,2363,O
of,2363,O
Src,2363,B-GENE-Y
and,2363,O
downstream,2363,O
MAPK,2363,B-GENE-N
(,2363,O
Erk-1/-2,2363,B-GENE-N
),2363,O
without,2363,O
relying,2363,O
on,2363,O
the,2363,O
transcriptional,2363,O
activity,2363,O
of,2363,O
the,2363,O
receptor,2363,O
.,2363,O
Here,2364,O
we,2364,O
investigated,2364,O
the,2364,O
role,2364,O
and,2364,O
intracellular,2364,O
location,2364,O
of,2364,O
this,2364,O
nontranscriptional,2364,O
activity,2364,O
of,2364,O
PR,2364,B-GENE-Y
.,2364,O
Progestin,2365,B-CHEMICAL
activation,2365,O
of,2365,O
Src/MAPK,2365,B-GENE-Y
occurred,2365,O
outside,2365,O
the,2365,O
nucleus,2365,O
with,2365,O
the,2365,O
B,2365,B-GENE-Y
isoform,2365,I-GENE-Y
of,2365,I-GENE-Y
PR,2365,I-GENE-Y
that,2365,O
was,2365,O
distributed,2365,O
between,2365,O
the,2365,O
cytoplasm,2365,O
and,2365,O
nucleus,2365,O
",",2365,O
but,2365,O
not,2365,O
with,2365,O
PR-A,2365,B-GENE-Y
that,2365,O
was,2365,O
predominantly,2365,O
nuclear,2365,O
.,2365,O
Breast,2366,O
cancer,2366,O
cells,2366,O
stably,2366,O
expressing,2366,O
wild-type,2366,O
PR-B,2366,B-GENE-Y
or,2366,O
PR-B,2366,B-GENE-Y
with,2366,O
disrupting,2366,O
point,2366,O
mutations,2366,O
in,2366,O
the,2366,O
SH3,2366,B-GENE-N
domain,2366,I-GENE-N
binding,2366,I-GENE-N
motif,2366,I-GENE-N
(,2366,O
PR-BDeltaSH3,2366,B-GENE-N
),2366,O
that,2366,O
do,2366,O
not,2366,O
affect,2366,O
the,2366,O
transcriptional,2366,O
activity,2366,O
of,2366,O
PR,2366,B-GENE-Y
",",2366,O
were,2366,O
compared,2366,O
for,2366,O
effects,2366,O
of,2366,O
progestin,2366,B-CHEMICAL
on,2366,O
endogenous,2366,O
target,2366,O
gene,2366,O
expression,2366,O
and,2366,O
cell,2366,O
proliferation,2366,O
.,2366,O
Progestin,2367,B-CHEMICAL
induction,2367,O
of,2367,O
the,2367,O
cyclin,2367,B-GENE-Y
D1,2367,I-GENE-Y
gene,2367,O
",",2367,O
which,2367,O
lacks,2367,O
a,2367,O
progesterone,2367,B-CHEMICAL
response,2367,I-GENE-N
element,2367,I-GENE-N
",",2367,O
was,2367,O
dependent,2367,O
on,2367,O
PR,2367,B-GENE-Y
activation,2367,O
of,2367,O
the,2367,O
Src/MAPK,2367,B-GENE-Y
pathway,2367,O
",",2367,O
whereas,2367,O
induction,2367,O
of,2367,O
the,2367,O
Sgk,2367,B-GENE-Y
(,2367,O
serum,2367,B-GENE-Y
and,2367,I-GENE-Y
glucocorticoid,2367,I-GENE-Y
regulated,2367,I-GENE-Y
kinase,2367,I-GENE-Y
),2367,O
gene,2367,O
that,2367,O
contains,2367,O
a,2367,O
functional,2367,O
progesterone,2367,B-CHEMICAL
response,2367,I-GENE-N
element,2367,I-GENE-N
was,2367,O
unaffected,2367,O
by,2367,O
mutations,2367,O
that,2367,O
interfere,2367,O
with,2367,O
PR,2367,B-GENE-Y
activation,2367,O
of,2367,O
Src,2367,B-GENE-Y
.,2367,O
Progestin,2368,B-CHEMICAL
induction,2368,O
of,2368,O
cell,2368,O
cycle,2368,O
progression,2368,O
was,2368,O
also,2368,O
abrogated,2368,O
in,2368,O
cells,2368,O
expressing,2368,O
PR-BDeltaSH3,2368,B-GENE-N
",",2368,O
and,2368,O
no,2368,O
effect,2368,O
of,2368,O
progestin,2368,B-CHEMICAL
on,2368,O
cyclin,2368,B-GENE-Y
D1,2368,I-GENE-Y
expression,2368,O
and,2368,O
cell,2368,O
cycle,2368,O
was,2368,O
observed,2368,O
in,2368,O
the,2368,O
presence,2368,O
of,2368,O
PR-A,2368,B-GENE-Y
.,2368,O
These,2369,O
results,2369,O
highlight,2369,O
the,2369,O
importance,2369,O
of,2369,O
PR,2369,B-GENE-Y
activation,2369,O
of,2369,O
the,2369,O
Src/MAPK,2369,B-GENE-Y
signaling,2369,O
pathway,2369,O
for,2369,O
progesterone-induced,2369,B-CHEMICAL
transcription,2369,O
of,2369,O
select,2369,O
target,2369,O
genes,2369,O
and,2369,O
cell,2369,O
cycle,2369,O
progression,2369,O
.,2369,O
Seizures,2370,O
and,2370,O
enhanced,2370,O
cortical,2370,O
GABAergic,2370,O
inhibition,2370,O
in,2370,O
two,2370,O
mouse,2370,O
models,2370,O
of,2370,O
human,2370,O
autosomal,2370,O
dominant,2370,O
nocturnal,2370,O
frontal,2370,O
lobe,2370,O
epilepsy,2370,O
.,2370,O
Selected,2371,O
mutations,2371,O
in,2371,O
the,2371,O
human,2371,B-GENE-N
alpha4,2371,I-GENE-N
or,2371,I-GENE-N
beta2,2371,I-GENE-N
neuronal,2371,I-GENE-N
nicotinic,2371,I-GENE-N
acetylcholine,2371,I-GENE-N
receptor,2371,I-GENE-N
subunit,2371,O
genes,2371,O
cosegregate,2371,O
with,2371,O
a,2371,O
partial,2371,O
epilepsy,2371,O
syndrome,2371,O
known,2371,O
as,2371,O
autosomal,2371,O
dominant,2371,O
nocturnal,2371,O
frontal,2371,O
lobe,2371,O
epilepsy,2371,O
(,2371,O
ADNFLE,2371,O
),2371,O
.,2371,O
To,2372,O
examine,2372,O
possible,2372,O
mechanisms,2372,O
underlying,2372,O
this,2372,O
inherited,2372,O
epilepsy,2372,O
",",2372,O
we,2372,O
engineered,2372,O
two,2372,O
ADNFLE,2372,O
mutations,2372,O
(,2372,O
Chrna4,2372,B-GENE-Y
(,2372,O
S252F,2372,B-GENE-N
),2372,O
and,2372,O
Chrna4,2372,B-GENE-Y
(,2372,O
+L264,2372,O
),2372,O
),2372,O
in,2372,O
mice,2372,O
.,2372,O
Heterozygous,2373,O
ADNFLE,2373,O
mutant,2373,O
mice,2373,O
show,2373,O
persistent,2373,O
",",2373,O
abnormal,2373,O
cortical,2373,O
electroencephalograms,2373,O
with,2373,O
prominent,2373,O
delta,2373,O
and,2373,O
theta,2373,O
frequencies,2373,O
",",2373,O
exhibit,2373,O
frequent,2373,O
spontaneous,2373,O
seizures,2373,O
",",2373,O
and,2373,O
show,2373,O
an,2373,O
increased,2373,O
sensitivity,2373,O
to,2373,O
the,2373,O
proconvulsant,2373,O
action,2373,O
of,2373,O
nicotine,2373,B-CHEMICAL
.,2373,O
Relative,2374,O
to,2374,O
WT,2374,O
",",2374,O
electrophysiological,2374,O
recordings,2374,O
from,2374,O
ADNFLE,2374,O
mouse,2374,O
layer,2374,O
II/III,2374,O
cortical,2374,O
pyramidal,2374,O
cells,2374,O
reveal,2374,O
a,2374,O
>,2374,O
20-fold,2374,O
increase,2374,O
in,2374,O
nicotine-evoked,2374,B-CHEMICAL
inhibitory,2374,O
postsynaptic,2374,O
currents,2374,O
with,2374,O
no,2374,O
effect,2374,O
on,2374,O
excitatory,2374,O
postsynaptic,2374,O
currents,2374,O
.,2374,O
i.p,2375,O
.,2375,O
injection,2376,O
of,2376,O
a,2376,O
subthreshold,2376,O
dose,2376,O
of,2376,O
picrotoxin,2376,B-CHEMICAL
",",2376,O
a,2376,O
use-dependent,2376,O
gamma-aminobutyric,2376,B-CHEMICAL
acid,2376,I-CHEMICAL
receptor,2376,I-GENE-N
antagonist,2376,O
",",2376,O
reduces,2376,O
cortical,2376,O
electroencephalogram,2376,O
delta,2376,O
power,2376,O
and,2376,O
transiently,2376,O
inhibits,2376,O
spontaneous,2376,O
seizure,2376,O
activity,2376,O
in,2376,O
ADNFLE,2376,O
mutant,2376,O
mice,2376,O
.,2376,O
Our,2377,O
studies,2377,O
suggest,2377,O
that,2377,O
the,2377,O
mechanism,2377,O
underlying,2377,O
ADNFLE,2377,O
seizures,2377,O
may,2377,O
involve,2377,O
inhibitory,2377,O
synchronization,2377,O
of,2377,O
cortical,2377,O
networks,2377,O
via,2377,O
activation,2377,O
of,2377,O
mutant,2377,O
alpha4-containing,2377,B-GENE-Y
nicotinic,2377,I-GENE-Y
acetylcholine,2377,I-GENE-Y
receptors,2377,I-GENE-Y
located,2377,O
on,2377,O
the,2377,O
presynaptic,2377,O
terminals,2377,O
and,2377,O
somatodendritic,2377,O
compartments,2377,O
of,2377,O
cortical,2377,O
GABAergic,2377,O
interneurons,2377,O
.,2377,O
Molecular,2378,O
recognition,2378,O
of,2378,O
histidine,2378,B-CHEMICAL
tRNA,2378,O
by,2378,O
histidyl-tRNA,2378,B-GENE-Y
synthetase,2378,I-GENE-Y
from,2378,O
hyperthermophilic,2378,O
archaeon,2378,O
",",2378,O
Aeropyrum,2378,O
pernix,2378,O
K1,2378,O
.,2378,O
To,2379,O
investigate,2379,O
the,2379,O
recognition,2379,O
sites,2379,O
of,2379,O
histidine,2379,B-CHEMICAL
tRNA,2379,O
for,2379,O
histidyl-tRNA,2379,B-GENE-Y
synthetase,2379,I-GENE-Y
from,2379,O
an,2379,O
extreme,2379,O
hyperthermophilic,2379,O
archaeon,2379,O
",",2379,O
Aeropyrum,2379,O
pernix,2379,O
K1,2379,O
",",2379,O
we,2379,O
examined,2379,O
histidylation,2379,O
activities,2379,O
by,2379,O
using,2379,O
overexpressed,2379,O
histidyl-tRNA,2379,B-GENE-Y
synthetase,2379,I-GENE-Y
and,2379,O
various,2379,O
histidine,2379,B-CHEMICAL
tRNA,2379,O
transcripts,2379,O
that,2379,O
were,2379,O
prepared,2379,O
by,2379,O
in,2379,O
vitro,2379,O
transcription,2379,O
system,2379,O
.,2379,O
Results,2380,O
indicated,2380,O
that,2380,O
anticodon,2380,O
was,2380,O
not,2380,O
recognized,2380,O
by,2380,O
the,2380,O
histidyl-tRNA,2380,B-GENE-Y
synthetase,2380,I-GENE-Y
similar,2380,O
to,2380,O
that,2380,O
of,2380,O
Escherichia,2380,O
coli,2380,O
histidine,2380,B-CHEMICAL
tRNA,2380,O
recognition,2380,O
system,2380,O
.,2380,O
Discriminator,2381,O
base,2381,O
C73,2381,O
was,2381,O
weekly,2381,O
recognized,2381,O
and,2381,O
an,2381,O
additional,2381,O
G,2381,O
residue,2381,O
was,2381,O
specifically,2381,O
recognized,2381,O
by,2381,O
the,2381,O
enzyme,2381,O
.,2381,O
Synthesis,2382,O
",",2382,O
radiosynthesis,2382,O
",",2382,O
and,2382,O
biological,2382,O
evaluation,2382,O
of,2382,O
carbon-11,2382,B-CHEMICAL
labeled,2382,I-CHEMICAL
2beta-carbomethoxy-3beta-,2382,I-CHEMICAL
(,2382,I-CHEMICAL
3'-,2382,I-CHEMICAL
(,2382,I-CHEMICAL
(,2382,I-CHEMICAL
Z,2382,I-CHEMICAL
),2382,I-CHEMICAL
-2-haloethenyl,2382,I-CHEMICAL
),2382,I-CHEMICAL
phenyl,2382,I-CHEMICAL
),2382,I-CHEMICAL
nortropanes,2382,I-CHEMICAL
:,2382,O
candidate,2382,O
radioligands,2382,O
for,2382,O
in,2382,O
vivo,2382,O
imaging,2382,O
of,2382,O
the,2382,O
serotonin,2382,B-GENE-Y
transporter,2382,I-GENE-Y
with,2382,O
positron,2382,O
emission,2382,O
tomography,2382,O
.,2382,O
2beta-carbomethoxy-3beta-,2383,B-CHEMICAL
(,2383,I-CHEMICAL
3'-,2383,I-CHEMICAL
(,2383,I-CHEMICAL
(,2383,I-CHEMICAL
Z,2383,I-CHEMICAL
),2383,I-CHEMICAL
-2-iodoethenyl,2383,I-CHEMICAL
),2383,I-CHEMICAL
phenyl,2383,I-CHEMICAL
),2383,I-CHEMICAL
nortropane,2383,I-CHEMICAL
(,2383,O
mZIENT,2383,B-CHEMICAL
",",2383,O
1,2383,O
),2383,O
and,2383,O
2beta-carbomethoxy-3beta-,2383,B-CHEMICAL
(,2383,I-CHEMICAL
3'-,2383,I-CHEMICAL
(,2383,I-CHEMICAL
(,2383,I-CHEMICAL
Z,2383,I-CHEMICAL
),2383,I-CHEMICAL
-2-bromoethenyl,2383,I-CHEMICAL
),2383,I-CHEMICAL
phenyl,2383,I-CHEMICAL
),2383,I-CHEMICAL
nortropane,2383,I-CHEMICAL
(,2383,O
mZBrENT,2383,B-CHEMICAL
",",2383,O
2,2383,O
),2383,O
were,2383,O
synthesized,2383,O
and,2383,O
evaluated,2383,O
for,2383,O
binding,2383,O
to,2383,O
the,2383,O
human,2383,B-GENE-N
serotonin,2383,B-CHEMICAL
",",2383,I-GENE-N
dopamine,2383,B-CHEMICAL
",",2383,I-GENE-N
and,2383,I-GENE-N
norepinephrine,2383,B-CHEMICAL
transporters,2383,I-GENE-N
(,2383,O
SERT,2383,B-GENE-Y
",",2383,O
DAT,2383,B-GENE-Y
",",2383,O
and,2383,O
NET,2383,B-GENE-Y
",",2383,O
respectively,2383,O
),2383,O
using,2383,O
transfected,2383,O
cells,2383,O
.,2383,O
Both,2384,O
1,2384,O
and,2384,O
2,2384,O
have,2384,O
a,2384,O
high,2384,O
affinity,2384,O
for,2384,O
the,2384,O
SERT,2384,B-GENE-Y
(,2384,O
Ki=0.2,2384,O
nM,2384,O
),2384,O
and,2384,O
are,2384,O
approximately,2384,O
160,2384,O
times,2384,O
more,2384,O
selective,2384,O
for,2384,O
the,2384,O
SERT,2384,B-GENE-Y
than,2384,O
the,2384,O
DAT,2384,B-GENE-Y
.,2384,O
Compound,2385,O
2,2385,O
has,2385,O
a,2385,O
significantly,2385,O
higher,2385,O
affinity,2385,O
for,2385,O
the,2385,O
NET,2385,B-GENE-Y
than,2385,O
1,2385,O
",",2385,O
and,2385,O
this,2385,O
may,2385,O
be,2385,O
a,2385,O
result,2385,O
of,2385,O
the,2385,O
different,2385,O
size,2385,O
and,2385,O
electronegativity,2385,O
of,2385,O
the,2385,O
halogen,2385,B-CHEMICAL
atoms,2385,O
.,2385,O
MicroPET,2386,O
imaging,2386,O
in,2386,O
nonhuman,2386,O
primates,2386,O
with,2386,O
[,2386,O
11C,2386,B-CHEMICAL
],2386,O
1,2386,O
and,2386,O
[,2386,O
11C,2386,B-CHEMICAL
],2386,O
2,2386,O
demonstrated,2386,O
that,2386,O
both,2386,O
tracers,2386,O
behave,2386,O
similarly,2386,O
in,2386,O
vivo,2386,O
with,2386,O
high,2386,O
uptake,2386,O
being,2386,O
observed,2386,O
in,2386,O
the,2386,O
SERT-rich,2386,B-GENE-N
brain,2386,O
regions,2386,O
and,2386,O
peak,2386,O
uptake,2386,O
being,2386,O
achieved,2386,O
in,2386,O
about,2386,O
55,2386,O
min,2386,O
postinjection,2386,O
.,2386,O
Chase,2387,O
studies,2387,O
with,2387,O
citalopram,2387,B-CHEMICAL
and,2387,O
methylphenidate,2387,B-CHEMICAL
demonstrated,2387,O
that,2387,O
this,2387,O
uptake,2387,O
is,2387,O
the,2387,O
result,2387,O
of,2387,O
preferential,2387,O
binding,2387,O
to,2387,O
the,2387,O
SERT,2387,B-GENE-N
.,2387,O
Pharmacokinetics,2388,O
of,2388,O
olmesartan,2388,B-CHEMICAL
medoxomil,2388,I-CHEMICAL
plus,2388,O
hydrochlorothiazide,2388,B-CHEMICAL
combination,2388,O
in,2388,O
healthy,2388,O
subjects,2388,O
.,2388,O
BACKGROUND,2389,O
:,2389,O
Hypertension,2389,O
treatment,2389,O
guidelines,2389,O
recommend,2389,O
combination,2389,O
therapy,2389,O
with,2389,O
diuretics,2389,O
and,2389,O
other,2389,O
antihypertensive,2389,O
agents,2389,O
",",2389,O
including,2389,O
angiotensin,2389,B-CHEMICAL
II,2389,I-CHEMICAL
type,2389,I-GENE-Y
1,2389,I-GENE-Y
(,2389,I-GENE-Y
AT1,2389,I-GENE-Y
),2389,I-GENE-Y
receptor,2389,I-GENE-Y
antagonists,2389,O
.,2389,O
This,2390,O
trial,2390,O
investigated,2390,O
the,2390,O
possibility,2390,O
of,2390,O
pharmacokinetic,2390,O
interactions,2390,O
between,2390,O
the,2390,O
AT1,2390,B-GENE-Y
receptor,2390,I-GENE-Y
antagonist,2390,O
olmesartan,2390,B-CHEMICAL
medoxomil,2390,I-CHEMICAL
and,2390,O
the,2390,O
thiazide,2390,B-CHEMICAL
diuretic,2390,O
hydrochlorothiazide,2390,B-CHEMICAL
in,2390,O
healthy,2390,O
subjects,2390,O
.,2390,O
METHODS,2391,O
:,2391,O
Twenty-four,2391,O
healthy,2391,O
normotensive,2391,O
adult,2391,O
male,2391,O
subjects,2391,O
underwent,2391,O
three,2391,O
consecutive,2391,O
7-day,2391,O
treatment,2391,O
periods,2391,O
(,2391,O
A,2391,O
",",2391,O
B,2391,O
and,2391,O
C,2391,O
",",2391,O
respectively,2391,O
),2391,O
during,2391,O
which,2391,O
they,2391,O
were,2391,O
randomised,2391,O
to,2391,O
receive,2391,O
:,2391,O
olmesartan,2391,B-CHEMICAL
medoxomil,2391,I-CHEMICAL
20,2391,O
mg,2391,O
once,2391,O
daily,2391,O
(,2391,O
regimen,2391,O
A,2391,O
),2391,O
",",2391,O
hydrochlorothiazide,2391,B-CHEMICAL
25,2391,O
mg,2391,O
once,2391,O
daily,2391,O
(,2391,O
regimen,2391,O
B,2391,O
),2391,O
",",2391,O
or,2391,O
olmesartan,2391,B-CHEMICAL
medoxomil,2391,I-CHEMICAL
20,2391,O
mg,2391,O
once,2391,O
daily,2391,O
plus,2391,O
hydrochlorothiazide,2391,B-CHEMICAL
25,2391,O
mg,2391,O
once,2391,O
daily,2391,O
(,2391,O
regimen,2391,O
C,2391,O
),2391,O
.,2391,O
Treatment,2392,O
periods,2392,O
were,2392,O
separated,2392,O
by,2392,O
washouts,2392,O
of,2392,O
7-14,2392,O
days,2392,O
.,2392,O
The,2393,O
primary,2393,O
pharmacokinetic,2393,O
parameters,2393,O
evaluated,2393,O
were,2393,O
:,2393,O
the,2393,O
area,2393,O
under,2393,O
the,2393,O
plasma,2393,O
concentration,2393,O
versus,2393,O
time,2393,O
curve,2393,O
at,2393,O
steady,2393,O
state,2393,O
(,2393,O
AUCss,2393,O
",",2393,O
tau,2393,O
),2393,O
",",2393,O
the,2393,O
maximum,2393,O
plasma,2393,O
concentration,2393,O
at,2393,O
steady,2393,O
state,2393,O
(,2393,O
Css,2393,O
",",2393,O
max,2393,O
),2393,O
",",2393,O
and,2393,O
the,2393,O
time,2393,O
at,2393,O
which,2393,O
Css,2393,O
",",2393,O
max,2393,O
occurred,2393,O
(,2393,O
tmax,2393,O
),2393,O
.,2393,O
RESULTS,2394,O
:,2394,O
Complete,2394,O
data,2394,O
sets,2394,O
from,2394,O
17,2394,O
subjects,2394,O
were,2394,O
available,2394,O
for,2394,O
pharmacokinetic,2394,O
analyses,2394,O
.,2394,O
Mean,2395,O
concentration,2395,O
versus,2395,O
time,2395,O
profiles,2395,O
were,2395,O
similar,2395,O
for,2395,O
monotherapy,2395,O
and,2395,O
combination,2395,O
treatment,2395,O
for,2395,O
both,2395,O
olmesartan,2395,B-CHEMICAL
(,2395,O
the,2395,O
active,2395,O
metabolite,2395,O
of,2395,O
olmesartan,2395,B-CHEMICAL
medoxomil,2395,I-CHEMICAL
),2395,O
and,2395,O
hydrochlorothiazide,2395,B-CHEMICAL
.,2395,O
For,2396,O
olmesartan,2396,B-CHEMICAL
",",2396,O
comparison,2396,O
of,2396,O
monotherapy,2396,O
with,2396,O
combination,2396,O
therapy,2396,O
showed,2396,O
that,2396,O
for,2396,O
AUCss,2396,O
",",2396,O
tau,2396,O
and,2396,O
Css,2396,O
",",2396,O
max,2396,O
point,2396,O
estimates,2396,O
were,2396,O
close,2396,O
to,2396,O
unity,2396,O
",",2396,O
demonstrating,2396,O
bioequivalence,2396,O
.,2396,O
For,2397,O
hydrochlorothiazide,2397,B-CHEMICAL
",",2397,O
combination,2397,O
therapy,2397,O
resulted,2397,O
in,2397,O
decreases,2397,O
in,2397,O
AUCss,2397,O
",",2397,O
tau,2397,O
and,2397,O
Css,2397,O
",",2397,O
max,2397,O
of,2397,O
approximately,2397,O
10,2397,O
%,2397,O
versus,2397,O
monotherapy,2397,O
;,2397,O
nevertheless,2397,O
",",2397,O
since,2397,O
90,2397,O
%,2397,O
CIs,2397,O
were,2397,O
within,2397,O
the,2397,O
acceptance,2397,O
range,2397,O
",",2397,O
bioequivalence,2397,O
was,2397,O
proven,2397,O
.,2397,O
Median,2398,O
tmax,2398,O
values,2398,O
for,2398,O
olmesartan,2398,B-CHEMICAL
and,2398,O
hydrochlorothiazide,2398,B-CHEMICAL
for,2398,O
periods,2398,O
A,2398,O
",",2398,O
B,2398,O
and,2398,O
C,2398,O
were,2398,O
identical,2398,O
",",2398,O
indicating,2398,O
bioequivalence,2398,O
.,2398,O
Both,2399,O
olmesartan,2399,B-CHEMICAL
medoxomil,2399,I-CHEMICAL
and,2399,O
hydrochlorothiazide,2399,B-CHEMICAL
were,2399,O
well,2399,O
tolerated,2399,O
.,2399,O
CONCLUSION,2400,O
:,2400,O
These,2400,O
results,2400,O
show,2400,O
that,2400,O
there,2400,O
is,2400,O
little,2400,O
or,2400,O
no,2400,O
potential,2400,O
for,2400,O
a,2400,O
clinically,2400,O
relevant,2400,O
pharmacokinetic,2400,O
interaction,2400,O
between,2400,O
olmesartan,2400,B-CHEMICAL
medoxomil,2400,I-CHEMICAL
20,2400,O
mg,2400,O
and,2400,O
hydrochlorothiazide,2400,B-CHEMICAL
25,2400,O
mg,2400,O
",",2400,O
and,2400,O
therefore,2400,O
dosage,2400,O
adjustment,2400,O
should,2400,O
not,2400,O
be,2400,O
necessary,2400,O
when,2400,O
they,2400,O
are,2400,O
co-administered,2400,O
.,2400,O
Effect,2401,O
of,2401,O
cromolyn,2401,O
on,2401,O
S100P,2401,B-GENE-Y
interactions,2401,O
with,2401,O
RAGE,2401,O
and,2401,O
pancreatic,2401,O
cancer,2401,O
growth,2401,O
and,2401,O
invasion,2401,O
in,2401,O
mouse,2401,O
models,2401,O
.,2401,O
BACKGROUND,2402,O
:,2402,O
We,2402,O
previously,2402,O
found,2402,O
that,2402,O
S100P,2402,B-GENE-Y
",",2402,O
a,2402,O
member,2402,O
of,2402,O
the,2402,O
S100,2402,B-GENE-N
protein,2402,O
family,2402,O
",",2402,O
is,2402,O
expressed,2402,O
in,2402,O
more,2402,O
than,2402,O
90,2402,O
%,2402,O
of,2402,O
pancreatic,2402,O
tumors,2402,O
and,2402,O
is,2402,O
associated,2402,O
with,2402,O
tumor,2402,O
growth,2402,O
and,2402,O
invasion,2402,O
.,2402,O
In,2403,O
the,2403,O
current,2403,O
study,2403,O
",",2403,O
we,2403,O
investigated,2403,O
the,2403,O
ability,2403,O
of,2403,O
the,2403,O
antiallergy,2403,O
drug,2403,O
",",2403,O
cromolyn,2403,O
",",2403,O
to,2403,O
block,2403,O
S100P,2403,B-GENE-Y
function,2403,O
.,2403,O
METHODS,2404,O
:,2404,O
Interactions,2404,O
between,2404,O
cromolyn,2404,O
and,2404,O
S100P,2404,B-GENE-Y
were,2404,O
investigated,2404,O
using,2404,O
a,2404,O
drug,2404,O
affinity,2404,O
column,2404,O
and,2404,O
by,2404,O
examining,2404,O
cromolyn,2404,O
's,2404,O
effects,2404,O
on,2404,O
coimmunoprecipitation,2404,O
of,2404,O
S100P,2404,B-GENE-Y
and,2404,O
receptor,2404,O
for,2404,O
advanced,2404,O
glycation,2404,O
end-products,2404,O
(,2404,O
RAGE,2404,O
),2404,O
.,2404,O
The,2405,O
effects,2405,O
of,2405,O
cromolyn,2405,O
on,2405,O
cell,2405,O
growth,2405,O
",",2405,O
invasion,2405,O
",",2405,O
and,2405,O
nuclear,2405,B-GENE-N
factor-kappaB,2405,I-GENE-N
(,2405,O
NFkappaB,2405,B-GENE-N
),2405,O
activity,2405,O
of,2405,O
pancreatic,2405,O
cancer,2405,O
cells,2405,O
with,2405,O
(,2405,O
BxPC-3,2405,O
and,2405,O
MPanc-96,2405,O
),2405,O
and,2405,O
without,2405,O
(,2405,O
Panc-1,2405,O
),2405,O
endogenous,2405,O
S100P,2405,B-GENE-Y
were,2405,O
investigated,2405,O
by,2405,O
cell,2405,O
proliferation,2405,O
assay,2405,O
",",2405,O
by,2405,O
cell,2405,O
invasion,2405,O
assay,2405,O
",",2405,O
and,2405,O
by,2405,O
luciferase,2405,O
reporter,2405,O
gene,2405,O
assay,2405,O
",",2405,O
respectively,2405,O
.,2405,O
The,2406,O
effects,2406,O
of,2406,O
cromolyn,2406,O
on,2406,O
tumor,2406,O
growth,2406,O
in,2406,O
vivo,2406,O
were,2406,O
investigated,2406,O
in,2406,O
three,2406,O
orthotopic,2406,O
models,2406,O
(,2406,O
n,2406,O
=,2406,O
20,2406,O
mice,2406,O
per,2406,O
model,2406,O
),2406,O
by,2406,O
administration,2406,O
of,2406,O
cromolyn,2406,O
(,2406,O
5,2406,O
mg/kg,2406,O
body,2406,O
weight,2406,O
",",2406,O
daily,2406,O
),2406,O
with,2406,O
and,2406,O
without,2406,O
gemcitabine,2406,B-CHEMICAL
(,2406,O
125,2406,O
mg/kg,2406,O
body,2406,O
weight,2406,O
",",2406,O
biweekly,2406,O
),2406,O
",",2406,O
the,2406,O
drug,2406,O
currently,2406,O
used,2406,O
to,2406,O
treat,2406,O
pancreatic,2406,O
cancer,2406,O
.,2406,O
Tumor,2407,O
growth,2407,O
was,2407,O
assayed,2407,O
by,2407,O
reporter,2407,O
gene,2407,O
expression,2407,O
.,2407,O
All,2408,O
statistical,2408,O
tests,2408,O
were,2408,O
two-sided,2408,O
.,2408,O
RESULTS,2409,O
:,2409,O
S100P,2409,B-GENE-Y
was,2409,O
retained,2409,O
on,2409,O
a,2409,O
cromolyn,2409,O
affinity,2409,O
column,2409,O
.,2409,O
Cromolyn,2410,O
blocked,2410,O
the,2410,O
coimmunoprecipitation,2410,O
of,2410,O
S100P,2410,B-GENE-Y
and,2410,O
RAGE,2410,O
.,2410,O
In,2411,O
vitro,2411,O
",",2411,O
cromolyn,2411,O
(,2411,O
100,2411,O
microM,2411,O
),2411,O
inhibited,2411,O
S100P-stimulated,2411,B-GENE-Y
Panc-1,2411,O
cell,2411,O
proliferation,2411,O
(,2411,O
S100P,2411,B-GENE-Y
",",2411,O
mean,2411,O
=,2411,O
0.93,2411,O
U,2411,O
",",2411,O
versus,2411,O
S100P,2411,B-GENE-Y
+,2411,O
cromolyn,2411,O
",",2411,O
mean,2411,O
=,2411,O
0.56,2411,O
U,2411,O
",",2411,O
difference,2411,O
=,2411,O
0.37,2411,O
U,2411,O
;,2411,O
95,2411,O
%,2411,O
confidence,2411,O
interval,2411,O
[,2411,O
CI,2411,O
],2411,O
=,2411,O
0.24,2411,O
to,2411,O
0.49,2411,O
U,2411,O
;,2411,O
P,2411,O
=,2411,O
.001,2411,O
",",2411,O
n,2411,O
=,2411,O
3,2411,O
),2411,O
",",2411,O
invasion,2411,O
(,2411,O
S100P,2411,B-GENE-Y
",",2411,O
mean,2411,O
=,2411,O
58.0,2411,O
%,2411,O
",",2411,O
versus,2411,O
S100P,2411,B-GENE-Y
+,2411,O
cromolyn,2411,O
",",2411,O
mean,2411,O
=,2411,O
9.4,2411,O
%,2411,O
",",2411,O
difference,2411,O
=,2411,O
48.6,2411,O
%,2411,O
;,2411,O
95,2411,O
%,2411,O
CI,2411,O
=,2411,O
38.8,2411,O
%,2411,O
to,2411,O
58.8,2411,O
%,2411,O
;,2411,O
P,2411,O
<,2411,O
.001,2411,O
",",2411,O
n,2411,O
=,2411,O
3,2411,O
),2411,O
",",2411,O
and,2411,O
NFkappaB,2411,B-GENE-N
activity,2411,O
(,2411,O
S100P,2411,B-GENE-Y
",",2411,O
mean,2411,O
=,2411,O
"14,460",2411,O
",",2411,O
versus,2411,O
S100P,2411,B-GENE-Y
+,2411,O
cromolyn,2411,O
",",2411,O
mean,2411,O
=,2411,O
7360,2411,O
photons/s,2411,O
",",2411,O
difference,2411,O
=,2411,O
7100,2411,O
photons/s,2411,O
;,2411,O
95,2411,O
%,2411,O
CI,2411,O
=,2411,O
3689,2411,O
to,2411,O
10,2411,O
510,2411,O
photons/s,2411,O
;,2411,O
P,2411,O
=,2411,O
.005,2411,O
",",2411,O
n,2411,O
=,2411,O
3,2411,O
),2411,O
.,2411,O
In,2412,O
vivo,2412,O
",",2412,O
cromolyn,2412,O
inhibited,2412,O
tumor,2412,O
growth,2412,O
in,2412,O
mice,2412,O
bearing,2412,O
tumor,2412,O
with,2412,O
endogenous,2412,O
S100P,2412,B-GENE-Y
(,2412,O
BxPC-3,2412,O
:,2412,O
control,2412,O
",",2412,O
mean,2412,O
=,2412,O
1.6,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
photons/s,2412,O
",",2412,O
versus,2412,O
cromolyn,2412,O
",",2412,O
mean,2412,O
=,2412,O
4.4,2412,O
x,2412,O
10,2412,O
(,2412,O
8,2412,O
),2412,O
photons/s,2412,O
",",2412,O
difference,2412,O
=,2412,O
1.2,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
photons/s,2412,O
;,2412,O
95,2412,O
%,2412,O
CI,2412,O
=,2412,O
6.2,2412,O
x,2412,O
10,2412,O
(,2412,O
8,2412,O
),2412,O
to,2412,O
1.6,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
photons/s,2412,O
;,2412,O
P,2412,O
<,2412,O
.001,2412,O
",",2412,O
n,2412,O
=,2412,O
5,2412,O
;,2412,O
MPanc-96,2412,O
:,2412,O
control,2412,O
",",2412,O
mean,2412,O
=,2412,O
1.1,2412,O
x,2412,O
10,2412,O
(,2412,O
10,2412,O
),2412,O
photons/s,2412,O
",",2412,O
versus,2412,O
cromolyn,2412,O
",",2412,O
mean,2412,O
=,2412,O
4.8,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
photons/s,2412,O
",",2412,O
difference,2412,O
=,2412,O
6.2,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
photons/s,2412,O
;,2412,O
95,2412,O
%,2412,O
CI,2412,O
=,2412,O
1.9,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
to,2412,O
1.0,2412,O
x,2412,O
10,2412,O
(,2412,O
10,2412,O
),2412,O
photons/s,2412,O
;,2412,O
P,2412,O
=,2412,O
.009,2412,O
",",2412,O
n,2412,O
=,2412,O
5,2412,O
),2412,O
and,2412,O
increased,2412,O
the,2412,O
effectiveness,2412,O
of,2412,O
gemcitabine,2412,B-CHEMICAL
(,2412,O
BxPC-3,2412,O
:,2412,O
gemcitabine,2412,B-CHEMICAL
",",2412,O
mean,2412,O
=,2412,O
9.2,2412,O
x,2412,O
10,2412,O
(,2412,O
8,2412,O
),2412,O
photons/s,2412,O
",",2412,O
versus,2412,O
combination,2412,O
",",2412,O
mean,2412,O
=,2412,O
1.8,2412,O
x,2412,O
10,2412,O
(,2412,O
8,2412,O
),2412,O
photons/s,2412,O
",",2412,O
difference,2412,O
=,2412,O
7.4,2412,O
x,2412,O
10,2412,O
(,2412,O
8,2412,O
),2412,O
photons/s,2412,O
;,2412,O
95,2412,O
%,2412,O
CI,2412,O
=,2412,O
4.5,2412,O
x,2412,O
10,2412,O
(,2412,O
8,2412,O
),2412,O
to,2412,O
1.0,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
photons/s,2412,O
;,2412,O
P,2412,O
<,2412,O
.001,2412,O
;,2412,O
MPanc-96,2412,O
:,2412,O
gemcitabine,2412,B-CHEMICAL
",",2412,O
mean,2412,O
=,2412,O
4.1,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
photons/s,2412,O
",",2412,O
versus,2412,O
combination,2412,O
",",2412,O
mean,2412,O
=,2412,O
2.0,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
photons/s,2412,O
",",2412,O
difference,2412,O
=,2412,O
2.1,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
photons/s,2412,O
;,2412,O
95,2412,O
%,2412,O
CI,2412,O
=,2412,O
4.4,2412,O
x,2412,O
10,2412,O
(,2412,O
8,2412,O
),2412,O
to,2412,O
3.8,2412,O
x,2412,O
10,2412,O
(,2412,O
9,2412,O
),2412,O
photons/s,2412,O
;,2412,O
P,2412,O
<,2412,O
.001,2412,O
),2412,O
.,2412,O
However,2413,O
",",2413,O
cromolyn,2413,O
had,2413,O
no,2413,O
effect,2413,O
on,2413,O
growth,2413,O
of,2413,O
tumors,2413,O
lacking,2413,O
S100P,2413,B-GENE-Y
(,2413,O
Panc-1,2413,O
),2413,O
.,2413,O
CONCLUSION,2414,O
:,2414,O
Cromolyn,2414,O
binds,2414,O
S100P,2414,B-GENE-Y
",",2414,O
prevents,2414,O
activation,2414,O
of,2414,O
RAGE,2414,O
",",2414,O
inhibits,2414,O
tumor,2414,O
growth,2414,O
",",2414,O
and,2414,O
increases,2414,O
the,2414,O
effectiveness,2414,O
of,2414,O
gemcitabine,2414,B-CHEMICAL
in,2414,O
experimental,2414,O
models,2414,O
.,2414,O
Genetic,2415,O
polymorphisms,2415,O
in,2415,O
the,2415,O
cyclooxygenase-2,2415,B-GENE-Y
gene,2415,O
",",2415,O
use,2415,O
of,2415,O
nonsteroidal,2415,O
anti-inflammatory,2415,O
drugs,2415,O
",",2415,O
and,2415,O
breast,2415,O
cancer,2415,O
risk,2415,O
.,2415,O
INTRODUCTION,2416,O
:,2416,O
The,2416,O
association,2416,O
between,2416,O
use,2416,O
of,2416,O
nonsteroidal,2416,O
anti-inflammatory,2416,O
drugs,2416,O
(,2416,O
NSAIDs,2416,O
),2416,O
and,2416,O
breast,2416,O
cancer,2416,O
risk,2416,O
remains,2416,O
unclear,2416,O
.,2416,O
Inconsistencies,2417,O
in,2417,O
previously,2417,O
reported,2417,O
findings,2417,O
may,2417,O
be,2417,O
partly,2417,O
due,2417,O
to,2417,O
differences,2417,O
in,2417,O
expression,2417,O
of,2417,O
cyclooxygenase,2417,B-GENE-Y
(,2417,I-GENE-Y
COX,2417,I-GENE-Y
),2417,I-GENE-Y
-2,2417,I-GENE-Y
.,2417,O
We,2418,O
hypothesized,2418,O
that,2418,O
genetic,2418,O
polymorphisms,2418,O
(,2418,O
COX-2,2418,B-GENE-Y
.926,2418,O
",",2418,O
COX-2,2418,B-GENE-Y
.5209,2418,O
",",2418,O
and,2418,O
COX-2,2418,B-GENE-Y
.8473,2418,O
),2418,O
may,2418,O
reduce,2418,O
overall,2418,O
breast,2418,O
cancer,2418,O
risk,2418,O
or,2418,O
risk,2418,O
for,2418,O
subtypes,2418,O
of,2418,O
breast,2418,O
cancer,2418,O
by,2418,O
modulating,2418,O
the,2418,O
inflammatory,2418,O
response,2418,O
and,2418,O
may,2418,O
interact,2418,O
with,2418,O
aspirin,2418,O
or,2418,O
any,2418,O
NSAID,2418,O
use,2418,O
.,2418,O
METHODS,2419,O
:,2419,O
We,2419,O
conducted,2419,O
a,2419,O
population-based,2419,O
",",2419,O
case-control,2419,O
study,2419,O
in,2419,O
which,2419,O
we,2419,O
genotyped,2419,O
"1,067",2419,O
breast,2419,O
cancer,2419,O
cases,2419,O
and,2419,O
"1,110",2419,O
control,2419,O
individuals,2419,O
included,2419,O
in,2419,O
the,2419,O
Long,2419,O
Island,2419,O
Breast,2419,O
Cancer,2419,O
Study,2419,O
Project,2419,O
.,2419,O
RESULTS,2420,O
:,2420,O
No,2420,O
major,2420,O
effects,2420,O
of,2420,O
the,2420,O
three,2420,O
COX-2,2420,B-GENE-Y
variant,2420,O
alleles,2420,O
on,2420,O
breast,2420,O
cancer,2420,O
risk,2420,O
were,2420,O
found,2420,O
.,2420,O
A,2421,O
total,2421,O
of,2421,O
eight,2421,O
distinct,2421,O
haplotypes,2421,O
and,2421,O
18,2421,O
diplotypes,2421,O
were,2421,O
observed,2421,O
in,2421,O
the,2421,O
population,2421,O
.,2421,O
Overall,2422,O
",",2422,O
no,2422,O
significant,2422,O
associations,2422,O
between,2422,O
COX-2,2422,B-GENE-N
haplotypes/diplotypes,2422,O
and,2422,O
breast,2422,O
cancer,2422,O
risk,2422,O
were,2422,O
observed,2422,O
.,2422,O
Among,2423,O
women,2423,O
who,2423,O
used,2423,O
aspirin,2423,O
or,2423,O
any,2423,O
NSAID,2423,O
there,2423,O
was,2423,O
little,2423,O
evidence,2423,O
for,2423,O
an,2423,O
interaction,2423,O
with,2423,O
the,2423,O
at-risk,2423,O
COX-2,2423,B-GENE-Y
genotypes,2423,O
",",2423,O
with,2423,O
one,2423,O
exception,2423,O
.,2423,O
Among,2424,O
women,2424,O
with,2424,O
hormone,2424,O
receptor,2424,O
positive,2424,O
breast,2424,O
cancer,2424,O
",",2424,O
the,2424,O
reduced,2424,O
risk,2424,O
for,2424,O
any,2424,O
NSAID,2424,O
use,2424,O
was,2424,O
only,2424,O
evident,2424,O
among,2424,O
those,2424,O
who,2424,O
had,2424,O
at,2424,O
least,2424,O
one,2424,O
variant,2424,O
C,2424,O
allele,2424,O
of,2424,O
COX-2,2424,B-GENE-Y
.8473,2424,O
(,2424,O
odds,2424,O
ratio,2424,O
=,2424,O
0.7,2424,O
",",2424,O
95,2424,O
%,2424,O
confidence,2424,O
interval,2424,O
=,2424,O
0.5,2424,O
to,2424,O
1.0,2424,O
;,2424,O
P,2424,O
for,2424,O
the,2424,O
interaction,2424,O
=,2424,O
0.02,2424,O
),2424,O
.,2424,O
There,2425,O
was,2425,O
no,2425,O
corresponding,2425,O
interaction,2425,O
for,2425,O
aspirin,2425,O
use,2425,O
",",2425,O
possibly,2425,O
because,2425,O
of,2425,O
limited,2425,O
power,2425,O
.,2425,O
CONCLUSION,2426,O
:,2426,O
These,2426,O
data,2426,O
provide,2426,O
modest,2426,O
evidence,2426,O
that,2426,O
the,2426,O
C,2426,O
allele,2426,O
of,2426,O
COX-2,2426,B-GENE-Y
.8473,2426,O
may,2426,O
interact,2426,O
with,2426,O
NSAIDs,2426,O
to,2426,O
reduce,2426,O
risk,2426,O
for,2426,O
hormone,2426,O
receptor,2426,O
positive,2426,O
breast,2426,O
cancer,2426,O
.,2426,O
Biosynthesis,2427,O
of,2427,O
selenocysteine,2427,B-CHEMICAL
on,2427,O
its,2427,O
tRNA,2427,O
in,2427,O
eukaryotes,2427,O
.,2427,O
Selenocysteine,2428,B-CHEMICAL
(,2428,O
Sec,2428,B-CHEMICAL
),2428,O
is,2428,O
cotranslationally,2428,O
inserted,2428,O
into,2428,O
protein,2428,O
in,2428,O
response,2428,O
to,2428,O
UGA,2428,B-GENE-N
codons,2428,O
and,2428,O
is,2428,O
the,2428,O
21st,2428,O
amino,2428,B-CHEMICAL
acid,2428,I-CHEMICAL
in,2428,O
the,2428,O
genetic,2428,O
code,2428,O
.,2428,O
However,2429,O
",",2429,O
the,2429,O
means,2429,O
by,2429,O
which,2429,O
Sec,2429,B-CHEMICAL
is,2429,O
synthesized,2429,O
in,2429,O
eukaryotes,2429,O
is,2429,O
not,2429,O
known,2429,O
.,2429,O
Herein,2430,O
",",2430,O
comparative,2430,O
genomics,2430,O
and,2430,O
experimental,2430,O
analyses,2430,O
revealed,2430,O
that,2430,O
the,2430,O
mammalian,2430,B-GENE-Y
Sec,2430,B-CHEMICAL
synthase,2430,I-GENE-Y
(,2430,O
SecS,2430,B-GENE-Y
),2430,O
is,2430,O
the,2430,O
previously,2430,O
identified,2430,O
pyridoxal,2430,B-CHEMICAL
phosphate-containing,2430,O
protein,2430,O
known,2430,O
as,2430,O
the,2430,O
soluble,2430,B-GENE-Y
liver,2430,I-GENE-Y
antigen,2430,I-GENE-Y
.,2430,O
SecS,2431,B-GENE-Y
required,2431,O
selenophosphate,2431,B-CHEMICAL
and,2431,O
O-phosphoseryl-tRNA,2431,B-CHEMICAL
(,2431,O
[,2431,O
Ser,2431,O
],2431,O
Sec,2431,O
),2431,O
as,2431,O
substrates,2431,O
to,2431,O
generate,2431,O
selenocysteyl-tRNA,2431,B-CHEMICAL
(,2431,O
[,2431,O
Ser,2431,O
],2431,O
Sec,2431,O
),2431,O
.,2431,O
Moreover,2432,O
",",2432,O
it,2432,O
was,2432,O
found,2432,O
that,2432,O
Sec,2432,B-GENE-Y
was,2432,O
synthesized,2432,O
on,2432,O
the,2432,O
tRNA,2432,O
scaffold,2432,O
from,2432,O
selenide,2432,B-CHEMICAL
",",2432,O
ATP,2432,B-CHEMICAL
",",2432,O
and,2432,O
serine,2432,B-CHEMICAL
using,2432,O
tRNA,2432,O
(,2432,O
[,2432,O
Ser,2432,O
],2432,O
Sec,2432,O
),2432,O
",",2432,O
seryl-tRNA,2432,B-GENE-Y
synthetase,2432,I-GENE-Y
",",2432,O
O-phosphoseryl-tRNA,2432,B-GENE-Y
(,2432,I-GENE-Y
[,2432,I-GENE-Y
Ser,2432,I-GENE-Y
],2432,I-GENE-Y
Sec,2432,I-GENE-Y
),2432,I-GENE-Y
kinase,2432,I-GENE-Y
",",2432,O
selenophosphate,2432,B-GENE-N
synthetase,2432,I-GENE-N
",",2432,O
and,2432,O
SecS,2432,B-GENE-Y
.,2432,O
By,2433,O
identifying,2433,O
the,2433,O
pathway,2433,O
of,2433,O
Sec,2433,B-CHEMICAL
biosynthesis,2433,O
in,2433,O
mammals,2433,O
",",2433,O
this,2433,O
study,2433,O
not,2433,O
only,2433,O
functionally,2433,O
characterized,2433,O
SecS,2433,B-GENE-Y
but,2433,O
also,2433,O
assigned,2433,O
the,2433,O
function,2433,O
of,2433,O
the,2433,O
O-phosphoseryl-tRNA,2433,B-GENE-Y
(,2433,I-GENE-Y
[,2433,I-GENE-Y
Ser,2433,I-GENE-Y
],2433,I-GENE-Y
Sec,2433,I-GENE-Y
),2433,I-GENE-Y
kinase,2433,I-GENE-Y
.,2433,O
In,2434,O
addition,2434,O
",",2434,O
we,2434,O
found,2434,O
that,2434,O
selenophosphate,2434,B-GENE-Y
synthetase,2434,I-GENE-Y
2,2434,I-GENE-Y
could,2434,O
synthesize,2434,O
monoselenophosphate,2434,B-CHEMICAL
in,2434,O
vitro,2434,O
but,2434,O
selenophosphate,2434,B-CHEMICAL
synthetase,2434,I-GENE-Y
1,2434,I-GENE-Y
could,2434,O
not,2434,O
.,2434,O
Conservation,2435,O
of,2435,O
the,2435,O
overall,2435,O
pathway,2435,O
of,2435,O
Sec,2435,O
biosynthesis,2435,O
suggests,2435,O
that,2435,O
this,2435,O
pathway,2435,O
is,2435,O
also,2435,O
active,2435,O
in,2435,O
other,2435,O
eukaryotes,2435,O
and,2435,O
archaea,2435,O
that,2435,O
synthesize,2435,O
selenoproteins,2435,B-GENE-N
.,2435,O
Effects,2436,O
of,2436,O
triflusal,2436,B-CHEMICAL
and,2436,O
aspirin,2436,B-CHEMICAL
in,2436,O
a,2436,O
rat,2436,O
model,2436,O
of,2436,O
cerebral,2436,O
ischemia,2436,O
.,2436,O
BACKGROUND,2437,O
AND,2437,O
PURPOSE,2437,O
:,2437,O
Neuroinflammation,2437,O
plays,2437,O
a,2437,O
critical,2437,O
role,2437,O
in,2437,O
the,2437,O
pathogenesis,2437,O
of,2437,O
cerebral,2437,O
ischemia,2437,O
.,2437,O
Triflusal,2438,B-CHEMICAL
",",2438,O
a,2438,O
selective,2438,O
cyclooxygenase-2,2438,B-GENE-Y
",",2438,O
and,2438,O
its,2438,O
active,2438,O
metabolite,2438,O
3-hydroxy-4-trifluoromethylbenzoic,2438,B-CHEMICAL
acid,2438,I-CHEMICAL
may,2438,O
inhibit,2438,O
apoptosis,2438,O
and,2438,O
inflammation,2438,O
after,2438,O
cerebral,2438,O
ischemia,2438,O
.,2438,O
An,2439,O
in,2439,O
vivo,2439,O
model,2439,O
of,2439,O
cerebral,2439,O
ischemia,2439,O
was,2439,O
used,2439,O
to,2439,O
investigate,2439,O
the,2439,O
effects,2439,O
of,2439,O
triflusal,2439,B-CHEMICAL
and,2439,O
aspirin,2439,B-CHEMICAL
treatment,2439,O
on,2439,O
infarct,2439,O
volume,2439,O
",",2439,O
and,2439,O
inflammation,2439,O
after,2439,O
cerebral,2439,O
ischemia,2439,O
in,2439,O
the,2439,O
rat,2439,O
.,2439,O
METHODS,2440,O
:,2440,O
Male,2440,O
Wistar,2440,O
rats,2440,O
were,2440,O
subjected,2440,O
to,2440,O
a,2440,O
permanent,2440,O
right-sided,2440,O
middle,2440,O
cerebral,2440,O
artery,2440,O
occlusion,2440,O
.,2440,O
Rats,2441,O
received,2441,O
oral,2441,O
administration,2441,O
of,2441,O
either,2441,O
triflusal,2441,B-CHEMICAL
or,2441,O
aspirin,2441,B-CHEMICAL
.,2441,O
After,2442,O
3,2442,O
days,2442,O
after,2442,O
surgery,2442,O
",",2442,O
immunostaining,2442,O
was,2442,O
used,2442,O
to,2442,O
detect,2442,O
neuroinflammatory,2442,O
cells,2442,O
and,2442,O
molecules,2442,O
",",2442,O
and,2442,O
infarct,2442,O
volumes,2442,O
were,2442,O
measured,2442,O
.,2442,O
RESULTS,2443,O
:,2443,O
Both,2443,O
triflusal,2443,B-CHEMICAL
and,2443,O
aspirin,2443,B-CHEMICAL
at,2443,O
a,2443,O
dose,2443,O
of,2443,O
30,2443,O
mg/kg,2443,O
but,2443,O
not,2443,O
10,2443,O
mg/kg,2443,O
significantly,2443,O
reduced,2443,O
infarct,2443,O
volume,2443,O
compared,2443,O
with,2443,O
vehicle,2443,O
treatment,2443,O
.,2443,O
Middle,2444,O
cerebral,2444,O
artery,2444,O
occlusion,2444,O
resulted,2444,O
in,2444,O
increased,2444,O
astrocyte,2444,O
and,2444,O
heat,2444,B-GENE-Y
shock,2444,I-GENE-Y
protein-27,2444,I-GENE-Y
(,2444,O
Hsp27,2444,B-GENE-Y
),2444,O
immunostaining,2444,O
in,2444,O
the,2444,O
ipsilateral,2444,O
cortex,2444,O
.,2444,O
Triflusal,2445,B-CHEMICAL
(,2445,O
30,2445,O
mg/kg,2445,O
),2445,O
or,2445,O
aspirin,2445,B-CHEMICAL
treatment,2445,O
(,2445,O
30,2445,O
mg/kg,2445,O
),2445,O
did,2445,O
not,2445,O
reduce,2445,O
the,2445,O
levels,2445,O
of,2445,O
GFAP,2445,B-GENE-Y
or,2445,O
Hsp27,2445,B-GENE-Y
immunostaining,2445,O
.,2445,O
Triflusal,2446,B-CHEMICAL
(,2446,O
30,2446,O
mg/kg,2446,O
),2446,O
also,2446,O
significantly,2446,O
decreased,2446,O
the,2446,O
protein,2446,O
levels,2446,O
of,2446,O
IL-Ibeta,2446,B-GENE-Y
but,2446,O
not,2446,O
nuclear,2446,B-GENE-N
factor,2446,I-GENE-N
kappa,2446,I-GENE-N
B,2446,I-GENE-N
or,2446,O
tumor,2446,B-GENE-Y
necrosis,2446,I-GENE-Y
factor-alpha,2446,I-GENE-Y
in,2446,O
the,2446,O
cortex,2446,O
ipsilateral,2446,O
to,2446,O
the,2446,O
middle,2446,O
cerebral,2446,O
artery,2446,O
occlusion,2446,O
.,2446,O
CONCLUSIONS,2447,O
:,2447,O
The,2447,O
results,2447,O
suggest,2447,O
that,2447,O
triflusal,2447,B-CHEMICAL
and,2447,O
aspirin,2447,B-CHEMICAL
appear,2447,O
to,2447,O
be,2447,O
equally,2447,O
neuroprotective,2447,O
against,2447,O
middle,2447,O
cerebral,2447,O
artery,2447,O
occlusion-induced,2447,O
cerebral,2447,O
ischemia,2447,O
.,2447,O
Therefore,2448,O
",",2448,O
strong,2448,O
rationale,2448,O
exists,2448,O
to,2448,O
continue,2448,O
the,2448,O
neuroprotective,2448,O
examination,2448,O
of,2448,O
triflusal,2448,B-CHEMICAL
in,2448,O
brain,2448,O
injury,2448,O
.,2448,O
Differential,2449,O
expression,2449,O
of,2449,O
glycans,2449,O
in,2449,O
the,2449,O
hippocampus,2449,O
of,2449,O
rats,2449,O
trained,2449,O
on,2449,O
an,2449,O
inhibitory,2449,O
learning,2449,O
paradigm,2449,O
.,2449,O
The,2450,O
glycan,2450,O
chains,2450,O
of,2450,O
glycoconjugates,2450,O
play,2450,O
important,2450,O
roles,2450,O
in,2450,O
cell-cell,2450,O
and,2450,O
cell-matrix,2450,O
interactions,2450,O
.,2450,O
In,2451,O
the,2451,O
CNS,2451,O
",",2451,O
previous,2451,O
studies,2451,O
on,2451,O
learning,2451,O
and,2451,O
memory,2451,O
suggest,2451,O
the,2451,O
importance,2451,O
of,2451,O
oligosaccharides,2451,O
attached,2451,O
to,2451,O
glycoconjugates,2451,O
in,2451,O
the,2451,O
modulation,2451,O
of,2451,O
synaptic,2451,O
connections,2451,O
.,2451,O
We,2452,O
studied,2452,O
the,2452,O
hippocampal,2452,O
glycan,2452,O
distribution,2452,O
of,2452,O
rats,2452,O
subject,2452,O
to,2452,O
an,2452,O
inhibitory,2452,O
avoidance,2452,O
task,2452,O
.,2452,O
The,2453,O
expression,2453,O
of,2453,O
glycans,2453,O
was,2453,O
examined,2453,O
by,2453,O
lectin-histochemistry,2453,B-GENE-N
using,2453,O
Vicia,2453,B-GENE-N
villosa,2453,I-GENE-N
lectin,2453,I-GENE-N
(,2453,O
VVL,2453,B-GENE-N
),2453,O
for,2453,O
terminal,2453,O
alpha/beta,2453,B-CHEMICAL
N-acetylgalactosamine,2453,I-CHEMICAL
(,2453,O
alpha/beta,2453,B-CHEMICAL
GalNAc,2453,I-CHEMICAL
),2453,O
;,2453,O
Galanthus,2453,B-GENE-Y
nivalus,2453,I-GENE-Y
lectin,2453,I-GENE-Y
(,2453,O
GNL,2453,B-GENE-Y
),2453,O
for,2453,O
terminal,2453,O
mannose,2453,B-CHEMICAL
"alpha-1,3",2453,I-CHEMICAL
(,2453,O
Man,2453,B-CHEMICAL
"alpha-1,3",2453,I-CHEMICAL
),2453,O
;,2453,O
Peanut,2453,B-GENE-Y
agglutinin,2453,I-GENE-Y
(,2453,O
PNA,2453,B-GENE-Y
),2453,O
for,2453,O
galactose,2453,B-CHEMICAL
"beta-1,3N-acetylgalactosamine",2453,I-CHEMICAL
(,2453,O
Gal,2453,B-CHEMICAL
"beta-1,3",2453,I-CHEMICAL
GalNAc,2453,I-CHEMICAL
),2453,O
;,2453,O
Erythrina,2453,B-GENE-Y
cristagalli,2453,I-GENE-Y
lectin,2453,I-GENE-Y
(,2453,O
ECL,2453,B-GENE-Y
),2453,O
for,2453,O
galactose,2453,B-CHEMICAL
"beta-1,4",2453,I-CHEMICAL
N-acetylglucosamine,2453,I-CHEMICAL
(,2453,O
Gal,2453,B-CHEMICAL
"beta-1,4",2453,I-CHEMICAL
GlcNAc,2453,I-CHEMICAL
),2453,O
;,2453,O
Sambucus,2453,B-GENE-Y
nigra,2453,I-GENE-Y
lectin,2453,I-GENE-Y
(,2453,O
SNA,2453,B-GENE-Y
),2453,O
for,2453,O
sialic,2453,B-CHEMICAL
acid,2453,I-CHEMICAL
alpha-2.6,2453,I-CHEMICAL
galactose,2453,I-CHEMICAL
(,2453,O
SA,2453,B-CHEMICAL
"alpha-2,6",2453,I-CHEMICAL
Gal,2453,I-CHEMICAL
),2453,O
;,2453,O
Maackia,2453,B-GENE-N
amurensis,2453,I-GENE-N
lectin,2453,I-GENE-N
II,2453,I-GENE-N
(,2453,O
MAL,2453,B-GENE-N
II,2453,I-GENE-N
),2453,O
for,2453,O
sialic,2453,B-CHEMICAL
acid,2453,I-CHEMICAL
"alpha-2,3",2453,I-CHEMICAL
(,2453,O
SA,2453,B-CHEMICAL
"alpha-2,3",2453,I-CHEMICAL
),2453,O
;,2453,O
Wheat,2453,B-GENE-N
germ,2453,I-GENE-N
agglutinin,2453,I-GENE-N
(,2453,O
WGA,2453,B-GENE-N
),2453,O
for,2453,O
terminal,2453,O
N-acetylglucosamine,2453,B-CHEMICAL
with/,2453,O
without,2453,O
sialic,2453,B-CHEMICAL
acid,2453,I-CHEMICAL
(,2453,O
GlcNAc,2453,B-CHEMICAL
wo,2453,O
SA,2453,B-CHEMICAL
),2453,O
;,2453,O
succynilated,2453,O
WGA,2453,O
(,2453,O
sWGA,2453,O
),2453,O
for,2453,O
terminal,2453,O
N-acetylglucosamine,2453,B-CHEMICAL
without,2453,O
sialic,2453,B-CHEMICAL
acid,2453,I-CHEMICAL
(,2453,O
terminal,2453,O
GlcNAc,2453,B-CHEMICAL
without,2453,O
SA,2453,B-CHEMICAL
),2453,O
;,2453,O
Griffonia,2453,B-GENE-N
simplicifolia,2453,I-GENE-N
lectin,2453,I-GENE-N
II,2453,I-GENE-N
(,2453,O
GSL,2453,B-GENE-N
II,2453,I-GENE-N
),2453,O
for,2453,O
terminal,2453,O
alpha/beta,2453,B-CHEMICAL
N-acetylglucosamine,2453,I-CHEMICAL
(,2453,O
alpha/beta,2453,B-CHEMICAL
GlcNAc,2453,I-CHEMICAL
terminal,2453,O
),2453,O
;,2453,O
and,2453,O
Lotus,2453,B-GENE-Y
tetragonolobus,2453,I-GENE-Y
lectin,2453,I-GENE-Y
(,2453,O
LTL,2453,B-GENE-Y
),2453,O
alpha-fucose,2453,B-CHEMICAL
.,2453,O
Two,2454,O
groups,2454,O
of,2454,O
10,2454,O
animals,2454,O
were,2454,O
examined,2454,O
:,2454,O
non-trained,2454,O
(,2454,O
Control,2454,O
),2454,O
and,2454,O
Trained,2454,O
rats,2454,O
.,2454,O
ECL,2455,B-GENE-N
",",2455,O
sWGA,2455,B-GENE-N
and,2455,O
GSL,2455,B-GENE-N
II,2455,I-GENE-N
were,2455,O
negative,2455,O
for,2455,O
both,2455,O
groups,2455,O
in,2455,O
all,2455,O
the,2455,O
hippocampal,2455,O
subfields,2455,O
studied,2455,O
.,2455,O
For,2456,O
both,2456,O
groups,2456,O
",",2456,O
VVL,2456,O
was,2456,O
negative,2456,O
in,2456,O
CA4,2456,O
and,2456,O
granular,2456,O
cells,2456,O
of,2456,O
the,2456,O
Dentate,2456,O
Gyrus,2456,O
(,2456,O
DG,2456,O
),2456,O
and,2456,O
LTL,2456,O
was,2456,O
negative,2456,O
in,2456,O
the,2456,O
CA4,2456,O
subfield,2456,O
.,2456,O
Expression,2457,O
of,2457,O
alpha/beta,2457,O
GalNAc,2457,B-CHEMICAL
",",2457,O
alpha-fucose,2457,B-CHEMICAL
and,2457,O
GlcNAc,2457,B-CHEMICAL
in,2457,O
other,2457,O
hippocampal,2457,O
subflields,2457,O
was,2457,O
positive,2457,O
",",2457,O
with,2457,O
no,2457,O
differences,2457,O
between,2457,O
groups,2457,O
.,2457,O
However,2458,O
",",2458,O
expression,2458,O
of,2458,O
Man,2458,B-CHEMICAL
"alpha-1,3",2458,I-CHEMICAL
was,2458,O
significantly,2458,O
higher,2458,O
in,2458,O
the,2458,O
CA1,2458,O
",",2458,O
CA2,2458,O
",",2458,O
CA3,2458,O
",",2458,O
and,2458,O
CA4,2458,O
subfields,2458,O
in,2458,O
the,2458,O
Trained,2458,O
group,2458,O
.,2458,O
On,2459,O
the,2459,O
other,2459,O
hand,2459,O
",",2459,O
expression,2459,O
of,2459,O
Gal,2459,B-CHEMICAL
"beta-1,3",2459,I-CHEMICAL
GalNAc,2459,I-CHEMICAL
was,2459,O
significantly,2459,O
low,2459,O
in,2459,O
CA4,2459,O
and,2459,O
DG,2459,O
in,2459,O
the,2459,O
Trained,2459,O
group,2459,O
.,2459,O
In,2460,O
conclusion,2460,O
",",2460,O
the,2460,O
results,2460,O
here,2460,O
presented,2460,O
indicate,2460,O
that,2460,O
the,2460,O
exposure,2460,O
of,2460,O
rats,2460,O
to,2460,O
an,2460,O
associative,2460,O
behavioral,2460,O
paradigm,2460,O
related,2460,O
to,2460,O
declarative,2460,O
memory,2460,O
",",2460,O
involves,2460,O
some,2460,O
regulatory,2460,O
mechanism/s,2460,O
for,2460,O
the,2460,O
differential,2460,O
patterns,2460,O
of,2460,O
glycan,2460,O
expression,2460,O
.,2460,O
Glutamate,2461,B-CHEMICAL
stimulates,2461,O
glutamate,2461,B-GENE-Y
receptor,2461,I-GENE-Y
interacting,2461,I-GENE-Y
protein,2461,I-GENE-Y
1,2461,I-GENE-Y
degradation,2461,O
by,2461,O
ubiquitin-proteasome,2461,B-GENE-N
system,2461,O
to,2461,O
regulate,2461,O
surface,2461,O
expression,2461,O
of,2461,O
GluR2,2461,B-GENE-Y
.,2461,O
The,2462,O
glutamate,2462,B-CHEMICAL
receptor,2462,I-GENE-Y
interacting,2462,I-GENE-Y
protein,2462,I-GENE-Y
1,2462,I-GENE-Y
(,2462,O
GRIP1,2462,B-GENE-Y
),2462,O
is,2462,O
a,2462,O
scaffolding,2462,O
protein,2462,O
in,2462,O
postsynaptic,2462,O
density,2462,O
(,2462,O
PSD,2462,O
),2462,O
",",2462,O
tethering,2462,O
AMPA,2462,B-GENE-N
receptors,2462,I-GENE-N
to,2462,O
other,2462,O
signaling,2462,O
proteins,2462,O
.,2462,O
Here,2463,O
we,2463,O
report,2463,O
that,2463,O
glutamate,2463,B-CHEMICAL
stimulation,2463,O
caused,2463,O
a,2463,O
rapid,2463,O
reduction,2463,O
in,2463,O
protein,2463,O
levels,2463,O
of,2463,O
GRIP1,2463,B-GENE-Y
",",2463,O
but,2463,O
not,2463,O
that,2463,O
of,2463,O
glutamate,2463,B-CHEMICAL
receptor,2463,O
(,2463,B-GENE-Y
GluR,2463,I-GENE-Y
),2463,I-GENE-Y
1,2463,I-GENE-Y
",",2463,O
GluR2,2463,B-GENE-Y
and,2463,O
protein,2463,B-GENE-Y
interacting,2463,I-GENE-Y
with,2463,I-GENE-Y
C,2463,I-GENE-Y
kinase,2463,I-GENE-Y
1,2463,I-GENE-Y
(,2463,O
PICK1,2463,B-GENE-Y
),2463,O
in,2463,O
rat,2463,O
primary,2463,O
cortical,2463,O
neuron,2463,O
cultures,2463,O
.,2463,O
Down-regulation,2464,O
of,2464,O
GRIP1,2464,B-GENE-Y
by,2464,O
glutamate,2464,B-CHEMICAL
was,2464,O
blocked,2464,O
by,2464,O
carbobenzoxyl-leucinyl-leucinyl-leucinal,2464,B-CHEMICAL
(,2464,O
MG132,2464,B-CHEMICAL
),2464,O
",",2464,O
a,2464,O
proteasome,2464,B-GENE-N
inhibitor,2464,O
and,2464,O
by,2464,O
expression,2464,O
of,2464,O
K48R-ubiquitin,2464,B-GENE-N
",",2464,O
a,2464,O
dominant,2464,O
negative,2464,O
form,2464,O
of,2464,O
ubiquitin,2464,B-GENE-N
.,2464,O
The,2465,O
GRIP1,2465,B-GENE-Y
reduction,2465,O
was,2465,O
inhibited,2465,O
by,2465,O
MK-801,2465,B-CHEMICAL
",",2465,O
an,2465,O
N-methyl-d-aspartate,2465,B-GENE-N
(,2465,I-GENE-N
NMDA,2465,I-GENE-N
),2465,I-GENE-N
receptor,2465,I-GENE-N
antagonist,2465,O
",",2465,O
but,2465,O
not,2465,O
by,2465,O
"6-cyano-7-nitroquinoxaline-2,3-dione",2465,B-CHEMICAL
(,2465,O
CNQX,2465,B-CHEMICAL
),2465,O
",",2465,O
an,2465,O
AMPA,2465,B-GENE-N
receptor,2465,I-GENE-N
antagonist,2465,O
.,2465,O
EGTA,2466,B-CHEMICAL
and,2466,O
"1,2-bis",2466,B-CHEMICAL
(,2466,I-CHEMICAL
2-aminophenoxy,2466,I-CHEMICAL
),2466,I-CHEMICAL
ethane-N,2466,I-CHEMICAL
",",2466,I-CHEMICAL
N,2466,I-CHEMICAL
",",2466,I-CHEMICAL
N,2466,I-CHEMICAL
',2466,I-CHEMICAL
",",2466,I-CHEMICAL
N'-tetra,2466,I-CHEMICAL
acetic,2466,I-CHEMICAL
acid,2466,I-CHEMICAL
tetrakis,2466,I-CHEMICAL
(,2466,O
BAPTA,2466,B-CHEMICAL
),2466,O
",",2466,O
two,2466,O
Ca2+,2466,B-CHEMICAL
chelators,2466,O
",",2466,O
but,2466,O
not,2466,O
nifedipine,2466,B-CHEMICAL
",",2466,O
an,2466,O
L-type,2466,B-GENE-N
Ca2+,2466,I-GENE-N
channel,2466,I-GENE-N
blocker,2466,O
",",2466,O
prevented,2466,O
GRIP1,2466,B-GENE-Y
degradation,2466,O
.,2466,O
Furthermore,2467,O
",",2467,O
MG132,2467,B-CHEMICAL
prevented,2467,O
glutamate-stimulated,2467,B-CHEMICAL
reduction,2467,O
in,2467,O
surface,2467,O
amount,2467,O
of,2467,O
GluR2,2467,B-GENE-Y
",",2467,O
and,2467,O
knockdown,2467,O
of,2467,O
GRIP1,2467,B-GENE-Y
by,2467,O
RNAi,2467,O
against,2467,O
GRIP1,2467,B-GENE-Y
reduced,2467,O
surface,2467,O
GluR2,2467,B-GENE-Y
in,2467,O
neurons,2467,O
.,2467,O
Our,2468,O
results,2468,O
suggest,2468,O
that,2468,O
glutamate,2468,B-CHEMICAL
induces,2468,O
GRIP1,2468,B-GENE-Y
degradation,2468,O
by,2468,O
proteasome,2468,B-GENE-N
through,2468,O
an,2468,O
NMDA,2468,B-CHEMICAL
receptor-Ca2+,2468,O
pathway,2468,O
and,2468,O
that,2468,O
GRIP1,2468,B-GENE-Y
degradation,2468,O
may,2468,O
play,2468,O
an,2468,O
important,2468,O
role,2468,O
in,2468,O
regulating,2468,O
GluR2,2468,B-GENE-Y
surface,2468,O
expression,2468,O
.,2468,O
Transgenic,2469,O
expression,2469,O
of,2469,O
the,2469,O
human,2469,B-GENE-Y
Vitamin,2469,I-GENE-Y
D,2469,I-GENE-Y
receptor,2469,I-GENE-Y
(,2469,O
hVDR,2469,B-GENE-Y
),2469,O
in,2469,O
the,2469,O
duodenum,2469,O
of,2469,O
VDR-null,2469,B-GENE-Y
mice,2469,O
attenuates,2469,O
the,2469,O
age-dependent,2469,O
decline,2469,O
in,2469,O
calcium,2469,B-CHEMICAL
absorption,2469,O
.,2469,O
"1,25",2470,B-CHEMICAL
(,2470,I-CHEMICAL
OH,2470,I-CHEMICAL
),2470,I-CHEMICAL
(,2470,I-CHEMICAL
2,2470,I-CHEMICAL
),2470,I-CHEMICAL
D,2470,I-CHEMICAL
(,2470,I-CHEMICAL
3,2470,I-CHEMICAL
),2470,I-CHEMICAL
regulates,2470,O
calcium,2470,B-CHEMICAL
homeostasis,2470,O
through,2470,O
its,2470,O
actions,2470,O
in,2470,O
the,2470,O
intestine,2470,O
",",2470,O
bone,2470,O
",",2470,O
and,2470,O
kidney,2470,O
.,2470,O
These,2471,O
actions,2471,O
are,2471,O
mediated,2471,O
through,2471,O
the,2471,O
VDR,2471,B-GENE-Y
.,2471,O
To,2472,O
determine,2472,O
if,2472,O
VDR,2472,B-GENE-Y
's,2472,O
actions,2472,O
in,2472,O
the,2472,O
proximal,2472,O
small,2472,O
intestine,2472,O
can,2472,O
sufficiently,2472,O
restore,2472,O
calcium,2472,B-CHEMICAL
homeostasis,2472,O
",",2472,O
we,2472,O
generated,2472,O
transgenic,2472,O
mice,2472,O
expressing,2472,O
hVDR,2472,B-GENE-Y
exclusively,2472,O
in,2472,O
the,2472,O
duodenum,2472,O
of,2472,O
mVDR-null,2472,B-GENE-Y
mice,2472,O
by,2472,O
using,2472,O
the,2472,O
adenosine,2472,B-CHEMICAL
deaminase,2472,I-GENE-N
enhancer,2472,I-GENE-N
(,2472,O
hVDR+/mVDR-null,2472,B-GENE-Y
),2472,O
.,2472,O
Unlike,2473,O
wild-type,2473,O
mice,2473,O
",",2473,O
hVDR+/mVDR-null,2473,B-GENE-Y
mice,2473,O
express,2473,O
hVDR,2473,B-GENE-Y
and,2473,O
VDR,2473,B-GENE-Y
target,2473,O
genes,2473,O
only,2473,O
in,2473,O
the,2473,O
proximal,2473,O
small,2473,O
intestine,2473,O
.,2473,O
Despite,2474,O
having,2474,O
functional,2474,O
hVDR,2474,B-GENE-Y
in,2474,O
the,2474,O
proximal,2474,O
small,2474,O
intestine,2474,O
",",2474,O
hVDR+/mVDR-null,2474,B-GENE-Y
mice,2474,O
were,2474,O
hypocalcaemic,2474,O
when,2474,O
fed,2474,O
a,2474,O
normal,2474,O
rodent,2474,O
diet,2474,O
at,2474,O
weaning,2474,O
",",2474,O
like,2474,O
mVDR-null,2474,B-GENE-Y
mice,2474,O
fed,2474,O
the,2474,O
same,2474,O
diet,2474,O
.,2474,O
The,2475,O
hypocalcemia,2475,O
in,2475,O
these,2475,O
mice,2475,O
is,2475,O
prevented,2475,O
if,2475,O
they,2475,O
are,2475,O
given,2475,O
the,2475,O
rescue,2475,O
diet,2475,O
before,2475,O
weaning,2475,O
.,2475,O
However,2476,O
",",2476,O
when,2476,O
90-day-old,2476,O
rachitic,2476,O
mice,2476,O
were,2476,O
fed,2476,O
a,2476,O
rescue,2476,O
diet,2476,O
",",2476,O
serum,2476,O
calcium,2476,B-CHEMICAL
improved,2476,O
in,2476,O
hVDR+/mVDR-null,2476,B-GENE-Y
mice,2476,O
",",2476,O
but,2476,O
not,2476,O
in,2476,O
mVDR-null,2476,B-GENE-Y
mice,2476,O
.,2476,O
In,2477,O
conclusion,2477,O
",",2477,O
transgenic,2477,O
hVDR,2477,B-GENE-Y
in,2477,O
the,2477,O
proximal,2477,O
small,2477,O
intestine,2477,O
of,2477,O
hVDR+/mVDR-null,2477,B-GENE-Y
mice,2477,O
was,2477,O
transcriptionally,2477,O
active,2477,O
and,2477,O
regulated,2477,O
calcium,2477,B-CHEMICAL
absorption,2477,O
",",2477,O
but,2477,O
VDR,2477,B-GENE-Y
actions,2477,O
elsewhere,2477,O
in,2477,O
the,2477,O
intestine,2477,O
are,2477,O
probably,2477,O
necessary,2477,O
to,2477,O
support,2477,O
adequate,2477,O
calcium,2477,B-CHEMICAL
homeostasis,2477,O
.,2477,O
In,2478,O
addition,2478,O
",",2478,O
hVDR+/mVDR-null,2478,B-GENE-Y
mice,2478,O
responded,2478,O
better,2478,O
to,2478,O
the,2478,O
late,2478,O
rescue,2478,O
diet,2478,O
suggesting,2478,O
that,2478,O
expression,2478,O
of,2478,O
VDR,2478,B-GENE-Y
in,2478,O
the,2478,O
proximal,2478,O
small,2478,O
intestine,2478,O
protected,2478,O
the,2478,O
calcium,2478,B-CHEMICAL
absorbing,2478,O
machinery,2478,O
from,2478,O
age-dependent,2478,O
decline,2478,O
.,2478,O
The,2479,O
inhibitory,2479,O
effect,2479,O
of,2479,O
the,2479,O
leukotriene,2479,B-GENE-N
receptor,2479,I-GENE-N
antagonist,2479,O
on,2479,O
leukotriene,2479,B-CHEMICAL
D4-induced,2479,O
MUC2/5AC,2479,B-GENE-N
gene,2479,O
expression,2479,O
and,2479,O
mucin,2479,B-GENE-N
secretion,2479,O
in,2479,O
human,2479,O
airway,2479,O
epithelial,2479,O
cells,2479,O
.,2479,O
OBJECTIVES,2480,O
:,2480,O
Mucin,2480,B-GENE-N
gene,2480,O
expression,2480,O
and,2480,O
mucin,2480,B-GENE-N
production,2480,O
are,2480,O
markedly,2480,O
increased,2480,O
in,2480,O
inflammatory,2480,O
airway,2480,O
disorders,2480,O
such,2480,O
as,2480,O
asthma,2480,O
",",2480,O
chronic,2480,O
bronchitis,2480,O
and,2480,O
rhinosinusitis,2480,O
.,2480,O
Cytokines,2481,B-GENE-N
",",2481,O
lipopolysaccharides,2481,O
and,2481,O
other,2481,O
inflammatory,2481,O
mediators,2481,O
such,2481,O
as,2481,O
prostaglandin,2481,B-CHEMICAL
and,2481,O
leukotriene,2481,B-CHEMICAL
are,2481,O
related,2481,O
to,2481,O
the,2481,O
secretion,2481,O
and,2481,O
production,2481,O
of,2481,O
mucin,2481,B-GENE-N
.,2481,O
However,2482,O
",",2482,O
the,2482,O
relationship,2482,O
of,2482,O
leukotrienes,2482,B-CHEMICAL
with,2482,O
mucin,2482,B-GENE-N
genes,2482,O
expression,2482,O
is,2482,O
not,2482,O
clear,2482,O
.,2482,O
The,2483,O
aim,2483,O
of,2483,O
this,2483,O
study,2483,O
is,2483,O
to,2483,O
evaluate,2483,O
MUC2/5AC,2483,B-GENE-N
gene,2483,O
expression,2483,O
and,2483,O
mucin,2483,B-GENE-N
secretion,2483,O
by,2483,O
the,2483,O
leukotriene,2483,B-CHEMICAL
receptor,2483,I-GENE-N
in,2483,O
human,2483,O
airway,2483,O
epithelial,2483,O
cells,2483,O
.,2483,O
METHODS,2484,O
:,2484,O
The,2484,O
effect,2484,O
of,2484,O
leukotriene,2484,B-CHEMICAL
D,2484,I-CHEMICAL
(,2484,I-CHEMICAL
4,2484,I-CHEMICAL
),2484,I-CHEMICAL
and,2484,O
the,2484,O
leukotriene,2484,B-GENE-N
receptor,2484,I-GENE-N
antagonist,2484,O
",",2484,O
pranlukast,2484,B-CHEMICAL
hydrate,2484,I-CHEMICAL
(,2484,O
ONO-1078,2484,B-CHEMICAL
),2484,O
on,2484,O
the,2484,O
regulation,2484,O
of,2484,O
MUC2/5AC,2484,B-GENE-N
gene,2484,O
expression,2484,O
and,2484,O
mucin,2484,B-GENE-N
secretion,2484,O
were,2484,O
observed,2484,O
in,2484,O
human,2484,O
airway,2484,O
NCI-H292,2484,O
epithelial,2484,O
cells,2484,O
.,2484,O
The,2485,O
mRNA,2485,O
levels,2485,O
of,2485,O
MUC2/5AC,2485,B-GENE-N
and,2485,O
the,2485,O
amount,2485,O
of,2485,O
mucin,2485,B-GENE-N
were,2485,O
determined,2485,O
by,2485,O
reverse,2485,O
transcription-polymerase,2485,O
chain,2485,O
reaction,2485,O
(,2485,O
RT-PCR,2485,O
),2485,O
and,2485,O
immunoassay,2485,O
.,2485,O
RESULTS,2486,O
:,2486,O
Leukotriene,2486,B-CHEMICAL
D,2486,I-CHEMICAL
(,2486,I-CHEMICAL
4,2486,I-CHEMICAL
),2486,I-CHEMICAL
upregulated,2486,O
MUC2/5AC,2486,B-GENE-N
gene,2486,O
expression,2486,O
and,2486,O
mucin,2486,B-GENE-N
secretion,2486,O
in,2486,O
a,2486,O
dose,2486,O
dependent,2486,O
pattern,2486,O
.,2486,O
Pranlukast,2487,B-CHEMICAL
hydrate,2487,I-CHEMICAL
(,2487,O
ONO-1078,2487,B-CHEMICAL
",",2487,O
100,2487,O
microM,2487,O
),2487,O
downregulated,2487,O
the,2487,O
leukotriene,2487,B-CHEMICAL
D,2487,I-CHEMICAL
(,2487,I-CHEMICAL
4,2487,I-CHEMICAL
),2487,I-CHEMICAL
-induced,2487,O
MUC2/5AC,2487,B-GENE-N
gene,2487,O
expression,2487,O
and,2487,O
mucin,2487,B-GENE-N
secretion,2487,O
.,2487,O
CONCLUSION,2488,O
:,2488,O
These,2488,O
results,2488,O
suggest,2488,O
that,2488,O
the,2488,O
leukotriene,2488,B-CHEMICAL
receptor,2488,I-GENE-N
system,2488,O
is,2488,O
one,2488,O
of,2488,O
the,2488,O
mechanisms,2488,O
related,2488,O
to,2488,O
MUC2/5AC,2488,B-GENE-N
gene,2488,O
expression,2488,O
and,2488,O
mucin,2488,B-GENE-N
secretion,2488,O
in,2488,O
the,2488,O
human,2488,O
airway,2488,O
epithelium,2488,O
.,2488,O
Effect,2489,O
of,2489,O
isolated,2489,O
isoflavone,2489,B-CHEMICAL
supplementation,2489,O
on,2489,O
ABCA1-dependent,2489,B-GENE-Y
cholesterol,2489,B-CHEMICAL
efflux,2489,O
potential,2489,O
in,2489,O
postmenopausal,2489,O
women,2489,O
.,2489,O
OBJECTIVE,2490,O
:,2490,O
Isoflavones,2490,B-CHEMICAL
may,2490,O
display,2490,O
beneficial,2490,O
health,2490,O
effects,2490,O
in,2490,O
postmenopausal,2490,O
women,2490,O
.,2490,O
We,2491,O
studied,2491,O
in,2491,O
a,2491,O
clinical,2491,O
trial,2491,O
whether,2491,O
isolated,2491,O
isoflavone,2491,B-CHEMICAL
treatment,2491,O
in,2491,O
postmenopausal,2491,O
women,2491,O
could,2491,O
affect,2491,O
reverse,2491,O
cholesterol,2491,B-CHEMICAL
transport,2491,O
as,2491,O
evaluated,2491,O
by,2491,O
adenosine,2491,B-GENE-Y
triphosphate-binding,2491,I-GENE-Y
cassette,2491,I-GENE-Y
A1-,2491,O
(,2491,O
ABCA1,2491,B-GENE-Y
),2491,O
",",2491,O
dependent,2491,O
cholesterol,2491,B-CHEMICAL
efflux,2491,O
from,2491,O
macrophages,2491,O
.,2491,O
In,2492,O
addition,2492,O
",",2492,O
various,2492,O
serum,2492,O
lipid,2492,O
and,2492,O
lipoprotein,2492,B-GENE-N
parameters,2492,O
were,2492,O
investigated,2492,O
.,2492,O
Furthermore,2493,O
",",2493,O
we,2493,O
separately,2493,O
assessed,2493,O
equol-producing,2493,O
and,2493,O
non-equol-producing,2493,O
women,2493,O
.,2493,O
DESIGN,2494,O
:,2494,O
Postmenopausal,2494,O
women,2494,O
(,2494,O
n=56,2494,O
),2494,O
were,2494,O
treated,2494,O
with,2494,O
either,2494,O
isoflavone,2494,B-CHEMICAL
or,2494,O
placebo,2494,O
tablets,2494,O
for,2494,O
3,2494,O
months,2494,O
in,2494,O
a,2494,O
crossover,2494,O
design,2494,O
",",2494,O
separated,2494,O
by,2494,O
a,2494,O
2-month,2494,O
washout,2494,O
period,2494,O
.,2494,O
Fifteen,2495,O
women,2495,O
were,2495,O
classified,2495,O
as,2495,O
equol,2495,O
producers,2495,O
",",2495,O
and,2495,O
15,2495,O
women,2495,O
were,2495,O
classified,2495,O
as,2495,O
non-equol,2495,O
producers,2495,O
.,2495,O
Serum,2496,O
samples,2496,O
were,2496,O
collected,2496,O
before,2496,O
and,2496,O
after,2496,O
each,2496,O
treatment,2496,O
period,2496,O
.,2496,O
[,2497,B-CHEMICAL
H,2497,I-CHEMICAL
],2497,I-CHEMICAL
-Cholesterol-labeled,2497,O
J774,2497,O
macrophage,2497,O
cells,2497,O
",",2497,O
with,2497,O
and,2497,O
without,2497,O
ABCA1,2497,B-GENE-Y
up-regulation,2497,O
",",2497,O
were,2497,O
incubated,2497,O
with,2497,O
the,2497,O
samples,2497,O
",",2497,O
and,2497,O
ABCA1-dependent,2497,B-GENE-Y
cholesterol,2497,B-CHEMICAL
efflux,2497,O
and,2497,O
serum,2497,O
lipid,2497,O
and,2497,O
lipoprotein,2497,B-GENE-N
levels,2497,O
were,2497,O
assessed,2497,O
.,2497,O
RESULTS,2498,O
:,2498,O
Serum,2498,O
promoted,2498,O
3.1,2498,O
%,2498,O
+/-1.1,2498,O
%,2498,O
and,2498,O
3.2,2498,O
%,2498,O
+/-1.1,2498,O
%,2498,O
cholesterol,2498,B-CHEMICAL
efflux,2498,O
from,2498,O
macrophages,2498,O
after,2498,O
isoflavone,2498,B-CHEMICAL
and,2498,O
placebo,2498,O
treatment,2498,O
",",2498,O
respectively,2498,O
.,2498,O
Thus,2499,O
",",2499,O
isoflavone,2499,B-CHEMICAL
supplementation,2499,O
did,2499,O
not,2499,O
affect,2499,O
ABCA1-dependent,2499,B-GENE-Y
cholesterol,2499,B-CHEMICAL
efflux,2499,O
to,2499,O
serum,2499,O
.,2499,O
However,2500,O
",",2500,O
as,2500,O
a,2500,O
novel,2500,O
finding,2500,O
",",2500,O
isoflavone,2500,B-CHEMICAL
treatment,2500,O
increased,2500,O
a,2500,O
subclass,2500,O
of,2500,O
high-density,2500,B-GENE-N
lipoprotein,2500,I-GENE-N
",",2500,O
the,2500,O
pre-beta,2500,B-GENE-N
high-density,2500,I-GENE-N
lipoprotein,2500,I-GENE-N
levels,2500,O
by,2500,O
18,2500,O
%,2500,O
without,2500,O
affecting,2500,O
any,2500,O
other,2500,O
serum,2500,O
lipid,2500,O
concentrations,2500,O
.,2500,O
ABCA1-facilitated,2501,B-GENE-Y
cholesterol,2501,B-CHEMICAL
efflux,2501,O
and,2501,O
lipid,2501,O
parameters,2501,O
did,2501,O
not,2501,O
differ,2501,O
between,2501,O
equol-producing,2501,B-CHEMICAL
and,2501,O
non-equol-producing,2501,O
women,2501,O
.,2501,O
CONCLUSION,2502,O
:,2502,O
In,2502,O
postmenopausal,2502,O
women,2502,O
",",2502,O
isolated,2502,O
isoflavone,2502,B-CHEMICAL
treatment,2502,O
does,2502,O
not,2502,O
affect,2502,O
ABCA1-dependent,2502,B-GENE-Y
cholesterol,2502,B-CHEMICAL
efflux,2502,O
potential,2502,O
from,2502,O
macrophages,2502,O
but,2502,O
increases,2502,O
circulating,2502,O
pre-beta,2502,B-GENE-N
high-density,2502,I-GENE-N
lipoprotein,2502,I-GENE-N
level,2502,O
",",2502,O
which,2502,O
could,2502,O
provide,2502,O
beneficial,2502,O
vascular,2502,O
effects,2502,O
.,2502,O
The,2503,O
ability,2503,O
of,2503,O
sorafenib,2503,B-CHEMICAL
to,2503,O
inhibit,2503,O
oncogenic,2503,O
PDGFRbeta,2503,B-GENE-Y
and,2503,O
FLT3,2503,B-GENE-Y
mutants,2503,O
and,2503,O
overcome,2503,O
resistance,2503,O
to,2503,O
other,2503,O
small,2503,O
molecule,2503,O
inhibitors,2503,O
.,2503,O
BACKGROUND,2504,O
AND,2504,O
OBJECTIVES,2504,O
:,2504,O
Activated,2504,O
tyrosine,2504,B-GENE-N
kinases,2504,I-GENE-N
are,2504,O
implicated,2504,O
in,2504,O
the,2504,O
pathogenesis,2504,O
of,2504,O
chronic,2504,O
and,2504,O
acute,2504,O
leukemia,2504,O
",",2504,O
and,2504,O
represent,2504,O
attractive,2504,O
targets,2504,O
for,2504,O
therapy,2504,O
.,2504,O
Sorafenib,2505,B-CHEMICAL
(,2505,O
BAY43-9006,2505,B-CHEMICAL
",",2505,O
Nexavar,2505,B-CHEMICAL
),2505,O
is,2505,O
a,2505,O
small,2505,O
molecule,2505,O
B-RAF,2505,B-GENE-Y
inhibitor,2505,O
that,2505,O
is,2505,O
used,2505,O
for,2505,O
the,2505,O
treatment,2505,O
of,2505,O
renal,2505,O
cell,2505,O
carcinoma,2505,O
",",2505,O
and,2505,O
has,2505,O
been,2505,O
shown,2505,O
to,2505,O
have,2505,O
activity,2505,O
against,2505,O
receptor,2505,B-GENE-N
tyrosine,2505,I-GENE-N
kinases,2505,I-GENE-N
from,2505,O
the,2505,O
platelet-derived,2505,B-GENE-Y
growth,2505,I-GENE-Y
factor,2505,I-GENE-Y
receptor,2505,I-GENE-Y
(,2505,O
PDGFR,2505,B-GENE-Y
),2505,O
and,2505,O
vascular,2505,B-GENE-N
endothelial,2505,I-GENE-N
growth,2505,I-GENE-N
factor,2505,I-GENE-N
receptor,2505,I-GENE-N
(,2505,O
VEGFR,2505,B-GENE-N
),2505,O
families,2505,O
.,2505,O
We,2506,O
investigated,2506,O
the,2506,O
efficacy,2506,O
of,2506,O
sorafenib,2506,B-CHEMICAL
at,2506,O
inhibiting,2506,O
mutants,2506,O
of,2506,O
the,2506,O
receptor,2506,B-GENE-N
tyrosine,2506,I-GENE-N
kinases,2506,I-GENE-N
PDGFRbeta,2506,B-GENE-Y
",",2506,O
KIT,2506,B-GENE-Y
",",2506,O
and,2506,O
FLT3,2506,B-GENE-Y
",",2506,O
which,2506,O
are,2506,O
implicated,2506,O
in,2506,O
the,2506,O
pathogenesis,2506,O
of,2506,O
myeloid,2506,O
malignancies,2506,O
.,2506,O
DESIGN,2507,O
AND,2507,O
METHODS,2507,O
:,2507,O
We,2507,O
tested,2507,O
the,2507,O
effect,2507,O
of,2507,O
sorafenib,2507,B-CHEMICAL
on,2507,O
the,2507,O
proliferation,2507,O
of,2507,O
hematopoietic,2507,O
cells,2507,O
transformed,2507,O
by,2507,O
ETV6-PDGFRbeta,2507,B-GENE-Y
",",2507,O
FLT3,2507,B-GENE-Y
with,2507,O
an,2507,O
internal,2507,O
tandem,2507,O
duplication,2507,O
or,2507,O
D835Y,2507,B-GENE-N
point,2507,O
mutation,2507,O
",",2507,O
and,2507,O
the,2507,O
KIT,2507,B-GENE-Y
(,2507,O
D816V,2507,B-GENE-N
),2507,O
mutant,2507,O
.,2507,O
The,2508,O
direct,2508,O
effect,2508,O
of,2508,O
sorafenib,2508,B-CHEMICAL
on,2508,O
the,2508,O
activity,2508,O
of,2508,O
these,2508,O
kinases,2508,B-GENE-N
and,2508,O
their,2508,O
downstream,2508,O
signaling,2508,O
was,2508,O
tested,2508,O
using,2508,O
phospho-specific,2508,B-CHEMICAL
antibodies,2508,O
.,2508,O
RESULTS,2509,O
:,2509,O
We,2509,O
show,2509,O
that,2509,O
sorafenib,2509,B-CHEMICAL
is,2509,O
a,2509,O
potent,2509,O
inhibitor,2509,O
of,2509,O
ETV6-PDGFRbeta,2509,B-GENE-Y
and,2509,O
FLT3,2509,B-GENE-Y
mutants,2509,O
",",2509,O
including,2509,O
some,2509,O
of,2509,O
the,2509,O
mutants,2509,O
that,2509,O
confer,2509,O
resistance,2509,O
to,2509,O
PKC412,2509,O
and,2509,O
other,2509,O
FLT3,2509,B-GENE-Y
inhibitors,2509,O
.,2509,O
Sorafenib,2510,B-CHEMICAL
induced,2510,O
a,2510,O
cell,2510,O
cycle,2510,O
block,2510,O
and,2510,O
apoptosis,2510,O
in,2510,O
the,2510,O
acute,2510,O
myeloid,2510,O
leukemia,2510,O
cell,2510,O
lines,2510,O
MV4-11,2510,O
and,2510,O
MOLM-13,2510,O
",",2510,O
both,2510,O
expressing,2510,O
FLT3,2510,B-GENE-Y
with,2510,O
an,2510,O
internal,2510,O
tandem,2510,O
duplication,2510,O
",",2510,O
whereas,2510,O
no,2510,O
effect,2510,O
was,2510,O
observed,2510,O
on,2510,O
four,2510,O
other,2510,O
acute,2510,O
myeloid,2510,O
leukemia,2510,O
cell,2510,O
lines,2510,O
.,2510,O
The,2511,O
imatinib-resistant,2511,B-CHEMICAL
KIT,2511,B-GENE-Y
(,2511,O
D816V,2511,B-GENE-N
),2511,O
mutant,2511,O
",",2511,O
associated,2511,O
with,2511,O
systemic,2511,O
mastocytosis,2511,O
",",2511,O
was,2511,O
found,2511,O
to,2511,O
be,2511,O
resistant,2511,O
to,2511,O
sorafenib,2511,B-CHEMICAL
.,2511,O
INTERPRETATION,2512,O
AND,2512,O
CONCLUSIONS,2512,O
:,2512,O
These,2512,O
results,2512,O
warrant,2512,O
further,2512,O
clinical,2512,O
studies,2512,O
of,2512,O
sorafenib,2512,B-CHEMICAL
for,2512,O
the,2512,O
treatment,2512,O
of,2512,O
myeloid,2512,O
malignancies,2512,O
expressing,2512,O
activated,2512,O
forms,2512,O
of,2512,O
PDGFRbeta,2512,B-GENE-Y
and,2512,O
FLT3,2512,B-GENE-Y
.,2512,O
Glucocorticoids,2513,O
stimulate,2513,O
ENaC,2513,B-GENE-N
upregulation,2513,O
in,2513,O
bovine,2513,O
mammary,2513,O
epithelium,2513,O
.,2513,O
Mammary,2514,O
epithelia,2514,O
produce,2514,O
an,2514,O
isotonic,2514,O
",",2514,O
low-Na,2514,O
(,2514,I-CHEMICAL
+,2514,I-CHEMICAL
),2514,I-CHEMICAL
fluid,2514,O
that,2514,O
is,2514,O
rich,2514,O
in,2514,O
nutrients,2514,O
.,2514,O
Mechanisms,2515,O
that,2515,O
account,2515,O
for,2515,O
the,2515,O
low,2515,O
electrolyte,2515,O
concentration,2515,O
have,2515,O
not,2515,O
been,2515,O
elucidated,2515,O
",",2515,O
although,2515,O
amiloride-sensitive,2515,B-CHEMICAL
ion,2515,O
transport,2515,O
has,2515,O
been,2515,O
reported,2515,O
in,2515,O
some,2515,O
situations,2515,O
.,2515,O
We,2516,O
hypothesized,2516,O
that,2516,O
corticosteroid,2516,O
exposure,2516,O
modulates,2516,O
epithelial,2516,B-GENE-N
Na,2516,B-CHEMICAL
(,2516,I-CHEMICAL
+,2516,I-CHEMICAL
),2516,I-CHEMICAL
channel,2516,I-GENE-N
(,2516,O
ENaC,2516,B-GENE-N
),2516,O
expression,2516,O
and/or,2516,O
activity,2516,O
in,2516,O
bovine,2516,O
mammary,2516,O
epithelial,2516,O
cells,2516,O
.,2516,O
BME-UV,2517,O
cells,2517,O
were,2517,O
grown,2517,O
to,2517,O
confluent,2517,O
monolayers,2517,O
on,2517,O
permeable,2517,O
supports,2517,O
with,2517,O
a,2517,O
standard,2517,O
basolateral,2517,O
medium,2517,O
and,2517,O
apical,2517,O
medium,2517,O
of,2517,O
low-electrolyte,2517,O
",",2517,O
high-lactose,2517,O
composition,2517,O
that,2517,O
resembles,2517,O
the,2517,O
ionic,2517,O
composition,2517,O
of,2517,O
milk,2517,O
.,2517,O
Ion,2518,O
transport,2518,O
was,2518,O
assessed,2518,O
in,2518,O
modified,2518,O
Ussing,2518,O
flux,2518,O
chambers,2518,O
.,2518,O
Exposure,2519,O
to,2519,O
glucocorticoids,2519,O
(,2519,O
dexamethasone,2519,B-CHEMICAL
",",2519,O
cortisol,2519,B-CHEMICAL
",",2519,O
or,2519,O
prednisolone,2519,B-CHEMICAL
),2519,O
",",2519,O
but,2519,O
not,2519,O
aldosterone,2519,B-CHEMICAL
",",2519,O
increased,2519,O
short-circuit,2519,O
current,2519,O
(,2519,O
I,2519,O
(,2519,O
sc,2519,O
),2519,O
),2519,O
",",2519,O
a,2519,O
sensitive,2519,O
measure,2519,O
of,2519,O
net,2519,O
ion,2519,O
transport,2519,O
",",2519,O
whereas,2519,O
apical,2519,O
exposure,2519,O
to,2519,O
amiloride,2519,B-CHEMICAL
or,2519,O
benzamil,2519,B-CHEMICAL
reduced,2519,O
corticosteroid-induced,2519,O
I,2519,O
(,2519,O
sc,2519,O
),2519,O
close,2519,O
to,2519,O
basal,2519,O
levels,2519,O
.,2519,O
Quantitative,2520,O
RT-PCR,2520,O
indicated,2520,O
a,2520,O
glucocorticoid-induced,2520,O
increase,2520,O
in,2520,O
mRNA,2520,O
for,2520,O
beta-,2520,B-GENE-N
and,2520,I-GENE-N
gamma-ENaC,2520,I-GENE-N
",",2520,O
whereas,2520,O
alpha-ENaC,2520,B-GENE-Y
mRNA,2520,O
expression,2520,O
was,2520,O
only,2520,O
mildly,2520,O
affected,2520,O
.,2520,O
Exposure,2521,O
to,2521,O
mifepristone,2521,B-CHEMICAL
(,2521,O
a,2521,O
glucocorticoid,2521,B-GENE-Y
receptor,2521,I-GENE-Y
antagonist,2521,O
),2521,O
",",2521,O
but,2521,O
not,2521,O
spironolactone,2521,B-CHEMICAL
(,2521,O
a,2521,O
mineralocorticoid,2521,B-GENE-N
receptor,2521,I-GENE-N
antagonist,2521,O
),2521,O
",",2521,O
precluded,2521,O
both,2521,O
the,2521,O
corticosteroid-induced,2521,O
elevation,2521,O
in,2521,O
amiloride-sensitive,2521,B-CHEMICAL
I,2521,O
(,2521,O
sc,2521,O
),2521,O
and,2521,O
the,2521,O
induced,2521,O
changes,2521,O
in,2521,O
beta-,2521,B-GENE-N
and,2521,I-GENE-N
gamma-ENaC,2521,I-GENE-N
mRNA,2521,O
.,2521,O
We,2522,O
conclude,2522,O
that,2522,O
Na,2522,B-CHEMICAL
(,2522,I-CHEMICAL
+,2522,I-CHEMICAL
),2522,I-CHEMICAL
movement,2522,O
across,2522,O
mammary,2522,O
epithelia,2522,O
is,2522,O
modulated,2522,O
by,2522,O
corticosteroids,2522,O
via,2522,O
a,2522,O
glucocorticoid,2522,B-GENE-Y
receptor-mediated,2522,O
mechanism,2522,O
that,2522,O
regulates,2522,O
the,2522,O
expression,2522,O
of,2522,O
the,2522,O
beta-,2522,B-GENE-N
and,2522,I-GENE-N
gamma-subunits,2522,I-GENE-N
of,2522,I-GENE-N
ENaC,2522,I-GENE-N
.,2522,O
ENaC,2523,B-GENE-N
expression,2523,O
and,2523,O
activity,2523,O
could,2523,O
account,2523,O
for,2523,O
the,2523,O
low,2523,O
Na,2523,B-CHEMICAL
(,2523,I-CHEMICAL
+,2523,I-CHEMICAL
),2523,I-CHEMICAL
concentration,2523,O
that,2523,O
is,2523,O
typical,2523,O
of,2523,O
milk,2523,O
.,2523,O
Salicylate-based,2524,B-CHEMICAL
anti-inflammatory,2524,O
drugs,2524,O
inhibit,2524,O
the,2524,O
early,2524,O
lesion,2524,O
of,2524,O
diabetic,2524,O
retinopathy,2524,O
.,2524,O
It,2525,O
has,2525,O
been,2525,O
previously,2525,O
reported,2525,O
that,2525,O
aspirin,2525,B-CHEMICAL
inhibited,2525,O
the,2525,O
development,2525,O
of,2525,O
diabetic,2525,O
retinopathy,2525,O
in,2525,O
diabetic,2525,O
animals,2525,O
",",2525,O
raising,2525,O
the,2525,O
possibility,2525,O
that,2525,O
anti-inflammatory,2525,O
drugs,2525,O
may,2525,O
have,2525,O
beneficial,2525,O
effects,2525,O
on,2525,O
diabetic,2525,O
retinopathy,2525,O
.,2525,O
To,2526,O
further,2526,O
explore,2526,O
this,2526,O
",",2526,O
we,2526,O
compared,2526,O
effects,2526,O
of,2526,O
oral,2526,O
consumption,2526,O
of,2526,O
three,2526,O
different,2526,O
salicylate-based,2526,B-CHEMICAL
drugs,2526,O
(,2526,O
aspirin,2526,B-CHEMICAL
",",2526,O
sodium,2526,B-CHEMICAL
salicylate,2526,I-CHEMICAL
",",2526,O
and,2526,O
sulfasalazine,2526,B-CHEMICAL
),2526,O
on,2526,O
the,2526,O
development,2526,O
of,2526,O
early,2526,O
stages,2526,O
of,2526,O
diabetic,2526,O
retinopathy,2526,O
in,2526,O
rats,2526,O
.,2526,O
These,2527,O
three,2527,O
drugs,2527,O
differ,2527,O
in,2527,O
their,2527,O
ability,2527,O
to,2527,O
inhibit,2527,O
cyclooxygenase,2527,B-GENE-N
but,2527,O
share,2527,O
an,2527,O
ability,2527,O
to,2527,O
inhibit,2527,O
nuclear,2527,B-GENE-N
factor-kappaB,2527,I-GENE-N
(,2527,O
NF-kappaB,2527,B-GENE-N
),2527,O
.,2527,O
Diabetes,2528,O
of,2528,O
9-10,2528,O
months,2528,O
duration,2528,O
significantly,2528,O
increased,2528,O
the,2528,O
number,2528,O
of,2528,O
TUNEL,2528,O
(,2528,O
transferase-mediated,2528,O
dUTP,2528,O
nick-end,2528,O
labeling,2528,O
),2528,O
-positive,2528,O
capillary,2528,O
cells,2528,O
and,2528,O
acellular,2528,O
(,2528,O
degenerate,2528,O
),2528,O
capillaries,2528,O
in,2528,O
the,2528,O
retinal,2528,O
vasculature,2528,O
",",2528,O
and,2528,O
all,2528,O
three,2528,O
salicylate-based,2528,B-CHEMICAL
drugs,2528,O
inhibited,2528,O
this,2528,O
cell,2528,O
death,2528,O
and,2528,O
formation,2528,O
of,2528,O
acellular,2528,O
capillaries,2528,O
without,2528,O
altering,2528,O
the,2528,O
severity,2528,O
of,2528,O
hyperglycemia,2528,O
.,2528,O
In,2529,O
short-term,2529,O
diabetes,2529,O
(,2529,O
2-4,2529,O
months,2529,O
),2529,O
",",2529,O
all,2529,O
three,2529,O
salicylates,2529,B-CHEMICAL
inhibited,2529,O
the,2529,O
diabetes-induced,2529,O
loss,2529,O
of,2529,O
neuronal,2529,O
cells,2529,O
from,2529,O
the,2529,O
ganglion,2529,O
cell,2529,O
layer,2529,O
.,2529,O
Oral,2530,O
aspirin,2530,B-CHEMICAL
(,2530,O
as,2530,O
a,2530,O
representative,2530,O
of,2530,O
the,2530,O
salicylate,2530,B-CHEMICAL
family,2530,O
),2530,O
inhibited,2530,O
diabetes-induced,2530,O
increase,2530,O
in,2530,O
NF-kappaB,2530,B-GENE-N
DNA-binding,2530,O
affinity,2530,O
in,2530,O
electrophoretic,2530,O
mobility,2530,O
shift,2530,O
assay,2530,O
and,2530,O
transcription,2530,O
factor,2530,O
array,2530,O
in,2530,O
nuclear,2530,O
extract,2530,O
isolated,2530,O
from,2530,O
whole,2530,O
retina,2530,O
.,2530,O
All,2531,O
three,2531,O
salicylates,2531,B-CHEMICAL
inhibited,2531,O
the,2531,O
diabetes-induced,2531,O
translocation,2531,O
of,2531,O
p50,2531,B-GENE-Y
(,2531,O
a,2531,O
subunit,2531,O
of,2531,O
NF-kappaB,2531,B-GENE-N
),2531,O
into,2531,O
nuclei,2531,O
of,2531,O
retinal,2531,O
vascular,2531,O
endothelial,2531,O
cells,2531,O
of,2531,O
the,2531,O
isolated,2531,O
retinal,2531,O
vasculature,2531,O
",",2531,O
as,2531,O
well,2531,O
as,2531,O
of,2531,O
p50,2531,B-GENE-Y
and,2531,O
p65,2531,B-GENE-Y
into,2531,O
nuclei,2531,O
of,2531,O
cells,2531,O
in,2531,O
the,2531,O
ganglion,2531,O
cell,2531,O
layer,2531,O
and,2531,O
inner,2531,O
nuclear,2531,O
layer,2531,O
on,2531,O
whole-retinal,2531,O
sections,2531,O
.,2531,O
Sulfasalazine,2532,B-CHEMICAL
(,2532,O
also,2532,O
as,2532,O
a,2532,O
representative,2532,O
of,2532,O
the,2532,O
salicylates,2532,B-CHEMICAL
),2532,O
inhibited,2532,O
the,2532,O
diabetes-induced,2532,O
upregulation,2532,O
of,2532,O
several,2532,O
inflammatory,2532,O
gene,2532,O
products,2532,O
",",2532,O
which,2532,O
are,2532,O
regulated,2532,O
by,2532,O
NF-kappaB,2532,B-GENE-N
",",2532,O
including,2532,O
vascular,2532,O
cell,2532,O
adhesion,2532,O
molecule,2532,O
",",2532,O
intracellular,2532,B-GENE-Y
adhesion,2532,I-GENE-Y
molecule-1,2532,I-GENE-Y
",",2532,O
inducible,2532,B-GENE-Y
nitric,2532,B-CHEMICAL
oxide,2532,I-CHEMICAL
synthase,2532,I-GENE-Y
",",2532,O
and,2532,O
cyclooxygenase-2,2532,B-GENE-Y
in,2532,O
whole-retinal,2532,O
lysate,2532,O
.,2532,O
Salicylates,2533,B-CHEMICAL
",",2533,O
in,2533,O
doses,2533,O
administrated,2533,O
in,2533,O
our,2533,O
experiments,2533,O
",",2533,O
inhibited,2533,O
NF-kappaB,2533,B-GENE-N
and,2533,O
perhaps,2533,O
other,2533,O
transcription,2533,O
factors,2533,O
in,2533,O
the,2533,O
retina,2533,O
",",2533,O
were,2533,O
well,2533,O
tolerated,2533,O
",",2533,O
and,2533,O
offered,2533,O
new,2533,O
tools,2533,O
to,2533,O
investigate,2533,O
and,2533,O
inhibit,2533,O
the,2533,O
development,2533,O
of,2533,O
diabetic,2533,O
retinopathy,2533,O
.,2533,O
Localization,2534,O
of,2534,O
an,2534,O
11,2534,B-GENE-Y
beta,2534,I-GENE-Y
hydroxysteroid,2534,I-GENE-Y
dehydrogenase,2534,I-GENE-Y
activity,2534,O
to,2534,O
the,2534,O
distal,2534,O
nephron,2534,O
.,2534,O
Evidence,2535,O
for,2535,O
the,2535,O
existence,2535,O
of,2535,O
two,2535,O
species,2535,O
of,2535,O
dehydrogenase,2535,B-GENE-N
in,2535,O
the,2535,O
rat,2535,O
kidney,2535,O
.,2535,O
An,2536,O
11,2536,B-GENE-Y
beta,2536,I-GENE-Y
hydroxysteroid,2536,I-GENE-Y
dehydrogenase,2536,I-GENE-Y
(,2536,O
11,2536,B-GENE-Y
beta,2536,I-GENE-Y
HSD,2536,I-GENE-Y
),2536,O
activity,2536,O
has,2536,O
been,2536,O
localized,2536,O
in,2536,O
the,2536,O
rat,2536,O
kidney,2536,O
by,2536,O
a,2536,O
histochemical,2536,O
technique,2536,O
which,2536,O
links,2536,O
steroid,2536,B-CHEMICAL
metabolism,2536,O
with,2536,O
the,2536,O
production,2536,O
of,2536,O
a,2536,O
color,2536,O
reaction,2536,O
.,2536,O
Oxidation,2537,O
of,2537,O
11,2537,B-CHEMICAL
beta-hydroxyandrostenedione,2537,I-CHEMICAL
was,2537,O
observed,2537,O
in,2537,O
cortical,2537,O
distal,2537,O
convoluted,2537,O
tubules,2537,O
and,2537,O
in,2537,O
medullary,2537,O
collecting,2537,O
ducts,2537,O
.,2537,O
Carbenoxolone,2538,B-CHEMICAL
abolished,2538,O
staining,2538,O
",",2538,O
no,2538,O
reaction,2538,O
was,2538,O
obtained,2538,O
with,2538,O
androstenedione,2538,B-CHEMICAL
hydroxylated,2538,O
at,2538,O
the,2538,O
17,2538,O
or,2538,O
19,2538,O
position,2538,O
",",2538,O
and,2538,O
oxidation,2538,O
of,2538,O
11,2538,B-CHEMICAL
beta-hydroxyandrostenedione,2538,I-CHEMICAL
was,2538,O
nicotinamide-adenine,2538,B-CHEMICAL
dinucleotide,2538,I-CHEMICAL
(,2538,O
NAD,2538,B-CHEMICAL
),2538,O
dependent,2538,O
.,2538,O
These,2539,O
results,2539,O
demonstrate,2539,O
the,2539,O
presence,2539,O
of,2539,O
a,2539,O
dehydrogenase,2539,B-GENE-N
activity,2539,O
separate,2539,O
from,2539,O
the,2539,O
nicotinamide-adenine,2539,B-CHEMICAL
dinucleotide,2539,I-CHEMICAL
phosphate,2539,I-CHEMICAL
(,2539,O
NADP,2539,B-CHEMICAL
),2539,O
-dependent,2539,O
11,2539,B-GENE-Y
beta,2539,I-GENE-Y
hydroxysteroid,2539,I-GENE-Y
dehydrogenase,2539,I-GENE-Y
recently,2539,O
purified,2539,O
and,2539,O
cloned,2539,O
from,2539,O
rat,2539,O
liver,2539,O
.,2539,O
We,2540,O
have,2540,O
named,2540,O
this,2540,O
activity,2540,O
11,2540,B-GENE-Y
beta,2540,I-GENE-Y
HSD2,2540,I-GENE-Y
to,2540,O
distinguish,2540,O
it,2540,O
from,2540,O
the,2540,O
NADP-dependent,2540,B-CHEMICAL
11,2540,B-GENE-Y
beta,2540,I-GENE-Y
HSD,2540,I-GENE-Y
.,2540,O
Histological,2541,O
studies,2541,O
showed,2541,O
that,2541,O
11,2541,B-GENE-Y
beta,2541,I-GENE-Y
HSD2,2541,I-GENE-Y
activity,2541,O
does,2541,O
not,2541,O
correlate,2541,O
with,2541,O
the,2541,O
immunocytochemical,2541,O
localization,2541,O
of,2541,O
the,2541,O
previously,2541,O
defined,2541,O
11,2541,B-GENE-Y
beta,2541,I-GENE-Y
HSD,2541,I-GENE-Y
enzyme,2541,O
",",2541,O
but,2541,O
rather,2541,O
the,2541,O
11,2541,B-GENE-Y
beta,2541,I-GENE-Y
HSD2,2541,I-GENE-Y
activity,2541,O
is,2541,O
localized,2541,O
in,2541,O
the,2541,O
distal,2541,O
tubules,2541,O
of,2541,O
the,2541,O
rat,2541,O
kidney,2541,O
.,2541,O
In,2542,O
this,2542,O
respect,2542,O
11,2542,B-GENE-Y
beta,2542,I-GENE-Y
HSD2,2542,I-GENE-Y
colocalizes,2542,O
with,2542,O
the,2542,O
mineralocorticoid,2542,B-GENE-Y
receptor,2542,I-GENE-Y
.,2542,O
No,2543,O
reaction,2543,O
product,2543,O
was,2543,O
obtained,2543,O
using,2543,O
cortisol,2543,B-CHEMICAL
or,2543,O
corticosterone,2543,B-CHEMICAL
as,2543,O
substrate,2543,O
with,2543,O
either,2543,O
NAD,2543,B-CHEMICAL
or,2543,O
NADP,2543,B-CHEMICAL
as,2543,O
cofactor,2543,O
.,2543,O
Furthermore,2544,O
incubation,2544,O
of,2544,O
tissue,2544,O
sections,2544,O
with,2544,O
11,2544,B-CHEMICAL
beta,2544,I-CHEMICAL
androstenedione,2544,I-CHEMICAL
in,2544,O
the,2544,O
presence,2544,O
of,2544,O
deoxycorticosterone,2544,B-CHEMICAL
completely,2544,O
inhibited,2544,O
cytochemical,2544,O
staining,2544,O
.,2544,O
We,2545,O
interpret,2545,O
these,2545,O
results,2545,O
as,2545,O
evidence,2545,O
of,2545,O
20,2545,B-GENE-N
reductase,2545,I-GENE-N
activity,2545,O
which,2545,O
uses,2545,O
the,2545,O
reduced,2545,O
cofactor,2545,O
at,2545,O
the,2545,O
expense,2545,O
of,2545,O
the,2545,O
color,2545,O
reaction,2545,O
.,2545,O
These,2546,O
results,2546,O
support,2546,O
the,2546,O
crucial,2546,O
role,2546,O
played,2546,O
by,2546,O
an,2546,O
11,2546,B-CHEMICAL
beta,2546,I-CHEMICAL
hydroxysteroid,2546,I-CHEMICAL
dehydrogenase,2546,I-GENE-Y
in,2546,O
the,2546,O
local,2546,O
protection,2546,O
of,2546,O
type,2546,O
I,2546,O
receptors,2546,O
in,2546,O
mineralocorticoid,2546,O
selective,2546,O
tissues,2546,O
.,2546,O
Effect,2547,O
of,2547,O
long-term,2547,O
fluoxetine,2547,B-CHEMICAL
treatment,2547,O
on,2547,O
the,2547,O
human,2547,B-GENE-Y
serotonin,2547,I-GENE-Y
transporter,2547,I-GENE-Y
in,2547,O
Caco-2,2547,O
cells,2547,O
.,2547,O
Fluoxetine,2548,B-CHEMICAL
is,2548,O
a,2548,O
selective,2548,O
serotonin,2548,B-CHEMICAL
reuptake,2548,O
inhibitor,2548,O
(,2548,O
SSRI,2548,O
),2548,O
broadly,2548,O
used,2548,O
in,2548,O
the,2548,O
treatment,2548,O
of,2548,O
human,2548,O
mood,2548,O
disorders,2548,O
and,2548,O
gastrointestinal,2548,O
diseases,2548,O
involving,2548,O
the,2548,O
serotoninergic,2548,O
system,2548,O
.,2548,O
The,2549,O
effectiveness,2549,O
of,2549,O
this,2549,O
therapy,2549,O
depends,2549,O
on,2549,O
repeated,2549,O
long-term,2549,O
treatment,2549,O
.,2549,O
Most,2550,O
of,2550,O
the,2550,O
long-term,2550,O
studies,2550,O
in,2550,O
vivo,2550,O
of,2550,O
SSRI,2550,O
effects,2550,O
on,2550,O
serotoninergic,2550,O
activity,2550,O
have,2550,O
focused,2550,O
on,2550,O
their,2550,O
effects,2550,O
on,2550,O
autoreceptors,2550,O
or,2550,O
postsynaptic,2550,O
receptors,2550,O
.,2550,O
The,2551,O
chronic,2551,O
effect,2551,O
of,2551,O
SSRIs,2551,O
on,2551,O
the,2551,O
activity,2551,O
of,2551,O
the,2551,O
serotonin,2551,B-CHEMICAL
transporter,2551,I-GENE-Y
(,2551,O
SERT,2551,B-GENE-Y
),2551,O
has,2551,O
been,2551,O
less,2551,O
studied,2551,O
and,2551,O
the,2551,O
results,2551,O
have,2551,O
been,2551,O
contradictory,2551,O
.,2551,O
The,2552,O
aim,2552,O
of,2552,O
this,2552,O
study,2552,O
was,2552,O
to,2552,O
determine,2552,O
the,2552,O
specific,2552,O
effect,2552,O
of,2552,O
long-term,2552,O
fluoxetine,2552,B-CHEMICAL
treatment,2552,O
on,2552,O
human,2552,B-GENE-Y
serotonin,2552,B-CHEMICAL
transporter,2552,I-GENE-Y
(,2552,O
hSERT,2552,B-GENE-Y
),2552,O
in,2552,O
vitro,2552,O
",",2552,O
by,2552,O
using,2552,O
the,2552,O
human,2552,O
enterocyte-like,2552,O
cell,2552,O
line,2552,O
Caco-2,2552,O
.,2552,O
Results,2553,O
show,2553,O
that,2553,O
fluoxetine,2553,B-CHEMICAL
diminished,2553,O
the,2553,O
5-HT,2553,B-CHEMICAL
uptake,2553,O
in,2553,O
a,2553,O
concentration-dependent,2553,O
way,2553,O
and,2553,O
that,2553,O
this,2553,O
effect,2553,O
was,2553,O
reversible,2553,O
.,2553,O
Fluoxetine,2554,B-CHEMICAL
affected,2554,O
mainly,2554,O
the,2554,O
hSERT,2554,B-GENE-Y
transport,2554,O
rate,2554,O
by,2554,O
reducing,2554,O
the,2554,O
availability,2554,O
of,2554,O
the,2554,O
transporter,2554,O
in,2554,O
the,2554,O
membrane,2554,O
with,2554,O
no,2554,O
significant,2554,O
alteration,2554,O
of,2554,O
either,2554,O
the,2554,O
total,2554,O
hSERT,2554,B-GENE-Y
protein,2554,O
content,2554,O
or,2554,O
the,2554,O
hSERT,2554,B-GENE-Y
mRNA,2554,O
level,2554,O
.,2554,O
These,2555,O
results,2555,O
suggest,2555,O
that,2555,O
the,2555,O
effect,2555,O
of,2555,O
fluoxetine,2555,B-CHEMICAL
on,2555,O
the,2555,O
expression,2555,O
of,2555,O
hSERT,2555,B-GENE-Y
is,2555,O
post-translational,2555,O
and,2555,O
has,2555,O
shown,2555,O
itself,2555,O
to,2555,O
be,2555,O
independent,2555,O
of,2555,O
PKC,2555,B-GENE-N
and,2555,O
PKA,2555,B-GENE-N
activity,2555,O
.,2555,O
This,2556,O
study,2556,O
may,2556,O
be,2556,O
useful,2556,O
to,2556,O
clarify,2556,O
the,2556,O
effect,2556,O
of,2556,O
the,2556,O
long-term,2556,O
fluoxetine,2556,B-CHEMICAL
therapy,2556,O
in,2556,O
both,2556,O
gastrointestinal,2556,O
and,2556,O
central,2556,O
nervous,2556,O
system,2556,O
disorders,2556,O
.,2556,O
Roles,2557,O
played,2557,O
by,2557,O
lymphocyte,2557,B-GENE-Y
function-associated,2557,I-GENE-Y
antigen-1,2557,I-GENE-Y
in,2557,O
the,2557,O
regulation,2557,O
of,2557,O
lymphocytic,2557,O
cholinergic,2557,O
activity,2557,O
.,2557,O
Lymphocytes,2558,O
possess,2558,O
the,2558,O
essential,2558,O
components,2558,O
of,2558,O
a,2558,O
cholinergic,2558,O
system,2558,O
",",2558,O
including,2558,O
acetylcholine,2558,B-CHEMICAL
(,2558,O
ACh,2558,B-CHEMICAL
),2558,O
;,2558,O
choline,2558,B-CHEMICAL
acetyltransferase,2558,I-GENE-Y
(,2558,O
ChAT,2558,B-GENE-Y
),2558,O
",",2558,O
its,2558,O
synthesizing,2558,O
enzyme,2558,O
;,2558,O
and,2558,O
both,2558,O
muscarinic,2558,B-GENE-N
and,2558,I-GENE-N
nicotinic,2558,I-GENE-N
ACh,2558,B-CHEMICAL
receptors,2558,I-GENE-N
(,2558,O
mAChRs,2558,B-GENE-N
and,2558,O
nAChRs,2558,B-GENE-N
",",2558,O
respectively,2558,O
),2558,O
.,2558,O
Stimulation,2559,O
of,2559,O
lymphocytes,2559,O
with,2559,O
phytohemagglutinin,2559,B-GENE-N
",",2559,O
which,2559,O
activates,2559,O
T,2559,O
cells,2559,O
via,2559,O
the,2559,O
T,2559,B-GENE-N
cell,2559,I-GENE-N
receptor/CD3,2559,O
complex,2559,O
",",2559,O
enhances,2559,O
the,2559,O
synthesis,2559,O
and,2559,O
release,2559,O
of,2559,O
ACh,2559,B-CHEMICAL
and,2559,O
up-regulates,2559,O
expression,2559,O
of,2559,O
ChAT,2559,B-GENE-Y
and,2559,O
M,2559,B-GENE-Y
(,2559,I-GENE-Y
5,2559,I-GENE-Y
),2559,I-GENE-Y
mAChR,2559,I-GENE-Y
mRNAs,2559,O
.,2559,O
In,2560,O
addition,2560,O
",",2560,O
activation,2560,O
of,2560,O
protein,2560,B-GENE-N
kinase,2560,I-GENE-N
C,2560,I-GENE-N
and,2560,O
increases,2560,O
in,2560,O
intracellular,2560,O
cAMP,2560,B-CHEMICAL
also,2560,O
enhance,2560,O
cholinergic,2560,O
activity,2560,O
in,2560,O
T,2560,O
cells,2560,O
",",2560,O
and,2560,O
lymphocyte,2560,B-GENE-Y
function,2560,I-GENE-Y
associated,2560,I-GENE-Y
antigen-1,2560,I-GENE-Y
(,2560,O
LFA-1,2560,B-GENE-Y
;,2560,O
CD11a/CD18,2560,B-GENE-Y
),2560,O
is,2560,O
an,2560,O
important,2560,O
mediator,2560,O
of,2560,O
leukocyte,2560,O
migration,2560,O
and,2560,O
T,2560,O
cell,2560,O
activation,2560,O
.,2560,O
Anti-CD11a,2561,O
monoclonal,2561,O
antibody,2561,O
(,2561,O
mAb,2561,O
),2561,O
as,2561,O
well,2561,O
as,2561,O
antithymocyte,2561,O
globulin,2561,B-GENE-N
containing,2561,O
antibodies,2561,O
against,2561,O
CD2,2561,B-GENE-Y
",",2561,O
CD7,2561,B-GENE-Y
and,2561,O
CD11a,2561,B-GENE-Y
all,2561,O
increase,2561,O
ChAT,2561,B-GENE-Y
activity,2561,O
",",2561,O
ACh,2561,B-CHEMICAL
synthesis,2561,O
and,2561,O
release,2561,O
",",2561,O
and,2561,O
expression,2561,O
of,2561,O
ChAT,2561,B-GENE-Y
and,2561,O
M,2561,B-GENE-Y
(,2561,I-GENE-Y
5,2561,I-GENE-Y
),2561,I-GENE-Y
mAChR,2561,I-GENE-Y
mRNAs,2561,O
in,2561,O
T,2561,O
cells,2561,O
.,2561,O
The,2562,O
cholesterol-lowering,2562,B-CHEMICAL
drug,2562,O
simvastatin,2562,O
inhibits,2562,O
LFA-1,2562,B-GENE-Y
signaling,2562,O
by,2562,O
binding,2562,O
to,2562,O
an,2562,O
allosteric,2562,O
site,2562,O
on,2562,O
CD11a,2562,B-GENE-Y
(,2562,O
LFA-1,2562,B-GENE-Y
alpha,2562,I-GENE-Y
chain,2562,O
),2562,O
",",2562,O
which,2562,O
leads,2562,O
to,2562,O
immunomodulation,2562,O
.,2562,O
We,2563,O
found,2563,O
that,2563,O
simvastatin,2563,B-CHEMICAL
abolishes,2563,O
anti-CD11a,2563,O
mAb-induced,2563,O
increases,2563,O
in,2563,O
lymphocytic,2563,O
cholinergic,2563,O
activity,2563,O
in,2563,O
a,2563,O
manner,2563,O
independent,2563,O
of,2563,O
its,2563,O
cholesterol-lowering,2563,B-CHEMICAL
activity,2563,O
.,2563,O
Collectively,2564,O
then,2564,O
",",2564,O
these,2564,O
results,2564,O
indicate,2564,O
that,2564,O
LFA-1,2564,B-GENE-Y
contributes,2564,O
to,2564,O
the,2564,O
regulation,2564,O
of,2564,O
lymphocytic,2564,O
cholinergic,2564,O
activity,2564,O
via,2564,O
CD11a-mediated,2564,B-GENE-Y
pathways,2564,O
and,2564,O
suggest,2564,O
that,2564,O
simvastatin,2564,B-CHEMICAL
exerts,2564,O
its,2564,O
immunosuppressive,2564,O
effects,2564,O
in,2564,O
part,2564,O
via,2564,O
modification,2564,O
of,2564,O
lymphocytic,2564,O
cholinergic,2564,O
activity,2564,O
.,2564,O
Association,2565,O
of,2565,O
estrogen,2565,B-GENE-Y
receptor-alpha,2565,I-GENE-Y
and,2565,O
progesterone,2565,B-GENE-Y
receptor,2565,I-GENE-Y
A,2565,O
expression,2565,O
with,2565,O
hormonal,2565,O
mammary,2565,O
carcinogenesis,2565,O
:,2565,O
role,2565,O
of,2565,O
the,2565,O
host,2565,O
microenvironment,2565,O
.,2565,O
INTRODUCTION,2566,O
:,2566,O
Medroxyprogesterone,2566,B-CHEMICAL
acetate,2566,I-CHEMICAL
(,2566,O
MPA,2566,B-CHEMICAL
),2566,O
induces,2566,O
estrogen,2566,B-GENE-Y
receptor,2566,I-GENE-Y
(,2566,O
ER,2566,B-GENE-Y
),2566,O
-positive,2566,O
and,2566,O
progesterone,2566,B-GENE-Y
receptor,2566,I-GENE-Y
(,2566,O
PR,2566,B-GENE-Y
),2566,O
-positive,2566,O
ductal,2566,O
invasive,2566,O
mammary,2566,O
carcinomas,2566,O
in,2566,O
BALB/c,2566,O
mice,2566,O
.,2566,O
We,2567,O
sought,2567,O
to,2567,O
reproduce,2567,O
this,2567,O
MPA,2567,B-CHEMICAL
cancer,2567,O
model,2567,O
in,2567,O
C57BL/6,2567,O
mice,2567,O
because,2567,O
of,2567,O
their,2567,O
widespread,2567,O
use,2567,O
in,2567,O
genetic,2567,O
engineering,2567,O
.,2567,O
Within,2568,O
this,2568,O
experimental,2568,O
setting,2568,O
",",2568,O
we,2568,O
studied,2568,O
the,2568,O
carcinogenic,2568,O
effects,2568,O
of,2568,O
MPA,2568,B-CHEMICAL
",",2568,O
the,2568,O
morphologic,2568,O
changes,2568,O
in,2568,O
mammary,2568,O
glands,2568,O
that,2568,O
are,2568,O
induced,2568,O
by,2568,O
MPA,2568,B-CHEMICAL
and,2568,O
progesterone,2568,B-CHEMICAL
",",2568,O
and,2568,O
the,2568,O
levels,2568,O
of,2568,O
ER,2568,B-GENE-Y
and,2568,O
PR,2568,B-GENE-Y
expression,2568,O
in,2568,O
MPA-treated,2568,B-CHEMICAL
and,2568,O
progesterone-treated,2568,B-CHEMICAL
mammary,2568,O
glands,2568,O
.,2568,O
Finally,2569,O
",",2569,O
we,2569,O
evaluated,2569,O
whether,2569,O
the,2569,O
differences,2569,O
found,2569,O
between,2569,O
BALB/c,2569,O
and,2569,O
C57BL/6,2569,O
mouse,2569,O
strains,2569,O
were,2569,O
due,2569,O
to,2569,O
intrinsic,2569,O
differences,2569,O
in,2569,O
epithelial,2569,O
cells,2569,O
.,2569,O
METHODS,2570,O
:,2570,O
The,2570,O
carcinogenic,2570,O
effect,2570,O
of,2570,O
MPA,2570,B-CHEMICAL
was,2570,O
evaluated,2570,O
in,2570,O
C57BL/6,2570,O
mice,2570,O
using,2570,O
protocols,2570,O
proven,2570,O
to,2570,O
be,2570,O
carcinogenic,2570,O
in,2570,O
BALB/c,2570,O
mice,2570,O
.,2570,O
In,2571,O
addition,2571,O
",",2571,O
BALB/c,2571,O
and,2571,O
C57BL/6,2571,O
females,2571,O
were,2571,O
treated,2571,O
with,2571,O
progesterone,2571,B-CHEMICAL
or,2571,O
MPA,2571,B-CHEMICAL
for,2571,O
1,2571,O
or,2571,O
2,2571,O
months,2571,O
",",2571,O
and,2571,O
mammary,2571,O
glands,2571,O
were,2571,O
excised,2571,O
for,2571,O
histologic,2571,O
studies,2571,O
and,2571,O
for,2571,O
immunohistochemical,2571,O
and,2571,O
Western,2571,O
blot,2571,O
evaluation,2571,O
of,2571,O
ER,2571,B-GENE-Y
and,2571,O
PR,2571,B-GENE-Y
.,2571,O
Hormone,2572,O
levels,2572,O
were,2572,O
determined,2572,O
by,2572,O
radioimmunoassay,2572,O
.,2572,O
Isolated,2573,O
mammary,2573,O
epithelial,2573,O
cells,2573,O
were,2573,O
transplanted,2573,O
into,2573,O
cleared,2573,O
fat,2573,O
pads,2573,O
of,2573,O
21-day-old,2573,O
female,2573,O
Swiss,2573,O
nu/nu,2573,O
mice,2573,O
or,2573,O
control,2573,O
congenic,2573,O
animals,2573,O
.,2573,O
RESULTS,2574,O
:,2574,O
MPA,2574,B-CHEMICAL
failed,2574,O
to,2574,O
induce,2574,O
mammary,2574,O
carcinomas,2574,O
or,2574,O
significant,2574,O
morphologic,2574,O
changes,2574,O
in,2574,O
the,2574,O
mammary,2574,O
glands,2574,O
of,2574,O
C57BL/6,2574,O
mice,2574,O
.,2574,O
The,2575,O
expression,2575,O
of,2575,O
ER-alpha,2575,B-GENE-Y
and,2575,O
PR,2575,B-GENE-Y
isoform,2575,I-GENE-Y
A,2575,I-GENE-Y
in,2575,O
virgin,2575,O
mice,2575,O
was,2575,O
surprisingly,2575,O
much,2575,O
higher,2575,O
in,2575,O
BALB/c,2575,O
than,2575,O
in,2575,O
C57BL/6,2575,O
mammary,2575,O
glands,2575,O
",",2575,O
and,2575,O
both,2575,O
receptors,2575,O
were,2575,O
downregulated,2575,O
in,2575,O
progestin-treated,2575,B-CHEMICAL
BALB/c,2575,O
mice,2575,O
(,2575,O
P,2575,O
<,2575,O
0.05,2575,O
),2575,O
.,2575,O
PR,2576,B-GENE-Y
isoform,2576,I-GENE-Y
B,2576,I-GENE-Y
levels,2576,O
were,2576,O
low,2576,O
in,2576,O
virgin,2576,O
control,2576,O
mice,2576,O
and,2576,O
increased,2576,O
after,2576,O
progestin,2576,B-CHEMICAL
treatment,2576,O
in,2576,O
both,2576,O
strains,2576,O
.,2576,O
ER-beta,2577,B-GENE-Y
expression,2577,O
followed,2577,O
a,2577,O
similar,2577,O
trend,2577,O
.,2577,O
No,2578,O
differences,2578,O
in,2578,O
hormone,2578,O
levels,2578,O
were,2578,O
found,2578,O
between,2578,O
strains,2578,O
.,2578,O
Surprisingly,2579,O
",",2579,O
the,2579,O
transplantation,2579,O
of,2579,O
the,2579,O
epithelial,2579,O
mammary,2579,O
gland,2579,O
cells,2579,O
of,2579,O
both,2579,O
strains,2579,O
into,2579,O
the,2579,O
cleared,2579,O
fat,2579,O
pads,2579,O
of,2579,O
Swiss,2579,O
(,2579,O
nu/nu,2579,O
),2579,O
mice,2579,O
abolished,2579,O
the,2579,O
mammary,2579,O
gland,2579,O
morphologic,2579,O
differences,2579,O
and,2579,O
the,2579,O
ER,2579,B-GENE-Y
and,2579,O
PR,2579,B-GENE-Y
differences,2579,O
between,2579,O
strains,2579,O
.,2579,O
CONCLUSION,2580,O
:,2580,O
C57BL/6,2580,O
mammary,2580,O
glands,2580,O
are,2580,O
resistant,2580,O
to,2580,O
MPA-induced,2580,B-CHEMICAL
carcinogenesis,2580,O
and,2580,O
to,2580,O
hormone,2580,O
action,2580,O
.,2580,O
MPA,2581,B-CHEMICAL
and,2581,O
progesterone,2581,B-CHEMICAL
have,2581,O
different,2581,O
effects,2581,O
on,2581,O
mammary,2581,O
glands,2581,O
.,2581,O
Low,2582,O
ER-alpha,2582,B-GENE-Y
and,2582,O
PR-A,2582,B-GENE-Y
levels,2582,O
in,2582,O
untreated,2582,O
mammary,2582,O
glands,2582,O
may,2582,O
be,2582,O
associated,2582,O
with,2582,O
a,2582,O
low-risk,2582,O
breast,2582,O
cancer,2582,O
profile,2582,O
.,2582,O
Although,2583,O
we,2583,O
can,2583,O
not,2583,O
at,2583,O
this,2583,O
time,2583,O
rule,2583,O
out,2583,O
the,2583,O
participation,2583,O
of,2583,O
other,2583,O
",",2583,O
untested,2583,O
factors,2583,O
",",2583,O
our,2583,O
findings,2583,O
implicate,2583,O
the,2583,O
stroma,2583,O
as,2583,O
playing,2583,O
a,2583,O
crucial,2583,O
role,2583,O
in,2583,O
the,2583,O
strain-specific,2583,O
differential,2583,O
hormone,2583,B-GENE-N
receptor,2583,I-GENE-N
expression,2583,O
and,2583,O
hormone,2583,O
responsiveness,2583,O
.,2583,O
Transplacental,2584,O
exposure,2584,O
to,2584,O
inorganic,2584,B-CHEMICAL
arsenic,2584,I-CHEMICAL
at,2584,O
a,2584,O
hepatocarcinogenic,2584,O
dose,2584,O
induces,2584,O
fetal,2584,O
gene,2584,O
expression,2584,O
changes,2584,O
in,2584,O
mice,2584,O
indicative,2584,O
of,2584,O
aberrant,2584,O
estrogen,2584,B-CHEMICAL
signaling,2584,O
and,2584,O
disrupted,2584,O
steroid,2584,B-CHEMICAL
metabolism,2584,O
.,2584,O
Exposure,2585,O
to,2585,O
inorganic,2585,B-CHEMICAL
arsenic,2585,I-CHEMICAL
in,2585,O
utero,2585,O
in,2585,O
C3H,2585,O
mice,2585,O
produces,2585,O
hepatocellular,2585,O
carcinoma,2585,O
in,2585,O
male,2585,O
offspring,2585,O
when,2585,O
they,2585,O
reach,2585,O
adulthood,2585,O
.,2585,O
To,2586,O
help,2586,O
define,2586,O
the,2586,O
molecular,2586,O
events,2586,O
associated,2586,O
with,2586,O
the,2586,O
fetal,2586,O
onset,2586,O
of,2586,O
arsenic,2586,B-CHEMICAL
hepatocarcinogenesis,2586,O
",",2586,O
pregnant,2586,O
C3H,2586,O
mice,2586,O
were,2586,O
given,2586,O
drinking,2586,O
water,2586,O
containing,2586,O
0,2586,O
(,2586,O
control,2586,O
),2586,O
or,2586,O
85,2586,O
ppm,2586,O
arsenic,2586,B-CHEMICAL
from,2586,O
day,2586,O
8,2586,O
to,2586,O
18,2586,O
of,2586,O
gestation,2586,O
.,2586,O
At,2587,O
the,2587,O
end,2587,O
of,2587,O
the,2587,O
arsenic,2587,B-CHEMICAL
exposure,2587,O
period,2587,O
",",2587,O
male,2587,O
fetal,2587,O
livers,2587,O
were,2587,O
removed,2587,O
and,2587,O
RNA,2587,O
isolated,2587,O
for,2587,O
microarray,2587,O
analysis,2587,O
using,2587,O
22K,2587,O
oligo,2587,O
chips,2587,O
.,2587,O
Arsenic,2588,B-CHEMICAL
exposure,2588,O
in,2588,O
utero,2588,O
produced,2588,O
significant,2588,O
(,2588,O
p,2588,O
<,2588,O
0.001,2588,O
),2588,O
alterations,2588,O
in,2588,O
expression,2588,O
of,2588,O
187,2588,O
genes,2588,O
",",2588,O
with,2588,O
approximately,2588,O
25,2588,O
%,2588,O
of,2588,O
aberrantly,2588,O
expressed,2588,O
genes,2588,O
related,2588,O
to,2588,O
either,2588,O
estrogen,2588,B-CHEMICAL
signaling,2588,O
or,2588,O
steroid,2588,B-CHEMICAL
metabolism,2588,O
.,2588,O
Real-time,2589,O
RT-PCR,2589,O
on,2589,O
selected,2589,O
genes,2589,O
confirmed,2589,O
these,2589,O
changes,2589,O
.,2589,O
Various,2590,O
genes,2590,O
controlled,2590,O
by,2590,O
estrogen,2590,B-CHEMICAL
",",2590,O
including,2590,O
X-inactive-specific,2590,B-GENE-Y
transcript,2590,I-GENE-Y
",",2590,O
anterior,2590,B-GENE-Y
gradient-2,2590,I-GENE-Y
",",2590,O
trefoil,2590,B-GENE-Y
factor-1,2590,I-GENE-Y
",",2590,O
CRP-ductin,2590,B-GENE-Y
",",2590,O
ghrelin,2590,B-GENE-Y
",",2590,O
and,2590,O
small,2590,B-GENE-Y
proline-rich,2590,I-GENE-Y
protein-2A,2590,I-GENE-Y
",",2590,O
were,2590,O
dramatically,2590,O
over-expressed,2590,O
.,2590,O
Estrogen-regulated,2591,B-CHEMICAL
genes,2591,O
including,2591,O
cytokeratin,2591,B-GENE-Y
1-19,2591,I-GENE-Y
and,2591,O
Cyp2a4,2591,B-GENE-Y
were,2591,O
over-expressed,2591,O
",",2591,O
although,2591,O
Cyp3a25,2591,B-GENE-Y
was,2591,O
suppressed,2591,O
.,2591,O
Several,2592,O
genes,2592,O
involved,2592,O
with,2592,O
steroid,2592,B-CHEMICAL
metabolism,2592,O
also,2592,O
showed,2592,O
remarkable,2592,O
expression,2592,O
changes,2592,O
",",2592,O
including,2592,O
increased,2592,O
expression,2592,O
of,2592,O
17beta-hydroxysteroid,2592,B-GENE-Y
dehydrogenase-7,2592,I-GENE-Y
(,2592,O
HSD17beta7,2592,B-GENE-Y
;,2592,O
involved,2592,O
in,2592,O
estradiol,2592,B-CHEMICAL
production,2592,O
),2592,O
and,2592,O
decreased,2592,O
expression,2592,O
of,2592,O
HSD17beta5,2592,B-GENE-Y
(,2592,O
involved,2592,O
in,2592,O
testosterone,2592,B-CHEMICAL
production,2592,O
),2592,O
.,2592,O
The,2593,O
expression,2593,O
of,2593,O
key,2593,O
genes,2593,O
important,2593,O
in,2593,O
methionine,2593,B-CHEMICAL
metabolism,2593,O
",",2593,O
such,2593,O
as,2593,O
methionine,2593,B-CHEMICAL
adenosyltransferase-1a,2593,I-GENE-Y
",",2593,O
betaine-homocysteine,2593,B-CHEMICAL
methyltransferase,2593,I-GENE-Y
and,2593,O
thioether,2593,B-GENE-Y
S-methyltransferase,2593,I-GENE-Y
",",2593,O
were,2593,O
suppressed,2593,O
.,2593,O
Thus,2594,O
",",2594,O
exposure,2594,O
of,2594,O
mouse,2594,O
fetus,2594,O
to,2594,O
inorganic,2594,B-CHEMICAL
arsenic,2594,I-CHEMICAL
during,2594,O
a,2594,O
critical,2594,O
period,2594,O
in,2594,O
development,2594,O
significantly,2594,O
alters,2594,O
the,2594,O
expression,2594,O
of,2594,O
various,2594,O
genes,2594,O
encoding,2594,O
estrogen,2594,B-CHEMICAL
signaling,2594,O
and,2594,O
steroid,2594,B-CHEMICAL
or,2594,O
methionine,2594,B-CHEMICAL
metabolism,2594,O
.,2594,O
These,2595,O
alterations,2595,O
could,2595,O
disrupt,2595,O
genetic,2595,O
programming,2595,O
at,2595,O
the,2595,O
very,2595,O
early,2595,O
life,2595,O
stage,2595,O
",",2595,O
which,2595,O
could,2595,O
impact,2595,O
tumor,2595,O
formation,2595,O
much,2595,O
later,2595,O
in,2595,O
adulthood,2595,O
.,2595,O
A,2596,O
pilot,2596,O
study,2596,O
of,2596,O
IL-1,2596,B-GENE-N
inhibition,2596,O
by,2596,O
anakinra,2596,O
in,2596,O
acute,2596,O
gout,2596,O
.,2596,O
Monosodium,2597,B-CHEMICAL
urate,2597,I-CHEMICAL
crystals,2597,O
stimulate,2597,O
monocytes,2597,O
and,2597,O
macrophages,2597,O
to,2597,O
release,2597,O
IL-1beta,2597,B-GENE-Y
through,2597,O
the,2597,O
NALP3,2597,B-GENE-Y
component,2597,O
of,2597,O
the,2597,O
inflammasome,2597,O
.,2597,O
The,2598,O
effectiveness,2598,O
of,2598,O
IL-1,2598,B-GENE-N
inhibition,2598,O
in,2598,O
hereditary,2598,O
autoinflammatory,2598,O
syndromes,2598,O
with,2598,O
mutations,2598,O
in,2598,O
the,2598,O
NALP3,2598,B-GENE-Y
protein,2598,O
suggested,2598,O
that,2598,O
IL-1,2598,B-GENE-N
inhibition,2598,O
might,2598,O
also,2598,O
be,2598,O
effective,2598,O
in,2598,O
relieving,2598,O
the,2598,O
inflammatory,2598,O
manifestations,2598,O
of,2598,O
acute,2598,O
gout,2598,O
.,2598,O
The,2599,O
effectiveness,2599,O
of,2599,O
IL-1,2599,B-GENE-N
inhibition,2599,O
was,2599,O
first,2599,O
evaluated,2599,O
in,2599,O
a,2599,O
mouse,2599,O
model,2599,O
of,2599,O
monosodium,2599,B-CHEMICAL
urate,2599,I-CHEMICAL
crystal-induced,2599,O
inflammation,2599,O
.,2599,O
IL-1,2600,B-GENE-N
inhibition,2600,O
prevented,2600,O
peritoneal,2600,O
neutrophil,2600,O
accumulation,2600,O
but,2600,O
TNF,2600,B-GENE-Y
blockade,2600,O
had,2600,O
no,2600,O
effect,2600,O
.,2600,O
Based,2601,O
on,2601,O
these,2601,O
findings,2601,O
",",2601,O
we,2601,O
performed,2601,O
a,2601,O
pilot,2601,O
",",2601,O
open-labeled,2601,O
study,2601,O
(,2601,O
trial,2601,O
registration,2601,O
number,2601,O
ISRCTN10862635,2601,O
),2601,O
in,2601,O
10,2601,O
patients,2601,O
with,2601,O
gout,2601,O
who,2601,O
could,2601,O
not,2601,O
tolerate,2601,O
or,2601,O
had,2601,O
failed,2601,O
standard,2601,O
antiinflammatory,2601,O
therapies,2601,O
.,2601,O
All,2602,O
patients,2602,O
received,2602,O
100,2602,O
mg,2602,O
anakinra,2602,O
daily,2602,O
for,2602,O
3,2602,O
days,2602,O
.,2602,O
All,2603,O
10,2603,O
patients,2603,O
with,2603,O
acute,2603,O
gout,2603,O
responded,2603,O
rapidly,2603,O
to,2603,O
anakinra,2603,O
.,2603,O
No,2604,O
adverse,2604,O
effects,2604,O
were,2604,O
observed,2604,O
.,2604,O
IL-1,2605,B-GENE-N
blockade,2605,O
appears,2605,O
to,2605,O
be,2605,O
an,2605,O
effective,2605,O
therapy,2605,O
for,2605,O
acute,2605,O
gouty,2605,O
arthritis,2605,O
.,2605,O
The,2606,O
clinical,2606,O
findings,2606,O
need,2606,O
to,2606,O
be,2606,O
confirmed,2606,O
in,2606,O
a,2606,O
controlled,2606,O
study,2606,O
.,2606,O
Structural,2607,O
basis,2607,O
of,2607,O
inhibition,2607,O
of,2607,O
the,2607,O
human,2607,B-GENE-Y
NAD+-dependent,2607,B-CHEMICAL
deacetylase,2607,I-GENE-Y
SIRT5,2607,I-GENE-Y
by,2607,O
suramin,2607,B-CHEMICAL
.,2607,O
Sirtuins,2608,O
are,2608,O
NAD,2608,B-CHEMICAL
(,2608,I-CHEMICAL
+,2608,I-CHEMICAL
),2608,I-CHEMICAL
-dependent,2608,O
protein,2608,O
deacetylases,2608,O
and,2608,O
are,2608,O
emerging,2608,O
as,2608,O
molecular,2608,O
targets,2608,O
for,2608,O
the,2608,O
development,2608,O
of,2608,O
pharmaceuticals,2608,O
to,2608,O
treat,2608,O
human,2608,O
metabolic,2608,O
and,2608,O
neurological,2608,O
diseases,2608,O
and,2608,O
cancer,2608,O
.,2608,O
To,2609,O
date,2609,O
",",2609,O
several,2609,O
sirtuin,2609,B-GENE-N
inhibitors,2609,O
and,2609,O
activators,2609,O
have,2609,O
been,2609,O
identified,2609,O
",",2609,O
but,2609,O
the,2609,O
structural,2609,O
mechanisms,2609,O
of,2609,O
how,2609,O
these,2609,O
compounds,2609,O
modulate,2609,O
sirtuin,2609,B-GENE-N
activity,2609,O
have,2609,O
not,2609,O
yet,2609,O
been,2609,O
determined,2609,O
.,2609,O
We,2610,O
identified,2610,O
suramin,2610,B-CHEMICAL
as,2610,O
a,2610,O
compound,2610,O
that,2610,O
binds,2610,O
to,2610,O
human,2610,B-GENE-Y
SIRT5,2610,I-GENE-Y
and,2610,O
showed,2610,O
that,2610,O
it,2610,O
inhibits,2610,O
SIRT5,2610,B-GENE-Y
NAD,2610,B-CHEMICAL
(,2610,I-CHEMICAL
+,2610,I-CHEMICAL
),2610,I-CHEMICAL
-dependent,2610,I-GENE-Y
deacetylase,2610,I-GENE-Y
activity,2610,O
with,2610,O
an,2610,O
IC,2610,O
(,2610,O
50,2610,O
),2610,O
value,2610,O
of,2610,O
22,2610,O
microM,2610,O
.,2610,O
To,2611,O
provide,2611,O
insights,2611,O
into,2611,O
how,2611,O
sirtuin,2611,O
function,2611,O
is,2611,O
altered,2611,O
by,2611,O
inhibitors,2611,O
",",2611,O
we,2611,O
determined,2611,O
two,2611,O
crystal,2611,O
structures,2611,O
of,2611,O
SIRT5,2611,B-GENE-Y
",",2611,O
one,2611,O
in,2611,O
complex,2611,O
with,2611,O
ADP-ribose,2611,B-CHEMICAL
",",2611,O
the,2611,O
other,2611,O
bound,2611,O
to,2611,O
suramin,2611,B-CHEMICAL
.,2611,O
Our,2612,O
structural,2612,O
studies,2612,O
provide,2612,O
a,2612,O
view,2612,O
of,2612,O
a,2612,O
synthetic,2612,O
inhibitory,2612,O
compound,2612,O
in,2612,O
a,2612,O
sirtuin,2612,B-GENE-N
active,2612,O
site,2612,O
revealing,2612,O
that,2612,O
suramin,2612,B-CHEMICAL
binds,2612,O
into,2612,O
the,2612,O
NAD,2612,B-CHEMICAL
(,2612,I-CHEMICAL
+,2612,I-CHEMICAL
),2612,I-CHEMICAL
",",2612,O
the,2612,O
product,2612,O
",",2612,O
and,2612,O
the,2612,O
substrate-binding,2612,O
site,2612,O
.,2612,O
Finally,2613,O
",",2613,O
our,2613,O
structures,2613,O
may,2613,O
enable,2613,O
the,2613,O
rational,2613,O
design,2613,O
of,2613,O
more,2613,O
potent,2613,O
inhibitors,2613,O
.,2613,O
Metabolic,2614,O
derangement,2614,O
of,2614,O
methionine,2614,B-CHEMICAL
and,2614,O
folate,2614,B-CHEMICAL
metabolism,2614,O
in,2614,O
mice,2614,O
deficient,2614,O
in,2614,O
methionine,2614,B-GENE-Y
synthase,2614,I-GENE-Y
reductase,2614,I-GENE-Y
.,2614,O
Hyperhomocyst,2615,O
(,2615,O
e,2615,O
),2615,O
inemia,2615,O
is,2615,O
a,2615,O
metabolic,2615,O
derangement,2615,O
that,2615,O
is,2615,O
linked,2615,O
to,2615,O
the,2615,O
distribution,2615,O
of,2615,O
folate,2615,B-CHEMICAL
pools,2615,O
",",2615,O
which,2615,O
provide,2615,O
one-carbon,2615,O
units,2615,O
for,2615,O
biosynthesis,2615,O
of,2615,O
purines,2615,B-CHEMICAL
and,2615,O
thymidylate,2615,B-CHEMICAL
and,2615,O
for,2615,O
remethylation,2615,O
of,2615,O
homocysteine,2615,B-CHEMICAL
to,2615,O
form,2615,O
methionine,2615,B-CHEMICAL
.,2615,O
In,2616,O
humans,2616,O
",",2616,O
methionine,2616,B-GENE-Y
synthase,2616,I-GENE-Y
deficiency,2616,O
results,2616,O
in,2616,O
the,2616,O
accumulation,2616,O
of,2616,O
methyltetrahydrofolate,2616,B-CHEMICAL
at,2616,O
the,2616,O
expense,2616,O
of,2616,O
folate,2616,B-CHEMICAL
derivatives,2616,O
required,2616,O
for,2616,O
purine,2616,B-CHEMICAL
and,2616,O
thymidylate,2616,B-CHEMICAL
biosynthesis,2616,O
.,2616,O
Complete,2617,O
ablation,2617,O
of,2617,O
methionine,2617,B-GENE-Y
synthase,2617,I-GENE-Y
activity,2617,O
in,2617,O
mice,2617,O
results,2617,O
in,2617,O
embryonic,2617,O
lethality,2617,O
.,2617,O
Other,2618,O
mouse,2618,O
models,2618,O
for,2618,O
hyperhomocyst,2618,O
(,2618,O
e,2618,O
),2618,O
inemia,2618,O
have,2618,O
normal,2618,O
or,2618,O
reduced,2618,O
levels,2618,O
of,2618,O
methyltetrahydrofolate,2618,B-CHEMICAL
and,2618,O
are,2618,O
not,2618,O
embryonic,2618,O
lethal,2618,O
",",2618,O
although,2618,O
they,2618,O
have,2618,O
decreased,2618,O
ratios,2618,O
of,2618,O
AdoMet/AdoHcy,2618,B-CHEMICAL
and,2618,O
impaired,2618,O
methylation,2618,O
.,2618,O
We,2619,O
have,2619,O
constructed,2619,O
a,2619,O
mouse,2619,O
model,2619,O
with,2619,O
a,2619,O
gene,2619,O
trap,2619,O
insertion,2619,O
in,2619,O
the,2619,O
Mtrr,2619,B-GENE-Y
gene,2619,O
specifying,2619,O
methionine,2619,B-GENE-Y
synthase,2619,I-GENE-Y
reductase,2619,I-GENE-Y
",",2619,O
an,2619,O
enzyme,2619,O
essential,2619,O
for,2619,O
the,2619,O
activity,2619,O
of,2619,O
methionine,2619,B-GENE-Y
synthase,2619,I-GENE-Y
.,2619,O
This,2620,O
model,2620,O
is,2620,O
a,2620,O
hypomorph,2620,O
",",2620,O
with,2620,O
reduced,2620,O
methionine,2620,B-GENE-Y
synthase,2620,I-GENE-Y
reductase,2620,I-GENE-Y
activity,2620,O
",",2620,O
thus,2620,O
avoiding,2620,O
the,2620,O
lethality,2620,O
associated,2620,O
with,2620,O
the,2620,O
absence,2620,O
of,2620,O
methionine,2620,B-GENE-Y
synthase,2620,I-GENE-Y
activity,2620,O
.,2620,O
Mtrr,2621,B-GENE-Y
(,2621,O
gt/gt,2621,O
),2621,O
mice,2621,O
have,2621,O
increased,2621,O
plasma,2621,O
homocyst,2621,B-CHEMICAL
(,2621,I-CHEMICAL
e,2621,I-CHEMICAL
),2621,I-CHEMICAL
ine,2621,I-CHEMICAL
",",2621,O
decreased,2621,O
plasma,2621,O
methionine,2621,B-CHEMICAL
",",2621,O
and,2621,O
increased,2621,O
tissue,2621,O
methyltetrahydrofolate,2621,B-CHEMICAL
.,2621,O
Unexpectedly,2622,O
",",2622,O
Mtrr,2622,B-GENE-Y
(,2622,O
gt/gt,2622,O
),2622,O
mice,2622,O
do,2622,O
not,2622,O
show,2622,O
decreases,2622,O
in,2622,O
the,2622,O
AdoMet/AdoHcy,2622,B-CHEMICAL
ratio,2622,O
in,2622,O
most,2622,O
tissues,2622,O
.,2622,O
The,2623,O
different,2623,O
metabolite,2623,O
profiles,2623,O
in,2623,O
the,2623,O
various,2623,O
genetic,2623,O
mouse,2623,O
models,2623,O
for,2623,O
hyperhomocyst,2623,O
(,2623,O
e,2623,O
),2623,O
inemia,2623,O
may,2623,O
be,2623,O
useful,2623,O
in,2623,O
understanding,2623,O
biological,2623,O
effects,2623,O
of,2623,O
elevated,2623,O
homocyst,2623,B-CHEMICAL
(,2623,I-CHEMICAL
e,2623,I-CHEMICAL
),2623,I-CHEMICAL
ine,2623,I-CHEMICAL
.,2623,O
Metformin,2624,B-CHEMICAL
and,2624,O
phenformin,2624,B-CHEMICAL
activate,2624,O
AMP-activated,2624,B-GENE-N
protein,2624,I-GENE-N
kinase,2624,I-GENE-N
in,2624,O
the,2624,O
heart,2624,O
by,2624,O
increasing,2624,O
cytosolic,2624,O
AMP,2624,B-CHEMICAL
concentration,2624,O
.,2624,O
AMP-activated,2625,B-GENE-N
protein,2625,I-GENE-N
kinase,2625,I-GENE-N
(,2625,O
AMPK,2625,B-GENE-N
),2625,O
acts,2625,O
as,2625,O
a,2625,O
cellular,2625,O
energy,2625,O
sensor,2625,O
:,2625,O
it,2625,O
responds,2625,O
to,2625,O
an,2625,O
increase,2625,O
in,2625,O
AMP,2625,B-CHEMICAL
concentration,2625,O
(,2625,O
[,2625,O
AMP,2625,B-CHEMICAL
],2625,O
),2625,O
or,2625,O
the,2625,O
AMP-to-ATP,2625,B-CHEMICAL
ratio,2625,O
(,2625,O
AMP/ATP,2625,B-CHEMICAL
),2625,O
.,2625,O
Metformin,2626,B-CHEMICAL
and,2626,O
phenformin,2626,B-CHEMICAL
",",2626,O
which,2626,O
are,2626,O
biguanides,2626,B-CHEMICAL
",",2626,O
have,2626,O
been,2626,O
reported,2626,O
to,2626,O
increase,2626,O
AMPK,2626,B-GENE-N
activity,2626,O
without,2626,O
increasing,2626,O
AMP/ATP,2626,B-CHEMICAL
.,2626,O
This,2627,O
study,2627,O
tests,2627,O
the,2627,O
hypothesis,2627,O
that,2627,O
these,2627,O
biguanides,2627,B-CHEMICAL
increase,2627,O
AMPK,2627,B-GENE-N
activity,2627,O
in,2627,O
the,2627,O
heart,2627,O
by,2627,O
increasing,2627,O
cytosolic,2627,O
[,2627,O
AMP,2627,B-CHEMICAL
],2627,O
.,2627,O
Groups,2628,O
of,2628,O
isolated,2628,O
rat,2628,O
hearts,2628,O
(,2628,O
n,2628,O
=,2628,O
5-7,2628,O
each,2628,O
),2628,O
were,2628,O
perfused,2628,O
with,2628,O
Krebs-Henseleit,2628,O
buffer,2628,O
with,2628,O
or,2628,O
without,2628,O
0.2,2628,O
mM,2628,O
phenformin,2628,B-CHEMICAL
or,2628,O
10,2628,O
mM,2628,O
metformin,2628,B-CHEMICAL
",",2628,O
and,2628,O
(,2628,B-CHEMICAL
31,2628,I-CHEMICAL
),2628,I-CHEMICAL
P-NMR-measured,2628,O
phosphocreatine,2628,B-CHEMICAL
",",2628,O
ATP,2628,B-CHEMICAL
",",2628,O
and,2628,O
intracellular,2628,O
pH,2628,O
were,2628,O
used,2628,O
to,2628,O
calculate,2628,O
cytosolic,2628,O
[,2628,O
AMP,2628,B-CHEMICAL
],2628,O
.,2628,O
At,2629,O
various,2629,O
times,2629,O
",",2629,O
hearts,2629,O
were,2629,O
freeze-clamped,2629,O
and,2629,O
assayed,2629,O
for,2629,O
AMPK,2629,B-GENE-N
activity,2629,O
",",2629,O
phosphorylation,2629,O
of,2629,O
Thr,2629,O
(,2629,O
172,2629,O
),2629,O
on,2629,O
AMPK-alpha,2629,B-GENE-N
",",2629,O
and,2629,O
phosphorylation,2629,O
of,2629,O
Ser,2629,O
(,2629,O
79,2629,O
),2629,O
on,2629,O
acetyl-CoA,2629,B-GENE-N
carboxylase,2629,I-GENE-N
",",2629,O
an,2629,O
AMPK,2629,B-GENE-N
target,2629,O
.,2629,O
In,2630,O
hearts,2630,O
treated,2630,O
with,2630,O
phenformin,2630,B-CHEMICAL
for,2630,O
18,2630,O
min,2630,O
and,2630,O
then,2630,O
perfused,2630,O
for,2630,O
20,2630,O
min,2630,O
with,2630,O
Krebs-Henseleit,2630,O
buffer,2630,O
",",2630,O
[,2630,O
AMP,2630,B-CHEMICAL
],2630,O
began,2630,O
to,2630,O
increase,2630,O
at,2630,O
26,2630,O
min,2630,O
and,2630,O
AMPK,2630,B-GENE-N
activity,2630,O
was,2630,O
elevated,2630,O
at,2630,O
36,2630,O
min,2630,O
.,2630,O
In,2631,O
hearts,2631,O
treated,2631,O
with,2631,O
metformin,2631,B-CHEMICAL
",",2631,O
[,2631,O
AMP,2631,B-CHEMICAL
],2631,O
was,2631,O
increased,2631,O
at,2631,O
50,2631,O
min,2631,O
and,2631,O
AMPK,2631,B-GENE-N
activity,2631,O
",",2631,O
phosphorylated,2631,O
AMPK,2631,B-GENE-N
",",2631,O
and,2631,O
phosphorylated,2631,B-GENE-N
acetyl-CoA,2631,B-CHEMICAL
carboxylase,2631,I-GENE-N
were,2631,O
elevated,2631,O
at,2631,O
61,2631,O
min,2631,O
.,2631,O
In,2632,O
metformin-treated,2632,B-CHEMICAL
hearts,2632,O
",",2632,O
HPLC-measured,2632,O
total,2632,O
AMP,2632,B-CHEMICAL
content,2632,O
and,2632,O
total,2632,O
AMP/ATP,2632,B-CHEMICAL
did,2632,O
not,2632,O
increase,2632,O
.,2632,O
In,2633,O
summary,2633,O
",",2633,O
phenformin,2633,B-CHEMICAL
and,2633,O
metformin,2633,B-CHEMICAL
increase,2633,O
AMPK,2633,B-GENE-N
activity,2633,O
and,2633,O
phosphorylation,2633,O
in,2633,O
the,2633,O
isolated,2633,O
heart,2633,O
.,2633,O
The,2634,O
increase,2634,O
in,2634,O
AMPK,2634,B-GENE-N
activity,2634,O
was,2634,O
always,2634,O
preceded,2634,O
by,2634,O
and,2634,O
correlated,2634,O
with,2634,O
increased,2634,O
cytosolic,2634,O
[,2634,O
AMP,2634,B-CHEMICAL
],2634,O
.,2634,O
Total,2635,O
AMP,2635,B-CHEMICAL
content,2635,O
and,2635,O
total,2635,O
AMP/ATP,2635,B-CHEMICAL
did,2635,O
not,2635,O
change,2635,O
.,2635,O
Cytosolic,2636,O
[,2636,O
AMP,2636,B-CHEMICAL
],2636,O
reported,2636,O
metabolically,2636,O
active,2636,O
AMP,2636,B-CHEMICAL
",",2636,O
which,2636,O
triggered,2636,O
increased,2636,O
AMPK,2636,B-GENE-N
activity,2636,O
",",2636,O
but,2636,O
measures,2636,O
of,2636,O
total,2636,O
AMP,2636,B-CHEMICAL
did,2636,O
not,2636,O
.,2636,O
The,2637,O
role,2637,O
of,2637,O
glutathione,2637,B-CHEMICAL
transferases,2637,I-GENE-N
M1,2637,I-GENE-N
and,2637,I-GENE-N
T1,2637,I-GENE-N
in,2637,O
individual,2637,O
susceptibility,2637,O
to,2637,O
bladder,2637,O
cancer,2637,O
in,2637,O
a,2637,O
Tunisian,2637,O
population,2637,O
.,2637,O
BACKGROUND,2638,O
:,2638,O
Susceptibility,2638,O
to,2638,O
bladder,2638,O
cancer,2638,O
is,2638,O
thought,2638,O
to,2638,O
depend,2638,O
on,2638,O
interplay,2638,O
between,2638,O
genetic,2638,O
factors,2638,O
and,2638,O
environmental,2638,O
chemical,2638,O
carcinogens,2638,O
.,2638,O
AIM,2639,O
:,2639,O
This,2639,O
study,2639,O
seeks,2639,O
to,2639,O
determine,2639,O
the,2639,O
role,2639,O
of,2639,O
the,2639,O
glutathione,2639,B-GENE-N
transferases,2639,I-GENE-N
M1,2639,I-GENE-N
and,2639,I-GENE-N
T1,2639,I-GENE-N
null,2639,O
genotypes,2639,O
(,2639,O
GSTM1,2639,B-GENE-Y
*,2639,O
0,2639,O
and,2639,O
GSTT1,2639,B-GENE-Y
*,2639,O
0,2639,O
),2639,O
in,2639,O
individual,2639,O
susceptibility,2639,O
to,2639,O
bladder,2639,O
cancer,2639,O
in,2639,O
a,2639,O
Tunisian,2639,O
population,2639,O
.,2639,O
METHOD,2640,O
:,2640,O
Sixty-two,2640,O
patients,2640,O
with,2640,O
transitional,2640,O
cell,2640,O
carcinoma,2640,O
of,2640,O
the,2640,O
bladder,2640,O
cancer,2640,O
and,2640,O
79,2640,O
controls,2640,O
were,2640,O
examined,2640,O
with,2640,O
respect,2640,O
to,2640,O
the,2640,O
frequency,2640,O
of,2640,O
GSTM1,2640,B-GENE-Y
and,2640,O
GSTT1,2640,B-GENE-Y
null,2640,O
genotypes,2640,O
.,2640,O
RESULTS,2641,O
:,2641,O
The,2641,O
frequencies,2641,O
of,2641,O
the,2641,O
GSTT1,2641,B-GENE-Y
null,2641,O
in,2641,O
the,2641,O
total,2641,O
group,2641,O
of,2641,O
bladder,2641,O
cancer,2641,O
cases,2641,O
vs.,2641,O
controls,2641,O
did,2641,O
not,2641,O
differ,2641,O
statistically,2641,O
.,2641,O
The,2642,O
proportion,2642,O
of,2642,O
GSTM1,2642,B-GENE-Y
null,2642,O
genotype,2642,O
in,2642,O
patients,2642,O
was,2642,O
63,2642,O
%,2642,O
compared,2642,O
to,2642,O
45,2642,O
%,2642,O
in,2642,O
controls,2642,O
group,2642,O
(,2642,O
OR,2642,O
=,2642,O
2.03,2642,O
;,2642,O
95,2642,O
%,2642,O
CI,2642,O
0.97-4.24,2642,O
;,2642,O
p,2642,O
=,2642,O
0.04,2642,O
),2642,O
.,2642,O
A,2643,O
significantly,2643,O
higher,2643,O
incidence,2643,O
of,2643,O
GSTM1,2643,B-GENE-Y
deletion,2643,O
genotype,2643,O
was,2643,O
found,2643,O
in,2643,O
smokers,2643,O
with,2643,O
bladder,2643,O
cancer,2643,O
compared,2643,O
to,2643,O
the,2643,O
controls,2643,O
(,2643,O
65.38,2643,O
%,2643,O
vs.,2643,O
45.5,2643,O
%,2643,O
),2643,O
.,2643,O
Smokers,2644,O
lacking,2644,O
the,2644,O
GSTM1,2644,B-GENE-Y
gene,2644,O
are,2644,O
at,2644,O
an,2644,O
approximately,2644,O
2.2-fold,2644,O
higher,2644,O
risk,2644,O
of,2644,O
bladder,2644,O
cancer,2644,O
(,2644,O
OR=,2644,O
2.23,2644,O
",",2644,O
95,2644,O
%,2644,O
CI,2644,O
1-5.15,2644,O
;,2644,O
p,2644,O
=,2644,O
0.03,2644,O
),2644,O
.,2644,O
CONCLUSION,2645,O
:,2645,O
This,2645,O
study,2645,O
suggests,2645,O
that,2645,O
in,2645,O
Tunisian,2645,O
subjects,2645,O
the,2645,O
GSTM1,2645,B-GENE-Y
null,2645,O
genotype,2645,O
may,2645,O
be,2645,O
associated,2645,O
with,2645,O
an,2645,O
increased,2645,O
risk,2645,O
of,2645,O
bladder,2645,O
cancer,2645,O
.,2645,O
This,2646,O
association,2646,O
appears,2646,O
to,2646,O
depend,2646,O
upon,2646,O
smoking,2646,O
status,2646,O
.,2646,O
Characterization,2647,O
of,2647,O
5-hydroxytryptamine1B,2647,B-GENE-Y
receptors,2647,O
in,2647,O
rat,2647,O
spinal,2647,O
cord,2647,O
via,2647,O
[,2647,B-CHEMICAL
125I,2647,I-CHEMICAL
],2647,I-CHEMICAL
iodocyanopindolol,2647,I-CHEMICAL
binding,2647,O
and,2647,O
inhibition,2647,O
of,2647,O
[,2647,B-CHEMICAL
3H,2647,I-CHEMICAL
],2647,I-CHEMICAL
-5-hydroxytryptamine,2647,I-CHEMICAL
release,2647,O
.,2647,O
The,2648,O
aim,2648,O
of,2648,O
the,2648,O
present,2648,O
study,2648,O
in,2648,O
rat,2648,O
spinal,2648,O
cord,2648,O
synaptosomes,2648,O
was,2648,O
to,2648,O
compare,2648,O
the,2648,O
pharmacological,2648,O
characteristics,2648,O
of,2648,O
the,2648,O
serotonin,2648,B-GENE-Y
(,2648,I-GENE-Y
5-HT,2648,I-GENE-Y
),2648,I-GENE-Y
1B,2648,I-GENE-Y
receptor,2648,I-GENE-Y
defined,2648,O
by,2648,O
[,2648,B-CHEMICAL
125I,2648,I-CHEMICAL
],2648,I-CHEMICAL
iodocyanopindolol,2648,I-CHEMICAL
[,2648,B-CHEMICAL
(,2648,I-CHEMICAL
125I,2648,I-CHEMICAL
],2648,I-CHEMICAL
ICYP,2648,I-CHEMICAL
),2648,I-CHEMICAL
binding,2648,O
and,2648,O
the,2648,O
5-HT,2648,B-GENE-Y
autoreceptor,2648,I-GENE-Y
defined,2648,O
by,2648,O
inhibition,2648,O
of,2648,O
[,2648,B-CHEMICAL
3H,2648,I-CHEMICAL
],2648,I-CHEMICAL
-5-HT,2648,I-CHEMICAL
release,2648,O
.,2648,O
In,2649,O
Percoll,2649,O
gradient,2649,O
Fractions,2649,O
3,2649,O
and,2649,O
4,2649,O
of,2649,O
spinal,2649,O
cord,2649,O
synaptosomes,2649,O
",",2649,O
a,2649,O
single,2649,O
saturable,2649,O
binding,2649,O
site,2649,O
for,2649,O
[,2649,B-CHEMICAL
125I,2649,I-CHEMICAL
],2649,I-CHEMICAL
ICYP,2649,I-CHEMICAL
with,2649,O
a,2649,O
maximum,2649,O
binding,2649,O
of,2649,O
70,2649,O
and,2649,O
134,2649,O
fmol/mg,2649,O
",",2649,O
respectively,2649,O
",",2649,O
was,2649,O
demonstrated,2649,O
in,2649,O
the,2649,O
presence,2649,O
of,2649,O
30,2649,O
microM,2649,O
isoproterenol,2649,B-CHEMICAL
.,2649,O
The,2650,O
Kd,2650,O
of,2650,O
0.16,2650,O
nM,2650,O
did,2650,O
not,2650,O
vary,2650,O
between,2650,O
fractions,2650,O
.,2650,O
Competition,2651,O
for,2651,O
[,2651,B-CHEMICAL
125I,2651,I-CHEMICAL
],2651,I-CHEMICAL
ICYP,2651,I-CHEMICAL
binding,2651,O
by,2651,O
various,2651,O
5-HT,2651,B-CHEMICAL
agonists,2651,O
and,2651,O
antagonists,2651,O
also,2651,O
indicated,2651,O
a,2651,O
single,2651,O
site,2651,O
model,2651,O
based,2651,O
on,2651,O
a,2651,O
Hill,2651,O
coefficient,2651,O
of,2651,O
approximately,2651,O
1.0,2651,O
.,2651,O
The,2652,O
most,2652,O
potent,2652,O
compounds,2652,O
at,2652,O
displacing,2652,O
[,2652,B-CHEMICAL
125I,2652,I-CHEMICAL
],2652,I-CHEMICAL
ICYP,2652,I-CHEMICAL
binding,2652,O
were,2652,O
RU,2652,B-CHEMICAL
24969,2652,I-CHEMICAL
(,2652,O
5-methoxy-3-,2652,B-CHEMICAL
[,2652,I-CHEMICAL
"1,2,3,6-tetrahydropyridin-4-yl",2652,I-CHEMICAL
],2652,I-CHEMICAL
-1H-indole,2652,I-CHEMICAL
),2652,O
",",2652,O
5-carboxyamidotryptamine,2652,B-CHEMICAL
HCl,2652,I-CHEMICAL
",",2652,O
5-methoxytryptamine,2652,B-CHEMICAL
",",2652,O
5-HT,2652,B-CHEMICAL
and,2652,O
CGS,2652,B-CHEMICAL
12066B,2652,I-CHEMICAL
(,2652,O
7-trifluoromethyl-4,2652,B-CHEMICAL
(,2652,I-CHEMICAL
4,2652,I-CHEMICAL
methyl-1-pyrolo,2652,I-CHEMICAL
[,2652,I-CHEMICAL
"1,2-a",2652,I-CHEMICAL
],2652,I-CHEMICAL
-quinoxaline,2652,I-CHEMICAL
malate,2652,I-CHEMICAL
),2652,O
.,2652,O
[,2653,B-CHEMICAL
125I,2653,I-CHEMICAL
],2653,I-CHEMICAL
ICYP,2653,I-CHEMICAL
binding,2653,O
was,2653,O
not,2653,O
altered,2653,O
by,2653,O
compounds,2653,O
with,2653,O
activity,2653,O
at,2653,O
5-HT1A,2653,B-GENE-Y
",",2653,O
5-HT1C,2653,B-GENE-Y
",",2653,O
5-HT2,2653,B-GENE-Y
",",2653,O
5-HT3,2653,B-GENE-Y
or,2653,O
alpha-2,2653,O
receptor,2653,O
sites,2653,O
.,2653,O
Similar,2654,O
to,2654,O
the,2654,O
pharmacological,2654,O
characteristics,2654,O
of,2654,O
the,2654,O
5HT1B,2654,B-GENE-Y
site,2654,O
defined,2654,O
by,2654,O
[,2654,B-CHEMICAL
125I,2654,I-CHEMICAL
],2654,I-CHEMICAL
ICYP,2654,I-CHEMICAL
",",2654,O
compounds,2654,O
most,2654,O
active,2654,O
at,2654,O
inhibiting,2654,O
15,2654,O
mM,2654,O
K,2654,B-CHEMICAL
(,2654,I-CHEMICAL
+,2654,I-CHEMICAL
),2654,I-CHEMICAL
-stimulated,2654,O
release,2654,O
of,2654,O
[,2654,B-CHEMICAL
3H,2654,I-CHEMICAL
],2654,I-CHEMICAL
-5-HT,2654,I-CHEMICAL
were,2654,O
RU24969,2654,B-CHEMICAL
=,2654,O
5-carboxyamidotryptamine,2654,B-CHEMICAL
HCl,2654,B-CHEMICAL
=,2654,O
CGS,2654,B-CHEMICAL
12066B,2654,I-CHEMICAL
greater,2654,O
than,2654,O
5-methoxytryptamine,2654,B-CHEMICAL
greater,2654,O
than,2654,O
5-HT,2654,B-CHEMICAL
.,2654,O
Compounds,2655,O
with,2655,O
activity,2655,O
at,2655,O
5-HT1A,2655,B-GENE-Y
",",2655,O
5-HT1C,2655,B-GENE-Y
",",2655,O
5-HT2,2655,B-GENE-Y
or,2655,O
5-HT3,2655,B-GENE-Y
sites,2655,O
were,2655,O
inactive,2655,O
.,2655,O
A,2656,O
correlation,2656,O
analysis,2656,O
of,2656,O
selective,2656,O
5-HT1B,2656,B-GENE-Y
compounds,2656,O
comparing,2656,O
the,2656,O
pKD,2656,O
for,2656,O
displacement,2656,O
of,2656,O
[,2656,B-CHEMICAL
125I,2656,I-CHEMICAL
],2656,I-CHEMICAL
ICYP,2656,I-CHEMICAL
vs.,2656,O
the,2656,O
IC50,2656,O
for,2656,O
inhibition,2656,O
of,2656,O
[,2656,B-CHEMICAL
3H,2656,I-CHEMICAL
],2656,I-CHEMICAL
-5-HT,2656,I-CHEMICAL
release,2656,O
demonstrated,2656,O
the,2656,O
pharmacological,2656,O
similarity,2656,O
of,2656,O
the,2656,O
presynaptic,2656,O
inhibitory,2656,O
5-HT,2656,B-GENE-Y
autoreceptor,2656,I-GENE-Y
and,2656,O
the,2656,O
5-HT,2656,B-GENE-Y
receptor,2656,I-GENE-Y
site,2656,O
defined,2656,O
by,2656,O
[,2656,B-CHEMICAL
125I,2656,I-CHEMICAL
],2656,I-CHEMICAL
ICYP,2656,I-CHEMICAL
binding,2656,O
in,2656,O
spinal,2656,O
cord,2656,O
synaptosomes,2656,O
(,2656,O
r,2656,O
=,2656,O
0.791,2656,O
",",2656,O
P,2656,O
=,2656,O
.0193,2656,O
),2656,O
.,2656,O
Although,2657,O
[,2657,B-CHEMICAL
125I,2657,I-CHEMICAL
],2657,I-CHEMICAL
ICYP,2657,I-CHEMICAL
binding,2657,O
was,2657,O
unaltered,2657,O
",",2657,O
alpha-2,2657,O
agonists,2657,O
such,2657,O
as,2657,O
clonidine,2657,B-CHEMICAL
",",2657,O
norepinephrine,2657,B-CHEMICAL
and,2657,O
UK,2657,B-CHEMICAL
14304,2657,I-CHEMICAL
[,2657,B-CHEMICAL
5-bromo-6-,2657,I-CHEMICAL
[,2657,I-CHEMICAL
2-imidazolin-2-ylamino,2657,I-CHEMICAL
],2657,I-CHEMICAL
-quinoxaline,2657,I-CHEMICAL
),2657,O
as,2657,O
well,2657,O
as,2657,O
the,2657,O
alpha-2,2657,O
antagonists,2657,O
rauwolscine,2657,B-CHEMICAL
and,2657,O
yohimbine,2657,B-CHEMICAL
also,2657,O
decreased,2657,O
the,2657,O
K,2657,B-CHEMICAL
(,2657,I-CHEMICAL
+,2657,I-CHEMICAL
),2657,I-CHEMICAL
-stimulated,2657,O
release,2657,O
of,2657,O
[,2657,B-CHEMICAL
3H,2657,I-CHEMICAL
],2657,I-CHEMICAL
-5-HT,2657,I-CHEMICAL
and,2657,O
phentolamine,2657,B-CHEMICAL
",",2657,O
an,2657,O
alpha-2,2657,O
antagonist,2657,O
increased,2657,O
release,2657,O
.,2657,O
The,2658,O
action,2658,O
of,2658,O
these,2658,O
alpha-2,2658,O
compounds,2658,O
to,2658,O
alter,2658,O
[,2658,B-CHEMICAL
3H,2658,I-CHEMICAL
],2658,I-CHEMICAL
-5-HT,2658,I-CHEMICAL
release,2658,O
suggests,2658,O
the,2658,O
presence,2658,O
of,2658,O
heteroreceptors,2658,O
localized,2658,O
on,2658,O
5-HT,2658,B-CHEMICAL
terminals,2658,O
in,2658,O
the,2658,O
spinal,2658,O
cord,2658,O
.,2658,O
These,2659,O
results,2659,O
point,2659,O
out,2659,O
that,2659,O
[,2659,B-CHEMICAL
125I,2659,I-CHEMICAL
],2659,I-CHEMICAL
ICYP,2659,I-CHEMICAL
identifies,2659,O
the,2659,O
5-HT1B,2659,B-GENE-Y
receptor,2659,O
",",2659,O
and,2659,O
affinity,2659,O
of,2659,O
compounds,2659,O
for,2659,O
this,2659,O
site,2659,O
predicts,2659,O
action,2659,O
at,2659,O
the,2659,O
5-HT1B,2659,B-GENE-Y
autoreceptor,2659,O
.,2659,O
(,2660,O
ABSTRACT,2660,O
TRUNCATED,2660,O
AT,2660,O
400,2660,O
WORDS,2660,O
),2660,O
Histamine,2661,B-GENE-Y
H1,2661,I-GENE-Y
receptor,2661,I-GENE-Y
involvement,2661,O
in,2661,O
prepulse,2661,O
inhibition,2661,O
and,2661,O
memory,2661,O
function,2661,O
:,2661,O
relevance,2661,O
for,2661,O
the,2661,O
antipsychotic,2661,O
actions,2661,O
of,2661,O
clozapine,2661,B-CHEMICAL
.,2661,O
Histamine,2662,B-GENE-Y
H,2662,I-GENE-Y
(,2662,I-GENE-Y
1,2662,I-GENE-Y
),2662,I-GENE-Y
blockade,2662,O
is,2662,O
one,2662,O
of,2662,O
the,2662,O
more,2662,O
prominent,2662,O
actions,2662,O
of,2662,O
the,2662,O
multi-receptor,2662,O
acting,2662,O
antipsychotic,2662,O
clozapine,2662,B-CHEMICAL
.,2662,O
It,2663,O
is,2663,O
currently,2663,O
not,2663,O
known,2663,O
how,2663,O
much,2663,O
this,2663,O
H,2663,B-GENE-Y
(,2663,I-GENE-Y
1,2663,I-GENE-Y
),2663,I-GENE-Y
antagonism,2663,O
of,2663,O
clozapine,2663,B-CHEMICAL
contributes,2663,O
to,2663,O
the,2663,O
therapeutic,2663,O
or,2663,O
adverse,2663,O
side,2663,O
effects,2663,O
of,2663,O
clozapine,2663,B-CHEMICAL
.,2663,O
The,2664,O
current,2664,O
studies,2664,O
with,2664,O
Sprague-Dawley,2664,O
rats,2664,O
were,2664,O
conducted,2664,O
to,2664,O
determine,2664,O
the,2664,O
participation,2664,O
of,2664,O
histaminergic,2664,B-GENE-Y
H,2664,I-GENE-Y
(,2664,I-GENE-Y
1,2664,I-GENE-Y
),2664,I-GENE-Y
receptor,2664,I-GENE-Y
subtype,2664,O
in,2664,O
sensorimotor,2664,O
plasticity,2664,O
and,2664,O
memory,2664,O
function,2664,O
affected,2664,O
by,2664,O
clozapine,2664,B-CHEMICAL
using,2664,O
tests,2664,O
of,2664,O
prepulse,2664,O
inhibition,2664,O
(,2664,O
PPI,2664,O
),2664,O
and,2664,O
radial-arm,2664,O
maze,2664,O
choice,2664,O
accuracy,2664,O
.,2664,O
The,2665,O
PPI,2665,O
impairment,2665,O
caused,2665,O
by,2665,O
the,2665,O
glutamate,2665,B-CHEMICAL
antagonist,2665,O
dizocilpine,2665,B-CHEMICAL
(,2665,O
MK-801,2665,B-CHEMICAL
),2665,O
was,2665,O
significantly,2665,O
attenuated,2665,O
by,2665,O
clozapine,2665,B-CHEMICAL
.,2665,O
In,2666,O
the,2666,O
current,2666,O
project,2666,O
",",2666,O
we,2666,O
found,2666,O
that,2666,O
the,2666,O
selective,2666,O
H,2666,B-GENE-Y
(,2666,I-GENE-Y
1,2666,I-GENE-Y
),2666,I-GENE-Y
antagonist,2666,O
pyrilamine,2666,B-CHEMICAL
also,2666,O
reversed,2666,O
the,2666,O
dizocilpine-induced,2666,B-CHEMICAL
impairment,2666,O
in,2666,O
PPI,2666,O
of,2666,O
tactile,2666,O
startle,2666,O
with,2666,O
an,2666,O
auditory,2666,O
prepulse,2666,O
.,2666,O
In,2667,O
the,2667,O
radial-arm,2667,O
maze,2667,O
(,2667,O
RAM,2667,O
),2667,O
",",2667,O
pyrilamine,2667,B-CHEMICAL
",",2667,O
like,2667,O
clozapine,2667,B-CHEMICAL
",",2667,O
impaired,2667,O
working,2667,O
memory,2667,O
and,2667,O
caused,2667,O
a,2667,O
significant,2667,O
dose-related,2667,O
slowing,2667,O
of,2667,O
response,2667,O
.,2667,O
Pyrilamine,2668,B-CHEMICAL
",",2668,O
however,2668,O
",",2668,O
decreased,2668,O
the,2668,O
number,2668,O
of,2668,O
reference,2668,O
memory,2668,O
errors,2668,O
.,2668,O
We,2669,O
have,2669,O
previously,2669,O
shown,2669,O
that,2669,O
nicotine,2669,B-CHEMICAL
effectively,2669,O
attenuates,2669,O
the,2669,O
clozapine-induced,2669,B-CHEMICAL
working,2669,O
memory,2669,O
impairment,2669,O
",",2669,O
but,2669,O
in,2669,O
the,2669,O
current,2669,O
study,2669,O
",",2669,O
nicotine,2669,B-CHEMICAL
did,2669,O
not,2669,O
significantly,2669,O
alter,2669,O
the,2669,O
effects,2669,O
of,2669,O
pyrilamine,2669,B-CHEMICAL
on,2669,O
the,2669,O
RAM,2669,O
.,2669,O
In,2670,O
summary,2670,O
",",2670,O
the,2670,O
therapeutic,2670,O
effect,2670,O
of,2670,O
clozapine,2670,B-CHEMICAL
in,2670,O
reversing,2670,O
PPI,2670,O
impairment,2670,O
was,2670,O
mimicked,2670,O
by,2670,O
the,2670,O
H,2670,B-GENE-Y
(,2670,I-GENE-Y
1,2670,I-GENE-Y
),2670,I-GENE-Y
antagonist,2670,O
pyrilamine,2670,B-CHEMICAL
",",2670,O
while,2670,O
pyrilamine,2670,B-CHEMICAL
had,2670,O
a,2670,O
mixed,2670,O
effect,2670,O
on,2670,O
cognition,2670,O
.,2670,O
Pyrilamine,2671,B-CHEMICAL
impaired,2671,O
working,2671,O
memory,2671,O
but,2671,O
improved,2671,O
reference,2671,O
memory,2671,O
in,2671,O
rats,2671,O
.,2671,O
Thus,2672,O
",",2672,O
H,2672,B-GENE-Y
(,2672,I-GENE-Y
1,2672,I-GENE-Y
),2672,I-GENE-Y
antagonism,2672,O
seems,2672,O
to,2672,O
play,2672,O
a,2672,O
role,2672,O
in,2672,O
part,2672,O
of,2672,O
the,2672,O
beneficial,2672,O
actions,2672,O
of,2672,O
antipsychotics,2672,O
",",2672,O
such,2672,O
as,2672,O
clozapine,2672,B-CHEMICAL
.,2672,O
Inhibition,2673,O
of,2673,O
phosphatidylserine,2673,O
biosynthesis,2673,O
in,2673,O
developing,2673,O
rat,2673,O
brain,2673,O
by,2673,O
maternal,2673,O
exposure,2673,O
to,2673,O
ethanol,2673,B-CHEMICAL
.,2673,O
Phosphatidylserine,2674,O
(,2674,O
PtdSer,2674,O
),2674,O
",",2674,O
major,2674,O
acidic,2674,O
phospholipids,2674,O
in,2674,O
neuronal,2674,O
membranes,2674,O
",",2674,O
participate,2674,O
in,2674,O
important,2674,O
cell,2674,O
signaling,2674,O
processes,2674,O
.,2674,O
The,2675,O
PtdSer,2675,O
in,2675,O
brain,2675,O
is,2675,O
highly,2675,O
enriched,2675,O
with,2675,O
docosahexaenoic,2675,B-CHEMICAL
acid,2675,I-CHEMICAL
(,2675,O
DHA,2675,B-CHEMICAL
;,2675,O
22:6n-3,2675,O
),2675,O
",",2675,O
and,2675,O
the,2675,O
DHA,2675,B-CHEMICAL
status,2675,O
or,2675,O
ethanol,2675,B-CHEMICAL
exposure,2675,O
has,2675,O
been,2675,O
shown,2675,O
to,2675,O
influence,2675,O
the,2675,O
PtdSer,2675,O
level,2675,O
.,2675,O
This,2676,O
study,2676,O
shows,2676,O
that,2676,O
ethanol,2676,B-CHEMICAL
exposure,2676,O
during,2676,O
prenatal,2676,O
and,2676,O
developmental,2676,O
period,2676,O
significantly,2676,O
attenuates,2676,O
microsomal,2676,O
PtdSer,2676,O
biosynthetic,2676,O
activities,2676,O
and,2676,O
reduces,2676,O
PtdSer,2676,O
",",2676,O
particularly,2676,O
18:0,2676,O
",",2676,O
22:6-PtdSer,2676,O
",",2676,O
in,2676,O
developing,2676,O
rat,2676,O
brain,2676,O
cortices,2676,O
.,2676,O
Brain,2677,O
microsomes,2677,O
were,2677,O
incubated,2677,O
with,2677,O
deuterium,2677,B-CHEMICAL
labeled,2677,O
exogenous,2677,O
substrates,2677,O
in,2677,O
vitro,2677,O
and,2677,O
the,2677,O
products,2677,O
formed,2677,O
were,2677,O
detected,2677,O
by,2677,O
reversed,2677,O
phase,2677,O
HPLC-electrospray,2677,O
ionization,2677,O
mass,2677,O
spectrometry,2677,O
(,2677,O
ESI-MS,2677,O
),2677,O
.,2677,O
These,2678,O
in,2678,O
vitro,2678,O
bioassays,2678,O
showed,2678,O
that,2678,O
1-stearoyl-2-docosahexaenoyl,2678,B-CHEMICAL
(,2678,O
18:0,2678,O
",",2678,O
22:6,2678,O
),2678,O
species,2678,O
is,2678,O
the,2678,O
best,2678,O
substrate,2678,O
for,2678,O
PtdSer,2678,O
synthesis,2678,O
from,2678,O
both,2678,O
phosphatidylcholine,2678,B-CHEMICAL
(,2678,O
PtdCho,2678,B-CHEMICAL
),2678,O
and,2678,O
phosphatidylethanolamine,2678,B-CHEMICAL
(,2678,O
PtdEtn,2678,B-CHEMICAL
),2678,O
.,2678,O
The,2679,O
PtdSer,2679,O
biosynthetic,2679,O
activity,2679,O
of,2679,O
brain,2679,O
",",2679,O
especially,2679,O
for,2679,O
18:0,2679,O
",",2679,O
22:6-PtdSer,2679,O
production,2679,O
",",2679,O
was,2679,O
hampered,2679,O
significantly,2679,O
by,2679,O
maternal,2679,O
exposure,2679,O
to,2679,O
ethanol,2679,B-CHEMICAL
.,2679,O
PtdSer,2680,O
levels,2680,O
were,2680,O
consistently,2680,O
reduced,2680,O
significantly,2680,O
in,2680,O
brain,2680,O
cortices,2680,O
of,2680,O
the,2680,O
pups,2680,O
from,2680,O
ethanol-exposed,2680,B-CHEMICAL
dams,2680,O
",",2680,O
due,2680,O
mainly,2680,O
to,2680,O
the,2680,O
depletion,2680,O
of,2680,O
18:0,2680,O
",",2680,O
22:6-PtdSer,2680,O
.,2680,O
The,2681,O
mRNA,2681,O
expression,2681,O
of,2681,O
PtdSer,2681,B-GENE-Y
synthase,2681,I-GENE-Y
1,2681,I-GENE-Y
(,2681,O
PSS1,2681,B-GENE-Y
),2681,O
and,2681,O
PtdSer,2681,B-GENE-Y
synthase,2681,I-GENE-Y
2,2681,I-GENE-Y
(,2681,O
PSS2,2681,B-GENE-Y
),2681,O
was,2681,O
not,2681,O
reduced,2681,O
by,2681,O
ethanol,2681,B-CHEMICAL
.,2681,O
Similarly,2682,O
",",2682,O
the,2682,O
PSS1,2682,B-GENE-Y
enzyme,2682,O
level,2682,O
did,2682,O
not,2682,O
change,2682,O
after,2682,O
ethanol,2682,B-CHEMICAL
exposure,2682,O
but,2682,O
PSS2,2682,B-GENE-Y
could,2682,O
not,2682,O
be,2682,O
probed,2682,O
with,2682,O
the,2682,O
antibody,2682,O
available,2682,O
currently,2682,O
.,2682,O
Degradation,2683,O
of,2683,O
PtdSer,2683,O
by,2683,O
mitochondrial,2683,O
PtdSer,2683,O
decarboxylation,2683,O
was,2683,O
not,2683,O
enhanced,2683,O
but,2683,O
also,2683,O
inhibited,2683,O
.,2683,O
Taken,2684,O
together,2684,O
",",2684,O
attenuated,2684,O
PtdSer,2684,O
biosynthetic,2684,O
activities,2684,O
are,2684,O
largely,2684,O
responsible,2684,O
for,2684,O
the,2684,O
PtdSer,2684,O
reduction,2684,O
observed,2684,O
in,2684,O
developing,2684,O
rat,2684,O
brains,2684,O
after,2684,O
maternal,2684,O
exposure,2684,O
to,2684,O
ethanol,2684,B-CHEMICAL
.,2684,O
Regulation,2685,O
of,2685,O
gluconeogenesis,2685,O
by,2685,O
Kruppel-like,2685,B-GENE-Y
factor,2685,I-GENE-Y
15,2685,I-GENE-Y
.,2685,O
In,2686,O
the,2686,O
postabsorptive,2686,O
state,2686,O
",",2686,O
certain,2686,O
tissues,2686,O
",",2686,O
including,2686,O
the,2686,O
brain,2686,O
",",2686,O
require,2686,O
glucose,2686,B-CHEMICAL
as,2686,O
the,2686,O
sole,2686,O
source,2686,O
of,2686,O
energy,2686,O
.,2686,O
After,2687,O
an,2687,O
overnight,2687,O
fast,2687,O
",",2687,O
hepatic,2687,O
glycogen,2687,O
stores,2687,O
are,2687,O
depleted,2687,O
",",2687,O
and,2687,O
gluconeogenesis,2687,O
becomes,2687,O
essential,2687,O
for,2687,O
preventing,2687,O
life-threatening,2687,O
hypoglycemia,2687,O
.,2687,O
Mice,2688,O
with,2688,O
a,2688,O
targeted,2688,O
deletion,2688,O
of,2688,O
KLF15,2688,B-GENE-Y
",",2688,O
a,2688,O
member,2688,O
of,2688,O
the,2688,O
Kruppel-like,2688,B-GENE-N
family,2688,O
of,2688,O
transcription,2688,O
factors,2688,O
",",2688,O
display,2688,O
severe,2688,O
hypoglycemia,2688,O
after,2688,O
an,2688,O
overnight,2688,O
(,2688,O
18,2688,O
hr,2688,O
),2688,O
fast,2688,O
.,2688,O
We,2689,O
provide,2689,O
evidence,2689,O
that,2689,O
defective,2689,O
amino,2689,B-CHEMICAL
acid,2689,I-CHEMICAL
catabolism,2689,O
promotes,2689,O
the,2689,O
development,2689,O
of,2689,O
fasting,2689,O
hypoglycemia,2689,O
in,2689,O
KLF15-/-,2689,B-GENE-Y
mice,2689,O
by,2689,O
limiting,2689,O
gluconeogenic,2689,O
substrate,2689,O
availability,2689,O
.,2689,O
KLF15-/-,2690,B-GENE-Y
liver,2690,O
and,2690,O
skeletal,2690,O
muscle,2690,O
show,2690,O
markedly,2690,O
reduced,2690,O
mRNA,2690,O
expression,2690,O
of,2690,O
amino,2690,B-CHEMICAL
acid-degrading,2690,O
enzymes,2690,O
.,2690,O
Furthermore,2691,O
",",2691,O
the,2691,O
enzymatic,2691,O
activity,2691,O
of,2691,O
alanine,2691,B-CHEMICAL
aminotransferase,2691,I-GENE-N
(,2691,O
ALT,2691,B-GENE-N
),2691,O
",",2691,O
which,2691,O
converts,2691,O
the,2691,O
critical,2691,O
gluconeogenic,2691,O
amino,2691,B-CHEMICAL
acid,2691,I-CHEMICAL
alanine,2691,B-CHEMICAL
into,2691,O
pyruvate,2691,B-CHEMICAL
",",2691,O
is,2691,O
decreased,2691,O
(,2691,O
approximately,2691,O
50,2691,O
%,2691,O
),2691,O
in,2691,O
KLF15-/-,2691,B-GENE-Y
hepatocytes,2691,O
.,2691,O
Consistent,2692,O
with,2692,O
this,2692,O
observation,2692,O
",",2692,O
intraperitoneal,2692,O
injection,2692,O
of,2692,O
pyruvate,2692,B-CHEMICAL
",",2692,O
but,2692,O
not,2692,O
alanine,2692,B-CHEMICAL
",",2692,O
rescues,2692,O
fasting,2692,O
hypoglycemia,2692,O
in,2692,O
KLF15-/-,2692,B-GENE-Y
mice,2692,O
.,2692,O
We,2693,O
conclude,2693,O
that,2693,O
KLF15,2693,B-GENE-Y
plays,2693,O
an,2693,O
important,2693,O
role,2693,O
in,2693,O
the,2693,O
regulation,2693,O
of,2693,O
gluconeogenesis,2693,O
.,2693,O
D-glucose,2694,B-CHEMICAL
stimulation,2694,O
of,2694,O
L-arginine,2694,B-CHEMICAL
transport,2694,O
and,2694,O
nitric,2694,B-CHEMICAL
oxide,2694,I-CHEMICAL
synthesis,2694,O
results,2694,O
from,2694,O
activation,2694,O
of,2694,O
mitogen-activated,2694,B-GENE-N
protein,2694,I-GENE-N
kinases,2694,I-GENE-N
p42/44,2694,I-GENE-N
and,2694,O
Smad2,2694,B-GENE-Y
requiring,2694,O
functional,2694,O
type,2694,B-GENE-Y
II,2694,I-GENE-Y
TGF-beta,2694,I-GENE-Y
receptors,2694,I-GENE-Y
in,2694,O
human,2694,O
umbilical,2694,O
vein,2694,O
endothelium,2694,O
.,2694,O
Elevated,2695,O
extracellular,2695,O
D-glucose,2695,B-CHEMICAL
increases,2695,O
transforming,2695,B-GENE-Y
growth,2695,I-GENE-Y
factor,2695,I-GENE-Y
beta1,2695,I-GENE-Y
(,2695,O
TGF-beta1,2695,B-GENE-Y
),2695,O
release,2695,O
from,2695,O
human,2695,O
umbilical,2695,O
vein,2695,O
endothelium,2695,O
(,2695,O
HUVEC,2695,O
),2695,O
.,2695,O
TGF-beta1,2696,B-GENE-Y
",",2696,O
via,2696,O
TGF-beta,2696,B-GENE-Y
receptors,2696,I-GENE-Y
I,2696,I-GENE-Y
(,2696,O
TbetaRI,2696,B-GENE-Y
),2696,O
and,2696,O
TbetaRII,2696,B-GENE-Y
",",2696,O
activates,2696,O
Smad2,2696,B-GENE-Y
and,2696,O
mitogen-activated,2696,B-GENE-N
protein,2696,I-GENE-N
kinases,2696,I-GENE-N
p44,2696,B-GENE-Y
and,2696,O
p42,2696,B-GENE-Y
(,2696,O
p42/44,2696,B-GENE-N
(,2696,O
mapk,2696,B-GENE-N
),2696,O
),2696,O
.,2696,O
We,2697,O
studied,2697,O
whether,2697,O
D-glucose-stimulation,2697,B-CHEMICAL
of,2697,O
L-arginine,2697,B-CHEMICAL
transport,2697,O
and,2697,O
nitric,2697,B-CHEMICAL
oxide,2697,I-CHEMICAL
synthesis,2697,O
involves,2697,O
TGF-beta1,2697,B-GENE-Y
in,2697,O
primary,2697,O
cultures,2697,O
of,2697,O
HUVEC,2697,O
.,2697,O
TGF-beta1,2698,B-GENE-Y
release,2698,O
was,2698,O
higher,2698,O
(,2698,O
approximately,2698,O
1.6-fold,2698,O
),2698,O
in,2698,O
25,2698,O
mM,2698,O
(,2698,O
high,2698,O
),2698,O
compared,2698,O
with,2698,O
5,2698,O
mM,2698,O
(,2698,O
normal,2698,O
),2698,O
D-glucose,2698,B-CHEMICAL
.,2698,O
TGF-beta1,2699,B-GENE-Y
increases,2699,O
L-arginine,2699,B-CHEMICAL
transport,2699,O
(,2699,O
half,2699,O
maximal,2699,O
effect,2699,O
approximately,2699,O
1.6,2699,O
ng/ml,2699,O
),2699,O
in,2699,O
normal,2699,O
D-glucose,2699,B-CHEMICAL
",",2699,O
but,2699,O
did,2699,O
not,2699,O
alter,2699,O
high,2699,O
D-glucose-increased,2699,B-CHEMICAL
L-arginine,2699,B-CHEMICAL
transport,2699,O
.,2699,O
TGF-beta1,2700,B-GENE-Y
and,2700,O
high,2700,O
D-glucose,2700,B-CHEMICAL
increased,2700,O
hCAT-1,2700,B-GENE-Y
mRNA,2700,O
expression,2700,O
(,2700,O
approximately,2700,O
8-fold,2700,O
),2700,O
and,2700,O
maximal,2700,O
transport,2700,O
velocity,2700,O
(,2700,O
V,2700,O
(,2700,O
max,2700,O
),2700,O
),2700,O
",",2700,O
L-,2700,B-CHEMICAL
[,2700,I-CHEMICAL
(,2700,I-CHEMICAL
3,2700,I-CHEMICAL
),2700,I-CHEMICAL
H,2700,I-CHEMICAL
],2700,I-CHEMICAL
citrulline,2700,I-CHEMICAL
formation,2700,O
from,2700,O
L-,2700,B-CHEMICAL
[,2700,I-CHEMICAL
(,2700,I-CHEMICAL
3,2700,I-CHEMICAL
),2700,I-CHEMICAL
H,2700,I-CHEMICAL
],2700,I-CHEMICAL
arginine,2700,I-CHEMICAL
(,2700,O
index,2700,O
of,2700,O
NO,2700,B-CHEMICAL
synthesis,2700,O
),2700,O
and,2700,O
endothelial,2700,B-GENE-Y
NO,2700,I-GENE-Y
synthase,2700,I-GENE-Y
(,2700,O
eNOS,2700,B-GENE-Y
),2700,O
protein,2700,O
abundance,2700,O
",",2700,O
but,2700,O
did,2700,O
not,2700,O
alter,2700,O
eNOS,2700,B-GENE-Y
phosphorylation,2700,O
.,2700,O
TGF-beta1,2701,B-GENE-Y
and,2701,O
high,2701,O
D-glucose,2701,B-CHEMICAL
increased,2701,O
p42/44,2701,B-GENE-N
(,2701,O
mapk,2701,B-GENE-N
),2701,O
and,2701,O
Smad2,2701,B-GENE-Y
phosphorylation,2701,O
",",2701,O
an,2701,O
effect,2701,O
blocked,2701,O
by,2701,O
PD-98059,2701,B-CHEMICAL
(,2701,O
MEK1/2,2701,B-GENE-N
inhibitor,2701,O
),2701,O
.,2701,O
However,2702,O
",",2702,O
TGF-beta1,2702,B-GENE-Y
and,2702,O
high,2702,O
D-glucose,2702,B-CHEMICAL
were,2702,O
ineffective,2702,O
in,2702,O
cells,2702,O
expressing,2702,O
a,2702,O
truncated,2702,O
",",2702,O
negative,2702,O
dominant,2702,O
TbetaRII,2702,B-GENE-Y
.,2702,O
High,2703,O
D-glucose,2703,B-CHEMICAL
increases,2703,O
L-arginine,2703,B-CHEMICAL
transport,2703,O
and,2703,O
eNOS,2703,B-GENE-Y
expression,2703,O
following,2703,O
TbetaRII,2703,B-GENE-Y
activation,2703,O
by,2703,O
TGF-beta1,2703,B-GENE-Y
involving,2703,O
p42/44,2703,B-GENE-N
(,2703,O
mapk,2703,B-GENE-N
),2703,O
and,2703,O
Smad2,2703,B-GENE-Y
in,2703,O
HUVEC,2703,O
.,2703,O
Thus,2704,O
",",2704,O
TGF-beta1,2704,B-GENE-Y
could,2704,O
play,2704,O
a,2704,O
crucial,2704,O
role,2704,O
under,2704,O
conditions,2704,O
of,2704,O
hyperglycemia,2704,O
",",2704,O
such,2704,O
as,2704,O
gestational,2704,O
diabetes,2704,O
mellitus,2704,O
",",2704,O
which,2704,O
is,2704,O
associated,2704,O
with,2704,O
fetal,2704,O
endothelial,2704,O
dysfunction,2704,O
.,2704,O
n-3,2705,B-CHEMICAL
and,2705,I-CHEMICAL
n-6,2705,I-CHEMICAL
polyunsaturated,2705,I-CHEMICAL
fatty,2705,I-CHEMICAL
acids,2705,I-CHEMICAL
induce,2705,O
the,2705,O
expression,2705,O
of,2705,O
COX-2,2705,B-GENE-Y
via,2705,O
PPARgamma,2705,B-GENE-Y
activation,2705,O
in,2705,O
human,2705,O
keratinocyte,2705,O
HaCaT,2705,O
cells,2705,O
.,2705,O
Polyunsaturated,2706,B-CHEMICAL
fatty,2706,I-CHEMICAL
acids,2706,I-CHEMICAL
(,2706,I-CHEMICAL
PUFA,2706,I-CHEMICAL
),2706,I-CHEMICAL
n-3,2706,I-CHEMICAL
inhibit,2706,O
inflammation,2706,O
",",2706,O
in,2706,O
vivo,2706,O
and,2706,O
in,2706,O
vitro,2706,O
in,2706,O
keratinocytes,2706,O
.,2706,O
We,2707,O
examined,2707,O
in,2707,O
HaCaT,2707,O
keratinocyte,2707,O
cell,2707,O
line,2707,O
whether,2707,O
eicosapentaenoic,2707,B-CHEMICAL
acid,2707,I-CHEMICAL
(,2707,O
EPA,2707,B-CHEMICAL
),2707,O
a,2707,O
n-3,2707,B-CHEMICAL
PUFA,2707,I-CHEMICAL
",",2707,O
gamma-linoleic,2707,B-CHEMICAL
acid,2707,I-CHEMICAL
(,2707,O
GLA,2707,B-CHEMICAL
),2707,O
a,2707,O
n-6,2707,B-CHEMICAL
PUFA,2707,I-CHEMICAL
",",2707,O
and,2707,O
arachidic,2707,B-CHEMICAL
acid,2707,I-CHEMICAL
a,2707,O
saturated,2707,B-CHEMICAL
fatty,2707,I-CHEMICAL
acid,2707,I-CHEMICAL
",",2707,O
modulate,2707,O
expression,2707,O
of,2707,O
cyclooxygenase-2,2707,B-GENE-Y
(,2707,O
COX-2,2707,B-GENE-Y
),2707,O
",",2707,O
an,2707,O
enzyme,2707,O
pivotal,2707,O
to,2707,O
skin,2707,O
inflammation,2707,O
and,2707,O
reparation,2707,O
.,2707,O
We,2708,O
demonstrate,2708,O
that,2708,O
only,2708,O
treatment,2708,O
of,2708,O
HaCaT,2708,O
with,2708,O
GLA,2708,B-CHEMICAL
and,2708,O
EPA,2708,B-CHEMICAL
or,2708,O
a,2708,O
PPARgamma,2708,B-GENE-Y
ligand,2708,O
(,2708,O
roziglitazone,2708,B-CHEMICAL
),2708,O
",",2708,O
induced,2708,O
COX-2,2708,B-GENE-Y
expression,2708,O
(,2708,O
protein,2708,O
and,2708,O
mRNA,2708,O
),2708,O
.,2708,O
Moreover,2709,O
stimulation,2709,O
of,2709,O
COX-2,2709,B-GENE-N
promoter,2709,I-GENE-N
activity,2709,O
was,2709,O
increased,2709,O
by,2709,O
those,2709,O
PUFAs,2709,B-CHEMICAL
or,2709,O
rosiglitazone,2709,B-CHEMICAL
.,2709,O
The,2710,O
inhibitory,2710,O
effects,2710,O
of,2710,O
GW9662,2710,B-CHEMICAL
and,2710,O
T0070907,2710,B-CHEMICAL
(,2710,O
PPARgamma,2710,B-GENE-Y
antagonists,2710,O
),2710,O
",",2710,O
on,2710,O
COX-2,2710,B-GENE-Y
expression,2710,O
and,2710,O
on,2710,O
stimulation,2710,O
of,2710,O
COX-2,2710,B-GENE-N
promoter,2710,I-GENE-N
activity,2710,O
by,2710,O
EPA,2710,B-CHEMICAL
and,2710,O
GLA,2710,B-CHEMICAL
suggest,2710,O
that,2710,O
PPARgamma,2710,B-GENE-Y
is,2710,O
implicated,2710,O
in,2710,O
COX-2,2710,B-GENE-Y
induction,2710,O
.,2710,O
Finally,2711,O
",",2711,O
PLA2,2711,B-GENE-Y
inhibitor,2711,O
methyl,2711,O
arachidonyl,2711,B-CHEMICAL
fluorophosphonate,2711,I-CHEMICAL
blocked,2711,O
the,2711,O
PUFA,2711,B-CHEMICAL
effects,2711,O
on,2711,O
COX-2,2711,B-GENE-Y
induction,2711,O
",",2711,O
promoter,2711,O
activity,2711,O
and,2711,O
arachidonic,2711,B-CHEMICAL
acid,2711,I-CHEMICAL
mobilization,2711,O
suggesting,2711,O
involvement,2711,O
of,2711,O
AA,2711,B-CHEMICAL
metabolites,2711,O
in,2711,O
PPAR,2711,B-GENE-N
activation,2711,O
.,2711,O
These,2712,O
findings,2712,O
demonstrate,2712,O
that,2712,O
n-3,2712,B-CHEMICAL
and,2712,I-CHEMICAL
n-6,2712,I-CHEMICAL
PUFA,2712,I-CHEMICAL
increased,2712,O
PPARgamma,2712,B-GENE-Y
activity,2712,O
is,2712,O
necessary,2712,O
for,2712,O
the,2712,O
COX-2,2712,B-GENE-Y
induction,2712,O
in,2712,O
HaCaT,2712,O
human,2712,O
keratinocyte,2712,O
cells,2712,O
.,2712,O
Given,2713,O
the,2713,O
anti-inflammatory,2713,O
properties,2713,O
of,2713,O
EPA,2713,B-CHEMICAL
",",2713,O
we,2713,O
suggest,2713,O
that,2713,O
induction,2713,O
of,2713,O
COX-2,2713,B-GENE-Y
in,2713,O
keratinocytes,2713,O
may,2713,O
be,2713,O
important,2713,O
in,2713,O
the,2713,O
anti-inflammatory,2713,O
and,2713,O
protective,2713,O
mechanism,2713,O
of,2713,O
action,2713,O
of,2713,O
PUFAs,2713,B-CHEMICAL
n-3,2713,I-CHEMICAL
or,2713,O
n-6,2713,O
.,2713,O
Methylation-mediated,2714,O
silencing,2714,O
of,2714,O
genes,2714,O
is,2714,O
not,2714,O
altered,2714,O
by,2714,O
selenium,2714,B-CHEMICAL
treatment,2714,O
of,2714,O
prostate,2714,O
cancer,2714,O
cells,2714,O
.,2714,O
BACKGROUND,2715,O
:,2715,O
The,2715,O
role,2715,O
of,2715,O
selenium,2715,B-CHEMICAL
in,2715,O
reducing,2715,O
the,2715,O
risk,2715,O
of,2715,O
multiple,2715,O
cancers,2715,O
has,2715,O
been,2715,O
described,2715,O
in,2715,O
the,2715,O
literature,2715,O
.,2715,O
Although,2716,O
reports,2716,O
have,2716,O
described,2716,O
the,2716,O
antiproliferative,2716,O
and,2716,O
pro-apoptotic,2716,O
function,2716,O
of,2716,O
selenium,2716,B-CHEMICAL
by,2716,O
up-regulation,2716,O
of,2716,O
genes,2716,O
in,2716,O
these,2716,O
pathways,2716,O
",",2716,O
information,2716,O
is,2716,O
lacking,2716,O
on,2716,O
the,2716,O
target,2716,O
mechanisms,2716,O
of,2716,O
selenium,2716,B-CHEMICAL
on,2716,O
specific,2716,O
genes,2716,O
.,2716,O
This,2717,O
study,2717,O
examines,2717,O
whether,2717,O
selenium,2717,B-CHEMICAL
treatment,2717,O
alters,2717,O
the,2717,O
methylation,2717,O
status,2717,O
of,2717,O
epigenetically,2717,O
silenced,2717,O
genes,2717,O
in,2717,O
prostate,2717,O
cancer,2717,O
cells,2717,O
.,2717,O
MATERIALS,2718,O
AND,2718,O
METHODS,2718,O
:,2718,O
Methylation,2718,O
of,2718,O
glutathione,2718,B-GENE-Y
sulfotransferase,2718,I-GENE-Y
pi,2718,I-GENE-Y
(,2718,O
GSTP1,2718,B-GENE-Y
),2718,O
and,2718,O
Ras,2718,B-GENE-Y
associated,2718,I-GENE-Y
family,2718,I-GENE-Y
1A,2718,I-GENE-Y
(,2718,O
RASSF1A,2718,B-GENE-Y
),2718,O
genes,2718,O
was,2718,O
studied,2718,O
using,2718,O
methylation,2718,O
sensitive,2718,O
PCR,2718,O
(,2718,O
MS-PCR,2718,O
),2718,O
.,2718,O
Gene,2719,O
expression,2719,O
was,2719,O
studied,2719,O
using,2719,O
Reverse,2719,O
Transcriptase,2719,O
PCR,2719,O
and,2719,O
Western,2719,O
Blotting,2719,O
.,2719,O
RESULTS,2720,O
AND,2720,O
CONCLUSION,2720,O
:,2720,O
Treatment,2720,O
of,2720,O
prostate,2720,O
cancer,2720,O
cells,2720,O
with,2720,O
selenium,2720,B-CHEMICAL
did,2720,O
not,2720,O
alter,2720,O
the,2720,O
expression,2720,O
of,2720,O
genes,2720,O
that,2720,O
were,2720,O
silenced,2720,O
by,2720,O
DNA,2720,O
methylation,2720,O
.,2720,O
Furthermore,2721,O
",",2721,O
the,2721,O
methylation,2721,O
status,2721,O
of,2721,O
these,2721,O
genes,2721,O
remained,2721,O
unaltered,2721,O
after,2721,O
treatment,2721,O
with,2721,O
seleno-DL-methionine,2721,B-CHEMICAL
.,2721,O
Nebulized,2722,O
arformoterol,2722,B-CHEMICAL
in,2722,O
patients,2722,O
with,2722,O
COPD,2722,O
:,2722,O
a,2722,O
12-week,2722,O
",",2722,O
multicenter,2722,O
",",2722,O
randomized,2722,O
",",2722,O
double-blind,2722,O
",",2722,O
double-dummy,2722,O
",",2722,O
placebo-,2722,O
and,2722,O
active-controlled,2722,O
trial,2722,O
.,2722,O
OBJECTIVE,2723,O
:,2723,O
The,2723,O
aim,2723,O
of,2723,O
this,2723,O
study,2723,O
was,2723,O
to,2723,O
assess,2723,O
the,2723,O
efficacy,2723,O
and,2723,O
tolerability,2723,O
of,2723,O
nebulized,2723,O
arformoterol,2723,B-CHEMICAL
tartrate,2723,I-CHEMICAL
(,2723,O
a,2723,O
selective,2723,O
",",2723,O
long-acting,2723,O
beta,2723,B-GENE-Y
(,2723,I-GENE-Y
2,2723,I-GENE-Y
),2723,I-GENE-Y
-adrenergic,2723,I-GENE-Y
agonist,2723,O
that,2723,O
is,2723,O
the,2723,O
[,2723,B-CHEMICAL
R,2723,I-CHEMICAL
",",2723,I-CHEMICAL
R,2723,I-CHEMICAL
],2723,I-CHEMICAL
isomer,2723,I-CHEMICAL
of,2723,I-CHEMICAL
formoterol,2723,I-CHEMICAL
),2723,O
and,2723,O
salmeterol,2723,B-CHEMICAL
xinafoate,2723,I-CHEMICAL
versus,2723,O
placebo,2723,O
in,2723,O
patients,2723,O
with,2723,O
chronic,2723,O
obstructive,2723,O
pulmonary,2723,O
disease,2723,O
(,2723,O
COPD,2723,O
),2723,O
.,2723,O
METHODS,2724,O
:,2724,O
This,2724,O
12-week,2724,O
",",2724,O
multicenter,2724,O
",",2724,O
randomized,2724,O
",",2724,O
double-blind,2724,O
",",2724,O
double-dummy,2724,O
",",2724,O
placebo-,2724,O
and,2724,O
active-controlled,2724,O
trial,2724,O
was,2724,O
conducted,2724,O
at,2724,O
60,2724,O
centers,2724,O
across,2724,O
the,2724,O
United,2724,O
States,2724,O
.,2724,O
Male,2725,O
and,2725,O
female,2725,O
patients,2725,O
aged,2725,O
>,2725,O
or=35,2725,O
years,2725,O
with,2725,O
physician-diagnosed,2725,O
COPD,2725,O
received,2725,O
arformoterol,2725,B-CHEMICAL
(,2725,O
15,2725,O
microg,2725,O
BID,2725,O
",",2725,O
25,2725,O
microg,2725,O
BID,2725,O
",",2725,O
or,2725,O
50,2725,O
microg,2725,O
QD,2725,O
via,2725,O
nebulizer,2725,O
),2725,O
",",2725,O
salmeterol,2725,B-CHEMICAL
(,2725,O
42,2725,O
microg,2725,O
BID,2725,O
via,2725,O
metered,2725,O
dose,2725,O
inhaler,2725,O
),2725,O
",",2725,O
or,2725,O
placebo,2725,O
.,2725,O
Pulmonary,2726,O
function,2726,O
was,2726,O
assessed,2726,O
by,2726,O
spirometry,2726,O
;,2726,O
dyspnea,2726,O
",",2726,O
by,2726,O
the,2726,O
Transitional,2726,O
Dyspnea,2726,O
Index,2726,O
(,2726,O
TDI,2726,O
),2726,O
;,2726,O
and,2726,O
health,2726,O
status,2726,O
",",2726,O
by,2726,O
the,2726,O
St.,2726,O
George,2726,O
's,2726,O
Respiratory,2726,O
Questionnaire,2726,O
(,2726,O
SGRQ,2726,O
),2726,O
.,2726,O
Adverse,2727,O
events,2727,O
(,2727,O
AEs,2727,O
),2727,O
were,2727,O
assessed,2727,O
by,2727,O
site,2727,O
personnel,2727,O
at,2727,O
all,2727,O
clinic,2727,O
visits,2727,O
(,2727,O
screening,2727,O
",",2727,O
first,2727,O
dose,2727,O
at,2727,O
week,2727,O
0,2727,O
",",2727,O
and,2727,O
at,2727,O
weeks,2727,O
3,2727,O
",",2727,O
6,2727,O
",",2727,O
9,2727,O
",",2727,O
12,2727,O
",",2727,O
and,2727,O
follow-up,2727,O
),2727,O
.,2727,O
COPD,2728,O
exacerbations,2728,O
were,2728,O
defined,2728,O
as,2728,O
worsening,2728,O
respiratory,2728,O
status,2728,O
requiring,2728,O
a,2728,O
change,2728,O
in,2728,O
medication,2728,O
or,2728,O
an,2728,O
unscheduled,2728,O
provider,2728,O
visit,2728,O
.,2728,O
RESULTS,2729,O
:,2729,O
A,2729,O
total,2729,O
of,2729,O
717,2729,O
patients,2729,O
received,2729,O
study,2729,O
medication,2729,O
.,2729,O
The,2730,O
demographic,2730,O
composition,2730,O
of,2730,O
all,2730,O
treatment,2730,O
arms,2730,O
was,2730,O
similar,2730,O
.,2730,O
The,2731,O
mean,2731,O
age,2731,O
was,2731,O
62.9,2731,O
years,2731,O
",",2731,O
58,2731,O
%,2731,O
were,2731,O
men,2731,O
",",2731,O
and,2731,O
mean,2731,O
baseline,2731,O
forced,2731,O
expiratory,2731,O
volume,2731,O
in,2731,O
1,2731,O
second,2731,O
(,2731,O
FEV,2731,O
(,2731,O
1,2731,O
),2731,O
),2731,O
was,2731,O
1.2,2731,O
L,2731,O
(,2731,O
41,2731,O
%,2731,O
predicted,2731,O
),2731,O
.,2731,O
Mean,2732,O
improvement,2732,O
in,2732,O
trough,2732,O
FEV,2732,O
(,2732,O
1,2732,O
),2732,O
over,2732,O
12,2732,O
weeks,2732,O
was,2732,O
significantly,2732,O
greater,2732,O
with,2732,O
all,2732,O
3,2732,O
arformoterol,2732,B-CHEMICAL
doses,2732,O
(,2732,O
15,2732,O
microg,2732,O
BID,2732,O
",",2732,O
+16.9,2732,O
%,2732,O
;,2732,O
25,2732,O
microg,2732,O
BID,2732,O
",",2732,O
+18.9,2732,O
%,2732,O
;,2732,O
50,2732,O
microg,2732,O
QD,2732,O
",",2732,O
+14.9,2732,O
%,2732,O
),2732,O
and,2732,O
for,2732,O
salmeterol,2732,B-CHEMICAL
(,2732,O
+17.4,2732,O
%,2732,O
),2732,O
relative,2732,O
to,2732,O
placebo,2732,O
(,2732,O
+6.0,2732,O
%,2732,O
;,2732,O
P,2732,O
<,2732,O
0.001,2732,O
),2732,O
.,2732,O
There,2733,O
were,2733,O
significantly,2733,O
greater,2733,O
improvements,2733,O
in,2733,O
the,2733,O
mean,2733,O
percentage,2733,O
change,2733,O
in,2733,O
FEV,2733,O
(,2733,O
1,2733,O
),2733,O
AUC,2733,O
(,2733,O
0-12h,2733,O
),2733,O
from,2733,O
the,2733,O
predose,2733,O
value,2733,O
over,2733,O
12,2733,O
weeks,2733,O
(,2733,O
15,2733,O
microg,2733,O
BID,2733,O
",",2733,O
12.7,2733,O
%,2733,O
",",2733,O
25,2733,O
microg,2733,O
BID,2733,O
",",2733,O
13.9,2733,O
%,2733,O
",",2733,O
50,2733,O
microg,2733,O
QD,2733,O
",",2733,O
18.9,2733,O
%,2733,O
;,2733,O
salmeterol,2733,B-CHEMICAL
",",2733,O
9.8,2733,O
%,2733,O
),2733,O
versus,2733,O
placebo,2733,O
(,2733,O
2.7,2733,O
%,2733,O
;,2733,O
P,2733,O
<,2733,O
or=,2733,O
0.001,2733,O
),2733,O
;,2733,O
all,2733,O
doses,2733,O
of,2733,O
arformoterol,2733,O
were,2733,O
statistically,2733,O
different,2733,O
from,2733,O
salmeterol,2733,O
for,2733,O
this,2733,O
end,2733,O
point,2733,O
(,2733,O
P,2733,O
<,2733,O
or=,2733,O
0.024,2733,O
),2733,O
.,2733,O
At,2734,O
week,2734,O
12,2734,O
",",2734,O
TDI,2734,O
focal,2734,O
scores,2734,O
were,2734,O
significantly,2734,O
greater,2734,O
with,2734,O
all,2734,O
arformoterol,2734,O
doses,2734,O
compared,2734,O
with,2734,O
placebo,2734,O
(,2734,O
mean,2734,O
[,2734,O
95,2734,O
%,2734,O
CI,2734,O
],2734,O
:,2734,O
15,2734,O
microg,2734,O
BID,2734,O
",",2734,O
0.97,2734,O
[,2734,O
0.25-1.69,2734,O
],2734,O
;,2734,O
25,2734,O
microg,2734,O
BID,2734,O
",",2734,O
1.08,2734,O
[,2734,O
0.3-1.86,2734,O
],2734,O
;,2734,O
50,2734,O
microg,2734,O
QD,2734,O
",",2734,O
1.04,2734,O
[,2734,O
0.32-1.771,2734,O
),2734,O
",",2734,O
suggesting,2734,O
treatment-associated,2734,O
improvement,2734,O
in,2734,O
dyspnea,2734,O
",",2734,O
however,2734,O
",",2734,O
the,2734,O
difference,2734,O
between,2734,O
salmeterol,2734,O
and,2734,O
placebo,2734,O
was,2734,O
not,2734,O
statistically,2734,O
significant,2734,O
(,2734,O
0.36,2734,O
[,2734,O
-0.40,2734,O
to,2734,O
1.12,2734,O
],2734,O
),2734,O
.,2734,O
Improvements,2735,O
in,2735,O
health,2735,O
status,2735,O
",",2735,O
as,2735,O
measured,2735,O
using,2735,O
SGRQ,2735,O
total,2735,O
scores,2735,O
",",2735,O
were,2735,O
-2.6,2735,O
to,2735,O
-3.6,2735,O
U,2735,O
in,2735,O
the,2735,O
arformoterol,2735,O
groups,2735,O
",",2735,O
-4.4,2735,O
U,2735,O
for,2735,O
salmeterol,2735,O
",",2735,O
and,2735,O
-1.2,2735,O
U,2735,O
for,2735,O
placebo,2735,O
;,2735,O
95,2735,O
%,2735,O
CI,2735,O
of,2735,O
differences,2735,O
versus,2735,O
placebo,2735,O
suggested,2735,O
significant,2735,O
improvement,2735,O
for,2735,O
the,2735,O
arformoterol,2735,O
25,2735,O
microg,2735,O
BID,2735,O
and,2735,O
salmeterol,2735,O
groups,2735,O
.,2735,O
There,2736,O
was,2736,O
a,2736,O
similar,2736,O
frequency,2736,O
of,2736,O
AEs,2736,O
and,2736,O
COPD,2736,O
exacerbations,2736,O
across,2736,O
all,2736,O
groups,2736,O
",",2736,O
including,2736,O
placebo,2736,O
.,2736,O
CONCLUSIONS,2737,O
:,2737,O
In,2737,O
this,2737,O
trial,2737,O
",",2737,O
patients,2737,O
with,2737,O
moderate,2737,O
to,2737,O
severe,2737,O
COPD,2737,O
administered,2737,O
nebulized,2737,O
arformoterol,2737,O
over,2737,O
12,2737,O
weeks,2737,O
were,2737,O
observed,2737,O
to,2737,O
have,2737,O
significant,2737,O
and,2737,O
sustained,2737,O
improvements,2737,O
in,2737,O
airway,2737,O
function,2737,O
and,2737,O
dyspnea,2737,O
compared,2737,O
with,2737,O
placebo,2737,O
.,2737,O
The,2738,O
results,2738,O
also,2738,O
suggest,2738,O
that,2738,O
all,2738,O
doses,2738,O
of,2738,O
arformoterol,2738,O
",",2738,O
including,2738,O
the,2738,O
lowest,2738,O
dose,2738,O
(,2738,O
15,2738,O
microg,2738,O
BID,2738,O
),2738,O
",",2738,O
were,2738,O
effective,2738,O
.,2738,O
Overall,2739,O
",",2739,O
nebulized,2739,O
arformoterol,2739,O
was,2739,O
well,2739,O
tolerated,2739,O
.,2739,O
Discovery,2740,O
of,2740,O
acetyl-coenzyme,2740,B-GENE-Y
A,2740,I-GENE-Y
carboxylase,2740,I-GENE-Y
2,2740,I-GENE-Y
inhibitors,2740,O
:,2740,O
comparison,2740,O
of,2740,O
a,2740,O
fluorescence,2740,O
intensity-based,2740,O
phosphate,2740,B-CHEMICAL
assay,2740,O
and,2740,O
a,2740,O
fluorescence,2740,O
polarization-based,2740,O
ADP,2740,B-CHEMICAL
Assay,2740,O
for,2740,O
high-throughput,2740,O
screening,2740,O
.,2740,O
Acetyl-coenzyme,2741,B-CHEMICAL
A,2741,I-CHEMICAL
carboxylase,2741,I-GENE-N
(,2741,O
ACC,2741,B-GENE-N
),2741,O
enzymes,2741,O
exist,2741,O
as,2741,O
two,2741,O
isoforms,2741,O
",",2741,O
ACC1,2741,B-GENE-Y
and,2741,O
ACC2,2741,B-GENE-Y
",",2741,O
which,2741,O
play,2741,O
critical,2741,O
roles,2741,O
in,2741,O
fatty,2741,B-CHEMICAL
acid,2741,I-CHEMICAL
biosynthesis,2741,O
and,2741,O
oxidation,2741,O
.,2741,O
Though,2742,O
each,2742,O
isoform,2742,O
differs,2742,O
in,2742,O
tissue,2742,O
and,2742,O
subcellular,2742,O
localization,2742,O
",",2742,O
both,2742,O
catalyze,2742,O
the,2742,O
biotin-,2742,B-CHEMICAL
and,2742,O
ATP-dependent,2742,B-CHEMICAL
carboxylation,2742,O
of,2742,O
acetyl-coenzyme,2742,B-CHEMICAL
A,2742,I-CHEMICAL
to,2742,O
generate,2742,O
malonyl-coenzyme,2742,B-CHEMICAL
A,2742,I-CHEMICAL
",",2742,O
a,2742,O
key,2742,O
metabolite,2742,O
in,2742,O
the,2742,O
control,2742,O
of,2742,O
fatty,2742,B-CHEMICAL
acid,2742,I-CHEMICAL
synthesis,2742,O
and,2742,O
oxidation,2742,O
.,2742,O
The,2743,O
cytosolic,2743,O
ACC1,2743,B-GENE-Y
is,2743,O
expressed,2743,O
primarily,2743,O
in,2743,O
liver,2743,O
and,2743,O
adipose,2743,O
tissue,2743,O
",",2743,O
and,2743,O
uses,2743,O
malonyl-coenzyme,2743,B-CHEMICAL
A,2743,I-CHEMICAL
as,2743,O
a,2743,O
key,2743,O
building,2743,O
block,2743,O
in,2743,O
fatty,2743,B-CHEMICAL
acid,2743,I-CHEMICAL
biosynthesis,2743,O
.,2743,O
The,2744,O
mitochondrial,2744,O
ACC2,2744,B-GENE-Y
is,2744,O
primarily,2744,O
expressed,2744,O
in,2744,O
heart,2744,O
and,2744,O
skeletal,2744,O
muscle,2744,O
",",2744,O
where,2744,O
it,2744,O
is,2744,O
involved,2744,O
in,2744,O
the,2744,O
regulation,2744,O
of,2744,O
fatty,2744,B-CHEMICAL
acid,2744,I-CHEMICAL
oxidation,2744,O
.,2744,O
Inhibitors,2745,O
of,2745,O
ACC,2745,B-GENE-N
enzymes,2745,O
may,2745,O
therefore,2745,O
be,2745,O
useful,2745,O
therapeutics,2745,O
for,2745,O
diabetes,2745,O
",",2745,O
obesity,2745,O
",",2745,O
and,2745,O
metabolic,2745,O
syndrome,2745,O
.,2745,O
Two,2746,O
assay,2746,O
formats,2746,O
for,2746,O
these,2746,O
ATP-utilizing,2746,B-CHEMICAL
enzymes,2746,O
amenable,2746,O
to,2746,O
high-throughput,2746,O
screening,2746,O
are,2746,O
compared,2746,O
:,2746,O
a,2746,O
fluorescence,2746,O
intensity-based,2746,O
assay,2746,O
to,2746,O
detect,2746,O
inorganic,2746,B-CHEMICAL
phosphate,2746,I-CHEMICAL
and,2746,O
a,2746,O
fluorescence,2746,O
polarization-based,2746,O
assay,2746,O
to,2746,O
detect,2746,O
ADP,2746,B-CHEMICAL
.,2746,O
Acetyl-coenzyme,2747,B-CHEMICAL
A,2747,I-CHEMICAL
carboxylase,2747,I-GENE-N
inhibitors,2747,O
were,2747,O
identified,2747,O
by,2747,O
these,2747,O
high-throughput,2747,O
screening,2747,O
methods,2747,O
and,2747,O
were,2747,O
confirmed,2747,O
in,2747,O
a,2747,O
radiometric,2747,O
high,2747,O
performance,2747,O
liquid,2747,O
chromatography,2747,O
assay,2747,O
of,2747,O
malonyl-coenzyme,2747,B-CHEMICAL
A,2747,I-CHEMICAL
production,2747,O
.,2747,O
Retinoic,2748,B-CHEMICAL
acid,2748,I-CHEMICAL
is,2748,O
required,2748,O
for,2748,O
specification,2748,O
of,2748,O
the,2748,O
ventral,2748,O
eye,2748,O
field,2748,O
and,2748,O
for,2748,O
Rathke,2748,O
's,2748,O
pouch,2748,O
in,2748,O
the,2748,O
avian,2748,O
embryo,2748,O
.,2748,O
We,2749,O
have,2749,O
investigated,2749,O
the,2749,O
role,2749,O
of,2749,O
retinoic,2749,B-CHEMICAL
acid,2749,I-CHEMICAL
(,2749,O
RA,2749,B-CHEMICAL
),2749,O
in,2749,O
eye,2749,O
development,2749,O
using,2749,O
the,2749,O
vitamin,2749,B-CHEMICAL
A,2749,I-CHEMICAL
deficient,2749,O
quail,2749,O
model,2749,O
system,2749,O
",",2749,O
which,2749,O
overcomes,2749,O
problems,2749,O
of,2749,O
retinoic,2749,B-CHEMICAL
acid,2749,I-CHEMICAL
synthesising,2749,O
enzyme,2749,O
redundancy,2749,O
in,2749,O
the,2749,O
embryo,2749,O
.,2749,O
In,2750,O
the,2750,O
absence,2750,O
of,2750,O
retinoic,2750,B-CHEMICAL
acid,2750,I-CHEMICAL
",",2750,O
the,2750,O
ventral,2750,O
optic,2750,O
stalk,2750,O
and,2750,O
ventral,2750,O
retina,2750,O
are,2750,O
missing,2750,O
",",2750,O
whereas,2750,O
the,2750,O
dorsal,2750,O
optic,2750,O
stalk,2750,O
and,2750,O
dorsal,2750,O
retina,2750,O
develop,2750,O
appropriately,2750,O
.,2750,O
Other,2751,O
ocular,2751,O
abnormalities,2751,O
observed,2751,O
were,2751,O
a,2751,O
thinner,2751,O
retina,2751,O
and,2751,O
the,2751,O
lack,2751,O
of,2751,O
differentiation,2751,O
of,2751,O
the,2751,O
lens,2751,O
.,2751,O
In,2752,O
an,2752,O
attempt,2752,O
to,2752,O
explain,2752,O
this,2752,O
",",2752,O
we,2752,O
studied,2752,O
the,2752,O
expression,2752,O
of,2752,O
various,2752,O
dorsally,2752,O
and,2752,O
ventrally,2752,O
expressed,2752,O
genes,2752,O
such,2752,O
as,2752,O
Pax2,2752,B-GENE-N
",",2752,O
Pax6,2752,B-GENE-Y
",",2752,O
Tbx6,2752,B-GENE-N
",",2752,O
Vax2,2752,B-GENE-N
",",2752,O
Raldh1,2752,B-GENE-N
and,2752,O
Raldh3,2752,B-GENE-N
and,2752,O
noted,2752,O
that,2752,O
they,2752,O
were,2752,O
unchanged,2752,O
in,2752,O
their,2752,O
expression,2752,O
patterns,2752,O
.,2752,O
In,2753,O
contrast,2753,O
",",2753,O
the,2753,O
RA,2753,B-CHEMICAL
catabolising,2753,O
enzymes,2753,O
Cyp26A1,2753,B-GENE-N
and,2753,O
Cyp26B1,2753,B-GENE-N
which,2753,O
are,2753,O
known,2753,O
to,2753,O
be,2753,O
RA-responsive,2753,B-CHEMICAL
were,2753,O
not,2753,O
expressed,2753,O
at,2753,O
all,2753,O
in,2753,O
the,2753,O
developing,2753,O
eye,2753,O
.,2753,O
At,2754,O
much,2754,O
earlier,2754,O
stages,2754,O
",",2754,O
the,2754,O
expression,2754,O
domain,2754,O
of,2754,O
Shh,2754,B-GENE-Y
in,2754,O
the,2754,O
prechordal,2754,O
plate,2754,O
was,2754,O
reduced,2754,O
",",2754,O
as,2754,O
was,2754,O
Nkx2.1,2754,B-GENE-N
and,2754,O
we,2754,O
suggest,2754,O
a,2754,O
model,2754,O
whereby,2754,O
the,2754,O
eye,2754,O
field,2754,O
is,2754,O
specified,2754,O
according,2754,O
to,2754,O
the,2754,O
concentration,2754,O
of,2754,O
SHH,2754,B-GENE-Y
protein,2754,O
that,2754,O
is,2754,O
present,2754,O
.,2754,O
We,2755,O
also,2755,O
describe,2755,O
another,2755,O
organ,2755,O
",",2755,O
Rathke,2755,O
's,2755,O
pouch,2755,O
which,2755,O
fails,2755,O
to,2755,O
develop,2755,O
in,2755,O
the,2755,O
absence,2755,O
of,2755,O
retinoic,2755,B-CHEMICAL
acid,2755,I-CHEMICAL
.,2755,O
We,2756,O
attribute,2756,O
this,2756,O
to,2756,O
the,2756,O
down-regulation,2756,O
of,2756,O
Bmp2,2756,B-GENE-N
",",2756,O
Shh,2756,B-GENE-Y
and,2756,O
Fgf8,2756,B-GENE-N
which,2756,O
are,2756,O
known,2756,O
to,2756,O
be,2756,O
involved,2756,O
in,2756,O
the,2756,O
induction,2756,O
of,2756,O
this,2756,O
structure,2756,O
.,2756,O
Distinct,2757,O
patterns,2757,O
of,2757,O
mutations,2757,O
occurring,2757,O
in,2757,O
de,2757,O
novo,2757,O
AML,2757,O
versus,2757,O
AML,2757,O
arising,2757,O
in,2757,O
the,2757,O
setting,2757,O
of,2757,O
severe,2757,O
congenital,2757,O
neutropenia,2757,O
.,2757,O
Severe,2758,O
congenital,2758,O
neutropenia,2758,O
(,2758,O
SCN,2758,O
),2758,O
is,2758,O
an,2758,O
inborn,2758,O
disorder,2758,O
of,2758,O
granulopoiesis,2758,O
.,2758,O
Like,2759,O
most,2759,O
other,2759,O
bone,2759,O
marrow,2759,O
failure,2759,O
syndromes,2759,O
",",2759,O
it,2759,O
is,2759,O
associated,2759,O
with,2759,O
a,2759,O
marked,2759,O
propensity,2759,O
to,2759,O
transform,2759,O
into,2759,O
a,2759,O
myelodysplastic,2759,O
syndrome,2759,O
(,2759,O
MDS,2759,O
),2759,O
or,2759,O
acute,2759,O
leukemia,2759,O
",",2759,O
with,2759,O
a,2759,O
cumulative,2759,O
rate,2759,O
of,2759,O
transformation,2759,O
to,2759,O
MDS/leukemia,2759,O
that,2759,O
exceeds,2759,O
20,2759,O
%,2759,O
.,2759,O
The,2760,O
genetic,2760,O
(,2760,O
and/or,2760,O
epigenetic,2760,O
),2760,O
changes,2760,O
that,2760,O
contribute,2760,O
to,2760,O
malignant,2760,O
transformation,2760,O
in,2760,O
SCN,2760,O
are,2760,O
largely,2760,O
unknown,2760,O
.,2760,O
In,2761,O
this,2761,O
study,2761,O
",",2761,O
we,2761,O
performed,2761,O
mutational,2761,O
profiling,2761,O
of,2761,O
14,2761,O
genes,2761,O
previously,2761,O
implicated,2761,O
in,2761,O
leukemogenesis,2761,O
using,2761,O
14,2761,O
MDS/leukemia,2761,O
samples,2761,O
from,2761,O
patients,2761,O
with,2761,O
SCN,2761,O
.,2761,O
We,2762,O
used,2762,O
high-throughput,2762,O
exon-based,2762,O
resequencing,2762,O
of,2762,O
whole-genome-amplified,2762,O
genomic,2762,O
DNA,2762,O
with,2762,O
a,2762,O
semiautomated,2762,O
method,2762,O
to,2762,O
detect,2762,O
mutations,2762,O
.,2762,O
The,2763,O
sensitivity,2763,O
and,2763,O
specificity,2763,O
of,2763,O
the,2763,O
sequencing,2763,O
pipeline,2763,O
was,2763,O
validated,2763,O
by,2763,O
determining,2763,O
the,2763,O
frequency,2763,O
of,2763,O
mutations,2763,O
in,2763,O
these,2763,O
14,2763,O
genes,2763,O
using,2763,O
188,2763,O
de,2763,O
novo,2763,O
AML,2763,O
samples,2763,O
.,2763,O
As,2764,O
expected,2764,O
",",2764,O
mutations,2764,O
of,2764,O
tyrosine,2764,B-GENE-N
kinase,2764,I-GENE-N
genes,2764,O
(,2764,O
FLT3,2764,B-GENE-Y
",",2764,O
KIT,2764,B-GENE-Y
",",2764,O
and,2764,O
JAK2,2764,B-GENE-Y
),2764,O
were,2764,O
common,2764,O
in,2764,O
de,2764,O
novo,2764,O
AML,2764,O
",",2764,O
with,2764,O
a,2764,O
cumulative,2764,O
frequency,2764,O
of,2764,O
30,2764,O
%,2764,O
.,2764,O
In,2765,O
contrast,2765,O
",",2765,O
no,2765,O
mutations,2765,O
in,2765,O
these,2765,O
genes,2765,O
were,2765,O
detected,2765,O
in,2765,O
the,2765,O
SCN,2765,O
samples,2765,O
;,2765,O
instead,2765,O
",",2765,O
mutations,2765,O
of,2765,O
CSF3R,2765,B-GENE-Y
",",2765,O
encoding,2765,O
the,2765,O
G-CSF,2765,B-GENE-Y
receptor,2765,I-GENE-Y
",",2765,O
were,2765,O
common,2765,O
.,2765,O
These,2766,O
data,2766,O
support,2766,O
the,2766,O
hypothesis,2766,O
that,2766,O
mutations,2766,O
of,2766,O
CSF3R,2766,B-GENE-Y
may,2766,O
provide,2766,O
the,2766,O
``,2766,O
activated,2766,O
tyrosine,2766,B-GENE-N
kinase,2766,I-GENE-N
signal,2766,O
'',2766,O
that,2766,O
is,2766,O
thought,2766,O
to,2766,O
be,2766,O
important,2766,O
for,2766,O
leukemogenesis,2766,O
.,2766,O
Biology,2767,O
of,2767,O
incretins,2767,B-GENE-N
:,2767,O
GLP-1,2767,B-GENE-Y
and,2767,O
GIP,2767,B-GENE-Y
.,2767,O
This,2768,O
review,2768,O
focuses,2768,O
on,2768,O
the,2768,O
mechanisms,2768,O
regulating,2768,O
the,2768,O
synthesis,2768,O
",",2768,O
secretion,2768,O
",",2768,O
biological,2768,O
actions,2768,O
",",2768,O
and,2768,O
therapeutic,2768,O
relevance,2768,O
of,2768,O
the,2768,O
incretin,2768,B-GENE-N
peptides,2768,O
glucose-dependent,2768,B-CHEMICAL
insulinotropic,2768,I-GENE-Y
polypeptide,2768,I-GENE-Y
(,2768,O
GIP,2768,B-GENE-Y
),2768,O
and,2768,O
glucagon-like,2768,B-GENE-Y
peptide-1,2768,I-GENE-Y
(,2768,O
GLP-1,2768,B-GENE-Y
),2768,O
.,2768,O
The,2769,O
published,2769,O
literature,2769,O
was,2769,O
reviewed,2769,O
",",2769,O
with,2769,O
emphasis,2769,O
on,2769,O
recent,2769,O
advances,2769,O
in,2769,O
our,2769,O
understanding,2769,O
of,2769,O
the,2769,O
biology,2769,O
of,2769,O
GIP,2769,B-GENE-Y
and,2769,O
GLP-1,2769,B-GENE-Y
.,2769,O
GIP,2770,B-GENE-Y
and,2770,O
GLP-1,2770,B-GENE-Y
are,2770,O
both,2770,O
secreted,2770,O
within,2770,O
minutes,2770,O
of,2770,O
nutrient,2770,O
ingestion,2770,O
and,2770,O
facilitate,2770,O
the,2770,O
rapid,2770,O
disposal,2770,O
of,2770,O
ingested,2770,O
nutrients,2770,O
.,2770,O
Both,2771,O
peptides,2771,O
share,2771,O
common,2771,O
actions,2771,O
on,2771,O
islet,2771,O
beta-cells,2771,O
acting,2771,O
through,2771,O
structurally,2771,O
distinct,2771,O
yet,2771,O
related,2771,O
receptors,2771,O
.,2771,O
Incretin-receptor,2772,B-GENE-N
activation,2772,O
leads,2772,O
to,2772,O
glucose-dependent,2772,B-CHEMICAL
insulin,2772,B-GENE-Y
secretion,2772,O
",",2772,O
induction,2772,O
of,2772,O
beta-cell,2772,O
proliferation,2772,O
",",2772,O
and,2772,O
enhanced,2772,O
resistance,2772,O
to,2772,O
apoptosis,2772,O
.,2772,O
GIP,2773,B-GENE-Y
also,2773,O
promotes,2773,O
energy,2773,O
storage,2773,O
via,2773,O
direct,2773,O
actions,2773,O
on,2773,O
adipose,2773,O
tissue,2773,O
",",2773,O
and,2773,O
enhances,2773,O
bone,2773,O
formation,2773,O
via,2773,O
stimulation,2773,O
of,2773,O
osteoblast,2773,O
proliferation,2773,O
and,2773,O
inhibition,2773,O
of,2773,O
apoptosis,2773,O
.,2773,O
In,2774,O
contrast,2774,O
",",2774,O
GLP-1,2774,B-GENE-Y
exerts,2774,O
glucoregulatory,2774,O
actions,2774,O
via,2774,O
slowing,2774,O
of,2774,O
gastric,2774,O
emptying,2774,O
and,2774,O
glucose-dependent,2774,B-CHEMICAL
inhibition,2774,O
of,2774,O
glucagon,2774,B-GENE-Y
secretion,2774,O
.,2774,O
GLP-1,2775,B-GENE-Y
also,2775,O
promotes,2775,O
satiety,2775,O
and,2775,O
sustained,2775,O
GLP-1-receptor,2775,B-GENE-N
activation,2775,O
is,2775,O
associated,2775,O
with,2775,O
weight,2775,O
loss,2775,O
in,2775,O
both,2775,O
preclinical,2775,O
and,2775,O
clinical,2775,O
studies,2775,O
.,2775,O
The,2776,O
rapid,2776,O
degradation,2776,O
of,2776,O
both,2776,O
GIP,2776,B-GENE-Y
and,2776,O
GLP-1,2776,B-GENE-Y
by,2776,O
the,2776,O
enzyme,2776,O
dipeptidyl,2776,B-GENE-Y
peptidase-4,2776,I-GENE-Y
has,2776,O
led,2776,O
to,2776,O
the,2776,O
development,2776,O
of,2776,O
degradation-resistant,2776,O
GLP-1-receptor,2776,B-GENE-Y
agonists,2776,O
and,2776,O
dipeptidyl,2776,B-GENE-Y
peptidase-4,2776,I-GENE-Y
inhibitors,2776,O
for,2776,O
the,2776,O
treatment,2776,O
of,2776,O
type,2776,O
2,2776,O
diabetes,2776,O
.,2776,O
These,2777,O
agents,2777,O
decrease,2777,O
hemoglobin,2777,B-GENE-Y
A1c,2777,I-GENE-Y
(,2777,O
HbA1c,2777,B-GENE-Y
),2777,O
safely,2777,O
without,2777,O
weight,2777,O
gain,2777,O
in,2777,O
subjects,2777,O
with,2777,O
type,2777,O
2,2777,O
diabetes,2777,O
.,2777,O
GLP-1,2778,B-GENE-Y
and,2778,O
GIP,2778,B-GENE-Y
integrate,2778,O
nutrient-derived,2778,O
signals,2778,O
to,2778,O
control,2778,O
food,2778,O
intake,2778,O
",",2778,O
energy,2778,O
absorption,2778,O
",",2778,O
and,2778,O
assimilation,2778,O
.,2778,O
Recently,2779,O
approved,2779,O
therapeutic,2779,O
agents,2779,O
based,2779,O
on,2779,O
potentiation,2779,O
of,2779,O
incretin,2779,B-GENE-N
action,2779,O
provide,2779,O
new,2779,O
physiologically,2779,O
based,2779,O
approaches,2779,O
for,2779,O
the,2779,O
treatment,2779,O
of,2779,O
type,2779,O
2,2779,O
diabetes,2779,O
.,2779,O
[,2780,O
Characteristics,2780,O
of,2780,O
A-interferon-generated,2780,B-GENE-N
dendritic,2780,O
cells,2780,O
in,2780,O
patients,2780,O
with,2780,O
pulmonary,2780,O
tuberculosis,2780,O
],2780,O
.,2780,O
The,2781,O
phenotype,2781,O
of,2781,O
the,2781,O
dendritic,2781,O
cells,2781,O
(,2781,O
DC,2781,O
),2781,O
generated,2781,O
from,2781,O
the,2781,O
adhesion,2781,O
fraction,2781,O
of,2781,O
mononuclear,2781,O
cells,2781,O
in,2781,O
the,2781,O
presence,2781,O
of,2781,O
GM-CSF,2781,O
and,2781,O
alpha-interferon,2781,B-GENE-N
was,2781,O
studied,2781,O
in,2781,O
patients,2781,O
with,2781,O
pulmonary,2781,O
tuberculosis,2781,O
.,2781,O
Despite,2782,O
the,2782,O
absence,2782,O
of,2782,O
significant,2782,O
differences,2782,O
in,2782,O
the,2782,O
count,2782,O
of,2782,O
mature,2782,O
CD83+DCs,2782,O
in,2782,O
the,2782,O
groups,2782,O
of,2782,O
patients,2782,O
(,2782,O
n,2782,O
=,2782,O
38,2782,O
),2782,O
and,2782,O
healthy,2782,O
donors,2782,O
(,2782,O
n,2782,O
=,2782,O
30,2782,O
),2782,O
",",2782,O
elevated,2782,O
CD14,2782,O
(,2782,O
+,2782,O
),2782,O
-monocyte,2782,O
levels,2782,O
and,2782,O
few,2782,O
activated,2782,O
CD25,2782,O
(,2782,O
+,2782,O
),2782,O
-DCs,2782,O
were,2782,O
indicative,2782,O
of,2782,O
the,2782,O
impaired,2782,O
process,2782,O
of,2782,O
DC,2782,O
maturation/generation,2782,O
in,2782,O
patients,2782,O
with,2782,O
pulmonary,2782,O
tuberculosis,2782,O
",",2782,O
particularly,2782,O
in,2782,O
a,2782,O
subgroup,2782,O
of,2782,O
patients,2782,O
with,2782,O
a,2782,O
low,2782,O
T-cell,2782,O
proliferative,2782,O
response,2782,O
against,2782,O
PPD,2782,O
(,2782,O
PPD-anergy,2782,O
",",2782,O
n,2782,O
=,2782,O
10,2782,O
),2782,O
.,2782,O
The,2783,O
patients,2783,O
with,2783,O
tuberculosis,2783,O
showed,2783,O
the,2783,O
lower,2783,O
relative,2783,O
levels,2783,O
of,2783,O
CD11c,2783,O
(,2783,O
-,2783,O
),2783,O
-CD123,2783,O
(,2783,O
+,2783,O
),2783,O
-DC,2783,O
and,2783,O
the,2783,O
normal,2783,O
levels,2783,O
of,2783,O
myeloid,2783,O
CD11c,2783,O
(,2783,O
+,2783,O
),2783,O
D123,2783,O
(,2783,O
-,2783,O
),2783,O
DCs,2783,O
.,2783,O
However,2784,O
",",2784,O
in,2784,O
patients,2784,O
with,2784,O
PPD-anergy,2784,O
",",2784,O
the,2784,O
content,2784,O
of,2784,O
myeloid,2784,O
CD11c,2784,O
(,2784,O
+,2784,O
),2784,O
CD123,2784,O
(,2784,O
-,2784,O
),2784,O
-DCs,2784,O
was,2784,O
significantly,2784,O
higher,2784,O
than,2784,O
that,2784,O
in,2784,O
PPD-reactive,2784,O
patients,2784,O
.,2784,O
Moreover,2785,O
",",2785,O
the,2785,O
patients,2785,O
with,2785,O
PPD-anergy,2785,O
were,2785,O
characterized,2785,O
by,2785,O
the,2785,O
elevated,2785,O
peripheral,2785,O
blood,2785,O
levels,2785,O
of,2785,O
CD14+CD16,2785,O
(,2785,O
+,2785,O
),2785,O
-monocytes,2785,O
",",2785,O
which,2785,O
was,2785,O
associated,2785,O
with,2785,O
the,2785,O
high,2785,O
suppressive,2785,O
activity,2785,O
of,2785,O
monocytes,2785,O
(,2785,O
r,2785,O
(,2785,O
s,2785,O
),2785,O
=,2785,O
0.53,2785,O
;,2785,O
p,2785,O
<,2785,O
0.05,2785,O
),2785,O
.,2785,O
The,2786,O
impaired,2786,O
process,2786,O
of,2786,O
DC,2786,O
generation/maturation,2786,O
in,2786,O
patients,2786,O
with,2786,O
pulmonary,2786,O
tuberculosis,2786,O
is,2786,O
believed,2786,O
to,2786,O
be,2786,O
associated,2786,O
with,2786,O
the,2786,O
changes,2786,O
in,2786,O
the,2786,O
phenotypic,2786,O
and,2786,O
functional,2786,O
properties,2786,O
of,2786,O
monocytes,2786,O
and,2786,O
to,2786,O
be,2786,O
a,2786,O
cause,2786,O
of,2786,O
an,2786,O
inadequate,2786,O
antigen-specific,2786,O
response,2786,O
in,2786,O
tuberculous,2786,O
infection,2786,O
.,2786,O
Aripiprazole,2787,O
acts,2787,O
as,2787,O
a,2787,O
selective,2787,O
dopamine,2787,B-GENE-Y
D2,2787,I-GENE-Y
receptor,2787,I-GENE-Y
partial,2787,O
agonist,2787,O
.,2787,O
Aripiprazole,2788,B-CHEMICAL
has,2788,O
made,2788,O
a,2788,O
significant,2788,O
contribution,2788,O
to,2788,O
the,2788,O
treatment,2788,O
of,2788,O
schizophrenia,2788,O
and,2788,O
related,2788,O
disorders,2788,O
with,2788,O
an,2788,O
improved,2788,O
safety,2788,O
and,2788,O
tolerability,2788,O
profile,2788,O
",",2788,O
which,2788,O
has,2788,O
been,2788,O
attributed,2788,O
to,2788,O
its,2788,O
unique,2788,O
pharmacological,2788,O
profile,2788,O
.,2788,O
It,2789,O
has,2789,O
been,2789,O
claimed,2789,O
that,2789,O
partial,2789,O
agonism,2789,O
of,2789,O
the,2789,O
dopamine,2789,B-CHEMICAL
D,2789,I-GENE-N
(,2789,I-GENE-N
2,2789,I-GENE-N
),2789,I-GENE-N
and,2789,I-GENE-N
5-HT,2789,I-GENE-N
(,2789,I-GENE-N
1A,2789,I-GENE-N
),2789,I-GENE-N
receptors,2789,I-GENE-N
and,2789,O
antagonism,2789,O
of,2789,O
the,2789,O
5-HT,2789,B-GENE-Y
(,2789,I-GENE-Y
2,2789,I-GENE-Y
),2789,I-GENE-Y
receptor,2789,O
contribute,2789,O
to,2789,O
the,2789,O
clinical,2789,O
profile,2789,O
of,2789,O
aripiprazole,2789,B-CHEMICAL
",",2789,O
a,2789,O
so-called,2789,O
dopamine-,2789,B-CHEMICAL
and,2789,O
5-HT,2789,B-CHEMICAL
stabiliser,2789,O
.,2789,O
However,2790,O
",",2790,O
recent,2790,O
studies,2790,O
have,2790,O
questioned,2790,O
the,2790,O
role,2790,O
of,2790,O
the,2790,O
5-HT-mediated,2790,B-CHEMICAL
systems,2790,O
in,2790,O
the,2790,O
mechanism,2790,O
of,2790,O
action,2790,O
of,2790,O
aripiprazole,2790,B-CHEMICAL
.,2790,O
This,2791,O
report,2791,O
reviews,2791,O
published,2791,O
and,2791,O
unpublished,2791,O
data,2791,O
that,2791,O
suggest,2791,O
that,2791,O
aripiprazole,2791,B-CHEMICAL
acts,2791,O
as,2791,O
a,2791,O
selective,2791,O
partial,2791,O
agonist,2791,O
at,2791,O
the,2791,O
dopamine,2791,B-CHEMICAL
D,2791,I-GENE-Y
(,2791,I-GENE-Y
2,2791,I-GENE-Y
),2791,I-GENE-Y
receptor,2791,I-GENE-Y
and,2791,O
does,2791,O
not,2791,O
affect,2791,O
5-HT,2791,B-GENE-N
receptors,2791,I-GENE-N
at,2791,O
therapeutic,2791,O
doses,2791,O
.,2791,O
Pharmacological,2792,O
therapy,2792,O
of,2792,O
Cushing,2792,O
's,2792,O
syndrome,2792,O
:,2792,O
drugs,2792,O
and,2792,O
indications,2792,O
.,2792,O
OBJECTIVE,2793,O
:,2793,O
To,2793,O
review,2793,O
the,2793,O
main,2793,O
pharmacological,2793,O
properties,2793,O
and,2793,O
clinical,2793,O
applications,2793,O
of,2793,O
the,2793,O
drugs,2793,O
used,2793,O
in,2793,O
the,2793,O
medical,2793,O
therapy,2793,O
of,2793,O
Cushing,2793,O
's,2793,O
syndrome,2793,O
.,2793,O
DATA,2794,O
SOURCES,2794,O
:,2794,O
Search,2794,O
for,2794,O
articles,2794,O
were,2794,O
performed,2794,O
in,2794,O
the,2794,O
following,2794,O
dababases,2794,O
:,2794,O
MEDLINE,2794,O
",",2794,O
EMBASE,2794,O
",",2794,O
Cochrane,2794,O
Database,2794,O
of,2794,O
systematic,2794,O
Reviews,2794,O
and,2794,O
The,2794,O
Cochrane,2794,O
Central,2794,O
Register,2794,O
of,2794,O
Controlled,2794,O
Trials,2794,O
(,2794,O
CENTRAL,2794,O
),2794,O
.,2794,O
Search,2795,O
terms,2795,O
included,2795,O
Cushing,2795,O
's,2795,O
syndrome,2795,O
and,2795,O
drug,2795,O
therapy,2795,O
.,2795,O
DATA,2796,O
SYNTHESIS,2796,O
:,2796,O
Available,2796,O
data,2796,O
suggest,2796,O
that,2796,O
neuromodulatory,2796,O
compounds,2796,O
affect,2796,O
corticotropin,2796,B-GENE-Y
(,2796,O
ACTH,2796,B-GENE-Y
),2796,O
or,2796,O
ACTH-releasing,2796,B-GENE-Y
hormone,2796,I-GENE-Y
(,2796,O
CRH,2796,B-GENE-Y
),2796,O
synthesis,2796,O
and,2796,O
release,2796,O
.,2796,O
They,2797,O
include,2797,O
serotonin,2797,B-CHEMICAL
antagonists,2797,O
",",2797,O
dopaminergic,2797,O
agonists,2797,O
",",2797,O
valproic,2797,B-CHEMICAL
acid,2797,I-CHEMICAL
",",2797,O
reserpine,2797,B-CHEMICAL
",",2797,O
somatostatin,2797,B-GENE-Y
analogs,2797,O
and,2797,O
thiazolidinediones,2797,B-CHEMICAL
.,2797,O
These,2798,O
agents,2798,O
have,2798,O
been,2798,O
effective,2798,O
in,2798,O
a,2798,O
limited,2798,O
number,2798,O
of,2798,O
patients,2798,O
with,2798,O
ACTH-dependent,2798,B-GENE-Y
Cushing,2798,O
's,2798,O
syndrome,2798,O
.,2798,O
Inhibitors,2799,O
of,2799,O
steroidogenesis,2799,O
reduce,2799,O
cortisol,2799,O
production,2799,O
by,2799,O
blocking,2799,O
one,2799,O
(,2799,O
metyrapone,2799,B-CHEMICAL
",",2799,O
trilostane,2799,B-CHEMICAL
),2799,O
or,2799,O
several,2799,O
(,2799,O
aminoglutethimide,2799,B-CHEMICAL
",",2799,O
ketoconazole,2799,B-CHEMICAL
",",2799,O
fluconazole,2799,B-CHEMICAL
",",2799,O
etomidate,2799,B-CHEMICAL
),2799,O
enzymes,2799,O
involved,2799,O
in,2799,O
steroid,2799,O
biosynthesis,2799,O
.,2799,O
Mitotane,2800,B-CHEMICAL
is,2800,O
a,2800,O
steroidogenesis,2800,O
inhibitor,2800,O
with,2800,O
adrenolitic,2800,O
properties,2800,O
.,2800,O
Mifepriston,2801,B-CHEMICAL
',2801,I-CHEMICAL
e,2801,I-CHEMICAL
blocks,2801,O
glucocorticoid,2801,B-GENE-Y
receptor,2801,I-GENE-Y
activation,2801,O
without,2801,O
modifying,2801,O
cortisol,2801,B-CHEMICAL
synthesis,2801,O
.,2801,O
CONCLUSION,2802,O
:,2802,O
Agents,2802,O
that,2802,O
inhibit,2802,O
steroidogenesis,2802,O
are,2802,O
useful,2802,O
in,2802,O
all,2802,O
forms,2802,O
of,2802,O
Cushing,2802,O
's,2802,O
syndrome,2802,O
and,2802,O
are,2802,O
effective,2802,O
in,2802,O
about,2802,O
70,2802,O
%,2802,O
of,2802,O
patients,2802,O
.,2802,O
Main,2803,O
indications,2803,O
for,2803,O
drug,2803,O
therapy,2803,O
include,2803,O
preparation,2803,O
for,2803,O
surgery,2803,O
",",2803,O
persistence,2803,O
or,2803,O
recurrence,2803,O
after,2803,O
surgery,2803,O
",",2803,O
while,2803,O
awaiting,2803,O
for,2803,O
the,2803,O
effect,2803,O
of,2803,O
radiation,2803,O
therapy,2803,O
",",2803,O
occult,2803,O
ectopic,2803,O
ACTH,2803,B-GENE-Y
syndrome,2803,O
",",2803,O
severe,2803,O
hypercortisolism,2803,O
and,2803,O
malignancy,2803,O
related,2803,O
hypercortisolism,2803,O
.,2803,O
Cannabinoid,2804,B-GENE-Y
CB1,2804,I-GENE-Y
receptors,2804,I-GENE-Y
in,2804,O
the,2804,O
paraventricular,2804,O
nucleus,2804,O
and,2804,O
central,2804,O
control,2804,O
of,2804,O
penile,2804,O
erection,2804,O
:,2804,O
immunocytochemistry,2804,O
",",2804,O
autoradiography,2804,O
and,2804,O
behavioral,2804,O
studies,2804,O
.,2804,O
[,2805,O
N-,2805,B-CHEMICAL
(,2805,I-CHEMICAL
piperidin-1-yl,2805,I-CHEMICAL
),2805,I-CHEMICAL
-5-,2805,I-CHEMICAL
(,2805,I-CHEMICAL
4-chlorophenyl,2805,I-CHEMICAL
),2805,I-CHEMICAL
-4-methyl-1H-pyrazole-3-carboxyamide,2805,I-CHEMICAL
],2805,O
(,2805,O
SR,2805,B-CHEMICAL
141716A,2805,I-CHEMICAL
),2805,O
",",2805,O
a,2805,O
selective,2805,O
cannabinoid,2805,B-CHEMICAL
CB1,2805,I-GENE-Y
receptor,2805,I-GENE-Y
antagonist,2805,O
",",2805,O
injected,2805,O
into,2805,O
the,2805,O
paraventricular,2805,O
nucleus,2805,O
of,2805,O
the,2805,O
hypothalamus,2805,O
(,2805,O
PVN,2805,O
),2805,O
of,2805,O
male,2805,O
rats,2805,O
",",2805,O
induces,2805,O
penile,2805,O
erection,2805,O
.,2805,O
This,2806,O
effect,2806,O
is,2806,O
mediated,2806,O
by,2806,O
the,2806,O
release,2806,O
of,2806,O
glutamic,2806,B-CHEMICAL
acid,2806,I-CHEMICAL
",",2806,O
which,2806,O
in,2806,O
turn,2806,O
activates,2806,O
central,2806,O
oxytocinergic,2806,O
neurons,2806,O
mediating,2806,O
penile,2806,O
erection,2806,O
.,2806,O
Double,2807,O
immunofluorescence,2807,O
studies,2807,O
with,2807,O
selective,2807,O
antibodies,2807,O
against,2807,O
CB1,2807,B-GENE-Y
receptors,2807,I-GENE-Y
",",2807,O
glutamic,2807,B-CHEMICAL
acid,2807,I-CHEMICAL
transporters,2807,I-GENE-N
(,2807,O
vesicular,2807,B-GENE-N
glutamate,2807,I-GENE-N
transporters,2807,I-GENE-N
1,2807,I-GENE-N
and,2807,I-GENE-N
2,2807,I-GENE-N
(,2807,O
VGlut1,2807,B-GENE-Y
and,2807,O
VGlut2,2807,B-GENE-Y
),2807,O
",",2807,O
glutamic,2807,B-GENE-Y
acid,2807,I-GENE-Y
decarboxylase-67,2807,I-GENE-Y
(,2807,O
GAD67,2807,B-GENE-Y
),2807,O
and,2807,O
oxytocin,2807,B-GENE-Y
itself,2807,O
",",2807,O
have,2807,O
shown,2807,O
that,2807,O
CB1,2807,B-GENE-Y
receptors,2807,I-GENE-Y
in,2807,O
the,2807,O
PVN,2807,O
are,2807,O
located,2807,O
mainly,2807,O
in,2807,O
GABAergic,2807,O
terminals,2807,O
and,2807,O
fibers,2807,O
surrounding,2807,O
oxytocinergic,2807,O
cell,2807,O
bodies,2807,O
.,2807,O
As,2808,O
GABAergic,2808,O
synapses,2808,O
in,2808,O
the,2808,O
PVN,2808,O
impinge,2808,O
directly,2808,O
on,2808,O
oxytocinergic,2808,O
neurons,2808,O
or,2808,O
on,2808,O
excitatory,2808,O
glutamatergic,2808,O
synapses,2808,O
",",2808,O
which,2808,O
also,2808,O
impinge,2808,O
on,2808,O
oxytocinergic,2808,O
neurons,2808,O
",",2808,O
these,2808,O
results,2808,O
suggest,2808,O
that,2808,O
the,2808,O
blockade,2808,O
of,2808,O
CB1,2808,B-GENE-Y
receptors,2808,I-GENE-Y
decreases,2808,O
GABA,2808,B-CHEMICAL
release,2808,O
in,2808,O
the,2808,O
PVN,2808,O
",",2808,O
increasing,2808,O
in,2808,O
turn,2808,O
glutamatergic,2808,O
neurotransmission,2808,O
to,2808,O
activate,2808,O
oxytocinergic,2808,O
neurons,2808,O
mediating,2808,O
penile,2808,O
erection,2808,O
.,2808,O
Autoradiography,2809,O
studies,2809,O
with,2809,O
[,2809,B-CHEMICAL
(,2809,I-CHEMICAL
3,2809,I-CHEMICAL
),2809,I-CHEMICAL
H,2809,I-CHEMICAL
],2809,I-CHEMICAL
(,2809,I-CHEMICAL
-,2809,I-CHEMICAL
),2809,I-CHEMICAL
-CP,2809,I-CHEMICAL
"55,940",2809,I-CHEMICAL
show,2809,O
that,2809,O
chronic,2809,O
treatment,2809,O
with,2809,O
SR,2809,B-CHEMICAL
141716A,2809,I-CHEMICAL
for,2809,O
15,2809,O
days,2809,O
twice,2809,O
daily,2809,O
(,2809,O
1,2809,O
mg/kg,2809,O
i.p,2809,O
.,2809,O
),2809,O
significantly,2810,O
increases,2810,O
the,2810,O
density,2810,O
of,2810,O
CB1,2810,B-GENE-Y
receptors,2810,I-GENE-Y
in,2810,O
the,2810,O
PVN,2810,O
.,2810,O
This,2811,O
increase,2811,O
occurs,2811,O
concomitantly,2811,O
with,2811,O
an,2811,O
almost,2811,O
twofold,2811,O
increase,2811,O
in,2811,O
the,2811,O
pro-erectile,2811,O
effect,2811,O
of,2811,O
SR,2811,B-CHEMICAL
141716A,2811,I-CHEMICAL
injected,2811,O
into,2811,O
the,2811,O
PVN,2811,O
as,2811,O
compared,2811,O
with,2811,O
control,2811,O
rats,2811,O
.,2811,O
The,2812,O
present,2812,O
findings,2812,O
confirm,2812,O
that,2812,O
PVN,2812,O
CB1,2812,B-GENE-Y
receptors,2812,I-GENE-Y
",",2812,O
localized,2812,O
mainly,2812,O
in,2812,O
GABAergic,2812,O
synapses,2812,O
that,2812,O
control,2812,O
in,2812,O
an,2812,O
inhibitory,2812,O
fashion,2812,O
excitatory,2812,O
synapses,2812,O
",",2812,O
exert,2812,O
an,2812,O
inhibitory,2812,O
control,2812,O
on,2812,O
penile,2812,O
erection,2812,O
",",2812,O
demonstrating,2812,O
for,2812,O
the,2812,O
first,2812,O
time,2812,O
that,2812,O
chronic,2812,O
blockade,2812,O
of,2812,O
CB1,2812,B-GENE-Y
receptors,2812,I-GENE-Y
by,2812,O
SR,2812,B-CHEMICAL
141716A,2812,I-CHEMICAL
increases,2812,O
the,2812,O
density,2812,O
of,2812,O
these,2812,O
receptors,2812,O
in,2812,O
the,2812,O
PVN,2812,O
.,2812,O
This,2813,O
increase,2813,O
is,2813,O
related,2813,O
to,2813,O
an,2813,O
enhanced,2813,O
pro-erectile,2813,O
effect,2813,O
of,2813,O
SR,2813,B-CHEMICAL
141716A,2813,I-CHEMICAL
",",2813,O
which,2813,O
is,2813,O
still,2813,O
present,2813,O
3,2813,O
days,2813,O
after,2813,O
the,2813,O
end,2813,O
of,2813,O
the,2813,O
chronic,2813,O
treatment,2813,O
.,2813,O
Activation,2814,O
of,2814,O
human,2814,O
platelets,2814,O
by,2814,O
misfolded,2814,O
proteins,2814,O
.,2814,O
OBJECTIVE,2815,O
:,2815,O
Protein,2815,O
misfolding,2815,O
diseases,2815,O
result,2815,O
from,2815,O
the,2815,O
deposition,2815,O
of,2815,O
insoluble,2815,O
protein,2815,O
aggregates,2815,O
that,2815,O
often,2815,O
contain,2815,O
fibrils,2815,O
called,2815,O
amyloid,2815,B-GENE-Y
.,2815,O
Amyloids,2816,B-GENE-Y
are,2816,O
found,2816,O
in,2816,O
Alzheimer,2816,O
disease,2816,O
",",2816,O
atherosclerosis,2816,O
",",2816,O
diabetes,2816,O
mellitus,2816,O
",",2816,O
and,2816,O
systemic,2816,O
amyloidosis,2816,O
",",2816,O
which,2816,O
are,2816,O
diseases,2816,O
where,2816,O
platelet,2816,O
activation,2816,O
might,2816,O
be,2816,O
implicated,2816,O
.,2816,O
METHODS,2817,O
AND,2817,O
RESULTS,2817,O
:,2817,O
We,2817,O
induced,2817,O
amyloid,2817,B-GENE-Y
properties,2817,O
in,2817,O
6,2817,O
unrelated,2817,O
proteins,2817,O
and,2817,O
found,2817,O
that,2817,O
all,2817,O
induced,2817,O
platelet,2817,O
aggregation,2817,O
in,2817,O
contrast,2817,O
to,2817,O
fresh,2817,O
controls,2817,O
.,2817,O
Amyloid-induced,2818,B-GENE-Y
platelet,2818,O
aggregation,2818,O
was,2818,O
independent,2818,O
of,2818,O
thromboxane,2818,B-CHEMICAL
A2,2818,I-CHEMICAL
formation,2818,O
and,2818,O
ADP,2818,B-CHEMICAL
secretion,2818,O
but,2818,O
enhanced,2818,O
by,2818,O
feedback,2818,O
stimulation,2818,O
through,2818,O
these,2818,O
pathways,2818,O
.,2818,O
Treatments,2819,O
that,2819,O
raised,2819,O
cAMP,2819,B-CHEMICAL
(,2819,O
iloprost,2819,B-CHEMICAL
),2819,O
",",2819,O
sequestered,2819,O
Ca2+,2819,B-CHEMICAL
(,2819,O
BAPTA-AM,2819,B-CHEMICAL
),2819,O
or,2819,O
prevented,2819,O
amyloid-platelet,2819,B-GENE-Y
interaction,2819,O
(,2819,O
sRAGE,2819,O
",",2819,O
tissue-type,2819,B-GENE-Y
plasminogen,2819,I-GENE-Y
activator,2819,I-GENE-Y
[,2819,O
tPA,2819,B-GENE-Y
],2819,O
),2819,O
induced,2819,O
almost,2819,O
complete,2819,O
inhibition,2819,O
.,2819,O
Modulation,2820,O
of,2820,O
the,2820,O
function,2820,O
of,2820,O
CD36,2820,B-GENE-N
(,2820,O
CD36-/-,2820,O
mice,2820,O
),2820,O
",",2820,O
p38,2820,B-GENE-N
(,2820,O
MAPK,2820,B-GENE-N
),2820,O
(,2820,O
SB203580,2820,B-CHEMICAL
),2820,O
",",2820,O
COX-1,2820,B-GENE-N
(,2820,O
indomethacin,2820,B-CHEMICAL
),2820,O
",",2820,O
and,2820,O
glycoprotein,2820,B-GENE-N
Ib,2820,I-GENE-N
alpha,2820,I-GENE-N
(,2820,O
Nk-protease,2820,B-GENE-N
",",2820,O
6D1,2820,O
antibody,2820,O
),2820,O
induced,2820,O
approximately,2820,O
50,2820,O
%,2820,O
inhibition,2820,O
.,2820,O
Interference,2821,O
with,2821,O
fibrinogen,2821,B-GENE-N
binding,2821,O
(,2821,O
RGDS,2821,O
),2821,O
revealed,2821,O
a,2821,O
major,2821,O
contribution,2821,O
of,2821,O
alphaIIb,2821,B-GENE-N
beta3-independent,2821,O
aggregation,2821,O
(,2821,O
agglutination,2821,O
),2821,O
.,2821,O
CONCLUSIONS,2822,O
:,2822,O
Protein,2822,O
misfolding,2822,O
resulting,2822,O
in,2822,O
the,2822,O
appearance,2822,O
of,2822,O
amyloid,2822,B-GENE-N
induces,2822,O
platelet,2822,O
aggregation,2822,O
.,2822,O
Amyloid,2823,B-GENE-N
activates,2823,O
platelets,2823,O
through,2823,O
2,2823,O
pathways,2823,O
:,2823,O
one,2823,O
is,2823,O
through,2823,O
CD36,2823,B-GENE-N
",",2823,O
p38,2823,B-GENE-N
(,2823,O
MAPK,2823,B-GENE-N
),2823,O
",",2823,O
thromboxane,2823,B-CHEMICAL
A2-mediated,2823,O
induction,2823,O
of,2823,O
aggregation,2823,O
;,2823,O
the,2823,O
other,2823,O
is,2823,O
through,2823,O
glycoprotein,2823,B-GENE-N
Ib,2823,I-GENE-N
alpha-mediated,2823,O
aggregation,2823,O
and,2823,O
agglutination,2823,O
.,2823,O
The,2824,O
platelet,2824,O
stimulating,2824,O
properties,2824,O
of,2824,O
amyloid,2824,O
might,2824,O
explain,2824,O
the,2824,O
enhanced,2824,O
platelet,2824,O
activation,2824,O
observed,2824,O
in,2824,O
many,2824,O
diseases,2824,O
accompanied,2824,O
by,2824,O
the,2824,O
appearance,2824,O
of,2824,O
misfolded,2824,O
proteins,2824,O
with,2824,O
amyloid,2824,O
.,2824,O
RDH12,2825,B-GENE-Y
",",2825,O
a,2825,O
retinol,2825,B-CHEMICAL
dehydrogenase,2825,I-GENE-N
causing,2825,O
Leber,2825,O
's,2825,O
congenital,2825,O
amaurosis,2825,O
",",2825,O
is,2825,O
also,2825,O
involved,2825,O
in,2825,O
steroid,2825,O
metabolism,2825,O
.,2825,O
Three,2826,O
retinol,2826,B-CHEMICAL
dehydrogenases,2826,I-GENE-N
(,2826,O
RDHs,2826,B-GENE-N
),2826,O
were,2826,O
tested,2826,O
for,2826,O
steroid,2826,O
converting,2826,O
abilities,2826,O
:,2826,O
human,2826,B-GENE-N
and,2826,I-GENE-N
murine,2826,I-GENE-N
RDH,2826,I-GENE-N
12,2826,I-GENE-N
and,2826,O
human,2826,B-GENE-Y
RDH13,2826,I-GENE-Y
.,2826,O
RDH12,2827,B-GENE-Y
is,2827,O
involved,2827,O
in,2827,O
retinal,2827,O
degeneration,2827,O
in,2827,O
Leber,2827,O
's,2827,O
congenital,2827,O
amaurosis,2827,O
(,2827,O
LCA,2827,O
),2827,O
.,2827,O
We,2828,O
show,2828,O
that,2828,O
murine,2828,B-GENE-Y
Rdh12,2828,I-GENE-Y
and,2828,O
human,2828,B-GENE-Y
RDH13,2828,I-GENE-Y
do,2828,O
not,2828,O
reveal,2828,O
activity,2828,O
towards,2828,O
the,2828,O
checked,2828,O
steroids,2828,O
",",2828,O
but,2828,O
that,2828,O
human,2828,B-GENE-Y
type,2828,I-GENE-Y
12,2828,I-GENE-Y
RDH,2828,I-GENE-Y
reduces,2828,O
dihydrotestosterone,2828,O
to,2828,O
androstanediol,2828,B-CHEMICAL
",",2828,O
and,2828,O
is,2828,O
thus,2828,O
also,2828,O
involved,2828,O
in,2828,O
steroid,2828,O
metabolism,2828,O
.,2828,O
Furthermore,2829,O
",",2829,O
we,2829,O
analyzed,2829,O
both,2829,O
expression,2829,O
and,2829,O
subcellular,2829,O
localization,2829,O
of,2829,O
these,2829,O
enzymes,2829,O
.,2829,O
Alteration,2830,O
of,2830,O
gastric,2830,O
functions,2830,O
and,2830,O
candidate,2830,O
genes,2830,O
associated,2830,O
with,2830,O
weight,2830,O
reduction,2830,O
in,2830,O
response,2830,O
to,2830,O
sibutramine,2830,B-CHEMICAL
.,2830,O
BACKGROUND,2831,O
&,2831,O
AIMS,2831,O
:,2831,O
It,2831,O
is,2831,O
unclear,2831,O
whether,2831,O
weight,2831,O
loss,2831,O
with,2831,O
the,2831,O
noradrenergic,2831,O
(,2831,O
norepinephrine,2831,B-CHEMICAL
),2831,O
and,2831,O
serotonergic,2831,O
(,2831,O
5-hydroxytryptamine,2831,B-CHEMICAL
),2831,O
reuptake,2831,O
inhibitor,2831,O
",",2831,O
sibutramine,2831,B-CHEMICAL
",",2831,O
is,2831,O
associated,2831,O
with,2831,O
altered,2831,O
stomach,2831,O
functions,2831,O
and,2831,O
whether,2831,O
genetics,2831,O
influence,2831,O
treatment,2831,O
response,2831,O
.,2831,O
METHODS,2832,O
:,2832,O
Forty-eight,2832,O
overweight,2832,O
and,2832,O
obese,2832,O
but,2832,O
otherwise,2832,O
healthy,2832,O
participants,2832,O
were,2832,O
randomized,2832,O
to,2832,O
placebo,2832,O
or,2832,O
sibutramine,2832,B-CHEMICAL
(,2832,O
15,2832,O
mg/day,2832,O
for,2832,O
12,2832,O
weeks,2832,O
),2832,O
.,2832,O
At,2833,O
baseline,2833,O
and,2833,O
posttreatment,2833,O
we,2833,O
measured,2833,O
the,2833,O
following,2833,O
:,2833,O
gastric,2833,O
emptying,2833,O
for,2833,O
solids,2833,O
and,2833,O
liquids,2833,O
by,2833,O
scintigraphy,2833,O
",",2833,O
gastric,2833,O
volumes,2833,O
by,2833,O
single-photon,2833,O
emission,2833,O
computed,2833,O
tomography,2833,O
",",2833,O
maximum,2833,O
tolerated,2833,O
volume,2833,O
and,2833,O
30-minute,2833,O
postnutrient,2833,O
challenge,2833,O
symptoms,2833,O
",",2833,O
and,2833,O
selected,2833,O
gastrointestinal,2833,O
hormones,2833,O
.,2833,O
All,2834,O
participants,2834,O
received,2834,O
structured,2834,O
behavior,2834,O
therapy,2834,O
for,2834,O
weight,2834,O
management,2834,O
.,2834,O
The,2835,O
influence,2835,O
of,2835,O
candidate,2835,O
gene,2835,O
polymorphisms,2835,O
involved,2835,O
in,2835,O
norepinephrine,2835,B-CHEMICAL
and,2835,O
5-hydroxytryptamine,2835,B-CHEMICAL
or,2835,O
receptor,2835,O
function,2835,O
(,2835,O
phenylethanolamine,2835,B-CHEMICAL
N-methyltransferase,2835,B-CHEMICAL
",",2835,O
guanine,2835,B-GENE-Y
nucleotide,2835,I-GENE-Y
binding,2835,I-GENE-Y
protein,2835,I-GENE-Y
beta,2835,I-GENE-Y
polypeptide,2835,I-GENE-Y
3,2835,I-GENE-Y
",",2835,O
alpha2A,2835,B-GENE-Y
adrenoreceptor,2835,I-GENE-Y
",",2835,O
and,2835,O
solute,2835,B-GENE-Y
carrier,2835,I-GENE-Y
family,2835,I-GENE-Y
6,2835,I-GENE-Y
[,2835,I-GENE-Y
neurotransmitter,2835,I-GENE-Y
transporter,2835,I-GENE-Y
",",2835,I-GENE-Y
serotonin,2835,B-CHEMICAL
],2835,I-GENE-Y
member,2835,I-GENE-Y
4,2835,I-GENE-Y
[,2835,O
homo,2835,O
sapiens,2835,O
],2835,O
[,2835,O
SLC6A4,2835,B-GENE-Y
],2835,O
),2835,O
on,2835,O
weight,2835,O
loss,2835,O
and,2835,O
gastric,2835,O
functions,2835,O
was,2835,O
evaluated,2835,O
.,2835,O
RESULTS,2836,O
:,2836,O
The,2836,O
overall,2836,O
average,2836,O
weight,2836,O
loss,2836,O
posttreatment,2836,O
was,2836,O
5.4,2836,O
+/-,2836,O
0.8,2836,O
(,2836,O
SEM,2836,O
),2836,O
kg,2836,O
with,2836,O
sibutramine,2836,B-CHEMICAL
and,2836,O
0.9,2836,O
+/-,2836,O
0.9,2836,O
kg,2836,O
with,2836,O
placebo,2836,O
(,2836,O
P,2836,O
<,2836,O
.001,2836,O
),2836,O
.,2836,O
The,2837,O
sibutramine,2837,B-CHEMICAL
group,2837,O
showed,2837,O
significant,2837,O
retardation,2837,O
in,2837,O
gastric,2837,O
emptying,2837,O
of,2837,O
solids,2837,O
(,2837,O
P,2837,O
=,2837,O
.03,2837,O
),2837,O
",",2837,O
reduced,2837,O
maximum,2837,O
tolerated,2837,O
volume,2837,O
(,2837,O
P,2837,O
=,2837,O
.03,2837,O
),2837,O
",",2837,O
and,2837,O
increased,2837,O
postprandial,2837,O
peptide,2837,B-GENE-Y
YY,2837,I-GENE-Y
compared,2837,O
with,2837,O
the,2837,O
placebo,2837,O
group,2837,O
.,2837,O
Obese,2838,O
females,2838,O
showed,2838,O
greater,2838,O
effects,2838,O
of,2838,O
sibutramine,2838,B-CHEMICAL
on,2838,O
weight,2838,O
loss,2838,O
and,2838,O
gastric,2838,O
emptying,2838,O
of,2838,O
solids,2838,O
and,2838,O
liquids,2838,O
.,2838,O
Gastric,2839,O
volumes,2839,O
and,2839,O
postchallenge,2839,O
symptoms,2839,O
were,2839,O
not,2839,O
significantly,2839,O
different,2839,O
in,2839,O
the,2839,O
2,2839,O
treatment,2839,O
groups,2839,O
.,2839,O
The,2840,O
LS/SS,2840,O
genotype,2840,O
of,2840,O
the,2840,O
promoter,2840,O
for,2840,O
SLC6A4,2840,B-GENE-Y
was,2840,O
associated,2840,O
with,2840,O
enhanced,2840,O
weight,2840,O
loss,2840,O
with,2840,O
sibutramine,2840,B-CHEMICAL
.,2840,O
CONCLUSIONS,2841,O
:,2841,O
Weight,2841,O
reduction,2841,O
with,2841,O
sibutramine,2841,B-CHEMICAL
is,2841,O
associated,2841,O
with,2841,O
altered,2841,O
gastric,2841,O
functions,2841,O
and,2841,O
increased,2841,O
peptide,2841,B-GENE-Y
YY,2841,I-GENE-Y
and,2841,O
is,2841,O
significantly,2841,O
associated,2841,O
with,2841,O
SLC6A4,2841,B-GENE-Y
genotype,2841,O
.,2841,O
The,2842,O
role,2842,O
of,2842,O
genetic,2842,O
variation,2842,O
in,2842,O
SLC6A4,2842,B-GENE-Y
on,2842,O
weight,2842,O
loss,2842,O
in,2842,O
response,2842,O
to,2842,O
sibutramine,2842,B-CHEMICAL
deserves,2842,O
further,2842,O
study,2842,O
.,2842,O
Multiple,2843,O
rat,2843,B-GENE-Y
brain,2843,I-GENE-Y
calpastatin,2843,I-GENE-Y
forms,2843,O
are,2843,O
produced,2843,O
by,2843,O
distinct,2843,O
starting,2843,O
points,2843,O
and,2843,O
alternative,2843,O
splicing,2843,O
of,2843,O
the,2843,O
N-terminal,2843,B-CHEMICAL
exons,2843,O
.,2843,O
5'-RACE,2844,O
was,2844,O
performed,2844,O
on,2844,O
rat,2844,B-GENE-Y
brain,2844,I-GENE-Y
calpastatin,2844,I-GENE-Y
mRNA,2844,O
and,2844,O
two,2844,O
new,2844,O
translation,2844,O
initiation,2844,O
ATG,2844,O
's,2844,O
were,2844,O
found,2844,O
.,2844,O
The,2845,O
first,2845,O
one,2845,O
is,2845,O
upstream,2845,O
of,2845,O
the,2845,O
previously,2845,O
designed,2845,O
initiation,2845,O
translation,2845,O
site,2845,O
localized,2845,O
in,2845,O
the,2845,O
rat,2845,B-GENE-N
calpastatin,2845,I-GENE-N
L-domain,2845,I-GENE-N
.,2845,O
The,2846,O
deduced,2846,O
protein,2846,O
sequence,2846,O
of,2846,O
this,2846,O
region,2846,O
is,2846,O
highly,2846,O
homologous,2846,O
to,2846,O
the,2846,O
XL-domain,2846,B-GENE-N
of,2846,O
calpastatin,2846,B-GENE-N
type,2846,I-GENE-N
I,2846,I-GENE-N
in,2846,O
other,2846,O
species,2846,O
.,2846,O
The,2847,O
other,2847,O
ATG,2847,O
has,2847,O
not,2847,O
previously,2847,O
been,2847,O
reported,2847,O
and,2847,O
is,2847,O
localized,2847,O
in,2847,O
exon,2847,O
8,2847,O
",",2847,O
thus,2847,O
originating,2847,O
a,2847,O
calpastatin,2847,B-GENE-Y
isoform,2847,O
constituted,2847,O
only,2847,O
by,2847,O
four,2847,O
repetitive,2847,O
inhibitory,2847,O
units,2847,O
without,2847,O
the,2847,O
XL-L-domains,2847,B-GENE-N
.,2847,O
Transcripts,2848,O
from,2848,O
the,2848,O
rat,2848,B-GENE-Y
brain,2848,I-GENE-Y
calpastatin,2848,I-GENE-Y
gene,2848,O
are,2848,O
also,2848,O
subjected,2848,O
to,2848,O
multiple,2848,O
splicing,2848,O
events,2848,O
involving,2848,O
exons,2848,O
4,2848,O
",",2848,O
6,2848,O
",",2848,O
8,2848,O
in,2848,O
different,2848,O
combinations,2848,O
.,2848,O
A,2849,O
series,2849,O
of,2849,O
recombinant,2849,O
calpastatin,2849,B-GENE-Y
forms,2849,O
was,2849,O
produced,2849,O
that,2849,O
differed,2849,O
in,2849,O
the,2849,O
exons,2849,O
present,2849,O
in,2849,O
the,2849,O
L-domain,2849,B-GENE-N
",",2849,O
and,2849,O
all,2849,O
the,2849,O
variants,2849,O
showed,2849,O
comparable,2849,O
inhibitory,2849,O
efficiency,2849,O
against,2849,O
calpain,2849,B-GENE-N
.,2849,O
It,2850,O
was,2850,O
concluded,2850,O
that,2850,O
the,2850,O
presence,2850,O
of,2850,O
the,2850,O
XL-domain,2850,B-GENE-N
in,2850,O
these,2850,O
isoforms,2850,O
is,2850,O
not,2850,O
relevant,2850,O
for,2850,O
the,2850,O
formation,2850,O
of,2850,O
the,2850,O
calpain/calpastatin,2850,B-GENE-N
complex,2850,O
in,2850,O
the,2850,O
absence,2850,O
of,2850,O
calcium,2850,B-CHEMICAL
",",2850,O
that,2850,O
is,2850,O
the,2850,O
interaction,2850,O
of,2850,O
calpastatin,2850,B-GENE-Y
with,2850,O
inactive,2850,O
calpain,2850,B-GENE-N
.,2850,O
Using,2851,O
exon-specific,2851,O
antisera,2851,O
",",2851,O
specific,2851,O
calpastatin,2851,B-GENE-Y
protein,2851,O
isoforms,2851,O
containing,2851,O
the,2851,O
XL-domain,2851,B-GENE-N
have,2851,O
been,2851,O
detected,2851,O
in,2851,O
rat,2851,O
brain,2851,O
homogenates,2851,O
.,2851,O
An,2852,O
investigation,2852,O
of,2852,O
the,2852,O
absolute,2852,O
configuration,2852,O
of,2852,O
the,2852,O
potent,2852,O
histamine,2852,B-GENE-Y
H3,2852,I-GENE-Y
receptor,2852,I-GENE-Y
antagonist,2852,O
GT-2331,2852,B-CHEMICAL
using,2852,O
vibrational,2852,O
circular,2852,O
dichroism,2852,O
.,2852,O
GT-2331,2853,B-CHEMICAL
[,2853,O
(,2853,O
+,2853,O
),2853,O
-1,2853,O
],2853,O
is,2853,O
one,2853,O
of,2853,O
the,2853,O
most,2853,O
potent,2853,O
members,2853,O
of,2853,O
a,2853,O
class,2853,O
of,2853,O
chiral,2853,O
drug,2853,O
substances,2853,O
used,2853,O
to,2853,O
regulate,2853,O
the,2853,O
synthesis,2853,O
and,2853,O
release,2853,O
of,2853,O
histamine,2853,B-CHEMICAL
by,2853,O
the,2853,O
histamine,2853,B-GENE-Y
H3,2853,I-GENE-Y
receptor,2853,I-GENE-Y
",",2853,O
and,2853,O
as,2853,O
such,2853,O
",",2853,O
is,2853,O
an,2853,O
important,2853,O
biomarker,2853,O
for,2853,O
pharmaceutical,2853,O
companies,2853,O
conducting,2853,O
research,2853,O
in,2853,O
this,2853,O
field,2853,O
.,2853,O
In,2854,O
addition,2854,O
to,2854,O
overall,2854,O
structural,2854,O
features,2854,O
",",2854,O
the,2854,O
bioactivity,2854,O
of,2854,O
this,2854,O
molecule,2854,O
has,2854,O
also,2854,O
been,2854,O
found,2854,O
to,2854,O
be,2854,O
highly,2854,O
dependent,2854,O
on,2854,O
absolute,2854,O
stereochemistry,2854,O
",",2854,O
making,2854,O
the,2854,O
reliable,2854,O
assignment,2854,O
of,2854,O
this,2854,O
property,2854,O
a,2854,O
necessity,2854,O
.,2854,O
X-ray,2855,O
diffraction,2855,O
studies,2855,O
have,2855,O
provided,2855,O
conflicting,2855,O
data,2855,O
",",2855,O
leaving,2855,O
its,2855,O
three-dimensional,2855,O
structure,2855,O
uncertain,2855,O
.,2855,O
In,2856,O
view,2856,O
of,2856,O
this,2856,O
",",2856,O
its,2856,O
absolute,2856,O
configuration,2856,O
was,2856,O
investigated,2856,O
by,2856,O
vibrational,2856,O
circular,2856,O
dichroism,2856,O
.,2856,O
Results,2857,O
from,2857,O
this,2857,O
study,2857,O
provided,2857,O
independent,2857,O
assignment,2857,O
of,2857,O
this,2857,O
important,2857,O
molecule,2857,O
as,2857,O
the,2857,O
(,2857,O
"1S,2S",2857,O
),2857,O
-enantiomer,2857,O
.,2857,O
Allosteric,2858,O
interaction,2858,O
of,2858,O
the,2858,O
neuromuscular,2858,O
blockers,2858,O
vecuronium,2858,B-CHEMICAL
and,2858,O
pancuronium,2858,B-CHEMICAL
with,2858,O
recombinant,2858,O
human,2858,B-GENE-Y
muscarinic,2858,I-GENE-Y
M2,2858,I-GENE-Y
receptors,2858,I-GENE-Y
.,2858,O
Neuromuscular,2859,O
blocking,2859,O
drugs,2859,O
produce,2859,O
muscle,2859,O
weakness,2859,O
by,2859,O
interaction,2859,O
with,2859,O
nicotinic-acetylcholine,2859,B-GENE-N
receptors,2859,I-GENE-N
.,2859,O
Cardiovascular,2860,O
side,2860,O
effects,2860,O
have,2860,O
been,2860,O
reported,2860,O
.,2860,O
In,2861,O
this,2861,O
study,2861,O
the,2861,O
neuromuscular,2861,O
blocking,2861,O
drug,2861,O
vecuronium,2861,B-CHEMICAL
and,2861,O
the,2861,O
controls,2861,O
gallamine,2861,B-CHEMICAL
and,2861,O
pancuronium,2861,B-CHEMICAL
slowed,2861,O
the,2861,O
rate,2861,O
of,2861,O
atropine,2861,B-CHEMICAL
induced,2861,O
[,2861,B-CHEMICAL
(,2861,I-CHEMICAL
3,2861,I-CHEMICAL
),2861,I-CHEMICAL
H,2861,I-CHEMICAL
],2861,I-CHEMICAL
N-methylscopolamine,2861,I-CHEMICAL
dissociation,2861,O
from,2861,O
Chinese,2861,O
hamster,2861,O
ovary,2861,O
cells,2861,O
expressing,2861,O
recombinant,2861,O
human,2861,B-GENE-Y
muscarinic,2861,I-GENE-Y
M2,2861,I-GENE-Y
receptors,2861,I-GENE-Y
K,2861,O
(,2861,O
off,2861,O
),2861,O
values,2861,O
min,2861,O
(,2861,O
-1,2861,O
),2861,O
;,2861,O
vecuronium,2861,B-CHEMICAL
(,2861,O
125,2861,O
nM,2861,O
),2861,O
",",2861,O
atropine,2861,B-CHEMICAL
0.45+/-0.07+blocker,2861,O
0.04+/-0.02,2861,O
;,2861,O
gallamine,2861,B-CHEMICAL
(,2861,O
21,2861,O
nM,2861,O
),2861,O
",",2861,O
atropine,2861,B-CHEMICAL
0.42+/-0.05+blocker,2861,O
0.15+/-0.04,2861,O
;,2861,O
pancuronium,2861,B-CHEMICAL
(,2861,O
21,2861,O
nM,2861,O
),2861,O
",",2861,O
atropine,2861,B-CHEMICAL
0.36+/-0.03+blocker,2861,O
0.03+/-0.01,2861,O
),2861,O
.,2861,O
These,2862,O
data,2862,O
indicate,2862,O
that,2862,O
vecuronium,2862,B-CHEMICAL
",",2862,O
gallamine,2862,B-CHEMICAL
and,2862,O
pancuronium,2862,B-CHEMICAL
interact,2862,O
with,2862,O
an,2862,O
allosteric,2862,O
site,2862,O
on,2862,O
the,2862,O
muscarinic,2862,B-GENE-Y
M2,2862,I-GENE-Y
receptor,2862,I-GENE-Y
(,2862,O
located,2862,O
on,2862,O
the,2862,O
heart,2862,O
),2862,O
and,2862,O
this,2862,O
may,2862,O
explain,2862,O
some,2862,O
of,2862,O
their,2862,O
cardiac,2862,O
side,2862,O
effects,2862,O
.,2862,O
Hydrogen,2863,B-CHEMICAL
peroxide-mediated,2863,O
oxidative,2863,O
stress,2863,O
disrupts,2863,O
calcium,2863,B-CHEMICAL
binding,2863,O
on,2863,O
calmodulin,2863,B-GENE-Y
:,2863,O
more,2863,O
evidence,2863,O
for,2863,O
oxidative,2863,O
stress,2863,O
in,2863,O
vitiligo,2863,O
.,2863,O
Patients,2864,O
with,2864,O
acute,2864,O
vitiligo,2864,O
have,2864,O
low,2864,O
epidermal,2864,O
catalase,2864,B-GENE-Y
expression/activities,2864,O
and,2864,O
accumulate,2864,O
10,2864,O
(,2864,O
-3,2864,O
),2864,O
M,2864,O
H,2864,B-CHEMICAL
(,2864,I-CHEMICAL
2,2864,I-CHEMICAL
),2864,I-CHEMICAL
O,2864,I-CHEMICAL
(,2864,I-CHEMICAL
2,2864,I-CHEMICAL
),2864,I-CHEMICAL
.,2864,O
One,2865,O
consequence,2865,O
of,2865,O
this,2865,O
severe,2865,O
oxidative,2865,O
stress,2865,O
is,2865,O
an,2865,O
altered,2865,O
calcium,2865,B-CHEMICAL
homeostasis,2865,O
in,2865,O
epidermal,2865,O
keratinocytes,2865,O
and,2865,O
melanocytes,2865,O
.,2865,O
Here,2866,O
",",2866,O
we,2866,O
show,2866,O
decreased,2866,O
epidermal,2866,O
calmodulin,2866,B-GENE-Y
expression,2866,O
in,2866,O
acute,2866,O
vitiligo,2866,O
.,2866,O
Since,2867,O
10,2867,O
(,2867,O
-3,2867,O
),2867,O
M,2867,O
H,2867,B-CHEMICAL
(,2867,I-CHEMICAL
2,2867,I-CHEMICAL
),2867,I-CHEMICAL
O,2867,I-CHEMICAL
(,2867,I-CHEMICAL
2,2867,I-CHEMICAL
),2867,I-CHEMICAL
oxidises,2867,O
methionine,2867,B-CHEMICAL
and,2867,O
tryptophan,2867,B-CHEMICAL
residues,2867,O
in,2867,O
proteins,2867,O
",",2867,O
we,2867,O
examined,2867,O
calcium,2867,B-CHEMICAL
binding,2867,O
to,2867,O
calmodulin,2867,B-GENE-Y
in,2867,O
the,2867,O
presence,2867,O
and,2867,O
absence,2867,O
of,2867,O
H,2867,B-CHEMICAL
(,2867,I-CHEMICAL
2,2867,I-CHEMICAL
),2867,I-CHEMICAL
O,2867,I-CHEMICAL
(,2867,I-CHEMICAL
2,2867,I-CHEMICAL
),2867,I-CHEMICAL
utilising,2867,O
(,2867,O
45,2867,O
),2867,O
calcium,2867,B-CHEMICAL
.,2867,O
The,2868,O
results,2868,O
showed,2868,O
that,2868,O
all,2868,O
four,2868,O
calcium,2868,B-CHEMICAL
atoms,2868,O
exchanged,2868,O
per,2868,O
molecule,2868,O
of,2868,O
calmodulin,2868,B-GENE-Y
.,2868,O
Since,2869,O
oxidised,2869,O
calmodulin,2869,B-GENE-Y
looses,2869,O
its,2869,O
ability,2869,O
to,2869,O
activate,2869,O
calcium,2869,B-GENE-N
ATPase,2869,I-GENE-N
",",2869,O
enzyme,2869,O
activities,2869,O
were,2869,O
followed,2869,O
in,2869,O
full,2869,O
skin,2869,O
biopsies,2869,O
from,2869,O
lesional,2869,O
skin,2869,O
of,2869,O
patients,2869,O
with,2869,O
acute,2869,O
vitiligo,2869,O
(,2869,O
n=6,2869,O
),2869,O
and,2869,O
healthy,2869,O
controls,2869,O
(,2869,O
n=6,2869,O
),2869,O
.,2869,O
The,2870,O
results,2870,O
yielded,2870,O
a,2870,O
4-fold,2870,O
decrease,2870,O
of,2870,O
ATPase,2870,O
activities,2870,O
in,2870,O
the,2870,O
patients,2870,O
.,2870,O
Computer,2871,O
simulation,2871,O
of,2871,O
native,2871,O
and,2871,O
oxidised,2871,O
calmodulin,2871,B-GENE-Y
confirmed,2871,O
the,2871,O
loss,2871,O
of,2871,O
all,2871,O
four,2871,O
calcium,2871,B-CHEMICAL
ions,2871,O
from,2871,O
their,2871,O
specific,2871,O
EF-hand,2871,B-GENE-N
domains,2871,I-GENE-N
.,2871,O
Taken,2872,O
together,2872,O
H,2872,B-CHEMICAL
(,2872,I-CHEMICAL
2,2872,I-CHEMICAL
),2872,I-CHEMICAL
O,2872,I-CHEMICAL
(,2872,I-CHEMICAL
2,2872,I-CHEMICAL
),2872,I-CHEMICAL
-mediated,2872,O
oxidation,2872,O
affects,2872,O
calcium,2872,B-CHEMICAL
binding,2872,O
in,2872,O
calmodulin,2872,B-GENE-Y
leading,2872,O
to,2872,O
perturbed,2872,O
calcium,2872,B-CHEMICAL
homeostasis,2872,O
and,2872,O
perturbed,2872,O
l-phenylalanine-uptake,2872,B-CHEMICAL
in,2872,O
the,2872,O
epidermis,2872,O
of,2872,O
acute,2872,O
vitiligo,2872,O
.,2872,O
The,2873,O
genetic,2873,O
interaction,2873,O
between,2873,O
VKORC1,2873,B-GENE-Y
c1173t,2873,B-GENE-N
and,2873,O
calumenin,2873,B-GENE-Y
a29809g,2873,B-GENE-N
modulates,2873,O
the,2873,O
anticoagulant,2873,O
response,2873,O
of,2873,O
acenocoumarol,2873,O
.,2873,O
BACKGROUND,2874,O
:,2874,O
The,2874,O
efficacy,2874,O
of,2874,O
oral,2874,O
anticoagulant,2874,O
therapy,2874,O
is,2874,O
largely,2874,O
conditioned,2874,O
by,2874,O
both,2874,O
environmental,2874,O
and,2874,O
genetic,2874,O
factors,2874,O
.,2874,O
OBJECTIVES,2875,O
:,2875,O
To,2875,O
attempt,2875,O
to,2875,O
define,2875,O
the,2875,O
genetic,2875,O
profile,2875,O
involved,2875,O
in,2875,O
the,2875,O
response,2875,O
to,2875,O
this,2875,O
treatment,2875,O
.,2875,O
PATIENTS,2876,O
AND,2876,O
METHODS,2876,O
:,2876,O
We,2876,O
selected,2876,O
100,2876,O
men,2876,O
younger,2876,O
than,2876,O
75,2876,O
years,2876,O
",",2876,O
with,2876,O
non-valvular,2876,O
atrial,2876,O
fibrillation,2876,O
",",2876,O
who,2876,O
started,2876,O
anticoagulation,2876,O
with,2876,O
acenocoumarol,2876,O
following,2876,O
the,2876,O
same,2876,O
protocol,2876,O
:,2876,O
3,2876,O
mg,2876,O
for,2876,O
three,2876,O
consecutive,2876,O
days,2876,O
.,2876,O
Then,2877,O
",",2877,O
doses,2877,O
were,2877,O
individually,2877,O
adjusted,2877,O
to,2877,O
achieve,2877,O
a,2877,O
steady,2877,O
International,2877,O
Normalized,2877,O
Ratio,2877,O
(,2877,O
INR,2877,O
),2877,O
.,2877,O
The,2878,O
basal,2878,O
plasma,2878,O
level,2878,O
and,2878,O
the,2878,O
level,2878,O
after,2878,O
3,2878,O
days,2878,O
were,2878,O
obtained,2878,O
",",2878,O
and,2878,O
the,2878,O
INR,2878,O
was,2878,O
determined,2878,O
.,2878,O
We,2879,O
studied,2879,O
five,2879,O
functional,2879,O
polymorphisms,2879,O
:,2879,O
FVII,2879,B-GENE-Y
-323,2879,O
Del/Ins,2879,O
",",2879,O
CYP2C,2879,B-GENE-Y
*,2879,I-GENE-Y
9,2879,I-GENE-Y
",",2879,O
VKORC1,2879,B-GENE-Y
c1173t,2879,B-GENE-N
",",2879,O
calumenin,2879,B-GENE-Y
(,2879,O
CALU,2879,B-GENE-Y
),2879,O
R4Q,2879,B-GENE-N
and,2879,O
CALU,2879,B-GENE-Y
a29809g,2879,B-GENE-N
.,2879,O
The,2880,O
dose,2880,O
required,2880,O
for,2880,O
a,2880,O
steady,2880,O
INR,2880,O
was,2880,O
also,2880,O
recorded,2880,O
.,2880,O
RESULTS,2881,O
:,2881,O
Only,2881,O
the,2881,O
VKORC1,2881,B-GENE-Y
genotype,2881,O
had,2881,O
significant,2881,O
impact,2881,O
on,2881,O
the,2881,O
efficacy,2881,O
of,2881,O
therapy,2881,O
.,2881,O
Carriers,2882,O
of,2882,O
the,2882,O
1173t,2882,O
allele,2882,O
were,2882,O
significantly,2882,O
more,2882,O
sensitive,2882,O
to,2882,O
therapy,2882,O
for,2882,O
3,2882,O
days,2882,O
[,2882,O
INR,2882,O
2.07,2882,O
(,2882,O
1.59-2.87,2882,O
),2882,O
vs.,2882,O
1.74,2882,O
(,2882,O
1.30-2.09,2882,O
),2882,O
;,2882,O
P,2882,O
=,2882,O
0.015,2882,O
],2882,O
and,2882,O
they,2882,O
needed,2882,O
lower,2882,O
acenocoumarol,2882,O
doses,2882,O
to,2882,O
stabilize,2882,O
their,2882,O
INR,2882,O
(,2882,O
15.8,2882,O
+/-,2882,O
5.6,2882,O
vs.,2882,O
19.5,2882,O
+/-,2882,O
6.0,2882,O
mg,2882,O
week,2882,O
(,2882,O
-1,2882,O
),2882,O
;,2882,O
P,2882,O
=,2882,O
0.004,2882,O
),2882,O
.,2882,O
Its,2883,O
effect,2883,O
was,2883,O
exacerbated,2883,O
by,2883,O
combination,2883,O
with,2883,O
the,2883,O
CALU,2883,B-GENE-Y
a29809g,2883,B-GENE-N
polymorphism,2883,O
.,2883,O
Carriers,2884,O
of,2884,O
both,2884,O
variants,2884,O
(,2884,O
27,2884,O
%,2884,O
of,2884,O
the,2884,O
sample,2884,O
),2884,O
achieved,2884,O
the,2884,O
highest,2884,O
INR,2884,O
[,2884,O
2.26,2884,O
(,2884,O
1.70-3.32,2884,O
),2884,O
],2884,O
and,2884,O
required,2884,O
the,2884,O
lowest,2884,O
dose,2884,O
(,2884,O
14.1,2884,O
+/-,2884,O
5.1,2884,O
mg,2884,O
week,2884,O
(,2884,O
-1,2884,O
),2884,O
),2884,O
.,2884,O
This,2885,O
genetic,2885,O
profile,2885,O
was,2885,O
particularly,2885,O
relevant,2885,O
in,2885,O
patients,2885,O
with,2885,O
INR,2885,O
>,2885,O
or=,2885,O
3.5,2885,O
at,2885,O
the,2885,O
start,2885,O
of,2885,O
therapy,2885,O
(,2885,O
P,2885,O
=,2885,O
0.005,2885,O
;,2885,O
odds,2885,O
ratio,2885,O
=,2885,O
6.67,2885,O
",",2885,O
95,2885,O
%,2885,O
confidence,2885,O
interval,2885,O
=,2885,O
1.32-37.43,2885,O
),2885,O
.,2885,O
CONCLUSIONS,2886,O
:,2886,O
Our,2886,O
results,2886,O
suggest,2886,O
that,2886,O
CALU,2886,B-GENE-Y
a29809g,2886,B-GENE-N
might,2886,O
be,2886,O
a,2886,O
new,2886,O
genetic,2886,O
factor,2886,O
involved,2886,O
in,2886,O
the,2886,O
pharmacogenetics,2886,O
of,2886,O
anticoagulant,2886,O
therapy,2886,O
",",2886,O
and,2886,O
confirm,2886,O
that,2886,O
specific,2886,O
genetic,2886,O
profiles,2886,O
defined,2886,O
by,2886,O
different,2886,O
polymorphisms,2886,O
will,2886,O
determine,2886,O
the,2886,O
initial,2886,O
response,2886,O
and,2886,O
dose,2886,O
required,2886,O
to,2886,O
achieve,2886,O
a,2886,O
stable,2886,O
and,2886,O
safe,2886,O
INR,2886,O
.,2886,O
Characterization,2887,O
of,2887,O
the,2887,O
nitrosyl,2887,B-CHEMICAL
adduct,2887,O
of,2887,O
substrate-bound,2887,O
mouse,2887,B-GENE-Y
cysteine,2887,I-GENE-Y
dioxygenase,2887,I-GENE-Y
by,2887,O
electron,2887,O
paramagnetic,2887,O
resonance,2887,O
:,2887,O
electronic,2887,O
structure,2887,O
of,2887,O
the,2887,O
active,2887,O
site,2887,O
and,2887,O
mechanistic,2887,O
implications,2887,O
.,2887,O
Mammalian,2888,B-GENE-Y
cysteine,2888,I-GENE-Y
dioxygenase,2888,I-GENE-Y
(,2888,O
CDO,2888,B-GENE-Y
),2888,O
is,2888,O
a,2888,O
non-heme,2888,O
iron,2888,B-CHEMICAL
metalloenzyme,2888,O
that,2888,O
catalyzes,2888,O
the,2888,O
first,2888,O
committed,2888,O
step,2888,O
in,2888,O
oxidative,2888,O
cysteine,2888,B-CHEMICAL
catabolism,2888,O
.,2888,O
The,2889,O
active,2889,O
site,2889,O
coordination,2889,O
of,2889,O
CDO,2889,B-GENE-Y
comprises,2889,O
a,2889,O
mononuclear,2889,O
iron,2889,B-CHEMICAL
ligated,2889,O
by,2889,O
the,2889,O
Nepsilon,2889,O
atoms,2889,O
of,2889,O
three,2889,O
protein-derived,2889,O
histidines,2889,B-CHEMICAL
",",2889,O
thus,2889,O
representing,2889,O
a,2889,O
new,2889,O
variant,2889,O
on,2889,O
the,2889,O
2-histidine-1-carboxylate,2889,B-GENE-N
(,2889,I-GENE-N
2H1C,2889,I-GENE-N
),2889,I-GENE-N
facial,2889,I-GENE-N
triad,2889,I-GENE-N
motif,2889,I-GENE-N
.,2889,O
Nitric,2890,B-CHEMICAL
oxide,2890,I-CHEMICAL
was,2890,O
used,2890,O
as,2890,O
a,2890,O
spectroscopic,2890,O
probe,2890,O
in,2890,O
investigating,2890,O
the,2890,O
order,2890,O
of,2890,O
substrate-O2,2890,O
binding,2890,O
by,2890,O
EPR,2890,O
spectroscopy,2890,O
.,2890,O
In,2891,O
these,2891,O
experiments,2891,O
",",2891,O
CDO,2891,B-GENE-Y
exhibits,2891,O
an,2891,O
ordered,2891,O
binding,2891,O
of,2891,O
l-cysteine,2891,B-CHEMICAL
prior,2891,O
to,2891,O
NO,2891,B-CHEMICAL
(,2891,O
and,2891,O
presumably,2891,O
O2,2891,B-CHEMICAL
),2891,O
similar,2891,O
to,2891,O
that,2891,O
observed,2891,O
for,2891,O
the,2891,O
2H1C,2891,B-GENE-N
class,2891,I-GENE-N
of,2891,I-GENE-N
non-heme,2891,I-GENE-N
iron,2891,I-GENE-N
enzymes,2891,I-GENE-N
.,2891,O
Moreover,2892,O
",",2892,O
the,2892,O
CDO,2892,B-GENE-Y
active,2892,O
site,2892,O
is,2892,O
essentially,2892,O
unreactive,2892,O
toward,2892,O
NO,2892,B-CHEMICAL
in,2892,O
the,2892,O
absence,2892,O
of,2892,O
substrate,2892,O
",",2892,O
suggesting,2892,O
an,2892,O
obligate,2892,O
ordered,2892,O
binding,2892,O
of,2892,O
l-cysteine,2892,B-CHEMICAL
prior,2892,O
to,2892,O
NO,2892,B-CHEMICAL
.,2892,O
Typically,2893,O
",",2893,O
addition,2893,O
of,2893,O
NO,2893,B-CHEMICAL
to,2893,O
a,2893,O
mononuclear,2893,O
non-heme,2893,O
iron,2893,B-CHEMICAL
center,2893,O
results,2893,O
in,2893,O
the,2893,O
formation,2893,O
of,2893,O
an,2893,O
{,2893,O
FeNO,2893,B-CHEMICAL
},2893,O
7,2893,O
(,2893,O
S,2893,O
=,2893,O
3/2,2893,O
),2893,O
species,2893,O
characterized,2893,O
by,2893,O
an,2893,O
axial,2893,O
EPR,2893,O
spectrum,2893,O
with,2893,O
gx,2893,O
",",2893,O
gy,2893,O
",",2893,O
and,2893,O
gz,2893,O
values,2893,O
of,2893,O
approximately,2893,O
4,2893,O
",",2893,O
approximately,2893,O
4,2893,O
",",2893,O
and,2893,O
approximately,2893,O
2,2893,O
",",2893,O
respectively,2893,O
.,2893,O
However,2894,O
",",2894,O
upon,2894,O
addition,2894,O
of,2894,O
NO,2894,B-CHEMICAL
to,2894,O
CDO,2894,B-GENE-Y
in,2894,O
the,2894,O
presence,2894,O
of,2894,O
substrate,2894,O
l-cysteine,2894,B-CHEMICAL
",",2894,O
a,2894,O
low-spin,2894,O
{,2894,O
FeNO,2894,B-CHEMICAL
},2894,O
7,2894,O
(,2894,O
S,2894,O
=,2894,O
1/2,2894,O
),2894,O
signal,2894,O
that,2894,O
accounts,2894,O
for,2894,O
approximately,2894,O
85,2894,O
%,2894,O
of,2894,O
the,2894,O
iron,2894,B-CHEMICAL
within,2894,O
the,2894,O
enzyme,2894,O
develops,2894,O
.,2894,O
Similar,2895,O
{,2895,O
FeNO,2895,B-CHEMICAL
},2895,O
7,2895,O
(,2895,O
S,2895,O
=,2895,O
1/2,2895,O
),2895,O
EPR,2895,O
signals,2895,O
have,2895,O
been,2895,O
observed,2895,O
for,2895,O
a,2895,O
variety,2895,O
of,2895,O
octahedral,2895,O
mononuclear,2895,O
iron-nitrosyl,2895,B-CHEMICAL
synthetic,2895,O
complexes,2895,O
;,2895,O
however,2895,O
",",2895,O
this,2895,O
type,2895,O
of,2895,O
iron-nitrosyl,2895,B-CHEMICAL
species,2895,O
is,2895,O
not,2895,O
commonly,2895,O
observed,2895,O
for,2895,O
non-heme,2895,O
iron,2895,B-CHEMICAL
enzymes,2895,O
.,2895,O
Substitution,2896,O
of,2896,O
l-cysteine,2896,B-CHEMICAL
with,2896,O
isosteric,2896,O
substrate,2896,O
analogues,2896,O
cysteamine,2896,B-CHEMICAL
",",2896,O
3-mercaptopropionic,2896,B-CHEMICAL
acid,2896,I-CHEMICAL
",",2896,O
and,2896,O
propane,2896,B-CHEMICAL
thiol,2896,I-CHEMICAL
did,2896,O
not,2896,O
produce,2896,O
any,2896,O
analogous,2896,O
{,2896,O
FeNO,2896,B-CHEMICAL
},2896,O
7,2896,O
signals,2896,O
(,2896,O
S,2896,O
=,2896,O
1/2,2896,O
or,2896,O
3/2,2896,O
),2896,O
",",2896,O
thus,2896,O
reflecting,2896,O
the,2896,O
high,2896,O
substrate,2896,O
specificity,2896,O
of,2896,O
the,2896,O
enzyme,2896,O
observed,2896,O
by,2896,O
a,2896,O
number,2896,O
of,2896,O
researchers,2896,O
.,2896,O
The,2897,O
unusual,2897,O
{,2897,O
FeNO,2897,B-CHEMICAL
},2897,O
7,2897,O
(,2897,O
S,2897,O
=,2897,O
1/2,2897,O
),2897,O
electronic,2897,O
configuration,2897,O
adopted,2897,O
by,2897,O
the,2897,O
substrate-bound,2897,O
iron-nitrosyl,2897,B-CHEMICAL
CDO,2897,B-GENE-Y
(,2897,O
termed,2897,O
{,2897,O
ES-NO,2897,O
},2897,O
7,2897,O
),2897,O
is,2897,O
a,2897,O
result,2897,O
of,2897,O
the,2897,O
bidentate,2897,B-CHEMICAL
thiol/amine,2897,I-CHEMICAL
coordination,2897,O
of,2897,O
l-cysteine,2897,B-CHEMICAL
in,2897,O
the,2897,O
NO-bound,2897,B-CHEMICAL
CDO,2897,B-GENE-Y
active,2897,O
site,2897,O
.,2897,O
DFT,2898,O
computations,2898,O
were,2898,O
performed,2898,O
to,2898,O
further,2898,O
characterize,2898,O
this,2898,O
species,2898,O
.,2898,O
The,2899,O
DFT-predicted,2899,O
geometric,2899,O
parameters,2899,O
for,2899,O
{,2899,O
ES-NO,2899,O
},2899,O
7,2899,O
are,2899,O
in,2899,O
good,2899,O
agreement,2899,O
with,2899,O
the,2899,O
crystallographically,2899,O
determined,2899,O
substrate-bound,2899,O
active,2899,O
site,2899,O
configuration,2899,O
of,2899,O
CDO,2899,B-GENE-Y
and,2899,O
are,2899,O
consistent,2899,O
with,2899,O
known,2899,O
iron-nitrosyl,2899,B-CHEMICAL
model,2899,O
complexes,2899,O
.,2899,O
Moreover,2900,O
",",2900,O
the,2900,O
computed,2900,O
EPR,2900,O
parameters,2900,O
(,2900,O
g,2900,O
and,2900,O
A,2900,O
values,2900,O
),2900,O
are,2900,O
in,2900,O
excellent,2900,O
agreement,2900,O
with,2900,O
experimental,2900,O
results,2900,O
for,2900,O
this,2900,O
CDO,2900,B-GENE-Y
species,2900,O
and,2900,O
those,2900,O
obtained,2900,O
from,2900,O
comparable,2900,O
synthetic,2900,O
{,2900,O
FeNO,2900,B-CHEMICAL
},2900,O
7,2900,O
(,2900,O
S,2900,O
=,2900,O
1/2,2900,O
),2900,O
iron-nitrosyl,2900,B-CHEMICAL
complexes,2900,O
.,2900,O
Ligand-dependent,2901,O
transcriptional,2901,O
activities,2901,O
of,2901,O
four,2901,O
torafugu,2901,O
pufferfish,2901,O
Takifugu,2901,O
rubripes,2901,O
peroxisome,2901,B-GENE-N
proliferator-activated,2901,I-GENE-N
receptors,2901,I-GENE-N
.,2901,O
Structural,2902,O
and,2902,O
functional,2902,O
properties,2902,O
were,2902,O
investigated,2902,O
for,2902,O
four,2902,O
peroxisome,2902,B-GENE-N
proliferator-activated,2902,I-GENE-N
receptors,2902,I-GENE-N
(,2902,O
PPARs,2902,B-GENE-N
),2902,O
",",2902,O
PPARalpha1,2902,B-GENE-Y
",",2902,O
PPARalpha2,2902,B-GENE-Y
",",2902,O
PPARbeta,2902,B-GENE-Y
",",2902,O
and,2902,O
PPARgamma,2902,B-GENE-Y
",",2902,O
from,2902,O
torafugu,2902,O
pufferfish,2902,O
Takifugu,2902,O
rubripes,2902,O
and,2902,O
determined,2902,O
for,2902,O
their,2902,O
transcriptional,2902,O
activity,2902,O
by,2902,O
the,2902,O
reporter,2902,O
assay,2902,O
using,2902,O
reporter,2902,O
plasmids,2902,O
containing,2902,O
three,2902,O
copies,2902,O
of,2902,O
the,2902,O
acyl-CoA,2902,B-CHEMICAL
oxidase,2902,I-GENE-N
PPAR,2902,I-GENE-N
response,2902,I-GENE-N
element,2902,I-GENE-N
.,2902,O
Although,2903,B-GENE-N
torafugu,2903,I-GENE-N
PPARs,2903,I-GENE-N
showed,2903,O
a,2903,O
high,2903,O
similarity,2903,O
in,2903,O
the,2903,O
primary,2903,O
structure,2903,O
to,2903,O
other,2903,O
vertebrate,2903,O
counterparts,2903,O
",",2903,O
torafugu,2903,B-GENE-N
PPARalpha2,2903,I-GENE-N
and,2903,I-GENE-N
gamma,2903,I-GENE-N
contained,2903,O
additional,2903,O
sequences,2903,O
of,2903,O
21,2903,O
and,2903,O
28,2903,O
amino,2903,B-CHEMICAL
acids,2903,I-CHEMICAL
",",2903,O
respectively,2903,O
",",2903,O
as,2903,O
in,2903,O
the,2903,O
case,2903,O
of,2903,O
other,2903,O
teleost,2903,O
fish,2903,O
species,2903,O
when,2903,O
compared,2903,O
with,2903,O
African,2903,O
clawed,2903,O
frog,2903,O
counterparts,2903,O
.,2903,O
The,2904,O
transcriptional,2904,O
activity,2904,O
of,2904,O
torafugu,2904,O
PPARalpha1,2904,B-GENE-Y
was,2904,O
enhanced,2904,O
4.5-,2904,O
and,2904,O
11.5-fold,2904,O
by,2904,O
Wy-14643,2904,B-CHEMICAL
and,2904,O
"5,8,11,14-eicosatetraynoic",2904,B-CHEMICAL
acid,2904,I-CHEMICAL
(,2904,O
ETYA,2904,B-CHEMICAL
),2904,O
each,2904,O
at,2904,O
10,2904,O
microM,2904,O
",",2904,O
respectively,2904,O
",",2904,O
whereas,2904,O
that,2904,O
of,2904,O
PPARalpha2,2904,B-GENE-Y
",",2904,O
4.5-,2904,O
and,2904,O
7.3-fold,2904,O
at,2904,O
the,2904,O
same,2904,O
concentration,2904,O
of,2904,O
the,2904,O
respective,2904,O
ligands,2904,O
",",2904,O
respectively,2904,O
.,2904,O
The,2905,O
activities,2905,O
of,2905,O
torafugu,2905,O
PPARalpha1,2905,B-GENE-N
and,2905,I-GENE-N
alpha2,2905,I-GENE-N
were,2905,O
also,2905,O
enhanced,2905,O
5.6-,2905,O
and,2905,O
6.3-fold,2905,O
by,2905,O
ETYA,2905,B-CHEMICAL
at,2905,O
1,2905,O
microM,2905,O
",",2905,O
respectively,2905,O
",",2905,O
but,2905,O
not,2905,O
by,2905,O
Wy-14643,2905,B-CHEMICAL
at,2905,O
this,2905,O
concentration,2905,O
.,2905,O
Furthermore,2906,O
",",2906,O
the,2906,O
activities,2906,O
of,2906,O
the,2906,O
two,2906,O
torafugu,2906,B-GENE-N
PPARalphas,2906,I-GENE-N
were,2906,O
enhanced,2906,O
4.3-,2906,O
and,2906,O
7.6-fold,2906,O
by,2906,O
arachidonic,2906,B-CHEMICAL
acid,2906,I-CHEMICAL
",",2906,O
4.4-,2906,O
and,2906,O
5.2-fold,2906,O
by,2906,O
docosahexaenoic,2906,B-CHEMICAL
acid,2906,I-CHEMICAL
",",2906,O
and,2906,O
6.7-,2906,O
and,2906,O
8.0-fold,2906,O
by,2906,O
eicosapentaenoic,2906,B-CHEMICAL
acid,2906,I-CHEMICAL
each,2906,O
at,2906,O
50,2906,O
microM,2906,O
",",2906,O
respectively,2906,O
.,2906,O
On,2907,O
the,2907,O
other,2907,O
hand,2907,O
",",2907,O
the,2907,O
activities,2907,O
of,2907,O
torafugu,2907,B-GENE-N
PPARbeta,2907,I-GENE-N
and,2907,I-GENE-N
gamma,2907,I-GENE-N
were,2907,O
not,2907,O
changed,2907,O
by,2907,O
Wy-14643,2907,B-CHEMICAL
",",2907,O
ETYA,2907,B-CHEMICAL
",",2907,O
rosiglitazone,2907,B-CHEMICAL
",",2907,O
nor,2907,O
PUFAs,2907,O
.,2907,O
These,2908,O
results,2908,O
suggest,2908,O
that,2908,O
the,2908,O
activities,2908,O
of,2908,O
torafugu,2908,B-GENE-N
PPARbeta,2908,I-GENE-N
and,2908,I-GENE-N
gamma,2908,I-GENE-N
require,2908,O
undefined,2908,O
ligands,2908,O
.,2908,O
Alternatively,2909,O
",",2909,O
the,2909,O
molecular,2909,O
mechanisms,2909,O
involved,2909,O
in,2909,O
their,2909,O
activation,2909,O
are,2909,O
different,2909,O
from,2909,O
those,2909,O
of,2909,O
other,2909,O
vertebrates,2909,O
.,2909,O
Combination,2910,O
chemotherapy,2910,O
with,2910,O
a,2910,O
substance,2910,B-GENE-Y
P,2910,I-GENE-Y
receptor,2910,I-GENE-Y
antagonist,2910,O
(,2910,O
aprepitant,2910,B-CHEMICAL
),2910,O
and,2910,O
melarsoprol,2910,B-CHEMICAL
in,2910,O
a,2910,O
mouse,2910,O
model,2910,O
of,2910,O
human,2910,O
African,2910,O
trypanosomiasis,2910,O
.,2910,O
Drug,2911,O
therapy,2911,O
for,2911,O
late-stage,2911,O
(,2911,O
encephalitic,2911,O
),2911,O
human,2911,O
African,2911,O
trypanosomiasis,2911,O
(,2911,O
HAT,2911,O
),2911,O
is,2911,O
currently,2911,O
very,2911,O
unsatisfactory,2911,O
with,2911,O
the,2911,O
most,2911,O
commonly,2911,O
used,2911,O
drug,2911,O
",",2911,O
melarsoprol,2911,B-CHEMICAL
",",2911,O
having,2911,O
a,2911,O
5,2911,O
%,2911,O
overall,2911,O
mortality,2911,O
.,2911,O
There,2912,O
is,2912,O
evidence,2912,O
in,2912,O
a,2912,O
mouse,2912,O
model,2912,O
of,2912,O
HAT,2912,O
that,2912,O
Substance,2912,B-CHEMICAL
P,2912,I-CHEMICAL
(,2912,I-GENE-Y
SP,2912,B-CHEMICAL
),2912,I-GENE-Y
receptor,2912,I-GENE-Y
antagonism,2912,O
reduces,2912,O
the,2912,O
neuroinflammatory,2912,O
reaction,2912,O
to,2912,O
CNS,2912,O
trypanosome,2912,O
infection,2912,O
.,2912,O
In,2913,O
this,2913,O
study,2913,O
we,2913,O
investigated,2913,O
the,2913,O
effects,2913,O
of,2913,O
combination,2913,O
chemotherapy,2913,O
with,2913,O
melarsoprol,2913,B-CHEMICAL
and,2913,O
a,2913,O
humanised,2913,B-GENE-Y
SP,2913,B-CHEMICAL
receptor,2913,I-GENE-Y
antagonist,2913,O
aprepitant,2913,B-CHEMICAL
(,2913,O
EMEND,2913,B-CHEMICAL
),2913,O
in,2913,O
this,2913,O
mouse,2913,O
model,2913,O
.,2913,O
The,2914,O
melarsoprol/aprepitant,2914,B-CHEMICAL
drug,2914,O
combination,2914,O
did,2914,O
not,2914,O
produce,2914,O
any,2914,O
clinical,2914,O
signs,2914,O
of,2914,O
illness,2914,O
in,2914,O
mice,2914,O
with,2914,O
CNS,2914,O
trypanosome,2914,O
infection,2914,O
.,2914,O
This,2915,O
lack,2915,O
of,2915,O
any,2915,O
additional,2915,O
or,2915,O
unexpected,2915,O
CNS,2915,O
toxicity,2915,O
in,2915,O
the,2915,O
mouse,2915,O
model,2915,O
of,2915,O
CNS,2915,O
HAT,2915,O
provides,2915,O
valuable,2915,O
safety,2915,O
data,2915,O
for,2915,O
the,2915,O
future,2915,O
possible,2915,O
use,2915,O
of,2915,O
this,2915,O
drug,2915,O
combination,2915,O
in,2915,O
patients,2915,O
with,2915,O
late-stage,2915,O
HAT,2915,O
.,2915,O
Identification,2916,O
of,2916,O
the,2916,O
RLBP1,2916,B-GENE-N
gene,2916,I-GENE-N
promoter,2916,I-GENE-N
.,2916,O
PURPOSE,2917,O
:,2917,O
Cellular,2917,B-GENE-Y
retinaldehyde-binding,2917,B-CHEMICAL
protein,2917,I-GENE-Y
(,2917,O
CRALBP,2917,B-GENE-Y
),2917,O
",",2917,O
transcribed,2917,O
from,2917,O
the,2917,O
RLBP1,2917,B-GENE-Y
gene,2917,O
",",2917,O
is,2917,O
a,2917,O
36-kDa,2917,B-GENE-N
water-soluble,2917,I-GENE-N
protein,2917,I-GENE-N
with,2917,O
316,2917,O
amino,2917,B-CHEMICAL
acids,2917,I-CHEMICAL
found,2917,O
in,2917,O
the,2917,O
retinal,2917,B-CHEMICAL
pigment,2917,O
epithelium,2917,O
(,2917,O
RPE,2917,O
),2917,O
and,2917,O
in,2917,O
retinal,2917,B-CHEMICAL
Muller,2917,O
cells,2917,O
.,2917,O
It,2918,O
is,2918,O
thought,2918,O
to,2918,O
play,2918,O
a,2918,O
critical,2918,O
role,2918,O
in,2918,O
the,2918,O
visual,2918,O
cycle,2918,O
by,2918,O
functioning,2918,O
as,2918,O
an,2918,O
acceptor,2918,O
of,2918,O
11-cis-retinol,2918,B-CHEMICAL
from,2918,O
the,2918,O
isomerohydrolase,2918,B-GENE-N
reaction,2918,O
.,2918,O
The,2919,O
goal,2919,O
here,2919,O
was,2919,O
to,2919,O
evaluate,2919,O
the,2919,O
functional,2919,O
promoter,2919,O
of,2919,O
this,2919,O
gene,2919,O
.,2919,O
METHODS,2920,O
:,2920,O
5,2920,O
',2920,O
RACE,2920,O
analysis,2920,O
",",2920,O
promoter-reporter,2920,O
assays,2920,O
",",2920,O
and,2920,O
semiquantitative,2920,O
PCR,2920,O
with,2920,O
exon-specific,2920,O
primers,2920,O
were,2920,O
performed,2920,O
using,2920,O
human-derived,2920,O
RPE,2920,O
cells,2920,O
(,2920,O
ARPE-19,2920,O
and,2920,O
D407,2920,O
),2920,O
in,2920,O
culture,2920,O
to,2920,O
evaluate,2920,O
the,2920,O
5,2920,O
',2920,O
sequence,2920,O
flanking,2920,O
the,2920,O
RLBP1,2920,B-GENE-Y
gene,2920,O
.,2920,O
In,2921,O
addition,2921,O
",",2921,O
the,2921,O
murine,2921,B-GENE-N
",",2921,I-GENE-N
bovine,2921,I-GENE-N
",",2921,I-GENE-N
and,2921,I-GENE-N
porcine,2921,I-GENE-N
RLBP1,2921,I-GENE-N
genes,2921,O
were,2921,O
evaluated,2921,O
in,2921,O
silico,2921,O
to,2921,O
identify,2921,O
likely,2921,O
proximal,2921,O
promoter/exon,2921,O
1,2921,O
sequences,2921,O
similar,2921,O
to,2921,O
the,2921,O
human,2921,O
gene,2921,O
.,2921,O
RESULTS,2922,O
:,2922,O
5,2922,O
',2922,O
RACE,2922,O
analysis,2922,O
revealed,2922,O
the,2922,O
presence,2922,O
of,2922,O
a,2922,O
previously,2922,O
undescribed,2922,O
exon,2922,O
in,2922,O
the,2922,O
RLBP1,2922,B-GENE-Y
gene,2922,O
.,2922,O
This,2923,O
was,2923,O
confirmed,2923,O
by,2923,O
analysis,2923,O
of,2923,O
the,2923,O
GenBank,2923,O
Human,2923,O
EST,2923,O
database,2923,O
",",2923,O
which,2923,O
revealed,2923,O
the,2923,O
presence,2923,O
of,2923,O
18,2923,O
sequences,2923,O
matching,2923,O
exon,2923,O
1,2923,O
.,2923,O
Exon-specific,2924,O
PCR,2924,O
revealed,2924,O
that,2924,O
most,2924,O
CRALBP,2924,B-GENE-Y
transcripts,2924,O
expressed,2924,O
in,2924,O
ARPE-19,2924,O
cells,2924,O
contain,2924,O
both,2924,O
exon,2924,O
1,2924,O
and,2924,O
the,2924,O
final,2924,O
exon,2924,O
",",2924,O
suggesting,2924,O
that,2924,O
the,2924,O
primary,2924,O
promoter,2924,O
of,2924,O
CRALBP,2924,B-GENE-Y
exists,2924,O
5,2924,O
',2924,O
of,2924,O
the,2924,O
newly,2924,O
identified,2924,O
exon,2924,O
1,2924,O
.,2924,O
Highly,2925,O
homologous,2925,O
sequences,2925,O
in,2925,O
the,2925,O
murine,2925,O
",",2925,O
bovine,2925,O
",",2925,O
and,2925,O
porcine,2925,O
genes,2925,O
were,2925,O
also,2925,O
identified,2925,O
.,2925,O
Finally,2926,O
",",2926,O
promoter-reporter,2926,O
constructs,2926,O
revealed,2926,O
a,2926,O
minimal,2926,O
sequence,2926,O
necessary,2926,O
for,2926,O
promoter,2926,O
function,2926,O
and,2926,O
indicated,2926,O
significantly,2926,O
greater,2926,O
promoter,2926,O
activity,2926,O
compared,2926,O
with,2926,O
previously,2926,O
described,2926,O
RLBP1,2926,B-GENE-N
promoters,2926,I-GENE-N
.,2926,O
CONCLUSIONS,2927,O
:,2927,O
The,2927,O
findings,2927,O
presented,2927,O
here,2927,O
suggest,2927,O
that,2927,O
CRALBP,2927,B-GENE-Y
transcripts,2927,O
in,2927,O
RPE,2927,O
cells,2927,O
contain,2927,O
a,2927,O
noncoding,2927,O
exon,2927,O
in,2927,O
addition,2927,O
to,2927,O
a,2927,O
newly,2927,O
described,2927,O
promoter,2927,O
and,2927,O
",",2927,O
by,2927,O
definition,2927,O
",",2927,O
an,2927,O
additional,2927,O
intron,2927,O
.,2927,O
This,2928,O
finding,2928,O
sets,2928,O
the,2928,O
stage,2928,O
for,2928,O
a,2928,O
mechanistic,2928,O
understanding,2928,O
of,2928,O
the,2928,O
high,2928,O
degree,2928,O
of,2928,O
cell,2928,O
type-specific,2928,O
expression,2928,O
of,2928,O
RLBP1,2928,B-GENE-Y
.,2928,O
Determination,2929,O
of,2929,O
dimethylarginine,2929,B-GENE-Y
dimethylaminohydrolase,2929,I-GENE-Y
activity,2929,O
in,2929,O
the,2929,O
kidney,2929,O
.,2929,O
Dimethylarginine,2930,B-CHEMICAL
dimethylaminohydrolase,2930,I-GENE-Y
(,2930,O
DDAH,2930,B-GENE-Y
),2930,O
metabolizes,2930,O
asymmetric,2930,O
dimethylarginine,2930,B-CHEMICAL
to,2930,O
generate,2930,O
L-citrulline,2930,B-CHEMICAL
and,2930,O
is,2930,O
present,2930,O
in,2930,O
large,2930,O
quantities,2930,O
in,2930,O
the,2930,O
kidney,2930,O
.,2930,O
We,2931,O
present,2931,O
a,2931,O
new,2931,O
study,2931,O
that,2931,O
optimizes,2931,O
the,2931,O
Prescott-Jones,2931,O
colorimetric,2931,O
assay,2931,O
to,2931,O
measure,2931,O
DDAH-dependent,2931,B-GENE-Y
L-citrulline,2931,B-CHEMICAL
generation,2931,O
in,2931,O
kidney,2931,O
homogenates,2931,O
.,2931,O
We,2932,O
found,2932,O
that,2932,O
the,2932,O
removal,2932,O
of,2932,O
urea,2932,B-CHEMICAL
with,2932,O
urease,2932,B-GENE-N
is,2932,O
necessary,2932,O
since,2932,O
urea,2932,B-CHEMICAL
also,2932,O
produces,2932,O
a,2932,O
positive,2932,O
reaction,2932,O
.,2932,O
Deproteinization,2933,O
with,2933,O
sulfosalicylic,2933,B-CHEMICAL
acid,2933,I-CHEMICAL
was,2933,O
found,2933,O
to,2933,O
be,2933,O
optimal,2933,O
and,2933,O
that,2933,O
protease,2933,B-GENE-N
inhibitors,2933,O
were,2933,O
not,2933,O
necessary,2933,O
.,2933,O
All,2934,O
assays,2934,O
were,2934,O
conducted,2934,O
in,2934,O
phosphate,2934,B-CHEMICAL
buffer,2934,O
",",2934,O
since,2934,O
other,2934,O
common,2934,O
additives,2934,O
can,2934,O
create,2934,O
false,2934,O
positive,2934,O
and,2934,O
false,2934,O
negative,2934,O
reactions,2934,O
.,2934,O
Arginase,2935,B-GENE-N
or,2935,O
nitric,2935,B-CHEMICAL
oxide,2935,I-CHEMICAL
synthase,2935,I-GENE-N
isoenzymes,2935,O
were,2935,O
not,2935,O
found,2935,O
to,2935,O
influence,2935,O
L-citrulline,2935,B-CHEMICAL
production,2935,O
.,2935,O
Our,2936,O
optimized,2936,O
L-citrulline,2936,B-CHEMICAL
production,2936,O
assay,2936,O
to,2936,O
measure,2936,O
DDAH,2936,B-GENE-Y
activity,2936,O
correlated,2936,O
closely,2936,O
with,2936,O
the,2936,O
direct,2936,O
measure,2936,O
of,2936,O
the,2936,O
rate,2936,O
of,2936,O
asymmetric,2936,O
dimethylarginine,2936,B-CHEMICAL
consumption,2936,O
.,2936,O
Using,2937,O
this,2937,O
assay,2937,O
",",2937,O
we,2937,O
found,2937,O
that,2937,O
both,2937,O
superoxide,2937,B-CHEMICAL
and,2937,O
nitric,2937,B-CHEMICAL
oxide,2937,I-CHEMICAL
inhibit,2937,O
renal,2937,O
cortical,2937,O
DDAH,2937,B-GENE-Y
activity,2937,O
in,2937,O
vitro,2937,O
.,2937,O
The,2938,O
role,2938,O
of,2938,O
trastuzumab,2938,O
in,2938,O
early,2938,O
stage,2938,O
breast,2938,O
cancer,2938,O
:,2938,O
current,2938,O
data,2938,O
and,2938,O
treatment,2938,O
recommendations,2938,O
.,2938,O
OPINION,2939,O
STATEMENT,2939,O
:,2939,O
Treatment,2939,O
of,2939,O
early,2939,O
stage,2939,O
breast,2939,O
cancer,2939,O
requires,2939,O
a,2939,O
multimodality,2939,O
approach,2939,O
in,2939,O
order,2939,O
to,2939,O
eradicate,2939,O
residual,2939,O
cancer,2939,O
and,2939,O
prevent,2939,O
recurrent,2939,O
disease,2939,O
.,2939,O
Targeting,2940,O
the,2940,O
pathways,2940,O
that,2940,O
promote,2940,O
or,2940,O
sustain,2940,O
cancer,2940,O
cell,2940,O
growth,2940,O
and,2940,O
invasion,2940,O
is,2940,O
critical,2940,O
to,2940,O
the,2940,O
effective,2940,O
treatment,2940,O
of,2940,O
breast,2940,O
and,2940,O
other,2940,O
cancers,2940,O
.,2940,O
Overexpression,2941,O
of,2941,O
the,2941,O
family,2941,O
of,2941,O
HER,2941,B-GENE-N
receptors,2941,O
have,2941,O
been,2941,O
associated,2941,O
with,2941,O
a,2941,O
variety,2941,O
of,2941,O
malignancies,2941,O
;,2941,O
the,2941,O
first,2941,O
and,2941,O
best,2941,O
studied,2941,O
is,2941,O
the,2941,O
association,2941,O
of,2941,O
overexpression,2941,O
of,2941,O
the,2941,O
HER2/neu,2941,B-GENE-Y
receptor,2941,I-GENE-Y
with,2941,O
a,2941,O
more,2941,O
aggressive,2941,O
breast,2941,O
cancer,2941,O
phenotype,2941,O
and,2941,O
poorer,2941,O
survival,2941,O
.,2941,O
A,2942,O
humanized,2942,O
antibody,2942,O
to,2942,O
HER2/neu,2942,B-GENE-Y
",",2942,O
trastuzumab,2942,O
",",2942,O
is,2942,O
now,2942,O
FDA,2942,O
approved,2942,O
for,2942,O
the,2942,O
treatment,2942,O
of,2942,O
early,2942,O
stage,2942,O
",",2942,O
HER2/neu,2942,B-GENE-Y
overexpressing,2942,O
breast,2942,O
cancer,2942,O
sequenced,2942,O
with,2942,O
chemotherapy,2942,O
including,2942,O
doxorubicin,2942,B-CHEMICAL
",",2942,O
cyclophosphamide,2942,B-CHEMICAL
",",2942,O
and,2942,O
paclitaxel,2942,B-CHEMICAL
.,2942,O
Additional,2943,O
international,2943,O
and,2943,O
national,2943,O
studies,2943,O
support,2943,O
the,2943,O
significant,2943,O
impact,2943,O
of,2943,O
trastuzumab,2943,O
on,2943,O
both,2943,O
disease,2943,O
free,2943,O
and,2943,O
overall,2943,O
survival,2943,O
in,2943,O
women,2943,O
with,2943,O
this,2943,O
aggressive,2943,O
form,2943,O
of,2943,O
breast,2943,O
cancer,2943,O
.,2943,O
Toxicity,2944,O
includes,2944,O
a,2944,O
low,2944,O
but,2944,O
clear,2944,O
risk,2944,O
of,2944,O
congestive,2944,O
heart,2944,O
failure,2944,O
",",2944,O
and,2944,O
the,2944,O
large,2944,O
phase,2944,O
III,2944,O
trials,2944,O
have,2944,O
helped,2944,O
to,2944,O
determine,2944,O
which,2944,O
patients,2944,O
are,2944,O
at,2944,O
higher,2944,O
risk,2944,O
for,2944,O
this,2944,O
complication,2944,O
.,2944,O
Non-anthracycline,2945,O
containing,2945,O
regimens,2945,O
are,2945,O
an,2945,O
alternative,2945,O
therapy,2945,O
associated,2945,O
with,2945,O
reduced,2945,O
cardiac,2945,O
toxicity,2945,O
.,2945,O
Trastuzumab,2946,O
therapy,2946,O
is,2946,O
now,2946,O
the,2946,O
standard,2946,O
of,2946,O
care,2946,O
for,2946,O
the,2946,O
treatment,2946,O
of,2946,O
early,2946,O
stage,2946,O
",",2946,O
HER2/neu,2946,B-GENE-Y
positive,2946,O
breast,2946,O
cancer,2946,O
given,2946,O
in,2946,O
combination,2946,O
with,2946,O
one,2946,O
of,2946,O
several,2946,O
chemotherapy,2946,O
regimens,2946,O
.,2946,O
Ongoing,2947,O
questions,2947,O
include,2947,O
the,2947,O
appropriate,2947,O
duration,2947,O
of,2947,O
trastuzumab,2947,O
treatment,2947,O
as,2947,O
well,2947,O
as,2947,O
the,2947,O
optimal,2947,O
chemotherapy,2947,O
regimen,2947,O
and,2947,O
sequence,2947,O
.,2947,O
The,2948,O
next,2948,O
large,2948,O
phase,2948,O
III,2948,O
adjuvant,2948,O
trial,2948,O
for,2948,O
this,2948,O
subset,2948,O
of,2948,O
breast,2948,O
cancer,2948,O
is,2948,O
an,2948,O
international,2948,O
collaboration,2948,O
designed,2948,O
to,2948,O
evaluate,2948,O
the,2948,O
added,2948,O
or,2948,O
alternative,2948,O
benefit,2948,O
of,2948,O
an,2948,O
oral,2948,O
tyrosine,2948,B-CHEMICAL
kinase,2948,O
inhibitor,2948,O
targeting,2948,O
HER2/neu,2948,B-GENE-Y
as,2948,O
well,2948,O
as,2948,O
the,2948,O
epidermal,2948,B-GENE-Y
growth,2948,I-GENE-Y
factor,2948,I-GENE-Y
receptor,2948,I-GENE-Y
(,2948,O
EGFR,2948,B-GENE-Y
),2948,O
",",2948,O
lapatinib,2948,B-CHEMICAL
.,2948,O
Other,2949,O
trials,2949,O
are,2949,O
investigating,2949,O
differences,2949,O
in,2949,O
duration,2949,O
.,2949,O
Studies,2950,O
in,2950,O
the,2950,O
neoadjuvant,2950,O
setting,2950,O
should,2950,O
help,2950,O
to,2950,O
define,2950,O
markers,2950,O
of,2950,O
trastuzumab,2950,O
and,2950,O
lapatinib,2950,B-CHEMICAL
sensitivity,2950,O
and,2950,O
resistance,2950,O
.,2950,O
Preliminary,2951,O
data,2951,O
combining,2951,O
trastuzumab,2951,O
with,2951,O
the,2951,O
antiangiogenic,2951,O
antibody,2951,O
bevacizumab,2951,O
is,2951,O
encouraging,2951,O
;,2951,O
this,2951,O
combination,2951,O
will,2951,O
be,2951,O
tested,2951,O
in,2951,O
both,2951,O
early,2951,O
stage,2951,O
and,2951,O
late,2951,O
stage,2951,O
disease,2951,O
.,2951,O
Stimulation,2952,O
of,2952,O
N-methyl-D-aspartate,2952,B-GENE-N
receptors,2952,I-GENE-N
modulates,2952,O
Jurkat,2952,O
T,2952,O
cell,2952,O
growth,2952,O
and,2952,O
adhesion,2952,O
to,2952,O
fibronectin,2952,B-GENE-Y
.,2952,O
The,2953,O
aims,2953,O
of,2953,O
this,2953,O
study,2953,O
were,2953,O
to,2953,O
investigate,2953,O
the,2953,O
expression,2953,O
and,2953,O
the,2953,O
functional,2953,O
roles,2953,O
of,2953,O
N-methyl-d-aspartate,2953,B-GENE-N
(,2953,I-GENE-N
NMDA,2953,B-CHEMICAL
),2953,I-GENE-N
receptors,2953,I-GENE-N
in,2953,O
leukemic,2953,O
Jurkat,2953,O
T,2953,O
cells,2953,O
.,2953,O
RT-PCR,2954,O
and,2954,O
immunofluorescence/confocal,2954,O
microscopy,2954,O
analysis,2954,O
showed,2954,O
that,2954,O
Jurkat,2954,O
T,2954,O
cells,2954,O
express,2954,O
the,2954,O
NR1,2954,B-GENE-Y
and,2954,O
NR2B,2954,B-GENE-Y
subunits,2954,O
of,2954,O
the,2954,O
NMDA,2954,B-CHEMICAL
receptors,2954,I-GENE-N
.,2954,O
Exposure,2955,O
of,2955,O
Jurkat,2955,O
cells,2955,O
to,2955,O
either,2955,O
(,2955,B-CHEMICAL
"5S,10R",2955,I-CHEMICAL
),2955,I-CHEMICAL
-,2955,I-CHEMICAL
(,2955,I-CHEMICAL
+,2955,I-CHEMICAL
),2955,I-CHEMICAL
"-5-methyl-10,11-dihydro-5H-dibenzo",2955,I-CHEMICAL
[,2955,I-CHEMICAL
a,2955,I-CHEMICAL
",",2955,I-CHEMICAL
b,2955,I-CHEMICAL
],2955,I-CHEMICAL
"cyclohepten-5,10-imine",2955,I-CHEMICAL
[,2955,O
(,2955,B-CHEMICAL
+,2955,I-CHEMICAL
),2955,I-CHEMICAL
-MK,2955,I-CHEMICAL
801,2955,I-CHEMICAL
],2955,O
or,2955,O
D-,2955,B-CHEMICAL
(,2955,I-CHEMICAL
-,2955,I-CHEMICAL
),2955,I-CHEMICAL
-2-amino-5-phosphonopentanoic,2955,I-CHEMICAL
acid,2955,I-CHEMICAL
(,2955,O
D-AP5,2955,B-CHEMICAL
),2955,O
",",2955,O
two,2955,O
selective,2955,O
NMDA,2955,B-CHEMICAL
receptor,2955,I-GENE-N
antagonists,2955,O
",",2955,O
limited,2955,O
cell,2955,O
growth,2955,O
by,2955,O
inhibiting,2955,O
cell,2955,O
cycle,2955,O
progression,2955,O
and,2955,O
inducing,2955,O
apoptosis,2955,O
",",2955,O
whereas,2955,O
l-glutamate,2955,B-CHEMICAL
(,2955,O
1,2955,O
microM,2955,O
),2955,O
and,2955,O
NMDA,2955,B-CHEMICAL
(,2955,O
10,2955,O
microM,2955,O
),2955,O
significantly,2955,O
increased,2955,O
(,2955,O
137.2+/-22.0,2955,O
%,2955,O
;,2955,O
P,2955,O
<,2955,O
0.01,2955,O
),2955,O
Jurkat,2955,O
T,2955,O
cell,2955,O
adhesion,2955,O
to,2955,O
fibronectin,2955,B-GENE-Y
.,2955,O
In,2956,O
conclusion,2956,O
",",2956,O
our,2956,O
results,2956,O
demonstrate,2956,O
that,2956,O
Jurkat,2956,O
T,2956,O
cells,2956,O
express,2956,O
NMDA,2956,B-GENE-N
receptors,2956,I-GENE-N
functionally,2956,O
active,2956,O
in,2956,O
controlling,2956,O
cell,2956,O
growth,2956,O
and,2956,O
adhesion,2956,O
to,2956,O
fibronectin,2956,B-GENE-Y
.,2956,O
Desvenlafaxine,2957,B-CHEMICAL
succinate,2957,I-CHEMICAL
identifies,2957,O
novel,2957,O
antagonist,2957,O
binding,2957,O
determinants,2957,O
in,2957,O
the,2957,O
human,2957,B-GENE-Y
norepinephrine,2957,I-GENE-Y
transporter,2957,I-GENE-Y
.,2957,O
Desvenlafaxine,2958,B-CHEMICAL
succinate,2958,I-CHEMICAL
(,2958,O
DVS,2958,B-CHEMICAL
),2958,O
is,2958,O
a,2958,O
recently,2958,O
introduced,2958,O
antagonist,2958,O
of,2958,O
the,2958,O
human,2958,B-GENE-N
norepinephrine,2958,I-GENE-N
and,2958,I-GENE-N
serotonin,2958,I-GENE-N
transporters,2958,I-GENE-N
(,2958,O
hNET,2958,B-GENE-Y
and,2958,O
hSERT,2958,B-GENE-Y
",",2958,O
respectively,2958,O
),2958,O
",",2958,O
currently,2958,O
in,2958,O
clinical,2958,O
development,2958,O
for,2958,O
use,2958,O
in,2958,O
the,2958,O
treatment,2958,O
of,2958,O
major,2958,O
depressive,2958,O
disorder,2958,O
and,2958,O
vasomotor,2958,O
symptoms,2958,O
associated,2958,O
with,2958,O
menopause,2958,O
.,2958,O
Initial,2959,O
evaluation,2959,O
of,2959,O
the,2959,O
pharmacological,2959,O
properties,2959,O
of,2959,O
DVS,2959,B-CHEMICAL
(,2959,O
J,2959,O
Pharmacol,2959,O
Exp,2959,O
Ther,2959,O
318:657-665,2959,O
",",2959,O
2006,2959,O
),2959,O
revealed,2959,O
significantly,2959,O
reduced,2959,O
potency,2959,O
for,2959,O
the,2959,O
hNET,2959,B-GENE-Y
expressed,2959,O
in,2959,O
membranes,2959,O
compared,2959,O
with,2959,O
whole,2959,O
cells,2959,O
when,2959,O
competing,2959,O
for,2959,O
[,2959,B-CHEMICAL
(,2959,I-CHEMICAL
3,2959,I-CHEMICAL
),2959,I-CHEMICAL
H,2959,I-CHEMICAL
],2959,I-CHEMICAL
nisoxetine,2959,I-CHEMICAL
(,2959,O
NIS,2959,B-CHEMICAL
),2959,O
binding,2959,O
.,2959,O
Using,2960,O
hNET,2960,B-GENE-Y
in,2960,O
transfected,2960,O
human,2960,O
embryonic,2960,O
kidney-293,2960,O
cells,2960,O
",",2960,O
this,2960,O
difference,2960,O
in,2960,O
potency,2960,O
for,2960,O
DVS,2960,B-CHEMICAL
at,2960,O
sites,2960,O
labeled,2960,O
by,2960,O
[,2960,B-CHEMICAL
(,2960,I-CHEMICAL
3,2960,I-CHEMICAL
),2960,I-CHEMICAL
H,2960,I-CHEMICAL
],2960,I-CHEMICAL
NIS,2960,I-CHEMICAL
was,2960,O
found,2960,O
to,2960,O
distinguish,2960,O
DVS,2960,B-CHEMICAL
",",2960,O
the,2960,O
DVS,2960,B-CHEMICAL
analog,2960,O
rac-,2960,B-CHEMICAL
(,2960,I-CHEMICAL
1-,2960,I-CHEMICAL
[,2960,I-CHEMICAL
1-,2960,I-CHEMICAL
(,2960,I-CHEMICAL
3-chloro-phenyl,2960,I-CHEMICAL
),2960,I-CHEMICAL
-2-,2960,I-CHEMICAL
(,2960,I-CHEMICAL
4-methylpiperazin-1-yl,2960,I-CHEMICAL
),2960,I-CHEMICAL
-ethyl,2960,I-CHEMICAL
],2960,I-CHEMICAL
cyclohexanol,2960,I-CHEMICAL
(,2960,O
WY-46824,2960,B-CHEMICAL
),2960,O
",",2960,O
methylphenidate,2960,B-CHEMICAL
",",2960,O
and,2960,O
the,2960,O
cocaine,2960,B-CHEMICAL
analog,2960,O
3beta-,2960,B-CHEMICAL
(,2960,I-CHEMICAL
4-iodophenyl,2960,I-CHEMICAL
),2960,I-CHEMICAL
tropane-2beta-carboxylic,2960,I-CHEMICAL
acid,2960,I-CHEMICAL
methyl,2960,I-CHEMICAL
ester,2960,I-CHEMICAL
(,2960,O
RTI-55,2960,B-CHEMICAL
),2960,O
from,2960,O
other,2960,O
hNET,2960,B-GENE-Y
antagonists,2960,O
",",2960,O
such,2960,O
as,2960,O
NIS,2960,B-CHEMICAL
",",2960,O
mazindol,2960,B-CHEMICAL
",",2960,O
tricyclic,2960,B-CHEMICAL
antidepressants,2960,O
",",2960,O
and,2960,O
cocaine,2960,B-CHEMICAL
.,2960,O
These,2961,O
differences,2961,O
seem,2961,O
not,2961,O
to,2961,O
arise,2961,O
from,2961,O
preparation-specific,2961,O
perturbations,2961,O
of,2961,O
ligand,2961,O
intrinsic,2961,O
affinity,2961,O
or,2961,O
antagonist-specific,2961,O
surface,2961,O
trafficking,2961,O
but,2961,O
rather,2961,O
from,2961,O
protein,2961,O
conformational,2961,O
alterations,2961,O
that,2961,O
perturb,2961,O
the,2961,O
relationships,2961,O
between,2961,O
distinct,2961,O
hNET,2961,B-GENE-Y
binding,2961,O
sites,2961,O
.,2961,O
In,2962,O
an,2962,O
initial,2962,O
search,2962,O
for,2962,O
molecular,2962,O
features,2962,O
that,2962,O
differentially,2962,O
define,2962,O
antagonist,2962,O
binding,2962,O
determinants,2962,O
",",2962,O
we,2962,O
document,2962,O
that,2962,O
Val148,2962,O
in,2962,O
hNET,2962,B-GENE-N
transmembrane,2962,I-GENE-N
domain,2962,I-GENE-N
3,2962,I-GENE-N
selectively,2962,O
disrupts,2962,O
NIS,2962,B-CHEMICAL
binding,2962,O
but,2962,O
not,2962,O
that,2962,O
of,2962,O
DVS,2962,O
.,2962,O
[,2963,O
Lipoprotein,2963,B-GENE-Y
(,2963,I-GENE-Y
a,2963,I-GENE-Y
),2963,I-GENE-Y
:,2963,O
a,2963,O
link,2963,O
between,2963,O
thrombogenesis,2963,O
and,2963,O
atherogenesis,2963,O
],2963,O
.,2963,O
INTRODUCTION,2964,O
:,2964,O
It,2964,O
is,2964,O
well,2964,O
known,2964,O
that,2964,O
numerous,2964,O
mechanisms,2964,O
of,2964,O
thrombogenesis,2964,O
can,2964,O
participate,2964,O
in,2964,O
every,2964,O
stage,2964,O
of,2964,O
atherosclerotic,2964,O
disease,2964,O
.,2964,O
The,2965,O
discovery,2965,O
of,2965,O
Lp,2965,B-GENE-Y
(,2965,I-GENE-Y
a,2965,I-GENE-Y
),2965,I-GENE-Y
lipoprotein,2965,B-GENE-N
and,2965,O
its,2965,O
structural,2965,O
similarity,2965,O
with,2965,O
plasminogen,2965,B-GENE-Y
suggests,2965,O
another,2965,O
pathogenic,2965,O
link,2965,O
between,2965,O
atherogenesis,2965,O
and,2965,O
thrombogenesis,2965,O
.,2965,O
SOME,2966,O
CHARACTERISTICS,2966,O
OF,2966,O
LP,2966,B-GENE-Y
(,2966,I-GENE-Y
A,2966,I-GENE-Y
),2966,I-GENE-Y
LIPOPROTEIN,2966,B-GENE-N
:,2966,O
This,2966,O
lipoprotein,2966,O
is,2966,O
present,2966,O
in,2966,O
the,2966,O
whole,2966,O
human,2966,O
population,2966,O
in,2966,O
a,2966,O
wide,2966,O
range,2966,O
of,2966,O
plasma,2966,O
concentrations,2966,O
.,2966,O
It,2967,O
has,2967,O
numerous,2967,O
different,2967,O
isoforms,2967,O
.,2967,O
Its,2968,O
synthesis,2968,O
occurs,2968,O
in,2968,O
the,2968,O
liver,2968,O
",",2968,O
but,2968,O
it,2968,O
is,2968,O
practically,2968,O
metabolically,2968,O
independent,2968,O
from,2968,O
other,2968,O
lipoproteins,2968,B-GENE-N
.,2968,O
Today,2969,O
",",2969,O
Lp,2969,B-GENE-Y
(,2969,I-GENE-Y
a,2969,I-GENE-Y
),2969,I-GENE-Y
lipoprotein,2969,B-GENE-N
is,2969,O
considered,2969,O
to,2969,O
be,2969,O
an,2969,O
independent,2969,O
risk,2969,O
factor,2969,O
for,2969,O
heart,2969,O
and,2969,O
brain,2969,O
ischemic,2969,O
disease,2969,O
.,2969,O
FIBRINOLYTIC,2970,O
MECHANISMS,2970,O
:,2970,O
The,2970,O
primary,2970,O
role,2970,O
of,2970,O
the,2970,O
fibrinolytic,2970,O
mechanism,2970,O
is,2970,O
to,2970,O
prevent,2970,O
thrombus,2970,O
Jormation,2970,O
during,2970,O
circulation,2970,O
and,2970,O
to,2970,O
remove,2970,O
already,2970,O
formed,2970,O
ones,2970,O
.,2970,O
Plasmin,2971,B-GENE-Y
has,2971,O
a,2971,O
central,2971,O
role,2971,O
in,2971,O
this,2971,O
process,2971,O
",",2971,O
due,2971,O
to,2971,O
the,2971,O
inactive,2971,O
proenzyme,2971,O
plasminogen,2971,B-GENE-Y
.,2971,O
Its,2972,O
basic,2972,O
activators,2972,O
are,2972,O
tissue-type,2972,B-GENE-Y
plasminogen,2972,I-GENE-Y
activator,2972,I-GENE-Y
(,2972,O
t-PA,2972,B-GENE-Y
),2972,O
and,2972,O
urokinase,2972,B-GENE-Y
plasminogen,2972,I-GENE-Y
activator,2972,I-GENE-Y
(,2972,O
u-PA,2972,B-GENE-Y
),2972,O
.,2972,O
The,2973,O
most,2973,O
important,2973,O
inhibitors,2973,O
of,2973,O
plasminogen,2973,B-GENE-Y
are,2973,O
alpha2-antiplasmin,2973,B-GENE-Y
and,2973,O
plasminogen,2973,B-GENE-N
activator,2973,I-GENE-N
inhibitors,2973,I-GENE-N
1,2973,I-GENE-N
and,2973,I-GENE-N
2,2973,I-GENE-N
(,2973,O
PA-1,2973,B-GENE-Y
and,2973,O
PAI-2,2973,B-GENE-Y
),2973,O
.,2973,O
Structural,2974,O
similarity,2974,O
of,2974,O
Lp,2974,B-GENE-Y
(,2974,I-GENE-Y
a,2974,I-GENE-Y
),2974,I-GENE-Y
and,2974,O
plasminogen,2974,B-GENE-Y
The,2974,O
apo,2974,B-GENE-N
(,2974,I-GENE-N
a,2974,I-GENE-N
),2974,I-GENE-N
and,2974,O
plasminogen,2974,B-GENE-Y
genes,2974,O
are,2974,O
very,2974,O
closely,2974,O
linked,2974,O
on,2974,O
the,2974,O
long,2974,O
arm,2974,O
of,2974,O
chromosome,2974,O
6,2974,O
.,2974,O
Because,2975,O
of,2975,O
that,2975,O
they,2975,O
are,2975,O
structuraly,2975,O
very,2975,O
similar,2975,O
and,2975,O
they,2975,O
have,2975,O
a,2975,O
cross,2975,O
immunological,2975,O
reactivity,2975,O
.,2975,O
Their,2976,O
common,2976,O
elements,2976,O
are,2976,O
so-called,2976,O
``,2976,O
kringle,2976,O
'',2976,O
structures,2976,O
.,2976,O
The,2977,O
key,2977,O
difference,2977,O
in,2977,O
structure,2977,O
of,2977,O
Lp,2977,B-GENE-Y
(,2977,I-GENE-Y
a,2977,I-GENE-Y
),2977,I-GENE-Y
and,2977,O
plasminogen,2977,B-GENE-Y
is,2977,O
replacement,2977,O
of,2977,O
Arg,2977,B-CHEMICAL
with,2977,O
Ser,2977,B-CHEMICAL
at,2977,O
position,2977,O
560,2977,O
.,2977,O
This,2978,O
prevents,2978,O
splitting,2978,O
of,2978,O
apo,2978,B-GENE-N
(,2978,I-GENE-N
a,2978,I-GENE-N
),2978,I-GENE-N
by,2978,O
plasminogen,2978,B-GENE-N
activators,2978,I-GENE-N
.,2978,O
LP,2979,B-GENE-Y
(,2979,I-GENE-Y
A,2979,I-GENE-Y
),2979,I-GENE-Y
AND,2979,O
FIBRINOLYSIS,2979,O
:,2979,O
Lp,2979,B-GENE-Y
(,2979,I-GENE-Y
a,2979,I-GENE-Y
),2979,I-GENE-Y
lipoprotein,2979,B-GENE-N
inhibits,2979,O
activation,2979,O
of,2979,O
plasminogen,2979,B-GENE-Y
by,2979,O
streptokinase,2979,B-GENE-N
.,2979,O
It,2980,O
is,2980,O
also,2980,O
a,2980,O
competitive,2980,O
inhibitor,2980,O
of,2980,O
plasminogen,2980,B-GENE-Y
for,2980,O
its,2980,O
binding,2980,O
to,2980,O
plasminogen,2980,B-GENE-N
receptors,2980,I-GENE-N
.,2980,O
Furthermore,2981,O
",",2981,O
it,2981,O
successfully,2981,O
achieves,2981,O
competitive,2981,O
inhibition,2981,O
of,2981,O
plasminogen,2981,B-GENE-Y
for,2981,O
binding,2981,O
to,2981,O
tetranectin,2981,B-GENE-Y
and,2981,O
thrombospondin,2981,B-GENE-Y
.,2981,O
Also,2982,O
",",2982,O
Lp,2982,B-GENE-Y
(,2982,I-GENE-Y
a,2982,I-GENE-Y
),2982,I-GENE-Y
inhibits,2982,O
activation,2982,O
of,2982,O
transforming,2982,B-GENE-Y
growth,2982,I-GENE-Y
factor,2982,I-GENE-Y
alpha,2982,I-GENE-Y
(,2982,O
TGF-alpha,2982,B-GENE-Y
),2982,O
.,2982,O
It,2983,O
positively,2983,O
correlates,2983,O
with,2983,O
PAI-1,2983,B-GENE-Y
and,2983,O
it,2983,O
is,2983,O
assumed,2983,O
that,2983,O
it,2983,O
promotes,2983,O
release,2983,O
of,2983,O
tissue,2983,B-GENE-Y
factor,2983,I-GENE-Y
pathway,2983,O
inhibitor,2983,O
(,2983,O
17FPI,2983,O
),2983,O
from,2983,O
endothelial,2983,O
cell,2983,O
surfaces,2983,O
.,2983,O
CONCLUSION,2984,O
:,2984,O
In,2984,O
regulation,2984,O
of,2984,O
the,2984,O
hemostatic,2984,O
system,2984,O
via,2984,O
apolipoprotein,2984,B-GENE-N
(,2984,I-GENE-N
a,2984,I-GENE-N
),2984,I-GENE-N
antifibrinolytic,2984,O
effects,2984,O
",",2984,O
Lp,2984,B-GENE-Y
(,2984,I-GENE-Y
a,2984,I-GENE-Y
),2984,I-GENE-Y
lipoprotein,2984,B-GENE-N
ojfers,2984,O
a,2984,O
molecular,2984,O
solution,2984,O
to,2984,O
the,2984,O
link,2984,O
between,2984,O
thrombogenesis,2984,O
and,2984,O
atherogenesis,2984,O
.,2984,O
Sunitinib,2985,B-CHEMICAL
",",2985,O
sorafenib,2985,B-CHEMICAL
and,2985,O
mTOR,2985,B-GENE-Y
inhibitors,2985,O
in,2985,O
renal,2985,O
cancer,2985,O
.,2985,O
Understanding,2986,O
the,2986,O
alterations,2986,O
in,2986,O
cellular,2986,O
protein,2986,O
interactions,2986,O
and,2986,O
their,2986,O
relations,2986,O
to,2986,O
genetic,2986,O
mutations,2986,O
that,2986,O
cause,2986,O
renal,2986,O
cell,2986,O
carcinoma,2986,O
(,2986,O
RCC,2986,O
),2986,O
provides,2986,O
a,2986,O
unique,2986,O
opportunity,2986,O
for,2986,O
the,2986,O
development,2986,O
of,2986,O
disease-specific,2986,O
therapy,2986,O
for,2986,O
patients,2986,O
with,2986,O
advanced,2986,O
forms,2986,O
of,2986,O
this,2986,O
disease,2986,O
.,2986,O
There,2987,O
is,2987,O
substantial,2987,O
evidence,2987,O
of,2987,O
an,2987,O
association,2987,O
between,2987,O
mutation,2987,O
on,2987,O
von,2987,B-GENE-Y
Hippel-Lindau,2987,I-GENE-Y
(,2987,O
VHL,2987,B-GENE-Y
),2987,O
gene,2987,O
and,2987,O
the,2987,O
earliest,2987,O
stages,2987,O
of,2987,O
tumorigenesis,2987,O
of,2987,O
RCC,2987,O
.,2987,O
The,2988,O
main,2988,O
consequence,2988,O
of,2988,O
VHL,2988,B-GENE-Y
loss,2988,O
is,2988,O
the,2988,O
upregulation,2988,O
of,2988,O
downstream,2988,O
proangiogenic,2988,O
factors,2988,O
leading,2988,O
to,2988,O
highly,2988,O
vascular,2988,O
tumors,2988,O
.,2988,O
Overexpression,2989,O
of,2989,O
hypoxia,2989,B-GENE-N
inducible,2989,I-GENE-N
factor,2989,I-GENE-N
(,2989,O
HIF,2989,B-GENE-N
),2989,O
is,2989,O
also,2989,O
caused,2989,O
by,2989,O
the,2989,O
mammalian,2989,B-GENE-Y
target,2989,I-GENE-Y
of,2989,I-GENE-Y
rapamycin,2989,I-GENE-Y
(,2989,O
mTOR,2989,B-GENE-Y
),2989,O
",",2989,O
a,2989,O
key,2989,O
component,2989,O
of,2989,O
signaling,2989,O
pathways,2989,O
inside,2989,O
the,2989,O
cell,2989,O
",",2989,O
involved,2989,O
in,2989,O
cell,2989,O
proliferation,2989,O
.,2989,O
The,2990,O
inhibition,2990,O
of,2990,O
proangiogenic,2990,O
factors,2990,O
and,2990,O
mTOR,2990,B-GENE-Y
was,2990,O
the,2990,O
main,2990,O
idea,2990,O
behind,2990,O
the,2990,O
development,2990,O
of,2990,O
new,2990,O
targeted,2990,O
agents,2990,O
in,2990,O
advanced,2990,O
RCC,2990,O
.,2990,O
Since,2991,O
December,2991,O
2005,2991,O
",",2991,O
3,2991,O
targeted,2991,O
agents,2991,O
have,2991,O
been,2991,O
approved,2991,O
by,2991,O
the,2991,O
U.S.,2991,O
Food,2991,O
and,2991,O
Drug,2991,O
Administration,2991,O
(,2991,O
FDA,2991,O
),2991,O
for,2991,O
the,2991,O
treatment,2991,O
of,2991,O
advanced,2991,O
RCC,2991,O
:,2991,O
sorafenib,2991,B-CHEMICAL
",",2991,O
sunitinib,2991,B-CHEMICAL
and,2991,O
temsirolimus,2991,B-CHEMICAL
.,2991,O
Sorafenib,2992,B-CHEMICAL
and,2992,O
sunitinib,2992,B-CHEMICAL
are,2992,O
synthetic,2992,O
",",2992,O
orally,2992,O
active,2992,O
agents,2992,O
shown,2992,O
to,2992,O
directly,2992,O
inhibit,2992,O
vascular,2992,B-GENE-N
endothelial,2992,I-GENE-N
growth,2992,I-GENE-N
factor,2992,I-GENE-N
receptors,2992,I-GENE-N
-2,2992,I-GENE-N
and,2992,I-GENE-N
-3,2992,I-GENE-N
(,2992,O
VEGFR-2,2992,B-GENE-Y
",",2992,O
VEGFR-3,2992,B-GENE-Y
),2992,O
and,2992,O
platelet-derived,2992,B-GENE-Y
growth,2992,I-GENE-Y
factor,2992,I-GENE-Y
receptor,2992,I-GENE-Y
beta,2992,I-GENE-Y
(,2992,O
PDGFR-beta,2992,B-GENE-Y
),2992,O
",",2992,O
while,2992,O
temsirolimus,2992,B-CHEMICAL
is,2992,O
an,2992,O
mTOR,2992,B-GENE-Y
inhibitor,2992,O
.,2992,O
Recent,2993,O
clinical,2993,O
studies,2993,O
form,2993,O
the,2993,O
basis,2993,O
for,2993,O
new,2993,O
guidelines,2993,O
for,2993,O
the,2993,O
treatment,2993,O
of,2993,O
advanced,2993,O
RCC,2993,O
:,2993,O
sorafenib,2993,B-CHEMICAL
should,2993,O
be,2993,O
used,2993,O
as,2993,O
a,2993,O
second-line,2993,O
treatment,2993,O
",",2993,O
sunitinib,2993,B-CHEMICAL
as,2993,O
the,2993,O
first-line,2993,O
therapy,2993,O
for,2993,O
good,2993,O
and,2993,O
intermediate-risk,2993,O
patients,2993,O
",",2993,O
and,2993,O
temsirolimus,2993,B-CHEMICAL
should,2993,O
be,2993,O
considered,2993,O
as,2993,O
first-line,2993,O
treatment,2993,O
for,2993,O
poor-risk,2993,O
patients,2993,O
.,2993,O
Future,2994,O
approaches,2994,O
to,2994,O
targeted,2994,O
therapy,2994,O
should,2994,O
focus,2994,O
on,2994,O
optimizing,2994,O
the,2994,O
use,2994,O
of,2994,O
current,2994,O
active,2994,O
drugs,2994,O
",",2994,O
exploring,2994,O
their,2994,O
combinations,2994,O
or,2994,O
investigating,2994,O
their,2994,O
sequential,2994,O
use,2994,O
.,2994,O
In,2995,O
addition,2995,O
",",2995,O
it,2995,O
is,2995,O
important,2995,O
to,2995,O
define,2995,O
the,2995,O
mechanisms,2995,O
of,2995,O
resistance,2995,O
on,2995,O
their,2995,O
use,2995,O
and,2995,O
to,2995,O
further,2995,O
investigate,2995,O
biomarkers,2995,O
and,2995,O
enhance,2995,O
treatment,2995,O
efficacy,2995,O
for,2995,O
the,2995,O
individual,2995,O
patients,2995,O
.,2995,O
The,2996,O
development,2996,O
of,2996,O
these,2996,O
targeted,2996,O
therapies,2996,O
represents,2996,O
an,2996,O
exciting,2996,O
step,2996,O
forward,2996,O
in,2996,O
the,2996,O
treatment,2996,O
of,2996,O
advanced,2996,O
RCC,2996,O
.,2996,O
Management,2997,O
of,2997,O
psoriasis,2997,O
:,2997,O
the,2997,O
position,2997,O
of,2997,O
retinoid,2997,B-CHEMICAL
drugs,2997,O
.,2997,O
Oral,2998,O
synthetic,2998,O
retinoids,2998,B-CHEMICAL
have,2998,O
been,2998,O
established,2998,O
as,2998,O
effective,2998,O
systemic,2998,O
therapy,2998,O
for,2998,O
psoriasis,2998,O
since,2998,O
their,2998,O
introduction,2998,O
for,2998,O
clinical,2998,O
use,2998,O
in,2998,O
the,2998,O
1970s,2998,O
;,2998,O
a,2998,O
compound,2998,O
for,2998,O
topical,2998,O
use,2998,O
",",2998,O
tazarotene,2998,B-CHEMICAL
has,2998,O
been,2998,O
recently,2998,O
marketed,2998,O
.,2998,O
Despite,2999,O
the,2999,O
demonstrated,2999,O
clinical,2999,O
success,2999,O
of,2999,O
retinoid,2999,B-CHEMICAL
therapy,2999,O
in,2999,O
psoriasis,2999,O
",",2999,O
its,2999,O
mechanism,2999,O
of,2999,O
action,2999,O
has,2999,O
not,2999,O
been,2999,O
fully,2999,O
elucidated,2999,O
",",2999,O
and,2999,O
investigators,2999,O
are,2999,O
confronted,2999,O
with,2999,O
two,2999,O
paradoxes,2999,O
.,2999,O
One,3000,O
is,3000,O
that,3000,O
the,3000,O
binding,3000,O
of,3000,O
retinoids,3000,B-CHEMICAL
to,3000,O
nuclear,3000,O
retinoic,3000,B-CHEMICAL
acid,3000,I-CHEMICAL
receptors,3000,I-GENE-N
(,3000,O
RARs,3000,B-GENE-N
),3000,O
does,3000,O
not,3000,O
match,3000,O
their,3000,O
therapeutic,3000,O
efficacy,3000,O
:,3000,O
acitretin,3000,B-CHEMICAL
activates,3000,O
the,3000,O
three,3000,O
receptor,3000,O
subtypes,3000,O
",",3000,O
RAR-alpha,3000,B-GENE-N
",",3000,I-GENE-N
-beta,3000,I-GENE-N
and,3000,I-GENE-N
-gamma,3000,I-GENE-N
",",3000,O
without,3000,O
measurable,3000,O
receptor,3000,O
binding,3000,O
",",3000,O
whereas,3000,O
tazarotene,3000,B-CHEMICAL
preferentially,3000,O
binds,3000,O
to,3000,O
and,3000,O
activates,3000,O
RAR-beta,3000,B-GENE-N
and,3000,I-GENE-N
-gamma,3000,I-GENE-N
in,3000,O
preference,3000,O
to,3000,O
RAR-alpha,3000,B-GENE-Y
.,3000,O
The,3001,O
other,3001,O
is,3001,O
that,3001,O
there,3001,O
is,3001,O
already,3001,O
increased,3001,O
formation,3001,O
of,3001,O
retinoic,3001,B-CHEMICAL
acid,3001,I-CHEMICAL
in,3001,O
the,3001,O
psoriatic,3001,O
lesion,3001,O
.,3001,O
Answering,3002,O
these,3002,O
questions,3002,O
should,3002,O
result,3002,O
in,3002,O
better,3002,O
use,3002,O
of,3002,O
these,3002,O
drugs,3002,O
in,3002,O
the,3002,O
treatment,3002,O
of,3002,O
psoriasis,3002,O
.,3002,O
Oral,3003,O
administration,3003,O
of,3003,O
acitretin,3003,B-CHEMICAL
remains,3003,O
one,3003,O
of,3003,O
the,3003,O
first,3003,O
therapeutic,3003,O
choices,3003,O
for,3003,O
severe,3003,O
psoriasis,3003,O
",",3003,O
particularly,3003,O
in,3003,O
association,3003,O
with,3003,O
ultraviolet,3003,O
light,3003,O
therapy,3003,O
",",3003,O
of,3003,O
which,3003,O
it,3003,O
may,3003,O
decrease,3003,O
the,3003,O
carcinogenic,3003,O
risk,3003,O
.,3003,O
Topical,3004,O
tazarotene,3004,B-CHEMICAL
is,3004,O
suitable,3004,O
for,3004,O
moderate,3004,O
plaque,3004,O
psoriasis,3004,O
.,3004,O
Its,3005,O
efficacy,3005,O
and,3005,O
tolerability,3005,O
can,3005,O
be,3005,O
enhanced,3005,O
by,3005,O
the,3005,O
addition,3005,O
of,3005,O
topical,3005,O
corticosteroids,3005,B-CHEMICAL
;,3005,O
its,3005,O
irritative,3005,O
potential,3005,O
is,3005,O
counterbalanced,3005,O
by,3005,O
a,3005,O
sustained,3005,O
therapeutic,3005,O
effect,3005,O
after,3005,O
the,3005,O
treatment,3005,O
is,3005,O
stopped,3005,O
.,3005,O
Comprehensive,3006,O
review,3006,O
of,3006,O
rasagiline,3006,B-CHEMICAL
",",3006,O
a,3006,O
second-generation,3006,O
monoamine,3006,B-GENE-N
oxidase,3006,I-GENE-N
inhibitor,3006,O
",",3006,O
for,3006,O
the,3006,O
treatment,3006,O
of,3006,O
Parkinson,3006,O
's,3006,O
disease,3006,O
.,3006,O
BACKGROUND,3007,O
:,3007,O
Inhibitors,3007,O
of,3007,O
monoamine,3007,B-GENE-N
oxidase,3007,I-GENE-N
(,3007,O
MAO,3007,B-GENE-N
),3007,O
with,3007,O
selectivity,3007,O
and,3007,O
specificity,3007,O
for,3007,O
MAO,3007,B-GENE-Y
type,3007,I-GENE-Y
B,3007,I-GENE-Y
(,3007,O
MAO-B,3007,B-GENE-Y
),3007,O
prolong,3007,O
the,3007,O
duration,3007,O
of,3007,O
action,3007,O
of,3007,O
both,3007,O
endogenously,3007,O
and,3007,O
exogenously,3007,O
derived,3007,O
dopamine,3007,B-CHEMICAL
.,3007,O
Rasagiline,3008,B-CHEMICAL
[,3008,O
N-propargyl-l,3008,B-CHEMICAL
(,3008,I-CHEMICAL
R,3008,I-CHEMICAL
),3008,I-CHEMICAL
-aminoindan,3008,I-CHEMICAL
],3008,O
is,3008,O
a,3008,O
second-generation,3008,O
propargylamine,3008,B-CHEMICAL
pharmacophore,3008,O
that,3008,O
selectively,3008,O
and,3008,O
irreversibly,3008,O
inhibits,3008,O
brain,3008,O
MAO-B,3008,B-GENE-Y
and,3008,O
is,3008,O
specifically,3008,O
designed,3008,O
for,3008,O
the,3008,O
treatment,3008,O
of,3008,O
Parkinson,3008,O
's,3008,O
disease,3008,O
(,3008,O
PD,3008,O
),3008,O
.,3008,O
OBJECTIVE,3009,O
:,3009,O
The,3009,O
aim,3009,O
of,3009,O
this,3009,O
study,3009,O
was,3009,O
to,3009,O
review,3009,O
the,3009,O
pharmacology,3009,O
",",3009,O
tolerability,3009,O
",",3009,O
and,3009,O
clinical,3009,O
efficacy,3009,O
of,3009,O
rasagiline,3009,B-CHEMICAL
in,3009,O
the,3009,O
treatment,3009,O
of,3009,O
PD,3009,O
.,3009,O
METHODS,3010,O
:,3010,O
MEDLINE,3010,O
(,3010,O
1966-April,3010,O
2007,3010,O
),3010,O
",",3010,O
the,3010,O
Cochrane,3010,O
Database,3010,O
of,3010,O
Systematic,3010,O
Reviews,3010,O
",",3010,O
and,3010,O
International,3010,O
Pharmaceutical,3010,O
Abstracts,3010,O
(,3010,O
1970-April,3010,O
2007,3010,O
),3010,O
were,3010,O
searched,3010,O
for,3010,O
original,3010,O
research,3010,O
and,3010,O
review,3010,O
articles,3010,O
published,3010,O
in,3010,O
English,3010,O
.,3010,O
The,3011,O
search,3011,O
terms,3011,O
were,3011,O
monoamine,3011,B-GENE-N
oxidase,3011,I-GENE-N
",",3011,O
neuroprotection,3011,O
",",3011,O
Parkinson,3011,O
disease,3011,O
",",3011,O
propargylamine,3011,B-CHEMICAL
",",3011,O
rasagiline,3011,B-CHEMICAL
",",3011,O
and,3011,O
selegiline,3011,B-CHEMICAL
.,3011,O
The,3012,O
reference,3012,O
lists,3012,O
of,3012,O
articles,3012,O
were,3012,O
also,3012,O
consulted,3012,O
",",3012,O
as,3012,O
was,3012,O
information,3012,O
provided,3012,O
by,3012,O
the,3012,O
manufacturer,3012,O
of,3012,O
rasagiline,3012,B-CHEMICAL
.,3012,O
RESULTS,3013,O
:,3013,O
Data,3013,O
from,3013,O
63,3013,O
clinical,3013,O
and,3013,O
laboratory,3013,O
studies,3013,O
were,3013,O
analyzed,3013,O
.,3013,O
Based,3014,O
on,3014,O
the,3014,O
results,3014,O
from,3014,O
those,3014,O
studies,3014,O
",",3014,O
we,3014,O
concluded,3014,O
that,3014,O
rasagiline,3014,B-CHEMICAL
PO,3014,O
QD,3014,O
",",3014,O
at,3014,O
the,3014,O
therapeutic,3014,O
dosage,3014,O
range,3014,O
of,3014,O
0.5,3014,O
to,3014,O
1,3014,O
rag/d,3014,O
",",3014,O
is,3014,O
effective,3014,O
and,3014,O
well,3014,O
tolerated,3014,O
and,3014,O
completely,3014,O
",",3014,O
selectively,3014,O
",",3014,O
and,3014,O
specifically,3014,O
inhibited,3014,O
MAO-B,3014,B-GENE-Y
.,3014,O
Pharmacologically,3015,O
",",3015,O
rasagiline,3015,B-CHEMICAL
was,3015,O
found,3015,O
to,3015,O
be,3015,O
<,3015,O
or,3015,O
=10-fold,3015,O
more,3015,O
potent,3015,O
than,3015,O
selegiline,3015,B-CHEMICAL
and,3015,O
was,3015,O
not,3015,O
metabolized,3015,O
to,3015,O
amphetamine,3015,B-CHEMICAL
derivatives,3015,O
.,3015,O
Rasagiline,3016,B-CHEMICAL
was,3016,O
effective,3016,O
both,3016,O
as,3016,O
monotherapy,3016,O
in,3016,O
early,3016,O
PD,3016,O
and,3016,O
as,3016,O
adjunctive,3016,O
treatment,3016,O
in,3016,O
patients,3016,O
with,3016,O
advancing,3016,O
PD,3016,O
and,3016,O
motor,3016,O
fluctuations,3016,O
.,3016,O
As,3017,O
monotherapy,3017,O
",",3017,O
rasagiline,3017,B-CHEMICAL
provided,3017,O
modest,3017,O
yet,3017,O
clinically,3017,O
meaningful,3017,O
benefit,3017,O
.,3017,O
A,3018,O
randomized,3018,O
",",3018,O
double-blind,3018,O
",",3018,O
placebo-controlled,3018,O
study,3018,O
found,3018,O
that,3018,O
",",3018,O
after,3018,O
26,3018,O
weeks,3018,O
of,3018,O
treatment,3018,O
",",3018,O
the,3018,O
adjusted,3018,O
effect,3018,O
size,3018,O
for,3018,O
total,3018,O
Unified,3018,O
Parkinson,3018,O
's,3018,O
Disease,3018,O
Rating,3018,O
Scale,3018,O
score,3018,O
was,3018,O
-4.20,3018,O
(,3018,O
95,3018,O
%,3018,O
CI,3018,O
",",3018,O
-5.66,3018,O
to,3018,O
-2.73,3018,O
),3018,O
for,3018,O
rasagiline,3018,O
1,3018,O
mg/d,3018,O
versus,3018,O
placebo,3018,O
(,3018,O
P,3018,O
<,3018,O
0.001,3018,O
),3018,O
.,3018,O
Preliminary,3019,O
long-term,3019,O
data,3019,O
from,3019,O
an,3019,O
open-label,3019,O
study,3019,O
suggest,3019,O
a,3019,O
sustained,3019,O
therapeutic,3019,O
advantage,3019,O
when,3019,O
rasagiline,3019,O
is,3019,O
initiated,3019,O
early,3019,O
(,3019,O
before,3019,O
the,3019,O
need,3019,O
for,3019,O
dopaminergic,3019,O
agents,3019,O
),3019,O
rather,3019,O
than,3019,O
later,3019,O
.,3019,O
In,3020,O
patients,3020,O
with,3020,O
more,3020,O
advanced,3020,O
disease,3020,O
who,3020,O
received,3020,O
treatment,3020,O
with,3020,O
dopaminergic,3020,O
agents,3020,O
",",3020,O
rasagiline,3020,B-CHEMICAL
and,3020,O
entacapone,3020,B-CHEMICAL
were,3020,O
associated,3020,O
with,3020,O
reductions,3020,O
of,3020,O
``,3020,O
off,3020,O
'',3020,O
time,3020,O
significantly,3020,O
greater,3020,O
than,3020,O
placebo,3020,O
(,3020,O
-1.18,3020,O
and,3020,O
-1.2,3020,O
vs,3020,O
0.4,3020,O
hour,3020,O
;,3020,O
both,3020,O
",",3020,O
P,3020,O
<,3020,O
or,3020,O
=,3020,O
0.001,3020,O
),3020,O
.,3020,O
Rasagiline,3021,B-CHEMICAL
was,3021,O
well,3021,O
tolerated,3021,O
in,3021,O
younger,3021,O
(,3021,O
aged,3021,O
<,3021,O
;,3021,O
70,3021,O
years,3021,O
),3021,O
and,3021,O
older,3021,O
(,3021,O
aged,3021,O
>,3021,O
or,3021,O
=70,3021,O
years,3021,O
),3021,O
patients,3021,O
with,3021,O
early,3021,O
or,3021,O
advanced,3021,O
PD,3021,O
.,3021,O
Pharmacologically,3022,O
",",3022,O
rasagiline,3022,O
has,3022,O
the,3022,O
potential,3022,O
to,3022,O
augment,3022,O
the,3022,O
vasopressor,3022,O
effects,3022,O
of,3022,O
diet-derived,3022,O
tyramine,3022,B-CHEMICAL
(,3022,O
ie,3022,O
",",3022,O
the,3022,O
``,3022,O
cheese,3022,O
reaction,3022,O
'',3022,O
),3022,O
.,3022,O
However,3023,O
",",3023,O
clinical,3023,O
challenge,3023,O
studies,3023,O
of,3023,O
tyramine,3023,B-CHEMICAL
have,3023,O
found,3023,O
this,3023,O
unlikely,3023,O
to,3023,O
occur,3023,O
even,3023,O
with,3023,O
ingestion,3023,O
of,3023,O
supraphysiologic,3023,O
amounts,3023,O
of,3023,O
tyramine,3023,B-CHEMICAL
.,3023,O
In,3024,O
experimental,3024,O
models,3024,O
",",3024,O
rasagiline,3024,B-CHEMICAL
has,3024,O
been,3024,O
found,3024,O
to,3024,O
have,3024,O
neuroprotective,3024,O
properties,3024,O
that,3024,O
may,3024,O
be,3024,O
independent,3024,O
of,3024,O
MAO-B,3024,B-GENE-Y
inhibition,3024,O
.,3024,O
CONCLUSIONS,3025,O
:,3025,O
Based,3025,O
on,3025,O
this,3025,O
review,3025,O
",",3025,O
rasagiline,3025,B-CHEMICAL
has,3025,O
been,3025,O
found,3025,O
to,3025,O
be,3025,O
well,3025,O
tolerated,3025,O
and,3025,O
effective,3025,O
in,3025,O
the,3025,O
treatment,3025,O
of,3025,O
early,3025,O
PD,3025,O
and,3025,O
as,3025,O
adjunctive,3025,O
treatment,3025,O
in,3025,O
motor,3025,O
fluctuations,3025,O
.,3025,O
Whether,3026,O
rasagiline,3026,O
is,3026,O
associated,3026,O
with,3026,O
clinically,3026,O
significant,3026,O
neuroprotection,3026,O
(,3026,O
ie,3026,O
",",3026,O
disease,3026,O
modification,3026,O
),3026,O
in,3026,O
PD,3026,O
is,3026,O
the,3026,O
subject,3026,O
of,3026,O
ongoing,3026,O
clinical,3026,O
trials,3026,O
.,3026,O
Mutation,3027,O
of,3027,O
Gly721,3027,O
alters,3027,O
DNA,3027,B-GENE-Y
topoisomerase,3027,I-GENE-Y
I,3027,I-GENE-Y
active,3027,O
site,3027,O
architecture,3027,O
and,3027,O
sensitivity,3027,O
to,3027,O
camptothecin,3027,B-CHEMICAL
.,3027,O
DNA,3028,B-GENE-Y
topoisomerase,3028,I-GENE-Y
I,3028,I-GENE-Y
(,3028,O
Top1p,3028,B-GENE-Y
),3028,O
catalyzes,3028,O
the,3028,O
relaxation,3028,O
of,3028,O
supercoiled,3028,O
DNA,3028,O
via,3028,O
a,3028,O
concerted,3028,O
mechanism,3028,O
of,3028,O
DNA,3028,O
strand,3028,O
cleavage,3028,O
and,3028,O
religation,3028,O
.,3028,O
Top1p,3029,B-GENE-Y
is,3029,O
the,3029,O
cellular,3029,O
target,3029,O
of,3029,O
the,3029,O
anti-cancer,3029,O
drug,3029,O
camptothecin,3029,B-CHEMICAL
(,3029,O
CPT,3029,B-CHEMICAL
),3029,O
",",3029,O
which,3029,O
reversibly,3029,O
stabilizes,3029,O
a,3029,O
covalent,3029,O
enzyme-DNA,3029,O
intermediate,3029,O
.,3029,O
Top1p,3030,B-GENE-Y
clamps,3030,O
around,3030,O
duplex,3030,O
DNA,3030,O
",",3030,O
wherein,3030,O
the,3030,O
core,3030,O
and,3030,O
C-terminal,3030,B-CHEMICAL
domains,3030,O
are,3030,O
connected,3030,O
by,3030,O
extended,3030,O
alpha-helices,3030,B-GENE-N
(,3030,O
linker,3030,B-GENE-N
domain,3030,I-GENE-N
),3030,O
",",3030,O
which,3030,O
position,3030,O
the,3030,O
active,3030,O
site,3030,O
Tyr,3030,B-CHEMICAL
of,3030,O
the,3030,O
C-terminal,3030,B-CHEMICAL
domain,3030,O
within,3030,O
the,3030,O
catalytic,3030,O
pocket,3030,O
.,3030,O
The,3031,O
physical,3031,O
connection,3031,O
of,3031,O
the,3031,O
linker,3031,O
with,3031,O
the,3031,O
Top1p,3031,B-GENE-Y
clamp,3031,O
as,3031,O
well,3031,O
as,3031,O
linker,3031,O
flexibility,3031,O
affect,3031,O
enzyme,3031,O
sensitivity,3031,O
to,3031,O
CPT,3031,B-CHEMICAL
.,3031,O
Crystallographic,3032,O
data,3032,O
reveal,3032,O
that,3032,O
a,3032,O
conserved,3032,O
Gly,3032,B-CHEMICAL
residue,3032,O
(,3032,O
located,3032,O
at,3032,O
the,3032,O
juncture,3032,O
between,3032,O
the,3032,O
linker,3032,O
and,3032,O
C-terminal,3032,B-CHEMICAL
domains,3032,O
),3032,O
is,3032,O
at,3032,O
one,3032,O
end,3032,O
of,3032,O
a,3032,O
short,3032,O
alpha-helix,3032,B-GENE-N
",",3032,O
which,3032,O
extends,3032,O
to,3032,O
the,3032,O
active,3032,O
site,3032,O
Tyr,3032,B-CHEMICAL
covalently,3032,O
linked,3032,O
to,3032,O
the,3032,O
DNA,3032,O
.,3032,O
In,3033,O
the,3033,O
presence,3033,O
of,3033,O
drug,3033,O
",",3033,O
the,3033,O
linker,3033,O
is,3033,O
rigid,3033,O
and,3033,O
this,3033,O
alpha-helix,3033,B-GENE-N
extends,3033,O
to,3033,O
include,3033,O
Gly,3033,B-CHEMICAL
and,3033,O
the,3033,O
preceding,3033,O
Leu,3033,B-CHEMICAL
.,3033,O
We,3034,O
report,3034,O
that,3034,O
mutation,3034,O
of,3034,O
this,3034,O
conserved,3034,O
Gly,3034,B-CHEMICAL
in,3034,O
yeast,3034,B-GENE-Y
Top1p,3034,I-GENE-Y
alters,3034,O
enzyme,3034,O
sensitivity,3034,O
to,3034,O
CPT,3034,B-CHEMICAL
.,3034,O
Mutating,3035,O
Gly,3035,B-CHEMICAL
to,3035,O
Asp,3035,B-CHEMICAL
",",3035,O
Glu,3035,B-CHEMICAL
",",3035,O
Asn,3035,B-CHEMICAL
",",3035,O
Gln,3035,B-CHEMICAL
",",3035,O
Leu,3035,B-CHEMICAL
",",3035,O
or,3035,O
Ala,3035,B-CHEMICAL
enhanced,3035,O
enzyme,3035,O
CPT,3035,B-CHEMICAL
sensitivity,3035,O
",",3035,O
with,3035,O
the,3035,O
acidic,3035,O
residues,3035,O
inducing,3035,O
the,3035,O
greatest,3035,O
increase,3035,O
in,3035,O
drug,3035,O
sensitivity,3035,O
in,3035,O
vivo,3035,O
and,3035,O
in,3035,O
vitro,3035,O
.,3035,O
By,3036,O
contrast,3036,O
",",3036,O
Val,3036,B-CHEMICAL
or,3036,O
Phe,3036,B-CHEMICAL
substituents,3036,O
rendered,3036,O
the,3036,O
enzyme,3036,O
CPT-resistant,3036,B-CHEMICAL
.,3036,O
Mutation-induced,3037,O
alterations,3037,O
in,3037,O
enzyme,3037,O
architecture,3037,O
preceding,3037,O
the,3037,O
active,3037,O
site,3037,O
Tyr,3037,B-CHEMICAL
suggest,3037,O
these,3037,O
structural,3037,O
transitions,3037,O
modulate,3037,O
enzyme,3037,O
sensitivity,3037,O
to,3037,O
CPT,3037,B-CHEMICAL
",",3037,O
while,3037,O
enhancing,3037,O
the,3037,O
rate,3037,O
of,3037,O
DNA,3037,O
cleavage,3037,O
.,3037,O
We,3038,O
postulate,3038,O
that,3038,O
this,3038,O
conserved,3038,O
Gly,3038,B-CHEMICAL
residue,3038,O
provides,3038,O
a,3038,O
flexible,3038,O
hinge,3038,O
within,3038,O
the,3038,O
Top1p,3038,B-GENE-Y
catalytic,3038,O
pocket,3038,O
to,3038,O
facilitate,3038,O
linker,3038,O
dynamics,3038,O
and,3038,O
the,3038,O
structural,3038,O
alterations,3038,O
that,3038,O
accompany,3038,O
drug,3038,O
binding,3038,O
of,3038,O
the,3038,O
covalent,3038,O
enzyme-DNA,3038,O
intermediate,3038,O
.,3038,O
Characterization,3039,O
of,3039,O
the,3039,O
substrate,3039,O
mimic,3039,O
bound,3039,O
to,3039,O
engineered,3039,O
prostacyclin,3039,B-GENE-Y
synthase,3039,I-GENE-Y
in,3039,O
solution,3039,O
using,3039,O
high-resolution,3039,O
NMR,3039,O
spectroscopy,3039,O
and,3039,O
mutagenesis,3039,O
:,3039,O
implication,3039,O
of,3039,O
the,3039,O
molecular,3039,O
mechanism,3039,O
in,3039,O
biosynthesis,3039,O
of,3039,O
prostacyclin,3039,B-CHEMICAL
.,3039,O
High-resolution,3040,O
NMR,3040,O
spectroscopy,3040,O
was,3040,O
used,3040,O
to,3040,O
determine,3040,O
the,3040,O
docking,3040,O
of,3040,O
a,3040,O
substrate,3040,O
(,3040,O
prostaglandin,3040,B-CHEMICAL
H2,3040,I-CHEMICAL
),3040,O
mimic,3040,O
(,3040,O
U46619,3040,B-CHEMICAL
),3040,O
to,3040,O
the,3040,O
engineered,3040,O
prostacyclin,3040,B-CHEMICAL
(,3040,I-GENE-Y
PGI2,3040,B-CHEMICAL
),3040,I-GENE-Y
synthase,3040,I-GENE-Y
(,3040,O
PGIS,3040,B-GENE-Y
),3040,O
in,3040,O
solution,3040,O
.,3040,O
The,3041,O
binding,3041,O
of,3041,O
U46619,3041,B-CHEMICAL
to,3041,O
the,3041,O
PGIS,3041,B-GENE-Y
protein,3041,O
was,3041,O
demonstrated,3041,O
by,3041,O
1D,3041,O
NMR,3041,O
titration,3041,O
",",3041,O
and,3041,O
the,3041,O
significant,3041,O
perturbation,3041,O
of,3041,O
the,3041,O
chemical,3041,O
shifts,3041,O
of,3041,O
protons,3041,O
at,3041,O
C-11,3041,B-CHEMICAL
",",3041,O
H2C,3041,B-CHEMICAL
",",3041,O
and,3041,O
H20,3041,B-CHEMICAL
of,3041,O
U46619,3041,B-CHEMICAL
were,3041,O
observed,3041,O
upon,3041,O
U46619,3041,B-CHEMICAL
binding,3041,O
to,3041,O
the,3041,O
engineered,3041,O
PGIS,3041,B-GENE-Y
in,3041,O
a,3041,O
concentration-dependent,3041,O
manner,3041,O
.,3041,O
The,3042,O
detailed,3042,O
conformational,3042,O
change,3042,O
and,3042,O
3D,3042,O
structure,3042,O
of,3042,O
the,3042,O
PGIS-bound,3042,B-GENE-Y
U46619,3042,B-CHEMICAL
were,3042,O
further,3042,O
demonstrated,3042,O
by,3042,O
2D,3042,O
1H,3042,B-CHEMICAL
NMR,3042,O
experiments,3042,O
using,3042,O
the,3042,O
transferred,3042,O
NOE,3042,O
technique,3042,O
.,3042,O
The,3043,O
distances,3043,O
between,3043,O
the,3043,O
protons,3043,O
H20,3043,B-CHEMICAL
and,3043,O
H2,3043,B-CHEMICAL
",",3043,O
H18,3043,B-CHEMICAL
and,3043,O
H2,3043,B-CHEMICAL
",",3043,O
and,3043,O
H18,3043,B-CHEMICAL
and,3043,O
H4,3043,B-CHEMICAL
are,3043,O
shorter,3043,O
following,3043,O
their,3043,O
binding,3043,O
to,3043,O
the,3043,O
PGIS,3043,B-GENE-Y
in,3043,O
solution-down,3043,O
to,3043,O
within,3043,O
5,3043,O
A,3043,O
.,3043,O
These,3044,O
shorter,3044,O
distances,3044,O
resulted,3044,O
in,3044,O
a,3044,O
widely,3044,O
open,3044,O
conformation,3044,O
",",3044,O
where,3044,O
the,3044,O
triangle,3044,O
shape,3044,O
of,3044,O
the,3044,O
unbound,3044,O
U46619,3044,B-CHEMICAL
changed,3044,O
to,3044,O
a,3044,O
more,3044,O
compact,3044,O
conformation,3044,O
with,3044,O
an,3044,O
oval,3044,O
shape,3044,O
.,3044,O
The,3045,O
bound,3045,O
conformation,3045,O
of,3045,O
U46619,3045,B-CHEMICAL
fits,3045,O
the,3045,O
crystal,3045,O
structure,3045,O
of,3045,O
the,3045,O
PGIS,3045,B-GENE-Y
substrate,3045,O
binding,3045,O
pocket,3045,O
considerably,3045,O
better,3045,O
than,3045,O
that,3045,O
of,3045,O
the,3045,O
unbound,3045,O
U46619,3045,B-CHEMICAL
.,3045,O
The,3046,O
residues,3046,O
important,3046,O
to,3046,O
the,3046,O
substrate,3046,O
binding,3046,O
in,3046,O
the,3046,O
active,3046,O
site,3046,O
pocket,3046,O
of,3046,O
PGIS,3046,B-GENE-Y
were,3046,O
also,3046,O
predicted,3046,O
.,3046,O
For,3047,O
example,3047,O
",",3047,O
Trp282,3047,O
could,3047,O
be,3047,O
one,3047,O
of,3047,O
the,3047,O
most,3047,O
important,3047,O
residues,3047,O
and,3047,O
is,3047,O
suspected,3047,O
to,3047,O
play,3047,O
a,3047,O
role,3047,O
in,3047,O
the,3047,O
determination,3047,O
of,3047,O
specific,3047,O
catalytic,3047,O
function,3047,O
",",3047,O
which,3047,O
has,3047,O
been,3047,O
established,3047,O
by,3047,O
the,3047,O
docking,3047,O
studies,3047,O
using,3047,O
the,3047,O
NMR,3047,O
structure,3047,O
of,3047,O
the,3047,O
PGIS-bound,3047,B-GENE-Y
form,3047,O
of,3047,O
U46619,3047,B-CHEMICAL
and,3047,O
the,3047,O
PGIS,3047,B-GENE-Y
crystal,3047,O
structure,3047,O
.,3047,O
These,3048,O
studies,3048,O
have,3048,O
provided,3048,O
the,3048,O
structural,3048,O
information,3048,O
for,3048,O
the,3048,O
interaction,3048,O
of,3048,O
the,3048,O
PGIS,3048,B-GENE-Y
with,3048,O
its,3048,O
substrate,3048,O
mimic,3048,O
.,3048,O
The,3049,O
noted,3049,O
conformational,3049,O
changes,3049,O
where,3049,O
the,3049,O
C-6,3049,B-CHEMICAL
position,3049,O
is,3049,O
closer,3049,O
to,3049,O
the,3049,O
C-9,3049,B-CHEMICAL
position,3049,O
of,3049,O
U46619,3049,B-CHEMICAL
provided,3049,O
the,3049,O
first,3049,O
experimental,3049,O
data,3049,O
for,3049,O
understanding,3049,O
the,3049,O
molecular,3049,O
mechanism,3049,O
of,3049,O
the,3049,O
catalytic,3049,O
function,3049,O
of,3049,O
PGIS,3049,B-GENE-Y
in,3049,O
the,3049,O
isomerization,3049,O
of,3049,O
PGH2,3049,B-CHEMICAL
to,3049,O
prostacyclin,3049,B-CHEMICAL
.,3049,O
Type,3050,O
2,3050,O
diabetes,3050,O
and,3050,O
oral,3050,O
antihyperglycemic,3050,O
drugs,3050,O
.,3050,O
Type,3051,O
II,3051,O
diabetes,3051,O
is,3051,O
a,3051,O
heterogeneous,3051,O
disease,3051,O
where,3051,O
environment,3051,O
and,3051,O
genetics,3051,O
are,3051,O
important,3051,O
factors,3051,O
for,3051,O
the,3051,O
expression,3051,O
of,3051,O
the,3051,O
disease,3051,O
.,3051,O
The,3052,O
high,3052,O
cost,3052,O
for,3052,O
treating,3052,O
complications,3052,O
of,3052,O
diabetes,3052,O
is,3052,O
a,3052,O
burden,3052,O
for,3052,O
public,3052,O
health,3052,O
systems,3052,O
and,3052,O
governments,3052,O
worldwide,3052,O
.,3052,O
Type,3053,O
II,3053,O
diabetes,3053,O
has,3053,O
been,3053,O
causing,3053,O
debilitation,3053,O
worldwide,3053,O
for,3053,O
many,3053,O
decades,3053,O
",",3053,O
and,3053,O
a,3053,O
single,3053,O
drug,3053,O
that,3053,O
safely,3053,O
treats,3053,O
the,3053,O
disease,3053,O
has,3053,O
yet,3053,O
to,3053,O
be,3053,O
discovered,3053,O
.,3053,O
Sulfonylureas,3054,B-CHEMICAL
",",3054,O
biguanides,3054,B-CHEMICAL
",",3054,O
alpha-glucosidase,3054,B-GENE-N
",",3054,O
meglitinides,3054,B-CHEMICAL
",",3054,O
DPP-4,3054,B-GENE-Y
inhibitors,3054,O
and,3054,O
thiazolidinediones,3054,B-CHEMICAL
are,3054,O
among,3054,O
the,3054,O
classes,3054,O
of,3054,O
oral,3054,O
hypoglycemic,3054,O
drugs,3054,O
available,3054,O
to,3054,O
treat,3054,O
Type,3054,O
II,3054,O
diabetes,3054,O
",",3054,O
but,3054,O
concerns,3054,O
exist,3054,O
regarding,3054,O
safety,3054,O
and,3054,O
efficacy,3054,O
of,3054,O
these,3054,O
drugs,3054,O
.,3054,O
In,3055,O
this,3055,O
article,3055,O
we,3055,O
present,3055,O
the,3055,O
pros,3055,O
and,3055,O
cons,3055,O
of,3055,O
the,3055,O
six,3055,O
classes,3055,O
and,3055,O
discuss,3055,O
some,3055,O
of,3055,O
the,3055,O
latest,3055,O
advances,3055,O
towards,3055,O
the,3055,O
development,3055,O
of,3055,O
new,3055,O
drugs,3055,O
for,3055,O
the,3055,O
treatment,3055,O
of,3055,O
Type,3055,O
II,3055,O
diabetes,3055,O
.,3055,O
Asenapine,3056,B-CHEMICAL
:,3056,O
a,3056,O
novel,3056,O
psychopharmacologic,3056,O
agent,3056,O
with,3056,O
a,3056,O
unique,3056,O
human,3056,O
receptor,3056,O
signature,3056,O
.,3056,O
Asenapine,3057,B-CHEMICAL
is,3057,O
a,3057,O
novel,3057,O
psychopharmacologic,3057,O
agent,3057,O
under,3057,O
development,3057,O
for,3057,O
the,3057,O
treatment,3057,O
of,3057,O
schizophrenia,3057,O
and,3057,O
bipolar,3057,O
disorder,3057,O
.,3057,O
We,3058,O
determined,3058,O
and,3058,O
compared,3058,O
the,3058,O
human,3058,O
receptor,3058,O
binding,3058,O
affinities,3058,O
and,3058,O
functional,3058,O
characteristics,3058,O
of,3058,O
asenapine,3058,B-CHEMICAL
and,3058,O
several,3058,O
antipsychotic,3058,O
drugs,3058,O
.,3058,O
Compounds,3059,O
were,3059,O
tested,3059,O
under,3059,O
comparable,3059,O
assay,3059,O
conditions,3059,O
using,3059,O
cloned,3059,O
human,3059,O
receptors,3059,O
.,3059,O
In,3060,O
comparison,3060,O
with,3060,O
the,3060,O
antipsychotics,3060,O
",",3060,O
asenapine,3060,O
showed,3060,O
high,3060,O
affinity,3060,O
and,3060,O
a,3060,O
different,3060,O
rank,3060,O
order,3060,O
of,3060,O
binding,3060,O
affinities,3060,O
(,3060,O
pKi,3060,O
),3060,O
for,3060,O
serotonin,3060,B-GENE-N
receptors,3060,I-GENE-N
(,3060,O
5-HT1A,3060,B-GENE-Y
[,3060,O
8.6,3060,O
],3060,O
",",3060,O
5-HT1B,3060,B-GENE-Y
[,3060,O
8.4,3060,O
],3060,O
",",3060,O
5-HT2A,3060,B-GENE-Y
[,3060,O
10.2,3060,O
],3060,O
",",3060,O
5-HT2B,3060,B-GENE-Y
[,3060,O
9.8,3060,O
],3060,O
",",3060,O
5-HT2C,3060,B-GENE-Y
[,3060,O
10.5,3060,O
],3060,O
",",3060,O
5-HT5,3060,B-GENE-Y
[,3060,O
8.8,3060,O
],3060,O
",",3060,O
5-HT6,3060,B-GENE-Y
[,3060,O
9.6,3060,O
],3060,O
and,3060,O
5-HT7,3060,B-GENE-Y
[,3060,O
9.9,3060,O
],3060,O
),3060,O
",",3060,O
adrenoceptors,3060,B-GENE-N
(,3060,I-GENE-N
alpha1,3060,I-GENE-N
[,3060,O
8.9,3060,O
],3060,O
",",3060,O
alpha2A,3060,B-GENE-Y
[,3060,O
8.9,3060,O
],3060,O
",",3060,O
alpha2B,3060,B-GENE-Y
[,3060,O
9.5,3060,O
],3060,O
and,3060,O
alpha2C,3060,B-GENE-Y
[,3060,O
8.9,3060,O
],3060,O
),3060,O
",",3060,O
dopamine,3060,B-CHEMICAL
receptors,3060,I-GENE-Y
(,3060,I-GENE-Y
D1,3060,I-GENE-Y
[,3060,O
8.9,3060,O
],3060,O
",",3060,O
D2,3060,B-GENE-Y
[,3060,O
8.9,3060,O
],3060,O
",",3060,O
D3,3060,B-GENE-Y
[,3060,O
9.4,3060,O
],3060,O
and,3060,O
D4,3060,B-GENE-Y
[,3060,O
9.0,3060,O
],3060,O
),3060,O
and,3060,O
histamine,3060,B-CHEMICAL
receptors,3060,I-GENE-Y
(,3060,I-GENE-Y
H1,3060,I-GENE-Y
[,3060,O
9.0,3060,O
],3060,O
and,3060,O
H2,3060,B-GENE-Y
[,3060,O
8.2,3060,O
],3060,O
),3060,O
.,3060,O
It,3061,O
had,3061,O
much,3061,O
lower,3061,O
affinity,3061,O
(,3061,O
pKi,3061,O
<,3061,O
or=5,3061,O
),3061,O
for,3061,O
muscarinic,3061,O
receptors,3061,O
and,3061,O
was,3061,O
the,3061,O
only,3061,O
agent,3061,O
with,3061,O
affinity,3061,O
for,3061,O
H2,3061,O
receptors,3061,O
.,3061,O
Relative,3062,O
to,3062,O
its,3062,O
D2,3062,O
receptor,3062,O
affinity,3062,O
",",3062,O
asenapine,3062,O
had,3062,O
a,3062,O
higher,3062,O
affinity,3062,O
for,3062,O
5-HT2C,3062,O
",",3062,O
5-HT2A,3062,O
",",3062,O
5-HT2B,3062,O
",",3062,O
5-HT7,3062,O
",",3062,O
5-HT6,3062,O
",",3062,O
alpha2B,3062,O
and,3062,O
D3,3062,O
receptors,3062,O
",",3062,O
suggesting,3062,O
stronger,3062,O
engagement,3062,O
of,3062,O
these,3062,O
targets,3062,O
at,3062,O
therapeutic,3062,O
doses,3062,O
.,3062,O
Asenapine,3063,O
behaved,3063,O
as,3063,O
a,3063,O
potent,3063,O
antagonist,3063,O
(,3063,O
pKB,3063,O
),3063,O
at,3063,O
5-HT1A,3063,O
(,3063,O
7.4,3063,O
),3063,O
",",3063,O
5-HT1B,3063,O
(,3063,O
8.1,3063,O
),3063,O
",",3063,O
5-HT2A,3063,O
(,3063,O
9.0,3063,O
),3063,O
",",3063,O
5-HT2B,3063,O
(,3063,O
9.3,3063,O
),3063,O
",",3063,O
5-HT2C,3063,O
(,3063,O
9.0,3063,O
),3063,O
",",3063,O
5-HT6,3063,O
(,3063,O
8.0,3063,O
),3063,O
",",3063,O
5-HT7,3063,O
(,3063,O
8.5,3063,O
),3063,O
",",3063,O
D2,3063,O
(,3063,O
9.1,3063,O
),3063,O
",",3063,O
D3,3063,O
(,3063,O
9.1,3063,O
),3063,O
",",3063,O
alpha2A,3063,O
(,3063,O
7.3,3063,O
),3063,O
",",3063,O
alpha2B,3063,O
(,3063,O
8.3,3063,O
),3063,O
",",3063,O
alpha2C,3063,O
(,3063,O
6.8,3063,O
),3063,O
and,3063,O
H1,3063,O
(,3063,O
8.4,3063,O
),3063,O
receptors,3063,O
.,3063,O
These,3064,O
functional,3064,O
effects,3064,O
differed,3064,O
from,3064,O
those,3064,O
of,3064,O
risperidone,3064,O
(,3064,O
pKB,3064,O
<,3064,O
5,3064,O
for,3064,O
5-HT6,3064,O
),3064,O
and,3064,O
olanzapine,3064,O
(,3064,O
pKB,3064,O
<,3064,O
5,3064,O
for,3064,O
5-HT1A,3064,O
and,3064,O
alpha2,3064,O
),3064,O
.,3064,O
Our,3065,O
results,3065,O
indicate,3065,O
that,3065,O
asenapine,3065,O
has,3065,O
a,3065,O
unique,3065,O
human,3065,O
receptor,3065,O
signature,3065,O
",",3065,O
with,3065,O
binding,3065,O
affinity,3065,O
and,3065,O
antagonistic,3065,O
properties,3065,O
that,3065,O
differ,3065,O
appreciably,3065,O
from,3065,O
those,3065,O
of,3065,O
antipsychotic,3065,O
drugs,3065,O
.,3065,O
Current,3066,O
and,3066,O
future,3066,O
prospects,3066,O
for,3066,O
anticoagulant,3066,O
therapy,3066,O
:,3066,O
inhibitors,3066,O
of,3066,O
factor,3066,B-GENE-Y
Xa,3066,I-GENE-Y
and,3066,O
factor,3066,B-GENE-Y
IIa,3066,I-GENE-Y
.,3066,O
Indirect,3067,O
systemic,3067,O
and,3067,O
direct,3067,O
oral,3067,O
factor,3067,O
Xa,3067,O
and,3067,O
direct,3067,O
oral,3067,O
factor,3067,B-GENE-Y
IIa,3067,I-GENE-Y
inhibitors,3067,O
with,3067,O
improved,3067,O
pharmacologic,3067,O
profiles,3067,O
compared,3067,O
with,3067,O
heparins,3067,O
and,3067,O
vitamin,3067,B-CHEMICAL
K,3067,I-CHEMICAL
antagonists,3067,O
are,3067,O
currently,3067,O
in,3067,O
clinical,3067,O
development,3067,O
.,3067,O
This,3068,O
overview,3068,O
focuses,3068,O
on,3068,O
the,3068,O
indirect,3068,O
antithrombin,3068,O
dependent,3068,O
pentasaccharide,3068,B-CHEMICAL
derivatives,3068,O
of,3068,O
idraparinux,3068,B-CHEMICAL
and,3068,O
on,3068,O
the,3068,O
most,3068,O
advanced,3068,O
oral,3068,O
direct,3068,O
inhibitors,3068,O
to,3068,O
factor,3068,B-GENE-Y
Xa,3068,I-GENE-Y
(,3068,O
rivaroxaban,3068,B-CHEMICAL
and,3068,O
apixaban,3068,B-CHEMICAL
),3068,O
and,3068,O
IIa,3068,O
(,3068,O
dabigatran,3068,B-CHEMICAL
),3068,O
.,3068,O
Specifically,3069,O
",",3069,O
the,3069,O
results,3069,O
of,3069,O
dose-finding,3069,O
studies,3069,O
for,3069,O
the,3069,O
prevention,3069,O
of,3069,O
venous,3069,O
thromboembolism,3069,O
after,3069,O
elective,3069,O
orthopedic,3069,O
surgery,3069,O
",",3069,O
the,3069,O
results,3069,O
of,3069,O
dose-finding,3069,O
studies,3069,O
for,3069,O
treatment,3069,O
of,3069,O
acute,3069,O
venous,3069,O
thromboembolism,3069,O
including,3069,O
prolonged,3069,O
prophylaxis,3069,O
of,3069,O
recurrent,3069,O
events,3069,O
",",3069,O
and,3069,O
the,3069,O
designs,3069,O
of,3069,O
ongoing,3069,O
clinical,3069,O
trials,3069,O
are,3069,O
reviewed,3069,O
.,3069,O
Triple,3070,O
pharmacological,3070,O
blockade,3070,O
of,3070,O
the,3070,O
renin-angiotensin-aldosterone,3070,B-GENE-Y
system,3070,O
in,3070,O
nondiabetic,3070,O
CKD,3070,O
:,3070,O
an,3070,O
open-label,3070,O
crossover,3070,O
randomized,3070,O
controlled,3070,O
trial,3070,O
.,3070,O
BACKGROUND,3071,O
:,3071,O
Agents,3071,O
inhibiting,3071,O
the,3071,O
renin-angiotensin-aldosterone,3071,B-GENE-Y
(,3071,O
RAAS,3071,O
),3071,O
system,3071,O
have,3071,O
an,3071,O
important,3071,O
role,3071,O
in,3071,O
slowing,3071,O
the,3071,O
progression,3071,O
of,3071,O
chronic,3071,O
kidney,3071,O
disease,3071,O
.,3071,O
We,3072,O
evaluated,3072,O
the,3072,O
hypothesis,3072,O
that,3072,O
the,3072,O
addition,3072,O
of,3072,O
an,3072,O
aldosterone,3072,B-CHEMICAL
receptor,3072,I-GENE-Y
antagonist,3072,O
to,3072,O
an,3072,O
angiotensin-converting,3072,B-GENE-Y
enzyme,3072,I-GENE-Y
(,3072,O
ACE,3072,B-GENE-Y
),3072,O
inhibitor,3072,O
and,3072,O
angiotensin,3072,B-CHEMICAL
II,3072,I-CHEMICAL
type,3072,I-GENE-Y
1,3072,I-GENE-Y
(,3072,I-GENE-Y
AT-1,3072,I-GENE-Y
),3072,I-GENE-Y
receptor,3072,I-GENE-Y
blocker,3072,O
(,3072,O
ARB,3072,O
),3072,O
(,3072,O
triple,3072,O
RAAS,3072,O
blockade,3072,O
),3072,O
may,3072,O
provide,3072,O
an,3072,O
additional,3072,O
benefit,3072,O
compared,3072,O
with,3072,O
an,3072,O
ACE,3072,B-GENE-Y
inhibitor,3072,O
and,3072,O
ARB,3072,O
(,3072,O
double,3072,O
RAAS,3072,O
blockade,3072,O
),3072,O
.,3072,O
DESIGN,3073,O
:,3073,O
Randomized,3073,O
open,3073,O
controlled,3073,O
crossover,3073,O
study,3073,O
.,3073,O
SETTING,3074,O
&,3074,O
PARTICIPANTS,3074,O
:,3074,O
18,3074,O
whites,3074,O
(,3074,O
7,3074,O
women,3074,O
",",3074,O
11,3074,O
men,3074,O
),3074,O
from,3074,O
the,3074,O
Outpatient,3074,O
Department,3074,O
of,3074,O
Nephrology,3074,O
with,3074,O
chronic,3074,O
nondiabetic,3074,O
proteinuric,3074,O
kidney,3074,O
diseases,3074,O
",",3074,O
mean,3074,O
age,3074,O
42.4,3074,O
+/-,3074,O
1.9,3074,O
years,3074,O
(,3074,O
SEM,3074,O
),3074,O
.,3074,O
INTERVENTIONS,3075,O
:,3075,O
In,3075,O
the,3075,O
8-week,3075,O
run-in,3075,O
period,3075,O
",",3075,O
all,3075,O
participants,3075,O
received,3075,O
the,3075,O
ACE,3075,B-GENE-Y
inhibitor,3075,O
cilazapril,3075,B-CHEMICAL
(,3075,O
5,3075,O
mg,3075,O
),3075,O
",",3075,O
the,3075,O
ARB,3075,O
telmisartan,3075,B-CHEMICAL
(,3075,O
80,3075,O
mg,3075,O
),3075,O
",",3075,O
and,3075,O
the,3075,O
diuretic,3075,O
hydrochlorothiazide,3075,B-CHEMICAL
(,3075,O
12.5,3075,O
mg,3075,O
),3075,O
as,3075,O
double,3075,O
RAAS,3075,O
blockade,3075,O
to,3075,O
achieve,3075,O
the,3075,O
target,3075,O
blood,3075,O
pressure,3075,O
of,3075,O
less,3075,O
than,3075,O
130/80,3075,O
mm,3075,O
Hg,3075,O
.,3075,O
Participants,3076,O
were,3076,O
then,3076,O
randomly,3076,O
assigned,3076,O
to,3076,O
2,3076,O
treatment,3076,O
sequences,3076,O
",",3076,O
either,3076,O
the,3076,O
addition,3076,O
of,3076,O
spironolactone,3076,B-CHEMICAL
(,3076,O
25,3076,O
mg,3076,O
),3076,O
(,3076,O
triple,3076,O
RAAS,3076,O
blockade,3076,O
),3076,O
through,3076,O
8,3076,O
weeks,3076,O
followed,3076,O
by,3076,O
double,3076,O
RAAS,3076,O
blockade,3076,O
through,3076,O
8,3076,O
weeks,3076,O
(,3076,O
sequence,3076,O
1,3076,O
),3076,O
or,3076,O
double,3076,O
RAAS,3076,O
blockade,3076,O
followed,3076,O
by,3076,O
triple,3076,O
RAAS,3076,O
blockade,3076,O
(,3076,O
sequence,3076,O
2,3076,O
),3076,O
.,3076,O
MAIN,3077,O
OUTCOME,3077,O
MEASURES,3077,O
:,3077,O
24-hour,3077,O
urine,3077,O
protein,3077,O
excretion,3077,O
(,3077,O
primary,3077,O
end,3077,O
point,3077,O
),3077,O
and,3077,O
markers,3077,O
of,3077,O
tubular,3077,O
injury,3077,O
and,3077,O
fibrosis,3077,O
(,3077,O
secondary,3077,O
end,3077,O
points,3077,O
),3077,O
.,3077,O
Analysis,3078,O
was,3078,O
performed,3078,O
using,3078,O
analysis,3078,O
of,3078,O
variance,3078,O
for,3078,O
repeated,3078,O
measurements,3078,O
.,3078,O
RESULTS,3079,O
:,3079,O
At,3079,O
baseline,3079,O
",",3079,O
mean,3079,O
serum,3079,O
creatinine,3079,O
level,3079,O
was,3079,O
1.16,3079,O
+/-,3079,O
0.09,3079,O
mg/dL,3079,O
(,3079,O
103,3079,O
+/-,3079,O
8,3079,O
micromol/L,3079,O
),3079,O
",",3079,O
estimated,3079,O
glomerular,3079,O
filtration,3079,O
rate,3079,O
was,3079,O
107.8,3079,O
mL/min,3079,O
(,3079,O
95,3079,O
%,3079,O
confidence,3079,O
interval,3079,O
",",3079,O
93,3079,O
to,3079,O
140.9,3079,O
[,3079,O
1.8,3079,O
mL/s,3079,O
;,3079,O
95,3079,O
%,3079,O
confidence,3079,O
interval,3079,O
",",3079,O
1.55,3079,O
to,3079,O
2.35,3079,O
;,3079,O
Cockcroft-Gault,3079,O
formula,3079,O
),3079,O
",",3079,O
and,3079,O
24-hour,3079,O
mean,3079,O
proteinuria,3079,O
was,3079,O
0.97,3079,O
+/-,3079,O
0.18,3079,O
g.,3079,O
Mean,3079,O
urine,3079,O
protein,3079,O
excretion,3079,O
was,3079,O
0.7,3079,O
g/24,3079,O
h,3079,O
(,3079,O
95,3079,O
%,3079,O
confidence,3079,O
interval,3079,O
",",3079,O
0.48,3079,O
to,3079,O
0.92,3079,O
),3079,O
less,3079,O
after,3079,O
triple,3079,O
RAAS,3079,O
blockade,3079,O
than,3079,O
after,3079,O
double,3079,O
RAAS,3079,O
blockade,3079,O
(,3079,O
P,3079,O
=,3079,O
0.01,3079,O
),3079,O
",",3079,O
without,3079,O
change,3079,O
in,3079,O
blood,3079,O
pressure,3079,O
.,3079,O
Urine,3080,O
excretion,3080,O
of,3080,O
N-acetyl-beta-d-glucosaminidase,3080,B-GENE-Y
(,3080,O
P,3080,O
=,3080,O
0.02,3080,O
),3080,O
and,3080,O
amino-terminal,3080,O
propeptide,3080,O
of,3080,O
type,3080,B-GENE-N
III,3080,I-GENE-N
procollagen,3080,I-GENE-N
(,3080,O
P,3080,O
=,3080,O
0.05,3080,O
),3080,O
also,3080,O
significantly,3080,O
decreased,3080,O
.,3080,O
Potassium,3081,B-CHEMICAL
levels,3081,O
increased,3081,O
significantly,3081,O
after,3081,O
triple,3081,O
therapy,3081,O
(,3081,O
P,3081,O
=,3081,O
0.02,3081,O
),3081,O
.,3081,O
However,3082,O
",",3082,O
no,3082,O
patient,3082,O
was,3082,O
withdrawn,3082,O
because,3082,O
of,3082,O
adverse,3082,O
effects,3082,O
.,3082,O
LIMITATIONS,3083,O
:,3083,O
Absence,3083,O
of,3083,O
blinding,3083,O
",",3083,O
small,3083,O
sample,3083,O
size,3083,O
",",3083,O
short,3083,O
treatment,3083,O
period,3083,O
",",3083,O
absence,3083,O
of,3083,O
histological,3083,O
assessment,3083,O
.,3083,O
CONCLUSIONS,3084,O
:,3084,O
Administration,3084,O
of,3084,O
an,3084,O
aldosterone,3084,B-CHEMICAL
receptor,3084,I-GENE-Y
antagonist,3084,O
in,3084,O
addition,3084,O
to,3084,O
double,3084,O
RAAS,3084,O
blockade,3084,O
with,3084,O
an,3084,O
ACE,3084,B-GENE-Y
inhibitor,3084,O
and,3084,O
ARB,3084,O
may,3084,O
slow,3084,O
the,3084,O
progression,3084,O
of,3084,O
chronic,3084,O
kidney,3084,O
disease,3084,O
.,3084,O
Additional,3085,O
studies,3085,O
are,3085,O
necessary,3085,O
to,3085,O
confirm,3085,O
this,3085,O
result,3085,O
.,3085,O
Porcine,3086,O
TLR8,3086,B-GENE-Y
and,3086,O
TLR7,3086,B-GENE-Y
are,3086,O
both,3086,O
activated,3086,O
by,3086,O
a,3086,O
selective,3086,O
TLR7,3086,B-GENE-Y
ligand,3086,O
",",3086,O
imiquimod,3086,B-CHEMICAL
.,3086,O
Toll-like,3087,B-GENE-N
receptors,3087,I-GENE-N
(,3087,O
TLRs,3087,B-GENE-N
),3087,O
are,3087,O
a,3087,O
family,3087,O
of,3087,O
highly,3087,O
conserved,3087,O
germline-encoded,3087,O
pattern-recognition,3087,B-GENE-N
receptors,3087,I-GENE-N
(,3087,O
PRR,3087,B-GENE-N
),3087,O
",",3087,O
which,3087,O
are,3087,O
utilized,3087,O
by,3087,O
the,3087,O
innate,3087,O
immune,3087,O
system,3087,O
to,3087,O
recognize,3087,O
microbial,3087,O
components,3087,O
",",3087,O
known,3087,O
as,3087,O
pathogen-associated,3087,O
molecular,3087,O
patterns,3087,O
(,3087,O
PAMP,3087,O
),3087,O
.,3087,O
We,3088,O
cloned,3088,O
and,3088,O
characterized,3088,O
porcine,3088,O
TLR7,3088,B-GENE-Y
and,3088,O
TLR8,3088,B-GENE-Y
genes,3088,O
from,3088,O
pig,3088,O
lymph,3088,O
node,3088,O
tissue,3088,O
.,3088,O
Sequence,3089,O
analysis,3089,O
showed,3089,O
that,3089,O
the,3089,O
aa,3089,O
sequence,3089,O
identities,3089,O
of,3089,O
porcine,3089,B-GENE-Y
TLR7,3089,I-GENE-Y
with,3089,O
human,3089,B-GENE-N
",",3089,I-GENE-N
mouse,3089,I-GENE-N
and,3089,I-GENE-N
bovine,3089,I-GENE-N
TLR7,3089,I-GENE-N
are,3089,O
85,3089,O
",",3089,O
78,3089,O
and,3089,O
90,3089,O
%,3089,O
",",3089,O
respectively,3089,O
",",3089,O
whereas,3089,O
porcine,3089,B-GENE-Y
TLR8,3089,I-GENE-Y
aa,3089,O
sequence,3089,O
identities,3089,O
with,3089,O
human,3089,B-GENE-N
",",3089,I-GENE-N
mouse,3089,I-GENE-N
and,3089,I-GENE-N
bovine,3089,I-GENE-N
TLR8,3089,I-GENE-N
are,3089,O
73,3089,O
",",3089,O
69,3089,O
and,3089,O
79,3089,O
%,3089,O
",",3089,O
respectively,3089,O
.,3089,O
Both,3090,O
porcine,3090,B-GENE-N
TLR7,3090,I-GENE-N
and,3090,O
TLR8,3090,B-GENE-N
proteins,3090,O
were,3090,O
expressed,3090,O
in,3090,O
cell,3090,O
lines,3090,O
and,3090,O
were,3090,O
N-glycosylated,3090,B-CHEMICAL
.,3090,O
The,3091,O
stimulatory,3091,O
activity,3091,O
of,3091,O
TLR7,3091,B-GENE-Y
and,3091,O
TLR8,3091,B-GENE-Y
ligands,3091,O
to,3091,O
porcine,3091,B-GENE-N
and,3091,I-GENE-N
human,3091,I-GENE-N
TLR7,3091,I-GENE-N
and,3091,O
TLR8,3091,B-GENE-N
in,3091,O
transiently,3091,O
transfected,3091,O
Cos-7,3091,O
and,3091,O
293T,3091,O
cells,3091,O
were,3091,O
analyzed,3091,O
using,3091,O
a,3091,O
NF-kappaB,3091,B-GENE-N
reporter,3091,O
assay,3091,O
.,3091,O
Two,3092,O
imidazoquinoline,3092,B-CHEMICAL
molecules,3092,O
",",3092,O
imiquimod,3092,B-CHEMICAL
and,3092,O
gardiquimod,3092,B-CHEMICAL
",",3092,O
markedly,3092,O
activated,3092,O
both,3092,O
porcine,3092,B-GENE-Y
TLR7,3092,I-GENE-Y
and,3092,O
TLR8,3092,B-GENE-Y
whereas,3092,O
only,3092,O
human,3092,B-GENE-Y
TLR7,3092,I-GENE-Y
",",3092,O
but,3092,O
not,3092,O
TLR8,3092,B-GENE-Y
",",3092,O
was,3092,O
activated,3092,O
by,3092,O
the,3092,O
ligands,3092,O
.,3092,O
Therefore,3093,O
",",3093,O
receptor,3093,O
specificity,3093,O
for,3093,O
porcine,3093,B-GENE-Y
TLR8,3093,I-GENE-Y
is,3093,O
clearly,3093,O
species,3093,O
specific,3093,O
.,3093,O
We,3094,O
further,3094,O
showed,3094,O
that,3094,O
porcine,3094,B-GENE-Y
TLR7,3094,I-GENE-Y
and,3094,O
TLR8,3094,B-GENE-Y
are,3094,O
located,3094,O
intracellularly,3094,O
and,3094,O
are,3094,O
mainly,3094,O
within,3094,O
the,3094,O
endoplasmic,3094,O
reticulum,3094,O
.,3094,O
Moreover,3095,O
",",3095,O
activation,3095,O
of,3095,O
transfected,3095,O
cells,3095,O
and,3095,O
porcine,3095,O
PBMC,3095,O
by,3095,O
TLR7,3095,B-GENE-Y
ligands,3095,O
was,3095,O
inhibited,3095,O
by,3095,O
bafilomycin,3095,B-CHEMICAL
A,3095,I-CHEMICAL
(,3095,I-CHEMICAL
1,3095,I-CHEMICAL
),3095,I-CHEMICAL
indicating,3095,O
the,3095,O
requirement,3095,O
of,3095,O
endosomal/lysosomal,3095,O
acidification,3095,O
for,3095,O
activation,3095,O
of,3095,O
the,3095,O
receptors,3095,O
.,3095,O
High-affinity,3096,O
blockade,3096,O
of,3096,O
voltage-operated,3096,B-GENE-N
skeletal,3096,I-GENE-N
muscle,3096,I-GENE-N
and,3096,I-GENE-N
neuronal,3096,I-GENE-N
sodium,3096,I-GENE-N
channels,3096,I-GENE-N
by,3096,O
halogenated,3096,B-CHEMICAL
propofol,3096,I-CHEMICAL
analogues,3096,O
.,3096,O
BACKGROUND,3097,O
AND,3097,O
PURPOSE,3097,O
:,3097,O
Voltage-operated,3097,B-GENE-N
sodium,3097,B-CHEMICAL
channels,3097,I-GENE-N
constitute,3097,O
major,3097,O
target,3097,O
sites,3097,O
for,3097,O
local,3097,O
anaesthetic-like,3097,O
action,3097,O
.,3097,O
The,3098,O
clinical,3098,O
use,3098,O
of,3098,O
local,3098,O
anaesthetics,3098,O
is,3098,O
still,3098,O
limited,3098,O
by,3098,O
severe,3098,O
side,3098,O
effects,3098,O
",",3098,O
in,3098,O
particular,3098,O
",",3098,O
arrhythmias,3098,O
and,3098,O
convulsions,3098,O
.,3098,O
These,3099,O
side,3099,O
effects,3099,O
render,3099,O
the,3099,O
search,3099,O
for,3099,O
new,3099,O
local,3099,O
anaesthetics,3099,O
a,3099,O
matter,3099,O
of,3099,O
high,3099,O
interest,3099,O
.,3099,O
EXPERIMENTAL,3100,O
APPROACH,3100,O
:,3100,O
We,3100,O
have,3100,O
investigated,3100,O
the,3100,O
effects,3100,O
of,3100,O
three,3100,O
halogenated,3100,O
structural,3100,O
analogues,3100,O
of,3100,O
propofol,3100,B-CHEMICAL
on,3100,O
voltage-operated,3100,B-GENE-N
human,3100,I-GENE-N
skeletal,3100,I-GENE-N
muscle,3100,I-GENE-N
sodium,3100,I-GENE-N
channels,3100,I-GENE-N
(,3100,O
Na,3100,B-GENE-Y
(,3100,I-GENE-Y
V,3100,I-GENE-Y
),3100,I-GENE-Y
1.4,3100,I-GENE-Y
),3100,O
and,3100,O
the,3100,O
effect,3100,O
of,3100,O
one,3100,O
compound,3100,O
(,3100,O
4-chloropropofol,3100,B-CHEMICAL
),3100,O
on,3100,O
neuronal,3100,B-GENE-N
sodium,3100,I-GENE-N
channels,3100,I-GENE-N
(,3100,O
Na,3100,B-GENE-Y
(,3100,I-GENE-Y
V,3100,I-GENE-Y
),3100,I-GENE-Y
1.2,3100,I-GENE-Y
),3100,O
heterologously,3100,O
expressed,3100,O
in,3100,O
human,3100,O
embryonic,3100,O
kidney,3100,O
cell,3100,O
line,3100,O
293,3100,O
.,3100,O
KEY,3101,O
RESULTS,3101,O
:,3101,O
4-Iodo-,3101,B-CHEMICAL
",",3101,O
4-bromo-,3101,B-CHEMICAL
and,3101,O
4-chloropropofol,3101,B-CHEMICAL
reversibly,3101,O
suppressed,3101,O
depolarization-induced,3101,O
whole-cell,3101,O
sodium,3101,B-CHEMICAL
inward,3101,O
currents,3101,O
with,3101,O
high,3101,O
potency,3101,O
.,3101,O
The,3102,O
IC,3102,O
(,3102,O
50,3102,O
),3102,O
for,3102,O
block,3102,O
of,3102,O
resting,3102,O
channels,3102,O
at,3102,O
-150,3102,O
mV,3102,O
was,3102,O
2.3,3102,O
",",3102,O
3.9,3102,O
and,3102,O
11.3,3102,O
microM,3102,O
in,3102,O
Na,3102,B-GENE-Y
(,3102,I-GENE-Y
V,3102,I-GENE-Y
),3102,I-GENE-Y
1.4,3102,I-GENE-Y
",",3102,O
respectively,3102,O
",",3102,O
and,3102,O
29.2,3102,O
microM,3102,O
for,3102,O
4-chloropropofol,3102,B-CHEMICAL
in,3102,O
Na,3102,B-GENE-Y
(,3102,I-GENE-Y
V,3102,I-GENE-Y
),3102,I-GENE-Y
1.2,3102,I-GENE-Y
.,3102,O
Membrane,3103,O
depolarization,3103,O
inducing,3103,O
inactivation,3103,O
strongly,3103,O
increased,3103,O
the,3103,O
blocking,3103,O
potency,3103,O
of,3103,O
all,3103,O
compounds,3103,O
.,3103,O
Estimated,3104,O
affinities,3104,O
for,3104,O
the,3104,O
fast-inactivated,3104,O
channel,3104,O
state,3104,O
were,3104,O
81,3104,O
nM,3104,O
",",3104,O
312,3104,O
nM,3104,O
and,3104,O
227,3104,O
nM,3104,O
for,3104,O
4-iodopropofol,3104,B-CHEMICAL
",",3104,O
4-bromopropofol,3104,B-CHEMICAL
and,3104,O
4-chloropropofol,3104,B-CHEMICAL
in,3104,O
Na,3104,B-GENE-Y
(,3104,I-GENE-Y
V,3104,I-GENE-Y
),3104,I-GENE-Y
1.4,3104,I-GENE-Y
",",3104,O
and,3104,O
450,3104,O
nM,3104,O
for,3104,O
4-chloropropofol,3104,B-CHEMICAL
in,3104,O
Na,3104,B-GENE-Y
(,3104,I-GENE-Y
V,3104,I-GENE-Y
),3104,I-GENE-Y
1.2,3104,I-GENE-Y
.,3104,O
Recovery,3105,O
from,3105,O
fast,3105,O
inactivation,3105,O
was,3105,O
prolonged,3105,O
in,3105,O
the,3105,O
presence,3105,O
of,3105,O
drug,3105,O
leading,3105,O
to,3105,O
an,3105,O
accumulation,3105,O
of,3105,O
block,3105,O
during,3105,O
repetitive,3105,O
stimulation,3105,O
at,3105,O
high,3105,O
frequencies,3105,O
(,3105,O
100,3105,O
Hz,3105,O
),3105,O
.,3105,O
CONCLUSIONS,3106,O
AND,3106,O
IMPLICATIONS,3106,O
:,3106,O
Halogenated,3106,B-CHEMICAL
propofol,3106,I-CHEMICAL
analogues,3106,O
constitute,3106,O
a,3106,O
novel,3106,O
class,3106,O
of,3106,O
sodium,3106,B-CHEMICAL
channel-blocking,3106,O
drugs,3106,O
possessing,3106,O
almost,3106,O
100-fold,3106,O
higher,3106,O
potency,3106,O
compared,3106,O
with,3106,O
the,3106,O
local,3106,O
anaesthetic,3106,O
and,3106,O
anti-arrhythmic,3106,O
drug,3106,O
lidocaine,3106,B-CHEMICAL
.,3106,O
Preferential,3107,O
drug,3107,O
binding,3107,O
to,3107,O
inactivated,3107,O
channel,3107,O
states,3107,O
suggests,3107,O
that,3107,O
halogenated,3107,B-CHEMICAL
propofol,3107,I-CHEMICAL
analogues,3107,O
might,3107,O
be,3107,O
especially,3107,O
effective,3107,O
in,3107,O
suppressing,3107,O
ectopic,3107,O
discharges,3107,O
in,3107,O
a,3107,O
variety,3107,O
of,3107,O
pathological,3107,O
conditions,3107,O
.,3107,O
Irbesartan,3108,B-CHEMICAL
:,3108,O
a,3108,O
review,3108,O
of,3108,O
its,3108,O
use,3108,O
in,3108,O
hypertension,3108,O
and,3108,O
diabetic,3108,O
nephropathy,3108,O
.,3108,O
Irbesartan,3109,B-CHEMICAL
(,3109,O
Aprovel,3109,B-CHEMICAL
",",3109,O
Avapro,3109,B-CHEMICAL
",",3109,O
Irbetan,3109,B-CHEMICAL
",",3109,O
Karvea,3109,B-CHEMICAL
),3109,O
",",3109,O
an,3109,O
angiotensin,3109,B-CHEMICAL
II,3109,I-CHEMICAL
receptor,3109,I-GENE-Y
type,3109,I-GENE-Y
1,3109,I-GENE-Y
antagonist,3109,O
",",3109,O
is,3109,O
approved,3109,O
in,3109,O
many,3109,O
countries,3109,O
worldwide,3109,O
for,3109,O
the,3109,O
treatment,3109,O
of,3109,O
hypertension,3109,O
.,3109,O
It,3110,O
is,3110,O
also,3110,O
approved,3110,O
in,3110,O
some,3110,O
regions,3110,O
for,3110,O
the,3110,O
treatment,3110,O
of,3110,O
nephropathy,3110,O
in,3110,O
patients,3110,O
with,3110,O
hypertension,3110,O
and,3110,O
type,3110,O
2,3110,O
diabetes,3110,O
mellitus,3110,O
.,3110,O
In,3111,O
adults,3111,O
with,3111,O
essential,3111,O
hypertension,3111,O
",",3111,O
irbesartan,3111,B-CHEMICAL
is,3111,O
effective,3111,O
at,3111,O
reducing,3111,O
blood,3111,O
pressure,3111,O
(,3111,O
BP,3111,O
),3111,O
over,3111,O
a,3111,O
24-hour,3111,O
period,3111,O
with,3111,O
once-daily,3111,O
administration,3111,O
.,3111,O
Irbesartan,3112,B-CHEMICAL
also,3112,O
slows,3112,O
the,3112,O
progression,3112,O
of,3112,O
renal,3112,O
disease,3112,O
in,3112,O
hypertensive,3112,O
patients,3112,O
with,3112,O
type,3112,O
2,3112,O
diabetes,3112,O
",",3112,O
with,3112,O
this,3112,O
effect,3112,O
partly,3112,O
independent,3112,O
of,3112,O
its,3112,O
BP-lowering,3112,O
effect,3112,O
.,3112,O
In,3113,O
addition,3113,O
",",3113,O
irbesartan,3113,B-CHEMICAL
was,3113,O
generally,3113,O
well,3113,O
tolerated,3113,O
in,3113,O
clinical,3113,O
trials,3113,O
.,3113,O
Thus,3114,O
",",3114,O
irbesartan,3114,B-CHEMICAL
is,3114,O
a,3114,O
useful,3114,O
treatment,3114,O
option,3114,O
for,3114,O
patients,3114,O
with,3114,O
hypertension,3114,O
",",3114,O
including,3114,O
those,3114,O
with,3114,O
type,3114,O
2,3114,O
diabetes,3114,O
and,3114,O
nephropathy,3114,O
.,3114,O
DNA,3115,O
damage,3115,O
and,3115,O
homologous,3115,O
recombination,3115,O
signaling,3115,O
induced,3115,O
by,3115,O
thymidylate,3115,B-CHEMICAL
deprivation,3115,O
.,3115,O
DNA,3116,O
damage,3116,O
is,3116,O
accepted,3116,O
as,3116,O
a,3116,O
consequence,3116,O
of,3116,O
thymidylate,3116,B-CHEMICAL
deprivation,3116,O
induced,3116,O
by,3116,O
chemotherapeutic,3116,O
inhibitors,3116,O
of,3116,O
thymidylate,3116,B-CHEMICAL
synthase,3116,I-GENE-Y
(,3116,O
TS,3116,B-GENE-Y
),3116,O
",",3116,O
but,3116,O
the,3116,O
types,3116,O
of,3116,O
damage,3116,O
and,3116,O
signaling,3116,O
responses,3116,O
remain,3116,O
incompletely,3116,O
understood,3116,O
.,3116,O
Thymidylate,3117,B-CHEMICAL
deprivation,3117,O
increases,3117,O
dUTP,3117,O
and,3117,O
uracil,3117,B-CHEMICAL
in,3117,O
DNA,3117,O
",",3117,O
which,3117,O
is,3117,O
removed,3117,O
by,3117,O
base,3117,O
excision,3117,O
repair,3117,O
(,3117,O
BER,3117,O
),3117,O
.,3117,O
Because,3118,O
BER,3118,O
requires,3118,O
a,3118,O
synthesis,3118,O
step,3118,O
",",3118,O
strand,3118,O
break,3118,O
intermediates,3118,O
presumably,3118,O
accumulate,3118,O
.,3118,O
Thymidylate,3119,B-CHEMICAL
deprivation,3119,O
also,3119,O
induces,3119,O
cell,3119,O
cycle,3119,O
arrest,3119,O
during,3119,O
replication,3119,O
.,3119,O
Homologous,3120,O
recombination,3120,O
(,3120,O
HR,3120,O
),3120,O
is,3120,O
a,3120,O
means,3120,O
of,3120,O
repairing,3120,O
persistent,3120,O
BER,3120,O
intermediates,3120,O
and,3120,O
collapsed,3120,O
replication,3120,O
forks,3120,O
.,3120,O
There,3121,O
are,3121,O
also,3121,O
intimate,3121,O
links,3121,O
between,3121,O
HR,3121,O
and,3121,O
S-phase,3121,O
checkpoint,3121,O
pathways,3121,O
.,3121,O
In,3122,O
this,3122,O
study,3122,O
",",3122,O
the,3122,O
goals,3122,O
were,3122,O
to,3122,O
determine,3122,O
the,3122,O
involvement,3122,O
of,3122,O
HR-associated,3122,O
proteins,3122,O
and,3122,O
DNA,3122,O
damage,3122,O
signaling,3122,O
responses,3122,O
to,3122,O
thymidylate,3122,B-CHEMICAL
deprivation,3122,O
.,3122,O
When,3123,O
RAD51,3123,B-GENE-Y
",",3123,O
which,3123,O
is,3123,O
a,3123,O
central,3123,O
component,3123,O
of,3123,O
HR,3123,O
",",3123,O
was,3123,O
depleted,3123,O
by,3123,O
siRNA,3123,O
cells,3123,O
were,3123,O
sensitized,3123,O
to,3123,O
raltitrexed,3123,B-CHEMICAL
(,3123,O
RTX,3123,B-CHEMICAL
),3123,O
",",3123,O
which,3123,O
specifically,3123,O
inhibits,3123,O
TS,3123,B-GENE-Y
.,3123,O
To,3124,O
our,3124,O
knowledge,3124,O
",",3124,O
this,3124,O
is,3124,O
the,3124,O
first,3124,O
demonstration,3124,O
in,3124,O
mammalian,3124,O
cells,3124,O
that,3124,O
depletion,3124,O
of,3124,O
RAD51,3124,B-GENE-Y
causes,3124,O
sensitivity,3124,O
to,3124,O
thymidylate,3124,B-CHEMICAL
deprivation,3124,O
.,3124,O
Activation,3125,O
of,3125,O
DNA,3125,O
damage,3125,O
signaling,3125,O
responses,3125,O
was,3125,O
examined,3125,O
following,3125,O
treatment,3125,O
with,3125,O
RTX,3125,B-CHEMICAL
.,3125,O
Phosphorylation,3126,O
of,3126,O
replication,3126,B-GENE-N
protein,3126,I-GENE-N
A,3126,I-GENE-N
(,3126,O
RPA2,3126,B-GENE-Y
subunit,3126,O
),3126,O
and,3126,O
formation,3126,O
of,3126,O
damage-induced,3126,O
foci,3126,O
were,3126,O
strikingly,3126,O
evident,3126,O
following,3126,O
IC,3126,O
(,3126,O
50,3126,O
),3126,O
doses,3126,O
of,3126,O
RTX,3126,B-CHEMICAL
.,3126,O
Induction,3127,O
was,3127,O
much,3127,O
more,3127,O
striking,3127,O
following,3127,O
RTX,3127,B-CHEMICAL
treatment,3127,O
than,3127,O
with,3127,O
hydroxyurea,3127,B-CHEMICAL
",",3127,O
which,3127,O
is,3127,O
commonly,3127,O
used,3127,O
to,3127,O
inhibit,3127,O
replication,3127,O
.,3127,O
RTX,3128,B-CHEMICAL
treatment,3128,O
also,3128,O
induced,3128,O
foci,3128,O
of,3128,O
RAD51,3128,B-GENE-Y
",",3128,O
gamma-H2AX,3128,B-GENE-Y
",",3128,O
phospho-Chk1,3128,B-GENE-Y
",",3128,O
and,3128,O
phospho-NBS1,3128,B-GENE-Y
",",3128,O
although,3128,O
the,3128,O
extent,3128,O
of,3128,O
co-localization,3128,O
with,3128,O
RPA2,3128,B-GENE-Y
foci,3128,O
varied,3128,O
.,3128,O
Collectively,3129,O
",",3129,O
the,3129,O
results,3129,O
suggest,3129,O
that,3129,O
HR,3129,O
and,3129,O
S-phase,3129,O
checkpoint,3129,O
signaling,3129,O
processes,3129,O
are,3129,O
invoked,3129,O
by,3129,O
thymidylate,3129,B-CHEMICAL
deprivation,3129,O
and,3129,O
influence,3129,O
cellular,3129,O
resistance,3129,O
to,3129,O
thymidylate,3129,B-CHEMICAL
deprivation,3129,O
.,3129,O
Corticosteroids,3130,B-CHEMICAL
and,3130,O
human,3130,B-GENE-Y
recombinant,3130,I-GENE-Y
activated,3130,I-GENE-Y
protein,3130,I-GENE-Y
C,3130,I-GENE-Y
for,3130,O
septic,3130,O
shock,3130,O
.,3130,O
This,3131,O
article,3131,O
summarizes,3131,O
the,3131,O
current,3131,O
knowledge,3131,O
on,3131,O
the,3131,O
benefit/risk,3131,O
profile,3131,O
from,3131,O
the,3131,O
use,3131,O
of,3131,O
low-dose,3131,O
corticosteroids,3131,B-CHEMICAL
and,3131,O
activated,3131,B-GENE-Y
protein,3131,I-GENE-Y
C,3131,I-GENE-Y
in,3131,O
treating,3131,O
septic,3131,O
shock,3131,O
.,3131,O
Physicians,3132,O
should,3132,O
consider,3132,O
using,3132,O
low-dose,3132,O
corticosteroids,3132,B-CHEMICAL
and,3132,O
drotrecogin,3132,B-GENE-Y
alpha,3132,I-GENE-Y
activated,3132,O
in,3132,O
the,3132,O
treatment,3132,O
of,3132,O
patients,3132,O
who,3132,O
have,3132,O
vasopressor-dependent,3132,O
septic,3132,O
shock,3132,O
with,3132,O
persistent,3132,O
signs,3132,O
of,3132,O
hypoperfusion,3132,O
",",3132,O
organ,3132,O
dysfunction,3132,O
",",3132,O
or,3132,O
hypotension,3132,O
.,3132,O
The,3133,O
optimal,3133,O
timing,3133,O
for,3133,O
initiating,3133,O
these,3133,O
treatments,3133,O
is,3133,O
from,3133,O
6,3133,O
to,3133,O
24,3133,O
hours,3133,O
from,3133,O
onset,3133,O
of,3133,O
shock,3133,O
.,3133,O
When,3134,O
patients,3134,O
are,3134,O
receiving,3134,O
these,3134,O
drugs,3134,O
",",3134,O
physicians,3134,O
should,3134,O
systematically,3134,O
screen,3134,O
for,3134,O
superinfection,3134,O
and,3134,O
serious,3134,O
bleeding,3134,O
events,3134,O
.,3134,O
Adipose,3135,O
tissue,3135,O
as,3135,O
a,3135,O
source,3135,O
of,3135,O
nicotinamide,3135,B-GENE-Y
N-methyltransferase,3135,I-GENE-Y
and,3135,O
homocysteine,3135,B-CHEMICAL
.,3135,O
Nicotinamide,3136,B-CHEMICAL
N-methyltransferase,3136,B-CHEMICAL
(,3136,O
NNMT,3136,B-GENE-Y
),3136,O
catalyses,3136,O
the,3136,O
conversion,3136,O
of,3136,O
nicotinamide,3136,B-CHEMICAL
to,3136,O
1-methylnicotinamide,3136,B-CHEMICAL
and,3136,O
plays,3136,O
an,3136,O
important,3136,O
role,3136,O
in,3136,O
hepatic,3136,O
detoxification,3136,O
reactions,3136,O
.,3136,O
Here,3137,O
we,3137,O
show,3137,O
that,3137,O
",",3137,O
in,3137,O
addition,3137,O
to,3137,O
the,3137,O
liver,3137,O
",",3137,O
3T3-L1,3137,O
adipocytes,3137,O
as,3137,O
well,3137,O
as,3137,O
human,3137,O
and,3137,O
murine,3137,O
adipose,3137,O
tissue,3137,O
explants,3137,O
express,3137,O
high,3137,O
amounts,3137,O
of,3137,O
enzymatically,3137,O
active,3137,O
NNMT,3137,B-GENE-Y
.,3137,O
NNMT,3138,B-GENE-Y
mRNA,3138,O
levels,3138,O
and,3138,O
enzyme,3138,O
activity,3138,O
increased,3138,O
in,3138,O
3T3-L1,3138,O
cells,3138,O
in,3138,O
a,3138,O
differentiation-dependent,3138,O
manner,3138,O
.,3138,O
Homocysteine,3139,B-CHEMICAL
",",3139,O
the,3139,O
atherogenic,3139,O
product,3139,O
of,3139,O
the,3139,O
NNMT-catalyzed,3139,B-GENE-Y
reaction,3139,O
",",3139,O
was,3139,O
secreted,3139,O
from,3139,O
3T3-L1,3139,O
cells,3139,O
or,3139,O
adipose,3139,O
tissue,3139,O
cultures,3139,O
.,3139,O
Homocysteine,3140,B-CHEMICAL
release,3140,O
increased,3140,O
during,3140,O
3T3-L1,3140,O
differentiation,3140,O
and,3140,O
was,3140,O
reduced,3140,O
when,3140,O
adipose,3140,O
tissue,3140,O
was,3140,O
treated,3140,O
with,3140,O
the,3140,O
NNMT,3140,B-GENE-Y
inhibitor,3140,O
1-methylnicotinamide,3140,B-CHEMICAL
.,3140,O
Nicotinic,3141,B-CHEMICAL
acid,3141,I-CHEMICAL
(,3141,O
NA,3141,B-CHEMICAL
),3141,O
",",3141,O
a,3141,O
widely,3141,O
used,3141,O
drug,3141,O
to,3141,O
lower,3141,O
elevated,3141,O
plasma,3141,O
lipid,3141,O
levels,3141,O
",",3141,O
induced,3141,O
NNMT,3141,B-GENE-Y
enzyme,3141,O
activity,3141,O
in,3141,O
white,3141,O
adipose,3141,O
tissue,3141,O
of,3141,O
mice,3141,O
.,3141,O
In,3142,O
tissue,3142,O
culture,3142,O
nicotinamide,3142,B-CHEMICAL
treatment,3142,O
led,3142,O
to,3142,O
an,3142,O
increase,3142,O
in,3142,O
adipose,3142,O
tissue,3142,O
homocysteine,3142,B-CHEMICAL
secretion,3142,O
.,3142,O
These,3143,O
data,3143,O
support,3143,O
the,3143,O
concept,3143,O
that,3143,O
adipose,3143,O
tissue,3143,O
NNMT,3143,B-GENE-Y
contributes,3143,O
to,3143,O
the,3143,O
increased,3143,O
plasma,3143,O
homocysteine,3143,B-CHEMICAL
levels,3143,O
in,3143,O
patients,3143,O
treated,3143,O
with,3143,O
NA,3143,B-CHEMICAL
.,3143,O
Expression,3144,O
and,3144,O
"1,4-dihydropyridine-binding",3144,B-CHEMICAL
properties,3144,O
of,3144,O
brain,3144,O
L-type,3144,B-GENE-N
calcium,3144,I-GENE-N
channel,3144,I-GENE-N
isoforms,3144,O
.,3144,O
The,3145,O
L-type,3145,B-GENE-N
calcium,3145,B-CHEMICAL
channel,3145,I-GENE-N
(,3145,O
LTCC,3145,B-GENE-N
),3145,O
isoforms,3145,O
Ca,3145,B-GENE-Y
(,3145,I-GENE-Y
v,3145,I-GENE-Y
),3145,I-GENE-Y
1.2,3145,I-GENE-Y
and,3145,O
Ca,3145,B-GENE-Y
(,3145,I-GENE-Y
v,3145,I-GENE-Y
),3145,I-GENE-Y
1.3,3145,I-GENE-Y
display,3145,O
similar,3145,O
"1,4-dihydropyridine",3145,B-CHEMICAL
(,3145,O
DHP,3145,B-CHEMICAL
),3145,O
binding,3145,O
properties,3145,O
and,3145,O
are,3145,O
both,3145,O
expressed,3145,O
in,3145,O
mammalian,3145,O
brain,3145,O
.,3145,O
Recent,3146,O
work,3146,O
implicates,3146,O
Ca,3146,B-GENE-Y
(,3146,I-GENE-Y
v,3146,I-GENE-Y
),3146,I-GENE-Y
1.3,3146,I-GENE-Y
channels,3146,O
as,3146,O
interesting,3146,O
drug,3146,O
targets,3146,O
",",3146,O
but,3146,O
no,3146,O
isoform-selective,3146,O
modulators,3146,O
exist,3146,O
.,3146,O
It,3147,O
is,3147,O
also,3147,O
unknown,3147,O
to,3147,O
what,3147,O
extent,3147,O
Ca,3147,B-GENE-Y
(,3147,I-GENE-Y
v,3147,I-GENE-Y
),3147,I-GENE-Y
1.1,3147,I-GENE-Y
and,3147,O
Ca,3147,B-GENE-Y
(,3147,I-GENE-Y
v,3147,I-GENE-Y
),3147,I-GENE-Y
1.4,3147,I-GENE-Y
contribute,3147,O
to,3147,O
L-type-specific,3147,O
DHP,3147,B-CHEMICAL
binding,3147,O
activity,3147,O
in,3147,O
brain,3147,O
.,3147,O
To,3148,O
address,3148,O
this,3148,O
question,3148,O
and,3148,O
to,3148,O
determine,3148,O
whether,3148,O
DHPs,3148,O
can,3148,O
discriminate,3148,O
between,3148,O
Ca,3148,B-GENE-Y
(,3148,I-GENE-Y
v,3148,I-GENE-Y
),3148,I-GENE-Y
1.2,3148,I-GENE-Y
and,3148,O
Ca,3148,B-GENE-Y
(,3148,I-GENE-Y
v,3148,I-GENE-Y
),3148,I-GENE-Y
1.3,3148,I-GENE-Y
binding,3148,O
pockets,3148,O
",",3148,O
we,3148,O
combined,3148,O
radioreceptor,3148,O
assays,3148,O
and,3148,O
quantitative,3148,O
polymerase,3148,O
chain,3148,O
reaction,3148,O
(,3148,O
qPCR,3148,O
),3148,O
.,3148,O
We,3149,O
bred,3149,O
double,3149,O
mutants,3149,O
(,3149,O
Ca,3149,B-GENE-N
(,3149,I-GENE-N
v,3149,I-GENE-N
),3149,I-GENE-N
-DM,3149,O
),3149,O
from,3149,O
mice,3149,O
expressing,3149,O
mutant,3149,O
Ca,3149,B-GENE-Y
(,3149,I-GENE-Y
v,3149,I-GENE-Y
),3149,I-GENE-Y
1.2,3149,I-GENE-Y
channels,3149,O
[,3149,O
Ca,3149,B-GENE-Y
(,3149,I-GENE-Y
v,3149,I-GENE-Y
),3149,I-GENE-Y
1.2DHP,3149,O
(,3149,O
-/-,3149,O
),3149,O
],3149,O
lacking,3149,O
high,3149,O
affinity,3149,O
for,3149,O
DHPs,3149,O
and,3149,O
from,3149,O
Ca,3149,B-GENE-Y
(,3149,I-GENE-Y
v,3149,I-GENE-Y
),3149,I-GENE-Y
1.3,3149,I-GENE-Y
knockouts,3149,O
[,3149,O
Ca,3149,B-GENE-Y
(,3149,I-GENE-Y
v,3149,I-GENE-Y
),3149,I-GENE-Y
1.3,3149,I-GENE-Y
(,3149,O
-/-,3149,O
),3149,O
],3149,O
.,3149,O
(,3150,B-CHEMICAL
+,3150,I-CHEMICAL
),3150,I-CHEMICAL
-,3150,I-CHEMICAL
[,3150,I-CHEMICAL
(,3150,I-CHEMICAL
3,3150,I-CHEMICAL
),3150,I-CHEMICAL
H,3150,I-CHEMICAL
],3150,I-CHEMICAL
isradipine,3150,I-CHEMICAL
binding,3150,O
to,3150,O
Ca,3150,B-GENE-Y
(,3150,I-GENE-Y
v,3150,I-GENE-Y
),3150,I-GENE-Y
1.2DHP,3150,O
(,3150,O
-/-,3150,O
),3150,O
and,3150,O
Ca,3150,B-GENE-N
(,3150,I-GENE-N
v,3150,I-GENE-N
),3150,I-GENE-N
-DM,3150,O
brains,3150,O
was,3150,O
reduced,3150,O
to,3150,O
15.1,3150,O
and,3150,O
4.4,3150,O
%,3150,O
of,3150,O
wild,3150,O
type,3150,O
",",3150,O
respectively,3150,O
",",3150,O
indicating,3150,O
that,3150,O
Ca,3150,B-GENE-Y
(,3150,I-GENE-Y
v,3150,I-GENE-Y
),3150,I-GENE-Y
1.3,3150,I-GENE-Y
accounts,3150,O
for,3150,O
10.7,3150,O
%,3150,O
of,3150,O
brain,3150,O
LTCCs,3150,B-GENE-N
.,3150,O
qPCR,3151,O
revealed,3151,O
that,3151,O
Ca,3151,B-GENE-Y
(,3151,I-GENE-Y
v,3151,I-GENE-Y
),3151,I-GENE-Y
1.1,3151,I-GENE-Y
and,3151,O
Ca,3151,B-GENE-Y
(,3151,I-GENE-Y
v,3151,I-GENE-Y
),3151,I-GENE-Y
1.4,3151,I-GENE-Y
alpha,3151,I-GENE-Y
(,3151,I-GENE-Y
1,3151,I-GENE-Y
),3151,I-GENE-Y
subunits,3151,O
comprised,3151,O
0.08,3151,O
%,3151,O
of,3151,O
the,3151,O
LTCC,3151,B-GENE-N
transcripts,3151,O
in,3151,O
mouse,3151,O
whole,3151,O
brain,3151,O
",",3151,O
suggesting,3151,O
that,3151,O
they,3151,O
can,3151,O
not,3151,O
account,3151,O
for,3151,O
the,3151,O
residual,3151,O
binding,3151,O
.,3151,O
Instead,3152,O
",",3152,O
this,3152,O
could,3152,O
be,3152,O
explained,3152,O
by,3152,O
low-affinity,3152,O
binding,3152,O
(,3152,O
127-fold,3152,O
K,3152,O
(,3152,O
d,3152,O
),3152,O
increase,3152,O
),3152,O
to,3152,O
the,3152,O
mutated,3152,O
Ca,3152,B-GENE-Y
(,3152,I-GENE-Y
v,3152,I-GENE-Y
),3152,I-GENE-Y
1.2,3152,I-GENE-Y
channels,3152,O
.,3152,O
Inhibition,3153,O
of,3153,O
(,3153,B-CHEMICAL
+,3153,I-CHEMICAL
),3153,I-CHEMICAL
-,3153,I-CHEMICAL
[,3153,I-CHEMICAL
(,3153,I-CHEMICAL
3,3153,I-CHEMICAL
),3153,I-CHEMICAL
H,3153,I-CHEMICAL
],3153,I-CHEMICAL
isradipine,3153,I-CHEMICAL
binding,3153,O
to,3153,O
Ca,3153,B-GENE-Y
(,3153,I-GENE-Y
v,3153,I-GENE-Y
),3153,I-GENE-Y
1.2DHP,3153,O
(,3153,O
-/-,3153,O
),3153,O
(,3153,O
predominantly,3153,O
Ca,3153,B-GENE-Y
(,3153,I-GENE-Y
v,3153,I-GENE-Y
),3153,I-GENE-Y
1.3,3153,I-GENE-Y
),3153,O
and,3153,O
wild-type,3153,O
(,3153,O
predominantly,3153,O
Ca,3153,B-GENE-Y
(,3153,I-GENE-Y
v,3153,I-GENE-Y
),3153,I-GENE-Y
1.2,3153,I-GENE-Y
),3153,O
brain,3153,O
membranes,3153,O
by,3153,O
unlabeled,3153,O
DHPs,3153,O
revealed,3153,O
a,3153,O
3-,3153,O
to,3153,O
4-fold,3153,O
selectivity,3153,O
of,3153,O
nitrendipine,3153,B-CHEMICAL
and,3153,O
nifedipine,3153,B-CHEMICAL
for,3153,O
the,3153,O
Ca,3153,B-GENE-Y
(,3153,I-GENE-Y
v,3153,I-GENE-Y
),3153,I-GENE-Y
1.2,3153,I-GENE-Y
binding,3153,O
pocket,3153,O
",",3153,O
a,3153,O
finding,3153,O
further,3153,O
confirmed,3153,O
with,3153,O
heterologously,3153,O
expressed,3153,O
channels,3153,O
.,3153,O
This,3154,O
suggests,3154,O
that,3154,O
small,3154,O
differences,3154,O
in,3154,O
their,3154,O
binding,3154,O
pockets,3154,O
may,3154,O
allow,3154,O
development,3154,O
of,3154,O
isoform-selective,3154,O
modulators,3154,O
for,3154,O
LTCCs,3154,B-GENE-N
and,3154,O
that,3154,O
",",3154,O
because,3154,O
of,3154,O
their,3154,O
very,3154,O
low,3154,O
expression,3154,O
",",3154,O
Ca,3154,B-GENE-Y
(,3154,I-GENE-Y
v,3154,I-GENE-Y
),3154,I-GENE-Y
1.1,3154,I-GENE-Y
and,3154,O
Ca,3154,B-GENE-Y
(,3154,I-GENE-Y
v,3154,I-GENE-Y
),3154,I-GENE-Y
1.4,3154,I-GENE-Y
are,3154,O
unlikely,3154,O
to,3154,O
serve,3154,O
as,3154,O
drug,3154,O
targets,3154,O
to,3154,O
treat,3154,O
CNS,3154,O
diseases,3154,O
.,3154,O
Global,3155,O
target,3155,O
profile,3155,O
of,3155,O
the,3155,O
kinase,3155,B-GENE-N
inhibitor,3155,O
bosutinib,3155,B-CHEMICAL
in,3155,O
primary,3155,O
chronic,3155,O
myeloid,3155,O
leukemia,3155,O
cells,3155,O
.,3155,O
The,3156,O
detailed,3156,O
molecular,3156,O
mechanism,3156,O
of,3156,O
action,3156,O
of,3156,O
second-generation,3156,O
BCR-ABL,3156,B-GENE-Y
tyrosine,3156,B-GENE-N
kinase,3156,I-GENE-N
inhibitors,3156,O
",",3156,O
including,3156,O
perturbed,3156,O
targets,3156,O
and,3156,O
pathways,3156,O
",",3156,O
should,3156,O
contribute,3156,O
to,3156,O
rationalized,3156,O
therapy,3156,O
in,3156,O
chronic,3156,O
myeloid,3156,O
leukemia,3156,O
(,3156,O
CML,3156,O
),3156,O
or,3156,O
in,3156,O
other,3156,O
affected,3156,O
diseases,3156,O
.,3156,O
Here,3157,O
",",3157,O
we,3157,O
characterized,3157,O
the,3157,O
target,3157,O
profile,3157,O
of,3157,O
the,3157,O
dual,3157,O
SRC/ABL,3157,B-GENE-Y
inhibitor,3157,O
bosutinib,3157,B-CHEMICAL
employing,3157,O
a,3157,O
two-tiered,3157,O
approach,3157,O
using,3157,O
chemical,3157,O
proteomics,3157,O
to,3157,O
identify,3157,O
natural,3157,O
binders,3157,O
in,3157,O
whole,3157,O
cell,3157,O
lysates,3157,O
of,3157,O
primary,3157,O
CML,3157,O
and,3157,O
K562,3157,O
cells,3157,O
in,3157,O
parallel,3157,O
to,3157,O
in,3157,O
vitro,3157,O
kinase,3157,B-GENE-N
assays,3157,O
against,3157,O
a,3157,O
large,3157,O
recombinant,3157,O
kinase,3157,B-GENE-N
panel,3157,O
.,3157,O
The,3158,O
combined,3158,O
strategy,3158,O
resulted,3158,O
in,3158,O
a,3158,O
global,3158,O
survey,3158,O
of,3158,O
bosutinib,3158,B-CHEMICAL
targets,3158,O
comprised,3158,O
of,3158,O
over,3158,O
45,3158,O
novel,3158,O
tyrosine,3158,B-CHEMICAL
and,3158,I-GENE-N
serine/threonine,3158,B-CHEMICAL
kinases,3158,I-GENE-N
.,3158,O
We,3159,O
have,3159,O
found,3159,O
clear,3159,O
differences,3159,O
in,3159,O
the,3159,O
target,3159,O
patterns,3159,O
of,3159,O
bosutinib,3159,B-CHEMICAL
in,3159,O
primary,3159,O
CML,3159,O
cells,3159,O
versus,3159,O
the,3159,O
K562,3159,O
cell,3159,O
line,3159,O
.,3159,O
A,3160,O
comparison,3160,O
of,3160,O
bosutinib,3160,B-CHEMICAL
with,3160,O
dasatinib,3160,B-CHEMICAL
across,3160,O
the,3160,O
whole,3160,O
kinase,3160,B-GENE-N
panel,3160,O
revealed,3160,O
overlapping,3160,O
",",3160,O
but,3160,O
distinct,3160,O
",",3160,O
inhibition,3160,O
profiles,3160,O
.,3160,O
Common,3161,O
among,3161,O
those,3161,O
were,3161,O
the,3161,O
SRC,3161,B-GENE-Y
",",3161,O
ABL,3161,B-GENE-Y
and,3161,O
TEC,3161,B-GENE-Y
family,3161,O
kinases,3161,B-GENE-N
.,3161,O
Bosutinib,3162,B-CHEMICAL
did,3162,O
not,3162,O
inhibit,3162,O
KIT,3162,B-GENE-Y
or,3162,O
platelet-derived,3162,B-GENE-N
growth,3162,I-GENE-N
factor,3162,I-GENE-N
receptor,3162,I-GENE-N
",",3162,O
but,3162,O
prominently,3162,O
targeted,3162,O
the,3162,O
apoptosis-linked,3162,O
STE20,3162,B-GENE-N
kinases,3162,I-GENE-N
.,3162,O
Although,3163,O
in,3163,O
vivo,3163,O
bosutinib,3163,B-CHEMICAL
is,3163,O
inactive,3163,O
against,3163,O
ABL,3163,B-GENE-Y
T315I,3163,B-GENE-N
",",3163,O
we,3163,O
found,3163,O
this,3163,O
clinically,3163,O
important,3163,O
mutant,3163,O
to,3163,O
be,3163,O
enzymatically,3163,O
inhibited,3163,O
in,3163,O
the,3163,O
mid-nanomolar,3163,O
range,3163,O
.,3163,O
Finally,3164,O
",",3164,O
bosutinib,3164,B-CHEMICAL
is,3164,O
the,3164,O
first,3164,O
kinase,3164,B-GENE-N
inhibitor,3164,O
shown,3164,O
to,3164,O
target,3164,O
CAMK2G,3164,B-GENE-Y
",",3164,O
recently,3164,O
implicated,3164,O
in,3164,O
myeloid,3164,O
leukemia,3164,O
cell,3164,O
proliferation,3164,O
.,3164,O
The,3165,O
effect,3165,O
of,3165,O
estramustine,3165,B-CHEMICAL
derivatives,3165,O
on,3165,O
microtubule,3165,O
assembly,3165,O
in,3165,O
vitro,3165,O
depends,3165,O
on,3165,O
the,3165,O
charge,3165,O
of,3165,O
the,3165,O
substituent,3165,O
.,3165,O
Estramustine,3166,B-CHEMICAL
",",3166,O
and,3166,O
derivatives,3166,O
of,3166,O
estramustine,3166,B-CHEMICAL
with,3166,O
a,3166,O
charged,3166,O
substituent,3166,O
at,3166,O
position,3166,O
17,3166,O
on,3166,O
the,3166,O
estrogen,3166,B-CHEMICAL
moiety,3166,O
",",3166,O
have,3166,O
been,3166,O
investigated,3166,O
for,3166,O
their,3166,O
effects,3166,O
on,3166,O
bovine,3166,O
brain,3166,O
microtubules,3166,O
in,3166,O
vitro,3166,O
.,3166,O
The,3167,O
negatively,3167,O
charged,3167,O
estramustine,3167,B-CHEMICAL
phosphate,3167,I-CHEMICAL
has,3167,O
been,3167,O
found,3167,O
previously,3167,O
to,3167,O
be,3167,O
a,3167,O
microtubule-associated,3167,B-GENE-N
protein,3167,I-GENE-N
(,3167,O
MAP,3167,B-GENE-N
),3167,O
-dependent,3167,O
microtubule,3167,O
inhibitor,3167,O
[,3167,O
Wallin,3167,O
M,3167,O
",",3167,O
Deinum,3167,O
J,3167,O
and,3167,O
Friden,3167,O
B,3167,O
",",3167,O
FEBS,3167,O
Lett,3167,O
179,3167,O
:,3167,O
289-293,3167,O
",",3167,O
1985,3167,O
],3167,O
.,3167,O
In,3168,O
the,3168,O
present,3168,O
study,3168,O
the,3168,O
binding,3168,O
of,3168,O
estramustine,3168,B-CHEMICAL
phosphate,3168,I-CHEMICAL
to,3168,O
MAP2,3168,B-GENE-Y
and,3168,O
tau,3168,B-GENE-Y
was,3168,O
investigated,3168,O
.,3168,O
Both,3169,O
these,3169,O
MAPs,3169,B-GENE-N
were,3169,O
found,3169,O
to,3169,O
have,3169,O
two,3169,O
to,3169,O
three,3169,O
binding,3169,O
sites,3169,O
for,3169,O
estramustine,3169,B-CHEMICAL
phosphate,3169,I-CHEMICAL
which,3169,O
is,3169,O
compatible,3169,O
with,3169,O
the,3169,O
reported,3169,O
number,3169,O
of,3169,O
basic,3169,O
amino,3169,B-CHEMICAL
acid,3169,I-CHEMICAL
repeats,3169,O
of,3169,O
these,3169,O
MAPs,3169,B-GENE-N
",",3169,O
considered,3169,O
to,3169,O
be,3169,O
the,3169,O
ultimate,3169,O
tubulin,3169,B-GENE-N
binding,3169,O
domains,3169,O
.,3169,O
The,3170,O
Kd,3170,O
for,3170,O
the,3170,O
binding,3170,O
of,3170,O
estramustine,3170,B-CHEMICAL
phosphate,3170,I-CHEMICAL
to,3170,O
MAP2,3170,B-GENE-N
was,3170,O
estimated,3170,O
to,3170,O
be,3170,O
20,3170,O
microM,3170,O
at,3170,O
4,3170,O
degrees,3170,O
",",3170,O
and,3170,O
for,3170,O
the,3170,O
binding,3170,O
of,3170,O
tau,3170,O
",",3170,O
200,3170,O
microM,3170,O
.,3170,O
The,3171,O
rate,3171,O
of,3171,O
dissociation,3171,O
was,3171,O
very,3171,O
low,3171,O
(,3171,O
T1/2,3171,O
greater,3171,O
than,3171,O
2,3171,O
hr,3171,O
),3171,O
",",3171,O
which,3171,O
indicates,3171,O
that,3171,O
the,3171,O
binding,3171,O
of,3171,O
estramustine,3171,B-CHEMICAL
phosphate,3171,I-CHEMICAL
may,3171,O
stabilize,3171,O
the,3171,O
protein-drug,3171,O
complex,3171,O
by,3171,O
changing,3171,O
the,3171,O
protein,3171,O
conformation,3171,O
.,3171,O
Two,3172,O
new,3172,O
negatively,3172,O
charged,3172,O
estramustine,3172,B-CHEMICAL
derivatives,3172,O
",",3172,O
estramustine,3172,B-CHEMICAL
sulphate,3172,I-CHEMICAL
and,3172,O
estramustine,3172,B-CHEMICAL
glucuronide,3172,I-CHEMICAL
",",3172,O
were,3172,O
found,3172,O
to,3172,O
be,3172,O
similar,3172,O
MAP-dependent,3172,B-GENE-N
microtubule,3172,O
inhibitors,3172,O
.,3172,O
The,3173,O
concentration,3173,O
for,3173,O
50,3173,O
%,3173,O
inhibition,3173,O
of,3173,O
assembly,3173,O
was,3173,O
100,3173,O
microM,3173,O
for,3173,O
the,3173,O
sulphate,3173,B-CHEMICAL
derivative,3173,O
",",3173,O
the,3173,O
same,3173,O
as,3173,O
found,3173,O
previously,3173,O
for,3173,O
estramustine,3173,B-CHEMICAL
phosphate,3173,I-CHEMICAL
",",3173,O
and,3173,O
250,3173,O
microM,3173,O
for,3173,O
the,3173,O
more,3173,O
bulky,3173,O
estramustine,3173,B-CHEMICAL
glucuronide,3173,I-CHEMICAL
.,3173,O
A,3174,O
positively,3174,O
charged,3174,O
derivative,3174,O
",",3174,O
estramustine,3174,B-CHEMICAL
sarcosinate,3174,I-CHEMICAL
",",3174,O
did,3174,O
not,3174,O
inhibit,3174,O
microtubule,3174,O
assembly,3174,O
or,3174,O
alter,3174,O
the,3174,O
composition,3174,O
of,3174,O
the,3174,O
coassembled,3174,O
MAPs,3174,B-GENE-N
.,3174,O
The,3175,O
morphology,3175,O
of,3175,O
the,3175,O
microtubules,3175,O
was,3175,O
",",3175,O
however,3175,O
",",3175,O
affected,3175,O
.,3175,O
The,3176,O
uncharged,3176,O
estramustine,3176,B-CHEMICAL
bound,3176,O
to,3176,O
both,3176,O
tubulin,3176,B-GENE-N
and,3176,O
MAPs,3176,B-GENE-N
",",3176,O
but,3176,O
no,3176,O
effects,3176,O
were,3176,O
seen,3176,O
on,3176,O
microtubule,3176,O
assembly,3176,O
",",3176,O
the,3176,O
composition,3176,O
of,3176,O
coassembled,3176,O
MAPs,3176,B-GENE-N
or,3176,O
the,3176,O
microtubule,3176,O
morphology,3176,O
.,3176,O
Our,3177,O
results,3177,O
suggest,3177,O
that,3177,O
only,3177,O
negatively,3177,O
charged,3177,O
estramustine,3177,B-CHEMICAL
derivatives,3177,O
have,3177,O
a,3177,O
MAP-dependent,3177,B-GENE-N
microtubule,3177,O
inhibitory,3177,O
effect,3177,O
.,3177,O
The,3178,O
two,3178,O
new,3178,O
negatively,3178,O
charged,3178,O
derivatives,3178,O
could,3178,O
therefore,3178,O
be,3178,O
valuable,3178,O
tools,3178,O
in,3178,O
the,3178,O
study,3178,O
of,3178,O
tubulin-MAP,3178,B-GENE-N
interactions,3178,O
.,3178,O
The,3179,O
results,3179,O
also,3179,O
confirm,3179,O
that,3179,O
these,3179,O
interactions,3179,O
between,3179,O
tubulin,3179,B-GENE-N
and,3179,O
MAPs,3179,B-GENE-N
are,3179,O
mainly,3179,O
electrostatic,3179,O
.,3179,O
Analysis,3180,O
of,3180,O
coenzyme,3180,O
binding,3180,O
by,3180,O
human,3180,B-GENE-N
placental,3180,I-GENE-N
3,3180,I-GENE-N
beta-hydroxy-5-ene-steroid,3180,I-GENE-N
dehydrogenase,3180,I-GENE-N
and,3180,O
steroid,3180,B-GENE-N
5,3180,I-GENE-N
--,3180,I-GENE-N
--,3180,I-GENE-N
4-ene-isomerase,3180,I-GENE-N
using,3180,O
5'-,3180,B-CHEMICAL
[,3180,I-CHEMICAL
p-,3180,I-CHEMICAL
(,3180,I-CHEMICAL
fluorosulfonyl,3180,I-CHEMICAL
),3180,I-CHEMICAL
benzoyl,3180,I-CHEMICAL
],3180,I-CHEMICAL
adenosine,3180,I-CHEMICAL
",",3180,O
an,3180,O
affinity,3180,O
labeling,3180,O
cofactor,3180,O
analog,3180,O
.,3180,O
3,3181,B-GENE-N
beta-Hydroxy-5-ene-steroid,3181,I-GENE-N
dehydrogenase,3181,I-GENE-N
and,3181,O
steroid,3181,B-GENE-N
5,3181,I-GENE-N
--,3181,I-GENE-N
--,3181,I-GENE-N
4-ene-isomerase,3181,I-GENE-N
copurify,3181,O
as,3181,O
a,3181,O
single,3181,O
",",3181,O
homogeneous,3181,O
protein,3181,O
from,3181,O
human,3181,O
placental,3181,O
microsomes,3181,O
.,3181,O
Affinity,3182,O
alkylation,3182,O
with,3182,O
2,3182,O
alpha-bromoacetoxyprogesterone,3182,B-CHEMICAL
suggests,3182,O
that,3182,O
the,3182,O
dehydrogenase,3182,B-GENE-N
and,3182,O
isomerase,3182,O
substrate,3182,O
steroids,3182,B-CHEMICAL
bind,3182,O
at,3182,O
different,3182,O
sites,3182,O
on,3182,O
the,3182,O
same,3182,O
protein,3182,O
.,3182,O
However,3183,O
",",3183,O
the,3183,O
coenzyme,3183,O
",",3183,O
NADH,3183,B-CHEMICAL
",",3183,O
completely,3183,O
abolishes,3183,O
the,3183,O
alkylation,3183,O
of,3183,O
both,3183,O
enzyme,3183,O
activities,3183,O
by,3183,O
the,3183,O
progestin,3183,B-CHEMICAL
analog,3183,O
[,3183,O
Thomas,3183,O
J,3183,O
.L.,3183,O
",",3183,O
Myers,3183,O
R.,3183,O
P.,3183,O
",",3183,O
Rosik,3183,O
L.,3183,O
O.,3183,O
and,3183,O
Strickler,3183,O
R.,3183,O
C.,3183,O
",",3183,O
J.,3183,O
Steroid,3183,O
Biochem,3183,O
.,3183,O
36,3184,O
(,3184,O
1990,3184,O
),3184,O
117-123,3184,O
],3184,O
.,3184,O
Unlike,3185,O
bacterial,3185,O
3-keto-5-ene-steroid,3185,B-GENE-N
isomerase,3185,I-GENE-N
",",3185,O
the,3185,O
human,3185,O
isomerase,3185,O
reaction,3185,O
is,3185,O
stimulated,3185,O
by,3185,O
diphosphopyridine,3185,B-CHEMICAL
nucleotides,3185,I-CHEMICAL
(,3185,O
NADH,3185,B-CHEMICAL
",",3185,O
NAD+,3185,B-CHEMICAL
),3185,O
.,3185,O
The,3186,O
affinity,3186,O
labeling,3186,O
nucleotide,3186,B-CHEMICAL
analog,3186,O
",",3186,O
5'-,3186,B-CHEMICAL
[,3186,I-CHEMICAL
p-,3186,I-CHEMICAL
(,3186,I-CHEMICAL
fluorosulfonyl,3186,I-CHEMICAL
),3186,I-CHEMICAL
benzoyl,3186,I-CHEMICAL
],3186,I-CHEMICAL
adenosine,3186,I-CHEMICAL
(,3186,O
FSA,3186,B-CHEMICAL
),3186,O
",",3186,O
inactivates,3186,O
the,3186,O
dehydrogenase,3186,B-GENE-N
and,3186,O
isomerase,3186,O
activities,3186,O
at,3186,O
similar,3186,O
rates,3186,O
in,3186,O
an,3186,O
irreversible,3186,O
manner,3186,O
which,3186,O
follows,3186,O
first,3186,O
order,3186,O
kinetics,3186,O
with,3186,O
respect,3186,O
to,3186,O
both,3186,O
time,3186,O
and,3186,O
alkylator,3186,O
concentration,3186,O
(,3186,O
0.2-0.6,3186,O
mM,3186,O
),3186,O
.,3186,O
FSA,3187,O
is,3187,O
a,3187,O
cofactor,3187,O
site-directed,3187,O
reagent,3187,O
that,3187,O
binds,3187,O
with,3187,O
similar,3187,O
affinity,3187,O
as,3187,O
a,3187,O
competitive,3187,O
inhibitor,3187,O
of,3187,O
NAD+,3187,B-CHEMICAL
reduction,3187,O
by,3187,O
dehydrogenase,3187,B-GENE-N
(,3187,O
Ki,3187,O
=,3187,O
162,3187,O
microM,3187,O
),3187,O
or,3187,O
as,3187,O
a,3187,O
stimulator,3187,O
of,3187,O
isomerase,3187,O
(,3187,O
Km,3187,O
=,3187,O
153,3187,O
microM,3187,O
),3187,O
.,3187,O
Parallel,3188,O
plots,3188,O
derived,3188,O
from,3188,O
Kitz,3188,O
and,3188,O
Wilson,3188,O
analysis,3188,O
indicate,3188,O
that,3188,O
FSA,3188,B-CHEMICAL
inactivates,3188,O
the,3188,O
two,3188,O
enzyme,3188,O
activities,3188,O
with,3188,O
equal,3188,O
alkylation,3188,O
efficiency,3188,O
(,3188,O
k3/Ki,3188,O
=,3188,O
1/slope,3188,O
=,3188,O
0.51/mol-s,3188,O
for,3188,O
both,3188,O
),3188,O
.,3188,O
The,3189,O
3,3189,B-CHEMICAL
beta-hydroxysteroid,3189,I-CHEMICAL
substrate,3189,O
",",3189,O
pregnenolone,3189,B-CHEMICAL
",",3189,O
protects,3189,O
isomerase,3189,O
as,3189,O
well,3189,O
as,3189,O
dehydrogenase,3189,B-GENE-N
from,3189,O
inactivation,3189,O
by,3189,O
FSA,3189,B-CHEMICAL
.,3189,O
These,3190,O
observations,3190,O
are,3190,O
evidence,3190,O
for,3190,O
a,3190,O
single,3190,O
cofactor,3190,O
binding,3190,O
region,3190,O
which,3190,O
services,3190,O
both,3190,O
enzyme,3190,O
activities,3190,O
.,3190,O
Tyrosine,3191,B-GENE-N
kinase,3191,I-GENE-N
blockers,3191,O
:,3191,O
new,3191,O
hope,3191,O
for,3191,O
successful,3191,O
cancer,3191,O
therapy,3191,O
.,3191,O
Tyrosine,3192,B-GENE-N
kinases,3192,I-GENE-N
(,3192,O
TKs,3192,B-GENE-N
),3192,O
are,3192,O
attractive,3192,O
targets,3192,O
for,3192,O
cancer,3192,O
therapy,3192,O
",",3192,O
as,3192,O
quite,3192,O
often,3192,O
their,3192,O
abnormal,3192,O
signaling,3192,O
has,3192,O
been,3192,O
linked,3192,O
with,3192,O
tumor,3192,O
development,3192,O
and,3192,O
growth,3192,O
.,3192,O
Constitutive,3193,O
activated,3193,O
TKs,3193,B-GENE-N
stimulate,3193,O
multiple,3193,O
signaling,3193,O
pathways,3193,O
responsible,3193,O
for,3193,O
DNA,3193,O
repair,3193,O
",",3193,O
apoptosis,3193,O
",",3193,O
and,3193,O
cell,3193,O
proliferation,3193,O
.,3193,O
During,3194,O
the,3194,O
last,3194,O
few,3194,O
years,3194,O
",",3194,O
thorough,3194,O
analysis,3194,O
of,3194,O
the,3194,O
mechanism,3194,O
underlying,3194,O
tyrosine,3194,B-GENE-N
kinase,3194,I-GENE-N
's,3194,O
activity,3194,O
led,3194,O
to,3194,O
novel,3194,O
cancer,3194,O
therapy,3194,O
using,3194,O
TKs,3194,B-GENE-N
blockers,3194,O
.,3194,O
These,3195,O
drugs,3195,O
are,3195,O
remarkably,3195,O
effective,3195,O
in,3195,O
the,3195,O
treatment,3195,O
of,3195,O
various,3195,O
human,3195,O
tumors,3195,O
including,3195,O
head,3195,O
and,3195,O
neck,3195,O
",",3195,O
gastric,3195,O
",",3195,O
prostate,3195,O
and,3195,O
breast,3195,O
cancer,3195,O
and,3195,O
leukemias,3195,O
.,3195,O
The,3196,O
most,3196,O
successful,3196,O
example,3196,O
of,3196,O
kinase,3196,B-GENE-N
blockers,3196,O
is,3196,O
Imatinib,3196,B-CHEMICAL
(,3196,O
Imatinib,3196,B-CHEMICAL
mesylate,3196,I-CHEMICAL
",",3196,O
Gleevec,3196,B-CHEMICAL
",",3196,O
STI571,3196,B-CHEMICAL
),3196,O
",",3196,O
the,3196,O
inhibitor,3196,O
of,3196,O
Bcr/Abl,3196,B-GENE-Y
oncoprotein,3196,O
",",3196,O
which,3196,O
has,3196,O
become,3196,O
a,3196,O
first-line,3196,O
therapy,3196,O
for,3196,O
chronic,3196,O
myelogenous,3196,O
leukemia,3196,O
.,3196,O
The,3197,O
introduction,3197,O
of,3197,O
STI571,3197,B-CHEMICAL
for,3197,O
the,3197,O
treatment,3197,O
of,3197,O
leukemia,3197,O
in,3197,O
clinical,3197,O
oncology,3197,O
has,3197,O
had,3197,O
a,3197,O
dramatic,3197,O
impact,3197,O
on,3197,O
how,3197,O
this,3197,O
disease,3197,O
is,3197,O
currently,3197,O
managed,3197,O
.,3197,O
Others,3198,O
kinase,3198,O
inhibitors,3198,O
used,3198,O
recently,3198,O
in,3198,O
cancer,3198,O
therapy,3198,O
include,3198,O
Dasatinib,3198,B-CHEMICAL
(,3198,O
BMS-354825,3198,B-CHEMICAL
),3198,O
specific,3198,O
for,3198,O
ABL,3198,B-GENE-Y
non-receptor,3198,B-GENE-N
cytoplasmic,3198,I-GENE-N
kinase,3198,I-GENE-N
",",3198,O
Gefitinib,3198,B-CHEMICAL
(,3198,O
Iressa,3198,B-CHEMICAL
),3198,O
",",3198,O
Erlotinib,3198,B-CHEMICAL
(,3198,O
OSI-774,3198,B-CHEMICAL
",",3198,O
Tarceva,3198,B-CHEMICAL
),3198,O
and,3198,O
Sunitinib,3198,B-CHEMICAL
(,3198,O
SU,3198,B-CHEMICAL
11248,3198,I-CHEMICAL
",",3198,O
Sutent,3198,B-CHEMICAL
),3198,O
specific,3198,O
for,3198,O
VEGF,3198,B-GENE-N
receptor,3198,I-GENE-N
kinase,3198,B-GENE-N
",",3198,O
AMN107,3198,B-CHEMICAL
(,3198,O
Nilotinib,3198,B-CHEMICAL
),3198,O
and,3198,O
INNO-406,3198,B-CHEMICAL
(,3198,O
NS-187,3198,B-CHEMICAL
),3198,O
specific,3198,O
for,3198,O
c-KIT,3198,B-GENE-Y
kinase,3198,O
.,3198,O
The,3199,O
following,3199,O
TK,3199,B-GENE-N
blockers,3199,O
for,3199,O
treatment,3199,O
of,3199,O
various,3199,O
human,3199,O
tumors,3199,O
are,3199,O
in,3199,O
clinical,3199,O
development,3199,O
:,3199,O
Lapatinib,3199,B-CHEMICAL
(,3199,O
Lapatinib,3199,B-CHEMICAL
ditosylate,3199,I-CHEMICAL
",",3199,O
Tykerb,3199,B-CHEMICAL
",",3199,O
GW-572016,3199,B-CHEMICAL
),3199,O
",",3199,O
Canertinib,3199,B-CHEMICAL
(,3199,O
CI-1033,3199,B-CHEMICAL
),3199,O
",",3199,O
Zactima,3199,B-CHEMICAL
(,3199,O
ZD6474,3199,B-CHEMICAL
),3199,O
",",3199,O
Vatalanib,3199,B-CHEMICAL
(,3199,O
PTK787/ZK,3199,B-CHEMICAL
222584,3199,I-CHEMICAL
),3199,O
",",3199,O
Sorafenib,3199,B-CHEMICAL
(,3199,O
Bay,3199,B-CHEMICAL
43-9006,3199,I-CHEMICAL
",",3199,O
Nexavar,3199,B-CHEMICAL
),3199,O
",",3199,O
and,3199,O
Leflunomide,3199,B-CHEMICAL
(,3199,O
SU101,3199,B-CHEMICAL
",",3199,O
Arava,3199,B-CHEMICAL
),3199,O
.,3199,O
Herein,3200,O
",",3200,O
we,3200,O
discuss,3200,O
the,3200,O
chemistry,3200,O
",",3200,O
biological,3200,O
activity,3200,O
and,3200,O
clinical,3200,O
potential,3200,O
of,3200,O
new,3200,O
drugs,3200,O
with,3200,O
tyrosine,3200,B-GENE-N
kinase,3200,I-GENE-N
blockers,3200,O
for,3200,O
cancer,3200,O
treatment,3200,O
.,3200,O
Transdermal,3201,O
selegiline,3201,B-CHEMICAL
for,3201,O
the,3201,O
treatment,3201,O
of,3201,O
major,3201,O
depressive,3201,O
disorder,3201,O
.,3201,O
Non-selective,3202,O
inhibition,3202,O
of,3202,O
monoamine,3202,B-CHEMICAL
oxidase,3202,I-GENE-N
(,3202,O
MAO,3202,B-GENE-N
),3202,O
enzymes,3202,O
(,3202,O
ie,3202,O
",",3202,O
isoforms,3202,O
A,3202,O
and,3202,O
B,3202,O
),3202,O
in,3202,O
the,3202,O
brain,3202,O
are,3202,O
associated,3202,O
with,3202,O
clinically,3202,O
significant,3202,O
antidepressant,3202,O
effects,3202,O
.,3202,O
In,3203,O
the,3203,O
US,3203,O
",",3203,O
the,3203,O
selegiline,3203,B-CHEMICAL
transdermal,3203,O
system,3203,O
(,3203,O
STS,3203,O
;,3203,O
EMSAM,3203,O
),3203,O
is,3203,O
the,3203,O
first,3203,O
antidepressant,3203,O
transdermal,3203,O
delivery,3203,O
system,3203,O
to,3203,O
receive,3203,O
Food,3203,O
and,3203,O
Drug,3203,O
Administration,3203,O
(,3203,O
FDA,3203,O
),3203,O
approved,3203,O
labeling,3203,O
for,3203,O
the,3203,O
treatment,3203,O
of,3203,O
major,3203,O
depressive,3203,O
disorder,3203,O
(,3203,O
MDD,3203,O
),3203,O
.,3203,O
Currently,3204,O
",",3204,O
the,3204,O
use,3204,O
of,3204,O
orally,3204,O
administered,3204,O
MAO,3204,B-GENE-N
inhibitor,3204,O
antidepressants,3204,O
(,3204,O
eg,3204,O
",",3204,O
phenelzine,3204,B-CHEMICAL
",",3204,O
tranylcypromine,3204,B-CHEMICAL
),3204,O
is,3204,O
limited,3204,O
by,3204,O
the,3204,O
risk,3204,O
of,3204,O
tyramine-provoked,3204,B-CHEMICAL
events,3204,O
(,3204,O
eg,3204,O
",",3204,O
acute,3204,O
hypertension,3204,O
and,3204,O
headache,3204,O
",",3204,O
also,3204,O
known,3204,O
as,3204,O
the,3204,O
``,3204,O
cheese,3204,O
reaction,3204,O
'',3204,O
),3204,O
when,3204,O
combined,3204,O
with,3204,O
dietary,3204,O
tyramine,3204,B-CHEMICAL
.,3204,O
The,3205,O
selegiline,3205,B-CHEMICAL
transdermal,3205,O
system,3205,O
is,3205,O
the,3205,O
only,3205,O
MAOI,3205,O
available,3205,O
in,3205,O
the,3205,O
US,3205,O
for,3205,O
the,3205,O
treatment,3205,O
of,3205,O
MDD,3205,O
that,3205,O
does,3205,O
not,3205,O
require,3205,O
dietary,3205,O
restriction,3205,O
at,3205,O
the,3205,O
clinically,3205,O
effective,3205,O
dose,3205,O
of,3205,O
6,3205,O
mg/24,3205,O
hours,3205,O
.,3205,O
Delivery,3206,O
of,3206,O
selegiline,3206,O
transdermally,3206,O
(,3206,O
EMSAM,3206,O
(,3206,O
(,3206,O
R,3206,O
),3206,O
),3206,O
),3206,O
bypasses,3206,O
hepatic,3206,O
first,3206,O
pass,3206,O
metabolism,3206,O
",",3206,O
thereby,3206,O
avoiding,3206,O
significant,3206,O
inhibition,3206,O
of,3206,O
gastrointestinal,3206,O
and,3206,O
hepatic,3206,O
MAO-A,3206,B-GENE-Y
activity,3206,O
(,3206,O
ie,3206,O
",",3206,O
reduced,3206,O
risk,3206,O
of,3206,O
tyramine-provoked,3206,B-CHEMICAL
events,3206,O
),3206,O
while,3206,O
still,3206,O
providing,3206,O
sufficient,3206,O
levels,3206,O
of,3206,O
selegiline,3206,B-CHEMICAL
in,3206,O
the,3206,O
brain,3206,O
to,3206,O
produce,3206,O
an,3206,O
antidepressant,3206,O
effect,3206,O
.,3206,O
At,3207,O
dosages,3207,O
of,3207,O
6-12,3207,O
mg/24,3207,O
hours,3207,O
",",3207,O
EMSAM,3207,O
has,3207,O
been,3207,O
shown,3207,O
to,3207,O
improve,3207,O
symptoms,3207,O
of,3207,O
depression,3207,O
",",3207,O
have,3207,O
good,3207,O
tolerability,3207,O
",",3207,O
and,3207,O
have,3207,O
high,3207,O
rates,3207,O
of,3207,O
medication,3207,O
adherence,3207,O
.,3207,O
However,3208,O
",",3208,O
at,3208,O
higher,3208,O
doses,3208,O
of,3208,O
EMSAM,3208,O
(,3208,O
ie,3208,O
",",3208,O
9,3208,O
mg/24,3208,O
hours,3208,O
or,3208,O
more,3208,O
),3208,O
",",3208,O
dietary,3208,O
restriction,3208,O
of,3208,O
tyramine,3208,B-CHEMICAL
intake,3208,O
is,3208,O
recommended,3208,O
.,3208,O
The,3209,O
introduction,3209,O
of,3209,O
EMSAM,3209,O
overcomes,3209,O
many,3209,O
of,3209,O
the,3209,O
safety,3209,O
concerns,3209,O
affiliated,3209,O
with,3209,O
the,3209,O
conventional,3209,O
oral,3209,O
MAO,3209,B-GENE-N
inhibitors,3209,O
and,3209,O
EMSAM,3209,O
may,3209,O
be,3209,O
considered,3209,O
another,3209,O
strategy,3209,O
for,3209,O
the,3209,O
treatment,3209,O
of,3209,O
MDD,3209,O
",",3209,O
especially,3209,O
in,3209,O
patients,3209,O
who,3209,O
can,3209,O
not,3209,O
tolerate,3209,O
oral,3209,O
antidepressants,3209,O
",",3209,O
are,3209,O
poorly,3209,O
adherent,3209,O
",",3209,O
who,3209,O
present,3209,O
with,3209,O
atypical,3209,O
depressive,3209,O
symptoms,3209,O
",",3209,O
or,3209,O
have,3209,O
failed,3209,O
other,3209,O
antidepressants,3209,O
.,3209,O
Atomoxetine,3210,B-CHEMICAL
:,3210,O
a,3210,O
review,3210,O
of,3210,O
its,3210,O
use,3210,O
in,3210,O
attention-deficit,3210,O
hyperactivity,3210,O
disorder,3210,O
in,3210,O
children,3210,O
and,3210,O
adolescents,3210,O
.,3210,O
Atomoxetine,3211,B-CHEMICAL
(,3211,O
Strattera,3211,B-CHEMICAL
(,3211,O
R,3211,O
),3211,O
),3211,O
is,3211,O
a,3211,O
selective,3211,O
norepinephrine,3211,B-CHEMICAL
(,3211,O
noradrenaline,3211,B-CHEMICAL
),3211,O
reuptake,3211,O
inhibitor,3211,O
that,3211,O
is,3211,O
not,3211,O
classified,3211,O
as,3211,O
a,3211,O
stimulant,3211,O
",",3211,O
and,3211,O
is,3211,O
indicated,3211,O
for,3211,O
use,3211,O
in,3211,O
patients,3211,O
with,3211,O
attention-deficit,3211,O
hyperactivity,3211,O
disorder,3211,O
(,3211,O
ADHD,3211,O
),3211,O
.,3211,O
Atomoxetine,3212,B-CHEMICAL
is,3212,O
effective,3212,O
and,3212,O
generally,3212,O
well,3212,O
tolerated,3212,O
.,3212,O
It,3213,O
is,3213,O
significantly,3213,O
more,3213,O
effective,3213,O
than,3213,O
placebo,3213,O
and,3213,O
standard,3213,O
current,3213,O
therapy,3213,O
and,3213,O
does,3213,O
not,3213,O
differ,3213,O
significantly,3213,O
from,3213,O
or,3213,O
is,3213,O
noninferior,3213,O
to,3213,O
immediate-release,3213,O
methylphenidate,3213,B-CHEMICAL
;,3213,O
however,3213,O
",",3213,O
it,3213,O
is,3213,O
significantly,3213,O
less,3213,O
effective,3213,O
than,3213,O
the,3213,O
extended-release,3213,O
methylphenidate,3213,B-CHEMICAL
formulation,3213,O
OROS,3213,O
(,3213,O
R,3213,O
),3213,O
methylphenidate,3213,B-CHEMICAL
(,3213,O
hereafter,3213,O
referred,3213,O
to,3213,O
as,3213,O
osmotically,3213,O
released,3213,O
methylphenidate,3213,B-CHEMICAL
),3213,O
and,3213,O
extended-release,3213,O
mixed,3213,O
amfetamine,3213,B-CHEMICAL
salts,3213,O
.,3213,O
Atomoxetine,3214,B-CHEMICAL
can,3214,O
be,3214,O
administered,3214,O
either,3214,O
as,3214,O
a,3214,O
single,3214,O
daily,3214,O
dose,3214,O
or,3214,O
split,3214,O
into,3214,O
two,3214,O
evenly,3214,O
divided,3214,O
doses,3214,O
",",3214,O
has,3214,O
a,3214,O
negligible,3214,O
risk,3214,O
of,3214,O
abuse,3214,O
or,3214,O
misuse,3214,O
",",3214,O
and,3214,O
is,3214,O
not,3214,O
a,3214,O
controlled,3214,O
substance,3214,O
in,3214,O
the,3214,O
US,3214,O
.,3214,O
Atomoxetine,3215,B-CHEMICAL
is,3215,O
particularly,3215,O
useful,3215,O
for,3215,O
patients,3215,O
at,3215,O
risk,3215,O
of,3215,O
substance,3215,O
abuse,3215,O
",",3215,O
as,3215,O
well,3215,O
as,3215,O
those,3215,O
who,3215,O
have,3215,O
co-morbid,3215,O
anxiety,3215,O
or,3215,O
tics,3215,O
",",3215,O
or,3215,O
who,3215,O
do,3215,O
not,3215,O
wish,3215,O
to,3215,O
take,3215,O
a,3215,O
controlled,3215,O
substance,3215,O
.,3215,O
Thus,3216,O
",",3216,O
atomoxetine,3216,B-CHEMICAL
is,3216,O
a,3216,O
useful,3216,O
option,3216,O
in,3216,O
the,3216,O
treatment,3216,O
of,3216,O
ADHD,3216,O
in,3216,O
children,3216,O
and,3216,O
adolescents,3216,O
.,3216,O
The,3217,O
mechanism,3217,O
of,3217,O
action,3217,O
of,3217,O
atomoxetine,3217,B-CHEMICAL
is,3217,O
unclear,3217,O
",",3217,O
but,3217,O
is,3217,O
thought,3217,O
to,3217,O
be,3217,O
related,3217,O
to,3217,O
its,3217,O
selective,3217,O
inhibition,3217,O
of,3217,O
presynaptic,3217,O
norepinephrine,3217,B-CHEMICAL
reuptake,3217,O
in,3217,O
the,3217,O
prefrontal,3217,O
cortex,3217,O
.,3217,O
Atomoxetine,3218,B-CHEMICAL
has,3218,O
a,3218,O
high,3218,O
affinity,3218,O
and,3218,O
selectivity,3218,O
for,3218,O
norepinephrine,3218,B-CHEMICAL
transporters,3218,I-GENE-Y
",",3218,O
but,3218,O
little,3218,O
or,3218,O
no,3218,O
affinity,3218,O
for,3218,O
various,3218,O
neurotransmitter,3218,B-GENE-N
receptors,3218,I-GENE-N
.,3218,O
Atomoxetine,3219,B-CHEMICAL
has,3219,O
a,3219,O
demonstrated,3219,O
ability,3219,O
to,3219,O
selectively,3219,O
inhibit,3219,O
norepinephrine,3219,B-CHEMICAL
uptake,3219,O
in,3219,O
humans,3219,O
and,3219,O
animals,3219,O
",",3219,O
and,3219,O
studies,3219,O
have,3219,O
shown,3219,O
that,3219,O
it,3219,O
preferentially,3219,O
binds,3219,O
to,3219,O
areas,3219,O
of,3219,O
known,3219,O
high,3219,O
distribution,3219,O
of,3219,O
noradrenergic,3219,O
neurons,3219,O
",",3219,O
such,3219,O
as,3219,O
the,3219,O
fronto-cortical,3219,O
subsystem,3219,O
.,3219,O
Atomoxetine,3220,B-CHEMICAL
was,3220,O
generally,3220,O
associated,3220,O
with,3220,O
statistically,3220,O
",",3220,O
but,3220,O
not,3220,O
clinically,3220,O
",",3220,O
significant,3220,O
increases,3220,O
in,3220,O
both,3220,O
heart,3220,O
rate,3220,O
and,3220,O
blood,3220,O
pressure,3220,O
in,3220,O
pediatric,3220,O
patients,3220,O
with,3220,O
ADHD,3220,O
.,3220,O
While,3221,O
there,3221,O
was,3221,O
an,3221,O
initial,3221,O
loss,3221,O
in,3221,O
expected,3221,O
height,3221,O
and,3221,O
weight,3221,O
among,3221,O
atomoxetine,3221,B-CHEMICAL
recipients,3221,O
",",3221,O
this,3221,O
eventually,3221,O
returned,3221,O
to,3221,O
normal,3221,O
in,3221,O
the,3221,O
longer,3221,O
term,3221,O
.,3221,O
Data,3222,O
suggest,3222,O
that,3222,O
atomoxetine,3222,B-CHEMICAL
is,3222,O
unlikely,3222,O
to,3222,O
have,3222,O
any,3222,O
abuse,3222,O
potential,3222,O
.,3222,O
Atomoxetine,3223,B-CHEMICAL
appeared,3223,O
less,3223,O
likely,3223,O
than,3223,O
methylphenidate,3223,B-CHEMICAL
to,3223,O
exacerbate,3223,O
disordered,3223,O
sleep,3223,O
in,3223,O
pediatric,3223,O
patients,3223,O
with,3223,O
ADHD,3223,O
.,3223,O
Atomoxetine,3224,B-CHEMICAL
is,3224,O
rapidly,3224,O
absorbed,3224,O
",",3224,O
and,3224,O
demonstrates,3224,O
dose-proportional,3224,O
increases,3224,O
in,3224,O
plasma,3224,O
exposure,3224,O
.,3224,O
It,3225,O
undergoes,3225,O
extensive,3225,O
biotransformation,3225,O
",",3225,O
which,3225,O
is,3225,O
affected,3225,O
by,3225,O
poor,3225,O
metabolism,3225,O
by,3225,O
cytochrome,3225,B-GENE-Y
P450,3225,I-GENE-Y
(,3225,I-GENE-Y
CYP,3225,I-GENE-Y
),3225,I-GENE-Y
2D6,3225,I-GENE-Y
in,3225,O
a,3225,O
small,3225,O
percentage,3225,O
of,3225,O
the,3225,O
population,3225,O
;,3225,O
these,3225,O
patients,3225,O
have,3225,O
greater,3225,O
exposure,3225,O
to,3225,O
and,3225,O
slower,3225,O
elimination,3225,O
of,3225,O
atomoxetine,3225,B-CHEMICAL
than,3225,O
extensive,3225,O
metabolizers,3225,O
.,3225,O
Patients,3226,O
with,3226,O
hepatic,3226,O
insufficiency,3226,O
show,3226,O
an,3226,O
increase,3226,O
in,3226,O
atomoxetine,3226,B-CHEMICAL
exposure,3226,O
.,3226,O
CYP2D6,3227,B-GENE-Y
inhibitors,3227,O
",",3227,O
such,3227,O
as,3227,O
paroxetine,3227,B-CHEMICAL
",",3227,O
are,3227,O
associated,3227,O
with,3227,O
changes,3227,O
in,3227,O
atomoxetine,3227,B-CHEMICAL
pharmacokinetics,3227,O
similar,3227,O
to,3227,O
those,3227,O
observed,3227,O
among,3227,O
poor,3227,O
CYP2D6,3227,B-GENE-Y
metabolizers,3227,O
.,3227,O
Once-,3228,O
or,3228,O
twice-daily,3228,O
atomoxetine,3228,B-CHEMICAL
was,3228,O
effective,3228,O
in,3228,O
the,3228,O
short-term,3228,O
treatment,3228,O
of,3228,O
ADHD,3228,O
in,3228,O
children,3228,O
and,3228,O
adolescents,3228,O
",",3228,O
as,3228,O
observed,3228,O
in,3228,O
several,3228,O
well,3228,O
designed,3228,O
placebo-controlled,3228,O
trials,3228,O
.,3228,O
Atomoxetine,3229,B-CHEMICAL
also,3229,O
demonstrated,3229,O
efficacy,3229,O
in,3229,O
the,3229,O
longer,3229,O
term,3229,O
treatment,3229,O
of,3229,O
these,3229,O
patients,3229,O
.,3229,O
A,3230,O
single,3230,O
morning,3230,O
dose,3230,O
was,3230,O
shown,3230,O
to,3230,O
be,3230,O
effective,3230,O
into,3230,O
the,3230,O
evening,3230,O
",",3230,O
and,3230,O
discontinuation,3230,O
of,3230,O
atomoxetine,3230,B-CHEMICAL
was,3230,O
not,3230,O
associated,3230,O
with,3230,O
symptom,3230,O
rebound,3230,O
.,3230,O
Atomoxetine,3231,B-CHEMICAL
efficacy,3231,O
did,3231,O
not,3231,O
appear,3231,O
to,3231,O
differ,3231,O
between,3231,O
children,3231,O
and,3231,O
adolescents,3231,O
.,3231,O
Stimulant-naive,3232,O
patients,3232,O
also,3232,O
responded,3232,O
well,3232,O
to,3232,O
atomoxetine,3232,B-CHEMICAL
treatment,3232,O
.,3232,O
Atomoxetine,3233,B-CHEMICAL
did,3233,O
not,3233,O
differ,3233,O
significantly,3233,O
from,3233,O
or,3233,O
was,3233,O
noninferior,3233,O
to,3233,O
immediate-release,3233,O
methylphenidate,3233,B-CHEMICAL
in,3233,O
children,3233,O
and,3233,O
adolescents,3233,O
with,3233,O
ADHD,3233,O
with,3233,O
regard,3233,O
to,3233,O
efficacy,3233,O
",",3233,O
and,3233,O
was,3233,O
significantly,3233,O
more,3233,O
effective,3233,O
than,3233,O
standard,3233,O
current,3233,O
therapy,3233,O
(,3233,O
any,3233,O
combination,3233,O
of,3233,O
medicines,3233,O
[,3233,O
excluding,3233,O
atomoxetine,3233,B-CHEMICAL
],3233,O
and/or,3233,O
behavioral,3233,O
counseling,3233,O
",",3233,O
or,3233,O
no,3233,O
treatment,3233,O
),3233,O
.,3233,O
However,3234,O
",",3234,O
atomoxetine,3234,B-CHEMICAL
was,3234,O
significantly,3234,O
less,3234,O
effective,3234,O
than,3234,O
osmotically,3234,O
released,3234,O
methylphenidate,3234,B-CHEMICAL
and,3234,O
extended-release,3234,O
mixed,3234,O
amfetamine,3234,B-CHEMICAL
salts,3234,O
.,3234,O
The,3235,O
efficacy,3235,O
of,3235,O
atomoxetine,3235,B-CHEMICAL
did,3235,O
not,3235,O
appear,3235,O
to,3235,O
be,3235,O
affected,3235,O
by,3235,O
the,3235,O
presence,3235,O
of,3235,O
co-morbid,3235,O
disorders,3235,O
",",3235,O
and,3235,O
symptoms,3235,O
of,3235,O
the,3235,O
co-morbid,3235,O
disorders,3235,O
were,3235,O
not,3235,O
affected,3235,O
or,3235,O
were,3235,O
improved,3235,O
by,3235,O
atomoxetine,3235,B-CHEMICAL
administration,3235,O
.,3235,O
Health-related,3236,O
quality,3236,O
of,3236,O
life,3236,O
(,3236,O
HR-QOL,3236,O
),3236,O
appeared,3236,O
to,3236,O
be,3236,O
positively,3236,O
affected,3236,O
by,3236,O
atomoxetine,3236,B-CHEMICAL
in,3236,O
both,3236,O
short-,3236,O
and,3236,O
long-term,3236,O
studies,3236,O
;,3236,O
atomoxetine,3236,B-CHEMICAL
also,3236,O
improved,3236,O
HR-QOL,3236,O
to,3236,O
a,3236,O
greater,3236,O
extent,3236,O
than,3236,O
standard,3236,O
current,3236,O
therapy,3236,O
.,3236,O
Atomoxetine,3237,B-CHEMICAL
was,3237,O
generally,3237,O
well,3237,O
tolerated,3237,O
in,3237,O
children,3237,O
and,3237,O
adolescents,3237,O
with,3237,O
ADHD,3237,O
.,3237,O
Common,3238,O
adverse,3238,O
events,3238,O
included,3238,O
headache,3238,O
",",3238,O
abdominal,3238,O
pain,3238,O
",",3238,O
decreased,3238,O
appetite,3238,O
",",3238,O
vomiting,3238,O
",",3238,O
somnolence,3238,O
",",3238,O
and,3238,O
nausea,3238,O
.,3238,O
The,3239,O
majority,3239,O
of,3239,O
adverse,3239,O
events,3239,O
were,3239,O
mild,3239,O
or,3239,O
moderate,3239,O
;,3239,O
there,3239,O
was,3239,O
a,3239,O
very,3239,O
low,3239,O
incidence,3239,O
of,3239,O
serious,3239,O
adverse,3239,O
events,3239,O
.,3239,O
Few,3240,O
patients,3240,O
discontinued,3240,O
atomoxetine,3240,B-CHEMICAL
treatment,3240,O
because,3240,O
of,3240,O
adverse,3240,O
events,3240,O
.,3240,O
Atomoxetine,3241,B-CHEMICAL
discontinuation,3241,O
appeared,3241,O
to,3241,O
be,3241,O
well,3241,O
tolerated,3241,O
",",3241,O
with,3241,O
a,3241,O
low,3241,O
incidence,3241,O
of,3241,O
discontinuation-emergent,3241,O
adverse,3241,O
events,3241,O
.,3241,O
Atomoxetine,3242,B-CHEMICAL
appeared,3242,O
better,3242,O
tolerated,3242,O
among,3242,O
extensive,3242,O
CYP2D6,3242,B-GENE-Y
metabolizers,3242,O
than,3242,O
among,3242,O
poor,3242,O
metabolizers,3242,O
.,3242,O
Slight,3243,O
differences,3243,O
were,3243,O
evident,3243,O
in,3243,O
the,3243,O
adverse,3243,O
event,3243,O
profiles,3243,O
of,3243,O
atomoxetine,3243,B-CHEMICAL
and,3243,O
stimulants,3243,O
",",3243,O
both,3243,O
immediate-,3243,O
and,3243,O
extended-release,3243,O
.,3243,O
Somnolence,3244,O
appeared,3244,O
more,3244,O
common,3244,O
among,3244,O
atomoxetine,3244,B-CHEMICAL
recipients,3244,O
and,3244,O
insomnia,3244,O
appeared,3244,O
more,3244,O
common,3244,O
among,3244,O
stimulant,3244,O
recipients,3244,O
.,3244,O
A,3245,O
black-box,3245,O
warning,3245,O
for,3245,O
suicidal,3245,O
ideation,3245,O
has,3245,O
been,3245,O
published,3245,O
in,3245,O
the,3245,O
US,3245,O
prescribing,3245,O
information,3245,O
",",3245,O
based,3245,O
on,3245,O
findings,3245,O
from,3245,O
a,3245,O
meta-analysis,3245,O
showing,3245,O
that,3245,O
atomoxetine,3245,B-CHEMICAL
is,3245,O
associated,3245,O
with,3245,O
a,3245,O
significantly,3245,O
higher,3245,O
incidence,3245,O
of,3245,O
suicidal,3245,O
ideation,3245,O
than,3245,O
placebo,3245,O
.,3245,O
Rarely,3246,O
",",3246,O
atomoxetine,3246,B-CHEMICAL
may,3246,O
also,3246,O
be,3246,O
associated,3246,O
with,3246,O
serious,3246,O
liver,3246,O
injury,3246,O
;,3246,O
postmarketing,3246,O
data,3246,O
show,3246,O
that,3246,O
three,3246,O
patients,3246,O
have,3246,O
had,3246,O
liver-related,3246,O
adverse,3246,O
events,3246,O
deemed,3246,O
probably,3246,O
related,3246,O
to,3246,O
atomoxetine,3246,B-CHEMICAL
treatment,3246,O
.,3246,O
Treatment,3247,O
algorithms,3247,O
involving,3247,O
the,3247,O
initial,3247,O
use,3247,O
of,3247,O
atomoxetine,3247,B-CHEMICAL
appear,3247,O
cost,3247,O
effective,3247,O
versus,3247,O
algorithms,3247,O
involving,3247,O
initial,3247,O
methylphenidate,3247,B-CHEMICAL
(,3247,O
immediate-,3247,O
or,3247,O
extended-release,3247,O
),3247,O
",",3247,O
dexamfetamine,3247,B-CHEMICAL
",",3247,O
tricyclic,3247,B-CHEMICAL
antidepressants,3247,O
",",3247,O
or,3247,O
no,3247,O
treatment,3247,O
in,3247,O
stimulant-naive,3247,O
",",3247,O
-failed,3247,O
",",3247,O
and,3247,O
-contraindicated,3247,O
children,3247,O
and,3247,O
adolescents,3247,O
with,3247,O
ADHD,3247,O
.,3247,O
The,3248,O
incremental,3248,O
cost,3248,O
per,3248,O
quality-adjusted,3248,O
life-year,3248,O
is,3248,O
below,3248,O
commonly,3248,O
accepted,3248,O
cost-effectiveness,3248,O
thresholds,3248,O
",",3248,O
as,3248,O
shown,3248,O
in,3248,O
several,3248,O
Markov,3248,O
model,3248,O
analyses,3248,O
conducted,3248,O
from,3248,O
the,3248,O
perspective,3248,O
of,3248,O
various,3248,O
European,3248,O
countries,3248,O
",",3248,O
with,3248,O
a,3248,O
time,3248,O
horizon,3248,O
of,3248,O
1,3248,O
year,3248,O
.,3248,O
Novel,3249,O
inhibitors,3249,O
complexed,3249,O
with,3249,O
glutamate,3249,B-GENE-Y
dehydrogenase,3249,I-GENE-Y
:,3249,O
allosteric,3249,O
regulation,3249,O
by,3249,O
control,3249,O
of,3249,O
protein,3249,O
dynamics,3249,O
.,3249,O
Mammalian,3250,B-GENE-N
glutamate,3250,B-CHEMICAL
dehydrogenase,3250,I-GENE-N
(,3250,O
GDH,3250,B-GENE-N
),3250,O
is,3250,O
a,3250,O
homohexameric,3250,O
enzyme,3250,O
that,3250,O
catalyzes,3250,O
the,3250,O
reversible,3250,O
oxidative,3250,O
deamination,3250,O
of,3250,O
l-glutamate,3250,B-CHEMICAL
to,3250,O
2-oxoglutarate,3250,B-CHEMICAL
using,3250,O
NAD,3250,B-CHEMICAL
(,3250,I-CHEMICAL
P,3250,I-CHEMICAL
),3250,I-CHEMICAL
(,3250,I-CHEMICAL
+,3250,I-CHEMICAL
),3250,I-CHEMICAL
as,3250,O
coenzyme,3250,O
.,3250,O
Unlike,3251,O
its,3251,O
counterparts,3251,O
from,3251,O
other,3251,O
animal,3251,O
kingdoms,3251,O
",",3251,O
mammalian,3251,B-GENE-N
GDH,3251,I-GENE-N
is,3251,O
regulated,3251,O
by,3251,O
a,3251,O
host,3251,O
of,3251,O
ligands,3251,O
.,3251,O
The,3252,O
recently,3252,O
discovered,3252,O
hyperinsulinism/hyperammonemia,3252,O
disorder,3252,O
showed,3252,O
that,3252,O
the,3252,O
loss,3252,O
of,3252,O
allosteric,3252,O
inhibition,3252,O
of,3252,O
GDH,3252,B-GENE-Y
by,3252,O
GTP,3252,B-CHEMICAL
causes,3252,O
excessive,3252,O
secretion,3252,O
of,3252,O
insulin,3252,B-GENE-Y
.,3252,O
Subsequent,3253,O
studies,3253,O
demonstrated,3253,O
that,3253,O
wild-type,3253,O
and,3253,O
hyperinsulinemia/hyperammonemia,3253,O
forms,3253,O
of,3253,O
GDH,3253,B-GENE-Y
are,3253,O
inhibited,3253,O
by,3253,O
the,3253,O
green,3253,O
tea,3253,O
polyphenols,3253,O
",",3253,O
epigallocatechin,3253,B-CHEMICAL
gallate,3253,I-CHEMICAL
and,3253,O
epicatechin,3253,B-CHEMICAL
gallate,3253,I-CHEMICAL
.,3253,O
This,3254,O
was,3254,O
followed,3254,O
by,3254,O
high,3254,O
throughput,3254,O
studies,3254,O
that,3254,O
identified,3254,O
more,3254,O
stable,3254,O
inhibitors,3254,O
",",3254,O
including,3254,O
hexachlorophene,3254,B-CHEMICAL
",",3254,O
GW5074,3254,B-CHEMICAL
",",3254,O
and,3254,O
bithionol,3254,B-CHEMICAL
.,3254,O
Shown,3255,O
here,3255,O
are,3255,O
the,3255,O
structures,3255,O
of,3255,O
GDH,3255,B-GENE-Y
complexed,3255,O
with,3255,O
these,3255,O
three,3255,O
compounds,3255,O
.,3255,O
Hexachlorophene,3256,B-CHEMICAL
forms,3256,O
a,3256,O
ring,3256,O
around,3256,O
the,3256,O
internal,3256,O
cavity,3256,O
in,3256,O
GDH,3256,B-GENE-Y
through,3256,O
aromatic,3256,O
stacking,3256,O
interactions,3256,O
between,3256,O
the,3256,O
drug,3256,O
and,3256,O
GDH,3256,B-GENE-Y
as,3256,O
well,3256,O
as,3256,O
between,3256,O
the,3256,O
drug,3256,O
molecules,3256,O
themselves,3256,O
.,3256,O
In,3257,O
contrast,3257,O
",",3257,O
GW5074,3257,B-CHEMICAL
and,3257,O
bithionol,3257,B-CHEMICAL
both,3257,O
bind,3257,O
as,3257,O
pairs,3257,O
of,3257,O
stacked,3257,O
compounds,3257,O
at,3257,O
hexameric,3257,O
2-fold,3257,O
axes,3257,O
between,3257,O
the,3257,O
dimers,3257,O
of,3257,O
subunits,3257,O
.,3257,O
The,3258,O
internal,3258,O
core,3258,O
of,3258,O
GDH,3258,B-GENE-Y
contracts,3258,O
when,3258,O
the,3258,O
catalytic,3258,O
cleft,3258,O
closes,3258,O
during,3258,O
enzymatic,3258,O
turnover,3258,O
.,3258,O
None,3259,O
of,3259,O
the,3259,O
drugs,3259,O
cause,3259,O
conformational,3259,O
changes,3259,O
in,3259,O
the,3259,O
contact,3259,O
residues,3259,O
",",3259,O
but,3259,O
all,3259,O
bind,3259,O
to,3259,O
key,3259,O
interfaces,3259,O
involved,3259,O
in,3259,O
this,3259,O
contraction,3259,O
process,3259,O
.,3259,O
Therefore,3260,O
",",3260,O
it,3260,O
seems,3260,O
likely,3260,O
that,3260,O
the,3260,O
drugs,3260,O
inhibit,3260,O
enzymatic,3260,O
turnover,3260,O
by,3260,O
inhibiting,3260,O
this,3260,O
transition,3260,O
.,3260,O
Indeed,3261,O
",",3261,O
this,3261,O
expansion/contraction,3261,O
process,3261,O
may,3261,O
play,3261,O
a,3261,O
major,3261,O
role,3261,O
in,3261,O
the,3261,O
inter-subunit,3261,O
communication,3261,O
and,3261,O
allosteric,3261,O
regulation,3261,O
observed,3261,O
in,3261,O
GDH,3261,B-GENE-Y
.,3261,O
The,3262,O
effect,3262,O
of,3262,O
a,3262,O
peripheral,3262,O
block,3262,O
on,3262,O
inflammation-induced,3262,O
prostaglandin,3262,B-CHEMICAL
E2,3262,I-CHEMICAL
and,3262,O
cyclooxygenase,3262,B-GENE-N
expression,3262,O
in,3262,O
rats,3262,O
.,3262,O
BACKGROUND,3263,O
:,3263,O
Peripheral,3263,O
inflammatory,3263,O
pain,3263,O
is,3263,O
associated,3263,O
with,3263,O
an,3263,O
upregulation,3263,O
of,3263,O
spinal,3263,O
cord,3263,O
COX-2,3263,B-GENE-Y
(,3263,O
cyclooxygenase-2,3263,B-GENE-Y
),3263,O
",",3263,O
with,3263,O
a,3263,O
subsequent,3263,O
increase,3263,O
in,3263,O
central,3263,O
prostaglandin,3263,B-CHEMICAL
E2,3263,I-CHEMICAL
(,3263,O
PGE2,3263,B-CHEMICAL
),3263,O
levels,3263,O
associated,3263,O
with,3263,O
the,3263,O
development,3263,O
of,3263,O
hyperalgesia,3263,O
.,3263,O
In,3264,O
this,3264,O
study,3264,O
",",3264,O
we,3264,O
evaluated,3264,O
the,3264,O
effect,3264,O
of,3264,O
bupivacaine,3264,B-CHEMICAL
administered,3264,O
via,3264,O
a,3264,O
nerve,3264,O
block,3264,O
or,3264,O
via,3264,O
a,3264,O
systemic,3264,O
route,3264,O
on,3264,O
the,3264,O
spinal,3264,O
expression,3264,O
of,3264,O
PGE2,3264,B-CHEMICAL
and,3264,O
COX,3264,B-GENE-N
in,3264,O
a,3264,O
model,3264,O
of,3264,O
peripheral,3264,O
inflammation,3264,O
in,3264,O
rats,3264,O
.,3264,O
METHODS,3265,O
:,3265,O
All,3265,O
rats,3265,O
randomly,3265,O
received,3265,O
three,3265,O
injections,3265,O
:,3265,O
1,3265,O
),3265,O
a,3265,O
left,3265,O
subcutaneous,3265,O
hindpaw,3265,O
injection,3265,O
(,3265,O
0.2,3265,O
mL,3265,O
with,3265,O
either,3265,O
carrageenan,3265,O
2,3265,O
%,3265,O
w/v,3265,O
or,3265,O
saline,3265,O
),3265,O
",",3265,O
2,3265,O
),3265,O
a,3265,O
left,3265,O
sciatic,3265,O
block,3265,O
(,3265,O
0.2,3265,O
mL,3265,O
with,3265,O
either,3265,O
bupivacaine,3265,B-CHEMICAL
0.5,3265,O
%,3265,O
or,3265,O
saline,3265,O
),3265,O
",",3265,O
and,3265,O
3,3265,O
),3265,O
a,3265,O
systemic,3265,O
injection,3265,O
(,3265,O
subcutaneous,3265,O
interscapular,3265,O
with,3265,O
0.2,3265,O
mL,3265,O
with,3265,O
either,3265,O
bupivacaine,3265,B-CHEMICAL
0.5,3265,O
%,3265,O
or,3265,O
saline,3265,O
),3265,O
.,3265,O
Local,3266,O
edema,3266,O
",",3266,O
thermal,3266,O
",",3266,O
and,3266,O
mechanical,3266,O
hyperalgesia,3266,O
as,3266,O
well,3266,O
as,3266,O
cerebrospinal,3266,O
fluid,3266,O
PGE2,3266,B-CHEMICAL
concentration,3266,O
and,3266,O
COX-1,3266,B-GENE-Y
and,3266,O
COX-2,3266,B-GENE-Y
expression,3266,O
in,3266,O
the,3266,O
spinal,3266,O
cord,3266,O
in,3266,O
dorsal,3266,O
root,3266,O
ganglions,3266,O
were,3266,O
measured,3266,O
.,3266,O
RESULTS,3267,O
:,3267,O
We,3267,O
confirmed,3267,O
that,3267,O
a,3267,O
bupivacaine,3267,B-CHEMICAL
block,3267,O
attenuates,3267,O
hyperalgesia,3267,O
and,3267,O
local,3267,O
inflammation,3267,O
in,3267,O
a,3267,O
model,3267,O
of,3267,O
inflammatory,3267,O
pain,3267,O
.,3267,O
This,3268,O
effect,3268,O
was,3268,O
associated,3268,O
with,3268,O
an,3268,O
inhibition,3268,O
of,3268,O
the,3268,O
increase,3268,O
in,3268,O
COX-2,3268,B-GENE-Y
expression,3268,O
induced,3268,O
by,3268,O
peripheral,3268,O
inflammation,3268,O
in,3268,O
dorsal,3268,O
root,3268,O
ganglions,3268,O
and,3268,O
cord,3268,O
.,3268,O
The,3269,O
subsequent,3269,O
production,3269,O
of,3269,O
PGE2,3269,B-CHEMICAL
in,3269,O
cerebrospinal,3269,O
fluid,3269,O
was,3269,O
also,3269,O
impaired,3269,O
.,3269,O
Systemic,3270,O
bupivacaine,3270,B-CHEMICAL
did,3270,O
not,3270,O
modify,3270,O
either,3270,O
the,3270,O
hyperalgesia,3270,O
and,3270,O
local,3270,O
inflammation,3270,O
or,3270,O
COX,3270,B-GENE-N
expression,3270,O
.,3270,O
CONCLUSION,3271,O
:,3271,O
These,3271,O
results,3271,O
constitute,3271,O
a,3271,O
key,3271,O
element,3271,O
strongly,3271,O
suggesting,3271,O
that,3271,O
local,3271,O
anesthetics,3271,O
act,3271,O
at,3271,O
a,3271,O
different,3271,O
level,3271,O
when,3271,O
administered,3271,O
systematically,3271,O
or,3271,O
via,3271,O
a,3271,O
nerve,3271,O
block,3271,O
.,3271,O
Two,3272,O
pharmacologically,3272,O
distinct,3272,O
alpha,3272,B-GENE-N
1-adrenoceptor,3272,I-GENE-N
subtypes,3272,O
in,3272,O
the,3272,O
contraction,3272,O
of,3272,O
rabbit,3272,O
aorta,3272,O
:,3272,O
each,3272,O
subtype,3272,O
couples,3272,O
with,3272,O
a,3272,O
different,3272,O
Ca2+,3272,B-CHEMICAL
signalling,3272,O
mechanism,3272,O
and,3272,O
plays,3272,O
a,3272,O
different,3272,O
physiological,3272,O
role,3272,O
.,3272,O
Using,3273,O
the,3273,O
alpha,3273,B-GENE-N
1-adrenoceptor,3273,I-GENE-N
subtype-selective,3273,O
antagonists,3273,O
chlorethylclonidine,3273,B-CHEMICAL
(,3273,O
CEC,3273,B-CHEMICAL
),3273,O
",",3273,O
WB4101,3273,B-CHEMICAL
",",3273,O
and,3273,O
5-methyl-urapidil,3273,B-CHEMICAL
",",3273,O
we,3273,O
have,3273,O
examined,3273,O
the,3273,O
possible,3273,O
heterogeneity,3273,O
in,3273,O
the,3273,O
alpha,3273,B-GENE-N
1-adrenoceptor,3273,I-GENE-N
populations,3273,O
in,3273,O
rabbit,3273,O
aorta,3273,O
.,3273,O
The,3274,O
alpha,3274,B-GENE-N
1-adrenoceptor,3274,I-GENE-N
alkylating,3274,O
agent,3274,O
CEC,3274,O
selectively,3274,O
inhibited,3274,O
the,3274,O
phasic,3274,O
component,3274,O
of,3274,O
the,3274,O
norepinephrine-induced,3274,B-CHEMICAL
contractile,3274,O
response,3274,O
",",3274,O
with,3274,O
little,3274,O
effect,3274,O
on,3274,O
the,3274,O
tonic,3274,O
component,3274,O
.,3274,O
The,3275,O
alpha,3275,B-GENE-N
1-adrenoceptor,3275,I-GENE-N
occupancy-response,3275,O
relationship,3275,O
defined,3275,O
by,3275,O
the,3275,O
phenoxybenzamine,3275,B-CHEMICAL
inactivation,3275,O
method,3275,O
was,3275,O
rectangular,3275,O
hyperbolic,3275,O
for,3275,O
the,3275,O
tonic,3275,O
response,3275,O
",",3275,O
whereas,3275,O
that,3275,O
for,3275,O
the,3275,O
phasic,3275,O
response,3275,O
was,3275,O
linear,3275,O
",",3275,O
indicating,3275,O
the,3275,O
different,3275,O
degree,3275,O
of,3275,O
receptor,3275,O
reserve,3275,O
for,3275,O
the,3275,O
two,3275,O
responses,3275,O
.,3275,O
Radioligand,3276,O
binding,3276,O
studies,3276,O
with,3276,O
the,3276,O
nonselective,3276,O
alpha,3276,B-GENE-N
1-adrenoceptor,3276,I-GENE-N
antagonist,3276,O
radioligand,3276,O
125I-BE2254,3276,B-CHEMICAL
showed,3276,O
that,3276,O
73-87,3276,O
%,3276,O
of,3276,O
the,3276,O
binding,3276,O
sites,3276,O
in,3276,O
rabbit,3276,O
aorta,3276,O
are,3276,O
CEC,3276,B-CHEMICAL
sensitive,3276,O
and,3276,O
they,3276,O
are,3276,O
predominantly,3276,O
low,3276,O
affinity,3276,O
sites,3276,O
both,3276,O
for,3276,O
WB4101,3276,B-CHEMICAL
(,3276,O
pKd,3276,O
=,3276,O
8.1,3276,O
),3276,O
and,3276,O
for,3276,O
5-methylurapidil,3276,B-CHEMICAL
(,3276,O
pKd,3276,O
=,3276,O
7.1,3276,O
),3276,O
.,3276,O
Moreover,3277,O
",",3277,O
alpha,3277,B-GENE-N
1-adrenoceptor-mediated,3277,O
phosphatidylinositol,3277,B-CHEMICAL
(,3277,O
PI,3277,B-CHEMICAL
),3277,O
hydrolysis,3277,O
was,3277,O
CEC,3277,B-CHEMICAL
sensitive,3277,O
",",3277,O
and,3277,O
fractional,3277,O
inactivation,3277,O
of,3277,O
alpha,3277,B-GENE-N
1,3277,I-GENE-N
receptors,3277,I-GENE-N
with,3277,O
CEC,3277,B-CHEMICAL
showed,3277,O
equivalent,3277,O
increments,3277,O
in,3277,O
the,3277,O
reduction,3277,O
of,3277,O
PI,3277,B-CHEMICAL
hydrolysis,3277,O
and,3277,O
phasic,3277,O
contractile,3277,O
response,3277,O
",",3277,O
suggesting,3277,O
that,3277,O
both,3277,O
responses,3277,O
are,3277,O
linearly,3277,O
related,3277,O
to,3277,O
the,3277,O
CEC-sensitive,3277,B-CHEMICAL
receptor,3277,O
sites,3277,O
.,3277,O
The,3278,O
Schild,3278,O
plots,3278,O
for,3278,O
the,3278,O
competitive,3278,O
antagonists,3278,O
WB4101,3278,B-CHEMICAL
and,3278,O
5-methyl-urapidil,3278,B-CHEMICAL
against,3278,O
alpha,3278,B-GENE-Y
1a-adrenoceptor-selective,3278,O
agonist,3278,O
methoxamine-induced,3278,B-CHEMICAL
contraction,3278,O
were,3278,O
linear,3278,O
and,3278,O
had,3278,O
slopes,3278,O
not,3278,O
significantly,3278,O
different,3278,O
from,3278,O
unity,3278,O
",",3278,O
with,3278,O
a,3278,O
pA2,3278,O
of,3278,O
9.07,3278,O
+/-,3278,O
0.07,3278,O
(,3278,O
n,3278,O
=,3278,O
5,3278,O
),3278,O
for,3278,O
WB4101,3278,B-CHEMICAL
and,3278,O
9.09,3278,O
+/-,3278,O
0.05,3278,O
(,3278,O
n,3278,O
=,3278,O
3,3278,O
),3278,O
for,3278,O
5-methyl-urapidil,3278,B-CHEMICAL
.,3278,O
However,3279,O
",",3279,O
the,3279,O
Schilod,3279,O
plots,3279,O
for,3279,O
these,3279,O
antagonists,3279,O
against,3279,O
norepinephrine,3279,B-CHEMICAL
were,3279,O
curvilinear,3279,O
.,3279,O
Computer-assisted,3280,O
analysis,3280,O
of,3280,O
these,3280,O
curvilinear,3280,O
Schild,3280,O
plots,3280,O
in,3280,O
a,3280,O
two-receptor,3280,O
system,3280,O
indicated,3280,O
that,3280,O
alpha,3280,B-GENE-N
1-adrenoceptor,3280,I-GENE-N
populations,3280,O
responsible,3280,O
for,3280,O
the,3280,O
constrictive,3280,O
response,3280,O
are,3280,O
predominantly,3280,O
(,3280,O
approximately,3280,O
80-90,3280,O
%,3280,O
),3280,O
low,3280,O
affinity,3280,O
sites,3280,O
for,3280,O
the,3280,O
two,3280,O
antagonists,3280,O
(,3280,O
pKd,3280,O
approximately,3280,O
8.1,3280,O
for,3280,O
WB4101,3280,B-CHEMICAL
and,3280,O
pKd,3280,O
approximately,3280,O
7.1,3280,O
for,3280,O
5-methyl-urapidil,3280,B-CHEMICAL
),3280,O
and,3280,O
a,3280,O
small,3280,O
population,3280,O
(,3280,O
approximately,3280,O
10-20,3280,O
%,3280,O
),3280,O
are,3280,O
high,3280,O
affinity,3280,O
sites,3280,O
(,3280,O
pKd,3280,O
approximately,3280,O
9.1,3280,O
for,3280,O
both,3280,O
WB4101,3280,B-CHEMICAL
and,3280,O
5-methyl-urapidil,3280,B-CHEMICAL
),3280,O
",",3280,O
which,3280,O
was,3280,O
in,3280,O
good,3280,O
agreement,3280,O
with,3280,O
radioligand,3280,O
binding,3280,O
studies,3280,O
.,3280,O
(,3281,O
ABSTRACT,3281,O
TRUNCATED,3281,O
AT,3281,O
400,3281,O
WORDS,3281,O
),3281,O
Ambrisentan,3282,B-CHEMICAL
for,3282,O
the,3282,O
treatment,3282,O
of,3282,O
pulmonary,3282,O
arterial,3282,O
hypertension,3282,O
.,3282,O
Ambrisentan,3283,B-CHEMICAL
is,3283,O
an,3283,O
endothelin,3283,B-GENE-N
receptor,3283,I-GENE-N
antagonist,3283,O
(,3283,O
ERA,3283,O
),3283,O
that,3283,O
was,3283,O
recently,3283,O
approved,3283,O
for,3283,O
treatment,3283,O
of,3283,O
pulmonary,3283,O
arterial,3283,O
hypertension,3283,O
(,3283,O
PAH,3283,O
),3283,O
.,3283,O
Endothelin,3284,B-GENE-N
(,3284,O
ET,3284,B-GENE-N
),3284,O
is,3284,O
a,3284,O
potent,3284,O
vasoconstrictor,3284,O
with,3284,O
mitogenic,3284,O
",",3284,O
hypertrophic,3284,O
and,3284,O
pro-inflammatory,3284,O
properties,3284,O
that,3284,O
is,3284,O
upregulated,3284,O
in,3284,O
pulmonary,3284,O
hypertensive,3284,O
diseases,3284,O
.,3284,O
The,3285,O
biologic,3285,O
effects,3285,O
of,3285,O
ET,3285,B-GENE-N
are,3285,O
mediated,3285,O
by,3285,O
2,3285,O
cell,3285,O
surface,3285,O
receptors,3285,O
termed,3285,O
ET,3285,B-GENE-Y
(,3285,I-GENE-Y
A,3285,I-GENE-Y
),3285,I-GENE-Y
and,3285,O
ET,3285,B-GENE-Y
(,3285,I-GENE-Y
B,3285,I-GENE-Y
),3285,I-GENE-Y
.,3285,O
ET,3286,B-GENE-Y
(,3286,I-GENE-Y
A,3286,I-GENE-Y
),3286,I-GENE-Y
mediates,3286,O
the,3286,O
vasoconstrictor,3286,O
effect,3286,O
of,3286,O
ET,3286,B-GENE-N
on,3286,O
vascular,3286,O
smooth,3286,O
muscle,3286,O
",",3286,O
whereas,3286,O
ET,3286,B-GENE-Y
(,3286,I-GENE-Y
B,3286,I-GENE-Y
),3286,I-GENE-Y
is,3286,O
expressed,3286,O
primarily,3286,O
on,3286,O
vascular,3286,O
endothelial,3286,O
cells,3286,O
where,3286,O
it,3286,O
induces,3286,O
nitric,3286,B-CHEMICAL
oxide,3286,I-CHEMICAL
synthesis,3286,O
and,3286,O
acts,3286,O
to,3286,O
clear,3286,O
ET,3286,B-GENE-N
from,3286,O
the,3286,O
circulation,3286,O
.,3286,O
Ambrisentan,3287,B-CHEMICAL
is,3287,O
the,3287,O
first,3287,O
ET,3287,B-GENE-Y
(,3287,I-GENE-Y
A,3287,I-GENE-Y
),3287,I-GENE-Y
selective,3287,O
ERA,3287,O
approved,3287,O
for,3287,O
use,3287,O
in,3287,O
the,3287,O
US,3287,O
.,3287,O
Recently,3288,O
published,3288,O
clinical,3288,O
trials,3288,O
in,3288,O
patients,3288,O
with,3288,O
PAH,3288,O
demonstrate,3288,O
improvement,3288,O
in,3288,O
functional,3288,O
capacity,3288,O
and,3288,O
pulmonary,3288,O
hemodynamics,3288,O
similar,3288,O
to,3288,O
other,3288,O
ET,3288,B-GENE-Y
(,3288,I-GENE-Y
A,3288,I-GENE-Y
),3288,I-GENE-Y
selective,3288,O
and,3288,O
non-selective,3288,O
ERAs,3288,O
.,3288,O
Its,3289,O
once,3289,O
daily,3289,O
dosing,3289,O
and,3289,O
lower,3289,O
incidence,3289,O
of,3289,O
serum,3289,O
aminotransferase,3289,B-GENE-N
elevation,3289,O
offer,3289,O
potential,3289,O
advantages,3289,O
over,3289,O
other,3289,O
ERAs,3289,O
",",3289,O
but,3289,O
further,3289,O
experience,3289,O
with,3289,O
this,3289,O
agent,3289,O
is,3289,O
needed,3289,O
to,3289,O
fully,3289,O
understand,3289,O
its,3289,O
long-term,3289,O
efficacy,3289,O
and,3289,O
safety,3289,O
.,3289,O
This,3290,O
review,3290,O
discusses,3290,O
the,3290,O
endothelin,3290,B-GENE-N
family,3290,O
of,3290,O
proteins,3290,O
and,3290,O
receptors,3290,O
and,3290,O
their,3290,O
role,3290,O
in,3290,O
the,3290,O
pathophysiology,3290,O
of,3290,O
pulmonary,3290,O
hypertensive,3290,O
diseases,3290,O
.,3290,O
It,3291,O
also,3291,O
examines,3291,O
the,3291,O
development,3291,O
process,3291,O
",",3291,O
safety,3291,O
profile,3291,O
and,3291,O
clinical,3291,O
trials,3291,O
that,3291,O
have,3291,O
resulted,3291,O
in,3291,O
ambrisentan,3291,B-CHEMICAL
being,3291,O
approved,3291,O
for,3291,O
treatment,3291,O
of,3291,O
PAH,3291,O
.,3291,O
Design,3292,O
",",3292,O
synthesis,3292,O
",",3292,O
and,3292,O
in-vivo,3292,O
evaluation,3292,O
of,3292,O
"4,5-diaryloxazole",3292,B-CHEMICAL
as,3292,O
novel,3292,O
nonsteroidal,3292,O
anti-inflammatory,3292,O
drug,3292,O
.,3292,O
A,3293,O
series,3293,O
of,3293,O
"4,5-diaryloxazole",3293,B-CHEMICAL
analogs,3293,O
were,3293,O
designed,3293,O
and,3293,O
the,3293,O
interaction,3293,O
between,3293,O
oxaprozin,3293,B-CHEMICAL
and,3293,O
cyclooxygenase-2,3293,B-GENE-Y
studied,3293,O
by,3293,O
the,3293,O
docking,3293,O
method,3293,O
to,3293,O
improve,3293,O
the,3293,O
biological,3293,O
activity,3293,O
and,3293,O
reduce,3293,O
the,3293,O
gastrointestinal,3293,O
side,3293,O
effects,3293,O
of,3293,O
oxaprozin,3293,B-CHEMICAL
.,3293,O
Finally,3294,O
",",3294,O
3-,3294,B-CHEMICAL
(,3294,I-CHEMICAL
4-,3294,I-CHEMICAL
(,3294,I-CHEMICAL
4-fluorophenyl,3294,I-CHEMICAL
),3294,I-CHEMICAL
-5-,3294,I-CHEMICAL
(,3294,I-CHEMICAL
4-aminosulfonyl-3-fluorophenyl,3294,I-CHEMICAL
),3294,I-CHEMICAL
-oxazole-2-yl,3294,I-CHEMICAL
),3294,I-CHEMICAL
propanoic,3294,I-CHEMICAL
acid,3294,I-CHEMICAL
(,3294,O
NC-2142,3294,B-CHEMICAL
),3294,O
",",3294,O
the,3294,O
best,3294,O
candidate,3294,O
",",3294,O
was,3294,O
selected,3294,O
for,3294,O
synthesis,3294,O
and,3294,O
bioassay,3294,O
based,3294,O
on,3294,O
the,3294,O
screening,3294,O
result,3294,O
.,3294,O
NC-2142,3295,B-CHEMICAL
could,3295,O
lower,3295,O
the,3295,O
tumefaction,3295,O
rates,3295,O
of,3295,O
back,3295,O
metatarsus,3295,O
in,3295,O
rats,3295,O
",",3295,O
as,3295,O
well,3295,O
as,3295,O
reduce,3295,O
the,3295,O
writhing,3295,O
times,3295,O
in,3295,O
mice,3295,O
.,3295,O
NC-2142,3296,B-CHEMICAL
produced,3296,O
fewer,3296,O
gastric,3296,O
lesions,3296,O
than,3296,O
oxaprozin,3296,B-CHEMICAL
.,3296,O
After,3297,O
the,3297,O
aminosulfonyl,3297,B-CHEMICAL
group,3297,O
was,3297,O
introduced,3297,O
into,3297,O
the,3297,O
benzene,3297,B-CHEMICAL
ring,3297,O
of,3297,O
oxaprozin,3297,B-CHEMICAL
",",3297,O
its,3297,O
analgesic,3297,O
and,3297,O
anti-inflammatory,3297,O
activities,3297,O
remained,3297,O
unchanged,3297,O
",",3297,O
and,3297,O
it,3297,O
reduced,3297,O
the,3297,O
number,3297,O
of,3297,O
gastric,3297,O
lesions,3297,O
.,3297,O
This,3298,O
provided,3298,O
a,3298,O
feasible,3298,O
method,3298,O
for,3298,O
further,3298,O
structure,3298,O
modification,3298,O
and,3298,O
optimization,3298,O
of,3298,O
oxaprozin,3298,B-CHEMICAL
.,3298,O
Breast,3299,O
cancer,3299,O
and,3299,O
steroid,3299,B-CHEMICAL
metabolizing,3299,O
enzymes,3299,O
:,3299,O
the,3299,O
role,3299,O
of,3299,O
progestogens,3299,B-CHEMICAL
.,3299,O
It,3300,O
is,3300,O
well,3300,O
documented,3300,O
that,3300,O
breast,3300,O
tissue,3300,O
",",3300,O
both,3300,O
normal,3300,O
and,3300,O
cancerous,3300,O
",",3300,O
contains,3300,O
all,3300,O
the,3300,O
enzymatic,3300,O
systems,3300,O
necessary,3300,O
for,3300,O
the,3300,O
bioformation,3300,O
and,3300,O
metabolic,3300,O
transformation,3300,O
of,3300,O
estrogens,3300,B-CHEMICAL
",",3300,O
androgens,3300,B-CHEMICAL
and,3300,O
progesterone,3300,B-CHEMICAL
.,3300,O
These,3301,O
include,3301,O
sulfatases,3301,B-GENE-N
",",3301,O
aromatase,3301,B-GENE-Y
",",3301,O
hydroxysteroid-dehydrogenases,3301,B-CHEMICAL
",",3301,O
sulfotransferases,3301,B-GENE-N
",",3301,O
hydroxylases,3301,B-GENE-N
and,3301,O
glucuronidases,3301,B-GENE-N
.,3301,O
The,3302,O
control,3302,O
of,3302,O
these,3302,O
enzymes,3302,O
plays,3302,O
an,3302,O
important,3302,O
role,3302,O
in,3302,O
the,3302,O
development,3302,O
and,3302,O
pathogenesis,3302,O
of,3302,O
hormone-dependent,3302,O
breast,3302,O
cancer,3302,O
.,3302,O
As,3303,O
discussed,3303,O
in,3303,O
this,3303,O
review,3303,O
",",3303,O
various,3303,O
progestogens,3303,B-CHEMICAL
including,3303,O
dydrogesterone,3303,B-CHEMICAL
and,3303,O
its,3303,O
20alpha-dihydro-derivative,3303,O
",",3303,O
medrogestone,3303,B-CHEMICAL
",",3303,O
promegestone,3303,B-CHEMICAL
",",3303,O
nomegestrol,3303,B-CHEMICAL
acetate,3303,I-CHEMICAL
and,3303,O
norelgestromin,3303,B-CHEMICAL
can,3303,O
reduce,3303,O
intratissular,3303,O
levels,3303,O
of,3303,O
estradiol,3303,B-CHEMICAL
in,3303,O
breast,3303,O
cancer,3303,O
by,3303,O
blocking,3303,O
sulfatase,3303,B-GENE-N
and,3303,O
17beta-hydroxysteroid-dehydrogenase,3303,B-GENE-Y
type,3303,I-GENE-Y
1,3303,I-GENE-Y
activities,3303,O
.,3303,O
A,3304,O
possible,3304,O
correlation,3304,O
has,3304,O
been,3304,O
postulated,3304,O
between,3304,O
breast,3304,O
cell,3304,O
proliferation,3304,O
and,3304,O
estrogen,3304,B-GENE-Y
sulfotransferase,3304,I-GENE-Y
activity,3304,O
.,3304,O
Progesterone,3305,B-CHEMICAL
is,3305,O
largely,3305,O
transformed,3305,O
in,3305,O
the,3305,O
breast,3305,O
;,3305,O
normal,3305,O
breast,3305,O
produces,3305,O
mainly,3305,O
4-ene,3305,O
derivatives,3305,O
",",3305,O
whereas,3305,O
5alpha-derivatives,3305,O
are,3305,O
most,3305,O
common,3305,O
in,3305,O
breast,3305,O
cancer,3305,O
tissue,3305,O
.,3305,O
It,3306,O
has,3306,O
been,3306,O
suggested,3306,O
that,3306,O
this,3306,O
specific,3306,O
conversion,3306,O
of,3306,O
progesterone,3306,B-CHEMICAL
may,3306,O
be,3306,O
involved,3306,O
in,3306,O
breast,3306,O
carcinogenesis,3306,O
.,3306,O
In,3307,O
conclusion,3307,O
",",3307,O
treatment,3307,O
with,3307,O
anti-aromatases,3307,O
combined,3307,O
with,3307,O
anti-sulfatase,3307,O
or,3307,O
17beta-hydroxysteroid-dehydrogenase,3307,B-CHEMICAL
type,3307,I-GENE-Y
1,3307,I-GENE-Y
could,3307,O
provide,3307,O
new,3307,O
therapeutic,3307,O
possibilities,3307,O
in,3307,O
the,3307,O
treatment,3307,O
of,3307,O
patients,3307,O
with,3307,O
hormone-dependent,3307,O
breast,3307,O
cancer,3307,O
.,3307,O
Mechanism,3308,O
of,3308,O
right,3308,O
precordial,3308,O
ST-segment,3308,O
elevation,3308,O
in,3308,O
structural,3308,O
heart,3308,O
disease,3308,O
:,3308,O
excitation,3308,O
failure,3308,O
by,3308,O
current-to-load,3308,O
mismatch,3308,O
.,3308,O
BACKGROUND,3309,O
:,3309,O
The,3309,O
Brugada,3309,O
sign,3309,O
has,3309,O
been,3309,O
associated,3309,O
with,3309,O
mutations,3309,O
in,3309,O
SCN5A,3309,B-GENE-Y
and,3309,O
with,3309,O
right,3309,O
ventricular,3309,O
structural,3309,O
abnormalities,3309,O
.,3309,O
Their,3310,O
role,3310,O
in,3310,O
the,3310,O
Brugada,3310,O
sign,3310,O
and,3310,O
the,3310,O
associated,3310,O
ventricular,3310,O
arrhythmias,3310,O
is,3310,O
unknown,3310,O
.,3310,O
OBJECTIVE,3311,O
:,3311,O
The,3311,O
purpose,3311,O
of,3311,O
this,3311,O
study,3311,O
was,3311,O
to,3311,O
delineate,3311,O
the,3311,O
role,3311,O
of,3311,O
structural,3311,O
abnormalities,3311,O
and,3311,O
sodium,3311,B-GENE-N
channel,3311,I-GENE-N
dysfunction,3311,O
in,3311,O
the,3311,O
Brugada,3311,O
sign,3311,O
.,3311,O
METHODS,3312,O
:,3312,O
Activation,3312,O
and,3312,O
repolarization,3312,O
characteristics,3312,O
of,3312,O
the,3312,O
explanted,3312,O
heart,3312,O
of,3312,O
a,3312,O
patient,3312,O
with,3312,O
a,3312,O
loss-of-function,3312,O
mutation,3312,O
in,3312,O
SCN5A,3312,B-GENE-Y
(,3312,O
G752R,3312,B-GENE-N
),3312,O
and,3312,O
dilated,3312,O
cardiomyopathy,3312,O
were,3312,O
determined,3312,O
after,3312,O
induction,3312,O
of,3312,O
right-sided,3312,O
ST-segment,3312,O
elevation,3312,O
by,3312,O
ajmaline,3312,B-CHEMICAL
.,3312,O
In,3313,O
addition,3313,O
",",3313,O
right,3313,O
ventricular,3313,O
structural,3313,O
discontinuities,3313,O
and,3313,O
sodium,3313,B-GENE-N
channel,3313,I-GENE-N
dysfunction,3313,O
were,3313,O
simulated,3313,O
in,3313,O
a,3313,O
computer,3313,O
model,3313,O
encompassing,3313,O
the,3313,O
heart,3313,O
and,3313,O
thorax,3313,O
.,3313,O
RESULTS,3314,O
:,3314,O
In,3314,O
the,3314,O
explanted,3314,O
heart,3314,O
",",3314,O
disappearance,3314,O
of,3314,O
local,3314,O
activation,3314,O
in,3314,O
unipolar,3314,O
electrograms,3314,O
at,3314,O
the,3314,O
basal,3314,O
right,3314,O
ventricular,3314,O
epicardium,3314,O
was,3314,O
followed,3314,O
by,3314,O
monophasic,3314,O
ST-segment,3314,O
elevation,3314,O
.,3314,O
The,3315,O
local,3315,O
origin,3315,O
of,3315,O
this,3315,O
phenomenon,3315,O
was,3315,O
confirmed,3315,O
by,3315,O
coaxial,3315,O
electrograms,3315,O
.,3315,O
Neither,3316,O
early,3316,O
repolarization,3316,O
nor,3316,O
late,3316,O
activation,3316,O
correlated,3316,O
with,3316,O
ST-segment,3316,O
elevation,3316,O
.,3316,O
At,3317,O
sites,3317,O
of,3317,O
local,3317,O
ST-segment,3317,O
elevation,3317,O
",",3317,O
the,3317,O
subepicardium,3317,O
was,3317,O
interspersed,3317,O
with,3317,O
adipose,3317,O
tissue,3317,O
and,3317,O
contained,3317,O
more,3317,O
fibrous,3317,O
tissue,3317,O
than,3317,O
either,3317,O
the,3317,O
left,3317,O
ventricle,3317,O
or,3317,O
control,3317,O
hearts,3317,O
.,3317,O
In,3318,O
computer,3318,O
simulations,3318,O
entailing,3318,O
right,3318,O
ventricular,3318,O
structural,3318,O
discontinuities,3318,O
",",3318,O
reduction,3318,O
of,3318,O
sodium,3318,B-GENE-N
channel,3318,I-GENE-N
conductance,3318,O
or,3318,O
size,3318,O
of,3318,O
the,3318,O
gaps,3318,O
between,3318,O
introduced,3318,O
barriers,3318,O
resulted,3318,O
in,3318,O
subepicardial,3318,O
excitation,3318,O
failure,3318,O
or,3318,O
delayed,3318,O
activation,3318,O
by,3318,O
current-to-load,3318,O
mismatch,3318,O
and,3318,O
in,3318,O
the,3318,O
Brugada,3318,O
sign,3318,O
on,3318,O
the,3318,O
ECG,3318,O
.,3318,O
CONCLUSION,3319,O
:,3319,O
Right,3319,O
ventricular,3319,O
excitation,3319,O
failure,3319,O
and,3319,O
activation,3319,O
delay,3319,O
by,3319,O
current-to-load,3319,O
mismatch,3319,O
in,3319,O
the,3319,O
subepicardium,3319,O
can,3319,O
cause,3319,O
the,3319,O
Brugada,3319,O
sign,3319,O
.,3319,O
Therefore,3320,O
",",3320,O
current-to-load,3320,O
mismatch,3320,O
may,3320,O
underlie,3320,O
the,3320,O
ventricular,3320,O
arrhythmias,3320,O
in,3320,O
patients,3320,O
with,3320,O
the,3320,O
Brugada,3320,O
sign,3320,O
.,3320,O
Combination,3321,O
therapy,3321,O
with,3321,O
mitiglinide,3321,B-CHEMICAL
and,3321,O
voglibose,3321,B-CHEMICAL
improves,3321,O
glycemic,3321,O
control,3321,O
in,3321,O
type,3321,O
2,3321,O
diabetic,3321,O
patients,3321,O
on,3321,O
hemodialysis,3321,O
.,3321,O
OBJECTIVE,3322,O
:,3322,O
Mitiglinide,3322,B-CHEMICAL
",",3322,O
a,3322,O
rapid-,3322,O
and,3322,O
short-acting,3322,O
insulinotropic,3322,O
sulfonylurea,3322,B-GENE-N
receptor,3322,I-GENE-N
ligand,3322,O
",",3322,O
exhibits,3322,O
hypoglycemic,3322,O
action,3322,O
unlike,3322,O
other,3322,O
sulfonylureas,3322,B-CHEMICAL
.,3322,O
The,3323,O
efficacy,3323,O
of,3323,O
the,3323,O
combination,3323,O
of,3323,O
mitiglinide,3323,B-CHEMICAL
and,3323,O
alpha-glucosidase,3323,B-GENE-Y
inhibitors,3323,O
for,3323,O
diabetic,3323,O
patients,3323,O
on,3323,O
hemodialysis,3323,O
(,3323,O
HD,3323,O
),3323,O
has,3323,O
not,3323,O
been,3323,O
prospectively,3323,O
evaluated,3323,O
;,3323,O
therefore,3323,O
",",3323,O
we,3323,O
evaluated,3323,O
the,3323,O
efficacy,3323,O
and,3323,O
safety,3323,O
of,3323,O
mitiglinide,3323,B-CHEMICAL
in,3323,O
these,3323,O
patients,3323,O
.,3323,O
RESEARCH,3324,O
DESIGN,3324,O
AND,3324,O
METHODS,3324,O
:,3324,O
We,3324,O
performed,3324,O
an,3324,O
open-label,3324,O
randomized,3324,O
study,3324,O
with,3324,O
36,3324,O
type,3324,O
2,3324,O
diabetics,3324,O
with,3324,O
poor,3324,O
glycemic,3324,O
control,3324,O
on,3324,O
HD,3324,O
and,3324,O
receiving,3324,O
daily,3324,O
doses,3324,O
of,3324,O
voglibose,3324,B-CHEMICAL
(,3324,O
0.9,3324,O
mg,3324,O
),3324,O
.,3324,O
The,3325,O
patients,3325,O
were,3325,O
randomly,3325,O
assigned,3325,O
to,3325,O
two,3325,O
groups,3325,O
:,3325,O
a,3325,O
combination-therapy,3325,O
group,3325,O
(,3325,O
mitiglinide,3325,B-CHEMICAL
group,3325,O
),3325,O
",",3325,O
mitiglinide,3325,B-CHEMICAL
initial,3325,O
dose,3325,O
7.5,3325,O
-,3325,O
15,3325,O
mg,3325,O
titrated,3325,O
to,3325,O
30,3325,O
mg,3325,O
daily,3325,O
and,3325,O
constant,3325,O
daily,3325,O
dose,3325,O
0.9,3325,O
mg,3325,O
of,3325,O
voglibose,3325,B-CHEMICAL
",",3325,O
and,3325,O
a,3325,O
monotherapy,3325,O
group,3325,O
(,3325,O
control,3325,O
group,3325,O
),3325,O
",",3325,O
constant,3325,O
daily,3325,O
dose,3325,O
0.9,3325,O
mg,3325,O
of,3325,O
voglibose,3325,B-CHEMICAL
alone,3325,O
.,3325,O
The,3326,O
efficacy,3326,O
of,3326,O
the,3326,O
treatment,3326,O
was,3326,O
determined,3326,O
by,3326,O
monitoring,3326,O
plasma,3326,O
glucose,3326,B-CHEMICAL
",",3326,O
hemoglobin,3326,B-GENE-Y
A1c,3326,I-GENE-Y
(,3326,O
Hb,3326,B-GENE-Y
(,3326,I-GENE-Y
A1c,3326,I-GENE-Y
),3326,I-GENE-Y
),3326,O
",",3326,O
and,3326,O
glycated,3326,B-GENE-Y
albumin,3326,I-GENE-Y
(,3326,O
GA,3326,B-GENE-Y
),3326,O
levels,3326,O
and,3326,O
using,3326,O
homeostasis,3326,O
model,3326,O
assessment,3326,O
of,3326,O
insulin,3326,B-GENE-Y
resistance,3326,O
(,3326,O
HOMA-IR,3326,O
),3326,O
.,3326,O
Safety,3327,O
and,3327,O
tolerance,3327,O
were,3327,O
determined,3327,O
by,3327,O
monitoring,3327,O
clinical,3327,O
and,3327,O
laboratory,3327,O
parameters,3327,O
.,3327,O
RESULTS,3328,O
:,3328,O
The,3328,O
final,3328,O
dose,3328,O
of,3328,O
mitiglinide,3328,B-CHEMICAL
was,3328,O
22.9,3328,O
+/-,3328,O
8.9,3328,O
(,3328,O
mean,3328,O
+/-,3328,O
s.d,3328,O
.,3328,O
),3328,O
mg,3329,O
(,3329,O
0.41,3329,O
mg/kg,3329,O
),3329,O
daily,3329,O
.,3329,O
Mitiglinide,3330,B-CHEMICAL
reduced,3330,O
fasting,3330,O
plasma,3330,O
glucose,3330,B-CHEMICAL
and,3330,O
GA,3330,B-GENE-Y
levels,3330,O
after,3330,O
4,3330,O
weeks,3330,O
and,3330,O
Hb,3330,B-GENE-Y
(,3330,I-GENE-Y
A1c,3330,I-GENE-Y
),3330,I-GENE-Y
levels,3330,O
after,3330,O
8,3330,O
weeks,3330,O
.,3330,O
Triglyceride,3331,B-CHEMICAL
levels,3331,O
and,3331,O
HOMA-IR,3331,O
values,3331,O
also,3331,O
decreased,3331,O
significantly,3331,O
after,3331,O
mitiglinide,3331,B-CHEMICAL
treatment,3331,O
.,3331,O
No,3332,O
significant,3332,O
changes,3332,O
in,3332,O
blood,3332,O
pressure,3332,O
levels,3332,O
or,3332,O
serious,3332,O
adverse,3332,O
effects,3332,O
such,3332,O
as,3332,O
hypoglycemia,3332,O
or,3332,O
liver,3332,O
impairment,3332,O
were,3332,O
observed,3332,O
.,3332,O
CONCLUSIONS,3333,O
:,3333,O
This,3333,O
study,3333,O
suggests,3333,O
a,3333,O
combination,3333,O
therapy,3333,O
of,3333,O
mitiglinide,3333,B-CHEMICAL
and,3333,O
voglibose,3333,B-CHEMICAL
may,3333,O
have,3333,O
potential,3333,O
for,3333,O
the,3333,O
treatment,3333,O
of,3333,O
diabetics,3333,O
on,3333,O
HD,3333,O
.,3333,O
Due,3334,O
to,3334,O
the,3334,O
small,3334,O
sample,3334,O
size,3334,O
used,3334,O
",",3334,O
further,3334,O
studies,3334,O
should,3334,O
be,3334,O
performed,3334,O
",",3334,O
particularly,3334,O
to,3334,O
assess,3334,O
the,3334,O
safety,3334,O
of,3334,O
mitiglinide,3334,B-CHEMICAL
treatment,3334,O
.,3334,O
A,3335,O
fluorescence,3335,O
resonance,3335,O
energy,3335,O
transfer-based,3335,O
M2,3335,B-GENE-Y
muscarinic,3335,I-GENE-Y
receptor,3335,I-GENE-Y
sensor,3335,O
reveals,3335,O
rapid,3335,O
kinetics,3335,O
of,3335,O
allosteric,3335,O
modulation,3335,O
.,3335,O
Allosteric,3336,O
modulators,3336,O
have,3336,O
been,3336,O
identified,3336,O
for,3336,O
several,3336,O
G,3336,B-GENE-N
protein-coupled,3336,I-GENE-N
receptors,3336,I-GENE-N
",",3336,O
most,3336,O
notably,3336,O
muscarinic,3336,B-GENE-N
receptors,3336,I-GENE-N
.,3336,O
To,3337,O
study,3337,O
their,3337,O
mechanism,3337,O
of,3337,O
action,3337,O
",",3337,O
we,3337,O
made,3337,O
use,3337,O
of,3337,O
a,3337,O
recently,3337,O
developed,3337,O
technique,3337,O
to,3337,O
generate,3337,O
fluorescence,3337,O
resonance,3337,O
energy,3337,O
transfer,3337,O
(,3337,O
FRET,3337,O
),3337,O
-based,3337,O
sensors,3337,O
to,3337,O
monitor,3337,O
G,3337,B-GENE-N
protein-coupled,3337,I-GENE-N
receptor,3337,I-GENE-N
activation,3337,O
.,3337,O
Cyan,3338,O
fluorescent,3338,O
protein,3338,O
was,3338,O
fused,3338,O
to,3338,O
the,3338,O
C,3338,B-CHEMICAL
terminus,3338,O
of,3338,O
the,3338,O
M,3338,B-GENE-Y
(,3338,I-GENE-Y
2,3338,I-GENE-Y
),3338,I-GENE-Y
muscarinic,3338,I-GENE-Y
receptor,3338,I-GENE-Y
",",3338,O
and,3338,O
a,3338,O
specific,3338,O
binding,3338,O
sequence,3338,O
for,3338,O
the,3338,O
small,3338,O
fluorescent,3338,O
compound,3338,O
fluorescein,3338,B-CHEMICAL
arsenical,3338,O
hairpin,3338,O
binder,3338,O
",",3338,O
FlAsH,3338,O
",",3338,O
was,3338,O
inserted,3338,O
into,3338,O
the,3338,O
third,3338,O
intracellular,3338,O
loop,3338,O
;,3338,O
the,3338,O
latter,3338,O
site,3338,O
was,3338,O
labeled,3338,O
in,3338,O
intact,3338,O
cells,3338,O
by,3338,O
incubation,3338,O
with,3338,O
FlAsH,3338,O
.,3338,O
We,3339,O
then,3339,O
measured,3339,O
FRET,3339,O
between,3339,O
the,3339,O
donor,3339,O
cyan,3339,O
fluorescent,3339,O
protein,3339,O
and,3339,O
the,3339,O
acceptor,3339,O
FlAsH,3339,O
in,3339,O
intact,3339,O
cells,3339,O
and,3339,O
monitored,3339,O
its,3339,O
changes,3339,O
in,3339,O
real,3339,O
time,3339,O
.,3339,O
Agonists,3340,O
such,3340,O
as,3340,O
acetylcholine,3340,B-CHEMICAL
and,3340,O
carbachol,3340,B-CHEMICAL
induced,3340,O
rapid,3340,O
changes,3340,O
in,3340,O
FRET,3340,O
",",3340,O
indicative,3340,O
of,3340,O
agonist-induced,3340,O
conformational,3340,O
changes,3340,O
.,3340,O
Removal,3341,O
of,3341,O
the,3341,O
agonists,3341,O
or,3341,O
addition,3341,O
of,3341,O
an,3341,O
antagonist,3341,O
caused,3341,O
a,3341,O
reversal,3341,O
of,3341,O
this,3341,O
signal,3341,O
with,3341,O
rate,3341,O
constants,3341,O
between,3341,O
400,3341,O
and,3341,O
1100,3341,O
ms,3341,O
.,3341,O
The,3342,O
allosteric,3342,O
ligands,3342,O
gallamine,3342,B-CHEMICAL
and,3342,O
dimethyl-W84,3342,B-CHEMICAL
caused,3342,O
no,3342,O
changes,3342,O
in,3342,O
FRET,3342,O
when,3342,O
given,3342,O
alone,3342,O
",",3342,O
but,3342,O
increased,3342,O
FRET,3342,O
when,3342,O
given,3342,O
in,3342,O
the,3342,O
presence,3342,O
of,3342,O
an,3342,O
agonist,3342,O
",",3342,O
compatible,3342,O
with,3342,O
an,3342,O
inactivation,3342,O
of,3342,O
the,3342,O
receptors,3342,O
.,3342,O
The,3343,O
kinetics,3343,O
of,3343,O
these,3343,O
effects,3343,O
were,3343,O
very,3343,O
rapid,3343,O
",",3343,O
with,3343,O
rate,3343,O
constants,3343,O
of,3343,O
80-100,3343,O
ms,3343,O
and,3343,O
approximately,3343,O
200,3343,O
ms,3343,O
for,3343,O
saturating,3343,O
concentrations,3343,O
of,3343,O
gallamine,3343,B-CHEMICAL
and,3343,O
dimethyl-W84,3343,B-CHEMICAL
",",3343,O
respectively,3343,O
.,3343,O
Because,3344,O
these,3344,O
speeds,3344,O
are,3344,O
significantly,3344,O
faster,3344,O
than,3344,O
the,3344,O
responses,3344,O
to,3344,O
antagonists,3344,O
",",3344,O
these,3344,O
data,3344,O
indicate,3344,O
that,3344,O
gallamine,3344,B-CHEMICAL
and,3344,O
dimethyl-W84,3344,B-CHEMICAL
are,3344,O
allosteric,3344,O
ligands,3344,O
and,3344,O
actively,3344,O
induce,3344,O
a,3344,O
conformation,3344,O
of,3344,O
the,3344,O
M,3344,B-GENE-Y
(,3344,I-GENE-Y
2,3344,I-GENE-Y
),3344,I-GENE-Y
receptor,3344,I-GENE-Y
with,3344,O
a,3344,O
reduced,3344,O
affinity,3344,O
for,3344,O
its,3344,O
agonists,3344,O
.,3344,O
A,3345,O
molecular,3345,O
mechanism,3345,O
for,3345,O
ibuprofen-mediated,3345,B-CHEMICAL
RhoA,3345,B-GENE-Y
inhibition,3345,O
in,3345,O
neurons,3345,O
.,3345,O
Ibuprofen,3346,B-CHEMICAL
is,3346,O
a,3346,O
nonsteroidal,3346,O
anti-inflammatory,3346,O
drug,3346,O
widely,3346,O
used,3346,O
to,3346,O
relieve,3346,O
pain,3346,O
and,3346,O
inflammation,3346,O
in,3346,O
many,3346,O
disorders,3346,O
via,3346,O
inhibition,3346,O
of,3346,O
cyclooxygenases,3346,B-GENE-N
.,3346,O
Recently,3347,O
",",3347,O
we,3347,O
have,3347,O
demonstrated,3347,O
that,3347,O
ibuprofen,3347,B-CHEMICAL
inhibits,3347,O
intracellular,3347,O
signaling,3347,O
of,3347,O
RhoA,3347,B-GENE-Y
and,3347,O
promotes,3347,O
significant,3347,O
axonal,3347,O
growth,3347,O
and,3347,O
functional,3347,O
recovery,3347,O
following,3347,O
spinal,3347,O
cord,3347,O
lesions,3347,O
in,3347,O
rodents,3347,O
.,3347,O
In,3348,O
addition,3348,O
",",3348,O
another,3348,O
study,3348,O
suggests,3348,O
that,3348,O
ibuprofen,3348,B-CHEMICAL
reduces,3348,O
generation,3348,O
of,3348,O
amyloid-beta42,3348,B-GENE-Y
peptide,3348,O
via,3348,O
inactivation,3348,O
of,3348,O
RhoA,3348,B-GENE-Y
signaling,3348,O
",",3348,O
although,3348,O
it,3348,O
may,3348,O
also,3348,O
regulate,3348,O
amyloid-beta42,3348,B-GENE-Y
formation,3348,O
by,3348,O
direct,3348,O
inhibition,3348,O
of,3348,O
the,3348,O
gamma-secretase,3348,B-GENE-N
complex,3348,I-GENE-N
.,3348,O
The,3349,O
molecular,3349,O
mechanisms,3349,O
by,3349,O
which,3349,O
ibuprofen,3349,B-CHEMICAL
inhibits,3349,O
the,3349,O
RhoA,3349,B-GENE-Y
signal,3349,O
in,3349,O
neurons,3349,O
",",3349,O
however,3349,O
",",3349,O
remain,3349,O
unclear,3349,O
.,3349,O
Here,3350,O
",",3350,O
we,3350,O
report,3350,O
that,3350,O
the,3350,O
transcription,3350,O
factor,3350,O
peroxisome,3350,B-GENE-Y
proliferator-activated,3350,I-GENE-Y
receptor,3350,I-GENE-Y
gamma,3350,I-GENE-Y
(,3350,O
PPARgamma,3350,B-GENE-Y
),3350,O
is,3350,O
essential,3350,O
for,3350,O
coupling,3350,O
ibuprofen,3350,B-CHEMICAL
to,3350,O
RhoA,3350,B-GENE-Y
inhibition,3350,O
and,3350,O
subsequent,3350,O
neurite,3350,O
growth,3350,O
promotion,3350,O
in,3350,O
neurons,3350,O
.,3350,O
Ibuprofen,3351,B-CHEMICAL
activates,3351,O
PPARgamma,3351,B-GENE-Y
in,3351,O
neuron-like,3351,O
PC12,3351,O
and,3351,O
B104,3351,O
cells,3351,O
.,3351,O
Activation,3352,O
of,3352,O
PPARgamma,3352,B-GENE-Y
with,3352,O
traditional,3352,O
agonists,3352,O
mimics,3352,O
the,3352,O
RhoA-inhibiting,3352,B-GENE-Y
properties,3352,O
of,3352,O
ibuprofen,3352,B-CHEMICAL
in,3352,O
PC12,3352,O
cells,3352,O
and,3352,O
",",3352,O
like,3352,O
ibuprofen,3352,B-CHEMICAL
",",3352,O
promotes,3352,O
neurite,3352,O
elongation,3352,O
in,3352,O
primary,3352,O
cultured,3352,O
neurons,3352,O
exposed,3352,O
to,3352,O
axonal,3352,O
growth,3352,O
inhibitors,3352,O
.,3352,O
Protein,3353,O
knockdown,3353,O
with,3353,O
small,3353,O
interfering,3353,O
RNA,3353,O
specific,3353,O
for,3353,O
PPARgamma,3353,B-GENE-Y
blocks,3353,O
RhoA,3353,B-GENE-Y
suppression,3353,O
of,3353,O
PPARgamma,3353,B-GENE-Y
agonists,3353,O
in,3353,O
PC12,3353,O
cells,3353,O
.,3353,O
Moreover,3354,O
",",3354,O
the,3354,O
effect,3354,O
of,3354,O
ibuprofen,3354,B-CHEMICAL
on,3354,O
RhoA,3354,B-GENE-Y
activity,3354,O
and,3354,O
neurite,3354,O
growth,3354,O
in,3354,O
neuronal,3354,O
cultures,3354,O
is,3354,O
prevented,3354,O
by,3354,O
selective,3354,O
PPARgamma,3354,B-GENE-Y
inhibition,3354,O
.,3354,O
These,3355,O
findings,3355,O
support,3355,O
that,3355,O
PPARgamma,3355,B-GENE-Y
plays,3355,O
an,3355,O
essential,3355,O
role,3355,O
in,3355,O
mediating,3355,O
the,3355,O
RhoA-inhibiting,3355,B-GENE-Y
effect,3355,O
of,3355,O
ibuprofen,3355,B-CHEMICAL
.,3355,O
Elucidation,3356,O
of,3356,O
the,3356,O
novel,3356,O
molecular,3356,O
mechanisms,3356,O
linking,3356,O
ibuprofen,3356,B-CHEMICAL
to,3356,O
RhoA,3356,B-GENE-Y
inhibition,3356,O
may,3356,O
provide,3356,O
additional,3356,O
therapeutic,3356,O
targets,3356,O
to,3356,O
the,3356,O
disorders,3356,O
characterized,3356,O
by,3356,O
RhoA,3356,B-GENE-Y
activation,3356,O
",",3356,O
including,3356,O
spinal,3356,O
cord,3356,O
injuries,3356,O
and,3356,O
Alzheimer,3356,O
's,3356,O
disease,3356,O
.,3356,O
Comparative,3357,O
efficacy,3357,O
and,3357,O
safety,3357,O
of,3357,O
the,3357,O
novel,3357,O
oral,3357,O
anticoagulants,3357,O
dabigatran,3357,B-CHEMICAL
",",3357,O
rivaroxaban,3357,B-CHEMICAL
and,3357,O
apixaban,3357,B-CHEMICAL
in,3357,O
preclinical,3357,O
and,3357,O
clinical,3357,O
development,3357,O
.,3357,O
Therapeutic,3358,O
oral,3358,O
anticoagulation,3358,O
is,3358,O
still,3358,O
commonly,3358,O
achieved,3358,O
by,3358,O
administration,3358,O
of,3358,O
warfarin,3358,B-CHEMICAL
or,3358,O
other,3358,O
vitamin,3358,B-CHEMICAL
K,3358,I-CHEMICAL
antagonists,3358,O
that,3358,O
are,3358,O
associated,3358,O
with,3358,O
an,3358,O
untoward,3358,O
pharmacokinetic,3358,O
/,3358,O
pharmacodynamic,3358,O
(,3358,O
PK/PD,3358,O
),3358,O
profile,3358,O
leading,3358,O
to,3358,O
a,3358,O
high,3358,O
incidence,3358,O
of,3358,O
bleeding,3358,O
complications,3358,O
or,3358,O
therapeutic,3358,O
failure,3358,O
.,3358,O
Hence,3359,O
",",3359,O
there,3359,O
is,3359,O
an,3359,O
unmet,3359,O
medical,3359,O
need,3359,O
of,3359,O
novel,3359,O
easy-to-use,3359,O
oral,3359,O
anticoagulants,3359,O
with,3359,O
improved,3359,O
efficacy,3359,O
and,3359,O
safety,3359,O
.,3359,O
Recent,3360,O
developments,3360,O
include,3360,O
the,3360,O
identification,3360,O
of,3360,O
non-peptidic,3360,O
small-molecules,3360,O
that,3360,O
selectively,3360,O
inhibit,3360,O
certain,3360,O
serine,3360,B-CHEMICAL
proteases,3360,I-GENE-N
within,3360,O
the,3360,O
coagulation,3360,O
cascade,3360,O
.,3360,O
Of,3361,O
these,3361,O
",",3361,O
the,3361,O
thrombin,3361,B-GENE-Y
inhibitor,3361,O
dabigatran,3361,B-CHEMICAL
and,3361,O
factor,3361,B-GENE-Y
Xa,3361,I-GENE-Y
inhibitor,3361,O
rivaroxaban,3361,B-CHEMICAL
have,3361,O
recently,3361,O
been,3361,O
licensed,3361,O
for,3361,O
thromboprophylaxis,3361,O
after,3361,O
orthopaedic,3361,O
surgery,3361,O
mainly,3361,O
in,3361,O
Europe,3361,O
.,3361,O
In,3362,O
addition,3362,O
",",3362,O
the,3362,O
factor,3362,B-GENE-Y
Xa,3362,I-GENE-Y
inhibitor,3362,O
apixaban,3362,B-CHEMICAL
is,3362,O
in,3362,O
late-stage,3362,O
clinical,3362,O
development,3362,O
.,3362,O
Each,3363,O
drug,3363,O
is,3363,O
prescribed,3363,O
at,3363,O
fixed,3363,O
doses,3363,O
without,3363,O
the,3363,O
need,3363,O
of,3363,O
anticoagulant,3363,O
monitoring,3363,O
.,3363,O
Phase,3364,O
III,3364,O
trials,3364,O
in,3364,O
orthopaedic,3364,O
patients,3364,O
essentially,3364,O
resulted,3364,O
in,3364,O
non-inferior,3364,O
efficacy,3364,O
of,3364,O
dabigatran,3364,B-CHEMICAL
and,3364,O
superior,3364,O
efficacy,3364,O
of,3364,O
rivaroxaban,3364,B-CHEMICAL
over,3364,O
enoxaparin,3364,O
without,3364,O
any,3364,O
marked,3364,O
differences,3364,O
of,3364,O
drug,3364,O
safety,3364,O
",",3364,O
while,3364,O
apixaban,3364,B-CHEMICAL
data,3364,O
is,3364,O
still,3364,O
controversial,3364,O
.,3364,O
However,3365,O
",",3365,O
alterations,3365,O
of,3365,O
rivaroxaban,3365,B-CHEMICAL
and,3365,O
apixaban,3365,B-CHEMICAL
pharmacokinetics,3365,O
upon,3365,O
interactions,3365,O
with,3365,O
inhibitors,3365,O
and,3365,O
inducers,3365,O
of,3365,O
CYP3A4,3365,B-GENE-Y
or,3365,O
P-glycoprotein,3365,B-GENE-N
may,3365,O
complicate,3365,O
the,3365,O
use,3365,O
of,3365,O
these,3365,O
compounds,3365,O
in,3365,O
daily,3365,O
practice,3365,O
",",3365,O
whereas,3365,O
dabigatran,3365,B-CHEMICAL
elimination,3365,O
largely,3365,O
depends,3365,O
on,3365,O
renal,3365,O
function,3365,O
.,3365,O
Hence,3366,O
",",3366,O
this,3366,O
review,3366,O
reports,3366,O
PK/PD,3366,O
",",3366,O
efficacy,3366,O
and,3366,O
safety,3366,O
data,3366,O
of,3366,O
dabigatran,3366,B-CHEMICAL
",",3366,O
rivaroxaban,3366,B-CHEMICAL
and,3366,O
apixaban,3366,B-CHEMICAL
throughout,3366,O
preclinical,3366,O
and,3366,O
clinical,3366,O
development,3366,O
.,3366,O
Captopril,3367,B-CHEMICAL
directly,3367,O
inhibits,3367,O
matrix,3367,B-GENE-Y
metalloproteinase-2,3367,I-GENE-Y
activity,3367,O
in,3367,O
continuous,3367,O
ambulatory,3367,O
peritoneal,3367,O
dialysis,3367,O
therapy,3367,O
.,3367,O
BACKGROUND,3368,O
:,3368,O
Matrix,3368,B-GENE-Y
metalloproteinase,3368,I-GENE-Y
(,3368,I-GENE-Y
MMP,3368,I-GENE-Y
),3368,I-GENE-Y
-2,3368,I-GENE-Y
plays,3368,O
an,3368,O
important,3368,O
role,3368,O
in,3368,O
tissue,3368,O
remodeling,3368,O
related,3368,O
to,3368,O
inflammation,3368,O
during,3368,O
continuous,3368,O
ambulatory,3368,O
peritoneal,3368,O
dialysis,3368,O
(,3368,O
CAPD,3368,O
),3368,O
therapy,3368,O
.,3368,O
But,3369,O
its,3369,O
inhibitors,3369,O
were,3369,O
not,3369,O
applied,3369,O
clinically,3369,O
.,3369,O
We,3370,O
determined,3370,O
whether,3370,O
an,3370,O
angiotensin-converting,3370,B-CHEMICAL
enzyme,3370,I-GENE-Y
(,3370,O
ACE,3370,B-GENE-Y
),3370,O
inhibitor,3370,O
",",3370,O
captopril,3370,B-CHEMICAL
",",3370,O
inhibits,3370,O
MMP-2,3370,B-GENE-Y
activity,3370,O
in,3370,O
peritoneal,3370,O
effluents,3370,O
from,3370,O
patients,3370,O
on,3370,O
CAPD,3370,O
",",3370,O
and,3370,O
simulated,3370,O
molecular,3370,O
models,3370,O
of,3370,O
the,3370,O
MMP-2-captopril,3370,B-GENE-Y
complex,3370,O
.,3370,O
METHODS,3371,O
:,3371,O
The,3371,O
inhibitory,3371,O
effect,3371,O
of,3371,O
captopril,3371,B-CHEMICAL
on,3371,O
MMP-2,3371,B-GENE-Y
activity,3371,O
was,3371,O
measured,3371,O
in,3371,O
peritoneal,3371,O
effluents,3371,O
from,3371,O
17,3371,O
patients,3371,O
on,3371,O
CAPD,3371,O
.,3371,O
Molecular,3372,O
models,3372,O
of,3372,O
the,3372,O
MMP-2-captopril,3372,B-GENE-Y
complex,3372,O
were,3372,O
simulated,3372,O
by,3372,O
1000,3372,O
iterations,3372,O
of,3372,O
random,3372,O
docking,3372,O
and,3372,O
energy,3372,O
minimization,3372,O
.,3372,O
RESULTS,3373,O
:,3373,O
Captopril,3373,B-CHEMICAL
directly,3373,O
inhibited,3373,O
MMP-2,3373,B-GENE-Y
activity,3373,O
in,3373,O
peritoneal,3373,O
effluents,3373,O
from,3373,O
patients,3373,O
on,3373,O
CAPD,3373,O
(,3373,O
IC50,3373,O
;,3373,O
48,3373,O
micromol/l,3373,O
),3373,O
",",3373,O
and,3373,O
that,3373,O
captopril,3373,B-CHEMICAL
binding,3373,O
to,3373,O
the,3373,O
MMP-2,3373,B-GENE-Y
active,3373,O
site,3373,O
could,3373,O
be,3373,O
formed,3373,O
in,3373,O
each,3373,O
complex,3373,O
model,3373,O
without,3373,O
molecular,3373,O
distortion,3373,O
.,3373,O
CONCLUSION,3374,O
:,3374,O
ACE,3374,B-GENE-Y
inhibitors,3374,O
",",3374,O
such,3374,O
as,3374,O
captopril,3374,B-CHEMICAL
",",3374,O
may,3374,O
be,3374,O
applied,3374,O
as,3374,O
important,3374,O
compounds,3374,O
for,3374,O
MMP-2,3374,B-GENE-Y
inhibition,3374,O
in,3374,O
inflammation,3374,O
caused,3374,O
by,3374,O
CAPD,3374,O
.,3374,O
Phenformin,3375,B-CHEMICAL
has,3375,O
a,3375,O
direct,3375,O
inhibitory,3375,O
effect,3375,O
on,3375,O
the,3375,O
ATP-sensitive,3375,B-GENE-N
potassium,3375,I-GENE-N
channel,3375,I-GENE-N
.,3375,O
The,3376,O
biguanides,3376,B-CHEMICAL
",",3376,O
phenformin,3376,B-CHEMICAL
and,3376,O
metformin,3376,B-CHEMICAL
",",3376,O
are,3376,O
used,3376,O
in,3376,O
the,3376,O
treatment,3376,O
of,3376,O
type,3376,O
II,3376,O
diabetes,3376,O
mellitus,3376,O
",",3376,O
as,3376,O
well,3376,O
as,3376,O
being,3376,O
routinely,3376,O
used,3376,O
in,3376,O
studies,3376,O
investigating,3376,O
AMPK,3376,B-GENE-N
activity,3376,O
.,3376,O
We,3377,O
used,3377,O
the,3377,O
patch-clamp,3377,O
technique,3377,O
and,3377,O
rubidium,3377,B-CHEMICAL
flux,3377,O
assays,3377,O
to,3377,O
determine,3377,O
the,3377,O
role,3377,O
of,3377,O
these,3377,O
drugs,3377,O
in,3377,O
ATP-sensitive,3377,B-GENE-N
K+,3377,I-GENE-N
channel,3377,I-GENE-N
(,3377,O
K,3377,B-GENE-N
(,3377,I-GENE-N
ATP,3377,I-GENE-N
),3377,I-GENE-N
),3377,O
regulation,3377,O
in,3377,O
cell,3377,O
lines,3377,O
expressing,3377,O
the,3377,O
cloned,3377,O
components,3377,O
of,3377,O
K,3377,B-GENE-N
(,3377,I-GENE-N
ATP,3377,I-GENE-N
),3377,I-GENE-N
and,3377,O
the,3377,O
current,3377,O
natively,3377,O
expressed,3377,O
in,3377,O
vascular,3377,O
smooth,3377,O
muscle,3377,O
cells,3377,O
(,3377,O
VSMCs,3377,O
),3377,O
.,3377,O
Phenformin,3378,B-CHEMICAL
but,3378,O
not,3378,O
metformin,3378,B-CHEMICAL
inhibits,3378,O
a,3378,O
number,3378,O
of,3378,O
variants,3378,O
of,3378,O
K,3378,B-GENE-N
(,3378,I-GENE-N
ATP,3378,I-GENE-N
),3378,I-GENE-N
including,3378,O
the,3378,O
cloned,3378,O
equivalents,3378,O
of,3378,O
currents,3378,O
present,3378,O
in,3378,O
vascular,3378,O
and,3378,O
non-vascular,3378,O
smooth,3378,O
muscle,3378,O
(,3378,O
Kir6.1/SUR2B,3378,B-GENE-Y
and,3378,O
Kir6.2/SUR2B,3378,B-GENE-Y
),3378,O
and,3378,O
pancreatic,3378,O
beta-cells,3378,O
(,3378,O
Kir6.2/SUR1,3378,B-GENE-Y
),3378,O
.,3378,O
However,3379,O
it,3379,O
does,3379,O
not,3379,O
inhibit,3379,O
the,3379,O
current,3379,O
potentially,3379,O
present,3379,O
in,3379,O
cardiac,3379,O
myocytes,3379,O
(,3379,O
Kir6.2/SUR2A,3379,B-GENE-Y
),3379,O
.,3379,O
The,3380,O
highest,3380,O
affinity,3380,O
interaction,3380,O
is,3380,O
seen,3380,O
with,3380,O
Kir6.1/SUR2B,3380,B-GENE-Y
(,3380,O
IC50=0.55,3380,O
mM,3380,O
),3380,O
and,3380,O
it,3380,O
also,3380,O
inhibits,3380,O
the,3380,O
current,3380,O
in,3380,O
native,3380,O
vascular,3380,O
smooth,3380,O
muscle,3380,O
cells,3380,O
.,3380,O
The,3381,O
extent,3381,O
and,3381,O
rate,3381,O
of,3381,O
inhibition,3381,O
are,3381,O
similar,3381,O
to,3381,O
that,3381,O
seen,3381,O
with,3381,O
the,3381,O
known,3381,O
K,3381,B-GENE-N
(,3381,I-GENE-N
ATP,3381,B-CHEMICAL
),3381,I-GENE-N
blocker,3381,O
PNU,3381,B-CHEMICAL
37883A,3381,I-CHEMICAL
.,3381,O
Additionally,3382,O
",",3382,O
phenformin,3382,B-CHEMICAL
inhibited,3382,O
the,3382,O
current,3382,O
elicited,3382,O
through,3382,O
the,3382,O
Kir6.2DeltaC26,3382,B-GENE-Y
(,3382,O
functional,3382,O
without,3382,O
SUR,3382,B-GENE-Y
),3382,O
channel,3382,O
with,3382,O
an,3382,O
IC50,3382,O
of,3382,O
1.78,3382,O
mM,3382,O
.,3382,O
Phenformin,3383,B-CHEMICAL
reduced,3383,O
the,3383,O
open,3383,O
probability,3383,O
of,3383,O
Kir6.1/SUR2B,3383,B-GENE-Y
channels,3383,O
by,3383,O
approximately,3383,O
90,3383,O
%,3383,O
in,3383,O
inside-out,3383,O
patches,3383,O
.,3383,O
These,3384,O
findings,3384,O
suggest,3384,O
that,3384,O
phenformin,3384,B-CHEMICAL
interacts,3384,O
directly,3384,O
with,3384,O
the,3384,O
pore-forming,3384,O
Kir6.0,3384,B-GENE-N
subunit,3384,O
however,3384,O
the,3384,O
sulphonylurea,3384,B-CHEMICAL
receptor,3384,I-GENE-Y
is,3384,O
able,3384,O
to,3384,O
significantly,3384,O
modulate,3384,O
the,3384,O
affinity,3384,O
.,3384,O
It,3385,O
is,3385,O
likely,3385,O
to,3385,O
block,3385,O
from,3385,O
the,3385,O
intracellular,3385,O
side,3385,O
of,3385,O
the,3385,O
channel,3385,O
in,3385,O
a,3385,O
manner,3385,O
analogous,3385,O
to,3385,O
that,3385,O
of,3385,O
PNU,3385,B-CHEMICAL
37883A,3385,I-CHEMICAL
.,3385,O
Comparison,3386,O
of,3386,O
the,3386,O
pharmacological,3386,O
effects,3386,O
of,3386,O
paricalcitol,3386,B-CHEMICAL
and,3386,O
doxercalciferol,3386,B-CHEMICAL
on,3386,O
the,3386,O
factors,3386,O
involved,3386,O
in,3386,O
mineral,3386,O
homeostasis,3386,O
.,3386,O
Vitamin,3387,B-GENE-Y
D,3387,I-GENE-Y
receptor,3387,I-GENE-Y
agonists,3387,O
(,3387,O
VDRAs,3387,O
),3387,O
directly,3387,O
suppress,3387,O
parathyroid,3387,B-GENE-Y
hormone,3387,I-GENE-Y
(,3387,O
PTH,3387,B-GENE-Y
),3387,O
mRNA,3387,O
expression,3387,O
.,3387,O
Different,3388,O
VDRAs,3388,O
are,3388,O
known,3388,O
to,3388,O
have,3388,O
differential,3388,O
effects,3388,O
on,3388,O
serum,3388,O
calcium,3388,B-CHEMICAL
(,3388,O
Ca,3388,B-CHEMICAL
),3388,O
",",3388,O
which,3388,O
may,3388,O
also,3388,O
affect,3388,O
serum,3388,O
PTH,3388,B-GENE-Y
levels,3388,O
since,3388,O
serum,3388,O
Ca,3388,B-CHEMICAL
regulates,3388,O
PTH,3388,B-GENE-Y
secretion,3388,O
mediated,3388,O
by,3388,O
the,3388,O
Ca-sensing,3388,B-CHEMICAL
receptor,3388,I-GENE-Y
(,3388,O
CaSR,3388,B-GENE-Y
),3388,O
.,3388,O
In,3389,O
this,3389,O
study,3389,O
",",3389,O
we,3389,O
compared,3389,O
the,3389,O
effects,3389,O
of,3389,O
paricalcitol,3389,B-CHEMICAL
and,3389,O
doxercalciferol,3389,B-CHEMICAL
on,3389,O
regulating,3389,O
serum,3389,O
Ca,3389,B-CHEMICAL
and,3389,O
PTH,3389,B-GENE-Y
",",3389,O
and,3389,O
also,3389,O
the,3389,O
expression,3389,O
of,3389,O
PTH,3389,B-GENE-Y
",",3389,O
VDR,3389,B-GENE-Y
",",3389,O
and,3389,O
CaSR,3389,B-GENE-Y
mRNA,3389,O
.,3389,O
The,3390,O
5/6,3390,O
nephrectomized,3390,O
(,3390,O
NX,3390,O
),3390,O
Sprague-Dawley,3390,O
rats,3390,O
on,3390,O
a,3390,O
normal,3390,O
or,3390,O
hyperphosphatemia-inducing,3390,O
diet,3390,O
were,3390,O
treated,3390,O
with,3390,O
vehicle,3390,O
",",3390,O
paricalcitol,3390,B-CHEMICAL
",",3390,O
or,3390,O
doxercalciferol,3390,B-CHEMICAL
for,3390,O
two,3390,O
weeks,3390,O
.,3390,O
Both,3391,O
drugs,3391,O
at,3391,O
the,3391,O
tested,3391,O
doses,3391,O
(,3391,O
0.042-0.33,3391,O
mug/kg,3391,O
),3391,O
suppressed,3391,O
PTH,3391,B-GENE-Y
mRNA,3391,O
expression,3391,O
and,3391,O
serum,3391,O
PTH,3391,B-GENE-Y
effectively,3391,O
in,3391,O
the,3391,O
5/6,3391,O
NX,3391,O
rats,3391,O
",",3391,O
but,3391,O
paricalcitol,3391,B-CHEMICAL
was,3391,O
less,3391,O
potent,3391,O
in,3391,O
raising,3391,O
serum,3391,O
Ca,3391,B-CHEMICAL
than,3391,O
doxercalciferol,3391,B-CHEMICAL
.,3391,O
In,3392,O
pig,3392,O
parathyroid,3392,O
cells,3392,O
",",3392,O
paricalcitol,3392,B-CHEMICAL
and,3392,O
the,3392,O
active,3392,O
form,3392,O
of,3392,O
doxercalciferol,3392,B-CHEMICAL
induced,3392,O
VDR,3392,B-GENE-Y
translocation,3392,O
from,3392,O
the,3392,O
cytoplasm,3392,O
into,3392,O
the,3392,O
nucleus,3392,O
",",3392,O
suppressed,3392,O
PTH,3392,B-GENE-Y
mRNA,3392,O
expression,3392,O
and,3392,O
inhibited,3392,O
cell,3392,O
proliferation,3392,O
in,3392,O
a,3392,O
similar,3392,O
manner,3392,O
",",3392,O
although,3392,O
paricalcitol,3392,B-CHEMICAL
induced,3392,O
the,3392,O
expression,3392,O
of,3392,O
CaSR,3392,B-GENE-Y
mRNA,3392,O
more,3392,O
effectively,3392,O
.,3392,O
The,3393,O
multiple,3393,O
effects,3393,O
of,3393,O
VDRAs,3393,O
on,3393,O
modulating,3393,O
serum,3393,O
Ca,3393,B-CHEMICAL
",",3393,O
parathyroid,3393,O
cell,3393,O
proliferation,3393,O
",",3393,O
and,3393,O
the,3393,O
expression,3393,O
of,3393,O
CaSR,3393,B-GENE-N
and,3393,O
PTH,3393,B-GENE-N
mRNA,3393,O
reflect,3393,O
the,3393,O
complex,3393,O
involvement,3393,O
of,3393,O
the,3393,O
vitamin,3393,B-CHEMICAL
D,3393,I-CHEMICAL
axis,3393,O
in,3393,O
regulating,3393,O
the,3393,O
mineral,3393,O
homeostasis,3393,O
system,3393,O
.,3393,O
Identification,3394,O
of,3394,O
a,3394,O
primary,3394,O
target,3394,O
of,3394,O
thalidomide,3394,B-CHEMICAL
teratogenicity,3394,O
.,3394,O
Half,3395,O
a,3395,O
century,3395,O
ago,3395,O
",",3395,O
thalidomide,3395,B-CHEMICAL
was,3395,O
widely,3395,O
prescribed,3395,O
to,3395,O
pregnant,3395,O
women,3395,O
as,3395,O
a,3395,O
sedative,3395,O
but,3395,O
was,3395,O
found,3395,O
to,3395,O
be,3395,O
teratogenic,3395,O
",",3395,O
causing,3395,O
multiple,3395,O
birth,3395,O
defects,3395,O
.,3395,O
Today,3396,O
",",3396,O
thalidomide,3396,B-CHEMICAL
is,3396,O
still,3396,O
used,3396,O
in,3396,O
the,3396,O
treatment,3396,O
of,3396,O
leprosy,3396,O
and,3396,O
multiple,3396,O
myeloma,3396,O
",",3396,O
although,3396,O
how,3396,O
it,3396,O
causes,3396,O
limb,3396,O
malformation,3396,O
and,3396,O
other,3396,O
developmental,3396,O
defects,3396,O
is,3396,O
unknown,3396,O
.,3396,O
Here,3397,O
",",3397,O
we,3397,O
identified,3397,O
cereblon,3397,B-GENE-N
(,3397,O
CRBN,3397,B-GENE-N
),3397,O
as,3397,O
a,3397,O
thalidomide-binding,3397,B-CHEMICAL
protein,3397,I-GENE-N
.,3397,O
CRBN,3398,B-GENE-N
forms,3398,O
an,3398,O
E3,3398,B-GENE-N
ubiquitin,3398,I-GENE-N
ligase,3398,I-GENE-N
complex,3398,I-GENE-N
with,3398,O
damaged,3398,B-GENE-N
DNA,3398,I-GENE-N
binding,3398,I-GENE-N
protein,3398,I-GENE-N
1,3398,I-GENE-N
(,3398,O
DDB1,3398,B-GENE-N
),3398,O
and,3398,O
Cul4A,3398,B-GENE-N
that,3398,O
is,3398,O
important,3398,O
for,3398,O
limb,3398,O
outgrowth,3398,O
and,3398,O
expression,3398,O
of,3398,O
the,3398,O
fibroblast,3398,B-GENE-N
growth,3398,I-GENE-N
factor,3398,I-GENE-N
Fgf8,3398,B-GENE-N
in,3398,O
zebrafish,3398,O
and,3398,O
chicks,3398,O
.,3398,O
Thalidomide,3399,B-CHEMICAL
initiates,3399,O
its,3399,O
teratogenic,3399,O
effects,3399,O
by,3399,O
binding,3399,O
to,3399,O
CRBN,3399,B-GENE-N
and,3399,O
inhibiting,3399,O
the,3399,O
associated,3399,O
ubiquitin,3399,B-GENE-N
ligase,3399,I-GENE-N
activity,3399,O
.,3399,O
This,3400,O
study,3400,O
reveals,3400,O
a,3400,O
basis,3400,O
for,3400,O
thalidomide,3400,B-CHEMICAL
teratogenicity,3400,O
and,3400,O
may,3400,O
contribute,3400,O
to,3400,O
the,3400,O
development,3400,O
of,3400,O
new,3400,O
thalidomide,3400,B-CHEMICAL
derivatives,3400,O
without,3400,O
teratogenic,3400,O
activity,3400,O
.,3400,O
A,3401,O
dilated,3401,O
cardiomyopathy,3401,O
troponin,3401,B-GENE-Y
C,3401,I-GENE-Y
mutation,3401,O
lowers,3401,O
contractile,3401,O
force,3401,O
by,3401,O
reducing,3401,O
strong,3401,O
myosin-actin,3401,B-GENE-N
binding,3401,O
.,3401,O
In,3402,O
this,3402,O
study,3402,O
we,3402,O
explore,3402,O
the,3402,O
mechanisms,3402,O
by,3402,O
which,3402,O
a,3402,O
double,3402,O
mutation,3402,O
(,3402,O
E59D/D75Y,3402,B-GENE-N
),3402,O
in,3402,O
cardiac,3402,B-GENE-Y
troponin,3402,I-GENE-Y
C,3402,I-GENE-Y
(,3402,O
CTnC,3402,B-GENE-Y
),3402,O
associated,3402,O
with,3402,O
dilated,3402,O
cardiomyopathy,3402,O
reduces,3402,O
the,3402,O
Ca,3402,B-CHEMICAL
(,3402,I-CHEMICAL
2+,3402,I-CHEMICAL
),3402,I-CHEMICAL
-activated,3402,O
maximal,3402,O
tension,3402,O
of,3402,O
cardiac,3402,O
muscle,3402,O
.,3402,O
Studying,3403,O
the,3403,O
single,3403,O
mutants,3403,O
(,3403,O
i.e,3403,O
.,3403,O
E59D,3404,B-GENE-N
or,3404,O
D75Y,3404,B-GENE-N
),3404,O
indicates,3404,O
that,3404,O
D75Y,3404,B-GENE-N
",",3404,O
but,3404,O
not,3404,O
E59D,3404,B-GENE-N
",",3404,O
causes,3404,O
a,3404,O
reduction,3404,O
in,3404,O
the,3404,O
calcium,3404,O
affinity,3404,O
of,3404,O
CTnC,3404,B-GENE-Y
in,3404,O
troponin,3404,B-GENE-N
complex,3404,O
",",3404,O
regulated,3404,B-GENE-N
thin,3404,I-GENE-N
filaments,3404,I-GENE-N
(,3404,O
RTF,3404,B-GENE-N
),3404,O
",",3404,O
and,3404,O
the,3404,O
Ca,3404,B-CHEMICAL
(,3404,I-CHEMICAL
2+,3404,I-CHEMICAL
),3404,I-CHEMICAL
sensitivity,3404,O
of,3404,O
contraction,3404,O
and,3404,O
ATPase,3404,B-GENE-N
in,3404,O
cardiac,3404,O
muscle,3404,O
preparations,3404,O
.,3404,O
However,3405,O
",",3405,O
both,3405,O
D75Y,3405,B-GENE-N
and,3405,O
E59D,3405,B-GENE-N
are,3405,O
required,3405,O
to,3405,O
reduce,3405,O
the,3405,O
actomyosin,3405,B-GENE-N
ATPase,3405,B-GENE-N
activity,3405,O
and,3405,O
maximal,3405,O
force,3405,O
in,3405,O
muscle,3405,O
fibers,3405,O
",",3405,O
indicating,3405,O
that,3405,O
E59D,3405,B-GENE-N
enhances,3405,O
the,3405,O
effects,3405,O
of,3405,O
D75Y,3405,B-GENE-N
.,3405,O
Part,3406,O
of,3406,O
the,3406,O
reduction,3406,O
in,3406,O
force/ATPase,3406,O
may,3406,O
be,3406,O
due,3406,O
to,3406,O
a,3406,O
defect,3406,O
in,3406,O
the,3406,O
interactions,3406,O
between,3406,O
CTnC,3406,B-GENE-Y
and,3406,O
cardiac,3406,B-GENE-Y
troponin,3406,I-GENE-Y
T,3406,I-GENE-Y
",",3406,O
which,3406,O
are,3406,O
known,3406,O
to,3406,O
be,3406,O
necessary,3406,O
for,3406,O
ATPase,3406,B-GENE-N
activation,3406,O
.,3406,O
An,3407,O
additional,3407,O
mechanism,3407,O
for,3407,O
the,3407,O
reduction,3407,O
in,3407,O
force/ATPase,3407,O
comes,3407,O
from,3407,O
measurements,3407,O
of,3407,O
the,3407,O
binding,3407,O
stoichiometry,3407,O
of,3407,O
myosin,3407,B-GENE-N
subfragment-1,3407,I-GENE-N
(,3407,O
S-1,3407,B-GENE-N
),3407,O
to,3407,O
the,3407,O
RTF,3407,B-GENE-N
.,3407,O
Using,3408,O
wild,3408,O
type,3408,O
RTFs,3408,B-GENE-N
",",3408,O
4.8,3408,O
mol,3408,O
S-1,3408,B-GENE-N
was,3408,O
bound,3408,O
per,3408,O
mol,3408,O
filament,3408,O
(,3408,O
seven,3408,O
actins,3408,O
),3408,O
",",3408,O
whereas,3408,O
with,3408,O
E59D/D75Y,3408,B-GENE-N
RTFs,3408,B-GENE-N
",",3408,O
the,3408,O
number,3408,O
of,3408,O
binding,3408,O
sites,3408,O
was,3408,O
reduced,3408,O
by,3408,O
approximately,3408,O
23,3408,O
%,3408,O
to,3408,O
3.7,3408,O
.,3408,O
Altogether,3409,O
",",3409,O
these,3409,O
results,3409,O
suggest,3409,O
that,3409,O
the,3409,O
reduction,3409,O
in,3409,O
force,3409,O
and,3409,O
ATPase,3409,B-GENE-N
activation,3409,O
is,3409,O
possibly,3409,O
due,3409,O
to,3409,O
a,3409,O
thin,3409,O
filament,3409,O
conformation,3409,O
that,3409,O
promotes,3409,O
fewer,3409,O
accessible,3409,O
S-1-binding,3409,B-GENE-N
sites,3409,I-GENE-N
.,3409,O
In,3410,O
the,3410,O
absence,3410,O
of,3410,O
any,3410,O
family,3410,O
segregation,3410,O
data,3410,O
",",3410,O
the,3410,O
functional,3410,O
results,3410,O
presented,3410,O
here,3410,O
support,3410,O
the,3410,O
concept,3410,O
that,3410,O
this,3410,O
is,3410,O
likely,3410,O
a,3410,O
dilated,3410,O
cardiomyopathy-causing,3410,O
mutation,3410,O
.,3410,O
Zolmitriptan,3411,B-CHEMICAL
and,3411,O
human,3411,O
aggression,3411,O
:,3411,O
interaction,3411,O
with,3411,O
alcohol,3411,B-CHEMICAL
.,3411,O
RATIONALE,3412,O
:,3412,O
The,3412,O
serotonin,3412,B-CHEMICAL
1,3412,I-GENE-N
(,3412,I-GENE-N
B/D,3412,I-GENE-N
),3412,I-GENE-N
(,3412,O
5-HT1,3412,B-GENE-N
(,3412,I-GENE-N
B/D,3412,I-GENE-N
),3412,I-GENE-N
),3412,O
receptor,3412,O
has,3412,O
shown,3412,O
potential,3412,O
as,3412,O
a,3412,O
target,3412,O
for,3412,O
decreasing,3412,O
aggression,3412,O
.,3412,O
The,3413,O
5-HT1,3413,B-GENE-N
(,3413,I-GENE-N
B/D,3413,I-GENE-N
),3413,I-GENE-N
agonist,3413,O
zolmitriptan,3413,O
's,3413,O
ability,3413,O
to,3413,O
reduce,3413,O
aggressive,3413,O
behavior,3413,O
in,3413,O
humans,3413,O
and,3413,O
its,3413,O
interaction,3413,O
with,3413,O
the,3413,O
well-known,3413,O
aggression-enhancing,3413,O
drug,3413,O
alcohol,3413,B-CHEMICAL
were,3413,O
examined,3413,O
.,3413,O
OBJECTIVES,3414,O
:,3414,O
Our,3414,O
objective,3414,O
was,3414,O
to,3414,O
investigate,3414,O
zolmitriptan,3414,O
's,3414,O
potential,3414,O
to,3414,O
modify,3414,O
human,3414,O
aggression,3414,O
in,3414,O
a,3414,O
laboratory,3414,O
paradigm,3414,O
across,3414,O
a,3414,O
range,3414,O
of,3414,O
alcohol,3414,B-CHEMICAL
doses,3414,O
.,3414,O
Alcohol,3415,B-CHEMICAL
has,3415,O
been,3415,O
consistently,3415,O
associated,3415,O
with,3415,O
aggression,3415,O
and,3415,O
violence,3415,O
",",3415,O
thus,3415,O
we,3415,O
hoped,3415,O
to,3415,O
expand,3415,O
current,3415,O
understanding,3415,O
of,3415,O
alcohol,3415,O
's,3415,O
role,3415,O
in,3415,O
aggressive,3415,O
behavior,3415,O
via,3415,O
manipulation,3415,O
of,3415,O
the,3415,O
serotonin,3415,B-CHEMICAL
(,3415,O
5-HT,3415,B-CHEMICAL
),3415,O
system,3415,O
.,3415,O
METHODS,3416,O
:,3416,O
Eleven,3416,O
social,3416,O
drinkers,3416,O
",",3416,O
seven,3416,O
male,3416,O
",",3416,O
were,3416,O
recruited,3416,O
to,3416,O
participate,3416,O
in,3416,O
a,3416,O
research,3416,O
study,3416,O
lasting,3416,O
3-4,3416,O
weeks,3416,O
.,3416,O
Aggression,3417,O
was,3417,O
measured,3417,O
using,3417,O
the,3417,O
point-subtraction,3417,O
aggression,3417,O
paradigm,3417,O
(,3417,O
PSAP,3417,O
),3417,O
",",3417,O
a,3417,O
laboratory,3417,O
model,3417,O
widely,3417,O
used,3417,O
in,3417,O
human,3417,O
aggression,3417,O
studies,3417,O
.,3417,O
Subjects,3418,O
were,3418,O
administered,3418,O
5-mg,3418,O
zolmitriptan,3418,B-CHEMICAL
and,3418,O
placebo,3418,O
capsules,3418,O
along,3418,O
with,3418,O
alcohol,3418,B-CHEMICAL
doses,3418,O
of,3418,O
0.0,3418,O
",",3418,O
0.4,3418,O
and,3418,O
0.8,3418,O
g/kg,3418,O
in,3418,O
a,3418,O
within-subject,3418,O
",",3418,O
counterbalanced,3418,O
dosing,3418,O
design,3418,O
.,3418,O
Data,3419,O
were,3419,O
analyzed,3419,O
as,3419,O
the,3419,O
ratio,3419,O
of,3419,O
aggressive/monetary-earning,3419,O
responses,3419,O
",",3419,O
to,3419,O
account,3419,O
for,3419,O
possible,3419,O
changes,3419,O
in,3419,O
overall,3419,O
motor,3419,O
function,3419,O
due,3419,O
to,3419,O
alcohol,3419,B-CHEMICAL
.,3419,O
RESULTS,3420,O
:,3420,O
There,3420,O
was,3420,O
a,3420,O
significant,3420,O
alcohol,3420,B-CHEMICAL
by,3420,O
zolmitriptan,3420,B-CHEMICAL
interaction,3420,O
on,3420,O
the,3420,O
aggressive/monetary,3420,O
response,3420,O
ratio,3420,O
.,3420,O
Specifically,3421,O
",",3421,O
compared,3421,O
to,3421,O
placebo,3421,O
",",3421,O
zolmitriptan,3421,B-CHEMICAL
decreased,3421,O
the,3421,O
aggressive/monetary,3421,O
ratio,3421,O
at,3421,O
the,3421,O
0.4-,3421,O
and,3421,O
0.8-g/kg,3421,O
alcohol,3421,B-CHEMICAL
doses,3421,O
.,3421,O
CONCLUSIONS,3422,O
:,3422,O
A,3422,O
5-mg,3422,O
dose,3422,O
of,3422,O
zolmitriptan,3422,B-CHEMICAL
effectively,3422,O
reduced,3422,O
alcohol-related,3422,B-CHEMICAL
aggression,3422,O
in,3422,O
an,3422,O
acute,3422,O
dosing,3422,O
protocol,3422,O
",",3422,O
demonstrating,3422,O
an,3422,O
interaction,3422,O
of,3422,O
5-HT,3422,B-CHEMICAL
and,3422,O
alcohol,3422,B-CHEMICAL
in,3422,O
human,3422,O
aggressive,3422,O
behavior,3422,O
.,3422,O
New,3423,O
standards,3423,O
in,3423,O
hypertension,3423,O
and,3423,O
cardiovascular,3423,O
risk,3423,O
management,3423,O
:,3423,O
focus,3423,O
on,3423,O
telmisartan,3423,B-CHEMICAL
.,3423,O
Blockade,3424,O
of,3424,O
the,3424,O
renin-angiotensin,3424,B-GENE-Y
system,3424,O
is,3424,O
an,3424,O
important,3424,O
approach,3424,O
in,3424,O
managing,3424,O
high,3424,O
blood,3424,O
pressure,3424,O
",",3424,O
and,3424,O
has,3424,O
increasingly,3424,O
been,3424,O
shown,3424,O
to,3424,O
affect,3424,O
cardiovascular,3424,O
disease,3424,O
processes,3424,O
mediated,3424,O
by,3424,O
angiotensin,3424,B-CHEMICAL
II,3424,I-CHEMICAL
throughout,3424,O
the,3424,O
cardiovascular,3424,O
and,3424,O
renal,3424,O
continua,3424,O
.,3424,O
Telmisartan,3425,B-CHEMICAL
is,3425,O
an,3425,O
angiotensin,3425,B-CHEMICAL
II,3425,I-CHEMICAL
receptor,3425,I-GENE-N
blocker,3425,O
(,3425,O
ARB,3425,O
),3425,O
displaying,3425,O
unique,3425,O
pharmacologic,3425,O
properties,3425,O
",",3425,O
including,3425,O
a,3425,O
longer,3425,O
half,3425,O
life,3425,O
than,3425,O
any,3425,O
other,3425,O
ARB,3425,O
",",3425,O
that,3425,O
result,3425,O
in,3425,O
large,3425,O
and,3425,O
sustained,3425,O
reductions,3425,O
of,3425,O
blood,3425,O
pressure,3425,O
.,3425,O
In,3426,O
patients,3426,O
with,3426,O
mild-to-moderate,3426,O
hypertension,3426,O
",",3426,O
telmisartan,3426,B-CHEMICAL
has,3426,O
proved,3426,O
superior,3426,O
to,3426,O
other,3426,O
antihypertensive,3426,O
agents,3426,O
(,3426,O
valsartan,3426,B-CHEMICAL
",",3426,O
losartan,3426,B-CHEMICAL
",",3426,O
ramipril,3426,B-CHEMICAL
",",3426,O
perindopril,3426,B-CHEMICAL
",",3426,O
and,3426,O
atenolol,3426,B-CHEMICAL
),3426,O
in,3426,O
controlling,3426,O
blood,3426,O
pressure,3426,O
particularly,3426,O
towards,3426,O
the,3426,O
end,3426,O
of,3426,O
the,3426,O
dosing,3426,O
interval,3426,O
.,3426,O
There,3427,O
is,3427,O
also,3427,O
clinical,3427,O
evidence,3427,O
that,3427,O
telmisartan,3427,B-CHEMICAL
reduces,3427,O
left,3427,O
ventricular,3427,O
hypertrophy,3427,O
",",3427,O
reduces,3427,O
arterial,3427,O
stiffness,3427,O
and,3427,O
the,3427,O
recurrence,3427,O
of,3427,O
atrial,3427,O
fibrillation,3427,O
",",3427,O
and,3427,O
confers,3427,O
renoprotection,3427,O
.,3427,O
The,3428,O
ONgoing,3428,O
Telmisartan,3428,B-CHEMICAL
Alone,3428,O
and,3428,O
in,3428,O
combination,3428,O
with,3428,O
Ramipril,3428,B-CHEMICAL
Global,3428,O
Endpoint,3428,O
Trial,3428,O
(,3428,O
ONTARGET,3428,O
),3428,O
study,3428,O
has,3428,O
demonstrated,3428,O
that,3428,O
telmisartan,3428,B-CHEMICAL
has,3428,O
similar,3428,O
cardiovascular,3428,O
protective,3428,O
effects,3428,O
to,3428,O
ramipril,3428,B-CHEMICAL
in,3428,O
a,3428,O
large,3428,O
",",3428,O
high-risk,3428,O
patient,3428,O
population,3428,O
but,3428,O
was,3428,O
better,3428,O
tolerated,3428,O
.,3428,O
The,3429,O
powerful,3429,O
and,3429,O
sustained,3429,O
blood,3429,O
pressure,3429,O
control,3429,O
apparent,3429,O
in,3429,O
clinical,3429,O
trials,3429,O
",",3429,O
together,3429,O
with,3429,O
cardiovascular,3429,O
protection,3429,O
and,3429,O
tolerability,3429,O
demonstrated,3429,O
in,3429,O
ONTARGET,3429,O
means,3429,O
that,3429,O
telmisartan,3429,B-CHEMICAL
may,3429,O
be,3429,O
a,3429,O
preferred,3429,O
option,3429,O
for,3429,O
patients,3429,O
with,3429,O
hypertension,3429,O
.,3429,O
Jostling,3430,O
for,3430,O
position,3430,O
:,3430,O
optimizing,3430,O
linker,3430,O
location,3430,O
in,3430,O
the,3430,O
design,3430,O
of,3430,O
estrogen,3430,B-GENE-N
receptor-targeting,3430,O
PROTACs,3430,O
.,3430,O
Estrogen,3431,B-CHEMICAL
receptor-alpha,3431,I-GENE-N
(,3431,O
ER,3431,B-GENE-N
),3431,O
antagonists,3431,O
have,3431,O
been,3431,O
widely,3431,O
used,3431,O
for,3431,O
breast,3431,O
cancer,3431,O
therapy,3431,O
.,3431,O
Despite,3432,O
initial,3432,O
responsiveness,3432,O
",",3432,O
hormone-sensitive,3432,O
ER-positive,3432,B-GENE-N
cancer,3432,O
cells,3432,O
eventually,3432,O
develop,3432,O
resistance,3432,O
to,3432,O
ER,3432,B-GENE-N
antagonists,3432,O
.,3432,O
It,3433,O
has,3433,O
been,3433,O
shown,3433,O
that,3433,O
in,3433,O
most,3433,O
of,3433,O
these,3433,O
resistant,3433,O
tumor,3433,O
cells,3433,O
",",3433,O
the,3433,O
ER,3433,B-GENE-N
is,3433,O
expressed,3433,O
and,3433,O
continues,3433,O
to,3433,O
regulate,3433,O
tumor,3433,O
growth,3433,O
.,3433,O
Recent,3434,O
studies,3434,O
indicate,3434,O
that,3434,O
tamoxifen,3434,B-CHEMICAL
initially,3434,O
acts,3434,O
as,3434,O
an,3434,O
antagonist,3434,O
",",3434,O
but,3434,O
later,3434,O
functions,3434,O
as,3434,O
an,3434,O
ER,3434,B-GENE-N
agonist,3434,O
",",3434,O
promoting,3434,O
tumor,3434,O
growth,3434,O
.,3434,O
This,3435,O
suggests,3435,O
that,3435,O
targeted,3435,O
ER,3435,B-GENE-N
degradation,3435,O
may,3435,O
provide,3435,O
an,3435,O
effective,3435,O
therapeutic,3435,O
approach,3435,O
for,3435,O
breast,3435,O
cancers,3435,O
",",3435,O
even,3435,O
those,3435,O
that,3435,O
are,3435,O
resistant,3435,O
to,3435,O
conventional,3435,O
therapies,3435,O
.,3435,O
With,3436,O
this,3436,O
in,3436,O
mind,3436,O
",",3436,O
we,3436,O
previously,3436,O
demonstrated,3436,O
that,3436,O
proteolysis,3436,O
targeting,3436,O
chimeras,3436,O
(,3436,O
PROTACs,3436,O
),3436,O
effectively,3436,O
induce,3436,O
degradation,3436,O
of,3436,O
the,3436,O
ER,3436,B-GENE-N
as,3436,O
a,3436,O
proof-of-concept,3436,O
experiment,3436,O
.,3436,O
Herein,3437,O
we,3437,O
further,3437,O
refined,3437,O
the,3437,O
PROTAC,3437,O
approach,3437,O
to,3437,O
target,3437,O
the,3437,O
ER,3437,B-GENE-N
for,3437,O
degradation,3437,O
.,3437,O
The,3438,O
ER-targeting,3438,B-GENE-N
PROTACs,3438,O
are,3438,O
composed,3438,O
of,3438,O
an,3438,O
estradiol,3438,B-CHEMICAL
on,3438,O
one,3438,O
end,3438,O
and,3438,O
a,3438,O
hypoxia-inducing,3438,B-GENE-N
factor,3438,I-GENE-N
1alpha,3438,I-GENE-N
(,3438,O
HIF-1alpha,3438,B-GENE-N
),3438,O
-derived,3438,O
synthetic,3438,O
pentapeptide,3438,O
on,3438,O
the,3438,O
other,3438,O
.,3438,O
The,3439,O
pentapeptide,3439,O
is,3439,O
recognized,3439,O
by,3439,O
an,3439,O
E3,3439,B-GENE-N
ubiquitin,3439,I-GENE-N
ligase,3439,I-GENE-N
called,3439,O
the,3439,O
von,3439,B-GENE-N
Hippel,3439,I-GENE-N
Lindau,3439,I-GENE-N
tumor,3439,I-GENE-N
suppressor,3439,I-GENE-N
protein,3439,I-GENE-N
(,3439,O
pVHL,3439,B-GENE-N
),3439,O
",",3439,O
thereby,3439,O
recruiting,3439,O
the,3439,O
ER,3439,B-GENE-N
to,3439,O
this,3439,O
E3,3439,B-GENE-N
ligase,3439,I-GENE-N
for,3439,O
ubiquitination,3439,O
and,3439,O
degradation,3439,O
.,3439,O
Specifically,3440,O
",",3440,O
the,3440,O
pentapeptide,3440,O
is,3440,O
attached,3440,O
at,3440,O
three,3440,O
different,3440,O
locations,3440,O
on,3440,O
estradiol,3440,B-CHEMICAL
to,3440,O
generate,3440,O
three,3440,O
different,3440,O
PROTAC,3440,O
types,3440,O
.,3440,O
With,3441,O
the,3441,O
pentapeptide,3441,O
linked,3441,O
through,3441,O
the,3441,O
C7alpha,3441,O
position,3441,O
of,3441,O
estradiol,3441,B-CHEMICAL
",",3441,O
the,3441,O
resulting,3441,O
PROTAC,3441,O
shows,3441,O
the,3441,O
most,3441,O
effective,3441,O
ER,3441,B-GENE-N
degradation,3441,O
and,3441,O
highest,3441,O
affinity,3441,O
for,3441,O
the,3441,O
estrogen,3441,B-CHEMICAL
receptor,3441,I-GENE-N
.,3441,O
This,3442,O
result,3442,O
provides,3442,O
an,3442,O
opportunity,3442,O
to,3442,O
develop,3442,O
a,3442,O
novel,3442,O
type,3442,O
of,3442,O
ER,3442,B-GENE-N
antagonist,3442,O
that,3442,O
may,3442,O
overcome,3442,O
the,3442,O
resistance,3442,O
of,3442,O
breast,3442,O
tumors,3442,O
to,3442,O
conventional,3442,O
drugs,3442,O
such,3442,O
as,3442,O
tamoxifen,3442,B-CHEMICAL
and,3442,O
fulvestrant,3442,B-CHEMICAL
(,3442,O
Faslodex,3442,B-CHEMICAL
),3442,O
.,3442,O
C677T,3443,B-GENE-N
polymorphism,3443,O
of,3443,O
the,3443,O
methylenetetrahydrofolate,3443,B-GENE-Y
reductase,3443,I-GENE-Y
gene,3443,O
does,3443,O
not,3443,O
affect,3443,O
folic,3443,B-CHEMICAL
acid,3443,I-CHEMICAL
",",3443,O
vitamin,3443,B-CHEMICAL
B12,3443,I-CHEMICAL
",",3443,O
and,3443,O
homocysteine,3443,B-CHEMICAL
serum,3443,O
levels,3443,O
in,3443,O
Turkish,3443,O
children,3443,O
with,3443,O
neural,3443,O
tube,3443,O
defects,3443,O
.,3443,O
Association,3444,O
between,3444,O
neural,3444,O
tube,3444,O
defects,3444,O
(,3444,O
NTDs,3444,O
),3444,O
and,3444,O
C677T,3444,B-GENE-N
polymorphism,3444,O
of,3444,O
the,3444,O
methylenetetrahydrofolate,3444,B-GENE-Y
reductase,3444,I-GENE-Y
(,3444,O
MTHFR,3444,B-GENE-Y
),3444,O
gene,3444,O
was,3444,O
suspected,3444,O
",",3444,O
because,3444,O
the,3444,O
MTHFR,3444,B-GENE-Y
gene,3444,O
codes,3444,O
for,3444,O
a,3444,O
key,3444,O
enzyme,3444,O
in,3444,O
folate,3444,B-CHEMICAL
metabolism,3444,O
.,3444,O
Its,3445,O
deficiency,3445,O
usually,3445,O
leads,3445,O
to,3445,O
significant,3445,O
reductions,3445,O
in,3445,O
plasma,3445,O
concentrations,3445,O
of,3445,O
folate,3445,B-CHEMICAL
",",3445,O
vitamin,3445,B-CHEMICAL
B,3445,I-CHEMICAL
(,3445,I-CHEMICAL
12,3445,I-CHEMICAL
),3445,I-CHEMICAL
and,3445,O
methionine,3445,B-CHEMICAL
",",3445,O
whereas,3445,O
homocysteine,3445,B-CHEMICAL
levels,3445,O
are,3445,O
increased,3445,O
.,3445,O
We,3446,O
examined,3446,O
folate,3446,B-CHEMICAL
",",3446,O
vitamin,3446,B-CHEMICAL
B,3446,I-CHEMICAL
(,3446,I-CHEMICAL
12,3446,I-CHEMICAL
),3446,I-CHEMICAL
and,3446,O
homocysteine,3446,B-CHEMICAL
serum,3446,O
concentrations,3446,O
and,3446,O
polymorphism,3446,O
of,3446,O
the,3446,O
C677T,3446,B-GENE-N
MTHFR,3446,B-GENE-Y
gene,3446,O
in,3446,O
Turkish,3446,O
children,3446,O
with,3446,O
neural,3446,O
tube,3446,O
defects,3446,O
.,3446,O
Thirty-three,3447,O
children,3447,O
with,3447,O
NTDs,3447,O
",",3447,O
26,3447,O
mothers,3447,O
and,3447,O
48,3447,O
healthy,3447,O
individuals,3447,O
were,3447,O
studied,3447,O
.,3447,O
C677T,3448,B-GENE-N
MTHFR,3448,B-GENE-Y
polymorphism,3448,O
was,3448,O
determined,3448,O
by,3448,O
melting,3448,O
curve,3448,O
analyses,3448,O
(,3448,O
LightCycler,3448,O
),3448,O
.,3448,O
The,3449,O
levels,3449,O
of,3449,O
folate,3449,B-CHEMICAL
",",3449,O
vitamin,3449,B-CHEMICAL
B,3449,I-CHEMICAL
(,3449,I-CHEMICAL
12,3449,I-CHEMICAL
),3449,I-CHEMICAL
and,3449,O
homocysteine,3449,B-CHEMICAL
serum,3449,O
concentrations,3449,O
in,3449,O
NTDs,3449,O
were,3449,O
evaluated,3449,O
and,3449,O
compared,3449,O
",",3449,O
along,3449,O
with,3449,O
information,3449,O
concerning,3449,O
alleles,3449,O
of,3449,O
the,3449,O
MTHFR,3449,B-GENE-Y
gene,3449,O
.,3449,O
C677T,3450,B-GENE-N
allele,3450,O
frequencies,3450,O
in,3450,O
NTD,3450,O
children,3450,O
and,3450,O
their,3450,O
mothers,3450,O
were,3450,O
similar,3450,O
to,3450,O
those,3450,O
found,3450,O
in,3450,O
controls,3450,O
.,3450,O
Serum,3451,O
folate,3451,B-CHEMICAL
and,3451,O
vitamin,3451,B-CHEMICAL
B,3451,I-CHEMICAL
(,3451,I-CHEMICAL
12,3451,I-CHEMICAL
),3451,I-CHEMICAL
concentrations,3451,O
were,3451,O
significantly,3451,O
higher,3451,O
in,3451,O
NTD,3451,O
children,3451,O
than,3451,O
that,3451,O
of,3451,O
controls,3451,O
.,3451,O
Serum,3452,O
homocysteine,3452,B-CHEMICAL
concentrations,3452,O
were,3452,O
not,3452,O
significantly,3452,O
higher,3452,O
in,3452,O
NTD,3452,O
children,3452,O
and,3452,O
mothers,3452,O
.,3452,O
We,3453,O
concluded,3453,O
that,3453,O
C677T,3453,B-GENE-N
MTHFR,3453,B-GENE-Y
gene,3453,O
polymorphism,3453,O
does,3453,O
not,3453,O
affect,3453,O
folic,3453,B-CHEMICAL
acid,3453,I-CHEMICAL
",",3453,O
vitamin,3453,B-CHEMICAL
B,3453,I-CHEMICAL
(,3453,I-CHEMICAL
12,3453,I-CHEMICAL
),3453,I-CHEMICAL
and,3453,O
homocysteine,3453,B-CHEMICAL
metabolism,3453,O
in,3453,O
Turkish,3453,O
children,3453,O
with,3453,O
NTDs,3453,O
.,3453,O
C677T,3454,B-GENE-N
polymorphism,3454,O
of,3454,O
the,3454,O
MTHFR,3454,B-GENE-Y
gene,3454,O
can,3454,O
not,3454,O
be,3454,O
regarded,3454,O
as,3454,O
a,3454,O
major,3454,O
risk,3454,O
factor,3454,O
for,3454,O
NTDs,3454,O
in,3454,O
Turkish,3454,O
children,3454,O
.,3454,O
The,3455,O
selectivity,3455,O
of,3455,O
beta-adrenoceptor,3455,B-GENE-N
agonists,3455,O
at,3455,O
human,3455,B-GENE-N
beta1-,3455,I-GENE-N
",",3455,I-GENE-N
beta2-,3455,I-GENE-N
and,3455,I-GENE-N
beta3-adrenoceptors,3455,I-GENE-N
.,3455,O
BACKGROUND,3456,O
AND,3456,O
PURPOSE,3456,O
:,3456,O
There,3456,O
are,3456,O
two,3456,O
important,3456,O
properties,3456,O
of,3456,O
receptor-ligand,3456,O
interactions,3456,O
:,3456,O
affinity,3456,O
(,3456,O
the,3456,O
ability,3456,O
of,3456,O
the,3456,O
ligand,3456,O
to,3456,O
bind,3456,O
to,3456,O
the,3456,O
receptor,3456,O
),3456,O
and,3456,O
efficacy,3456,O
(,3456,O
the,3456,O
ability,3456,O
of,3456,O
the,3456,O
receptor-ligand,3456,O
complex,3456,O
to,3456,O
induce,3456,O
a,3456,O
response,3456,O
),3456,O
.,3456,O
Ligands,3457,O
are,3457,O
classified,3457,O
as,3457,O
agonists,3457,O
or,3457,O
antagonists,3457,O
depending,3457,O
on,3457,O
whether,3457,O
or,3457,O
not,3457,O
they,3457,O
have,3457,O
efficacy,3457,O
.,3457,O
In,3458,O
theory,3458,O
",",3458,O
it,3458,O
is,3458,O
possible,3458,O
to,3458,O
develop,3458,O
selective,3458,O
agonists,3458,O
based,3458,O
on,3458,O
selective,3458,O
affinity,3458,O
",",3458,O
selective,3458,O
intrinsic,3458,O
efficacy,3458,O
or,3458,O
both,3458,O
.,3458,O
This,3459,O
study,3459,O
examined,3459,O
the,3459,O
affinity,3459,O
and,3459,O
intrinsic,3459,O
efficacy,3459,O
of,3459,O
31,3459,O
beta-adrenoceptor,3459,B-GENE-N
agonists,3459,O
at,3459,O
the,3459,O
three,3459,O
human,3459,B-GENE-N
beta-adrenoceptors,3459,I-GENE-N
to,3459,O
determine,3459,O
whether,3459,O
the,3459,O
current,3459,O
agonists,3459,O
are,3459,O
subtype,3459,O
selective,3459,O
because,3459,O
of,3459,O
affinity,3459,O
or,3459,O
intrinsic,3459,O
efficacy,3459,O
.,3459,O
EXPERIMENTAL,3460,O
APPROACH,3460,O
:,3460,O
Stable,3460,O
clonal,3460,O
CHO-K1,3460,O
cell,3460,O
lines,3460,O
",",3460,O
transfected,3460,O
with,3460,O
either,3460,O
the,3460,O
human,3460,B-GENE-N
beta,3460,I-GENE-N
(,3460,I-GENE-N
1,3460,I-GENE-N
),3460,I-GENE-N
",",3460,I-GENE-N
beta,3460,I-GENE-N
(,3460,I-GENE-N
2,3460,I-GENE-N
),3460,I-GENE-N
or,3460,I-GENE-N
beta,3460,I-GENE-N
(,3460,I-GENE-N
3,3460,I-GENE-N
),3460,I-GENE-N
-adrenoceptor,3460,I-GENE-N
",",3460,O
were,3460,O
used,3460,O
",",3460,O
and,3460,O
whole-cell,3460,O
[,3460,B-CHEMICAL
(,3460,I-CHEMICAL
3,3460,I-CHEMICAL
),3460,I-CHEMICAL
H,3460,I-CHEMICAL
],3460,I-CHEMICAL
-CGP,3460,I-CHEMICAL
12177,3460,I-CHEMICAL
radioligand,3460,O
binding,3460,O
and,3460,O
[,3460,B-CHEMICAL
(,3460,I-CHEMICAL
3,3460,I-CHEMICAL
),3460,I-CHEMICAL
H,3460,I-CHEMICAL
],3460,I-CHEMICAL
-cAMP,3460,I-CHEMICAL
accumulation,3460,O
were,3460,O
measured,3460,O
.,3460,O
KEY,3461,O
RESULTS,3461,O
:,3461,O
Several,3461,O
agonists,3461,O
were,3461,O
found,3461,O
to,3461,O
be,3461,O
highly,3461,O
subtype,3461,O
selective,3461,O
because,3461,O
of,3461,O
selective,3461,O
affinity,3461,O
(,3461,O
e.g,3461,O
.,3461,O
salmeterol,3462,B-CHEMICAL
and,3462,O
formoterol,3462,B-CHEMICAL
",",3462,O
for,3462,O
the,3462,O
beta,3462,B-GENE-Y
(,3462,I-GENE-Y
2,3462,I-GENE-Y
),3462,I-GENE-Y
-adrenoceptor,3462,I-GENE-Y
over,3462,O
the,3462,O
beta,3462,B-GENE-Y
(,3462,I-GENE-Y
1,3462,I-GENE-Y
),3462,I-GENE-Y
or,3462,O
beta,3462,B-GENE-Y
(,3462,I-GENE-Y
3,3462,I-GENE-Y
),3462,I-GENE-Y
),3462,O
",",3462,O
while,3462,O
others,3462,O
(,3462,O
e.g,3462,O
.,3462,O
isoprenaline,3463,B-CHEMICAL
),3463,O
had,3463,O
little,3463,O
affinity-selectivity,3463,O
.,3463,O
However,3464,O
",",3464,O
the,3464,O
intrinsic,3464,O
efficacy,3464,O
of,3464,O
salmeterol,3464,B-CHEMICAL
",",3464,O
formoterol,3464,B-CHEMICAL
and,3464,O
isoprenaline,3464,B-CHEMICAL
was,3464,O
similar,3464,O
across,3464,O
all,3464,O
three,3464,O
receptor,3464,O
subtypes,3464,O
.,3464,O
Other,3465,O
ligands,3465,O
(,3465,O
e.g,3465,O
.,3465,O
denopamine,3466,B-CHEMICAL
for,3466,O
beta,3466,B-GENE-Y
(,3466,I-GENE-Y
1,3466,I-GENE-Y
),3466,I-GENE-Y
;,3466,O
clenbuterol,3466,B-CHEMICAL
",",3466,O
AZ,3466,B-CHEMICAL
40140d,3466,I-CHEMICAL
",",3466,O
salbutamol,3466,B-CHEMICAL
for,3466,O
beta,3466,B-GENE-Y
(,3466,I-GENE-Y
2,3466,I-GENE-Y
),3466,I-GENE-Y
),3466,O
were,3466,O
found,3466,O
to,3466,O
have,3466,O
subtype-selective,3466,O
intrinsic,3466,O
efficacy,3466,O
.,3466,O
Several,3467,O
ligands,3467,O
appeared,3467,O
to,3467,O
activate,3467,O
two,3467,O
agonist,3467,O
conformations,3467,O
of,3467,O
the,3467,O
beta,3467,B-GENE-N
(,3467,I-GENE-N
1,3467,I-GENE-N
),3467,I-GENE-N
-,3467,I-GENE-N
and,3467,I-GENE-N
beta,3467,I-GENE-N
(,3467,I-GENE-N
3,3467,I-GENE-N
),3467,I-GENE-N
-adrenoceptors,3467,I-GENE-N
.,3467,O
CONCLUSIONS,3468,O
AND,3468,O
IMPLICATIONS,3468,O
:,3468,O
There,3468,O
are,3468,O
agonists,3468,O
with,3468,O
subtype,3468,O
selectivity,3468,O
based,3468,O
upon,3468,O
both,3468,O
selective,3468,O
affinity,3468,O
and,3468,O
selective,3468,O
intrinsic,3468,O
efficacy,3468,O
.,3468,O
Therefore,3469,O
",",3469,O
there,3469,O
is,3469,O
scope,3469,O
to,3469,O
develop,3469,O
better,3469,O
selective,3469,O
agonists,3469,O
based,3469,O
upon,3469,O
both,3469,O
selective,3469,O
affinity,3469,O
and,3469,O
selective,3469,O
intrinsic,3469,O
efficacy,3469,O
.,3469,O
Rasagiline,3470,B-CHEMICAL
:,3470,O
a,3470,O
novel,3470,O
anti-Parkinsonian,3470,O
monoamine,3470,B-GENE-Y
oxidase-B,3470,I-GENE-Y
inhibitor,3470,O
with,3470,O
neuroprotective,3470,O
activity,3470,O
.,3470,O
Rasagiline,3471,B-CHEMICAL
(,3471,O
N-propargyl-1-,3471,B-CHEMICAL
(,3471,I-CHEMICAL
R,3471,I-CHEMICAL
),3471,I-CHEMICAL
-aminoindan,3471,I-CHEMICAL
),3471,O
is,3471,O
a,3471,O
novel,3471,O
",",3471,O
highly,3471,O
potent,3471,O
irreversible,3471,O
monoamine,3471,B-GENE-Y
oxidase,3471,I-GENE-Y
(,3471,I-GENE-Y
MAO,3471,I-GENE-Y
),3471,I-GENE-Y
-B,3471,I-GENE-Y
inhibitor,3471,O
",",3471,O
anti-Parkinsonian,3471,O
drug,3471,O
.,3471,O
Rasagiline,3472,B-CHEMICAL
is,3472,O
effective,3472,O
as,3472,O
monotherapy,3472,O
or,3472,O
adjunct,3472,O
to,3472,O
L-Dopa,3472,B-CHEMICAL
for,3472,O
patients,3472,O
with,3472,O
early,3472,O
and,3472,O
late,3472,O
Parkinson,3472,O
's,3472,O
disease,3472,O
(,3472,O
PD,3472,O
),3472,O
.,3472,O
Its,3473,O
S-isomer,3473,O
",",3473,O
TVP1022,3473,B-CHEMICAL
is,3473,O
thousand,3473,O
times,3473,O
less,3473,O
potent,3473,O
as,3473,O
an,3473,O
MAO-B,3473,B-GENE-Y
inhibitor,3473,O
.,3473,O
However,3474,O
",",3474,O
both,3474,O
compounds,3474,O
have,3474,O
similar,3474,O
molecular,3474,O
mechanisms,3474,O
of,3474,O
neuroprotection,3474,O
in,3474,O
neuronal,3474,O
cell,3474,O
cultures,3474,O
and,3474,O
animal,3474,O
neurodegenerative,3474,O
models,3474,O
",",3474,O
indicating,3474,O
that,3474,O
the,3474,O
neuroprotective,3474,O
effect,3474,O
of,3474,O
rasagiline,3474,B-CHEMICAL
does,3474,O
not,3474,O
depend,3474,O
on,3474,O
inhibition,3474,O
of,3474,O
MAO-B,3474,B-GENE-Y
",",3474,O
but,3474,O
rather,3474,O
is,3474,O
associated,3474,O
with,3474,O
the,3474,O
N-propargyl,3474,B-CHEMICAL
moiety,3474,O
",",3474,O
which,3474,O
promotes,3474,O
mitochondrial,3474,O
viability,3474,O
and,3474,O
stabilizes,3474,O
permeability,3474,O
transition,3474,O
by,3474,O
regulating,3474,O
Bcl-2,3474,B-GENE-Y
family,3474,O
proteins,3474,O
.,3474,O
Novel,3475,O
findings,3475,O
demonstrated,3475,O
that,3475,O
the,3475,O
major,3475,O
metabolite,3475,O
of,3475,O
rasagiline,3475,B-CHEMICAL
",",3475,O
1-,3475,B-CHEMICAL
(,3475,I-CHEMICAL
R,3475,I-CHEMICAL
),3475,I-CHEMICAL
-aminoindan,3475,I-CHEMICAL
has,3475,O
antioxidant,3475,O
and,3475,O
neuroprotective,3475,O
capabilities,3475,O
and,3475,O
thus,3475,O
",",3475,O
may,3475,O
contribute,3475,O
to,3475,O
the,3475,O
overt,3475,O
activity,3475,O
of,3475,O
its,3475,O
parent,3475,O
compound,3475,O
",",3475,O
rasagiline,3475,B-CHEMICAL
.,3475,O
This,3476,O
paper,3476,O
will,3476,O
review,3476,O
the,3476,O
earlier,3476,O
and,3476,O
present,3476,O
studies,3476,O
in,3476,O
the,3476,O
development,3476,O
of,3476,O
rasagiline,3476,B-CHEMICAL
for,3476,O
treatment,3476,O
of,3476,O
PD,3476,O
and,3476,O
discuss,3476,O
its,3476,O
pharmacology,3476,O
and,3476,O
applicable,3476,O
mechanism,3476,O
of,3476,O
action,3476,O
.,3476,O
Resistance,3477,O
to,3477,O
thyroid,3477,O
hormone,3477,O
due,3477,O
to,3477,O
a,3477,O
novel,3477,O
thyroid,3477,B-GENE-N
hormone,3477,I-GENE-N
receptor,3477,I-GENE-N
mutant,3477,O
in,3477,O
a,3477,O
patient,3477,O
with,3477,O
hypothyroidism,3477,O
secondary,3477,O
to,3477,O
lingual,3477,O
thyroid,3477,O
and,3477,O
functional,3477,O
characterization,3477,O
of,3477,O
the,3477,O
mutant,3477,O
receptor,3477,O
.,3477,O
BACKGROUND,3478,O
:,3478,O
We,3478,O
describe,3478,O
a,3478,O
rare,3478,O
case,3478,O
of,3478,O
congenital,3478,O
hypothyroidism,3478,O
and,3478,O
an,3478,O
extremely,3478,O
high,3478,O
serum,3478,O
thyrotropin,3478,B-GENE-N
(,3478,O
TSH,3478,B-GENE-N
),3478,O
level,3478,O
caused,3478,O
by,3478,O
a,3478,O
combination,3478,O
of,3478,O
resistance,3478,O
to,3478,O
thyroid,3478,O
hormone,3478,O
(,3478,O
RTH,3478,O
),3478,O
and,3478,O
a,3478,O
lingual,3478,O
thyroid,3478,O
.,3478,O
As,3479,O
the,3479,O
RTH,3479,O
mutant,3479,O
",",3479,O
R316C,3479,B-GENE-N
",",3479,O
was,3479,O
new,3479,O
",",3479,O
the,3479,O
optimum,3479,O
dose,3479,O
of,3479,O
levothyroxine,3479,B-CHEMICAL
was,3479,O
unclear,3479,O
.,3479,O
To,3480,O
aid,3480,O
in,3480,O
assessment,3480,O
of,3480,O
the,3480,O
therapy,3480,O
",",3480,O
we,3480,O
characterized,3480,O
the,3480,O
mutant,3480,O
R316C,3480,B-GENE-N
thyroid,3480,B-GENE-N
hormone,3480,I-GENE-N
receptor,3480,I-GENE-N
(,3480,O
TR,3480,B-GENE-N
),3480,O
and,3480,O
compared,3480,O
it,3480,O
with,3480,O
a,3480,O
common,3480,O
mutant,3480,O
",",3480,O
R316H,3480,B-GENE-N
",",3480,O
using,3480,O
in,3480,O
vitro,3480,O
studies,3480,O
.,3480,O
SUMMARY,3481,O
:,3481,O
The,3481,O
patient,3481,O
was,3481,O
a,3481,O
newborn,3481,O
female,3481,O
having,3481,O
severe,3481,O
hypothyroidism,3481,O
with,3481,O
a,3481,O
free,3481,O
thyroxine,3481,B-CHEMICAL
level,3481,O
of,3481,O
0.36,3481,O
ng/dL,3481,O
and,3481,O
a,3481,O
serum,3481,O
TSH,3481,B-GENE-N
level,3481,O
of,3481,O
177,3481,O
microU/mL,3481,O
.,3481,O
A,3482,O
scintiscan,3482,O
showed,3482,O
ectopic,3482,O
lingual,3482,O
thyroid,3482,O
tissue,3482,O
without,3482,O
a,3482,O
normal,3482,O
thyroid,3482,O
gland,3482,O
.,3482,O
Supplementation,3483,O
with,3483,O
levothyroxine,3483,B-CHEMICAL
at,3483,O
a,3483,O
dose,3483,O
of,3483,O
>,3483,O
350,3483,O
microg/day,3483,O
did,3483,O
not,3483,O
normalize,3483,O
the,3483,O
serum,3483,O
TSH,3483,B-GENE-N
level,3483,O
;,3483,O
however,3483,O
",",3483,O
the,3483,O
patient,3483,O
showed,3483,O
normal,3483,O
growth,3483,O
and,3483,O
intelligence,3483,O
at,3483,O
14,3483,O
years,3483,O
of,3483,O
age,3483,O
.,3483,O
Consistent,3484,O
with,3484,O
the,3484,O
results,3484,O
of,3484,O
a,3484,O
computer,3484,O
analysis,3484,O
",",3484,O
the,3484,O
binding,3484,O
of,3484,O
R316C,3484,B-GENE-N
to,3484,O
triiodothyronine,3484,B-CHEMICAL
(,3484,O
T3,3484,B-CHEMICAL
),3484,O
was,3484,O
significantly,3484,O
decreased,3484,O
to,3484,O
38,3484,O
%,3484,O
that,3484,O
of,3484,O
the,3484,O
wild,3484,O
type,3484,O
.,3484,O
Electrophoretic,3485,O
mobility,3485,O
shift,3485,O
assay,3485,O
demonstrated,3485,O
that,3485,O
like,3485,O
R316H,3485,B-GENE-N
",",3485,O
R316C,3485,B-GENE-N
did,3485,O
not,3485,O
form,3485,O
a,3485,O
homodimer,3485,O
",",3485,O
but,3485,O
formed,3485,O
a,3485,O
heterodimer,3485,O
with,3485,O
RXR,3485,B-GENE-N
.,3485,O
However,3486,O
",",3486,O
a,3486,O
glutathione-S-transferase,3486,B-CHEMICAL
pull-down,3486,O
assay,3486,O
showed,3486,O
reduced,3486,O
binding,3486,O
of,3486,O
R316C,3486,B-GENE-N
with,3486,O
NCoR,3486,B-GENE-Y
in,3486,O
the,3486,O
absence,3486,O
of,3486,O
T3,3486,B-CHEMICAL
and,3486,O
impaired,3486,O
release,3486,O
in,3486,O
the,3486,O
presence,3486,O
of,3486,O
T3,3486,B-CHEMICAL
.,3486,O
In,3487,O
addition,3487,O
",",3487,O
transient,3487,O
transfection,3487,O
experiments,3487,O
demonstrated,3487,O
that,3487,O
unlike,3487,O
R316H,3487,B-GENE-N
",",3487,O
R316C,3487,B-GENE-N
had,3487,O
severe,3487,O
impairment,3487,O
of,3487,O
transcriptional,3487,O
activity,3487,O
on,3487,O
genes,3487,O
both,3487,O
positively,3487,O
and,3487,O
negatively,3487,O
regulated,3487,O
by,3487,O
thyroid,3487,O
hormone,3487,O
.,3487,O
It,3488,O
also,3488,O
had,3488,O
a,3488,O
clear,3488,O
dominant,3488,O
negative,3488,O
effect,3488,O
on,3488,O
genes,3488,O
negatively,3488,O
",",3488,O
but,3488,O
not,3488,O
positively,3488,O
",",3488,O
regulated,3488,O
by,3488,O
thyroid,3488,O
hormone,3488,O
",",3488,O
including,3488,O
the,3488,O
TSH-releasing,3488,B-GENE-Y
hormone,3488,I-GENE-Y
and,3488,O
TSHbeta,3488,B-GENE-Y
genes,3488,O
.,3488,O
CONCLUSION,3489,O
:,3489,O
This,3489,O
is,3489,O
the,3489,O
first,3489,O
reported,3489,O
case,3489,O
of,3489,O
a,3489,O
R316C,3489,B-GENE-N
TR,3489,B-GENE-N
mutation,3489,O
.,3489,O
The,3490,O
characteristics,3490,O
of,3490,O
the,3490,O
R316C,3490,B-GENE-N
mutant,3490,O
differed,3490,O
from,3490,O
those,3490,O
of,3490,O
the,3490,O
R316H,3490,B-GENE-N
mutant,3490,O
.,3490,O
Our,3491,O
findings,3491,O
suggest,3491,O
that,3491,O
R316C,3491,B-GENE-N
causes,3491,O
reduced,3491,O
association,3491,O
with,3491,O
and,3491,O
impaired,3491,O
release,3491,O
of,3491,O
NCoR,3491,B-GENE-Y
",",3491,O
resulting,3491,O
in,3491,O
RTH,3491,O
predominantly,3491,O
at,3491,O
the,3491,O
pituitary,3491,O
level,3491,O
",",3491,O
and,3491,O
that,3491,O
slightly,3491,O
elevated,3491,O
serum,3491,O
TSH,3491,B-GENE-N
level,3491,O
with,3491,O
high,3491,O
dose,3491,O
of,3491,O
levothyroxine,3491,B-CHEMICAL
might,3491,O
be,3491,O
optimum,3491,O
for,3491,O
normal,3491,O
growth,3491,O
.,3491,O
Identification,3492,O
of,3492,O
neuronal,3492,O
target,3492,O
areas,3492,O
for,3492,O
nerve,3492,O
agents,3492,O
and,3492,O
specification,3492,O
of,3492,O
receptors,3492,O
for,3492,O
pharmacological,3492,O
treatment,3492,O
.,3492,O
In,3493,O
order,3493,O
to,3493,O
shorten,3493,O
the,3493,O
list,3493,O
of,3493,O
candidate,3493,O
drugs,3493,O
with,3493,O
anticonvulsant,3493,O
potential,3493,O
against,3493,O
nerve,3493,O
agents,3493,O
",",3493,O
critical,3493,O
subreceptors,3493,O
in,3493,O
seizure,3493,O
controlling,3493,O
brain,3493,O
regions,3493,O
should,3493,O
be,3493,O
specified,3493,O
.,3493,O
Epileptiform,3494,O
activity,3494,O
does,3494,O
not,3494,O
spread,3494,O
randomly,3494,O
throughout,3494,O
the,3494,O
brain,3494,O
",",3494,O
but,3494,O
appears,3494,O
to,3494,O
be,3494,O
generated,3494,O
and,3494,O
propagated,3494,O
by,3494,O
specific,3494,O
anatomical,3494,O
routes,3494,O
.,3494,O
Nerve,3495,O
agents,3495,O
evoke,3495,O
seizure,3495,O
activity,3495,O
in,3495,O
the,3495,O
forebrain,3495,O
that,3495,O
progresses,3495,O
to,3495,O
the,3495,O
hind,3495,O
brain,3495,O
resulting,3495,O
in,3495,O
tonic-clonic,3495,O
convulsions,3495,O
.,3495,O
In,3496,O
some,3496,O
recent,3496,O
studies,3496,O
",",3496,O
it,3496,O
was,3496,O
shown,3496,O
that,3496,O
lesion,3496,O
of,3496,O
the,3496,O
area,3496,O
tempestas,3496,O
(,3496,O
AT,3496,O
),3496,O
",",3496,O
medial,3496,O
septum,3496,O
(,3496,O
MS,3496,O
),3496,O
",",3496,O
perirhinal,3496,O
cortex,3496,O
(,3496,O
PRC,3496,O
),3496,O
",",3496,O
or,3496,O
posterior,3496,O
piriform,3496,O
cortex,3496,O
(,3496,O
PPC,3496,O
),3496,O
produces,3496,O
anticonvulsant,3496,O
effects,3496,O
(,3496,O
prevention,3496,O
of,3496,O
convulsions,3496,O
or,3496,O
delayed,3496,O
onset,3496,O
of,3496,O
convulsions,3496,O
),3496,O
in,3496,O
rats,3496,O
exposed,3496,O
to,3496,O
soman,3496,B-CHEMICAL
",",3496,O
whereas,3496,O
damage,3496,O
to,3496,O
nucleus,3496,O
accumbens,3496,O
",",3496,O
nucleus,3496,O
basalis,3496,O
magnocellularis,3496,O
",",3496,O
amygdala,3496,O
",",3496,O
hippocampus,3496,O
",",3496,O
or,3496,O
entorhinal,3496,O
cortex,3496,O
does,3496,O
not,3496,O
cause,3496,O
anticonvulsant,3496,O
impact,3496,O
.,3496,O
These,3497,O
results,3497,O
are,3497,O
in,3497,O
compliance,3497,O
with,3497,O
findings,3497,O
that,3497,O
seizures,3497,O
can,3497,O
be,3497,O
generated,3497,O
in,3497,O
AT,3497,O
",",3497,O
MS,3497,O
",",3497,O
PRC,3497,O
",",3497,O
and,3497,O
PPC,3497,O
by,3497,O
means,3497,O
of,3497,O
nerve,3497,O
agents,3497,O
",",3497,O
chemoconvulsants,3497,O
",",3497,O
or,3497,O
kindling,3497,O
.,3497,O
Results,3498,O
from,3498,O
microinfusion,3498,O
studies,3498,O
show,3498,O
that,3498,O
anticonvulsant,3498,O
efficacy,3498,O
is,3498,O
obtained,3498,O
by,3498,O
GABA,3498,B-CHEMICAL
(,3498,I-GENE-N
A,3498,I-GENE-N
),3498,I-GENE-N
modulators,3498,O
or,3498,O
cholinergic,3498,O
antagonists,3498,O
(,3498,O
M1-M5,3498,B-GENE-Y
),3498,O
in,3498,O
AT,3498,O
",",3498,O
cholinergic,3498,O
antagonists,3498,O
(,3498,O
M1-M5,3498,B-GENE-Y
),3498,O
in,3498,O
MS,3498,O
",",3498,O
combined,3498,O
glutamatergic,3498,O
(,3498,O
NMDA,3498,B-CHEMICAL
),3498,O
and,3498,O
cholinergic,3498,O
antagonist,3498,O
(,3498,O
M1-M4,3498,B-GENE-Y
),3498,O
",",3498,O
AMPA,3498,B-CHEMICAL
antagonist,3498,O
",",3498,O
or,3498,O
modulators,3498,O
of,3498,O
metabotropic,3498,B-GENE-N
glutamate,3498,B-CHEMICAL
receptors,3498,I-GENE-N
(,3498,O
mGluR5,3498,B-GENE-Y
",",3498,O
mGluR2/3,3498,B-GENE-N
),3498,O
in,3498,O
PRC,3498,O
",",3498,O
and,3498,O
cholinergic,3498,O
antagonist,3498,O
(,3498,O
M1-M5,3498,B-GENE-Y
),3498,O
or,3498,O
GABA,3498,B-GENE-N
(,3498,I-GENE-N
A,3498,I-GENE-N
),3498,I-GENE-N
agonist,3498,O
in,3498,O
PPC,3498,O
.,3498,O
Calculation,3499,O
of,3499,O
impact,3499,O
factors,3499,O
for,3499,O
the,3499,O
most,3499,O
potent,3499,O
drugs,3499,O
(,3499,O
percentage,3499,O
of,3499,O
positive,3499,O
effects,3499,O
in,3499,O
the,3499,O
seizure,3499,O
controlling,3499,O
sites,3499,O
),3499,O
showed,3499,O
that,3499,O
scopolamine,3499,B-CHEMICAL
and,3499,O
procyclidine,3499,B-CHEMICAL
were,3499,O
ranking,3499,O
highest,3499,O
(,3499,O
75,3499,O
),3499,O
followed,3499,O
by,3499,O
muscimol,3499,B-CHEMICAL
(,3499,O
50,3499,O
),3499,O
",",3499,O
NBQX,3499,B-CHEMICAL
(,3499,O
33,3499,O
),3499,O
",",3499,O
and,3499,O
caramiphen,3499,B-CHEMICAL
(,3499,O
33,3499,O
),3499,O
.,3499,O
Potential,3500,O
strategies,3500,O
for,3500,O
prophylactic,3500,O
and,3500,O
post-exposure,3500,O
treatments,3500,O
are,3500,O
discussed,3500,O
.,3500,O
Selective,3501,O
cyclooxygenase-2,3501,B-GENE-Y
(,3501,O
COX-2,3501,B-GENE-Y
),3501,O
inhibitors,3501,O
and,3501,O
breast,3501,O
cancer,3501,O
risk,3501,O
.,3501,O
BACKGROUND,3502,O
:,3502,O
Recent,3502,O
epidemiologic,3502,O
and,3502,O
laboratory,3502,O
studies,3502,O
have,3502,O
suggested,3502,O
that,3502,O
non-steroidal,3502,O
anti-inflammatory,3502,O
drugs,3502,O
(,3502,O
NSAIDs,3502,O
),3502,O
may,3502,O
reduce,3502,O
the,3502,O
risk,3502,O
of,3502,O
breast,3502,O
cancer,3502,O
through,3502,O
inhibition,3502,O
of,3502,O
cyclooxygenase-2,3502,B-GENE-Y
(,3502,O
COX-2,3502,B-GENE-Y
),3502,O
.,3502,O
METHODS,3503,O
:,3503,O
We,3503,O
conducted,3503,O
a,3503,O
case-control,3503,O
study,3503,O
to,3503,O
measure,3503,O
the,3503,O
association,3503,O
between,3503,O
selective,3503,O
cox-2,3503,B-GENE-Y
inhibitors,3503,O
",",3503,O
particularly,3503,O
celecoxib,3503,B-CHEMICAL
",",3503,O
rofecoxib,3503,B-CHEMICAL
",",3503,O
valdecoxib,3503,B-CHEMICAL
and,3503,O
non-specific,3503,O
NSAID,3503,O
subgroups,3503,O
",",3503,O
and,3503,O
breast,3503,O
cancer,3503,O
risk,3503,O
.,3503,O
Between,3504,O
2003,3504,O
and,3504,O
2006,3504,O
",",3504,O
a,3504,O
total,3504,O
of,3504,O
"18,368",3504,O
incident,3504,O
breast,3504,O
cancer,3504,O
cases,3504,O
were,3504,O
identified,3504,O
in,3504,O
the,3504,O
Ingenix/Lab,3504,O
Rx,3504,O
insurance,3504,O
database,3504,O
",",3504,O
which,3504,O
contains,3504,O
clinical,3504,O
encounter,3504,O
and,3504,O
drug,3504,O
prescription,3504,O
data,3504,O
.,3504,O
Four,3505,O
controls,3505,O
per,3505,O
case,3505,O
were,3505,O
randomly,3505,O
selected,3505,O
",",3505,O
matched,3505,O
on,3505,O
age,3505,O
and,3505,O
time,3505,O
in,3505,O
database,3505,O
.,3505,O
Odds,3506,O
ratios,3506,O
(,3506,O
OR,3506,O
),3506,O
and,3506,O
95,3506,O
%,3506,O
confidence,3506,O
intervals,3506,O
(,3506,O
CI,3506,O
),3506,O
were,3506,O
estimated,3506,O
using,3506,O
conditional,3506,O
logistic,3506,O
regression,3506,O
.,3506,O
RESULTS,3507,O
:,3507,O
Breast,3507,O
cancer,3507,O
risk,3507,O
was,3507,O
inversely,3507,O
associated,3507,O
with,3507,O
both,3507,O
non-specific,3507,O
NSAID,3507,O
and,3507,O
selective,3507,O
COX-2,3507,B-GENE-Y
inhibitor,3507,O
use,3507,O
.,3507,O
Greater,3508,O
than,3508,O
12,3508,O
months,3508,O
',3508,O
duration,3508,O
of,3508,O
use,3508,O
of,3508,O
Celecoxib,3508,B-CHEMICAL
at,3508,O
a,3508,O
standard,3508,O
dose,3508,O
(,3508,O
200mg/day,3508,O
),3508,O
was,3508,O
associated,3508,O
with,3508,O
a,3508,O
16,3508,O
%,3508,O
decrease,3508,O
in,3508,O
breast,3508,O
cancer,3508,O
risk,3508,O
(,3508,O
OR=0.84,3508,O
",",3508,O
95,3508,O
%,3508,O
CI=0.73,3508,O
",",3508,O
0.97,3508,O
),3508,O
.,3508,O
We,3509,O
observed,3509,O
the,3509,O
greatest,3509,O
risk,3509,O
reduction,3509,O
in,3509,O
association,3509,O
with,3509,O
>,3509,O
2,3509,O
years,3509,O
of,3509,O
rofecoxib,3509,B-CHEMICAL
exposure,3509,O
(,3509,O
OR=0.54,3509,O
",",3509,O
95,3509,O
%,3509,O
CI=0.37,3509,O
",",3509,O
0.80,3509,O
),3509,O
.,3509,O
Acetaminophen,3510,B-CHEMICAL
",",3510,O
a,3510,O
compound,3510,O
with,3510,O
less,3510,O
biological,3510,O
plausibility,3510,O
for,3510,O
chemoprevention,3510,O
",",3510,O
showed,3510,O
no,3510,O
significant,3510,O
association,3510,O
with,3510,O
the,3510,O
risk,3510,O
of,3510,O
developing,3510,O
breast,3510,O
cancer,3510,O
.,3510,O
CONCLUSION,3511,O
:,3511,O
Consistent,3511,O
with,3511,O
animal,3511,O
models,3511,O
and,3511,O
laboratory,3511,O
investigations,3511,O
",",3511,O
higher,3511,O
doses,3511,O
of,3511,O
selective,3511,O
COX-2,3511,B-GENE-Y
inhibitors,3511,O
were,3511,O
more,3511,O
protective,3511,O
against,3511,O
breast,3511,O
cancer,3511,O
than,3511,O
non-specific,3511,O
NSAIDs,3511,O
.,3511,O
With,3512,O
exposure,3512,O
to,3512,O
rofecoxib,3512,B-CHEMICAL
",",3512,O
a,3512,O
selective,3512,O
COX-2,3512,B-GENE-Y
inhibitor,3512,O
",",3512,O
breast,3512,O
cancer,3512,O
risk,3512,O
reduction,3512,O
was,3512,O
appreciable,3512,O
(,3512,O
46,3512,O
%,3512,O
),3512,O
",",3512,O
suggesting,3512,O
a,3512,O
possible,3512,O
role,3512,O
for,3512,O
selective,3512,O
COX-2,3512,B-GENE-Y
inhibitors,3512,O
in,3512,O
breast,3512,O
cancer,3512,O
prophylaxis,3512,O
.,3512,O
Barrel,3513,O
rotation,3513,O
in,3513,O
rats,3513,O
induced,3513,O
by,3513,O
SMS,3513,B-CHEMICAL
201-995,3513,I-CHEMICAL
:,3513,O
suppression,3513,O
by,3513,O
ceruletide,3513,B-CHEMICAL
.,3513,O
Intracerebroventricular,3514,O
administration,3514,O
of,3514,O
SMS,3514,B-CHEMICAL
201-995,3514,I-CHEMICAL
(,3514,O
5,3514,O
micrograms/rat,3514,O
),3514,O
",",3514,O
a,3514,O
somatostatin,3514,B-GENE-Y
analogue,3514,O
",",3514,O
induced,3514,O
barrel,3514,O
rotation,3514,O
in,3514,O
rats,3514,O
.,3514,O
Pretreatment,3515,O
with,3515,O
ceruletide,3515,B-CHEMICAL
(,3515,O
40,3515,O
micrograms/100,3515,O
g,3515,O
b,3515,O
.,3515,O
wt.,3516,O
",",3516,O
IP,3516,O
),3516,O
3,3516,O
days,3516,O
or,3516,O
7,3516,O
days,3516,O
prior,3516,O
to,3516,O
the,3516,O
injection,3516,O
of,3516,O
SMS,3516,B-CHEMICAL
201-995,3516,I-CHEMICAL
significantly,3516,O
inhibited,3516,O
the,3516,O
response,3516,O
rate,3516,O
of,3516,O
barrel,3516,O
rotation,3516,O
induced,3516,O
by,3516,O
SMS,3516,B-CHEMICAL
201-995,3516,I-CHEMICAL
",",3516,O
but,3516,O
not,3516,O
that,3516,O
induced,3516,O
by,3516,O
arginine-vasopressin,3516,B-CHEMICAL
(,3516,O
1,3516,O
microgram/rat,3516,O
",",3516,O
ICV,3516,O
),3516,O
.,3516,O
The,3517,O
suppressive,3517,O
effect,3517,O
of,3517,O
ceruletide,3517,B-CHEMICAL
on,3517,O
barrel,3517,O
rotation,3517,O
could,3517,O
be,3517,O
partially,3517,O
countered,3517,O
by,3517,O
MK-329,3517,B-CHEMICAL
",",3517,O
a,3517,O
selective,3517,O
peripheral,3517,O
CCK,3517,B-GENE-Y
(,3517,B-GENE-Y
CCK-A,3517,I-GENE-Y
),3517,I-GENE-Y
receptor,3517,I-GENE-Y
antagonist,3517,O
.,3517,O
Desulfated,3518,O
cerulein,3518,O
did,3518,O
not,3518,O
affect,3518,O
the,3518,O
barrel,3518,O
rotation,3518,O
induced,3518,O
by,3518,O
SMS,3518,B-CHEMICAL
201-995,3518,I-CHEMICAL
.,3518,O
These,3519,O
findings,3519,O
suggest,3519,O
that,3519,O
ceruletide,3519,B-CHEMICAL
specifically,3519,O
suppresses,3519,O
the,3519,O
barrel,3519,O
rotation,3519,O
evoked,3519,O
by,3519,O
SMS,3519,B-CHEMICAL
201-995,3519,I-CHEMICAL
in,3519,O
a,3519,O
long-lasting,3519,O
manner,3519,O
possibly,3519,O
acting,3519,O
through,3519,O
CCK-A,3519,B-GENE-Y
receptor,3519,I-GENE-Y
.,3519,O
Effects,3520,O
of,3520,O
the,3520,O
histamine,3520,B-CHEMICAL
H1,3520,I-GENE-Y
antagonist,3520,O
chlorcyclizine,3520,B-CHEMICAL
on,3520,O
rat,3520,O
fetal,3520,O
palate,3520,O
development,3520,O
.,3520,O
BACKGROUND,3521,O
:,3521,O
The,3521,O
effects,3521,O
of,3521,O
histamine,3521,B-CHEMICAL
H1,3521,I-GENE-Y
antagonist,3521,O
chlorcyclizine,3521,B-CHEMICAL
on,3521,O
rat,3521,O
palate,3521,O
development,3521,O
were,3521,O
characterized,3521,O
following,3521,O
in,3521,O
utero,3521,O
exposure,3521,O
.,3521,O
METHODS,3522,O
:,3522,O
To,3522,O
identify,3522,O
the,3522,O
optimum,3522,O
dose,3522,O
for,3522,O
inducing,3522,O
cleft,3522,O
palate,3522,O
",",3522,O
pregnant,3522,O
rats,3522,O
were,3522,O
administered,3522,O
30,3522,O
",",3522,O
60,3522,O
",",3522,O
or,3522,O
90,3522,O
mg/kg,3522,O
chlorcyclizine,3522,B-CHEMICAL
on,3522,O
Gestation,3522,O
Days,3522,O
11,3522,O
to,3522,O
14,3522,O
.,3522,O
Fetal,3523,O
palate,3523,O
gene,3523,O
expression,3523,O
was,3523,O
also,3523,O
assessed,3523,O
after,3523,O
90,3523,O
mg/kg,3523,O
chlorcyclizine,3523,B-CHEMICAL
at,3523,O
8,3523,O
",",3523,O
15,3523,O
and,3523,O
30,3523,O
hours,3523,O
post-dose,3523,O
on,3523,O
Gestation,3523,O
Day,3523,O
14,3523,O
using,3523,O
microarray,3523,O
and,3523,O
qRT-PCR,3523,O
.,3523,O
RESULTS,3524,O
:,3524,O
Rats,3524,O
in,3524,O
the,3524,O
60-,3524,O
and,3524,O
90-mg/kg,3524,O
groups,3524,O
exhibited,3524,O
adverse,3524,O
clinical,3524,O
signs,3524,O
and,3524,O
body,3524,O
weight,3524,O
loss,3524,O
.,3524,O
Rats,3525,O
in,3525,O
the,3525,O
90-mg/kg,3525,O
group,3525,O
also,3525,O
demonstrated,3525,O
increases,3525,O
in,3525,O
late,3525,O
resorptions,3525,O
and,3525,O
decreases,3525,O
in,3525,O
fetal,3525,O
weight,3525,O
.,3525,O
Effects,3526,O
in,3526,O
the,3526,O
low-dose,3526,O
group,3526,O
were,3526,O
limited,3526,O
to,3526,O
decreases,3526,O
in,3526,O
body,3526,O
weight,3526,O
gain,3526,O
.,3526,O
Fetal,3527,O
assessment,3527,O
on,3527,O
Gestation,3527,O
Day,3527,O
21,3527,O
revealed,3527,O
that,3527,O
findings,3527,O
were,3527,O
limited,3527,O
to,3527,O
the,3527,O
60-,3527,O
and,3527,O
90-mg/kg,3527,O
groups,3527,O
",",3527,O
and,3527,O
included,3527,O
cleft,3527,O
palate,3527,O
(,3527,O
80,3527,O
%,3527,O
of,3527,O
litters,3527,O
for,3527,O
both,3527,O
groups,3527,O
),3527,O
",",3527,O
high,3527,O
arched,3527,O
palate,3527,O
",",3527,O
small,3527,O
nose,3527,O
",",3527,O
micrognathia,3527,O
",",3527,O
high,3527,O
domed,3527,O
head,3527,O
",",3527,O
digits,3527,O
shortened/absent,3527,O
and,3527,O
small,3527,O
limb,3527,O
.,3527,O
The,3528,O
fetal,3528,O
incidence,3528,O
of,3528,O
cleft,3528,O
palate,3528,O
was,3528,O
higher,3528,O
at,3528,O
90,3528,O
mg/kg,3528,O
",",3528,O
thus,3528,O
this,3528,O
dose,3528,O
was,3528,O
selected,3528,O
to,3528,O
assess,3528,O
palate,3528,O
gene,3528,O
expression,3528,O
.,3528,O
The,3529,O
altered,3529,O
genes,3529,O
associated,3529,O
with,3529,O
chlorcyclizine-induced,3529,B-CHEMICAL
cleft,3529,O
palate,3529,O
included,3529,O
Wnt5a,3529,B-GENE-Y
",",3529,O
Bmp2,3529,B-GENE-Y
",",3529,O
Bmp4,3529,B-GENE-Y
",",3529,O
Fgf10,3529,B-GENE-Y
",",3529,O
Fgfr2,3529,B-GENE-Y
",",3529,O
Msx1,3529,B-GENE-Y
",",3529,O
and,3529,O
Insig1,3529,B-GENE-Y
but,3529,O
the,3529,O
magnitude,3529,O
of,3529,O
the,3529,O
change,3529,O
was,3529,O
relatively,3529,O
small,3529,O
(,3529,O
1.5-,3529,O
to,3529,O
2-fold,3529,O
),3529,O
.,3529,O
CONCLUSIONS,3530,O
:,3530,O
Expression,3530,O
of,3530,O
several,3530,O
genes,3530,O
involved,3530,O
in,3530,O
palate,3530,O
",",3530,O
limb,3530,O
and,3530,O
digit,3530,O
development,3530,O
was,3530,O
altered,3530,O
in,3530,O
the,3530,O
fetal,3530,O
palate,3530,O
following,3530,O
in,3530,O
utero,3530,O
exposure,3530,O
to,3530,O
chlorcyclizine,3530,B-CHEMICAL
.,3530,O
The,3531,O
subtle,3531,O
perturbation,3531,O
and,3531,O
interplay,3531,O
of,3531,O
these,3531,O
genes,3531,O
may,3531,O
have,3531,O
profound,3531,O
effects,3531,O
on,3531,O
the,3531,O
dynamics,3531,O
of,3531,O
fetal,3531,O
palate,3531,O
development,3531,O
.,3531,O
GABA,3532,B-GENE-N
(,3532,I-GENE-N
A,3532,I-GENE-N
),3532,I-GENE-N
receptors,3532,I-GENE-N
as,3532,O
molecular,3532,O
targets,3532,O
of,3532,O
general,3532,O
anesthetics,3532,O
:,3532,O
identification,3532,O
of,3532,O
binding,3532,O
sites,3532,O
provides,3532,O
clues,3532,O
to,3532,O
allosteric,3532,O
modulation,3532,O
.,3532,O
PURPOSE,3533,O
:,3533,O
The,3533,O
purpose,3533,O
of,3533,O
this,3533,O
review,3533,O
is,3533,O
to,3533,O
summarize,3533,O
current,3533,O
knowledge,3533,O
of,3533,O
detailed,3533,O
biochemical,3533,O
evidence,3533,O
for,3533,O
the,3533,O
role,3533,O
of,3533,O
gamma-aminobutyric,3533,B-CHEMICAL
acid,3533,I-CHEMICAL
type,3533,I-GENE-N
A,3533,I-GENE-N
receptors,3533,I-GENE-N
(,3533,O
GABA,3533,B-GENE-N
(,3533,I-GENE-N
A,3533,I-GENE-N
),3533,I-GENE-N
-Rs,3533,I-GENE-N
),3533,O
in,3533,O
the,3533,O
mechanisms,3533,O
of,3533,O
general,3533,O
anesthesia,3533,O
.,3533,O
PRINCIPAL,3534,O
FINDINGS,3534,O
:,3534,O
With,3534,O
the,3534,O
knowledge,3534,O
that,3534,O
all,3534,O
general,3534,O
anesthetics,3534,O
positively,3534,O
modulate,3534,O
GABA,3534,B-GENE-N
(,3534,I-GENE-N
A,3534,I-GENE-N
),3534,I-GENE-N
-R-mediated,3534,O
inhibitory,3534,O
transmission,3534,O
",",3534,O
site-directed,3534,O
mutagenesis,3534,O
comparing,3534,O
sequences,3534,O
of,3534,O
GABA,3534,B-GENE-N
(,3534,I-GENE-N
A,3534,I-GENE-N
),3534,I-GENE-N
-R,3534,I-GENE-N
subunits,3534,O
of,3534,O
varying,3534,O
sensitivity,3534,O
led,3534,O
to,3534,O
identification,3534,O
of,3534,O
amino,3534,B-CHEMICAL
acid,3534,I-CHEMICAL
residues,3534,O
in,3534,O
the,3534,O
transmembrane,3534,O
domain,3534,O
that,3534,O
are,3534,O
critical,3534,O
for,3534,O
the,3534,O
drug,3534,O
actions,3534,O
in,3534,O
vitro,3534,O
.,3534,O
Using,3535,O
a,3535,O
photo,3535,O
incorporable,3535,O
analogue,3535,O
of,3535,O
the,3535,O
general,3535,O
anesthetic,3535,O
",",3535,O
R,3535,B-CHEMICAL
(,3535,I-CHEMICAL
+,3535,I-CHEMICAL
),3535,I-CHEMICAL
etomidate,3535,I-CHEMICAL
",",3535,O
we,3535,O
identified,3535,O
two,3535,O
transmembrane,3535,O
amino,3535,B-CHEMICAL
acids,3535,I-CHEMICAL
that,3535,O
were,3535,O
affinity,3535,O
labelled,3535,O
in,3535,O
purified,3535,O
bovine,3535,B-GENE-N
brain,3535,I-GENE-N
GABA,3535,I-GENE-N
(,3535,I-GENE-N
A,3535,I-GENE-N
),3535,I-GENE-N
-R.,3535,O
Homology,3535,O
protein,3535,O
structural,3535,O
modelling,3535,O
positions,3535,O
these,3535,O
two,3535,O
residues,3535,O
",",3535,O
alphaM1-11,3535,O
',3535,O
and,3535,O
betaM3-4,3535,O
',3535,O
",",3535,O
close,3535,O
to,3535,O
each,3535,O
other,3535,O
in,3535,O
a,3535,O
single,3535,O
type,3535,O
of,3535,O
intersubunit,3535,B-GENE-N
etomidate,3535,I-GENE-N
binding,3535,I-GENE-N
pocket,3535,I-GENE-N
at,3535,O
the,3535,O
beta/alpha,3535,B-GENE-N
interface,3535,I-GENE-N
.,3535,O
This,3536,O
position,3536,O
would,3536,O
be,3536,O
appropriate,3536,O
for,3536,O
modulation,3536,O
of,3536,O
agonist,3536,O
channel,3536,O
gating,3536,O
.,3536,O
Overall,3537,O
",",3537,O
available,3537,O
information,3537,O
suggests,3537,O
that,3537,O
these,3537,O
two,3537,O
etomidate,3537,B-CHEMICAL
binding,3537,O
residues,3537,O
are,3537,O
allosterically,3537,O
coupled,3537,O
to,3537,O
sites,3537,O
of,3537,O
action,3537,O
of,3537,O
steroids,3537,B-CHEMICAL
",",3537,O
barbiturates,3537,B-CHEMICAL
",",3537,O
volatile,3537,O
agents,3537,O
",",3537,O
and,3537,O
propofol,3537,B-CHEMICAL
",",3537,O
but,3537,O
not,3537,O
alcohols,3537,B-CHEMICAL
.,3537,O
Residue,3538,O
alpha/betaM2-15,3538,O
',3538,O
is,3538,O
probably,3538,O
not,3538,O
a,3538,O
binding,3538,O
site,3538,O
but,3538,O
allosterically,3538,O
coupled,3538,O
to,3538,O
action,3538,O
of,3538,O
volatile,3538,O
agents,3538,O
",",3538,O
alcohols,3538,B-CHEMICAL
",",3538,O
and,3538,O
intravenous,3538,O
agents,3538,O
",",3538,O
and,3538,O
alpha/betaM1-,3538,O
(,3538,O
-2,3538,O
',3538,O
),3538,O
is,3538,O
coupled,3538,O
to,3538,O
action,3538,O
of,3538,O
intravenous,3538,O
agents,3538,O
.,3538,O
CONCLUSIONS,3539,O
:,3539,O
Establishment,3539,O
of,3539,O
a,3539,O
coherent,3539,O
and,3539,O
consistent,3539,O
structural,3539,O
model,3539,O
of,3539,O
the,3539,O
GABA,3539,B-GENE-N
(,3539,I-GENE-N
A,3539,I-GENE-N
),3539,I-GENE-N
-R,3539,I-GENE-N
lends,3539,O
support,3539,O
to,3539,O
the,3539,O
conclusion,3539,O
that,3539,O
general,3539,O
anesthetics,3539,O
can,3539,O
modulate,3539,O
function,3539,O
by,3539,O
binding,3539,O
to,3539,O
appropriate,3539,O
domains,3539,O
on,3539,O
the,3539,O
protein,3539,O
.,3539,O
Genetic,3540,O
engineering,3540,O
of,3540,O
mice,3540,O
with,3540,O
mutation,3540,O
in,3540,O
some,3540,O
of,3540,O
these,3540,O
GABA,3540,B-GENE-N
(,3540,I-GENE-N
A,3540,I-GENE-N
),3540,I-GENE-N
-R,3540,I-GENE-N
residues,3540,O
are,3540,O
insensitive,3540,O
to,3540,O
general,3540,O
anesthetics,3540,O
in,3540,O
vivo,3540,O
",",3540,O
suggesting,3540,O
that,3540,O
further,3540,O
analysis,3540,O
of,3540,O
these,3540,O
domains,3540,O
could,3540,O
lead,3540,O
to,3540,O
development,3540,O
of,3540,O
more,3540,O
potent,3540,O
and,3540,O
specific,3540,O
drugs,3540,O
.,3540,O
Role,3541,O
of,3541,O
extracellular,3541,O
calcium,3541,B-CHEMICAL
and,3541,O
calmodulin,3541,B-GENE-Y
in,3541,O
prolactin,3541,B-GENE-Y
secretion,3541,O
induced,3541,O
by,3541,O
hyposmolarity,3541,O
",",3541,O
thyrotropin-releasing,3541,B-GENE-Y
hormone,3541,I-GENE-Y
",",3541,O
and,3541,O
high,3541,O
K+,3541,B-CHEMICAL
in,3541,O
GH4C1,3541,O
cells,3541,O
.,3541,O
The,3542,O
mechanism,3542,O
by,3542,O
which,3542,O
30,3542,O
%,3542,O
medium,3542,O
hyposmolarity,3542,O
induces,3542,O
PRL,3542,B-GENE-Y
secretion,3542,O
by,3542,O
GH4C1,3542,O
cells,3542,O
was,3542,O
compared,3542,O
with,3542,O
that,3542,O
induced,3542,O
by,3542,O
100,3542,O
nmol/l,3542,O
TRH,3542,B-GENE-Y
or,3542,O
30,3542,O
mmol/l,3542,O
K+,3542,B-CHEMICAL
.,3542,O
Removing,3543,O
medium,3543,O
Ca2+,3543,B-CHEMICAL
",",3543,O
blocking,3543,O
Ca2+,3543,B-CHEMICAL
channels,3543,I-GENE-N
with,3543,O
50,3543,O
mumol/l,3543,O
verapamil,3543,B-CHEMICAL
",",3543,O
or,3543,O
inhibiting,3543,O
calmodulin,3543,B-GENE-Y
activation,3543,O
with,3543,O
20,3543,O
mumol/l,3543,O
trifluoperazine,3543,B-CHEMICAL
",",3543,O
10,3543,O
mumol/l,3543,O
chlorpromazine,3543,B-CHEMICAL
or,3543,O
10,3543,O
mumol/l,3543,O
pimozide,3543,B-CHEMICAL
almost,3543,O
completely,3543,O
blocked,3543,O
hyposmolarity-induced,3543,O
secretion,3543,O
.,3543,O
The,3544,O
smooth,3544,O
muscle,3544,O
relaxant,3544,O
",",3544,O
W-7,3544,B-CHEMICAL
",",3544,O
which,3544,O
is,3544,O
believed,3544,O
relatively,3544,O
specific,3544,O
in,3544,O
inhibiting,3544,O
the,3544,O
Ca2,3544,B-CHEMICAL
(,3544,I-CHEMICAL
+,3544,I-CHEMICAL
),3544,I-CHEMICAL
-calmodulin,3544,O
interaction,3544,O
",",3544,O
depressed,3544,O
hyposmolarity-induced,3544,O
PRL,3544,B-GENE-Y
secretion,3544,O
in,3544,O
a,3544,O
dose-dependent,3544,O
manner,3544,O
(,3544,O
r,3544,O
=,3544,O
-0.991,3544,O
",",3544,O
p,3544,O
less,3544,O
than,3544,O
0.01,3544,O
),3544,O
.,3544,O
The,3545,O
above,3545,O
drugs,3545,O
also,3545,O
blocked,3545,O
or,3545,O
decreased,3545,O
high,3545,O
K,3545,B-CHEMICAL
(,3545,I-CHEMICAL
+,3545,I-CHEMICAL
),3545,I-CHEMICAL
-induced,3545,O
secretion,3545,O
",",3545,O
but,3545,O
had,3545,O
much,3545,O
less,3545,O
effect,3545,O
on,3545,O
TRH-induced,3545,B-GENE-Y
secretion,3545,O
.,3545,O
Secretion,3546,O
induced,3546,O
by,3546,O
TRH,3546,B-GENE-Y
",",3546,O
hyposmolarity,3546,O
",",3546,O
or,3546,O
high,3546,O
K+,3546,B-CHEMICAL
was,3546,O
optimal,3546,O
at,3546,O
pH,3546,O
7.3-7.65,3546,O
and,3546,O
was,3546,O
significantly,3546,O
depressed,3546,O
at,3546,O
pH,3546,O
6.0,3546,O
or,3546,O
8.0,3546,O
",",3546,O
indicating,3546,O
that,3546,O
release,3546,O
of,3546,O
hormone,3546,O
induced,3546,O
by,3546,O
all,3546,O
3,3546,O
stimuli,3546,O
is,3546,O
due,3546,O
to,3546,O
an,3546,O
active,3546,O
cell,3546,O
process,3546,O
requiring,3546,O
a,3546,O
physiologic,3546,O
extracellular,3546,O
pH,3546,O
and,3546,O
is,3546,O
not,3546,O
produced,3546,O
by,3546,O
nonspecific,3546,O
cell,3546,O
toxicity,3546,O
.,3546,O
The,3547,O
data,3547,O
suggest,3547,O
hyposmolarity,3547,O
and,3547,O
high,3547,O
K+,3547,B-CHEMICAL
may,3547,O
share,3547,O
some,3547,O
similarities,3547,O
in,3547,O
their,3547,O
mechanism,3547,O
of,3547,O
stimulating,3547,O
secretion,3547,O
",",3547,O
which,3547,O
is,3547,O
different,3547,O
from,3547,O
that,3547,O
of,3547,O
TRH,3547,B-GENE-Y
.,3547,O
Use,3548,O
of,3548,O
(,3548,O
Gyro,3548,O
),3548,O
Gy,3548,O
and,3548,O
spermine,3548,B-GENE-Y
synthase,3548,I-GENE-Y
transgenic,3548,O
mice,3548,O
to,3548,O
study,3548,O
functions,3548,O
of,3548,O
spermine,3548,B-CHEMICAL
.,3548,O
The,3549,O
polyamines,3549,B-CHEMICAL
putrescine,3549,B-CHEMICAL
",",3549,O
spermidine,3549,B-CHEMICAL
",",3549,O
and,3549,O
spermine,3549,B-CHEMICAL
are,3549,O
essential,3549,O
for,3549,O
mammalian,3549,O
cell,3549,O
growth,3549,O
",",3549,O
-differentiation,3549,O
",",3549,O
and,3549,O
cell,3549,O
death,3549,O
and,3549,O
have,3549,O
important,3549,O
physiological,3549,O
roles,3549,O
in,3549,O
all,3549,O
tissues,3549,O
.,3549,O
Many,3550,O
of,3550,O
the,3550,O
properties,3550,O
of,3550,O
polyamines,3550,B-CHEMICAL
that,3550,O
can,3550,O
be,3550,O
demonstrated,3550,O
in,3550,O
vitro,3550,O
are,3550,O
common,3550,O
to,3550,O
all,3550,O
three,3550,O
molecules,3550,O
with,3550,O
differences,3550,O
only,3550,O
in,3550,O
potency,3550,O
.,3550,O
Loss,3551,O
of,3551,O
any,3551,O
of,3551,O
the,3551,O
enzymes,3551,O
needed,3551,O
to,3551,O
make,3551,O
either,3551,O
putrescine,3551,B-CHEMICAL
or,3551,O
spermidine,3551,B-CHEMICAL
(,3551,O
which,3551,O
also,3551,O
-prevent,3551,O
the,3551,O
production,3551,O
of,3551,O
spermine,3551,B-CHEMICAL
),3551,O
is,3551,O
lethal,3551,O
",",3551,O
but,3551,O
male,3551,O
mice,3551,O
lacking,3551,O
spermine,3551,B-GENE-Y
synthase,3551,I-GENE-Y
(,3551,O
SpmS,3551,B-GENE-Y
),3551,O
due,3551,O
to,3551,O
a,3551,O
deletion,3551,O
of,3551,O
part,3551,O
of,3551,O
the,3551,O
X,3551,O
chromosome,3551,O
are,3551,O
viable,3551,O
on,3551,O
the,3551,O
B6C3H,3551,O
background,3551,O
.,3551,O
These,3552,O
mice,3552,O
are,3552,O
termed,3552,O
Gyro,3552,O
(,3552,O
Gy,3552,O
),3552,O
due,3552,O
to,3552,O
their,3552,O
circling,3552,O
behavior,3552,O
.,3552,O
They,3553,O
have,3553,O
a,3553,O
variety,3553,O
of,3553,O
abnormalities,3553,O
including,3553,O
deafness,3553,O
",",3553,O
neurological,3553,O
problems,3553,O
",",3553,O
small,3553,O
size,3553,O
",",3553,O
and,3553,O
a,3553,O
tendency,3553,O
to,3553,O
early,3553,O
death,3553,O
.,3553,O
They,3554,O
can,3554,O
therefore,3554,O
be,3554,O
used,3554,O
to,3554,O
evaluate,3554,O
the,3554,O
physiological,3554,O
function,3554,O
(,3554,O
s,3554,O
),3554,O
uniquely,3554,O
provided,3554,O
by,3554,O
spermine,3554,B-CHEMICAL
.,3554,O
They,3555,O
also,3555,O
provide,3555,O
a,3555,O
potential,3555,O
animal,3555,O
model,3555,O
for,3555,O
Snyder-Robinson,3555,O
syndrome,3555,O
(,3555,O
SRS,3555,O
),3555,O
",",3555,O
a,3555,O
rare,3555,O
human,3555,O
inherited,3555,O
disease,3555,O
due,3555,O
to,3555,O
a,3555,O
loss,3555,O
of,3555,O
SpmS,3555,B-GENE-Y
activity,3555,O
.,3555,O
An,3556,O
essential,3556,O
control,3556,O
in,3556,O
experiments,3556,O
using,3556,O
Gy,3556,O
mice,3556,O
is,3556,O
to,3556,O
demonstrate,3556,O
that,3556,O
the,3556,O
abnormal,3556,O
phenotypes,3556,O
exhibited,3556,O
by,3556,O
these,3556,O
mice,3556,O
are,3556,O
abolished,3556,O
by,3556,O
providing,3556,O
replacement,3556,O
spermine,3556,B-CHEMICAL
and,3556,O
this,3556,O
can,3556,O
be,3556,O
accomplished,3556,O
by,3556,O
breeding,3556,O
with,3556,O
CAG-SMS,3556,O
mice,3556,O
that,3556,O
express,3556,O
SpmS,3556,B-GENE-Y
from,3556,O
a,3556,O
ubiquitous,3556,O
promoter,3556,O
.,3556,O
Techniques,3557,O
for,3557,O
identifying,3557,O
",",3557,O
characterizing,3557,O
",",3557,O
and,3557,O
using,3557,O
these,3557,O
mouse,3557,O
strains,3557,O
and,3557,O
limitations,3557,O
of,3557,O
this,3557,O
approach,3557,O
are,3557,O
described,3557,O
in,3557,O
this,3557,O
chapter,3557,O
.,3557,O
Cabozantinib,3558,B-CHEMICAL
(,3558,O
XL184,3558,B-CHEMICAL
),3558,O
",",3558,O
a,3558,O
novel,3558,O
MET,3558,B-GENE-Y
and,3558,O
VEGFR2,3558,B-GENE-Y
inhibitor,3558,O
",",3558,O
simultaneously,3558,O
suppresses,3558,O
metastasis,3558,O
",",3558,O
angiogenesis,3558,O
",",3558,O
and,3558,O
tumor,3558,O
growth,3558,O
.,3558,O
The,3559,O
signaling,3559,O
pathway,3559,O
of,3559,O
the,3559,O
receptor,3559,B-GENE-Y
tyrosine,3559,I-GENE-Y
kinase,3559,I-GENE-Y
MET,3559,I-GENE-Y
and,3559,O
its,3559,O
ligand,3559,O
hepatocyte,3559,B-GENE-Y
growth,3559,I-GENE-Y
factor,3559,I-GENE-Y
(,3559,O
HGF,3559,B-GENE-Y
),3559,O
is,3559,O
important,3559,O
for,3559,O
cell,3559,O
growth,3559,O
",",3559,O
survival,3559,O
",",3559,O
and,3559,O
motility,3559,O
and,3559,O
is,3559,O
functionally,3559,O
linked,3559,O
to,3559,O
the,3559,O
signaling,3559,O
pathway,3559,O
of,3559,O
VEGF,3559,B-GENE-Y
",",3559,O
which,3559,O
is,3559,O
widely,3559,O
recognized,3559,O
as,3559,O
a,3559,O
key,3559,O
effector,3559,O
in,3559,O
angiogenesis,3559,O
and,3559,O
cancer,3559,O
progression,3559,O
.,3559,O
Dysregulation,3560,O
of,3560,O
the,3560,O
MET/VEGF,3560,B-GENE-Y
axis,3560,O
is,3560,O
found,3560,O
in,3560,O
a,3560,O
number,3560,O
of,3560,O
human,3560,O
malignancies,3560,O
and,3560,O
has,3560,O
been,3560,O
associated,3560,O
with,3560,O
tumorigenesis,3560,O
.,3560,O
Cabozantinib,3561,B-CHEMICAL
(,3561,O
XL184,3561,B-CHEMICAL
),3561,O
is,3561,O
a,3561,O
small-molecule,3561,O
kinase,3561,B-GENE-N
inhibitor,3561,O
with,3561,O
potent,3561,O
activity,3561,O
toward,3561,O
MET,3561,B-GENE-Y
and,3561,O
VEGF,3561,B-GENE-Y
receptor,3561,I-GENE-Y
2,3561,I-GENE-Y
(,3561,O
VEGFR2,3561,B-GENE-Y
),3561,O
",",3561,O
as,3561,O
well,3561,O
as,3561,O
a,3561,O
number,3561,O
of,3561,O
other,3561,O
receptor,3561,B-GENE-N
tyrosine,3561,B-CHEMICAL
kinases,3561,I-GENE-N
that,3561,O
have,3561,O
also,3561,O
been,3561,O
implicated,3561,O
in,3561,O
tumor,3561,O
pathobiology,3561,O
",",3561,O
including,3561,O
RET,3561,B-GENE-Y
",",3561,O
KIT,3561,B-GENE-Y
",",3561,O
AXL,3561,B-GENE-Y
",",3561,O
and,3561,O
FLT3,3561,B-GENE-Y
.,3561,O
Treatment,3562,O
with,3562,O
cabozantinib,3562,B-CHEMICAL
inhibited,3562,O
MET,3562,B-GENE-Y
and,3562,O
VEGFR2,3562,B-GENE-Y
phosphorylation,3562,O
in,3562,O
vitro,3562,O
and,3562,O
in,3562,O
tumor,3562,O
models,3562,O
in,3562,O
vivo,3562,O
and,3562,O
led,3562,O
to,3562,O
significant,3562,O
reductions,3562,O
in,3562,O
cell,3562,O
invasion,3562,O
in,3562,O
vitro,3562,O
.,3562,O
In,3563,O
mouse,3563,O
models,3563,O
",",3563,O
cabozantinib,3563,B-CHEMICAL
dramatically,3563,O
altered,3563,O
tumor,3563,O
pathology,3563,O
",",3563,O
resulting,3563,O
in,3563,O
decreased,3563,O
tumor,3563,O
and,3563,O
endothelial,3563,O
cell,3563,O
proliferation,3563,O
coupled,3563,O
with,3563,O
increased,3563,O
apoptosis,3563,O
and,3563,O
dose-dependent,3563,O
inhibition,3563,O
of,3563,O
tumor,3563,O
growth,3563,O
in,3563,O
breast,3563,O
",",3563,O
lung,3563,O
",",3563,O
and,3563,O
glioma,3563,O
tumor,3563,O
models,3563,O
.,3563,O
Importantly,3564,O
",",3564,O
treatment,3564,O
with,3564,O
cabozantinib,3564,B-CHEMICAL
did,3564,O
not,3564,O
increase,3564,O
lung,3564,O
tumor,3564,O
burden,3564,O
in,3564,O
an,3564,O
experimental,3564,O
model,3564,O
of,3564,O
metastasis,3564,O
",",3564,O
which,3564,O
has,3564,O
been,3564,O
observed,3564,O
with,3564,O
inhibitors,3564,O
of,3564,O
VEGF,3564,B-GENE-Y
signaling,3564,O
that,3564,O
do,3564,O
not,3564,O
target,3564,O
MET,3564,B-GENE-Y
.,3564,O
Collectively,3565,O
",",3565,O
these,3565,O
data,3565,O
suggest,3565,O
that,3565,O
cabozantinib,3565,B-CHEMICAL
is,3565,O
a,3565,O
promising,3565,O
agent,3565,O
for,3565,O
inhibiting,3565,O
tumor,3565,O
angiogenesis,3565,O
and,3565,O
metastasis,3565,O
in,3565,O
cancers,3565,O
with,3565,O
dysregulated,3565,O
MET,3565,B-GENE-Y
and,3565,O
VEGFR,3565,B-GENE-N
signaling,3565,O
.,3565,O
Thiocolchicoside,3566,B-CHEMICAL
suppresses,3566,O
osteoclastogenesis,3566,O
induced,3566,O
by,3566,O
RANKL,3566,B-GENE-Y
and,3566,O
cancer,3566,O
cells,3566,O
through,3566,O
inhibition,3566,O
of,3566,O
inflammatory,3566,O
pathways,3566,O
:,3566,O
a,3566,O
new,3566,O
use,3566,O
for,3566,O
an,3566,O
old,3566,O
drug,3566,O
.,3566,O
BACKGROUND,3567,O
AND,3567,O
PURPOSE,3567,O
:,3567,O
Most,3567,O
patients,3567,O
with,3567,O
cancer,3567,O
die,3567,O
not,3567,O
because,3567,O
of,3567,O
the,3567,O
tumour,3567,O
in,3567,O
the,3567,O
primary,3567,O
site,3567,O
",",3567,O
but,3567,O
because,3567,O
it,3567,O
has,3567,O
spread,3567,O
to,3567,O
other,3567,O
sites,3567,O
.,3567,O
Common,3568,O
tumours,3568,O
",",3568,O
such,3568,O
as,3568,O
breast,3568,O
",",3568,O
multiple,3568,O
myeloma,3568,O
",",3568,O
and,3568,O
prostate,3568,O
tumours,3568,O
",",3568,O
frequently,3568,O
metastasize,3568,O
to,3568,O
the,3568,O
bone,3568,O
.,3568,O
To,3569,O
search,3569,O
for,3569,O
an,3569,O
inhibitor,3569,O
of,3569,O
cancer-induced,3569,O
bone,3569,O
loss,3569,O
",",3569,O
we,3569,O
investigated,3569,O
the,3569,O
effect,3569,O
of,3569,O
thiocolchicoside,3569,B-CHEMICAL
",",3569,O
a,3569,O
semi-synthetic,3569,O
colchicoside,3569,B-CHEMICAL
derived,3569,O
from,3569,O
the,3569,O
plant,3569,O
Gloriosa,3569,O
superba,3569,O
and,3569,O
clinically,3569,O
used,3569,O
as,3569,O
a,3569,O
muscle,3569,O
relaxant,3569,O
",",3569,O
on,3569,O
osteoclastogenesis,3569,O
induced,3569,O
by,3569,O
receptor,3569,B-GENE-Y
activator,3569,I-GENE-Y
of,3569,I-GENE-Y
NF-kappaB,3569,I-GENE-Y
ligand,3569,I-GENE-Y
(,3569,O
RANKL,3569,B-GENE-Y
),3569,O
and,3569,O
tumour,3569,O
cells,3569,O
.,3569,O
EXPERIMENTAL,3570,O
APPROACH,3570,O
:,3570,O
We,3570,O
used,3570,O
RAW,3570,O
264.7,3570,O
(,3570,O
murine,3570,O
macrophage,3570,O
),3570,O
cells,3570,O
",",3570,O
a,3570,O
well-established,3570,O
system,3570,O
for,3570,O
osteoclastogenesis,3570,O
",",3570,O
and,3570,O
evaluated,3570,O
the,3570,O
effect,3570,O
of,3570,O
thiocolchicoside,3570,B-CHEMICAL
on,3570,O
RANKL-induced,3570,B-GENE-Y
NF-kappaB,3570,B-GENE-N
signalling,3570,O
and,3570,O
osteoclastogenesis,3570,O
as,3570,O
well,3570,O
as,3570,O
on,3570,O
osteoclastogenesis,3570,O
induced,3570,O
by,3570,O
tumour,3570,O
cells,3570,O
.,3570,O
KEY,3571,O
RESULTS,3571,O
:,3571,O
Thiocolchicoside,3571,B-CHEMICAL
suppressed,3571,O
osteoclastogenesis,3571,O
induced,3571,O
by,3571,O
RANKL,3571,B-GENE-Y
",",3571,O
and,3571,O
by,3571,O
breast,3571,O
cancer,3571,O
and,3571,O
multiple,3571,O
myeloma,3571,O
cells,3571,O
.,3571,O
Inhibition,3572,O
of,3572,O
the,3572,O
NF-kappaB,3572,B-GENE-N
pathway,3572,O
was,3572,O
responsible,3572,O
for,3572,O
this,3572,O
effect,3572,O
since,3572,O
the,3572,O
colchicoside,3572,B-CHEMICAL
inhibited,3572,O
RANKL-induced,3572,B-GENE-Y
NF-kappaB,3572,B-GENE-N
activation,3572,O
",",3572,O
activation,3572,O
of,3572,O
IkappaB,3572,B-GENE-N
kinase,3572,I-GENE-N
(,3572,O
IKK,3572,B-GENE-N
),3572,O
and,3572,O
suppressed,3572,O
inhibitor,3572,O
of,3572,O
NF-kappaBalpha,3572,B-GENE-Y
(,3572,O
IkappaBalpha,3572,B-GENE-Y
),3572,O
phosphorylation,3572,O
and,3572,O
degradation,3572,O
",",3572,O
an,3572,O
inhibitor,3572,O
of,3572,O
NF-kappaB,3572,B-GENE-N
.,3572,O
Furthermore,3573,O
",",3573,O
an,3573,O
inhibitor,3573,O
of,3573,O
the,3573,O
IkappaBalpha,3573,B-GENE-Y
kinase,3573,B-GENE-N
gamma,3573,O
or,3573,O
NF-kappaB,3573,B-GENE-N
essential,3573,O
modulator,3573,O
",",3573,O
the,3573,O
regulatory,3573,O
component,3573,O
of,3573,O
the,3573,O
IKK,3573,B-GENE-N
complex,3573,O
",",3573,O
demonstrated,3573,O
that,3573,O
the,3573,O
NF-kappaB,3573,B-GENE-N
signalling,3573,O
pathway,3573,O
is,3573,O
mandatory,3573,O
for,3573,O
osteoclastogenesis,3573,O
induced,3573,O
by,3573,O
RANKL,3573,B-GENE-Y
.,3573,O
CONCLUSIONS,3574,O
AND,3574,O
IMPLICATIONS,3574,O
:,3574,O
Together,3574,O
",",3574,O
these,3574,O
data,3574,O
suggest,3574,O
that,3574,O
thiocolchicoside,3574,B-CHEMICAL
significantly,3574,O
suppressed,3574,O
osteoclastogenesis,3574,O
induced,3574,O
by,3574,O
RANKL,3574,B-GENE-Y
and,3574,O
tumour,3574,O
cells,3574,O
via,3574,O
the,3574,O
NF-kappaB,3574,B-GENE-N
signalling,3574,O
pathway,3574,O
.,3574,O
Thus,3575,O
",",3575,O
thiocolchicoside,3575,B-CHEMICAL
",",3575,O
a,3575,O
drug,3575,O
that,3575,O
has,3575,O
been,3575,O
used,3575,O
for,3575,O
almost,3575,O
half,3575,O
a,3575,O
century,3575,O
to,3575,O
treat,3575,O
muscle,3575,O
pain,3575,O
",",3575,O
may,3575,O
also,3575,O
be,3575,O
considered,3575,O
as,3575,O
a,3575,O
new,3575,O
treatment,3575,O
for,3575,O
bone,3575,O
loss,3575,O
.,3575,O
Endothelial,3576,B-GENE-Y
nitric,3576,B-CHEMICAL
oxide,3576,I-CHEMICAL
synthase,3576,I-GENE-Y
genotypes,3576,O
and,3576,O
haplotypes,3576,O
modify,3576,O
the,3576,O
responses,3576,O
to,3576,O
sildenafil,3576,B-CHEMICAL
in,3576,O
patients,3576,O
with,3576,O
erectile,3576,O
dysfunction,3576,O
.,3576,O
Erectile,3577,O
dysfunction,3577,O
(,3577,O
ED,3577,O
),3577,O
is,3577,O
usually,3577,O
treated,3577,O
with,3577,O
sildenafil,3577,B-CHEMICAL
.,3577,O
Although,3578,O
genetic,3578,O
polymorphisms,3578,O
in,3578,O
the,3578,O
endothelial,3578,B-GENE-Y
nitric,3578,I-GENE-Y
oxide,3578,I-GENE-Y
synthase,3578,I-GENE-Y
(,3578,O
eNOS,3578,B-GENE-Y
),3578,O
gene,3578,O
may,3578,O
impair,3578,O
endogenous,3578,O
NO,3578,B-CHEMICAL
formation,3578,O
",",3578,O
there,3578,O
is,3578,O
little,3578,O
information,3578,O
about,3578,O
how,3578,O
eNOS,3578,B-GENE-Y
polymorphisms,3578,O
and,3578,O
haplotypes,3578,O
affect,3578,O
the,3578,O
responses,3578,O
to,3578,O
sildenafil,3578,B-CHEMICAL
.,3578,O
We,3579,O
studied,3579,O
118,3579,O
patients,3579,O
;,3579,O
63,3579,O
patients,3579,O
had,3579,O
ED,3579,O
secondary,3579,O
to,3579,O
radical,3579,O
prostatectomy,3579,O
(,3579,O
PED,3579,O
),3579,O
and,3579,O
55,3579,O
had,3579,O
organic,3579,O
",",3579,O
clinical,3579,O
ED,3579,O
.,3579,O
eNOS,3580,B-GENE-Y
genotypes,3580,O
for,3580,O
three,3580,O
eNOS,3580,B-GENE-Y
polymorphisms,3580,O
(,3580,O
T,3580,O
(,3580,O
-786,3580,O
),3580,O
C,3580,O
",",3580,O
rs2070744,3580,O
;,3580,O
a,3580,O
variable,3580,O
number,3580,O
of,3580,O
tandem,3580,O
repeats,3580,O
(,3580,O
VNTR,3580,O
),3580,O
in,3580,O
intron,3580,O
4,3580,O
;,3580,O
and,3580,O
Glu298Asp,3580,O
",",3580,O
rs1799983,3580,O
),3580,O
were,3580,O
determined,3580,O
",",3580,O
and,3580,O
eNOS,3580,B-GENE-Y
haplotypes,3580,O
were,3580,O
estimated,3580,O
using,3580,O
PHASE,3580,O
2.1,3580,O
.,3580,O
The,3581,O
clinical,3581,O
responses,3581,O
to,3581,O
sildenafil,3581,B-CHEMICAL
were,3581,O
evaluated,3581,O
and,3581,O
the,3581,O
patients,3581,O
were,3581,O
classified,3581,O
as,3581,O
good,3581,O
responders,3581,O
(,3581,O
GR,3581,O
),3581,O
or,3581,O
poor,3581,O
responders,3581,O
(,3581,O
PR,3581,O
),3581,O
when,3581,O
their,3581,O
changes,3581,O
in,3581,O
five-item,3581,O
version,3581,O
of,3581,O
International,3581,O
Index,3581,O
for,3581,O
Erectile,3581,O
Function,3581,O
questionnaire,3581,O
were,3581,O
above,3581,O
or,3581,O
below,3581,O
the,3581,O
median,3581,O
value,3581,O
.,3581,O
The,3582,O
TC/CC,3582,O
genotypes,3582,O
and,3582,O
the,3582,O
C,3582,O
allele,3582,O
for,3582,O
the,3582,O
T,3582,O
(,3582,O
-786,3582,O
),3582,O
C,3582,O
polymorphism,3582,O
were,3582,O
more,3582,O
common,3582,O
in,3582,O
GR,3582,O
",",3582,O
compared,3582,O
with,3582,O
PR,3582,O
patients,3582,O
with,3582,O
PED,3582,O
.,3582,O
However,3583,O
",",3583,O
the,3583,O
4b4a/4a4a,3583,O
genotypes,3583,O
and,3583,O
the,3583,O
4a,3583,O
allele,3583,O
for,3583,O
the,3583,O
VNTR,3583,O
polymorphism,3583,O
in,3583,O
intron,3583,O
4,3583,O
were,3583,O
more,3583,O
common,3583,O
in,3583,O
GR,3583,O
",",3583,O
compared,3583,O
with,3583,O
PR,3583,O
patients,3583,O
with,3583,O
clinical,3583,O
ED,3583,O
.,3583,O
The,3584,O
C-4a-Glu,3584,O
haplotype,3584,O
was,3584,O
more,3584,O
common,3584,O
in,3584,O
GR,3584,O
than,3584,O
in,3584,O
PR,3584,O
patients,3584,O
with,3584,O
PED,3584,O
.,3584,O
Conversely,3585,O
",",3585,O
the,3585,O
T-4b-Asp,3585,O
haplotype,3585,O
was,3585,O
less,3585,O
common,3585,O
in,3585,O
GR,3585,O
than,3585,O
in,3585,O
PR,3585,O
patients,3585,O
with,3585,O
PED,3585,O
.,3585,O
No,3586,O
other,3586,O
significant,3586,O
differences,3586,O
were,3586,O
found,3586,O
.,3586,O
Our,3587,O
findings,3587,O
show,3587,O
evidence,3587,O
that,3587,O
eNOS,3587,B-GENE-Y
polymorphisms,3587,O
affect,3587,O
the,3587,O
responses,3587,O
of,3587,O
PED,3587,O
and,3587,O
clinical,3587,O
ED,3587,O
patients,3587,O
to,3587,O
sildenafil,3587,B-CHEMICAL
.,3587,O
Mercury,3588,B-CHEMICAL
induces,3588,O
the,3588,O
expression,3588,O
of,3588,O
cyclooxygenase-2,3588,B-GENE-Y
and,3588,O
inducible,3588,B-GENE-Y
nitric,3588,B-CHEMICAL
oxide,3588,I-CHEMICAL
synthase,3588,I-GENE-Y
.,3588,O
Nuclear,3589,B-GENE-N
factor-κB,3589,I-GENE-N
(,3589,O
NF-κB,3589,B-GENE-N
),3589,O
is,3589,O
a,3589,O
transcription,3589,O
factor,3589,O
that,3589,O
mediates,3589,O
the,3589,O
inducible,3589,O
expression,3589,O
of,3589,O
a,3589,O
variety,3589,O
of,3589,O
genes,3589,O
involved,3589,O
in,3589,O
immune,3589,O
and,3589,O
inflammatory,3589,O
responses,3589,O
.,3589,O
NF-κB,3590,B-GENE-N
activation,3590,O
induces,3590,O
numerous,3590,O
proinflammatory,3590,O
gene,3590,O
products,3590,O
including,3590,O
cytokines,3590,B-GENE-N
",",3590,O
cyclooxygenase-2,3590,B-GENE-Y
(,3590,O
COX-2,3590,B-GENE-Y
),3590,O
",",3590,O
and,3590,O
inducible,3590,B-GENE-Y
nitric,3590,B-CHEMICAL
oxide,3590,I-CHEMICAL
synthase,3590,I-GENE-Y
(,3590,O
iNOS,3590,B-GENE-Y
),3590,O
.,3590,O
The,3591,O
divalent,3591,O
heavy,3591,O
metal,3591,O
mercury,3591,B-CHEMICAL
has,3591,O
been,3591,O
used,3591,O
for,3591,O
thousands,3591,O
of,3591,O
years,3591,O
.,3591,O
Although,3592,O
mercury,3592,B-CHEMICAL
is,3592,O
clearly,3592,O
toxic,3592,O
to,3592,O
most,3592,O
mammalian,3592,O
organ,3592,O
systems,3592,O
",",3592,O
especially,3592,O
the,3592,O
immune,3592,O
system,3592,O
",",3592,O
exposure,3592,O
has,3592,O
still,3592,O
increased,3592,O
in,3592,O
some,3592,O
areas,3592,O
of,3592,O
the,3592,O
world,3592,O
.,3592,O
However,3593,O
",",3593,O
the,3593,O
underlying,3593,O
toxic,3593,O
mechanism,3593,O
is,3593,O
not,3593,O
clearly,3593,O
identified,3593,O
.,3593,O
Here,3594,O
",",3594,O
we,3594,O
report,3594,O
biochemical,3594,O
evidence,3594,O
that,3594,O
mercury,3594,B-CHEMICAL
alone,3594,O
induces,3594,O
NF-κB,3594,B-GENE-N
activation,3594,O
",",3594,O
resulting,3594,O
in,3594,O
the,3594,O
induced,3594,O
expression,3594,O
of,3594,O
COX-2,3594,B-GENE-Y
and,3594,O
iNOS,3594,B-GENE-Y
.,3594,O
The,3595,O
results,3595,O
suggest,3595,O
that,3595,O
mercury,3595,B-CHEMICAL
can,3595,O
induce,3595,O
inflammatory,3595,O
diseases,3595,O
by,3595,O
lowering,3595,O
host,3595,O
defense,3595,O
.,3595,O
Pharmacological,3596,O
evidence,3596,O
of,3596,O
functional,3596,O
inhibitory,3596,O
metabotrophic,3596,B-GENE-N
glutamate,3596,I-GENE-N
receptors,3596,I-GENE-N
on,3596,O
mouse,3596,O
arousal-related,3596,O
cholinergic,3596,O
laterodorsal,3596,O
tegmental,3596,O
neurons,3596,O
.,3596,O
Cholinergic,3597,O
neurons,3597,O
of,3597,O
the,3597,O
pontine,3597,O
laterodorsal,3597,O
tegmentum,3597,O
(,3597,O
LDT,3597,O
),3597,O
are,3597,O
importantly,3597,O
involved,3597,O
in,3597,O
neurobiological,3597,O
mechanisms,3597,O
governing,3597,O
states,3597,O
of,3597,O
arousal,3597,O
such,3597,O
as,3597,O
sleep,3597,O
and,3597,O
wakefulness,3597,O
as,3597,O
well,3597,O
as,3597,O
other,3597,O
appetitive,3597,O
behaviors,3597,O
",",3597,O
such,3597,O
as,3597,O
drug-seeking,3597,O
.,3597,O
Accordingly,3598,O
",",3598,O
mechanisms,3598,O
controlling,3598,O
their,3598,O
excitability,3598,O
are,3598,O
important,3598,O
to,3598,O
elucidate,3598,O
if,3598,O
we,3598,O
are,3598,O
to,3598,O
understand,3598,O
how,3598,O
these,3598,O
LDT,3598,O
neurons,3598,O
generate,3598,O
arousal,3598,O
states,3598,O
.,3598,O
Glutamate,3599,B-CHEMICAL
mediates,3599,O
the,3599,O
vast,3599,O
majority,3599,O
of,3599,O
excitatory,3599,O
synaptic,3599,O
transmission,3599,O
in,3599,O
the,3599,O
vertebrate,3599,O
CNS,3599,O
and,3599,O
while,3599,O
presence,3599,O
of,3599,O
glutamate,3599,B-CHEMICAL
input,3599,O
in,3599,O
the,3599,O
LDT,3599,O
has,3599,O
been,3599,O
shown,3599,O
and,3599,O
ionotropic,3599,O
responses,3599,O
to,3599,O
glutamate,3599,B-CHEMICAL
have,3599,O
been,3599,O
reported,3599,O
in,3599,O
the,3599,O
LDT,3599,O
",",3599,O
characterization,3599,O
of,3599,O
metabotropic,3599,O
responses,3599,O
is,3599,O
lacking,3599,O
.,3599,O
Therefore,3600,O
",",3600,O
electrophysiological,3600,O
responses,3600,O
and,3600,O
changes,3600,O
in,3600,O
levels,3600,O
of,3600,O
intracellular,3600,O
Ca,3600,B-CHEMICAL
(,3600,I-CHEMICAL
2+,3600,I-CHEMICAL
),3600,I-CHEMICAL
in,3600,O
mouse,3600,O
cholinergic,3600,O
LDT,3600,O
neurons,3600,O
following,3600,O
application,3600,O
of,3600,O
specific,3600,O
mGluR,3600,B-GENE-N
agonists,3600,O
and,3600,O
antagonists,3600,O
were,3600,O
examined,3600,O
.,3600,O
Unexpectedly,3601,O
",",3601,O
both,3601,O
the,3601,O
mGluR,3601,B-GENE-Y
(,3601,I-GENE-Y
5,3601,I-GENE-Y
),3601,I-GENE-Y
specific,3601,O
agonist,3601,O
",",3601,O
CHPG,3601,B-CHEMICAL
",",3601,O
and,3601,O
the,3601,O
group,3601,B-GENE-N
II,3601,I-GENE-N
mGluR,3601,I-GENE-N
(,3601,O
mGlu,3601,B-GENE-N
(,3601,I-GENE-N
2/3,3601,I-GENE-N
),3601,I-GENE-N
),3601,O
agonist,3601,O
",",3601,O
LY379268,3601,B-CHEMICAL
(,3601,O
LY,3601,O
),3601,O
",",3601,O
induced,3601,O
a,3601,O
TTX-insensitive,3601,B-CHEMICAL
outward,3601,O
current/hyperpolarization,3601,O
.,3601,O
Both,3602,O
outward,3602,O
currents,3602,O
were,3602,O
significantly,3602,O
reduced,3602,O
by,3602,O
the,3602,O
mGluR,3602,B-GENE-N
antagonist,3602,O
MCPG,3602,B-CHEMICAL
and,3602,O
the,3602,O
CHPG-induced,3602,B-CHEMICAL
current,3602,O
was,3602,O
blocked,3602,O
by,3602,O
the,3602,O
specific,3602,O
mGluR,3602,B-GENE-Y
(,3602,I-GENE-Y
5,3602,I-GENE-Y
),3602,I-GENE-Y
antagonist,3602,O
MTEP,3602,B-CHEMICAL
.,3602,O
Concurrent,3603,O
Ca,3603,B-CHEMICAL
(,3603,I-CHEMICAL
2+,3603,I-CHEMICAL
),3603,I-CHEMICAL
imaging,3603,O
revealed,3603,O
that,3603,O
while,3603,O
CHPG,3603,B-CHEMICAL
actions,3603,O
did,3603,O
include,3603,O
release,3603,O
of,3603,O
Ca,3603,B-CHEMICAL
(,3603,I-CHEMICAL
2+,3603,I-CHEMICAL
),3603,I-CHEMICAL
from,3603,O
CPA/thapsigargin-sensitive,3603,B-CHEMICAL
intracellular,3603,O
stores,3603,O
",",3603,O
actions,3603,O
of,3603,O
LY,3603,O
did,3603,O
not,3603,O
.,3603,O
Both,3604,O
CHPG-,3604,B-CHEMICAL
and,3604,O
LY-induced,3604,O
outward,3604,O
currents,3604,O
were,3604,O
mediated,3604,O
by,3604,O
a,3604,O
TEA-sensitive,3604,B-CHEMICAL
potassium,3604,B-CHEMICAL
conductance,3604,O
.,3604,O
The,3605,O
large-conductance,3605,O
",",3605,O
Ca,3605,B-GENE-N
(,3605,I-GENE-N
2+,3605,I-GENE-N
),3605,I-GENE-N
-dependent,3605,I-GENE-N
potassium,3605,I-GENE-N
(,3605,I-GENE-N
BK,3605,I-GENE-N
),3605,I-GENE-N
channel,3605,I-GENE-N
blocker,3605,O
",",3605,O
iberiotoxin,3605,O
",",3605,O
attenuated,3605,O
CHPG,3605,B-CHEMICAL
actions,3605,O
.,3605,O
Consistent,3606,O
with,3606,O
actions,3606,O
on,3606,O
the,3606,O
BK,3606,O
conductance,3606,O
",",3606,O
CHPG,3606,B-CHEMICAL
enhanced,3606,O
the,3606,O
amplitude,3606,O
of,3606,O
the,3606,O
fast,3606,O
component,3606,O
of,3606,O
the,3606,O
after,3606,O
hyperpolarizing,3606,O
potential,3606,O
",",3606,O
concurrent,3606,O
with,3606,O
a,3606,O
reduction,3606,O
in,3606,O
the,3606,O
firing,3606,O
rate,3606,O
.,3606,O
We,3607,O
conclude,3607,O
that,3607,O
stimulation,3607,O
of,3607,O
mGluR,3607,B-GENE-Y
(,3607,I-GENE-Y
5,3607,I-GENE-Y
),3607,I-GENE-Y
and,3607,O
group,3607,O
II,3607,O
(,3607,O
mGluR,3607,B-GENE-N
(,3607,I-GENE-N
2/3,3607,I-GENE-N
),3607,I-GENE-N
),3607,O
elicits,3607,O
postsynaptically-mediated,3607,O
outward,3607,O
currents/hyperpolarizations,3607,O
in,3607,O
cholinergic,3607,O
LDT,3607,O
neurons,3607,O
.,3607,O
Effects,3608,O
of,3608,O
glutamatergic,3608,O
input,3608,O
would,3608,O
be,3608,O
",",3608,O
thus,3608,O
",",3608,O
expected,3608,O
not,3608,O
only,3608,O
to,3608,O
be,3608,O
excitation,3608,O
via,3608,O
stimulation,3608,O
of,3608,O
ionotropic,3608,B-GENE-N
glutamate,3608,I-GENE-N
receptors,3608,I-GENE-N
and,3608,O
mGluR,3608,B-GENE-Y
(,3608,I-GENE-Y
1,3608,I-GENE-Y
),3608,I-GENE-Y
",",3608,O
but,3608,O
also,3608,O
inhibition,3608,O
via,3608,O
actions,3608,O
at,3608,O
mGluR,3608,B-GENE-Y
(,3608,I-GENE-Y
5,3608,I-GENE-Y
),3608,I-GENE-Y
and,3608,O
mGluR,3608,B-GENE-N
(,3608,I-GENE-N
2/3,3608,I-GENE-N
),3608,I-GENE-N
on,3608,O
these,3608,O
neurons,3608,O
.,3608,O
As,3609,O
these,3609,O
two,3609,O
processes,3609,O
counteract,3609,O
each,3609,O
other,3609,O
",",3609,O
these,3609,O
surprising,3609,O
findings,3609,O
necessitate,3609,O
revision,3609,O
of,3609,O
predictions,3609,O
regarding,3609,O
the,3609,O
net,3609,O
level,3609,O
of,3609,O
excitation,3609,O
generated,3609,O
by,3609,O
glutamate,3609,B-CHEMICAL
input,3609,O
to,3609,O
cholinergic,3609,O
LDT,3609,O
cells,3609,O
and,3609,O
",",3609,O
by,3609,O
extension,3609,O
",",3609,O
the,3609,O
functional,3609,O
outcome,3609,O
of,3609,O
glutamate,3609,B-CHEMICAL
transmission,3609,O
on,3609,O
processes,3609,O
which,3609,O
these,3609,O
neurons,3609,O
regulate,3609,O
.,3609,O
This,3610,O
article,3610,O
is,3610,O
part,3610,O
of,3610,O
a,3610,O
Special,3610,O
Issue,3610,O
entitled,3610,O
'Metabotropic,3610,O
Glutamate,3610,I-GENE-N
Receptors,3610,I-GENE-N
',3610,O
.,3610,O
A,3611,O
potent,3611,O
Chk1,3611,B-GENE-Y
inhibitor,3611,O
is,3611,O
selectively,3611,O
cytotoxic,3611,O
in,3611,O
melanomas,3611,O
with,3611,O
high,3611,O
levels,3611,O
of,3611,O
replicative,3611,O
stress,3611,O
.,3611,O
There,3612,O
are,3612,O
few,3612,O
effective,3612,O
treatments,3612,O
for,3612,O
metastatic,3612,O
melanoma,3612,O
.,3612,O
Checkpoint,3613,B-GENE-Y
kinase,3613,I-GENE-Y
1,3613,I-GENE-Y
(,3613,O
Chk1,3613,B-GENE-Y
),3613,O
inhibitors,3613,O
are,3613,O
being,3613,O
trialled,3613,O
for,3613,O
their,3613,O
efficacy,3613,O
in,3613,O
enhancing,3613,O
conventional,3613,O
chemotherapeutic,3613,O
agents,3613,O
",",3613,O
but,3613,O
their,3613,O
effectiveness,3613,O
as,3613,O
single,3613,O
agents,3613,O
is,3613,O
not,3613,O
known,3613,O
.,3613,O
We,3614,O
have,3614,O
examined,3614,O
the,3614,O
effectiveness,3614,O
of,3614,O
two,3614,O
novel,3614,O
Chk1,3614,B-GENE-Y
selective,3614,O
inhibitors,3614,O
",",3614,O
AR323,3614,B-CHEMICAL
and,3614,O
AR678,3614,B-CHEMICAL
",",3614,O
in,3614,O
a,3614,O
panel,3614,O
of,3614,O
melanoma,3614,O
cell,3614,O
lines,3614,O
and,3614,O
normal,3614,O
cell,3614,O
types,3614,O
.,3614,O
We,3615,O
demonstrate,3615,O
that,3615,O
these,3615,O
drugs,3615,O
display,3615,O
single-agent,3615,O
activity,3615,O
",",3615,O
with,3615,O
IC50s,3615,O
in,3615,O
the,3615,O
low,3615,O
nanomolar,3615,O
range,3615,O
.,3615,O
The,3616,O
drugs,3616,O
produce,3616,O
cytotoxic,3616,O
effects,3616,O
in,3616,O
cell,3616,O
lines,3616,O
that,3616,O
are,3616,O
most,3616,O
sensitive,3616,O
to,3616,O
these,3616,O
drugs,3616,O
",",3616,O
whereas,3616,O
normal,3616,O
cells,3616,O
are,3616,O
only,3616,O
sensitive,3616,O
to,3616,O
these,3616,O
drugs,3616,O
at,3616,O
the,3616,O
higher,3616,O
concentrations,3616,O
where,3616,O
they,3616,O
have,3616,O
cytostatic,3616,O
activity,3616,O
.,3616,O
The,3617,O
cytotoxic,3617,O
effect,3617,O
is,3617,O
the,3617,O
consequence,3617,O
of,3617,O
inhibition,3617,O
of,3617,O
S-phase,3617,O
Chk1,3617,B-GENE-Y
",",3617,O
which,3617,O
drives,3617,O
cells,3617,O
prematurely,3617,O
from,3617,O
late,3617,O
S,3617,O
phase,3617,O
into,3617,O
an,3617,O
aberrant,3617,O
mitosis,3617,O
and,3617,O
results,3617,O
in,3617,O
either,3617,O
failure,3617,O
of,3617,O
cytokinesis,3617,O
or,3617,O
cell,3617,O
death,3617,O
through,3617,O
an,3617,O
apoptotic,3617,O
mechanism,3617,O
.,3617,O
The,3618,O
sensitivity,3618,O
to,3618,O
the,3618,O
Chk1,3618,B-GENE-Y
inhibitors,3618,O
was,3618,O
correlated,3618,O
with,3618,O
the,3618,O
level,3618,O
of,3618,O
endogenous,3618,O
DNA,3618,O
damage,3618,O
indicating,3618,O
replicative,3618,O
stress,3618,O
.,3618,O
Chk1,3619,B-GENE-Y
inhibitors,3619,O
are,3619,O
viable,3619,O
single-agent,3619,O
therapies,3619,O
that,3619,O
target,3619,O
melanoma,3619,O
cells,3619,O
with,3619,O
high,3619,O
levels,3619,O
of,3619,O
endogenous,3619,O
DNA,3619,O
damage,3619,O
.,3619,O
This,3620,O
sensitivity,3620,O
suggests,3620,O
that,3620,O
Chk1,3620,B-GENE-Y
is,3620,O
a,3620,O
critical,3620,O
component,3620,O
of,3620,O
an,3620,O
adaptation,3620,O
to,3620,O
replicative,3620,O
stress,3620,O
in,3620,O
these,3620,O
cells,3620,O
.,3620,O
It,3621,O
also,3621,O
suggests,3621,O
that,3621,O
markers,3621,O
of,3621,O
DNA,3621,O
damage,3621,O
may,3621,O
be,3621,O
useful,3621,O
in,3621,O
identifying,3621,O
the,3621,O
melanomas,3621,O
and,3621,O
potentially,3621,O
other,3621,O
tumour,3621,O
types,3621,O
that,3621,O
are,3621,O
more,3621,O
likely,3621,O
to,3621,O
be,3621,O
sensitive,3621,O
to,3621,O
Chk1,3621,B-GENE-Y
inhibitors,3621,O
as,3621,O
single,3621,O
agents,3621,O
.,3621,O
Aspirin,3622,B-CHEMICAL
inhibits,3622,O
mTOR,3622,B-GENE-Y
signaling,3622,O
",",3622,O
activates,3622,O
AMP-activated,3622,B-GENE-N
protein,3622,I-GENE-N
kinase,3622,I-GENE-N
",",3622,O
and,3622,O
induces,3622,O
autophagy,3622,O
in,3622,O
colorectal,3622,O
cancer,3622,O
cells,3622,O
.,3622,O
BACKGROUND,3623,O
&,3623,O
AIMS,3623,O
:,3623,O
Aspirin,3623,B-CHEMICAL
reduces,3623,O
the,3623,O
incidence,3623,O
of,3623,O
and,3623,O
mortality,3623,O
from,3623,O
colorectal,3623,O
cancer,3623,O
(,3623,O
CRC,3623,O
),3623,O
by,3623,O
unknown,3623,O
mechanisms,3623,O
.,3623,O
Cancer,3624,O
cells,3624,O
have,3624,O
defects,3624,O
in,3624,O
signaling,3624,O
via,3624,O
the,3624,O
mechanistic,3624,B-GENE-Y
target,3624,I-GENE-Y
of,3624,I-GENE-Y
rapamycin,3624,I-GENE-Y
(,3624,O
mTOR,3624,B-GENE-Y
),3624,O
",",3624,O
which,3624,O
regulates,3624,O
proliferation,3624,O
.,3624,O
We,3625,O
investigated,3625,O
whether,3625,O
aspirin,3625,B-CHEMICAL
affects,3625,O
adenosine,3625,B-GENE-N
monophosphate-activated,3625,I-GENE-N
protein,3625,I-GENE-N
kinase,3625,I-GENE-N
(,3625,O
AMPK,3625,B-GENE-N
),3625,O
and,3625,O
mTOR,3625,B-GENE-Y
signaling,3625,O
in,3625,O
CRC,3625,O
cells,3625,O
.,3625,O
METHODS,3626,O
:,3626,O
The,3626,O
effects,3626,O
of,3626,O
aspirin,3626,B-CHEMICAL
on,3626,O
mTOR,3626,B-GENE-Y
signaling,3626,O
",",3626,O
the,3626,O
ribosomal,3626,B-GENE-Y
protein,3626,I-GENE-Y
S6,3626,I-GENE-Y
",",3626,O
S6,3626,B-GENE-Y
kinase,3626,I-GENE-Y
1,3626,I-GENE-Y
(,3626,O
S6K1,3626,B-GENE-Y
),3626,O
",",3626,O
and,3626,O
eukaryotic,3626,B-GENE-Y
translation,3626,I-GENE-Y
initiation,3626,I-GENE-Y
factor,3626,I-GENE-Y
4E,3626,I-GENE-Y
binding,3626,I-GENE-Y
protein,3626,I-GENE-Y
1,3626,I-GENE-Y
(,3626,O
4E-BP1,3626,B-GENE-Y
),3626,O
were,3626,O
examined,3626,O
in,3626,O
CRC,3626,O
cells,3626,O
by,3626,O
immunoblotting,3626,O
.,3626,O
Phosphorylation,3627,O
of,3627,O
AMPK,3627,B-GENE-N
was,3627,O
measured,3627,O
;,3627,O
the,3627,O
effects,3627,O
of,3627,O
loss,3627,O
of,3627,O
AMPKalpha,3627,B-GENE-N
on,3627,O
the,3627,O
aspirin-induced,3627,B-CHEMICAL
effects,3627,O
of,3627,O
mTOR,3627,B-GENE-Y
were,3627,O
determined,3627,O
using,3627,O
small,3627,O
interfering,3627,O
RNA,3627,O
(,3627,O
siRNA,3627,O
),3627,O
in,3627,O
CRC,3627,O
cells,3627,O
and,3627,O
in,3627,O
AMPK,3627,B-GENE-N
(,3627,I-GENE-N
alpha1/alpha2-/-,3627,O
),3627,O
mouse,3627,O
embryonic,3627,O
fibroblasts,3627,O
.,3627,O
LC3,3628,B-GENE-N
and,3628,O
ULK1,3628,B-GENE-Y
were,3628,O
used,3628,O
as,3628,O
markers,3628,O
of,3628,O
autophagy,3628,O
.,3628,O
We,3629,O
analyzed,3629,O
rectal,3629,O
mucosa,3629,O
samples,3629,O
from,3629,O
patients,3629,O
given,3629,O
600,3629,O
mg,3629,O
aspirin,3629,B-CHEMICAL
",",3629,O
once,3629,O
daily,3629,O
for,3629,O
1,3629,O
week,3629,O
.,3629,O
RESULTS,3630,O
:,3630,O
Aspirin,3630,B-CHEMICAL
reduced,3630,O
mTOR,3630,B-GENE-Y
signaling,3630,O
in,3630,O
CRC,3630,O
cells,3630,O
by,3630,O
inhibiting,3630,O
the,3630,O
mTOR,3630,B-GENE-Y
effectors,3630,O
S6K1,3630,B-GENE-Y
and,3630,O
4E-BP1,3630,B-GENE-Y
.,3630,O
Aspirin,3631,B-CHEMICAL
changed,3631,O
nucleotide,3631,O
ratios,3631,O
and,3631,O
activated,3631,O
AMPK,3631,B-GENE-N
in,3631,O
CRC,3631,O
cells,3631,O
.,3631,O
mTOR,3632,B-CHEMICAL
was,3632,O
still,3632,O
inhibited,3632,O
by,3632,O
aspirin,3632,B-CHEMICAL
in,3632,O
CRC,3632,O
cells,3632,O
after,3632,O
siRNA,3632,O
knockdown,3632,O
of,3632,O
AMPKalpha,3632,B-GENE-N
",",3632,O
indicating,3632,O
AMPK-dependent,3632,B-GENE-N
and,3632,O
AMPK-independent,3632,B-GENE-N
mechanisms,3632,O
of,3632,O
aspirin-induced,3632,B-CHEMICAL
inhibition,3632,O
of,3632,O
mTOR,3632,B-CHEMICAL
.,3632,O
Aspirin,3633,B-CHEMICAL
induced,3633,O
autophagy,3633,O
",",3633,O
a,3633,O
feature,3633,O
of,3633,O
mTOR,3633,B-CHEMICAL
inhibition,3633,O
.,3633,O
Aspirin,3634,B-CHEMICAL
and,3634,O
metformin,3634,B-CHEMICAL
(,3634,O
an,3634,O
activator,3634,O
of,3634,O
AMPK,3634,B-GENE-N
),3634,O
increased,3634,O
inhibition,3634,O
of,3634,O
mTOR,3634,B-GENE-Y
and,3634,O
Akt,3634,B-GENE-N
",",3634,O
as,3634,O
well,3634,O
as,3634,O
autophagy,3634,O
in,3634,O
CRC,3634,O
cells,3634,O
.,3634,O
Rectal,3635,O
mucosal,3635,O
samples,3635,O
from,3635,O
patients,3635,O
given,3635,O
aspirin,3635,B-CHEMICAL
had,3635,O
reduced,3635,O
phosphorylation,3635,O
of,3635,O
S6K1,3635,B-GENE-Y
and,3635,O
S6,3635,B-GENE-Y
.,3635,O
CONCLUSIONS,3636,O
:,3636,O
Aspirin,3636,B-CHEMICAL
is,3636,O
an,3636,O
inhibitor,3636,O
of,3636,O
mTOR,3636,B-GENE-Y
and,3636,O
an,3636,O
activator,3636,O
of,3636,O
AMPK,3636,B-GENE-N
",",3636,O
targeting,3636,O
regulators,3636,O
of,3636,O
intracellular,3636,O
energy,3636,O
homeostasis,3636,O
and,3636,O
metabolism,3636,O
.,3636,O
These,3637,O
could,3637,O
contribute,3637,O
to,3637,O
its,3637,O
protective,3637,O
effects,3637,O
against,3637,O
development,3637,O
of,3637,O
CRC,3637,O
.,3637,O
Oncogenic,3638,O
K-ras,3638,B-GENE-Y
expression,3638,O
is,3638,O
associated,3638,O
with,3638,O
derangement,3638,O
of,3638,O
the,3638,O
cAMP/PKA,3638,B-CHEMICAL
pathway,3638,O
and,3638,O
forskolin-reversible,3638,B-CHEMICAL
alterations,3638,O
of,3638,O
mitochondrial,3638,O
dynamics,3638,O
and,3638,O
respiration,3638,O
.,3638,O
The,3639,O
Warburg,3639,O
effect,3639,O
in,3639,O
cancer,3639,O
cells,3639,O
has,3639,O
been,3639,O
proposed,3639,O
to,3639,O
involve,3639,O
several,3639,O
mechanisms,3639,O
",",3639,O
including,3639,O
adaptation,3639,O
to,3639,O
hypoxia,3639,O
",",3639,O
oncogenes,3639,O
activation,3639,O
or,3639,O
loss,3639,O
of,3639,O
oncosuppressors,3639,O
and,3639,O
impaired,3639,O
mitochondrial,3639,O
function,3639,O
.,3639,O
In,3640,O
previous,3640,O
papers,3640,O
",",3640,O
it,3640,O
has,3640,O
been,3640,O
shown,3640,O
that,3640,O
K-ras,3640,B-GENE-Y
transformed,3640,O
mouse,3640,O
cells,3640,O
are,3640,O
much,3640,O
more,3640,O
sensitive,3640,O
as,3640,O
compared,3640,O
with,3640,O
normal,3640,O
cells,3640,O
to,3640,O
glucose,3640,B-CHEMICAL
withdrawal,3640,O
(,3640,O
undergoing,3640,O
apoptosis,3640,O
),3640,O
and,3640,O
present,3640,O
a,3640,O
high,3640,O
glycolytic,3640,O
rate,3640,O
and,3640,O
a,3640,O
strong,3640,O
reduction,3640,O
of,3640,O
mitochondrial,3640,B-GENE-N
complex,3640,I-GENE-N
I,3640,I-GENE-N
.,3640,O
Recent,3641,O
observations,3641,O
suggest,3641,O
that,3641,O
transformed,3641,O
cells,3641,O
have,3641,O
a,3641,O
derangement,3641,O
in,3641,O
the,3641,O
cyclic,3641,B-CHEMICAL
adenosine,3641,I-CHEMICAL
monophosphate/cAMP-dependent,3641,O
protein,3641,I-GENE-N
kinase,3641,I-GENE-N
(,3641,O
cAMP/PKA,3641,B-CHEMICAL
),3641,O
pathway,3641,O
",",3641,O
which,3641,O
is,3641,O
known,3641,O
to,3641,O
regulate,3641,O
several,3641,O
mitochondrial,3641,O
functions,3641,O
.,3641,O
Herein,3642,O
",",3642,O
the,3642,O
derangement,3642,O
of,3642,O
the,3642,O
cAMP/PKA,3642,B-CHEMICAL
pathway,3642,O
and,3642,O
its,3642,O
impact,3642,O
on,3642,O
transformation-linked,3642,O
changes,3642,O
of,3642,O
mitochondrial,3642,O
functions,3642,O
is,3642,O
investigated,3642,O
.,3642,O
Exogenous,3643,O
stimulation,3643,O
of,3643,O
PKA,3643,B-GENE-N
activity,3643,O
",",3643,O
achieved,3643,O
by,3643,O
forskolin,3643,B-CHEMICAL
treatment,3643,O
",",3643,O
protected,3643,O
K-ras-transformed,3643,B-GENE-Y
cells,3643,O
from,3643,O
apoptosis,3643,O
induced,3643,O
by,3643,O
glucose,3643,B-CHEMICAL
deprivation,3643,O
",",3643,O
enhanced,3643,O
complex,3643,B-GENE-N
I,3643,I-GENE-N
activity,3643,O
",",3643,O
intracellular,3643,O
adenosine,3643,B-CHEMICAL
triphosphate,3643,I-CHEMICAL
(,3643,O
ATP,3643,B-CHEMICAL
),3643,O
levels,3643,O
",",3643,O
mitochondrial,3643,O
fusion,3643,O
and,3643,O
decreased,3643,O
intracellular,3643,O
reactive,3643,O
oxygen,3643,B-CHEMICAL
species,3643,O
(,3643,O
ROS,3643,O
),3643,O
levels,3643,O
.,3643,O
Several,3644,O
of,3644,O
these,3644,O
effects,3644,O
were,3644,O
almost,3644,O
completely,3644,O
prevented,3644,O
by,3644,O
inhibiting,3644,O
the,3644,O
PKA,3644,B-GENE-N
activity,3644,O
.,3644,O
Short-time,3645,O
treatment,3645,O
with,3645,O
compounds,3645,O
favoring,3645,O
mitochondrial,3645,O
fusion,3645,O
strongly,3645,O
decreased,3645,O
the,3645,O
cellular,3645,O
ROS,3645,O
levels,3645,O
especially,3645,O
in,3645,O
transformed,3645,O
cells,3645,O
.,3645,O
These,3646,O
findings,3646,O
support,3646,O
the,3646,O
notion,3646,O
that,3646,O
glucose,3646,B-CHEMICAL
shortage-induced,3646,O
apoptosis,3646,O
",",3646,O
specific,3646,O
of,3646,O
K-ras-transformed,3646,B-GENE-Y
cells,3646,O
",",3646,O
is,3646,O
associated,3646,O
to,3646,O
a,3646,O
derangement,3646,O
of,3646,O
PKA,3646,B-GENE-N
signaling,3646,O
that,3646,O
leads,3646,O
to,3646,O
mitochondrial,3646,B-GENE-N
complex,3646,I-GENE-N
I,3646,I-GENE-N
decrease,3646,O
",",3646,O
reduction,3646,O
of,3646,O
ATP,3646,B-CHEMICAL
formation,3646,O
",",3646,O
prevalence,3646,O
of,3646,O
mitochondrial,3646,O
fission,3646,O
over,3646,O
fusion,3646,O
",",3646,O
and,3646,O
thereby,3646,O
opening,3646,O
new,3646,O
approaches,3646,O
for,3646,O
development,3646,O
of,3646,O
anticancer,3646,O
drugs,3646,O
.,3646,O
Berberine,3647,B-CHEMICAL
inhibits,3647,O
myofibroblast,3647,O
differentiation,3647,O
in,3647,O
nasal,3647,O
polyp-derived,3647,O
fibroblasts,3647,O
via,3647,O
the,3647,O
p38,3647,B-GENE-N
pathway,3647,O
.,3647,O
The,3648,O
purposes,3648,O
of,3648,O
this,3648,O
study,3648,O
were,3648,O
to,3648,O
determine,3648,O
whether,3648,O
berberine,3648,B-CHEMICAL
has,3648,O
any,3648,O
effect,3648,O
on,3648,O
phenotype,3648,O
changes,3648,O
and,3648,O
extracellular,3648,O
matrix,3648,O
(,3648,O
ECM,3648,O
),3648,O
production,3648,O
in,3648,O
nasal,3648,O
polyp-derived,3648,O
fibroblasts,3648,O
(,3648,O
NPDFs,3648,O
),3648,O
and,3648,O
to,3648,O
investigate,3648,O
the,3648,O
underlying,3648,O
molecular,3648,O
mechanism,3648,O
.,3648,O
NPDFs,3649,O
were,3649,O
pre-treated,3649,O
with,3649,O
berberine,3649,B-CHEMICAL
prior,3649,O
to,3649,O
induction,3649,O
by,3649,O
transforming,3649,B-GENE-Y
growth,3649,I-GENE-Y
factor,3649,I-GENE-Y
(,3649,I-GENE-Y
TGF,3649,I-GENE-Y
),3649,I-GENE-Y
-β1,3649,I-GENE-Y
.,3649,O
The,3650,O
expression,3650,O
of,3650,O
α-smooth,3650,B-GENE-Y
muscle,3650,I-GENE-Y
actin,3650,I-GENE-Y
(,3650,O
SMA,3650,B-GENE-Y
),3650,O
and,3650,O
collagen,3650,B-GENE-N
type,3650,I-GENE-N
I,3650,I-GENE-N
mRNA,3650,O
was,3650,O
determined,3650,O
by,3650,O
a,3650,O
reverse,3650,O
transcription-polymerase,3650,O
chain,3650,O
reaction,3650,O
",",3650,O
and,3650,O
the,3650,O
expression,3650,O
of,3650,O
α-SMA,3650,B-GENE-Y
protein,3650,O
and,3650,O
collagen,3650,B-GENE-N
type,3650,I-GENE-N
I,3650,I-GENE-N
was,3650,O
determined,3650,O
by,3650,O
western,3650,O
blotting,3650,O
and/or,3650,O
immunofluorescent,3650,O
staining,3650,O
.,3650,O
The,3651,O
total,3651,O
soluble,3651,O
collagen,3651,B-GENE-N
production,3651,O
was,3651,O
analysed,3651,O
by,3651,O
the,3651,O
SirCol,3651,O
collagen,3651,O
assay,3651,O
.,3651,O
The,3652,O
expression,3652,O
of,3652,O
several,3652,O
signaling,3652,O
molecules,3652,O
of,3652,O
the,3652,O
TGF-β1,3652,B-GENE-Y
pathway,3652,O
was,3652,O
evaluated,3652,O
by,3652,O
western,3652,O
blot,3652,O
analysis,3652,O
.,3652,O
In,3653,O
TGF-β1-induced,3653,B-GENE-Y
NPDFs,3653,O
",",3653,O
berberine,3653,B-CHEMICAL
significantly,3653,O
inhibited,3653,O
the,3653,O
expression,3653,O
of,3653,O
α-SMA,3653,B-GENE-Y
and,3653,O
collagen,3653,B-GENE-N
type,3653,I-GENE-N
I,3653,I-GENE-N
mRNA,3653,O
and,3653,O
reduced,3653,O
α-SMA,3653,B-GENE-Y
and,3653,O
collagen,3653,B-GENE-N
protein,3653,O
levels,3653,O
.,3653,O
Berberine,3654,B-CHEMICAL
only,3654,O
suppressed,3654,O
the,3654,O
expression,3654,O
of,3654,O
pp38,3654,B-GENE-N
among,3654,O
the,3654,O
evaluated,3654,O
signaling,3654,O
molecules,3654,O
.,3654,O
SB203580,3655,B-CHEMICAL
(,3655,O
a,3655,O
specific,3655,O
inhibitor,3655,O
of,3655,O
p38,3655,B-GENE-N
kinase,3655,B-GENE-N
),3655,O
markedly,3655,O
suppressed,3655,O
the,3655,O
increased,3655,O
expression,3655,O
of,3655,O
collagen,3655,B-GENE-N
type,3655,I-GENE-N
I,3655,I-GENE-N
and,3655,O
α-SMA,3655,B-GENE-Y
in,3655,O
TGF-β1-induced,3655,B-GENE-Y
NPDFs,3655,O
.,3655,O
Berberine,3656,B-CHEMICAL
exerts,3656,O
suppressive,3656,O
effects,3656,O
on,3656,O
phenotype,3656,O
changes,3656,O
and,3656,O
ECM,3656,O
production,3656,O
in,3656,O
NPDFs,3656,O
via,3656,O
p38,3656,B-GENE-N
signaling,3656,O
pathway,3656,O
interference,3656,O
.,3656,O
The,3657,O
findings,3657,O
provide,3657,O
new,3657,O
therapeutic,3657,O
options,3657,O
for,3657,O
ECM,3657,O
production,3657,O
in,3657,O
nasal,3657,O
polyps,3657,O
.,3657,O
Glaucogenin,3658,B-CHEMICAL
E,3658,I-CHEMICAL
",",3658,O
a,3658,O
new,3658,O
C21,3658,B-CHEMICAL
steroid,3658,B-CHEMICAL
from,3658,O
Cynanchum,3658,O
stauntonii,3658,O
.,3658,O
Glaucogenin,3659,B-CHEMICAL
E,3659,I-CHEMICAL
(,3659,O
1,3659,O
),3659,O
",",3659,O
a,3659,O
new,3659,O
C,3659,B-CHEMICAL
(,3659,I-CHEMICAL
21,3659,I-CHEMICAL
),3659,I-CHEMICAL
steroid,3659,B-CHEMICAL
sapogenin,3659,O
",",3659,O
along,3659,O
with,3659,O
three,3659,O
known,3659,O
ones,3659,O
(,3659,O
2-4,3659,O
),3659,O
were,3659,O
isolated,3659,O
from,3659,O
the,3659,O
rhizomes,3659,O
of,3659,O
Cynanchum,3659,O
stauntonii,3659,O
(,3659,O
Decne,3659,O
.,3659,O
),3659,O
Schltr,3660,O
.,3660,O
ex,3661,O
Levl,3661,O
.,3661,O
Their,3662,O
structures,3662,O
were,3662,O
established,3662,O
mainly,3662,O
by,3662,O
the,3662,O
spectroscopic,3662,O
analysis,3662,O
",",3662,O
including,3662,O
2D,3662,O
NMR,3662,O
.,3662,O
All,3663,O
the,3663,O
isolated,3663,O
compounds,3663,O
were,3663,O
evaluated,3663,O
for,3663,O
their,3663,O
cytotoxicity,3663,O
against,3663,O
human,3663,O
cancer,3663,O
cell,3663,O
lines,3663,O
HeLa,3663,O
",",3663,O
Bel-7402,3663,O
",",3663,O
SGC-7901,3663,O
and,3663,O
BGC-823,3663,O
.,3663,O
New,3664,O
triterpenoids,3664,B-CHEMICAL
from,3664,O
the,3664,O
stem,3664,O
bark,3664,O
of,3664,O
Hypodaphnis,3664,O
zenkeri,3664,O
.,3664,O
A,3665,O
new,3665,O
pentacyclic,3665,B-CHEMICAL
triterpenoid,3665,I-CHEMICAL
and,3665,O
three,3665,O
new,3665,O
derivatives,3665,O
based,3665,O
on,3665,O
the,3665,O
taraxer-14-ene,3665,B-CHEMICAL
skeleton,3665,O
with,3665,O
a,3665,O
C-28,3665,O
attached,3665,O
a,3665,O
carboxylic,3665,B-CHEMICAL
acid,3665,I-CHEMICAL
group,3665,O
have,3665,O
been,3665,O
isolated,3665,O
from,3665,O
the,3665,O
stem,3665,O
bark,3665,O
of,3665,O
Hypodaphnis,3665,O
zenkeri,3665,O
",",3665,O
together,3665,O
with,3665,O
six,3665,O
known,3665,O
compounds,3665,O
.,3665,O
The,3666,O
new,3666,O
product,3666,O
was,3666,O
identified,3666,O
as,3666,O
"2α,3α-dihydroxytaraxer-14-en-28-oic",3666,B-CHEMICAL
acid,3666,I-CHEMICAL
(,3666,O
1,3666,O
),3666,O
.,3666,O
Its,3667,O
derivatives,3667,O
",",3667,O
"2α,3α-diacetyltaraxer-14-en-28-oic",3667,B-CHEMICAL
acid,3667,I-CHEMICAL
(,3667,O
2,3667,O
),3667,O
",",3667,O
"2α,3α-di-O-carbonyl-2α,3α-dihydroxytaraxer-14-en-28-oic",3667,B-CHEMICAL
acid,3667,I-CHEMICAL
(,3667,O
3,3667,O
),3667,O
and,3667,O
"2α,3α-dipropionyltaraxer-14-en-28-oic",3667,B-CHEMICAL
acid,3667,I-CHEMICAL
(,3667,O
4,3667,O
),3667,O
were,3667,O
obtained,3667,O
by,3667,O
semisynthesis,3667,O
.,3667,O
The,3668,O
known,3668,O
compounds,3668,O
were,3668,O
identified,3668,O
as,3668,O
3β-hydroxytaraxer-14-en-28-oic,3668,B-CHEMICAL
acid,3668,I-CHEMICAL
or,3668,O
aleuritolic,3668,B-CHEMICAL
acid,3668,I-CHEMICAL
(,3668,O
5,3668,O
),3668,O
(,3668,O
McPhail,3668,O
",",3668,O
A.T.,3668,O
",",3668,O
McPhail,3668,O
",",3668,O
D.R.,3668,O
",",3668,O
Wani,3668,O
",",3668,O
M.C.,3668,O
",",3668,O
Wall,3668,O
",",3668,O
M.E,3668,O
.,3668,O
&,3669,O
A.W.,3669,O
",",3669,O
Nicholas,3669,O
",",3669,O
A.W,3669,O
.,3669,O
(,3670,O
1989,3670,O
),3670,O
.,3670,O
Identity,3671,O
of,3671,O
maprounic,3671,B-CHEMICAL
acid,3671,I-CHEMICAL
with,3671,O
aleuritolic,3671,B-CHEMICAL
acid,3671,I-CHEMICAL
.,3671,O
Revision,3672,O
of,3672,O
the,3672,O
structure,3672,O
of,3672,O
maprounic,3672,B-CHEMICAL
acid,3672,I-CHEMICAL
:,3672,O
X-ray,3672,O
crystal,3672,O
structure,3672,O
of,3672,O
p-bromobenzyl,3672,B-CHEMICAL
acetylmaprounate,3672,I-CHEMICAL
.,3672,O
Journal,3673,O
Natural,3673,O
Products,3673,O
",",3673,O
52,3673,O
",",3673,O
212,3673,O
),3673,O
",",3673,O
3α-hydroxytaraxer-14-en-28-oic,3673,B-CHEMICAL
acid,3673,I-CHEMICAL
or,3673,O
isoaleuritolic,3673,B-CHEMICAL
acid,3673,I-CHEMICAL
(,3673,O
6,3673,O
),3673,O
",",3673,O
3α-acetyltaraxer-14-en-28-oic,3673,B-CHEMICAL
acid,3673,I-CHEMICAL
acetate,3673,I-CHEMICAL
or,3673,O
aleuritolic,3673,B-CHEMICAL
acid,3673,I-CHEMICAL
acetate,3673,I-CHEMICAL
(,3673,O
7,3673,O
),3673,O
(,3673,O
Chaudhuri,3673,O
",",3673,O
S.K.,3673,O
",",3673,O
Fullas,3673,O
",",3673,O
F.,3673,O
",",3673,O
Brown,3673,O
",",3673,O
D.M.,3673,O
",",3673,O
Wani,3673,O
",",3673,O
M.C.,3673,O
",",3673,O
Wall,3673,O
",",3673,O
M.E.,3673,O
",",3673,O
Cai,3673,O
",",3673,O
L.,3673,O
",",3673,O
…,3673,O
Kinghorn,3673,O
",",3673,O
A.D.,3673,O
(,3673,O
1995,3673,O
),3673,O
.,3673,O
Isolation,3674,O
and,3674,O
structural,3674,O
elucidation,3674,O
of,3674,O
pentacyclic,3674,O
triterpenoids,3674,O
from,3674,O
Maprounea,3674,O
africana,3674,O
.,3674,O
Journal,3675,O
of,3675,O
Natural,3675,O
Products,3675,O
",",3675,O
58,3675,O
",",3675,O
1-9,3675,O
),3675,O
",",3675,O
3-oxo-taraxer-14-ene,3675,B-CHEMICAL
or,3675,O
taraxerone,3675,B-CHEMICAL
(,3675,O
8,3675,O
),3675,O
β-sitosterol,3675,B-CHEMICAL
(,3675,O
9,3675,O
),3675,O
and,3675,O
stigmasterol,3675,B-CHEMICAL
(,3675,O
10,3675,O
),3675,O
(,3675,O
Kamboj,3675,O
&,3675,O
Saluja,3675,O
",",3675,O
2011,3675,O
),3675,O
",",3675,O
together,3675,O
with,3675,O
fatty,3675,O
acids,3675,O
.,3675,O
Their,3676,O
structures,3676,O
were,3676,O
established,3676,O
on,3676,O
the,3676,O
basis,3676,O
of,3676,O
spectroscopic,3676,O
studies,3676,O
and,3676,O
chemical,3676,O
transformations,3676,O
.,3676,O
Two,3677,O
new,3677,O
C-15,3677,O
enolic,3677,B-CHEMICAL
acyl,3677,I-CHEMICAL
phragmalin-type,3677,O
limonoids,3677,B-CHEMICAL
from,3677,O
Chukrasia,3677,O
tabularis,3677,O
var,3677,O
.,3677,O
velutina,3678,O
.,3678,O
Two,3679,O
new,3679,O
C-15,3679,O
enolic,3679,B-CHEMICAL
acyl,3679,I-CHEMICAL
phragmalin-type,3679,O
limonoid,3679,B-CHEMICAL
orthoesters,3679,I-CHEMICAL
",",3679,O
chukvelutilide,3679,B-CHEMICAL
G,3679,I-CHEMICAL
(,3679,O
1,3679,O
),3679,O
and,3679,O
chukrasine,3679,B-CHEMICAL
F,3679,I-CHEMICAL
(,3679,O
2,3679,O
),3679,O
",",3679,O
were,3679,O
isolated,3679,O
from,3679,O
the,3679,O
stem,3679,O
barks,3679,O
of,3679,O
Chukrasia,3679,O
tabularis,3679,O
var,3679,O
.,3679,O
velutina,3680,O
.,3680,O
Their,3681,O
structures,3681,O
were,3681,O
elucidated,3681,O
by,3681,O
their,3681,O
extensive,3681,O
high,3681,O
resolution-electrospray,3681,O
ionization,3681,O
mass,3681,O
spectrometry,3681,O
(,3681,O
HR-ESI-MS,3681,O
),3681,O
",",3681,O
one-,3681,O
and,3681,O
two-dimensional,3681,O
spectroscopic,3681,O
analysis,3681,O
",",3681,O
including,3681,O
heteronuclear,3681,O
single,3681,O
quantum,3681,O
coherence,3681,O
(,3681,O
HSQC,3681,O
),3681,O
",",3681,O
HMBC,3681,O
and,3681,O
NOESY,3681,O
experiments,3681,O
.,3681,O
Cereblon,3682,B-GENE-Y
is,3682,O
a,3682,O
direct,3682,O
protein,3682,O
target,3682,O
for,3682,O
immunomodulatory,3682,O
and,3682,O
antiproliferative,3682,O
activities,3682,O
of,3682,O
lenalidomide,3682,B-CHEMICAL
and,3682,O
pomalidomide,3682,B-CHEMICAL
.,3682,O
Thalidomide,3683,B-CHEMICAL
and,3683,O
the,3683,O
immunomodulatory,3683,O
drug,3683,O
",",3683,O
lenalidomide,3683,B-CHEMICAL
",",3683,O
are,3683,O
therapeutically,3683,O
active,3683,O
in,3683,O
hematological,3683,O
malignancies,3683,O
.,3683,O
The,3684,O
ubiquitously,3684,O
expressed,3684,O
E3,3684,O
ligase,3684,O
protein,3684,O
cereblon,3684,B-GENE-Y
(,3684,O
CRBN,3684,B-GENE-Y
),3684,O
has,3684,O
been,3684,O
identified,3684,O
as,3684,O
the,3684,O
primary,3684,O
teratogenic,3684,O
target,3684,O
of,3684,O
thalidomide,3684,B-CHEMICAL
.,3684,O
Our,3685,O
studies,3685,O
demonstrate,3685,O
that,3685,O
thalidomide,3685,B-CHEMICAL
",",3685,O
lenalidomide,3685,B-CHEMICAL
and,3685,O
another,3685,O
immunomodulatory,3685,O
drug,3685,O
",",3685,O
pomalidomide,3685,B-CHEMICAL
",",3685,O
bound,3685,O
endogenous,3685,O
CRBN,3685,B-GENE-Y
and,3685,O
recombinant,3685,O
CRBN-DNA,3685,B-GENE-Y
damage,3685,I-GENE-Y
binding,3685,I-GENE-Y
protein-1,3685,I-GENE-Y
(,3685,O
DDB1,3685,B-GENE-Y
),3685,O
complexes,3685,O
.,3685,O
CRBN,3686,B-GENE-Y
mediated,3686,O
antiproliferative,3686,O
activities,3686,O
of,3686,O
lenalidomide,3686,B-CHEMICAL
and,3686,O
pomalidomide,3686,B-CHEMICAL
in,3686,O
myeloma,3686,O
cells,3686,O
",",3686,O
as,3686,O
well,3686,O
as,3686,O
lenalidomide-,3686,B-CHEMICAL
and,3686,O
pomalidomide-induced,3686,B-CHEMICAL
cytokine,3686,B-GENE-N
production,3686,O
in,3686,O
T,3686,O
cells,3686,O
.,3686,O
Lenalidomide,3687,B-CHEMICAL
and,3687,O
pomalidomide,3687,B-CHEMICAL
inhibited,3687,O
autoubiquitination,3687,O
of,3687,O
CRBN,3687,B-GENE-Y
in,3687,O
HEK293T,3687,O
cells,3687,O
expressing,3687,O
thalidomide-binding,3687,B-CHEMICAL
competent,3687,O
wild-type,3687,O
CRBN,3687,B-GENE-Y
",",3687,O
but,3687,O
not,3687,O
thalidomide-binding,3687,B-CHEMICAL
defective,3687,O
CRBN,3687,B-GENE-Y
(,3687,O
YW/AA,3687,O
),3687,O
.,3687,O
Overexpression,3688,O
of,3688,O
CRBN,3688,B-GENE-Y
wild-type,3688,O
protein,3688,O
",",3688,O
but,3688,O
not,3688,O
CRBN,3688,B-GENE-Y
(,3688,O
YW/AA,3688,O
),3688,O
mutant,3688,O
protein,3688,O
",",3688,O
in,3688,O
KMS12,3688,O
myeloma,3688,O
cells,3688,O
",",3688,O
amplified,3688,O
pomalidomide-mediated,3688,B-CHEMICAL
reductions,3688,O
in,3688,O
c-myc,3688,B-GENE-Y
and,3688,O
IRF4,3688,B-GENE-Y
expression,3688,O
and,3688,O
increases,3688,O
in,3688,O
p21,3688,B-GENE-Y
(,3688,O
WAF-1,3688,B-GENE-Y
),3688,O
expression,3688,O
.,3688,O
Long-term,3689,O
selection,3689,O
for,3689,O
lenalidomide,3689,B-CHEMICAL
resistance,3689,O
in,3689,O
H929,3689,O
myeloma,3689,O
cell,3689,O
lines,3689,O
was,3689,O
accompanied,3689,O
by,3689,O
a,3689,O
reduction,3689,O
in,3689,O
CRBN,3689,B-GENE-Y
",",3689,O
while,3689,O
in,3689,O
DF15R,3689,O
myeloma,3689,O
cells,3689,O
resistant,3689,O
to,3689,O
both,3689,O
pomalidomide,3689,B-CHEMICAL
and,3689,O
lenalidomide,3689,B-CHEMICAL
",",3689,O
CRBN,3689,B-GENE-Y
protein,3689,O
was,3689,O
undetectable,3689,O
.,3689,O
Our,3690,O
biophysical,3690,O
",",3690,O
biochemical,3690,O
and,3690,O
gene,3690,O
silencing,3690,O
studies,3690,O
show,3690,O
that,3690,O
CRBN,3690,B-GENE-Y
is,3690,O
a,3690,O
proximate,3690,O
",",3690,O
therapeutically,3690,O
important,3690,O
molecular,3690,O
target,3690,O
of,3690,O
lenalidomide,3690,B-CHEMICAL
and,3690,O
pomalidomide,3690,B-CHEMICAL
.,3690,O
Evaluation,3691,O
of,3691,O
food-drug,3691,O
interaction,3691,O
of,3691,O
guava,3691,O
leaf,3691,O
tea,3691,O
.,3691,O
Guava,3692,O
leaf,3692,O
tea,3692,O
(,3692,O
GLT,3692,O
),3692,O
contains,3692,O
guava,3692,O
leaf,3692,O
polyphenol,3692,B-CHEMICAL
(,3692,O
Gvpp,3692,O
),3692,O
",",3692,O
which,3692,O
regulates,3692,O
the,3692,O
absorption,3692,O
of,3692,O
dietary,3692,O
carbohydrate,3692,B-CHEMICAL
from,3692,O
the,3692,O
intestines,3692,O
.,3692,O
Borderline,3693,O
diabetics,3693,O
",",3693,O
who,3693,O
are,3693,O
at,3693,O
high,3693,O
risk,3693,O
of,3693,O
development,3693,O
of,3693,O
diabetes,3693,O
",",3693,O
take,3693,O
GLT,3693,O
to,3693,O
suppress,3693,O
a,3693,O
rapid,3693,O
increase,3693,O
of,3693,O
blood,3693,O
sugar,3693,B-CHEMICAL
level,3693,O
after,3693,O
meals,3693,O
.,3693,O
However,3694,O
",",3694,O
patients,3694,O
with,3694,O
diabetes,3694,O
in,3694,O
whom,3694,O
diabetic,3694,O
drugs,3694,O
or,3694,O
warfarin,3694,B-CHEMICAL
as,3694,O
a,3694,O
blood,3694,O
thinner,3694,O
are,3694,O
prescribed,3694,O
also,3694,O
take,3694,O
GLT,3694,O
with,3694,O
the,3694,O
expectation,3694,O
of,3694,O
glycemic,3694,O
control,3694,O
.,3694,O
Therefore,3695,O
",",3695,O
we,3695,O
studied,3695,O
whether,3695,O
GLT,3695,O
had,3695,O
potential,3695,O
for,3695,O
inhibition,3695,O
or,3695,O
induction,3695,O
of,3695,O
cytochrome,3695,B-GENE-N
P450,3695,I-GENE-N
(,3695,O
CYP,3695,B-GENE-N
),3695,O
and,3695,O
an,3695,O
influence,3695,O
on,3695,O
the,3695,O
action,3695,O
of,3695,O
warfarin,3695,B-CHEMICAL
.,3695,O
Extract,3696,O
of,3696,O
guava,3696,O
leaf,3696,O
(,3696,O
GvEx,3696,O
),3696,O
consists,3696,O
of,3696,O
carbohydrate,3696,B-CHEMICAL
and,3696,O
polyphenols,3696,B-CHEMICAL
",",3696,O
which,3696,O
are,3696,O
Gvpp,3696,O
",",3696,O
quercetin,3696,B-CHEMICAL
",",3696,O
and,3696,O
ellagic,3696,B-CHEMICAL
acid,3696,I-CHEMICAL
.,3696,O
These,3697,O
polyphenols,3697,B-CHEMICAL
",",3697,O
but,3697,O
not,3697,O
GvEx,3697,O
",",3697,O
showed,3697,O
a,3697,O
certain,3697,O
level,3697,O
of,3697,O
inhibition,3697,O
of,3697,O
human-cDNA-expressed,3697,O
CYPs,3697,B-GENE-N
.,3697,O
In,3698,O
a,3698,O
comparison,3698,O
of,3698,O
GLT,3698,O
and,3698,O
grapefruit,3698,O
juice,3698,O
",",3698,O
GLT,3698,O
showed,3698,O
weaker,3698,O
inhibition,3698,O
of,3698,O
CYP,3698,B-GENE-N
activities,3698,O
and,3698,O
of,3698,O
midazolam,3698,B-CHEMICAL
1'-hydroxylation,3698,O
than,3698,O
grapefruit,3698,O
juice,3698,O
.,3698,O
Furthermore,3699,O
",",3699,O
neither,3699,O
liver,3699,O
weight,3699,O
nor,3699,O
CYP3A,3699,B-GENE-N
expression,3699,O
in,3699,O
the,3699,O
liver,3699,O
was,3699,O
changed,3699,O
in,3699,O
rats,3699,O
that,3699,O
received,3699,O
GvEx,3699,O
for,3699,O
90,3699,O
days,3699,O
compared,3699,O
with,3699,O
the,3699,O
control,3699,O
group,3699,O
.,3699,O
When,3700,O
rats,3700,O
were,3700,O
concomitantly,3700,O
treated,3700,O
with,3700,O
GLT,3700,O
and,3700,O
warfarin,3700,B-CHEMICAL
",",3700,O
the,3700,O
prolongation,3700,O
of,3700,O
clotting,3700,O
time,3700,O
of,3700,O
blood,3700,O
by,3700,O
warfarin,3700,B-CHEMICAL
was,3700,O
not,3700,O
influenced,3700,O
.,3700,O
These,3701,O
data,3701,O
suggest,3701,O
that,3701,O
GLT,3701,O
is,3701,O
unlikely,3701,O
to,3701,O
interact,3701,O
with,3701,O
drugs,3701,O
.,3701,O
Crizotinib,3702,B-CHEMICAL
in,3702,O
the,3702,O
treatment,3702,O
of,3702,O
non-small-cell,3702,O
lung,3702,O
cancer,3702,O
.,3702,O
INTRODUCTION,3703,O
:,3703,O
Recent,3703,O
progress,3703,O
in,3703,O
identifying,3703,O
distinct,3703,O
subsets,3703,O
of,3703,O
lung,3703,O
cancer,3703,O
",",3703,O
based,3703,O
on,3703,O
critical,3703,O
driver,3703,O
mutations,3703,O
",",3703,O
has,3703,O
led,3703,O
to,3703,O
increasingly,3703,O
focused,3703,O
efforts,3703,O
in,3703,O
the,3703,O
development,3703,O
of,3703,O
selectively,3703,O
targeted,3703,O
therapies,3703,O
.,3703,O
The,3704,O
fusion,3704,O
oncogene,3704,O
",",3704,O
echinoderm,3704,B-GENE-Y
microtubule-associated,3704,I-GENE-Y
protein-like,3704,I-GENE-Y
4,3704,I-GENE-Y
-,3704,O
anaplastic,3704,B-GENE-Y
lymphoma,3704,I-GENE-Y
kinase,3704,I-GENE-Y
(,3704,O
EML4-ALK,3704,B-GENE-N
),3704,O
",",3704,O
is,3704,O
present,3704,O
in,3704,O
approximately,3704,O
5,3704,O
%,3704,O
of,3704,O
non-small-cell,3704,O
lung,3704,O
cancer,3704,O
(,3704,O
NSCLC,3704,O
),3704,O
tumors,3704,O
.,3704,O
Crizotinib,3705,B-CHEMICAL
is,3705,O
an,3705,O
oral,3705,O
tyrosine,3705,B-CHEMICAL
kinase,3705,I-GENE-N
inhibitor,3705,O
(,3705,O
TKI,3705,O
),3705,O
",",3705,O
which,3705,O
silences,3705,O
the,3705,O
protein,3705,O
product,3705,O
of,3705,O
the,3705,O
ALK,3705,B-GENE-Y
fusion,3705,O
gene,3705,O
and,3705,O
has,3705,O
recently,3705,O
been,3705,O
approved,3705,O
for,3705,O
the,3705,O
treatment,3705,O
of,3705,O
NSCLC,3705,O
aberrantly,3705,O
expressing,3705,O
ALK,3705,B-GENE-Y
.,3705,O
Emerging,3706,O
data,3706,O
suggest,3706,O
that,3706,O
crizotinib,3706,B-CHEMICAL
may,3706,O
also,3706,O
have,3706,O
activity,3706,O
in,3706,O
other,3706,O
subsets,3706,O
of,3706,O
lung,3706,O
cancer,3706,O
",",3706,O
including,3706,O
tumors,3706,O
demonstrating,3706,O
amplification,3706,O
or,3706,O
mutation,3706,O
of,3706,O
the,3706,O
MET,3706,B-GENE-Y
oncogene,3706,O
",",3706,O
or,3706,O
translocation,3706,O
of,3706,O
the,3706,O
ROS1,3706,B-GENE-Y
oncogene,3706,O
.,3706,O
AREAS,3707,O
COVERED,3707,O
:,3707,O
This,3707,O
paper,3707,O
gives,3707,O
an,3707,O
overview,3707,O
of,3707,O
the,3707,O
molecular,3707,O
pathogenesis,3707,O
of,3707,O
ALK-associated,3707,B-GENE-Y
NSCLC,3707,O
.,3707,O
It,3708,O
also,3708,O
reviews,3708,O
the,3708,O
pharmacokinetic,3708,O
and,3708,O
pharmacodynamic,3708,O
data,3708,O
on,3708,O
crizotinib,3708,B-CHEMICAL
and,3708,O
outlines,3708,O
the,3708,O
preclinical,3708,O
and,3708,O
clinical,3708,O
studies,3708,O
leading,3708,O
to,3708,O
the,3708,O
approval,3708,O
of,3708,O
crizotinib,3708,B-CHEMICAL
.,3708,O
In,3709,O
addition,3709,O
",",3709,O
it,3709,O
discusses,3709,O
its,3709,O
role,3709,O
in,3709,O
the,3709,O
treatment,3709,O
of,3709,O
NSCLC,3709,O
expressing,3709,O
ALK,3709,B-GENE-Y
.,3709,O
EXPERT,3710,O
OPINION,3710,O
:,3710,O
Crizotinib,3710,B-CHEMICAL
represents,3710,O
the,3710,O
newest,3710,O
example,3710,O
of,3710,O
a,3710,O
focused,3710,O
strategy,3710,O
for,3710,O
drug,3710,O
development,3710,O
in,3710,O
lung,3710,O
cancer,3710,O
",",3710,O
based,3710,O
on,3710,O
identification,3710,O
and,3710,O
targeted,3710,O
inhibition,3710,O
of,3710,O
critical,3710,O
tumor-specific,3710,O
driver,3710,O
mutations,3710,O
.,3710,O
Crizotinib,3711,B-CHEMICAL
has,3711,O
demonstrated,3711,O
efficacy,3711,O
against,3711,O
ALK-rearranged,3711,B-GENE-Y
NSCLC,3711,O
",",3711,O
and,3711,O
has,3711,O
potential,3711,O
for,3711,O
broader,3711,O
application,3711,O
in,3711,O
select,3711,O
subsets,3711,O
of,3711,O
lung,3711,O
cancer,3711,O
.,3711,O
Central,3712,O
adenosinergic,3712,O
system,3712,O
involvement,3712,O
in,3712,O
ethanol-induced,3712,B-CHEMICAL
motor,3712,O
incoordination,3712,O
in,3712,O
mice,3712,O
.,3712,O
To,3713,O
clarify,3713,O
if,3713,O
the,3713,O
behavioral,3713,O
interaction,3713,O
between,3713,O
ethanol,3713,B-CHEMICAL
and,3713,O
adenosine,3713,B-GENE-N
reported,3713,O
previously,3713,O
occur,3713,O
centrally,3713,O
or,3713,O
due,3713,O
to,3713,O
a,3713,O
peripheral,3713,O
hemodynamic,3713,O
change,3713,O
",",3713,O
the,3713,O
effect,3713,O
of,3713,O
i.c.v,3713,O
.,3713,O
adenosine,3714,B-GENE-N
agonists,3714,O
",",3714,O
N6-,3714,B-CHEMICAL
(,3714,I-CHEMICAL
R-phenylisopropyl,3714,I-CHEMICAL
),3714,I-CHEMICAL
adenosine,3714,I-CHEMICAL
(,3714,O
R-PIA,3714,B-CHEMICAL
),3714,O
",",3714,O
N6-,3714,B-CHEMICAL
(,3714,I-CHEMICAL
S-phenylisopropyl,3714,I-CHEMICAL
),3714,I-CHEMICAL
adenosine,3714,I-CHEMICAL
",",3714,O
5'-,3714,B-CHEMICAL
(,3714,I-CHEMICAL
N-cyclopropyl,3714,I-CHEMICAL
),3714,I-CHEMICAL
-carboxamidoadenosine,3714,I-CHEMICAL
",",3714,O
antagonists,3714,O
",",3714,O
theophylline,3714,B-CHEMICAL
and,3714,O
8-p-,3714,B-CHEMICAL
(,3714,I-CHEMICAL
sulfophenyl,3714,I-CHEMICAL
),3714,I-CHEMICAL
theophylline,3714,I-CHEMICAL
as,3714,O
well,3714,O
as,3714,O
enprofylline,3714,B-CHEMICAL
on,3714,O
ethanol-,3714,B-CHEMICAL
(,3714,O
i.p,3714,O
.,3714,O
),3715,O
-induced,3715,O
motor,3715,O
incoordination,3715,O
was,3715,O
evaluated,3715,O
by,3715,O
rotorod,3715,O
.,3715,O
Adenosine,3716,O
agonists,3716,O
and,3716,O
antagonists,3716,O
dose,3716,O
dependently,3716,O
accentuated,3716,O
and,3716,O
attenuated,3716,O
",",3716,O
respectively,3716,O
",",3716,O
ethanol-induced,3716,O
motor,3716,O
incoordination,3716,O
",",3716,O
thereby,3716,O
suggesting,3716,O
a,3716,O
central,3716,O
mechanism,3716,O
of,3716,O
adenosine,3716,O
modulation,3716,O
of,3716,O
this,3716,O
effect,3716,O
of,3716,O
ethanol,3716,O
and,3716,O
confirmed,3716,O
our,3716,O
previous,3716,O
reports,3716,O
in,3716,O
which,3716,O
adenosine,3716,O
agonists,3716,O
and,3716,O
antagonists,3716,O
were,3716,O
given,3716,O
i.p,3716,O
.,3716,O
Enprofylline,3717,O
",",3717,O
a,3717,O
weak,3717,O
adenosine,3717,O
antagonist,3717,O
but,3717,O
potent,3717,O
inhibitor,3717,O
of,3717,O
cyclic,3717,I-GENE-N
AMP,3717,I-GENE-N
phosphodiesterase,3717,O
",",3717,O
did,3717,O
not,3717,O
alter,3717,O
ethanol,3717,O
's,3717,O
motor,3717,O
incoordination,3717,O
",",3717,O
further,3717,O
supporting,3717,O
involvement,3717,O
of,3717,O
brain,3717,O
adenosine,3717,I-GENE-N
receptor,3717,O
mechanism,3717,O
(,3717,O
s,3717,O
),3717,O
in,3717,O
ethanol-adenosine,3717,O
interactions,3717,O
.,3717,O
Results,3718,O
from,3718,O
R-PIA,3718,O
and,3718,O
N6-,3718,I-CHEMICAL
(,3718,I-CHEMICAL
S-phenylisopropyl,3718,I-CHEMICAL
),3718,I-CHEMICAL
adenosine,3718,O
experiments,3718,O
showed,3718,O
nearly,3718,O
a,3718,O
40-fold,3718,O
greater,3718,O
potency,3718,O
of,3718,O
R-vs.,3718,O
S-diastereoisomer,3718,O
",",3718,O
suggesting,3718,O
predominance,3718,O
of,3718,O
adenosine,3718,I-GENE-Y
A1,3718,O
subtype,3718,O
.,3718,O
However,3719,O
",",3719,O
5'-,3719,I-CHEMICAL
(,3719,I-CHEMICAL
N-cyclopropyl,3719,I-CHEMICAL
),3719,I-CHEMICAL
-carboxamidoadenosine,3719,O
data,3719,O
indicate,3719,O
complexity,3719,O
of,3719,O
the,3719,O
mechanism,3719,O
(,3719,O
s,3719,O
),3719,O
and,3719,O
point,3719,O
toward,3719,O
an,3719,O
additional,3719,O
involvement,3719,O
of,3719,O
a,3719,O
yet,3719,O
unknown,3719,O
subtype,3719,O
of,3719,O
adenosine,3719,I-GENE-N
A2,3719,O
.,3719,O
No,3720,O
effect,3720,O
of,3720,O
ethanol,3720,O
on,3720,O
blood,3720,O
or,3720,O
brain,3720,O
levels,3720,O
of,3720,O
[,3720,I-CHEMICAL
3H,3720,I-CHEMICAL
],3720,I-CHEMICAL
R-PIA,3720,O
was,3720,O
noted,3720,O
and,3720,O
sufficient,3720,O
amount,3720,O
of,3720,O
the,3720,O
latter,3720,O
entered,3720,O
the,3720,O
brain,3720,O
to,3720,O
suggest,3720,O
adenosine,3720,I-GENE-N
receptor,3720,O
activation,3720,O
adequate,3720,O
to,3720,O
produce,3720,O
behavioral,3720,O
interaction,3720,O
with,3720,O
ethanol,3720,O
.,3720,O
There,3721,O
was,3721,O
no,3721,O
escape,3721,O
of,3721,O
i.c.v.-administered,3721,O
[,3721,I-CHEMICAL
3H,3721,I-CHEMICAL
],3721,I-CHEMICAL
R-PIA,3721,O
from,3721,O
brain,3721,O
to,3721,O
the,3721,O
peripheral,3721,O
circulation,3721,O
ruling,3721,O
out,3721,O
a,3721,O
peripheral,3721,O
and,3721,O
supporting,3721,O
a,3721,O
central,3721,O
mechanism,3721,O
of,3721,O
ethanol-adenosine,3721,O
interaction,3721,O
.,3721,O
(,3722,O
ABSTRACT,3722,O
TRUNCATED,3722,O
AT,3722,O
250,3722,O
WORDS,3722,O
),3722,O
TGF-β,3723,B-GENE-Y
and,3723,O
NF-κB,3723,B-GENE-N
signal,3723,O
pathway,3723,O
cross-talk,3723,O
is,3723,O
mediated,3723,O
through,3723,O
TAK1,3723,B-GENE-Y
and,3723,O
SMAD7,3723,B-GENE-Y
in,3723,O
a,3723,O
subset,3723,O
of,3723,O
head,3723,O
and,3723,O
neck,3723,O
cancers,3723,O
.,3723,O
Transforming,3724,B-GENE-Y
growth,3724,I-GENE-Y
factor-beta,3724,I-GENE-Y
(,3724,O
TGF-β,3724,B-GENE-Y
),3724,O
has,3724,O
a,3724,O
dual,3724,O
role,3724,O
in,3724,O
epithelial,3724,O
malignancies,3724,O
",",3724,O
including,3724,O
head,3724,O
and,3724,O
neck,3724,O
squamous,3724,O
cell,3724,O
carcinoma,3724,O
(,3724,O
HNSCC,3724,O
),3724,O
.,3724,O
Attenuation,3725,O
of,3725,O
canonical,3725,O
TGF-β,3725,B-GENE-Y
signaling,3725,O
enhances,3725,O
de,3725,O
novo,3725,O
tumor,3725,O
development,3725,O
",",3725,O
whereas,3725,O
TGF-β,3725,B-GENE-Y
overexpression,3725,O
and,3725,O
signaling,3725,O
paradoxically,3725,O
promotes,3725,O
malignant,3725,O
progression,3725,O
.,3725,O
We,3726,O
recently,3726,O
observed,3726,O
that,3726,O
TGF-β-induced,3726,B-GENE-Y
growth,3726,O
arrest,3726,O
response,3726,O
is,3726,O
attenuated,3726,O
",",3726,O
in,3726,O
association,3726,O
with,3726,O
aberrant,3726,O
activation,3726,O
of,3726,O
nuclear,3726,B-GENE-N
factor-κB,3726,I-GENE-N
(,3726,O
NF-κB,3726,B-GENE-N
),3726,O
",",3726,O
a,3726,O
transcription,3726,O
factor,3726,O
",",3726,O
which,3726,O
promotes,3726,O
malignant,3726,O
progression,3726,O
in,3726,O
HNSCC,3726,O
.,3726,O
However,3727,O
",",3727,O
what,3727,O
role,3727,O
cross-talk,3727,O
between,3727,O
components,3727,O
of,3727,O
the,3727,O
TGF-β,3727,B-GENE-Y
and,3727,O
NF-κB,3727,B-GENE-N
pathways,3727,O
plays,3727,O
in,3727,O
altered,3727,O
activation,3727,O
of,3727,O
these,3727,O
pathways,3727,O
has,3727,O
not,3727,O
been,3727,O
established,3727,O
.,3727,O
Here,3728,O
",",3728,O
we,3728,O
show,3728,O
TGF-β,3728,B-GENE-Y
receptor,3728,I-GENE-Y
II,3728,I-GENE-Y
and,3728,O
TGF-β-activated,3728,B-GENE-Y
kinase,3728,I-GENE-Y
1,3728,I-GENE-Y
(,3728,O
TAK1,3728,B-GENE-Y
),3728,O
are,3728,O
predominantly,3728,O
expressed,3728,O
in,3728,O
a,3728,O
subset,3728,O
of,3728,O
HNSCC,3728,O
tumors,3728,O
with,3728,O
nuclear,3728,O
activation,3728,O
of,3728,O
NF-κB,3728,B-GENE-N
family,3728,O
member,3728,O
RELA,3728,B-GENE-Y
(,3728,O
p65,3728,B-GENE-Y
),3728,O
.,3728,O
Further,3729,O
",",3729,O
TGF-β1,3729,B-GENE-Y
treatment,3729,O
induced,3729,O
sequential,3729,O
phosphorylation,3729,O
of,3729,O
TAK1,3729,B-GENE-Y
",",3729,O
IKK,3729,B-GENE-N
",",3729,O
IκBα,3729,B-GENE-Y
and,3729,O
RELA,3729,B-GENE-Y
in,3729,O
human,3729,O
HNSCC,3729,O
lines,3729,O
.,3729,O
TAK1,3730,B-GENE-Y
enhances,3730,O
TGF-β-induced,3730,B-GENE-Y
NF-κB,3730,B-GENE-N
activation,3730,O
",",3730,O
as,3730,O
TAK1,3730,B-GENE-Y
siRNA,3730,O
knockdown,3730,O
decreased,3730,O
TGF-β1-induced,3730,B-GENE-Y
phosphorylation,3730,O
of,3730,O
IKK,3730,B-GENE-N
",",3730,O
IκB,3730,B-GENE-Y
and,3730,O
RELA,3730,B-GENE-Y
",",3730,O
degradation,3730,O
of,3730,O
IκBα,3730,B-GENE-Y
",",3730,O
RELA,3730,B-GENE-Y
nuclear,3730,O
translocation,3730,O
and,3730,O
DNA,3730,O
binding,3730,O
",",3730,O
and,3730,O
NF-κB-induced,3730,B-GENE-N
reporter,3730,O
and,3730,O
target,3730,O
gene,3730,O
transcription,3730,O
.,3730,O
Functionally,3731,O
",",3731,O
TAK1,3731,B-GENE-Y
siRNA,3731,O
inhibited,3731,O
cell,3731,O
proliferation,3731,O
",",3731,O
migration,3731,O
and,3731,O
invasion,3731,O
.,3731,O
Celastrol,3732,B-CHEMICAL
",",3732,O
a,3732,O
TAK1,3732,B-GENE-Y
inhibitor,3732,O
and,3732,O
anti-inflammatory,3732,O
compound,3732,O
used,3732,O
in,3732,O
traditional,3732,O
Chinese,3732,O
medicine,3732,O
",",3732,O
also,3732,O
decreased,3732,O
TGF-β1-induced,3732,B-GENE-Y
phosphorylation,3732,O
of,3732,O
TAK1,3732,B-GENE-Y
and,3732,O
RELA,3732,B-GENE-Y
",",3732,O
and,3732,O
suppressed,3732,O
basal,3732,O
",",3732,O
TGF-β1-,3732,B-GENE-Y
and,3732,O
tumor,3732,B-GENE-Y
necrosis,3732,I-GENE-Y
factor-alpha,3732,I-GENE-Y
(,3732,O
TNF-α,3732,B-GENE-Y
),3732,O
-induced,3732,O
NF-κB,3732,B-GENE-N
reporter,3732,O
gene,3732,O
activity,3732,O
.,3732,O
Celastrol,3733,B-CHEMICAL
also,3733,O
inhibited,3733,O
cell,3733,O
proliferation,3733,O
",",3733,O
while,3733,O
increasing,3733,O
sub-G0,3733,O
DNA,3733,O
fragmentation,3733,O
and,3733,O
Annexin,3733,B-GENE-Y
V,3733,I-GENE-Y
markers,3733,O
of,3733,O
apoptosis,3733,O
.,3733,O
Furthermore,3734,O
",",3734,O
TGF-β,3734,B-GENE-Y
and,3734,O
RELA,3734,B-GENE-Y
activation,3734,O
promoted,3734,O
SMAD7,3734,B-GENE-Y
expression,3734,O
.,3734,O
In,3735,O
turn,3735,O
",",3735,O
SMAD7,3735,B-GENE-Y
preferentially,3735,O
suppressed,3735,O
TGF-β-induced,3735,B-GENE-Y
SMAD,3735,B-GENE-N
and,3735,O
NF-κB,3735,B-GENE-N
reporters,3735,O
when,3735,O
compared,3735,O
with,3735,O
constitutive,3735,O
or,3735,O
TNF-α-induced,3735,B-GENE-Y
NF-κB,3735,B-GENE-N
reporter,3735,O
gene,3735,O
activation,3735,O
.,3735,O
Thus,3736,O
",",3736,O
cross-talk,3736,O
by,3736,O
TGF-β,3736,B-GENE-Y
via,3736,O
TAK1,3736,B-GENE-Y
and,3736,O
NF-κB,3736,B-GENE-N
promotes,3736,O
the,3736,O
malignant,3736,O
phenotype,3736,O
of,3736,O
HNSCC,3736,O
.,3736,O
Moreover,3737,O
",",3737,O
NF-κB,3737,B-GENE-N
may,3737,O
contribute,3737,O
to,3737,O
the,3737,O
downstream,3737,O
attenuation,3737,O
of,3737,O
canonical,3737,O
TGF-β,3737,B-GENE-Y
signaling,3737,O
through,3737,O
increased,3737,O
SMAD7,3737,B-GENE-Y
expression,3737,O
.,3737,O
Celastrol,3738,B-CHEMICAL
highlights,3738,O
the,3738,O
therapeutic,3738,O
potential,3738,O
of,3738,O
agents,3738,O
targeting,3738,O
TAK1,3738,B-GENE-Y
as,3738,O
a,3738,O
key,3738,O
node,3738,O
in,3738,O
this,3738,O
pro-oncogenic,3738,O
TGF-β-NF-κB,3738,B-GENE-Y
signal,3738,O
pathway,3738,O
.,3738,O
Dendritic,3739,O
cell,3739,O
migration,3739,O
assay,3739,O
:,3739,O
a,3739,O
potential,3739,O
prediction,3739,O
model,3739,O
for,3739,O
identification,3739,O
of,3739,O
contact,3739,O
allergens,3739,O
.,3739,O
This,3740,O
manuscript,3740,O
describes,3740,O
methodology,3740,O
and,3740,O
a,3740,O
prediction,3740,O
model,3740,O
for,3740,O
the,3740,O
MUTZ-LC,3740,O
migration,3740,O
assay,3740,O
.,3740,O
The,3741,O
assay,3741,O
represents,3741,O
the,3741,O
physiological,3741,O
change,3741,O
in,3741,O
Langerhans,3741,O
cell,3741,O
(,3741,O
LC,3741,O
),3741,O
behavior,3741,O
after,3741,O
exposure,3741,O
to,3741,O
a,3741,O
sensitizing,3741,O
chemical,3741,O
",",3741,O
resulting,3741,O
in,3741,O
LC,3741,O
migration,3741,O
from,3741,O
the,3741,O
epidermis,3741,O
to,3741,O
the,3741,O
dermis,3741,O
.,3741,O
MUTZ-LC,3742,O
are,3742,O
derived,3742,O
from,3742,O
the,3742,O
commercially,3742,O
available,3742,O
MUTZ-3,3742,O
cell,3742,O
line,3742,O
.,3742,O
Upon,3743,O
exposure,3743,O
to,3743,O
a,3743,O
sensitizer,3743,O
MUTZ-LC,3743,O
migrate,3743,O
preferentially,3743,O
towards,3743,O
CXCL12,3743,B-GENE-Y
whereas,3743,O
upon,3743,O
exposure,3743,O
to,3743,O
a,3743,O
non-sensitizer,3743,O
MUTZ-LC,3743,O
migrate,3743,O
towards,3743,O
CCL5,3743,B-GENE-Y
.,3743,O
A,3744,O
CXCL12/CCL5,3744,B-GENE-Y
ratio,3744,O
>,3744,O
1.10,3744,O
in,3744,O
2/3,3744,O
independent,3744,O
experiments,3744,O
is,3744,O
indicative,3744,O
of,3744,O
a,3744,O
sensitizer,3744,O
",",3744,O
whereas,3744,O
a,3744,O
CXCL12/CCL5,3744,B-GENE-Y
ratio,3744,O
≤1.10,3744,O
is,3744,O
indicative,3744,O
of,3744,O
a,3744,O
non-sensitizer,3744,O
.,3744,O
At,3745,O
non,3745,O
cytotoxic,3745,O
chemical,3745,O
concentrations,3745,O
9,3745,O
sensitizers,3745,O
(,3745,O
"2,4-dinitrochlorobenzene",3745,B-CHEMICAL
",",3745,O
paraphenylendiamine,3745,B-CHEMICAL
",",3745,O
cinnamaldehyde,3745,B-CHEMICAL
",",3745,O
isoeugenol,3745,B-CHEMICAL
",",3745,O
nickel-sulfate,3745,B-CHEMICAL
",",3745,O
tetramethylthiuram,3745,B-CHEMICAL
disulfide,3745,I-CHEMICAL
",",3745,O
eugenol,3745,B-CHEMICAL
",",3745,O
cinnamic-alcohol,3745,B-CHEMICAL
",",3745,O
ammonium-hexachloroplatinate,3745,B-CHEMICAL
),3745,O
were,3745,O
distinguished,3745,O
from,3745,O
4,3745,O
non,3745,O
sensitizers,3745,O
(,3745,O
sodium,3745,B-CHEMICAL
lauryl,3745,I-CHEMICAL
sulfate,3745,I-CHEMICAL
",",3745,O
salicylic,3745,B-CHEMICAL
acid,3745,I-CHEMICAL
",",3745,O
phenol,3745,B-CHEMICAL
",",3745,O
octanoic,3745,B-CHEMICAL
acid,3745,I-CHEMICAL
),3745,O
.,3745,O
Critical,3746,O
points,3746,O
in,3746,O
assay,3746,O
performance,3746,O
are,3746,O
(,3746,O
i,3746,O
),3746,O
MUTZ-3,3746,O
passage,3746,O
number,3746,O
after,3746,O
thawing,3746,O
(,3746,O
p6-p40,3746,O
),3746,O
;,3746,O
(,3746,O
ii,3746,O
),3746,O
cell,3746,O
viability,3746,O
(,3746,O
>,3746,O
80,3746,O
%,3746,O
),3746,O
;,3746,O
(,3746,O
iii,3746,O
),3746,O
standard,3746,O
curve,3746,O
to,3746,O
optimize,3746,O
correlation,3746,O
of,3746,O
fluorescence,3746,O
with,3746,O
cell,3746,O
number,3746,O
;,3746,O
and,3746,O
(,3746,O
iv,3746,O
),3746,O
optimization,3746,O
of,3746,O
the,3746,O
concentration,3746,O
of,3746,O
rhCXCL12,3746,B-GENE-Y
and,3746,O
rhCCL5,3746,B-GENE-Y
in,3746,O
transwell,3746,O
.,3746,O
The,3747,O
protocol,3747,O
has,3747,O
been,3747,O
tested,3747,O
in,3747,O
three,3747,O
European,3747,O
laboratories,3747,O
and,3747,O
results,3747,O
suggest,3747,O
that,3747,O
it,3747,O
may,3747,O
provide,3747,O
working,3747,O
conditions,3747,O
for,3747,O
performing,3747,O
the,3747,O
DC,3747,O
migration,3747,O
assay,3747,O
which,3747,O
is,3747,O
aimed,3747,O
at,3747,O
distinguishing,3747,O
sensitizers,3747,O
from,3747,O
non,3747,O
sensitizers,3747,O
.,3747,O
The,3748,O
atypical,3748,O
antidepressant,3748,O
mianserin,3748,B-CHEMICAL
exhibits,3748,O
agonist,3748,O
activity,3748,O
at,3748,O
kappa-opioid,3748,B-GENE-Y
receptors,3748,I-GENE-Y
.,3748,O
BACKGROUND,3749,O
AND,3749,O
PURPOSE,3749,O
:,3749,O
Antidepressants,3749,O
are,3749,O
known,3749,O
to,3749,O
interact,3749,O
with,3749,O
the,3749,O
opioid,3749,O
system,3749,O
through,3749,O
mechanisms,3749,O
not,3749,O
completely,3749,O
understood,3749,O
.,3749,O
We,3750,O
previously,3750,O
reported,3750,O
that,3750,O
tricyclic,3750,B-CHEMICAL
antidepressants,3750,O
act,3750,O
as,3750,O
agonists,3750,O
at,3750,O
distinct,3750,O
opioid,3750,B-GENE-N
receptors,3750,I-GENE-N
.,3750,O
Here,3751,O
",",3751,O
we,3751,O
investigated,3751,O
the,3751,O
effect,3751,O
of,3751,O
the,3751,O
atypical,3751,O
antidepressant,3751,O
mianserin,3751,B-CHEMICAL
at,3751,O
cloned,3751,O
and,3751,O
native,3751,O
opioid,3751,B-GENE-N
receptors,3751,I-GENE-N
.,3751,O
EXPERIMENTAL,3752,O
APPROACH,3752,O
:,3752,O
Effects,3752,O
of,3752,O
mianserin,3752,B-CHEMICAL
were,3752,O
examined,3752,O
in,3752,O
CHO,3752,O
cells,3752,O
transfected,3752,O
with,3752,O
human,3752,B-GENE-N
opioid,3752,I-GENE-N
receptors,3752,I-GENE-N
",",3752,O
C6,3752,O
glioma,3752,O
cells,3752,O
and,3752,O
rat,3752,O
brain,3752,O
membranes,3752,O
by,3752,O
the,3752,O
use,3752,O
of,3752,O
radioligand,3752,O
binding,3752,O
and,3752,O
functional,3752,O
assays,3752,O
including,3752,O
the,3752,O
stimulation,3752,O
of,3752,O
[,3752,B-CHEMICAL
(,3752,I-CHEMICAL
35,3752,I-CHEMICAL
),3752,I-CHEMICAL
S,3752,I-CHEMICAL
],3752,I-CHEMICAL
GTPgammaS,3752,I-CHEMICAL
binding,3752,O
and,3752,O
MAPK,3752,B-GENE-N
phosphorylation,3752,O
.,3752,O
KEY,3753,O
RESULTS,3753,O
:,3753,O
Mianserin,3753,B-CHEMICAL
displayed,3753,O
12-,3753,O
and,3753,O
18-fold,3753,O
higher,3753,O
affinity,3753,O
for,3753,O
kappa-,3753,B-GENE-N
than,3753,I-GENE-N
micro-,3753,I-GENE-N
and,3753,I-GENE-N
delta-opioid,3753,I-GENE-N
receptors,3753,I-GENE-N
respectively,3753,O
.,3753,O
In,3754,O
[,3754,B-CHEMICAL
(,3754,I-CHEMICAL
35,3754,I-CHEMICAL
),3754,I-CHEMICAL
S,3754,I-CHEMICAL
],3754,I-CHEMICAL
GTPgammaS,3754,I-CHEMICAL
assays,3754,O
",",3754,O
mianserin,3754,B-CHEMICAL
selectively,3754,O
activated,3754,O
kappa-opioid,3754,B-GENE-Y
receptors,3754,I-GENE-Y
.,3754,O
The,3755,O
agonist,3755,O
activity,3755,O
was,3755,O
antagonized,3755,O
by,3755,O
the,3755,O
selective,3755,O
kappa-opioid,3755,B-GENE-Y
blocker,3755,O
nor-binaltorphimine,3755,B-CHEMICAL
(,3755,O
nor-BNI,3755,B-CHEMICAL
),3755,O
.,3755,O
The,3756,O
mianserin,3756,B-CHEMICAL
analogue,3756,O
mirtazapine,3756,B-CHEMICAL
also,3756,O
displayed,3756,O
kappa-opioid,3756,B-GENE-Y
agonist,3756,O
activity,3756,O
.,3756,O
Mianserin,3757,B-CHEMICAL
and,3757,O
mirtazapine,3757,B-CHEMICAL
increased,3757,O
ERK1/2,3757,B-GENE-N
phosphorylation,3757,O
in,3757,O
CHO,3757,O
cells,3757,O
expressing,3757,O
kappa-opioid,3757,B-GENE-Y
receptors,3757,I-GENE-Y
and,3757,O
C6,3757,O
cells,3757,O
",",3757,O
and,3757,O
these,3757,O
effects,3757,O
were,3757,O
antagonized,3757,O
by,3757,O
nor-BNI,3757,B-CHEMICAL
.,3757,O
In,3758,O
rat,3758,O
striatum,3758,O
and,3758,O
nucleus,3758,O
accumbens,3758,O
",",3758,O
mianserin,3758,B-CHEMICAL
stimulated,3758,O
[,3758,B-CHEMICAL
35S,3758,I-CHEMICAL
],3758,I-CHEMICAL
GTPgammaS,3758,I-CHEMICAL
binding,3758,O
in,3758,O
a,3758,O
nor-BNI-sensitive,3758,B-CHEMICAL
manner,3758,O
with,3758,O
maximal,3758,O
effects,3758,O
lower,3758,O
than,3758,O
those,3758,O
of,3758,O
the,3758,O
full,3758,O
kappa-opioid,3758,B-GENE-Y
agonists,3758,O
(,3758,B-CHEMICAL
-,3758,I-CHEMICAL
),3758,I-CHEMICAL
"-U50,488",3758,I-CHEMICAL
and,3758,O
dynorphin,3758,B-CHEMICAL
A,3758,I-CHEMICAL
.,3758,O
When,3759,O
combined,3759,O
",",3759,O
mianserin,3759,B-CHEMICAL
antagonized,3759,O
the,3759,O
effects,3759,O
of,3759,O
the,3759,O
full,3759,O
kappa-opioid,3759,B-GENE-Y
receptor,3759,I-GENE-Y
agonists,3759,O
in,3759,O
[,3759,B-CHEMICAL
(,3759,I-CHEMICAL
35,3759,I-CHEMICAL
),3759,I-CHEMICAL
S,3759,I-CHEMICAL
],3759,I-CHEMICAL
GTPgammaS,3759,I-CHEMICAL
assays,3759,O
and,3759,O
reduced,3759,O
the,3759,O
stimulation,3759,O
of,3759,O
p38,3759,B-GENE-N
MAPK,3759,B-GENE-N
and,3759,O
ERK1/2,3759,B-GENE-N
phosphorylation,3759,O
by,3759,O
dynorphin,3759,B-GENE-Y
A,3759,I-GENE-Y
.,3759,O
CONCLUSIONS,3760,O
AND,3760,O
IMPLICATIONS,3760,O
:,3760,O
In,3760,O
different,3760,O
cell,3760,O
systems,3760,O
",",3760,O
mianserin,3760,B-CHEMICAL
directly,3760,O
activates,3760,O
kappa-opioid,3760,B-GENE-Y
receptors,3760,I-GENE-Y
",",3760,O
displaying,3760,O
partial,3760,O
agonist,3760,O
activity,3760,O
at,3760,O
brain,3760,O
receptors,3760,O
.,3760,O
Thus,3761,O
",",3761,O
this,3761,O
property,3761,O
appears,3761,O
to,3761,O
be,3761,O
a,3761,O
common,3761,O
feature,3761,O
of,3761,O
different,3761,O
classes,3761,O
of,3761,O
antidepressants,3761,O
.,3761,O
Lipid,3762,O
biomarkers,3762,O
of,3762,O
oxidative,3762,O
stress,3762,O
in,3762,O
a,3762,O
genetic,3762,O
mouse,3762,O
model,3762,O
of,3762,O
Smith-Lemli-Opitz,3762,O
syndrome,3762,O
.,3762,O
7-Dehydrocholesterol,3763,B-CHEMICAL
(,3763,O
7-DHC,3763,B-CHEMICAL
),3763,O
accumulates,3763,O
in,3763,O
tissues,3763,O
and,3763,O
fluids,3763,O
of,3763,O
patients,3763,O
with,3763,O
Smith-Lemli-Opitz,3763,O
syndrome,3763,O
(,3763,O
SLOS,3763,O
),3763,O
",",3763,O
which,3763,O
is,3763,O
caused,3763,O
by,3763,O
mutations,3763,O
in,3763,O
the,3763,O
gene,3763,O
encoding,3763,O
3β-hydroxysterol-Δ,3763,B-GENE-Y
(,3763,I-GENE-Y
7,3763,I-GENE-Y
),3763,I-GENE-Y
-reductase,3763,I-GENE-Y
(,3763,O
DHCR7,3763,B-GENE-Y
),3763,O
.,3763,O
We,3764,O
recently,3764,O
reported,3764,O
that,3764,O
7-DHC,3764,B-CHEMICAL
is,3764,O
the,3764,O
most,3764,O
reactive,3764,O
lipid,3764,O
molecule,3764,O
toward,3764,O
free,3764,O
radical,3764,O
oxidation,3764,O
(,3764,O
lipid,3764,O
peroxidation,3764,O
),3764,O
and,3764,O
14,3764,O
oxysterols,3764,B-CHEMICAL
have,3764,O
been,3764,O
identified,3764,O
as,3764,O
products,3764,O
of,3764,O
oxidation,3764,O
of,3764,O
7-DHC,3764,B-CHEMICAL
in,3764,O
solution,3764,O
.,3764,O
As,3765,O
the,3765,O
high,3765,O
oxidizability,3765,O
of,3765,O
7-DHC,3765,B-CHEMICAL
may,3765,O
lead,3765,O
to,3765,O
systemic,3765,O
oxidative,3765,O
stress,3765,O
in,3765,O
SLOS,3765,O
patients,3765,O
",",3765,O
we,3765,O
report,3765,O
here,3765,O
lipid,3765,O
biomarkers,3765,O
of,3765,O
oxidative,3765,O
stress,3765,O
in,3765,O
a,3765,O
Dhcr7-KO,3765,B-GENE-Y
mouse,3765,O
model,3765,O
of,3765,O
SLOS,3765,O
",",3765,O
including,3765,O
oxysterols,3765,B-CHEMICAL
",",3765,O
isoprostanes,3765,B-CHEMICAL
(,3765,O
IsoPs,3765,B-CHEMICAL
),3765,O
",",3765,O
and,3765,O
neuroprostanes,3765,B-CHEMICAL
(,3765,O
NeuroPs,3765,B-CHEMICAL
),3765,O
that,3765,O
are,3765,O
formed,3765,O
from,3765,O
the,3765,O
oxidation,3765,O
of,3765,O
7-DHC,3765,B-CHEMICAL
",",3765,O
arachidonic,3765,B-CHEMICAL
acid,3765,I-CHEMICAL
and,3765,O
docosahexaenoic,3765,B-CHEMICAL
acid,3765,I-CHEMICAL
",",3765,O
respectively,3765,O
.,3765,O
In,3766,O
addition,3766,O
to,3766,O
a,3766,O
previously,3766,O
described,3766,O
oxysterol,3766,B-CHEMICAL
",",3766,O
"3β,5α-dihydroxycholest-7-en-6-one",3766,B-CHEMICAL
(,3766,O
DHCEO,3766,B-CHEMICAL
),3766,O
",",3766,O
we,3766,O
provide,3766,O
evidence,3766,O
for,3766,O
the,3766,O
chemical,3766,O
structures,3766,O
of,3766,O
three,3766,O
new,3766,O
oxysterols,3766,B-CHEMICAL
in,3766,O
the,3766,O
brain,3766,O
and/or,3766,O
liver,3766,O
tissue,3766,O
of,3766,O
Dhcr7-KO,3766,B-GENE-Y
mice,3766,O
",",3766,O
two,3766,O
of,3766,O
which,3766,O
were,3766,O
quantified,3766,O
.,3766,O
We,3767,O
find,3767,O
that,3767,O
levels,3767,O
of,3767,O
IsoPs,3767,B-CHEMICAL
and,3767,O
NeuroPs,3767,B-CHEMICAL
are,3767,O
also,3767,O
elevated,3767,O
in,3767,O
brain,3767,O
and/or,3767,O
liver,3767,O
tissues,3767,O
of,3767,O
Dhcr7-KO,3767,B-GENE-Y
mice,3767,O
relative,3767,O
to,3767,O
matching,3767,O
WT,3767,O
mice,3767,O
.,3767,O
While,3768,O
IsoPs,3768,B-CHEMICAL
and,3768,O
NeuroPs,3768,B-CHEMICAL
have,3768,O
been,3768,O
established,3768,O
as,3768,O
a,3768,O
reliable,3768,O
measurement,3768,O
of,3768,O
lipid,3768,O
peroxidation,3768,O
and,3768,O
oxidative,3768,O
stress,3768,O
in,3768,O
vivo,3768,O
",",3768,O
we,3768,O
show,3768,O
that,3768,O
in,3768,O
this,3768,O
genetic,3768,O
SLOS,3768,O
mouse,3768,O
model,3768,O
",",3768,O
7-DHC-derived,3768,B-CHEMICAL
oxysterols,3768,B-CHEMICAL
are,3768,O
present,3768,O
at,3768,O
much,3768,O
higher,3768,O
levels,3768,O
than,3768,O
IsoPs,3768,B-CHEMICAL
and,3768,O
NeuroPs,3768,B-CHEMICAL
and,3768,O
thus,3768,O
are,3768,O
better,3768,O
markers,3768,O
of,3768,O
lipid,3768,O
oxidation,3768,O
and,3768,O
related,3768,O
oxidative,3768,O
stress,3768,O
.,3768,O
Correlation,3769,O
of,3769,O
high,3769,O
urinary,3769,O
Smad1,3769,B-GENE-Y
level,3769,O
with,3769,O
glomerular,3769,O
hyperfiltration,3769,O
in,3769,O
type,3769,O
2,3769,O
diabetes,3769,O
mellitus,3769,O
.,3769,O
The,3770,O
aim,3770,O
of,3770,O
this,3770,O
study,3770,O
was,3770,O
to,3770,O
assess,3770,O
the,3770,O
relationship,3770,O
between,3770,O
urinary,3770,O
Smad1,3770,B-GENE-Y
and,3770,O
glomerular,3770,O
hyperfiltration,3770,O
(,3770,O
GHF,3770,O
),3770,O
in,3770,O
type,3770,O
2,3770,O
diabetes,3770,O
mellitus,3770,O
(,3770,O
T2DM,3770,O
),3770,O
",",3770,O
and,3770,O
to,3770,O
explore,3770,O
the,3770,O
factors,3770,O
related,3770,O
to,3770,O
the,3770,O
urinary,3770,O
Smad1,3770,B-GENE-Y
in,3770,O
T2DM,3770,O
.,3770,O
The,3771,O
reference,3771,O
value,3771,O
of,3771,O
the,3771,O
estimated,3771,O
glomerular,3771,O
filtration,3771,O
rate,3771,O
(,3771,O
eGFR,3771,O
),3771,O
was,3771,O
determined,3771,O
in,3771,O
248,3771,O
healthy,3771,O
individuals,3771,O
.,3771,O
30,3772,O
patients,3772,O
with,3772,O
GHF,3772,O
",",3772,O
58,3772,O
patients,3772,O
with,3772,O
norm-GFR,3772,O
T2DM,3772,O
",",3772,O
and,3772,O
24,3772,O
healthy,3772,O
patients,3772,O
who,3772,O
served,3772,O
as,3772,O
controls,3772,O
were,3772,O
recruited,3772,O
.,3772,O
Urinary,3773,O
Smad1,3773,B-GENE-Y
",",3773,O
fasting,3773,O
plasma,3773,O
glucose,3773,B-CHEMICAL
(,3773,O
FPG,3773,O
),3773,O
",",3773,O
fasting,3773,O
serum,3773,O
C-Peptide,3773,B-GENE-Y
(,3773,O
C-P,3773,B-GENE-Y
),3773,O
",",3773,O
hemoglobin,3773,B-GENE-Y
A1C,3773,I-GENE-Y
(,3773,O
HbA1c,3773,B-GENE-Y
),3773,O
",",3773,O
cystatin,3773,B-GENE-Y
C,3773,I-GENE-Y
",",3773,O
and,3773,O
other,3773,O
chemistry,3773,O
laboratory,3773,O
parameters,3773,O
of,3773,O
T2DM,3773,O
participants,3773,O
and,3773,O
controls,3773,O
were,3773,O
measured,3773,O
.,3773,O
Patients,3774,O
with,3774,O
GHF,3774,O
had,3774,O
higher,3774,O
levels,3774,O
of,3774,O
urinary,3774,O
Smad1,3774,B-GENE-Y
than,3774,O
the,3774,O
control,3774,O
group,3774,O
",",3774,O
and,3774,O
those,3774,O
with,3774,O
norm-GFR,3774,O
.,3774,O
For,3775,O
T2DM,3775,O
patients,3775,O
with,3775,O
body,3775,O
mass,3775,O
index,3775,O
",",3775,O
age,3775,O
",",3775,O
and,3775,O
gender,3775,O
adjustments,3775,O
",",3775,O
urinary,3775,O
Smad1,3775,B-GENE-Y
was,3775,O
positively,3775,O
correlated,3775,O
with,3775,O
FPG,3775,O
",",3775,O
HbA1C,3775,B-GENE-Y
",",3775,O
and,3775,O
eGFR,3775,O
",",3775,O
but,3775,O
negatively,3775,O
correlated,3775,O
with,3775,O
fasting,3775,O
serum,3775,O
C-P.,3775,B-GENE-N
Multivariate,3775,O
linear,3775,O
regression,3775,O
analysis,3775,O
demonstrated,3775,O
that,3775,O
eGFR,3775,O
",",3775,O
HbA1C,3775,B-GENE-Y
",",3775,O
and,3775,O
fasting,3775,O
serum,3775,O
C-P,3775,B-GENE-Y
were,3775,O
independently,3775,O
associated,3775,O
with,3775,O
urinary,3775,O
Smad1,3775,B-GENE-Y
.,3775,O
High,3776,O
levels,3776,O
of,3776,O
urinary,3776,O
Smad1,3776,B-GENE-Y
were,3776,O
found,3776,O
in,3776,O
GHF,3776,O
patients,3776,O
with,3776,O
T2DM,3776,O
",",3776,O
which,3776,O
may,3776,O
be,3776,O
another,3776,O
potential,3776,O
mechanism,3776,O
of,3776,O
GHF,3776,O
in,3776,O
relation,3776,O
to,3776,O
diabetic,3776,O
nephropathy,3776,O
.,3776,O
Propranolol,3777,B-CHEMICAL
restores,3777,O
cognitive,3777,O
deficits,3777,O
and,3777,O
improves,3777,O
amyloid,3777,B-GENE-Y
and,3777,O
Tau,3777,B-GENE-Y
pathologies,3777,O
in,3777,O
a,3777,O
senescence-accelerated,3777,O
mouse,3777,O
model,3777,O
.,3777,O
Ageing,3778,O
is,3778,O
associated,3778,O
with,3778,O
a,3778,O
deterioration,3778,O
of,3778,O
cognitive,3778,O
performance,3778,O
and,3778,O
with,3778,O
increased,3778,O
risk,3778,O
of,3778,O
neurodegenerative,3778,O
disorders,3778,O
.,3778,O
Hypertension,3779,O
is,3779,O
the,3779,O
most-prevalent,3779,O
modifiable,3779,O
risk,3779,O
factor,3779,O
for,3779,O
cardiovascular,3779,O
morbidity,3779,O
and,3779,O
mortality,3779,O
worldwide,3779,O
",",3779,O
and,3779,O
clinical,3779,O
data,3779,O
suggest,3779,O
that,3779,O
hypertension,3779,O
is,3779,O
a,3779,O
risk,3779,O
factor,3779,O
for,3779,O
Alzheimer,3779,O
's,3779,O
disease,3779,O
(,3779,O
AD,3779,O
),3779,O
.,3779,O
In,3780,O
the,3780,O
present,3780,O
study,3780,O
we,3780,O
tested,3780,O
whether,3780,O
propranolol,3780,B-CHEMICAL
",",3780,O
a,3780,O
β-receptor,3780,B-GENE-N
antagonist,3780,O
commonly,3780,O
used,3780,O
as,3780,O
antihypertensive,3780,O
drug,3780,O
",",3780,O
could,3780,O
ameliorate,3780,O
the,3780,O
cognitive,3780,O
impairments,3780,O
and,3780,O
increases,3780,O
in,3780,O
AD-related,3780,O
markers,3780,O
shown,3780,O
by,3780,O
the,3780,O
senescence-accelerated,3780,O
mouse,3780,O
prone-8,3780,O
(,3780,O
SAMP8,3780,O
),3780,O
.,3780,O
Propranolol,3781,B-CHEMICAL
administration,3781,O
(,3781,O
5,3781,O
mg/kg,3781,O
for,3781,O
3,3781,O
weeks,3781,O
),3781,O
to,3781,O
6-month-old,3781,O
SAMP8,3781,O
mice,3781,O
attenuated,3781,O
cognitive,3781,O
memory,3781,O
impairments,3781,O
shown,3781,O
by,3781,O
these,3781,O
mice,3781,O
in,3781,O
the,3781,O
novel,3781,O
object,3781,O
recognition,3781,O
test,3781,O
.,3781,O
In,3782,O
the,3782,O
hippocampus,3782,O
of,3782,O
SAMP8,3782,O
mice,3782,O
it,3782,O
has,3782,O
been,3782,O
found,3782,O
increases,3782,O
in,3782,O
Aβ,3782,B-GENE-Y
(,3782,I-GENE-Y
42,3782,I-GENE-Y
),3782,I-GENE-Y
levels,3782,O
",",3782,O
the,3782,O
principal,3782,O
constituent,3782,O
of,3782,O
amyloid,3782,B-GENE-Y
plaques,3782,O
observed,3782,O
in,3782,O
AD,3782,O
",",3782,O
accompanied,3782,O
by,3782,O
both,3782,O
an,3782,O
increased,3782,O
expression,3782,O
of,3782,O
the,3782,O
cleaving,3782,O
enzyme,3782,O
BACE1,3782,B-GENE-Y
and,3782,O
a,3782,O
decreased,3782,O
expression,3782,O
of,3782,O
the,3782,O
degrading,3782,O
enzyme,3782,O
IDE,3782,B-GENE-Y
.,3782,O
All,3783,O
these,3783,O
effects,3783,O
were,3783,O
reversed,3783,O
by,3783,O
propranolol,3783,B-CHEMICAL
treatment,3783,O
.,3783,O
Tau,3784,B-GENE-Y
hyperphosphorylation,3784,O
(,3784,O
PHF-1,3784,O
epitope,3784,O
),3784,O
shown,3784,O
by,3784,O
SAMP8,3784,O
mice,3784,O
at,3784,O
this,3784,O
age,3784,O
was,3784,O
also,3784,O
decreased,3784,O
in,3784,O
the,3784,O
hippocampus,3784,O
of,3784,O
propranolol-treated,3784,B-CHEMICAL
mice,3784,O
",",3784,O
an,3784,O
effect,3784,O
probably,3784,O
related,3784,O
to,3784,O
a,3784,O
decrease,3784,O
in,3784,O
JNK1,3784,B-GENE-Y
expression,3784,O
.,3784,O
Interestingly,3785,O
",",3785,O
propranolol,3785,B-CHEMICAL
also,3785,O
phosphorylated,3785,O
Akt,3785,B-GENE-N
in,3785,O
SAMP8,3785,O
mice,3785,O
",",3785,O
which,3785,O
was,3785,O
associated,3785,O
with,3785,O
an,3785,O
increase,3785,O
of,3785,O
glycogen,3785,B-GENE-Y
synthase,3785,I-GENE-Y
kinase-3β,3785,I-GENE-Y
phosphorylation,3785,O
",",3785,O
contributing,3785,O
therefore,3785,O
to,3785,O
the,3785,O
reductions,3785,O
in,3785,O
Tau,3785,B-GENE-Y
hyperphosphorylation,3785,O
.,3785,O
Synaptic,3786,O
pathology,3786,O
in,3786,O
SAMP8,3786,O
mice,3786,O
",",3786,O
as,3786,O
shown,3786,O
by,3786,O
decreases,3786,O
in,3786,O
synaptophysin,3786,B-GENE-Y
and,3786,O
BDNF,3786,B-GENE-Y
",",3786,O
was,3786,O
also,3786,O
counteracted,3786,O
by,3786,O
propranolol,3786,B-CHEMICAL
treatment,3786,O
.,3786,O
Overall,3787,O
",",3787,O
propranolol,3787,B-CHEMICAL
might,3787,O
be,3787,O
beneficial,3787,O
in,3787,O
age-related,3787,O
brain,3787,O
dysfunction,3787,O
and,3787,O
could,3787,O
be,3787,O
an,3787,O
emerging,3787,O
candidate,3787,O
for,3787,O
the,3787,O
treatment,3787,O
of,3787,O
other,3787,O
neurodegenerative,3787,O
diseases,3787,O
.,3787,O
This,3788,O
article,3788,O
is,3788,O
part,3788,O
of,3788,O
a,3788,O
Special,3788,O
Issue,3788,O
entitled,3788,O
'Cognitive,3788,O
Enhancers,3788,O
',3788,O
.,3788,O
Leydig,3789,O
cell,3789,O
hyperplasia,3789,O
and,3789,O
Leydig,3789,O
cell,3789,O
tumour,3789,O
in,3789,O
postmenopausal,3789,O
women,3789,O
:,3789,O
report,3789,O
of,3789,O
two,3789,O
cases,3789,O
.,3789,O
Leydig,3790,O
cell,3790,O
hyperplasia,3790,O
and,3790,O
Leydig,3790,O
cell,3790,O
tumours,3790,O
of,3790,O
the,3790,O
ovary,3790,O
are,3790,O
rare,3790,O
.,3790,O
We,3791,O
present,3791,O
two,3791,O
cases,3791,O
in,3791,O
which,3791,O
patients,3791,O
had,3791,O
increased,3791,O
blood,3791,O
levels,3791,O
of,3791,O
testosterone,3791,B-CHEMICAL
and,3791,O
frank,3791,O
hirsutism,3791,O
.,3791,O
Imaging,3792,O
showed,3792,O
minimal,3792,O
abnormalities,3792,O
.,3792,O
After,3793,O
adrenal,3793,O
disease,3793,O
had,3793,O
been,3793,O
ruled,3793,O
out,3793,O
",",3793,O
they,3793,O
underwent,3793,O
a,3793,O
bilateral,3793,O
oophorectomy,3793,O
.,3793,O
One,3794,O
case,3794,O
showed,3794,O
a,3794,O
Leydig,3794,O
cell,3794,O
hyperplasia,3794,O
",",3794,O
the,3794,O
other,3794,O
a,3794,O
Leydig,3794,O
cell,3794,O
tumour,3794,O
.,3794,O
An,3795,O
androgen,3795,B-CHEMICAL
producing,3795,O
tumour,3795,O
should,3795,O
be,3795,O
excluded,3795,O
in,3795,O
every,3795,O
woman,3795,O
with,3795,O
evidence,3795,O
of,3795,O
hirsutism,3795,O
or,3795,O
frank,3795,O
virilization,3795,O
and,3795,O
markedly,3795,O
elevated,3795,O
testosterone,3795,B-CHEMICAL
levels,3795,O
.,3795,O
Adrenal,3796,O
disease,3796,O
with,3796,O
androgen,3796,B-CHEMICAL
hypersecretion,3796,O
can,3796,O
be,3796,O
suspected,3796,O
by,3796,O
detailed,3796,O
clinical,3796,O
",",3796,O
laboratory,3796,O
and,3796,O
radiologic,3796,O
imaging,3796,O
.,3796,O
Although,3797,O
DHEAS,3797,B-CHEMICAL
has,3797,O
a,3797,O
good,3797,O
sensitivity,3797,O
in,3797,O
the,3797,O
detection,3797,O
of,3797,O
adrenal,3797,O
origin,3797,O
of,3797,O
hyperandrogenism,3797,O
(,3797,O
and,3797,O
hence,3797,O
a,3797,O
good,3797,O
negative,3797,O
predictive,3797,O
value,3797,O
),3797,O
it,3797,O
is,3797,O
not,3797,O
specific,3797,O
(,3797,O
specificity,3797,O
ranging,3797,O
from,3797,O
85,3797,O
to,3797,O
98,3797,O
%,3797,O
),3797,O
.,3797,O
Imaging,3798,O
of,3798,O
the,3798,O
ovaries,3798,O
can,3798,O
be,3798,O
helpful,3798,O
but,3798,O
does,3798,O
not,3798,O
rule,3798,O
out,3798,O
ovarian,3798,O
disease,3798,O
if,3798,O
normal,3798,O
.,3798,O
Indeed,3799,O
",",3799,O
diffuse,3799,O
stromal,3799,O
Leydig,3799,O
cell,3799,O
hyperplasia,3799,O
and,3799,O
Leydig,3799,O
cell,3799,O
tumours,3799,O
(,3799,O
usually,3799,O
small,3799,O
),3799,O
may,3799,O
escape,3799,O
imaging,3799,O
and,3799,O
in,3799,O
some,3799,O
cases,3799,O
diagnosis,3799,O
can,3799,O
only,3799,O
be,3799,O
made,3799,O
on,3799,O
pathology,3799,O
.,3799,O
As,3800,O
these,3800,O
clinical,3800,O
entities,3800,O
represent,3800,O
a,3800,O
diagnostic,3800,O
and,3800,O
therapeutic,3800,O
challenge,3800,O
",",3800,O
oophorectomy,3800,O
should,3800,O
be,3800,O
considered,3800,O
in,3800,O
postmenopausal,3800,O
women,3800,O
with,3800,O
hirsutism,3800,O
and,3800,O
elevated,3800,O
testosterone,3800,B-CHEMICAL
levels,3800,O
",",3800,O
after,3800,O
the,3800,O
exclusion,3800,O
of,3800,O
adrenal,3800,O
causes,3800,O
.,3800,O
The,3801,O
procedure,3801,O
is,3801,O
relatively,3801,O
safe,3801,O
and,3801,O
effective,3801,O
.,3801,O
Follow-up,3802,O
remains,3802,O
indicated,3802,O
.,3802,O
Incretin,3803,B-GENE-Y
and,3803,O
pancreatic,3803,O
hormone,3803,O
secretion,3803,O
in,3803,O
Caucasian,3803,O
non-diabetic,3803,O
carriers,3803,O
of,3803,O
the,3803,O
TCF7L2,3803,B-GENE-Y
rs7903146,3803,O
risk,3803,O
T,3803,O
allele,3803,O
.,3803,O
We,3804,O
characterised,3804,O
62,3804,O
non-diabetic,3804,O
",",3804,O
middle-aged,3804,O
",",3804,O
Caucasians,3804,O
with,3804,O
and,3804,O
without,3804,O
the,3804,O
T,3804,O
risk,3804,O
allele,3804,O
of,3804,O
rs7903146,3804,O
in,3804,O
transcription,3804,B-GENE-Y
factor,3804,I-GENE-Y
7-like,3804,I-GENE-Y
2,3804,I-GENE-Y
(,3804,O
TCF7L2,3804,B-GENE-Y
),3804,O
with,3804,O
regard,3804,O
to,3804,O
secretion,3804,O
of,3804,O
insulin,3804,B-GENE-Y
",",3804,O
glucagon,3804,B-GENE-Y
",",3804,O
glucose-dependent,3804,B-CHEMICAL
insulinotropic,3804,I-GENE-Y
polypeptide,3804,I-GENE-Y
(,3804,O
GIP,3804,B-GENE-Y
),3804,O
",",3804,O
glucagon-like,3804,B-GENE-Y
peptide-1,3804,I-GENE-Y
(,3804,O
GLP-1,3804,B-GENE-Y
),3804,O
as,3804,O
well,3804,O
as,3804,O
insulin,3804,B-GENE-Y
sensitivity,3804,O
and,3804,O
endogenous,3804,O
glucose,3804,B-CHEMICAL
production,3804,O
.,3804,O
All,3805,O
participants,3805,O
had,3805,O
a,3805,O
3-h,3805,O
oral,3805,O
glucose,3805,B-CHEMICAL
tolerance,3805,O
test,3805,O
(,3805,O
OGTT,3805,O
),3805,O
",",3805,O
an,3805,O
intravenous,3805,O
glucose,3805,B-CHEMICAL
tolerance,3805,O
test,3805,O
and,3805,O
a,3805,O
euglycaemic,3805,O
",",3805,O
hyperinsulinaemic,3805,O
clamp,3805,O
.,3805,O
After,3806,O
adjustment,3806,O
for,3806,O
age,3806,O
and,3806,O
sex,3806,O
",",3806,O
risk,3806,O
T,3806,O
allele,3806,O
carriers,3806,O
had,3806,O
higher,3806,O
haemoglobin,3806,B-GENE-Y
A1c,3806,I-GENE-Y
levels,3806,O
(,3806,O
p,3806,O
=,3806,O
0.030,3806,O
),3806,O
",",3806,O
reduced,3806,O
first-phase,3806,O
insulin,3806,B-GENE-Y
response,3806,O
(,3806,O
p,3806,O
=,3806,O
0.048,3806,O
),3806,O
",",3806,O
higher,3806,O
peripheral,3806,O
insulin,3806,B-GENE-Y
sensitivity,3806,O
(,3806,O
p,3806,O
=,3806,O
0.050,3806,O
),3806,O
and,3806,O
lower,3806,O
fasting,3806,O
GIP,3806,B-GENE-Y
concentrations,3806,O
(,3806,O
p,3806,O
=,3806,O
0.003,3806,O
),3806,O
than,3806,O
CC,3806,O
allele,3806,O
carriers,3806,O
.,3806,O
The,3807,O
latter,3807,O
was,3807,O
also,3807,O
reflected,3807,O
by,3807,O
lower,3807,O
total,3807,O
GIP,3807,B-GENE-Y
secretion,3807,O
during,3807,O
the,3807,O
OGTT,3807,O
(,3807,O
p,3807,O
=,3807,O
0.018,3807,O
),3807,O
.,3807,O
We,3808,O
found,3808,O
no,3808,O
significant,3808,O
differences,3808,O
in,3808,O
endogenous,3808,O
glucose,3808,B-CHEMICAL
production,3808,O
",",3808,O
hepatic,3808,O
insulin,3808,B-GENE-Y
sensitivity,3808,O
or,3808,O
fasting,3808,O
concentrations,3808,O
of,3808,O
glucose,3808,B-CHEMICAL
",",3808,O
insulin,3808,B-GENE-Y
",",3808,O
glucagon,3808,B-GENE-Y
and,3808,O
GLP-1,3808,B-GENE-Y
between,3808,O
the,3808,O
groups,3808,O
.,3808,O
The,3809,O
findings,3809,O
suggest,3809,O
that,3809,O
the,3809,O
effect,3809,O
of,3809,O
TCF7L2,3809,B-GENE-Y
on,3809,O
diabetes,3809,O
risk,3809,O
may,3809,O
include,3809,O
reduced,3809,O
secretion,3809,O
of,3809,O
GIP,3809,B-GENE-Y
.,3809,O
Anti-inflammatory,3810,O
trends,3810,O
of,3810,O
1,3810,B-CHEMICAL
",",3810,I-CHEMICAL
3-diphenyl-2-propen-1-one,3810,I-CHEMICAL
derivatives,3810,O
.,3810,O
Chalcones,3811,B-CHEMICAL
(,3811,O
1,3811,B-CHEMICAL
",",3811,I-CHEMICAL
3-Diphenyl-2-propen-1-one,3811,I-CHEMICAL
),3811,O
are,3811,O
constituted,3811,O
by,3811,O
a,3811,O
three,3811,O
carbon,3811,B-CHEMICAL
α,3811,B-CHEMICAL
",",3811,I-CHEMICAL
β-unsaturated,3811,I-CHEMICAL
carbonyl,3811,I-CHEMICAL
system,3811,O
.,3811,O
The,3812,O
biosynthesis,3812,O
of,3812,O
flavonoids,3812,B-CHEMICAL
and,3812,O
isoflavonoids,3812,B-CHEMICAL
is,3812,O
initiated,3812,O
by,3812,O
chalcones,3812,B-CHEMICAL
.,3812,O
Notable,3813,O
pharmacological,3813,O
activities,3813,O
of,3813,O
chalcones,3813,B-CHEMICAL
and,3813,O
its,3813,O
derivatives,3813,O
include,3813,O
anti-inflammatory,3813,O
",",3813,O
antifungal,3813,O
",",3813,O
antibacterial,3813,O
",",3813,O
antimalarial,3813,O
",",3813,O
antituberculosis,3813,O
",",3813,O
antitumor,3813,O
",",3813,O
antimicrobial,3813,O
and,3813,O
antiviral,3813,O
effects,3813,O
respectively,3813,O
.,3813,O
Owing,3814,O
to,3814,O
simplicity,3814,O
of,3814,O
the,3814,O
chemical,3814,O
structures,3814,O
and,3814,O
a,3814,O
huge,3814,O
variety,3814,O
of,3814,O
pharmacological,3814,O
actions,3814,O
exhibited,3814,O
",",3814,O
the,3814,O
entities,3814,O
derived,3814,O
from,3814,O
chalcones,3814,B-CHEMICAL
are,3814,O
subjected,3814,O
to,3814,O
extensive,3814,O
consideration,3814,O
.,3814,O
This,3815,O
review,3815,O
article,3815,O
is,3815,O
an,3815,O
effort,3815,O
to,3815,O
sum,3815,O
up,3815,O
the,3815,O
anti-inflammatory,3815,O
activities,3815,O
of,3815,O
chalcone,3815,B-CHEMICAL
derived,3815,O
chemical,3815,O
entities,3815,O
.,3815,O
Effect,3816,O
of,3816,O
chalcones,3816,B-CHEMICAL
on,3816,O
lipid,3816,O
peroxidation,3816,O
",",3816,O
heme,3816,B-GENE-Y
oxygenase,3816,I-GENE-Y
1,3816,I-GENE-Y
(,3816,O
HO-1,3816,B-GENE-Y
),3816,O
",",3816,O
cyclooxygenase,3816,B-GENE-N
(,3816,O
COX,3816,B-GENE-N
),3816,O
",",3816,O
interleukin,3816,B-GENE-Y
5,3816,I-GENE-Y
(,3816,O
IL-5,3816,B-GENE-Y
),3816,O
",",3816,O
nitric,3816,B-CHEMICAL
oxide,3816,I-CHEMICAL
(,3816,O
NO,3816,B-CHEMICAL
),3816,O
and,3816,O
expression,3816,O
of,3816,O
cell,3816,O
adhesion,3816,O
molecules,3816,O
(,3816,O
CAM,3816,O
),3816,O
is,3816,O
summarized,3816,O
stepwise,3816,O
.,3816,O
Oxysterol,3817,B-CHEMICAL
generation,3817,O
and,3817,O
liver,3817,B-GENE-N
X,3817,I-GENE-N
receptor-dependent,3817,O
reverse,3817,O
cholesterol,3817,B-CHEMICAL
transport,3817,O
:,3817,O
not,3817,O
all,3817,O
roads,3817,O
lead,3817,O
to,3817,O
Rome,3817,O
.,3817,O
Cell,3818,O
cholesterol,3818,B-CHEMICAL
metabolism,3818,O
is,3818,O
a,3818,O
tightly,3818,O
regulated,3818,O
process,3818,O
",",3818,O
dependent,3818,O
in,3818,O
part,3818,O
on,3818,O
activation,3818,O
of,3818,O
nuclear,3818,B-GENE-N
liver,3818,I-GENE-N
X,3818,I-GENE-N
receptors,3818,I-GENE-N
(,3818,O
LXRs,3818,B-GENE-N
),3818,O
to,3818,O
increase,3818,O
expression,3818,O
of,3818,O
genes,3818,O
mediating,3818,O
removal,3818,O
of,3818,O
excess,3818,O
cholesterol,3818,B-CHEMICAL
from,3818,O
cells,3818,O
in,3818,O
the,3818,O
reverse,3818,O
cholesterol,3818,B-CHEMICAL
transport,3818,O
pathway,3818,O
.,3818,O
LXRs,3819,B-GENE-N
are,3819,O
thought,3819,O
to,3819,O
be,3819,O
activated,3819,O
predominantly,3819,O
by,3819,O
oxysterols,3819,B-CHEMICAL
generated,3819,O
enzymatically,3819,O
from,3819,O
cholesterol,3819,B-CHEMICAL
in,3819,O
different,3819,O
cell,3819,O
organelles,3819,O
.,3819,O
Defects,3820,O
resulting,3820,O
in,3820,O
slowed,3820,O
release,3820,O
of,3820,O
cholesterol,3820,B-CHEMICAL
from,3820,O
late,3820,O
endosomes,3820,O
and,3820,O
lysosomes,3820,O
or,3820,O
reduction,3820,O
in,3820,O
sterol-27-hydroxylase,3820,B-CHEMICAL
activity,3820,O
lead,3820,O
to,3820,O
specific,3820,O
blocks,3820,O
in,3820,O
oxysterol,3820,B-CHEMICAL
production,3820,O
and,3820,O
impaired,3820,O
LXR-dependent,3820,B-GENE-N
gene,3820,O
activation,3820,O
.,3820,O
This,3821,O
block,3821,O
does,3821,O
not,3821,O
appear,3821,O
to,3821,O
be,3821,O
compensated,3821,O
by,3821,O
oxysterol,3821,B-CHEMICAL
production,3821,O
in,3821,O
other,3821,O
cell,3821,O
compartments,3821,O
.,3821,O
The,3822,O
purpose,3822,O
of,3822,O
this,3822,O
review,3822,O
is,3822,O
to,3822,O
summarize,3822,O
current,3822,O
knowledge,3822,O
about,3822,O
oxysterol-dependent,3822,B-CHEMICAL
activation,3822,O
by,3822,O
LXR,3822,B-GENE-N
of,3822,O
genes,3822,O
involved,3822,O
in,3822,O
reverse,3822,O
cholesterol,3822,B-CHEMICAL
transport,3822,O
",",3822,O
and,3822,O
what,3822,O
these,3822,O
defects,3822,O
of,3822,O
cell,3822,O
cholesterol,3822,B-CHEMICAL
homeostasis,3822,O
can,3822,O
teach,3822,O
us,3822,O
about,3822,O
the,3822,O
critical,3822,O
pathways,3822,O
of,3822,O
oxysterol,3822,B-CHEMICAL
generation,3822,O
for,3822,O
expression,3822,O
of,3822,O
LXR-dependent,3822,B-GENE-N
genes,3822,O
.,3822,O
Assessment,3823,O
of,3823,O
developmental,3823,O
delay,3823,O
in,3823,O
the,3823,O
zebrafish,3823,O
embryo,3823,O
teratogenicity,3823,O
assay,3823,O
.,3823,O
In,3824,O
this,3824,O
study,3824,O
we,3824,O
analyzed,3824,O
some,3824,O
aspects,3824,O
of,3824,O
the,3824,O
assessment,3824,O
of,3824,O
developmental,3824,O
delay,3824,O
in,3824,O
the,3824,O
zebrafish,3824,O
embryotoxicity/teratogenicity,3824,O
test,3824,O
and,3824,O
explored,3824,O
the,3824,O
suitability,3824,O
of,3824,O
acetylcholinesterase,3824,B-GENE-Y
(,3824,O
AChE,3824,B-GENE-Y
),3824,O
activity,3824,O
as,3824,O
a,3824,O
biochemical,3824,O
marker,3824,O
and,3824,O
as,3824,O
a,3824,O
higher,3824,O
throughput,3824,O
alternative,3824,O
to,3824,O
morphological,3824,O
endpoints,3824,O
such,3824,O
as,3824,O
head-trunk,3824,O
angle,3824,O
",",3824,O
tail,3824,O
length,3824,O
and,3824,O
morphological,3824,O
score,3824,O
.,3824,O
Embryos,3825,O
were,3825,O
exposed,3825,O
from,3825,O
4,3825,O
to,3825,O
52,3825,O
h,3825,O
post-fertilization,3825,O
(,3825,O
hpf,3825,O
),3825,O
to,3825,O
a,3825,O
selection,3825,O
of,3825,O
known,3825,O
embryotoxic/teratogen,3825,O
compounds,3825,O
(,3825,O
valproic,3825,B-CHEMICAL
acid,3825,I-CHEMICAL
",",3825,O
retinoic,3825,B-CHEMICAL
acid,3825,I-CHEMICAL
",",3825,O
caffeine,3825,B-CHEMICAL
",",3825,O
sodium,3825,B-CHEMICAL
salicylate,3825,I-CHEMICAL
",",3825,O
glucose,3825,B-CHEMICAL
",",3825,O
hydroxyurea,3825,B-CHEMICAL
",",3825,O
methoxyacetic,3825,B-CHEMICAL
acid,3825,I-CHEMICAL
",",3825,O
boric,3825,B-CHEMICAL
acid,3825,I-CHEMICAL
and,3825,O
paraoxon-methyl,3825,B-CHEMICAL
),3825,O
over,3825,O
a,3825,O
concentration,3825,O
range,3825,O
.,3825,O
They,3826,O
were,3826,O
evaluated,3826,O
for,3826,O
AChE,3826,B-GENE-Y
activity,3826,O
",",3826,O
head-trunk,3826,O
angle,3826,O
",",3826,O
tail,3826,O
length,3826,O
and,3826,O
several,3826,O
qualitative,3826,O
parameters,3826,O
integrated,3826,O
in,3826,O
a,3826,O
morphological,3826,O
score,3826,O
.,3826,O
In,3827,O
general,3827,O
",",3827,O
the,3827,O
different,3827,O
patterns,3827,O
of,3827,O
the,3827,O
concentration-response,3827,O
curves,3827,O
allowed,3827,O
distinguishing,3827,O
between,3827,O
chemicals,3827,O
that,3827,O
produced,3827,O
growth,3827,O
retardation,3827,O
(,3827,O
valproic,3827,B-CHEMICAL
and,3827,I-CHEMICAL
methoxyacetic,3827,I-CHEMICAL
acid,3827,I-CHEMICAL
),3827,O
and,3827,O
chemicals,3827,O
that,3827,O
produced,3827,O
non-growth-delay,3827,O
related,3827,O
malformations,3827,O
.,3827,O
An,3828,O
acceptable,3828,O
correlation,3828,O
between,3828,O
the,3828,O
morphological,3828,O
score,3828,O
",",3828,O
AChE,3828,B-GENE-Y
activity,3828,O
and,3828,O
head-trunk,3828,O
angle,3828,O
as,3828,O
markers,3828,O
of,3828,O
developmental,3828,O
delay,3828,O
was,3828,O
observed,3828,O
",",3828,O
being,3828,O
AChE,3828,B-GENE-Y
activity,3828,O
particularly,3828,O
sensitive,3828,O
to,3828,O
detect,3828,O
delay,3828,O
in,3828,O
the,3828,O
absence,3828,O
of,3828,O
malformations,3828,O
.,3828,O
Cresyl,3829,B-CHEMICAL
saligenin,3829,I-CHEMICAL
phosphate,3829,I-CHEMICAL
makes,3829,O
multiple,3829,O
adducts,3829,O
on,3829,O
free,3829,O
histidine,3829,B-CHEMICAL
",",3829,O
but,3829,O
does,3829,O
not,3829,O
form,3829,O
an,3829,O
adduct,3829,O
on,3829,O
histidine,3829,B-CHEMICAL
438,3829,O
of,3829,O
human,3829,B-GENE-Y
butyrylcholinesterase,3829,I-GENE-Y
.,3829,O
Cresyl,3830,B-CHEMICAL
saligenin,3830,I-CHEMICAL
phosphate,3830,I-CHEMICAL
(,3830,O
CBDP,3830,B-CHEMICAL
),3830,O
is,3830,O
a,3830,O
suspected,3830,O
causative,3830,O
agent,3830,O
of,3830,O
``,3830,O
aerotoxic,3830,O
syndrome,3830,O
'',3830,O
",",3830,O
affecting,3830,O
pilots,3830,O
",",3830,O
crew,3830,O
members,3830,O
and,3830,O
passengers,3830,O
.,3830,O
CBDP,3831,B-CHEMICAL
is,3831,O
produced,3831,O
in,3831,O
vivo,3831,O
from,3831,O
ortho-containing,3831,O
isomers,3831,O
of,3831,O
tricresyl,3831,B-CHEMICAL
phosphate,3831,I-CHEMICAL
(,3831,O
TCP,3831,B-CHEMICAL
),3831,O
",",3831,O
a,3831,O
component,3831,O
of,3831,O
jet,3831,O
engine,3831,O
lubricants,3831,O
and,3831,O
hydraulic,3831,O
fluids,3831,O
.,3831,O
CBDP,3832,B-CHEMICAL
irreversibly,3832,O
inhibits,3832,O
butyrylcholinesterase,3832,B-GENE-Y
(,3832,O
BChE,3832,B-GENE-Y
),3832,O
in,3832,O
human,3832,O
plasma,3832,O
by,3832,O
forming,3832,O
adducts,3832,O
on,3832,O
the,3832,O
active,3832,O
site,3832,O
serine,3832,B-CHEMICAL
(,3832,O
Ser-198,3832,B-CHEMICAL
),3832,O
.,3832,O
Inhibited,3833,O
BChE,3833,B-GENE-Y
undergoes,3833,O
aging,3833,O
to,3833,O
release,3833,O
saligenin,3833,B-CHEMICAL
and,3833,O
o-cresol,3833,B-CHEMICAL
.,3833,O
The,3834,O
active,3834,O
site,3834,O
histidine,3834,B-CHEMICAL
(,3834,O
His-438,3834,B-CHEMICAL
),3834,O
was,3834,O
hypothesized,3834,O
to,3834,O
abstract,3834,O
o-hydroxybenzyl,3834,B-CHEMICAL
moiety,3834,O
from,3834,O
the,3834,O
initial,3834,O
adduct,3834,O
on,3834,O
Ser-198,3834,B-CHEMICAL
.,3834,O
Our,3835,O
goal,3835,O
was,3835,O
to,3835,O
test,3835,O
this,3835,O
hypothesis,3835,O
.,3835,O
Mass,3836,O
spectral,3836,O
analysis,3836,O
of,3836,O
CBDP-inhibited,3836,B-CHEMICAL
BChE,3836,B-GENE-Y
digested,3836,O
with,3836,O
Glu-C,3836,B-CHEMICAL
showed,3836,O
an,3836,O
o-hydroxybenzyl,3836,B-CHEMICAL
adduct,3836,O
(,3836,O
+106amu,3836,O
),3836,O
on,3836,O
lysine,3836,B-CHEMICAL
499,3836,O
",",3836,O
a,3836,O
residue,3836,O
far,3836,O
from,3836,O
the,3836,O
active,3836,O
site,3836,O
",",3836,O
but,3836,O
not,3836,O
on,3836,O
His-438,3836,B-CHEMICAL
.,3836,O
Nevertheless,3837,O
",",3837,O
the,3837,O
nitrogen,3837,B-CHEMICAL
of,3837,O
the,3837,O
imidazole,3837,B-CHEMICAL
ring,3837,O
of,3837,O
free,3837,O
l-histidine,3837,B-CHEMICAL
formed,3837,O
a,3837,O
variety,3837,O
of,3837,O
adducts,3837,O
upon,3837,O
reaction,3837,O
with,3837,O
CBDP,3837,B-CHEMICAL
",",3837,O
including,3837,O
the,3837,O
o-hydroxybenzyl,3837,B-CHEMICAL
adduct,3837,O
",",3837,O
suggesting,3837,O
that,3837,O
histidine-CBDP,3837,B-CHEMICAL
adducts,3837,O
may,3837,O
form,3837,O
on,3837,O
other,3837,O
proteins,3837,O
.,3837,O
The,3838,O
role,3838,O
of,3838,O
long,3838,O
chain,3838,O
omega-3,3838,B-CHEMICAL
polyunsaturated,3838,I-CHEMICAL
fatty,3838,I-CHEMICAL
acids,3838,I-CHEMICAL
in,3838,O
reducing,3838,O
lipid,3838,O
peroxidation,3838,O
among,3838,O
elderly,3838,O
patients,3838,O
with,3838,O
mild,3838,O
cognitive,3838,O
impairment,3838,O
:,3838,O
a,3838,O
case-control,3838,O
study,3838,O
.,3838,O
The,3839,O
present,3839,O
work,3839,O
explores,3839,O
the,3839,O
effect,3839,O
of,3839,O
dietary,3839,O
omega-3,3839,B-CHEMICAL
polyunsaturated,3839,I-CHEMICAL
fatty,3839,I-CHEMICAL
acids,3839,I-CHEMICAL
(,3839,O
PUFAs,3839,B-CHEMICAL
),3839,O
intake,3839,O
on,3839,O
lipid,3839,O
peroxidation,3839,O
among,3839,O
mild,3839,O
cognitive,3839,O
impairment,3839,O
(,3839,O
MCI,3839,O
),3839,O
patients,3839,O
.,3839,O
The,3840,O
plasma,3840,O
lipid,3840,O
hydroperoxide,3840,B-CHEMICAL
(,3840,O
LPO,3840,O
),3840,O
levels,3840,O
in,3840,O
67,3840,O
MCI,3840,O
patients,3840,O
were,3840,O
compared,3840,O
to,3840,O
those,3840,O
of,3840,O
134,3840,O
healthy,3840,O
elderly,3840,O
controls,3840,O
.,3840,O
Omega-3,3841,B-CHEMICAL
PUFA,3841,I-CHEMICAL
intake,3841,O
was,3841,O
assessed,3841,O
using,3841,O
an,3841,O
interviewer-administered,3841,O
food,3841,O
frequency,3841,O
questionnaire,3841,O
.,3841,O
Apolipoprotein,3842,B-GENE-Y
E,3842,I-GENE-Y
genotyping,3842,O
was,3842,O
performed,3842,O
using,3842,O
polymerase,3842,O
chain,3842,O
reaction,3842,O
and,3842,O
restriction,3842,O
enzyme,3842,O
digestion,3842,O
.,3842,O
The,3843,O
association,3843,O
between,3843,O
various,3843,O
confounders,3843,O
and,3843,O
lipid,3843,O
peroxidation,3843,O
was,3843,O
evaluated,3843,O
using,3843,O
regression,3843,O
analysis,3843,O
.,3843,O
The,3844,O
influence,3844,O
of,3844,O
docosahexaenoic,3844,B-CHEMICAL
acid,3844,I-CHEMICAL
(,3844,O
DHA,3844,B-CHEMICAL
),3844,O
and,3844,O
eicosapentaenoic,3844,B-CHEMICAL
acid,3844,I-CHEMICAL
(,3844,O
EPA,3844,B-CHEMICAL
),3844,O
intake,3844,O
on,3844,O
LPO,3844,O
level,3844,O
was,3844,O
investigated,3844,O
.,3844,O
The,3845,O
results,3845,O
revealed,3845,O
that,3845,O
LPO,3845,O
levels,3845,O
were,3845,O
significantly,3845,O
higher,3845,O
in,3845,O
the,3845,O
MCI,3845,O
group,3845,O
than,3845,O
in,3845,O
the,3845,O
control,3845,O
group,3845,O
.,3845,O
Inverse,3846,O
correlations,3846,O
were,3846,O
found,3846,O
between,3846,O
DHA,3846,B-CHEMICAL
and,3846,O
EPA,3846,B-CHEMICAL
intake,3846,O
and,3846,O
LPO,3846,O
level,3846,O
among,3846,O
the,3846,O
MCI,3846,O
group,3846,O
.,3846,O
LPO,3847,O
levels,3847,O
decreased,3847,O
significantly,3847,O
with,3847,O
increasing,3847,O
DHA,3847,B-CHEMICAL
and,3847,O
EPA,3847,B-CHEMICAL
intake,3847,O
.,3847,O
In,3848,O
summary,3848,O
",",3848,O
the,3848,O
findings,3848,O
revealed,3848,O
that,3848,O
DHA,3848,B-CHEMICAL
and,3848,O
EPA,3848,B-CHEMICAL
can,3848,O
play,3848,O
a,3848,O
role,3848,O
in,3848,O
alleviating,3848,O
oxidative,3848,O
stress,3848,O
and,3848,O
reducing,3848,O
the,3848,O
risk,3848,O
of,3848,O
neurodegenerative,3848,O
diseases,3848,O
.,3848,O
Vitamin,3849,B-CHEMICAL
E,3849,I-CHEMICAL
deficiency,3849,O
impairs,3849,O
the,3849,O
somatostatinergic,3849,B-GENE-N
receptor-effector,3849,O
system,3849,O
and,3849,O
leads,3849,O
to,3849,O
phosphotyrosine,3849,B-GENE-N
phosphatase,3849,I-GENE-N
overactivation,3849,O
and,3849,O
cell,3849,O
death,3849,O
in,3849,O
the,3849,O
rat,3849,O
hippocampus,3849,O
.,3849,O
Vitamin,3850,B-CHEMICAL
E,3850,I-CHEMICAL
plays,3850,O
an,3850,O
essential,3850,O
role,3850,O
in,3850,O
maintaining,3850,O
the,3850,O
structure,3850,O
and,3850,O
function,3850,O
of,3850,O
the,3850,O
nervous,3850,O
system,3850,O
",",3850,O
and,3850,O
its,3850,O
deficiency,3850,O
",",3850,O
commonly,3850,O
associated,3850,O
with,3850,O
fat,3850,O
malabsorption,3850,O
diseases,3850,O
",",3850,O
may,3850,O
reduce,3850,O
neuronal,3850,O
survival,3850,O
.,3850,O
We,3851,O
previously,3851,O
demonstrated,3851,O
that,3851,O
the,3851,O
somatostatinergic,3851,O
system,3851,O
",",3851,O
implicated,3851,O
in,3851,O
neuronal,3851,O
survival,3851,O
control,3851,O
",",3851,O
can,3851,O
be,3851,O
modulated,3851,O
by,3851,O
α-tocopherol,3851,B-CHEMICAL
in,3851,O
the,3851,O
rat,3851,O
dentate,3851,O
gyrus,3851,O
",",3851,O
increasing,3851,O
cyclic,3851,B-GENE-N
adenosine,3851,I-GENE-N
monophosphate,3851,I-GENE-N
response,3851,I-GENE-N
element,3851,I-GENE-N
binding,3851,I-GENE-N
protein,3851,I-GENE-N
phosphorylation,3851,O
.,3851,O
To,3852,O
gain,3852,O
a,3852,O
better,3852,O
understanding,3852,O
of,3852,O
the,3852,O
molecular,3852,O
actions,3852,O
of,3852,O
tocopherols,3852,B-CHEMICAL
and,3852,O
examine,3852,O
the,3852,O
link,3852,O
among,3852,O
vitamin,3852,B-CHEMICAL
E,3852,I-CHEMICAL
",",3852,O
somatostatin,3852,B-GENE-Y
and,3852,O
neuronal,3852,O
survival,3852,O
",",3852,O
we,3852,O
have,3852,O
investigated,3852,O
the,3852,O
effects,3852,O
of,3852,O
a,3852,O
deficiency,3852,O
and,3852,O
subsequent,3852,O
administration,3852,O
of,3852,O
tocopherol,3852,B-CHEMICAL
on,3852,O
the,3852,O
somatostatin,3852,B-GENE-Y
signaling,3852,O
pathway,3852,O
and,3852,O
neuronal,3852,O
survival,3852,O
in,3852,O
the,3852,O
rat,3852,O
hippocampus,3852,O
.,3852,O
No,3853,O
changes,3853,O
in,3853,O
somatostatin,3853,B-GENE-Y
expression,3853,O
were,3853,O
detected,3853,O
in,3853,O
vitamin-E-deficient,3853,B-CHEMICAL
rats,3853,O
.,3853,O
These,3854,O
rats,3854,O
",",3854,O
however,3854,O
",",3854,O
showed,3854,O
a,3854,O
significant,3854,O
increase,3854,O
in,3854,O
the,3854,O
somatostatin,3854,B-GENE-N
receptor,3854,I-GENE-N
density,3854,O
and,3854,O
dissociation,3854,O
constant,3854,O
",",3854,O
which,3854,O
correlated,3854,O
with,3854,O
a,3854,O
significant,3854,O
increase,3854,O
in,3854,O
the,3854,O
protein,3854,O
levels,3854,O
of,3854,O
somatostatin,3854,B-CHEMICAL
receptors,3854,I-GENE-N
.,3854,O
Nevertheless,3855,O
",",3855,O
vitamin,3855,B-CHEMICAL
E,3855,I-CHEMICAL
deficiency,3855,O
impaired,3855,O
the,3855,O
ability,3855,O
of,3855,O
the,3855,O
somatostatin,3855,B-CHEMICAL
receptors,3855,I-GENE-N
to,3855,O
couple,3855,O
to,3855,O
the,3855,O
effectors,3855,O
adenylyl,3855,B-CHEMICAL
cyclase,3855,O
and,3855,O
phosphotyrosine,3855,B-CHEMICAL
phosphatase,3855,I-GENE-N
by,3855,O
diminishing,3855,O
Gi,3855,B-GENE-N
protein,3855,I-GENE-N
functionality,3855,O
.,3855,O
Furthermore,3856,O
",",3856,O
vitamin,3856,B-CHEMICAL
E,3856,I-CHEMICAL
deficiency,3856,O
significantly,3856,O
increased,3856,O
phosphotyrosine,3856,B-CHEMICAL
phosphatase,3856,I-GENE-N
activity,3856,O
and,3856,O
PTPη,3856,B-GENE-Y
expression,3856,O
",",3856,O
as,3856,O
well,3856,O
as,3856,O
PKCδ,3856,B-GENE-Y
activation,3856,O
",",3856,O
and,3856,O
decreased,3856,O
extracellular-signal-regulated,3856,B-GENE-N
kinase,3856,I-GENE-N
phosphorylation,3856,O
.,3856,O
All,3857,O
these,3857,O
changes,3857,O
were,3857,O
accompanied,3857,O
by,3857,O
an,3857,O
increase,3857,O
in,3857,O
neuronal,3857,O
cell,3857,O
death,3857,O
.,3857,O
Subsequent,3858,O
α-tocopherol,3858,B-CHEMICAL
administration,3858,O
partially,3858,O
or,3858,O
completely,3858,O
reversed,3858,O
all,3858,O
these,3858,O
values,3858,O
to,3858,O
control,3858,O
levels,3858,O
.,3858,O
Altogether,3859,O
",",3859,O
our,3859,O
results,3859,O
prove,3859,O
the,3859,O
importance,3859,O
of,3859,O
vitamin,3859,B-CHEMICAL
E,3859,I-CHEMICAL
homeostasis,3859,O
in,3859,O
the,3859,O
somatostatin,3859,B-GENE-N
receptor-effector,3859,O
system,3859,O
and,3859,O
suggest,3859,O
a,3859,O
possible,3859,O
mechanism,3859,O
by,3859,O
which,3859,O
this,3859,O
vitamin,3859,O
may,3859,O
regulate,3859,O
the,3859,O
neuronal,3859,O
cell,3859,O
survival,3859,O
in,3859,O
the,3859,O
adult,3859,O
hippocampus,3859,O
.,3859,O
CCAAT/Enhancer-binding,3860,B-GENE-Y
protein-homologous,3860,I-GENE-Y
protein,3860,I-GENE-Y
sensitizes,3860,O
to,3860,O
SU5416,3860,B-CHEMICAL
by,3860,O
modulating,3860,O
p21,3860,B-GENE-Y
and,3860,O
PI3K/Akt,3860,B-GENE-N
signal,3860,O
pathway,3860,O
in,3860,O
FRO,3860,O
anaplastic,3860,O
thyroid,3860,O
carcinoma,3860,O
cells,3860,O
.,3860,O
SU5416,3861,B-CHEMICAL
",",3861,O
vascular,3861,O
endothelial,3861,O
cell,3861,O
growth,3861,O
factor,3861,O
receptor,3861,O
inhibitor,3861,O
",",3861,O
suppresses,3861,O
hypoxia-induced,3861,O
angiogenesis,3861,O
",",3861,O
growth,3861,O
",",3861,O
proliferation,3861,O
",",3861,O
and,3861,O
metastasis,3861,O
in,3861,O
cancer,3861,O
cells,3861,O
.,3861,O
CCAAT/enhancer-binding,3862,B-GENE-Y
protein-homologous,3862,I-GENE-Y
protein,3862,I-GENE-Y
(,3862,O
CHOP,3862,B-GENE-Y
),3862,O
has,3862,O
pivotal,3862,O
roles,3862,O
in,3862,O
regulation,3862,O
of,3862,O
growth,3862,O
and,3862,O
survival,3862,O
.,3862,O
In,3863,O
the,3863,O
present,3863,O
study,3863,O
",",3863,O
we,3863,O
evaluated,3863,O
the,3863,O
effects,3863,O
of,3863,O
SU5416,3863,B-CHEMICAL
on,3863,O
cell,3863,O
survival,3863,O
",",3863,O
p21,3863,B-GENE-Y
",",3863,O
and,3863,O
PI3K/Akt,3863,B-GENE-N
signal,3863,O
pathway,3863,O
in,3863,O
FRO,3863,O
anaplastic,3863,O
thyroid,3863,O
carcinoma,3863,O
(,3863,O
ATC,3863,O
),3863,O
cells,3863,O
.,3863,O
Moreover,3864,O
",",3864,O
we,3864,O
investigated,3864,O
the,3864,O
roles,3864,O
of,3864,O
CHOP,3864,B-GENE-Y
in,3864,O
cell,3864,O
survival,3864,O
under,3864,O
condition,3864,O
of,3864,O
SU5416,3864,B-CHEMICAL
treatment,3864,O
in,3864,O
FRO,3864,O
ATC,3864,O
cells,3864,O
.,3864,O
After,3865,O
SU5416,3865,B-CHEMICAL
treatment,3865,O
",",3865,O
cell,3865,O
viability,3865,O
",",3865,O
PARP-1,3865,B-GENE-Y
",",3865,O
and,3865,O
caspase-3,3865,B-GENE-Y
protein,3865,O
levels,3865,O
were,3865,O
not,3865,O
changed,3865,O
.,3865,O
p53,3866,B-GENE-Y
and,3866,O
p27,3866,B-GENE-Y
protein,3866,O
levels,3866,O
decreased,3866,O
while,3866,O
p21,3866,B-GENE-Y
protein,3866,O
levels,3866,O
increased,3866,O
.,3866,O
Phospho-Akt,3867,B-CHEMICAL
protein,3867,O
levels,3867,O
were,3867,O
not,3867,O
altered,3867,O
.,3867,O
In,3868,O
SU5416-treated,3868,B-CHEMICAL
situation,3868,O
",",3868,O
cell,3868,O
viability,3868,O
was,3868,O
not,3868,O
different,3868,O
before,3868,O
and,3868,O
after,3868,O
administration,3868,O
of,3868,O
either,3868,O
p21,3868,B-GENE-Y
siRNA,3868,O
or,3868,O
LY294002,3868,B-CHEMICAL
whereas,3868,O
it,3868,O
was,3868,O
lessened,3868,O
after,3868,O
co-administration,3868,O
of,3868,O
p21,3868,B-GENE-Y
siRNA,3868,O
and,3868,O
LY294002,3868,B-CHEMICAL
.,3868,O
Compared,3869,O
to,3869,O
SU5416,3869,B-CHEMICAL
treatment,3869,O
alone,3869,O
",",3869,O
cell,3869,O
viability,3869,O
was,3869,O
reduced,3869,O
with,3869,O
CHOP,3869,B-GENE-Y
plasmid,3869,O
but,3869,O
it,3869,O
was,3869,O
unchanged,3869,O
with,3869,O
CHOP,3869,B-GENE-Y
siRNA,3869,O
.,3869,O
PARP-1,3870,B-GENE-N
and,3870,O
caspase-3,3870,B-GENE-N
protein,3870,O
levels,3870,O
with,3870,O
CHOP,3870,B-GENE-Y
plasmid,3870,O
were,3870,O
elevated,3870,O
whereas,3870,O
the,3870,O
protein,3870,O
levels,3870,O
with,3870,O
CHOP,3870,B-GENE-Y
siRNA,3870,O
were,3870,O
similar,3870,O
.,3870,O
While,3871,O
CHOP,3871,B-GENE-Y
plasmid,3871,O
transfection,3871,O
diminished,3871,O
p21,3871,B-GENE-Y
and,3871,O
phospho-Akt,3871,B-CHEMICAL
protein,3871,O
levels,3871,O
",",3871,O
CHOP,3871,B-GENE-Y
siRNA,3871,O
transfection,3871,O
did,3871,O
not,3871,O
alter,3871,O
the,3871,O
protein,3871,O
levels,3871,O
.,3871,O
In,3872,O
conclusion,3872,O
",",3872,O
these,3872,O
results,3872,O
suggest,3872,O
that,3872,O
CHOP,3872,B-GENE-Y
may,3872,O
sensitize,3872,O
FRO,3872,O
ATC,3872,O
cells,3872,O
to,3872,O
SU5416,3872,B-CHEMICAL
thereby,3872,O
inhibiting,3872,O
cell,3872,O
survival,3872,O
by,3872,O
modulating,3872,O
p21,3872,B-GENE-Y
and,3872,O
PI3K/Akt,3872,B-GENE-N
signal,3872,O
pathway,3872,O
.,3872,O
Furthermore,3873,O
",",3873,O
these,3873,O
findings,3873,O
imply,3873,O
that,3873,O
CHOP,3873,B-GENE-Y
may,3873,O
be,3873,O
a,3873,O
possible,3873,O
candidate,3873,O
as,3873,O
the,3873,O
chemosensitizing,3873,O
factor,3873,O
for,3873,O
induction,3873,O
of,3873,O
cytotoxicity,3873,O
in,3873,O
ATC,3873,O
cells,3873,O
exposed,3873,O
to,3873,O
SU5416,3873,B-CHEMICAL
.,3873,O
An,3874,O
overview,3874,O
of,3874,O
transcriptional,3874,O
regulation,3874,O
in,3874,O
response,3874,O
to,3874,O
toxicological,3874,O
insult,3874,O
.,3874,O
The,3875,O
completion,3875,O
of,3875,O
the,3875,O
human,3875,O
genome,3875,O
project,3875,O
and,3875,O
the,3875,O
subsequent,3875,O
advent,3875,O
of,3875,O
DNA,3875,O
microarray,3875,O
and,3875,O
high-throughput,3875,O
sequencing,3875,O
technologies,3875,O
have,3875,O
led,3875,O
to,3875,O
a,3875,O
renaissance,3875,O
in,3875,O
molecular,3875,O
toxicology,3875,O
.,3875,O
Toxicogenomic,3876,O
data,3876,O
sets,3876,O
",",3876,O
from,3876,O
both,3876,O
in,3876,O
vivo,3876,O
and,3876,O
in,3876,O
vitro,3876,O
studies,3876,O
",",3876,O
are,3876,O
growing,3876,O
exponentially,3876,O
",",3876,O
providing,3876,O
a,3876,O
wealth,3876,O
of,3876,O
information,3876,O
on,3876,O
regulation,3876,O
of,3876,O
stress,3876,O
pathways,3876,O
at,3876,O
the,3876,O
transcriptome,3876,O
level,3876,O
.,3876,O
Through,3877,O
such,3877,O
studies,3877,O
",",3877,O
we,3877,O
are,3877,O
now,3877,O
beginning,3877,O
to,3877,O
appreciate,3877,O
the,3877,O
diversity,3877,O
and,3877,O
complexity,3877,O
of,3877,O
biological,3877,O
responses,3877,O
to,3877,O
xenobiotics,3877,O
.,3877,O
In,3878,O
this,3878,O
review,3878,O
",",3878,O
we,3878,O
aim,3878,O
to,3878,O
consolidate,3878,O
and,3878,O
summarise,3878,O
the,3878,O
major,3878,O
toxicologically,3878,O
relevant,3878,O
transcription,3878,O
factor-governed,3878,O
molecular,3878,O
pathways,3878,O
.,3878,O
It,3879,O
is,3879,O
becoming,3879,O
clear,3879,O
that,3879,O
different,3879,O
chemical,3879,O
entities,3879,O
can,3879,O
cause,3879,O
oxidative,3879,O
",",3879,O
genotoxic,3879,O
and,3879,O
proteotoxic,3879,O
stress,3879,O
",",3879,O
which,3879,O
induce,3879,O
cellular,3879,O
responses,3879,O
in,3879,O
an,3879,O
effort,3879,O
to,3879,O
restore,3879,O
homoeostasis,3879,O
.,3879,O
Primary,3880,O
among,3880,O
the,3880,O
response,3880,O
pathways,3880,O
involved,3880,O
are,3880,O
NFE2L2,3880,B-GENE-Y
(,3880,O
Nrf2,3880,B-GENE-Y
),3880,O
",",3880,O
NFE2L1,3880,B-GENE-Y
(,3880,O
Nrf1,3880,B-GENE-Y
),3880,O
",",3880,O
p53,3880,B-GENE-Y
",",3880,O
heat,3880,B-GENE-N
shock,3880,I-GENE-N
factor,3880,I-GENE-N
and,3880,O
the,3880,O
unfolded,3880,O
protein,3880,O
response,3880,O
.,3880,O
Additionally,3881,O
",",3881,O
more,3881,O
specific,3881,O
mechanisms,3881,O
exist,3881,O
where,3881,O
xenobiotics,3881,O
act,3881,O
as,3881,O
ligands,3881,O
",",3881,O
including,3881,O
the,3881,O
aryl,3881,B-GENE-Y
hydrocarbon,3881,I-GENE-Y
receptor,3881,I-GENE-Y
",",3881,O
metal-responsive,3881,B-GENE-Y
transcription,3881,I-GENE-Y
factor-1,3881,I-GENE-Y
and,3881,O
the,3881,O
nuclear,3881,B-GENE-N
receptor,3881,I-GENE-N
family,3881,O
of,3881,O
transcription,3881,O
factors,3881,O
.,3881,O
Other,3882,O
pathways,3882,O
including,3882,O
the,3882,O
immunomodulatory,3882,O
transcription,3882,O
factors,3882,O
NF-κB,3882,B-GENE-N
and,3882,O
STAT,3882,B-GENE-N
together,3882,O
with,3882,O
the,3882,O
hypoxia-inducible,3882,B-GENE-N
transcription,3882,I-GENE-N
factor,3882,I-GENE-N
HIF,3882,B-GENE-N
are,3882,O
also,3882,O
implicated,3882,O
in,3882,O
cellular,3882,O
responses,3882,O
to,3882,O
xenobiotic,3882,O
exposure,3882,O
.,3882,O
A,3883,O
less,3883,O
specific,3883,O
but,3883,O
equally,3883,O
important,3883,O
aspect,3883,O
to,3883,O
cellular,3883,O
injury,3883,O
controlled,3883,O
by,3883,O
transcriptional,3883,O
activity,3883,O
is,3883,O
loss,3883,O
of,3883,O
tissue-specific,3883,O
gene,3883,O
expression,3883,O
",",3883,O
resulting,3883,O
in,3883,O
dedifferentiation,3883,O
of,3883,O
target,3883,O
cells,3883,O
and,3883,O
compromise,3883,O
of,3883,O
tissue,3883,O
function,3883,O
.,3883,O
Here,3884,O
",",3884,O
we,3884,O
review,3884,O
these,3884,O
pathways,3884,O
and,3884,O
the,3884,O
genes,3884,O
they,3884,O
regulate,3884,O
in,3884,O
order,3884,O
to,3884,O
provide,3884,O
an,3884,O
overview,3884,O
of,3884,O
this,3884,O
growing,3884,O
field,3884,O
of,3884,O
molecular,3884,O
toxicology,3884,O
.,3884,O
Cholinergic,3885,O
modulation,3885,O
by,3885,O
opioid,3885,B-GENE-N
receptor,3885,I-GENE-N
ligands,3885,O
:,3885,O
potential,3885,O
application,3885,O
to,3885,O
Alzheimer,3885,O
's,3885,O
disease,3885,O
.,3885,O
Morphinans,3886,B-CHEMICAL
have,3886,O
a,3886,O
storied,3886,O
history,3886,O
in,3886,O
medicinal,3886,O
chemistry,3886,O
as,3886,O
pain,3886,O
management,3886,O
drugs,3886,O
but,3886,O
have,3886,O
received,3886,O
attention,3886,O
as,3886,O
modulators,3886,O
of,3886,O
cholinergic,3886,O
signaling,3886,O
for,3886,O
the,3886,O
treatment,3886,O
of,3886,O
Alzheimer,3886,O
's,3886,O
Disease,3886,O
(,3886,O
AD,3886,O
),3886,O
.,3886,O
Galantamine,3887,B-CHEMICAL
is,3887,O
a,3887,O
reversible,3887,O
",",3887,O
competitive,3887,O
acetylcholinesterase,3887,B-GENE-Y
(,3887,O
AChE,3887,B-GENE-Y
),3887,O
inhibitor,3887,O
and,3887,O
allosteric,3887,O
potentiating,3887,O
ligand,3887,O
of,3887,O
nicotinic,3887,B-GENE-N
acetylcholine,3887,B-CHEMICAL
receptors,3887,I-GENE-N
(,3887,O
nAChR-APL,3887,B-GENE-N
),3887,O
that,3887,O
shares,3887,O
many,3887,O
common,3887,O
structural,3887,O
elements,3887,O
with,3887,O
morphinan-based,3887,B-CHEMICAL
opioids,3887,O
.,3887,O
The,3888,O
structurally,3888,O
diverse,3888,O
opioids,3888,O
codeine,3888,B-CHEMICAL
and,3888,O
eseroline,3888,B-CHEMICAL
",",3888,O
like,3888,O
galantamine,3888,B-CHEMICAL
",",3888,O
are,3888,O
also,3888,O
nAChR-APL,3888,B-GENE-N
that,3888,O
have,3888,O
greatly,3888,O
diminished,3888,O
affinity,3888,O
for,3888,O
AChE,3888,B-GENE-Y
",",3888,O
representing,3888,O
potential,3888,O
lead,3888,O
compounds,3888,O
for,3888,O
selective,3888,O
nAChR-APL,3888,B-GENE-N
development,3888,O
.,3888,O
In,3889,O
accordance,3889,O
with,3889,O
the,3889,O
emerging,3889,O
repurposing,3889,O
trend,3889,O
of,3889,O
evaluating,3889,O
known,3889,O
compounds,3889,O
for,3889,O
novel,3889,O
pharmacological,3889,O
activity,3889,O
",",3889,O
ongoing,3889,O
research,3889,O
on,3889,O
augmentation,3889,O
of,3889,O
cholinergic,3889,O
signaling,3889,O
that,3889,O
has,3889,O
been,3889,O
aided,3889,O
by,3889,O
the,3889,O
use,3889,O
of,3889,O
opioids,3889,O
will,3889,O
be,3889,O
reviewed,3889,O
.,3889,O
Adhesion,3890,O
of,3890,O
osteoblasts,3890,O
to,3890,O
a,3890,O
vertically,3890,O
aligned,3890,O
TiO2,3890,B-CHEMICAL
nanotube,3890,O
surface,3890,O
.,3890,O
The,3891,O
adhesion,3891,O
of,3891,O
cells,3891,O
to,3891,O
vertically,3891,O
aligned,3891,O
TiO2,3891,B-CHEMICAL
nanotubes,3891,O
is,3891,O
reviewed,3891,O
.,3891,O
The,3892,O
attraction,3892,O
between,3892,O
a,3892,O
negatively,3892,O
charged,3892,O
nanotube,3892,O
surface,3892,O
and,3892,O
a,3892,O
negatively,3892,O
charged,3892,O
osteoblast,3892,O
is,3892,O
facilitated,3892,O
by,3892,O
charged,3892,O
protein-mediators,3892,O
like,3892,O
proteins,3892,O
with,3892,O
a,3892,O
quadrupolar,3892,O
internal,3892,O
charge,3892,O
distribution,3892,O
",",3892,O
fibronectin,3892,B-GENE-Y
and,3892,O
vitronectin,3892,B-GENE-Y
.,3892,O
It,3893,O
is,3893,O
shown,3893,O
that,3893,O
adhesion,3893,O
and,3893,O
spreading,3893,O
of,3893,O
osteoblasts,3893,O
on,3893,O
vertically,3893,O
aligned,3893,O
TiO2,3893,B-CHEMICAL
nanotube,3893,O
surfaces,3893,O
depend,3893,O
on,3893,O
the,3893,O
diameter,3893,O
of,3893,O
the,3893,O
nanotubes,3893,O
.,3893,O
Apparently,3894,O
",",3894,O
a,3894,O
small,3894,O
diameter,3894,O
nanotube,3894,O
surface,3894,O
has,3894,O
on,3894,O
average,3894,O
more,3894,O
sharp,3894,O
convex,3894,O
edges,3894,O
per,3894,O
unit,3894,O
area,3894,O
than,3894,O
a,3894,O
large,3894,O
one,3894,O
",",3894,O
leading,3894,O
to,3894,O
stronger,3894,O
binding,3894,O
affinity,3894,O
on,3894,O
its,3894,O
surface,3894,O
.,3894,O
Abnormal,3895,O
uterine,3895,O
bleeding,3895,O
and,3895,O
dysfunctional,3895,O
uterine,3895,O
bleeding,3895,O
in,3895,O
pediatric,3895,O
and,3895,O
adolescent,3895,O
gynecology,3895,O
.,3895,O
Abnormal,3896,O
uterine,3896,O
bleeding,3896,O
(,3896,O
AUB,3896,O
),3896,O
",",3896,O
which,3896,O
is,3896,O
defined,3896,O
as,3896,O
excessively,3896,O
heavy,3896,O
",",3896,O
prolonged,3896,O
and/or,3896,O
frequent,3896,O
bleeding,3896,O
of,3896,O
uterine,3896,O
origin,3896,O
",",3896,O
is,3896,O
a,3896,O
frequent,3896,O
cause,3896,O
of,3896,O
visits,3896,O
to,3896,O
the,3896,O
Emergency,3896,O
Department,3896,O
and/or,3896,O
health,3896,O
care,3896,O
provider,3896,O
.,3896,O
While,3897,O
there,3897,O
are,3897,O
many,3897,O
etiologies,3897,O
of,3897,O
AUB,3897,O
",",3897,O
the,3897,O
one,3897,O
most,3897,O
likely,3897,O
among,3897,O
otherwise,3897,O
healthy,3897,O
adolescents,3897,O
is,3897,O
dysfunctional,3897,O
uterine,3897,O
bleeding,3897,O
(,3897,O
DUB,3897,O
),3897,O
",",3897,O
which,3897,O
is,3897,O
characterizing,3897,O
any,3897,O
AUB,3897,O
when,3897,O
all,3897,O
possible,3897,O
underlying,3897,O
pathologic,3897,O
causes,3897,O
have,3897,O
been,3897,O
previously,3897,O
excluded,3897,O
.,3897,O
The,3898,O
most,3898,O
common,3898,O
cause,3898,O
of,3898,O
DUB,3898,O
in,3898,O
adolescence,3898,O
is,3898,O
anovulation,3898,O
",",3898,O
which,3898,O
is,3898,O
very,3898,O
frequent,3898,O
in,3898,O
the,3898,O
first,3898,O
2-3,3898,O
post-menarchal,3898,O
years,3898,O
and,3898,O
is,3898,O
associated,3898,O
with,3898,O
immaturity,3898,O
of,3898,O
the,3898,O
hypothalamic,3898,O
-,3898,O
pituitary,3898,O
-,3898,O
ovarian,3898,O
axis,3898,O
.,3898,O
Management,3899,O
of,3899,O
AUB,3899,O
is,3899,O
based,3899,O
on,3899,O
the,3899,O
underlying,3899,O
etiology,3899,O
and,3899,O
the,3899,O
severity,3899,O
of,3899,O
the,3899,O
bleeding,3899,O
and,3899,O
primary,3899,O
goals,3899,O
are,3899,O
prevention,3899,O
of,3899,O
complications,3899,O
",",3899,O
such,3899,O
as,3899,O
anemia,3899,O
and,3899,O
reestablishment,3899,O
of,3899,O
regular,3899,O
cyclical,3899,O
bleeding,3899,O
",",3899,O
while,3899,O
the,3899,O
management,3899,O
of,3899,O
DUB,3899,O
can,3899,O
in,3899,O
part,3899,O
be,3899,O
directed,3899,O
by,3899,O
the,3899,O
amount,3899,O
of,3899,O
flow,3899,O
",",3899,O
the,3899,O
degree,3899,O
of,3899,O
associated,3899,O
anemia,3899,O
",",3899,O
as,3899,O
well,3899,O
as,3899,O
patient,3899,O
and,3899,O
family,3899,O
comfort,3899,O
with,3899,O
different,3899,O
treatment,3899,O
modalities,3899,O
.,3899,O
Treatment,3900,O
options,3900,O
for,3900,O
DUB,3900,O
are,3900,O
:,3900,O
combined,3900,O
oral,3900,O
contraceptives,3900,O
(,3900,O
COCs,3900,O
),3900,O
",",3900,O
progestogens,3900,B-CHEMICAL
",",3900,O
non,3900,O
steroidal,3900,O
anti,3900,O
inflammatory,3900,O
drugs,3900,O
(,3900,O
NSAIDs,3900,O
),3900,O
",",3900,O
tranexamic,3900,B-CHEMICAL
acid,3900,I-CHEMICAL
(,3900,O
anti-fibrinolytic,3900,O
),3900,O
",",3900,O
GnRH,3900,B-GENE-Y
analogues,3900,O
",",3900,O
Danazol,3900,B-CHEMICAL
and,3900,O
Levonorgestrel,3900,B-CHEMICAL
releasing,3900,O
intra,3900,O
uterine,3900,O
system,3900,O
(,3900,O
LNG,3900,O
IUS,3900,O
),3900,O
.,3900,O
Role,3901,O
of,3901,O
oestrogen,3901,B-GENE-Y
receptors,3901,I-GENE-Y
on,3901,O
the,3901,O
modulation,3901,O
of,3901,O
NADPH-diaphorase-positive,3901,B-GENE-N
cell,3901,O
number,3901,O
in,3901,O
supraoptic,3901,O
and,3901,O
paraventricular,3901,O
nuclei,3901,O
of,3901,O
ovariectomised,3901,O
female,3901,O
rats,3901,O
.,3901,O
Modulation,3902,O
of,3902,O
the,3902,O
nitric,3902,B-CHEMICAL
oxide,3902,I-CHEMICAL
producing,3902,O
system,3902,O
(,3902,O
demonstrated,3902,O
via,3902,O
the,3902,O
NADPH-diaphorase,3902,B-GENE-N
histochemical,3902,O
reaction,3902,O
),3902,O
by,3902,O
oestradiol,3902,B-CHEMICAL
has,3902,O
been,3902,O
established,3902,O
in,3902,O
several,3902,O
structures,3902,O
of,3902,O
the,3902,O
rat,3902,O
brain,3902,O
.,3902,O
The,3903,O
present,3903,O
study,3903,O
aimed,3903,O
to,3903,O
explore,3903,O
the,3903,O
possible,3903,O
regulation,3903,O
of,3903,O
NADPH-diaphorase,3903,B-CHEMICAL
activity,3903,O
by,3903,O
oestradiol,3903,B-CHEMICAL
in,3903,O
neurones,3903,O
of,3903,O
the,3903,O
supraoptic,3903,O
(,3903,O
SON,3903,O
),3903,O
and,3903,O
paraventricular,3903,O
(,3903,O
PVN,3903,O
),3903,O
nuclei,3903,O
and,3903,O
the,3903,O
role,3903,O
of,3903,O
oestrogen,3903,B-CHEMICAL
receptors,3903,I-GENE-Y
(,3903,O
ERα,3903,B-GENE-Y
and,3903,O
ERβ,3903,B-GENE-Y
),3903,O
in,3903,O
this,3903,O
regulation,3903,O
.,3903,O
Adult,3904,O
ovariectomised,3904,O
rats,3904,O
were,3904,O
divided,3904,O
into,3904,O
six,3904,O
groups,3904,O
and,3904,O
injected,3904,O
either,3904,O
with,3904,O
vehicle,3904,O
or,3904,O
a,3904,O
single,3904,O
dose,3904,O
of,3904,O
oestradiol,3904,B-CHEMICAL
",",3904,O
a,3904,O
selective,3904,O
ERα,3904,B-GENE-Y
agonist-PPT,3904,O
[,3904,O
"4,4',4″-",3904,B-CHEMICAL
(,3904,I-CHEMICAL
4-propyl-,3904,I-CHEMICAL
[,3904,I-CHEMICAL
1H,3904,I-CHEMICAL
],3904,I-CHEMICAL
"-pyrazole-1,3,5-triyl",3904,I-CHEMICAL
),3904,I-CHEMICAL
trisphenol,3904,I-CHEMICAL
],3904,O
",",3904,O
a,3904,O
selective,3904,O
ERβ,3904,B-GENE-Y
agonist-DPN,3904,O
[,3904,O
"2,3-bis",3904,B-CHEMICAL
(,3904,I-CHEMICAL
4-hydroxyphenyl,3904,I-CHEMICAL
),3904,I-CHEMICAL
-propionitrile,3904,I-CHEMICAL
],3904,O
",",3904,O
a,3904,O
selective,3904,O
ERα,3904,B-GENE-Y
antagonist-MPP,3904,O
[,3904,O
"1,3-bis",3904,B-CHEMICAL
(,3904,I-CHEMICAL
4-hydroxyphenyl,3904,I-CHEMICAL
),3904,I-CHEMICAL
-4-methyl-5-,3904,I-CHEMICAL
[,3904,I-CHEMICAL
4-,3904,I-CHEMICAL
(,3904,I-CHEMICAL
2-piperidinylethoxy,3904,I-CHEMICAL
),3904,I-CHEMICAL
phenol,3904,I-CHEMICAL
],3904,O
-1H-pyrazole,3904,O
dihydrochloride,3904,I-CHEMICAL
],3904,O
or,3904,O
a,3904,O
selective,3904,O
ERβ,3904,B-GENE-Y
antagonist-PHTPP,3904,O
(,3904,O
4-,3904,B-CHEMICAL
[,3904,I-CHEMICAL
"2-phenyl-5,7-bis",3904,I-CHEMICAL
(,3904,I-CHEMICAL
trifluoromethyl,3904,I-CHEMICAL
),3904,I-CHEMICAL
pyrazolo,3904,I-CHEMICAL
[,3904,I-CHEMICAL
"1,5-a",3904,I-CHEMICAL
],3904,I-CHEMICAL
pyrimidin-3-yl,3904,I-CHEMICAL
],3904,I-CHEMICAL
phenol,3904,I-CHEMICAL
),3904,O
.,3904,O
The,3905,O
number,3905,O
of,3905,O
NADPH-diaphorase,3905,B-GENE-N
positive,3905,O
elements,3905,O
in,3905,O
the,3905,O
SON,3905,O
and,3905,O
the,3905,O
PVN,3905,O
was,3905,O
modulated,3905,O
by,3905,O
both,3905,O
ERs,3905,B-GENE-Y
but,3905,O
",",3905,O
depending,3905,O
on,3905,O
the,3905,O
nucleus,3905,O
",",3905,O
ERα,3905,B-GENE-Y
and,3905,O
ERβ,3905,B-GENE-Y
ligands,3905,O
induced,3905,O
different,3905,O
effects,3905,O
.,3905,O
These,3906,O
results,3906,O
suggest,3906,O
that,3906,O
the,3906,O
regulation,3906,O
of,3906,O
nitrergic,3906,O
system,3906,O
by,3906,O
ERs,3906,B-GENE-Y
may,3906,O
play,3906,O
a,3906,O
role,3906,O
in,3906,O
the,3906,O
control,3906,O
of,3906,O
oestrogen-dependent,3906,B-CHEMICAL
physiological,3906,O
mechanisms,3906,O
regulated,3906,O
by,3906,O
the,3906,O
SON,3906,O
and,3906,O
the,3906,O
PVN,3906,O
.,3906,O
Human,3907,B-GENE-Y
plasma-derived,3907,I-GENE-Y
BuChE,3907,I-GENE-Y
as,3907,O
a,3907,O
stoichiometric,3907,O
bioscavenger,3907,O
for,3907,O
treatment,3907,O
of,3907,O
nerve,3907,O
agent,3907,O
poisoning,3907,O
.,3907,O
Potent,3908,O
organophosphorous,3908,B-CHEMICAL
(,3908,O
OP,3908,O
),3908,O
agents,3908,O
",",3908,O
such,3908,O
as,3908,O
VX,3908,O
",",3908,O
are,3908,O
hazardous,3908,O
by,3908,O
absorption,3908,O
through,3908,O
the,3908,O
skin,3908,O
and,3908,O
are,3908,O
resistant,3908,O
to,3908,O
conventional,3908,O
pharmacological,3908,O
antidotal,3908,O
treatments,3908,O
.,3908,O
The,3909,O
residence,3909,O
time,3909,O
of,3909,O
a,3909,O
stoichiometric,3909,O
bioscavenger,3909,O
",",3909,O
human,3909,B-GENE-Y
butyrylcholinesterase,3909,I-GENE-Y
(,3909,O
huBuChE,3909,B-GENE-Y
),3909,O
",",3909,O
in,3909,O
the,3909,O
plasma,3909,O
more,3909,O
closely,3909,O
matches,3909,O
that,3909,O
of,3909,O
VX,3909,O
than,3909,O
do,3909,O
the,3909,O
residence,3909,O
times,3909,O
of,3909,O
conventional,3909,O
therapy,3909,O
drugs,3909,O
(,3909,O
oxime,3909,B-CHEMICAL
",",3909,O
anti-muscarinic,3909,O
",",3909,O
anticonvulsant,3909,O
),3909,O
.,3909,O
Intramuscular,3910,O
(,3910,O
i.m,3910,O
.,3910,O
),3910,O
huBuChE,3911,B-GENE-Y
afforded,3911,O
almost,3911,O
complete,3911,O
protection,3911,O
when,3911,O
administered,3911,O
prior,3911,O
to,3911,O
the,3911,O
onset,3911,O
of,3911,O
observable,3911,O
cholinergic,3911,O
signs,3911,O
of,3911,O
VX,3911,O
poisoning,3911,O
",",3911,O
but,3911,O
once,3911,O
signs,3911,O
of,3911,O
poisoning,3911,O
became,3911,O
evident,3911,O
the,3911,O
efficacy,3911,O
of,3911,O
i.m,3911,O
.,3911,O
huBuChE,3912,B-GENE-Y
decreased,3912,O
.,3912,O
A,3913,O
combination,3913,O
of,3913,O
nerve,3913,O
agent,3913,O
therapy,3913,O
drugs,3913,O
(,3913,O
oxime,3913,B-CHEMICAL
",",3913,O
anti-muscarinic,3913,O
",",3913,O
anticonvulsant,3913,O
),3913,O
with,3913,O
huBuChE,3913,B-GENE-Y
(,3913,O
i.m,3913,O
.,3913,O
),3913,O
protected,3914,O
100,3914,O
%,3914,O
(,3914,O
8/8,3914,O
),3914,O
of,3914,O
guinea-pigs,3914,O
from,3914,O
a,3914,O
lethal,3914,O
dose,3914,O
of,3914,O
VX,3914,O
(,3914,O
0.74mg/kg,3914,O
),3914,O
to,3914,O
48h,3914,O
",",3914,O
even,3914,O
when,3914,O
administered,3914,O
on,3914,O
signs,3914,O
of,3914,O
poisoning,3914,O
.,3914,O
Survival,3915,O
was,3915,O
presumed,3915,O
to,3915,O
be,3915,O
due,3915,O
to,3915,O
immediate,3915,O
alleviation,3915,O
of,3915,O
the,3915,O
cholinergic,3915,O
crisis,3915,O
by,3915,O
the,3915,O
conventional,3915,O
pharmacological,3915,O
treatment,3915,O
drugs,3915,O
",",3915,O
in,3915,O
conjunction,3915,O
with,3915,O
bioscavenger,3915,O
that,3915,O
prevented,3915,O
further,3915,O
absorbed,3915,O
agent,3915,O
reaching,3915,O
the,3915,O
AChE,3915,B-GENE-Y
targets,3915,O
.,3915,O
Evidence,3916,O
to,3916,O
support,3916,O
this,3916,O
proposed,3916,O
mechanism,3916,O
of,3916,O
action,3916,O
was,3916,O
obtained,3916,O
from,3916,O
PKPD,3916,O
experiments,3916,O
in,3916,O
which,3916,O
multiple,3916,O
blood,3916,O
samples,3916,O
and,3916,O
microdialysate,3916,O
samples,3916,O
were,3916,O
collected,3916,O
from,3916,O
individual,3916,O
conscious,3916,O
ambulatory,3916,O
animals,3916,O
.,3916,O
Plasma,3917,O
concentrations,3917,O
of,3917,O
intramuscularly-administered,3917,O
atropine,3917,B-CHEMICAL
",",3917,O
diazepam,3917,B-CHEMICAL
and,3917,O
HI-6,3917,B-CHEMICAL
reached,3917,O
a,3917,O
peak,3917,O
within,3917,O
15min,3917,O
and,3917,O
were,3917,O
eliminated,3917,O
rapidly,3917,O
within,3917,O
4h,3917,O
.,3917,O
Plasma,3918,O
concentrations,3918,O
of,3918,O
huBuChE,3918,B-GENE-Y
administered,3918,O
by,3918,O
the,3918,O
i.m,3918,O
.,3918,O
route,3919,O
took,3919,O
approximately,3919,O
24h,3919,O
to,3919,O
reach,3919,O
a,3919,O
peak,3919,O
",",3919,O
but,3919,O
were,3919,O
well-maintained,3919,O
over,3919,O
the,3919,O
subsequent,3919,O
7days,3919,O
.,3919,O
Thus,3920,O
",",3920,O
the,3920,O
pharmacological,3920,O
therapy,3920,O
rapidly,3920,O
treated,3920,O
the,3920,O
initial,3920,O
signs,3920,O
of,3920,O
poisoning,3920,O
",",3920,O
whilst,3920,O
the,3920,O
bioscavenger,3920,O
provided,3920,O
prolonged,3920,O
protection,3920,O
by,3920,O
neutralising,3920,O
further,3920,O
nerve,3920,O
agent,3920,O
entering,3920,O
the,3920,O
bloodstream,3920,O
and,3920,O
preventing,3920,O
it,3920,O
from,3920,O
reaching,3920,O
the,3920,O
target,3920,O
organs,3920,O
.,3920,O
Verrucarin,3921,B-CHEMICAL
A,3921,I-CHEMICAL
sensitizes,3921,O
TRAIL-induced,3921,B-GENE-Y
apoptosis,3921,O
via,3921,O
the,3921,O
upregulation,3921,O
of,3921,O
DR5,3921,B-GENE-Y
in,3921,O
an,3921,O
eIF2α/CHOP-dependent,3921,B-GENE-Y
manner,3921,O
.,3921,O
Tumor,3922,B-GENE-Y
necrosis,3922,I-GENE-Y
factor-related,3922,I-GENE-Y
apoptosis-inducing,3922,I-GENE-Y
ligand,3922,I-GENE-Y
(,3922,O
TRAIL,3922,B-GENE-Y
),3922,O
is,3922,O
one,3922,O
of,3922,O
the,3922,O
most,3922,O
promising,3922,O
candidates,3922,O
for,3922,O
new,3922,O
cancer,3922,O
therapeutics,3922,O
.,3922,O
However,3923,O
",",3923,O
resistance,3923,O
to,3923,O
TRAIL,3923,B-GENE-Y
in,3923,O
some,3923,O
cancers,3923,O
remains,3923,O
a,3923,O
current,3923,O
problem,3923,O
in,3923,O
recent,3923,O
.,3923,O
The,3924,O
protein-folding,3924,O
compartment,3924,O
of,3924,O
the,3924,O
endoplasmic,3924,O
reticulum,3924,O
(,3924,O
ER,3924,O
),3924,O
is,3924,O
particularly,3924,O
sensitive,3924,O
to,3924,O
disturbances,3924,O
",",3924,O
which,3924,O
",",3924,O
if,3924,O
severe,3924,O
",",3924,O
may,3924,O
trigger,3924,O
apoptosis,3924,O
.,3924,O
Therefore,3925,O
",",3925,O
we,3925,O
examined,3925,O
whether,3925,O
verrucarin,3925,B-CHEMICAL
A,3925,I-CHEMICAL
(,3925,O
VA,3925,O
),3925,O
sensitize,3925,O
TRAIL-induced,3925,B-GENE-Y
apoptosis,3925,O
in,3925,O
cancer,3925,O
cells,3925,O
by,3925,O
induction,3925,O
of,3925,O
ER,3925,O
stress,3925,O
.,3925,O
We,3926,O
first,3926,O
found,3926,O
that,3926,O
VA,3926,O
induces,3926,O
a,3926,O
major,3926,O
molecule,3926,O
of,3926,O
ER,3926,O
stress,3926,O
",",3926,O
CCAAT/enhancer,3926,B-GENE-Y
binding,3926,I-GENE-Y
protein,3926,I-GENE-Y
homologous,3926,I-GENE-Y
protein,3926,I-GENE-Y
(,3926,O
CHOP,3926,B-GENE-Y
),3926,O
-dependent,3926,O
DR5,3926,B-GENE-N
induction,3926,O
and,3926,O
subsequently,3926,O
increases,3926,O
TRAIL-induced,3926,B-GENE-Y
cleavage,3926,O
of,3926,O
caspases,3926,B-GENE-N
and,3926,O
PARP,3926,B-GENE-N
in,3926,O
TRAIL-resistant,3926,B-GENE-Y
Hep3B,3926,O
cells,3926,O
.,3926,O
Importantly,3927,O
",",3927,O
the,3927,O
transient,3927,O
knockdown,3927,O
using,3927,O
siRNA,3927,O
for,3927,O
CHOP,3927,B-GENE-Y
abrogated,3927,O
VA-induced,3927,O
DR5,3927,B-GENE-Y
expression,3927,O
and,3927,O
attenuated,3927,O
TRAIL-induced,3927,B-GENE-Y
apoptosis,3927,O
.,3927,O
Treatment,3928,O
with,3928,O
VA,3928,O
also,3928,O
increased,3928,O
the,3928,O
levels,3928,O
of,3928,O
phosphorylation,3928,O
of,3928,O
eukaryotic,3928,B-GENE-Y
translation,3928,I-GENE-Y
initiation,3928,I-GENE-Y
factor-2α,3928,I-GENE-Y
(,3928,O
eIF2α,3928,B-GENE-Y
),3928,O
",",3928,O
which,3928,O
is,3928,O
a,3928,O
common,3928,O
cellular,3928,O
response,3928,O
of,3928,O
ER,3928,O
stress,3928,O
.,3928,O
Furthermore,3929,O
",",3929,O
salubrinal,3929,B-CHEMICAL
",",3929,O
a,3929,O
specific,3929,O
eIF2α,3929,B-GENE-Y
phosphorylation-inducing,3929,O
agent,3929,O
",",3929,O
increased,3929,O
CHOP,3929,B-GENE-Y
and,3929,O
DR5,3929,B-GENE-Y
expression,3929,O
in,3929,O
the,3929,O
presence,3929,O
of,3929,O
VA,3929,O
.,3929,O
In,3930,O
contrast,3930,O
",",3930,O
transfection,3930,O
of,3930,O
mutant-eIF2α,3930,O
significantly,3930,O
reversed,3930,O
VA-induced,3930,O
apoptosis,3930,O
with,3930,O
downregulation,3930,O
of,3930,O
CHOP-dependent,3930,B-GENE-Y
DR5,3930,B-GENE-Y
expression,3930,O
.,3930,O
Therefore,3931,O
",",3931,O
VA-induced,3931,O
eIF2α,3931,B-GENE-Y
phosphorylation,3931,O
seemed,3931,O
to,3931,O
be,3931,O
important,3931,O
for,3931,O
CHOP,3931,B-GENE-Y
and,3931,O
DR5,3931,B-GENE-Y
upregulation,3931,O
and,3931,O
TRAIL-induced,3931,B-GENE-Y
apoptosis,3931,O
.,3931,O
In,3932,O
addition,3932,O
",",3932,O
generation,3932,O
of,3932,O
reactive,3932,O
oxygen,3932,B-CHEMICAL
species,3932,O
(,3932,O
ROS,3932,O
),3932,O
is,3932,O
an,3932,O
effector,3932,O
molecular,3932,O
in,3932,O
sensitization,3932,O
of,3932,O
VA-induced,3932,O
ER,3932,O
stress,3932,O
.,3932,O
We,3933,O
concluded,3933,O
that,3933,O
VA,3933,O
triggers,3933,O
TRAIL-induced,3933,B-GENE-Y
apoptosis,3933,O
by,3933,O
eIF2α/CHOP-dependent,3933,B-GENE-Y
DR5,3933,B-GENE-Y
induction,3933,O
via,3933,O
ROS,3933,O
generation,3933,O
.,3933,O
Proteolytic,3934,O
processing,3934,O
of,3934,O
osteopontin,3934,B-GENE-Y
by,3934,O
PHEX,3934,B-GENE-Y
and,3934,O
accumulation,3934,O
of,3934,O
osteopontin,3934,B-GENE-Y
fragments,3934,O
in,3934,O
Hyp,3934,O
mouse,3934,O
bone,3934,O
",",3934,O
the,3934,O
murine,3934,O
model,3934,O
of,3934,O
X-linked,3934,O
hypophosphatemia,3934,O
.,3934,O
X-linked,3935,O
hypophosphatemia,3935,O
(,3935,O
XLH/HYP,3935,O
),3935,O
-with,3935,O
renal,3935,O
phosphate,3935,B-CHEMICAL
wasting,3935,O
",",3935,O
hypophosphatemia,3935,O
",",3935,O
osteomalacia,3935,O
",",3935,O
and,3935,O
tooth,3935,O
abscesses-is,3935,O
caused,3935,O
by,3935,O
mutations,3935,O
in,3935,O
the,3935,O
zinc-metallopeptidase,3935,B-CHEMICAL
PHEX,3935,B-GENE-Y
gene,3935,O
(,3935,O
phosphate-regulating,3935,B-CHEMICAL
gene,3935,O
with,3935,O
homologies,3935,O
to,3935,O
endopeptidase,3935,B-GENE-N
on,3935,O
the,3935,O
X,3935,O
chromosome,3935,O
),3935,O
.,3935,O
PHEX,3936,B-GENE-Y
is,3936,O
highly,3936,O
expressed,3936,O
by,3936,O
mineralized,3936,O
tissue,3936,O
cells,3936,O
.,3936,O
Inactivating,3937,O
mutations,3937,O
in,3937,O
PHEX,3937,B-GENE-Y
lead,3937,O
to,3937,O
distal,3937,O
renal,3937,O
effects,3937,O
(,3937,O
implying,3937,O
accumulation,3937,O
of,3937,O
a,3937,O
secreted,3937,O
",",3937,O
circulating,3937,O
phosphaturic,3937,O
factor,3937,O
),3937,O
and,3937,O
accumulation,3937,O
in,3937,O
bone,3937,O
and,3937,O
teeth,3937,O
of,3937,O
mineralization-inhibiting,3937,O
",",3937,O
acidic,3937,B-GENE-N
serine-,3937,B-CHEMICAL
and,3937,I-GENE-N
aspartate-rich,3937,B-CHEMICAL
motif,3937,I-GENE-N
(,3937,O
ASARM,3937,B-GENE-N
),3937,O
-containing,3937,O
peptides,3937,O
",",3937,O
which,3937,O
are,3937,O
proteolytically,3937,O
derived,3937,O
from,3937,O
the,3937,O
mineral-binding,3937,O
matrix,3937,O
proteins,3937,O
of,3937,O
the,3937,O
SIBLING,3937,B-GENE-N
family,3937,O
(,3937,O
small,3937,B-GENE-N
",",3937,I-GENE-N
integrin-binding,3937,I-GENE-N
ligand,3937,I-GENE-N
N-linked,3937,B-CHEMICAL
glycoproteins,3937,I-GENE-N
),3937,O
.,3937,O
Although,3938,O
the,3938,O
latter,3938,O
observation,3938,O
suggests,3938,O
a,3938,O
local,3938,O
",",3938,O
direct,3938,O
matrix,3938,O
effect,3938,O
for,3938,O
PHEX,3938,B-GENE-Y
",",3938,O
its,3938,O
physiologically,3938,O
relevant,3938,O
substrate,3938,O
protein,3938,O
(,3938,O
s,3938,O
),3938,O
have,3938,O
not,3938,O
been,3938,O
identified,3938,O
.,3938,O
Here,3939,O
",",3939,O
we,3939,O
investigated,3939,O
two,3939,O
SIBLING,3939,B-GENE-N
proteins,3939,O
containing,3939,O
the,3939,O
ASARM,3939,B-GENE-N
motif-osteopontin,3939,O
(,3939,O
OPN,3939,B-GENE-Y
),3939,O
and,3939,O
bone,3939,B-GENE-Y
sialoprotein,3939,I-GENE-Y
(,3939,O
BSP,3939,B-GENE-Y
),3939,O
-as,3939,O
potential,3939,O
substrates,3939,O
for,3939,O
PHEX,3939,B-GENE-Y
.,3939,O
Using,3940,O
cleavage,3940,O
assays,3940,O
",",3940,O
gel,3940,O
electrophoresis,3940,O
",",3940,O
and,3940,O
mass,3940,O
spectrometry,3940,O
",",3940,O
we,3940,O
report,3940,O
that,3940,O
OPN,3940,B-GENE-Y
is,3940,O
a,3940,O
full-length,3940,O
protein,3940,O
substrate,3940,O
for,3940,O
PHEX,3940,B-GENE-Y
.,3940,O
Degradation,3941,O
of,3941,O
OPN,3941,B-GENE-Y
was,3941,O
essentially,3941,O
complete,3941,O
",",3941,O
including,3941,O
hydrolysis,3941,O
of,3941,O
the,3941,O
ASARM,3941,B-GENE-N
motif,3941,I-GENE-N
",",3941,O
resulting,3941,O
in,3941,O
only,3941,O
very,3941,O
small,3941,O
residual,3941,O
fragments,3941,O
.,3941,O
Western,3942,O
blotting,3942,O
of,3942,O
Hyp,3942,B-GENE-Y
(,3942,O
the,3942,O
murine,3942,O
homolog,3942,O
of,3942,O
human,3942,B-GENE-Y
XLH,3942,I-GENE-Y
),3942,O
mouse,3942,O
bone,3942,O
extracts,3942,O
having,3942,O
no,3942,O
PHEX,3942,B-GENE-Y
activity,3942,O
clearly,3942,O
showed,3942,O
accumulation,3942,O
of,3942,O
an,3942,O
∼35,3942,O
kDa,3942,O
OPN,3942,B-GENE-Y
fragment,3942,O
that,3942,O
was,3942,O
not,3942,O
present,3942,O
in,3942,O
wild-type,3942,O
mouse,3942,O
bone,3942,O
.,3942,O
Immunohistochemistry,3943,O
and,3943,O
immunogold,3943,O
labeling,3943,O
(,3943,O
electron,3943,O
microscopy,3943,O
),3943,O
for,3943,O
OPN,3943,B-GENE-Y
in,3943,O
Hyp,3943,O
bone,3943,O
likewise,3943,O
showed,3943,O
an,3943,O
accumulation,3943,O
of,3943,O
OPN,3943,B-GENE-Y
and/or,3943,O
its,3943,O
fragments,3943,O
compared,3943,O
with,3943,O
normal,3943,O
wild-type,3943,O
bone,3943,O
.,3943,O
Incubation,3944,O
of,3944,O
Hyp,3944,O
mouse,3944,O
bone,3944,O
extracts,3944,O
with,3944,O
PHEX,3944,B-GENE-Y
resulted,3944,O
in,3944,O
the,3944,O
complete,3944,O
degradation,3944,O
of,3944,O
these,3944,O
fragments,3944,O
.,3944,O
In,3945,O
conclusion,3945,O
",",3945,O
these,3945,O
results,3945,O
identify,3945,O
full-length,3945,O
OPN,3945,B-GENE-Y
and,3945,O
its,3945,O
fragments,3945,O
as,3945,O
novel,3945,O
",",3945,O
physiologically,3945,O
relevant,3945,O
substrates,3945,O
for,3945,O
PHEX,3945,B-GENE-Y
",",3945,O
suggesting,3945,O
that,3945,O
accumulation,3945,O
of,3945,O
mineralization-inhibiting,3945,O
OPN,3945,B-GENE-Y
fragments,3945,O
may,3945,O
contribute,3945,O
to,3945,O
the,3945,O
mineralization,3945,O
defect,3945,O
seen,3945,O
in,3945,O
the,3945,O
osteomalacic,3945,O
bone,3945,O
characteristic,3945,O
of,3945,O
XLH/HYP,3945,O
.,3945,O
Targeted,3946,O
disruption,3946,O
of,3946,O
inducible,3946,B-GENE-Y
nitric,3946,B-CHEMICAL
oxide,3946,I-CHEMICAL
synthase,3946,I-GENE-Y
protects,3946,O
against,3946,O
aging,3946,O
",",3946,O
S-nitrosation,3946,B-CHEMICAL
",",3946,O
and,3946,O
insulin,3946,B-GENE-N
resistance,3946,O
in,3946,O
muscle,3946,O
of,3946,O
male,3946,O
mice,3946,O
.,3946,O
Accumulating,3947,O
evidence,3947,O
has,3947,O
demonstrated,3947,O
that,3947,O
S-nitrosation,3947,B-CHEMICAL
of,3947,O
proteins,3947,O
plays,3947,O
a,3947,O
critical,3947,O
role,3947,O
in,3947,O
several,3947,O
human,3947,O
diseases,3947,O
.,3947,O
Here,3948,O
",",3948,O
we,3948,O
explored,3948,O
the,3948,O
role,3948,O
of,3948,O
inducible,3948,B-GENE-Y
nitric,3948,B-CHEMICAL
oxide,3948,I-CHEMICAL
synthase,3948,I-GENE-Y
(,3948,O
iNOS,3948,B-GENE-Y
),3948,O
in,3948,O
the,3948,O
S-nitrosation,3948,B-CHEMICAL
of,3948,O
proteins,3948,O
involved,3948,O
in,3948,O
the,3948,O
early,3948,O
steps,3948,O
of,3948,O
the,3948,O
insulin-signaling,3948,B-GENE-N
pathway,3948,O
and,3948,O
insulin,3948,B-GENE-N
resistance,3948,O
in,3948,O
the,3948,O
skeletal,3948,O
muscle,3948,O
of,3948,O
aged,3948,O
mice,3948,O
.,3948,O
Aging,3949,O
increased,3949,O
iNOS,3949,B-GENE-Y
expression,3949,O
and,3949,O
S-nitrosation,3949,B-CHEMICAL
of,3949,O
major,3949,O
proteins,3949,O
involved,3949,O
in,3949,O
insulin,3949,B-GENE-N
signaling,3949,O
",",3949,O
thereby,3949,O
reducing,3949,O
insulin,3949,B-GENE-N
sensitivity,3949,O
in,3949,O
skeletal,3949,O
muscle,3949,O
.,3949,O
Conversely,3950,O
",",3950,O
aged,3950,O
iNOS-null,3950,B-GENE-Y
mice,3950,O
were,3950,O
protected,3950,O
from,3950,O
S-nitrosation-induced,3950,B-CHEMICAL
insulin,3950,B-GENE-N
resistance,3950,O
.,3950,O
Moreover,3951,O
",",3951,O
pharmacological,3951,O
treatment,3951,O
with,3951,O
an,3951,O
iNOS,3951,B-GENE-Y
inhibitor,3951,O
and,3951,O
acute,3951,O
exercise,3951,O
reduced,3951,O
iNOS-induced,3951,B-GENE-Y
S-nitrosation,3951,B-CHEMICAL
and,3951,O
increased,3951,O
insulin,3951,B-GENE-N
sensitivity,3951,O
in,3951,O
the,3951,O
muscle,3951,O
of,3951,O
aged,3951,O
animals,3951,O
.,3951,O
These,3952,O
findings,3952,O
indicate,3952,O
that,3952,O
the,3952,O
insulin,3952,B-GENE-N
resistance,3952,O
observed,3952,O
in,3952,O
aged,3952,O
mice,3952,O
is,3952,O
mainly,3952,O
mediated,3952,O
through,3952,O
the,3952,O
S-nitrosation,3952,B-CHEMICAL
of,3952,O
the,3952,O
insulin-signaling,3952,B-GENE-N
pathway,3952,O
.,3952,O
Genetic,3953,O
correlate,3953,O
of,3953,O
cognitive,3953,O
training,3953,O
response,3953,O
in,3953,O
schizophrenia,3953,O
.,3953,O
Intensive,3954,O
computerized,3954,O
auditory,3954,O
training,3954,O
results,3954,O
in,3954,O
improved,3954,O
cognition,3954,O
for,3954,O
schizophrenia,3954,O
patients,3954,O
",",3954,O
but,3954,O
participants,3954,O
show,3954,O
variation,3954,O
in,3954,O
their,3954,O
cognitive,3954,O
gains,3954,O
and,3954,O
the,3954,O
biological,3954,O
factors,3954,O
that,3954,O
affect,3954,O
the,3954,O
response,3954,O
to,3954,O
training,3954,O
are,3954,O
unknown,3954,O
.,3954,O
Single,3955,O
nucleotide,3955,O
polymorphisms,3955,O
(,3955,O
SNPs,3955,O
),3955,O
in,3955,O
the,3955,O
catechol-O-methyltransferase,3955,B-GENE-Y
(,3955,O
COMT,3955,B-GENE-Y
),3955,O
gene,3955,O
have,3955,O
been,3955,O
related,3955,O
to,3955,O
cognitive,3955,O
function,3955,O
.,3955,O
Here,3956,O
we,3956,O
asked,3956,O
if,3956,O
functional,3956,O
variation,3956,O
in,3956,O
this,3956,O
gene,3956,O
has,3956,O
an,3956,O
impact,3956,O
on,3956,O
the,3956,O
response,3956,O
of,3956,O
schizophrenia,3956,O
patients,3956,O
to,3956,O
cognitive,3956,O
training,3956,O
.,3956,O
We,3957,O
genotyped,3957,O
48,3957,O
schizophrenia,3957,O
patients,3957,O
who,3957,O
completed,3957,O
50,3957,O
h,3957,O
of,3957,O
computerized,3957,O
cognitive,3957,O
training,3957,O
and,3957,O
analyzed,3957,O
the,3957,O
association,3957,O
between,3957,O
DNA,3957,O
variants,3957,O
in,3957,O
the,3957,O
COMT,3957,B-GENE-Y
gene,3957,O
and,3957,O
the,3957,O
improvement,3957,O
in,3957,O
global,3957,O
cognition,3957,O
.,3957,O
Although,3958,O
conventional,3958,O
analyses,3958,O
did,3958,O
not,3958,O
reveal,3958,O
any,3958,O
significant,3958,O
associations,3958,O
",",3958,O
a,3958,O
set-based,3958,O
analysis,3958,O
examining,3958,O
the,3958,O
aggregate,3958,O
effect,3958,O
of,3958,O
common,3958,O
variation,3958,O
in,3958,O
the,3958,O
COMT,3958,B-GENE-Y
gene,3958,O
(,3958,O
42,3958,O
SNPs,3958,O
),3958,O
suggested,3958,O
association,3958,O
with,3958,O
improvement,3958,O
in,3958,O
global,3958,O
cognition,3958,O
.,3958,O
Eight,3959,O
SNPs,3959,O
",",3959,O
mostly,3959,O
located,3959,O
in,3959,O
the,3959,O
3,3959,O
',3959,O
end,3959,O
of,3959,O
the,3959,O
COMT,3959,B-GENE-Y
gene,3959,O
",",3959,O
were,3959,O
nominally,3959,O
associated,3959,O
with,3959,O
improvement,3959,O
in,3959,O
cognition,3959,O
.,3959,O
These,3960,O
data,3960,O
suggest,3960,O
that,3960,O
genotype,3960,O
influences,3960,O
the,3960,O
response,3960,O
to,3960,O
intensive,3960,O
cognitive,3960,O
training,3960,O
in,3960,O
schizophrenia,3960,O
",",3960,O
and,3960,O
may,3960,O
indicate,3960,O
that,3960,O
cognitive,3960,O
training,3960,O
regimens,3960,O
need,3960,O
to,3960,O
be,3960,O
personalized,3960,O
to,3960,O
the,3960,O
underlying,3960,O
biosignatures,3960,O
of,3960,O
each,3960,O
individual,3960,O
patient,3960,O
.,3960,O
This,3961,O
article,3961,O
is,3961,O
part,3961,O
of,3961,O
a,3961,O
Special,3961,O
Issue,3961,O
entitled,3961,O
'Cognitive,3961,O
Enhancers,3961,O
',3961,O
.,3961,O
Microtubule,3962,O
network,3962,O
is,3962,O
required,3962,O
for,3962,O
insulin-induced,3962,B-GENE-Y
signal,3962,O
transduction,3962,O
and,3962,O
actin,3962,O
remodeling,3962,O
.,3962,O
Both,3963,O
microtubule,3963,O
and,3963,O
actin,3963,B-GENE-N
are,3963,O
required,3963,O
for,3963,O
insulin-induced,3963,B-GENE-Y
glucose,3963,B-CHEMICAL
uptake,3963,O
.,3963,O
However,3964,O
",",3964,O
the,3964,O
roles,3964,O
of,3964,O
these,3964,O
two,3964,O
cytoskeletons,3964,O
and,3964,O
their,3964,O
relationship,3964,O
in,3964,O
insulin,3964,B-GENE-Y
action,3964,O
still,3964,O
remain,3964,O
unclear,3964,O
.,3964,O
In,3965,O
this,3965,O
work,3965,O
",",3965,O
we,3965,O
examined,3965,O
the,3965,O
morphological,3965,O
change,3965,O
of,3965,O
microtubule/actin,3965,O
and,3965,O
their,3965,O
involvement,3965,O
in,3965,O
insulin,3965,B-GENE-N
signal,3965,O
transduction,3965,O
using,3965,O
rat,3965,O
skeletal,3965,O
muscle,3965,O
cells,3965,O
.,3965,O
Insulin,3966,B-GENE-N
rapidly,3966,O
led,3966,O
to,3966,O
microtubule,3966,O
clustering,3966,O
from,3966,O
ventral,3966,O
to,3966,O
dorsal,3966,O
surface,3966,O
of,3966,O
the,3966,O
cell,3966,O
.,3966,O
Microtubule,3967,O
filaments,3967,O
were,3967,O
rearranged,3967,O
to,3967,O
create,3967,O
space,3967,O
where,3967,O
new,3967,O
actin,3967,B-GENE-N
structures,3967,O
formed,3967,O
.,3967,O
Disruption,3968,O
of,3968,O
microtubule,3968,O
prevented,3968,O
insulin-induced,3968,B-GENE-N
actin,3968,B-GENE-N
remodeling,3968,O
and,3968,O
distal,3968,O
insulin,3968,B-GENE-N
signal,3968,O
transduction,3968,O
",",3968,O
with,3968,O
reduction,3968,O
in,3968,O
surface,3968,O
glucose,3968,B-CHEMICAL
transporter,3968,I-GENE-Y
isoform,3968,I-GENE-Y
4,3968,I-GENE-Y
(,3968,O
GLUT4,3968,B-GENE-Y
),3968,O
and,3968,O
glucose,3968,B-CHEMICAL
uptake,3968,O
.,3968,O
Though,3969,O
microtubule,3969,O
mediated,3969,O
actin,3969,B-GENE-N
remodeling,3969,O
through,3969,O
PKCζ,3969,B-GENE-Y
",",3969,O
reorganization,3969,O
of,3969,O
microtubule,3969,O
depended,3969,O
on,3969,O
tyrosine,3969,B-CHEMICAL
phosphorylation,3969,O
of,3969,O
insulin,3969,B-GENE-Y
receptor,3969,I-GENE-Y
",",3969,O
the,3969,O
mechanism,3969,O
is,3969,O
different,3969,O
from,3969,O
insulin-induced,3969,B-GENE-N
actin,3969,B-GENE-N
remodeling,3969,O
",",3969,O
which,3969,O
relied,3969,O
on,3969,O
the,3969,O
activity,3969,O
of,3969,O
PI3-kinase,3969,B-GENE-N
and,3969,O
PKCζ,3969,B-GENE-Y
.,3969,O
We,3970,O
propose,3970,O
that,3970,O
microtubule,3970,O
network,3970,O
is,3970,O
required,3970,O
for,3970,O
insulin-induced,3970,B-GENE-N
signal,3970,O
transduction,3970,O
and,3970,O
actin,3970,B-GENE-N
remodeling,3970,O
in,3970,O
skeletal,3970,O
muscle,3970,O
cells,3970,O
.,3970,O
The,3971,O
influence,3971,O
of,3971,O
chronic,3971,O
fluorosis,3971,O
on,3971,O
mitochondrial,3971,O
dynamics,3971,O
morphology,3971,O
and,3971,O
distribution,3971,O
in,3971,O
cortical,3971,O
neurons,3971,O
of,3971,O
the,3971,O
rat,3971,O
brain,3971,O
.,3971,O
The,3972,O
present,3972,O
study,3972,O
was,3972,O
designed,3972,O
to,3972,O
evaluate,3972,O
the,3972,O
effects,3972,O
of,3972,O
chronic,3972,O
fluorosis,3972,O
on,3972,O
the,3972,O
dynamics,3972,O
(,3972,O
including,3972,O
fusion,3972,O
and,3972,O
fission,3972,O
proteins,3972,O
),3972,O
",",3972,O
fragmentation,3972,O
",",3972,O
and,3972,O
distribution,3972,O
of,3972,O
mitochondria,3972,O
in,3972,O
the,3972,O
cortical,3972,O
neurons,3972,O
of,3972,O
the,3972,O
rat,3972,O
brain,3972,O
in,3972,O
an,3972,O
attempt,3972,O
to,3972,O
elucidate,3972,O
molecular,3972,O
mechanisms,3972,O
underlying,3972,O
the,3972,O
brain,3972,O
damage,3972,O
associated,3972,O
with,3972,O
excess,3972,O
accumulation,3972,O
of,3972,O
fluoride,3972,B-CHEMICAL
.,3972,O
Sixty,3973,O
Sprague-Dawley,3973,O
rats,3973,O
were,3973,O
divided,3973,O
randomly,3973,O
into,3973,O
three,3973,O
groups,3973,O
of,3973,O
20,3973,O
each,3973,O
",",3973,O
that,3973,O
is,3973,O
",",3973,O
the,3973,O
untreated,3973,O
control,3973,O
group,3973,O
(,3973,O
drinking,3973,O
water,3973,O
naturally,3973,O
containing,3973,O
<,3973,O
0.5,3973,O
mg,3973,O
fluoride/l,3973,B-CHEMICAL
",",3973,O
NaF,3973,B-CHEMICAL
),3973,O
",",3973,O
the,3973,O
low-fluoride,3973,O
group,3973,O
(,3973,O
whose,3973,O
drinking,3973,O
water,3973,O
was,3973,O
supplemented,3973,O
with,3973,O
10,3973,O
mg,3973,O
fluoride/l,3973,B-CHEMICAL
),3973,O
and,3973,O
the,3973,O
high-fluoride,3973,O
group,3973,O
(,3973,O
50,3973,O
mg,3973,O
fluoride/l,3973,B-CHEMICAL
),3973,O
.,3973,O
After,3974,O
6,3974,O
months,3974,O
of,3974,O
exposure,3974,O
",",3974,O
the,3974,O
expression,3974,O
of,3974,O
mitofusin-1,3974,B-GENE-Y
(,3974,O
Mfn1,3974,B-GENE-Y
),3974,O
",",3974,O
fission-1,3974,B-GENE-Y
(,3974,O
Fis1,3974,B-GENE-Y
),3974,O
",",3974,O
and,3974,O
dynamin-related,3974,B-GENE-Y
protein-1,3974,I-GENE-Y
(,3974,O
Drp1,3974,B-GENE-Y
),3974,O
at,3974,O
both,3974,O
the,3974,O
protein,3974,O
and,3974,O
mRNA,3974,O
levels,3974,O
were,3974,O
detected,3974,O
by,3974,O
Western,3974,O
blotting,3974,O
",",3974,O
immunohistochemistry,3974,O
",",3974,O
and,3974,O
real-time,3974,O
PCR,3974,O
",",3974,O
respectively,3974,O
.,3974,O
Moreover,3975,O
",",3975,O
mitochondrial,3975,O
morphology,3975,O
and,3975,O
distribution,3975,O
in,3975,O
neurons,3975,O
were,3975,O
observed,3975,O
by,3975,O
transmission,3975,O
electron,3975,O
or,3975,O
fluorescence,3975,O
microscopy,3975,O
.,3975,O
In,3976,O
the,3976,O
cortices,3976,O
of,3976,O
the,3976,O
brains,3976,O
of,3976,O
rats,3976,O
with,3976,O
chronic,3976,O
fluorosis,3976,O
",",3976,O
the,3976,O
level,3976,O
of,3976,O
Mfn1,3976,B-GENE-Y
protein,3976,O
was,3976,O
clearly,3976,O
reduced,3976,O
",",3976,O
whereas,3976,O
the,3976,O
levels,3976,O
of,3976,O
Fis1,3976,B-GENE-Y
and,3976,O
Drp1,3976,B-GENE-Y
were,3976,O
elevated,3976,O
.,3976,O
The,3977,O
alternations,3977,O
of,3977,O
expression,3977,O
of,3977,O
the,3977,O
mRNAs,3977,O
encoding,3977,O
all,3977,O
three,3977,O
of,3977,O
these,3977,O
proteins,3977,O
were,3977,O
almost,3977,O
the,3977,O
same,3977,O
as,3977,O
the,3977,O
corresponding,3977,O
changes,3977,O
at,3977,O
the,3977,O
protein,3977,O
levels,3977,O
.,3977,O
The,3978,O
mitochondria,3978,O
were,3978,O
fragmented,3978,O
and,3978,O
the,3978,O
redistributed,3978,O
away,3978,O
from,3978,O
the,3978,O
axons,3978,O
of,3978,O
the,3978,O
cortical,3978,O
neurons,3978,O
.,3978,O
These,3979,O
findings,3979,O
indicate,3979,O
that,3979,O
chronic,3979,O
fluorosis,3979,O
induces,3979,O
abnormal,3979,O
mitochondrial,3979,O
dynamics,3979,O
",",3979,O
which,3979,O
might,3979,O
in,3979,O
turn,3979,O
result,3979,O
in,3979,O
a,3979,O
high,3979,O
level,3979,O
of,3979,O
oxidative,3979,O
stress,3979,O
.,3979,O
Quantitative,3980,O
analysis,3980,O
of,3980,O
the,3980,O
interaction,3980,O
of,3980,O
constitutive,3980,B-GENE-N
androstane,3980,B-CHEMICAL
receptor,3980,I-GENE-N
with,3980,O
chemicals,3980,O
and,3980,O
steroid,3980,B-GENE-N
receptor,3980,I-GENE-N
coactivator,3980,I-GENE-N
1,3980,I-GENE-N
using,3980,O
surface,3980,O
plasmon,3980,O
resonance,3980,O
biosensor,3980,O
systems,3980,O
:,3980,O
a,3980,O
case,3980,O
study,3980,O
of,3980,O
the,3980,O
Baikal,3980,O
seal,3980,O
(,3980,O
Pusa,3980,O
sibirica,3980,O
),3980,O
and,3980,O
the,3980,O
mouse,3980,O
.,3980,O
The,3981,O
constitutive,3981,B-GENE-Y
androstane,3981,B-CHEMICAL
receptor,3981,I-GENE-Y
(,3981,O
CAR,3981,B-GENE-Y
),3981,O
not,3981,O
only,3981,O
displays,3981,O
a,3981,O
high,3981,O
basal,3981,O
transcriptional,3981,O
activity,3981,O
but,3981,O
also,3981,O
acts,3981,O
as,3981,O
a,3981,O
ligand-dependent,3981,O
transcriptional,3981,O
factor,3981,O
.,3981,O
It,3982,O
is,3982,O
known,3982,O
that,3982,O
CAR,3982,B-GENE-Y
exhibits,3982,O
different,3982,O
ligand,3982,O
profiles,3982,O
across,3982,O
species,3982,O
.,3982,O
However,3983,O
",",3983,O
the,3983,O
mechanisms,3983,O
underlying,3983,O
CAR,3983,B-GENE-Y
activation,3983,O
by,3983,O
chemicals,3983,O
and,3983,O
the,3983,O
species-specific,3983,O
responses,3983,O
are,3983,O
not,3983,O
fully,3983,O
understood,3983,O
.,3983,O
The,3984,O
objectives,3984,O
of,3984,O
this,3984,O
study,3984,O
are,3984,O
to,3984,O
establish,3984,O
a,3984,O
high-throughput,3984,O
tool,3984,O
to,3984,O
screen,3984,O
CAR,3984,B-GENE-N
ligands,3984,O
and,3984,O
to,3984,O
clarify,3984,O
how,3984,O
CAR,3984,B-GENE-N
proteins,3984,O
from,3984,O
the,3984,O
Baikal,3984,O
seal,3984,O
(,3984,O
bsCAR,3984,B-GENE-Y
),3984,O
and,3984,O
the,3984,O
mouse,3984,O
(,3984,O
mCAR,3984,B-GENE-Y
),3984,O
interact,3984,O
with,3984,O
chemicals,3984,O
and,3984,O
steroid,3984,B-CHEMICAL
receptor,3984,I-GENE-N
coactivator,3984,I-GENE-N
1,3984,I-GENE-N
(,3984,O
SRC1,3984,B-GENE-N
),3984,O
.,3984,O
We,3985,O
developed,3985,O
the,3985,O
surface,3985,O
plasmon,3985,O
resonance,3985,O
(,3985,O
SPR,3985,O
),3985,O
system,3985,O
to,3985,O
assess,3985,O
quantitatively,3985,O
the,3985,O
interaction,3985,O
of,3985,O
CAR,3985,B-GENE-N
with,3985,O
potential,3985,O
ligands,3985,O
and,3985,O
SRC1,3985,B-GENE-N
.,3985,O
The,3986,O
ligand-binding,3986,O
domain,3986,O
(,3986,O
LBD,3986,O
),3986,O
of,3986,O
bsCAR,3986,B-GENE-Y
and,3986,O
mCAR,3986,B-GENE-Y
was,3986,O
synthesized,3986,O
in,3986,O
a,3986,O
wheat,3986,O
germ,3986,O
cell-free,3986,O
system,3986,O
.,3986,O
The,3987,O
purified,3987,O
CAR,3987,B-GENE-N
LBD,3987,I-GENE-N
was,3987,O
then,3987,O
immobilized,3987,O
on,3987,O
the,3987,O
sensor,3987,O
chip,3987,O
for,3987,O
the,3987,O
SPR,3987,O
assay,3987,O
",",3987,O
and,3987,O
the,3987,O
kinetics,3987,O
of,3987,O
direct,3987,O
interaction,3987,O
of,3987,O
CARs,3987,B-GENE-N
with,3987,O
ligand,3987,O
candidates,3987,O
was,3987,O
measured,3987,O
.,3987,O
Androstanol,3988,B-CHEMICAL
and,3988,O
androstenol,3988,B-CHEMICAL
",",3988,O
estrone,3988,B-CHEMICAL
",",3988,O
17β-estradiol,3988,B-CHEMICAL
",",3988,O
TCPOBOP,3988,B-CHEMICAL
",",3988,O
and,3988,O
CITCO,3988,B-CHEMICAL
showed,3988,O
compound-specific,3988,O
but,3988,O
similar,3988,O
affinities,3988,O
for,3988,O
both,3988,O
CARs,3988,B-GENE-N
.,3988,O
The,3989,O
CAR-SRC1,3989,B-GENE-N
interaction,3989,O
was,3989,O
ligand,3989,O
dependent,3989,O
but,3989,O
exhibited,3989,O
a,3989,O
different,3989,O
ligand,3989,O
profile,3989,O
between,3989,O
the,3989,O
seal,3989,O
and,3989,O
the,3989,O
mouse,3989,O
.,3989,O
The,3990,O
results,3990,O
of,3990,O
SRC1,3990,B-GENE-N
interaction,3990,O
assay,3990,O
accounted,3990,O
for,3990,O
those,3990,O
of,3990,O
our,3990,O
previous,3990,O
in,3990,O
vitro,3990,O
CAR-mediated,3990,B-GENE-N
transactivation,3990,O
assay,3990,O
.,3990,O
In,3991,O
silico,3991,O
analyses,3991,O
also,3991,O
supported,3991,O
the,3991,O
results,3991,O
of,3991,O
CAR-SRC1,3991,B-GENE-N
interaction,3991,O
;,3991,O
there,3991,O
is,3991,O
little,3991,O
structural,3991,O
difference,3991,O
in,3991,O
the,3991,O
ligand-binding,3991,O
pocket,3991,O
of,3991,O
bsCAR,3991,B-GENE-Y
and,3991,O
mCAR,3991,B-GENE-Y
",",3991,O
but,3991,O
there,3991,O
is,3991,O
a,3991,O
distinct,3991,O
discrimination,3991,O
in,3991,O
the,3991,O
helix,3991,O
11,3991,O
and,3991,O
12,3991,O
of,3991,O
these,3991,O
receptors,3991,O
",",3991,O
suggesting,3991,O
that,3991,O
the,3991,O
interaction,3991,O
of,3991,O
ligand-bound,3991,O
CAR,3991,B-GENE-N
and,3991,O
SRC1,3991,B-GENE-N
is,3991,O
critical,3991,O
for,3991,O
determining,3991,O
species-specific,3991,O
and,3991,O
ligand-dependent,3991,O
transactivation,3991,O
over,3991,O
the,3991,O
basal,3991,O
activity,3991,O
.,3991,O
The,3992,O
SPR,3992,O
assays,3992,O
demonstrated,3992,O
a,3992,O
potential,3992,O
as,3992,O
a,3992,O
high-throughput,3992,O
screening,3992,O
tool,3992,O
of,3992,O
CAR,3992,B-GENE-N
ligands,3992,O
.,3992,O
Studies,3993,O
on,3993,O
the,3993,O
antioxidant,3993,O
potential,3993,O
of,3993,O
flavones,3993,B-CHEMICAL
of,3993,O
Allium,3993,O
vineale,3993,O
isolated,3993,O
from,3993,O
its,3993,O
water-soluble,3993,O
fraction,3993,O
.,3993,O
The,3994,O
aim,3994,O
of,3994,O
this,3994,O
work,3994,O
was,3994,O
to,3994,O
examine,3994,O
the,3994,O
chemical,3994,O
constituents,3994,O
and,3994,O
antioxidant,3994,O
potential,3994,O
of,3994,O
water-soluble,3994,O
fractions,3994,O
from,3994,O
the,3994,O
commonly,3994,O
consumed,3994,O
vegetable,3994,O
",",3994,O
Allium,3994,O
vineale,3994,O
.,3994,O
The,3995,O
water-soluble,3995,O
fraction,3995,O
",",3995,O
containing,3995,O
phenolic,3995,O
compounds,3995,O
",",3995,O
was,3995,O
extracted,3995,O
with,3995,O
ethyl,3995,B-CHEMICAL
acetate,3995,I-CHEMICAL
to,3995,O
obtain,3995,O
flavonoids,3995,B-CHEMICAL
which,3995,O
were,3995,O
separated,3995,O
and,3995,O
purified,3995,O
by,3995,O
repeated,3995,O
column,3995,O
chromatography,3995,O
over,3995,O
Sephadex,3995,O
LH-20,3995,O
",",3995,O
RP,3995,O
C18,3995,O
and,3995,O
silica,3995,B-CHEMICAL
gel,3995,I-CHEMICAL
.,3995,O
The,3996,O
isolated,3996,O
compounds,3996,O
were,3996,O
identified,3996,O
according,3996,O
to,3996,O
their,3996,O
physicochemical,3996,O
properties,3996,O
and,3996,O
spectral,3996,O
data,3996,O
(,3996,O
UV,3996,O
",",3996,O
HPLC-TOF/MS,3996,O
",",3996,O
(,3996,B-CHEMICAL
1,3996,I-CHEMICAL
),3996,I-CHEMICAL
H,3996,I-CHEMICAL
NMR,3996,O
",",3996,O
(,3996,B-CHEMICAL
13,3996,I-CHEMICAL
),3996,I-CHEMICAL
C,3996,I-CHEMICAL
NMR,3996,O
and,3996,O
2D,3996,O
NMR,3996,O
),3996,O
.,3996,O
Three,3997,O
flavonoids,3997,O
were,3997,O
isolated,3997,O
and,3997,O
identified,3997,O
as,3997,O
chrysoeriol-7-O-,3997,B-CHEMICAL
[,3997,I-CHEMICAL
2″-O-E-feruloyl,3997,I-CHEMICAL
],3997,I-CHEMICAL
-β-d-glucoside,3997,I-CHEMICAL
(,3997,O
1,3997,O
),3997,O
",",3997,O
chrysoeriol,3997,B-CHEMICAL
(,3997,O
2,3997,O
),3997,O
",",3997,O
and,3997,O
isorhamnetin-3-β-d-glucoside,3997,B-CHEMICAL
(,3997,O
3,3997,O
),3997,O
.,3997,O
Antioxidant,3998,O
studies,3998,O
of,3998,O
the,3998,O
aqueous,3998,O
extract,3998,O
and,3998,O
three,3998,O
isolated,3998,O
compounds,3998,O
",",3998,O
1,3998,O
",",3998,O
2,3998,O
",",3998,O
3,3998,O
",",3998,O
were,3998,O
undertaken,3998,O
and,3998,O
they,3998,O
were,3998,O
found,3998,O
to,3998,O
have,3998,O
significant,3998,O
antioxidant,3998,O
activity,3998,O
.,3998,O
Antioxidant,3999,O
activities,3999,O
were,3999,O
evaluated,3999,O
for,3999,O
total,3999,O
antioxidant,3999,O
activity,3999,O
by,3999,O
the,3999,O
ferric,3999,B-CHEMICAL
thiocyanate,3999,I-CHEMICAL
method,3999,O
",",3999,O
ferric,3999,B-CHEMICAL
ion,3999,O
(,3999,O
Fe,3999,B-CHEMICAL
(,3999,I-CHEMICAL
3+,3999,I-CHEMICAL
),3999,I-CHEMICAL
),3999,O
reducing,3999,O
antioxidant,3999,O
power,3999,O
assay,3999,O
(,3999,O
FRAP,3999,O
),3999,O
",",3999,O
ferrous,3999,B-CHEMICAL
ion,3999,O
(,3999,O
Fe,3999,B-CHEMICAL
(,3999,I-CHEMICAL
2+,3999,I-CHEMICAL
),3999,I-CHEMICAL
),3999,O
metal,3999,O
chelating,3999,O
activity,3999,O
",",3999,O
and,3999,O
DPPH,3999,B-CHEMICAL
free,3999,O
radical-scavenging,3999,O
activity,3999,O
.,3999,O
The,4000,O
water-soluble,4000,O
ethyl,4000,B-CHEMICAL
acetate,4000,I-CHEMICAL
and,4000,O
methanol,4000,B-CHEMICAL
extraction,4000,O
methods,4000,O
were,4000,O
also,4000,O
compared,4000,O
using,4000,O
HPLC-TOF/MS,4000,O
.,4000,O
Amino,4001,B-CHEMICAL
acid,4001,I-CHEMICAL
composition,4001,O
",",4001,O
antinutrients,4001,O
and,4001,O
allergens,4001,O
in,4001,O
the,4001,O
peanut,4001,O
protein,4001,O
fraction,4001,O
obtained,4001,O
by,4001,O
an,4001,O
aqueous,4001,O
enzymatic,4001,O
process,4001,O
.,4001,O
Enzyme-assisted,4002,O
aqueous,4002,O
extraction,4002,O
(,4002,O
EAE,4002,O
),4002,O
of,4002,O
peanut,4002,O
kernel,4002,O
was,4002,O
used,4002,O
to,4002,O
extract,4002,O
oil,4002,O
and,4002,O
protein,4002,O
.,4002,O
The,4003,O
aqueous,4003,O
fraction,4003,O
(,4003,O
AF,4003,O
),4003,O
obtained,4003,O
by,4003,O
EAE,4003,O
had,4003,O
a,4003,O
better,4003,O
essential,4003,O
amino,4003,B-CHEMICAL
acid,4003,I-CHEMICAL
profile,4003,O
than,4003,O
the,4003,O
residues,4003,O
obtained,4003,O
by,4003,O
solvent,4003,O
extraction,4003,O
(,4003,O
Rs,4003,O
),4003,O
and,4003,O
cold,4003,O
pressing,4003,O
(,4003,O
Rc,4003,O
),4003,O
.,4003,O
No,4004,O
major,4004,O
difference,4004,O
in,4004,O
the,4004,O
trypsin,4004,B-GENE-N
inhibitor,4004,O
activity,4004,O
among,4004,O
AF,4004,O
",",4004,O
Rs,4004,O
and,4004,O
Rc,4004,O
was,4004,O
observed,4004,O
;,4004,O
however,4004,O
",",4004,O
the,4004,O
trypsin,4004,B-GENE-N
inhibitor,4004,O
activity,4004,O
was,4004,O
drastically,4004,O
reduced,4004,O
in,4004,O
the,4004,O
residue,4004,O
obtained,4004,O
after,4004,O
EAE,4004,O
.,4004,O
AF,4005,O
was,4005,O
subjected,4005,O
to,4005,O
MALDI-TOF/MS,4005,O
",",4005,O
revealing,4005,O
it,4005,O
to,4005,O
be,4005,O
rich,4005,O
in,4005,O
peptides,4005,O
(,4005,O
107,4005,O
),4005,O
with,4005,O
molecular,4005,O
masses,4005,O
from,4005,O
m/z,4005,O
700,4005,O
to,4005,O
2369Da,4005,O
.,4005,O
AF,4006,O
had,4006,O
an,4006,O
extremely,4006,O
low,4006,O
phytate,4006,B-CHEMICAL
content,4006,O
and,4006,O
was,4006,O
rich,4006,O
in,4006,O
peptides,4006,O
",",4006,O
which,4006,O
could,4006,O
be,4006,O
used,4006,O
as,4006,O
a,4006,O
food,4006,O
supplement,4006,O
.,4006,O
ESI-MS/MS,4007,O
data,4007,O
were,4007,O
used,4007,O
for,4007,O
the,4007,O
identification,4007,O
of,4007,O
major,4007,O
peanut,4007,B-GENE-N
allergens,4007,I-GENE-N
",",4007,O
viz.,4007,O
",",4007,O
Ara,4007,B-GENE-N
h1,4007,I-GENE-N
",",4007,I-GENE-N
h3,4007,I-GENE-N
",",4007,I-GENE-N
h6-8,4007,I-GENE-N
.,4007,O
Their,4008,O
allergenic,4008,O
potential,4008,O
needs,4008,O
to,4008,O
be,4008,O
established,4008,O
.,4008,O
NMDA,4009,B-GENE-N
receptor,4009,I-GENE-N
blockade,4009,O
impairs,4009,O
the,4009,O
muscarinic,4009,O
conversion,4009,O
of,4009,O
sub-threshold,4009,O
transient,4009,O
depression,4009,O
into,4009,O
long-lasting,4009,O
LTD,4009,O
in,4009,O
the,4009,O
hippocampus-prefrontal,4009,O
cortex,4009,O
pathway,4009,O
in,4009,O
vivo,4009,O
:,4009,O
correlation,4009,O
with,4009,O
gamma,4009,O
oscillations,4009,O
.,4009,O
Cholinergic,4010,O
fibers,4010,O
from,4010,O
the,4010,O
brainstem,4010,O
and,4010,O
basal,4010,O
forebrain,4010,O
innervate,4010,O
the,4010,O
medial,4010,O
prefrontal,4010,O
cortex,4010,O
(,4010,O
mPFC,4010,O
),4010,O
modulating,4010,O
neuronal,4010,O
activity,4010,O
and,4010,O
synaptic,4010,O
plasticity,4010,O
responses,4010,O
to,4010,O
hippocampal,4010,O
inputs,4010,O
.,4010,O
Here,4011,O
",",4011,O
we,4011,O
investigated,4011,O
the,4011,O
muscarinic,4011,O
and,4011,O
glutamatergic,4011,O
modulation,4011,O
of,4011,O
long-term,4011,O
depression,4011,O
(,4011,O
LTD,4011,O
),4011,O
in,4011,O
the,4011,O
intact,4011,O
projections,4011,O
from,4011,O
CA1,4011,O
to,4011,O
mPFC,4011,O
in,4011,O
vivo,4011,O
.,4011,O
Cortical-evoked,4012,O
responses,4012,O
were,4012,O
recorded,4012,O
in,4012,O
urethane-anesthetized,4012,B-CHEMICAL
rats,4012,O
for,4012,O
30,4012,O
min,4012,O
during,4012,O
baseline,4012,O
and,4012,O
4,4012,O
h,4012,O
following,4012,O
LTD,4012,O
.,4012,O
In,4013,O
order,4013,O
to,4013,O
test,4013,O
the,4013,O
potentiating,4013,O
effects,4013,O
of,4013,O
pilocarpine,4013,B-CHEMICAL
(,4013,O
PILO,4013,B-CHEMICAL
),4013,O
",",4013,O
independent,4013,O
groups,4013,O
of,4013,O
rats,4013,O
received,4013,O
either,4013,O
a,4013,O
microinjection,4013,O
of,4013,O
PILO,4013,B-CHEMICAL
(,4013,O
40,4013,O
nmol,4013,O
;,4013,O
i.c.v,4013,O
.,4013,O
),4013,O
or,4014,O
vehicle,4014,O
",",4014,O
immediately,4014,O
before,4014,O
or,4014,O
20,4014,O
min,4014,O
after,4014,O
a,4014,O
sub-threshold,4014,O
LTD,4014,O
protocol,4014,O
(,4014,O
600,4014,O
pulses,4014,O
",",4014,O
1,4014,O
Hz,4014,O
;,4014,O
LFS600,4014,O
),4014,O
.,4014,O
Other,4015,O
groups,4015,O
received,4015,O
either,4015,O
an,4015,O
infusion,4015,O
of,4015,O
the,4015,O
selective,4015,O
NMDA,4015,B-GENE-N
receptor,4015,I-GENE-N
antagonist,4015,O
(,4015,O
AP7,4015,B-CHEMICAL
;,4015,O
10,4015,O
nmol,4015,O
;,4015,O
intra-mPFC,4015,O
),4015,O
or,4015,O
vehicle,4015,O
",",4015,O
10,4015,O
min,4015,O
prior,4015,O
to,4015,O
PILO,4015,B-CHEMICAL
preceding,4015,O
LFS600,4015,O
",",4015,O
or,4015,O
prior,4015,O
to,4015,O
a,4015,O
supra-threshold,4015,O
LTD,4015,O
protocol,4015,O
(,4015,O
900,4015,O
pulses,4015,O
",",4015,O
1,4015,O
Hz,4015,O
;,4015,O
LFS900,4015,O
),4015,O
.,4015,O
Our,4016,O
results,4016,O
show,4016,O
that,4016,O
PILO,4016,B-CHEMICAL
converts,4016,O
a,4016,O
transient,4016,O
cortical,4016,O
depression,4016,O
induced,4016,O
by,4016,O
LFS600,4016,O
into,4016,O
a,4016,O
robust,4016,O
LTD,4016,O
",",4016,O
stable,4016,O
for,4016,O
at,4016,O
least,4016,O
4,4016,O
h.,4016,O
When,4016,O
applied,4016,O
after,4016,O
LFS600,4016,O
",",4016,O
PILO,4016,B-CHEMICAL
does,4016,O
not,4016,O
change,4016,O
either,4016,O
mPFC,4016,O
basal,4016,O
neurotransmission,4016,O
or,4016,O
late,4016,O
LTD.,4016,O
Our,4016,O
data,4016,O
also,4016,O
indicate,4016,O
that,4016,O
NMDA,4016,B-CHEMICAL
receptor,4016,I-GENE-N
pre-activation,4016,O
is,4016,O
essential,4016,O
to,4016,O
the,4016,O
muscarinic,4016,O
enhancement,4016,O
of,4016,O
mPFC,4016,O
synaptic,4016,O
depression,4016,O
",",4016,O
since,4016,O
AP7,4016,B-CHEMICAL
microinjection,4016,O
into,4016,O
the,4016,O
mPFC,4016,O
blocked,4016,O
the,4016,O
conversion,4016,O
of,4016,O
transient,4016,O
depression,4016,O
into,4016,O
long-lasting,4016,O
LTD,4016,O
produced,4016,O
by,4016,O
PILO,4016,B-CHEMICAL
.,4016,O
In,4017,O
addition,4017,O
",",4017,O
AP7,4017,B-CHEMICAL
effectively,4017,O
blocked,4017,O
the,4017,O
long-lasting,4017,O
LTD,4017,O
induced,4017,O
by,4017,O
LFS900,4017,O
.,4017,O
Therefore,4018,O
",",4018,O
our,4018,O
findings,4018,O
suggest,4018,O
that,4018,O
the,4018,O
glutamatergic,4018,O
co-activation,4018,O
of,4018,O
prefrontal,4018,O
neurons,4018,O
is,4018,O
important,4018,O
for,4018,O
the,4018,O
effects,4018,O
of,4018,O
PILO,4018,B-CHEMICAL
on,4018,O
mPFC,4018,O
synaptic,4018,O
depression,4018,O
",",4018,O
which,4018,O
could,4018,O
play,4018,O
an,4018,O
important,4018,O
role,4018,O
in,4018,O
the,4018,O
control,4018,O
of,4018,O
executive,4018,O
and,4018,O
emotional,4018,O
functions,4018,O
.,4018,O
Metabolism,4019,O
of,4019,O
triethylenetetramine,4019,B-CHEMICAL
and,4019,O
"1,12-diamino-3,6,9-triazadodecane",4019,B-CHEMICAL
by,4019,O
the,4019,O
spermidine/spermine-N,4019,B-GENE-Y
(,4019,I-GENE-Y
1,4019,I-GENE-Y
),4019,I-GENE-Y
-acetyltransferase,4019,I-GENE-Y
and,4019,O
thialysine,4019,B-GENE-N
acetyltransferase,4019,I-GENE-N
.,4019,O
Triethylenetetramine,4020,B-CHEMICAL
(,4020,O
TETA,4020,B-CHEMICAL
;,4020,O
Syprine,4020,B-CHEMICAL
;,4020,O
Merck,4020,O
Rahway,4020,O
",",4020,O
NJ,4020,O
),4020,O
",",4020,O
a,4020,O
drug,4020,O
for,4020,O
Wilson,4020,O
's,4020,O
disease,4020,O
",",4020,O
is,4020,O
a,4020,O
copper,4020,B-CHEMICAL
chelator,4020,O
and,4020,O
a,4020,O
charge-deficient,4020,O
analog,4020,O
of,4020,O
polyamine,4020,B-CHEMICAL
spermidine,4020,B-CHEMICAL
.,4020,O
We,4021,O
recently,4021,O
showed,4021,O
that,4021,O
TETA,4021,B-CHEMICAL
is,4021,O
metabolized,4021,O
in,4021,O
vitro,4021,O
by,4021,O
polyamine,4021,B-CHEMICAL
catabolic,4021,O
enzyme,4021,O
spermidine/spermine-N,4021,B-GENE-Y
(,4021,I-GENE-Y
1,4021,I-GENE-Y
),4021,I-GENE-Y
-acetyltransferase,4021,I-GENE-Y
(,4021,O
SSAT1,4021,B-GENE-Y
),4021,O
and,4021,O
by,4021,O
thialysine,4021,B-GENE-Y
acetyltransferase,4021,I-GENE-Y
(,4021,O
SSAT2,4021,B-GENE-Y
),4021,O
to,4021,O
its,4021,O
monoacetylated,4021,O
derivative,4021,O
(,4021,O
MAT,4021,O
),4021,O
.,4021,O
The,4022,O
acetylation,4022,O
of,4022,O
TETA,4022,B-CHEMICAL
is,4022,O
increased,4022,O
in,4022,O
SSAT1-overexpressing,4022,B-GENE-Y
mice,4022,O
compared,4022,O
with,4022,O
wild-type,4022,O
mice,4022,O
.,4022,O
However,4023,O
",",4023,O
SSAT1-deficient,4023,B-GENE-Y
mice,4023,O
metabolize,4023,O
TETA,4023,B-CHEMICAL
at,4023,O
the,4023,O
same,4023,O
rate,4023,O
as,4023,O
the,4023,O
wild-type,4023,O
mice,4023,O
",",4023,O
indicating,4023,O
the,4023,O
existence,4023,O
of,4023,O
another,4023,O
N-acetylase,4023,B-GENE-N
respons,4023,O
2ible,4023,O
for,4023,O
its,4023,O
metabolism,4023,O
in,4023,O
mice,4023,O
.,4023,O
Here,4024,O
",",4024,O
we,4024,O
show,4024,O
that,4024,O
siRNA-mediated,4024,O
knockdown,4024,O
of,4024,O
SSAT2,4024,B-GENE-Y
in,4024,O
HEPG2,4024,O
cells,4024,O
and,4024,O
in,4024,O
primary,4024,O
hepatocytes,4024,O
from,4024,O
the,4024,O
SSAT1-deficient,4024,B-GENE-Y
or,4024,O
wild-type,4024,O
mice,4024,O
reduced,4024,O
the,4024,O
metabolism,4024,O
of,4024,O
TETA,4024,B-CHEMICAL
to,4024,O
MAT,4024,O
.,4024,O
By,4025,O
contrast,4025,O
",",4025,O
"1,12-diamino-3,6,9-triazadodecane",4025,B-CHEMICAL
(,4025,O
SpmTrien,4025,B-CHEMICAL
),4025,O
",",4025,O
a,4025,O
charge-deficient,4025,O
spermine,4025,B-CHEMICAL
analog,4025,O
",",4025,O
was,4025,O
an,4025,O
extremely,4025,O
poor,4025,O
substrate,4025,O
of,4025,O
human,4025,B-GENE-Y
recombinant,4025,I-GENE-Y
SSAT2,4025,I-GENE-Y
and,4025,O
was,4025,O
metabolized,4025,O
by,4025,O
SSAT1,4025,B-GENE-Y
in,4025,O
HEPG2,4025,O
cells,4025,O
and,4025,O
in,4025,O
wild-type,4025,O
primary,4025,O
hepatocytes,4025,O
.,4025,O
Thus,4026,O
",",4026,O
despite,4026,O
the,4026,O
similar,4026,O
structures,4026,O
of,4026,O
TETA,4026,B-CHEMICAL
and,4026,O
SpmTrien,4026,B-CHEMICAL
",",4026,O
SSAT2,4026,B-GENE-Y
is,4026,O
the,4026,O
main,4026,O
acetylator,4026,O
of,4026,O
TETA,4026,B-CHEMICAL
",",4026,O
whereas,4026,O
SpmTrien,4026,B-CHEMICAL
is,4026,O
primarily,4026,O
acetylated,4026,O
by,4026,O
SSAT1,4026,B-GENE-Y
.,4026,O
In,4027,O
vitro,4027,O
metabolism,4027,O
of,4027,O
the,4027,O
5-hydroxytryptamine1B,4027,B-GENE-Y
receptor,4027,O
antagonist,4027,O
elzasonan,4027,B-CHEMICAL
.,4027,O
The,4028,O
metabolism,4028,O
of,4028,O
elzasonan,4028,B-CHEMICAL
has,4028,O
been,4028,O
examined,4028,O
in,4028,O
vitro,4028,O
using,4028,O
hepatic,4028,O
microsomes,4028,O
from,4028,O
human,4028,O
and,4028,O
recombinant,4028,O
heterologously,4028,O
expressed,4028,O
P450,4028,B-GENE-N
enzymes,4028,I-GENE-N
(,4028,O
rCYP,4028,B-GENE-N
),4028,O
.,4028,O
Metabolism,4029,O
occurs,4029,O
primarily,4029,O
via,4029,O
oxidative,4029,O
N-demethylation,4029,B-CHEMICAL
to,4029,O
form,4029,O
M4,4029,O
and,4029,O
oxidation,4029,O
reactions,4029,O
to,4029,O
form,4029,O
elzasonan,4029,B-CHEMICAL
N-oxide,4029,I-CHEMICAL
(,4029,O
M5,4029,O
),4029,O
and,4029,O
5-hydroxyelzasonan,4029,B-CHEMICAL
metabolite,4029,O
(,4029,O
M3,4029,O
),4029,O
.,4029,O
Additionally,4030,O
",",4030,O
elzasonan,4030,B-CHEMICAL
was,4030,O
shown,4030,O
to,4030,O
be,4030,O
metabolized,4030,O
to,4030,O
the,4030,O
novel,4030,O
cyclized,4030,O
indole,4030,B-CHEMICAL
metabolite,4030,O
(,4030,O
M6,4030,O
),4030,O
which,4030,O
undergoes,4030,O
subsequent,4030,O
oxidation,4030,O
to,4030,O
form,4030,O
the,4030,O
iminium,4030,B-CHEMICAL
ion,4030,O
metabolite,4030,O
(,4030,O
M3a,4030,O
),4030,O
.,4030,O
The,4031,O
rCYP,4031,B-GENE-N
data,4031,O
was,4031,O
normalized,4031,O
relative,4031,O
to,4031,O
the,4031,O
levels,4031,O
of,4031,O
each,4031,O
CYP,4031,B-GENE-N
form,4031,O
in,4031,O
native,4031,O
human,4031,O
liver,4031,O
microsomes,4031,O
to,4031,O
better,4031,O
assess,4031,O
the,4031,O
contribution,4031,O
of,4031,O
each,4031,O
rCYP,4031,B-GENE-N
in,4031,O
the,4031,O
metabolism,4031,O
of,4031,O
elzasonan,4031,B-CHEMICAL
.,4031,O
Results,4032,O
demonstrated,4032,O
the,4032,O
involvement,4032,O
of,4032,O
CYP3A4,4032,B-GENE-Y
in,4032,O
the,4032,O
pathways,4032,O
leading,4032,O
to,4032,O
M3a,4032,O
",",4032,O
M3,4032,O
",",4032,O
M5,4032,O
and,4032,O
M6,4032,O
and,4032,O
CYP2C8,4032,B-GENE-Y
in,4032,O
the,4032,O
formation,4032,O
of,4032,O
M4,4032,O
.,4032,O
Kinetic,4033,O
constants,4033,O
for,4033,O
the,4033,O
formation,4033,O
of,4033,O
M3,4033,O
were,4033,O
determined,4033,O
and,4033,O
correlation,4033,O
and,4033,O
inhibition,4033,O
studies,4033,O
suggested,4033,O
that,4033,O
CYP3A4,4033,B-GENE-Y
is,4033,O
primarily,4033,O
responsible,4033,O
for,4033,O
the,4033,O
formation,4033,O
of,4033,O
M3,4033,O
and,4033,O
CYP2C19,4033,B-GENE-Y
plays,4033,O
a,4033,O
very,4033,O
minor,4033,O
role,4033,O
in,4033,O
its,4033,O
formation,4033,O
.,4033,O
Cytochrome,4034,B-GENE-Y
b5,4034,I-GENE-Y
has,4034,O
shown,4034,O
to,4034,O
be,4034,O
an,4034,O
essential,4034,O
component,4034,O
in,4034,O
P450,4034,B-GENE-Y
3A4,4034,I-GENE-Y
catalyzed,4034,O
5-hydroxyelzasonan,4034,B-CHEMICAL
formation,4034,O
and,4034,O
provides,4034,O
insights,4034,O
on,4034,O
the,4034,O
disconnect,4034,O
between,4034,O
human,4034,O
liver,4034,O
microsomes,4034,O
data,4034,O
and,4034,O
that,4034,O
of,4034,O
rCYP,4034,B-GENE-N
.,4034,O
Furthermore,4035,O
",",4035,O
rCYP3A4,4035,B-GENE-Y
containing,4035,O
b5,4035,O
are,4035,O
useful,4035,O
models,4035,O
for,4035,O
predicting,4035,O
the,4035,O
rates,4035,O
for,4035,O
liver,4035,O
microsomes,4035,O
P450-dependent,4035,B-GENE-N
drug,4035,O
oxidations,4035,O
and,4035,O
should,4035,O
be,4035,O
utilized,4035,O
routinely,4035,O
.,4035,O
Effective,4036,O
phagocytosis,4036,O
of,4036,O
low,4036,O
Her2,4036,B-GENE-Y
tumor,4036,O
cell,4036,O
lines,4036,O
with,4036,O
engineered,4036,O
",",4036,O
aglycosylated,4036,B-GENE-N
IgG,4036,I-GENE-N
displaying,4036,O
high,4036,O
FcγRIIa,4036,B-GENE-Y
affinity,4036,O
and,4036,O
selectivity,4036,O
.,4036,O
Glycans,4037,O
anchored,4037,O
to,4037,O
residue,4037,O
N297,4037,O
of,4037,O
the,4037,O
antibody,4037,O
IgG,4037,B-GENE-N
Fc,4037,I-GENE-N
domain,4037,I-GENE-N
are,4037,O
critical,4037,O
in,4037,O
mediating,4037,O
binding,4037,O
toward,4037,O
FcγRs,4037,B-GENE-N
to,4037,O
direct,4037,O
both,4037,O
adaptive,4037,O
and,4037,O
innate,4037,O
immune,4037,O
responses,4037,O
.,4037,O
However,4038,O
",",4038,O
using,4038,O
a,4038,O
full,4038,O
length,4038,O
bacterial,4038,B-GENE-N
IgG,4038,I-GENE-N
display,4038,O
system,4038,O
",",4038,O
we,4038,O
have,4038,O
isolated,4038,O
aglycosylated,4038,B-GENE-N
Fc,4038,I-GENE-N
domains,4038,I-GENE-N
with,4038,O
mutations,4038,O
that,4038,O
confer,4038,O
up,4038,O
to,4038,O
a,4038,O
160-fold,4038,O
increase,4038,O
in,4038,O
the,4038,O
affinity,4038,O
toward,4038,O
the,4038,O
low,4038,O
affinity,4038,O
FcγRIIa-R131,4038,B-GENE-Y
allele,4038,O
as,4038,O
well,4038,O
as,4038,O
high,4038,O
selectivity,4038,O
against,4038,O
binding,4038,O
to,4038,O
the,4038,O
remarkably,4038,O
homologous,4038,O
human,4038,O
inhibitory,4038,O
receptor,4038,O
",",4038,O
FcγRIIb,4038,B-GENE-Y
.,4038,O
The,4039,O
mutant,4039,O
Fc,4039,B-GENE-N
domain,4039,I-GENE-N
(,4039,O
AglycoT-Fc1004,4039,B-GENE-N
),4039,O
contained,4039,O
a,4039,O
total,4039,O
of,4039,O
5,4039,O
amino,4039,B-CHEMICAL
acid,4039,I-CHEMICAL
substitutions,4039,O
that,4039,O
conferred,4039,O
an,4039,O
activating,4039,O
to,4039,O
inhibitory,4039,O
ratio,4039,O
of,4039,O
25,4039,O
(,4039,O
A/I,4039,O
ratio,4039,O
;,4039,O
FcyRIIa-R131,4039,B-GENE-Y
:,4039,O
FcγRIIb,4039,B-GENE-Y
),4039,O
.,4039,O
Incorporation,4040,O
of,4040,O
this,4040,O
engineered,4040,O
Fc,4040,B-GENE-N
into,4040,O
trastuzumab,4040,O
",",4040,O
an,4040,O
anti-Her2,4040,O
antibody,4040,O
",",4040,O
resulted,4040,O
in,4040,O
a,4040,O
75,4040,O
%,4040,O
increase,4040,O
in,4040,O
tumor,4040,O
cell,4040,O
phagocytosis,4040,O
by,4040,O
macrophages,4040,O
compared,4040,O
to,4040,O
that,4040,O
of,4040,O
the,4040,O
parental,4040,O
glycosylated,4040,O
trastuzumab,4040,O
with,4040,O
both,4040,O
medium,4040,O
and,4040,O
low,4040,O
Her2-expressing,4040,B-GENE-Y
cancer,4040,O
cells,4040,O
.,4040,O
A,4041,O
mathematical,4041,O
model,4041,O
has,4041,O
been,4041,O
developed,4041,O
to,4041,O
help,4041,O
explain,4041,O
how,4041,O
receptor,4041,O
affinity,4041,O
and,4041,O
the,4041,O
A/I,4041,O
ratio,4041,O
relate,4041,O
to,4041,O
improved,4041,O
antibody,4041,O
dependent,4041,O
cell-mediated,4041,O
phagocytosis,4041,O
.,4041,O
Our,4042,O
model,4042,O
provides,4042,O
guidelines,4042,O
for,4042,O
the,4042,O
future,4042,O
engineering,4042,O
of,4042,O
Fc,4042,B-GENE-N
domains,4042,I-GENE-N
with,4042,O
enhanced,4042,O
effector,4042,O
function,4042,O
.,4042,O
Exposure,4043,O
to,4043,O
valproic,4043,B-CHEMICAL
acid,4043,I-CHEMICAL
inhibits,4043,O
chondrogenesis,4043,O
and,4043,O
osteogenesis,4043,O
in,4043,O
mid-organogenesis,4043,O
mouse,4043,O
limbs,4043,O
.,4043,O
In,4044,O
utero,4044,O
exposure,4044,O
to,4044,O
valproic,4044,B-CHEMICAL
acid,4044,I-CHEMICAL
(,4044,O
VPA,4044,B-CHEMICAL
),4044,O
",",4044,O
a,4044,O
histone,4044,B-GENE-N
deacetylase,4044,I-GENE-N
(,4044,O
HDAC,4044,B-GENE-N
),4044,O
inhibitor,4044,O
",",4044,O
causes,4044,O
neural,4044,O
tube,4044,O
",",4044,O
heart,4044,O
",",4044,O
and,4044,O
limb,4044,O
defects,4044,O
.,4044,O
Valpromide,4045,B-CHEMICAL
(,4045,O
VPD,4045,B-CHEMICAL
),4045,O
",",4045,O
the,4045,O
amide,4045,B-CHEMICAL
derivative,4045,O
of,4045,O
VPA,4045,B-CHEMICAL
",",4045,O
does,4045,O
not,4045,O
inhibit,4045,O
HDAC,4045,B-GENE-N
activity,4045,O
and,4045,O
is,4045,O
a,4045,O
weak,4045,O
teratogen,4045,O
in,4045,O
vivo,4045,O
.,4045,O
The,4046,O
detailed,4046,O
mechanism,4046,O
of,4046,O
action,4046,O
of,4046,O
VPA,4046,B-CHEMICAL
as,4046,O
a,4046,O
teratogen,4046,O
is,4046,O
not,4046,O
known,4046,O
.,4046,O
The,4047,O
goal,4047,O
of,4047,O
this,4047,O
study,4047,O
was,4047,O
to,4047,O
test,4047,O
the,4047,O
hypothesis,4047,O
that,4047,O
VPA,4047,B-CHEMICAL
disrupts,4047,O
regulation,4047,O
of,4047,O
the,4047,O
expression,4047,O
of,4047,O
genes,4047,O
that,4047,O
are,4047,O
critical,4047,O
in,4047,O
chondrogenesis,4047,O
and,4047,O
osteogenesis,4047,O
during,4047,O
limb,4047,O
development,4047,O
.,4047,O
Murine,4048,O
gestation,4048,O
day-12,4048,O
embryonic,4048,O
forelimbs,4048,O
were,4048,O
excised,4048,O
and,4048,O
exposed,4048,O
to,4048,O
VPA,4048,B-CHEMICAL
or,4048,O
VPD,4048,B-CHEMICAL
in,4048,O
a,4048,O
limb,4048,O
bud,4048,O
culture,4048,O
system,4048,O
.,4048,O
VPA,4049,B-CHEMICAL
caused,4049,O
a,4049,O
significant,4049,O
concentration-,4049,O
dependent,4049,O
increase,4049,O
in,4049,O
limb,4049,O
abnormalities,4049,O
",",4049,O
which,4049,O
was,4049,O
correlated,4049,O
with,4049,O
its,4049,O
HDAC,4049,B-GENE-N
inhibitory,4049,O
effect,4049,O
.,4049,O
The,4050,O
signaling,4050,O
of,4050,O
both,4050,O
Sox9,4050,B-GENE-Y
and,4050,O
Runx2,4050,B-GENE-Y
",",4050,O
key,4050,O
regulators,4050,O
of,4050,O
chondrogenesis,4050,O
",",4050,O
was,4050,O
downregulated,4050,O
by,4050,O
VPA,4050,B-CHEMICAL
.,4050,O
In,4051,O
contrast,4051,O
",",4051,O
VPD,4051,B-CHEMICAL
had,4051,O
little,4051,O
effect,4051,O
on,4051,O
limb,4051,O
morphology,4051,O
and,4051,O
no,4051,O
significant,4051,O
effect,4051,O
on,4051,O
HDAC,4051,B-GENE-N
activity,4051,O
or,4051,O
the,4051,O
expression,4051,O
of,4051,O
marker,4051,O
genes,4051,O
.,4051,O
Thus,4052,O
",",4052,O
VPA,4052,B-CHEMICAL
exposure,4052,O
dysregulated,4052,O
the,4052,O
expression,4052,O
of,4052,O
target,4052,O
genes,4052,O
directly,4052,O
involved,4052,O
in,4052,O
chondrogenesis,4052,O
and,4052,O
osteogenesis,4052,O
in,4052,O
the,4052,O
developing,4052,O
limb,4052,O
.,4052,O
Disturbances,4053,O
in,4053,O
these,4053,O
signaling,4053,O
pathways,4053,O
are,4053,O
likely,4053,O
to,4053,O
be,4053,O
a,4053,O
consequence,4053,O
of,4053,O
HDAC,4053,B-GENE-N
inhibition,4053,O
because,4053,O
VPD,4053,B-CHEMICAL
did,4053,O
not,4053,O
affect,4053,O
their,4053,O
expressions,4053,O
.,4053,O
Tumor,4054,B-GENE-Y
necrosis,4054,I-GENE-Y
factor-alpha,4054,I-GENE-Y
potentiates,4054,O
the,4054,O
cytotoxicity,4054,O
of,4054,O
amiodarone,4054,B-CHEMICAL
in,4054,O
Hepa1c1c7,4054,O
cells,4054,O
:,4054,O
roles,4054,O
of,4054,O
caspase,4054,B-GENE-N
activation,4054,O
and,4054,O
oxidative,4054,O
stress,4054,O
.,4054,O
Amiodarone,4055,B-CHEMICAL
(,4055,O
AMD,4055,B-CHEMICAL
),4055,O
",",4055,O
a,4055,O
class,4055,O
III,4055,O
antiarrhythmic,4055,O
drug,4055,O
",",4055,O
causes,4055,O
idiosyncratic,4055,O
hepatotoxicity,4055,O
in,4055,O
human,4055,O
patients,4055,O
.,4055,O
We,4056,O
demonstrated,4056,O
previously,4056,O
that,4056,O
tumor,4056,B-GENE-Y
necrosis,4056,I-GENE-Y
factor-alpha,4056,I-GENE-Y
(,4056,O
TNF-α,4056,B-GENE-Y
),4056,O
plays,4056,O
an,4056,O
important,4056,O
role,4056,O
in,4056,O
a,4056,O
rat,4056,O
model,4056,O
of,4056,O
AMD-induced,4056,B-CHEMICAL
hepatotoxicity,4056,O
under,4056,O
inflammatory,4056,O
stress,4056,O
.,4056,O
In,4057,O
this,4057,O
study,4057,O
",",4057,O
we,4057,O
developed,4057,O
a,4057,O
model,4057,O
in,4057,O
vitro,4057,O
to,4057,O
study,4057,O
the,4057,O
roles,4057,O
of,4057,O
caspase,4057,B-GENE-N
activation,4057,O
and,4057,O
oxidative,4057,O
stress,4057,O
in,4057,O
TNF,4057,B-GENE-Y
potentiation,4057,O
of,4057,O
AMD,4057,B-CHEMICAL
cytotoxicity,4057,O
.,4057,O
AMD,4058,B-CHEMICAL
caused,4058,O
cell,4058,O
death,4058,O
in,4058,O
Hepa1c1c7,4058,O
cells,4058,O
",",4058,O
and,4058,O
TNF,4058,B-GENE-Y
cotreatment,4058,O
potentiated,4058,O
its,4058,O
toxicity,4058,O
.,4058,O
Activation,4059,O
of,4059,O
caspases,4059,B-GENE-N
9,4059,I-GENE-N
and,4059,I-GENE-N
3/7,4059,I-GENE-N
was,4059,O
observed,4059,O
in,4059,O
AMD/TNF-cotreated,4059,B-CHEMICAL
cells,4059,O
",",4059,O
and,4059,O
caspase,4059,O
inhibitors,4059,O
provided,4059,O
minor,4059,O
protection,4059,O
from,4059,O
cytotoxicity,4059,O
.,4059,O
Intracellular,4060,O
reactive,4060,O
oxygen,4060,B-CHEMICAL
species,4060,O
(,4060,O
ROS,4060,O
),4060,O
generation,4060,O
and,4060,O
lipid,4060,O
peroxidation,4060,O
were,4060,O
observed,4060,O
after,4060,O
treatment,4060,O
with,4060,O
AMD,4060,B-CHEMICAL
and,4060,O
were,4060,O
further,4060,O
elevated,4060,O
by,4060,O
TNF,4060,B-GENE-Y
cotreatment,4060,O
.,4060,O
Adding,4061,O
water-soluble,4061,O
antioxidants,4061,O
(,4061,O
trolox,4061,B-CHEMICAL
",",4061,O
N-acetylcysteine,4061,B-CHEMICAL
",",4061,O
glutathione,4061,B-CHEMICAL
",",4061,O
or,4061,O
ascorbate,4061,B-CHEMICAL
),4061,O
produced,4061,O
only,4061,O
minor,4061,O
attenuation,4061,O
of,4061,O
AMD/TNF-induced,4061,B-CHEMICAL
cytotoxicity,4061,O
and,4061,O
did,4061,O
not,4061,O
influence,4061,O
the,4061,O
effect,4061,O
of,4061,O
AMD,4061,B-CHEMICAL
alone,4061,O
.,4061,O
On,4062,O
the,4062,O
other,4062,O
hand,4062,O
",",4062,O
α-tocopherol,4062,B-CHEMICAL
(,4062,O
TOCO,4062,B-CHEMICAL
),4062,O
",",4062,O
which,4062,O
reduced,4062,O
lipid,4062,O
peroxidation,4062,O
and,4062,O
ROS,4062,O
generation,4062,O
",",4062,O
prevented,4062,O
AMD,4062,B-CHEMICAL
toxicity,4062,O
and,4062,O
caused,4062,O
pronounced,4062,O
reduction,4062,O
in,4062,O
cytotoxicity,4062,O
from,4062,O
AMD/TNF,4062,B-CHEMICAL
cotreatment,4062,O
.,4062,O
α-TOCO,4063,B-CHEMICAL
plus,4063,O
a,4063,O
pancaspase,4063,B-GENE-N
inhibitor,4063,O
completely,4063,O
abolished,4063,O
AMD/TNF-induced,4063,B-CHEMICAL
cytotoxicity,4063,O
.,4063,O
In,4064,O
summary,4064,O
",",4064,O
activation,4064,O
of,4064,O
caspases,4064,B-GENE-N
and,4064,O
oxidative,4064,O
stress,4064,O
were,4064,O
observed,4064,O
after,4064,O
AMD/TNF,4064,B-CHEMICAL
cotreatment,4064,O
",",4064,O
and,4064,O
caspase,4064,B-GENE-N
inhibitors,4064,O
and,4064,O
a,4064,O
lipid-soluble,4064,O
free-radical,4064,O
scavenger,4064,O
attenuated,4064,O
AMD/TNF-induced,4064,B-CHEMICAL
cytotoxicity,4064,O
.,4064,O
Amino,4065,B-CHEMICAL
acid,4065,I-CHEMICAL
residues,4065,O
at,4065,O
the,4065,O
N-,4065,O
and,4065,O
C-termini,4065,O
are,4065,O
essential,4065,O
for,4065,O
the,4065,O
folding,4065,O
of,4065,O
active,4065,O
human,4065,B-GENE-Y
butyrylcholinesterase,4065,I-GENE-Y
polypeptide,4065,O
.,4065,O
Human,4066,B-GENE-Y
serum,4066,I-GENE-Y
butyrylcholinesterase,4066,I-GENE-Y
(,4066,O
HuBChE,4066,B-GENE-Y
),4066,O
is,4066,O
currently,4066,O
the,4066,O
most,4066,O
suitable,4066,O
bioscavenger,4066,O
for,4066,O
the,4066,O
prophylaxis,4066,O
of,4066,O
highly,4066,O
toxic,4066,O
organophosphate,4066,B-CHEMICAL
(,4066,O
OP,4066,O
),4066,O
nerve,4066,O
agents,4066,O
.,4066,O
A,4067,O
dose,4067,O
of,4067,O
200mg,4067,O
of,4067,O
HuBChE,4067,B-GENE-Y
is,4067,O
envisioned,4067,O
as,4067,O
a,4067,O
prophylactic,4067,O
treatment,4067,O
that,4067,O
can,4067,O
protect,4067,O
humans,4067,O
from,4067,O
an,4067,O
exposure,4067,O
of,4067,O
up,4067,O
to,4067,O
2×LD50,4067,O
of,4067,O
soman,4067,O
.,4067,O
The,4068,O
limited,4068,O
availability,4068,O
and,4068,O
administration,4068,O
of,4068,O
multiple,4068,O
doses,4068,O
of,4068,O
this,4068,O
stoichiometric,4068,O
bioscavenger,4068,O
make,4068,O
this,4068,O
pretreatment,4068,O
difficult,4068,O
.,4068,O
Thus,4069,O
",",4069,O
the,4069,O
goal,4069,O
of,4069,O
this,4069,O
study,4069,O
was,4069,O
to,4069,O
produce,4069,O
a,4069,O
smaller,4069,O
enzymatically,4069,O
active,4069,O
HuBChE,4069,B-GENE-Y
polypeptide,4069,O
(,4069,O
HBP,4069,O
),4069,O
that,4069,O
could,4069,O
bind,4069,O
to,4069,O
nerve,4069,O
agents,4069,O
with,4069,O
high,4069,O
affinity,4069,O
thereby,4069,O
reducing,4069,O
the,4069,O
dose,4069,O
of,4069,O
enzyme,4069,O
.,4069,O
Studies,4070,O
have,4070,O
indicated,4070,O
that,4070,O
the,4070,O
three-dimensional,4070,O
structure,4070,O
and,4070,O
the,4070,O
domains,4070,O
of,4070,O
HuBChE,4070,B-GENE-Y
(,4070,O
acyl,4070,B-CHEMICAL
pocket,4070,O
",",4070,O
lip,4070,O
of,4070,O
the,4070,O
active,4070,O
center,4070,O
gorge,4070,O
",",4070,O
and,4070,O
the,4070,O
anionic,4070,O
substrate-binding,4070,O
domain,4070,O
),4070,O
that,4070,O
are,4070,O
critical,4070,O
for,4070,O
the,4070,O
binding,4070,O
of,4070,O
substrate,4070,O
are,4070,O
also,4070,O
essential,4070,O
for,4070,O
the,4070,O
selectivity,4070,O
and,4070,O
binding,4070,O
of,4070,O
inhibitors,4070,O
including,4070,O
OPs,4070,O
.,4070,O
Therefore,4071,O
",",4071,O
we,4071,O
designed,4071,O
three,4071,O
HBPs,4071,O
by,4071,O
deleting,4071,O
some,4071,O
N-,4071,O
and,4071,O
C-terminal,4071,O
residues,4071,O
of,4071,O
HuBChE,4071,B-GENE-Y
by,4071,O
maintaining,4071,O
the,4071,O
folds,4071,O
of,4071,O
the,4071,O
active,4071,O
site,4071,O
core,4071,O
that,4071,O
includes,4071,O
the,4071,O
three,4071,O
active,4071,O
site,4071,O
residues,4071,O
(,4071,O
S198,4071,O
",",4071,O
E325,4071,O
",",4071,O
and,4071,O
H438,4071,O
),4071,O
.,4071,O
HBP-4,4072,B-GENE-N
that,4072,O
lacks,4072,O
45,4072,O
residues,4072,O
from,4072,O
C-terminus,4072,O
but,4072,O
known,4072,O
to,4072,O
have,4072,O
BChE,4072,B-GENE-Y
activity,4072,O
was,4072,O
used,4072,O
as,4072,O
a,4072,O
control,4072,O
.,4072,O
The,4073,O
cDNAs,4073,O
for,4073,O
the,4073,O
HBPs,4073,O
containing,4073,O
signal,4073,O
sequences,4073,O
were,4073,O
synthesized,4073,O
",",4073,O
cloned,4073,O
into,4073,O
different,4073,O
mammalian,4073,O
expression,4073,O
vectors,4073,O
",",4073,O
and,4073,O
recombinant,4073,O
polypeptides,4073,O
were,4073,O
transiently,4073,O
expressed,4073,O
in,4073,O
different,4073,O
cell,4073,O
lines,4073,O
.,4073,O
No,4074,O
BChE,4074,B-GENE-Y
activity,4074,O
was,4074,O
detected,4074,O
in,4074,O
the,4074,O
culture,4074,O
media,4074,O
of,4074,O
cells,4074,O
transfected,4074,O
with,4074,O
any,4074,O
of,4074,O
the,4074,O
newly,4074,O
designed,4074,O
HBPs,4074,O
",",4074,O
and,4074,O
the,4074,O
inactive,4074,O
polypeptides,4074,O
remained,4074,O
inside,4074,O
the,4074,O
cells,4074,O
.,4074,O
Only,4075,O
enzymatically,4075,O
active,4075,O
HBP-4,4075,B-GENE-N
was,4075,O
secreted,4075,O
into,4075,O
the,4075,O
culture,4075,O
medium,4075,O
.,4075,O
These,4076,O
results,4076,O
suggest,4076,O
that,4076,O
residues,4076,O
at,4076,O
the,4076,O
N-,4076,O
and,4076,O
C-termini,4076,O
are,4076,O
required,4076,O
for,4076,O
the,4076,O
folding,4076,O
and/or,4076,O
maintenance,4076,O
of,4076,O
HBP,4076,O
into,4076,O
an,4076,O
active,4076,O
stable,4076,O
",",4076,O
conformation,4076,O
.,4076,O
Claudin-3,4077,B-GENE-Y
and,4077,O
claudin-4,4077,B-GENE-Y
regulate,4077,O
sensitivity,4077,O
to,4077,O
cisplatin,4077,B-CHEMICAL
by,4077,O
controlling,4077,O
expression,4077,O
of,4077,O
the,4077,O
copper,4077,B-GENE-N
and,4077,I-GENE-N
cisplatin,4077,I-GENE-N
influx,4077,I-GENE-N
transporter,4077,I-GENE-N
CTR1,4077,B-GENE-Y
.,4077,O
Claudin-3,4078,B-GENE-Y
(,4078,O
CLDN3,4078,B-GENE-Y
),4078,O
and,4078,O
claudin-4,4078,B-GENE-Y
(,4078,O
CLDN4,4078,B-GENE-Y
),4078,O
are,4078,O
the,4078,O
major,4078,O
structural,4078,O
molecules,4078,O
that,4078,O
form,4078,O
tight,4078,O
junctions,4078,O
(,4078,O
TJs,4078,O
),4078,O
between,4078,O
epithelial,4078,O
cells,4078,O
.,4078,O
We,4079,O
found,4079,O
that,4079,O
knockdown,4079,O
of,4079,O
the,4079,O
expression,4079,O
of,4079,O
either,4079,O
CLDN3,4079,B-GENE-Y
or,4079,O
CLDN4,4079,B-GENE-Y
produced,4079,O
marked,4079,O
changes,4079,O
in,4079,O
the,4079,O
phenotype,4079,O
of,4079,O
ovarian,4079,O
cancer,4079,O
cells,4079,O
",",4079,O
including,4079,O
an,4079,O
increase,4079,O
in,4079,O
resistance,4079,O
to,4079,O
cisplatin,4079,B-CHEMICAL
(,4079,O
cDDP,4079,O
),4079,O
.,4079,O
The,4080,O
effect,4080,O
of,4080,O
CLND3,4080,B-GENE-Y
and,4080,O
CLDN4,4080,B-GENE-Y
on,4080,O
cDDP,4080,O
cytotoxicity,4080,O
",",4080,O
cDDP,4080,O
cellular,4080,O
accumulation,4080,O
",",4080,O
and,4080,O
DNA,4080,O
adduct,4080,O
formation,4080,O
was,4080,O
compared,4080,O
in,4080,O
the,4080,O
CLDN3-,4080,B-GENE-Y
and,4080,O
CLDN4-expressing,4080,B-GENE-Y
parental,4080,O
human,4080,O
ovarian,4080,O
carcinoma,4080,O
2008,4080,O
cells,4080,O
and,4080,O
CLDN3,4080,B-GENE-Y
and,4080,O
CLDN4,4080,B-GENE-Y
knockdown,4080,O
sublines,4080,O
(,4080,O
CLDN3KD,4080,B-GENE-Y
and,4080,O
CLDN4KD,4080,B-GENE-Y
",",4080,O
respectively,4080,O
),4080,O
.,4080,O
Knockdown,4081,O
of,4081,O
CLDN3,4081,B-GENE-Y
or,4081,O
CLDN4,4081,B-GENE-Y
rendered,4081,O
human,4081,O
ovarian,4081,O
carcinoma,4081,O
2008,4081,O
cells,4081,O
resistant,4081,O
to,4081,O
cDDP,4081,O
in,4081,O
both,4081,O
in,4081,O
vitro,4081,O
culture,4081,O
and,4081,O
in,4081,O
vivo,4081,O
xenograft,4081,O
model,4081,O
.,4081,O
The,4082,O
net,4082,O
accumulation,4082,O
of,4082,O
platinum,4082,B-CHEMICAL
(,4082,O
Pt,4082,B-CHEMICAL
),4082,O
and,4082,O
the,4082,O
Pt-DNA,4082,B-CHEMICAL
adduct,4082,O
levels,4082,O
were,4082,O
reduced,4082,O
in,4082,O
CLDN3KD,4082,B-GENE-Y
and,4082,O
CLDN4KD,4082,B-GENE-Y
cells,4082,O
.,4082,O
The,4083,O
endogenous,4083,O
mRNA,4083,O
levels,4083,O
of,4083,O
copper,4083,B-GENE-N
influx,4083,I-GENE-N
transporter,4083,I-GENE-N
CTR1,4083,B-GENE-Y
were,4083,O
found,4083,O
to,4083,O
be,4083,O
significantly,4083,O
reduced,4083,O
in,4083,O
the,4083,O
knockdown,4083,O
cells,4083,O
",",4083,O
and,4083,O
exogenous,4083,O
expression,4083,O
of,4083,O
CTR1,4083,B-GENE-Y
restored,4083,O
their,4083,O
sensitivity,4083,O
to,4083,O
cDDP,4083,O
.,4083,O
Reexpression,4084,O
of,4084,O
an,4084,O
shRNAi-resistant,4084,O
CLDN3,4084,B-GENE-Y
or,4084,O
CLDN4,4084,B-GENE-Y
up-regulated,4084,O
CTR1,4084,B-GENE-Y
levels,4084,O
",",4084,O
reversed,4084,O
the,4084,O
cDDP,4084,O
resistance,4084,O
",",4084,O
and,4084,O
enhanced,4084,O
TJ,4084,O
formation,4084,O
in,4084,O
the,4084,O
knockdown,4084,O
cells,4084,O
.,4084,O
Baseline,4085,O
copper,4085,B-CHEMICAL
(,4085,O
Cu,4085,B-CHEMICAL
),4085,O
level,4085,O
",",4085,O
Cu,4085,B-CHEMICAL
uptake,4085,O
",",4085,O
and,4085,O
Cu,4085,B-CHEMICAL
cytotoxicity,4085,O
were,4085,O
also,4085,O
reduced,4085,O
in,4085,O
CLDN3KD,4085,B-GENE-Y
and,4085,O
CLDN4KD,4085,B-GENE-Y
cells,4085,O
.,4085,O
Cu-dependent,4086,B-CHEMICAL
tyrosinase,4086,B-GENE-Y
activity,4086,O
was,4086,O
also,4086,O
markedly,4086,O
reduced,4086,O
in,4086,O
both,4086,O
types,4086,O
of,4086,O
CLDN,4086,B-GENE-N
knockdown,4086,O
cells,4086,O
when,4086,O
incubated,4086,O
with,4086,O
the,4086,O
substrate,4086,O
l-DOPA,4086,B-CHEMICAL
.,4086,O
These,4087,O
results,4087,O
indicate,4087,O
that,4087,O
CLDN3,4087,B-GENE-Y
and,4087,O
CLDN4,4087,B-GENE-Y
affect,4087,O
sensitivity,4087,O
of,4087,O
the,4087,O
ovarian,4087,O
cancer,4087,O
cells,4087,O
to,4087,O
the,4087,O
cytotoxic,4087,O
effect,4087,O
of,4087,O
cDDP,4087,O
by,4087,O
regulating,4087,O
expression,4087,O
of,4087,O
the,4087,O
Cu,4087,B-CHEMICAL
transporter,4087,I-GENE-N
CTR1,4087,B-GENE-Y
.,4087,O
Regulation,4088,O
of,4088,O
hepatic,4088,O
phase,4088,O
II,4088,O
metabolism,4088,O
in,4088,O
pregnant,4088,O
mice,4088,O
.,4088,O
Phase,4089,O
II,4089,O
enzymes,4089,O
",",4089,O
including,4089,O
Ugts,4089,B-GENE-N
",",4089,O
Sults,4089,B-GENE-N
",",4089,O
and,4089,O
Gsts,4089,B-GENE-N
",",4089,O
are,4089,O
critical,4089,O
for,4089,O
the,4089,O
disposition,4089,O
and,4089,O
detoxification,4089,O
of,4089,O
endo-,4089,O
and,4089,O
xenobiotics,4089,O
.,4089,O
In,4090,O
this,4090,O
study,4090,O
",",4090,O
the,4090,O
mRNA,4090,O
and,4090,O
protein,4090,O
expression,4090,O
of,4090,O
major,4090,O
phase,4090,O
II,4090,O
enzymes,4090,O
",",4090,O
as,4090,O
well,4090,O
as,4090,O
key,4090,O
regulatory,4090,O
transcription,4090,O
factors,4090,O
",",4090,O
were,4090,O
quantified,4090,O
in,4090,O
livers,4090,O
of,4090,O
time-matched,4090,O
pregnant,4090,O
and,4090,O
virgin,4090,O
control,4090,O
C57BL/6,4090,O
mice,4090,O
on,4090,O
gestation,4090,O
days,4090,O
(,4090,O
GD,4090,O
),4090,O
7,4090,O
",",4090,O
11,4090,O
",",4090,O
14,4090,O
",",4090,O
17,4090,O
",",4090,O
and,4090,O
postnatal,4090,O
days,4090,O
(,4090,O
PND,4090,O
),4090,O
1,4090,O
",",4090,O
15,4090,O
",",4090,O
and,4090,O
30,4090,O
.,4090,O
Compared,4091,O
with,4091,O
virgin,4091,O
controls,4091,O
",",4091,O
the,4091,O
mRNA,4091,O
expression,4091,O
of,4091,O
Ugt1a1,4091,B-GENE-N
",",4091,I-GENE-N
1a6,4091,I-GENE-N
",",4091,I-GENE-N
1a9,4091,I-GENE-N
",",4091,I-GENE-N
2a3,4091,I-GENE-N
",",4091,I-GENE-N
2b1,4091,I-GENE-N
",",4091,I-GENE-N
2b34,4091,I-GENE-N
",",4091,I-GENE-N
and,4091,I-GENE-N
2b35,4091,I-GENE-N
decreased,4091,O
40,4091,O
to,4091,O
80,4091,O
%,4091,O
in,4091,O
pregnant,4091,O
dams,4091,O
.,4091,O
Protein,4092,O
expression,4092,O
of,4092,O
Ugt1a6,4092,B-GENE-Y
also,4092,O
decreased,4092,O
and,4092,O
corresponded,4092,O
with,4092,O
reduced,4092,O
in,4092,O
vitro,4092,O
glucuronidation,4092,O
of,4092,O
bisphenol,4092,B-CHEMICAL
A,4092,I-CHEMICAL
in,4092,O
S9,4092,O
fractions,4092,O
from,4092,O
livers,4092,O
of,4092,O
pregnant,4092,O
mice,4092,O
.,4092,O
Similar,4093,O
to,4093,O
Ugts,4093,B-GENE-N
levels,4093,O
",",4093,O
Gsta1,4093,B-GENE-N
and,4093,I-GENE-N
a4,4093,I-GENE-N
mRNAs,4093,O
were,4093,O
reduced,4093,O
in,4093,O
pregnant,4093,O
dams,4093,O
in,4093,O
mid,4093,O
to,4093,O
late,4093,O
gestation,4093,O
;,4093,O
however,4093,O
no,4093,O
change,4093,O
in,4093,O
protein,4093,O
expression,4093,O
was,4093,O
observed,4093,O
.,4093,O
Conversely,4094,O
",",4094,O
Sult1a1,4094,B-GENE-N
",",4094,I-GENE-N
2a1/2,4094,I-GENE-N
",",4094,I-GENE-N
and,4094,I-GENE-N
3a1,4094,I-GENE-N
mRNAs,4094,O
increased,4094,O
100,4094,O
to,4094,O
500,4094,O
%,4094,O
at,4094,O
various,4094,O
time,4094,O
points,4094,O
in,4094,O
pregnant,4094,O
and,4094,O
lactating,4094,O
mice,4094,O
and,4094,O
corresponded,4094,O
with,4094,O
enhanced,4094,O
in,4094,O
vitro,4094,O
sulfation,4094,O
of,4094,O
acetaminophen,4094,B-CHEMICAL
in,4094,O
liver,4094,O
S9,4094,O
fractions,4094,O
.,4094,O
Coinciding,4095,O
with,4095,O
maximal,4095,O
decreases,4095,O
in,4095,O
Ugts,4095,B-GENE-N
as,4095,O
well,4095,O
as,4095,O
increases,4095,O
in,4095,O
Sults,4095,B-GENE-N
",",4095,O
the,4095,O
expression,4095,O
of,4095,O
transcription,4095,O
factors,4095,O
CAR,4095,B-GENE-Y
",",4095,O
PPARα,4095,B-GENE-Y
",",4095,O
and,4095,O
PXR,4095,B-GENE-Y
and,4095,O
their,4095,O
target,4095,O
genes,4095,O
were,4095,O
downregulated,4095,O
",",4095,O
whereas,4095,O
ERα,4095,B-GENE-Y
mRNA,4095,O
was,4095,O
upregulated,4095,O
.,4095,O
Collectively,4096,O
",",4096,O
these,4096,O
data,4096,O
demonstrate,4096,O
altered,4096,O
regulation,4096,O
of,4096,O
hepatic,4096,O
phase,4096,O
II,4096,O
metabolism,4096,O
in,4096,O
mice,4096,O
during,4096,O
pregnancy,4096,O
and,4096,O
suggest,4096,O
that,4096,O
CAR,4096,B-GENE-Y
",",4096,O
PPARα,4096,B-GENE-Y
",",4096,O
PXR,4096,B-GENE-Y
",",4096,O
and,4096,O
ERα,4096,B-GENE-Y
signaling,4096,O
pathways,4096,O
may,4096,O
be,4096,O
candidate,4096,O
signaling,4096,O
pathways,4096,O
responsible,4096,O
for,4096,O
these,4096,O
changes,4096,O
.,4096,O
Dimethylfumarate,4097,B-CHEMICAL
attenuates,4097,O
renal,4097,O
fibrosis,4097,O
via,4097,O
NF-E2-related,4097,B-GENE-Y
factor,4097,I-GENE-Y
2-mediated,4097,O
inhibition,4097,O
of,4097,O
transforming,4097,B-GENE-Y
growth,4097,I-GENE-Y
factor-beta/Smad,4097,O
signaling,4097,O
.,4097,O
TGF-beta,4098,B-GENE-Y
plays,4098,O
a,4098,O
key,4098,O
role,4098,O
in,4098,O
the,4098,O
development,4098,O
of,4098,O
renal,4098,O
fibrosis,4098,O
.,4098,O
Suppressing,4099,O
the,4099,O
TGF-beta,4099,B-GENE-Y
signaling,4099,O
pathway,4099,O
is,4099,O
a,4099,O
possible,4099,O
therapeutic,4099,O
approach,4099,O
for,4099,O
preventing,4099,O
this,4099,O
disease,4099,O
",",4099,O
and,4099,O
reports,4099,O
have,4099,O
suggested,4099,O
that,4099,O
Nrf2,4099,B-GENE-Y
protects,4099,O
against,4099,O
renal,4099,O
fibrosis,4099,O
by,4099,O
inhibiting,4099,O
TGF-beta,4099,B-GENE-Y
signaling,4099,O
.,4099,O
This,4100,O
study,4100,O
examines,4100,O
whether,4100,O
dimethylfumarate,4100,B-CHEMICAL
(,4100,O
DMF,4100,B-CHEMICAL
),4100,O
",",4100,O
which,4100,O
stimulates,4100,O
Nrf2,4100,B-GENE-Y
",",4100,O
prevents,4100,O
renal,4100,O
fibrosis,4100,O
via,4100,O
the,4100,O
Nrf2-mediated,4100,B-GENE-Y
suppression,4100,O
of,4100,O
TGF-beta,4100,B-GENE-Y
signaling,4100,O
.,4100,O
Results,4101,O
showed,4101,O
that,4101,O
DMF,4101,B-CHEMICAL
increased,4101,O
nuclear,4101,O
levels,4101,O
of,4101,O
Nrf2,4101,B-GENE-Y
",",4101,O
and,4101,O
both,4101,O
DMF,4101,B-CHEMICAL
and,4101,O
adenovirus-mediated,4101,O
overexpression,4101,O
of,4101,O
Nrf2,4101,B-GENE-Y
(,4101,O
Ad-Nrf2,4101,O
),4101,O
decreased,4101,O
PAI-1,4101,B-GENE-Y
",",4101,O
alpha-smooth,4101,B-GENE-Y
muscle,4101,I-GENE-Y
actin,4101,I-GENE-Y
(,4101,O
alpha-SMA,4101,B-GENE-Y
),4101,O
",",4101,O
fibronectin,4101,B-GENE-Y
and,4101,O
type,4101,B-GENE-N
1,4101,I-GENE-N
collagen,4101,I-GENE-N
expression,4101,O
in,4101,O
TGF-beta-treated,4101,B-GENE-Y
rat,4101,O
mesangial,4101,O
cells,4101,O
(,4101,O
RMCs,4101,O
),4101,O
and,4101,O
renal,4101,O
fibroblast,4101,O
cells,4101,O
(,4101,O
NRK-49F,4101,O
),4101,O
.,4101,O
Additionally,4102,O
",",4102,O
DMF,4102,B-CHEMICAL
and,4102,O
Ad-Nrf2,4102,O
repressed,4102,O
TGF-beta-stimulated,4102,B-GENE-Y
Smad3,4102,B-GENE-Y
activity,4102,O
by,4102,O
inhibiting,4102,O
Smad3,4102,B-GENE-Y
phosphorylation,4102,O
",",4102,O
which,4102,O
was,4102,O
restored,4102,O
by,4102,O
siRNA-mediated,4102,O
knockdown,4102,O
of,4102,O
Nrf2,4102,B-GENE-Y
expression,4102,O
.,4102,O
However,4103,O
",",4103,O
downregulation,4103,O
of,4103,O
the,4103,O
antioxidant,4103,B-GENE-N
response,4103,I-GENE-N
element,4103,I-GENE-N
(,4103,O
ARE,4103,B-GENE-N
),4103,O
-driven,4103,O
Nrf2,4103,B-GENE-Y
target,4103,O
genes,4103,O
such,4103,O
as,4103,O
NQO1,4103,B-GENE-Y
",",4103,O
HO-1,4103,B-GENE-Y
and,4103,O
glutathione,4103,B-CHEMICAL
S-transferase,4103,B-CHEMICAL
(,4103,O
GST,4103,B-GENE-N
),4103,O
did,4103,O
not,4103,O
reverse,4103,O
the,4103,O
inhibitory,4103,O
effect,4103,O
of,4103,O
DMF,4103,B-CHEMICAL
on,4103,O
TGF-beta-induced,4103,B-GENE-Y
upregulation,4103,O
of,4103,O
profibrotic,4103,O
genes,4103,O
or,4103,O
extracellular,4103,O
matrix,4103,O
proteins,4103,O
",",4103,O
suggesting,4103,O
an,4103,O
ARE-independent,4103,B-GENE-N
anti-fibrotic,4103,O
activity,4103,O
of,4103,O
DMF,4103,B-CHEMICAL
.,4103,O
Finally,4104,O
",",4104,O
DMF,4104,B-CHEMICAL
suppressed,4104,O
unilateral,4104,O
ureteral,4104,O
obstruction,4104,O
(,4104,O
UUO,4104,O
),4104,O
-induced,4104,O
renal,4104,O
fibrosis,4104,O
and,4104,O
alpha-SMA,4104,B-GENE-Y
",",4104,O
fibronectin,4104,B-GENE-Y
and,4104,O
type,4104,B-GENE-N
1,4104,I-GENE-N
collagen,4104,I-GENE-N
expression,4104,O
in,4104,O
the,4104,O
obstructed,4104,O
kidneys,4104,O
from,4104,O
UUO,4104,O
mice,4104,O
",",4104,O
along,4104,O
with,4104,O
increased,4104,O
and,4104,O
decreased,4104,O
expression,4104,O
of,4104,O
Nrf2,4104,B-GENE-Y
and,4104,O
phospho-Smad3,4104,B-GENE-Y
",",4104,O
respectively,4104,O
.,4104,O
In,4105,O
summary,4105,O
",",4105,O
DMF,4105,B-CHEMICAL
attenuated,4105,O
renal,4105,O
fibrosis,4105,O
via,4105,O
the,4105,O
Nrf2-mediated,4105,B-GENE-Y
inhibition,4105,O
of,4105,O
TGF-beta/Smad3,4105,B-GENE-Y
signaling,4105,O
in,4105,O
an,4105,O
ARE-independent,4105,B-GENE-N
manner,4105,O
",",4105,O
suggesting,4105,O
that,4105,O
DMF,4105,B-CHEMICAL
could,4105,O
be,4105,O
used,4105,O
to,4105,O
treat,4105,O
renal,4105,O
fibrosis,4105,O
.,4105,O
The,4106,O
effect,4106,O
of,4106,O
CCL3,4106,B-GENE-Y
and,4106,O
CCR1,4106,B-GENE-Y
in,4106,O
bone,4106,O
remodeling,4106,O
induced,4106,O
by,4106,O
mechanical,4106,O
loading,4106,O
during,4106,O
orthodontic,4106,O
tooth,4106,O
movement,4106,O
in,4106,O
mice,4106,O
.,4106,O
Bone,4107,O
remodeling,4107,O
is,4107,O
affected,4107,O
by,4107,O
mechanical,4107,O
loading,4107,O
and,4107,O
inflammatory,4107,O
mediators,4107,O
",",4107,O
including,4107,O
chemokines,4107,B-GENE-N
.,4107,O
The,4108,O
chemokine,4108,B-GENE-Y
(,4108,I-GENE-Y
C-C,4108,I-GENE-Y
motif,4108,I-GENE-Y
),4108,I-GENE-Y
ligand,4108,I-GENE-Y
3,4108,I-GENE-Y
(,4108,O
CCL3,4108,B-GENE-Y
),4108,O
is,4108,O
involved,4108,O
in,4108,O
bone,4108,O
remodeling,4108,O
by,4108,O
binding,4108,O
to,4108,O
C-C,4108,B-GENE-N
chemokine,4108,I-GENE-N
receptors,4108,I-GENE-N
1,4108,I-GENE-N
and,4108,I-GENE-N
5,4108,I-GENE-N
(,4108,O
CCR1,4108,B-GENE-Y
and,4108,O
CCR5,4108,B-GENE-Y
),4108,O
expressed,4108,O
on,4108,O
osteoclasts,4108,O
and,4108,O
osteoblasts,4108,O
.,4108,O
Our,4109,O
group,4109,O
has,4109,O
previously,4109,O
demonstrated,4109,O
that,4109,O
CCR5,4109,B-GENE-Y
down-regulates,4109,O
mechanical,4109,O
loading-induced,4109,O
bone,4109,O
resorption,4109,O
.,4109,O
Thus,4110,O
",",4110,O
the,4110,O
present,4110,O
study,4110,O
aimed,4110,O
to,4110,O
investigate,4110,O
the,4110,O
role,4110,O
of,4110,O
CCR1,4110,B-GENE-Y
and,4110,O
CCL3,4110,B-GENE-Y
in,4110,O
bone,4110,O
remodeling,4110,O
induced,4110,O
by,4110,O
mechanical,4110,O
loading,4110,O
during,4110,O
orthodontic,4110,O
tooth,4110,O
movement,4110,O
in,4110,O
mice,4110,O
.,4110,O
Our,4111,O
results,4111,O
showed,4111,O
that,4111,O
bone,4111,O
remodeling,4111,O
was,4111,O
significantly,4111,O
decreased,4111,O
in,4111,O
CCL3,4111,B-GENE-Y
(,4111,O
-/-,4111,O
),4111,O
and,4111,O
CCR1,4111,B-GENE-Y
(,4111,O
-/-,4111,O
),4111,O
mice,4111,O
and,4111,O
in,4111,O
animals,4111,O
treated,4111,O
with,4111,O
Met-RANTES,4111,B-CHEMICAL
(,4111,O
an,4111,O
antagonist,4111,O
of,4111,O
CCR5,4111,B-GENE-Y
and,4111,O
CCR1,4111,B-GENE-Y
),4111,O
.,4111,O
mRNA,4112,O
levels,4112,O
of,4112,O
receptor,4112,B-GENE-Y
activator,4112,I-GENE-Y
of,4112,I-GENE-Y
nuclear,4112,I-GENE-Y
factor,4112,I-GENE-Y
kappa-B,4112,I-GENE-Y
(,4112,O
RANK,4112,B-GENE-Y
),4112,O
",",4112,O
its,4112,O
ligand,4112,O
RANKL,4112,B-GENE-Y
",",4112,O
tumor,4112,B-GENE-Y
necrosis,4112,I-GENE-Y
factor,4112,I-GENE-Y
alpha,4112,I-GENE-Y
(,4112,O
TNF-α,4112,B-GENE-Y
),4112,O
and,4112,O
RANKL/osteoprotegerin,4112,B-GENE-Y
(,4112,O
OPG,4112,B-GENE-Y
),4112,O
ratio,4112,O
were,4112,O
diminished,4112,O
in,4112,O
the,4112,O
periodontium,4112,O
of,4112,O
CCL3,4112,B-GENE-Y
(,4112,O
-/-,4112,O
),4112,O
mice,4112,O
and,4112,O
in,4112,O
the,4112,O
group,4112,O
treated,4112,O
with,4112,O
Met-RANTES,4112,B-CHEMICAL
.,4112,O
Met-RANTES,4113,B-CHEMICAL
treatment,4113,O
also,4113,O
reduced,4113,O
the,4113,O
levels,4113,O
of,4113,O
cathepsin,4113,B-GENE-Y
K,4113,I-GENE-Y
and,4113,O
metalloproteinase,4113,B-GENE-Y
13,4113,I-GENE-Y
(,4113,O
MMP13,4113,B-GENE-Y
),4113,O
.,4113,O
The,4114,O
expression,4114,O
of,4114,O
the,4114,O
osteoblast,4114,O
markers,4114,O
runt-related,4114,B-GENE-Y
transcription,4114,I-GENE-Y
factor,4114,I-GENE-Y
2,4114,I-GENE-Y
(,4114,O
RUNX2,4114,B-GENE-Y
),4114,O
and,4114,O
periostin,4114,B-GENE-Y
was,4114,O
decreased,4114,O
",",4114,O
while,4114,O
osteocalcin,4114,B-GENE-Y
(,4114,O
OCN,4114,B-GENE-Y
),4114,O
was,4114,O
augmented,4114,O
in,4114,O
CCL3,4114,B-GENE-Y
(,4114,O
-/-,4114,O
),4114,O
and,4114,O
Met-RANTES-treated,4114,B-CHEMICAL
mice,4114,O
.,4114,O
Altogether,4115,O
",",4115,O
these,4115,O
findings,4115,O
show,4115,O
that,4115,O
CCR1,4115,B-GENE-Y
is,4115,O
pivotal,4115,O
for,4115,O
bone,4115,O
remodeling,4115,O
induced,4115,O
by,4115,O
mechanical,4115,O
loading,4115,O
during,4115,O
orthodontic,4115,O
tooth,4115,O
movement,4115,O
and,4115,O
these,4115,O
actions,4115,O
depend,4115,O
",",4115,O
at,4115,O
least,4115,O
in,4115,O
part,4115,O
",",4115,O
on,4115,O
CCL3,4115,B-GENE-Y
.,4115,O
Nano-graphene,4116,O
in,4116,O
biomedicine,4116,O
:,4116,O
theranostic,4116,O
applications,4116,O
.,4116,O
Owing,4117,O
to,4117,O
their,4117,O
unique,4117,O
physical,4117,O
and,4117,O
chemical,4117,O
properties,4117,O
",",4117,O
graphene,4117,B-CHEMICAL
and,4117,O
its,4117,O
derivatives,4117,O
such,4117,O
as,4117,O
graphene,4117,B-CHEMICAL
oxide,4117,I-CHEMICAL
(,4117,O
GO,4117,O
),4117,O
",",4117,O
reduced,4117,B-CHEMICAL
graphene,4117,I-CHEMICAL
oxide,4117,I-CHEMICAL
(,4117,O
RGO,4117,B-CHEMICAL
),4117,O
and,4117,O
GO-nanocomposites,4117,O
have,4117,O
attracted,4117,O
tremendous,4117,O
interest,4117,O
in,4117,O
many,4117,O
different,4117,O
fields,4117,O
including,4117,O
biomedicine,4117,O
in,4117,O
recent,4117,O
years,4117,O
.,4117,O
With,4118,O
every,4118,O
atom,4118,O
exposed,4118,O
on,4118,O
its,4118,O
surface,4118,O
",",4118,O
single-layered,4118,O
graphene,4118,B-CHEMICAL
shows,4118,O
ultra-high,4118,O
surface,4118,O
area,4118,O
available,4118,O
for,4118,O
efficient,4118,O
molecular,4118,O
loading,4118,O
and,4118,O
bioconjugation,4118,O
",",4118,O
and,4118,O
has,4118,O
been,4118,O
widely,4118,O
explored,4118,O
as,4118,O
novel,4118,O
nano-carriers,4118,O
for,4118,O
drug,4118,O
and,4118,O
gene,4118,O
delivery,4118,O
.,4118,O
Utilizing,4119,O
the,4119,O
intrinsic,4119,O
near-infrared,4119,O
(,4119,O
NIR,4119,O
),4119,O
optical,4119,O
absorbance,4119,O
",",4119,O
in,4119,O
vivo,4119,O
graphene-based,4119,B-CHEMICAL
photothermal,4119,O
therapy,4119,O
has,4119,O
been,4119,O
realized,4119,O
",",4119,O
achieving,4119,O
excellent,4119,O
anti-tumor,4119,O
therapeutic,4119,O
efficacy,4119,O
in,4119,O
animal,4119,O
experiments,4119,O
.,4119,O
A,4120,O
variety,4120,O
of,4120,O
inorganic,4120,O
nanoparticles,4120,O
can,4120,O
be,4120,O
grown,4120,O
on,4120,O
the,4120,O
surface,4120,O
of,4120,O
nano-graphene,4120,O
",",4120,O
obtaining,4120,O
functional,4120,O
graphene-based,4120,B-CHEMICAL
nanocomposites,4120,O
with,4120,O
interesting,4120,O
optical,4120,O
and,4120,O
magnetic,4120,O
properties,4120,O
useful,4120,O
for,4120,O
multi-modal,4120,O
imaging,4120,O
and,4120,O
imaging-guided,4120,O
cancer,4120,O
therapy,4120,O
.,4120,O
Moreover,4121,O
",",4121,O
significant,4121,O
efforts,4121,O
have,4121,O
also,4121,O
been,4121,O
devoted,4121,O
to,4121,O
study,4121,O
the,4121,O
behaviors,4121,O
and,4121,O
toxicology,4121,O
of,4121,O
functionalized,4121,O
nano-graphene,4121,O
in,4121,O
animals,4121,O
.,4121,O
It,4122,O
has,4122,O
been,4122,O
uncovered,4122,O
that,4122,O
both,4122,O
surface,4122,O
chemistry,4122,O
and,4122,O
sizes,4122,O
play,4122,O
key,4122,O
roles,4122,O
in,4122,O
controlling,4122,O
the,4122,O
biodistribution,4122,O
",",4122,O
excretion,4122,O
",",4122,O
and,4122,O
toxicity,4122,O
of,4122,O
nano-graphene,4122,O
.,4122,O
Biocompatibly,4123,O
coated,4123,O
nano-graphene,4123,O
with,4123,O
ultra-small,4123,O
sizes,4123,O
can,4123,O
be,4123,O
cleared,4123,O
out,4123,O
from,4123,O
body,4123,O
after,4123,O
systemic,4123,O
administration,4123,O
",",4123,O
without,4123,O
rendering,4123,O
noticeable,4123,O
toxicity,4123,O
to,4123,O
the,4123,O
treated,4123,O
mice,4123,O
.,4123,O
In,4124,O
this,4124,O
review,4124,O
article,4124,O
",",4124,O
we,4124,O
will,4124,O
summarize,4124,O
the,4124,O
latest,4124,O
progress,4124,O
in,4124,O
this,4124,O
rapidly,4124,O
growing,4124,O
field,4124,O
",",4124,O
and,4124,O
discuss,4124,O
future,4124,O
prospects,4124,O
and,4124,O
challenges,4124,O
of,4124,O
using,4124,O
graphene-based,4124,B-CHEMICAL
materials,4124,O
for,4124,O
theranostic,4124,O
applications,4124,O
.,4124,O
Human,4125,B-GENE-Y
ether-a-go-go-related,4125,I-GENE-Y
gene,4125,I-GENE-Y
channel,4125,O
blockers,4125,O
and,4125,O
its,4125,O
structural,4125,O
analysis,4125,O
for,4125,O
drug,4125,O
design,4125,O
.,4125,O
The,4126,O
human,4126,B-GENE-Y
ether-a-go-go-related,4126,B-CHEMICAL
gene,4126,I-GENE-Y
(,4126,O
hERG,4126,B-GENE-Y
),4126,O
is,4126,O
a,4126,O
K+,4126,B-CHEMICAL
channel,4126,I-GENE-N
protein,4126,O
mainly,4126,O
expressed,4126,O
in,4126,O
the,4126,O
heart,4126,O
and,4126,O
the,4126,O
nervous,4126,O
systems,4126,O
and,4126,O
its,4126,O
blockade,4126,O
by,4126,O
non-cardiovascular,4126,O
acting,4126,O
drugs,4126,O
resulted,4126,O
in,4126,O
tachycardia,4126,O
and,4126,O
sudden,4126,O
death,4126,O
.,4126,O
In,4127,O
this,4127,O
present,4127,O
review,4127,O
",",4127,O
we,4127,O
have,4127,O
focused,4127,O
the,4127,O
physicochemical,4127,O
properties,4127,O
responsible,4127,O
for,4127,O
the,4127,O
hERG,4127,B-GENE-Y
blocking,4127,O
activity,4127,O
of,4127,O
structurally,4127,O
different,4127,O
compounds,4127,O
.,4127,O
The,4128,O
reported,4128,O
research,4128,O
works,4128,O
showed,4128,O
that,4128,O
the,4128,O
hydrophobicity,4128,O
on,4128,O
the,4128,O
van,4128,O
der,4128,O
Waals,4128,O
(,4128,O
vdW,4128,O
),4128,O
surface,4128,O
of,4128,O
the,4128,O
molecules,4128,O
(,4128,O
aroused,4128,O
from,4128,O
the,4128,O
aromatic,4128,O
ring,4128,O
),4128,O
necessary,4128,O
for,4128,O
the,4128,O
hERG,4128,B-GENE-Y
blocking,4128,O
activity,4128,O
along,4128,O
with,4128,O
topological,4128,O
and,4128,O
electronic,4128,O
properties,4128,O
.,4128,O
The,4129,O
quinolizidine,4129,B-CHEMICAL
alkaloids,4129,I-CHEMICAL
(,4129,O
natural,4129,O
products,4129,O
),4129,O
such,4129,O
as,4129,O
oxymatrine,4129,B-CHEMICAL
",",4129,O
sophoridine,4129,B-CHEMICAL
",",4129,O
sophocarpine,4129,B-CHEMICAL
and,4129,O
matrine,4129,B-CHEMICAL
carry,4129,O
the,4129,O
common,4129,O
molecular,4129,O
structure,4129,O
of,4129,O
O=C=N-C-C-C-N,4129,B-CHEMICAL
that,4129,O
possessed,4129,O
positive,4129,O
ionotropic,4129,O
effect,4129,O
and,4129,O
hERG,4129,B-GENE-Y
blocking,4129,O
activity,4129,O
.,4129,O
Acehytisine,4130,B-CHEMICAL
hydrochloride,4130,I-CHEMICAL
(,4130,O
previously,4130,O
named,4130,O
Guangfu,4130,B-CHEMICAL
base,4130,I-CHEMICAL
A,4130,I-CHEMICAL
),4130,O
was,4130,O
isolated,4130,O
from,4130,O
the,4130,O
root,4130,O
of,4130,O
Aconitum,4130,O
coreanum,4130,O
(,4130,O
Levl,4130,O
.,4130,O
),4131,O
",",4131,O
is,4131,O
an,4131,O
anti-arrhythmic,4131,O
drug,4131,O
in,4131,O
phase,4131,O
IV,4131,O
clinical,4131,O
trial,4131,O
.,4131,O
The,4132,O
isoquinoline,4132,I-CHEMICAL
alkaloid,4132,O
",",4132,O
neferine,4132,O
(,4132,B-CHEMICAL
Nef,4132,O
),4132,O
induces,4132,O
a,4132,O
concentration-dependent,4132,O
decrease,4132,O
in,4132,O
current,4132,O
amplitude,4132,O
(,4132,O
IC50,4132,O
of,4132,O
7.419,4132,O
MM,4132,O
),4132,O
.,4132,O
Most,4133,O
of,4133,O
these,4133,O
natural,4133,O
product,4133,O
compounds,4133,O
contain,4133,O
non-flexible,4133,O
aromatic,4133,O
structures,4133,O
but,4133,O
have,4133,O
significant,4133,O
activity,4133,O
due,4133,O
to,4133,O
the,4133,O
presence,4133,O
of,4133,O
optimum,4133,O
hydrophobicity,4133,O
.,4133,O
Recent,4134,O
research,4134,O
works,4134,O
revealed,4134,O
that,4134,O
Eag,4134,O
and,4134,O
hERG,4134,O
channels,4134,O
are,4134,O
expressed,4134,O
by,4134,O
a,4134,O
variety,4134,O
of,4134,O
cancer,4134,O
cell,4134,O
lines,4134,O
and,4134,O
tissues,4134,O
.,4134,O
The,4135,O
Eag,4135,O
channel,4135,O
showed,4135,O
an,4135,O
oncogenic,4135,O
potential,4135,O
while,4135,O
hERG,4135,O
channels,4135,O
are,4135,O
associated,4135,O
with,4135,O
more,4135,O
aggressive,4135,O
tumors,4135,O
and,4135,O
have,4135,O
a,4135,O
role,4135,O
in,4135,O
mediating,4135,O
invasion,4135,O
.,4135,O
This,4136,O
review,4136,O
concluded,4136,O
that,4136,O
the,4136,O
consideration,4136,O
of,4136,O
physicochemical,4136,O
properties,4136,O
necessary,4136,O
for,4136,O
the,4136,O
hERG,4136,O
blocking,4136,O
activity,4136,O
will,4136,O
guide,4136,O
to,4136,O
develop,4136,O
novel,4136,O
drugs,4136,O
with,4136,O
less,4136,O
cardiotoxicity,4136,O
.,4136,O
Multifunctional,4137,O
targets,4137,O
of,4137,O
dietary,4137,O
polyphenols,4137,B-CHEMICAL
in,4137,O
disease,4137,O
:,4137,O
a,4137,O
case,4137,O
for,4137,O
the,4137,O
chemokine,4137,B-GENE-N
network,4137,O
and,4137,O
energy,4137,O
metabolism,4137,O
.,4137,O
Chronic,4138,O
",",4138,O
non-acute,4138,O
inflammation,4138,O
is,4138,O
behind,4138,O
conditions,4138,O
that,4138,O
represent,4138,O
most,4138,O
of,4138,O
the,4138,O
disease,4138,O
burden,4138,O
in,4138,O
humans,4138,O
and,4138,O
is,4138,O
clearly,4138,O
linked,4138,O
to,4138,O
immune,4138,O
and,4138,O
metabolic,4138,O
mechanisms,4138,O
.,4138,O
The,4139,O
convergence,4139,O
of,4139,O
pathways,4139,O
involving,4139,O
the,4139,O
immune,4139,O
response,4139,O
",",4139,O
oxidative,4139,O
stress,4139,O
",",4139,O
increased,4139,O
circulating,4139,O
lipids,4139,O
and,4139,O
aberrant,4139,O
insulin,4139,B-GENE-Y
signaling,4139,O
results,4139,O
in,4139,O
CCL2-associated,4139,B-GENE-Y
macrophage,4139,O
recruitment,4139,O
and,4139,O
altered,4139,O
energy,4139,O
metabolism,4139,O
.,4139,O
The,4140,O
CCL2/CCR2,4140,B-GENE-Y
pathway,4140,O
and,4140,O
the,4140,O
energy,4140,O
sensor,4140,O
AMP-activated,4140,B-GENE-Y
protein,4140,I-GENE-Y
kinase,4140,I-GENE-Y
(,4140,O
AMPK,4140,B-GENE-Y
),4140,O
are,4140,O
attractive,4140,O
therapeutic,4140,O
targets,4140,O
as,4140,O
a,4140,O
part,4140,O
of,4140,O
preventive,4140,O
management,4140,O
of,4140,O
disease,4140,O
.,4140,O
Several,4141,O
effects,4141,O
of,4141,O
polyphenols,4141,B-CHEMICAL
are,4141,O
useful,4141,O
in,4141,O
this,4141,O
scenario,4141,O
",",4141,O
including,4141,O
a,4141,O
reduction,4141,O
in,4141,O
the,4141,O
activities,4141,O
of,4141,O
cytokines,4141,B-GENE-N
and,4141,O
modulation,4141,O
of,4141,O
cellular,4141,O
metabolism,4141,O
through,4141,O
histone,4141,B-GENE-N
deacetylase,4141,I-GENE-N
inhibitors,4141,O
",",4141,O
AMPK,4141,B-GENE-Y
activators,4141,O
",",4141,O
calorie-restriction,4141,O
mimetics,4141,O
or,4141,O
epigenetic,4141,O
regulators,4141,O
.,4141,O
Research,4142,O
is,4142,O
currently,4142,O
underway,4142,O
to,4142,O
develop,4142,O
orally,4142,O
active,4142,O
drugs,4142,O
with,4142,O
these,4142,O
effects,4142,O
",",4142,O
but,4142,O
it,4142,O
is,4142,O
convenient,4142,O
to,4142,O
examine,4142,O
more,4142,O
closely,4142,O
what,4142,O
we,4142,O
are,4142,O
eating,4142,O
.,4142,O
If,4143,O
a,4143,O
lack,4143,O
of,4143,O
relevance,4143,O
in,4143,O
terms,4143,O
of,4143,O
toxicity,4143,O
and,4143,O
substantial,4143,O
effectiveness,4143,O
are,4143,O
confirmed,4143,O
",",4143,O
plant-derived,4143,O
components,4143,O
may,4143,O
provide,4143,O
useful,4143,O
druggable,4143,O
components,4143,O
and,4143,O
dietary,4143,O
supplements,4143,O
.,4143,O
We,4144,O
consider,4144,O
therapeutic,4144,O
actions,4144,O
as,4144,O
a,4144,O
combination,4144,O
of,4144,O
synergistic,4144,O
and/or,4144,O
antagonistic,4144,O
interactions,4144,O
in,4144,O
a,4144,O
multi-target,4144,O
strategy,4144,O
.,4144,O
Hence,4145,O
",",4145,O
improvement,4145,O
in,4145,O
food,4145,O
through,4145,O
enrichment,4145,O
with,4145,O
polyphenols,4145,B-CHEMICAL
with,4145,O
demonstrated,4145,O
activity,4145,O
may,4145,O
represent,4145,O
a,4145,O
major,4145,O
advance,4145,O
in,4145,O
the,4145,O
design,4145,O
of,4145,O
diets,4145,O
with,4145,O
both,4145,O
industrial,4145,O
and,4145,O
sanitary,4145,O
value,4145,O
.,4145,O
Inhibition,4146,O
of,4146,O
EGF/EGFR,4146,B-GENE-Y
activation,4146,O
with,4146,O
naphtho,4146,B-CHEMICAL
[,4146,I-CHEMICAL
"1,2-b",4146,I-CHEMICAL
],4146,I-CHEMICAL
"furan-4,5-dione",4146,I-CHEMICAL
blocks,4146,O
migration,4146,O
and,4146,O
invasion,4146,O
of,4146,O
MDA-MB-231,4146,O
cells,4146,O
.,4146,O
Naphtho,4147,B-CHEMICAL
[,4147,I-CHEMICAL
"1,2-b",4147,I-CHEMICAL
],4147,I-CHEMICAL
"furan-4,5-dione",4147,I-CHEMICAL
(,4147,O
NFD,4147,B-CHEMICAL
),4147,O
",",4147,O
a,4147,O
bioactive,4147,O
component,4147,O
of,4147,O
Avicennia,4147,O
marina,4147,O
",",4147,O
has,4147,O
been,4147,O
demonstrated,4147,O
to,4147,O
display,4147,O
anti-cancer,4147,O
activity,4147,O
.,4147,O
Activation,4148,O
of,4148,O
epidermal,4148,B-GENE-Y
growth,4148,I-GENE-Y
factor,4148,I-GENE-Y
receptor,4148,I-GENE-Y
(,4148,O
EGFR,4148,B-GENE-Y
),4148,O
-induced,4148,O
signaling,4148,O
pathway,4148,O
has,4148,O
been,4148,O
correlated,4148,O
with,4148,O
cancer,4148,O
metastasis,4148,O
in,4148,O
various,4148,O
tumors,4148,O
",",4148,O
including,4148,O
breast,4148,O
carcinoma,4148,O
.,4148,O
We,4149,O
use,4149,O
EGF,4149,B-GENE-Y
as,4149,O
a,4149,O
metastatic,4149,O
inducer,4149,O
of,4149,O
MDA-MB-231,4149,O
cells,4149,O
to,4149,O
investigate,4149,O
the,4149,O
effect,4149,O
of,4149,O
NFD,4149,B-CHEMICAL
on,4149,O
cell,4149,O
migration,4149,O
and,4149,O
invasion,4149,O
.,4149,O
NFD,4150,B-CHEMICAL
suppressed,4150,O
EGF-mediated,4150,B-GENE-Y
protein,4150,O
levels,4150,O
of,4150,O
c-Jun,4150,B-GENE-Y
and,4150,O
c-Fos,4150,B-GENE-Y
",",4150,O
and,4150,O
reduced,4150,O
MMP-9,4150,B-GENE-Y
expression,4150,O
and,4150,O
activity,4150,O
",",4150,O
concomitantly,4150,O
with,4150,O
a,4150,O
marked,4150,O
inhibition,4150,O
on,4150,O
cell,4150,O
migration,4150,O
and,4150,O
invasion,4150,O
without,4150,O
obvious,4150,O
cellular,4150,O
cytotoxicity,4150,O
.,4150,O
NFD,4151,B-CHEMICAL
abrogated,4151,O
EGF-induced,4151,B-GENE-Y
phosphorylation,4151,O
of,4151,O
EGF,4151,B-GENE-Y
receptor,4151,I-GENE-Y
(,4151,O
EGFR,4151,B-GENE-Y
),4151,O
and,4151,O
phosphatidylinositol,4151,B-CHEMICAL
3-kinase,4151,I-GENE-N
(,4151,O
PI3K,4151,B-GENE-N
),4151,O
/Akt,4151,O
.,4151,O
The,4152,O
specific,4152,O
PI3K,4152,B-GENE-N
inhibitor,4152,O
",",4152,O
wortmannin,4152,B-CHEMICAL
",",4152,O
blocked,4152,O
significantly,4152,O
EGF-induced,4152,B-GENE-Y
cell,4152,O
migration,4152,O
and,4152,O
invasion,4152,O
.,4152,O
Furthermore,4153,O
",",4153,O
the,4153,O
EGFR,4153,B-GENE-Y
inhibitor,4153,O
AG1478,4153,B-CHEMICAL
inhibited,4153,O
EGF-induced,4153,B-GENE-Y
MMP-9,4153,B-GENE-Y
expression,4153,O
",",4153,O
cell,4153,O
migration,4153,O
and,4153,O
invasion,4153,O
",",4153,O
as,4153,O
well,4153,O
as,4153,O
the,4153,O
activation,4153,O
of,4153,O
PI3K/Akt,4153,B-GENE-N
",",4153,O
suggesting,4153,O
that,4153,O
PI3K/Akt,4153,B-GENE-N
activation,4153,O
occur,4153,O
downstream,4153,O
of,4153,O
EGFR,4153,B-GENE-Y
activation,4153,O
.,4153,O
These,4154,O
findings,4154,O
suggest,4154,O
that,4154,O
NFD,4154,B-CHEMICAL
inhibited,4154,O
the,4154,O
EGF-induced,4154,B-GENE-Y
invasion,4154,O
and,4154,O
migration,4154,O
of,4154,O
MDA-MB-231,4154,O
cells,4154,O
via,4154,O
EGFR-dependent,4154,B-GENE-Y
PI3K/Akt,4154,B-GENE-N
signaling,4154,O
",",4154,O
leading,4154,O
to,4154,O
the,4154,O
down-regulation,4154,O
of,4154,O
MMP-9,4154,B-GENE-Y
expression,4154,O
.,4154,O
These,4155,O
results,4155,O
provide,4155,O
a,4155,O
novel,4155,O
mechanism,4155,O
to,4155,O
explain,4155,O
the,4155,O
role,4155,O
of,4155,O
NFD,4155,B-CHEMICAL
as,4155,O
a,4155,O
potent,4155,O
anti-metastatic,4155,O
agent,4155,O
in,4155,O
MDA-MB-231,4155,O
cells,4155,O
.,4155,O
A,4156,O
novel,4156,O
EPAC-specific,4156,B-GENE-Y
inhibitor,4156,O
suppresses,4156,O
pancreatic,4156,O
cancer,4156,O
cell,4156,O
migration,4156,O
and,4156,O
invasion,4156,O
.,4156,O
Exchange,4157,B-GENE-Y
protein,4157,I-GENE-Y
directly,4157,I-GENE-Y
activated,4157,I-GENE-Y
by,4157,I-GENE-Y
cAMP,4157,I-GENE-Y
(,4157,O
EPAC,4157,B-GENE-Y
),4157,O
and,4157,O
cAMP-dependent,4157,B-CHEMICAL
protein,4157,I-GENE-N
kinase,4157,I-GENE-N
(,4157,O
PKA,4157,B-GENE-N
),4157,O
are,4157,O
two,4157,O
intracellular,4157,O
receptors,4157,O
that,4157,O
mediate,4157,O
the,4157,O
effects,4157,O
of,4157,O
the,4157,O
prototypic,4157,O
second,4157,O
messenger,4157,O
cAMP,4157,B-CHEMICAL
.,4157,O
Identifying,4158,O
pharmacological,4158,O
probes,4158,O
for,4158,O
selectively,4158,O
modulating,4158,O
EPAC,4158,B-GENE-Y
activity,4158,O
represents,4158,O
a,4158,O
significant,4158,O
unmet,4158,O
need,4158,O
within,4158,O
the,4158,O
research,4158,O
field,4158,O
.,4158,O
Herein,4159,O
",",4159,O
we,4159,O
report,4159,O
the,4159,O
identification,4159,O
and,4159,O
characterization,4159,O
of,4159,O
3-,4159,B-CHEMICAL
(,4159,I-CHEMICAL
5-tert-butyl-isoxazol-3-yl,4159,I-CHEMICAL
),4159,I-CHEMICAL
-2-,4159,I-CHEMICAL
[,4159,I-CHEMICAL
(,4159,I-CHEMICAL
3-chloro-phenyl,4159,I-CHEMICAL
),4159,I-CHEMICAL
-hydrazono,4159,I-CHEMICAL
],4159,I-CHEMICAL
-3-oxo-propionitrile,4159,I-CHEMICAL
(,4159,O
ESI-09,4159,B-CHEMICAL
),4159,O
",",4159,O
a,4159,O
novel,4159,O
noncyclic,4159,O
nucleotide,4159,B-CHEMICAL
EPAC,4159,B-GENE-Y
antagonist,4159,O
that,4159,O
is,4159,O
capable,4159,O
of,4159,O
specifically,4159,O
blocking,4159,O
intracellular,4159,O
EPAC-mediated,4159,B-GENE-Y
Rap1,4159,B-GENE-Y
activation,4159,O
and,4159,O
Akt,4159,B-GENE-N
phosphorylation,4159,O
",",4159,O
as,4159,O
well,4159,O
as,4159,O
EPAC-mediated,4159,B-GENE-Y
insulin,4159,B-GENE-Y
secretion,4159,O
in,4159,O
pancreatic,4159,O
β,4159,O
cells,4159,O
.,4159,O
Using,4160,O
this,4160,O
novel,4160,O
EPAC-specific,4160,B-GENE-Y
inhibitor,4160,O
",",4160,O
we,4160,O
have,4160,O
probed,4160,O
the,4160,O
functional,4160,O
roles,4160,O
of,4160,O
overexpression,4160,O
of,4160,O
EPAC1,4160,B-GENE-Y
in,4160,O
pancreatic,4160,O
cancer,4160,O
cells,4160,O
.,4160,O
Our,4161,O
studies,4161,O
show,4161,O
that,4161,O
EPAC1,4161,B-GENE-Y
plays,4161,O
an,4161,O
important,4161,O
role,4161,O
in,4161,O
pancreatic,4161,O
cancer,4161,O
cell,4161,O
migration,4161,O
and,4161,O
invasion,4161,O
",",4161,O
and,4161,O
thus,4161,O
represents,4161,O
a,4161,O
potential,4161,O
target,4161,O
for,4161,O
developing,4161,O
novel,4161,O
therapeutic,4161,O
strategies,4161,O
for,4161,O
pancreatic,4161,O
cancer,4161,O
.,4161,O
Metformin,4162,B-CHEMICAL
directly,4162,O
inhibits,4162,O
ghrelin,4162,B-GENE-Y
secretion,4162,O
through,4162,O
AMP-activated,4162,B-GENE-Y
protein,4162,I-GENE-Y
kinase,4162,I-GENE-Y
in,4162,O
rat,4162,O
primary,4162,O
gastric,4162,O
cells,4162,O
.,4162,O
The,4163,O
antidiabetic,4163,O
drug,4163,O
Metformin,4163,B-CHEMICAL
causes,4163,O
weight,4163,O
loss,4163,O
in,4163,O
both,4163,O
diabetic,4163,O
and,4163,O
non-diabetic,4163,O
individuals,4163,O
.,4163,O
Metformin,4164,B-CHEMICAL
treatment,4164,O
is,4164,O
also,4164,O
associated,4164,O
with,4164,O
lower,4164,O
circulating,4164,O
levels,4164,O
of,4164,O
the,4164,O
orexigenic,4164,B-GENE-N
hormone,4164,I-GENE-N
ghrelin,4164,B-GENE-Y
.,4164,O
To,4165,O
test,4165,O
whether,4165,O
Metformin,4165,B-CHEMICAL
directly,4165,O
affects,4165,O
ghrelin,4165,B-GENE-Y
cells,4165,O
",",4165,O
rat,4165,O
primary,4165,O
stomach,4165,O
cells,4165,O
were,4165,O
treated,4165,O
with,4165,O
Metformin,4165,B-CHEMICAL
and,4165,O
the,4165,O
levels,4165,O
of,4165,O
ghrelin,4165,B-GENE-Y
secretion,4165,O
",",4165,O
proghrelin,4165,B-GENE-Y
gene,4165,O
expression,4165,O
and,4165,O
activation,4165,O
of,4165,O
adenosine,4165,B-CHEMICAL
monophosphate-activated,4165,I-GENE-Y
protein,4165,I-GENE-Y
kinase,4165,I-GENE-Y
(,4165,O
AMPK,4165,B-GENE-Y
),4165,O
were,4165,O
examined,4165,O
.,4165,O
Metformin,4166,B-CHEMICAL
significantly,4166,O
reduced,4166,O
ghrelin,4166,B-GENE-Y
secretion,4166,O
and,4166,O
proghrelin,4166,B-GENE-Y
mRNA,4166,O
production,4166,O
and,4166,O
both,4166,O
these,4166,O
effects,4166,O
were,4166,O
blocked,4166,O
by,4166,O
co-incubation,4166,O
with,4166,O
the,4166,O
AMPK,4166,B-GENE-Y
inhibitor,4166,O
compound,4166,B-CHEMICAL
C.,4166,O
Furthermore,4166,O
",",4166,O
the,4166,O
AMPK,4166,B-GENE-Y
activator,4166,O
5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide,4166,B-CHEMICAL
(,4166,O
AICAR,4166,B-CHEMICAL
),4166,O
significantly,4166,O
inhibited,4166,O
ghrelin,4166,B-GENE-Y
secretion,4166,O
.,4166,O
Additionally,4167,O
",",4167,O
ghrelin,4167,B-GENE-Y
cells,4167,O
were,4167,O
shown,4167,O
to,4167,O
express,4167,O
AMPK,4167,B-GENE-Y
.,4167,O
Finally,4168,O
",",4168,O
Metformin,4168,B-CHEMICAL
treatment,4168,O
caused,4168,O
a,4168,O
significant,4168,O
increase,4168,O
in,4168,O
the,4168,O
level,4168,O
of,4168,O
phosphorylated,4168,B-GENE-Y
(,4168,I-GENE-Y
active,4168,I-GENE-Y
),4168,I-GENE-Y
AMPK,4168,I-GENE-Y
.,4168,O
Our,4169,O
results,4169,O
show,4169,O
that,4169,O
Metformin,4169,B-CHEMICAL
directly,4169,O
inhibits,4169,O
stomach,4169,O
ghrelin,4169,B-GENE-Y
production,4169,O
and,4169,O
secretion,4169,O
through,4169,O
AMPK,4169,B-GENE-Y
.,4169,O
This,4170,O
reduction,4170,O
in,4170,O
ghrelin,4170,O
secretion,4170,O
may,4170,O
be,4170,O
one,4170,O
of,4170,O
the,4170,O
key,4170,O
components,4170,O
in,4170,O
Metformin,4170,B-CHEMICAL
's,4170,O
mechanism,4170,O
of,4170,O
weight,4170,O
loss,4170,O
.,4170,O
Fungicide,4171,O
prochloraz,4171,B-CHEMICAL
and,4171,O
environmental,4171,O
pollutant,4171,O
dioxin,4171,B-CHEMICAL
induce,4171,O
the,4171,O
ABCG2,4171,B-GENE-Y
transporter,4171,O
in,4171,O
bovine,4171,O
mammary,4171,O
epithelial,4171,O
cells,4171,O
by,4171,O
the,4171,O
arylhydrocarbon,4171,B-GENE-Y
receptor,4171,I-GENE-Y
signaling,4171,O
pathway,4171,O
.,4171,O
The,4172,O
molecular,4172,O
mechanisms,4172,O
by,4172,O
which,4172,O
environmental,4172,O
pollutants,4172,O
including,4172,O
"2,3,7,8-tetrachlorodibenzo-p-dioxin",4172,B-CHEMICAL
(,4172,O
TCDD,4172,B-CHEMICAL
),4172,O
or,4172,O
widely,4172,O
used,4172,O
imidazole,4172,B-CHEMICAL
fungicide,4172,O
prochloraz,4172,B-CHEMICAL
display,4172,O
their,4172,O
toxic,4172,O
effects,4172,O
in,4172,O
vertebrates,4172,O
are,4172,O
still,4172,O
not,4172,O
well,4172,O
understood,4172,O
.,4172,O
Using,4173,O
computer,4173,O
analysis,4173,O
",",4173,O
we,4173,O
recently,4173,O
identified,4173,O
nuclear,4173,O
aryl,4173,B-CHEMICAL
hydrocarbon,4173,I-CHEMICAL
receptor,4173,I-GENE-Y
(,4173,O
AhR,4173,B-GENE-Y
),4173,O
binding,4173,O
sites,4173,O
termed,4173,O
``,4173,O
dioxin,4173,B-GENE-N
response,4173,I-GENE-N
elements,4173,I-GENE-N
'',4173,O
(,4173,O
DREs,4173,B-GENE-N
),4173,O
in,4173,O
the,4173,O
5'-untranslated,4173,O
region,4173,O
(,4173,O
5'-UTR,4173,O
),4173,O
of,4173,O
efflux,4173,B-GENE-N
transporter,4173,I-GENE-N
ABCG2,4173,B-GENE-Y
(,4173,O
Accession,4173,O
No,4173,O
.,4173,O
EU570105,4174,B-GENE-Y
),4174,O
from,4174,O
the,4174,O
bovine,4174,O
mammary,4174,O
gland,4174,O
.,4174,O
As,4175,O
these,4175,O
regulatory,4175,O
motifs,4175,O
mediate,4175,O
regulation,4175,O
of,4175,O
target,4175,O
genes,4175,O
by,4175,O
AhR,4175,B-GENE-Y
agonists,4175,O
including,4175,O
TCDD,4175,B-CHEMICAL
and,4175,O
prochloraz,4175,B-CHEMICAL
",",4175,O
we,4175,O
have,4175,O
systematically,4175,O
investigated,4175,O
the,4175,O
effect,4175,O
of,4175,O
both,4175,O
contaminants,4175,O
on,4175,O
functional,4175,O
ABCG2,4175,B-GENE-Y
transport,4175,O
activity,4175,O
in,4175,O
primary,4175,O
bovine,4175,O
mammary,4175,O
epithelial,4175,O
cells,4175,O
.,4175,O
TCDD,4176,B-CHEMICAL
or,4176,O
prochloraz,4176,B-CHEMICAL
doubled,4176,O
ABCG2-mediated,4176,B-GENE-Y
Hoechst,4176,B-CHEMICAL
H33342,4176,I-CHEMICAL
secretion,4176,O
.,4176,O
This,4177,O
effect,4177,O
was,4177,O
almost,4177,O
completely,4177,O
reversed,4177,O
by,4177,O
specific,4177,O
ABCG2,4177,B-GENE-Y
inhibitor,4177,O
Ko143,4177,B-CHEMICAL
.,4177,O
In,4178,O
further,4178,O
mechanistic,4178,O
studies,4178,O
",",4178,O
we,4178,O
showed,4178,O
that,4178,O
this,4178,O
induction,4178,O
was,4178,O
due,4178,O
to,4178,O
binding,4178,O
of,4178,O
activated,4178,O
AhR,4178,B-GENE-Y
to,4178,O
DRE,4178,B-GENE-N
sequences,4178,O
in,4178,O
the,4178,O
ABCG2,4178,B-GENE-Y
5'-UTR,4178,O
.,4178,O
Receptor,4179,O
binding,4179,O
was,4179,O
significantly,4179,O
reduced,4179,O
by,4179,O
specific,4179,O
AhR,4179,B-GENE-Y
antagonist,4179,O
salicyl,4179,B-CHEMICAL
amide,4179,I-CHEMICAL
.,4179,O
Induction,4180,O
of,4180,O
AhR,4180,B-GENE-Y
by,4180,O
TCDD,4180,B-CHEMICAL
and,4180,O
prochloraz,4180,B-CHEMICAL
resulted,4180,O
in,4180,O
a,4180,O
time-,4180,O
and,4180,O
dose-dependent,4180,O
increase,4180,O
of,4180,O
ABCG2,4180,B-GENE-Y
gene,4180,O
expression,4180,O
and,4180,O
transporter,4180,O
protein,4180,O
levels,4180,O
.,4180,O
As,4181,O
ABCG2,4181,B-GENE-Y
represents,4181,O
the,4181,O
main,4181,O
mammary,4181,O
transporter,4181,O
for,4181,O
xenobiotics,4181,O
including,4181,O
drugs,4181,O
and,4181,O
toxins,4181,O
",",4181,O
exposure,4181,O
to,4181,O
prevalent,4181,O
AhR,4181,B-GENE-Y
agonists,4181,O
may,4181,O
enhance,4181,O
transporter-mediated,4181,O
secretion,4181,O
of,4181,O
potential,4181,O
harmful,4181,O
compounds,4181,O
into,4181,O
milk,4181,O
.,4181,O
Through,4182,O
identification,4182,O
of,4182,O
mammary,4182,O
ABCG2,4182,B-GENE-Y
as,4182,O
a,4182,O
novel,4182,O
target,4182,O
gene,4182,O
of,4182,O
pesticide,4182,O
prochloraz,4182,B-CHEMICAL
and,4182,O
dioxin,4182,B-CHEMICAL
",",4182,O
our,4182,O
results,4182,O
may,4182,O
therefore,4182,O
help,4182,O
to,4182,O
improve,4182,O
the,4182,O
protection,4182,O
of,4182,O
breast-feeding,4182,O
infants,4182,O
and,4182,O
the,4182,O
consumer,4182,O
of,4182,O
dairy,4182,O
products,4182,O
.,4182,O
Molecular,4183,O
analyses,4183,O
of,4183,O
dinosaur,4183,O
osteocytes,4183,O
support,4183,O
the,4183,O
presence,4183,O
of,4183,O
endogenous,4183,O
molecules,4183,O
.,4183,O
The,4184,O
discovery,4184,O
of,4184,O
soft,4184,O
",",4184,O
transparent,4184,O
microstructures,4184,O
in,4184,O
dinosaur,4184,O
bone,4184,O
consistent,4184,O
in,4184,O
morphology,4184,O
with,4184,O
osteocytes,4184,O
was,4184,O
controversial,4184,O
.,4184,O
We,4185,O
hypothesize,4185,O
that,4185,O
",",4185,O
if,4185,O
original,4185,O
",",4185,O
these,4185,O
microstructures,4185,O
will,4185,O
have,4185,O
molecular,4185,O
features,4185,O
in,4185,O
common,4185,O
with,4185,O
extant,4185,O
osteocytes,4185,O
.,4185,O
We,4186,O
present,4186,O
immunological,4186,O
and,4186,O
mass,4186,O
spectrometry,4186,O
evidence,4186,O
for,4186,O
preservation,4186,O
of,4186,O
proteins,4186,O
comprising,4186,O
extant,4186,O
osteocytes,4186,O
(,4186,O
Actin,4186,B-GENE-N
",",4186,O
Tubulin,4186,B-GENE-N
",",4186,O
PHEX,4186,B-GENE-N
",",4186,O
Histone,4186,B-GENE-N
H4,4186,I-GENE-N
),4186,O
in,4186,O
osteocytes,4186,O
recovered,4186,O
from,4186,O
two,4186,O
non-avian,4186,O
dinosaurs,4186,O
.,4186,O
Furthermore,4187,O
",",4187,O
antibodies,4187,O
to,4187,O
DNA,4187,O
show,4187,O
localized,4187,O
binding,4187,O
to,4187,O
these,4187,O
microstructures,4187,O
",",4187,O
which,4187,O
also,4187,O
react,4187,O
positively,4187,O
with,4187,O
DNA,4187,O
intercalating,4187,O
stains,4187,O
propidium,4187,B-CHEMICAL
iodide,4187,I-CHEMICAL
(,4187,O
PI,4187,O
),4187,O
and,4187,O
"4',6'-diamidino-2-phenylindole",4187,B-CHEMICAL
dihydrochloride,4187,I-CHEMICAL
(,4187,O
DAPI,4187,B-CHEMICAL
),4187,O
.,4187,O
Each,4188,O
antibody,4188,O
binds,4188,O
dinosaur,4188,O
cells,4188,O
in,4188,O
patterns,4188,O
similar,4188,O
to,4188,O
extant,4188,O
cells,4188,O
.,4188,O
These,4189,O
data,4189,O
are,4189,O
the,4189,O
first,4189,O
to,4189,O
support,4189,O
preservation,4189,O
of,4189,O
multiple,4189,O
proteins,4189,O
and,4189,O
to,4189,O
present,4189,O
multiple,4189,O
lines,4189,O
of,4189,O
evidence,4189,O
for,4189,O
material,4189,O
consistent,4189,O
with,4189,O
DNA,4189,O
in,4189,O
dinosaurs,4189,O
",",4189,O
supporting,4189,O
the,4189,O
hypothesis,4189,O
that,4189,O
these,4189,O
structures,4189,O
were,4189,O
part,4189,O
of,4189,O
the,4189,O
once,4189,O
living,4189,O
animals,4189,O
.,4189,O
We,4190,O
propose,4190,O
mechanisms,4190,O
for,4190,O
preservation,4190,O
of,4190,O
cells,4190,O
and,4190,O
component,4190,O
molecules,4190,O
",",4190,O
and,4190,O
discuss,4190,O
implications,4190,O
for,4190,O
dinosaurian,4190,O
cellular,4190,O
biology,4190,O
.,4190,O
Effects,4191,O
of,4191,O
silver,4191,B-CHEMICAL
nanoparticles,4191,O
on,4191,O
the,4191,O
liver,4191,O
and,4191,O
hepatocytes,4191,O
in,4191,O
vitro,4191,O
.,4191,O
With,4192,O
the,4192,O
increasing,4192,O
use,4192,O
and,4192,O
incorporation,4192,O
of,4192,O
nanoparticles,4192,O
(,4192,O
NPs,4192,O
),4192,O
into,4192,O
consumer,4192,O
products,4192,O
",",4192,O
screening,4192,O
for,4192,O
potential,4192,O
toxicity,4192,O
is,4192,O
necessary,4192,O
to,4192,O
ensure,4192,O
customer,4192,O
safety,4192,O
.,4192,O
NPs,4193,O
have,4193,O
been,4193,O
shown,4193,O
to,4193,O
translocate,4193,O
to,4193,O
the,4193,O
bloodstream,4193,O
following,4193,O
inhalation,4193,O
and,4193,O
ingestion,4193,O
",",4193,O
and,4193,O
such,4193,O
studies,4193,O
demonstrate,4193,O
that,4193,O
the,4193,O
liver,4193,O
is,4193,O
an,4193,O
important,4193,O
organ,4193,O
for,4193,O
accumulation,4193,O
.,4193,O
Silver,4194,B-CHEMICAL
(,4194,O
Ag,4194,B-CHEMICAL
),4194,O
NPs,4194,O
are,4194,O
highly,4194,O
relevant,4194,O
for,4194,O
human,4194,O
exposure,4194,O
due,4194,O
to,4194,O
their,4194,O
use,4194,O
in,4194,O
food,4194,O
contact,4194,O
materials,4194,O
",",4194,O
dietary,4194,O
supplements,4194,O
",",4194,O
and,4194,O
antibacterial,4194,O
wound,4194,O
treatments,4194,O
.,4194,O
Due,4195,O
to,4195,O
the,4195,O
large,4195,O
number,4195,O
of,4195,O
different,4195,O
NPs,4195,O
already,4195,O
used,4195,O
in,4195,O
various,4195,O
products,4195,O
and,4195,O
being,4195,O
developed,4195,O
for,4195,O
new,4195,O
applications,4195,O
",",4195,O
it,4195,O
is,4195,O
essential,4195,O
that,4195,O
relevant,4195,O
",",4195,O
quick,4195,O
",",4195,O
and,4195,O
cheap,4195,O
methods,4195,O
of,4195,O
in,4195,O
vitro,4195,O
risk,4195,O
assessment,4195,O
suitable,4195,O
for,4195,O
these,4195,O
new,4195,O
materials,4195,O
are,4195,O
established,4195,O
.,4195,O
Therefore,4196,O
",",4196,O
this,4196,O
study,4196,O
used,4196,O
a,4196,O
simple,4196,O
hepatocytes,4196,O
model,4196,O
combined,4196,O
with,4196,O
an,4196,O
in,4196,O
vivo,4196,O
injection,4196,O
model,4196,O
to,4196,O
simulate,4196,O
the,4196,O
passage,4196,O
of,4196,O
a,4196,O
small,4196,O
amount,4196,O
of,4196,O
NPs,4196,O
into,4196,O
the,4196,O
bloodstream,4196,O
following,4196,O
exposure,4196,O
",",4196,O
e.g.,4196,O
",",4196,O
via,4196,O
ingestion,4196,O
or,4196,O
inhalation,4196,O
",",4196,O
and,4196,O
examined,4196,O
the,4196,O
potential,4196,O
of,4196,O
Ag,4196,B-CHEMICAL
NPs,4196,O
of,4196,O
20,4196,O
nm,4196,O
diameter,4196,O
to,4196,O
cause,4196,O
toxicity,4196,O
",",4196,O
inflammation,4196,O
",",4196,O
and,4196,O
oxidative,4196,O
stress,4196,O
in,4196,O
the,4196,O
liver,4196,O
following,4196,O
in,4196,O
vivo,4196,O
exposures,4196,O
of,4196,O
female,4196,O
Wistar,4196,O
rats,4196,O
via,4196,O
iv,4196,O
injection,4196,O
to,4196,O
50,4196,O
μg,4196,O
of,4196,O
NPs,4196,O
and,4196,O
in,4196,O
vitro,4196,O
exposures,4196,O
using,4196,O
the,4196,O
human,4196,O
hepatocyte,4196,O
cell,4196,O
line,4196,O
C3A,4196,O
.,4196,O
We,4197,O
found,4197,O
that,4197,O
Ag,4197,B-CHEMICAL
NPs,4197,O
were,4197,O
highly,4197,O
cytotoxic,4197,O
to,4197,O
hepatocytes,4197,O
(,4197,O
LC,4197,O
(,4197,O
50,4197,O
),4197,O
lactate,4197,B-CHEMICAL
dehydrogenase,4197,I-GENE-N
:,4197,O
2.5,4197,O
μg/cm,4197,O
(,4197,O
2,4197,O
),4197,O
),4197,O
and,4197,O
affected,4197,O
hepatocyte,4197,O
homeostasis,4197,O
by,4197,O
reducing,4197,O
albumin,4197,B-GENE-Y
release,4197,O
.,4197,O
At,4198,O
sublethal,4198,O
concentrations,4198,O
with,4198,O
normal,4198,O
cell,4198,O
or,4198,O
tissue,4198,O
morphology,4198,O
",",4198,O
Ag,4198,B-CHEMICAL
NPs,4198,O
were,4198,O
detected,4198,O
in,4198,O
cytoplasm,4198,O
and,4198,O
nuclei,4198,O
of,4198,O
hepatocytes,4198,O
.,4198,O
We,4199,O
observed,4199,O
similar,4199,O
effects,4199,O
of,4199,O
Ag,4199,B-CHEMICAL
NPs,4199,O
on,4199,O
inflammatory,4199,O
mediator,4199,O
expression,4199,O
in,4199,O
vitro,4199,O
and,4199,O
in,4199,O
vivo,4199,O
with,4199,O
increase,4199,O
of,4199,O
interleukin-8,4199,B-GENE-Y
(,4199,O
IL-8,4199,B-GENE-Y
),4199,O
/macrophage,4199,O
inflammatory,4199,I-GENE-N
protein,4199,I-GENE-N
2,4199,I-GENE-N
",",4199,O
IL-1RI,4199,B-GENE-Y
",",4199,O
and,4199,O
tumor,4199,B-GENE-Y
necrosis,4199,I-GENE-Y
factor-α,4199,I-GENE-Y
expression,4199,O
in,4199,O
both,4199,O
models,4199,O
and,4199,O
increased,4199,O
IL-8,4199,B-GENE-Y
protein,4199,O
release,4199,O
in,4199,O
vitro,4199,O
.,4199,O
This,4200,O
article,4200,O
presents,4200,O
evidence,4200,O
of,4200,O
the,4200,O
potential,4200,O
toxicity,4200,O
and,4200,O
inflammogenic,4200,O
potential,4200,O
of,4200,O
Ag,4200,B-CHEMICAL
NPs,4200,O
in,4200,O
the,4200,O
liver,4200,O
following,4200,O
ingestion,4200,O
.,4200,O
In,4201,O
addition,4201,O
",",4201,O
the,4201,O
similarities,4201,O
between,4201,O
in,4201,O
vitro,4201,O
and,4201,O
in,4201,O
vivo,4201,O
responses,4201,O
are,4201,O
striking,4201,O
and,4201,O
encouraging,4201,O
for,4201,O
future,4201,O
reduction,4201,O
",",4201,O
refinement,4201,O
",",4201,O
and,4201,O
replacement,4201,O
of,4201,O
animal,4201,O
studies,4201,O
by,4201,O
the,4201,O
use,4201,O
of,4201,O
hepatocyte,4201,O
cell,4201,O
lines,4201,O
in,4201,O
particle,4201,O
risk,4201,O
assessment,4201,O
.,4201,O
Extracellular,4202,B-GENE-N
loop,4202,I-GENE-N
II,4202,I-GENE-N
modulates,4202,O
GTP,4202,B-CHEMICAL
sensitivity,4202,O
of,4202,O
the,4202,O
prostaglandin,4202,B-GENE-Y
EP3,4202,I-GENE-Y
receptor,4202,I-GENE-Y
.,4202,O
Unlike,4203,O
the,4203,O
majority,4203,O
of,4203,O
G,4203,B-GENE-N
protein-coupled,4203,I-GENE-N
receptors,4203,I-GENE-N
",",4203,O
the,4203,O
prostaglandin,4203,B-CHEMICAL
E,4203,I-CHEMICAL
(,4203,I-CHEMICAL
2,4203,I-CHEMICAL
),4203,I-CHEMICAL
(,4203,I-GENE-Y
PGE,4203,I-GENE-Y
(,4203,I-GENE-Y
2,4203,I-GENE-Y
),4203,I-GENE-Y
),4203,I-GENE-Y
E-prostanoid,4203,I-GENE-Y
3,4203,I-GENE-Y
(,4203,I-GENE-Y
EP3,4203,I-GENE-Y
),4203,I-GENE-Y
receptor,4203,I-GENE-Y
binds,4203,O
agonist,4203,O
with,4203,O
high,4203,O
affinity,4203,O
that,4203,O
is,4203,O
insensitive,4203,O
to,4203,O
the,4203,O
presence,4203,O
of,4203,O
guanosine,4203,B-CHEMICAL
5,4203,I-CHEMICAL
[,4203,I-CHEMICAL
prime,4203,I-CHEMICAL
],4203,I-CHEMICAL
-O-,4203,I-CHEMICAL
(,4203,I-CHEMICAL
3-thio,4203,I-CHEMICAL
),4203,I-CHEMICAL
triphosphate,4203,I-CHEMICAL
(,4203,O
GTPγS,4203,B-CHEMICAL
),4203,O
.,4203,O
We,4204,O
report,4204,O
the,4204,O
identification,4204,O
of,4204,O
mutations,4204,O
that,4204,O
confer,4204,O
GTPγS,4204,B-CHEMICAL
sensitivity,4204,O
to,4204,O
agonist,4204,O
binding,4204,O
.,4204,O
Seven,4205,O
point,4205,O
mutations,4205,O
were,4205,O
introduced,4205,O
into,4205,O
the,4205,O
conserved,4205,O
motif,4205,O
in,4205,O
the,4205,O
second,4205,B-GENE-N
extracellular,4205,I-GENE-N
loop,4205,I-GENE-N
(,4205,O
ECII,4205,B-GENE-N
),4205,O
of,4205,O
EP3,4205,B-GENE-Y
",",4205,O
resulting,4205,O
in,4205,O
acquisition,4205,O
of,4205,O
GTP-sensitive,4205,B-CHEMICAL
agonist,4205,O
binding,4205,O
.,4205,O
One,4206,O
receptor,4206,O
mutation,4206,O
W203A,4206,B-GENE-N
was,4206,O
studied,4206,O
in,4206,O
detail,4206,O
.,4206,O
Loss,4207,O
of,4207,O
agonist,4207,O
binding,4207,O
was,4207,O
observed,4207,O
on,4207,O
intact,4207,O
human,4207,O
embryonic,4207,O
kidney,4207,O
293,4207,O
cells,4207,O
expressing,4207,O
the,4207,O
W203A,4207,B-GENE-N
receptor,4207,O
",",4207,O
conditions,4207,O
where,4207,O
high,4207,O
GTP,4207,B-CHEMICAL
levels,4207,O
are,4207,O
present,4207,O
;,4207,O
however,4207,O
",",4207,O
high,4207,O
affinity,4207,O
binding,4207,O
[,4207,B-CHEMICAL
(,4207,I-CHEMICAL
3,4207,I-CHEMICAL
),4207,I-CHEMICAL
H,4207,I-CHEMICAL
],4207,I-CHEMICAL
PGE,4207,I-CHEMICAL
(,4207,I-CHEMICAL
2,4207,I-CHEMICAL
),4207,I-CHEMICAL
was,4207,O
observed,4207,O
in,4207,O
broken,4207,O
cell,4207,O
preparations,4207,O
washed,4207,O
free,4207,O
of,4207,O
GTP,4207,B-CHEMICAL
.,4207,O
The,4208,O
[,4208,B-CHEMICAL
(,4208,I-CHEMICAL
3,4208,I-CHEMICAL
),4208,I-CHEMICAL
H,4208,I-CHEMICAL
],4208,I-CHEMICAL
PGE,4208,I-CHEMICAL
(,4208,I-CHEMICAL
2,4208,I-CHEMICAL
),4208,I-CHEMICAL
binding,4208,O
of,4208,O
W203A,4208,B-GENE-N
in,4208,O
broken,4208,O
cell,4208,O
membrane,4208,O
fractions,4208,O
was,4208,O
inhibited,4208,O
by,4208,O
addition,4208,O
of,4208,O
GTPγS,4208,B-CHEMICAL
(,4208,O
IC,4208,O
(,4208,O
50,4208,O
),4208,O
21,4208,O
±,4208,O
1.8,4208,O
nM,4208,O
),4208,O
.,4208,O
Taken,4209,O
together,4209,O
",",4209,O
these,4209,O
results,4209,O
suggest,4209,O
that,4209,O
the,4209,O
wild-type,4209,O
EP3,4209,B-GENE-Y
receptor,4209,O
displays,4209,O
unusual,4209,O
characteristics,4209,O
of,4209,O
the,4209,O
complex,4209,O
coupled,4209,O
equilibria,4209,O
between,4209,O
agonist-receptor,4209,O
and,4209,O
receptor-G,4209,O
protein,4209,I-GENE-N
interaction,4209,O
.,4209,O
Moreover,4210,O
",",4210,O
mutation,4210,O
of,4210,O
ECII,4210,B-GENE-N
can,4210,O
alter,4210,O
this,4210,O
coupled,4210,O
equilibrium,4210,O
from,4210,O
GTP-insensitive,4210,B-CHEMICAL
agonist,4210,O
binding,4210,O
to,4210,O
more,4210,O
conventional,4210,O
GTP-sensitive,4210,B-CHEMICAL
binding,4210,O
.,4210,O
This,4211,O
suggests,4211,O
that,4211,O
for,4211,O
the,4211,O
mutant,4211,O
receptors,4211,O
",",4211,O
ECII,4211,B-GENE-N
plays,4211,O
a,4211,O
critical,4211,O
role,4211,O
in,4211,O
linking,4211,O
the,4211,O
agonist,4211,O
bound,4211,O
receptor,4211,O
conformation,4211,O
to,4211,O
the,4211,O
G,4211,B-GENE-N
protein,4211,I-GENE-N
nucleotide,4211,B-CHEMICAL
bound,4211,O
state,4211,O
.,4211,O
Identification,4212,O
of,4212,O
Dlk1-Dio3,4212,B-GENE-Y
imprinted,4212,O
gene,4212,O
cluster,4212,O
noncoding,4212,O
RNAs,4212,O
as,4212,O
novel,4212,O
candidate,4212,O
biomarkers,4212,O
for,4212,O
liver,4212,O
tumor,4212,O
promotion,4212,O
.,4212,O
The,4213,O
molecular,4213,O
events,4213,O
during,4213,O
nongenotoxic,4213,O
carcinogenesis,4213,O
and,4213,O
their,4213,O
temporal,4213,O
order,4213,O
are,4213,O
poorly,4213,O
understood,4213,O
but,4213,O
thought,4213,O
to,4213,O
include,4213,O
long-lasting,4213,O
perturbations,4213,O
of,4213,O
gene,4213,O
expression,4213,O
.,4213,O
Here,4214,O
",",4214,O
we,4214,O
have,4214,O
investigated,4214,O
the,4214,O
temporal,4214,O
sequence,4214,O
of,4214,O
molecular,4214,O
and,4214,O
pathological,4214,O
perturbations,4214,O
at,4214,O
early,4214,O
stages,4214,O
of,4214,O
phenobarbital,4214,B-CHEMICAL
(,4214,O
PB,4214,O
),4214,O
mediated,4214,O
liver,4214,O
tumor,4214,O
promotion,4214,O
in,4214,O
vivo,4214,O
.,4214,O
Molecular,4215,O
profiling,4215,O
(,4215,O
mRNA,4215,O
",",4215,O
microRNA,4215,O
[,4215,O
miRNA,4215,O
],4215,O
",",4215,O
DNA,4215,O
methylation,4215,O
",",4215,O
and,4215,O
proteins,4215,O
),4215,O
of,4215,O
mouse,4215,O
liver,4215,O
during,4215,O
13,4215,O
weeks,4215,O
of,4215,O
PB,4215,O
treatment,4215,O
revealed,4215,O
progressive,4215,O
increases,4215,O
in,4215,O
hepatic,4215,O
expression,4215,O
of,4215,O
long,4215,O
noncoding,4215,O
RNAs,4215,O
and,4215,O
miRNAs,4215,O
originating,4215,O
from,4215,O
the,4215,O
Dlk1-Dio3,4215,B-GENE-Y
imprinted,4215,O
gene,4215,O
cluster,4215,O
",",4215,O
a,4215,O
locus,4215,O
that,4215,O
has,4215,O
recently,4215,O
been,4215,O
associated,4215,O
with,4215,O
stem,4215,O
cell,4215,O
pluripotency,4215,O
in,4215,O
mice,4215,O
and,4215,O
various,4215,O
neoplasms,4215,O
in,4215,O
humans,4215,O
.,4215,O
PB,4216,O
induction,4216,O
of,4216,O
the,4216,O
Dlk1-Dio3,4216,B-GENE-Y
cluster,4216,O
noncoding,4216,O
RNA,4216,O
(,4216,O
ncRNA,4216,O
),4216,O
Meg3,4216,O
was,4216,O
localized,4216,O
to,4216,O
glutamine,4216,B-CHEMICAL
synthetase-positive,4216,O
hypertrophic,4216,O
perivenous,4216,O
hepatocytes,4216,O
",",4216,O
suggesting,4216,O
a,4216,O
role,4216,O
for,4216,O
β-catenin,4216,B-GENE-N
signaling,4216,O
in,4216,O
the,4216,O
dysregulation,4216,O
of,4216,O
Dlk1-Dio3,4216,B-GENE-Y
ncRNAs,4216,O
.,4216,O
The,4217,O
carcinogenic,4217,O
relevance,4217,O
of,4217,O
Dlk1-Dio3,4217,B-GENE-Y
locus,4217,O
ncRNA,4217,O
induction,4217,O
was,4217,O
further,4217,O
supported,4217,O
by,4217,O
in,4217,O
vivo,4217,O
genetic,4217,O
dependence,4217,O
on,4217,O
constitutive,4217,B-GENE-N
androstane,4217,I-GENE-N
receptor,4217,I-GENE-N
and,4217,O
β-catenin,4217,B-GENE-N
pathways,4217,O
.,4217,O
Our,4218,O
data,4218,O
identify,4218,O
Dlk1-Dio3,4218,B-GENE-Y
ncRNAs,4218,O
as,4218,O
novel,4218,O
candidate,4218,O
early,4218,O
biomarkers,4218,O
for,4218,O
mouse,4218,O
liver,4218,O
tumor,4218,O
promotion,4218,O
and,4218,O
provide,4218,O
new,4218,O
opportunities,4218,O
for,4218,O
assessing,4218,O
the,4218,O
carcinogenic,4218,O
potential,4218,O
of,4218,O
novel,4218,O
compounds,4218,O
.,4218,O
GH,4219,B-GENE-Y
improves,4219,O
spatial,4219,O
memory,4219,O
and,4219,O
reverses,4219,O
certain,4219,O
anabolic,4219,O
androgenic,4219,O
steroid-induced,4219,O
effects,4219,O
in,4219,O
intact,4219,O
rats,4219,O
.,4219,O
GH,4220,B-GENE-Y
has,4220,O
previously,4220,O
been,4220,O
shown,4220,O
to,4220,O
promote,4220,O
cognitive,4220,O
functions,4220,O
in,4220,O
GH-deficient,4220,B-GENE-Y
rodents,4220,O
.,4220,O
In,4221,O
this,4221,O
study,4221,O
we,4221,O
report,4221,O
the,4221,O
effects,4221,O
of,4221,O
GH,4221,B-GENE-Y
on,4221,O
learning,4221,O
and,4221,O
memory,4221,O
in,4221,O
intact,4221,O
rats,4221,O
pretreated,4221,O
with,4221,O
the,4221,O
anabolic,4221,O
androgenic,4221,O
steroid,4221,B-CHEMICAL
nandrolone,4221,B-CHEMICAL
.,4221,O
Male,4222,O
Wistar,4222,O
rats,4222,O
received,4222,O
nandrolone,4222,B-CHEMICAL
decanoate,4222,I-CHEMICAL
(,4222,O
15,4222,O
mg/kg,4222,O
),4222,O
or,4222,O
peanut,4222,O
oil,4222,O
every,4222,O
third,4222,O
day,4222,O
for,4222,O
3,4222,O
weeks,4222,O
and,4222,O
were,4222,O
subsequently,4222,O
treated,4222,O
with,4222,O
recombinant,4222,O
human,4222,B-GENE-Y
GH,4222,I-GENE-Y
(,4222,O
1.0,4222,O
IU/kg,4222,O
),4222,O
or,4222,O
saline,4222,O
for,4222,O
10,4222,O
consecutive,4222,O
days,4222,O
.,4222,O
During,4223,O
the,4223,O
GH/saline,4223,B-GENE-Y
treatment,4223,O
spatial,4223,O
learning,4223,O
and,4223,O
memory,4223,O
were,4223,O
tested,4223,O
in,4223,O
the,4223,O
Morris,4223,O
water,4223,O
maze,4223,O
(,4223,O
MWM,4223,O
),4223,O
.,4223,O
Also,4224,O
",",4224,O
plasma,4224,O
levels,4224,O
of,4224,O
IGF1,4224,B-GENE-Y
were,4224,O
assessed,4224,O
and,4224,O
the,4224,O
gene,4224,O
expression,4224,O
of,4224,O
the,4224,O
GH,4224,B-GENE-Y
receptors,4224,I-GENE-Y
(,4224,O
Ghr,4224,B-GENE-Y
),4224,O
",",4224,O
Igf1,4224,B-GENE-Y
and,4224,O
Igf2,4224,B-GENE-Y
",",4224,O
in,4224,O
hippocampus,4224,O
and,4224,O
frontal,4224,O
cortex,4224,O
was,4224,O
analyzed,4224,O
.,4224,O
The,4225,O
results,4225,O
demonstrated,4225,O
a,4225,O
significant,4225,O
positive,4225,O
effect,4225,O
of,4225,O
GH,4225,B-GENE-Y
on,4225,O
memory,4225,O
functions,4225,O
and,4225,O
increased,4225,O
gene,4225,O
expression,4225,O
of,4225,O
Igf1,4225,B-GENE-Y
in,4225,O
the,4225,O
hippocampus,4225,O
was,4225,O
found,4225,O
in,4225,O
the,4225,O
animals,4225,O
treated,4225,O
with,4225,O
GH,4225,B-GENE-Y
.,4225,O
In,4226,O
addition,4226,O
",",4226,O
GH,4226,B-GENE-Y
was,4226,O
demonstrated,4226,O
to,4226,O
increase,4226,O
the,4226,O
body,4226,O
weight,4226,O
gain,4226,O
and,4226,O
was,4226,O
able,4226,O
to,4226,O
attenuate,4226,O
the,4226,O
reduced,4226,O
body,4226,O
weight,4226,O
seen,4226,O
in,4226,O
nandrolone-treated,4226,B-CHEMICAL
animals,4226,O
.,4226,O
In,4227,O
general,4227,O
",",4227,O
the,4227,O
rats,4227,O
treated,4227,O
with,4227,O
nandrolone,4227,B-CHEMICAL
alone,4227,O
did,4227,O
not,4227,O
exhibit,4227,O
any,4227,O
pronounced,4227,O
alteration,4227,O
in,4227,O
memory,4227,O
compared,4227,O
with,4227,O
controls,4227,O
in,4227,O
the,4227,O
MWM,4227,O
",",4227,O
and,4227,O
in,4227,O
many,4227,O
cases,4227,O
GH,4227,B-GENE-Y
did,4227,O
not,4227,O
induce,4227,O
any,4227,O
alteration,4227,O
.,4227,O
Regarding,4228,O
target,4228,O
zone,4228,O
crossings,4228,O
",",4228,O
considered,4228,O
to,4228,O
be,4228,O
associated,4228,O
with,4228,O
spatial,4228,O
memory,4228,O
",",4228,O
the,4228,O
difference,4228,O
between,4228,O
GH-,4228,B-GENE-Y
and,4228,O
steroid-treated,4228,O
animals,4228,O
was,4228,O
significant,4228,O
and,4228,O
administration,4228,O
of,4228,O
GH,4228,B-GENE-Y
improved,4228,O
this,4228,O
parameter,4228,O
in,4228,O
the,4228,O
latter,4228,O
group,4228,O
.,4228,O
In,4229,O
conclusion,4229,O
",",4229,O
GH,4229,B-GENE-Y
improves,4229,O
spatial,4229,O
memory,4229,O
in,4229,O
intact,4229,O
rats,4229,O
and,4229,O
can,4229,O
reverse,4229,O
certain,4229,O
effects,4229,O
induced,4229,O
by,4229,O
anabolic,4229,O
androgenic,4229,O
steroid,4229,B-CHEMICAL
.,4229,O
Phosphoinositide-dependent,4230,B-GENE-Y
kinase-1,4230,I-GENE-Y
and,4230,O
protein,4230,B-GENE-Y
kinase,4230,I-GENE-Y
Cδ,4230,I-GENE-Y
contribute,4230,O
to,4230,O
endothelin-1,4230,B-GENE-Y
constriction,4230,O
and,4230,O
elevated,4230,O
blood,4230,O
pressure,4230,O
in,4230,O
intermittent,4230,O
hypoxia,4230,O
.,4230,O
Obstructive,4231,O
sleep,4231,O
apnea,4231,O
(,4231,O
OSA,4231,O
),4231,O
is,4231,O
associated,4231,O
with,4231,O
cardiovascular,4231,O
complications,4231,O
including,4231,O
hypertension,4231,O
.,4231,O
Previous,4232,O
findings,4232,O
from,4232,O
our,4232,O
laboratory,4232,O
indicate,4232,O
that,4232,O
exposure,4232,O
to,4232,O
intermittent,4232,O
hypoxia,4232,O
(,4232,O
IH,4232,O
),4232,O
",",4232,O
to,4232,O
mimic,4232,O
sleep,4232,O
apnea,4232,O
",",4232,O
increases,4232,O
blood,4232,O
pressure,4232,O
in,4232,O
rats,4232,O
.,4232,O
IH,4233,O
also,4233,O
increases,4233,O
endothelin-1,4233,B-GENE-Y
(,4233,O
ET-1,4233,B-GENE-Y
),4233,O
constrictor,4233,O
sensitivity,4233,O
in,4233,O
a,4233,O
protein,4233,B-GENE-Y
kinase,4233,I-GENE-Y
C,4233,I-GENE-Y
(,4233,I-GENE-Y
PKC,4233,I-GENE-Y
),4233,I-GENE-Y
δ-dependent,4233,O
manner,4233,O
in,4233,O
mesenteric,4233,O
arteries,4233,O
.,4233,O
Because,4234,O
phosphoinositide-dependent,4234,B-GENE-Y
kinase-1,4234,I-GENE-Y
(,4234,O
PDK-1,4234,B-GENE-Y
),4234,O
regulates,4234,O
PKCδ,4234,B-GENE-Y
activity,4234,O
",",4234,O
we,4234,O
hypothesized,4234,O
that,4234,O
PDK-1,4234,B-GENE-Y
contributes,4234,O
to,4234,O
the,4234,O
augmented,4234,O
ET-1,4234,B-GENE-Y
constrictor,4234,O
sensitivity,4234,O
and,4234,O
elevated,4234,O
blood,4234,O
pressure,4234,O
following,4234,O
IH,4234,O
.,4234,O
Male,4235,O
Sprague-Dawley,4235,O
rats,4235,O
were,4235,O
exposed,4235,O
to,4235,O
either,4235,O
sham,4235,O
or,4235,O
IH,4235,O
(,4235,O
cycles,4235,O
between,4235,O
21,4235,O
%,4235,O
O,4235,B-CHEMICAL
(,4235,I-CHEMICAL
2,4235,I-CHEMICAL
),4235,I-CHEMICAL
/0,4235,O
%,4235,O
CO,4235,B-CHEMICAL
(,4235,I-CHEMICAL
2,4235,I-CHEMICAL
),4235,I-CHEMICAL
and,4235,O
5,4235,O
%,4235,O
O,4235,B-CHEMICAL
(,4235,I-CHEMICAL
2,4235,I-CHEMICAL
),4235,I-CHEMICAL
/5,4235,O
%,4235,O
CO,4235,B-CHEMICAL
(,4235,I-CHEMICAL
2,4235,I-CHEMICAL
),4235,I-CHEMICAL
),4235,O
conditions,4235,O
for,4235,O
7,4235,O
h/day,4235,O
for,4235,O
14,4235,O
or,4235,O
21,4235,O
days,4235,O
.,4235,O
The,4236,O
contribution,4236,O
of,4236,O
PKCδ,4236,B-GENE-Y
and,4236,O
PDK-1,4236,B-GENE-Y
to,4236,O
ET-1-mediated,4236,B-GENE-Y
vasoconstriction,4236,O
was,4236,O
assessed,4236,O
in,4236,O
mesenteric,4236,O
arteries,4236,O
using,4236,O
pharmacological,4236,O
inhibitors,4236,O
.,4236,O
Constrictor,4237,O
sensitivity,4237,O
to,4237,O
ET-1,4237,B-GENE-Y
was,4237,O
enhanced,4237,O
in,4237,O
arteries,4237,O
from,4237,O
IH-exposed,4237,O
rats,4237,O
.,4237,O
Inhibition,4238,O
of,4238,O
PKCδ,4238,B-GENE-Y
or,4238,O
PDK-1,4238,B-GENE-Y
blunted,4238,O
ET-1,4238,B-GENE-Y
constriction,4238,O
in,4238,O
arteries,4238,O
from,4238,O
IH,4238,O
but,4238,O
not,4238,O
sham,4238,O
group,4238,O
rats,4238,O
.,4238,O
Western,4239,O
analysis,4239,O
revealed,4239,O
similar,4239,O
levels,4239,O
of,4239,O
total,4239,O
and,4239,O
phosphorylated,4239,B-GENE-Y
PDK-1,4239,I-GENE-Y
in,4239,O
arteries,4239,O
from,4239,O
sham,4239,O
and,4239,O
IH,4239,O
group,4239,O
rats,4239,O
but,4239,O
decreased,4239,O
protein-protein,4239,O
interaction,4239,O
between,4239,O
PKCδ,4239,B-GENE-Y
and,4239,O
PDK-1,4239,B-GENE-Y
in,4239,O
arteries,4239,O
from,4239,O
IH-,4239,O
compared,4239,O
with,4239,O
sham-exposed,4239,O
rats,4239,O
.,4239,O
Blood,4240,O
pressure,4240,O
was,4240,O
increased,4240,O
in,4240,O
rats,4240,O
exposed,4240,O
to,4240,O
IH,4240,O
",",4240,O
and,4240,O
treatment,4240,O
with,4240,O
the,4240,O
PDK-1,4240,B-GENE-Y
inhibitor,4240,O
OSU-03012,4240,B-CHEMICAL
[,4240,O
2-amino-N-,4240,B-CHEMICAL
{,4240,I-CHEMICAL
4-,4240,I-CHEMICAL
[,4240,I-CHEMICAL
5-,4240,I-CHEMICAL
(,4240,I-CHEMICAL
2-phenanthrenyl,4240,I-CHEMICAL
),4240,I-CHEMICAL
-3-,4240,I-CHEMICAL
(,4240,I-CHEMICAL
trifluoromethyl,4240,I-CHEMICAL
),4240,I-CHEMICAL
-1H-pyrazol-1-yl,4240,I-CHEMICAL
],4240,I-CHEMICAL
-phenyl,4240,I-CHEMICAL
},4240,I-CHEMICAL
-acetamide,4240,I-CHEMICAL
],4240,O
(,4240,O
33,4240,O
mg/day,4240,O
),4240,O
lowered,4240,O
blood,4240,O
pressure,4240,O
in,4240,O
IH,4240,O
but,4240,O
not,4240,O
sham,4240,O
group,4240,O
rats,4240,O
.,4240,O
Our,4241,O
results,4241,O
suggest,4241,O
that,4241,O
exposure,4241,O
to,4241,O
IH,4241,O
unmasks,4241,O
a,4241,O
role,4241,O
for,4241,O
PDK-1,4241,B-GENE-Y
in,4241,O
regulating,4241,O
ET-1,4241,B-GENE-Y
constrictor,4241,O
sensitivity,4241,O
and,4241,O
blood,4241,O
pressure,4241,O
that,4241,O
is,4241,O
not,4241,O
present,4241,O
under,4241,O
normal,4241,O
conditions,4241,O
.,4241,O
These,4242,O
novel,4242,O
findings,4242,O
suggest,4242,O
that,4242,O
PDK-1,4242,B-GENE-Y
may,4242,O
be,4242,O
a,4242,O
uniquely,4242,O
effective,4242,O
antihypertensive,4242,O
therapy,4242,O
for,4242,O
OSA,4242,O
patients,4242,O
.,4242,O
Intercellular,4243,B-GENE-Y
adhesion,4243,I-GENE-Y
molecule-2,4243,I-GENE-Y
is,4243,O
involved,4243,O
in,4243,O
apical,4243,O
ectoplasmic,4243,O
specialization,4243,O
dynamics,4243,O
during,4243,O
spermatogenesis,4243,O
in,4243,O
the,4243,O
rat,4243,O
.,4243,O
In,4244,O
this,4244,O
study,4244,O
",",4244,O
we,4244,O
investigated,4244,O
the,4244,O
role,4244,O
of,4244,O
intercellular,4244,B-GENE-Y
adhesion,4244,I-GENE-Y
molecule-2,4244,I-GENE-Y
(,4244,O
ICAM2,4244,B-GENE-Y
),4244,O
in,4244,O
the,4244,O
testis,4244,O
.,4244,O
ICAM2,4245,B-GENE-Y
is,4245,O
a,4245,O
cell,4245,O
adhesion,4245,O
protein,4245,O
having,4245,O
important,4245,O
roles,4245,O
in,4245,O
cell,4245,O
migration,4245,O
",",4245,O
especially,4245,O
during,4245,O
inflammation,4245,O
when,4245,O
leukocytes,4245,O
cross,4245,O
the,4245,O
endothelium,4245,O
.,4245,O
Herein,4246,O
",",4246,O
we,4246,O
showed,4246,O
ICAM2,4246,B-GENE-Y
to,4246,O
be,4246,O
expressed,4246,O
by,4246,O
germ,4246,O
and,4246,O
Sertoli,4246,O
cells,4246,O
in,4246,O
the,4246,O
rat,4246,O
testis,4246,O
.,4246,O
When,4247,O
a,4247,O
monospecific,4247,O
antibody,4247,O
was,4247,O
used,4247,O
for,4247,O
immunolocalization,4247,O
experiments,4247,O
",",4247,O
ICAM2,4247,B-GENE-Y
was,4247,O
found,4247,O
to,4247,O
surround,4247,O
the,4247,O
heads,4247,O
of,4247,O
elongating/elongated,4247,O
spermatids,4247,O
in,4247,O
all,4247,O
stages,4247,O
of,4247,O
the,4247,O
seminiferous,4247,O
epithelial,4247,O
cycle,4247,O
.,4247,O
To,4248,O
determine,4248,O
whether,4248,O
ICAM2,4248,B-GENE-Y
is,4248,O
a,4248,O
constituent,4248,O
of,4248,O
apical,4248,O
ectoplasmic,4248,O
specialization,4248,O
(,4248,O
ES,4248,O
),4248,O
",",4248,O
co-immunoprecipitation,4248,O
and,4248,O
dual,4248,O
immunofluorescence,4248,O
staining,4248,O
were,4248,O
performed,4248,O
.,4248,O
Interestingly,4249,O
",",4249,O
ICAM2,4249,B-GENE-Y
was,4249,O
found,4249,O
to,4249,O
associate,4249,O
with,4249,O
β1-integrin,4249,B-GENE-Y
",",4249,O
nectin-3,4249,B-GENE-Y
",",4249,O
afadin,4249,B-GENE-Y
",",4249,O
Src,4249,B-GENE-Y
",",4249,O
proline-rich,4249,B-GENE-Y
tyrosine,4249,B-CHEMICAL
kinase,4249,I-GENE-Y
2,4249,I-GENE-Y
",",4249,O
annexin,4249,B-GENE-Y
II,4249,I-GENE-Y
",",4249,O
and,4249,O
actin,4249,B-GENE-N
.,4249,O
Following,4250,O
CdCl₂,4250,B-CHEMICAL
treatment,4250,O
",",4250,O
ICAM2,4250,B-GENE-Y
was,4250,O
found,4250,O
to,4250,O
be,4250,O
upregulated,4250,O
during,4250,O
restructuring,4250,O
of,4250,O
the,4250,O
seminiferous,4250,O
epithelium,4250,O
",",4250,O
with,4250,O
round,4250,O
spermatids,4250,O
becoming,4250,O
increasingly,4250,O
immunoreactive,4250,O
for,4250,O
ICAM2,4250,B-GENE-Y
by,4250,O
6-16,4250,O
h.,4250,O
Interestingly,4250,O
",",4250,O
there,4250,O
was,4250,O
a,4250,O
loss,4250,O
in,4250,O
the,4250,O
binding,4250,O
of,4250,O
ICAM2,4250,B-GENE-Y
to,4250,O
actin,4250,B-GENE-N
during,4250,O
CdCl₂-induced,4250,B-CHEMICAL
germ,4250,O
cell,4250,O
loss,4250,O
",",4250,O
suggesting,4250,O
that,4250,O
a,4250,O
loss,4250,O
of,4250,O
ICAM2-actin,4250,B-GENE-Y
interactions,4250,O
might,4250,O
have,4250,O
facilitated,4250,O
junction,4250,O
restructuring,4250,O
.,4250,O
Taken,4251,O
collectively,4251,O
",",4251,O
these,4251,O
results,4251,O
illustrate,4251,O
that,4251,O
ICAM2,4251,B-GENE-Y
plays,4251,O
an,4251,O
important,4251,O
role,4251,O
in,4251,O
apical,4251,O
ES,4251,O
dynamics,4251,O
during,4251,O
spermatogenesis,4251,O
.,4251,O
The,4252,O
catalytic,4252,O
competence,4252,O
of,4252,O
cytochrome,4252,B-GENE-N
P450,4252,I-GENE-N
in,4252,O
the,4252,O
synthesis,4252,O
of,4252,O
serotonin,4252,B-CHEMICAL
from,4252,O
5-methoxytryptamine,4252,B-CHEMICAL
in,4252,O
the,4252,O
brain,4252,O
:,4252,O
an,4252,O
in,4252,O
vitro,4252,O
study,4252,O
.,4252,O
Brain,4253,O
serotonin,4253,B-CHEMICAL
has,4253,O
been,4253,O
implicated,4253,O
in,4253,O
the,4253,O
pathophysiology,4253,O
of,4253,O
a,4253,O
wide,4253,O
spectrum,4253,O
of,4253,O
psychiatric,4253,O
disorders,4253,O
",",4253,O
as,4253,O
well,4253,O
as,4253,O
in,4253,O
the,4253,O
mechanism,4253,O
of,4253,O
action,4253,O
of,4253,O
psychotropic,4253,O
drugs,4253,O
.,4253,O
The,4254,O
aim,4254,O
of,4254,O
present,4254,O
study,4254,O
was,4254,O
to,4254,O
identify,4254,O
rat,4254,B-GENE-N
cytochrome,4254,I-GENE-N
P450,4254,I-GENE-N
(,4254,O
CYP,4254,B-GENE-N
),4254,O
isoforms,4254,O
which,4254,O
can,4254,O
catalyze,4254,O
the,4254,O
O-demethylation,4254,B-CHEMICAL
of,4254,O
5-methoxytryptamine,4254,B-CHEMICAL
to,4254,O
serotonin,4254,B-CHEMICAL
",",4254,O
and,4254,O
to,4254,O
find,4254,O
out,4254,O
whether,4254,O
that,4254,O
alternative,4254,O
pathway,4254,O
of,4254,O
serotonin,4254,B-CHEMICAL
synthesis,4254,O
may,4254,O
take,4254,O
place,4254,O
in,4254,O
the,4254,O
brain,4254,O
.,4254,O
The,4255,O
study,4255,O
was,4255,O
conducted,4255,O
on,4255,O
cDNA-expressed,4255,O
CYPs,4255,B-GENE-N
(,4255,O
rat,4255,B-GENE-N
CYP1A1/2,4255,I-GENE-N
",",4255,I-GENE-N
2A1/2,4255,I-GENE-N
",",4255,I-GENE-N
2B1,4255,I-GENE-N
",",4255,I-GENE-N
2C6/11/13,4255,I-GENE-N
",",4255,I-GENE-N
2D1/2/4/18,4255,I-GENE-N
",",4255,I-GENE-N
2E1,4255,I-GENE-N
",",4255,I-GENE-N
3A2,4255,I-GENE-N
and,4255,O
human,4255,B-GENE-Y
CYP2D6,4255,I-GENE-Y
),4255,O
",",4255,O
on,4255,O
rat,4255,O
brain,4255,O
and,4255,O
liver,4255,O
microsomes,4255,O
and,4255,O
on,4255,O
human,4255,O
liver,4255,O
microsomes,4255,O
(,4255,O
the,4255,O
wild-type,4255,O
CYP2D6,4255,B-GENE-N
or,4255,O
the,4255,O
allelic,4255,O
variant,4255,O
2D6,4255,B-GENE-N
*,4255,O
4,4255,O
*,4255,O
4,4255,O
),4255,O
.,4255,O
Of,4256,O
the,4256,O
rat,4256,B-GENE-N
CYP,4256,I-GENE-N
isoforms,4256,O
studied,4256,O
",",4256,O
CYP2D,4256,B-GENE-N
isoforms,4256,O
were,4256,O
the,4256,O
most,4256,O
efficient,4256,O
in,4256,O
catalyzing,4256,O
the,4256,O
O-demethylation,4256,B-CHEMICAL
of,4256,O
5-methoxytryptamine,4256,B-CHEMICAL
to,4256,O
serotonin,4256,B-CHEMICAL
",",4256,O
but,4256,O
they,4256,O
were,4256,O
less,4256,O
effective,4256,O
than,4256,O
the,4256,O
human,4256,B-GENE-Y
isoform,4256,I-GENE-Y
CYP2D6,4256,I-GENE-Y
.,4256,O
Microsomes,4257,O
from,4257,O
different,4257,O
brain,4257,O
regions,4257,O
were,4257,O
capable,4257,O
of,4257,O
metabolizing,4257,O
5-methoxytryptamine,4257,B-CHEMICAL
to,4257,O
serotonin,4257,B-CHEMICAL
.,4257,O
The,4258,O
reaction,4258,O
was,4258,O
inhibited,4258,O
by,4258,O
the,4258,O
specific,4258,O
CYP2D,4258,B-GENE-N
inhibitors,4258,O
quinine,4258,B-CHEMICAL
and,4258,O
fluoxetine,4258,B-CHEMICAL
.,4258,O
Human,4259,O
liver,4259,O
microsomes,4259,O
of,4259,O
the,4259,O
wild-type,4259,O
CYP2D6,4259,B-GENE-Y
metabolized,4259,O
5-methoxytryptamine,4259,B-CHEMICAL
to,4259,O
serotonin,4259,B-CHEMICAL
more,4259,O
effectively,4259,O
than,4259,O
did,4259,O
the,4259,O
defective,4259,O
CYP2D6,4259,B-GENE-Y
*,4259,O
4,4259,O
*,4259,O
4,4259,O
ones,4259,O
.,4259,O
The,4260,O
obtained,4260,O
results,4260,O
indicate,4260,O
that,4260,O
rat,4260,B-GENE-N
brain,4260,I-GENE-N
CYP2D,4260,I-GENE-N
isoforms,4260,O
catalyze,4260,O
the,4260,O
formation,4260,O
of,4260,O
serotonin,4260,B-CHEMICAL
from,4260,O
5-methoxytryptamine,4260,B-CHEMICAL
",",4260,O
and,4260,O
that,4260,O
the,4260,O
deficit,4260,O
or,4260,O
genetic,4260,O
defect,4260,O
of,4260,O
CYP2D,4260,B-GENE-N
may,4260,O
affect,4260,O
serotonin,4260,B-CHEMICAL
metabolism,4260,O
in,4260,O
the,4260,O
brain,4260,O
.,4260,O
The,4261,O
results,4261,O
are,4261,O
discussed,4261,O
in,4261,O
the,4261,O
context,4261,O
of,4261,O
their,4261,O
possible,4261,O
physiological,4261,O
and,4261,O
pharmacological,4261,O
significance,4261,O
in,4261,O
vivo,4261,O
.,4261,O
Estrogen,4262,B-CHEMICAL
receptor,4262,I-GENE-Y
signaling,4262,O
as,4262,O
a,4262,O
target,4262,O
for,4262,O
novel,4262,O
breast,4262,O
cancer,4262,O
therapeutics,4262,O
.,4262,O
In,4263,O
breast,4263,O
cancer,4263,O
(,4263,O
BC,4263,O
),4263,O
epithelial,4263,O
cells,4263,O
",",4263,O
the,4263,O
mitogenic,4263,O
action,4263,O
of,4263,O
estradiol,4263,B-CHEMICAL
is,4263,O
transduced,4263,O
through,4263,O
binding,4263,O
to,4263,O
two,4263,O
receptors,4263,O
",",4263,O
ERα,4263,B-GENE-Y
and,4263,O
ERβ,4263,B-GENE-Y
",",4263,O
which,4263,O
act,4263,O
as,4263,O
transcription,4263,O
factors,4263,O
.,4263,O
Anti-estrogens,4264,O
(,4264,O
AEs,4264,O
),4264,O
and,4264,O
aromatase,4264,B-GENE-Y
inhibitors,4264,O
(,4264,O
AIs,4264,O
),4264,O
are,4264,O
used,4264,O
clinically,4264,O
to,4264,O
arrest,4264,O
the,4264,O
estrogen-dependent,4264,B-CHEMICAL
growth,4264,O
of,4264,O
BC,4264,O
.,4264,O
In,4265,O
the,4265,O
case,4265,O
of,4265,O
AE,4265,O
or,4265,O
AI,4265,O
resistance,4265,O
",",4265,O
Herceptin,4265,O
or,4265,O
lapatinib,4265,B-CHEMICAL
may,4265,O
be,4265,O
used,4265,O
to,4265,O
inhibit,4265,O
growth,4265,O
factors,4265,O
.,4265,O
Estrogen,4266,B-CHEMICAL
effects,4266,O
are,4266,O
mediated,4266,O
not,4266,O
only,4266,O
through,4266,O
nuclear,4266,O
ERs,4266,B-GENE-Y
but,4266,O
also,4266,O
through,4266,O
cytoplasmic/membrane,4266,O
ERs,4266,B-GENE-Y
and,4266,O
G-protein-coupled,4266,B-GENE-N
ERs,4266,B-GENE-Y
.,4266,O
These,4267,O
estrogen-binding,4267,B-CHEMICAL
systems,4267,O
associate,4267,O
with,4267,O
various,4267,O
proteins,4267,O
that,4267,O
direct,4267,O
cell,4267,O
cycle,4267,O
signaling,4267,O
",",4267,O
proliferation,4267,O
and,4267,O
survival,4267,O
.,4267,O
The,4268,O
partners,4268,O
of,4268,O
nuclear,4268,O
ER,4268,B-GENE-Y
include,4268,O
SRC1-3,4268,B-GENE-N
",",4268,O
HDACs,4268,B-GENE-N
and,4268,O
ERβ,4268,B-GENE-Y
itself,4268,O
as,4268,O
well,4268,O
as,4268,O
newly,4268,O
identified,4268,O
proteins,4268,O
",",4268,O
such,4268,O
as,4268,O
E6-AP,4268,B-GENE-Y
",",4268,O
LKB1,4268,B-GENE-Y
",",4268,O
PELP1,4268,B-GENE-Y
",",4268,O
PAX-2,4268,B-GENE-Y
and,4268,O
FOXA1,4268,B-GENE-Y
.,4268,O
The,4269,O
partners,4269,O
of,4269,O
extra-nuclear,4269,O
ERα,4269,B-GENE-Y
include,4269,O
PI3K,4269,B-GENE-N
and,4269,O
the,4269,O
tyrosine,4269,B-CHEMICAL
kinase,4269,I-GENE-N
Src,4269,B-GENE-Y
.,4269,O
These,4270,O
various,4270,O
factors,4270,O
are,4270,O
all,4270,O
potential,4270,O
targets,4270,O
for,4270,O
therapeutic,4270,O
intervention,4270,O
.,4270,O
In,4271,O
addition,4271,O
",",4271,O
BC,4271,O
proliferation,4271,O
is,4271,O
enhanced,4271,O
by,4271,O
insulin,4271,B-GENE-Y
and,4271,O
EGF,4271,B-GENE-Y
",",4271,O
which,4271,O
stimulate,4271,O
signaling,4271,O
through,4271,O
the,4271,O
MAPK,4271,B-GENE-N
and,4271,O
PI3K/AKT,4271,B-GENE-N
pathways,4271,O
by,4271,O
activation,4271,O
of,4271,O
the,4271,O
IGF-1R,4271,B-GENE-Y
and,4271,O
EGFR,4271,B-GENE-Y
axes,4271,O
",",4271,O
respectively,4271,O
.,4271,O
These,4272,O
pathways,4272,O
are,4272,O
tightly,4272,O
interconnected,4272,O
with,4272,O
ER-activated,4272,B-GENE-Y
signaling,4272,O
",",4272,O
and,4272,O
membrane,4272,O
ERα,4272,B-GENE-Y
forms,4272,O
complexes,4272,O
with,4272,O
Src,4272,B-GENE-Y
and,4272,O
PI3K,4272,B-GENE-N
.,4272,O
Chemokine-mediated,4273,B-GENE-N
signaling,4273,O
also,4273,O
modulates,4273,O
the,4273,O
estrogen,4273,B-CHEMICAL
response,4273,O
.,4273,O
Inhibiting,4274,O
these,4274,O
pathways,4274,O
with,4274,O
specific,4274,O
inhibitors,4274,O
or,4274,O
activating,4274,O
some,4274,O
of,4274,O
the,4274,O
pathways,4274,O
by,4274,O
gene,4274,O
manipulation,4274,O
may,4274,O
be,4274,O
therapeutically,4274,O
valuable,4274,O
for,4274,O
arresting,4274,O
BC,4274,O
cell,4274,O
cycle,4274,O
progression,4274,O
and,4274,O
for,4274,O
inducing,4274,O
apoptosis,4274,O
to,4274,O
antagonize,4274,O
hormone-resistance,4274,O
.,4274,O
Here,4275,O
",",4275,O
we,4275,O
review,4275,O
some,4275,O
newly,4275,O
identified,4275,O
putatively,4275,O
targetable,4275,O
ER,4275,B-GENE-Y
partners,4275,O
and,4275,O
highlight,4275,O
the,4275,O
need,4275,O
to,4275,O
develop,4275,O
tumor-targeting,4275,O
drug,4275,O
carrier,4275,O
systems,4275,O
affecting,4275,O
both,4275,O
the,4275,O
tumor,4275,O
cells,4275,O
and,4275,O
the,4275,O
tumor,4275,O
environment,4275,O
.,4275,O
Toosendanin,4276,B-CHEMICAL
induces,4276,O
apoptosis,4276,O
through,4276,O
suppression,4276,O
of,4276,O
JNK,4276,B-GENE-N
signaling,4276,O
pathway,4276,O
in,4276,O
HL-60,4276,O
cells,4276,O
.,4276,O
Toosendanin,4277,B-CHEMICAL
(,4277,O
TSN,4277,B-CHEMICAL
),4277,O
",",4277,O
a,4277,O
triterpenoid,4277,B-CHEMICAL
isolated,4277,O
from,4277,O
Melia,4277,O
toosendan,4277,O
Sieb,4277,O
.,4277,O
et,4278,O
Zucc.,4278,O
",",4278,O
has,4278,O
been,4278,O
found,4278,O
to,4278,O
suppress,4278,O
proliferation,4278,O
and,4278,O
induce,4278,O
apoptosis,4278,O
in,4278,O
a,4278,O
variety,4278,O
of,4278,O
human,4278,O
cancer,4278,O
cells,4278,O
.,4278,O
However,4279,O
",",4279,O
the,4279,O
mechanism,4279,O
how,4279,O
TSN,4279,B-CHEMICAL
induces,4279,O
apoptosis,4279,O
remains,4279,O
poorly,4279,O
understood,4279,O
.,4279,O
In,4280,O
this,4280,O
study,4280,O
",",4280,O
we,4280,O
examined,4280,O
the,4280,O
effects,4280,O
of,4280,O
TSN,4280,B-CHEMICAL
on,4280,O
the,4280,O
growth,4280,O
",",4280,O
cell,4280,O
cycle,4280,O
arrest,4280,O
",",4280,O
induction,4280,O
of,4280,O
apoptosis,4280,O
and,4280,O
the,4280,O
involved,4280,O
signaling,4280,O
pathway,4280,O
in,4280,O
human,4280,O
promyelocytic,4280,O
leukemia,4280,O
HL-60,4280,O
cells,4280,O
.,4280,O
Proliferation,4281,O
of,4281,O
HL-60,4281,O
cells,4281,O
was,4281,O
inhibited,4281,O
in,4281,O
a,4281,O
dose-dependent,4281,O
manner,4281,O
with,4281,O
the,4281,O
IC,4281,O
(,4281,O
50,4281,O
(,4281,O
48,4281,O
h,4281,O
),4281,O
),4281,O
of,4281,O
28,4281,O
ng/mL,4281,O
.,4281,O
The,4282,O
growth,4282,O
inhibition,4282,O
was,4282,O
due,4282,O
primarily,4282,O
to,4282,O
the,4282,O
S,4282,O
phase,4282,O
arrest,4282,O
and,4282,O
cell,4282,O
apoptosis,4282,O
.,4282,O
Cell,4283,O
apoptosis,4283,O
induced,4283,O
by,4283,O
TSN,4283,B-CHEMICAL
was,4283,O
confirmed,4283,O
by,4283,O
Annexin,4283,O
V-FITC/propidium,4283,O
iodide,4283,I-CHEMICAL
staining,4283,O
.,4283,O
The,4284,O
increase,4284,O
of,4284,O
the,4284,O
pro-apoptotic,4284,O
protein,4284,O
Bax,4284,B-GENE-Y
",",4284,O
cleaved,4284,O
PARP,4284,B-GENE-N
and,4284,O
caspase-3,4284,B-GENE-Y
",",4284,O
and,4284,O
the,4284,O
decrease,4284,O
of,4284,O
anti-apoptotic,4284,O
protein,4284,O
Bcl-2,4284,B-GENE-Y
were,4284,O
observed,4284,O
.,4284,O
Western,4285,O
blot,4285,O
analysis,4285,O
indicated,4285,O
that,4285,O
TSN,4285,B-CHEMICAL
inhibits,4285,O
the,4285,O
CDC42/MEKK1/JNK,4285,B-GENE-Y
pathway,4285,O
.,4285,O
Taken,4286,O
together,4286,O
",",4286,O
our,4286,O
study,4286,O
suggested,4286,O
",",4286,O
for,4286,O
the,4286,O
first,4286,O
time,4286,O
",",4286,O
that,4286,O
the,4286,O
pro-apoptotic,4286,O
effects,4286,O
of,4286,O
TSN,4286,B-CHEMICAL
on,4286,O
HL-60,4286,O
cells,4286,O
were,4286,O
mediated,4286,O
through,4286,O
JNK,4286,B-GENE-N
signaling,4286,O
pathway,4286,O
.,4286,O
Novel,4287,O
insights,4287,O
on,4287,O
the,4287,O
effect,4287,O
of,4287,O
nicotine,4287,B-CHEMICAL
in,4287,O
a,4287,O
murine,4287,O
colitis,4287,O
model,4287,O
.,4287,O
Studies,4288,O
showed,4288,O
that,4288,O
nicotine,4288,B-CHEMICAL
has,4288,O
a,4288,O
positive,4288,O
influence,4288,O
on,4288,O
symptoms,4288,O
of,4288,O
ulcerative,4288,O
colitis,4288,O
.,4288,O
In,4289,O
the,4289,O
present,4289,O
study,4289,O
",",4289,O
we,4289,O
explored,4289,O
the,4289,O
effect,4289,O
of,4289,O
nicotine,4289,B-CHEMICAL
treatment,4289,O
using,4289,O
different,4289,O
routes,4289,O
of,4289,O
administration,4289,O
in,4289,O
the,4289,O
dextran,4289,O
sodium,4289,B-CHEMICAL
sulfate,4289,I-CHEMICAL
(,4289,O
DSS,4289,O
),4289,O
colitis,4289,O
mouse,4289,O
model,4289,O
.,4289,O
We,4290,O
also,4290,O
investigated,4290,O
the,4290,O
effects,4290,O
of,4290,O
cotinine,4290,B-CHEMICAL
",",4290,O
a,4290,O
major,4290,O
metabolite,4290,O
of,4290,O
nicotine,4290,B-CHEMICAL
",",4290,O
in,4290,O
the,4290,O
model,4290,O
.,4290,O
C57BL6,4291,O
adult,4291,O
male,4291,O
mice,4291,O
were,4291,O
given,4291,O
DSS,4291,O
solution,4291,O
freely,4291,O
in,4291,O
the,4291,O
drinking,4291,O
water,4291,O
for,4291,O
seven,4291,O
consecutive,4291,O
days,4291,O
",",4291,O
and,4291,O
tap,4291,O
water,4291,O
was,4291,O
given,4291,O
thereafter,4291,O
.,4291,O
Disease,4292,O
severity,4292,O
",",4292,O
length,4292,O
of,4292,O
the,4292,O
colon,4292,O
",",4292,O
colon,4292,O
tissue,4292,O
histology,4292,O
",",4292,O
and,4292,O
inflammatory,4292,O
markers,4292,O
",",4292,O
including,4292,O
colonic,4292,B-GENE-Y
myeloperoxidase,4292,I-GENE-Y
activity,4292,O
and,4292,O
colonic,4292,B-GENE-Y
tumor,4292,I-GENE-Y
necrosis,4292,I-GENE-Y
factor-α,4292,I-GENE-Y
levels,4292,O
",",4292,O
were,4292,O
evaluated,4292,O
.,4292,O
The,4293,O
effect,4293,O
of,4293,O
nicotine,4293,B-CHEMICAL
and,4293,O
cotinine,4293,B-CHEMICAL
treatments,4293,O
via,4293,O
various,4293,O
different,4293,O
routes,4293,O
of,4293,O
administration,4293,O
were,4293,O
examined,4293,O
the,4293,O
DSS,4293,O
model,4293,O
.,4293,O
In,4294,O
addition,4294,O
",",4294,O
we,4294,O
measured,4294,O
the,4294,O
plasma,4294,O
levels,4294,O
of,4294,O
nicotine,4294,B-CHEMICAL
and,4294,O
cotinine,4294,B-CHEMICAL
in,4294,O
our,4294,O
treatment,4294,O
protocols,4294,O
.,4294,O
Administration,4295,O
of,4295,O
low,4295,O
",",4295,O
but,4295,O
not,4295,O
high,4295,O
",",4295,O
doses,4295,O
of,4295,O
oral,4295,O
nicotine,4295,B-CHEMICAL
in,4295,O
DSS-treated,4295,O
mice,4295,O
resulted,4295,O
in,4295,O
a,4295,O
significant,4295,O
decrease,4295,O
in,4295,O
disease,4295,O
severity,4295,O
",",4295,O
histologic,4295,O
damage,4295,O
scores,4295,O
",",4295,O
as,4295,O
well,4295,O
as,4295,O
colonic,4295,O
level,4295,O
of,4295,O
tumor,4295,B-GENE-Y
necrosis,4295,I-GENE-Y
factor-α,4295,I-GENE-Y
.,4295,O
However,4296,O
",",4296,O
the,4296,O
anti-inflammatory,4296,O
effect,4296,O
of,4296,O
nicotine,4296,B-CHEMICAL
was,4296,O
not,4296,O
seen,4296,O
after,4296,O
chronic,4296,O
s.c.,4296,O
or,4296,O
minipump,4296,O
infusion,4296,O
of,4296,O
the,4296,O
drug,4296,O
.,4296,O
Differences,4297,O
in,4297,O
plasma,4297,O
levels,4297,O
of,4297,O
nicotine,4297,B-CHEMICAL
and,4297,O
cotinine,4297,B-CHEMICAL
do,4297,O
not,4297,O
seem,4297,O
to,4297,O
account,4297,O
for,4297,O
this,4297,O
lack,4297,O
of,4297,O
effect,4297,O
.,4297,O
Finally,4298,O
",",4298,O
oral,4298,O
cotinine,4298,B-CHEMICAL
alone,4298,O
failed,4298,O
to,4298,O
show,4298,O
a,4298,O
significant,4298,O
effect,4298,O
in,4298,O
the,4298,O
DSS,4298,O
model,4298,O
of,4298,O
colitis,4298,O
.,4298,O
These,4299,O
results,4299,O
highlight,4299,O
that,4299,O
dose,4299,O
and,4299,O
route,4299,O
of,4299,O
administration,4299,O
play,4299,O
a,4299,O
critical,4299,O
role,4299,O
in,4299,O
the,4299,O
protective,4299,O
effect,4299,O
of,4299,O
nicotine,4299,B-CHEMICAL
in,4299,O
the,4299,O
DSS,4299,O
mouse,4299,O
colitis,4299,O
model,4299,O
.,4299,O
The,4300,O
S349T,4300,B-GENE-N
mutation,4300,O
of,4300,O
SQSTM1,4300,B-GENE-Y
links,4300,O
Keap1/Nrf2,4300,B-GENE-Y
signalling,4300,O
to,4300,O
Paget,4300,O
's,4300,O
disease,4300,O
of,4300,O
bone,4300,O
.,4300,O
Mutations,4301,O
affecting,4301,O
the,4301,O
Sequestosome,4301,B-GENE-Y
1,4301,I-GENE-Y
(,4301,O
SQSTM1,4301,B-GENE-Y
),4301,O
gene,4301,O
commonly,4301,O
occur,4301,O
in,4301,O
patients,4301,O
with,4301,O
the,4301,O
skeletal,4301,O
disorder,4301,O
Paget,4301,O
's,4301,O
disease,4301,O
of,4301,O
bone,4301,O
(,4301,O
PDB,4301,O
),4301,O
",",4301,O
a,4301,O
condition,4301,O
characterised,4301,O
by,4301,O
defective,4301,O
osteoclast,4301,O
differentiation,4301,O
and,4301,O
function,4301,O
.,4301,O
Whilst,4302,O
most,4302,O
mutations,4302,O
cluster,4302,O
within,4302,O
the,4302,O
ubiquitin-associated,4302,B-GENE-N
(,4302,I-GENE-N
UBA,4302,I-GENE-N
),4302,I-GENE-N
domain,4302,I-GENE-N
of,4302,O
the,4302,O
SQSTM1,4302,B-GENE-Y
protein,4302,O
",",4302,O
and,4302,O
are,4302,O
associated,4302,O
with,4302,O
dysregulated,4302,O
NFκB,4302,B-GENE-N
signalling,4302,O
",",4302,O
several,4302,O
non-UBA,4302,O
domain,4302,I-GENE-N
mutations,4302,O
have,4302,O
also,4302,O
been,4302,O
identified,4302,O
.,4302,O
Keap1,4303,B-GENE-Y
is,4303,O
a,4303,O
SQSTM1-interacting,4303,B-GENE-Y
protein,4303,O
that,4303,O
regulates,4303,O
the,4303,O
levels,4303,O
and,4303,O
activity,4303,O
of,4303,O
the,4303,O
Nrf2,4303,B-GENE-Y
transcription,4303,O
factor,4303,O
.,4303,O
This,4304,O
in,4304,O
turn,4304,O
controls,4304,O
the,4304,O
expression,4304,O
of,4304,O
numerous,4304,O
cytoprotective,4304,O
genes,4304,O
that,4304,O
contribute,4304,O
to,4304,O
the,4304,O
cell,4304,O
's,4304,O
capacity,4304,O
to,4304,O
defend,4304,O
itself,4304,O
against,4304,O
chemical,4304,O
and,4304,O
oxidative,4304,O
stress,4304,O
",",4304,O
through,4304,O
binding,4304,O
to,4304,O
the,4304,O
antioxidant,4304,B-GENE-N
response,4304,I-GENE-N
element,4304,I-GENE-N
(,4304,O
ARE,4304,B-GENE-N
),4304,O
.,4304,O
The,4305,O
PDB-associated,4305,O
S349T,4305,B-GENE-N
mutation,4305,O
maps,4305,O
to,4305,O
the,4305,O
Keap1-interacting,4305,B-GENE-N
region,4305,I-GENE-N
(,4305,O
KIR,4305,B-GENE-N
),4305,O
of,4305,O
SQSTM1,4305,B-GENE-Y
",",4305,O
however,4305,O
the,4305,O
effects,4305,O
of,4305,O
PDB,4305,O
mutant,4305,O
SQSTM1,4305,B-GENE-Y
on,4305,O
Keap1,4305,B-GENE-Y
function,4305,O
have,4305,O
not,4305,O
been,4305,O
investigated,4305,O
.,4305,O
Here,4306,O
we,4306,O
show,4306,O
that,4306,O
unlike,4306,O
other,4306,O
SQSTM1,4306,B-GENE-Y
mutations,4306,O
",",4306,O
the,4306,O
S349T,4306,B-GENE-N
mutation,4306,O
results,4306,O
in,4306,O
neither,4306,O
impaired,4306,O
ubiquitin-binding,4306,B-GENE-N
function,4306,O
in,4306,O
pull-down,4306,O
assays,4306,O
",",4306,O
nor,4306,O
dysregulated,4306,O
NFκB,4306,B-GENE-N
signalling,4306,O
in,4306,O
luciferase,4306,O
reporter,4306,O
assays,4306,O
.,4306,O
Keap1,4307,B-GENE-Y
is,4307,O
expressed,4307,O
in,4307,O
differentiating,4307,O
osteoclast-like,4307,O
cells,4307,O
and,4307,O
the,4307,O
S349T,4307,B-GENE-N
mutation,4307,O
selectively,4307,O
impairs,4307,O
the,4307,O
SQSTM1-Keap1,4307,B-GENE-Y
interaction,4307,O
in,4307,O
co-immunoprecipitations,4307,O
",",4307,O
which,4307,O
molecular,4307,O
modelling,4307,O
indicates,4307,O
results,4307,O
from,4307,O
effects,4307,O
on,4307,O
critical,4307,O
hydrogen,4307,B-CHEMICAL
bonds,4307,O
required,4307,O
to,4307,O
stabilise,4307,O
the,4307,O
KIR-Keap1,4307,B-GENE-N
complex,4307,O
.,4307,O
Further,4308,O
",",4308,O
S349T,4308,B-GENE-N
mutant,4308,O
SQSTM1,4308,B-GENE-Y
",",4308,O
but,4308,O
not,4308,O
other,4308,O
PDB-associated,4308,O
mutants,4308,O
",",4308,O
showed,4308,O
reduced,4308,O
ability,4308,O
to,4308,O
activate,4308,O
Nrf2,4308,B-GENE-Y
signalling,4308,O
as,4308,O
assessed,4308,O
by,4308,O
ARE-luciferase,4308,B-GENE-N
reporter,4308,O
assays,4308,O
.,4308,O
Thus,4309,O
",",4309,O
SQSTM1-mediated,4309,B-GENE-Y
dysregulation,4309,O
of,4309,O
the,4309,O
Keap1-Nrf2,4309,B-GENE-Y
axis,4309,O
",",4309,O
which,4309,O
could,4309,O
potentially,4309,O
lead,4309,O
to,4309,O
aberrant,4309,O
production,4309,O
of,4309,O
oxidative,4309,O
response,4309,O
genes,4309,O
",",4309,O
may,4309,O
contribute,4309,O
to,4309,O
disease,4309,O
aetiology,4309,O
in,4309,O
a,4309,O
subset,4309,O
of,4309,O
PDB,4309,O
patients,4309,O
.,4309,O
Orexin-A,4310,B-GENE-Y
suppresses,4310,O
postischemic,4310,O
glucose,4310,B-CHEMICAL
intolerance,4310,O
and,4310,O
neuronal,4310,O
damage,4310,O
through,4310,O
hypothalamic,4310,O
brain-derived,4310,B-GENE-Y
neurotrophic,4310,I-GENE-Y
factor,4310,I-GENE-Y
.,4310,O
Orexin-A,4311,B-GENE-Y
(,4311,O
a,4311,O
glucose-sensing,4311,B-CHEMICAL
neuropeptide,4311,O
in,4311,O
the,4311,O
hypothalamus,4311,O
),4311,O
and,4311,O
brain-derived,4311,B-GENE-Y
neurotrophic,4311,I-GENE-Y
factor,4311,I-GENE-Y
(,4311,O
BDNF,4311,B-GENE-Y
;,4311,O
a,4311,O
member,4311,O
of,4311,O
the,4311,O
neurotrophin,4311,B-GENE-N
family,4311,O
),4311,O
play,4311,O
roles,4311,O
in,4311,O
many,4311,O
physiologic,4311,O
functions,4311,O
",",4311,O
including,4311,O
regulation,4311,O
of,4311,O
glucose,4311,B-CHEMICAL
metabolism,4311,O
.,4311,O
We,4312,O
previously,4312,O
showed,4312,O
that,4312,O
the,4312,O
development,4312,O
of,4312,O
postischemic,4312,O
glucose,4312,B-CHEMICAL
intolerance,4312,O
is,4312,O
one,4312,O
of,4312,O
the,4312,O
triggers,4312,O
of,4312,O
ischemic,4312,O
neuronal,4312,O
damage,4312,O
.,4312,O
The,4313,O
aim,4313,O
of,4313,O
this,4313,O
study,4313,O
was,4313,O
to,4313,O
determine,4313,O
whether,4313,O
there,4313,O
was,4313,O
an,4313,O
interaction,4313,O
between,4313,O
orexin-A,4313,B-GENE-Y
and,4313,O
BDNF,4313,B-GENE-Y
functions,4313,O
in,4313,O
the,4313,O
hypothalamus,4313,O
after,4313,O
cerebral,4313,O
ischemic,4313,O
stress,4313,O
.,4313,O
Male,4314,O
ddY,4314,O
mice,4314,O
were,4314,O
subjected,4314,O
to,4314,O
2,4314,O
hours,4314,O
of,4314,O
middle,4314,O
cerebral,4314,O
artery,4314,O
occlusion,4314,O
(,4314,O
MCAO,4314,O
),4314,O
.,4314,O
Neuronal,4315,O
damage,4315,O
was,4315,O
estimated,4315,O
by,4315,O
histologic,4315,O
and,4315,O
behavioral,4315,O
analyses,4315,O
.,4315,O
Expression,4316,O
of,4316,O
protein,4316,O
levels,4316,O
was,4316,O
analyzed,4316,O
by,4316,O
Western,4316,O
blot,4316,O
.,4316,O
Small,4317,O
interfering,4317,O
RNA,4317,O
directed,4317,O
BDNF,4317,B-GENE-Y
",",4317,O
orexin-A,4317,B-GENE-Y
",",4317,O
and,4317,O
SB334867,4317,B-CHEMICAL
[,4317,O
N-,4317,B-CHEMICAL
(,4317,I-CHEMICAL
2-methyl-6-benzoxazolyl,4317,I-CHEMICAL
),4317,I-CHEMICAL
"-N'-1,5-naphthyridin-4-yl",4317,I-CHEMICAL
urea,4317,I-CHEMICAL
;,4317,O
a,4317,O
specific,4317,O
orexin-1,4317,B-GENE-Y
receptor,4317,I-GENE-Y
antagonist,4317,O
],4317,O
were,4317,O
administered,4317,O
directly,4317,O
into,4317,O
the,4317,O
hypothalamus,4317,O
.,4317,O
The,4318,O
level,4318,O
of,4318,O
hypothalamic,4318,O
orexin-A,4318,B-GENE-Y
",",4318,O
detected,4318,O
by,4318,O
immunohistochemistry,4318,O
",",4318,O
was,4318,O
decreased,4318,O
on,4318,O
day,4318,O
1,4318,O
after,4318,O
MCAO,4318,O
.,4318,O
Intrahypothalamic,4319,O
administration,4319,O
of,4319,O
orexin-A,4319,B-GENE-Y
(,4319,O
1,4319,O
or,4319,O
5,4319,O
pmol/mouse,4319,O
),4319,O
significantly,4319,O
and,4319,O
dose-dependently,4319,O
suppressed,4319,O
the,4319,O
development,4319,O
of,4319,O
postischemic,4319,O
glucose,4319,B-CHEMICAL
intolerance,4319,O
on,4319,O
day,4319,O
1,4319,O
and,4319,O
development,4319,O
of,4319,O
neuronal,4319,O
damage,4319,O
on,4319,O
day,4319,O
3,4319,O
.,4319,O
The,4320,O
MCAO-induced,4320,O
decrease,4320,O
in,4320,O
insulin,4320,B-GENE-Y
receptor,4320,I-GENE-Y
levels,4320,O
in,4320,O
the,4320,O
liver,4320,O
and,4320,O
skeletal,4320,O
muscle,4320,O
on,4320,O
day,4320,O
1,4320,O
was,4320,O
recovered,4320,O
to,4320,O
control,4320,O
levels,4320,O
by,4320,O
orexin-A,4320,B-GENE-Y
",",4320,O
and,4320,O
this,4320,O
effect,4320,O
of,4320,O
orexin-A,4320,B-GENE-Y
was,4320,O
reversed,4320,O
by,4320,O
the,4320,O
administration,4320,O
of,4320,O
SB334867,4320,B-CHEMICAL
as,4320,O
well,4320,O
as,4320,O
by,4320,O
hypothalamic,4320,O
BDNF,4320,B-GENE-Y
knockdown,4320,O
.,4320,O
These,4321,O
results,4321,O
suggest,4321,O
that,4321,O
suppression,4321,O
of,4321,O
postischemic,4321,O
glucose,4321,B-CHEMICAL
intolerance,4321,O
by,4321,O
orexin-A,4321,B-GENE-Y
assists,4321,O
in,4321,O
the,4321,O
prevention,4321,O
of,4321,O
cerebral,4321,O
ischemic,4321,O
neuronal,4321,O
damage,4321,O
.,4321,O
In,4322,O
addition,4322,O
",",4322,O
hypothalamic,4322,O
BDNF,4322,B-GENE-Y
may,4322,O
play,4322,O
an,4322,O
important,4322,O
role,4322,O
in,4322,O
this,4322,O
effect,4322,O
of,4322,O
orexin-A,4322,B-GENE-Y
.,4322,O
Mesalamine,4323,B-CHEMICAL
modulates,4323,O
intercellular,4323,O
adhesion,4323,O
through,4323,O
inhibition,4323,O
of,4323,O
p-21,4323,B-GENE-Y
activated,4323,I-GENE-Y
kinase-1,4323,I-GENE-Y
.,4323,O
Mesalamine,4324,B-CHEMICAL
(,4324,O
5-ASA,4324,B-CHEMICAL
),4324,O
is,4324,O
widely,4324,O
used,4324,O
for,4324,O
the,4324,O
treatment,4324,O
of,4324,O
ulcerative,4324,O
colitis,4324,O
",",4324,O
a,4324,O
remitting,4324,O
condition,4324,O
characterized,4324,O
by,4324,O
chronic,4324,O
inflammation,4324,O
of,4324,O
the,4324,O
colon,4324,O
.,4324,O
Knowledge,4325,O
about,4325,O
the,4325,O
molecular,4325,O
and,4325,O
cellular,4325,O
targets,4325,O
of,4325,O
5-ASA,4325,B-CHEMICAL
is,4325,O
limited,4325,O
and,4325,O
a,4325,O
clear,4325,O
understanding,4325,O
of,4325,O
its,4325,O
activity,4325,O
in,4325,O
intestinal,4325,O
homeostasis,4325,O
and,4325,O
interference,4325,O
with,4325,O
neoplastic,4325,O
progression,4325,O
is,4325,O
lacking,4325,O
.,4325,O
We,4326,O
sought,4326,O
to,4326,O
identify,4326,O
molecular,4326,O
pathways,4326,O
interfered,4326,O
by,4326,O
5-ASA,4326,B-CHEMICAL
",",4326,O
using,4326,O
CRC,4326,O
cell,4326,O
lines,4326,O
with,4326,O
different,4326,O
genetic,4326,O
background,4326,O
.,4326,O
Microarray,4327,O
was,4327,O
performed,4327,O
for,4327,O
gene,4327,O
expression,4327,O
profile,4327,O
of,4327,O
5-ASA-treated,4327,B-CHEMICAL
and,4327,O
untreated,4327,O
cells,4327,O
(,4327,O
HCT116,4327,O
and,4327,O
HT29,4327,O
),4327,O
.,4327,O
Filtering,4328,O
and,4328,O
analysis,4328,O
of,4328,O
data,4328,O
identified,4328,O
three,4328,O
oncogenic,4328,O
pathways,4328,O
interfered,4328,O
by,4328,O
5-ASA,4328,B-CHEMICAL
:,4328,O
MAPK/ERK,4328,B-GENE-N
pathway,4328,O
",",4328,O
cell,4328,O
adhesion,4328,O
and,4328,O
β-catenin/Wnt,4328,B-GENE-Y
signaling,4328,O
.,4328,O
PAK1,4329,B-GENE-Y
emerged,4329,O
as,4329,O
a,4329,O
consensus,4329,O
target,4329,O
of,4329,O
5-ASA,4329,B-CHEMICAL
",",4329,O
orchestrating,4329,O
these,4329,O
pathways,4329,O
.,4329,O
We,4330,O
further,4330,O
investigated,4330,O
the,4330,O
effect,4330,O
of,4330,O
5-ASA,4330,B-CHEMICAL
on,4330,O
cell,4330,O
adhesion,4330,O
.,4330,O
5-ASA,4331,B-CHEMICAL
increased,4331,O
cell,4331,O
adhesion,4331,O
which,4331,O
was,4331,O
measured,4331,O
by,4331,O
cell,4331,O
adhesion,4331,O
assay,4331,O
and,4331,O
transcellular-resistance,4331,O
measurement,4331,O
.,4331,O
Moreover,4332,O
",",4332,O
5-ASA,4332,B-CHEMICAL
treatment,4332,O
restored,4332,O
membranous,4332,O
expression,4332,O
of,4332,O
adhesion,4332,O
molecules,4332,O
E-cadherin,4332,B-GENE-Y
and,4332,O
β-catenin,4332,B-GENE-Y
.,4332,O
Role,4333,O
of,4333,O
PAK1,4333,B-GENE-Y
as,4333,O
a,4333,O
mediator,4333,O
of,4333,O
mesalamine,4333,O
activity,4333,O
was,4333,O
validated,4333,O
in,4333,O
vitro,4333,O
and,4333,O
in,4333,O
vivo,4333,O
.,4333,O
Inhibition,4334,O
of,4334,O
PAK1,4334,B-GENE-Y
by,4334,O
RNA,4334,O
interference,4334,O
also,4334,O
increased,4334,O
cell,4334,O
adhesion,4334,O
.,4334,O
PAK1,4335,B-GENE-Y
expression,4335,O
was,4335,O
elevated,4335,O
in,4335,O
APC,4335,O
(,4335,O
min,4335,O
),4335,O
polyps,4335,O
and,4335,O
5-ASA,4335,B-CHEMICAL
treatment,4335,O
reduced,4335,O
its,4335,O
expression,4335,O
.,4335,O
Our,4336,O
data,4336,O
demonstrates,4336,O
novel,4336,O
pharmacological,4336,O
mechanism,4336,O
of,4336,O
mesalamine,4336,B-CHEMICAL
in,4336,O
modulation,4336,O
of,4336,O
cell,4336,O
adhesion,4336,O
and,4336,O
role,4336,O
of,4336,O
PAK1,4336,B-GENE-Y
in,4336,O
APC,4336,O
(,4336,O
min,4336,O
),4336,O
polyposis,4336,O
.,4336,O
We,4337,O
propose,4337,O
that,4337,O
inhibition,4337,O
of,4337,O
PAK1,4337,B-GENE-Y
expression,4337,O
by,4337,O
5-ASA,4337,B-CHEMICAL
can,4337,O
impede,4337,O
with,4337,O
neoplastic,4337,O
progression,4337,O
in,4337,O
colorectal,4337,O
carcinogenesis,4337,O
.,4337,O
The,4338,O
mechanism,4338,O
of,4338,O
PAK1,4338,B-GENE-Y
inhibition,4338,O
and,4338,O
induction,4338,O
of,4338,O
membranous,4338,O
translocation,4338,O
of,4338,O
adhesion,4338,O
proteins,4338,O
by,4338,O
5-ASA,4338,B-CHEMICAL
might,4338,O
be,4338,O
independent,4338,O
of,4338,O
its,4338,O
known,4338,O
anti-inflammatory,4338,O
action,4338,O
.,4338,O
Cholestatic,4339,O
effect,4339,O
of,4339,O
epigallocatechin,4339,B-CHEMICAL
gallate,4339,I-CHEMICAL
in,4339,O
rats,4339,O
is,4339,O
mediated,4339,O
via,4339,O
decreased,4339,O
expression,4339,O
of,4339,O
Mrp2,4339,B-GENE-Y
.,4339,O
Epigallocatechin,4340,B-CHEMICAL
gallate,4340,I-CHEMICAL
(,4340,O
EGCG,4340,B-CHEMICAL
),4340,O
has,4340,O
been,4340,O
shown,4340,O
to,4340,O
be,4340,O
protective,4340,O
in,4340,O
various,4340,O
experimental,4340,O
models,4340,O
of,4340,O
liver,4340,O
injury,4340,O
",",4340,O
although,4340,O
opposite,4340,O
effects,4340,O
have,4340,O
also,4340,O
been,4340,O
reported,4340,O
.,4340,O
Since,4341,O
its,4341,O
effect,4341,O
on,4341,O
biliary,4341,O
physiology,4341,O
has,4341,O
not,4341,O
been,4341,O
thoroughly,4341,O
investigated,4341,O
",",4341,O
the,4341,O
present,4341,O
study,4341,O
evaluated,4341,O
effect,4341,O
of,4341,O
EGCG,4341,B-CHEMICAL
on,4341,O
bile,4341,O
flow,4341,O
and,4341,O
bile,4341,B-CHEMICAL
acid,4341,I-CHEMICAL
homeostasis,4341,O
in,4341,O
rats,4341,O
.,4341,O
Compared,4342,O
to,4342,O
controls,4342,O
",",4342,O
EGCG,4342,B-CHEMICAL
treatment,4342,O
decreased,4342,O
bile,4342,O
flow,4342,O
by,4342,O
23,4342,O
%,4342,O
.,4342,O
Hepatic,4343,O
paracellular,4343,O
permeability,4343,O
and,4343,O
biliary,4343,O
bile,4343,B-CHEMICAL
acid,4343,I-CHEMICAL
excretion,4343,O
were,4343,O
not,4343,O
altered,4343,O
by,4343,O
EGCG,4343,B-CHEMICAL
administration,4343,O
",",4343,O
but,4343,O
biliary,4343,O
glutathione,4343,B-CHEMICAL
excretion,4343,O
was,4343,O
reduced,4343,O
by,4343,O
70,4343,O
%,4343,O
.,4343,O
Accordingly,4344,O
",",4344,O
the,4344,O
main,4344,O
glutathione,4344,B-GENE-N
transporter,4344,I-GENE-N
on,4344,O
the,4344,O
hepatocyte,4344,O
canalicular,4344,O
membrane,4344,O
",",4344,O
multidrug,4344,B-GENE-Y
resistance-associated,4344,I-GENE-Y
protein,4344,I-GENE-Y
2,4344,I-GENE-Y
(,4344,O
Mrp2,4344,B-GENE-Y
),4344,O
",",4344,O
was,4344,O
significantly,4344,O
decreased,4344,O
at,4344,O
the,4344,O
protein,4344,O
level,4344,O
.,4344,O
EGCG,4345,B-CHEMICAL
administration,4345,O
also,4345,O
doubled,4345,O
plasma,4345,O
bile,4345,B-CHEMICAL
acid,4345,I-CHEMICAL
levels,4345,O
compared,4345,O
to,4345,O
controls,4345,O
.,4345,O
While,4346,O
protein,4346,O
levels,4346,O
of,4346,O
the,4346,O
main,4346,O
hepatic,4346,B-GENE-Y
bile,4346,I-GENE-Y
acid,4346,I-GENE-Y
transporters,4346,I-GENE-Y
were,4346,O
unchanged,4346,O
",",4346,O
the,4346,O
rate-limiting,4346,O
enzyme,4346,O
in,4346,O
the,4346,O
bile,4346,B-CHEMICAL
acid,4346,I-CHEMICAL
synthesis,4346,O
",",4346,O
Cyp7a1,4346,B-GENE-Y
",",4346,O
was,4346,O
significantly,4346,O
increased,4346,O
by,4346,O
EGCG,4346,B-CHEMICAL
.,4346,O
Enhanced,4347,O
bile,4347,B-CHEMICAL
acid,4347,I-CHEMICAL
synthesis,4347,O
in,4347,O
these,4347,O
animals,4347,O
was,4347,O
also,4347,O
confirmed,4347,O
by,4347,O
a,4347,O
2-fold,4347,O
increase,4347,O
in,4347,O
plasma,4347,O
marker,4347,O
7α-hydroxy-4-cholesten-3-one,4347,B-CHEMICAL
.,4347,O
In,4348,O
contrast,4348,O
",",4348,O
EGCG,4348,B-CHEMICAL
markedly,4348,O
downregulated,4348,O
major,4348,O
bile,4348,B-CHEMICAL
acid,4348,I-CHEMICAL
transporters,4348,I-GENE-N
(,4348,O
Asbt,4348,B-GENE-Y
and,4348,O
Ostα,4348,B-GENE-Y
),4348,O
and,4348,O
regulatory,4348,O
molecules,4348,O
(,4348,O
Shp,4348,B-GENE-Y
and,4348,O
Fgf15,4348,B-GENE-Y
),4348,O
in,4348,O
the,4348,O
ileum,4348,O
.,4348,O
When,4349,O
EGCG,4349,B-CHEMICAL
was,4349,O
coadministered,4349,O
with,4349,O
ethinylestradiol,4349,B-CHEMICAL
",",4349,O
a,4349,O
potent,4349,O
cholestatic,4349,O
agent,4349,O
",",4349,O
it,4349,O
did,4349,O
not,4349,O
show,4349,O
any,4349,O
additional,4349,O
effect,4349,O
on,4349,O
the,4349,O
induced,4349,O
cholestasis,4349,O
.,4349,O
This,4350,O
study,4350,O
shows,4350,O
ability,4350,O
of,4350,O
EGCG,4350,B-CHEMICAL
to,4350,O
raise,4350,O
plasma,4350,O
bile,4350,B-CHEMICAL
acid,4350,I-CHEMICAL
concentrations,4350,O
",",4350,O
mainly,4350,O
through,4350,O
Cyp7a1,4350,B-GENE-Y
upregulation,4350,O
",",4350,O
and,4350,O
to,4350,O
decrease,4350,O
bile,4350,O
production,4350,O
through,4350,O
reduction,4350,O
in,4350,O
Mrp2-mediated,4350,B-GENE-Y
bile,4350,B-CHEMICAL
acid-independent,4350,O
bile,4350,O
flow,4350,O
.,4350,O
In,4351,O
conclusion,4351,O
",",4351,O
our,4351,O
data,4351,O
demonstrate,4351,O
that,4351,O
under,4351,O
certain,4351,O
conditions,4351,O
EGCG,4351,B-CHEMICAL
may,4351,O
induce,4351,O
cholestasis,4351,O
.,4351,O
Effects-based,4352,O
marine,4352,O
ecological,4352,O
risk,4352,O
assessment,4352,O
at,4352,O
a,4352,O
polychlorinated,4352,B-CHEMICAL
biphenyl-contaminated,4352,O
site,4352,O
in,4352,O
Saglek,4352,O
",",4352,O
Labrador,4352,O
",",4352,O
Canada,4352,O
.,4352,O
Although,4353,O
the,4353,O
presence,4353,O
and,4353,O
distribution,4353,O
of,4353,O
polychlorinated,4353,B-CHEMICAL
biphenyls,4353,I-CHEMICAL
(,4353,O
PCBs,4353,B-CHEMICAL
),4353,O
in,4353,O
Arctic,4353,O
marine,4353,O
environments,4353,O
has,4353,O
been,4353,O
well,4353,O
documented,4353,O
",",4353,O
the,4353,O
implications,4353,O
for,4353,O
the,4353,O
health,4353,O
of,4353,O
biota,4353,O
are,4353,O
poorly,4353,O
understood,4353,O
.,4353,O
In,4354,O
the,4354,O
present,4354,O
study,4354,O
",",4354,O
multiple,4354,O
lines,4354,O
of,4354,O
evidence,4354,O
",",4354,O
including,4354,O
site-specific,4354,O
effects,4354,O
data,4354,O
",",4354,O
were,4354,O
used,4354,O
to,4354,O
assess,4354,O
PCB-related,4354,B-CHEMICAL
risks,4354,O
to,4354,O
marine,4354,O
biota,4354,O
at,4354,O
a,4354,O
contaminated,4354,O
military,4354,O
site,4354,O
in,4354,O
Saglek,4354,O
Bay,4354,O
",",4354,O
Labrador,4354,O
",",4354,O
Canada,4354,O
",",4354,O
from,4354,O
1997,4354,O
to,4354,O
1999,4354,O
.,4354,O
Risks,4355,O
were,4355,O
evaluated,4355,O
for,4355,O
three,4355,O
components,4355,O
of,4355,O
the,4355,O
ecosystem,4355,O
:,4355,O
benthic,4355,O
invertebrates,4355,O
",",4355,O
a,4355,O
bottom-feeding,4355,O
fish,4355,O
(,4355,O
shorthorn,4355,O
sculpin,4355,O
",",4355,O
Myoxocephalus,4355,O
scorpius,4355,O
),4355,O
",",4355,O
and,4355,O
a,4355,O
diving,4355,O
seabird,4355,O
(,4355,O
black,4355,O
guillemot,4355,O
",",4355,O
Cepphus,4355,O
grylle,4355,O
),4355,O
.,4355,O
Average,4356,O
sediment,4356,O
PCB,4356,B-CHEMICAL
concentrations,4356,O
exceeded,4356,O
the,4356,O
Canadian,4356,O
interim,4356,O
sediment,4356,O
quality,4356,O
guideline,4356,O
level,4356,O
by,4356,O
41-fold,4356,O
.,4356,O
However,4357,O
",",4357,O
sediment,4357,O
toxicity,4357,O
testing,4357,O
and,4357,O
a,4357,O
benthic,4357,O
community,4357,O
survey,4357,O
showed,4357,O
no,4357,O
evidence,4357,O
of,4357,O
adverse,4357,O
effects,4357,O
.,4357,O
In,4358,O
contrast,4358,O
",",4358,O
shorthorn,4358,O
sculpin,4358,O
and,4358,O
black,4358,O
guillemot,4358,O
PCB,4358,B-CHEMICAL
exposures,4358,O
(,4358,O
measured,4358,O
as,4358,O
sum,4358,O
of,4358,O
55,4358,O
congeners,4358,O
),4358,O
were,4358,O
elevated,4358,O
enough,4358,O
to,4358,O
pose,4358,O
risks,4358,O
to,4358,O
survival,4358,O
or,4358,O
reproduction,4358,O
.,4358,O
Based,4359,O
on,4359,O
the,4359,O
collective,4359,O
evidence,4359,O
",",4359,O
the,4359,O
authors,4359,O
estimated,4359,O
that,4359,O
risks,4359,O
were,4359,O
posed,4359,O
by,4359,O
sediment,4359,O
PCB,4359,B-CHEMICAL
concentrations,4359,O
greater,4359,O
than,4359,O
77,4359,O
ng/g,4359,O
dry,4359,O
weight,4359,O
for,4359,O
black,4359,O
guillemots,4359,O
and,4359,O
750,4359,O
ng/g,4359,O
dry,4359,O
weight,4359,O
for,4359,O
shorthorn,4359,O
sculpins,4359,O
.,4359,O
The,4360,O
present,4360,O
study,4360,O
",",4360,O
along,4360,O
with,4360,O
two,4360,O
parallel,4360,O
studies,4360,O
",",4360,O
provided,4360,O
information,4360,O
to,4360,O
support,4360,O
the,4360,O
management,4360,O
decisions,4360,O
concerning,4360,O
potential,4360,O
remedial,4360,O
action,4360,O
on,4360,O
the,4360,O
contaminated,4360,O
sediments,4360,O
.,4360,O
This,4361,O
ecological,4361,O
risk,4361,O
assessment,4361,O
describes,4361,O
the,4361,O
steps,4361,O
and,4361,O
rationale,4361,O
taken,4361,O
to,4361,O
evaluate,4361,O
the,4361,O
risk,4361,O
posed,4361,O
by,4361,O
an,4361,O
area,4361,O
of,4361,O
PCB-contaminated,4361,B-CHEMICAL
marine,4361,O
sediments,4361,O
in,4361,O
an,4361,O
otherwise,4361,O
relatively,4361,O
pristine,4361,O
northern,4361,O
coastal,4361,O
environment,4361,O
.,4361,O
Ablation,4362,O
of,4362,O
Egr2-positive,4362,B-GENE-Y
cells,4362,O
in,4362,O
male,4362,O
mouse,4362,O
anterior,4362,O
pituitary,4362,O
leads,4362,O
to,4362,O
atypical,4362,O
isolated,4362,O
GH,4362,O
deficiency,4362,O
.,4362,O
In,4363,O
this,4363,O
study,4363,O
",",4363,O
we,4363,O
have,4363,O
investigated,4363,O
the,4363,O
expression,4363,O
and,4363,O
function,4363,O
of,4363,O
the,4363,O
transcription,4363,O
factor,4363,O
early,4363,B-GENE-Y
growth,4363,I-GENE-Y
response,4363,I-GENE-Y
factor,4363,I-GENE-Y
2,4363,I-GENE-Y
(,4363,O
Egr2,4363,B-GENE-Y
),4363,O
/Krox20,4363,O
in,4363,O
the,4363,O
developing,4363,O
anterior,4363,O
pituitary,4363,O
.,4363,O
Egr2,4364,B-GENE-Y
is,4364,O
initially,4364,O
expressed,4364,O
in,4364,O
all,4364,O
differentiating,4364,O
hormonal,4364,O
cells,4364,O
types,4364,O
",",4364,O
but,4364,O
its,4364,O
expression,4364,O
is,4364,O
mostly,4364,O
restricted,4364,O
to,4364,O
the,4364,O
somatotroph,4364,O
lineage,4364,O
after,4364,O
birth,4364,O
.,4364,O
Egr2,4365,B-GENE-Y
knockout,4365,O
results,4365,O
in,4365,O
anterior,4365,O
pituitary,4365,O
hypoplasia,4365,O
.,4365,O
However,4366,O
",",4366,O
the,4366,O
analysis,4366,O
of,4366,O
a,4366,O
conditional,4366,O
mutant,4366,O
demonstrates,4366,O
that,4366,O
this,4366,O
phenotype,4366,O
does,4366,O
not,4366,O
originate,4366,O
from,4366,O
a,4366,O
lack,4366,O
of,4366,O
Egr2,4366,B-GENE-Y
expression,4366,O
in,4366,O
the,4366,O
pituitary,4366,O
.,4366,O
Using,4367,O
an,4367,O
Egr2,4367,B-GENE-Y
allele,4367,O
driving,4367,O
a,4367,O
Cre-activable,4367,O
toxin,4367,O
gene,4367,O
",",4367,O
we,4367,O
performed,4367,O
a,4367,O
genetic,4367,O
ablation,4367,O
of,4367,O
Egr2-positive,4367,B-GENE-Y
cells,4367,O
in,4367,O
the,4367,O
pituitary,4367,O
.,4367,O
During,4368,O
the,4368,O
postnatal,4368,O
period,4368,O
",",4368,O
this,4368,O
ablation,4368,O
leads,4368,O
to,4368,O
specific,4368,O
and,4368,O
progressive,4368,O
depletion,4368,O
of,4368,O
the,4368,O
somatotroph,4368,O
population,4368,O
",",4368,O
creating,4368,O
a,4368,O
novel,4368,O
model,4368,O
of,4368,O
early-onset,4368,O
isolated,4368,O
GH,4368,O
deficiency,4368,O
(,4368,O
GHD,4368,O
),4368,O
.,4368,O
Mutant,4369,O
animals,4369,O
were,4369,O
subjected,4369,O
to,4369,O
a,4369,O
complete,4369,O
metabolic,4369,O
analysis,4369,O
",",4369,O
revealing,4369,O
atypical,4369,O
and,4369,O
expected,4369,O
features,4369,O
.,4369,O
Consistent,4370,O
with,4370,O
an,4370,O
adult-onset,4370,O
isolated,4370,O
GHD,4370,O
model,4370,O
",",4370,O
mutant,4370,O
animals,4370,O
are,4370,O
hypoglycemic,4370,O
and,4370,O
display,4370,O
increased,4370,O
insulin,4370,B-GENE-N
sensitivity,4370,O
and,4370,O
glucose,4370,B-CHEMICAL
clearance,4370,O
.,4370,O
This,4371,O
latter,4371,O
phenotype,4371,O
is,4371,O
in,4371,O
contrast,4371,O
to,4371,O
the,4371,O
glucose,4371,B-CHEMICAL
intolerance,4371,O
observed,4371,O
in,4371,O
another,4371,O
early-onset,4371,O
GHD,4371,O
model,4371,O
.,4371,O
Surprisingly,4372,O
",",4372,O
increased,4372,O
insulin,4372,O
sensitivity,4372,O
is,4372,O
not,4372,O
accompanied,4372,O
by,4372,O
a,4372,O
modified,4372,O
balance,4372,O
between,4372,O
fat,4372,O
and,4372,O
lean,4372,O
tissues,4372,O
",",4372,O
but,4372,O
by,4372,O
reduced,4372,O
metabolic,4372,O
adaptability,4372,O
between,4372,O
glucose,4372,B-CHEMICAL
and,4372,O
lipid,4372,O
oxidation,4372,O
conditions,4372,O
.,4372,O
This,4373,O
suggests,4373,O
that,4373,O
the,4373,O
relationship,4373,O
between,4373,O
these,4373,O
metabolic,4373,O
features,4373,O
and,4373,O
insulin,4373,O
sensitivity,4373,O
should,4373,O
be,4373,O
reconsidered,4373,O
.,4373,O
In,4374,O
conclusion,4374,O
",",4374,O
our,4374,O
mutant,4374,O
may,4374,O
be,4374,O
a,4374,O
valuable,4374,O
genetic,4374,O
model,4374,O
with,4374,O
which,4374,O
to,4374,O
study,4374,O
the,4374,O
effects,4374,O
of,4374,O
long-term,4374,O
GH,4374,O
deficiency,4374,O
",",4374,O
in,4374,O
conditions,4374,O
of,4374,O
normal,4374,O
pancreatic,4374,O
function,4374,O
and,4374,O
unaffected,4374,O
balance,4374,O
between,4374,O
fat,4374,O
and,4374,O
glucose,4374,B-CHEMICAL
metabolism,4374,O
.,4374,O
The,4375,O
scintigraphic,4375,O
evaluation,4375,O
and,4375,O
genetic,4375,O
correlation,4375,O
of,4375,O
joint,4375,O
involvements,4375,O
in,4375,O
pediatric,4375,O
patients,4375,O
with,4375,O
familial,4375,O
Mediterranean,4375,O
fever,4375,O
.,4375,O
Purpose,4376,O
:,4376,O
We,4376,O
aimed,4376,O
to,4376,O
evaluate,4376,O
the,4376,O
articular,4376,O
involvements,4376,O
in,4376,O
pediatric,4376,O
patients,4376,O
with,4376,O
familial,4376,O
Mediterranean,4376,O
fever,4376,O
(,4376,O
FMF,4376,O
),4376,O
with,4376,O
joint,4376,O
symptoms,4376,O
by,4376,O
bone,4376,O
scintigraphy,4376,O
and,4376,O
to,4376,O
correlate,4376,O
the,4376,O
involved,4376,O
joints,4376,O
with,4376,O
the,4376,O
gene,4376,O
mutations,4376,O
.,4376,O
Materials,4377,O
and,4377,O
methods,4377,O
:,4377,O
A,4377,O
total,4377,O
of,4377,O
41,4377,O
newly,4377,O
diagnosed,4377,O
patients,4377,O
in,4377,O
pediatric,4377,O
age,4377,O
group,4377,O
(,4377,O
28,4377,O
girls,4377,O
and,4377,O
13,4377,O
boys,4377,O
;,4377,O
mean,4377,O
age,4377,O
9.14,4377,O
±,4377,O
2.91,4377,O
years,4377,O
),4377,O
with,4377,O
joint,4377,O
involvement,4377,O
symptoms,4377,O
were,4377,O
included,4377,O
in,4377,O
this,4377,O
study,4377,O
.,4377,O
Scintigraphic,4378,O
images,4378,O
were,4378,O
obtained,4378,O
at,4378,O
5th,4378,O
min,4378,O
(,4378,O
blood,4378,O
pool,4378,O
or,4378,O
early,4378,O
phase,4378,O
),4378,O
and,4378,O
starting,4378,O
at,4378,O
3,4378,O
h,4378,O
(,4378,O
late,4378,O
phase,4378,O
),4378,O
after,4378,O
(,4378,O
after,4378,O
tracer,4378,O
injection,4378,O
),4378,O
intravenous,4378,O
administration,4378,O
of,4378,O
technetium-99m,4378,B-CHEMICAL
(,4378,O
99mTc,4378,B-CHEMICAL
),4378,O
-methylendiphosphonate,4378,O
(,4378,O
MDP,4378,B-CHEMICAL
),4378,O
.,4378,O
Genomic,4379,O
DNA,4379,O
was,4379,O
isolated,4379,O
from,4379,O
leukocytes,4379,O
using,4379,O
standard,4379,O
salting,4379,O
out,4379,O
procedure,4379,O
.,4379,O
The,4380,O
sequencing,4380,O
data,4380,O
were,4380,O
analyzed,4380,O
.,4380,O
Results,4381,O
:,4381,O
Of,4381,O
the,4381,O
41,4381,O
patients,4381,O
",",4381,O
arthritis,4381,O
was,4381,O
found,4381,O
in,4381,O
21,4381,O
(,4381,O
51.2,4381,O
%,4381,O
),4381,O
patients,4381,O
.,4381,O
Of,4382,O
the,4382,O
21,4382,O
patients,4382,O
",",4382,O
there,4382,O
was,4382,O
single,4382,O
joint,4382,O
involvement,4382,O
in,4382,O
15,4382,O
(,4382,O
71.4,4382,O
%,4382,O
),4382,O
patients,4382,O
and,4382,O
multiple,4382,O
joint,4382,O
involvement,4382,O
in,4382,O
six,4382,O
(,4382,O
28.6,4382,O
%,4382,O
),4382,O
patients,4382,O
.,4382,O
The,4383,O
mean,4383,O
age,4383,O
of,4383,O
patients,4383,O
with,4383,O
joint,4383,O
involvement,4383,O
(,4383,O
8,4383,O
±,4383,O
2.3,4383,O
years,4383,O
),4383,O
were,4383,O
considerably,4383,O
lower,4383,O
than,4383,O
the,4383,O
patients,4383,O
without,4383,O
joint,4383,O
involvement,4383,O
(,4383,O
10.35,4383,O
±,4383,O
3.04,4383,O
years,4383,O
),4383,O
",",4383,O
and,4383,O
this,4383,O
was,4383,O
statistically,4383,O
significant,4383,O
(,4383,O
p,4383,O
=,4383,O
0.008,4383,O
),4383,O
.,4383,O
The,4384,O
most,4384,O
commonly,4384,O
involved,4384,O
joints,4384,O
were,4384,O
ankles,4384,O
and,4384,O
knees,4384,O
.,4384,O
Multiple,4385,O
joint,4385,O
involvements,4385,O
were,4385,O
most,4385,O
frequently,4385,O
observed,4385,O
in,4385,O
the,4385,O
M694V,4385,B-GENE-N
and,4385,O
M694I,4385,B-GENE-N
gene,4385,O
mutations,4385,O
(,4385,O
16.7,4385,O
%,4385,O
),4385,O
.,4385,O
Conclusions,4386,O
:,4386,O
We,4386,O
use,4386,O
and,4386,O
recommend,4386,O
the,4386,O
bone,4386,O
scintigraphy,4386,O
in,4386,O
patients,4386,O
with,4386,O
FMF,4386,O
to,4386,O
determine,4386,O
the,4386,O
presence,4386,O
and,4386,O
distribution,4386,O
of,4386,O
arthritis,4386,O
",",4386,O
since,4386,O
bone,4386,O
scintigraphy,4386,O
is,4386,O
inexpensive,4386,O
",",4386,O
noninvasive,4386,O
",",4386,O
easy-to-use,4386,O
",",4386,O
and,4386,O
also,4386,O
is,4386,O
more,4386,O
sensitive,4386,O
in,4386,O
the,4386,O
diagnosis,4386,O
and,4386,O
distribution,4386,O
of,4386,O
arthritis,4386,O
than,4386,O
conventional,4386,O
radiological,4386,O
methods,4386,O
and,4386,O
clinical,4386,O
examination,4386,O
.,4386,O
Serotonin,4387,B-CHEMICAL
receptors,4387,I-GENE-N
of,4387,O
type,4387,O
6,4387,O
(,4387,O
5-HT6,4387,B-GENE-Y
),4387,O
:,4387,O
from,4387,O
neuroscience,4387,O
to,4387,O
clinical,4387,O
pharmacology,4387,O
.,4387,O
The,4388,O
serotonin,4388,B-GENE-N
(,4388,I-GENE-N
5-HT,4388,I-GENE-N
),4388,I-GENE-N
receptors,4388,I-GENE-N
of,4388,O
type,4388,O
6,4388,O
(,4388,O
5-HT6,4388,B-GENE-Y
),4388,O
are,4388,O
quite,4388,O
different,4388,O
from,4388,O
all,4388,O
other,4388,O
5-HT,4388,B-CHEMICAL
receptors,4388,I-GENE-N
",",4388,O
as,4388,O
they,4388,O
include,4388,O
a,4388,O
short,4388,O
third,4388,O
cytoplasmatic,4388,O
loop,4388,O
and,4388,O
a,4388,O
long,4388,O
C-terminal,4388,B-CHEMICAL
tail,4388,O
",",4388,O
and,4388,O
one,4388,O
intron,4388,O
located,4388,O
in,4388,O
the,4388,O
middle,4388,O
of,4388,O
the,4388,O
third,4388,O
cytoplasmatic,4388,O
loop,4388,O
.,4388,O
A,4389,O
lot,4389,O
of,4389,O
controversies,4389,O
still,4389,O
exist,4389,O
regarding,4389,O
their,4389,O
binding,4389,O
affinity,4389,O
",",4389,O
effects,4389,O
of,4389,O
5-HT6,4389,B-GENE-Y
ligands,4389,O
on,4389,O
brain,4389,O
catecholamines,4389,B-CHEMICAL
",",4389,O
behavioral,4389,O
syndromes,4389,O
regulated,4389,O
by,4389,O
them,4389,O
",",4389,O
and,4389,O
brain,4389,O
distribution,4389,O
.,4389,O
In,4390,O
spite,4390,O
of,4390,O
the,4390,O
lack,4390,O
of,4390,O
information,4390,O
on,4390,O
metabolic,4390,O
pattern,4390,O
of,4390,O
the,4390,O
various,4390,O
compounds,4390,O
",",4390,O
some,4390,O
of,4390,O
5-HT6,4390,B-GENE-Y
receptor,4390,O
ligands,4390,O
entered,4390,O
the,4390,O
clinical,4390,O
development,4390,O
as,4390,O
potential,4390,O
anti-dementia,4390,O
",",4390,O
antipsychotic,4390,O
",",4390,O
antidepressant,4390,O
and,4390,O
anti-obese,4390,O
drugs,4390,O
.,4390,O
The,4391,O
present,4391,O
paper,4391,O
is,4391,O
a,4391,O
comprehensive,4391,O
review,4391,O
on,4391,O
the,4391,O
state,4391,O
of,4391,O
art,4391,O
of,4391,O
the,4391,O
5-HT6,4391,B-GENE-Y
receptors,4391,O
",",4391,O
while,4391,O
highlighting,4391,O
the,4391,O
potential,4391,O
clinical,4391,O
applications,4391,O
of,4391,O
5-HT6,4391,B-GENE-Y
receptor,4391,O
agonists/antagonists,4391,O
.,4391,O
Expression,4392,O
of,4392,O
cAMP-responsive,4392,B-CHEMICAL
element,4392,I-GENE-N
binding,4392,I-GENE-N
proteins,4392,I-GENE-N
(,4392,O
CREBs,4392,B-GENE-N
),4392,O
in,4392,O
fast-,4392,O
and,4392,O
slow-twitch,4392,O
muscles,4392,O
:,4392,O
A,4392,O
signaling,4392,O
pathway,4392,O
to,4392,O
account,4392,O
for,4392,O
the,4392,O
synaptic,4392,O
expression,4392,O
of,4392,O
collagen-tailed,4392,B-GENE-Y
subunit,4392,I-GENE-Y
(,4392,O
ColQ,4392,B-GENE-Y
),4392,O
of,4392,O
acetylcholinesterase,4392,B-GENE-Y
at,4392,O
the,4392,O
rat,4392,O
neuromuscular,4392,O
junction,4392,O
.,4392,O
The,4393,O
gene,4393,O
encoding,4393,O
the,4393,O
collagen-tailed,4393,B-GENE-Y
subunit,4393,I-GENE-Y
(,4393,O
ColQ,4393,B-GENE-Y
),4393,O
of,4393,O
acetylcholinesterase,4393,B-GENE-Y
(,4393,O
AChE,4393,B-GENE-Y
),4393,O
contains,4393,O
two,4393,O
distinct,4393,O
promoters,4393,O
that,4393,O
drive,4393,O
the,4393,O
production,4393,O
of,4393,O
two,4393,O
ColQ,4393,B-GENE-Y
mRNAs,4393,O
",",4393,O
ColQ-1,4393,B-GENE-Y
and,4393,O
ColQ-1a,4393,B-GENE-Y
",",4393,O
in,4393,O
slow-,4393,O
and,4393,O
fast-twitch,4393,O
muscles,4393,O
",",4393,O
respectively,4393,O
.,4393,O
ColQ-1a,4394,B-GENE-Y
is,4394,O
expressed,4394,O
at,4394,O
the,4394,O
neuromuscular,4394,O
junction,4394,O
(,4394,O
NMJ,4394,O
),4394,O
in,4394,O
fast-twitch,4394,O
muscle,4394,O
",",4394,O
and,4394,O
this,4394,O
expression,4394,O
depends,4394,O
on,4394,O
trophic,4394,O
factors,4394,O
supplied,4394,O
by,4394,O
motor,4394,O
neurons,4394,O
signaling,4394,O
via,4394,O
a,4394,O
cAMP-dependent,4394,B-CHEMICAL
pathway,4394,O
in,4394,O
muscle,4394,O
.,4394,O
To,4395,O
further,4395,O
elucidate,4395,O
the,4395,O
molecular,4395,O
basis,4395,O
of,4395,O
ColQ-1a,4395,B-GENE-Y
's,4395,I-GENE-Y
synaptic,4395,O
expression,4395,O
",",4395,O
here,4395,O
we,4395,O
investigated,4395,O
the,4395,O
expression,4395,O
and,4395,O
localization,4395,O
of,4395,O
cAMP-responsive,4395,B-CHEMICAL
element,4395,I-GENE-N
binding,4395,I-GENE-N
protein,4395,I-GENE-N
(,4395,O
CREB,4395,B-GENE-N
),4395,O
at,4395,O
the,4395,O
synaptic,4395,O
and,4395,O
extra-synaptic,4395,O
regions,4395,O
of,4395,O
fast-,4395,O
and,4395,O
slow-twitch,4395,O
muscles,4395,O
from,4395,O
adult,4395,O
rats,4395,O
.,4395,O
The,4396,O
total,4396,O
amount,4396,O
of,4396,O
active,4396,O
",",4396,O
phosphorylated,4396,B-GENE-N
CREB,4396,I-GENE-N
(,4396,O
P-CREB,4396,B-GENE-N
),4396,O
present,4396,O
in,4396,O
slow-twitch,4396,O
soleus,4396,O
muscle,4396,O
was,4396,O
higher,4396,O
than,4396,O
that,4396,O
in,4396,O
fast-twitch,4396,O
tibialis,4396,O
muscle,4396,O
",",4396,O
but,4396,O
P-CREB,4396,B-GENE-N
was,4396,O
predominantly,4396,O
expressed,4396,O
in,4396,O
the,4396,O
fast-twitch,4396,O
muscle,4396,O
at,4396,O
NMJs,4396,O
.,4396,O
In,4397,O
contrast,4397,O
",",4397,O
P-CREB,4397,B-GENE-N
was,4397,O
detected,4397,O
in,4397,O
both,4397,O
synaptic,4397,O
and,4397,O
extra-synaptic,4397,O
regions,4397,O
of,4397,O
slow-twitch,4397,O
muscle,4397,O
.,4397,O
These,4398,O
results,4398,O
reveal,4398,O
",",4398,O
for,4398,O
the,4398,O
first,4398,O
time,4398,O
",",4398,O
the,4398,O
differential,4398,O
distribution,4398,O
of,4398,O
P-CREB,4398,B-GENE-N
in,4398,O
fast-,4398,O
and,4398,O
slow-twitch,4398,O
muscles,4398,O
",",4398,O
which,4398,O
might,4398,O
support,4398,O
the,4398,O
crucial,4398,O
role,4398,O
of,4398,O
cAMP-dependent,4398,B-CHEMICAL
signaling,4398,O
in,4398,O
controlling,4398,O
the,4398,O
synapse-specific,4398,O
expression,4398,O
of,4398,O
ColQ-1a,4398,B-GENE-Y
in,4398,O
fast-twitch,4398,O
muscles,4398,O
.,4398,O
Analysis,4399,O
of,4399,O
mammalian,4399,B-GENE-Y
alcohol,4399,B-CHEMICAL
dehydrogenase,4399,I-GENE-Y
5,4399,I-GENE-Y
(,4399,O
ADH5,4399,B-GENE-Y
),4399,O
:,4399,O
characterisation,4399,O
of,4399,O
rat,4399,B-GENE-Y
ADH5,4399,I-GENE-Y
with,4399,O
comparisons,4399,O
to,4399,O
the,4399,O
corresponding,4399,O
human,4399,O
variant,4399,O
.,4399,O
Alcohol,4400,B-GENE-Y
dehydrogenase,4400,I-GENE-Y
5,4400,I-GENE-Y
(,4400,O
ADH5,4400,B-GENE-Y
),4400,O
is,4400,O
a,4400,O
member,4400,O
of,4400,O
the,4400,O
mammalian,4400,B-GENE-N
alcohol,4400,B-CHEMICAL
dehydrogenase,4400,I-GENE-N
family,4400,O
of,4400,O
yet,4400,O
undefined,4400,O
functions,4400,O
.,4400,O
ADH5,4401,B-GENE-Y
was,4401,O
first,4401,O
identified,4401,O
at,4401,O
the,4401,O
DNA,4401,O
level,4401,O
in,4401,O
human,4401,O
and,4401,O
deer,4401,O
mouse,4401,O
.,4401,O
A,4402,O
rat,4402,B-GENE-N
alcohol,4402,B-CHEMICAL
dehydrogenase,4402,I-GENE-N
structure,4402,O
of,4402,O
similar,4402,O
type,4402,O
has,4402,O
been,4402,O
isolated,4402,O
at,4402,O
the,4402,O
cDNA,4402,O
level,4402,O
using,4402,O
human,4402,B-GENE-Y
ADH5,4402,I-GENE-Y
as,4402,O
a,4402,O
screening,4402,O
probe,4402,O
",",4402,O
where,4402,O
the,4402,O
rat,4402,O
cDNA,4402,O
structure,4402,O
displayed,4402,O
several,4402,O
atypical,4402,O
properties,4402,O
.,4402,O
mRNA,4403,O
for,4403,O
rat,4403,B-GENE-Y
ADH5,4403,I-GENE-Y
was,4403,O
found,4403,O
in,4403,O
multiple,4403,O
tissues,4403,O
",",4403,O
especially,4403,O
in,4403,O
the,4403,O
kidney,4403,O
.,4403,O
In,4404,O
vitro,4404,O
translation,4404,O
experiments,4404,O
indicated,4404,O
that,4404,O
rat,4404,B-GENE-Y
ADH5,4404,I-GENE-Y
is,4404,O
expressed,4404,O
as,4404,O
efficiently,4404,O
as,4404,O
ADH1,4404,B-GENE-Y
and,4404,O
furthermore,4404,O
",",4404,O
rat,4404,B-GENE-Y
ADH5,4404,I-GENE-Y
was,4404,O
readily,4404,O
expressed,4404,O
in,4404,O
COS,4404,O
cells,4404,O
fused,4404,O
to,4404,O
Green,4404,O
Fluorescent,4404,O
Protein,4404,O
.,4404,O
However,4405,O
",",4405,O
no,4405,O
soluble,4405,O
ADH5,4405,B-GENE-Y
protein,4405,O
could,4405,O
be,4405,O
heterologously,4405,O
expressed,4405,O
in,4405,O
Escherichia,4405,O
coli,4405,O
cells,4405,O
with,4405,O
expression,4405,O
systems,4405,O
successfully,4405,O
used,4405,O
for,4405,O
other,4405,O
mammalian,4405,B-GENE-N
ADHs,4405,I-GENE-N
",",4405,O
including,4405,O
fused,4405,O
to,4405,O
glutathione-S-transferase,4405,B-CHEMICAL
.,4405,O
Molecular,4406,O
modelling,4406,O
of,4406,O
the,4406,O
enzyme,4406,O
indicated,4406,O
that,4406,O
the,4406,O
protein,4406,O
does,4406,O
not,4406,O
fold,4406,O
in,4406,O
a,4406,O
productive,4406,O
way,4406,O
",",4406,O
which,4406,O
can,4406,O
be,4406,O
the,4406,O
explanation,4406,O
why,4406,O
no,4406,O
stable,4406,O
and,4406,O
active,4406,O
ADH5,4406,B-GENE-Y
has,4406,O
been,4406,O
isolated,4406,O
.,4406,O
These,4407,O
results,4407,O
indicate,4407,O
that,4407,O
ADH5,4407,B-GENE-Y
",",4407,O
while,4407,O
readily,4407,O
expressed,4407,O
at,4407,O
the,4407,O
mRNA,4407,O
level,4407,O
",",4407,O
does,4407,O
not,4407,O
behave,4407,O
similarly,4407,O
to,4407,O
other,4407,O
mammalian,4407,B-GENE-N
ADHs,4407,I-GENE-N
investigated,4407,O
.,4407,O
The,4408,O
results,4408,O
",",4408,O
in,4408,O
vitro,4408,O
and,4408,O
in,4408,O
silico,4408,O
",",4408,O
suggest,4408,O
an,4408,O
unstable,4408,O
ADH5,4408,B-GENE-Y
structure,4408,O
",",4408,O
which,4408,O
can,4408,O
explain,4408,O
for,4408,O
why,4408,O
no,4408,O
active,4408,O
and,4408,O
stable,4408,O
protein,4408,O
can,4408,O
be,4408,O
isolated,4408,O
.,4408,O
Further,4409,O
possibilities,4409,O
are,4409,O
conceivable,4409,O
:,4409,O
the,4409,O
ADH5,4409,B-GENE-Y
protein,4409,O
may,4409,O
have,4409,O
to,4409,O
interact,4409,O
with,4409,O
a,4409,O
stabiliser,4409,O
",",4409,O
or,4409,O
the,4409,O
gene,4409,O
is,4409,O
actually,4409,O
a,4409,O
pseudogene,4409,O
.,4409,O
Combining,4410,O
quantum,4410,O
mechanical,4410,O
ligand,4410,O
conformation,4410,O
analysis,4410,O
and,4410,O
protein,4410,O
modeling,4410,O
to,4410,O
elucidate,4410,O
GPCR-ligand,4410,B-GENE-N
binding,4410,O
modes,4410,O
.,4410,O
SAR,4411,O
beyond,4411,O
protein-ligand,4411,O
interactions,4411,O
:,4411,O
By,4411,O
combining,4411,O
structure-affinity,4411,O
relationships,4411,O
",",4411,O
protein-ligand,4411,O
modeling,4411,O
studies,4411,O
",",4411,O
and,4411,O
quantum,4411,O
mechanical,4411,O
calculations,4411,O
",",4411,O
we,4411,O
show,4411,O
that,4411,O
ligand,4411,O
conformational,4411,O
energies,4411,O
and,4411,O
basicity,4411,O
play,4411,O
critical,4411,O
roles,4411,O
in,4411,O
ligand,4411,O
binding,4411,O
to,4411,O
the,4411,O
histamine,4411,B-GENE-Y
H4,4411,I-GENE-Y
receptor,4411,I-GENE-Y
",",4411,O
a,4411,O
GPCR,4411,B-GENE-N
that,4411,O
plays,4411,O
a,4411,O
key,4411,O
role,4411,O
in,4411,O
inflammation,4411,O
.,4411,O
Catalpol,4412,B-CHEMICAL
inhibits,4412,O
LPS,4412,O
plus,4412,O
IFN-γ-induced,4412,B-GENE-Y
inflammatory,4412,O
response,4412,O
in,4412,O
astrocytes,4412,O
primary,4412,O
cultures,4412,O
.,4412,O
A,4413,O
large,4413,O
body,4413,O
of,4413,O
evidence,4413,O
suggests,4413,O
that,4413,O
the,4413,O
inflammatory,4413,O
reaction,4413,O
plays,4413,O
an,4413,O
important,4413,O
role,4413,O
in,4413,O
the,4413,O
pathogenesis,4413,O
of,4413,O
neurodegenerative,4413,O
diseases,4413,O
.,4413,O
Our,4414,O
previous,4414,O
studies,4414,O
described,4414,O
the,4414,O
neuroprotective,4414,O
effects,4414,O
of,4414,O
catalpol,4414,B-CHEMICAL
in,4414,O
lipopolysaccharide,4414,O
(,4414,O
LPS,4414,O
),4414,O
-induced,4414,O
inflammatory,4414,O
models,4414,O
",",4414,O
in,4414,O
which,4414,O
catalpol,4414,B-CHEMICAL
was,4414,O
shown,4414,O
to,4414,O
prevent,4414,O
mesencephalic,4414,O
neuron,4414,O
death,4414,O
and,4414,O
ameliorate,4414,O
cognitive,4414,O
ability,4414,O
animals,4414,O
.,4414,O
To,4415,O
further,4415,O
investigate,4415,O
the,4415,O
protective,4415,O
effect,4415,O
and,4415,O
underlying,4415,O
mechanism,4415,O
of,4415,O
catalpol,4415,B-CHEMICAL
",",4415,O
astrocytes,4415,O
were,4415,O
pretreated,4415,O
with,4415,O
low,4415,O
(,4415,O
0.1mM,4415,O
),4415,O
and,4415,O
high,4415,O
dose,4415,O
(,4415,O
0.5mM,4415,O
),4415,O
catalpol,4415,B-CHEMICAL
for,4415,O
1h,4415,O
prior,4415,O
to,4415,O
LPS,4415,O
plus,4415,O
interferon-γ,4415,B-GENE-Y
stimulation,4415,O
.,4415,O
Biochemical,4416,O
analyses,4416,O
showed,4416,O
that,4416,O
NO,4416,B-CHEMICAL
and,4416,O
ROS,4416,O
production,4416,O
and,4416,O
iNOS,4416,B-GENE-Y
activity,4416,O
were,4416,O
significantly,4416,O
reduced,4416,O
by,4416,O
catalpol,4416,B-CHEMICAL
.,4416,O
Data,4417,O
at,4417,O
transcriptional,4417,O
level,4417,O
also,4417,O
demonstrated,4417,O
that,4417,O
catalpol,4417,B-CHEMICAL
potently,4417,O
attenuated,4417,O
gene,4417,O
expressions,4417,O
involved,4417,O
in,4417,O
inflammation,4417,O
",",4417,O
such,4417,O
as,4417,O
iNOS,4417,B-GENE-Y
",",4417,O
COX-2,4417,B-GENE-Y
and,4417,O
TLR4,4417,B-GENE-Y
.,4417,O
In,4418,O
addition,4418,O
",",4418,O
our,4418,O
exploration,4418,O
further,4418,O
revealed,4418,O
that,4418,O
the,4418,O
suppressive,4418,O
action,4418,O
of,4418,O
catalpol,4418,B-CHEMICAL
on,4418,O
inflammation,4418,O
was,4418,O
mediated,4418,O
via,4418,O
inhibiting,4418,O
nuclear,4418,B-GENE-N
factor-κB,4418,I-GENE-N
(,4418,O
NF-κB,4418,B-GENE-N
),4418,O
activation,4418,O
.,4418,O
Collectively,4419,O
",",4419,O
these,4419,O
results,4419,O
suggest,4419,O
that,4419,O
catalpol,4419,B-CHEMICAL
can,4419,O
exert,4419,O
inhibitory,4419,O
effects,4419,O
on,4419,O
the,4419,O
inflammatory,4419,O
reaction,4419,O
in,4419,O
astrocytes,4419,O
and,4419,O
that,4419,O
inactivation,4419,O
of,4419,O
NF-κB,4419,B-GENE-N
could,4419,O
be,4419,O
the,4419,O
major,4419,O
determinant,4419,O
for,4419,O
its,4419,O
anti-inflammatory,4419,O
mechanism,4419,O
.,4419,O
Therefore,4420,O
",",4420,O
catalpol,4420,B-CHEMICAL
may,4420,O
potentially,4420,O
be,4420,O
a,4420,O
highly,4420,O
effective,4420,O
therapeutic,4420,O
agent,4420,O
in,4420,O
treating,4420,O
neurodegenerative,4420,O
diseases,4420,O
associated,4420,O
with,4420,O
inflammation,4420,O
.,4420,O
Cardiolipin-dependent,4421,B-CHEMICAL
reconstitution,4421,O
of,4421,O
respiratory,4421,O
supercomplexes,4421,O
from,4421,O
purified,4421,O
Saccharomyces,4421,O
cerevisiae,4421,O
complexes,4421,O
III,4421,O
and,4421,O
IV,4421,O
.,4421,O
Here,4422,O
",",4422,O
we,4422,O
report,4422,O
for,4422,O
the,4422,O
first,4422,O
time,4422,O
in,4422,O
vitro,4422,O
reconstitution,4422,O
of,4422,O
the,4422,O
respiratory,4422,O
supercomplexes,4422,O
from,4422,O
individual,4422,O
complexes,4422,O
III,4422,O
and,4422,O
IV,4422,O
.,4422,O
Complexes,4423,O
III,4423,O
and,4423,O
IV,4423,O
were,4423,O
purified,4423,O
from,4423,O
Saccharomyces,4423,O
cerevisiae,4423,O
mitochondria,4423,O
.,4423,O
Complex,4424,O
III,4424,O
contained,4424,O
eight,4424,O
molecules,4424,O
of,4424,O
cardiolipin,4424,B-CHEMICAL
",",4424,O
and,4424,O
complex,4424,O
IV,4424,O
contained,4424,O
two,4424,O
molecules,4424,O
of,4424,O
cardiolipin,4424,B-CHEMICAL
",",4424,O
as,4424,O
determined,4424,O
by,4424,O
electrospray,4424,O
ionization-mass,4424,O
spectrometry,4424,O
.,4424,O
Complex,4425,O
IV,4425,O
also,4425,O
contained,4425,O
Rcf1p,4425,B-GENE-Y
.,4425,O
No,4426,O
supercomplexes,4426,O
were,4426,O
formed,4426,O
upon,4426,O
mixing,4426,O
of,4426,O
the,4426,O
purified,4426,O
complexes,4426,O
",",4426,O
and,4426,O
low,4426,O
amounts,4426,O
of,4426,O
the,4426,O
supercomplex,4426,O
trimer,4426,O
III,4426,O
(,4426,O
2,4426,O
),4426,O
IV,4426,O
(,4426,O
1,4426,O
),4426,O
were,4426,O
formed,4426,O
after,4426,O
reconstitution,4426,O
into,4426,O
proteoliposomes,4426,O
containing,4426,O
only,4426,O
phosphatidylcholine,4426,B-CHEMICAL
and,4426,O
phosphatidylethanolamine,4426,B-CHEMICAL
.,4426,O
Further,4427,O
addition,4427,O
of,4427,O
cardiolipin,4427,O
to,4427,O
the,4427,O
proteoliposome,4427,O
reconstitution,4427,O
mixture,4427,O
resulted,4427,O
in,4427,O
distinct,4427,O
formation,4427,O
of,4427,O
both,4427,O
the,4427,O
III,4427,O
(,4427,O
2,4427,O
),4427,O
IV,4427,O
(,4427,O
1,4427,O
),4427,O
supercomplex,4427,O
trimer,4427,O
and,4427,O
III,4427,O
(,4427,O
2,4427,O
),4427,O
IV,4427,O
(,4427,O
2,4427,O
),4427,O
supercomplex,4427,O
tetramer,4427,O
.,4427,O
No,4428,O
other,4428,O
anionic,4428,O
phospholipid,4428,O
was,4428,O
as,4428,O
effective,4428,O
as,4428,O
cardiolipin,4428,B-CHEMICAL
in,4428,O
supporting,4428,O
tetramer,4428,O
formation,4428,O
.,4428,O
Phospholipase,4429,B-GENE-N
treatment,4429,O
of,4429,O
complex,4429,O
IV,4429,O
prevented,4429,O
trimer,4429,O
formation,4429,O
in,4429,O
the,4429,O
absence,4429,O
of,4429,O
cardiolipin,4429,B-CHEMICAL
.,4429,O
Both,4430,O
trimer,4430,O
and,4430,O
tetramer,4430,O
formations,4430,O
were,4430,O
restored,4430,O
by,4430,O
cardiolipin,4430,B-CHEMICAL
.,4430,O
Analysis,4431,O
of,4431,O
the,4431,O
reconstituted,4431,O
tetramer,4431,O
by,4431,O
single,4431,O
particle,4431,O
electron,4431,O
microscopy,4431,O
confirmed,4431,O
native,4431,O
organization,4431,O
of,4431,O
individual,4431,O
complexes,4431,O
within,4431,O
the,4431,O
supercomplex,4431,O
.,4431,O
In,4432,O
conclusion,4432,O
",",4432,O
although,4432,O
some,4432,O
trimer,4432,O
formation,4432,O
occurred,4432,O
dependent,4432,O
only,4432,O
on,4432,O
tightly,4432,O
bound,4432,O
cardiolipin,4432,B-CHEMICAL
",",4432,O
tetramer,4432,O
formation,4432,O
required,4432,O
additional,4432,O
cardiolipin,4432,B-CHEMICAL
.,4432,O
This,4433,O
is,4433,O
consistent,4433,O
with,4433,O
the,4433,O
high,4433,O
cardiolipin,4433,B-CHEMICAL
content,4433,O
in,4433,O
the,4433,O
native,4433,O
tetramer,4433,O
.,4433,O
The,4434,O
dependence,4434,O
on,4434,O
cardiolipin,4434,B-CHEMICAL
for,4434,O
supercomplex,4434,O
formation,4434,O
suggests,4434,O
that,4434,O
changes,4434,O
in,4434,O
cardiolipin,4434,B-CHEMICAL
levels,4434,O
resulting,4434,O
from,4434,O
changes,4434,O
in,4434,O
physiological,4434,O
conditions,4434,O
may,4434,O
control,4434,O
the,4434,O
equilibrium,4434,O
between,4434,O
individual,4434,O
respiratory,4434,O
complexes,4434,O
and,4434,O
supercomplexes,4434,O
in,4434,O
vivo,4434,O
.,4434,O
Protein,4435,B-GENE-Y
tyrosine,4435,B-CHEMICAL
phosphatase,4435,I-GENE-Y
1B,4435,I-GENE-Y
inhibitory,4435,O
effect,4435,O
by,4435,O
dammarane-type,4435,B-CHEMICAL
triterpenes,4435,B-CHEMICAL
from,4435,O
hydrolyzate,4435,O
of,4435,O
total,4435,O
Gynostemma,4435,O
pentaphyllum,4435,O
saponins,4435,B-CHEMICAL
.,4435,O
Protein,4436,B-GENE-Y
tyrosine,4436,I-GENE-Y
phosphatase,4436,I-GENE-Y
1B,4436,I-GENE-Y
(,4436,O
PTP1B,4436,B-GENE-Y
),4436,O
is,4436,O
an,4436,O
important,4436,O
factor,4436,O
in,4436,O
non-insulin-dependent,4436,O
diabetes,4436,O
mellitus,4436,O
(,4436,O
type-2,4436,O
diabetes,4436,O
),4436,O
",",4436,O
and,4436,O
a,4436,O
promising,4436,O
target,4436,O
for,4436,O
treatment,4436,O
of,4436,O
diabetes,4436,O
and,4436,O
obesity,4436,O
.,4436,O
Therefore,4437,O
",",4437,O
the,4437,O
aim,4437,O
of,4437,O
this,4437,O
study,4437,O
is,4437,O
to,4437,O
investigate,4437,O
the,4437,O
inhibitory,4437,O
activities,4437,O
of,4437,O
constituents,4437,O
(,4437,O
three,4437,O
new,4437,O
together,4437,O
with,4437,O
twelve,4437,O
known,4437,O
triterpenes,4437,B-CHEMICAL
compounds,4437,O
),4437,O
isolated,4437,O
from,4437,O
the,4437,O
hydrolyzate,4437,O
of,4437,O
total,4437,O
saponins,4437,B-CHEMICAL
from,4437,O
Gynostemma,4437,O
pentaphyllum,4437,O
.,4437,O
Their,4438,O
structures,4438,O
were,4438,O
accomplished,4438,O
mainly,4438,O
base,4438,O
on,4438,O
the,4438,O
spectroscopic,4438,O
methods,4438,O
",",4438,O
and,4438,O
then,4438,O
were,4438,O
further,4438,O
confirmed,4438,O
by,4438,O
X-ray,4438,O
crystal,4438,O
diffraction,4438,O
.,4438,O
All,4439,O
the,4439,O
compounds,4439,O
were,4439,O
evaluated,4439,O
for,4439,O
inhibitory,4439,O
activity,4439,O
against,4439,O
PTP1B,4439,B-GENE-Y
.,4439,O
Current,4440,O
data,4440,O
suggested,4440,O
that,4440,O
the,4440,O
compounds,4440,O
1,4440,O
",",4440,O
3,4440,O
",",4440,O
12,4440,O
",",4440,O
13,4440,O
and,4440,O
14,4440,O
were,4440,O
considered,4440,O
to,4440,O
be,4440,O
potential,4440,O
as,4440,O
antidiabetic,4440,O
agents,4440,O
",",4440,O
in,4440,O
which,4440,O
they,4440,O
could,4440,O
significantly,4440,O
inhibit,4440,O
the,4440,O
PTP1B,4440,B-GENE-Y
enzyme,4440,O
activity,4440,O
in,4440,O
a,4440,O
dose-dependent,4440,O
manner,4440,O
.,4440,O
Disrupted,4441,O
cytoskeletal,4441,O
homeostasis,4441,O
",",4441,O
astrogliosis,4441,O
and,4441,O
apoptotic,4441,O
cell,4441,O
death,4441,O
in,4441,O
the,4441,O
cerebellum,4441,O
of,4441,O
preweaning,4441,O
rats,4441,O
injected,4441,O
with,4441,O
diphenyl,4441,B-CHEMICAL
ditelluride,4441,I-CHEMICAL
.,4441,O
In,4442,O
the,4442,O
present,4442,O
report,4442,O
15,4442,O
day-old,4442,O
rats,4442,O
were,4442,O
injected,4442,O
with,4442,O
0.3μmol,4442,O
of,4442,O
diphenyl,4442,B-CHEMICAL
ditelluride,4442,I-CHEMICAL
(,4442,B-CHEMICAL
PhTe,4442,I-CHEMICAL
),4442,I-CHEMICAL
(,4442,I-CHEMICAL
2,4442,I-CHEMICAL
),4442,I-CHEMICAL
/kg,4442,O
body,4442,O
weight,4442,O
and,4442,O
parameters,4442,O
of,4442,O
neurodegeneration,4442,O
were,4442,O
analyzed,4442,O
in,4442,O
slices,4442,O
from,4442,O
cerebellum,4442,O
3,4442,O
and,4442,O
6,4442,O
days,4442,O
afterwards,4442,O
.,4442,O
The,4443,O
earlier,4443,O
responses,4443,O
",",4443,O
at,4443,O
day,4443,O
3,4443,O
after,4443,O
injection,4443,O
",",4443,O
included,4443,O
hyperphosphorylation,4443,O
of,4443,O
intermediate,4443,O
filament,4443,O
(,4443,O
IF,4443,O
),4443,O
proteins,4443,O
from,4443,O
astrocyte,4443,O
(,4443,O
glial,4443,B-GENE-Y
fibrillary,4443,I-GENE-Y
acidic,4443,I-GENE-Y
protein,4443,I-GENE-Y
-,4443,O
GFAP,4443,B-GENE-Y
-,4443,O
and,4443,O
vimentin,4443,B-GENE-Y
),4443,O
and,4443,O
neuron,4443,O
(,4443,O
low-,4443,B-GENE-N
",",4443,I-GENE-N
medium-,4443,I-GENE-N
and,4443,I-GENE-N
high,4443,I-GENE-N
molecular,4443,I-GENE-N
weight,4443,I-GENE-N
neurofilament,4443,I-GENE-N
subunits,4443,I-GENE-N
:,4443,O
NF-L,4443,B-GENE-Y
",",4443,O
NF-M,4443,B-GENE-Y
and,4443,O
NF-H,4443,B-GENE-Y
),4443,O
;,4443,O
increased,4443,O
mitogen-activated,4443,B-GENE-N
protein,4443,I-GENE-N
kinase,4443,I-GENE-N
(,4443,O
MAPK,4443,B-GENE-N
),4443,O
(,4443,O
Erk,4443,B-GENE-N
and,4443,O
p38MAPK,4443,B-GENE-N
),4443,O
and,4443,O
cAMP-dependent,4443,B-CHEMICAL
protein,4443,I-GENE-N
kinase,4443,I-GENE-N
(,4443,O
PKA,4443,B-GENE-N
),4443,O
activities,4443,O
.,4443,O
Also,4444,O
",",4444,O
reactive,4444,O
astrogliosis,4444,O
takes,4444,O
part,4444,O
of,4444,O
the,4444,O
early,4444,O
responses,4444,O
to,4444,O
the,4444,O
insult,4444,O
with,4444,O
(,4444,B-CHEMICAL
PhTe,4444,I-CHEMICAL
),4444,I-CHEMICAL
(,4444,I-CHEMICAL
2,4444,I-CHEMICAL
),4444,I-CHEMICAL
",",4444,O
evidenced,4444,O
by,4444,O
upregulated,4444,O
GFAP,4444,B-GENE-Y
in,4444,O
Western,4444,O
blot,4444,O
",",4444,O
PCR,4444,O
and,4444,O
immunofluorescence,4444,O
analysis,4444,O
.,4444,O
Six,4445,O
days,4445,O
after,4445,O
(,4445,B-CHEMICAL
PhTe,4445,I-CHEMICAL
),4445,I-CHEMICAL
(,4445,I-CHEMICAL
2,4445,I-CHEMICAL
),4445,I-CHEMICAL
injection,4445,O
we,4445,O
found,4445,O
persistent,4445,O
astrogliosis,4445,O
",",4445,O
increased,4445,O
propidium,4445,B-CHEMICAL
iodide,4445,I-CHEMICAL
(,4445,O
PI,4445,O
),4445,O
positive,4445,O
cells,4445,O
in,4445,O
NeuN,4445,B-GENE-Y
positive,4445,O
population,4445,O
evidenced,4445,O
by,4445,O
flow,4445,O
cytometry,4445,O
and,4445,O
reduced,4445,O
immunofluorescence,4445,O
for,4445,O
NeuN,4445,B-GENE-Y
",",4445,O
suggesting,4445,O
that,4445,O
the,4445,O
in,4445,O
vivo,4445,O
exposure,4445,O
to,4445,O
(,4445,B-CHEMICAL
PhTe,4445,I-CHEMICAL
),4445,I-CHEMICAL
(,4445,I-CHEMICAL
2,4445,I-CHEMICAL
),4445,I-CHEMICAL
progressed,4445,O
to,4445,O
neuronal,4445,O
death,4445,O
.,4445,O
Moreover,4446,O
",",4446,O
activated,4446,O
caspase,4446,B-GENE-Y
3,4446,I-GENE-Y
suggested,4446,O
apoptotic,4446,O
neuronal,4446,O
death,4446,O
.,4446,O
Neurodegeneration,4447,O
was,4447,O
related,4447,O
with,4447,O
decreased,4447,O
[,4447,B-CHEMICAL
(,4447,I-CHEMICAL
3,4447,I-CHEMICAL
),4447,I-CHEMICAL
H,4447,I-CHEMICAL
],4447,I-CHEMICAL
glutamate,4447,I-CHEMICAL
uptake,4447,O
and,4447,O
decreased,4447,O
Akt,4447,B-GENE-N
immunoreactivity,4447,O
",",4447,O
however,4447,O
phospho-GSK-3-β,4447,B-GENE-Y
(,4447,O
Ser9,4447,B-CHEMICAL
),4447,O
was,4447,O
not,4447,O
altered,4447,O
in,4447,O
(,4447,B-CHEMICAL
PhTe,4447,I-CHEMICAL
),4447,I-CHEMICAL
(,4447,I-CHEMICAL
2,4447,I-CHEMICAL
),4447,I-CHEMICAL
injected,4447,O
rat,4447,O
.,4447,O
Therefore,4448,O
",",4448,O
the,4448,O
present,4448,O
results,4448,O
show,4448,O
that,4448,O
the,4448,O
earlier,4448,O
cerebellar,4448,O
responses,4448,O
to,4448,O
(,4448,B-CHEMICAL
PhTe,4448,I-CHEMICAL
),4448,I-CHEMICAL
(,4448,I-CHEMICAL
2,4448,I-CHEMICAL
),4448,I-CHEMICAL
include,4448,O
disruption,4448,O
of,4448,O
cytoskeletal,4448,O
homeostasis,4448,O
that,4448,O
could,4448,O
be,4448,O
related,4448,O
with,4448,O
MAPK,4448,B-GENE-N
and,4448,O
PKA,4448,B-GENE-N
activation,4448,O
and,4448,O
reactive,4448,O
astrogliosis,4448,O
.,4448,O
Akt,4449,B-GENE-N
inhibition,4449,O
observed,4449,O
at,4449,O
this,4449,O
time,4449,O
could,4449,O
also,4449,O
play,4449,O
a,4449,O
role,4449,O
in,4449,O
the,4449,O
neuronal,4449,O
death,4449,O
evidenced,4449,O
afterwards,4449,O
.,4449,O
The,4450,O
later,4450,O
events,4450,O
of,4450,O
the,4450,O
neurodegenerative,4450,O
process,4450,O
are,4450,O
characterized,4450,O
by,4450,O
persistent,4450,O
astrogliosis,4450,O
and,4450,O
activation,4450,O
of,4450,O
apoptotic,4450,O
neuronal,4450,O
death,4450,O
through,4450,O
caspase,4450,B-GENE-Y
3,4450,I-GENE-Y
mediated,4450,O
mechanisms,4450,O
",",4450,O
which,4450,O
could,4450,O
be,4450,O
related,4450,O
with,4450,O
glutamate,4450,B-CHEMICAL
excitotoxicity,4450,O
.,4450,O
The,4451,O
progression,4451,O
of,4451,O
these,4451,O
responses,4451,O
are,4451,O
therefore,4451,O
likely,4451,O
to,4451,O
be,4451,O
critical,4451,O
for,4451,O
the,4451,O
outcome,4451,O
of,4451,O
the,4451,O
neurodegeneration,4451,O
provoked,4451,O
by,4451,O
(,4451,B-CHEMICAL
PhTe,4451,I-CHEMICAL
),4451,I-CHEMICAL
(,4451,I-CHEMICAL
2,4451,I-CHEMICAL
),4451,I-CHEMICAL
in,4451,O
rat,4451,O
cerebellum,4451,O
.,4451,O
The,4452,O
presence,4452,O
of,4452,O
D-fagomine,4452,B-CHEMICAL
in,4452,O
the,4452,O
human,4452,O
diet,4452,O
from,4452,O
buckwheat-based,4452,O
foodstuffs,4452,O
.,4452,O
Buckwheat,4453,O
(,4453,O
Fagopyrum,4453,O
esculentum,4453,O
Moench,4453,O
),4453,O
groats,4453,O
contain,4453,O
the,4453,O
iminosugar,4453,O
D-fagomine,4453,B-CHEMICAL
as,4453,O
a,4453,O
minor,4453,O
component,4453,O
that,4453,O
might,4453,O
contribute,4453,O
to,4453,O
the,4453,O
alleged,4453,O
health,4453,O
benefits,4453,O
of,4453,O
this,4453,O
pseudo-cereal,4453,O
.,4453,O
This,4454,O
study,4454,O
presents,4454,O
analysis,4454,O
of,4454,O
D-fagomine,4454,B-CHEMICAL
in,4454,O
buckwheat-based,4454,O
foodstuffs,4454,O
by,4454,O
liquid,4454,O
chromatography,4454,O
coupled,4454,O
to,4454,O
mass,4454,O
spectrometry,4454,O
and,4454,O
an,4454,O
estimation,4454,O
of,4454,O
its,4454,O
presence,4454,O
in,4454,O
the,4454,O
human,4454,O
diet,4454,O
based,4454,O
on,4454,O
a,4454,O
published,4454,O
population-based,4454,O
cross-sectional,4454,O
nutrition,4454,O
survey,4454,O
.,4454,O
D-fagomine,4455,B-CHEMICAL
is,4455,O
present,4455,O
in,4455,O
common,4455,O
buckwheat-based,4455,O
foodstuffs,4455,O
in,4455,O
amounts,4455,O
ranging,4455,O
from,4455,O
1,4455,O
to,4455,O
25,4455,O
mg/kg,4455,O
or,4455,O
mg/L,4455,O
",",4455,O
it,4455,O
is,4455,O
stable,4455,O
during,4455,O
boiling,4455,O
",",4455,O
baking,4455,O
",",4455,O
frying,4455,O
and,4455,O
fermentation,4455,O
",",4455,O
and,4455,O
it,4455,O
is,4455,O
biosynthesised,4455,O
upon,4455,O
sprouting,4455,O
.,4455,O
The,4456,O
estimated,4456,O
total,4456,O
intake,4456,O
of,4456,O
D-fagomine,4456,B-CHEMICAL
resulting,4456,O
from,4456,O
a,4456,O
diet,4456,O
that,4456,O
includes,4456,O
such,4456,O
foodstuffs,4456,O
would,4456,O
be,4456,O
between,4456,O
3,4456,O
and,4456,O
17,4456,O
mg,4456,O
per,4456,O
day,4456,O
(,4456,O
mean,4456,O
for,4456,O
both,4456,O
genders,4456,O
;,4456,O
range,4456,O
from,4456,O
P5,4456,O
to,4456,O
P95,4456,O
),4456,O
.,4456,O
A,4457,O
diet,4457,O
rich,4457,O
in,4457,O
buckwheat,4457,O
products,4457,O
would,4457,O
provide,4457,O
a,4457,O
daily,4457,O
amount,4457,O
of,4457,O
D-fagomine,4457,B-CHEMICAL
that,4457,O
may,4457,O
in,4457,O
part,4457,O
explain,4457,O
the,4457,O
beneficial,4457,O
properties,4457,O
traditionally,4457,O
attributed,4457,O
to,4457,O
buckwheat,4457,O
consumption,4457,O
.,4457,O
Profluorogenic,4458,O
reductase,4458,O
substrate,4458,O
for,4458,O
rapid,4458,O
",",4458,O
selective,4458,O
",",4458,O
and,4458,O
sensitive,4458,O
visualization,4458,O
and,4458,O
detection,4458,O
of,4458,O
human,4458,O
cancer,4458,O
cells,4458,O
that,4458,O
overexpress,4458,O
NQO1,4458,B-GENE-Y
.,4458,O
Achieving,4459,O
the,4459,O
vision,4459,O
of,4459,O
identifying,4459,O
and,4459,O
quantifying,4459,O
cancer-related,4459,O
events,4459,O
and,4459,O
targets,4459,O
for,4459,O
future,4459,O
personalized,4459,O
oncology,4459,O
is,4459,O
predicated,4459,O
on,4459,O
the,4459,O
existence,4459,O
of,4459,O
synthetically,4459,O
accessible,4459,O
and,4459,O
economically,4459,O
viable,4459,O
probe,4459,O
molecules,4459,O
fully,4459,O
able,4459,O
to,4459,O
report,4459,O
the,4459,O
presence,4459,O
of,4459,O
these,4459,O
events,4459,O
and,4459,O
targets,4459,O
in,4459,O
a,4459,O
rapid,4459,O
and,4459,O
highly,4459,O
selective,4459,O
and,4459,O
sensitive,4459,O
fashion,4459,O
.,4459,O
Delineated,4460,O
here,4460,O
are,4460,O
the,4460,O
design,4460,O
and,4460,O
evaluation,4460,O
of,4460,O
a,4460,O
newly,4460,O
synthesized,4460,O
turn-on,4460,O
probe,4460,O
whose,4460,O
intense,4460,O
fluorescent,4460,O
reporter,4460,O
signature,4460,O
is,4460,O
revealed,4460,O
only,4460,O
through,4460,O
probe,4460,O
activation,4460,O
by,4460,O
a,4460,O
specific,4460,O
intracellular,4460,O
enzyme,4460,O
present,4460,O
in,4460,O
tumor,4460,O
cells,4460,O
of,4460,O
multiple,4460,O
origins,4460,O
.,4460,O
Quenching,4461,O
of,4461,O
molecular,4461,O
probe,4461,O
fluorescence,4461,O
is,4461,O
achieved,4461,O
through,4461,O
unique,4461,O
photoinduced,4461,O
electron,4461,O
transfer,4461,O
between,4461,O
the,4461,O
naphthalimide,4461,B-CHEMICAL
dye,4461,O
reporter,4461,O
and,4461,O
a,4461,O
covalently,4461,O
attached,4461,O
",",4461,O
quinone-based,4461,B-CHEMICAL
enzyme,4461,O
substrate,4461,O
.,4461,O
Fluorescence,4462,O
of,4462,O
the,4462,O
reporter,4462,O
dye,4462,O
is,4462,O
turned,4462,O
on,4462,O
by,4462,O
rapid,4462,O
removal,4462,O
of,4462,O
the,4462,O
quinone,4462,B-CHEMICAL
quencher,4462,O
",",4462,O
an,4462,O
event,4462,O
that,4462,O
immediately,4462,O
occurs,4462,O
only,4462,O
after,4462,O
highly,4462,O
selective,4462,O
",",4462,O
two-electron,4462,O
reduction,4462,O
of,4462,O
the,4462,O
sterically,4462,O
and,4462,O
conformationally,4462,O
restricted,4462,O
quinone,4462,B-CHEMICAL
substrate,4462,O
by,4462,O
the,4462,O
cancer-associated,4462,O
human,4462,B-GENE-Y
NAD,4462,I-GENE-Y
(,4462,I-GENE-Y
P,4462,I-GENE-Y
),4462,I-GENE-Y
H,4462,I-GENE-Y
:,4462,I-GENE-Y
quinone,4462,I-GENE-Y
oxidoreductase,4462,I-GENE-Y
isozyme,4462,I-GENE-Y
1,4462,I-GENE-Y
(,4462,O
hNQO1,4462,B-GENE-Y
),4462,O
.,4462,O
Successes,4463,O
of,4463,O
the,4463,O
approach,4463,O
include,4463,O
rapid,4463,O
differentiation,4463,O
of,4463,O
NQO1-expressing,4463,B-GENE-Y
and,4463,O
-nonexpressing,4463,O
cancer,4463,O
cell,4463,O
lines,4463,O
via,4463,O
the,4463,O
unaided,4463,O
eye,4463,O
",",4463,O
flow,4463,O
cytometry,4463,O
",",4463,O
fluorescence,4463,O
imaging,4463,O
",",4463,O
and,4463,O
two-photon,4463,O
microscopy,4463,O
.,4463,O
The,4464,O
potential,4464,O
for,4464,O
use,4464,O
of,4464,O
the,4464,O
turn-on,4464,O
probe,4464,O
in,4464,O
longer-term,4464,O
cellular,4464,O
studies,4464,O
is,4464,O
indicated,4464,O
by,4464,O
its,4464,O
lack,4464,O
of,4464,O
influence,4464,O
on,4464,O
cell,4464,O
viability,4464,O
and,4464,O
its,4464,O
in,4464,O
vitro,4464,O
stability,4464,O
.,4464,O
Synthesis,4465,O
",",4465,O
biological,4465,O
evaluation,4465,O
",",4465,O
and,4465,O
molecular,4465,O
modeling,4465,O
of,4465,O
glycyrrhizin,4465,B-CHEMICAL
derivatives,4465,O
as,4465,O
potent,4465,O
high-mobility,4465,B-GENE-Y
group,4465,I-GENE-Y
box-1,4465,I-GENE-Y
inhibitors,4465,O
with,4465,O
anti-heart-failure,4465,O
activity,4465,O
in,4465,O
vivo,4465,O
.,4465,O
Novel,4466,O
glycyrrhizin,4466,B-CHEMICAL
(,4466,O
GL,4466,O
),4466,O
derivatives,4466,O
were,4466,O
designed,4466,O
and,4466,O
synthesized,4466,O
by,4466,O
introducing,4466,O
various,4466,O
amine,4466,B-CHEMICAL
or,4466,O
amino,4466,B-CHEMICAL
acid,4466,I-CHEMICAL
residues,4466,O
into,4466,O
the,4466,O
carbohydrate,4466,B-CHEMICAL
chain,4466,O
and,4466,O
at,4466,O
C-30,4466,O
.,4466,O
Their,4467,O
inhibitory,4467,O
effects,4467,O
on,4467,O
high-mobility,4467,B-GENE-Y
group,4467,I-GENE-Y
box,4467,I-GENE-Y
1,4467,I-GENE-Y
(,4467,O
HMGB1,4467,B-GENE-Y
),4467,O
were,4467,O
evaluated,4467,O
using,4467,O
a,4467,O
cell-based,4467,O
lipopolysaccharide,4467,O
(,4467,O
LPS,4467,O
),4467,O
induced,4467,O
tumor,4467,B-GENE-Y
necrosis,4467,I-GENE-Y
factor,4467,I-GENE-Y
α,4467,I-GENE-Y
(,4467,O
TNF-α,4467,B-GENE-Y
),4467,O
release,4467,O
study,4467,O
.,4467,O
Compounds,4468,O
10,4468,O
",",4468,O
12,4468,O
",",4468,O
18-20,4468,O
",",4468,O
23,4468,O
",",4468,O
and,4468,O
24,4468,O
",",4468,O
which,4468,O
had,4468,O
substituents,4468,O
introduced,4468,O
at,4468,O
C-30,4468,O
",",4468,O
demonstrated,4468,O
moderate,4468,O
HMGB1,4468,B-GENE-Y
inhibition,4468,O
with,4468,O
ED₅₀,4468,O
values,4468,O
ranging,4468,O
from,4468,O
337,4468,O
to,4468,O
141,4468,O
μM,4468,O
",",4468,O
which,4468,O
are,4468,O
values,4468,O
comparable,4468,O
to,4468,O
that,4468,O
of,4468,O
the,4468,O
leading,4468,O
GL,4468,O
compound,4468,O
(,4468,O
1,4468,O
),4468,O
(,4468,O
ED₅₀,4468,O
=,4468,O
70,4468,O
μM,4468,O
),4468,O
.,4468,O
Compounds,4469,O
23,4469,O
and,4469,O
24,4469,O
emerged,4469,O
as,4469,O
novel,4469,O
and,4469,O
interesting,4469,O
HMGB1,4469,B-GENE-Y
inhibitors,4469,O
.,4469,O
These,4470,O
compounds,4470,O
were,4470,O
able,4470,O
to,4470,O
extend,4470,O
the,4470,O
survival,4470,O
of,4470,O
mice,4470,O
with,4470,O
chronic,4470,O
heart,4470,O
failure,4470,O
(,4470,O
CHF,4470,O
),4470,O
and,4470,O
acute,4470,O
heart,4470,O
failure,4470,O
(,4470,O
AHF,4470,O
),4470,O
",",4470,O
respectively,4470,O
.,4470,O
In,4471,O
addition,4471,O
",",4471,O
molecular,4471,O
modeling,4471,O
studies,4471,O
were,4471,O
performed,4471,O
to,4471,O
support,4471,O
the,4471,O
biological,4471,O
data,4471,O
.,4471,O
Further,4472,O
exploration,4472,O
of,4472,O
M₁,4472,O
allosteric,4472,O
agonists,4472,O
:,4472,O
subtle,4472,O
structural,4472,O
changes,4472,O
abolish,4472,O
M₁,4472,O
allosteric,4472,O
agonism,4472,O
and,4472,O
result,4472,O
in,4472,O
pan-mAChR,4472,O
orthosteric,4472,O
antagonism,4472,O
.,4472,O
This,4473,O
letter,4473,O
describes,4473,O
the,4473,O
further,4473,O
exploration,4473,O
of,4473,O
two,4473,O
series,4473,O
of,4473,O
M,4473,O
(,4473,O
1,4473,O
),4473,O
allosteric,4473,O
agonists,4473,O
",",4473,O
TBPB,4473,B-CHEMICAL
and,4473,O
VU0357017,4473,B-CHEMICAL
",",4473,O
previously,4473,O
reported,4473,O
from,4473,O
our,4473,O
lab,4473,O
.,4473,O
Within,4474,O
the,4474,O
TPBP,4474,B-CHEMICAL
scaffold,4474,O
",",4474,O
either,4474,O
electronic,4474,O
or,4474,O
steric,4474,O
perturbations,4474,O
to,4474,O
the,4474,O
central,4474,O
piperidine,4474,B-CHEMICAL
ring,4474,O
led,4474,O
to,4474,O
a,4474,O
loss,4474,O
of,4474,O
selective,4474,O
M,4474,O
(,4474,O
1,4474,O
),4474,O
allosteric,4474,O
agonism,4474,O
and,4474,O
afforded,4474,O
pan-mAChR,4474,O
antagonism,4474,O
",",4474,O
which,4474,O
was,4474,O
demonstrated,4474,O
to,4474,O
be,4474,O
mediated,4474,O
via,4474,O
the,4474,O
orthosteric,4474,O
site,4474,O
.,4474,O
Additional,4475,O
SAR,4475,O
around,4475,O
a,4475,O
related,4475,O
M,4475,O
(,4475,O
1,4475,O
),4475,O
allosteric,4475,O
agonist,4475,O
family,4475,O
(,4475,O
VU0357017,4475,B-CHEMICAL
),4475,O
identified,4475,O
similar,4475,O
",",4475,O
subtle,4475,O
'molecular,4475,O
switches,4475,O
',4475,O
that,4475,O
modulated,4475,O
modes,4475,O
of,4475,O
pharmacology,4475,O
from,4475,O
allosteric,4475,O
agonism,4475,O
to,4475,O
pan-mAChR,4475,O
orthosteric,4475,O
antagonism,4475,O
.,4475,O
Therefore,4476,O
",",4476,O
all,4476,O
of,4476,O
these,4476,O
ligands,4476,O
are,4476,O
best,4476,O
classified,4476,O
as,4476,O
bi-topic,4476,O
ligands,4476,O
that,4476,O
possess,4476,O
high,4476,O
affinity,4476,O
binding,4476,O
at,4476,O
an,4476,O
allosteric,4476,O
site,4476,O
to,4476,O
engender,4476,O
selective,4476,O
M,4476,O
(,4476,O
1,4476,O
),4476,O
activation,4476,O
",",4476,O
but,4476,O
all,4476,O
bind,4476,O
",",4476,O
at,4476,O
higher,4476,O
concentrations,4476,O
",",4476,O
to,4476,O
the,4476,O
orthosteric,4476,O
ACh,4476,O
site,4476,O
",",4476,O
leading,4476,O
to,4476,O
non-selective,4476,O
orthosteric,4476,O
site,4476,O
binding,4476,O
and,4476,O
mAChR,4476,B-GENE-N
antagonism,4476,O
.,4476,O
Effects,4477,O
of,4477,O
single,4477,O
or,4477,O
repeated,4477,O
silymarin,4477,O
administration,4477,O
on,4477,O
pharmacokinetics,4477,O
of,4477,O
risperidone,4477,B-CHEMICAL
and,4477,O
its,4477,O
major,4477,O
metabolite,4477,O
",",4477,O
9-hydroxyrisperidone,4477,B-CHEMICAL
in,4477,O
rats,4477,O
.,4477,O
1,4478,O
.,4478,O
The,4479,O
interactions,4479,O
between,4479,O
herbal,4479,O
dietary,4479,O
supplements,4479,O
and,4479,O
therapeutic,4479,O
drugs,4479,O
have,4479,O
emerged,4479,O
as,4479,O
an,4479,O
important,4479,O
issue,4479,O
and,4479,O
P-glycoprotein,4479,B-GENE-Y
(,4479,O
P-gp,4479,B-GENE-Y
),4479,O
has,4479,O
been,4479,O
reported,4479,O
as,4479,O
one,4479,O
of,4479,O
the,4479,O
significant,4479,O
factors,4479,O
of,4479,O
these,4479,O
interactions,4479,O
.,4479,O
2,4480,O
.,4480,O
The,4481,O
objective,4481,O
of,4481,O
this,4481,O
article,4481,O
is,4481,O
to,4481,O
examine,4481,O
the,4481,O
effects,4481,O
of,4481,O
single,4481,O
and,4481,O
repeated,4481,O
administrations,4481,O
of,4481,O
silymarin,4481,O
on,4481,O
pharmacokinetics,4481,O
of,4481,O
a,4481,O
P-gp,4481,B-GENE-Y
substrate,4481,O
",",4481,O
risperidone,4481,B-CHEMICAL
",",4481,O
and,4481,O
its,4481,O
major,4481,O
metabolite,4481,O
",",4481,O
9-hydroxyrisperidone,4481,B-CHEMICAL
",",4481,O
in,4481,O
rats,4481,O
.,4481,O
3,4482,O
.,4482,O
To,4483,O
determine,4483,O
the,4483,O
plasma,4483,O
levels,4483,O
of,4483,O
risperidone,4483,B-CHEMICAL
and,4483,O
9-hydroxyrisperidone,4483,B-CHEMICAL
in,4483,O
rats,4483,O
",",4483,O
a,4483,O
HPLC,4483,O
method,4483,O
was,4483,O
developed,4483,O
using,4483,O
a,4483,O
liquid-liquid,4483,O
acid,4483,O
back,4483,O
extraction,4483,O
.,4483,O
When,4484,O
risperidone,4484,B-CHEMICAL
(,4484,O
6,4484,O
mg/kg,4484,O
),4484,O
was,4484,O
co-administered,4484,O
with,4484,O
silymarin,4484,O
(,4484,O
40,4484,O
mg/kg,4484,O
),4484,O
to,4484,O
rats,4484,O
orally,4484,O
",",4484,O
the,4484,O
C,4484,O
(,4484,O
max,4484,O
),4484,O
of,4484,O
9-hydroxyrisperidone,4484,B-CHEMICAL
was,4484,O
significantly,4484,O
increased,4484,O
to1.3-fold,4484,O
(,4484,O
p,4484,O
<,4484,O
0.05,4484,O
),4484,O
",",4484,O
while,4484,O
the,4484,O
other,4484,O
pharmacokinetic,4484,O
parameters,4484,O
did,4484,O
not,4484,O
show,4484,O
any,4484,O
significant,4484,O
differences,4484,O
.,4484,O
Expanding,4485,O
the,4485,O
experiment,4485,O
where,4485,O
rats,4485,O
were,4485,O
repeatedly,4485,O
administered,4485,O
with,4485,O
silymarin,4485,O
for,4485,O
5,4485,O
days,4485,O
prior,4485,O
to,4485,O
giving,4485,O
risperidone,4485,B-CHEMICAL
",",4485,O
the,4485,O
C,4485,O
(,4485,O
max,4485,O
),4485,O
of,4485,O
risperidone,4485,B-CHEMICAL
and,4485,O
9-hydroxyrisperidone,4485,B-CHEMICAL
were,4485,O
significantly,4485,O
increased,4485,O
to,4485,O
2.4-fold,4485,O
(,4485,O
p,4485,O
<,4485,O
0.001,4485,O
),4485,O
and,4485,O
1.7-fold,4485,O
(,4485,O
p,4485,O
<,4485,O
0.001,4485,O
),4485,O
",",4485,O
respectively,4485,O
",",4485,O
and,4485,O
the,4485,O
AUC,4485,O
(,4485,O
0-t,4485,O
),4485,O
",",4485,O
as,4485,O
well,4485,O
to,4485,O
1.7-fold,4485,O
(,4485,O
p,4485,O
<,4485,O
0.05,4485,O
),4485,O
and,4485,O
2.1-fold,4485,O
(,4485,O
p,4485,O
<,4485,O
0.01,4485,O
),4485,O
",",4485,O
respectively,4485,O
.,4485,O
4,4486,O
.,4486,O
The,4487,O
repeated,4487,O
exposures,4487,O
of,4487,O
silymarin,4487,O
",",4487,O
compared,4487,O
to,4487,O
single,4487,O
administration,4487,O
of,4487,O
silymarin,4487,O
",",4487,O
increased,4487,O
oral,4487,O
bioavailability,4487,O
and,4487,O
affected,4487,O
the,4487,O
pharmacokinetics,4487,O
of,4487,O
risperidone,4487,B-CHEMICAL
and,4487,O
9-hydroxyrisperidone,4487,B-CHEMICAL
",",4487,O
by,4487,O
inhibiting,4487,O
P-gp,4487,B-GENE-Y
.,4487,O
Design,4488,O
",",4488,O
synthesis,4488,O
and,4488,O
structure-activity,4488,O
relationship,4488,O
of,4488,O
new,4488,O
arginine,4488,B-GENE-Y
vasopressin,4488,I-GENE-Y
analogues,4488,O
containing,4488,O
proline,4488,B-CHEMICAL
derivatives,4488,O
in,4488,O
position,4488,O
2,4488,O
.,4488,O
In,4489,O
this,4489,O
study,4489,O
",",4489,O
we,4489,O
present,4489,O
the,4489,O
synthesis,4489,O
and,4489,O
pharmacological,4489,O
properties,4489,O
of,4489,O
new,4489,O
analogues,4489,O
of,4489,O
arginine,4489,B-GENE-Y
vasopressin,4489,I-GENE-Y
modified,4489,O
in,4489,O
the,4489,O
N-terminal,4489,B-CHEMICAL
part,4489,O
of,4489,O
the,4489,O
molecule,4489,O
with,4489,O
proline,4489,B-CHEMICAL
derivatives,4489,O
:,4489,O
indoline-2-carboxylic,4489,B-CHEMICAL
acid,4489,I-CHEMICAL
(,4489,O
Ica,4489,B-CHEMICAL
),4489,O
and,4489,O
(,4489,B-CHEMICAL
"2S,4R",4489,I-CHEMICAL
),4489,I-CHEMICAL
-4-,4489,I-CHEMICAL
(,4489,I-CHEMICAL
naphthalene-2-ylmethyl,4489,I-CHEMICAL
),4489,I-CHEMICAL
pyrrolidine-2-carboxylic,4489,I-CHEMICAL
acid,4489,I-CHEMICAL
.,4489,O
All,4490,O
the,4490,O
peptides,4490,O
were,4490,O
tested,4490,O
for,4490,O
pressor,4490,O
",",4490,O
antidiuretic,4490,O
and,4490,O
in,4490,O
vitro,4490,O
uterotonic,4490,O
activities,4490,O
.,4490,O
We,4491,O
also,4491,O
determined,4491,O
their,4491,O
binding,4491,O
affinity,4491,O
to,4491,O
the,4491,O
human,4491,B-GENE-Y
oxytocin,4491,B-CHEMICAL
receptor,4491,I-GENE-Y
.,4491,O
The,4492,O
Ica,4492,B-CHEMICAL
(,4492,O
2,4492,O
),4492,O
substitution,4492,O
resulted,4492,O
in,4492,O
two,4492,O
moderately,4492,O
potent,4492,O
and,4492,O
selective,4492,O
antioxytocic,4492,O
agents,4492,O
:,4492,O
[,4492,B-CHEMICAL
Mpa,4492,I-CHEMICAL
(,4492,I-CHEMICAL
1,4492,I-CHEMICAL
),4492,I-CHEMICAL
",",4492,I-CHEMICAL
Ica,4492,I-CHEMICAL
(,4492,I-CHEMICAL
2,4492,I-CHEMICAL
),4492,I-CHEMICAL
",",4492,I-CHEMICAL
D-Arg,4492,I-CHEMICAL
(,4492,I-CHEMICAL
8,4492,I-CHEMICAL
),4492,I-CHEMICAL
],4492,I-CHEMICAL
VP,4492,I-CHEMICAL
and,4492,O
[,4492,B-CHEMICAL
Mpa,4492,I-CHEMICAL
(,4492,I-CHEMICAL
1,4492,I-CHEMICAL
),4492,I-CHEMICAL
",",4492,I-CHEMICAL
Ica,4492,I-CHEMICAL
(,4492,I-CHEMICAL
2,4492,I-CHEMICAL
),4492,I-CHEMICAL
",",4492,I-CHEMICAL
Val,4492,I-CHEMICAL
(,4492,I-CHEMICAL
4,4492,I-CHEMICAL
),4492,I-CHEMICAL
",",4492,I-CHEMICAL
D-Arg,4492,I-CHEMICAL
(,4492,I-CHEMICAL
8,4492,I-CHEMICAL
),4492,I-CHEMICAL
],4492,I-CHEMICAL
VP,4492,I-CHEMICAL
(,4492,O
pA,4492,O
(,4492,O
2,4492,O
),4492,O
=,4492,O
7.09,4492,O
and,4492,O
7.50,4492,O
",",4492,O
respectively,4492,O
),4492,O
.,4492,O
On,4493,O
the,4493,O
other,4493,O
hand,4493,O
",",4493,O
peptides,4493,O
modified,4493,O
with,4493,O
(,4493,B-CHEMICAL
"2S,4R",4493,I-CHEMICAL
),4493,I-CHEMICAL
-4-,4493,I-CHEMICAL
(,4493,I-CHEMICAL
naphthalene-2-ylmethyl,4493,I-CHEMICAL
),4493,I-CHEMICAL
pyrrolidine-2-carboxylic,4493,I-CHEMICAL
acid,4493,I-CHEMICAL
",",4493,O
apart,4493,O
from,4493,O
their,4493,O
moderate,4493,O
antioxytocic,4493,O
activity,4493,O
",",4493,O
turned,4493,O
out,4493,O
to,4493,O
be,4493,O
weak,4493,O
antagonists,4493,O
of,4493,O
the,4493,O
pressor,4493,O
response,4493,O
to,4493,O
arginine,4493,B-GENE-Y
vasopressin,4493,I-GENE-Y
.,4493,O
The,4494,O
results,4494,O
of,4494,O
this,4494,O
study,4494,O
provide,4494,O
useful,4494,O
information,4494,O
about,4494,O
the,4494,O
structure-activity,4494,O
relationship,4494,O
of,4494,O
arginine,4494,B-GENE-Y
vasopressin,4494,I-GENE-Y
analogues,4494,O
and,4494,O
can,4494,O
help,4494,O
to,4494,O
design,4494,O
compounds,4494,O
with,4494,O
desired,4494,O
biological,4494,O
properties,4494,O
.,4494,O
Liver,4495,B-GENE-N
X,4495,I-GENE-N
Receptors,4495,I-GENE-N
and,4495,O
female,4495,O
reproduction,4495,O
:,4495,O
when,4495,O
cholesterol,4495,B-CHEMICAL
meets,4495,O
fertility,4495,O
!,4495,O
The,4496,O
role,4496,O
of,4496,O
cholesterol,4496,B-CHEMICAL
in,4496,O
female,4496,O
reproductive,4496,O
physiology,4496,O
has,4496,O
been,4496,O
suspected,4496,O
for,4496,O
a,4496,O
long,4496,O
time,4496,O
",",4496,O
while,4496,O
the,4496,O
molecular,4496,O
bases,4496,O
were,4496,O
unknown,4496,O
.,4496,O
Cholesterol,4497,B-CHEMICAL
is,4497,O
the,4497,O
precursor,4497,O
of,4497,O
ovarian,4497,O
steroid,4497,B-CHEMICAL
biosynthesis,4497,O
and,4497,O
is,4497,O
also,4497,O
essential,4497,O
for,4497,O
fertility,4497,O
.,4497,O
In,4498,O
the,4498,O
uterus,4498,O
",",4498,O
cholesterol,4498,B-CHEMICAL
is,4498,O
essential,4498,O
to,4498,O
achieve,4498,O
correct,4498,O
contractions,4498,O
at,4498,O
term,4498,O
",",4498,O
but,4498,O
an,4498,O
excessive,4498,O
uterine,4498,O
cholesterol,4498,B-CHEMICAL
concentration,4498,O
has,4498,O
been,4498,O
associated,4498,O
with,4498,O
contractility,4498,O
defects,4498,O
.,4498,O
Liver,4499,B-GENE-Y
X,4499,I-GENE-Y
Receptor,4499,I-GENE-Y
(,4499,I-GENE-Y
LXR,4499,I-GENE-Y
),4499,I-GENE-Y
α,4499,I-GENE-Y
and,4499,O
LXR,4499,B-GENE-Y
β,4499,I-GENE-Y
are,4499,O
nuclear,4499,O
receptors,4499,O
activated,4499,O
by,4499,O
oxysterols,4499,B-CHEMICAL
",",4499,O
oxidized,4499,O
derivatives,4499,O
of,4499,O
cholesterol,4499,B-CHEMICAL
.,4499,O
Since,4500,O
their,4500,O
discovery,4500,O
",",4500,O
the,4500,O
role,4500,O
of,4500,O
LXR,4500,B-GENE-N
in,4500,O
the,4500,O
control,4500,O
of,4500,O
cholesterol,4500,B-CHEMICAL
homeostasis,4500,O
has,4500,O
been,4500,O
widely,4500,O
described,4500,O
.,4500,O
Beyond,4501,O
their,4501,O
cholesterol-lowering,4501,B-CHEMICAL
role,4501,O
",",4501,O
more,4501,O
recent,4501,O
data,4501,O
have,4501,O
linked,4501,O
these,4501,O
nuclear,4501,O
receptors,4501,O
to,4501,O
various,4501,O
physiological,4501,O
processes,4501,O
.,4501,O
In,4502,O
particular,4502,O
",",4502,O
they,4502,O
control,4502,O
ovarian,4502,O
endocrine,4502,O
and,4502,O
exocrine,4502,O
functions,4502,O
",",4502,O
as,4502,O
well,4502,O
as,4502,O
uterine,4502,O
contractility,4502,O
.,4502,O
Their,4503,O
contribution,4503,O
to,4503,O
female,4503,O
reproductive,4503,O
cancers,4503,O
will,4503,O
also,4503,O
be,4503,O
discussed,4503,O
.,4503,O
This,4504,O
review,4504,O
will,4504,O
try,4504,O
to,4504,O
enlighten,4504,O
on,4504,O
the,4504,O
LXR,4504,B-GENE-N
as,4504,O
a,4504,O
molecular,4504,O
link,4504,O
between,4504,O
dietary,4504,O
cholesterol,4504,B-CHEMICAL
and,4504,O
reproductive,4504,O
diseases,4504,O
in,4504,O
women,4504,O
.,4504,O
In,4505,O
the,4505,O
future,4505,O
",",4505,O
a,4505,O
better,4505,O
comprehension,4505,O
of,4505,O
the,4505,O
various,4505,O
physiological,4505,O
processes,4505,O
regulated,4505,O
by,4505,O
the,4505,O
LXR,4505,B-GENE-N
will,4505,O
help,4505,O
to,4505,O
develop,4505,O
new,4505,O
ligands,4505,O
to,4505,O
prevent,4505,O
or,4505,O
to,4505,O
cure,4505,O
these,4505,O
pathologies,4505,O
in,4505,O
women,4505,O
.,4505,O
β-catenin,4506,B-GENE-Y
regulates,4506,O
GnRH-induced,4506,B-GENE-Y
FSHβ,4506,B-GENE-Y
gene,4506,O
expression,4506,O
.,4506,O
The,4507,O
regulation,4507,O
of,4507,O
gonadotropin,4507,B-GENE-N
synthesis,4507,O
by,4507,O
GnRH,4507,B-CHEMICAL
plays,4507,O
an,4507,O
essential,4507,O
role,4507,O
in,4507,O
the,4507,O
neuroendocrine,4507,O
control,4507,O
of,4507,O
reproduction,4507,O
.,4507,O
The,4508,O
known,4508,O
signaling,4508,O
mechanisms,4508,O
involved,4508,O
in,4508,O
gonadotropin,4508,B-GENE-N
synthesis,4508,O
have,4508,O
been,4508,O
expanding,4508,O
.,4508,O
For,4509,O
example,4509,O
",",4509,O
involvement,4509,O
of,4509,O
β-catenin,4509,B-GENE-Y
in,4509,O
LHβ,4509,O
induction,4509,O
by,4509,O
GnRH,4509,B-CHEMICAL
has,4509,O
been,4509,O
discovered,4509,O
.,4509,O
We,4510,O
examined,4510,O
the,4510,O
role,4510,O
of,4510,O
β-catenin,4510,B-GENE-Y
in,4510,O
FSHβ,4510,B-GENE-Y
gene,4510,O
expression,4510,O
in,4510,O
LβT2,4510,O
gonadotrope,4510,O
cells,4510,O
.,4510,O
GnRH,4511,B-CHEMICAL
caused,4511,O
a,4511,O
sustained,4511,O
increase,4511,O
in,4511,O
nuclear,4511,O
β-catenin,4511,B-GENE-Y
levels,4511,O
",",4511,O
which,4511,O
was,4511,O
significantly,4511,O
reduced,4511,O
by,4511,O
c-Jun,4511,B-GENE-N
N-terminal,4511,B-CHEMICAL
kinase,4511,I-GENE-N
(,4511,O
JNK,4511,B-GENE-N
),4511,O
inhibition,4511,O
.,4511,O
Small,4512,O
interfering,4512,O
RNA-mediated,4512,O
knockdown,4512,O
of,4512,O
β-catenin,4512,B-GENE-Y
mRNA,4512,O
demonstrated,4512,O
that,4512,O
induction,4512,O
of,4512,O
FSHβ,4512,B-GENE-Y
mRNA,4512,O
by,4512,O
GnRH,4512,B-CHEMICAL
depended,4512,O
on,4512,O
β-catenin,4512,B-GENE-Y
and,4512,O
that,4512,O
regulation,4512,O
of,4512,O
FSHβ,4512,B-GENE-Y
by,4512,O
β-catenin,4512,B-GENE-Y
occurred,4512,O
independently,4512,O
of,4512,O
the,4512,O
JNK-c-jun,4512,B-GENE-N
pathway,4512,O
.,4512,O
β-Catenin,4513,B-GENE-Y
depletion,4513,O
had,4513,O
no,4513,O
impact,4513,O
on,4513,O
FSHβ,4513,B-GENE-Y
mRNA,4513,O
stability,4513,O
.,4513,O
In,4514,O
LβT2,4514,O
cells,4514,O
transfected,4514,O
with,4514,O
FSHβ,4514,B-GENE-N
promoter,4514,I-GENE-N
luciferase,4514,O
fusion,4514,O
constructs,4514,O
",",4514,O
GnRH,4514,B-CHEMICAL
responsiveness,4514,O
was,4514,O
conferred,4514,O
by,4514,O
the,4514,O
proximal,4514,O
promoter,4514,O
(,4514,O
-944/-1,4514,O
),4514,O
and,4514,O
was,4514,O
markedly,4514,O
decreased,4514,O
by,4514,O
β-catenin,4514,B-GENE-Y
knockdown,4514,O
.,4514,O
However,4515,O
",",4515,O
none,4515,O
of,4515,O
the,4515,O
T-cell,4515,B-GENE-N
factor/lymphoid,4515,I-GENE-N
enhancer,4515,I-GENE-N
factor,4515,I-GENE-N
binding,4515,I-GENE-N
sites,4515,I-GENE-N
in,4515,O
that,4515,O
region,4515,O
were,4515,O
required,4515,O
for,4515,O
promoter,4515,O
activation,4515,O
by,4515,O
GnRH,4515,B-CHEMICAL
.,4515,O
Chromatin,4516,O
immunoprecipitation,4516,O
further,4516,O
corroborated,4516,O
the,4516,O
absence,4516,O
of,4516,O
direct,4516,O
interaction,4516,O
between,4516,O
β-catenin,4516,B-GENE-Y
and,4516,O
the,4516,O
1.8-kb,4516,O
FSHβ,4516,B-GENE-N
promoter,4516,I-GENE-N
.,4516,O
To,4517,O
elucidate,4517,O
the,4517,O
mechanism,4517,O
for,4517,O
the,4517,O
β-catenin,4517,B-GENE-Y
effect,4517,O
",",4517,O
we,4517,O
analyzed,4517,O
approximately,4517,O
1,4517,O
billion,4517,O
reads,4517,O
of,4517,O
next-generation,4517,O
RNA,4517,O
sequencing,4517,O
β-catenin,4517,B-GENE-Y
knockdown,4517,O
assays,4517,O
and,4517,O
selected,4517,O
the,4517,O
nuclear,4517,O
cofactor,4517,O
breast,4517,B-GENE-Y
cancer,4517,I-GENE-Y
metastasis-suppressor,4517,I-GENE-Y
1-like,4517,I-GENE-Y
(,4517,O
Brms1L,4517,B-GENE-Y
),4517,O
as,4517,O
one,4517,O
candidate,4517,O
for,4517,O
further,4517,O
study,4517,O
.,4517,O
Subsequent,4518,O
experiments,4518,O
confirmed,4518,O
that,4518,O
Brms1L,4518,B-GENE-Y
mRNA,4518,O
expression,4518,O
was,4518,O
decreased,4518,O
by,4518,O
β-catenin,4518,B-GENE-Y
knockdown,4518,O
as,4518,O
well,4518,O
as,4518,O
by,4518,O
JNK,4518,B-GENE-N
inhibition,4518,O
.,4518,O
Furthermore,4519,O
",",4519,O
knockdown,4519,O
of,4519,O
Brms1L,4519,B-GENE-Y
significantly,4519,O
attenuated,4519,O
GnRH-induced,4519,B-CHEMICAL
FSHβ,4519,B-GENE-Y
expression,4519,O
.,4519,O
Thus,4520,O
",",4520,O
our,4520,O
findings,4520,O
indicate,4520,O
that,4520,O
the,4520,O
expression,4520,O
of,4520,O
Brms1L,4520,B-GENE-Y
depends,4520,O
on,4520,O
β-catenin,4520,B-GENE-Y
activity,4520,O
and,4520,O
contributes,4520,O
to,4520,O
FSHβ,4520,B-GENE-Y
induction,4520,O
by,4520,O
GnRH,4520,B-CHEMICAL
.,4520,O
Doxorubicin,4521,B-CHEMICAL
decreases,4521,O
paraquat,4521,B-CHEMICAL
accumulation,4521,O
and,4521,O
toxicity,4521,O
in,4521,O
Caco-2,4521,O
cells,4521,O
.,4521,O
P-glycoprotein,4522,B-GENE-N
(,4522,O
P-gp,4522,B-GENE-N
),4522,O
is,4522,O
an,4522,O
efflux,4522,B-GENE-N
pump,4522,I-GENE-N
belonging,4522,O
to,4522,O
the,4522,O
ATP-binding,4522,B-GENE-N
cassette,4522,I-GENE-N
transporter,4522,I-GENE-N
superfamily,4522,O
expressed,4522,O
in,4522,O
several,4522,O
organs,4522,O
.,4522,O
Considering,4523,O
its,4523,O
potential,4523,O
protective,4523,O
effects,4523,O
",",4523,O
the,4523,O
induction,4523,O
of,4523,O
de,4523,O
novo,4523,O
synthesis,4523,O
of,4523,O
P-gp,4523,B-GENE-N
could,4523,O
be,4523,O
used,4523,O
therapeutically,4523,O
in,4523,O
the,4523,O
treatment,4523,O
of,4523,O
intoxications,4523,O
by,4523,O
its,4523,O
substrates,4523,O
.,4523,O
The,4524,O
herbicide,4524,O
paraquat,4524,B-CHEMICAL
(,4524,O
PQ,4524,O
),4524,O
is,4524,O
a,4524,O
P-gp,4524,B-GENE-N
substrate,4524,O
responsible,4524,O
for,4524,O
thousands,4524,O
of,4524,O
fatal,4524,O
intoxications,4524,O
worldwide,4524,O
that,4524,O
still,4524,O
lacks,4524,O
an,4524,O
effective,4524,O
antidote,4524,O
.,4524,O
The,4525,O
aim,4525,O
of,4525,O
the,4525,O
present,4525,O
work,4525,O
was,4525,O
to,4525,O
evaluate,4525,O
the,4525,O
effectiveness,4525,O
of,4525,O
such,4525,O
an,4525,O
antidote,4525,O
by,4525,O
testing,4525,O
whether,4525,O
doxorubicin,4525,B-CHEMICAL
(,4525,O
DOX,4525,B-CHEMICAL
),4525,O
",",4525,O
a,4525,O
known,4525,O
P-gp,4525,B-GENE-N
inducer,4525,O
",",4525,O
could,4525,O
efficiently,4525,O
protect,4525,O
Caco-2,4525,O
cells,4525,O
against,4525,O
PQ,4525,O
cytotoxicity,4525,O
",",4525,O
6,4525,O
h,4525,O
after,4525,O
the,4525,O
incubation,4525,O
with,4525,O
the,4525,O
herbicide,4525,O
",",4525,O
reflecting,4525,O
a,4525,O
real-life,4525,O
intoxication,4525,O
scenario,4525,O
.,4525,O
Cytotoxicity,4526,O
was,4526,O
evaluated,4526,O
by,4526,O
the,4526,O
MTT,4526,B-CHEMICAL
assay,4526,O
and,4526,O
PQ,4526,O
intracellular,4526,O
concentrations,4526,O
were,4526,O
measured,4526,O
by,4526,O
gas,4526,O
chromatography-ion,4526,O
trap-mass,4526,O
spectrometry,4526,O
(,4526,O
GC-IT-MS,4526,O
),4526,O
.,4526,O
Also,4527,O
",",4527,O
the,4527,O
DOX,4527,B-CHEMICAL
modulatory,4527,O
effect,4527,O
on,4527,O
choline,4527,B-CHEMICAL
uptake,4527,O
transport,4527,O
system,4527,O
was,4527,O
assessed,4527,O
by,4527,O
measuring,4527,O
the,4527,O
uptake,4527,O
of,4527,O
[,4527,B-CHEMICAL
³H,4527,I-CHEMICAL
],4527,I-CHEMICAL
-choline,4527,I-CHEMICAL
.,4527,O
The,4528,O
results,4528,O
show,4528,O
that,4528,O
DOX,4528,B-CHEMICAL
exerts,4528,O
protective,4528,O
effects,4528,O
against,4528,O
PQ,4528,O
cytotoxicity,4528,O
",",4528,O
preventing,4528,O
the,4528,O
intracellular,4528,O
accumulation,4528,O
of,4528,O
the,4528,O
herbicide,4528,O
.,4528,O
These,4529,O
protective,4529,O
effects,4529,O
were,4529,O
not,4529,O
completely,4529,O
prevented,4529,O
by,4529,O
the,4529,O
incubation,4529,O
with,4529,O
the,4529,O
UIC2,4529,O
antibody,4529,O
",",4529,O
a,4529,O
specific,4529,O
P-gp,4529,B-GENE-N
inhibitor,4529,O
",",4529,O
suggesting,4529,O
the,4529,O
involvement,4529,O
of,4529,O
alternative,4529,O
protection,4529,O
mechanisms,4529,O
.,4529,O
In,4530,O
fact,4530,O
",",4530,O
DOX,4530,B-CHEMICAL
also,4530,O
efficiently,4530,O
inhibited,4530,O
the,4530,O
choline,4530,B-CHEMICAL
transport,4530,O
system,4530,O
that,4530,O
influences,4530,O
PQ,4530,O
cellular,4530,O
uptake,4530,O
.,4530,O
In,4531,O
conclusion,4531,O
",",4531,O
in,4531,O
this,4531,O
cellular,4531,O
model,4531,O
",",4531,O
DOX,4531,B-CHEMICAL
effectively,4531,O
protects,4531,O
against,4531,O
PQ,4531,O
toxicity,4531,O
by,4531,O
inducing,4531,O
P-gp,4531,B-GENE-N
and,4531,O
through,4531,O
the,4531,O
interaction,4531,O
with,4531,O
the,4531,O
choline,4531,B-CHEMICAL
transporter,4531,I-GENE-N
",",4531,O
suggesting,4531,O
that,4531,O
compounds,4531,O
presenting,4531,O
this,4531,O
double,4531,O
feature,4531,O
of,4531,O
promoting,4531,O
the,4531,O
efflux,4531,O
and,4531,O
limiting,4531,O
the,4531,O
uptake,4531,O
of,4531,O
PQ,4531,O
could,4531,O
be,4531,O
used,4531,O
as,4531,O
effective,4531,O
antidotes,4531,O
to,4531,O
treat,4531,O
intoxications,4531,O
.,4531,O
Sirtuins,4532,B-GENE-N
as,4532,O
emerging,4532,O
anti-parasitic,4532,O
targets,4532,O
.,4532,O
Silent,4533,B-GENE-Y
information,4533,I-GENE-Y
regulator,4533,I-GENE-Y
2,4533,I-GENE-Y
(,4533,O
Sir2,4533,B-GENE-Y
),4533,O
enzymes,4533,O
or,4533,O
sirtuins,4533,B-GENE-N
are,4533,O
a,4533,O
family,4533,O
of,4533,O
NAD,4533,B-CHEMICAL
(,4533,I-CHEMICAL
+,4533,I-CHEMICAL
),4533,I-CHEMICAL
-dependent,4533,I-GENE-N
protein,4533,I-GENE-N
N,4533,B-CHEMICAL
(,4533,I-CHEMICAL
ε,4533,I-CHEMICAL
),4533,I-CHEMICAL
-acetyl-lysine,4533,I-CHEMICAL
(,4533,I-GENE-N
AcK,4533,B-CHEMICAL
),4533,I-GENE-N
deacetylases,4533,I-GENE-N
.,4533,O
Sirtuins,4534,B-GENE-N
are,4534,O
also,4534,O
evolutionarily,4534,O
conserved,4534,O
proteins,4534,O
that,4534,O
are,4534,O
present,4534,O
in,4534,O
all,4534,O
kingdoms,4534,O
of,4534,O
life,4534,O
ranging,4534,O
from,4534,O
bacteria,4534,O
to,4534,O
humans,4534,O
.,4534,O
Interestingly,4535,O
",",4535,O
it,4535,O
was,4535,O
recently,4535,O
found,4535,O
that,4535,O
the,4535,O
sirtuins,4535,B-GENE-N
found,4535,O
in,4535,O
various,4535,O
human,4535,O
parasites,4535,O
(,4535,O
especially,4535,O
the,4535,O
Plasmodium,4535,O
",",4535,O
Trypanosoma,4535,O
",",4535,O
and,4535,O
Leishmania,4535,O
species,4535,O
),4535,O
were,4535,O
pro-survival,4535,O
for,4535,O
the,4535,O
parasites,4535,O
under,4535,O
various,4535,O
conditions,4535,O
.,4535,O
Therefore,4536,O
",",4536,O
these,4536,O
parasitic,4536,B-GENE-N
sirtuins,4536,I-GENE-N
have,4536,O
emerged,4536,O
as,4536,O
novel,4536,O
anti-parasitic,4536,O
therapeutic,4536,O
targets,4536,O
.,4536,O
This,4537,O
article,4537,O
reviews,4537,O
the,4537,O
currently,4537,O
available,4537,O
structural,4537,O
",",4537,O
biochemical,4537,O
",",4537,O
pharmacological,4537,O
",",4537,O
and,4537,O
medicinal,4537,O
chemistry,4537,O
studies,4537,O
on,4537,O
these,4537,O
enzymes,4537,O
",",4537,O
and,4537,O
discusses,4537,O
the,4537,O
perspectives,4537,O
of,4537,O
selectively,4537,O
targeting,4537,O
the,4537,O
parasitic,4537,B-GENE-N
sirtuins,4537,I-GENE-N
as,4537,O
a,4537,O
novel,4537,O
therapeutic,4537,O
strategy,4537,O
for,4537,O
the,4537,O
human,4537,O
parasitic,4537,O
diseases,4537,O
.,4537,O
The,4538,O
selective,4538,O
SYK,4538,B-GENE-Y
inhibitor,4538,O
P505-15,4538,B-CHEMICAL
(,4538,O
PRT062607,4538,B-CHEMICAL
),4538,O
inhibits,4538,O
B,4538,O
cell,4538,O
signaling,4538,O
and,4538,O
function,4538,O
in,4538,O
vitro,4538,O
and,4538,O
in,4538,O
vivo,4538,O
and,4538,O
augments,4538,O
the,4538,O
activity,4538,O
of,4538,O
fludarabine,4538,B-CHEMICAL
in,4538,O
chronic,4538,O
lymphocytic,4538,O
leukemia,4538,O
.,4538,O
B-cell,4539,B-GENE-N
receptor,4539,I-GENE-N
(,4539,O
BCR,4539,B-GENE-N
),4539,O
associated,4539,O
kinases,4539,B-GENE-N
including,4539,O
spleen,4539,B-GENE-Y
tyrosine,4539,B-CHEMICAL
kinase,4539,I-GENE-Y
(,4539,O
SYK,4539,B-GENE-Y
),4539,O
contribute,4539,O
to,4539,O
the,4539,O
pathogenesis,4539,O
of,4539,O
B-cell,4539,O
malignancies,4539,O
.,4539,O
SYK,4540,B-GENE-Y
is,4540,O
persistently,4540,O
phosphorylated,4540,O
in,4540,O
a,4540,O
subset,4540,O
of,4540,O
non-Hodgkin,4540,O
lymphoma,4540,O
(,4540,O
NHL,4540,O
),4540,O
and,4540,O
chronic,4540,O
lymphocytic,4540,O
leukemia,4540,O
(,4540,O
CLL,4540,O
),4540,O
",",4540,O
and,4540,O
SYK,4540,B-GENE-Y
inhibition,4540,O
results,4540,O
in,4540,O
abrogation,4540,O
of,4540,O
downstream,4540,O
kinase,4540,B-GENE-N
activity,4540,O
and,4540,O
apoptosis,4540,O
.,4540,O
P505-15,4541,B-CHEMICAL
(,4541,O
also,4541,O
known,4541,O
as,4541,O
PRT062607,4541,B-CHEMICAL
),4541,O
is,4541,O
a,4541,O
novel,4541,O
",",4541,O
highly,4541,O
selective,4541,O
",",4541,O
and,4541,O
orally,4541,O
bioavailable,4541,O
small,4541,O
molecule,4541,O
SYK,4541,B-GENE-Y
inhibitor,4541,O
(,4541,O
SYK,4541,B-GENE-Y
IC,4541,O
(,4541,O
50,4541,O
),4541,O
=,4541,O
1,4541,O
nM,4541,O
),4541,O
with,4541,O
anti-SYK,4541,O
activity,4541,O
that,4541,O
is,4541,O
at,4541,O
least,4541,O
80-fold,4541,O
greater,4541,O
than,4541,O
its,4541,O
affinity,4541,O
for,4541,O
other,4541,O
kinases,4541,B-GENE-N
.,4541,O
We,4542,O
evaluated,4542,O
the,4542,O
preclinical,4542,O
characteristics,4542,O
of,4542,O
P505-15,4542,B-CHEMICAL
in,4542,O
models,4542,O
of,4542,O
NHL,4542,O
and,4542,O
CLL,4542,O
.,4542,O
P505-15,4543,B-CHEMICAL
successfully,4543,O
inhibited,4543,O
SYK-mediated,4543,B-GENE-Y
B-cell,4543,B-GENE-N
receptor,4543,I-GENE-N
signaling,4543,O
and,4543,O
decreased,4543,O
cell,4543,O
viability,4543,O
in,4543,O
NHL,4543,O
and,4543,O
CLL,4543,O
.,4543,O
Oral,4544,O
dosing,4544,O
in,4544,O
mice,4544,O
prevented,4544,O
BCR-mediated,4544,B-GENE-N
splenomegaly,4544,O
and,4544,O
significantly,4544,O
inhibited,4544,O
NHL,4544,O
tumor,4544,O
growth,4544,O
in,4544,O
a,4544,O
xenograft,4544,O
model,4544,O
.,4544,O
In,4545,O
addition,4545,O
",",4545,O
combination,4545,O
treatment,4545,O
of,4545,O
primary,4545,O
CLL,4545,O
cells,4545,O
with,4545,O
P505-15,4545,B-CHEMICAL
plus,4545,O
fludarabine,4545,B-CHEMICAL
produced,4545,O
synergistic,4545,O
enhancement,4545,O
of,4545,O
activity,4545,O
at,4545,O
nanomolar,4545,O
concentrations,4545,O
.,4545,O
Our,4546,O
findings,4546,O
support,4546,O
the,4546,O
ongoing,4546,O
development,4546,O
of,4546,O
P505-15,4546,B-CHEMICAL
as,4546,O
a,4546,O
therapeutic,4546,O
agent,4546,O
for,4546,O
B-cell,4546,O
malignancies,4546,O
.,4546,O
A,4547,O
dose,4547,O
finding,4547,O
study,4547,O
in,4547,O
healthy,4547,O
volunteers,4547,O
has,4547,O
been,4547,O
completed,4547,O
.,4547,O
The,4548,O
fidelity,4548,O
of,4548,O
transcription,4548,O
:,4548,O
RPB1,4548,B-GENE-Y
(,4548,O
RPO21,4548,B-GENE-Y
),4548,O
mutations,4548,O
that,4548,O
increase,4548,O
transcriptional,4548,O
slippage,4548,O
in,4548,O
S.,4548,O
cerevisiae,4548,O
.,4548,O
The,4549,O
fidelity,4549,O
of,4549,O
RNA,4549,O
synthesis,4549,O
depends,4549,O
on,4549,O
both,4549,O
accurate,4549,O
template-mediated,4549,O
nucleotide,4549,B-CHEMICAL
selection,4549,O
and,4549,O
proper,4549,O
maintenance,4549,O
of,4549,O
register,4549,O
between,4549,O
template,4549,O
and,4549,O
RNA,4549,O
.,4549,O
Loss,4550,O
of,4550,O
register,4550,O
",",4550,O
or,4550,O
transcriptional,4550,O
slippage,4550,O
",",4550,O
is,4550,O
particularly,4550,O
likely,4550,O
on,4550,O
homopolymeric,4550,O
runs,4550,O
in,4550,O
the,4550,O
template,4550,O
.,4550,O
Transcriptional,4551,O
slippage,4551,O
can,4551,O
alter,4551,O
the,4551,O
coding,4551,O
capacity,4551,O
of,4551,O
mRNAs,4551,O
and,4551,O
is,4551,O
used,4551,O
as,4551,O
a,4551,O
regulatory,4551,O
mechanism,4551,O
.,4551,O
Here,4552,O
we,4552,O
describe,4552,O
mutations,4552,O
in,4552,O
the,4552,O
largest,4552,O
subunit,4552,O
of,4552,O
Saccharomyces,4552,B-GENE-N
cerevisiae,4552,I-GENE-N
RNA,4552,I-GENE-N
polymerase,4552,I-GENE-N
II,4552,I-GENE-N
that,4552,O
substantially,4552,O
increase,4552,O
the,4552,O
level,4552,O
of,4552,O
transcriptional,4552,O
slippage,4552,O
.,4552,O
Alleles,4553,O
of,4553,O
RPB1,4553,B-GENE-Y
(,4553,O
RPO21,4553,B-GENE-Y
),4553,O
with,4553,O
elevated,4553,O
slippage,4553,O
rates,4553,O
were,4553,O
identified,4553,O
among,4553,O
6-azauracil-sensitive,4553,B-CHEMICAL
mutants,4553,O
and,4553,O
were,4553,O
also,4553,O
isolated,4553,O
using,4553,O
a,4553,O
slippage-dependent,4553,O
reporter,4553,O
gene,4553,O
.,4553,O
Biochemical,4554,O
characterization,4554,O
of,4554,O
polymerase,4554,B-GENE-N
II,4554,I-GENE-N
isolated,4554,O
from,4554,O
these,4554,O
mutants,4554,O
confirms,4554,O
elevated,4554,O
levels,4554,O
of,4554,O
transcriptional,4554,O
slippage,4554,O
.,4554,O
Effect,4555,O
of,4555,O
nuclear,4555,O
vibrations,4555,O
",",4555,O
temperature,4555,O
",",4555,O
co-adsorbed,4555,O
water,4555,O
",",4555,O
and,4555,O
dye,4555,O
orientation,4555,O
on,4555,O
light,4555,O
absorption,4555,O
",",4555,O
charge,4555,O
injection,4555,O
and,4555,O
recombination,4555,O
conditions,4555,O
in,4555,O
organic,4555,O
dyes,4555,O
on,4555,O
TiO2,4555,B-CHEMICAL
.,4555,O
We,4556,O
study,4556,O
the,4556,O
effect,4556,O
of,4556,O
nuclear,4556,O
motions,4556,O
at,4556,O
different,4556,O
temperatures,4556,O
",",4556,O
including,4556,O
the,4556,O
effect,4556,O
of,4556,O
a,4556,O
dye,4556,O
molecule,4556,O
's,4556,O
orientation,4556,O
with,4556,O
respect,4556,O
to,4556,O
the,4556,O
oxide,4556,B-CHEMICAL
surface,4556,O
",",4556,O
on,4556,O
factors,4556,O
determining,4556,O
the,4556,O
performance,4556,O
of,4556,O
dye,4556,O
sensitized,4556,O
solar,4556,O
cells,4556,O
:,4556,O
light,4556,O
absorption,4556,O
",",4556,O
electron,4556,O
injection,4556,O
",",4556,O
and,4556,O
back-donation,4556,O
.,4556,O
We,4557,O
perform,4557,O
ab,4557,O
initio,4557,O
molecular,4557,O
dynamics,4557,O
simulations,4557,O
of,4557,O
aminophenyl,4557,B-CHEMICAL
acid,4557,I-CHEMICAL
dyes,4557,O
NK1,4557,B-CHEMICAL
and,4557,O
NK7,4557,B-CHEMICAL
",",4557,O
differing,4557,O
by,4557,O
the,4557,O
electron,4557,O
donating,4557,O
group,4557,O
",",4557,O
in,4557,O
a,4557,O
vacuum,4557,O
and,4557,O
adsorbed,4557,O
in,4557,O
mono-,4557,O
and,4557,O
bi-dentate,4557,O
modes,4557,O
on,4557,O
a,4557,O
dry,4557,O
and,4557,O
a,4557,O
water-covered,4557,O
anatase,4557,B-CHEMICAL
(,4557,I-CHEMICAL
101,4557,I-CHEMICAL
),4557,I-CHEMICAL
surface,4557,O
of,4557,O
TiO,4557,B-CHEMICAL
(,4557,I-CHEMICAL
2,4557,I-CHEMICAL
),4557,I-CHEMICAL
",",4557,O
at,4557,O
300,4557,O
and,4557,O
350,4557,O
K.,4557,O
Nuclear,4557,O
vibrations,4557,O
and,4557,O
an,4557,O
increase,4557,O
of,4557,O
temperature,4557,O
cause,4557,O
a,4557,O
red,4557,O
shift,4557,O
in,4557,O
the,4557,O
absorption,4557,O
spectra,4557,O
of,4557,O
free,4557,O
dyes,4557,O
.,4557,O
This,4558,O
effect,4558,O
is,4558,O
preserved,4558,O
in,4558,O
dyes,4558,O
on,4558,O
dry,4558,O
TiO,4558,B-CHEMICAL
(,4558,I-CHEMICAL
2,4558,I-CHEMICAL
),4558,I-CHEMICAL
but,4558,O
largely,4558,O
disappears,4558,O
in,4558,O
the,4558,O
presence,4558,O
of,4558,O
water,4558,O
.,4558,O
Averaged,4559,O
over,4559,O
nuclear,4559,O
vibrations,4559,O
",",4559,O
the,4559,O
driving,4559,O
force,4559,O
to,4559,O
injection,4559,O
",",4559,O
ΔG,4559,O
",",4559,O
differs,4559,O
from,4559,O
the,4559,O
static,4559,O
estimate,4559,O
.,4559,O
It,4560,O
depends,4560,O
on,4560,O
the,4560,O
adsorption,4560,O
mode,4560,O
and,4560,O
the,4560,O
presence,4560,O
of,4560,O
H,4560,B-CHEMICAL
(,4560,I-CHEMICAL
2,4560,I-CHEMICAL
),4560,I-CHEMICAL
O,4560,I-CHEMICAL
but,4560,O
is,4560,O
almost,4560,O
the,4560,O
same,4560,O
for,4560,O
300,4560,O
and,4560,O
350,4560,O
K.,4560,O
Recombination,4560,O
to,4560,O
the,4560,O
dye,4560,O
cation,4560,O
is,4560,O
expected,4560,O
to,4560,O
be,4560,O
much,4560,O
enhanced,4560,O
by,4560,O
the,4560,O
approach,4560,O
of,4560,O
the,4560,O
dye,4560,O
oxidation,4560,O
equivalent,4560,O
hole,4560,O
to,4560,O
the,4560,O
surface,4560,O
during,4560,O
dye,4560,O
wagging,4560,O
around,4560,O
TiO,4560,B-CHEMICAL
(,4560,I-CHEMICAL
2,4560,I-CHEMICAL
),4560,I-CHEMICAL
.,4560,O
This,4561,O
effect,4561,O
is,4561,O
somewhat,4561,O
mitigated,4561,O
by,4561,O
the,4561,O
co-adsorbed,4561,O
water,4561,O
.,4561,O
The,4562,O
dynamics,4562,O
of,4562,O
ΔG,4562,O
(,4562,O
t,4562,O
),4562,O
are,4562,O
explained,4562,O
by,4562,O
uncorrelated,4562,O
evolution,4562,O
of,4562,O
the,4562,O
energies,4562,O
of,4562,O
the,4562,O
dye,4562,O
excited,4562,O
state,4562,O
and,4562,O
the,4562,O
conduction,4562,O
band,4562,O
minimum,4562,O
of,4562,O
the,4562,O
oxide,4562,B-CHEMICAL
due,4562,O
to,4562,O
their,4562,O
respective,4562,O
vibrations,4562,O
",",4562,O
and,4562,O
are,4562,O
almost,4562,O
independent,4562,O
of,4562,O
dye,4562,O
orientation,4562,O
.,4562,O
It,4563,O
may,4563,O
therefore,4563,O
be,4563,O
possible,4563,O
to,4563,O
independently,4563,O
control,4563,O
the,4563,O
conditions,4563,O
of,4563,O
recombination,4563,O
and,4563,O
of,4563,O
injection,4563,O
.,4563,O
Proteomic,4564,O
and,4564,O
metabolomic,4564,O
responses,4564,O
to,4564,O
connexin43,4564,B-GENE-Y
silencing,4564,O
in,4564,O
primary,4564,O
hepatocyte,4564,O
cultures,4564,O
.,4564,O
Freshly,4565,O
established,4565,O
cultures,4565,O
of,4565,O
primary,4565,O
hepatocytes,4565,O
progressively,4565,O
adopt,4565,O
a,4565,O
foetal-like,4565,O
phenotype,4565,O
and,4565,O
display,4565,O
increased,4565,O
production,4565,O
of,4565,O
connexin43,4565,B-GENE-Y
.,4565,O
The,4566,O
latter,4566,O
is,4566,O
a,4566,O
multifaceted,4566,O
cellular,4566,O
entity,4566,O
with,4566,O
variable,4566,O
subcellular,4566,O
locations,4566,O
",",4566,O
including,4566,O
the,4566,O
mitochondrial,4566,O
compartment,4566,O
.,4566,O
Cx43,4567,B-GENE-Y
forms,4567,O
hemichannels,4567,B-GENE-N
and,4567,O
gap,4567,O
junctions,4567,O
that,4567,O
are,4567,O
involved,4567,O
in,4567,O
a,4567,O
plethora,4567,O
of,4567,O
physiological,4567,O
and,4567,O
pathological,4567,O
processes,4567,O
",",4567,O
such,4567,O
as,4567,O
apoptosis,4567,O
.,4567,O
The,4568,O
present,4568,O
study,4568,O
was,4568,O
conducted,4568,O
with,4568,O
the,4568,O
goal,4568,O
of,4568,O
shedding,4568,O
more,4568,O
light,4568,O
onto,4568,O
the,4568,O
role,4568,O
of,4568,O
connexin43,4568,B-GENE-Y
in,4568,O
primary,4568,O
hepatocyte,4568,O
cultures,4568,O
.,4568,O
Connexin43,4569,B-GENE-Y
expression,4569,O
was,4569,O
suppressed,4569,O
by,4569,O
means,4569,O
of,4569,O
RNA,4569,O
interference,4569,O
technology,4569,O
",",4569,O
and,4569,O
the,4569,O
overall,4569,O
outcome,4569,O
of,4569,O
this,4569,O
treatment,4569,O
on,4569,O
the,4569,O
hepatocellular,4569,O
proteome,4569,O
and,4569,O
metabolome,4569,O
was,4569,O
investigated,4569,O
using,4569,O
tandem,4569,O
mass,4569,O
tag-based,4569,O
differential,4569,O
protein,4569,O
profiling,4569,O
and,4569,O
(,4569,B-CHEMICAL
1,4569,I-CHEMICAL
),4569,I-CHEMICAL
H,4569,I-CHEMICAL
NMR,4569,O
spectroscopy,4569,O
",",4569,O
respectively,4569,O
.,4569,O
Global,4570,O
protein,4570,O
profiling,4570,O
revealed,4570,O
a,4570,O
number,4570,O
of,4570,O
targets,4570,O
of,4570,O
the,4570,O
connexin43,4570,B-GENE-Y
knock-down,4570,O
procedure,4570,O
",",4570,O
including,4570,O
mitochondrial,4570,O
proteins,4570,O
(,4570,O
heat,4570,B-GENE-Y
shock,4570,I-GENE-Y
protein,4570,I-GENE-Y
60,4570,I-GENE-Y
",",4570,O
glucose-regulated,4570,B-CHEMICAL
protein,4570,I-GENE-Y
75,4570,I-GENE-Y
",",4570,O
thiosulphate,4570,B-CHEMICAL
sulphurtransferase,4570,I-GENE-Y
and,4570,O
adenosine,4570,B-GENE-N
triphosphate,4570,I-GENE-N
synthase,4570,I-GENE-N
),4570,O
and,4570,O
detoxifying,4570,O
enzymes,4570,O
(,4570,O
glutathione,4570,B-GENE-Y
S-transferase,4570,I-GENE-Y
μ,4570,I-GENE-Y
2,4570,I-GENE-Y
and,4570,O
cytochrome,4570,B-GENE-N
P450,4570,I-GENE-N
2C70,4570,I-GENE-N
),4570,O
.,4570,O
At,4571,O
the,4571,O
metabolomic,4571,O
level,4571,O
",",4571,O
connexin43,4571,B-GENE-Y
silencing,4571,O
caused,4571,O
no,4571,O
overt,4571,O
changes,4571,O
",",4571,O
though,4571,O
there,4571,O
was,4571,O
some,4571,O
evidence,4571,O
for,4571,O
a,4571,O
subtle,4571,O
increase,4571,O
in,4571,O
intracellular,4571,O
glycine,4571,B-CHEMICAL
quantities,4571,O
.,4571,O
Collectively,4572,O
",",4572,O
these,4572,O
data,4572,O
could,4572,O
further,4572,O
substantiate,4572,O
the,4572,O
established,4572,O
existence,4572,O
of,4572,O
a,4572,O
mitochondrial,4572,O
connexin,4572,B-GENE-N
pool,4572,O
and,4572,O
could,4572,O
be,4572,O
reconciled,4572,O
with,4572,O
the,4572,O
previously,4572,O
reported,4572,O
involvement,4572,O
of,4572,O
connexin43,4572,B-GENE-N
signalling,4572,O
in,4572,O
spontaneously,4572,O
occurring,4572,O
apoptosis,4572,O
in,4572,O
primary,4572,O
hepatocyte,4572,O
cultures,4572,O
.,4572,O
Aryl,4573,B-GENE-Y
hydrocarbon,4573,I-GENE-Y
receptor,4573,I-GENE-Y
is,4573,O
a,4573,O
target,4573,O
of,4573,O
17-Allylamino-17-demethoxygeldanamycin,4573,B-CHEMICAL
and,4573,O
enhances,4573,O
its,4573,O
anticancer,4573,O
activity,4573,O
in,4573,O
lung,4573,O
adenocarcinoma,4573,O
cells,4573,O
.,4573,O
We,4574,O
have,4574,O
demonstrated,4574,O
that,4574,O
aryl,4574,B-GENE-Y
hydrocarbon,4574,I-GENE-Y
receptor,4574,I-GENE-Y
(,4574,O
AhR,4574,B-GENE-Y
),4574,O
is,4574,O
overexpressed,4574,O
in,4574,O
lung,4574,O
adenocarcinoma,4574,O
(,4574,O
AD,4574,O
),4574,O
.,4574,O
AhR,4575,B-GENE-Y
is,4575,O
usually,4575,O
associated,4575,O
with,4575,O
heat,4575,B-GENE-N
shock,4575,I-GENE-N
protein,4575,I-GENE-N
90,4575,I-GENE-N
(,4575,O
Hsp90,4575,B-GENE-N
),4575,O
in,4575,O
the,4575,O
cytoplasm,4575,O
.,4575,O
17-Allylamino-17-demethoxygeldanamycin,4576,B-CHEMICAL
(,4576,O
17-AAG,4576,B-CHEMICAL
),4576,O
",",4576,O
an,4576,O
Hsp90,4576,B-GENE-N
inhibitor,4576,O
",",4576,O
is,4576,O
currently,4576,O
under,4576,O
evaluation,4576,O
for,4576,O
its,4576,O
anticancer,4576,O
activity,4576,O
in,4576,O
clinical,4576,O
trials,4576,O
.,4576,O
Here,4577,O
we,4577,O
investigated,4577,O
whether,4577,O
AhR,4577,B-GENE-Y
plays,4577,O
a,4577,O
role,4577,O
in,4577,O
17-AAG-mediated,4577,B-CHEMICAL
anticancer,4577,O
activity,4577,O
by,4577,O
functioning,4577,O
as,4577,O
a,4577,O
downstream,4577,O
target,4577,O
or,4577,O
by,4577,O
modulating,4577,O
its,4577,O
anticancer,4577,O
efficacy,4577,O
.,4577,O
AhR,4578,B-GENE-Y
expression,4578,O
in,4578,O
lung,4578,O
AD,4578,O
cells,4578,O
was,4578,O
modulated,4578,O
by,4578,O
siRNA,4578,O
interference,4578,O
or,4578,O
overexpression,4578,O
.,4578,O
Tumor,4579,O
growth,4579,O
was,4579,O
determined,4579,O
with,4579,O
colony,4579,O
formation,4579,O
in,4579,O
vitro,4579,O
or,4579,O
in,4579,O
vivo,4579,O
.,4579,O
Anticancer,4580,O
activity,4580,O
of,4580,O
17-AAG,4580,B-CHEMICAL
was,4580,O
determined,4580,O
by,4580,O
measuring,4580,O
cell,4580,O
viability,4580,O
",",4580,O
cell,4580,O
cycle,4580,O
distribution,4580,O
",",4580,O
and,4580,O
expression,4580,O
of,4580,O
cell,4580,O
cycle,4580,O
regulators,4580,O
.,4580,O
Proteins,4581,O
and,4581,O
mRNA,4581,O
levels,4581,O
were,4581,O
examined,4581,O
by,4581,O
immunoblotting,4581,O
and,4581,O
the,4581,O
real-time,4581,O
reverse,4581,O
transcription-polymerase,4581,O
chain,4581,O
reaction,4581,O
",",4581,O
respectively,4581,O
.,4581,O
In,4582,O
this,4582,O
study,4582,O
",",4582,O
AhR,4582,B-GENE-Y
overexpression,4582,O
positively,4582,O
modulated,4582,O
growth,4582,O
of,4582,O
lung,4582,O
AD,4582,O
cells,4582,O
",",4582,O
at,4582,O
least,4582,O
partially,4582,O
",",4582,O
via,4582,O
RelA-dependent,4582,B-GENE-Y
mechanisms,4582,O
.,4582,O
Although,4583,O
treatment,4583,O
with,4583,O
17-AAG,4583,B-CHEMICAL
reduced,4583,O
AhR,4583,B-GENE-Y
levels,4583,O
and,4583,O
AhR-regulated,4583,B-GENE-Y
gene,4583,O
expression,4583,O
in,4583,O
lung,4583,O
AD,4583,O
cells,4583,O
",",4583,O
AhR,4583,B-GENE-Y
expression,4583,O
increased,4583,O
anticancer,4583,O
activity,4583,O
of,4583,O
17-AAG,4583,B-CHEMICAL
.,4583,O
In,4584,O
addition,4584,O
",",4584,O
17-AAG,4584,B-CHEMICAL
treatment,4584,O
reduced,4584,O
cell,4584,O
viability,4584,O
",",4584,O
CDK2,4584,B-GENE-Y
",",4584,O
CDK4,4584,B-GENE-Y
",",4584,O
cyclin,4584,B-GENE-N
E,4584,I-GENE-N
",",4584,O
cyclin,4584,B-GENE-Y
D1,4584,I-GENE-Y
",",4584,O
and,4584,O
phosphorylated,4584,B-GENE-Y
Rb,4584,I-GENE-Y
levels,4584,O
in,4584,O
AhR-expressing,4584,B-GENE-Y
lung,4584,O
AD,4584,O
cells,4584,O
.,4584,O
NAD,4585,B-CHEMICAL
(,4585,I-CHEMICAL
P,4585,I-CHEMICAL
),4585,I-CHEMICAL
H,4585,I-CHEMICAL
:,4585,I-GENE-Y
quinone,4585,B-CHEMICAL
oxidoreductase,4585,I-GENE-Y
(,4585,O
NQO1,4585,B-GENE-Y
),4585,O
",",4585,O
which,4585,O
is,4585,O
regulated,4585,O
by,4585,O
AhR,4585,B-GENE-Y
",",4585,O
was,4585,O
shown,4585,O
to,4585,O
increase,4585,O
anticancer,4585,O
activity,4585,O
of,4585,O
17-AAG,4585,B-CHEMICAL
in,4585,O
cells,4585,O
.,4585,O
Knockdown,4586,O
of,4586,O
NQO1,4586,B-GENE-Y
expression,4586,O
attenuated,4586,O
the,4586,O
reduction,4586,O
of,4586,O
cell,4586,O
cycle,4586,O
regulators,4586,O
by,4586,O
17-AAG,4586,B-CHEMICAL
treatment,4586,O
in,4586,O
AhR,4586,B-GENE-Y
overexpressed,4586,O
cells,4586,O
.,4586,O
We,4587,O
demonstrated,4587,O
that,4587,O
AhR,4587,B-GENE-Y
protein,4587,O
not,4587,O
only,4587,O
functions,4587,O
as,4587,O
a,4587,O
downstream,4587,O
target,4587,O
of,4587,O
17-AAG,4587,B-CHEMICAL
",",4587,O
but,4587,O
also,4587,O
enhances,4587,O
anticancer,4587,O
activity,4587,O
of,4587,O
17-AAG,4587,B-CHEMICAL
in,4587,O
lung,4587,O
AD,4587,O
cells,4587,O
.,4587,O
Pharmacogenomics,4588,O
of,4588,O
gemcitabine,4588,B-CHEMICAL
metabolism,4588,O
:,4588,O
functional,4588,O
analysis,4588,O
of,4588,O
genetic,4588,O
variants,4588,O
in,4588,O
cytidine,4588,B-GENE-Y
deaminase,4588,I-GENE-Y
and,4588,O
deoxycytidine,4588,B-GENE-Y
kinase,4588,I-GENE-Y
.,4588,O
Gemcitabine,4589,B-CHEMICAL
(,4589,O
dFdC,4589,B-CHEMICAL
",",4589,O
"2',2'-difluorodeoxycytidine",4589,B-CHEMICAL
),4589,O
is,4589,O
metabolized,4589,O
by,4589,O
cytidine,4589,B-GENE-Y
deaminase,4589,I-GENE-Y
(,4589,O
CDA,4589,B-GENE-Y
),4589,O
and,4589,O
deoxycytidine,4589,B-GENE-Y
kinase,4589,I-GENE-Y
(,4589,O
DCK,4589,B-GENE-Y
),4589,O
",",4589,O
but,4589,O
the,4589,O
contribution,4589,O
of,4589,O
genetic,4589,O
variation,4589,O
in,4589,O
these,4589,O
enzymes,4589,O
to,4589,O
the,4589,O
variability,4589,O
in,4589,O
systemic,4589,O
exposure,4589,O
and,4589,O
response,4589,O
observed,4589,O
in,4589,O
cancer,4589,O
patients,4589,O
is,4589,O
unclear,4589,O
.,4589,O
Wild-type,4590,O
enzymes,4590,O
and,4590,O
variants,4590,O
of,4590,O
CDA,4590,B-GENE-Y
(,4590,O
Lys27Gln,4590,B-GENE-N
and,4590,O
Ala70Thr,4590,B-GENE-N
),4590,O
and,4590,O
DCK,4590,B-GENE-Y
(,4590,O
Ile24Val,4590,B-GENE-N
",",4590,O
Ala119Gly,4590,B-GENE-N
",",4590,O
and,4590,O
Pro122Ser,4590,B-GENE-N
),4590,O
were,4590,O
expressed,4590,O
in,4590,O
and,4590,O
purified,4590,O
from,4590,O
Escherichia,4590,O
coli,4590,O
",",4590,O
and,4590,O
enzyme,4590,O
kinetic,4590,O
parameters,4590,O
were,4590,O
estimated,4590,O
for,4590,O
cytarabine,4590,B-CHEMICAL
(,4590,O
Ara-C,4590,B-CHEMICAL
),4590,O
",",4590,O
dFdC,4590,B-CHEMICAL
",",4590,O
and,4590,O
its,4590,O
metabolite,4590,O
"2',2'-difluorodeoxyuridine",4590,B-CHEMICAL
(,4590,O
dFdU,4590,B-CHEMICAL
),4590,O
as,4590,O
substrates,4590,O
.,4590,O
All,4591,O
three,4591,O
CDA,4591,B-GENE-Y
proteins,4591,O
showed,4591,O
similar,4591,O
K,4591,O
(,4591,O
m,4591,O
),4591,O
and,4591,O
V,4591,O
(,4591,O
max,4591,O
),4591,O
for,4591,O
Ara-C,4591,B-CHEMICAL
and,4591,O
dFdC,4591,B-CHEMICAL
deamination,4591,O
",",4591,O
except,4591,O
for,4591,O
CDA70Thr,4591,B-GENE-Y
",",4591,O
which,4591,O
had,4591,O
a,4591,O
2.5-fold,4591,O
lower,4591,O
K,4591,O
(,4591,O
m,4591,O
),4591,O
and,4591,O
6-fold,4591,O
lower,4591,O
V,4591,O
(,4591,O
max,4591,O
),4591,O
for,4591,O
Ara-C,4591,B-CHEMICAL
deamination,4591,O
.,4591,O
All,4592,O
four,4592,O
DCK,4592,B-GENE-Y
proteins,4592,O
yielded,4592,O
comparable,4592,O
metabolic,4592,O
activity,4592,O
for,4592,O
Ara-C,4592,B-CHEMICAL
and,4592,O
dFdC,4592,B-CHEMICAL
monophosphorylation,4592,O
",",4592,O
except,4592,O
for,4592,O
DCK24Val,4592,B-GENE-Y
",",4592,O
which,4592,O
demonstrated,4592,O
an,4592,O
approximately,4592,O
2-fold,4592,O
increase,4592,O
(,4592,O
P,4592,O
<,4592,O
0.05,4592,O
),4592,O
in,4592,O
the,4592,O
intrinsic,4592,O
clearance,4592,O
of,4592,O
dFdC,4592,B-CHEMICAL
monophosphorylation,4592,O
due,4592,O
to,4592,O
a,4592,O
40,4592,O
%,4592,O
decrease,4592,O
in,4592,O
K,4592,O
(,4592,O
m,4592,O
),4592,O
(,4592,O
P,4592,O
<,4592,O
0.05,4592,O
),4592,O
.,4592,O
DCK,4593,B-GENE-Y
did,4593,O
not,4593,O
significantly,4593,O
contribute,4593,O
to,4593,O
dFdU,4593,B-CHEMICAL
monophosphorylation,4593,O
.,4593,O
In,4594,O
conclusion,4594,O
",",4594,O
the,4594,O
Lys27Gln,4594,B-GENE-N
substitution,4594,O
does,4594,O
not,4594,O
significantly,4594,O
modulate,4594,O
CDA,4594,B-GENE-Y
activity,4594,O
toward,4594,O
dFdC,4594,B-CHEMICAL
",",4594,O
and,4594,O
therefore,4594,O
would,4594,O
not,4594,O
contribute,4594,O
to,4594,O
interindividual,4594,O
variability,4594,O
in,4594,O
response,4594,O
to,4594,O
gemcitabine,4594,B-CHEMICAL
.,4594,O
The,4595,O
higher,4595,O
in,4595,O
vitro,4595,O
catalytic,4595,O
efficiency,4595,O
of,4595,O
DCK24Val,4595,B-GENE-Y
toward,4595,O
dFdC,4595,B-CHEMICAL
monophosphorylation,4595,O
may,4595,O
be,4595,O
relevant,4595,O
to,4595,O
dFdC,4595,B-CHEMICAL
clinical,4595,O
response,4595,O
.,4595,O
The,4596,O
substrate-dependent,4596,O
alterations,4596,O
in,4596,O
activities,4596,O
of,4596,O
CDA70Thr,4596,B-GENE-Y
and,4596,O
DCK24Val,4596,B-GENE-Y
in,4596,O
vitro,4596,O
were,4596,O
observed,4596,O
for,4596,O
the,4596,O
first,4596,O
time,4596,O
",",4596,O
and,4596,O
demonstrate,4596,O
that,4596,O
the,4596,O
in,4596,O
vivo,4596,O
consequences,4596,O
of,4596,O
these,4596,O
genetic,4596,O
variations,4596,O
should,4596,O
not,4596,O
be,4596,O
extrapolated,4596,O
from,4596,O
one,4596,O
substrate,4596,O
of,4596,O
these,4596,O
enzymes,4596,O
to,4596,O
another,4596,O
.,4596,O
Discovery,4597,O
of,4597,O
4-phenyl-2-phenylaminopyridine,4597,B-CHEMICAL
based,4597,O
TNIK,4597,B-GENE-Y
inhibitors,4597,O
.,4597,O
A,4598,O
series,4598,O
of,4598,O
compounds,4598,O
based,4598,O
on,4598,O
a,4598,O
4-phenyl-2-phenylaminopyridine,4598,B-CHEMICAL
scaffold,4598,O
that,4598,O
are,4598,O
potent,4598,O
and,4598,O
selective,4598,O
inhibitors,4598,O
of,4598,O
Traf2-,4598,B-GENE-Y
and,4598,I-GENE-Y
Nck-interacting,4598,I-GENE-Y
kinase,4598,I-GENE-Y
(,4598,O
TNIK,4598,B-GENE-Y
),4598,O
activity,4598,O
are,4598,O
described,4598,O
.,4598,O
These,4599,O
compounds,4599,O
were,4599,O
used,4599,O
as,4599,O
tools,4599,O
to,4599,O
test,4599,O
the,4599,O
importance,4599,O
of,4599,O
TNIK,4599,B-GENE-Y
kinase,4599,B-GENE-N
activity,4599,O
in,4599,O
signaling,4599,O
and,4599,O
proliferation,4599,O
in,4599,O
Wnt-activated,4599,B-GENE-N
colorectal,4599,O
cancer,4599,O
cells,4599,O
.,4599,O
The,4600,O
results,4600,O
indicate,4600,O
that,4600,O
pharmacological,4600,O
inhibition,4600,O
of,4600,O
TNIK,4600,B-GENE-Y
kinase,4600,B-GENE-N
activity,4600,O
has,4600,O
minimal,4600,O
effects,4600,O
on,4600,O
either,4600,O
Wnt/TCF4/β-catenin-driven,4600,B-GENE-N
transcription,4600,O
or,4600,O
viability,4600,O
.,4600,O
The,4601,O
findings,4601,O
suggest,4601,O
that,4601,O
the,4601,O
kinase,4601,B-GENE-N
activity,4601,O
of,4601,O
TNIK,4601,B-GENE-Y
may,4601,O
be,4601,O
less,4601,O
important,4601,O
to,4601,O
Wnt,4601,B-GENE-N
signaling,4601,O
than,4601,O
other,4601,O
aspects,4601,O
of,4601,O
TNIK,4601,B-GENE-Y
function,4601,O
",",4601,O
such,4601,O
as,4601,O
its,4601,O
putative,4601,O
role,4601,O
in,4601,O
stabilizing,4601,O
the,4601,O
TCF4/β-catenin,4601,B-GENE-Y
transcriptional,4601,O
complex,4601,O
.,4601,O
Hybrid,4602,O
carbon,4602,B-CHEMICAL
nanotube,4602,O
networks,4602,O
as,4602,O
efficient,4602,O
hole,4602,O
extraction,4602,O
layers,4602,O
for,4602,O
organic,4602,O
photovoltaics,4602,O
.,4602,O
Transparent,4603,O
",",4603,O
highly,4603,O
percolated,4603,O
networks,4603,O
of,4603,O
regioregular,4603,O
poly,4603,B-CHEMICAL
(,4603,I-CHEMICAL
3-hexylthiophene,4603,I-CHEMICAL
),4603,I-CHEMICAL
(,4603,O
rr-P3HT,4603,O
),4603,O
-wrapped,4603,O
semiconducting,4603,O
single-walled,4603,O
carbon,4603,B-CHEMICAL
nanotubes,4603,O
(,4603,O
s-SWNTs,4603,O
),4603,O
are,4603,O
deposited,4603,O
",",4603,O
and,4603,O
the,4603,O
charge,4603,O
transfer,4603,O
processes,4603,O
of,4603,O
these,4603,O
nanohybrids,4603,O
are,4603,O
studied,4603,O
using,4603,O
spectroscopic,4603,O
and,4603,O
electrical,4603,O
measurements,4603,O
.,4603,O
The,4604,O
data,4604,O
disclose,4604,O
hole,4604,O
doping,4604,O
of,4604,O
s-SWNTs,4604,O
by,4604,O
the,4604,O
polymer,4604,O
",",4604,O
challenging,4604,O
the,4604,O
prevalent,4604,O
electron-doping,4604,O
hypothesis,4604,O
.,4604,O
Through,4605,O
controlled,4605,O
fabrication,4605,O
",",4605,O
high-,4605,O
to,4605,O
low-density,4605,O
nanohybrid,4605,O
networks,4605,O
are,4605,O
achieved,4605,O
",",4605,O
with,4605,O
low-density,4605,O
hybrid,4605,O
carbon,4605,B-CHEMICAL
nanotube,4605,O
networks,4605,O
tested,4605,O
as,4605,O
hole,4605,O
transport,4605,O
layers,4605,O
(,4605,O
HTLs,4605,O
),4605,O
for,4605,O
bulk,4605,O
heterojunction,4605,O
(,4605,O
BHJ,4605,O
),4605,O
organic,4605,O
photovoltaics,4605,O
(,4605,O
OPV,4605,O
),4605,O
.,4605,O
OPVs,4606,O
incorporating,4606,O
these,4606,O
rr-P3HT/s-SWNT,4606,O
networks,4606,O
as,4606,O
the,4606,O
HTL,4606,O
demonstrate,4606,O
the,4606,O
best,4606,O
large,4606,O
area,4606,O
(,4606,O
70,4606,O
mm,4606,O
(,4606,O
2,4606,O
),4606,O
),4606,O
carbon,4606,B-CHEMICAL
nanotube,4606,O
incorporated,4606,O
organic,4606,O
solar,4606,O
cells,4606,O
to,4606,O
date,4606,O
with,4606,O
a,4606,O
power,4606,O
conversion,4606,O
efficiency,4606,O
of,4606,O
7.6,4606,O
%,4606,O
.,4606,O
This,4607,O
signifies,4607,O
the,4607,O
strong,4607,O
capability,4607,O
of,4607,O
nanohybrids,4607,O
as,4607,O
an,4607,O
efficient,4607,O
hole,4607,O
extraction,4607,O
layer,4607,O
",",4607,O
and,4607,O
we,4607,O
believe,4607,O
that,4607,O
dense,4607,O
nanohybrid,4607,O
networks,4607,O
have,4607,O
the,4607,O
potential,4607,O
to,4607,O
replace,4607,O
expensive,4607,O
and,4607,O
material,4607,O
scarce,4607,O
inorganic,4607,O
transparent,4607,O
electrodes,4607,O
in,4607,O
large,4607,O
area,4607,O
electronics,4607,O
toward,4607,O
the,4607,O
realization,4607,O
of,4607,O
low-cost,4607,O
flexible,4607,O
electronics,4607,O
.,4607,O
Chemical,4608,O
assessment,4608,O
and,4608,O
antioxidant,4608,O
capacity,4608,O
of,4608,O
pepper,4608,O
(,4608,O
Capsicum,4608,O
annuum,4608,O
L.,4608,O
),4608,O
seeds,4608,O
.,4608,O
Capsicum,4609,O
annuum,4609,O
L.,4609,O
is,4609,O
reported,4609,O
to,4609,O
be,4609,O
the,4609,O
most,4609,O
widely,4609,O
cultivated,4609,O
species,4609,O
.,4609,O
Recently,4610,O
",",4610,O
waste,4610,O
of,4610,O
vegetable,4610,O
processing,4610,O
",",4610,O
like,4610,O
seeds,4610,O
",",4610,O
has,4610,O
been,4610,O
the,4610,O
subject,4610,O
of,4610,O
many,4610,O
studies,4610,O
as,4610,O
an,4610,O
attempt,4610,O
to,4610,O
find,4610,O
new,4610,O
",",4610,O
alternative,4610,O
and,4610,O
cheap,4610,O
resources,4610,O
of,4610,O
bioactive,4610,O
compounds,4610,O
with,4610,O
application,4610,O
in,4610,O
several,4610,O
industries,4610,O
.,4610,O
Despite,4611,O
their,4611,O
chemical,4611,O
",",4611,O
biological,4611,O
and,4611,O
ecological,4611,O
importance,4611,O
",",4611,O
C.,4611,O
annuum,4611,O
seeds,4611,O
are,4611,O
still,4611,O
poorly,4611,O
studied,4611,O
.,4611,O
To,4612,O
improve,4612,O
the,4612,O
knowledge,4612,O
on,4612,O
the,4612,O
metabolic,4612,O
profile,4612,O
of,4612,O
this,4612,O
matrix,4612,O
",",4612,O
a,4612,O
targeted,4612,O
metabolite,4612,O
analysis,4612,O
was,4612,O
performed,4612,O
in,4612,O
``,4612,O
sweet,4612,O
Italian,4612,O
'',4612,O
and,4612,O
``,4612,O
Reus,4612,O
long,4612,O
pairal,4612,O
'',4612,O
pepper,4612,O
seeds,4612,O
.,4612,O
Sterols,4613,B-CHEMICAL
",",4613,O
triterpenes,4613,B-CHEMICAL
",",4613,O
organic,4613,O
acids,4613,O
",",4613,O
fatty,4613,B-CHEMICAL
acids,4613,I-CHEMICAL
and,4613,O
volatile,4613,O
compounds,4613,O
were,4613,O
determined,4613,O
by,4613,O
different,4613,O
chromatographic,4613,O
methods,4613,O
.,4613,O
The,4614,O
antioxidant,4614,O
activity,4614,O
was,4614,O
assessed,4614,O
against,4614,O
DPPH,4614,B-CHEMICAL
(,4614,I-CHEMICAL
·,4614,I-CHEMICAL
),4614,I-CHEMICAL
",",4614,O
superoxide,4614,B-CHEMICAL
and,4614,O
nitric,4614,B-CHEMICAL
oxide,4614,I-CHEMICAL
radicals,4614,O
.,4614,O
A,4615,O
concentration-dependent,4615,O
activity,4615,O
was,4615,O
noticed,4615,O
against,4615,O
all,4615,O
radicals,4615,O
.,4615,O
Acetylcholinesterase,4616,B-GENE-Y
inhibitory,4616,O
capacity,4616,O
was,4616,O
also,4616,O
evaluated,4616,O
",",4616,O
but,4616,O
no,4616,O
effect,4616,O
was,4616,O
found,4616,O
.,4616,O
Data,4617,O
provide,4617,O
evidence,4617,O
of,4617,O
great,4617,O
similarities,4617,O
between,4617,O
``,4617,O
sweet,4617,O
Italian,4617,O
'',4617,O
and,4617,O
``,4617,O
Reus,4617,O
long,4617,O
pairal,4617,O
'',4617,O
pepper,4617,O
seeds,4617,O
.,4617,O
The,4618,O
present,4618,O
study,4618,O
indicates,4618,O
that,4618,O
C.,4618,O
annuum,4618,O
seeds,4618,O
are,4618,O
a,4618,O
potential,4618,O
source,4618,O
of,4618,O
valuable,4618,O
bioactive,4618,O
compounds,4618,O
that,4618,O
could,4618,O
be,4618,O
used,4618,O
in,4618,O
food,4618,O
industry,4618,O
.,4618,O
Boron-based,4619,B-CHEMICAL
inhibitors,4619,O
of,4619,O
acyl,4619,B-CHEMICAL
protein,4619,I-GENE-N
thioesterases,4619,I-GENE-N
1,4619,I-GENE-N
and,4619,I-GENE-N
2,4619,I-GENE-N
.,4619,O
Ras,4620,B-GENE-N
proteins,4620,O
are,4620,O
of,4620,O
importance,4620,O
in,4620,O
cell,4620,O
proliferation,4620,O
",",4620,O
and,4620,O
hence,4620,O
their,4620,O
mutated,4620,O
forms,4620,O
play,4620,O
causative,4620,O
roles,4620,O
in,4620,O
many,4620,O
kinds,4620,O
of,4620,O
cancer,4620,O
in,4620,O
different,4620,O
tissues,4620,O
.,4620,O
Inhibition,4621,O
of,4621,O
the,4621,O
Ras-depalmitoylating,4621,B-GENE-N
enzyme,4621,O
acyl,4621,B-GENE-N
protein,4621,I-GENE-N
thioesterases,4621,I-GENE-N
APT1,4621,I-GENE-N
and,4621,I-GENE-N
-2,4621,I-GENE-N
is,4621,O
a,4621,O
new,4621,O
approach,4621,O
to,4621,O
modulating,4621,O
the,4621,O
Ras,4621,B-GENE-N
cycle,4621,O
.,4621,O
Here,4622,O
we,4622,O
present,4622,O
boronic,4622,B-CHEMICAL
and,4622,O
borinic,4622,B-CHEMICAL
acid,4622,I-CHEMICAL
derivatives,4622,O
as,4622,O
a,4622,O
new,4622,O
class,4622,O
of,4622,O
potent,4622,O
and,4622,O
nontoxic,4622,O
APT,4622,B-GENE-N
inhibitors,4622,O
.,4622,O
These,4623,O
compounds,4623,O
were,4623,O
detected,4623,O
by,4623,O
extensive,4623,O
library,4623,O
screening,4623,O
using,4623,O
chemical,4623,O
arrays,4623,O
and,4623,O
turned,4623,O
out,4623,O
to,4623,O
inhibit,4623,O
human,4623,B-GENE-N
APT1,4623,I-GENE-N
and,4623,I-GENE-N
-2,4623,I-GENE-N
in,4623,O
a,4623,O
competitive,4623,O
mode,4623,O
.,4623,O
Furthermore,4624,O
",",4624,O
one,4624,O
of,4624,O
the,4624,O
molecules,4624,O
was,4624,O
demonstrated,4624,O
to,4624,O
inhibit,4624,O
Erk1/2,4624,B-GENE-N
phosphorylation,4624,O
significantly,4624,O
.,4624,O
Three-Dimensional,4625,O
CdS-Titanate,4625,B-CHEMICAL
Composite,4625,O
Nanomaterials,4625,O
for,4625,O
Enhanced,4625,O
Visible-Light-Driven,4625,O
Hydrogen,4625,B-CHEMICAL
Evolution,4625,O
.,4625,O
3D,4626,O
Hierarchical,4626,O
echinus-like,4626,O
titanate,4626,B-CHEMICAL
spheres,4626,O
(,4626,O
HETSs,4626,O
),4626,O
",",4626,O
serving,4626,O
as,4626,O
the,4626,O
supporting,4626,O
material,4626,O
for,4626,O
CdS,4626,B-CHEMICAL
nanoparticles,4626,O
",",4626,O
are,4626,O
synthesized,4626,O
via,4626,O
a,4626,O
fast,4626,O
one-step,4626,O
hydrothermal,4626,O
method,4626,O
.,4626,O
The,4627,O
obtained,4627,O
3D,4627,O
CdS-HETS,4627,B-CHEMICAL
composite,4627,O
materials,4627,O
show,4627,O
enhanced,4627,O
H2,4627,B-CHEMICAL
generation,4627,O
under,4627,O
visible,4627,O
light,4627,O
irradiation,4627,O
.,4627,O
UPLC-Q-TOF/HSMS/MS,4628,O
(,4628,O
E,4628,O
),4628,O
-based,4628,O
metabonomics,4628,O
for,4628,O
adenine-induced,4628,B-CHEMICAL
changes,4628,O
in,4628,O
metabolic,4628,O
profiles,4628,O
of,4628,O
rat,4628,O
faeces,4628,O
and,4628,O
intervention,4628,O
effects,4628,O
of,4628,O
"ergosta-4,6,8",4628,B-CHEMICAL
(,4628,I-CHEMICAL
14,4628,I-CHEMICAL
),4628,I-CHEMICAL
",22-tetraen-3-one",4628,I-CHEMICAL
.,4628,O
"Ergosta-4,6,8",4629,B-CHEMICAL
(,4629,I-CHEMICAL
14,4629,I-CHEMICAL
),4629,I-CHEMICAL
",22-tetraen-3-one",4629,I-CHEMICAL
(,4629,O
ergone,4629,B-CHEMICAL
),4629,O
",",4629,O
isolated,4629,O
from,4629,O
the,4629,O
medicinal,4629,O
fungus,4629,O
Polyporus,4629,O
umbellatus,4629,O
",",4629,O
has,4629,O
been,4629,O
proven,4629,O
to,4629,O
prevent,4629,O
the,4629,O
progression,4629,O
of,4629,O
renal,4629,O
injury,4629,O
and,4629,O
the,4629,O
subsequent,4629,O
renal,4629,O
fibrosis,4629,O
.,4629,O
Ultra,4630,O
performance,4630,O
liquid,4630,O
chromatography,4630,O
coupled,4630,O
with,4630,O
quadrupole,4630,O
time-of-flight,4630,O
high-sensitivity,4630,O
mass,4630,O
spectrometry,4630,O
and,4630,O
a,4630,O
novel,4630,O
mass,4630,O
spectrometry,4630,O
(,4630,O
Elevated,4630,O
Energy,4630,O
),4630,O
(,4630,O
MS,4630,O
(,4630,O
E,4630,O
),4630,O
),4630,O
data,4630,O
collection,4630,O
technique,4630,O
was,4630,O
employed,4630,O
to,4630,O
investigate,4630,O
metabonomic,4630,O
characters,4630,O
of,4630,O
chronic,4630,O
renal,4630,O
failure,4630,O
(,4630,O
CRF,4630,O
),4630,O
induced,4630,O
adenine,4630,B-CHEMICAL
and,4630,O
the,4630,O
protective,4630,O
effects,4630,O
of,4630,O
"ergosta-4,6,8",4630,B-CHEMICAL
(,4630,I-CHEMICAL
14,4630,I-CHEMICAL
),4630,I-CHEMICAL
",22-tetraen-3-one",4630,I-CHEMICAL
(,4630,O
ergone,4630,B-CHEMICAL
),4630,O
.,4630,O
Coupled,4631,O
with,4631,O
blood,4631,O
biochemistry,4631,O
and,4631,O
kidney,4631,O
histopathology,4631,O
results,4631,O
",",4631,O
the,4631,O
significant,4631,O
difference,4631,O
in,4631,O
metabolic,4631,O
profiling,4631,O
between,4631,O
adenine-induced,4631,B-CHEMICAL
CRF,4631,O
group,4631,O
and,4631,O
ergone-treated,4631,B-CHEMICAL
CRF,4631,O
group,4631,O
by,4631,O
using,4631,O
pattern,4631,O
recognition,4631,O
analysis,4631,O
indicated,4631,O
that,4631,O
changes,4631,O
in,4631,O
global,4631,O
faecal,4631,O
metabolites,4631,O
were,4631,O
occurred,4631,O
.,4631,O
Seven,4632,O
endogenous,4632,O
metabolites,4632,O
were,4632,O
identified,4632,O
by,4632,O
using,4632,O
metabonomic,4632,O
method,4632,O
combined,4632,O
with,4632,O
multivariate,4632,O
data,4632,O
analysis,4632,O
",",4632,O
the,4632,O
accurate,4632,O
mass,4632,O
",",4632,O
isotopic,4632,O
pattern,4632,O
",",4632,O
MS,4632,O
(,4632,O
E,4632,O
),4632,O
fragments,4632,O
information,4632,O
and,4632,O
MassLynx,4632,O
i-FIT,4632,O
algorithm,4632,O
.,4632,O
These,4633,O
biochemical,4633,O
changes,4633,O
in,4633,O
faecal,4633,O
metabolites,4633,O
are,4633,O
related,4633,O
to,4633,O
the,4633,O
perturbations,4633,O
of,4633,O
bile,4633,B-CHEMICAL
acid,4633,I-CHEMICAL
metabolism,4633,O
and,4633,O
phospholipid,4633,O
metabolism,4633,O
",",4633,O
which,4633,O
may,4633,O
be,4633,O
helpful,4633,O
to,4633,O
further,4633,O
understand,4633,O
the,4633,O
CRF,4633,O
and,4633,O
therapeutic,4633,O
mechanisms,4633,O
of,4633,O
ergone,4633,B-CHEMICAL
.,4633,O
This,4634,O
research,4634,O
proved,4634,O
that,4634,O
MS,4634,O
(,4634,O
E,4634,O
),4634,O
can,4634,O
simultaneous,4634,O
acquire,4634,O
precursor,4634,O
ion,4634,O
information,4634,O
and,4634,O
fragment,4634,O
ion,4634,O
data,4634,O
at,4634,O
high,4634,O
and,4634,O
low,4634,O
collision,4634,O
energy,4634,O
in,4634,O
one,4634,O
analytical,4634,O
run,4634,O
",",4634,O
which,4634,O
facilitated,4634,O
the,4634,O
fast,4634,O
structural,4634,O
characterization,4634,O
of,4634,O
metabolites,4634,O
.,4634,O
Selective,4635,O
separation,4635,O
of,4635,O
similarly,4635,O
sized,4635,O
proteins,4635,O
with,4635,O
tunable,4635,O
nanoporous,4635,O
block,4635,O
copolymer,4635,O
membranes,4635,O
.,4635,O
An,4636,O
integral,4636,O
asymmetric,4636,O
membrane,4636,O
was,4636,O
fabricated,4636,O
in,4636,O
a,4636,O
fast,4636,O
and,4636,O
one-step,4636,O
process,4636,O
by,4636,O
combining,4636,O
the,4636,O
self-assembly,4636,O
of,4636,O
an,4636,O
amphiphilic,4636,O
block,4636,O
copolymer,4636,O
(,4636,O
PS-b-P4VP,4636,B-CHEMICAL
),4636,O
with,4636,O
nonsolvent-induced,4636,O
phase,4636,O
separation,4636,O
.,4636,O
The,4637,O
structure,4637,O
was,4637,O
found,4637,O
to,4637,O
be,4637,O
composed,4637,O
of,4637,O
a,4637,O
thin,4637,O
layer,4637,O
of,4637,O
densely,4637,O
packed,4637,O
highly,4637,O
ordered,4637,O
cylindrical,4637,O
channels,4637,O
with,4637,O
uniform,4637,O
pore,4637,O
sizes,4637,O
perpendicular,4637,O
to,4637,O
the,4637,O
surface,4637,O
on,4637,O
top,4637,O
of,4637,O
a,4637,O
nonordered,4637,O
sponge-like,4637,O
layer,4637,O
.,4637,O
The,4638,O
as-assembled,4638,O
membrane,4638,O
obtained,4638,O
a,4638,O
water,4638,O
flux,4638,O
of,4638,O
more,4638,O
than,4638,O
3200,4638,O
L,4638,O
m,4638,O
(,4638,O
-2,4638,O
),4638,O
h,4638,O
(,4638,O
-1,4638,O
),4638,O
bar,4638,O
(,4638,O
-1,4638,O
),4638,O
",",4638,O
which,4638,O
was,4638,O
at,4638,O
least,4638,O
an,4638,O
order,4638,O
of,4638,O
magnitude,4638,O
higher,4638,O
than,4638,O
the,4638,O
water,4638,O
fluxes,4638,O
of,4638,O
commercially,4638,O
available,4638,O
membranes,4638,O
with,4638,O
comparable,4638,O
pore,4638,O
sizes,4638,O
",",4638,O
making,4638,O
this,4638,O
membrane,4638,O
particularly,4638,O
well,4638,O
suited,4638,O
to,4638,O
size-selective,4638,O
and,4638,O
charge-based,4638,O
separation,4638,O
of,4638,O
biomolecules,4638,O
.,4638,O
To,4639,O
test,4639,O
the,4639,O
performance,4639,O
of,4639,O
the,4639,O
membrane,4639,O
",",4639,O
we,4639,O
conducted,4639,O
diffusion,4639,O
experiments,4639,O
at,4639,O
the,4639,O
physiological,4639,O
pH,4639,O
of,4639,O
7.4,4639,O
using,4639,O
bovine,4639,B-GENE-Y
serum,4639,I-GENE-Y
albumin,4639,I-GENE-Y
(,4639,O
BSA,4639,B-GENE-Y
),4639,O
and,4639,O
globulin-γ,4639,B-GENE-N
",",4639,O
two,4639,O
proteins,4639,O
with,4639,O
different,4639,O
diameters,4639,O
but,4639,O
too,4639,O
close,4639,O
in,4639,O
size,4639,O
(,4639,O
2-fold,4639,O
difference,4639,O
in,4639,O
molecular,4639,O
mass,4639,O
),4639,O
to,4639,O
be,4639,O
efficiently,4639,O
separated,4639,O
via,4639,O
conventional,4639,O
dialysis,4639,O
membrane,4639,O
processes,4639,O
.,4639,O
The,4640,O
diffusion,4640,O
rate,4640,O
differed,4640,O
by,4640,O
a,4640,O
factor,4640,O
of,4640,O
87,4640,O
",",4640,O
the,4640,O
highest,4640,O
value,4640,O
reported,4640,O
to,4640,O
date,4640,O
.,4640,O
We,4641,O
also,4641,O
analyzed,4641,O
charge-based,4641,O
diffusive,4641,O
transport,4641,O
and,4641,O
separation,4641,O
of,4641,O
two,4641,O
proteins,4641,O
of,4641,O
similar,4641,O
molecular,4641,O
weight,4641,O
(,4641,O
BSA,4641,B-GENE-Y
and,4641,O
bovine,4641,B-GENE-N
hemoglobin,4641,I-GENE-N
(,4641,O
BHb,4641,B-GENE-N
),4641,O
),4641,O
through,4641,O
the,4641,O
membrane,4641,O
as,4641,O
a,4641,O
function,4641,O
of,4641,O
external,4641,O
pH,4641,O
.,4641,O
The,4642,O
membrane,4642,O
achieved,4642,O
a,4642,O
selectivity,4642,O
of,4642,O
about,4642,O
10,4642,O
at,4642,O
pH,4642,O
4.7,4642,O
",",4642,O
the,4642,O
isoelectric,4642,O
point,4642,O
(,4642,O
pI,4642,O
),4642,O
of,4642,O
BSA,4642,B-GENE-Y
.,4642,O
We,4643,O
then,4643,O
positively,4643,O
charged,4643,O
the,4643,O
membrane,4643,O
to,4643,O
improve,4643,O
the,4643,O
separation,4643,O
selectivity,4643,O
.,4643,O
With,4644,O
the,4644,O
modified,4644,O
membrane,4644,O
BSA,4644,B-GENE-Y
was,4644,O
completely,4644,O
blocked,4644,O
when,4644,O
the,4644,O
pH,4644,O
was,4644,O
7.0,4644,O
",",4644,O
the,4644,O
pI,4644,O
of,4644,O
BHb,4644,B-GENE-N
",",4644,O
while,4644,O
BHb,4644,B-GENE-N
was,4644,O
completely,4644,O
blocked,4644,O
at,4644,O
pH,4644,O
4.7,4644,O
.,4644,O
Our,4645,O
results,4645,O
demonstrate,4645,O
the,4645,O
potential,4645,O
of,4645,O
our,4645,O
asymmetric,4645,O
membrane,4645,O
to,4645,O
efficiently,4645,O
separate,4645,O
biological,4645,O
substances/pharmaceuticals,4645,O
in,4645,O
bioscience,4645,O
",",4645,O
biotechnology,4645,O
",",4645,O
and,4645,O
biomedicine,4645,O
applications,4645,O
.,4645,O
Phytoestrogen,4646,O
genistein,4646,B-CHEMICAL
protects,4646,O
against,4646,O
endothelial,4646,O
barrier,4646,O
dysfunction,4646,O
in,4646,O
vascular,4646,O
endothelial,4646,O
cells,4646,O
through,4646,O
PKA-mediated,4646,B-GENE-N
suppression,4646,O
of,4646,O
RhoA,4646,B-GENE-Y
signaling,4646,O
.,4646,O
The,4647,O
soy-derived,4647,O
phytoestrogen,4647,O
genistein,4647,B-CHEMICAL
has,4647,O
received,4647,O
attention,4647,O
for,4647,O
its,4647,O
potential,4647,O
to,4647,O
improve,4647,O
vascular,4647,O
function,4647,O
",",4647,O
but,4647,O
its,4647,O
mechanism,4647,O
remains,4647,O
unclear,4647,O
.,4647,O
Here,4648,O
",",4648,O
we,4648,O
report,4648,O
that,4648,O
genistein,4648,B-CHEMICAL
at,4648,O
physiologically,4648,O
relevant,4648,O
concentrations,4648,O
(,4648,O
0.1-10,4648,O
μM,4648,O
),4648,O
significantly,4648,O
inhibited,4648,O
thrombin-induced,4648,B-GENE-Y
increase,4648,O
in,4648,O
endothelial,4648,O
monolayer,4648,O
permeability,4648,O
.,4648,O
Genistein,4649,B-CHEMICAL
also,4649,O
reduced,4649,O
the,4649,O
formation,4649,O
of,4649,O
stress,4649,O
fibers,4649,O
by,4649,O
thrombin,4649,B-GENE-Y
and,4649,O
suppressed,4649,O
thrombin-induced,4649,B-GENE-Y
phosphorylation,4649,O
of,4649,O
myosin,4649,B-GENE-N
light,4649,I-GENE-N
chain,4649,I-GENE-N
(,4649,O
MLC,4649,B-GENE-N
),4649,O
on,4649,O
Ser,4649,B-CHEMICAL
(,4649,O
19,4649,O
),4649,O
/Thr,4649,O
(,4649,O
18,4649,O
),4649,O
in,4649,O
endothelial,4649,O
cells,4649,O
(,4649,O
ECs,4649,O
),4649,O
.,4649,O
Genistein,4650,B-CHEMICAL
had,4650,O
no,4650,O
effect,4650,O
on,4650,O
resting,4650,O
intracellular,4650,O
[,4650,O
Ca,4650,B-CHEMICAL
(,4650,I-CHEMICAL
2+,4650,I-CHEMICAL
),4650,I-CHEMICAL
],4650,O
or,4650,O
thrombin-induced,4650,B-GENE-Y
increase,4650,O
in,4650,O
Ca,4650,B-CHEMICAL
(,4650,I-CHEMICAL
2+,4650,I-CHEMICAL
),4650,I-CHEMICAL
mobilization,4650,O
.,4650,O
Addition,4651,O
of,4651,O
the,4651,O
inhibitors,4651,O
of,4651,O
endothelial,4651,B-GENE-Y
nitric,4651,I-GENE-Y
oxide,4651,I-GENE-Y
synthase,4651,I-GENE-Y
or,4651,O
estrogen,4651,B-GENE-Y
receptor,4651,I-GENE-Y
did,4651,O
not,4651,O
alter,4651,O
the,4651,O
protective,4651,O
effect,4651,O
of,4651,O
genistein,4651,B-CHEMICAL
.,4651,O
RhoA,4652,B-GENE-Y
is,4652,O
a,4652,O
small,4652,O
GTPase,4652,B-GENE-N
that,4652,O
plays,4652,O
an,4652,O
important,4652,O
role,4652,O
in,4652,O
actin-myosin,4652,B-GENE-N
contraction,4652,O
and,4652,O
endothelial,4652,O
barrier,4652,O
dysfunction,4652,O
.,4652,O
RhoA,4653,B-GENE-Y
inhibitor,4653,O
blocked,4653,O
the,4653,O
protective,4653,O
effect,4653,O
of,4653,O
genistein,4653,B-CHEMICAL
on,4653,O
endothelial,4653,O
permeability,4653,O
and,4653,O
also,4653,O
ablated,4653,O
thrombin-induced,4653,B-GENE-Y
MLC-phosphorylation,4653,B-GENE-N
in,4653,O
ECs,4653,O
.,4653,O
Inhibition,4654,O
of,4654,O
PKA,4654,B-GENE-N
significantly,4654,O
attenuated,4654,O
the,4654,O
effect,4654,O
of,4654,O
genistein,4654,B-CHEMICAL
on,4654,O
thrombin-induced,4654,B-GENE-Y
EC,4654,O
permeability,4654,O
",",4654,O
MLC,4654,B-GENE-N
phosphorylation,4654,O
",",4654,O
and,4654,O
RhoA,4654,B-GENE-Y
membrane,4654,O
translocation,4654,O
in,4654,O
ECs,4654,O
.,4654,O
Furthermore,4655,O
",",4655,O
thrombin,4655,B-GENE-Y
diminished,4655,O
cAMP,4655,B-CHEMICAL
production,4655,O
in,4655,O
ECs,4655,O
",",4655,O
which,4655,O
were,4655,O
prevented,4655,O
by,4655,O
treatment,4655,O
with,4655,O
genistein,4655,B-CHEMICAL
.,4655,O
These,4656,O
findings,4656,O
demonstrated,4656,O
that,4656,O
genistein,4656,B-CHEMICAL
improves,4656,O
thrombin-induced,4656,B-GENE-Y
endothelial,4656,O
barrier,4656,O
dysfunction,4656,O
in,4656,O
ECs,4656,O
through,4656,O
PKA-mediated,4656,B-GENE-N
suppression,4656,O
of,4656,O
RhoA,4656,B-GENE-Y
signaling,4656,O
.,4656,O
Metabolic,4657,O
effects,4657,O
of,4657,O
honey,4657,O
in,4657,O
type,4657,O
1,4657,O
diabetes,4657,O
mellitus,4657,O
:,4657,O
a,4657,O
randomized,4657,O
crossover,4657,O
pilot,4657,O
study,4657,O
.,4657,O
The,4658,O
aim,4658,O
of,4658,O
this,4658,O
study,4658,O
was,4658,O
to,4658,O
evaluate,4658,O
the,4658,O
metabolic,4658,O
effects,4658,O
of,4658,O
12-week,4658,O
honey,4658,O
consumption,4658,O
on,4658,O
patients,4658,O
suffering,4658,O
from,4658,O
type,4658,O
1,4658,O
diabetes,4658,O
mellitus,4658,O
(,4658,O
DM,4658,O
),4658,O
.,4658,O
This,4659,O
was,4659,O
a,4659,O
randomized,4659,O
crossover,4659,O
clinical,4659,O
trial,4659,O
done,4659,O
in,4659,O
the,4659,O
National,4659,O
Institute,4659,O
for,4659,O
Diabetes,4659,O
and,4659,O
Endocrinology,4659,O
",",4659,O
Cairo,4659,O
",",4659,O
Egypt,4659,O
.,4659,O
Twenty,4660,O
patients,4660,O
of,4660,O
both,4660,O
sexes,4660,O
aged,4660,O
4-18,4660,O
years,4660,O
with,4660,O
type,4660,O
1,4660,O
DM,4660,O
and,4660,O
HbA1C,4660,B-GENE-Y
<,4660,O
10,4660,O
%,4660,O
participated,4660,O
in,4660,O
the,4660,O
study,4660,O
.,4660,O
They,4661,O
were,4661,O
randomized,4661,O
into,4661,O
two,4661,O
equal,4661,O
groups,4661,O
(,4661,O
intervention,4661,O
to,4661,O
control,4661,O
and,4661,O
control,4661,O
to,4661,O
intervention,4661,O
),4661,O
.,4661,O
The,4662,O
dietary,4662,O
intervention,4662,O
was,4662,O
12-week,4662,O
honey,4662,O
consumption,4662,O
in,4662,O
a,4662,O
dose,4662,O
of,4662,O
0.5,4662,O
mL/kg,4662,O
body,4662,O
weight,4662,O
per,4662,O
day,4662,O
.,4662,O
The,4663,O
main,4663,O
outcome,4663,O
measures,4663,O
were,4663,O
serum,4663,O
glucose,4663,B-CHEMICAL
",",4663,O
lipids,4663,O
",",4663,O
and,4663,O
C-peptide,4663,B-GENE-Y
",",4663,O
and,4663,O
anthropometric,4663,O
measurements,4663,O
.,4663,O
None,4664,O
of,4664,O
participants,4664,O
were,4664,O
lost,4664,O
in,4664,O
follow-up,4664,O
.,4664,O
The,4665,O
intervention,4665,O
resulted,4665,O
in,4665,O
significant,4665,O
decreases,4665,O
in,4665,O
subscapular,4665,O
skin,4665,O
fold,4665,O
thickness,4665,O
(,4665,O
SSFT,4665,O
;,4665,O
P=.002,4665,O
),4665,O
",",4665,O
fasting,4665,O
serum,4665,O
glucose,4665,B-CHEMICAL
(,4665,O
FSG,4665,O
;,4665,O
P=.001,4665,O
),4665,O
",",4665,O
total,4665,O
cholesterol,4665,B-CHEMICAL
(,4665,O
P=.0001,4665,O
),4665,O
",",4665,O
serum,4665,O
triglycerides,4665,B-CHEMICAL
(,4665,O
TG,4665,O
;,4665,O
P=.0001,4665,O
),4665,O
",",4665,O
and,4665,O
low-density,4665,B-GENE-N
lipoprotein,4665,I-GENE-N
(,4665,O
P=.0009,4665,O
),4665,O
",",4665,O
and,4665,O
significant,4665,O
increases,4665,O
in,4665,O
fasting,4665,B-GENE-Y
C-peptide,4665,I-GENE-Y
(,4665,O
FCP,4665,B-GENE-Y
;,4665,O
P=.0004,4665,O
),4665,O
and,4665,O
2-h,4665,O
postprandial,4665,B-GENE-Y
C-peptide,4665,I-GENE-Y
(,4665,O
PCP,4665,B-GENE-Y
;,4665,O
P=.002,4665,O
),4665,O
.,4665,O
As,4666,O
possible,4666,O
long-term,4666,O
effects,4666,O
of,4666,O
honey,4666,O
after,4666,O
its,4666,O
withdrawal,4666,O
",",4666,O
statistically,4666,O
significant,4666,O
reductions,4666,O
in,4666,O
midarm,4666,O
circumference,4666,O
(,4666,O
P=.000,4666,O
),4666,O
",",4666,O
triceps,4666,O
skin,4666,O
fold,4666,O
thickness,4666,O
(,4666,O
P=.006,4666,O
),4666,O
",",4666,O
SSFT,4666,O
(,4666,O
P=.003,4666,O
),4666,O
",",4666,O
FSG,4666,O
(,4666,O
P=.005,4666,O
),4666,O
",",4666,O
2-h,4666,O
postprandial,4666,O
serum,4666,O
glucose,4666,B-CHEMICAL
(,4666,O
P=.000,4666,O
),4666,O
",",4666,O
TG,4666,O
(,4666,O
P=.003,4666,O
),4666,O
",",4666,O
and,4666,O
HbA1C,4666,B-GENE-Y
(,4666,O
P=.043,4666,O
),4666,O
",",4666,O
and,4666,O
significant,4666,O
increases,4666,O
in,4666,O
FCP,4666,B-GENE-Y
(,4666,O
P=.002,4666,O
),4666,O
and,4666,O
PCP,4666,B-GENE-Y
(,4666,O
P=.003,4666,O
),4666,O
were,4666,O
observed,4666,O
.,4666,O
This,4667,O
small,4667,O
clinical,4667,O
trial,4667,O
suggests,4667,O
that,4667,O
long-term,4667,O
consumption,4667,O
of,4667,O
honey,4667,O
might,4667,O
have,4667,O
positive,4667,O
effects,4667,O
on,4667,O
the,4667,O
metabolic,4667,O
derangements,4667,O
of,4667,O
type,4667,O
1,4667,O
DM,4667,O
.,4667,O
Evaluation,4668,O
of,4668,O
drug,4668,O
interactions,4668,O
of,4668,O
GSK1292263,4668,B-CHEMICAL
(,4668,O
a,4668,O
GPR119,4668,B-GENE-Y
agonist,4668,O
),4668,O
with,4668,O
statins,4668,O
:,4668,O
from,4668,O
in,4668,O
vitro,4668,O
data,4668,O
to,4668,O
clinical,4668,O
study,4668,O
design,4668,O
.,4668,O
1,4669,O
.,4669,O
This,4670,O
work,4670,O
investigated,4670,O
the,4670,O
drug,4670,O
interaction,4670,O
potential,4670,O
of,4670,O
GSK1292263,4670,B-CHEMICAL
",",4670,O
a,4670,O
novel,4670,O
GPR119,4670,B-GENE-Y
agonist,4670,O
",",4670,O
with,4670,O
the,4670,O
HMG-coA,4670,B-GENE-Y
reductase,4670,I-GENE-Y
inhibitors,4670,O
simvastatin,4670,B-CHEMICAL
and,4670,O
rosuvastatin,4670,B-CHEMICAL
.,4670,O
2,4671,O
.,4671,O
In,4672,O
vitro,4672,O
experiments,4672,O
assessed,4672,O
the,4672,O
inhibition,4672,O
of,4672,O
transporters,4672,B-GENE-N
and,4672,O
CYP,4672,B-GENE-N
enzymes,4672,O
by,4672,O
GSK1292263,4672,B-CHEMICAL
",",4672,O
and,4672,O
a,4672,O
clinical,4672,O
drug,4672,O
interaction,4672,O
study,4672,O
investigated,4672,O
the,4672,O
effect,4672,O
of,4672,O
GSK1292263,4672,B-CHEMICAL
(,4672,O
300,4672,O
mg,4672,O
BID,4672,O
),4672,O
on,4672,O
the,4672,O
pharmacokinetic,4672,O
profile,4672,O
of,4672,O
simvastatin,4672,B-CHEMICAL
(,4672,O
40,4672,O
mg,4672,O
single,4672,O
dose,4672,O
),4672,O
and,4672,O
rosuvastatin,4672,B-CHEMICAL
(,4672,O
10,4672,O
mg,4672,O
single,4672,O
dose,4672,O
),4672,O
.,4672,O
3,4673,O
.,4673,O
In,4674,O
vitro,4674,O
",",4674,O
GSK1292263,4674,B-CHEMICAL
demonstrated,4674,O
little/weak,4674,O
inhibition,4674,O
(,4674,O
IC50,4674,O
values,4674,O
>,4674,O
30,4674,O
μM,4674,O
),4674,O
towards,4674,O
CYPs,4674,B-GENE-N
(,4674,O
CYP1A2,4674,B-GENE-Y
",",4674,O
2C9,4674,B-GENE-Y
",",4674,O
2C19,4674,B-GENE-Y
",",4674,O
2D6,4674,B-GENE-Y
",",4674,O
3A4,4674,B-GENE-Y
),4674,O
",",4674,O
Pgp,4674,B-GENE-N
",",4674,O
OATP1B3,4674,B-GENE-Y
",",4674,O
or,4674,O
OCT2,4674,B-GENE-Y
.,4674,O
However,4675,O
",",4675,O
GSK1292263,4675,B-CHEMICAL
inhibited,4675,O
BCRP,4675,B-GENE-Y
and,4675,O
OATP1B1,4675,B-GENE-Y
",",4675,O
which,4675,O
are,4675,O
transporters,4675,O
involved,4675,O
in,4675,O
statin,4675,O
disposition,4675,O
.,4675,O
4,4676,O
.,4676,O
In,4677,O
the,4677,O
clinical,4677,O
study,4677,O
",",4677,O
small,4677,O
increases,4677,O
in,4677,O
the,4677,O
AUC,4677,O
(,4677,O
0-inf,4677,O
),4677,O
of,4677,O
simvastatin,4677,B-CHEMICAL
[,4677,O
mean,4677,O
ratio,4677,O
(,4677,O
90,4677,O
%,4677,O
CI,4677,O
),4677,O
of,4677,O
1.34,4677,O
(,4677,O
1.22,4677,O
",",4677,O
1.48,4677,O
),4677,O
],4677,O
and,4677,O
rosuvastatin,4677,B-CHEMICAL
[,4677,O
mean,4677,O
ratio,4677,O
(,4677,O
90,4677,O
%,4677,O
CI,4677,O
),4677,O
of,4677,O
1.39,4677,O
(,4677,O
1.30,4677,O
",",4677,O
1.49,4677,O
),4677,O
],4677,O
were,4677,O
observed,4677,O
when,4677,O
co-administered,4677,O
with,4677,O
GSK1292263,4677,B-CHEMICAL
",",4677,O
which,4677,O
is,4677,O
consistent,4677,O
with,4677,O
an,4677,O
inhibitory,4677,O
effect,4677,O
on,4677,O
intestinal,4677,O
BCRP,4677,B-GENE-Y
and,4677,O
CYP3A4,4677,B-GENE-Y
.,4677,O
In,4678,O
contrast,4678,O
",",4678,O
GSK1292263,4678,B-CHEMICAL
did,4678,O
not,4678,O
inhibit,4678,O
OATP1B1,4678,B-GENE-Y
based,4678,O
on,4678,O
the,4678,O
lack,4678,O
of,4678,O
changes,4678,O
in,4678,O
simvastatin,4678,B-CHEMICAL
acid,4678,O
exposure,4678,O
[,4678,O
mean,4678,O
AUC,4678,O
(,4678,O
0-inf,4678,O
),4678,O
ratio,4678,O
(,4678,O
90,4678,O
%,4678,O
CI,4678,O
),4678,O
of,4678,O
1.05,4678,O
(,4678,O
0.91,4678,O
",",4678,O
1.21,4678,O
),4678,O
],4678,O
.,4678,O
5,4679,O
.,4679,O
GSK1292263,4680,B-CHEMICAL
has,4680,O
a,4680,O
weak,4680,O
drug,4680,O
interaction,4680,O
with,4680,O
simvastatin,4680,B-CHEMICAL
and,4680,O
rosuvastain,4680,B-CHEMICAL
.,4680,O
This,4681,O
study,4681,O
provides,4681,O
a,4681,O
mechanistic,4681,O
understanding,4681,O
of,4681,O
the,4681,O
in,4681,O
vivo,4681,O
inhibition,4681,O
of,4681,O
transporters,4681,B-GENE-N
and,4681,O
enzymes,4681,O
by,4681,O
GSK1292263,4681,B-CHEMICAL
.,4681,O
Antioxidants,4682,O
and,4682,O
mucolytics,4682,O
in,4682,O
COPD,4682,O
management,4682,O
:,4682,O
when,4682,O
(,4682,O
if,4682,O
ever,4682,O
),4682,O
and,4682,O
in,4682,O
whom,4682,O
?,4682,O
Chronic,4683,O
obstructive,4683,O
pulmonary,4683,O
disease,4683,O
(,4683,O
COPD,4683,O
),4683,O
is,4683,O
a,4683,O
major,4683,O
cause,4683,O
of,4683,O
morbidity,4683,O
and,4683,O
mortality,4683,O
worldwide,4683,O
.,4683,O
Oxidative,4684,O
stress,4684,O
is,4684,O
an,4684,O
important,4684,O
mechanism,4684,O
in,4684,O
the,4684,O
pathogenesis,4684,O
of,4684,O
this,4684,O
disease,4684,O
.,4684,O
The,4685,O
oxidant/,4685,O
antioxidant,4685,O
imbalance,4685,O
occurring,4685,O
in,4685,O
smokers,4685,O
and,4685,O
patients,4685,O
with,4685,O
COPD,4685,O
is,4685,O
well,4685,O
established,4685,O
.,4685,O
Thus,4686,O
",",4686,O
therapeutic,4686,O
strategies,4686,O
targeting,4686,O
oxidative,4686,O
stress,4686,O
with,4686,O
pharmacological,4686,O
antioxidant,4686,O
agents,4686,O
or,4686,O
boosting,4686,O
the,4686,O
endogenous,4686,O
levels,4686,O
of,4686,O
antioxidants,4686,O
is,4686,O
likely,4686,O
to,4686,O
be,4686,O
beneficial,4686,O
as,4686,O
an,4686,O
adjunctive,4686,O
tool,4686,O
in,4686,O
the,4686,O
treatment,4686,O
of,4686,O
COPD,4686,O
patients,4686,O
.,4686,O
Thiol,4687,B-CHEMICAL
compounts,4687,O
such,4687,O
as,4687,O
N-acetyl-L-cysteine,4687,B-CHEMICAL
(,4687,O
NAC,4687,B-CHEMICAL
),4687,O
",",4687,O
carbocysteine,4687,B-CHEMICAL
",",4687,O
erdosteine,4687,B-CHEMICAL
",",4687,O
and,4687,O
fudosteine,4687,B-CHEMICAL
have,4687,O
been,4687,O
extensively,4687,O
studied,4687,O
.,4687,O
Although,4688,O
some,4688,O
results,4688,O
remain,4688,O
controversial,4688,O
",",4688,O
NAC,4688,B-CHEMICAL
and,4688,O
carbocysteine,4688,B-CHEMICAL
seem,4688,O
to,4688,O
have,4688,O
beneficial,4688,O
effect,4688,O
in,4688,O
patients,4688,O
not,4688,O
receiving,4688,O
inhaled,4688,O
corticosteroids,4688,B-CHEMICAL
who,4688,O
suffer,4688,O
from,4688,O
frequent,4688,O
exacerbations,4688,O
.,4688,O
In,4689,O
addition,4689,O
",",4689,O
other,4689,O
antioxidants,4689,O
like,4689,O
superoxide,4689,B-GENE-N
dismutase,4689,I-GENE-N
(,4689,O
SOD,4689,B-GENE-N
),4689,O
mimetics,4689,O
and,4689,O
nuclear,4689,B-GENE-Y
factor-erythroid,4689,I-GENE-Y
2,4689,I-GENE-Y
related,4689,I-GENE-Y
factor,4689,I-GENE-Y
2,4689,I-GENE-Y
(,4689,O
Nrf2,4689,B-GENE-Y
),4689,O
are,4689,O
shown,4689,O
to,4689,O
decrease,4689,O
markers,4689,O
of,4689,O
oxidative,4689,O
stress,4689,O
in,4689,O
patients,4689,O
with,4689,O
emphysema,4689,O
",",4689,O
while,4689,O
others,4689,O
like,4689,O
glutathione,4689,B-CHEMICAL
peroxidase,4689,I-GENE-N
(,4689,O
GPx,4689,B-GENE-N
),4689,O
mimetics,4689,O
and,4689,O
NO,4689,B-CHEMICAL
synthase,4689,I-GENE-N
(,4689,O
iNOS,4689,B-GENE-Y
),4689,O
can,4689,O
prevent,4689,O
both,4689,O
inflammation,4689,O
and,4689,O
oxidative,4689,O
stress,4689,O
in,4689,O
clinical,4689,O
trials,4689,O
in,4689,O
vivo,4689,O
(,4689,O
or,4689,O
in,4689,O
mouse,4689,O
models,4689,O
),4689,O
.,4689,O
In,4690,O
this,4690,O
article,4690,O
we,4690,O
review,4690,O
the,4690,O
effectiveness,4690,O
of,4690,O
various,4690,O
antioxidant,4690,O
factors,4690,O
in,4690,O
COPD,4690,O
and,4690,O
their,4690,O
potential,4690,O
beneficial,4690,O
effect,4690,O
in,4690,O
the,4690,O
treatment,4690,O
of,4690,O
the,4690,O
disease,4690,O
.,4690,O
Steroid,4691,B-CHEMICAL
toxicity,4691,O
and,4691,O
detoxification,4691,O
in,4691,O
ascomycetous,4691,O
fungi,4691,O
.,4691,O
In,4692,O
the,4692,O
last,4692,O
couple,4692,O
of,4692,O
decades,4692,O
fungal,4692,O
infections,4692,O
have,4692,O
become,4692,O
a,4692,O
significant,4692,O
clinical,4692,O
problem,4692,O
.,4692,O
A,4693,O
major,4693,O
interest,4693,O
into,4693,O
fungal,4693,O
steroid,4693,B-CHEMICAL
action,4693,O
has,4693,O
been,4693,O
provoked,4693,O
since,4693,O
research,4693,O
has,4693,O
proven,4693,O
that,4693,O
steroid,4693,B-CHEMICAL
hormones,4693,O
are,4693,O
toxic,4693,O
to,4693,O
fungi,4693,O
and,4693,O
affect,4693,O
the,4693,O
host/fungus,4693,O
relationship,4693,O
.,4693,O
Steroid,4694,B-CHEMICAL
hormones,4694,O
were,4694,O
found,4694,O
to,4694,O
differ,4694,O
in,4694,O
their,4694,O
antifungal,4694,O
activity,4694,O
in,4694,O
ascomycetous,4694,O
fungi,4694,O
Hortaea,4694,O
werneckii,4694,O
",",4694,O
Saccharomyces,4694,O
cerevisiae,4694,O
and,4694,O
Aspergillus,4694,O
oryzae,4694,O
.,4694,O
Dehydroepiandrosterone,4695,O
was,4695,O
shown,4695,O
to,4695,O
be,4695,O
the,4695,O
strongest,4695,O
inhibitor,4695,O
of,4695,O
growth,4695,O
in,4695,O
all,4695,O
three,4695,O
varieties,4695,O
of,4695,O
fungi,4695,O
followed,4695,O
by,4695,O
androstenedione,4695,B-CHEMICAL
and,4695,O
testosterone,4695,B-CHEMICAL
.,4695,O
For,4696,O
their,4696,O
protection,4696,O
",",4696,O
fungi,4696,O
use,4696,O
several,4696,O
mechanisms,4696,O
to,4696,O
lower,4696,O
the,4696,O
toxic,4696,O
effects,4696,O
of,4696,O
steroids,4696,B-CHEMICAL
.,4696,O
The,4697,O
efficiency,4697,O
of,4697,O
biotransformation,4697,O
in,4697,O
detoxification,4697,O
depended,4697,O
on,4697,O
the,4697,O
microorganism,4697,O
and,4697,O
steroid,4697,B-CHEMICAL
substrate,4697,O
used,4697,O
.,4697,O
Biotransformation,4698,O
was,4698,O
a,4698,O
relatively,4698,O
slow,4698,O
process,4698,O
as,4698,O
it,4698,O
also,4698,O
depended,4698,O
on,4698,O
the,4698,O
growth,4698,O
phase,4698,O
of,4698,O
the,4698,O
fungus,4698,O
.,4698,O
In,4699,O
addition,4699,O
to,4699,O
biotransformation,4699,O
",",4699,O
steroid,4699,B-CHEMICAL
extrusion,4699,O
out,4699,O
of,4699,O
the,4699,O
cells,4699,O
contributed,4699,O
to,4699,O
the,4699,O
lowering,4699,O
of,4699,O
the,4699,O
active,4699,O
intracellular,4699,O
steroid,4699,B-CHEMICAL
concentration,4699,O
.,4699,O
Plasma,4700,O
membrane,4700,O
Pdr5,4700,B-GENE-N
transporter,4700,O
was,4700,O
found,4700,O
to,4700,O
be,4700,O
the,4700,O
most,4700,O
effective,4700,O
",",4700,O
followed,4700,O
by,4700,O
Snq2,4700,B-GENE-N
transporter,4700,O
and,4700,O
vacuolar,4700,O
transporters,4700,O
Ybt1,4700,B-GENE-N
and,4700,O
Ycf1,4700,B-GENE-N
.,4700,O
Proteins,4701,O
Aus1,4701,B-GENE-N
and,4701,O
Dan1,4701,B-GENE-N
were,4701,O
not,4701,O
found,4701,O
to,4701,O
be,4701,O
involved,4701,O
in,4701,O
steroid,4701,B-CHEMICAL
import,4701,O
.,4701,O
The,4702,O
research,4702,O
of,4702,O
possible,4702,O
targets,4702,O
of,4702,O
steroid,4702,B-CHEMICAL
hormone,4702,O
action,4702,O
in,4702,O
fungi,4702,O
suggests,4702,O
that,4702,O
steroid,4702,B-CHEMICAL
hormones,4702,O
inhibit,4702,O
ergosterol,4702,B-CHEMICAL
biosynthesis,4702,O
in,4702,O
S.,4702,O
cerevisiae,4702,O
and,4702,O
H.,4702,O
werneckii,4702,O
.,4702,O
Results,4703,O
of,4703,O
this,4703,O
inhibition,4703,O
caused,4703,O
changes,4703,O
in,4703,O
the,4703,O
sterol,4703,B-CHEMICAL
content,4703,O
of,4703,O
the,4703,O
cellular,4703,O
membrane,4703,O
.,4703,O
The,4704,O
presence,4704,O
of,4704,O
steroid,4704,B-CHEMICAL
hormones,4704,O
most,4704,O
probably,4704,O
causes,4704,O
the,4704,O
degradation,4704,O
of,4704,O
the,4704,O
Tat2,4704,B-GENE-N
permease,4704,O
and,4704,O
impairment,4704,O
of,4704,O
tryptophan,4704,B-CHEMICAL
import,4704,O
.,4704,O
Cell-cycle,4705,O
and,4705,O
DNA,4705,O
damage,4705,O
regulation,4705,O
of,4705,O
the,4705,O
DNA,4705,B-GENE-Y
mismatch,4705,I-GENE-Y
repair,4705,I-GENE-Y
protein,4705,I-GENE-Y
Msh2,4705,I-GENE-Y
occurs,4705,O
at,4705,O
the,4705,O
transcriptional,4705,O
and,4705,O
post-transcriptional,4705,O
level,4705,O
.,4705,O
DNA,4706,O
mismatch,4706,O
repair,4706,O
during,4706,O
replication,4706,O
is,4706,O
a,4706,O
conserved,4706,O
process,4706,O
essential,4706,O
for,4706,O
maintaining,4706,O
genomic,4706,O
stability,4706,O
.,4706,O
Mismatch,4707,O
repair,4707,O
is,4707,O
also,4707,O
implicated,4707,O
in,4707,O
cell-cycle,4707,O
arrest,4707,O
and,4707,O
apoptosis,4707,O
after,4707,O
DNA,4707,O
damage,4707,O
.,4707,O
Because,4708,O
yeast,4708,O
and,4708,O
human,4708,O
mismatch,4708,O
repair,4708,O
systems,4708,O
are,4708,O
well,4708,O
conserved,4708,O
",",4708,O
we,4708,O
have,4708,O
employed,4708,O
the,4708,O
budding,4708,O
yeast,4708,O
Saccharomyces,4708,O
cerevisiae,4708,O
to,4708,O
understand,4708,O
the,4708,O
regulation,4708,O
and,4708,O
function,4708,O
of,4708,O
the,4708,O
mismatch,4708,O
repair,4708,O
gene,4708,O
MSH2,4708,B-GENE-Y
.,4708,O
Using,4709,O
a,4709,O
luciferase-based,4709,O
transcriptional,4709,O
reporter,4709,O
",",4709,O
we,4709,O
defined,4709,O
a,4709,O
218-bp,4709,O
region,4709,O
upstream,4709,O
of,4709,O
MSH2,4709,B-GENE-Y
that,4709,O
contains,4709,O
cell-cycle,4709,B-GENE-N
and,4709,I-GENE-N
DNA,4709,I-GENE-N
damage,4709,I-GENE-N
responsive,4709,I-GENE-N
elements,4709,I-GENE-N
.,4709,O
The,4710,O
5,4710,O
',4710,O
end,4710,O
of,4710,O
the,4710,O
MSH2,4710,B-GENE-Y
transcript,4710,O
was,4710,O
mapped,4710,O
by,4710,O
primer,4710,O
extension,4710,O
and,4710,O
was,4710,O
found,4710,O
to,4710,O
encode,4710,O
a,4710,O
small,4710,O
upstream,4710,B-GENE-N
open,4710,I-GENE-N
reading,4710,I-GENE-N
frame,4710,I-GENE-N
(,4710,O
uORF,4710,B-GENE-N
),4710,O
.,4710,O
Mutagenesis,4711,O
of,4711,O
the,4711,O
uORF,4711,B-GENE-N
start,4711,I-GENE-N
codon,4711,I-GENE-N
or,4711,O
of,4711,O
the,4711,O
uORF,4711,B-GENE-N
stop,4711,I-GENE-N
codon,4711,I-GENE-N
",",4711,O
which,4711,O
creates,4711,O
a,4711,O
continuous,4711,O
reading,4711,O
frame,4711,O
with,4711,O
MSH2,4711,B-GENE-Y
",",4711,O
increased,4711,O
Msh2,4711,B-GENE-Y
steady-state,4711,O
protein,4711,O
levels,4711,O
∼2-fold,4711,O
.,4711,O
Furthermore,4712,O
",",4712,O
we,4712,O
found,4712,O
that,4712,O
the,4712,O
cell-cycle,4712,O
transcription,4712,O
factors,4712,O
Swi6,4712,B-GENE-Y
",",4712,O
Swi4,4712,B-GENE-Y
",",4712,O
and,4712,O
Mbp1-along,4712,B-GENE-Y
with,4712,O
SCB/MCB,4712,B-GENE-N
cell-cycle,4712,I-GENE-N
binding,4712,I-GENE-N
sites,4712,O
upstream,4712,O
of,4712,O
MSH2-are,4712,B-GENE-Y
all,4712,O
required,4712,O
for,4712,O
full,4712,O
basal,4712,O
expression,4712,O
of,4712,O
MSH2,4712,B-GENE-Y
.,4712,O
Mutagenesis,4713,O
of,4713,O
the,4713,O
cell-cycle,4713,B-GENE-N
boxes,4713,I-GENE-N
resulted,4713,O
in,4713,O
a,4713,O
minor,4713,O
reduction,4713,O
in,4713,O
basal,4713,O
Msh2,4713,B-GENE-Y
levels,4713,O
and,4713,O
a,4713,O
3-fold,4713,O
defect,4713,O
in,4713,O
mismatch,4713,O
repair,4713,O
.,4713,O
Disruption,4714,O
of,4714,O
the,4714,O
cell-cycle,4714,B-GENE-N
boxes,4714,I-GENE-N
also,4714,O
affected,4714,O
growth,4714,O
in,4714,O
a,4714,O
DNA,4714,B-GENE-N
polymerase-defective,4714,O
strain,4714,O
background,4714,O
where,4714,O
mismatch,4714,O
repair,4714,O
is,4714,O
essential,4714,O
",",4714,O
particularly,4714,O
in,4714,O
the,4714,O
presence,4714,O
of,4714,O
the,4714,O
DNA,4714,O
damaging,4714,O
agent,4714,O
methyl,4714,B-CHEMICAL
methane,4714,I-CHEMICAL
sulfonate,4714,I-CHEMICAL
(,4714,O
MMS,4714,B-CHEMICAL
),4714,O
.,4714,O
Promoter,4715,O
replacements,4715,O
conferring,4715,O
constitutive,4715,O
expression,4715,O
of,4715,O
MSH2,4715,B-GENE-Y
revealed,4715,O
that,4715,O
the,4715,O
transcriptional,4715,O
induction,4715,O
in,4715,O
response,4715,O
to,4715,O
MMS,4715,B-CHEMICAL
is,4715,O
required,4715,O
to,4715,O
maintain,4715,O
induced,4715,O
levels,4715,O
of,4715,O
Msh2,4715,B-GENE-Y
.,4715,O
Turnover,4716,O
experiments,4716,O
confirmed,4716,O
an,4716,O
elevated,4716,O
rate,4716,O
of,4716,O
degradation,4716,O
in,4716,O
the,4716,O
presence,4716,O
of,4716,O
MMS,4716,B-CHEMICAL
.,4716,O
Taken,4717,O
together,4717,O
",",4717,O
the,4717,O
data,4717,O
show,4717,O
that,4717,O
the,4717,O
DNA,4717,O
damage,4717,O
regulation,4717,O
of,4717,O
Msh2,4717,B-GENE-Y
occurs,4717,O
at,4717,O
the,4717,O
transcriptional,4717,O
and,4717,O
post-transcriptional,4717,O
levels,4717,O
.,4717,O
The,4718,O
transcriptional,4718,O
and,4718,O
translational,4718,O
control,4718,O
elements,4718,O
identified,4718,O
are,4718,O
conserved,4718,O
in,4718,O
mammalian,4718,O
cells,4718,O
",",4718,O
underscoring,4718,O
the,4718,O
use,4718,O
of,4718,O
yeast,4718,O
as,4718,O
a,4718,O
model,4718,O
system,4718,O
to,4718,O
examine,4718,O
the,4718,O
regulation,4718,O
of,4718,O
MSH2,4718,B-GENE-Y
.,4718,O
Inhibition,4719,O
of,4719,O
Th1/Th17,4719,O
responses,4719,O
via,4719,O
suppression,4719,O
of,4719,O
STAT1,4719,B-GENE-Y
and,4719,O
STAT3,4719,B-GENE-Y
activation,4719,O
contributes,4719,O
to,4719,O
the,4719,O
amelioration,4719,O
of,4719,O
murine,4719,O
experimental,4719,O
colitis,4719,O
by,4719,O
a,4719,O
natural,4719,O
flavonoid,4719,B-CHEMICAL
glucoside,4719,O
icariin,4719,B-CHEMICAL
.,4719,O
Inflammatory,4720,O
bowel,4720,O
disease,4720,O
(,4720,O
IBD,4720,O
),4720,O
is,4720,O
a,4720,O
chronic,4720,O
inflammatory,4720,O
disorder,4720,O
in,4720,O
the,4720,O
intestine,4720,O
which,4720,O
involves,4720,O
overproduction,4720,O
of,4720,O
pro-inflammatory,4720,O
cytokines,4720,B-GENE-N
and,4720,O
excessive,4720,O
functions,4720,O
of,4720,O
inflammatory,4720,O
cells,4720,O
.,4720,O
However,4721,O
",",4721,O
current,4721,O
treatments,4721,O
for,4721,O
IBD,4721,O
may,4721,O
have,4721,O
potential,4721,O
adverse,4721,O
effects,4721,O
including,4721,O
steroid,4721,B-CHEMICAL
dependence,4721,O
",",4721,O
infections,4721,O
and,4721,O
lymphoma,4721,O
.,4721,O
Therefore,4722,O
new,4722,O
therapies,4722,O
or,4722,O
drug,4722,O
candidates,4722,O
for,4722,O
the,4722,O
treatment,4722,O
of,4722,O
IBD,4722,O
are,4722,O
desperately,4722,O
needed,4722,O
.,4722,O
In,4723,O
the,4723,O
present,4723,O
study,4723,O
we,4723,O
found,4723,O
that,4723,O
icariin,4723,B-CHEMICAL
",",4723,O
a,4723,O
major,4723,O
bioactive,4723,O
compound,4723,O
from,4723,O
plants,4723,O
in,4723,O
Epimedium,4723,O
family,4723,O
",",4723,O
exerted,4723,O
protective,4723,O
effect,4723,O
on,4723,O
intestinal,4723,O
inflammation,4723,O
in,4723,O
mice,4723,O
induced,4723,O
by,4723,O
dextran,4723,O
sulfate,4723,B-CHEMICAL
sodium,4723,B-CHEMICAL
.,4723,O
Oral,4724,O
administration,4724,O
of,4724,O
icariin,4724,B-CHEMICAL
significantly,4724,O
attenuated,4724,O
the,4724,O
disease,4724,O
progression,4724,O
and,4724,O
alleviated,4724,O
the,4724,O
pathological,4724,O
changes,4724,O
of,4724,O
colitis,4724,O
.,4724,O
It,4725,O
also,4725,O
inhibited,4725,O
the,4725,O
production,4725,O
of,4725,O
pro-inflammatory,4725,O
cytokines,4725,B-GENE-N
and,4725,O
expression,4725,O
of,4725,O
p-p65,4725,B-GENE-Y
",",4725,O
p-STAT1,4725,B-GENE-Y
and,4725,O
p-STAT3,4725,B-GENE-Y
in,4725,O
colon,4725,O
tissues,4725,O
.,4725,O
Further,4726,O
study,4726,O
showed,4726,O
that,4726,O
icariin,4726,B-CHEMICAL
dose-dependently,4726,O
inhibited,4726,O
the,4726,O
proliferation,4726,O
and,4726,O
activation,4726,O
of,4726,O
T,4726,O
lymphocytes,4726,O
",",4726,O
and,4726,O
suppressed,4726,O
pro-inflammatory,4726,O
cytokine,4726,B-GENE-N
levels,4726,O
of,4726,O
activated,4726,O
T,4726,O
cells,4726,O
.,4726,O
Moreover,4727,O
",",4727,O
icariin,4727,B-CHEMICAL
treatment,4727,O
inhibited,4727,O
the,4727,O
phosphorylations,4727,O
of,4727,O
STAT1,4727,B-GENE-Y
and,4727,O
STAT3,4727,B-GENE-Y
in,4727,O
CD4,4727,O
(,4727,O
+,4727,O
),4727,O
T,4727,O
cells,4727,O
",",4727,O
which,4727,O
were,4727,O
the,4727,O
crucial,4727,O
transcription,4727,O
factors,4727,O
for,4727,O
Th1,4727,O
and,4727,O
Th17,4727,O
respectively,4727,O
.,4727,O
Taken,4728,O
together,4728,O
",",4728,O
these,4728,O
results,4728,O
indicate,4728,O
that,4728,O
icariin,4728,B-CHEMICAL
is,4728,O
a,4728,O
potential,4728,O
therapeutic,4728,O
agent,4728,O
for,4728,O
IBD,4728,O
.,4728,O
Stimulatory,4729,O
effect,4729,O
of,4729,O
insulin,4729,B-GENE-Y
on,4729,O
theca-interstitial,4729,O
cell,4729,O
proliferation,4729,O
and,4729,O
cell,4729,O
cycle,4729,O
regulatory,4729,O
proteins,4729,O
through,4729,O
MTORC1,4729,B-GENE-N
dependent,4729,O
pathway,4729,O
.,4729,O
The,4730,O
present,4730,O
study,4730,O
examined,4730,O
the,4730,O
effect,4730,O
of,4730,O
insulin-mediated,4730,B-GENE-Y
activation,4730,O
of,4730,O
the,4730,O
mammalian,4730,B-GENE-N
target,4730,I-GENE-N
of,4730,I-GENE-N
rapamycin,4730,B-CHEMICAL
complex,4730,I-GENE-N
1,4730,I-GENE-N
(,4730,O
MTORC1,4730,B-GENE-N
),4730,O
signaling,4730,O
network,4730,O
on,4730,O
the,4730,O
proliferation,4730,O
of,4730,O
primary,4730,O
culture,4730,O
of,4730,O
theca-interstitial,4730,O
(,4730,O
T-I,4730,O
),4730,O
cells,4730,O
.,4730,O
Our,4731,O
results,4731,O
show,4731,O
that,4731,O
insulin,4731,O
treatment,4731,O
increased,4731,O
proliferation,4731,O
of,4731,O
the,4731,O
T-I,4731,O
cells,4731,O
through,4731,O
the,4731,O
MTORC1-dependent,4731,B-GENE-N
signaling,4731,O
pathway,4731,O
by,4731,O
increasing,4731,O
cell,4731,O
cycle,4731,O
regulatory,4731,O
proteins,4731,O
.,4731,O
Inhibition,4732,O
of,4732,O
ERK1/2,4732,B-GENE-N
signaling,4732,O
caused,4732,O
partial,4732,O
reduction,4732,O
of,4732,O
insulin-induced,4732,B-GENE-Y
phosphorylation,4732,O
of,4732,O
RPS6KB1,4732,B-GENE-Y
and,4732,O
RPS6,4732,B-GENE-Y
whereas,4732,O
inhibition,4732,O
of,4732,O
PI3-kinase,4732,B-GENE-N
signaling,4732,O
completely,4732,O
blocked,4732,O
the,4732,O
insulin,4732,B-GENE-Y
response,4732,O
.,4732,O
Pharmacological,4733,O
inhibition,4733,O
of,4733,O
MTORC1,4733,B-GENE-N
with,4733,O
rapamycin,4733,B-CHEMICAL
abrogated,4733,O
the,4733,O
insulin-induced,4733,B-GENE-Y
phosphorylation,4733,O
of,4733,O
EIF4EBP1,4733,B-GENE-Y
",",4733,O
RPS6KB1,4733,B-GENE-Y
and,4733,O
its,4733,O
downstream,4733,O
effector,4733,O
",",4733,O
RPS6,4733,B-GENE-Y
.,4733,O
These,4734,O
results,4734,O
were,4734,O
further,4734,O
confirmed,4734,O
by,4734,O
demonstrating,4734,O
that,4734,O
knockdown,4734,O
of,4734,O
Mtor,4734,B-GENE-Y
using,4734,O
siRNA,4734,O
reduced,4734,O
the,4734,O
insulin-stimulated,4734,B-GENE-Y
MTORC1,4734,B-GENE-N
signaling,4734,O
.,4734,O
Furthermore,4735,O
",",4735,O
insulin-stimulated,4735,B-GENE-Y
T-I,4735,O
cell,4735,O
proliferation,4735,O
and,4735,O
the,4735,O
expression,4735,O
of,4735,O
cell,4735,B-GENE-N
cycle,4735,I-GENE-N
regulatory,4735,I-GENE-N
proteins,4735,I-GENE-N
CDK4,4735,B-GENE-Y
",",4735,O
CCND3,4735,B-GENE-Y
and,4735,O
PCNA,4735,B-GENE-Y
were,4735,O
also,4735,O
blocked,4735,O
by,4735,O
rapamycin,4735,B-CHEMICAL
.,4735,O
Taken,4736,O
together,4736,O
",",4736,O
the,4736,O
present,4736,O
studies,4736,O
show,4736,O
that,4736,O
insulin,4736,O
stimulates,4736,O
cell,4736,O
proliferation,4736,O
and,4736,O
cell,4736,O
cycle,4736,O
regulatory,4736,O
proteins,4736,O
in,4736,O
T-I,4736,O
cells,4736,O
via,4736,O
activation,4736,O
of,4736,O
the,4736,O
MTORC1,4736,B-GENE-N
signaling,4736,O
pathway,4736,O
.,4736,O
The,4737,O
conserved,4737,O
PHD1-PHD2,4737,B-GENE-N
domain,4737,I-GENE-N
of,4737,O
ZFP-1/AF10,4737,B-GENE-Y
is,4737,O
a,4737,O
discrete,4737,O
functional,4737,O
module,4737,O
essential,4737,O
for,4737,O
viability,4737,O
in,4737,O
Caenorhabditis,4737,O
elegans,4737,O
.,4737,O
Plant,4738,B-GENE-N
homeodomain,4738,I-GENE-N
(,4738,I-GENE-N
PHD,4738,I-GENE-N
),4738,I-GENE-N
-type,4738,I-GENE-N
zinc,4738,I-GENE-N
fingers,4738,I-GENE-N
play,4738,O
an,4738,O
important,4738,O
role,4738,O
in,4738,O
recognizing,4738,O
chromatin,4738,O
modifications,4738,O
and,4738,O
recruiting,4738,O
regulatory,4738,O
proteins,4738,O
to,4738,O
specific,4738,O
genes,4738,O
.,4738,O
A,4739,O
specific,4739,O
module,4739,O
containing,4739,O
a,4739,O
conventional,4739,O
PHD,4739,B-GENE-N
finger,4739,I-GENE-N
followed,4739,O
by,4739,O
an,4739,O
extended,4739,O
PHD,4739,B-GENE-N
finger,4739,I-GENE-N
exists,4739,O
in,4739,O
the,4739,O
mammalian,4739,O
AF10,4739,B-GENE-N
protein,4739,O
",",4739,O
among,4739,O
a,4739,O
few,4739,O
others,4739,O
.,4739,O
AF10,4740,B-GENE-Y
has,4740,O
mostly,4740,O
been,4740,O
studied,4740,O
in,4740,O
the,4740,O
context,4740,O
of,4740,O
the,4740,O
leukemic,4740,O
MLL-AF10,4740,B-GENE-Y
fusion,4740,O
protein,4740,O
",",4740,O
which,4740,O
lacks,4740,O
the,4740,O
N-terminal,4740,B-CHEMICAL
PHD,4740,I-GENE-N
fingers,4740,I-GENE-N
of,4740,O
AF10,4740,B-GENE-Y
.,4740,O
Although,4741,O
this,4741,O
domain,4741,O
of,4741,O
AF10,4741,B-GENE-Y
is,4741,O
the,4741,O
most,4741,O
conserved,4741,O
region,4741,O
of,4741,O
the,4741,O
protein,4741,O
",",4741,O
its,4741,O
biological,4741,O
significance,4741,O
has,4741,O
not,4741,O
been,4741,O
elucidated,4741,O
.,4741,O
In,4742,O
this,4742,O
study,4742,O
",",4742,O
we,4742,O
used,4742,O
genetic,4742,O
and,4742,O
biochemical,4742,O
approaches,4742,O
to,4742,O
examine,4742,O
the,4742,O
PHD1-PHD2,4742,B-GENE-N
region,4742,O
of,4742,O
the,4742,O
Caenorhabditis,4742,O
elegans,4742,O
ortholog,4742,O
of,4742,O
AF10,4742,B-GENE-Y
",",4742,O
zinc,4742,B-CHEMICAL
finger,4742,I-GENE-Y
protein,4742,I-GENE-Y
1,4742,I-GENE-Y
(,4742,O
ZFP-1,4742,B-GENE-Y
),4742,O
.,4742,O
We,4743,O
demonstrate,4743,O
that,4743,O
the,4743,O
PHD1-PHD2,4743,B-GENE-N
region,4743,O
is,4743,O
essential,4743,O
for,4743,O
viability,4743,O
and,4743,O
that,4743,O
the,4743,O
first,4743,O
PHD,4743,B-GENE-N
finger,4743,I-GENE-N
contributes,4743,O
to,4743,O
the,4743,O
preferred,4743,O
binding,4743,O
of,4743,O
PHD1-PHD2,4743,B-GENE-N
to,4743,O
lysine,4743,B-CHEMICAL
4-methylated,4743,O
histone,4743,O
H3,4743,O
tails,4743,O
.,4743,O
Moreover,4744,O
",",4744,O
we,4744,O
show,4744,O
that,4744,O
ZFP-1,4744,B-GENE-Y
localization,4744,O
peaks,4744,O
overlap,4744,O
with,4744,O
H3K4,4744,O
methylation-enriched,4744,O
promoters,4744,O
of,4744,O
actively,4744,O
expressed,4744,O
genes,4744,O
genomewide,4744,O
and,4744,O
that,4744,O
H3K4,4744,O
methylation,4744,O
is,4744,O
important,4744,O
for,4744,O
ZFP-1,4744,B-GENE-Y
localization,4744,O
to,4744,O
promoters,4744,O
in,4744,O
the,4744,O
embryo,4744,O
.,4744,O
We,4745,O
predict,4745,O
that,4745,O
the,4745,O
essential,4745,O
biological,4745,O
role,4745,O
of,4745,O
the,4745,O
PHD1-PHD2,4745,B-GENE-N
module,4745,O
of,4745,O
ZFP-1/AF10,4745,B-GENE-Y
is,4745,O
connected,4745,O
to,4745,O
the,4745,O
regulation,4745,O
of,4745,O
actively,4745,O
expressed,4745,O
genes,4745,O
during,4745,O
early,4745,O
development,4745,O
.,4745,O
Novel,4746,O
limonene,4746,B-CHEMICAL
and,4746,O
citral,4746,B-CHEMICAL
based,4746,O
"2,5-disubstituted-1,3,4-oxadiazoles",4746,B-CHEMICAL
:,4746,O
a,4746,O
natural,4746,O
product,4746,O
coupled,4746,O
approach,4746,O
to,4746,O
semicarbazones,4746,B-CHEMICAL
for,4746,O
antiepileptic,4746,O
activity,4746,O
.,4746,O
Two,4747,O
novel,4747,O
series,4747,O
of,4747,O
N,4747,B-CHEMICAL
(,4747,I-CHEMICAL
4,4747,I-CHEMICAL
),4747,I-CHEMICAL
-,4747,I-CHEMICAL
(,4747,I-CHEMICAL
5-,4747,I-CHEMICAL
(,4747,I-CHEMICAL
2/3/4-substituted-phenyl,4747,I-CHEMICAL
),4747,I-CHEMICAL
"-1,3,4-oxadiazol-2-yl",4747,I-CHEMICAL
),4747,I-CHEMICAL
-N,4747,I-CHEMICAL
(,4747,I-CHEMICAL
1,4747,I-CHEMICAL
),4747,I-CHEMICAL
-,4747,I-CHEMICAL
(,4747,I-CHEMICAL
2-methyl-5-,4747,I-CHEMICAL
(,4747,I-CHEMICAL
prop-1-en-2-yl,4747,I-CHEMICAL
),4747,I-CHEMICAL
cyclohex-2-enylidene,4747,I-CHEMICAL
),4747,I-CHEMICAL
semicarbazide,4747,I-CHEMICAL
and,4747,O
N,4747,B-CHEMICAL
(,4747,I-CHEMICAL
4,4747,I-CHEMICAL
),4747,I-CHEMICAL
-,4747,I-CHEMICAL
(,4747,I-CHEMICAL
5-,4747,I-CHEMICAL
(,4747,I-CHEMICAL
2/3/4-substituted-phenyl,4747,I-CHEMICAL
),4747,I-CHEMICAL
"-1,3,4-oxadiazol-2-yl",4747,I-CHEMICAL
),4747,I-CHEMICAL
-N,4747,I-CHEMICAL
(,4747,I-CHEMICAL
1,4747,I-CHEMICAL
),4747,I-CHEMICAL
-,4747,I-CHEMICAL
(,4747,I-CHEMICAL
"3,7-dimethylocta-3,6-dienylidene",4747,I-CHEMICAL
),4747,I-CHEMICAL
-semicarbazide,4747,I-CHEMICAL
were,4747,O
synthesized,4747,O
to,4747,O
meet,4747,O
structural,4747,O
prerequisite,4747,O
indispensable,4747,O
for,4747,O
anticonvulsant,4747,O
activity,4747,O
.,4747,O
The,4748,O
anticonvulsant,4748,O
activities,4748,O
of,4748,O
the,4748,O
compounds,4748,O
were,4748,O
investigated,4748,O
using,4748,O
maximal,4748,O
electroshock,4748,O
seizure,4748,O
(,4748,O
MES,4748,O
),4748,O
",",4748,O
subcutaneous,4748,O
pentylenetrtrazole,4748,B-CHEMICAL
(,4748,O
scPTZ,4748,O
),4748,O
and,4748,O
subcutaneous,4748,O
strychnine,4748,B-CHEMICAL
(,4748,O
scSTY,4748,O
),4748,O
models,4748,O
.,4748,O
The,4749,O
rotorod,4749,O
test,4749,O
was,4749,O
conducted,4749,O
to,4749,O
evaluate,4749,O
neurotoxicity,4749,O
.,4749,O
Some,4750,O
of,4750,O
the,4750,O
selected,4750,O
active,4750,O
compounds,4750,O
were,4750,O
subjected,4750,O
to,4750,O
GABA,4750,B-CHEMICAL
assay,4750,O
to,4750,O
confirm,4750,O
their,4750,O
mode,4750,O
of,4750,O
action,4750,O
.,4750,O
The,4751,O
outcome,4751,O
of,4751,O
the,4751,O
present,4751,O
investigations,4751,O
proved,4751,O
that,4751,O
the,4751,O
four,4751,O
binding,4751,O
sites,4751,O
pharmacophore,4751,O
model,4751,O
is,4751,O
vital,4751,O
for,4751,O
anticonvulsant,4751,O
activity,4751,O
.,4751,O
The,4752,O
efforts,4752,O
were,4752,O
also,4752,O
made,4752,O
to,4752,O
establish,4752,O
structure-activity,4752,O
relationships,4752,O
among,4752,O
test,4752,O
compounds,4752,O
.,4752,O
Synthesis,4753,O
and,4753,O
evaluation,4753,O
of,4753,O
8-oxoadenine,4753,B-CHEMICAL
derivatives,4753,O
as,4753,O
potent,4753,O
Toll-like,4753,B-GENE-Y
receptor,4753,I-GENE-Y
7,4753,I-GENE-Y
agonists,4753,O
with,4753,O
high,4753,O
water,4753,O
solubility,4753,O
.,4753,O
We,4754,O
report,4754,O
the,4754,O
discovery,4754,O
of,4754,O
novel,4754,O
series,4754,O
of,4754,O
highly,4754,O
potent,4754,O
TLR7,4754,B-GENE-Y
agonists,4754,O
based,4754,O
on,4754,O
8-oxoadenines,4754,B-CHEMICAL
",",4754,O
1,4754,O
and,4754,O
2,4754,O
by,4754,O
introducing,4754,O
and,4754,O
optimizing,4754,O
various,4754,O
tertiary,4754,B-CHEMICAL
amines,4754,I-CHEMICAL
onto,4754,O
the,4754,O
N,4754,B-CHEMICAL
(,4754,O
9,4754,O
),4754,O
-position,4754,O
of,4754,O
the,4754,O
adenine,4754,B-CHEMICAL
moiety,4754,O
.,4754,O
The,4755,O
introduction,4755,O
of,4755,O
the,4755,O
amino,4755,B-CHEMICAL
group,4755,O
resulted,4755,O
in,4755,O
not,4755,O
only,4755,O
improved,4755,O
water,4755,O
solubility,4755,O
but,4755,O
also,4755,O
enhanced,4755,O
TLR7,4755,B-GENE-Y
agonistic,4755,O
activity,4755,O
.,4755,O
In,4756,O
particular,4756,O
compound,4756,O
20,4756,O
(,4756,O
DSR-6434,4756,B-CHEMICAL
),4756,O
indicated,4756,O
an,4756,O
optimal,4756,O
balance,4756,O
between,4756,O
the,4756,O
agonistic,4756,O
potency,4756,O
and,4756,O
high,4756,O
water,4756,O
solubility,4756,O
.,4756,O
It,4757,O
also,4757,O
demonstrated,4757,O
a,4757,O
strong,4757,O
antitumor,4757,O
effect,4757,O
in,4757,O
vivo,4757,O
by,4757,O
intravenous,4757,O
administration,4757,O
in,4757,O
a,4757,O
tumor,4757,O
bearing,4757,O
mice,4757,O
model,4757,O
.,4757,O
Discovery,4758,O
of,4758,O
liver-targeted,4758,O
inhibitors,4758,O
of,4758,O
stearoyl-CoA,4758,B-GENE-Y
desaturase,4758,I-GENE-Y
(,4758,O
SCD1,4758,B-GENE-Y
),4758,O
.,4758,O
Inhibitors,4759,O
based,4759,O
on,4759,O
a,4759,O
benzo-fused,4759,B-CHEMICAL
spirocyclic,4759,I-CHEMICAL
oxazepine,4759,I-CHEMICAL
scaffold,4759,O
were,4759,O
discovered,4759,O
for,4759,O
stearoyl-coenzyme,4759,B-GENE-Y
A,4759,I-GENE-Y
(,4759,I-GENE-Y
CoA,4759,B-CHEMICAL
),4759,I-GENE-Y
desaturase,4759,I-GENE-Y
1,4759,I-GENE-Y
(,4759,O
SCD1,4759,B-GENE-Y
),4759,O
and,4759,O
subsequently,4759,O
optimized,4759,O
to,4759,O
potent,4759,O
compounds,4759,O
with,4759,O
favorable,4759,O
pharmacokinetic,4759,O
profiles,4759,O
and,4759,O
in,4759,O
vivo,4759,O
efficacy,4759,O
in,4759,O
reducing,4759,O
the,4759,O
desaturation,4759,O
index,4759,O
in,4759,O
a,4759,O
mouse,4759,O
model,4759,O
.,4759,O
Initial,4760,O
optimization,4760,O
revealed,4760,O
potency,4760,O
preferences,4760,O
for,4760,O
the,4760,O
oxazepine,4760,B-CHEMICAL
core,4760,O
and,4760,O
benzylic,4760,B-CHEMICAL
positions,4760,O
",",4760,O
while,4760,O
substituents,4760,O
on,4760,O
the,4760,O
piperidine,4760,B-CHEMICAL
portions,4760,O
were,4760,O
more,4760,O
tolerant,4760,O
and,4760,O
allowed,4760,O
for,4760,O
tuning,4760,O
of,4760,O
potency,4760,O
and,4760,O
PK,4760,O
properties,4760,O
.,4760,O
After,4761,O
preparation,4761,O
and,4761,O
testing,4761,O
of,4761,O
a,4761,O
range,4761,O
of,4761,O
functional,4761,O
groups,4761,O
on,4761,O
the,4761,O
piperidine,4761,B-CHEMICAL
nitrogen,4761,B-CHEMICAL
",",4761,O
three,4761,O
classes,4761,O
of,4761,O
analogs,4761,O
were,4761,O
identified,4761,O
with,4761,O
single,4761,O
digit,4761,O
nanomolar,4761,O
potency,4761,O
:,4761,O
glycine,4761,B-CHEMICAL
amides,4761,I-CHEMICAL
",",4761,O
heterocycle-linked,4761,O
amides,4761,B-CHEMICAL
",",4761,O
and,4761,O
thiazoles,4761,B-CHEMICAL
.,4761,O
Responding,4762,O
to,4762,O
concerns,4762,O
about,4762,O
target,4762,O
localization,4762,O
and,4762,O
potential,4762,O
mechanism-based,4762,O
side,4762,O
effects,4762,O
",",4762,O
an,4762,O
initial,4762,O
effort,4762,O
was,4762,O
also,4762,O
made,4762,O
to,4762,O
improve,4762,O
liver,4762,O
concentration,4762,O
in,4762,O
an,4762,O
available,4762,O
rat,4762,O
PK,4762,O
model,4762,O
.,4762,O
An,4763,O
advanced,4763,O
compound,4763,O
17m,4763,O
with,4763,O
a,4763,O
5-carboxy-2-thiazole,4763,B-CHEMICAL
substructure,4763,O
appended,4763,O
to,4763,O
the,4763,O
spirocyclic,4763,B-CHEMICAL
piperidine,4763,I-CHEMICAL
scaffold,4763,O
was,4763,O
developed,4763,O
which,4763,O
satisfied,4763,O
the,4763,O
in,4763,O
vitro,4763,O
and,4763,O
in,4763,O
vivo,4763,O
requirements,4763,O
for,4763,O
more,4763,O
detailed,4763,O
studies,4763,O
.,4763,O
N-acetylgalactosamine,4764,B-CHEMICAL
functionalized,4764,O
mixed,4764,O
micellar,4764,O
nanoparticles,4764,O
for,4764,O
targeted,4764,O
delivery,4764,O
of,4764,O
siRNA,4764,O
to,4764,O
liver,4764,O
.,4764,O
Due,4765,O
to,4765,O
its,4765,O
efficient,4765,O
and,4765,O
specific,4765,O
gene,4765,O
silencing,4765,O
ability,4765,O
",",4765,O
RNA,4765,O
interference,4765,O
has,4765,O
shown,4765,O
great,4765,O
potential,4765,O
in,4765,O
the,4765,O
treatment,4765,O
of,4765,O
liver,4765,O
diseases,4765,O
.,4765,O
However,4766,O
",",4766,O
achieving,4766,O
in,4766,O
vivo,4766,O
delivery,4766,O
of,4766,O
siRNA,4766,O
to,4766,O
critical,4766,O
liver,4766,O
cells,4766,O
remains,4766,O
the,4766,O
biggest,4766,O
obstacle,4766,O
for,4766,O
this,4766,O
technique,4766,O
to,4766,O
be,4766,O
a,4766,O
real,4766,O
clinic,4766,O
therapeutic,4766,O
modality,4766,O
.,4766,O
Here,4767,O
",",4767,O
we,4767,O
describe,4767,O
a,4767,O
promising,4767,O
liver,4767,O
targeting,4767,O
siRNA,4767,O
delivery,4767,O
system,4767,O
based,4767,O
on,4767,O
N-acetylgalactosamine,4767,B-CHEMICAL
functionalized,4767,O
mixed,4767,O
micellar,4767,O
nanoparticles,4767,O
(,4767,O
Gal-MNP,4767,O
),4767,O
",",4767,O
which,4767,O
can,4767,O
efficiently,4767,O
deliver,4767,O
siRNA,4767,O
to,4767,O
hepatocytes,4767,O
and,4767,O
silence,4767,O
the,4767,O
target,4767,O
gene,4767,O
expression,4767,O
after,4767,O
systemic,4767,O
administration,4767,O
.,4767,O
The,4768,O
Gal-MNP,4768,O
were,4768,O
assembled,4768,O
in,4768,O
aqueous,4768,O
solution,4768,O
from,4768,O
mixed,4768,O
N-acetylgalactosamine,4768,B-CHEMICAL
functionalized,4768,O
poly,4768,B-CHEMICAL
(,4768,I-CHEMICAL
ethylene,4768,I-CHEMICAL
glycol,4768,I-CHEMICAL
),4768,I-CHEMICAL
-b-poly,4768,I-CHEMICAL
(,4768,I-CHEMICAL
ε-caprolactone,4768,I-CHEMICAL
),4768,I-CHEMICAL
and,4768,O
cationic,4768,O
poly,4768,B-CHEMICAL
(,4768,I-CHEMICAL
ε-caprolactone,4768,I-CHEMICAL
),4768,I-CHEMICAL
-b-poly,4768,I-CHEMICAL
(,4768,I-CHEMICAL
2-aminoethyl,4768,I-CHEMICAL
ethylene,4768,I-CHEMICAL
phosphate,4768,I-CHEMICAL
),4768,I-CHEMICAL
(,4768,O
PCL-b-PPEEA,4768,B-CHEMICAL
),4768,O
;,4768,O
the,4768,O
properties,4768,O
of,4768,O
nanoparticles,4768,O
",",4768,O
including,4768,O
particle,4768,O
size,4768,O
",",4768,O
zeta,4768,O
potential,4768,O
and,4768,O
the,4768,O
density,4768,O
of,4768,O
poly,4768,B-CHEMICAL
(,4768,I-CHEMICAL
ethylene,4768,I-CHEMICAL
glycol,4768,I-CHEMICAL
),4768,I-CHEMICAL
could,4768,O
be,4768,O
easily,4768,O
regulated,4768,O
.,4768,O
The,4769,O
hepatocyte-targeting,4769,O
effect,4769,O
of,4769,O
Gal-MNP,4769,O
was,4769,O
demonstrated,4769,O
by,4769,O
significant,4769,O
enriching,4769,O
of,4769,O
fluorescent,4769,O
siRNA,4769,O
in,4769,O
primary,4769,O
hepatocytes,4769,O
in,4769,O
vitro,4769,O
and,4769,O
in,4769,O
vivo,4769,O
.,4769,O
Successful,4770,O
down-regulation,4770,O
of,4770,O
liver-specific,4770,O
apolipoprotein,4770,B-GENE-Y
B,4770,I-GENE-Y
(,4770,O
apoB,4770,B-GENE-Y
),4770,O
expression,4770,O
was,4770,O
achieved,4770,O
in,4770,O
mouse,4770,O
liver,4770,O
",",4770,O
at,4770,O
both,4770,O
the,4770,O
transcriptional,4770,O
and,4770,O
protein,4770,O
level,4770,O
",",4770,O
following,4770,O
intravenous,4770,O
injection,4770,O
of,4770,O
Gal-MNP/siapoB,4770,O
to,4770,O
BALB/c,4770,O
mice,4770,O
.,4770,O
Systemic,4771,O
delivery,4771,O
of,4771,O
Gal-MNP/siRNA,4771,O
did,4771,O
not,4771,O
induce,4771,O
the,4771,O
innate,4771,O
immune,4771,O
response,4771,O
or,4771,O
positive,4771,O
hepatotoxicity,4771,O
.,4771,O
The,4772,O
results,4772,O
of,4772,O
this,4772,O
study,4772,O
suggested,4772,O
therapeutic,4772,O
potential,4772,O
for,4772,O
the,4772,O
Gal-MNP/siRNA,4772,O
system,4772,O
in,4772,O
liver,4772,O
disease,4772,O
.,4772,O
Effects,4773,O
of,4773,O
Yerba,4773,O
Mate,4773,O
tea,4773,O
(,4773,O
Ilex,4773,O
paraguariensis,4773,O
),4773,O
on,4773,O
vascular,4773,O
endothelial,4773,O
function,4773,O
and,4773,O
liver,4773,O
lipoprotein,4773,B-GENE-N
receptor,4773,I-GENE-N
gene,4773,O
expression,4773,O
in,4773,O
hyperlipidemic,4773,O
rats,4773,O
.,4773,O
Yerba,4774,O
Mate,4774,O
tea,4774,O
(,4774,O
Mate,4774,O
),4774,O
",",4774,O
an,4774,O
infusion,4774,O
made,4774,O
from,4774,O
the,4774,O
leaves,4774,O
of,4774,O
the,4774,O
tree,4774,O
Ilex,4774,O
paraguariensis,4774,O
",",4774,O
is,4774,O
a,4774,O
widely,4774,O
consumed,4774,O
beverage,4774,O
in,4774,O
South,4774,O
America,4774,O
.,4774,O
This,4775,O
study,4775,O
was,4775,O
performed,4775,O
to,4775,O
investigate,4775,O
the,4775,O
effect,4775,O
of,4775,O
Mate,4775,O
tea,4775,O
on,4775,O
vascular,4775,O
endothelial,4775,O
dysfunction,4775,O
and,4775,O
liver,4775,O
lipoprotein,4775,B-GENE-N
receptor,4775,I-GENE-N
gene,4775,O
expression,4775,O
in,4775,O
hyperlipidemic,4775,O
rats,4775,O
",",4775,O
with,4775,O
the,4775,O
aim,4775,O
of,4775,O
gaining,4775,O
insight,4775,O
into,4775,O
its,4775,O
known,4775,O
lipid-lowering,4775,O
protective,4775,O
mechanisms,4775,O
.,4775,O
Sixty,4776,O
male,4776,O
Sprague-Dawley,4776,O
rats,4776,O
were,4776,O
randomly,4776,O
divided,4776,O
into,4776,O
five,4776,O
groups,4776,O
:,4776,O
a,4776,O
normal,4776,O
control,4776,O
group,4776,O
(,4776,O
NC,4776,O
),4776,O
",",4776,O
a,4776,O
high-fat,4776,O
diet,4776,O
group,4776,O
(,4776,O
HC,4776,O
),4776,O
",",4776,O
and,4776,O
three,4776,O
Mate,4776,O
tea-treated,4776,O
groups,4776,O
.,4776,O
In,4777,O
the,4777,O
NC,4777,O
group,4777,O
",",4777,O
rats,4777,O
were,4777,O
fed,4777,O
with,4777,O
standard,4777,O
diet,4777,O
while,4777,O
in,4777,O
the,4777,O
other,4777,O
groups,4777,O
the,4777,O
rats,4777,O
were,4777,O
fed,4777,O
a,4777,O
high-fat,4777,O
diet,4777,O
for,4777,O
8weeks,4777,O
.,4777,O
In,4778,O
the,4778,O
Mate,4778,O
tea-treated,4778,O
groups,4778,O
",",4778,O
the,4778,O
rats,4778,O
were,4778,O
fed,4778,O
a,4778,O
high-fat,4778,O
diet,4778,O
supplemented,4778,O
with,4778,O
low,4778,O
",",4778,O
moderate,4778,O
or,4778,O
high,4778,O
concentrations,4778,O
of,4778,O
aqueous,4778,O
Mate,4778,O
tea,4778,O
extract,4778,O
for,4778,O
the,4778,O
final,4778,O
4weeks,4778,O
.,4778,O
Compared,4779,O
to,4779,O
the,4779,O
HC,4779,O
group,4779,O
",",4779,O
aqueous,4779,O
Mate,4779,O
tea,4779,O
extract,4779,O
significantly,4779,O
reduced,4779,O
endothelin,4779,B-GENE-N
(,4779,O
ET,4779,B-GENE-N
),4779,O
and,4779,O
thromboxane,4779,B-CHEMICAL
B,4779,I-CHEMICAL
(,4779,I-CHEMICAL
2,4779,I-CHEMICAL
),4779,I-CHEMICAL
(,4779,O
TXB,4779,B-CHEMICAL
(,4779,I-CHEMICAL
2,4779,I-CHEMICAL
),4779,I-CHEMICAL
),4779,O
levels,4779,O
and,4779,O
increased,4779,O
nitric,4779,B-CHEMICAL
oxide,4779,I-CHEMICAL
(,4779,O
NO,4779,B-CHEMICAL
),4779,O
and,4779,O
6-keto,4779,B-CHEMICAL
prostaglandin,4779,I-CHEMICAL
F,4779,I-CHEMICAL
(,4779,I-CHEMICAL
1α,4779,I-CHEMICAL
),4779,I-CHEMICAL
(,4779,O
6-keto-PGF,4779,B-CHEMICAL
(,4779,I-CHEMICAL
1α,4779,I-CHEMICAL
),4779,I-CHEMICAL
),4779,O
levels,4779,O
in,4779,O
the,4779,O
blood,4779,O
",",4779,O
reduced,4779,O
the,4779,O
pathological,4779,O
damage,4779,O
of,4779,O
vascular,4779,O
endothelial,4779,O
cells,4779,O
",",4779,O
decreased,4779,O
intercellular,4779,B-GENE-Y
adhesion,4779,I-GENE-Y
molecule-1,4779,I-GENE-Y
(,4779,O
ICAM-1,4779,B-GENE-Y
),4779,O
protein,4779,O
expression,4779,O
in,4779,O
the,4779,O
thoracic,4779,O
aorta,4779,O
",",4779,O
and,4779,O
upregulated,4779,O
mRNA,4779,O
expression,4779,O
of,4779,O
hepatic,4779,O
low,4779,B-GENE-Y
density,4779,I-GENE-Y
lipoprotein,4779,I-GENE-Y
receptor,4779,I-GENE-Y
(,4779,O
LDLR,4779,B-GENE-Y
),4779,O
and,4779,O
scavenger,4779,B-GENE-Y
receptor,4779,I-GENE-Y
B1,4779,I-GENE-Y
(,4779,O
SR-B1,4779,B-GENE-Y
),4779,O
.,4779,O
These,4780,O
findings,4780,O
indicate,4780,O
that,4780,O
Mate,4780,O
tea,4780,O
administration,4780,O
might,4780,O
have,4780,O
a,4780,O
regulatory,4780,O
effect,4780,O
on,4780,O
blood,4780,O
fat,4780,O
and,4780,O
endothelial,4780,O
function,4780,O
in,4780,O
hyperlipidemia,4780,O
rats,4780,O
.,4780,O
The,4781,O
mechanism,4781,O
may,4781,O
involve,4781,O
protecting,4781,O
vascular,4781,O
endothelial,4781,O
cell,4781,O
function,4781,O
and,4781,O
upregulating,4781,O
the,4781,O
expression,4781,O
of,4781,O
LDLR,4781,B-GENE-Y
and,4781,O
SR-B1,4781,B-GENE-Y
genes,4781,O
",",4781,O
thereby,4781,O
inhibiting,4781,O
the,4781,O
occurrence,4781,O
of,4781,O
atherosclerosis,4781,O
.,4781,O
Development,4782,O
of,4782,O
hypoxia-inducible,4782,B-GENE-Y
factor,4782,I-GENE-Y
(,4782,I-GENE-Y
HIF,4782,I-GENE-Y
),4782,I-GENE-Y
-1α,4782,I-GENE-Y
inhibitors,4782,O
:,4782,O
effect,4782,O
of,4782,O
ortho-carborane,4782,B-CHEMICAL
substituents,4782,O
on,4782,O
HIF,4782,B-GENE-N
transcriptional,4782,O
activity,4782,O
under,4782,O
hypoxia,4782,O
.,4782,O
A,4783,O
series,4783,O
of,4783,O
substituted,4783,O
ortho-carboranylphenoxyacetanilides,4783,B-CHEMICAL
were,4783,O
synthesized,4783,O
and,4783,O
evaluated,4783,O
for,4783,O
their,4783,O
ability,4783,O
to,4783,O
inhibit,4783,O
hypoxia-induced,4783,O
HIF-1,4783,B-GENE-N
transcriptional,4783,O
activity,4783,O
using,4783,O
a,4783,O
cell-based,4783,O
reporter,4783,O
assay,4783,O
in,4783,O
HeLa,4783,O
cells,4783,O
expressing,4783,O
the,4783,O
HRE-dependent,4783,B-GENE-N
firefly,4783,O
luciferase,4783,O
reporter,4783,O
construct,4783,O
(,4783,O
HRE-Luc,4783,B-GENE-N
),4783,O
and,4783,O
constitutively,4783,O
expressing,4783,O
CMV-driven,4783,O
Renilla,4783,O
luciferase,4783,O
reporter,4783,O
",",4783,O
and,4783,O
their,4783,O
ability,4783,O
to,4783,O
inhibit,4783,O
cell,4783,O
growth,4783,O
(,4783,O
GI,4783,O
(,4783,O
50,4783,O
),4783,O
),4783,O
using,4783,O
the,4783,O
MTT,4783,B-CHEMICAL
assay,4783,O
.,4783,O
Among,4784,O
the,4784,O
compounds,4784,O
synthesized,4784,O
",",4784,O
1g,4784,O
and,4784,O
1l,4784,O
showed,4784,O
significant,4784,O
inhibition,4784,O
of,4784,O
hypoxia-induced,4784,O
HIF-1,4784,B-GENE-N
transcriptional,4784,O
activity,4784,O
(,4784,O
IC,4784,O
(,4784,O
50,4784,O
),4784,O
:,4784,O
1.9,4784,O
±,4784,O
0.4,4784,O
and,4784,O
1.4,4784,O
±,4784,O
0.2,4784,O
μM,4784,O
",",4784,O
respectively,4784,O
),4784,O
.,4784,O
Both,4785,O
compounds,4785,O
suppressed,4785,O
HIF-1α,4785,B-GENE-Y
accumulation,4785,O
in,4785,O
a,4785,O
concentration-dependent,4785,O
manner,4785,O
.,4785,O
The,4786,O
porcine,4786,B-GENE-N
heart,4786,I-GENE-N
malate,4786,B-CHEMICAL
dehydrogenase,4786,I-GENE-N
(,4786,O
MDH,4786,B-GENE-N
),4786,O
refolding,4786,O
assay,4786,O
revealed,4786,O
that,4786,O
compound,4786,O
1l,4786,O
inhibited,4786,O
human,4786,B-GENE-Y
Hsp60,4786,I-GENE-Y
chaperone,4786,O
activity,4786,O
(,4786,O
IC,4786,O
(,4786,O
50,4786,O
),4786,O
:,4786,O
6.80,4786,O
±,4786,O
0.25,4786,O
μM,4786,O
),4786,O
and,4786,O
this,4786,O
inhibition,4786,O
activity,4786,O
was,4786,O
higher,4786,O
than,4786,O
that,4786,O
of,4786,O
ETB,4786,B-CHEMICAL
(,4786,O
IC,4786,O
(,4786,O
50,4786,O
),4786,O
:,4786,O
10.9,4786,O
±,4786,O
0.63,4786,O
μM,4786,O
),4786,O
.,4786,O
Apocynin,4787,B-CHEMICAL
and,4787,O
raisanberine,4787,B-CHEMICAL
alleviate,4787,O
intermittent,4787,O
hypoxia,4787,O
induced,4787,O
abnormal,4787,O
StAR,4787,B-GENE-Y
and,4787,O
3β-HSD,4787,B-GENE-N
and,4787,O
low,4787,O
testosterone,4787,B-CHEMICAL
by,4787,O
suppressing,4787,O
endoplasmic,4787,O
reticulum,4787,O
stress,4787,O
and,4787,O
activated,4787,O
p66Shc,4787,B-GENE-Y
in,4787,O
rat,4787,O
testes,4787,O
.,4787,O
We,4788,O
hypothesized,4788,O
that,4788,O
hypoxia,4788,O
induced,4788,O
testicular,4788,O
damage,4788,O
is,4788,O
mediated,4788,O
by,4788,O
an,4788,O
activated,4788,O
NADPH,4788,B-CHEMICAL
oxidase,4788,I-GENE-N
(,4788,O
NOX,4788,B-GENE-N
),4788,O
",",4788,O
therefore,4788,O
",",4788,O
APO,4788,B-CHEMICAL
(,4788,O
apocynin,4788,B-CHEMICAL
),4788,O
an,4788,O
inhibitor,4788,O
of,4788,O
NOX,4788,B-GENE-N
and,4788,O
raisanberine,4788,B-CHEMICAL
(,4788,O
RS,4788,O
),4788,O
",",4788,O
a,4788,O
calcium,4788,B-CHEMICAL
influx,4788,O
inhibitor,4788,O
were,4788,O
tested,4788,O
if,4788,O
they,4788,O
could,4788,O
attenuate,4788,O
hypoxic,4788,O
toxicity,4788,O
to,4788,O
the,4788,O
testis,4788,O
.,4788,O
Male,4789,O
Sprague-Dawley,4789,O
rats,4789,O
were,4789,O
exposed,4789,O
to,4789,O
hypoxia,4789,O
(,4789,O
10±0.5,4789,O
%,4789,O
O2,4789,O
),4789,O
for,4789,O
17d,4789,O
and,4789,O
intervened,4789,O
with,4789,O
APO,4789,B-CHEMICAL
and,4789,O
RS,4789,O
in,4789,O
the,4789,O
last,4789,O
6d,4789,O
.,4789,O
Histological,4790,O
changes,4790,O
and,4790,O
expression,4790,O
of,4790,O
pro-inflammation,4790,O
factors,4790,O
were,4790,O
evaluated,4790,O
in,4790,O
vivo,4790,O
.,4790,O
Biomarkers,4791,O
in,4791,O
isolated,4791,O
Leydig,4791,O
cells,4791,O
incubated,4791,O
with,4791,O
H2O2,4791,B-CHEMICAL
were,4791,O
also,4791,O
assayed,4791,O
in,4791,O
vitro,4791,O
.,4791,O
Hypoxic,4792,O
rats,4792,O
displayed,4792,O
lower,4792,O
serum,4792,O
testosterone,4792,B-CHEMICAL
and,4792,O
higher,4792,O
LH,4792,B-GENE-N
and,4792,O
FSH,4792,B-GENE-N
.,4792,O
Upregulation,4793,O
of,4793,O
p22/p47,4793,B-GENE-N
(,4793,I-GENE-N
phox,4793,I-GENE-N
),4793,I-GENE-N
",",4793,O
NOX2,4793,B-GENE-Y
",",4793,O
MMP9,4793,B-GENE-Y
",",4793,O
PERK,4793,B-GENE-Y
and,4793,O
p66Shc,4793,B-GENE-Y
was,4793,O
associated,4793,O
with,4793,O
downregulation,4793,O
of,4793,O
StAR,4793,B-GENE-Y
",",4793,O
3β-HSD,4793,B-GENE-N
and,4793,O
Cx43,4793,B-GENE-Y
in,4793,O
the,4793,O
hypoxia,4793,O
testis,4793,O
",",4793,O
revealed,4793,O
by,4793,O
Western,4793,O
blot,4793,O
and,4793,O
immunohistochemical,4793,O
assay,4793,O
",",4793,O
respectively,4793,O
.,4793,O
APO,4794,B-CHEMICAL
and,4794,O
RS,4794,O
at,4794,O
least,4794,O
partially,4794,O
normalize,4794,O
hypoxia,4794,O
caused,4794,O
male,4794,O
hypogonadism,4794,O
by,4794,O
suppressing,4794,O
ER,4794,O
stress,4794,O
",",4794,O
and,4794,O
p66Shc,4794,B-GENE-Y
in,4794,O
testes,4794,O
.,4794,O
Coming,4795,O
full,4795,O
circle,4795,O
:,4795,O
contributions,4795,O
of,4795,O
central,4795,O
and,4795,O
peripheral,4795,O
oxytocin,4795,B-CHEMICAL
actions,4795,O
to,4795,O
energy,4795,O
balance,4795,O
.,4795,O
The,4796,O
neuropeptide,4796,O
oxytocin,4796,B-GENE-Y
has,4796,O
emerged,4796,O
as,4796,O
an,4796,O
important,4796,O
anorexigen,4796,B-CHEMICAL
in,4796,O
the,4796,O
regulation,4796,O
of,4796,O
energy,4796,O
balance,4796,O
.,4796,O
Its,4797,O
effects,4797,O
on,4797,O
food,4797,O
intake,4797,O
have,4797,O
largely,4797,O
been,4797,O
attributed,4797,O
to,4797,O
limiting,4797,O
meal,4797,O
size,4797,O
through,4797,O
interactions,4797,O
in,4797,O
key,4797,O
regulatory,4797,O
brain,4797,O
regions,4797,O
such,4797,O
as,4797,O
the,4797,O
hypothalamus,4797,O
and,4797,O
hindbrain,4797,O
.,4797,O
Pharmacologic,4798,O
and,4798,O
pair-feeding,4798,O
studies,4798,O
indicate,4798,O
that,4798,O
its,4798,O
ability,4798,O
to,4798,O
reduce,4798,O
body,4798,O
mass,4798,O
extends,4798,O
beyond,4798,O
that,4798,O
of,4798,O
food,4798,O
intake,4798,O
",",4798,O
affecting,4798,O
multiple,4798,O
factors,4798,O
that,4798,O
determine,4798,O
energy,4798,O
balance,4798,O
such,4798,O
as,4798,O
energy,4798,O
expenditure,4798,O
",",4798,O
lipolysis,4798,O
",",4798,O
and,4798,O
glucose,4798,B-CHEMICAL
regulation,4798,O
.,4798,O
Systemic,4799,O
administration,4799,O
of,4799,O
oxytocin,4799,B-GENE-Y
recapitulates,4799,O
many,4799,O
of,4799,O
its,4799,O
effects,4799,O
when,4799,O
administered,4799,O
centrally,4799,O
",",4799,O
raising,4799,O
the,4799,O
questions,4799,O
of,4799,O
whether,4799,O
and,4799,O
to,4799,O
what,4799,O
extent,4799,O
circulating,4799,O
oxytocin,4799,B-CHEMICAL
contributes,4799,O
to,4799,O
energy,4799,O
regulation,4799,O
.,4799,O
Its,4800,O
therapeutic,4800,O
potential,4800,O
to,4800,O
treat,4800,O
metabolic,4800,O
conditions,4800,O
remains,4800,O
to,4800,O
be,4800,O
determined,4800,O
",",4800,O
but,4800,O
data,4800,O
from,4800,O
diet-induced,4800,O
and,4800,O
genetically,4800,O
obese,4800,O
rodent,4800,O
models,4800,O
as,4800,O
well,4800,O
as,4800,O
application,4800,O
of,4800,O
oxytocin,4800,B-CHEMICAL
in,4800,O
humans,4800,O
in,4800,O
other,4800,O
areas,4800,O
of,4800,O
research,4800,O
have,4800,O
revealed,4800,O
promising,4800,O
results,4800,O
thus,4800,O
far,4800,O
.,4800,O
Arsenic,4801,B-CHEMICAL
suppresses,4801,O
cell,4801,O
survival,4801,O
via,4801,O
Pirh2-mediated,4801,B-GENE-Y
proteasomal,4801,O
degradation,4801,O
of,4801,O
ΔNp63,4801,B-GENE-Y
protein,4801,O
.,4801,O
Transcription,4802,B-GENE-Y
factor,4802,I-GENE-Y
p63,4802,I-GENE-Y
",",4802,O
a,4802,O
member,4802,O
of,4802,O
the,4802,O
p53,4802,B-GENE-Y
family,4802,O
",",4802,O
shares,4802,O
a,4802,O
high,4802,O
degree,4802,O
of,4802,O
sequence,4802,O
similarity,4802,O
with,4802,O
p53,4802,B-GENE-Y
.,4802,O
Because,4803,O
of,4803,O
transcription,4803,O
from,4803,O
two,4803,O
distinct,4803,O
promoters,4803,O
",",4803,O
the,4803,O
p63,4803,B-GENE-N
gene,4803,O
encodes,4803,O
two,4803,O
isoforms,4803,O
",",4803,O
TAp63,4803,B-GENE-Y
and,4803,O
ΔNp63,4803,B-GENE-Y
.,4803,O
Although,4804,O
TAp63,4804,B-GENE-Y
acts,4804,O
as,4804,O
a,4804,O
tumor,4804,O
suppressor,4804,O
",",4804,O
ΔNp63,4804,B-GENE-Y
functions,4804,O
as,4804,O
an,4804,O
oncogene,4804,O
and,4804,O
is,4804,O
often,4804,O
overexpressed,4804,O
in,4804,O
squamous,4804,O
cell,4804,O
carcinomas,4804,O
.,4804,O
Thus,4805,O
",",4805,O
therapeutic,4805,O
agents,4805,O
targeting,4805,O
ΔNp63,4805,B-GENE-Y
might,4805,O
be,4805,O
used,4805,O
to,4805,O
manage,4805,O
tumors,4805,O
that,4805,O
overexpress,4805,O
ΔNp63,4805,B-GENE-Y
.,4805,O
Here,4806,O
we,4806,O
found,4806,O
that,4806,O
arsenic,4806,B-CHEMICAL
trioxide,4806,I-CHEMICAL
",",4806,O
a,4806,O
frontline,4806,O
agent,4806,O
for,4806,O
acute,4806,O
promyelocytic,4806,O
leukemia,4806,O
",",4806,O
inhibits,4806,O
ΔNp63,4806,B-GENE-Y
but,4806,O
not,4806,O
TAp63,4806,B-GENE-Y
expression,4806,O
in,4806,O
time-,4806,O
and,4806,O
dose-dependent,4806,O
manners,4806,O
.,4806,O
In,4807,O
addition,4807,O
",",4807,O
we,4807,O
found,4807,O
that,4807,O
arsenic,4807,B-CHEMICAL
trioxide,4807,I-CHEMICAL
decreases,4807,O
the,4807,O
stability,4807,O
of,4807,O
ΔNp63,4807,B-GENE-Y
protein,4807,O
via,4807,O
a,4807,O
proteasome-dependent,4807,B-GENE-N
pathway,4807,O
but,4807,O
has,4807,O
little,4807,O
effect,4807,O
on,4807,O
the,4807,O
level,4807,O
of,4807,O
ΔNp63,4807,B-GENE-Y
transcript,4807,O
.,4807,O
Furthermore,4808,O
",",4808,O
we,4808,O
found,4808,O
that,4808,O
arsenic,4808,B-CHEMICAL
trioxide,4808,I-CHEMICAL
activates,4808,O
the,4808,O
Pirh2,4808,B-GENE-N
promoter,4808,I-GENE-N
and,4808,O
consequently,4808,O
induces,4808,O
Pirh2,4808,B-GENE-Y
expression,4808,O
.,4808,O
Consistent,4809,O
with,4809,O
this,4809,O
",",4809,O
we,4809,O
found,4809,O
that,4809,O
knockdown,4809,O
of,4809,O
Pirh2,4809,B-GENE-Y
inhibits,4809,O
",",4809,O
whereas,4809,O
ectopic,4809,O
expression,4809,O
of,4809,O
Pirh2,4809,B-GENE-Y
enhances,4809,O
",",4809,O
arsenic-induced,4809,B-CHEMICAL
degradation,4809,O
of,4809,O
ΔNp63,4809,B-GENE-Y
protein,4809,O
.,4809,O
Importantly,4810,O
",",4810,O
we,4810,O
found,4810,O
that,4810,O
knockdown,4810,O
of,4810,O
ΔNp63,4810,B-GENE-Y
sensitizes,4810,O
",",4810,O
whereas,4810,O
ectopic,4810,O
expression,4810,O
of,4810,O
ΔNp63,4810,B-GENE-Y
inhibits,4810,O
",",4810,O
growth,4810,O
suppression,4810,O
induced,4810,O
by,4810,O
arsenic,4810,B-CHEMICAL
.,4810,O
Together,4811,O
",",4811,O
these,4811,O
data,4811,O
suggest,4811,O
that,4811,O
arsenic,4811,B-CHEMICAL
degrades,4811,O
ΔNp63,4811,B-GENE-Y
protein,4811,O
at,4811,O
least,4811,O
in,4811,O
part,4811,O
via,4811,O
Pirh2-dependent,4811,B-GENE-Y
proteolysis,4811,O
and,4811,O
that,4811,O
inhibition,4811,O
of,4811,O
ΔNp63,4811,B-GENE-Y
expression,4811,O
facilitates,4811,O
tumor,4811,O
cells,4811,O
to,4811,O
arsenic-induced,4811,B-CHEMICAL
death,4811,O
.,4811,O
Jaceosidin,4812,B-CHEMICAL
",",4812,O
isolated,4812,O
from,4812,O
dietary,4812,O
mugwort,4812,O
(,4812,O
Artemisia,4812,O
princeps,4812,O
),4812,O
",",4812,O
induces,4812,O
G2/M,4812,O
cell,4812,O
cycle,4812,O
arrest,4812,O
by,4812,O
inactivating,4812,O
cdc25C-cdc2,4812,B-GENE-Y
via,4812,O
ATM-Chk1/2,4812,B-GENE-Y
activation,4812,O
.,4812,O
Jaceosidin,4813,B-CHEMICAL
",",4813,O
a,4813,O
flavonoid,4813,B-CHEMICAL
derived,4813,O
from,4813,O
Artemisia,4813,O
princeps,4813,O
(,4813,O
Japanese,4813,O
mugwort,4813,O
),4813,O
",",4813,O
has,4813,O
been,4813,O
shown,4813,O
to,4813,O
inhibit,4813,O
the,4813,O
growth,4813,O
of,4813,O
several,4813,O
human,4813,O
cancer,4813,O
cells,4813,O
",",4813,O
However,4813,O
",",4813,O
the,4813,O
exact,4813,O
mechanism,4813,O
for,4813,O
the,4813,O
cytotoxic,4813,O
effect,4813,O
of,4813,O
jaceosidin,4813,B-CHEMICAL
is,4813,O
not,4813,O
completely,4813,O
understood,4813,O
.,4813,O
In,4814,O
this,4814,O
study,4814,O
",",4814,O
we,4814,O
investigated,4814,O
the,4814,O
molecular,4814,O
mechanism,4814,O
involved,4814,O
in,4814,O
the,4814,O
antiproliferative,4814,O
effect,4814,O
of,4814,O
jaceosidin,4814,B-CHEMICAL
in,4814,O
human,4814,O
endometrial,4814,O
cancer,4814,O
cells,4814,O
.,4814,O
We,4815,O
demonstrated,4815,O
that,4815,O
jaceosidin,4815,B-CHEMICAL
is,4815,O
a,4815,O
more,4815,O
potent,4815,O
inhibitor,4815,O
of,4815,O
cell,4815,O
growth,4815,O
than,4815,O
cisplatin,4815,B-CHEMICAL
in,4815,O
human,4815,O
endometrial,4815,O
cancer,4815,O
cells,4815,O
.,4815,O
In,4816,O
contrast,4816,O
",",4816,O
jaceosidin-induced,4816,B-CHEMICAL
cytotoxicity,4816,O
in,4816,O
normal,4816,O
endometrial,4816,O
cells,4816,O
was,4816,O
lower,4816,O
than,4816,O
that,4816,O
observed,4816,O
for,4816,O
cisplatin,4816,B-CHEMICAL
.,4816,O
Jaceosidin,4817,B-CHEMICAL
induced,4817,O
G2/M,4817,O
phase,4817,O
cell,4817,O
cycle,4817,O
arrest,4817,O
and,4817,O
modulated,4817,O
the,4817,O
levels,4817,O
of,4817,O
cyclin,4817,B-GENE-Y
B,4817,I-GENE-Y
and,4817,O
p-Cdc2,4817,B-GENE-Y
in,4817,O
Hec1A,4817,O
cells,4817,O
.,4817,O
Knockdown,4818,O
of,4818,O
p21,4818,B-GENE-Y
using,4818,O
specific,4818,O
siRNAs,4818,O
partially,4818,O
abrogated,4818,O
jaceosidin-induced,4818,B-CHEMICAL
cell,4818,O
growth,4818,O
inhibition,4818,O
.,4818,O
Additional,4819,O
mechanistic,4819,O
studies,4819,O
revealed,4819,O
that,4819,O
jaceosidin,4819,B-CHEMICAL
treatment,4819,O
resulted,4819,O
in,4819,O
an,4819,O
increase,4819,O
in,4819,O
phosphorylation,4819,O
of,4819,O
Cdc25C,4819,B-GENE-Y
and,4819,O
ATM-Chk1/2,4819,B-GENE-Y
.,4819,O
Ku55933,4820,O
",",4820,O
an,4820,O
ATM,4820,B-GENE-Y
inhibitor,4820,O
",",4820,O
reversed,4820,O
jaceosidin-induced,4820,B-CHEMICAL
cell,4820,O
growth,4820,O
inhibition,4820,O
",",4820,O
in,4820,O
part,4820,O
.,4820,O
Moreover,4821,O
",",4821,O
jaceosidin,4821,B-CHEMICAL
treatment,4821,O
resulted,4821,O
in,4821,O
phosphorylation,4821,O
of,4821,O
ERK,4821,B-GENE-N
",",4821,O
and,4821,O
pretreatment,4821,O
with,4821,O
the,4821,O
ERK,4821,B-GENE-N
inhibitor,4821,O
",",4821,O
PD98059,4821,B-CHEMICAL
",",4821,O
attenuated,4821,O
cell,4821,O
growth,4821,O
inhibition,4821,O
by,4821,O
jaceosidin,4821,B-CHEMICAL
.,4821,O
These,4822,O
data,4822,O
suggest,4822,O
that,4822,O
jaceosidin,4822,B-CHEMICAL
",",4822,O
isolated,4822,O
from,4822,O
Japanese,4822,O
mugwort,4822,O
",",4822,O
modulates,4822,O
the,4822,O
ERK/ATM/Chk1/2,4822,B-GENE-N
pathway,4822,O
",",4822,O
leading,4822,O
to,4822,O
inactivation,4822,O
of,4822,O
the,4822,O
Cdc2-cyclin,4822,B-GENE-Y
B1,4822,I-GENE-Y
complex,4822,O
",",4822,O
followed,4822,O
by,4822,O
G2/M,4822,O
cell,4822,O
cycle,4822,O
arrest,4822,O
in,4822,O
endometrial,4822,O
cancer,4822,O
cells,4822,O
.,4822,O
EphA5-EphrinA5,4823,B-GENE-Y
interactions,4823,O
within,4823,O
the,4823,O
ventromedial,4823,O
hypothalamus,4823,O
influence,4823,O
counterregulatory,4823,O
hormone,4823,O
release,4823,O
and,4823,O
local,4823,O
glutamine/glutamate,4823,B-CHEMICAL
balance,4823,O
during,4823,O
hypoglycemia,4823,O
.,4823,O
Activation,4824,O
of,4824,O
β-cell,4824,O
EphA5,4824,B-GENE-Y
receptors,4824,I-GENE-Y
by,4824,O
its,4824,O
ligand,4824,O
ephrinA5,4824,B-GENE-Y
from,4824,O
adjacent,4824,O
β-cells,4824,O
has,4824,O
been,4824,O
reported,4824,O
to,4824,O
decrease,4824,O
insulin,4824,O
secretion,4824,O
during,4824,O
hypoglycemia,4824,O
.,4824,O
Given,4825,O
the,4825,O
similarities,4825,O
between,4825,O
islet,4825,O
and,4825,O
ventromedial,4825,O
hypothalamus,4825,O
(,4825,O
VMH,4825,O
),4825,O
glucose,4825,B-CHEMICAL
sensing,4825,O
",",4825,O
we,4825,O
tested,4825,O
the,4825,O
hypothesis,4825,O
that,4825,O
the,4825,O
EphA5/ephrinA5,4825,B-GENE-Y
system,4825,O
might,4825,O
function,4825,O
within,4825,O
the,4825,O
VMH,4825,O
during,4825,O
hypoglycemia,4825,O
to,4825,O
stimulate,4825,O
counterregulatory,4825,O
hormone,4825,O
release,4825,O
as,4825,O
well,4825,O
.,4825,O
Counterregulatory,4826,O
responses,4826,O
and,4826,O
glutamine/glutamate,4826,B-CHEMICAL
concentrations,4826,O
in,4826,O
the,4826,O
VMH,4826,O
were,4826,O
assessed,4826,O
during,4826,O
a,4826,O
hyperinsulinemic-hypoglycemic,4826,O
glucose,4826,B-CHEMICAL
clamp,4826,O
study,4826,O
in,4826,O
chronically,4826,O
catheterized,4826,O
awake,4826,O
male,4826,O
Sprague-Dawley,4826,O
rats,4826,O
that,4826,O
received,4826,O
an,4826,O
acute,4826,O
VMH,4826,O
microinjection,4826,O
of,4826,O
ephrinA5-Fc,4826,B-GENE-Y
",",4826,O
chronic,4826,O
VMH,4826,O
knockdown,4826,O
",",4826,O
or,4826,O
overexpression,4826,O
of,4826,O
ephrinA5,4826,B-GENE-Y
using,4826,O
an,4826,O
adenoassociated,4826,O
viral,4826,O
construct,4826,O
.,4826,O
Local,4827,O
stimulation,4827,O
of,4827,O
VMH,4827,O
EphA5,4827,B-GENE-Y
receptors,4827,I-GENE-Y
by,4827,O
ephrinA5-Fc,4827,B-GENE-Y
or,4827,O
ephrinA5,4827,B-GENE-Y
overexpression,4827,O
increased,4827,O
",",4827,O
whereas,4827,O
knockdown,4827,O
of,4827,O
VMH,4827,O
ephrinA5,4827,B-GENE-Y
reduced,4827,O
counterregulatory,4827,O
responses,4827,O
during,4827,O
hypoglycemia,4827,O
.,4827,O
Overexpression,4828,O
of,4828,O
VMH,4828,O
ephrinA5,4828,B-GENE-Y
transiently,4828,O
increased,4828,O
local,4828,O
glutamate,4828,B-CHEMICAL
concentrations,4828,O
",",4828,O
whereas,4828,O
ephrinA5,4828,B-GENE-Y
knockdown,4828,O
produced,4828,O
profound,4828,O
suppression,4828,O
of,4828,O
VMH,4828,O
interstitial,4828,O
fluid,4828,O
glutamine,4828,B-CHEMICAL
concentrations,4828,O
in,4828,O
the,4828,O
basal,4828,O
state,4828,O
and,4828,O
during,4828,O
hypoglycemia,4828,O
.,4828,O
Changes,4829,O
in,4829,O
ephrinA5/EphA5,4829,B-GENE-Y
interactions,4829,O
within,4829,O
the,4829,O
VMH,4829,O
",",4829,O
a,4829,O
key,4829,O
brain,4829,O
glucose-sensing,4829,B-CHEMICAL
region,4829,O
",",4829,O
act,4829,O
in,4829,O
concert,4829,O
with,4829,O
islets,4829,O
to,4829,O
restore,4829,O
glucose,4829,B-CHEMICAL
homeostasis,4829,O
during,4829,O
acute,4829,O
hypoglycemia,4829,O
",",4829,O
and,4829,O
its,4829,O
effect,4829,O
on,4829,O
counterregulation,4829,O
may,4829,O
be,4829,O
mediated,4829,O
by,4829,O
changes,4829,O
in,4829,O
glutamate/glutamine,4829,B-CHEMICAL
cycling,4829,O
.,4829,O
Electrical,4830,O
Stimuli,4830,O
Release,4830,O
ATP,4830,B-CHEMICAL
to,4830,O
Increase,4830,O
GLUT4,4830,B-GENE-Y
Translocation,4830,O
and,4830,O
Glucose,4830,B-CHEMICAL
Uptake,4830,O
via,4830,O
PI3Kγ-Akt-AS160,4830,B-GENE-Y
in,4830,O
Skeletal,4830,O
Muscle,4830,O
Cells,4830,O
.,4830,O
Skeletal,4831,O
muscle,4831,O
glucose,4831,B-CHEMICAL
uptake,4831,O
in,4831,O
response,4831,O
to,4831,O
exercise,4831,O
is,4831,O
preserved,4831,O
in,4831,O
insulin-resistant,4831,B-GENE-Y
conditions,4831,O
",",4831,O
but,4831,O
the,4831,O
signals,4831,O
involved,4831,O
are,4831,O
debated,4831,O
.,4831,O
ATP,4832,B-CHEMICAL
is,4832,O
released,4832,O
from,4832,O
skeletal,4832,O
muscle,4832,O
by,4832,O
contractile,4832,O
activity,4832,O
and,4832,O
can,4832,O
autocrinely,4832,O
signal,4832,O
through,4832,O
purinergic,4832,B-GENE-N
receptors,4832,I-GENE-N
",",4832,O
and,4832,O
we,4832,O
hypothesized,4832,O
it,4832,O
may,4832,O
influence,4832,O
glucose,4832,B-CHEMICAL
uptake,4832,O
.,4832,O
Electrical,4833,O
stimulation,4833,O
",",4833,O
ATP,4833,B-CHEMICAL
",",4833,O
and,4833,O
insulin,4833,B-GENE-Y
each,4833,O
increased,4833,O
fluorescent,4833,O
2-NBD-Glucose,4833,B-CHEMICAL
(,4833,O
2-NBDG,4833,B-CHEMICAL
),4833,O
uptake,4833,O
in,4833,O
primary,4833,O
myotubes,4833,O
",",4833,O
but,4833,O
only,4833,O
electrical,4833,O
stimulation,4833,O
and,4833,O
ATP-dependent,4833,B-CHEMICAL
2-NBDG,4833,B-CHEMICAL
uptake,4833,O
were,4833,O
inhibited,4833,O
by,4833,O
adenosine-phosphate,4833,B-GENE-N
phosphatase,4833,I-GENE-N
and,4833,O
by,4833,O
purinergic,4833,B-GENE-N
receptor,4833,I-GENE-N
blockade,4833,O
(,4833,O
suramin,4833,B-CHEMICAL
),4833,O
.,4833,O
Electrical,4834,O
stimulation,4834,O
transiently,4834,O
elevated,4834,O
extracellular,4834,O
ATP,4834,B-CHEMICAL
and,4834,O
caused,4834,O
Akt,4834,B-GENE-N
phosphorylation,4834,O
that,4834,O
was,4834,O
additive,4834,O
to,4834,O
insulin,4834,B-GENE-Y
and,4834,O
inhibited,4834,O
by,4834,O
suramin,4834,B-CHEMICAL
.,4834,O
Exogenous,4835,O
ATP,4835,B-CHEMICAL
transiently,4835,O
activated,4835,O
Akt,4835,B-GENE-N
and,4835,O
",",4835,O
inhibiting,4835,O
phosphatidylinositol,4835,B-GENE-N
3-kinase,4835,I-GENE-N
(,4835,O
PI3K,4835,B-GENE-N
),4835,O
or,4835,O
Akt,4835,B-GENE-N
as,4835,O
well,4835,O
as,4835,O
dominant-negative,4835,O
Akt,4835,B-GENE-N
mutant,4835,O
",",4835,O
reduced,4835,O
ATP-dependent,4835,B-CHEMICAL
2-NBDG,4835,B-CHEMICAL
uptake,4835,O
and,4835,O
Akt,4835,B-GENE-N
phosphorylation,4835,O
.,4835,O
ATP-dependent,4836,B-CHEMICAL
2-NBDG,4836,B-CHEMICAL
uptake,4836,O
was,4836,O
also,4836,O
inhibited,4836,O
by,4836,O
the,4836,O
G,4836,B-GENE-N
protein,4836,I-GENE-N
βγ,4836,I-GENE-N
subunit-interacting,4836,O
peptide,4836,O
βark-ct,4836,O
and,4836,O
by,4836,O
the,4836,O
phosphatidylinositol,4836,B-GENE-Y
3-kinase-γ,4836,I-GENE-Y
(,4836,O
PI3Kγ,4836,B-GENE-Y
),4836,O
inhibitor,4836,O
AS605240,4836,B-CHEMICAL
.,4836,O
ATP,4837,B-CHEMICAL
caused,4837,O
translocation,4837,O
of,4837,O
GLUT4myc-eGFP,4837,B-GENE-Y
to,4837,O
the,4837,O
cell,4837,O
surface,4837,O
",",4837,O
mechanistically,4837,O
mediated,4837,O
by,4837,O
increased,4837,O
exocytosis,4837,O
involving,4837,O
AS160/Rab8A,4837,B-GENE-Y
reduced,4837,O
by,4837,O
dominant-negative,4837,O
Akt,4837,B-GENE-N
or,4837,O
PI3Kγ,4837,B-GENE-Y
kinase-dead,4837,B-GENE-N
mutants,4837,O
",",4837,O
and,4837,O
potentiated,4837,O
by,4837,O
myristoylated,4837,B-GENE-Y
PI3Kγ,4837,I-GENE-Y
.,4837,O
ATP,4838,B-CHEMICAL
stimulated,4838,O
2-NBDG,4838,B-CHEMICAL
uptake,4838,O
in,4838,O
normal,4838,O
and,4838,O
insulin-resistant,4838,B-GENE-Y
adult,4838,O
muscle,4838,O
fibers,4838,O
",",4838,O
resembling,4838,O
the,4838,O
reported,4838,O
effect,4838,O
of,4838,O
exercise,4838,O
.,4838,O
Hence,4839,O
",",4839,O
the,4839,O
ATP-induced,4839,B-CHEMICAL
pathway,4839,O
may,4839,O
be,4839,O
tapped,4839,O
to,4839,O
bypass,4839,O
insulin,4839,B-GENE-Y
resistance,4839,O
.,4839,O
The,4840,O
COP9,4840,B-GENE-N
signalosome,4840,I-GENE-N
interacts,4840,O
with,4840,O
and,4840,O
regulates,4840,O
interferon,4840,B-GENE-Y
regulatory,4840,I-GENE-Y
factor,4840,I-GENE-Y
5,4840,I-GENE-Y
protein,4840,I-GENE-Y
stability,4840,O
.,4840,O
The,4841,O
transcription,4841,O
factor,4841,O
interferon,4841,B-GENE-Y
regulatory,4841,I-GENE-Y
factor,4841,I-GENE-Y
5,4841,I-GENE-Y
(,4841,O
IRF5,4841,B-GENE-Y
),4841,O
exerts,4841,O
crucial,4841,O
functions,4841,O
in,4841,O
the,4841,O
regulation,4841,O
of,4841,O
host,4841,O
immunity,4841,O
against,4841,O
extracellular,4841,O
pathogens,4841,O
",",4841,O
DNA,4841,O
damage-induced,4841,O
apoptosis,4841,O
",",4841,O
death,4841,B-GENE-N
receptor,4841,I-GENE-N
signaling,4841,O
",",4841,O
and,4841,O
macrophage,4841,O
polarization,4841,O
.,4841,O
Tight,4842,O
regulation,4842,O
of,4842,O
IRF5,4842,B-GENE-Y
is,4842,O
thus,4842,O
warranted,4842,O
for,4842,O
an,4842,O
efficient,4842,O
response,4842,O
toward,4842,O
extracellular,4842,O
stressors,4842,O
and,4842,O
for,4842,O
limiting,4842,O
autoimmune,4842,O
and,4842,O
inflammatory,4842,O
responses,4842,O
.,4842,O
Here,4843,O
we,4843,O
report,4843,O
that,4843,O
the,4843,O
COP9,4843,B-GENE-N
signalosome,4843,I-GENE-N
(,4843,O
CSN,4843,B-GENE-N
),4843,O
",",4843,O
a,4843,O
general,4843,O
modulator,4843,O
of,4843,O
diverse,4843,O
cellular,4843,O
and,4843,O
developmental,4843,O
processes,4843,O
",",4843,O
associates,4843,O
constitutively,4843,O
with,4843,O
IRF5,4843,B-GENE-Y
and,4843,O
promotes,4843,O
its,4843,O
protein,4843,O
stability,4843,O
.,4843,O
The,4844,O
constitutive,4844,O
CSN/IRF5,4844,B-GENE-N
interaction,4844,O
was,4844,O
identified,4844,O
using,4844,O
proteomics,4844,O
and,4844,O
confirmed,4844,O
by,4844,O
endogenous,4844,O
immunoprecipitations,4844,O
.,4844,O
The,4845,O
CSN/IRF5,4845,B-GENE-N
interaction,4845,O
occurred,4845,O
on,4845,O
the,4845,O
carboxyl,4845,B-CHEMICAL
and,4845,O
amino,4845,B-CHEMICAL
termini,4845,O
of,4845,O
IRF5,4845,B-GENE-Y
;,4845,O
a,4845,O
single,4845,O
internal,4845,O
deletion,4845,O
from,4845,O
amino,4845,B-CHEMICAL
acids,4845,I-CHEMICAL
455,4845,O
to,4845,O
466,4845,O
(,4845,O
Δ455-466,4845,O
),4845,O
was,4845,O
found,4845,O
to,4845,O
significantly,4845,O
reduce,4845,O
IRF5,4845,B-GENE-Y
protein,4845,O
stability,4845,O
.,4845,O
CSN,4846,B-GENE-Y
subunit,4846,I-GENE-Y
3,4846,I-GENE-Y
(,4846,O
CSN3,4846,B-GENE-Y
),4846,O
was,4846,O
identified,4846,O
as,4846,O
a,4846,O
direct,4846,O
interacting,4846,O
partner,4846,O
of,4846,O
IRF5,4846,B-GENE-Y
",",4846,O
and,4846,O
knockdown,4846,O
of,4846,O
this,4846,O
subunit,4846,O
with,4846,O
small,4846,O
interfering,4846,O
RNAs,4846,O
resulted,4846,O
in,4846,O
enhanced,4846,O
degradation,4846,O
.,4846,O
Degradation,4847,O
was,4847,O
further,4847,O
augmented,4847,O
by,4847,O
knockdown,4847,O
of,4847,O
CSN1,4847,B-GENE-Y
and,4847,O
CSN3,4847,B-GENE-Y
together,4847,O
.,4847,O
The,4848,O
ubiquitin,4848,B-GENE-N
E1,4848,I-GENE-N
inhibitor,4848,O
UBEI-41,4848,O
or,4848,O
the,4848,O
proteasome,4848,B-GENE-N
inhibitor,4848,O
MG132,4848,O
prevented,4848,O
IRF5,4848,B-GENE-Y
degradation,4848,O
",",4848,O
supporting,4848,O
the,4848,O
idea,4848,O
that,4848,O
its,4848,O
stability,4848,O
is,4848,O
regulated,4848,O
by,4848,O
the,4848,O
ubiquitin-proteasome,4848,B-GENE-N
system,4848,O
.,4848,O
Importantly,4849,O
",",4849,O
activation,4849,O
of,4849,O
IRF5,4849,B-GENE-Y
by,4849,O
the,4849,O
death,4849,B-GENE-N
receptor,4849,I-GENE-N
ligand,4849,O
tumor,4849,B-GENE-Y
necrosis,4849,I-GENE-Y
factor-related,4849,I-GENE-Y
apoptosis-inducing,4849,I-GENE-Y
ligand,4849,I-GENE-Y
(,4849,O
TRAIL,4849,B-GENE-Y
),4849,O
resulted,4849,O
in,4849,O
enhanced,4849,O
degradation,4849,O
via,4849,O
loss,4849,O
of,4849,O
the,4849,O
CSN/IRF5,4849,B-GENE-N
interaction,4849,O
.,4849,O
This,4850,O
study,4850,O
defines,4850,O
CSN,4850,B-GENE-N
to,4850,O
be,4850,O
a,4850,O
new,4850,O
interacting,4850,O
partner,4850,O
of,4850,O
IRF5,4850,B-GENE-Y
that,4850,O
controls,4850,O
its,4850,O
stability,4850,O
.,4850,O
Structure-based,4851,O
design,4851,O
",",4851,O
synthesis,4851,O
and,4851,O
evaluation,4851,O
of,4851,O
novel,4851,O
anthra,4851,B-CHEMICAL
[,4851,I-CHEMICAL
"1,2-d",4851,I-CHEMICAL
],4851,I-CHEMICAL
"imidazole-6,11-dione",4851,I-CHEMICAL
derivatives,4851,O
as,4851,O
telomerase,4851,B-GENE-Y
inhibitors,4851,O
and,4851,O
potential,4851,O
for,4851,O
cancer,4851,O
polypharmacology,4851,O
.,4851,O
A,4852,O
series,4852,O
of,4852,O
anthra,4852,B-CHEMICAL
[,4852,I-CHEMICAL
"1,2-d",4852,I-CHEMICAL
],4852,I-CHEMICAL
"imidazole-6,11-dione",4852,I-CHEMICAL
derivatives,4852,O
were,4852,O
synthesized,4852,O
and,4852,O
evaluated,4852,O
for,4852,O
telomerase,4852,B-GENE-Y
inhibition,4852,O
",",4852,O
hTERT,4852,B-GENE-Y
expression,4852,O
and,4852,O
suppression,4852,O
of,4852,O
cancer,4852,O
cell,4852,O
growth,4852,O
in,4852,O
vitro,4852,O
.,4852,O
All,4853,O
of,4853,O
the,4853,O
compounds,4853,O
tested,4853,O
",",4853,O
except,4853,O
for,4853,O
compounds,4853,O
4,4853,O
",",4853,O
7,4853,O
",",4853,O
16,4853,O
",",4853,O
24,4853,O
",",4853,O
27,4853,O
and,4853,O
28,4853,O
were,4853,O
selected,4853,O
by,4853,O
the,4853,O
NCI,4853,O
screening,4853,O
system,4853,O
.,4853,O
Among,4854,O
them,4854,O
",",4854,O
compounds,4854,O
16,4854,O
",",4854,O
39,4854,O
",",4854,O
and,4854,O
40,4854,O
repressed,4854,O
hTERT,4854,B-GENE-Y
expression,4854,O
without,4854,O
greatly,4854,O
affecting,4854,O
cell,4854,O
growth,4854,O
",",4854,O
suggesting,4854,O
for,4854,O
the,4854,O
selectivity,4854,O
toward,4854,O
hTERT,4854,B-GENE-Y
expression,4854,O
.,4854,O
Taken,4855,O
together,4855,O
",",4855,O
our,4855,O
findings,4855,O
indicated,4855,O
that,4855,O
the,4855,O
analysis,4855,O
of,4855,O
cytotoxicity,4855,O
and,4855,O
telomerase,4855,B-GENE-Y
inhibition,4855,O
might,4855,O
provide,4855,O
information,4855,O
applicable,4855,O
for,4855,O
further,4855,O
developing,4855,O
potential,4855,O
telomerase,4855,B-GENE-Y
and,4855,O
polypharmacological,4855,O
targeting,4855,O
strategy,4855,O
.,4855,O
Zinc,4856,B-CHEMICAL
sulphate,4856,I-CHEMICAL
and,4856,O
vitamin,4856,B-CHEMICAL
E,4856,I-CHEMICAL
alleviate,4856,O
reproductive,4856,O
toxicity,4856,O
caused,4856,O
by,4856,O
aluminium,4856,B-CHEMICAL
sulphate,4856,I-CHEMICAL
in,4856,O
male,4856,O
albino,4856,O
rats,4856,O
.,4856,O
This,4857,O
study,4857,O
was,4857,O
designed,4857,O
to,4857,O
investigate,4857,O
the,4857,O
reproductive,4857,O
toxicity,4857,O
of,4857,O
aluminium,4857,B-CHEMICAL
sulphate,4857,I-CHEMICAL
and,4857,O
the,4857,O
therapeutic,4857,O
effects,4857,O
of,4857,O
administration,4857,O
of,4857,O
zinc,4857,B-CHEMICAL
sulphate,4857,I-CHEMICAL
and,4857,O
vitamin,4857,B-CHEMICAL
E,4857,I-CHEMICAL
individually,4857,O
or,4857,O
in,4857,O
combination,4857,O
against,4857,O
the,4857,O
toxic,4857,O
effect,4857,O
caused,4857,O
by,4857,O
aluminium,4857,B-CHEMICAL
(,4857,O
Al,4857,B-CHEMICAL
),4857,O
in,4857,O
male,4857,O
albino,4857,O
rats,4857,O
.,4857,O
The,4858,O
animals,4858,O
were,4858,O
divided,4858,O
into,4858,O
five,4858,O
groups,4858,O
:,4858,O
group,4858,O
1,4858,O
received,4858,O
distilled,4858,O
water,4858,O
and,4858,O
served,4858,O
as,4858,O
control,4858,O
;,4858,O
group,4858,O
2,4858,O
received,4858,O
only,4858,O
aluminium,4858,B-CHEMICAL
sulphate,4858,I-CHEMICAL
(,4858,O
50,4858,O
mg/kg,4858,O
body,4858,O
weight,4858,O
(,4858,O
b.w,4858,O
.,4858,O
),4859,O
),4859,O
;,4859,O
group,4859,O
3,4859,O
received,4859,O
aluminium,4859,I-CHEMICAL
sulphate,4859,O
(,4859,O
50,4859,O
mg/kg,4859,O
b.w,4859,O
.,4859,O
),4859,O
plus,4860,O
zinc,4860,I-CHEMICAL
sulphate,4860,O
(,4860,O
50,4860,O
mg/kg,4860,O
b.w,4860,O
.,4860,O
),4861,O
;,4861,O
group,4861,O
4,4861,O
received,4861,O
aluminium,4861,I-CHEMICAL
sulphate,4861,O
(,4861,O
50,4861,O
mg/kg,4861,O
b.w,4861,O
.,4861,O
),4861,O
and,4862,O
vitamin,4862,I-CHEMICAL
E,4862,O
(,4862,O
15,4862,O
mg/kg,4862,O
b.w,4862,O
.,4862,O
),4863,O
;,4863,O
group,4863,O
5,4863,O
received,4863,O
aluminium,4863,I-CHEMICAL
sulphate,4863,O
plus,4863,O
a,4863,O
combination,4863,O
of,4863,B-CHEMICAL
zinc,4863,I-CHEMICAL
sulphate,4863,O
and,4863,O
vitamin,4863,O
E,4863,O
in,4863,O
similar,4863,O
doses,4863,O
as,4863,O
above,4863,O
.,4863,O
Doses,4864,O
were,4864,O
administered,4864,O
orally,4864,O
once,4864,O
daily,4864,O
for,4864,O
45,4864,O
consecutive,4864,O
days,4864,O
.,4864,O
The,4865,O
results,4865,O
revealed,4865,O
that,4865,O
aluminium,4865,I-CHEMICAL
sulphate,4865,O
induced,4865,O
significant,4865,O
decrease,4865,O
in,4865,O
body,4865,O
weight,4865,O
gain,4865,O
and,4865,O
testis,4865,O
weight,4865,O
and,4865,O
significant,4865,O
increase,4865,O
in,4865,B-CHEMICAL
Al,4865,O
level,4865,O
in,4865,O
both,4865,O
serum,4865,O
and,4865,O
testes,4865,O
of,4865,O
male,4865,O
rats,4865,O
.,4865,O
Biochemical,4866,O
analysis,4866,O
showed,4866,O
significant,4866,O
decrease,4866,O
in,4866,O
serum,4866,O
total,4866,O
protein,4866,O
and,4866,O
phospholipids,4866,O
levels,4866,O
",",4866,O
while,4866,O
serum,4866,O
total,4866,O
lipid,4866,O
was,4866,O
significantly,4866,O
elevated,4866,O
post,4866,O
Al,4866,O
treatment,4866,O
.,4866,O
In,4867,O
addition,4867,O
",",4867,O
significant,4867,O
decrease,4867,O
in,4867,O
total,4867,O
protein,4867,O
",",4867,O
phospholipids,4867,O
and,4867,O
cholesterol,4867,O
levels,4867,O
in,4867,O
the,4867,O
testes,4867,O
of,4867,B-CHEMICAL
Al-treated,4867,O
rats,4867,O
was,4867,O
recorded,4867,O
.,4867,O
The,4868,O
data,4868,O
also,4868,O
showed,4868,O
significant,4868,O
decrease,4868,O
in,4868,O
the,4868,O
levels,4868,O
of,4868,O
serum,4868,O
testosterone,4868,O
",",4868,I-GENE-N
leutinizing,4868,I-GENE-N
hormone,4868,O
and,4868,O
follicle,4868,I-GENE-N
stimulating,4868,I-GENE-N
hormone,4868,O
and,4868,O
significant,4868,O
increase,4868,O
in,4868,O
the,4868,O
level,4868,O
of,4868,O
serum,4868,O
prolactin,4868,O
in,4868,B-CHEMICAL
Al-intoxicated,4868,O
rats,4868,O
.,4868,O
Moreover,4869,O
",",4869,O
histological,4869,O
examination,4869,O
showed,4869,O
that,4869,O
aluminium,4869,I-CHEMICAL
sulphate,4869,O
caused,4869,O
apparent,4869,O
alterations,4869,O
in,4869,O
the,4869,O
testicular,4869,O
structure,4869,O
of,4869,O
the,4869,O
treated,4869,O
animals,4869,O
.,4869,O
Treatment,4870,O
with,4870,O
zinc,4870,I-CHEMICAL
sulphate,4870,O
and,4870,O
vitamin,4870,O
E,4870,O
individually,4870,O
or,4870,O
in,4870,O
combination,4870,O
ameliorated,4870,O
the,4870,O
harmful,4870,O
effects,4870,O
of,4870,B-CHEMICAL
Al,4870,O
",",4870,O
which,4870,O
was,4870,O
proved,4870,O
histopathologically,4870,O
by,4870,O
the,4870,O
noticeable,4870,O
improvement,4870,O
in,4870,O
the,4870,O
testicular,4870,O
tissues,4870,O
.,4870,O
We,4871,O
can,4871,O
conclude,4871,O
that,4871,O
the,4871,O
tested,4871,O
dose,4871,O
of,4871,B-CHEMICAL
aluminium,4871,I-CHEMICAL
sulphate,4871,O
induced,4871,O
toxic,4871,O
effect,4871,O
on,4871,O
the,4871,O
reproductive,4871,O
system,4871,O
of,4871,O
male,4871,O
albino,4871,O
rats,4871,O
and,4871,O
the,4871,O
treatment,4871,O
with,4871,O
zinc,4871,I-CHEMICAL
sulphate,4871,O
and/or,4871,O
vitamin,4871,O
E,4871,O
alleviated,4871,O
these,4871,O
toxic,4871,O
effects,4871,O
.,4871,O
In,4872,O
some,4872,O
cases,4872,O
",",4872,I-CHEMICAL
vitamin,4872,O
E,4872,O
exerted,4872,O
a,4872,O
more,4872,O
potent,4872,O
effect,4872,O
",",4872,O
while,4872,O
in,4872,O
other,4872,O
cases,4872,O
",",4872,O
the,4872,O
more,4872,O
potent,4872,O
effect,4872,O
is,4872,O
related,4872,O
to,4872,B-CHEMICAL
zinc,4872,I-CHEMICAL
sulphate,4872,O
and,4872,O
the,4872,O
combination,4872,O
of,4872,O
both,4872,O
at,4872,O
most,4872,O
of,4872,O
the,4872,O
recorded,4872,O
data,4872,O
.,4872,O
Trichostatin,4873,B-CHEMICAL
A,4873,I-CHEMICAL
inhibits,4873,O
transforming,4873,B-GENE-Y
growth,4873,I-GENE-Y
factor-β-induced,4873,O
reactive,4873,O
oxygen,4873,B-CHEMICAL
species,4873,O
accumulation,4873,O
and,4873,O
myofibroblast,4873,O
differentiation,4873,O
via,4873,O
enhanced,4873,O
NF-E2-related,4873,B-GENE-Y
factor,4873,I-GENE-Y
2-antioxidant,4873,O
response,4873,I-GENE-N
element,4873,I-GENE-N
signaling,4873,O
.,4873,O
Trichostatin,4874,B-CHEMICAL
A,4874,I-CHEMICAL
(,4874,O
TSA,4874,B-CHEMICAL
),4874,O
has,4874,O
been,4874,O
shown,4874,O
to,4874,O
prevent,4874,O
fibrosis,4874,O
in,4874,O
vitro,4874,O
and,4874,O
in,4874,O
vivo,4874,O
.,4874,O
The,4875,O
present,4875,O
study,4875,O
aimed,4875,O
at,4875,O
investigating,4875,O
the,4875,O
role,4875,O
of,4875,O
reactive,4875,O
oxygen,4875,B-CHEMICAL
species,4875,O
(,4875,O
ROS,4875,O
),4875,O
scavenging,4875,O
by,4875,O
TSA,4875,B-CHEMICAL
on,4875,O
transforming,4875,B-GENE-Y
growth,4875,I-GENE-Y
factor-β,4875,I-GENE-Y
(,4875,O
TGF-β,4875,B-GENE-Y
),4875,I-GENE-Y
-induced,4875,O
myofibroblast,4875,O
differentiation,4875,O
of,4875,O
corneal,4875,O
fibroblasts,4875,O
in,4875,O
vitro,4875,O
.,4875,O
Human,4876,O
immortalized,4876,O
corneal,4876,O
fibroblasts,4876,O
were,4876,O
treated,4876,O
with,4876,O
TGF-β,4876,B-GENE-Y
in,4876,O
the,4876,O
presence,4876,O
of,4876,O
TSA,4876,B-CHEMICAL
",",4876,O
the,4876,O
NAD,4876,B-GENE-N
(,4876,I-GENE-N
P,4876,I-GENE-N
),4876,I-GENE-N
H,4876,I-GENE-N
oxidase,4876,I-GENE-N
inhibitor,4876,O
diphenyleneiodonium,4876,B-CHEMICAL
(,4876,O
DPI,4876,B-CHEMICAL
),4876,O
",",4876,O
the,4876,O
antioxidant,4876,O
N-acetyl-cysteine,4876,B-CHEMICAL
(,4876,O
NAC,4876,B-CHEMICAL
),4876,O
",",4876,O
the,4876,O
NF-E2-related,4876,B-GENE-Y
factor,4876,I-GENE-Y
2-antioxidant,4876,O
response,4876,I-GENE-N
element,4876,I-GENE-N
(,4876,O
Nrf2-ARE,4876,B-GENE-Y
),4876,O
activator,4876,O
sulforaphane,4876,B-CHEMICAL
",",4876,O
or,4876,O
small,4876,O
interfering,4876,O
RNA,4876,O
.,4876,O
Myofibroblast,4877,O
differentiation,4877,O
was,4877,O
assessed,4877,O
by,4877,O
α-smooth,4877,B-GENE-Y
muscle,4877,I-GENE-Y
actin,4877,I-GENE-Y
(,4877,O
α-SMA,4877,B-GENE-Y
),4877,O
expression,4877,O
",",4877,O
F-actin,4877,B-GENE-N
bundle,4877,O
formation,4877,O
",",4877,O
and,4877,O
collagen,4877,B-GENE-N
gel,4877,O
contraction,4877,O
.,4877,O
ROS,4878,O
",",4878,O
H,4878,B-CHEMICAL
(,4878,I-CHEMICAL
2,4878,I-CHEMICAL
),4878,I-CHEMICAL
O,4878,I-CHEMICAL
(,4878,I-CHEMICAL
2,4878,I-CHEMICAL
),4878,I-CHEMICAL
",",4878,O
intracellular,4878,O
glutathione,4878,B-CHEMICAL
(,4878,O
GSH,4878,B-CHEMICAL
),4878,O
level,4878,O
",",4878,O
cellular,4878,O
total,4878,O
antioxidant,4878,O
capacity,4878,O
",",4878,O
and,4878,O
the,4878,O
activation,4878,O
of,4878,O
Nrf2-ARE,4878,B-GENE-Y
signaling,4878,O
were,4878,O
determined,4878,O
with,4878,O
various,4878,O
assays,4878,O
.,4878,O
Treatment,4879,O
with,4879,O
TSA,4879,B-CHEMICAL
and,4879,O
the,4879,O
Nrf2-ARE,4879,B-GENE-Y
activator,4879,O
resulted,4879,O
in,4879,O
increased,4879,O
inhibition,4879,O
of,4879,O
the,4879,O
TGF-β-induced,4879,B-GENE-Y
myofibroblast,4879,O
differentiation,4879,O
as,4879,O
compared,4879,O
with,4879,O
treatment,4879,O
with,4879,O
DPI,4879,B-CHEMICAL
or,4879,O
NAC,4879,B-CHEMICAL
.,4879,O
Furthermore,4880,O
",",4880,O
TSA,4880,B-CHEMICAL
also,4880,O
decreased,4880,O
cellular,4880,O
ROS,4880,O
and,4880,O
H,4880,B-CHEMICAL
(,4880,I-CHEMICAL
2,4880,I-CHEMICAL
),4880,I-CHEMICAL
O,4880,I-CHEMICAL
(,4880,I-CHEMICAL
2,4880,I-CHEMICAL
),4880,I-CHEMICAL
accumulation,4880,O
induced,4880,O
by,4880,O
TGF-β,4880,B-GENE-Y
",",4880,O
whereas,4880,O
it,4880,O
elevated,4880,O
intracellular,4880,O
GSH,4880,B-CHEMICAL
level,4880,O
and,4880,O
cellular,4880,O
total,4880,O
antioxidant,4880,O
capacity,4880,O
.,4880,O
In,4881,O
addition,4881,O
",",4881,O
TSA,4881,B-CHEMICAL
induced,4881,O
Nrf2,4881,B-GENE-Y
nuclear,4881,O
translocation,4881,O
and,4881,O
up-regulated,4881,O
the,4881,O
expression,4881,O
of,4881,O
Nrf2-ARE,4881,B-GENE-Y
downstream,4881,O
antioxidant,4881,O
genes,4881,O
",",4881,O
whereas,4881,O
Nrf2,4881,B-GENE-Y
knockdown,4881,O
by,4881,O
RNA,4881,O
interference,4881,O
blocked,4881,O
the,4881,O
inhibition,4881,O
of,4881,O
TSA,4881,B-CHEMICAL
on,4881,O
myofibroblast,4881,O
differentiation,4881,O
.,4881,O
In,4882,O
conclusion,4882,O
",",4882,O
this,4882,O
study,4882,O
provides,4882,O
the,4882,O
first,4882,O
evidence,4882,O
implicating,4882,O
that,4882,O
TSA,4882,B-CHEMICAL
inhibits,4882,O
TGF-β-induced,4882,B-GENE-Y
ROS,4882,O
accumulation,4882,O
and,4882,O
myofibroblast,4882,O
differentiation,4882,O
via,4882,O
enhanced,4882,O
Nrf2-ARE,4882,B-GENE-Y
signaling,4882,O
.,4882,O
Cannabinoid,4883,B-CHEMICAL
discrimination,4883,O
and,4883,O
antagonism,4883,O
by,4883,O
CB,4883,B-GENE-N
(,4883,I-GENE-N
1,4883,I-GENE-N
),4883,I-GENE-N
neutral,4883,O
and,4883,O
inverse,4883,O
agonist,4883,O
antagonists,4883,O
.,4883,O
Cannabinoid,4884,B-CHEMICAL
receptor,4884,I-GENE-N
1,4884,I-GENE-N
(,4884,O
CB,4884,B-GENE-N
(,4884,I-GENE-N
1,4884,I-GENE-N
),4884,I-GENE-N
),4884,O
inverse,4884,O
agonists,4884,O
(,4884,O
e.g.,4884,O
",",4884,O
rimonabant,4884,B-CHEMICAL
),4884,O
have,4884,O
been,4884,O
reported,4884,O
to,4884,O
produce,4884,O
adverse,4884,O
effects,4884,O
including,4884,O
nausea,4884,O
",",4884,O
emesis,4884,O
",",4884,O
and,4884,O
anhedonia,4884,O
that,4884,O
limit,4884,O
their,4884,O
clinical,4884,O
applications,4884,O
.,4884,O
Recent,4885,O
laboratory,4885,O
studies,4885,O
suggest,4885,O
that,4885,O
the,4885,O
effects,4885,O
of,4885,O
CB,4885,B-GENE-N
(,4885,I-GENE-N
1,4885,I-GENE-N
),4885,I-GENE-N
neutral,4885,O
antagonists,4885,O
differ,4885,O
from,4885,O
those,4885,O
of,4885,O
such,4885,O
inverse,4885,O
agonists,4885,O
",",4885,O
raising,4885,O
the,4885,O
possibility,4885,O
of,4885,O
improved,4885,O
clinical,4885,O
utility,4885,O
.,4885,O
However,4886,O
",",4886,O
little,4886,O
is,4886,O
known,4886,O
regarding,4886,O
the,4886,O
antagonist,4886,O
properties,4886,O
of,4886,O
neutral,4886,O
antagonists,4886,O
.,4886,O
In,4887,O
the,4887,O
present,4887,O
studies,4887,O
",",4887,O
the,4887,O
CB,4887,B-GENE-N
(,4887,I-GENE-N
1,4887,I-GENE-N
),4887,I-GENE-N
inverse,4887,O
agonist,4887,O
SR141716A,4887,B-CHEMICAL
(,4887,O
rimonabant,4887,B-CHEMICAL
),4887,O
and,4887,O
the,4887,O
CB,4887,B-GENE-N
(,4887,I-GENE-N
1,4887,I-GENE-N
),4887,I-GENE-N
neutral,4887,O
antagonist,4887,O
AM4113,4887,B-CHEMICAL
were,4887,O
compared,4887,O
for,4887,O
their,4887,O
ability,4887,O
to,4887,O
modify,4887,O
CB,4887,B-GENE-N
(,4887,I-GENE-N
1,4887,I-GENE-N
),4887,I-GENE-N
receptor-mediated,4887,O
discriminative,4887,O
stimulus,4887,O
effects,4887,O
in,4887,O
nonhuman,4887,O
primates,4887,O
trained,4887,O
to,4887,O
discriminate,4887,O
the,4887,O
novel,4887,O
CB,4887,B-GENE-N
(,4887,I-GENE-N
1,4887,I-GENE-N
),4887,I-GENE-N
full,4887,O
agonist,4887,O
AM4054,4887,B-CHEMICAL
.,4887,O
Results,4888,O
indicate,4888,O
that,4888,O
AM4054,4888,B-CHEMICAL
serves,4888,O
as,4888,O
an,4888,O
effective,4888,O
CB,4888,B-GENE-N
(,4888,I-GENE-N
1,4888,I-GENE-N
),4888,I-GENE-N
discriminative,4888,O
stimulus,4888,O
",",4888,O
with,4888,O
an,4888,O
onset,4888,O
and,4888,O
time,4888,O
course,4888,O
of,4888,O
action,4888,O
comparable,4888,O
with,4888,O
that,4888,O
of,4888,O
the,4888,O
CB,4888,B-GENE-N
(,4888,I-GENE-N
1,4888,I-GENE-N
),4888,I-GENE-N
agonist,4888,O
Δ,4888,B-CHEMICAL
(,4888,I-CHEMICAL
9,4888,I-CHEMICAL
),4888,I-CHEMICAL
-tetrahydrocannabinol,4888,I-CHEMICAL
",",4888,O
and,4888,O
that,4888,O
the,4888,O
inverse,4888,O
agonist,4888,O
rimonabant,4888,B-CHEMICAL
and,4888,O
the,4888,O
neutral,4888,O
antagonist,4888,O
AM4113,4888,B-CHEMICAL
produce,4888,O
dose-related,4888,O
rightward,4888,O
shifts,4888,O
in,4888,O
the,4888,O
AM4054,4888,B-CHEMICAL
dose-effect,4888,O
curve,4888,O
",",4888,O
indicating,4888,O
that,4888,O
both,4888,O
drugs,4888,O
surmountably,4888,O
antagonize,4888,O
the,4888,O
discriminative,4888,O
stimulus,4888,O
effects,4888,O
of,4888,O
AM4054,4888,B-CHEMICAL
.,4888,O
Schild,4889,O
analyses,4889,O
further,4889,O
show,4889,O
that,4889,O
rimonabant,4889,B-CHEMICAL
and,4889,O
AM4113,4889,B-CHEMICAL
produce,4889,O
highly,4889,O
similar,4889,O
antagonist,4889,O
effects,4889,O
",",4889,O
as,4889,O
evident,4889,O
in,4889,O
comparable,4889,O
pA,4889,O
(,4889,O
2,4889,O
),4889,O
values,4889,O
(,4889,O
6.9,4889,O
),4889,O
.,4889,O
Taken,4890,O
together,4890,O
with,4890,O
previous,4890,O
studies,4890,O
",",4890,O
the,4890,O
present,4890,O
data,4890,O
suggest,4890,O
that,4890,O
the,4890,O
improved,4890,O
safety,4890,O
profile,4890,O
suggested,4890,O
for,4890,O
CB,4890,B-GENE-N
(,4890,I-GENE-N
1,4890,I-GENE-N
),4890,I-GENE-N
neutral,4890,O
antagonists,4890,O
over,4890,O
inverse,4890,O
agonists,4890,O
is,4890,O
not,4890,O
accompanied,4890,O
by,4890,O
a,4890,O
loss,4890,O
of,4890,O
antagonist,4890,O
action,4890,O
at,4890,O
CB,4890,B-GENE-N
(,4890,I-GENE-N
1,4890,I-GENE-N
),4890,I-GENE-N
receptors,4890,I-GENE-N
.,4890,O
Marked,4891,O
decline,4891,O
in,4891,O
beta,4891,O
cell,4891,O
function,4891,O
during,4891,O
pregnancy,4891,O
leads,4891,O
to,4891,O
the,4891,O
development,4891,O
of,4891,O
glucose,4891,B-CHEMICAL
intolerance,4891,O
in,4891,O
Japanese,4891,O
women,4891,O
.,4891,O
The,4892,O
aim,4892,O
of,4892,O
this,4892,O
study,4892,O
is,4892,O
to,4892,O
investigate,4892,O
glucose,4892,B-CHEMICAL
metabolism,4892,O
longitudinally,4892,O
during,4892,O
pregnancy,4892,O
to,4892,O
explore,4892,O
mechanisms,4892,O
underlying,4892,O
gestational,4892,O
diabetes,4892,O
mellitus,4892,O
(,4892,O
GDM,4892,O
),4892,O
.,4892,O
We,4893,O
reviewed,4893,O
a,4893,O
total,4893,O
of,4893,O
62,4893,O
pregnant,4893,O
Japanese,4893,O
women,4893,O
who,4893,O
underwent,4893,O
a,4893,O
75g,4893,O
oral,4893,O
glucose,4893,B-CHEMICAL
tolerance,4893,O
test,4893,O
(,4893,O
OGTT,4893,O
),4893,O
twice,4893,O
during,4893,O
pregnancy,4893,O
(,4893,O
median,4893,O
:,4893,O
early,4893,O
",",4893,O
13,4893,O
;,4893,O
late,4893,O
",",4893,O
28,4893,O
weeks,4893,O
',4893,O
gestation,4893,O
),4893,O
because,4893,O
of,4893,O
positive,4893,O
GDM,4893,O
screening,4893,O
.,4893,O
All,4894,O
showed,4894,O
normal,4894,O
OGTT,4894,O
results,4894,O
in,4894,O
early,4894,O
pregnancy,4894,O
.,4894,O
Based,4895,O
on,4895,O
late,4895,O
OGTT,4895,O
",",4895,O
15,4895,O
had,4895,O
GDM,4895,O
(,4895,O
late-onset,4895,O
GDM,4895,O
),4895,O
and,4895,O
47,4895,O
normal,4895,O
glucose,4895,B-CHEMICAL
tolerance,4895,O
(,4895,O
NGT,4895,O
),4895,O
.,4895,O
In,4896,O
early,4896,O
pregnancy,4896,O
",",4896,O
there,4896,O
were,4896,O
no,4896,O
significant,4896,O
differences,4896,O
in,4896,O
insulin,4896,B-GENE-Y
sensitivity,4896,O
(,4896,O
insulin,4896,B-GENE-Y
sensitivity,4896,O
index,4896,O
derived,4896,O
from,4896,O
OGTT,4896,O
[,4896,O
ISOGTT,4896,O
],4896,O
and,4896,O
homeostasis,4896,O
model,4896,O
assessment,4896,O
for,4896,O
insulin,4896,B-GENE-Y
resistance,4896,O
[,4896,O
HOMA-IR,4896,O
],4896,O
),4896,O
and,4896,O
insulin,4896,B-GENE-Y
secretion,4896,O
(,4896,O
a,4896,O
ratio,4896,O
of,4896,O
the,4896,O
total,4896,O
area-under-the-insulin-curve,4896,O
to,4896,O
the,4896,O
total,4896,O
area-under-the-glucose-curve,4896,O
[,4896,O
AUCins/glu,4896,O
],4896,O
and,4896,O
insulinogenic,4896,O
index,4896,O
[,4896,O
IGI,4896,O
],4896,O
),4896,O
between,4896,O
the,4896,O
NGT,4896,O
and,4896,O
late-onset,4896,O
GDM,4896,O
groups,4896,O
.,4896,O
In,4897,O
each,4897,O
group,4897,O
",",4897,O
insulin,4897,B-GENE-Y
sensitivity,4897,O
significantly,4897,O
decreased,4897,O
from,4897,O
early,4897,O
to,4897,O
late,4897,O
pregnancy,4897,O
",",4897,O
most,4897,O
in,4897,O
the,4897,O
late-onset,4897,O
GDM,4897,O
group,4897,O
(,4897,O
each,4897,O
p,4897,O
<,4897,O
0.05,4897,O
),4897,O
.,4897,O
The,4898,O
insulin,4898,B-GENE-Y
secretion,4898,O
showed,4898,O
no,4898,O
significant,4898,O
changes,4898,O
with,4898,O
advancing,4898,O
pregnancy,4898,O
in,4898,O
both,4898,O
of,4898,O
the,4898,O
groups,4898,O
",",4898,O
although,4898,O
late-onset,4898,O
GDM,4898,O
showed,4898,O
significantly,4898,O
lower,4898,O
IGI,4898,O
compared,4898,O
with,4898,O
NGT,4898,O
in,4898,O
late,4898,O
OGTT,4898,O
(,4898,O
p,4898,O
<,4898,O
0.05,4898,O
),4898,O
.,4898,O
When,4899,O
assessed,4899,O
beta,4899,O
cell,4899,O
function,4899,O
by,4899,O
OGTT-derived,4899,O
disposition,4899,O
index,4899,O
(,4899,O
i.e,4899,O
.,4899,O
Insulin,4900,B-GENE-Y
Secretion-Sensitivity,4900,O
Index-2,4900,O
and,4900,O
IGI/fasting,4900,O
insulin,4900,B-GENE-Y
),4900,O
",",4900,O
the,4900,O
indices,4900,O
significantly,4900,O
decreased,4900,O
from,4900,O
early,4900,O
to,4900,O
late,4900,O
pregnancy,4900,O
in,4900,O
the,4900,O
both,4900,O
groups,4900,O
(,4900,O
each,4900,O
p,4900,O
<,4900,O
0.05,4900,O
),4900,O
.,4900,O
Women,4901,O
with,4901,O
late-onset,4901,O
GDM,4901,O
showed,4901,O
significantly,4901,O
lower,4901,O
indices,4901,O
compared,4901,O
with,4901,O
NGT,4901,O
(,4901,O
each,4901,O
p,4901,O
<,4901,O
0.05,4901,O
),4901,O
.,4901,O
The,4902,O
failure,4902,O
of,4902,O
beta,4902,O
cell,4902,O
to,4902,O
compensate,4902,O
for,4902,O
decreased,4902,O
insulin,4902,B-GENE-Y
sensitivity,4902,O
could,4902,O
contribute,4902,O
to,4902,O
the,4902,O
development,4902,O
of,4902,O
the,4902,O
late-onset,4902,O
GDM,4902,O
.,4902,O
New,4903,O
oral,4903,O
anticoagulants,4903,O
:,4903,O
comparative,4903,O
pharmacology,4903,O
with,4903,O
vitamin,4903,B-CHEMICAL
K,4903,I-CHEMICAL
antagonists,4903,O
.,4903,O
New,4904,O
oral,4904,O
anticoagulants,4904,O
(,4904,O
OACs,4904,O
),4904,O
that,4904,O
directly,4904,O
inhibit,4904,O
Factor,4904,B-GENE-Y
Xa,4904,I-GENE-Y
(,4904,O
FXa,4904,B-GENE-Y
),4904,O
or,4904,O
thrombin,4904,B-GENE-Y
have,4904,O
been,4904,O
developed,4904,O
for,4904,O
the,4904,O
long-term,4904,O
prevention,4904,O
of,4904,O
thromboembolic,4904,O
disorders,4904,O
.,4904,O
These,4905,O
novel,4905,O
agents,4905,O
provide,4905,O
numerous,4905,O
benefits,4905,O
over,4905,O
older,4905,O
vitamin,4905,B-CHEMICAL
K,4905,I-CHEMICAL
antagonists,4905,O
(,4905,O
VKAs,4905,O
),4905,O
due,4905,O
to,4905,O
major,4905,O
pharmacological,4905,O
differences,4905,O
.,4905,O
VKAs,4906,O
are,4906,O
economical,4906,O
and,4906,O
very,4906,O
well,4906,O
characterized,4906,O
",",4906,O
but,4906,O
have,4906,O
important,4906,O
limitations,4906,O
that,4906,O
can,4906,O
outweigh,4906,O
these,4906,O
advantages,4906,O
",",4906,O
such,4906,O
as,4906,O
slow,4906,O
onset,4906,O
of,4906,O
action,4906,O
",",4906,O
narrow,4906,O
therapeutic,4906,O
window,4906,O
and,4906,O
unpredictable,4906,O
anticoagulant,4906,O
effect,4906,O
.,4906,O
VKA-associated,4907,O
dietary,4907,O
precautions,4907,O
",",4907,O
monitoring,4907,O
and,4907,O
dosing,4907,O
adjustments,4907,O
to,4907,O
maintain,4907,O
international,4907,O
normalized,4907,O
ratio,4907,O
(,4907,O
INR,4907,O
),4907,O
within,4907,O
therapeutic,4907,O
range,4907,O
",",4907,O
and,4907,O
bridging,4907,O
therapy,4907,O
",",4907,O
are,4907,O
inconvenient,4907,O
for,4907,O
patients,4907,O
",",4907,O
expensive,4907,O
",",4907,O
and,4907,O
may,4907,O
result,4907,O
in,4907,O
inappropriate,4907,O
use,4907,O
of,4907,O
VKA,4907,O
therapy,4907,O
.,4907,O
This,4908,O
may,4908,O
lead,4908,O
to,4908,O
increased,4908,O
bleeding,4908,O
risk,4908,O
or,4908,O
reduced,4908,O
anticoagulation,4908,O
and,4908,O
increased,4908,O
risk,4908,O
of,4908,O
thrombotic,4908,O
events,4908,O
.,4908,O
The,4909,O
new,4909,O
OACs,4909,O
have,4909,O
rapid,4909,O
onset,4909,O
of,4909,O
action,4909,O
",",4909,O
low,4909,O
potential,4909,O
for,4909,O
food,4909,O
and,4909,O
drug,4909,O
interactions,4909,O
",",4909,O
and,4909,O
predictable,4909,O
anticoagulant,4909,O
effect,4909,O
that,4909,O
removes,4909,O
the,4909,O
need,4909,O
for,4909,O
routine,4909,O
monitoring,4909,O
.,4909,O
FXa,4910,B-GENE-Y
inhibitors,4910,O
",",4910,O
e.g,4910,O
.,4910,O
rivaroxaban,4911,B-CHEMICAL
and,4911,O
apixaban,4911,B-CHEMICAL
",",4911,O
are,4911,O
potent,4911,O
",",4911,O
oral,4911,O
direct,4911,O
inhibitors,4911,O
of,4911,O
prothrombinase-bound,4911,B-GENE-N
",",4911,O
clot-associated,4911,O
or,4911,O
free,4911,O
FXa,4911,B-GENE-Y
.,4911,O
Both,4912,O
agents,4912,O
have,4912,O
a,4912,O
rapid,4912,O
onset,4912,O
of,4912,O
action,4912,O
",",4912,O
a,4912,O
wide,4912,O
therapeutic,4912,O
window,4912,O
",",4912,O
little,4912,O
or,4912,O
no,4912,O
interaction,4912,O
with,4912,O
food,4912,O
and,4912,O
other,4912,O
drugs,4912,O
",",4912,O
minimal,4912,O
inter-patient,4912,O
variability,4912,O
",",4912,O
and,4912,O
display,4912,O
similar,4912,O
pharmacokinetics,4912,O
in,4912,O
different,4912,O
patient,4912,O
populations,4912,O
.,4912,O
Since,4913,O
both,4913,O
are,4913,O
substrates,4913,O
",",4913,O
co-administration,4913,O
of,4913,O
rivaroxaban,4913,B-CHEMICAL
and,4913,O
apixaban,4913,B-CHEMICAL
with,4913,O
strong,4913,O
cytochrome,4913,B-GENE-Y
P450,4913,I-GENE-Y
(,4913,I-GENE-Y
CYP,4913,I-GENE-Y
),4913,I-GENE-Y
3A4,4913,I-GENE-Y
and,4913,O
permeability,4913,B-GENE-Y
glycoprotein,4913,I-GENE-Y
(,4913,O
P-gp,4913,B-GENE-Y
),4913,O
inhibitors,4913,O
and,4913,O
inducers,4913,O
can,4913,O
result,4913,O
in,4913,O
substantial,4913,O
changes,4913,O
in,4913,O
plasma,4913,O
concentrations,4913,O
due,4913,O
to,4913,O
altered,4913,O
clearance,4913,O
rates,4913,O
;,4913,O
consequently,4913,O
",",4913,O
their,4913,O
concomitant,4913,O
use,4913,O
is,4913,O
contraindicated,4913,O
and,4913,O
caution,4913,O
is,4913,O
required,4913,O
when,4913,O
used,4913,O
concomitantly,4913,O
with,4913,O
strong,4913,O
CYP3A4,4913,B-GENE-Y
and,4913,O
P-gp,4913,B-GENE-Y
inducers,4913,O
.,4913,O
Although,4914,O
parenteral,4914,O
oral,4914,O
direct,4914,O
thrombin,4914,B-GENE-Y
inhibitors,4914,O
(,4914,O
DTIs,4914,O
),4914,O
",",4914,O
such,4914,O
as,4914,O
argatroban,4914,B-CHEMICAL
and,4914,O
bivalirudin,4914,O
",",4914,O
have,4914,O
been,4914,O
on,4914,O
the,4914,O
market,4914,O
for,4914,O
years,4914,O
",",4914,O
DTIs,4914,O
such,4914,O
as,4914,O
dabigatran,4914,B-CHEMICAL
are,4914,O
novel,4914,O
synthetic,4914,O
thrombin,4914,B-GENE-Y
antagonists,4914,O
.,4914,O
Dabigatran,4915,B-CHEMICAL
etexilate,4915,I-CHEMICAL
is,4915,O
a,4915,O
low-molecular-weight,4915,O
non-active,4915,O
pro-drug,4915,O
that,4915,O
is,4915,O
administered,4915,O
orally,4915,O
and,4915,O
converted,4915,O
rapidly,4915,O
to,4915,O
its,4915,O
active,4915,O
form,4915,O
",",4915,O
dabigatran,4915,B-CHEMICAL
--,4915,O
a,4915,O
potent,4915,O
",",4915,O
competitive,4915,O
and,4915,O
reversible,4915,O
DTI,4915,O
.,4915,O
Dabigatran,4916,B-CHEMICAL
has,4916,O
an,4916,O
advantage,4916,O
over,4916,O
the,4916,O
indirect,4916,O
thrombin,4916,B-GENE-Y
inhibitors,4916,O
",",4916,O
unfractionated,4916,O
heparin,4916,O
and,4916,O
low-molecular-weight,4916,O
heparin,4916,O
",",4916,O
in,4916,O
that,4916,O
it,4916,O
inhibits,4916,O
free,4916,O
and,4916,O
fibrin-bound,4916,B-GENE-N
thrombin,4916,B-GENE-Y
.,4916,O
The,4917,O
reversible,4917,O
binding,4917,O
of,4917,O
dabigatran,4917,B-CHEMICAL
may,4917,O
provide,4917,O
safer,4917,O
and,4917,O
more,4917,O
predictable,4917,O
anticoagulant,4917,O
treatment,4917,O
than,4917,O
seen,4917,O
with,4917,O
irreversible,4917,O
",",4917,O
non-covalent,4917,O
thrombin,4917,B-GENE-Y
inhibitors,4917,O
",",4917,O
e.g,4917,O
.,4917,O
hirudin,4918,O
.,4918,O
Dabigatran,4919,B-CHEMICAL
shows,4919,O
a,4919,O
very,4919,O
low,4919,O
potential,4919,O
for,4919,O
drug-drug,4919,O
interactions,4919,O
.,4919,O
However,4920,O
",",4920,O
co-administration,4920,O
of,4920,O
dabigatran,4920,B-CHEMICAL
etexilate,4920,I-CHEMICAL
with,4920,O
other,4920,O
anticoagulants,4920,O
and,4920,O
antiplatelet,4920,O
agents,4920,O
can,4920,O
increase,4920,O
the,4920,O
bleeding,4920,O
risk,4920,O
.,4920,O
Although,4921,O
the,4921,O
new,4921,O
agents,4921,O
are,4921,O
pharmacologically,4921,O
better,4921,O
than,4921,O
VKAs,4921,O
--,4921,O
particularly,4921,O
in,4921,O
terms,4921,O
of,4921,O
fixed,4921,O
dosing,4921,O
",",4921,O
rapid,4921,O
onset,4921,O
of,4921,O
action,4921,O
",",4921,O
no,4921,O
INR,4921,O
monitoring,4921,O
and,4921,O
lower,4921,O
risk,4921,O
of,4921,O
drug,4921,O
interactions,4921,O
--,4921,O
there,4921,O
are,4921,O
some,4921,O
differences,4921,O
between,4921,O
them,4921,O
:,4921,O
the,4921,O
bioavailability,4921,O
of,4921,O
dabigatran,4921,B-CHEMICAL
is,4921,O
lower,4921,O
than,4921,O
rivaroxaban,4921,B-CHEMICAL
and,4921,O
apixaban,4921,B-CHEMICAL
",",4921,O
and,4921,O
so,4921,O
the,4921,O
dabigatran,4921,B-CHEMICAL
dosage,4921,O
required,4921,O
is,4921,O
higher,4921,O
;,4921,O
lower,4921,O
protein,4921,O
binding,4921,O
of,4921,O
dabigatran,4921,B-CHEMICAL
reduces,4921,O
the,4921,O
variability,4921,O
related,4921,O
to,4921,O
albuminaemia,4921,O
.,4921,O
The,4922,O
risk,4922,O
of,4922,O
metabolic,4922,O
drug-drug,4922,O
interactions,4922,O
also,4922,O
appears,4922,O
to,4922,O
differ,4922,O
between,4922,O
OACs,4922,O
:,4922,O
VKAs,4922,O
>,4922,O
rivaroxaban,4922,B-CHEMICAL
>,4922,O
apixaban,4922,B-CHEMICAL
>,4922,O
dabigatran,4922,B-CHEMICAL
.,4922,O
The,4923,O
convenience,4923,O
of,4923,O
the,4923,O
new,4923,O
OACs,4923,O
has,4923,O
translated,4923,O
into,4923,O
improvements,4923,O
in,4923,O
efficacy,4923,O
and,4923,O
safety,4923,O
as,4923,O
shown,4923,O
in,4923,O
phase,4923,O
III,4923,O
randomized,4923,O
trials,4923,O
.,4923,O
The,4924,O
new,4924,O
anticoagulants,4924,O
so,4924,O
far,4924,O
offer,4924,O
the,4924,O
greatest,4924,O
promise,4924,O
and,4924,O
opportunity,4924,O
for,4924,O
the,4924,O
replacement,4924,O
of,4924,O
VKAs,4924,O
.,4924,O
Effects,4925,O
of,4925,O
smoking,4925,O
on,4925,O
the,4925,O
oxidant/antioxidant,4925,O
balance,4925,O
and,4925,O
the,4925,O
blood,4925,O
lipids,4925,O
in,4925,O
pesticide,4925,O
sprayers,4925,O
.,4925,O
The,4926,O
present,4926,O
study,4926,O
was,4926,O
conducted,4926,O
on,4926,O
80,4926,O
pesticide,4926,O
male,4926,O
sprayers,4926,O
(,4926,O
42,4926,O
nonsmokers,4926,O
and,4926,O
38,4926,O
smokers,4926,O
),4926,O
.,4926,O
Our,4927,O
aim,4927,O
was,4927,O
to,4927,O
estimate,4927,O
the,4927,O
smoking,4927,O
effects,4927,O
on,4927,O
blood,4927,O
lipids,4927,O
and,4927,O
oxidant/antioxidant,4927,O
status,4927,O
in,4927,O
pesticide,4927,O
sprayers,4927,O
.,4927,O
Results,4928,O
revealed,4928,O
that,4928,O
cholesterol,4928,B-CHEMICAL
",",4928,O
low-density,4928,B-GENE-N
lipoprotein,4928,I-GENE-N
(,4928,O
LDL,4928,B-GENE-N
),4928,O
and,4928,O
glutathion,4928,B-CHEMICAL
peroxidase,4928,I-GENE-N
(,4928,O
GPx,4928,B-GENE-N
),4928,O
enzyme,4928,O
were,4928,O
significantly,4928,O
higher,4928,O
in,4928,O
the,4928,O
38,4928,O
smoker,4928,O
sprayers,4928,O
than,4928,O
in,4928,O
the,4928,O
42,4928,O
nonsmoker,4928,O
sprayers,4928,O
.,4928,O
Cholesterol,4929,B-CHEMICAL
and,4929,O
LDL,4929,B-GENE-N
were,4929,O
correlated,4929,O
with,4929,O
smoking,4929,O
index,4929,O
and,4929,O
high-density,4929,B-GENE-N
lipoprotein,4929,I-GENE-N
(,4929,O
HDL,4929,B-GENE-N
),4929,O
",",4929,O
superoxide,4929,B-CHEMICAL
dismutase,4929,I-GENE-N
(,4929,O
SOD,4929,B-GENE-N
),4929,O
enzyme,4929,O
and,4929,O
zinc,4929,B-CHEMICAL
(,4929,O
Zn,4929,B-CHEMICAL
),4929,O
were,4929,O
inversely,4929,O
correlated,4929,O
with,4929,O
duration,4929,O
of,4929,O
pesticides,4929,O
',4929,O
exposure,4929,O
.,4929,O
In,4930,O
nonsmokers,4930,O
",",4930,O
LDL,4930,B-GENE-N
and,4930,O
cholesterol,4930,B-CHEMICAL
were,4930,O
negatively,4930,O
correlated,4930,O
with,4930,O
SOD,4930,B-GENE-N
and,4930,O
correlated,4930,O
with,4930,O
malondialdehyde,4930,B-CHEMICAL
(,4930,O
MDA,4930,B-CHEMICAL
),4930,O
",",4930,O
and,4930,O
cholesterol,4930,B-CHEMICAL
was,4930,O
negatively,4930,O
correlated,4930,O
with,4930,O
Zn,4930,B-CHEMICAL
.,4930,O
HDL,4931,B-GENE-N
was,4931,O
negatively,4931,O
correlated,4931,O
with,4931,O
MDA,4931,B-CHEMICAL
in,4931,O
all,4931,O
the,4931,O
sprayers,4931,O
",",4931,O
but,4931,O
was,4931,O
correlated,4931,O
with,4931,O
GPx,4931,B-GENE-N
in,4931,O
smokers,4931,O
and,4931,O
with,4931,O
Zn,4931,B-CHEMICAL
in,4931,O
nonsmokers,4931,O
.,4931,O
In,4932,O
smokers,4932,O
",",4932,O
LDL,4932,B-GENE-N
was,4932,O
negatively,4932,O
correlated,4932,O
with,4932,O
GPx,4932,B-GENE-N
",",4932,O
HDL,4932,B-GENE-N
was,4932,O
negatively,4932,O
correlated,4932,O
with,4932,O
MDA,4932,B-CHEMICAL
and,4932,O
triglycerides,4932,B-CHEMICAL
and,4932,O
very-low-density,4932,B-GENE-N
lipoprotein,4932,I-GENE-N
were,4932,O
negatively,4932,O
correlated,4932,O
with,4932,O
Zn,4932,B-CHEMICAL
.,4932,O
MDA,4933,B-CHEMICAL
was,4933,O
negatively,4933,O
correlated,4933,O
with,4933,O
SOD,4933,B-GENE-N
",",4933,O
GPx,4933,B-GENE-N
and,4933,O
Zn,4933,B-CHEMICAL
.,4933,O
Smoking,4934,O
and,4934,O
pesticide,4934,O
exposure,4934,O
could,4934,O
be,4934,O
responsible,4934,O
for,4934,O
hyperlipidemia,4934,O
and,4934,O
oxidative,4934,O
stress,4934,O
.,4934,O
Therefore,4935,O
",",4935,O
improvement,4935,O
in,4935,O
the,4935,O
antioxidant,4935,O
status,4935,O
is,4935,O
mandatory,4935,O
for,4935,O
pesticide,4935,O
sprayers,4935,O
especially,4935,O
the,4935,O
ones,4935,O
who,4935,O
smoke,4935,O
.,4935,O
Fluorescence,4936,O
lifetime,4936,O
analysis,4936,O
and,4936,O
effect,4936,O
of,4936,O
magnesium,4936,B-CHEMICAL
ions,4936,O
on,4936,O
binding,4936,O
of,4936,O
NADH,4936,B-CHEMICAL
to,4936,O
human,4936,B-GENE-Y
aldehyde,4936,I-GENE-Y
dehydrogenase,4936,I-GENE-Y
1,4936,I-GENE-Y
.,4936,O
Aldehyde,4937,B-GENE-Y
dehydrogenase,4937,I-GENE-Y
1,4937,I-GENE-Y
(,4937,O
ALDH1A1,4937,B-GENE-Y
),4937,O
catalyzes,4937,O
the,4937,O
oxidation,4937,O
of,4937,O
toxic,4937,O
aldehydes,4937,B-CHEMICAL
to,4937,O
carboxylic,4937,B-CHEMICAL
acids,4937,I-CHEMICAL
.,4937,O
Physiologic,4938,O
levels,4938,O
of,4938,O
Mg,4938,B-CHEMICAL
(,4938,I-CHEMICAL
2+,4938,I-CHEMICAL
),4938,I-CHEMICAL
ions,4938,O
decrease,4938,O
ALDH1,4938,B-GENE-Y
activity,4938,O
in,4938,O
part,4938,O
by,4938,O
increasing,4938,O
NADH,4938,B-CHEMICAL
binding,4938,O
affinity,4938,O
to,4938,O
the,4938,O
enzyme,4938,O
.,4938,O
By,4939,O
using,4939,O
time-resolved,4939,O
fluorescence,4939,O
spectroscopy,4939,O
",",4939,O
we,4939,O
have,4939,O
resolved,4939,O
the,4939,O
fluorescent,4939,O
lifetimes,4939,O
(,4939,O
τ,4939,O
),4939,O
of,4939,O
free,4939,O
NADH,4939,B-CHEMICAL
in,4939,O
solution,4939,O
(,4939,O
τ=0.4,4939,O
ns,4939,O
),4939,O
and,4939,O
two,4939,O
enzyme-bound,4939,O
NADH,4939,B-CHEMICAL
states,4939,O
(,4939,O
τ=2.0,4939,O
ns,4939,O
and,4939,O
τ=7.7,4939,O
ns,4939,O
),4939,O
.,4939,O
We,4940,O
used,4940,O
this,4940,O
technique,4940,O
to,4940,O
investigate,4940,O
the,4940,O
effects,4940,O
of,4940,O
Mg,4940,B-CHEMICAL
(,4940,I-CHEMICAL
2+,4940,I-CHEMICAL
),4940,I-CHEMICAL
ions,4940,O
on,4940,O
the,4940,O
ALDH1A1-NADH,4940,B-GENE-Y
binding,4940,O
characteristics,4940,O
and,4940,O
enzyme,4940,O
catalysis,4940,O
.,4940,O
From,4941,O
the,4941,O
resolved,4941,O
free,4941,O
and,4941,O
bound,4941,O
NADH,4941,B-CHEMICAL
fluorescence,4941,O
signatures,4941,O
",",4941,O
the,4941,O
KD,4941,O
values,4941,O
for,4941,O
both,4941,O
NADH,4941,B-CHEMICAL
conformations,4941,O
in,4941,O
ALDH1A1,4941,B-GENE-Y
ranged,4941,O
from,4941,O
about,4941,O
24,4941,O
μM,4941,O
to,4941,O
1,4941,O
μM,4941,O
for,4941,O
Mg,4941,B-CHEMICAL
(,4941,I-CHEMICAL
2+,4941,I-CHEMICAL
),4941,I-CHEMICAL
ion,4941,O
concentrations,4941,O
of,4941,O
0-6000,4941,O
μM,4941,O
",",4941,O
respectively,4941,O
.,4941,O
The,4942,O
rate,4942,O
constants,4942,O
for,4942,O
dissociation,4942,O
of,4942,O
the,4942,O
enzyme-NADH,4942,O
complex,4942,O
ranged,4942,O
from,4942,O
0.03,4942,O
s,4942,O
(,4942,O
-1,4942,O
),4942,O
(,4942,O
6000,4942,O
μM,4942,O
Mg,4942,B-CHEMICAL
(,4942,I-CHEMICAL
2+,4942,I-CHEMICAL
),4942,I-CHEMICAL
),4942,O
to,4942,O
0.30s,4942,O
(,4942,O
-1,4942,O
),4942,O
(,4942,O
0,4942,O
μM,4942,O
Mg,4942,B-CHEMICAL
(,4942,I-CHEMICAL
2+,4942,I-CHEMICAL
),4942,I-CHEMICAL
),4942,O
as,4942,O
determined,4942,O
by,4942,O
addition,4942,O
of,4942,O
excess,4942,O
NAD,4942,B-CHEMICAL
(,4942,I-CHEMICAL
+,4942,I-CHEMICAL
),4942,I-CHEMICAL
to,4942,O
prevent,4942,O
re-association,4942,O
of,4942,O
NADH,4942,B-CHEMICAL
and,4942,O
resolving,4942,O
the,4942,O
real-time,4942,O
NADH,4942,B-CHEMICAL
fluorescence,4942,O
signal,4942,O
.,4942,O
During,4943,O
the,4943,O
initial,4943,O
reaction,4943,O
of,4943,O
enzyme,4943,O
with,4943,O
NAD,4943,B-CHEMICAL
(,4943,I-CHEMICAL
+,4943,I-CHEMICAL
),4943,I-CHEMICAL
and,4943,O
butyraldehyde,4943,B-CHEMICAL
",",4943,O
there,4943,O
was,4943,O
an,4943,O
immediate,4943,O
rise,4943,O
in,4943,O
the,4943,O
NADH,4943,B-CHEMICAL
fluorescence,4943,O
",",4943,O
due,4943,O
to,4943,O
the,4943,O
formation,4943,O
of,4943,O
bound,4943,O
NADH,4943,B-CHEMICAL
complexes,4943,O
",",4943,O
with,4943,O
a,4943,O
constant,4943,O
steady-state,4943,O
rate,4943,O
of,4943,O
production,4943,O
of,4943,O
free,4943,O
NADH,4943,B-CHEMICAL
.,4943,O
As,4944,O
the,4944,O
Mg,4944,B-CHEMICAL
(,4944,I-CHEMICAL
2+,4944,I-CHEMICAL
),4944,I-CHEMICAL
ion,4944,O
concentration,4944,O
was,4944,O
increased,4944,O
",",4944,O
there,4944,O
was,4944,O
a,4944,O
consistent,4944,O
decrease,4944,O
of,4944,O
the,4944,O
enzyme,4944,O
catalytic,4944,O
turnover,4944,O
from,4944,O
0.31,4944,O
s,4944,O
(,4944,O
-1,4944,O
),4944,O
(,4944,O
0,4944,O
μM,4944,O
Mg,4944,B-CHEMICAL
(,4944,I-CHEMICAL
2+,4944,I-CHEMICAL
),4944,I-CHEMICAL
),4944,O
to,4944,O
0.050,4944,O
s,4944,O
(,4944,O
-1,4944,O
),4944,O
(,4944,O
6000,4944,O
μM,4944,O
Mg,4944,B-CHEMICAL
(,4944,I-CHEMICAL
2+,4944,I-CHEMICAL
),4944,I-CHEMICAL
),4944,O
and,4944,O
a,4944,O
distinct,4944,O
shift,4944,O
in,4944,O
steady-state,4944,O
conformational,4944,O
population,4944,O
from,4944,O
one,4944,O
that,4944,O
favors,4944,O
the,4944,O
ALDH1-NADH,4944,B-GENE-Y
complex,4944,O
with,4944,O
the,4944,O
shorter,4944,O
fluorescence,4944,O
lifetime,4944,O
(,4944,O
33,4944,O
%,4944,O
excess,4944,O
),4944,O
in,4944,O
the,4944,O
absence,4944,O
of,4944,O
magnesium,4944,B-CHEMICAL
ion,4944,O
to,4944,O
one,4944,O
that,4944,O
favors,4944,O
the,4944,O
ALDH1-NADH,4944,B-GENE-Y
complex,4944,O
with,4944,O
the,4944,O
longer,4944,O
fluorescence,4944,O
lifetime,4944,O
(,4944,O
13,4944,O
%,4944,O
excess,4944,O
),4944,O
at,4944,O
6000,4944,O
μM,4944,O
Mg,4944,B-CHEMICAL
(,4944,I-CHEMICAL
2+,4944,I-CHEMICAL
),4944,I-CHEMICAL
.,4944,O
This,4945,O
shift,4945,O
in,4945,O
conformational,4945,O
population,4945,O
at,4945,O
higher,4945,O
Mg,4945,B-CHEMICAL
(,4945,I-CHEMICAL
2+,4945,I-CHEMICAL
),4945,I-CHEMICAL
ion,4945,O
concentrations,4945,O
and,4945,O
to,4945,O
lower,4945,O
enzyme,4945,O
activity,4945,O
may,4945,O
be,4945,O
due,4945,O
to,4945,O
longer,4945,O
residence,4945,O
time,4945,O
of,4945,O
the,4945,O
NADH,4945,B-CHEMICAL
in,4945,O
the,4945,O
ALDH1,4945,B-GENE-Y
pocket,4945,O
.,4945,O
The,4946,O
results,4946,O
from,4946,O
monitoring,4946,O
enzyme,4946,O
catalysis,4946,O
in,4946,O
the,4946,O
absence,4946,O
of,4946,O
magnesium,4946,B-CHEMICAL
suggests,4946,O
that,4946,O
the,4946,O
ALDH1-NADH,4946,B-GENE-Y
complex,4946,O
with,4946,O
the,4946,O
shorter,4946,O
fluorescence,4946,O
lifetime,4946,O
is,4946,O
the,4946,O
form,4946,O
initially,4946,O
produced,4946,O
",",4946,O
and,4946,O
the,4946,O
complex,4946,O
with,4946,O
the,4946,O
longer,4946,O
fluorescence,4946,O
lifetime,4946,O
is,4946,O
produced,4946,O
through,4946,O
isomerization,4946,O
.,4946,O
Acrolein,4947,B-CHEMICAL
induces,4947,O
Alzheimer,4947,O
's,4947,O
disease-like,4947,O
pathologies,4947,O
in,4947,O
vitro,4947,O
and,4947,O
in,4947,O
vivo,4947,O
.,4947,O
The,4948,O
pathologic,4948,O
mechanisms,4948,O
of,4948,O
Alzheimer,4948,O
's,4948,O
disease,4948,O
(,4948,O
AD,4948,O
),4948,O
have,4948,O
not,4948,O
been,4948,O
fully,4948,O
uncovered,4948,O
.,4948,O
Acrolein,4949,B-CHEMICAL
",",4949,O
a,4949,O
ubiquitous,4949,O
dietary,4949,O
pollutant,4949,O
and,4949,O
by-product,4949,O
of,4949,O
oxidative,4949,O
stress,4949,O
",",4949,O
can,4949,O
induce,4949,O
cytotoxicity,4949,O
in,4949,O
neurons,4949,O
",",4949,O
which,4949,O
might,4949,O
play,4949,O
an,4949,O
important,4949,O
role,4949,O
in,4949,O
the,4949,O
etiology,4949,O
of,4949,O
AD,4949,O
.,4949,O
Here,4950,O
",",4950,O
we,4950,O
examined,4950,O
the,4950,O
effects,4950,O
of,4950,O
Acrolein,4950,B-CHEMICAL
on,4950,O
the,4950,O
AD,4950,O
pathologies,4950,O
in,4950,O
vitro,4950,O
and,4950,O
in,4950,O
vivo,4950,O
.,4950,O
We,4951,O
found,4951,O
Acrolein,4951,B-CHEMICAL
induced,4951,O
HT22,4951,O
cells,4951,O
death,4951,O
in,4951,O
concentration-,4951,O
and,4951,O
time-dependent,4951,O
manners,4951,O
.,4951,O
Interestingly,4952,O
",",4952,O
Acrolein,4952,B-CHEMICAL
increased,4952,O
proteins,4952,O
',4952,O
levels,4952,O
of,4952,O
amyloid,4952,B-GENE-Y
precursor,4952,I-GENE-Y
protein,4952,I-GENE-Y
(,4952,O
APP,4952,B-GENE-Y
),4952,O
",",4952,O
β-secretase,4952,B-GENE-N
(,4952,O
BACE-1,4952,B-GENE-Y
),4952,O
and,4952,O
the,4952,O
amyloid,4952,B-GENE-Y
β-peptide,4952,I-GENE-Y
transporter,4952,I-GENE-Y
receptor,4952,B-GENE-Y
for,4952,I-GENE-Y
advanced,4952,I-GENE-Y
glycation,4952,I-GENE-Y
end,4952,I-GENE-Y
products,4952,I-GENE-Y
",",4952,O
and,4952,O
decreased,4952,O
A-disintegrin,4952,B-GENE-Y
and,4952,I-GENE-Y
metalloprotease,4952,I-GENE-Y
(,4952,I-GENE-Y
ADAM,4952,I-GENE-Y
),4952,I-GENE-Y
10,4952,I-GENE-Y
levels,4952,O
.,4952,O
In,4953,O
vivo,4953,O
",",4953,O
chronic,4953,O
oral,4953,O
exposure,4953,O
to,4953,O
Acrolein,4953,B-CHEMICAL
(,4953,O
2.5,4953,O
mg/kg/day,4953,O
by,4953,O
intragastric,4953,O
gavage,4953,O
for,4953,O
8,4953,O
weeks,4953,O
),4953,O
induced,4953,O
mild,4953,O
cognitive,4953,O
declination,4953,O
and,4953,O
pyknosis/atrophy,4953,O
of,4953,O
hippocampal,4953,O
neurons,4953,O
.,4953,O
The,4954,O
activity,4954,O
of,4954,O
superoxide,4954,B-CHEMICAL
dismutase,4954,I-GENE-N
was,4954,O
down-regulated,4954,O
while,4954,O
the,4954,O
level,4954,O
of,4954,O
malondialdehyde,4954,B-CHEMICAL
was,4954,O
up-regulated,4954,O
in,4954,O
rat,4954,O
brain,4954,O
.,4954,O
Moreover,4955,O
",",4955,O
Acrolein,4955,B-CHEMICAL
resulted,4955,O
in,4955,O
activation,4955,O
of,4955,O
astrocytes,4955,O
",",4955,O
up-regulation,4955,O
of,4955,O
BACE-1,4955,B-GENE-Y
in,4955,O
cortex,4955,O
and,4955,O
down-regulation,4955,O
of,4955,O
ADAM-10,4955,B-GENE-Y
in,4955,O
hippocampus,4955,O
and,4955,O
cortex,4955,O
.,4955,O
Taken,4956,O
together,4956,O
",",4956,O
our,4956,O
findings,4956,O
suggest,4956,O
that,4956,O
exposure,4956,O
to,4956,O
Acrolein,4956,B-CHEMICAL
induces,4956,O
AD-like,4956,O
pathology,4956,O
in,4956,O
vitro,4956,O
and,4956,O
in,4956,O
vivo,4956,O
.,4956,O
Scavenging,4957,O
Acrolein,4957,B-CHEMICAL
might,4957,O
be,4957,O
beneficial,4957,O
for,4957,O
the,4957,O
therapy,4957,O
of,4957,O
AD,4957,O
.,4957,O
Membrane-initiated,4958,O
estradiol,4958,B-CHEMICAL
signaling,4958,O
in,4958,O
immortalized,4958,O
hypothalamic,4958,O
N-38,4958,O
neurons,4958,O
.,4958,O
Regulation,4959,O
of,4959,O
sexual,4959,O
reproduction,4959,O
by,4959,O
estradiol,4959,B-CHEMICAL
involves,4959,O
the,4959,O
activation,4959,O
of,4959,O
estrogen,4959,B-CHEMICAL
receptors,4959,I-GENE-Y
(,4959,O
ERs,4959,B-GENE-Y
),4959,O
in,4959,O
the,4959,O
hypothalamus,4959,O
.,4959,O
Of,4960,O
the,4960,O
two,4960,O
classical,4960,O
ERs,4960,B-GENE-Y
involved,4960,O
in,4960,O
reproduction,4960,O
",",4960,O
ERα,4960,B-GENE-Y
appears,4960,O
to,4960,O
be,4960,O
the,4960,O
critical,4960,O
isoform,4960,O
.,4960,O
The,4961,O
role,4961,O
of,4961,O
ERα,4961,B-GENE-Y
in,4961,O
reproduction,4961,O
has,4961,O
been,4961,O
found,4961,O
to,4961,O
involve,4961,O
a,4961,O
nuclear,4961,O
ERα,4961,B-GENE-Y
that,4961,O
induces,4961,O
a,4961,O
genomic,4961,O
mechanism,4961,O
of,4961,O
action,4961,O
.,4961,O
More,4962,O
recently,4962,O
",",4962,O
a,4962,O
plasma,4962,O
membrane,4962,O
ERα,4962,B-GENE-Y
has,4962,O
been,4962,O
shown,4962,O
to,4962,O
trigger,4962,O
signaling,4962,O
pathways,4962,O
involved,4962,O
in,4962,O
reproduction,4962,O
.,4962,O
Mechanisms,4963,O
underlying,4963,O
membrane-initiated,4963,O
estradiol,4963,O
signaling,4963,O
are,4963,O
emerging,4963,O
",",4963,O
including,4963,O
evidence,4963,O
that,4963,O
activation,4963,O
of,4963,O
plasma,4963,O
membrane,4963,O
ERα,4963,B-GENE-Y
involves,4963,O
receptor,4963,O
trafficking,4963,O
.,4963,O
The,4964,O
present,4964,O
study,4964,O
examined,4964,O
the,4964,O
insertion,4964,O
of,4964,O
ERα,4964,B-GENE-Y
into,4964,O
the,4964,O
plasma,4964,O
membrane,4964,O
of,4964,O
N-38,4964,O
neurons,4964,O
",",4964,O
an,4964,O
immortalized,4964,O
murine,4964,O
hypothalamic,4964,O
cell,4964,O
line,4964,O
.,4964,O
We,4965,O
identified,4965,O
",",4965,O
using,4965,O
western,4965,O
blotting,4965,O
and,4965,O
PCR,4965,O
that,4965,O
N-38,4965,O
neurons,4965,O
express,4965,O
full-length,4965,O
66kDa,4965,O
ERα,4965,B-GENE-Y
and,4965,O
a,4965,O
52kDa,4965,O
ERα,4965,B-GENE-Y
spliced,4965,O
variant,4965,O
missing,4965,O
the,4965,O
fourth,4965,O
exon,4965,O
-,4965,O
ERαΔ4,4965,B-GENE-Y
.,4965,O
Using,4966,O
surface,4966,O
biotinylation,4966,O
",",4966,O
we,4966,O
observed,4966,O
that,4966,O
treatment,4966,O
of,4966,O
N-38,4966,O
neurons,4966,O
with,4966,O
estradiol,4966,B-CHEMICAL
or,4966,O
with,4966,O
a,4966,O
membrane,4966,O
impermeant,4966,O
estradiol,4966,B-CHEMICAL
elevated,4966,O
plasma,4966,O
membrane,4966,O
ERα,4966,B-GENE-Y
protein,4966,O
levels,4966,O
",",4966,O
indicating,4966,O
that,4966,O
membrane,4966,O
signaling,4966,O
increased,4966,O
receptor,4966,O
insertion,4966,O
into,4966,O
the,4966,O
cell,4966,O
membrane,4966,O
.,4966,O
Insertion,4967,O
of,4967,O
ERα,4967,B-GENE-Y
was,4967,O
blocked,4967,O
by,4967,O
the,4967,O
ER,4967,B-GENE-Y
antagonist,4967,O
ICI,4967,B-CHEMICAL
"182,780",4967,I-CHEMICAL
or,4967,O
with,4967,O
the,4967,O
protein,4967,B-GENE-N
kinase,4967,I-GENE-N
C,4967,I-GENE-N
(,4967,O
PKC,4967,B-GENE-N
),4967,O
pathway,4967,O
inhibitor,4967,O
bisindolylmaleimide,4967,B-CHEMICAL
(,4967,O
BIS,4967,B-CHEMICAL
),4967,O
.,4967,O
Downstream,4968,O
membrane-initiated,4968,O
signaling,4968,O
was,4968,O
confirmed,4968,O
by,4968,O
estradiol,4968,B-CHEMICAL
activation,4968,O
of,4968,O
PKC-theta,4968,B-GENE-Y
(,4968,O
PKCθ,4968,B-GENE-Y
),4968,O
and,4968,O
the,4968,O
release,4968,O
of,4968,O
intracellular,4968,O
calcium,4968,O
.,4968,O
These,4969,O
results,4969,O
indicate,4969,O
that,4969,O
membrane,4969,O
ERα,4969,B-GENE-Y
levels,4969,O
in,4969,O
N-38,4969,O
neurons,4969,O
are,4969,O
dynamically,4969,O
autoregulated,4969,O
by,4969,O
estradiol,4969,B-CHEMICAL
.,4969,O
Neuroprotective,4970,O
and,4970,O
anti-inflammatory,4970,O
properties,4970,O
of,4970,O
a,4970,O
coffee,4970,O
component,4970,O
in,4970,O
the,4970,O
MPTP,4970,B-CHEMICAL
model,4970,O
of,4970,O
Parkinson,4970,O
's,4970,O
disease,4970,O
.,4970,O
Consumption,4971,O
of,4971,O
coffee,4971,O
is,4971,O
associated,4971,O
with,4971,O
reduced,4971,O
risk,4971,O
of,4971,O
Parkinson,4971,O
's,4971,O
disease,4971,O
(,4971,O
PD,4971,O
),4971,O
",",4971,O
an,4971,O
effect,4971,O
that,4971,O
has,4971,O
largely,4971,O
been,4971,O
attributed,4971,O
to,4971,O
caffeine,4971,O
.,4971,O
However,4972,O
",",4972,O
coffee,4972,O
contains,4972,O
numerous,4972,O
components,4972,O
that,4972,O
may,4972,O
also,4972,O
be,4972,O
neuroprotective,4972,O
.,4972,O
One,4973,O
of,4973,O
these,4973,O
compounds,4973,O
is,4973,O
eicosanoyl-5-hydroxytryptamide,4973,B-CHEMICAL
(,4973,O
EHT,4973,B-CHEMICAL
),4973,O
",",4973,O
which,4973,O
ameliorates,4973,O
the,4973,O
phenotype,4973,O
of,4973,O
α-synuclein,4973,B-GENE-Y
transgenic,4973,O
mice,4973,O
associated,4973,O
with,4973,O
decreased,4973,O
protein,4973,O
aggregation,4973,O
and,4973,O
phosphorylation,4973,O
",",4973,O
improved,4973,O
neuronal,4973,O
integrity,4973,O
and,4973,O
reduced,4973,O
neuroinflammation,4973,O
.,4973,O
Here,4974,O
",",4974,O
we,4974,O
sought,4974,O
to,4974,O
investigate,4974,O
if,4974,O
EHT,4974,B-CHEMICAL
has,4974,O
an,4974,O
effect,4974,O
in,4974,O
the,4974,O
MPTP,4974,B-CHEMICAL
model,4974,O
of,4974,O
PD,4974,O
.,4974,O
Mice,4975,O
fed,4975,O
a,4975,O
diet,4975,O
containing,4975,O
EHT,4975,B-CHEMICAL
for,4975,O
four,4975,O
weeks,4975,O
exhibited,4975,O
dose-dependent,4975,O
preservation,4975,O
of,4975,O
nigral,4975,O
dopaminergic,4975,O
neurons,4975,O
following,4975,O
MPTP,4975,B-CHEMICAL
challenge,4975,O
compared,4975,O
to,4975,O
animals,4975,O
given,4975,O
control,4975,O
feed,4975,O
.,4975,O
Reductions,4976,O
in,4976,O
striatal,4976,O
dopamine,4976,B-CHEMICAL
and,4976,O
tyrosine,4976,B-GENE-Y
hydroxylase,4976,I-GENE-Y
content,4976,O
were,4976,O
also,4976,O
less,4976,O
pronounced,4976,O
with,4976,O
EHT,4976,B-CHEMICAL
treatment,4976,O
.,4976,O
The,4977,O
neuroinflammatory,4977,O
response,4977,O
to,4977,O
MPTP,4977,B-CHEMICAL
was,4977,O
markedly,4977,O
attenuated,4977,O
",",4977,O
and,4977,O
indices,4977,O
of,4977,O
oxidative,4977,O
stress,4977,O
and,4977,O
JNK,4977,B-GENE-N
activation,4977,O
were,4977,O
significantly,4977,O
prevented,4977,O
with,4977,O
EHT,4977,B-CHEMICAL
.,4977,O
In,4978,O
cultured,4978,O
primary,4978,O
microglia,4978,O
and,4978,O
astrocytes,4978,O
",",4978,O
EHT,4978,B-CHEMICAL
had,4978,O
a,4978,O
direct,4978,O
anti-inflammatory,4978,O
effect,4978,O
demonstrated,4978,O
by,4978,O
repression,4978,O
of,4978,O
lipopolysaccharide-induced,4978,O
NFκB,4978,B-GENE-N
activation,4978,O
",",4978,O
iNOS,4978,B-GENE-Y
induction,4978,O
",",4978,O
and,4978,O
nitric,4978,B-CHEMICAL
oxide,4978,I-CHEMICAL
production,4978,O
.,4978,O
EHT,4979,B-CHEMICAL
also,4979,O
exhibited,4979,O
a,4979,O
robust,4979,O
anti-oxidant,4979,O
activity,4979,O
in,4979,O
vitro,4979,O
.,4979,O
Additionally,4980,O
",",4980,O
in,4980,O
SH-SY5Y,4980,O
cells,4980,O
",",4980,O
MPP,4980,B-CHEMICAL
(,4980,I-CHEMICAL
+,4980,I-CHEMICAL
),4980,I-CHEMICAL
-induced,4980,O
demethylation,4980,O
of,4980,O
phosphoprotein,4980,B-GENE-N
phosphatase,4980,I-GENE-N
2A,4980,I-GENE-N
(,4980,O
PP2A,4980,B-GENE-N
),4980,O
",",4980,O
the,4980,O
master,4980,O
regulator,4980,O
of,4980,O
the,4980,O
cellular,4980,O
phosphoregulatory,4980,O
network,4980,O
",",4980,O
and,4980,O
cytotoxicity,4980,O
were,4980,O
ameliorated,4980,O
by,4980,O
EHT,4980,B-CHEMICAL
.,4980,O
These,4981,O
findings,4981,O
indicate,4981,O
that,4981,O
the,4981,O
neuroprotective,4981,O
effect,4981,O
of,4981,O
EHT,4981,B-CHEMICAL
against,4981,O
MPTP,4981,B-CHEMICAL
is,4981,O
through,4981,O
several,4981,O
mechanisms,4981,O
including,4981,O
its,4981,O
anti-inflammatory,4981,O
and,4981,O
antioxidant,4981,O
activities,4981,O
as,4981,O
well,4981,O
as,4981,O
its,4981,O
ability,4981,O
to,4981,O
modulate,4981,O
the,4981,O
methylation,4981,O
and,4981,O
hence,4981,O
activity,4981,O
of,4981,O
PP2A,4981,B-GENE-N
.,4981,O
Our,4982,O
data,4982,O
",",4982,O
therefore,4982,O
",",4982,O
reveal,4982,O
a,4982,O
strong,4982,O
beneficial,4982,O
effect,4982,O
of,4982,O
a,4982,O
novel,4982,O
component,4982,O
of,4982,O
coffee,4982,O
in,4982,O
multiple,4982,O
endpoints,4982,O
relevant,4982,O
to,4982,O
PD,4982,O
.,4982,O
Hydrogen,4983,B-CHEMICAL
sulfide,4983,I-CHEMICAL
",",4983,O
the,4983,O
next,4983,O
potent,4983,O
preventive,4983,O
and,4983,O
therapeutic,4983,O
agent,4983,O
in,4983,O
aging,4983,O
and,4983,O
age-associated,4983,O
diseases,4983,O
.,4983,O
Hydrogen,4984,B-CHEMICAL
sulfide,4984,I-CHEMICAL
(,4984,O
H,4984,B-CHEMICAL
(,4984,I-CHEMICAL
2,4984,I-CHEMICAL
),4984,I-CHEMICAL
S,4984,I-CHEMICAL
),4984,O
is,4984,O
the,4984,O
third,4984,O
endogenous,4984,O
signaling,4984,O
gasotransmitter,4984,O
",",4984,O
following,4984,O
nitric,4984,B-CHEMICAL
oxide,4984,I-CHEMICAL
and,4984,O
carbon,4984,B-CHEMICAL
monoxide,4984,I-CHEMICAL
.,4984,O
It,4985,O
is,4985,O
physiologically,4985,O
generated,4985,O
by,4985,O
cystathionine-γ-lyase,4985,B-CHEMICAL
",",4985,O
cystathionine-β-synthase,4985,B-CHEMICAL
",",4985,O
and,4985,O
3-mercaptopyruvate,4985,B-CHEMICAL
sulfurtransferase,4985,I-GENE-Y
.,4985,O
H,4986,B-CHEMICAL
(,4986,I-CHEMICAL
2,4986,I-CHEMICAL
),4986,I-CHEMICAL
S,4986,I-CHEMICAL
has,4986,O
been,4986,O
gaining,4986,O
increasing,4986,O
attention,4986,O
as,4986,O
an,4986,O
important,4986,O
endogenous,4986,O
signaling,4986,O
molecule,4986,O
because,4986,O
of,4986,O
its,4986,O
significant,4986,O
effects,4986,O
on,4986,O
the,4986,O
cardiovascular,4986,O
and,4986,O
nervous,4986,O
systems,4986,O
.,4986,O
Substantial,4987,O
evidence,4987,O
shows,4987,O
that,4987,O
H,4987,B-CHEMICAL
(,4987,I-CHEMICAL
2,4987,I-CHEMICAL
),4987,I-CHEMICAL
S,4987,I-CHEMICAL
is,4987,O
involved,4987,O
in,4987,O
aging,4987,O
by,4987,O
inhibiting,4987,O
free-radical,4987,O
reactions,4987,O
",",4987,O
activating,4987,O
SIRT1,4987,B-GENE-Y
",",4987,O
and,4987,O
probably,4987,O
interacting,4987,O
with,4987,O
the,4987,O
age-related,4987,O
gene,4987,O
Klotho,4987,B-GENE-Y
.,4987,O
Moreover,4988,O
",",4988,O
H,4988,B-CHEMICAL
(,4988,I-CHEMICAL
2,4988,I-CHEMICAL
),4988,I-CHEMICAL
S,4988,I-CHEMICAL
has,4988,O
been,4988,O
shown,4988,O
to,4988,O
have,4988,O
therapeutic,4988,O
potential,4988,O
in,4988,O
age-associated,4988,O
diseases,4988,O
.,4988,O
This,4989,O
article,4989,O
provides,4989,O
an,4989,O
overview,4989,O
of,4989,O
the,4989,O
physiological,4989,O
functions,4989,O
and,4989,O
effects,4989,O
of,4989,O
H,4989,B-CHEMICAL
(,4989,I-CHEMICAL
2,4989,I-CHEMICAL
),4989,I-CHEMICAL
S,4989,I-CHEMICAL
in,4989,O
aging,4989,O
and,4989,O
age-associated,4989,O
diseases,4989,O
",",4989,O
and,4989,O
proposes,4989,O
the,4989,O
potential,4989,O
health,4989,O
and,4989,O
therapeutic,4989,O
benefits,4989,O
of,4989,O
H,4989,B-CHEMICAL
(,4989,I-CHEMICAL
2,4989,I-CHEMICAL
),4989,I-CHEMICAL
S,4989,I-CHEMICAL
.,4989,O
Induction,4990,O
of,4990,O
HO-1,4990,B-GENE-Y
through,4990,O
p38,4990,B-GENE-N
MAPK/Nrf2,4990,B-GENE-N
signaling,4990,O
pathway,4990,O
by,4990,O
ethanol,4990,B-CHEMICAL
extract,4990,O
of,4990,O
Inula,4990,O
helenium,4990,O
L.,4990,O
reduces,4990,O
inflammation,4990,O
in,4990,O
LPS-activated,4990,O
RAW,4990,O
264.7,4990,O
cells,4990,O
and,4990,O
CLP-induced,4990,O
septic,4990,O
mice,4990,O
.,4990,O
High,4991,B-GENE-Y
mobility,4991,I-GENE-Y
group,4991,I-GENE-Y
box,4991,I-GENE-Y
1,4991,I-GENE-Y
(,4991,O
HMGB1,4991,B-GENE-Y
),4991,O
plays,4991,O
a,4991,O
crucial,4991,O
mediator,4991,O
in,4991,O
the,4991,O
pathogenesis,4991,O
of,4991,O
many,4991,O
inflammatory,4991,O
diseases,4991,O
.,4991,O
We,4992,O
recently,4992,O
proposed,4992,O
that,4992,O
heme,4992,B-CHEMICAL
oxygenase-1,4992,I-GENE-Y
(,4992,O
HO-1,4992,B-GENE-Y
),4992,O
negatively,4992,O
regulates,4992,O
HMGB1,4992,B-GENE-Y
in,4992,O
inflammatory,4992,O
conditions,4992,O
.,4992,O
We,4993,O
investigated,4993,O
whether,4993,O
ethanol,4993,B-CHEMICAL
extract,4993,O
of,4993,O
Inula,4993,O
helenium,4993,O
L.,4993,O
(,4993,O
EIH,4993,O
),4993,O
activates,4993,O
p38,4993,B-GENE-N
MAPK/Nrf2/HO-1,4993,B-GENE-N
pathways,4993,O
in,4993,O
RAW264.7,4993,O
cells,4993,O
and,4993,O
reduces,4993,O
inflammation,4993,O
in,4993,O
CLP-induced,4993,O
septic,4993,O
mice,4993,O
.,4993,O
EIH,4994,O
induced,4994,O
expression,4994,O
of,4994,O
HO-1,4994,B-GENE-Y
protein,4994,O
in,4994,O
a,4994,O
time-,4994,O
and,4994,O
concentration-dependent,4994,O
manner,4994,O
.,4994,O
EIH,4995,O
significantly,4995,O
diminished,4995,O
HO-1,4995,B-GENE-Y
expression,4995,O
in,4995,O
siNrf2,4995,B-GENE-Y
RNA-transfected,4995,O
cells,4995,O
.,4995,O
As,4996,O
expected,4996,O
",",4996,O
the,4996,O
inhibited,4996,O
expression,4996,O
of,4996,O
iNOS/NO,4996,B-GENE-Y
",",4996,O
COX-2/PGE2,4996,B-GENE-Y
",",4996,O
HMGB1,4996,B-GENE-Y
release,4996,O
by,4996,O
EIH,4996,O
in,4996,O
LPS-activated,4996,O
RAW264.7,4996,O
cells,4996,O
was,4996,O
significantly,4996,O
reversed,4996,O
by,4996,O
siHO-1RNA,4996,B-GENE-Y
transfection,4996,O
.,4996,O
Furthermore,4997,O
",",4997,O
EIH,4997,O
not,4997,O
only,4997,O
inhibited,4997,O
NF-κB,4997,B-GENE-N
luciferase,4997,O
activity,4997,O
",",4997,O
phosphorylation,4997,O
of,4997,O
IκBα,4997,B-GENE-Y
in,4997,O
LPS-activated,4997,O
cells,4997,O
but,4997,O
also,4997,O
significantly,4997,O
suppressed,4997,O
expression,4997,O
of,4997,O
adhesion,4997,O
molecules,4997,O
(,4997,O
ICAM-1,4997,B-GENE-Y
and,4997,O
VCAM-1,4997,B-GENE-Y
),4997,O
in,4997,O
TNF-α,4997,B-GENE-Y
activated,4997,O
human,4997,O
umbilical,4997,O
vein,4997,O
endothelial,4997,O
cells,4997,O
.,4997,O
The,4998,O
induction,4998,O
of,4998,O
HO-1,4998,B-GENE-Y
by,4998,O
EIH,4998,O
was,4998,O
inhibited,4998,O
by,4998,O
SB203580,4998,B-CHEMICAL
but,4998,O
not,4998,O
by,4998,O
SP600125,4998,B-CHEMICAL
",",4998,O
PD98059,4998,B-CHEMICAL
",",4998,O
nor,4998,O
LY294002,4998,B-CHEMICAL
.,4998,O
Most,4999,O
importantly,4999,O
",",4999,O
administration,4999,O
of,4999,O
EIH,4999,O
significantly,4999,O
reduced,4999,O
not,4999,O
only,4999,O
increase,4999,O
in,4999,O
blood,4999,O
HMGB1,4999,B-GENE-Y
",",4999,O
ALT,4999,B-GENE-N
",",4999,I-GENE-N
AST,4999,B-GENE-N
",",4999,O
BUN,4999,O
",",4999,O
creatinine,4999,B-CHEMICAL
levels,4999,O
but,4999,O
also,4999,O
decrease,4999,O
macrophage,4999,O
infiltrate,4999,O
in,4999,O
the,4999,O
liver,4999,O
of,4999,O
septic,4999,O
mice,4999,O
",",4999,O
which,4999,O
were,4999,O
reversed,4999,O
by,4999,O
ZnPPIX,4999,O
",",4999,O
a,4999,O
HO-1,4999,B-GENE-Y
inhibitor,4999,O
.,4999,O
We,5000,O
concluded,5000,O
that,5000,O
EIH,5000,O
has,5000,O
anti-inflammatory,5000,O
effect,5000,O
via,5000,O
the,5000,O
induction,5000,O
of,5000,O
p38,5000,B-GENE-N
MAPK-dependent,5000,B-GENE-N
HO-1,5000,B-GENE-Y
signaling,5000,O
pathway,5000,O
.,5000,O
Protease-activated,5001,B-GENE-Y
receptor,5001,I-GENE-Y
(,5001,I-GENE-Y
PAR,5001,I-GENE-Y
),5001,I-GENE-Y
1,5001,I-GENE-Y
and,5001,O
PAR4,5001,B-GENE-Y
differentially,5001,O
regulate,5001,O
factor,5001,B-GENE-Y
V,5001,I-GENE-Y
expression,5001,O
from,5001,O
human,5001,O
platelets,5001,O
.,5001,O
With,5002,O
the,5002,O
recent,5002,O
interest,5002,O
of,5002,O
protease-activated,5002,B-GENE-Y
receptors,5002,I-GENE-Y
(,5002,I-GENE-Y
PAR,5002,I-GENE-Y
),5002,I-GENE-Y
1,5002,I-GENE-Y
and,5002,O
PAR4,5002,B-GENE-Y
as,5002,O
possible,5002,O
targets,5002,O
for,5002,O
the,5002,O
treatment,5002,O
of,5002,O
thrombotic,5002,O
disorders,5002,O
",",5002,O
we,5002,O
compared,5002,O
the,5002,O
efficacy,5002,O
of,5002,O
protease-activated,5002,B-GENE-Y
receptor,5002,I-GENE-Y
(,5002,I-GENE-Y
PAR,5002,I-GENE-Y
),5002,I-GENE-Y
1,5002,I-GENE-Y
and,5002,O
PAR4,5002,B-GENE-Y
in,5002,O
the,5002,O
generation,5002,O
of,5002,O
procoagulant,5002,O
phenotypes,5002,O
on,5002,O
platelet,5002,O
membranes,5002,O
.,5002,O
PAR4-activating,5003,B-GENE-Y
peptide,5003,O
(,5003,O
AP,5003,O
),5003,O
-stimulated,5003,O
platelets,5003,O
promoted,5003,O
thrombin,5003,B-GENE-Y
generation,5003,O
in,5003,O
plasma,5003,O
up,5003,O
to,5003,O
5,5003,O
minutes,5003,O
earlier,5003,O
than,5003,O
PAR1-AP-stimulated,5003,B-GENE-Y
platelets,5003,O
.,5003,O
PAR4-AP-mediated,5004,B-GENE-Y
factor,5004,B-GENE-Y
V,5004,I-GENE-Y
(,5004,O
FV,5004,B-GENE-Y
),5004,O
association,5004,O
with,5004,O
the,5004,O
platelet,5004,O
surface,5004,O
was,5004,O
1.6-fold,5004,O
greater,5004,O
than,5004,O
for,5004,O
PAR1-AP,5004,B-GENE-Y
.,5004,O
Moreover,5005,O
",",5005,O
PAR4,5005,B-GENE-Y
stimulation,5005,O
resulted,5005,O
in,5005,O
a,5005,O
3-fold,5005,O
greater,5005,O
release,5005,O
of,5005,O
microparticles,5005,O
",",5005,O
compared,5005,O
with,5005,O
PAR1,5005,B-GENE-Y
stimulation,5005,O
.,5005,O
More,5006,O
robust,5006,O
FV,5006,B-GENE-Y
secretion,5006,O
and,5006,O
microparticle,5006,O
generation,5006,O
with,5006,O
PAR4-AP,5006,B-GENE-Y
was,5006,O
attributable,5006,O
to,5006,O
stronger,5006,O
and,5006,O
more,5006,O
sustained,5006,O
phosphorylation,5006,O
of,5006,O
myosin,5006,O
light,5006,O
chain,5006,O
at,5006,O
serine,5006,B-CHEMICAL
19,5006,O
and,5006,O
threonine,5006,B-CHEMICAL
18,5006,O
.,5006,O
Inhibition,5007,O
of,5007,O
Rho-kinase,5007,B-GENE-N
reduced,5007,O
PAR4-AP-mediated,5007,B-GENE-Y
FV,5007,B-GENE-Y
secretion,5007,O
and,5007,O
microparticle,5007,O
generation,5007,O
to,5007,O
PAR1-AP-mediated,5007,B-GENE-Y
levels,5007,O
.,5007,O
Thrombin,5008,B-GENE-Y
generation,5008,O
assays,5008,O
measuring,5008,O
prothrombinase,5008,B-GENE-N
complex,5008,O
activity,5008,O
demonstrated,5008,O
1.5-fold,5008,O
higher,5008,O
peak,5008,O
thrombin,5008,B-GENE-Y
levels,5008,O
on,5008,O
PAR4-AP-stimulated,5008,B-GENE-Y
platelets,5008,O
",",5008,O
compared,5008,O
with,5008,O
PAR1-AP-stimulated,5008,B-GENE-Y
platelets,5008,O
.,5008,O
Rho-kinase,5009,B-GENE-N
inhibition,5009,O
reduced,5009,O
PAR4-AP-mediated,5009,B-GENE-Y
peak,5009,O
thrombin,5009,O
generation,5009,O
by,5009,O
25,5009,O
%,5009,O
but,5009,O
had,5009,O
no,5009,O
significant,5009,O
effect,5009,O
on,5009,O
PAR1-AP-mediated,5009,B-GENE-Y
thrombin,5009,B-GENE-Y
generation,5009,O
.,5009,O
In,5010,O
conclusion,5010,O
",",5010,O
stimulation,5010,O
of,5010,O
PAR4,5010,B-GENE-Y
on,5010,O
platelets,5010,O
leads,5010,O
to,5010,O
faster,5010,O
and,5010,O
more,5010,O
robust,5010,O
thrombin,5010,O
generation,5010,O
",",5010,O
compared,5010,O
with,5010,O
PAR1,5010,B-GENE-Y
stimulation,5010,O
.,5010,O
The,5011,O
greater,5011,O
procoagulant,5011,O
potential,5011,O
is,5011,O
related,5011,O
to,5011,O
more,5011,O
efficient,5011,O
FV,5011,B-GENE-Y
release,5011,O
from,5011,O
intracellular,5011,O
stores,5011,O
and,5011,O
microparticle,5011,O
production,5011,O
driven,5011,O
by,5011,O
stronger,5011,O
and,5011,O
more,5011,O
sustained,5011,O
myosin,5011,O
light,5011,O
chain,5011,O
phosphorylation,5011,O
.,5011,O
These,5012,O
data,5012,O
have,5012,O
implications,5012,O
about,5012,O
the,5012,O
role,5012,O
of,5012,O
PAR4,5012,B-GENE-Y
during,5012,O
hemostasis,5012,O
and,5012,O
are,5012,O
clinically,5012,O
relevant,5012,O
in,5012,O
light,5012,O
of,5012,O
recent,5012,O
efforts,5012,O
to,5012,O
develop,5012,O
PAR,5012,B-GENE-N
antagonists,5012,O
to,5012,O
treat,5012,O
thrombotic,5012,O
disorders,5012,O
.,5012,O
Diels-Alder,5013,O
mediated,5013,O
controlled,5013,O
release,5013,O
from,5013,O
a,5013,O
poly,5013,B-CHEMICAL
(,5013,I-CHEMICAL
ethylene,5013,I-CHEMICAL
glycol,5013,I-CHEMICAL
),5013,I-CHEMICAL
based,5013,O
hydrogel,5013,O
.,5013,O
A,5014,O
synthetic,5014,O
amino,5014,B-CHEMICAL
acid,5014,I-CHEMICAL
bearing,5014,O
a,5014,O
furan,5014,B-CHEMICAL
functionality,5014,O
was,5014,O
developed,5014,O
and,5014,O
incorporated,5014,O
into,5014,O
peptide,5014,O
sequences,5014,O
using,5014,O
solid,5014,O
phase,5014,O
synthesis,5014,O
.,5014,O
Peptides,5015,O
expressing,5015,O
the,5015,O
furan,5015,B-CHEMICAL
moiety,5015,O
were,5015,O
attached,5015,O
to,5015,O
poly,5015,B-CHEMICAL
(,5015,I-CHEMICAL
ethylene,5015,I-CHEMICAL
glycol,5015,I-CHEMICAL
),5015,I-CHEMICAL
(,5015,O
PEG,5015,B-CHEMICAL
),5015,O
hydrogels,5015,O
through,5015,O
a,5015,O
thermally,5015,O
reversible,5015,O
covalent,5015,O
bond,5015,O
formed,5015,O
by,5015,O
a,5015,O
Diels-Alder,5015,O
reaction,5015,O
.,5015,O
Reactions,5016,O
of,5016,O
thiol,5016,B-CHEMICAL
and,5016,O
maleimide,5016,B-CHEMICAL
PEG,5016,I-CHEMICAL
macromers,5016,O
in,5016,O
an,5016,O
off-stoichiometric,5016,O
Michael,5016,O
addition,5016,O
were,5016,O
performed,5016,O
",",5016,O
such,5016,O
that,5016,O
the,5016,O
maleimide,5016,B-CHEMICAL
moiety,5016,O
was,5016,O
in,5016,O
excess,5016,O
",",5016,O
to,5016,O
create,5016,O
hydrogel,5016,O
networks,5016,O
with,5016,O
pendant,5016,O
Diels-Alder,5016,O
compatible,5016,O
tethering,5016,O
sites,5016,O
",",5016,O
that,5016,O
is,5016,O
",",5016,O
the,5016,O
maleimide,5016,B-CHEMICAL
.,5016,O
By,5017,O
making,5017,O
use,5017,O
of,5017,O
the,5017,O
Diels-Alder,5017,O
reaction,5017,O
",",5017,O
it,5017,O
was,5017,O
possible,5017,O
to,5017,O
control,5017,O
the,5017,O
release,5017,O
rate,5017,O
of,5017,O
reversibly,5017,O
bound,5017,O
moieties,5017,O
from,5017,O
the,5017,O
hydrogel,5017,O
by,5017,O
changing,5017,O
the,5017,O
temperature,5017,O
;,5017,O
higher,5017,O
temperatures,5017,O
favor,5017,O
a,5017,O
faster,5017,O
retro-Diels-Alder,5017,O
reaction,5017,O
and,5017,O
",",5017,O
therefore,5017,O
",",5017,O
a,5017,O
faster,5017,O
release,5017,O
from,5017,O
the,5017,O
polymer,5017,O
network,5017,O
.,5017,O
This,5018,O
concept,5018,O
was,5018,O
demonstrated,5018,O
by,5018,O
incorporating,5018,O
a,5018,O
fluorescently,5018,O
labeled,5018,O
furan-RGDS,5018,B-CHEMICAL
sequence,5018,O
into,5018,O
a,5018,O
hydrogel,5018,O
possessing,5018,O
excess,5018,O
maleimide,5018,B-CHEMICAL
functionalities,5018,O
and,5018,O
monitoring,5018,O
the,5018,O
subsequent,5018,O
liberation,5018,O
of,5018,O
RGDS,5018,O
at,5018,O
various,5018,O
temperatures,5018,O
",",5018,O
illustrating,5018,O
a,5018,O
Diels-Alder,5018,O
mediated,5018,O
release,5018,O
mechanism,5018,O
.,5018,O
The,5019,O
release,5019,O
profile,5019,O
was,5019,O
quantified,5019,O
at,5019,O
temperatures,5019,O
ranging,5019,O
from,5019,O
physiological,5019,O
(,5019,O
37,5019,O
°C,5019,O
),5019,O
to,5019,O
80,5019,O
°C,5019,O
.,5019,O
By,5020,O
changing,5020,O
the,5020,O
temperature,5020,O
",",5020,O
varying,5020,O
extents,5020,O
of,5020,O
release,5020,O
were,5020,O
attained,5020,O
over,5020,O
the,5020,O
time,5020,O
course,5020,O
of,5020,O
several,5020,O
days,5020,O
",",5020,O
ranging,5020,O
from,5020,O
40,5020,O
%,5020,O
release,5020,O
for,5020,O
lower,5020,O
temperatures,5020,O
to,5020,O
complete,5020,O
release,5020,O
for,5020,O
the,5020,O
highest,5020,O
temperature,5020,O
considered,5020,O
.,5020,O
Further,5021,O
confirmation,5021,O
of,5021,O
a,5021,O
reaction-diffusion,5021,O
controlled,5021,O
release,5021,O
mechanism,5021,O
was,5021,O
obtained,5021,O
through,5021,O
comparison,5021,O
of,5021,O
experimental,5021,O
release,5021,O
data,5021,O
to,5021,O
a,5021,O
reaction-diffusion,5021,O
model,5021,O
of,5021,O
the,5021,O
release,5021,O
.,5021,O
In,5022,O
addition,5022,O
to,5022,O
thermal,5022,O
modulation,5022,O
",",5022,O
tuning,5022,O
of,5022,O
the,5022,O
release,5022,O
rate,5022,O
was,5022,O
accomplished,5022,O
by,5022,O
altering,5022,O
the,5022,O
number,5022,O
of,5022,O
possible,5022,O
Diels-Alder,5022,O
tethering,5022,O
sites,5022,O
present,5022,O
in,5022,O
the,5022,O
hydrogel,5022,O
.,5022,O
Increasing,5023,O
the,5023,O
amount,5023,O
of,5023,O
free,5023,O
maleimide,5023,B-CHEMICAL
and,5023,O
",",5023,O
therefore,5023,O
",",5023,O
the,5023,O
number,5023,O
of,5023,O
potential,5023,O
Diels-Alder,5023,O
reaction,5023,O
sites,5023,O
",",5023,O
effectively,5023,O
slowed,5023,O
the,5023,O
release,5023,O
of,5023,O
peptide,5023,O
from,5023,O
the,5023,O
polymer,5023,O
.,5023,O
For,5024,O
instance,5024,O
",",5024,O
doubling,5024,O
the,5024,O
amount,5024,O
of,5024,O
maleimide,5024,B-CHEMICAL
sites,5024,O
present,5024,O
in,5024,O
the,5024,O
hydrogel,5024,O
system,5024,O
decreased,5024,O
the,5024,O
amount,5024,O
of,5024,O
peptide,5024,O
released,5024,O
from,5024,O
approximately,5024,O
60,5024,O
%,5024,O
to,5024,O
about,5024,O
40,5024,O
%,5024,O
in,5024,O
the,5024,O
same,5024,O
span,5024,O
of,5024,O
time,5024,O
.,5024,O
Trimethylamine-N-oxide,5025,B-CHEMICAL
",",5025,O
a,5025,O
metabolite,5025,O
associated,5025,O
with,5025,O
atherosclerosis,5025,O
",",5025,O
exhibits,5025,O
complex,5025,O
genetic,5025,O
and,5025,O
dietary,5025,O
regulation,5025,O
.,5025,O
Circulating,5026,O
trimethylamine-N-oxide,5026,B-CHEMICAL
(,5026,O
TMAO,5026,B-CHEMICAL
),5026,O
levels,5026,O
are,5026,O
strongly,5026,O
associated,5026,O
with,5026,O
atherosclerosis,5026,O
.,5026,O
We,5027,O
now,5027,O
examine,5027,O
genetic,5027,O
",",5027,O
dietary,5027,O
",",5027,O
and,5027,O
hormonal,5027,O
factors,5027,O
regulating,5027,O
TMAO,5027,B-CHEMICAL
levels,5027,O
.,5027,O
We,5028,O
demonstrate,5028,O
that,5028,O
two,5028,O
flavin,5028,B-CHEMICAL
mono-oxygenase,5028,I-GENE-N
family,5028,O
members,5028,O
",",5028,O
FMO1,5028,B-GENE-Y
and,5028,O
FMO3,5028,B-GENE-Y
",",5028,O
oxidize,5028,O
trimethylamine,5028,B-CHEMICAL
(,5028,O
TMA,5028,B-CHEMICAL
),5028,O
",",5028,O
derived,5028,O
from,5028,O
gut,5028,O
flora,5028,O
metabolism,5028,O
of,5028,O
choline,5028,B-CHEMICAL
",",5028,O
to,5028,O
TMAO,5028,B-CHEMICAL
.,5028,O
Further,5029,O
",",5029,O
we,5029,O
show,5029,O
that,5029,O
FMO3,5029,B-GENE-Y
exhibits,5029,O
10-fold,5029,O
higher,5029,O
specific,5029,O
activity,5029,O
than,5029,O
FMO1,5029,B-GENE-Y
.,5029,O
FMO3,5030,B-GENE-Y
overexpression,5030,O
in,5030,O
mice,5030,O
significantly,5030,O
increases,5030,O
plasma,5030,O
TMAO,5030,B-CHEMICAL
levels,5030,O
while,5030,O
silencing,5030,O
FMO3,5030,B-GENE-Y
decreases,5030,O
TMAO,5030,B-CHEMICAL
levels,5030,O
.,5030,O
In,5031,O
both,5031,O
humans,5031,O
and,5031,O
mice,5031,O
",",5031,O
hepatic,5031,O
FMO3,5031,B-GENE-Y
expression,5031,O
is,5031,O
reduced,5031,O
in,5031,O
males,5031,O
compared,5031,O
to,5031,O
females,5031,O
.,5031,O
In,5032,O
mice,5032,O
",",5032,O
this,5032,O
reduction,5032,O
in,5032,O
FMO3,5032,B-GENE-Y
expression,5032,O
is,5032,O
due,5032,O
primarily,5032,O
to,5032,O
downregulation,5032,O
by,5032,O
androgens,5032,B-CHEMICAL
.,5032,O
FMO3,5033,B-GENE-Y
expression,5033,O
is,5033,O
induced,5033,O
by,5033,O
dietary,5033,O
bile,5033,B-CHEMICAL
acids,5033,I-CHEMICAL
by,5033,O
a,5033,O
mechanism,5033,O
that,5033,O
involves,5033,O
the,5033,O
farnesoid,5033,B-GENE-Y
X,5033,I-GENE-Y
receptor,5033,I-GENE-Y
(,5033,O
FXR,5033,B-GENE-Y
),5033,O
",",5033,O
a,5033,O
bile,5033,B-CHEMICAL
acid-activated,5033,O
nuclear,5033,O
receptor,5033,O
.,5033,O
Analysis,5034,O
of,5034,O
natural,5034,O
genetic,5034,O
variation,5034,O
among,5034,O
inbred,5034,O
strains,5034,O
of,5034,O
mice,5034,O
indicates,5034,O
that,5034,O
FMO3,5034,B-GENE-Y
and,5034,O
TMAO,5034,B-CHEMICAL
are,5034,O
significantly,5034,O
correlated,5034,O
",",5034,O
and,5034,O
TMAO,5034,B-CHEMICAL
levels,5034,O
explain,5034,O
11,5034,O
%,5034,O
of,5034,O
the,5034,O
variation,5034,O
in,5034,O
atherosclerosis,5034,O
.,5034,O
Tricycloalternarenes,5035,B-CHEMICAL
F-H,5035,I-CHEMICAL
:,5035,O
three,5035,O
new,5035,O
mixed,5035,O
terpenoids,5035,B-CHEMICAL
produced,5035,O
by,5035,O
an,5035,O
endolichenic,5035,O
fungus,5035,O
Ulocladium,5035,O
sp,5035,O
.,5035,O
using,5036,O
OSMAC,5036,O
method,5036,O
.,5036,O
Three,5037,O
new,5037,O
mixed,5037,O
terpenoids,5037,B-CHEMICAL
",",5037,O
tricycloalternarenes,5037,B-CHEMICAL
(,5037,O
TCAs,5037,B-CHEMICAL
),5037,O
F-H,5037,O
(,5037,O
1-3,5037,O
),5037,O
",",5037,O
together,5037,O
with,5037,O
ten,5037,O
known,5037,O
tricycloalternarenes,5037,B-CHEMICAL
(,5037,O
4-13,5037,O
),5037,O
",",5037,O
were,5037,O
isolated,5037,O
from,5037,O
the,5037,O
Czapek,5037,O
's,5037,O
culture,5037,O
of,5037,O
an,5037,O
endophytic,5037,O
fungus,5037,O
Ulocladium,5037,O
sp,5037,O
.,5037,O
Their,5038,O
structures,5038,O
were,5038,O
identified,5038,O
by,5038,O
extensive,5038,O
spectroscopic,5038,O
experiments,5038,O
(,5038,O
NMR,5038,O
and,5038,O
MS,5038,O
),5038,O
and,5038,O
comparison,5038,O
with,5038,O
literature,5038,O
data,5038,O
.,5038,O
TCA,5039,B-CHEMICAL
1b,5039,O
(,5039,O
5,5039,O
),5039,O
showed,5039,O
weak,5039,O
activity,5039,O
against,5039,O
the,5039,O
Bacille,5039,O
Calmette-Guerin,5039,O
strain,5039,O
with,5039,O
the,5039,O
MIC,5039,O
of,5039,O
125μg/mL,5039,O
.,5039,O
TCA,5040,B-CHEMICAL
9b,5040,O
(,5040,O
10,5040,O
),5040,O
exhibited,5040,O
strong,5040,O
cytotoxic,5040,O
activity,5040,O
against,5040,O
Hela,5040,O
cell,5040,O
line,5040,O
with,5040,O
IC50,5040,O
of,5040,O
8.58μM,5040,O
.,5040,O
What,5041,O
are,5041,O
the,5041,O
physiological,5041,O
estrogens,5041,B-CHEMICAL
?,5041,O
Estradiol,5042,B-CHEMICAL
(,5042,O
E2,5042,O
),5042,O
is,5042,O
the,5042,O
principal,5042,O
physiological,5042,O
estrogen,5042,O
in,5042,O
mammals,5042,O
.,5042,O
E2,5043,O
and,5043,O
its,5043,O
active,5043,O
metabolites,5043,O
",",5043,O
estrone,5043,B-CHEMICAL
and,5043,O
estriol,5043,B-CHEMICAL
have,5043,O
a,5043,O
characteristic,5043,O
phenolic,5043,O
A,5043,O
ring,5043,O
",",5043,O
unlike,5043,O
progesterone,5043,B-CHEMICAL
",",5043,O
testosterone,5043,B-CHEMICAL
",",5043,O
cortisol,5043,B-CHEMICAL
and,5043,O
aldosterone,5043,B-CHEMICAL
",",5043,O
which,5043,O
have,5043,O
an,5043,O
A,5043,O
ring,5043,O
containing,5043,O
a,5043,O
C3-ketone,5043,O
",",5043,O
a,5043,O
Δ,5043,O
(,5043,O
4,5043,O
),5043,O
bond,5043,O
and,5043,O
a,5043,O
C19,5043,O
methyl,5043,B-CHEMICAL
group,5043,O
.,5043,O
Crystal,5044,O
structures,5044,O
of,5044,O
E2,5044,O
in,5044,O
the,5044,O
estrogen,5044,B-CHEMICAL
receptor,5044,I-GENE-Y
(,5044,O
ER,5044,B-GENE-Y
),5044,O
confirm,5044,O
the,5044,O
importance,5044,O
of,5044,O
the,5044,O
A,5044,O
ring,5044,O
in,5044,O
stabilizing,5044,O
E2,5044,O
in,5044,O
the,5044,O
ER,5044,B-GENE-Y
.,5044,O
However,5045,O
",",5045,O
other,5045,O
steroids,5045,B-CHEMICAL
",",5045,O
including,5045,O
Δ,5045,B-CHEMICAL
(,5045,I-CHEMICAL
5,5045,I-CHEMICAL
),5045,I-CHEMICAL
-androstenediol,5045,I-CHEMICAL
",",5045,O
5α-androstanediol,5045,B-CHEMICAL
and,5045,O
27-hydroxycholesterol,5045,B-CHEMICAL
",",5045,O
which,5045,O
have,5045,O
a,5045,O
saturated,5045,O
A,5045,O
ring,5045,O
containing,5045,O
a,5045,O
3β-hydroxyl,5045,B-CHEMICAL
and,5045,O
a,5045,O
C19,5045,O
methyl,5045,B-CHEMICAL
group,5045,O
",",5045,O
also,5045,O
mediate,5045,O
physiological,5045,O
responses,5045,O
through,5045,O
binding,5045,O
to,5045,O
estrogen,5045,B-GENE-Y
receptor-α,5045,I-GENE-Y
(,5045,O
ERα,5045,B-GENE-Y
),5045,O
and,5045,O
ERβ,5045,B-GENE-Y
.,5045,O
Moreover,5046,O
",",5046,O
selective,5046,O
estrogen,5046,B-CHEMICAL
response,5046,O
modulators,5046,O
(,5046,O
SERMs,5046,O
),5046,O
with,5046,O
diverse,5046,O
structures,5046,O
also,5046,O
regulate,5046,O
transcription,5046,O
of,5046,O
ERα,5046,B-GENE-Y
and,5046,O
ERβ,5046,B-GENE-Y
.,5046,O
Our,5047,O
understanding,5047,O
of,5047,O
the,5047,O
physiological,5047,O
responses,5047,O
mediated,5047,O
by,5047,O
these,5047,O
``,5047,O
alternative,5047,O
'',5047,O
estrogens,5047,B-CHEMICAL
is,5047,O
in,5047,O
its,5047,O
infancy,5047,O
.,5047,O
Further,5048,O
studies,5048,O
of,5048,O
the,5048,O
role,5048,O
of,5048,O
these,5048,O
steroids,5048,B-CHEMICAL
and,5048,O
SERMs,5048,O
in,5048,O
regulating,5048,O
responses,5048,O
mediated,5048,O
by,5048,O
ERα,5048,B-GENE-Y
and,5048,O
ERβ,5048,B-GENE-Y
a,5048,O
variety,5048,O
of,5048,O
tissues,5048,O
",",5048,O
during,5048,O
different,5048,O
stages,5048,O
of,5048,O
development,5048,O
",",5048,O
are,5048,O
likely,5048,O
to,5048,O
uncover,5048,O
additional,5048,O
estrogenic,5048,O
activities,5048,O
.,5048,O
Synthesis,5049,O
of,5049,O
quinoline,5049,B-CHEMICAL
derivatives,5049,O
:,5049,O
discovery,5049,O
of,5049,O
a,5049,O
potent,5049,O
and,5049,O
selective,5049,O
phosphodiesterase,5049,B-GENE-Y
5,5049,I-GENE-Y
inhibitor,5049,O
for,5049,O
the,5049,O
treatment,5049,O
of,5049,O
Alzheimer,5049,O
's,5049,O
disease,5049,O
.,5049,O
Phosphodiesterase,5050,B-GENE-Y
type,5050,I-GENE-Y
5,5050,I-GENE-Y
(,5050,O
PDE5,5050,B-GENE-Y
),5050,O
mediates,5050,O
the,5050,O
degradation,5050,O
of,5050,O
cGMP,5050,B-CHEMICAL
in,5050,O
a,5050,O
variety,5050,O
of,5050,O
tissues,5050,O
including,5050,O
brain,5050,O
.,5050,O
Recent,5051,O
studies,5051,O
have,5051,O
demonstrated,5051,O
the,5051,O
importance,5051,O
of,5051,O
the,5051,O
nitric,5051,B-CHEMICAL
oxide/cGMP/cAMP-responsive,5051,O
element-binding,5051,I-GENE-N
protein,5051,I-GENE-N
(,5051,O
CREB,5051,B-GENE-N
),5051,O
pathway,5051,O
to,5051,O
the,5051,O
process,5051,O
of,5051,O
learning,5051,O
and,5051,O
memory,5051,O
.,5051,O
Thus,5052,O
",",5052,O
PDE5,5052,B-GENE-Y
inhibitors,5052,O
(,5052,O
PDE5Is,5052,O
),5052,O
are,5052,O
thought,5052,O
to,5052,O
be,5052,O
promising,5052,O
new,5052,O
therapeutic,5052,O
agents,5052,O
for,5052,O
the,5052,O
treatment,5052,O
of,5052,O
Alzheimer,5052,O
's,5052,O
disease,5052,O
(,5052,O
AD,5052,O
),5052,O
",",5052,O
a,5052,O
neurodegenerative,5052,O
disorder,5052,O
characterized,5052,O
by,5052,O
memory,5052,O
loss,5052,O
.,5052,O
To,5053,O
explore,5053,O
this,5053,O
possibility,5053,O
",",5053,O
a,5053,O
series,5053,O
of,5053,O
quinoline,5053,B-CHEMICAL
derivatives,5053,O
were,5053,O
synthesized,5053,O
and,5053,O
evaluated,5053,O
.,5053,O
We,5054,O
found,5054,O
that,5054,O
compound,5054,O
7a,5054,O
selectively,5054,O
inhibits,5054,O
PDE5,5054,B-GENE-Y
with,5054,O
an,5054,O
IC,5054,O
(,5054,O
50,5054,O
),5054,O
of,5054,O
0.27,5054,O
nM,5054,O
and,5054,O
readily,5054,O
crosses,5054,O
the,5054,O
blood,5054,O
brain,5054,O
barrier,5054,O
.,5054,O
In,5055,O
an,5055,O
in,5055,O
vivo,5055,O
mouse,5055,O
model,5055,O
of,5055,O
AD,5055,O
",",5055,O
compound,5055,O
7a,5055,O
rescues,5055,O
synaptic,5055,O
and,5055,O
memory,5055,O
defects,5055,O
.,5055,O
Quinoline-based,5056,B-CHEMICAL
",",5056,O
CNS-permeant,5056,O
PDE5Is,5056,O
have,5056,O
potential,5056,O
for,5056,O
AD,5056,O
therapeutic,5056,O
development,5056,O
.,5056,O
Fragment-based,5057,O
design,5057,O
",",5057,O
synthesis,5057,O
",",5057,O
and,5057,O
biological,5057,O
evaluation,5057,O
of,5057,O
N-substituted-5-,5057,B-CHEMICAL
(,5057,I-CHEMICAL
4-isopropylthiophenol,5057,I-CHEMICAL
),5057,I-CHEMICAL
-2-hydroxynicotinamide,5057,I-CHEMICAL
derivatives,5057,O
as,5057,O
novel,5057,O
Mcl-1,5057,B-GENE-N
inhibitors,5057,O
.,5057,O
We,5058,O
have,5058,O
previously,5058,O
reported,5058,O
a,5058,O
nanomolar,5058,O
inhibitor,5058,O
of,5058,O
antiapoptotic,5058,O
Mcl-1,5058,B-GENE-Y
protein,5058,O
",",5058,O
3-thiomorpholin-8-oxo-8H-acenaphtho,5058,B-CHEMICAL
[,5058,I-CHEMICAL
"1,2-b",5058,I-CHEMICAL
],5058,I-CHEMICAL
pyrrole-9-carbonitrile,5058,I-CHEMICAL
(,5058,O
S1,5058,O
),5058,O
.,5058,O
S1,5059,O
plays,5059,O
its,5059,O
function,5059,O
by,5059,O
binding,5059,O
to,5059,O
the,5059,O
BH3,5059,O
groove,5059,O
of,5059,O
Mcl-1,5059,B-GENE-Y
.,5059,O
Basing,5060,O
on,5060,O
this,5060,O
spacial,5060,O
structural,5060,O
characteristic,5060,O
",",5060,O
we,5060,O
developed,5060,O
a,5060,O
novel,5060,O
class,5060,O
of,5060,O
Mcl-1,5060,B-GENE-Y
inhibitor,5060,O
using,5060,O
fragment-based,5060,O
drug,5060,O
discovery,5060,O
approach,5060,O
.,5060,O
By,5061,O
dissecting,5061,O
S1,5061,O
",",5061,O
we,5061,O
identified,5061,O
the,5061,O
compound,5061,O
4,5061,O
with,5061,O
a,5061,O
2-hydroxypyridine,5061,B-CHEMICAL
core,5061,O
as,5061,O
the,5061,O
starting,5061,O
fragment,5061,O
.,5061,O
In,5062,O
the,5062,O
following,5062,O
molecular,5062,O
growth,5062,O
",",5062,O
we,5062,O
used,5062,O
the,5062,O
ligand,5062,O
efficiency,5062,O
evaluation,5062,O
and,5062,O
fit,5062,O
quality,5062,O
score,5062,O
to,5062,O
assess,5062,O
the,5062,O
fragments,5062,O
.,5062,O
A,5063,O
novel,5063,O
potent,5063,O
compound,5063,O
",",5063,O
N-benzyl-5-,5063,B-CHEMICAL
(,5063,I-CHEMICAL
4-isopropylthiophenol,5063,I-CHEMICAL
),5063,I-CHEMICAL
-2-hydroxyl,5063,I-CHEMICAL
nicotinamide,5063,I-CHEMICAL
(,5063,O
12c,5063,O
),5063,O
",",5063,O
which,5063,O
binds,5063,O
Mcl-1,5063,B-GENE-Y
with,5063,O
an,5063,O
IC,5063,O
(,5063,O
50,5063,O
),5063,O
value,5063,O
of,5063,O
54,5063,O
nM,5063,O
was,5063,O
obtained,5063,O
.,5063,O
Compound,5064,O
12c,5064,O
demonstrated,5064,O
a,5064,O
better,5064,O
aqueous,5064,O
solubility,5064,O
than,5064,O
S1,5064,O
.,5064,O
Transaldolase,5065,B-GENE-Y
deficiency,5065,O
:,5065,O
report,5065,O
of,5065,O
12,5065,O
new,5065,O
cases,5065,O
and,5065,O
further,5065,O
delineation,5065,O
of,5065,O
the,5065,O
phenotype,5065,O
.,5065,O
PURPOSE,5066,O
:,5066,O
Transaldolase,5066,B-GENE-Y
deficiency,5066,O
is,5066,O
a,5066,O
recently,5066,O
described,5066,O
inborn,5066,O
error,5066,O
of,5066,O
pentose,5066,B-CHEMICAL
phosphate,5066,I-CHEMICAL
pathway,5066,O
.,5066,O
We,5067,O
conducted,5067,O
this,5067,O
study,5067,O
to,5067,O
further,5067,O
delineate,5067,O
the,5067,O
associated,5067,O
phenotype,5067,O
.,5067,O
METHODS,5068,O
AND,5068,O
RESULTS,5068,O
:,5068,O
We,5068,O
report,5068,O
on,5068,O
12,5068,O
new,5068,O
cases,5068,O
representing,5068,O
six,5068,O
families,5068,O
with,5068,O
this,5068,O
metabolic,5068,O
defect,5068,O
that,5068,O
were,5068,O
observed,5068,O
over,5068,O
an,5068,O
8,5068,O
year,5068,O
span,5068,O
.,5068,O
None,5069,O
of,5069,O
these,5069,O
cases,5069,O
received,5069,O
the,5069,O
correct,5069,O
diagnosis,5069,O
initially,5069,O
because,5069,O
of,5069,O
significant,5069,O
overlap,5069,O
in,5069,O
the,5069,O
presenting,5069,O
symptoms,5069,O
(,5069,O
growth,5069,O
retardation,5069,O
",",5069,O
dysmorphic,5069,O
features,5069,O
",",5069,O
cutis,5069,O
laxa,5069,O
",",5069,O
congenital,5069,O
heart,5069,O
disease,5069,O
",",5069,O
hepatosplenomegaly,5069,O
",",5069,O
pancytopenia,5069,O
",",5069,O
and,5069,O
bleeding,5069,O
tendency,5069,O
),5069,O
with,5069,O
a,5069,O
wide,5069,O
range,5069,O
of,5069,O
genetic,5069,O
disorders,5069,O
.,5069,O
However,5070,O
",",5070,O
the,5070,O
consanguineous,5070,O
nature,5070,O
of,5070,O
these,5070,O
families,5070,O
allowed,5070,O
us,5070,O
to,5070,O
pursue,5070,O
autozygome,5070,O
analysis,5070,O
",",5070,O
which,5070,O
highlighted,5070,O
TALDO,5070,B-GENE-Y
as,5070,O
the,5070,O
likely,5070,O
candidate,5070,O
gene,5070,O
and,5070,O
sequencing,5070,O
confirmed,5070,O
segregation,5070,O
of,5070,O
a,5070,O
novel,5070,O
homozygous,5070,O
mutation,5070,O
with,5070,O
the,5070,O
disease,5070,O
in,5070,O
all,5070,O
the,5070,O
studied,5070,O
families,5070,O
.,5070,O
Biochemical,5071,O
analysis,5071,O
was,5071,O
also,5071,O
consistent,5071,O
with,5071,O
transaldolase,5071,B-GENE-Y
deficiency,5071,O
.,5071,O
CONCLUSION,5072,O
:,5072,O
This,5072,O
study,5072,O
expands,5072,O
the,5072,O
clinical,5072,O
definition,5072,O
of,5072,O
transaldolase,5072,B-GENE-Y
deficiency,5072,O
",",5072,O
and,5072,O
adds,5072,O
to,5072,O
its,5072,O
allelic,5072,O
heterogeneity,5072,O
.,5072,O
In,5073,O
addition,5073,O
",",5073,O
we,5073,O
emphasize,5073,O
the,5073,O
diagnostic,5073,O
challenge,5073,O
posed,5073,O
by,5073,O
this,5073,O
rare,5073,O
and,5073,O
pleiotropic,5073,O
metabolic,5073,O
disorder,5073,O
.,5073,O
Cellular,5074,O
signaling,5074,O
crosstalk,5074,O
between,5074,O
multiple,5074,O
receptors,5074,O
for,5074,O
investigation,5074,O
of,5074,O
pathophysiology,5074,O
in,5074,O
multifactorial,5074,O
diseases,5074,O
--,5074,O
what,5074,O
is,5074,O
clinically-relevant,5074,O
crosstalk,5074,O
?,5074,O
Recently,5075,O
",",5075,O
genomics,5075,O
and,5075,O
proteomics,5075,O
have,5075,O
been,5075,O
utilized,5075,O
as,5075,O
advanced,5075,O
tools,5075,O
for,5075,O
investigation,5075,O
of,5075,O
cellular,5075,O
signaling,5075,O
pathways,5075,O
and,5075,O
molecular,5075,O
interactions,5075,O
",",5075,O
and,5075,O
elucidated,5075,O
promiscuous,5075,O
networks,5075,O
composed,5075,O
of,5075,O
numerous,5075,O
interactions,5075,O
among,5075,O
pathways,5075,O
.,5075,O
However,5076,O
",",5076,O
some,5076,O
of,5076,O
these,5076,O
interactions,5076,O
are,5076,O
considered,5076,O
to,5076,O
be,5076,O
simply,5076,O
contributing,5076,O
to,5076,O
background,5076,O
'noise,5076,O
',5076,O
and,5076,O
others,5076,O
are,5076,O
as,5076,O
'crosstalk,5076,O
',5076,O
biologically-relevant,5076,O
to,5076,O
cellular,5076,O
physiology,5076,O
",",5076,O
leading,5076,O
to,5076,O
synergy,5076,O
effects,5076,O
more,5076,O
than,5076,O
additive,5076,O
responses,5076,O
in,5076,O
an,5076,O
entire,5076,O
organism,5076,O
.,5076,O
Effort,5077,O
is,5077,O
now,5077,O
required,5077,O
to,5077,O
determine,5077,O
which,5077,O
interactions,5077,O
truly,5077,O
contribute,5077,O
to,5077,O
final,5077,O
physiological,5077,O
output,5077,O
.,5077,O
A,5078,O
receptor,5078,O
is,5078,O
the,5078,O
prime,5078,O
example,5078,O
of,5078,O
connectors,5078,O
among,5078,O
the,5078,O
networks,5078,O
.,5078,O
It,5079,O
functions,5079,O
",",5079,O
not,5079,O
simply,5079,O
as,5079,O
a,5079,O
signaling,5079,O
gateway,5079,O
",",5079,O
but,5079,O
also,5079,O
as,5079,O
an,5079,O
active,5079,O
trader,5079,O
by,5079,O
forming,5079,O
inter-receptor,5079,O
dimers,5079,O
.,5079,O
Furthermore,5080,O
",",5080,O
various,5080,O
receptors,5080,O
can,5080,O
modulate,5080,O
the,5080,O
function,5080,O
of,5080,O
the,5080,O
other,5080,O
receptors,5080,O
by,5080,O
input,5080,O
to,5080,O
common,5080,O
intracellular,5080,O
signaling,5080,O
pathways,5080,O
",",5080,O
establishing,5080,O
functional,5080,O
crosstalk,5080,O
among,5080,O
networks,5080,O
.,5080,O
Our,5081,O
findings,5081,O
by,5081,O
combined,5081,O
analyses,5081,O
of,5081,O
gene,5081,O
polymorphisms,5081,O
of,5081,O
two,5081,O
separate,5081,O
genes,5081,O
present,5081,O
evidences,5081,O
that,5081,O
such,5081,O
is,5081,O
the,5081,O
case,5081,O
with,5081,O
human,5081,O
body,5081,O
in,5081,O
a,5081,O
clinical,5081,O
setting,5081,O
:,5081,O
1,5081,O
),5081,O
an,5081,O
integrated,5081,O
effect,5081,O
of,5081,O
epidermal,5081,B-GENE-Y
growth,5081,I-GENE-Y
factor,5081,I-GENE-Y
receptor,5081,I-GENE-Y
(,5081,O
EGFR,5081,B-GENE-Y
),5081,O
and,5081,O
protease,5081,B-GENE-Y
activated,5081,I-GENE-Y
receptor-1,5081,I-GENE-Y
(,5081,O
PAR-1,5081,B-GENE-Y
),5081,O
on,5081,O
susceptibility,5081,O
to,5081,O
airway,5081,O
hyperresponsiveness,5081,O
(,5081,O
AHR,5081,O
),5081,O
",",5081,O
and,5081,O
2,5081,O
),5081,O
a,5081,O
crosstalk,5081,O
effect,5081,O
between,5081,O
muscarinic,5081,B-GENE-N
acetylcholine,5081,I-GENE-N
receptor,5081,I-GENE-N
(,5081,O
mAChRs,5081,B-GENE-N
),5081,O
and,5081,O
β,5081,B-GENE-Y
(,5081,I-GENE-Y
2,5081,I-GENE-Y
),5081,I-GENE-Y
adrenoceptor,5081,I-GENE-Y
(,5081,O
β,5081,B-GENE-Y
(,5081,I-GENE-Y
2,5081,I-GENE-Y
),5081,I-GENE-Y
AR,5081,I-GENE-Y
),5081,O
on,5081,O
bronchodilatory,5081,O
response,5081,O
to,5081,O
anticholinergic,5081,O
agents,5081,O
in,5081,O
patients,5081,O
with,5081,O
COPD,5081,O
.,5081,O
These,5082,O
results,5082,O
indicate,5082,O
that,5082,O
these,5082,O
interactions,5082,O
are,5082,O
unlikely,5082,O
to,5082,O
be,5082,O
'noise,5082,O
',5082,O
but,5082,O
functionally-relevant,5082,O
'crosstalk,5082,O
',5082,O
in,5082,O
a,5082,O
human,5082,O
body,5082,O
.,5082,O
This,5083,O
review,5083,O
attempts,5083,O
to,5083,O
highlight,5083,O
the,5083,O
clinically-relevant,5083,O
'crosstalk,5083,O
',5083,O
paradigm,5083,O
in,5083,O
a,5083,O
human,5083,O
body,5083,O
which,5083,O
provides,5083,O
us,5083,O
a,5083,O
novel,5083,O
insight,5083,O
necessary,5083,O
to,5083,O
investigate,5083,O
pathophysiology,5083,O
in,5083,O
common,5083,O
multifactorial,5083,O
diseases,5083,O
and,5083,O
to,5083,O
develop,5083,O
new,5083,O
drugs,5083,O
.,5083,O
Peginesatide,5084,B-CHEMICAL
clearance,5084,O
",",5084,O
distribution,5084,O
",",5084,O
metabolism,5084,O
",",5084,O
and,5084,O
excretion,5084,O
in,5084,O
monkeys,5084,O
following,5084,O
intravenous,5084,O
administration,5084,O
.,5084,O
Peginesatide,5085,B-CHEMICAL
",",5085,O
a,5085,O
polyethylene,5085,B-CHEMICAL
glycol,5085,I-CHEMICAL
(,5085,O
PEG,5085,B-CHEMICAL
),5085,O
ylated,5085,O
peptide-based,5085,O
erythropoiesis-stimulating,5085,O
agent,5085,O
",",5085,O
stimulates,5085,O
the,5085,O
erythropoietin,5085,B-GENE-N
receptor,5085,I-GENE-N
dimer,5085,O
that,5085,O
governs,5085,O
erythropoiesis,5085,O
.,5085,O
Studies,5086,O
were,5086,O
designed,5086,O
to,5086,O
determine,5086,O
the,5086,O
erythropoietic,5086,O
response,5086,O
",",5086,O
pharmacokinetics,5086,O
(,5086,O
PK,5086,O
),5086,O
",",5086,O
tissue,5086,O
distribution,5086,O
",",5086,O
metabolism,5086,O
",",5086,O
and,5086,O
excretion,5086,O
of,5086,O
peginesatide,5086,B-CHEMICAL
in,5086,O
nonhuman,5086,O
primates,5086,O
following,5086,O
a,5086,O
single,5086,O
i.v,5086,O
.,5086,O
dose,5087,O
.,5087,O
The,5088,O
PK,5088,O
profile,5088,O
of,5088,O
peginesatide,5088,B-CHEMICAL
(,5088,O
0.1-5,5088,O
mg/kg,5088,O
),5088,O
is,5088,O
characterized,5088,O
by,5088,O
low,5088,O
",",5088,O
dose-dependent,5088,O
plasma,5088,O
clearance,5088,O
;,5088,O
small,5088,O
volume,5088,O
of,5088,O
distribution,5088,O
;,5088,O
and,5088,O
long,5088,O
half-life,5088,O
.,5088,O
The,5089,O
peginesatide,5089,B-CHEMICAL
PK,5089,O
profile,5089,O
following,5089,O
a,5089,O
single,5089,O
i.v,5089,O
.,5089,O
dose,5090,O
is,5090,O
consistent,5090,O
with,5090,O
the,5090,O
sustained,5090,O
erythropoiesis,5090,O
.,5090,O
Biodistribution,5091,O
quantitative,5091,O
whole-body,5091,O
autoradiography,5091,O
demonstrated,5091,O
high,5091,O
peginesatide,5091,B-CHEMICAL
levels,5091,O
in,5091,O
bone,5091,O
marrow,5091,O
(,5091,O
i.e.,5091,O
",",5091,O
primary,5091,O
hematopoietic,5091,O
site,5091,O
),5091,O
as,5091,O
well,5091,O
as,5091,O
other,5091,O
known,5091,O
hematopoietic,5091,O
sites,5091,O
persisting,5091,O
through,5091,O
at,5091,O
least,5091,O
3,5091,O
weeks,5091,O
at,5091,O
2.1,5091,O
mg/kg,5091,O
.,5091,O
Microautoradiography,5092,O
analysis,5092,O
at,5092,O
48,5092,O
hours,5092,O
postdose,5092,O
revealed,5092,O
uniform,5092,O
and,5092,O
high,5092,O
distribution,5092,O
of,5092,O
radioactivity,5092,O
in,5092,O
the,5092,O
bone,5092,O
marrow,5092,O
and,5092,O
splenic,5092,O
red,5092,O
pulp,5092,O
with,5092,O
less,5092,O
extensive,5092,O
distribution,5092,O
in,5092,O
the,5092,O
renal,5092,O
cortex,5092,O
(,5092,O
glomeruli,5092,O
",",5092,O
associated,5092,O
ducts,5092,O
",",5092,O
interstitial,5092,O
cells,5092,O
),5092,O
.,5092,O
Radioactivity,5093,O
in,5093,O
the,5093,O
kidney,5093,O
was,5093,O
most,5093,O
prominent,5093,O
in,5093,O
the,5093,O
outer,5093,O
medullary,5093,O
and,5093,O
papillary,5093,O
interstitium,5093,O
.,5093,O
At,5094,O
2,5094,O
weeks,5094,O
after,5094,O
dosing,5094,O
",",5094,O
cumulative,5094,O
radioactivity,5094,O
recovery,5094,O
in,5094,O
the,5094,O
urine,5094,O
and,5094,O
feces,5094,O
was,5094,O
60,5094,O
and,5094,O
7,5094,O
%,5094,O
of,5094,O
the,5094,O
administered,5094,O
dose,5094,O
",",5094,O
respectively,5094,O
",",5094,O
with,5094,O
most,5094,O
of,5094,O
the,5094,O
radioactivity,5094,O
associated,5094,O
with,5094,O
the,5094,O
parent,5094,O
molecule,5094,O
.,5094,O
In,5095,O
conclusion,5095,O
",",5095,O
the,5095,O
PK,5095,O
characteristics,5095,O
are,5095,O
consistent,5095,O
with,5095,O
a,5095,O
PEGylated,5095,O
peptide,5095,O
of,5095,O
a,5095,O
45-kDa,5095,O
molecular,5095,O
mass,5095,O
",",5095,O
specifically,5095,O
low,5095,O
volume,5095,O
of,5095,O
distribution,5095,O
and,5095,O
long,5095,O
half-life,5095,O
.,5095,O
Drug,5096,O
was,5096,O
localized,5096,O
principally,5096,O
to,5096,O
hematopoietic,5096,O
sites,5096,O
",",5096,O
and,5096,O
nonspecific,5096,O
tissue,5096,O
retention,5096,O
was,5096,O
not,5096,O
observed,5096,O
.,5096,O
The,5097,O
nonhuman,5097,O
primate,5097,O
data,5097,O
indicate,5097,O
that,5097,O
peginesatide,5097,B-CHEMICAL
is,5097,O
metabolically,5097,O
stable,5097,O
and,5097,O
primarily,5097,O
excreted,5097,O
in,5097,O
the,5097,O
urine,5097,O
.,5097,O
Comparison,5098,O
of,5098,O
orientation,5098,O
and,5098,O
rotational,5098,O
motion,5098,O
of,5098,O
skeletal,5098,O
muscle,5098,O
cross-bridges,5098,O
containing,5098,O
phosphorylated,5098,B-GENE-Y
and,5098,I-GENE-Y
dephosphorylated,5098,I-GENE-Y
myosin,5098,I-GENE-Y
regulatory,5098,I-GENE-Y
light,5098,I-GENE-Y
chain,5098,I-GENE-Y
.,5098,O
Calcium,5099,B-CHEMICAL
binding,5099,O
to,5099,O
thin,5099,O
filaments,5099,O
is,5099,O
a,5099,O
major,5099,O
element,5099,O
controlling,5099,O
active,5099,O
force,5099,O
generation,5099,O
in,5099,O
striated,5099,O
muscles,5099,O
.,5099,O
Recent,5100,O
evidence,5100,O
suggests,5100,O
that,5100,O
processes,5100,O
other,5100,O
than,5100,O
Ca,5100,B-CHEMICAL
(,5100,I-CHEMICAL
2+,5100,I-CHEMICAL
),5100,I-CHEMICAL
binding,5100,O
",",5100,O
such,5100,O
as,5100,O
phosphorylation,5100,O
of,5100,O
myosin,5100,B-GENE-Y
regulatory,5100,I-GENE-Y
light,5100,I-GENE-Y
chain,5100,I-GENE-Y
(,5100,O
RLC,5100,B-GENE-Y
),5100,O
also,5100,O
controls,5100,O
contraction,5100,O
of,5100,O
vertebrate,5100,O
striated,5100,O
muscle,5100,O
(,5100,O
Cooke,5100,O
",",5100,O
R.,5100,O
(,5100,O
2011,5100,O
),5100,O
Biophys,5100,O
.,5100,O
Rev,5101,O
.,5101,O
3,5102,O
",",5102,O
33-45,5102,O
),5102,O
.,5102,O
Electron,5103,O
paramagnetic,5103,O
resonance,5103,O
(,5103,O
EPR,5103,O
),5103,O
studies,5103,O
using,5103,O
nucleotide,5103,B-CHEMICAL
analog,5103,O
spin,5103,O
label,5103,O
probes,5103,O
showed,5103,O
that,5103,O
dephosphorylated,5103,B-GENE-N
myosin,5103,I-GENE-N
heads,5103,O
are,5103,O
highly,5103,O
ordered,5103,O
in,5103,O
the,5103,O
relaxed,5103,O
fibers,5103,O
and,5103,O
have,5103,O
very,5103,O
low,5103,O
ATPase,5103,B-GENE-N
activity,5103,O
.,5103,O
This,5104,O
ordered,5104,O
structure,5104,O
of,5104,O
myosin,5104,B-GENE-N
cross-bridges,5104,O
disappears,5104,O
with,5104,O
the,5104,O
phosphorylation,5104,O
of,5104,O
RLC,5104,O
(,5104,O
Stewart,5104,O
",",5104,O
M.,5104,O
(,5104,O
2010,5104,O
),5104,O
Proc,5104,O
.,5104,O
Natl,5105,O
.,5105,O
Acad,5106,O
.,5106,O
Sci,5107,O
.,5107,O
U.S.A.,5108,O
107,5108,O
",",5108,O
430-435,5108,O
),5108,O
.,5108,O
The,5109,O
slower,5109,O
ATPase,5109,B-GENE-N
activity,5109,O
in,5109,O
the,5109,O
dephosporylated,5109,O
moiety,5109,O
has,5109,O
been,5109,O
defined,5109,O
as,5109,O
a,5109,O
new,5109,O
super-relaxed,5109,O
state,5109,O
(,5109,O
SRX,5109,O
),5109,O
.,5109,O
It,5110,O
can,5110,O
be,5110,O
observed,5110,O
in,5110,O
both,5110,O
skeletal,5110,O
and,5110,O
cardiac,5110,O
muscle,5110,O
fibers,5110,O
(,5110,O
Hooijman,5110,O
",",5110,O
P.,5110,O
",",5110,O
Stewart,5110,O
",",5110,O
M.,5110,O
A.,5110,O
",",5110,O
and,5110,O
Cooke,5110,O
",",5110,O
R.,5110,O
(,5110,O
2011,5110,O
),5110,O
Biophys,5110,O
.,5110,O
J,5111,O
.,5111,O
100,5112,O
",",5112,O
1969-1976,5112,O
),5112,O
.,5112,O
Given,5113,O
the,5113,O
importance,5113,O
of,5113,O
the,5113,O
finding,5113,O
that,5113,O
suggests,5113,O
a,5113,O
novel,5113,O
pathway,5113,O
of,5113,O
regulation,5113,O
of,5113,O
skeletal,5113,O
muscle,5113,O
",",5113,O
we,5113,O
aim,5113,O
to,5113,O
examine,5113,O
the,5113,O
effects,5113,O
of,5113,O
phosphorylation,5113,O
on,5113,O
cross-bridge,5113,O
orientation,5113,O
and,5113,O
rotational,5113,O
motion,5113,O
.,5113,O
We,5114,O
find,5114,O
that,5114,O
:,5114,O
(,5114,O
i,5114,O
),5114,O
relaxed,5114,O
cross-bridges,5114,O
",",5114,O
but,5114,O
not,5114,O
active,5114,O
ones,5114,O
",",5114,O
are,5114,O
statistically,5114,O
better,5114,O
ordered,5114,O
in,5114,O
muscle,5114,O
where,5114,O
the,5114,O
RLC,5114,B-GENE-Y
is,5114,O
dephosporylated,5114,O
compared,5114,O
with,5114,O
phosphorylated,5114,B-GENE-Y
RLC,5114,I-GENE-Y
;,5114,O
(,5114,O
ii,5114,O
),5114,O
relaxed,5114,O
phosphorylated,5114,O
and,5114,O
dephosphorylated,5114,O
cross-bridges,5114,O
rotate,5114,O
equally,5114,O
slowly,5114,O
;,5114,O
and,5114,O
(,5114,O
iii,5114,O
),5114,O
active,5114,O
phosphorylated,5114,O
cross-bridges,5114,O
rotate,5114,O
considerably,5114,O
faster,5114,O
than,5114,O
dephosphorylated,5114,O
ones,5114,O
during,5114,O
isometric,5114,O
contraction,5114,O
but,5114,O
the,5114,O
duty,5114,O
cycle,5114,O
remained,5114,O
the,5114,O
same,5114,O
",",5114,O
suggesting,5114,O
that,5114,O
both,5114,O
phosphorylated,5114,O
and,5114,O
dephosphorylated,5114,O
muscles,5114,O
develop,5114,O
the,5114,O
same,5114,O
isometric,5114,O
tension,5114,O
at,5114,O
full,5114,O
Ca,5114,B-CHEMICAL
(,5114,I-CHEMICAL
2+,5114,I-CHEMICAL
),5114,I-CHEMICAL
saturation,5114,O
.,5114,O
A,5115,O
simple,5115,O
theory,5115,O
was,5115,O
developed,5115,O
to,5115,O
account,5115,O
for,5115,O
this,5115,O
fact,5115,O
.,5115,O
LPA1-induced,5116,B-GENE-Y
cytoskeleton,5116,O
reorganization,5116,O
drives,5116,O
fibrosis,5116,O
through,5116,O
CTGF-dependent,5116,B-GENE-Y
fibroblast,5116,O
proliferation,5116,O
.,5116,O
There,5117,O
has,5117,O
been,5117,O
much,5117,O
recent,5117,O
interest,5117,O
in,5117,O
lysophosphatidic,5117,B-CHEMICAL
acid,5117,I-CHEMICAL
(,5117,O
LPA,5117,B-CHEMICAL
),5117,O
signaling,5117,O
through,5117,O
one,5117,O
of,5117,O
its,5117,O
receptors,5117,O
",",5117,O
LPA1,5117,B-GENE-Y
",",5117,O
in,5117,O
fibrotic,5117,O
diseases,5117,O
",",5117,O
but,5117,O
the,5117,O
mechanisms,5117,O
by,5117,O
which,5117,O
LPA-LPA1,5117,B-CHEMICAL
signaling,5117,O
promotes,5117,O
pathological,5117,O
fibrosis,5117,O
remain,5117,O
to,5117,O
be,5117,O
fully,5117,O
elucidated,5117,O
.,5117,O
Using,5118,O
a,5118,O
mouse,5118,O
peritoneal,5118,O
fibrosis,5118,O
model,5118,O
",",5118,O
we,5118,O
demonstrate,5118,O
central,5118,O
roles,5118,O
for,5118,O
LPA,5118,B-CHEMICAL
and,5118,O
LPA1,5118,B-GENE-Y
in,5118,O
fibroblast,5118,O
proliferation,5118,O
.,5118,O
Genetic,5119,O
deletion,5119,O
or,5119,O
pharmacological,5119,O
antagonism,5119,O
of,5119,O
LPA1,5119,B-GENE-Y
protected,5119,O
mice,5119,O
from,5119,O
peritoneal,5119,O
fibrosis,5119,O
",",5119,O
blunting,5119,O
the,5119,O
increases,5119,O
in,5119,O
peritoneal,5119,O
collagen,5119,B-GENE-N
by,5119,O
65.4,5119,O
and,5119,O
52.9,5119,O
%,5119,O
",",5119,O
respectively,5119,O
",",5119,O
compared,5119,O
to,5119,O
control,5119,O
animals,5119,O
and,5119,O
demonstrated,5119,O
that,5119,O
peritoneal,5119,O
fibroblast,5119,O
proliferation,5119,O
was,5119,O
highly,5119,O
LPA1,5119,B-GENE-Y
dependent,5119,O
.,5119,O
Activation,5120,O
of,5120,O
LPA1,5120,B-GENE-Y
on,5120,O
mesothelial,5120,O
cells,5120,O
induced,5120,O
these,5120,O
cells,5120,O
to,5120,O
express,5120,O
connective,5120,B-GENE-Y
tissue,5120,I-GENE-Y
growth,5120,I-GENE-Y
factor,5120,I-GENE-Y
(,5120,O
CTGF,5120,B-GENE-Y
),5120,O
",",5120,O
driving,5120,O
fibroblast,5120,O
proliferation,5120,O
in,5120,O
a,5120,O
paracrine,5120,O
fashion,5120,O
.,5120,O
Activation,5121,O
of,5121,O
mesothelial,5121,O
cell,5121,O
LPA1,5121,B-GENE-Y
induced,5121,O
CTGF,5121,B-GENE-Y
expression,5121,O
by,5121,O
inducing,5121,O
cytoskeleton,5121,O
reorganization,5121,O
in,5121,O
these,5121,O
cells,5121,O
",",5121,O
causing,5121,O
nuclear,5121,O
translocation,5121,O
of,5121,O
myocardin-related,5121,B-GENE-Y
transcription,5121,I-GENE-Y
factor,5121,I-GENE-Y
(,5121,I-GENE-Y
MRTF,5121,I-GENE-Y
),5121,I-GENE-Y
-A,5121,I-GENE-Y
and,5121,O
MRTF-B,5121,B-GENE-Y
.,5121,O
Pharmacological,5122,O
inhibition,5122,O
of,5122,O
MRTF-induced,5122,B-GENE-N
transcription,5122,O
also,5122,O
diminished,5122,O
CTGF,5122,B-GENE-Y
expression,5122,O
and,5122,O
fibrosis,5122,O
in,5122,O
the,5122,O
peritoneal,5122,O
fibrosis,5122,O
model,5122,O
",",5122,O
mitigating,5122,O
the,5122,O
increase,5122,O
in,5122,O
peritoneal,5122,O
collagen,5122,B-GENE-N
content,5122,O
by,5122,O
57.9,5122,O
%,5122,O
compared,5122,O
to,5122,O
controls,5122,O
.,5122,O
LPA1-induced,5123,B-GENE-Y
cytoskeleton,5123,O
reorganization,5123,O
therefore,5123,O
makes,5123,O
a,5123,O
previously,5123,O
unrecognized,5123,O
but,5123,O
critically,5123,O
important,5123,O
contribution,5123,O
to,5123,O
the,5123,O
profibrotic,5123,O
activities,5123,O
of,5123,O
LPA,5123,B-CHEMICAL
by,5123,O
driving,5123,O
MRTF-dependent,5123,B-GENE-N
CTGF,5123,B-GENE-Y
expression,5123,O
",",5123,O
which,5123,O
",",5123,O
in,5123,O
turn,5123,O
",",5123,O
drives,5123,O
fibroblast,5123,O
proliferation.-Sakai,5123,O
",",5123,O
N.,5123,O
",",5123,O
Chun,5123,O
",",5123,O
J.,5123,O
",",5123,O
Duffield,5123,O
",",5123,O
J.,5123,O
S.,5123,O
",",5123,O
Wada,5123,O
",",5123,O
T.,5123,O
",",5123,O
Luster,5123,O
",",5123,O
A.,5123,O
D.,5123,O
",",5123,O
Tager,5123,O
",",5123,O
A.,5123,O
M.,5123,O
LPA1-induced,5123,B-GENE-Y
cytoskeleton,5123,O
reorganization,5123,O
drives,5123,O
fibrosis,5123,O
through,5123,O
CTGF-dependent,5123,B-GENE-Y
fibroblast,5123,O
proliferation,5123,O
.,5123,O
Cooperative,5124,O
effects,5124,O
for,5124,O
CYP2E1,5124,B-GENE-Y
differ,5124,O
between,5124,O
styrene,5124,B-CHEMICAL
and,5124,O
its,5124,O
metabolites,5124,O
.,5124,O
Abstract,5125,O
1,5125,O
.,5125,O
Cooperative,5126,O
interactions,5126,O
are,5126,O
frequently,5126,O
observed,5126,O
in,5126,O
the,5126,O
metabolism,5126,O
of,5126,O
drugs,5126,O
and,5126,O
pollutants,5126,O
by,5126,O
cytochrome,5126,B-GENE-N
P450s,5126,I-GENE-N
;,5126,O
nevertheless,5126,O
",",5126,O
the,5126,O
molecular,5126,O
determinants,5126,O
for,5126,O
cooperativity,5126,O
remain,5126,O
elusive,5126,O
.,5126,O
Previously,5127,O
",",5127,O
we,5127,O
demonstrated,5127,O
that,5127,O
steady-state,5127,O
styrene,5127,O
metabolism,5127,O
by,5127,O
CYP2E1,5127,B-GENE-Y
exhibits,5127,O
positive,5127,O
cooperativity,5127,O
.,5127,O
2,5128,O
.,5128,O
We,5129,O
hypothesized,5129,O
that,5129,O
styrene,5129,B-CHEMICAL
metabolites,5129,O
have,5129,O
lower,5129,O
affinity,5129,O
than,5129,O
styrene,5129,B-CHEMICAL
toward,5129,O
CYP2E1,5129,B-GENE-Y
and,5129,O
limited,5129,O
ability,5129,O
to,5129,O
induce,5129,O
cooperative,5129,O
effects,5129,O
during,5129,O
metabolism,5129,O
.,5129,O
To,5130,O
test,5130,O
the,5130,O
hypothesis,5130,O
",",5130,O
we,5130,O
determined,5130,O
the,5130,O
potency,5130,O
and,5130,O
mechanism,5130,O
of,5130,O
inhibition,5130,O
for,5130,O
styrene,5130,B-CHEMICAL
and,5130,O
its,5130,O
metabolites,5130,O
toward,5130,O
oxidation,5130,O
of,5130,O
4-nitrophenol,5130,B-CHEMICAL
using,5130,O
CYP2E1,5130,B-GENE-Y
Supersomes®,5130,O
and,5130,O
human,5130,O
liver,5130,O
microsomes,5130,O
.,5130,O
3,5131,O
.,5131,O
Styrene,5132,B-CHEMICAL
inhibited,5132,O
the,5132,O
reaction,5132,O
through,5132,O
a,5132,O
mixed,5132,O
cooperative,5132,O
mechanism,5132,O
with,5132,O
high,5132,O
affinity,5132,O
for,5132,O
the,5132,O
catalytic,5132,O
site,5132,O
(,5132,O
67,5132,O
µM,5132,O
),5132,O
and,5132,O
lower,5132,O
affinity,5132,O
for,5132,O
the,5132,O
cooperative,5132,O
site,5132,O
(,5132,O
1100,5132,O
µM,5132,O
),5132,O
",",5132,O
while,5132,O
increasing,5132,O
substrate,5132,O
turnover,5132,O
at,5132,O
high,5132,O
concentrations,5132,O
.,5132,O
Styrene,5133,B-CHEMICAL
oxide,5133,I-CHEMICAL
and,5133,O
4-vinylphenol,5133,B-CHEMICAL
possessed,5133,O
similar,5133,O
affinity,5133,O
for,5133,O
CYP2E1,5133,B-GENE-Y
.,5133,O
Styrene,5134,B-CHEMICAL
oxide,5134,I-CHEMICAL
behaved,5134,O
cooperatively,5134,O
like,5134,O
styrene,5134,B-CHEMICAL
",",5134,O
but,5134,O
4-vinylphenol,5134,B-CHEMICAL
decreased,5134,O
turnover,5134,O
at,5134,O
high,5134,O
concentrations,5134,O
.,5134,O
Styrene,5135,B-CHEMICAL
glycol,5135,I-CHEMICAL
was,5135,O
a,5135,O
very,5135,O
poor,5135,O
competitive,5135,O
inhibitor,5135,O
.,5135,O
Among,5136,O
all,5136,O
compounds,5136,O
",",5136,O
there,5136,O
was,5136,O
a,5136,O
positive,5136,O
correlation,5136,O
with,5136,O
binding,5136,O
and,5136,O
hydrophobicity,5136,O
.,5136,O
4,5137,O
.,5137,O
Taken,5138,O
together,5138,O
",",5138,O
these,5138,O
findings,5138,O
for,5138,O
CYP2E1,5138,B-GENE-Y
further,5138,O
validate,5138,O
contributions,5138,O
of,5138,O
cooperative,5138,O
mechanisms,5138,O
to,5138,O
metabolic,5138,O
processes,5138,O
",",5138,O
demonstrate,5138,O
the,5138,O
role,5138,O
of,5138,O
molecular,5138,O
structure,5138,O
on,5138,O
those,5138,O
mechanisms,5138,O
and,5138,O
underscore,5138,O
the,5138,O
potential,5138,O
for,5138,O
heterotropic,5138,O
cooperative,5138,O
effects,5138,O
between,5138,O
different,5138,O
compounds,5138,O
.,5138,O
Nonalcoholic,5139,O
fatty,5139,O
liver,5139,O
disease,5139,O
:,5139,O
current,5139,O
issues,5139,O
and,5139,O
novel,5139,O
treatment,5139,O
approaches,5139,O
.,5139,O
Nonalcoholic,5140,O
fatty,5140,O
liver,5140,O
disease,5140,O
(,5140,O
NAFLD,5140,O
),5140,O
is,5140,O
considered,5140,O
the,5140,O
most,5140,O
common,5140,O
liver,5140,O
disorder,5140,O
in,5140,O
the,5140,O
Western,5140,O
world,5140,O
.,5140,O
It,5141,O
is,5141,O
commonly,5141,O
associated,5141,O
with,5141,O
insulin,5141,B-GENE-Y
resistance,5141,O
",",5141,O
obesity,5141,O
",",5141,O
dyslipidaemia,5141,O
",",5141,O
type,5141,O
2,5141,O
diabetes,5141,O
mellitus,5141,O
(,5141,O
T2DM,5141,O
),5141,O
and,5141,O
cardiovascular,5141,O
disease,5141,O
.,5141,O
Nonalcoholic,5142,O
steatohepatitis,5142,O
(,5142,O
NASH,5142,O
),5142,O
is,5142,O
characterized,5142,O
by,5142,O
steatosis,5142,O
with,5142,O
necroinflammation,5142,O
and,5142,O
eventual,5142,O
fibrosis,5142,O
",",5142,O
which,5142,O
can,5142,O
lead,5142,O
to,5142,O
end-stage,5142,O
liver,5142,O
disease,5142,O
and,5142,O
hepatocellular,5142,O
carcinoma,5142,O
.,5142,O
Its,5143,O
pathogenesis,5143,O
is,5143,O
complex,5143,O
",",5143,O
and,5143,O
involves,5143,O
a,5143,O
state,5143,O
of,5143,O
'lipotoxicity,5143,O
',5143,O
in,5143,O
which,5143,O
insulin,5143,B-GENE-Y
resistance,5143,O
",",5143,O
with,5143,O
increased,5143,O
free,5143,B-CHEMICAL
fatty,5143,I-CHEMICAL
acid,5143,I-CHEMICAL
release,5143,O
from,5143,O
adipose,5143,O
tissue,5143,O
to,5143,O
the,5143,O
liver,5143,O
",",5143,O
play,5143,O
a,5143,O
key,5143,O
role,5143,O
in,5143,O
the,5143,O
onset,5143,O
of,5143,O
a,5143,O
'lipotoxic,5143,O
liver,5143,O
disease,5143,O
',5143,O
and,5143,O
its,5143,O
progression,5143,O
to,5143,O
NASH,5143,O
.,5143,O
The,5144,O
diagnosis,5144,O
of,5144,O
NASH,5144,O
is,5144,O
challenging,5144,O
",",5144,O
as,5144,O
most,5144,O
affected,5144,O
patients,5144,O
are,5144,O
symptom,5144,O
free,5144,O
and,5144,O
the,5144,O
role,5144,O
of,5144,O
routine,5144,O
screening,5144,O
is,5144,O
not,5144,O
clearly,5144,O
established,5144,O
.,5144,O
A,5145,O
complete,5145,O
medical,5145,O
history,5145,O
is,5145,O
important,5145,O
to,5145,O
rule,5145,O
out,5145,O
other,5145,O
causes,5145,O
of,5145,O
fatty,5145,O
liver,5145,O
disease,5145,O
(,5145,O
alcohol,5145,B-CHEMICAL
abuse,5145,O
",",5145,O
medications,5145,O
",",5145,O
other,5145,O
),5145,O
.,5145,O
Plasma,5146,B-GENE-N
aminotransferase,5146,I-GENE-N
levels,5146,O
and,5146,O
liver,5146,O
ultrasound,5146,O
are,5146,O
helpful,5146,O
in,5146,O
the,5146,O
diagnosis,5146,O
of,5146,O
NAFLD/NASH,5146,O
",",5146,O
but,5146,O
a,5146,O
liver,5146,O
biopsy,5146,O
is,5146,O
often,5146,O
required,5146,O
for,5146,O
a,5146,O
definitive,5146,O
diagnosis,5146,O
.,5146,O
However,5147,O
",",5147,O
there,5147,O
is,5147,O
an,5147,O
active,5147,O
search,5147,O
for,5147,O
plasma,5147,O
biomarkers,5147,O
and,5147,O
imaging,5147,O
techniques,5147,O
that,5147,O
may,5147,O
non-invasively,5147,O
aid,5147,O
in,5147,O
the,5147,O
diagnosis,5147,O
.,5147,O
The,5148,O
treatment,5148,O
of,5148,O
NASH,5148,O
requires,5148,O
a,5148,O
multifaceted,5148,O
approach,5148,O
.,5148,O
The,5149,O
goal,5149,O
is,5149,O
to,5149,O
reverse,5149,O
obesity-associated,5149,O
lipotoxicity,5149,O
and,5149,O
insulin,5149,B-GENE-Y
resistance,5149,O
via,5149,O
lifestyle,5149,O
intervention,5149,O
.,5149,O
Although,5150,O
there,5150,O
is,5150,O
no,5150,O
pharmacological,5150,O
agent,5150,O
approved,5150,O
for,5150,O
the,5150,O
treatment,5150,O
of,5150,O
NAFLD,5150,O
",",5150,O
vitamin,5150,B-CHEMICAL
E,5150,I-CHEMICAL
(,5150,O
in,5150,O
patients,5150,O
without,5150,O
T2DM,5150,O
),5150,O
and,5150,O
the,5150,O
thiazolidinedione,5150,O
pioglitazone,5150,B-CHEMICAL
(,5150,O
in,5150,O
patients,5150,O
with,5150,O
and,5150,O
without,5150,O
T2DM,5150,O
),5150,O
have,5150,O
shown,5150,O
the,5150,O
most,5150,O
consistent,5150,O
results,5150,O
in,5150,O
randomized,5150,O
controlled,5150,O
trials,5150,O
.,5150,O
This,5151,O
review,5151,O
concentrates,5151,O
on,5151,O
our,5151,O
current,5151,O
understanding,5151,O
of,5151,O
the,5151,O
disease,5151,O
",",5151,O
with,5151,O
a,5151,O
focus,5151,O
on,5151,O
the,5151,O
existing,5151,O
therapeutic,5151,O
approaches,5151,O
and,5151,O
potential,5151,O
future,5151,O
pharmacological,5151,O
developments,5151,O
for,5151,O
NAFLD,5151,O
and,5151,O
NASH,5151,O
.,5151,O
Nuclear,5152,B-GENE-N
receptors,5152,I-GENE-N
in,5152,O
bile,5152,B-CHEMICAL
acid,5152,I-CHEMICAL
metabolism,5152,O
.,5152,O
Bile,5153,B-CHEMICAL
acids,5153,I-CHEMICAL
are,5153,O
signaling,5153,O
molecules,5153,O
that,5153,O
activate,5153,O
nuclear,5153,B-GENE-N
receptors,5153,I-GENE-N
",",5153,O
such,5153,O
as,5153,O
farnesoid,5153,B-GENE-Y
X,5153,I-GENE-Y
receptor,5153,I-GENE-Y
",",5153,O
pregnane,5153,B-CHEMICAL
X,5153,I-GENE-Y
receptor,5153,I-GENE-Y
",",5153,O
constitutive,5153,B-GENE-Y
androstane,5153,B-CHEMICAL
receptor,5153,I-GENE-Y
",",5153,O
and,5153,O
vitamin,5153,B-CHEMICAL
D,5153,I-CHEMICAL
receptor,5153,I-GENE-Y
",",5153,O
and,5153,O
play,5153,O
a,5153,O
critical,5153,O
role,5153,O
in,5153,O
the,5153,O
regulation,5153,O
of,5153,O
lipid,5153,O
",",5153,O
glucose,5153,B-CHEMICAL
",",5153,O
energy,5153,O
",",5153,O
and,5153,O
drug,5153,O
metabolism,5153,O
.,5153,O
These,5154,O
xenobiotic/endobiotic-sensing,5154,B-GENE-N
nuclear,5154,I-GENE-N
receptors,5154,I-GENE-N
regulate,5154,O
phase,5154,O
I,5154,O
oxidation,5154,O
",",5154,O
phase,5154,O
II,5154,O
conjugation,5154,O
",",5154,O
and,5154,O
phase,5154,O
III,5154,O
transport,5154,O
in,5154,O
bile,5154,B-CHEMICAL
acid,5154,I-CHEMICAL
and,5154,O
drug,5154,O
metabolism,5154,O
in,5154,O
the,5154,O
digestive,5154,O
system,5154,O
.,5154,O
Integration,5155,O
of,5155,O
bile,5155,B-CHEMICAL
acid,5155,I-CHEMICAL
metabolism,5155,O
with,5155,O
drug,5155,O
metabolism,5155,O
controls,5155,O
absorption,5155,O
",",5155,O
transport,5155,O
",",5155,O
and,5155,O
metabolism,5155,O
of,5155,O
nutrients,5155,O
and,5155,O
drugs,5155,O
to,5155,O
maintain,5155,O
metabolic,5155,O
homeostasis,5155,O
and,5155,O
also,5155,O
protects,5155,O
against,5155,O
liver,5155,O
injury,5155,O
",",5155,O
inflammation,5155,O
",",5155,O
and,5155,O
related,5155,O
metabolic,5155,O
diseases,5155,O
",",5155,O
such,5155,O
as,5155,O
nonalcoholic,5155,O
fatty,5155,O
liver,5155,O
disease,5155,O
",",5155,O
diabetes,5155,O
",",5155,O
and,5155,O
obesity,5155,O
.,5155,O
Bile-acid-based,5156,B-CHEMICAL
drugs,5156,O
targeting,5156,O
nuclear,5156,O
receptors,5156,O
are,5156,O
in,5156,O
clinical,5156,O
trials,5156,O
for,5156,O
treating,5156,O
cholestatic,5156,O
liver,5156,O
diseases,5156,O
and,5156,O
fatty,5156,O
liver,5156,O
disease,5156,O
.,5156,O
Green,5157,O
tea,5157,O
catechin,5157,B-CHEMICAL
leads,5157,O
to,5157,O
global,5157,O
improvement,5157,O
among,5157,O
Alzheimer,5157,O
's,5157,O
disease-related,5157,O
phenotypes,5157,O
in,5157,O
NSE/hAPP-C105,5157,B-GENE-Y
Tg,5157,O
mice,5157,O
.,5157,O
Amyloid,5158,B-GENE-Y
β,5158,I-GENE-Y
(,5158,O
Αβ,5158,B-GENE-Y
),5158,O
has,5158,O
been,5158,O
reported,5158,O
to,5158,O
be,5158,O
responsible,5158,O
for,5158,O
the,5158,O
functional,5158,O
and,5158,O
structural,5158,O
abnormalities,5158,O
of,5158,O
Alzheimer,5158,O
's,5158,O
disease,5158,O
(,5158,O
AD,5158,O
),5158,O
through,5158,O
the,5158,O
induction,5158,O
of,5158,O
oxidative,5158,O
stress,5158,O
.,5158,O
The,5159,O
aim,5159,O
of,5159,O
this,5159,O
study,5159,O
was,5159,O
to,5159,O
determine,5159,O
whether,5159,O
or,5159,O
not,5159,O
treatment,5159,O
of,5159,O
transgenic,5159,O
(,5159,O
Tg,5159,O
),5159,O
mice,5159,O
with,5159,O
green,5159,O
tea,5159,O
catechin,5159,B-CHEMICAL
(,5159,O
GTC,5159,O
),5159,O
",",5159,O
a,5159,O
radical,5159,O
scavenger,5159,O
",",5159,O
improves,5159,O
AD,5159,O
phenotypes,5159,O
.,5159,O
To,5160,O
test,5160,O
this,5160,O
",",5160,O
7-month-old,5160,O
Tg,5160,O
mice,5160,O
were,5160,O
treated,5160,O
with,5160,O
a,5160,O
low,5160,O
(,5160,O
1,5160,O
mg,5160,O
),5160,O
or,5160,O
high,5160,O
(,5160,O
10,5160,O
mg,5160,O
),5160,O
dose,5160,O
of,5160,O
GTC,5160,O
for,5160,O
6,5160,O
months,5160,O
.,5160,O
Surprisingly,5161,O
",",5161,O
GTC-treated,5161,O
Tg,5161,O
mice,5161,O
exhibited,5161,O
significant,5161,O
decreases,5161,O
in,5161,O
behavioral,5161,O
impairment,5161,O
",",5161,O
Aβ-42,5161,B-GENE-Y
production,5161,O
",",5161,O
APP-C99/89,5161,B-GENE-Y
expression,5161,O
",",5161,O
γ-secretase,5161,B-GENE-Y
component,5161,O
and,5161,O
Wnt,5161,B-GENE-N
protein,5161,O
levels,5161,O
",",5161,O
γ-secretase,5161,B-GENE-Y
activity,5161,O
and,5161,O
MAPK,5161,B-GENE-N
activation,5161,O
.,5161,O
In,5162,O
contrast,5162,O
",",5162,O
the,5162,O
levels,5162,O
of,5162,O
APP-C83,5162,B-GENE-Y
protein,5162,O
and,5162,O
enzyme,5162,O
activities,5162,O
(,5162,O
α-secretase,5162,B-GENE-Y
",",5162,O
neprilysin,5162,B-GENE-Y
and,5162,O
Pin1,5162,B-GENE-Y
),5162,O
were,5162,O
elevated,5162,O
in,5162,O
the,5162,O
GTC-treated,5162,O
groups,5162,O
.,5162,O
Moreover,5163,O
",",5163,O
GTC-treated,5163,O
groups,5163,O
showed,5163,O
lower,5163,O
levels,5163,O
of,5163,O
total,5163,O
cholesterol,5163,B-CHEMICAL
and,5163,O
low-density,5163,B-GENE-N
lipoprotein,5163,I-GENE-N
cholesterol,5163,B-CHEMICAL
",",5163,O
whereas,5163,O
the,5163,O
level,5163,O
of,5163,O
high-density,5163,B-GENE-N
lipoprotein,5163,I-GENE-N
cholesterol,5163,B-CHEMICAL
increased,5163,O
.,5163,O
These,5164,O
results,5164,O
provide,5164,O
the,5164,O
first,5164,O
experimental,5164,O
evidence,5164,O
that,5164,O
GTC,5164,O
improves,5164,O
AD,5164,O
phenotypes,5164,O
",",5164,O
thereby,5164,O
suggesting,5164,O
that,5164,O
GTC,5164,O
can,5164,O
be,5164,O
used,5164,O
in,5164,O
the,5164,O
prevention,5164,O
of,5164,O
AD,5164,O
or,5164,O
treatment,5164,O
of,5164,O
AD,5164,O
patients,5164,O
.,5164,O
RIF1,5165,B-GENE-Y
is,5165,O
essential,5165,O
for,5165,O
53BP1-dependent,5165,B-GENE-Y
nonhomologous,5165,O
end,5165,O
joining,5165,O
and,5165,O
suppression,5165,O
of,5165,O
DNA,5165,O
double-strand,5165,O
break,5165,O
resection,5165,O
.,5165,O
The,5166,O
appropriate,5166,O
execution,5166,O
of,5166,O
DNA,5166,O
double-strand,5166,O
break,5166,O
(,5166,O
DSB,5166,O
),5166,O
repair,5166,O
is,5166,O
critical,5166,O
for,5166,O
genome,5166,O
stability,5166,O
and,5166,O
tumor,5166,O
avoidance,5166,O
.,5166,O
53BP1,5167,B-GENE-Y
and,5167,O
BRCA1,5167,B-GENE-Y
directly,5167,O
influence,5167,O
DSB,5167,O
repair,5167,O
pathway,5167,O
choice,5167,O
by,5167,O
regulating,5167,O
5,5167,O
',5167,O
end,5167,O
resection,5167,O
",",5167,O
but,5167,O
how,5167,O
this,5167,O
is,5167,O
achieved,5167,O
remains,5167,O
uncertain,5167,O
.,5167,O
Here,5168,O
we,5168,O
report,5168,O
that,5168,O
Rif1,5168,B-GENE-Y
(,5168,O
-/-,5168,O
),5168,O
mice,5168,O
are,5168,O
severely,5168,O
compromised,5168,O
for,5168,O
53BP1-dependent,5168,B-GENE-Y
class,5168,O
switch,5168,O
recombination,5168,O
(,5168,O
CSR,5168,O
),5168,O
and,5168,O
fusion,5168,O
of,5168,O
dysfunctional,5168,O
telomeres,5168,O
.,5168,O
The,5169,O
inappropriate,5169,O
accumulation,5169,O
of,5169,O
RIF1,5169,B-GENE-Y
at,5169,O
DSBs,5169,O
in,5169,O
S,5169,O
phase,5169,O
is,5169,O
antagonized,5169,O
by,5169,O
BRCA1,5169,B-GENE-Y
",",5169,O
and,5169,O
deletion,5169,O
of,5169,O
Rif1,5169,B-GENE-Y
suppresses,5169,O
toxic,5169,O
nonhomologous,5169,O
end,5169,O
joining,5169,O
(,5169,O
NHEJ,5169,O
),5169,O
induced,5169,O
by,5169,O
PARP,5169,B-GENE-N
inhibition,5169,O
in,5169,O
Brca1-deficient,5169,B-GENE-Y
cells,5169,O
.,5169,O
Mechanistically,5170,O
",",5170,O
RIF1,5170,B-GENE-Y
is,5170,O
recruited,5170,O
to,5170,O
DSBs,5170,O
via,5170,O
the,5170,O
N-terminal,5170,B-CHEMICAL
phospho-SQ/TQ,5170,B-CHEMICAL
domain,5170,I-GENE-N
of,5170,O
53BP1,5170,B-GENE-Y
",",5170,O
and,5170,O
DSBs,5170,O
generated,5170,O
by,5170,O
ionizing,5170,O
radiation,5170,O
or,5170,O
during,5170,O
CSR,5170,O
are,5170,O
hyperresected,5170,O
in,5170,O
the,5170,O
absence,5170,O
of,5170,O
RIF1,5170,B-GENE-Y
.,5170,O
Thus,5171,O
",",5171,O
RIF1,5171,B-GENE-Y
and,5171,O
53BP1,5171,B-GENE-Y
cooperate,5171,O
to,5171,O
block,5171,O
DSB,5171,O
resection,5171,O
to,5171,O
promote,5171,O
NHEJ,5171,O
in,5171,O
G1,5171,O
",",5171,O
which,5171,O
is,5171,O
antagonized,5171,O
by,5171,O
BRCA1,5171,B-GENE-Y
in,5171,O
S,5171,O
phase,5171,O
to,5171,O
ensure,5171,O
a,5171,O
switch,5171,O
of,5171,O
DSB,5171,O
repair,5171,O
mode,5171,O
to,5171,O
homologous,5171,O
recombination,5171,O
.,5171,O
RANKL,5172,B-GENE-Y
targeted,5172,O
peptides,5172,O
inhibit,5172,O
osteoclastogenesis,5172,O
and,5172,O
attenuate,5172,O
adjuvant,5172,O
induced,5172,O
arthritis,5172,O
by,5172,O
inhibiting,5172,O
NF-κB,5172,B-GENE-N
activation,5172,O
and,5172,O
down,5172,O
regulating,5172,O
inflammatory,5172,O
cytokines,5172,B-GENE-N
.,5172,O
Peptides,5173,O
designed,5173,O
from,5173,O
osteoprotegerin,5173,O
(,5173,O
OPG,5173,O
),5173,O
have,5173,O
previously,5173,O
been,5173,O
shown,5173,O
to,5173,O
inhibit,5173,O
receptor,5173,B-GENE-Y
activator,5173,I-GENE-Y
of,5173,I-GENE-Y
NF-κB,5173,I-GENE-Y
ligand,5173,I-GENE-Y
(,5173,O
RANKL,5173,B-GENE-Y
),5173,O
and,5173,O
prevent,5173,O
bone,5173,O
loss,5173,O
without,5173,O
significantly,5173,O
inhibiting,5173,O
inflammation,5173,O
.,5173,O
The,5174,O
objective,5174,O
of,5174,O
this,5174,O
study,5174,O
was,5174,O
to,5174,O
develop,5174,O
a,5174,O
novel,5174,O
peptide,5174,O
with,5174,O
dual,5174,O
inhibitory,5174,O
activity,5174,O
against,5174,O
bone,5174,O
loss,5174,O
and,5174,O
inflammation,5174,O
using,5174,O
site-directed,5174,O
mutagenesis,5174,O
.,5174,O
Out,5175,O
of,5175,O
the,5175,O
three,5175,O
putative,5175,O
sites,5175,O
(,5175,O
i.e.,5175,O
",",5175,O
Tyr70-Asp78,5175,B-CHEMICAL
",",5175,O
Tyr82-Glu96,5175,B-CHEMICAL
",",5175,O
and,5175,O
Leu113-Arg122,5175,B-CHEMICAL
),5175,O
available,5175,O
on,5175,O
OPG,5175,O
for,5175,O
RANKL,5175,B-GENE-Y
binding,5175,O
",",5175,O
Leu113-Arg122,5175,B-CHEMICAL
was,5175,O
used,5175,O
as,5175,O
a,5175,O
template,5175,O
for,5175,O
peptide,5175,O
synthesis,5175,O
.,5175,O
Peptide,5176,O
mutants,5176,O
of,5176,O
the,5176,O
template,5176,O
sequence,5176,O
(,5176,O
112YLEIEFCLKHR122,5176,O
),5176,O
were,5176,O
synthesized,5176,O
and,5176,O
initially,5176,O
screened,5176,O
for,5176,O
their,5176,O
inhibitory,5176,O
effect,5176,O
on,5176,O
RANK-RANKL,5176,B-GENE-Y
binding,5176,O
by,5176,O
competitive,5176,O
ELISA,5176,O
.,5176,O
The,5177,O
most,5177,O
active,5177,O
peptide,5177,O
was,5177,O
further,5177,O
evaluated,5177,O
in,5177,O
vitro,5177,O
for,5177,O
RANKL,5177,B-GENE-Y
induced,5177,O
osteoclastogenesis,5177,O
in,5177,O
mouse,5177,O
macrophage,5177,O
cells,5177,O
",",5177,O
and,5177,O
in,5177,O
vivo,5177,O
for,5177,O
Freund,5177,O
's,5177,O
complete,5177,O
adjuvant,5177,O
induced,5177,O
arthritis,5177,O
(,5177,O
AIA,5177,O
),5177,O
in,5177,O
Lewis,5177,O
rats,5177,O
.,5177,O
The,5178,O
efficacy,5178,O
of,5178,O
the,5178,O
candidate,5178,O
peptide,5178,O
was,5178,O
compared,5178,O
with,5178,O
that,5178,O
of,5178,O
the,5178,O
standard,5178,O
drug,5178,O
celecoxib,5178,B-CHEMICAL
.,5178,O
The,5179,O
peptide,5179,O
YR-11,5179,B-CHEMICAL
(,5179,O
YLEIEFSLKHR,5179,O
),5179,O
",",5179,O
obtained,5179,O
by,5179,O
direct,5179,O
substitution,5179,O
of,5179,O
cysteine,5179,B-CHEMICAL
with,5179,O
a,5179,O
serine,5179,B-CHEMICAL
residue,5179,O
in,5179,O
the,5179,O
template,5179,O
sequence,5179,O
",",5179,O
significantly,5179,O
(,5179,O
p,5179,O
<,5179,O
0.05,5179,O
),5179,O
inhibited,5179,O
RANK-RANKL,5179,B-GENE-Y
binding,5179,O
",",5179,O
and,5179,O
RANKL,5179,B-GENE-Y
induced,5179,O
TRAP,5179,B-GENE-Y
activity,5179,O
and,5179,O
formation,5179,O
of,5179,O
multinucleated,5179,O
osteoclasts,5179,O
without,5179,O
any,5179,O
cytotoxicity,5179,O
.,5179,O
Administration,5180,O
of,5180,O
YR-11,5180,B-CHEMICAL
peptide,5180,O
at,5180,O
the,5180,O
dose,5180,O
of,5180,O
30mg/kg,5180,O
(,5180,O
i.p,5180,O
.,5180,O
),5180,O
ameliorated,5181,O
both,5181,O
bone,5181,O
loss,5181,O
and,5181,O
inflammation,5181,O
in,5181,O
AIA,5181,O
rats,5181,O
.,5181,O
To,5182,O
elucidate,5182,O
the,5182,O
mechanism,5182,O
for,5182,O
inhibition,5182,O
of,5182,O
inflammation,5182,O
in,5182,O
arthritic,5182,O
rats,5182,O
",",5182,O
serum,5182,O
and,5182,O
tissue,5182,O
cytokines,5182,B-GENE-N
(,5182,O
TNF-α,5182,B-GENE-Y
",",5182,O
IL-1β,5182,B-GENE-Y
",",5182,O
and,5182,O
IL-6,5182,B-GENE-Y
),5182,O
were,5182,O
analyzed,5182,O
by,5182,O
ELISA,5182,O
and,5182,O
RT-PCR,5182,O
methods,5182,O
.,5182,O
Results,5183,O
confirmed,5183,O
that,5183,O
YR-11,5183,B-CHEMICAL
peptide,5183,O
inhibited,5183,O
pro-inflammatory,5183,O
cytokines,5183,B-GENE-N
in,5183,O
the,5183,O
sera,5183,O
and,5183,O
hind,5183,O
paw,5183,O
tissues,5183,O
of,5183,O
AIA,5183,O
rats,5183,O
through,5183,O
its,5183,O
suppressive,5183,O
effect,5183,O
on,5183,O
RANKL,5183,B-GENE-Y
induced,5183,O
nuclear,5183,O
translocation,5183,O
of,5183,O
NF-κB,5183,B-GENE-N
.,5183,O
The,5184,O
results,5184,O
obtained,5184,O
in,5184,O
this,5184,O
study,5184,O
substantiate,5184,O
the,5184,O
therapeutic,5184,O
benefit,5184,O
of,5184,O
this,5184,O
novel,5184,O
peptide,5184,O
in,5184,O
the,5184,O
prevention,5184,O
of,5184,O
bone,5184,O
loss,5184,O
and,5184,O
inflammation,5184,O
in,5184,O
rheumatoid,5184,O
arthritis,5184,O
with,5184,O
reduced,5184,O
side,5184,O
effects,5184,O
.,5184,O
Activation,5185,O
of,5185,O
Rac1,5185,B-GENE-Y
GTPase,5185,B-GENE-N
by,5185,O
nanoparticulate,5185,O
structures,5185,O
in,5185,O
human,5185,O
macrophages,5185,O
.,5185,O
Inflammatory,5186,O
activation,5186,O
of,5186,O
alveolar,5186,O
macrophages,5186,O
by,5186,O
ambient,5186,O
particles,5186,O
can,5186,O
be,5186,O
facilitated,5186,O
via,5186,O
Toll-like,5186,B-GENE-N
receptors,5186,I-GENE-N
(,5186,O
TLR,5186,B-GENE-N
),5186,O
.,5186,O
The,5187,O
action,5187,O
of,5187,O
TLR,5187,B-GENE-N
agonists,5187,O
and,5187,O
antagonists,5187,O
has,5187,O
been,5187,O
reported,5187,O
to,5187,O
depend,5187,O
on,5187,O
the,5187,O
formation,5187,O
of,5187,O
nanoparticulate,5187,O
structures,5187,O
.,5187,O
Aim,5188,O
of,5188,O
the,5188,O
present,5188,O
study,5188,O
was,5188,O
to,5188,O
identify,5188,O
the,5188,O
signaling,5188,O
pathways,5188,O
induced,5188,O
by,5188,O
nanoparticulate,5188,O
structures,5188,O
in,5188,O
human,5188,O
macrophages,5188,O
",",5188,O
which,5188,O
might,5188,O
be,5188,O
critical,5188,O
for,5188,O
inflammatory,5188,O
cell,5188,O
activation,5188,O
.,5188,O
METHODS,5189,O
:,5189,O
Studies,5189,O
were,5189,O
performed,5189,O
in,5189,O
primary,5189,O
human,5189,O
alveolar,5189,O
macrophages,5189,O
or,5189,O
in,5189,O
differentiated,5189,O
THP-1,5189,O
macrophages,5189,O
.,5189,O
Silica,5190,B-CHEMICAL
nanoparticles,5190,O
were,5190,O
prepared,5190,O
by,5190,O
Stöber,5190,O
synthesis,5190,O
and,5190,O
characterized,5190,O
by,5190,O
dynamic,5190,O
light,5190,O
scattering,5190,O
and,5190,O
scanning,5190,O
electron,5190,O
microscopy,5190,O
.,5190,O
Mycobacterial,5191,O
DNA,5191,O
was,5191,O
isolated,5191,O
from,5191,O
Mycobacterium,5191,O
bovis,5191,O
BCG,5191,O
",",5191,O
and,5191,O
nanoparticle,5191,O
formation,5191,O
was,5191,O
assessed,5191,O
by,5191,O
atomic,5191,O
force,5191,O
microscopy,5191,O
and,5191,O
dynamic,5191,O
light,5191,O
scattering,5191,O
.,5191,O
Actin,5192,B-GENE-N
polymerization,5192,O
was,5192,O
measured,5192,O
by,5192,O
phalloidin-TRITC,5192,B-CHEMICAL
staining,5192,O
",",5192,O
and,5192,O
cell,5192,O
activation,5192,O
was,5192,O
determined,5192,O
by,5192,O
reverse,5192,O
transcription,5192,O
quantitative,5192,O
PCR,5192,O
analysis,5192,O
",",5192,O
L929,5192,O
cytotoxicity,5192,O
assay,5192,O
(,5192,O
cytokine,5192,B-GENE-N
induction,5192,O
),5192,O
",",5192,O
and,5192,O
pull-down,5192,O
assays,5192,O
(,5192,O
Rho,5192,B-GENE-N
GTPases,5192,B-GENE-N
),5192,O
.,5192,O
RESULTS,5193,O
:,5193,O
In,5193,O
contrast,5193,O
to,5193,O
immune,5193,O
stimulatory,5193,O
sequence,5193,O
ISS,5193,O
1018,5193,O
",",5193,O
BCG,5193,O
DNA,5193,O
spontaneously,5193,O
formed,5193,O
nanoparticulate,5193,O
structures,5193,O
and,5193,O
induced,5193,O
actin,5193,B-GENE-N
polymerization,5193,O
as,5193,O
did,5193,O
synthetic,5193,O
silica,5193,B-CHEMICAL
nanoparticles,5193,O
.,5193,O
Co-incubation,5194,O
with,5194,O
silica,5194,B-CHEMICAL
nanoparticles,5194,O
amplified,5194,O
the,5194,O
responsiveness,5194,O
of,5194,O
macrophages,5194,O
toward,5194,O
the,5194,O
TLR9,5194,B-GENE-Y
ligand,5194,O
ISS,5194,O
1018,5194,O
.,5194,O
The,5195,O
activation,5195,O
of,5195,O
Rac1,5195,B-GENE-Y
was,5195,O
induced,5195,O
by,5195,O
silica,5195,B-CHEMICAL
nanoparticles,5195,O
as,5195,O
well,5195,O
as,5195,O
BCG,5195,O
DNA,5195,O
and,5195,O
is,5195,O
suggested,5195,O
as,5195,O
the,5195,O
critical,5195,O
signaling,5195,O
event,5195,O
inducing,5195,O
both,5195,O
cytoskeleton,5195,O
changes,5195,O
as,5195,O
well,5195,O
as,5195,O
inflammatory,5195,O
cell,5195,O
activation,5195,O
.,5195,O
CONCLUSION,5196,O
:,5196,O
Nanoparticles,5196,O
can,5196,O
induce,5196,O
signaling,5196,O
pathways,5196,O
",",5196,O
which,5196,O
amplify,5196,O
an,5196,O
inflammatory,5196,O
response,5196,O
in,5196,O
macrophages,5196,O
.,5196,O
Enhancing,5197,O
macrocyclic,5197,O
diterpenes,5197,B-CHEMICAL
as,5197,O
multidrug-resistance,5197,O
reversers,5197,O
:,5197,O
structure-activity,5197,O
studies,5197,O
on,5197,O
jolkinol,5197,B-CHEMICAL
D,5197,I-CHEMICAL
derivatives,5197,O
.,5197,O
The,5198,O
phytochemical,5198,O
study,5198,O
of,5198,O
Euphorbia,5198,O
piscatoria,5198,O
yielded,5198,O
jolkinol,5198,B-CHEMICAL
D,5198,I-CHEMICAL
(,5198,O
1,5198,O
),5198,O
in,5198,O
a,5198,O
large,5198,O
amount,5198,O
",",5198,O
whose,5198,O
derivatization,5198,O
gave,5198,O
rise,5198,O
to,5198,O
12,5198,O
ester,5198,B-CHEMICAL
derivatives,5198,O
(,5198,O
2-13,5198,O
),5198,O
and,5198,O
hydrolysis,5198,O
to,5198,O
compound,5198,O
14,5198,O
.,5198,O
The,5199,O
in,5199,O
vitro,5199,O
modulation,5199,O
of,5199,O
P-gp,5199,B-GENE-N
of,5199,O
compounds,5199,O
1-14,5199,O
was,5199,O
evaluated,5199,O
through,5199,O
a,5199,O
combination,5199,O
of,5199,O
transport,5199,O
and,5199,O
chemosensitivity,5199,O
assays,5199,O
",",5199,O
using,5199,O
the,5199,O
L5178,5199,O
mouse,5199,O
T,5199,O
lymphoma,5199,O
cell,5199,O
line,5199,O
transfected,5199,O
with,5199,O
the,5199,O
human,5199,B-GENE-Y
MDR1,5199,I-GENE-Y
gene,5199,O
.,5199,O
Apart,5200,O
from,5200,O
jolkinol,5200,B-CHEMICAL
D,5200,I-CHEMICAL
",",5200,O
all,5200,O
derivatives,5200,O
(,5200,O
2-14,5200,O
),5200,O
showed,5200,O
potential,5200,O
as,5200,O
MDR,5200,O
reversal,5200,O
agents,5200,O
.,5200,O
In,5201,O
this,5201,O
small,5201,O
library,5201,O
of,5201,O
novel,5201,O
bioactive,5201,O
macrocyclic,5201,O
lathyrane,5201,B-CHEMICAL
diterpene,5201,I-CHEMICAL
derivatives,5201,O
",",5201,O
designed,5201,O
to,5201,O
evaluate,5201,O
structure-activity,5201,O
relationships,5201,O
essential,5201,O
in,5201,O
overcoming,5201,O
multidrug,5201,O
resistance,5201,O
(,5201,O
MDR,5201,O
),5201,O
",",5201,O
some,5201,O
correlations,5201,O
between,5201,O
MDR,5201,O
reversal,5201,O
and,5201,O
molecular,5201,O
weight,5201,O
",",5201,O
accessible,5201,O
solvent,5201,O
areas,5201,O
",",5201,O
and,5201,O
octanol/water,5201,B-CHEMICAL
partition,5201,O
coefficient,5201,O
were,5201,O
identified,5201,O
that,5201,O
can,5201,O
contribute,5201,O
to,5201,O
the,5201,O
development,5201,O
of,5201,O
new,5201,O
selective,5201,O
P-gp,5201,B-GENE-N
reversal,5201,O
agents,5201,O
.,5201,O
Osteoblasts,5202,O
survive,5202,O
the,5202,O
arsenic,5202,B-CHEMICAL
trioxide,5202,I-CHEMICAL
treatment,5202,O
by,5202,O
activation,5202,O
of,5202,O
ATM-mediated,5202,B-GENE-Y
pathway,5202,O
.,5202,O
Arsenic,5203,B-CHEMICAL
trioxide,5203,I-CHEMICAL
(,5203,O
ATO,5203,B-CHEMICAL
),5203,O
is,5203,O
widely,5203,O
used,5203,O
in,5203,O
tumor,5203,O
treatment,5203,O
",",5203,O
but,5203,O
excessive,5203,O
arsenic,5203,B-CHEMICAL
exposure,5203,O
can,5203,O
have,5203,O
adverse,5203,O
effects,5203,O
.,5203,O
We,5204,O
recently,5204,O
found,5204,O
that,5204,O
",",5204,O
in,5204,O
primary,5204,O
osteoblasts,5204,O
",",5204,O
ATO,5204,B-CHEMICAL
produces,5204,O
oxidative,5204,O
stress,5204,O
and,5204,O
causes,5204,O
DNA,5204,O
tailing,5204,O
",",5204,O
but,5204,O
does,5204,O
not,5204,O
induce,5204,O
apoptosis,5204,O
.,5204,O
We,5205,O
further,5205,O
examined,5205,O
the,5205,O
signaling,5205,O
pathway,5205,O
by,5205,O
which,5205,O
osteoblasts,5205,O
survive,5205,O
ATO,5205,B-CHEMICAL
treatment,5205,O
",",5205,O
and,5205,O
found,5205,O
that,5205,O
they,5205,O
were,5205,O
arrested,5205,O
at,5205,O
G2/M,5205,O
phase,5205,O
of,5205,O
the,5205,O
cell,5205,O
cycle,5205,O
at,5205,O
30h,5205,O
and,5205,O
overrode,5205,O
the,5205,O
G2/M,5205,O
boundary,5205,O
at,5205,O
48h,5205,O
.,5205,O
After,5206,O
treatment,5206,O
for,5206,O
30h,5206,O
",",5206,O
there,5206,O
was,5206,O
increased,5206,O
Cdc2,5206,B-GENE-Y
phosphorylation,5206,O
and,5206,O
expression,5206,O
of,5206,O
Wee1,5206,B-GENE-Y
",",5206,O
a,5206,O
Cdc2,5206,B-GENE-Y
kinase,5206,B-GENE-N
",",5206,O
and,5206,O
expression,5206,O
of,5206,O
the,5206,O
cell,5206,O
cycle,5206,O
inhibitor,5206,O
",",5206,O
p21,5206,B-GENE-Y
(,5206,O
waf1/cip1,5206,B-GENE-Y
),5206,O
",",5206,O
which,5206,O
interacts,5206,O
with,5206,O
Cdc2,5206,B-GENE-Y
.,5206,O
Furthermore,5207,O
",",5207,O
levels,5207,O
of,5207,O
the,5207,O
phosphatase,5207,B-GENE-Y
Cdc25C,5207,I-GENE-Y
",",5207,O
which,5207,O
activates,5207,O
Cdc2,5207,B-GENE-Y
",",5207,O
were,5207,O
decreased,5207,O
",",5207,O
while,5207,O
the,5207,O
ratio,5207,O
of,5207,O
its,5207,O
phosphorylated/inactivated,5207,O
form,5207,O
to,5207,O
the,5207,O
total,5207,O
amount,5207,O
was,5207,O
increased,5207,O
.,5207,O
Moreover,5208,O
",",5208,O
phosphorylation/activation,5208,O
of,5208,O
the,5208,O
checkpoint,5208,O
kinases,5208,O
Chk1,5208,B-GENE-Y
",",5208,O
Chk2,5208,B-GENE-Y
and,5208,O
p53,5208,B-GENE-Y
levels,5208,O
were,5208,O
increased,5208,O
",",5208,O
as,5208,O
were,5208,O
levels,5208,O
of,5208,O
activated,5208,O
ATM,5208,B-GENE-Y
and,5208,O
γ-H2AX,5208,O
.,5208,O
The,5209,O
cell,5209,O
viability,5209,O
was,5209,O
decreased,5209,O
as,5209,O
an,5209,O
ATM,5209,B-GENE-Y
inhibitor,5209,O
was,5209,O
added,5209,O
.,5209,O
Additionally,5210,O
",",5210,O
these,5210,O
effects,5210,O
of,5210,O
ATO,5210,B-CHEMICAL
on,5210,O
γ-H2AX,5210,O
",",5210,O
Chk1,5210,B-GENE-Y
",",5210,O
Chk2,5210,B-GENE-Y
",",5210,O
p53,5210,B-GENE-Y
",",5210,O
and,5210,O
p21,5210,B-GENE-Y
(,5210,O
waf1/cip1,5210,B-GENE-Y
),5210,O
were,5210,O
reduced,5210,O
by,5210,O
an,5210,O
ATM,5210,B-GENE-Y
inhibitor,5210,O
.,5210,O
These,5211,O
findings,5211,O
suggest,5211,O
that,5211,O
G2/M,5211,O
phase,5211,O
arrest,5211,O
of,5211,O
osteoblasts,5211,O
is,5211,O
mediated,5211,O
by,5211,O
Chk1/Chk2,5211,B-GENE-Y
activation,5211,O
via,5211,O
an,5211,O
ATM-dependent,5211,B-GENE-Y
pathway,5211,O
by,5211,O
which,5211,O
osteoblasts,5211,O
survive,5211,O
.,5211,O
Structure,5212,O
prediction,5212,O
of,5212,O
binary,5212,O
pernitride,5212,B-CHEMICAL
MN2,5212,B-CHEMICAL
compounds,5212,O
(,5212,O
M=Ca,5212,O
",",5212,O
Sr,5212,B-CHEMICAL
",",5212,O
Ba,5212,B-CHEMICAL
",",5212,O
La,5212,B-CHEMICAL
",",5212,O
and,5212,O
Ti,5212,B-CHEMICAL
),5212,O
.,5212,O
Metal-pernitride,5213,B-CHEMICAL
compounds,5213,O
belong,5213,O
to,5213,O
a,5213,O
class,5213,O
of,5213,O
chemical,5213,O
systems,5213,O
in,5213,O
which,5213,O
both,5213,O
the,5213,O
complex,5213,O
ions,5213,O
and,5213,O
the,5213,O
non-bonding,5213,O
electrons,5213,O
may,5213,O
play,5213,O
roles,5213,O
in,5213,O
the,5213,O
formation,5213,O
of,5213,O
their,5213,O
modified,5213,O
crystalline,5213,O
structures,5213,O
.,5213,O
To,5214,O
investigate,5214,O
this,5214,O
issue,5214,O
",",5214,O
the,5214,O
energy,5214,O
landscapes,5214,O
of,5214,O
pernitrides,5214,B-CHEMICAL
of,5214,O
metals,5214,O
with,5214,O
different,5214,O
maximum,5214,O
valence,5214,O
(,5214,O
M=Ca,5214,O
",",5214,O
Sr,5214,B-CHEMICAL
",",5214,O
Ba,5214,B-CHEMICAL
",",5214,O
La,5214,B-CHEMICAL
",",5214,O
and,5214,O
Ti,5214,B-CHEMICAL
),5214,O
were,5214,O
globally,5214,O
explored,5214,O
on,5214,O
the,5214,O
ab,5214,O
initio,5214,O
level,5214,O
at,5214,O
standard,5214,O
and,5214,O
high,5214,O
pressures,5214,O
",",5214,O
thereby,5214,O
yielding,5214,O
possible,5214,O
(,5214,O
meta,5214,O
),5214,O
stable,5214,O
modifications,5214,O
in,5214,O
these,5214,O
systems,5214,O
together,5214,O
with,5214,O
information,5214,O
on,5214,O
how,5214,O
the,5214,O
landscape,5214,O
changed,5214,O
as,5214,O
function,5214,O
of,5214,O
the,5214,O
valence,5214,O
of,5214,O
the,5214,O
metal,5214,O
cation,5214,O
.,5214,O
For,5215,O
all,5215,O
of,5215,O
the,5215,O
systems,5215,O
in,5215,O
which,5215,O
no,5215,O
compounds,5215,O
had,5215,O
been,5215,O
synthesized,5215,O
so,5215,O
far,5215,O
",",5215,O
we,5215,O
predicted,5215,O
the,5215,O
existence,5215,O
of,5215,O
kinetically,5215,O
stable,5215,O
modifications,5215,O
that,5215,O
should,5215,O
",",5215,O
in,5215,O
principle,5215,O
",",5215,O
be,5215,O
experimentally,5215,O
accessible,5215,O
.,5215,O
In,5216,O
particular,5216,O
",",5216,O
TiN2,5216,B-CHEMICAL
should,5216,O
crystallize,5216,O
in,5216,O
a,5216,O
new,5216,O
structure,5216,O
type,5216,O
",",5216,O
TiN2-I,5216,B-CHEMICAL
.,5216,O
25-Hydroxyvitamin,5217,B-CHEMICAL
D,5217,I-CHEMICAL
in,5217,O
Obese,5217,O
Youth,5217,O
Across,5217,O
the,5217,O
Spectrum,5217,O
of,5217,O
Glucose,5217,B-CHEMICAL
Tolerance,5217,O
From,5217,O
Normal,5217,O
to,5217,O
Prediabetes,5217,O
to,5217,O
Type,5217,O
2,5217,O
Diabetes,5217,O
.,5217,O
OBJECTIVETo,5218,O
1,5218,O
),5218,O
determine,5218,O
if,5218,O
plasma,5218,O
25-hydroxyvitamin,5218,B-CHEMICAL
D,5218,I-CHEMICAL
(,5218,O
25,5218,B-CHEMICAL
[,5218,I-CHEMICAL
OH,5218,I-CHEMICAL
],5218,I-CHEMICAL
D,5218,I-CHEMICAL
),5218,O
concentrations,5218,O
differ,5218,O
among,5218,O
obese,5218,O
youth,5218,O
with,5218,O
normal,5218,O
glucose,5218,B-CHEMICAL
tolerance,5218,O
(,5218,O
NGT,5218,O
),5218,O
versus,5218,O
prediabetes,5218,O
versus,5218,O
type,5218,O
2,5218,O
diabetes,5218,O
",",5218,O
and,5218,O
2,5218,O
),5218,O
assess,5218,O
the,5218,O
relationships,5218,O
between,5218,O
25,5218,B-CHEMICAL
(,5218,I-CHEMICAL
OH,5218,I-CHEMICAL
),5218,I-CHEMICAL
D,5218,I-CHEMICAL
and,5218,O
in,5218,O
vivo,5218,O
insulin,5218,B-GENE-Y
sensitivity,5218,O
and,5218,O
β-cell,5218,O
function,5218,O
in,5218,O
this,5218,O
cohort.RESEARCH,5218,O
DESIGN,5218,O
AND,5218,O
METHODSPlasma,5218,O
25,5218,B-CHEMICAL
(,5218,I-CHEMICAL
OH,5218,I-CHEMICAL
),5218,I-CHEMICAL
D,5218,I-CHEMICAL
concentrations,5218,O
were,5218,O
examined,5218,O
in,5218,O
banked,5218,O
specimens,5218,O
in,5218,O
9-,5218,O
to,5218,O
20-year-old,5218,O
obese,5218,O
youth,5218,O
(,5218,O
n,5218,O
=,5218,O
175,5218,O
;,5218,O
male,5218,O
42.3,5218,O
%,5218,O
",",5218,O
black,5218,O
46.3,5218,O
%,5218,O
),5218,O
(,5218,O
NGT,5218,O
",",5218,O
n,5218,O
=,5218,O
105,5218,O
;,5218,O
impaired,5218,O
glucose,5218,B-CHEMICAL
tolerance,5218,O
[,5218,O
IGT,5218,O
],5218,O
",",5218,O
n,5218,O
=,5218,O
43,5218,O
;,5218,O
type,5218,O
2,5218,O
diabetes,5218,O
",",5218,O
n,5218,O
=,5218,O
27,5218,O
),5218,O
who,5218,O
had,5218,O
in,5218,O
vivo,5218,O
insulin,5218,B-GENE-Y
sensitivity,5218,O
and,5218,O
secretion,5218,O
measured,5218,O
by,5218,O
hyperinsulinemic-euglycemic,5218,O
and,5218,O
hyperglycemic,5218,O
clamp,5218,O
techniques,5218,O
and,5218,O
had,5218,O
an,5218,O
assessment,5218,O
of,5218,O
total,5218,O
body,5218,O
composition,5218,O
and,5218,O
abdominal,5218,O
adiposity.RESULTSThe,5218,O
mean,5218,O
age,5218,O
and,5218,O
BMI,5218,O
of,5218,O
the,5218,O
subjects,5218,O
were,5218,O
14.3,5218,O
±,5218,O
2.1,5218,O
years,5218,O
and,5218,O
35.7,5218,O
±,5218,O
5.6,5218,O
kg/m,5218,O
(,5218,O
2,5218,O
),5218,O
",",5218,O
respectively,5218,O
.,5218,O
BMI,5219,O
",",5219,O
plasma,5219,O
25,5219,B-CHEMICAL
(,5219,I-CHEMICAL
OH,5219,I-CHEMICAL
),5219,I-CHEMICAL
D,5219,I-CHEMICAL
",",5219,O
and,5219,O
the,5219,O
proportion,5219,O
of,5219,O
vitamin,5219,B-CHEMICAL
D-deficient,5219,O
and,5219,O
-insufficient,5219,O
children,5219,O
did,5219,O
not,5219,O
differ,5219,O
across,5219,O
the,5219,O
three,5219,O
groups,5219,O
.,5219,O
Furthermore,5220,O
",",5220,O
there,5220,O
was,5220,O
no,5220,O
association,5220,O
between,5220,O
25,5220,B-CHEMICAL
(,5220,I-CHEMICAL
OH,5220,I-CHEMICAL
),5220,I-CHEMICAL
D,5220,I-CHEMICAL
and,5220,O
in,5220,O
vivo,5220,O
insulin,5220,B-GENE-Y
sensitivity,5220,O
or,5220,O
β-cell,5220,O
function,5220,O
relative,5220,O
to,5220,O
insulin,5220,B-GENE-Y
sensitivity,5220,O
(,5220,O
disposition,5220,O
index,5220,O
),5220,O
in,5220,O
all,5220,O
groups,5220,O
combined,5220,O
or,5220,O
in,5220,O
each,5220,O
group,5220,O
separately.CONCLUSIONSOur,5220,O
data,5220,O
in,5220,O
obese,5220,O
youth,5220,O
show,5220,O
1,5220,O
),5220,O
no,5220,O
differences,5220,O
in,5220,O
plasma,5220,O
25,5220,B-CHEMICAL
(,5220,I-CHEMICAL
OH,5220,I-CHEMICAL
),5220,I-CHEMICAL
D,5220,I-CHEMICAL
concentrations,5220,O
across,5220,O
the,5220,O
glucose,5220,B-CHEMICAL
tolerance,5220,O
groups,5220,O
",",5220,O
and,5220,O
2,5220,O
),5220,O
no,5220,O
relationship,5220,O
between,5220,O
25,5220,B-CHEMICAL
(,5220,I-CHEMICAL
OH,5220,I-CHEMICAL
),5220,I-CHEMICAL
D,5220,I-CHEMICAL
and,5220,O
in,5220,O
vivo,5220,O
insulin,5220,B-GENE-Y
sensitivity,5220,O
and,5220,O
β-cell,5220,O
function,5220,O
relative,5220,O
to,5220,O
insulin,5220,B-GENE-Y
sensitivity,5220,O
in,5220,O
any,5220,O
of,5220,O
the,5220,O
groups,5220,O
.,5220,O
It,5221,O
remains,5221,O
uncertain,5221,O
if,5221,O
enhancement,5221,O
of,5221,O
the,5221,O
vitamin,5221,B-CHEMICAL
D,5221,I-CHEMICAL
status,5221,O
could,5221,O
improve,5221,O
pathophysiological,5221,O
mechanisms,5221,O
of,5221,O
prediabetes,5221,O
and,5221,O
type,5221,O
2,5221,O
diabetes,5221,O
in,5221,O
obese,5221,O
youth,5221,O
.,5221,O
Binary,5222,O
diffusion,5222,O
coefficients,5222,O
for,5222,O
mixtures,5222,O
of,5222,O
ionic,5222,O
liquids,5222,O
[,5222,B-CHEMICAL
EMIM,5222,I-CHEMICAL
],5222,I-CHEMICAL
[,5222,I-CHEMICAL
N,5222,I-CHEMICAL
(,5222,I-CHEMICAL
CN,5222,I-CHEMICAL
),5222,I-CHEMICAL
2,5222,I-CHEMICAL
],5222,I-CHEMICAL
",",5222,O
[,5222,B-CHEMICAL
EMIM,5222,I-CHEMICAL
],5222,I-CHEMICAL
[,5222,I-CHEMICAL
NTf2,5222,I-CHEMICAL
],5222,I-CHEMICAL
",",5222,O
and,5222,O
[,5222,B-CHEMICAL
HMIM,5222,I-CHEMICAL
],5222,I-CHEMICAL
[,5222,I-CHEMICAL
NTf2,5222,I-CHEMICAL
],5222,I-CHEMICAL
with,5222,O
acetone,5222,B-CHEMICAL
and,5222,O
ethanol,5222,B-CHEMICAL
by,5222,O
dynamic,5222,O
light,5222,O
scattering,5222,O
(,5222,O
DLS,5222,O
),5222,O
.,5222,O
Mutual,5223,O
diffusivities,5223,O
for,5223,O
binary,5223,O
mixtures,5223,O
of,5223,O
the,5223,O
ionic,5223,O
liquids,5223,O
(,5223,O
ILs,5223,O
),5223,O
[,5223,B-CHEMICAL
EMIM,5223,I-CHEMICAL
],5223,I-CHEMICAL
[,5223,I-CHEMICAL
N,5223,I-CHEMICAL
(,5223,I-CHEMICAL
CN,5223,I-CHEMICAL
),5223,I-CHEMICAL
2,5223,I-CHEMICAL
],5223,I-CHEMICAL
(,5223,O
1-ethyl-3-methylimidazolium,5223,B-CHEMICAL
dicyanimide,5223,I-CHEMICAL
),5223,O
",",5223,O
[,5223,B-CHEMICAL
EMIM,5223,I-CHEMICAL
],5223,I-CHEMICAL
[,5223,I-CHEMICAL
NTf2,5223,I-CHEMICAL
],5223,I-CHEMICAL
(,5223,O
1-ethyl-3-methylimidazolium,5223,B-CHEMICAL
bis,5223,I-CHEMICAL
(,5223,I-CHEMICAL
trifluoromethylsulfonyl,5223,I-CHEMICAL
),5223,I-CHEMICAL
imide,5223,I-CHEMICAL
),5223,O
",",5223,O
and,5223,O
[,5223,B-CHEMICAL
HMIM,5223,I-CHEMICAL
],5223,I-CHEMICAL
[,5223,I-CHEMICAL
NTf2,5223,I-CHEMICAL
],5223,I-CHEMICAL
(,5223,O
1-hexyl-3-methylimidazolium,5223,B-CHEMICAL
bis,5223,I-CHEMICAL
(,5223,I-CHEMICAL
trifluoromethylsulfonyl,5223,I-CHEMICAL
),5223,I-CHEMICAL
imide,5223,I-CHEMICAL
),5223,O
with,5223,O
acetone,5223,B-CHEMICAL
and,5223,O
ethanol,5223,B-CHEMICAL
were,5223,O
studied,5223,O
in,5223,O
dependence,5223,O
on,5223,O
composition,5223,O
in,5223,O
the,5223,O
temperature,5223,O
range,5223,O
from,5223,O
283.15,5223,O
to,5223,O
323.15,5223,O
K,5223,O
",",5223,O
applying,5223,O
dynamic,5223,O
light,5223,O
scattering,5223,O
(,5223,O
DLS,5223,O
),5223,O
.,5223,O
The,5224,O
influence,5224,O
of,5224,O
experimental,5224,O
parameters,5224,O
on,5224,O
the,5224,O
achievable,5224,O
uncertainties,5224,O
was,5224,O
analyzed,5224,O
to,5224,O
ensure,5224,O
the,5224,O
acquisition,5224,O
of,5224,O
accurate,5224,O
data,5224,O
in,5224,O
adequate,5224,O
measurement,5224,O
times,5224,O
.,5224,O
For,5225,O
all,5225,O
probed,5225,O
systems,5225,O
",",5225,O
increasing,5225,O
binary,5225,O
diffusion,5225,O
coefficients,5225,O
were,5225,O
found,5225,O
for,5225,O
increasing,5225,O
temperatures,5225,O
.,5225,O
The,5226,O
systematic,5226,O
variation,5226,O
of,5226,O
anion,5226,O
and,5226,O
cation,5226,O
of,5226,O
the,5226,O
investigated,5226,O
ILs,5226,O
as,5226,O
well,5226,O
as,5226,O
a,5226,O
comparison,5226,O
with,5226,O
the,5226,O
literature,5226,O
data,5226,O
demonstrates,5226,O
the,5226,O
considerable,5226,O
influence,5226,O
of,5226,O
different,5226,O
ions,5226,O
on,5226,O
the,5226,O
resulting,5226,O
binary,5226,O
diffusion,5226,O
coefficients,5226,O
.,5226,O
Mutual,5227,O
diffusivities,5227,O
were,5227,O
found,5227,O
to,5227,O
be,5227,O
lower,5227,O
for,5227,O
the,5227,O
mixtures,5227,O
with,5227,O
ethanol,5227,B-CHEMICAL
than,5227,O
for,5227,O
those,5227,O
with,5227,O
acetone,5227,B-CHEMICAL
",",5227,O
which,5227,O
could,5227,O
be,5227,O
related,5227,O
to,5227,O
the,5227,O
formation,5227,O
of,5227,O
hydrogen,5227,B-CHEMICAL
bonds,5227,O
between,5227,O
ethanol,5227,B-CHEMICAL
and,5227,O
the,5227,O
ions,5227,O
.,5227,O
Most,5228,O
of,5228,O
the,5228,O
investigated,5228,O
IL,5228,O
solvent,5228,O
mixtures,5228,O
show,5228,O
increasing,5228,O
binary,5228,O
diffusion,5228,O
coefficients,5228,O
with,5228,O
increasing,5228,O
solvent,5228,O
concentration,5228,O
.,5228,O
For,5229,O
the,5229,O
mixtures,5229,O
of,5229,O
[,5229,B-CHEMICAL
EMIM,5229,I-CHEMICAL
],5229,I-CHEMICAL
[,5229,I-CHEMICAL
NTf2,5229,I-CHEMICAL
],5229,I-CHEMICAL
with,5229,O
ethanol,5229,B-CHEMICAL
",",5229,O
however,5229,O
",",5229,O
a,5229,O
minimum,5229,O
of,5229,O
the,5229,O
mutual,5229,O
diffusivities,5229,O
was,5229,O
found,5229,O
in,5229,O
the,5229,O
ethanol,5229,B-CHEMICAL
mole,5229,O
fraction,5229,O
range,5229,O
from,5229,O
0.7,5229,O
to,5229,O
0.8,5229,O
",",5229,O
which,5229,O
may,5229,O
hint,5229,O
at,5229,O
the,5229,O
vicinity,5229,O
of,5229,O
a,5229,O
critical,5229,O
demixing,5229,O
point,5229,O
.,5229,O
The,5230,O
viscosity,5230,O
of,5230,O
the,5230,O
pure,5230,O
ILs,5230,O
turned,5230,O
out,5230,O
to,5230,O
be,5230,O
no,5230,O
reliable,5230,O
indicator,5230,O
for,5230,O
the,5230,O
mutual,5230,O
diffusivity,5230,O
in,5230,O
mixtures,5230,O
with,5230,O
the,5230,O
same,5230,O
solvent,5230,O
.,5230,O
Quercetin-loaded,5231,B-CHEMICAL
microcapsules,5231,O
ameliorate,5231,O
experimental,5231,O
colitis,5231,O
in,5231,O
mice,5231,O
by,5231,O
anti-inflammatory,5231,O
and,5231,O
antioxidant,5231,O
mechanisms,5231,O
.,5231,O
Quercetin,5232,B-CHEMICAL
(,5232,O
1,5232,O
),5232,O
is,5232,O
an,5232,O
anti-inflammatory,5232,O
and,5232,O
antioxidant,5232,O
flavonoid,5232,B-CHEMICAL
.,5232,O
However,5233,O
",",5233,O
the,5233,O
oral,5233,O
administration,5233,O
of,5233,O
1,5233,O
did,5233,O
not,5233,O
lead,5233,O
to,5233,O
beneficial,5233,O
effects,5233,O
in,5233,O
experimental,5233,O
animal,5233,O
colitis,5233,O
models,5233,O
",",5233,O
which,5233,O
involve,5233,O
cytokines,5233,B-GENE-N
and,5233,O
oxidative,5233,O
stress,5233,O
.,5233,O
A,5234,O
possible,5234,O
explanation,5234,O
is,5234,O
that,5234,O
the,5234,O
absorption,5234,O
profile,5234,O
of,5234,O
1,5234,O
prevents,5234,O
its,5234,O
activity,5234,O
.,5234,O
Therefore,5235,O
",",5235,O
it,5235,O
was,5235,O
reasoned,5235,O
that,5235,O
the,5235,O
controlled,5235,O
release,5235,O
of,5235,O
1,5235,O
would,5235,O
improve,5235,O
its,5235,O
therapeutic,5235,O
effect,5235,O
.,5235,O
Thus,5236,O
",",5236,O
the,5236,O
therapeutic,5236,O
effect,5236,O
and,5236,O
mechanisms,5236,O
of,5236,O
1-loaded,5236,O
microcapsules,5236,O
in,5236,O
acetic,5236,B-CHEMICAL
acid-induced,5236,O
colitis,5236,O
in,5236,O
mice,5236,O
were,5236,O
evaluated,5236,O
.,5236,O
Microcapsules,5237,O
were,5237,O
prepared,5237,O
using,5237,O
pectin/casein,5237,O
polymer,5237,O
and,5237,O
1,5237,O
.,5237,O
The,5238,O
oral,5238,O
administration,5238,O
of,5238,O
1-loaded,5238,O
microcapsules,5238,O
decreased,5238,O
neutrophil,5238,O
recruitment,5238,O
",",5238,O
attenuated,5238,O
histological,5238,O
alterations,5238,O
",",5238,O
and,5238,O
reduced,5238,O
macroscopical,5238,O
damage,5238,O
",",5238,O
edema,5238,O
",",5238,O
and,5238,O
IL-1β,5238,B-GENE-Y
and,5238,O
IL-33,5238,B-GENE-Y
production,5238,O
in,5238,O
the,5238,O
colon,5238,O
samples,5238,O
.,5238,O
Microcapsules,5239,O
loaded,5239,O
with,5239,O
1,5239,O
also,5239,O
prevented,5239,O
the,5239,O
reduction,5239,O
of,5239,O
anti-inflammatory,5239,O
cytokine,5239,B-GENE-N
IL-10,5239,B-GENE-Y
and,5239,O
the,5239,O
antioxidant,5239,O
capacity,5239,O
of,5239,O
the,5239,O
colon,5239,O
.,5239,O
These,5240,O
preclinical,5240,O
data,5240,O
indicate,5240,O
that,5240,O
pectin/casein,5240,O
polymer,5240,O
microcapsules,5240,O
loaded,5240,O
with,5240,O
1,5240,O
improved,5240,O
the,5240,O
anti-inflammatory,5240,O
and,5240,O
antioxidant,5240,O
effects,5240,O
of,5240,O
1,5240,O
compared,5240,O
to,5240,O
the,5240,O
nonencapsulated,5240,O
drug,5240,O
.,5240,O
Therefore,5241,O
",",5241,O
quercetin,5241,B-CHEMICAL
seems,5241,O
to,5241,O
be,5241,O
a,5241,O
promising,5241,O
active,5241,O
molecule,5241,O
in,5241,O
inflammatory,5241,O
bowel,5241,O
disease,5241,O
if,5241,O
provided,5241,O
with,5241,O
adequate,5241,O
controlled,5241,O
release,5241,O
.,5241,O
Dietary,5242,O
relevant,5242,O
mixtures,5242,O
of,5242,O
phytoestrogens,5242,O
inhibit,5242,O
adipocyte,5242,O
differentiation,5242,O
in,5242,O
vitro,5242,O
.,5242,O
Phytoestrogens,5243,O
(,5243,O
PEs,5243,O
),5243,O
are,5243,O
naturally,5243,O
occurring,5243,O
plant,5243,O
components,5243,O
",",5243,O
with,5243,O
the,5243,O
ability,5243,O
to,5243,O
induce,5243,O
biological,5243,O
responses,5243,O
in,5243,O
vertebrates,5243,O
by,5243,O
mimicking,5243,O
or,5243,O
modulating,5243,O
the,5243,O
action,5243,O
of,5243,O
endogenous,5243,O
hormones,5243,O
.,5243,O
Single,5244,O
isoflavones,5244,B-CHEMICAL
have,5244,O
been,5244,O
shown,5244,O
to,5244,O
affect,5244,O
adipocyte,5244,O
differentiation,5244,O
",",5244,O
but,5244,O
knowledge,5244,O
on,5244,O
the,5244,O
effect,5244,O
of,5244,O
dietary,5244,O
relevant,5244,O
mixtures,5244,O
of,5244,O
PEs,5244,O
",",5244,O
including,5244,O
for,5244,O
instance,5244,O
lignans,5244,O
",",5244,O
is,5244,O
lacking,5244,O
.,5244,O
In,5245,O
the,5245,O
current,5245,O
study,5245,O
dietary,5245,O
relevant,5245,O
mixtures,5245,O
of,5245,O
isoflavones,5245,B-CHEMICAL
and,5245,O
their,5245,O
metabolites,5245,O
",",5245,O
lignans,5245,B-CHEMICAL
and,5245,O
their,5245,O
metabolites,5245,O
",",5245,O
coumestrol,5245,B-CHEMICAL
",",5245,O
and,5245,O
a,5245,O
mixture,5245,O
containing,5245,O
all,5245,O
of,5245,O
them,5245,O
",",5245,O
were,5245,O
examined,5245,O
for,5245,O
effects,5245,O
on,5245,O
adipogenesis,5245,O
in,5245,O
3T3-L1,5245,O
adipocytes,5245,O
",",5245,O
as,5245,O
well,5245,O
as,5245,O
tested,5245,O
for,5245,O
their,5245,O
PPARγ,5245,B-GENE-Y
activating,5245,O
abilities,5245,O
.,5245,O
The,5246,O
results,5246,O
showed,5246,O
that,5246,O
mixtures,5246,O
of,5246,O
isoflavonoid,5246,B-CHEMICAL
parent,5246,O
compounds,5246,O
and,5246,O
metabolites,5246,O
",",5246,O
respectively,5246,O
",",5246,O
a,5246,O
mixture,5246,O
of,5246,O
lignan,5246,B-CHEMICAL
metabolites,5246,O
",",5246,O
as,5246,O
well,5246,O
as,5246,O
coumestrol,5246,B-CHEMICAL
concentration-dependently,5246,O
inhibited,5246,O
adipocyte,5246,O
differentiation,5246,O
.,5246,O
Furthermore,5247,O
",",5247,O
a,5247,O
mixture,5247,O
of,5247,O
isoflavonoid,5247,B-CHEMICAL
parent,5247,O
compounds,5247,O
",",5247,O
and,5247,O
a,5247,O
mixture,5247,O
of,5247,O
isoflavonoid,5247,B-CHEMICAL
metabolites,5247,O
were,5247,O
found,5247,O
to,5247,O
have,5247,O
PPARγ,5247,B-GENE-Y
activating,5247,O
abilities,5247,O
.,5247,O
These,5248,O
results,5248,O
suggest,5248,O
that,5248,O
PEs,5248,O
can,5248,O
affect,5248,O
pathways,5248,O
known,5248,O
to,5248,O
play,5248,O
a,5248,O
role,5248,O
in,5248,O
obesity,5248,O
development,5248,O
",",5248,O
and,5248,O
indicate,5248,O
that,5248,O
the,5248,O
inhibitory,5248,O
effect,5248,O
on,5248,O
adipocyte,5248,O
differentiation,5248,O
does,5248,O
not,5248,O
appear,5248,O
to,5248,O
be,5248,O
strictly,5248,O
associated,5248,O
with,5248,O
PPARγ,5248,B-GENE-Y
activation/inhibition,5248,O
.,5248,O
The,5249,O
current,5249,O
study,5249,O
support,5249,O
the,5249,O
hypothesis,5249,O
that,5249,O
compounds,5249,O
with,5249,O
endocrine,5249,O
activity,5249,O
can,5249,O
affect,5249,O
pathways,5249,O
playing,5249,O
a,5249,O
role,5249,O
in,5249,O
the,5249,O
development,5249,O
obesity,5249,O
and,5249,O
obesity,5249,O
related,5249,O
diseases,5249,O
.,5249,O
Anti-inflammatory,5250,O
activity,5250,O
of,5250,O
patchouli,5250,B-CHEMICAL
alcohol,5250,I-CHEMICAL
in,5250,O
RAW264.7,5250,O
and,5250,O
HT-29,5250,O
cells,5250,O
.,5250,O
Patchouli,5251,B-CHEMICAL
alcohol,5251,I-CHEMICAL
(,5251,O
PA,5251,O
),5251,O
is,5251,O
a,5251,O
chemical,5251,O
compound,5251,O
extracted,5251,O
from,5251,O
patchouli,5251,O
which,5251,O
belongs,5251,O
to,5251,O
the,5251,O
genus,5251,O
Pogostemon,5251,O
",",5251,O
herb,5251,O
of,5251,O
mint,5251,O
family,5251,O
.,5251,O
Recently,5252,O
",",5252,O
it,5252,O
has,5252,O
been,5252,O
reported,5252,O
that,5252,O
PA,5252,O
inhibits,5252,O
the,5252,O
production,5252,O
of,5252,O
inflammatory,5252,O
mediators,5252,O
.,5252,O
However,5253,O
",",5253,O
the,5253,O
biological,5253,O
mechanisms,5253,O
of,5253,O
PA,5253,O
for,5253,O
anti-inflammatory,5253,O
activities,5253,O
have,5253,O
not,5253,O
been,5253,O
studied,5253,O
.,5253,O
In,5254,O
this,5254,O
study,5254,O
",",5254,O
we,5254,O
investigated,5254,O
whether,5254,O
PA,5254,O
decreases,5254,O
the,5254,O
production,5254,O
of,5254,O
inflammatory,5254,O
mediators,5254,O
through,5254,O
downregulation,5254,O
of,5254,O
the,5254,O
NF-κB,5254,B-GENE-N
and,5254,O
ERK,5254,B-GENE-N
pathway,5254,O
.,5254,O
Our,5255,O
data,5255,O
indicated,5255,O
that,5255,O
PA,5255,O
inhibits,5255,O
the,5255,O
over-expression,5255,O
of,5255,O
iNOS,5255,B-GENE-N
and,5255,O
IL-6,5255,B-GENE-N
in,5255,O
protein,5255,O
and,5255,O
mRNA,5255,O
levels,5255,O
in,5255,O
LPS-stimulated,5255,O
RAW264.7,5255,O
and,5255,O
TNF-α,5255,B-GENE-Y
stimulated,5255,O
HT-29,5255,O
cells,5255,O
.,5255,O
PA,5256,O
inhibited,5256,O
IκB-α,5256,B-GENE-N
degradation,5256,O
and,5256,O
p65,5256,B-GENE-N
nuclear,5256,O
translocation,5256,O
",",5256,O
and,5256,O
subsequently,5256,O
suppressed,5256,O
transcriptional,5256,O
activity,5256,O
of,5256,O
NF-κB,5256,B-GENE-N
in,5256,O
LPS-stimulated,5256,O
RAW264.7,5256,O
and,5256,O
TNF-α-stimulated,5256,B-GENE-Y
HT-29,5256,O
cells,5256,O
.,5256,O
In,5257,O
addition,5257,O
",",5257,O
PA,5257,O
inhibited,5257,O
LPS-,5257,O
or,5257,O
TNF-α-stimulated,5257,B-GENE-Y
ERK1/2,5257,B-GENE-N
activation,5257,O
by,5257,O
decreasing,5257,O
phosphorylation,5257,O
of,5257,O
ERK1/2,5257,B-GENE-N
.,5257,O
These,5258,O
findings,5258,O
suggest,5258,O
that,5258,O
PA,5258,O
shows,5258,O
anti-inflammatory,5258,O
activities,5258,O
through,5258,O
suppressing,5258,O
ERK-mediated,5258,B-GENE-N
NF-κB,5258,B-GENE-N
pathway,5258,O
in,5258,O
mouse,5258,O
macrophage,5258,O
and,5258,O
human,5258,O
colorectal,5258,O
cancer,5258,O
cells,5258,O
.,5258,O
Evaluation,5259,O
of,5259,O
suppressive,5259,O
and,5259,O
pro-resolving,5259,O
effects,5259,O
of,5259,O
EPA,5259,B-CHEMICAL
and,5259,O
DHA,5259,B-CHEMICAL
in,5259,O
human,5259,O
primary,5259,O
monocytes,5259,O
and,5259,O
T-helper,5259,O
cells,5259,O
.,5259,O
Despite,5260,O
their,5260,O
beneficial,5260,O
anti-inflammatory,5260,O
properties,5260,O
",",5260,O
eicosapentaenoic,5260,B-CHEMICAL
acid,5260,I-CHEMICAL
(,5260,O
EPA,5260,B-CHEMICAL
),5260,O
and,5260,O
docosahexaenoic,5260,B-CHEMICAL
acid,5260,I-CHEMICAL
(,5260,O
DHA,5260,B-CHEMICAL
),5260,O
may,5260,O
increase,5260,O
the,5260,O
infection,5260,O
risk,5260,O
at,5260,O
high,5260,O
doses,5260,O
",",5260,O
likely,5260,O
by,5260,O
generating,5260,O
an,5260,O
immune-depressed,5260,O
state,5260,O
.,5260,O
To,5261,O
assess,5261,O
the,5261,O
contribution,5261,O
of,5261,O
different,5261,O
immune,5261,O
cell,5261,O
populations,5261,O
to,5261,O
the,5261,O
immunomodulatory,5261,O
fatty,5261,B-CHEMICAL
acid,5261,I-CHEMICAL
effect,5261,O
",",5261,O
we,5261,O
comparatively,5261,O
investigated,5261,O
several,5261,O
aspects,5261,O
of,5261,O
inflammation,5261,O
in,5261,O
human,5261,O
T-helper,5261,O
(,5261,O
Th,5261,O
),5261,O
cells,5261,O
and,5261,O
monocytes,5261,O
.,5261,O
Both,5262,O
fatty,5262,B-CHEMICAL
acids,5262,I-CHEMICAL
",",5262,O
but,5262,O
DHA,5262,B-CHEMICAL
to,5262,O
a,5262,O
lesser,5262,O
extent,5262,O
compared,5262,O
with,5262,O
EPA,5262,B-CHEMICAL
",",5262,O
selectively,5262,O
and,5262,O
dose-dependently,5262,O
reduced,5262,O
the,5262,O
percentage,5262,O
of,5262,O
cytokine-expressing,5262,B-GENE-N
Th,5262,O
cells,5262,O
in,5262,O
a,5262,O
peroxisome,5262,B-GENE-Y
proliferator-activated,5262,I-GENE-Y
receptor,5262,I-GENE-Y
(,5262,I-GENE-Y
PPAR,5262,I-GENE-Y
),5262,I-GENE-Y
γ-dependent,5262,O
fashion,5262,O
",",5262,O
whereas,5262,O
the,5262,O
expression,5262,O
of,5262,O
the,5262,O
cell,5262,O
surface,5262,O
marker,5262,O
CD69,5262,B-GENE-Y
was,5262,O
unaltered,5262,O
on,5262,O
activated,5262,O
T,5262,O
cells,5262,O
.,5262,O
In,5263,O
monocytes,5263,O
",",5263,O
both,5263,O
EPA,5263,B-CHEMICAL
and,5263,O
DHA,5263,B-CHEMICAL
increased,5263,O
interleukin,5263,B-GENE-Y
(,5263,I-GENE-Y
IL,5263,I-GENE-Y
),5263,I-GENE-Y
-10,5263,I-GENE-Y
without,5263,O
affecting,5263,O
tumor,5263,B-GENE-Y
necrosis,5263,I-GENE-Y
factor,5263,I-GENE-Y
(,5263,I-GENE-Y
TNF,5263,I-GENE-Y
),5263,I-GENE-Y
-α,5263,I-GENE-Y
and,5263,O
IL-6,5263,B-GENE-Y
.,5263,O
Cellular,5264,O
incorporation,5264,O
of,5264,O
EPA,5264,B-CHEMICAL
and,5264,O
DHA,5264,B-CHEMICAL
occurred,5264,O
mainly,5264,O
at,5264,O
the,5264,O
expense,5264,O
of,5264,O
arachidonic,5264,B-CHEMICAL
acid,5264,I-CHEMICAL
.,5264,O
Concomitantly,5265,O
",",5265,O
thromboxane,5265,B-CHEMICAL
B,5265,I-CHEMICAL
(,5265,B-CHEMICAL
TXB,5265,I-CHEMICAL
),5265,I-CHEMICAL
2,5265,I-CHEMICAL
and,5265,O
leukotriene,5265,B-CHEMICAL
B,5265,I-CHEMICAL
(,5265,B-CHEMICAL
LTB,5265,I-CHEMICAL
),5265,I-CHEMICAL
4,5265,I-CHEMICAL
in,5265,O
supernatants,5265,O
decreased,5265,O
",",5265,O
while,5265,O
levels,5265,O
of,5265,O
TXB3,5265,B-CHEMICAL
and,5265,O
LTB5,5265,B-CHEMICAL
increased,5265,O
.,5265,O
This,5266,O
increase,5266,O
was,5266,O
independent,5266,O
of,5266,O
activation,5266,O
and,5266,O
in,5266,O
accordance,5266,O
with,5266,O
cyclooxygenase,5266,B-GENE-N
expression,5266,O
patterns,5266,O
in,5266,O
monocytes,5266,O
.,5266,O
Moreover,5267,O
",",5267,O
EPA,5267,B-CHEMICAL
and,5267,O
DHA,5267,B-CHEMICAL
gave,5267,O
rise,5267,O
to,5267,O
a,5267,O
variety,5267,O
of,5267,O
mono-,5267,B-CHEMICAL
and,5267,I-CHEMICAL
trihydroxy,5267,I-CHEMICAL
derivatives,5267,O
of,5267,O
highly,5267,O
anti-inflammatory,5267,O
potential,5267,O
",",5267,O
such,5267,O
as,5267,O
resolvins,5267,B-CHEMICAL
and,5267,O
their,5267,O
precursors,5267,O
.,5267,O
Our,5268,O
results,5268,O
suggest,5268,O
that,5268,O
EPA,5268,B-CHEMICAL
and,5268,O
DHA,5268,B-CHEMICAL
do,5268,O
not,5268,O
generally,5268,O
affect,5268,O
immune,5268,O
cell,5268,O
functions,5268,O
in,5268,O
an,5268,O
inhibitory,5268,O
manner,5268,O
but,5268,O
rather,5268,O
promote,5268,O
pro-resolving,5268,O
responses,5268,O
.,5268,O
Cell,5269,O
penetrating,5269,O
peptide,5269,O
tethered,5269,O
bi-ligand,5269,O
liposomes,5269,O
for,5269,O
delivery,5269,O
to,5269,O
brain,5269,O
in,5269,O
vivo,5269,O
:,5269,O
Biodistribution,5269,O
and,5269,O
transfection,5269,O
.,5269,O
Targeted,5270,O
nano-particulate,5270,O
systems,5270,O
hold,5270,O
extraordinary,5270,O
potential,5270,O
for,5270,O
delivery,5270,O
of,5270,O
therapeutics,5270,O
across,5270,O
blood,5270,O
brain,5270,O
barrier,5270,O
(,5270,O
BBB,5270,O
),5270,O
.,5270,O
In,5271,O
this,5271,O
work,5271,O
",",5271,O
we,5271,O
investigated,5271,O
the,5271,O
potential,5271,O
of,5271,O
novel,5271,O
bi-ligand,5271,O
(,5271,O
transferrin-poly-l-arginine,5271,O
),5271,O
liposomal,5271,O
vector,5271,O
for,5271,O
delivery,5271,O
of,5271,O
desired,5271,O
gene,5271,O
to,5271,O
brain,5271,O
",",5271,O
in,5271,O
vivo,5271,O
.,5271,O
The,5272,O
in,5272,O
vivo,5272,O
evaluation,5272,O
of,5272,O
the,5272,O
delivery,5272,O
vectors,5272,O
is,5272,O
essential,5272,O
for,5272,O
clinical,5272,O
translation,5272,O
.,5272,O
We,5273,O
followed,5273,O
an,5273,O
innovative,5273,O
approach,5273,O
of,5273,O
combining,5273,O
transferrin,5273,O
receptor,5273,O
targeting,5273,O
with,5273,O
enhanced,5273,O
cell,5273,O
penetration,5273,O
to,5273,O
design,5273,O
liposomal,5273,O
vectors,5273,O
for,5273,O
improving,5273,O
the,5273,O
transport,5273,O
of,5273,O
molecules,5273,O
into,5273,O
brain,5273,O
.,5273,O
The,5274,O
biodistribution,5274,O
profile,5274,O
of,5274,O
1,5274,B-CHEMICAL
",",5274,I-CHEMICAL
"1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine",5274,I-CHEMICAL
iodide,5274,I-CHEMICAL
(,5274,O
DiR,5274,B-CHEMICAL
),5274,O
-labeled,5274,O
liposomes,5274,O
was,5274,O
evaluated,5274,O
in,5274,O
adult,5274,O
rats,5274,O
after,5274,O
single,5274,O
intravenous,5274,O
injection,5274,O
at,5274,O
dose,5274,O
of,5274,O
15.2μmoles,5274,O
of,5274,O
phospholipids/kg,5274,O
body,5274,O
weight,5274,O
.,5274,O
We,5275,O
demonstrated,5275,O
that,5275,O
bi-ligand,5275,O
liposomes,5275,O
accumulated,5275,O
in,5275,O
rat,5275,O
brain,5275,O
at,5275,O
significantly,5275,O
(,5275,O
p,5275,O
<,5275,O
0.05,5275,O
),5275,O
higher,5275,O
concentrations,5275,O
as,5275,O
compared,5275,O
to,5275,O
the,5275,O
single-ligand,5275,O
(,5275,O
transferrin,5275,B-GENE-Y
),5275,O
or,5275,O
plain,5275,O
liposomes,5275,O
.,5275,O
In,5276,O
addition,5276,O
",",5276,O
the,5276,O
bi-ligand,5276,O
liposomes,5276,O
resulted,5276,O
in,5276,O
increased,5276,O
expression,5276,O
of,5276,O
β-galactosidase,5276,B-GENE-Y
(,5276,O
β-gal,5276,B-GENE-Y
),5276,O
plasmid,5276,O
in,5276,O
rat,5276,O
brain,5276,O
tissue,5276,O
in,5276,O
comparison,5276,O
to,5276,O
the,5276,O
single-ligand,5276,O
liposomes,5276,O
.,5276,O
Histological,5277,O
examination,5277,O
of,5277,O
the,5277,O
transfected,5277,O
tissues,5277,O
did,5277,O
not,5277,O
show,5277,O
any,5277,O
signs,5277,O
of,5277,O
tissue,5277,O
necrosis,5277,O
or,5277,O
inflammation,5277,O
.,5277,O
Hemolysis,5278,O
assay,5278,O
further,5278,O
authenticated,5278,O
the,5278,O
biocompatibility,5278,O
of,5278,O
bi-ligand,5278,O
liposomes,5278,O
in,5278,O
blood,5278,O
up,5278,O
to,5278,O
600,5278,O
nmoles,5278,O
of,5278,O
phospholipids/1.4×10,5278,O
(,5278,O
7,5278,O
),5278,O
erythrocytes,5278,O
.,5278,O
The,5279,O
findings,5279,O
of,5279,O
this,5279,O
study,5279,O
provide,5279,O
important,5279,O
and,5279,O
detailed,5279,O
information,5279,O
regarding,5279,O
the,5279,O
distribution,5279,O
of,5279,O
bi-ligand,5279,O
liposomes,5279,O
in,5279,O
vivo,5279,O
and,5279,O
accentuate,5279,O
their,5279,O
ability,5279,O
to,5279,O
demonstrate,5279,O
improved,5279,O
brain,5279,O
penetration,5279,O
and,5279,O
transfection,5279,O
potential,5279,O
over,5279,O
single-ligand,5279,O
liposomes,5279,O
.,5279,O
Encapsulation,5280,O
of,5280,O
Nod1,5280,B-GENE-Y
and,5280,O
Nod2,5280,B-GENE-Y
receptor,5280,O
ligands,5280,O
into,5280,O
poly,5280,B-CHEMICAL
(,5280,I-CHEMICAL
lactic,5280,I-CHEMICAL
acid,5280,I-CHEMICAL
),5280,I-CHEMICAL
nanoparticles,5280,O
potentiates,5280,O
their,5280,O
immune,5280,O
properties,5280,O
.,5280,O
Most,5281,O
successful,5281,O
vaccines,5281,O
are,5281,O
able,5281,O
to,5281,O
induce,5281,O
persistent,5281,O
antibody,5281,O
responses,5281,O
that,5281,O
can,5281,O
last,5281,O
a,5281,O
lifetime,5281,O
.,5281,O
Emerging,5282,O
evidences,5282,O
indicate,5282,O
that,5282,O
activation,5282,O
of,5282,O
immune,5282,O
cells,5282,O
through,5282,O
pattern,5282,B-GENE-N
recognition,5282,I-GENE-N
receptors,5282,I-GENE-N
(,5282,O
PRRs,5282,B-GENE-N
),5282,O
such,5282,O
as,5282,O
Toll-like,5282,B-GENE-N
receptors,5282,I-GENE-N
(,5282,O
TLRs,5282,B-GENE-N
),5282,O
or,5282,O
Nod-like,5282,B-GENE-N
receptors,5282,I-GENE-N
(,5282,O
NLRs,5282,B-GENE-N
),5282,O
may,5282,O
be,5282,O
critical,5282,O
mechanisms,5282,O
.,5282,O
Among,5283,O
PRRs,5283,B-GENE-N
",",5283,O
the,5283,O
use,5283,O
of,5283,O
TLR,5283,B-GENE-N
ligands,5283,O
as,5283,O
adjuvants,5283,O
is,5283,O
already,5283,O
largely,5283,O
described,5283,O
whereas,5283,O
the,5283,O
use,5283,O
of,5283,O
NLRs,5283,B-GENE-N
ligands,5283,O
remains,5283,O
largely,5283,O
unexplored,5283,O
.,5283,O
As,5284,O
activation,5284,O
of,5284,O
intracytoplasmic,5284,O
NLRs,5284,B-GENE-N
is,5284,O
able,5284,O
to,5284,O
induce,5284,O
proinflammatory,5284,O
molecules,5284,O
",",5284,O
the,5284,O
added,5284,O
value,5284,O
of,5284,O
encapsulation,5284,O
of,5284,O
Nod1,5284,B-GENE-Y
and,5284,O
Nod2,5284,B-GENE-Y
receptor,5284,O
ligands,5284,O
into,5284,O
Poly,5284,B-CHEMICAL
(,5284,I-CHEMICAL
Lactic,5284,I-CHEMICAL
Acid,5284,I-CHEMICAL
),5284,I-CHEMICAL
(,5284,O
PLA,5284,B-CHEMICAL
),5284,O
biodegradable,5284,O
nanocarriers,5284,O
to,5284,O
modulate,5284,O
their,5284,O
immune,5284,O
properties,5284,O
on,5284,O
human,5284,O
dendritic,5284,O
cells,5284,O
(,5284,O
DCs,5284,O
),5284,O
maturation,5284,O
has,5284,O
been,5284,O
evaluated,5284,O
.,5284,O
Their,5285,O
ability,5285,O
to,5285,O
induce,5285,O
systemic,5285,O
immune,5285,O
responses,5285,O
in,5285,O
mice,5285,O
was,5285,O
also,5285,O
measured,5285,O
and,5285,O
compared,5285,O
to,5285,O
free,5285,O
ligands,5285,O
and,5285,O
the,5285,O
Alum,5285,O
adjuvant,5285,O
.,5285,O
Nod,5286,B-GENE-N
ligands,5286,O
encapsulated,5286,O
into,5286,O
PLA,5286,B-CHEMICAL
NPs,5286,O
were,5286,O
efficiently,5286,O
taken,5286,O
up,5286,O
by,5286,O
DCs,5286,O
and,5286,O
subsequently,5286,O
induced,5286,O
a,5286,O
strong,5286,O
up-regulation,5286,O
of,5286,O
maturation,5286,O
markers,5286,O
and,5286,O
the,5286,O
enhancement,5286,O
of,5286,O
proinflammatory,5286,O
cytokine,5286,B-GENE-N
secretion,5286,O
by,5286,O
DCs,5286,O
.,5286,O
Furthermore,5287,O
",",5287,O
co-injection,5287,O
of,5287,O
encapsulated,5287,O
Nod-ligands,5287,B-GENE-N
with,5287,O
PLA,5287,B-CHEMICAL
particles,5287,O
carrying,5287,O
Gag,5287,B-GENE-N
p24,5287,I-GENE-N
HIV-1,5287,O
antigen,5287,O
allowed,5287,O
a,5287,O
100,5287,O
fold,5287,O
increase,5287,O
in,5287,O
antibody,5287,O
responses,5287,O
in,5287,O
comparison,5287,O
to,5287,O
Alum,5287,O
.,5287,O
These,5288,O
results,5288,O
suggest,5288,O
that,5288,O
encapsulation,5288,O
of,5288,O
Nod,5288,B-GENE-N
ligands,5288,O
into,5288,O
PLA-NPs,5288,B-CHEMICAL
could,5288,O
be,5288,O
an,5288,O
effective,5288,O
way,5288,O
to,5288,O
improve,5288,O
vaccine,5288,O
efficiency,5288,O
.,5288,O
In,5289,O
vitro,5289,O
permeability,5289,O
analysis,5289,O
",",5289,O
pharmacokinetic,5289,O
and,5289,O
brain,5289,O
distribution,5289,O
study,5289,O
in,5289,O
mice,5289,O
of,5289,O
imperatorin,5289,B-CHEMICAL
",",5289,O
isoimperatorin,5289,B-CHEMICAL
and,5289,O
cnidilin,5289,B-CHEMICAL
in,5289,O
Radix,5289,O
Angelicae,5289,O
Dahuricae,5289,O
.,5289,O
Coumarins,5290,B-CHEMICAL
are,5290,O
important,5290,O
constituents,5290,O
of,5290,O
Radix,5290,O
Angelicae,5290,O
Dahuricae,5290,O
",",5290,O
a,5290,O
well-known,5290,O
traditional,5290,O
Chinese,5290,O
medicine,5290,O
possess,5290,O
several,5290,O
known,5290,O
bioactivities,5290,O
with,5290,O
potentials,5290,O
in,5290,O
the,5290,O
treatment,5290,O
of,5290,O
central,5290,O
nervous,5290,O
system,5290,O
diseases,5290,O
.,5290,O
By,5291,O
using,5291,O
an,5291,O
HPLC-MS/MS,5291,O
method,5291,O
",",5291,O
we,5291,O
analyzed,5291,O
the,5291,O
in,5291,O
vivo,5291,O
plasma,5291,O
and,5291,O
brain,5291,O
pharmacokinetics,5291,O
of,5291,O
three,5291,O
ingredients,5291,O
of,5291,O
coumarins,5291,B-CHEMICAL
",",5291,O
including,5291,O
imperatorin,5291,B-CHEMICAL
",",5291,O
isoimperatorin,5291,B-CHEMICAL
and,5291,O
cnidilin,5291,B-CHEMICAL
in,5291,O
mice,5291,O
after,5291,O
oral,5291,O
administration,5291,O
of,5291,O
Dahuricae,5291,O
extract,5291,O
at,5291,O
doses,5291,O
of,5291,O
800mg/kg,5291,O
.,5291,O
The,5292,O
biosamples,5292,O
were,5292,O
prepared,5292,O
using,5292,O
acetonitrile,5292,B-CHEMICAL
precipitation,5292,O
and,5292,O
the,5292,O
separation,5292,O
was,5292,O
achieved,5292,O
on,5292,O
an,5292,O
XDB-C18,5292,O
column,5292,O
by,5292,O
gradient,5292,O
elution,5292,O
.,5292,O
The,5293,O
BBB,5293,O
permeability,5293,O
and,5293,O
P-gp-mediated,5293,B-GENE-N
efflux,5293,O
were,5293,O
further,5293,O
examined,5293,O
in,5293,O
Madin,5293,O
Canine,5293,O
kidney,5293,O
cells,5293,O
transfected,5293,O
with,5293,O
full,5293,O
length,5293,O
cDNA,5293,O
for,5293,O
human,5293,B-GENE-Y
multidrug,5293,I-GENE-Y
resistance,5293,I-GENE-Y
gene1,5293,I-GENE-Y
(,5293,O
MDCKII-MDR1,5293,O
),5293,O
.,5293,O
Our,5294,O
results,5294,O
demonstrate,5294,O
that,5294,O
the,5294,O
method,5294,O
has,5294,O
excellent,5294,O
and,5294,O
satisfactory,5294,O
selectivity,5294,O
",",5294,O
sensitivity,5294,O
",",5294,O
linearity,5294,O
",",5294,O
precision,5294,O
",",5294,O
and,5294,O
accuracy,5294,O
for,5294,O
simultaneous,5294,O
determination,5294,O
of,5294,O
imperatorin,5294,B-CHEMICAL
",",5294,O
isoimperatorin,5294,B-CHEMICAL
and,5294,O
cnidilin,5294,B-CHEMICAL
.,5294,O
The,5295,O
pharmacokinetics,5295,O
parameters,5295,O
were,5295,O
determined,5295,O
by,5295,O
using,5295,O
noncompartmental,5295,O
analyses,5295,O
",",5295,O
including,5295,O
the,5295,O
AUC,5295,O
(,5295,O
0-t,5295,O
),5295,O
in,5295,O
plasma,5295,O
(,5295,O
1695.22,5295,O
",",5295,O
1326.45,5295,O
and,5295,O
636.98mg,5295,O
*,5295,O
h/L,5295,O
),5295,O
",",5295,O
the,5295,O
AUC,5295,O
(,5295,O
0-t,5295,O
),5295,O
in,5295,O
brain,5295,O
(,5295,O
1812.35,5295,O
",",5295,O
2125.17,5295,O
and,5295,O
1145.83ng,5295,O
*,5295,O
h/g,5295,O
),5295,O
as,5295,O
well,5295,O
as,5295,O
the,5295,O
T1/2,5295,O
in,5295,O
plasma,5295,O
(,5295,O
0.66,5295,O
",",5295,O
0.82,5295,O
",",5295,O
0.97h,5295,O
),5295,O
and,5295,O
brain,5295,O
(,5295,O
0.96,5295,O
",",5295,O
1.1,5295,O
",",5295,O
0.99h,5295,O
),5295,O
for,5295,O
imperatorin,5295,B-CHEMICAL
",",5295,O
isoimperatorin,5295,B-CHEMICAL
and,5295,O
cnidilin,5295,B-CHEMICAL
",",5295,O
respectively,5295,O
",",5295,O
suggesting,5295,O
that,5295,O
the,5295,O
three,5295,O
coumarins,5295,B-CHEMICAL
could,5295,O
easily,5295,O
pass,5295,O
through,5295,O
the,5295,O
BBB,5295,O
in,5295,O
vivo,5295,O
.,5295,O
In,5296,O
the,5296,O
in,5296,O
vitro,5296,O
model,5296,O
we,5296,O
observed,5296,O
high,5296,O
permeability,5296,O
of,5296,O
imperatorin,5296,B-CHEMICAL
and,5296,O
isoimperatorin,5296,B-CHEMICAL
with,5296,O
the,5296,O
P-gp-mediated,5296,B-GENE-N
efflux,5296,O
ratios,5296,O
of,5296,O
0.53,5296,O
and,5296,O
0.06,5296,O
",",5296,O
as,5296,O
well,5296,O
as,5296,O
medium,5296,O
permeability,5296,O
of,5296,O
cnidilin,5296,B-CHEMICAL
with,5296,O
0.82,5296,O
.,5296,O
All,5297,O
data,5297,O
suggest,5297,O
that,5297,O
these,5297,O
three,5297,O
coumarins,5297,B-CHEMICAL
have,5297,O
high,5297,O
BBB,5297,O
permeability,5297,O
and,5297,O
have,5297,O
pharmacokinetic,5297,O
potentials,5297,O
for,5297,O
the,5297,O
treatment,5297,O
of,5297,O
central,5297,O
nervous,5297,O
system,5297,O
diseases,5297,O
.,5297,O
Involvement,5298,O
of,5298,O
Src,5298,B-GENE-Y
and,5298,O
the,5298,O
actin,5298,B-GENE-N
cytoskeleton,5298,O
in,5298,O
the,5298,O
antitumorigenic,5298,O
action,5298,O
of,5298,O
adenosine,5298,B-CHEMICAL
dialdehyde,5298,I-CHEMICAL
.,5298,O
Transmethylation,5299,O
is,5299,O
an,5299,O
important,5299,O
reaction,5299,O
that,5299,O
transfers,5299,O
a,5299,O
methyl,5299,B-CHEMICAL
group,5299,O
in,5299,O
S-adenosylmethionine,5299,B-CHEMICAL
(,5299,O
SAM,5299,B-CHEMICAL
),5299,O
to,5299,O
substrates,5299,O
such,5299,O
as,5299,O
DNA,5299,O
",",5299,O
RNA,5299,O
",",5299,O
and,5299,O
proteins,5299,O
.,5299,O
It,5300,O
is,5300,O
known,5300,O
that,5300,O
transmethylation,5300,O
plays,5300,O
critical,5300,O
roles,5300,O
in,5300,O
various,5300,O
cellular,5300,O
responses,5300,O
.,5300,O
In,5301,O
this,5301,O
study,5301,O
",",5301,O
we,5301,O
examined,5301,O
the,5301,O
effects,5301,O
of,5301,O
transmethylation,5301,O
on,5301,O
tumorigenic,5301,O
responses,5301,O
and,5301,O
its,5301,O
regulatory,5301,O
mechanism,5301,O
using,5301,O
an,5301,O
upregulation,5301,O
strategy,5301,O
of,5301,O
adenosylhomocysteine,5301,B-CHEMICAL
(,5301,O
SAH,5301,B-CHEMICAL
),5301,O
acting,5301,O
as,5301,O
a,5301,O
negative,5301,O
feedback,5301,O
inhibitor,5301,O
.,5301,O
Treatment,5302,O
with,5302,O
adenosine,5302,B-CHEMICAL
dialdehyde,5302,I-CHEMICAL
(,5302,O
AdOx,5302,B-CHEMICAL
),5302,O
",",5302,O
an,5302,O
inhibitor,5302,O
of,5302,O
transmethylation-suppressive,5302,O
adenosylhomocysteine,5302,B-GENE-Y
(,5302,I-GENE-Y
SAH,5302,I-GENE-Y
),5302,I-GENE-Y
hydrolase,5302,I-GENE-Y
(,5302,O
SAHH,5302,B-GENE-Y
),5302,O
",",5302,O
enhanced,5302,O
the,5302,O
level,5302,O
of,5302,O
SAH,5302,B-CHEMICAL
and,5302,O
effectively,5302,O
blocked,5302,O
the,5302,O
proliferation,5302,O
",",5302,O
migration,5302,O
",",5302,O
and,5302,O
invasion,5302,O
of,5302,O
cancer,5302,O
cells,5302,O
;,5302,O
the,5302,O
treatment,5302,O
also,5302,O
induced,5302,O
the,5302,O
differentiation,5302,O
of,5302,O
C6,5302,O
glioma,5302,O
cells,5302,O
and,5302,O
suppressed,5302,O
the,5302,O
neovascular,5302,O
genesis,5302,O
of,5302,O
eggs,5302,O
in,5302,O
a,5302,O
dose-dependent,5302,O
manner,5302,O
.,5302,O
Through,5303,O
immunoblotting,5303,O
analysis,5303,O
",",5303,O
it,5303,O
was,5303,O
found,5303,O
that,5303,O
AdOx,5303,B-CHEMICAL
was,5303,O
capable,5303,O
of,5303,O
indirectly,5303,O
diminishing,5303,O
the,5303,O
phosphorylation,5303,O
of,5303,O
oncogenic,5303,O
Src,5303,B-GENE-Y
and,5303,O
its,5303,O
kinase,5303,B-GENE-N
activity,5303,O
.,5303,O
Interestingly,5304,O
",",5304,O
AdOx,5304,B-CHEMICAL
disrupted,5304,O
actin,5304,B-GENE-N
cytoskeleton,5304,O
structures,5304,O
",",5304,O
leading,5304,O
to,5304,O
morphological,5304,O
changes,5304,O
",",5304,O
and,5304,O
suppressed,5304,O
the,5304,O
formation,5304,O
of,5304,O
a,5304,O
signaling,5304,O
complex,5304,O
composed,5304,O
of,5304,O
Src,5304,B-GENE-Y
and,5304,O
p85/PI3K,5304,B-GENE-N
",",5304,O
which,5304,O
is,5304,O
linked,5304,O
to,5304,O
various,5304,O
tumorigenic,5304,O
responses,5304,O
.,5304,O
In,5305,O
agreement,5305,O
with,5305,O
these,5305,O
data,5305,O
",",5305,O
the,5305,O
exogenous,5305,O
treatment,5305,O
of,5305,O
SAH,5305,B-CHEMICAL
or,5305,O
inhibition,5305,O
of,5305,O
SAHH,5305,B-GENE-Y
by,5305,O
specific,5305,O
siRNA,5305,O
or,5305,O
another,5305,O
type,5305,O
of,5305,O
inhibitor,5305,O
",",5305,O
3-deazaadenosine,5305,B-CHEMICAL
(,5305,O
DAZA,5305,B-CHEMICAL
),5305,O
",",5305,O
similarly,5305,O
resulted,5305,O
in,5305,O
antitumorigenic,5305,O
responses,5305,O
",",5305,O
suppressive,5305,O
activity,5305,O
on,5305,O
Src,5305,B-GENE-Y
",",5305,O
the,5305,O
alteration,5305,O
of,5305,O
actin,5305,B-GENE-N
cytoskeleton,5305,O
",",5305,O
and,5305,O
a,5305,O
change,5305,O
of,5305,O
the,5305,O
colocalization,5305,O
pattern,5305,O
between,5305,O
actin,5305,B-GENE-N
and,5305,O
Src,5305,B-GENE-Y
.,5305,O
Taken,5306,O
together,5306,O
",",5306,O
these,5306,O
results,5306,O
suggest,5306,O
that,5306,O
SAH/SAHH-mediated,5306,B-CHEMICAL
transmethylation,5306,O
could,5306,O
be,5306,O
linked,5306,O
to,5306,O
the,5306,O
tumorigenic,5306,O
processes,5306,O
through,5306,O
cross-regulation,5306,O
between,5306,O
the,5306,O
actin,5306,B-GENE-N
cytoskeleton,5306,O
and,5306,O
Src,5306,B-GENE-Y
kinase,5306,B-GENE-N
activity,5306,O
.,5306,O
Synthesis,5307,O
of,5307,O
derivatives,5307,O
of,5307,O
methyl,5307,B-CHEMICAL
rosmarinate,5307,I-CHEMICAL
and,5307,O
their,5307,O
inhibitory,5307,O
activities,5307,O
against,5307,O
matrix,5307,B-GENE-Y
metalloproteinase-1,5307,I-GENE-Y
(,5307,O
MMP-1,5307,B-GENE-Y
),5307,O
.,5307,O
A,5308,O
series,5308,O
of,5308,O
MMP-1,5308,B-GENE-Y
inhibitors,5308,O
have,5308,O
been,5308,O
identified,5308,O
based,5308,O
upon,5308,O
a,5308,O
methyl,5308,B-CHEMICAL
rosmarinate,5308,I-CHEMICAL
scaffold,5308,O
using,5308,O
structure-based,5308,O
drug,5308,O
design,5308,O
methods,5308,O
.,5308,O
The,5309,O
best,5309,O
compound,5309,O
in,5309,O
the,5309,O
series,5309,O
showed,5309,O
an,5309,O
IC50,5309,O
value,5309,O
of,5309,O
0.4,5309,O
μM,5309,O
.,5309,O
A,5310,O
docking,5310,O
study,5310,O
was,5310,O
conducted,5310,O
for,5310,O
compound,5310,O
(,5310,O
S,5310,O
),5310,O
-10n,5310,O
in,5310,O
order,5310,O
to,5310,O
investigate,5310,O
its,5310,O
binding,5310,O
interactions,5310,O
with,5310,O
MMP-1,5310,B-GENE-Y
.,5310,O
The,5311,O
structure-activity,5311,O
relationships,5311,O
(,5311,O
SAR,5311,O
),5311,O
were,5311,O
also,5311,O
briefly,5311,O
discussed,5311,O
.,5311,O
Useful,5312,O
SAR,5312,O
was,5312,O
established,5312,O
which,5312,O
provides,5312,O
important,5312,O
guidelines,5312,O
for,5312,O
the,5312,O
design,5312,O
of,5312,O
future,5312,O
generations,5312,O
of,5312,O
potent,5312,O
inhibitors,5312,O
against,5312,O
MMP-1,5312,B-GENE-Y
.,5312,O
Synthesis,5313,O
and,5313,O
biological,5313,O
evaluation,5313,O
of,5313,O
some,5313,O
novel,5313,O
resveratrol,5313,B-CHEMICAL
amide,5313,I-CHEMICAL
derivatives,5313,O
as,5313,O
potential,5313,O
anti-tumor,5313,O
agents,5313,O
.,5313,O
Three,5314,O
series,5314,O
of,5314,O
novel,5314,O
resveratrol,5314,B-CHEMICAL
amide,5314,I-CHEMICAL
derivatives,5314,O
(,5314,O
1a-q,5314,O
",",5314,O
2a-h,5314,O
",",5314,O
3a-l,5314,O
),5314,O
were,5314,O
synthesized,5314,O
and,5314,O
evaluated,5314,O
for,5314,O
their,5314,O
biological,5314,O
activities,5314,O
.,5314,O
All,5315,O
compounds,5315,O
were,5315,O
characterized,5315,O
by,5315,O
(,5315,B-CHEMICAL
1,5315,I-CHEMICAL
),5315,I-CHEMICAL
H,5315,I-CHEMICAL
NMR,5315,O
",",5315,O
(,5315,B-CHEMICAL
13,5315,I-CHEMICAL
),5315,I-CHEMICAL
C,5315,I-CHEMICAL
NMR,5315,O
",",5315,O
MS,5315,O
and,5315,O
elemental,5315,O
analysis,5315,O
.,5315,O
Furthermore,5316,O
",",5316,O
compound,5316,O
3e,5316,O
was,5316,O
also,5316,O
characterized,5316,O
by,5316,O
X-ray,5316,O
crystallography,5316,O
.,5316,O
All,5317,O
the,5317,O
compounds,5317,O
were,5317,O
evaluated,5317,O
for,5317,O
their,5317,O
anti-tumor,5317,O
activity,5317,O
against,5317,O
MCF-7,5317,O
",",5317,O
A549,5317,O
and,5317,O
B16-F10,5317,O
tumor,5317,O
cell,5317,O
lines,5317,O
as,5317,O
well,5317,O
as,5317,O
cyclooxygenase-2,5317,B-GENE-Y
(,5317,O
COX-2,5317,B-GENE-Y
),5317,O
-derived,5317,O
prostaglandin,5317,B-CHEMICAL
E2,5317,I-CHEMICAL
(,5317,O
PGE2,5317,B-CHEMICAL
),5317,O
inhibitory,5317,O
activity,5317,O
of,5317,O
murine,5317,O
macrophage,5317,O
RAW,5317,O
264.7,5317,O
cell,5317,O
line,5317,O
.,5317,O
Among,5318,O
them,5318,O
",",5318,O
compounds,5318,O
1c,5318,O
",",5318,O
1g,5318,O
and,5318,O
3e,5318,O
displayed,5318,O
the,5318,O
most,5318,O
potent,5318,O
COX-2,5318,B-GENE-Y
inhibitory,5318,O
activity,5318,O
with,5318,O
the,5318,O
IC50,5318,O
values,5318,O
of,5318,O
1.02,5318,O
",",5318,O
1.27,5318,O
and,5318,O
1.98,5318,O
μM,5318,O
",",5318,O
respectively,5318,O
.,5318,O
Molecular,5319,O
docking,5319,O
studies,5319,O
were,5319,O
performed,5319,O
to,5319,O
position,5319,O
compounds,5319,O
1c,5319,O
and,5319,O
3e,5319,O
into,5319,O
the,5319,O
active,5319,O
site,5319,O
of,5319,O
COX-2,5319,B-GENE-Y
to,5319,O
determine,5319,O
the,5319,O
probable,5319,O
binding,5319,O
modes,5319,O
.,5319,O
Cystathionase,5320,B-GENE-Y
mediates,5320,O
senescence,5320,O
evasion,5320,O
in,5320,O
melanocytes,5320,O
and,5320,O
melanoma,5320,O
cells,5320,O
.,5320,O
The,5321,O
development,5321,O
of,5321,O
malignant,5321,O
melanoma,5321,O
is,5321,O
a,5321,O
highly,5321,O
complex,5321,O
process,5321,O
",",5321,O
which,5321,O
is,5321,O
still,5321,O
poorly,5321,O
understood,5321,O
.,5321,O
A,5322,O
majority,5322,O
of,5322,O
human,5322,O
melanomas,5322,O
are,5322,O
found,5322,O
to,5322,O
express,5322,O
a,5322,O
few,5322,O
oncogenic,5322,O
proteins,5322,O
",",5322,O
such,5322,O
as,5322,O
mutant,5322,O
RAS,5322,B-GENE-N
and,5322,O
BRAF,5322,B-GENE-Y
variants,5322,O
.,5322,O
However,5323,O
",",5323,O
these,5323,O
oncogenes,5323,O
are,5323,O
also,5323,O
found,5323,O
in,5323,O
nevi,5323,O
",",5323,O
and,5323,O
it,5323,O
is,5323,O
now,5323,O
a,5323,O
well-accepted,5323,O
fact,5323,O
that,5323,O
their,5323,O
expression,5323,O
alone,5323,O
leads,5323,O
to,5323,O
senescence,5323,O
.,5323,O
This,5324,O
renders,5324,O
the,5324,O
understanding,5324,O
of,5324,O
senescence,5324,O
escape,5324,O
mechanisms,5324,O
an,5324,O
important,5324,O
point,5324,O
to,5324,O
understand,5324,O
tumor,5324,O
development,5324,O
.,5324,O
Here,5325,O
",",5325,O
we,5325,O
approached,5325,O
the,5325,O
question,5325,O
of,5325,O
senescence,5325,O
evasion,5325,O
by,5325,O
expressing,5325,O
the,5325,O
transcription,5325,O
factor,5325,O
v-myc,5325,B-GENE-Y
myelocytomatosis,5325,I-GENE-Y
viral,5325,I-GENE-Y
oncogene,5325,I-GENE-Y
homolog,5325,I-GENE-Y
(,5325,O
c-MYC,5325,B-GENE-Y
),5325,O
",",5325,O
which,5325,O
is,5325,O
known,5325,O
to,5325,O
act,5325,O
synergistically,5325,O
with,5325,O
many,5325,O
oncogenes,5325,O
",",5325,O
in,5325,O
melanocytes,5325,O
.,5325,O
We,5326,O
observed,5326,O
that,5326,O
MYC,5326,B-GENE-Y
drives,5326,O
the,5326,O
evasion,5326,O
of,5326,O
reactive-oxygen,5326,O
stress-induced,5326,O
melanocyte,5326,O
senescence,5326,O
",",5326,O
caused,5326,O
by,5326,O
activated,5326,O
receptor,5326,B-GENE-N
tyrosine,5326,B-CHEMICAL
kinase,5326,I-GENE-N
signaling,5326,O
.,5326,O
Conversely,5327,O
",",5327,O
MIZ1,5327,B-GENE-Y
",",5327,O
the,5327,O
growth,5327,O
suppressing,5327,O
interaction,5327,O
partner,5327,O
of,5327,O
MYC,5327,B-GENE-Y
",",5327,O
is,5327,O
involved,5327,O
in,5327,O
mediating,5327,O
melanocyte,5327,O
senescence,5327,O
.,5327,O
Both,5328,O
",",5328,O
MYC,5328,B-GENE-Y
overexpression,5328,O
and,5328,O
Miz1,5328,B-GENE-Y
knockdown,5328,O
led,5328,O
to,5328,O
a,5328,O
strong,5328,O
reduction,5328,O
of,5328,O
endogenous,5328,O
reactive-oxygen,5328,O
species,5328,O
(,5328,O
ROS,5328,O
),5328,O
",",5328,O
DNA,5328,O
damage,5328,O
and,5328,O
senescence,5328,O
.,5328,O
We,5329,O
identified,5329,O
the,5329,O
cystathionase,5329,B-GENE-Y
(,5329,O
CTH,5329,B-GENE-Y
),5329,O
gene,5329,O
product,5329,O
as,5329,O
mediator,5329,O
of,5329,O
the,5329,O
ROS-related,5329,O
MYC,5329,B-GENE-Y
and,5329,O
MIZ1,5329,B-GENE-Y
effects,5329,O
.,5329,O
Blocking,5330,O
CTH,5330,B-GENE-Y
enzymatic,5330,O
activity,5330,O
in,5330,O
MYC-overexpressing,5330,B-GENE-Y
and,5330,O
Miz1,5330,B-GENE-Y
knockdown,5330,O
cells,5330,O
increased,5330,O
intracellular,5330,O
stress,5330,O
and,5330,O
senescence,5330,O
.,5330,O
Importantly,5331,O
",",5331,O
pharmacological,5331,O
inhibition,5331,O
of,5331,O
CTH,5331,B-GENE-Y
in,5331,O
human,5331,O
melanoma,5331,O
cells,5331,O
also,5331,O
reconstituted,5331,O
senescence,5331,O
in,5331,O
the,5331,O
majority,5331,O
of,5331,O
cell,5331,O
lines,5331,O
",",5331,O
and,5331,O
CTH,5331,B-GENE-Y
knockdown,5331,O
reduced,5331,O
tumorigenic,5331,O
effects,5331,O
such,5331,O
as,5331,O
proliferation,5331,O
",",5331,O
H,5331,B-CHEMICAL
(,5331,I-CHEMICAL
2,5331,I-CHEMICAL
),5331,I-CHEMICAL
O,5331,I-CHEMICAL
(,5331,I-CHEMICAL
2,5331,I-CHEMICAL
),5331,I-CHEMICAL
resistance,5331,O
and,5331,O
soft,5331,O
agar,5331,O
growth,5331,O
.,5331,O
Thus,5332,O
",",5332,O
we,5332,O
identified,5332,O
CTH,5332,B-GENE-Y
as,5332,O
new,5332,O
MYC,5332,B-GENE-Y
target,5332,O
gene,5332,O
with,5332,O
an,5332,O
important,5332,O
function,5332,O
in,5332,O
senescence,5332,O
evasion.Oncogene,5332,O
advance,5332,O
online,5332,O
publication,5332,O
",",5332,O
28,5332,O
January,5332,O
2013,5332,O
;,5332,O
doi:10.1038/onc.2012.641,5332,O
.,5332,O
Investigational,5333,O
anti-hyperglycemic,5333,O
agents,5333,O
:,5333,O
the,5333,O
future,5333,O
of,5333,O
type,5333,O
2,5333,O
diabetes,5333,O
therapy,5333,O
?,5333,O
As,5334,O
the,5334,O
pandemic,5334,O
of,5334,O
type,5334,O
2,5334,O
diabetes,5334,O
spreads,5334,O
globally,5334,O
",",5334,O
clinicians,5334,O
face,5334,O
many,5334,O
challenges,5334,O
in,5334,O
treating,5334,O
an,5334,O
increasingly,5334,O
diverse,5334,O
patient,5334,O
population,5334,O
varying,5334,O
in,5334,O
age,5334,O
",",5334,O
comorbidities,5334,O
",",5334,O
and,5334,O
socioeconomic,5334,O
status,5334,O
.,5334,O
Current,5335,O
therapies,5335,O
for,5335,O
type,5335,O
2,5335,O
diabetes,5335,O
are,5335,O
often,5335,O
unable,5335,O
to,5335,O
alter,5335,O
the,5335,O
natural,5335,O
course,5335,O
of,5335,O
the,5335,O
disease,5335,O
and,5335,O
provide,5335,O
durable,5335,O
glycemic,5335,O
control,5335,O
",",5335,O
and,5335,O
side,5335,O
effects,5335,O
in,5335,O
the,5335,O
context,5335,O
of,5335,O
individual,5335,O
patient,5335,O
characteristics,5335,O
often,5335,O
limit,5335,O
treatment,5335,O
choices,5335,O
.,5335,O
This,5336,O
often,5336,O
results,5336,O
in,5336,O
the,5336,O
progression,5336,O
to,5336,O
insulin,5336,B-GENE-Y
use,5336,O
and,5336,O
complex,5336,O
regimens,5336,O
that,5336,O
are,5336,O
difficult,5336,O
to,5336,O
maintain,5336,O
.,5336,O
Therefore,5337,O
",",5337,O
a,5337,O
number,5337,O
of,5337,O
agents,5337,O
are,5337,O
being,5337,O
developed,5337,O
to,5337,O
better,5337,O
address,5337,O
the,5337,O
pathogenesis,5337,O
of,5337,O
type,5337,O
2,5337,O
diabetes,5337,O
and,5337,O
to,5337,O
overcome,5337,O
limitations,5337,O
of,5337,O
current,5337,O
therapies,5337,O
.,5337,O
The,5338,O
hope,5338,O
is,5338,O
to,5338,O
provide,5338,O
more,5338,O
options,5338,O
for,5338,O
glucose,5338,B-CHEMICAL
lowering,5338,O
and,5338,O
complication,5338,O
reduction,5338,O
with,5338,O
less,5338,O
risk,5338,O
for,5338,O
hypoglycemia,5338,O
and,5338,O
other,5338,O
adverse,5338,O
effects,5338,O
.,5338,O
These,5339,O
agents,5339,O
include,5339,O
newer,5339,O
incretin-based,5339,B-GENE-N
therapies,5339,O
and,5339,O
PPAR,5339,B-GENE-N
agonists,5339,O
",",5339,O
as,5339,O
well,5339,O
as,5339,O
new,5339,O
therapeutic,5339,O
classes,5339,O
such,5339,O
as,5339,O
sodium-coupled,5339,B-CHEMICAL
glucose,5339,B-CHEMICAL
cotransporter,5339,I-GENE-Y
2,5339,I-GENE-Y
inhibitors,5339,O
",",5339,O
free,5339,B-GENE-N
fatty,5339,I-GENE-N
acid,5339,I-GENE-N
receptor,5339,I-GENE-N
agonists,5339,O
",",5339,O
11-β-hydroxysteroid,5339,B-GENE-Y
dehydrogenase,5339,I-GENE-Y
type,5339,I-GENE-Y
1,5339,I-GENE-Y
inhibitors,5339,O
",",5339,O
glucokinase,5339,B-GENE-Y
activators,5339,O
",",5339,O
and,5339,O
several,5339,O
others,5339,O
that,5339,O
may,5339,O
enter,5339,O
clinical,5339,O
use,5339,O
over,5339,O
the,5339,O
next,5339,O
decade,5339,O
.,5339,O
Herein,5340,O
we,5340,O
review,5340,O
these,5340,O
agents,5340,O
that,5340,O
are,5340,O
advancing,5340,O
through,5340,O
clinical,5340,O
trials,5340,O
and,5340,O
describe,5340,O
the,5340,O
rationale,5340,O
behind,5340,O
their,5340,O
use,5340,O
",",5340,O
mechanisms,5340,O
of,5340,O
action,5340,O
",",5340,O
and,5340,O
potential,5340,O
for,5340,O
glucose,5340,B-CHEMICAL
lowering,5340,O
",",5340,O
as,5340,O
well,5340,O
as,5340,O
what,5340,O
is,5340,O
known,5340,O
of,5340,O
their,5340,O
limitations,5340,O
.,5340,O
3-Methylglutaconic,5341,B-CHEMICAL
aciduria-lessons,5341,O
from,5341,O
50,5341,O
genes,5341,O
and,5341,O
977,5341,O
patients,5341,O
.,5341,O
Elevated,5342,O
urinary,5342,O
excretion,5342,O
of,5342,O
3-methylglutaconic,5342,B-CHEMICAL
acid,5342,I-CHEMICAL
is,5342,O
considered,5342,O
rare,5342,O
in,5342,O
patients,5342,O
suspected,5342,O
of,5342,O
a,5342,O
metabolic,5342,O
disorder,5342,O
.,5342,O
In,5343,O
3-methylglutaconyl-CoA,5343,B-CHEMICAL
hydratase,5343,I-GENE-Y
deficiency,5343,O
(,5343,O
mutations,5343,O
in,5343,O
AUH,5343,B-GENE-Y
),5343,O
",",5343,O
it,5343,O
derives,5343,O
from,5343,O
leucine,5343,B-CHEMICAL
degradation,5343,O
.,5343,O
In,5344,O
all,5344,O
other,5344,O
disorders,5344,O
with,5344,O
3-methylglutaconic,5344,B-CHEMICAL
aciduria,5344,O
the,5344,O
origin,5344,O
is,5344,O
unknown,5344,O
",",5344,O
yet,5344,O
mitochondrial,5344,O
dysfunction,5344,O
is,5344,O
thought,5344,O
to,5344,O
be,5344,O
the,5344,O
common,5344,O
denominator,5344,O
.,5344,O
We,5345,O
investigate,5345,O
the,5345,O
biochemical,5345,O
",",5345,O
clinical,5345,O
and,5345,O
genetic,5345,O
data,5345,O
of,5345,O
388,5345,O
patients,5345,O
referred,5345,O
to,5345,O
our,5345,O
centre,5345,O
under,5345,O
suspicion,5345,O
of,5345,O
a,5345,O
metabolic,5345,O
disorder,5345,O
showing,5345,O
3-methylglutaconic,5345,B-CHEMICAL
aciduria,5345,O
in,5345,O
routine,5345,O
metabolic,5345,O
screening,5345,O
.,5345,O
Furthermore,5346,O
",",5346,O
we,5346,O
investigate,5346,O
591,5346,O
patients,5346,O
with,5346,O
50,5346,O
different,5346,O
",",5346,O
genetically,5346,O
proven,5346,O
",",5346,O
mitochondrial,5346,O
disorders,5346,O
for,5346,O
the,5346,O
presence,5346,O
of,5346,O
3-methylglutaconic,5346,B-CHEMICAL
aciduria,5346,O
.,5346,O
Three,5347,O
percent,5347,O
of,5347,O
all,5347,O
urine,5347,O
samples,5347,O
of,5347,O
the,5347,O
patients,5347,O
referred,5347,O
showed,5347,O
3-methylglutaconic,5347,B-CHEMICAL
aciduria,5347,O
",",5347,O
often,5347,O
in,5347,O
correlation,5347,O
with,5347,O
disorders,5347,O
not,5347,O
reported,5347,O
earlier,5347,O
in,5347,O
association,5347,O
with,5347,O
3-methylglutaconic,5347,B-CHEMICAL
aciduria,5347,O
(,5347,O
e.g,5347,O
.,5347,O
organic,5348,O
acidurias,5348,O
",",5348,O
urea,5348,B-CHEMICAL
cycle,5348,O
disorders,5348,O
",",5348,O
haematological,5348,O
and,5348,O
neuromuscular,5348,O
disorders,5348,O
),5348,O
.,5348,O
In,5349,O
the,5349,O
patient,5349,O
cohort,5349,O
with,5349,O
genetically,5349,O
proven,5349,O
mitochondrial,5349,O
disorders,5349,O
11,5349,O
%,5349,O
presented,5349,O
3-methylglutaconic,5349,B-CHEMICAL
aciduria,5349,O
.,5349,O
It,5350,O
was,5350,O
more,5350,O
frequently,5350,O
seen,5350,O
in,5350,O
ATPase,5350,B-GENE-N
related,5350,O
disorders,5350,O
",",5350,O
with,5350,O
mitochondrial,5350,O
DNA,5350,O
depletion,5350,O
or,5350,O
deletion,5350,O
",",5350,O
but,5350,O
not,5350,O
in,5350,O
patients,5350,O
with,5350,O
single,5350,O
respiratory,5350,B-GENE-N
chain,5350,I-GENE-N
complex,5350,I-GENE-N
deficiencies,5350,O
.,5350,O
Besides,5351,O
",",5351,O
it,5351,O
was,5351,O
a,5351,O
consistent,5351,O
feature,5351,O
of,5351,O
patients,5351,O
with,5351,O
mutations,5351,O
in,5351,O
TAZ,5351,B-GENE-Y
",",5351,O
SERAC1,5351,B-GENE-Y
",",5351,O
OPA3,5351,B-GENE-Y
",",5351,O
DNAJC19,5351,B-GENE-Y
and,5351,O
TMEM70,5351,B-GENE-Y
accounting,5351,O
for,5351,O
mitochondrial,5351,O
membrane,5351,O
related,5351,O
pathology,5351,O
.,5351,O
3-methylglutaconic,5352,B-CHEMICAL
aciduria,5352,O
is,5352,O
found,5352,O
quite,5352,O
frequently,5352,O
in,5352,O
patients,5352,O
suspected,5352,O
of,5352,O
a,5352,O
metabolic,5352,O
disorder,5352,O
",",5352,O
and,5352,O
mitochondrial,5352,O
dysfunction,5352,O
is,5352,O
indeed,5352,O
a,5352,O
common,5352,O
denominator,5352,O
.,5352,O
It,5353,O
is,5353,O
only,5353,O
a,5353,O
discriminative,5353,O
feature,5353,O
of,5353,O
patients,5353,O
with,5353,O
mutations,5353,O
in,5353,O
AUH,5353,B-GENE-Y
",",5353,O
TAZ,5353,B-GENE-Y
",",5353,O
SERAC1,5353,B-GENE-Y
",",5353,O
OPA3,5353,B-GENE-Y
",",5353,O
DNAJC19,5353,B-GENE-Y
TMEM70,5353,B-GENE-Y
.,5353,O
These,5354,O
conditions,5354,O
should,5354,O
therefore,5354,O
be,5354,O
referred,5354,O
to,5354,O
as,5354,O
inborn,5354,O
errors,5354,O
of,5354,O
metabolism,5354,O
with,5354,O
3-methylglutaconic,5354,B-CHEMICAL
aciduria,5354,O
as,5354,O
discriminative,5354,O
feature,5354,O
.,5354,O
Bioactives,5355,O
and,5355,O
nutraceutical,5355,O
phytochemicals,5355,O
naturally,5355,O
occurring,5355,O
in,5355,O
virgin,5355,O
olive,5355,O
oil,5355,O
.,5355,O
The,5356,O
case,5356,O
study,5356,O
of,5356,O
the,5356,O
Nocellara,5356,O
del,5356,O
Belice,5356,O
Italian,5356,O
olive,5356,O
cultivar,5356,O
.,5356,O
This,5357,O
work,5357,O
reports,5357,O
on,5357,O
the,5357,O
composition,5357,O
and,5357,O
bionutritional,5357,O
value,5357,O
of,5357,O
organic,5357,O
virgin,5357,O
olive,5357,O
oil,5357,O
from,5357,O
the,5357,O
Nocellara,5357,O
del,5357,O
Belice,5357,O
variety,5357,O
",",5357,O
one,5357,O
cultivated,5357,O
in,5357,O
the,5357,O
olive,5357,O
areas,5357,O
of,5357,O
the,5357,O
Sicily,5357,O
region,5357,O
",",5357,O
Italy,5357,O
.,5357,O
Destoned,5358,O
oils,5358,O
obtained,5358,O
by,5358,O
processing,5358,O
olives,5358,O
with,5358,O
a,5358,O
destoning-based,5358,O
procedure,5358,O
were,5358,O
compared,5358,O
with,5358,O
conventional,5358,O
oils,5358,O
.,5358,O
This,5359,O
innovative,5359,O
technique,5359,O
",",5359,O
consisting,5359,O
in,5359,O
removing,5359,O
the,5359,O
stone,5359,O
from,5359,O
fruits,5359,O
prior,5359,O
to,5359,O
processing,5359,O
",",5359,O
strongly,5359,O
enhanced,5359,O
the,5359,O
already,5359,O
high-quality,5359,O
level,5359,O
of,5359,O
the,5359,O
conventional,5359,O
product,5359,O
.,5359,O
An,5360,O
in-depth,5360,O
analytical,5360,O
investigation,5360,O
from,5360,O
2008,5360,O
to,5360,O
2010,5360,O
showed,5360,O
how,5360,O
this,5360,O
innovative,5360,O
olive,5360,O
extraction,5360,O
process,5360,O
led,5360,O
to,5360,O
an,5360,O
excellent,5360,O
peculiar,5360,O
final,5360,O
product,5360,O
",",5360,O
mainly,5360,O
attributable,5360,O
to,5360,O
the,5360,O
improved,5360,O
biophenol,5360,O
and,5360,O
volatile,5360,O
composition,5360,O
",",5360,O
as,5360,O
well,5360,O
as,5360,O
higher,5360,O
concentrations,5360,O
of,5360,O
the,5360,O
lipophilic,5360,O
and,5360,O
vitamin,5360,O
antioxidants,5360,O
(,5360,O
tocopherols,5360,B-CHEMICAL
and,5360,O
tocotrienols,5360,B-CHEMICAL
),5360,O
.,5360,O
It,5361,O
had,5361,O
higher,5361,O
levels,5361,O
of,5361,O
oleocanthal,5361,B-CHEMICAL
(,5361,O
p-HPEA-EDA,5361,B-CHEMICAL
),5361,O
",",5361,O
a,5361,O
nutraceutical,5361,O
compound,5361,O
exerting,5361,O
actions,5361,O
against,5361,O
COX1,5361,B-GENE-Y
and,5361,O
COX2,5361,B-GENE-Y
(,5361,O
cycloxygenases,5361,B-GENE-N
),5361,O
.,5361,O
Its,5362,O
head-space,5362,O
aroma,5362,O
displayed,5362,O
new,5362,O
volatile,5362,O
phytomolecules,5362,O
and,5362,O
also,5362,O
had,5362,O
higher,5362,O
levels,5362,O
of,5362,O
green,5362,O
volatiles,5362,O
from,5362,O
the,5362,O
lipoxygenase,5362,B-GENE-N
(,5362,O
LOX,5362,B-GENE-N
),5362,O
-pathway,5362,O
(,5362,O
one,5362,O
having,5362,O
as,5362,O
precursors,5362,O
the,5362,O
polyunsaturated,5362,B-CHEMICAL
fatty,5362,I-CHEMICAL
acids,5362,I-CHEMICAL
containing,5362,O
a,5362,O
"cis-cis-1,4-pentadiene",5362,B-CHEMICAL
system,5362,O
),5362,O
.,5362,O
Among,5363,O
the,5363,O
other,5363,O
bioactives,5363,O
",",5363,O
we,5363,O
highlight,5363,O
its,5363,O
significant,5363,O
levels,5363,O
of,5363,O
trans-β-carotene,5363,B-CHEMICAL
and,5363,O
xanthophylls,5363,B-CHEMICAL
(,5363,O
lutein,5363,B-CHEMICAL
",",5363,O
violaxanthin,5363,B-CHEMICAL
",",5363,O
neoxanthin,5363,B-CHEMICAL
and,5363,O
other,5363,O
carotenoids,5363,O
),5363,O
.,5363,O
Its,5364,O
enhanced,5364,O
nutritional,5364,O
value,5364,O
was,5364,O
also,5364,O
attributable,5364,O
to,5364,O
the,5364,O
increased,5364,O
intensity,5364,O
of,5364,O
valuable,5364,O
tasting,5364,O
notes,5364,O
.,5364,O
Synthesis,5365,O
",",5365,O
DNA,5365,O
binding,5365,O
and,5365,O
antitumor,5365,O
evaluation,5365,O
of,5365,O
styelsamine,5365,B-CHEMICAL
and,5365,O
cystodytin,5365,B-CHEMICAL
analogues,5365,O
.,5365,O
A,5366,O
series,5366,O
of,5366,O
N-14,5366,O
sidechain,5366,O
substituted,5366,O
analogues,5366,O
of,5366,O
styelsamine,5366,B-CHEMICAL
(,5366,O
pyrido,5366,B-CHEMICAL
[,5366,I-CHEMICAL
"4,3,2-mn",5366,I-CHEMICAL
],5366,I-CHEMICAL
acridine,5366,I-CHEMICAL
),5366,O
and,5366,O
cystodytin,5366,B-CHEMICAL
(,5366,O
pyrido,5366,B-CHEMICAL
[,5366,I-CHEMICAL
"4,3,2-mn",5366,I-CHEMICAL
],5366,I-CHEMICAL
acridin-4-one,5366,I-CHEMICAL
),5366,O
alkaloids,5366,O
have,5366,O
been,5366,O
prepared,5366,O
and,5366,O
evaluated,5366,O
for,5366,O
their,5366,O
DNA,5366,O
binding,5366,O
affinity,5366,O
and,5366,O
antiproliferative,5366,O
activity,5366,O
towards,5366,O
a,5366,O
panel,5366,O
of,5366,O
human,5366,O
tumor,5366,O
cell,5366,O
lines,5366,O
.,5366,O
Overall,5367,O
it,5367,O
was,5367,O
found,5367,O
that,5367,O
styelsamine,5367,B-CHEMICAL
analogues,5367,O
were,5367,O
stronger,5367,O
DNA,5367,O
binders,5367,O
",",5367,O
with,5367,O
the,5367,O
natural,5367,O
products,5367,O
styelsamines,5367,B-CHEMICAL
B,5367,I-CHEMICAL
and,5367,I-CHEMICAL
D,5367,I-CHEMICAL
having,5367,O
particularly,5367,O
high,5367,O
affinity,5367,O
(,5367,O
K,5367,O
(,5367,O
app,5367,O
),5367,O
5.33,5367,O
×,5367,O
10,5367,O
(,5367,O
6,5367,O
),5367,O
and,5367,O
3.64,5367,O
×,5367,O
10,5367,O
(,5367,O
6,5367,O
),5367,O
M,5367,O
(,5367,O
-1,5367,O
),5367,O
",",5367,O
respectively,5367,O
),5367,O
.,5367,O
In,5368,O
comparison,5368,O
",",5368,O
the,5368,O
cystodytin,5368,B-CHEMICAL
iminoquinone,5368,I-CHEMICAL
alkaloids,5368,I-CHEMICAL
showed,5368,O
lower,5368,O
affinity,5368,O
for,5368,O
DNA,5368,O
",",5368,O
but,5368,O
were,5368,O
typically,5368,O
just,5368,O
as,5368,O
active,5368,O
as,5368,O
styelsamine,5368,B-CHEMICAL
analogues,5368,O
at,5368,O
inhibiting,5368,O
proliferation,5368,O
of,5368,O
tumor,5368,O
cells,5368,O
in,5368,O
vitro,5368,O
.,5368,O
Sub-panel,5369,O
selectivity,5369,O
towards,5369,O
non-small,5369,O
cell,5369,O
lung,5369,O
",",5369,O
melanoma,5369,O
and,5369,O
renal,5369,O
cancer,5369,O
cell,5369,O
lines,5369,O
were,5369,O
observed,5369,O
for,5369,O
a,5369,O
number,5369,O
of,5369,O
the,5369,O
analogues,5369,O
.,5369,O
Correlation,5370,O
was,5370,O
observed,5370,O
between,5370,O
whole,5370,O
cell,5370,O
activity,5370,O
and,5370,O
clogP,5370,O
",",5370,O
with,5370,O
the,5370,O
most,5370,O
potent,5370,O
antiproliferative,5370,O
activity,5370,O
being,5370,O
observed,5370,O
for,5370,O
3-phenylpropanamide,5370,B-CHEMICAL
analogues,5370,O
37,5370,O
and,5370,O
41,5370,O
(,5370,O
NCI,5370,O
panel,5370,O
average,5370,O
GI,5370,O
(,5370,O
50,5370,O
),5370,O
0.4,5370,O
μM,5370,O
and,5370,O
0.32,5370,O
μM,5370,O
",",5370,O
respectively,5370,O
),5370,O
with,5370,O
clogP,5370,O
~4.0-4.5,5370,O
.,5370,O
Intercalation,5371,O
pathway,5371,O
in,5371,O
many-particle,5371,O
LiFePO4,5371,B-CHEMICAL
electrode,5371,O
revealed,5371,O
by,5371,O
nanoscale,5371,O
state-of-charge,5371,O
mapping,5371,O
.,5371,O
The,5372,O
intercalation,5372,O
pathway,5372,O
of,5372,O
lithium,5372,B-CHEMICAL
iron,5372,I-CHEMICAL
phosphate,5372,I-CHEMICAL
(,5372,O
LFP,5372,B-CHEMICAL
),5372,O
in,5372,O
the,5372,O
positive,5372,O
electrode,5372,O
of,5372,O
a,5372,O
lithium-ion,5372,B-CHEMICAL
battery,5372,O
was,5372,O
probed,5372,O
at,5372,O
the,5372,O
∼40,5372,O
nm,5372,O
length,5372,O
scale,5372,O
using,5372,O
oxidation-state-sensitive,5372,O
X-ray,5372,O
microscopy,5372,O
.,5372,O
Combined,5373,O
with,5373,O
morphological,5373,O
observations,5373,O
of,5373,O
the,5373,O
same,5373,O
exact,5373,O
locations,5373,O
using,5373,O
transmission,5373,O
electron,5373,O
microscopy,5373,O
",",5373,O
we,5373,O
quantified,5373,O
the,5373,O
local,5373,O
state-of-charge,5373,O
of,5373,O
approximately,5373,O
450,5373,O
individual,5373,O
LFP,5373,B-CHEMICAL
particles,5373,O
over,5373,O
nearly,5373,O
the,5373,O
entire,5373,O
thickness,5373,O
of,5373,O
the,5373,O
porous,5373,O
electrode,5373,O
.,5373,O
With,5374,O
the,5374,O
electrode,5374,O
charged,5374,O
to,5374,O
50,5374,O
%,5374,O
state-of-charge,5374,O
in,5374,O
0.5,5374,O
h,5374,O
",",5374,O
we,5374,O
observed,5374,O
that,5374,O
the,5374,O
overwhelming,5374,O
majority,5374,O
of,5374,O
particles,5374,O
were,5374,O
either,5374,O
almost,5374,O
completely,5374,O
delithiated,5374,O
or,5374,O
lithiated,5374,O
.,5374,O
Specifically,5375,O
",",5375,O
only,5375,O
∼2,5375,O
%,5375,O
of,5375,O
individual,5375,O
particles,5375,O
were,5375,O
at,5375,O
an,5375,O
intermediate,5375,O
state-of-charge,5375,O
.,5375,O
From,5376,O
this,5376,O
small,5376,O
fraction,5376,O
of,5376,O
particles,5376,O
that,5376,O
were,5376,O
actively,5376,O
undergoing,5376,O
delithiation,5376,O
",",5376,O
we,5376,O
conclude,5376,O
that,5376,O
the,5376,O
time,5376,O
needed,5376,O
to,5376,O
charge,5376,O
a,5376,O
particle,5376,O
is,5376,O
∼1/50,5376,O
the,5376,O
time,5376,O
needed,5376,O
to,5376,O
charge,5376,O
the,5376,O
entire,5376,O
particle,5376,O
ensemble,5376,O
.,5376,O
Surprisingly,5377,O
",",5377,O
we,5377,O
observed,5377,O
a,5377,O
very,5377,O
weak,5377,O
correlation,5377,O
between,5377,O
the,5377,O
sequence,5377,O
of,5377,O
delithiation,5377,O
and,5377,O
the,5377,O
particle,5377,O
size,5377,O
",",5377,O
contrary,5377,O
to,5377,O
the,5377,O
common,5377,O
expectation,5377,O
that,5377,O
smaller,5377,O
particles,5377,O
delithiate,5377,O
before,5377,O
larger,5377,O
ones,5377,O
.,5377,O
Our,5378,O
quantitative,5378,O
results,5378,O
unambiguously,5378,O
confirm,5378,O
the,5378,O
mosaic,5378,O
(,5378,O
particle-by-particle,5378,O
),5378,O
pathway,5378,O
of,5378,O
intercalation,5378,O
and,5378,O
suggest,5378,O
that,5378,O
the,5378,O
rate-limiting,5378,O
process,5378,O
of,5378,O
charging,5378,O
is,5378,O
initiating,5378,O
the,5378,O
phase,5378,O
transformation,5378,O
by,5378,O
",",5378,O
for,5378,O
example,5378,O
",",5378,O
a,5378,O
nucleation-like,5378,O
event,5378,O
.,5378,O
Therefore,5379,O
",",5379,O
strategies,5379,O
for,5379,O
further,5379,O
enhancing,5379,O
the,5379,O
performance,5379,O
of,5379,O
LFP,5379,B-CHEMICAL
electrodes,5379,O
should,5379,O
not,5379,O
focus,5379,O
on,5379,O
increasing,5379,O
the,5379,O
phase-boundary,5379,O
velocity,5379,O
but,5379,O
on,5379,O
the,5379,O
rate,5379,O
of,5379,O
phase-transformation,5379,O
initiation,5379,O
.,5379,O
Silica,5380,B-CHEMICAL
precipitation,5380,O
by,5380,O
synthetic,5380,O
minicollagens,5380,O
.,5380,O
Oligomeric,5381,O
Pro-Hyp-Gly-,5381,B-CHEMICAL
(,5381,O
POG-,5381,O
),5381,O
peptides,5381,O
",",5381,O
wherein,5381,O
the,5381,O
collagenous,5381,B-GENE-N
triple,5381,I-GENE-N
helix,5381,I-GENE-N
is,5381,O
supported,5381,O
by,5381,O
C-terminal,5381,B-CHEMICAL
capping,5381,O
",",5381,O
exhibit,5381,O
silica,5381,B-CHEMICAL
precipitation,5381,O
properties,5381,O
(,5381,O
O,5381,O
",",5381,O
Hyp,5381,B-CHEMICAL
=,5381,O
(,5381,B-CHEMICAL
"2S,4R",5381,I-CHEMICAL
),5381,I-CHEMICAL
hydroxyproline,5381,I-CHEMICAL
),5381,O
.,5381,O
As,5382,O
quantified,5382,O
by,5382,O
a,5382,O
molybdate,5382,O
assay,5382,O
",",5382,O
the,5382,O
length,5382,O
of,5382,O
the,5382,O
covalently,5382,O
tethered,5382,O
triple,5382,B-GENE-N
helix,5382,I-GENE-N
(,5382,O
number,5382,O
of,5382,O
POG,5382,O
units,5382,O
),5382,O
determines,5382,O
the,5382,O
amount,5382,O
of,5382,O
amorphous,5382,O
silica,5382,B-CHEMICAL
obtained,5382,O
from,5382,O
silicic,5382,B-CHEMICAL
acid,5382,I-CHEMICAL
solution,5382,O
.,5382,O
Although,5383,O
lacking,5383,O
charged,5383,O
side,5383,O
chains,5383,O
",",5383,O
the,5383,O
synthetic,5383,O
collagens,5383,B-GENE-N
precipitate,5383,O
large,5383,O
quantities,5383,O
of,5383,O
silicic,5383,B-CHEMICAL
acid,5383,I-CHEMICAL
resulting,5383,O
in,5383,O
micrometer-sized,5383,O
spheres,5383,O
of,5383,O
varying,5383,O
surface,5383,O
morphologies,5383,O
as,5383,O
analyzed,5383,O
by,5383,O
scanning,5383,O
electron,5383,O
microscopy,5383,O
.,5383,O
Similar,5384,O
precipitation,5384,O
efficiencies,5384,O
on,5384,O
a,5384,O
fast,5384,O
time,5384,O
scale,5384,O
of,5384,O
less,5384,O
than,5384,O
10,5384,O
min,5384,O
were,5384,O
previously,5384,O
described,5384,O
only,5384,O
for,5384,O
biogenic,5384,O
diatom,5384,O
proteins,5384,O
and,5384,O
sponge,5384,B-GENE-N
collagen,5384,I-GENE-N
",",5384,O
respectively,5384,O
",",5384,O
which,5384,O
have,5384,O
a,5384,O
considerably,5384,O
higher,5384,O
structural,5384,O
complexity,5384,O
and,5384,O
limited,5384,O
accessibility,5384,O
.,5384,O
The,5385,O
minicollagens,5385,O
described,5385,O
here,5385,O
provide,5385,O
an,5385,O
unexpected,5385,O
alternative,5385,O
to,5385,O
the,5385,O
widely,5385,O
used,5385,O
precipitation,5385,O
conditions,5385,O
",",5385,O
which,5385,O
generally,5385,O
depend,5385,O
on,5385,O
(,5385,B-CHEMICAL
poly-,5385,I-CHEMICAL
),5385,I-CHEMICAL
amines,5385,I-CHEMICAL
in,5385,O
phosphate,5385,B-CHEMICAL
buffer,5385,O
.,5385,O
Collagen,5386,B-GENE-N
can,5386,O
form,5386,O
intimate,5386,O
connections,5386,O
with,5386,O
inorganic,5386,O
matter,5386,O
.,5386,O
Hence,5387,O
",",5387,O
silica-enclosed,5387,B-CHEMICAL
collagens,5387,B-GENE-N
have,5387,O
promising,5387,O
perspectives,5387,O
as,5387,O
composite,5387,O
materials,5387,O
.,5387,O
Pharmacodynamic,5388,O
characteristics,5388,O
of,5388,O
lixisenatide,5388,O
once,5388,O
daily,5388,O
versus,5388,O
liraglutide,5388,O
once,5388,O
daily,5388,O
in,5388,O
patients,5388,O
with,5388,O
type,5388,O
2,5388,O
diabetes,5388,O
insufficiently,5388,O
controlled,5388,O
on,5388,O
metformin,5388,B-CHEMICAL
.,5388,O
AIM,5389,O
:,5389,O
Assess,5389,O
the,5389,O
pharmacodynamics,5389,O
of,5389,O
lixisenatide,5389,O
once,5389,O
daily,5389,O
(,5389,O
QD,5389,O
),5389,O
versus,5389,O
liraglutide,5389,O
QD,5389,O
in,5389,O
type,5389,O
2,5389,O
diabetes,5389,O
insufficiently,5389,O
controlled,5389,O
on,5389,O
metformin,5389,B-CHEMICAL
.,5389,O
METHODS,5390,O
:,5390,O
In,5390,O
this,5390,O
28-day,5390,O
",",5390,O
randomized,5390,O
",",5390,O
open-label,5390,O
",",5390,O
parallel-group,5390,O
",",5390,O
multicentre,5390,O
study,5390,O
(,5390,O
NCT01175473,5390,O
),5390,O
",",5390,O
patients,5390,O
(,5390,O
mean,5390,O
HbA1c,5390,B-GENE-Y
7.3,5390,O
%,5390,O
),5390,O
received,5390,O
subcutaneous,5390,O
lixisenatide,5390,O
QD,5390,O
(,5390,O
10,5390,O
µg,5390,O
weeks,5390,O
1-2,5390,O
",",5390,O
then,5390,O
20,5390,O
µg,5390,O
;,5390,O
n,5390,O
=,5390,O
77,5390,O
),5390,O
or,5390,O
liraglutide,5390,O
QD,5390,O
(,5390,O
0.6,5390,O
mg,5390,O
week,5390,O
1,5390,O
",",5390,O
1.2,5390,O
mg,5390,O
week,5390,O
2,5390,O
",",5390,O
then,5390,O
1.8,5390,O
mg,5390,O
;,5390,O
n,5390,O
=,5390,O
71,5390,O
),5390,O
30,5390,O
min,5390,O
before,5390,O
breakfast,5390,O
.,5390,O
Primary,5391,O
endpoint,5391,O
was,5391,O
change,5391,O
in,5391,O
postprandial,5391,O
plasma,5391,O
glucose,5391,B-CHEMICAL
(,5391,O
PPG,5391,O
),5391,O
exposure,5391,O
from,5391,O
baseline,5391,O
to,5391,O
day,5391,O
28,5391,O
during,5391,O
a,5391,O
breakfast,5391,O
test,5391,O
meal,5391,O
.,5391,O
RESULTS,5392,O
:,5392,O
Lixisenatide,5392,O
reduced,5392,O
PPG,5392,O
significantly,5392,O
more,5392,O
than,5392,O
liraglutide,5392,O
[,5392,O
mean,5392,O
change,5392,O
in,5392,O
AUC,5392,O
(,5392,O
0,5392,O
),5392,O
(,5392,O
:30-4:30h,5392,O
),5392,O
:,5392,O
-12.6,5392,O
vs.,5392,O
-4.0,5392,O
h/mmol/l,5392,O
",",5392,O
respectively,5392,O
;,5392,O
p,5392,O
<,5392,O
0.0001,5392,O
(,5392,O
0:30,5392,O
h,5392,O
=,5392,O
start,5392,O
of,5392,O
meal,5392,O
),5392,O
],5392,O
.,5392,O
Change,5393,O
in,5393,O
maximum,5393,O
PPG,5393,O
excursion,5393,O
was,5393,O
-3.9,5393,O
mmol/l,5393,O
vs.,5393,O
-1.4,5393,O
mmol/l,5393,O
",",5393,O
respectively,5393,O
(,5393,O
p,5393,O
<,5393,O
0.0001,5393,O
),5393,O
.,5393,O
More,5394,O
lixisenatide-treated,5394,O
patients,5394,O
achieved,5394,O
2-h,5394,O
PPG,5394,O
<,5394,O
7.8,5394,O
mmol/l,5394,O
(,5394,O
69,5394,O
%,5394,O
vs.,5394,O
29,5394,O
%,5394,O
),5394,O
.,5394,O
Changes,5395,O
in,5395,O
fasting,5395,O
plasma,5395,O
glucose,5395,O
were,5395,O
greater,5395,O
with,5395,O
liraglutide,5395,O
(,5395,O
-0.3,5395,O
vs.,5395,O
-1.3,5395,O
mmol/l,5395,O
",",5395,O
p,5395,O
<,5395,O
0.0001,5395,O
),5395,O
.,5395,O
Lixisenatide,5396,O
provided,5396,O
greater,5396,O
decreases,5396,O
in,5396,O
postprandial,5396,O
glucagon,5396,B-GENE-Y
(,5396,O
p,5396,O
<,5396,O
0.05,5396,O
),5396,O
",",5396,O
insulin,5396,B-GENE-Y
(,5396,O
p,5396,O
<,5396,O
0.0001,5396,O
),5396,O
and,5396,O
C-peptide,5396,B-GENE-Y
(,5396,O
p,5396,O
<,5396,O
0.0001,5396,O
),5396,O
.,5396,O
Mean,5397,O
HbA1c,5397,B-GENE-N
decreased,5397,O
in,5397,O
both,5397,O
treatment,5397,O
groups,5397,O
(,5397,O
from,5397,O
7.2,5397,O
%,5397,O
to,5397,O
6.9,5397,O
%,5397,O
with,5397,O
lixisenatide,5397,O
vs.,5397,O
7.4,5397,O
%,5397,O
to,5397,O
6.9,5397,O
%,5397,O
with,5397,O
liraglutide,5397,O
),5397,O
as,5397,O
did,5397,O
body,5397,O
weight,5397,O
(,5397,O
-1.6,5397,O
kg,5397,O
vs.,5397,O
-2.4,5397,O
kg,5397,O
",",5397,O
respectively,5397,O
),5397,O
.,5397,O
Overall,5398,O
incidence,5398,O
of,5398,O
adverse,5398,O
events,5398,O
was,5398,O
lower,5398,O
with,5398,O
lixisenatide,5398,O
(,5398,O
55,5398,O
%,5398,O
),5398,O
versus,5398,O
liraglutide,5398,O
(,5398,O
65,5398,O
%,5398,O
),5398,O
",",5398,O
with,5398,O
no,5398,O
serious,5398,O
events,5398,O
or,5398,O
hypoglycaemia,5398,O
reported,5398,O
.,5398,O
CONCLUSIONS,5399,O
:,5399,O
Once,5399,O
daily,5399,O
prebreakfast,5399,O
lixisenatide,5399,O
provided,5399,O
a,5399,O
significantly,5399,O
greater,5399,O
reduction,5399,O
in,5399,O
PPG,5399,O
(,5399,O
AUC,5399,O
),5399,O
during,5399,O
a,5399,O
morning,5399,O
test,5399,O
meal,5399,O
versus,5399,O
prebreakfast,5399,O
liraglutide,5399,O
.,5399,O
Lixisenatide,5400,O
provided,5400,O
significant,5400,O
decreases,5400,O
in,5400,O
postprandial,5400,O
insulin,5400,B-GENE-Y
",",5400,O
C-peptide,5400,B-GENE-Y
(,5400,O
vs.,5400,O
an,5400,O
increase,5400,O
with,5400,O
liraglutide,5400,O
),5400,O
and,5400,O
glucagon,5400,B-GENE-Y
",",5400,O
and,5400,O
better,5400,O
gastrointestinal,5400,O
tolerability,5400,O
than,5400,O
liraglutide,5400,O
.,5400,O
The,5401,O
contrasting,5401,O
activity,5401,O
of,5401,O
iodido,5401,B-CHEMICAL
versus,5401,O
chlorido,5401,B-CHEMICAL
ruthenium,5401,I-CHEMICAL
and,5401,O
osmium,5401,B-CHEMICAL
arene,5401,I-CHEMICAL
azo-,5401,I-CHEMICAL
and,5401,I-CHEMICAL
imino-pyridine,5401,I-CHEMICAL
anticancer,5401,O
complexes,5401,O
:,5401,O
control,5401,O
of,5401,O
cell,5401,O
selectivity,5401,O
",",5401,O
cross-resistance,5401,O
",",5401,O
p53,5401,B-GENE-Y
dependence,5401,O
",",5401,O
and,5401,O
apoptosis,5401,O
pathway,5401,O
.,5401,O
Organometallic,5402,O
half-sandwich,5402,O
complexes,5402,O
[,5402,B-CHEMICAL
M,5402,I-CHEMICAL
(,5402,I-CHEMICAL
p-cymene,5402,I-CHEMICAL
),5402,I-CHEMICAL
(,5402,I-CHEMICAL
azo/imino-pyridine,5402,I-CHEMICAL
),5402,I-CHEMICAL
X,5402,I-CHEMICAL
],5402,I-CHEMICAL
(,5402,I-CHEMICAL
+,5402,I-CHEMICAL
),5402,I-CHEMICAL
where,5402,O
M,5402,B-CHEMICAL
=,5402,I-CHEMICAL
Ru,5402,I-CHEMICAL
(,5402,I-CHEMICAL
II,5402,I-CHEMICAL
),5402,I-CHEMICAL
or,5402,I-CHEMICAL
Os,5402,I-CHEMICAL
(,5402,I-CHEMICAL
II,5402,I-CHEMICAL
),5402,I-CHEMICAL
and,5402,O
X,5402,B-CHEMICAL
═,5402,I-CHEMICAL
Cl,5402,B-CHEMICAL
or,5402,I-CHEMICAL
I,5402,B-CHEMICAL
",",5402,O
exhibit,5402,O
potent,5402,O
antiproliferative,5402,O
activity,5402,O
toward,5402,O
a,5402,O
range,5402,O
of,5402,O
cancer,5402,O
cells,5402,O
.,5402,O
Not,5403,O
only,5403,O
are,5403,O
the,5403,O
iodido,5403,B-CHEMICAL
complexes,5403,O
more,5403,O
potent,5403,O
than,5403,O
the,5403,O
chlorido,5403,B-CHEMICAL
analogues,5403,O
",",5403,O
but,5403,O
they,5403,O
are,5403,O
not,5403,O
cross-resistant,5403,O
with,5403,O
the,5403,O
clinical,5403,O
platinum,5403,B-CHEMICAL
drugs,5403,O
cisplatin,5403,B-CHEMICAL
and,5403,O
oxaliplatin,5403,B-CHEMICAL
.,5403,O
They,5404,O
are,5404,O
also,5404,O
more,5404,O
selective,5404,O
for,5404,O
cancer,5404,O
cells,5404,O
versus,5404,O
normal,5404,O
cells,5404,O
(,5404,O
fibroblasts,5404,O
),5404,O
and,5404,O
show,5404,O
high,5404,O
accumulation,5404,O
in,5404,O
cell,5404,O
membranes,5404,O
.,5404,O
They,5405,O
arrest,5405,O
cell,5405,O
growth,5405,O
in,5405,O
G1,5405,O
phase,5405,O
in,5405,O
contrast,5405,O
to,5405,O
cisplatin,5405,B-CHEMICAL
(,5405,O
S,5405,O
phase,5405,O
),5405,O
with,5405,O
a,5405,O
high,5405,O
incidence,5405,O
of,5405,O
late-stage,5405,O
apoptosis,5405,O
.,5405,O
The,5406,O
iodido,5406,B-CHEMICAL
complexes,5406,O
retain,5406,O
potency,5406,O
in,5406,O
p53,5406,B-GENE-Y
mutant,5406,O
colon,5406,O
cells,5406,O
.,5406,O
All,5407,O
complexes,5407,O
activate,5407,O
caspase,5407,B-GENE-Y
3,5407,I-GENE-Y
.,5407,O
In,5408,O
general,5408,O
",",5408,O
antiproliferative,5408,O
activity,5408,O
is,5408,O
greatly,5408,O
enhanced,5408,O
by,5408,O
low,5408,O
levels,5408,O
of,5408,O
the,5408,O
glutathione,5408,B-GENE-Y
synthase,5408,I-GENE-Y
inhibitor,5408,O
l-buthionine,5408,B-CHEMICAL
sulfoxime,5408,I-CHEMICAL
.,5408,O
The,5409,O
work,5409,O
illustrates,5409,O
how,5409,O
subtle,5409,O
changes,5409,O
to,5409,O
the,5409,O
design,5409,O
of,5409,O
low-spin,5409,O
d,5409,O
(,5409,O
6,5409,O
),5409,O
metal,5409,O
complexes,5409,O
can,5409,O
lead,5409,O
to,5409,O
major,5409,O
changes,5409,O
in,5409,O
cellular,5409,O
metabolism,5409,O
and,5409,O
to,5409,O
potent,5409,O
complexes,5409,O
with,5409,O
novel,5409,O
mechanisms,5409,O
of,5409,O
anticancer,5409,O
activity,5409,O
.,5409,O
Zinc-dependent,5410,B-CHEMICAL
lysosomal,5410,O
enlargement,5410,O
in,5410,O
TRPML1-deficient,5410,B-GENE-Y
cells,5410,O
involves,5410,O
MTF-1,5410,B-GENE-Y
transcription,5410,O
factor,5410,O
and,5410,O
ZnT4,5410,B-GENE-Y
(,5410,O
Slc30a4,5410,B-GENE-Y
),5410,O
transporter,5410,O
.,5410,O
Zinc,5411,B-CHEMICAL
is,5411,O
critical,5411,O
for,5411,O
a,5411,O
multitude,5411,O
of,5411,O
cellular,5411,O
processes,5411,O
",",5411,O
including,5411,O
gene,5411,O
expression,5411,O
",",5411,O
secretion,5411,O
and,5411,O
enzymatic,5411,O
activities,5411,O
.,5411,O
Cellular,5412,O
zinc,5412,B-CHEMICAL
is,5412,O
controlled,5412,O
by,5412,O
zinc-chelating,5412,B-CHEMICAL
proteins,5412,I-GENE-N
and,5412,O
by,5412,O
zinc,5412,B-CHEMICAL
transporters,5412,I-GENE-N
.,5412,O
The,5413,O
recent,5413,O
identification,5413,O
of,5413,O
zinc,5413,B-CHEMICAL
permeability,5413,O
of,5413,O
the,5413,O
lysosomal,5413,O
ion,5413,B-GENE-N
channel,5413,I-GENE-N
TRPML1,5413,B-GENE-Y
(,5413,O
transient,5413,B-GENE-Y
receptor,5413,I-GENE-Y
potential,5413,I-GENE-Y
mucolipin,5413,I-GENE-Y
1,5413,I-GENE-Y
),5413,O
",",5413,O
and,5413,O
the,5413,O
evidence,5413,O
of,5413,O
abnormal,5413,O
zinc,5413,B-CHEMICAL
levels,5413,O
in,5413,O
cells,5413,O
deficient,5413,O
in,5413,O
TRPML1,5413,B-GENE-Y
",",5413,O
suggested,5413,O
a,5413,O
role,5413,O
for,5413,O
TRPML1,5413,B-GENE-Y
in,5413,O
zinc,5413,B-CHEMICAL
transport,5413,O
.,5413,O
In,5414,O
the,5414,O
present,5414,O
study,5414,O
we,5414,O
provide,5414,O
new,5414,O
evidence,5414,O
for,5414,O
such,5414,O
a,5414,O
role,5414,O
and,5414,O
identify,5414,O
additional,5414,O
cellular,5414,O
components,5414,O
responsible,5414,O
for,5414,O
it,5414,O
.,5414,O
In,5415,O
agreement,5415,O
with,5415,O
the,5415,O
previously,5415,O
published,5415,O
data,5415,O
",",5415,O
an,5415,O
acute,5415,O
siRNA,5415,O
(,5415,O
small,5415,O
interfering,5415,O
RNA,5415,O
),5415,O
-driven,5415,O
TRPML1,5415,B-GENE-Y
KD,5415,O
(,5415,O
knockdown,5415,O
),5415,O
leads,5415,O
to,5415,O
the,5415,O
build-up,5415,O
of,5415,O
large,5415,O
cytoplasmic,5415,O
vesicles,5415,O
positive,5415,O
for,5415,O
LysoTracker™,5415,O
and,5415,O
zinc,5415,B-CHEMICAL
staining,5415,O
",",5415,O
when,5415,O
cells,5415,O
are,5415,O
exposed,5415,O
to,5415,O
high,5415,O
concentrations,5415,O
of,5415,O
zinc,5415,B-CHEMICAL
.,5415,O
We,5416,O
now,5416,O
show,5416,O
that,5416,O
lysosomal,5416,O
enlargement,5416,O
and,5416,O
zinc,5416,B-CHEMICAL
build-up,5416,O
in,5416,O
TRPML1-KD,5416,B-GENE-Y
cells,5416,O
exposed,5416,O
to,5416,O
zinc,5416,B-CHEMICAL
are,5416,O
ameliorated,5416,O
by,5416,O
KD,5416,O
of,5416,O
the,5416,O
zinc-sensitive,5416,B-GENE-N
transcription,5416,I-GENE-N
factor,5416,I-GENE-N
MTF-1,5416,B-GENE-Y
(,5416,O
metal-regulatory-element-binding,5416,B-GENE-Y
transcription,5416,I-GENE-Y
factor-1,5416,I-GENE-Y
),5416,O
or,5416,O
the,5416,O
zinc,5416,B-CHEMICAL
transporter,5416,I-GENE-Y
ZnT4,5416,I-GENE-Y
.,5416,O
TRPML1,5417,B-GENE-Y
KD,5417,O
is,5417,O
associated,5417,O
with,5417,O
a,5417,O
build-up,5417,O
of,5417,O
cytoplasmic,5417,O
zinc,5417,B-CHEMICAL
and,5417,O
with,5417,O
enhanced,5417,O
transcriptional,5417,O
response,5417,O
of,5417,O
mRNA,5417,O
for,5417,O
MT2a,5417,B-GENE-Y
(,5417,O
metallothionein,5417,B-GENE-Y
2a,5417,I-GENE-Y
),5417,O
.,5417,O
TRPML1,5418,B-GENE-Y
KD,5418,O
did,5418,O
not,5418,O
suppress,5418,O
lysosomal,5418,O
secretion,5418,O
",",5418,O
but,5418,O
it,5418,O
did,5418,O
delay,5418,O
zinc,5418,B-CHEMICAL
leak,5418,O
from,5418,O
the,5418,O
lysosomes,5418,O
into,5418,O
the,5418,O
cytoplasm,5418,O
.,5418,O
These,5419,O
results,5419,O
underscore,5419,O
a,5419,O
role,5419,O
for,5419,O
TRPML1,5419,B-GENE-Y
in,5419,O
zinc,5419,B-CHEMICAL
metabolism,5419,O
.,5419,O
Furthermore,5420,O
",",5420,O
they,5420,O
suggest,5420,O
that,5420,O
TRPML1,5420,B-GENE-Y
works,5420,O
in,5420,O
concert,5420,O
with,5420,O
ZnT4,5420,B-GENE-Y
to,5420,O
regulate,5420,O
zinc,5420,B-CHEMICAL
translocation,5420,O
between,5420,O
the,5420,O
cytoplasm,5420,O
and,5420,O
lysosomes,5420,O
.,5420,O
Evaluation,5421,O
of,5421,O
in,5421,O
vivo,5421,O
anti-hyperglycemic,5421,O
and,5421,O
antioxidant,5421,O
potentials,5421,O
of,5421,O
α-santalol,5421,B-CHEMICAL
and,5421,O
sandalwood,5421,O
oil,5421,O
.,5421,O
Sandalwood,5422,O
finds,5422,O
numerous,5422,O
mentions,5422,O
across,5422,O
diverse,5422,O
traditional,5422,O
medicinal,5422,O
systems,5422,O
in,5422,O
use,5422,O
worldwide,5422,O
.,5422,O
The,5423,O
objective,5423,O
of,5423,O
this,5423,O
study,5423,O
was,5423,O
to,5423,O
evaluate,5423,O
the,5423,O
in,5423,O
vivo,5423,O
anti-hyperglycemic,5423,O
and,5423,O
antioxidant,5423,O
potential,5423,O
of,5423,O
sandalwood,5423,O
oil,5423,O
and,5423,O
its,5423,O
major,5423,O
constituent,5423,O
α-santalol,5423,B-CHEMICAL
.,5423,O
The,5424,O
in,5424,O
vivo,5424,O
anti-hyperglycemic,5424,O
experiment,5424,O
was,5424,O
conducted,5424,O
in,5424,O
alloxan-induced,5424,B-CHEMICAL
diabetic,5424,O
male,5424,O
Swiss,5424,O
albino,5424,O
mice,5424,O
models,5424,O
.,5424,O
The,5425,O
in,5425,O
vivo,5425,O
antioxidant,5425,O
experiment,5425,O
was,5425,O
performed,5425,O
in,5425,O
d-galactose,5425,B-CHEMICAL
mediated,5425,O
oxidative,5425,O
stress,5425,O
induced,5425,O
male,5425,O
Swiss,5425,O
albino,5425,O
mice,5425,O
models,5425,O
.,5425,O
Intraperitoneal,5426,O
administration,5426,O
of,5426,O
α-santalol,5426,B-CHEMICAL
(,5426,O
100mg/kg,5426,O
BW,5426,O
),5426,O
and,5426,O
sandalwood,5426,O
oil,5426,O
(,5426,O
1g/kg,5426,O
BW,5426,O
),5426,O
for,5426,O
an,5426,O
week,5426,O
modulated,5426,O
parameters,5426,O
such,5426,O
as,5426,O
body,5426,O
weight,5426,O
",",5426,O
blood,5426,O
glucose,5426,B-CHEMICAL
",",5426,O
serum,5426,O
bilirubin,5426,B-CHEMICAL
",",5426,O
liver,5426,O
glycogen,5426,O
",",5426,O
and,5426,O
lipid,5426,O
peroxides,5426,B-CHEMICAL
contents,5426,O
to,5426,O
normoglycemic,5426,O
levels,5426,O
in,5426,O
the,5426,O
alloxan-induced,5426,B-CHEMICAL
diabetic,5426,O
mice,5426,O
.,5426,O
Similarly,5427,O
",",5427,O
intraperitoneal,5427,O
administration,5427,O
of,5427,O
α-santalol,5427,B-CHEMICAL
(,5427,O
100mg/kg,5427,O
BW,5427,O
),5427,O
and,5427,O
sandalwood,5427,O
oil,5427,O
(,5427,O
1g/kg,5427,O
BW,5427,O
),5427,O
for,5427,O
two,5427,O
weeks,5427,O
modulated,5427,O
parameters,5427,O
such,5427,O
as,5427,O
serum,5427,O
aminotransferases,5427,B-GENE-N
",",5427,O
alkaline,5427,B-GENE-N
phosphatase,5427,I-GENE-N
",",5427,O
bilirubin,5427,B-CHEMICAL
",",5427,O
superoxide,5427,B-GENE-N
dismutase,5427,I-GENE-N
",",5427,O
catalase,5427,B-GENE-Y
",",5427,O
free,5427,O
sulfhydryl,5427,B-CHEMICAL
",",5427,O
protein,5427,O
carbonyl,5427,B-CHEMICAL
",",5427,O
nitric,5427,B-CHEMICAL
oxide,5427,I-CHEMICAL
",",5427,O
liver,5427,O
lipid,5427,O
peroxide,5427,B-CHEMICAL
contents,5427,O
",",5427,O
and,5427,O
antioxidant,5427,O
capacity,5427,O
in,5427,O
d-galactose,5427,B-CHEMICAL
mediated,5427,O
oxidative,5427,O
stress,5427,O
induced,5427,O
mice,5427,O
.,5427,O
Besides,5428,O
",",5428,O
it,5428,O
was,5428,O
observed,5428,O
that,5428,O
the,5428,O
beneficial,5428,O
effects,5428,O
of,5428,O
α-santalol,5428,B-CHEMICAL
were,5428,O
well,5428,O
complimented,5428,O
",",5428,O
differentially,5428,O
by,5428,O
other,5428,O
constituents,5428,O
present,5428,O
in,5428,O
sandalwood,5428,O
oil,5428,O
",",5428,O
thus,5428,O
indicating,5428,O
synergism,5428,O
in,5428,O
biological,5428,O
activity,5428,O
of,5428,O
this,5428,O
traditionally,5428,O
used,5428,O
bioresource,5428,O
.,5428,O
Serum,5429,B-GENE-N
amyloid,5429,I-GENE-N
A,5429,I-GENE-N
upsurge,5429,O
precedes,5429,O
standard,5429,O
biomarkers,5429,O
of,5429,O
hepatotoxicity,5429,O
in,5429,O
ritodrine-injected,5429,B-CHEMICAL
mice,5429,O
.,5429,O
The,5430,O
tocolytic,5430,O
agent,5430,O
ritodrine,5430,B-CHEMICAL
acts,5430,O
on,5430,O
the,5430,O
β2-adrenoceptor,5430,B-GENE-Y
and,5430,O
is,5430,O
an,5430,O
effective,5430,O
treatment,5430,O
option,5430,O
for,5430,O
preterm,5430,O
labor,5430,O
.,5430,O
However,5431,O
",",5431,O
several,5431,O
adverse,5431,O
effects,5431,O
of,5431,O
ritodrine,5431,B-CHEMICAL
therapy,5431,O
",",5431,O
including,5431,O
liver,5431,O
damage,5431,O
",",5431,O
have,5431,O
been,5431,O
noted,5431,O
.,5431,O
To,5432,O
elucidate,5432,O
the,5432,O
underlying,5432,O
mechanisms,5432,O
of,5432,O
ritodrine-induced,5432,B-CHEMICAL
adverse,5432,O
effects,5432,O
",",5432,O
development,5432,O
of,5432,O
sensitive,5432,O
biomarkers,5432,O
of,5432,O
these,5432,O
adverse,5432,O
events,5432,O
is,5432,O
necessary,5432,O
.,5432,O
Here,5433,O
",",5433,O
we,5433,O
report,5433,O
the,5433,O
development,5433,O
and,5433,O
analysis,5433,O
of,5433,O
an,5433,O
animal,5433,O
model,5433,O
of,5433,O
ritodrine-induced,5433,B-CHEMICAL
liver,5433,O
damage,5433,O
.,5433,O
Female,5434,O
mice,5434,O
received,5434,O
daily,5434,O
ritodrine,5434,B-CHEMICAL
injections,5434,O
for,5434,O
2,5434,O
weeks,5434,O
;,5434,O
liver,5434,O
samples,5434,O
were,5434,O
then,5434,O
collected,5434,O
and,5434,O
subjected,5434,O
to,5434,O
DNA,5434,O
microarray,5434,O
analysis,5434,O
.,5434,O
Ritodrine,5435,B-CHEMICAL
significantly,5435,O
altered,5435,O
the,5435,O
expression,5435,O
of,5435,O
genes,5435,O
related,5435,O
to,5435,O
steroid,5435,B-CHEMICAL
and,5435,O
lipid,5435,O
metabolism,5435,O
",",5435,O
as,5435,O
well,5435,O
as,5435,O
the,5435,O
metabolism,5435,O
of,5435,O
ritodrine,5435,B-CHEMICAL
itself,5435,O
.,5435,O
Importantly,5436,O
",",5436,O
expression,5436,O
of,5436,O
the,5436,O
acute-phase,5436,O
reactant,5436,O
serum,5436,B-GENE-N
amyloid,5436,I-GENE-N
A,5436,I-GENE-N
(,5436,O
SAA,5436,B-GENE-N
),5436,O
significantly,5436,O
increased,5436,O
after,5436,O
ritodrine,5436,B-CHEMICAL
injection,5436,O
",",5436,O
with,5436,O
values,5436,O
indicating,5436,O
the,5436,O
largest,5436,O
fold-change,5436,O
.,5436,O
This,5437,O
large,5437,O
increase,5437,O
in,5437,O
blood,5437,O
SAA,5437,B-GENE-N
levels,5437,O
serves,5437,O
as,5437,O
a,5437,O
more,5437,O
sensitive,5437,O
biomarker,5437,O
than,5437,O
conventional,5437,O
liver,5437,O
enzymes,5437,O
",",5437,O
such,5437,O
as,5437,O
aspartate,5437,B-GENE-Y
aminotransferase,5437,I-GENE-Y
and,5437,O
alanine,5437,B-CHEMICAL
aminotransferase,5437,I-GENE-N
.,5437,O
The,5438,O
increase,5438,O
in,5438,O
SAA,5438,B-GENE-N
expression,5438,O
is,5438,O
specific,5438,O
to,5438,O
ritodrine-induced,5438,B-CHEMICAL
liver,5438,O
damage,5438,O
",",5438,O
because,5438,O
SAA,5438,B-GENE-N
expression,5438,O
was,5438,O
not,5438,O
induced,5438,O
by,5438,O
other,5438,O
hepatotoxic,5438,O
drugs,5438,O
such,5438,O
as,5438,O
acetaminophen,5438,B-CHEMICAL
",",5438,O
valproic,5438,B-CHEMICAL
acid,5438,I-CHEMICAL
",",5438,O
or,5438,O
metformin,5438,B-CHEMICAL
.,5438,O
Our,5439,O
in,5439,O
vitro,5439,O
studies,5439,O
showed,5439,O
that,5439,O
cyclic,5439,B-CHEMICAL
adenosine,5439,I-CHEMICAL
"3',5'-monophosphate",5439,I-CHEMICAL
(,5439,O
cAMP,5439,B-CHEMICAL
),5439,O
accumulation,5439,O
was,5439,O
not,5439,O
a,5439,O
primary,5439,O
cause,5439,O
of,5439,O
the,5439,O
ritodrine-induced,5439,B-CHEMICAL
SAA,5439,B-GENE-N
increase,5439,O
.,5439,O
Instead,5440,O
",",5440,O
SAA,5440,B-GENE-N
expression,5440,O
was,5440,O
enhanced,5440,O
by,5440,O
indirect,5440,O
phosphorylation,5440,O
of,5440,O
the,5440,O
signal,5440,B-GENE-Y
transducer,5440,I-GENE-Y
and,5440,I-GENE-Y
activator,5440,I-GENE-Y
of,5440,I-GENE-Y
transcription-3,5440,I-GENE-Y
(,5440,O
STAT3,5440,B-GENE-Y
),5440,O
mediated,5440,O
by,5440,O
interleukin-6,5440,B-GENE-Y
.,5440,O
Therefore,5441,O
",",5441,O
our,5441,O
study,5441,O
provides,5441,O
a,5441,O
method,5441,O
for,5441,O
sensitive,5441,O
and,5441,O
early,5441,O
detection,5441,O
of,5441,O
hepatic,5441,O
injury,5441,O
",",5441,O
and,5441,O
may,5441,O
thus,5441,O
help,5441,O
preclude,5441,O
serious,5441,O
liver,5441,O
damage,5441,O
due,5441,O
to,5441,O
ritodrine,5441,B-CHEMICAL
use,5441,O
in,5441,O
preterm,5441,O
labor,5441,O
.,5441,O
Ceftazidime-avibactam,5442,B-CHEMICAL
:,5442,O
a,5442,O
novel,5442,O
cephalosporin/β-lactamase,5442,B-CHEMICAL
inhibitor,5442,O
combination,5442,O
.,5442,O
Avibactam,5443,B-CHEMICAL
(,5443,O
formerly,5443,O
NXL104,5443,B-CHEMICAL
",",5443,O
AVE1330A,5443,B-CHEMICAL
),5443,O
is,5443,O
a,5443,O
synthetic,5443,O
non-β-lactam,5443,O
",",5443,O
β-lactamase,5443,B-GENE-N
inhibitor,5443,O
that,5443,O
inhibits,5443,O
the,5443,O
activities,5443,O
of,5443,O
Ambler,5443,B-GENE-N
class,5443,I-GENE-N
A,5443,I-GENE-N
and,5443,I-GENE-N
C,5443,I-GENE-N
β-lactamases,5443,I-GENE-N
and,5443,O
some,5443,O
Ambler,5443,B-GENE-N
class,5443,I-GENE-N
D,5443,I-GENE-N
enzymes,5443,O
.,5443,O
This,5444,O
review,5444,O
summarizes,5444,O
the,5444,O
existing,5444,O
data,5444,O
published,5444,O
for,5444,O
ceftazidime-avibactam,5444,B-CHEMICAL
",",5444,O
including,5444,O
relevant,5444,O
chemistry,5444,O
",",5444,O
mechanisms,5444,O
of,5444,O
action,5444,O
and,5444,O
resistance,5444,O
",",5444,O
microbiology,5444,O
",",5444,O
pharmacokinetics,5444,O
",",5444,O
pharmacodynamics,5444,O
",",5444,O
and,5444,O
efficacy,5444,O
and,5444,O
safety,5444,O
data,5444,O
from,5444,O
animal,5444,O
and,5444,O
human,5444,O
trials,5444,O
.,5444,O
Although,5445,O
not,5445,O
a,5445,O
β-lactam,5445,B-CHEMICAL
",",5445,O
the,5445,O
chemical,5445,O
structure,5445,O
of,5445,O
avibactam,5445,B-CHEMICAL
closely,5445,O
resembles,5445,O
portions,5445,O
of,5445,O
the,5445,O
cephem,5445,B-CHEMICAL
bicyclic,5445,O
ring,5445,O
system,5445,O
",",5445,O
and,5445,O
avibactam,5445,B-CHEMICAL
has,5445,O
been,5445,O
shown,5445,O
to,5445,O
bond,5445,O
covalently,5445,O
to,5445,O
β-lactamases,5445,B-GENE-N
.,5445,O
Very,5446,O
little,5446,O
is,5446,O
known,5446,O
about,5446,O
the,5446,O
potential,5446,O
for,5446,O
avibactam,5446,B-CHEMICAL
to,5446,O
select,5446,O
for,5446,O
resistance,5446,O
.,5446,O
The,5447,O
addition,5447,O
of,5447,O
avibactam,5447,B-CHEMICAL
greatly,5447,O
(,5447,O
4-1024-fold,5447,O
minimum,5447,O
inhibitory,5447,O
concentration,5447,O
[,5447,O
MIC,5447,O
],5447,O
reduction,5447,O
),5447,O
improves,5447,O
the,5447,O
activity,5447,O
of,5447,O
ceftazidime,5447,B-CHEMICAL
versus,5447,O
most,5447,O
species,5447,O
of,5447,O
Enterobacteriaceae,5447,O
depending,5447,O
on,5447,O
the,5447,O
presence,5447,O
or,5447,O
absence,5447,O
of,5447,O
β-lactamase,5447,B-GENE-N
enzyme,5447,O
(,5447,O
s,5447,O
),5447,O
.,5447,O
Against,5448,O
Pseudomonas,5448,O
aeruginosa,5448,O
",",5448,O
the,5448,O
addition,5448,O
of,5448,O
avibactam,5448,B-CHEMICAL
also,5448,O
improves,5448,O
the,5448,O
activity,5448,O
of,5448,O
ceftazidime,5448,B-CHEMICAL
(,5448,O
~fourfold,5448,O
MIC,5448,O
reduction,5448,O
),5448,O
.,5448,O
Limited,5449,O
data,5449,O
suggest,5449,O
that,5449,O
the,5449,O
addition,5449,O
of,5449,O
avibactam,5449,B-CHEMICAL
does,5449,O
not,5449,O
improve,5449,O
the,5449,O
activity,5449,O
of,5449,O
ceftazidime,5449,B-CHEMICAL
versus,5449,O
Acinetobacter,5449,O
species,5449,O
or,5449,O
most,5449,O
anaerobic,5449,O
bacteria,5449,O
(,5449,O
exceptions,5449,O
:,5449,O
Bacteroides,5449,O
fragilis,5449,O
",",5449,O
Clostridium,5449,O
perfringens,5449,O
",",5449,O
Prevotella,5449,O
spp,5449,O
.,5449,O
and,5450,O
Porphyromonas,5450,O
spp,5450,O
.,5450,O
),5450,O
.,5450,O
The,5451,O
pharmacokinetics,5451,O
of,5451,O
avibactam,5451,B-CHEMICAL
follow,5451,O
a,5451,O
two-compartment,5451,O
model,5451,O
and,5451,O
do,5451,O
not,5451,O
appear,5451,O
to,5451,O
be,5451,O
altered,5451,O
by,5451,O
the,5451,O
co-administration,5451,O
of,5451,O
ceftazidime,5451,B-CHEMICAL
.,5451,O
The,5452,O
maximum,5452,O
plasma,5452,O
drug,5452,O
concentration,5452,O
(,5452,O
C,5452,O
(,5452,O
max,5452,O
),5452,O
),5452,O
and,5452,O
area,5452,O
under,5452,O
the,5452,O
plasma,5452,O
concentration-time,5452,O
curve,5452,O
(,5452,O
AUC,5452,O
),5452,O
of,5452,O
avibactam,5452,B-CHEMICAL
increase,5452,O
linearly,5452,O
with,5452,O
doses,5452,O
ranging,5452,O
from,5452,O
50,5452,O
mg,5452,O
to,5452,O
"2,000",5452,O
mg,5452,O
.,5452,O
The,5453,O
mean,5453,O
volume,5453,O
of,5453,O
distribution,5453,O
and,5453,O
half-life,5453,O
of,5453,O
22,5453,O
L,5453,O
(,5453,O
~0.3,5453,O
L/kg,5453,O
),5453,O
and,5453,O
~2,5453,O
hours,5453,O
",",5453,O
respectively,5453,O
",",5453,O
are,5453,O
similar,5453,O
to,5453,O
ceftazidime,5453,B-CHEMICAL
.,5453,O
Like,5454,O
ceftazidime,5454,B-CHEMICAL
",",5454,O
avibactam,5454,B-CHEMICAL
is,5454,O
primarily,5454,O
renally,5454,O
excreted,5454,O
",",5454,O
and,5454,O
clearance,5454,O
correlates,5454,O
with,5454,O
creatinine,5454,B-CHEMICAL
clearance,5454,O
.,5454,O
Pharmacodynamic,5455,O
data,5455,O
suggest,5455,O
that,5455,O
ceftazidime-avibactam,5455,B-CHEMICAL
is,5455,O
rapidly,5455,O
bactericidal,5455,O
versus,5455,O
β-lactamase-producing,5455,B-GENE-N
Gram-negative,5455,O
bacilli,5455,O
that,5455,O
are,5455,O
not,5455,O
inhibited,5455,O
by,5455,O
ceftazidime,5455,B-CHEMICAL
alone.Clinical,5455,O
trials,5455,O
to,5455,O
date,5455,O
have,5455,O
reported,5455,O
that,5455,O
ceftazidime-avibactam,5455,B-CHEMICAL
is,5455,O
as,5455,O
effective,5455,O
as,5455,O
standard,5455,O
carbapenem,5455,B-CHEMICAL
therapy,5455,O
in,5455,O
complicated,5455,O
intra-abdominal,5455,O
infection,5455,O
and,5455,O
complicated,5455,O
urinary,5455,O
tract,5455,O
infection,5455,O
",",5455,O
including,5455,O
infection,5455,O
caused,5455,O
by,5455,O
cephalosporin-resistant,5455,B-CHEMICAL
Gram-negative,5455,O
isolates,5455,O
.,5455,O
The,5456,O
safety,5456,O
and,5456,O
tolerability,5456,O
of,5456,O
ceftazidime-avibactam,5456,B-CHEMICAL
has,5456,O
been,5456,O
reported,5456,O
in,5456,O
three,5456,O
phase,5456,O
I,5456,O
pharmacokinetic,5456,O
studies,5456,O
and,5456,O
two,5456,O
phase,5456,O
II,5456,O
clinical,5456,O
studies,5456,O
.,5456,O
Ceftazidime-avibactam,5457,B-CHEMICAL
appears,5457,O
to,5457,O
be,5457,O
well,5457,O
tolerated,5457,O
in,5457,O
healthy,5457,O
subjects,5457,O
and,5457,O
hospitalized,5457,O
patients,5457,O
",",5457,O
with,5457,O
few,5457,O
serious,5457,O
drug-related,5457,O
treatment-emergent,5457,O
adverse,5457,O
events,5457,O
reported,5457,O
to,5457,O
date.In,5457,O
conclusion,5457,O
",",5457,O
avibactam,5457,B-CHEMICAL
serves,5457,O
to,5457,O
broaden,5457,O
the,5457,O
spectrum,5457,O
of,5457,O
ceftazidime,5457,B-CHEMICAL
versus,5457,O
ß-lactamase-producing,5457,B-GENE-N
Gram-negative,5457,O
bacilli,5457,O
.,5457,O
The,5458,O
exact,5458,O
roles,5458,O
for,5458,O
ceftazidime-avibactam,5458,B-CHEMICAL
will,5458,O
be,5458,O
defined,5458,O
by,5458,O
efficacy,5458,O
and,5458,O
safety,5458,O
data,5458,O
from,5458,O
further,5458,O
clinical,5458,O
trials,5458,O
.,5458,O
Potential,5459,O
future,5459,O
roles,5459,O
for,5459,O
ceftazidime-avibactam,5459,B-CHEMICAL
include,5459,O
the,5459,O
treatment,5459,O
of,5459,O
suspected,5459,O
or,5459,O
documented,5459,O
infections,5459,O
caused,5459,O
by,5459,O
resistant,5459,O
Gram-negative-bacilli,5459,O
producing,5459,O
extended-spectrum,5459,B-GENE-N
ß-lactamase,5459,I-GENE-N
(,5459,O
ESBL,5459,B-GENE-N
),5459,O
",",5459,O
Klebsiella,5459,B-GENE-N
pneumoniae,5459,I-GENE-N
carbapenemases,5459,I-GENE-N
(,5459,O
KPCs,5459,B-GENE-N
),5459,O
and/or,5459,O
AmpC,5459,B-GENE-N
ß-lactamases,5459,I-GENE-N
.,5459,O
In,5460,O
addition,5460,O
",",5460,O
ceftazidime-avibactam,5460,B-CHEMICAL
may,5460,O
be,5460,O
used,5460,O
in,5460,O
combination,5460,O
(,5460,O
with,5460,O
metronidazole,5460,B-CHEMICAL
),5460,O
for,5460,O
suspected,5460,O
polymicrobial,5460,O
infections,5460,O
.,5460,O
Finally,5461,O
",",5461,O
the,5461,O
increased,5461,O
activity,5461,O
of,5461,O
ceftazidime-avibactam,5461,B-CHEMICAL
versus,5461,O
P.,5461,O
aeruginosa,5461,O
may,5461,O
be,5461,O
of,5461,O
clinical,5461,O
benefit,5461,O
in,5461,O
patients,5461,O
with,5461,O
suspected,5461,O
or,5461,O
documented,5461,O
P.,5461,O
aeruginosa,5461,O
infections,5461,O
.,5461,O
Increased,5462,O
human,5462,O
dermal,5462,O
microvascular,5462,O
endothelial,5462,O
cell,5462,O
survival,5462,O
induced,5462,O
by,5462,O
cysteamine,5462,B-CHEMICAL
.,5462,O
BACKGROUND,5463,O
:,5463,O
Cystinosis,5463,O
is,5463,O
an,5463,O
autosomal,5463,O
recessive,5463,O
disease,5463,O
caused,5463,O
by,5463,O
intralysosomal,5463,O
cystine,5463,O
accumulation,5463,O
",",5463,O
treated,5463,O
with,5463,O
cysteamine,5463,B-CHEMICAL
.,5463,O
Recently,5464,O
",",5464,O
new,5464,O
adverse,5464,O
effects,5464,O
of,5464,O
cysteamine,5464,B-CHEMICAL
were,5464,O
reported,5464,O
.,5464,O
Skin,5465,O
biopsies,5465,O
showed,5465,O
microvascular,5465,O
proliferation,5465,O
(,5465,O
angioendotheliomatosis,5465,O
),5465,O
.,5465,O
To,5466,O
examine,5466,O
the,5466,O
mechanism,5466,O
of,5466,O
angioendotheliomatosis,5466,O
associated,5466,O
with,5466,O
cysteamine,5466,B-CHEMICAL
toxicity,5466,O
",",5466,O
we,5466,O
examined,5466,O
the,5466,O
effect,5466,O
of,5466,O
cysteamine,5466,B-CHEMICAL
on,5466,O
human,5466,O
dermal,5466,O
microvascular,5466,O
endothelial,5466,O
cells,5466,O
(,5466,O
HDMVEC,5466,O
),5466,O
.,5466,O
METHODS,5467,O
:,5467,O
After,5467,O
cysteamine,5467,B-CHEMICAL
exposure,5467,O
(,5467,O
range,5467,O
0-3.0,5467,O
mM,5467,O
),5467,O
during,5467,O
24,5467,O
h,5467,O
",",5467,O
cell,5467,O
viability,5467,O
was,5467,O
measured,5467,O
using,5467,O
water,5467,O
soluble,5467,O
tetrazolium,5467,B-CHEMICAL
salt-1,5467,I-CHEMICAL
(,5467,O
WST-1,5467,O
),5467,O
in,5467,O
both,5467,O
control,5467,O
HDMVEC,5467,O
and,5467,O
fibroblasts,5467,O
.,5467,O
Cell,5468,O
proliferation,5468,O
and,5468,O
apoptosis,5468,O
rate,5468,O
were,5468,O
measured,5468,O
in,5468,O
HDMVEC,5468,O
by,5468,O
bromodeoxyuridine,5468,B-CHEMICAL
(,5468,O
BrdU,5468,B-CHEMICAL
),5468,O
incorporation,5468,O
and,5468,O
caspase,5468,B-GENE-Y
3,5468,I-GENE-Y
and,5468,O
caspase,5468,B-GENE-Y
7,5468,I-GENE-Y
activity,5468,O
",",5468,O
respectively,5468,O
.,5468,O
Intracellular,5469,O
glutathione,5469,B-CHEMICAL
(,5469,O
GSH,5469,B-CHEMICAL
),5469,O
was,5469,O
measured,5469,O
in,5469,O
HDMVEC,5469,O
after,5469,O
cysteamine,5469,B-CHEMICAL
exposure,5469,O
of,5469,O
0,5469,O
",",5469,O
0.1,5469,O
or,5469,O
1.0,5469,O
mM,5469,O
.,5469,O
Medium,5470,O
and,5470,O
cysteamine,5470,B-CHEMICAL
were,5470,O
refreshed,5470,O
every,5470,O
6,5470,O
h,5470,O
to,5470,O
mimic,5470,O
the,5470,O
in,5470,O
vivo,5470,O
situation,5470,O
.,5470,O
Next,5471,O
",",5471,O
cell,5471,O
viability,5471,O
in,5471,O
HDMVEC,5471,O
was,5471,O
measured,5471,O
after,5471,O
24,5471,O
h,5471,O
of,5471,O
GSH,5471,B-CHEMICAL
exposure,5471,O
(,5471,O
range,5471,O
0-10.0,5471,O
mM,5471,O
),5471,O
.,5471,O
RESULTS,5472,O
:,5472,O
HDMVEC,5472,O
viability,5472,O
and,5472,O
proliferation,5472,O
increased,5472,O
after,5472,O
cysteamine,5472,B-CHEMICAL
exposure,5472,O
0.03-3.0,5472,O
mM,5472,O
(,5472,O
p,5472,O
<,5472,O
0.01,5472,O
),5472,O
and,5472,O
0.03-1.0,5472,O
mM,5472,O
(,5472,O
p,5472,O
=,5472,O
0.01,5472,O
),5472,O
respectively,5472,O
;,5472,O
cell,5472,O
viability,5472,O
in,5472,O
fibroblasts,5472,O
was,5472,O
not,5472,O
affected,5472,O
by,5472,O
incubation,5472,O
with,5472,O
cysteamine,5472,B-CHEMICAL
.,5472,O
Apoptosis,5473,O
remained,5473,O
unaffected,5473,O
by,5473,O
incubation,5473,O
with,5473,O
0-1.0,5473,O
mM,5473,O
cysteamine,5473,B-CHEMICAL
",",5473,O
3.0,5473,O
mM,5473,O
caused,5473,O
increased,5473,O
apoptosis,5473,O
.,5473,O
Intracellular,5474,O
GSH,5474,B-CHEMICAL
was,5474,O
significantly,5474,O
increased,5474,O
after,5474,O
incubation,5474,O
with,5474,O
cysteamine,5474,B-CHEMICAL
0.1,5474,O
mM,5474,O
(,5474,O
p,5474,O
=,5474,O
0.02,5474,O
),5474,O
and,5474,O
1.0,5474,O
mM,5474,O
(,5474,O
p,5474,O
<,5474,O
0.01,5474,O
),5474,O
.,5474,O
HDMVEC,5475,O
viability,5475,O
increased,5475,O
after,5475,O
exposure,5475,O
to,5475,O
GSH,5475,B-CHEMICAL
1.0-5.0,5475,O
mM,5475,O
(,5475,O
p,5475,O
<,5475,O
0.01,5475,O
),5475,O
.,5475,O
CONCLUSION,5476,O
:,5476,O
Cysteamine,5476,B-CHEMICAL
concentrations,5476,O
",",5476,O
similar,5476,O
to,5476,O
those,5476,O
described,5476,O
in,5476,O
plasma,5476,O
of,5476,O
cystinosis,5476,O
patients,5476,O
",",5476,O
stimulate,5476,O
HDMVEC,5476,O
viability,5476,O
and,5476,O
proliferation,5476,O
and,5476,O
increase,5476,O
intracellular,5476,O
GSH,5476,B-CHEMICAL
content,5476,O
.,5476,O
We,5477,O
postulate,5477,O
that,5477,O
this,5477,O
mechanism,5477,O
might,5477,O
underlie,5477,O
angioendotheliomatosis,5477,O
induced,5477,O
by,5477,O
cysteamine,5477,B-CHEMICAL
.,5477,O
Novel,5478,O
locus,5478,O
including,5478,O
FGF21,5478,B-GENE-Y
is,5478,O
associated,5478,O
with,5478,O
dietary,5478,O
macronutrient,5478,O
intake,5478,O
.,5478,O
Dietary,5479,O
intake,5479,O
of,5479,O
macronutrients,5479,O
(,5479,O
carbohydrate,5479,B-CHEMICAL
",",5479,O
protein,5479,O
",",5479,O
and,5479,O
fat,5479,O
),5479,O
has,5479,O
been,5479,O
associated,5479,O
with,5479,O
risk,5479,O
of,5479,O
chronic,5479,O
conditions,5479,O
such,5479,O
as,5479,O
obesity,5479,O
and,5479,O
diabetes,5479,O
.,5479,O
Family,5480,O
studies,5480,O
have,5480,O
reported,5480,O
a,5480,O
moderate,5480,O
contribution,5480,O
of,5480,O
genetics,5480,O
to,5480,O
variation,5480,O
in,5480,O
macronutrient,5480,O
intake,5480,O
.,5480,O
In,5481,O
a,5481,O
genome-wide,5481,O
meta-analysis,5481,O
of,5481,O
a,5481,O
population-based,5481,O
discovery,5481,O
cohort,5481,O
(,5481,O
n,5481,O
=,5481,O
33,5481,O
533,5481,O
),5481,O
",",5481,O
rs838133,5481,O
in,5481,O
FGF21,5481,B-GENE-Y
(,5481,O
19q13.33,5481,O
),5481,O
",",5481,O
rs197273,5481,O
near,5481,O
TRAF,5481,B-GENE-Y
family,5481,I-GENE-Y
member-associated,5481,I-GENE-Y
NF-kappa-B,5481,I-GENE-Y
activator,5481,I-GENE-Y
(,5481,O
TANK,5481,B-GENE-Y
),5481,O
(,5481,O
2p24.2,5481,O
),5481,O
",",5481,O
and,5481,O
rs10163409,5481,O
in,5481,O
FTO,5481,B-GENE-Y
(,5481,O
16q12.2,5481,O
),5481,O
were,5481,O
among,5481,O
the,5481,O
top,5481,O
associations,5481,O
(,5481,O
P,5481,O
<,5481,O
10,5481,O
(,5481,O
-5,5481,O
),5481,O
),5481,O
for,5481,O
percentage,5481,O
of,5481,O
total,5481,O
caloric,5481,O
intake,5481,O
from,5481,O
protein,5481,O
and,5481,O
carbohydrate,5481,B-CHEMICAL
.,5481,O
rs838133,5482,O
was,5482,O
replicated,5482,O
in,5482,O
silico,5482,O
in,5482,O
an,5482,O
independent,5482,O
sample,5482,O
from,5482,O
the,5482,O
Cohorts,5482,O
for,5482,O
Heart,5482,O
and,5482,O
Aging,5482,O
Research,5482,O
in,5482,O
Genomic,5482,O
Epidemiology,5482,O
Consortium,5482,O
(,5482,O
CHARGE,5482,O
),5482,O
Nutrition,5482,O
Working,5482,O
Group,5482,O
(,5482,O
n,5482,O
=,5482,O
38,5482,O
360,5482,O
),5482,O
and,5482,O
attained,5482,O
genome-wide,5482,O
significance,5482,O
in,5482,O
combined,5482,O
analysis,5482,O
(,5482,O
Pjoint,5482,O
=,5482,O
7.9,5482,O
×,5482,O
10,5482,O
(,5482,O
-9,5482,O
),5482,O
),5482,O
.,5482,O
A,5483,O
cytokine,5483,B-GENE-N
involved,5483,O
in,5483,O
cellular,5483,O
metabolism,5483,O
",",5483,O
FGF21,5483,B-GENE-Y
is,5483,O
a,5483,O
potential,5483,O
susceptibility,5483,O
gene,5483,O
for,5483,O
obesity,5483,O
and,5483,O
type,5483,O
2,5483,O
diabetes,5483,O
.,5483,O
Our,5484,O
results,5484,O
highlight,5484,O
the,5484,O
potential,5484,O
of,5484,O
genetic,5484,O
variation,5484,O
for,5484,O
determining,5484,O
dietary,5484,O
macronutrient,5484,O
intake,5484,O
.,5484,O
Investigation,5485,O
of,5485,O
astatine,5485,B-CHEMICAL
(,5485,I-CHEMICAL
III,5485,I-CHEMICAL
),5485,I-CHEMICAL
hydrolyzed,5485,O
species,5485,O
:,5485,O
experiments,5485,O
and,5485,O
relativistic,5485,O
calculations,5485,O
.,5485,O
This,5486,O
work,5486,O
aims,5486,O
to,5486,O
resolve,5486,O
some,5486,O
controversies,5486,O
about,5486,O
astatine,5486,B-CHEMICAL
(,5486,I-CHEMICAL
III,5486,I-CHEMICAL
),5486,I-CHEMICAL
hydroxide,5486,I-CHEMICAL
species,5486,O
present,5486,O
in,5486,O
oxidant,5486,O
aqueous,5486,O
solution,5486,O
.,5486,O
AtO,5487,B-CHEMICAL
(,5487,I-CHEMICAL
+,5487,I-CHEMICAL
),5487,I-CHEMICAL
is,5487,O
the,5487,O
dominant,5487,O
species,5487,O
existing,5487,O
under,5487,O
oxidizing,5487,O
and,5487,O
acidic,5487,O
pH,5487,O
conditions,5487,O
.,5487,O
This,5488,O
is,5488,O
consistent,5488,O
with,5488,O
high-performance,5488,O
ion-exchange,5488,O
chromatography,5488,O
data,5488,O
showing,5488,O
the,5488,O
existence,5488,O
of,5488,O
one,5488,O
species,5488,O
holding,5488,O
one,5488,O
positive,5488,O
charge,5488,O
.,5488,O
A,5489,O
change,5489,O
in,5489,O
speciation,5489,O
occurs,5489,O
as,5489,O
the,5489,O
pH,5489,O
changes,5489,O
from,5489,O
1,5489,O
to,5489,O
4,5489,O
",",5489,O
while,5489,O
remaining,5489,O
under,5489,O
oxidizing,5489,O
conditions,5489,O
.,5489,O
Dynamic,5490,O
experiments,5490,O
with,5490,O
ion-exchange,5490,O
resins,5490,O
evidence,5490,O
the,5490,O
existence,5490,O
of,5490,O
a,5490,O
neutral,5490,O
species,5490,O
witnessed,5490,O
by,5490,O
its,5490,O
elution,5490,O
in,5490,O
the,5490,O
void,5490,O
volume,5490,O
.,5490,O
Batch-experiments,5491,O
using,5491,O
a,5491,O
competition,5491,O
method,5491,O
show,5491,O
the,5491,O
exchange,5491,O
of,5491,O
one,5491,O
proton,5491,O
indicating,5491,O
the,5491,O
formation,5491,O
of,5491,O
the,5491,O
AtO,5491,B-CHEMICAL
(,5491,I-CHEMICAL
OH,5491,I-CHEMICAL
),5491,I-CHEMICAL
species,5491,O
.,5491,O
The,5492,O
hydrolysis,5492,O
thermodynamic,5492,O
constant,5492,O
",",5492,O
extrapolated,5492,O
to,5492,O
zero,5492,O
ionic,5492,O
strength,5492,O
",",5492,O
was,5492,O
determined,5492,O
to,5492,O
be,5492,O
10,5492,O
(,5492,O
-1.9,5492,O
),5492,O
.,5492,O
This,5493,O
value,5493,O
is,5493,O
supported,5493,O
by,5493,O
two-component,5493,O
relativistic,5493,O
quantum,5493,O
calculations,5493,O
and,5493,O
therefore,5493,O
allows,5493,O
disclosing,5493,O
unambiguously,5493,O
the,5493,O
structure,5493,O
of,5493,O
the,5493,O
formed,5493,O
species,5493,O
.,5493,O
Trim24-repressed,5494,B-GENE-Y
VL30,5494,B-GENE-N
retrotransposons,5494,I-GENE-N
regulate,5494,O
gene,5494,O
expression,5494,O
by,5494,O
producing,5494,O
noncoding,5494,O
RNA,5494,O
.,5494,O
Trim24,5495,B-GENE-Y
(,5495,O
Tif1α,5495,B-GENE-Y
),5495,O
and,5495,O
Trim33,5495,B-GENE-Y
(,5495,O
Tif1γ,5495,B-GENE-Y
),5495,O
interact,5495,O
to,5495,O
form,5495,O
a,5495,O
co-repressor,5495,O
complex,5495,O
that,5495,O
suppresses,5495,O
murine,5495,O
hepatocellular,5495,O
carcinoma,5495,O
.,5495,O
Here,5496,O
we,5496,O
show,5496,O
that,5496,O
Trim24,5496,B-GENE-Y
and,5496,O
Trim33,5496,B-GENE-Y
cooperatively,5496,O
repress,5496,O
retinoic,5496,B-GENE-N
acid,5496,I-GENE-N
receptor-dependent,5496,O
activity,5496,O
of,5496,O
VL30-class,5496,B-GENE-N
endogenous,5496,O
retroviruses,5496,O
(,5496,O
ERVs,5496,O
),5496,O
in,5496,O
liver,5496,O
.,5496,O
In,5497,O
Trim24-knockout,5497,B-GENE-Y
hepatocytes,5497,O
",",5497,O
VL30,5497,B-GENE-N
derepression,5497,O
leads,5497,O
to,5497,O
accumulation,5497,O
of,5497,O
reverse-transcribed,5497,O
VL30,5497,B-GENE-N
cDNA,5497,O
in,5497,O
the,5497,O
cytoplasm,5497,O
that,5497,O
correlates,5497,O
with,5497,O
activation,5497,O
of,5497,O
the,5497,O
viral-defense,5497,O
interferon,5497,B-GENE-N
responses,5497,O
mimicking,5497,O
the,5497,O
preneoplastic,5497,O
inflammatory,5497,O
state,5497,O
seen,5497,O
in,5497,O
human,5497,O
liver,5497,O
following,5497,O
exogenous,5497,O
viral,5497,O
infection,5497,O
.,5497,O
Furthermore,5498,O
",",5498,O
upon,5498,O
derepression,5498,O
",",5498,O
VL30,5498,B-GENE-N
long,5498,I-GENE-N
terminal,5498,I-GENE-N
repeats,5498,I-GENE-N
(,5498,O
LTRs,5498,B-GENE-N
),5498,O
act,5498,O
as,5498,O
promoter,5498,B-GENE-N
and,5498,I-GENE-N
enhancer,5498,I-GENE-N
elements,5498,I-GENE-N
deregulating,5498,O
expression,5498,O
of,5498,O
neighboring,5498,O
genes,5498,O
and,5498,O
generating,5498,O
enhancer,5498,O
RNAs,5498,O
that,5498,O
are,5498,O
required,5498,O
for,5498,O
LTR,5498,B-GENE-N
enhancer,5498,I-GENE-N
activity,5498,O
in,5498,O
hepatocytes,5498,O
in,5498,O
vivo,5498,O
.,5498,O
These,5499,O
data,5499,O
reinforce,5499,O
the,5499,O
role,5499,O
of,5499,O
the,5499,O
TRIM,5499,B-GENE-N
family,5499,O
of,5499,O
proteins,5499,O
in,5499,O
retroviral,5499,O
restriction,5499,O
and,5499,O
antiviral,5499,O
defense,5499,O
and,5499,O
provide,5499,O
an,5499,O
example,5499,O
of,5499,O
an,5499,O
ERV-derived,5499,O
oncogenic,5499,O
regulatory,5499,O
network,5499,O
.,5499,O
Apelin,5500,B-GENE-Y
inhibits,5500,O
diet-induced,5500,O
obesity,5500,O
by,5500,O
enhancing,5500,O
lymphatic,5500,O
and,5500,O
blood,5500,O
vessel,5500,O
integrity,5500,O
.,5500,O
Angiogenesis,5501,O
is,5501,O
tightly,5501,O
associated,5501,O
with,5501,O
the,5501,O
outgrowth,5501,O
of,5501,O
adipose,5501,O
tissue,5501,O
",",5501,O
leading,5501,O
to,5501,O
obesity,5501,O
",",5501,O
which,5501,O
is,5501,O
a,5501,O
risk,5501,O
factor,5501,O
for,5501,O
type,5501,O
2,5501,O
diabetes,5501,O
and,5501,O
hypertension,5501,O
",",5501,O
mainly,5501,O
because,5501,O
expanding,5501,O
adipose,5501,O
tissue,5501,O
requires,5501,O
an,5501,O
increased,5501,O
nutrient,5501,O
supply,5501,O
from,5501,O
blood,5501,O
vessels,5501,O
.,5501,O
Therefore,5502,O
",",5502,O
induction,5502,O
of,5502,O
vessel,5502,O
abnormality,5502,O
by,5502,O
adipokines,5502,B-GENE-N
has,5502,O
been,5502,O
well,5502,O
studied,5502,O
",",5502,O
whereas,5502,O
how,5502,O
altered,5502,O
vascular,5502,O
function,5502,O
promotes,5502,O
obesity,5502,O
is,5502,O
relatively,5502,O
unexplored,5502,O
.,5502,O
Also,5503,O
",",5503,O
surviving,5503,O
Prox1,5503,B-GENE-Y
heterozygous,5503,O
mice,5503,O
showed,5503,O
abnormal,5503,O
lymphatic,5503,O
patterning,5503,O
and,5503,O
adult-onset,5503,O
obesity,5503,O
",",5503,O
indicating,5503,O
that,5503,O
accumulation,5503,O
of,5503,O
adipocytes,5503,O
could,5503,O
be,5503,O
closely,5503,O
linked,5503,O
with,5503,O
lymphatic,5503,O
function,5503,O
.,5503,O
Here,5504,O
we,5504,O
propose,5504,O
a,5504,O
new,5504,O
anti-obesity,5504,O
strategy,5504,O
based,5504,O
on,5504,O
enhancement,5504,O
of,5504,O
lymphatic,5504,O
and,5504,O
blood,5504,O
vessel,5504,O
integrity,5504,O
with,5504,O
apelin,5504,B-GENE-Y
.,5504,O
Apelin-knockout,5505,B-GENE-Y
mice,5505,O
given,5505,O
a,5505,O
high-fat,5505,O
diet,5505,O
showed,5505,O
an,5505,O
obese,5505,O
phenotype,5505,O
associated,5505,O
with,5505,O
abnormal,5505,O
lymphatic,5505,O
and,5505,O
blood,5505,O
vessel,5505,O
enlargement,5505,O
.,5505,O
Fatty,5506,B-CHEMICAL
acids,5506,I-CHEMICAL
present,5506,O
in,5506,O
the,5506,O
high-fat,5506,O
diet,5506,O
induced,5506,O
hyperpermeability,5506,O
of,5506,O
endothelial,5506,O
cells,5506,O
",",5506,O
causing,5506,O
adipocyte,5506,O
differentiation,5506,O
",",5506,O
whereas,5506,O
apelin,5506,O
promoted,5506,O
vascular,5506,O
stabilization,5506,O
.,5506,O
Moreover,5507,O
",",5507,O
treatment,5507,O
of,5507,O
high-fat-diet-fed,5507,O
apelin-knockout,5507,B-GENE-Y
mice,5507,O
with,5507,O
a,5507,O
selective,5507,O
cyclooxygenase-2,5507,B-GENE-Y
inhibitor,5507,O
",",5507,O
celecoxib,5507,B-CHEMICAL
",",5507,O
improved,5507,O
vascular,5507,O
function,5507,O
",",5507,O
and,5507,O
also,5507,O
attenuated,5507,O
obesity,5507,O
.,5507,O
Finally,5508,O
",",5508,O
apelin,5508,B-GENE-Y
transgenic,5508,O
mice,5508,O
showed,5508,O
decreased,5508,O
subcutaneous,5508,O
adipose,5508,O
tissue,5508,O
owing,5508,O
to,5508,O
inhibition,5508,O
of,5508,O
high-fat-diet-induced,5508,O
hyperpermeability,5508,O
of,5508,O
vessels,5508,O
.,5508,O
These,5509,O
results,5509,O
indicate,5509,O
that,5509,O
apelin,5509,O
inhibits,5509,O
high-fat-diet-induced,5509,O
obesity,5509,O
by,5509,O
enhancing,5509,O
vessel,5509,O
integrity,5509,O
.,5509,O
Apelin,5510,B-GENE-Y
could,5510,O
serve,5510,O
as,5510,O
a,5510,O
therapeutic,5510,O
target,5510,O
for,5510,O
treating,5510,O
obesity,5510,O
and,5510,O
related,5510,O
diseases,5510,O
.,5510,O
Activation,5511,O
of,5511,O
the,5511,O
anti-cancer,5511,O
agent,5511,O
upamostat,5511,B-CHEMICAL
by,5511,O
the,5511,O
mARC,5511,B-GENE-N
enzyme,5511,O
system,5511,O
.,5511,O
Abstract,5512,O
1,5512,O
.,5512,O
Upamostat,5513,B-CHEMICAL
(,5513,O
Mesupron®,5513,B-CHEMICAL
),5513,O
is,5513,O
a,5513,O
new,5513,O
small,5513,O
molecule,5513,O
serine,5513,B-GENE-N
protease,5513,I-GENE-N
inhibitor,5513,O
.,5513,O
The,5514,O
drug,5514,O
candidate,5514,O
was,5514,O
developed,5514,O
to,5514,O
inhibit,5514,O
the,5514,O
urokinase-type,5514,B-GENE-Y
plasminogen,5514,I-GENE-Y
activator,5514,I-GENE-Y
(,5514,O
uPA,5514,B-GENE-Y
),5514,O
system,5514,O
",",5514,O
which,5514,O
plays,5514,O
a,5514,O
major,5514,O
role,5514,O
in,5514,O
tumor,5514,O
invasion,5514,O
and,5514,O
metastasis,5514,O
.,5514,O
Upamostat,5515,B-CHEMICAL
is,5515,O
currently,5515,O
in,5515,O
clinical,5515,O
development,5515,O
as,5515,O
an,5515,O
anti-metastatic,5515,O
and,5515,O
non-cytotoxic,5515,O
agent,5515,O
against,5515,O
pancreatic,5515,O
and,5515,O
breast,5515,O
cancer,5515,O
.,5515,O
2,5516,O
.,5516,O
Upamostat,5517,B-CHEMICAL
is,5517,O
the,5517,O
orally,5517,O
available,5517,O
amidoxime-,5517,B-CHEMICAL
(,5517,O
i.e,5517,O
.,5517,O
hydroxyamidine-,5518,B-CHEMICAL
),5518,O
prodrug,5518,O
of,5518,O
the,5518,O
pharmacologically,5518,O
active,5518,O
form,5518,O
",",5518,O
WX-UK1,5518,B-CHEMICAL
.,5518,O
In,5519,O
this,5519,O
study,5519,O
",",5519,O
the,5519,O
reductive,5519,O
enzymatic,5519,O
activation,5519,O
of,5519,O
upamostat,5519,B-CHEMICAL
to,5519,O
its,5519,O
corresponding,5519,O
amidine,5519,O
WX-UK1,5519,B-CHEMICAL
was,5519,O
analyzed,5519,O
.,5519,O
3,5520,O
.,5520,O
The,5521,O
recently,5521,O
discovered,5521,O
molybdenum,5521,B-CHEMICAL
enzyme,5521,O
``,5521,O
mitochondrial,5521,B-GENE-N
Amidoxime,5521,I-GENE-N
Reducing,5521,I-GENE-N
Component,5521,I-GENE-N
'',5521,O
(,5521,O
mARC,5521,B-GENE-N
),5521,O
catalyses,5521,O
together,5521,O
with,5521,O
its,5521,O
electron,5521,B-GENE-N
transport,5521,I-GENE-N
proteins,5521,I-GENE-N
cytochrome,5521,B-GENE-Y
b,5521,I-GENE-Y
(,5521,I-GENE-Y
5,5521,I-GENE-Y
),5521,I-GENE-Y
and,5521,O
NADH,5521,B-GENE-N
cytochrome,5521,I-GENE-N
b,5521,I-GENE-N
(,5521,I-GENE-N
5,5521,I-GENE-N
),5521,I-GENE-N
reductase,5521,I-GENE-N
the,5521,O
reduction,5521,O
of,5521,O
N-hydroxylated,5521,B-CHEMICAL
prodrugs,5521,O
.,5521,O
In,5522,O
vitro,5522,O
biotransformation,5522,O
assays,5522,O
with,5522,O
porcine,5522,O
subcellular,5522,O
fractions,5522,O
and,5522,O
the,5522,O
reconstituted,5522,O
human,5522,O
enzymes,5522,O
demonstrate,5522,O
an,5522,O
mARC-dependent,5522,B-GENE-N
N-reduction,5522,B-CHEMICAL
of,5522,O
upamostat,5522,B-CHEMICAL
.,5522,O
Differential,5523,O
autophagic,5523,O
cell,5523,O
death,5523,O
under,5523,O
stress,5523,O
with,5523,O
ectopic,5523,O
cytoplasmic,5523,O
and,5523,O
mitochondrial-specific,5523,O
PPP2R2B,5523,B-GENE-Y
in,5523,O
human,5523,O
neuroblastoma,5523,O
cells,5523,O
.,5523,O
Protein,5524,B-GENE-N
phosphatase,5524,I-GENE-N
2A,5524,I-GENE-N
is,5524,O
one,5524,O
of,5524,O
four,5524,O
major,5524,O
classes,5524,O
of,5524,O
serine/threonine,5524,B-CHEMICAL
phosphatases,5524,I-GENE-N
.,5524,O
Overexpression,5525,O
of,5525,O
brain-specific,5525,O
regulatory,5525,O
subunit,5525,O
PPP2R2,5525,B-GENE-N
in,5525,O
neuron,5525,O
cells,5525,O
is,5525,O
implicated,5525,O
in,5525,O
pathogenesis,5525,O
.,5525,O
The,5526,O
alternative,5526,O
splicing,5526,O
of,5526,O
PPP2R2B,5526,B-GENE-Y
encodes,5526,O
two,5526,O
isoforms,5526,O
.,5526,O
They,5527,O
are,5527,O
subunit,5527,O
of,5527,O
cytoplasmic,5527,O
specific,5527,O
Bβ1,5527,B-GENE-Y
and,5527,O
mitochondria-targeted,5527,O
Bβ2,5527,B-GENE-Y
.,5527,O
The,5528,O
two,5528,O
constructs,5528,O
were,5528,O
transfected,5528,O
into,5528,O
human,5528,O
neuroblastoma,5528,O
cells,5528,O
",",5528,O
SK-N-SH,5528,O
",",5528,O
respectively,5528,O
",",5528,O
and,5528,O
the,5528,O
stable,5528,O
clones,5528,O
overexpressing,5528,O
either,5528,O
Bβ1,5528,B-GENE-Y
or,5528,O
Bβ2,5528,B-GENE-Y
established,5528,O
.,5528,O
We,5529,O
have,5529,O
reported,5529,O
that,5529,O
Bβ2,5529,B-GENE-Y
clones,5529,O
are,5529,O
sensitive,5529,O
to,5529,O
reactive,5529,O
oxygen,5529,B-CHEMICAL
species,5529,O
(,5529,O
ROS,5529,O
),5529,O
treatment,5529,O
by,5529,O
inducing,5529,O
autophagic,5529,O
cell,5529,O
death,5529,O
.,5529,O
To,5530,O
study,5530,O
more,5530,O
on,5530,O
the,5530,O
onset,5530,O
of,5530,O
neuropathogenesis,5530,O
under,5530,O
strain,5530,O
",",5530,O
both,5530,O
clones,5530,O
were,5530,O
exposed,5530,O
to,5530,O
different,5530,O
environmental,5530,O
stress,5530,O
",",5530,O
e.g,5530,O
.,5530,O
starvation,5531,O
and,5531,O
endoplasmic,5531,O
reticulum,5531,O
(,5531,O
ER,5531,O
),5531,O
stress,5531,O
.,5531,O
To,5532,O
learn,5532,O
how,5532,O
PPP2R2B,5532,B-GENE-N
overexpression,5532,O
responds,5532,O
to,5532,O
starvation,5532,O
",",5532,O
cells,5532,O
were,5532,O
incubated,5532,O
in,5532,O
Hank,5532,O
's,5532,O
buffered,5532,O
salt,5532,O
solution,5532,O
of,5532,O
deprived,5532,O
nutrient,5532,O
.,5532,O
Cell,5533,O
death,5533,O
was,5533,O
induced,5533,O
in,5533,O
Bβ1,5533,B-GENE-Y
clones,5533,O
after,5533,O
6,5533,O
h,5533,O
starvation,5533,O
",",5533,O
but,5533,O
not,5533,O
in,5533,O
Bβ2,5533,B-GENE-Y
clones,5533,O
.,5533,O
The,5534,O
pharmacological,5534,O
inhibitor,5534,O
",",5534,O
Bafilomycin,5534,B-CHEMICAL
A1,5534,I-CHEMICAL
",",5534,O
rescued,5534,O
the,5534,O
cell,5534,O
death,5534,O
while,5534,O
suppressing,5534,O
autophagy,5534,O
.,5534,O
On,5535,O
the,5535,O
other,5535,O
hand,5535,O
",",5535,O
to,5535,O
assess,5535,O
how,5535,O
cells,5535,O
respond,5535,O
to,5535,O
ER,5535,O
stress,5535,O
",",5535,O
the,5535,O
cells,5535,O
were,5535,O
treated,5535,O
with,5535,O
0.1,5535,O
μM,5535,O
of,5535,O
N-glycosylation,5535,B-CHEMICAL
inhibitor,5535,O
",",5535,O
tunicamycin,5535,B-CHEMICAL
(,5535,O
TM,5535,O
),5535,O
.,5535,O
In,5536,O
contrast,5536,O
with,5536,O
Bβ1,5536,B-GENE-Y
",",5536,O
the,5536,O
apoptotic,5536,O
cell,5536,O
death,5536,O
appeared,5536,O
in,5536,O
Bβ2,5536,B-GENE-Y
after,5536,O
48,5536,O
h,5536,O
treatment,5536,O
.,5536,O
The,5537,O
formation,5537,O
of,5537,O
autophagolysosome,5537,O
was,5537,O
detected,5537,O
in,5537,O
Bβ2,5537,B-GENE-N
following,5537,O
12,5537,O
h,5537,O
treatment,5537,O
with,5537,O
TM,5537,O
as,5537,O
evidenced,5537,O
by,5537,O
lysotracker,5537,O
and,5537,O
GFP-LC3,5537,O
staining,5537,O
for,5537,O
fluorescence,5537,O
microscopy,5537,O
analysis,5537,O
.,5537,O
The,5538,O
autophagy,5538,O
inhibitor,5538,O
",",5538,O
3-methyladenine,5538,B-CHEMICAL
",",5538,O
salvaged,5538,O
the,5538,O
final,5538,O
apoptosis,5538,O
.,5538,O
The,5539,O
stable,5539,O
cell,5539,O
lines,5539,O
with,5539,O
ectopically,5539,O
transfected,5539,O
PPP2R2B,5539,B-GENE-Y
genes,5539,O
encoding,5539,O
isoforms,5539,O
of,5539,O
brain-specific,5539,O
regulatory,5539,O
subunit,5539,O
exhibit,5539,O
distinct,5539,O
apoptosis,5539,O
under,5539,O
different,5539,O
stressors,5539,O
.,5539,O
The,5540,O
induced,5540,O
autophagic,5540,O
apoptotic,5540,O
cell,5540,O
death,5540,O
is,5540,O
related,5540,O
to,5540,O
mitochondrial,5540,O
membrane,5540,O
potential,5540,O
drop,5540,O
and,5540,O
ROS,5540,O
generation,5540,O
.,5540,O
Disturbance,5541,O
of,5541,O
autophagy,5541,O
alleviates,5541,O
the,5541,O
induced,5541,O
cell,5541,O
death,5541,O
.,5541,O
The,5542,O
results,5542,O
promised,5542,O
a,5542,O
good,5542,O
model,5542,O
for,5542,O
understanding,5542,O
the,5542,O
onset,5542,O
in,5542,O
pathogenesis,5542,O
under,5542,O
stress,5542,O
in,5542,O
neuron,5542,O
cells,5542,O
with,5542,O
aberrant,5542,O
PPP2R2B,5542,B-GENE-Y
expression,5542,O
.,5542,O
Population,5543,O
pharmacokinetics,5543,O
of,5543,O
atorvastatin,5543,B-CHEMICAL
and,5543,O
its,5543,O
active,5543,O
metabolites,5543,O
in,5543,O
children,5543,O
and,5543,O
adolescents,5543,O
with,5543,O
heterozygous,5543,O
familial,5543,O
hypercholesterolemia,5543,O
:,5543,O
selective,5543,O
use,5543,O
of,5543,O
informative,5543,O
prior,5543,O
distributions,5543,O
from,5543,O
adults,5543,O
.,5543,O
The,5544,O
population,5544,O
pharmacokinetics,5544,O
(,5544,O
PPK,5544,O
),5544,O
of,5544,O
atorvastatin,5544,B-CHEMICAL
and,5544,O
its,5544,O
principal,5544,O
active,5544,O
metabolite,5544,O
",",5544,O
o-hydroxyatorvastatin,5544,B-CHEMICAL
",",5544,O
were,5544,O
described,5544,O
in,5544,O
6-17,5544,O
years,5544,O
old,5544,O
pediatric,5544,O
hypercholesterolemia,5544,O
patients,5544,O
with,5544,O
a,5544,O
2-compartment,5544,O
model,5544,O
for,5544,O
both,5544,O
parent,5544,O
and,5544,O
metabolite,5544,O
.,5544,O
Informative,5545,O
prior,5545,O
distributions,5545,O
on,5545,O
selected,5545,O
parameters,5545,O
",",5545,O
based,5545,O
on,5545,O
adult,5545,O
data,5545,O
",",5545,O
were,5545,O
required,5545,O
to,5545,O
stabilize,5545,O
the,5545,O
model,5545,O
and,5545,O
were,5545,O
implemented,5545,O
using,5545,O
a,5545,O
Bayesian,5545,O
penalty,5545,O
term,5545,O
on,5545,O
the,5545,O
likelihood,5545,O
function,5545,O
in,5545,O
the,5545,O
nonlinear,5545,O
mixed,5545,O
effects,5545,O
model,5545,O
(,5545,O
NONMEM,5545,O
VI,5545,O
with,5545,O
PRIOR,5545,O
),5545,O
.,5545,O
Concentrations,5546,O
below,5546,O
the,5546,O
limit,5546,O
of,5546,O
quantitation,5546,O
were,5546,O
treated,5546,O
as,5546,O
censored,5546,O
data,5546,O
using,5546,O
a,5546,O
conditional,5546,O
likelihood,5546,O
function,5546,O
.,5546,O
Atorvastatin,5547,B-CHEMICAL
apparent,5547,O
oral,5547,O
clearance,5547,O
(,5547,O
CL/F,5547,O
),5547,O
was,5547,O
described,5547,O
as,5547,O
a,5547,O
function,5547,O
of,5547,O
body,5547,O
weight,5547,O
using,5547,O
an,5547,O
allometric,5547,O
equation,5547,O
.,5547,O
Based,5548,O
on,5548,O
the,5548,O
final,5548,O
model,5548,O
",",5548,O
the,5548,O
typical,5548,O
CL/F,5548,O
estimates,5548,O
for,5548,O
a,5548,O
Tanner,5548,O
Stage,5548,O
1,5548,O
patient,5548,O
(,5548,O
35,5548,O
kg,5548,O
weight,5548,O
),5548,O
and,5548,O
Tanner,5548,O
Stage,5548,O
≥2,5548,O
(,5548,O
50,5548,O
kg,5548,O
weight,5548,O
),5548,O
",",5548,O
would,5548,O
be,5548,O
553,5548,O
and,5548,O
543,5548,O
L/hour,5548,O
",",5548,O
respectively,5548,O
.,5548,O
When,5549,O
scaled,5549,O
allometrically,5549,O
",",5549,O
CL/F,5549,O
was,5549,O
similar,5549,O
to,5549,O
values,5549,O
reported,5549,O
for,5549,O
adults,5549,O
.,5549,O
Variability,5550,O
in,5550,O
atorvastatin,5550,B-CHEMICAL
PK,5550,O
was,5550,O
primarily,5550,O
affected,5550,O
by,5550,O
weight,5550,O
.,5550,O
A,5551,O
high-confidence,5551,O
interaction,5551,O
map,5551,O
identifies,5551,O
SIRT1,5551,B-GENE-Y
as,5551,O
a,5551,O
mediator,5551,O
of,5551,O
acetylation,5551,O
of,5551,O
USP22,5551,B-GENE-Y
and,5551,O
the,5551,O
SAGA,5551,B-GENE-N
coactivator,5551,O
complex,5551,O
.,5551,O
Although,5552,O
many,5552,O
functions,5552,O
and,5552,O
targets,5552,O
have,5552,O
been,5552,O
attributed,5552,O
to,5552,O
the,5552,O
histone,5552,B-GENE-N
and,5552,O
protein,5552,B-GENE-N
deacetylase,5552,I-GENE-N
SIRT1,5552,B-GENE-Y
",",5552,O
a,5552,O
comprehensive,5552,O
analysis,5552,O
of,5552,O
SIRT1,5552,B-GENE-Y
binding,5552,O
proteins,5552,O
yielding,5552,O
a,5552,O
high-confidence,5552,O
interaction,5552,O
map,5552,O
has,5552,O
not,5552,O
been,5552,O
established,5552,O
.,5552,O
Using,5553,O
a,5553,O
comparative,5553,O
statistical,5553,O
analysis,5553,O
of,5553,O
binding,5553,O
partners,5553,O
",",5553,O
we,5553,O
have,5553,O
assembled,5553,O
a,5553,O
high-confidence,5553,O
SIRT1,5553,B-GENE-Y
interactome,5553,O
.,5553,O
Employing,5554,O
this,5554,O
method,5554,O
",",5554,O
we,5554,O
identified,5554,O
the,5554,O
deubiquitinating,5554,O
enzyme,5554,O
ubiquitin-specific,5554,B-GENE-Y
protease,5554,I-GENE-Y
22,5554,I-GENE-Y
(,5554,O
USP22,5554,B-GENE-Y
),5554,O
",",5554,O
a,5554,O
component,5554,O
of,5554,O
the,5554,O
deubiquitinating,5554,O
module,5554,O
(,5554,O
DUBm,5554,O
),5554,O
of,5554,O
the,5554,O
SAGA,5554,B-GENE-N
transcriptional,5554,O
coactivating,5554,O
complex,5554,O
",",5554,O
as,5554,O
a,5554,O
SIRT1-interacting,5554,B-GENE-Y
partner,5554,O
.,5554,O
We,5555,O
found,5555,O
that,5555,O
this,5555,O
interaction,5555,O
is,5555,O
highly,5555,O
specific,5555,O
",",5555,O
requires,5555,O
the,5555,O
ZnF-UBP,5555,B-CHEMICAL
domain,5555,I-GENE-N
of,5555,O
USP22,5555,B-GENE-Y
",",5555,O
and,5555,O
is,5555,O
disrupted,5555,O
by,5555,O
the,5555,O
inactivating,5555,O
H363Y,5555,B-GENE-N
mutation,5555,O
within,5555,O
SIRT1,5555,B-GENE-Y
.,5555,O
Moreover,5556,O
",",5556,O
we,5556,O
show,5556,O
that,5556,O
USP22,5556,B-GENE-Y
is,5556,O
acetylated,5556,O
on,5556,O
multiple,5556,O
lysine,5556,B-CHEMICAL
residues,5556,O
and,5556,O
that,5556,O
alteration,5556,O
of,5556,O
a,5556,O
single,5556,O
lysine,5556,B-CHEMICAL
(,5556,O
K129,5556,O
),5556,O
within,5556,O
the,5556,O
ZnF-UBP,5556,B-CHEMICAL
domain,5556,I-GENE-N
is,5556,O
sufficient,5556,O
to,5556,O
alter,5556,O
interaction,5556,O
of,5556,O
the,5556,O
DUBm,5556,B-GENE-N
with,5556,O
the,5556,O
core,5556,O
SAGA,5556,B-GENE-N
complex,5556,O
.,5556,O
Furthermore,5557,O
",",5557,O
USP22-mediated,5557,B-GENE-Y
recruitment,5557,O
of,5557,O
SIRT1,5557,B-GENE-Y
activity,5557,O
promotes,5557,O
the,5557,O
deacetylation,5557,O
of,5557,O
individual,5557,O
SAGA,5557,B-GENE-N
complex,5557,O
components,5557,O
.,5557,O
Our,5558,O
results,5558,O
indicate,5558,O
an,5558,O
important,5558,O
role,5558,O
of,5558,O
SIRT1-mediated,5558,B-GENE-Y
deacetylation,5558,O
in,5558,O
regulating,5558,O
the,5558,O
formation,5558,O
of,5558,O
DUBm,5558,B-GENE-N
subcomplexes,5558,O
within,5558,O
the,5558,O
larger,5558,O
SAGA,5558,B-GENE-N
complex,5558,O
.,5558,O
Characterization,5559,O
of,5559,O
cytosolic,5559,B-GENE-Y
glutathione,5559,I-GENE-Y
peroxidase,5559,I-GENE-Y
and,5559,O
phospholipid-hydroperoxide,5559,B-GENE-N
glutathione,5559,I-GENE-N
peroxidase,5559,I-GENE-N
genes,5559,O
in,5559,O
rainbow,5559,O
trout,5559,O
(,5559,O
Oncorhynchus,5559,O
mykiss,5559,O
),5559,O
and,5559,O
their,5559,O
modulation,5559,O
by,5559,O
in,5559,O
vitro,5559,O
selenium,5559,B-CHEMICAL
exposure,5559,O
.,5559,O
Selenium,5560,B-CHEMICAL
(,5560,O
Se,5560,B-CHEMICAL
),5560,O
is,5560,O
an,5560,O
oligonutrient,5560,O
with,5560,O
both,5560,O
essential,5560,O
biological,5560,O
functions,5560,O
and,5560,O
recognized,5560,O
harmful,5560,O
effects,5560,O
.,5560,O
As,5561,O
the,5561,O
selenocysteine,5561,B-CHEMICAL
(,5561,O
SeCys,5561,B-CHEMICAL
),5561,O
amino,5561,B-CHEMICAL
acid,5561,I-CHEMICAL
",",5561,O
selenium,5561,B-CHEMICAL
is,5561,O
integrated,5561,O
in,5561,O
several,5561,O
Se-containing,5561,B-CHEMICAL
proteins,5561,O
(,5561,O
selenoproteins,5561,O
),5561,O
",",5561,O
many,5561,O
of,5561,O
which,5561,O
are,5561,O
fundamental,5561,O
for,5561,O
cell,5561,O
homeostasis,5561,O
.,5561,O
Nevertheless,5562,O
",",5562,O
selenium,5562,O
may,5562,O
exert,5562,O
toxic,5562,O
effects,5562,O
at,5562,O
levels,5562,O
marginally,5562,O
above,5562,O
those,5562,O
required,5562,O
",",5562,O
mainly,5562,O
through,5562,O
the,5562,O
generation,5562,O
of,5562,O
reactive,5562,O
oxygen,5562,B-CHEMICAL
species,5562,O
(,5562,O
ROS,5562,O
),5562,O
.,5562,O
The,5563,O
selenium,5563,B-CHEMICAL
chemical,5563,O
speciation,5563,O
can,5563,O
strongly,5563,O
affect,5563,O
the,5563,O
bioavailability,5563,O
of,5563,O
this,5563,O
metal,5563,O
and,5563,O
its,5563,O
impact,5563,O
on,5563,O
metabolism,5563,O
",",5563,O
dictating,5563,O
the,5563,O
levels,5563,O
that,5563,O
can,5563,O
be,5563,O
beneficial,5563,O
or,5563,O
detrimental,5563,O
towards,5563,O
an,5563,O
organism,5563,O
.,5563,O
Glutathione,5564,B-GENE-N
peroxidase,5564,I-GENE-N
(,5564,O
GPxs,5564,B-GENE-N
),5564,O
is,5564,O
the,5564,O
largest,5564,O
and,5564,O
the,5564,O
most,5564,O
studied,5564,O
selenoprotein,5564,B-GENE-N
family,5564,O
.,5564,O
Cytosolic,5565,B-GENE-Y
glutathione,5565,I-GENE-Y
peroxidase,5565,I-GENE-Y
(,5565,O
cGPx,5565,B-GENE-Y
",",5565,O
GPx1,5565,B-GENE-Y
),5565,O
and,5565,O
phospholipid,5565,B-GENE-N
hydroperoxide,5565,I-GENE-N
glutathione,5565,I-GENE-N
peroxidase,5565,I-GENE-N
(,5565,O
PHGPx,5565,B-GENE-N
",",5565,O
GPx4,5565,B-GENE-N
),5565,O
are,5565,O
widely,5565,O
distributed,5565,O
throughout,5565,O
tissues,5565,O
",",5565,O
and,5565,O
play,5565,O
a,5565,O
pivotal,5565,O
role,5565,O
in,5565,O
regulating,5565,O
the,5565,O
oxidative,5565,O
status,5565,O
in,5565,O
the,5565,O
cell,5565,O
.,5565,O
In,5566,O
this,5566,O
study,5566,O
we,5566,O
have,5566,O
cloned,5566,O
GPx1,5566,B-GENE-Y
and,5566,O
GPx4,5566,B-GENE-N
genes,5566,O
in,5566,O
rainbow,5566,O
trout,5566,O
(,5566,O
Oncorhynchus,5566,O
mykiss,5566,O
),5566,O
.,5566,O
The,5567,O
constitutive,5567,O
mRNA,5567,O
expression,5567,O
of,5567,O
these,5567,O
GPx,5567,B-GENE-N
genes,5567,O
was,5567,O
examined,5567,O
in,5567,O
18,5567,O
trout,5567,O
tissues,5567,O
and,5567,O
their,5567,O
responsiveness,5567,O
to,5567,O
Se,5567,O
availability,5567,O
was,5567,O
analysed,5567,O
using,5567,O
a,5567,O
rainbow,5567,O
trout,5567,O
liver,5567,O
cell,5567,O
line,5567,O
(,5567,O
RTL,5567,O
),5567,O
.,5567,O
An,5568,O
inorganic,5568,O
(,5568,O
sodium,5568,B-CHEMICAL
selenite,5568,I-CHEMICAL
",",5568,O
Na2SeO3,5568,B-CHEMICAL
),5568,O
and,5568,O
organic,5568,O
(,5568,O
selenocysteine,5568,B-CHEMICAL
",",5568,O
Cys-Se-Se-Cys,5568,B-CHEMICAL
),5568,O
selenocompound,5568,O
have,5568,O
been,5568,O
used,5568,O
as,5568,O
Se,5568,B-CHEMICAL
sources,5568,O
.,5568,O
GPx1,5569,B-GENE-Y
activity,5569,O
was,5569,O
also,5569,O
tested,5569,O
to,5569,O
verify,5569,O
the,5569,O
impact,5569,O
of,5569,O
transcript,5569,O
changes,5569,O
on,5569,O
the,5569,O
enzymatic,5569,O
function,5569,O
of,5569,O
these,5569,O
molecules,5569,O
.,5569,O
To,5570,O
understand,5570,O
if,5570,O
the,5570,O
results,5570,O
obtained,5570,O
from,5570,O
the,5570,O
transcript,5570,O
expression,5570,O
analysis,5570,O
were,5570,O
due,5570,O
to,5570,O
Se,5570,B-CHEMICAL
bioavailability,5570,O
or,5570,O
generation,5570,O
of,5570,O
ROS,5570,O
",",5570,O
the,5570,O
cytoxicity,5570,O
of,5570,O
the,5570,O
two,5570,O
selenocompounds,5570,O
was,5570,O
tested,5570,O
by,5570,O
measuring,5570,O
the,5570,O
impact,5570,O
of,5570,O
Se,5570,B-CHEMICAL
on,5570,O
cell,5570,O
membrane,5570,O
integrity,5570,O
.,5570,O
Lastly,5571,O
",",5571,O
Se,5571,B-CHEMICAL
availability,5571,O
was,5571,O
quantified,5571,O
by,5571,O
mass,5571,O
spectrophotometry,5571,O
to,5571,O
determine,5571,O
the,5571,O
amount,5571,O
of,5571,O
Se,5571,B-CHEMICAL
in,5571,O
the,5571,O
cell,5571,O
culture,5571,O
media,5571,O
",",5571,O
the,5571,O
Se,5571,B-CHEMICAL
background,5571,O
due,5571,O
to,5571,O
the,5571,O
foetal,5571,O
calf,5571,O
serum,5571,O
supplement,5571,O
and,5571,O
the,5571,O
contribution,5571,O
from,5571,O
the,5571,O
two,5571,O
selenocompounds,5571,O
used,5571,O
in,5571,O
the,5571,O
treatments,5571,O
.,5571,O
Three,5572,O
isoforms,5572,O
of,5572,O
genes,5572,O
for,5572,O
both,5572,O
GPx1,5572,B-GENE-Y
(,5572,O
GPx1a,5572,B-GENE-N
",",5572,I-GENE-N
1b1,5572,I-GENE-N
and,5572,I-GENE-N
1b2,5572,I-GENE-N
),5572,O
and,5572,O
GPx4,5572,B-GENE-N
(,5572,O
GPx4a1,5572,B-GENE-N
",",5572,I-GENE-N
a2,5572,I-GENE-N
and,5572,I-GENE-N
b,5572,I-GENE-N
),5572,O
have,5572,O
been,5572,O
identified,5572,O
.,5572,O
The,5573,O
discovery,5573,O
of,5573,O
a,5573,O
third,5573,O
gene,5573,O
encoding,5573,O
for,5573,O
GPx1,5573,B-GENE-Y
and,5573,O
GPx4,5573,B-GENE-N
hints,5573,O
that,5573,O
salmonids,5573,O
may,5573,O
have,5573,O
the,5573,O
biggest,5573,O
selenoproteome,5573,O
amongst,5573,O
all,5573,O
vertebrates,5573,O
.,5573,O
Transcripts,5574,O
of,5574,O
GPx4,5574,B-GENE-N
genes,5574,O
were,5574,O
more,5574,O
highly,5574,O
expressed,5574,O
in,5574,O
most,5574,O
tissues,5574,O
examined,5574,O
in,5574,O
vivo,5574,O
(,5574,O
except,5574,O
blood,5574,O
",",5574,O
head,5574,O
kidney,5574,O
and,5574,O
spleen,5574,O
),5574,O
",",5574,O
whereas,5574,O
those,5574,O
of,5574,O
the,5574,O
GPx1,5574,B-GENE-Y
genes,5574,O
were,5574,O
more,5574,O
responsive,5574,O
to,5574,O
selenium,5574,B-CHEMICAL
exposure,5574,O
in,5574,O
vitro,5574,O
",",5574,O
especially,5574,O
to,5574,O
the,5574,O
organic,5574,O
form,5574,O
.,5574,O
Interestingly,5575,O
",",5575,O
GPx1a,5575,B-GENE-Y
was,5575,O
the,5575,O
most,5575,O
sensitive,5575,O
to,5575,O
selenium,5575,B-CHEMICAL
availability,5575,O
in,5575,O
non,5575,O
stressful,5575,O
conditions,5575,O
",",5575,O
whereas,5575,O
GPx1b1,5575,B-GENE-Y
and,5575,O
GPx1b2,5575,B-GENE-Y
were,5575,O
highly,5575,O
induced,5575,O
by,5575,O
exposure,5575,O
to,5575,O
selenium,5575,B-CHEMICAL
levels,5575,O
that,5575,O
had,5575,O
some,5575,O
toxic,5575,O
effects,5575,O
on,5575,O
the,5575,O
cells,5575,O
.,5575,O
Although,5576,O
the,5576,O
different,5576,O
concentrations,5576,O
tested,5576,O
of,5576,O
the,5576,O
two,5576,O
selenocompounds,5576,O
modulate,5576,O
GPx1,5576,B-GENE-Y
transcript,5576,O
expression,5576,O
to,5576,O
various,5576,O
degrees,5576,O
",",5576,O
no,5576,O
significant,5576,O
change,5576,O
of,5576,O
GPx1,5576,B-GENE-Y
enzymatic,5576,O
activity,5576,O
was,5576,O
detectable,5576,O
.,5576,O
Our,5577,O
results,5577,O
lead,5577,O
us,5577,O
to,5577,O
conclude,5577,O
that,5577,O
trout,5577,O
GPx1,5577,B-GENE-Y
transcripts,5577,O
expression,5577,O
level,5577,O
may,5577,O
represent,5577,O
a,5577,O
sensitive,5577,O
biomarker,5577,O
for,5577,O
selenium,5577,B-CHEMICAL
intake,5577,O
",",5577,O
helping,5577,O
to,5577,O
evaluate,5577,O
if,5577,O
selenium,5577,B-CHEMICAL
concentration,5577,O
and,5577,O
chemical,5577,O
speciation,5577,O
impact,5577,O
on,5577,O
cell,5577,O
homeostasis,5577,O
.,5577,O
Manganese-exposed,5578,B-CHEMICAL
developing,5578,O
rats,5578,O
display,5578,O
motor,5578,O
deficits,5578,O
and,5578,O
striatal,5578,O
oxidative,5578,O
stress,5578,O
that,5578,O
are,5578,O
reversed,5578,O
by,5578,O
Trolox,5578,B-CHEMICAL
.,5578,O
While,5579,O
manganese,5579,B-CHEMICAL
(,5579,O
Mn,5579,B-CHEMICAL
),5579,O
is,5579,O
essential,5579,O
for,5579,O
proper,5579,O
central,5579,O
nervous,5579,O
system,5579,O
(,5579,O
CNS,5579,O
),5579,O
development,5579,O
",",5579,O
excessive,5579,O
Mn,5579,B-CHEMICAL
exposure,5579,O
may,5579,O
lead,5579,O
to,5579,O
neurotoxicity,5579,O
.,5579,O
Mn,5580,B-CHEMICAL
preferentially,5580,O
accumulates,5580,O
in,5580,O
the,5580,O
basal,5580,O
ganglia,5580,O
",",5580,O
and,5580,O
in,5580,O
adults,5580,O
it,5580,O
may,5580,O
cause,5580,O
Parkinson,5580,O
's,5580,O
disease-like,5580,O
disorder,5580,O
.,5580,O
Compared,5581,O
to,5581,O
adults,5581,O
",",5581,O
younger,5581,O
individuals,5581,O
accumulate,5581,O
greater,5581,O
Mn,5581,B-CHEMICAL
levels,5581,O
in,5581,O
the,5581,O
CNS,5581,O
and,5581,O
are,5581,O
more,5581,O
vulnerable,5581,O
to,5581,O
its,5581,O
toxicity,5581,O
.,5581,O
Moreover,5582,O
",",5582,O
the,5582,O
mechanisms,5582,O
mediating,5582,O
developmental,5582,O
Mn-induced,5582,B-CHEMICAL
neurotoxicity,5582,O
are,5582,O
not,5582,O
completely,5582,O
understood,5582,O
.,5582,O
The,5583,O
present,5583,O
study,5583,O
investigated,5583,O
the,5583,O
developmental,5583,O
neurotoxicity,5583,O
elicited,5583,O
by,5583,O
Mn,5583,B-CHEMICAL
exposure,5583,O
(,5583,O
5,5583,O
",",5583,O
10,5583,O
and,5583,O
20,5583,O
mg/kg,5583,O
;,5583,O
i.p,5583,O
.,5583,O
),5583,O
from,5584,O
postnatal,5584,O
day,5584,O
8,5584,O
to,5584,O
PN27,5584,O
in,5584,O
rats,5584,O
.,5584,O
Neurochemical,5585,O
analyses,5585,O
were,5585,O
carried,5585,O
out,5585,O
on,5585,O
PN29,5585,O
",",5585,O
with,5585,O
a,5585,O
particular,5585,O
focus,5585,O
on,5585,O
striatal,5585,O
alterations,5585,O
in,5585,O
intracellular,5585,O
signaling,5585,O
pathways,5585,O
(,5585,O
MAPKs,5585,B-GENE-N
",",5585,O
Akt,5585,B-GENE-N
and,5585,O
DARPP-32,5585,B-GENE-Y
),5585,O
",",5585,O
oxidative,5585,O
stress,5585,O
generation,5585,O
and,5585,O
cell,5585,O
death,5585,O
.,5585,O
Motor,5586,O
alterations,5586,O
were,5586,O
evaluated,5586,O
later,5586,O
in,5586,O
life,5586,O
at,5586,O
3,5586,O
",",5586,O
4,5586,O
or,5586,O
5,5586,O
weeks,5586,O
of,5586,O
age,5586,O
.,5586,O
Mn,5587,B-CHEMICAL
exposure,5587,O
(,5587,O
20,5587,O
mg/kg,5587,O
),5587,O
increased,5587,O
p38,5587,B-GENE-N
(,5587,O
MAPK,5587,B-GENE-N
),5587,O
and,5587,O
Akt,5587,B-GENE-N
phosphorylation,5587,O
",",5587,O
but,5587,O
decreased,5587,O
DARPP-32-Thr-34,5587,B-GENE-Y
phosphorylation,5587,O
.,5587,O
Mn,5588,B-CHEMICAL
(,5588,O
10,5588,O
and,5588,O
20,5588,O
mg/kg,5588,O
),5588,O
increased,5588,O
caspase,5588,B-GENE-N
activity,5588,O
and,5588,O
F,5588,B-CHEMICAL
(,5588,I-CHEMICAL
2,5588,I-CHEMICAL
),5588,I-CHEMICAL
-isoprostane,5588,I-CHEMICAL
production,5588,O
(,5588,O
a,5588,O
biological,5588,O
marker,5588,O
of,5588,O
lipid,5588,O
peroxidation,5588,O
),5588,O
.,5588,O
Paralleling,5589,O
the,5589,O
changes,5589,O
in,5589,O
striatal,5589,O
biochemical,5589,O
parameters,5589,O
",",5589,O
Mn,5589,B-CHEMICAL
(,5589,O
20,5589,O
mg/kg,5589,O
),5589,O
also,5589,O
caused,5589,O
motor,5589,O
impairment,5589,O
",",5589,O
evidenced,5589,O
by,5589,O
increased,5589,O
falling,5589,O
latency,5589,O
in,5589,O
the,5589,O
rotarod,5589,O
test,5589,O
",",5589,O
decreased,5589,O
distance,5589,O
traveled,5589,O
and,5589,O
motor,5589,O
speed,5589,O
in,5589,O
the,5589,O
open-field,5589,O
test,5589,O
.,5589,O
Notably,5590,O
",",5590,O
the,5590,O
antioxidant,5590,O
Trolox™,5590,B-CHEMICAL
reversed,5590,O
the,5590,O
Mn,5590,B-CHEMICAL
(,5590,O
20,5590,O
mg/kg,5590,O
),5590,O
-dependent,5590,O
augmentation,5590,O
in,5590,O
p38,5590,B-GENE-N
(,5590,O
MAPK,5590,B-GENE-N
),5590,O
phosphorylation,5590,O
and,5590,O
reduced,5590,O
the,5590,O
Mn,5590,B-CHEMICAL
(,5590,O
20,5590,O
mg/kg,5590,O
),5590,O
-induced,5590,O
caspase,5590,B-GENE-N
activity,5590,O
and,5590,O
F,5590,B-CHEMICAL
(,5590,I-CHEMICAL
2,5590,I-CHEMICAL
),5590,I-CHEMICAL
-isoprostane,5590,I-CHEMICAL
production,5590,O
.,5590,O
Trolox™,5591,B-CHEMICAL
also,5591,O
reversed,5591,O
the,5591,O
Mn-induced,5591,B-CHEMICAL
motor,5591,O
coordination,5591,O
deficits,5591,O
.,5591,O
These,5592,O
findings,5592,O
are,5592,O
the,5592,O
first,5592,O
to,5592,O
show,5592,O
that,5592,O
long-term,5592,O
exposure,5592,O
to,5592,O
Mn,5592,B-CHEMICAL
during,5592,O
a,5592,O
critical,5592,O
period,5592,O
of,5592,O
neurodevelopment,5592,O
causes,5592,O
motor,5592,O
coordination,5592,O
dysfunction,5592,O
with,5592,O
parallel,5592,O
increment,5592,O
in,5592,O
oxidative,5592,O
stress,5592,O
markers,5592,O
",",5592,O
p38,5592,B-GENE-N
(,5592,O
MAPK,5592,B-GENE-N
),5592,O
phosphorylation,5592,O
and,5592,O
caspase,5592,B-GENE-N
activity,5592,O
in,5592,O
the,5592,O
striatum,5592,O
.,5592,O
Moreover,5593,O
",",5593,O
we,5593,O
establish,5593,O
Trolox™,5593,B-CHEMICAL
as,5593,O
a,5593,O
potential,5593,O
neuroprotective,5593,O
agent,5593,O
given,5593,O
its,5593,O
efficacy,5593,O
in,5593,O
reversing,5593,O
the,5593,O
Mn-induced,5593,B-CHEMICAL
neurodevelopmental,5593,O
effects,5593,O
.,5593,O
Nocapyrones,5594,B-CHEMICAL
H-J,5594,I-CHEMICAL
",",5594,O
"3,6-Disubstituted",5594,B-CHEMICAL
α-Pyrones,5594,I-CHEMICAL
from,5594,O
the,5594,O
Marine,5594,O
Actinomycete,5594,O
Nocardiopsis,5594,O
sp,5594,O
.,5594,O
KMF-001,5595,O
.,5595,O
Three,5596,O
new,5596,O
"3,6-disubstituted",5596,B-CHEMICAL
α-pyrones,5596,I-CHEMICAL
",",5596,O
nocapyrones,5596,B-CHEMICAL
H-J,5596,I-CHEMICAL
(,5596,O
1-3,5596,O
),5596,O
",",5596,O
were,5596,O
isolated,5596,O
from,5596,O
the,5596,O
marine,5596,O
actinomycete,5596,O
Nocardiopsis,5596,O
sp,5596,O
.,5596,O
KMF-001,5597,O
.,5597,O
Their,5598,O
structures,5598,O
were,5598,O
assigned,5598,O
to,5598,O
be,5598,O
3-alkylated,5598,B-CHEMICAL
6-,5598,I-CHEMICAL
(,5598,I-CHEMICAL
1-methyl-1-propenyl,5598,I-CHEMICAL
),5598,I-CHEMICAL
-2H-pyran-2-ones,5598,I-CHEMICAL
on,5598,O
the,5598,O
basis,5598,O
of,5598,O
UV,5598,O
",",5598,O
MS,5598,O
",",5598,O
NMR,5598,O
",",5598,O
and,5598,O
high,5598,O
resolution,5598,O
(,5598,O
HR,5598,O
),5598,O
-FAB-MS,5598,O
analyses,5598,O
.,5598,O
Nocapyrone,5599,B-CHEMICAL
H,5599,I-CHEMICAL
(,5599,O
1,5599,O
),5599,O
reduced,5599,O
the,5599,O
pro-inflammatory,5599,O
factor,5599,O
such,5599,O
as,5599,O
nitric,5599,B-CHEMICAL
oxide,5599,I-CHEMICAL
(,5599,O
NO,5599,B-CHEMICAL
),5599,O
",",5599,O
prostaglandin,5599,B-CHEMICAL
E2,5599,I-CHEMICAL
(,5599,O
PGE2,5599,B-CHEMICAL
),5599,O
and,5599,O
interleukin-1β,5599,B-GENE-Y
(,5599,O
IL-1β,5599,B-GENE-Y
),5599,O
.,5599,O
Moreover,5600,O
",",5600,O
nocapyrone,5600,B-CHEMICAL
H,5600,I-CHEMICAL
showed,5600,O
5.82,5600,O
%,5600,O
stronger,5600,O
inhibitory,5600,O
effect,5600,O
on,5600,O
NO,5600,B-CHEMICAL
production,5600,O
than,5600,O
chrysin,5600,O
at,5600,O
a,5600,O
concentration,5600,O
of,5600,O
10,5600,O
µm,5600,O
in,5600,O
lipopolysaccharide,5600,O
(,5600,O
LPS,5600,O
),5600,O
-stimulated,5600,O
BV-2,5600,O
microglial,5600,O
cells,5600,O
.,5600,O
Investigating,5601,O
the,5601,O
enteroenteric,5601,O
recirculation,5601,O
of,5601,O
apixaban,5601,B-CHEMICAL
",",5601,O
a,5601,O
factor,5601,B-GENE-N
Xa,5601,I-GENE-N
inhibitor,5601,O
:,5601,O
administration,5601,O
of,5601,O
activated,5601,O
charcoal,5601,O
to,5601,O
bile,5601,O
duct-cannulated,5601,O
rats,5601,O
and,5601,O
dogs,5601,O
receiving,5601,O
an,5601,O
intravenous,5601,O
dose,5601,O
and,5601,O
use,5601,O
of,5601,O
drug,5601,O
transporter,5601,O
knockout,5601,O
rats,5601,O
.,5601,O
The,5602,O
study,5602,O
described,5602,O
here,5602,O
investigated,5602,O
the,5602,O
impact,5602,O
of,5602,O
intestinal,5602,O
excretion,5602,O
(,5602,O
IE,5602,O
;,5602,O
excretion,5602,O
of,5602,O
drug,5602,O
directly,5602,O
from,5602,O
circulation,5602,O
to,5602,O
intestinal,5602,O
lumen,5602,O
),5602,O
",",5602,O
enteroenteric,5602,O
recirculation,5602,O
(,5602,O
EER,5602,O
),5602,O
",",5602,O
and,5602,O
renal,5602,O
tubule,5602,O
recirculation,5602,O
(,5602,O
RTR,5602,O
),5602,O
on,5602,O
apixaban,5602,B-CHEMICAL
pharmacokinetics,5602,O
and,5602,O
disposition,5602,O
.,5602,O
The,5603,O
experimental,5603,O
approaches,5603,O
involve,5603,O
integrating,5603,O
apixaban,5603,B-CHEMICAL
elimination,5603,O
pathways,5603,O
with,5603,O
pharmacokinetic,5603,O
profiles,5603,O
obtained,5603,O
from,5603,O
bile,5603,O
duct-cannulated,5603,O
(,5603,O
BDC,5603,O
),5603,O
rats,5603,O
and,5603,O
dogs,5603,O
receiving,5603,O
i.v,5603,O
.,5603,O
doses,5604,O
together,5604,O
with,5604,O
oral,5604,O
administration,5604,O
of,5604,O
activated,5604,O
charcoal,5604,B-CHEMICAL
(,5604,O
AC,5604,O
),5604,O
.,5604,O
Additionally,5605,O
",",5605,O
the,5605,O
role,5605,O
of,5605,O
P-gp,5605,B-GENE-Y
(,5605,O
P-glycoprotein,5605,B-GENE-Y
;,5605,O
abcb1,5605,B-GENE-Y
),5605,O
and,5605,O
BCRP,5605,B-GENE-Y
(,5605,O
breast,5605,B-GENE-Y
cancer,5605,I-GENE-Y
resistance,5605,I-GENE-Y
protein,5605,I-GENE-Y
;,5605,O
abcg2,5605,B-GENE-Y
),5605,O
in,5605,O
apixaban,5605,B-CHEMICAL
disposition,5605,O
was,5605,O
evaluated,5605,O
in,5605,O
experiments,5605,O
using,5605,O
transporter,5605,O
inhibitors,5605,O
and,5605,O
transporter,5605,O
knockout,5605,O
(,5605,O
KO,5605,O
),5605,O
rats,5605,O
.,5605,O
Approximately,5606,O
20-50,5606,O
%,5606,O
of,5606,O
an,5606,O
apixaban,5606,B-CHEMICAL
i.v,5606,O
.,5606,O
dose,5607,O
was,5607,O
found,5607,O
in,5607,O
feces,5607,O
of,5607,O
BDC,5607,O
rats,5607,O
and,5607,O
dogs,5607,O
",",5607,O
suggesting,5607,O
IE,5607,O
leading,5607,O
to,5607,O
fecal,5607,O
elimination,5607,O
and,5607,O
intestinal,5607,O
clearance,5607,O
(,5607,O
IC,5607,O
),5607,O
.,5607,O
The,5608,O
fecal,5608,O
elimination,5608,O
",",5608,O
IC,5608,O
",",5608,O
and,5608,O
systemic,5608,O
clearance,5608,O
of,5608,O
apixaban,5608,B-CHEMICAL
were,5608,O
increased,5608,O
upon,5608,O
AC,5608,O
administration,5608,O
in,5608,O
both,5608,O
BDC,5608,O
rats,5608,O
and,5608,O
dogs,5608,O
and,5608,O
were,5608,O
decreased,5608,O
in,5608,O
BDC,5608,O
rats,5608,O
dosed,5608,O
with,5608,O
GF-120918,5608,B-CHEMICAL
",",5608,O
a,5608,O
dual,5608,O
BCRP,5608,B-GENE-Y
and,5608,O
P-gp,5608,B-GENE-N
inhibitor,5608,O
),5608,O
.,5608,O
BCRP,5609,B-GENE-Y
appeared,5609,O
to,5609,O
play,5609,O
a,5609,O
more,5609,O
important,5609,O
role,5609,O
for,5609,O
absorption,5609,O
and,5609,O
intestinal,5609,O
and,5609,O
renal,5609,O
elimination,5609,O
of,5609,O
apixaban,5609,B-CHEMICAL
than,5609,O
P-gp,5609,B-GENE-N
in,5609,O
transporter-KO,5609,O
rats,5609,O
after,5609,O
oral,5609,O
and,5609,O
i.v,5609,O
.,5609,O
dosing,5610,O
",",5610,O
which,5610,O
led,5610,O
to,5610,O
a,5610,O
higher,5610,O
level,5610,O
of,5610,O
active,5610,O
renal,5610,O
excretion,5610,O
in,5610,O
rat,5610,O
than,5610,O
other,5610,O
species,5610,O
.,5610,O
These,5611,O
data,5611,O
demonstrate,5611,O
that,5611,O
apixaban,5611,B-CHEMICAL
undergoes,5611,O
IE,5611,O
",",5611,O
EER,5611,O
",",5611,O
and,5611,O
RTR,5611,O
that,5611,O
are,5611,O
facilitated,5611,O
by,5611,O
efflux,5611,O
transporters,5611,O
.,5611,O
Intestinal,5612,O
reabsorption,5612,O
of,5612,O
apixaban,5612,B-CHEMICAL
could,5612,O
be,5612,O
interrupted,5612,O
by,5612,O
AC,5612,O
even,5612,O
at,5612,O
3,5612,O
hours,5612,O
post-drug,5612,O
dose,5612,O
in,5612,O
dogs,5612,O
(,5612,O
late,5612,O
charcoal,5612,B-CHEMICAL
effect,5612,O
),5612,O
.,5612,O
This,5613,O
study,5613,O
demonstrates,5613,O
that,5613,O
the,5613,O
intestine,5613,O
is,5613,O
an,5613,O
organ,5613,O
for,5613,O
direct,5613,O
clearance,5613,O
and,5613,O
redistribution,5613,O
of,5613,O
apixaban,5613,B-CHEMICAL
.,5613,O
The,5614,O
IE,5614,O
",",5614,O
EER,5614,O
",",5614,O
and,5614,O
RTR,5614,O
contribute,5614,O
to,5614,O
overall,5614,O
pharmacokinetic,5614,O
profiles,5614,O
of,5614,O
apixaban,5614,B-CHEMICAL
.,5614,O
IE,5615,O
as,5615,O
a,5615,O
clearance,5615,O
pathway,5615,O
",",5615,O
balanced,5615,O
with,5615,O
metabolism,5615,O
and,5615,O
renal,5615,O
excretion,5615,O
",",5615,O
helps,5615,O
decrease,5615,O
the,5615,O
impacts,5615,O
of,5615,O
intrinsic,5615,O
(,5615,O
renal,5615,O
or,5615,O
hepatic,5615,O
impairment,5615,O
),5615,O
and,5615,O
extrinsic,5615,O
(,5615,O
drug-drug,5615,O
interactions,5615,O
),5615,O
factors,5615,O
on,5615,O
apixaban,5615,B-CHEMICAL
disposition,5615,O
.,5615,O
Cloning,5616,O
",",5616,O
Characterization,5616,O
",",5616,O
and,5616,O
Sulfonamide,5616,B-CHEMICAL
and,5616,O
Thiol,5616,B-CHEMICAL
Inhibition,5616,O
Studies,5616,O
of,5616,O
an,5616,O
α-Carbonic,5616,B-GENE-Y
Anhydrase,5616,I-GENE-Y
from,5616,O
Trypanosoma,5616,O
cruzi,5616,O
",",5616,O
the,5616,O
Causative,5616,O
Agent,5616,O
of,5616,O
Chagas,5616,O
Disease,5616,O
.,5616,O
An,5617,O
α-carbonic,5617,B-GENE-Y
anhydrase,5617,I-GENE-Y
(,5617,O
CA,5617,B-GENE-Y
",",5617,O
EC,5617,B-GENE-Y
4.2.1.1,5617,I-GENE-Y
),5617,O
has,5617,O
been,5617,O
identified,5617,O
",",5617,O
cloned,5617,O
",",5617,O
and,5617,O
characterized,5617,O
from,5617,O
the,5617,O
unicellular,5617,O
protozoan,5617,O
Trypanosoma,5617,O
cruzi,5617,O
",",5617,O
the,5617,O
causative,5617,O
agent,5617,O
of,5617,O
Chagas,5617,O
disease,5617,O
.,5617,O
The,5618,O
enzyme,5618,O
(,5618,O
TcCA,5618,B-GENE-Y
),5618,O
has,5618,O
a,5618,O
very,5618,O
high,5618,O
catalytic,5618,O
activity,5618,O
for,5618,O
the,5618,O
CO,5618,B-CHEMICAL
(,5618,I-CHEMICAL
2,5618,I-CHEMICAL
),5618,I-CHEMICAL
hydration,5618,O
reaction,5618,O
",",5618,O
being,5618,O
similar,5618,O
kinetically,5618,O
to,5618,O
the,5618,O
human,5618,O
(,5618,O
h,5618,O
),5618,O
isoform,5618,O
hCA,5618,B-GENE-Y
II,5618,I-GENE-Y
",",5618,O
although,5618,O
it,5618,O
is,5618,O
devoid,5618,O
of,5618,O
the,5618,O
His64,5618,B-CHEMICAL
proton,5618,O
shuttle,5618,O
.,5618,O
A,5619,O
large,5619,O
number,5619,O
of,5619,O
aromatic/heterocyclic,5619,B-CHEMICAL
sulfonamides,5619,I-CHEMICAL
and,5619,O
some,5619,O
"5-mercapto-1,3,4-thiadiazoles",5619,B-CHEMICAL
were,5619,O
investigated,5619,O
as,5619,O
TcCA,5619,B-GENE-Y
inhibitors,5619,O
.,5619,O
The,5620,O
aromatic,5620,B-CHEMICAL
sulfonamides,5620,I-CHEMICAL
were,5620,O
weak,5620,O
inhibitors,5620,O
(,5620,O
K,5620,O
(,5620,O
I,5620,O
),5620,O
values,5620,O
of,5620,O
192,5620,O
nM,5620,O
to,5620,O
84,5620,O
μM,5620,O
),5620,O
",",5620,O
whereas,5620,O
some,5620,O
heterocyclic,5620,O
compounds,5620,O
inhibited,5620,O
the,5620,O
enzyme,5620,O
with,5620,O
K,5620,O
(,5620,O
I,5620,O
),5620,O
values,5620,O
in,5620,O
the,5620,O
range,5620,O
61.6-93.6,5620,O
nM,5620,O
.,5620,O
The,5621,O
thiols,5621,B-CHEMICAL
were,5621,O
the,5621,O
most,5621,O
potent,5621,O
in,5621,O
vitro,5621,O
inhibitors,5621,O
(,5621,O
K,5621,O
(,5621,O
I,5621,O
),5621,O
values,5621,O
of,5621,O
21.1-79.0,5621,O
nM,5621,O
),5621,O
",",5621,O
and,5621,O
some,5621,O
of,5621,O
them,5621,O
also,5621,O
inhibited,5621,O
the,5621,O
epimastigotes,5621,O
growth,5621,O
of,5621,O
two,5621,O
T.,5621,O
cruzi,5621,O
strains,5621,O
in,5621,O
vivo,5621,O
.,5621,O
The,5622,O
increased,5622,O
number,5622,O
of,5622,O
Leydig,5622,O
cells,5622,O
by,5622,O
di,5622,B-CHEMICAL
(,5622,I-CHEMICAL
2-ethylhexyl,5622,I-CHEMICAL
),5622,I-CHEMICAL
phthalate,5622,I-CHEMICAL
comes,5622,O
from,5622,O
the,5622,O
differentiation,5622,O
of,5622,O
stem,5622,O
cells,5622,O
into,5622,O
Leydig,5622,O
cell,5622,O
lineage,5622,O
in,5622,O
the,5622,O
adult,5622,O
rat,5622,O
testis,5622,O
.,5622,O
The,5623,O
objective,5623,O
of,5623,O
the,5623,O
present,5623,O
study,5623,O
is,5623,O
to,5623,O
determine,5623,O
whether,5623,O
di,5623,B-CHEMICAL
(,5623,I-CHEMICAL
2-ethylhexyl,5623,I-CHEMICAL
),5623,I-CHEMICAL
phthalate,5623,I-CHEMICAL
(,5623,O
DEHP,5623,B-CHEMICAL
),5623,O
exposure,5623,O
at,5623,O
adulthood,5623,O
increases,5623,O
rat,5623,O
Leydig,5623,O
cell,5623,O
number,5623,O
and,5623,O
to,5623,O
investigate,5623,O
the,5623,O
possible,5623,O
mechanism,5623,O
.,5623,O
90-day-old,5624,O
Long-Evans,5624,O
rats,5624,O
were,5624,O
randomly,5624,O
divided,5624,O
into,5624,O
3,5624,O
groups,5624,O
",",5624,O
and,5624,O
were,5624,O
gavaged,5624,O
with,5624,O
the,5624,O
corn,5624,O
oil,5624,O
(,5624,O
control,5624,O
),5624,O
or,5624,O
10,5624,O
or,5624,O
750mg/kg,5624,O
DEHP,5624,B-CHEMICAL
daily,5624,O
for,5624,O
7,5624,O
days,5624,O
",",5624,O
and,5624,O
then,5624,O
received,5624,O
an,5624,O
intraperitoneal,5624,O
injection,5624,O
of,5624,O
75mg/kg,5624,O
ethane,5624,B-CHEMICAL
dimethanesulfonate,5624,I-CHEMICAL
(,5624,O
EDS,5624,B-CHEMICAL
),5624,O
to,5624,O
eliminate,5624,O
Leydig,5624,O
cells,5624,O
.,5624,O
Serum,5625,O
testosterone,5625,B-CHEMICAL
concentrations,5625,O
were,5625,O
assessed,5625,O
by,5625,O
RIA,5625,O
",",5625,O
and,5625,O
the,5625,O
mRNA,5625,O
levels,5625,O
of,5625,O
Leydig,5625,O
cell,5625,O
genes,5625,O
were,5625,O
measured,5625,O
by,5625,O
qPCR,5625,O
.,5625,O
EDS,5626,B-CHEMICAL
eliminated,5626,O
all,5626,O
Leydig,5626,O
cells,5626,O
in,5626,O
the,5626,O
control,5626,O
testis,5626,O
on,5626,O
day,5626,O
4,5626,O
post-EDS,5626,O
",",5626,O
as,5626,O
judged,5626,O
by,5626,O
undetectable,5626,O
serum,5626,O
testosterone,5626,B-CHEMICAL
level,5626,O
and,5626,O
no,5626,O
3β-hydroxysteroid,5626,B-GENE-N
dehydrogenase,5626,I-GENE-N
positive,5626,O
(,5626,O
3β-HSD,5626,B-GENE-N
(,5626,O
pos,5626,O
),5626,O
),5626,O
cells,5626,O
in,5626,O
the,5626,O
interstitium,5626,O
.,5626,O
However,5627,O
",",5627,O
in,5627,O
DEHP-treated,5627,B-CHEMICAL
groups,5627,O
",",5627,O
there,5627,O
were,5627,O
detectable,5627,O
serum,5627,O
testosterone,5627,B-CHEMICAL
concentrations,5627,O
and,5627,O
some,5627,O
oval-shaped,5627,O
3β-HSD,5627,B-GENE-N
(,5627,O
pos,5627,O
),5627,O
cells,5627,O
in,5627,O
the,5627,O
interstitium,5627,O
.,5627,O
These,5628,O
3β-HSD,5628,B-GENE-N
(,5628,O
pos,5628,O
),5628,O
cells,5628,O
were,5628,O
not,5628,O
stained,5628,O
by,5628,O
the,5628,O
antibody,5628,O
against,5628,O
11β-hydroxysteroid,5628,B-GENE-Y
dehydrogenase,5628,I-GENE-Y
1,5628,I-GENE-Y
(,5628,O
11β-HSD1,5628,B-GENE-Y
),5628,O
",",5628,O
a,5628,O
marker,5628,O
for,5628,O
Leydig,5628,O
cells,5628,O
at,5628,O
a,5628,O
more,5628,O
advanced,5628,O
stage,5628,O
.,5628,O
The,5629,O
disappearance,5629,O
of,5629,O
mRNAs,5629,O
of,5629,O
Leydig,5629,O
cell,5629,O
biomarkers,5629,O
including,5629,O
Lhcgr,5629,O
",",5629,O
Cyp11a1,5629,O
",",5629,O
Cyp17a1,5629,O
",",5629,O
Insl3,5629,O
and,5629,O
Hsd11b1,5629,O
in,5629,O
the,5629,O
control,5629,O
testis,5629,O
was,5629,O
observed,5629,O
on,5629,O
day,5629,O
4,5629,O
post-EDS,5629,O
.,5629,O
However,5630,O
",",5630,O
there,5630,O
were,5630,O
detectable,5630,O
concentrations,5630,O
of,5630,O
Lhcgr,5630,B-GENE-Y
",",5630,O
Cyp11a1,5630,B-GENE-Y
and,5630,O
Cyp17a1,5630,B-GENE-Y
mRNAs,5630,O
but,5630,O
undetectable,5630,O
concentrations,5630,O
of,5630,O
Insl3,5630,B-GENE-Y
",",5630,O
Hsd17b3,5630,B-GENE-Y
and,5630,O
Hsd11b1,5630,B-GENE-Y
in,5630,O
the,5630,O
DEHP-treated,5630,B-CHEMICAL
testes,5630,O
",",5630,O
indicating,5630,O
that,5630,O
these,5630,O
3β-HSD,5630,B-GENE-N
(,5630,O
pos,5630,O
),5630,O
cells,5630,O
were,5630,O
newly,5630,O
formed,5630,O
progenitor,5630,O
Leydig,5630,O
cells,5630,O
.,5630,O
The,5631,O
mRNA,5631,O
level,5631,O
for,5631,O
nestin,5631,B-GENE-Y
(,5631,O
Nes,5631,B-GENE-Y
",",5631,O
biomarker,5631,O
for,5631,O
stem,5631,O
Leydig,5631,O
cells,5631,O
),5631,O
was,5631,O
significantly,5631,O
increased,5631,O
in,5631,O
the,5631,O
control,5631,O
testis,5631,O
on,5631,O
day,5631,O
4,5631,O
post-EDS,5631,O
",",5631,O
but,5631,O
not,5631,O
in,5631,O
the,5631,O
DEHP,5631,B-CHEMICAL
treated,5631,O
testes,5631,O
",",5631,O
suggesting,5631,O
that,5631,O
these,5631,O
nestin,5631,B-GENE-Y
positive,5631,O
stem,5631,O
cells,5631,O
were,5631,O
differentiated,5631,O
into,5631,O
progenitor,5631,O
Leydig,5631,O
cells,5631,O
in,5631,O
the,5631,O
DEHP-treated,5631,B-CHEMICAL
testes,5631,O
.,5631,O
The,5632,O
present,5632,O
study,5632,O
suggests,5632,O
that,5632,O
DEHP,5632,B-CHEMICAL
increases,5632,O
the,5632,O
differentiation,5632,O
of,5632,O
stem,5632,O
cells,5632,O
into,5632,O
progenitor,5632,O
Leydig,5632,O
cells,5632,O
.,5632,O
GnRH,5633,B-GENE-N
pulse,5633,O
frequency-dependent,5633,O
stimulation,5633,O
of,5633,O
FSHβ,5633,B-GENE-Y
transcription,5633,O
is,5633,O
mediated,5633,O
via,5633,O
activation,5633,O
of,5633,O
PKA,5633,B-GENE-N
and,5633,O
CREB,5633,B-GENE-N
.,5633,O
Expression,5634,O
of,5634,O
pituitary,5634,O
FSH,5634,B-GENE-N
and,5634,O
LH,5634,B-GENE-N
",",5634,O
under,5634,O
the,5634,O
control,5634,O
of,5634,O
pulsatile,5634,O
GnRH,5634,B-GENE-N
",",5634,O
is,5634,O
essential,5634,O
for,5634,O
fertility,5634,O
.,5634,O
cAMP,5635,B-CHEMICAL
response,5635,I-GENE-N
element-binding,5635,I-GENE-N
protein,5635,I-GENE-N
(,5635,O
CREB,5635,B-GENE-N
),5635,O
has,5635,O
been,5635,O
implicated,5635,O
in,5635,O
the,5635,O
regulation,5635,O
of,5635,O
FSHβ,5635,B-GENE-Y
gene,5635,O
expression,5635,O
",",5635,O
but,5635,O
the,5635,O
molecular,5635,O
mechanisms,5635,O
by,5635,O
which,5635,O
pulsatile,5635,O
GnRH,5635,B-CHEMICAL
regulates,5635,O
CREB,5635,B-GENE-N
activation,5635,O
remain,5635,O
poorly,5635,O
understood,5635,O
.,5635,O
We,5636,O
hypothesized,5636,O
that,5636,O
CREB,5636,B-GENE-N
is,5636,O
activated,5636,O
by,5636,O
a,5636,O
distinct,5636,O
signaling,5636,O
pathway,5636,O
in,5636,O
response,5636,O
to,5636,O
pulsatile,5636,O
GnRH,5636,B-CHEMICAL
in,5636,O
a,5636,O
frequency-dependent,5636,O
manner,5636,O
to,5636,O
dictate,5636,O
the,5636,O
FSHβ,5636,B-GENE-Y
transcriptional,5636,O
response,5636,O
.,5636,O
GnRH,5637,B-CHEMICAL
stimulation,5637,O
of,5637,O
CREB,5637,B-GENE-N
phosphorylation,5637,O
(,5637,O
pCREB,5637,B-GENE-N
),5637,O
in,5637,O
the,5637,O
gonadotrope-derived,5637,O
LβT2,5637,O
cell,5637,O
line,5637,O
was,5637,O
attenuated,5637,O
by,5637,O
a,5637,O
protein,5637,B-GENE-N
kinase,5637,I-GENE-N
A,5637,I-GENE-N
(,5637,O
PKA,5637,B-GENE-N
),5637,O
inhibitor,5637,O
",",5637,O
H89,5637,B-CHEMICAL
.,5637,O
A,5638,O
dominant,5638,B-GENE-N
negative,5638,I-GENE-N
PKA,5638,I-GENE-N
(,5638,O
DNPKA,5638,B-GENE-N
),5638,O
reduced,5638,O
GnRH-stimulated,5638,B-GENE-N
pCREB,5638,B-GENE-N
and,5638,O
markedly,5638,O
decreased,5638,O
GnRH,5638,B-GENE-N
stimulation,5638,O
of,5638,O
FSHβ,5638,B-GENE-Y
mRNA,5638,O
and,5638,O
FSHβLUC,5638,B-GENE-Y
activity,5638,O
",",5638,O
but,5638,O
had,5638,O
little,5638,O
effect,5638,O
on,5638,O
LHβLUC,5638,B-GENE-Y
activity,5638,O
",",5638,O
indicating,5638,O
relative,5638,O
specificity,5638,O
of,5638,O
this,5638,O
pathway,5638,O
.,5638,O
In,5639,O
perifusion,5639,O
studies,5639,O
",",5639,O
FSHβ,5639,B-GENE-Y
mRNA,5639,O
levels,5639,O
and,5639,O
FSHβLUC,5639,B-GENE-Y
activities,5639,O
were,5639,O
increased,5639,O
by,5639,O
pulsatile,5639,O
GnRH,5639,B-GENE-N
",",5639,O
with,5639,O
significantly,5639,O
greater,5639,O
increases,5639,O
at,5639,O
low,5639,O
compared,5639,O
with,5639,O
high,5639,O
pulse,5639,O
frequencies,5639,O
.,5639,O
DNPKA,5640,B-GENE-N
markedly,5640,O
reduced,5640,O
these,5640,O
GnRH-stimulated,5640,B-CHEMICAL
FSHβ,5640,B-GENE-Y
responses,5640,O
at,5640,O
both,5640,O
low,5640,O
and,5640,O
high,5640,O
pulse,5640,O
frequencies,5640,O
.,5640,O
Correlating,5641,O
with,5641,O
FSHβ,5641,B-GENE-Y
activation,5641,O
",",5641,O
both,5641,O
PKA,5641,B-GENE-N
activity,5641,O
and,5641,O
levels,5641,O
of,5641,O
pCREB,5641,B-GENE-N
were,5641,O
increased,5641,O
to,5641,O
a,5641,O
greater,5641,O
extent,5641,O
by,5641,O
low,5641,O
compared,5641,O
with,5641,O
high,5641,O
GnRH,5641,B-CHEMICAL
pulse,5641,O
frequencies,5641,O
",",5641,O
and,5641,O
the,5641,O
induction,5641,O
of,5641,O
pCREB,5641,B-GENE-N
was,5641,O
also,5641,O
attenuated,5641,O
by,5641,O
overexpression,5641,O
of,5641,O
DNPKA,5641,B-GENE-N
at,5641,O
both,5641,O
low,5641,O
and,5641,O
high,5641,O
pulse,5641,O
frequencies,5641,O
.,5641,O
Taken,5642,O
together,5642,O
",",5642,O
these,5642,O
data,5642,O
indicate,5642,O
that,5642,O
a,5642,O
PKA-mediated,5642,B-GENE-N
signaling,5642,O
pathway,5642,O
mediates,5642,O
GnRH,5642,B-CHEMICAL
activation,5642,O
of,5642,O
CREB,5642,B-GENE-N
at,5642,O
low-pulse,5642,O
frequencies,5642,O
",",5642,O
playing,5642,O
a,5642,O
significant,5642,O
role,5642,O
in,5642,O
the,5642,O
decoding,5642,O
of,5642,O
the,5642,O
hypothalamic,5642,O
GnRH,5642,B-CHEMICAL
signal,5642,O
to,5642,O
result,5642,O
in,5642,O
frequency-dependent,5642,O
FSHβ,5642,B-GENE-Y
activation,5642,O
.,5642,O
Sophocarpine,5643,B-CHEMICAL
alleviates,5643,O
hepatocyte,5643,O
steatosis,5643,O
through,5643,O
activating,5643,O
AMPK,5643,B-GENE-Y
signaling,5643,O
pathway,5643,O
.,5643,O
Sophocarpine,5644,B-CHEMICAL
",",5644,O
an,5644,O
effective,5644,O
compound,5644,O
derived,5644,O
from,5644,O
foxtail-like,5644,O
sophora,5644,O
herb,5644,O
and,5644,O
seed,5644,O
",",5644,O
has,5644,O
been,5644,O
reported,5644,O
that,5644,O
it,5644,O
can,5644,O
alleviate,5644,O
non-alcoholic,5644,O
steatohepatitis,5644,O
(,5644,O
NASH,5644,O
),5644,O
in,5644,O
rats,5644,O
and,5644,O
affect,5644,O
adipocytokine,5644,B-GENE-N
synthesis,5644,O
.,5644,O
Meanwhile,5645,O
",",5645,O
adipocytokines,5645,B-GENE-N
could,5645,O
adjust,5645,O
hepatic,5645,O
lipid,5645,O
metabolism,5645,O
through,5645,O
AMPK,5645,B-GENE-Y
signaling,5645,O
pathway,5645,O
.,5645,O
In,5646,O
the,5646,O
work,5646,O
presented,5646,O
here,5646,O
",",5646,O
primary,5646,O
hepatocytes,5646,O
were,5646,O
isolated,5646,O
from,5646,O
specific,5646,O
pathogen-free,5646,O
male,5646,O
SD,5646,O
rats,5646,O
and,5646,O
incubated,5646,O
with,5646,O
200,5646,O
μmol/L,5646,O
oleic,5646,B-CHEMICAL
acid,5646,I-CHEMICAL
for,5646,O
24h,5646,O
to,5646,O
induce,5646,O
steatotic,5646,O
model,5646,O
",",5646,O
then,5646,O
treated,5646,O
with,5646,O
sophocarpine,5646,B-CHEMICAL
for,5646,O
72,5646,O
h.,5646,O
Oil,5646,O
red,5646,O
staining,5646,O
was,5646,O
performed,5646,O
to,5646,O
evaluate,5646,O
steatosis,5646,O
",",5646,O
total,5646,O
RNA,5646,O
and,5646,O
protein,5646,O
of,5646,O
primary,5646,O
hepatocytes,5646,O
were,5646,O
extracted,5646,O
for,5646,O
real-time,5646,O
RT-PCR,5646,O
and,5646,O
western,5646,O
blot,5646,O
analysis,5646,O
.,5646,O
A,5647,O
cluster,5647,O
of,5647,O
aberrances,5647,O
were,5647,O
observed,5647,O
in,5647,O
the,5647,O
model,5647,O
group,5647,O
",",5647,O
including,5647,O
hepatocyte,5647,O
steatosis,5647,O
",",5647,O
increased,5647,O
leptin,5647,B-GENE-Y
and,5647,O
decreased,5647,O
adiponectin,5647,B-GENE-Y
mRNA,5647,O
expressions,5647,O
.,5647,O
While,5648,O
sophocarpine,5648,B-CHEMICAL
treatment,5648,O
resulted,5648,O
in,5648,O
:,5648,O
significant,5648,O
improvement,5648,O
of,5648,O
steatosis,5648,O
(,5648,O
>,5648,O
50,5648,O
%,5648,O
decrease,5648,O
),5648,O
",",5648,O
decrease,5648,O
of,5648,O
leptin,5648,B-GENE-Y
expression,5648,O
(,5648,O
<,5648,O
0.57-fold,5648,O
),5648,O
and,5648,O
increase,5648,O
of,5648,O
adiponectin,5648,B-GENE-Y
expression,5648,O
(,5648,O
>,5648,O
1.48-fold,5648,O
),5648,O
.,5648,O
Moreover,5649,O
",",5649,O
compared,5649,O
with,5649,O
the,5649,O
model,5649,O
group,5649,O
",",5649,O
sophocarpine,5649,B-CHEMICAL
could,5649,O
significantly,5649,O
increase,5649,O
P-AMPKα,5649,B-GENE-N
(,5649,O
>,5649,O
5.82-fold,5649,O
),5649,O
",",5649,O
AMPKα,5649,B-GENE-N
(,5649,O
>,5649,O
1.29-fold,5649,O
),5649,O
and,5649,O
ACC,5649,B-GENE-N
(,5649,O
>,5649,O
3.27-fold,5649,O
),5649,O
protein,5649,O
expressions,5649,O
",",5649,O
and,5649,O
reduce,5649,O
P-ACC,5649,B-GENE-N
(,5649,O
<,5649,O
0.30-fold,5649,O
),5649,O
and,5649,O
HNF-4α,5649,B-GENE-Y
(,5649,O
<,5649,O
0.20-fold,5649,O
),5649,O
protein,5649,O
expression,5649,O
.,5649,O
The,5650,O
mRNA,5650,O
expression,5650,O
of,5650,O
Srebp-1c,5650,B-GENE-Y
was,5650,O
downregulated,5650,O
significantly,5650,O
simultaneously,5650,O
(,5650,O
<,5650,O
0.68-fold,5650,O
),5650,O
.,5650,O
We,5651,O
concluded,5651,O
that,5651,O
sophocarpine,5651,B-CHEMICAL
could,5651,O
alleviate,5651,O
hepatocyte,5651,O
steatosis,5651,O
and,5651,O
the,5651,O
potential,5651,O
mechanism,5651,O
might,5651,O
be,5651,O
the,5651,O
activated,5651,O
signaling,5651,O
pathway,5651,O
of,5651,O
AMPK,5651,B-GENE-Y
.,5651,O
Elevation,5652,O
of,5652,O
4-hydroxynonenal,5652,B-CHEMICAL
and,5652,O
malondialdehyde,5652,B-CHEMICAL
modified,5652,O
protein,5652,O
levels,5652,O
in,5652,O
cerebral,5652,O
cortex,5652,O
with,5652,O
cognitive,5652,O
dysfunction,5652,O
in,5652,O
rats,5652,O
exposed,5652,O
to,5652,O
1-bromopropane,5652,B-CHEMICAL
.,5652,O
1-Bromopropane,5653,B-CHEMICAL
(,5653,O
1-BP,5653,B-CHEMICAL
),5653,O
",",5653,O
an,5653,O
alternative,5653,O
to,5653,O
ozone-depleting,5653,B-CHEMICAL
solvents,5653,O
(,5653,O
ODS,5653,O
),5653,O
",",5653,O
exhibits,5653,O
central,5653,O
nervous,5653,O
system,5653,O
(,5653,O
CNS,5653,O
),5653,O
toxicity,5653,O
in,5653,O
animals,5653,O
and,5653,O
humans,5653,O
.,5653,O
This,5654,O
study,5654,O
was,5654,O
designed,5654,O
to,5654,O
relate,5654,O
CNS,5654,O
damage,5654,O
by,5654,O
Morris,5654,O
water,5654,O
maze,5654,O
(,5654,O
MWM,5654,O
),5654,O
test,5654,O
and,5654,O
oxidative,5654,O
stress,5654,O
to,5654,O
1-BP,5654,B-CHEMICAL
exposure,5654,O
in,5654,O
the,5654,O
rat,5654,O
.,5654,O
Male,5655,O
Wistar,5655,O
rats,5655,O
were,5655,O
randomly,5655,O
divided,5655,O
into,5655,O
4,5655,O
groups,5655,O
(,5655,O
n=10,5655,O
),5655,O
",",5655,O
and,5655,O
treated,5655,O
with,5655,O
0,5655,O
",",5655,O
200,5655,O
",",5655,O
400,5655,O
and,5655,O
800mg/kgbw,5655,O
1-BP,5655,B-CHEMICAL
for,5655,O
consecutive,5655,O
12,5655,O
days,5655,O
",",5655,O
respectively,5655,O
.,5655,O
From,5656,O
day,5656,O
8,5656,O
to,5656,O
day,5656,O
12,5656,O
of,5656,O
the,5656,O
experiment,5656,O
",",5656,O
MWM,5656,O
test,5656,O
was,5656,O
employed,5656,O
to,5656,O
assess,5656,O
the,5656,O
cognitive,5656,O
function,5656,O
of,5656,O
rats,5656,O
.,5656,O
The,5657,O
cerebral,5657,O
cortex,5657,O
of,5657,O
rats,5657,O
was,5657,O
obtained,5657,O
immediately,5657,O
following,5657,O
the,5657,O
24h,5657,O
after,5657,O
MWM,5657,O
test,5657,O
conclusion,5657,O
.,5657,O
Glutathione,5658,B-CHEMICAL
(,5658,O
GSH,5658,B-CHEMICAL
),5658,O
",",5658,O
oxidized,5658,B-CHEMICAL
glutathione,5658,I-CHEMICAL
(,5658,O
GSSG,5658,B-CHEMICAL
),5658,O
and,5658,O
total,5658,O
thiol,5658,B-CHEMICAL
(,5658,O
total-SH,5658,O
),5658,O
content,5658,O
",",5658,O
GSH,5658,B-GENE-Y
reductase,5658,I-GENE-Y
(,5658,O
GR,5658,B-GENE-Y
),5658,O
and,5658,O
GSH,5658,B-GENE-N
peroxidase,5658,I-GENE-N
(,5658,O
GSH-Px,5658,B-GENE-N
),5658,O
activities,5658,O
",",5658,O
malondialdehyde,5658,B-CHEMICAL
(,5658,O
MDA,5658,B-CHEMICAL
),5658,O
level,5658,O
",",5658,O
as,5658,O
well,5658,O
as,5658,O
4-hydroxynonenal,5658,B-CHEMICAL
(,5658,O
4-HNE,5658,B-CHEMICAL
),5658,O
and,5658,O
MDA,5658,B-CHEMICAL
modified,5658,O
proteins,5658,O
in,5658,O
homogenates,5658,O
of,5658,O
cerebral,5658,O
cortex,5658,O
were,5658,O
measured,5658,O
.,5658,O
The,5659,O
obtained,5659,O
results,5659,O
showed,5659,O
that,5659,O
1-BP,5659,B-CHEMICAL
led,5659,O
to,5659,O
cognitive,5659,O
dysfunction,5659,O
of,5659,O
rats,5659,O
",",5659,O
which,5659,O
was,5659,O
evidenced,5659,O
by,5659,O
delayed,5659,O
escape,5659,O
latency,5659,O
time,5659,O
and,5659,O
swimming,5659,O
distances,5659,O
in,5659,O
MWM,5659,O
performance,5659,O
.,5659,O
GSH,5660,B-CHEMICAL
and,5660,O
total-SH,5660,O
content,5660,O
",",5660,O
GSH/GSSG,5660,B-CHEMICAL
ratio,5660,O
",",5660,O
GR,5660,B-GENE-Y
activity,5660,O
significantly,5660,O
decreased,5660,O
in,5660,O
cerebral,5660,O
cortex,5660,O
of,5660,O
rats,5660,O
",",5660,O
coupling,5660,O
with,5660,O
the,5660,O
increase,5660,O
of,5660,O
MDA,5660,B-CHEMICAL
level,5660,O
.,5660,O
4-HNE,5661,B-CHEMICAL
and,5661,O
MDA,5661,B-CHEMICAL
modified,5661,O
protein,5661,O
levels,5661,O
obviously,5661,O
elevated,5661,O
after,5661,O
1-BP,5661,B-CHEMICAL
exposure,5661,O
.,5661,O
GSH-Px,5662,B-GENE-N
activities,5662,O
in,5662,O
cerebral,5662,O
cortex,5662,O
of,5662,O
rats,5662,O
also,5662,O
increased,5662,O
.,5662,O
These,5663,O
data,5663,O
suggested,5663,O
that,5663,O
1-BP,5663,B-CHEMICAL
resulted,5663,O
in,5663,O
enhanced,5663,O
lipid,5663,O
peroxidation,5663,O
of,5663,O
brain,5663,O
",",5663,O
which,5663,O
might,5663,O
play,5663,O
an,5663,O
important,5663,O
role,5663,O
in,5663,O
CNS,5663,O
damage,5663,O
induced,5663,O
by,5663,O
1-BP,5663,B-CHEMICAL
.,5663,O
Site,5664,O
dependent,5664,O
intestinal,5664,O
absorption,5664,O
of,5664,O
darunavir,5664,B-CHEMICAL
and,5664,O
its,5664,O
interaction,5664,O
with,5664,O
ketoconazole,5664,B-CHEMICAL
.,5664,O
The,5665,O
expression,5665,O
of,5665,O
P-gp,5665,B-GENE-N
increases,5665,O
from,5665,O
proximal,5665,O
to,5665,O
distal,5665,O
parts,5665,O
of,5665,O
the,5665,O
small,5665,O
intestine,5665,O
",",5665,O
whereas,5665,O
for,5665,O
P450,5665,B-GENE-N
enzymes,5665,I-GENE-N
the,5665,O
expression,5665,O
is,5665,O
reported,5665,O
to,5665,O
be,5665,O
highest,5665,O
in,5665,O
duodenum,5665,O
and,5665,O
jejunum,5665,O
",",5665,O
decreasing,5665,O
to,5665,O
more,5665,O
distal,5665,O
sites,5665,O
.,5665,O
To,5666,O
evaluate,5666,O
to,5666,O
what,5666,O
extent,5666,O
the,5666,O
regional,5666,O
differences,5666,O
in,5666,O
expression,5666,O
of,5666,O
P-gp,5666,B-GENE-N
and,5666,O
P450,5666,B-GENE-N
enzymes,5666,I-GENE-N
affect,5666,O
the,5666,O
absorption,5666,O
of,5666,O
a,5666,O
dual,5666,O
substrate,5666,O
",",5666,O
we,5666,O
investigated,5666,O
the,5666,O
transport,5666,O
of,5666,O
darunavir,5666,B-CHEMICAL
across,5666,O
different,5666,O
small,5666,O
intestinal,5666,O
segments,5666,O
(,5666,O
duodenum,5666,O
",",5666,O
proximal,5666,O
jejunum,5666,O
and,5666,O
ileum,5666,O
),5666,O
.,5666,O
Moreover,5667,O
",",5667,O
the,5667,O
effect,5667,O
of,5667,O
ketoconazole,5667,B-CHEMICAL
on,5667,O
the,5667,O
intestinal,5667,O
absorption,5667,O
of,5667,O
darunavir,5667,B-CHEMICAL
was,5667,O
explored,5667,O
",",5667,O
since,5667,O
these,5667,O
drugs,5667,O
are,5667,O
commonly,5667,O
co-administered,5667,O
.,5667,O
Performing,5668,O
the,5668,O
rat,5668,O
in,5668,O
situ,5668,O
intestinal,5668,O
perfusion,5668,O
technique,5668,O
with,5668,O
mesenteric,5668,O
blood,5668,O
sampling,5668,O
",",5668,O
we,5668,O
found,5668,O
no,5668,O
significant,5668,O
differences,5668,O
in,5668,O
the,5668,O
transport,5668,O
of,5668,O
darunavir,5668,B-CHEMICAL
at,5668,O
the,5668,O
different,5668,O
intestinal,5668,O
segments,5668,O
.,5668,O
The,5669,O
involvement,5669,O
of,5669,O
P-gp,5669,B-GENE-N
in,5669,O
the,5669,O
absorption,5669,O
of,5669,O
darunavir,5669,B-CHEMICAL
was,5669,O
clearly,5669,O
shown,5669,O
by,5669,O
coperfusion,5669,O
of,5669,O
darunavir,5669,B-CHEMICAL
with,5669,O
the,5669,O
P-gp,5669,B-GENE-N
inhibitor,5669,O
zosuquidar,5669,B-CHEMICAL
.,5669,O
In,5670,O
presence,5670,O
of,5670,O
zosuquidar,5670,B-CHEMICAL
",",5670,O
a,5670,O
2.2-,5670,O
",",5670,O
4.2-,5670,O
and,5670,O
5.7-fold,5670,O
increase,5670,O
in,5670,O
Papp,5670,O
values,5670,O
were,5670,O
measured,5670,O
for,5670,O
duodenum,5670,O
",",5670,O
proximal,5670,O
jejunum,5670,O
and,5670,O
ileum,5670,O
",",5670,O
respectively,5670,O
.,5670,O
Involvement,5671,O
of,5671,O
P450,5671,B-GENE-N
mediated,5671,O
metabolism,5671,O
in,5671,O
the,5671,O
absorption,5671,O
of,5671,O
darunavir,5671,B-CHEMICAL
could,5671,O
not,5671,O
be,5671,O
demonstrated,5671,O
in,5671,O
this,5671,O
rat,5671,O
model,5671,O
.,5671,O
Upon,5672,O
studying,5672,O
the,5672,O
drug-drug,5672,O
interaction,5672,O
of,5672,O
darunavir,5672,B-CHEMICAL
with,5672,O
ketoconazole,5672,B-CHEMICAL
",",5672,O
data,5672,O
were,5672,O
indicative,5672,O
for,5672,O
an,5672,O
inhibitory,5672,O
effect,5672,O
of,5672,O
ketoconazole,5672,B-CHEMICAL
on,5672,O
P-gp,5672,B-GENE-N
as,5672,O
the,5672,O
main,5672,O
mechanism,5672,O
for,5672,O
the,5672,O
increased,5672,O
transport,5672,O
of,5672,O
darunavir,5672,B-CHEMICAL
across,5672,O
the,5672,O
small,5672,O
intestine,5672,O
.,5672,O
Protective,5673,O
effect,5673,O
of,5673,O
Codium,5673,O
fragile,5673,O
against,5673,O
UVB-induced,5673,O
pro-inflammatory,5673,O
and,5673,O
oxidative,5673,O
damages,5673,O
in,5673,O
HaCaT,5673,O
cells,5673,O
and,5673,O
BALB/c,5673,O
mice,5673,O
.,5673,O
Acute,5674,O
exposure,5674,O
to,5674,O
ultraviolet,5674,O
(,5674,O
UV,5674,O
),5674,O
radiation,5674,O
causes,5674,O
pro-inflammatory,5674,O
responses,5674,O
via,5674,O
diverse,5674,O
mechanisms,5674,O
including,5674,O
oxidative,5674,O
stress,5674,O
.,5674,O
Codium,5675,O
fragile,5675,O
is,5675,O
a,5675,O
green,5675,O
alga,5675,O
of,5675,O
Codiales,5675,O
family,5675,O
and,5675,O
has,5675,O
been,5675,O
reported,5675,O
to,5675,O
exhibit,5675,O
anti-edema,5675,O
",",5675,O
anti-allergic,5675,O
",",5675,O
anti-protozoal,5675,O
and,5675,O
anti-mycobacterial,5675,O
activities,5675,O
.,5675,O
In,5676,O
this,5676,O
study,5676,O
",",5676,O
we,5676,O
have,5676,O
investigated,5676,O
a,5676,O
novel,5676,O
anti-inflammatory,5676,O
potential,5676,O
of,5676,O
C.,5676,O
fragile,5676,O
using,5676,O
in,5676,O
vitro,5676,O
cell,5676,O
culture,5676,O
as,5676,O
well,5676,O
as,5676,O
in,5676,O
vivo,5676,O
animal,5676,O
models,5676,O
.,5676,O
In,5677,O
HaCaT,5677,O
cells,5677,O
",",5677,O
buthanol,5677,B-CHEMICAL
and,5677,O
ethylacetate,5677,B-CHEMICAL
fractions,5677,O
of,5677,O
80,5677,O
%,5677,O
methanol,5677,B-CHEMICAL
C.,5677,O
fragile,5677,O
extract,5677,O
(,5677,O
CFB,5677,O
or,5677,O
CFE,5677,O
),5677,O
and,5677,O
a,5677,O
single,5677,O
compound,5677,O
",",5677,O
clerosterol,5677,B-CHEMICAL
(,5677,O
CLS,5677,B-CHEMICAL
),5677,O
isolated,5677,O
from,5677,O
CFE,5677,O
attenuated,5677,O
UVB,5677,O
(,5677,O
60mJ/cm,5677,O
(,5677,O
2,5677,O
),5677,O
),5677,O
-induced,5677,O
cytotoxicity,5677,O
and,5677,O
reduced,5677,O
expression,5677,O
of,5677,O
pro-inflammatory,5677,O
proteins,5677,O
including,5677,O
cyclooxygenase-2,5677,B-GENE-Y
(,5677,O
COX-2,5677,B-GENE-Y
),5677,O
",",5677,O
inducible,5677,B-GENE-Y
nitric,5677,B-CHEMICAL
oxide,5677,I-CHEMICAL
synthase,5677,I-GENE-Y
(,5677,O
iNOS,5677,B-GENE-Y
),5677,O
",",5677,O
and,5677,O
tumor,5677,B-GENE-Y
necrosis,5677,I-GENE-Y
factor-α,5677,I-GENE-Y
(,5677,O
TNF-,5677,B-GENE-Y
α,5677,I-GENE-Y
),5677,O
.,5677,O
Moreover,5678,O
",",5678,O
CFB,5678,O
",",5678,O
CFE,5678,O
and,5678,O
CLS,5678,B-CHEMICAL
effectively,5678,O
suppressed,5678,O
UVB-induced,5678,O
production,5678,O
of,5678,O
pro-inflammatory,5678,O
mediators,5678,O
such,5678,O
as,5678,O
prostaglandin,5678,B-CHEMICAL
E2,5678,I-CHEMICAL
(,5678,O
PGE2,5678,B-CHEMICAL
),5678,O
and,5678,O
nitric,5678,B-CHEMICAL
oxide,5678,I-CHEMICAL
(,5678,O
NO,5678,B-CHEMICAL
),5678,O
.,5678,O
In,5679,O
another,5679,O
experiment,5679,O
",",5679,O
topical,5679,O
application,5679,O
of,5679,O
CFB,5679,O
",",5679,O
CFE,5679,O
or,5679,O
CLS,5679,B-CHEMICAL
prior,5679,O
to,5679,O
UVB,5679,O
irradiation,5679,O
(,5679,O
200mJ/cm,5679,O
(,5679,O
2,5679,O
),5679,O
),5679,O
on,5679,O
BALB/c,5679,O
mice,5679,O
",",5679,O
inhibited,5679,O
the,5679,O
UVB-elevated,5679,O
protein,5679,O
levels,5679,O
of,5679,O
COX-2,5679,B-GENE-Y
",",5679,O
iNOS,5679,B-GENE-Y
",",5679,O
and,5679,O
TNF-α,5679,B-GENE-Y
.,5679,O
Furthermore,5680,O
",",5680,O
CFB,5680,O
",",5680,O
CFE,5680,O
and,5680,O
CLS,5680,B-CHEMICAL
suppressed,5680,O
oxidative,5680,O
damages,5680,O
caused,5680,O
by,5680,O
UVB,5680,O
irradiation,5680,O
for,5680,O
example,5680,O
lipid,5680,O
peroxidation,5680,O
and/or,5680,O
protein,5680,O
carbonylation,5680,O
",",5680,O
which,5680,O
seemed,5680,O
to,5680,O
be,5680,O
mediated,5680,O
by,5680,O
up-regulation,5680,O
of,5680,O
antioxidant,5680,O
defense,5680,O
enzymes,5680,O
.,5680,O
These,5681,O
results,5681,O
suggest,5681,O
that,5681,O
C.,5681,O
fragile,5681,O
could,5681,O
be,5681,O
an,5681,O
effective,5681,O
therapeutic,5681,O
agent,5681,O
providing,5681,O
protection,5681,O
against,5681,O
UVB-induced,5681,O
inflammatory,5681,O
and,5681,O
oxidative,5681,O
skin,5681,O
damages,5681,O
.,5681,O
Strong,5682,O
effects,5682,O
of,5682,O
cluster,5682,O
size,5682,O
and,5682,O
air,5682,O
exposure,5682,O
on,5682,O
oxygen,5682,B-CHEMICAL
reduction,5682,O
and,5682,O
carbon,5682,B-CHEMICAL
oxidation,5682,O
electrocatalysis,5682,O
by,5682,O
size-selected,5682,O
Pt,5682,B-CHEMICAL
(,5682,I-CHEMICAL
n,5682,I-CHEMICAL
),5682,I-CHEMICAL
(,5682,O
n,5682,O
≤,5682,O
11,5682,O
),5682,O
on,5682,O
glassy,5682,B-CHEMICAL
carbon,5682,I-CHEMICAL
electrodes,5682,O
.,5682,O
Model,5683,O
Pt,5683,B-CHEMICAL
(,5683,I-CHEMICAL
n,5683,I-CHEMICAL
),5683,I-CHEMICAL
/glassy,5683,O
carbon,5683,I-CHEMICAL
electrodes,5683,O
(,5683,O
Pt,5683,B-CHEMICAL
(,5683,I-CHEMICAL
n,5683,I-CHEMICAL
),5683,I-CHEMICAL
/GCE,5683,O
),5683,O
were,5683,O
prepared,5683,O
by,5683,O
deposition,5683,O
of,5683,O
mass-selected,5683,O
Pt,5683,B-CHEMICAL
(,5683,I-CHEMICAL
n,5683,I-CHEMICAL
),5683,I-CHEMICAL
(,5683,I-CHEMICAL
+,5683,I-CHEMICAL
),5683,I-CHEMICAL
(,5683,O
n,5683,O
≤,5683,O
11,5683,O
),5683,O
on,5683,O
GCE,5683,O
substrates,5683,O
in,5683,O
ultrahigh,5683,O
vacuum,5683,O
.,5683,O
Electrocatalysis,5684,O
under,5684,O
conditions,5684,O
appropriate,5684,O
for,5684,O
the,5684,O
oxygen,5684,B-CHEMICAL
reduction,5684,O
reaction,5684,O
(,5684,O
ORR,5684,O
),5684,O
was,5684,O
studied,5684,O
",",5684,O
for,5684,O
samples,5684,O
both,5684,O
in,5684,O
situ,5684,O
with,5684,O
no,5684,O
exposure,5684,O
to,5684,O
laboratory,5684,O
air,5684,O
and,5684,O
with,5684,O
air,5684,O
exposure,5684,O
prior,5684,O
to,5684,O
electrochemical,5684,O
measurements,5684,O
.,5684,O
Of,5685,O
the,5685,O
small,5685,O
clusters,5685,O
",",5685,O
only,5685,O
a,5685,O
few,5685,O
cluster,5685,O
sizes,5685,O
show,5685,O
the,5685,O
expected,5685,O
ORR,5685,O
activity,5685,O
",",5685,O
and,5685,O
in,5685,O
those,5685,O
cases,5685,O
",",5685,O
the,5685,O
activity,5685,O
per,5685,O
Pt,5685,B-CHEMICAL
atom,5685,O
is,5685,O
similar,5685,O
to,5685,O
that,5685,O
seen,5685,O
under,5685,O
identical,5685,O
conditions,5685,O
with,5685,O
a,5685,O
conventionally,5685,O
prepared,5685,O
electrode,5685,O
with,5685,O
Pt,5685,B-CHEMICAL
nanoparticles,5685,O
grown,5685,O
on,5685,O
a,5685,O
GCE,5685,O
.,5685,O
For,5686,O
other,5686,O
small,5686,O
Pt,5686,B-CHEMICAL
(,5686,I-CHEMICAL
n,5686,I-CHEMICAL
),5686,I-CHEMICAL
on,5686,O
GCE,5686,O
",",5686,O
any,5686,O
ORR,5686,O
signal,5686,O
is,5686,O
overwhelmed,5686,O
by,5686,O
large,5686,O
oxidative,5686,O
currents,5686,O
attributed,5686,O
to,5686,O
catalysis,5686,O
of,5686,O
carbon,5686,B-CHEMICAL
oxidation,5686,O
by,5686,O
water,5686,O
.,5686,O
If,5687,O
the,5687,O
samples,5687,O
are,5687,O
exposed,5687,O
to,5687,O
air,5687,O
prior,5687,O
to,5687,O
electrochemistry,5687,O
",",5687,O
both,5687,O
ORR,5687,O
and,5687,O
carbon,5687,B-CHEMICAL
oxidation,5687,O
signals,5687,O
are,5687,O
absent,5687,O
",",5687,O
and,5687,O
instead,5687,O
only,5687,O
small,5687,O
capacitive,5687,O
currents,5687,O
or,5687,O
currents,5687,O
attributed,5687,O
to,5687,O
redox,5687,O
chemistry,5687,O
of,5687,O
adventitious,5687,O
organic,5687,O
adsorbates,5687,O
are,5687,O
observed,5687,O
",",5687,O
indicating,5687,O
that,5687,O
air,5687,O
exposure,5687,O
results,5687,O
in,5687,O
passivation,5687,O
of,5687,O
the,5687,O
small,5687,O
Pt,5687,B-CHEMICAL
clusters,5687,O
.,5687,O
Inhibition,5688,O
of,5688,O
ghrelin,5688,B-GENE-Y
O-acyltransferase,5688,B-CHEMICAL
attenuates,5688,O
food,5688,O
deprivation-induced,5688,O
increases,5688,O
in,5688,O
ingestive,5688,O
behavior,5688,O
.,5688,O
Ghrelin,5689,B-GENE-Y
is,5689,O
an,5689,O
orexigenic,5689,B-GENE-N
hormone,5689,I-GENE-N
produced,5689,O
by,5689,O
the,5689,O
stomach,5689,O
in,5689,O
direct,5689,O
proportion,5689,O
to,5689,O
the,5689,O
time,5689,O
since,5689,O
the,5689,O
last,5689,O
meal,5689,O
and,5689,O
has,5689,O
therefore,5689,O
been,5689,O
called,5689,O
a,5689,O
'hunger,5689,O
signal,5689,O
',5689,O
.,5689,O
The,5690,O
octanoylation,5690,O
of,5690,O
ghrelin,5690,B-GENE-Y
is,5690,O
critical,5690,O
for,5690,O
its,5690,O
orexigenic,5690,O
functions,5690,O
and,5690,O
is,5690,O
dependent,5690,O
upon,5690,O
ghrelin,5690,B-GENE-Y
O-acyltransferase,5690,I-GENE-Y
(,5690,O
GOAT,5690,B-GENE-Y
),5690,O
catalyzation,5690,O
.,5690,O
The,5691,O
GOAT,5691,B-GENE-Y
inhibitor,5691,O
",",5691,O
GO-CoA-Tat,5691,O
",",5691,O
decreases,5691,O
the,5691,O
circulating,5691,O
concentrations,5691,O
of,5691,O
octanoylated,5691,B-GENE-Y
ghrelin,5691,I-GENE-Y
and,5691,O
attenuates,5691,O
weight,5691,O
gain,5691,O
on,5691,O
a,5691,O
high,5691,O
fat,5691,O
diet,5691,O
in,5691,O
mice,5691,O
.,5691,O
Unlike,5692,O
rats,5692,O
and,5692,O
mice,5692,O
",",5692,O
Siberian,5692,O
hamsters,5692,O
and,5692,O
humans,5692,O
do,5692,O
not,5692,O
increase,5692,O
food,5692,O
intake,5692,O
after,5692,O
food,5692,O
deprivation,5692,O
",",5692,O
but,5692,O
increase,5692,O
food,5692,O
hoarding,5692,O
after,5692,O
food,5692,O
deprivation,5692,O
.,5692,O
In,5693,O
Siberian,5693,O
hamsters,5693,O
",",5693,O
exogenous,5693,O
ghrelin,5693,B-GENE-Y
increases,5693,O
ingestive,5693,O
behaviors,5693,O
similarly,5693,O
to,5693,O
48-56h,5693,O
food,5693,O
deprivation,5693,O
.,5693,O
Therefore,5694,O
",",5694,O
we,5694,O
tested,5694,O
the,5694,O
necessity,5694,O
of,5694,O
increased,5694,O
ghrelin,5694,B-GENE-Y
in,5694,O
food-deprived,5694,O
Siberian,5694,O
hamsters,5694,O
to,5694,O
stimulate,5694,O
ingestive,5694,O
behaviors,5694,O
.,5694,O
To,5695,O
do,5695,O
so,5695,O
we,5695,O
used,5695,O
our,5695,O
simulated,5695,O
natural,5695,O
housing,5695,O
system,5695,O
that,5695,O
allows,5695,O
hamsters,5695,O
to,5695,O
forage,5695,O
for,5695,O
and,5695,O
hoard,5695,O
food,5695,O
.,5695,O
Animals,5696,O
were,5696,O
given,5696,O
an,5696,O
injection,5696,O
of,5696,O
GO-CoA-Tat,5696,O
(,5696,O
i.p.,5696,O
",",5696,O
11μmol/kg,5696,O
),5696,O
every,5696,O
6h,5696,O
because,5696,O
that,5696,O
is,5696,O
the,5696,O
duration,5696,O
of,5696,O
its,5696,O
effective,5696,O
inhibition,5696,O
of,5696,O
octanoylated,5696,B-GENE-N
ghrelin,5696,I-GENE-N
concentrations,5696,O
during,5696,O
a,5696,O
48h,5696,O
food,5696,O
deprivation,5696,O
.,5696,O
We,5697,O
found,5697,O
that,5697,O
GO-CoA-Tat,5697,O
attenuated,5697,O
food,5697,O
foraging,5697,O
(,5697,O
0-1h,5697,O
),5697,O
",",5697,O
food,5697,O
intake,5697,O
(,5697,O
0-1,5697,O
and,5697,O
2-4h,5697,O
),5697,O
",",5697,O
and,5697,O
food,5697,O
hoarding,5697,O
(,5697,O
0-1h,5697,O
and,5697,O
2,5697,O
and,5697,O
3days,5697,O
),5697,O
post-refeeding,5697,O
compared,5697,O
with,5697,O
saline,5697,O
treated,5697,O
animals,5697,O
.,5697,O
This,5698,O
suggests,5698,O
that,5698,O
increased,5698,O
octanoylated,5698,B-GENE-N
ghrelin,5698,I-GENE-N
concentrations,5698,O
play,5698,O
a,5698,O
role,5698,O
in,5698,O
the,5698,O
food,5698,O
deprivation-induced,5698,O
increases,5698,O
in,5698,O
ingestive,5698,O
behavior,5698,O
.,5698,O
Therefore,5699,O
",",5699,O
ghrelin,5699,B-GENE-Y
is,5699,O
a,5699,O
critical,5699,O
aspect,5699,O
of,5699,O
the,5699,O
multi-faceted,5699,O
mechanisms,5699,O
that,5699,O
stimulate,5699,O
ingestive,5699,O
behaviors,5699,O
",",5699,O
and,5699,O
might,5699,O
be,5699,O
a,5699,O
critical,5699,O
point,5699,O
for,5699,O
a,5699,O
successful,5699,O
clinical,5699,O
intervention,5699,O
scheme,5699,O
in,5699,O
humans,5699,O
.,5699,O
The,5700,O
accumulation,5700,O
of,5700,O
metal,5700,O
(,5700,O
Co,5700,B-CHEMICAL
",",5700,O
Cr,5700,B-CHEMICAL
",",5700,O
Cu,5700,B-CHEMICAL
",",5700,O
Mn,5700,B-CHEMICAL
and,5700,O
Zn,5700,B-CHEMICAL
),5700,O
in,5700,O
freshwater,5700,O
Ulva,5700,O
(,5700,O
Chlorophyta,5700,O
),5700,O
and,5700,O
its,5700,O
habitat,5700,O
.,5700,O
The,5701,O
possibility,5701,O
of,5701,O
using,5701,O
freshwater,5701,O
Ulva,5701,O
(,5701,O
Chlorophyta,5701,O
),5701,O
as,5701,O
a,5701,O
bioaccumulator,5701,O
of,5701,O
metals,5701,O
(,5701,O
Co,5701,B-CHEMICAL
",",5701,O
Cr,5701,B-CHEMICAL
",",5701,O
Cu,5701,B-CHEMICAL
",",5701,O
Mn,5701,B-CHEMICAL
and,5701,O
Zn,5701,B-CHEMICAL
),5701,O
in,5701,O
lake,5701,O
and,5701,O
river,5701,O
water,5701,O
was,5701,O
examined,5701,O
weekly,5701,O
in,5701,O
the,5701,O
summer,5701,O
of,5701,O
2010,5701,O
in,5701,O
three,5701,O
types,5701,O
of,5701,O
samples,5701,O
:,5701,O
the,5701,O
water,5701,O
",",5701,O
the,5701,O
sediment,5701,O
and,5701,O
the,5701,O
thalli,5701,O
of,5701,O
Ulva,5701,O
.,5701,O
Samples,5702,O
of,5702,O
freshwater,5702,O
Ulva,5702,O
were,5702,O
collected,5702,O
from,5702,O
two,5702,O
aqueous,5702,O
ecosystems,5702,O
lie,5702,O
250,5702,O
km,5702,O
away,5702,O
from,5702,O
the,5702,O
basin,5702,O
of,5702,O
the,5702,O
Baltic,5702,O
Sea,5702,O
and,5702,O
53,5702,O
km,5702,O
from,5702,O
each,5702,O
other,5702,O
.,5702,O
A,5703,O
flow,5703,O
lake,5703,O
located,5703,O
in,5703,O
the,5703,O
centre,5703,O
of,5703,O
the,5703,O
big,5703,O
city,5703,O
was,5703,O
the,5703,O
first,5703,O
water,5703,O
reservoir,5703,O
(,5703,O
ten,5703,O
sites,5703,O
),5703,O
and,5703,O
second,5703,O
",",5703,O
the,5703,O
suburban,5703,O
river,5703,O
(,5703,O
six,5703,O
sites,5703,O
),5703,O
.,5703,O
The,5704,O
mean,5704,O
metal,5704,O
concentrations,5704,O
in,5704,O
the,5704,O
Ulva,5704,O
tissue,5704,O
from,5704,O
the,5704,O
river,5704,O
and,5704,O
the,5704,O
lake,5704,O
decreased,5704,O
in,5704,O
the,5704,O
following,5704,O
order,5704,O
:,5704,O
Mn,5704,B-CHEMICAL
>,5704,O
Zn,5704,B-CHEMICAL
>,5704,O
Cr,5704,B-CHEMICAL
>,5704,O
Cu,5704,B-CHEMICAL
>,5704,O
Co,5704,B-CHEMICAL
and,5704,O
Mn,5704,B-CHEMICAL
>,5704,O
Cr,5704,B-CHEMICAL
>,5704,O
Zn,5704,B-CHEMICAL
>,5704,O
Cu,5704,B-CHEMICAL
>,5704,O
Co,5704,B-CHEMICAL
",",5704,O
respectively,5704,O
.,5704,O
Moreover,5705,O
",",5705,O
a,5705,O
negative,5705,O
and,5705,O
statistically,5705,O
significant,5705,O
correlation,5705,O
between,5705,O
Mn,5705,B-CHEMICAL
concentrations,5705,O
in,5705,O
the,5705,O
Ulva,5705,O
thalli,5705,O
and,5705,O
the,5705,O
river,5705,O
water,5705,O
was,5705,O
observed,5705,O
.,5705,O
Additionally,5706,O
",",5706,O
numerous,5706,O
correlations,5706,O
were,5706,O
noted,5706,O
between,5706,O
the,5706,O
different,5706,O
concentrations,5706,O
of,5706,O
metals,5706,O
within,5706,O
the,5706,O
Ulva,5706,O
thalli,5706,O
",",5706,O
in,5706,O
the,5706,O
water,5706,O
and,5706,O
in,5706,O
the,5706,O
sediment,5706,O
.,5706,O
The,5707,O
great,5707,O
concentrations,5707,O
of,5707,O
Mn,5707,B-CHEMICAL
and,5707,O
Zn,5707,B-CHEMICAL
and,5707,O
the,5707,O
smallest,5707,O
of,5707,O
Co,5707,B-CHEMICAL
were,5707,O
found,5707,O
in,5707,O
thalli,5707,O
of,5707,O
Ulva,5707,O
",",5707,O
irrespective,5707,O
of,5707,O
the,5707,O
type,5707,O
of,5707,O
the,5707,O
ecosystem,5707,O
from,5707,O
which,5707,O
samples,5707,O
of,5707,O
algal,5707,O
thalli,5707,O
originated,5707,O
.,5707,O
Freshwater,5708,O
Ulva,5708,O
populations,5708,O
examined,5708,O
in,5708,O
this,5708,O
study,5708,O
were,5708,O
clearly,5708,O
characterized,5708,O
a,5708,O
dozen,5708,O
or,5708,O
so,5708,O
times,5708,O
by,5708,O
the,5708,O
higher,5708,O
Mn,5708,B-CHEMICAL
and,5708,O
Cr,5708,B-CHEMICAL
accumulation,5708,O
than,5708,O
taxa,5708,O
from,5708,O
that,5708,O
genera,5708,O
coming,5708,O
from,5708,O
sea,5708,O
ecosystems,5708,O
.,5708,O
The,5709,O
calculated,5709,O
bioconcentration,5709,O
factor,5709,O
confirm,5709,O
the,5709,O
high,5709,O
potential,5709,O
for,5709,O
freshwater,5709,O
Ulva,5709,O
to,5709,O
be,5709,O
a,5709,O
bioaccumulator,5709,O
of,5709,O
trace,5709,O
metals,5709,O
in,5709,O
freshwater,5709,O
ecosystems,5709,O
.,5709,O
Exploring,5710,O
the,5710,O
Interplay,5710,O
Between,5710,O
Ligand,5710,O
Derivatisation,5710,O
and,5710,O
Cation,5710,O
Type,5710,O
in,5710,O
the,5710,O
Assembly,5710,O
of,5710,O
Hybrid,5710,O
Polyoxometalate,5710,B-CHEMICAL
Mn-Andersons,5710,B-CHEMICAL
.,5710,O
Herein,5711,O
a,5711,O
library,5711,O
of,5711,O
hybrid,5711,O
Mn-Anderson,5711,B-CHEMICAL
polyoxometalates,5711,B-CHEMICAL
anions,5711,O
are,5711,O
presented,5711,O
:,5711,O
1,5711,O
",",5711,O
[,5711,B-CHEMICAL
(,5711,I-CHEMICAL
MnMo,5711,I-CHEMICAL
(,5711,I-CHEMICAL
6,5711,I-CHEMICAL
),5711,I-CHEMICAL
O,5711,I-CHEMICAL
(,5711,I-CHEMICAL
18,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
(,5711,I-CHEMICAL
OCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
3,5711,I-CHEMICAL
),5711,I-CHEMICAL
-C-,5711,I-CHEMICAL
(,5711,I-CHEMICAL
CH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
7,5711,I-CHEMICAL
),5711,I-CHEMICAL
CHCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
],5711,I-CHEMICAL
(,5711,I-CHEMICAL
3-,5711,I-CHEMICAL
),5711,I-CHEMICAL
;,5711,O
compound,5711,O
2,5711,O
",",5711,O
[,5711,B-CHEMICAL
(,5711,I-CHEMICAL
MnMo,5711,I-CHEMICAL
(,5711,I-CHEMICAL
6,5711,I-CHEMICAL
),5711,I-CHEMICAL
O,5711,I-CHEMICAL
(,5711,I-CHEMICAL
18,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
(,5711,I-CHEMICAL
OCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
3,5711,I-CHEMICAL
),5711,I-CHEMICAL
C-NHCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
C,5711,I-CHEMICAL
(,5711,I-CHEMICAL
16,5711,I-CHEMICAL
),5711,I-CHEMICAL
H,5711,I-CHEMICAL
(,5711,I-CHEMICAL
9,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
],5711,I-CHEMICAL
(,5711,I-CHEMICAL
3-,5711,I-CHEMICAL
),5711,I-CHEMICAL
;,5711,O
compound,5711,O
3,5711,O
",",5711,O
[,5711,B-CHEMICAL
(,5711,I-CHEMICAL
MnMo,5711,I-CHEMICAL
(,5711,I-CHEMICAL
6,5711,I-CHEMICAL
),5711,I-CHEMICAL
O,5711,I-CHEMICAL
(,5711,I-CHEMICAL
18,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
(,5711,I-CHEMICAL
OCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
3,5711,I-CHEMICAL
),5711,I-CHEMICAL
C-,5711,I-CHEMICAL
(,5711,I-CHEMICAL
CH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
7,5711,I-CHEMICAL
),5711,I-CHEMICAL
CHCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
1,5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
(,5711,I-CHEMICAL
OCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
3,5711,I-CHEMICAL
),5711,I-CHEMICAL
C-NHCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
C,5711,I-CHEMICAL
(,5711,I-CHEMICAL
16,5711,I-CHEMICAL
),5711,I-CHEMICAL
H,5711,I-CHEMICAL
(,5711,I-CHEMICAL
9,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
1,5711,I-CHEMICAL
),5711,I-CHEMICAL
],5711,I-CHEMICAL
(,5711,I-CHEMICAL
3-,5711,I-CHEMICAL
),5711,I-CHEMICAL
;,5711,O
compound,5711,O
4,5711,O
",",5711,O
[,5711,B-CHEMICAL
(,5711,I-CHEMICAL
MnMo,5711,I-CHEMICAL
(,5711,I-CHEMICAL
6,5711,I-CHEMICAL
),5711,I-CHEMICAL
O,5711,I-CHEMICAL
(,5711,I-CHEMICAL
18,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
(,5711,I-CHEMICAL
OCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
3,5711,I-CHEMICAL
),5711,I-CHEMICAL
C-NHC,5711,I-CHEMICAL
(,5711,I-CHEMICAL
O,5711,I-CHEMICAL
),5711,I-CHEMICAL
CH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
CHCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
],5711,I-CHEMICAL
(,5711,I-CHEMICAL
3-,5711,I-CHEMICAL
),5711,I-CHEMICAL
and,5711,O
compounds,5711,O
5-9,5711,O
",",5711,O
[,5711,B-CHEMICAL
(,5711,I-CHEMICAL
MnMo,5711,I-CHEMICAL
(,5711,I-CHEMICAL
6,5711,I-CHEMICAL
),5711,I-CHEMICAL
O,5711,I-CHEMICAL
(,5711,I-CHEMICAL
18,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
(,5711,I-CHEMICAL
OCH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
3,5711,I-CHEMICAL
),5711,I-CHEMICAL
C-NHC,5711,I-CHEMICAL
(,5711,I-CHEMICAL
O,5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
CH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
x,5711,I-CHEMICAL
),5711,I-CHEMICAL
CH,5711,I-CHEMICAL
(,5711,I-CHEMICAL
3,5711,I-CHEMICAL
),5711,I-CHEMICAL
),5711,I-CHEMICAL
(,5711,I-CHEMICAL
2,5711,I-CHEMICAL
),5711,I-CHEMICAL
],5711,I-CHEMICAL
),5711,O
",",5711,O
where,5711,O
x,5711,O
=,5711,O
4,5711,O
",",5711,O
10,5711,O
",",5711,O
12,5711,O
",",5711,O
14,5711,O
",",5711,O
and,5711,O
18,5711,O
respectively,5711,O
.,5711,O
The,5712,O
compounds,5712,O
resulting,5712,O
from,5712,O
the,5712,O
cation,5712,O
exchange,5712,O
of,5712,O
the,5712,O
anions,5712,O
1-9,5712,O
to,5712,O
give,5712,O
TBA,5712,B-CHEMICAL
(,5712,O
a,5712,O
),5712,O
and,5712,O
DMDOA,5712,B-CHEMICAL
(,5712,O
b,5712,O
),5712,O
salts,5712,O
",",5712,O
and,5712,O
additionally,5712,O
for,5712,O
compounds,5712,O
1,5712,O
",",5712,O
2,5712,O
and,5712,O
3,5712,O
",",5712,O
tetraphenylphosphonium,5712,B-CHEMICAL
(,5712,O
PPh,5712,B-CHEMICAL
(,5712,I-CHEMICAL
4,5712,I-CHEMICAL
),5712,I-CHEMICAL
),5712,O
(,5712,O
c,5712,O
),5712,O
salts,5712,O
",",5712,O
are,5712,O
explored,5712,O
at,5712,O
the,5712,O
air/water,5712,O
interface,5712,O
using,5712,O
scanning,5712,O
force,5712,O
microscopy,5712,O
",",5712,O
showing,5712,O
a,5712,O
range,5712,O
of,5712,O
architectures,5712,O
including,5712,O
hexagonal,5712,O
structures,5712,O
",",5712,O
nanofibers,5712,O
and,5712,O
other,5712,O
supramolecular,5712,O
forms,5712,O
.,5712,O
Additionally,5713,O
the,5713,O
solid-state,5713,O
structures,5713,O
for,5713,O
compounds,5713,O
1c,5713,O
",",5713,O
2c,5713,O
",",5713,O
4a,5713,O
",",5713,O
6a,5713,O
",",5713,O
9a,5713,O
",",5713,O
are,5713,O
presented,5713,O
for,5713,O
the,5713,O
first,5713,O
time,5713,O
and,5713,O
these,5713,O
investigations,5713,O
demonstrate,5713,O
the,5713,O
delicate,5713,O
interplay,5713,O
between,5713,O
the,5713,O
structure,5713,O
of,5713,O
the,5713,O
covalently,5713,O
derivatised,5713,O
hybrid,5713,O
organo-clusters,5713,O
as,5713,O
well,5713,O
as,5713,O
the,5713,O
ion-exchange,5713,O
cation,5713,O
types,5713,O
.,5713,O
Interaction,5714,O
of,5714,O
silymarin,5714,O
flavonolignans,5714,B-CHEMICAL
with,5714,O
organic,5714,B-GENE-N
anion-transporting,5714,I-GENE-N
polypeptides,5714,I-GENE-N
.,5714,O
Organic,5715,B-GENE-N
anion-transporting,5715,I-GENE-N
polypeptides,5715,I-GENE-N
(,5715,O
OATPs,5715,B-GENE-N
),5715,O
are,5715,O
multispecific,5715,B-GENE-N
transporters,5715,I-GENE-N
mediating,5715,O
the,5715,O
uptake,5715,O
of,5715,O
endogenous,5715,O
compounds,5715,O
and,5715,O
xenobiotics,5715,O
in,5715,O
tissues,5715,O
that,5715,O
are,5715,O
important,5715,O
for,5715,O
drug,5715,O
absorption,5715,O
and,5715,O
elimination,5715,O
",",5715,O
including,5715,O
the,5715,O
intestine,5715,O
and,5715,O
liver,5715,O
.,5715,O
Silymarin,5716,O
is,5716,O
a,5716,O
popular,5716,O
herbal,5716,O
supplement,5716,O
often,5716,O
used,5716,O
by,5716,O
patients,5716,O
with,5716,O
chronic,5716,O
liver,5716,O
disease,5716,O
;,5716,O
higher,5716,O
oral,5716,O
doses,5716,O
than,5716,O
those,5716,O
customarily,5716,O
used,5716,O
(,5716,O
140,5716,O
mg,5716,O
three,5716,O
times/day,5716,O
),5716,O
are,5716,O
being,5716,O
evaluated,5716,O
clinically,5716,O
.,5716,O
The,5717,O
present,5717,O
study,5717,O
examined,5717,O
the,5717,O
effect,5717,O
of,5717,O
silymarin,5717,O
flavonolignans,5717,B-CHEMICAL
on,5717,O
OATP1B1-,5717,B-GENE-Y
",",5717,O
OATP1B3-,5717,B-GENE-Y
",",5717,O
and,5717,O
OATP2B1-mediated,5717,B-GENE-Y
transport,5717,O
in,5717,O
cell,5717,O
lines,5717,O
stably,5717,O
expressing,5717,O
these,5717,O
transporters,5717,O
and,5717,O
in,5717,O
human,5717,O
hepatocytes,5717,O
.,5717,O
In,5718,O
overexpressing,5718,O
cell,5718,O
lines,5718,O
",",5718,O
OATP1B1-,5718,B-GENE-Y
and,5718,O
OATP1B3-mediated,5718,B-GENE-Y
estradiol-17β-glucuronide,5718,B-CHEMICAL
uptake,5718,O
and,5718,O
OATP2B1-mediated,5718,B-GENE-Y
estrone-3-sulfate,5718,B-CHEMICAL
uptake,5718,O
were,5718,O
inhibited,5718,O
by,5718,O
most,5718,O
of,5718,O
the,5718,O
silymarin,5718,O
flavonolignans,5718,B-CHEMICAL
investigated,5718,O
.,5718,O
OATP1B1-,5719,B-GENE-Y
",",5719,O
OATP1B3-,5719,B-GENE-Y
",",5719,O
and,5719,O
OATP2B1-mediated,5719,B-GENE-Y
substrate,5719,O
transport,5719,O
was,5719,O
inhibited,5719,O
efficiently,5719,O
by,5719,O
silymarin,5719,O
(,5719,O
IC50,5719,O
values,5719,O
of,5719,O
1.3,5719,O
",",5719,O
2.2,5719,O
and,5719,O
0.3,5719,O
µM,5719,O
",",5719,O
respectively,5719,O
),5719,O
",",5719,O
silybin,5719,B-CHEMICAL
A,5719,I-CHEMICAL
(,5719,O
IC50,5719,O
values,5719,O
of,5719,O
9.7,5719,O
",",5719,O
2.7,5719,O
and,5719,O
4.5,5719,O
µM,5719,O
",",5719,O
respectively,5719,O
),5719,O
",",5719,O
silybin,5719,B-CHEMICAL
B,5719,I-CHEMICAL
(,5719,O
IC50,5719,O
values,5719,O
of,5719,O
8.5,5719,O
",",5719,O
5.0,5719,O
and,5719,O
0.8,5719,O
µM,5719,O
",",5719,O
respectively,5719,O
),5719,O
",",5719,O
and,5719,O
silychristin,5719,B-CHEMICAL
(,5719,O
IC50,5719,O
values,5719,O
of,5719,O
9.0,5719,O
",",5719,O
36.4,5719,O
",",5719,O
and,5719,O
3.6,5719,O
µM,5719,O
",",5719,O
respectively,5719,O
),5719,O
.,5719,O
Furthermore,5720,O
",",5720,O
silymarin,5720,O
",",5720,O
silybin,5720,B-CHEMICAL
A,5720,I-CHEMICAL
",",5720,O
and,5720,O
silybin,5720,B-CHEMICAL
B,5720,I-CHEMICAL
(,5720,O
100,5720,O
µM,5720,O
),5720,O
significantly,5720,O
inhibited,5720,O
OATP-mediated,5720,B-GENE-N
estradiol-17β-glucuronide,5720,B-CHEMICAL
and,5720,O
rosuvastatin,5720,B-CHEMICAL
uptake,5720,O
into,5720,O
human,5720,O
hepatocytes,5720,O
.,5720,O
Calculation,5721,O
of,5721,O
the,5721,O
maximal,5721,O
unbound,5721,O
portal,5721,O
vein,5721,O
concentrations/IC50,5721,O
values,5721,O
indicated,5721,O
a,5721,O
low,5721,O
risk,5721,O
for,5721,O
silymarin-drug,5721,O
interactions,5721,O
in,5721,O
hepatic,5721,O
uptake,5721,O
with,5721,O
a,5721,O
customary,5721,O
silymarin,5721,O
dose,5721,O
.,5721,O
The,5722,O
extent,5722,O
of,5722,O
silymarin-drug,5722,O
interactions,5722,O
depends,5722,O
on,5722,O
OATP,5722,B-GENE-N
isoform,5722,O
specificity,5722,O
and,5722,O
concentrations,5722,O
of,5722,O
flavonolignans,5722,B-CHEMICAL
at,5722,O
the,5722,O
site,5722,O
of,5722,O
drug,5722,O
transport,5722,O
.,5722,O
Higher,5723,O
than,5723,O
customary,5723,O
doses,5723,O
of,5723,O
silymarin,5723,O
",",5723,O
or,5723,O
formulations,5723,O
with,5723,O
improved,5723,O
bioavailability,5723,O
",",5723,O
may,5723,O
increase,5723,O
the,5723,O
risk,5723,O
of,5723,O
flavonolignan,5723,B-CHEMICAL
interactions,5723,O
with,5723,O
OATP,5723,B-GENE-N
substrates,5723,O
in,5723,O
patients,5723,O
.,5723,O
Oxidation,5724,O
of,5724,O
tertiary,5724,B-CHEMICAL
amine-derivatized,5724,O
surfaces,5724,O
to,5724,O
control,5724,O
protein,5724,O
adhesion,5724,O
.,5724,O
Selective,5725,O
oxidation,5725,O
of,5725,O
ω-tertiary,5725,B-CHEMICAL
amine,5725,I-CHEMICAL
self-assembled,5725,O
thiol,5725,B-CHEMICAL
monolayers,5725,O
to,5725,O
tertiary,5725,B-CHEMICAL
amine,5725,I-CHEMICAL
N-oxides,5725,I-CHEMICAL
is,5725,O
shown,5725,O
to,5725,O
transform,5725,O
the,5725,O
adhesion,5725,O
of,5725,O
model,5725,O
proteins,5725,O
lysozyme,5725,B-GENE-Y
and,5725,O
fibrinogen,5725,B-GENE-N
upon,5725,O
them,5725,O
.,5725,O
Efficient,5726,O
preparation,5726,O
of,5726,O
both,5726,O
secondary,5726,B-CHEMICAL
and,5726,I-CHEMICAL
tertiary,5726,I-CHEMICAL
linker,5726,I-CHEMICAL
amides,5726,I-CHEMICAL
as,5726,O
judged,5726,O
by,5726,O
X-ray,5726,O
photoelectron,5726,O
spectroscopy,5726,O
(,5726,O
XPS,5726,O
),5726,O
and,5726,O
water,5726,O
droplet,5726,O
contact,5726,O
angle,5726,O
was,5726,O
achieved,5726,O
with,5726,O
an,5726,O
improved,5726,O
amide,5726,B-CHEMICAL
bond,5726,O
formation,5726,O
on,5726,O
gold,5726,O
quartz,5726,B-CHEMICAL
crystal,5726,O
microbalance,5726,O
(,5726,O
QCM,5726,O
),5726,O
sensors,5726,O
using,5726,O
2-,5726,B-CHEMICAL
(,5726,I-CHEMICAL
1H-7-azabenzotriazol-1-yl,5726,I-CHEMICAL
),5726,I-CHEMICAL
"-1,1,3,3-tetramethyl",5726,I-CHEMICAL
hexafluorophosphate,5726,I-CHEMICAL
methanaminium,5726,I-CHEMICAL
uronium,5726,I-CHEMICAL
(,5726,O
HATU,5726,B-CHEMICAL
),5726,O
.,5726,O
Oxidation,5727,O
with,5727,O
hydrogen,5727,B-CHEMICAL
peroxide,5727,I-CHEMICAL
was,5727,O
similarly,5727,O
assessed,5727,O
",",5727,O
and,5727,O
adhesion,5727,O
of,5727,O
lysozyme,5727,B-GENE-Y
and,5727,O
fibrinogen,5727,B-GENE-N
from,5727,O
phosphate,5727,B-CHEMICAL
buffered,5727,O
saline,5727,O
was,5727,O
then,5727,O
assayed,5727,O
by,5727,O
QCM,5727,O
and,5727,O
imaged,5727,O
by,5727,O
AFM,5727,O
.,5727,O
Tertiary,5728,B-CHEMICAL
amine-functionalized,5728,O
sensors,5728,O
adsorbed,5728,O
multilayers,5728,O
of,5728,O
aggregated,5728,O
lysozyme,5728,B-GENE-Y
",",5728,O
whereas,5728,O
tertiary,5728,B-CHEMICAL
amine,5728,I-CHEMICAL
N-oxides,5728,I-CHEMICAL
and,5728,O
triethylene,5728,B-CHEMICAL
glycol-terminated,5728,O
monolayers,5728,O
are,5728,O
consistent,5728,O
with,5728,O
small,5728,O
protein,5728,O
aggregates,5728,O
.,5728,O
The,5729,O
surface,5729,O
containing,5729,O
a,5729,O
dimethylamine,5729,B-CHEMICAL
N-oxide,5729,I-CHEMICAL
headgroup,5729,O
and,5729,O
ethyl,5729,B-CHEMICAL
secondary,5729,I-CHEMICAL
amide,5729,I-CHEMICAL
linker,5729,O
showed,5729,O
the,5729,O
largest,5729,O
difference,5729,O
in,5729,O
adsorption,5729,O
of,5729,O
both,5729,O
proteins,5729,O
.,5729,O
Oxidation,5730,O
of,5730,O
tertiary,5730,B-CHEMICAL
amine,5730,I-CHEMICAL
decorated,5730,O
surfaces,5730,O
therefore,5730,O
holds,5730,O
the,5730,O
potential,5730,O
for,5730,O
selective,5730,O
deposition,5730,O
of,5730,O
proteins,5730,O
and,5730,O
cells,5730,O
through,5730,O
masking,5730,O
and,5730,O
other,5730,O
patterning,5730,O
techniques,5730,O
.,5730,O
Stabilisation,5731,O
of,5731,O
amorphous,5731,O
drugs,5731,O
under,5731,O
high,5731,O
humidity,5731,O
using,5731,O
pharmaceutical,5731,O
thin,5731,O
films,5731,O
.,5731,O
In,5732,O
this,5732,O
study,5732,O
",",5732,O
the,5732,O
stabilization,5732,O
effects,5732,O
of,5732,O
three,5732,O
polymers,5732,O
on,5732,O
four,5732,O
model,5732,O
drugs,5732,O
(,5732,O
felodipine,5732,B-CHEMICAL
",",5732,O
fenofibrate,5732,B-CHEMICAL
",",5732,O
carbamazepine,5732,B-CHEMICAL
",",5732,O
and,5732,O
celecoxib,5732,B-CHEMICAL
),5732,O
under,5732,O
saturated,5732,O
humidity,5732,O
were,5732,O
investigated,5732,O
.,5732,O
Three,5733,O
different,5733,O
types,5733,O
of,5733,O
thin,5733,O
films,5733,O
(,5733,O
solid,5733,O
dispersions,5733,O
",",5733,O
drug,5733,O
films,5733,O
with,5733,O
a,5733,O
polymer,5733,O
film,5733,O
coating,5733,O
and,5733,O
drug,5733,O
films,5733,O
laid,5733,O
on,5733,O
top,5733,O
of,5733,O
polymer,5733,O
coated,5733,O
surfaces,5733,O
),5733,O
were,5733,O
prepared,5733,O
and,5733,O
compared,5733,O
with,5733,O
films,5733,O
containing,5733,O
the,5733,O
drug,5733,O
alone,5733,O
.,5733,O
ATR-FTIR,5734,O
spectroscopy,5734,O
",",5734,O
polarised,5734,O
light,5734,O
microscopy,5734,O
(,5734,O
PLM,5734,O
),5734,O
",",5734,O
scanning,5734,O
electron,5734,O
microscopy,5734,O
(,5734,O
SEM,5734,O
),5734,O
and,5734,O
nano-thermal,5734,O
analysis,5734,O
(,5734,O
nano-TA,5734,O
),5734,O
were,5734,O
performed,5734,O
on,5734,O
the,5734,O
model,5734,O
systems,5734,O
after,5734,O
storage,5734,O
under,5734,O
saturated,5734,O
humidity,5734,O
.,5734,O
The,5735,O
recrystallisation,5735,O
tendency,5735,O
of,5735,O
the,5735,O
drug,5735,O
in,5735,O
the,5735,O
drug,5735,O
containing,5735,O
thin,5735,O
films,5735,O
was,5735,O
found,5735,O
to,5735,O
be,5735,O
strongly,5735,O
related,5735,O
to,5735,O
the,5735,O
intrinsic,5735,O
crystallization,5735,O
tendency,5735,O
of,5735,O
the,5735,O
drug,5735,O
film,5735,O
alone,5735,O
and,5735,O
the,5735,O
strength,5735,O
of,5735,O
drug-polymer,5735,O
interactions,5735,O
.,5735,O
Additionally,5736,O
",",5736,O
under,5736,O
high,5736,O
humidity,5736,O
",",5736,O
the,5736,O
glass,5736,O
transition,5736,O
temperature,5736,O
of,5736,O
the,5736,O
polymer,5736,O
is,5736,O
no,5736,O
longer,5736,O
an,5736,O
indicator,5736,O
of,5736,O
its,5736,O
drug,5736,O
stabilization,5736,O
capability,5736,O
.,5736,O
Instead,5737,O
",",5737,O
it,5737,O
is,5737,O
the,5737,O
hygroscobicity,5737,O
of,5737,O
the,5737,O
polymer,5737,O
that,5737,O
appears,5737,O
to,5737,O
be,5737,O
the,5737,O
most,5737,O
important,5737,O
parameter,5737,O
.,5737,O
Amongst,5738,O
the,5738,O
polymers,5738,O
tested,5738,O
in,5738,O
this,5738,O
study,5738,O
",",5738,O
EUDRAGIT,5738,B-CHEMICAL
E,5738,I-CHEMICAL
PO,5738,I-CHEMICAL
was,5738,O
found,5738,O
to,5738,O
have,5738,O
the,5738,O
greatest,5738,O
inhibitory,5738,O
effect,5738,O
on,5738,O
crystallization,5738,O
",",5738,O
whilst,5738,O
PVP,5738,B-CHEMICAL
K30,5738,I-CHEMICAL
was,5738,O
found,5738,O
to,5738,O
have,5738,O
the,5738,O
least,5738,O
protective,5738,O
effect,5738,O
;,5738,O
presumably,5738,O
because,5738,O
of,5738,O
its,5738,O
hygroscopic,5738,O
nature,5738,O
.,5738,O
Neuroprotective,5739,O
effects,5739,O
of,5739,O
mercaptoethylleonurine,5739,B-CHEMICAL
and,5739,O
mercaptoethylguanidine,5739,B-CHEMICAL
analogs,5739,O
on,5739,O
hydrogen,5739,B-CHEMICAL
peroxide-induced,5739,O
apoptosis,5739,O
in,5739,O
human,5739,O
neuronal,5739,O
SH-SY5Y,5739,O
cells,5739,O
.,5739,O
A,5740,O
series,5740,O
of,5740,O
mercaptoethylleonurine,5740,B-CHEMICAL
and,5740,O
mercaptoethylguanidine,5740,B-CHEMICAL
derivatives,5740,O
were,5740,O
designed,5740,O
and,5740,O
synthesized,5740,O
.,5740,O
Their,5741,O
neuroprotective,5741,O
effects,5741,O
toward,5741,O
H2O2-induced,5741,B-CHEMICAL
apoptosis,5741,O
were,5741,O
investigated,5741,O
in,5741,O
human,5741,O
SH-SY5Y,5741,O
cells,5741,O
.,5741,O
The,5742,O
results,5742,O
from,5742,O
these,5742,O
studies,5742,O
identified,5742,O
several,5742,O
potent,5742,O
compounds,5742,O
",",5742,O
with,5742,O
compound,5742,O
8k,5742,O
emerging,5742,O
as,5742,O
the,5742,O
most,5742,O
effective,5742,O
.,5742,O
Further,5743,O
investigation,5743,O
demonstrated,5743,O
that,5743,O
8k,5743,O
reduced,5743,O
H2O2-induced,5743,B-CHEMICAL
activation,5743,O
of,5743,O
mitochondrial,5743,O
apoptosis,5743,O
by,5743,O
inhibiting,5743,O
the,5743,O
expression,5743,O
of,5743,O
Bax,5743,B-GENE-N
and,5743,O
elevating,5743,O
the,5743,O
expression,5743,O
of,5743,O
Bcl-2,5743,B-GENE-N
.,5743,O
Moreover,5744,O
",",5744,O
the,5744,O
molecular,5744,O
mechanism,5744,O
underlying,5744,O
the,5744,O
observed,5744,O
neuroprotective,5744,O
effects,5744,O
of,5744,O
8k,5744,O
was,5744,O
exerted,5744,O
via,5744,O
the,5744,O
Akt,5744,B-GENE-N
and,5744,O
JNK,5744,B-GENE-N
pathways,5744,O
.,5744,O
Compound,5745,O
8k,5745,O
can,5745,O
be,5745,O
a,5745,O
lead,5745,O
compound,5745,O
for,5745,O
further,5745,O
discovery,5745,O
of,5745,O
neuroprotective,5745,O
medicine,5745,O
.,5745,O
Effects,5746,O
of,5746,O
induced,5746,O
hyperinsulinaemia,5746,O
with,5746,O
and,5746,O
without,5746,O
hyperglycaemia,5746,O
on,5746,O
measures,5746,O
of,5746,O
cardiac,5746,O
vagal,5746,O
control,5746,O
.,5746,O
AIMS/HYPOTHESIS,5747,O
:,5747,O
We,5747,O
examined,5747,O
the,5747,O
effects,5747,O
of,5747,O
serum,5747,B-GENE-Y
insulin,5747,I-GENE-Y
levels,5747,O
on,5747,O
vagal,5747,O
control,5747,O
over,5747,O
the,5747,O
heart,5747,O
and,5747,O
tested,5747,O
the,5747,O
hypothesis,5747,O
that,5747,O
higher,5747,O
fasting,5747,O
insulin,5747,B-GENE-Y
levels,5747,O
are,5747,O
associated,5747,O
with,5747,O
lower,5747,O
vagal,5747,O
control,5747,O
.,5747,O
We,5748,O
also,5748,O
examined,5748,O
whether,5748,O
experimentally,5748,O
induced,5748,O
increases,5748,O
in,5748,O
insulin,5748,B-GENE-Y
by,5748,O
beta,5748,O
cell,5748,O
secretagogues,5748,O
",",5748,O
including,5748,O
glucagon-like,5748,B-GENE-Y
peptide-1,5748,I-GENE-Y
(,5748,O
GLP-1,5748,B-GENE-Y
),5748,O
",",5748,O
will,5748,O
decrease,5748,O
vagal,5748,O
control,5748,O
.,5748,O
METHODS,5749,O
:,5749,O
Respiration,5749,O
and,5749,O
ECGs,5749,O
were,5749,O
recorded,5749,O
for,5749,O
130,5749,O
healthy,5749,O
participants,5749,O
undergoing,5749,O
clamps,5749,O
.,5749,O
Three,5750,O
variables,5750,O
of,5750,O
cardiac,5750,O
vagal,5750,O
effects,5750,O
(,5750,O
the,5750,O
root,5750,O
mean,5750,O
square,5750,O
of,5750,O
successive,5750,O
differences,5750,O
[,5750,O
rMSSD,5750,O
],5750,O
in,5750,O
the,5750,O
interbeat,5750,O
interval,5750,O
of,5750,O
the,5750,O
heart,5750,O
rate,5750,O
[,5750,O
IBI,5750,O
],5750,O
",",5750,O
heart-rate,5750,O
variability,5750,O
[,5750,O
HRV,5750,O
],5750,O
caused,5750,O
by,5750,O
peak-valley,5750,O
respiratory,5750,O
sinus,5750,O
arrhythmia,5750,O
[,5750,O
pvRSA,5750,O
],5750,O
",",5750,O
and,5750,O
high-frequency,5750,O
power,5750,O
[,5750,O
HF,5750,O
],5750,O
),5750,O
and,5750,O
heart,5750,O
rate,5750,O
(,5750,O
HR,5750,O
),5750,O
were,5750,O
obtained,5750,O
at,5750,O
seven,5750,O
time,5750,O
points,5750,O
during,5750,O
the,5750,O
clamps,5750,O
",",5750,O
characterised,5750,O
by,5750,O
increasing,5750,O
levels,5750,O
of,5750,O
insulin,5750,B-GENE-Y
(,5750,O
achieved,5750,O
by,5750,O
administering,5750,O
insulin,5750,B-GENE-Y
plus,5750,O
glucose,5750,B-CHEMICAL
",",5750,O
glucose,5750,B-CHEMICAL
only,5750,O
",",5750,O
glucose,5750,B-CHEMICAL
and,5750,O
GLP-1,5750,B-GENE-Y
",",5750,O
and,5750,O
glucose,5750,B-CHEMICAL
and,5750,O
GLP-1,5750,B-GENE-Y
combined,5750,O
with,5750,O
arginine,5750,B-CHEMICAL
),5750,O
.,5750,O
RESULTS,5751,O
:,5751,O
Serum,5751,B-GENE-Y
insulin,5751,I-GENE-Y
level,5751,O
was,5751,O
positively,5751,O
associated,5751,O
with,5751,O
HR,5751,O
at,5751,O
all,5751,O
time,5751,O
points,5751,O
during,5751,O
the,5751,O
clamps,5751,O
except,5751,O
the,5751,O
first-phase,5751,O
hyperglycaemic,5751,O
clamp,5751,O
.,5751,O
Insulin,5752,B-GENE-Y
levels,5752,O
were,5752,O
negatively,5752,O
correlated,5752,O
with,5752,O
variables,5752,O
of,5752,O
vagal,5752,O
control,5752,O
",",5752,O
reaching,5752,O
significance,5752,O
for,5752,O
rMSSD,5752,O
and,5752,O
log,5752,O
(,5752,O
10,5752,O
),5752,O
HF,5752,O
",",5752,O
but,5752,O
not,5752,O
for,5752,O
pvRSA,5752,O
",",5752,O
during,5752,O
the,5752,O
last,5752,O
four,5752,O
phases,5752,O
of,5752,O
the,5752,O
hyperglycaemic,5752,O
clamp,5752,O
(,5752,O
hyperglycaemic,5752,O
second,5752,O
phase,5752,O
",",5752,O
GLP-1,5752,B-GENE-Y
first,5752,O
and,5752,O
second,5752,O
phases,5752,O
",",5752,O
and,5752,O
arginine,5752,B-CHEMICAL
),5752,O
.,5752,O
These,5753,O
associations,5753,O
disappeared,5753,O
when,5753,O
adjusted,5753,O
for,5753,O
age,5753,O
",",5753,O
BMI,5753,O
and,5753,O
insulin,5753,B-GENE-Y
sensitivity,5753,O
.,5753,O
Administration,5754,O
of,5754,O
the,5754,O
beta,5754,O
cell,5754,O
secretagogues,5754,O
GLP-1,5754,B-GENE-Y
and,5754,O
arginine,5754,B-CHEMICAL
led,5754,O
to,5754,O
a,5754,O
significant,5754,O
increase,5754,O
in,5754,O
HR,5754,O
",",5754,O
but,5754,O
this,5754,O
was,5754,O
not,5754,O
paired,5754,O
with,5754,O
a,5754,O
significant,5754,O
reduction,5754,O
in,5754,O
HRV,5754,O
measures,5754,O
.,5754,O
CONCLUSION/INTERPRETATION,5755,O
:,5755,O
Experimentally,5755,O
induced,5755,O
hyperinsulinaemia,5755,O
is,5755,O
not,5755,O
correlated,5755,O
with,5755,O
cardiac,5755,O
vagal,5755,O
control,5755,O
or,5755,O
HR,5755,O
when,5755,O
adjusting,5755,O
for,5755,O
age,5755,O
",",5755,O
BMI,5755,O
and,5755,O
insulin,5755,B-GENE-Y
sensitivity,5755,O
index,5755,O
.,5755,O
Our,5756,O
findings,5756,O
suggest,5756,O
that,5756,O
exposure,5756,O
to,5756,O
a,5756,O
GLP-1,5756,B-GENE-Y
during,5756,O
hyperglycaemia,5756,O
leads,5756,O
to,5756,O
a,5756,O
small,5756,O
acute,5756,O
increase,5756,O
in,5756,O
HR,5756,O
but,5756,O
not,5756,O
to,5756,O
an,5756,O
acute,5756,O
decrease,5756,O
in,5756,O
cardiac,5756,O
vagal,5756,O
control,5756,O
.,5756,O
The,5757,O
propeptides,5757,O
of,5757,O
VEGF-D,5757,B-GENE-Y
determine,5757,O
heparin,5757,O
binding,5757,O
",",5757,O
receptor,5757,O
heterodimerization,5757,O
",",5757,O
and,5757,O
effects,5757,O
on,5757,O
tumor,5757,O
biology,5757,O
.,5757,O
VEGF-D,5758,B-GENE-Y
is,5758,O
an,5758,O
angiogenic,5758,O
and,5758,O
lymphangiogenic,5758,O
glycoprotein,5758,O
that,5758,O
can,5758,O
be,5758,O
proteolytically,5758,O
processed,5758,O
generating,5758,O
various,5758,O
forms,5758,O
differing,5758,O
in,5758,O
subunit,5758,O
composition,5758,O
due,5758,O
to,5758,O
the,5758,O
presence,5758,O
or,5758,O
absence,5758,O
of,5758,O
N-,5758,B-CHEMICAL
and,5758,O
C-terminal,5758,B-CHEMICAL
propeptides,5758,O
.,5758,O
These,5759,O
propeptides,5759,O
flank,5759,O
the,5759,O
central,5759,O
VEGF,5759,B-GENE-N
homology,5759,I-GENE-N
domain,5759,I-GENE-N
",",5759,O
that,5759,O
contains,5759,O
the,5759,O
binding,5759,O
sites,5759,O
for,5759,O
VEGF,5759,B-GENE-N
receptors,5759,I-GENE-N
(,5759,O
VEGFRs,5759,B-GENE-N
),5759,O
",",5759,O
but,5759,O
their,5759,O
biological,5759,O
functions,5759,O
were,5759,O
unclear,5759,O
.,5759,O
Characterization,5760,O
of,5760,O
propeptide,5760,O
function,5760,O
will,5760,O
be,5760,O
important,5760,O
to,5760,O
clarify,5760,O
which,5760,O
forms,5760,O
of,5760,O
VEGF-D,5760,B-GENE-Y
are,5760,O
biologically,5760,O
active,5760,O
and,5760,O
therefore,5760,O
clinically,5760,O
relevant,5760,O
.,5760,O
Here,5761,O
we,5761,O
use,5761,O
VEGF-D,5761,B-GENE-Y
mutants,5761,O
deficient,5761,O
in,5761,O
either,5761,O
propeptide,5761,O
",",5761,O
and,5761,O
in,5761,O
the,5761,O
capacity,5761,O
to,5761,O
process,5761,O
the,5761,O
remaining,5761,O
propeptide,5761,O
",",5761,O
to,5761,O
monitor,5761,O
the,5761,O
functions,5761,O
of,5761,O
these,5761,O
domains,5761,O
.,5761,O
We,5762,O
report,5762,O
for,5762,O
the,5762,O
first,5762,O
time,5762,O
that,5762,O
VEGF-D,5762,B-GENE-Y
binds,5762,O
heparin,5762,O
",",5762,O
and,5762,O
that,5762,O
the,5762,O
C-terminal,5762,B-CHEMICAL
propeptide,5762,O
significantly,5762,O
enhances,5762,O
this,5762,O
interaction,5762,O
(,5762,O
removal,5762,O
of,5762,O
this,5762,O
propeptide,5762,O
from,5762,O
full-length,5762,O
VEGF-D,5762,B-GENE-Y
completely,5762,O
prevents,5762,O
heparin,5762,O
binding,5762,O
),5762,O
.,5762,O
We,5763,O
also,5763,O
show,5763,O
that,5763,O
removal,5763,O
of,5763,O
either,5763,O
the,5763,O
N-,5763,B-CHEMICAL
or,5763,O
C-terminal,5763,B-CHEMICAL
propeptide,5763,O
is,5763,O
required,5763,O
for,5763,O
VEGF-D,5763,B-GENE-Y
to,5763,O
drive,5763,O
formation,5763,O
of,5763,O
VEGFR-2/VEGFR-3,5763,B-GENE-Y
heterodimers,5763,O
which,5763,O
have,5763,O
recently,5763,O
been,5763,O
shown,5763,O
to,5763,O
positively,5763,O
regulate,5763,O
angiogenic,5763,O
sprouting,5763,O
.,5763,O
The,5764,O
mature,5764,O
form,5764,O
of,5764,O
VEGF-D,5764,B-GENE-Y
",",5764,O
lacking,5764,O
both,5764,O
propeptides,5764,O
",",5764,O
can,5764,O
also,5764,O
promote,5764,O
formation,5764,O
of,5764,O
these,5764,O
receptor,5764,O
heterodimers,5764,O
.,5764,O
In,5765,O
a,5765,O
mouse,5765,O
tumor,5765,O
model,5765,O
",",5765,O
removal,5765,O
of,5765,O
only,5765,O
the,5765,O
C-terminal,5765,B-CHEMICAL
propeptide,5765,O
from,5765,O
full-length,5765,O
VEGF-D,5765,B-GENE-Y
was,5765,O
sufficient,5765,O
to,5765,O
enhance,5765,O
angiogenesis,5765,O
and,5765,O
tumor,5765,O
growth,5765,O
.,5765,O
In,5766,O
contrast,5766,O
",",5766,O
removal,5766,O
of,5766,O
both,5766,O
propeptides,5766,O
is,5766,O
required,5766,O
for,5766,O
high,5766,O
rates,5766,O
of,5766,O
lymph,5766,O
node,5766,O
metastasis,5766,O
.,5766,O
The,5767,O
findings,5767,O
reported,5767,O
here,5767,O
show,5767,O
that,5767,O
the,5767,O
propeptides,5767,O
profoundly,5767,O
influence,5767,O
molecular,5767,O
interactions,5767,O
of,5767,O
VEGF-D,5767,B-GENE-Y
with,5767,O
VEGF,5767,B-GENE-N
receptors,5767,I-GENE-N
",",5767,O
co-receptors,5767,O
",",5767,O
and,5767,O
heparin,5767,O
",",5767,O
and,5767,O
its,5767,O
effects,5767,O
on,5767,O
tumor,5767,O
biology,5767,O
.,5767,O
Switchable,5768,O
Elastin-Like,5768,B-GENE-N
Polypeptides,5768,I-GENE-N
that,5768,O
Respond,5768,O
to,5768,O
Chemical,5768,O
Inducers,5768,O
of,5768,O
Dimerization,5768,O
.,5768,O
Elastin-like,5769,B-GENE-N
polypeptides,5769,I-GENE-N
(,5769,O
ELPs,5769,B-GENE-N
),5769,O
are,5769,O
protein,5769,O
polymers,5769,O
that,5769,O
reversibly,5769,O
phase,5769,O
separate,5769,O
in,5769,O
response,5769,O
to,5769,O
increased,5769,O
temperature,5769,O
",",5769,O
pressure,5769,O
",",5769,O
concentration,5769,O
",",5769,O
ionic,5769,O
strength,5769,O
",",5769,O
and,5769,O
molecular,5769,O
weight,5769,O
.,5769,O
If,5770,O
it,5770,O
were,5770,O
possible,5770,O
to,5770,O
engineer,5770,O
their,5770,O
phase,5770,O
separation,5770,O
to,5770,O
respond,5770,O
to,5770,O
specific,5770,O
molecular,5770,O
substrates,5770,O
",",5770,O
ELP,5770,B-GENE-N
fusion,5770,O
proteins,5770,O
might,5770,O
be,5770,O
engineered,5770,O
as,5770,O
biosensors,5770,O
",",5770,O
smart,5770,O
biomaterials,5770,O
",",5770,O
diagnostic,5770,O
imaging,5770,O
agents,5770,O
",",5770,O
and,5770,O
targeted,5770,O
therapies,5770,O
.,5770,O
What,5771,O
has,5771,O
been,5771,O
lacking,5771,O
is,5771,O
a,5771,O
strategy,5771,O
to,5771,O
design,5771,O
ELPs,5771,B-GENE-N
to,5771,O
respond,5771,O
to,5771,O
specific,5771,O
substrates,5771,O
.,5771,O
To,5772,O
address,5772,O
this,5772,O
deficiency,5772,O
",",5772,O
we,5772,O
report,5772,O
that,5772,O
ELP,5772,B-GENE-N
fusion,5772,O
proteins,5772,O
phase,5772,O
separate,5772,O
in,5772,O
response,5772,O
to,5772,O
chemical,5772,O
inducers,5772,O
of,5772,O
dimerization,5772,O
(,5772,O
CID,5772,O
),5772,O
.,5772,O
The,5773,O
rationale,5773,O
is,5773,O
that,5773,O
ELP,5773,B-GENE-N
phase,5773,O
separation,5773,O
depends,5773,O
on,5773,O
molecular,5773,O
weight,5773,O
",",5773,O
concentration,5773,O
",",5773,O
and,5773,O
local,5773,O
hydrophobicity,5773,O
;,5773,O
therefore,5773,O
",",5773,O
processes,5773,O
that,5773,O
affect,5773,O
these,5773,O
properties,5773,O
",",5773,O
including,5773,O
noncovalent,5773,O
dimerization,5773,O
",",5773,O
can,5773,O
be,5773,O
tuned,5773,O
to,5773,O
produce,5773,O
isothermal,5773,O
phase,5773,O
separation,5773,O
.,5773,O
To,5774,O
test,5774,O
this,5774,O
hypothesis,5774,O
",",5774,O
constructs,5774,O
were,5774,O
evaluated,5774,O
consisting,5774,O
of,5774,O
an,5774,O
immunophilin,5774,B-GENE-N
:,5774,O
human,5774,B-GENE-Y
FK-506,5774,B-CHEMICAL
binding,5774,I-GENE-Y
protein,5774,I-GENE-Y
12,5774,I-GENE-Y
(,5774,O
FKBP,5774,B-GENE-Y
),5774,O
attached,5774,O
to,5774,O
an,5774,O
ELP,5774,B-GENE-N
.,5774,O
Under,5775,O
stoichiometric,5775,O
binding,5775,O
of,5775,O
a,5775,O
CID,5775,O
",",5775,O
the,5775,O
fusion,5775,O
protein,5775,O
homodimerizes,5775,O
and,5775,O
triggers,5775,O
phase,5775,O
separation,5775,O
.,5775,O
This,5776,O
dimerization,5776,O
is,5776,O
reversible,5776,O
upon,5776,O
saturation,5776,O
with,5776,O
excess,5776,O
CID,5776,O
or,5776,O
competitive,5776,O
binding,5776,O
of,5776,O
a,5776,O
small,5776,O
lipophilic,5776,O
macrolide,5776,O
to,5776,O
FKBP,5776,O
.,5776,O
By,5777,O
modulating,5777,O
the,5777,O
ELP,5777,B-GENE-N
molecular,5777,O
weight,5777,O
",",5777,O
phase,5777,O
separation,5777,O
was,5777,O
tuned,5777,O
for,5777,O
isothermal,5777,O
response,5777,O
to,5777,O
CID,5777,O
at,5777,O
physiological,5777,O
ionic,5777,O
strength,5777,O
and,5777,O
temperature,5777,O
(,5777,O
37,5777,O
°C,5777,O
),5777,O
.,5777,O
To,5778,O
interpret,5778,O
the,5778,O
relationship,5778,O
between,5778,O
transition,5778,O
temperature,5778,O
and,5778,O
equilibrium,5778,O
binding,5778,O
constants,5778,O
",",5778,O
an,5778,O
empirical,5778,O
mathematical,5778,O
model,5778,O
was,5778,O
employed,5778,O
.,5778,O
To,5779,O
the,5779,O
best,5779,O
of,5779,O
our,5779,O
knowledge,5779,O
",",5779,O
this,5779,O
report,5779,O
is,5779,O
the,5779,O
first,5779,O
demonstration,5779,O
of,5779,O
reversible,5779,O
ELP,5779,B-GENE-N
switching,5779,O
in,5779,O
response,5779,O
to,5779,O
controlled,5779,O
dimerization,5779,O
.,5779,O
Due,5780,O
to,5780,O
its,5780,O
simplicity,5780,O
",",5780,O
this,5780,O
strategy,5780,O
may,5780,O
be,5780,O
useful,5780,O
to,5780,O
design,5780,O
ELP,5780,B-GENE-N
fusion,5780,O
proteins,5780,O
that,5780,O
respond,5780,O
to,5780,O
specific,5780,O
dimeric,5780,O
biological,5780,O
entities,5780,O
.,5780,O
Protective,5781,O
role,5781,O
of,5781,O
L-carnitine,5781,B-CHEMICAL
and,5781,O
vitamin,5781,B-CHEMICAL
E,5781,I-CHEMICAL
on,5781,O
the,5781,O
testis,5781,O
of,5781,O
atherosclerotic,5781,O
rats,5781,O
.,5781,O
Atherosclerosis,5782,O
is,5782,O
a,5782,O
condition,5782,O
caused,5782,O
by,5782,O
lipid,5782,O
build-up,5782,O
and,5782,O
inflammation,5782,O
in,5782,O
the,5782,O
arteries,5782,O
",",5782,O
so,5782,O
hyperlipidemia,5782,O
is,5782,O
the,5782,O
major,5782,O
reason,5782,O
for,5782,O
atherosclerosis,5782,O
.,5782,O
Testis,5783,O
was,5783,O
found,5783,O
to,5783,O
be,5783,O
negatively,5783,O
affected,5783,O
by,5783,O
hyperlipidemia,5783,O
which,5783,O
leads,5783,O
to,5783,O
its,5783,O
impaired,5783,O
functions,5783,O
.,5783,O
Vitamin,5784,B-CHEMICAL
E,5784,I-CHEMICAL
and,5784,O
<,5784,B-CHEMICAL
sc,5784,I-CHEMICAL
>,5784,I-CHEMICAL
l,5784,I-CHEMICAL
<,5784,I-CHEMICAL
/sc,5784,I-CHEMICAL
>,5784,I-CHEMICAL
-carnitine,5784,I-CHEMICAL
have,5784,O
well-known,5784,O
lipid-lowering,5784,O
and,5784,O
antioxidative,5784,O
activities,5784,O
.,5784,O
Triton,5785,B-CHEMICAL
WR,5785,I-CHEMICAL
1339,5785,I-CHEMICAL
is,5785,O
a,5785,O
non-ionic,5785,O
detergent,5785,O
",",5785,O
which,5785,O
induces,5785,O
severe,5785,O
hyperlipidemia,5785,O
by,5785,O
inhibition,5785,O
of,5785,O
lipoprotein,5785,O
lipase,5785,O
.,5785,O
The,5786,O
present,5786,O
study,5786,O
evaluates,5786,O
the,5786,O
protective,5786,O
role,5786,O
of,5786,O
vitamin,5786,B-CHEMICAL
E,5786,I-CHEMICAL
and,5786,O
<,5786,B-CHEMICAL
sc,5786,I-CHEMICAL
>,5786,I-CHEMICAL
l,5786,I-CHEMICAL
<,5786,I-CHEMICAL
/sc,5786,I-CHEMICAL
>,5786,I-CHEMICAL
-carnitine,5786,I-CHEMICAL
on,5786,O
the,5786,O
testis,5786,O
in,5786,O
atherosclerosis,5786,O
and,5786,O
detects,5786,O
the,5786,O
most,5786,O
effective,5786,O
choice,5786,O
for,5786,O
protection,5786,O
against,5786,O
atherosclerosis,5786,O
;,5786,O
vitamin,5786,B-CHEMICAL
E,5786,I-CHEMICAL
",",5786,O
<,5786,B-CHEMICAL
sc,5786,I-CHEMICAL
>,5786,I-CHEMICAL
l,5786,I-CHEMICAL
<,5786,I-CHEMICAL
/sc,5786,I-CHEMICAL
>,5786,I-CHEMICAL
-carnitine,5786,I-CHEMICAL
or,5786,O
a,5786,O
combination,5786,O
of,5786,O
both,5786,O
.,5786,O
A,5787,O
total,5787,O
of,5787,O
80,5787,O
albino,5787,O
male,5787,O
rats,5787,O
were,5787,O
divided,5787,O
into,5787,O
eight,5787,O
groups,5787,O
(,5787,O
10,5787,O
rats,5787,O
for,5787,O
each,5787,O
group,5787,O
),5787,O
:,5787,O
control,5787,O
(,5787,O
G,5787,O
(,5787,O
1,5787,O
),5787,O
),5787,O
",",5787,O
triton,5787,B-CHEMICAL
(,5787,O
G,5787,O
(,5787,O
2,5787,O
),5787,O
),5787,O
",",5787,O
<,5787,B-CHEMICAL
sc,5787,I-CHEMICAL
>,5787,I-CHEMICAL
l,5787,I-CHEMICAL
<,5787,I-CHEMICAL
/sc,5787,I-CHEMICAL
>,5787,I-CHEMICAL
-carnitine,5787,I-CHEMICAL
(,5787,O
G,5787,O
(,5787,O
3,5787,O
),5787,O
),5787,O
",",5787,O
triton,5787,B-CHEMICAL
+,5787,O
<,5787,B-CHEMICAL
sc,5787,I-CHEMICAL
>,5787,I-CHEMICAL
l,5787,I-CHEMICAL
<,5787,I-CHEMICAL
/sc,5787,I-CHEMICAL
>,5787,I-CHEMICAL
-carnitine,5787,I-CHEMICAL
(,5787,O
G,5787,O
(,5787,O
4,5787,O
),5787,O
),5787,O
",",5787,O
vitamin,5787,B-CHEMICAL
E,5787,I-CHEMICAL
(,5787,O
G,5787,O
(,5787,O
5,5787,O
),5787,O
),5787,O
",",5787,O
triton,5787,B-CHEMICAL
+,5787,O
vitamin,5787,B-CHEMICAL
E,5787,I-CHEMICAL
(,5787,O
G,5787,O
(,5787,O
6,5787,O
),5787,O
),5787,O
",",5787,O
<,5787,B-CHEMICAL
sc,5787,I-CHEMICAL
>,5787,I-CHEMICAL
l,5787,I-CHEMICAL
<,5787,I-CHEMICAL
/sc,5787,I-CHEMICAL
>,5787,I-CHEMICAL
-carnitine,5787,I-CHEMICAL
+,5787,O
vitamin,5787,B-CHEMICAL
E,5787,I-CHEMICAL
(,5787,O
G,5787,O
(,5787,O
7,5787,O
),5787,O
),5787,O
and,5787,O
triton,5787,B-CHEMICAL
+,5787,O
<,5787,B-CHEMICAL
sc,5787,I-CHEMICAL
>,5787,I-CHEMICAL
l,5787,I-CHEMICAL
<,5787,I-CHEMICAL
/sc,5787,I-CHEMICAL
>,5787,I-CHEMICAL
-carnitine,5787,I-CHEMICAL
+,5787,O
vitamin,5787,B-CHEMICAL
E,5787,I-CHEMICAL
(,5787,O
G,5787,O
(,5787,O
8,5787,O
),5787,O
),5787,O
.,5787,O
Data,5788,O
showed,5788,O
a,5788,O
significant,5788,O
increase,5788,O
in,5788,O
the,5788,O
levels,5788,O
of,5788,O
total,5788,O
cholesterol,5788,B-CHEMICAL
(,5788,O
TC,5788,O
),5788,O
",",5788,O
triglycerides,5788,B-CHEMICAL
(,5788,O
TGs,5788,O
),5788,O
",",5788,O
low-density,5788,O
lipoprotein,5788,O
cholesterol,5788,B-CHEMICAL
(,5788,O
LDL-C,5788,O
),5788,O
",",5788,O
17,5788,B-CHEMICAL
beta,5788,I-CHEMICAL
hydroxysteroid,5788,I-CHEMICAL
dehydrogenase,5788,O
(,5788,O
17,5788,O
β,5788,O
HSD,5788,O
),5788,O
",",5788,O
testicular,5788,O
catalase,5788,O
and,5788,O
malondialdehyde,5788,B-CHEMICAL
(,5788,O
MDA,5788,B-CHEMICAL
),5788,O
in,5788,O
G,5788,O
(,5788,O
2,5788,O
),5788,O
when,5788,O
compared,5788,O
with,5788,O
G,5788,O
(,5788,O
1,5788,O
),5788,O
",",5788,O
whereas,5788,O
high-density,5788,O
lipoprotein,5788,O
cholesterol,5788,B-CHEMICAL
(,5788,O
HDL-C,5788,O
),5788,O
",",5788,O
serum,5788,O
testosterone,5788,B-CHEMICAL
",",5788,O
testicular,5788,O
17,5788,O
ketosteroid,5788,B-CHEMICAL
reductase,5788,O
(,5788,O
17,5788,O
KSR,5788,O
),5788,O
",",5788,O
total,5788,O
thiol,5788,B-CHEMICAL
and,5788,O
glutathione-S-transferase,5788,B-CHEMICAL
(,5788,O
GST,5788,O
),5788,O
data,5788,O
showed,5788,O
a,5788,O
significant,5788,O
decrease,5788,O
in,5788,O
G,5788,O
(,5788,O
2,5788,O
),5788,O
when,5788,O
compared,5788,O
with,5788,O
G,5788,O
(,5788,O
1,5788,O
),5788,O
.,5788,O
Treatment,5789,O
with,5789,O
<,5789,B-CHEMICAL
sc,5789,I-CHEMICAL
>,5789,I-CHEMICAL
l,5789,I-CHEMICAL
<,5789,I-CHEMICAL
/sc,5789,I-CHEMICAL
>,5789,I-CHEMICAL
-carnitine,5789,I-CHEMICAL
or/and,5789,O
vitamin,5789,B-CHEMICAL
E,5789,I-CHEMICAL
helps,5789,O
in,5789,O
improving,5789,O
the,5789,O
adverse,5789,O
effect,5789,O
of,5789,O
triton,5789,B-CHEMICAL
;,5789,O
also,5789,O
the,5789,O
histological,5789,O
changes,5789,O
confirm,5789,O
this,5789,O
finding,5789,O
.,5789,O
So,5790,O
the,5790,O
present,5790,O
study,5790,O
recommends,5790,O
all,5790,O
people,5790,O
to,5790,O
include,5790,O
<,5790,B-CHEMICAL
sc,5790,I-CHEMICAL
>,5790,I-CHEMICAL
l,5790,I-CHEMICAL
<,5790,I-CHEMICAL
/sc,5790,I-CHEMICAL
>,5790,I-CHEMICAL
-carnitine,5790,I-CHEMICAL
and,5790,O
vitamin,5790,B-CHEMICAL
E,5790,I-CHEMICAL
in,5790,O
their,5790,O
diet,5790,O
to,5790,O
be,5790,O
protected,5790,O
against,5790,O
atherosclerosis,5790,O
.,5790,O
The,5791,O
CRF,5791,B-GENE-Y
(,5791,I-GENE-Y
1,5791,I-GENE-Y
),5791,I-GENE-Y
receptor,5791,I-GENE-Y
antagonist,5791,O
SSR125543,5791,B-CHEMICAL
prevents,5791,O
stress-induced,5791,O
cognitive,5791,O
deficit,5791,O
associated,5791,O
with,5791,O
hippocampal,5791,O
dysfunction,5791,O
:,5791,O
Comparison,5791,O
with,5791,O
paroxetine,5791,B-CHEMICAL
and,5791,O
D-cycloserine,5791,B-CHEMICAL
.,5791,O
RATIONALE,5792,O
:,5792,O
The,5792,O
selective,5792,O
CRF,5792,B-GENE-Y
(,5792,I-GENE-Y
1,5792,I-GENE-Y
),5792,I-GENE-Y
(,5792,I-GENE-Y
corticotropin,5792,I-GENE-Y
releasing,5792,I-GENE-Y
factor,5792,I-GENE-Y
type,5792,I-GENE-Y
1,5792,I-GENE-Y
),5792,I-GENE-Y
receptor,5792,I-GENE-Y
antagonist,5792,O
SSR125543,5792,B-CHEMICAL
has,5792,O
been,5792,O
previously,5792,O
shown,5792,O
to,5792,O
attenuate,5792,O
the,5792,O
long-term,5792,O
cognitive,5792,O
deficit,5792,O
produced,5792,O
by,5792,O
traumatic,5792,O
stress,5792,O
exposure,5792,O
.,5792,O
Memory,5793,O
disturbances,5793,O
described,5793,O
in,5793,O
post-traumatic,5793,O
stress,5793,O
disorder,5793,O
(,5793,O
PTSD,5793,O
),5793,O
patients,5793,O
are,5793,O
believed,5793,O
to,5793,O
be,5793,O
associated,5793,O
with,5793,O
changes,5793,O
in,5793,O
neuronal,5793,O
activity,5793,O
",",5793,O
in,5793,O
particular,5793,O
at,5793,O
the,5793,O
level,5793,O
of,5793,O
the,5793,O
hippocampus,5793,O
.,5793,O
OBJECTIVES,5794,O
:,5794,O
The,5794,O
present,5794,O
study,5794,O
aims,5794,O
at,5794,O
investigating,5794,O
whether,5794,O
the,5794,O
effects,5794,O
of,5794,O
SSR125543,5794,B-CHEMICAL
(,5794,O
10,5794,O
mg/kg/day,5794,O
for,5794,O
2,5794,O
weeks,5794,O
),5794,O
on,5794,O
cognitive,5794,O
impairment,5794,O
induced,5794,O
by,5794,O
traumatic,5794,O
stress,5794,O
exposure,5794,O
are,5794,O
associated,5794,O
with,5794,O
changes,5794,O
in,5794,O
hippocampal,5794,O
excitability,5794,O
.,5794,O
Effects,5795,O
of,5795,O
SSR125543,5795,B-CHEMICAL
were,5795,O
compared,5795,O
to,5795,O
those,5795,O
of,5795,O
the,5795,O
5-HT,5795,B-CHEMICAL
reuptake,5795,O
inhibitor,5795,O
",",5795,O
paroxetine,5795,B-CHEMICAL
(,5795,O
10,5795,O
mg/kg/day,5795,O
),5795,O
",",5795,O
and,5795,O
the,5795,O
partial,5795,O
N-methyl-D-aspartate,5795,B-CHEMICAL
(,5795,I-GENE-N
NMDA,5795,I-GENE-N
),5795,I-GENE-N
receptor,5795,I-GENE-N
agonist,5795,O
",",5795,O
D-cycloserine,5795,B-CHEMICAL
(,5795,O
10,5795,O
mg/kg/day,5795,O
),5795,O
",",5795,O
two,5795,O
compounds,5795,O
which,5795,O
have,5795,O
demonstrated,5795,O
clinical,5795,O
efficacy,5795,O
against,5795,O
PTSD,5795,O
.,5795,O
METHODS,5796,O
:,5796,O
Mice,5796,O
received,5796,O
two,5796,O
unavoidable,5796,O
electric,5796,O
foot-shocks,5796,O
.,5796,O
Then,5797,O
",",5797,O
1,5797,O
or,5797,O
16,5797,O
days,5797,O
after,5797,O
stress,5797,O
",",5797,O
they,5797,O
were,5797,O
tested,5797,O
for,5797,O
their,5797,O
memory,5797,O
performance,5797,O
using,5797,O
the,5797,O
object,5797,O
recognition,5797,O
test,5797,O
.,5797,O
Neuronal,5798,O
excitability,5798,O
was,5798,O
recorded,5798,O
during,5798,O
the,5798,O
third,5798,O
week,5798,O
post-stress,5798,O
in,5798,O
the,5798,O
CA1,5798,O
area,5798,O
of,5798,O
the,5798,O
hippocampus,5798,O
.,5798,O
Drugs,5799,O
were,5799,O
administered,5799,O
from,5799,O
day,5799,O
1,5799,O
post-stress,5799,O
to,5799,O
the,5799,O
day,5799,O
preceding,5799,O
the,5799,O
electrophysiological,5799,O
study,5799,O
.,5799,O
RESULTS,5800,O
:,5800,O
Application,5800,O
of,5800,O
electric,5800,O
shocks,5800,O
produced,5800,O
cognitive,5800,O
impairment,5800,O
16,5800,O
",",5800,O
but,5800,O
not,5800,O
1,5800,O
day,5800,O
after,5800,O
stress,5800,O
",",5800,O
an,5800,O
effect,5800,O
which,5800,O
was,5800,O
associated,5800,O
with,5800,O
a,5800,O
decrease,5800,O
in,5800,O
hippocampal,5800,O
neuronal,5800,O
excitability,5800,O
.,5800,O
Both,5801,O
stress-induced,5801,O
effects,5801,O
were,5801,O
prevented,5801,O
by,5801,O
repeated,5801,O
administration,5801,O
of,5801,O
SSR125543,5801,B-CHEMICAL
",",5801,O
paroxetine,5801,B-CHEMICAL
and,5801,O
D-cycloserine,5801,B-CHEMICAL
.,5801,O
CONCLUSIONS,5802,O
:,5802,O
These,5802,O
findings,5802,O
confirm,5802,O
that,5802,O
the,5802,O
CRF,5802,B-GENE-Y
(,5802,I-GENE-Y
1,5802,I-GENE-Y
),5802,I-GENE-Y
receptor,5802,I-GENE-Y
antagonist,5802,O
SSR125543,5802,B-CHEMICAL
is,5802,O
able,5802,O
to,5802,O
attenuate,5802,O
the,5802,O
behavioral,5802,O
effects,5802,O
of,5802,O
traumatic,5802,O
stress,5802,O
exposure,5802,O
and,5802,O
indicate,5802,O
that,5802,O
these,5802,O
effects,5802,O
are,5802,O
associated,5802,O
with,5802,O
a,5802,O
normalization,5802,O
of,5802,O
hippocampal,5802,O
neuronal,5802,O
excitability,5802,O
impaired,5802,O
by,5802,O
stress,5802,O
.,5802,O
Synthesis,5803,O
and,5803,O
structure-activity,5803,O
relationships,5803,O
of,5803,O
indazole,5803,B-CHEMICAL
arylsulfonamides,5803,I-CHEMICAL
as,5803,O
allosteric,5803,O
CC-chemokine,5803,B-GENE-Y
receptor,5803,I-GENE-Y
4,5803,I-GENE-Y
(,5803,O
CCR4,5803,B-GENE-Y
),5803,O
antagonists,5803,O
.,5803,O
A,5804,O
series,5804,O
of,5804,O
indazole,5804,B-CHEMICAL
arylsulfonamides,5804,I-CHEMICAL
were,5804,O
synthesized,5804,O
and,5804,O
examined,5804,O
as,5804,O
human,5804,B-GENE-Y
CCR4,5804,I-GENE-Y
antagonists,5804,O
.,5804,O
Methoxy-,5805,B-CHEMICAL
or,5805,O
hydroxyl-containing,5805,B-CHEMICAL
groups,5805,O
were,5805,O
the,5805,O
more,5805,O
potent,5805,O
indazole,5805,B-CHEMICAL
C4,5805,O
substituents,5805,O
.,5805,O
Only,5806,O
small,5806,O
groups,5806,O
were,5806,O
tolerated,5806,O
at,5806,O
C5,5806,O
",",5806,O
C6,5806,O
",",5806,O
or,5806,O
C7,5806,O
",",5806,O
with,5806,O
the,5806,O
C6,5806,O
analogues,5806,O
being,5806,O
preferred,5806,O
.,5806,O
The,5807,O
most,5807,O
potent,5807,O
N3-substituent,5807,O
was,5807,O
5-chlorothiophene-2-sulfonamide,5807,B-CHEMICAL
.,5807,O
N1,5808,O
meta-substituted,5808,O
benzyl,5808,B-CHEMICAL
groups,5808,O
possessing,5808,O
an,5808,O
α-amino-3-,5808,O
[,5808,I-CHEMICAL
(,5808,I-CHEMICAL
methylamino,5808,I-CHEMICAL
),5808,I-CHEMICAL
acyl,5808,I-CHEMICAL
],5808,I-CHEMICAL
-group,5808,O
were,5808,O
the,5808,O
most,5808,O
potent,5808,O
N1-substituents,5808,O
.,5808,O
Strongly,5809,O
basic,5809,O
amino,5809,B-CHEMICAL
groups,5809,O
had,5809,O
low,5809,O
oral,5809,O
absorption,5809,O
in,5809,O
vivo,5809,O
.,5809,O
Less,5810,O
basic,5810,O
analogues,5810,O
",",5810,O
such,5810,O
as,5810,O
morpholines,5810,B-CHEMICAL
",",5810,O
had,5810,O
good,5810,O
oral,5810,O
absorption,5810,O
;,5810,O
however,5810,O
",",5810,O
they,5810,O
also,5810,O
had,5810,O
high,5810,O
clearance,5810,O
.,5810,O
The,5811,O
most,5811,O
potent,5811,O
compound,5811,O
with,5811,O
high,5811,O
absorption,5811,O
in,5811,O
two,5811,O
species,5811,O
was,5811,O
analogue,5811,O
6,5811,O
(,5811,O
GSK2239633A,5811,B-CHEMICAL
),5811,O
",",5811,O
which,5811,O
was,5811,O
selected,5811,O
for,5811,O
further,5811,O
development,5811,O
.,5811,O
Aryl,5812,B-CHEMICAL
sulfonamide,5812,I-CHEMICAL
antagonists,5812,O
bind,5812,O
to,5812,O
CCR4,5812,B-GENE-Y
at,5812,O
an,5812,O
intracellular,5812,O
allosteric,5812,O
site,5812,O
denoted,5812,O
site,5812,O
II,5812,O
.,5812,O
X-ray,5813,O
diffraction,5813,O
studies,5813,O
on,5813,O
two,5813,O
indazole,5813,B-CHEMICAL
sulfonamide,5813,I-CHEMICAL
fragments,5813,O
suggested,5813,O
the,5813,O
presence,5813,O
of,5813,O
an,5813,O
important,5813,O
intramolecular,5813,O
interaction,5813,O
in,5813,O
the,5813,O
active,5813,O
conformation,5813,O
.,5813,O
Comparative,5814,O
analysis,5814,O
of,5814,O
nutritional,5814,O
compositions,5814,O
of,5814,O
transgenic,5814,O
high,5814,O
iron,5814,B-CHEMICAL
rice,5814,O
with,5814,O
its,5814,O
non-transgenic,5814,O
counterpart,5814,O
.,5814,O
Iron,5815,B-CHEMICAL
is,5815,O
an,5815,O
essential,5815,O
micronutrient,5815,O
for,5815,O
human,5815,O
nutrition,5815,O
and,5815,O
polished,5815,O
rice,5815,O
contains,5815,O
very,5815,O
low,5815,O
amount,5815,O
of,5815,O
iron,5815,B-CHEMICAL
.,5815,O
Rice,5816,O
with,5816,O
high,5816,O
iron,5816,B-CHEMICAL
content,5816,O
in,5816,O
seed,5816,O
endosperm,5816,O
has,5816,O
been,5816,O
developed,5816,O
by,5816,O
insertion,5816,O
of,5816,O
soybean,5816,B-GENE-N
ferritin,5816,I-GENE-N
gene,5816,O
under,5816,O
the,5816,O
control,5816,O
of,5816,O
the,5816,O
endosperm,5816,O
specific,5816,O
glutelin,5816,B-GENE-N
promoter,5816,I-GENE-N
into,5816,O
the,5816,O
genome,5816,O
of,5816,O
indica,5816,O
rice,5816,O
line,5816,O
IR68144,5816,O
.,5816,O
The,5817,O
nutritional,5817,O
composition,5817,O
of,5817,O
the,5817,O
brown,5817,O
and,5817,O
milled,5817,O
rice,5817,O
grain,5817,O
has,5817,O
been,5817,O
compared,5817,O
with,5817,O
that,5817,O
of,5817,O
the,5817,O
non-transgenic,5817,O
rice,5817,O
of,5817,O
the,5817,O
same,5817,O
variety,5817,O
.,5817,O
In,5818,O
this,5818,O
study,5818,O
",",5818,O
the,5818,O
nutritional,5818,O
components,5818,O
",",5818,O
as,5818,O
well,5818,O
as,5818,O
the,5818,O
anti-nutrient,5818,O
levels,5818,O
",",5818,O
were,5818,O
measured,5818,O
.,5818,O
Our,5819,O
studies,5819,O
established,5819,O
that,5819,O
apart,5819,O
from,5819,O
the,5819,O
increased,5819,O
level,5819,O
of,5819,O
iron,5819,B-CHEMICAL
and,5819,O
zinc,5819,B-CHEMICAL
in,5819,O
transgenic,5819,O
seeds,5819,O
",",5819,O
the,5819,O
nutritional,5819,O
quality,5819,O
of,5819,O
both,5819,O
the,5819,O
brown,5819,O
and,5819,O
milled,5819,O
rice,5819,O
grains,5819,O
from,5819,O
the,5819,O
transgenic,5819,O
line,5819,O
was,5819,O
substantially,5819,O
equivalent,5819,O
to,5819,O
that,5819,O
of,5819,O
the,5819,O
non-transgenic,5819,O
rice,5819,O
plants,5819,O
.,5819,O
The,5820,O
result,5820,O
clearly,5820,O
shows,5820,O
that,5820,O
the,5820,O
measured,5820,O
amounts,5820,O
of,5820,O
the,5820,O
nutritional,5820,O
components,5820,O
are,5820,O
well,5820,O
within,5820,O
the,5820,O
range,5820,O
of,5820,O
values,5820,O
reported,5820,O
for,5820,O
other,5820,O
commercial,5820,O
lines,5820,O
.,5820,O
Repeated,5821,O
Low,5821,O
Dose,5821,O
Administration,5821,O
of,5821,O
the,5821,O
Monoacylglycerol,5821,B-GENE-Y
Lipase,5821,I-GENE-Y
Inhibitor,5821,O
JZL184,5821,B-CHEMICAL
Retains,5821,O
CB1,5821,B-GENE-Y
Receptor,5821,O
Mediated,5821,O
Antinociceptive,5821,O
and,5821,O
Gastroprotective,5821,O
Effects,5821,O
.,5821,O
The,5822,O
monoacylglycerol,5822,B-GENE-Y
lipase,5822,I-GENE-Y
(,5822,O
MAGL,5822,B-GENE-Y
),5822,O
inhibitor,5822,O
JZL184,5822,B-CHEMICAL
produces,5822,O
antinociceptive,5822,O
and,5822,O
anti-inflammatory,5822,O
effects,5822,O
.,5822,O
However,5823,O
",",5823,O
repeated,5823,O
administration,5823,O
of,5823,O
high,5823,O
dose,5823,O
JZL184,5823,B-CHEMICAL
(,5823,O
40,5823,O
mg/kg,5823,O
),5823,O
causes,5823,O
dependence,5823,O
",",5823,O
antinociceptive,5823,O
tolerance,5823,O
",",5823,O
cross-tolerance,5823,O
to,5823,O
the,5823,O
pharmacological,5823,O
effects,5823,O
of,5823,O
cannabinoid,5823,B-GENE-N
receptor,5823,I-GENE-N
agonists,5823,O
",",5823,O
and,5823,O
CB,5823,B-GENE-Y
(,5823,I-GENE-Y
1,5823,I-GENE-Y
),5823,I-GENE-Y
receptor,5823,O
downregulation,5823,O
and,5823,O
desensitization,5823,O
.,5823,O
This,5824,O
functional,5824,O
CB,5824,B-GENE-Y
(,5824,I-GENE-Y
1,5824,I-GENE-Y
),5824,I-GENE-Y
receptor,5824,O
tolerance,5824,O
poses,5824,O
a,5824,O
hurdle,5824,O
in,5824,O
the,5824,O
development,5824,O
of,5824,O
MAGL,5824,B-GENE-Y
inhibitors,5824,O
for,5824,O
therapeutic,5824,O
use,5824,O
.,5824,O
Consequently,5825,O
",",5825,O
the,5825,O
present,5825,O
study,5825,O
tested,5825,O
whether,5825,O
repeated,5825,O
administration,5825,O
of,5825,O
low,5825,O
dose,5825,O
JZL184,5825,B-CHEMICAL
maintains,5825,O
its,5825,O
antinociceptive,5825,O
actions,5825,O
in,5825,O
the,5825,O
chronic,5825,O
constrictive,5825,O
injury,5825,O
(,5825,O
CCI,5825,O
),5825,O
of,5825,O
the,5825,O
sciatic,5825,O
nerve,5825,O
neuropathic,5825,O
pain,5825,O
model,5825,O
and,5825,O
protective,5825,O
effects,5825,O
in,5825,O
a,5825,O
model,5825,O
of,5825,O
NSAlD-induced,5825,O
gastric,5825,O
hemorrhages,5825,O
.,5825,O
Mice,5826,O
given,5826,O
daily,5826,O
injections,5826,O
of,5826,O
high,5826,O
dose,5826,O
JZL184,5826,B-CHEMICAL
(,5826,O
≥16,5826,O
mg/kg,5826,O
),5826,O
for,5826,O
six,5826,O
days,5826,O
displayed,5826,O
decreased,5826,O
CB,5826,B-GENE-Y
(,5826,I-GENE-Y
1,5826,I-GENE-Y
),5826,I-GENE-Y
receptor,5826,O
density,5826,O
and,5826,O
function,5826,O
in,5826,O
brain,5826,O
",",5826,O
as,5826,O
assessed,5826,O
in,5826,O
[,5826,B-CHEMICAL
(,5826,I-CHEMICAL
3,5826,I-CHEMICAL
),5826,I-CHEMICAL
H,5826,I-CHEMICAL
],5826,I-CHEMICAL
SR141716A,5826,I-CHEMICAL
binding,5826,O
and,5826,O
"CP55,940-stimulated",5826,B-CHEMICAL
[,5826,O
(,5826,B-CHEMICAL
35,5826,I-CHEMICAL
),5826,I-CHEMICAL
S,5826,I-CHEMICAL
],5826,O
GTPγS,5826,O
binding,5826,O
assays,5826,O
",",5826,O
respectively,5826,O
.,5826,O
In,5827,O
contrast,5827,O
",",5827,O
normal,5827,O
CB,5827,B-GENE-Y
(,5827,I-GENE-Y
1,5827,I-GENE-Y
),5827,I-GENE-Y
receptor,5827,O
expression,5827,O
and,5827,O
function,5827,O
were,5827,O
maintained,5827,O
following,5827,O
repeated,5827,O
administration,5827,O
of,5827,O
low,5827,O
dose,5827,O
JZL184,5827,B-CHEMICAL
(,5827,O
≤8,5827,O
mg/kg,5827,O
),5827,O
.,5827,O
Likewise,5828,O
",",5828,O
the,5828,O
antinociceptive,5828,O
and,5828,O
gastroprotective,5828,O
effects,5828,O
of,5828,O
high,5828,O
dose,5828,O
JZL184,5828,B-CHEMICAL
underwent,5828,O
tolerance,5828,O
following,5828,O
repeated,5828,O
administration,5828,O
",",5828,O
but,5828,O
these,5828,O
effects,5828,O
were,5828,O
maintained,5828,O
following,5828,O
repeated,5828,O
low,5828,O
dose,5828,O
JZL184,5828,B-CHEMICAL
treatment,5828,O
.,5828,O
Consistent,5829,O
with,5829,O
these,5829,O
observations,5829,O
",",5829,O
repeated,5829,O
high,5829,O
dose,5829,O
JZL184,5829,B-CHEMICAL
",",5829,O
but,5829,O
not,5829,O
repeated,5829,O
low,5829,O
dose,5829,O
JZL184,5829,B-CHEMICAL
",",5829,O
elicited,5829,O
cross-tolerance,5829,O
to,5829,O
the,5829,O
common,5829,O
pharmacological,5829,O
effects,5829,O
of,5829,O
Δ,5829,B-CHEMICAL
(,5829,I-CHEMICAL
9,5829,I-CHEMICAL
),5829,I-CHEMICAL
-tetrahydrocannabinol,5829,I-CHEMICAL
(,5829,O
THC,5829,B-CHEMICAL
),5829,O
.,5829,O
This,5830,O
same,5830,O
pattern,5830,O
of,5830,O
effects,5830,O
was,5830,O
found,5830,O
in,5830,O
a,5830,O
rimonabant-precipitated,5830,B-CHEMICAL
withdrawal,5830,O
model,5830,O
of,5830,O
cannabinoid,5830,O
dependence,5830,O
.,5830,O
Taken,5831,O
together,5831,O
",",5831,O
these,5831,O
results,5831,O
indicate,5831,O
that,5831,O
prolonged,5831,O
",",5831,O
partial,5831,O
MAGL,5831,B-GENE-Y
inhibition,5831,O
maintains,5831,O
potentially,5831,O
beneficial,5831,O
antinociceptive,5831,O
and,5831,O
anti-inflammatory,5831,O
effects,5831,O
",",5831,O
without,5831,O
producing,5831,O
functional,5831,O
CB,5831,B-GENE-Y
(,5831,I-GENE-Y
1,5831,I-GENE-Y
),5831,I-GENE-Y
receptor,5831,O
tachyphylaxsis/tolerance,5831,O
or,5831,O
cannabinoid,5831,O
dependence,5831,O
.,5831,O
Differential,5832,O
gene,5832,O
expression,5832,O
in,5832,O
ERα-positive,5832,B-GENE-Y
and,5832,O
ERα-negative,5832,B-GENE-Y
breast,5832,O
cancer,5832,O
cells,5832,O
upon,5832,O
leptin,5832,B-GENE-Y
stimulation,5832,O
.,5832,O
In,5833,O
postmenopausal,5833,O
women,5833,O
",",5833,O
adipositas,5833,O
represents,5833,O
a,5833,O
serious,5833,O
risk,5833,O
factor,5833,O
for,5833,O
cancer,5833,O
development,5833,O
and,5833,O
progression,5833,O
.,5833,O
White,5834,O
adipose,5834,O
tissue,5834,O
secretes,5834,O
the,5834,O
16,5834,O
kDa,5834,O
hormone,5834,O
leptin,5834,B-GENE-Y
which,5834,O
plays,5834,O
a,5834,O
key,5834,O
role,5834,O
in,5834,O
the,5834,O
regulation,5834,O
of,5834,O
appetite,5834,O
and,5834,O
metabolism,5834,O
.,5834,O
An,5835,O
increasing,5835,O
number,5835,O
of,5835,O
reports,5835,O
indicate,5835,O
that,5835,O
leptin,5835,B-GENE-Y
also,5835,O
interferes,5835,O
with,5835,O
signal,5835,O
transduction,5835,O
pathways,5835,O
implicated,5835,O
in,5835,O
the,5835,O
development,5835,O
of,5835,O
breast,5835,O
cancer,5835,O
.,5835,O
In,5836,O
our,5836,O
previous,5836,O
study,5836,O
",",5836,O
we,5836,O
identified,5836,O
the,5836,O
estrogen,5836,B-CHEMICAL
receptor,5836,I-GENE-Y
alpha,5836,I-GENE-Y
(,5836,O
ERα,5836,B-GENE-Y
),5836,O
as,5836,O
a,5836,O
relevant,5836,O
enhancer,5836,O
of,5836,O
leptin-induced,5836,B-GENE-Y
signal,5836,O
transduction,5836,O
leading,5836,O
to,5836,O
transactivation,5836,O
of,5836,O
signal,5836,B-GENE-Y
transducer,5836,I-GENE-Y
and,5836,I-GENE-Y
activator,5836,I-GENE-Y
of,5836,I-GENE-Y
transcription,5836,I-GENE-Y
3,5836,I-GENE-Y
(,5836,O
Stat3,5836,B-GENE-Y
),5836,O
.,5836,O
The,5837,O
purpose,5837,O
of,5837,O
this,5837,O
study,5837,O
is,5837,O
the,5837,O
investigation,5837,O
of,5837,O
specific,5837,O
target,5837,O
gene,5837,O
expression,5837,O
in,5837,O
response,5837,O
to,5837,O
leptin-mediated,5837,B-GENE-Y
Stat3,5837,B-GENE-N
signaling,5837,O
.,5837,O
We,5838,O
performed,5838,O
a,5838,O
comprehensive,5838,O
microarray,5838,O
analysis,5838,O
of,5838,O
ERα-positive,5838,B-GENE-Y
and,5838,O
ERα-negative,5838,B-GENE-Y
MDA-MB-231,5838,O
cells,5838,O
upon,5838,O
leptin,5838,B-GENE-Y
treatment,5838,O
and,5838,O
identified,5838,O
49,5838,O
genes,5838,O
which,5838,O
showed,5838,O
a,5838,O
significant,5838,O
ERα-dependent,5838,B-GENE-Y
regulation,5838,O
in,5838,O
leptin-treated,5838,B-GENE-Y
MDA-MB-231,5838,O
cells,5838,O
.,5838,O
There,5839,O
was,5839,O
no,5839,O
intersection,5839,O
with,5839,O
genes,5839,O
which,5839,O
were,5839,O
merely,5839,O
up-,5839,O
or,5839,O
downregulated,5839,O
by,5839,O
ERα,5839,B-GENE-Y
expression,5839,O
and,5839,O
only,5839,O
9,5839,O
and,5839,O
11,5839,O
genes,5839,O
overlapping,5839,O
targets,5839,O
which,5839,O
were,5839,O
regulated,5839,O
by,5839,O
leptin,5839,B-GENE-Y
stimulation,5839,O
either,5839,O
in,5839,O
ERα-expressing,5839,B-GENE-Y
or,5839,O
ERα-negative,5839,B-GENE-Y
MDA-MB-231,5839,O
cells,5839,O
",",5839,O
respectively,5839,O
.,5839,O
To,5840,O
demonstrate,5840,O
the,5840,O
specificity,5840,O
",",5840,O
expression,5840,O
of,5840,O
three,5840,O
target,5840,O
genes,5840,O
was,5840,O
validated,5840,O
by,5840,O
quantitative,5840,O
real-time,5840,O
PCR,5840,O
.,5840,O
In,5841,O
conclusion,5841,O
",",5841,O
these,5841,O
data,5841,O
imply,5841,O
that,5841,O
leptin,5841,B-GENE-Y
can,5841,O
induce,5841,O
a,5841,O
different,5841,O
set,5841,O
of,5841,O
target,5841,O
genes,5841,O
dependent,5841,O
on,5841,O
ERα,5841,B-GENE-Y
expression,5841,O
",",5841,O
which,5841,O
might,5841,O
contribute,5841,O
to,5841,O
the,5841,O
development,5841,O
and,5841,O
progression,5841,O
of,5841,O
cancer,5841,O
diseases,5841,O
.,5841,O
Design,5842,O
and,5842,O
synthesis,5842,O
of,5842,O
bicyclic,5842,B-CHEMICAL
pyrazinone,5842,I-CHEMICAL
and,5842,I-CHEMICAL
pyrimidinone,5842,I-CHEMICAL
amides,5842,I-CHEMICAL
as,5842,O
potent,5842,O
TF-FVIIa,5842,B-GENE-Y
inhibitors,5842,O
.,5842,O
Bicyclic,5843,B-CHEMICAL
pyrazinone,5843,I-CHEMICAL
and,5843,I-CHEMICAL
pyrimidinone,5843,I-CHEMICAL
amides,5843,I-CHEMICAL
were,5843,O
designed,5843,O
and,5843,O
synthesized,5843,O
as,5843,O
potent,5843,O
TF-FVIIa,5843,B-GENE-Y
inhibitors,5843,O
.,5843,O
SAR,5844,O
demonstrated,5844,O
that,5844,O
the,5844,O
S2,5844,O
and,5844,O
S3,5844,O
pockets,5844,O
of,5844,O
FVIIa,5844,B-GENE-Y
prefer,5844,O
to,5844,O
bind,5844,O
small,5844,O
",",5844,O
lipophilic,5844,O
groups,5844,O
.,5844,O
An,5845,O
X-ray,5845,O
crystal,5845,O
structure,5845,O
of,5845,O
optimized,5845,O
compound,5845,O
9b,5845,O
bound,5845,O
in,5845,O
the,5845,O
active,5845,O
site,5845,O
of,5845,O
FVIIa,5845,B-GENE-Y
showed,5845,O
that,5845,O
the,5845,O
bicyclic,5845,O
scaffold,5845,O
provides,5845,O
5,5845,O
hydrogen,5845,B-CHEMICAL
bonding,5845,O
interactions,5845,O
in,5845,O
addition,5845,O
to,5845,O
projecting,5845,O
groups,5845,O
for,5845,O
interactions,5845,O
within,5845,O
the,5845,O
S1,5845,O
",",5845,O
S2,5845,O
and,5845,O
S3,5845,O
pockets,5845,O
.,5845,O
Compound,5846,O
9b,5846,O
showed,5846,O
excellent,5846,O
FVIIa,5846,B-GENE-Y
potency,5846,O
",",5846,O
good,5846,O
selectivity,5846,O
against,5846,O
FIXa,5846,B-GENE-N
",",5846,I-GENE-N
Xa,5846,I-GENE-N
",",5846,I-GENE-N
XIa,5846,I-GENE-N
and,5846,O
chymotrypsin,5846,B-GENE-N
",",5846,O
and,5846,O
good,5846,O
clotting,5846,O
activity,5846,O
.,5846,O
A,5847,O
multivalent,5847,O
peptide,5847,O
as,5847,O
an,5847,O
activator,5847,O
of,5847,O
hypoxia,5847,B-GENE-Y
inducible,5847,I-GENE-Y
factor-1α,5847,I-GENE-Y
.,5847,O
Hypoxia,5848,B-GENE-N
inducible,5848,I-GENE-N
factor-1α,5848,I-GENE-N
(,5848,O
HIF-1α,5848,B-GENE-N
),5848,O
is,5848,O
a,5848,O
transcription,5848,O
factor,5848,O
found,5848,O
in,5848,O
mammalian,5848,O
cells,5848,O
under,5848,O
hypoxia,5848,O
.,5848,O
While,5849,O
HIF-1α,5849,B-GENE-Y
in,5849,O
hypoxia,5849,O
translocates,5849,O
to,5849,O
the,5849,O
nucleus,5849,O
where,5849,O
it,5849,O
transcribes,5849,O
the,5849,O
target,5849,O
genes,5849,O
including,5849,O
vascular,5849,B-GENE-Y
endothelial,5849,I-GENE-Y
growth,5849,I-GENE-Y
factor,5849,I-GENE-Y
(,5849,O
VEGF,5849,B-GENE-Y
),5849,O
mRNA,5849,O
",",5849,O
HIF-1α,5849,B-GENE-Y
is,5849,O
degraded,5849,O
under,5849,O
normoxia,5849,O
",",5849,O
which,5849,O
involves,5849,O
its,5849,O
proline,5849,B-CHEMICAL
hydroxylation,5849,O
and,5849,O
subsequent,5849,O
binding,5849,O
to,5849,O
the,5849,O
von,5849,B-GENE-Y
Hippel-Lindau,5849,I-GENE-Y
protein-Elongin,5849,O
B-Elogin,5849,O
C,5849,I-GENE-Y
(,5849,O
VBC,5849,B-GENE-N
),5849,O
complex,5849,O
.,5849,O
Previously,5850,O
",",5850,O
peptide,5850,O
inhibitors,5850,O
against,5850,O
this,5850,O
interaction,5850,O
between,5850,O
hydroxylated,5850,O
HIF-1α,5850,B-GENE-Y
and,5850,O
VBC,5850,B-GENE-N
have,5850,O
been,5850,O
developed,5850,O
to,5850,O
stabilize,5850,O
the,5850,O
transcriptional,5850,O
activity,5850,O
of,5850,O
HIF-1α,5850,B-GENE-Y
by,5850,O
preventing,5850,O
the,5850,O
degradation,5850,O
of,5850,O
the,5850,O
protein,5850,O
even,5850,O
under,5850,O
normoxia,5850,O
.,5850,O
Despite,5851,O
the,5851,O
specific,5851,O
inhibition,5851,O
by,5851,O
these,5851,O
peptides,5851,O
",",5851,O
their,5851,O
poor,5851,O
inhibition,5851,O
potency,5851,O
needs,5851,O
to,5851,O
be,5851,O
improved,5851,O
for,5851,O
further,5851,O
clinical,5851,O
application,5851,O
.,5851,O
In,5852,O
this,5852,O
work,5852,O
",",5852,O
we,5852,O
have,5852,O
designed,5852,O
and,5852,O
prepared,5852,O
a,5852,O
streptavidin-based,5852,O
multivalent,5852,O
peptide,5852,O
inhibitor,5852,O
against,5852,O
the,5852,O
HIF-1α-VBC,5852,B-GENE-Y
complexation,5852,O
.,5852,O
We,5853,O
have,5853,O
evaluated,5853,O
the,5853,O
potency,5853,O
of,5853,O
the,5853,O
multivalent,5853,O
peptide,5853,O
in,5853,O
terms,5853,O
of,5853,O
stabilization,5853,O
of,5853,O
HIF-1α,5853,B-GENE-Y
and,5853,O
the,5853,O
downstream,5853,O
effect,5853,O
.,5853,O
As,5854,O
the,5854,O
result,5854,O
",",5854,O
we,5854,O
have,5854,O
found,5854,O
that,5854,O
the,5854,O
inhibitor,5854,O
showed,5854,O
about,5854,O
13-fold,5854,O
lowered,5854,O
IC50,5854,O
value,5854,O
compared,5854,O
with,5854,O
that,5854,O
of,5854,O
the,5854,O
corresponding,5854,O
monovalent,5854,O
peptide,5854,O
",",5854,O
thereby,5854,O
activating,5854,O
HIF-1α,5854,B-GENE-Y
and,5854,O
leading,5854,O
to,5854,O
up-regulation,5854,O
of,5854,O
VEGF,5854,B-GENE-Y
protein,5854,O
at,5854,O
the,5854,O
cellular,5854,O
level,5854,O
.,5854,O
Glucagon-induced,5855,B-GENE-Y
acetylation,5855,O
of,5855,O
Foxa2,5855,B-GENE-Y
regulates,5855,O
hepatic,5855,O
lipid,5855,O
metabolism,5855,O
.,5855,O
Circulating,5856,O
levels,5856,O
of,5856,O
insulin,5856,B-GENE-Y
and,5856,O
glucagon,5856,B-GENE-Y
reflect,5856,O
the,5856,O
nutritional,5856,O
state,5856,O
of,5856,O
animals,5856,O
and,5856,O
elicit,5856,O
regulatory,5856,O
responses,5856,O
in,5856,O
the,5856,O
liver,5856,O
that,5856,O
maintain,5856,O
glucose,5856,B-CHEMICAL
and,5856,O
lipid,5856,O
homeostasis,5856,O
.,5856,O
The,5857,O
transcription,5857,O
factor,5857,O
Foxa2,5857,B-GENE-Y
activates,5857,O
lipid,5857,O
metabolism,5857,O
and,5857,O
ketogenesis,5857,O
during,5857,O
fasting,5857,O
and,5857,O
is,5857,O
inhibited,5857,O
via,5857,O
insulin-PI3K-Akt,5857,B-GENE-Y
signaling-mediated,5857,O
phosphorylation,5857,O
at,5857,O
Thr156,5857,O
and,5857,O
nuclear,5857,O
exclusion,5857,O
.,5857,O
Here,5858,O
we,5858,O
show,5858,O
that,5858,O
",",5858,O
in,5858,O
addition,5858,O
",",5858,O
Foxa2,5858,B-GENE-Y
is,5858,O
acetylated,5858,O
at,5858,O
the,5858,O
conserved,5858,O
residue,5858,O
Lys259,5858,O
following,5858,O
inhibition,5858,O
of,5858,O
histone,5858,B-GENE-N
deacetylases,5858,I-GENE-N
(,5858,I-GENE-N
HDACs,5858,I-GENE-N
),5858,I-GENE-N
class,5858,I-GENE-N
I-III,5858,I-GENE-N
and,5858,O
the,5858,O
cofactors,5858,O
p300,5858,B-GENE-Y
and,5858,O
SirT1,5858,B-GENE-Y
are,5858,O
involved,5858,O
in,5858,O
Foxa2,5858,B-GENE-Y
acetylation,5858,O
and,5858,O
deacetylation,5858,O
",",5858,O
respectively,5858,O
.,5858,O
Physiologically,5859,O
",",5859,O
fasting,5859,O
states,5859,O
and,5859,O
glucagon,5859,B-GENE-Y
stimulation,5859,O
are,5859,O
sufficient,5859,O
to,5859,O
induce,5859,O
Foxa2,5859,B-GENE-Y
acetylation,5859,O
.,5859,O
Introduction,5860,O
of,5860,O
the,5860,O
acetylation-mimicking,5860,O
(,5860,O
K259Q,5860,B-GENE-N
),5860,O
or,5860,O
-deficient,5860,O
(,5860,O
K259R,5860,B-GENE-N
),5860,O
mutations,5860,O
promotes,5860,O
or,5860,O
inhibits,5860,O
Foxa2,5860,B-GENE-Y
activity,5860,O
",",5860,O
respectively,5860,O
",",5860,O
and,5860,O
adenoviral,5860,O
expression,5860,O
of,5860,O
Foxa2-K259Q,5860,B-GENE-Y
augments,5860,O
expression,5860,O
of,5860,O
genes,5860,O
involved,5860,O
in,5860,O
fatty,5860,B-CHEMICAL
acid,5860,I-CHEMICAL
oxidation,5860,O
and,5860,O
ketogenesis,5860,O
.,5860,O
Our,5861,O
study,5861,O
reveals,5861,O
a,5861,O
molecular,5861,O
mechanism,5861,O
by,5861,O
which,5861,O
glucagon,5861,B-GENE-Y
signaling,5861,O
activates,5861,O
a,5861,O
fasting,5861,O
response,5861,O
through,5861,O
acetylation,5861,O
of,5861,O
Foxa2,5861,B-GENE-Y
.,5861,O
Antitumor,5862,O
and,5862,O
immunomodulatory,5862,O
activity,5862,O
of,5862,O
a,5862,O
water-soluble,5862,O
low,5862,O
molecular,5862,O
weight,5862,O
polysaccharide,5862,O
from,5862,O
Schisandra,5862,O
chinensis,5862,O
(,5862,O
Turcz,5862,O
.,5862,O
),5862,O
Baill,5863,O
.,5863,O
A,5864,O
water-soluble,5864,O
low,5864,O
molecular,5864,O
weight,5864,O
polysaccharide,5864,O
(,5864,O
SCPP11,5864,O
),5864,O
was,5864,O
extracted,5864,O
and,5864,O
purified,5864,O
using,5864,O
DEAE-cellulose,5864,O
and,5864,O
Sephadex,5864,O
G-100,5864,O
column,5864,O
from,5864,O
Schisandra,5864,O
chinensis,5864,O
(,5864,O
Turcz,5864,O
.,5864,O
),5864,O
Baill,5865,O
.,5865,O
Its,5866,O
in,5866,O
vivo,5866,O
and,5866,O
in,5866,O
vitro,5866,O
antitumor,5866,O
and,5866,O
immunomodulatory,5866,O
activity,5866,O
were,5866,O
investigated,5866,O
.,5866,O
The,5867,O
results,5867,O
showed,5867,O
that,5867,O
SCPP11,5867,O
with,5867,O
a,5867,O
molecular,5867,O
weight,5867,O
of,5867,O
3.4×10,5867,O
(,5867,O
3,5867,O
),5867,O
Da,5867,O
exhibited,5867,O
indirect,5867,O
cyctotoxic,5867,O
activity,5867,O
against,5867,O
tumor,5867,O
cells,5867,O
in,5867,O
vitro,5867,O
",",5867,O
but,5867,O
could,5867,O
significantly,5867,O
inhibit,5867,O
the,5867,O
growth,5867,O
of,5867,O
Heps,5867,O
cells,5867,O
in,5867,O
vivo,5867,O
at,5867,O
dose,5867,O
of,5867,O
50mg/kg,5867,O
",",5867,O
and,5867,O
its,5867,O
inhibition,5867,O
rate,5867,O
is,5867,O
higher,5867,O
than,5867,O
that,5867,O
in,5867,O
the,5867,O
positive,5867,O
group,5867,O
.,5867,O
Moreover,5868,O
",",5868,O
SCPP11,5868,O
could,5868,O
ameliorate,5868,O
the,5868,O
hematological,5868,O
and,5868,O
biochemical,5868,O
parameters,5868,O
to,5868,O
almost,5868,O
normal,5868,O
and,5868,O
no,5868,O
significant,5868,O
changes,5868,O
in,5868,O
organ,5868,O
weight,5868,O
",",5868,O
and,5868,O
could,5868,O
increase,5868,O
the,5868,O
body,5868,O
weight,5868,O
.,5868,O
In,5869,O
addition,5869,O
",",5869,O
SCPP11,5869,O
(,5869,O
at,5869,O
50mg/kg,5869,O
),5869,O
could,5869,O
also,5869,O
increased,5869,O
in,5869,O
thymus,5869,O
indexes,5869,O
as,5869,O
well,5869,O
as,5869,O
IL-2,5869,B-GENE-Y
and,5869,O
TNF-α,5869,B-GENE-Y
levels,5869,O
in,5869,O
serum,5869,O
in,5869,O
vivo,5869,O
and,5869,O
significantly,5869,O
enhance,5869,O
the,5869,O
phagocytosis,5869,O
activity,5869,O
and,5869,O
the,5869,O
productions,5869,O
of,5869,O
NO,5869,B-CHEMICAL
of,5869,O
RAW264.7,5869,O
in,5869,O
vitro,5869,O
.,5869,O
The,5870,O
results,5870,O
indicated,5870,O
that,5870,O
antitumor,5870,O
properties,5870,O
of,5870,O
SCPP11,5870,O
might,5870,O
be,5870,O
achieved,5870,O
by,5870,O
improving,5870,O
immune,5870,O
response,5870,O
.,5870,O
It,5871,O
could,5871,O
be,5871,O
explored,5871,O
as,5871,O
a,5871,O
potential,5871,O
adjuvant,5871,O
against,5871,O
cancer,5871,O
used,5871,O
in,5871,O
the,5871,O
health,5871,O
food,5871,O
and,5871,O
pharmaceutical,5871,O
therapy,5871,O
.,5871,O
Fragment-based,5872,O
drug,5872,O
design,5872,O
and,5872,O
identification,5872,O
of,5872,O
HJC0123,5872,B-CHEMICAL
",",5872,O
a,5872,O
novel,5872,O
orally,5872,O
bioavailable,5872,O
STAT3,5872,B-GENE-Y
inhibitor,5872,O
for,5872,O
cancer,5872,O
therapy,5872,O
.,5872,O
Fragment-based,5873,O
drug,5873,O
design,5873,O
(,5873,O
FBDD,5873,O
),5873,O
is,5873,O
a,5873,O
promising,5873,O
approach,5873,O
for,5873,O
the,5873,O
generation,5873,O
of,5873,O
lead,5873,O
molecules,5873,O
with,5873,O
enhanced,5873,O
activity,5873,O
and,5873,O
especially,5873,O
drug-like,5873,O
properties,5873,O
against,5873,O
therapeutic,5873,O
targets,5873,O
.,5873,O
Herein,5874,O
",",5874,O
we,5874,O
report,5874,O
the,5874,O
fragment-based,5874,O
drug,5874,O
design,5874,O
",",5874,O
systematic,5874,O
chemical,5874,O
synthesis,5874,O
and,5874,O
pharmacological,5874,O
evaluation,5874,O
of,5874,O
novel,5874,O
scaffolds,5874,O
as,5874,O
potent,5874,O
anticancer,5874,O
agents,5874,O
by,5874,O
utilizing,5874,O
six,5874,O
privileged,5874,O
fragments,5874,O
from,5874,O
known,5874,O
STAT3,5874,B-GENE-Y
inhibitors,5874,O
.,5874,O
Several,5875,O
new,5875,O
molecules,5875,O
such,5875,O
as,5875,O
compounds,5875,O
5,5875,O
",",5875,O
12,5875,O
",",5875,O
and,5875,O
19,5875,O
that,5875,O
may,5875,O
act,5875,O
as,5875,O
advanced,5875,O
chemical,5875,O
leads,5875,O
have,5875,O
been,5875,O
identified,5875,O
.,5875,O
The,5876,O
most,5876,O
potent,5876,O
compound,5876,O
5,5876,O
(,5876,O
HJC0123,5876,B-CHEMICAL
),5876,O
has,5876,O
demonstrated,5876,O
to,5876,O
inhibit,5876,O
STAT3,5876,B-GENE-N
promoter,5876,I-GENE-N
activity,5876,O
",",5876,O
downregulate,5876,O
phosphorylation,5876,O
of,5876,O
STAT3,5876,B-GENE-Y
",",5876,O
increase,5876,O
the,5876,O
expression,5876,O
of,5876,O
cleaved,5876,O
caspase-3,5876,B-GENE-Y
",",5876,O
inhibit,5876,O
cell,5876,O
cycle,5876,O
progression,5876,O
and,5876,O
promote,5876,O
apoptosis,5876,O
in,5876,O
breast,5876,O
and,5876,O
pancreatic,5876,O
cancer,5876,O
cells,5876,O
with,5876,O
low,5876,O
micromolar,5876,O
to,5876,O
nanomolar,5876,O
IC50,5876,O
values,5876,O
.,5876,O
Furthermore,5877,O
",",5877,O
compound,5877,O
5,5877,O
significantly,5877,O
suppressed,5877,O
estrogen,5877,B-GENE-Y
receptor,5877,I-GENE-Y
(,5877,O
ER,5877,B-GENE-Y
),5877,O
-negative,5877,O
breast,5877,O
cancer,5877,O
MDA-MB-231,5877,O
xenograft,5877,O
tumor,5877,O
growth,5877,O
in,5877,O
vivo,5877,O
(,5877,O
p.o,5877,O
.,5877,O
),5878,O
",",5878,O
indicating,5878,O
its,5878,O
great,5878,O
potential,5878,O
as,5878,O
an,5878,O
efficacious,5878,O
and,5878,O
orally,5878,O
bioavailable,5878,O
drug,5878,O
candidate,5878,O
for,5878,O
human,5878,O
cancer,5878,O
therapy,5878,O
.,5878,O
Transcription,5879,O
forms,5879,O
and,5879,O
remodels,5879,O
supercoiling,5879,B-GENE-N
domains,5879,I-GENE-N
unfolding,5879,O
large-scale,5879,O
chromatin,5879,O
structures,5879,O
.,5879,O
DNA,5880,O
supercoiling,5880,O
is,5880,O
an,5880,O
inherent,5880,O
consequence,5880,O
of,5880,O
twisting,5880,O
DNA,5880,O
and,5880,O
is,5880,O
critical,5880,O
for,5880,O
regulating,5880,O
gene,5880,O
expression,5880,O
and,5880,O
DNA,5880,O
replication,5880,O
.,5880,O
However,5881,O
",",5881,O
DNA,5881,O
supercoiling,5881,O
at,5881,O
a,5881,O
genomic,5881,O
scale,5881,O
in,5881,O
human,5881,O
cells,5881,O
is,5881,O
uncharacterized,5881,O
.,5881,O
To,5882,O
map,5882,O
supercoiling,5882,O
",",5882,O
we,5882,O
used,5882,O
biotinylated,5882,B-CHEMICAL
trimethylpsoralen,5882,I-CHEMICAL
as,5882,O
a,5882,O
DNA,5882,O
structure,5882,O
probe,5882,O
to,5882,O
show,5882,O
that,5882,O
the,5882,O
human,5882,O
genome,5882,O
is,5882,O
organized,5882,O
into,5882,O
supercoiling,5882,B-GENE-N
domains,5882,I-GENE-N
.,5882,O
Domains,5883,O
are,5883,O
formed,5883,O
and,5883,O
remodeled,5883,O
by,5883,O
RNA,5883,B-GENE-N
polymerase,5883,I-GENE-N
and,5883,O
topoisomerase,5883,B-GENE-N
activities,5883,O
and,5883,O
are,5883,O
flanked,5883,O
by,5883,O
GC-AT,5883,O
boundaries,5883,O
and,5883,O
CTCF,5883,B-GENE-Y
insulator,5883,O
protein-binding,5883,O
sites,5883,O
.,5883,O
Underwound,5884,B-GENE-N
domains,5884,I-GENE-N
are,5884,O
transcriptionally,5884,O
active,5884,O
and,5884,O
enriched,5884,O
in,5884,O
topoisomerase,5884,B-GENE-Y
I,5884,I-GENE-Y
",",5884,O
'open,5884,O
',5884,O
chromatin,5884,O
fibers,5884,O
and,5884,O
DNase,5884,B-GENE-Y
I,5884,I-GENE-Y
sites,5884,O
",",5884,O
but,5884,O
they,5884,O
are,5884,O
depleted,5884,O
of,5884,O
topoisomerase,5884,B-GENE-Y
II,5884,I-GENE-Y
.,5884,O
Furthermore,5885,O
",",5885,O
DNA,5885,O
supercoiling,5885,O
affects,5885,O
additional,5885,O
levels,5885,O
of,5885,O
chromatin,5885,O
compaction,5885,O
as,5885,O
underwound,5885,B-GENE-N
domains,5885,I-GENE-N
are,5885,O
cytologically,5885,O
decondensed,5885,O
",",5885,O
topologically,5885,O
constrained,5885,O
and,5885,O
decompacted,5885,O
by,5885,O
transcription,5885,O
of,5885,O
short,5885,O
RNAs,5885,O
.,5885,O
We,5886,O
suggest,5886,O
that,5886,O
supercoiling,5886,O
domains,5886,O
create,5886,O
a,5886,O
topological,5886,O
environment,5886,O
that,5886,O
facilitates,5886,O
gene,5886,O
activation,5886,O
",",5886,O
providing,5886,O
an,5886,O
evolutionary,5886,O
purpose,5886,O
for,5886,O
clustering,5886,O
genes,5886,O
along,5886,O
chromosomes,5886,O
.,5886,O
Four,5887,O
new,5887,O
eudesmane-type,5887,B-CHEMICAL
sesquiterpenoid,5887,B-CHEMICAL
lactones,5887,I-CHEMICAL
from,5887,O
atractylenolide,5887,B-CHEMICAL
II,5887,I-CHEMICAL
by,5887,O
biotransformation,5887,O
of,5887,O
rat,5887,O
hepatic,5887,O
microsomes,5887,O
.,5887,O
The,5888,O
biotransformation,5888,O
of,5888,O
atractylenolide,5888,B-CHEMICAL
II,5888,I-CHEMICAL
",",5888,O
a,5888,O
major,5888,O
bioactive,5888,O
principle,5888,O
of,5888,O
the,5888,O
rhizomes,5888,O
of,5888,O
Atractylodes,5888,O
macrocephala,5888,O
Koidz.,5888,O
",",5888,O
was,5888,O
investigated,5888,O
in,5888,O
vitro,5888,O
by,5888,O
incubation,5888,O
with,5888,O
rat,5888,O
hepatic,5888,O
microsomes,5888,O
pretreated,5888,O
with,5888,O
sodium,5888,B-CHEMICAL
phenobarbital,5888,I-CHEMICAL
.,5888,O
The,5889,O
biotransformation,5889,O
products,5889,O
were,5889,O
extracted,5889,O
and,5889,O
purified,5889,O
by,5889,O
chromatographic,5889,O
methods,5889,O
.,5889,O
Seven,5890,O
biotransformation,5890,O
products,5890,O
(,5890,O
BP1-BP7,5890,O
),5890,O
were,5890,O
obtained,5890,O
and,5890,O
their,5890,O
structures,5890,O
were,5890,O
elucidated,5890,O
by,5890,O
NMR,5890,O
and,5890,O
MS,5890,O
data,5890,O
analyses,5890,O
and,5890,O
by,5890,O
comparison,5890,O
with,5890,O
the,5890,O
previously,5890,O
reported,5890,O
values,5890,O
",",5890,O
including,5890,O
four,5890,O
new,5890,O
compounds,5890,O
",",5890,O
namely,5890,O
4,5890,B-CHEMICAL
(,5890,I-CHEMICAL
R,5890,I-CHEMICAL
),5890,I-CHEMICAL
",15-epoxy-atractylenolide",5890,I-CHEMICAL
II,5890,I-CHEMICAL
(,5890,O
BP1,5890,O
),5890,O
",",5890,O
4,5890,B-CHEMICAL
(,5890,I-CHEMICAL
R,5890,I-CHEMICAL
),5890,I-CHEMICAL
",15-epoxy-13-hydroxyatractylenolide",5890,I-CHEMICAL
II,5890,I-CHEMICAL
(,5890,O
BP5,5890,O
),5890,O
",",5890,O
4,5890,B-CHEMICAL
(,5890,I-CHEMICAL
R,5890,I-CHEMICAL
),5890,I-CHEMICAL
",15-epoxy-1β-hydroxyatractylenolide",5890,I-CHEMICAL
II,5890,I-CHEMICAL
(,5890,O
BP6,5890,O
),5890,O
",",5890,O
and,5890,O
4,5890,B-CHEMICAL
(,5890,I-CHEMICAL
R,5890,I-CHEMICAL
),5890,I-CHEMICAL
",15-dihydroxyatractylenolide",5890,I-CHEMICAL
II,5890,I-CHEMICAL
(,5890,O
BP7,5890,O
),5890,O
.,5890,O
The,5891,O
biotransformation,5891,O
pathway,5891,O
of,5891,O
atractylenolide,5891,B-CHEMICAL
II,5891,I-CHEMICAL
by,5891,O
hepatic,5891,O
microsomes,5891,O
was,5891,O
deducted,5891,O
based,5891,O
on,5891,O
the,5891,O
structure,5891,O
resolution,5891,O
of,5891,O
the,5891,O
products,5891,O
.,5891,O
The,5892,O
effects,5892,O
of,5892,O
the,5892,O
phosphodiesterase,5892,B-GENE-Y
type,5892,I-GENE-Y
5,5892,I-GENE-Y
inhibitor,5892,O
vardenafil,5892,B-CHEMICAL
on,5892,O
cognitive,5892,O
performance,5892,O
in,5892,O
healthy,5892,O
adults,5892,O
:,5892,O
a,5892,O
behavioral-,5892,O
electroencephalography,5892,O
study,5892,O
.,5892,O
Phosphodiesterase,5893,B-GENE-Y
type,5893,I-GENE-Y
5,5893,I-GENE-Y
inhibitors,5893,O
(,5893,O
PDE5-Is,5893,B-GENE-Y
),5893,O
improve,5893,O
cognitive,5893,O
performance,5893,O
of,5893,O
rodents,5893,O
",",5893,O
but,5893,O
the,5893,O
few,5893,O
human,5893,O
studies,5893,O
investigating,5893,O
their,5893,O
effects,5893,O
did,5893,O
not,5893,O
systematically,5893,O
investigate,5893,O
cognitive,5893,O
effects,5893,O
and,5893,O
the,5893,O
results,5893,O
have,5893,O
been,5893,O
quite,5893,O
contradictory,5893,O
.,5893,O
Therefore,5894,O
",",5894,O
we,5894,O
examined,5894,O
whether,5894,O
the,5894,O
PDE5-I,5894,B-GENE-Y
vardenafil,5894,B-CHEMICAL
improves,5894,O
memory,5894,O
and,5894,O
executive,5894,O
functioning,5894,O
and,5894,O
affect,5894,O
electroencephalography,5894,O
(,5894,O
EEG,5894,O
),5894,O
in,5894,O
healthy,5894,O
young,5894,O
adults,5894,O
.,5894,O
Participants,5895,O
were,5895,O
selected,5895,O
out,5895,O
of,5895,O
a,5895,O
group,5895,O
of,5895,O
volunteers,5895,O
",",5895,O
based,5895,O
on,5895,O
their,5895,O
performance,5895,O
on,5895,O
a,5895,O
memory,5895,O
screening,5895,O
and,5895,O
they,5895,O
were,5895,O
orally,5895,O
treated,5895,O
with,5895,O
vardenafil,5895,B-CHEMICAL
(,5895,O
10-20,5895,O
mg,5895,O
or,5895,O
placebo,5895,O
),5895,O
.,5895,O
Memory,5896,O
and,5896,O
executive,5896,O
functioning,5896,O
were,5896,O
tested,5896,O
while,5896,O
EEG,5896,O
activity,5896,O
was,5896,O
recorded,5896,O
.,5896,O
Additionally,5897,O
",",5897,O
a,5897,O
simple,5897,O
reaction,5897,O
time,5897,O
task,5897,O
and,5897,O
questionnaires,5897,O
addressing,5897,O
various,5897,O
complaints,5897,O
were,5897,O
presented,5897,O
.,5897,O
No,5898,O
prominent,5898,O
effects,5898,O
of,5898,O
vardenafil,5898,B-CHEMICAL
on,5898,O
cognition,5898,O
were,5898,O
found,5898,O
:,5898,O
participants,5898,O
only,5898,O
made,5898,O
more,5898,O
mistakes,5898,O
on,5898,O
a,5898,O
reaction,5898,O
time,5898,O
task,5898,O
after,5898,O
20,5898,O
mg,5898,O
vardenafil,5898,B-CHEMICAL
.,5898,O
During,5899,O
encoding,5899,O
of,5899,O
words,5899,O
",",5899,O
the,5899,O
P300,5899,O
was,5899,O
generally,5899,O
smaller,5899,O
after,5899,O
vardenafil,5899,B-CHEMICAL
treatment,5899,O
.,5899,O
Furthermore,5900,O
",",5900,O
the,5900,O
N400,5900,O
was,5900,O
larger,5900,O
after,5900,O
vardenafil,5900,B-CHEMICAL
10,5900,O
mg,5900,O
than,5900,O
placebo,5900,O
treatment,5900,O
in,5900,O
a,5900,O
spatial,5900,O
memory,5900,O
task,5900,O
at,5900,O
Fz,5900,O
.,5900,O
Finally,5901,O
",",5901,O
headache,5901,O
and,5901,O
feeling,5901,O
weak,5901,O
were,5901,O
reported,5901,O
more,5901,O
after,5901,O
vardenafil,5901,B-CHEMICAL
treatment,5901,O
.,5901,O
Vardenafil,5902,B-CHEMICAL
did,5902,O
not,5902,O
affect,5902,O
cognitive,5902,O
performance,5902,O
of,5902,O
healthy,5902,O
adults,5902,O
and,5902,O
showed,5902,O
only,5902,O
some,5902,O
incidental,5902,O
effects,5902,O
on,5902,O
ERPs,5902,O
.,5902,O
These,5903,O
findings,5903,O
in,5903,O
humans,5903,O
do,5903,O
not,5903,O
corroborate,5903,O
the,5903,O
cognition-enhancing,5903,O
effects,5903,O
of,5903,O
PDE5-Is,5903,B-GENE-Y
in,5903,O
healthy,5903,O
animals,5903,O
.,5903,O
Atorvastatin,5904,B-CHEMICAL
withdrawal,5904,O
elicits,5904,O
oxidative/nitrosative,5904,O
damage,5904,O
in,5904,O
the,5904,O
rat,5904,O
cerebral,5904,O
cortex,5904,O
.,5904,O
Statins,5905,O
are,5905,O
inhibitors,5905,O
of,5905,O
the,5905,O
enzyme,5905,O
3-hydroxy-3-methylglutaryl,5905,B-GENE-Y
coenzyme,5905,I-GENE-Y
A,5905,I-GENE-Y
reductase,5905,I-GENE-Y
",",5905,O
the,5905,O
rate-limiting,5905,O
step,5905,O
in,5905,O
cholesterol,5905,B-CHEMICAL
biosynthesis,5905,O
.,5905,O
Statins,5906,O
effectively,5906,O
prevent,5906,O
and,5906,O
reduce,5906,O
the,5906,O
risk,5906,O
of,5906,O
coronary,5906,O
artery,5906,O
disease,5906,O
through,5906,O
lowering,5906,O
serum,5906,O
cholesterol,5906,B-CHEMICAL
",",5906,O
and,5906,O
also,5906,O
exert,5906,O
anti-thrombotic,5906,O
",",5906,O
anti-inflammatory,5906,O
and,5906,O
antioxidant,5906,O
effects,5906,O
independently,5906,O
of,5906,O
changes,5906,O
in,5906,O
cholesterol,5906,B-CHEMICAL
levels,5906,O
.,5906,O
On,5907,O
the,5907,O
other,5907,O
hand,5907,O
",",5907,O
clinical,5907,O
and,5907,O
experimental,5907,O
evidence,5907,O
suggests,5907,O
that,5907,O
abrupt,5907,O
cessation,5907,O
of,5907,O
statin,5907,O
treatment,5907,O
(,5907,O
i.e,5907,O
.,5907,O
statin,5908,O
withdrawal,5908,O
),5908,O
is,5908,O
associated,5908,O
with,5908,O
a,5908,O
deleterious,5908,O
rebound,5908,O
phenomenon,5908,O
.,5908,O
In,5909,O
fact,5909,O
",",5909,O
statin,5909,O
withdrawal,5909,O
increases,5909,O
the,5909,O
risk,5909,O
of,5909,O
thrombotic,5909,O
vascular,5909,O
events,5909,O
",",5909,O
causes,5909,O
impairment,5909,O
of,5909,O
endothelium-dependent,5909,O
relaxation,5909,O
and,5909,O
facilitates,5909,O
experimental,5909,O
seizures,5909,O
.,5909,O
However,5910,O
",",5910,O
evidence,5910,O
for,5910,O
statin,5910,O
withdrawal-induced,5910,O
detrimental,5910,O
effects,5910,O
to,5910,O
the,5910,O
brain,5910,O
parenchyma,5910,O
is,5910,O
still,5910,O
lacking,5910,O
.,5910,O
In,5911,O
the,5911,O
present,5911,O
study,5911,O
adult,5911,O
male,5911,O
Wistar,5911,O
rats,5911,O
were,5911,O
treated,5911,O
with,5911,O
atorvastatin,5911,B-CHEMICAL
for,5911,O
seven,5911,O
days,5911,O
(,5911,O
10mg/kg/day,5911,O
),5911,O
and,5911,O
neurochemical,5911,O
assays,5911,O
were,5911,O
performed,5911,O
in,5911,O
the,5911,O
cerebral,5911,O
cortex,5911,O
30min,5911,O
(,5911,O
atorvastatin,5911,B-CHEMICAL
treatment,5911,O
),5911,O
or,5911,O
24h,5911,O
(,5911,O
atorvastatin,5911,B-CHEMICAL
withdrawal,5911,O
),5911,O
after,5911,O
the,5911,O
last,5911,O
atorvastatin,5911,B-CHEMICAL
administration,5911,O
.,5911,O
We,5912,O
found,5912,O
that,5912,O
atorvastatin,5912,B-CHEMICAL
withdrawal,5912,O
decreased,5912,O
levels,5912,O
of,5912,O
nitric,5912,B-CHEMICAL
oxide,5912,I-CHEMICAL
and,5912,O
mitochondrial,5912,B-GENE-Y
superoxide,5912,B-CHEMICAL
dismutase,5912,I-GENE-Y
activity,5912,O
",",5912,O
whereas,5912,O
increased,5912,O
NADPH,5912,B-CHEMICAL
oxidase,5912,I-GENE-N
activity,5912,O
and,5912,O
immunoreactivity,5912,O
for,5912,O
the,5912,O
protein,5912,O
nitration,5912,O
marker,5912,O
3-nitrotyrosine,5912,B-CHEMICAL
in,5912,O
the,5912,O
cerebral,5912,O
cortex,5912,O
.,5912,O
Catalase,5913,B-GENE-Y
",",5913,O
glutathione-S-transferase,5913,B-GENE-N
and,5913,O
xanthine,5913,B-GENE-Y
oxidase,5913,I-GENE-Y
activities,5913,O
were,5913,O
not,5913,O
altered,5913,O
by,5913,O
atorvastatin,5913,B-CHEMICAL
treatment,5913,O
or,5913,O
withdrawal,5913,O
",",5913,O
as,5913,O
well,5913,O
as,5913,O
protein,5913,O
carbonyl,5913,B-CHEMICAL
and,5913,O
4-hydroxy-2-nonenal,5913,B-CHEMICAL
immunoreactivity,5913,O
.,5913,O
Immunoprecipitation,5914,O
of,5914,O
mitochondrial,5914,B-GENE-Y
SOD,5914,I-GENE-Y
followed,5914,O
by,5914,O
analysis,5914,O
of,5914,O
3-nitrotyrosine,5914,B-CHEMICAL
revealed,5914,O
increased,5914,O
levels,5914,O
of,5914,O
nitrated,5914,O
mitochondrial,5914,B-GENE-Y
SOD,5914,I-GENE-Y
",",5914,O
suggesting,5914,O
the,5914,O
mechanism,5914,O
underlying,5914,O
the,5914,O
atorvastatin,5914,B-CHEMICAL
withdrawal-induced,5914,O
decrease,5914,O
in,5914,O
enzyme,5914,O
activity,5914,O
.,5914,O
Altogether,5915,O
",",5915,O
our,5915,O
results,5915,O
indicate,5915,O
the,5915,O
atorvastatin,5915,B-CHEMICAL
withdrawal,5915,O
elicits,5915,O
oxidative/nitrosative,5915,O
damage,5915,O
in,5915,O
the,5915,O
rat,5915,O
cerebral,5915,O
cortex,5915,O
",",5915,O
and,5915,O
that,5915,O
changes,5915,O
in,5915,O
NADPH,5915,B-GENE-N
oxidase,5915,I-GENE-N
activity,5915,O
and,5915,O
mitochondrial,5915,B-GENE-Y
superoxide,5915,I-GENE-Y
dismutase,5915,I-GENE-Y
activities,5915,O
may,5915,O
underlie,5915,O
such,5915,O
harmful,5915,O
effects,5915,O
.,5915,O
Hyperthyroidism,5916,O
causes,5916,O
cardiac,5916,O
dysfunction,5916,O
by,5916,O
mitochondrial,5916,O
impairment,5916,O
and,5916,O
energy,5916,O
depletion,5916,O
.,5916,O
This,5917,O
study,5917,O
elucidates,5917,O
the,5917,O
role,5917,O
of,5917,O
metabolic,5917,O
remodeling,5917,O
in,5917,O
cardiac,5917,O
dysfunction,5917,O
induced,5917,O
by,5917,O
hyperthyroidism,5917,O
.,5917,O
Cardiac,5918,O
hypertrophy,5918,O
",",5918,O
structural,5918,O
remodeling,5918,O
",",5918,O
and,5918,O
expression,5918,O
of,5918,O
the,5918,O
genes,5918,O
associated,5918,O
with,5918,O
fatty,5918,B-CHEMICAL
acid,5918,I-CHEMICAL
metabolism,5918,O
were,5918,O
examined,5918,O
in,5918,O
rats,5918,O
treated,5918,O
with,5918,O
triiodothyronine,5918,B-CHEMICAL
(,5918,O
T3,5918,O
),5918,O
alone,5918,O
(,5918,O
8,5918,O
μg/100,5918,O
g,5918,O
body,5918,O
weight,5918,O
(,5918,O
BW,5918,O
),5918,O
",",5918,O
i.p,5918,O
.,5918,O
),5918,O
for,5919,O
15,5919,O
days,5919,O
or,5919,O
along,5919,O
with,5919,O
a,5919,O
peroxisome,5919,B-GENE-Y
proliferator-activated,5919,I-GENE-Y
receptor,5919,I-GENE-Y
alpha,5919,I-GENE-Y
agonist,5919,O
bezafibrate,5919,B-CHEMICAL
(,5919,O
Bzf,5919,B-CHEMICAL
;,5919,O
30,5919,O
μg/100,5919,O
g,5919,O
BW,5919,O
",",5919,O
oral,5919,O
),5919,O
and,5919,O
were,5919,O
found,5919,O
to,5919,O
improve,5919,O
in,5919,O
the,5919,O
Bzf,5919,B-CHEMICAL
co-treated,5919,O
condition,5919,O
.,5919,O
Ultrastructure,5920,O
of,5920,O
mitochondria,5920,O
was,5920,O
damaged,5920,O
in,5920,O
T3-treated,5920,O
rat,5920,O
heart,5920,O
",",5920,O
which,5920,O
was,5920,O
prevented,5920,O
by,5920,O
Bzf,5920,B-CHEMICAL
co-administration,5920,O
.,5920,O
Hyperthyroidism-induced,5921,O
oxidative,5921,O
stress,5921,O
",",5921,O
reduction,5921,O
in,5921,O
cytochrome,5921,B-GENE-N
c,5921,I-GENE-N
oxidase,5921,I-GENE-N
activity,5921,O
",",5921,O
and,5921,O
myocardial,5921,O
ATP,5921,B-CHEMICAL
concentration,5921,O
were,5921,O
also,5921,O
significantly,5921,O
checked,5921,O
by,5921,O
Bzf,5921,B-CHEMICAL
.,5921,O
Heart,5922,O
function,5922,O
studied,5922,O
at,5922,O
different,5922,O
time,5922,O
points,5922,O
during,5922,O
the,5922,O
course,5922,O
of,5922,O
T3,5922,O
treatment,5922,O
shows,5922,O
an,5922,O
initial,5922,O
improvement,5922,O
and,5922,O
then,5922,O
a,5922,O
gradual,5922,O
but,5922,O
progressive,5922,O
decline,5922,O
with,5922,O
time,5922,O
",",5922,O
which,5922,O
is,5922,O
prevented,5922,O
by,5922,O
Bzf,5922,B-CHEMICAL
co-treatment,5922,O
.,5922,O
In,5923,O
summary,5923,O
",",5923,O
the,5923,O
results,5923,O
demonstrate,5923,O
that,5923,O
hyperthyroidism,5923,O
inflicts,5923,O
structural,5923,O
and,5923,O
functional,5923,O
damage,5923,O
to,5923,O
mitochondria,5923,O
",",5923,O
leading,5923,O
to,5923,O
energy,5923,O
depletion,5923,O
and,5923,O
cardiac,5923,O
dysfunction,5923,O
.,5923,O
Endothelial,5924,O
cell,5924,O
response,5924,O
to,5924,O
(,5924,O
co,5924,O
),5924,O
polymer,5924,O
nanoparticles,5924,O
depending,5924,O
on,5924,O
the,5924,O
inflammatory,5924,O
environment,5924,O
and,5924,O
comonomer,5924,O
ratio,5924,O
.,5924,O
Endothelial,5925,O
cells,5925,O
lining,5925,O
the,5925,O
lumen,5925,O
of,5925,O
blood,5925,O
vessels,5925,O
serve,5925,O
as,5925,O
a,5925,O
physiological,5925,O
barrier,5925,O
controlling,5925,O
nanoparticle,5925,O
movement,5925,O
from,5925,O
the,5925,O
vasculature,5925,O
into,5925,O
the,5925,O
tissue,5925,O
.,5925,O
For,5926,O
exploring,5926,O
the,5926,O
effect,5926,O
of,5926,O
polymer,5926,O
hydrophilicity,5926,O
on,5926,O
nanoparticle,5926,O
interactions,5926,O
with,5926,O
human,5926,O
umbilical,5926,O
vein,5926,O
endothelial,5926,O
cells,5926,O
(,5926,O
HUVECs,5926,O
),5926,O
in,5926,O
vitro,5926,O
",",5926,O
a,5926,O
series,5926,O
of,5926,O
monomodal,5926,O
poly,5926,B-CHEMICAL
[,5926,I-CHEMICAL
acrylonitrile-co-,5926,I-CHEMICAL
(,5926,I-CHEMICAL
N-vinylpyrrolidone,5926,I-CHEMICAL
),5926,I-CHEMICAL
],5926,I-CHEMICAL
model,5926,O
nanoparticles,5926,O
with,5926,O
increasing,5926,O
hydrophilicity,5926,O
as,5926,O
related,5926,O
to,5926,O
their,5926,O
increasing,5926,O
content,5926,O
(,5926,O
0-30mol.,5926,O
%,5926,O
),5926,O
of,5926,O
N-vinylpyrrolidone,5926,B-CHEMICAL
(,5926,O
NVP,5926,B-CHEMICAL
),5926,O
were,5926,O
synthesized,5926,O
by,5926,O
miniemulsion,5926,O
polymerization,5926,O
.,5926,O
Nanoparticles,5927,O
with,5927,O
a,5927,O
low,5927,O
NVP,5927,B-CHEMICAL
content,5927,O
were,5927,O
rapidly,5927,O
endocytized,5927,O
into,5927,O
all,5927,O
cells,5927,O
independent,5927,O
from,5927,O
the,5927,O
particle,5927,O
dose,5927,O
with,5927,O
toxic,5927,O
effects,5927,O
only,5927,O
observed,5927,O
at,5927,O
high,5927,O
particle,5927,O
concentrations,5927,O
",",5927,O
while,5927,O
only,5927,O
10-30,5927,O
%,5927,O
of,5927,O
the,5927,O
cells,5927,O
incorporated,5927,O
particles,5927,O
with,5927,O
⩾20mol.,5927,O
%,5927,O
NVP,5927,B-CHEMICAL
.,5927,O
Since,5928,O
pathologies,5928,O
are,5928,O
often,5928,O
related,5928,O
to,5928,O
inflammation,5928,O
",",5928,O
an,5928,O
inflammatory,5928,O
HUVEC,5928,O
culture,5928,O
condition,5928,O
with,5928,O
IL-1β,5928,B-GENE-Y
stimulation,5928,O
has,5928,O
been,5928,O
introduced,5928,O
and,5928,O
suggested,5928,O
to,5928,O
be,5928,O
widely,5928,O
applied,5928,O
for,5928,O
studying,5928,O
nanocarriers,5928,O
",",5928,O
since,5928,O
cellular,5928,O
uptake,5928,O
in,5928,O
this,5928,O
assay,5928,O
was,5928,O
clearly,5928,O
increased,5928,O
for,5928,O
NVP,5928,B-CHEMICAL
contents,5928,O
⩾20mol.,5928,O
%,5928,O
.,5928,O
Importantly,5929,O
",",5929,O
the,5929,O
secretion,5929,O
of,5929,O
functional,5929,O
biological,5929,O
mediators,5929,O
by,5929,O
HUVEC,5929,O
was,5929,O
not,5929,O
relevantly,5929,O
influenced,5929,O
by,5929,O
the,5929,O
nanoparticles,5929,O
for,5929,O
both,5929,O
homeostatic,5929,O
and,5929,O
inflammatory,5929,O
conditions,5929,O
.,5929,O
These,5930,O
findings,5930,O
may,5930,O
motivate,5930,O
concepts,5930,O
for,5930,O
nanocarriers,5930,O
specifically,5930,O
targeted,5930,O
to,5930,O
pathologic,5930,O
regions,5930,O
.,5930,O
Additionally,5931,O
",",5931,O
rapidly,5931,O
endocytized,5931,O
RhodaminB,5931,B-CHEMICAL
loaded,5931,O
particles,5931,O
with,5931,O
low,5931,O
NVP,5931,B-CHEMICAL
content,5931,O
may,5931,O
be,5931,O
explored,5931,O
for,5931,O
cell,5931,O
labeling,5931,O
and,5931,O
tracking,5931,O
.,5931,O
Molecular,5932,O
mechanism,5932,O
regulating,5932,O
24-hour,5932,O
rhythm,5932,O
of,5932,O
dopamine,5932,B-CHEMICAL
d3,5932,I-GENE-Y
receptor,5932,I-GENE-Y
expression,5932,O
in,5932,O
mouse,5932,O
ventral,5932,O
striatum,5932,O
.,5932,O
The,5933,O
dopamine,5933,B-CHEMICAL
D3,5933,I-GENE-Y
receptor,5933,I-GENE-Y
(,5933,O
DRD3,5933,B-GENE-Y
),5933,O
in,5933,O
the,5933,O
ventral,5933,O
striatum,5933,O
is,5933,O
thought,5933,O
to,5933,O
influence,5933,O
motivation,5933,O
and,5933,O
motor,5933,O
functions,5933,O
.,5933,O
Although,5934,O
the,5934,O
expression,5934,O
of,5934,O
DRD3,5934,B-GENE-Y
in,5934,O
the,5934,O
ventral,5934,O
striatum,5934,O
has,5934,O
been,5934,O
shown,5934,O
to,5934,O
exhibit,5934,O
24-hour,5934,O
variations,5934,O
",",5934,O
the,5934,O
mechanisms,5934,O
underlying,5934,O
the,5934,O
variation,5934,O
remain,5934,O
obscure,5934,O
.,5934,O
Here,5935,O
",",5935,O
we,5935,O
demonstrated,5935,O
that,5935,O
molecular,5935,O
components,5935,O
of,5935,O
the,5935,O
circadian,5935,O
clock,5935,O
act,5935,O
as,5935,O
regulators,5935,O
that,5935,O
control,5935,O
the,5935,O
24-hour,5935,O
variation,5935,O
in,5935,O
the,5935,O
expression,5935,O
of,5935,O
DRD3,5935,B-GENE-Y
.,5935,O
The,5936,O
transcription,5936,O
of,5936,O
DRD3,5936,B-GENE-Y
was,5936,O
enhanced,5936,O
by,5936,O
the,5936,O
retinoic,5936,B-CHEMICAL
acid-related,5936,I-GENE-Y
orphan,5936,I-GENE-Y
receptor,5936,I-GENE-Y
α,5936,I-GENE-Y
(,5936,O
RORα,5936,B-GENE-Y
),5936,O
",",5936,O
and,5936,O
its,5936,O
activation,5936,O
was,5936,O
inhibited,5936,O
by,5936,O
the,5936,O
orphan,5936,B-GENE-N
receptor,5936,I-GENE-N
REV-ERBα,5936,B-GENE-Y
",",5936,O
an,5936,O
endogenous,5936,O
antagonist,5936,O
of,5936,O
RORα,5936,B-GENE-Y
.,5936,O
The,5937,O
serum,5937,O
or,5937,O
dexamethasone-induced,5937,B-CHEMICAL
oscillation,5937,O
in,5937,O
the,5937,O
expression,5937,O
of,5937,O
DRD3,5937,B-GENE-Y
in,5937,O
cells,5937,O
was,5937,O
abrogated,5937,O
by,5937,O
the,5937,O
downregulation,5937,O
or,5937,O
overexpression,5937,O
of,5937,O
REV-ERBα,5937,B-GENE-Y
",",5937,O
suggesting,5937,O
that,5937,O
REV-ERBα,5937,B-GENE-Y
functions,5937,O
as,5937,O
a,5937,O
regulator,5937,O
of,5937,O
DRD3,5937,B-GENE-Y
oscillations,5937,O
in,5937,O
the,5937,O
cellular,5937,O
autonomous,5937,O
clock,5937,O
.,5937,O
Chromatin,5938,O
immunoprecipitation,5938,O
assays,5938,O
of,5938,O
the,5938,O
DRD3,5938,B-GENE-N
promoter,5938,I-GENE-N
indicated,5938,O
that,5938,O
the,5938,O
binding,5938,O
of,5938,O
the,5938,O
REV-ERBα,5938,B-GENE-Y
protein,5938,O
to,5938,O
the,5938,O
DRD3,5938,B-GENE-N
promoter,5938,I-GENE-N
increased,5938,O
in,5938,O
the,5938,O
early,5938,O
dark,5938,O
phase,5938,O
.,5938,O
DRD3,5939,B-GENE-Y
protein,5939,O
expression,5939,O
varied,5939,O
with,5939,O
higher,5939,O
levels,5939,O
during,5939,O
the,5939,O
dark,5939,O
phase,5939,O
.,5939,O
Moreover,5940,O
",",5940,O
the,5940,O
effects,5940,O
of,5940,O
the,5940,O
DRD3,5940,B-GENE-Y
agonist,5940,O
7-hydroxy-N,5940,B-CHEMICAL
",",5940,I-CHEMICAL
N-dipropyl-2-aminotetralin,5940,I-CHEMICAL
(,5940,O
7-OH-DPAT,5940,B-CHEMICAL
),5940,O
-induced,5940,O
locomotor,5940,O
hypoactivity,5940,O
were,5940,O
significantly,5940,O
increased,5940,O
when,5940,O
DRD3,5940,B-GENE-Y
proteins,5940,O
were,5940,O
abundant,5940,O
.,5940,O
These,5941,O
results,5941,O
suggest,5941,O
that,5941,O
RORα,5941,B-GENE-Y
and,5941,O
REV-ERBα,5941,B-GENE-Y
consist,5941,O
of,5941,O
a,5941,O
reciprocating,5941,O
mechanism,5941,O
wherein,5941,O
RORα,5941,B-GENE-Y
upregulates,5941,O
the,5941,O
expression,5941,O
of,5941,O
DRD3,5941,B-GENE-Y
",",5941,O
whereas,5941,O
REV-ERBα,5941,B-GENE-Y
periodically,5941,O
suppresses,5941,O
the,5941,O
expression,5941,O
at,5941,O
the,5941,O
time,5941,O
of,5941,O
day,5941,O
when,5941,O
REV-ERBα,5941,B-GENE-Y
is,5941,O
abundant,5941,O
.,5941,O
Our,5942,O
present,5942,O
findings,5942,O
revealed,5942,O
that,5942,O
a,5942,O
molecular,5942,O
link,5942,O
between,5942,O
the,5942,O
circadian,5942,O
clock,5942,O
and,5942,O
the,5942,O
function,5942,O
of,5942,O
DRD3,5942,B-GENE-Y
in,5942,O
the,5942,O
ventral,5942,O
striatum,5942,O
acts,5942,O
as,5942,O
a,5942,O
modulator,5942,O
of,5942,O
the,5942,O
pharmacological,5942,O
actions,5942,O
of,5942,O
DRD3,5942,B-GENE-Y
agonists/antagonists,5942,O
.,5942,O
Studies,5943,O
on,5943,O
an,5943,O
(,5943,B-CHEMICAL
S,5943,I-CHEMICAL
),5943,I-CHEMICAL
-2-amino-3-,5943,I-CHEMICAL
(,5943,I-CHEMICAL
3-hydroxy-5-methyl-4-isoxazolyl,5943,I-CHEMICAL
),5943,I-CHEMICAL
propionic,5943,I-CHEMICAL
acid,5943,I-CHEMICAL
(,5943,B-GENE-N
AMPA,5943,I-GENE-N
),5943,I-GENE-N
receptor,5943,I-GENE-N
antagonist,5943,O
IKM-159,5943,B-CHEMICAL
:,5943,O
asymmetric,5943,O
synthesis,5943,O
",",5943,O
neuroactivity,5943,O
",",5943,O
and,5943,O
structural,5943,O
characterization,5943,O
.,5943,O
IKM-159,5944,B-CHEMICAL
was,5944,O
developed,5944,O
and,5944,O
identified,5944,O
as,5944,O
a,5944,O
member,5944,O
of,5944,O
a,5944,O
new,5944,O
class,5944,O
of,5944,O
heterotricyclic,5944,O
glutamate,5944,B-CHEMICAL
analogues,5944,O
that,5944,O
act,5944,O
as,5944,O
AMPA,5944,B-CHEMICAL
receptor-selective,5944,O
antagonists,5944,O
.,5944,O
However,5945,O
",",5945,O
it,5945,O
was,5945,O
not,5945,O
known,5945,O
which,5945,O
enantiomer,5945,O
of,5945,O
IKM-159,5945,B-CHEMICAL
was,5945,O
responsible,5945,O
for,5945,O
its,5945,O
pharmacological,5945,O
activities,5945,O
.,5945,O
Here,5946,O
",",5946,O
we,5946,O
report,5946,O
in,5946,O
vivo,5946,O
and,5946,O
in,5946,O
vitro,5946,O
neuronal,5946,O
activities,5946,O
of,5946,O
both,5946,O
enantiomers,5946,O
of,5946,O
IKM-159,5946,B-CHEMICAL
prepared,5946,O
by,5946,O
enantioselective,5946,O
asymmetric,5946,O
synthesis,5946,O
.,5946,O
By,5947,O
employment,5947,O
of,5947,O
(,5947,B-CHEMICAL
R,5947,I-CHEMICAL
),5947,I-CHEMICAL
-2-amino-2-,5947,I-CHEMICAL
(,5947,I-CHEMICAL
4-methoxyphenyl,5947,I-CHEMICAL
),5947,I-CHEMICAL
ethanol,5947,I-CHEMICAL
as,5947,O
a,5947,O
chiral,5947,O
auxiliary,5947,O
",",5947,O
(,5947,B-CHEMICAL
2R,5947,I-CHEMICAL
),5947,I-CHEMICAL
-IKM-159,5947,I-CHEMICAL
and,5947,O
the,5947,O
(,5947,O
2S,5947,O
),5947,O
-counterpart,5947,O
were,5947,O
successfully,5947,O
synthesized,5947,O
in,5947,O
0.70,5947,O
%,5947,O
and,5947,O
1.5,5947,O
%,5947,O
yields,5947,O
",",5947,O
respectively,5947,O
",",5947,O
over,5947,O
a,5947,O
total,5947,O
of,5947,O
18,5947,O
steps,5947,O
.,5947,O
Both,5948,O
behavioral,5948,O
and,5948,O
electrophysiological,5948,O
assays,5948,O
showed,5948,O
that,5948,O
the,5948,O
biological,5948,O
activity,5948,O
observed,5948,O
for,5948,O
the,5948,O
racemic,5948,O
mixture,5948,O
was,5948,O
reproduced,5948,O
only,5948,O
with,5948,O
(,5948,B-CHEMICAL
2R,5948,I-CHEMICAL
),5948,I-CHEMICAL
-IKM-159,5948,I-CHEMICAL
",",5948,O
whereas,5948,O
the,5948,O
(,5948,O
2S,5948,O
),5948,O
-counterpart,5948,O
was,5948,O
inactive,5948,O
in,5948,O
both,5948,O
assays,5948,O
.,5948,O
Racemic,5949,B-CHEMICAL
IKM-159,5949,I-CHEMICAL
was,5949,O
crystallized,5949,O
with,5949,O
the,5949,O
ligand-binding,5949,O
domain,5949,O
of,5949,O
GluA2,5949,B-GENE-Y
",",5949,O
and,5949,O
the,5949,O
structure,5949,O
revealed,5949,O
a,5949,O
complex,5949,O
containing,5949,O
(,5949,B-CHEMICAL
2R,5949,I-CHEMICAL
),5949,I-CHEMICAL
-IKM-159,5949,I-CHEMICAL
at,5949,O
the,5949,O
glutamate,5949,O
binding,5949,O
site,5949,O
.,5949,O
(,5950,B-CHEMICAL
2R,5950,I-CHEMICAL
),5950,I-CHEMICAL
-IKM-159,5950,I-CHEMICAL
locks,5950,O
the,5950,O
GluA2,5950,B-GENE-Y
in,5950,O
an,5950,O
open,5950,O
form,5950,O
",",5950,O
consistent,5950,O
with,5950,O
a,5950,O
pharmacological,5950,O
action,5950,O
as,5950,O
competitive,5950,O
antagonist,5950,O
of,5950,O
AMPA,5950,B-GENE-N
receptors,5950,I-GENE-N
.,5950,O
Binding,5951,O
of,5951,O
Diverse,5951,O
Environmental,5951,O
Chemicals,5951,O
with,5951,O
Human,5951,B-GENE-N
Cytochromes,5951,I-GENE-N
P450,5951,I-GENE-N
2A13,5951,I-GENE-N
",",5951,I-GENE-N
2A6,5951,I-GENE-N
",",5951,I-GENE-N
and,5951,I-GENE-N
1B1,5951,I-GENE-N
and,5951,O
Enzyme,5951,O
Inhibition,5951,O
.,5951,O
A,5952,O
total,5952,O
of,5952,O
68,5952,O
chemicals,5952,O
including,5952,O
derivatives,5952,O
of,5952,O
naphthalene,5952,B-CHEMICAL
",",5952,O
phenanthrene,5952,B-CHEMICAL
",",5952,O
fluoranthene,5952,B-CHEMICAL
",",5952,O
pyrene,5952,B-CHEMICAL
",",5952,O
biphenyl,5952,B-CHEMICAL
",",5952,O
and,5952,O
flavone,5952,B-CHEMICAL
were,5952,O
examined,5952,O
for,5952,O
their,5952,O
abilities,5952,O
to,5952,O
interact,5952,O
with,5952,O
human,5952,B-GENE-N
P450s,5952,I-GENE-N
2A13,5952,I-GENE-N
and,5952,I-GENE-N
2A6,5952,I-GENE-N
.,5952,O
Fifty-one,5953,O
of,5953,O
these,5953,O
68,5953,O
chemicals,5953,O
induced,5953,O
stronger,5953,O
Type,5953,O
I,5953,O
binding,5953,O
spectra,5953,O
(,5953,O
iron,5953,B-CHEMICAL
low-,5953,O
to,5953,O
high-spin,5953,O
state,5953,O
shift,5953,O
),5953,O
with,5953,O
P450,5953,B-GENE-Y
2A13,5953,I-GENE-Y
than,5953,O
those,5953,O
seen,5953,O
with,5953,O
P450,5953,B-GENE-N
2A6,5953,I-GENE-N
",",5953,O
i.e.,5953,O
",",5953,O
the,5953,O
spectral,5953,O
binding,5953,O
intensities,5953,O
(,5953,O
ΔAmax/Ks,5953,O
ratio,5953,O
),5953,O
determined,5953,O
with,5953,O
these,5953,O
chemicals,5953,O
were,5953,O
always,5953,O
higher,5953,O
for,5953,O
P450,5953,B-GENE-Y
2A13,5953,I-GENE-Y
.,5953,O
In,5954,O
addition,5954,O
",",5954,O
benzo,5954,B-CHEMICAL
[,5954,I-CHEMICAL
c,5954,I-CHEMICAL
],5954,I-CHEMICAL
phenanthrene,5954,I-CHEMICAL
",",5954,O
fluoranthene,5954,B-CHEMICAL
",",5954,O
"2,3-dihydroxy-2,3-dihydrofluoranthene",5954,B-CHEMICAL
",",5954,O
pyrene,5954,B-CHEMICAL
",",5954,O
1-hydroxypyrene,5954,B-CHEMICAL
",",5954,O
1-nitropyrene,5954,B-CHEMICAL
",",5954,O
1-acetylpyrene,5954,B-CHEMICAL
",",5954,O
2-acetylpyrene,5954,B-CHEMICAL
",",5954,O
"2,5,2',5'-tetrachlorobiphenyl",5954,B-CHEMICAL
",",5954,O
7-hydroxyflavone,5954,B-CHEMICAL
",",5954,O
chrysin,5954,B-CHEMICAL
",",5954,O
and,5954,O
galangin,5954,B-CHEMICAL
were,5954,O
found,5954,O
to,5954,O
induce,5954,O
a,5954,O
Type,5954,O
I,5954,O
spectral,5954,O
change,5954,O
only,5954,O
with,5954,O
P450,5954,B-GENE-Y
2A13,5954,I-GENE-Y
.,5954,O
Coumarin,5955,B-CHEMICAL
7-hydroxylation,5955,O
",",5955,O
catalyzed,5955,O
by,5955,O
P450,5955,B-GENE-Y
2A13,5955,I-GENE-Y
",",5955,O
was,5955,O
strongly,5955,O
inhibited,5955,O
by,5955,O
"2'-methoxy-5,7-dihydroxyflavone",5955,B-CHEMICAL
",",5955,O
2-ethynylnaphthalene,5955,B-CHEMICAL
",",5955,O
2'-methoxyflavone,5955,B-CHEMICAL
",",5955,O
2-naphththalene,5955,B-CHEMICAL
propargyl,5955,I-CHEMICAL
ether,5955,I-CHEMICAL
",",5955,O
acenaphthene,5955,B-CHEMICAL
",",5955,O
acenaphthylene,5955,B-CHEMICAL
",",5955,O
naphthalene,5955,B-CHEMICAL
",",5955,O
1-acetylpyrene,5955,B-CHEMICAL
",",5955,O
flavanone,5955,B-CHEMICAL
",",5955,O
chrysin,5955,B-CHEMICAL
",",5955,O
3-ethynylphenanthrene,5955,B-CHEMICAL
",",5955,O
flavone,5955,B-CHEMICAL
",",5955,O
and,5955,O
7-hydroxyflavone,5955,B-CHEMICAL
;,5955,O
these,5955,O
chemicals,5955,O
induced,5955,O
Type,5955,O
I,5955,O
spectral,5955,O
changes,5955,O
with,5955,O
low,5955,O
Ks,5955,O
values,5955,O
.,5955,O
On,5956,O
the,5956,O
basis,5956,O
of,5956,O
the,5956,O
intensities,5956,O
of,5956,O
the,5956,O
spectral,5956,O
changes,5956,O
and,5956,O
inhibition,5956,O
of,5956,O
P450,5956,B-GENE-Y
2A13,5956,I-GENE-Y
",",5956,O
we,5956,O
classified,5956,O
the,5956,O
68,5956,O
chemicals,5956,O
into,5956,O
eight,5956,O
groups,5956,O
based,5956,O
on,5956,O
the,5956,O
order,5956,O
of,5956,O
affinities,5956,O
for,5956,O
these,5956,O
chemicals,5956,O
and,5956,O
inhibition,5956,O
of,5956,O
P450,5956,B-GENE-Y
2A13,5956,I-GENE-Y
.,5956,O
The,5957,O
metabolism,5957,O
of,5957,O
chemicals,5957,O
by,5957,O
P450,5957,B-GENE-Y
2A13,5957,I-GENE-Y
during,5957,O
the,5957,O
assays,5957,O
explained,5957,O
why,5957,O
some,5957,O
of,5957,O
the,5957,O
chemicals,5957,O
that,5957,O
bound,5957,O
well,5957,O
were,5957,O
poor,5957,O
inhibitors,5957,O
of,5957,O
P450,5957,B-GENE-Y
2A13,5957,I-GENE-Y
.,5957,O
Finally,5958,O
",",5958,O
we,5958,O
compared,5958,O
the,5958,O
68,5958,O
chemicals,5958,O
for,5958,O
their,5958,O
abilities,5958,O
to,5958,O
induce,5958,O
Type,5958,O
I,5958,O
spectral,5958,O
changes,5958,O
of,5958,O
P450,5958,B-GENE-Y
2A13,5958,I-GENE-Y
with,5958,O
the,5958,O
Reverse,5958,O
Type,5958,O
I,5958,O
binding,5958,O
spectra,5958,O
observed,5958,O
with,5958,O
P450,5958,B-GENE-Y
1B1,5958,I-GENE-Y
:,5958,O
45,5958,O
chemicals,5958,O
interacted,5958,O
with,5958,O
both,5958,O
P450s,5958,B-GENE-N
2A13,5958,I-GENE-N
and,5958,I-GENE-N
1B1,5958,I-GENE-N
",",5958,O
indicating,5958,O
that,5958,O
the,5958,O
two,5958,O
enzymes,5958,O
have,5958,O
some,5958,O
similarty,5958,O
of,5958,O
structural,5958,O
features,5958,O
regarding,5958,O
these,5958,O
chemicals,5958,O
.,5958,O
Molecular,5959,O
docking,5959,O
analyses,5959,O
suggest,5959,O
similarities,5959,O
at,5959,O
the,5959,O
active,5959,O
sites,5959,O
of,5959,O
these,5959,O
P450,5959,B-GENE-N
enzymes,5959,I-GENE-N
.,5959,O
These,5960,O
results,5960,O
indicate,5960,O
that,5960,O
P450,5960,B-GENE-Y
2A13,5960,I-GENE-Y
",",5960,O
as,5960,O
well,5960,O
as,5960,O
Family,5960,O
1,5960,O
P450,5960,B-GENE-N
enzymes,5960,I-GENE-N
",",5960,O
is,5960,O
able,5960,O
to,5960,O
catalyze,5960,O
many,5960,O
detoxication,5960,O
and,5960,O
activation,5960,O
reactions,5960,O
with,5960,O
chemicals,5960,O
of,5960,O
environmental,5960,O
interest,5960,O
.,5960,O
Discovery,5961,O
of,5961,O
a,5961,O
Novel,5961,O
Selective,5961,O
PPARγ,5961,B-GENE-Y
Ligand,5961,O
with,5961,O
Partial,5961,O
Agonist,5961,O
Binding,5961,O
Properties,5961,O
by,5961,O
Integrated,5961,O
in,5961,O
Silico/in,5961,O
Vitro,5961,O
Work,5961,O
Flow,5961,O
.,5961,O
Full,5962,O
agonists,5962,O
to,5962,O
the,5962,O
peroxisome,5962,B-GENE-Y
proliferator-activated,5962,I-GENE-Y
receptor,5962,I-GENE-Y
(,5962,I-GENE-Y
PPAR,5962,I-GENE-Y
),5962,I-GENE-Y
γ,5962,I-GENE-Y
",",5962,O
such,5962,O
as,5962,O
Rosiglitazone,5962,B-CHEMICAL
",",5962,O
have,5962,O
been,5962,O
associated,5962,O
with,5962,O
a,5962,O
series,5962,O
of,5962,O
undesired,5962,O
side,5962,O
effects,5962,O
",",5962,O
such,5962,O
as,5962,O
weight,5962,O
gain,5962,O
",",5962,O
fluid,5962,O
retention,5962,O
",",5962,O
cardiac,5962,O
hypertrophy,5962,O
",",5962,O
and,5962,O
hepatotoxicity,5962,O
.,5962,O
Nevertheless,5963,O
",",5963,O
PPARγ,5963,B-GENE-Y
is,5963,O
involved,5963,O
in,5963,O
the,5963,O
expression,5963,O
of,5963,O
genes,5963,O
that,5963,O
control,5963,O
glucose,5963,B-CHEMICAL
and,5963,O
lipid,5963,O
metabolism,5963,O
and,5963,O
is,5963,O
an,5963,O
important,5963,O
target,5963,O
for,5963,O
drugs,5963,O
against,5963,O
type,5963,O
2,5963,O
diabetes,5963,O
",",5963,O
dyslipidemia,5963,O
",",5963,O
atherosclerosis,5963,O
",",5963,O
and,5963,O
cardiovascular,5963,O
disease,5963,O
.,5963,O
In,5964,O
an,5964,O
effort,5964,O
to,5964,O
identify,5964,O
novel,5964,O
PPARγ,5964,B-GENE-Y
ligands,5964,O
with,5964,O
an,5964,O
improved,5964,O
pharmacological,5964,O
profile,5964,O
",",5964,O
emphasis,5964,O
has,5964,O
shifted,5964,O
to,5964,O
selective,5964,O
ligands,5964,O
with,5964,O
partial,5964,O
agonist,5964,O
binding,5964,O
properties,5964,O
.,5964,O
Toward,5965,O
this,5965,O
end,5965,O
we,5965,O
applied,5965,O
an,5965,O
integrated,5965,O
in,5965,O
silico/in,5965,O
vitro,5965,O
workflow,5965,O
",",5965,O
based,5965,O
on,5965,O
pharmacophore-,5965,O
and,5965,O
structure-based,5965,O
virtual,5965,O
screening,5965,O
of,5965,O
the,5965,O
ZINC,5965,O
library,5965,O
",",5965,O
coupled,5965,O
with,5965,O
competitive,5965,O
binding,5965,O
and,5965,O
transactivation,5965,O
assays,5965,O
",",5965,O
and,5965,O
adipocyte,5965,O
differentiation,5965,O
and,5965,O
gene,5965,O
expression,5965,O
studies,5965,O
.,5965,O
Hit,5966,O
compound,5966,O
9,5966,O
was,5966,O
identified,5966,O
as,5966,O
the,5966,O
most,5966,O
potent,5966,O
ligand,5966,O
(,5966,O
IC50,5966,O
=,5966,O
0.3,5966,O
μM,5966,O
),5966,O
and,5966,O
a,5966,O
relatively,5966,O
poor,5966,O
inducer,5966,O
of,5966,O
adipocyte,5966,O
differentiation,5966,O
.,5966,O
The,5967,O
binding,5967,O
mode,5967,O
of,5967,O
compound,5967,O
9,5967,O
was,5967,O
confirmed,5967,O
by,5967,O
molecular,5967,O
dynamics,5967,O
simulation,5967,O
",",5967,O
and,5967,O
the,5967,O
calculated,5967,O
free,5967,O
energy,5967,O
of,5967,O
binding,5967,O
was,5967,O
-8.4,5967,O
kcal/mol,5967,O
.,5967,O
A,5968,O
novel,5968,O
functional,5968,O
group,5968,O
",",5968,O
the,5968,O
carbonitrile,5968,B-CHEMICAL
group,5968,O
",",5968,O
was,5968,O
identified,5968,O
to,5968,O
be,5968,O
a,5968,O
key,5968,O
substituent,5968,O
in,5968,O
the,5968,O
ligand-protein,5968,O
interactions,5968,O
.,5968,O
Further,5969,O
studies,5969,O
on,5969,O
the,5969,O
transcriptional,5969,O
regulation,5969,O
properties,5969,O
of,5969,O
compound,5969,O
9,5969,O
revealed,5969,O
a,5969,O
gene,5969,O
regulatory,5969,O
profile,5969,O
that,5969,O
was,5969,O
to,5969,O
a,5969,O
large,5969,O
extent,5969,O
unique,5969,O
",",5969,O
however,5969,O
functionally,5969,O
closer,5969,O
to,5969,O
that,5969,O
of,5969,O
a,5969,O
partial,5969,O
agonist,5969,O
.,5969,O
Structural,5970,O
Characterization,5970,O
of,5970,O
an,5970,O
LPA1,5970,B-GENE-Y
Second,5970,B-GENE-N
Extracellular,5970,I-GENE-N
Loop,5970,I-GENE-N
Mimetic,5970,O
with,5970,O
a,5970,O
Self-Assembling,5970,O
Coiled-Coil,5970,B-GENE-N
Folding,5970,O
Constraint,5970,O
.,5970,O
G,5971,B-GENE-N
protein-coupled,5971,I-GENE-N
receptor,5971,I-GENE-N
(,5971,O
GPCR,5971,B-GENE-N
),5971,O
structures,5971,O
are,5971,O
of,5971,O
interest,5971,O
as,5971,O
a,5971,O
means,5971,O
to,5971,O
understand,5971,O
biological,5971,O
signal,5971,O
transduction,5971,O
and,5971,O
as,5971,O
tools,5971,O
for,5971,O
therapeutic,5971,O
discovery,5971,O
.,5971,O
The,5972,O
growing,5972,O
number,5972,O
of,5972,O
GPCR,5972,B-GENE-N
crystal,5972,O
structures,5972,O
demonstrates,5972,O
that,5972,O
the,5972,O
extracellular,5972,B-GENE-N
loops,5972,I-GENE-N
(,5972,O
EL,5972,B-GENE-N
),5972,O
connecting,5972,O
the,5972,O
membrane-spanning,5972,B-GENE-N
helices,5972,I-GENE-N
show,5972,O
tremendous,5972,O
structural,5972,O
variability,5972,O
relative,5972,O
to,5972,O
the,5972,O
more,5972,O
structurally-conserved,5972,O
seven,5972,O
transmembrane,5972,O
α-helical,5972,B-GENE-N
domains,5972,I-GENE-N
.,5972,O
The,5973,O
EL,5973,B-GENE-N
of,5973,O
the,5973,O
LPA,5973,B-CHEMICAL
(,5973,I-GENE-Y
1,5973,I-GENE-Y
),5973,I-GENE-Y
receptor,5973,O
have,5973,O
not,5973,O
yet,5973,O
been,5973,O
conclusively,5973,O
resolved,5973,O
",",5973,O
and,5973,O
bear,5973,O
limited,5973,O
sequence,5973,O
identity,5973,O
to,5973,O
known,5973,O
structures,5973,O
.,5973,O
This,5974,O
study,5974,O
involved,5974,O
development,5974,O
of,5974,O
a,5974,O
peptide,5974,O
to,5974,O
characterize,5974,O
the,5974,O
intrinsic,5974,O
structure,5974,O
of,5974,O
the,5974,O
LPA,5974,B-CHEMICAL
(,5974,I-GENE-Y
1,5974,I-GENE-Y
),5974,I-GENE-Y
GPCR,5974,B-GENE-N
second,5974,O
EL,5974,B-GENE-N
.,5974,O
The,5975,O
loop,5975,O
was,5975,O
embedded,5975,O
between,5975,O
two,5975,O
helices,5975,O
that,5975,O
assemble,5975,O
into,5975,O
a,5975,O
coiled-coil,5975,B-GENE-N
",",5975,O
which,5975,O
served,5975,O
as,5975,O
a,5975,O
receptor-mimetic,5975,O
folding,5975,O
constraint,5975,O
(,5975,O
LPA,5975,B-CHEMICAL
(,5975,I-GENE-Y
1,5975,I-GENE-Y
),5975,I-GENE-Y
-CC-EL2,5975,O
peptide,5975,O
),5975,O
.,5975,O
The,5976,O
ensemble,5976,O
of,5976,O
structures,5976,O
from,5976,O
multi-dimensional,5976,O
NMR,5976,O
experiments,5976,O
demonstrated,5976,O
that,5976,O
a,5976,O
robust,5976,O
coiled-coil,5976,B-GENE-N
formed,5976,O
without,5976,O
noticeable,5976,O
deformation,5976,O
due,5976,O
to,5976,O
the,5976,O
EL2,5976,B-GENE-N
sequence,5976,O
.,5976,O
In,5977,O
contrast,5977,O
",",5977,O
the,5977,O
EL2,5977,B-GENE-N
sequence,5977,O
showed,5977,O
well-defined,5977,O
structure,5977,O
only,5977,O
near,5977,O
its,5977,O
C-terminal,5977,B-CHEMICAL
residues,5977,O
.,5977,O
The,5978,O
NMR,5978,O
ensemble,5978,O
was,5978,O
combined,5978,O
with,5978,O
a,5978,O
computational,5978,O
model,5978,O
of,5978,O
the,5978,O
LPA,5978,B-GENE-Y
(,5978,I-GENE-Y
1,5978,I-GENE-Y
),5978,I-GENE-Y
receptor,5978,O
that,5978,O
had,5978,O
previously,5978,O
been,5978,O
validated,5978,O
.,5978,O
The,5979,O
resulting,5979,O
hybrid,5979,O
models,5979,O
were,5979,O
evaluated,5979,O
using,5979,O
docking,5979,O
.,5979,O
Nine,5980,O
different,5980,O
hybrid,5980,O
models,5980,O
interacted,5980,O
with,5980,O
LPA,5980,B-CHEMICAL
18:1,5980,O
as,5980,O
expected,5980,O
",",5980,O
based,5980,O
on,5980,O
prior,5980,O
mutagenesis,5980,O
studies,5980,O
",",5980,O
and,5980,O
one,5980,O
was,5980,O
additionally,5980,O
consistent,5980,O
with,5980,O
antagonist,5980,O
affinity,5980,O
trends,5980,O
.,5980,O
The,5981,O
(,5981,B-CHEMICAL
R,5981,I-CHEMICAL
),5981,I-CHEMICAL
-omeprazole,5981,I-CHEMICAL
hydroxylation,5981,O
index,5981,O
reflects,5981,O
CYP2C19,5981,B-GENE-Y
activity,5981,O
in,5981,O
healthy,5981,O
Japanese,5981,O
volunteers,5981,O
.,5981,O
PURPOSE,5982,O
:,5982,O
Omeprazole,5982,B-CHEMICAL
has,5982,O
(,5982,O
R,5982,O
),5982,O
-,5982,O
and,5982,O
(,5982,O
S,5982,O
),5982,O
-enantiomers,5982,O
",",5982,O
which,5982,O
exhibit,5982,O
different,5982,O
pharmacokinetics,5982,O
(,5982,O
PK,5982,O
),5982,O
among,5982,O
patients,5982,O
with,5982,O
cytochrome,5982,B-GENE-Y
P450,5982,I-GENE-Y
(,5982,I-GENE-Y
CYP,5982,I-GENE-Y
),5982,I-GENE-Y
2C19,5982,I-GENE-Y
genotype,5982,O
groups,5982,O
.,5982,O
The,5983,O
aim,5983,O
of,5983,O
this,5983,O
study,5983,O
was,5983,O
to,5983,O
investigate,5983,O
whether,5983,O
the,5983,O
1-point,5983,O
",",5983,O
4-h,5983,O
postdose,5983,O
(,5983,B-CHEMICAL
R,5983,I-CHEMICAL
),5983,I-CHEMICAL
-omeprazole,5983,I-CHEMICAL
hydroxylation,5983,O
index,5983,O
(,5983,O
HI,5983,O
),5983,O
of,5983,O
racemic,5983,B-CHEMICAL
omeprazole,5983,I-CHEMICAL
reflects,5983,O
the,5983,O
three,5983,O
CYP2C19,5983,B-GENE-Y
genotype,5983,O
groups,5983,O
in,5983,O
Japanese,5983,O
individuals,5983,O
.,5983,O
METHODS,5984,O
:,5984,O
Ninety,5984,O
healthy,5984,O
Japanese,5984,O
individuals,5984,O
were,5984,O
enrolled,5984,O
and,5984,O
classified,5984,O
into,5984,O
the,5984,O
three,5984,O
different,5984,O
CYP2C19,5984,B-GENE-Y
genotype,5984,O
groups,5984,O
:,5984,O
homozygous,5984,O
extensive,5984,O
metabolizers,5984,O
(,5984,O
hmEMs,5984,O
;,5984,O
n,5984,O
=,5984,O
34,5984,O
),5984,O
",",5984,O
heterozygous,5984,O
EMs,5984,O
(,5984,O
htEMs,5984,O
;,5984,O
n,5984,O
=,5984,O
44,5984,O
),5984,O
",",5984,O
and,5984,O
poor,5984,O
metabolizers,5984,O
(,5984,O
PMs,5984,O
;,5984,O
n,5984,O
=,5984,O
12,5984,O
),5984,O
.,5984,O
Blood,5985,O
samples,5985,O
were,5985,O
drawn,5985,O
4,5985,O
h,5985,O
after,5985,O
the,5985,O
intake,5985,O
of,5985,O
an,5985,O
oral,5985,O
dose,5985,O
of,5985,O
omeprazole,5985,B-CHEMICAL
40,5985,O
mg,5985,O
",",5985,O
and,5985,O
plasma,5985,O
levels,5985,O
of,5985,O
omeprazole,5985,B-CHEMICAL
and,5985,O
its,5985,O
metabolites,5985,O
were,5985,O
analyzed,5985,O
by,5985,O
high-performance,5985,O
liquid,5985,O
chromatography,5985,O
(,5985,O
HPLC,5985,O
),5985,O
using,5985,O
a,5985,O
chiral,5985,O
column,5985,O
.,5985,O
RESULTS,5986,O
:,5986,O
Mean,5986,O
plasma,5986,O
concentrations,5986,O
of,5986,O
(,5986,B-CHEMICAL
R,5986,I-CHEMICAL
),5986,I-CHEMICAL
-,5986,I-CHEMICAL
and,5986,I-CHEMICAL
(,5986,I-CHEMICAL
S,5986,I-CHEMICAL
),5986,I-CHEMICAL
-omeprazole,5986,I-CHEMICAL
in,5986,O
PMs,5986,O
were,5986,O
significantly,5986,O
higher,5986,O
than,5986,O
those,5986,O
in,5986,O
hmEMs,5986,O
and,5986,O
htEMs,5986,O
",",5986,O
and,5986,O
similar,5986,O
results,5986,O
were,5986,O
obtained,5986,O
in,5986,O
the,5986,O
case,5986,O
of,5986,O
omeprazole,5986,B-CHEMICAL
sulfone,5986,I-CHEMICAL
.,5986,O
Additionally,5987,O
",",5987,O
there,5987,O
was,5987,O
a,5987,O
significant,5987,O
difference,5987,O
in,5987,O
plasma,5987,O
concentrations,5987,O
of,5987,O
(,5987,B-CHEMICAL
R,5987,I-CHEMICAL
),5987,I-CHEMICAL
-5-hydroxyomeprazole,5987,I-CHEMICAL
among,5987,O
CYP2C19,5987,B-GENE-Y
genotype,5987,O
groups,5987,O
",",5987,O
whereas,5987,O
no,5987,O
significant,5987,O
differences,5987,O
were,5987,O
observed,5987,O
in,5987,O
that,5987,O
of,5987,O
(,5987,B-CHEMICAL
S,5987,I-CHEMICAL
),5987,I-CHEMICAL
-5-hydroxyomeprazole,5987,I-CHEMICAL
.,5987,O
Similarly,5988,O
",",5988,O
(,5988,B-CHEMICAL
R,5988,I-CHEMICAL
),5988,I-CHEMICAL
-omeprazole,5988,I-CHEMICAL
HI,5988,O
in,5988,O
hmEMs,5988,O
",",5988,O
htEMs,5988,O
",",5988,O
and,5988,O
PMs,5988,O
were,5988,O
5.6,5988,O
",",5988,O
3.1,5988,O
",",5988,O
and,5988,O
0.3,5988,O
",",5988,O
respectively,5988,O
",",5988,O
which,5988,O
were,5988,O
significantly,5988,O
different,5988,O
",",5988,O
but,5988,O
no,5988,O
significant,5988,O
difference,5988,O
was,5988,O
present,5988,O
in,5988,O
the,5988,O
(,5988,B-CHEMICAL
S,5988,I-CHEMICAL
),5988,I-CHEMICAL
-omeprazole,5988,I-CHEMICAL
HI,5988,O
.,5988,O
CONCLUSION,5989,O
:,5989,O
Our,5989,O
findings,5989,O
demonstrate,5989,O
that,5989,O
(,5989,B-CHEMICAL
R,5989,I-CHEMICAL
),5989,I-CHEMICAL
-omeprazole,5989,I-CHEMICAL
HI,5989,O
correlated,5989,O
better,5989,O
with,5989,O
CYP2C19,5989,B-GENE-Y
genotype,5989,O
groups,5989,O
than,5989,O
racemic-omeprazole,5989,B-CHEMICAL
HI,5989,O
",",5989,O
and,5989,O
these,5989,O
results,5989,O
may,5989,O
be,5989,O
useful,5989,O
for,5989,O
classification,5989,O
among,5989,O
patients,5989,O
in,5989,O
CYP2C19,5989,B-GENE-Y
genotype,5989,O
groups,5989,O
prior,5989,O
to,5989,O
omeprazole,5989,O
treatment,5989,O
.,5989,O
Induction,5990,O
of,5990,O
xenobiotic,5990,B-GENE-N
receptors,5990,I-GENE-N
",",5990,O
transporters,5990,O
",",5990,O
and,5990,O
drug,5990,O
metabolizing,5990,O
enzymes,5990,O
by,5990,O
oxycodone,5990,B-CHEMICAL
.,5990,O
Perturbations,5991,O
of,5991,O
the,5991,O
expression,5991,O
of,5991,O
transporters,5991,O
and,5991,O
drug-metabolizing,5991,O
enzymes,5991,O
(,5991,O
DMEs,5991,O
),5991,O
by,5991,O
opioids,5991,O
can,5991,O
be,5991,O
the,5991,O
locus,5991,O
of,5991,O
deleterious,5991,O
drug-drug,5991,O
interactions,5991,O
(,5991,O
DDIs,5991,O
),5991,O
.,5991,O
Many,5992,O
transporters,5992,O
and,5992,O
DMEs,5992,O
are,5992,O
regulated,5992,O
by,5992,O
xenobiotic,5992,B-GENE-N
receptors,5992,I-GENE-N
[,5992,O
XRs,5992,B-GENE-N
;,5992,O
e.g.,5992,O
",",5992,O
pregnane,5992,B-GENE-Y
X,5992,I-GENE-Y
receptor,5992,I-GENE-Y
(,5992,O
PXR,5992,B-GENE-Y
),5992,O
",",5992,O
constitutive,5992,B-GENE-Y
androstane,5992,B-CHEMICAL
receptor,5992,I-GENE-Y
(,5992,O
CAR,5992,B-GENE-Y
),5992,O
",",5992,O
and,5992,O
Aryl,5992,B-CHEMICAL
hydrocarbon,5992,I-CHEMICAL
receptor,5992,I-GENE-Y
(,5992,O
AhR,5992,B-GENE-Y
),5992,O
],5992,O
;,5992,O
however,5992,O
",",5992,O
there,5992,O
is,5992,O
a,5992,O
paucity,5992,O
of,5992,O
information,5992,O
regarding,5992,O
the,5992,O
influence,5992,O
of,5992,O
opioids,5992,O
on,5992,O
XRs,5992,B-GENE-N
.,5992,O
The,5993,O
objective,5993,O
of,5993,O
this,5993,O
study,5993,O
was,5993,O
to,5993,O
determine,5993,O
the,5993,O
influence,5993,O
of,5993,O
oxycodone,5993,B-CHEMICAL
administration,5993,O
(,5993,O
15,5993,O
mg/kg,5993,O
intraperitoneally,5993,O
twice,5993,O
daily,5993,O
for,5993,O
8,5993,O
days,5993,O
),5993,O
on,5993,O
liver,5993,O
expression,5993,O
of,5993,O
XRs,5993,B-GENE-N
",",5993,O
transporters,5993,O
",",5993,O
and,5993,O
DMEs,5993,O
in,5993,O
rats,5993,O
.,5993,O
Microarray,5994,O
",",5994,O
quantitative,5994,O
real-time,5994,O
polymerase,5994,O
chain,5994,O
reaction,5994,O
and,5994,O
immunoblotting,5994,O
analyses,5994,O
were,5994,O
used,5994,O
to,5994,O
identify,5994,O
significantly,5994,O
regulated,5994,O
genes,5994,O
.,5994,O
Three,5995,O
XRs,5995,B-GENE-N
(,5995,O
e.g.,5995,O
",",5995,O
PXR,5995,B-GENE-Y
",",5995,O
CAR,5995,B-GENE-Y
",",5995,O
and,5995,O
AhR,5995,B-GENE-Y
),5995,O
",",5995,O
27,5995,O
transporters,5995,O
(,5995,O
e.g.,5995,O
",",5995,O
ABCB1,5995,B-GENE-Y
and,5995,O
SLC22A8,5995,B-GENE-Y
),5995,O
",",5995,O
and,5995,O
19,5995,O
DMEs,5995,O
(,5995,O
e.g.,5995,O
",",5995,O
CYP2B2,5995,B-GENE-Y
and,5995,O
CYP3A1,5995,B-GENE-Y
),5995,O
were,5995,O
regulated,5995,O
(,5995,O
P,5995,O
<,5995,O
0.05,5995,O
),5995,O
with,5995,O
fold,5995,O
changes,5995,O
ranging,5995,O
from,5995,O
-46.3,5995,O
to,5995,O
17.1,5995,O
.,5995,O
Using,5996,O
MetaCore,5996,O
(,5996,O
computational,5996,O
platform,5996,O
),5996,O
",",5996,O
we,5996,O
identified,5996,O
a,5996,O
unique,5996,O
gene-network,5996,O
of,5996,O
transporters,5996,O
and,5996,O
DMEs,5996,O
assembled,5996,O
around,5996,O
PXR,5996,B-GENE-Y
",",5996,O
CAR,5996,B-GENE-Y
",",5996,O
and,5996,O
AhR,5996,B-GENE-Y
.,5996,O
Therefore,5997,O
",",5997,O
a,5997,O
series,5997,O
of,5997,O
transactivation/translocation,5997,O
assays,5997,O
were,5997,O
conducted,5997,O
to,5997,O
determine,5997,O
whether,5997,O
the,5997,O
observed,5997,O
changes,5997,O
of,5997,O
transporters/DMEs,5997,O
are,5997,O
mediated,5997,O
by,5997,O
direct,5997,O
activation,5997,O
of,5997,O
PXR,5997,B-GENE-Y
",",5997,O
CAR,5997,B-GENE-Y
",",5997,O
or,5997,O
AhR,5997,B-GENE-Y
by,5997,O
oxycodone,5997,B-CHEMICAL
or,5997,O
its,5997,O
major,5997,O
metabolites,5997,O
(,5997,O
noroxycodone,5997,B-CHEMICAL
and,5997,O
oxymorphone,5997,B-CHEMICAL
),5997,O
.,5997,O
Neither,5998,O
oxycodone,5998,B-CHEMICAL
nor,5998,O
its,5998,O
metabolites,5998,O
activated,5998,O
PXR,5998,B-GENE-Y
",",5998,O
CAR,5998,B-GENE-Y
",",5998,O
or,5998,O
AhR,5998,B-GENE-Y
.,5998,O
Taken,5999,O
together,5999,O
",",5999,O
these,5999,O
findings,5999,O
identify,5999,O
a,5999,O
signature,5999,O
hepatic,5999,O
gene-network,5999,O
associated,5999,O
with,5999,O
repeated,5999,O
oxycodone,5999,B-CHEMICAL
administration,5999,O
in,5999,O
rats,5999,O
and,5999,O
demonstrate,5999,O
that,5999,O
oxycodone,5999,B-CHEMICAL
alters,5999,O
the,5999,O
expression,5999,O
of,5999,O
many,5999,O
transporters,5999,O
and,5999,O
DMEs,5999,O
(,5999,O
without,5999,O
direct,5999,O
activation,5999,O
of,5999,O
PXR,5999,B-GENE-Y
",",5999,O
CAR,5999,B-GENE-Y
",",5999,O
and,5999,O
AhR,5999,B-GENE-Y
),5999,O
",",5999,O
which,5999,O
could,5999,O
lead,5999,O
to,5999,O
undesirable,5999,O
DDIs,5999,O
after,5999,O
coadministration,5999,O
of,5999,O
substrates,5999,O
of,5999,O
these,5999,O
transporters/DMEs,5999,O
with,5999,O
oxycodone,5999,B-CHEMICAL
.,5999,O
Strain-dependent,6000,O
dysregulation,6000,O
of,6000,O
one-carbon,6000,O
metabolism,6000,O
in,6000,O
male,6000,O
mice,6000,O
is,6000,O
associated,6000,O
with,6000,O
choline-,6000,B-CHEMICAL
and,6000,O
folate-deficient,6000,B-CHEMICAL
diet-induced,6000,O
liver,6000,O
injury,6000,O
.,6000,O
Dysregulation,6001,O
of,6001,O
one-carbon,6001,O
metabolism-related,6001,O
metabolic,6001,O
processes,6001,O
is,6001,O
a,6001,O
major,6001,O
contributor,6001,O
to,6001,O
the,6001,O
pathogenesis,6001,O
of,6001,O
nonalcoholic,6001,O
fatty,6001,O
liver,6001,O
disease,6001,O
(,6001,O
NAFLD,6001,O
),6001,O
.,6001,O
It,6002,O
is,6002,O
well,6002,O
established,6002,O
that,6002,O
genetic,6002,O
and,6002,O
gender-specific,6002,O
variations,6002,O
in,6002,O
one-carbon,6002,O
metabolism,6002,O
contribute,6002,O
to,6002,O
the,6002,O
vulnerability,6002,O
to,6002,O
NAFLD,6002,O
in,6002,O
humans,6002,O
.,6002,O
To,6003,O
examine,6003,O
the,6003,O
role,6003,O
of,6003,O
one-carbon,6003,O
metabolism,6003,O
dysregulation,6003,O
in,6003,O
the,6003,O
pathogenesis,6003,O
and,6003,O
individual,6003,O
susceptibility,6003,O
to,6003,O
NAFLD,6003,O
",",6003,O
we,6003,O
used,6003,O
a,6003,O
``,6003,O
population-based,6003,O
'',6003,O
mouse,6003,O
model,6003,O
where,6003,O
male,6003,O
mice,6003,O
from,6003,O
7,6003,O
inbred,6003,O
were,6003,O
fed,6003,O
a,6003,O
choline-,6003,B-CHEMICAL
and,6003,O
folate-deficient,6003,B-CHEMICAL
(,6003,O
CFD,6003,O
),6003,O
diet,6003,O
for,6003,O
12,6003,O
wk,6003,O
.,6003,O
Strain-dependent,6004,O
down-regulation,6004,O
of,6004,O
several,6004,O
key,6004,O
one-carbon,6004,O
metabolism,6004,O
genes,6004,O
",",6004,O
including,6004,O
methionine,6004,B-GENE-Y
adenosyltransferase,6004,I-GENE-Y
1α,6004,I-GENE-Y
(,6004,O
Mat1a,6004,B-GENE-Y
),6004,O
",",6004,O
cystathionine-β-synthase,6004,B-GENE-Y
(,6004,O
Cbs,6004,B-GENE-Y
),6004,O
",",6004,O
methylenetetrahydrofolate,6004,B-GENE-Y
reductase,6004,I-GENE-Y
(,6004,O
Mthfr,6004,B-GENE-Y
),6004,O
",",6004,O
adenosyl-homocysteinase,6004,B-GENE-Y
(,6004,O
Ahcy,6004,B-GENE-Y
),6004,O
",",6004,O
and,6004,O
methylenetetrahydrofolate,6004,B-GENE-Y
dehydrogenase,6004,I-GENE-Y
1,6004,I-GENE-Y
(,6004,O
Mthfd1,6004,B-GENE-Y
),6004,O
",",6004,O
was,6004,O
observed,6004,O
.,6004,O
These,6005,O
changes,6005,O
were,6005,O
strongly,6005,O
associated,6005,O
with,6005,O
interstrain,6005,O
variability,6005,O
in,6005,O
liver,6005,O
injury,6005,O
(,6005,O
steatosis,6005,O
",",6005,O
necrosis,6005,O
",",6005,O
inflammation,6005,O
",",6005,O
and,6005,O
activation,6005,O
of,6005,O
fibrogenesis,6005,O
),6005,O
and,6005,O
hyperhomocysteinemia,6005,O
.,6005,O
Mechanistically,6006,O
",",6006,O
the,6006,O
decreased,6006,O
expression,6006,O
of,6006,O
Mat1a,6006,B-GENE-Y
",",6006,O
Ahcy,6006,B-GENE-Y
",",6006,O
and,6006,O
Mthfd1,6006,B-GENE-Y
was,6006,O
linked,6006,O
to,6006,O
a,6006,O
reduced,6006,O
level,6006,O
and,6006,O
promoter,6006,O
binding,6006,O
of,6006,O
transcription,6006,O
factor,6006,O
CCAAT/enhancer,6006,B-GENE-Y
binding,6006,I-GENE-Y
protein,6006,I-GENE-Y
β,6006,I-GENE-Y
(,6006,O
CEBPβ,6006,B-GENE-Y
),6006,O
",",6006,O
which,6006,O
directly,6006,O
regulates,6006,O
their,6006,O
transcription,6006,O
.,6006,O
The,6007,O
strain,6007,O
specificity,6007,O
of,6007,O
diet-induced,6007,O
dysregulation,6007,O
of,6007,O
one-carbon,6007,O
metabolism,6007,O
suggests,6007,O
that,6007,O
interstrain,6007,O
variation,6007,O
in,6007,O
the,6007,O
regulation,6007,O
of,6007,O
one-carbon,6007,O
metabolism,6007,O
may,6007,O
contribute,6007,O
to,6007,O
the,6007,O
differential,6007,O
vulnerability,6007,O
to,6007,O
NFLD,6007,O
and,6007,O
that,6007,O
correcting,6007,O
the,6007,O
imbalance,6007,O
may,6007,O
be,6007,O
considered,6007,O
as,6007,O
preventive,6007,O
and,6007,O
treatment,6007,O
strategies,6007,O
for,6007,O
NAFLD.-Pogribny,6007,O
",",6007,O
I.,6007,O
P.,6007,O
",",6007,O
Kutanzi,6007,O
",",6007,O
K.,6007,O
",",6007,O
Melnyk,6007,O
",",6007,O
S.,6007,O
",",6007,O
de,6007,O
Conti,6007,O
",",6007,O
A.,6007,O
",",6007,O
Tryndyak,6007,O
",",6007,O
V.,6007,O
",",6007,O
Montgomery,6007,O
",",6007,O
B.,6007,O
",",6007,O
Pogribna,6007,O
",",6007,O
M.,6007,O
",",6007,O
Muskhelishvili,6007,O
",",6007,O
L.,6007,O
",",6007,O
Latendresse,6007,O
",",6007,O
J.,6007,O
R.,6007,O
",",6007,O
James,6007,O
",",6007,O
S.,6007,O
J.,6007,O
",",6007,O
Beland,6007,O
",",6007,O
F.,6007,O
A.,6007,O
",",6007,O
Rusyn,6007,O
",",6007,O
I.,6007,O
Strain-dependent,6007,O
dysregulation,6007,O
of,6007,O
one-carbon,6007,O
metabolism,6007,O
in,6007,O
male,6007,O
mice,6007,O
is,6007,O
associated,6007,O
with,6007,O
choline-,6007,B-CHEMICAL
and,6007,O
folate-deficient,6007,B-CHEMICAL
diet-induced,6007,O
liver,6007,O
injury,6007,O
.,6007,O
Vitamin,6008,B-CHEMICAL
A,6008,I-CHEMICAL
and,6008,O
retinoid,6008,B-CHEMICAL
signaling,6008,O
:,6008,O
genomic,6008,O
and,6008,O
non-genomic,6008,O
effects,6008,O
.,6008,O
Vitamin,6009,B-CHEMICAL
A,6009,I-CHEMICAL
or,6009,O
retinol,6009,B-CHEMICAL
is,6009,O
arguably,6009,O
the,6009,O
most,6009,O
multifunctional,6009,O
vitamin,6009,B-CHEMICAL
in,6009,O
the,6009,O
human,6009,O
body,6009,O
as,6009,O
it,6009,O
is,6009,O
essential,6009,O
from,6009,O
embryogenesis,6009,O
to,6009,O
adulthood,6009,O
.,6009,O
The,6010,O
pleiotropic,6010,O
effects,6010,O
of,6010,O
vitamin,6010,B-CHEMICAL
A,6010,I-CHEMICAL
are,6010,O
exerted,6010,O
mainly,6010,O
by,6010,O
one,6010,O
active,6010,O
metabolite,6010,O
",",6010,O
all-trans,6010,B-CHEMICAL
retinoic,6010,I-CHEMICAL
acid,6010,I-CHEMICAL
(,6010,O
atRA,6010,B-CHEMICAL
),6010,O
",",6010,O
which,6010,O
regulates,6010,O
the,6010,O
expression,6010,O
of,6010,O
a,6010,O
battery,6010,O
of,6010,O
target,6010,O
genes,6010,O
through,6010,O
several,6010,O
families,6010,O
of,6010,O
nuclear,6010,B-GENE-N
receptors,6010,I-GENE-N
(,6010,O
RARs,6010,B-GENE-N
",",6010,O
RXRs,6010,B-GENE-N
and,6010,O
PPARβ/δ,6010,B-GENE-N
),6010,O
",",6010,O
polymorphic,6010,B-GENE-N
retinoic,6010,B-CHEMICAL
acid,6010,I-CHEMICAL
(,6010,I-GENE-N
RA,6010,I-GENE-N
),6010,I-GENE-N
response,6010,I-GENE-N
elements,6010,I-GENE-N
and,6010,O
multiple,6010,O
coregulators,6010,O
.,6010,O
It,6011,O
also,6011,O
involves,6011,O
extra,6011,O
nuclear,6011,O
and,6011,O
non-transcriptional,6011,O
effects,6011,O
such,6011,O
as,6011,O
the,6011,O
activation,6011,O
of,6011,O
kinase,6011,B-GENE-N
cascades,6011,O
",",6011,O
which,6011,O
are,6011,O
integrated,6011,O
in,6011,O
the,6011,O
nucleus,6011,O
via,6011,O
the,6011,O
phosphorylation,6011,O
of,6011,O
several,6011,O
actors,6011,O
of,6011,O
RA,6011,O
signaling,6011,O
.,6011,O
However,6012,O
",",6012,O
vitamin,6012,B-CHEMICAL
A,6012,I-CHEMICAL
itself,6012,O
proved,6012,O
recently,6012,O
to,6012,O
be,6012,O
active,6012,O
and,6012,O
RARs,6012,B-GENE-N
to,6012,O
be,6012,O
present,6012,O
in,6012,O
the,6012,O
cytosol,6012,O
to,6012,O
regulate,6012,O
translation,6012,O
and,6012,O
cell,6012,O
plasticity,6012,O
.,6012,O
All,6013,O
these,6013,O
new,6013,O
concepts,6013,O
expand,6013,O
the,6013,O
scope,6013,O
of,6013,O
the,6013,O
biologic,6013,O
functions,6013,O
of,6013,O
vitamin,6013,B-CHEMICAL
A,6013,I-CHEMICAL
and,6013,O
RA,6013,O
.,6013,O
Phase,6014,O
stability,6014,O
and,6014,O
elastic,6014,O
properties,6014,O
of,6014,O
chromium,6014,B-CHEMICAL
borides,6014,I-CHEMICAL
with,6014,O
various,6014,O
stoichiometries,6014,O
.,6014,O
Phase,6015,O
stability,6015,O
is,6015,O
important,6015,O
to,6015,O
the,6015,O
application,6015,O
of,6015,O
materials,6015,O
.,6015,O
By,6016,O
first-principles,6016,O
calculations,6016,O
",",6016,O
we,6016,O
establish,6016,O
the,6016,O
phase,6016,O
stability,6016,O
of,6016,O
chromium,6016,B-CHEMICAL
borides,6016,I-CHEMICAL
with,6016,O
various,6016,O
stoichiometries,6016,O
.,6016,O
Moreover,6017,O
",",6017,O
the,6017,O
phases,6017,O
of,6017,O
CrB3,6017,B-CHEMICAL
and,6017,O
CrB4,6017,B-CHEMICAL
have,6017,O
been,6017,O
predicted,6017,O
by,6017,O
using,6017,O
a,6017,O
newly,6017,O
developed,6017,O
particle,6017,O
swarm,6017,O
optimization,6017,O
(,6017,O
PSO,6017,O
),6017,O
algorithm,6017,O
.,6017,O
Formation,6018,O
enthalpy-pressure,6018,O
diagrams,6018,O
reveal,6018,O
that,6018,O
the,6018,O
MoB-type,6018,B-CHEMICAL
structure,6018,O
is,6018,O
more,6018,O
energetically,6018,O
favorable,6018,O
than,6018,O
the,6018,O
TiI-type,6018,B-CHEMICAL
structure,6018,O
for,6018,O
CrB,6018,B-CHEMICAL
.,6018,O
For,6019,O
CrB2,6019,B-CHEMICAL
",",6019,O
the,6019,O
WB2,6019,B-CHEMICAL
-type,6019,O
structure,6019,O
is,6019,O
preferred,6019,O
at,6019,O
zero,6019,O
pressure,6019,O
.,6019,O
The,6020,O
predicted,6020,O
new,6020,O
phase,6020,O
of,6020,O
CrB3,6020,B-CHEMICAL
belongs,6020,O
to,6020,O
the,6020,O
hexagonal,6020,O
P-6m2,6020,O
space,6020,O
group,6020,O
and,6020,O
it,6020,O
transforms,6020,O
into,6020,O
an,6020,O
orthorhombic,6020,O
phase,6020,O
as,6020,O
the,6020,O
pressure,6020,O
exceeds,6020,O
93,6020,O
GPa,6020,O
.,6020,O
The,6021,O
predicted,6021,O
CrB4,6021,B-CHEMICAL
(,6021,O
space,6021,O
group,6021,O
:,6021,O
Pnnm,6021,O
),6021,O
phase,6021,O
is,6021,O
more,6021,O
energetically,6021,O
favorable,6021,O
than,6021,O
the,6021,O
previously,6021,O
proposed,6021,O
Immm,6021,O
structure,6021,O
.,6021,O
The,6022,O
mechanical,6022,O
and,6022,O
thermodynamic,6022,O
stabilities,6022,O
of,6022,O
predicted,6022,O
CrB3,6022,B-CHEMICAL
and,6022,O
CrB4,6022,B-CHEMICAL
are,6022,O
verified,6022,O
by,6022,O
the,6022,O
calculated,6022,O
elastic,6022,O
constants,6022,O
and,6022,O
formation,6022,O
enthalpies,6022,O
.,6022,O
The,6023,O
full,6023,O
phonon,6023,O
dispersion,6023,O
calculations,6023,O
confirm,6023,O
the,6023,O
dynamic,6023,O
stability,6023,O
of,6023,O
WB2,6023,B-CHEMICAL
-type,6023,O
CrB2,6023,B-CHEMICAL
and,6023,O
predicted,6023,O
CrB3,6023,B-CHEMICAL
.,6023,O
The,6024,O
large,6024,O
shear,6024,O
moduli,6024,O
",",6024,O
large,6024,O
Young,6024,O
's,6024,O
moduli,6024,O
",",6024,O
low,6024,O
Poisson,6024,O
ratios,6024,O
",",6024,O
and,6024,O
low,6024,O
bulk,6024,O
and,6024,O
shear,6024,O
modulus,6024,O
ratios,6024,O
of,6024,O
CrB4,6024,B-CHEMICAL
PSC,6024,O
and,6024,O
CrB4,6024,B-CHEMICAL
PSD,6024,O
indicate,6024,O
that,6024,O
they,6024,O
are,6024,O
potential,6024,O
hard,6024,O
materials,6024,O
.,6024,O
Analyses,6025,O
of,6025,O
Debye,6025,O
temperature,6025,O
",",6025,O
electronic,6025,O
localization,6025,O
function,6025,O
",",6025,O
and,6025,O
electronic,6025,O
structure,6025,O
provide,6025,O
further,6025,O
understanding,6025,O
of,6025,O
the,6025,O
chemical,6025,O
and,6025,O
physical,6025,O
properties,6025,O
of,6025,O
these,6025,O
borides,6025,O
.,6025,O
Effect,6026,O
of,6026,O
miR-21,6026,B-GENE-Y
on,6026,O
Renal,6026,O
Fibrosis,6026,O
by,6026,O
Regulating,6026,O
MMP-9,6026,B-GENE-Y
and,6026,O
TIMP1,6026,B-GENE-Y
in,6026,O
kk-ay,6026,O
Diabetic,6026,O
Nephropathy,6026,O
Mice,6026,O
.,6026,O
MicroRNAs,6027,O
(,6027,O
miRs,6027,O
),6027,O
play,6027,O
important,6027,O
roles,6027,O
in,6027,O
initiation,6027,O
and,6027,O
progression,6027,O
of,6027,O
many,6027,O
pathologic,6027,O
processes,6027,O
.,6027,O
However,6028,O
",",6028,O
the,6028,O
roles,6028,O
of,6028,O
miRs,6028,O
in,6028,O
diabetic,6028,O
nephropathy,6028,O
remain,6028,O
unclear,6028,O
.,6028,O
This,6029,O
study,6029,O
was,6029,O
to,6029,O
determine,6029,O
whether,6029,O
miR-21,6029,B-GENE-Y
was,6029,O
involved,6029,O
in,6029,O
diabetic,6029,O
nephropathy,6029,O
and,6029,O
to,6029,O
explore,6029,O
the,6029,O
relationship,6029,O
between,6029,O
miR-21,6029,B-GENE-Y
and,6029,O
MMP9/TIMP1,6029,B-GENE-Y
expression,6029,O
in,6029,O
diabetic,6029,O
nephropathy,6029,O
.,6029,O
In,6030,O
situ,6030,O
hybridization,6030,O
studies,6030,O
showed,6030,O
that,6030,O
miR-21,6030,B-GENE-Y
was,6030,O
primarily,6030,O
localized,6030,O
and,6030,O
distributed,6030,O
in,6030,O
cortical,6030,O
glomerular,6030,O
and,6030,O
renal,6030,O
tubular,6030,O
cells,6030,O
in,6030,O
diabetic,6030,O
kk-ay,6030,O
kidney,6030,O
.,6030,O
Real-time,6031,O
quantitative,6031,O
RT-PCR,6031,O
demonstrated,6031,O
that,6031,O
the,6031,O
expression,6031,O
of,6031,O
miR-21,6031,B-GENE-Y
was,6031,O
significantly,6031,O
increased,6031,O
in,6031,O
kk-ay,6031,O
mice,6031,O
",",6031,O
compared,6031,O
with,6031,O
control,6031,O
C57BL,6031,O
mice,6031,O
.,6031,O
Interestingly,6032,O
",",6032,O
miR-21,6032,B-GENE-Y
expression,6032,O
positively,6032,O
correlated,6032,O
with,6032,O
urine,6032,O
albumin,6032,B-GENE-Y
creatine,6032,B-CHEMICAL
ratio,6032,O
(,6032,O
ACR,6032,O
),6032,O
",",6032,O
TIMP1,6032,B-GENE-Y
",",6032,O
collagen,6032,B-GENE-N
IV,6032,I-GENE-N
(,6032,O
ColIV,6032,B-GENE-N
),6032,O
",",6032,O
and,6032,O
fibronectin,6032,B-GENE-Y
(,6032,O
FN,6032,B-GENE-Y
),6032,O
;,6032,O
while,6032,O
negatively,6032,O
correlated,6032,O
with,6032,O
creatine,6032,B-CHEMICAL
clearance,6032,O
ratio,6032,O
(,6032,O
Ccr,6032,O
),6032,O
and,6032,O
MMP-9,6032,B-GENE-Y
protein,6032,O
.,6032,O
Importantly,6033,O
",",6033,O
antagomir-21,6033,O
not,6033,O
only,6033,O
ameliorated,6033,O
Ccr,6033,O
and,6033,O
ACR,6033,O
but,6033,O
also,6033,O
decreased,6033,O
TIMP1,6033,B-GENE-Y
",",6033,O
ColIV,6033,B-GENE-N
",",6033,O
and,6033,O
FN,6033,B-GENE-Y
proteins,6033,O
.,6033,O
In,6034,O
conclusion,6034,O
",",6034,O
our,6034,O
data,6034,O
demonstrate,6034,O
that,6034,O
miR-21,6034,B-GENE-Y
contributes,6034,O
to,6034,O
renal,6034,O
fibrosis,6034,O
by,6034,O
mediating,6034,O
MMP9/TIMP1,6034,B-GENE-Y
and,6034,O
that,6034,O
inhibition,6034,O
of,6034,O
miR-21,6034,B-GENE-Y
may,6034,O
be,6034,O
a,6034,O
novel,6034,O
target,6034,O
for,6034,O
diabetic,6034,O
nephropathy,6034,O
.,6034,O
Modification,6035,O
of,6035,O
the,6035,O
Catalytic,6035,O
Function,6035,O
of,6035,O
Human,6035,B-GENE-Y
Hydroxysteroid,6035,I-GENE-Y
Sulfotransferase,6035,I-GENE-Y
hSULT2A1,6035,I-GENE-Y
by,6035,O
Formation,6035,O
of,6035,O
Disulfide,6035,B-CHEMICAL
Bonds,6035,O
.,6035,O
The,6036,O
human,6036,B-GENE-Y
cytosolic,6036,I-GENE-Y
sulfotransferase,6036,I-GENE-Y
hSULT2A1,6036,I-GENE-Y
catalyzes,6036,O
the,6036,O
sulfation,6036,O
of,6036,O
a,6036,O
broad,6036,O
range,6036,O
of,6036,O
xenobiotics,6036,O
",",6036,O
as,6036,O
well,6036,O
as,6036,O
endogenous,6036,O
hydroxysteroids,6036,B-CHEMICAL
and,6036,O
bile,6036,B-CHEMICAL
acids,6036,I-CHEMICAL
.,6036,O
Reversible,6037,O
modulation,6037,O
of,6037,O
the,6037,O
catalytic,6037,O
activity,6037,O
of,6037,O
this,6037,O
enzyme,6037,O
could,6037,O
play,6037,O
important,6037,O
roles,6037,O
in,6037,O
its,6037,O
physiologic,6037,O
functions,6037,O
.,6037,O
Whereas,6038,O
other,6038,O
mammalian,6038,B-GENE-N
sulfotransferases,6038,I-GENE-N
are,6038,O
known,6038,O
to,6038,O
be,6038,O
reversibly,6038,O
altered,6038,O
by,6038,O
changes,6038,O
in,6038,O
their,6038,O
redox,6038,O
environment,6038,O
",",6038,O
this,6038,O
has,6038,O
not,6038,O
been,6038,O
previously,6038,O
shown,6038,O
for,6038,O
hSULT2A1,6038,B-GENE-Y
.,6038,O
We,6039,O
have,6039,O
examined,6039,O
the,6039,O
hypothesis,6039,O
that,6039,O
the,6039,O
formation,6039,O
of,6039,O
disulfide,6039,B-CHEMICAL
bonds,6039,O
in,6039,O
hSULT2A1,6039,B-GENE-Y
can,6039,O
reversibly,6039,O
regulate,6039,O
the,6039,O
catalytic,6039,O
function,6039,O
of,6039,O
the,6039,O
enzyme,6039,O
.,6039,O
Three,6040,O
thiol,6040,B-CHEMICAL
oxidants,6040,O
were,6040,O
used,6040,O
as,6040,O
model,6040,O
compounds,6040,O
to,6040,O
investigate,6040,O
their,6040,O
effects,6040,O
on,6040,O
homogeneous,6040,O
preparations,6040,O
of,6040,O
hSULT2A1,6040,B-GENE-Y
:,6040,O
glutathione,6040,B-CHEMICAL
disulfide,6040,I-CHEMICAL
",",6040,O
"5,5'-dithiobis",6040,B-CHEMICAL
(,6040,I-CHEMICAL
2-nitrobenzoic,6040,I-CHEMICAL
acid,6040,I-CHEMICAL
),6040,I-CHEMICAL
",",6040,O
and,6040,O
"1,1'-azobis",6040,B-CHEMICAL
(,6040,I-CHEMICAL
N,6040,I-CHEMICAL
",",6040,I-CHEMICAL
N-dimethylformamide,6040,I-CHEMICAL
),6040,O
(,6040,O
diamide,6040,B-CHEMICAL
),6040,O
.,6040,O
Examination,6041,O
of,6041,O
the,6041,O
effects,6041,O
of,6041,O
disulfide,6041,B-CHEMICAL
bond,6041,O
formation,6041,O
with,6041,O
these,6041,O
agents,6041,O
indicated,6041,O
that,6041,O
the,6041,O
activity,6041,O
of,6041,O
the,6041,O
enzyme,6041,O
is,6041,O
reversibly,6041,O
altered,6041,O
.,6041,O
Studies,6042,O
on,6042,O
the,6042,O
kinetics,6042,O
of,6042,O
the,6042,O
hSULT2A1-catalyzed,6042,B-GENE-Y
sulfation,6042,O
of,6042,O
dehydroepiandrosterone,6042,B-CHEMICAL
(,6042,O
DHEA,6042,B-CHEMICAL
),6042,O
showed,6042,O
the,6042,O
effects,6042,O
of,6042,O
disulfide,6042,B-CHEMICAL
bond,6042,O
formation,6042,O
on,6042,O
the,6042,O
substrate,6042,O
inhibition,6042,O
characteristics,6042,O
of,6042,O
the,6042,O
enzyme,6042,O
.,6042,O
The,6043,O
effects,6043,O
of,6043,O
these,6043,O
agents,6043,O
on,6043,O
the,6043,O
binding,6043,O
of,6043,O
substrates,6043,O
and,6043,O
products,6043,O
",",6043,O
liquid,6043,O
chromatography-mass,6043,O
spectrometry,6043,O
identification,6043,O
of,6043,O
the,6043,O
disulfides,6043,B-CHEMICAL
formed,6043,O
",",6043,O
and,6043,O
structural,6043,O
modeling,6043,O
of,6043,O
the,6043,O
modified,6043,O
enzyme,6043,O
were,6043,O
examined,6043,O
.,6043,O
Our,6044,O
results,6044,O
indicate,6044,O
that,6044,O
conformational,6044,O
changes,6044,O
at,6044,O
cysteines,6044,B-CHEMICAL
near,6044,O
the,6044,O
nucleotide,6044,B-CHEMICAL
binding,6044,O
site,6044,O
affect,6044,O
the,6044,O
binding,6044,O
of,6044,O
both,6044,O
the,6044,O
nucleotide,6044,B-CHEMICAL
and,6044,O
DHEA,6044,B-CHEMICAL
to,6044,O
the,6044,O
enzyme,6044,O
",",6044,O
with,6044,O
the,6044,O
specific,6044,O
effects,6044,O
dependent,6044,O
on,6044,O
the,6044,O
structure,6044,O
of,6044,O
the,6044,O
resulting,6044,O
disulfide,6044,B-CHEMICAL
.,6044,O
Thus,6045,O
",",6045,O
the,6045,O
formation,6045,O
of,6045,O
disulfide,6045,B-CHEMICAL
bonds,6045,O
in,6045,O
hSULT2A1,6045,B-GENE-Y
is,6045,O
a,6045,O
potentially,6045,O
important,6045,O
reversible,6045,O
mechanism,6045,O
for,6045,O
alterations,6045,O
in,6045,O
the,6045,O
rates,6045,O
of,6045,O
sulfation,6045,O
of,6045,O
both,6045,O
endogenous,6045,O
and,6045,O
xenobiotic,6045,O
substrates,6045,O
.,6045,O
Synthesis,6046,O
of,6046,O
novel,6046,O
estrogen,6046,B-CHEMICAL
receptor,6046,I-GENE-Y
antagonists,6046,O
using,6046,O
metal-catalyzed,6046,O
coupling,6046,O
reactions,6046,O
and,6046,O
characterization,6046,O
of,6046,O
their,6046,O
biological,6046,O
activity,6046,O
.,6046,O
Estrogen,6047,B-GENE-Y
receptor,6047,I-GENE-Y
(,6047,O
ER,6047,B-GENE-N
),6047,O
antagonists,6047,O
are,6047,O
valuable,6047,O
in,6047,O
the,6047,O
treatment,6047,O
of,6047,O
ER-positive,6047,B-GENE-Y
human,6047,O
breast,6047,O
cancer,6047,O
.,6047,O
In,6048,O
this,6048,O
study,6048,O
",",6048,O
we,6048,O
designed,6048,O
and,6048,O
synthesized,6048,O
nine,6048,O
new,6048,O
derivatives,6048,O
of,6048,O
17β-estradiol,6048,B-CHEMICAL
(,6048,O
E2,6048,O
),6048,O
with,6048,O
a,6048,O
bulky,6048,O
side,6048,O
chain,6048,O
attached,6048,O
to,6048,O
its,6048,O
C-7α,6048,O
position,6048,O
",",6048,O
and,6048,O
determined,6048,O
their,6048,O
ER,6048,B-GENE-Y
antagonistic,6048,O
activity,6048,O
using,6048,O
in,6048,O
vitro,6048,O
bioassays,6048,O
.,6048,O
Four,6049,O
of,6049,O
the,6049,O
derivatives,6049,O
showed,6049,O
a,6049,O
strong,6049,O
inhibition,6049,O
of,6049,O
ERα,6049,B-GENE-Y
transactivation,6049,O
activity,6049,O
in,6049,O
a,6049,O
luciferase,6049,O
reporter,6049,O
assay,6049,O
and,6049,O
blocked,6049,O
ERα,6049,B-GENE-Y
interactions,6049,O
with,6049,O
coactivators,6049,O
.,6049,O
Similarly,6050,O
",",6050,O
these,6050,O
derivatives,6050,O
also,6050,O
strongly,6050,O
inhibited,6050,O
the,6050,O
growth,6050,O
of,6050,O
the,6050,O
ERα-positive,6050,B-GENE-Y
human,6050,O
breast,6050,O
cancer,6050,O
cells,6050,O
.,6050,O
Computational,6051,O
docking,6051,O
analysis,6051,O
was,6051,O
conducted,6051,O
to,6051,O
model,6051,O
the,6051,O
interaction,6051,O
of,6051,O
these,6051,O
antagonists,6051,O
with,6051,O
the,6051,O
human,6051,B-GENE-Y
ERα,6051,I-GENE-Y
and,6051,O
showed,6051,O
that,6051,O
they,6051,O
could,6051,O
tightly,6051,O
bind,6051,O
to,6051,O
the,6051,O
ERα,6051,B-GENE-N
in,6051,O
a,6051,O
manner,6051,O
similar,6051,O
to,6051,O
that,6051,O
of,6051,O
"ICI-182,780",6051,B-CHEMICAL
",",6051,O
a,6051,O
pure,6051,O
ER,6051,B-GENE-Y
antagonist,6051,O
.,6051,O
These,6052,O
results,6052,O
provide,6052,O
an,6052,O
example,6052,O
that,6052,O
attachment,6052,O
of,6052,O
a,6052,O
bulky,6052,O
side,6052,O
chain,6052,O
to,6052,O
the,6052,O
C-7α,6052,O
position,6052,O
of,6052,O
E2,6052,O
can,6052,O
produce,6052,O
ER,6052,B-GENE-Y
antagonists,6052,O
with,6052,O
ER,6052,B-GENE-Y
affinity,6052,O
comparable,6052,O
to,6052,O
that,6052,O
of,6052,O
"ICI-182,780",6052,B-CHEMICAL
.,6052,O
Discovery,6053,O
of,6053,O
7-methoxy-6-,6053,B-CHEMICAL
[,6053,I-CHEMICAL
4-,6053,I-CHEMICAL
(,6053,I-CHEMICAL
"4-methyl-1,3-thiazol-2-yl",6053,I-CHEMICAL
),6053,I-CHEMICAL
-1H-imidazol-5-yl,6053,I-CHEMICAL
],6053,I-CHEMICAL
"-1,3-benzothiazole",6053,I-CHEMICAL
(,6053,O
TASP0382088,6053,B-CHEMICAL
),6053,O
:,6053,O
a,6053,O
potent,6053,O
and,6053,O
selective,6053,O
transforming,6053,B-GENE-Y
growth,6053,I-GENE-Y
factor-β,6053,I-GENE-Y
type,6053,I-GENE-Y
I,6053,I-GENE-Y
receptor,6053,I-GENE-Y
inhibitor,6053,O
as,6053,O
a,6053,O
topical,6053,O
drug,6053,O
for,6053,O
alopecia,6053,O
.,6053,O
7-Methoxy-6-,6054,B-CHEMICAL
[,6054,I-CHEMICAL
4-,6054,I-CHEMICAL
(,6054,I-CHEMICAL
"4-methyl-1,3-thiazol-2-yl",6054,I-CHEMICAL
),6054,I-CHEMICAL
-1H-imidazol-5-yl,6054,I-CHEMICAL
],6054,I-CHEMICAL
"-1,3-benzothiazole",6054,I-CHEMICAL
11,6054,O
(,6054,O
TASP0382088,6054,B-CHEMICAL
),6054,O
was,6054,O
synthesized,6054,O
and,6054,O
evaluated,6054,O
as,6054,O
transforming,6054,B-GENE-Y
growth,6054,I-GENE-Y
factor-β,6054,I-GENE-Y
(,6054,I-GENE-Y
TGF-β,6054,I-GENE-Y
),6054,I-GENE-Y
type,6054,I-GENE-Y
I,6054,I-GENE-Y
receptor,6054,I-GENE-Y
(,6054,O
also,6054,O
known,6054,O
as,6054,O
activin,6054,B-GENE-Y
receptor-like,6054,I-GENE-Y
kinase,6054,I-GENE-Y
5,6054,I-GENE-Y
or,6054,O
ALK5,6054,B-GENE-Y
),6054,O
inhibitor,6054,O
.,6054,O
Compound,6055,O
11,6055,O
",",6055,O
a,6055,O
potent,6055,O
and,6055,O
selective,6055,O
ALK5,6055,B-GENE-Y
inhibitor,6055,O
",",6055,O
exhibited,6055,O
good,6055,O
enzyme,6055,O
inhibitory,6055,O
activity,6055,O
(,6055,O
IC50=4.8,6055,O
nM,6055,O
),6055,O
as,6055,O
well,6055,O
as,6055,O
inhibitory,6055,O
activity,6055,O
against,6055,O
TGF-β-induced,6055,B-GENE-Y
Smad2/3,6055,B-GENE-N
phosphorylation,6055,I-GENE-N
at,6055,O
a,6055,O
cellular,6055,O
level,6055,O
(,6055,O
IC50=17,6055,O
nM,6055,O
),6055,O
.,6055,O
The,6056,O
introduction,6056,O
of,6056,O
a,6056,O
methoxy,6056,B-CHEMICAL
group,6056,O
to,6056,O
the,6056,O
benzothiazole,6056,B-CHEMICAL
ring,6056,O
in,6056,O
1,6056,O
and,6056,O
the,6056,O
break,6056,O
up,6056,O
of,6056,O
the,6056,O
planarity,6056,O
between,6056,O
the,6056,O
imidazole,6056,B-CHEMICAL
ring,6056,O
and,6056,O
the,6056,O
thiazole,6056,B-CHEMICAL
ring,6056,O
improved,6056,O
the,6056,O
solubility,6056,O
in,6056,O
the,6056,O
lotion,6056,O
base,6056,O
of,6056,O
11,6056,O
.,6056,O
Furthermore,6057,O
",",6057,O
the,6057,O
topical,6057,O
application,6057,O
of,6057,O
3,6057,O
%,6057,O
11,6057,O
lotion,6057,O
significantly,6057,O
inhibited,6057,O
Smad2,6057,B-GENE-Y
phosphorylation,6057,I-GENE-Y
in,6057,O
mouse,6057,O
skin,6057,O
at,6057,O
8,6057,O
h,6057,O
after,6057,O
application,6057,O
(,6057,O
71,6057,O
%,6057,O
inhibition,6057,O
",",6057,O
compared,6057,O
with,6057,O
vehicle-treated,6057,O
animals,6057,O
),6057,O
.,6057,O
ARF,6058,O
represses,6058,O
androgen,6058,B-CHEMICAL
receptor,6058,I-GENE-Y
transactivation,6058,O
in,6058,O
prostate,6058,O
cancer,6058,O
.,6058,O
Androgen,6059,B-CHEMICAL
receptor,6059,I-GENE-Y
(,6059,O
AR,6059,B-GENE-Y
),6059,O
signaling,6059,O
is,6059,O
essential,6059,O
for,6059,O
prostate,6059,O
cancer,6059,O
(,6059,O
PCa,6059,O
),6059,O
development,6059,O
in,6059,O
humans,6059,O
.,6059,O
The,6060,O
initiation,6060,O
of,6060,O
prostate,6060,O
malignancy,6060,O
and,6060,O
progression,6060,O
to,6060,O
a,6060,O
castration-resistant,6060,O
stage,6060,O
are,6060,O
largely,6060,O
contributed,6060,O
by,6060,O
the,6060,O
modulation,6060,O
of,6060,O
AR,6060,B-GENE-Y
activity,6060,O
through,6060,O
its,6060,O
coregulatory,6060,O
proteins,6060,O
.,6060,O
We,6061,O
and,6061,O
others,6061,O
previously,6061,O
reported,6061,O
that,6061,O
p14,6061,B-GENE-Y
alternative,6061,I-GENE-Y
reading,6061,I-GENE-Y
frame,6061,I-GENE-Y
(,6061,O
ARF,6061,B-GENE-Y
),6061,O
expression,6061,O
is,6061,O
positively,6061,O
correlated,6061,O
with,6061,O
the,6061,O
disease,6061,O
progression,6061,O
and,6061,O
severity,6061,O
of,6061,O
PCa,6061,O
.,6061,O
Here,6062,O
",",6062,O
we,6062,O
provide,6062,O
evidence,6062,O
that,6062,O
p14ARF,6062,B-GENE-Y
physically,6062,O
interacts,6062,O
with,6062,O
AR,6062,B-GENE-Y
and,6062,O
functions,6062,O
as,6062,O
an,6062,O
AR,6062,B-GENE-Y
corespressor,6062,O
in,6062,O
both,6062,O
an,6062,O
androgen-dependent,6062,B-CHEMICAL
and,6062,O
androgen-independent,6062,B-CHEMICAL
manner,6062,O
.,6062,O
Endogenous,6063,O
ARF,6063,B-GENE-Y
(,6063,O
p14ARF,6063,B-GENE-Y
in,6063,O
human,6063,O
and,6063,O
p19ARF,6063,B-GENE-Y
in,6063,O
mouse,6063,O
),6063,O
and,6063,O
AR,6063,B-GENE-Y
colocalize,6063,O
in,6063,O
both,6063,O
human,6063,O
PCa,6063,O
cells,6063,O
in,6063,O
vitro,6063,O
and,6063,O
PCa,6063,O
tissues,6063,O
of,6063,O
mouse,6063,O
and,6063,O
human,6063,O
in,6063,O
vivo,6063,O
.,6063,O
Overexpression,6064,O
of,6064,O
p14ARF,6064,B-GENE-Y
in,6064,O
PCa,6064,O
cells,6064,O
significantly,6064,O
attenuates,6064,O
the,6064,O
activities,6064,O
of,6064,O
androgen,6064,B-CHEMICAL
response,6064,I-GENE-N
region,6064,I-GENE-N
(,6064,O
ARR2,6064,B-GENE-N
),6064,O
-probasin,6064,O
and,6064,I-GENE-N
prostate-specific,6064,I-GENE-N
antigen,6064,I-GENE-N
(,6064,I-GENE-N
PSA,6064,I-GENE-N
),6064,I-GENE-N
promoters,6064,I-GENE-N
.,6064,O
The,6065,O
forced,6065,O
expression,6065,O
of,6065,O
p14ARF,6065,B-GENE-Y
in,6065,O
cells,6065,O
resulted,6065,O
in,6065,O
a,6065,O
suppression,6065,O
of,6065,O
PSA,6065,B-GENE-Y
and,6065,O
NK,6065,B-GENE-Y
transcription,6065,I-GENE-Y
factor,6065,I-GENE-Y
locus,6065,I-GENE-Y
1,6065,I-GENE-Y
(,6065,O
NKX3.1,6065,B-GENE-Y
),6065,O
expression,6065,O
.,6065,O
Conversely,6066,O
",",6066,O
knockdown,6066,O
of,6066,O
endogenous,6066,O
p14ARF,6066,B-GENE-Y
in,6066,O
human,6066,O
PCa,6066,O
cells,6066,O
with,6066,O
short,6066,O
hairpin,6066,O
RNA,6066,O
enhanced,6066,O
AR,6066,B-GENE-Y
transactivation,6066,O
activities,6066,O
in,6066,O
a,6066,O
dose-dependent,6066,O
and,6066,O
p53-independent,6066,B-GENE-Y
manner,6066,O
.,6066,O
Furthermore,6067,O
",",6067,O
we,6067,O
demonstrated,6067,O
that,6067,O
p14ARF,6067,B-GENE-Y
binds,6067,O
to,6067,O
both,6067,O
the,6067,O
N-terminal,6067,B-CHEMICAL
domain,6067,O
and,6067,O
the,6067,O
ligand-binding,6067,O
domain,6067,O
of,6067,O
AR,6067,B-GENE-Y
",",6067,O
and,6067,O
the,6067,O
human,6067,B-GENE-N
double,6067,I-GENE-N
minute,6067,I-GENE-N
2,6067,I-GENE-N
(,6067,I-GENE-N
HDM2,6067,I-GENE-N
),6067,I-GENE-N
-binding,6067,I-GENE-N
motif,6067,I-GENE-N
of,6067,O
p14ARF,6067,B-GENE-Y
is,6067,O
required,6067,O
for,6067,O
the,6067,O
interaction,6067,O
of,6067,O
p14ARF,6067,B-GENE-Y
and,6067,O
AR,6067,B-GENE-Y
proteins,6067,O
.,6067,O
p14ARF,6068,B-GENE-Y
perturbs,6068,O
the,6068,O
androgen-induced,6068,B-CHEMICAL
interaction,6068,O
between,6068,O
the,6068,O
N,6068,B-CHEMICAL
terminus,6068,O
and,6068,O
C,6068,B-CHEMICAL
terminus,6068,O
of,6068,O
AR,6068,B-GENE-Y
.,6068,O
Most,6069,O
importantly,6069,O
",",6069,O
we,6069,O
observed,6069,O
that,6069,O
the,6069,O
expression,6069,O
of,6069,O
PSA,6069,B-GENE-Y
is,6069,O
reversely,6069,O
correlated,6069,O
with,6069,O
p14ARF,6069,B-GENE-Y
in,6069,O
human,6069,O
prostate,6069,O
tissues,6069,O
.,6069,O
Taken,6070,O
together,6070,O
",",6070,O
our,6070,O
results,6070,O
reveal,6070,O
a,6070,O
novel,6070,O
function,6070,O
of,6070,O
ARF,6070,B-GENE-Y
in,6070,O
modulation,6070,O
of,6070,O
AR,6070,B-GENE-Y
transactivation,6070,O
in,6070,O
PCa,6070,O
.,6070,O
Role,6071,O
of,6071,O
oxidative,6071,O
stress,6071,O
in,6071,O
chemical,6071,O
allergens,6071,O
induced,6071,O
skin,6071,O
cells,6071,O
activation,6071,O
.,6071,O
Allergic,6072,O
contact,6072,O
dermatitis,6072,O
(,6072,O
ACD,6072,O
),6072,O
is,6072,O
an,6072,O
important,6072,O
occupational,6072,O
and,6072,O
environmental,6072,O
disease,6072,O
caused,6072,O
by,6072,O
topical,6072,O
exposure,6072,O
to,6072,O
chemical,6072,O
allergens,6072,O
.,6072,O
It,6073,O
describes,6073,O
the,6073,O
adverse,6073,O
effects,6073,O
that,6073,O
may,6073,O
results,6073,O
when,6073,O
exposure,6073,O
to,6073,O
a,6073,O
chemical,6073,O
elicits,6073,O
a,6073,O
T,6073,O
cell-mediated,6073,O
inflammatory,6073,O
skin,6073,O
disease,6073,O
.,6073,O
The,6074,O
ability,6074,O
of,6074,O
contact,6074,O
sensitizers,6074,O
to,6074,O
induce,6074,O
the,6074,O
oxidative,6074,O
stress,6074,O
pathway,6074,O
in,6074,O
keratinocytes,6074,O
and,6074,O
dendritic,6074,O
cells,6074,O
has,6074,O
been,6074,O
confirmed,6074,O
by,6074,O
several,6074,O
authors,6074,O
.,6074,O
Reactive,6075,O
oxygen,6075,B-CHEMICAL
species,6075,O
(,6075,O
ROS,6075,O
),6075,O
can,6075,O
serve,6075,O
as,6075,O
essential,6075,O
second,6075,O
messengers,6075,O
mediating,6075,O
cellular,6075,O
responses,6075,O
resulting,6075,O
in,6075,O
immune,6075,O
cells,6075,O
activation,6075,O
.,6075,O
Oxidative,6076,O
stress,6076,O
may,6076,O
be,6076,O
the,6076,O
starter,6076,O
point,6076,O
",",6076,O
as,6076,O
it,6076,O
leads,6076,O
to,6076,O
the,6076,O
activation,6076,O
of,6076,O
transcription,6076,O
factors,6076,O
and,6076,O
signaling,6076,O
pathways,6076,O
",",6076,O
including,6076,O
NF-kB,6076,B-GENE-N
and,6076,O
p38,6076,B-GENE-N
MAPK,6076,B-GENE-N
",",6076,O
which,6076,O
leads,6076,O
to,6076,O
the,6076,O
release,6076,O
of,6076,O
cytokines,6076,B-GENE-N
and,6076,O
chemokines,6076,B-GENE-N
.,6076,O
ROS,6077,O
are,6077,O
also,6077,O
involved,6077,O
in,6077,O
the,6077,O
activation,6077,O
of,6077,O
the,6077,O
NLRP3/NALP3,6077,B-GENE-Y
inflammasome,6077,O
",",6077,O
which,6077,O
is,6077,O
required,6077,O
to,6077,O
direct,6077,O
the,6077,O
proteolytic,6077,O
maturation,6077,O
of,6077,O
inflammatory,6077,O
cytokines,6077,B-GENE-N
such,6077,O
as,6077,O
IL-1β,6077,B-GENE-Y
and,6077,O
IL-18,6077,B-GENE-Y
",",6077,O
which,6077,O
are,6077,O
all,6077,O
integral,6077,O
to,6077,O
the,6077,O
process,6077,O
of,6077,O
dendritic,6077,O
cells,6077,O
mobilization,6077,O
",",6077,O
migration,6077,O
and,6077,O
functional,6077,O
maturation,6077,O
.,6077,O
Moreover,6078,O
",",6078,O
emerging,6078,O
evidence,6078,O
correlates,6078,O
ROS,6078,O
to,6078,O
changes,6078,O
in,6078,O
the,6078,O
constitution,6078,O
of,6078,O
the,6078,O
extracellular,6078,O
microenvironment,6078,O
found,6078,O
to,6078,O
facilitate,6078,O
ACD,6078,O
.,6078,O
The,6079,O
purpose,6079,O
of,6079,O
this,6079,O
review,6079,O
is,6079,O
to,6079,O
provide,6079,O
both,6079,O
conceptual,6079,O
and,6079,O
technical,6079,O
frameworks,6079,O
on,6079,O
the,6079,O
role,6079,O
of,6079,O
oxidative,6079,O
stress,6079,O
in,6079,O
chemical,6079,O
allergy,6079,O
.,6079,O
Relative,6080,O
expression,6080,O
of,6080,O
cholesterol,6080,B-CHEMICAL
transport-related,6080,I-GENE-N
proteins,6080,I-GENE-N
and,6080,O
inflammation,6080,O
markers,6080,O
through,6080,O
the,6080,O
induction,6080,O
of,6080,O
7-ketosterol-mediated,6080,B-CHEMICAL
stress,6080,O
in,6080,O
Caco-2,6080,O
cells,6080,O
.,6080,O
Human,6081,O
diets,6081,O
contain,6081,O
sterol,6081,B-CHEMICAL
oxidation,6081,O
products,6081,O
that,6081,O
can,6081,O
induce,6081,O
cytotoxic,6081,O
effects,6081,O
",",6081,O
mainly,6081,O
caused,6081,O
by,6081,O
cholesterol,6081,B-CHEMICAL
oxides,6081,I-CHEMICAL
.,6081,O
However,6082,O
",",6082,O
phytosterol,6082,B-CHEMICAL
oxides,6082,I-CHEMICAL
effects,6082,O
have,6082,O
been,6082,O
less,6082,O
extensively,6082,O
investigated,6082,O
.,6082,O
This,6083,O
study,6083,O
evaluates,6083,O
the,6083,O
production,6083,O
of,6083,O
inflammatory,6083,O
biomarkers,6083,O
(,6083,O
IL-1β,6083,B-GENE-Y
",",6083,O
IL-8,6083,B-GENE-Y
",",6083,O
IL-10,6083,B-GENE-Y
",",6083,O
TNFα,6083,B-GENE-Y
),6083,O
and,6083,O
the,6083,O
influence,6083,O
of,6083,O
gene,6083,O
expression,6083,O
transporters,6083,O
and,6083,O
enzymes,6083,O
related,6083,O
to,6083,O
cholesterol,6083,B-CHEMICAL
absorption,6083,O
and,6083,O
metabolism,6083,O
(,6083,O
NPC1L1,6083,B-GENE-Y
",",6083,O
ABCG5/8,6083,B-GENE-N
",",6083,O
HMGCoA,6083,B-GENE-Y
",",6083,O
ACAT,6083,B-GENE-Y
),6083,O
produced,6083,O
by,6083,O
7-ketosterols,6083,B-CHEMICAL
(,6083,O
stigmasterol/cholesterol,6083,B-CHEMICAL
),6083,O
in,6083,O
Caco-2,6083,O
cells,6083,O
.,6083,O
These,6084,O
effects,6084,O
were,6084,O
linked,6084,O
to,6084,O
intracellular,6084,O
signaling,6084,O
pathways,6084,O
by,6084,O
using,6084,O
several,6084,O
inhibitors,6084,O
.,6084,O
Results,6085,O
showed,6085,O
7-ketostigmasterol,6085,B-CHEMICAL
to,6085,O
have,6085,O
a,6085,O
greater,6085,O
proinflammatory,6085,O
potential,6085,O
than,6085,O
7-ketocholesterol,6085,B-CHEMICAL
.,6085,O
In,6086,O
non-pre-treated,6086,O
cells,6086,O
",",6086,O
only,6086,O
efflux,6086,B-GENE-N
transporters,6086,I-GENE-N
were,6086,O
down-regulated,6086,O
by,6086,O
7-ketosterols,6086,B-CHEMICAL
",",6086,O
showing,6086,O
a,6086,O
greater,6086,O
influence,6086,O
upon,6086,O
ABCG5,6086,B-GENE-Y
expression,6086,O
.,6086,O
Cell-pre-incubation,6087,O
with,6087,O
bradykinin,6087,B-GENE-Y
induced,6087,O
changes,6087,O
in,6087,O
ABCG,6087,B-GENE-N
expression,6087,O
levels,6087,O
after,6087,O
7-ketostigmasterol-incubation,6087,B-CHEMICAL
;,6087,O
however,6087,O
",",6087,O
the,6087,O
energetic,6087,O
metabolism,6087,O
inhibition,6087,O
reduced,6087,O
NPC1L1,6087,B-GENE-Y
expression,6087,O
only,6087,O
in,6087,O
7-ketocholesterol-incubated,6087,B-CHEMICAL
cells,6087,O
.,6087,O
In,6088,O
non-pre-treated,6088,O
cells,6088,O
",",6088,O
HMG-CoA,6088,B-CHEMICAL
was,6088,O
up-regulated,6088,O
by,6088,O
both,6088,O
7-ketosterols,6088,B-CHEMICAL
.,6088,O
However,6089,O
",",6089,O
exposure,6089,O
to,6089,O
inhibitors,6089,O
down-regulated,6089,O
the,6089,O
expression,6089,O
levels,6089,O
",",6089,O
mainly,6089,O
in,6089,O
7-ketocholesterol-incubated,6089,B-CHEMICAL
cells,6089,O
.,6089,O
While,6090,O
ACAT,6090,B-GENE-Y
expression,6090,O
values,6090,O
in,6090,O
non-pre-treated,6090,O
cells,6090,O
were,6090,O
unchanged,6090,O
",",6090,O
exposure,6090,O
to,6090,O
inhibitors,6090,O
caused,6090,O
down-regulation,6090,O
of,6090,O
mRNA,6090,O
levels,6090,O
.,6090,O
These,6091,O
results,6091,O
suggest,6091,O
that,6091,O
internalization,6091,O
and,6091,O
excretion,6091,O
of,6091,O
7-ketostigmasterol,6091,B-CHEMICAL
is,6091,O
probably,6091,O
influenced,6091,O
by,6091,O
[,6091,O
Ca,6091,B-CHEMICAL
],6091,O
i,6091,O
",",6091,O
which,6091,O
also,6091,O
could,6091,O
mediate,6091,O
HMGCoA,6091,B-CHEMICAL
activity,6091,O
in,6091,O
POPs,6091,O
metabolism,6091,O
.,6091,O
However,6092,O
",",6092,O
energetic,6092,O
metabolism,6092,O
and,6092,O
reducing,6092,O
equivalents,6092,O
exert,6092,O
different,6092,O
influences,6092,O
upon,6092,O
the,6092,O
7-ketosterol,6092,B-CHEMICAL
internalization,6092,O
.,6092,O
Caffeic,6093,B-CHEMICAL
acid,6093,I-CHEMICAL
treatment,6093,O
alters,6093,O
the,6093,O
extracellular,6093,O
adenine,6093,B-CHEMICAL
nucleotide,6093,I-CHEMICAL
hydrolysis,6093,O
in,6093,O
platelets,6093,O
and,6093,O
lymphocytes,6093,O
of,6093,O
adult,6093,O
rats,6093,O
.,6093,O
This,6094,O
study,6094,O
evaluated,6094,O
the,6094,O
effects,6094,O
of,6094,O
caffeic,6094,B-CHEMICAL
acid,6094,I-CHEMICAL
on,6094,O
ectonucleotidase,6094,O
activities,6094,O
such,6094,O
as,6094,O
NTPDase,6094,B-GENE-N
(,6094,O
nucleoside,6094,B-GENE-N
triphosphate,6094,I-GENE-N
diphosphohydrolase,6094,I-GENE-N
),6094,O
",",6094,O
Ecto-NPP,6094,B-GENE-N
(,6094,I-GENE-N
nucleotide,6094,B-CHEMICAL
pyrophosphatase/phosphodiesterase,6094,I-GENE-N
),6094,I-GENE-N
",",6094,O
5'-nucleotidase,6094,B-GENE-Y
and,6094,O
adenosine,6094,B-CHEMICAL
deaminase,6094,I-GENE-Y
(,6094,O
ADA,6094,B-GENE-Y
),6094,O
in,6094,O
platelets,6094,O
and,6094,O
lymphocytes,6094,O
of,6094,O
rats,6094,O
",",6094,O
as,6094,O
well,6094,O
as,6094,O
in,6094,O
the,6094,O
profile,6094,O
of,6094,O
platelet,6094,O
aggregation,6094,O
.,6094,O
Animals,6095,O
were,6095,O
divided,6095,O
into,6095,O
five,6095,O
groups,6095,O
:,6095,O
I,6095,O
(,6095,O
control,6095,O
),6095,O
;,6095,O
II,6095,O
(,6095,O
oil,6095,O
),6095,O
;,6095,O
III,6095,O
(,6095,O
caffeic,6095,B-CHEMICAL
acid,6095,I-CHEMICAL
10mg/kg,6095,O
),6095,O
;,6095,O
IV,6095,O
(,6095,O
caffeic,6095,B-CHEMICAL
acid,6095,I-CHEMICAL
50mg/kg,6095,O
),6095,O
;,6095,O
and,6095,O
V,6095,O
(,6095,O
caffeic,6095,B-CHEMICAL
acid,6095,I-CHEMICAL
100mg/kg,6095,O
),6095,O
.,6095,O
Animals,6096,O
were,6096,O
treated,6096,O
with,6096,O
caffeic,6096,B-CHEMICAL
acid,6096,I-CHEMICAL
diluted,6096,O
in,6096,O
oil,6096,O
for,6096,O
30days,6096,O
.,6096,O
In,6097,O
platelets,6097,O
",",6097,O
caffeic,6097,B-CHEMICAL
acid,6097,I-CHEMICAL
decreased,6097,O
the,6097,O
ATP,6097,B-CHEMICAL
hydrolysis,6097,O
and,6097,O
increased,6097,O
ADP,6097,B-CHEMICAL
hydrolysis,6097,O
in,6097,O
groups,6097,O
III,6097,O
",",6097,O
IV,6097,O
and,6097,O
V,6097,O
when,6097,O
compared,6097,O
to,6097,O
control,6097,O
(,6097,O
P,6097,O
<,6097,O
0.05,6097,O
),6097,O
.,6097,O
The,6098,O
5'-nucleotidase,6098,O
activity,6098,O
was,6098,O
decreased,6098,O
",",6098,O
while,6098,O
E-NPP,6098,B-GENE-N
and,6098,O
ADA,6098,B-GENE-Y
activities,6098,O
were,6098,O
increased,6098,O
in,6098,O
platelets,6098,O
of,6098,O
rats,6098,O
of,6098,O
groups,6098,O
III,6098,O
",",6098,O
IV,6098,O
and,6098,O
V,6098,O
(,6098,O
P,6098,O
<,6098,O
0.05,6098,O
),6098,O
.,6098,O
Caffeic,6099,B-CHEMICAL
acid,6099,I-CHEMICAL
reduced,6099,O
significantly,6099,O
the,6099,O
platelet,6099,O
aggregation,6099,O
in,6099,O
the,6099,O
animals,6099,O
of,6099,O
groups,6099,O
III,6099,O
",",6099,O
IV,6099,O
and,6099,O
V,6099,O
in,6099,O
relation,6099,O
to,6099,O
group,6099,O
I,6099,O
(,6099,O
P,6099,O
<,6099,O
0.05,6099,O
),6099,O
.,6099,O
In,6100,O
lymphocytes,6100,O
",",6100,O
the,6100,O
NTPDase,6100,B-GENE-N
and,6100,O
ADA,6100,B-GENE-Y
activities,6100,O
were,6100,O
increased,6100,O
in,6100,O
all,6100,O
groups,6100,O
treated,6100,O
with,6100,O
caffeic,6100,B-CHEMICAL
acid,6100,I-CHEMICAL
when,6100,O
compared,6100,O
to,6100,O
control,6100,O
(,6100,O
P,6100,O
<,6100,O
0.05,6100,O
),6100,O
.,6100,O
These,6101,O
findings,6101,O
demonstrated,6101,O
that,6101,O
the,6101,O
enzymes,6101,O
were,6101,O
altered,6101,O
in,6101,O
tissues,6101,O
by,6101,O
caffeic,6101,B-CHEMICAL
acid,6101,I-CHEMICAL
and,6101,O
this,6101,O
compound,6101,O
decreased,6101,O
the,6101,O
platelet,6101,O
aggregation,6101,O
suggesting,6101,O
that,6101,O
caffeic,6101,B-CHEMICAL
acid,6101,I-CHEMICAL
should,6101,O
be,6101,O
considered,6101,O
a,6101,O
potentially,6101,O
therapeutic,6101,O
agent,6101,O
in,6101,O
disorders,6101,O
related,6101,O
to,6101,O
the,6101,O
purinergic,6101,O
system,6101,O
.,6101,O
Mutant,6102,O
B-RAF-Mcl-1,6102,B-GENE-Y
survival,6102,O
signaling,6102,O
depends,6102,O
on,6102,O
the,6102,O
STAT3,6102,B-GENE-Y
transcription,6102,O
factor,6102,O
.,6102,O
Approximately,6103,O
50,6103,O
%,6103,O
of,6103,O
melanomas,6103,O
depend,6103,O
on,6103,O
mutant,6103,O
B-RAF,6103,B-GENE-Y
for,6103,O
proliferation,6103,O
",",6103,O
metastasis,6103,O
and,6103,O
survival,6103,O
.,6103,O
The,6104,O
inhibition,6104,O
of,6104,O
oncogenic,6104,O
B-RAF,6104,B-GENE-Y
with,6104,O
highly,6104,O
targeted,6104,O
compounds,6104,O
has,6104,O
produced,6104,O
remarkable,6104,O
albeit,6104,O
short-lived,6104,O
clinical,6104,O
responses,6104,O
in,6104,O
B-RAF,6104,B-GENE-Y
mutant,6104,O
melanoma,6104,O
patients,6104,O
.,6104,O
Reactivation,6105,O
of,6105,O
signaling,6105,O
downstream,6105,O
of,6105,O
B-RAF,6105,B-GENE-Y
is,6105,O
frequently,6105,O
associated,6105,O
with,6105,O
acquired,6105,O
resistance,6105,O
to,6105,O
B-RAF,6105,B-GENE-Y
inhibitors,6105,O
",",6105,O
and,6105,O
the,6105,O
identification,6105,O
of,6105,O
B-RAF,6105,B-GENE-Y
targets,6105,O
may,6105,O
provide,6105,O
new,6105,O
strategies,6105,O
for,6105,O
managing,6105,O
melanoma,6105,O
.,6105,O
Oncogenic,6106,O
B-RAF,6106,B-GENE-Y
(,6106,O
V600E,6106,B-GENE-N
),6106,O
is,6106,O
known,6106,O
to,6106,O
promote,6106,O
the,6106,O
stabilizing,6106,O
phosphorylation,6106,O
of,6106,O
the,6106,O
anti-apoptotic,6106,O
protein,6106,O
Mcl-1,6106,B-GENE-Y
",",6106,O
implicated,6106,O
in,6106,O
melanoma,6106,O
survival,6106,O
and,6106,O
chemoresistance,6106,O
.,6106,O
We,6107,O
now,6107,O
show,6107,O
that,6107,O
B-RAF,6107,B-GENE-Y
(,6107,O
V600E,6107,B-GENE-N
),6107,O
signaling,6107,O
also,6107,O
induces,6107,O
the,6107,O
transcription,6107,O
of,6107,O
Mcl-1,6107,B-GENE-Y
in,6107,O
melanocytes,6107,O
and,6107,O
melanoma,6107,O
.,6107,O
We,6108,O
demonstrate,6108,O
that,6108,O
activation,6108,O
of,6108,O
STAT3,6108,B-GENE-Y
serine-727,6108,B-CHEMICAL
and,6108,O
tyrosine-705,6108,B-CHEMICAL
phosphorylations,6108,O
is,6108,O
promoted,6108,O
by,6108,O
B-RAF,6108,B-GENE-Y
(,6108,O
V600E,6108,B-GENE-N
),6108,O
activity,6108,O
and,6108,O
that,6108,O
the,6108,O
Mcl-1,6108,B-GENE-N
promoter,6108,I-GENE-N
is,6108,O
dependent,6108,O
on,6108,O
a,6108,O
STAT,6108,B-GENE-N
consensus-site,6108,O
for,6108,O
B-RAF-mediated,6108,B-GENE-Y
activation,6108,O
.,6108,O
Consequently,6109,O
",",6109,O
suppression,6109,O
of,6109,O
STAT3,6109,B-GENE-Y
activity,6109,O
disrupted,6109,O
B-RAF,6109,B-GENE-Y
(,6109,O
V600E,6109,B-GENE-N
),6109,O
-mediated,6109,O
induction,6109,O
of,6109,O
Mcl-1,6109,B-GENE-Y
and,6109,O
reduced,6109,O
melanoma,6109,O
cell,6109,O
survival,6109,O
.,6109,O
We,6110,O
propose,6110,O
that,6110,O
STAT3,6110,B-GENE-Y
has,6110,O
a,6110,O
central,6110,O
role,6110,O
in,6110,O
the,6110,O
survival,6110,O
and,6110,O
contributes,6110,O
to,6110,O
chemoresistance,6110,O
of,6110,O
B-RAF,6110,B-GENE-Y
(,6110,O
V600E,6110,B-GENE-N
),6110,O
melanoma.Oncogene,6110,O
advance,6110,O
online,6110,O
publication,6110,O
",",6110,O
4,6110,O
March,6110,O
2013,6110,O
;,6110,O
doi:10.1038/onc.2013.45,6110,O
.,6110,O
Aldehyde,6111,B-GENE-N
oxidase,6111,I-GENE-N
importance,6111,O
in,6111,O
vivo,6111,O
in,6111,O
xenobiotic,6111,O
metabolism,6111,O
:,6111,O
imidacloprid,6111,B-CHEMICAL
nitroreduction,6111,O
in,6111,O
mice,6111,O
.,6111,O
Aldehyde,6112,B-GENE-N
oxidase,6112,I-GENE-N
(,6112,O
AOX,6112,B-GENE-N
),6112,O
metabolizes,6112,O
many,6112,O
xenobiotics,6112,O
in,6112,O
vitro,6112,O
",",6112,O
but,6112,O
its,6112,O
importance,6112,O
in,6112,O
vivo,6112,O
is,6112,O
usually,6112,O
unknown,6112,O
relative,6112,O
to,6112,O
cytochrome,6112,B-GENE-N
P450s,6112,I-GENE-N
(,6112,O
CYPs,6112,B-GENE-N
),6112,O
and,6112,O
other,6112,O
detoxification,6112,O
systems,6112,O
.,6112,O
Currently,6113,O
",",6113,O
the,6113,O
most,6113,O
important,6113,O
insecticides,6113,O
are,6113,O
neonicotinoids,6113,B-CHEMICAL
",",6113,O
which,6113,O
are,6113,O
metabolized,6113,O
in,6113,O
vitro,6113,O
by,6113,O
AOX,6113,B-GENE-N
on,6113,O
reduction,6113,O
of,6113,O
the,6113,O
nitroimino,6113,B-CHEMICAL
group,6113,O
and,6113,O
by,6113,O
CYPs,6113,B-GENE-N
via,6113,O
oxidation,6113,O
reactions,6113,O
.,6113,O
The,6114,O
goal,6114,O
of,6114,O
this,6114,O
study,6114,O
was,6114,O
to,6114,O
establish,6114,O
the,6114,O
relative,6114,O
importance,6114,O
of,6114,O
AOX,6114,B-GENE-N
and,6114,O
CYPs,6114,B-GENE-N
in,6114,O
vivo,6114,O
using,6114,O
the,6114,O
mouse,6114,O
model,6114,O
.,6114,O
The,6115,O
procedure,6115,O
was,6115,O
to,6115,O
reduce,6115,O
liver,6115,O
AOX,6115,B-GENE-N
activity,6115,O
by,6115,O
providing,6115,O
tungsten,6115,B-CHEMICAL
or,6115,O
hydralazine,6115,B-CHEMICAL
in,6115,O
the,6115,O
drinking,6115,O
water,6115,O
or,6115,O
to,6115,O
use,6115,O
the,6115,O
AOX-deficient,6115,B-GENE-N
DBA/2,6115,O
mouse,6115,O
strain,6115,O
.,6115,O
None,6116,O
of,6116,O
these,6116,O
approaches,6116,O
reduced,6116,O
CYP,6116,B-GENE-N
activity,6116,O
measured,6116,O
in,6116,O
vitro,6116,O
with,6116,O
an,6116,O
isozyme,6116,O
nonspecific,6116,O
substrate,6116,O
.,6116,O
Liver,6117,O
AOX,6117,B-GENE-N
activity,6117,O
was,6117,O
reduced,6117,O
by,6117,O
45,6117,O
%,6117,O
with,6117,O
tungsten,6117,B-CHEMICAL
and,6117,O
61,6117,O
%,6117,O
with,6117,O
hydralazine,6117,B-CHEMICAL
and,6117,O
81,6117,O
%,6117,O
in,6117,O
AOX-deficient,6117,B-GENE-N
mice,6117,O
relative,6117,O
to,6117,O
controls,6117,O
.,6117,O
When,6118,O
mice,6118,O
were,6118,O
treated,6118,O
ip,6118,O
with,6118,O
the,6118,O
major,6118,O
neonicotinoid,6118,O
imidacloprid,6118,B-CHEMICAL
(,6118,O
IMI,6118,B-CHEMICAL
),6118,O
",",6118,O
metabolism,6118,O
by,6118,O
CYP,6118,B-GENE-N
oxidation,6118,O
reactions,6118,O
was,6118,O
not,6118,O
appreciably,6118,O
affected,6118,O
",",6118,O
whereas,6118,O
the,6118,O
AOX-generated,6118,B-GENE-N
nitrosoguanidine,6118,B-CHEMICAL
metabolite,6118,O
was,6118,O
decreased,6118,O
by,6118,O
30,6118,O
%,6118,O
with,6118,O
tungsten,6118,B-CHEMICAL
and,6118,O
56,6118,O
%,6118,O
with,6118,O
hydralazine,6118,B-CHEMICAL
and,6118,O
86,6118,O
%,6118,O
in,6118,O
the,6118,O
AOX-deficient,6118,B-GENE-N
mice,6118,O
.,6118,O
The,6119,O
other,6119,O
IMI,6119,B-CHEMICAL
nitroreduction,6119,O
metabolite,6119,O
",",6119,O
desnitro-IMI,6119,O
",",6119,O
was,6119,O
decreased,6119,O
by,6119,O
55,6119,O
%,6119,O
",",6119,O
65,6119,O
%,6119,O
",",6119,O
and,6119,O
81,6119,O
%,6119,O
with,6119,O
tungsten,6119,B-CHEMICAL
",",6119,O
hydralazine,6119,B-CHEMICAL
",",6119,O
and,6119,O
in,6119,O
the,6119,O
AOX-deficient,6119,B-GENE-N
mice,6119,O
",",6119,O
respectively,6119,O
.,6119,O
Thus,6120,O
",",6120,O
decreasing,6120,O
liver,6120,O
AOX,6120,B-GENE-N
activity,6120,O
by,6120,O
three,6120,O
quite,6120,O
different,6120,O
procedures,6120,O
gave,6120,O
a,6120,O
corresponding,6120,O
decrease,6120,O
for,6120,O
in,6120,O
vivo,6120,O
reductive,6120,O
metabolites,6120,O
in,6120,O
the,6120,O
liver,6120,O
of,6120,O
IMI-treated,6120,B-CHEMICAL
mice,6120,O
.,6120,O
Possible,6121,O
AOX,6121,B-GENE-N
involvement,6121,O
in,6121,O
IMI,6121,B-CHEMICAL
metabolism,6121,O
in,6121,O
insects,6121,O
was,6121,O
evaluated,6121,O
using,6121,O
AOX-expressing,6121,B-GENE-N
and,6121,O
AOX-deficient,6121,B-GENE-N
Drosophila,6121,O
",",6121,O
but,6121,O
no,6121,O
differences,6121,O
were,6121,O
found,6121,O
in,6121,O
IMI,6121,B-CHEMICAL
nitroreduction,6121,O
or,6121,O
sensitivity,6121,O
between,6121,O
the,6121,O
two,6121,O
strains,6121,O
.,6121,O
This,6122,O
is,6122,O
the,6122,O
first,6122,O
study,6122,O
to,6122,O
establish,6122,O
the,6122,O
in,6122,O
vivo,6122,O
relevance,6122,O
of,6122,O
AOX,6122,B-GENE-N
in,6122,O
neonicotinoid,6122,B-CHEMICAL
metabolism,6122,O
in,6122,O
mammals,6122,O
and,6122,O
one,6122,O
of,6122,O
the,6122,O
first,6122,O
for,6122,O
xenobiotics,6122,O
in,6122,O
general,6122,O
.,6122,O
Non-front-fanged,6123,O
colubroid,6123,O
snakes,6123,O
:,6123,O
A,6123,O
current,6123,O
evidence-based,6123,O
analysis,6123,O
of,6123,O
medical,6123,O
significance,6123,O
.,6123,O
Non-front-fanged,6124,O
colubroid,6124,O
snakes,6124,O
(,6124,O
NFFC,6124,O
;,6124,O
formerly,6124,O
and,6124,O
artificially,6124,O
taxonomically,6124,O
assembled,6124,O
as,6124,O
``,6124,O
colubrids,6124,O
'',6124,O
),6124,O
comprise,6124,O
about,6124,O
70,6124,O
%,6124,O
of,6124,O
extant,6124,O
snake,6124,O
species,6124,O
and,6124,O
include,6124,O
several,6124,O
taxa,6124,O
now,6124,O
known,6124,O
to,6124,O
cause,6124,O
lethal,6124,O
or,6124,O
life,6124,O
threatening,6124,O
envenoming,6124,O
in,6124,O
humans,6124,O
.,6124,O
Although,6125,O
the,6125,O
medical,6125,O
risks,6125,O
of,6125,O
bites,6125,O
by,6125,O
only,6125,O
a,6125,O
handful,6125,O
of,6125,O
species,6125,O
have,6125,O
been,6125,O
documented,6125,O
",",6125,O
a,6125,O
growing,6125,O
number,6125,O
of,6125,O
NFFC,6125,O
are,6125,O
implicated,6125,O
in,6125,O
medically,6125,O
significant,6125,O
bites,6125,O
.,6125,O
The,6126,O
majority,6126,O
of,6126,O
these,6126,O
snakes,6126,O
have,6126,O
oral,6126,O
products,6126,O
(,6126,O
Duvernoy,6126,O
's,6126,O
secretions,6126,O
",",6126,O
or,6126,O
venoms,6126,O
),6126,O
with,6126,O
unknown,6126,O
biomedical,6126,O
properties,6126,O
and,6126,O
their,6126,O
potential,6126,O
for,6126,O
causing,6126,O
harm,6126,O
in,6126,O
humans,6126,O
is,6126,O
unknown,6126,O
.,6126,O
Increasingly,6127,O
",",6127,O
multiple,6127,O
NFFC,6127,O
species,6127,O
are,6127,O
entering,6127,O
the,6127,O
commercial,6127,O
snake,6127,O
trade,6127,O
posing,6127,O
an,6127,O
uncertain,6127,O
risk,6127,O
.,6127,O
Published,6128,O
case,6128,O
reports,6128,O
describing,6128,O
NFFC,6128,O
bites,6128,O
were,6128,O
assessed,6128,O
for,6128,O
evidence-based,6128,O
value,6128,O
",",6128,O
clinical,6128,O
detail,6128,O
and,6128,O
verified,6128,O
species,6128,O
identification,6128,O
.,6128,O
These,6129,O
data,6129,O
were,6129,O
subjected,6129,O
to,6129,O
meta-analysis,6129,O
and,6129,O
a,6129,O
hazard,6129,O
index,6129,O
was,6129,O
generated,6129,O
for,6129,O
select,6129,O
taxa,6129,O
.,6129,O
Cases,6130,O
on,6130,O
which,6130,O
we,6130,O
consulted,6130,O
or,6130,O
personally,6130,O
treated,6130,O
were,6130,O
included,6130,O
and,6130,O
subjected,6130,O
to,6130,O
the,6130,O
same,6130,O
assessment,6130,O
criteria,6130,O
.,6130,O
Cases,6131,O
involving,6131,O
approximately,6131,O
120,6131,O
species,6131,O
met,6131,O
the,6131,O
selection,6131,O
criteria,6131,O
",",6131,O
and,6131,O
a,6131,O
small,6131,O
subset,6131,O
designated,6131,O
Hazard,6131,O
Level,6131,O
1,6131,O
(,6131,O
most,6131,O
hazardous,6131,O
),6131,O
",",6131,O
contained,6131,O
5,6131,O
species,6131,O
with,6131,O
lethal,6131,O
potential,6131,O
.,6131,O
Recommended,6132,O
management,6132,O
of,6132,O
these,6132,O
cases,6132,O
included,6132,O
antivenom,6132,O
for,6132,O
3,6132,O
species,6132,O
",",6132,O
Dispholidus,6132,O
typus,6132,O
",",6132,O
Rhabdophis,6132,O
tiginis,6132,O
",",6132,O
Rhabdophis,6132,O
subminiatus,6132,O
",",6132,O
whereas,6132,O
others,6132,O
in,6132,O
this,6132,O
subset,6132,O
without,6132,O
commercially,6132,O
available,6132,O
antivenoms,6132,O
(,6132,O
Thelotornis,6132,O
spp,6132,O
.,6132,O
),6132,O
were,6133,O
treated,6133,O
with,6133,O
plasma/erythrocyte,6133,O
replacement,6133,O
therapy,6133,O
and,6133,O
supportive,6133,O
care,6133,O
.,6133,O
Heparin,6134,O
",",6134,O
antifibrinolytics,6134,O
and/or,6134,O
plasmapheresis/exchange,6134,O
transfusion,6134,O
have,6134,O
been,6134,O
used,6134,O
in,6134,O
the,6134,O
management,6134,O
of,6134,O
some,6134,O
Hazard,6134,O
Level,6134,O
1,6134,O
envenomings,6134,O
",",6134,O
but,6134,O
evidence-based,6134,O
analysis,6134,O
positively,6134,O
contraindicates,6134,O
the,6134,O
use,6134,O
of,6134,O
any,6134,O
of,6134,O
these,6134,O
interventions,6134,O
.,6134,O
Hazard,6135,O
Level,6135,O
2/3,6135,O
species,6135,O
were,6135,O
involved,6135,O
in,6135,O
cases,6135,O
containing,6135,O
mixed,6135,O
quality,6135,O
data,6135,O
that,6135,O
implicated,6135,O
these,6135,O
taxa,6135,O
(,6135,O
e.g,6135,O
.,6135,O
Boiga,6136,O
irregularis,6136,O
",",6136,O
Philodryas,6136,O
olfersii,6136,O
",",6136,O
Malpolon,6136,O
monspessulanus,6136,O
),6136,O
with,6136,O
bites,6136,O
that,6136,O
caused,6136,O
rare,6136,O
systemic,6136,O
effects,6136,O
.,6136,O
Recommended,6137,O
management,6137,O
may,6137,O
include,6137,O
use,6137,O
of,6137,O
acetylcholinesterase,6137,B-GENE-Y
inhibitors,6137,O
(,6137,O
e.g,6137,O
.,6137,O
neostigmine,6138,B-CHEMICAL
),6138,O
and,6138,O
wound,6138,O
care,6138,O
on,6138,O
a,6138,O
case-by-case,6138,O
basis,6138,O
.,6138,O
Hazard,6139,O
level,6139,O
3,6139,O
species,6139,O
comprised,6139,O
a,6139,O
larger,6139,O
group,6139,O
capable,6139,O
of,6139,O
producing,6139,O
significant,6139,O
local,6139,O
effects,6139,O
only,6139,O
",",6139,O
often,6139,O
associated,6139,O
with,6139,O
a,6139,O
protracted,6139,O
bite,6139,O
(,6139,O
eg,6139,O
Heterodon,6139,O
nasicus,6139,O
",",6139,O
Borikenophis,6139,O
(,6139,O
Alsophis,6139,O
),6139,O
portoricensis,6139,O
",",6139,O
Platyceps,6139,O
(,6139,O
Coluber,6139,O
),6139,O
rhodorachis,6139,O
),6139,O
.,6139,O
Management,6140,O
is,6140,O
restricted,6140,O
to,6140,O
wound,6140,O
care,6140,O
.,6140,O
Bites,6141,O
by,6141,O
Hazard,6141,O
level,6141,O
4,6141,O
species,6141,O
comprised,6141,O
the,6141,O
majority,6141,O
of,6141,O
surveyed,6141,O
taxa,6141,O
and,6141,O
these,6141,O
showed,6141,O
only,6141,O
minor,6141,O
effects,6141,O
of,6141,O
no,6141,O
clinical,6141,O
importance,6141,O
.,6141,O
This,6142,O
study,6142,O
has,6142,O
produced,6142,O
a,6142,O
comprehensive,6142,O
evidence-based,6142,O
listing,6142,O
of,6142,O
NFFC,6142,O
snakes,6142,O
tabulated,6142,O
against,6142,O
medical,6142,O
significance,6142,O
of,6142,O
bites,6142,O
",",6142,O
together,6142,O
with,6142,O
best-practice,6142,O
management,6142,O
recommendations,6142,O
.,6142,O
This,6143,O
analysis,6143,O
assumes,6143,O
increasing,6143,O
importance,6143,O
",",6143,O
as,6143,O
there,6143,O
is,6143,O
growing,6143,O
exposure,6143,O
to,6143,O
lesser-known,6143,O
NFFC,6143,O
snakes,6143,O
",",6143,O
particularly,6143,O
in,6143,O
captive,6143,O
collections,6143,O
that,6143,O
may,6143,O
uncover,6143,O
further,6143,O
species,6143,O
of,6143,O
significance,6143,O
in,6143,O
the,6143,O
future,6143,O
.,6143,O
Careful,6144,O
and,6144,O
accurate,6144,O
documentation,6144,O
of,6144,O
bites,6144,O
by,6144,O
verified,6144,O
species,6144,O
of,6144,O
NFFC,6144,O
snakes,6144,O
is,6144,O
required,6144,O
to,6144,O
increase,6144,O
the,6144,O
evidence,6144,O
base,6144,O
and,6144,O
establish,6144,O
the,6144,O
best,6144,O
medical,6144,O
management,6144,O
approach,6144,O
for,6144,O
each,6144,O
species,6144,O
.,6144,O
Cell,6145,O
cycle,6145,O
arrest,6145,O
",",6145,O
extracellular,6145,O
matrix,6145,O
changes,6145,O
and,6145,O
intrinsic,6145,O
apoptosis,6145,O
in,6145,O
human,6145,O
melanoma,6145,O
cells,6145,O
are,6145,O
induced,6145,O
by,6145,O
Boron,6145,B-CHEMICAL
Neutron,6145,O
Capture,6145,O
Therapy,6145,O
.,6145,O
Boron,6146,B-CHEMICAL
Neutron,6146,O
Capture,6146,O
Therapy,6146,O
(,6146,O
BNCT,6146,O
),6146,O
involves,6146,O
the,6146,O
selective,6146,O
accumulation,6146,O
of,6146,O
boron,6146,O
carriers,6146,O
in,6146,O
tumor,6146,O
tissue,6146,O
followed,6146,O
by,6146,O
irradiation,6146,O
with,6146,O
a,6146,O
thermal,6146,O
or,6146,O
epithermal,6146,O
neutron,6146,O
beam,6146,O
.,6146,O
This,6147,O
therapy,6147,O
is,6147,O
therefore,6147,O
a,6147,O
cellular,6147,O
irradiation,6147,O
suited,6147,O
to,6147,O
treat,6147,O
tumors,6147,O
that,6147,O
have,6147,O
infiltrated,6147,O
into,6147,O
healthy,6147,O
tissues,6147,O
.,6147,O
BNCT,6148,O
has,6148,O
been,6148,O
used,6148,O
clinically,6148,O
to,6148,O
treat,6148,O
patients,6148,O
with,6148,O
cutaneous,6148,O
melanomas,6148,O
which,6148,O
have,6148,O
a,6148,O
high,6148,O
mortality,6148,O
.,6148,O
Human,6149,O
normal,6149,O
melanocytes,6149,O
and,6149,O
melanoma,6149,O
cells,6149,O
were,6149,O
treated,6149,O
with,6149,O
BNCT,6149,O
at,6149,O
different,6149,O
boronophenylalanine,6149,B-CHEMICAL
concentrations,6149,O
for,6149,O
signaling,6149,O
pathways,6149,O
analysis,6149,O
.,6149,O
BNCT,6150,O
induced,6150,O
few,6150,O
morphological,6150,O
alterations,6150,O
in,6150,O
normal,6150,O
melanocytes,6150,O
",",6150,O
with,6150,O
a,6150,O
negligible,6150,O
increase,6150,O
in,6150,O
free,6150,O
radical,6150,O
production,6150,O
.,6150,O
Melanoma,6151,O
cells,6151,O
treated,6151,O
with,6151,O
BNCT,6151,O
showed,6151,O
significant,6151,O
extracellular,6151,O
matrix,6151,O
(,6151,O
ECM,6151,O
),6151,O
changes,6151,O
and,6151,O
a,6151,O
significant,6151,O
cyclin,6151,B-GENE-Y
D1,6151,I-GENE-Y
decrease,6151,O
",",6151,O
suggesting,6151,O
cell,6151,O
death,6151,O
by,6151,O
necrosis,6151,O
and,6151,O
apoptosis,6151,O
and,6151,O
cell,6151,O
cycle,6151,O
arrest,6151,O
",",6151,O
respectively,6151,O
.,6151,O
BNCT,6152,O
also,6152,O
induced,6152,O
a,6152,O
significant,6152,O
increase,6152,O
in,6152,O
cleaved,6152,O
caspase-3,6152,B-GENE-Y
and,6152,O
a,6152,O
decrease,6152,O
in,6152,O
the,6152,O
mitochondrial,6152,O
electrical,6152,O
potential,6152,O
with,6152,O
selectivity,6152,O
for,6152,O
melanoma,6152,O
cells,6152,O
.,6152,O
Normal,6153,O
melanocytes,6153,O
had,6153,O
no,6153,O
significant,6153,O
differences,6153,O
due,6153,O
to,6153,O
BNCT,6153,O
treatment,6153,O
",",6153,O
confirming,6153,O
the,6153,O
data,6153,O
from,6153,O
the,6153,O
literature,6153,O
regarding,6153,O
the,6153,O
selectivity,6153,O
of,6153,O
BNCT,6153,O
.,6153,O
The,6154,O
results,6154,O
from,6154,O
this,6154,O
study,6154,O
suggest,6154,O
that,6154,O
some,6154,O
signaling,6154,O
pathways,6154,O
are,6154,O
involved,6154,O
in,6154,O
human,6154,O
melanoma,6154,O
treatment,6154,O
by,6154,O
BNCT,6154,O
",",6154,O
such,6154,O
as,6154,O
cell,6154,O
cycle,6154,O
arrest,6154,O
",",6154,O
ECM,6154,O
changes,6154,O
and,6154,O
intrinsic,6154,O
apoptosis,6154,O
.,6154,O
Anti-adipogenic,6155,O
diarylheptanoids,6155,B-CHEMICAL
from,6155,O
Alnus,6155,O
hirsuta,6155,O
f.,6155,O
sibirica,6155,O
on,6155,O
3T3-L1,6155,O
cells,6155,O
.,6155,O
A,6156,O
new,6156,O
diarylheptanoid,6156,B-CHEMICAL
",",6156,O
(,6156,B-CHEMICAL
5S,6156,I-CHEMICAL
),6156,I-CHEMICAL
-hydroxy-1-,6156,I-CHEMICAL
(,6156,I-CHEMICAL
"3,4-dihydroxyphenyl",6156,I-CHEMICAL
),6156,I-CHEMICAL
-7-,6156,I-CHEMICAL
(,6156,I-CHEMICAL
4-hydroxyphenyl,6156,I-CHEMICAL
),6156,I-CHEMICAL
-hepta-1E-en-3-one,6156,I-CHEMICAL
(,6156,O
1,6156,O
),6156,O
",",6156,O
was,6156,O
isolated,6156,O
along,6156,O
with,6156,O
seventeen,6156,O
known,6156,O
diarylheptanoids,6156,B-CHEMICAL
(,6156,O
2-18,6156,O
),6156,O
from,6156,O
the,6156,O
methanol,6156,B-CHEMICAL
extract,6156,O
of,6156,O
Alnus,6156,O
hirsuta,6156,O
f.,6156,O
sibirica,6156,O
leaves,6156,O
using,6156,O
bioactivity-guided,6156,O
fractionation,6156,O
.,6156,O
Among,6157,O
the,6157,O
isolated,6157,O
compounds,6157,O
",",6157,O
compounds,6157,O
1,6157,O
and,6157,O
2,6157,O
and,6157,O
4-12,6157,O
reduced,6157,O
lipid,6157,O
accumulation,6157,O
dose-dependently,6157,O
in,6157,O
3T3-L1,6157,O
preadipocytes,6157,O
.,6157,O
Of,6158,O
the,6158,O
compounds,6158,O
active,6158,O
in,6158,O
the,6158,O
present,6158,O
assay,6158,O
system,6158,O
",",6158,O
the,6158,O
most,6158,O
potent,6158,O
compound,6158,O
7,6158,O
",",6158,O
platyphyllonol-5-O-β-d-xylopyranoside,6158,B-CHEMICAL
",",6158,O
significantly,6158,O
suppressed,6158,O
the,6158,O
induction,6158,O
of,6158,O
peroxisome,6158,B-GENE-Y
proliferator,6158,I-GENE-Y
activated,6158,I-GENE-Y
receptor,6158,I-GENE-Y
γ,6158,I-GENE-Y
(,6158,O
PPARγ,6158,B-GENE-Y
and,6158,O
CCAAT/enhancer,6158,B-GENE-Y
binding,6158,I-GENE-Y
protein,6158,I-GENE-Y
α,6158,I-GENE-Y
(,6158,O
C/EBPα,6158,B-GENE-Y
),6158,O
protein,6158,O
expression,6158,O
",",6158,O
and,6158,O
inhibited,6158,O
adipocyte,6158,O
differentiation,6158,O
induced,6158,O
by,6158,O
troglitazone,6158,B-CHEMICAL
",",6158,O
a,6158,O
PPARγ,6158,B-GENE-Y
agonist,6158,O
.,6158,O
It,6159,O
was,6159,O
demonstrated,6159,O
that,6159,O
compound,6159,O
7,6159,O
has,6159,O
anti-adipogenic,6159,O
activity,6159,O
mediated,6159,O
by,6159,O
the,6159,O
regulation,6159,O
of,6159,O
PPARγ,6159,B-GENE-Y
dependent,6159,O
pathways,6159,O
.,6159,O
Benzenesulfonamides,6160,B-CHEMICAL
:,6160,O
a,6160,O
unique,6160,O
class,6160,O
of,6160,O
chemokine,6160,B-GENE-Y
receptor,6160,I-GENE-Y
type,6160,I-GENE-Y
4,6160,I-GENE-Y
inhibitors,6160,O
.,6160,O
The,6161,O
interaction,6161,O
of,6161,O
CXCR4,6161,B-GENE-Y
with,6161,O
CXCL12,6161,B-GENE-Y
(,6161,O
SDF-1,6161,B-GENE-Y
),6161,O
plays,6161,O
a,6161,O
critical,6161,O
role,6161,O
in,6161,O
cancer,6161,O
metastasis,6161,O
by,6161,O
facilitating,6161,O
the,6161,O
homing,6161,O
of,6161,O
tumor,6161,O
cells,6161,O
to,6161,O
metastatic,6161,O
sites,6161,O
.,6161,O
Based,6162,O
on,6162,O
our,6162,O
previously,6162,O
published,6162,O
work,6162,O
on,6162,O
CXCR4,6162,B-GENE-Y
antagonists,6162,O
",",6162,O
we,6162,O
have,6162,O
synthesized,6162,O
a,6162,O
series,6162,O
of,6162,O
aryl,6162,B-CHEMICAL
sulfonamides,6162,I-CHEMICAL
that,6162,O
inhibit,6162,O
the,6162,O
CXCR4/CXCL12,6162,B-GENE-Y
interaction,6162,O
.,6162,O
Analogue,6163,O
bioactivities,6163,O
were,6163,O
assessed,6163,O
with,6163,O
binding,6163,O
affinity,6163,O
and,6163,O
Matrigel,6163,O
invasion,6163,O
assays,6163,O
.,6163,O
Computer,6164,O
modeling,6164,O
was,6164,O
employed,6164,O
to,6164,O
evaluate,6164,O
a,6164,O
selection,6164,O
of,6164,O
the,6164,O
new,6164,O
analogues,6164,O
docked,6164,O
into,6164,O
the,6164,O
CXCR4,6164,B-GENE-Y
X-ray,6164,O
structure,6164,O
and,6164,O
to,6164,O
rationalize,6164,O
discrepancies,6164,O
between,6164,O
the,6164,O
affinity,6164,O
and,6164,O
Matrigel,6164,O
in,6164,O
vitro,6164,O
assays,6164,O
.,6164,O
A,6165,O
lead,6165,O
compound,6165,O
displays,6165,O
nanomolar,6165,O
potency,6165,O
in,6165,O
the,6165,O
binding,6165,O
affinity,6165,O
assay,6165,O
(,6165,O
IC,6165,O
(,6165,O
50,6165,O
),6165,O
=8.0,6165,O
nM,6165,O
),6165,O
and,6165,O
the,6165,O
Matrigel,6165,O
invasion,6165,O
assay,6165,O
(,6165,O
100,6165,O
%,6165,O
blockade,6165,O
of,6165,O
invasion,6165,O
at,6165,O
10,6165,O
nM,6165,O
),6165,O
.,6165,O
These,6166,O
data,6166,O
demonstrate,6166,O
that,6166,O
benzenesulfonamides,6166,B-CHEMICAL
are,6166,O
a,6166,O
unique,6166,O
class,6166,O
of,6166,O
CXCR4,6166,B-GENE-Y
inhibitors,6166,O
with,6166,O
high,6166,O
potency,6166,O
.,6166,O
Oncolytic,6167,O
activity,6167,O
and,6167,O
mechanism,6167,O
of,6167,O
action,6167,O
of,6167,O
a,6167,O
novel,6167,O
L-cysteine,6167,B-CHEMICAL
derivative,6167,O
",",6167,O
L-cysteine,6167,B-CHEMICAL
",",6167,I-CHEMICAL
ethyl,6167,I-CHEMICAL
ester,6167,I-CHEMICAL
",",6167,I-CHEMICAL
S-,6167,I-CHEMICAL
(,6167,I-CHEMICAL
N-methylcarbamate,6167,I-CHEMICAL
),6167,I-CHEMICAL
monohydrochloride,6167,I-CHEMICAL
.,6167,O
A,6168,O
study,6168,O
on,6168,O
the,6168,O
oncolytic,6168,O
activity,6168,O
of,6168,O
the,6168,O
L-cysteine,6168,B-CHEMICAL
derivative,6168,O
L-cysteine,6168,B-CHEMICAL
",",6168,I-CHEMICAL
ethyl,6168,I-CHEMICAL
ester,6168,I-CHEMICAL
",",6168,I-CHEMICAL
S-,6168,I-CHEMICAL
(,6168,I-CHEMICAL
N-methylcarbamate,6168,I-CHEMICAL
),6168,I-CHEMICAL
monohydrochloride,6168,I-CHEMICAL
(,6168,O
NSC,6168,B-CHEMICAL
303861,6168,I-CHEMICAL
),6168,O
",",6168,O
revealed,6168,O
that,6168,O
the,6168,O
drug,6168,O
caused,6168,O
complete,6168,O
regression,6168,O
of,6168,O
the,6168,O
MX-1,6168,O
human,6168,O
mammary,6168,O
tumor,6168,O
xenograft,6168,O
.,6168,O
The,6169,O
compound,6169,O
also,6169,O
exhibited,6169,O
moderate,6169,O
antitumor,6169,O
activity,6169,O
against,6169,O
murine,6169,O
leukemia,6169,O
P388,6169,O
(,6169,O
T/C,6169,O
value,6169,O
of,6169,O
169,6169,O
%,6169,O
at,6169,O
a,6169,O
daily,6169,O
dose,6169,O
of,6169,O
400,6169,O
mg/kg,6169,O
),6169,O
and,6169,O
against,6169,O
M5076,6169,O
sarcoma,6169,O
(,6169,O
T/C,6169,O
value,6169,O
of,6169,O
135,6169,O
%,6169,O
at,6169,O
a,6169,O
daily,6169,O
dose,6169,O
of,6169,O
600,6169,O
mg/kg,6169,O
),6169,O
.,6169,O
The,6170,O
drug,6170,O
was,6170,O
inactive,6170,O
against,6170,O
B16,6170,O
melanoma,6170,O
",",6170,O
Lewis,6170,O
lung,6170,O
",",6170,O
colon,6170,O
38,6170,O
and,6170,O
CD8F1,6170,O
mammary,6170,O
carcinomas,6170,O
.,6170,O
The,6171,O
compound,6171,O
exhibited,6171,O
significant,6171,O
cytotoxicity,6171,O
against,6171,O
hepatoma,6171,O
3924A,6171,O
cells,6171,O
in,6171,O
culture,6171,O
(,6171,O
LC50,6171,O
=,6171,O
6,6171,O
microM,6171,O
),6171,O
.,6171,O
Studies,6172,O
on,6172,O
the,6172,O
mechanism,6172,O
of,6172,O
action,6172,O
revealed,6172,O
that,6172,O
the,6172,O
cytotoxicity,6172,O
of,6172,O
the,6172,O
drug,6172,O
could,6172,O
be,6172,O
partially,6172,O
abrogated,6172,O
by,6172,O
protecting,6172,O
hepatoma,6172,O
3924A,6172,O
cells,6172,O
in,6172,O
culture,6172,O
with,6172,O
L-glutamine,6172,B-CHEMICAL
.,6172,O
At,6173,O
6,6173,O
h,6173,O
after,6173,O
injection,6173,O
of,6173,O
the,6173,O
compound,6173,O
(,6173,O
400,6173,O
mg/kg,6173,O
),6173,O
into,6173,O
rats,6173,O
bearing,6173,O
hepatoma,6173,O
3924A,6173,O
",",6173,O
the,6173,O
pools,6173,O
of,6173,O
L-glutamine,6173,B-CHEMICAL
and,6173,O
L-glutamate,6173,B-CHEMICAL
in,6173,O
the,6173,O
tumor,6173,O
decreased,6173,O
to,6173,O
33,6173,O
%,6173,O
and,6173,O
71,6173,O
%,6173,O
",",6173,O
respectively,6173,O
",",6173,O
of,6173,O
control,6173,O
levels,6173,O
;,6173,O
the,6173,O
drug,6173,O
selectively,6173,O
inhibited,6173,O
the,6173,O
activities,6173,O
of,6173,O
L-glutamine-requiring,6173,B-CHEMICAL
enzymes,6173,O
of,6173,O
purine,6173,B-CHEMICAL
nucleotide,6173,I-CHEMICAL
biosynthesis,6173,O
",",6173,O
amidophosphoribosyltransferase,6173,B-GENE-Y
",",6173,O
FGAM,6173,B-CHEMICAL
synthase,6173,I-GENE-Y
",",6173,O
and,6173,O
GMP,6173,B-CHEMICAL
synthase,6173,I-GENE-Y
",",6173,O
to,6173,O
21,6173,O
%,6173,O
",",6173,O
1,6173,O
%,6173,O
",",6173,O
and,6173,O
69,6173,O
%,6173,O
",",6173,O
respectively,6173,O
",",6173,O
without,6173,O
significantly,6173,O
altering,6173,O
the,6173,O
activities,6173,O
of,6173,O
pyrimidine,6173,B-CHEMICAL
biosynthetic,6173,O
enzymes,6173,O
",",6173,O
carbamoylphosphate,6173,B-CHEMICAL
synthase,6173,I-GENE-Y
II,6173,I-GENE-Y
and,6173,O
CTP,6173,B-CHEMICAL
synthase,6173,I-GENE-Y
.,6173,O
Measurement,6174,O
of,6174,O
the,6174,O
nucleotide,6174,B-CHEMICAL
concentrations,6174,O
further,6174,O
corroborated,6174,O
the,6174,O
actions,6174,O
of,6174,O
the,6174,O
drug,6174,O
on,6174,O
the,6174,O
purine,6174,B-CHEMICAL
nucleotide,6174,I-CHEMICAL
biosynthetic,6174,O
enzyme,6174,O
activities,6174,O
.,6174,O
Drug,6175,O
injection,6175,O
(,6175,O
400,6175,O
mg/kg,6175,O
),6175,O
in,6175,O
the,6175,O
hepatoma,6175,O
3924A-bearing,6175,O
rats,6175,O
reduced,6175,O
the,6175,O
concentrations,6175,O
of,6175,O
IMP,6175,B-CHEMICAL
in,6175,O
the,6175,O
tumor,6175,O
to,6175,O
52,6175,O
%,6175,O
",",6175,O
those,6175,O
of,6175,O
total,6175,O
adenylates,6175,B-CHEMICAL
to,6175,O
52,6175,O
%,6175,O
",",6175,O
those,6175,O
of,6175,O
total,6175,O
guanylates,6175,B-CHEMICAL
to,6175,O
57,6175,O
%,6175,O
",",6175,O
and,6175,O
those,6175,O
of,6175,O
NAD,6175,B-CHEMICAL
to,6175,O
73,6175,O
%,6175,O
",",6175,O
without,6175,O
significantly,6175,O
perturbing,6175,O
the,6175,O
pyrimidine,6175,B-CHEMICAL
nucleotide,6175,I-CHEMICAL
pools,6175,O
.,6175,O
Studies,6176,O
on,6176,O
the,6176,O
mechanism,6176,O
of,6176,O
action,6176,O
of,6176,O
the,6176,O
L-cysteine,6176,B-CHEMICAL
derivative,6176,O
suggested,6176,O
that,6176,O
the,6176,O
compound,6176,O
behaved,6176,O
as,6176,O
an,6176,O
L-glutamine,6176,B-CHEMICAL
antagonist,6176,O
",",6176,O
selectively,6176,O
acting,6176,O
on,6176,O
the,6176,O
enzymes,6176,O
of,6176,O
purine,6176,B-CHEMICAL
nucleotide,6176,I-CHEMICAL
biosynthesis,6176,O
.,6176,O
Measurement,6177,O
of,6177,O
Transport,6177,O
Activities,6177,O
of,6177,O
3β-Hydroxy-Δ,6177,B-CHEMICAL
(,6177,I-CHEMICAL
5,6177,I-CHEMICAL
),6177,I-CHEMICAL
-bile,6177,I-CHEMICAL
Acids,6177,I-CHEMICAL
in,6177,O
Bile,6177,B-GENE-Y
Salt,6177,I-GENE-Y
Export,6177,I-GENE-Y
Pump,6177,I-GENE-Y
and,6177,O
Multidrug,6177,B-GENE-N
Resistance-Associated,6177,I-GENE-N
Proteins,6177,I-GENE-N
Using,6177,O
LC-MS/MS,6177,O
.,6177,O
A,6178,O
method,6178,O
has,6178,O
been,6178,O
developed,6178,O
for,6178,O
the,6178,O
measurement,6178,O
of,6178,O
transport,6178,O
activities,6178,O
in,6178,O
membrane,6178,O
vesicles,6178,O
obtained,6178,O
from,6178,O
Sf9,6178,O
cells,6178,O
for,6178,O
3β-hydroxy-Δ,6178,B-CHEMICAL
(,6178,I-CHEMICAL
5,6178,I-CHEMICAL
),6178,I-CHEMICAL
-bile,6178,I-CHEMICAL
acids,6178,I-CHEMICAL
by,6178,O
high-performance,6178,O
liquid,6178,O
chromatography-electrospray,6178,O
ionization-tandem,6178,O
mass,6178,O
spectrometry,6178,O
.,6178,O
Calibration,6179,O
curves,6179,O
for,6179,O
the,6179,O
bile,6179,B-CHEMICAL
acids,6179,I-CHEMICAL
were,6179,O
linear,6179,O
over,6179,O
the,6179,O
range,6179,O
of,6179,O
10,6179,O
to,6179,O
2000,6179,O
pmol/mL,6179,O
",",6179,O
and,6179,O
the,6179,O
detection,6179,O
limit,6179,O
was,6179,O
less,6179,O
than,6179,O
1,6179,O
pmol/mL,6179,O
for,6179,O
3β-hydroxy-Δ,6179,B-CHEMICAL
(,6179,I-CHEMICAL
5,6179,I-CHEMICAL
),6179,I-CHEMICAL
-bile,6179,I-CHEMICAL
acids,6179,I-CHEMICAL
using,6179,O
selected,6179,O
reaction,6179,O
monitoring,6179,O
analysis,6179,O
.,6179,O
The,6180,O
analytical,6180,O
method,6180,O
was,6180,O
applied,6180,O
to,6180,O
measurements,6180,O
of,6180,O
transport,6180,O
activities,6180,O
in,6180,O
membrane,6180,O
vesicles,6180,O
obtained,6180,O
from,6180,O
human,6180,B-GENE-N
multidrug,6180,I-GENE-N
resistance-associated,6180,I-GENE-N
protein,6180,I-GENE-N
2-,6180,I-GENE-N
",",6180,I-GENE-N
3-,6180,O
",",6180,O
and,6180,O
human,6180,B-GENE-Y
bile,6180,B-CHEMICAL
salt,6180,I-CHEMICAL
export,6180,I-GENE-Y
pump-expressing,6180,O
Sf9,6180,O
cells,6180,O
for,6180,O
conjugated,6180,O
3β-hydroxy-Δ,6180,B-CHEMICAL
(,6180,I-CHEMICAL
5,6180,I-CHEMICAL
),6180,I-CHEMICAL
-bile,6180,I-CHEMICAL
acids,6180,I-CHEMICAL
.,6180,O
The,6181,O
present,6181,O
study,6181,O
demonstrated,6181,O
that,6181,O
human,6181,B-GENE-Y
multidrug,6181,I-GENE-Y
resistance-associated,6181,I-GENE-Y
protein,6181,I-GENE-Y
3,6181,I-GENE-Y
vesicles,6181,O
accepted,6181,O
conjugated,6181,O
3β-hydroxy-Δ,6181,B-CHEMICAL
(,6181,I-CHEMICAL
5,6181,I-CHEMICAL
),6181,I-CHEMICAL
-bile,6181,I-CHEMICAL
acids,6181,I-CHEMICAL
along,6181,O
with,6181,O
common,6181,O
bile,6181,B-CHEMICAL
acids,6181,I-CHEMICAL
such,6181,O
as,6181,O
glycocholic,6181,B-CHEMICAL
acid,6181,I-CHEMICAL
and,6181,O
taurolithocholic,6181,B-CHEMICAL
acid,6181,I-CHEMICAL
3-sulfate,6181,I-CHEMICAL
.,6181,O
An,6182,O
Intracellular,6182,O
Domain,6182,O
Fragment,6182,O
of,6182,O
the,6182,O
p75,6182,B-GENE-Y
Neurotrophin,6182,I-GENE-Y
Receptor,6182,I-GENE-Y
(,6182,O
p75NTR,6182,B-GENE-Y
),6182,O
Enhances,6182,O
Tropomyosin,6182,B-GENE-Y
Receptor,6182,I-GENE-Y
Kinase,6182,I-GENE-Y
A,6182,I-GENE-Y
(,6182,O
TrkA,6182,B-GENE-Y
),6182,O
Receptor,6182,O
Function,6182,O
.,6182,O
Facilitation,6183,O
of,6183,O
nerve,6183,B-GENE-Y
growth,6183,I-GENE-Y
factor,6183,I-GENE-Y
(,6183,O
NGF,6183,B-GENE-Y
),6183,O
signaling,6183,O
by,6183,O
the,6183,O
p75,6183,B-GENE-Y
neurotrophin,6183,I-GENE-Y
receptor,6183,I-GENE-Y
(,6183,O
p75,6183,B-GENE-Y
(,6183,I-GENE-Y
NTR,6183,I-GENE-Y
),6183,I-GENE-Y
),6183,O
is,6183,O
critical,6183,O
for,6183,O
neuronal,6183,O
survival,6183,O
and,6183,O
differentiation,6183,O
.,6183,O
However,6184,O
",",6184,O
the,6184,O
interaction,6184,O
between,6184,O
p75,6184,B-GENE-Y
(,6184,I-GENE-Y
NTR,6184,I-GENE-Y
),6184,I-GENE-Y
and,6184,O
TrkA,6184,B-GENE-Y
receptors,6184,O
required,6184,O
for,6184,O
this,6184,O
activity,6184,O
is,6184,O
not,6184,O
understood,6184,O
.,6184,O
Here,6185,O
",",6185,O
we,6185,O
report,6185,O
that,6185,O
a,6185,O
specific,6185,O
29-amino,6185,O
acid,6185,I-CHEMICAL
peptide,6185,O
derived,6185,O
from,6185,O
the,6185,O
intracellular,6185,O
domain,6185,O
fragment,6185,O
of,6185,O
p75,6185,B-GENE-Y
(,6185,I-GENE-Y
NTR,6185,I-GENE-Y
),6185,I-GENE-Y
interacts,6185,O
with,6185,O
and,6185,O
potentiates,6185,O
binding,6185,O
of,6185,O
NGF,6185,B-GENE-Y
to,6185,O
TrkA-expressing,6185,B-GENE-Y
cells,6185,O
",",6185,O
leading,6185,O
to,6185,O
increased,6185,O
neurite,6185,O
outgrowth,6185,O
in,6185,O
sympathetic,6185,O
neurons,6185,O
as,6185,O
a,6185,O
result,6185,O
of,6185,O
enhanced,6185,O
Erk1/2,6185,B-GENE-N
and,6185,O
Akt,6185,B-GENE-N
signaling,6185,O
.,6185,O
An,6186,O
endogenous,6186,O
intracellular,6186,O
domain,6186,O
fragment,6186,O
of,6186,O
p75,6186,B-GENE-Y
(,6186,I-GENE-Y
NTR,6186,I-GENE-Y
),6186,I-GENE-Y
(,6186,O
p75,6186,B-GENE-N
(,6186,I-GENE-N
ICD,6186,I-GENE-N
),6186,I-GENE-N
),6186,O
containing,6186,O
these,6186,O
29,6186,O
amino,6186,B-CHEMICAL
acids,6186,I-CHEMICAL
is,6186,O
produced,6186,O
by,6186,O
regulated,6186,O
proteolysis,6186,O
of,6186,O
the,6186,O
full-length,6186,O
receptor,6186,O
.,6186,O
We,6187,O
demonstrate,6187,O
that,6187,O
generation,6187,O
of,6187,O
this,6187,O
fragment,6187,O
is,6187,O
a,6187,O
requirement,6187,O
for,6187,O
p75,6187,B-GENE-Y
(,6187,I-GENE-Y
NTR,6187,I-GENE-Y
),6187,I-GENE-Y
to,6187,O
facilitate,6187,O
TrkA,6187,B-GENE-Y
signaling,6187,O
in,6187,O
neurons,6187,O
and,6187,O
propose,6187,O
that,6187,O
the,6187,O
juxtamembrane,6187,O
region,6187,O
of,6187,O
p75,6187,B-GENE-N
(,6187,I-GENE-N
ICD,6187,I-GENE-N
),6187,I-GENE-N
acts,6187,O
to,6187,O
cause,6187,O
a,6187,O
conformational,6187,O
change,6187,O
within,6187,O
the,6187,O
extracellular,6187,O
domain,6187,O
of,6187,O
TrkA,6187,B-GENE-Y
.,6187,O
This,6188,O
finding,6188,O
provides,6188,O
new,6188,O
insight,6188,O
into,6188,O
the,6188,O
mechanism,6188,O
by,6188,O
which,6188,O
p75,6188,B-GENE-Y
(,6188,I-GENE-Y
NTR,6188,I-GENE-Y
),6188,I-GENE-Y
and,6188,O
TrkA,6188,B-GENE-Y
interact,6188,O
to,6188,O
enhance,6188,O
neurotrophic,6188,O
signaling,6188,O
.,6188,O
Synthesis,6189,O
and,6189,O
evaluation,6189,O
of,6189,O
3-,6189,B-CHEMICAL
(,6189,I-CHEMICAL
benzylthio,6189,I-CHEMICAL
),6189,I-CHEMICAL
-5-,6189,I-CHEMICAL
(,6189,I-CHEMICAL
1H-indol-3-yl,6189,I-CHEMICAL
),6189,I-CHEMICAL
"-1,2,4-triazol-4-amines",6189,I-CHEMICAL
as,6189,O
Bcl-2,6189,B-GENE-Y
inhibitory,6189,O
anticancer,6189,O
agents,6189,O
.,6189,O
A,6190,O
series,6190,O
of,6190,O
substituted,6190,O
3-,6190,B-CHEMICAL
(,6190,I-CHEMICAL
benzylthio,6190,I-CHEMICAL
),6190,I-CHEMICAL
-5-,6190,I-CHEMICAL
(,6190,I-CHEMICAL
1H-indol-3-yl,6190,I-CHEMICAL
),6190,I-CHEMICAL
"-4H-1,2,4-triazol-4-amines",6190,I-CHEMICAL
has,6190,O
been,6190,O
synthesised,6190,O
and,6190,O
tested,6190,O
in,6190,O
vitro,6190,O
as,6190,O
potential,6190,O
pro-apoptotic,6190,O
Bcl-2-inhibitory,6190,B-GENE-Y
anticancer,6190,O
agents,6190,O
.,6190,O
Synthesis,6191,O
of,6191,O
the,6191,O
target,6191,O
compounds,6191,O
was,6191,O
readily,6191,O
accomplished,6191,O
in,6191,O
good,6191,O
yields,6191,O
through,6191,O
a,6191,O
cyclisation,6191,O
reaction,6191,O
between,6191,O
indole-3-carboxylic,6191,B-CHEMICAL
acid,6191,I-CHEMICAL
hydrazide,6191,I-CHEMICAL
and,6191,O
carbon,6191,B-CHEMICAL
disulfide,6191,I-CHEMICAL
under,6191,O
basic,6191,O
conditions,6191,O
",",6191,O
followed,6191,O
by,6191,O
S-benzylation,6191,B-CHEMICAL
.,6191,O
Active,6192,O
compounds,6192,O
",",6192,O
such,6192,O
as,6192,O
the,6192,O
nitrobenzyl,6192,B-CHEMICAL
analogue,6192,O
6c,6192,O
",",6192,O
were,6192,O
found,6192,O
to,6192,O
exhibit,6192,O
sub-micromolar,6192,O
IC50,6192,O
values,6192,O
in,6192,O
Bcl-2,6192,B-GENE-Y
expressing,6192,O
human,6192,O
cancer,6192,O
cell,6192,O
lines,6192,O
.,6192,O
Molecular,6193,O
modelling,6193,O
and,6193,O
ELISA,6193,O
studies,6193,O
further,6193,O
implicated,6193,O
anti-apoptotic,6193,O
Bcl-2,6193,B-GENE-Y
as,6193,O
a,6193,O
candidate,6193,O
molecular,6193,O
target,6193,O
underpinning,6193,O
anticancer,6193,O
activity,6193,O
.,6193,O
Effect,6194,O
of,6194,O
nicotine,6194,B-CHEMICAL
pretreatment,6194,O
on,6194,O
arsenic-induced,6194,B-CHEMICAL
oxidative,6194,O
stress,6194,O
in,6194,O
male,6194,O
Wistar,6194,O
rats,6194,O
.,6194,O
Humans,6195,O
are,6195,O
commonly,6195,O
exposed,6195,O
to,6195,O
nicotine,6195,B-CHEMICAL
",",6195,O
one,6195,O
of,6195,O
the,6195,O
most,6195,O
important,6195,O
lifestyle,6195,O
chemicals,6195,O
.,6195,O
The,6196,O
occurrence,6196,O
of,6196,O
high,6196,O
levels,6196,O
of,6196,O
arsenic,6196,B-CHEMICAL
in,6196,O
the,6196,O
groundwater,6196,O
of,6196,O
the,6196,O
southeast,6196,O
region,6196,O
of,6196,O
Asia,6196,O
has,6196,O
received,6196,O
much,6196,O
attention,6196,O
in,6196,O
the,6196,O
past,6196,O
decade,6196,O
and,6196,O
has,6196,O
become,6196,O
a,6196,O
global,6196,O
health,6196,O
concern,6196,O
.,6196,O
Predominant,6197,O
occurrence,6197,O
of,6197,O
both,6197,O
these,6197,O
chemicals,6197,O
and,6197,O
ease,6197,O
of,6197,O
their,6197,O
human,6197,O
exposure,6197,O
led,6197,O
us,6197,O
to,6197,O
investigate,6197,O
the,6197,O
effect,6197,O
of,6197,O
nicotine,6197,B-CHEMICAL
",",6197,O
a,6197,O
major,6197,O
tobacco,6197,O
alkaloid,6197,O
",",6197,O
on,6197,O
arsenic,6197,B-CHEMICAL
toxicity,6197,O
.,6197,O
Adult,6198,O
male,6198,O
rats,6198,O
were,6198,O
pre-exposed,6198,O
to,6198,O
two,6198,O
different,6198,O
doses,6198,O
of,6198,O
nicotine,6198,B-CHEMICAL
(,6198,O
0.75,6198,O
and,6198,O
3,6198,O
mg/kg,6198,O
",",6198,O
intraperitoneally,6198,O
),6198,O
for,6198,O
7,6198,O
days,6198,O
followed,6198,O
by,6198,O
30,6198,O
days,6198,O
of,6198,O
arsenic,6198,B-CHEMICAL
exposure,6198,O
(,6198,O
50,6198,O
ppm,6198,O
sodium,6198,B-CHEMICAL
arsenite,6198,I-CHEMICAL
in,6198,O
drinking,6198,O
water,6198,O
),6198,O
.,6198,O
Nicotine,6199,B-CHEMICAL
pre-exposure,6199,O
resulted,6199,O
in,6199,O
an,6199,O
increased,6199,O
brain,6199,O
arsenic,6199,B-CHEMICAL
accumulation,6199,O
and,6199,O
a,6199,O
decreased,6199,O
liver,6199,O
arsenic,6199,B-CHEMICAL
concentration,6199,O
.,6199,O
Arsenic,6200,B-CHEMICAL
also,6200,O
caused,6200,O
a,6200,O
significant,6200,O
oxidative,6200,O
stress,6200,O
in,6200,O
the,6200,O
blood,6200,O
",",6200,O
brain,6200,O
and,6200,O
liver,6200,O
of,6200,O
the,6200,O
exposed,6200,O
rats,6200,O
.,6200,O
Glutathione-S-transferase,6201,B-GENE-N
",",6201,O
a,6201,O
phase,6201,O
II,6201,O
enzyme,6201,O
",",6201,O
was,6201,O
inhibited,6201,O
by,6201,O
both,6201,O
arsenic,6201,B-CHEMICAL
and,6201,O
nicotine,6201,B-CHEMICAL
but,6201,O
no,6201,O
such,6201,O
inhibition,6201,O
was,6201,O
noted,6201,O
in,6201,O
arsenic-treated,6201,B-CHEMICAL
animals,6201,O
pre-exposed,6201,O
to,6201,O
nicotine,6201,B-CHEMICAL
.,6201,O
Upon,6202,O
nicotine,6202,B-CHEMICAL
pre-exposure,6202,O
",",6202,O
brain,6202,O
acetylcholinesterase,6202,B-GENE-Y
increased,6202,O
",",6202,O
while,6202,O
monoamine,6202,B-GENE-N
oxidase,6202,I-GENE-N
(,6202,O
MAO,6202,B-GENE-N
),6202,O
decreased,6202,O
.,6202,O
The,6203,O
toxic,6203,O
effects,6203,O
of,6203,O
MAO,6203,B-GENE-N
significantly,6203,O
attenuated,6203,O
with,6203,O
nicotine,6203,B-CHEMICAL
pre-exposure,6203,O
.,6203,O
The,6204,O
present,6204,O
study,6204,O
suggests,6204,O
that,6204,O
nicotine,6204,B-CHEMICAL
may,6204,O
not,6204,O
be,6204,O
the,6204,O
major,6204,O
contributing,6204,O
factor,6204,O
for,6204,O
the,6204,O
previously,6204,O
reported,6204,O
synergistic,6204,O
toxic,6204,O
interaction,6204,O
between,6204,O
tobacco,6204,O
and,6204,O
arsenic,6204,B-CHEMICAL
.,6204,O
Nicotine,6205,B-CHEMICAL
pre-exposure,6205,O
in,6205,O
arsenic-exposed,6205,B-CHEMICAL
animals,6205,O
revealed,6205,O
interesting,6205,O
toxicokinetics,6205,O
and,6205,O
oxidative,6205,O
stress,6205,O
modulating,6205,O
interactions,6205,O
in,6205,O
the,6205,O
brain,6205,O
and,6205,O
liver,6205,O
of,6205,O
rats,6205,O
",",6205,O
which,6205,O
requires,6205,O
further,6205,O
exploration,6205,O
.,6205,O
Developing,6206,O
Predictive,6206,O
Approaches,6206,O
to,6206,O
Characterize,6206,O
Adaptive,6206,O
Responses,6206,O
of,6206,O
the,6206,O
Reproductive,6206,O
Endocrine,6206,O
Axis,6206,O
to,6206,O
Aromatase,6206,B-GENE-Y
Inhibition,6206,O
:,6206,O
II,6206,O
.,6206,O
Computational,6207,O
Modeling,6207,O
.,6207,O
Endocrine-disrupting,6208,O
chemicals,6208,O
can,6208,O
affect,6208,O
reproduction,6208,O
and,6208,O
development,6208,O
in,6208,O
humans,6208,O
and,6208,O
wildlife,6208,O
.,6208,O
We,6209,O
developed,6209,O
a,6209,O
computational,6209,O
model,6209,O
of,6209,O
the,6209,O
hypothalamic-pituitary-gonadal,6209,O
(,6209,O
HPG,6209,O
),6209,O
axis,6209,O
in,6209,O
female,6209,O
fathead,6209,O
minnows,6209,O
to,6209,O
predict,6209,O
dose-response,6209,O
and,6209,O
time-course,6209,O
(,6209,O
DRTC,6209,O
),6209,O
behaviors,6209,O
for,6209,O
endocrine,6209,O
effects,6209,O
of,6209,O
the,6209,O
aromatase,6209,B-GENE-Y
inhibitor,6209,O
",",6209,O
fadrozole,6209,B-CHEMICAL
(,6209,O
FAD,6209,B-CHEMICAL
),6209,O
.,6209,O
The,6210,O
model,6210,O
describes,6210,O
adaptive,6210,O
responses,6210,O
to,6210,O
endocrine,6210,O
stress,6210,O
involving,6210,O
regulated,6210,O
secretion,6210,O
of,6210,O
a,6210,O
generic,6210,O
gonadotropin,6210,B-GENE-N
(,6210,O
LH/FSH,6210,B-GENE-N
),6210,O
from,6210,O
the,6210,O
hypothalamic-pituitary,6210,O
complex,6210,O
.,6210,O
For,6211,O
model,6211,O
development,6211,O
",",6211,O
we,6211,O
used,6211,O
plasma,6211,O
17β-estradiol,6211,B-CHEMICAL
(,6211,O
E2,6211,O
),6211,O
concentrations,6211,O
and,6211,O
ovarian,6211,O
cytochrome,6211,B-GENE-Y
P450,6211,I-GENE-Y
(,6211,I-GENE-Y
CYP,6211,I-GENE-Y
),6211,I-GENE-Y
19A,6211,I-GENE-Y
aromatase,6211,I-GENE-Y
mRNA,6211,O
data,6211,O
from,6211,O
two,6211,O
time-course,6211,O
experiments,6211,O
",",6211,O
each,6211,O
of,6211,O
which,6211,O
included,6211,O
both,6211,O
an,6211,O
exposure,6211,O
and,6211,O
a,6211,O
depuration,6211,O
phase,6211,O
",",6211,O
and,6211,O
plasma,6211,O
E2,6211,O
data,6211,O
from,6211,O
a,6211,O
third,6211,O
4-day,6211,O
study,6211,O
.,6211,O
Model,6212,O
parameters,6212,O
were,6212,O
estimated,6212,O
using,6212,O
E2,6212,O
concentrations,6212,O
for,6212,O
0,6212,O
",",6212,O
0.5,6212,O
",",6212,O
and,6212,O
3,6212,O
µg/l,6212,O
FAD,6212,B-CHEMICAL
exposure,6212,O
concentrations,6212,O
",",6212,O
and,6212,O
good,6212,O
fits,6212,O
to,6212,O
these,6212,O
data,6212,O
were,6212,O
obtained,6212,O
.,6212,O
The,6213,O
model,6213,O
accurately,6213,O
predicted,6213,O
CYP19A,6213,B-GENE-Y
mRNA,6213,O
fold,6213,O
changes,6213,O
for,6213,O
controls,6213,O
and,6213,O
three,6213,O
FAD,6213,B-CHEMICAL
doses,6213,O
(,6213,O
0,6213,O
",",6213,O
0.5,6213,O
",",6213,O
and,6213,O
3,6213,O
µg/l,6213,O
),6213,O
and,6213,O
plasma,6213,O
E2,6213,O
dose,6213,O
response,6213,O
from,6213,O
the,6213,O
4-day,6213,O
study,6213,O
.,6213,O
Comparing,6214,O
the,6214,O
model-predicted,6214,O
DRTC,6214,O
with,6214,O
experimental,6214,O
data,6214,O
provided,6214,O
insight,6214,O
into,6214,O
how,6214,O
the,6214,O
feedback,6214,O
control,6214,O
mechanisms,6214,O
in,6214,O
the,6214,O
HPG,6214,O
axis,6214,O
mediate,6214,O
these,6214,O
changes,6214,O
:,6214,O
specifically,6214,O
",",6214,O
adaptive,6214,O
changes,6214,O
in,6214,O
plasma,6214,O
E2,6214,O
levels,6214,O
occurring,6214,O
during,6214,O
exposure,6214,O
and,6214,O
``,6214,O
overshoot,6214,O
'',6214,O
occurring,6214,O
postexposure,6214,O
.,6214,O
This,6215,O
study,6215,O
demonstrates,6215,O
the,6215,O
value,6215,O
of,6215,O
mechanistic,6215,O
modeling,6215,O
to,6215,O
examine,6215,O
and,6215,O
predict,6215,O
dynamic,6215,O
behaviors,6215,O
in,6215,O
perturbed,6215,O
systems,6215,O
.,6215,O
As,6216,O
this,6216,O
work,6216,O
progresses,6216,O
",",6216,O
we,6216,O
will,6216,O
obtain,6216,O
a,6216,O
refined,6216,O
understanding,6216,O
of,6216,O
how,6216,O
adaptive,6216,O
responses,6216,O
within,6216,O
the,6216,O
vertebrate,6216,O
HPG,6216,O
axis,6216,O
affect,6216,O
DRTC,6216,O
behaviors,6216,O
for,6216,O
aromatase,6216,B-GENE-Y
inhibitors,6216,O
and,6216,O
other,6216,O
types,6216,O
of,6216,O
endocrine-active,6216,O
chemicals,6216,O
and,6216,O
apply,6216,O
that,6216,O
knowledge,6216,O
in,6216,O
support,6216,O
of,6216,O
risk,6216,O
assessments,6216,O
.,6216,O
Benzoquinone,6217,B-CHEMICAL
Reveals,6217,O
a,6217,O
Cysteine-Dependent,6217,B-CHEMICAL
Desensitization,6217,O
Mechanism,6217,O
of,6217,O
TRPA1,6217,B-GENE-Y
.,6217,O
The,6218,O
transient,6218,B-GENE-Y
receptor,6218,I-GENE-Y
potential,6218,I-GENE-Y
ankyrin,6218,I-GENE-Y
1,6218,I-GENE-Y
(,6218,O
TRPA1,6218,B-GENE-Y
),6218,I-GENE-Y
nonselective,6218,O
cation,6218,B-GENE-N
channel,6218,I-GENE-N
has,6218,O
a,6218,O
conserved,6218,O
function,6218,O
as,6218,O
a,6218,O
noxious,6218,O
chemical,6218,O
sensor,6218,O
throughout,6218,O
much,6218,O
of,6218,O
Metazoa,6218,O
.,6218,O
Electrophilic,6219,O
chemicals,6219,O
activate,6219,O
both,6219,O
insect,6219,O
and,6219,O
vertebrate,6219,O
TRPA1,6219,B-GENE-Y
via,6219,O
covalent,6219,O
modification,6219,O
of,6219,O
cysteine,6219,B-CHEMICAL
residues,6219,O
in,6219,O
the,6219,O
amino-terminal,6219,B-CHEMICAL
region,6219,O
.,6219,O
Although,6220,O
naturally,6220,O
occurring,6220,O
electrophilic,6220,O
plant,6220,O
compounds,6220,O
",",6220,O
such,6220,O
as,6220,O
mustard,6220,O
oil,6220,O
and,6220,O
cinnamaldehyde,6220,B-CHEMICAL
",",6220,O
are,6220,O
TRPA1,6220,B-GENE-Y
agonists,6220,O
",",6220,O
it,6220,O
is,6220,O
unknown,6220,O
whether,6220,O
arthropod-produced,6220,O
electrophiles,6220,O
activate,6220,O
mammalian,6220,B-GENE-Y
TRPA1,6220,I-GENE-Y
.,6220,O
We,6221,O
characterized,6221,O
the,6221,O
effects,6221,O
of,6221,O
the,6221,O
electrophilic,6221,O
arthropod,6221,O
defensive,6221,O
compound,6221,O
para-benzoquinone,6221,B-CHEMICAL
(,6221,O
pBQN,6221,B-CHEMICAL
),6221,O
on,6221,O
the,6221,O
human,6221,B-GENE-Y
TRPA1,6221,I-GENE-Y
channel,6221,O
.,6221,O
We,6222,O
used,6222,O
whole-cell,6222,O
recordings,6222,O
of,6222,O
human,6222,O
embryonic,6222,O
kidney,6222,O
cells,6222,O
heterologously,6222,O
expressing,6222,O
either,6222,O
wild-type,6222,O
TRPA1,6222,B-GENE-Y
or,6222,O
TRPA1,6222,B-GENE-Y
with,6222,O
three,6222,O
serine-substituted,6222,B-CHEMICAL
cysteines,6222,B-CHEMICAL
crucial,6222,O
for,6222,O
electrophile,6222,O
activation,6222,O
(,6222,O
C621S,6222,B-GENE-N
",",6222,O
C641S,6222,B-GENE-N
",",6222,O
C665S,6222,B-GENE-N
),6222,O
.,6222,O
We,6223,O
found,6223,O
that,6223,O
pBQN,6223,B-CHEMICAL
activates,6223,O
TRPA1,6223,B-GENE-Y
starting,6223,O
at,6223,O
10,6223,O
nM,6223,O
and,6223,O
peaking,6223,O
at,6223,O
300,6223,O
nM,6223,O
;,6223,O
higher,6223,O
concentrations,6223,O
caused,6223,O
rapid,6223,O
activation,6223,O
followed,6223,O
by,6223,O
a,6223,O
fast,6223,O
decline,6223,O
.,6223,O
Activation,6224,O
by,6224,O
pBQN,6224,B-CHEMICAL
required,6224,O
reactivity,6224,O
with,6224,O
cysteine,6224,B-CHEMICAL
residues,6224,O
",",6224,O
but,6224,O
ones,6224,O
that,6224,O
are,6224,O
distinct,6224,O
from,6224,O
those,6224,O
previously,6224,O
reported,6224,O
to,6224,O
be,6224,O
the,6224,O
key,6224,O
targets,6224,O
of,6224,O
electrophiles,6224,O
.,6224,O
The,6225,O
current,6225,O
reduction,6225,O
we,6225,O
found,6225,O
at,6225,O
higher,6225,O
pBQN,6225,B-CHEMICAL
concentrations,6225,O
was,6225,O
a,6225,O
cysteine-dependent,6225,O
desensitization,6225,O
of,6225,O
TRPA1,6225,B-GENE-Y
",",6225,O
and,6225,O
did,6225,O
not,6225,O
require,6225,O
prior,6225,O
activation,6225,O
.,6225,O
The,6226,O
cysteines,6226,B-CHEMICAL
required,6226,O
for,6226,O
desensitization,6226,O
are,6226,O
not,6226,O
accessible,6226,O
to,6226,O
all,6226,O
electrophiles,6226,O
as,6226,O
iodoacetamide,6226,B-CHEMICAL
and,6226,O
internally,6226,O
applied,6226,O
2-,6226,B-CHEMICAL
(,6226,I-CHEMICAL
trimethylammonium,6226,I-CHEMICAL
),6226,I-CHEMICAL
ethyl,6226,I-CHEMICAL
methanesulfonate,6226,I-CHEMICAL
failed,6226,O
to,6226,O
cause,6226,O
desensitization,6226,O
(,6226,O
despite,6226,O
large,6226,O
activation,6226,O
),6226,O
.,6226,O
Interestingly,6227,O
",",6227,O
following,6227,O
pBQN,6227,B-CHEMICAL
desensitization,6227,O
",",6227,O
wild-type,6227,O
TRPA1,6227,B-GENE-Y
had,6227,O
dramatically,6227,O
reduced,6227,O
response,6227,O
to,6227,O
the,6227,O
nonelectrophile,6227,O
agonist,6227,O
carvacrol,6227,B-CHEMICAL
",",6227,O
whereas,6227,O
the,6227,O
triple,6227,O
cysteine,6227,B-CHEMICAL
mutant,6227,O
TRPA1,6227,B-GENE-Y
retained,6227,O
its,6227,O
full,6227,O
response,6227,O
.,6227,O
Our,6228,O
results,6228,O
suggest,6228,O
that,6228,O
modification,6228,O
of,6228,O
multiple,6228,O
cysteine,6228,B-CHEMICAL
residues,6228,O
by,6228,O
electrophilic,6228,O
compounds,6228,O
can,6228,O
generate,6228,O
both,6228,O
activation,6228,O
and,6228,O
desensitization,6228,O
of,6228,O
the,6228,O
TRPA1,6228,B-GENE-Y
channel,6228,O
.,6228,O
A,6229,O
study,6229,O
of,6229,O
parabens,6229,B-CHEMICAL
and,6229,O
bisphenol,6229,B-CHEMICAL
A,6229,I-CHEMICAL
in,6229,O
surface,6229,O
water,6229,O
and,6229,O
fish,6229,O
brain,6229,O
tissue,6229,O
from,6229,O
the,6229,O
Greater,6229,O
Pittsburgh,6229,O
Area,6229,O
.,6229,O
Pollution,6230,O
from,6230,O
xenoestrogens,6230,B-CHEMICAL
has,6230,O
been,6230,O
discovered,6230,O
in,6230,O
the,6230,O
aquatic,6230,O
environment,6230,O
of,6230,O
the,6230,O
Greater,6230,O
Pittsburgh,6230,O
Area,6230,O
and,6230,O
is,6230,O
suspected,6230,O
to,6230,O
be,6230,O
caused,6230,O
by,6230,O
the,6230,O
failing,6230,O
sewer,6230,O
system,6230,O
.,6230,O
Personal,6231,O
care,6231,O
products,6231,O
and,6231,O
plasticizers,6231,O
have,6231,O
the,6231,O
potential,6231,O
to,6231,O
enter,6231,O
the,6231,O
water,6231,O
supply,6231,O
though,6231,O
treated,6231,O
and,6231,O
untreated,6231,O
sewage,6231,O
.,6231,O
Many,6232,O
of,6232,O
these,6232,O
compounds,6232,O
are,6232,O
suspected,6232,O
xenoestrogens,6232,B-CHEMICAL
.,6232,O
Paraben,6233,B-CHEMICAL
detection,6233,O
in,6233,O
surface,6233,O
waters,6233,O
was,6233,O
as,6233,O
follows,6233,O
:,6233,O
methyl,6233,B-CHEMICAL
paraben,6233,I-CHEMICAL
ranged,6233,O
between,6233,O
2.2,6233,O
to,6233,O
17.3,6233,O
ppt,6233,O
;,6233,O
ethyl,6233,B-CHEMICAL
paraben,6233,I-CHEMICAL
was,6233,O
not,6233,O
detectable,6233,O
;,6233,O
propyl,6233,B-CHEMICAL
paraben,6233,I-CHEMICAL
was,6233,O
detected,6233,O
at,6233,O
9.2,6233,O
and,6233,O
12.0,6233,O
ppt,6233,O
;,6233,O
butyl,6233,B-CHEMICAL
paraben,6233,I-CHEMICAL
was,6233,O
detected,6233,O
at,6233,O
0.2,6233,O
ppt,6233,O
.,6233,O
BPA,6234,B-CHEMICAL
was,6234,O
detected,6234,O
between,6234,O
0.6,6234,O
and,6234,O
15.4,6234,O
ppt,6234,O
.,6234,O
Estrogenic,6235,O
potential,6235,O
of,6235,O
extracts,6235,O
from,6235,O
fish,6235,O
brain,6235,O
tissue,6235,O
was,6235,O
tested,6235,O
via,6235,O
Bromodeoxyuridine,6235,B-CHEMICAL
MCF-7,6235,O
analysis,6235,O
and,6235,O
paired,6235,O
with,6235,O
HPLC-MS,6235,O
to,6235,O
investigate,6235,O
the,6235,O
presence,6235,O
of,6235,O
xenoestrogens,6235,B-CHEMICAL
.,6235,O
All,6236,O
samples,6236,O
were,6236,O
non-detectable,6236,O
for,6236,O
parabens,6236,O
.,6236,O
BPA,6237,B-CHEMICAL
was,6237,O
detected,6237,O
in,6237,O
44,6237,O
of,6237,O
the,6237,O
58,6237,O
samples,6237,O
",",6237,O
with,6237,O
a,6237,O
range,6237,O
from,6237,O
non-detectable,6237,O
to,6237,O
120,6237,O
pg/g,6237,O
.,6237,O
BCFs,6238,O
were,6238,O
calculated,6238,O
.,6238,O
Results,6239,O
were,6239,O
statistically,6239,O
significant,6239,O
for,6239,O
location,6239,O
of,6239,O
capture,6239,O
(,6239,O
p,6239,O
<,6239,O
0.05,6239,O
),6239,O
and,6239,O
correlation,6239,O
existed,6239,O
between,6239,O
estrogenicity,6239,O
and,6239,O
BPA,6239,B-CHEMICAL
.,6239,O
Synthesis,6240,O
and,6240,O
in-silico,6240,O
studies,6240,O
of,6240,O
some,6240,O
diaryltriazole,6240,B-CHEMICAL
derivatives,6240,O
as,6240,O
potential,6240,O
cyclooxygenase,6240,B-GENE-N
inhibitors,6240,O
.,6240,O
The,6241,O
synthesis,6241,O
of,6241,O
several,6241,O
"4-phenyl-5-pyridin-4-yl-2,3-dihydro-3H-1,2,4-triazole-3-thiones",6241,B-CHEMICAL
possessing,6241,O
N-2,6241,O
Mannich,6241,B-CHEMICAL
bases,6241,I-CHEMICAL
or,6241,O
S-alkyl,6241,B-CHEMICAL
substituents,6241,O
",",6241,O
is,6241,O
reported,6241,O
.,6241,O
Several,6242,O
of,6242,O
them,6242,O
exhibited,6242,O
a,6242,O
low,6242,O
nanomolar,6242,O
COX,6242,B-GENE-N
enzyme,6242,O
inhibition,6242,O
activity,6242,O
.,6242,O
Most,6243,O
of,6243,O
the,6243,O
compounds,6243,O
showed,6243,O
inhibition,6243,O
of,6243,O
edema,6243,O
was,6243,O
similar,6243,O
to,6243,O
that,6243,O
evoked,6243,O
by,6243,O
celocoxib,6243,B-CHEMICAL
in,6243,O
animal,6243,O
model,6243,O
.,6243,O
Molecular,6244,O
docking,6244,O
studies,6244,O
of,6244,O
the,6244,O
compounds,6244,O
into,6244,O
the,6244,O
binding,6244,O
sites,6244,O
of,6244,O
COX-1,6244,B-GENE-Y
and,6244,O
COX-2,6244,B-GENE-Y
allowed,6244,O
us,6244,O
to,6244,O
shed,6244,O
light,6244,O
on,6244,O
the,6244,O
binding,6244,O
mode,6244,O
of,6244,O
these,6244,O
novel,6244,O
COX,6244,B-GENE-N
inhibitors,6244,O
.,6244,O
Multilevel,6245,O
regulation,6245,O
of,6245,O
2-cys,6245,B-GENE-N
peroxiredoxin,6245,I-GENE-N
reaction,6245,O
cycle,6245,O
by,6245,O
s-nitrosylation,6245,O
.,6245,O
S-Nitrosothiols,6246,B-CHEMICAL
(,6246,O
SNOs,6246,B-CHEMICAL
),6246,O
",",6246,O
formed,6246,O
by,6246,O
nitric,6246,B-CHEMICAL
oxide,6246,I-CHEMICAL
(,6246,O
NO,6246,B-CHEMICAL
),6246,O
-mediated,6246,O
S-nitrosylation,6246,B-CHEMICAL
",",6246,O
and,6246,O
hydrogen,6246,B-CHEMICAL
peroxide,6246,I-CHEMICAL
(,6246,O
H2O2,6246,B-CHEMICAL
),6246,O
",",6246,O
a,6246,O
prominent,6246,O
reactive,6246,O
oxygen,6246,B-CHEMICAL
species,6246,O
",",6246,O
are,6246,O
implicated,6246,O
in,6246,O
diverse,6246,O
physiological,6246,O
and,6246,O
pathological,6246,O
processes,6246,O
.,6246,O
Recent,6247,O
research,6247,O
has,6247,O
shown,6247,O
that,6247,O
the,6247,O
cellular,6247,O
action,6247,O
and,6247,O
metabolism,6247,O
of,6247,O
SNOs,6247,B-CHEMICAL
and,6247,O
H2O2,6247,B-CHEMICAL
involve,6247,O
overlapping,6247,O
",",6247,O
thiol-based,6247,B-CHEMICAL
mechanisms,6247,O
",",6247,O
but,6247,O
how,6247,O
these,6247,O
reactive,6247,O
species,6247,O
may,6247,O
affect,6247,O
each,6247,O
other,6247,O
's,6247,O
fate,6247,O
and,6247,O
function,6247,O
is,6247,O
not,6247,O
well,6247,O
understood,6247,O
.,6247,O
In,6248,O
this,6248,O
study,6248,O
we,6248,O
investigated,6248,O
how,6248,O
NO/SNO,6248,B-CHEMICAL
may,6248,O
affect,6248,O
the,6248,O
redox,6248,O
cycle,6248,O
of,6248,O
mammalian,6248,B-GENE-Y
peroxiredoxin-1,6248,I-GENE-Y
(,6248,O
Prx1,6248,B-GENE-Y
),6248,O
",",6248,O
a,6248,O
representative,6248,O
of,6248,O
the,6248,O
2-Cys,6248,B-GENE-N
Prxs,6248,I-GENE-N
",",6248,O
a,6248,O
group,6248,O
of,6248,O
thioredoxin,6248,B-GENE-Y
(,6248,O
Trx,6248,B-GENE-Y
),6248,O
-dependent,6248,O
peroxidases,6248,B-GENE-N
.,6248,O
We,6249,O
found,6249,O
that,6249,O
",",6249,O
both,6249,O
in,6249,O
a,6249,O
cell-free,6249,O
system,6249,O
and,6249,O
in,6249,O
cells,6249,O
",",6249,O
NO/SNO,6249,B-CHEMICAL
donors,6249,O
such,6249,O
as,6249,O
S-nitrosocysteine,6249,B-CHEMICAL
and,6249,O
S-nitrosoglutathione,6249,B-CHEMICAL
readily,6249,O
induced,6249,O
the,6249,O
S-nitrosylation,6249,B-CHEMICAL
of,6249,O
Prx1,6249,B-GENE-Y
",",6249,O
causing,6249,O
structural,6249,O
and,6249,O
functional,6249,O
alterations,6249,O
.,6249,O
In,6250,O
particular,6250,O
",",6250,O
nitrosylation,6250,O
promoted,6250,O
disulfide,6250,B-CHEMICAL
formation,6250,O
involving,6250,O
the,6250,O
pair,6250,O
of,6250,O
catalytic,6250,O
cysteines,6250,B-CHEMICAL
(,6250,O
Cys-52,6250,B-CHEMICAL
and,6250,O
Cys-173,6250,B-CHEMICAL
),6250,O
and,6250,O
disrupted,6250,O
the,6250,O
oligomeric,6250,O
structure,6250,O
of,6250,O
Prx1,6250,B-GENE-Y
",",6250,O
leading,6250,O
to,6250,O
loss,6250,O
of,6250,O
peroxidase,6250,B-GENE-N
activity,6250,O
.,6250,O
A,6251,O
highly,6251,O
potent,6251,O
inhibition,6251,O
of,6251,O
the,6251,O
peroxidase,6251,B-GENE-N
catalytic,6251,O
reaction,6251,O
by,6251,O
NO/SNO,6251,B-CHEMICAL
was,6251,O
seen,6251,O
in,6251,O
assays,6251,O
employing,6251,O
the,6251,O
coupled,6251,O
Prx-Trx,6251,B-GENE-N
system,6251,O
.,6251,O
In,6252,O
this,6252,O
setting,6252,O
",",6252,O
S-nitrosocysteine,6252,B-CHEMICAL
(,6252,O
10,6252,O
μm,6252,O
),6252,O
effectively,6252,O
blocked,6252,O
the,6252,O
Trx-mediated,6252,B-GENE-Y
regeneration,6252,O
of,6252,O
oxidized,6252,B-GENE-Y
Prx1,6252,I-GENE-Y
.,6252,O
This,6253,O
effect,6253,O
appeared,6253,O
to,6253,O
be,6253,O
due,6253,O
to,6253,O
both,6253,O
competition,6253,O
between,6253,O
S-nitrosocysteine,6253,B-CHEMICAL
and,6253,O
Prx1,6253,B-GENE-Y
for,6253,O
the,6253,O
Trx,6253,B-GENE-Y
system,6253,O
and,6253,O
direct,6253,O
modulation,6253,O
by,6253,O
S-nitrosocysteine,6253,B-CHEMICAL
of,6253,O
Trx,6253,B-GENE-N
reductase,6253,I-GENE-N
activity,6253,O
.,6253,O
Our,6254,O
findings,6254,O
that,6254,O
NO/SNO,6254,B-CHEMICAL
target,6254,O
both,6254,O
Prx,6254,B-GENE-N
and,6254,O
Trx,6254,B-GENE-N
reductase,6254,I-GENE-N
may,6254,O
have,6254,O
implications,6254,O
for,6254,O
understanding,6254,O
the,6254,O
impact,6254,O
of,6254,O
nitrosylation,6254,O
on,6254,O
cellular,6254,O
redox,6254,O
homeostasis,6254,O
.,6254,O
A,6255,O
Novel,6255,O
CUG,6255,O
(,6255,O
exp,6255,O
),6255,O
·MBNL1,6255,O
Inhibitor,6255,O
with,6255,O
Therapeutic,6255,O
Potential,6255,O
for,6255,O
Myotonic,6255,O
Dystrophy,6255,O
Type,6255,O
1,6255,O
.,6255,O
Myotonic,6256,O
dystrophy,6256,O
type,6256,O
1,6256,O
(,6256,O
DM1,6256,O
),6256,O
is,6256,O
caused,6256,O
by,6256,O
an,6256,O
expanded,6256,O
CUG,6256,O
repeat,6256,O
(,6256,O
CUG,6256,O
(,6256,O
exp,6256,O
),6256,O
),6256,O
that,6256,O
sequesters,6256,O
muscleblind-like,6256,B-GENE-N
1,6256,I-GENE-N
protein,6256,I-GENE-N
(,6256,O
MBNL1,6256,B-GENE-Y
),6256,O
",",6256,O
a,6256,O
protein,6256,O
that,6256,O
regulates,6256,O
alternative,6256,O
splicing,6256,O
.,6256,O
CUG,6257,O
(,6257,O
exp,6257,O
),6257,O
RNA,6257,O
is,6257,O
a,6257,O
validated,6257,O
drug,6257,O
target,6257,O
for,6257,O
this,6257,O
currently,6257,O
untreatable,6257,O
disease,6257,O
.,6257,O
Herein,6258,O
",",6258,O
we,6258,O
develop,6258,O
a,6258,O
bioactive,6258,O
small,6258,O
molecule,6258,O
(,6258,O
1,6258,O
),6258,O
that,6258,O
targets,6258,O
CUG,6258,O
(,6258,O
exp,6258,O
),6258,O
RNA,6258,O
and,6258,O
is,6258,O
able,6258,O
to,6258,O
inhibit,6258,O
the,6258,O
CUG,6258,O
(,6258,O
exp,6258,O
),6258,O
·MBNL1,6258,O
interaction,6258,O
in,6258,O
cells,6258,O
that,6258,O
model,6258,O
DM1,6258,O
.,6258,O
The,6259,O
core,6259,O
of,6259,O
this,6259,O
small,6259,O
molecule,6259,O
is,6259,O
based,6259,O
on,6259,O
ligand,6259,O
2,6259,O
",",6259,O
which,6259,O
was,6259,O
previously,6259,O
reported,6259,O
to,6259,O
be,6259,O
active,6259,O
in,6259,O
an,6259,O
in,6259,O
vitro,6259,O
assay,6259,O
.,6259,O
A,6260,O
polyamine-derivative,6260,B-CHEMICAL
side,6260,O
chain,6260,O
was,6260,O
conjugated,6260,O
to,6260,O
this,6260,O
core,6260,O
to,6260,O
make,6260,O
it,6260,O
aqueous-soluble,6260,O
and,6260,O
cell-penetrable,6260,O
.,6260,O
In,6261,O
a,6261,O
DM1,6261,O
cell,6261,O
model,6261,O
this,6261,O
conjugate,6261,O
was,6261,O
found,6261,O
to,6261,O
disperse,6261,O
CUG,6261,O
(,6261,O
exp,6261,O
),6261,O
ribonuclear,6261,O
foci,6261,O
",",6261,O
release,6261,O
MBNL1,6261,B-GENE-Y
",",6261,O
and,6261,O
partially,6261,O
reverse,6261,O
the,6261,O
mis-splicing,6261,O
of,6261,O
the,6261,O
insulin,6261,B-GENE-Y
receptor,6261,I-GENE-Y
pre-mRNA,6261,O
.,6261,O
Direct,6262,O
evidence,6262,O
for,6262,O
ribonuclear,6262,O
foci,6262,O
dispersion,6262,O
by,6262,O
this,6262,O
ligand,6262,O
was,6262,O
obtained,6262,O
in,6262,O
a,6262,O
live,6262,O
DM1,6262,O
cell,6262,O
model,6262,O
using,6262,O
time-lapse,6262,O
confocal,6262,O
microscopy,6262,O
.,6262,O
The,6263,O
induction,6263,O
of,6263,O
mitochondria-mediated,6263,O
apoptosis,6263,O
in,6263,O
cancer,6263,O
cells,6263,O
by,6263,O
ruthenium,6263,B-CHEMICAL
(,6263,I-CHEMICAL
ii,6263,I-CHEMICAL
),6263,I-CHEMICAL
asymmetric,6263,O
complexes,6263,O
.,6263,O
Four,6264,O
ruthenium,6264,B-CHEMICAL
(,6264,I-CHEMICAL
ii,6264,I-CHEMICAL
),6264,I-CHEMICAL
asymmetric,6264,O
complexes,6264,O
",",6264,O
[,6264,B-CHEMICAL
Ru,6264,I-CHEMICAL
(,6264,I-CHEMICAL
bpy,6264,I-CHEMICAL
),6264,I-CHEMICAL
2,6264,I-CHEMICAL
(,6264,I-CHEMICAL
PAIDH,6264,I-CHEMICAL
),6264,I-CHEMICAL
],6264,I-CHEMICAL
(,6264,I-CHEMICAL
2+,6264,I-CHEMICAL
),6264,I-CHEMICAL
(,6264,O
bpy,6264,B-CHEMICAL
=,6264,O
"2,2'-bipyridine",6264,B-CHEMICAL
",",6264,O
PAIDH,6264,B-CHEMICAL
=,6264,O
2-pyridyl-1H-anthra,6264,B-CHEMICAL
[,6264,I-CHEMICAL
"1,2-d",6264,I-CHEMICAL
],6264,I-CHEMICAL
"imidazole-6,11-dione",6264,I-CHEMICAL
",",6264,O
),6264,O
",",6264,O
[,6264,B-CHEMICAL
Ru,6264,I-CHEMICAL
(,6264,I-CHEMICAL
phen,6264,I-CHEMICAL
),6264,I-CHEMICAL
2,6264,I-CHEMICAL
(,6264,I-CHEMICAL
PAIDH,6264,I-CHEMICAL
),6264,I-CHEMICAL
],6264,I-CHEMICAL
(,6264,I-CHEMICAL
2+,6264,I-CHEMICAL
),6264,I-CHEMICAL
(,6264,O
phen,6264,B-CHEMICAL
=,6264,O
"1,10-phenanthroline",6264,B-CHEMICAL
",",6264,O
),6264,O
",",6264,O
[,6264,B-CHEMICAL
Ru,6264,I-CHEMICAL
(,6264,I-CHEMICAL
dmp,6264,I-CHEMICAL
),6264,I-CHEMICAL
2,6264,I-CHEMICAL
(,6264,I-CHEMICAL
PAIDH,6264,I-CHEMICAL
),6264,I-CHEMICAL
],6264,I-CHEMICAL
(,6264,I-CHEMICAL
2+,6264,I-CHEMICAL
),6264,I-CHEMICAL
(,6264,O
dmp,6264,B-CHEMICAL
=,6264,O
"4,7-dimethyl-1,10-phenanthroline",6264,B-CHEMICAL
",",6264,O
),6264,O
and,6264,O
[,6264,B-CHEMICAL
Ru,6264,I-CHEMICAL
(,6264,I-CHEMICAL
dip,6264,I-CHEMICAL
),6264,I-CHEMICAL
2,6264,I-CHEMICAL
(,6264,I-CHEMICAL
PAIDH,6264,I-CHEMICAL
),6264,I-CHEMICAL
],6264,I-CHEMICAL
(,6264,I-CHEMICAL
2+,6264,I-CHEMICAL
),6264,I-CHEMICAL
(,6264,O
dip,6264,B-CHEMICAL
=,6264,O
"4,7-diphenyl-1,10-phenanthroline",6264,B-CHEMICAL
",",6264,O
),6264,O
",",6264,O
have,6264,O
been,6264,O
synthesized,6264,O
and,6264,O
characterized,6264,O
.,6264,O
These,6265,O
complexes,6265,O
displayed,6265,O
potent,6265,O
anti-proliferation,6265,O
activity,6265,O
against,6265,O
various,6265,O
cancer,6265,O
cell,6265,O
lines,6265,O
and,6265,O
had,6265,O
high,6265,O
selectivity,6265,O
between,6265,O
tumor,6265,O
cells,6265,O
and,6265,O
normal,6265,O
cells,6265,O
.,6265,O
HeLa,6266,O
cells,6266,O
exhibited,6266,O
the,6266,O
highest,6266,O
sensitivity,6266,O
to,6266,O
complex,6266,O
",",6266,O
accounting,6266,O
for,6266,O
the,6266,O
greatest,6266,O
cellular,6266,O
uptake,6266,O
.,6266,O
Complex,6267,O
was,6267,O
shown,6267,O
to,6267,O
accumulate,6267,O
preferentially,6267,O
in,6267,O
the,6267,O
mitochondria,6267,O
of,6267,O
HeLa,6267,O
cells,6267,O
and,6267,O
induced,6267,O
apoptosis,6267,O
via,6267,O
the,6267,O
mitochondrial,6267,O
pathway,6267,O
",",6267,O
which,6267,O
involved,6267,O
ROS,6267,O
generation,6267,O
",",6267,O
mitochondrial,6267,O
membrane,6267,O
potential,6267,O
depolarisation,6267,O
",",6267,O
and,6267,O
Bcl-2,6267,B-GENE-Y
and,6267,O
caspase,6267,B-GENE-N
family,6267,O
members,6267,O
activation,6267,O
.,6267,O
These,6268,O
results,6268,O
demonstrated,6268,O
that,6268,O
complex,6268,O
induced,6268,O
cancer,6268,O
cell,6268,O
apoptosis,6268,O
by,6268,O
acting,6268,O
on,6268,O
mitochondrial,6268,O
pathways,6268,O
.,6268,O
Platycodi,6269,O
Radix,6269,O
attenuates,6269,O
dimethylnitrosamine-induced,6269,B-CHEMICAL
liver,6269,O
fibrosis,6269,O
in,6269,O
rats,6269,O
by,6269,O
inducing,6269,O
Nrf2-mediated,6269,B-GENE-Y
antioxidant,6269,O
enzymes,6269,O
.,6269,O
The,6270,O
purpose,6270,O
of,6270,O
this,6270,O
study,6270,O
was,6270,O
to,6270,O
investigate,6270,O
the,6270,O
anti-fibrotic,6270,O
effects,6270,O
of,6270,O
the,6270,O
aqueous,6270,O
extract,6270,O
of,6270,O
the,6270,O
Platycodi,6270,O
Radix,6270,O
root,6270,O
(,6270,O
Changkil,6270,O
:,6270,O
CK,6270,O
),6270,O
on,6270,O
dimethylnitrosamine,6270,B-CHEMICAL
(,6270,O
DMN,6270,B-CHEMICAL
),6270,O
-induced,6270,O
liver,6270,O
fibrosis,6270,O
in,6270,O
rats,6270,O
.,6270,O
DMN,6271,B-CHEMICAL
treatment,6271,O
for,6271,O
4weeks,6271,O
led,6271,O
to,6271,O
marked,6271,O
liver,6271,O
fibrosis,6271,O
as,6271,O
assessed,6271,O
by,6271,O
serum,6271,O
biochemistry,6271,O
",",6271,O
histopathological,6271,O
examination,6271,O
",",6271,O
and,6271,O
hepatic,6271,O
lipid,6271,O
peroxidation,6271,O
and,6271,O
collagen,6271,B-GENE-N
content,6271,O
.,6271,O
CK,6272,O
significantly,6272,O
inhibited,6272,O
DMN-induced,6272,B-CHEMICAL
increases,6272,O
in,6272,O
serum,6272,O
alanine,6272,B-GENE-N
aminotransferase,6272,I-GENE-N
(,6272,O
ALT,6272,B-GENE-N
),6272,O
and,6272,O
aspartate,6272,B-GENE-N
aminotransferase,6272,I-GENE-N
(,6272,O
AST,6272,B-GENE-N
),6272,O
activities,6272,O
",",6272,O
fibrosis,6272,O
score,6272,O
",",6272,O
and,6272,O
hepatic,6272,O
malondialdehyde,6272,B-CHEMICAL
and,6272,O
collagen,6272,B-GENE-N
content,6272,O
.,6272,O
CK,6273,O
also,6273,O
inhibited,6273,O
DMN-induced,6273,B-CHEMICAL
reductions,6273,O
in,6273,O
rat,6273,O
body,6273,O
and,6273,O
liver,6273,O
weights,6273,O
.,6273,O
Reverse,6274,O
transcription,6274,O
polymerase,6274,O
chain,6274,O
reaction,6274,O
(,6274,O
RT-PCR,6274,O
),6274,O
and,6274,O
western,6274,O
blot,6274,O
analyses,6274,O
revealed,6274,O
that,6274,O
CK,6274,O
inhibited,6274,O
DMN-induced,6274,B-CHEMICAL
increases,6274,O
in,6274,O
matrix,6274,B-GENE-Y
metalloproteinase-13,6274,I-GENE-Y
(,6274,O
MMP-13,6274,B-GENE-Y
),6274,O
",",6274,O
tissue,6274,B-GENE-Y
inhibitor,6274,I-GENE-Y
of,6274,I-GENE-Y
metalloproteinase-1,6274,I-GENE-Y
(,6274,O
TIMP-1,6274,B-GENE-Y
),6274,O
",",6274,O
and,6274,O
tumor,6274,B-GENE-Y
necrosis,6274,I-GENE-Y
factor-α,6274,I-GENE-Y
(,6274,O
TNF-α,6274,B-GENE-Y
),6274,O
mRNA,6274,O
",",6274,O
and,6274,O
collagen,6274,B-GENE-N
type,6274,I-GENE-N
I,6274,I-GENE-N
and,6274,O
α-smooth,6274,B-GENE-Y
muscle,6274,I-GENE-Y
actin,6274,I-GENE-Y
protein,6274,O
.,6274,O
DMN-induced,6275,B-CHEMICAL
cyclooxygenase-2,6275,B-GENE-Y
(,6275,O
COX-2,6275,B-GENE-Y
),6275,O
expression,6275,O
and,6275,O
nuclear,6275,B-GENE-N
factor-kappa,6275,I-GENE-N
B,6275,I-GENE-N
(,6275,O
NF-κB,6275,B-GENE-N
),6275,O
activation,6275,O
was,6275,O
reduced,6275,O
by,6275,O
CK,6275,O
treatment,6275,O
.,6275,O
Furthermore,6276,O
",",6276,O
CK,6276,O
induced,6276,O
activation,6276,O
of,6276,O
nuclear,6276,B-GENE-Y
erythroid,6276,I-GENE-Y
2-related,6276,I-GENE-Y
factor,6276,I-GENE-Y
2,6276,I-GENE-Y
(,6276,O
Nrf2,6276,B-GENE-Y
),6276,O
-mediated,6276,O
antioxidant,6276,O
enzymes,6276,O
such,6276,O
as,6276,O
γ-glutamylcysteine,6276,B-GENE-Y
synthetase,6276,I-GENE-Y
(,6276,O
γ-GCS,6276,B-GENE-Y
),6276,O
",",6276,O
heme,6276,B-CHEMICAL
oxygenase-1,6276,I-GENE-Y
(,6276,O
HO-1,6276,B-GENE-Y
),6276,O
",",6276,O
NAD,6276,B-CHEMICAL
(,6276,I-CHEMICAL
P,6276,I-CHEMICAL
),6276,I-CHEMICAL
H,6276,I-CHEMICAL
quinone,6276,B-CHEMICAL
oxidoreductase,6276,I-GENE-Y
1,6276,I-GENE-Y
(,6276,O
NQO1,6276,B-GENE-Y
),6276,O
",",6276,O
and,6276,O
glutathione-S-transferase,6276,B-CHEMICAL
(,6276,O
GST,6276,B-GENE-N
),6276,O
in,6276,O
HepG2,6276,O
cells,6276,O
.,6276,O
These,6277,O
results,6277,O
demonstrated,6277,O
that,6277,O
CK,6277,O
attenuates,6277,O
DMN-induced,6277,B-CHEMICAL
liver,6277,O
fibrosis,6277,O
through,6277,O
the,6277,O
activation,6277,O
of,6277,O
Nrf2-mediated,6277,B-GENE-Y
antioxidant,6277,O
enzymes,6277,O
.,6277,O
Cadmium,6278,B-CHEMICAL
telluride,6278,I-CHEMICAL
quantum,6278,O
dots,6278,O
cause,6278,O
oxidative,6278,O
stress,6278,O
leading,6278,O
to,6278,O
extrinsic,6278,O
and,6278,O
intrinsic,6278,O
apoptosis,6278,O
in,6278,O
hepatocellular,6278,O
carcinoma,6278,O
HepG2,6278,O
cells,6278,O
.,6278,O
The,6279,O
mechanisms,6279,O
of,6279,O
toxicity,6279,O
related,6279,O
to,6279,O
human,6279,O
hepatocellular,6279,O
carcinoma,6279,O
HepG2,6279,O
cell,6279,O
exposures,6279,O
to,6279,O
cadmium,6279,B-CHEMICAL
telluride,6279,I-CHEMICAL
quantum,6279,O
dots,6279,O
(,6279,O
CdTe-QDs,6279,B-CHEMICAL
),6279,O
were,6279,O
investigated,6279,O
.,6279,O
CdTe-QDs,6280,B-CHEMICAL
caused,6280,O
cytotoxicity,6280,O
in,6280,O
HepG2,6280,O
cells,6280,O
in,6280,O
a,6280,O
dose-,6280,O
and,6280,O
time-dependent,6280,O
manner,6280,O
.,6280,O
Treated,6281,O
cells,6281,O
showed,6281,O
an,6281,O
increase,6281,O
in,6281,O
reactive,6281,O
oxygen,6281,B-CHEMICAL
species,6281,O
(,6281,O
ROS,6281,O
),6281,O
.,6281,O
Altered,6282,O
antioxidant,6282,O
levels,6282,O
were,6282,O
demonstrated,6282,O
by,6282,O
depletion,6282,O
of,6282,O
reduced,6282,B-CHEMICAL
glutathione,6282,I-CHEMICAL
(,6282,O
GSH,6282,B-CHEMICAL
),6282,O
",",6282,O
a,6282,O
decreased,6282,O
ratio,6282,O
of,6282,O
reduced,6282,O
glutathione,6282,B-CHEMICAL
to,6282,O
oxidized,6282,B-CHEMICAL
glutathione,6282,I-CHEMICAL
(,6282,O
GSH/GSSG,6282,B-CHEMICAL
),6282,O
and,6282,O
an,6282,O
increased,6282,O
NF-E2-related,6282,B-GENE-Y
Factor,6282,I-GENE-Y
2,6282,I-GENE-Y
(,6282,O
Nrf2,6282,B-GENE-Y
),6282,O
activation,6282,O
.,6282,O
Enzyme,6283,O
assays,6283,O
showed,6283,O
that,6283,O
superoxide,6283,B-GENE-N
dismutase,6283,I-GENE-N
(,6283,O
SOD,6283,B-GENE-N
),6283,O
activity,6283,O
was,6283,O
elevated,6283,O
whereas,6283,O
catalase,6283,B-GENE-Y
(,6283,O
CAT,6283,B-GENE-Y
),6283,O
and,6283,O
glutathione-S-transferase,6283,B-GENE-N
(,6283,O
GST,6283,B-GENE-N
),6283,O
activities,6283,O
were,6283,O
depressed,6283,O
.,6283,O
Further,6284,O
analyses,6284,O
revealed,6284,O
that,6284,O
CdTe-QD,6284,B-CHEMICAL
exposure,6284,O
resulted,6284,O
in,6284,O
apoptosis,6284,O
",",6284,O
indicated,6284,O
by,6284,O
changes,6284,O
in,6284,O
levels,6284,O
of,6284,O
caspase-3,6284,B-GENE-Y
activity,6284,O
",",6284,O
poly,6284,B-GENE-N
ADP-ribose,6284,I-GENE-N
polymerase,6284,I-GENE-N
(,6284,O
PARP,6284,B-GENE-N
),6284,O
cleavage,6284,O
and,6284,O
phosphatidylserine,6284,B-CHEMICAL
externalization,6284,O
.,6284,O
Extrinsic,6285,O
apoptotic,6285,O
pathway,6285,O
markers,6285,O
such,6285,O
as,6285,O
Fas,6285,B-GENE-Y
levels,6285,O
and,6285,O
caspase-8,6285,B-GENE-Y
activity,6285,O
increased,6285,O
as,6285,O
a,6285,O
result,6285,O
of,6285,O
CdTe-QD,6285,B-CHEMICAL
exposure,6285,O
.,6285,O
Involvement,6286,O
of,6286,O
the,6286,O
intrinsic/mitochondrial,6286,O
apoptotic,6286,O
pathway,6286,O
was,6286,O
indicated,6286,O
by,6286,O
decreased,6286,O
levels,6286,O
of,6286,O
B-cell,6286,B-GENE-Y
lymphoma,6286,I-GENE-Y
2,6286,I-GENE-Y
(,6286,O
Bcl2,6286,B-GENE-Y
),6286,O
protein,6286,O
and,6286,O
mitochondrial,6286,O
cytochrome,6286,B-GENE-Y
c,6286,I-GENE-Y
",",6286,O
and,6286,O
by,6286,O
increased,6286,O
levels,6286,O
of,6286,O
mitochondrial,6286,O
Bcl-2-associated,6286,B-GENE-Y
X,6286,I-GENE-Y
protein,6286,I-GENE-Y
(,6286,O
Bax,6286,B-GENE-Y
),6286,O
and,6286,O
cytosolic,6286,O
cytochrome,6286,B-GENE-Y
c.,6286,O
Further,6286,O
",",6286,O
mitogen-activated,6286,B-GENE-N
protein,6286,I-GENE-N
kinases,6286,I-GENE-N
(,6286,O
MAPKs,6286,B-GENE-N
),6286,O
such,6286,O
as,6286,O
c-Jun,6286,B-GENE-N
N-terminal,6286,I-GENE-N
kinases,6286,I-GENE-N
(,6286,O
JNK,6286,B-GENE-N
),6286,O
",",6286,O
extracellular,6286,B-GENE-N
signal-regulated,6286,I-GENE-N
kinases,6286,I-GENE-N
(,6286,O
Erk1/2,6286,B-GENE-N
),6286,O
",",6286,O
and,6286,O
p38,6286,B-GENE-N
were,6286,O
all,6286,O
activated,6286,O
.,6286,O
Our,6287,O
findings,6287,O
reveal,6287,O
that,6287,O
CdTe-QDs,6287,B-CHEMICAL
cause,6287,O
oxidative,6287,O
stress,6287,O
",",6287,O
interfere,6287,O
with,6287,O
antioxidant,6287,O
defenses,6287,O
and,6287,O
activate,6287,O
protein,6287,O
kinases,6287,B-GENE-N
",",6287,O
leading,6287,O
to,6287,O
apoptosis,6287,O
via,6287,O
both,6287,O
extrinsic,6287,O
and,6287,O
intrinsic,6287,O
pathways,6287,O
.,6287,O
Since,6288,O
the,6288,O
effects,6288,O
of,6288,O
CdTe-QDs,6288,B-CHEMICAL
on,6288,O
selected,6288,O
biomarkers,6288,O
were,6288,O
similar,6288,O
or,6288,O
greater,6288,O
compared,6288,O
to,6288,O
those,6288,O
of,6288,O
CdCl2,6288,B-CHEMICAL
at,6288,O
equivalent,6288,O
concentrations,6288,O
of,6288,O
cadmium,6288,B-CHEMICAL
",",6288,O
the,6288,O
study,6288,O
suggests,6288,O
that,6288,O
the,6288,O
toxicity,6288,O
of,6288,O
CdTe-QDs,6288,B-CHEMICAL
arises,6288,O
from,6288,O
a,6288,O
combination,6288,O
of,6288,O
the,6288,O
effects,6288,O
of,6288,O
cadmium,6288,O
and,6288,O
ROS,6288,O
generated,6288,O
from,6288,O
the,6288,O
NPs,6288,O
.,6288,O
Reinforcement,6289,O
enhancing,6289,O
effects,6289,O
of,6289,O
nicotine,6289,B-CHEMICAL
via,6289,O
smoking,6289,O
.,6289,O
RATIONALE,6290,O
:,6290,O
In,6290,O
animals,6290,O
",",6290,O
nicotine,6290,B-CHEMICAL
enhances,6290,O
reinforcement,6290,O
from,6290,O
stimuli,6290,O
unrelated,6290,O
to,6290,O
nicotine,6290,B-CHEMICAL
intake,6290,O
.,6290,O
Human,6291,O
research,6291,O
is,6291,O
suggestive,6291,O
but,6291,O
has,6291,O
not,6291,O
clearly,6291,O
shown,6291,O
a,6291,O
similar,6291,O
influence,6291,O
of,6291,O
nicotine,6291,B-CHEMICAL
.,6291,O
OBJECTIVES,6292,O
:,6292,O
We,6292,O
assessed,6292,O
acute,6292,O
effects,6292,O
of,6292,O
nicotine,6292,B-CHEMICAL
via,6292,O
smoking,6292,O
on,6292,O
enhancement,6292,O
of,6292,O
positive,6292,O
(,6292,O
money,6292,O
",",6292,O
music,6292,O
),6292,O
or,6292,O
negative,6292,O
(,6292,O
termination,6292,O
of,6292,O
noise,6292,O
),6292,O
reinforcers,6292,O
",",6292,O
or,6292,O
no,6292,O
``,6292,O
reward,6292,O
'',6292,O
(,6292,O
control,6292,O
),6292,O
.,6292,O
These,6293,O
different,6293,O
rewards,6293,O
determined,6293,O
the,6293,O
generalizability,6293,O
of,6293,O
nicotine,6293,B-CHEMICAL
effects,6293,O
.,6293,O
MATERIALS,6294,O
AND,6294,O
METHODS,6294,O
:,6294,O
Dependent,6294,O
(,6294,O
n,6294,O
=,6294,O
25,6294,O
),6294,O
and,6294,O
nondependent,6294,O
(,6294,O
n,6294,O
=,6294,O
27,6294,O
),6294,O
smokers,6294,O
participated,6294,O
in,6294,O
three,6294,O
sessions,6294,O
",",6294,O
each,6294,O
after,6294,O
overnight,6294,O
abstinence,6294,O
.,6294,O
Using,6295,O
a,6295,O
within-subjects,6295,O
design,6295,O
",",6295,O
sessions,6295,O
involved,6295,O
no,6295,O
smoking,6295,O
or,6295,O
smoking,6295,O
denicotinized,6295,O
(,6295,O
0.05,6295,O
mg,6295,O
),6295,O
or,6295,O
nicotine,6295,B-CHEMICAL
(,6295,O
0.6,6295,O
mg,6295,O
),6295,O
Quest,6295,O
(,6295,O
R,6295,O
),6295,O
brand,6295,O
cigarettes,6295,O
.,6295,O
For,6296,O
comparison,6296,O
",",6296,O
a,6296,O
fourth,6296,O
session,6296,O
involved,6296,O
no,6296,O
abstinence,6296,O
prior,6296,O
to,6296,O
smoking,6296,O
one,6296,O
's,6296,O
own,6296,O
brand,6296,O
to,6296,O
gauge,6296,O
responses,6296,O
under,6296,O
typical,6296,O
nicotine,6296,B-CHEMICAL
satiation,6296,O
.,6296,O
Reinforcement,6297,O
was,6297,O
assessed,6297,O
by,6297,O
responses,6297,O
on,6297,O
a,6297,O
simple,6297,O
operant,6297,O
computer,6297,O
task,6297,O
for,6297,O
the,6297,O
rewards,6297,O
",",6297,O
each,6297,O
available,6297,O
singly,6297,O
on,6297,O
a,6297,O
progressive,6297,O
ratio,6297,O
schedule,6297,O
during,6297,O
separate,6297,O
trials,6297,O
.,6297,O
RESULTS,6298,O
:,6298,O
The,6298,O
reinforcing,6298,O
effect,6298,O
of,6298,O
music,6298,O
",",6298,O
but,6298,O
not,6298,O
other,6298,O
rewards,6298,O
",",6298,O
was,6298,O
greater,6298,O
due,6298,O
to,6298,O
the,6298,O
nicotine,6298,B-CHEMICAL
cigarette,6298,O
",",6298,O
compared,6298,O
to,6298,O
the,6298,O
denicotinized,6298,O
cigarette,6298,O
or,6298,O
no,6298,O
smoking,6298,O
.,6298,O
Reinforcement,6299,O
enhancing,6299,O
effects,6299,O
of,6299,O
nicotine,6299,B-CHEMICAL
did,6299,O
not,6299,O
differ,6299,O
between,6299,O
dependent,6299,O
and,6299,O
nondependent,6299,O
groups,6299,O
",",6299,O
indicating,6299,O
no,6299,O
influence,6299,O
of,6299,O
withdrawal,6299,O
relief,6299,O
.,6299,O
Responding,6300,O
due,6300,O
to,6300,O
acute,6300,O
nicotine,6300,B-CHEMICAL
after,6300,O
abstinence,6300,O
was,6300,O
very,6300,O
similar,6300,O
to,6300,O
responding,6300,O
to,6300,O
one,6300,O
's,6300,O
own,6300,O
brand,6300,O
after,6300,O
no,6300,O
abstinence,6300,O
.,6300,O
CONCLUSIONS,6301,O
:,6301,O
Acute,6301,O
nicotine,6301,B-CHEMICAL
intake,6301,O
per,6301,O
se,6301,O
from,6301,O
smoking,6301,O
after,6301,O
abstinence,6301,O
enhances,6301,O
the,6301,O
reinforcing,6301,O
value,6301,O
of,6301,O
rewards,6301,O
unassociated,6301,O
with,6301,O
smoking,6301,O
",",6301,O
perhaps,6301,O
in,6301,O
a,6301,O
manner,6301,O
comparable,6301,O
to,6301,O
ad,6301,O
lib,6301,O
smoking,6301,O
after,6301,O
no,6301,O
abstinence,6301,O
.,6301,O
Nicotine,6302,B-CHEMICAL
's,6302,O
reinforcement,6302,O
enhancing,6302,O
effects,6302,O
may,6302,O
be,6302,O
specific,6302,O
to,6302,O
certain,6302,O
rewards,6302,O
",",6302,O
perhaps,6302,O
those,6302,O
sensory,6302,O
in,6302,O
nature,6302,O
.,6302,O
Anti-apoptotic,6303,O
cardioprotective,6303,O
effects,6303,O
of,6303,O
SHP-1,6303,B-GENE-Y
gene,6303,O
silencing,6303,O
against,6303,O
ischemia-reperfusion,6303,O
injury,6303,O
:,6303,O
Use,6303,O
of,6303,O
deoxycholic,6303,B-CHEMICAL
acid-modified,6303,O
low,6303,O
molecular,6303,O
weight,6303,O
polyethyleneimine,6303,B-CHEMICAL
as,6303,O
a,6303,O
cardiac,6303,O
siRNA-carrier,6303,O
.,6303,O
The,6304,O
cardiomyocyte,6304,O
apoptosis,6304,O
plays,6304,O
a,6304,O
critical,6304,O
role,6304,O
in,6304,O
the,6304,O
development,6304,O
of,6304,O
myocardial,6304,O
injury,6304,O
after,6304,O
ischemia,6304,O
and,6304,O
reperfusion,6304,O
.,6304,O
Thus,6305,O
",",6305,O
alteration,6305,O
of,6305,O
the,6305,O
major,6305,O
apoptosis-regulatory,6305,O
factors,6305,O
during,6305,O
myocardial,6305,O
ischemia-reperfusion,6305,O
is,6305,O
expected,6305,O
to,6305,O
have,6305,O
favorable,6305,O
cardioprotective,6305,O
effects,6305,O
.,6305,O
Herein,6306,O
",",6306,O
we,6306,O
report,6306,O
ischemic-reperfused,6306,O
myocardial,6306,O
infarction,6306,O
(,6306,O
MI,6306,O
),6306,O
repair,6306,O
with,6306,O
siRNA,6306,O
against,6306,O
Src,6306,B-GENE-Y
homology,6306,I-GENE-Y
region,6306,I-GENE-Y
2,6306,I-GENE-Y
domain-containing,6306,I-GENE-Y
tyrosine,6306,B-CHEMICAL
phosphatase-1,6306,I-GENE-Y
(,6306,O
SHP-1,6306,B-GENE-Y
),6306,O
",",6306,O
which,6306,O
is,6306,O
known,6306,O
as,6306,O
a,6306,O
key,6306,O
factor,6306,O
involved,6306,O
in,6306,O
regulating,6306,O
the,6306,O
progress,6306,O
of,6306,O
apoptosis,6306,O
in,6306,O
many,6306,O
cell,6306,O
types,6306,O
.,6306,O
A,6307,O
low,6307,O
molecular,6307,O
weight,6307,O
polyethyleneimine,6307,B-CHEMICAL
modified,6307,O
with,6307,O
deoxycholic,6307,B-CHEMICAL
acid,6307,I-CHEMICAL
(,6307,O
PEI1.8-DA,6307,O
),6307,O
-based,6307,O
delivery,6307,O
strategy,6307,O
was,6307,O
suggested,6307,O
for,6307,O
the,6307,O
cardiac,6307,O
application,6307,O
of,6307,O
SHP-1,6307,B-GENE-Y
siRNA,6307,O
to,6307,O
overcome,6307,O
the,6307,O
poor,6307,O
gene,6307,O
delivery,6307,O
efficiency,6307,O
to,6307,O
myocardium,6307,O
due,6307,O
to,6307,O
the,6307,O
highly,6307,O
charged,6307,O
structures,6307,O
of,6307,O
the,6307,O
compact,6307,O
cardiac,6307,O
muscles,6307,O
.,6307,O
The,6308,O
PEI1.8-DA,6308,O
conjugates,6308,O
formed,6308,O
stable,6308,O
nanocomplexes,6308,O
with,6308,O
SHP-1,6308,B-GENE-Y
siRNA,6308,O
via,6308,O
electrostatic,6308,O
and,6308,O
hydrophobic,6308,O
interactions,6308,O
.,6308,O
The,6309,O
PEI1.8-DA/SHP-1,6309,O
siRNA,6309,O
polyplexes,6309,O
effectively,6309,O
silenced,6309,O
SHP-1,6309,B-GENE-Y
gene,6309,O
expression,6309,O
in,6309,O
cardiomyocytes,6309,O
",",6309,O
leading,6309,O
to,6309,O
a,6309,O
significant,6309,O
inhibition,6309,O
of,6309,O
cardiomyocyte,6309,O
apoptosis,6309,O
under,6309,O
hypoxia,6309,O
.,6309,O
In,6310,O
comparison,6310,O
to,6310,O
conventional,6310,O
gene,6310,O
carriers,6310,O
",",6310,O
relatively,6310,O
large,6310,O
amounts,6310,O
of,6310,O
siRNA,6310,O
molecules,6310,O
remained,6310,O
after,6310,O
treatment,6310,O
with,6310,O
the,6310,O
PEI1.8-DA/SHP-1,6310,O
siRNA,6310,O
polyplexes,6310,O
.,6310,O
Cardiac,6311,O
administration,6311,O
of,6311,O
the,6311,O
PEI1.8-DA/SHP-1,6311,O
siRNA,6311,O
polyplexes,6311,O
resulted,6311,O
in,6311,O
substantial,6311,O
improvement,6311,O
in,6311,O
SHP-1,6311,B-GENE-Y
gene,6311,O
silencing,6311,O
",",6311,O
which,6311,O
can,6311,O
be,6311,O
explained,6311,O
by,6311,O
the,6311,O
enhancement,6311,O
of,6311,O
cardiac,6311,O
delivery,6311,O
efficiency,6311,O
of,6311,O
the,6311,O
PEI1.8-DA,6311,O
conjugates,6311,O
.,6311,O
In,6312,O
addition,6312,O
",",6312,O
in,6312,O
vivo,6312,O
treatment,6312,O
with,6312,O
the,6312,O
PEI1.8-DA/SHP-1,6312,O
siRNA,6312,O
polyplexes,6312,O
induced,6312,O
a,6312,O
highly,6312,O
significant,6312,O
reduction,6312,O
in,6312,O
myocardial,6312,O
apoptosis,6312,O
and,6312,O
infarct,6312,O
size,6312,O
in,6312,O
rat,6312,O
MI,6312,O
models,6312,O
.,6312,O
These,6313,O
results,6313,O
demonstrate,6313,O
that,6313,O
the,6313,O
PEI1.8-DA/SHP-1,6313,O
siRNA,6313,O
polyplex,6313,O
formulation,6313,O
is,6313,O
a,6313,O
useful,6313,O
system,6313,O
for,6313,O
efficient,6313,O
gene,6313,O
delivery,6313,O
into,6313,O
the,6313,O
compact,6313,O
myocardium,6313,O
that,6313,O
provides,6313,O
a,6313,O
fundamental,6313,O
advantage,6313,O
in,6313,O
treating,6313,O
ischemic-reperfused,6313,O
MI,6313,O
.,6313,O
Synthesis,6314,O
of,6314,O
C17-OH-north,6314,O
unit,6314,O
of,6314,O
ritterazine,6314,B-CHEMICAL
G,6314,I-CHEMICAL
via,6314,O
``,6314,O
Red-Ox,6314,O
'',6314,O
modifications,6314,O
of,6314,O
hecogenin,6314,B-CHEMICAL
acetate,6314,I-CHEMICAL
.,6314,O
The,6315,O
C17-OH-north,6315,O
unit,6315,O
of,6315,O
ritterazine,6315,B-CHEMICAL
G,6315,I-CHEMICAL
was,6315,O
prepared,6315,O
in,6315,O
13,6315,O
steps,6315,O
from,6315,O
hecogenin,6315,B-CHEMICAL
acetate,6315,I-CHEMICAL
.,6315,O
This,6316,O
synthesis,6316,O
features,6316,O
a,6316,O
highly,6316,O
efficient,6316,O
and,6316,O
stereoselective,6316,O
introduction,6316,O
of,6316,O
the,6316,O
C17-OH,6316,O
via,6316,O
E-ring,6316,O
cleavage/F-ring,6316,O
formation,6316,O
",",6316,O
D-ring,6316,O
oxidation,6316,O
",",6316,O
and,6316,O
F-ring,6316,O
cleavage/E-ring,6316,O
formation,6316,O
.,6316,O
Inhibitory,6317,O
effects,6317,O
of,6317,O
in,6317,O
vivo,6317,O
oxidized,6317,B-GENE-N
high-density,6317,I-GENE-N
lipoproteins,6317,I-GENE-N
on,6317,O
platelet,6317,O
aggregation,6317,O
:,6317,O
evidence,6317,O
from,6317,O
patients,6317,O
with,6317,O
abetalipoproteinemia,6317,O
.,6317,O
There,6318,O
is,6318,O
evidence,6318,O
that,6318,O
high-density,6318,B-GENE-N
lipoproteins,6318,I-GENE-N
(,6318,O
HDLs,6318,B-GENE-N
),6318,O
may,6318,O
regulate,6318,O
platelet,6318,O
function,6318,O
",",6318,O
but,6318,O
disparate,6318,O
results,6318,O
exist,6318,O
regarding,6318,O
the,6318,O
effects,6318,O
of,6318,O
oxidized,6318,O
HDLs,6318,B-GENE-N
on,6318,O
platelets,6318,O
.,6318,O
The,6319,O
objective,6319,O
of,6319,O
our,6319,O
study,6319,O
was,6319,O
to,6319,O
determine,6319,O
the,6319,O
role,6319,O
of,6319,O
in,6319,O
vivo,6319,O
oxidized,6319,B-GENE-N
HDLs,6319,I-GENE-N
on,6319,O
platelet,6319,O
aggregation,6319,O
.,6319,O
Platelet,6320,O
aggregation,6320,O
and,6320,O
redox,6320,O
status,6320,O
were,6320,O
investigated,6320,O
in,6320,O
5,6320,O
patients,6320,O
with,6320,O
abetalipoproteinemia,6320,O
(,6320,O
ABLP,6320,O
),6320,O
or,6320,O
homozygous,6320,O
hypobetalipoproteinemia,6320,O
",",6320,O
two,6320,O
rare,6320,O
metabolic,6320,O
diseases,6320,O
characterized,6320,O
by,6320,O
the,6320,O
absence,6320,O
of,6320,O
apolipoprotein,6320,B-GENE-Y
B-containing,6320,O
lipoproteins,6320,B-GENE-N
",",6320,O
compared,6320,O
to,6320,O
5,6320,O
control,6320,O
subjects,6320,O
.,6320,O
Platelets,6321,O
isolated,6321,O
from,6321,O
plasma,6321,O
of,6321,O
patients,6321,O
with,6321,O
ABLP,6321,O
aggregated,6321,O
4,6321,O
to,6321,O
10,6321,O
times,6321,O
more,6321,O
than,6321,O
control,6321,O
platelets,6321,O
",",6321,O
depending,6321,O
on,6321,O
the,6321,O
agonist,6321,O
.,6321,O
By,6322,O
contrast,6322,O
",",6322,O
no,6322,O
differences,6322,O
in,6322,O
the,6322,O
extent,6322,O
of,6322,O
platelet,6322,O
aggregation,6322,O
were,6322,O
observed,6322,O
between,6322,O
ABLP,6322,O
platelet-rich,6322,O
plasma,6322,O
(,6322,O
PRP,6322,O
),6322,O
and,6322,O
control,6322,O
PRP,6322,O
",",6322,O
suggesting,6322,O
the,6322,O
presence,6322,O
of,6322,O
a,6322,O
protective,6322,O
factor,6322,O
in,6322,O
ABLP,6322,O
plasma,6322,O
.,6322,O
ABLP,6323,O
HDLs,6323,B-GENE-N
inhibited,6323,O
agonist-induced,6323,O
platelet,6323,O
aggregation,6323,O
by,6323,O
binding,6323,O
to,6323,O
SR-BI,6323,B-GENE-Y
",",6323,O
while,6323,O
control,6323,O
HDLs,6323,B-GENE-N
had,6323,O
no,6323,O
effect,6323,O
.,6323,O
On,6324,O
the,6324,O
other,6324,O
hand,6324,O
",",6324,O
lipoprotein-deficient,6324,B-GENE-N
plasma,6324,O
from,6324,O
patients,6324,O
with,6324,O
ABLP,6324,O
did,6324,O
not,6324,O
inhibit,6324,O
platelet,6324,O
aggregation,6324,O
.,6324,O
Severe,6325,O
oxidative,6325,O
stress,6325,O
was,6325,O
evidenced,6325,O
in,6325,O
patients,6325,O
with,6325,O
ABLP,6325,O
.,6325,O
Compared,6326,O
to,6326,O
control,6326,O
HDLs,6326,B-GENE-N
",",6326,O
ABLP,6326,O
HDLs,6326,B-GENE-N
showed,6326,O
a,6326,O
40,6326,O
%,6326,O
decrease,6326,O
of,6326,O
α-tocopherol,6326,B-CHEMICAL
and,6326,O
an,6326,O
11-fold,6326,O
increased,6326,O
malondialdehyde,6326,B-CHEMICAL
concentration,6326,O
.,6326,O
These,6327,O
results,6327,O
demonstrate,6327,O
that,6327,O
in,6327,O
vivo,6327,O
oxidized,6327,B-GENE-N
HDLs,6327,I-GENE-N
do,6327,O
not,6327,O
lose,6327,O
their,6327,O
antiaggregatory,6327,O
properties,6327,O
despite,6327,O
oxidation.-Calzada,6327,O
",",6327,O
C.,6327,O
",",6327,O
Véricel,6327,O
",",6327,O
E.,6327,O
",",6327,O
Colas,6327,O
",",6327,O
R.,6327,O
",",6327,O
Guillot,6327,O
",",6327,O
N.,6327,O
",",6327,O
El,6327,O
Khoury,6327,O
",",6327,O
G.,6327,O
",",6327,O
Drai,6327,O
",",6327,O
J.,6327,O
",",6327,O
Sassolas,6327,O
",",6327,O
A.,6327,O
",",6327,O
Peretti,6327,O
",",6327,O
N.,6327,O
",",6327,O
Ponsin,6327,O
",",6327,O
G.,6327,O
",",6327,O
Lagarde,6327,O
",",6327,O
M.,6327,O
",",6327,O
Moulin,6327,O
",",6327,O
P.,6327,O
Inhibitory,6327,O
effects,6327,O
of,6327,O
in,6327,O
vivo,6327,O
oxidized,6327,B-GENE-N
high-density,6327,I-GENE-N
lipoproteins,6327,I-GENE-N
on,6327,O
platelet,6327,O
aggregation,6327,O
:,6327,O
evidence,6327,O
from,6327,O
patients,6327,O
with,6327,O
abetalipoproteinemia,6327,O
.,6327,O
Derivatives,6328,O
of,6328,O
Dictyostelium,6328,O
discoideum,6328,O
differentiation-inducing,6328,O
factor-3,6328,O
suppress,6328,O
the,6328,O
activities,6328,O
of,6328,O
Trypanosoma,6328,O
cruzi,6328,O
in,6328,O
vitro,6328,O
and,6328,O
in,6328,O
vivo,6328,O
.,6328,O
Chagas,6329,O
disease,6329,O
(,6329,O
human,6329,O
American,6329,O
trypanosomiasis,6329,O
),6329,O
",",6329,O
which,6329,O
is,6329,O
caused,6329,O
by,6329,O
the,6329,O
protozoan,6329,O
parasite,6329,O
Trypanosoma,6329,O
cruzi,6329,O
",",6329,O
is,6329,O
responsible,6329,O
for,6329,O
numerous,6329,O
deaths,6329,O
each,6329,O
year,6329,O
;,6329,O
however,6329,O
",",6329,O
established,6329,O
treatments,6329,O
for,6329,O
the,6329,O
disease,6329,O
are,6329,O
limited,6329,O
.,6329,O
Differentiation-inducing,6330,O
factor-1,6330,O
(,6330,O
DIF-1,6330,O
),6330,O
and,6330,O
DIF-3,6330,O
are,6330,O
chlorinated,6330,O
alkylphenones,6330,B-CHEMICAL
originally,6330,O
found,6330,O
in,6330,O
the,6330,O
cellular,6330,O
slime,6330,O
mold,6330,O
Dictyostelium,6330,O
discoideum,6330,O
that,6330,O
have,6330,O
been,6330,O
shown,6330,O
to,6330,O
possess,6330,O
pharmacological,6330,O
activities,6330,O
.,6330,O
Here,6331,O
",",6331,O
we,6331,O
investigated,6331,O
the,6331,O
effects,6331,O
of,6331,O
DIF-3,6331,O
derivatives,6331,O
on,6331,O
the,6331,O
infection,6331,O
rate,6331,O
and,6331,O
growth,6331,O
of,6331,O
T.,6331,O
cruzi,6331,O
by,6331,O
using,6331,O
an,6331,O
in,6331,O
vitro,6331,O
assay,6331,O
system,6331,O
utilizing,6331,O
host,6331,O
human,6331,O
fibrosarcoma,6331,O
HT1080,6331,O
cells,6331,O
.,6331,O
Certain,6332,O
DIF-3,6332,O
derivatives,6332,O
",",6332,O
such,6332,O
as,6332,O
butoxy-DIF-3,6332,B-CHEMICAL
(,6332,O
Bu-DIF-3,6332,O
),6332,O
",",6332,O
at,6332,O
micro-molar,6332,O
levels,6332,O
strongly,6332,O
suppressed,6332,O
both,6332,O
the,6332,O
infection,6332,O
rate,6332,O
and,6332,O
growth,6332,O
of,6332,O
T.,6332,O
cruzi,6332,O
in,6332,O
HT1080,6332,O
cells,6332,O
and,6332,O
exhibited,6332,O
little,6332,O
toxicity,6332,O
for,6332,O
HT1080,6332,O
cells,6332,O
.,6332,O
For,6333,O
example,6333,O
",",6333,O
the,6333,O
IC50,6333,O
of,6333,O
DIF-3,6333,O
and,6333,O
Bu-DIF-3,6333,O
versus,6333,O
the,6333,O
growth,6333,O
of,6333,O
T.,6333,O
cruzi,6333,O
in,6333,O
HT1080,6333,O
cells,6333,O
were,6333,O
3.95,6333,O
and,6333,O
0.72μM,6333,O
",",6333,O
respectively,6333,O
",",6333,O
and,6333,O
the,6333,O
LD50,6333,O
of,6333,O
the,6333,O
two,6333,O
compounds,6333,O
versus,6333,O
HT1080,6333,O
cells,6333,O
were,6333,O
both,6333,O
greater,6333,O
than,6333,O
100μM,6333,O
.,6333,O
We,6334,O
also,6334,O
examined,6334,O
the,6334,O
effects,6334,O
of,6334,O
DIF-3,6334,O
and,6334,O
Bu-DIF-3,6334,O
on,6334,O
T.,6334,O
cruzi,6334,O
activity,6334,O
in,6334,O
C57BL/6,6334,O
mice,6334,O
.,6334,O
Intraperitoneally,6335,O
administered,6335,O
Bu-DIF-3,6335,O
(,6335,O
50mg/kg,6335,O
),6335,O
significantly,6335,O
suppressed,6335,O
the,6335,O
number,6335,O
of,6335,O
trypomastigotes,6335,O
in,6335,O
blood,6335,O
with,6335,O
no,6335,O
apparent,6335,O
adverse,6335,O
effects,6335,O
.,6335,O
These,6336,O
results,6336,O
strongly,6336,O
suggest,6336,O
that,6336,O
DIF-3,6336,O
derivatives,6336,O
could,6336,O
be,6336,O
new,6336,O
lead,6336,O
compounds,6336,O
in,6336,O
the,6336,O
development,6336,O
of,6336,O
anti-trypanosomiasis,6336,O
drugs,6336,O
.,6336,O
Neuroprotective,6337,O
Effects,6337,O
of,6337,O
Puerarin,6337,B-CHEMICAL
on,6337,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",6337,B-CHEMICAL
induced,6337,O
Parkinson,6337,O
's,6337,O
Disease,6337,O
Model,6337,O
in,6337,O
Mice,6337,O
.,6337,O
Puerarin,6338,B-CHEMICAL
",",6338,O
an,6338,O
active,6338,O
component,6338,O
of,6338,O
Pueraria,6338,O
montana,6338,O
var,6338,O
.,6338,O
lobata,6339,O
(,6339,O
Willd,6339,O
.,6339,O
),6339,O
Sanjappa,6340,O
&,6340,O
Pradeep,6340,O
is,6340,O
well-known,6340,O
for,6340,O
its,6340,O
anti-oxidative,6340,O
and,6340,O
neuroprotective,6340,O
activities,6340,O
.,6340,O
Although,6341,O
anti-Parkinson,6341,O
's,6341,O
disease,6341,O
activity,6341,O
of,6341,O
puerarin,6341,B-CHEMICAL
was,6341,O
reported,6341,O
in,6341,O
both,6341,O
of,6341,O
in,6341,O
vivo,6341,O
and,6341,O
in,6341,O
vitro,6341,O
model,6341,O
",",6341,O
detailed,6341,O
mechanisms,6341,O
are,6341,O
not,6341,O
clarified,6341,O
.,6341,O
In,6342,O
this,6342,O
study,6342,O
",",6342,O
we,6342,O
addressed,6342,O
that,6342,O
puerarin,6342,B-CHEMICAL
attenuated,6342,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",6342,B-CHEMICAL
(,6342,O
MPTP,6342,B-CHEMICAL
),6342,O
-induced,6342,O
behavioral,6342,O
deficits,6342,O
",",6342,O
dopaminergic,6342,O
neuronal,6342,O
degeneration,6342,O
and,6342,O
dopamine,6342,B-CHEMICAL
depletion,6342,O
.,6342,O
Puerarin,6343,B-CHEMICAL
administration,6343,O
enhanced,6343,O
glutathione,6343,B-CHEMICAL
(,6343,O
GSH,6343,B-CHEMICAL
),6343,O
activity,6343,O
",",6343,O
glial,6343,B-GENE-Y
cell,6343,I-GENE-Y
line-derived,6343,I-GENE-Y
neurotrophic,6343,I-GENE-Y
factor,6343,I-GENE-Y
(,6343,O
GDNF,6343,B-GENE-Y
),6343,O
expression,6343,O
and,6343,O
PI3K/Akt,6343,B-GENE-N
pathway,6343,O
activation,6343,O
",",6343,O
which,6343,O
might,6343,O
ameliorate,6343,O
MPTP,6343,B-CHEMICAL
injection-induced,6343,O
progressive,6343,O
elevation,6343,O
of,6343,O
reactive,6343,O
oxygen,6343,B-CHEMICAL
species,6343,O
(,6343,O
ROS,6343,O
),6343,O
formation,6343,O
in,6343,O
mice,6343,O
.,6343,O
In,6344,O
addition,6344,O
to,6344,O
the,6344,O
effect,6344,O
on,6344,O
ROS,6344,O
",",6344,O
puerarin,6344,B-CHEMICAL
ameliorated,6344,O
MPTP-reduced,6344,B-CHEMICAL
lysosome-associated,6344,B-GENE-Y
membrane,6344,I-GENE-Y
protein,6344,I-GENE-Y
type,6344,I-GENE-Y
2A,6344,I-GENE-Y
(,6344,O
Lamp,6344,B-GENE-Y
2A,6344,I-GENE-Y
),6344,O
expression,6344,O
.,6344,O
Taken,6345,O
together,6345,O
",",6345,O
our,6345,O
data,6345,O
demonstrate,6345,O
that,6345,O
puerarin,6345,B-CHEMICAL
attenuates,6345,O
MPTP-induced,6345,B-CHEMICAL
dopaminergic,6345,O
neuronal,6345,O
degeneration,6345,O
via,6345,O
modulating,6345,O
GDNF,6345,B-GENE-Y
expression,6345,O
",",6345,O
PI3K/Akt,6345,B-GENE-N
pathway,6345,O
and,6345,O
GSH,6345,B-CHEMICAL
activation,6345,O
",",6345,O
which,6345,O
subsequently,6345,O
ameliorate,6345,O
MPTP-induced,6345,B-CHEMICAL
ROS,6345,O
formation,6345,O
and,6345,O
decrease,6345,O
of,6345,O
Lamp,6345,B-GENE-Y
2A,6345,I-GENE-Y
expression,6345,O
.,6345,O
Copyright,6346,O
©,6346,O
2013,6346,O
John,6346,O
Wiley,6346,O
&,6346,O
Sons,6346,O
",",6346,O
Ltd,6346,O
.,6346,O
Efficient,6347,O
induction,6347,O
of,6347,O
apoptosis,6347,O
in,6347,O
HeLa,6347,O
cells,6347,O
by,6347,O
a,6347,O
novel,6347,O
cationic,6347,O
porphycene,6347,B-CHEMICAL
photosensitizer,6347,O
.,6347,O
In,6348,O
the,6348,O
present,6348,O
study,6348,O
we,6348,O
analyze,6348,O
the,6348,O
photobiological,6348,O
properties,6348,O
of,6348,O
"2,7,12-tris",6348,B-CHEMICAL
(,6348,I-CHEMICAL
α-pyridinio-p-tolyl,6348,I-CHEMICAL
),6348,I-CHEMICAL
-17-,6348,I-CHEMICAL
(,6348,I-CHEMICAL
p-,6348,I-CHEMICAL
(,6348,I-CHEMICAL
methoxymethyl,6348,I-CHEMICAL
),6348,I-CHEMICAL
phenyl,6348,I-CHEMICAL
),6348,I-CHEMICAL
porphycene,6348,I-CHEMICAL
(,6348,O
Py3MeO-TBPo,6348,B-CHEMICAL
),6348,O
in,6348,O
Hela,6348,O
cells,6348,O
",",6348,O
in,6348,O
order,6348,O
to,6348,O
assess,6348,O
its,6348,O
potential,6348,O
as,6348,O
a,6348,O
new,6348,O
photosensitizer,6348,O
for,6348,O
photodynamic,6348,O
therapy,6348,O
of,6348,O
cultured,6348,O
tumor,6348,O
cells,6348,O
.,6348,O
Using,6349,O
0.5,6349,O
μM,6349,O
Py3MeO-TBPo,6349,B-CHEMICAL
",",6349,O
flow,6349,O
cytometry,6349,O
studies,6349,O
demonstrated,6349,O
an,6349,O
increase,6349,O
of,6349,O
intracellular,6349,O
drug,6349,O
levels,6349,O
related,6349,O
to,6349,O
the,6349,O
incubation,6349,O
time,6349,O
",",6349,O
reaching,6349,O
a,6349,O
maximum,6349,O
at,6349,O
18,6349,O
h.,6349,O
LysoTracker,6349,O
(,6349,O
®,6349,O
),6349,O
Green,6349,O
(,6349,O
LTG,6349,O
),6349,O
and,6349,O
MitoTracker,6349,O
(,6349,O
®,6349,O
),6349,O
Green,6349,O
(,6349,O
MTG,6349,O
),6349,O
probes,6349,O
were,6349,O
used,6349,O
to,6349,O
identify,6349,O
the,6349,O
subcellular,6349,O
localization,6349,O
.,6349,O
Upon,6350,O
exposure,6350,O
to,6350,O
ultraviolet,6350,O
excitation,6350,O
",",6350,O
red,6350,O
porphycene,6350,B-CHEMICAL
fluorescence,6350,O
was,6350,O
detected,6350,O
as,6350,O
red,6350,O
granules,6350,O
in,6350,O
the,6350,O
cytoplasm,6350,O
that,6350,O
colocalized,6350,O
with,6350,O
LTG,6350,O
.,6350,O
No,6351,O
significant,6351,O
toxic,6351,O
effects,6351,O
were,6351,O
detected,6351,O
for,6351,O
Py3MeO-TBPo,6351,B-CHEMICAL
in,6351,O
the,6351,O
dark,6351,O
at,6351,O
concentrations,6351,O
below,6351,O
1,6351,O
μM,6351,O
.,6351,O
In,6352,O
contrast,6352,O
",",6352,O
Py3MeO-TBPo,6352,B-CHEMICAL
combined,6352,O
with,6352,O
red-light,6352,O
irradiation,6352,O
induced,6352,O
concentration-,6352,O
and,6352,O
fluence-dependent,6352,O
HeLa,6352,O
cells,6352,O
inactivation,6352,O
.,6352,O
Besides,6353,O
",",6353,O
all,6353,O
photodynamic,6353,O
protocols,6353,O
assayed,6353,O
induced,6353,O
a,6353,O
clear,6353,O
effect,6353,O
of,6353,O
cell,6353,O
detachment,6353,O
inhibition,6353,O
after,6353,O
trypsin,6353,B-GENE-N
treatment,6353,O
.,6353,O
Both,6354,O
apoptotic,6354,O
and,6354,O
necrotic,6354,O
cell,6354,O
death,6354,O
mechanisms,6354,O
can,6354,O
occur,6354,O
in,6354,O
HeLa,6354,O
cells,6354,O
depending,6354,O
on,6354,O
the,6354,O
experimental,6354,O
protocol,6354,O
.,6354,O
After,6355,O
18,6355,O
h,6355,O
incubation,6355,O
with,6355,O
0.5,6355,O
μM,6355,O
Py3MeO-TBPo,6355,B-CHEMICAL
and,6355,O
subsequent,6355,O
red,6355,O
light,6355,O
irradiation,6355,O
(,6355,O
3.6,6355,O
J/cm,6355,O
(,6355,O
2,6355,O
),6355,O
),6355,O
",",6355,O
a,6355,O
high,6355,O
number,6355,O
of,6355,O
cells,6355,O
die,6355,O
by,6355,O
apoptosis,6355,O
",",6355,O
as,6355,O
evaluated,6355,O
by,6355,O
morphological,6355,O
alterations,6355,O
",",6355,O
immunofluorescent,6355,O
relocalization,6355,O
of,6355,O
Bax,6355,B-GENE-Y
from,6355,O
cytosol,6355,O
to,6355,O
mitochondria,6355,O
",",6355,O
and,6355,O
TUNEL,6355,O
assay,6355,O
.,6355,O
Likewise,6356,O
",",6356,O
immunofluorescence,6356,O
techniques,6356,O
showed,6356,O
that,6356,O
cytochrome,6356,B-GENE-Y
c,6356,I-GENE-Y
is,6356,O
released,6356,O
from,6356,O
mitochondria,6356,O
into,6356,O
cytosol,6356,O
in,6356,O
cells,6356,O
undergoing,6356,O
apoptosis,6356,O
",",6356,O
which,6356,O
occurs,6356,O
immediately,6356,O
after,6356,O
relocation,6356,O
of,6356,O
Bax,6356,B-GENE-Y
in,6356,O
mitochondria,6356,O
.,6356,O
The,6357,O
highest,6357,O
amount,6357,O
of,6357,O
apoptosis,6357,O
appeared,6357,O
24,6357,O
h,6357,O
after,6357,O
treatment,6357,O
(,6357,O
70,6357,O
%,6357,O
),6357,O
and,6357,O
this,6357,O
cell,6357,O
death,6357,O
occurred,6357,O
without,6357,O
cell,6357,O
detachment,6357,O
to,6357,O
the,6357,O
substrate,6357,O
.,6357,O
In,6358,O
contrast,6358,O
",",6358,O
with,6358,O
0.75,6358,O
μM,6358,O
Py3MeO-TBPo,6358,B-CHEMICAL
and,6358,O
3.6,6358,O
J/cm,6358,O
(,6358,O
2,6358,O
),6358,O
irradiation,6358,O
",",6358,O
morphological,6358,O
changes,6358,O
showed,6358,O
a,6358,O
preferential,6358,O
necrotic,6358,O
cell,6358,O
death,6358,O
.,6358,O
Singlet,6359,O
oxygen,6359,B-CHEMICAL
was,6359,O
identified,6359,O
as,6359,O
the,6359,O
cytotoxic,6359,O
agent,6359,O
involved,6359,O
in,6359,O
cell,6359,O
photoinactivation,6359,O
.,6359,O
Moreover,6360,O
",",6360,O
cell,6360,O
cultures,6360,O
pre-exposed,6360,O
to,6360,O
the,6360,O
singlet,6360,O
oxygen,6360,B-CHEMICAL
scavenger,6360,O
sodium,6360,B-CHEMICAL
azide,6360,I-CHEMICAL
showed,6360,O
pronounced,6360,O
protection,6360,O
against,6360,O
the,6360,O
loss,6360,O
of,6360,O
viability,6360,O
induced,6360,O
by,6360,O
Py3MeO-TBPo,6360,B-CHEMICAL
and,6360,O
light,6360,O
.,6360,O
Different,6361,O
changes,6361,O
in,6361,O
distribution,6361,O
and,6361,O
organization,6361,O
of,6361,O
cytoskeletal,6361,O
elements,6361,O
(,6361,O
microtubules,6361,B-GENE-N
and,6361,O
actin,6361,B-GENE-N
microfilaments,6361,O
),6361,O
as,6361,O
well,6361,O
as,6361,O
the,6361,O
protein,6361,O
vinculin,6361,B-GENE-Y
",",6361,O
after,6361,O
apoptotic,6361,O
and,6361,O
necrotic,6361,O
photodynamic,6361,O
treatments,6361,O
have,6361,O
been,6361,O
analyzed,6361,O
.,6361,O
Neither,6362,O
of,6362,O
these,6362,O
two,6362,O
cell,6362,O
death,6362,O
mechanisms,6362,O
(,6362,O
apoptosis,6362,O
or,6362,O
necrosis,6362,O
),6362,O
induced,6362,O
cell,6362,O
detachment,6362,O
.,6362,O
In,6363,O
summary,6363,O
",",6363,O
Py3MeO-TBPo,6363,B-CHEMICAL
appears,6363,O
to,6363,O
meet,6363,O
the,6363,O
requirements,6363,O
for,6363,O
further,6363,O
scrutiny,6363,O
as,6363,O
a,6363,O
very,6363,O
good,6363,O
photosensitizer,6363,O
for,6363,O
photodynamic,6363,O
therapy,6363,O
:,6363,O
it,6363,O
is,6363,O
water,6363,O
soluble,6363,O
",",6363,O
has,6363,O
a,6363,O
high,6363,O
absorption,6363,O
in,6363,O
the,6363,O
red,6363,O
spectral,6363,O
region,6363,O
(,6363,O
where,6363,O
light,6363,O
penetration,6363,O
in,6363,O
tissue,6363,O
is,6363,O
higher,6363,O
),6363,O
",",6363,O
and,6363,O
is,6363,O
able,6363,O
to,6363,O
induce,6363,O
effective,6363,O
high,6363,O
apoptotic,6363,O
rate,6363,O
(,6363,O
70,6363,O
%,6363,O
),6363,O
related,6363,O
to,6363,O
the,6363,O
more,6363,O
widely,6363,O
studied,6363,O
photosensitizers,6363,O
.,6363,O
Addition,6364,O
of,6364,O
artificial,6364,O
salt,6364,O
bridge,6364,O
by,6364,O
Ile646Lys,6364,B-GENE-N
mutation,6364,O
in,6364,O
gp41,6364,B-GENE-N
coiled-coil,6364,I-GENE-N
domain,6364,I-GENE-N
regulates,6364,O
6-helical,6364,O
bundle,6364,O
formation,6364,O
.,6364,O
HIV,6365,O
entry,6365,O
is,6365,O
mediated,6365,O
by,6365,O
the,6365,O
envelope,6365,B-GENE-Y
glycoproteins,6365,I-GENE-Y
gp120,6365,I-GENE-Y
and,6365,O
gp41,6365,B-GENE-Y
.,6365,O
The,6366,O
gp41,6366,B-GENE-Y
subunit,6366,O
contains,6366,O
several,6366,O
functional,6366,O
domains,6366,O
:,6366,O
the,6366,O
N-terminal,6366,B-GENE-N
heptad,6366,I-GENE-N
repeat,6366,I-GENE-N
(,6366,I-GENE-N
NHR,6366,I-GENE-N
),6366,I-GENE-N
domains,6366,I-GENE-N
fold,6366,O
a,6366,O
triple,6366,O
stranded,6366,O
coiled-coil,6366,O
forming,6366,O
a,6366,O
meta-stable,6366,O
prefusion,6366,O
intermediate,6366,O
.,6366,O
C-terminal,6367,B-CHEMICAL
heptad,6367,O
repeat,6367,O
(,6367,O
CHR,6367,O
),6367,O
subsequently,6367,O
folds,6367,O
onto,6367,O
the,6367,O
hydrophobic,6367,O
grooves,6367,O
of,6367,O
the,6367,O
NHR,6367,O
coiled-coil,6367,O
to,6367,O
form,6367,O
a,6367,O
stable,6367,O
6-helix,6367,O
bundle,6367,O
",",6367,O
which,6367,O
juxtaposes,6367,O
the,6367,O
viral,6367,O
and,6367,O
cellular,6367,O
membranes,6367,O
for,6367,O
fusion,6367,O
.,6367,O
The,6368,O
C34,6368,O
which,6368,O
has,6368,O
34,6368,O
amino,6368,B-CHEMICAL
acid,6368,I-CHEMICAL
residues,6368,O
is,6368,O
known,6368,O
as,6368,O
the,6368,O
core,6368,O
structure,6368,O
in,6368,O
CHR,6368,O
.,6368,O
A,6369,O
highly,6369,O
anti-HIV,6369,O
peptide,6369,O
inhibitor,6369,O
derived,6369,O
from,6369,O
C34,6369,O
was,6369,O
designed,6369,O
.,6369,O
An,6370,O
artificial,6370,O
salt,6370,O
bridge,6370,O
was,6370,O
added,6370,O
in,6370,O
the,6370,O
6-helical,6370,O
bundle,6370,O
by,6370,O
substitution,6370,O
of,6370,O
lysine,6370,B-CHEMICAL
for,6370,O
Ile646,6370,B-CHEMICAL
.,6370,O
With,6371,O
a,6371,O
cholesterol,6371,B-CHEMICAL
modification,6371,O
at,6371,O
C-terminal,6371,B-CHEMICAL
",",6371,O
the,6371,O
inhibitor,6371,O
containing,6371,O
I646K,6371,B-GENE-N
mutation,6371,O
represented,6371,O
higher,6371,O
anti-viral,6371,O
activity,6371,O
than,6371,O
C34-cholesterol,6371,O
combination,6371,O
without,6371,O
mutation,6371,O
.,6371,O
Cytotoxic,6372,O
mechanism,6372,O
of,6372,O
Piper,6372,O
gaudichaudianum,6372,O
Kunth,6372,O
essential,6372,O
oil,6372,O
and,6372,O
its,6372,O
major,6372,O
compound,6372,O
nerolidol,6372,B-CHEMICAL
.,6372,O
Piper,6373,O
gaudichaudianum,6373,O
Kunth,6373,O
is,6373,O
used,6373,O
in,6373,O
popular,6373,O
medicine,6373,O
as,6373,O
anti-inflamatory,6373,O
and,6373,O
against,6373,O
liver,6373,O
disorders,6373,O
.,6373,O
One,6374,O
of,6374,O
the,6374,O
most,6374,O
studied,6374,O
components,6374,O
of,6374,O
the,6374,O
plant,6374,O
is,6374,O
the,6374,O
essential,6374,O
oil,6374,O
for,6374,O
which,6374,O
chemical,6374,O
analysis,6374,O
revealed,6374,O
(,6374,B-CHEMICAL
E,6374,I-CHEMICAL
),6374,I-CHEMICAL
-nerolidol,6374,I-CHEMICAL
as,6374,O
major,6374,O
compound,6374,O
.,6374,O
Recently,6375,O
",",6375,O
we,6375,O
have,6375,O
shown,6375,O
that,6375,O
P.,6375,O
gaudichaudianum,6375,O
essential,6375,O
oil,6375,O
possesses,6375,O
strong,6375,O
cytotoxic,6375,O
effects,6375,O
in,6375,O
mammalian,6375,O
V79,6375,O
cells,6375,O
.,6375,O
The,6376,O
aim,6376,O
of,6376,O
this,6376,O
study,6376,O
was,6376,O
to,6376,O
analyze,6376,O
the,6376,O
cytotoxicity,6376,O
and,6376,O
mutagenicity,6376,O
of,6376,O
P.,6376,O
gaudichaudianum,6376,O
essential,6376,O
oil,6376,O
and,6376,O
nerolidol,6376,B-CHEMICAL
using,6376,O
Saccharomyces,6376,O
cerevisiae,6376,O
as,6376,O
model,6376,O
study,6376,O
.,6376,O
Treatment,6377,O
of,6377,O
the,6377,O
XV185-14c,6377,O
and,6377,O
N123,6377,O
strains,6377,O
with,6377,O
essential,6377,O
oil,6377,O
and,6377,O
nerolidol,6377,B-CHEMICAL
led,6377,O
to,6377,O
cytotoxicity,6377,O
but,6377,O
did,6377,O
not,6377,O
induce,6377,O
mutagenicity,6377,O
.,6377,O
Our,6378,O
results,6378,O
revealed,6378,O
an,6378,O
important,6378,O
role,6378,O
of,6378,O
base,6378,O
excision,6378,O
repair,6378,O
(,6378,O
BER,6378,O
),6378,O
as,6378,O
the,6378,O
ntg1,6378,B-GENE-Y
",",6378,O
ntg2,6378,B-GENE-Y
",",6378,O
apn1,6378,B-GENE-Y
and,6378,O
apn2,6378,B-GENE-Y
mutants,6378,O
showed,6378,O
pronounced,6378,O
sensitivity,6378,O
to,6378,O
essential,6378,O
oil,6378,O
and,6378,O
nerolidol,6378,B-CHEMICAL
.,6378,O
In,6379,O
the,6379,O
absence,6379,O
of,6379,O
superoxide,6379,B-CHEMICAL
dismutase,6379,I-GENE-Y
(,6379,O
in,6379,O
sod1Δ,6379,B-GENE-Y
mutant,6379,O
strain,6379,O
),6379,O
sensitivity,6379,O
to,6379,O
the,6379,O
essential,6379,O
oil,6379,O
and,6379,O
nerolidol,6379,B-CHEMICAL
increased,6379,O
indicating,6379,O
that,6379,O
this,6379,O
oil,6379,O
and,6379,O
nerolidol,6379,B-CHEMICAL
are,6379,O
generating,6379,O
reactive,6379,O
oxygen,6379,B-CHEMICAL
species,6379,O
(,6379,O
ROS,6379,O
),6379,O
.,6379,O
The,6380,O
ROS,6380,O
production,6380,O
was,6380,O
confirmed,6380,O
by,6380,O
DCF-DA,6380,B-CHEMICAL
probing,6380,O
assay,6380,O
in,6380,O
Sod-deficient,6380,B-GENE-Y
strains,6380,O
.,6380,O
From,6381,O
this,6381,O
",",6381,O
we,6381,O
conclude,6381,O
that,6381,O
the,6381,O
observed,6381,O
cytotoxicity,6381,O
to,6381,O
P.,6381,O
gaudichaudianum,6381,O
essential,6381,O
oil,6381,O
and,6381,O
nerolidol,6381,B-CHEMICAL
is,6381,O
mainly,6381,O
related,6381,O
to,6381,O
ROS,6381,O
and,6381,O
DNA,6381,O
single,6381,O
strand,6381,O
breaks,6381,O
generated,6381,O
by,6381,O
the,6381,O
presence,6381,O
of,6381,O
oxidative,6381,O
lesions,6381,O
.,6381,O
Synthesis,6382,O
and,6382,O
biological,6382,O
evaluation,6382,O
of,6382,O
novel,6382,O
"pyrrolidine-2,5-dione",6382,B-CHEMICAL
derivatives,6382,O
as,6382,O
potential,6382,O
antidepressant,6382,O
agents,6382,O
.,6382,O
Part,6383,O
1,6383,O
.,6383,O
A,6384,O
series,6384,O
of,6384,O
3-,6384,B-CHEMICAL
(,6384,I-CHEMICAL
1H-indol-3-yl,6384,I-CHEMICAL
),6384,I-CHEMICAL
"pyrrolidine-2,5-dione",6384,I-CHEMICAL
derivatives,6384,O
was,6384,O
synthesized,6384,O
and,6384,O
their,6384,O
biological,6384,O
activity,6384,O
was,6384,O
evaluated,6384,O
.,6384,O
The,6385,O
chemical,6385,O
structures,6385,O
of,6385,O
the,6385,O
newly,6385,O
prepared,6385,O
compounds,6385,O
were,6385,O
confirmed,6385,O
by,6385,O
(,6385,B-CHEMICAL
1,6385,I-CHEMICAL
),6385,I-CHEMICAL
H,6385,I-CHEMICAL
NMR,6385,O
",",6385,O
(,6385,B-CHEMICAL
13,6385,I-CHEMICAL
),6385,I-CHEMICAL
C,6385,I-CHEMICAL
NMR,6385,O
and,6385,O
ESI-HRMS,6385,O
spectra,6385,O
data,6385,O
.,6385,O
All,6386,O
tested,6386,O
compounds,6386,O
proved,6386,O
to,6386,O
be,6386,O
potent,6386,O
5-HT1A,6386,B-GENE-Y
receptor,6386,O
and,6386,O
serotonin,6386,B-GENE-Y
transporter,6386,I-GENE-Y
protein,6386,I-GENE-Y
(,6386,O
SERT,6386,B-GENE-Y
),6386,O
ligands,6386,O
.,6386,O
Among,6387,O
them,6387,O
",",6387,O
compounds,6387,O
15,6387,O
",",6387,O
18,6387,O
",",6387,O
19,6387,O
and,6387,O
30,6387,O
showed,6387,O
significant,6387,O
affinity,6387,O
for,6387,O
5-HT1A,6387,B-GENE-Y
and,6387,O
SERT,6387,B-GENE-Y
.,6387,O
Computer,6388,O
docking,6388,O
simulations,6388,O
carried,6388,O
out,6388,O
for,6388,O
compounds,6388,O
15,6388,O
",",6388,O
31,6388,O
and,6388,O
32,6388,O
to,6388,O
models,6388,O
of,6388,O
5-HT1A,6388,B-GENE-Y
receptor,6388,O
and,6388,O
SERT,6388,B-GENE-Y
confirm,6388,O
the,6388,O
results,6388,O
of,6388,O
biological,6388,O
tests,6388,O
.,6388,O
Due,6389,O
to,6389,O
high,6389,O
affinity,6389,O
for,6389,O
the,6389,O
5-HT1A,6389,B-GENE-Y
receptor,6389,O
and,6389,O
moderate,6389,O
affinity,6389,O
for,6389,O
SERT,6389,B-GENE-Y
",",6389,O
compounds,6389,O
31,6389,O
",",6389,O
32,6389,O
",",6389,O
35,6389,O
",",6389,O
and,6389,O
37,6389,O
were,6389,O
evaluated,6389,O
for,6389,O
their,6389,O
affinity,6389,O
for,6389,O
D2L,6389,B-GENE-Y
",",6389,O
5-HT6,6389,B-GENE-Y
",",6389,O
5-HT7,6389,B-GENE-Y
and,6389,O
5-HT2A,6389,B-GENE-Y
receptors,6389,O
.,6389,O
In,6390,O
vivo,6390,O
tests,6390,O
",",6390,O
in,6390,O
turn,6390,O
",",6390,O
resulted,6390,O
in,6390,O
determining,6390,O
the,6390,O
functional,6390,O
activity,6390,O
of,6390,O
compounds,6390,O
15,6390,O
",",6390,O
18,6390,O
",",6390,O
19,6390,O
and,6390,O
30,6390,O
to,6390,O
the,6390,O
5-HT1A,6390,B-GENE-Y
receptor,6390,O
.,6390,O
The,6391,O
results,6391,O
of,6391,O
these,6391,O
tests,6391,O
indicate,6391,O
that,6391,O
all,6391,O
of,6391,O
the,6391,O
ligands,6391,O
possess,6391,O
properties,6391,O
characteristic,6391,O
of,6391,O
5-HT1A,6391,B-GENE-Y
receptor,6391,O
agonists,6391,O
.,6391,O
Metabolism,6392,O
Studies,6392,O
of,6392,O
Unformulated,6392,O
Internally,6392,O
[,6392,O
3H,6392,B-CHEMICAL
],6392,O
-labeled,6392,O
siRNAs,6392,O
in,6392,O
Mice,6392,O
.,6392,O
Absorption,6393,O
",",6393,O
distribution,6393,O
",",6393,O
metabolism,6393,O
",",6393,O
and,6393,O
excretion,6393,O
properties,6393,O
of,6393,O
two,6393,O
unformulated,6393,O
model,6393,O
siRNAs,6393,O
were,6393,O
determined,6393,O
using,6393,O
a,6393,O
single,6393,O
internal,6393,O
[,6393,O
(,6393,B-CHEMICAL
3,6393,I-CHEMICAL
),6393,I-CHEMICAL
H,6393,I-CHEMICAL
],6393,O
-radiolabeling,6393,O
procedure,6393,O
",",6393,O
where,6393,O
the,6393,O
full-length,6393,O
oligonucleotides,6393,O
were,6393,O
radiolabeled,6393,O
by,6393,O
Br/,6393,B-CHEMICAL
(,6393,B-CHEMICAL
3,6393,I-CHEMICAL
),6393,I-CHEMICAL
H-exchange,6393,O
.,6393,O
Tissue,6394,O
distribution,6394,O
",",6394,O
excretion,6394,O
",",6394,O
and,6394,O
mass,6394,O
balance,6394,O
of,6394,O
radioactivity,6394,O
were,6394,O
investigated,6394,O
in,6394,O
male,6394,O
CD-1,6394,O
mice,6394,O
",",6394,O
following,6394,O
a,6394,O
single,6394,O
intravenous,6394,O
administration,6394,O
of,6394,O
the,6394,O
[,6394,O
(,6394,B-CHEMICAL
3,6394,I-CHEMICAL
),6394,I-CHEMICAL
H,6394,I-CHEMICAL
],6394,O
-siRNAs,6394,O
",",6394,O
at,6394,O
a,6394,O
target,6394,O
dose,6394,O
level,6394,O
of,6394,O
5,6394,O
mg/kg,6394,O
.,6394,O
Quantitative,6395,O
whole-body,6395,O
autoradiography,6395,O
(,6395,O
QWBA,6395,O
),6395,O
and,6395,O
liquid,6395,O
scintillation,6395,O
counting,6395,O
techniques,6395,O
were,6395,O
used,6395,O
to,6395,O
determine,6395,O
tissue,6395,O
distribution,6395,O
.,6395,O
Radiochromatogram,6396,O
profiles,6396,O
were,6396,O
determined,6396,O
in,6396,O
plasma,6396,O
",",6396,O
tissue,6396,O
extracts,6396,O
and,6396,O
urine,6396,O
.,6396,O
Metabolites,6397,O
were,6397,O
separated,6397,O
by,6397,O
liquid,6397,O
chromatography,6397,O
and,6397,O
identified,6397,O
by,6397,O
radiodetection,6397,O
and,6397,O
high-resolution,6397,O
accurate,6397,O
mass,6397,O
spectrometry,6397,O
.,6397,O
In,6398,O
general,6398,O
",",6398,O
there,6398,O
was,6398,O
little,6398,O
difference,6398,O
in,6398,O
the,6398,O
distribution,6398,O
of,6398,O
total,6398,O
radiolabeled,6398,O
components,6398,O
after,6398,O
administration,6398,O
of,6398,O
the,6398,O
two,6398,O
unformulated,6398,O
[,6398,O
(,6398,B-CHEMICAL
3,6398,I-CHEMICAL
),6398,I-CHEMICAL
H,6398,I-CHEMICAL
],6398,O
-siRNAs,6398,O
.,6398,O
The,6399,O
radioactivity,6399,O
was,6399,O
rapidly,6399,O
and,6399,O
widely,6399,O
distributed,6399,O
throughout,6399,O
the,6399,O
body,6399,O
",",6399,O
and,6399,O
remained,6399,O
detectable,6399,O
in,6399,O
all,6399,O
tissues,6399,O
investigated,6399,O
at,6399,O
later,6399,O
time,6399,O
points,6399,O
(,6399,O
24,6399,O
and,6399,O
48,6399,O
hours,6399,O
for,6399,O
[,6399,O
(,6399,B-CHEMICAL
3,6399,I-CHEMICAL
),6399,I-CHEMICAL
H,6399,I-CHEMICAL
],6399,O
-MRP4,6399,O
and,6399,O
[,6399,O
(,6399,B-CHEMICAL
3,6399,I-CHEMICAL
),6399,I-CHEMICAL
H,6399,I-CHEMICAL
],6399,O
-SSB,6399,O
siRNA,6399,O
",",6399,O
respectively,6399,O
),6399,O
.,6399,O
After,6400,O
an,6400,O
initial,6400,O
rapid,6400,O
decline,6400,O
",",6400,O
concentrations,6400,O
of,6400,O
total,6400,O
radiolabeled,6400,O
components,6400,O
in,6400,O
dried,6400,O
blood,6400,O
declined,6400,O
at,6400,O
a,6400,O
much,6400,O
slower,6400,O
rate,6400,O
.,6400,O
A,6401,O
nearly,6401,O
complete,6401,O
mass,6401,O
balance,6401,O
was,6401,O
obtained,6401,O
for,6401,O
the,6401,O
[,6401,O
(,6401,B-CHEMICAL
3,6401,I-CHEMICAL
),6401,I-CHEMICAL
H,6401,I-CHEMICAL
],6401,O
-SSB,6401,O
siRNA,6401,O
and,6401,O
renal,6401,O
excretion,6401,O
was,6401,O
the,6401,O
main,6401,O
route,6401,O
of,6401,O
elimination,6401,O
(,6401,O
38,6401,O
%,6401,O
),6401,O
.,6401,O
The,6402,O
metabolism,6402,O
of,6402,O
the,6402,O
two,6402,O
model,6402,O
siRNAs,6402,O
was,6402,O
rapid,6402,O
and,6402,O
extensive,6402,O
.,6402,O
Five,6403,O
minutes,6403,O
after,6403,O
administration,6403,O
",",6403,O
no,6403,O
parent,6403,O
compound,6403,O
could,6403,O
be,6403,O
detected,6403,O
in,6403,O
plasma,6403,O
.,6403,O
Instead,6404,O
",",6404,O
radiolabeled,6404,O
nucleosides,6404,B-CHEMICAL
resulting,6404,O
from,6404,O
nuclease,6404,B-GENE-N
hydrolysis,6404,O
were,6404,O
observed,6404,O
.,6404,O
In,6405,O
the,6405,O
metabolism,6405,O
profiles,6405,O
obtained,6405,O
from,6405,O
various,6405,O
tissues,6405,O
only,6405,O
radiolabeled,6405,O
nucleosides,6405,B-CHEMICAL
were,6405,O
found,6405,O
",",6405,O
suggesting,6405,O
that,6405,O
siRNAs,6405,O
are,6405,O
rapidly,6405,O
metabolized,6405,O
and,6405,O
that,6405,O
the,6405,O
distribution,6405,O
pattern,6405,O
of,6405,O
total,6405,O
radiolabeled,6405,O
components,6405,O
can,6405,O
be,6405,O
ascribed,6405,O
to,6405,O
small,6405,O
molecular,6405,O
weight,6405,O
metabolites,6405,O
.,6405,O
Chemical,6406,O
genetic,6406,O
analyses,6406,O
of,6406,O
quantitative,6406,O
changes,6406,O
in,6406,O
Cdk1,6406,B-GENE-Y
activity,6406,O
during,6406,O
the,6406,O
human,6406,O
cell,6406,O
cycle,6406,O
.,6406,O
Cyclin-dependent,6407,B-GENE-Y
kinase,6407,I-GENE-Y
1,6407,I-GENE-Y
(,6407,O
Cdk1,6407,B-GENE-Y
),6407,O
controls,6407,O
cell,6407,O
proliferation,6407,O
and,6407,O
is,6407,O
inhibited,6407,O
by,6407,O
promising,6407,O
anticancer,6407,O
agents,6407,O
",",6407,O
but,6407,O
its,6407,O
mode,6407,O
of,6407,O
action,6407,O
and,6407,O
the,6407,O
consequences,6407,O
of,6407,O
its,6407,O
inhibition,6407,O
are,6407,O
incompletely,6407,O
understood,6407,O
.,6407,O
Cdk1,6408,B-GENE-Y
promotes,6408,O
S-,6408,O
and,6408,O
M-phases,6408,O
during,6408,O
the,6408,O
cell-cycle,6408,O
but,6408,O
also,6408,O
suppresses,6408,O
endoreduplication,6408,O
",",6408,O
which,6408,O
is,6408,O
associated,6408,O
with,6408,O
polyploidy,6408,O
and,6408,O
genome,6408,O
instability,6408,O
.,6408,O
The,6409,O
complexity,6409,O
of,6409,O
Cdk1,6409,B-GENE-Y
regulation,6409,O
has,6409,O
made,6409,O
it,6409,O
difficult,6409,O
to,6409,O
determine,6409,O
whether,6409,O
these,6409,O
different,6409,O
roles,6409,O
require,6409,O
different,6409,O
thresholds,6409,O
of,6409,O
kinase,6409,B-GENE-N
activity,6409,O
and,6409,O
whether,6409,O
the,6409,O
surge,6409,O
of,6409,O
activity,6409,O
as,6409,O
inhibitory,6409,O
phosphates,6409,B-CHEMICAL
are,6409,O
removed,6409,O
at,6409,O
mitotic,6409,O
onset,6409,O
is,6409,O
essential,6409,O
for,6409,O
cell,6409,O
proliferation,6409,O
.,6409,O
Here,6410,O
",",6410,O
we,6410,O
have,6410,O
used,6410,O
chemical,6410,O
genetics,6410,O
in,6410,O
a,6410,O
human,6410,O
cell,6410,O
line,6410,O
to,6410,O
address,6410,O
these,6410,O
issues,6410,O
.,6410,O
We,6411,O
rescued,6411,O
cells,6411,O
lethally,6411,O
depleted,6411,O
of,6411,O
endogenous,6411,O
Cdk1,6411,B-GENE-Y
with,6411,O
an,6411,O
exogenous,6411,O
Cdk1,6411,B-GENE-Y
conferring,6411,O
sensitivity,6411,O
to,6411,O
one,6411,O
ATP,6411,B-CHEMICAL
analogue,6411,O
inhibitor,6411,O
(,6411,O
1NMPP1,6411,B-CHEMICAL
),6411,O
and,6411,O
resistance,6411,O
to,6411,O
another,6411,O
(,6411,O
RO3306,6411,B-CHEMICAL
),6411,O
.,6411,O
At,6412,O
no,6412,O
1NMPP1,6412,B-CHEMICAL
concentration,6412,O
was,6412,O
mitosis,6412,O
in,6412,O
rescued,6412,O
clones,6412,O
prevented,6412,O
without,6412,O
also,6412,O
inducing,6412,O
endoreduplication,6412,O
",",6412,O
suggesting,6412,O
that,6412,O
these,6412,O
two,6412,O
key,6412,O
roles,6412,O
for,6412,O
Cdk1,6412,B-GENE-Y
are,6412,O
not,6412,O
simply,6412,O
controlled,6412,O
by,6412,O
different,6412,O
Cdk1,6412,B-GENE-Y
activity,6412,O
thresholds,6412,O
.,6412,O
We,6413,O
also,6413,O
rescued,6413,O
RO3306-resistant,6413,B-CHEMICAL
clones,6413,O
using,6413,O
exogenous,6413,O
Cdk1,6413,B-GENE-Y
without,6413,O
inhibitory,6413,O
phosphorylation,6413,O
sites,6413,O
",",6413,O
indicating,6413,O
that,6413,O
the,6413,O
mitotic,6413,O
surge,6413,O
of,6413,O
Cdk1,6413,B-GENE-Y
activity,6413,O
is,6413,O
dispensable,6413,O
for,6413,O
cell,6413,O
proliferation,6413,O
.,6413,O
These,6414,O
results,6414,O
suggest,6414,O
that,6414,O
the,6414,O
basic,6414,O
mammalian,6414,O
cycle,6414,O
requires,6414,O
at,6414,O
least,6414,O
some,6414,O
qualitative,6414,O
changes,6414,O
in,6414,O
Cdk1,6414,B-GENE-Y
activity,6414,O
and,6414,O
that,6414,O
quantitative,6414,O
increases,6414,O
in,6414,O
activity,6414,O
need,6414,O
not,6414,O
be,6414,O
rapid,6414,O
.,6414,O
Furthermore,6415,O
",",6415,O
the,6415,O
viability,6415,O
of,6415,O
cells,6415,O
that,6415,O
are,6415,O
unable,6415,O
to,6415,O
undergo,6415,O
rapid,6415,O
Cdk1,6415,B-GENE-Y
activation,6415,O
",",6415,O
and,6415,O
the,6415,O
strong,6415,O
association,6415,O
between,6415,O
endoreduplication,6415,O
and,6415,O
impaired,6415,O
proliferation,6415,O
",",6415,O
may,6415,O
place,6415,O
restrictions,6415,O
on,6415,O
the,6415,O
therapeutic,6415,O
use,6415,O
of,6415,O
a,6415,O
Cdk1,6415,B-GENE-Y
inhibitors,6415,O
.,6415,O
Inhibition,6416,O
of,6416,O
Ebola,6416,O
Virus,6416,O
Infection,6416,O
:,6416,O
Identification,6416,O
of,6416,O
Niemann-Pick,6416,B-GENE-Y
C1,6416,I-GENE-Y
as,6416,O
the,6416,O
Target,6416,O
by,6416,O
Optimization,6416,O
of,6416,O
a,6416,O
Chemical,6416,O
Probe,6416,O
.,6416,O
A,6417,O
high,6417,O
throughput,6417,O
screen,6417,O
identified,6417,O
adamantane,6417,B-CHEMICAL
dipeptide,6417,O
1,6417,O
as,6417,O
an,6417,O
inhibitor,6417,O
of,6417,O
Ebola,6417,O
virus,6417,O
(,6417,O
EboV,6417,O
),6417,O
infection,6417,O
.,6417,O
Hit-to-lead,6418,O
optimization,6418,O
to,6418,O
determine,6418,O
the,6418,O
structure-activity,6418,O
relationship,6418,O
(,6418,O
SAR,6418,O
),6418,O
identified,6418,O
the,6418,O
more,6418,O
potent,6418,O
EboV,6418,O
inhibitor,6418,O
2,6418,O
and,6418,O
a,6418,O
photoaffinity,6418,O
labeling,6418,O
agent,6418,O
3,6418,O
.,6418,O
These,6419,O
anti-viral,6419,O
compounds,6419,O
were,6419,O
employed,6419,O
to,6419,O
identify,6419,O
the,6419,O
target,6419,O
as,6419,O
Niemann-Pick,6419,B-GENE-Y
C1,6419,I-GENE-Y
(,6419,O
NPC1,6419,B-GENE-Y
),6419,O
",",6419,O
a,6419,O
host,6419,O
protein,6419,O
that,6419,O
binds,6419,O
the,6419,O
EboV,6419,B-GENE-N
glycoprotein,6419,I-GENE-N
and,6419,O
is,6419,O
essential,6419,O
for,6419,O
infection,6419,O
.,6419,O
These,6420,O
studies,6420,O
establish,6420,O
NPC1,6420,B-GENE-Y
as,6420,O
a,6420,O
promising,6420,O
target,6420,O
for,6420,O
anti-viral,6420,O
therapy,6420,O
.,6420,O
Exploring,6421,O
the,6421,O
effect,6421,O
of,6421,O
N-substitution,6421,B-CHEMICAL
in,6421,O
nor-lobelane,6421,B-CHEMICAL
on,6421,O
the,6421,O
interaction,6421,O
with,6421,O
VMAT2,6421,B-GENE-Y
:,6421,O
discovery,6421,O
of,6421,O
a,6421,O
potential,6421,O
clinical,6421,O
candidate,6421,O
for,6421,O
treatment,6421,O
of,6421,O
methamphetamine,6421,B-CHEMICAL
abuse,6421,O
.,6421,O
A,6422,O
series,6422,O
of,6422,O
N-substituted,6422,B-CHEMICAL
lobelane,6422,B-CHEMICAL
analogues,6422,O
was,6422,O
synthesized,6422,O
and,6422,O
evaluated,6422,O
for,6422,O
their,6422,O
[,6422,B-CHEMICAL
(,6422,I-CHEMICAL
3,6422,I-CHEMICAL
),6422,I-CHEMICAL
H,6422,I-CHEMICAL
],6422,I-CHEMICAL
dihydrotetrabenazine,6422,I-CHEMICAL
binding,6422,O
affinity,6422,O
at,6422,O
the,6422,O
vesicular,6422,B-GENE-N
monoamine,6422,B-CHEMICAL
transporter,6422,I-GENE-N
and,6422,O
for,6422,O
their,6422,O
inhibition,6422,O
of,6422,O
vesicular,6422,O
[,6422,B-CHEMICAL
(,6422,I-CHEMICAL
3,6422,I-CHEMICAL
),6422,I-CHEMICAL
H,6422,I-CHEMICAL
],6422,I-CHEMICAL
dopamine,6422,I-CHEMICAL
uptake,6422,O
.,6422,O
Compound,6423,O
19a,6423,O
",",6423,O
which,6423,O
contains,6423,O
an,6423,O
"N-1,2",6423,B-CHEMICAL
(,6423,I-CHEMICAL
R,6423,I-CHEMICAL
),6423,I-CHEMICAL
-dihydroxypropyl,6423,I-CHEMICAL
group,6423,O
",",6423,O
had,6423,O
been,6423,O
identified,6423,O
as,6423,O
a,6423,O
potential,6423,O
clinical,6423,O
candidate,6423,O
for,6423,O
the,6423,O
treatment,6423,O
of,6423,O
methamphetamine,6423,B-CHEMICAL
abuse,6423,O
.,6423,O
The,6424,O
pre-clinical,6424,O
absorption,6424,O
",",6424,O
distribution,6424,O
",",6424,O
metabolism,6424,O
and,6424,O
excretion,6424,O
properties,6424,O
of,6424,O
IPI-926,6424,B-CHEMICAL
",",6424,O
an,6424,O
orally,6424,O
bioavailable,6424,O
antagonist,6424,O
of,6424,O
the,6424,O
hedgehog,6424,O
signal,6424,O
transduction,6424,O
pathway,6424,O
.,6424,O
Abstract,6425,O
1,6425,O
.,6425,O
IPI-926,6426,B-CHEMICAL
is,6426,O
a,6426,O
novel,6426,O
semisynthetic,6426,O
cyclopamine,6426,B-CHEMICAL
derivative,6426,O
that,6426,O
is,6426,O
a,6426,O
potent,6426,O
and,6426,O
selective,6426,O
Smoothened,6426,O
inhibitor,6426,O
that,6426,O
blocks,6426,O
the,6426,O
hedgehog,6426,O
signal,6426,O
transduction,6426,O
pathway,6426,O
.,6426,O
2,6427,O
.,6427,O
The,6428,O
in,6428,O
vivo,6428,O
clearance,6428,O
of,6428,O
IPI-926,6428,B-CHEMICAL
is,6428,O
low,6428,O
in,6428,O
mouse,6428,O
and,6428,O
dog,6428,O
and,6428,O
moderate,6428,O
in,6428,O
monkey,6428,O
.,6428,O
The,6429,O
volume,6429,O
of,6429,O
distribution,6429,O
is,6429,O
high,6429,O
across,6429,O
species,6429,O
.,6429,O
Oral,6430,O
bioavailability,6430,O
ranges,6430,O
from,6430,O
moderate,6430,O
in,6430,O
monkey,6430,O
to,6430,O
high,6430,O
in,6430,O
mouse,6430,O
and,6430,O
dog,6430,O
.,6430,O
Predicted,6431,O
human,6431,O
clearance,6431,O
using,6431,O
simple,6431,O
allometry,6431,O
is,6431,O
low,6431,O
(,6431,O
24,6431,O
L,6431,O
h,6431,O
(,6431,O
-1,6431,O
),6431,O
),6431,O
",",6431,O
predicted,6431,O
volume,6431,O
of,6431,O
distribution,6431,O
is,6431,O
high,6431,O
(,6431,O
469,6431,O
L,6431,O
),6431,O
and,6431,O
predicted,6431,O
half-life,6431,O
is,6431,O
long,6431,O
(,6431,O
20,6431,O
h,6431,O
),6431,O
.,6431,O
3,6432,O
.,6432,O
IPI-926,6433,B-CHEMICAL
is,6433,O
highly,6433,O
bound,6433,O
to,6433,O
plasma,6433,O
proteins,6433,O
and,6433,O
has,6433,O
minimal,6433,O
interaction,6433,O
with,6433,O
human,6433,B-GENE-N
α-1-acid,6433,I-GENE-N
glycoprotein,6433,I-GENE-N
.,6433,O
4,6434,O
.,6434,O
In,6435,O
vitro,6435,O
metabolic,6435,O
stability,6435,O
ranges,6435,O
from,6435,O
stable,6435,O
to,6435,O
moderately,6435,O
stable,6435,O
.,6435,O
Twelve,6436,O
oxidative,6436,O
metabolites,6436,O
were,6436,O
detected,6436,O
in,6436,O
mouse,6436,O
",",6436,O
rat,6436,O
",",6436,O
dog,6436,O
",",6436,O
monkey,6436,O
and,6436,O
human,6436,O
liver,6436,O
microsome,6436,O
incubations,6436,O
and,6436,O
none,6436,O
were,6436,O
unique,6436,O
to,6436,O
human,6436,O
.,6436,O
5,6437,O
.,6437,O
IPI-926,6438,B-CHEMICAL
is,6438,O
not,6438,O
a,6438,O
potent,6438,O
reversible,6438,O
inhibitor,6438,O
of,6438,O
CYP1A2,6438,B-GENE-N
",",6438,I-GENE-N
2C8,6438,I-GENE-N
",",6438,I-GENE-N
2C9,6438,I-GENE-N
or,6438,I-GENE-N
3A4,6438,I-GENE-N
(,6438,O
testosterone,6438,B-CHEMICAL
),6438,O
.,6438,O
IPI-926,6439,B-CHEMICAL
is,6439,O
a,6439,O
moderate,6439,O
inhibitor,6439,O
of,6439,O
CYP2C19,6439,B-GENE-N
",",6439,I-GENE-N
2D6,6439,I-GENE-N
and,6439,I-GENE-N
3A4,6439,I-GENE-N
(,6439,O
midazolam,6439,B-CHEMICAL
),6439,O
with,6439,O
KI,6439,O
values,6439,O
of,6439,O
19,6439,O
",",6439,O
16,6439,O
and,6439,O
4.5,6439,O
µM,6439,O
",",6439,O
respectively,6439,O
.,6439,O
IPI-926,6440,B-CHEMICAL
is,6440,O
both,6440,O
a,6440,O
substrate,6440,O
and,6440,O
inhibitor,6440,O
(,6440,O
IC50,6440,O
=,6440,O
1.9,6440,O
µM,6440,O
),6440,O
of,6440,O
P-glycoprotein,6440,B-GENE-N
.,6440,O
6,6441,O
.,6441,O
In,6442,O
summary,6442,O
",",6442,O
IPI-926,6442,B-CHEMICAL
has,6442,O
desirable,6442,O
pre-clinical,6442,O
absorption,6442,O
",",6442,O
distribution,6442,O
",",6442,O
metabolism,6442,O
and,6442,O
excretion,6442,O
properties,6442,O
.,6442,O
Protection,6443,O
of,6443,O
glycyrrhizic,6443,B-CHEMICAL
acid,6443,I-CHEMICAL
against,6443,O
AGEs-induced,6443,O
endothelial,6443,O
dysfunction,6443,O
through,6443,O
inhibiting,6443,O
RAGE/NF-κB,6443,B-GENE-Y
pathway,6443,O
activation,6443,O
in,6443,O
human,6443,O
umbilical,6443,O
vein,6443,O
endothelial,6443,O
cells,6443,O
.,6443,O
ETHNOPHARMACOLOGICAL,6444,O
RELEVANCE,6444,O
:,6444,O
Licorice,6444,O
(,6444,O
Glycyrrhiza,6444,O
uralensis,6444,O
roots,6444,O
),6444,O
is,6444,O
used,6444,O
as,6444,O
a,6444,O
traditional,6444,O
medicine,6444,O
for,6444,O
the,6444,O
treatment,6444,O
of,6444,O
diabetes,6444,O
mellitus,6444,O
and,6444,O
its,6444,O
vascular,6444,O
complications,6444,O
.,6444,O
Glycyrrhizic,6445,B-CHEMICAL
acid,6445,I-CHEMICAL
(,6445,O
GA,6445,O
",",6445,O
also,6445,O
known,6445,O
as,6445,O
Glycyrrhizin,6445,B-CHEMICAL
),6445,O
",",6445,O
a,6445,O
triterpenoid,6445,B-CHEMICAL
saponin,6445,I-CHEMICAL
glycoside,6445,I-CHEMICAL
",",6445,O
is,6445,O
considered,6445,O
to,6445,O
be,6445,O
a,6445,O
bioactive,6445,O
component,6445,O
in,6445,O
Licorice,6445,O
and,6445,O
is,6445,O
beneficial,6445,O
to,6445,O
diabetic,6445,O
vascular,6445,O
complications,6445,O
.,6445,O
AIM,6446,O
OF,6446,O
STUDY,6446,O
:,6446,O
The,6446,O
present,6446,O
study,6446,O
was,6446,O
conducted,6446,O
to,6446,O
evaluate,6446,O
the,6446,O
potential,6446,O
protective,6446,O
activities,6446,O
on,6446,O
AGEs-induced,6446,O
endothelial,6446,O
dysfunction,6446,O
",",6446,O
including,6446,O
anti-apoptosis,6446,O
",",6446,O
antioxidant,6446,O
stress,6446,O
and,6446,O
anti-proinflammatory,6446,O
responses,6446,O
",",6446,O
and,6446,O
explore,6446,O
the,6446,O
underlying,6446,O
mechanism,6446,O
.,6446,O
MATERIALS,6447,O
AND,6447,O
METHODS,6447,O
:,6447,O
Human,6447,O
umbilical,6447,O
vein,6447,O
endothelial,6447,O
cells,6447,O
(,6447,O
HUVECs,6447,O
),6447,O
were,6447,O
incubated,6447,O
and,6447,O
pre-treated,6447,O
with,6447,O
GA,6447,O
(,6447,O
10,6447,O
(,6447,O
-9,6447,O
),6447,O
-10,6447,O
(,6447,O
-6,6447,O
),6447,O
M,6447,O
),6447,O
or,6447,O
RAGE-Ab,6447,B-GENE-Y
(,6447,O
5μg/ml,6447,O
),6447,O
in,6447,O
the,6447,O
presence,6447,O
or,6447,O
absence,6447,O
of,6447,O
200μg/ml,6447,O
AGEs,6447,O
.,6447,O
AO/EB,6448,O
fluorescence,6448,O
staining,6448,O
assay,6448,O
was,6448,O
performed,6448,O
to,6448,O
evaluate,6448,O
anti-apoptosis,6448,O
activity,6448,O
.,6448,O
The,6449,O
superoxide,6449,B-CHEMICAL
dismutase,6449,I-GENE-N
(,6449,O
SOD,6449,B-GENE-N
),6449,O
activity,6449,O
and,6449,O
malondialdehyde,6449,B-CHEMICAL
(,6449,O
MDA,6449,B-CHEMICAL
),6449,O
level,6449,O
in,6449,O
cell,6449,O
supernatant,6449,O
were,6449,O
detected,6449,O
by,6449,O
kits,6449,O
while,6449,O
the,6449,O
intracellular,6449,O
reactive,6449,O
oxygen,6449,B-CHEMICAL
species,6449,O
(,6449,O
ROS,6449,O
),6449,O
generation,6449,O
was,6449,O
determined,6449,O
by,6449,O
"2,7-dichlorodihydrofluorescin",6449,B-CHEMICAL
diacetate,6449,I-CHEMICAL
(,6449,O
DCFH-DA,6449,B-CHEMICAL
),6449,O
kit,6449,O
.,6449,O
Immunocytochemistry,6450,O
analysis,6450,O
was,6450,O
designed,6450,O
to,6450,O
determine,6450,O
transforming,6450,B-GENE-Y
growth,6450,I-GENE-Y
factor,6450,I-GENE-Y
beta1,6450,I-GENE-Y
(,6450,O
TGF-β1,6450,B-GENE-Y
),6450,O
protein,6450,O
expression,6450,O
while,6450,O
immunofluorescence,6450,O
analysis,6450,O
for,6450,O
RAGE,6450,B-GENE-Y
and,6450,O
NF-kB,6450,B-GENE-N
.,6450,O
The,6451,O
protein,6451,O
expressions,6451,O
of,6451,O
TGF-β1,6451,B-GENE-Y
",",6451,O
RAGE,6451,B-GENE-Y
and,6451,O
NF-kB,6451,B-GENE-N
were,6451,O
analyzed,6451,O
by,6451,O
Western,6451,O
blot,6451,O
analysis,6451,O
.,6451,O
RESULTS,6452,O
:,6452,O
Pretreatment,6452,O
with,6452,O
GA,6452,O
at,6452,O
a,6452,O
concentration,6452,O
of,6452,O
10,6452,O
(,6452,O
-8,6452,O
),6452,O
-10,6452,O
(,6452,O
-6,6452,O
),6452,O
M,6452,O
significantly,6452,O
reduced,6452,O
the,6452,O
AGEs-induced,6452,O
apoptosis,6452,O
in,6452,O
HUVECs,6452,O
.,6452,O
GA,6453,O
significantly,6453,O
increased,6453,O
antioxidant,6453,O
enzyme,6453,O
SOD,6453,B-GENE-N
activity,6453,O
and,6453,O
decreased,6453,O
peroxide,6453,O
degradation,6453,O
product,6453,O
MDA,6453,B-CHEMICAL
level,6453,O
in,6453,O
a,6453,O
dose-dependent,6453,O
manner,6453,O
.,6453,O
Furthermore,6454,O
",",6454,O
GA,6454,O
also,6454,O
remarkably,6454,O
inhibited,6454,O
the,6454,O
overgeneration,6454,O
of,6454,O
AGEs-induced,6454,O
ROS,6454,O
.,6454,O
Both,6455,O
immunocytochemistry,6455,O
analysis,6455,O
and,6455,O
western,6455,O
blot,6455,O
analysis,6455,O
showed,6455,O
that,6455,O
GA,6455,O
significantly,6455,O
decreased,6455,O
the,6455,O
protein,6455,O
expression,6455,O
of,6455,O
poinflammatory,6455,O
cytokine,6455,B-GENE-N
TGF-β1,6455,B-GENE-Y
in,6455,O
a,6455,O
similar,6455,O
manner,6455,O
which,6455,O
RAGE-Ab,6455,B-GENE-Y
did,6455,O
.,6455,O
Additionally,6456,O
",",6456,O
AGEs-induced,6456,O
RAGE,6456,B-GENE-Y
and,6456,O
NF-kB,6456,B-GENE-N
protein,6456,O
expressions,6456,O
were,6456,O
down-regulated,6456,O
significantly,6456,O
by,6456,O
the,6456,O
pretreatment,6456,O
with,6456,O
GA,6456,O
or,6456,O
RAGE-Ab,6456,B-GENE-Y
.,6456,O
CONCLUSION,6457,O
:,6457,O
These,6457,O
findings,6457,O
provide,6457,O
evidences,6457,O
that,6457,O
GA,6457,O
possesses,6457,O
protective,6457,O
activity,6457,O
on,6457,O
AGEs-induced,6457,O
endothelial,6457,O
dysfunction,6457,O
",",6457,O
including,6457,O
anti-apoptosis,6457,O
",",6457,O
anti-inflammation,6457,O
and,6457,O
antioxidant,6457,O
stress,6457,O
",",6457,O
via,6457,O
inhibiting,6457,O
RAGE/NF-kB,6457,B-GENE-Y
pathway,6457,O
.,6457,O
GA,6458,O
might,6458,O
be,6458,O
an,6458,O
alternative,6458,O
for,6458,O
the,6458,O
prevention,6458,O
and,6458,O
treatment,6458,O
of,6458,O
diabetic,6458,O
vascular,6458,O
complications,6458,O
in,6458,O
an,6458,O
appropriate,6458,O
dosage,6458,O
.,6458,O
Evaluation,6459,O
of,6459,O
body,6459,O
weight,6459,O
",",6459,O
insulin,6459,B-GENE-Y
resistance,6459,O
",",6459,O
leptin,6459,B-GENE-N
and,6459,O
adiponectin,6459,B-GENE-N
levels,6459,O
in,6459,O
premenopausal,6459,O
women,6459,O
with,6459,O
hyperprolactinemia,6459,O
.,6459,O
The,6460,O
effects,6460,O
of,6460,O
hyperprolactinemia,6460,O
on,6460,O
metabolic,6460,O
parameters,6460,O
are,6460,O
not,6460,O
clear,6460,O
and,6460,O
a,6460,O
few,6460,O
data,6460,O
evaluating,6460,O
adiponectin,6460,B-GENE-Y
levels,6460,O
in,6460,O
prolactinoma,6460,O
and,6460,O
idiopathic,6460,O
hyperprolactinemia,6460,O
exist,6460,O
.,6460,O
The,6461,O
aim,6461,O
of,6461,O
this,6461,O
study,6461,O
was,6461,O
to,6461,O
evaluate,6461,O
the,6461,O
effects,6461,O
of,6461,O
hyperprolactinemia,6461,O
on,6461,O
body,6461,O
weight,6461,O
",",6461,O
insulin,6461,O
resistance,6461,O
",",6461,O
beta,6461,O
cell,6461,O
function,6461,O
",",6461,O
and,6461,O
leptin,6461,B-GENE-Y
and,6461,O
adiponectin,6461,B-GENE-Y
levels,6461,O
in,6461,O
premenopausal,6461,O
women,6461,O
with,6461,O
hyperprolactinemia,6461,O
.,6461,O
Forty,6462,O
premenopausal,6462,O
women,6462,O
with,6462,O
prolactinoma,6462,O
or,6462,O
idiopathic,6462,O
hyperprolactinemia,6462,O
were,6462,O
compared,6462,O
to,6462,O
41,6462,O
age-matched,6462,O
healthy,6462,O
premenopausal,6462,O
women,6462,O
with,6462,O
regard,6462,O
to,6462,O
body,6462,O
weight,6462,O
",",6462,O
body,6462,O
mass,6462,O
index,6462,O
",",6462,O
waist,6462,O
and,6462,O
hip,6462,O
circumferences,6462,O
",",6462,O
waist,6462,O
to,6462,O
hip,6462,O
ratio,6462,O
",",6462,O
fasting,6462,O
plasma,6462,O
glucose,6462,B-CHEMICAL
",",6462,O
insulin,6462,B-GENE-Y
levels,6462,O
",",6462,O
insulin,6462,B-GENE-Y
resistance,6462,O
measured,6462,O
by,6462,O
homeostasis,6462,O
model,6462,O
assessment,6462,O
(,6462,O
HOMA,6462,O
),6462,O
-insulin,6462,O
resistance,6462,O
index,6462,O
",",6462,O
beta,6462,O
cell,6462,O
function,6462,O
measured,6462,O
by,6462,O
HOMA-β,6462,O
index,6462,O
",",6462,O
leptin,6462,B-GENE-Y
and,6462,O
adiponectin,6462,B-GENE-Y
levels,6462,O
.,6462,O
Plasma,6463,O
insulin,6463,B-GENE-Y
levels,6463,O
and,6463,O
HOMA,6463,O
indexes,6463,O
(,6463,O
both,6463,O
insulin,6463,B-GENE-Y
resistance,6463,O
and,6463,O
beta,6463,O
indexes,6463,O
),6463,O
were,6463,O
significantly,6463,O
higher,6463,O
in,6463,O
hyperprolactinemic,6463,O
women,6463,O
.,6463,O
The,6464,O
other,6464,O
parameters,6464,O
were,6464,O
similar,6464,O
between,6464,O
both,6464,O
groups,6464,O
.,6464,O
There,6465,O
was,6465,O
a,6465,O
positive,6465,O
correlation,6465,O
between,6465,O
prolactin,6465,B-GENE-Y
levels,6465,O
and,6465,O
fasting,6465,O
plasma,6465,O
glucose,6465,B-CHEMICAL
in,6465,O
hyperprolactinemic,6465,O
women,6465,O
.,6465,O
The,6466,O
results,6466,O
of,6466,O
this,6466,O
study,6466,O
showed,6466,O
that,6466,O
high,6466,O
prolactin,6466,B-GENE-Y
levels,6466,O
may,6466,O
be,6466,O
associated,6466,O
with,6466,O
hyperinsulinemia,6466,O
and,6466,O
insulin,6466,B-GENE-Y
resistance,6466,O
in,6466,O
premenopausal,6466,O
women,6466,O
.,6466,O
This,6467,O
effect,6467,O
seems,6467,O
to,6467,O
be,6467,O
independent,6467,O
of,6467,O
body,6467,O
weight,6467,O
",",6467,O
leptin,6467,B-GENE-Y
and,6467,O
adiponectin,6467,B-GENE-Y
levels,6467,O
.,6467,O
High,6468,O
prolactin,6468,B-GENE-Y
levels,6468,O
may,6468,O
directly,6468,O
stimulate,6468,O
insulin,6468,B-GENE-Y
secretion,6468,O
from,6468,O
pancreas,6468,O
and,6468,O
directly,6468,O
cause,6468,O
hepatic,6468,O
and,6468,O
whole-body,6468,O
insulin,6468,B-GENE-Y
resistance,6468,O
.,6468,O
Lorcaserin,6469,B-CHEMICAL
:,6469,O
a,6469,O
review,6469,O
of,6469,O
its,6469,O
use,6469,O
in,6469,O
chronic,6469,O
weight,6469,O
management,6469,O
.,6469,O
Oral,6470,O
lorcaserin,6470,B-CHEMICAL
(,6470,O
BELVIQ,6470,B-CHEMICAL
(,6470,O
®,6470,O
),6470,O
),6470,O
",",6470,O
a,6470,O
selective,6470,O
serotonin,6470,B-CHEMICAL
5-HT2C,6470,B-GENE-Y
receptor,6470,O
agonist,6470,O
",",6470,O
is,6470,O
indicated,6470,O
in,6470,O
the,6470,O
US,6470,O
as,6470,O
an,6470,O
adjunct,6470,O
to,6470,O
diet,6470,O
and,6470,O
exercise,6470,O
in,6470,O
the,6470,O
chronic,6470,O
weight,6470,O
management,6470,O
of,6470,O
obese,6470,O
adults,6470,O
",",6470,O
or,6470,O
overweight,6470,O
adults,6470,O
with,6470,O
at,6470,O
least,6470,O
one,6470,O
weight-related,6470,O
comorbidity,6470,O
(,6470,O
e.g,6470,O
.,6470,O
dyslipidaemia,6471,O
",",6471,O
hypertension,6471,O
",",6471,O
type,6471,O
2,6471,O
diabetes,6471,O
),6471,O
.,6471,O
This,6472,O
article,6472,O
reviews,6472,O
the,6472,O
pharmacological,6472,O
properties,6472,O
",",6472,O
therapeutic,6472,O
efficacy,6472,O
and,6472,O
tolerability,6472,O
of,6472,O
oral,6472,O
lorcaserin,6472,B-CHEMICAL
in,6472,O
this,6472,O
patient,6472,O
population,6472,O
.,6472,O
In,6473,O
three,6473,O
large,6473,O
randomized,6473,O
",",6473,O
double-blind,6473,O
",",6473,O
multicentre,6473,O
studies,6473,O
",",6473,O
oral,6473,O
lorcaserin,6473,B-CHEMICAL
was,6473,O
more,6473,O
effective,6473,O
than,6473,O
placebo,6473,O
in,6473,O
the,6473,O
management,6473,O
of,6473,O
obese,6473,O
and,6473,O
overweight,6473,O
adults,6473,O
with,6473,O
or,6473,O
without,6473,O
type,6473,O
2,6473,O
diabetes,6473,O
mellitus,6473,O
.,6473,O
Following,6474,O
12,6474,O
months,6474,O
',6474,O
therapy,6474,O
",",6474,O
significantly,6474,O
higher,6474,O
proportions,6474,O
of,6474,O
lorcaserin,6474,B-CHEMICAL
than,6474,O
placebo,6474,O
recipients,6474,O
achieved,6474,O
a,6474,O
≥5,6474,O
and,6474,O
≥10,6474,O
%,6474,O
reduction,6474,O
from,6474,O
baseline,6474,O
in,6474,O
their,6474,O
bodyweight,6474,O
and,6474,O
a,6474,O
significant,6474,O
between-group,6474,O
difference,6474,O
favouring,6474,O
lorcaserin,6474,B-CHEMICAL
over,6474,O
placebo,6474,O
was,6474,O
observed,6474,O
for,6474,O
the,6474,O
change,6474,O
from,6474,O
baseline,6474,O
in,6474,O
bodyweight,6474,O
.,6474,O
Moreover,6475,O
",",6475,O
among,6475,O
patients,6475,O
who,6475,O
had,6475,O
achieved,6475,O
a,6475,O
≥5,6475,O
%,6475,O
reduction,6475,O
in,6475,O
their,6475,O
bodyweight,6475,O
after,6475,O
12,6475,O
months,6475,O
',6475,O
therapy,6475,O
with,6475,O
lorcaserin,6475,B-CHEMICAL
",",6475,O
a,6475,O
significantly,6475,O
higher,6475,O
proportion,6475,O
who,6475,O
received,6475,O
lorcaserin,6475,B-CHEMICAL
for,6475,O
a,6475,O
further,6475,O
12,6475,O
months,6475,O
than,6475,O
those,6475,O
who,6475,O
switched,6475,O
to,6475,O
placebo,6475,O
maintained,6475,O
≥5,6475,O
%,6475,O
weight,6475,O
loss,6475,O
at,6475,O
24,6475,O
months,6475,O
.,6475,O
In,6476,O
general,6476,O
",",6476,O
oral,6476,O
lorcaserin,6476,B-CHEMICAL
was,6476,O
well,6476,O
tolerated,6476,O
in,6476,O
clinical,6476,O
studies,6476,O
",",6476,O
with,6476,O
hypoglycaemia,6476,O
and,6476,O
headache,6476,O
the,6476,O
most,6476,O
frequently,6476,O
reported,6476,O
adverse,6476,O
events,6476,O
in,6476,O
those,6476,O
with,6476,O
or,6476,O
without,6476,O
type,6476,O
2,6476,O
diabetes,6476,O
",",6476,O
respectively,6476,O
.,6476,O
According,6477,O
to,6477,O
a,6477,O
pooled,6477,O
analysis,6477,O
",",6477,O
the,6477,O
risk,6477,O
of,6477,O
US-FDA-defined,6477,O
valvulopathy,6477,O
with,6477,O
lorcaserin,6477,B-CHEMICAL
is,6477,O
generally,6477,O
low,6477,O
and,6477,O
not,6477,O
statistically,6477,O
significantly,6477,O
different,6477,O
from,6477,O
placebo,6477,O
.,6477,O
From,6478,O
these,6478,O
and,6478,O
other,6478,O
data,6478,O
",",6478,O
the,6478,O
FDA,6478,O
has,6478,O
concluded,6478,O
that,6478,O
lorcaserin,6478,B-CHEMICAL
is,6478,O
unlikely,6478,O
to,6478,O
elevate,6478,O
the,6478,O
risk,6478,O
of,6478,O
valvulopathy,6478,O
.,6478,O
Design,6479,O
",",6479,O
Synthesis,6479,O
",",6479,O
Biological,6479,O
Evaluation,6479,O
",",6479,O
and,6479,O
Docking,6479,O
Studies,6479,O
of,6479,O
(,6479,B-CHEMICAL
S,6479,I-CHEMICAL
),6479,I-CHEMICAL
-Phenylalanine,6479,I-CHEMICAL
Derivatives,6479,O
with,6479,O
a,6479,O
2-Cyanopyrrolidine,6479,B-CHEMICAL
Moiety,6479,O
as,6479,O
Potent,6479,O
Dipeptidyl,6479,B-GENE-Y
Peptidase,6479,I-GENE-Y
4,6479,I-GENE-Y
Inhibitors,6479,O
.,6479,O
A,6480,O
novel,6480,O
series,6480,O
of,6480,O
(,6480,B-CHEMICAL
S,6480,I-CHEMICAL
),6480,I-CHEMICAL
-phenylalanine,6480,I-CHEMICAL
derivatives,6480,O
with,6480,O
a,6480,O
2-cyanopyrrolidine,6480,B-CHEMICAL
moiety,6480,O
were,6480,O
designed,6480,O
and,6480,O
synthesized,6480,O
through,6480,O
a,6480,O
rational,6480,O
drug,6480,O
design,6480,O
strategy,6480,O
.,6480,O
Biological,6481,O
evaluation,6481,O
revealed,6481,O
that,6481,O
most,6481,O
tested,6481,O
compounds,6481,O
were,6481,O
potent,6481,O
dipeptidyl,6481,B-GENE-Y
peptidase,6481,I-GENE-Y
4,6481,I-GENE-Y
(,6481,O
DPP-4,6481,B-GENE-Y
),6481,O
inhibitors,6481,O
",",6481,O
among,6481,O
them,6481,O
",",6481,O
the,6481,O
cyclopropyl-substituted,6481,B-CHEMICAL
phenylalanine,6481,I-CHEMICAL
derivative,6481,O
11h,6481,O
displayed,6481,O
the,6481,O
most,6481,O
potent,6481,O
DPP-4,6481,B-GENE-Y
inhibitory,6481,O
activity,6481,O
with,6481,O
an,6481,O
IC50,6481,O
value,6481,O
of,6481,O
0.247,6481,O
μM,6481,O
.,6481,O
In,6482,O
addition,6482,O
",",6482,O
molecular,6482,O
docking,6482,O
analysis,6482,O
of,6482,O
the,6482,O
representative,6482,O
compounds,6482,O
11h,6482,O
",",6482,O
11k,6482,O
",",6482,O
and,6482,O
15a,6482,O
were,6482,O
performed,6482,O
",",6482,O
which,6482,O
not,6482,O
only,6482,O
revealed,6482,O
the,6482,O
impact,6482,O
of,6482,O
binding,6482,O
modes,6482,O
on,6482,O
DPP-4,6482,B-GENE-Y
inhibitory,6482,O
activity,6482,O
",",6482,O
but,6482,O
also,6482,O
provided,6482,O
additional,6482,O
methodological,6482,O
values,6482,O
for,6482,O
design,6482,O
and,6482,O
optimization,6482,O
.,6482,O
©,6483,O
2013,6483,O
John,6483,O
Wiley,6483,O
&,6483,O
Sons,6483,O
A/S,6483,O
.,6483,O
Bioimaging,6484,O
real-time,6484,O
PXR-dependent,6484,B-GENE-Y
mdr1a,6484,B-GENE-Y
gene,6484,O
regulation,6484,O
in,6484,O
mdr1a.fLUC,6484,B-GENE-Y
reporter,6484,O
mice,6484,O
.,6484,O
The,6485,O
MDR1,6485,B-GENE-Y
gene,6485,O
encodes,6485,O
P-glycoprotein,6485,B-GENE-Y
",",6485,I-GENE-Y
a,6485,O
transmembrane,6485,B-GENE-N
drug,6485,I-GENE-N
efflux,6485,I-GENE-N
transporter,6485,I-GENE-N
that,6485,O
confers,6485,O
multidrug,6485,O
resistance,6485,O
in,6485,O
cancer,6485,O
cells,6485,O
and,6485,O
affects,6485,O
drug,6485,O
pharmacokinetics,6485,O
by,6485,O
virtue,6485,O
of,6485,O
its,6485,O
expression,6485,O
in,6485,O
the,6485,O
liver,6485,O
",",6485,O
kidney,6485,O
",",6485,O
and,6485,O
colon,6485,O
.,6485,O
Nuclear,6486,B-GENE-N
receptors,6486,I-GENE-N
SXR,6486,B-GENE-Y
and,6486,O
CAR,6486,B-GENE-Y
are,6486,O
possible,6486,O
master,6486,O
regulators,6486,O
of,6486,O
xenobiotic-inducible,6486,O
MDR1,6486,B-GENE-Y
expression,6486,O
in,6486,O
drug,6486,O
processing,6486,O
organs,6486,O
",",6486,O
but,6486,O
the,6486,O
mechanism,6486,O
of,6486,O
MDR1,6486,B-GENE-Y
regulation,6486,O
has,6486,O
yet,6486,O
to,6486,O
be,6486,O
directly,6486,O
demonstrated,6486,O
in,6486,O
vivo,6486,O
.,6486,O
Moreover,6487,O
",",6487,O
it,6487,O
has,6487,O
previously,6487,O
been,6487,O
impossible,6487,O
to,6487,O
determine,6487,O
the,6487,O
sustained,6487,O
or,6487,O
cumulative,6487,O
effect,6487,O
of,6487,O
repeated,6487,O
doses,6487,O
of,6487,O
xenobiotics,6487,O
on,6487,O
in,6487,O
vivo,6487,O
MDR1,6487,B-GENE-Y
expression,6487,O
.,6487,O
We,6488,O
previously,6488,O
reported,6488,O
a,6488,O
mouse,6488,O
model,6488,O
containing,6488,O
firefly,6488,O
luciferase,6488,O
(,6488,O
fLUC,6488,O
),6488,O
knocked,6488,O
into,6488,O
the,6488,O
mdr1a,6488,B-GENE-Y
genomic,6488,O
locus,6488,O
",",6488,O
allowing,6488,O
non-invasive,6488,O
bioimaging,6488,O
of,6488,O
intestinal,6488,O
mdr1a,6488,B-GENE-Y
gene,6488,O
expression,6488,O
in,6488,O
live,6488,O
animals,6488,O
.,6488,O
In,6489,O
the,6489,O
current,6489,O
study,6489,O
",",6489,O
we,6489,O
crossed,6489,O
mdr1a.fLUC,6489,B-GENE-Y
mice,6489,O
into,6489,O
the,6489,O
pxr,6489,B-GENE-Y
knockout,6489,O
(,6489,O
pxr,6489,B-GENE-Y
(,6489,O
-/-,6489,O
),6489,O
),6489,O
genetic,6489,O
background,6489,O
and,6489,O
injected,6489,O
mice,6489,O
with,6489,O
pregnenolone-16α-carbonitrile,6489,B-CHEMICAL
(,6489,O
PCN,6489,B-CHEMICAL
),6489,O
",",6489,O
a,6489,O
strong,6489,O
PXR,6489,B-GENE-Y
ligand,6489,O
",",6489,O
and,6489,O
two,6489,O
therapeutically,6489,O
relevant,6489,O
taxanes,6489,B-CHEMICAL
",",6489,O
paclitaxel,6489,B-CHEMICAL
and,6489,O
docetaxel,6489,B-CHEMICAL
.,6489,O
All,6490,O
three,6490,O
agents,6490,O
induced,6490,O
mdr1a.fLUC,6490,B-GENE-Y
expression,6490,O
(,6490,O
bioluminescence,6490,O
),6490,O
",",6490,O
but,6490,O
only,6490,O
PCN,6490,B-CHEMICAL
and,6490,O
docetaxel,6490,B-CHEMICAL
appeared,6490,O
to,6490,O
act,6490,O
primarily,6490,O
via,6490,O
PXR,6490,B-GENE-Y
.,6490,O
Luminescence,6491,O
returned,6491,O
to,6491,O
baseline,6491,O
by,6491,O
24-48,6491,O
hrs,6491,O
after,6491,O
drug,6491,O
injection,6491,O
and,6491,O
was,6491,O
re-inducible,6491,O
over,6491,O
two,6491,O
additional,6491,O
rounds,6491,O
of,6491,O
drug,6491,O
dosing,6491,O
in,6491,O
pxr,6491,B-GENE-Y
(,6491,O
+/+,6491,O
),6491,O
mice,6491,O
.,6491,O
TCPOBOP,6492,B-CHEMICAL
",",6492,O
a,6492,O
CAR,6492,B-GENE-Y
ligand,6492,O
",",6492,O
modestly,6492,O
induced,6492,O
mdr1a.fLUC,6492,B-GENE-Y
in,6492,O
pxr,6492,B-GENE-Y
(,6492,O
+/+,6492,O
),6492,O
and,6492,O
pxr,6492,B-GENE-Y
(,6492,O
-/-,6492,O
),6492,O
strains,6492,O
",",6492,O
consistent,6492,O
with,6492,O
CAR,6492,B-GENE-Y
's,6492,O
minor,6492,O
role,6492,O
in,6492,O
mdr1a,6492,B-GENE-Y
regulation,6492,O
.,6492,O
Collectively,6493,O
",",6493,O
these,6493,O
results,6493,O
demonstrate,6493,O
that,6493,O
the,6493,O
mdr1a.fLUC,6493,B-GENE-Y
bioimaging,6493,O
model,6493,O
can,6493,O
capture,6493,O
changes,6493,O
in,6493,O
mdr1,6493,B-GENE-Y
gene,6493,O
expression,6493,O
under,6493,O
conditions,6493,O
of,6493,O
repeated,6493,O
xenobiotic,6493,O
treatment,6493,O
in,6493,O
vivo,6493,O
and,6493,O
that,6493,O
it,6493,O
can,6493,O
be,6493,O
used,6493,O
to,6493,O
probe,6493,O
the,6493,O
mechanism,6493,O
of,6493,O
gene,6493,O
regulation,6493,O
in,6493,O
response,6493,O
to,6493,O
different,6493,O
xenobiotic,6493,O
agents,6493,O
.,6493,O
Bioinformatics,6494,O
and,6494,O
Molecular,6494,O
Dynamics,6494,O
Simulation,6494,O
Study,6494,O
of,6494,O
L1,6494,B-GENE-N
Stalk,6494,I-GENE-N
Non-Canonical,6494,I-GENE-N
rRNA,6494,I-GENE-N
Elements,6494,I-GENE-N
:,6494,O
Kink-Turns,6494,B-GENE-N
",",6494,O
Loops,6494,O
",",6494,O
and,6494,O
Tetraloops,6494,O
.,6494,O
The,6495,O
L1,6495,B-GENE-N
stalk,6495,I-GENE-N
is,6495,O
a,6495,O
prominent,6495,O
mobile,6495,O
element,6495,O
of,6495,O
the,6495,O
large,6495,O
ribosomal,6495,O
subunit,6495,O
.,6495,O
We,6496,O
explore,6496,O
the,6496,O
structure,6496,O
and,6496,O
dynamics,6496,O
of,6496,O
its,6496,O
non-canonical,6496,O
rRNA,6496,O
elements,6496,O
",",6496,O
which,6496,O
include,6496,O
two,6496,O
kink-turns,6496,B-GENE-N
",",6496,O
an,6496,O
internal,6496,B-GENE-N
loop,6496,I-GENE-N
",",6496,O
and,6496,O
a,6496,O
tetraloop,6496,B-GENE-N
.,6496,O
We,6497,O
use,6497,O
bioinformatics,6497,O
to,6497,O
identify,6497,O
the,6497,O
L1,6497,B-GENE-N
stalk,6497,I-GENE-N
RNA,6497,O
conservation,6497,O
patterns,6497,O
and,6497,O
carry,6497,O
out,6497,O
over,6497,O
11.5,6497,O
μs,6497,O
of,6497,O
MD,6497,O
simulations,6497,O
for,6497,O
a,6497,O
set,6497,O
of,6497,O
systems,6497,O
ranging,6497,O
from,6497,O
isolated,6497,O
RNA,6497,O
building,6497,O
blocks,6497,O
up,6497,O
to,6497,O
complexes,6497,O
of,6497,O
L1,6497,B-GENE-N
stalk,6497,I-GENE-N
rRNA,6497,O
with,6497,O
the,6497,O
L1,6497,B-GENE-Y
protein,6497,I-GENE-Y
and,6497,O
tRNA,6497,O
fragment,6497,O
.,6497,O
We,6498,O
show,6498,O
that,6498,O
the,6498,O
L1,6498,B-GENE-N
stalk,6498,I-GENE-N
tetraloop,6498,I-GENE-N
has,6498,O
an,6498,O
unusual,6498,O
GNNA,6498,B-GENE-N
or,6498,O
UNNG,6498,B-GENE-N
conservation,6498,O
pattern,6498,O
deviating,6498,O
from,6498,O
major,6498,O
GNRA,6498,B-GENE-N
and,6498,O
YNMG,6498,B-GENE-N
RNA,6498,B-GENE-N
tetraloop,6498,I-GENE-N
families,6498,O
.,6498,O
We,6499,O
suggest,6499,O
that,6499,O
this,6499,O
deviation,6499,O
is,6499,O
related,6499,O
to,6499,O
a,6499,O
highly,6499,O
conserved,6499,O
tertiary,6499,O
contact,6499,O
within,6499,O
the,6499,O
L1,6499,B-GENE-N
stalk,6499,I-GENE-N
.,6499,O
The,6500,O
available,6500,O
X-ray,6500,O
structures,6500,O
contain,6500,O
only,6500,O
UCCG,6500,B-GENE-N
tetraloops,6500,B-GENE-N
which,6500,O
in,6500,O
addition,6500,O
differ,6500,O
in,6500,O
orientation,6500,O
(,6500,O
anti,6500,O
vs,6500,O
syn,6500,O
),6500,O
of,6500,O
the,6500,O
guanine,6500,B-CHEMICAL
.,6500,O
Our,6501,O
analysis,6501,O
suggests,6501,O
that,6501,O
the,6501,O
anti,6501,O
orientation,6501,O
might,6501,O
be,6501,O
a,6501,O
mis-refinement,6501,O
",",6501,O
although,6501,O
even,6501,O
the,6501,O
anti,6501,O
interaction,6501,O
would,6501,O
be,6501,O
compatible,6501,O
with,6501,O
the,6501,O
sequence,6501,O
pattern,6501,O
and,6501,O
observed,6501,O
tertiary,6501,O
interaction,6501,O
.,6501,O
Alternatively,6502,O
",",6502,O
the,6502,O
anti,6502,O
conformation,6502,O
may,6502,O
be,6502,O
a,6502,O
real,6502,O
substate,6502,O
whose,6502,O
population,6502,O
could,6502,O
be,6502,O
pH-dependent,6502,O
",",6502,O
since,6502,O
the,6502,O
guanine,6502,B-CHEMICAL
syn,6502,O
orientation,6502,O
requires,6502,O
protonation,6502,O
of,6502,O
cytosine,6502,B-CHEMICAL
in,6502,O
the,6502,O
tertiary,6502,O
contact,6502,O
.,6502,O
In,6503,O
absence,6503,O
of,6503,O
structural,6503,O
data,6503,O
",",6503,O
we,6503,O
use,6503,O
molecular,6503,O
modeling,6503,O
to,6503,O
explore,6503,O
the,6503,O
GCCA,6503,B-GENE-N
tetraloop,6503,B-GENE-N
that,6503,O
is,6503,O
dominant,6503,O
in,6503,O
bacteria,6503,O
and,6503,O
suggest,6503,O
that,6503,O
the,6503,O
GCCA,6503,B-GENE-N
tetraloop,6503,B-GENE-N
is,6503,O
structurally,6503,O
similar,6503,O
to,6503,O
the,6503,O
YNMG,6503,B-GENE-N
tetraloop,6503,B-GENE-N
.,6503,O
Kink-turn,6504,B-GENE-N
Kt-77,6504,I-GENE-N
is,6504,O
unusual,6504,O
due,6504,O
to,6504,O
its,6504,O
11-nucleotide,6504,O
bulge,6504,O
.,6504,O
The,6505,O
simulations,6505,O
indicate,6505,O
that,6505,O
the,6505,O
long,6505,O
bulge,6505,O
is,6505,O
a,6505,O
stalk-specific,6505,O
eight-nucleotide,6505,O
insertion,6505,O
into,6505,O
consensual,6505,O
kink-turn,6505,B-GENE-N
only,6505,O
subtly,6505,O
modifying,6505,O
its,6505,O
structural,6505,O
dynamics,6505,O
.,6505,O
We,6506,O
discuss,6506,O
a,6506,O
possible,6506,O
evolutionary,6506,O
role,6506,O
of,6506,O
helix,6506,B-GENE-N
H78,6506,I-GENE-N
and,6506,O
a,6506,O
mechanism,6506,O
of,6506,O
L1,6506,B-GENE-N
stalk,6506,I-GENE-N
interaction,6506,O
with,6506,O
tRNA,6506,O
.,6506,O
We,6507,O
also,6507,O
assess,6507,O
the,6507,O
simulation,6507,O
methodology,6507,O
.,6507,O
The,6508,O
simulations,6508,O
provide,6508,O
a,6508,O
good,6508,O
description,6508,O
of,6508,O
the,6508,O
studied,6508,O
systems,6508,O
with,6508,O
the,6508,O
latest,6508,O
bsc0χOL3,6508,O
force,6508,O
field,6508,O
showing,6508,O
improved,6508,O
performance,6508,O
.,6508,O
Still,6509,O
",",6509,O
even,6509,O
bsc0χOL3,6509,O
is,6509,O
unable,6509,O
to,6509,O
fully,6509,O
stabilize,6509,O
an,6509,O
essential,6509,O
sugar-edge,6509,B-CHEMICAL
H-bond,6509,B-CHEMICAL
between,6509,O
the,6509,O
bulge,6509,O
and,6509,O
non-canonical,6509,O
stem,6509,O
of,6509,O
the,6509,O
kink-turn,6509,B-GENE-N
.,6509,O
Inclusion,6510,O
of,6510,O
Mg,6510,B-CHEMICAL
(,6510,I-CHEMICAL
2+,6510,I-CHEMICAL
),6510,I-CHEMICAL
ions,6510,O
may,6510,O
deteriorate,6510,O
the,6510,O
simulations,6510,O
.,6510,O
On,6511,O
the,6511,O
other,6511,O
hand,6511,O
",",6511,O
monovalent,6511,O
ions,6511,O
can,6511,O
in,6511,O
simulations,6511,O
readily,6511,O
occupy,6511,O
experimental,6511,O
Mg,6511,B-CHEMICAL
(,6511,I-CHEMICAL
2+,6511,I-CHEMICAL
),6511,I-CHEMICAL
binding,6511,O
sites,6511,O
.,6511,O
Galangin,6512,B-CHEMICAL
attenuates,6512,O
mast,6512,O
cell-mediated,6512,O
allergic,6512,O
inflammation,6512,O
.,6512,O
A,6513,O
great,6513,O
number,6513,O
of,6513,O
people,6513,O
are,6513,O
suffering,6513,O
from,6513,O
allergic,6513,O
inflammatory,6513,O
disease,6513,O
such,6513,O
as,6513,O
asthma,6513,O
",",6513,O
atopic,6513,O
dermatitis,6513,O
",",6513,O
and,6513,O
sinusitis,6513,O
.,6513,O
Therefore,6514,O
discovery,6514,O
of,6514,O
drugs,6514,O
for,6514,O
the,6514,O
treatment,6514,O
of,6514,O
these,6514,O
diseases,6514,O
is,6514,O
an,6514,O
important,6514,O
subject,6514,O
in,6514,O
human,6514,O
health,6514,O
.,6514,O
In,6515,O
this,6515,O
study,6515,O
",",6515,O
we,6515,O
investigated,6515,O
anti-allergic,6515,O
inflammatory,6515,O
effect,6515,O
of,6515,O
galangin,6515,B-CHEMICAL
and,6515,O
underlying,6515,O
mechanisms,6515,O
of,6515,O
action,6515,O
using,6515,O
in,6515,O
vitro,6515,O
and,6515,O
in,6515,O
vivo,6515,O
models,6515,O
.,6515,O
Galangin,6516,B-CHEMICAL
inhibited,6516,O
histamine,6516,B-CHEMICAL
release,6516,O
by,6516,O
the,6516,O
reduction,6516,O
of,6516,O
intracellular,6516,O
calcium,6516,B-CHEMICAL
in,6516,O
phorbol,6516,B-CHEMICAL
12-mystate,6516,I-CHEMICAL
13-acetate,6516,I-CHEMICAL
plus,6516,O
calcium,6516,B-CHEMICAL
ionophore,6516,O
A23187-stimulated,6516,O
human,6516,O
mast,6516,O
cells,6516,O
(,6516,O
HMC-1,6516,O
),6516,O
.,6516,O
Galangin,6517,B-CHEMICAL
decreased,6517,O
expression,6517,O
of,6517,O
pro-inflammatory,6517,O
cytokines,6517,B-GENE-N
",",6517,O
such,6517,O
as,6517,O
tumor,6517,B-GENE-Y
necrosis,6517,I-GENE-Y
factor,6517,I-GENE-Y
(,6517,I-GENE-Y
TNF,6517,I-GENE-Y
),6517,I-GENE-Y
-α,6517,I-GENE-Y
",",6517,O
interleukin,6517,B-GENE-Y
(,6517,B-GENE-Y
IL,6517,I-GENE-Y
),6517,I-GENE-Y
-6,6517,I-GENE-Y
",",6517,O
IL-1β,6517,B-GENE-Y
",",6517,O
and,6517,O
IL-8,6517,B-GENE-Y
.,6517,O
The,6518,O
inhibitory,6518,O
effect,6518,O
of,6518,O
galangin,6518,B-CHEMICAL
on,6518,O
theses,6518,O
pro-inflammatory,6518,O
cytokines,6518,B-GENE-N
was,6518,O
related,6518,O
with,6518,O
c-Jun,6518,B-GENE-Y
N-terminal,6518,B-GENE-N
kinases,6518,I-GENE-N
",",6518,O
and,6518,O
p38,6518,B-GENE-N
mitogen-activated,6518,B-GENE-N
protein,6518,I-GENE-N
kinase,6518,I-GENE-N
",",6518,O
nuclear,6518,B-GENE-N
factor-κB,6518,I-GENE-N
",",6518,O
and,6518,O
caspase-1,6518,B-GENE-Y
.,6518,O
Furthermore,6519,O
",",6519,O
galangin,6519,B-CHEMICAL
attenuated,6519,O
IgE-mediated,6519,B-GENE-N
passive,6519,O
cutaneous,6519,O
anaphylaxis,6519,O
and,6519,O
the,6519,O
expression,6519,O
of,6519,O
histamine,6519,B-GENE-Y
receptor,6519,I-GENE-Y
1,6519,I-GENE-Y
at,6519,O
the,6519,O
inflamed,6519,O
tissue,6519,O
.,6519,O
The,6520,O
inhibitory,6520,O
effects,6520,O
of,6520,O
galangin,6520,B-CHEMICAL
were,6520,O
more,6520,O
potent,6520,O
than,6520,O
cromolyn,6520,B-CHEMICAL
",",6520,O
a,6520,O
known,6520,O
anti-allergic,6520,O
drug,6520,O
.,6520,O
Our,6521,O
results,6521,O
showed,6521,O
that,6521,O
galangin,6521,B-CHEMICAL
down-regulates,6521,O
mast,6521,O
cell-derived,6521,O
allergic,6521,O
inflammatory,6521,O
reactions,6521,O
by,6521,O
blocking,6521,O
histamine,6521,B-CHEMICAL
release,6521,O
and,6521,O
expression,6521,O
of,6521,O
pro-inflammatory,6521,O
cytokines,6521,B-GENE-N
.,6521,O
In,6522,O
light,6522,O
of,6522,O
in,6522,O
vitro,6522,O
and,6522,O
in,6522,O
vivo,6522,O
anti-allergic,6522,O
inflammatory,6522,O
effects,6522,O
",",6522,O
galangin,6522,B-CHEMICAL
could,6522,O
be,6522,O
a,6522,O
beneficial,6522,O
anti-allergic,6522,O
inflammatory,6522,O
agent,6522,O
.,6522,O
Aberrant,6523,O
activation,6523,O
of,6523,O
M,6523,B-GENE-N
phase,6523,I-GENE-N
proteins,6523,I-GENE-N
by,6523,O
cell,6523,O
proliferation-evoking,6523,O
carcinogens,6523,O
after,6523,O
28-day,6523,O
administration,6523,O
in,6523,O
rats,6523,O
.,6523,O
We,6524,O
have,6524,O
previously,6524,O
reported,6524,O
that,6524,O
hepatocarcinogens,6524,O
increase,6524,O
liver,6524,O
cells,6524,O
expressing,6524,O
p21,6524,B-GENE-Y
(,6524,O
Cip1,6524,B-GENE-Y
),6524,O
",",6524,O
a,6524,O
G1,6524,O
checkpoint,6524,O
protein,6524,O
and,6524,O
M,6524,B-GENE-N
phase,6524,I-GENE-N
proteins,6524,I-GENE-N
after,6524,O
28-day,6524,O
treatment,6524,O
in,6524,O
rats,6524,O
.,6524,O
This,6525,O
study,6525,O
aimed,6525,O
to,6525,O
identify,6525,O
early,6525,O
prediction,6525,O
markers,6525,O
of,6525,O
carcinogens,6525,O
available,6525,O
in,6525,O
many,6525,O
target,6525,O
organs,6525,O
after,6525,O
28-day,6525,O
treatment,6525,O
in,6525,O
rats,6525,O
.,6525,O
Immunohistochemical,6526,O
analysis,6526,O
was,6526,O
performed,6526,O
on,6526,O
Ki-67,6526,B-GENE-Y
",",6526,O
p21,6526,B-GENE-Y
(,6526,O
Cip1,6526,B-GENE-Y
),6526,O
and,6526,O
M,6526,B-GENE-N
phase,6526,I-GENE-N
proteins,6526,I-GENE-N
[,6526,O
nuclear,6526,O
Cdc2,6526,B-GENE-Y
",",6526,O
phospho-Histone,6526,B-GENE-N
H3,6526,I-GENE-N
(,6526,O
p-Histone,6526,B-GENE-N
H3,6526,I-GENE-N
),6526,O
",",6526,O
Aurora,6526,B-GENE-Y
B,6526,I-GENE-Y
and,6526,O
heterochromatin,6526,B-GENE-Y
protein,6526,I-GENE-Y
1α,6526,I-GENE-Y
(,6526,O
HP1α,6526,B-GENE-Y
),6526,O
],6526,O
with,6526,O
carcinogens,6526,O
targeting,6526,O
different,6526,O
organs,6526,O
.,6526,O
Carcinogens,6527,O
targeting,6527,O
thyroid,6527,O
(,6527,O
sulfadimethoxine,6527,B-CHEMICAL
;,6527,O
SDM,6527,B-CHEMICAL
),6527,O
",",6527,O
urinary,6527,O
bladder,6527,O
(,6527,O
phenylethyl,6527,B-CHEMICAL
isothiocyanate,6527,I-CHEMICAL
),6527,O
",",6527,O
forestomach,6527,O
(,6527,O
butylated,6527,B-CHEMICAL
hydroxyanisole,6527,I-CHEMICAL
;,6527,O
BHA,6527,B-CHEMICAL
),6527,O
",",6527,O
glandular,6527,O
stomach,6527,O
(,6527,O
catechol,6527,B-CHEMICAL
;,6527,O
CC,6527,O
),6527,O
",",6527,O
and,6527,O
colon,6527,O
(,6527,O
2-amino-1-methyl-6-phenylimidazo,6527,B-CHEMICAL
[,6527,I-CHEMICAL
"4,5-b",6527,I-CHEMICAL
],6527,I-CHEMICAL
pyridine,6527,I-CHEMICAL
and,6527,O
chenodeoxycholic,6527,B-CHEMICAL
acid,6527,I-CHEMICAL
),6527,O
were,6527,O
examined,6527,O
using,6527,O
a,6527,O
non-carcinogenic,6527,O
toxicant,6527,O
(,6527,O
caprolactam,6527,B-CHEMICAL
),6527,O
and,6527,O
carcinogens,6527,O
targeting,6527,O
other,6527,O
organs,6527,O
as,6527,O
negative,6527,O
controls,6527,O
.,6527,O
All,6528,O
carcinogens,6528,O
increased,6528,O
Ki-67,6528,B-GENE-Y
(,6528,O
+,6528,O
),6528,O
",",6528,O
nuclear,6528,O
Cdc2,6528,B-GENE-Y
(,6528,O
+,6528,O
),6528,O
",",6528,O
p-Histone,6528,B-GENE-N
H3,6528,I-GENE-N
(,6528,O
+,6528,O
),6528,O
or,6528,O
Aurora,6528,B-GENE-Y
B,6528,I-GENE-Y
(,6528,O
+,6528,O
),6528,O
carcinogenic,6528,O
target,6528,O
cells,6528,O
",",6528,O
except,6528,O
for,6528,O
both,6528,O
colon,6528,O
carcinogens,6528,O
",",6528,O
which,6528,O
did,6528,O
not,6528,O
increase,6528,O
cell,6528,O
proliferation,6528,O
.,6528,O
On,6529,O
the,6529,O
other,6529,O
hand,6529,O
",",6529,O
p21,6529,B-GENE-Y
(,6529,O
Cip1+,6529,B-GENE-Y
),6529,O
cells,6529,O
increased,6529,O
with,6529,O
SDM,6529,O
and,6529,O
CC,6529,O
.,6529,O
HP1α,6530,B-GENE-Y
responded,6530,O
only,6530,O
to,6530,O
BHA,6530,B-CHEMICAL
.,6530,O
Results,6531,O
revealed,6531,O
carcinogens,6531,O
evoking,6531,O
cell,6531,O
proliferation,6531,O
concurrently,6531,O
induced,6531,O
cell,6531,O
cycle,6531,O
arrest,6531,O
at,6531,O
M,6531,O
phase,6531,O
or,6531,O
showing,6531,O
chromosomal,6531,O
instability,6531,O
reflecting,6531,O
aberration,6531,O
in,6531,O
cell,6531,O
cycle,6531,O
regulation,6531,O
",",6531,O
irrespective,6531,O
of,6531,O
target,6531,O
organs,6531,O
",",6531,O
after,6531,O
28-day,6531,O
treatment,6531,O
.,6531,O
Therefore,6532,O
",",6532,O
M,6532,B-GENE-N
phase,6532,I-GENE-N
proteins,6532,I-GENE-N
may,6532,O
be,6532,O
early,6532,O
prediction,6532,O
markers,6532,O
of,6532,O
carcinogens,6532,O
evoking,6532,O
cell,6532,O
proliferation,6532,O
in,6532,O
many,6532,O
target,6532,O
organs,6532,O
.,6532,O
Nobiletin,6533,B-CHEMICAL
attenuates,6533,O
metastasis,6533,O
via,6533,O
both,6533,O
ERK,6533,B-GENE-N
and,6533,O
PI3K/Akt,6533,B-GENE-N
pathways,6533,O
in,6533,O
HGF-treated,6533,B-GENE-Y
liver,6533,O
cancer,6533,O
HepG2,6533,O
cells,6533,O
.,6533,O
Hepatocyte,6534,B-GENE-Y
growth,6534,I-GENE-Y
factor,6534,I-GENE-Y
(,6534,O
HGF,6534,B-GENE-Y
),6534,O
",",6534,O
and,6534,O
its,6534,O
receptor,6534,O
",",6534,O
c-Met,6534,B-GENE-Y
activation,6534,O
has,6534,O
recently,6534,O
been,6534,O
shown,6534,O
to,6534,O
play,6534,O
important,6534,O
roles,6534,O
in,6534,O
cancer,6534,O
invasion,6534,O
and,6534,O
metastasis,6534,O
in,6534,O
a,6534,O
wide,6534,O
variety,6534,O
of,6534,O
tumor,6534,O
cells,6534,O
.,6534,O
We,6535,O
use,6535,O
HGF,6535,B-GENE-Y
as,6535,O
an,6535,O
invasive,6535,O
inducer,6535,O
of,6535,O
human,6535,O
HepG2,6535,O
cells,6535,O
to,6535,O
investigate,6535,O
the,6535,O
effect,6535,O
of,6535,O
four,6535,O
flavones,6535,O
including,6535,O
apigenin,6535,B-CHEMICAL
",",6535,O
tricetin,6535,B-CHEMICAL
",",6535,O
tangeretin,6535,B-CHEMICAL
",",6535,O
and,6535,O
nobiletin,6535,B-CHEMICAL
on,6535,O
HGF/c-Met-mediated,6535,B-GENE-Y
tumor,6535,O
invasion,6535,O
and,6535,O
metastasis,6535,O
.,6535,O
Among,6536,O
them,6536,O
",",6536,O
nobiletin,6536,B-CHEMICAL
markedly,6536,O
inhibited,6536,O
HGF-induced,6536,B-GENE-Y
the,6536,O
abilities,6536,O
of,6536,O
the,6536,O
adhesion,6536,O
",",6536,O
invasion,6536,O
",",6536,O
and,6536,O
migration,6536,O
by,6536,O
cell-matrix,6536,O
adhesion,6536,O
assay,6536,O
and,6536,O
transwell-chamber,6536,O
invasion/migration,6536,O
assay,6536,O
under,6536,O
non-cytotoxic,6536,O
concentrations,6536,O
.,6536,O
Data,6537,O
also,6537,O
showed,6537,O
nobiletin,6537,B-CHEMICAL
inhibited,6537,O
HGF-induced,6537,B-GENE-Y
cell,6537,O
scattering,6537,O
and,6537,O
cytoskeleton,6537,O
changed,6537,O
such,6537,O
as,6537,O
filopodia,6537,O
and,6537,O
lamellipodia,6537,O
.,6537,O
Furthermore,6538,O
",",6538,O
nobiletin,6538,B-CHEMICAL
could,6538,O
inhibit,6538,O
HGF-induced,6538,B-GENE-Y
the,6538,O
membrane,6538,O
localization,6538,O
of,6538,O
phosphorylated,6538,O
c-Met,6538,B-GENE-Y
",",6538,O
ERK2,6538,B-GENE-Y
",",6538,O
and,6538,O
Akt,6538,B-GENE-N
",",6538,O
but,6538,O
not,6538,O
phosphorylated,6538,B-GENE-N
JNK1/2,6538,I-GENE-N
and,6538,O
p38,6538,B-GENE-N
.,6538,O
Next,6539,O
",",6539,O
nobiletin,6539,B-CHEMICAL
significantly,6539,O
decreased,6539,O
the,6539,O
levels,6539,O
of,6539,O
phospho-ERK2,6539,B-GENE-Y
and,6539,O
phospho-Akt,6539,B-GENE-N
in,6539,O
ERK2,6539,B-GENE-Y
or,6539,O
Akt,6539,B-GENE-N
siRNA-transfected,6539,O
cells,6539,O
concomitantly,6539,O
with,6539,O
a,6539,O
marked,6539,O
reduction,6539,O
on,6539,O
cell,6539,O
invasion,6539,O
and,6539,O
migration,6539,O
.,6539,O
In,6540,O
conclusion,6540,O
",",6540,O
nobiletin,6540,B-CHEMICAL
attenuates,6540,O
HGF-induced,6540,B-GENE-Y
HepG2,6540,O
cells,6540,O
metastasis,6540,O
involving,6540,O
both,6540,O
ERK,6540,B-GENE-N
and,6540,O
PI3K/Akt,6540,B-GENE-N
pathways,6540,O
and,6540,O
are,6540,O
potentially,6540,O
useful,6540,O
as,6540,O
anti-metastatic,6540,O
agents,6540,O
for,6540,O
the,6540,O
treatment,6540,O
of,6540,O
hepatoma,6540,O
.,6540,O
Cardiac,6541,B-GENE-N
natriuretic,6541,I-GENE-N
Peptide,6541,I-GENE-N
gene,6541,O
expression,6541,O
and,6541,O
plasma,6541,O
concentrations,6541,O
during,6541,O
the,6541,O
first,6541,O
72,6541,O
hours,6541,O
of,6541,O
life,6541,O
in,6541,O
piglets,6541,O
.,6541,O
Plasma,6542,O
measurement,6542,O
of,6542,O
cardiac,6542,B-GENE-N
natriuretic,6542,I-GENE-N
peptides,6542,I-GENE-N
constitutes,6542,O
promising,6542,O
markers,6542,O
of,6542,O
congenital,6542,O
heart,6542,O
disease,6542,O
.,6542,O
However,6543,O
",",6543,O
concentrations,6543,O
change,6543,O
rapidly,6543,O
and,6543,O
dramatically,6543,O
during,6543,O
the,6543,O
first,6543,O
days,6543,O
after,6543,O
delivery,6543,O
even,6543,O
in,6543,O
healthy,6543,O
neonates,6543,O
",",6543,O
which,6543,O
complicates,6543,O
clinical,6543,O
interpretation,6543,O
.,6543,O
It,6544,O
is,6544,O
unknown,6544,O
whether,6544,O
these,6544,O
changes,6544,O
in,6544,O
plasma,6544,O
concentrations,6544,O
are,6544,O
explained,6544,O
by,6544,O
corresponding,6544,O
changes,6544,O
in,6544,O
the,6544,O
cardiac,6544,O
gene,6544,O
expression,6544,O
.,6544,O
We,6545,O
quantified,6545,O
the,6545,O
chamber-specific,6545,O
mRNA,6545,O
levels,6545,O
of,6545,O
ANP,6545,B-GENE-Y
(,6545,O
A-type,6545,B-GENE-Y
natriuretic,6545,I-GENE-Y
peptide,6545,I-GENE-Y
),6545,O
and,6545,O
BNP,6545,B-GENE-Y
(,6545,O
B-type,6545,B-GENE-N
natriuretic,6545,I-GENE-N
peptide,6545,I-GENE-N
),6545,O
and,6545,O
plasma,6545,O
pro-ANP,6545,O
and,6545,O
BNP-32,6545,B-GENE-Y
concentrations,6545,O
in,6545,O
healthy,6545,O
piglets,6545,O
during,6545,O
the,6545,O
first,6545,O
72,6545,O
hours,6545,O
of,6545,O
life,6545,O
(,6545,O
from,6545,O
2,6545,O
litters,6545,O
",",6545,O
n,6545,O
=,6545,O
44,6545,O
),6545,O
.,6545,O
Chamber-specific,6546,O
ANP,6546,B-GENE-Y
and,6546,O
BNP,6546,B-GENE-Y
mRNA,6546,O
levels,6546,O
reflected,6546,O
hemodynamic,6546,O
neonate,6546,O
changes,6546,O
at,6546,O
birth,6546,O
but,6546,O
did,6546,O
not,6546,O
correlate,6546,O
with,6546,O
circulating,6546,O
natriuretic,6546,B-GENE-N
peptide,6546,I-GENE-N
concentrations,6546,O
.,6546,O
However,6547,O
",",6547,O
plasma,6547,O
pro-ANP,6547,O
and,6547,O
creatinine,6547,B-CHEMICAL
concentrations,6547,O
were,6547,O
closely,6547,O
correlated,6547,O
(,6547,O
P,6547,O
<,6547,O
.0001,6547,O
;,6547,O
r,6547,O
=,6547,O
0.73,6547,O
),6547,O
.,6547,O
Plasma,6548,O
pro-ANP,6548,O
levels,6548,O
were,6548,O
highest,6548,O
on,6548,O
the,6548,O
day,6548,O
of,6548,O
delivery,6548,O
(,6548,O
5580,6548,O
pmol/L,6548,O
[,6548,O
4320-6786,6548,O
],6548,O
decreasing,6548,O
to,6548,O
2484,6548,O
pmol/L,6548,O
[,6548,O
1602-2898,6548,O
],6548,O
after,6548,O
72,6548,O
hours,6548,O
",",6548,O
P,6548,O
<,6548,O
.0001,6548,O
),6548,O
.,6548,O
During,6549,O
the,6549,O
72,6549,O
hours,6549,O
",",6549,O
gel,6549,O
chromatography,6549,O
suggested,6549,O
that,6549,O
the,6549,O
translational,6549,O
products,6549,O
in,6549,O
circulation,6549,O
and,6549,O
in,6549,O
atrial,6549,O
tissue,6549,O
were,6549,O
immature,6549,O
",",6549,O
ie,6549,O
",",6549,O
unprocessed,6549,O
pro-ANP,6549,O
.,6549,O
In,6550,O
contrast,6550,O
to,6550,O
pro-ANP,6550,O
",",6550,O
BNP-32,6550,B-GENE-Y
plasma,6550,O
concentrations,6550,O
were,6550,O
low,6550,O
at,6550,O
delivery,6550,O
and,6550,O
peaked,6550,O
after,6550,O
48,6550,O
hours,6550,O
(,6550,O
12,6550,O
[,6550,O
10.5-20.6,6550,O
],6550,O
vs.,6550,O
88.8,6550,O
[,6550,O
71.7-101.4,6550,O
],6550,O
pmol/L,6550,O
",",6550,O
P,6550,O
<,6550,O
.0001,6550,O
),6550,O
.,6550,O
To,6551,O
conclude,6551,O
",",6551,O
ANP,6551,B-GENE-Y
and,6551,O
BNP,6551,B-GENE-Y
gene,6551,O
expression,6551,O
differs,6551,O
considerably,6551,O
between,6551,O
cardiac,6551,O
chambers,6551,O
in,6551,O
the,6551,O
first,6551,O
72,6551,O
hours,6551,O
of,6551,O
life,6551,O
in,6551,O
healthy,6551,O
piglets,6551,O
",",6551,O
resembling,6551,O
the,6551,O
transition,6551,O
from,6551,O
fetal,6551,O
to,6551,O
neonate,6551,O
circulation,6551,O
.,6551,O
However,6552,O
",",6552,O
the,6552,O
cardiac,6552,O
gene,6552,O
expression,6552,O
does,6552,O
not,6552,O
explain,6552,O
plasma,6552,O
concentrations,6552,O
.,6552,O
T-Cells,6553,O
from,6553,O
HLA-B,6553,B-GENE-Y
*,6553,I-GENE-Y
57:01+,6553,O
Human,6553,O
Subjects,6553,O
Are,6553,O
Activated,6553,O
with,6553,O
Abacavir,6553,B-CHEMICAL
through,6553,O
Two,6553,O
Independent,6553,O
Pathways,6553,O
and,6553,O
Induce,6553,O
Cell,6553,O
Death,6553,O
by,6553,O
Multiple,6553,O
Mechanisms,6553,O
.,6553,O
Susceptibility,6554,O
to,6554,O
abacavir,6554,O
hypersensitivity,6554,O
has,6554,O
been,6554,O
attributed,6554,O
to,6554,O
possession,6554,O
of,6554,O
the,6554,O
specific,6554,O
human,6554,B-GENE-Y
leukocyte,6554,I-GENE-Y
antigen,6554,I-GENE-Y
allele,6554,I-GENE-Y
HLA-B,6554,I-GENE-Y
*,6554,I-GENE-Y
57:01,6554,I-GENE-Y
.,6554,O
HLA-B,6555,B-GENE-Y
*,6555,I-GENE-Y
57:01-restricted,6555,O
activation,6555,O
of,6555,O
CD8+,6555,O
T-cells,6555,O
provides,6555,O
a,6555,O
link,6555,O
between,6555,O
the,6555,O
genetic,6555,O
association,6555,O
and,6555,O
the,6555,O
iatrogenic,6555,O
disease,6555,O
.,6555,O
The,6556,O
objectives,6556,O
of,6556,O
this,6556,O
study,6556,O
were,6556,O
to,6556,O
characterize,6556,O
the,6556,O
functionality,6556,O
of,6556,O
drug-responsive,6556,O
CD8+,6556,O
T-cell,6556,O
clones,6556,O
generated,6556,O
from,6556,O
HLA-B,6556,B-GENE-Y
*,6556,I-GENE-Y
57:01+,6556,O
drug-naive,6556,O
subjects,6556,O
and,6556,O
to,6556,O
explore,6556,O
the,6556,O
relationship,6556,O
between,6556,O
abacavir,6556,B-CHEMICAL
accumulation,6556,O
in,6556,O
antigen,6556,O
presenting,6556,O
cells,6556,O
and,6556,O
the,6556,O
T-cell,6556,O
response,6556,O
.,6556,O
Seventy-four,6557,O
CD8+,6557,O
clones,6557,O
expressing,6557,O
different,6557,O
Vβ,6557,B-GENE-N
receptors,6557,I-GENE-N
were,6557,O
shown,6557,O
to,6557,O
proliferate,6557,O
and,6557,O
kill,6557,O
target,6557,O
cells,6557,O
via,6557,O
different,6557,O
mechanisms,6557,O
when,6557,O
exposed,6557,O
to,6557,O
abacavir,6557,B-CHEMICAL
.,6557,O
Certain,6558,O
clones,6558,O
were,6558,O
activated,6558,O
with,6558,O
abacavir,6558,B-CHEMICAL
in,6558,O
the,6558,O
absence,6558,O
of,6558,O
antigen,6558,O
presenting,6558,O
cells,6558,O
.,6558,O
Analysis,6559,O
of,6559,O
the,6559,O
remaining,6559,O
clones,6559,O
revealed,6559,O
two,6559,O
pathways,6559,O
of,6559,O
drug-dependent,6559,O
T-cell,6559,O
activation,6559,O
.,6559,O
Overnight,6560,O
incubation,6560,O
of,6560,O
antigen,6560,O
presenting,6560,O
cells,6560,O
with,6560,O
abacavir,6560,B-CHEMICAL
",",6560,O
followed,6560,O
by,6560,O
repeated,6560,O
washing,6560,O
to,6560,O
remove,6560,O
soluble,6560,O
drug,6560,O
",",6560,O
activated,6560,O
approximately,6560,O
50,6560,O
%,6560,O
of,6560,O
the,6560,O
clones,6560,O
",",6560,O
and,6560,O
the,6560,O
response,6560,O
was,6560,O
blocked,6560,O
by,6560,O
glutaraldehyde,6560,B-CHEMICAL
fixation,6560,O
.,6560,O
In,6561,O
contrast,6561,O
",",6561,O
a,6561,O
1,6561,O
h,6561,O
antigen,6561,O
presenting,6561,O
cell,6561,O
pulse,6561,O
did,6561,O
not,6561,O
activate,6561,O
any,6561,O
of,6561,O
the,6561,O
clones,6561,O
.,6561,O
Accumulation,6562,O
of,6562,O
abacavir,6562,B-CHEMICAL
in,6562,O
antigen,6562,O
presenting,6562,O
cells,6562,O
was,6562,O
rapid,6562,O
(,6562,O
less,6562,O
than,6562,O
1,6562,O
h,6562,O
),6562,O
",",6562,O
and,6562,O
the,6562,O
intracellular,6562,O
concentrations,6562,O
were,6562,O
maintained,6562,O
for,6562,O
16,6562,O
h.,6562,O
However,6562,O
",",6562,O
intracellular,6562,O
abacavir,6562,B-CHEMICAL
was,6562,O
not,6562,O
detectable,6562,O
by,6562,O
mass,6562,O
spectrometry,6562,O
after,6562,O
pulsing,6562,O
.,6562,O
These,6563,O
data,6563,O
suggest,6563,O
that,6563,O
T-cells,6563,O
can,6563,O
be,6563,O
activated,6563,O
by,6563,O
abacavir,6563,B-CHEMICAL
through,6563,O
a,6563,O
direct,6563,O
interaction,6563,O
with,6563,O
surface,6563,O
and,6563,O
intracellular,6563,O
major,6563,B-GENE-N
histocompatibility,6563,I-GENE-N
complex,6563,I-GENE-N
(,6563,O
MHC,6563,B-GENE-N
),6563,O
molecules,6563,O
.,6563,O
With,6564,O
the,6564,O
former,6564,O
",",6564,O
abacavir,6564,B-CHEMICAL
seemingly,6564,O
participates,6564,O
in,6564,O
the,6564,O
MHC,6564,B-GENE-N
T-cell,6564,B-GENE-N
receptor,6564,I-GENE-N
binding,6564,O
interaction,6564,O
.,6564,O
In,6565,O
contrast,6565,O
",",6565,O
the,6565,O
latter,6565,O
pathway,6565,O
likely,6565,O
involves,6565,O
MHC,6565,B-GENE-N
binding,6565,O
peptides,6565,O
displayed,6565,O
as,6565,O
a,6565,O
consequence,6565,O
of,6565,O
abacavir,6565,B-CHEMICAL
exposure,6565,O
",",6565,O
but,6565,O
not,6565,O
abacavir,6565,B-CHEMICAL
itself,6565,O
.,6565,O
Potential,6566,O
diagnostic,6566,O
applications,6566,O
of,6566,O
side,6566,O
chain,6566,O
oxysterols,6566,B-CHEMICAL
analysis,6566,O
in,6566,O
plasma,6566,O
and,6566,O
cerebrospinal,6566,O
fluid,6566,O
.,6566,O
The,6567,O
neurospecific,6567,O
cholesterol,6567,B-CHEMICAL
24-hydroxylase,6567,O
converts,6567,O
excess,6567,O
brain,6567,O
cholesterol,6567,B-CHEMICAL
into,6567,O
24S-hydroxycholesterol,6567,B-CHEMICAL
(,6567,O
24OHC,6567,B-CHEMICAL
),6567,O
which,6567,O
",",6567,O
via,6567,O
the,6567,O
liver,6567,B-GENE-N
X,6567,I-GENE-N
receptor,6567,I-GENE-N
(,6567,O
LXR,6567,B-GENE-N
),6567,O
",",6567,O
can,6567,O
increase,6567,O
the,6567,O
expression,6567,O
and,6567,O
synthesis,6567,O
of,6567,O
astrocyte,6567,O
ApoE,6567,B-GENE-Y
.,6567,O
24OHC,6568,B-CHEMICAL
effluxes,6568,O
directly,6568,O
from,6568,O
brain,6568,O
into,6568,O
plasma,6568,O
where,6568,O
it,6568,O
is,6568,O
considered,6568,O
an,6568,O
indicator,6568,O
of,6568,O
brain,6568,O
cholesterol,6568,B-CHEMICAL
turnover,6568,O
.,6568,O
It,6569,O
is,6569,O
reduced,6569,O
in,6569,O
neurodegenerative,6569,O
disease,6569,O
states,6569,O
proportionally,6569,O
to,6569,O
the,6569,O
severity,6569,O
of,6569,O
disease,6569,O
and,6569,O
the,6569,O
degree,6569,O
of,6569,O
brain,6569,O
atrophy,6569,O
.,6569,O
In,6570,O
the,6570,O
early,6570,O
phases,6570,O
of,6570,O
active,6570,O
disease,6570,O
",",6570,O
a,6570,O
higher,6570,O
rate,6570,O
of,6570,O
turnover,6570,O
may,6570,O
result,6570,O
in,6570,O
transitory,6570,O
increases,6570,O
in,6570,O
plasma,6570,O
24OHC,6570,B-CHEMICAL
.,6570,O
Less,6571,O
than,6571,O
1,6571,O
%,6571,O
of,6571,O
the,6571,O
total,6571,O
brain,6571,O
excretion,6571,O
of,6571,O
24OHC,6571,B-CHEMICAL
occurs,6571,O
via,6571,O
the,6571,O
cerebrospinal,6571,O
fluid,6571,O
(,6571,O
CSF,6571,O
),6571,O
whereas,6571,O
almost,6571,O
all,6571,O
27-hydroxycholesterol,6571,B-CHEMICAL
(,6571,O
27OHC,6571,B-CHEMICAL
),6571,O
excretion,6571,O
is,6571,O
dependent,6571,O
on,6571,O
the,6571,O
function,6571,O
of,6571,O
the,6571,O
blood-cerebrospinal,6571,O
fluid,6571,O
barrier,6571,O
.,6571,O
Iincreased,6572,O
CSF,6572,O
oxysterols,6572,B-CHEMICAL
were,6572,O
found,6572,O
in,6572,O
patients,6572,O
with,6572,O
neurodegenerative,6572,O
and,6572,O
neuroinflammatory,6572,O
diseases,6572,O
in,6572,O
the,6572,O
presence,6572,O
of,6572,O
barrier,6572,O
dysfunction,6572,O
.,6572,O
In,6573,O
neurodegeneration,6573,O
",",6573,O
free,6573,O
cholesterol,6573,B-CHEMICAL
released,6573,O
from,6573,O
dying,6573,O
cells,6573,O
may,6573,O
engulf,6573,O
neurons,6573,O
.,6573,O
Cholesterol,6574,B-CHEMICAL
also,6574,O
increases,6574,O
Amyloid,6574,B-GENE-Y
β,6574,I-GENE-Y
(,6574,O
Aβ,6574,B-GENE-Y
),6574,O
deposition,6574,O
and,6574,O
tau,6574,B-GENE-Y
pathology,6574,O
.,6574,O
ApoE,6575,B-GENE-Y
",",6575,O
24OHC,6575,B-CHEMICAL
",",6575,O
tau,6575,B-GENE-Y
and,6575,O
soluble,6575,B-GENE-Y
APP,6575,I-GENE-Y
were,6575,O
correlated,6575,O
in,6575,O
Alzheimer,6575,O
disease,6575,O
(,6575,O
AD,6575,O
),6575,O
samples,6575,O
.,6575,O
Excess,6576,O
of,6576,O
cholesterol,6576,B-CHEMICAL
converted,6576,O
into,6576,O
24OHC,6576,B-CHEMICAL
may,6576,O
up-regulate,6576,O
ApoE,6576,B-GENE-Y
synthesis,6576,O
which,6576,O
is,6576,O
a,6576,O
scavenger,6576,O
for,6576,O
Aβ,6576,B-GENE-Y
and,6576,O
Tau,6576,B-GENE-Y
.,6576,O
In,6577,O
AD,6577,O
this,6577,O
protective,6577,O
mechanism,6577,O
seems,6577,O
to,6577,O
be,6577,O
inefficient,6577,O
",",6577,O
probably,6577,O
due,6577,O
to,6577,O
the,6577,O
presence,6577,O
of,6577,O
high,6577,O
concentrations,6577,O
of,6577,O
27OHC,6577,B-CHEMICAL
",",6577,O
microvascular,6577,O
dysfunction,6577,O
and,6577,O
the,6577,O
decreased,6577,O
efficiency,6577,O
of,6577,O
ApoE4,6577,B-GENE-Y
as,6577,O
lipid,6577,O
transporter,6577,O
and,6577,O
Aβ,6577,B-GENE-Y
scavenger,6577,O
.,6577,O
24OHC,6578,B-CHEMICAL
itself,6578,O
was,6578,O
cytotoxic,6578,O
.,6578,O
Analysis,6579,O
of,6579,O
side,6579,O
chain,6579,O
oxysterols,6579,B-CHEMICAL
in,6579,O
the,6579,O
CSF,6579,O
is,6579,O
likely,6579,O
to,6579,O
provided,6579,O
useful,6579,O
information,6579,O
about,6579,O
cholesterol,6579,B-CHEMICAL
metabolism,6579,O
and,6579,O
ApoE,6579,B-GENE-Y
function,6579,O
in,6579,O
the,6579,O
pathogenesis,6579,O
of,6579,O
AD,6579,O
.,6579,O
Loss,6580,O
of,6580,O
Calcium/Calmodulin-Dependent,6580,B-GENE-N
Protein,6580,I-GENE-N
Kinase,6580,I-GENE-N
II,6580,I-GENE-N
Activity,6580,O
in,6580,O
Cortical,6580,O
Astrocytes,6580,O
Decreases,6580,O
Glutamate,6580,B-CHEMICAL
Uptake,6580,O
and,6580,O
Induces,6580,O
Neurotoxic,6580,O
Release,6580,O
of,6580,O
ATP,6580,B-CHEMICAL
.,6580,O
The,6581,O
extent,6581,O
of,6581,O
calcium/calmodulin-dependent,6581,B-CHEMICAL
protein,6581,I-GENE-N
kinase,6581,I-GENE-N
II,6581,I-GENE-N
(,6581,O
CaMKII,6581,B-GENE-N
),6581,O
inactivation,6581,O
in,6581,O
the,6581,O
brain,6581,O
following,6581,O
ischemia,6581,O
correlates,6581,O
with,6581,O
the,6581,O
extent,6581,O
of,6581,O
damage,6581,O
.,6581,O
We,6582,O
have,6582,O
previously,6582,O
shown,6582,O
that,6582,O
a,6582,O
loss,6582,O
of,6582,O
CaMKII,6582,B-GENE-N
activity,6582,O
in,6582,O
neurons,6582,O
is,6582,O
detrimental,6582,O
to,6582,O
neuronal,6582,O
viability,6582,O
by,6582,O
inducing,6582,O
excitotoxic,6582,O
glutamate,6582,B-CHEMICAL
release,6582,O
.,6582,O
In,6583,O
the,6583,O
current,6583,O
study,6583,O
",",6583,O
we,6583,O
extend,6583,O
these,6583,O
findings,6583,O
to,6583,O
show,6583,O
that,6583,O
the,6583,O
ability,6583,O
of,6583,O
astrocytes,6583,O
to,6583,O
buffer,6583,O
extracellular,6583,O
glutamate,6583,B-CHEMICAL
is,6583,O
reduced,6583,O
when,6583,O
CaMKII,6583,B-GENE-N
is,6583,O
inhibited,6583,O
.,6583,O
Furthermore,6584,O
",",6584,O
CaMKII,6584,B-GENE-N
inhibition,6584,O
in,6584,O
astrocytes,6584,O
is,6584,O
associated,6584,O
with,6584,O
the,6584,O
rapid,6584,O
onset,6584,O
of,6584,O
intracellular,6584,O
calcium,6584,B-CHEMICAL
oscillations,6584,O
.,6584,O
Surprisingly,6585,O
",",6585,O
this,6585,O
rapid,6585,O
calcium,6585,B-CHEMICAL
influx,6585,O
is,6585,O
blocked,6585,O
by,6585,O
the,6585,O
N-type,6585,B-GENE-N
calcium,6585,I-GENE-N
channel,6585,I-GENE-N
antagonist,6585,O
",",6585,O
omega-conotoxin,6585,B-GENE-N
.,6585,O
While,6586,O
the,6586,O
function,6586,O
of,6586,O
N-type,6586,B-GENE-N
calcium,6586,I-GENE-N
channels,6586,I-GENE-N
within,6586,O
astrocytes,6586,O
is,6586,O
controversial,6586,O
",",6586,O
these,6586,O
voltage-gated,6586,B-GENE-N
calcium,6586,I-GENE-N
channels,6586,I-GENE-N
have,6586,O
been,6586,O
linked,6586,O
to,6586,O
calcium-dependent,6586,B-CHEMICAL
vesicular,6586,O
gliotransmitter,6586,O
release,6586,O
.,6586,O
When,6587,O
extracellular,6587,O
glutamate,6587,B-CHEMICAL
and,6587,O
ATP,6587,B-CHEMICAL
levels,6587,O
are,6587,O
measured,6587,O
following,6587,O
CaMKII,6587,B-GENE-N
inhibition,6587,O
within,6587,O
our,6587,O
enriched,6587,O
astrocyte,6587,O
cultures,6587,O
",",6587,O
no,6587,O
alterations,6587,O
in,6587,O
glutamate,6587,B-CHEMICAL
levels,6587,O
are,6587,O
observed,6587,O
",",6587,O
whereas,6587,O
ATP,6587,B-CHEMICAL
levels,6587,O
in,6587,O
the,6587,O
extracellular,6587,O
environment,6587,O
significantly,6587,O
increase,6587,O
.,6587,O
Extracellular,6588,O
ATP,6588,B-CHEMICAL
accumulation,6588,O
associated,6588,O
with,6588,O
CaMKII,6588,B-GENE-N
inhibition,6588,O
contributes,6588,O
both,6588,O
to,6588,O
calcium,6588,B-CHEMICAL
oscillations,6588,O
within,6588,O
astrocytes,6588,O
and,6588,O
ultimately,6588,O
cortical,6588,O
neuron,6588,O
toxicity,6588,O
.,6588,O
Thus,6589,O
",",6589,O
a,6589,O
loss,6589,O
of,6589,O
CaMKII,6589,B-GENE-N
signaling,6589,O
within,6589,O
astrocytes,6589,O
dysregulates,6589,O
glutamate,6589,B-CHEMICAL
uptake,6589,O
and,6589,O
supports,6589,O
ATP,6589,B-CHEMICAL
release,6589,O
",",6589,O
two,6589,O
processes,6589,O
that,6589,O
would,6589,O
compromise,6589,O
neuronal,6589,O
survival,6589,O
following,6589,O
ischemic/excitotoxic,6589,O
insults,6589,O
.,6589,O
Stable,6590,O
and,6590,O
high-rate,6590,O
overcharge,6590,O
protection,6590,O
for,6590,O
rechargeable,6590,O
lithium,6590,B-CHEMICAL
batteries,6590,O
.,6590,O
Rechargeable,6591,O
lithium,6591,B-CHEMICAL
or,6591,O
lithium-ion,6591,B-CHEMICAL
cells,6591,O
can,6591,O
be,6591,O
overcharge-protected,6591,O
by,6591,O
an,6591,O
electroactive,6591,O
polymer,6591,O
composite,6591,O
separator,6591,O
.,6591,O
The,6592,O
use,6592,O
of,6592,O
non-woven,6592,O
fibrous,6592,O
membranes,6592,O
instead,6592,O
of,6592,O
conventional,6592,O
microporous,6592,O
membranes,6592,O
as,6592,O
the,6592,O
composite,6592,O
substrates,6592,O
allowed,6592,O
better,6592,O
distribution,6592,O
of,6592,O
the,6592,O
electroactive,6592,O
polymer,6592,O
",",6592,O
which,6592,O
led,6592,O
to,6592,O
improved,6592,O
utilization,6592,O
and,6592,O
a,6592,O
40-fold,6592,O
increase,6592,O
in,6592,O
sustainable,6592,O
current,6592,O
density,6592,O
.,6592,O
For,6593,O
the,6593,O
first,6593,O
time,6593,O
",",6593,O
stable,6593,O
overcharge,6593,O
protection,6593,O
for,6593,O
hundreds,6593,O
of,6593,O
cycles,6593,O
was,6593,O
demonstrated,6593,O
in,6593,O
several,6593,O
cell,6593,O
chemistries,6593,O
",",6593,O
including,6593,O
LiNi1/3Co1/3Mn1/3O2,6593,B-CHEMICAL
",",6593,O
LiFePO4,6593,B-CHEMICAL
",",6593,O
and,6593,O
spinel,6593,O
Li1.05Mn1.95O4,6593,B-CHEMICAL
half-cells,6593,O
.,6593,O
Protection,6594,O
at,6594,O
a,6594,O
charging,6594,O
rate,6594,O
as,6594,O
high,6594,O
as,6594,O
5,6594,O
C,6594,O
was,6594,O
achieved,6594,O
at,6594,O
a,6594,O
steady,6594,O
state,6594,O
cell,6594,O
potential,6594,O
below,6594,O
4.85,6594,O
V,6594,O
.,6594,O
3-Hydroxypyridin-2-thione,6595,B-CHEMICAL
as,6595,O
Novel,6595,O
Zinc,6595,B-CHEMICAL
Binding,6595,O
Group,6595,O
for,6595,O
Selective,6595,O
Histone,6595,B-GENE-N
Deacetylase,6595,I-GENE-N
Inhibition,6595,O
.,6595,O
Small,6596,O
molecules,6596,O
bearing,6596,O
hydroxamic,6596,O
acid,6596,O
as,6596,O
the,6596,O
zinc,6596,B-CHEMICAL
binding,6596,O
group,6596,O
(,6596,O
ZBG,6596,O
),6596,O
have,6596,O
been,6596,O
the,6596,O
most,6596,O
effective,6596,O
histone,6596,B-GENE-N
deacetylase,6596,I-GENE-N
inhibitors,6596,O
(,6596,O
HDACi,6596,B-GENE-N
),6596,O
to,6596,O
date,6596,O
.,6596,O
However,6597,O
",",6597,O
concerns,6597,O
about,6597,O
the,6597,O
pharmacokinetic,6597,O
liabilities,6597,O
of,6597,O
the,6597,O
hydroxamic,6597,B-CHEMICAL
acid,6597,I-CHEMICAL
moiety,6597,O
have,6597,O
stimulated,6597,O
research,6597,O
efforts,6597,O
aimed,6597,O
at,6597,O
finding,6597,O
alternative,6597,O
nonhydroxamate,6597,O
ZBGs,6597,O
.,6597,O
We,6598,O
have,6598,O
identified,6598,O
3-hydroxypyridin-2-thione,6598,B-CHEMICAL
(,6598,O
3-HPT,6598,B-CHEMICAL
),6598,O
as,6598,O
a,6598,O
novel,6598,O
ZBG,6598,O
that,6598,O
is,6598,O
compatible,6598,O
with,6598,O
HDAC,6598,B-GENE-N
inhibition,6598,O
.,6598,O
3-HPT,6599,B-CHEMICAL
inhibits,6599,O
HDAC,6599,B-GENE-Y
6,6599,I-GENE-Y
and,6599,O
HDAC,6599,B-GENE-Y
8,6599,I-GENE-Y
with,6599,O
an,6599,O
IC50,6599,O
of,6599,O
681,6599,O
and,6599,O
3675,6599,O
nM,6599,O
",",6599,O
respectively,6599,O
.,6599,O
Remarkably,6600,O
",",6600,O
3-HPT,6600,B-CHEMICAL
gives,6600,O
no,6600,O
inhibition,6600,O
of,6600,O
HDAC,6600,B-GENE-Y
1,6600,I-GENE-Y
.,6600,O
Subsequent,6601,O
optimization,6601,O
led,6601,O
to,6601,O
several,6601,O
novel,6601,O
3HPT-based,6601,B-CHEMICAL
HDACi,6601,B-GENE-N
that,6601,O
are,6601,O
selective,6601,O
for,6601,O
HDAC,6601,B-GENE-Y
6,6601,I-GENE-Y
and,6601,O
HDAC,6601,B-GENE-Y
8,6601,I-GENE-Y
.,6601,O
Furthermore,6602,O
",",6602,O
a,6602,O
subset,6602,O
of,6602,O
these,6602,O
inhibitors,6602,O
induces,6602,O
apoptosis,6602,O
in,6602,O
various,6602,O
cancer,6602,O
cell,6602,O
lines,6602,O
.,6602,O
Histological,6603,O
",",6603,O
ultrastructural,6603,O
and,6603,O
immunohistochemical,6603,O
studies,6603,O
on,6603,O
the,6603,O
protective,6603,O
effect,6603,O
of,6603,O
ginger,6603,O
extract,6603,O
against,6603,O
cisplatin-induced,6603,B-CHEMICAL
nephrotoxicity,6603,O
in,6603,O
male,6603,O
rats,6603,O
.,6603,O
Cisplatin,6604,B-CHEMICAL
(,6604,O
CP,6604,O
),6604,O
is,6604,O
a,6604,O
widely,6604,O
used,6604,O
anticancer,6604,O
drug,6604,O
;,6604,O
however,6604,O
",",6604,O
it,6604,O
has,6604,O
several,6604,O
side,6604,O
effects,6604,O
such,6604,O
as,6604,O
nephrotoxicity,6604,O
.,6604,O
Ginger,6605,O
",",6605,O
the,6605,O
rhizome,6605,O
of,6605,O
Zingiber,6605,O
officinale,6605,O
",",6605,O
consumed,6605,O
since,6605,O
ancient,6605,O
times,6605,O
has,6605,O
numerous,6605,O
health,6605,O
benefits,6605,O
.,6605,O
The,6606,O
objective,6606,O
of,6606,O
this,6606,O
work,6606,O
was,6606,O
to,6606,O
evaluate,6606,O
the,6606,O
protective,6606,O
effect,6606,O
of,6606,O
ginger,6606,O
extract,6606,O
(,6606,O
GE,6606,O
),6606,O
against,6606,O
CP-induced,6606,O
nephrotoxicity,6606,O
.,6606,O
CP,6607,O
group,6607,O
displayed,6607,O
a,6607,O
marked,6607,O
renal,6607,O
failure,6607,O
characterized,6607,O
by,6607,O
a,6607,O
significant,6607,O
increase,6607,O
in,6607,O
serum,6607,O
creatinine,6607,B-CHEMICAL
and,6607,O
blood,6607,O
urea,6607,B-CHEMICAL
nitrogen,6607,B-CHEMICAL
(,6607,O
BUN,6607,O
),6607,O
levels,6607,O
in,6607,O
addition,6607,O
to,6607,O
severe,6607,O
histopathological,6607,O
and,6607,O
ultrastructural,6607,O
renal,6607,O
alterations,6607,O
.,6607,O
Also,6608,O
",",6608,O
CP,6608,O
group,6608,O
showed,6608,O
an,6608,O
increase,6608,O
in,6608,O
the,6608,O
immunohistochemical,6608,O
expression,6608,O
of,6608,O
Bax,6608,B-GENE-Y
proapoptotic,6608,O
protein,6608,O
.,6608,O
In,6609,O
contrast,6609,O
",",6609,O
GE+CP,6609,O
group,6609,O
showed,6609,O
significant,6609,O
decrease,6609,O
in,6609,O
the,6609,O
elevated,6609,O
serum,6609,O
creatinine,6609,B-CHEMICAL
and,6609,O
BUN,6609,O
levels,6609,O
and,6609,O
an,6609,O
improvement,6609,O
in,6609,O
the,6609,O
histopathological,6609,O
and,6609,O
ultrastructural,6609,O
renal,6609,O
injury,6609,O
induced,6609,O
by,6609,O
CP,6609,O
.,6609,O
The,6610,O
overexpression,6610,O
of,6610,O
Bax,6610,B-GENE-Y
proapoptotic,6610,O
protein,6610,O
was,6610,O
significantly,6610,O
decreased,6610,O
in,6610,O
the,6610,O
GE+CP,6610,O
group,6610,O
.,6610,O
Hence,6611,O
",",6611,O
the,6611,O
present,6611,O
results,6611,O
indicated,6611,O
that,6611,O
GE,6611,O
has,6611,O
a,6611,O
protective,6611,O
effect,6611,O
against,6611,O
CP-induced,6611,O
renal,6611,O
damage,6611,O
in,6611,O
rats,6611,O
.,6611,O
Thereby,6612,O
",",6612,O
such,6612,O
findings,6612,O
recommended,6612,O
the,6612,O
usage,6612,O
of,6612,O
GE,6612,O
to,6612,O
prevent,6612,O
and/or,6612,O
decrease,6612,O
the,6612,O
renal,6612,O
damage,6612,O
induced,6612,O
by,6612,O
CP,6612,O
chemotherapeutic,6612,O
treatment,6612,O
.,6612,O
An,6613,O
analysis,6613,O
of,6613,O
skeletal,6613,O
development,6613,O
in,6613,O
osteoblast-,6613,O
and,6613,O
chondrocyte-specific,6613,O
Runx2,6613,B-GENE-Y
knockout,6613,O
mice,6613,O
.,6613,O
Global,6614,O
gene,6614,O
deletion,6614,O
studies,6614,O
in,6614,O
mice,6614,O
and,6614,O
humans,6614,O
have,6614,O
established,6614,O
the,6614,O
pivotal,6614,O
role,6614,O
of,6614,O
runt,6614,B-GENE-Y
related,6614,I-GENE-Y
transcription,6614,I-GENE-Y
factor-2,6614,I-GENE-Y
(,6614,O
Runx2,6614,B-GENE-Y
),6614,O
in,6614,O
both,6614,O
intramembranous,6614,O
and,6614,O
endochondral,6614,O
ossification,6614,O
processes,6614,O
during,6614,O
skeletogenesis,6614,O
.,6614,O
In,6615,O
this,6615,O
study,6615,O
",",6615,O
we,6615,O
for,6615,O
the,6615,O
first,6615,O
time,6615,O
generated,6615,O
mice,6615,O
carrying,6615,O
a,6615,O
conditional,6615,O
Runx2,6615,B-GENE-Y
allele,6615,O
with,6615,O
exon,6615,O
4,6615,O
",",6615,O
which,6615,O
encodes,6615,O
the,6615,O
Runt,6615,B-GENE-N
domain,6615,I-GENE-N
",",6615,O
flanked,6615,O
by,6615,O
loxP,6615,B-GENE-N
sites,6615,I-GENE-N
.,6615,O
These,6616,O
mice,6616,O
were,6616,O
crossed,6616,O
with,6616,O
α1,6616,B-GENE-Y
(,6616,I-GENE-Y
I,6616,I-GENE-Y
),6616,I-GENE-Y
-collagen-Cre,6616,O
or,6616,O
α1,6616,B-GENE-Y
(,6616,I-GENE-Y
II,6616,I-GENE-Y
),6616,I-GENE-Y
-collagen-Cre,6616,O
transgenic,6616,O
mice,6616,O
to,6616,O
obtain,6616,O
osteoblast-,6616,O
or,6616,O
chondrocyte-specific,6616,O
Runx2,6616,B-GENE-Y
deficient,6616,O
mice,6616,O
",",6616,O
respectively,6616,O
.,6616,O
As,6617,O
seen,6617,O
in,6617,O
Runx2,6617,B-GENE-Y
(,6617,O
-/-,6617,O
),6617,O
mice,6617,O
",",6617,O
perinatal,6617,O
lethality,6617,O
was,6617,O
observed,6617,O
in,6617,O
α1,6617,B-GENE-Y
(,6617,I-GENE-Y
II,6617,I-GENE-Y
),6617,I-GENE-Y
-Cre,6617,O
;,6617,O
Runx2,6617,B-GENE-Y
(,6617,O
flox/flox,6617,O
),6617,O
mice,6617,O
",",6617,O
but,6617,O
this,6617,O
was,6617,O
not,6617,O
the,6617,O
case,6617,O
in,6617,O
animals,6617,O
in,6617,O
which,6617,O
α1,6617,B-GENE-Y
(,6617,I-GENE-Y
I,6617,I-GENE-Y
),6617,I-GENE-Y
-collagen-Cre,6617,O
was,6617,O
used,6617,O
to,6617,O
delete,6617,O
Runx2,6617,B-GENE-Y
.,6617,O
When,6618,O
using,6618,O
double,6618,O
staining,6618,O
with,6618,O
Alizarin,6618,B-CHEMICAL
red,6618,I-CHEMICAL
for,6618,O
mineralized,6618,O
matrix,6618,O
and,6618,O
Alcian,6618,B-CHEMICAL
blue,6618,I-CHEMICAL
for,6618,O
cartilaginous,6618,O
matrix,6618,O
",",6618,O
we,6618,O
observed,6618,O
previously,6618,O
that,6618,O
mineralization,6618,O
was,6618,O
totally,6618,O
absent,6618,O
at,6618,O
embryonic,6618,O
day,6618,O
15.5,6618,O
throughout,6618,O
the,6618,O
body,6618,O
in,6618,O
Runx2,6618,B-GENE-Y
(,6618,O
-/-,6618,O
),6618,O
mice,6618,O
",",6618,O
but,6618,O
was,6618,O
found,6618,O
in,6618,O
areas,6618,O
undergoing,6618,O
intramembranous,6618,O
ossification,6618,O
such,6618,O
as,6618,O
skull,6618,O
and,6618,O
clavicles,6618,O
in,6618,O
α1,6618,B-GENE-Y
(,6618,I-GENE-Y
II,6618,I-GENE-Y
),6618,I-GENE-Y
-Cre,6618,O
;,6618,O
Runx2,6618,B-GENE-Y
(,6618,O
flox/flox,6618,O
),6618,O
mice,6618,O
.,6618,O
In,6619,O
newborn,6619,O
α1,6619,B-GENE-Y
(,6619,I-GENE-Y
II,6619,I-GENE-Y
),6619,I-GENE-Y
-Cre,6619,O
;,6619,O
Runx2,6619,B-GENE-Y
(,6619,O
flox/flox,6619,O
),6619,O
mice,6619,O
",",6619,O
mineralization,6619,O
impairment,6619,O
was,6619,O
restricted,6619,O
to,6619,O
skeletal,6619,O
areas,6619,O
undergoing,6619,O
endochondral,6619,O
ossification,6619,O
including,6619,O
long,6619,O
bones,6619,O
and,6619,O
vertebrae,6619,O
.,6619,O
In,6620,O
contrast,6620,O
",",6620,O
no,6620,O
apparent,6620,O
skeletal,6620,O
abnormalities,6620,O
were,6620,O
seen,6620,O
in,6620,O
mutant,6620,O
embryo,6620,O
",",6620,O
newborn,6620,O
",",6620,O
and,6620,O
3-,6620,O
to,6620,O
6-week,6620,O
old-mice,6620,O
in,6620,O
which,6620,O
Runx2,6620,B-GENE-Y
had,6620,O
been,6620,O
deleted,6620,O
with,6620,O
the,6620,O
α1,6620,B-GENE-Y
(,6620,I-GENE-Y
I,6620,I-GENE-Y
),6620,I-GENE-Y
-collagen-Cre,6620,O
driver,6620,O
.,6620,O
These,6621,O
results,6621,O
suggest,6621,O
that,6621,O
Runx2,6621,B-GENE-Y
is,6621,O
absolutely,6621,O
required,6621,O
for,6621,O
endochondral,6621,O
ossification,6621,O
during,6621,O
embryonic,6621,O
and,6621,O
postnatal,6621,O
skeletogenesis,6621,O
",",6621,O
but,6621,O
that,6621,O
disrupting,6621,O
its,6621,O
expression,6621,O
in,6621,O
already,6621,O
committed,6621,O
osteoblasts,6621,O
as,6621,O
achieved,6621,O
here,6621,O
with,6621,O
the,6621,O
α1,6621,B-GENE-Y
(,6621,I-GENE-Y
I,6621,I-GENE-Y
),6621,I-GENE-Y
-collagen-Cre,6621,O
driver,6621,O
does,6621,O
not,6621,O
affect,6621,O
overtly,6621,O
intramembranous,6621,O
and,6621,O
endochondral,6621,O
ossification,6621,O
.,6621,O
The,6622,O
Runx2,6622,B-GENE-Y
floxed,6622,O
allele,6622,O
established,6622,O
here,6622,O
is,6622,O
undoubtedly,6622,O
useful,6622,O
for,6622,O
investigating,6622,O
the,6622,O
role,6622,O
of,6622,O
Runx2,6622,B-GENE-Y
in,6622,O
particular,6622,O
cells,6622,O
.,6622,O
©,6623,O
2013,6623,O
American,6623,O
Society,6623,O
for,6623,O
Bone,6623,O
and,6623,O
Mineral,6623,O
Research,6623,O
.,6623,O
A,6624,O
Mineral,6624,O
Extract,6624,O
from,6624,O
red,6624,O
Algae,6624,O
Ameliorates,6624,O
Chronic,6624,O
Spontaneous,6624,O
Colitis,6624,O
in,6624,O
IL-10,6624,B-GENE-Y
Deficient,6624,O
Mice,6624,O
in,6624,O
a,6624,O
Mouse,6624,O
Strain,6624,O
Dependent,6624,O
Manner,6624,O
.,6624,O
Inflammatory,6625,O
bowel,6625,O
disease,6625,O
is,6625,O
an,6625,O
urgent,6625,O
public,6625,O
health,6625,O
problem,6625,O
with,6625,O
a,6625,O
high,6625,O
incidence,6625,O
in,6625,O
developed,6625,O
countries,6625,O
.,6625,O
Alterations,6626,O
of,6626,O
lifestyle,6626,O
or,6626,O
dietary,6626,O
interventions,6626,O
may,6626,O
attenuate,6626,O
the,6626,O
disease,6626,O
progression,6626,O
and,6626,O
increase,6626,O
the,6626,O
efficacy,6626,O
of,6626,O
current,6626,O
therapies,6626,O
.,6626,O
Here,6627,O
we,6627,O
tested,6627,O
the,6627,O
effect,6627,O
of,6627,O
chronic,6627,O
supplementation,6627,O
with,6627,O
a,6627,O
mineral,6627,O
extract,6627,O
from,6627,O
red,6627,O
marine,6627,O
algae,6627,O
-,6627,O
rich,6627,O
in,6627,O
calcium,6627,B-CHEMICAL
(,6627,O
34,6627,O
%,6627,O
),6627,O
",",6627,O
magnesium,6627,B-CHEMICAL
",",6627,O
phosphorus,6627,B-CHEMICAL
",",6627,O
selenium,6627,B-CHEMICAL
and,6627,O
other,6627,O
trace,6627,O
minerals,6627,O
-,6627,O
in,6627,O
a,6627,O
clinically,6627,O
relevant,6627,O
model,6627,O
of,6627,O
spontaneous,6627,O
enterocolitis,6627,O
",",6627,O
interleukin,6627,B-GENE-Y
(,6627,I-GENE-Y
IL,6627,I-GENE-Y
),6627,I-GENE-Y
-10,6627,I-GENE-Y
(,6627,O
-/-,6627,O
),6627,O
mice,6627,O
.,6627,O
The,6628,O
mineral,6628,O
extract,6628,O
was,6628,O
administered,6628,O
in,6628,O
the,6628,O
drinking,6628,O
water,6628,O
of,6628,O
Il10,6628,B-GENE-Y
(,6628,O
-/-,6628,O
),6628,O
mice,6628,O
on,6628,O
C57BL/6,6628,O
J,6628,O
and,6628,O
BALB/c,6628,O
strain,6628,O
backgrounds,6628,O
for,6628,O
25,6628,O
weeks,6628,O
commencing,6628,O
from,6628,O
3,6628,O
to,6628,O
4,6628,O
weeks,6628,O
of,6628,O
age,6628,O
.,6628,O
The,6629,O
mineral,6629,O
extract,6629,O
ameliorated,6629,O
the,6629,O
spontaneous,6629,O
development,6629,O
of,6629,O
colitis,6629,O
and,6629,O
severity,6629,O
of,6629,O
disease,6629,O
in,6629,O
Il10,6629,B-GENE-Y
(,6629,O
-/-,6629,O
),6629,O
mice,6629,O
on,6629,O
a,6629,O
C57BL/6,6629,O
J,6629,O
background,6629,O
.,6629,O
Mineral,6630,O
extract-treated,6630,O
Il10,6630,B-GENE-Y
(,6630,O
-/-,6630,O
),6630,O
C57BL/6,6630,O
J,6630,O
strain,6630,O
mice,6630,O
had,6630,O
significantly,6630,O
reduced,6630,O
mortality,6630,O
",",6630,O
circulating,6630,O
levels,6630,O
of,6630,O
serum,6630,B-GENE-N
Amyloid,6630,I-GENE-N
A,6630,I-GENE-N
and,6630,O
reduced,6630,O
colonic,6630,O
tissue,6630,O
damage,6630,O
.,6630,O
In,6631,O
contrast,6631,O
",",6631,O
comparable,6631,O
treatment,6631,O
of,6631,O
Il10,6631,B-GENE-Y
(,6631,O
-/-,6631,O
),6631,O
mice,6631,O
on,6631,O
a,6631,O
BALB/c,6631,O
background,6631,O
with,6631,O
the,6631,O
mineral,6631,O
extract,6631,O
did,6631,O
not,6631,O
alter,6631,O
the,6631,O
course,6631,O
of,6631,O
colitis,6631,O
.,6631,O
These,6632,O
data,6632,O
demonstrate,6632,O
that,6632,O
chronic,6632,O
supplementation,6632,O
with,6632,O
a,6632,O
natural,6632,O
mineral,6632,O
extract,6632,O
selectively,6632,O
ameliorates,6632,O
spontaneous,6632,O
mild-moderate,6632,O
colitis,6632,O
in,6632,O
Il10,6632,B-GENE-Y
(,6632,O
-/-,6632,O
),6632,O
mice,6632,O
on,6632,O
a,6632,O
C57BL/6,6632,O
J,6632,O
",",6632,O
but,6632,O
does,6632,O
not,6632,O
attenuate,6632,O
more,6632,O
moderate-severe,6632,O
colitis,6632,O
in,6632,O
BALB/c,6632,O
strain,6632,O
animals,6632,O
.,6632,O
Copyright,6633,O
©,6633,O
2013,6633,O
John,6633,O
Wiley,6633,O
&,6633,O
Sons,6633,O
",",6633,O
Ltd,6633,O
.,6633,O
Neuronal,6634,O
expression,6634,O
of,6634,O
glucosylceramide,6634,B-CHEMICAL
synthase,6634,I-GENE-Y
in,6634,O
central,6634,O
nervous,6634,O
system,6634,O
regulates,6634,O
body,6634,O
weight,6634,O
and,6634,O
energy,6634,O
homeostasis,6634,O
.,6634,O
Hypothalamic,6635,O
neurons,6635,O
are,6635,O
main,6635,O
regulators,6635,O
of,6635,O
energy,6635,O
homeostasis,6635,O
.,6635,O
Neuronal,6636,O
function,6636,O
essentially,6636,O
depends,6636,O
on,6636,O
plasma,6636,O
membrane-located,6636,O
gangliosides,6636,O
.,6636,O
The,6637,O
present,6637,O
work,6637,O
demonstrates,6637,O
that,6637,O
hypothalamic,6637,O
integration,6637,O
of,6637,O
metabolic,6637,O
signals,6637,O
requires,6637,O
neuronal,6637,O
expression,6637,O
of,6637,O
glucosylceramide,6637,B-GENE-Y
synthase,6637,I-GENE-Y
(,6637,O
GCS,6637,B-GENE-Y
;,6637,O
UDP-glucose,6637,B-CHEMICAL
:,6637,I-GENE-Y
ceramide,6637,B-CHEMICAL
glucosyltransferase,6637,I-GENE-Y
),6637,O
.,6637,O
As,6638,O
a,6638,O
major,6638,O
mechanism,6638,O
of,6638,O
central,6638,O
nervous,6638,O
system,6638,O
(,6638,O
CNS,6638,O
),6638,O
metabolic,6638,O
control,6638,O
",",6638,O
we,6638,O
demonstrate,6638,O
that,6638,O
GCS-derived,6638,B-GENE-Y
gangliosides,6638,O
interacting,6638,O
with,6638,O
leptin,6638,B-GENE-Y
receptors,6638,I-GENE-Y
(,6638,O
ObR,6638,B-GENE-Y
),6638,O
in,6638,O
the,6638,O
neuronal,6638,O
membrane,6638,O
modulate,6638,O
leptin-stimulated,6638,B-GENE-Y
formation,6638,O
of,6638,O
signaling,6638,O
metabolites,6638,O
in,6638,O
hypothalamic,6638,O
neurons,6638,O
.,6638,O
Furthermore,6639,O
",",6639,O
ganglioside-depleted,6639,O
hypothalamic,6639,O
neurons,6639,O
fail,6639,O
to,6639,O
adapt,6639,O
their,6639,O
activity,6639,O
(,6639,O
c-Fos,6639,B-GENE-Y
),6639,O
in,6639,O
response,6639,O
to,6639,O
alterations,6639,O
in,6639,O
peripheral,6639,O
energy,6639,O
signals,6639,O
.,6639,O
Consequently,6640,O
",",6640,O
mice,6640,O
with,6640,O
inducible,6640,O
forebrain,6640,O
neuron-specific,6640,O
deletion,6640,O
of,6640,O
the,6640,O
UDP-glucose,6640,B-CHEMICAL
:,6640,I-GENE-Y
ceramide,6640,B-CHEMICAL
glucosyltransferase,6640,I-GENE-Y
gene,6640,O
(,6640,O
Ugcg,6640,B-GENE-Y
),6640,O
display,6640,O
obesity,6640,O
",",6640,O
hypothermia,6640,O
",",6640,O
and,6640,O
lower,6640,O
sympathetic,6640,O
activity,6640,O
.,6640,O
Recombinant,6641,O
adeno-associated,6641,O
virus,6641,O
(,6641,O
rAAV,6641,O
),6641,O
-mediated,6641,O
Ugcg,6641,B-GENE-Y
delivery,6641,O
to,6641,O
the,6641,O
arcuate,6641,O
nucleus,6641,O
(,6641,O
Arc,6641,O
),6641,O
significantly,6641,O
ameliorated,6641,O
obesity,6641,O
",",6641,O
specifying,6641,O
gangliosides,6641,O
as,6641,O
seminal,6641,O
components,6641,O
for,6641,O
hypothalamic,6641,O
regulation,6641,O
of,6641,O
body,6641,O
energy,6641,O
homeostasis,6641,O
.,6641,O
Environmental,6642,O
pesticide,6642,O
exposure,6642,O
modulates,6642,O
cytokines,6642,B-GENE-N
",",6642,O
arginase,6642,B-GENE-N
and,6642,O
ornithine,6642,B-CHEMICAL
decarboxylase,6642,I-GENE-Y
expression,6642,O
in,6642,O
human,6642,O
placenta,6642,O
.,6642,O
To,6643,O
evaluate,6643,O
the,6643,O
cytokine,6643,B-GENE-N
balance,6643,O
and,6643,O
enzymatic,6643,O
alterations,6643,O
induced,6643,O
by,6643,O
environmental,6643,O
pesticide,6643,O
exposure,6643,O
during,6643,O
pregnancy,6643,O
",",6643,O
this,6643,O
transversal,6643,O
study,6643,O
explored,6643,O
placentas,6643,O
derived,6643,O
from,6643,O
non-exposed,6643,O
women,6643,O
(,6643,O
control,6643,O
group-CG,6643,O
),6643,O
",",6643,O
and,6643,O
from,6643,O
women,6643,O
living,6643,O
in,6643,O
a,6643,O
rural,6643,O
area,6643,O
(,6643,O
rural,6643,O
group-RG,6643,O
),6643,O
",",6643,O
collected,6643,O
during,6643,O
intensive,6643,O
organophosphate,6643,B-CHEMICAL
(,6643,O
OP,6643,O
),6643,O
pesticide,6643,O
spraying,6643,O
season,6643,O
(,6643,O
RG-SS,6643,O
),6643,O
and,6643,O
during,6643,O
non-spraying,6643,O
season,6643,O
(,6643,O
RG-NSS,6643,O
),6643,O
.,6643,O
The,6644,O
exposure,6644,O
biomarkers,6644,O
blood,6644,O
cholinesterase,6644,B-GENE-Y
and,6644,O
placental,6644,O
carboxylesterase,6644,B-GENE-N
(,6644,O
CaE,6644,B-GENE-N
),6644,O
were,6644,O
significantly,6644,O
decreased,6644,O
in,6644,O
RG-SS,6644,O
.,6644,O
Among,6645,O
the,6645,O
cytokines,6645,B-GENE-N
studied,6645,O
IL-8,6645,B-GENE-Y
",",6645,O
IL-6,6645,B-GENE-Y
",",6645,O
TNFα,6645,B-GENE-Y
",",6645,O
IL-10,6645,B-GENE-Y
",",6645,O
TGFβ,6645,B-GENE-Y
and,6645,O
IL-13,6645,B-GENE-Y
",",6645,O
the,6645,O
expression,6645,O
frequency,6645,O
of,6645,O
IL-13,6645,B-GENE-Y
increased,6645,O
in,6645,O
RG-SS,6645,O
.,6645,O
Arginase,6646,B-GENE-N
and,6646,O
ornithine,6646,B-CHEMICAL
decarboxylase,6646,I-GENE-Y
(,6646,O
ODC,6646,B-GENE-Y
),6646,O
enzymes,6646,O
were,6646,O
induced,6646,O
in,6646,O
syncytiotrophoblast,6646,O
and,6646,O
endothelial,6646,O
cells,6646,O
.,6646,O
Interestingly,6647,O
",",6647,O
the,6647,O
decrease,6647,O
in,6647,O
CaE,6647,B-GENE-N
activity,6647,O
was,6647,O
associated,6647,O
with,6647,O
arginase,6647,O
and,6647,O
ODC,6647,B-GENE-Y
activity,6647,O
induction,6647,O
.,6647,O
These,6648,O
findings,6648,O
suggest,6648,O
that,6648,O
environmental,6648,O
pesticide,6648,O
exposure,6648,O
impacts,6648,O
the,6648,O
placenta,6648,O
by,6648,O
increasing,6648,O
the,6648,O
expression,6648,O
frequency,6648,O
of,6648,O
the,6648,O
anti-inflammatory,6648,O
cytokine,6648,B-GENE-N
IL-13,6648,B-GENE-Y
",",6648,O
which,6648,O
may,6648,O
be,6648,O
related,6648,O
to,6648,O
the,6648,O
up-regulation,6648,O
of,6648,O
enzymes,6648,O
implicated,6648,O
in,6648,O
tissue,6648,O
repair,6648,O
.,6648,O
Lixisenatide,6649,O
:,6649,O
first,6649,O
global,6649,O
approval,6649,O
.,6649,O
The,6650,O
selective,6650,O
once-daily,6650,O
prandial,6650,O
glucagon-like,6650,B-GENE-Y
peptide-1,6650,I-GENE-Y
(,6650,I-GENE-Y
GLP-1,6650,I-GENE-Y
),6650,I-GENE-Y
receptor,6650,I-GENE-Y
agonist,6650,O
lixisenatide,6650,O
(,6650,O
Lyxumia,6650,O
(,6650,O
®,6650,O
),6650,O
),6650,O
is,6650,O
under,6650,O
development,6650,O
with,6650,O
Sanofi,6650,O
for,6650,O
the,6650,O
treatment,6650,O
of,6650,O
type,6650,O
2,6650,O
diabetes,6650,O
mellitus,6650,O
.,6650,O
Lixisenatide,6651,O
belongs,6651,O
to,6651,O
a,6651,O
class,6651,O
of,6651,O
GLP-1,6651,B-GENE-Y
compounds,6651,O
designed,6651,O
to,6651,O
mimic,6651,O
the,6651,O
endogenous,6651,O
hormone,6651,O
GLP-1,6651,B-GENE-Y
.,6651,O
Native,6652,O
GLP-1,6652,B-GENE-Y
stimulates,6652,O
insulin,6652,B-GENE-Y
secretion,6652,O
in,6652,O
a,6652,O
glucose-dependent,6652,B-CHEMICAL
manner,6652,O
",",6652,O
as,6652,O
well,6652,O
as,6652,O
suppressing,6652,O
glucagon,6652,B-GENE-Y
production,6652,O
and,6652,O
slowing,6652,O
gastric,6652,O
emptying,6652,O
.,6652,O
A,6653,O
once-daily,6653,O
subcutaneous,6653,O
formulation,6653,O
of,6653,O
lixisenatide,6653,O
has,6653,O
been,6653,O
approved,6653,O
in,6653,O
the,6653,O
EU,6653,O
",",6653,O
Iceland,6653,O
",",6653,O
Liechtenstein,6653,O
",",6653,O
Norway,6653,O
and,6653,O
Mexico,6653,O
for,6653,O
the,6653,O
treatment,6653,O
of,6653,O
type,6653,O
2,6653,O
diabetes,6653,O
",",6653,O
and,6653,O
is,6653,O
under,6653,O
regulatory,6653,O
review,6653,O
in,6653,O
the,6653,O
USA,6653,O
",",6653,O
Switzerland,6653,O
",",6653,O
Brazil,6653,O
",",6653,O
Canada,6653,O
",",6653,O
Ukraine,6653,O
",",6653,O
South,6653,O
Africa,6653,O
",",6653,O
Japan,6653,O
and,6653,O
Australia,6653,O
.,6653,O
This,6654,O
article,6654,O
summarizes,6654,O
the,6654,O
milestones,6654,O
in,6654,O
the,6654,O
development,6654,O
of,6654,O
lixisenatide,6654,O
",",6654,O
leading,6654,O
to,6654,O
this,6654,O
first,6654,O
approval,6654,O
for,6654,O
use,6654,O
in,6654,O
adults,6654,O
with,6654,O
type,6654,O
2,6654,O
diabetes,6654,O
.,6654,O
Maqui,6655,O
berry,6655,O
(,6655,O
Aristotelia,6655,O
chilensis,6655,O
),6655,O
and,6655,O
the,6655,O
constituent,6655,O
delphinidin,6655,B-CHEMICAL
glycoside,6655,I-CHEMICAL
inhibit,6655,O
photoreceptor,6655,B-GENE-N
cell,6655,O
death,6655,O
induced,6655,O
by,6655,O
visible,6655,O
light,6655,O
.,6655,O
The,6656,O
protective,6656,O
effects,6656,O
of,6656,O
maqui,6656,O
berry,6656,O
(,6656,O
Aristotelia,6656,O
chilensis,6656,O
),6656,O
extract,6656,O
(,6656,O
MBE,6656,O
),6656,O
and,6656,O
its,6656,O
major,6656,O
anthocyanins,6656,B-CHEMICAL
[,6656,O
delphinidin,6656,B-CHEMICAL
"3,5-O-diglucoside",6656,I-CHEMICAL
(,6656,O
D3G5G,6656,B-CHEMICAL
),6656,O
and,6656,O
delphinidin,6656,B-CHEMICAL
3-O-sambubioside-5-O-glucoside,6656,I-CHEMICAL
(,6656,O
D3S5G,6656,B-CHEMICAL
),6656,O
],6656,O
against,6656,O
light-induced,6656,O
murine,6656,O
photoreceptor,6656,O
cells,6656,O
(,6656,O
661W,6656,O
),6656,O
death,6656,O
were,6656,O
evaluated,6656,O
.,6656,O
Viability,6657,O
of,6657,O
661W,6657,O
after,6657,O
light,6657,O
treatment,6657,O
for,6657,O
24h,6657,O
",",6657,O
assessed,6657,O
by,6657,O
the,6657,O
tetrazolium,6657,B-CHEMICAL
salt,6657,O
(,6657,O
WST-8,6657,O
),6657,O
assay,6657,O
and,6657,O
Hoechst,6657,B-CHEMICAL
33342,6657,I-CHEMICAL
nuclear,6657,O
staining,6657,O
",",6657,O
was,6657,O
improved,6657,O
by,6657,O
addition,6657,O
of,6657,O
MBE,6657,O
",",6657,O
D3G5G,6657,B-CHEMICAL
",",6657,O
and,6657,O
D3S5G,6657,B-CHEMICAL
.,6657,O
Intracellular,6658,O
radical,6658,O
activation,6658,O
in,6658,O
661W,6658,O
",",6658,O
evaluated,6658,O
using,6658,O
the,6658,O
reactive,6658,O
oxygen,6658,B-CHEMICAL
species,6658,O
(,6658,O
ROS,6658,O
),6658,O
-sensitive,6658,O
probe,6658,O
5-,6658,B-CHEMICAL
(,6658,I-CHEMICAL
and-6,6658,I-CHEMICAL
),6658,I-CHEMICAL
"-chloromethyl-2,7-dichlorodihydro",6658,I-CHEMICAL
fluorescein,6658,I-CHEMICAL
diacetate,6658,I-CHEMICAL
acetyl,6658,I-CHEMICAL
ester,6658,I-CHEMICAL
(,6658,O
CM-H2DCFDA,6658,B-CHEMICAL
),6658,O
",",6658,O
was,6658,O
reduced,6658,O
by,6658,O
MBE,6658,O
and,6658,O
its,6658,O
anthocyanins,6658,B-CHEMICAL
.,6658,O
The,6659,O
anti-apoptosis,6659,O
mechanism,6659,O
of,6659,O
MBE,6659,O
was,6659,O
evaluated,6659,O
by,6659,O
light-induced,6659,O
phosphorylation,6659,O
of,6659,O
p38,6659,B-GENE-N
.,6659,O
MBE,6660,O
significantly,6660,O
suppressed,6660,O
the,6660,O
light-induced,6660,O
phosphorylation,6660,O
of,6660,O
p38,6660,B-GENE-N
.,6660,O
These,6661,O
findings,6661,O
indicate,6661,O
that,6661,O
MBE,6661,O
and,6661,O
its,6661,O
anthocyanidins,6661,B-CHEMICAL
suppress,6661,O
the,6661,O
light-induced,6661,O
photoreceptor,6661,O
cell,6661,O
death,6661,O
by,6661,O
inhibiting,6661,O
ROS,6661,O
production,6661,O
",",6661,O
suggesting,6661,O
that,6661,O
the,6661,O
inhibition,6661,O
of,6661,O
phosphorylated-p38,6661,B-GENE-N
may,6661,O
be,6661,O
involved,6661,O
in,6661,O
the,6661,O
underlying,6661,O
mechanism,6661,O
.,6661,O
Influence,6662,O
of,6662,O
triterpenoids,6662,B-CHEMICAL
present,6662,O
in,6662,O
apple,6662,O
peel,6662,O
on,6662,O
inflammatory,6662,O
gene,6662,O
expression,6662,O
associated,6662,O
with,6662,O
inflammatory,6662,O
bowel,6662,O
disease,6662,O
(,6662,O
IBD,6662,O
),6662,O
.,6662,O
Various,6663,O
ursanic,6663,B-CHEMICAL
",",6663,I-CHEMICAL
oleanic,6663,I-CHEMICAL
and,6663,I-CHEMICAL
lupanic,6663,I-CHEMICAL
pentacyclic,6663,I-CHEMICAL
triterpenoids,6663,I-CHEMICAL
found,6663,O
in,6663,O
apple,6663,O
peel,6663,O
were,6663,O
studied,6663,O
for,6663,O
anti-inflammatory,6663,O
effects,6663,O
in,6663,O
vitro,6663,O
using,6663,O
T84,6663,O
colon,6663,O
carcinoma,6663,O
cells,6663,O
.,6663,O
After,6664,O
pretreatment,6664,O
with,6664,O
single,6664,O
triterpenoids,6664,B-CHEMICAL
",",6664,O
cells,6664,O
were,6664,O
stimulated,6664,O
with,6664,O
pro-inflammatory,6664,O
cytokines,6664,B-GENE-N
(,6664,O
TNF-α,6664,B-GENE-Y
",",6664,O
INF-γ,6664,B-GENE-Y
",",6664,O
IL-1β,6664,B-GENE-Y
),6664,O
.,6664,O
Regulation,6665,O
of,6665,O
mRNA,6665,O
expression,6665,O
was,6665,O
analysed,6665,O
for,6665,O
three,6665,O
specific,6665,O
inflammation-associated,6665,O
marker,6665,O
genes,6665,O
(,6665,O
TNF-α,6665,B-GENE-Y
",",6665,O
IL-8,6665,B-GENE-Y
",",6665,O
IP-10,6665,B-GENE-Y
),6665,O
using,6665,O
qRT-PCR,6665,O
.,6665,O
Furthermore,6666,O
",",6666,O
the,6666,O
effects,6666,O
of,6666,O
ursolic,6666,B-CHEMICAL
acid,6666,I-CHEMICAL
(,6666,O
UA,6666,O
),6666,O
and,6666,O
oleanolic,6666,B-CHEMICAL
acid,6666,I-CHEMICAL
(,6666,O
OA,6666,O
),6666,O
on,6666,O
the,6666,O
synthesis,6666,O
of,6666,O
certain,6666,O
pro-inflammatory,6666,O
proteins,6666,O
were,6666,O
examined,6666,O
.,6666,O
IP-10,6667,B-GENE-Y
expression,6667,O
was,6667,O
inhibited,6667,O
in,6667,O
a,6667,O
dose-dependent,6667,O
manner,6667,O
by,6667,O
all,6667,O
the,6667,O
tested,6667,O
compounds,6667,O
at,6667,O
concentrations,6667,O
⩾25μM,6667,O
.,6667,O
The,6668,O
mRNA,6668,O
expression,6668,O
of,6668,O
TNF-α,6668,B-GENE-Y
was,6668,O
slightly,6668,O
affected,6668,O
and,6668,O
the,6668,O
IL-8,6668,B-GENE-Y
level,6668,O
was,6668,O
increased,6668,O
.,6668,O
At,6669,O
the,6669,O
protein,6669,O
level,6669,O
",",6669,O
UA,6669,O
and,6669,O
OA,6669,O
(,6669,O
25μM,6669,O
),6669,O
reduced,6669,O
the,6669,O
synthesis,6669,O
of,6669,O
IP-10,6669,B-GENE-Y
;,6669,O
sICAM-1,6669,B-GENE-Y
",",6669,O
IL-23,6669,B-GENE-Y
and,6669,O
GROα,6669,B-GENE-Y
were,6669,O
slightly,6669,O
repressed,6669,O
.,6669,O
The,6670,O
TNF-α,6670,B-GENE-Y
level,6670,O
was,6670,O
not,6670,O
modulated,6670,O
",",6670,O
whereas,6670,O
induction,6670,O
of,6670,O
IL-8,6670,B-GENE-Y
was,6670,O
increased,6670,O
.,6670,O
UA,6671,O
also,6671,O
enhanced,6671,O
the,6671,O
synthesis,6671,O
of,6671,O
IL-1ra,6671,B-GENE-Y
",",6671,O
while,6671,O
OA,6671,O
suppressed,6671,O
the,6671,O
level,6671,O
of,6671,O
I-TAC,6671,B-GENE-Y
.,6671,O
The,6672,O
present,6672,O
study,6672,O
confirms,6672,O
that,6672,O
triterpenoids,6672,B-CHEMICAL
present,6672,O
in,6672,O
apple,6672,O
peel,6672,O
and,6672,O
β-damascone,6672,B-CHEMICAL
may,6672,O
be,6672,O
implicated,6672,O
in,6672,O
the,6672,O
anti-inflammatory,6672,O
properties,6672,O
of,6672,O
apple,6672,O
constituents,6672,O
",",6672,O
suggesting,6672,O
that,6672,O
these,6672,O
substances,6672,O
might,6672,O
be,6672,O
helpful,6672,O
in,6672,O
the,6672,O
treatment,6672,O
of,6672,O
IBD,6672,O
as,6672,O
nutrient,6672,O
supplements,6672,O
.,6672,O
Curcumin,6673,B-CHEMICAL
inhibits,6673,O
invasion,6673,O
and,6673,O
metastasis,6673,O
in,6673,O
K1,6673,O
papillary,6673,O
thyroid,6673,O
cancer,6673,O
cells,6673,O
.,6673,O
Curcumin,6674,B-CHEMICAL
",",6674,O
the,6674,O
active,6674,O
constituent,6674,O
of,6674,O
dietary,6674,O
spice,6674,O
turmeric,6674,O
",",6674,O
possesses,6674,O
a,6674,O
strong,6674,O
potential,6674,O
for,6674,O
cancer,6674,O
prevention,6674,O
and,6674,O
treatment,6674,O
.,6674,O
However,6675,O
",",6675,O
there,6675,O
is,6675,O
no,6675,O
study,6675,O
to,6675,O
address,6675,O
the,6675,O
effects,6675,O
of,6675,O
curcumin,6675,B-CHEMICAL
on,6675,O
invasion,6675,O
and,6675,O
metastasis,6675,O
of,6675,O
thyroid,6675,O
cancers,6675,O
.,6675,O
Thyroid,6676,O
cancer,6676,O
is,6676,O
the,6676,O
most,6676,O
common,6676,O
malignancy,6676,O
of,6676,O
endocrine,6676,O
organs,6676,O
",",6676,O
and,6676,O
its,6676,O
incidence,6676,O
rates,6676,O
have,6676,O
steadily,6676,O
increased,6676,O
over,6676,O
recent,6676,O
decades,6676,O
.,6676,O
Although,6677,O
most,6677,O
indolent,6677,O
tumours,6677,O
can,6677,O
be,6677,O
effectively,6677,O
managed,6677,O
",",6677,O
metastatic,6677,O
tumours,6677,O
at,6677,O
distant,6677,O
secondary,6677,O
sites,6677,O
behave,6677,O
aggressively,6677,O
and,6677,O
currently,6677,O
there,6677,O
is,6677,O
no,6677,O
effective,6677,O
form,6677,O
of,6677,O
treatment,6677,O
.,6677,O
Here,6678,O
",",6678,O
for,6678,O
the,6678,O
first,6678,O
time,6678,O
it,6678,O
has,6678,O
been,6678,O
reported,6678,O
that,6678,O
curcumin,6678,B-CHEMICAL
inhibit,6678,O
multiple,6678,O
metastasis,6678,O
steps,6678,O
of,6678,O
K1,6678,O
papillary,6678,O
thyroid,6678,O
cancer,6678,O
cells,6678,O
.,6678,O
Curcumin,6679,B-CHEMICAL
dose-dependently,6679,O
suppressed,6679,O
viability,6679,O
of,6679,O
K1,6679,O
cells,6679,O
as,6679,O
well,6679,O
as,6679,O
its,6679,O
cell,6679,O
attachment,6679,O
",",6679,O
spreading,6679,O
",",6679,O
migration,6679,O
and,6679,O
invasion,6679,O
abilities,6679,O
.,6679,O
Moreover,6680,O
",",6680,O
curcumin,6680,B-CHEMICAL
could,6680,O
also,6680,O
down-regulate,6680,O
the,6680,O
expression,6680,O
and,6680,O
activity,6680,O
of,6680,O
matrix,6680,B-GENE-Y
metalloproteinase-9,6680,I-GENE-Y
(,6680,O
MMP-9,6680,B-GENE-Y
),6680,O
.,6680,O
The,6681,O
findings,6681,O
showed,6681,O
that,6681,O
curcumin,6681,B-CHEMICAL
might,6681,O
be,6681,O
an,6681,O
effective,6681,O
tumouristatic,6681,O
agent,6681,O
for,6681,O
the,6681,O
treatment,6681,O
of,6681,O
aggressive,6681,O
papillary,6681,O
thyroid,6681,O
carcinomas,6681,O
.,6681,O
Lignans,6682,B-CHEMICAL
extracted,6682,O
from,6682,O
Vitex,6682,O
negundo,6682,O
possess,6682,O
cytotoxic,6682,O
activity,6682,O
by,6682,O
G2/M,6682,O
phase,6682,O
cell,6682,O
cycle,6682,O
arrest,6682,O
and,6682,O
apoptosis,6682,O
induction,6682,O
.,6682,O
Evn-50,6683,B-CHEMICAL
is,6683,O
a,6683,O
lignan,6683,B-CHEMICAL
compounds,6683,O
mixture,6683,O
extracted,6683,O
from,6683,O
Vitex,6683,O
negundo,6683,O
",",6683,O
a,6683,O
widely,6683,O
used,6683,O
herb,6683,O
in,6683,O
traditional,6683,O
Chinese,6683,O
medicine,6683,O
.,6683,O
This,6684,O
study,6684,O
is,6684,O
aimed,6684,O
to,6684,O
define,6684,O
the,6684,O
spectrum,6684,O
of,6684,O
cytotoxic,6684,O
activity,6684,O
of,6684,O
EVn-50,6684,B-CHEMICAL
",",6684,O
and,6684,O
also,6684,O
to,6684,O
investigate,6684,O
mechanisms,6684,O
underlying,6684,O
the,6684,O
anticancer,6684,O
actions,6684,O
via,6684,O
assessing,6684,O
the,6684,O
influence,6684,O
on,6684,O
cell,6684,O
cycle,6684,O
using,6684,O
EVn-50,6684,B-CHEMICAL
",",6684,O
and,6684,O
the,6684,O
lignan,6684,B-CHEMICAL
compound,6684,O
VB1,6684,B-CHEMICAL
purified,6684,O
from,6684,O
EVn-50,6684,B-CHEMICAL
.,6684,O
The,6685,O
cytotoxic,6685,O
effect,6685,O
of,6685,O
EVn-50,6685,B-CHEMICAL
and,6685,O
VB1,6685,B-CHEMICAL
was,6685,O
determined,6685,O
with,6685,O
SRB,6685,O
assay,6685,O
using,6685,O
a,6685,O
panel,6685,O
of,6685,O
cancer,6685,O
cell,6685,O
lines,6685,O
.,6685,O
Breast,6686,O
cancer,6686,O
cell,6686,O
line,6686,O
MDA-MB-435,6686,O
and,6686,O
liver,6686,O
cancer,6686,O
cell,6686,O
line,6686,O
SMMC-7721,6686,O
were,6686,O
selected,6686,O
for,6686,O
further,6686,O
evaluating,6686,O
the,6686,O
effect,6686,O
of,6686,O
EVn-50,6686,B-CHEMICAL
or,6686,O
VB1,6686,B-CHEMICAL
on,6686,O
cell,6686,O
cycle,6686,O
by,6686,O
flow,6686,O
cytometric,6686,O
analysis,6686,O
.,6686,O
Apoptosis,6687,O
exerted,6687,O
by,6687,O
EVn-50,6687,B-CHEMICAL
or,6687,O
VB1,6687,B-CHEMICAL
was,6687,O
measured,6687,O
by,6687,O
TUNEL,6687,O
assay,6687,O
and,6687,O
DAPI,6687,O
staining,6687,O
",",6687,O
and,6687,O
Western,6687,O
blot,6687,O
analysis,6687,O
was,6687,O
utilized,6687,O
to,6687,O
assess,6687,O
the,6687,O
influence,6687,O
on,6687,O
expression,6687,O
and,6687,O
phosphorylation,6687,O
of,6687,O
proteins,6687,O
which,6687,O
are,6687,O
closely,6687,O
related,6687,O
to,6687,O
cell,6687,O
cycle,6687,O
and,6687,O
apoptosis,6687,O
.,6687,O
EVn-50,6688,B-CHEMICAL
possessed,6688,O
a,6688,O
broad,6688,O
spectrum,6688,O
of,6688,O
in,6688,O
vitro,6688,O
anticancer,6688,O
activity,6688,O
for,6688,O
those,6688,O
tested,6688,O
cancer,6688,O
cells,6688,O
",",6688,O
especially,6688,O
sensitive,6688,O
to,6688,O
MDA-MB-435,6688,O
",",6688,O
SKOV-3,6688,O
",",6688,O
BXPC-3,6688,O
",",6688,O
SMMC-7721,6688,O
",",6688,O
MCF-7,6688,O
",",6688,O
HO-8910,6688,O
",",6688,O
SGC-7901,6688,O
",",6688,O
BEL-7402,6688,O
",",6688,O
HCT-116,6688,O
",",6688,O
and,6688,O
786-O,6688,O
",",6688,O
with,6688,O
the,6688,O
respective,6688,O
IC50,6688,O
below,6688,O
10μg/ml,6688,O
.,6688,O
Treatment,6689,O
with,6689,O
EVn-50,6689,B-CHEMICAL
or,6689,O
VB1,6689,B-CHEMICAL
resulted,6689,O
in,6689,O
arresting,6689,O
the,6689,O
MDA-MB-435,6689,O
and,6689,O
SMMC-7721,6689,O
cells,6689,O
at,6689,O
G2/M,6689,O
phase,6689,O
",",6689,O
which,6689,O
was,6689,O
further,6689,O
supported,6689,O
by,6689,O
observations,6689,O
of,6689,O
increased,6689,O
phosphorylation,6689,O
of,6689,O
Histone,6689,B-GENE-N
3,6689,I-GENE-N
at,6689,O
Ser10,6689,B-CHEMICAL
",",6689,O
phosphorylation,6689,O
of,6689,O
Cdk1,6689,B-GENE-Y
at,6689,O
Tyr15,6689,B-CHEMICAL
",",6689,O
expression,6689,O
of,6689,O
cyclin,6689,B-GENE-Y
B1,6689,I-GENE-Y
",",6689,O
and,6689,O
decreased,6689,O
expression,6689,O
of,6689,O
Cdc25c,6689,B-GENE-Y
.,6689,O
Moreover,6690,O
",",6690,O
we,6690,O
found,6690,O
that,6690,O
exposure,6690,O
of,6690,O
MDA-MB-435,6690,O
cells,6690,O
to,6690,O
EVn-50,6690,B-CHEMICAL
or,6690,O
VB1,6690,B-CHEMICAL
caused,6690,O
obvious,6690,O
apoptosis,6690,O
of,6690,O
MDA-MB-435,6690,O
cells,6690,O
.,6690,O
Our,6691,O
data,6691,O
show,6691,O
that,6691,O
EVn-50,6691,B-CHEMICAL
",",6691,O
lignan,6691,B-CHEMICAL
compounds,6691,O
extracted,6691,O
from,6691,O
Vitex,6691,O
negundo,6691,O
",",6691,O
possesses,6691,O
a,6691,O
broad,6691,O
spectrum,6691,O
cytotoxic,6691,O
effect,6691,O
via,6691,O
arresting,6691,O
cancer,6691,O
cells,6691,O
at,6691,O
G2/M,6691,O
phase,6691,O
cell,6691,O
cycle,6691,O
and,6691,O
subsequently,6691,O
inducing,6691,O
apoptosis,6691,O
.,6691,O
TRP,6692,B-GENE-N
and,6692,I-GENE-N
ASIC,6692,I-GENE-N
channels,6692,I-GENE-N
mediate,6692,O
the,6692,O
antinociceptive,6692,O
effect,6692,O
of,6692,O
citronellyl,6692,B-CHEMICAL
acetate,6692,I-CHEMICAL
.,6692,O
Background,6693,O
Citronellyl,6693,B-CHEMICAL
acetate,6693,I-CHEMICAL
(,6693,O
CAT,6693,B-CHEMICAL
),6693,O
",",6693,O
a,6693,O
monoterpene,6693,B-CHEMICAL
product,6693,O
of,6693,O
the,6693,O
secondary,6693,O
metabolism,6693,O
of,6693,O
plants,6693,O
",",6693,O
has,6693,O
been,6693,O
shown,6693,O
in,6693,O
the,6693,O
literature,6693,O
to,6693,O
possess,6693,O
several,6693,O
different,6693,O
biological,6693,O
activities,6693,O
.,6693,O
However,6694,O
",",6694,O
no,6694,O
antinociceptive,6694,O
abilities,6694,O
have,6694,O
yet,6694,O
been,6694,O
discussed,6694,O
.,6694,O
Here,6695,O
",",6695,O
we,6695,O
used,6695,O
acute,6695,O
pain,6695,O
animal,6695,O
models,6695,O
to,6695,O
describe,6695,O
the,6695,O
antinociceptive,6695,O
action,6695,O
of,6695,O
CAT,6695,B-CHEMICAL
.,6695,O
Methods,6696,O
The,6696,O
acetic,6696,B-CHEMICAL
acid-induced,6696,O
writhing,6696,O
test,6696,O
and,6696,O
the,6696,O
paw-licking,6696,O
test,6696,O
",",6696,O
in,6696,O
which,6696,O
paw,6696,O
licking,6696,O
was,6696,O
induced,6696,O
by,6696,O
glutamate,6696,B-CHEMICAL
and,6696,O
formalin,6696,B-CHEMICAL
",",6696,O
were,6696,O
performed,6696,O
to,6696,O
evaluate,6696,O
the,6696,O
antinociceptive,6696,O
action,6696,O
of,6696,O
CAT,6696,B-CHEMICAL
and,6696,O
to,6696,O
determine,6696,O
the,6696,O
involvement,6696,O
of,6696,O
PKC,6696,B-GENE-N
",",6696,O
PKA,6696,B-GENE-N
",",6696,O
TRPV1,6696,B-GENE-Y
",",6696,O
TRPA1,6696,B-GENE-Y
",",6696,O
TRPM8,6696,B-GENE-Y
and,6696,O
ASIC,6696,B-GENE-N
in,6696,O
its,6696,O
antinociceptive,6696,O
mechanism,6696,O
.,6696,O
To,6697,O
do,6697,O
so,6697,O
",",6697,O
we,6697,O
induced,6697,O
paw-linking,6697,O
using,6697,O
agonists,6697,O
.,6697,O
Results,6698,O
CAT,6698,B-CHEMICAL
was,6698,O
administered,6698,O
intragastrically,6698,O
(,6698,O
25,6698,O
",",6698,O
50,6698,O
",",6698,O
75,6698,O
",",6698,O
100,6698,O
and,6698,O
200mg/kg,6698,O
),6698,O
",",6698,O
and,6698,O
the,6698,O
two,6698,O
higher,6698,O
doses,6698,O
caused,6698,O
antinociceptive,6698,O
effects,6698,O
in,6698,O
the,6698,O
acetic,6698,B-CHEMICAL
acid,6698,I-CHEMICAL
model,6698,O
;,6698,O
the,6698,O
highest,6698,O
dose,6698,O
reduced,6698,O
pain,6698,O
for,6698,O
4h,6698,O
after,6698,O
it,6698,O
was,6698,O
administered,6698,O
(,6698,O
200mg/kg,6698,O
),6698,O
.,6698,O
In,6699,O
the,6699,O
formalin,6699,B-CHEMICAL
test,6699,O
",",6699,O
two,6699,O
doses,6699,O
of,6699,O
CAT,6699,B-CHEMICAL
promoted,6699,O
antinociception,6699,O
in,6699,O
both,6699,O
the,6699,O
early,6699,O
and,6699,O
later,6699,O
phases,6699,O
of,6699,O
the,6699,O
test,6699,O
.,6699,O
The,6700,O
glutamate,6700,B-CHEMICAL
test,6700,O
showed,6700,O
that,6700,O
its,6700,O
receptors,6700,O
are,6700,O
involved,6700,O
in,6700,O
the,6700,O
antinociceptive,6700,O
mechanism,6700,O
of,6700,O
CAT,6700,B-CHEMICAL
.,6700,O
Pretreatment,6701,O
with,6701,O
CAT,6701,B-CHEMICAL
did,6701,O
not,6701,O
alter,6701,O
locomotor,6701,O
activity,6701,O
or,6701,O
motor,6701,O
coordination,6701,O
.,6701,O
In,6702,O
an,6702,O
investigation,6702,O
into,6702,O
the,6702,O
participation,6702,O
of,6702,O
TRP,6702,B-GENE-N
channels,6702,I-GENE-N
and,6702,O
ASICs,6702,B-GENE-N
in,6702,O
CAT,6702,B-CHEMICAL
's,6702,O
antinociceptive,6702,O
mechanism,6702,O
",",6702,O
we,6702,O
used,6702,O
capsaicin,6702,B-CHEMICAL
(,6702,O
2.2μg/paw,6702,O
),6702,O
",",6702,O
cinnamaldehyde,6702,B-CHEMICAL
(,6702,O
10mmol/paw,6702,O
),6702,O
",",6702,O
menthol,6702,B-CHEMICAL
(,6702,O
1.2mmol/paw,6702,O
),6702,O
and,6702,O
acidified,6702,O
saline,6702,O
(,6702,O
2,6702,O
%,6702,O
acetic,6702,B-CHEMICAL
acid,6702,I-CHEMICAL
",",6702,O
pH,6702,O
1.98,6702,O
),6702,O
.,6702,O
The,6703,O
results,6703,O
showed,6703,O
that,6703,O
TRPV1,6703,B-GENE-Y
",",6703,O
TRPM8,6703,B-GENE-Y
and,6703,O
ASIC,6703,B-GENE-N
",",6703,O
but,6703,O
not,6703,O
TRPA1,6703,B-GENE-Y
",",6703,O
are,6703,O
involved,6703,O
in,6703,O
the,6703,O
antinociceptive,6703,O
mechanism,6703,O
.,6703,O
Finally,6704,O
",",6704,O
the,6704,O
involvement,6704,O
of,6704,O
PKC,6704,B-GENE-N
and,6704,O
PKA,6704,B-GENE-N
was,6704,O
also,6704,O
studied,6704,O
",",6704,O
and,6704,O
we,6704,O
showed,6704,O
that,6704,O
both,6704,O
play,6704,O
a,6704,O
role,6704,O
in,6704,O
the,6704,O
antinociceptive,6704,O
mechanism,6704,O
of,6704,O
CAT,6704,B-CHEMICAL
.,6704,O
Conclusion,6705,O
The,6705,O
results,6705,O
of,6705,O
this,6705,O
work,6705,O
contribute,6705,O
information,6705,O
regarding,6705,O
the,6705,O
antinociceptive,6705,O
properties,6705,O
of,6705,O
CAT,6705,B-CHEMICAL
on,6705,O
acute,6705,O
pain,6705,O
and,6705,O
show,6705,O
that,6705,O
",",6705,O
at,6705,O
least,6705,O
in,6705,O
part,6705,O
",",6705,O
TRPV1,6705,B-GENE-Y
",",6705,O
TRPM8,6705,B-GENE-Y
",",6705,O
ASIC,6705,B-GENE-N
",",6705,O
glutamate,6705,B-GENE-N
receptors,6705,I-GENE-N
",",6705,O
PKC,6705,B-GENE-N
and,6705,O
PKA,6705,B-GENE-N
participate,6705,O
in,6705,O
CAT,6705,B-CHEMICAL
's,6705,O
antinociceptive,6705,O
mechanism,6705,O
.,6705,O
2-Hydroxychalcone,6706,B-CHEMICAL
and,6706,O
xanthohumol,6706,B-CHEMICAL
inhibit,6706,O
invasion,6706,O
of,6706,O
triple,6706,O
negative,6706,O
breast,6706,O
cancer,6706,O
cells,6706,O
.,6706,O
Breast,6707,O
cancer,6707,O
is,6707,O
estimated,6707,O
as,6707,O
one,6707,O
of,6707,O
the,6707,O
most,6707,O
common,6707,O
causes,6707,O
of,6707,O
cancer,6707,O
death,6707,O
among,6707,O
women,6707,O
.,6707,O
In,6708,O
particular,6708,O
",",6708,O
triple,6708,O
negative,6708,O
breast,6708,O
cancers,6708,O
(,6708,O
TNBCs,6708,O
),6708,O
",",6708,O
which,6708,O
do,6708,O
not,6708,O
express,6708,O
the,6708,O
genes,6708,O
for,6708,O
estrogen/progesterone,6708,B-GENE-Y
receptors,6708,I-GENE-Y
(,6708,O
ER/PR,6708,B-GENE-Y
),6708,O
and,6708,O
human,6708,B-GENE-Y
epidermal,6708,I-GENE-Y
growth,6708,I-GENE-Y
factor,6708,I-GENE-Y
receptor,6708,I-GENE-Y
2,6708,I-GENE-Y
(,6708,O
HER2,6708,B-GENE-Y
),6708,O
",",6708,O
have,6708,O
been,6708,O
associated,6708,O
with,6708,O
poor,6708,O
prognosis,6708,O
and,6708,O
metastasis,6708,O
.,6708,O
Chalcones,6709,B-CHEMICAL
",",6709,O
the,6709,O
biosynthetic,6709,O
precursors,6709,O
of,6709,O
flavonoids,6709,B-CHEMICAL
present,6709,O
in,6709,O
edible,6709,O
plants,6709,O
",",6709,O
exert,6709,O
cytotoxic,6709,O
and,6709,O
chemopreventive,6709,O
activities,6709,O
.,6709,O
Although,6710,O
mounting,6710,O
evidence,6710,O
suggests,6710,O
the,6710,O
anticancer,6710,O
properties,6710,O
of,6710,O
chalcones,6710,B-CHEMICAL
",",6710,O
limited,6710,O
information,6710,O
is,6710,O
available,6710,O
regarding,6710,O
the,6710,O
inhibitory,6710,O
effects,6710,O
of,6710,O
chalcones,6710,B-CHEMICAL
on,6710,O
the,6710,O
aggressiveness,6710,O
of,6710,O
breast,6710,O
cancer,6710,O
cells,6710,O
.,6710,O
The,6711,O
present,6711,O
study,6711,O
aimed,6711,O
to,6711,O
investigate,6711,O
the,6711,O
effects,6711,O
of,6711,O
chalcone,6711,B-CHEMICAL
and,6711,O
its,6711,O
derivatives,6711,O
on,6711,O
the,6711,O
growth,6711,O
and,6711,O
the,6711,O
invasiveness,6711,O
of,6711,O
TNBC,6711,O
cells,6711,O
.,6711,O
Here,6712,O
",",6712,O
we,6712,O
showed,6712,O
that,6712,O
treatment,6712,O
with,6712,O
chalcone,6712,B-CHEMICAL
",",6712,O
2-hydroxychalcone,6712,B-CHEMICAL
",",6712,O
and,6712,O
xanthohumol,6712,B-CHEMICAL
for,6712,O
24h,6712,O
inhibited,6712,O
the,6712,O
growth,6712,O
of,6712,O
MDA-MB-231cells,6712,O
with,6712,O
IC50,6712,O
values,6712,O
of,6712,O
18.1,6712,O
",",6712,O
4.6,6712,O
",",6712,O
and,6712,O
6.7μM,6712,O
",",6712,O
respectively,6712,O
.,6712,O
Similarly,6713,O
",",6713,O
Chalcone,6713,B-CHEMICAL
",",6713,O
2-hydroxychalcone,6713,B-CHEMICAL
",",6713,O
and,6713,O
xanthohumol,6713,B-CHEMICAL
also,6713,O
exerted,6713,O
cytotoxicity,6713,O
in,6713,O
another,6713,O
TNBC,6713,O
cell,6713,O
line,6713,O
",",6713,O
Hs578T,6713,O
.,6713,O
Neohesperidin,6714,B-CHEMICAL
dihydrochalcone,6714,I-CHEMICAL
",",6714,O
4-methoxychalcone,6714,B-CHEMICAL
",",6714,O
and,6714,O
hesperidin,6714,B-CHEMICAL
methylchalcone,6714,I-CHEMICAL
did,6714,O
not,6714,O
show,6714,O
the,6714,O
cytotoxicity,6714,O
on,6714,O
the,6714,O
MDA-MB-231cells,6714,O
.,6714,O
Xanthohumol,6715,B-CHEMICAL
and,6715,O
2-hydroxychalcone,6715,B-CHEMICAL
induced,6715,O
apoptosis,6715,O
by,6715,O
Bcl-2,6715,B-GENE-Y
downregulation,6715,O
.,6715,O
Importantly,6716,O
",",6716,O
2-hydroxychalcone,6716,B-CHEMICAL
and,6716,O
xanthohumol,6716,B-CHEMICAL
exerted,6716,O
more,6716,O
potent,6716,O
inhibitory,6716,O
effects,6716,O
on,6716,O
the,6716,O
proliferation,6716,O
",",6716,O
MMP-9,6716,B-GENE-Y
expression,6716,O
and,6716,O
invasive,6716,O
phenotype,6716,O
of,6716,O
MDA-MB-231,6716,O
than,6716,O
chalcone,6716,B-CHEMICAL
.,6716,O
These,6717,O
results,6717,O
suggest,6717,O
a,6717,O
potential,6717,O
application,6717,O
of,6717,O
these,6717,O
chalcones,6717,B-CHEMICAL
as,6717,O
anticancer,6717,O
agents,6717,O
that,6717,O
can,6717,O
alleviate,6717,O
malignant,6717,O
progression,6717,O
of,6717,O
TNBC,6717,O
.,6717,O
4-Hydroxypyridazin-3,6718,B-CHEMICAL
(,6718,I-CHEMICAL
2H,6718,I-CHEMICAL
),6718,I-CHEMICAL
-one,6718,I-CHEMICAL
Derivatives,6718,O
as,6718,O
Novel,6718,O
d-Amino,6718,B-GENE-Y
Acid,6718,I-GENE-Y
Oxidase,6718,I-GENE-Y
Inhibitors,6718,O
.,6718,O
d-Amino,6719,B-CHEMICAL
acid,6719,I-CHEMICAL
oxidase,6719,I-GENE-Y
(,6719,O
DAAO,6719,B-GENE-Y
),6719,O
catalyzes,6719,O
the,6719,O
oxidation,6719,O
of,6719,O
d-amino,6719,B-CHEMICAL
acids,6719,I-CHEMICAL
including,6719,O
d-serine,6719,B-CHEMICAL
",",6719,O
a,6719,O
coagonist,6719,O
of,6719,O
the,6719,O
N-methyl-d-aspartate,6719,B-CHEMICAL
receptor,6719,I-GENE-N
.,6719,O
We,6720,O
identified,6720,O
a,6720,O
series,6720,O
of,6720,O
4-hydroxypyridazin-3,6720,B-CHEMICAL
(,6720,I-CHEMICAL
2H,6720,I-CHEMICAL
),6720,I-CHEMICAL
-one,6720,I-CHEMICAL
derivatives,6720,O
as,6720,O
novel,6720,O
DAAO,6720,B-GENE-Y
inhibitors,6720,O
with,6720,O
high,6720,O
potency,6720,O
and,6720,O
substantial,6720,O
cell,6720,O
permeability,6720,O
using,6720,O
fragment-based,6720,O
drug,6720,O
design,6720,O
.,6720,O
Comparisons,6721,O
of,6721,O
complex,6721,O
structures,6721,O
deposited,6721,O
in,6721,O
the,6721,O
Protein,6721,O
Data,6721,O
Bank,6721,O
as,6721,O
well,6721,O
as,6721,O
those,6721,O
determined,6721,O
with,6721,O
in-house,6721,O
fragment,6721,O
hits,6721,O
revealed,6721,O
that,6721,O
a,6721,O
hydrophobic,6721,O
subpocket,6721,O
was,6721,O
formed,6721,O
perpendicular,6721,O
to,6721,O
the,6721,O
flavin,6721,O
ring,6721,O
by,6721,O
flipping,6721,O
Tyr224,6721,B-CHEMICAL
in,6721,O
a,6721,O
ligand-dependent,6721,O
manner,6721,O
.,6721,O
We,6722,O
investigated,6722,O
the,6722,O
ability,6722,O
of,6722,O
the,6722,O
initial,6722,O
fragment,6722,O
hit,6722,O
",",6722,O
3-hydroxy-pyridine-2,6722,B-CHEMICAL
(,6722,I-CHEMICAL
1H,6722,I-CHEMICAL
),6722,I-CHEMICAL
-one,6722,I-CHEMICAL
",",6722,O
to,6722,O
fill,6722,O
this,6722,O
subpocket,6722,O
with,6722,O
the,6722,O
aid,6722,O
of,6722,O
complex,6722,O
structure,6722,O
information,6722,O
.,6722,O
3-Hydroxy-5-,6723,B-CHEMICAL
(,6723,I-CHEMICAL
2-phenylethyl,6723,I-CHEMICAL
),6723,I-CHEMICAL
pyridine-2,6723,I-CHEMICAL
(,6723,I-CHEMICAL
1H,6723,I-CHEMICAL
),6723,I-CHEMICAL
-one,6723,I-CHEMICAL
exhibited,6723,O
the,6723,O
predicted,6723,O
binding,6723,O
mode,6723,O
and,6723,O
demonstrated,6723,O
high,6723,O
inhibitory,6723,O
activity,6723,O
for,6723,O
human,6723,B-GENE-Y
DAAO,6723,I-GENE-Y
in,6723,O
enzyme-,6723,O
and,6723,O
cell-based,6723,O
assays,6723,O
.,6723,O
We,6724,O
further,6724,O
designed,6724,O
and,6724,O
synthesized,6724,O
4-hydroxypyridazin-3,6724,B-CHEMICAL
(,6724,I-CHEMICAL
2H,6724,I-CHEMICAL
),6724,I-CHEMICAL
-one,6724,I-CHEMICAL
derivatives,6724,O
",",6724,O
which,6724,O
are,6724,O
equivalent,6724,O
to,6724,O
the,6724,O
3-hydroxy-pyridine-2,6724,B-CHEMICAL
(,6724,I-CHEMICAL
1H,6724,I-CHEMICAL
),6724,I-CHEMICAL
-one,6724,I-CHEMICAL
series,6724,O
but,6724,O
lack,6724,O
cell,6724,O
toxicity,6724,O
.,6724,O
6-,6725,B-CHEMICAL
[,6725,I-CHEMICAL
2-,6725,I-CHEMICAL
(,6725,I-CHEMICAL
"3,5-Difluorophenyl",6725,I-CHEMICAL
),6725,I-CHEMICAL
ethyl,6725,I-CHEMICAL
],6725,I-CHEMICAL
-4-hydroxypyridazin-3,6725,I-CHEMICAL
(,6725,I-CHEMICAL
2H,6725,I-CHEMICAL
),6725,I-CHEMICAL
-one,6725,I-CHEMICAL
was,6725,O
found,6725,O
to,6725,O
be,6725,O
effective,6725,O
against,6725,O
MK-801-induced,6725,B-CHEMICAL
cognitive,6725,O
deficit,6725,O
in,6725,O
the,6725,O
Y-maze,6725,O
.,6725,O
Comparative,6726,O
study,6726,O
on,6726,O
transcriptional,6726,O
activity,6726,O
of,6726,O
17,6726,O
parabens,6726,B-CHEMICAL
mediated,6726,O
by,6726,O
estrogen,6726,B-GENE-N
receptor,6726,I-GENE-N
α,6726,I-GENE-N
and,6726,I-GENE-N
β,6726,I-GENE-N
and,6726,O
androgen,6726,B-GENE-Y
receptor,6726,I-GENE-Y
.,6726,O
The,6727,O
structure-activity,6727,O
relationships,6727,O
of,6727,O
parabens,6727,B-CHEMICAL
which,6727,O
are,6727,O
widely,6727,O
used,6727,O
as,6727,O
preservatives,6727,O
for,6727,O
transcriptional,6727,O
activities,6727,O
mediated,6727,O
by,6727,O
human,6727,B-GENE-Y
estrogen,6727,B-CHEMICAL
receptor,6727,I-GENE-Y
α,6727,I-GENE-Y
(,6727,O
hERα,6727,B-GENE-Y
),6727,O
",",6727,O
hERβ,6727,B-GENE-Y
and,6727,O
androgen,6727,B-CHEMICAL
receptor,6727,I-GENE-Y
(,6727,O
hAR,6727,B-GENE-Y
),6727,O
were,6727,O
investigated,6727,O
.,6727,O
Fourteen,6728,O
of,6728,O
17,6728,O
parabens,6728,B-CHEMICAL
exhibited,6728,O
hERα,6728,B-GENE-Y
and/or,6728,O
hERβ,6728,B-GENE-Y
agonistic,6728,O
activity,6728,O
at,6728,O
concentrations,6728,O
of,6728,O
⩽1×10,6728,O
(,6728,O
-5,6728,O
),6728,O
M,6728,O
",",6728,O
whereas,6728,O
none,6728,O
of,6728,O
the,6728,O
17,6728,O
parabens,6728,B-CHEMICAL
showed,6728,O
AR,6728,B-GENE-Y
agonistic,6728,O
or,6728,O
antagonistic,6728,O
activity,6728,O
.,6728,O
Among,6729,O
12,6729,O
parabens,6729,B-CHEMICAL
with,6729,O
linear,6729,O
alkyl,6729,B-CHEMICAL
chains,6729,O
ranging,6729,O
in,6729,O
length,6729,O
from,6729,O
C1,6729,O
to,6729,O
C12,6729,O
",",6729,O
heptylparaben,6729,B-CHEMICAL
(,6729,O
C7,6729,O
),6729,O
and,6729,O
pentylparaben,6729,B-CHEMICAL
(,6729,O
C5,6729,O
),6729,O
showed,6729,O
the,6729,O
most,6729,O
potent,6729,O
ERα,6729,B-GENE-Y
and,6729,O
ERβ,6729,B-GENE-Y
agonistic,6729,O
activity,6729,O
in,6729,O
the,6729,O
order,6729,O
of,6729,O
10,6729,O
(,6729,O
-7,6729,O
),6729,O
M,6729,O
and,6729,O
10,6729,O
(,6729,O
-8,6729,O
),6729,O
M,6729,O
",",6729,O
respectively,6729,O
",",6729,O
and,6729,O
the,6729,O
activities,6729,O
decreased,6729,O
in,6729,O
a,6729,O
stepwise,6729,O
manner,6729,O
as,6729,O
the,6729,O
alkyl,6729,O
chain,6729,O
was,6729,O
shortened,6729,O
to,6729,O
C1,6729,O
or,6729,O
lengthened,6729,O
to,6729,O
C12,6729,O
.,6729,O
Most,6730,O
parabens,6730,B-CHEMICAL
showing,6730,O
estrogenic,6730,O
activity,6730,O
exhibited,6730,O
ERβ-agonistic,6730,B-GENE-Y
activity,6730,O
at,6730,O
lower,6730,O
concentrations,6730,O
than,6730,O
those,6730,O
inducing,6730,O
ERα-agonistic,6730,B-GENE-Y
activity,6730,O
.,6730,O
The,6731,O
estrogenic,6731,O
activity,6731,O
of,6731,O
butylparaben,6731,B-CHEMICAL
was,6731,O
markedly,6731,O
decreased,6731,O
by,6731,O
incubation,6731,O
with,6731,O
rat,6731,O
liver,6731,O
microsomes,6731,O
",",6731,O
and,6731,O
the,6731,O
decrease,6731,O
of,6731,O
activity,6731,O
was,6731,O
blocked,6731,O
by,6731,O
a,6731,O
carboxylesterase,6731,B-GENE-N
inhibitor,6731,O
.,6731,O
These,6732,O
results,6732,O
indicate,6732,O
that,6732,O
parabens,6732,B-CHEMICAL
are,6732,O
selective,6732,O
agonists,6732,O
for,6732,O
ERβ,6732,B-GENE-Y
over,6732,O
ERα,6732,B-GENE-Y
;,6732,O
their,6732,O
interactions,6732,O
with,6732,O
ERα/β,6732,B-GENE-N
are,6732,O
dependent,6732,O
on,6732,O
the,6732,O
size,6732,O
and,6732,O
bulkiness,6732,O
of,6732,O
the,6732,O
alkyl,6732,B-CHEMICAL
groups,6732,O
;,6732,O
and,6732,O
they,6732,O
are,6732,O
metabolized,6732,O
by,6732,O
carboxylesterases,6732,B-GENE-N
",",6732,O
leading,6732,O
to,6732,O
attenuation,6732,O
of,6732,O
their,6732,O
estrogenic,6732,O
activity,6732,O
.,6732,O
The,6733,O
cyclin,6733,B-GENE-Y
D1,6733,I-GENE-Y
(,6733,O
CCND1,6733,B-GENE-Y
),6733,O
rs9344,6733,B-GENE-N
G,6733,I-GENE-N
>,6733,I-GENE-N
A,6733,I-GENE-N
polymorphism,6733,O
predicts,6733,O
clinical,6733,O
outcome,6733,O
in,6733,O
colon,6733,O
cancer,6733,O
patients,6733,O
treated,6733,O
with,6733,O
adjuvant,6733,O
5-FU-based,6733,B-CHEMICAL
chemotherapy,6733,O
.,6733,O
Recent,6734,O
evidence,6734,O
indicates,6734,O
a,6734,O
potential,6734,O
prognostic,6734,O
and,6734,O
predictive,6734,O
value,6734,O
for,6734,O
germline,6734,O
polymorphisms,6734,O
in,6734,O
genes,6734,O
involved,6734,O
in,6734,O
cell,6734,O
cycle,6734,O
control,6734,O
.,6734,O
We,6735,O
investigated,6735,O
the,6735,O
effect,6735,O
of,6735,O
cyclin,6735,B-GENE-Y
D1,6735,I-GENE-Y
(,6735,O
CCND1,6735,B-GENE-Y
),6735,O
rs9344,6735,B-GENE-N
G,6735,I-GENE-N
>,6735,I-GENE-N
A,6735,I-GENE-N
in,6735,O
stage,6735,O
II/III,6735,O
colon,6735,O
cancer,6735,O
patients,6735,O
and,6735,O
validated,6735,O
the,6735,O
findings,6735,O
in,6735,O
an,6735,O
independent,6735,O
study,6735,O
cohort,6735,O
.,6735,O
For,6736,O
evaluation,6736,O
and,6736,O
validation,6736,O
set,6736,O
",",6736,O
a,6736,O
total,6736,O
of,6736,O
264,6736,O
and,6736,O
234,6736,O
patients,6736,O
were,6736,O
included,6736,O
.,6736,O
Patients,6737,O
treated,6737,O
with,6737,O
5-fluorouracil-based,6737,B-CHEMICAL
chemotherapy,6737,O
",",6737,O
carrying,6737,O
the,6737,O
CCND1,6737,B-GENE-Y
rs9344,6737,B-GENE-N
A/A,6737,I-GENE-N
genotype,6737,O
had,6737,O
significantly,6737,O
decreased,6737,O
time-to-tumor,6737,O
recurrence,6737,O
(,6737,O
TTR,6737,O
),6737,O
in,6737,O
univariate,6737,O
analysis,6737,O
and,6737,O
multivariate,6737,O
analysis,6737,O
(,6737,O
hazard,6737,O
ratio,6737,O
(,6737,O
HR,6737,O
),6737,O
2.47,6737,O
;,6737,O
95,6737,O
%,6737,O
confidence,6737,O
interval,6737,O
(,6737,O
CI,6737,O
),6737,O
1.16-5.29,6737,O
;,6737,O
P=0.019,6737,O
),6737,O
.,6737,O
There,6738,O
was,6738,O
no,6738,O
significant,6738,O
association,6738,O
between,6738,O
CCND1,6738,B-GENE-Y
rs9344,6738,B-GENE-N
G,6738,I-GENE-N
>,6738,I-GENE-N
A,6738,I-GENE-N
and,6738,O
TTR,6738,O
in,6738,O
patients,6738,O
with,6738,O
curative,6738,O
surgery,6738,O
alone,6738,O
.,6738,O
In,6739,O
the,6739,O
validation,6739,O
set,6739,O
",",6739,O
the,6739,O
A,6739,O
allele,6739,O
of,6739,O
CCND1,6739,B-GENE-Y
rs9344,6739,B-GENE-N
G,6739,I-GENE-N
>,6739,I-GENE-N
A,6739,I-GENE-N
remained,6739,O
significantly,6739,O
associated,6739,O
with,6739,O
decreased,6739,O
TTR,6739,O
in,6739,O
univariate,6739,O
and,6739,O
multivariate,6739,O
analyses,6739,O
(,6739,O
HR,6739,O
1.94,6739,O
;,6739,O
95,6739,O
%,6739,O
CI,6739,O
1.05-3.58,6739,O
;,6739,O
P=0.035,6739,O
),6739,O
.,6739,O
CCND1,6740,B-GENE-Y
rs9344,6740,B-GENE-N
G,6740,I-GENE-N
>,6740,I-GENE-N
A,6740,I-GENE-N
may,6740,O
be,6740,O
a,6740,O
predictive,6740,O
and/or,6740,O
prognostic,6740,O
biomarker,6740,O
in,6740,O
stage,6740,O
II/III,6740,O
colon,6740,O
cancer,6740,O
patients,6740,O
",",6740,O
however,6740,O
",",6740,O
prospective,6740,O
trials,6740,O
are,6740,O
warranted,6740,O
to,6740,O
confirm,6740,O
our,6740,O
findings.The,6740,O
Pharmacogenomics,6740,O
Journal,6740,O
advance,6740,O
online,6740,O
publication,6740,O
",",6740,O
9,6740,O
April,6740,O
2013,6740,O
;,6740,O
doi:10.1038/tpj.2013.15,6740,O
.,6740,O
Evaluation,6741,O
of,6741,O
7-O-galloyl-d-sedoheptulose,6741,B-CHEMICAL
",",6741,O
isolated,6741,O
from,6741,O
Corni,6741,O
Fructus,6741,O
",",6741,O
in,6741,O
the,6741,O
adipose,6741,O
tissue,6741,O
of,6741,O
type,6741,O
2,6741,O
diabetic,6741,O
db/db,6741,O
mice,6741,O
.,6741,O
The,6742,O
aim,6742,O
of,6742,O
the,6742,O
present,6742,O
study,6742,O
was,6742,O
to,6742,O
evaluate,6742,O
the,6742,O
beneficial,6742,O
effects,6742,O
of,6742,O
7-O-galloyl-d-sedoheptulose,6742,B-CHEMICAL
(,6742,O
GS,6742,O
),6742,O
",",6742,O
isolated,6742,O
from,6742,O
Corni,6742,O
Fructus,6742,O
",",6742,O
using,6742,O
type,6742,O
2,6742,O
diabetic,6742,O
mice,6742,O
.,6742,O
GS,6743,O
was,6743,O
orally,6743,O
administered,6743,O
to,6743,O
db/db,6743,O
mice,6743,O
at,6743,O
doses,6743,O
of,6743,O
20,6743,O
and,6743,O
100mg/kg,6743,O
body,6743,O
weight,6743,O
per,6743,O
day,6743,O
for,6743,O
6weeks,6743,O
",",6743,O
and,6743,O
the,6743,O
effects,6743,O
of,6743,O
GS,6743,O
on,6743,O
biochemical,6743,O
factors,6743,O
in,6743,O
serum,6743,O
and,6743,O
adipose,6743,O
tissue,6743,O
were,6743,O
investigated,6743,O
.,6743,O
To,6744,O
define,6744,O
the,6744,O
underlying,6744,O
mechanism,6744,O
of,6744,O
these,6744,O
effects,6744,O
",",6744,O
protein,6744,O
expressions,6744,O
related,6744,O
to,6744,O
lipid,6744,O
metabolism,6744,O
",",6744,O
inflammation,6744,O
",",6744,O
fibrosis,6744,O
",",6744,O
and,6744,O
apoptosis,6744,O
",",6744,O
were,6744,O
measured,6744,O
.,6744,O
The,6745,O
results,6745,O
showed,6745,O
that,6745,O
levels,6745,O
of,6745,O
glucose,6745,B-CHEMICAL
",",6745,O
leptin,6745,B-GENE-Y
",",6745,O
insulin,6745,B-GENE-N
",",6745,O
C-peptide,6745,B-GENE-N
",",6745,O
resistin,6745,B-GENE-Y
",",6745,O
tumor,6745,B-GENE-Y
necrosis,6745,I-GENE-Y
factor-α,6745,I-GENE-Y
",",6745,O
interleukin-6,6745,B-GENE-Y
",",6745,O
triglycerides,6745,B-CHEMICAL
",",6745,O
total,6745,O
cholesterol,6745,B-CHEMICAL
",",6745,O
non-esterified,6745,O
fatty,6745,B-CHEMICAL
acids,6745,I-CHEMICAL
",",6745,O
high-density,6745,B-GENE-N
lipoprotein,6745,I-GENE-N
cholesterol,6745,B-CHEMICAL
",",6745,O
very,6745,O
low-density,6745,B-GENE-N
lipoprotein,6745,I-GENE-N
cholesterol/low-density,6745,B-CHEMICAL
lipoprotein,6745,I-GENE-N
cholesterol,6745,B-CHEMICAL
",",6745,O
reactive,6745,O
oxygen,6745,B-CHEMICAL
species,6745,O
(,6745,O
ROS,6745,O
),6745,O
",",6745,O
and,6745,O
thiobarbituric,6745,B-CHEMICAL
acid-reactive,6745,O
substance,6745,O
(,6745,O
TBARS,6745,O
),6745,O
in,6745,O
serum,6745,O
were,6745,O
down-regulated,6745,O
",",6745,O
while,6745,O
adiponectin,6745,B-GENE-Y
was,6745,O
augmented,6745,O
by,6745,O
GS,6745,O
treatment,6745,O
.,6745,O
In,6746,O
addition,6746,O
",",6746,O
the,6746,O
elevated,6746,O
lipid,6746,O
",",6746,O
ROS,6746,O
",",6746,O
and,6746,O
TBARS,6746,O
contents,6746,O
in,6746,O
adipose,6746,O
tissue,6746,O
as,6746,O
well,6746,O
as,6746,O
serum,6746,O
levels,6746,O
in,6746,O
db/db,6746,O
mice,6746,O
were,6746,O
significantly,6746,O
decreased,6746,O
by,6746,O
the,6746,O
oral,6746,O
administration,6746,O
of,6746,O
GS,6746,O
.,6746,O
From,6747,O
protein,6747,O
analysis,6747,O
",",6747,O
the,6747,O
decreased,6747,O
expressions,6747,O
of,6747,O
peroxisome,6747,B-GENE-Y
proliferator,6747,I-GENE-Y
activated,6747,I-GENE-Y
receptor,6747,I-GENE-Y
(,6747,I-GENE-Y
PPAR,6747,I-GENE-Y
),6747,I-GENE-Y
α,6747,I-GENE-Y
",",6747,O
PPARγ,6747,B-GENE-Y
",",6747,O
and,6747,O
B-cell,6747,B-GENE-Y
lymphoma,6747,I-GENE-Y
2,6747,I-GENE-Y
were,6747,O
up-regulated,6747,O
in,6747,O
the,6747,O
adipose,6747,O
tissue,6747,O
of,6747,O
db/db,6747,O
mice,6747,O
.,6747,O
The,6748,O
administration,6748,O
of,6748,O
GS,6748,O
significantly,6748,O
decreased,6748,O
sterol,6748,B-CHEMICAL
regulatory,6748,I-GENE-Y
element,6748,I-GENE-Y
binding,6748,I-GENE-Y
protein-1,6748,I-GENE-Y
",",6748,O
nuclear,6748,B-GENE-N
factor-kappa,6748,I-GENE-N
?,6748,O
>,6748,O
Bp65,6748,O
",",6748,O
cyclooxygenase-2,6748,B-GENE-Y
",",6748,O
inducible,6748,B-GENE-Y
nitric,6748,B-CHEMICAL
oxide,6748,I-CHEMICAL
synthase,6748,I-GENE-Y
",",6748,O
monocyte,6748,B-GENE-Y
chemotactic,6748,I-GENE-Y
protein-1,6748,I-GENE-Y
",",6748,O
intracellular,6748,B-GENE-Y
adhesion,6748,I-GENE-Y
molecule-1,6748,I-GENE-Y
",",6748,O
phosphor,6748,B-GENE-Y
c-Jun,6748,I-GENE-Y
N-terminal,6748,B-CHEMICAL
kinase,6748,B-GENE-N
",",6748,O
activator,6748,B-GENE-Y
protein-1,6748,I-GENE-Y
",",6748,O
transforming,6748,B-GENE-Y
growth,6748,I-GENE-Y
factor-β1,6748,I-GENE-Y
",",6748,O
Bax,6748,B-GENE-Y
",",6748,O
cytochrome,6748,B-GENE-Y
c,6748,I-GENE-Y
",",6748,O
and,6748,O
caspase-3,6748,B-GENE-Y
expressions,6748,O
.,6748,O
These,6749,O
results,6749,O
suggest,6749,O
that,6749,O
GS,6749,O
acts,6749,O
as,6749,O
a,6749,O
regulator,6749,O
of,6749,O
oxidative,6749,O
stress,6749,O
",",6749,O
inflammation,6749,O
",",6749,O
fibrosis,6749,O
",",6749,O
and,6749,O
apoptosis,6749,O
in,6749,O
the,6749,O
adipose,6749,O
tissue,6749,O
of,6749,O
db/db,6749,O
mice,6749,O
.,6749,O
Extracellular,6750,B-GENE-N
Signal-Regulated,6750,I-GENE-N
Kinases,6750,I-GENE-N
(,6750,O
ERK,6750,B-GENE-N
),6750,O
Inhibitors,6750,O
from,6750,O
Aristolochia,6750,O
yunnanensis,6750,O
.,6750,O
Six,6751,O
new,6751,O
sesquiterpenoids,6751,B-CHEMICAL
",",6751,O
aristoyunnolins,6751,B-CHEMICAL
A-F,6751,I-CHEMICAL
(,6751,O
1-6,6751,O
),6751,O
",",6751,O
an,6751,O
artifact,6751,O
of,6751,O
isolation,6751,O
[,6751,O
7-O-ethyl,6751,B-CHEMICAL
madolin,6751,I-CHEMICAL
W,6751,I-CHEMICAL
(,6751,O
7,6751,O
),6751,O
],6751,O
",",6751,O
and,6751,O
12,6751,O
known,6751,O
analogues,6751,O
were,6751,O
isolated,6751,O
from,6751,O
stems,6751,O
of,6751,O
Aristolochia,6751,O
yunnanensis,6751,O
.,6751,O
The,6752,O
structures,6752,O
were,6752,O
determined,6752,O
by,6752,O
combined,6752,O
chemical,6752,O
and,6752,O
spectral,6752,O
methods,6752,O
",",6752,O
and,6752,O
the,6752,O
absolute,6752,O
configurations,6752,O
of,6752,O
compounds,6752,O
2,6752,O
",",6752,O
3,6752,O
",",6752,O
5-7,6752,O
",",6752,O
9,6752,O
",",6752,O
14,6752,O
",",6752,O
and,6752,O
17,6752,O
were,6752,O
determined,6752,O
by,6752,O
the,6752,O
modified,6752,O
Mosher,6752,O
's,6752,O
method,6752,O
and,6752,O
CD,6752,O
analysis,6752,O
.,6752,O
Compounds,6753,O
1-19,6753,O
were,6753,O
screened,6753,O
using,6753,O
a,6753,O
bioassay,6753,O
system,6753,O
designed,6753,O
to,6753,O
evaluate,6753,O
the,6753,O
effect,6753,O
on,6753,O
mitogen-activated,6753,B-GENE-N
protein,6753,I-GENE-N
kinases,6753,I-GENE-N
(,6753,O
MAPKs,6753,B-GENE-N
),6753,O
signaling,6753,O
pathways,6753,O
.,6753,O
Among,6754,O
three,6754,O
MAPKs,6754,B-GENE-N
(,6754,O
ERK1/2,6754,B-GENE-N
",",6754,O
JNK,6754,B-GENE-N
",",6754,O
and,6754,O
p38,6754,B-GENE-N
),6754,O
",",6754,O
compounds,6754,O
1,6754,O
",",6754,O
4,6754,O
",",6754,O
10-13,6754,O
",",6754,O
16,6754,O
",",6754,O
18,6754,O
",",6754,O
and,6754,O
19,6754,O
exhibited,6754,O
selective,6754,O
inhibition,6754,O
of,6754,O
the,6754,O
phosphorylation,6754,O
of,6754,O
ERK1/2,6754,B-GENE-N
.,6754,O
Compounds,6755,O
16,6755,O
and,6755,O
19,6755,O
were,6755,O
more,6755,O
active,6755,O
than,6755,O
the,6755,O
positive,6755,O
control,6755,O
PD98059,6755,B-CHEMICAL
",",6755,O
a,6755,O
known,6755,O
inhibitor,6755,O
of,6755,O
the,6755,O
ERK1/2,6755,B-GENE-N
signaling,6755,O
pathway,6755,O
.,6755,O
In,6756,O
vivo,6756,O
and,6756,O
in,6756,O
vitro,6756,O
anti-inflammatory,6756,O
potential,6756,O
of,6756,O
pentahydroxy-pregn-14-ol,6756,B-CHEMICAL
",",6756,I-CHEMICAL
20-one-β-d-thevetopyranoside,6756,I-CHEMICAL
in,6756,O
rats,6756,O
.,6756,O
Polyhydroxy,6757,B-CHEMICAL
pregnane,6757,I-CHEMICAL
glycoside,6757,I-CHEMICAL
(,6757,O
PPG,6757,B-CHEMICAL
),6757,O
",",6757,O
a,6757,O
steroidal,6757,B-CHEMICAL
glycoside,6757,I-CHEMICAL
was,6757,O
isolated,6757,O
from,6757,O
Wattakaka,6757,O
volubilis,6757,O
Linn,6757,O
.,6757,O
(,6758,O
Stap.f,6758,O
.,6758,O
),6758,O
.,6758,O
PPG,6759,B-CHEMICAL
was,6759,O
evaluated,6759,O
for,6759,O
in,6759,O
vivo,6759,O
and,6759,O
in,6759,O
vitro,6759,O
anti-inflammatory,6759,O
activity,6759,O
using,6759,O
acute,6759,O
inflammation,6759,O
and,6759,O
chronic,6759,O
model,6759,O
of,6759,O
inflammation,6759,O
in,6759,O
rats,6759,O
and,6759,O
LPS-induced,6759,O
RAW,6759,O
264.7,6759,O
macrophage,6759,O
cells,6759,O
.,6759,O
PPG,6760,B-CHEMICAL
seemed,6760,O
to,6760,O
be,6760,O
responsible,6760,O
for,6760,O
the,6760,O
anti-inflammatory,6760,O
activity,6760,O
in,6760,O
the,6760,O
studied,6760,O
models,6760,O
.,6760,O
PPG,6761,B-CHEMICAL
at,6761,O
dose,6761,O
level,6761,O
of,6761,O
both,6761,O
5,6761,O
and,6761,O
10mg/kg,6761,O
significantly,6761,O
reduced,6761,O
the,6761,O
edema,6761,O
induced,6761,O
by,6761,O
the,6761,O
carrageenan,6761,O
in,6761,O
acute,6761,O
model,6761,O
of,6761,O
inflammation,6761,O
.,6761,O
It,6762,O
also,6762,O
showed,6762,O
significant,6762,O
anti-proliferative,6762,O
effect,6762,O
(,6762,O
dry,6762,O
pellet,6762,O
weight,6762,O
basis,6762,O
),6762,O
in,6762,O
chronic,6762,O
model,6762,O
of,6762,O
inflammation,6762,O
.,6762,O
Cellular,6763,O
content,6763,O
of,6763,O
granuloma,6763,O
was,6763,O
measured,6763,O
by,6763,O
assaying,6763,O
activity,6763,O
of,6763,O
N-acetyl,6763,B-CHEMICAL
glucosaminidase,6763,O
(,6763,O
NAG,6763,O
),6763,O
and,6763,O
total,6763,O
nucleic,6763,O
acid,6763,O
content,6763,O
.,6763,O
PPG,6764,B-CHEMICAL
at,6764,O
5,6764,O
and,6764,O
10mg/kg,6764,O
significantly,6764,O
suppressed,6764,O
the,6764,O
cellular,6764,O
infiltration,6764,O
measured,6764,O
by,6764,O
total,6764,O
nucleic,6764,O
acid,6764,O
content,6764,O
.,6764,O
In,6765,O
contrast,6765,O
",",6765,O
NAG,6765,O
activity,6765,O
decreased,6765,O
over,6765,O
a,6765,O
period,6765,O
of,6765,O
10,6765,O
days,6765,O
resulting,6765,O
in,6765,O
inhibition,6765,O
of,6765,O
granuloma,6765,O
weight,6765,O
gain,6765,O
.,6765,O
PPG,6766,B-CHEMICAL
had,6766,O
a,6766,O
more,6766,O
effective,6766,O
response,6766,O
than,6766,O
the,6766,O
reference,6766,O
drug,6766,O
diclofenac,6766,B-CHEMICAL
sodium,6766,I-CHEMICAL
in,6766,O
both,6766,O
the,6766,O
models,6766,O
of,6766,O
inflammation,6766,O
.,6766,O
Wattakaka,6767,O
volubilis,6767,O
steroidal,6767,B-CHEMICAL
glycoside,6767,I-CHEMICAL
mixture,6767,O
(,6767,O
WVSM,6767,O
),6767,O
and,6767,O
PPG,6767,B-CHEMICAL
(,6767,O
1-50μM,6767,O
),6767,O
significantly,6767,O
inhibited,6767,O
the,6767,O
COX-2,6767,B-GENE-Y
and,6767,O
iNOS,6767,B-GENE-Y
enzymes,6767,O
resulting,6767,O
in,6767,O
low,6767,O
levels,6767,O
of,6767,O
PGE2,6767,O
and,6767,O
NO,6767,O
in,6767,O
LPS-induced,6767,O
RAW,6767,O
264.7,6767,O
macrophage,6767,O
cells,6767,O
.,6767,O
Hence,6768,O
the,6768,O
study,6768,O
supports,6768,O
the,6768,O
traditional,6768,O
use,6768,O
of,6768,O
Wattakaka,6768,O
volubilis,6768,O
and,6768,O
its,6768,O
constituent,6768,O
PPG,6768,B-CHEMICAL
in,6768,O
treatment,6768,O
of,6768,O
inflammatory,6768,O
disorders,6768,O
.,6768,O
Hypermethylation,6769,O
of,6769,O
P15,6769,B-GENE-Y
",",6769,O
P16,6769,B-GENE-Y
",",6769,O
and,6769,O
E-cadherin,6769,B-GENE-Y
genes,6769,O
in,6769,O
ovarian,6769,O
cancer,6769,O
.,6769,O
Both,6770,O
p16,6770,B-GENE-Y
and,6770,O
p15,6770,B-GENE-Y
proteins,6770,O
are,6770,O
inhibitors,6770,O
of,6770,O
cyclin-dependent,6770,B-GENE-N
kinases,6770,I-GENE-N
that,6770,O
prevent,6770,O
the,6770,O
cell,6770,O
going,6770,O
through,6770,O
the,6770,O
G1/S,6770,O
phase,6770,O
transaction,6770,O
.,6770,O
E-cadherin,6771,B-GENE-Y
is,6771,O
a,6771,O
transmembrane,6771,O
glycoprotein,6771,O
that,6771,O
mediates,6771,O
calcium-dependent,6771,B-CHEMICAL
interactions,6771,O
between,6771,O
adjacent,6771,O
epithelial,6771,O
cells,6771,O
.,6771,O
Two,6772,O
groups,6772,O
of,6772,O
patients,6772,O
were,6772,O
selected,6772,O
:,6772,O
the,6772,O
first,6772,O
group,6772,O
suffered,6772,O
from,6772,O
epithelial,6772,O
serous,6772,O
ovarian,6772,O
tumors,6772,O
and,6772,O
the,6772,O
second,6772,O
group,6772,O
suffered,6772,O
from,6772,O
benign,6772,O
ovarian,6772,O
lesions,6772,O
;,6772,O
ovarian,6772,O
tissue,6772,O
samples,6772,O
from,6772,O
all,6772,O
the,6772,O
subjects,6772,O
(,6772,O
benign,6772,O
and,6772,O
malignant,6772,O
),6772,O
were,6772,O
subjected,6772,O
to,6772,O
methylation-specific,6772,O
polymerase,6772,O
chain,6772,O
reaction,6772,O
for,6772,O
methylated,6772,O
and,6772,O
unmethylated,6772,O
alleles,6772,O
of,6772,O
the,6772,O
genes,6772,O
(,6772,O
E-cadherin,6772,B-GENE-Y
",",6772,O
p15,6772,B-GENE-Y
",",6772,O
and,6772,O
p16,6772,B-GENE-Y
),6772,O
.,6772,O
Results,6773,O
obtained,6773,O
showed,6773,O
that,6773,O
aberrant,6773,O
methylation,6773,O
of,6773,O
p15,6773,B-GENE-Y
and,6773,O
p16,6773,B-GENE-Y
genes,6773,O
were,6773,O
detected,6773,O
in,6773,O
64.29,6773,O
and,6773,O
50,6773,O
%,6773,O
of,6773,O
ovarian,6773,O
cancer,6773,O
patients,6773,O
",",6773,O
while,6773,O
E-cadherin,6773,B-GENE-Y
hypermethylation,6773,O
was,6773,O
detected,6773,O
in,6773,O
78.57,6773,O
%,6773,O
of,6773,O
ovarian,6773,O
cancer,6773,O
patients,6773,O
.,6773,O
Methylation,6774,O
of,6774,O
E-cadherin,6774,B-GENE-Y
was,6774,O
significantly,6774,O
correlated,6774,O
with,6774,O
different,6774,O
stage,6774,O
of,6774,O
disease,6774,O
(,6774,O
p,6774,O
<,6774,O
0.05,6774,O
),6774,O
.,6774,O
It,6775,O
was,6775,O
found,6775,O
that,6775,O
the,6775,O
risk,6775,O
of,6775,O
E-cadherin,6775,B-GENE-Y
hypermethylation,6775,O
was,6775,O
1.347-fold,6775,O
",",6775,O
while,6775,O
risk,6775,O
of,6775,O
p15,6775,B-GENE-Y
hypermethylation,6775,O
was,6775,O
1.543-fold,6775,O
and,6775,O
p16,6775,O
was,6775,O
1.2-fold,6775,O
among,6775,O
patients,6775,O
with,6775,O
ovarian,6775,O
cancer,6775,O
than,6775,O
that,6775,O
among,6775,O
patients,6775,O
with,6775,O
benign,6775,O
ovarian,6775,O
lesions,6775,O
.,6775,O
In,6776,O
conclusion,6776,O
",",6776,O
Dysfunction,6776,O
of,6776,O
the,6776,O
cell,6776,O
cycle,6776,O
and/or,6776,O
the,6776,O
cell-cell,6776,O
adhesion,6776,O
molecule,6776,O
plays,6776,O
a,6776,O
role,6776,O
in,6776,O
the,6776,O
pathogenesis,6776,O
of,6776,O
ovarian,6776,O
cancer,6776,O
and,6776,O
that,6776,O
the,6776,O
analysis,6776,O
of,6776,O
the,6776,O
methylation,6776,O
of,6776,O
p15,6776,B-GENE-Y
and,6776,O
E-cadherin,6776,B-GENE-Y
genes,6776,O
can,6776,O
provide,6776,O
clinically,6776,O
important,6776,O
evidence,6776,O
on,6776,O
which,6776,O
to,6776,O
base,6776,O
the,6776,O
treatment,6776,O
.,6776,O
Circulating,6777,O
glucagon,6777,B-GENE-Y
to,6777,O
ghrelin,6777,B-GENE-Y
ratio,6777,O
as,6777,O
a,6777,O
determinant,6777,O
of,6777,O
insulin,6777,B-GENE-Y
resistance,6777,O
in,6777,O
hyperthyroidism,6777,O
.,6777,O
Due,6778,O
to,6778,O
stimulated,6778,O
overall,6778,O
metabolism,6778,O
",",6778,O
a,6778,O
state,6778,O
of,6778,O
nutritional,6778,O
inadequacy,6778,O
often,6778,O
ensues,6778,O
",",6778,O
during,6778,O
thyrotoxicosis,6778,O
.,6778,O
We,6779,O
aimed,6779,O
to,6779,O
investigate,6779,O
circulating,6779,O
levels,6779,O
of,6779,O
some,6779,O
major,6779,O
components,6779,O
of,6779,O
the,6779,O
system,6779,O
that,6779,O
regulates,6779,O
energy,6779,O
stores,6779,O
",",6779,O
glucose,6779,B-CHEMICAL
",",6779,O
and,6779,O
fat,6779,O
metabolism,6779,O
",",6779,O
during,6779,O
thyrotoxicosis,6779,O
compared,6779,O
to,6779,O
euthyroidism,6779,O
.,6779,O
Fasting,6780,O
serum,6780,O
ghrelin,6780,B-GENE-Y
",",6780,O
leptin,6780,B-GENE-Y
",",6780,O
adiponectin,6780,B-GENE-Y
",",6780,O
insulin,6780,B-GENE-Y
",",6780,O
glucagon,6780,B-GENE-Y
",",6780,O
glucose,6780,B-CHEMICAL
",",6780,O
as,6780,O
well,6780,O
as,6780,O
body,6780,O
fat,6780,O
composition,6780,O
were,6780,O
analyzed,6780,O
during,6780,O
thyrotoxicosis,6780,O
in,6780,O
40,6780,O
hyperthyroid,6780,O
patients,6780,O
(,6780,O
50.5,6780,O
±,6780,O
15.2,6780,O
years,6780,O
old,6780,O
",",6780,O
22,6780,O
females,6780,O
",",6780,O
31,6780,O
with,6780,O
Graves,6780,O
disease,6780,O
",",6780,O
and,6780,O
9,6780,O
with,6780,O
toxic,6780,O
nodular,6780,O
goiter,6780,O
),6780,O
.,6780,O
The,6781,O
same,6781,O
measurements,6781,O
were,6781,O
repeated,6781,O
an,6781,O
average,6781,O
3,6781,O
months,6781,O
later,6781,O
",",6781,O
when,6781,O
all,6781,O
patients,6781,O
achieved,6781,O
euthyroidism,6781,O
.,6781,O
Compared,6782,O
to,6782,O
euthyroidism,6782,O
",",6782,O
in,6782,O
thyrotoxicosis,6782,O
",",6782,O
patients,6782,O
had,6782,O
lower,6782,O
ghrelin,6782,B-GENE-Y
and,6782,O
fat,6782,O
mass,6782,O
;,6782,O
had,6782,O
comparable,6782,O
insulin,6782,B-GENE-Y
",",6782,O
HOMA-IR,6782,O
",",6782,O
glucagon,6782,B-GENE-Y
",",6782,O
and,6782,O
leptin,6782,B-GENE-Y
levels,6782,O
;,6782,O
higher,6782,O
levels,6782,O
of,6782,O
circulating,6782,O
adiponectin,6782,B-GENE-Y
.,6782,O
Fasting,6783,O
serum,6783,O
glucose,6783,B-CHEMICAL
tended,6783,O
to,6783,O
be,6783,O
higher,6783,O
during,6783,O
thyrotoxicosis,6783,O
.,6783,O
The,6784,O
unique,6784,O
correlation,6784,O
of,6784,O
HOMA-IR,6784,O
was,6784,O
with,6784,O
the-glucagon,6784,O
to,6784,O
ghrelin,6784,B-GENE-Y
ratio-,6784,O
(,6784,O
r,6784,O
=,6784,O
0.801,6784,O
",",6784,O
p,6784,O
<,6784,O
0.001,6784,O
),6784,O
in,6784,O
hyperthyrodism,6784,O
",",6784,O
and,6784,O
with,6784,O
glucagon,6784,B-GENE-Y
itself,6784,O
in,6784,O
euthyroidism,6784,O
(,6784,O
r,6784,O
=,6784,O
-0.844,6784,O
",",6784,O
p,6784,O
<,6784,O
0.001,6784,O
),6784,O
.,6784,O
Circulating,6785,O
levels,6785,O
of,6785,O
ghrelin,6785,B-GENE-Y
are,6785,O
decreased,6785,O
;,6785,O
leptin,6785,B-GENE-Y
",",6785,O
insulin,6785,B-GENE-Y
",",6785,O
glucagon,6785,B-GENE-Y
are,6785,O
unchanged,6785,O
;,6785,O
adiponectin,6785,B-GENE-Y
are,6785,O
increased,6785,O
during,6785,O
hyperthyroidism,6785,O
.,6785,O
The,6786,O
fasting,6786,O
HOMA-IR,6786,O
tends,6786,O
to,6786,O
be,6786,O
higher,6786,O
",",6786,O
despite,6786,O
the,6786,O
decreased,6786,O
adiposity,6786,O
in,6786,O
hyperthyroidism,6786,O
.,6786,O
The-glucagon,6787,O
to,6787,O
ghrelin,6787,B-GENE-Y
ratio-strongly,6787,O
correlates,6787,O
with,6787,O
fasting,6787,O
HOMA-IR,6787,O
in,6787,O
hyperthyroidism,6787,O
.,6787,O
Proposed,6788,O
diagnostic,6788,O
criteria,6788,O
for,6788,O
subclinical,6788,O
Cushing,6788,O
's,6788,O
syndrome,6788,O
associated,6788,O
with,6788,O
adrenal,6788,O
incidentaloma,6788,O
.,6788,O
Subclinical,6789,O
Cushing,6789,O
's,6789,O
syndrome,6789,O
(,6789,O
SCS,6789,O
),6789,O
associated,6789,O
with,6789,O
adrenal,6789,O
incidentaloma,6789,O
is,6789,O
usually,6789,O
characterized,6789,O
by,6789,O
autonomous,6789,O
cortisol,6789,B-CHEMICAL
secretion,6789,O
without,6789,O
overt,6789,O
symptoms,6789,O
of,6789,O
Cushing,6789,O
's,6789,O
syndrome,6789,O
(,6789,O
CS,6789,O
),6789,O
.,6789,O
Although,6790,O
the,6790,O
diagnostic,6790,O
criteria,6790,O
for,6790,O
SCS,6790,O
differ,6790,O
among,6790,O
countries,6790,O
",",6790,O
the,6790,O
1,6790,O
mg,6790,O
dexamethasone,6790,B-CHEMICAL
suppression,6790,O
test,6790,O
(,6790,O
DST,6790,O
),6790,O
is,6790,O
essential,6790,O
to,6790,O
confirm,6790,O
the,6790,O
presence,6790,O
and,6790,O
the,6790,O
extent,6790,O
of,6790,O
cortisol,6790,B-CHEMICAL
overproduction,6790,O
.,6790,O
Since,6791,O
1995,6791,O
",",6791,O
SCS,6791,O
has,6791,O
been,6791,O
diagnosed,6791,O
in,6791,O
Japan,6791,O
based,6791,O
on,6791,O
serum,6791,O
cortisol,6791,B-CHEMICAL
levels,6791,O
≥3,6791,O
μg/dl,6791,O
(,6791,O
measured,6791,O
by,6791,O
radioimmunoassay,6791,O
[,6791,O
RIA,6791,O
],6791,O
),6791,O
after,6791,O
a,6791,O
1,6791,O
mg,6791,O
DST,6791,O
.,6791,O
However,6792,O
",",6792,O
the,6792,O
increasing,6792,O
use,6792,O
of,6792,O
enzyme,6792,O
immunoassays,6792,O
(,6792,O
EIA,6792,O
),6792,O
instead,6792,O
of,6792,O
RIA,6792,O
has,6792,O
hindered,6792,O
the,6792,O
diagnosis,6792,O
of,6792,O
SCS,6792,O
because,6792,O
of,6792,O
the,6792,O
differing,6792,O
sensitivities,6792,O
of,6792,O
commercially,6792,O
available,6792,O
assays,6792,O
",",6792,O
particularly,6792,O
for,6792,O
serum,6792,O
cortisol,6792,B-CHEMICAL
levels,6792,O
of,6792,O
around,6792,O
3,6792,O
μg/dl,6792,O
.,6792,O
One,6793,O
way,6793,O
to,6793,O
overcome,6793,O
this,6793,O
problem,6793,O
is,6793,O
to,6793,O
lower,6793,O
the,6793,O
cortisol,6793,B-CHEMICAL
threshold,6793,O
level,6793,O
after,6793,O
a,6793,O
1,6793,O
mg,6793,O
DST,6793,O
.,6793,O
In,6794,O
the,6794,O
present,6794,O
study,6794,O
",",6794,O
we,6794,O
examined,6794,O
the,6794,O
clinical,6794,O
applicability,6794,O
of,6794,O
lowering,6794,O
the,6794,O
cortisol,6794,B-CHEMICAL
threshold,6794,O
to,6794,O
1.8,6794,O
μg/dl,6794,O
",",6794,O
similar,6794,O
to,6794,O
the,6794,O
American,6794,O
Endocrine,6794,O
Society,6794,O
's,6794,O
guidelines,6794,O
for,6794,O
CS,6794,O
",",6794,O
by,6794,O
reanalyzing,6794,O
119,6794,O
patients,6794,O
with,6794,O
adrenal,6794,O
incidentaloma,6794,O
.,6794,O
Our,6795,O
findings,6795,O
indicate,6795,O
that,6795,O
serum,6795,O
cortisol,6795,B-CHEMICAL
levels,6795,O
≥1.8,6795,O
μg/dl,6795,O
after,6795,O
1,6795,O
mg,6795,O
DST,6795,O
are,6795,O
useful,6795,O
to,6795,O
confirm,6795,O
the,6795,O
diagnosis,6795,O
of,6795,O
SCS,6795,O
if,6795,O
both,6795,O
of,6795,O
the,6795,O
following,6795,O
criteria,6795,O
are,6795,O
met,6795,O
:,6795,O
(,6795,O
1,6795,O
),6795,O
basal,6795,O
ACTH,6795,B-GENE-Y
level,6795,O
<,6795,O
10,6795,O
pg/ml,6795,O
(,6795,O
or,6795,O
poor,6795,O
plasma,6795,O
ACTH,6795,B-GENE-Y
response,6795,O
to,6795,O
corticotrophin-releasing,6795,B-GENE-Y
hormone,6795,I-GENE-Y
),6795,O
and,6795,O
(,6795,O
2,6795,O
),6795,O
serum,6795,O
cortisol,6795,B-CHEMICAL
≥5,6795,O
μg/dl,6795,O
at,6795,O
21:00,6795,O
to,6795,O
23:00,6795,O
h.,6795,O
If,6795,O
only,6795,O
one,6795,O
of,6795,O
(,6795,O
1,6795,O
),6795,O
and,6795,O
(,6795,O
2,6795,O
),6795,O
are,6795,O
met,6795,O
",",6795,O
we,6795,O
recommend,6795,O
that,6795,O
other,6795,O
clinical,6795,O
features,6795,O
are,6795,O
considered,6795,O
in,6795,O
the,6795,O
diagnosis,6795,O
of,6795,O
SCS,6795,O
",",6795,O
including,6795,O
serum,6795,O
dehydroepiandrosterone,6795,B-CHEMICAL
sulfate,6795,I-CHEMICAL
levels,6795,O
",",6795,O
urine,6795,O
free,6795,O
cortisol,6795,B-CHEMICAL
levels,6795,O
",",6795,O
adrenal,6795,O
scintigraphy,6795,O
",",6795,O
and,6795,O
clinical,6795,O
manifestation,6795,O
.,6795,O
Flexibly,6796,O
timed,6796,O
once-daily,6796,O
dosing,6796,O
with,6796,O
degludec,6796,O
:,6796,O
a,6796,O
new,6796,O
ultra-long-acting,6796,O
basal,6796,O
insulin,6796,B-GENE-Y
.,6796,O
Insulin,6797,B-GENE-Y
treatment,6797,O
in,6797,O
type,6797,O
1,6797,O
and,6797,O
type,6797,O
2,6797,O
diabetes,6797,O
(,6797,O
T1D,6797,O
and,6797,O
T2D,6797,O
),6797,O
is,6797,O
highly,6797,O
efficacious,6797,O
",",6797,O
but,6797,O
in,6797,O
practice,6797,O
",",6797,O
non-adherence,6797,O
and,6797,O
ineffective,6797,O
dose,6797,O
titration,6797,O
limit,6797,O
its,6797,O
effectiveness,6797,O
.,6797,O
Barriers,6798,O
to,6798,O
more,6798,O
effective,6798,O
insulin,6798,B-GENE-Y
treatment,6798,O
are,6798,O
numerous,6798,O
",",6798,O
including,6798,O
hypoglycaemia,6798,O
",",6798,O
fear,6798,O
of,6798,O
hypoglycaemia,6798,O
and,6798,O
concern,6798,O
about,6798,O
weight,6798,O
gain,6798,O
.,6798,O
The,6799,O
regular,6799,O
treatment,6799,O
timing,6799,O
needed,6799,O
with,6799,O
conventional,6799,O
basal,6799,O
insulins,6799,B-GENE-Y
[,6799,O
neutral,6799,O
protamine,6799,O
Hagedorn,6799,O
(,6799,O
NPH,6799,O
),6799,O
insulin,6799,B-GENE-Y
and,6799,O
the,6799,O
first-generation,6799,O
analogues,6799,O
glargine,6799,O
and,6799,O
detemir,6799,O
],6799,O
may,6799,O
also,6799,O
make,6799,O
adherence,6799,O
to,6799,O
these,6799,O
treatments,6799,O
problematic,6799,O
for,6799,O
many,6799,O
patients,6799,O
.,6799,O
Indeed,6800,O
",",6800,O
surveys,6800,O
indicate,6800,O
that,6800,O
the,6800,O
rigidity,6800,O
of,6800,O
this,6800,O
schedule,6800,O
induces,6800,O
some,6800,O
patients,6800,O
with,6800,O
T1D,6800,O
and,6800,O
T2D,6800,O
to,6800,O
omit,6800,O
insulin,6800,B-GENE-Y
doses,6800,O
.,6800,O
Degludec,6801,O
is,6801,O
a,6801,O
novel,6801,O
",",6801,O
ultra-long-acting,6801,O
basal,6801,O
insulin,6801,B-GENE-Y
analogue,6801,O
that,6801,O
is,6801,O
as,6801,O
effective,6801,O
as,6801,O
insulin,6801,B-GENE-Y
glargine,6801,O
",",6801,O
but,6801,O
significantly,6801,O
reduces,6801,O
patients,6801,O
',6801,O
risk,6801,O
of,6801,O
nocturnal,6801,O
hypoglycaemia,6801,O
.,6801,O
Because,6802,O
of,6802,O
its,6802,O
peakless,6802,O
",",6802,O
extended,6802,O
and,6802,O
highly,6802,O
predictable,6802,O
glucose-lowering,6802,B-CHEMICAL
effect,6802,O
",",6802,O
once-daily,6802,O
dosing,6802,O
on,6802,O
a,6802,O
flexible,6802,O
schedule,6802,O
may,6802,O
be,6802,O
feasible,6802,O
with,6802,O
degludec,6802,O
.,6802,O
Studies,6803,O
testing,6803,O
this,6803,O
possibility,6803,O
suggest,6803,O
that,6803,O
degludec,6803,O
tolerates,6803,O
day-to-day,6803,O
variation,6803,O
in,6803,O
dose,6803,O
timing,6803,O
while,6803,O
maintaining,6803,O
full,6803,O
efficacy,6803,O
and,6803,O
low,6803,O
risk,6803,O
of,6803,O
nocturnal,6803,O
hypoglycaemia,6803,O
.,6803,O
Degludec,6804,O
would,6804,O
appear,6804,O
to,6804,O
be,6804,O
an,6804,O
appropriate,6804,O
choice,6804,O
for,6804,O
patients,6804,O
being,6804,O
considered,6804,O
for,6804,O
a,6804,O
basal,6804,O
analogue,6804,O
",",6804,O
and,6804,O
it,6804,O
may,6804,O
be,6804,O
particularly,6804,O
well,6804,O
suited,6804,O
to,6804,O
patients,6804,O
with,6804,O
unpredictable,6804,O
social,6804,O
or,6804,O
work,6804,O
schedules,6804,O
",",6804,O
those,6804,O
who,6804,O
travel,6804,O
frequently,6804,O
and,6804,O
those,6804,O
who,6804,O
find,6804,O
rigid,6804,O
scheduling,6804,O
of,6804,O
their,6804,O
insulin,6804,B-GENE-Y
injections,6804,O
a,6804,O
burden,6804,O
or,6804,O
barrier,6804,O
to,6804,O
regular,6804,O
treatment,6804,O
.,6804,O
Evaluation,6805,O
of,6805,O
a,6805,O
predictive,6805,O
in,6805,O
vitro,6805,O
Leydig,6805,O
cell,6805,O
assay,6805,O
for,6805,O
anti-androgenicity,6805,O
of,6805,O
phthalate,6805,B-CHEMICAL
esters,6805,I-CHEMICAL
in,6805,O
the,6805,O
rat,6805,O
.,6805,O
An,6806,O
in,6806,O
vitro,6806,O
assay,6806,O
using,6806,O
the,6806,O
rat,6806,O
Leydig,6806,O
cell,6806,O
line,6806,O
R2C,6806,O
was,6806,O
evaluated,6806,O
for,6806,O
its,6806,O
ability,6806,O
to,6806,O
quantitatively,6806,O
predict,6806,O
inhibition,6806,O
of,6806,O
testosterone,6806,B-CHEMICAL
synthesis,6806,O
.,6806,O
Results,6807,O
obtained,6807,O
for,6807,O
endocrine,6807,O
active,6807,O
phthalates,6807,B-CHEMICAL
(,6807,O
MEHP,6807,B-CHEMICAL
",",6807,O
MBP,6807,B-CHEMICAL
),6807,O
",",6807,O
and,6807,O
inactive,6807,O
phthalates,6807,B-CHEMICAL
(,6807,O
MMP,6807,B-CHEMICAL
and,6807,O
MEP,6807,B-CHEMICAL
),6807,O
were,6807,O
highly,6807,O
consistent,6807,O
with,6807,O
in,6807,O
vivo,6807,O
results,6807,O
based,6807,O
on,6807,O
tissue,6807,O
and,6807,O
media,6807,O
concentrations,6807,O
.,6807,O
Statistically,6808,O
significant,6808,O
inhibition,6808,O
of,6808,O
testosterone,6808,B-CHEMICAL
synthesis,6808,O
(,6808,O
p,6808,O
<,6808,O
0.05,6808,O
",",6808,O
1-way,6808,O
ANOVA,6808,O
),6808,O
was,6808,O
observed,6808,O
at,6808,O
1μM,6808,O
MBP,6808,B-CHEMICAL
and,6808,O
3μM,6808,O
MEHP,6808,B-CHEMICAL
",",6808,O
while,6808,O
MEP,6808,B-CHEMICAL
and,6808,O
MMP,6808,B-CHEMICAL
did,6808,O
not,6808,O
affect,6808,O
inhibition,6808,O
of,6808,O
testosterone,6808,B-CHEMICAL
synthesis,6808,O
until,6808,O
much,6808,O
higher,6808,O
concentrations,6808,O
(,6808,O
≫100μM,6808,O
),6808,O
.,6808,O
Concentrations,6809,O
causing,6809,O
50,6809,O
%,6809,O
inhibition,6809,O
of,6809,O
testosterone,6809,B-CHEMICAL
synthesis,6809,O
for,6809,O
MBP,6809,B-CHEMICAL
and,6809,O
MEHP,6809,B-CHEMICAL
(,6809,O
3,6809,O
and,6809,O
6μM,6809,O
respectively,6809,O
),6809,O
",",6809,O
were,6809,O
similar,6809,O
to,6809,O
in,6809,O
vivo,6809,O
values,6809,O
(,6809,O
3,6809,O
and,6809,O
7μM,6809,O
),6809,O
.,6809,O
The,6810,O
R2C,6810,O
assay,6810,O
was,6810,O
used,6810,O
to,6810,O
determine,6810,O
the,6810,O
relative,6810,O
potency,6810,O
of,6810,O
14,6810,O
structurally,6810,O
diverse,6810,O
monoesters,6810,B-CHEMICAL
and,6810,O
oxidative,6810,O
metabolites,6810,O
of,6810,O
MEHP,6810,B-CHEMICAL
.,6810,O
Monoesters,6811,B-CHEMICAL
with,6811,O
alkyl,6811,O
chains,6811,O
4-5,6811,O
carbons,6811,B-CHEMICAL
in,6811,O
length,6811,O
had,6811,O
the,6811,O
highest,6811,O
potency,6811,O
for,6811,O
testosterone,6811,B-CHEMICAL
inhibition,6811,O
",",6811,O
while,6811,O
0-2,6811,O
carbon,6811,B-CHEMICAL
alkyl,6811,O
chains,6811,O
were,6811,O
least,6811,O
potent,6811,O
.,6811,O
Phase,6812,O
I,6812,O
metabolism,6812,O
did,6812,O
not,6812,O
completely,6812,O
inactivate,6812,O
MEHP,6812,B-CHEMICAL
",",6812,O
underscoring,6812,O
the,6812,O
need,6812,O
for,6812,O
metabolism,6812,O
data,6812,O
when,6812,O
interpreting,6812,O
in,6812,O
vitro,6812,O
pharmacodynamic,6812,O
data,6812,O
.,6812,O
This,6813,O
steroid,6813,B-CHEMICAL
inhibition,6813,O
assay,6813,O
provides,6813,O
a,6813,O
predictive,6813,O
in,6813,O
vitro,6813,O
alternative,6813,O
to,6813,O
expensive,6813,O
and,6813,O
timeconsuming,6813,O
developmental,6813,O
rat,6813,O
studies,6813,O
for,6813,O
phthalate-induced,6813,B-CHEMICAL
antiandrogenicity,6813,O
.,6813,O
Quercetin,6814,B-CHEMICAL
suppressed,6814,O
CYP2E1-dependent,6814,B-GENE-Y
ethanol,6814,B-CHEMICAL
hepatotoxicity,6814,O
via,6814,O
depleting,6814,O
heme,6814,O
pool,6814,O
and,6814,O
releasing,6814,O
CO,6814,B-CHEMICAL
.,6814,O
Naturally,6815,O
occuring,6815,O
quercetin,6815,B-CHEMICAL
protects,6815,O
hepatocytes,6815,O
from,6815,O
ethanol-induced,6815,B-CHEMICAL
oxidative,6815,O
stress,6815,O
",",6815,O
and,6815,O
heme,6815,B-GENE-Y
oxygenase-1,6815,I-GENE-Y
(,6815,O
HO-1,6815,B-GENE-Y
),6815,O
induction,6815,O
and,6815,O
carbon,6815,B-CHEMICAL
monoxide,6815,I-CHEMICAL
(,6815,O
CO,6815,B-CHEMICAL
),6815,O
metabolite,6815,O
may,6815,O
be,6815,O
implicated,6815,O
in,6815,O
the,6815,O
beneficial,6815,O
effect,6815,O
.,6815,O
However,6816,O
",",6816,O
the,6816,O
precise,6816,O
mechanism,6816,O
by,6816,O
which,6816,O
quercetin,6816,B-CHEMICAL
counteracts,6816,O
CYP2E1-mediated,6816,B-GENE-Y
ethanol,6816,B-CHEMICAL
hepatotoxicity,6816,O
through,6816,O
HO-1,6816,B-GENE-Y
system,6816,O
is,6816,O
still,6816,O
remained,6816,O
unclear,6816,O
.,6816,O
To,6817,O
explore,6817,O
the,6817,O
potential,6817,O
mechanism,6817,O
",",6817,O
herein,6817,O
",",6817,O
ethanol,6817,B-CHEMICAL
(,6817,O
4.0g/kg.bw,6817,O
.,6817,O
),6817,O
was,6818,O
administrated,6818,O
to,6818,O
rats,6818,O
for,6818,O
90,6818,O
days,6818,O
.,6818,O
Our,6819,O
data,6819,O
showed,6819,O
that,6819,O
chronic,6819,O
ethanol,6819,B-CHEMICAL
over-activated,6819,O
CYP2E1,6819,B-GENE-Y
but,6819,O
suppressed,6819,O
HO-1,6819,B-GENE-Y
with,6819,O
concurrent,6819,O
hepatic,6819,O
oxidative,6819,O
damage,6819,O
",",6819,O
which,6819,O
was,6819,O
partially,6819,O
normalized,6819,O
by,6819,O
quercetin,6819,B-CHEMICAL
(,6819,O
100mg/kg.bw,6819,O
.,6819,O
),6819,O
.,6819,O
Quercetin,6820,B-CHEMICAL
(,6820,O
100μM,6820,O
),6820,O
induced,6820,O
HO-1,6820,B-GENE-Y
and,6820,O
depleted,6820,O
heme,6820,O
pool,6820,O
when,6820,O
incubated,6820,O
to,6820,O
human,6820,O
hepatocytes,6820,O
.,6820,O
Ethanol-stimulated,6821,B-CHEMICAL
(,6821,O
100mM,6821,O
),6821,O
CYP2E1,6821,B-GENE-Y
upregulation,6821,O
was,6821,O
suppressed,6821,O
by,6821,O
quercetin,6821,B-CHEMICAL
but,6821,O
further,6821,O
enhanced,6821,O
by,6821,O
HO-1,6821,B-GENE-Y
inhibition,6821,O
with,6821,O
resultant,6821,O
heme,6821,B-CHEMICAL
accumulation,6821,O
.,6821,O
CO,6822,B-CHEMICAL
scavenging,6822,O
blocked,6822,O
the,6822,O
suppression,6822,O
of,6822,O
quercetin,6822,B-CHEMICAL
only,6822,O
on,6822,O
CYP2E1,6822,B-GENE-Y
activity,6822,O
.,6822,O
CO,6823,B-CHEMICAL
donor,6823,O
dose-dependently,6823,O
inactivated,6823,O
CYP2E1,6823,B-GENE-Y
of,6823,O
ethanol-incubated,6823,B-CHEMICAL
microsome,6823,O
",",6823,O
which,6823,O
was,6823,O
mimicked,6823,O
by,6823,O
HO-1,6823,B-GENE-Y
substrate,6823,O
but,6823,O
abolished,6823,O
by,6823,O
CO,6823,B-CHEMICAL
scavenger,6823,O
.,6823,O
Thus,6824,O
",",6824,O
CYP2E1-mediated,6824,B-GENE-Y
ethanol,6824,B-CHEMICAL
hepatotoxicity,6824,O
was,6824,O
alleviated,6824,O
by,6824,O
quercetin,6824,B-CHEMICAL
through,6824,O
HO-1,6824,B-GENE-Y
induction,6824,O
.,6824,O
Depleted,6825,O
heme,6825,O
pool,6825,O
and,6825,O
CO,6825,B-CHEMICAL
releasing,6825,O
limited,6825,O
protein,6825,O
synthesis,6825,O
and,6825,O
inhibited,6825,O
enzymatic,6825,O
activity,6825,O
of,6825,O
CYP2E1,6825,B-GENE-Y
",",6825,O
respectively,6825,O
.,6825,O
Novel,6826,O
racemic,6826,O
tetrahydrocurcuminoid,6826,B-CHEMICAL
dihydropyrimidinone,6826,I-CHEMICAL
analogues,6826,O
as,6826,O
potent,6826,O
acetylcholinesterase,6826,B-GENE-Y
inhibitors,6826,O
.,6826,O
The,6827,O
synthesis,6827,O
of,6827,O
racemic,6827,O
tetrahydrocurcumin-,6827,B-CHEMICAL
(,6827,O
THC-,6827,B-CHEMICAL
),6827,O
",",6827,O
tetrahydrodemethoxycurcumin-,6827,B-CHEMICAL
(,6827,O
THDC-,6827,B-CHEMICAL
),6827,O
and,6827,O
tetrahydrobisdemethoxycurcumin-,6827,B-CHEMICAL
(,6827,O
THBDC-,6827,B-CHEMICAL
),6827,O
dihydropyrimidinone,6827,B-CHEMICAL
(,6827,O
DHPM,6827,B-CHEMICAL
),6827,O
analogues,6827,O
was,6827,O
achieved,6827,O
by,6827,O
utilizing,6827,O
the,6827,O
multi-component,6827,O
Biginelli,6827,O
reaction,6827,O
in,6827,O
the,6827,O
presence,6827,O
of,6827,O
copper,6827,B-CHEMICAL
sulphate,6827,I-CHEMICAL
as,6827,O
a,6827,O
catalyst,6827,O
.,6827,O
The,6828,O
evaluation,6828,O
of,6828,O
acetylcholinesterase,6828,B-GENE-Y
inhibitors,6828,O
for,6828,O
Alzheimer,6828,O
's,6828,O
disease,6828,O
of,6828,O
these,6828,O
compounds,6828,O
showed,6828,O
that,6828,O
they,6828,O
exhibited,6828,O
higher,6828,O
inhibitory,6828,O
activity,6828,O
than,6828,O
their,6828,O
parent,6828,O
analogues,6828,O
.,6828,O
THBDC-DHPM,6829,B-CHEMICAL
demonstrated,6829,O
the,6829,O
most,6829,O
potent,6829,O
inhibitory,6829,O
activity,6829,O
with,6829,O
an,6829,O
IC50,6829,O
value,6829,O
of,6829,O
1.34±0.03μM,6829,O
which,6829,O
was,6829,O
more,6829,O
active,6829,O
than,6829,O
the,6829,O
approved,6829,O
drug,6829,O
galanthamine,6829,B-CHEMICAL
(,6829,O
IC50=1.45±0.04μM,6829,O
),6829,O
.,6829,O
Agonistic,6830,O
activity,6830,O
of,6830,O
ICI,6830,B-CHEMICAL
182,6830,I-CHEMICAL
780,6830,I-CHEMICAL
on,6830,O
activation,6830,O
of,6830,O
GSK,6830,B-GENE-Y
3β/AKT,6830,O
pathway,6830,O
in,6830,O
the,6830,O
rat,6830,O
uterus,6830,O
during,6830,O
the,6830,O
estrous,6830,O
cycle,6830,O
.,6830,O
We,6831,O
examined,6831,O
the,6831,O
ability,6831,O
of,6831,O
ICI,6831,B-CHEMICAL
"182,780",6831,I-CHEMICAL
(,6831,O
ICI,6831,B-CHEMICAL
),6831,O
to,6831,O
block,6831,O
uterine,6831,O
cell,6831,O
proliferation,6831,O
via,6831,O
protein,6831,B-GENE-N
kinase,6831,I-GENE-N
b/AKT,6831,O
pathway,6831,O
in,6831,O
the,6831,O
uterus,6831,O
of,6831,O
the,6831,O
rat,6831,O
during,6831,O
the,6831,O
estrous,6831,O
cycle,6831,O
.,6831,O
Intact,6832,O
rats,6832,O
",",6832,O
with,6832,O
regular,6832,O
estrous,6832,O
cycles,6832,O
",",6832,O
received,6832,O
a,6832,O
subcutaneous,6832,O
(,6832,O
s.c.,6832,O
),6832,O
injection,6832,O
of,6832,O
either,6832,O
vehicle,6832,O
or,6832,O
ICI,6832,B-CHEMICAL
at,6832,O
08:00h,6832,O
on,6832,O
the,6832,O
day,6832,O
of,6832,O
proestrus,6832,O
or,6832,O
at,6832,O
00:00h,6832,O
on,6832,O
the,6832,O
day,6832,O
of,6832,O
estrus,6832,O
and,6832,O
sacrificed,6832,O
at,6832,O
13:00h,6832,O
of,6832,O
metaestrus,6832,O
.,6832,O
Estradiol,6833,B-CHEMICAL
(,6833,O
E2,6833,O
),6833,O
and,6833,O
progesterone,6833,B-CHEMICAL
(,6833,O
P4,6833,O
),6833,O
plasma,6833,O
levels,6833,O
were,6833,O
measured,6833,O
by,6833,O
radioimmunoassay,6833,O
.,6833,O
Both,6834,O
ICI,6834,B-CHEMICAL
treatments,6834,O
",",6834,O
induced,6834,O
a,6834,O
significant,6834,O
decrease,6834,O
(,6834,O
p,6834,O
<,6834,O
0.01,6834,O
),6834,O
in,6834,O
uterine,6834,O
estrogen,6834,B-GENE-Y
receptor,6834,I-GENE-Y
alpha,6834,I-GENE-Y
(,6834,O
ERα,6834,B-GENE-Y
),6834,O
content,6834,O
",",6834,O
had,6834,O
no,6834,O
effect,6834,O
on,6834,O
uterine,6834,O
progesterone,6834,B-GENE-Y
receptor,6834,I-GENE-Y
(,6834,O
PR,6834,B-GENE-Y
),6834,O
protein,6834,O
expression,6834,O
and,6834,O
caused,6834,O
marked,6834,O
nuclear,6834,O
localization,6834,O
of,6834,O
cyclin,6834,B-GENE-Y
D1,6834,I-GENE-Y
",",6834,O
in,6834,O
both,6834,O
luminal,6834,O
and,6834,O
glandular,6834,O
uterine,6834,O
epithelium,6834,O
",",6834,O
as,6834,O
compared,6834,O
to,6834,O
vehicle-treated,6834,O
animals,6834,O
.,6834,O
Furthermore,6835,O
",",6835,O
we,6835,O
detected,6835,O
that,6835,O
ICI,6835,B-CHEMICAL
treatment,6835,O
induced,6835,O
glycogen,6835,B-GENE-N
synthase,6835,I-GENE-N
kinase,6835,I-GENE-N
(,6835,O
Gsk3-β,6835,B-GENE-Y
),6835,O
Ser,6835,O
9,6835,O
phosphorylation,6835,O
",",6835,O
which,6835,O
correlates,6835,O
with,6835,O
cyclin,6835,B-GENE-Y
D1,6835,I-GENE-Y
nuclear,6835,O
localization,6835,O
.,6835,O
However,6836,O
",",6836,O
some,6836,O
differences,6836,O
were,6836,O
observed,6836,O
between,6836,O
the,6836,O
two,6836,O
different,6836,O
time,6836,O
schedules,6836,O
of,6836,O
administration,6836,O
.,6836,O
We,6837,O
observed,6837,O
that,6837,O
the,6837,O
administration,6837,O
of,6837,O
ICI,6837,B-CHEMICAL
at,6837,O
08:00h,6837,O
on,6837,O
proestrus,6837,O
day,6837,O
produced,6837,O
a,6837,O
15,6837,O
%,6837,O
inhibition,6837,O
of,6837,O
luminal,6837,O
epithelial,6837,O
cell,6837,O
proliferation,6837,O
",",6837,O
reduced,6837,O
uterine,6837,O
wet,6837,O
weight,6837,O
by,6837,O
21,6837,O
%,6837,O
and,6837,O
caused,6837,O
reduction,6837,O
of,6837,O
Akt,6837,B-GENE-N
phosphorylation,6837,O
at,6837,O
Ser,6837,B-CHEMICAL
473,6837,O
as,6837,O
compared,6837,O
to,6837,O
vehicle-treated,6837,O
animals,6837,O
",",6837,O
whereas,6837,O
ICI,6837,B-CHEMICAL
treatment,6837,O
at,6837,O
00:00h,6837,O
on,6837,O
estrus,6837,O
day,6837,O
had,6837,O
no,6837,O
effect,6837,O
on,6837,O
these,6837,O
parameters,6837,O
.,6837,O
The,6838,O
overall,6838,O
results,6838,O
indicate,6838,O
that,6838,O
ICI,6838,B-CHEMICAL
may,6838,O
exert,6838,O
agonistic,6838,O
and,6838,O
antagonistic,6838,O
effects,6838,O
on,6838,O
uterine,6838,O
cell,6838,O
proliferation,6838,O
through,6838,O
differential,6838,O
activation,6838,O
of,6838,O
the,6838,O
Akt,6838,B-GENE-N
pathway,6838,O
depending,6838,O
on,6838,O
the,6838,O
administration,6838,O
period,6838,O
during,6838,O
the,6838,O
estrous,6838,O
cycle,6838,O
",",6838,O
and,6838,O
indicates,6838,O
that,6838,O
the,6838,O
mechanism,6838,O
of,6838,O
cell,6838,O
proliferation,6838,O
during,6838,O
the,6838,O
physiological,6838,O
conditions,6838,O
of,6838,O
the,6838,O
estrous,6838,O
cycle,6838,O
",",6838,O
is,6838,O
under,6838,O
a,6838,O
different,6838,O
and,6838,O
more,6838,O
complex,6838,O
regulation,6838,O
than,6838,O
in,6838,O
the,6838,O
ovariectomized,6838,O
+E2,6838,O
animal,6838,O
model,6838,O
.,6838,O
Aminopropylindenes,6839,B-CHEMICAL
derived,6839,O
from,6839,O
Grundmann,6839,B-CHEMICAL
's,6839,I-CHEMICAL
ketone,6839,I-CHEMICAL
as,6839,O
a,6839,O
novel,6839,O
chemotype,6839,O
of,6839,O
oxidosqualene,6839,B-GENE-Y
cyclase,6839,I-GENE-Y
inhibitors,6839,O
.,6839,O
A,6840,O
series,6840,O
of,6840,O
aminopropylindenes,6840,B-CHEMICAL
",",6840,O
designed,6840,O
as,6840,O
mimics,6840,O
of,6840,O
a,6840,O
cationic,6840,O
high,6840,O
energy,6840,O
intermediate,6840,O
in,6840,O
the,6840,O
oxidosqualene,6840,B-CHEMICAL
cyclase,6840,I-GENE-Y
(,6840,I-GENE-Y
1,6840,I-GENE-Y
),6840,I-GENE-Y
(,6840,O
OSC,6840,B-GENE-Y
),6840,O
-mediated,6840,O
cyclization,6840,O
of,6840,O
"2,3-oxidosqualen",6840,B-CHEMICAL
to,6840,O
lanosterol,6840,B-CHEMICAL
was,6840,O
prepared,6840,O
from,6840,O
Grundmann,6840,B-CHEMICAL
's,6840,I-CHEMICAL
ketone,6840,I-CHEMICAL
.,6840,O
Screening,6841,O
on,6841,O
OSCs,6841,B-GENE-N
from,6841,O
five,6841,O
different,6841,O
organisms,6841,O
revealed,6841,O
interesting,6841,O
activities,6841,O
and,6841,O
selectivities,6841,O
of,6841,O
some,6841,O
of,6841,O
the,6841,O
compounds,6841,O
.,6841,O
A,6842,O
N,6842,B-CHEMICAL
",",6842,I-CHEMICAL
N-dimethylaminopropyl,6842,I-CHEMICAL
derivative,6842,O
showed,6842,O
promising,6842,O
inhibition,6842,O
of,6842,O
Trypanosoma,6842,B-GENE-Y
cruzi,6842,I-GENE-Y
OSC,6842,I-GENE-Y
in,6842,O
combination,6842,O
with,6842,O
low,6842,O
cytotoxicity,6842,O
",",6842,O
and,6842,O
showed,6842,O
significant,6842,O
reduction,6842,O
of,6842,O
cholesterol,6842,B-CHEMICAL
biosynthesis,6842,O
in,6842,O
a,6842,O
human,6842,O
cell,6842,O
line,6842,O
.,6842,O
The,6843,O
ATP,6843,B-CHEMICAL
required,6843,O
for,6843,O
potentiation,6843,O
of,6843,O
skeletal,6843,O
muscle,6843,O
contraction,6843,O
is,6843,O
released,6843,O
via,6843,O
pannexin,6843,B-GENE-N
hemichannels,6843,O
.,6843,O
During,6844,O
repetitive,6844,O
stimulation,6844,O
of,6844,O
skeletal,6844,O
muscle,6844,O
",",6844,O
extracellular,6844,O
ATP,6844,B-CHEMICAL
levels,6844,O
raise,6844,O
",",6844,O
activating,6844,O
purinergic,6844,B-GENE-N
receptors,6844,I-GENE-N
",",6844,O
increasing,6844,O
Ca,6844,B-CHEMICAL
(,6844,I-CHEMICAL
2+,6844,I-CHEMICAL
),6844,I-CHEMICAL
influx,6844,O
",",6844,O
and,6844,O
enhancing,6844,O
contractile,6844,O
force,6844,O
",",6844,O
a,6844,O
response,6844,O
called,6844,O
potentiation,6844,O
.,6844,O
We,6845,O
found,6845,O
that,6845,O
ATP,6845,B-CHEMICAL
appears,6845,O
to,6845,O
be,6845,O
released,6845,O
through,6845,O
pannexin1,6845,B-GENE-Y
hemichannels,6845,O
(,6845,O
Panx1,6845,B-GENE-Y
HCs,6845,O
),6845,O
.,6845,O
Immunocytochemical,6846,O
analyses,6846,O
and,6846,O
function,6846,O
were,6846,O
consistent,6846,O
with,6846,O
pannexin1,6846,B-GENE-Y
localization,6846,O
to,6846,O
T-tubules,6846,O
intercalated,6846,O
with,6846,O
dihydropyridine,6846,B-CHEMICAL
and,6846,O
ryanodine,6846,B-GENE-N
receptors,6846,I-GENE-N
in,6846,O
slow,6846,O
(,6846,O
soleus,6846,O
),6846,O
and,6846,O
fast,6846,O
(,6846,O
extensor,6846,O
digitorum,6846,O
longus,6846,O
",",6846,O
EDL,6846,O
),6846,O
muscles,6846,O
.,6846,O
Isolated,6847,O
myofibers,6847,O
took,6847,O
up,6847,O
ethidium,6847,B-CHEMICAL
(,6847,O
Etd,6847,B-CHEMICAL
(,6847,I-CHEMICAL
+,6847,I-CHEMICAL
),6847,I-CHEMICAL
),6847,O
and,6847,O
released,6847,O
small,6847,O
molecules,6847,O
(,6847,O
as,6847,O
ATP,6847,B-CHEMICAL
),6847,O
during,6847,O
electrical,6847,O
stimulation,6847,O
.,6847,O
Consistent,6848,O
with,6848,O
two,6848,O
glucose,6848,B-CHEMICAL
uptake,6848,O
pathways,6848,O
",",6848,O
induced,6848,O
uptake,6848,O
of,6848,O
2-NBDG,6848,B-CHEMICAL
",",6848,O
a,6848,O
fluorescent,6848,O
glucose,6848,B-CHEMICAL
derivative,6848,O
",",6848,O
was,6848,O
decreased,6848,O
by,6848,O
inhibition,6848,O
of,6848,O
HCs,6848,O
or,6848,O
glucose,6848,B-GENE-N
transporter,6848,I-GENE-N
(,6848,O
GLUT4,6848,B-GENE-Y
),6848,O
",",6848,O
and,6848,O
blocked,6848,O
by,6848,O
dual,6848,O
blockade,6848,O
.,6848,O
Adult,6849,O
skeletal,6849,O
muscles,6849,O
apparently,6849,O
do,6849,O
not,6849,O
express,6849,O
connexins,6849,B-GENE-N
",",6849,O
making,6849,O
it,6849,O
unlikely,6849,O
that,6849,O
connexin,6849,B-GENE-N
hemichannels,6849,O
contribute,6849,O
to,6849,O
the,6849,O
uptake,6849,O
and,6849,O
release,6849,O
of,6849,O
small,6849,O
molecules,6849,O
.,6849,O
ATP,6850,B-CHEMICAL
release,6850,O
",",6850,O
Etd,6850,B-CHEMICAL
(,6850,I-CHEMICAL
+,6850,I-CHEMICAL
),6850,I-CHEMICAL
uptake,6850,O
",",6850,O
and,6850,O
potentiation,6850,O
induced,6850,O
by,6850,O
repetitive,6850,O
electrical,6850,O
stimulation,6850,O
were,6850,O
blocked,6850,O
by,6850,O
HC,6850,O
blockers,6850,O
and,6850,O
did,6850,O
not,6850,O
occur,6850,O
in,6850,O
muscles,6850,O
of,6850,O
pannexin1,6850,B-GENE-Y
knockout,6850,O
mice,6850,O
.,6850,O
MRS2179,6851,O
",",6851,O
a,6851,O
P2Y1R,6851,B-GENE-Y
blocker,6851,O
",",6851,O
prevented,6851,O
potentiation,6851,O
in,6851,O
EDL,6851,O
",",6851,O
but,6851,O
not,6851,O
soleus,6851,O
muscles,6851,O
",",6851,O
suggesting,6851,O
that,6851,O
in,6851,O
fast,6851,O
muscles,6851,O
ATP,6851,B-CHEMICAL
activates,6851,O
P2Y1,6851,B-GENE-Y
but,6851,O
not,6851,O
P2X,6851,B-GENE-N
receptors,6851,I-GENE-N
.,6851,O
Phosphorylation,6852,O
on,6852,O
Ser,6852,B-CHEMICAL
and,6852,O
Thr,6852,B-CHEMICAL
residues,6852,O
of,6852,O
pannexin1,6852,B-GENE-Y
was,6852,O
increased,6852,O
during,6852,O
potentiation,6852,O
",",6852,O
possibly,6852,O
mediating,6852,O
HC,6852,O
opening,6852,O
.,6852,O
Opening,6853,O
of,6853,O
Panx1,6853,B-GENE-Y
HCs,6853,O
during,6853,O
repetitive,6853,O
activation,6853,O
allows,6853,O
efflux,6853,O
of,6853,O
ATP,6853,B-CHEMICAL
",",6853,O
influx,6853,O
of,6853,O
glucose,6853,B-CHEMICAL
and,6853,O
possibly,6853,O
Ca,6853,B-CHEMICAL
(,6853,I-CHEMICAL
2+,6853,I-CHEMICAL
),6853,I-CHEMICAL
too,6853,O
",",6853,O
which,6853,O
are,6853,O
required,6853,O
for,6853,O
potentiation,6853,O
of,6853,O
contraction,6853,O
.,6853,O
This,6854,O
article,6854,O
is,6854,O
part,6854,O
of,6854,O
a,6854,O
Special,6854,O
Issue,6854,O
entitled,6854,O
'Connexin,6854,O
based,6854,O
channels,6854,O
',6854,O
.,6854,O
tert-Butylhydroquinone,6855,B-CHEMICAL
reduces,6855,O
lipid,6855,O
accumulation,6855,O
in,6855,O
C57BL/6,6855,O
mice,6855,O
with,6855,O
lower,6855,O
body,6855,O
weight,6855,O
gain,6855,O
.,6855,O
tert-Butylhydroquinone,6856,B-CHEMICAL
(,6856,O
tBHQ,6856,B-CHEMICAL
),6856,O
is,6856,O
a,6856,O
commonly,6856,O
used,6856,O
antioxidant,6856,O
additive,6856,O
that,6856,O
is,6856,O
approved,6856,O
for,6856,O
human,6856,O
use,6856,O
by,6856,O
both,6856,O
the,6856,O
Food,6856,O
and,6856,O
Agriculture,6856,O
Organization,6856,O
and,6856,O
the,6856,O
World,6856,O
Health,6856,O
Organization,6856,O
(,6856,O
FAO/WHO,6856,O
),6856,O
.,6856,O
In,6857,O
this,6857,O
study,6857,O
",",6857,O
we,6857,O
examined,6857,O
the,6857,O
effect,6857,O
of,6857,O
tBHQ,6857,B-CHEMICAL
on,6857,O
body,6857,O
weight,6857,O
gain,6857,O
and,6857,O
found,6857,O
that,6857,O
food,6857,O
supplementation,6857,O
with,6857,O
0.001,6857,O
%,6857,O
(,6857,O
w/w,6857,O
),6857,O
tBHQ,6857,B-CHEMICAL
inhibited,6857,O
61.4,6857,O
%,6857,O
(,6857,O
P,6857,O
<,6857,O
0.01,6857,O
),6857,O
of,6857,O
body,6857,O
weight,6857,O
gain,6857,O
in,6857,O
high-fat,6857,O
diet,6857,O
(,6857,O
HFD,6857,O
),6857,O
-induced,6857,O
C57BL/6,6857,O
mice,6857,O
",",6857,O
and,6857,O
the,6857,O
oral,6857,O
administration,6857,O
of,6857,O
tBHQ,6857,B-CHEMICAL
(,6857,O
1.5,6857,O
mg/kg,6857,O
),6857,O
reduced,6857,O
47.5,6857,O
%,6857,O
(,6857,O
P,6857,O
<,6857,O
0.05,6857,O
),6857,O
of,6857,O
body,6857,O
weight,6857,O
gain,6857,O
in,6857,O
normal,6857,O
diet,6857,O
fed,6857,O
db/db,6857,O
mice,6857,O
.,6857,O
The,6858,O
HFD,6858,O
increased,6858,O
lipid,6858,O
deposit,6858,O
in,6858,O
adipocytes,6858,O
",",6858,O
but,6858,O
these,6858,O
were,6858,O
reduced,6858,O
significantly,6858,O
by,6858,O
tBHQ,6858,B-CHEMICAL
treatment,6858,O
in,6858,O
C57BL/6,6858,O
mice,6858,O
.,6858,O
tBHQ,6859,B-CHEMICAL
supplementation,6859,O
significantly,6859,O
lowered,6859,O
the,6859,O
plasma,6859,O
triglyceride,6859,B-CHEMICAL
and,6859,O
total,6859,O
cholesterol,6859,B-CHEMICAL
",",6859,O
with,6859,O
reduced,6859,O
size,6859,O
of,6859,O
accumulated,6859,O
fat,6859,O
mass,6859,O
.,6859,O
The,6860,O
rate,6860,O
limiting,6860,O
enzyme,6860,O
of,6860,O
beta-oxidation,6860,O
(,6860,O
ACOX1,6860,B-GENE-Y
),6860,O
was,6860,O
significantly,6860,O
over-expressed,6860,O
in,6860,O
the,6860,O
liver,6860,O
with,6860,O
tBHQ,6860,B-CHEMICAL
treatment,6860,O
.,6860,O
These,6861,O
results,6861,O
indicate,6861,O
that,6861,O
tBHQ,6861,B-CHEMICAL
suppresses,6861,O
body,6861,O
weight,6861,O
gain,6861,O
in,6861,O
mice,6861,O
",",6861,O
possibly,6861,O
at,6861,O
least,6861,O
related,6861,O
to,6861,O
the,6861,O
up-regulation,6861,O
of,6861,O
ACOX1,6861,B-GENE-Y
gene,6861,O
expression,6861,O
.,6861,O
Dual,6862,O
Growth,6862,O
Factor,6862,O
Delivery,6862,O
Using,6862,O
Biocompatible,6862,O
Core-Shell,6862,O
Microcapsules,6862,O
for,6862,O
Angiogenesis,6862,O
.,6862,O
An,6863,O
optimized,6863,O
electrodropping,6863,O
system,6863,O
produces,6863,O
homogeneous,6863,O
core-shell,6863,O
microcapsules,6863,O
(,6863,O
C-S,6863,O
MCs,6863,O
),6863,O
by,6863,O
using,6863,O
poly,6863,B-CHEMICAL
(,6863,I-CHEMICAL
L-lactic-co-glycolic,6863,I-CHEMICAL
acid,6863,I-CHEMICAL
),6863,I-CHEMICAL
(,6863,O
PLGA,6863,B-CHEMICAL
),6863,O
and,6863,O
alginate,6863,O
.,6863,O
Fluorescence,6864,O
imaging,6864,O
clearly,6864,O
shows,6864,O
the,6864,O
C-S,6864,O
domain,6864,O
in,6864,O
the,6864,O
MC,6864,O
.,6864,O
For,6865,O
release,6865,O
control,6865,O
",",6865,O
the,6865,O
use,6865,O
of,6865,O
high-molecular-weight,6865,O
PLGA,6865,B-CHEMICAL
(,6865,O
HMW,6865,O
270,6865,O
000,6865,O
),6865,O
restrains,6865,O
the,6865,O
initial,6865,O
burst,6865,O
release,6865,O
of,6865,O
protein,6865,O
compared,6865,O
to,6865,O
that,6865,O
of,6865,O
low-MW,6865,O
PLGA,6865,B-CHEMICAL
(,6865,O
LMW,6865,O
40,6865,O
000,6865,O
),6865,O
.,6865,O
Layer-by-layer,6866,O
(,6866,O
LBL,6866,O
),6866,O
assembly,6866,O
of,6866,O
chitosan,6866,O
and,6866,O
alginate,6866,O
on,6866,O
MCs,6866,O
is,6866,O
also,6866,O
useful,6866,O
in,6866,O
controlling,6866,O
the,6866,O
release,6866,O
profile,6866,O
of,6866,O
biomolecules,6866,O
.,6866,O
LBL,6867,O
(,6867,O
7-layer,6867,O
),6867,O
treatment,6867,O
is,6867,O
effective,6867,O
in,6867,O
suppressing,6867,O
the,6867,O
initial,6867,O
burst,6867,O
release,6867,O
of,6867,O
protein,6867,O
compared,6867,O
to,6867,O
no,6867,O
LBL,6867,O
(,6867,O
0-layer,6867,O
),6867,O
.,6867,O
The,6868,O
difference,6868,O
of,6868,O
cumulative,6868,O
albumin,6868,O
release,6868,O
between,6868,O
HMW,6868,O
(,6868,O
7-layer,6868,O
LBL,6868,O
),6868,O
and,6868,O
LMW,6868,O
(,6868,O
0-layer,6868,O
LBL,6868,O
),6868,O
PLGA,6868,B-CHEMICAL
is,6868,O
determined,6868,O
to,6868,O
be,6868,O
more,6868,O
than,6868,O
40,6868,O
%,6868,O
on,6868,O
day,6868,O
5,6868,O
.,6868,O
When,6869,O
dual,6869,O
angiogenic,6869,O
growth,6869,O
factors,6869,O
(,6869,O
GFs,6869,O
),6869,O
",",6869,O
such,6869,O
as,6869,O
platelet-derived,6869,B-GENE-N
GF,6869,I-GENE-N
(,6869,O
PDGF,6869,B-GENE-N
),6869,O
and,6869,O
vascular,6869,B-GENE-N
endothelial,6869,I-GENE-N
GF,6869,I-GENE-N
(,6869,O
VEGF,6869,B-GENE-N
),6869,O
",",6869,O
are,6869,O
encapsulated,6869,O
separately,6869,O
in,6869,O
the,6869,O
core,6869,O
and,6869,O
shell,6869,O
domains,6869,O
",",6869,O
respectively,6869,O
",",6869,O
the,6869,O
VEGF,6869,B-GENE-N
release,6869,O
rate,6869,O
is,6869,O
much,6869,O
greater,6869,O
than,6869,O
that,6869,O
of,6869,O
PDGF,6869,B-GENE-N
",",6869,O
and,6869,O
the,6869,O
difference,6869,O
of,6869,O
the,6869,O
cumulative,6869,O
release,6869,O
percentage,6869,O
between,6869,O
the,6869,O
two,6869,O
GFs,6869,O
is,6869,O
about,6869,O
30,6869,O
%,6869,O
on,6869,O
day,6869,O
7,6869,O
with,6869,O
LMW,6869,O
core,6869,O
PLGA,6869,B-CHEMICAL
and,6869,O
more,6869,O
than,6869,O
45,6869,O
%,6869,O
with,6869,O
HMW,6869,O
core,6869,O
PLGA,6869,B-CHEMICAL
.,6869,O
As,6870,O
for,6870,O
the,6870,O
angiogenic,6870,O
potential,6870,O
of,6870,O
MC,6870,O
GFs,6870,O
with,6870,O
human,6870,O
umbilical,6870,O
vein,6870,O
endothelial,6870,O
cells,6870,O
(,6870,O
HUVECs,6870,O
),6870,O
",",6870,O
the,6870,O
fluorescence,6870,O
signal,6870,O
of,6870,O
CD31+,6870,B-GENE-Y
suggests,6870,O
that,6870,O
the,6870,O
angiogenic,6870,O
sprout,6870,O
of,6870,O
ECs,6870,O
is,6870,O
more,6870,O
active,6870,O
in,6870,O
MC-mediated,6870,O
GF,6870,O
delivery,6870,O
than,6870,O
conventional,6870,O
GF,6870,O
delivery,6870,O
",",6870,O
and,6870,O
this,6870,O
difference,6870,O
is,6870,O
significant,6870,O
",",6870,O
based,6870,O
on,6870,O
the,6870,O
number,6870,O
of,6870,O
capillary,6870,O
branches,6870,O
in,6870,O
the,6870,O
unit,6870,O
area,6870,O
.,6870,O
This,6871,O
study,6871,O
demonstrates,6871,O
that,6871,O
the,6871,O
fabrication,6871,O
of,6871,O
biocompatible,6871,O
C-S,6871,O
MCs,6871,O
is,6871,O
possible,6871,O
",",6871,O
and,6871,O
that,6871,O
the,6871,O
release,6871,O
control,6871,O
of,6871,O
biomolecules,6871,O
is,6871,O
adjustable,6871,O
.,6871,O
Furthermore,6872,O
",",6872,O
MC-mediated,6872,O
GFs,6872,O
remain,6872,O
in,6872,O
an,6872,O
active,6872,O
form,6872,O
and,6872,O
can,6872,O
upregulate,6872,O
the,6872,O
angiogenic,6872,O
activity,6872,O
of,6872,O
ECs,6872,O
.,6872,O
Potency,6873,O
switch,6873,O
between,6873,O
CHK1,6873,B-GENE-Y
and,6873,O
MK2,6873,B-GENE-Y
:,6873,O
Discovery,6873,O
of,6873,O
imidazo,6873,B-CHEMICAL
[,6873,I-CHEMICAL
"1,2-a",6873,I-CHEMICAL
],6873,I-CHEMICAL
pyrazine-,6873,O
and,6873,O
imidazo,6873,B-CHEMICAL
[,6873,I-CHEMICAL
"1,2-c",6873,I-CHEMICAL
],6873,I-CHEMICAL
pyrimidine-based,6873,O
kinase,6873,B-GENE-N
inhibitors,6873,O
.,6873,O
Chemistry,6874,O
has,6874,O
been,6874,O
developed,6874,O
to,6874,O
access,6874,O
both,6874,O
imidazo,6874,B-CHEMICAL
[,6874,I-CHEMICAL
"1,2-a",6874,I-CHEMICAL
],6874,I-CHEMICAL
pyrazines,6874,I-CHEMICAL
and,6874,O
imidazo,6874,B-CHEMICAL
[,6874,I-CHEMICAL
"1,2-c",6874,I-CHEMICAL
],6874,I-CHEMICAL
pyrimidines,6874,I-CHEMICAL
.,6874,O
Small,6875,O
structural,6875,O
modifications,6875,O
in,6875,O
both,6875,O
series,6875,O
led,6875,O
to,6875,O
a,6875,O
switch,6875,O
of,6875,O
potency,6875,O
between,6875,O
two,6875,O
kinases,6875,B-GENE-N
involved,6875,O
in,6875,O
mediating,6875,O
cell,6875,O
cycle,6875,O
checkpoint,6875,O
control,6875,O
",",6875,O
CHK1,6875,B-GENE-Y
and,6875,O
MK2,6875,B-GENE-Y
.,6875,O
The,6876,O
Fer,6876,B-GENE-Y
tyrosine,6876,B-CHEMICAL
kinase,6876,I-GENE-N
is,6876,O
important,6876,O
for,6876,O
platelet-derived,6876,B-GENE-Y
growth,6876,I-GENE-Y
factor-BB-induced,6876,O
Stat3,6876,B-GENE-Y
phosphorylation,6876,O
",",6876,O
colony,6876,O
formation,6876,O
in,6876,O
soft,6876,O
agar,6876,O
and,6876,O
tumor,6876,O
growth,6876,O
in,6876,O
vivo,6876,O
.,6876,O
Fer,6877,B-GENE-Y
is,6877,O
a,6877,O
cytoplasmic,6877,O
tyrosine,6877,B-CHEMICAL
kinase,6877,I-GENE-N
that,6877,O
is,6877,O
activated,6877,O
in,6877,O
response,6877,O
to,6877,O
platelet-derived,6877,B-GENE-N
growth,6877,I-GENE-N
factor,6877,I-GENE-N
(,6877,O
PDGF,6877,B-GENE-N
),6877,O
stimulation,6877,O
.,6877,O
In,6878,O
the,6878,O
present,6878,O
report,6878,O
",",6878,O
we,6878,O
show,6878,O
that,6878,O
Fer,6878,B-GENE-Y
associates,6878,O
with,6878,O
the,6878,O
activated,6878,O
PDGFbeta,6878,B-GENE-Y
receptor,6878,I-GENE-Y
(,6878,O
PDGFRbeta,6878,B-GENE-Y
),6878,O
through,6878,O
multiple,6878,O
autophosphorylation,6878,O
sites,6878,O
",",6878,O
i.e,6878,O
.,6878,O
Tyr579,6879,B-CHEMICAL
",",6879,O
Tyr581,6879,B-CHEMICAL
",",6879,O
Tyr740,6879,B-CHEMICAL
and,6879,O
Tyr1021,6879,B-CHEMICAL
.,6879,O
Using,6880,O
low,6880,O
molecular,6880,O
weight,6880,O
inhibitors,6880,O
",",6880,O
we,6880,O
found,6880,O
that,6880,O
PDGF-BB-induced,6880,B-GENE-Y
Fer,6880,B-GENE-Y
activation,6880,O
is,6880,O
dependent,6880,O
on,6880,O
PDGFRbeta,6880,B-GENE-Y
kinase,6880,B-GENE-N
activity,6880,O
",",6880,O
but,6880,O
not,6880,O
on,6880,O
the,6880,O
enzymatic,6880,O
activity,6880,O
of,6880,O
Src,6880,B-GENE-Y
or,6880,O
Jak,6880,B-GENE-N
kinases,6880,B-GENE-N
.,6880,O
In,6881,O
cells,6881,O
in,6881,O
which,6881,O
Fer,6881,B-GENE-Y
was,6881,O
downregulated,6881,O
using,6881,O
siRNA,6881,O
",",6881,O
PDGF-BB,6881,B-GENE-Y
was,6881,O
unable,6881,O
to,6881,O
induce,6881,O
phosphorylation,6881,O
of,6881,O
Stat3,6881,B-GENE-Y
",",6881,O
whereas,6881,O
phosphorylations,6881,O
of,6881,O
Stat5,6881,B-GENE-N
",",6881,O
Erk1/2,6881,B-GENE-N
and,6881,O
Akt,6881,B-GENE-N
were,6881,O
unaffected,6881,O
.,6881,O
PDGF-BB-induced,6882,B-GENE-Y
activation,6882,O
of,6882,O
Stat3,6882,B-GENE-Y
occurred,6882,O
also,6882,O
in,6882,O
cells,6882,O
expressing,6882,O
kinase-dead,6882,B-GENE-N
Fer,6882,B-GENE-Y
",",6882,O
suggesting,6882,O
a,6882,O
kinase-independent,6882,B-GENE-N
adaptor,6882,O
role,6882,O
of,6882,O
Fer,6882,B-GENE-Y
.,6882,O
Expression,6883,O
of,6883,O
Fer,6883,B-GENE-Y
was,6883,O
dispensable,6883,O
for,6883,O
PDGF-BB-induced,6883,B-GENE-Y
proliferation,6883,O
and,6883,O
migration,6883,O
",",6883,O
but,6883,O
essential,6883,O
for,6883,O
colony,6883,O
formation,6883,O
in,6883,O
soft,6883,O
agar,6883,O
.,6883,O
Tumor,6884,O
growth,6884,O
in,6884,O
vivo,6884,O
was,6884,O
delayed,6884,O
in,6884,O
cells,6884,O
depleted,6884,O
of,6884,O
Fer,6884,B-GENE-Y
expression,6884,O
.,6884,O
Our,6885,O
data,6885,O
suggests,6885,O
a,6885,O
critical,6885,O
role,6885,O
of,6885,O
Fer,6885,B-GENE-Y
in,6885,O
PDGF-BB-induced,6885,B-GENE-Y
Stat3,6885,B-GENE-Y
activation,6885,O
and,6885,O
cell,6885,O
transformation,6885,O
.,6885,O
Discovery,6886,O
of,6886,O
aryl,6886,B-CHEMICAL
ureas,6886,I-CHEMICAL
and,6886,O
aryl,6886,B-CHEMICAL
amides,6886,I-CHEMICAL
as,6886,O
potent,6886,O
and,6886,O
selective,6886,O
histamine,6886,B-CHEMICAL
H3,6886,I-GENE-Y
receptor,6886,I-GENE-Y
antagonists,6886,O
for,6886,O
the,6886,O
treatment,6886,O
of,6886,O
obesity,6886,O
(,6886,O
Part,6886,O
I,6886,O
),6886,O
.,6886,O
A,6887,O
series,6887,O
of,6887,O
structurally,6887,O
novel,6887,O
aryl,6887,B-CHEMICAL
ureas,6887,I-CHEMICAL
was,6887,O
derived,6887,O
from,6887,O
optimization,6887,O
of,6887,O
the,6887,O
HTS,6887,O
lead,6887,O
as,6887,O
selective,6887,O
histamine,6887,B-GENE-Y
H3,6887,I-GENE-Y
receptor,6887,I-GENE-Y
(,6887,O
H3R,6887,B-GENE-Y
),6887,O
antagonists,6887,O
.,6887,O
The,6888,O
SAR,6888,O
was,6888,O
explored,6888,O
and,6888,O
the,6888,O
data,6888,O
obtained,6888,O
set,6888,O
up,6888,O
the,6888,O
starting,6888,O
point,6888,O
and,6888,O
foundation,6888,O
for,6888,O
further,6888,O
optimization,6888,O
.,6888,O
The,6889,O
most,6889,O
potent,6889,O
tool,6889,O
compounds,6889,O
",",6889,O
as,6889,O
exemplified,6889,O
by,6889,O
compounds,6889,O
2l,6889,O
",",6889,O
5b,6889,O
",",6889,O
5d,6889,O
",",6889,O
and,6889,O
5e,6889,O
",",6889,O
displayed,6889,O
antagonism,6889,O
potencies,6889,O
in,6889,O
the,6889,O
subnanomolar,6889,O
range,6889,O
in,6889,O
in,6889,O
vitro,6889,O
human-H3R,6889,B-GENE-Y
FLIPR,6889,O
assays,6889,O
and,6889,O
rhesus,6889,B-GENE-Y
monkey,6889,I-GENE-Y
H3R,6889,I-GENE-Y
binding,6889,O
assays,6889,O
.,6889,O
Structure,6890,O
and,6890,O
energetics,6890,O
of,6890,O
gas,6890,O
phase,6890,O
halogen-bonding,6890,B-CHEMICAL
in,6890,O
mono-,6890,B-GENE-N
",",6890,I-GENE-N
bi-,6890,I-GENE-N
",",6890,I-GENE-N
and,6890,I-GENE-N
tri-dentate,6890,I-GENE-N
anion,6890,I-GENE-N
receptors,6890,I-GENE-N
as,6890,O
studied,6890,O
by,6890,O
BIRD,6890,O
.,6890,O
Complexes,6891,O
of,6891,O
mono-,6891,B-GENE-N
",",6891,I-GENE-N
bi-,6891,I-GENE-N
(,6891,I-GENE-N
RB,6891,I-GENE-N
),6891,I-GENE-N
",",6891,I-GENE-N
and,6891,I-GENE-N
tridentate,6891,I-GENE-N
(,6891,I-GENE-N
RT,6891,I-GENE-N
),6891,I-GENE-N
receptors,6891,I-GENE-N
with,6891,O
a,6891,O
range,6891,O
of,6891,O
anions,6891,O
(,6891,O
Cl,6891,B-CHEMICAL
(,6891,I-CHEMICAL
-,6891,I-CHEMICAL
),6891,I-CHEMICAL
",",6891,O
Br,6891,B-CHEMICAL
(,6891,I-CHEMICAL
-,6891,I-CHEMICAL
),6891,I-CHEMICAL
",",6891,O
I,6891,B-CHEMICAL
(,6891,I-CHEMICAL
-,6891,I-CHEMICAL
),6891,I-CHEMICAL
",",6891,O
NO3,6891,B-CHEMICAL
(,6891,I-CHEMICAL
-,6891,I-CHEMICAL
),6891,I-CHEMICAL
",",6891,O
H2PO4,6891,B-CHEMICAL
(,6891,I-CHEMICAL
-,6891,I-CHEMICAL
),6891,I-CHEMICAL
",",6891,O
HSO4,6891,B-CHEMICAL
(,6891,I-CHEMICAL
-,6891,I-CHEMICAL
),6891,I-CHEMICAL
",",6891,O
and,6891,O
tosylate,6891,B-CHEMICAL
(,6891,O
TsO,6891,B-CHEMICAL
(,6891,I-CHEMICAL
-,6891,I-CHEMICAL
),6891,I-CHEMICAL
),6891,O
),6891,O
have,6891,O
been,6891,O
studied,6891,O
in,6891,O
the,6891,O
gas,6891,O
phase,6891,O
by,6891,O
both,6891,O
experimental,6891,O
and,6891,O
theoretical,6891,O
methods,6891,O
.,6891,O
Temperature,6892,O
dependent,6892,O
blackbody,6892,O
infrared,6892,O
radiative,6892,O
dissociation,6892,O
(,6892,O
BIRD,6892,O
),6892,O
experiments,6892,O
were,6892,O
performed,6892,O
on,6892,O
complexes,6892,O
of,6892,O
C8F17I,6892,B-CHEMICAL
with,6892,O
Br,6892,B-CHEMICAL
(,6892,I-CHEMICAL
-,6892,I-CHEMICAL
),6892,I-CHEMICAL
and,6892,O
I,6892,B-CHEMICAL
(,6892,I-CHEMICAL
-,6892,I-CHEMICAL
),6892,I-CHEMICAL
",",6892,O
RB,6892,O
with,6892,O
I,6892,B-CHEMICAL
(,6892,I-CHEMICAL
-,6892,I-CHEMICAL
),6892,I-CHEMICAL
",",6892,O
NO3,6892,B-CHEMICAL
(,6892,I-CHEMICAL
-,6892,I-CHEMICAL
),6892,I-CHEMICAL
",",6892,O
HSO4,6892,B-CHEMICAL
(,6892,I-CHEMICAL
-,6892,I-CHEMICAL
),6892,I-CHEMICAL
",",6892,O
H2PO4,6892,B-CHEMICAL
(,6892,I-CHEMICAL
-,6892,I-CHEMICAL
),6892,I-CHEMICAL
",",6892,O
and,6892,O
TsO,6892,B-CHEMICAL
(,6892,I-CHEMICAL
-,6892,I-CHEMICAL
),6892,I-CHEMICAL
",",6892,O
and,6892,O
RT,6892,O
with,6892,O
I,6892,B-CHEMICAL
(,6892,I-CHEMICAL
-,6892,I-CHEMICAL
),6892,I-CHEMICAL
",",6892,O
HSO4,6892,B-CHEMICAL
(,6892,I-CHEMICAL
-,6892,I-CHEMICAL
),6892,I-CHEMICAL
and,6892,O
TsO,6892,B-CHEMICAL
(,6892,I-CHEMICAL
-,6892,I-CHEMICAL
),6892,I-CHEMICAL
and,6892,O
the,6892,O
observed,6892,O
Arrhenius,6892,O
parameters,6892,O
are,6892,O
reported,6892,O
here,6892,O
.,6892,O
Master,6893,O
equation,6893,O
modeling,6893,O
of,6893,O
the,6893,O
BIRD,6893,O
kinetics,6893,O
data,6893,O
was,6893,O
carried,6893,O
out,6893,O
to,6893,O
determine,6893,O
threshold,6893,O
dissociation,6893,O
energies,6893,O
.,6893,O
Geometry,6894,O
optimizations,6894,O
and,6894,O
thermochemistry,6894,O
calculations,6894,O
were,6894,O
performed,6894,O
using,6894,O
the,6894,O
B3LYP/6-31+G,6894,O
(,6894,O
d,6894,O
",",6894,O
p,6894,O
),6894,O
level,6894,O
of,6894,O
theory,6894,O
.,6894,O
Additional,6895,O
single,6895,O
point,6895,O
energies,6895,O
were,6895,O
calculated,6895,O
using,6895,O
MP2/6-311++G,6895,O
(,6895,O
2d,6895,O
",",6895,O
p,6895,O
),6895,O
.,6895,O
Results,6896,O
were,6896,O
examined,6896,O
in,6896,O
terms,6896,O
of,6896,O
the,6896,O
binding,6896,O
order,6896,O
of,6896,O
various,6896,O
anions,6896,O
as,6896,O
well,6896,O
as,6896,O
the,6896,O
added,6896,O
binding,6896,O
strength,6896,O
from,6896,O
additional,6896,O
halogen,6896,B-CHEMICAL
bonding,6896,O
(,6896,O
XB,6896,O
),6896,O
interactions,6896,O
.,6896,O
The,6897,O
relative,6897,O
binding,6897,O
energies,6897,O
of,6897,O
ions,6897,O
were,6897,O
generally,6897,O
consistent,6897,O
with,6897,O
the,6897,O
ordering,6897,O
previously,6897,O
reported,6897,O
from,6897,O
solution,6897,O
phase,6897,O
experiments,6897,O
;,6897,O
however,6897,O
",",6897,O
the,6897,O
relatively,6897,O
strong,6897,O
binding,6897,O
of,6897,O
H2PO4,6897,B-CHEMICAL
(,6897,I-CHEMICAL
-,6897,I-CHEMICAL
),6897,I-CHEMICAL
to,6897,O
the,6897,O
bidentate,6897,O
receptor,6897,O
contrasted,6897,O
the,6897,O
solution,6897,O
phase,6897,O
observation,6897,O
of,6897,O
oxoanions,6897,B-CHEMICAL
having,6897,O
weaker,6897,O
interactions,6897,O
when,6897,O
compared,6897,O
to,6897,O
halides,6897,B-CHEMICAL
.,6897,O
An,6898,O
increase,6898,O
in,6898,O
the,6898,O
energy,6898,O
required,6898,O
to,6898,O
remove,6898,O
the,6898,O
same,6898,O
anion,6898,O
from,6898,O
the,6898,O
tridentate,6898,B-GENE-N
receptor,6898,I-GENE-N
when,6898,O
compared,6898,O
to,6898,O
the,6898,O
bidentate,6898,B-GENE-N
and,6898,I-GENE-N
monodentate,6898,I-GENE-N
receptors,6898,I-GENE-N
is,6898,O
explained,6898,O
as,6898,O
being,6898,O
due,6898,O
to,6898,O
the,6898,O
increase,6898,O
in,6898,O
halogen,6898,B-CHEMICAL
bonding,6898,O
interactions,6898,O
.,6898,O
The,6899,O
possibility,6899,O
of,6899,O
mixed,6899,O
halogen,6899,B-CHEMICAL
and,6899,O
hydrogen,6899,B-CHEMICAL
bonded,6899,O
complexes,6899,O
were,6899,O
considered,6899,O
.,6899,O
Anandamide,6900,B-CHEMICAL
deficiency,6900,O
and,6900,O
heightened,6900,O
neuropathic,6900,O
pain,6900,O
in,6900,O
aged,6900,O
mice,6900,O
.,6900,O
Damaging,6901,O
of,6901,O
peripheral,6901,O
nerves,6901,O
may,6901,O
result,6901,O
in,6901,O
chronic,6901,O
neuropathic,6901,O
pain,6901,O
for,6901,O
which,6901,O
the,6901,O
likelihood,6901,O
is,6901,O
increased,6901,O
in,6901,O
the,6901,O
elderly,6901,O
.,6901,O
We,6902,O
assessed,6902,O
in,6902,O
mice,6902,O
if,6902,O
age-dependent,6902,O
alterations,6902,O
of,6902,O
endocannabinoids,6902,O
contributed,6902,O
to,6902,O
the,6902,O
heightened,6902,O
vulnerability,6902,O
to,6902,O
neuropathic,6902,O
pain,6902,O
at,6902,O
old,6902,O
age,6902,O
.,6902,O
We,6903,O
assessed,6903,O
nociception,6903,O
",",6903,O
endocannabinoids,6903,O
and,6903,O
the,6903,O
therapeutic,6903,O
efficacy,6903,O
of,6903,O
R-flurbiprofen,6903,B-CHEMICAL
in,6903,O
young,6903,O
and,6903,O
aged,6903,O
mice,6903,O
in,6903,O
the,6903,O
spared,6903,O
nerve,6903,O
injury,6903,O
model,6903,O
of,6903,O
neuropathic,6903,O
pain,6903,O
.,6903,O
R-flurbiprofen,6904,B-CHEMICAL
was,6904,O
used,6904,O
because,6904,O
it,6904,O
is,6904,O
able,6904,O
to,6904,O
reduce,6904,O
neuropathic,6904,O
pain,6904,O
in,6904,O
young,6904,O
mice,6904,O
in,6904,O
part,6904,O
by,6904,O
increasing,6904,O
anandamide,6904,B-CHEMICAL
.,6904,O
Aged,6905,O
mice,6905,O
developed,6905,O
stronger,6905,O
nociceptive,6905,O
hypersensitivity,6905,O
after,6905,O
sciatic,6905,O
nerve,6905,O
injury,6905,O
than,6905,O
young,6905,O
mice,6905,O
.,6905,O
This,6906,O
was,6906,O
associated,6906,O
with,6906,O
low,6906,O
anandamide,6906,B-CHEMICAL
levels,6906,O
in,6906,O
the,6906,O
dorsal,6906,O
root,6906,O
ganglia,6906,O
",",6906,O
spinal,6906,O
cord,6906,O
",",6906,O
thalamus,6906,O
and,6906,O
cortex,6906,O
",",6906,O
which,6906,O
further,6906,O
decreased,6906,O
after,6906,O
nerve,6906,O
injury,6906,O
.,6906,O
In,6907,O
aged,6907,O
mice,6907,O
",",6907,O
R-flurbiprofen,6907,B-CHEMICAL
had,6907,O
only,6907,O
weak,6907,O
antinociceptive,6907,O
efficacy,6907,O
and,6907,O
it,6907,O
failed,6907,O
to,6907,O
restore,6907,O
normal,6907,O
anandamide,6907,B-CHEMICAL
levels,6907,O
after,6907,O
nerve,6907,O
injury,6907,O
.,6907,O
In,6908,O
terms,6908,O
of,6908,O
the,6908,O
mechanisms,6908,O
",",6908,O
we,6908,O
found,6908,O
that,6908,O
fatty,6908,B-GENE-N
acid,6908,I-GENE-N
amide,6908,I-GENE-N
hydrolase,6908,I-GENE-N
(,6908,O
FAAH,6908,B-GENE-N
),6908,O
which,6908,O
degrades,6908,O
anandamide,6908,B-CHEMICAL
",",6908,O
was,6908,O
upregulated,6908,O
after,6908,O
nerve,6908,O
injury,6908,O
at,6908,O
both,6908,O
ages,6908,O
",",6908,O
so,6908,O
that,6908,O
this,6908,O
upregulation,6908,O
likely,6908,O
did,6908,O
not,6908,O
account,6908,O
for,6908,O
the,6908,O
age-dependent,6908,O
differences,6908,O
.,6908,O
However,6909,O
",",6909,O
enzymes,6909,O
contributing,6909,O
to,6909,O
oxidative,6909,O
metabolism,6909,O
of,6909,O
anandamide,6909,B-CHEMICAL
",",6909,O
namely,6909,O
cyclooxygenase-1,6909,B-GENE-Y
and,6909,O
Cyp2D6,6909,B-GENE-N
",",6909,O
were,6909,O
increased,6909,O
in,6909,O
the,6909,O
brain,6909,O
of,6909,O
aged,6909,O
mice,6909,O
",",6909,O
possibly,6909,O
enhancing,6909,O
the,6909,O
oxidative,6909,O
breakdown,6909,O
of,6909,O
anandamide,6909,B-CHEMICAL
.,6909,O
This,6910,O
may,6910,O
overwhelm,6910,O
the,6910,O
capacity,6910,O
of,6910,O
R-flurbiprofen,6910,B-CHEMICAL
to,6910,O
restore,6910,O
anandamide,6910,B-CHEMICAL
homeostasis,6910,O
and,6910,O
may,6910,O
contribute,6910,O
to,6910,O
the,6910,O
heightened,6910,O
risk,6910,O
for,6910,O
neuropathic,6910,O
pain,6910,O
at,6910,O
old,6910,O
age,6910,O
.,6910,O
Polymer-based,6911,O
protein,6911,O
engineering,6911,O
can,6911,O
rationally,6911,O
tune,6911,O
enzyme,6911,O
activity,6911,O
",",6911,O
pH-dependence,6911,O
",",6911,O
and,6911,O
stability,6911,O
.,6911,O
The,6912,O
attachment,6912,O
of,6912,O
inert,6912,O
polymers,6912,O
",",6912,O
such,6912,O
as,6912,O
polyethyleneglycol,6912,B-CHEMICAL
",",6912,O
to,6912,O
proteins,6912,O
has,6912,O
driven,6912,O
the,6912,O
emergence,6912,O
of,6912,O
a,6912,O
multibillion,6912,O
dollar,6912,O
biotechnology,6912,O
industry,6912,O
.,6912,O
In,6913,O
all,6913,O
cases,6913,O
",",6913,O
proteins,6913,O
have,6913,O
been,6913,O
stabilized,6913,O
or,6913,O
altered,6913,O
by,6913,O
covalently,6913,O
coupling,6913,O
the,6913,O
pre-existing,6913,O
polymer,6913,O
to,6913,O
the,6913,O
surface,6913,O
of,6913,O
the,6913,O
protein,6913,O
.,6913,O
This,6914,O
approach,6914,O
is,6914,O
inherently,6914,O
limited,6914,O
by,6914,O
a,6914,O
lack,6914,O
of,6914,O
exquisite,6914,O
control,6914,O
of,6914,O
polymer,6914,O
architecture,6914,O
",",6914,O
chain,6914,O
length,6914,O
",",6914,O
site,6914,O
and,6914,O
density,6914,O
of,6914,O
attachment,6914,O
.,6914,O
Using,6915,O
a,6915,O
novel,6915,O
water-soluble,6915,O
atom,6915,O
transfer,6915,O
radical,6915,O
polymerization,6915,O
initiator,6915,O
",",6915,O
we,6915,O
have,6915,O
grown,6915,O
temperature-,6915,O
and,6915,O
pH-responsive,6915,O
polymers,6915,O
from,6915,O
the,6915,O
surface,6915,O
of,6915,O
a,6915,O
model,6915,O
protein,6915,O
",",6915,O
the,6915,O
enzyme,6915,O
chymotrypsin,6915,B-GENE-N
.,6915,O
Poly,6916,B-CHEMICAL
(,6916,I-CHEMICAL
2-,6916,I-CHEMICAL
(,6916,I-CHEMICAL
dimethylamino,6916,I-CHEMICAL
),6916,I-CHEMICAL
ethyl,6916,I-CHEMICAL
methacrylate,6916,I-CHEMICAL
),6916,I-CHEMICAL
changes,6916,O
in,6916,O
conformation,6916,O
with,6916,O
altered,6916,O
temperature,6916,O
and,6916,O
pH,6916,O
.,6916,O
Growing,6917,O
the,6917,O
polymer,6917,O
from,6917,O
the,6917,O
surface,6917,O
of,6917,O
chymotrypsin,6917,B-GENE-N
we,6917,O
were,6917,O
able,6917,O
to,6917,O
demonstrate,6917,O
that,6917,O
changes,6917,O
in,6917,O
temperature,6917,O
or,6917,O
pH,6917,O
can,6917,O
change,6917,O
predictably,6917,O
the,6917,O
conformation,6917,O
of,6917,O
the,6917,O
polymer,6917,O
surrounding,6917,O
the,6917,O
enzyme,6917,O
",",6917,O
which,6917,O
in,6917,O
turn,6917,O
enabled,6917,O
the,6917,O
rational,6917,O
tailoring,6917,O
of,6917,O
enzyme,6917,O
activity,6917,O
and,6917,O
stability,6917,O
.,6917,O
Using,6918,O
what,6918,O
we,6918,O
now,6918,O
term,6918,O
``,6918,O
Polymer-Based,6918,O
Protein,6918,O
Engineering,6918,O
'',6918,O
we,6918,O
have,6918,O
increased,6918,O
the,6918,O
activity,6918,O
and,6918,O
stability,6918,O
of,6918,O
chymotrypsin,6918,B-GENE-N
by,6918,O
an,6918,O
order,6918,O
of,6918,O
magnitude,6918,O
at,6918,O
pH,6918,O
's,6918,O
where,6918,O
the,6918,O
enzyme,6918,O
is,6918,O
usually,6918,O
inactive,6918,O
or,6918,O
unstable,6918,O
.,6918,O
24,6919,B-CHEMICAL
(,6919,I-CHEMICAL
S,6919,I-CHEMICAL
),6919,I-CHEMICAL
-hydroxycholesterol,6919,I-CHEMICAL
is,6919,O
actively,6919,O
eliminated,6919,O
from,6919,O
neuronal,6919,O
cells,6919,O
by,6919,O
ABCA1,6919,B-GENE-Y
.,6919,O
High,6920,O
cholesterol,6920,B-CHEMICAL
turnover,6920,O
catalyzed,6920,O
by,6920,O
cholesterol,6920,B-CHEMICAL
24-hydroxylase,6920,I-GENE-Y
is,6920,O
essential,6920,O
for,6920,O
neural,6920,O
functions,6920,O
",",6920,O
especially,6920,O
learning,6920,O
.,6920,O
Because,6921,O
24,6921,B-CHEMICAL
(,6921,I-CHEMICAL
S,6921,I-CHEMICAL
),6921,I-CHEMICAL
-hydroxycholesterol,6921,I-CHEMICAL
(,6921,O
24-OHC,6921,B-CHEMICAL
),6921,O
",",6921,O
produced,6921,O
by,6921,O
24-hydroxylase,6921,B-GENE-Y
",",6921,O
induces,6921,O
apoptosis,6921,O
of,6921,O
neuronal,6921,O
cells,6921,O
",",6921,O
it,6921,O
is,6921,O
vital,6921,O
to,6921,O
eliminate,6921,O
it,6921,O
rapidly,6921,O
from,6921,O
cells,6921,O
.,6921,O
Here,6922,O
",",6922,O
using,6922,O
differentiated,6922,O
SH-SY5Y,6922,O
neuron-like,6922,O
cells,6922,O
as,6922,O
a,6922,O
model,6922,O
",",6922,O
we,6922,O
examined,6922,O
whether,6922,O
24-OHC,6922,B-CHEMICAL
is,6922,O
actively,6922,O
eliminated,6922,O
via,6922,O
transporters,6922,B-GENE-N
induced,6922,O
by,6922,O
its,6922,O
accumulation,6922,O
.,6922,O
The,6923,O
expression,6923,O
of,6923,O
ABCA1,6923,B-GENE-Y
and,6923,O
ABCG1,6923,B-GENE-Y
was,6923,O
induced,6923,O
by,6923,O
24-OHC,6923,B-CHEMICAL
",",6923,O
as,6923,O
well,6923,O
as,6923,O
TO901317,6923,B-CHEMICAL
and,6923,O
retinoic,6923,B-CHEMICAL
acid,6923,I-CHEMICAL
",",6923,O
which,6923,O
are,6923,O
ligands,6923,O
of,6923,O
the,6923,O
nuclear,6923,B-GENE-N
receptors,6923,I-GENE-N
LXR/RXR,6923,B-GENE-N
.,6923,O
When,6924,O
the,6924,O
expression,6924,O
of,6924,O
ABCA1,6924,B-GENE-Y
and,6924,O
ABCG1,6924,B-GENE-Y
was,6924,O
induced,6924,O
",",6924,O
24-OHC,6924,B-CHEMICAL
efflux,6924,O
was,6924,O
stimulated,6924,O
in,6924,O
the,6924,O
presence,6924,O
of,6924,O
high,6924,B-GENE-N
density,6924,I-GENE-N
lipoprotein,6924,I-GENE-N
(,6924,O
HDL,6924,B-GENE-N
),6924,O
",",6924,O
whereas,6924,O
apolipoprotein,6924,B-GENE-Y
A-I,6924,I-GENE-Y
was,6924,O
not,6924,O
an,6924,O
efficient,6924,O
acceptor,6924,O
.,6924,O
The,6925,O
efflux,6925,O
was,6925,O
suppressed,6925,O
by,6925,O
the,6925,O
addition,6925,O
of,6925,O
siRNA,6925,O
against,6925,O
ABCA1,6925,B-GENE-Y
",",6925,O
but,6925,O
not,6925,O
by,6925,O
ABCG1,6925,B-GENE-Y
siRNA,6925,O
.,6925,O
To,6926,O
confirm,6926,O
the,6926,O
role,6926,O
of,6926,O
each,6926,O
transporter,6926,O
",",6926,O
we,6926,O
analyzed,6926,O
HEK293,6926,O
cells,6926,O
stably,6926,O
expressing,6926,O
human,6926,B-GENE-Y
ABCA1,6926,I-GENE-Y
or,6926,O
ABCG1,6926,B-GENE-Y
;,6926,O
we,6926,O
clearly,6926,O
observed,6926,O
24-OHC,6926,B-CHEMICAL
efflux,6926,O
in,6926,O
the,6926,O
presence,6926,O
of,6926,O
HDL,6926,B-GENE-N
",",6926,O
whereas,6926,O
efflux,6926,O
in,6926,O
the,6926,O
presence,6926,O
of,6926,O
apolipoprotein,6926,B-GENE-Y
A-I,6926,I-GENE-Y
was,6926,O
marginal,6926,O
.,6926,O
Furthermore,6927,O
",",6927,O
the,6927,O
treatment,6927,O
of,6927,O
primary,6927,O
cerebral,6927,O
neurons,6927,O
with,6927,O
LXR/RXR,6927,B-GENE-N
ligands,6927,O
suppressed,6927,O
the,6927,O
toxicity,6927,O
of,6927,O
24-OHC,6927,B-CHEMICAL
.,6927,O
These,6928,O
results,6928,O
suggest,6928,O
that,6928,O
ABCA1,6928,B-GENE-Y
actively,6928,O
eliminates,6928,O
24-OHC,6928,B-CHEMICAL
in,6928,O
the,6928,O
presence,6928,O
of,6928,O
HDL,6928,B-GENE-N
as,6928,O
a,6928,O
lipid,6928,O
acceptor,6928,O
and,6928,O
protects,6928,O
neuronal,6928,O
cells,6928,O
.,6928,O
This,6929,O
article,6929,O
is,6929,O
protected,6929,O
by,6929,O
copyright,6929,O
.,6929,O
All,6930,O
rights,6930,O
reserved,6930,O
.,6930,O
Design,6931,O
",",6931,O
Synthesis,6931,O
and,6931,O
biological,6931,O
evaluation,6931,O
of,6931,O
catecholamine,6931,B-CHEMICAL
vehicle,6931,O
for,6931,O
studying,6931,O
dopaminergic,6931,O
system,6931,O
.,6931,O
Catecholamine,6932,B-CHEMICAL
mimetic,6932,O
EDTA-bis,6932,B-CHEMICAL
(,6932,I-CHEMICAL
tyramide,6932,I-CHEMICAL
),6932,I-CHEMICAL
was,6932,O
synthesized,6932,O
and,6932,O
characterized,6932,O
by,6932,O
various,6932,O
spectroscopic,6932,O
techniques,6932,O
(,6932,O
NMR,6932,O
",",6932,O
Mass,6932,O
spectroscopy,6932,O
),6932,O
and,6932,O
λem,6932,O
310,6932,O
nm,6932,O
for,6932,O
the,6932,O
excitation,6932,O
at,6932,O
270,6932,O
nm,6932,O
.,6932,O
Molecular,6933,O
docking,6933,O
studies,6933,O
were,6933,O
performed,6933,O
with,6933,O
Human,6933,B-GENE-Y
Serum,6933,I-GENE-Y
Albumin,6933,I-GENE-Y
(,6933,O
HSA,6933,B-GENE-Y
:,6933,O
PDB,6933,O
1E78,6933,O
),6933,O
",",6933,O
showing,6933,O
binding,6933,O
pattern,6933,O
with,6933,O
amino,6933,B-CHEMICAL
acid,6933,I-CHEMICAL
residues,6933,O
Arg218,6933,B-CHEMICAL
",",6933,O
Arg222,6933,B-CHEMICAL
and,6933,O
Lys444,6933,B-CHEMICAL
",",6933,O
identifies,6933,O
the,6933,O
ligand-HSA,6933,O
interaction,6933,O
for,6933,O
the,6933,O
transportation,6933,O
affinity,6933,O
of,6933,O
the,6933,O
ligand,6933,O
at,6933,O
the,6933,O
specific,6933,O
site,6933,O
of,6933,O
the,6933,O
target,6933,O
.,6933,O
Subsequently,6934,O
binding,6934,O
study,6934,O
with,6934,O
HSA,6934,O
at,6934,O
λex,6934,O
=350,6934,O
nm,6934,O
found,6934,O
to,6934,O
be,6934,O
5.847x10,6934,O
(,6934,O
4,6934,O
),6934,O
M,6934,O
(,6934,O
-1,6934,O
),6934,O
shows,6934,O
effective,6934,O
quenching,6934,O
effect,6934,O
.,6934,O
Additionally,6935,O
to,6935,O
go,6935,O
more,6935,O
insight,6935,O
AChE,6935,O
binding,6935,O
affinity,6935,O
was,6935,O
investigated,6935,O
",",6935,O
which,6935,O
shows,6935,O
90,6935,O
%,6935,O
binding,6935,O
affinity,6935,O
for,6935,O
the,6935,O
10,6935,O
mM,6935,O
concentration,6935,O
.,6935,O
IC50,6936,O
value,6936,O
was,6936,O
was,6936,O
found,6936,O
18.60,6936,O
μM,6936,O
for,6936,O
MAO-B,6936,B-GENE-Y
inhibition,6936,O
.,6936,O
Finally,6937,O
",",6937,O
EDTA-bis,6937,B-CHEMICAL
(,6937,I-CHEMICAL
tyramide,6937,I-CHEMICAL
),6937,I-CHEMICAL
labeled,6937,O
with,6937,O
(,6937,B-CHEMICAL
99m,6937,I-CHEMICAL
),6937,I-CHEMICAL
Tc,6937,I-CHEMICAL
to,6937,O
investigate,6937,O
its,6937,O
in-vivo,6937,O
radiopharmaceutical,6937,O
efficiency,6937,O
",",6937,O
having,6937,O
97,6937,O
%,6937,O
binding,6937,O
affinity,6937,O
with,6937,O
98,6937,O
%,6937,O
radiochemical,6937,O
purity,6937,O
.,6937,O
In-vivo,6938,O
studies,6938,O
were,6938,O
carried,6938,O
out,6938,O
for,6938,O
(,6938,B-CHEMICAL
99m,6938,I-CHEMICAL
),6938,I-CHEMICAL
Tc-,6938,I-CHEMICAL
EDTA-bis,6938,I-CHEMICAL
(,6938,I-CHEMICAL
tyramide,6938,I-CHEMICAL
),6938,I-CHEMICAL
included,6938,O
blood,6938,O
kinetics,6938,O
showed,6938,O
a,6938,O
quick,6938,O
wash,6938,O
out,6938,O
from,6938,O
the,6938,O
circulation,6938,O
via,6938,O
renal,6938,O
route,6938,O
and,6938,O
biodistribution,6938,O
revealed,6938,O
that,6938,O
maximum,6938,O
%,6938,O
ID/g,6938,O
was,6938,O
found,6938,O
in,6938,O
kidney,6938,O
at,6938,O
1h,6938,O
and,6938,O
its,6938,O
scintigraphy,6938,O
image,6938,O
shows,6938,O
3.96,6938,O
%,6938,O
brain,6938,O
uptake,6938,O
with,6938,O
respect,6938,O
to,6938,O
whole,6938,O
body,6938,O
.,6938,O
This,6939,O
article,6939,O
is,6939,O
protected,6939,O
by,6939,O
copyright,6939,O
.,6939,O
All,6940,O
rights,6940,O
reserved,6940,O
.,6940,O
Synergistic,6941,O
enhancement,6941,O
of,6941,O
cancer,6941,O
therapy,6941,O
using,6941,O
a,6941,O
combination,6941,O
of,6941,O
heat,6941,B-GENE-N
shock,6941,I-GENE-N
protein,6941,I-GENE-N
targeted,6941,O
HPMA,6941,B-CHEMICAL
copolymer-drug,6941,O
conjugates,6941,O
and,6941,O
gold,6941,O
nanorod,6941,O
induced,6941,O
hyperthermia,6941,O
.,6941,O
In,6942,O
the,6942,O
field,6942,O
of,6942,O
nanomedicine,6942,O
",",6942,O
selective,6942,O
delivery,6942,O
to,6942,O
cancer,6942,O
cells,6942,O
is,6942,O
a,6942,O
common,6942,O
goal,6942,O
",",6942,O
where,6942,O
active,6942,O
targeting,6942,O
strategies,6942,O
are,6942,O
often,6942,O
employed,6942,O
to,6942,O
increase,6942,O
tumor,6942,O
accumulation,6942,O
.,6942,O
In,6943,O
this,6943,O
study,6943,O
",",6943,O
tumor,6943,O
hyperthermia,6943,O
was,6943,O
utilized,6943,O
as,6943,O
a,6943,O
means,6943,O
to,6943,O
increase,6943,O
the,6943,O
active,6943,O
delivery,6943,O
of,6943,O
heat,6943,B-GENE-N
shock,6943,I-GENE-N
protein,6943,I-GENE-N
(,6943,O
HSP,6943,B-GENE-N
),6943,O
targeted,6943,O
N-,6943,B-CHEMICAL
(,6943,I-CHEMICAL
2-hydroxypropyl,6943,I-CHEMICAL
),6943,I-CHEMICAL
methacrylamide,6943,I-CHEMICAL
(,6943,O
HPMA,6943,B-CHEMICAL
),6943,O
copolymer-drug,6943,O
conjugates,6943,O
.,6943,O
Following,6944,O
hyperthermia,6944,O
",",6944,O
induced,6944,O
expression,6944,O
of,6944,O
cell,6944,O
surface,6944,O
heat,6944,B-GENE-N
shock,6944,I-GENE-N
protein,6944,I-GENE-N
(,6944,O
HSP,6944,B-GENE-N
),6944,O
glucose,6944,B-CHEMICAL
regulated,6944,I-GENE-Y
protein,6944,I-GENE-Y
78kDa,6944,I-GENE-Y
(,6944,O
GRP78,6944,B-GENE-Y
),6944,O
was,6944,O
utilized,6944,O
for,6944,O
targeted,6944,O
drug,6944,O
therapy,6944,O
.,6944,O
Conjugates,6945,O
bearing,6945,O
the,6945,O
anticancer,6945,O
agents,6945,O
aminohexylgeldanamycin,6945,B-CHEMICAL
(,6945,O
AHGDM,6945,B-CHEMICAL
),6945,O
",",6945,O
docetaxel,6945,B-CHEMICAL
(,6945,O
DOC,6945,B-CHEMICAL
),6945,O
",",6945,O
or,6945,O
cisplatin,6945,B-CHEMICAL
and,6945,O
the,6945,O
GRP78,6945,B-GENE-Y
targeting,6945,O
peptide,6945,O
WDLAWMFRLPVG,6945,O
were,6945,O
synthesized,6945,O
and,6945,O
characterized,6945,O
.,6945,O
Binding,6946,O
to,6946,O
cell,6946,O
surface,6946,O
expressed,6946,O
heat,6946,B-GENE-N
shock,6946,I-GENE-N
protein,6946,I-GENE-N
GRP78,6946,B-GENE-Y
on,6946,O
the,6946,O
surface,6946,O
of,6946,O
human,6946,O
prostate,6946,O
cancer,6946,O
DU145,6946,O
cells,6946,O
was,6946,O
evaluated,6946,O
.,6946,O
HSP,6947,B-GENE-N
targeted,6947,O
AHGDM,6947,B-CHEMICAL
and,6947,O
DOC,6947,B-CHEMICAL
conjugates,6947,O
demonstrated,6947,O
active,6947,O
binding,6947,O
comparable,6947,O
to,6947,O
native,6947,O
targeting,6947,O
peptide,6947,O
.,6947,O
They,6948,O
were,6948,O
then,6948,O
assessed,6948,O
in,6948,O
vitro,6948,O
for,6948,O
the,6948,O
ability,6948,O
to,6948,O
synergistically,6948,O
induce,6948,O
cytotoxicity,6948,O
in,6948,O
combination,6948,O
with,6948,O
moderate,6948,O
hyperthermia,6948,O
(,6948,O
43°C,6948,O
",",6948,O
30min,6948,O
),6948,O
.,6948,O
HSP,6949,B-GENE-N
targeted,6949,O
DOC,6949,B-CHEMICAL
conjugates,6949,O
exhibited,6949,O
high,6949,O
potency,6949,O
against,6949,O
DU145,6949,O
cells,6949,O
with,6949,O
an,6949,O
IC50,6949,O
of,6949,O
2.4nM,6949,O
.,6949,O
HSP,6950,B-GENE-N
targeted,6950,O
AHGDM,6950,B-CHEMICAL
and,6950,O
DOC,6950,B-CHEMICAL
conjugates,6950,O
demonstrated,6950,O
synergistic,6950,O
effects,6950,O
in,6950,O
combination,6950,O
with,6950,O
hyperthermia,6950,O
with,6950,O
combination,6950,O
index,6950,O
values,6950,O
of,6950,O
0.65,6950,O
and,6950,O
0.45,6950,O
respectively,6950,O
.,6950,O
Based,6951,O
on,6951,O
these,6951,O
results,6951,O
",",6951,O
HSP,6951,B-GENE-N
targeted,6951,O
DOC,6951,B-CHEMICAL
conjugates,6951,O
were,6951,O
selected,6951,O
for,6951,O
in,6951,O
vivo,6951,O
evaluation,6951,O
.,6951,O
In,6952,O
DU145,6952,O
tumor,6952,O
bearing,6952,O
mice,6952,O
",",6952,O
a,6952,O
single,6952,O
treatment,6952,O
of,6952,O
tumor,6952,O
hyperthermia,6952,O
",",6952,O
induced,6952,O
via,6952,O
gold,6952,O
nanorod,6952,O
mediated,6952,O
plasmonic,6952,O
photothermal,6952,O
therapy,6952,O
",",6952,O
and,6952,O
intravenous,6952,O
administration,6952,O
of,6952,O
HSP,6952,B-GENE-N
targeted,6952,O
HPMA,6952,B-CHEMICAL
copolymer-docetaxel,6952,O
at,6952,O
10mg/kg,6952,O
resulted,6952,O
in,6952,O
maintained,6952,O
tumor,6952,O
regression,6952,O
for,6952,O
a,6952,O
period,6952,O
of,6952,O
30days,6952,O
.,6952,O
These,6953,O
results,6953,O
demonstrate,6953,O
the,6953,O
potential,6953,O
for,6953,O
tumor,6953,O
hyperthermia,6953,O
to,6953,O
increase,6953,O
the,6953,O
delivery,6953,O
of,6953,O
HSP,6953,B-GENE-N
targeted,6953,O
macromolecular,6953,O
chemotherapeutics,6953,O
.,6953,O
Presynaptic,6954,O
CaMKIIα,6954,B-GENE-Y
modulates,6954,O
dopamine,6954,B-GENE-Y
D3,6954,I-GENE-Y
receptor,6954,I-GENE-Y
activation,6954,O
in,6954,O
striatonigral,6954,O
terminals,6954,O
of,6954,O
the,6954,O
rat,6954,O
brain,6954,O
in,6954,O
a,6954,O
Ca,6954,B-CHEMICAL
(,6954,I-CHEMICAL
2+,6954,I-CHEMICAL
),6954,I-CHEMICAL
dependent,6954,O
manner,6954,O
.,6954,O
CaMKIIα,6955,B-GENE-Y
is,6955,O
expressed,6955,O
at,6955,O
high,6955,O
density,6955,O
in,6955,O
the,6955,O
nucleus,6955,O
accumbens,6955,O
where,6955,O
it,6955,O
binds,6955,O
to,6955,O
postsynaptic,6955,O
D3,6955,B-GENE-Y
receptors,6955,I-GENE-Y
inhibiting,6955,O
their,6955,O
effects,6955,O
.,6955,O
In,6956,O
striatonigral,6956,O
projections,6956,O
",",6956,O
activation,6956,O
of,6956,O
presynaptic,6956,O
D3,6956,B-GENE-Y
receptors,6956,I-GENE-Y
potentiates,6956,O
D1,6956,B-GENE-Y
receptor-induced,6956,O
stimulation,6956,O
of,6956,O
cAMP,6956,O
production,6956,O
and,6956,O
GABA,6956,O
release,6956,O
.,6956,O
In,6957,O
this,6957,O
study,6957,O
we,6957,O
examined,6957,O
whether,6957,O
the,6957,O
presynaptic,6957,O
effects,6957,O
of,6957,O
D3,6957,B-GENE-Y
receptor,6957,I-GENE-Y
stimulation,6957,O
in,6957,O
the,6957,O
substantia,6957,O
nigra,6957,O
reticulata,6957,O
(,6957,O
SNr,6957,O
),6957,O
are,6957,O
modulated,6957,O
by,6957,O
Ca,6957,B-CHEMICAL
(,6957,I-CHEMICAL
2+,6957,I-CHEMICAL
),6957,I-CHEMICAL
activation,6957,O
of,6957,O
CaMKIIα,6957,B-GENE-Y
.,6957,O
In,6958,O
SNr,6958,O
synaptosomes,6958,O
two,6958,O
procedures,6958,O
that,6958,O
increase,6958,O
cytoplasmic,6958,O
Ca,6958,B-CHEMICAL
(,6958,I-CHEMICAL
2+,6958,I-CHEMICAL
),6958,I-CHEMICAL
",",6958,O
ionomycin,6958,B-CHEMICAL
and,6958,O
K,6958,B-CHEMICAL
(,6958,I-CHEMICAL
+,6958,I-CHEMICAL
),6958,I-CHEMICAL
-depolarization,6958,O
",",6958,O
blocked,6958,O
the,6958,O
additional,6958,O
stimulation,6958,O
of,6958,O
cAMP,6958,B-CHEMICAL
accumulation,6958,O
produced,6958,O
by,6958,O
coactivating,6958,O
D3,6958,B-GENE-N
and,6958,I-GENE-N
D1,6958,I-GENE-N
dopamine,6958,I-GENE-N
receptors,6958,I-GENE-N
.,6958,O
The,6959,O
selective,6959,O
CaMKIIα,6959,B-GENE-Y
inhibitor,6959,O
KN-62,6959,B-CHEMICAL
reversed,6959,O
the,6959,O
blockade,6959,O
produced,6959,O
by,6959,O
ionomycin,6959,B-CHEMICAL
and,6959,O
K,6959,B-CHEMICAL
(,6959,I-CHEMICAL
+,6959,I-CHEMICAL
),6959,I-CHEMICAL
-depolarization,6959,O
.,6959,O
Incubation,6960,O
in,6960,O
either,6960,O
Ca,6960,B-CHEMICAL
(,6960,I-CHEMICAL
2,6960,I-CHEMICAL
),6960,I-CHEMICAL
-free,6960,O
solutions,6960,O
or,6960,O
with,6960,O
the,6960,O
selective,6960,O
Ca,6960,B-CHEMICAL
(,6960,I-CHEMICAL
2+,6960,I-CHEMICAL
),6960,I-CHEMICAL
blocker,6960,O
nifedipine,6960,B-CHEMICAL
",",6960,O
also,6960,O
reversed,6960,O
the,6960,O
blocking,6960,O
effects,6960,O
of,6960,O
K,6960,B-CHEMICAL
(,6960,I-CHEMICAL
+,6960,I-CHEMICAL
),6960,I-CHEMICAL
-depolarization,6960,O
.,6960,O
Immunoblot,6961,O
studies,6961,O
showed,6961,O
that,6961,O
K,6961,B-CHEMICAL
(,6961,I-CHEMICAL
+,6961,I-CHEMICAL
),6961,I-CHEMICAL
-depolarization,6961,O
increased,6961,O
CaMKIIα,6961,B-GENE-Y
phosphorylation,6961,O
in,6961,O
a,6961,O
KN-62,6961,B-CHEMICAL
sensitive,6961,O
manner,6961,O
and,6961,O
promoted,6961,O
CaMKIIα,6961,B-GENE-Y
binding,6961,O
to,6961,O
D3,6961,B-GENE-Y
receptors,6961,I-GENE-Y
.,6961,O
In,6962,O
K,6962,B-CHEMICAL
(,6962,I-CHEMICAL
+,6962,I-CHEMICAL
),6962,I-CHEMICAL
-depolarized,6962,O
tissues,6962,O
",",6962,O
D3,6962,B-GENE-Y
receptors,6962,I-GENE-Y
potentiated,6962,O
D1,6962,B-GENE-N
receptor-induced,6962,O
stimulation,6962,O
of,6962,O
[,6962,B-CHEMICAL
(,6962,I-CHEMICAL
3,6962,I-CHEMICAL
),6962,I-CHEMICAL
H,6962,I-CHEMICAL
],6962,I-CHEMICAL
GABA,6962,I-CHEMICAL
release,6962,O
only,6962,O
when,6962,O
CaMKIIα,6962,B-GENE-Y
was,6962,O
blocked,6962,O
with,6962,O
KN-62,6962,B-CHEMICAL
.,6962,O
In,6963,O
the,6963,O
presence,6963,O
of,6963,O
this,6963,O
inhibitor,6963,O
",",6963,O
the,6963,O
selective,6963,O
D3,6963,B-GENE-Y
agonist,6963,O
PD,6963,B-CHEMICAL
"128,907",6963,I-CHEMICAL
reduced,6963,O
the,6963,O
ED50,6963,O
for,6963,O
the,6963,O
D1,6963,B-GENE-Y
agonist,6963,O
SKF,6963,B-CHEMICAL
38393,6963,I-CHEMICAL
from,6963,O
56,6963,O
to,6963,O
4,6963,O
nM,6963,O
.,6963,O
KN-62,6964,B-CHEMICAL
also,6964,O
enhanced,6964,O
the,6964,O
effects,6964,O
of,6964,O
dopamine,6964,B-CHEMICAL
on,6964,O
depolarization,6964,O
induced,6964,O
[,6964,B-CHEMICAL
(,6964,I-CHEMICAL
3,6964,I-CHEMICAL
),6964,I-CHEMICAL
H,6964,I-CHEMICAL
],6964,I-CHEMICAL
GABA,6964,I-CHEMICAL
release,6964,O
.,6964,O
KN-62,6965,B-CHEMICAL
changed,6965,O
ED50,6965,O
for,6965,O
dopamine,6965,B-CHEMICAL
from,6965,O
584,6965,O
to,6965,O
56,6965,O
nM,6965,O
.,6965,O
KN-62,6966,B-CHEMICAL
did,6966,O
not,6966,O
affect,6966,O
D1,6966,B-GENE-N
and,6966,I-GENE-N
D4,6966,I-GENE-N
receptor,6966,I-GENE-N
responses,6966,O
.,6966,O
These,6967,O
experiments,6967,O
show,6967,O
that,6967,O
in,6967,O
striatonigral,6967,O
projections,6967,O
",",6967,O
CaMKIIα,6967,B-GENE-Y
inhibits,6967,O
the,6967,O
action,6967,O
of,6967,O
D3,6967,B-GENE-Y
receptors,6967,I-GENE-Y
in,6967,O
a,6967,O
Ca,6967,B-CHEMICAL
(,6967,I-CHEMICAL
2+,6967,I-CHEMICAL
),6967,I-CHEMICAL
dependent,6967,O
manner,6967,O
blocking,6967,O
their,6967,O
modulatory,6967,O
effects,6967,O
on,6967,O
GABA,6967,B-CHEMICAL
release,6967,O
.,6967,O
These,6968,O
findings,6968,O
suggest,6968,O
a,6968,O
mechanism,6968,O
through,6968,O
which,6968,O
the,6968,O
frequency,6968,O
of,6968,O
action,6968,O
potential,6968,O
discharge,6968,O
in,6968,O
presynaptic,6968,O
terminals,6968,O
regulates,6968,O
dopamine,6968,B-CHEMICAL
effects,6968,O
.,6968,O
Ellagic,6969,B-CHEMICAL
acid,6969,I-CHEMICAL
attenuates,6969,O
bleomycin,6969,B-CHEMICAL
and,6969,O
cyclophosphamide-induced,6969,B-CHEMICAL
pulmonary,6969,O
toxicity,6969,O
in,6969,O
Wistar,6969,O
rats,6969,O
.,6969,O
Use,6970,O
of,6970,O
bleomycin,6970,B-CHEMICAL
(,6970,O
BLM,6970,B-CHEMICAL
),6970,O
and,6970,O
cyclophosphamide,6970,B-CHEMICAL
(,6970,O
CP,6970,O
),6970,O
as,6970,O
chemotherapeutic,6970,O
drugs,6970,O
is,6970,O
associated,6970,O
with,6970,O
side,6970,O
effects,6970,O
including,6970,O
toxicity,6970,O
to,6970,O
respiratory,6970,O
system,6970,O
.,6970,O
Their,6971,O
co-administration,6971,O
may,6971,O
enhance,6971,O
lung,6971,O
toxicity,6971,O
which,6971,O
may,6971,O
subsequently,6971,O
progress,6971,O
to,6971,O
the,6971,O
lung,6971,O
fibrosis,6971,O
.,6971,O
Natural,6972,O
compounds,6972,O
have,6972,O
shown,6972,O
mitigating,6972,O
effects,6972,O
against,6972,O
toxicity,6972,O
of,6972,O
anticancer,6972,O
drugs,6972,O
.,6972,O
Ellagic,6973,B-CHEMICAL
acid,6973,I-CHEMICAL
(,6973,O
EA,6973,O
),6973,O
",",6973,O
a,6973,O
polyphenolic,6973,O
compound,6973,O
present,6973,O
in,6973,O
many,6973,O
fruits,6973,O
and,6973,O
nuts,6973,O
in,6973,O
addition,6973,O
to,6973,O
walnut,6973,O
has,6973,O
shown,6973,O
promising,6973,O
protective,6973,O
effect,6973,O
against,6973,O
toxicity,6973,O
of,6973,O
drugs,6973,O
and,6973,O
chemicals,6973,O
.,6973,O
We,6974,O
studied,6974,O
the,6974,O
ameliorative,6974,O
effect,6974,O
of,6974,O
EA,6974,O
on,6974,O
lung,6974,O
toxicity,6974,O
in,6974,O
rats,6974,O
exposed,6974,O
to,6974,O
CP,6974,O
(,6974,O
150mg/kgb.w.,6974,O
",",6974,O
i.p,6974,O
.,6974,O
),6974,O
and,6975,O
BLM,6975,B-CHEMICAL
(,6975,O
10U/kgb.w.,6975,O
",",6975,O
i.t,6975,O
.,6975,O
),6975,O
.,6975,O
EA,6976,O
(,6976,O
15mg/kgb.w.,6976,O
",",6976,O
p.o.×14days,6976,O
),6976,O
treatment,6976,O
modulated,6976,O
enhanced,6976,O
hydroxyproline,6976,B-CHEMICAL
level,6976,O
",",6976,O
lipid,6976,O
peroxidation,6976,O
",",6976,O
myeloperoxidase,6976,B-GENE-Y
activity,6976,O
",",6976,O
nitric,6976,B-CHEMICAL
oxide,6976,I-CHEMICAL
production,6976,O
and,6976,O
protein,6976,O
carbonyl,6976,B-CHEMICAL
formation,6976,O
in,6976,O
lungs,6976,O
of,6976,O
rats,6976,O
exposed,6976,O
to,6976,O
toxic,6976,O
anticancer,6976,O
drugs,6976,O
.,6976,O
There,6977,O
was,6977,O
a,6977,O
marked,6977,O
decrease,6977,O
in,6977,O
GSH,6977,B-CHEMICAL
content,6977,O
and,6977,O
activities,6977,O
of,6977,O
antioxidant,6977,O
enzymes,6977,O
as,6977,O
a,6977,O
result,6977,O
of,6977,O
BLM,6977,B-CHEMICAL
and,6977,O
CP,6977,O
treatment,6977,O
.,6977,O
Bronchoalveolar,6978,O
lavage,6978,O
fluid,6978,O
showed,6978,O
increased,6978,O
level,6978,O
of,6978,O
cytotoxicity,6978,O
markers,6978,O
in,6978,O
drug,6978,O
treated,6978,O
animals,6978,O
.,6978,O
Treatment,6979,O
with,6979,O
EA,6979,O
attenuated,6979,O
these,6979,O
changes,6979,O
.,6979,O
Histopathological,6980,O
findings,6980,O
also,6980,O
showed,6980,O
protective,6980,O
effects,6980,O
of,6980,O
EA,6980,O
.,6980,O
In,6981,O
conclusion,6981,O
",",6981,O
EA,6981,O
emerged,6981,O
as,6981,O
a,6981,O
natural,6981,O
protectant,6981,O
with,6981,O
an,6981,O
ability,6981,O
to,6981,O
protect,6981,O
lungs,6981,O
from,6981,O
onslaught,6981,O
of,6981,O
pulmonary,6981,O
toxicity,6981,O
of,6981,O
anticancer,6981,O
drugs,6981,O
.,6981,O
Effects,6982,O
of,6982,O
High,6982,O
Iron,6982,B-CHEMICAL
and,6982,O
Glucose,6982,B-CHEMICAL
Concentrations,6982,O
over,6982,O
the,6982,O
Relative,6982,O
Expression,6982,O
of,6982,O
Bcl2,6982,B-GENE-Y
",",6982,O
Bax,6982,B-GENE-Y
",",6982,O
and,6982,O
Mfn2,6982,B-GENE-Y
in,6982,O
MIN6,6982,O
Cells,6982,O
.,6982,O
Type,6983,O
2,6983,O
diabetes,6983,O
is,6983,O
characterized,6983,O
by,6983,O
hyperglycemia,6983,O
and,6983,O
oxidative,6983,O
stress,6983,O
.,6983,O
Hyperglycemia,6984,O
is,6984,O
linked,6984,O
to,6984,O
mitochondrial,6984,O
dysfunction,6984,O
and,6984,O
reduced,6984,O
β-cell,6984,O
mass,6984,O
due,6984,O
to,6984,O
the,6984,O
reduced,6984,O
expression,6984,O
of,6984,O
genes,6984,O
such,6984,O
as,6984,O
Mfn2,6984,B-GENE-Y
as,6984,O
well,6984,O
as,6984,O
the,6984,O
participation,6984,O
of,6984,O
the,6984,O
Bcl2,6984,B-GENE-Y
gene,6984,O
family,6984,O
",",6984,O
responsible,6984,O
for,6984,O
increased,6984,O
apoptosis,6984,O
.,6984,O
The,6985,O
purpose,6985,O
of,6985,O
this,6985,O
study,6985,O
was,6985,O
to,6985,O
describe,6985,O
the,6985,O
effect,6985,O
of,6985,O
different,6985,O
iron,6985,B-CHEMICAL
and/or,6985,O
glucose,6985,B-CHEMICAL
concentrations,6985,O
over,6985,O
Mfn2,6985,B-GENE-Y
",",6985,O
Bax,6985,B-GENE-Y
",",6985,O
and,6985,O
Bcl2,6985,B-GENE-Y
expressions,6985,O
in,6985,O
a,6985,O
β-pancreatic,6985,O
cell,6985,O
line,6985,O
(,6985,O
MIN6,6985,O
cells,6985,O
),6985,O
.,6985,O
MIN6,6986,O
cells,6986,O
were,6986,O
pre-incubated,6986,O
with,6986,O
different,6986,O
iron,6986,B-CHEMICAL
and/or,6986,O
glucose,6986,B-CHEMICAL
concentrations,6986,O
",",6986,O
and,6986,O
the,6986,O
relative,6986,O
mRNA,6986,O
abundance,6986,O
of,6986,O
the,6986,O
Bcl2/Bax,6986,B-GENE-Y
ratio,6986,O
and,6986,O
of,6986,O
Mfn2,6986,B-GENE-Y
genes,6986,O
was,6986,O
measured,6986,O
by,6986,O
qRT-PCR,6986,O
.,6986,O
Heme,6987,B-GENE-N
oxygenase,6987,I-GENE-N
(,6987,O
HO,6987,B-GENE-N
),6987,O
activity,6987,O
",",6987,O
iron,6987,B-CHEMICAL
uptake,6987,O
",",6987,O
superoxide,6987,B-CHEMICAL
dismutase,6987,I-GENE-N
activity,6987,O
",",6987,O
and,6987,O
glutathione,6987,B-CHEMICAL
content,6987,O
were,6987,O
also,6987,O
determined,6987,O
.,6987,O
The,6988,O
Bcl2/Bax,6988,B-GENE-Y
ratio,6988,O
increased,6988,O
and,6988,O
Mfn2,6988,B-GENE-Y
expression,6988,O
decreased,6988,O
in,6988,O
MIN6,6988,O
cells,6988,O
after,6988,O
glucose,6988,B-CHEMICAL
stimulation,6988,O
.,6988,O
These,6989,O
effects,6989,O
were,6989,O
higher,6989,O
when,6989,O
glucose,6989,B-CHEMICAL
and,6989,O
iron,6989,B-CHEMICAL
were,6989,O
incubated,6989,O
together,6989,O
.,6989,O
Additionally,6990,O
",",6990,O
treatment,6990,O
with,6990,O
glucose/iron,6990,B-CHEMICAL
showed,6990,O
a,6990,O
higher,6990,O
HO,6990,B-GENE-N
activity,6990,O
.,6990,O
Our,6991,O
study,6991,O
revealed,6991,O
that,6991,O
high,6991,O
glucose/Fe,6991,B-CHEMICAL
concentrations,6991,O
in,6991,O
MIN6,6991,O
cells,6991,O
induced,6991,O
an,6991,O
increase,6991,O
of,6991,O
the,6991,O
Bcl2/Bax,6991,B-GENE-Y
ratio,6991,O
",",6991,O
an,6991,O
indicator,6991,O
of,6991,O
increased,6991,O
cell,6991,O
apoptosis,6991,O
.,6991,O
Genetic,6992,O
Insights,6992,O
into,6992,O
Pyralomicin,6992,B-CHEMICAL
Biosynthesis,6992,O
in,6992,O
Nonomuraea,6992,O
spiralis,6992,O
IMC,6992,O
A-0156,6992,O
.,6992,O
The,6993,O
biosynthetic,6993,O
gene,6993,O
cluster,6993,O
for,6993,O
the,6993,O
pyralomicin,6993,B-CHEMICAL
antibiotics,6993,O
has,6993,O
been,6993,O
cloned,6993,O
and,6993,O
sequenced,6993,O
from,6993,O
Nonomuraea,6993,O
spiralis,6993,O
IMC,6993,O
A-0156,6993,O
.,6993,O
The,6994,O
41,6994,O
kb,6994,O
gene,6994,O
cluster,6994,O
contains,6994,O
27,6994,O
ORFs,6994,O
predicted,6994,O
to,6994,O
encode,6994,O
all,6994,O
of,6994,O
the,6994,O
functions,6994,O
for,6994,O
pyralomicin,6994,B-CHEMICAL
biosynthesis,6994,O
.,6994,O
This,6995,O
includes,6995,O
nonribosomal,6995,B-GENE-N
peptide,6995,I-GENE-N
synthetases,6995,I-GENE-N
(,6995,O
NRPS,6995,B-GENE-N
),6995,O
and,6995,O
polyketide,6995,B-GENE-N
synthases,6995,I-GENE-N
(,6995,O
PKS,6995,B-GENE-N
),6995,O
required,6995,O
for,6995,O
the,6995,O
formation,6995,O
of,6995,O
the,6995,O
benzopyranopyrrole,6995,B-CHEMICAL
core,6995,O
unit,6995,O
",",6995,O
as,6995,O
well,6995,O
as,6995,O
a,6995,O
suite,6995,O
of,6995,O
tailoring,6995,O
enzymes,6995,O
(,6995,O
e.g.,6995,O
",",6995,O
four,6995,O
halogenases,6995,B-GENE-N
",",6995,O
an,6995,O
O-methyltransferase,6995,B-CHEMICAL
",",6995,O
and,6995,O
an,6995,O
N-glycosyltransferase,6995,B-CHEMICAL
),6995,O
necessary,6995,O
for,6995,O
further,6995,O
modifications,6995,O
of,6995,O
the,6995,O
core,6995,O
structure,6995,O
.,6995,O
The,6996,O
N-glycosyltransferase,6996,B-CHEMICAL
is,6996,O
predicted,6996,O
to,6996,O
transfer,6996,O
either,6996,O
glucose,6996,B-CHEMICAL
or,6996,O
a,6996,O
pseudosugar,6996,O
(,6996,O
cyclitol,6996,B-CHEMICAL
),6996,O
to,6996,O
the,6996,O
aglycone,6996,O
.,6996,O
A,6997,O
gene,6997,O
cassette,6997,O
encoding,6997,O
C7-cyclitol,6997,B-CHEMICAL
biosynthetic,6997,O
enzymes,6997,O
was,6997,O
identified,6997,O
upstream,6997,O
of,6997,O
the,6997,O
benzopyranopyrrole-specific,6997,B-CHEMICAL
ORFs,6997,O
.,6997,O
Targeted,6998,O
disruption,6998,O
of,6998,O
the,6998,O
gene,6998,O
encoding,6998,O
the,6998,O
N-glycosyltransferase,6998,B-GENE-N
",",6998,O
prlH,6998,B-GENE-Y
",",6998,O
abolished,6998,O
pyralomicin,6998,B-CHEMICAL
production,6998,O
",",6998,O
and,6998,O
recombinant,6998,O
expression,6998,O
of,6998,O
PrlA,6998,B-GENE-Y
confirms,6998,O
the,6998,O
activity,6998,O
of,6998,O
this,6998,O
enzyme,6998,O
as,6998,O
a,6998,O
sugar,6998,B-GENE-N
phosphate,6998,I-GENE-N
cyclase,6998,I-GENE-N
involved,6998,O
in,6998,O
the,6998,O
formation,6998,O
of,6998,O
the,6998,O
C7-cyclitol,6998,B-CHEMICAL
moiety,6998,O
.,6998,O
Synaptotagmin,6999,B-GENE-Y
1,6999,I-GENE-Y
is,6999,O
required,6999,O
for,6999,O
vesicular,6999,O
Ca,6999,B-CHEMICAL
(,6999,I-CHEMICAL
2+,6999,I-CHEMICAL
),6999,I-CHEMICAL
/H,6999,O
(,6999,I-CHEMICAL
+,6999,I-CHEMICAL
),6999,I-CHEMICAL
-antiport,6999,O
activity,6999,O
.,6999,O
A,7000,O
low-affinity,7000,O
Ca,7000,B-CHEMICAL
(,7000,I-CHEMICAL
2+,7000,I-CHEMICAL
),7000,I-CHEMICAL
/H,7000,O
(,7000,I-CHEMICAL
+,7000,I-CHEMICAL
),7000,I-CHEMICAL
-antiport,7000,O
was,7000,O
described,7000,O
in,7000,O
the,7000,O
membrane,7000,O
of,7000,O
mammalian,7000,O
brain,7000,O
synaptic,7000,O
vesicles,7000,O
.,7000,O
Electrophysiological,7001,O
studies,7001,O
showed,7001,O
that,7001,O
this,7001,O
antiport,7001,O
contributes,7001,O
to,7001,O
the,7001,O
extreme,7001,O
brevity,7001,O
of,7001,O
excitation-release,7001,O
coupling,7001,O
in,7001,O
rapid,7001,O
synapses,7001,O
.,7001,O
Synaptotagmin-1,7002,B-GENE-Y
",",7002,O
a,7002,O
vesicular,7002,O
protein,7002,O
interacting,7002,O
with,7002,O
membranes,7002,O
upon,7002,O
low-affinity,7002,O
Ca,7002,B-CHEMICAL
(,7002,I-CHEMICAL
2+,7002,I-CHEMICAL
),7002,I-CHEMICAL
-binding,7002,O
",",7002,O
plays,7002,O
a,7002,O
major,7002,O
role,7002,O
in,7002,O
excitation-release,7002,O
coupling,7002,O
",",7002,O
by,7002,O
synchronizing,7002,O
calcium,7002,B-CHEMICAL
entry,7002,O
with,7002,O
fast,7002,O
neurotransmitter,7002,O
release,7002,O
.,7002,O
Here,7003,O
",",7003,O
we,7003,O
report,7003,O
that,7003,O
synaptotagmin-1,7003,B-GENE-Y
is,7003,O
necessary,7003,O
for,7003,O
expression,7003,O
of,7003,O
the,7003,O
vesicular,7003,O
Ca,7003,B-CHEMICAL
(,7003,I-CHEMICAL
2+,7003,I-CHEMICAL
),7003,I-CHEMICAL
/H,7003,O
(,7003,I-CHEMICAL
+,7003,I-CHEMICAL
),7003,I-CHEMICAL
-antiport,7003,O
.,7003,O
We,7004,O
measured,7004,O
Ca,7004,B-CHEMICAL
(,7004,I-CHEMICAL
2+,7004,I-CHEMICAL
),7004,I-CHEMICAL
/H,7004,O
(,7004,I-CHEMICAL
+,7004,I-CHEMICAL
),7004,I-CHEMICAL
-antiport,7004,O
activity,7004,O
in,7004,O
vesicles,7004,O
and,7004,O
granules,7004,O
of,7004,O
pheochromocytoma,7004,O
PC12,7004,O
cells,7004,O
by,7004,O
three,7004,O
methods,7004,O
:,7004,O
(,7004,O
1,7004,O
),7004,O
Ca,7004,B-CHEMICAL
(,7004,I-CHEMICAL
2+,7004,I-CHEMICAL
),7004,I-CHEMICAL
-induced,7004,O
dissipation,7004,O
of,7004,O
the,7004,O
vesicular,7004,O
H,7004,B-CHEMICAL
(,7004,I-CHEMICAL
+,7004,I-CHEMICAL
),7004,I-CHEMICAL
-gradient,7004,O
;,7004,O
(,7004,O
2,7004,O
),7004,O
bafilomycin-sensitive,7004,B-CHEMICAL
calcium,7004,B-CHEMICAL
accumulation,7004,O
and,7004,O
(,7004,O
3,7004,O
),7004,O
pH-jump-induced,7004,O
calcium,7004,B-CHEMICAL
accumulation,7004,O
.,7004,O
The,7005,O
results,7005,O
were,7005,O
congruent,7005,O
and,7005,O
highly,7005,O
significant,7005,O
:,7005,O
Ca,7005,B-CHEMICAL
(,7005,I-CHEMICAL
2+,7005,I-CHEMICAL
),7005,I-CHEMICAL
/H,7005,O
(,7005,I-CHEMICAL
+,7005,I-CHEMICAL
),7005,I-CHEMICAL
-antiport,7005,O
activity,7005,O
is,7005,O
detectable,7005,O
only,7005,O
in,7005,O
acidic,7005,O
organelles,7005,O
expressing,7005,O
functional,7005,O
synaptotagmin-1,7005,B-GENE-Y
.,7005,O
In,7006,O
contrast,7006,O
",",7006,O
synaptotagmin-1-deficient,7006,B-GENE-Y
cells,7006,O
-,7006,O
and,7006,O
cells,7006,O
where,7006,O
transgenically,7006,O
encoded,7006,O
synaptotagmin-1,7006,B-GENE-Y
was,7006,O
acutely,7006,O
photo-inactivated,7006,O
-,7006,O
were,7006,O
devoid,7006,O
of,7006,O
any,7006,O
Ca,7006,B-CHEMICAL
(,7006,I-CHEMICAL
2+,7006,I-CHEMICAL
),7006,I-CHEMICAL
/H,7006,O
(,7006,I-CHEMICAL
+,7006,I-CHEMICAL
),7006,I-CHEMICAL
-antiport,7006,O
activity,7006,O
.,7006,O
Therefore,7007,O
",",7007,O
in,7007,O
addition,7007,O
to,7007,O
its,7007,O
previously,7007,O
described,7007,O
functions,7007,O
",",7007,O
synaptotagmin-1,7007,B-GENE-Y
is,7007,O
involved,7007,O
in,7007,O
a,7007,O
rapid,7007,O
vesicular,7007,O
Ca,7007,B-CHEMICAL
(,7007,I-CHEMICAL
2+,7007,I-CHEMICAL
),7007,I-CHEMICAL
sequestration,7007,O
through,7007,O
a,7007,O
Ca,7007,B-CHEMICAL
(,7007,I-CHEMICAL
2+,7007,I-CHEMICAL
),7007,I-CHEMICAL
/H,7007,O
(,7007,I-CHEMICAL
+,7007,I-CHEMICAL
),7007,I-CHEMICAL
antiport,7007,O
.,7007,O
This,7008,O
article,7008,O
is,7008,O
protected,7008,O
by,7008,O
copyright,7008,O
.,7008,O
All,7009,O
rights,7009,O
reserved,7009,O
.,7009,O
Estradiol,7010,B-CHEMICAL
replacement,7010,O
enhances,7010,O
cocaine-stimulated,7010,B-CHEMICAL
locomotion,7010,O
in,7010,O
female,7010,O
C57BL/6,7010,O
mice,7010,O
through,7010,O
estrogen,7010,B-GENE-Y
receptor,7010,I-GENE-Y
alpha,7010,I-GENE-Y
.,7010,O
Psychostimulant,7011,O
effects,7011,O
are,7011,O
enhanced,7011,O
by,7011,O
ovarian,7011,O
hormones,7011,O
in,7011,O
women,7011,O
and,7011,O
female,7011,O
rodents,7011,O
.,7011,O
Estradiol,7012,B-CHEMICAL
increases,7012,O
behavioral,7012,O
responses,7012,O
to,7012,O
psychostimulants,7012,O
in,7012,O
women,7012,O
and,7012,O
female,7012,O
rats,7012,O
",",7012,O
although,7012,O
the,7012,O
underlying,7012,O
mechanism,7012,O
is,7012,O
unknown,7012,O
.,7012,O
This,7013,O
study,7013,O
utilized,7013,O
mice,7013,O
to,7013,O
investigate,7013,O
the,7013,O
time,7013,O
frame,7013,O
and,7013,O
receptor,7013,O
mediation,7013,O
of,7013,O
estradiol,7013,B-CHEMICAL
's,7013,O
enhancement,7013,O
of,7013,O
cocaine-induced,7013,B-CHEMICAL
behavior,7013,O
as,7013,O
mice,7013,O
enable,7013,O
parallel,7013,O
use,7013,O
of,7013,O
genetic,7013,O
",",7013,O
surgical,7013,O
and,7013,O
pharmacological,7013,O
methods,7013,O
.,7013,O
The,7014,O
spontaneous,7014,O
behavior,7014,O
of,7014,O
Sham,7014,O
and,7014,O
Ovariectomized,7014,O
(,7014,O
Ovx,7014,O
),7014,O
female,7014,O
wildtype,7014,O
(,7014,O
WT,7014,O
),7014,O
mice,7014,O
was,7014,O
determined,7014,O
during,7014,O
habituation,7014,O
to,7014,O
a,7014,O
novel,7014,O
environment,7014,O
and,7014,O
after,7014,O
cocaine,7014,B-CHEMICAL
administration,7014,O
.,7014,O
Ovx,7015,O
mice,7015,O
were,7015,O
replaced,7015,O
with,7015,O
vehicle,7015,O
(,7015,O
sesame,7015,O
oil,7015,O
),7015,O
or,7015,O
17β-estradiol,7015,B-CHEMICAL
(,7015,O
E2,7015,O
),7015,O
for,7015,O
2,7015,O
days,7015,O
or,7015,O
30,7015,O
min,7015,O
prior,7015,O
to,7015,O
a,7015,O
cocaine,7015,B-CHEMICAL
challenge,7015,O
to,7015,O
investigate,7015,O
the,7015,O
time,7015,O
course,7015,O
of,7015,O
E2,7015,O
's,7015,O
effects,7015,O
.,7015,O
To,7016,O
examine,7016,O
receptor,7016,O
mediation,7016,O
of,7016,O
estradiol,7016,B-CHEMICAL
effects,7016,O
",",7016,O
Ovx,7016,O
mice,7016,O
replaced,7016,O
for,7016,O
2,7016,O
days,7016,O
with,7016,O
either,7016,O
the,7016,O
ERα-selective,7016,B-GENE-Y
agonist,7016,O
PPT,7016,B-CHEMICAL
or,7016,O
the,7016,O
ERβ-selective,7016,B-GENE-Y
agonist,7016,O
DPN,7016,B-CHEMICAL
were,7016,O
compared,7016,O
to,7016,O
Sham,7016,O
mice,7016,O
",",7016,O
and,7016,O
mice,7016,O
lacking,7016,O
either,7016,O
ERα,7016,B-GENE-Y
(,7016,O
αERKO,7016,B-GENE-Y
),7016,O
or,7016,O
ERβ,7016,B-GENE-Y
(,7016,O
βERKO,7016,B-GENE-Y
),7016,O
were,7016,O
compared,7016,O
to,7016,O
WT,7016,O
littermates,7016,O
.,7016,O
Ovx,7017,O
mice,7017,O
exhibited,7017,O
fewer,7017,O
ambulations,7017,O
during,7017,O
habituation,7017,O
than,7017,O
Sham,7017,O
females,7017,O
.,7017,O
Cocaine-induced,7018,B-CHEMICAL
increases,7018,O
in,7018,O
behavioral,7018,O
ratings,7018,O
were,7018,O
greater,7018,O
in,7018,O
Sham,7018,O
than,7018,O
in,7018,O
Ovx,7018,O
mice,7018,O
.,7018,O
Two,7019,O
days,7019,O
but,7019,O
not,7019,O
30,7019,O
min,7019,O
of,7019,O
E2,7019,O
replacement,7019,O
in,7019,O
Ovx,7019,O
mice,7019,O
increased,7019,O
cocaine,7019,B-CHEMICAL
responses,7019,O
to,7019,O
Sham,7019,O
levels,7019,O
.,7019,O
PPT,7020,B-CHEMICAL
replacement,7020,O
also,7020,O
increased,7020,O
the,7020,O
cocaine,7020,B-CHEMICAL
response,7020,O
relative,7020,O
to,7020,O
vehicle-,7020,O
or,7020,O
DPN-,7020,B-CHEMICAL
treated,7020,O
Ovx,7020,O
mice,7020,O
.,7020,O
αERKO,7021,B-GENE-Y
mice,7021,O
displayed,7021,O
modestly,7021,O
attenuated,7021,O
behavioral,7021,O
responses,7021,O
to,7021,O
novelty,7021,O
and,7021,O
cocaine,7021,B-CHEMICAL
compared,7021,O
to,7021,O
αWT,7021,O
littermates,7021,O
",",7021,O
but,7021,O
no,7021,O
behavioral,7021,O
differences,7021,O
were,7021,O
found,7021,O
between,7021,O
βERKO,7021,B-GENE-Y
and,7021,O
βWT,7021,O
mice,7021,O
.,7021,O
These,7022,O
results,7022,O
suggest,7022,O
that,7022,O
E2,7022,O
enhances,7022,O
cocaine-stimulated,7022,B-CHEMICAL
locomotion,7022,O
in,7022,O
mice,7022,O
predominantly,7022,O
through,7022,O
ERα,7022,B-GENE-Y
.,7022,O
Dynamics,7023,O
and,7023,O
structural,7023,O
changes,7023,O
of,7023,O
small,7023,O
water,7023,O
clusters,7023,O
on,7023,O
ionization,7023,O
.,7023,O
Despite,7024,O
utmost,7024,O
importance,7024,O
in,7024,O
understanding,7024,O
water,7024,O
ionization,7024,O
process,7024,O
",",7024,O
reliable,7024,O
theoretical,7024,O
results,7024,O
of,7024,O
structural,7024,O
changes,7024,O
and,7024,O
molecular,7024,O
dynamics,7024,O
(,7024,O
MD,7024,O
),7024,O
of,7024,O
water,7024,O
clusters,7024,O
on,7024,O
ionization,7024,O
have,7024,O
hardly,7024,O
been,7024,O
reported,7024,O
yet,7024,O
.,7024,O
Here,7025,O
",",7025,O
we,7025,O
investigate,7025,O
the,7025,O
water,7025,O
cations,7025,O
[,7025,O
(,7025,B-CHEMICAL
H2,7025,I-CHEMICAL
O,7025,I-CHEMICAL
),7025,I-CHEMICAL
n,7025,I-CHEMICAL
=,7025,O
2-6,7025,O
(,7025,O
+,7025,O
),7025,O
],7025,O
with,7025,O
density,7025,O
functional,7025,O
theory,7025,O
(,7025,O
DFT,7025,O
),7025,O
",",7025,O
Möller-Plesset,7025,O
second-order,7025,O
perturbation,7025,O
theory,7025,O
(,7025,O
MP2,7025,O
),7025,O
",",7025,O
and,7025,O
coupled,7025,O
cluster,7025,O
theory,7025,O
with,7025,O
single,7025,O
",",7025,O
double,7025,O
",",7025,O
and,7025,O
perturbative,7025,O
triple,7025,O
excitations,7025,O
[,7025,O
CCSD,7025,O
(,7025,O
T,7025,O
),7025,O
],7025,O
.,7025,O
The,7026,O
complete,7026,O
basis,7026,O
set,7026,O
limits,7026,O
of,7026,O
interaction,7026,O
energies,7026,O
at,7026,O
the,7026,O
CCSD,7026,O
(,7026,O
T,7026,O
),7026,O
level,7026,O
are,7026,O
reported,7026,O
",",7026,O
and,7026,O
the,7026,O
geometrical,7026,O
structures,7026,O
",",7026,O
electronic,7026,O
properties,7026,O
",",7026,O
and,7026,O
infrared,7026,O
spectra,7026,O
are,7026,O
investigated,7026,O
.,7026,O
The,7027,O
characteristics,7027,O
of,7027,O
structures,7027,O
and,7027,O
spectra,7027,O
of,7027,O
the,7027,O
water,7027,O
cluster,7027,O
cations,7027,O
reflect,7027,O
the,7027,O
formation,7027,O
of,7027,O
the,7027,O
hydronium,7027,B-CHEMICAL
cation,7027,O
moiety,7027,O
(,7027,O
H3,7027,B-CHEMICAL
O,7027,I-CHEMICAL
(,7027,I-CHEMICAL
+,7027,I-CHEMICAL
),7027,I-CHEMICAL
),7027,O
and,7027,O
the,7027,O
hydroxyl,7027,B-CHEMICAL
radical,7027,O
.,7027,O
Although,7028,O
most,7028,O
density,7028,O
functionals,7028,O
fail,7028,O
to,7028,O
predict,7028,O
reasonable,7028,O
energetics,7028,O
of,7028,O
the,7028,O
water,7028,O
cations,7028,O
",",7028,O
some,7028,O
functionals,7028,O
are,7028,O
found,7028,O
to,7028,O
be,7028,O
reliable,7028,O
",",7028,O
in,7028,O
reasonable,7028,O
agreement,7028,O
with,7028,O
high-level,7028,O
ab,7028,O
initio,7028,O
results,7028,O
.,7028,O
To,7029,O
understand,7029,O
the,7029,O
ionization,7029,O
process,7029,O
of,7029,O
water,7029,O
clusters,7029,O
",",7029,O
DFT-,7029,O
and,7029,O
MP2-based,7029,O
Born-Oppenheimer,7029,O
MD,7029,O
(,7029,O
BOMD,7029,O
),7029,O
simulations,7029,O
are,7029,O
performed,7029,O
on,7029,O
ionization,7029,O
.,7029,O
On,7030,O
ionization,7030,O
",",7030,O
the,7030,O
water,7030,O
clusters,7030,O
tend,7030,O
to,7030,O
have,7030,O
an,7030,O
Eigen-like,7030,O
form,7030,O
with,7030,O
the,7030,O
hydronium,7030,B-CHEMICAL
cation,7030,O
instead,7030,O
of,7030,O
a,7030,O
Zundel-like,7030,O
form,7030,O
",",7030,O
based,7030,O
on,7030,O
reliable,7030,O
BOMD,7030,O
simulations,7030,O
.,7030,O
For,7031,O
the,7031,O
vertically,7031,O
ionized,7031,O
water,7031,O
hexamer,7031,O
",",7031,O
the,7031,O
relatively,7031,O
stable,7031,O
(,7031,B-CHEMICAL
H2,7031,I-CHEMICAL
O,7031,I-CHEMICAL
),7031,I-CHEMICAL
5,7031,I-CHEMICAL
(,7031,I-CHEMICAL
+,7031,I-CHEMICAL
),7031,I-CHEMICAL
(,7031,O
5sL4A,7031,O
),7031,O
cluster,7031,O
tends,7031,O
to,7031,O
form,7031,O
with,7031,O
a,7031,O
detached,7031,O
water,7031,O
molecule,7031,O
(,7031,O
H2,7031,B-CHEMICAL
O,7031,I-CHEMICAL
),7031,O
.,7031,O
©,7032,O
2013,7032,O
Wiley,7032,O
Periodicals,7032,O
",",7032,O
Inc,7032,O
.,7032,O
The,7033,O
Intermediate-conductance,7033,B-GENE-Y
Calcium-activated,7033,I-GENE-Y
Potassium,7033,I-GENE-Y
Channel,7033,I-GENE-Y
KCa3.1,7033,I-GENE-Y
Regulates,7033,O
Vascular,7033,O
Smooth,7033,O
Muscle,7033,O
Cell,7033,O
Proliferation,7033,O
via,7033,O
Controlling,7033,O
Calcium-dependent,7033,B-CHEMICAL
Signaling,7033,O
.,7033,O
The,7034,O
intermediate-conductance,7034,B-GENE-Y
calcium-activated,7034,B-CHEMICAL
potassium,7034,B-CHEMICAL
channel,7034,I-GENE-Y
KCa3.1,7034,I-GENE-Y
contributes,7034,O
to,7034,O
a,7034,O
variety,7034,O
of,7034,O
cell,7034,O
activation,7034,O
processes,7034,O
in,7034,O
pathologies,7034,O
such,7034,O
as,7034,O
inflammation,7034,O
",",7034,O
carcinogenesis,7034,O
and,7034,O
vascular,7034,O
remodeling,7034,O
.,7034,O
We,7035,O
examined,7035,O
the,7035,O
electrophysiological,7035,O
and,7035,O
transcriptional,7035,O
mechanisms,7035,O
by,7035,O
which,7035,O
KCa3.1,7035,B-GENE-Y
regulates,7035,O
vascular,7035,O
smooth,7035,O
muscle,7035,O
cell,7035,O
(,7035,O
VSMC,7035,O
),7035,O
proliferation,7035,O
.,7035,O
Platelet-derived,7036,B-GENE-Y
growth,7036,I-GENE-Y
factor-BB,7036,I-GENE-Y
(,7036,O
PDGF,7036,B-GENE-N
),7036,O
-induced,7036,O
proliferation,7036,O
of,7036,O
human,7036,O
coronary,7036,O
artery,7036,O
VSMCs,7036,O
was,7036,O
attenuated,7036,O
by,7036,O
lowering,7036,O
intracellular,7036,O
Ca,7036,B-CHEMICAL
(,7036,I-CHEMICAL
2+,7036,I-CHEMICAL
),7036,I-CHEMICAL
concentration,7036,O
(,7036,O
[,7036,O
Ca,7036,B-CHEMICAL
(,7036,I-CHEMICAL
2+,7036,I-CHEMICAL
),7036,I-CHEMICAL
],7036,O
i,7036,O
),7036,O
and,7036,O
was,7036,O
enhanced,7036,O
by,7036,O
elevating,7036,O
[,7036,O
Ca,7036,B-CHEMICAL
(,7036,I-CHEMICAL
2+,7036,I-CHEMICAL
),7036,I-CHEMICAL
],7036,O
i.,7036,O
KCa3.1,7036,B-GENE-Y
blockade,7036,O
or,7036,O
knockdown,7036,O
inhibited,7036,O
proliferation,7036,O
by,7036,O
suppressing,7036,O
the,7036,O
rise,7036,O
in,7036,O
[,7036,O
Ca,7036,B-CHEMICAL
(,7036,I-CHEMICAL
2+,7036,I-CHEMICAL
),7036,I-CHEMICAL
],7036,O
i,7036,O
and,7036,O
attenuating,7036,O
the,7036,O
expression,7036,O
of,7036,O
phosphorylated,7036,B-GENE-N
cAMP,7036,B-CHEMICAL
response,7036,I-GENE-N
element,7036,I-GENE-N
binding,7036,I-GENE-N
protein,7036,I-GENE-N
(,7036,O
CREB,7036,B-GENE-N
),7036,O
",",7036,O
c-fos,7036,B-GENE-Y
and,7036,O
neuron-derived,7036,B-GENE-Y
orphan,7036,I-GENE-Y
receptor-1,7036,I-GENE-Y
(,7036,O
NOR-1,7036,B-GENE-Y
),7036,O
.,7036,O
This,7037,O
anti-proliferative,7037,O
effect,7037,O
was,7037,O
abolished,7037,O
by,7037,O
elevating,7037,O
[,7037,O
Ca,7037,B-CHEMICAL
(,7037,I-CHEMICAL
2+,7037,I-CHEMICAL
),7037,I-CHEMICAL
],7037,O
i.,7037,O
KCa3.1,7037,B-GENE-Y
overexpression,7037,O
induced,7037,O
VSMC,7037,O
proliferation,7037,O
",",7037,O
and,7037,O
potentiated,7037,O
PDGF-induced,7037,B-GENE-N
proliferation,7037,O
",",7037,O
by,7037,O
inducing,7037,O
CREB,7037,B-GENE-N
phosphorylation,7037,O
",",7037,O
c-fos,7037,B-GENE-Y
and,7037,O
NOR-1,7037,B-GENE-Y
.,7037,O
Pharmacological,7038,O
stimulation,7038,O
of,7038,O
KCa3.1,7038,B-GENE-Y
unexpectedly,7038,O
suppressed,7038,O
proliferation,7038,O
by,7038,O
inhibiting,7038,O
the,7038,O
rise,7038,O
in,7038,O
[,7038,O
Ca,7038,B-CHEMICAL
(,7038,I-CHEMICAL
2+,7038,I-CHEMICAL
),7038,I-CHEMICAL
],7038,O
i,7038,O
and,7038,O
abolishing,7038,O
the,7038,O
expression,7038,O
and,7038,O
activity,7038,O
of,7038,O
KCa3.1,7038,B-GENE-Y
and,7038,O
PDGF,7038,B-GENE-Y
β-receptors,7038,I-GENE-Y
.,7038,O
The,7039,O
stimulation,7039,O
also,7039,O
attenuated,7039,O
the,7039,O
levels,7039,O
of,7039,O
phosphorylated,7039,B-GENE-N
CREB,7039,I-GENE-N
",",7039,O
c-fos,7039,B-GENE-Y
and,7039,O
cyclins,7039,B-GENE-N
expression,7039,O
.,7039,O
After,7040,O
KCa3.1,7040,B-GENE-Y
blockade,7040,O
",",7040,O
the,7040,O
characteristic,7040,O
round,7040,O
shape,7040,O
of,7040,O
VSMCs,7040,O
expressing,7040,O
high,7040,O
l-caldesmon,7040,B-GENE-Y
and,7040,O
low,7040,O
calponin-1,7040,B-GENE-Y
(,7040,O
dedifferentiation,7040,O
state,7040,O
),7040,O
was,7040,O
maintained,7040,O
",",7040,O
whereas,7040,O
KCa3.1,7040,B-GENE-Y
stimulation,7040,O
induced,7040,O
a,7040,O
spindle-shape,7040,O
cellular,7040,O
appearance,7040,O
",",7040,O
with,7040,O
low,7040,O
l-caldesmon,7040,B-GENE-Y
and,7040,O
high,7040,O
calponin-1,7040,B-GENE-Y
.,7040,O
In,7041,O
conclusion,7041,O
",",7041,O
KCa3.1,7041,B-GENE-Y
plays,7041,O
an,7041,O
important,7041,O
role,7041,O
in,7041,O
VSMC,7041,O
proliferation,7041,O
via,7041,O
controlling,7041,O
Ca,7041,B-CHEMICAL
(,7041,I-CHEMICAL
2+,7041,I-CHEMICAL
),7041,I-CHEMICAL
-dependent,7041,O
signaling,7041,O
pathways,7041,O
and,7041,O
its,7041,O
modulation,7041,O
may,7041,O
therefore,7041,O
constitute,7041,O
a,7041,O
new,7041,O
therapeutic,7041,O
target,7041,O
for,7041,O
cell,7041,O
proliferative,7041,O
diseases,7041,O
such,7041,O
as,7041,O
atherosclerosis,7041,O
.,7041,O
Reactive,7042,O
Metabolite,7042,O
Trapping,7042,O
Studies,7042,O
on,7042,O
Imidazo-,7042,B-CHEMICAL
and,7042,I-CHEMICAL
2-Methylimidazo,7042,I-CHEMICAL
[,7042,I-CHEMICAL
"2,1-b",7042,I-CHEMICAL
],7042,I-CHEMICAL
thiazole-based,7042,O
Inverse,7042,O
Agonists,7042,O
of,7042,O
the,7042,O
Ghrelin,7042,B-GENE-Y
Receptor,7042,I-GENE-Y
.,7042,O
The,7043,O
current,7043,O
study,7043,O
examined,7043,O
the,7043,O
bioactivation,7043,O
potential,7043,O
of,7043,O
ghrelin,7043,B-GENE-Y
receptor,7043,I-GENE-Y
inverse,7043,O
agonists,7043,O
",",7043,O
1-,7043,B-CHEMICAL
(,7043,I-CHEMICAL
2-,7043,I-CHEMICAL
(,7043,I-CHEMICAL
2-chloro-4-,7043,I-CHEMICAL
(,7043,I-CHEMICAL
"2H-1,2,3-triazol-2-yl",7043,I-CHEMICAL
),7043,I-CHEMICAL
benzyl,7043,I-CHEMICAL
),7043,I-CHEMICAL
"-2,7-diazaspiro",7043,I-CHEMICAL
[,7043,I-CHEMICAL
3.5,7043,I-CHEMICAL
],7043,I-CHEMICAL
nonan-7-yl,7043,I-CHEMICAL
),7043,I-CHEMICAL
-2-,7043,I-CHEMICAL
(,7043,I-CHEMICAL
imidazo,7043,I-CHEMICAL
[,7043,I-CHEMICAL
"2,1-b",7043,I-CHEMICAL
],7043,I-CHEMICAL
thiazol-6-yl,7043,I-CHEMICAL
),7043,I-CHEMICAL
ethanone,7043,I-CHEMICAL
(,7043,O
1,7043,O
),7043,O
and,7043,O
1-,7043,B-CHEMICAL
(,7043,I-CHEMICAL
2-,7043,I-CHEMICAL
(,7043,I-CHEMICAL
2-chloro-4-,7043,I-CHEMICAL
(,7043,I-CHEMICAL
"2H-1,2,3-triazol-2-yl",7043,I-CHEMICAL
),7043,I-CHEMICAL
benzyl,7043,I-CHEMICAL
),7043,I-CHEMICAL
"-2,7-diazaspiro",7043,I-CHEMICAL
[,7043,I-CHEMICAL
3.5,7043,I-CHEMICAL
],7043,I-CHEMICAL
nonan-7-yl,7043,I-CHEMICAL
),7043,I-CHEMICAL
-2-,7043,I-CHEMICAL
(,7043,I-CHEMICAL
2-methylimidazo,7043,I-CHEMICAL
[,7043,I-CHEMICAL
"2,1-b",7043,I-CHEMICAL
],7043,I-CHEMICAL
thiazol-6-yl,7043,I-CHEMICAL
),7043,I-CHEMICAL
ethanone,7043,I-CHEMICAL
(,7043,O
2,7043,O
),7043,O
",",7043,O
containing,7043,O
a,7043,O
fused,7043,O
imidazo,7043,B-CHEMICAL
[,7043,I-CHEMICAL
"2,1-b",7043,I-CHEMICAL
],7043,I-CHEMICAL
thiazole,7043,I-CHEMICAL
motif,7043,O
in,7043,O
the,7043,O
core,7043,O
structure,7043,O
.,7043,O
Both,7044,O
compounds,7044,O
underwent,7044,O
oxidative,7044,O
metabolism,7044,O
in,7044,O
NADPH-,7044,B-CHEMICAL
and,7044,O
glutathione-supplemented,7044,B-CHEMICAL
human,7044,O
liver,7044,O
microsomes,7044,O
to,7044,O
yield,7044,O
glutathione,7044,B-CHEMICAL
conjugates,7044,O
",",7044,O
which,7044,O
was,7044,O
consistent,7044,O
with,7044,O
their,7044,O
bioactivation,7044,O
to,7044,O
reactive,7044,O
species,7044,O
.,7044,O
Mass,7045,O
spectral,7045,O
fragmentation,7045,O
and,7045,O
NMR,7045,O
analysis,7045,O
indicated,7045,O
that,7045,O
the,7045,O
site,7045,O
of,7045,O
attachment,7045,O
of,7045,O
the,7045,O
glutathionyl,7045,B-CHEMICAL
moiety,7045,O
in,7045,O
the,7045,O
thiol,7045,B-CHEMICAL
conjugates,7045,O
was,7045,O
on,7045,O
the,7045,O
thiazole,7045,B-CHEMICAL
ring,7045,O
within,7045,O
the,7045,O
bicycle,7045,O
.,7045,O
Two,7046,O
glutathione,7046,B-CHEMICAL
conjugates,7046,O
were,7046,O
discerned,7046,O
with,7046,O
the,7046,O
imidazo,7046,B-CHEMICAL
[,7046,I-CHEMICAL
"2,1-b",7046,I-CHEMICAL
],7046,I-CHEMICAL
thiazole,7046,I-CHEMICAL
derivative,7046,O
1,7046,O
.,7046,O
One,7047,O
adduct,7047,O
was,7047,O
derived,7047,O
from,7047,O
the,7047,O
Michael,7047,O
addition,7047,O
of,7047,O
glutathione,7047,B-CHEMICAL
to,7047,O
a,7047,O
putative,7047,O
S-oxide,7047,B-CHEMICAL
metabolite,7047,O
of,7047,O
1,7047,O
",",7047,O
whereas,7047,O
",",7047,O
the,7047,O
second,7047,O
adduct,7047,O
was,7047,O
formed,7047,O
via,7047,O
the,7047,O
reaction,7047,O
of,7047,O
a,7047,O
second,7047,O
glutathione,7047,B-CHEMICAL
molecule,7047,O
with,7047,O
the,7047,O
initial,7047,O
glutathione-S-oxide,7047,B-CHEMICAL
adduct,7047,O
.,7047,O
In,7048,O
the,7048,O
case,7048,O
of,7048,O
the,7048,O
2-methylimidazo,7048,B-CHEMICAL
[,7048,I-CHEMICAL
"2,1-b",7048,I-CHEMICAL
],7048,I-CHEMICAL
thiazole,7048,I-CHEMICAL
analog,7048,O
2,7048,O
",",7048,O
glutathione,7048,B-CHEMICAL
conjugation,7048,O
occurred,7048,O
via,7048,O
an,7048,O
oxidative,7048,O
desulfation,7048,O
mechanism,7048,O
",",7048,O
possibly,7048,O
involving,7048,O
thiazole,7048,B-CHEMICAL
ring,7048,O
epoxidation,7048,O
as,7048,O
the,7048,O
rate-limiting,7048,O
step,7048,O
.,7048,O
Additional,7049,O
insights,7049,O
into,7049,O
the,7049,O
mechanism,7049,O
were,7049,O
obtained,7049,O
via,7049,O
18O,7049,B-CHEMICAL
exchange,7049,O
and,7049,O
trapping,7049,O
studies,7049,O
with,7049,O
potassium,7049,B-CHEMICAL
cyanide,7049,I-CHEMICAL
.,7049,O
The,7050,O
mechanistic,7050,O
insights,7050,O
into,7050,O
the,7050,O
bioactivation,7050,O
pathways,7050,O
of,7050,O
1,7050,O
and,7050,O
2,7050,O
allowed,7050,O
the,7050,O
deployment,7050,O
of,7050,O
a,7050,O
rational,7050,O
chemical,7050,O
intervention,7050,O
strategy,7050,O
that,7050,O
involved,7050,O
replacement,7050,O
of,7050,O
the,7050,O
thiazole,7050,B-CHEMICAL
ring,7050,O
with,7050,O
a,7050,O
"1,2,4-thiadiazole",7050,B-CHEMICAL
group,7050,O
to,7050,O
yield,7050,O
-,7050,B-CHEMICAL
(,7050,I-CHEMICAL
2-,7050,I-CHEMICAL
(,7050,I-CHEMICAL
2-chloro-4-,7050,I-CHEMICAL
(,7050,I-CHEMICAL
"2H-1,2,3-triazol-2-yl",7050,I-CHEMICAL
),7050,I-CHEMICAL
benzyl,7050,I-CHEMICAL
),7050,I-CHEMICAL
"-2,7-diazaspiro",7050,I-CHEMICAL
[,7050,I-CHEMICAL
3.5,7050,I-CHEMICAL
],7050,I-CHEMICAL
nonan-7-yl,7050,I-CHEMICAL
),7050,I-CHEMICAL
-2-,7050,I-CHEMICAL
(,7050,I-CHEMICAL
2-methylimidazo,7050,I-CHEMICAL
[,7050,I-CHEMICAL
"2,1-b",7050,I-CHEMICAL
],7050,I-CHEMICAL
[,7050,I-CHEMICAL
"1,3,4",7050,I-CHEMICAL
],7050,I-CHEMICAL
thiadiazol-6-yl,7050,I-CHEMICAL
),7050,I-CHEMICAL
ethanone,7050,I-CHEMICAL
(,7050,O
3,7050,O
),7050,O
.,7050,O
These,7051,O
structural,7051,O
changes,7051,O
not,7051,O
only,7051,O
abrogated,7051,O
the,7051,O
bioactivation,7051,O
liability,7051,O
but,7051,O
also,7051,O
retained,7051,O
the,7051,O
attractive,7051,O
pharmacological,7051,O
attributes,7051,O
of,7051,O
the,7051,O
prototype,7051,O
agents,7051,O
.,7051,O
Adenovirus-delivered,7052,O
angiopoietin-1,7052,B-GENE-Y
treatment,7052,O
for,7052,O
phosgene-induced,7052,B-CHEMICAL
acute,7052,O
lung,7052,O
injury,7052,O
.,7052,O
Abstract,7053,O
Context,7053,O
:,7053,O
Exposure,7053,O
to,7053,O
phosgene,7053,B-CHEMICAL
can,7053,O
result,7053,O
in,7053,O
an,7053,O
acute,7053,O
lung,7053,O
injury,7053,O
",",7053,O
leading,7053,O
to,7053,O
pulmonary,7053,O
edema,7053,O
and,7053,O
even,7053,O
death,7053,O
.,7053,O
Angiopoietin-1,7054,B-GENE-Y
(,7054,O
Ang1,7054,B-GENE-Y
),7054,O
is,7054,O
a,7054,O
critical,7054,O
factor,7054,O
for,7054,O
vascular,7054,O
stabilization,7054,O
due,7054,O
to,7054,O
its,7054,O
ability,7054,O
to,7054,O
reduce,7054,O
endothelial,7054,O
permeability,7054,O
and,7054,O
inflammation,7054,O
.,7054,O
Objective,7055,O
:,7055,O
In,7055,O
this,7055,O
study,7055,O
",",7055,O
the,7055,O
histopathological,7055,O
changes,7055,O
of,7055,O
the,7055,O
lungs,7055,O
after,7055,O
exposure,7055,O
to,7055,O
phosgene,7055,B-CHEMICAL
and,7055,O
the,7055,O
effect,7055,O
of,7055,O
Ang1,7055,B-GENE-Y
treatment,7055,O
were,7055,O
examined,7055,O
.,7055,O
Materials,7056,O
and,7056,O
methods,7056,O
:,7056,O
Rats,7056,O
were,7056,O
exposed,7056,O
to,7056,O
phosgene,7056,B-CHEMICAL
gas,7056,O
at,7056,O
8.33,7056,O
g/m,7056,O
(,7056,O
3,7056,O
),7056,O
for,7056,O
5,7056,O
min,7056,O
.,7056,O
Ang1,7057,O
overexpressing,7057,O
rats,7057,O
were,7057,O
established,7057,O
by,7057,O
an,7057,O
intravenous,7057,O
injection,7057,O
of,7057,O
adenovirus-Ang1,7057,O
(,7057,O
Ad/Ang1,7057,O
),7057,O
.,7057,O
The,7058,O
histological,7058,O
changes,7058,O
of,7058,O
the,7058,O
lung,7058,O
were,7058,O
examined,7058,O
by,7058,O
Haematoxylin-Eosin,7058,B-CHEMICAL
(,7058,O
H,7058,O
&,7058,O
E,7058,O
),7058,O
staining,7058,O
and,7058,O
fluorescence,7058,O
microscopy,7058,O
.,7058,O
The,7059,O
inferior,7059,O
lobe,7059,O
was,7059,O
used,7059,O
for,7059,O
the,7059,O
determination,7059,O
of,7059,O
the,7059,O
ratio,7059,O
of,7059,O
wet,7059,O
weight,7059,O
to,7059,O
dry,7059,O
weight,7059,O
of,7059,O
the,7059,O
lung,7059,O
.,7059,O
The,7060,O
concentration,7060,O
of,7060,O
cytokines,7060,B-GENE-N
in,7060,O
the,7060,O
serum,7060,O
and,7060,O
bronchoalveolar,7060,O
lavage,7060,O
fluid,7060,O
was,7060,O
determined,7060,O
by,7060,O
enzyme-linked,7060,O
immunosorbent,7060,O
assay,7060,O
.,7060,O
Results,7061,O
:,7061,O
The,7061,O
pathological,7061,O
analysis,7061,O
showed,7061,O
signs,7061,O
of,7061,O
inflammation,7061,O
and,7061,O
edema,7061,O
",",7061,O
evident,7061,O
from,7061,O
a,7061,O
significant,7061,O
increase,7061,O
in,7061,O
the,7061,O
number,7061,O
of,7061,O
leukocytes,7061,O
in,7061,O
bronchoalveolar,7061,O
lavage,7061,O
fluid,7061,O
and,7061,O
the,7061,O
ratio,7061,O
of,7061,O
wet,7061,O
to,7061,O
dry,7061,O
weight,7061,O
of,7061,O
the,7061,O
lungs,7061,O
.,7061,O
The,7062,O
lung,7062,O
injury,7062,O
induced,7062,O
by,7062,O
phosgene,7062,B-CHEMICAL
was,7062,O
markedly,7062,O
reduced,7062,O
after,7062,O
the,7062,O
injection,7062,O
of,7062,O
Ad/Ang1,7062,O
.,7062,O
The,7063,O
increase,7063,O
of,7063,O
IL-1β,7063,B-GENE-Y
and,7063,O
IL-17,7063,B-GENE-Y
and,7063,O
decrease,7063,O
of,7063,O
vascular,7063,B-GENE-Y
endothelial,7063,I-GENE-Y
growth,7063,I-GENE-Y
factor,7063,I-GENE-Y
in,7063,O
the,7063,O
serum,7063,O
and,7063,O
bronchoalveolar,7063,O
lavage,7063,O
fluid,7063,O
of,7063,O
phosgene-exposed,7063,B-CHEMICAL
animals,7063,O
were,7063,O
abolished,7063,O
by,7063,O
the,7063,O
administration,7063,O
of,7063,O
Ad/Ang1,7063,O
.,7063,O
Discussion,7064,O
and,7064,O
conclusions,7064,O
:,7064,O
Ang1,7064,B-GENE-Y
has,7064,O
the,7064,O
beneficial,7064,O
effects,7064,O
on,7064,O
phosgene-induced,7064,B-CHEMICAL
lung,7064,O
injury,7064,O
.,7064,O
The,7065,O
adenovirus-delivered,7065,O
Ang1,7065,B-GENE-Y
may,7065,O
have,7065,O
the,7065,O
potential,7065,O
as,7065,O
a,7065,O
novel,7065,O
approach,7065,O
for,7065,O
the,7065,O
treatment,7065,O
of,7065,O
the,7065,O
acute,7065,O
lung,7065,O
injury,7065,O
caused,7065,O
by,7065,O
phosgene,7065,B-CHEMICAL
gas,7065,O
inhalation,7065,O
in,7065,O
humans,7065,O
.,7065,O
Probing,7066,O
the,7066,O
Role,7066,O
of,7066,O
the,7066,O
Vancomycin,7066,B-CHEMICAL
E-Ring,7066,O
Aryl,7066,B-CHEMICAL
Chloride,7066,I-CHEMICAL
:,7066,O
Selective,7066,O
Divergent,7066,O
Synthesis,7066,O
and,7066,O
Evaluation,7066,O
of,7066,O
Alternatively,7066,O
Substituted,7066,O
E-Ring,7066,O
Analogues,7066,O
.,7066,O
The,7067,O
selective,7067,O
functionalization,7067,O
of,7067,O
a,7067,O
vancomycin,7067,B-CHEMICAL
aglycon,7067,O
derivative,7067,O
through,7067,O
direct,7067,O
conversion,7067,O
of,7067,O
the,7067,O
E-ring,7067,O
aryl,7067,B-CHEMICAL
chloride,7067,I-CHEMICAL
to,7067,O
a,7067,O
reactive,7067,O
boronic,7067,B-CHEMICAL
acid,7067,I-CHEMICAL
",",7067,O
and,7067,O
its,7067,O
use,7067,O
in,7067,O
the,7067,O
synthesis,7067,O
of,7067,O
a,7067,O
systematic,7067,O
series,7067,O
of,7067,O
vancomycin,7067,B-CHEMICAL
E-ring,7067,O
analogues,7067,O
are,7067,O
described,7067,O
.,7067,O
The,7068,O
series,7068,O
of,7068,O
analogues,7068,O
was,7068,O
used,7068,O
to,7068,O
examine,7068,O
the,7068,O
impact,7068,O
of,7068,O
the,7068,O
E-ring,7068,O
chloride,7068,O
in,7068,O
binding,7068,O
D-Ala-D-Ala,7068,B-CHEMICAL
and,7068,O
on,7068,O
antimicrobial,7068,O
activity,7068,O
.,7068,O
In,7069,O
contrast,7069,O
to,7069,O
the,7069,O
reduced,7069,O
activity,7069,O
of,7069,O
the,7069,O
unsubstituted,7069,O
E-ring,7069,O
derivatives,7069,O
",",7069,O
hydrophobic,7069,O
and,7069,O
relatively,7069,O
non-polar,7069,O
substituents,7069,O
approach,7069,O
or,7069,O
match,7069,O
the,7069,O
chloro,7069,B-CHEMICAL
substituted,7069,I-CHEMICAL
vancomycin,7069,I-CHEMICAL
and,7069,O
was,7069,O
insensitive,7069,O
to,7069,O
the,7069,O
electronic,7069,O
character,7069,O
of,7069,O
the,7069,O
substituent,7069,O
(,7069,O
e.g,7069,O
.,7069,O
Cl,7070,B-CHEMICAL
vs,7070,O
CN,7070,B-CHEMICAL
or,7070,O
OMe,7070,B-CHEMICAL
),7070,O
",",7070,O
whereas,7070,O
highly,7070,O
polar,7070,O
substituents,7070,O
fail,7070,O
to,7070,O
provide,7070,O
the,7070,O
enhancements,7070,O
.,7070,O
Moreover,7071,O
",",7071,O
the,7071,O
active,7071,O
permethylated,7071,O
vancomycin,7071,B-CHEMICAL
aglycon,7071,O
derivatives,7071,O
examined,7071,O
exhibit,7071,O
VanB,7071,B-GENE-N
VRE,7071,O
antimicrobial,7071,O
activity,7071,O
at,7071,O
levels,7071,O
that,7071,O
approach,7071,O
(,7071,O
typically,7071,O
within,7071,O
2-fold,7071,O
),7071,O
their,7071,O
activity,7071,O
against,7071,O
sensitive,7071,O
bacteria,7071,O
.,7071,O
The,7072,O
robust,7072,O
borylation,7072,O
reaction,7072,O
also,7072,O
enabled,7072,O
the,7072,O
selective,7072,O
functionalization,7072,O
of,7072,O
a,7072,O
minimally,7072,O
protected,7072,O
vancomycin,7072,B-CHEMICAL
aglycon,7072,O
(,7072,O
N-Boc,7072,B-CHEMICAL
vancomycin,7072,B-CHEMICAL
aglycon,7072,O
),7072,O
",",7072,O
and,7072,O
provides,7072,O
a,7072,O
direct,7072,O
method,7072,O
for,7072,O
the,7072,O
preparation,7072,O
of,7072,O
previously,7072,O
inaccessible,7072,O
analogues,7072,O
.,7072,O
Exposure,7073,O
to,7073,O
DEHP,7073,B-CHEMICAL
decreased,7073,O
four,7073,O
fatty,7073,B-CHEMICAL
acid,7073,I-CHEMICAL
levels,7073,O
in,7073,O
plasma,7073,O
of,7073,O
prepartum,7073,O
mice,7073,O
.,7073,O
Maternal,7074,O
exposure,7074,O
to,7074,O
di,7074,B-CHEMICAL
(,7074,I-CHEMICAL
2-ethylhexyl,7074,I-CHEMICAL
),7074,I-CHEMICAL
phthalate,7074,I-CHEMICAL
(,7074,O
DEHP,7074,B-CHEMICAL
),7074,O
decreased,7074,O
the,7074,O
plasma,7074,O
triglyceride,7074,B-CHEMICAL
in,7074,O
prepartum,7074,O
mice,7074,O
.,7074,O
To,7075,O
identify,7075,O
the,7075,O
fatty,7075,B-CHEMICAL
acid,7075,I-CHEMICAL
(,7075,O
FA,7075,O
),7075,O
species,7075,O
involved,7075,O
and,7075,O
to,7075,O
understand,7075,O
the,7075,O
underlying,7075,O
mechanisms,7075,O
",",7075,O
pregnant,7075,O
Sv/129,7075,O
wild-type,7075,O
(,7075,O
mPPARα,7075,B-GENE-Y
),7075,O
",",7075,O
peroxisome,7075,B-GENE-Y
proliferator-activated,7075,I-GENE-Y
receptor,7075,I-GENE-Y
α-null,7075,O
(,7075,O
Pparα-null,7075,B-GENE-Y
),7075,O
and,7075,O
humanized,7075,B-GENE-Y
PPARα,7075,I-GENE-Y
(,7075,O
hPPARα,7075,B-GENE-Y
),7075,O
mice,7075,O
were,7075,O
treated,7075,O
with,7075,O
diets,7075,O
containing,7075,O
0,7075,O
%,7075,O
",",7075,O
0.01,7075,O
%,7075,O
",",7075,O
0.05,7075,O
%,7075,O
or,7075,O
0.1,7075,O
%,7075,O
DEHP,7075,B-CHEMICAL
.,7075,O
Dams,7076,O
were,7076,O
dissected,7076,O
on,7076,O
gestational,7076,O
day,7076,O
18,7076,O
together,7076,O
with,7076,O
fetuses,7076,O
",",7076,O
and,7076,O
on,7076,O
postnatal,7076,O
day,7076,O
2,7076,O
together,7076,O
with,7076,O
newborns,7076,O
.,7076,O
n-3/n-6,7077,B-CHEMICAL
polyunsaturated,7077,I-CHEMICAL
",",7077,I-CHEMICAL
saturated,7077,I-CHEMICAL
",",7077,I-CHEMICAL
and,7077,I-CHEMICAL
monounsaturated,7077,I-CHEMICAL
FAs,7077,I-CHEMICAL
in,7077,O
maternal,7077,O
plasma,7077,O
and,7077,O
in,7077,O
liver,7077,O
of,7077,O
wild-type,7077,O
offspring,7077,O
",",7077,O
and,7077,O
representative,7077,O
enzymes,7077,O
for,7077,O
FA,7077,O
desaturation,7077,O
and,7077,O
elongation,7077,O
in,7077,O
maternal,7077,O
liver,7077,O
",",7077,O
were,7077,O
measured,7077,O
.,7077,O
The,7078,O
plasma,7078,O
levels,7078,O
of,7078,O
linoleic,7078,B-CHEMICAL
acid,7078,I-CHEMICAL
",",7078,O
α-linolenic,7078,B-CHEMICAL
acid,7078,I-CHEMICAL
",",7078,O
palmitic,7078,B-CHEMICAL
acid,7078,I-CHEMICAL
and,7078,O
oleic,7078,B-CHEMICAL
acid,7078,I-CHEMICAL
were,7078,O
higher,7078,O
in,7078,O
the,7078,O
pregnant,7078,O
control,7078,O
mPPARa,7078,B-GENE-Y
mice,7078,O
than,7078,O
in,7078,O
Ppara-null,7078,B-GENE-Y
and,7078,O
hPPARa,7078,B-GENE-Y
mice,7078,O
.,7078,O
DEHP,7079,B-CHEMICAL
exposure,7079,O
significantly,7079,O
decreased,7079,O
the,7079,O
levels,7079,O
of,7079,O
these,7079,O
four,7079,O
FAs,7079,O
only,7079,O
in,7079,O
pregnant,7079,O
mPPARα,7079,B-GENE-Y
mice,7079,O
.,7079,O
Plasma,7080,O
levels,7080,O
of,7080,O
many,7080,O
FAs,7080,O
were,7080,O
higher,7080,O
in,7080,O
pregnant,7080,O
mice,7080,O
than,7080,O
in,7080,O
postpartum,7080,O
ones,7080,O
in,7080,O
a,7080,O
genotype-independent,7080,O
manner,7080,O
",",7080,O
while,7080,O
it,7080,O
was,7080,O
lower,7080,O
in,7080,O
the,7080,O
livers,7080,O
of,7080,O
fetuses,7080,O
than,7080,O
pups,7080,O
.,7080,O
DEHP,7081,B-CHEMICAL
exposure,7081,O
slightly,7081,O
increased,7081,O
hepatic,7081,O
arachidonic,7081,B-CHEMICAL
acid,7081,I-CHEMICAL
",",7081,O
α-linolenic,7081,B-CHEMICAL
acid,7081,I-CHEMICAL
",",7081,O
palmitoleic,7081,B-CHEMICAL
acid,7081,I-CHEMICAL
and,7081,O
oleic,7081,B-CHEMICAL
acid,7081,I-CHEMICAL
in,7081,O
fetuses,7081,O
",",7081,O
but,7081,O
not,7081,O
in,7081,O
pups,7081,O
.,7081,O
However,7082,O
",",7082,O
DEHP,7082,B-CHEMICAL
exposure,7082,O
did,7082,O
not,7082,O
clearly,7082,O
influence,7082,O
FA,7082,B-GENE-N
desaturase,7082,I-GENE-N
1,7082,I-GENE-N
and,7082,I-GENE-N
2,7082,I-GENE-N
nor,7082,O
elongase,7082,B-GENE-N
2,7082,I-GENE-N
and,7082,I-GENE-N
5,7082,I-GENE-N
expressions,7082,O
in,7082,O
the,7082,O
liver,7082,O
of,7082,O
all,7082,O
maternal,7082,O
mice,7082,O
.,7082,O
Taken,7083,O
together,7083,O
",",7083,O
the,7083,O
levels,7083,O
of,7083,O
plasma,7083,O
four,7083,O
FAs,7083,O
with,7083,O
shorter,7083,O
carbon,7083,B-CHEMICAL
chains,7083,O
were,7083,O
higher,7083,O
in,7083,O
pregnant,7083,O
mPPARα,7083,B-GENE-Y
mice,7083,O
than,7083,O
in,7083,O
other,7083,O
genotypes,7083,O
",",7083,O
and,7083,O
DEHP,7083,B-CHEMICAL
exposure,7083,O
decreased,7083,O
these,7083,O
specific,7083,O
FA,7083,O
concentrations,7083,O
only,7083,O
in,7083,O
mPPARα,7083,B-GENE-Y
mice,7083,O
",",7083,O
similarly,7083,O
to,7083,O
triglyceride,7083,B-CHEMICAL
levels,7083,O
.,7083,O
Soluble,7084,O
polysialylated,7084,B-GENE-Y
NCAM,7084,I-GENE-Y
:,7084,O
a,7084,O
novel,7084,O
player,7084,O
of,7084,O
the,7084,O
innate,7084,O
immune,7084,O
system,7084,O
in,7084,O
the,7084,O
lung,7084,O
.,7084,O
Posttranslational,7085,O
modification,7085,O
of,7085,O
the,7085,O
neural,7085,B-GENE-Y
cell,7085,I-GENE-Y
adhesion,7085,I-GENE-Y
molecule,7085,I-GENE-Y
(,7085,O
NCAM,7085,B-GENE-Y
),7085,O
by,7085,O
polysialic,7085,B-CHEMICAL
acid,7085,I-CHEMICAL
(,7085,O
polySia,7085,B-CHEMICAL
),7085,O
is,7085,O
well,7085,O
studied,7085,O
in,7085,O
the,7085,O
nervous,7085,O
system,7085,O
and,7085,O
described,7085,O
as,7085,O
a,7085,O
dynamic,7085,O
modulator,7085,O
of,7085,O
plastic,7085,O
processes,7085,O
like,7085,O
precursor,7085,O
cell,7085,O
migration,7085,O
",",7085,O
axon,7085,O
fasciculation,7085,O
",",7085,O
and,7085,O
synaptic,7085,O
plasticity,7085,O
.,7085,O
Here,7086,O
",",7086,O
we,7086,O
describe,7086,O
a,7086,O
novel,7086,O
function,7086,O
of,7086,O
polysialylated,7086,B-GENE-Y
NCAM,7086,I-GENE-Y
(,7086,O
polySia-NCAM,7086,B-CHEMICAL
),7086,O
in,7086,O
innate,7086,O
immunity,7086,O
of,7086,O
the,7086,O
lung,7086,O
.,7086,O
In,7087,O
mature,7087,O
lung,7087,O
tissue,7087,O
of,7087,O
healthy,7087,O
donors,7087,O
",",7087,O
polySia,7087,B-CHEMICAL
was,7087,O
exclusively,7087,O
attached,7087,O
to,7087,O
the,7087,O
transmembrane,7087,O
isoform,7087,O
NCAM-140,7087,B-GENE-Y
and,7087,O
located,7087,O
to,7087,O
intracellular,7087,O
compartments,7087,O
of,7087,O
epithelial,7087,O
cells,7087,O
.,7087,O
In,7088,O
patients,7088,O
with,7088,O
chronic,7088,O
obstructive,7088,O
pulmonary,7088,O
disease,7088,O
",",7088,O
however,7088,O
",",7088,O
increased,7088,O
polySia,7088,B-CHEMICAL
levels,7088,O
and,7088,O
processing,7088,O
of,7088,O
the,7088,O
NCAM,7088,B-GENE-Y
carrier,7088,O
were,7088,O
observed,7088,O
.,7088,O
Processing,7089,O
of,7089,O
polysialylated,7089,B-GENE-Y
NCAM,7089,I-GENE-Y
was,7089,O
reproduced,7089,O
in,7089,O
a,7089,O
mouse,7089,O
model,7089,O
by,7089,O
bleomycin,7089,B-CHEMICAL
administration,7089,O
leading,7089,O
to,7089,O
an,7089,O
activation,7089,O
of,7089,O
the,7089,O
inflammasome,7089,O
and,7089,O
secretion,7089,O
of,7089,O
interleukin,7089,B-GENE-Y
(,7089,I-GENE-Y
IL,7089,I-GENE-Y
),7089,I-GENE-Y
-1β,7089,I-GENE-Y
.,7089,O
As,7090,O
shown,7090,O
in,7090,O
a,7090,O
cell,7090,O
culture,7090,O
model,7090,O
",",7090,O
polySia-NCAM-140,7090,B-CHEMICAL
was,7090,O
kept,7090,O
in,7090,O
the,7090,O
late,7090,O
trans-Golgi,7090,O
apparatus,7090,O
of,7090,O
lung,7090,O
epithelial,7090,O
cells,7090,O
and,7090,O
stimulation,7090,O
by,7090,O
IL-1β,7090,B-GENE-Y
or,7090,O
lipopolysaccharide,7090,O
induced,7090,O
metalloprotease-mediated,7090,B-GENE-N
ectodomain,7090,B-GENE-N
shedding,7090,O
",",7090,O
resulting,7090,O
in,7090,O
the,7090,O
secretion,7090,O
of,7090,O
soluble,7090,O
polySia-NCAM,7090,B-CHEMICAL
.,7090,O
Interestingly,7091,O
",",7091,O
polySia,7091,B-CHEMICAL
chains,7091,O
of,7091,O
secreted,7091,O
NCAM,7091,B-GENE-Y
neutralized,7091,O
the,7091,O
cytotoxic,7091,O
activity,7091,O
of,7091,O
extracellular,7091,O
histones,7091,B-GENE-N
as,7091,O
well,7091,O
as,7091,O
DNA/histone-network-containing,7091,O
``,7091,O
neutrophil,7091,O
extracellular,7091,O
traps,7091,O
'',7091,O
",",7091,O
which,7091,O
are,7091,O
formed,7091,O
during,7091,O
invasion,7091,O
of,7091,O
microorganisms,7091,O
.,7091,O
Thus,7092,O
",",7092,O
shedding,7092,O
of,7092,O
polySia-NCAM,7092,B-CHEMICAL
by,7092,O
lung,7092,O
epithelial,7092,O
cells,7092,O
may,7092,O
provide,7092,O
a,7092,O
host-protective,7092,O
mechanism,7092,O
to,7092,O
reduce,7092,O
tissue,7092,O
damage,7092,O
during,7092,O
inflammatory,7092,O
processes,7092,O
.,7092,O
Study,7093,O
of,7093,O
endothelial,7093,O
cell,7093,O
apoptosis,7093,O
using,7093,O
fluorescence,7093,O
resonance,7093,O
energy,7093,O
transfer,7093,O
(,7093,O
FRET,7093,O
),7093,O
biosensor,7093,O
cell,7093,O
line,7093,O
with,7093,O
hemodynamic,7093,O
microfluidic,7093,O
chip,7093,O
system,7093,O
.,7093,O
To,7094,O
better,7094,O
understand,7094,O
how,7094,O
hyperglycemia,7094,O
induces,7094,O
endothelial,7094,O
cell,7094,O
dysfunction,7094,O
under,7094,O
the,7094,O
diabetic,7094,O
conditions,7094,O
",",7094,O
a,7094,O
hemodynamic,7094,O
microfluidic,7094,O
chip,7094,O
system,7094,O
was,7094,O
developed,7094,O
.,7094,O
The,7095,O
system,7095,O
combines,7095,O
a,7095,O
caspase-3-based,7095,B-GENE-Y
fluorescence,7095,O
resonance,7095,O
energy,7095,O
transfer,7095,O
(,7095,O
FRET,7095,O
),7095,O
biosensor,7095,O
cell,7095,O
line,7095,O
which,7095,O
can,7095,O
detect,7095,O
endothelial,7095,O
cell,7095,O
apoptosis,7095,O
in,7095,O
real-time,7095,O
",",7095,O
post-treatment,7095,O
effect,7095,O
and,7095,O
with,7095,O
a,7095,O
limited,7095,O
cell,7095,O
sample,7095,O
",",7095,O
by,7095,O
using,7095,O
a,7095,O
microfluidic,7095,O
chip,7095,O
which,7095,O
can,7095,O
mimic,7095,O
the,7095,O
physiological,7095,O
pulsatile,7095,O
flow,7095,O
profile,7095,O
in,7095,O
the,7095,O
blood,7095,O
vessel,7095,O
.,7095,O
The,7096,O
caspase-3-based,7096,B-GENE-Y
FRET,7096,O
biosensor,7096,O
endothelial,7096,O
cell,7096,O
line,7096,O
(,7096,O
HUVEC-C3,7096,O
),7096,O
can,7096,O
produce,7096,O
a,7096,O
FRET-based,7096,O
sensor,7096,O
protein,7096,O
capable,7096,O
of,7096,O
probing,7096,O
caspase-3,7096,B-GENE-Y
activation,7096,O
.,7096,O
When,7097,O
the,7097,O
endothelial,7097,O
cells,7097,O
undergo,7097,O
apoptosis,7097,O
",",7097,O
the,7097,O
color,7097,O
of,7097,O
the,7097,O
sensor,7097,O
cells,7097,O
changes,7097,O
from,7097,O
green,7097,O
to,7097,O
blue,7097,O
",",7097,O
thus,7097,O
sensing,7097,O
apoptosis,7097,O
.,7097,O
A,7098,O
double-labeling,7098,O
fluorescent,7098,O
technique,7098,O
(,7098,O
yo,7098,B-CHEMICAL
pro-1,7098,I-CHEMICAL
and,7098,O
propidium,7098,B-CHEMICAL
iodide,7098,I-CHEMICAL
),7098,O
was,7098,O
used,7098,O
to,7098,O
validate,7098,O
the,7098,O
findings,7098,O
revealed,7098,O
by,7098,O
the,7098,O
FRET-based,7098,O
caspase,7098,B-GENE-N
sensor,7098,O
.,7098,O
The,7099,O
results,7099,O
show,7099,O
high,7099,O
rates,7099,O
of,7099,O
apoptosis,7099,O
and,7099,O
necrosis,7099,O
of,7099,O
endothelial,7099,O
cells,7099,O
when,7099,O
high,7099,O
glucose,7099,B-CHEMICAL
concentration,7099,O
was,7099,O
applied,7099,O
in,7099,O
our,7099,O
hemodynamic,7099,O
microfluidic,7099,O
chip,7099,O
combined,7099,O
with,7099,O
an,7099,O
exhaustive,7099,O
pulsatile,7099,O
flow,7099,O
profile,7099,O
.,7099,O
The,7100,O
two,7100,O
apoptosis,7100,O
detection,7100,O
techniques,7100,O
(,7100,O
fluorescent,7100,O
method,7100,O
and,7100,O
FRET,7100,O
biosensor,7100,O
),7100,O
are,7100,O
comparable,7100,O
;,7100,O
but,7100,O
FRET,7100,O
biosensor,7100,O
offers,7100,O
more,7100,O
advantages,7100,O
such,7100,O
as,7100,O
real-time,7100,O
observation,7100,O
and,7100,O
a,7100,O
convenient,7100,O
operating,7100,O
process,7100,O
to,7100,O
generate,7100,O
more,7100,O
accurate,7100,O
and,7100,O
reliable,7100,O
data,7100,O
.,7100,O
Furthermore,7101,O
",",7101,O
the,7101,O
activation,7101,O
of,7101,O
the,7101,O
FRET,7101,O
biosensor,7101,O
also,7101,O
confirms,7101,O
the,7101,O
endothelial,7101,O
cell,7101,O
apoptosis,7101,O
induced,7101,O
by,7101,O
the,7101,O
abnormal,7101,O
pulsatile,7101,O
shear,7101,O
stress,7101,O
and,7101,O
high,7101,O
glucose,7101,B-CHEMICAL
concentration,7101,O
is,7101,O
through,7101,O
caspase-3,7101,B-GENE-Y
pathway,7101,O
.,7101,O
A,7102,O
12,7102,O
%,7102,O
apoptotic,7102,O
rate,7102,O
(,7102,O
nearly,7102,O
a,7102,O
4-fold,7102,O
increase,7102,O
compared,7102,O
to,7102,O
the,7102,O
static,7102,O
condition,7102,O
),7102,O
was,7102,O
observed,7102,O
when,7102,O
the,7102,O
endothelial,7102,O
cells,7102,O
were,7102,O
exposed,7102,O
to,7102,O
a,7102,O
high,7102,O
glucose,7102,B-CHEMICAL
concentration,7102,O
of,7102,O
20,7102,O
mM,7102,O
under,7102,O
2,7102,O
h,7102,O
exhaustive,7102,O
pulsatile,7102,O
shear,7102,O
stress,7102,O
of,7102,O
30,7102,O
dyne,7102,O
cm,7102,O
(,7102,O
-2,7102,O
),7102,O
and,7102,O
followed,7102,O
with,7102,O
another,7102,O
10,7102,O
h,7102,O
normal,7102,O
pulsatile,7102,O
shear,7102,O
stress,7102,O
of,7102,O
15,7102,O
dyne,7102,O
cm,7102,O
(,7102,O
-2,7102,O
),7102,O
.,7102,O
Therefore,7103,O
",",7103,O
the,7103,O
most,7103,O
important,7103,O
finding,7103,O
of,7103,O
this,7103,O
study,7103,O
is,7103,O
to,7103,O
develop,7103,O
a,7103,O
novel,7103,O
endothelial,7103,O
cell,7103,O
apoptosis,7103,O
detection,7103,O
method,7103,O
",",7103,O
which,7103,O
combines,7103,O
the,7103,O
microfluidic,7103,O
chip,7103,O
system,7103,O
and,7103,O
FRET,7103,O
biosensor,7103,O
.,7103,O
This,7104,O
finding,7104,O
may,7104,O
provide,7104,O
new,7104,O
insight,7104,O
into,7104,O
how,7104,O
glucose,7104,B-CHEMICAL
causes,7104,O
endothelial,7104,O
cell,7104,O
dysfunction,7104,O
",",7104,O
which,7104,O
is,7104,O
the,7104,O
major,7104,O
cause,7104,O
of,7104,O
diabetes-derived,7104,O
complications,7104,O
.,7104,O
High,7105,O
salt,7105,O
diets,7105,O
during,7105,O
pregnancy,7105,O
affected,7105,O
fetal,7105,O
and,7105,O
offspring,7105,O
renal,7105,O
renin-angiotensin,7105,B-GENE-Y
system,7105,O
.,7105,O
Intrauterine,7106,O
environments,7106,O
are,7106,O
linked,7106,O
to,7106,O
fetal,7106,O
renal,7106,O
development,7106,O
and,7106,O
postnatal,7106,O
health,7106,O
.,7106,O
Influence,7107,O
of,7107,O
salt,7107,O
diets,7107,O
during,7107,O
pregnancy,7107,O
on,7107,O
renal,7107,O
functions,7107,O
and,7107,O
renin-angiotensin,7107,B-GENE-Y
system,7107,O
(,7107,O
RAS,7107,O
),7107,O
were,7107,O
determined,7107,O
in,7107,O
the,7107,O
ovine,7107,O
fetus,7107,O
and,7107,O
offspring,7107,O
.,7107,O
Pregnant,7108,O
ewes,7108,O
were,7108,O
fed,7108,O
high-salt,7108,O
diet,7108,O
(,7108,O
HSD,7108,O
),7108,O
or,7108,O
normal-salt,7108,O
diet,7108,O
(,7108,O
NSD,7108,O
),7108,O
for,7108,O
two,7108,O
months,7108,O
during,7108,O
middle-later,7108,O
gestation,7108,O
.,7108,O
Fetal,7109,O
renal,7109,O
functions,7109,O
",",7109,O
plasma,7109,O
hormones,7109,O
",",7109,O
mRNA,7109,O
and,7109,O
protein,7109,O
expressions,7109,O
of,7109,O
the,7109,O
key,7109,O
elements,7109,O
of,7109,O
renal,7109,O
RAS,7109,O
were,7109,O
measured,7109,O
in,7109,O
the,7109,O
fetus,7109,O
and,7109,O
offspring,7109,O
.,7109,O
Fetal,7110,O
renal,7110,O
excretion,7110,O
of,7110,O
sodium,7110,B-CHEMICAL
was,7110,O
increased,7110,O
while,7110,O
urine,7110,O
volume,7110,O
decreased,7110,O
in,7110,O
HSD,7110,O
group,7110,O
.,7110,O
Fetal,7111,O
blood,7111,O
urea,7111,B-CHEMICAL
nitrogen,7111,B-CHEMICAL
was,7111,O
increased,7111,O
",",7111,O
while,7111,O
kidney/body,7111,O
weight,7111,O
ratio,7111,O
decreased,7111,O
in,7111,O
HSD,7111,O
group,7111,O
.,7111,O
The,7112,O
altered,7112,O
ratio,7112,O
also,7112,O
was,7112,O
observed,7112,O
in,7112,O
the,7112,O
offspring,7112,O
at,7112,O
15-day-old,7112,O
and,7112,O
90-day-old,7112,O
.,7112,O
Maternal,7113,O
and,7113,O
fetal,7113,O
plasma,7113,O
antidiuretic,7113,B-GENE-Y
hormone,7113,I-GENE-Y
was,7113,O
elevated,7113,O
without,7113,O
change,7113,O
in,7113,O
plasma,7113,O
renin,7113,B-GENE-Y
activity,7113,O
and,7113,O
Ang,7113,B-GENE-Y
I,7113,I-GENE-Y
levels,7113,O
",",7113,O
while,7113,O
plasma,7113,O
Ang,7113,B-GENE-Y
II,7113,I-GENE-Y
was,7113,O
decreased,7113,O
.,7113,O
The,7114,O
key,7114,O
elements,7114,O
of,7114,O
local,7114,O
renal,7114,O
RAS,7114,O
",",7114,O
including,7114,O
angiotensinogen,7114,B-GENE-Y
",",7114,O
ACE,7114,B-GENE-Y
",",7114,O
ACE2,7114,B-GENE-Y
",",7114,O
AT1,7114,B-GENE-Y
and,7114,O
AT2,7114,B-GENE-Y
receptor,7114,I-GENE-Y
expression,7114,O
in,7114,O
both,7114,O
mRNA,7114,O
and,7114,O
protein,7114,O
",",7114,O
except,7114,O
renin,7114,B-GENE-Y
",",7114,O
were,7114,O
altered,7114,O
following,7114,O
maternal,7114,O
high,7114,O
salt,7114,O
intake,7114,O
.,7114,O
The,7115,O
results,7115,O
suggest,7115,O
that,7115,O
High,7115,O
intake,7115,O
of,7115,O
salt,7115,O
during,7115,O
pregnancy,7115,O
affected,7115,O
fetal,7115,O
renal,7115,O
development,7115,O
associated,7115,O
with,7115,O
an,7115,O
altered,7115,O
expression,7115,O
of,7115,O
the,7115,O
renal,7115,O
key,7115,O
elements,7115,O
of,7115,O
RAS,7115,O
",",7115,O
some,7115,O
alterations,7115,O
of,7115,O
fetal,7115,O
origins,7115,O
remained,7115,O
after,7115,O
birth,7115,O
as,7115,O
possible,7115,O
risks,7115,O
in,7115,O
developing,7115,O
renal,7115,O
or,7115,O
cardiovascular,7115,O
diseases,7115,O
.,7115,O
Synthesis,7116,O
of,7116,O
pyrazolo,7116,B-CHEMICAL
[,7116,I-CHEMICAL
"1,5-a",7116,I-CHEMICAL
],7116,I-CHEMICAL
pyrimidine,7116,I-CHEMICAL
linked,7116,O
aminobenzothiazole,7116,B-CHEMICAL
conjugates,7116,O
as,7116,O
potential,7116,O
anticancer,7116,O
agents,7116,O
.,7116,O
A,7117,O
series,7117,O
of,7117,O
pyrazolo,7117,B-CHEMICAL
[,7117,I-CHEMICAL
"1,5-a",7117,I-CHEMICAL
],7117,I-CHEMICAL
pyrimidine,7117,I-CHEMICAL
linked,7117,O
2-aminobenzothizole,7117,B-CHEMICAL
conjugates,7117,O
(,7117,O
6a-t,7117,O
),7117,O
were,7117,O
synthesized,7117,O
and,7117,O
evaluated,7117,O
for,7117,O
their,7117,O
anticancer,7117,O
activity,7117,O
against,7117,O
five,7117,O
human,7117,O
cancer,7117,O
cell,7117,O
lines,7117,O
.,7117,O
Among,7118,O
them,7118,O
two,7118,O
compounds,7118,O
6p,7118,O
and,7118,O
6m,7118,O
showed,7118,O
significant,7118,O
anticancer,7118,O
activity,7118,O
with,7118,O
IC50,7118,O
values,7118,O
ranging,7118,O
from,7118,O
2.01,7118,O
to,7118,O
7.07,7118,O
and,7118,O
1.94-3.46μM,7118,O
",",7118,O
respectively,7118,O
.,7118,O
Moreover,7119,O
",",7119,O
cell,7119,O
cycle,7119,O
arrest,7119,O
in,7119,O
G2/M,7119,O
and,7119,O
reduction,7119,O
in,7119,O
Cdk1,7119,B-GENE-Y
expression,7119,O
level,7119,O
were,7119,O
observed,7119,O
upon,7119,O
treatment,7119,O
of,7119,O
these,7119,O
compounds,7119,O
and,7119,O
they,7119,O
also,7119,O
induced,7119,O
caspase-3,7119,B-GENE-Y
dependent,7119,O
apoptosis,7119,O
.,7119,O
This,7120,O
was,7120,O
further,7120,O
confirmed,7120,O
by,7120,O
staining,7120,O
as,7120,O
well,7120,O
as,7120,O
DNA,7120,O
fragmentation,7120,O
analysis,7120,O
.,7120,O
Evaluation,7121,O
of,7121,O
the,7121,O
positive,7121,O
effects,7121,O
on,7121,O
insulin-resistance,7121,B-GENE-Y
and,7121,O
β-cell,7121,O
measurements,7121,O
of,7121,O
vildagliptin,7121,B-CHEMICAL
in,7121,O
addition,7121,O
to,7121,O
metformin,7121,B-CHEMICAL
in,7121,O
type,7121,O
2,7121,O
diabetic,7121,O
patients,7121,O
.,7121,O
We,7122,O
evaluated,7122,O
the,7122,O
positive,7122,O
effects,7122,O
of,7122,O
vildagliptin,7122,B-CHEMICAL
in,7122,O
addition,7122,O
to,7122,O
metformin,7122,B-CHEMICAL
on,7122,O
glycemic,7122,O
control,7122,O
and,7122,O
β-cell,7122,O
function,7122,O
in,7122,O
type,7122,O
2,7122,O
diabetic,7122,O
patients,7122,O
.,7122,O
One,7123,O
hundred,7123,O
and,7123,O
seventy-one,7123,O
type,7123,O
2,7123,O
diabetic,7123,O
patients,7123,O
were,7123,O
instructed,7123,O
to,7123,O
add,7123,O
vildaglipin,7123,B-CHEMICAL
50mg,7123,O
twice,7123,O
a,7123,O
day,7123,O
or,7123,O
placebo,7123,O
to,7123,O
metformin,7123,B-CHEMICAL
for,7123,O
12,7123,O
months,7123,O
.,7123,O
Body,7124,O
mass,7124,O
index,7124,O
(,7124,O
BMI,7124,O
),7124,O
",",7124,O
glycemic,7124,O
control,7124,O
",",7124,O
fasting,7124,O
plasma,7124,O
insulin,7124,B-GENE-Y
(,7124,O
FPI,7124,O
),7124,O
",",7124,O
HOMA-IR,7124,O
",",7124,O
HOMA-β,7124,O
",",7124,O
fasting,7124,O
plasma,7124,O
proinsulin,7124,B-GENE-Y
(,7124,O
FPPr,7124,O
),7124,O
",",7124,O
proinsulin/fasting,7124,B-GENE-Y
plasma,7124,O
insulin,7124,B-GENE-Y
ratio,7124,O
(,7124,O
Pr/FPI,7124,O
ratio,7124,O
),7124,O
",",7124,O
C-peptide,7124,B-GENE-Y
",",7124,O
glucagon,7124,B-GENE-Y
",",7124,O
vaspin,7124,B-GENE-Y
",",7124,O
visfatin,7124,B-GENE-Y
",",7124,O
and,7124,O
omentin-1,7124,B-GENE-Y
were,7124,O
evaluated,7124,O
.,7124,O
Before,7125,O
",",7125,O
and,7125,O
after,7125,O
12,7125,O
months,7125,O
since,7125,O
the,7125,O
addition,7125,O
of,7125,O
vildagliptin,7125,B-CHEMICAL
",",7125,O
patients,7125,O
underwent,7125,O
a,7125,O
combined,7125,O
euglycemic,7125,O
hyperinsulinemic,7125,O
and,7125,O
hyperglycemic,7125,O
clamp,7125,O
",",7125,O
with,7125,O
subsequent,7125,O
arginine,7125,B-CHEMICAL
stimulation,7125,O
.,7125,O
Vildagliptin+metformin,7126,B-CHEMICAL
were,7126,O
more,7126,O
effective,7126,O
than,7126,O
placebo+metformin,7126,O
in,7126,O
reducing,7126,O
body,7126,O
weight,7126,O
and,7126,O
BMI,7126,O
",",7126,O
glycemic,7126,O
control,7126,O
",",7126,O
HOMA-IR,7126,O
",",7126,O
glucagon,7126,B-GENE-Y
and,7126,O
insulin,7126,B-GENE-Y
resistance,7126,O
measurements,7126,O
.,7126,O
Vildagliptin+metformin,7127,B-CHEMICAL
gave,7127,O
also,7127,O
a,7127,O
better,7127,O
increase,7127,O
of,7127,O
HOMA-β,7127,O
",",7127,O
and,7127,O
of,7127,O
all,7127,O
β-cell,7127,O
parameters,7127,O
after,7127,O
the,7127,O
clamp,7127,O
.,7127,O
We,7128,O
also,7128,O
recorded,7128,O
a,7128,O
significant,7128,O
correlation,7128,O
between,7128,O
M,7128,O
value,7128,O
increase,7128,O
and,7128,O
the,7128,O
decrease,7128,O
of,7128,O
vaspin,7128,B-GENE-Y
",",7128,O
visfatin,7128,B-GENE-Y
",",7128,O
and,7128,O
omentin-1,7128,B-GENE-Y
obtained,7128,O
with,7128,O
vildagliptin+metformin,7128,B-CHEMICAL
.,7128,O
Vildagliptin,7129,B-CHEMICAL
",",7129,O
in,7129,O
addition,7129,O
to,7129,O
metformin,7129,B-CHEMICAL
",",7129,O
proved,7129,O
to,7129,O
be,7129,O
effective,7129,O
in,7129,O
improving,7129,O
β-cell,7129,O
function,7129,O
and,7129,O
in,7129,O
reducing,7129,O
insulin,7129,B-GENE-Y
resistance,7129,O
measurements,7129,O
.,7129,O
4-Hydroxytamoxifen-stimulated,7130,B-CHEMICAL
processing,7130,O
of,7130,O
cyclin,7130,B-GENE-Y
E,7130,I-GENE-Y
is,7130,O
mediated,7130,O
via,7130,O
G,7130,B-GENE-Y
protein-coupled,7130,I-GENE-Y
receptor,7130,I-GENE-Y
30,7130,I-GENE-Y
(,7130,O
GPR30,7130,B-GENE-Y
),7130,I-GENE-Y
and,7130,O
accompanied,7130,O
by,7130,O
enhanced,7130,O
migration,7130,O
in,7130,O
MCF-7,7130,O
breast,7130,O
cancer,7130,O
cells,7130,O
.,7130,O
Over-expression,7131,O
of,7131,O
cleaved,7131,O
cyclin,7131,B-GENE-Y
E,7131,I-GENE-Y
in,7131,O
breast,7131,O
tumors,7131,O
is,7131,O
closely,7131,O
associated,7131,O
with,7131,O
tumor,7131,O
progression,7131,O
and,7131,O
resistance,7131,O
to,7131,O
antiestrogens,7131,O
.,7131,O
17β-Estradiol,7132,B-CHEMICAL
(,7132,O
E2,7132,O
),7132,O
has,7132,O
been,7132,O
recently,7132,O
shown,7132,O
to,7132,O
induce,7132,O
cyclin,7132,B-GENE-Y
E,7132,I-GENE-Y
processing,7132,O
in,7132,O
breast,7132,O
cancer,7132,O
cells,7132,O
.,7132,O
Tamoxifen,7133,B-CHEMICAL
has,7133,O
been,7133,O
used,7133,O
in,7133,O
patients,7133,O
with,7133,O
estrogen-sensitive,7133,B-CHEMICAL
breast,7133,O
cancer,7133,O
",",7133,O
yet,7133,O
resistance,7133,O
to,7133,O
antiestrogens,7133,O
and,7133,O
recurrence,7133,O
will,7133,O
appear,7133,O
in,7133,O
some,7133,O
of,7133,O
the,7133,O
patients,7133,O
after,7133,O
its,7133,O
continued,7133,O
use,7133,O
.,7133,O
We,7134,O
therefore,7134,O
addressed,7134,O
possible,7134,O
effects,7134,O
of,7134,O
tamoxifen,7134,B-CHEMICAL
on,7134,O
the,7134,O
generation,7134,O
of,7134,O
cleaved,7134,O
cyclin,7134,B-GENE-Y
E,7134,I-GENE-Y
and,7134,O
its,7134,O
signal,7134,O
mechanism,7134,O
(,7134,O
s,7134,O
),7134,O
in,7134,O
estrogen-responsive,7134,B-CHEMICAL
MCF-7,7134,O
breast,7134,O
cancer,7134,O
cells,7134,O
that,7134,O
express,7134,O
both,7134,O
G,7134,B-GENE-Y
protein-coupled,7134,I-GENE-Y
protein,7134,I-GENE-Y
(,7134,I-GENE-Y
GPR,7134,I-GENE-Y
),7134,I-GENE-Y
30,7134,I-GENE-Y
and,7134,O
estrogen,7134,B-CHEMICAL
receptor,7134,I-GENE-Y
α,7134,I-GENE-Y
(,7134,O
ERα,7134,B-GENE-N
),7134,O
.,7134,O
4-Hydroxytamoxifen,7135,B-CHEMICAL
(,7135,O
OHT,7135,B-CHEMICAL
",",7135,O
tamoxifen,7135,B-CHEMICAL
's,7135,O
active,7135,O
form,7135,O
),7135,O
failed,7135,O
to,7135,O
prevent,7135,O
E2-induced,7135,O
proteolysis,7135,O
of,7135,O
cyclin,7135,B-GENE-Y
E,7135,I-GENE-Y
and,7135,O
migration,7135,O
",",7135,O
but,7135,O
rather,7135,O
triggered,7135,O
cyclin,7135,B-GENE-Y
E,7135,I-GENE-Y
cleavage,7135,O
coincident,7135,O
with,7135,O
augmented,7135,O
migration,7135,O
.,7135,O
OHT-induced,7136,B-CHEMICAL
cyclin,7136,B-GENE-Y
E,7136,I-GENE-Y
truncation,7136,O
also,7136,O
occurred,7136,O
in,7136,O
SK-BR-3,7136,O
cells,7136,O
that,7136,O
express,7136,O
GPR30,7136,B-GENE-Y
and,7136,O
lack,7136,O
ERα,7136,B-GENE-Y
",",7136,O
but,7136,O
not,7136,O
in,7136,O
MDA-MB-231,7136,O
cells,7136,O
that,7136,O
express,7136,O
neither,7136,O
GPR30,7136,B-GENE-Y
nor,7136,O
ERα,7136,B-GENE-Y
.,7136,O
G1,7137,O
",",7137,O
a,7137,O
specific,7137,O
GPR,7137,B-GENE-Y
30,7137,I-GENE-Y
agonist,7137,O
",",7137,O
caused,7137,O
dramatic,7137,O
proteolysis,7137,O
of,7137,O
cyclin,7137,B-GENE-Y
E,7137,I-GENE-Y
and,7137,O
enhanced,7137,O
migration,7137,O
.,7137,O
Furthermore,7138,O
",",7138,O
OHT-stimulated,7138,B-CHEMICAL
cleavage,7138,O
of,7138,O
cyclin,7138,B-GENE-Y
E,7138,I-GENE-Y
and,7138,O
migration,7138,O
were,7138,O
tremendously,7138,O
attenuated,7138,O
by,7138,O
G15,7138,O
",",7138,O
a,7138,O
GPR30,7138,B-GENE-Y
antagonist,7138,O
",",7138,O
or,7138,O
siRNA,7138,O
against,7138,O
GPR30,7138,B-GENE-Y
.,7138,O
In,7139,O
addition,7139,O
",",7139,O
inhibitors,7139,O
for,7139,O
EGFR,7139,B-GENE-Y
or,7139,O
ERK1/2,7139,B-GENE-N
remarkably,7139,O
suppressed,7139,O
OHT-induced,7139,B-CHEMICAL
truncation,7139,O
of,7139,O
cyclin,7139,B-GENE-Y
E,7139,I-GENE-Y
",",7139,O
suggesting,7139,O
involvement,7139,O
of,7139,O
EGFR,7139,B-GENE-Y
signaling,7139,O
.,7139,O
Collectively,7140,O
",",7140,O
our,7140,O
data,7140,O
indicate,7140,O
that,7140,O
OHT,7140,B-CHEMICAL
contributes,7140,O
to,7140,O
the,7140,O
production,7140,O
of,7140,O
proteolyzed,7140,O
cyclin,7140,B-GENE-Y
E,7140,I-GENE-Y
via,7140,O
GPR30,7140,B-GENE-Y
with,7140,O
augmented,7140,O
migration,7140,O
in,7140,O
MCF-7,7140,O
cells,7140,O
.,7140,O
Mechanistic,7141,O
Aspects,7141,O
of,7141,O
hSOD1,7141,B-GENE-Y
Maturation,7141,O
from,7141,O
the,7141,O
Solution,7141,O
Structure,7141,O
of,7141,O
Cu,7141,B-CHEMICAL
(,7141,I-CHEMICAL
I,7141,I-CHEMICAL
),7141,I-CHEMICAL
-Loaded,7141,O
hCCS,7141,B-GENE-N
Domain,7141,I-GENE-N
1,7141,I-GENE-N
and,7141,O
Analysis,7141,O
of,7141,O
Disulfide-Free,7141,B-CHEMICAL
hSOD1,7141,B-GENE-Y
Mutants,7141,O
.,7141,O
Superoxide,7142,B-GENE-Y
dismutase,7142,I-GENE-Y
1,7142,I-GENE-Y
(,7142,O
SOD1,7142,B-GENE-Y
),7142,O
maturation,7142,O
within,7142,O
the,7142,O
cell,7142,O
is,7142,O
mainly,7142,O
accomplished,7142,O
with,7142,O
the,7142,O
SOD1-specific,7142,B-GENE-Y
chaperone,7142,I-GENE-Y
",",7142,O
CCS,7142,B-GENE-Y
",",7142,O
a,7142,O
dimeric,7142,O
protein,7142,O
with,7142,O
three,7142,O
distinct,7142,O
domains,7142,O
in,7142,O
each,7142,O
monomer,7142,O
.,7142,O
We,7143,O
recently,7143,O
showed,7143,O
that,7143,O
the,7143,O
first,7143,O
domain,7143,O
of,7143,O
human,7143,B-GENE-Y
CCS,7143,I-GENE-Y
(,7143,O
hCCSD1,7143,B-GENE-N
),7143,O
is,7143,O
responsible,7143,O
for,7143,O
copper,7143,B-CHEMICAL
transfer,7143,O
to,7143,O
its,7143,O
protein,7143,O
partner,7143,O
",",7143,O
human,7143,B-GENE-Y
SOD1,7143,I-GENE-Y
(,7143,O
hSOD1,7143,B-GENE-Y
),7143,O
.,7143,O
The,7144,O
NMR,7144,O
solution,7144,O
structure,7144,O
of,7144,O
the,7144,O
copper,7144,B-CHEMICAL
(,7144,I-CHEMICAL
I,7144,I-CHEMICAL
),7144,I-CHEMICAL
-loaded,7144,O
form,7144,O
of,7144,O
hCCSD1,7144,B-GENE-N
reported,7144,O
here,7144,O
contributes,7144,O
further,7144,O
to,7144,O
characterization,7144,O
of,7144,O
the,7144,O
copper-transfer,7144,O
mechanism,7144,O
to,7144,O
hSOD1,7144,B-GENE-Y
.,7144,O
NMR,7145,O
spectroscopy,7145,O
was,7145,O
also,7145,O
used,7145,O
to,7145,O
examine,7145,O
the,7145,O
hSOD1,7145,B-GENE-Y
mutants,7145,O
C57A,7145,B-GENE-N
",",7145,O
C146A,7145,B-GENE-N
",",7145,O
and,7145,O
C57A/C146A,7145,B-GENE-N
",",7145,O
which,7145,O
are,7145,O
unable,7145,O
to,7145,O
form,7145,O
the,7145,O
structurally,7145,O
conserved,7145,O
disulfide,7145,B-CHEMICAL
bond,7145,O
in,7145,O
SOD1,7145,B-GENE-Y
",",7145,O
in,7145,O
order,7145,O
to,7145,O
investigate,7145,O
the,7145,O
role,7145,O
of,7145,O
these,7145,O
cysteines,7145,B-CHEMICAL
during,7145,O
hSOD1,7145,B-GENE-Y
copper,7145,O
acquisition,7145,O
.,7145,O
Together,7146,O
",",7146,O
the,7146,O
information,7146,O
on,7146,O
both,7146,O
hCCS,7146,B-GENE-Y
and,7146,O
hSOD1,7146,B-GENE-Y
",",7146,O
along,7146,O
with,7146,O
a,7146,O
sequence,7146,O
analysis,7146,O
of,7146,O
eukaryotic,7146,O
CCSD1,7146,B-GENE-N
",",7146,O
allows,7146,O
us,7146,O
to,7146,O
propose,7146,O
important,7146,O
mechanistic,7146,O
aspects,7146,O
regarding,7146,O
the,7146,O
copper-transfer,7146,B-CHEMICAL
process,7146,O
from,7146,O
hCCS,7146,B-GENE-Y
to,7146,O
hSOD1,7146,B-GENE-Y
.,7146,O
Novel,7147,O
pentablock,7147,O
copolymer,7147,O
(,7147,O
PLA-PCL-PEG-PCL-PLA,7147,B-CHEMICAL
),7147,O
based,7147,O
nanoparticles,7147,O
for,7147,O
controlled,7147,O
drug,7147,O
delivery,7147,O
:,7147,O
Effect,7147,O
of,7147,O
copolymer,7147,O
compositions,7147,O
on,7147,O
the,7147,O
crystallinity,7147,O
of,7147,O
copolymers,7147,O
and,7147,O
in,7147,O
vitro,7147,O
drug,7147,O
release,7147,O
profile,7147,O
from,7147,O
nanoparticles,7147,O
.,7147,O
The,7148,O
purpose,7148,O
of,7148,O
this,7148,O
investigation,7148,O
was,7148,O
to,7148,O
design,7148,O
novel,7148,O
pentablock,7148,O
copolymers,7148,O
(,7148,O
polylatide-polycaprolactone-polyethylene,7148,B-CHEMICAL
glycol-,7148,O
polycaprolactone-polylatide,7148,B-CHEMICAL
),7148,O
(,7148,O
PLA-PCL-PEG-PCL-PLA,7148,B-CHEMICAL
),7148,O
to,7148,O
prepare,7148,O
nanoparticle,7148,O
formulations,7148,O
which,7148,O
provide,7148,O
continuous,7148,O
delivery,7148,O
of,7148,O
steroids,7148,B-CHEMICAL
over,7148,O
a,7148,O
longer,7148,O
duration,7148,O
with,7148,O
minimal,7148,O
burst,7148,O
effect,7148,O
.,7148,O
Another,7149,O
purpose,7149,O
was,7149,O
to,7149,O
evaluate,7149,O
the,7149,O
effect,7149,O
of,7149,O
poly,7149,B-CHEMICAL
(,7149,I-CHEMICAL
L-lactide,7149,I-CHEMICAL
),7149,I-CHEMICAL
(,7149,O
PLLA,7149,B-CHEMICAL
),7149,O
or,7149,O
poly,7149,B-CHEMICAL
(,7149,I-CHEMICAL
D,7149,I-CHEMICAL
",",7149,I-CHEMICAL
L-lactide,7149,I-CHEMICAL
),7149,I-CHEMICAL
(,7149,O
PDLLA,7149,B-CHEMICAL
),7149,O
incorporation,7149,O
on,7149,O
crystallinity,7149,O
of,7149,O
pentablock,7149,O
copolymers,7149,O
and,7149,O
in,7149,O
vitro,7149,O
release,7149,O
profile,7149,O
of,7149,O
triamcinolone,7149,B-CHEMICAL
acetonide,7149,I-CHEMICAL
(,7149,O
selected,7149,O
as,7149,O
model,7149,O
drug,7149,O
),7149,O
from,7149,O
nanoparticles,7149,O
.,7149,O
PLA-PCL-PEG-PCL-PLA,7150,B-CHEMICAL
copolymers,7150,O
with,7150,O
different,7150,O
block,7150,O
ratio,7150,O
of,7150,O
PCL/PLA,7150,B-CHEMICAL
segment,7150,O
were,7150,O
synthesized,7150,O
.,7150,O
Release,7151,O
of,7151,O
triamcinolone,7151,B-CHEMICAL
acetonide,7151,I-CHEMICAL
from,7151,O
nanoparticles,7151,O
was,7151,O
significantly,7151,O
affected,7151,O
by,7151,O
crystallinity,7151,O
of,7151,O
the,7151,O
copolymers,7151,O
.,7151,O
Burst,7152,O
release,7152,O
of,7152,O
triamcinolone,7152,B-CHEMICAL
acetonide,7152,I-CHEMICAL
from,7152,O
nanoparticles,7152,O
was,7152,O
significantly,7152,O
minimized,7152,O
with,7152,O
incorporation,7152,O
of,7152,O
proper,7152,O
ratio,7152,O
of,7152,O
PDLLA,7152,B-CHEMICAL
in,7152,O
the,7152,O
existing,7152,O
triblock,7152,O
(,7152,O
PCL-PEG-PCL,7152,B-CHEMICAL
),7152,O
copolymer,7152,O
.,7152,O
Moreover,7153,O
",",7153,O
pentablock,7153,O
copolymer,7153,O
based,7153,O
nanoparticles,7153,O
exhibited,7153,O
continuous,7153,O
release,7153,O
of,7153,O
triamcinolone,7153,B-CHEMICAL
acetonide,7153,I-CHEMICAL
.,7153,O
Pentablock,7154,O
copolymer,7154,O
based,7154,O
nanoparticles,7154,O
can,7154,O
be,7154,O
utilized,7154,O
to,7154,O
achieve,7154,O
continuous,7154,O
near,7154,O
zero-order,7154,O
delivery,7154,O
of,7154,O
corticosteroids,7154,O
from,7154,O
nanoparticles,7154,O
without,7154,O
any,7154,O
burst,7154,O
effect,7154,O
.,7154,O
PICK1,7155,B-GENE-Y
Deficiency,7155,O
Impairs,7155,O
Secretory,7155,O
Vesicle,7155,O
Biogenesis,7155,O
and,7155,O
Leads,7155,O
to,7155,O
Growth,7155,O
Retardation,7155,O
and,7155,O
Decreased,7155,O
Glucose,7155,B-CHEMICAL
Tolerance,7155,O
.,7155,O
Secretory,7156,O
vesicles,7156,O
in,7156,O
endocrine,7156,O
cells,7156,O
store,7156,O
hormones,7156,O
such,7156,O
as,7156,O
growth,7156,B-GENE-Y
hormone,7156,I-GENE-Y
(,7156,O
GH,7156,B-GENE-Y
),7156,O
and,7156,O
insulin,7156,B-GENE-Y
before,7156,O
their,7156,O
release,7156,O
into,7156,O
the,7156,O
bloodstream,7156,O
.,7156,O
The,7157,O
molecular,7157,O
mechanisms,7157,O
governing,7157,O
budding,7157,O
of,7157,O
immature,7157,O
secretory,7157,O
vesicles,7157,O
from,7157,O
the,7157,O
trans-Golgi,7157,O
network,7157,O
(,7157,O
TGN,7157,O
),7157,O
and,7157,O
their,7157,O
subsequent,7157,O
maturation,7157,O
remain,7157,O
unclear,7157,O
.,7157,O
Here,7158,O
",",7158,O
we,7158,O
identify,7158,O
the,7158,O
lipid,7158,B-GENE-N
binding,7158,I-GENE-N
BAR,7158,I-GENE-N
(,7158,I-GENE-N
Bin/amphiphysin/Rvs,7158,I-GENE-N
),7158,I-GENE-N
domain,7158,I-GENE-N
protein,7158,I-GENE-N
PICK1,7158,B-GENE-Y
(,7158,O
protein,7158,B-GENE-Y
interacting,7158,I-GENE-Y
with,7158,I-GENE-Y
C,7158,I-GENE-Y
kinase,7158,I-GENE-Y
1,7158,I-GENE-Y
),7158,O
as,7158,O
a,7158,O
key,7158,O
component,7158,O
early,7158,O
in,7158,O
the,7158,O
biogenesis,7158,O
of,7158,O
secretory,7158,O
vesicles,7158,O
in,7158,O
GH-producing,7158,B-GENE-Y
cells,7158,O
.,7158,O
Both,7159,O
PICK1-deficient,7159,B-GENE-N
Drosophila,7159,O
and,7159,O
mice,7159,O
displayed,7159,O
somatic,7159,O
growth,7159,O
retardation,7159,O
.,7159,O
Growth,7160,O
retardation,7160,O
was,7160,O
rescued,7160,O
in,7160,O
flies,7160,O
by,7160,O
reintroducing,7160,O
PICK1,7160,B-GENE-Y
in,7160,O
neurosecretory,7160,O
cells,7160,O
producing,7160,O
somatotropic,7160,O
peptides,7160,O
.,7160,O
PICK1-deficient,7161,B-GENE-Y
mice,7161,O
were,7161,O
characterized,7161,O
by,7161,O
decreased,7161,O
body,7161,O
weight,7161,O
and,7161,O
length,7161,O
",",7161,O
increased,7161,O
fat,7161,O
accumulation,7161,O
",",7161,O
impaired,7161,O
GH,7161,B-GENE-Y
secretion,7161,O
",",7161,O
and,7161,O
decreased,7161,O
storage,7161,O
of,7161,O
GH,7161,B-GENE-Y
in,7161,O
the,7161,O
pituitary,7161,O
.,7161,O
Decreased,7162,O
GH,7162,B-GENE-Y
storage,7162,O
was,7162,O
supported,7162,O
by,7162,O
electron,7162,O
microscopy,7162,O
showing,7162,O
prominent,7162,O
reduction,7162,O
in,7162,O
secretory,7162,O
vesicle,7162,O
number,7162,O
.,7162,O
Evidence,7163,O
was,7163,O
also,7163,O
obtained,7163,O
for,7163,O
impaired,7163,O
insulin,7163,O
secretion,7163,O
associated,7163,O
with,7163,O
decreased,7163,O
glucose,7163,B-CHEMICAL
tolerance,7163,O
.,7163,O
PICK1,7164,B-GENE-Y
localized,7164,O
in,7164,O
cells,7164,O
to,7164,O
immature,7164,O
secretory,7164,O
vesicles,7164,O
",",7164,O
and,7164,O
the,7164,O
PICK1,7164,B-GENE-N
BAR,7164,I-GENE-N
domain,7164,I-GENE-N
was,7164,O
shown,7164,O
by,7164,O
live,7164,O
imaging,7164,O
to,7164,O
associate,7164,O
with,7164,O
vesicles,7164,O
budding,7164,O
from,7164,O
the,7164,O
TGN,7164,O
and,7164,O
to,7164,O
possess,7164,O
membrane-sculpting,7164,O
properties,7164,O
in,7164,O
vitro,7164,O
.,7164,O
In,7165,O
mouse,7165,O
pituitary,7165,O
",",7165,O
PICK1,7165,B-GENE-Y
co-localized,7165,O
with,7165,O
the,7165,O
BAR,7165,B-GENE-N
domain,7165,I-GENE-N
protein,7165,I-GENE-N
ICA69,7165,B-GENE-Y
",",7165,O
and,7165,O
PICK1,7165,B-GENE-Y
deficiency,7165,O
abolished,7165,O
ICA69,7165,B-GENE-Y
protein,7165,O
expression,7165,O
.,7165,O
In,7166,O
the,7166,O
Drosophila,7166,O
brain,7166,O
",",7166,O
PICK1,7166,B-GENE-Y
and,7166,O
ICA69,7166,B-GENE-Y
co-immunoprecipitated,7166,O
and,7166,O
showed,7166,O
mutually,7166,O
dependent,7166,O
expression,7166,O
.,7166,O
Finally,7167,O
",",7167,O
both,7167,O
in,7167,O
a,7167,O
Drosophila,7167,O
model,7167,O
of,7167,O
type,7167,O
2,7167,O
diabetes,7167,O
and,7167,O
in,7167,O
high-fat-diet-induced,7167,O
obese,7167,O
mice,7167,O
",",7167,O
we,7167,O
observed,7167,O
up-regulation,7167,O
of,7167,O
PICK1,7167,B-GENE-N
mRNA,7167,O
expression,7167,O
.,7167,O
Our,7168,O
findings,7168,O
suggest,7168,O
that,7168,O
PICK1,7168,B-GENE-N
",",7168,O
together,7168,O
with,7168,O
ICA69,7168,B-GENE-N
",",7168,O
is,7168,O
critical,7168,O
during,7168,O
budding,7168,O
of,7168,O
immature,7168,O
secretory,7168,O
vesicles,7168,O
from,7168,O
the,7168,O
TGN,7168,O
and,7168,O
thus,7168,O
for,7168,O
vesicular,7168,O
storage,7168,O
of,7168,O
GH,7168,B-GENE-N
and,7168,O
possibly,7168,O
other,7168,O
hormones,7168,O
.,7168,O
The,7169,O
data,7169,O
link,7169,O
two,7169,O
BAR,7169,B-GENE-N
domain,7169,I-GENE-N
proteins,7169,I-GENE-N
to,7169,O
membrane,7169,O
remodeling,7169,O
processes,7169,O
in,7169,O
the,7169,O
secretory,7169,O
pathway,7169,O
of,7169,O
peptidergic,7169,O
endocrine,7169,O
cells,7169,O
and,7169,O
support,7169,O
an,7169,O
important,7169,O
role,7169,O
of,7169,O
PICK1/ICA69,7169,B-GENE-Y
in,7169,O
maintenance,7169,O
of,7169,O
metabolic,7169,O
homeostasis,7169,O
.,7169,O
Design,7170,O
",",7170,O
Synthesis,7170,O
and,7170,O
Biological,7170,O
Evaluation,7170,O
of,7170,O
Aminoalkylindole,7170,B-CHEMICAL
Derivatives,7170,O
as,7170,O
Cannabinoid,7170,B-GENE-Y
Receptor,7170,I-GENE-Y
Ligands,7170,O
with,7170,O
Potential,7170,O
for,7170,O
Treatment,7170,O
of,7170,O
Alcohol,7170,B-CHEMICAL
Abuse,7170,O
.,7170,O
Attenuation,7171,O
of,7171,O
increased,7171,O
endocannabinoid,7171,O
signaling,7171,O
with,7171,O
a,7171,O
CB1R,7171,B-GENE-Y
neutral,7171,O
antagonist,7171,O
might,7171,O
offer,7171,O
a,7171,O
new,7171,O
therapeutic,7171,O
direction,7171,O
for,7171,O
treatment,7171,O
of,7171,O
alcohol,7171,B-CHEMICAL
abuse,7171,O
.,7171,O
We,7172,O
have,7172,O
recently,7172,O
reported,7172,O
that,7172,O
a,7172,O
mono-hydroxylated,7172,O
metabolite,7172,O
of,7172,O
the,7172,O
synthetic,7172,O
aminoalkylindole,7172,B-CHEMICAL
cannabinoid,7172,O
JHW-073,7172,B-CHEMICAL
(,7172,O
3,7172,O
),7172,O
exhibits,7172,O
neutral,7172,O
antagonist,7172,O
activity,7172,O
at,7172,O
CB1Rs,7172,B-GENE-Y
and,7172,O
thus,7172,O
may,7172,O
serve,7172,O
as,7172,O
a,7172,O
promising,7172,O
lead,7172,O
for,7172,O
the,7172,O
development,7172,O
of,7172,O
novel,7172,O
alcohol,7172,B-CHEMICAL
abuse,7172,O
therapies,7172,O
.,7172,O
In,7173,O
the,7173,O
current,7173,O
study,7173,O
",",7173,O
we,7173,O
show,7173,O
that,7173,O
systematic,7173,O
modification,7173,O
of,7173,O
an,7173,O
aminoalkylindole,7173,B-CHEMICAL
scaffold,7173,O
identifies,7173,O
two,7173,O
new,7173,O
compounds,7173,O
with,7173,O
dual,7173,O
CB1R,7173,B-GENE-Y
antagonist/CB2R,7173,O
agonist,7173,O
activity,7173,O
.,7173,O
Similar,7174,O
to,7174,O
the,7174,O
CB1R,7174,B-GENE-N
antagonist/inverse,7174,O
agonist,7174,O
rimonabant,7174,O
",",7174,O
analogues,7174,O
27,7174,O
and,7174,O
30,7174,O
decrease,7174,O
oral,7174,O
alcohol,7174,B-CHEMICAL
self-administration,7174,O
",",7174,O
without,7174,O
affecting,7174,O
total,7174,O
fluid,7174,O
intake,7174,O
and,7174,O
block,7174,O
the,7174,O
development,7174,O
of,7174,O
alcohol-conditioned,7174,B-CHEMICAL
place,7174,O
preference,7174,O
.,7174,O
Collectively,7175,O
",",7175,O
these,7175,O
initial,7175,O
findings,7175,O
suggest,7175,O
that,7175,O
design,7175,O
and,7175,O
systematic,7175,O
modification,7175,O
of,7175,O
aminoalkylindoles,7175,B-CHEMICAL
such,7175,O
as,7175,O
3,7175,O
may,7175,O
lead,7175,O
to,7175,O
development,7175,O
of,7175,O
novel,7175,O
cannabinoid,7175,O
ligands,7175,O
with,7175,O
dual,7175,O
CB1R,7175,B-GENE-Y
antagonist/CB2R,7175,O
agonist,7175,O
activity,7175,O
with,7175,O
potential,7175,O
for,7175,O
use,7175,O
as,7175,O
treatments,7175,O
of,7175,O
alcohol,7175,B-CHEMICAL
abuse,7175,O
.,7175,O
Immunoregulatory,7176,O
effects,7176,O
of,7176,O
Glycyrrhizic,7176,B-CHEMICAL
acid,7176,I-CHEMICAL
exerts,7176,O
anti-asthmatic,7176,O
effects,7176,O
via,7176,O
modulation,7176,O
of,7176,O
Th1/Th2,7176,O
cytokines,7176,B-GENE-N
and,7176,O
enhancement,7176,O
of,7176,O
CD4,7176,O
(,7176,O
+,7176,O
),7176,O
CD25,7176,O
(,7176,O
+,7176,O
),7176,O
Foxp3,7176,O
(,7176,O
+,7176,O
),7176,O
regulatory,7176,O
T,7176,O
cells,7176,O
in,7176,O
ovalbumin-sensitized,7176,B-GENE-Y
mice,7176,O
.,7176,O
ETHNOPHARMACOLOGICAL,7177,O
RELEVANCE,7177,O
:,7177,O
Glycyrrhizic,7177,B-CHEMICAL
acid,7177,I-CHEMICAL
(,7177,O
GA,7177,O
),7177,O
is,7177,O
the,7177,O
main,7177,O
bioactive,7177,O
ingredient,7177,O
of,7177,O
licorice,7177,O
(,7177,O
Glycyrrhiza,7177,O
glabra,7177,O
),7177,O
",",7177,O
and,7177,O
has,7177,O
been,7177,O
found,7177,O
to,7177,O
be,7177,O
associated,7177,O
with,7177,O
multiple,7177,O
therapeutic,7177,O
properties,7177,O
.,7177,O
AIM,7178,O
OF,7178,O
THE,7178,O
STUDY,7178,O
:,7178,O
In,7178,O
this,7178,O
study,7178,O
",",7178,O
we,7178,O
investigated,7178,O
immunoregulatory,7178,O
effects,7178,O
of,7178,O
glycyrrhizic,7178,B-CHEMICAL
acid,7178,I-CHEMICAL
on,7178,O
anti-asthmatic,7178,O
effects,7178,O
and,7178,O
underlying,7178,O
mechanisms,7178,O
.,7178,O
MATERIALS,7179,O
AND,7179,O
METHODS,7179,O
:,7179,O
Asthma,7179,O
model,7179,O
was,7179,O
established,7179,O
by,7179,O
ovalbumin-induced,7179,B-GENE-Y
.,7179,O
A,7180,O
total,7180,O
of,7180,O
60,7180,O
mice,7180,O
were,7180,O
randomly,7180,O
assigned,7180,O
to,7180,O
six,7180,O
experimental,7180,O
groups,7180,O
:,7180,O
control,7180,O
",",7180,O
model,7180,O
",",7180,O
dexamethasone,7180,B-CHEMICAL
(,7180,O
2mg/kg,7180,O
),7180,O
and,7180,O
GA,7180,O
(,7180,O
10mg/kg,7180,O
",",7180,O
20mg/kg,7180,O
",",7180,O
40mg/kg,7180,O
),7180,O
.,7180,O
Airway,7181,O
resistance,7181,O
(,7181,O
Raw,7181,O
),7181,O
were,7181,O
measured,7181,O
by,7181,O
the,7181,O
forced,7181,O
oscillation,7181,O
technique,7181,O
",",7181,O
histological,7181,O
studies,7181,O
were,7181,O
evaluated,7181,O
by,7181,O
The,7181,O
hematoxylin,7181,B-CHEMICAL
and,7181,O
eosin,7181,B-CHEMICAL
(,7181,O
HE,7181,O
),7181,O
staining,7181,O
",",7181,O
Th1/Th2,7181,O
and,7181,O
Th17,7181,O
cytokines,7181,B-GENE-N
were,7181,O
evaluated,7181,O
by,7181,O
enzyme-linked,7181,O
immunosorbent,7181,O
assay,7181,O
(,7181,O
ELISA,7181,O
),7181,O
",",7181,O
and,7181,O
CD4,7181,O
(,7181,O
+,7181,O
),7181,O
CD25,7181,O
(,7181,O
+,7181,O
),7181,O
Foxp3,7181,O
(,7181,O
+,7181,O
),7181,O
regulatory,7181,O
T,7181,O
cells,7181,O
(,7181,O
Tregs,7181,O
),7181,O
was,7181,O
evaluated,7181,O
by,7181,O
Flow,7181,O
Cytometry,7181,O
(,7181,O
FCM,7181,O
),7181,O
",",7181,O
the,7181,O
forkhead/winged,7181,B-GENE-N
helix,7181,I-GENE-N
transcription,7181,I-GENE-N
factor,7181,I-GENE-N
(,7181,O
Foxp3,7181,B-GENE-Y
),7181,O
was,7181,O
evaluated,7181,O
by,7181,O
western,7181,O
blotting,7181,O
.,7181,O
RESULTS,7182,O
:,7182,O
Our,7182,O
study,7182,O
demonstrated,7182,O
that,7182,O
",",7182,O
compared,7182,O
with,7182,O
model,7182,O
group,7182,O
",",7182,O
GA,7182,O
inhibited,7182,O
OVA-induced,7182,B-GENE-Y
increases,7182,O
in,7182,O
Raw,7182,O
and,7182,O
eosinophil,7182,O
count,7182,O
;,7182,O
interleukin,7182,B-GENE-Y
(,7182,I-GENE-Y
IL,7182,I-GENE-Y
),7182,I-GENE-Y
-4,7182,I-GENE-Y
",",7182,O
IL-5,7182,B-GENE-Y
",",7182,O
IL-13,7182,B-GENE-Y
levels,7182,O
were,7182,O
recovered,7182,O
in,7182,O
bronchoalveolar,7182,O
lavage,7182,O
fluid,7182,O
compared,7182,O
;,7182,O
increased,7182,O
IFN-γlevel,7182,B-GENE-Y
in,7182,O
bronchoalveolar,7182,O
lavage,7182,O
fluid,7182,O
;,7182,O
histological,7182,O
studies,7182,O
demonstrated,7182,O
that,7182,O
GA,7182,O
substantially,7182,O
inhibited,7182,O
OVA-induced,7182,B-GENE-Y
eosinophilia,7182,O
in,7182,O
lung,7182,O
tissue,7182,O
and,7182,O
airway,7182,O
tissue,7182,O
compared,7182,O
with,7182,O
model,7182,O
group,7182,O
.,7182,O
Flow,7183,O
cytometry,7183,O
studies,7183,O
demonstrated,7183,O
that,7183,O
GA,7183,O
substantially,7183,O
enhanced,7183,O
Tregs,7183,O
compared,7183,O
with,7183,O
model,7183,O
group,7183,O
.,7183,O
CONCLUSION,7184,O
:,7184,O
These,7184,O
findings,7184,O
suggest,7184,O
that,7184,O
GA,7184,O
may,7184,O
effectively,7184,O
ameliorate,7184,O
the,7184,O
progression,7184,O
of,7184,O
asthma,7184,O
and,7184,O
could,7184,O
be,7184,O
used,7184,O
as,7184,O
a,7184,O
therapy,7184,O
for,7184,O
patients,7184,O
with,7184,O
allergic,7184,O
asthma,7184,O
.,7184,O
Enhanced,7185,O
beta,7185,O
cell,7185,O
function,7185,O
and,7185,O
anti-inflammatory,7185,O
effect,7185,O
after,7185,O
chronic,7185,O
treatment,7185,O
with,7185,O
the,7185,O
dipeptidyl,7185,B-GENE-Y
peptidase-4,7185,I-GENE-Y
inhibitor,7185,O
vildagliptin,7185,B-CHEMICAL
in,7185,O
an,7185,O
advanced-aged,7185,O
diet-induced,7185,O
obesity,7185,O
mouse,7185,O
model,7185,O
.,7185,O
AIMS/HYPOTHESIS,7186,O
:,7186,O
Studies,7186,O
have,7186,O
shown,7186,O
that,7186,O
dipeptidyl,7186,B-GENE-Y
peptidase-4,7186,I-GENE-Y
(,7186,O
DPP4,7186,B-GENE-Y
),7186,O
inhibitors,7186,O
stimulate,7186,O
insulin,7186,B-GENE-N
secretion,7186,O
and,7186,O
increase,7186,O
beta,7186,O
cell,7186,O
mass,7186,O
in,7186,O
rodents,7186,O
.,7186,O
However,7187,O
",",7187,O
in,7187,O
these,7187,O
models,7187,O
hyperglycaemia,7187,O
has,7187,O
been,7187,O
induced,7187,O
early,7187,O
on,7187,O
in,7187,O
life,7187,O
and,7187,O
the,7187,O
treatment,7187,O
periods,7187,O
have,7187,O
been,7187,O
short,7187,O
.,7187,O
To,7188,O
explore,7188,O
the,7188,O
long-term,7188,O
effects,7188,O
of,7188,O
DPP4,7188,B-GENE-Y
inhibition,7188,O
on,7188,O
insulin,7188,B-GENE-N
secretion,7188,O
and,7188,O
beta,7188,O
cell,7188,O
mass,7188,O
",",7188,O
we,7188,O
have,7188,O
generated,7188,O
a,7188,O
high-fat,7188,O
diet,7188,O
(,7188,O
HFD,7188,O
),7188,O
-induced-obesity,7188,O
model,7188,O
in,7188,O
mice,7188,O
of,7188,O
advanced,7188,O
age,7188,O
(,7188,O
10,7188,O
months,7188,O
old,7188,O
),7188,O
.,7188,O
METHODS,7189,O
:,7189,O
After,7189,O
1,7189,O
month,7189,O
of,7189,O
HFD,7189,O
alone,7189,O
",",7189,O
the,7189,O
mice,7189,O
were,7189,O
given,7189,O
the,7189,O
DPP4,7189,B-GENE-Y
inhibitor,7189,O
vildagliptin,7189,B-CHEMICAL
for,7189,O
a,7189,O
further,7189,O
11,7189,O
months,7189,O
.,7189,O
At,7190,O
multiple,7190,O
time,7190,O
points,7190,O
throughout,7190,O
the,7190,O
study,7190,O
",",7190,O
OGTTs,7190,O
were,7190,O
performed,7190,O
and,7190,O
beta,7190,O
cell,7190,O
area,7190,O
and,7190,O
long-term,7190,O
survival,7190,O
were,7190,O
evaluated,7190,O
.,7190,O
RESULTS,7191,O
:,7191,O
Beta,7191,O
cell,7191,O
function,7191,O
and,7191,O
glucose,7191,B-CHEMICAL
tolerance,7191,O
were,7191,O
significantly,7191,O
improved,7191,O
by,7191,O
vildagliptin,7191,B-CHEMICAL
with,7191,O
both,7191,O
diets,7191,O
.,7191,O
In,7192,O
contrast,7192,O
",",7192,O
in,7192,O
spite,7192,O
of,7192,O
the,7192,O
long,7192,O
treatment,7192,O
period,7192,O
",",7192,O
beta,7192,O
cell,7192,O
area,7192,O
was,7192,O
not,7192,O
significantly,7192,O
different,7192,O
between,7192,O
vildagliptin-treated,7192,B-CHEMICAL
mice,7192,O
and,7192,O
controls,7192,O
.,7192,O
Mice,7193,O
of,7193,O
advanced,7193,O
age,7193,O
chronically,7193,O
fed,7193,O
an,7193,O
HFD,7193,O
displayed,7193,O
clear,7193,O
and,7193,O
extensive,7193,O
pancreatic,7193,O
inflammation,7193,O
and,7193,O
peri-insulitis,7193,O
",",7193,O
mainly,7193,O
formed,7193,O
by,7193,O
CD3-positive,7193,O
T,7193,O
cells,7193,O
",",7193,O
which,7193,O
were,7193,O
completely,7193,O
prevented,7193,O
by,7193,O
vildagliptin,7193,B-CHEMICAL
treatment,7193,O
.,7193,O
Chronic,7194,O
vildagliptin,7194,B-CHEMICAL
treatment,7194,O
also,7194,O
improved,7194,O
survival,7194,O
rates,7194,O
for,7194,O
HFD-fed,7194,O
mice,7194,O
.,7194,O
CONCLUSIONS/INTERPRETATION,7195,O
:,7195,O
In,7195,O
a,7195,O
unique,7195,O
advanced-aged,7195,O
HFD-induced-obesity,7195,O
mouse,7195,O
model,7195,O
",",7195,O
insulin,7195,B-GENE-N
secretion,7195,O
was,7195,O
improved,7195,O
and,7195,O
the,7195,O
extensive,7195,O
peri-insulitis,7195,O
prevented,7195,O
by,7195,O
chronic,7195,O
DPP4,7195,B-GENE-Y
inhibition,7195,O
.,7195,O
The,7196,O
improved,7196,O
survival,7196,O
rates,7196,O
for,7196,O
obese,7196,O
mice,7196,O
chronically,7196,O
treated,7196,O
with,7196,O
vildagliptin,7196,B-CHEMICAL
suggest,7196,O
that,7196,O
chronic,7196,O
DPP4,7196,B-GENE-Y
inhibition,7196,O
potentially,7196,O
results,7196,O
in,7196,O
additional,7196,O
quality-adjusted,7196,O
life-years,7196,O
for,7196,O
individuals,7196,O
with,7196,O
type,7196,O
2,7196,O
diabetes,7196,O
",",7196,O
which,7196,O
is,7196,O
the,7196,O
primary,7196,O
goal,7196,O
of,7196,O
any,7196,O
diabetes,7196,O
therapy,7196,O
.,7196,O
Amelioration,7197,O
of,7197,O
palmitate-induced,7197,B-CHEMICAL
insulin,7197,B-GENE-N
resistance,7197,O
in,7197,O
C2C12,7197,O
muscle,7197,O
cells,7197,O
by,7197,O
rooibos,7197,O
(,7197,O
Aspalathus,7197,O
linearis,7197,O
),7197,O
.,7197,O
Increased,7198,O
levels,7198,O
of,7198,O
free,7198,B-CHEMICAL
fatty,7198,I-CHEMICAL
acids,7198,I-CHEMICAL
(,7198,O
FFAs,7198,B-CHEMICAL
),7198,O
",",7198,O
specifically,7198,O
saturated,7198,B-CHEMICAL
free,7198,I-CHEMICAL
fatty,7198,I-CHEMICAL
acids,7198,I-CHEMICAL
such,7198,O
as,7198,O
palmitate,7198,B-CHEMICAL
are,7198,O
associated,7198,O
with,7198,O
insulin,7198,B-GENE-Y
resistance,7198,O
of,7198,O
muscle,7198,O
",",7198,O
fat,7198,O
and,7198,O
liver,7198,O
.,7198,O
Skeletal,7199,O
muscle,7199,O
",",7199,O
responsible,7199,O
for,7199,O
up,7199,O
to,7199,O
80,7199,O
%,7199,O
of,7199,O
the,7199,O
glucose,7199,B-CHEMICAL
disposal,7199,O
from,7199,O
the,7199,O
peripheral,7199,O
circulation,7199,O
",",7199,O
is,7199,O
particularly,7199,O
vulnerable,7199,O
to,7199,O
increased,7199,O
levels,7199,O
of,7199,O
saturated,7199,O
FFAs,7199,B-CHEMICAL
.,7199,O
Rooibos,7200,O
(,7200,O
Aspalathus,7200,O
linearis,7200,O
),7200,O
and,7200,O
its,7200,O
unique,7200,O
dihydrochalcone,7200,B-CHEMICAL
C-glucoside,7200,I-CHEMICAL
",",7200,O
aspalathin,7200,B-CHEMICAL
",",7200,O
shown,7200,O
to,7200,O
reduce,7200,O
hyperglycemia,7200,O
in,7200,O
diabetic,7200,O
rats,7200,O
",",7200,O
could,7200,O
play,7200,O
a,7200,O
role,7200,O
in,7200,O
preventing,7200,O
or,7200,O
ameliorating,7200,O
the,7200,O
development,7200,O
of,7200,O
insulin,7200,B-GENE-N
resistance,7200,O
.,7200,O
This,7201,O
study,7201,O
aims,7201,O
to,7201,O
establish,7201,O
whether,7201,O
rooibos,7201,O
can,7201,O
ameliorate,7201,O
experimentally-induced,7201,O
insulin-resistance,7201,B-GENE-N
in,7201,O
C2C12,7201,O
skeletal,7201,O
muscle,7201,O
cells,7201,O
.,7201,O
Palmitate-induced,7202,B-CHEMICAL
insulin,7202,O
resistant,7202,O
C2C12,7202,O
cells,7202,O
were,7202,O
treated,7202,O
with,7202,O
an,7202,O
aspalathin-enriched,7202,B-CHEMICAL
green,7202,O
(,7202,O
unfermented,7202,O
),7202,O
rooibos,7202,O
extract,7202,O
(,7202,O
GRE,7202,O
),7202,O
",",7202,O
previously,7202,O
shown,7202,O
for,7202,O
its,7202,O
blood,7202,O
glucose,7202,B-CHEMICAL
lowering,7202,O
effect,7202,O
in,7202,O
vitro,7202,O
and,7202,O
in,7202,O
vivo,7202,O
or,7202,O
an,7202,O
aqueous,7202,O
extract,7202,O
of,7202,O
fermented,7202,O
rooibos,7202,O
(,7202,O
FRE,7202,O
),7202,O
.,7202,O
Glucose,7203,B-CHEMICAL
uptake,7203,O
and,7203,O
mitochondrial,7203,O
activity,7203,O
were,7203,O
measured,7203,O
using,7203,O
2-deoxy-,7203,B-CHEMICAL
[,7203,I-CHEMICAL
(,7203,I-CHEMICAL
3,7203,I-CHEMICAL
),7203,I-CHEMICAL
H,7203,I-CHEMICAL
],7203,I-CHEMICAL
-d-glucose,7203,I-CHEMICAL
",",7203,O
MTT,7203,B-CHEMICAL
and,7203,O
ATP,7203,B-CHEMICAL
assays,7203,O
",",7203,O
respectively,7203,O
.,7203,O
Expression,7204,O
of,7204,O
proteins,7204,O
relevant,7204,O
to,7204,O
glucose,7204,B-CHEMICAL
metabolism,7204,O
was,7204,O
analysed,7204,O
by,7204,O
Western,7204,O
blot,7204,O
.,7204,O
GRE,7205,O
contained,7205,O
higher,7205,O
levels,7205,O
of,7205,O
all,7205,O
compounds,7205,O
",",7205,O
except,7205,O
the,7205,O
enolic,7205,O
phenylpyruvic,7205,B-CHEMICAL
acid-2-O-glucoside,7205,I-CHEMICAL
and,7205,O
luteolin-7-O-glucoside,7205,B-CHEMICAL
.,7205,O
Both,7206,O
rooibos,7206,O
extracts,7206,O
increased,7206,O
glucose,7206,B-CHEMICAL
uptake,7206,O
",",7206,O
mitochondrial,7206,O
activity,7206,O
and,7206,O
ATP,7206,B-CHEMICAL
production,7206,O
.,7206,O
Compared,7207,O
to,7207,O
FRE,7207,O
",",7207,O
GRE,7207,O
was,7207,O
more,7207,O
effective,7207,O
at,7207,O
increasing,7207,O
glucose,7207,B-CHEMICAL
uptake,7207,O
and,7207,O
ATP,7207,B-CHEMICAL
production,7207,O
.,7207,O
At,7208,O
a,7208,O
mechanistic,7208,O
level,7208,O
both,7208,O
extracts,7208,O
down-regulated,7208,O
PKC,7208,B-GENE-Y
θ,7208,I-GENE-Y
activation,7208,O
",",7208,O
which,7208,O
is,7208,O
associated,7208,O
with,7208,O
palmitate-induced,7208,B-CHEMICAL
insulin,7208,B-GENE-N
resistance,7208,O
.,7208,O
Furthermore,7209,O
",",7209,O
the,7209,O
extracts,7209,O
increased,7209,O
activation,7209,O
of,7209,O
key,7209,O
regulatory,7209,O
proteins,7209,O
(,7209,O
AKT,7209,B-GENE-Y
and,7209,O
AMPK,7209,B-GENE-Y
),7209,O
involved,7209,O
in,7209,O
insulin-dependent,7209,B-GENE-N
and,7209,O
non-insulin,7209,O
regulated,7209,O
signalling,7209,O
pathways,7209,O
.,7209,O
Protein,7210,O
levels,7210,O
of,7210,O
the,7210,O
glucose,7210,B-GENE-N
transporter,7210,I-GENE-N
(,7210,O
GLUT4,7210,B-GENE-Y
),7210,O
involved,7210,O
in,7210,O
glucose,7210,B-CHEMICAL
transport,7210,O
via,7210,O
these,7210,O
two,7210,O
pathways,7210,O
were,7210,O
also,7210,O
increased,7210,O
.,7210,O
This,7211,O
in,7211,O
vitro,7211,O
study,7211,O
therefore,7211,O
confirms,7211,O
that,7211,O
rooibos,7211,O
can,7211,O
ameliorate,7211,O
palmitate-induced,7211,B-CHEMICAL
insulin,7211,B-GENE-N
resistance,7211,O
in,7211,O
C2C12,7211,O
skeletal,7211,O
muscle,7211,O
cells,7211,O
.,7211,O
Inhibition,7212,O
of,7212,O
PKC,7212,B-GENE-Y
θ,7212,I-GENE-Y
activation,7212,O
and,7212,O
increased,7212,O
activation,7212,O
of,7212,O
AMPK,7212,B-GENE-Y
and,7212,O
AKT,7212,B-GENE-Y
offer,7212,O
a,7212,O
plausible,7212,O
mechanistic,7212,O
explanation,7212,O
for,7212,O
this,7212,O
ameliorative,7212,O
effect,7212,O
.,7212,O
Puerarin,7213,B-CHEMICAL
stimulates,7213,O
proliferation,7213,O
and,7213,O
differentiation,7213,O
and,7213,O
protects,7213,O
against,7213,O
cell,7213,O
death,7213,O
in,7213,O
human,7213,O
osteoblastic,7213,O
MG-63,7213,O
cells,7213,O
via,7213,O
ER-dependent,7213,B-GENE-Y
MEK/ERK,7213,B-GENE-N
and,7213,O
PI3K/Akt,7213,B-GENE-N
activation,7213,O
.,7213,O
Puerarin,7214,B-CHEMICAL
",",7214,O
the,7214,O
main,7214,O
isoflavone,7214,B-CHEMICAL
glycoside,7214,I-CHEMICAL
found,7214,O
in,7214,O
the,7214,O
Chinese,7214,O
herb,7214,O
radix,7214,O
of,7214,O
Pueraria,7214,O
lobata,7214,O
(,7214,O
Willd,7214,O
.,7214,O
),7214,O
Ohwi,7215,O
",",7215,O
has,7215,O
received,7215,O
increasing,7215,O
attention,7215,O
because,7215,O
of,7215,O
its,7215,O
possible,7215,O
role,7215,O
in,7215,O
the,7215,O
prevention,7215,O
of,7215,O
osteoporosis,7215,O
.,7215,O
Previously,7216,O
",",7216,O
we,7216,O
showed,7216,O
that,7216,O
puerarin,7216,B-CHEMICAL
could,7216,O
inhibit,7216,O
the,7216,O
bone,7216,O
absorption,7216,O
of,7216,O
osteoclasts,7216,O
and,7216,O
promote,7216,O
long,7216,O
bone,7216,O
growth,7216,O
in,7216,O
fetal,7216,O
mouse,7216,O
in,7216,O
vitro,7216,O
.,7216,O
Further,7217,O
study,7217,O
confirmed,7217,O
that,7217,O
puerarin,7217,B-CHEMICAL
stimulated,7217,O
proliferation,7217,O
and,7217,O
differentiation,7217,O
of,7217,O
osteoblasts,7217,O
in,7217,O
rat,7217,O
.,7217,O
However,7218,O
",",7218,O
the,7218,O
mechanisms,7218,O
underlying,7218,O
its,7218,O
actions,7218,O
on,7218,O
human,7218,O
bone,7218,O
cells,7218,O
have,7218,O
not,7218,O
been,7218,O
well,7218,O
defined,7218,O
.,7218,O
Here,7219,O
we,7219,O
show,7219,O
that,7219,O
puerarin,7219,B-CHEMICAL
increases,7219,O
proliferation,7219,O
and,7219,O
differentiation,7219,O
and,7219,O
opposes,7219,O
cisplatin-induced,7219,B-CHEMICAL
apoptosis,7219,O
in,7219,O
human,7219,O
osteoblastic,7219,O
MG-63,7219,O
cells,7219,O
containing,7219,O
two,7219,O
estrogen,7219,B-GENE-Y
receptor,7219,I-GENE-Y
(,7219,O
ER,7219,B-GENE-Y
),7219,O
isoforms,7219,O
.,7219,O
Puerarin,7220,B-CHEMICAL
promotes,7220,O
proliferation,7220,O
by,7220,O
altering,7220,O
cell,7220,O
cycle,7220,O
distribution,7220,O
whereas,7220,O
puerarin-mediated,7220,B-CHEMICAL
survival,7220,O
may,7220,O
be,7220,O
associated,7220,O
with,7220,O
up-regulation,7220,O
of,7220,O
Bcl-xL,7220,B-GENE-Y
expression,7220,O
.,7220,O
Treatment,7221,O
with,7221,O
the,7221,O
ER,7221,B-GENE-Y
antagonist,7221,O
ICI,7221,B-CHEMICAL
"182,780",7221,I-CHEMICAL
abolishes,7221,O
the,7221,O
above,7221,O
actions,7221,O
of,7221,O
puerarin,7221,B-CHEMICAL
on,7221,O
osteoblast-derived,7221,O
cells,7221,O
.,7221,O
Using,7222,O
small,7222,O
interfering,7222,O
double-stranded,7222,O
RNA,7222,O
technology,7222,O
",",7222,O
we,7222,O
further,7222,O
demonstrate,7222,O
that,7222,O
the,7222,O
effects,7222,O
of,7222,O
puerarin,7222,B-CHEMICAL
on,7222,O
proliferation,7222,O
",",7222,O
differentiation,7222,O
and,7222,O
survival,7222,O
are,7222,O
mediated,7222,O
by,7222,O
both,7222,O
ERα,7222,B-GENE-Y
and,7222,O
ERβ,7222,B-GENE-Y
.,7222,O
Moreover,7223,O
",",7223,O
we,7223,O
also,7223,O
demonstrate,7223,O
that,7223,O
puerarin,7223,B-CHEMICAL
functions,7223,O
at,7223,O
least,7223,O
partially,7223,O
through,7223,O
activation,7223,O
of,7223,O
MEK/ERK,7223,B-GENE-N
and,7223,O
PI3K/Akt,7223,B-GENE-N
signaling,7223,O
.,7223,O
This,7224,O
agent,7224,O
also,7224,O
shows,7224,O
much,7224,O
weaker,7224,O
effect,7224,O
on,7224,O
breast,7224,O
epithelial,7224,O
cell,7224,O
growth,7224,O
than,7224,O
that,7224,O
of,7224,O
estrogen,7224,B-CHEMICAL
.,7224,O
Therefore,7225,O
",",7225,O
puerarin,7225,B-CHEMICAL
will,7225,O
be,7225,O
a,7225,O
promising,7225,O
agent,7225,O
that,7225,O
prevents,7225,O
or,7225,O
retards,7225,O
osteoporosis,7225,O
.,7225,O
Bone,7226,B-GENE-Y
Morphogenetic,7226,I-GENE-Y
Protein-7,7226,I-GENE-Y
inhibits,7226,O
silica-induced,7226,B-CHEMICAL
pulmonary,7226,O
fibrosis,7226,O
in,7226,O
rats,7226,O
.,7226,O
Bone,7227,B-GENE-Y
morphogenetic,7227,I-GENE-Y
protein-7,7227,I-GENE-Y
(,7227,O
BMP-7,7227,B-GENE-Y
),7227,O
has,7227,O
been,7227,O
shown,7227,O
to,7227,O
inhibit,7227,O
liver,7227,O
and,7227,O
renal,7227,O
fibrosis,7227,O
in,7227,O
in,7227,O
vivo,7227,O
and,7227,O
in,7227,O
vitro,7227,O
studies,7227,O
.,7227,O
There,7228,O
is,7228,O
no,7228,O
study,7228,O
to,7228,O
investigate,7228,O
BMP-7,7228,B-GENE-Y
's,7228,O
role,7228,O
in,7228,O
the,7228,O
development,7228,O
of,7228,O
pulmonary,7228,O
fibrosis,7228,O
induced,7228,O
by,7228,O
silica,7228,B-CHEMICAL
.,7228,O
In,7229,O
the,7229,O
current,7229,O
study,7229,O
",",7229,O
we,7229,O
used,7229,O
the,7229,O
rat,7229,O
model,7229,O
to,7229,O
explore,7229,O
the,7229,O
potential,7229,O
antifibrotic,7229,O
role,7229,O
of,7229,O
BMP-7,7229,B-GENE-Y
and,7229,O
its,7229,O
underlying,7229,O
mechanism,7229,O
in,7229,O
silica-induced,7229,B-CHEMICAL
pulmonary,7229,O
fibrosis,7229,O
.,7229,O
Sixty,7230,O
Wistar,7230,O
rats,7230,O
were,7230,O
randomly,7230,O
assigned,7230,O
into,7230,O
three,7230,O
groups,7230,O
.,7230,O
Control,7231,O
group,7231,O
received,7231,O
saline,7231,O
",",7231,O
silica,7231,B-CHEMICAL
group,7231,O
received,7231,O
silica,7231,B-CHEMICAL
and,7231,O
BMP-7,7231,B-GENE-Y
treated,7231,O
group,7231,O
received,7231,O
silica,7231,B-CHEMICAL
and,7231,O
BMP-7,7231,B-GENE-Y
.,7231,O
BMP-7,7232,B-GENE-Y
was,7232,O
administered,7232,O
to,7232,O
silica-treated,7232,B-CHEMICAL
rats,7232,O
intraperitoneally,7232,O
at,7232,O
a,7232,O
dose,7232,O
of,7232,O
300μg/kg/injection,7232,O
from,7232,O
day,7232,O
8,7232,O
to,7232,O
day,7232,O
30,7232,O
every,7232,O
other,7232,O
day,7232,O
.,7232,O
After,7233,O
the,7233,O
animals,7233,O
were,7233,O
sacrificed,7233,O
on,7233,O
day,7233,O
15,7233,O
and,7233,O
30,7233,O
",",7233,O
hydroxyproline,7233,B-CHEMICAL
levels,7233,O
",",7233,O
the,7233,O
protein,7233,O
expressions,7233,O
of,7233,O
BMP/Smad,7233,B-GENE-N
and,7233,O
TGF-β/Smad,7233,B-GENE-Y
signaling,7233,O
",",7233,O
and,7233,O
histopathology,7233,O
in,7233,O
lung,7233,O
tissues,7233,O
were,7233,O
analyzed,7233,O
.,7233,O
The,7234,O
hydroxyproline,7234,B-CHEMICAL
contents,7234,O
in,7234,O
BMP-7,7234,B-GENE-Y
treated,7234,O
groups,7234,O
were,7234,O
significantly,7234,O
lower,7234,O
than,7234,O
the,7234,O
silica,7234,B-CHEMICAL
groups,7234,O
(,7234,O
P,7234,O
<,7234,O
0.05,7234,O
),7234,O
.,7234,O
Histopathological,7235,O
results,7235,O
showed,7235,O
BMP-7,7235,B-GENE-Y
could,7235,O
reduce,7235,O
the,7235,O
progression,7235,O
of,7235,O
silica,7235,B-CHEMICAL
induced,7235,O
fibrosis,7235,O
.,7235,O
Furthermore,7236,O
",",7236,O
the,7236,O
expression,7236,O
of,7236,O
p-Smad1/5/8,7236,B-GENE-N
",",7236,O
a,7236,O
marker,7236,O
of,7236,O
BMP/Smad,7236,B-GENE-N
signaling,7236,O
",",7236,O
was,7236,O
significantly,7236,O
up-regulated,7236,O
in,7236,O
BMP-7,7236,B-GENE-Y
treated,7236,O
groups,7236,O
(,7236,O
P,7236,O
<,7236,O
0.05,7236,O
),7236,O
compared,7236,O
with,7236,O
the,7236,O
silica,7236,B-CHEMICAL
groups,7236,O
.,7236,O
On,7237,O
the,7237,O
contrary,7237,O
",",7237,O
the,7237,O
expression,7237,O
of,7237,O
p-Smad2/3,7237,B-GENE-N
",",7237,O
a,7237,O
marker,7237,O
for,7237,O
TGF-β/Smad,7237,B-GENE-Y
signaling,7237,O
",",7237,O
reduced,7237,O
significantly,7237,O
in,7237,O
BMP-7-treated,7237,B-GENE-Y
groups,7237,O
compared,7237,O
with,7237,O
silica,7237,B-CHEMICAL
groups,7237,O
(,7237,O
P,7237,O
<,7237,O
0.05,7237,O
),7237,O
.,7237,O
In,7238,O
conclusion,7238,O
",",7238,O
the,7238,O
pulmonary,7238,O
fibrosis,7238,O
induced,7238,O
by,7238,O
silica,7238,B-CHEMICAL
in,7238,O
rats,7238,O
was,7238,O
significantly,7238,O
reduced,7238,O
with,7238,O
the,7238,O
therapeutic,7238,O
treatment,7238,O
of,7238,O
BMP-7,7238,B-GENE-Y
.,7238,O
The,7239,O
antifibrotic,7239,O
effect,7239,O
of,7239,O
BMP-7,7239,B-GENE-Y
could,7239,O
be,7239,O
related,7239,O
to,7239,O
the,7239,O
activation,7239,O
of,7239,O
BMP/Smad,7239,B-GENE-N
signaling,7239,O
and,7239,O
inhibition,7239,O
of,7239,O
TGF-β/Smad,7239,B-GENE-Y
pathways,7239,O
.,7239,O
The,7240,O
preventive,7240,O
effect,7240,O
of,7240,O
uncarboxylated,7240,O
osteocalcin,7240,B-GENE-Y
against,7240,O
free,7240,B-CHEMICAL
fatty,7240,I-CHEMICAL
acid-induced,7240,O
endothelial,7240,O
apoptosis,7240,O
through,7240,O
the,7240,O
activation,7240,O
of,7240,O
phosphatidylinositol,7240,B-GENE-N
3-kinase/Akt,7240,O
signaling,7240,O
pathway,7240,O
:,7240,O
Uncarboxylated,7240,B-GENE-Y
osteocalcin,7240,I-GENE-Y
and,7240,O
endothelial,7240,O
apoptosis,7240,O
.,7240,O
OBJECTIVE,7241,O
:,7241,O
Increasing,7241,O
evidence,7241,O
suggests,7241,O
that,7241,O
osteocalcin,7241,B-GENE-Y
(,7241,O
OC,7241,B-GENE-Y
),7241,O
",",7241,O
one,7241,O
of,7241,O
the,7241,O
osteoblast-specific,7241,B-GENE-N
proteins,7241,I-GENE-N
",",7241,O
has,7241,O
been,7241,O
associated,7241,O
with,7241,O
atherosclerosis,7241,O
",",7241,O
but,7241,O
results,7241,O
are,7241,O
conflicting,7241,O
.,7241,O
The,7242,O
aim,7242,O
of,7242,O
this,7242,O
study,7242,O
was,7242,O
to,7242,O
elucidate,7242,O
the,7242,O
independent,7242,O
effect,7242,O
of,7242,O
uncarboxylated,7242,B-GENE-Y
osteocalcin,7242,I-GENE-Y
(,7242,O
ucOC,7242,B-GENE-Y
),7242,O
",",7242,O
an,7242,O
active,7242,O
form,7242,O
of,7242,O
osteocalcin,7242,B-GENE-Y
which,7242,O
has,7242,O
been,7242,O
suggested,7242,O
to,7242,O
have,7242,O
an,7242,O
insulin,7242,B-GENE-Y
sensitizing,7242,O
effect,7242,O
",",7242,O
on,7242,O
vascular,7242,O
endothelial,7242,O
cells,7242,O
.,7242,O
MATERIALS,7243,O
AND,7243,O
METHODS,7243,O
:,7243,O
We,7243,O
used,7243,O
human,7243,O
aortic,7243,O
endothelial,7243,O
cells,7243,O
and,7243,O
treated,7243,O
them,7243,O
with,7243,O
ucOC,7243,B-GENE-Y
.,7243,O
Linoleic,7244,B-CHEMICAL
acid,7244,I-CHEMICAL
(,7244,O
LA,7244,O
),7244,O
was,7244,O
used,7244,O
as,7244,O
a,7244,O
representative,7244,O
free,7244,B-CHEMICAL
fatty,7244,I-CHEMICAL
acid,7244,I-CHEMICAL
.,7244,O
Apoptosis,7245,O
was,7245,O
evaluated,7245,O
using,7245,O
various,7245,O
methods,7245,O
including,7245,O
a,7245,O
terminal,7245,O
deoxyribonucleotide,7245,B-CHEMICAL
transferase-mediated,7245,O
deoxyuridine,7245,B-CHEMICAL
triphosphate,7245,I-CHEMICAL
nick-end,7245,O
labeling,7245,O
analysis,7245,O
kit,7245,O
and,7245,O
Western,7245,O
blotting,7245,O
for,7245,O
cleaved,7245,O
caspase,7245,B-GENE-Y
3,7245,I-GENE-Y
",",7245,O
cleaved,7245,O
poly,7245,B-CHEMICAL
(,7245,I-CHEMICAL
ADP-ribose,7245,I-CHEMICAL
),7245,I-CHEMICAL
polymerase,7245,I-GENE-N
and,7245,O
Bcl-xL,7245,B-GENE-Y
.,7245,O
The,7246,O
phosphorylations,7246,O
of,7246,O
Akt,7246,B-GENE-N
and,7246,O
endothelial,7246,B-GENE-Y
nitric,7246,B-CHEMICAL
oxide,7246,I-CHEMICAL
synthase,7246,I-GENE-Y
(,7246,O
eNOS,7246,B-GENE-Y
),7246,O
as,7246,O
well,7246,O
as,7246,O
the,7246,O
level,7246,O
of,7246,O
NO,7246,B-CHEMICAL
were,7246,O
measured,7246,O
to,7246,O
confirm,7246,O
the,7246,O
effect,7246,O
of,7246,O
ucOC,7246,B-GENE-Y
on,7246,O
insulin,7246,B-GENE-Y
signaling,7246,O
pathway,7246,O
.,7246,O
RESULTS,7247,O
:,7247,O
Pretreatment,7247,O
of,7247,O
ucOC,7247,B-GENE-Y
(,7247,O
30ng/ml,7247,O
),7247,O
prevented,7247,O
LA-induced,7247,O
apoptosis,7247,O
in,7247,O
insulin-stimulated,7247,B-GENE-Y
endothelial,7247,O
cells,7247,O
;,7247,O
effects,7247,O
were,7247,O
abolished,7247,O
by,7247,O
pretreatment,7247,O
with,7247,O
the,7247,O
phosphatidylinositol,7247,B-CHEMICAL
3-kinase,7247,I-GENE-N
(,7247,O
PI3-kinase,7247,B-GENE-N
),7247,O
inhibitor,7247,O
",",7247,O
wortmannin,7247,B-CHEMICAL
.,7247,O
Treatment,7248,O
of,7248,O
ucOC,7248,B-GENE-Y
(,7248,O
ranged,7248,O
from,7248,O
0.3,7248,O
to,7248,O
30ng/ml,7248,O
),7248,O
significantly,7248,O
increased,7248,O
the,7248,O
phosphorylation,7248,O
of,7248,O
Akt,7248,B-GENE-N
and,7248,O
eNOS,7248,B-GENE-Y
and,7248,O
nitric,7248,B-CHEMICAL
oxide,7248,I-CHEMICAL
secretion,7248,O
from,7248,O
endothelial,7248,O
cells,7248,O
in,7248,O
a,7248,O
PI3-kinase,7248,B-GENE-N
dependent,7248,O
manner,7248,O
.,7248,O
CONCLUSIONS,7249,O
:,7249,O
Our,7249,O
study,7249,O
is,7249,O
the,7249,O
first,7249,O
to,7249,O
demonstrate,7249,O
the,7249,O
independent,7249,O
effect,7249,O
of,7249,O
ucOC,7249,B-GENE-Y
on,7249,O
vascular,7249,O
endothelial,7249,O
cells,7249,O
.,7249,O
Our,7250,O
results,7250,O
further,7250,O
suggest,7250,O
that,7250,O
ucOC,7250,B-GENE-Y
could,7250,O
have,7250,O
beneficial,7250,O
effects,7250,O
on,7250,O
atherosclerosis,7250,O
.,7250,O
Free,7251,O
volume,7251,O
in,7251,O
ionic,7251,O
liquids,7251,O
:,7251,O
a,7251,O
connection,7251,O
of,7251,O
experimentally,7251,O
accessible,7251,O
observables,7251,O
from,7251,O
PALS,7251,O
and,7251,O
PVT,7251,O
experiments,7251,O
with,7251,O
the,7251,O
molecular,7251,O
structure,7251,O
from,7251,O
XRD,7251,O
data,7251,O
.,7251,O
In,7252,O
the,7252,O
current,7252,O
work,7252,O
",",7252,O
free,7252,O
volume,7252,O
concepts,7252,O
",",7252,O
primarily,7252,O
applied,7252,O
to,7252,O
glass,7252,O
formers,7252,O
in,7252,O
the,7252,O
literature,7252,O
",",7252,O
were,7252,O
transferred,7252,O
to,7252,O
ionic,7252,O
liquids,7252,O
(,7252,O
ILs,7252,O
),7252,O
.,7252,O
A,7253,O
series,7253,O
of,7253,O
1-butyl-3-methylimidazolium,7253,B-CHEMICAL
(,7253,O
[,7253,B-CHEMICAL
C4MIM,7253,I-CHEMICAL
],7253,I-CHEMICAL
(,7253,I-CHEMICAL
+,7253,I-CHEMICAL
),7253,I-CHEMICAL
),7253,O
based,7253,O
ILs,7253,O
was,7253,O
investigated,7253,O
by,7253,O
Positron,7253,O
Annihilation,7253,O
Lifetime,7253,O
Spectroscopy,7253,O
(,7253,O
PALS,7253,O
),7253,O
.,7253,O
The,7254,O
phase,7254,O
transition,7254,O
and,7254,O
dynamic,7254,O
properties,7254,O
of,7254,O
the,7254,O
ILs,7254,O
[,7254,O
C4MIM,7254,B-CHEMICAL
],7254,O
[,7254,O
X,7254,O
],7254,O
with,7254,O
[,7254,O
X,7254,O
],7254,O
(,7254,O
-,7254,O
),7254,O
=,7254,O
[,7254,B-CHEMICAL
Cl,7254,I-CHEMICAL
],7254,I-CHEMICAL
(,7254,I-CHEMICAL
-,7254,I-CHEMICAL
),7254,I-CHEMICAL
",",7254,O
[,7254,B-CHEMICAL
BF4,7254,I-CHEMICAL
],7254,I-CHEMICAL
(,7254,I-CHEMICAL
-,7254,I-CHEMICAL
),7254,I-CHEMICAL
",",7254,O
[,7254,B-CHEMICAL
PF6,7254,I-CHEMICAL
],7254,I-CHEMICAL
(,7254,I-CHEMICAL
-,7254,I-CHEMICAL
),7254,I-CHEMICAL
",",7254,O
[,7254,B-CHEMICAL
OTf,7254,I-CHEMICAL
],7254,I-CHEMICAL
(,7254,I-CHEMICAL
-,7254,I-CHEMICAL
),7254,I-CHEMICAL
",",7254,O
[,7254,B-CHEMICAL
NTf2,7254,I-CHEMICAL
],7254,I-CHEMICAL
(,7254,I-CHEMICAL
-,7254,I-CHEMICAL
),7254,I-CHEMICAL
and,7254,O
[,7254,B-CHEMICAL
B,7254,I-CHEMICAL
(,7254,I-CHEMICAL
hfip,7254,I-CHEMICAL
),7254,I-CHEMICAL
4,7254,I-CHEMICAL
],7254,I-CHEMICAL
(,7254,I-CHEMICAL
-,7254,I-CHEMICAL
),7254,I-CHEMICAL
were,7254,O
reported,7254,O
recently,7254,O
(,7254,O
Yu,7254,O
et,7254,O
al.,7254,O
",",7254,O
Phys,7254,O
.,7254,O
Chem,7255,O
.,7255,O
Chem,7256,O
.,7256,O
Phys.,7257,O
",",7257,O
2012,7257,O
",",7257,O
14,7257,O
",",7257,O
6856-6868,7257,O
),7257,O
.,7257,O
In,7258,O
this,7258,O
subsequent,7258,O
work,7258,O
",",7258,O
attention,7258,O
was,7258,O
paid,7258,O
to,7258,O
the,7258,O
connection,7258,O
of,7258,O
the,7258,O
free,7258,O
volume,7258,O
from,7258,O
PALS,7258,O
(,7258,O
here,7258,O
the,7258,O
mean,7258,O
hole,7258,O
volume,7258,O
",",7258,O
〈vh〉,7258,O
),7258,O
with,7258,O
the,7258,O
molecular,7258,O
structure,7258,O
",",7258,O
represented,7258,O
by,7258,O
volumes,7258,O
derived,7258,O
from,7258,O
X-ray,7258,O
diffraction,7258,O
(,7258,O
XRD,7258,O
),7258,O
data,7258,O
.,7258,O
These,7259,O
were,7259,O
the,7259,O
scaled,7259,O
molecular,7259,O
volume,7259,O
Vm,7259,O
",",7259,O
scaled,7259,O
and,7259,O
the,7259,O
van,7259,O
der,7259,O
Waals,7259,O
volume,7259,O
Vvdw,7259,O
.,7259,O
Linear,7260,O
correlations,7260,O
of,7260,O
〈vh〉,7260,O
at,7260,O
the,7260,O
``,7260,O
knee,7260,O
'',7260,O
temperature,7260,O
(,7260,O
〈vh〉,7260,O
(,7260,O
Tk,7260,O
),7260,O
),7260,O
with,7260,O
Vm,7260,O
",",7260,O
scaled,7260,O
and,7260,O
Vvdw,7260,O
gave,7260,O
good,7260,O
results,7260,O
for,7260,O
the,7260,O
[,7260,B-CHEMICAL
C4MIM,7260,I-CHEMICAL
],7260,I-CHEMICAL
(,7260,I-CHEMICAL
+,7260,I-CHEMICAL
),7260,I-CHEMICAL
series,7260,O
.,7260,O
Further,7261,O
relationships,7261,O
between,7261,O
volumes,7261,O
from,7261,O
XRD,7261,O
data,7261,O
with,7261,O
the,7261,O
occupied,7261,O
volume,7261,O
Vocc,7261,O
determined,7261,O
from,7261,O
PALS/PVT,7261,O
(,7261,O
Pressure,7261,O
Volume,7261,O
Temperature,7261,O
),7261,O
measurements,7261,O
and,7261,O
from,7261,O
Sanchez-Lacombe,7261,O
Equation,7261,O
of,7261,O
State,7261,O
(,7261,O
SL-EOS,7261,O
),7261,O
fits,7261,O
were,7261,O
elaborated,7261,O
(,7261,O
Vocc,7261,O
(,7261,O
SL-EOS,7261,O
),7261,O
≈,7261,O
1.63,7261,O
Vvdw,7261,O
",",7261,O
R,7261,O
(,7261,O
2,7261,O
),7261,O
=,7261,O
0.981,7261,O
and,7261,O
Vocc,7261,O
(,7261,O
SL-EOS,7261,O
),7261,O
≈,7261,O
1.12,7261,O
Vm,7261,O
",",7261,O
scaled,7261,O
",",7261,O
R,7261,O
(,7261,O
2,7261,O
),7261,O
=,7261,O
0.980,7261,O
),7261,O
.,7261,O
Finally,7262,O
",",7262,O
the,7262,O
usability,7262,O
of,7262,O
Vm,7262,O
",",7262,O
scaled,7262,O
was,7262,O
justified,7262,O
in,7262,O
terms,7262,O
of,7262,O
the,7262,O
Cohen-Turnbull,7262,O
(,7262,O
CT,7262,O
),7262,O
free,7262,O
volume,7262,O
theory,7262,O
.,7262,O
Empirical,7263,O
CT,7263,O
type,7263,O
plots,7263,O
of,7263,O
viscosity,7263,O
and,7263,O
electrical,7263,O
conductivity,7263,O
showed,7263,O
a,7263,O
systematic,7263,O
increase,7263,O
in,7263,O
the,7263,O
critical,7263,O
free,7263,O
volume,7263,O
with,7263,O
molecular,7263,O
size,7263,O
.,7263,O
Such,7264,O
correlations,7264,O
allow,7264,O
descriptions,7264,O
of,7264,O
IL,7264,O
properties,7264,O
with,7264,O
the,7264,O
easily,7264,O
accessible,7264,O
quantity,7264,O
Vm,7264,O
",",7264,O
scaled,7264,O
within,7264,O
the,7264,O
context,7264,O
of,7264,O
the,7264,O
free,7264,O
volume,7264,O
.,7264,O
Distinct,7265,O
role,7265,O
of,7265,O
PYK2,7265,B-GENE-Y
in,7265,O
mediating,7265,O
thromboxane,7265,B-CHEMICAL
generation,7265,O
downstream,7265,O
of,7265,O
both,7265,O
G12/13,7265,B-GENE-N
and,7265,O
integrin,7265,B-GENE-Y
αiibβ,7265,I-GENE-Y
in,7265,O
platelets,7265,O
.,7265,O
Proline-rich,7266,B-CHEMICAL
tyrosine,7266,B-CHEMICAL
kinase,7266,I-GENE-Y
2,7266,I-GENE-Y
(,7266,O
Pyk2,7266,B-GENE-Y
),7266,O
is,7266,O
activated,7266,O
by,7266,O
various,7266,O
agonists,7266,O
in,7266,O
platelets,7266,O
.,7266,O
We,7267,O
evaluated,7267,O
the,7267,O
signaling,7267,O
mechanism,7267,O
and,7267,O
the,7267,O
functional,7267,O
role,7267,O
of,7267,O
Pyk2,7267,B-GENE-Y
in,7267,O
platelets,7267,O
by,7267,O
using,7267,O
pharmacological,7267,O
inhibitors,7267,O
and,7267,O
Pyk2-deficient,7267,B-GENE-Y
platelets,7267,O
.,7267,O
We,7268,O
found,7268,O
that,7268,O
platelet,7268,O
aggregation,7268,O
and,7268,O
secretion,7268,O
in,7268,O
response,7268,O
to,7268,O
2-MeSADP,7268,B-CHEMICAL
and,7268,O
AYPGKF,7268,O
were,7268,O
diminished,7268,O
in,7268,O
the,7268,O
presence,7268,O
of,7268,O
Pyk2,7268,B-GENE-Y
inhibitors,7268,O
or,7268,O
in,7268,O
Pyk2-deficient,7268,B-GENE-Y
platelets,7268,O
",",7268,O
suggesting,7268,O
that,7268,O
Pyk2,7268,B-GENE-Y
plays,7268,O
a,7268,O
positive,7268,O
regulatory,7268,O
role,7268,O
in,7268,O
platelet,7268,O
functional,7268,O
responses,7268,O
.,7268,O
It,7269,O
has,7269,O
been,7269,O
shown,7269,O
that,7269,O
ADP-,7269,B-CHEMICAL
",",7269,O
but,7269,O
not,7269,O
thrombin-,7269,B-GENE-Y
",",7269,O
induced,7269,O
thromboxane,7269,B-CHEMICAL
(,7269,O
TxA2,7269,B-CHEMICAL
),7269,O
generation,7269,O
depends,7269,O
on,7269,O
integrin,7269,B-GENE-N
signaling,7269,O
.,7269,O
Unlike,7270,O
ADP,7270,B-CHEMICAL
",",7270,O
thrombin,7270,B-GENE-Y
activates,7270,O
G12/13,7270,B-GENE-N
pathways,7270,O
",",7270,O
and,7270,O
G12/13,7270,B-GENE-N
pathways,7270,O
can,7270,O
substitute,7270,O
for,7270,O
integrin,7270,B-GENE-N
signaling,7270,O
for,7270,O
TxA2,7270,B-CHEMICAL
generation,7270,O
.,7270,O
We,7271,O
found,7271,O
that,7271,O
Pyk2,7271,B-GENE-Y
was,7271,O
activated,7271,O
downstream,7271,O
of,7271,O
both,7271,O
G12/13,7271,B-GENE-N
and,7271,O
integrin-mediated,7271,B-GENE-N
pathways,7271,O
",",7271,O
and,7271,O
both,7271,O
2-MeSADP-,7271,B-CHEMICAL
and,7271,O
AYPGKF-induced,7271,O
TxA2,7271,B-CHEMICAL
generation,7271,O
was,7271,O
significantly,7271,O
diminished,7271,O
in,7271,O
Pyk2-deficient,7271,B-GENE-Y
platelets,7271,O
.,7271,O
In,7272,O
addition,7272,O
",",7272,O
TxA2,7272,B-CHEMICAL
generation,7272,O
induced,7272,O
by,7272,O
co-stimulation,7272,O
of,7272,O
Gi,7272,B-GENE-N
and,7272,O
Gz,7272,B-GENE-Y
pathways,7272,O
",",7272,O
which,7272,O
is,7272,O
dependent,7272,O
on,7272,O
integrin,7272,B-GENE-N
signaling,7272,O
",",7272,O
was,7272,O
inhibited,7272,O
by,7272,O
blocking,7272,O
Pyk2,7272,B-GENE-Y
.,7272,O
Furthermore,7273,O
",",7273,O
inhibition,7273,O
of,7273,O
2-MeSADP-induced,7273,B-CHEMICAL
TxA2,7273,B-CHEMICAL
generation,7273,O
by,7273,O
fibrinogen,7273,B-GENE-Y
receptor,7273,I-GENE-Y
antagonist,7273,O
was,7273,O
not,7273,O
rescued,7273,O
by,7273,O
co-stimulation,7273,O
of,7273,O
G12/13,7273,B-GENE-N
pathways,7273,O
in,7273,O
the,7273,O
presence,7273,O
of,7273,O
Pyk2,7273,B-GENE-Y
inhibitor,7273,O
.,7273,O
We,7274,O
conclude,7274,O
that,7274,O
Pyk2,7274,B-GENE-Y
is,7274,O
a,7274,O
common,7274,O
signaling,7274,O
effector,7274,O
downstream,7274,O
of,7274,O
both,7274,O
G12/13,7274,B-GENE-N
and,7274,O
integrin,7274,B-GENE-Y
αIIbβ3,7274,I-GENE-Y
signaling,7274,O
which,7274,O
contributes,7274,O
to,7274,O
thromboxane,7274,B-CHEMICAL
generation,7274,O
.,7274,O
The,7275,O
use,7275,O
of,7275,O
antioxidant,7275,O
enzymes,7275,O
in,7275,O
freshwater,7275,O
biofilms,7275,O
:,7275,O
Temporal,7275,O
variability,7275,O
vs.,7275,O
toxicological,7275,O
responses,7275,O
.,7275,O
This,7276,O
study,7276,O
aims,7276,O
to,7276,O
investigate,7276,O
the,7276,O
potential,7276,O
of,7276,O
antioxidant,7276,O
enzyme,7276,O
activities,7276,O
(,7276,O
AEA,7276,O
),7276,O
as,7276,O
biomarkers,7276,O
of,7276,O
oxidative,7276,O
stress,7276,O
in,7276,O
freshwater,7276,O
biofilms,7276,O
.,7276,O
Therefore,7277,O
",",7277,O
biofilms,7277,O
were,7277,O
grown,7277,O
in,7277,O
channels,7277,O
for,7277,O
38,7277,O
days,7277,O
and,7277,O
then,7277,O
exposed,7277,O
to,7277,O
different,7277,O
concentrations,7277,O
(,7277,O
0-150μgL,7277,O
(,7277,O
-1,7277,O
),7277,O
),7277,O
of,7277,O
the,7277,O
herbicide,7277,O
oxyfluorfen,7277,B-CHEMICAL
for,7277,O
5,7277,O
more,7277,O
weeks,7277,O
.,7277,O
Under,7278,O
control,7278,O
conditions,7278,O
",",7278,O
the,7278,O
AEA,7278,O
of,7278,O
biofilms,7278,O
were,7278,O
found,7278,O
to,7278,O
change,7278,O
throughout,7278,O
time,7278,O
with,7278,O
a,7278,O
significant,7278,O
increase,7278,O
in,7278,O
ascorbate,7278,B-CHEMICAL
peroxidase,7278,I-GENE-N
(,7278,O
APX,7278,B-GENE-N
),7278,O
activity,7278,O
during,7278,O
the,7278,O
exponential,7278,O
growth,7278,O
and,7278,O
a,7278,O
more,7278,O
important,7278,O
role,7278,O
of,7278,O
catalase,7278,B-GENE-N
(,7278,O
CAT,7278,B-GENE-N
),7278,O
and,7278,O
glutathione,7278,B-CHEMICAL
reductase,7278,I-GENE-N
(,7278,O
GR,7278,B-GENE-N
),7278,O
activities,7278,O
during,7278,O
the,7278,O
slow,7278,O
growth,7278,O
phase,7278,O
.,7278,O
Chronic,7279,O
exposure,7279,O
to,7279,O
oxyfluorfen,7279,B-CHEMICAL
led,7279,O
to,7279,O
slight,7279,O
variations,7279,O
in,7279,O
AEA,7279,O
",",7279,O
however,7279,O
",",7279,O
the,7279,O
ranges,7279,O
of,7279,O
variability,7279,O
of,7279,O
AEA,7279,O
in,7279,O
controls,7279,O
and,7279,O
exposed,7279,O
communities,7279,O
were,7279,O
similar,7279,O
",",7279,O
highlighting,7279,O
the,7279,O
difficulty,7279,O
of,7279,O
a,7279,O
direct,7279,O
interpretation,7279,O
of,7279,O
AEA,7279,O
values,7279,O
.,7279,O
After,7280,O
5,7280,O
weeks,7280,O
of,7280,O
exposure,7280,O
to,7280,O
oxyfluorfen,7280,B-CHEMICAL
",",7280,O
no,7280,O
clear,7280,O
effects,7280,O
were,7280,O
observed,7280,O
on,7280,O
chl-a,7280,B-CHEMICAL
concentration,7280,O
or,7280,O
on,7280,O
the,7280,O
composition,7280,O
of,7280,O
other,7280,O
pigments,7280,O
suggesting,7280,O
that,7280,O
algal,7280,O
group,7280,O
composition,7280,O
was,7280,O
not,7280,O
affected,7280,O
.,7280,O
Eukaryotic,7281,O
communities,7281,O
were,7281,O
structured,7281,O
clearly,7281,O
by,7281,O
toxicant,7281,O
concentration,7281,O
and,7281,O
both,7281,O
eukaryotic,7281,O
and,7281,O
bacterial,7281,O
richness,7281,O
were,7281,O
reduced,7281,O
in,7281,O
communities,7281,O
exposed,7281,O
to,7281,O
the,7281,O
highest,7281,O
concentration,7281,O
.,7281,O
In,7282,O
addition,7282,O
",",7282,O
during,7282,O
acute,7282,O
exposure,7282,O
tests,7282,O
performed,7282,O
at,7282,O
the,7282,O
end,7282,O
of,7282,O
the,7282,O
chronic,7282,O
exposure,7282,O
",",7282,O
biofilms,7282,O
chronically,7282,O
exposed,7282,O
to,7282,O
75,7282,O
and,7282,O
150μgL,7282,O
(,7282,O
-1,7282,O
),7282,O
oxyfluorfen,7282,B-CHEMICAL
showed,7282,O
a,7282,O
higher,7282,O
CAT,7282,B-GENE-N
activity,7282,O
than,7282,O
controls,7282,O
.,7282,O
Chronic,7283,O
exposure,7283,O
to,7283,O
oxyfluorfen,7283,B-CHEMICAL
provoked,7283,O
then,7283,O
structural,7283,O
changes,7283,O
but,7283,O
also,7283,O
functional,7283,O
changes,7283,O
in,7283,O
the,7283,O
capacity,7283,O
of,7283,O
biofilm,7283,O
CAT,7283,B-GENE-N
activity,7283,O
to,7283,O
respond,7283,O
to,7283,O
a,7283,O
sudden,7283,O
increase,7283,O
in,7283,O
concentration,7283,O
",",7283,O
suggesting,7283,O
a,7283,O
selection,7283,O
of,7283,O
species,7283,O
with,7283,O
higher,7283,O
antioxidant,7283,O
capacity,7283,O
.,7283,O
This,7284,O
study,7284,O
highlighted,7284,O
the,7284,O
difficulty,7284,O
of,7284,O
interpretation,7284,O
of,7284,O
AEA,7284,O
values,7284,O
due,7284,O
to,7284,O
their,7284,O
temporal,7284,O
variation,7284,O
and,7284,O
to,7284,O
the,7284,O
absence,7284,O
of,7284,O
absolute,7284,O
threshold,7284,O
value,7284,O
indicative,7284,O
of,7284,O
oxidative,7284,O
stress,7284,O
induced,7284,O
by,7284,O
contaminants,7284,O
.,7284,O
Nevertheless,7285,O
",",7285,O
the,7285,O
determination,7285,O
of,7285,O
AEA,7285,O
pattern,7285,O
throughout,7285,O
acute,7285,O
exposure,7285,O
test,7285,O
is,7285,O
of,7285,O
high,7285,O
interest,7285,O
to,7285,O
compare,7285,O
oxidative,7285,O
stress,7285,O
levels,7285,O
undergone,7285,O
by,7285,O
different,7285,O
biofilm,7285,O
communities,7285,O
and,7285,O
thus,7285,O
determine,7285,O
their,7285,O
antioxidant,7285,O
capacity,7285,O
.,7285,O
Pharmacological,7286,O
and,7286,O
genetic,7286,O
evidence,7286,O
for,7286,O
pre-,7286,O
and,7286,O
postsynaptic,7286,O
D2,7286,B-GENE-Y
receptor,7286,I-GENE-Y
involvement,7286,O
in,7286,O
motor,7286,O
responses,7286,O
to,7286,O
nociceptin/orphanin,7286,B-GENE-Y
FQ,7286,I-GENE-Y
receptor,7286,I-GENE-Y
ligands,7286,O
.,7286,O
A,7287,O
combined,7287,O
pharmacological,7287,O
and,7287,O
genetic,7287,O
approach,7287,O
was,7287,O
undertaken,7287,O
to,7287,O
investigate,7287,O
the,7287,O
contribution,7287,O
of,7287,O
endogenous,7287,O
dopamine,7287,B-CHEMICAL
to,7287,O
the,7287,O
motor,7287,O
actions,7287,O
of,7287,O
nociceptin/orphanin,7287,B-GENE-Y
FQ,7287,I-GENE-Y
(,7287,I-GENE-Y
N/OFQ,7287,I-GENE-Y
),7287,I-GENE-Y
receptor,7287,I-GENE-Y
(,7287,O
NOP,7287,B-GENE-Y
receptor,7287,I-GENE-Y
),7287,O
ligands,7287,O
.,7287,O
Motor,7288,O
activity,7288,O
was,7288,O
evaluated,7288,O
by,7288,O
a,7288,O
battery,7288,O
of,7288,O
behavioural,7288,O
tests,7288,O
in,7288,O
mice,7288,O
.,7288,O
The,7289,O
involvement,7289,O
of,7289,O
the,7289,O
various,7289,O
DA,7289,B-GENE-N
receptor,7289,I-GENE-N
subtypes,7289,O
in,7289,O
the,7289,O
motor,7289,O
effects,7289,O
of,7289,O
N/OFQ,7289,B-GENE-Y
and,7289,O
NOP,7289,B-GENE-Y
receptor,7289,I-GENE-Y
antagonists,7289,O
was,7289,O
evaluated,7289,O
pharmacologically,7289,O
",",7289,O
using,7289,O
D1/D5,7289,B-GENE-Y
(,7289,O
SCH23390,7289,B-CHEMICAL
),7289,O
",",7289,O
D2/D3,7289,B-GENE-Y
(,7289,O
raclopride,7289,B-CHEMICAL
",",7289,O
amisulpride,7289,B-CHEMICAL
),7289,O
and,7289,O
D3,7289,B-GENE-Y
(,7289,O
S33084,7289,B-CHEMICAL
),7289,O
receptor,7289,O
antagonists,7289,O
",",7289,O
and,7289,O
by,7289,O
using,7289,O
D2,7289,B-GENE-Y
receptor,7289,I-GENE-Y
knockout,7289,O
mice,7289,O
.,7289,O
Low,7290,O
doses,7290,O
of,7290,O
N/OFQ,7290,B-GENE-Y
and,7290,O
NOP,7290,B-GENE-Y
receptor,7290,I-GENE-Y
antagonists,7290,O
promoted,7290,O
movement,7290,O
whereas,7290,O
higher,7290,O
doses,7290,O
inhibited,7290,O
it,7290,O
.,7290,O
Motor,7291,O
facilitation,7291,O
was,7291,O
selectively,7291,O
prevented,7291,O
by,7291,O
raclopride,7291,B-CHEMICAL
while,7291,O
motor,7291,O
inhibition,7291,O
was,7291,O
prevented,7291,O
by,7291,O
amisulpride,7291,B-CHEMICAL
.,7291,O
Amisulpride,7292,B-CHEMICAL
also,7292,O
attenuated,7292,O
the,7292,O
hypolocomotion,7292,O
induced,7292,O
by,7292,O
the,7292,O
D2/D3,7292,B-GENE-N
receptor,7292,I-GENE-N
agonist,7292,O
pramipexole,7292,B-CHEMICAL
and,7292,O
dopamine,7292,B-CHEMICAL
precursor,7292,O
"L-3,4-dihydroxyphenylalanine",7292,B-CHEMICAL
",",7292,O
whereas,7292,O
raclopride,7292,B-CHEMICAL
(,7292,O
and,7292,O
S33084,7292,B-CHEMICAL
),7292,O
worsened,7292,O
it,7292,O
.,7292,O
To,7293,O
dissect,7293,O
out,7293,O
the,7293,O
contribution,7293,O
of,7293,O
pre-,7293,O
and,7293,O
postsynaptic,7293,O
D2,7293,B-GENE-Y
receptors,7293,I-GENE-Y
",",7293,O
mice,7293,O
lacking,7293,O
the,7293,O
D2,7293,B-GENE-Y
receptor,7293,I-GENE-Y
(,7293,O
D2R,7293,B-GENE-Y
(,7293,O
-/-,7293,O
),7293,O
),7293,O
or,7293,O
its,7293,O
long,7293,O
isoform,7293,O
(,7293,O
D2L,7293,B-GENE-Y
(,7293,O
-/-,7293,O
),7293,O
),7293,O
were,7293,O
used,7293,O
.,7293,O
Motor,7294,O
facilitation,7294,O
induced,7294,O
by,7294,O
N/OFQ,7294,B-GENE-Y
and,7294,O
NOP,7294,B-GENE-Y
receptor,7294,I-GENE-Y
antagonists,7294,O
was,7294,O
lost,7294,O
in,7294,O
D2R,7294,B-GENE-Y
(,7294,O
-/-,7294,O
),7294,O
and,7294,O
D2L,7294,B-GENE-Y
(,7294,O
-/-,7294,O
),7294,O
mice,7294,O
whereas,7294,O
motor,7294,O
inhibition,7294,O
induced,7294,O
by,7294,O
NOP,7294,B-GENE-Y
receptor,7294,I-GENE-Y
antagonists,7294,O
(,7294,O
and,7294,O
pramipexole,7294,B-CHEMICAL
),7294,O
was,7294,O
lost,7294,O
in,7294,O
D2R,7294,B-GENE-Y
(,7294,O
-/-,7294,O
),7294,O
but,7294,O
preserved,7294,O
in,7294,O
D2L,7294,B-GENE-Y
(,7294,O
-/-,7294,O
),7294,O
mice,7294,O
.,7294,O
N/OFQ-induced,7295,B-GENE-Y
hypolocomotion,7295,O
was,7295,O
observed,7295,O
in,7295,O
both,7295,O
genotypes,7295,O
.,7295,O
We,7296,O
demonstrate,7296,O
that,7296,O
motor,7296,O
actions,7296,O
of,7296,O
NOP,7296,B-GENE-Y
receptor,7296,I-GENE-Y
ligands,7296,O
rely,7296,O
on,7296,O
the,7296,O
modulation,7296,O
of,7296,O
endogenous,7296,O
dopamine,7296,B-CHEMICAL
.,7296,O
Motor,7297,O
facilitation,7297,O
induced,7297,O
by,7297,O
NOP,7297,B-GENE-Y
receptor,7297,I-GENE-Y
antagonists,7297,O
as,7297,O
well,7297,O
as,7297,O
low,7297,O
dose,7297,O
N/OFQ,7297,B-GENE-Y
is,7297,O
mediated,7297,O
through,7297,O
D2L,7297,B-GENE-Y
postsynaptic,7297,O
receptors,7297,O
whereas,7297,O
motor,7297,O
inhibition,7297,O
observed,7297,O
with,7297,O
higher,7297,O
doses,7297,O
of,7297,O
N/OFQ,7297,B-GENE-Y
occurs,7297,O
by,7297,O
direct,7297,O
inhibition,7297,O
of,7297,O
mesencephalic,7297,O
DA,7297,O
neurons,7297,O
.,7297,O
Motor,7298,O
inhibition,7298,O
seen,7298,O
with,7298,O
high,7298,O
doses,7298,O
of,7298,O
NOP,7298,B-GENE-Y
receptor,7298,I-GENE-Y
antagonists,7298,O
appears,7298,O
to,7298,O
be,7298,O
mediated,7298,O
through,7298,O
the,7298,O
D2,7298,B-GENE-Y
presynaptic,7298,I-GENE-Y
autoreceptors,7298,I-GENE-Y
.,7298,O
These,7299,O
data,7299,O
confirm,7299,O
that,7299,O
endogenous,7299,O
N/OFQ,7299,B-GENE-Y
is,7299,O
a,7299,O
powerful,7299,O
modulator,7299,O
of,7299,O
dopamine,7299,O
transmission,7299,O
in,7299,O
vivo,7299,O
and,7299,O
that,7299,O
the,7299,O
effects,7299,O
of,7299,O
NOP,7299,B-GENE-Y
receptor,7299,I-GENE-Y
antagonists,7299,O
on,7299,O
motor,7299,O
function,7299,O
reflect,7299,O
the,7299,O
blockade,7299,O
of,7299,O
this,7299,O
endogenous,7299,O
N/OFQ,7299,B-GENE-Y
tone,7299,O
.,7299,O
Haloperidol,7300,B-CHEMICAL
promotes,7300,O
mTORC1-dependent,7300,B-GENE-N
phosphorylation,7300,O
of,7300,O
ribosomal,7300,B-GENE-Y
protein,7300,I-GENE-Y
S6,7300,I-GENE-Y
via,7300,O
dopamine-,7300,B-GENE-Y
and,7300,I-GENE-Y
cAMP-regulated,7300,I-GENE-Y
phosphoprotein,7300,I-GENE-Y
of,7300,I-GENE-Y
32,7300,I-GENE-Y
kDa,7300,I-GENE-Y
and,7300,O
inhibition,7300,O
of,7300,O
protein,7300,B-GENE-N
phosphatase-1,7300,I-GENE-N
.,7300,O
The,7301,O
ribosomal,7301,B-GENE-Y
protein,7301,I-GENE-Y
S6,7301,I-GENE-Y
(,7301,O
rpS6,7301,B-GENE-Y
),7301,O
is,7301,O
a,7301,O
component,7301,O
of,7301,O
the,7301,O
small,7301,O
40S,7301,B-GENE-N
ribosomal,7301,I-GENE-N
subunit,7301,I-GENE-N
",",7301,O
involved,7301,O
in,7301,O
multiple,7301,O
physiological,7301,O
functions,7301,O
.,7301,O
Here,7302,O
",",7302,O
we,7302,O
examined,7302,O
the,7302,O
effects,7302,O
produced,7302,O
by,7302,O
haloperidol,7302,B-CHEMICAL
",",7302,O
a,7302,O
typical,7302,O
antipsychotic,7302,O
drug,7302,O
",",7302,O
on,7302,O
the,7302,O
phosphorylation,7302,O
of,7302,O
rpS6,7302,B-GENE-Y
at,7302,O
Ser240/244,7302,B-CHEMICAL
in,7302,O
the,7302,O
striatum,7302,O
",",7302,O
a,7302,O
brain,7302,O
region,7302,O
involved,7302,O
in,7302,O
neurodegenerative,7302,O
and,7302,O
neuropsychiatric,7302,O
disorders,7302,O
.,7302,O
Administration,7303,O
of,7303,O
haloperidol,7303,B-CHEMICAL
increased,7303,O
Ser240/244,7303,B-CHEMICAL
phosphorylation,7303,O
in,7303,O
a,7303,O
subpopulation,7303,O
of,7303,O
GABA-ergic,7303,B-CHEMICAL
medium,7303,O
spiny,7303,O
neurons,7303,O
(,7303,O
MSNs,7303,O
),7303,O
",",7303,O
which,7303,O
express,7303,O
dopamine,7303,B-GENE-Y
D2,7303,I-GENE-Y
receptors,7303,I-GENE-Y
(,7303,O
D2Rs,7303,B-GENE-Y
),7303,O
.,7303,O
This,7304,O
effect,7304,O
was,7304,O
prevented,7304,O
by,7304,O
rapamycin,7304,B-CHEMICAL
",",7304,O
an,7304,O
inhibitor,7304,O
of,7304,O
the,7304,O
mammalian,7304,B-GENE-N
target,7304,I-GENE-N
of,7304,I-GENE-N
rapamycin,7304,I-GENE-N
complex,7304,I-GENE-N
1,7304,I-GENE-N
(,7304,O
mTORC1,7304,B-GENE-N
),7304,O
",",7304,O
or,7304,O
by,7304,O
PF470867,7304,B-CHEMICAL
",",7304,O
a,7304,O
selective,7304,O
inhibitor,7304,O
of,7304,O
the,7304,O
p70,7304,B-GENE-Y
ribosomal,7304,I-GENE-Y
S6,7304,I-GENE-Y
kinase,7304,I-GENE-Y
1,7304,I-GENE-Y
(,7304,O
S6K1,7304,B-GENE-N
),7304,O
.,7304,O
We,7305,O
also,7305,O
found,7305,O
that,7305,O
the,7305,O
effect,7305,O
of,7305,O
haloperidol,7305,B-CHEMICAL
on,7305,O
Ser240/244,7305,B-CHEMICAL
phosphorylation,7305,O
was,7305,O
prevented,7305,O
by,7305,O
functional,7305,O
inactivation,7305,O
of,7305,O
dopamine-,7305,B-GENE-Y
and,7305,I-GENE-Y
cAMP-regulated,7305,I-GENE-Y
phosphoprotein,7305,I-GENE-Y
of,7305,I-GENE-Y
32,7305,I-GENE-Y
kDa,7305,I-GENE-Y
(,7305,O
DARPP-32,7305,B-GENE-Y
),7305,O
",",7305,O
an,7305,O
endogenous,7305,O
inhibitor,7305,O
of,7305,O
protein,7305,B-GENE-N
phosphatase-1,7305,I-GENE-N
(,7305,O
PP-1,7305,B-GENE-N
),7305,O
.,7305,O
In,7306,O
line,7306,O
with,7306,O
this,7306,O
observation,7306,O
",",7306,O
incubation,7306,O
of,7306,O
striatal,7306,O
slices,7306,O
with,7306,O
okadaic,7306,B-CHEMICAL
acid,7306,I-CHEMICAL
and,7306,O
calyculin,7306,B-CHEMICAL
A,7306,I-CHEMICAL
",",7306,O
two,7306,O
inhibitors,7306,O
of,7306,O
PP-1,7306,B-GENE-N
",",7306,O
increased,7306,O
Ser240/244,7306,B-CHEMICAL
phosphorylation,7306,O
.,7306,O
These,7307,O
results,7307,O
show,7307,O
that,7307,O
haloperidol,7307,B-CHEMICAL
promotes,7307,O
mTORC1-,7307,B-GENE-N
and,7307,O
S6K1-dependent,7307,B-GENE-N
phosphorylation,7307,O
of,7307,O
rpS6,7307,B-GENE-Y
at,7307,O
Ser240/244,7307,B-CHEMICAL
",",7307,O
in,7307,O
a,7307,O
subpopulation,7307,O
of,7307,O
striatal,7307,O
MSNs,7307,O
expressing,7307,O
D2Rs,7307,B-GENE-Y
.,7307,O
They,7308,O
also,7308,O
indicate,7308,O
that,7308,O
this,7308,O
effect,7308,O
is,7308,O
exerted,7308,O
by,7308,O
suppressing,7308,O
dephosphorylation,7308,O
at,7308,O
Ser240/244,7308,B-CHEMICAL
",",7308,O
through,7308,O
PKA-dependent,7308,B-GENE-N
activation,7308,O
of,7308,O
DARPP-32,7308,B-GENE-Y
and,7308,O
inhibition,7308,O
of,7308,O
PP-1,7308,B-GENE-N
.,7308,O
Designing,7309,O
",",7309,O
structural,7309,O
elucidation,7309,O
",",7309,O
comparison,7309,O
of,7309,O
DNA,7309,O
binding,7309,O
",",7309,O
cleavage,7309,O
",",7309,O
radical,7309,O
scavenging,7309,O
activity,7309,O
and,7309,O
anticancer,7309,O
activity,7309,O
of,7309,O
copper,7309,B-CHEMICAL
(,7309,I-CHEMICAL
I,7309,I-CHEMICAL
),7309,I-CHEMICAL
complex,7309,O
with,7309,O
5-dimethyl-2-phenyl-4-,7309,B-CHEMICAL
[,7309,I-CHEMICAL
(,7309,I-CHEMICAL
pyridin-2-ylmethylene,7309,I-CHEMICAL
),7309,I-CHEMICAL
-amino,7309,I-CHEMICAL
],7309,I-CHEMICAL
"-1,2-dihydro-pyrazol-3-one",7309,I-CHEMICAL
Schiff,7309,B-CHEMICAL
base,7309,I-CHEMICAL
ligand,7309,O
.,7309,O
A,7310,O
novel,7310,O
copper,7310,B-CHEMICAL
(,7310,I-CHEMICAL
I,7310,I-CHEMICAL
),7310,I-CHEMICAL
Schiff,7310,I-CHEMICAL
base,7310,I-CHEMICAL
complex,7310,O
has,7310,O
been,7310,O
synthesized,7310,O
and,7310,O
fully,7310,O
characterized,7310,O
by,7310,O
spectral,7310,O
",",7310,O
analytical,7310,O
and,7310,O
structural,7310,O
modes,7310,O
.,7310,O
Single,7311,O
crystal,7311,O
X-ray,7311,O
diffraction,7311,O
studies,7311,O
revealed,7311,O
that,7311,O
the,7311,O
copper,7311,B-CHEMICAL
(,7311,I-CHEMICAL
I,7311,I-CHEMICAL
),7311,I-CHEMICAL
complex,7311,O
[,7311,B-CHEMICAL
CuCl,7311,I-CHEMICAL
(,7311,I-CHEMICAL
PPh3,7311,I-CHEMICAL
),7311,I-CHEMICAL
L,7311,I-CHEMICAL
],7311,I-CHEMICAL
has,7311,O
a,7311,O
distorted,7311,O
tetrahedral,7311,O
geometry,7311,O
around,7311,O
the,7311,O
central,7311,O
copper,7311,B-CHEMICAL
(,7311,I-CHEMICAL
I,7311,I-CHEMICAL
),7311,I-CHEMICAL
ion,7311,O
.,7311,O
The,7312,O
interaction,7312,O
of,7312,O
the,7312,O
ligand,7312,O
and,7312,O
the,7312,O
complex,7312,O
with,7312,O
CT-DNA,7312,O
has,7312,O
been,7312,O
explored,7312,O
by,7312,O
absorption,7312,O
titration,7312,O
method,7312,O
which,7312,O
revealed,7312,O
that,7312,O
the,7312,O
compounds,7312,O
could,7312,O
interact,7312,O
with,7312,O
CT-DNA,7312,O
through,7312,O
intercalation,7312,O
.,7312,O
A,7313,O
gel,7313,O
electrophoresis,7313,O
assay,7313,O
demonstrated,7313,O
the,7313,O
ability,7313,O
of,7313,O
the,7313,O
complex,7313,O
to,7313,O
cleave,7313,O
the,7313,O
pBR322,7313,O
DNA,7313,O
.,7313,O
The,7314,O
antioxidative,7314,O
properties,7314,O
showed,7314,O
that,7314,O
the,7314,O
copper,7314,B-CHEMICAL
(,7314,I-CHEMICAL
I,7314,I-CHEMICAL
),7314,I-CHEMICAL
complex,7314,O
has,7314,O
a,7314,O
strong,7314,O
radical-scavenging,7314,O
potency,7314,O
than,7314,O
ligands,7314,O
.,7314,O
Further,7315,O
the,7315,O
cytotoxic,7315,O
effect,7315,O
of,7315,O
the,7315,O
compounds,7315,O
examined,7315,O
on,7315,O
cancerous,7315,O
cell,7315,O
lines,7315,O
showed,7315,O
that,7315,O
the,7315,O
complex,7315,O
exhibited,7315,O
substantial,7315,O
anticancer,7315,O
activity,7315,O
.,7315,O
Low,7316,O
molecular,7316,O
weight,7316,O
dual,7316,O
inhibitors,7316,O
of,7316,O
factor,7316,B-GENE-Y
Xa,7316,I-GENE-Y
and,7316,O
fibrinogen,7316,B-GENE-N
binding,7316,O
to,7316,O
GPIIb/IIIa,7316,B-GENE-Y
with,7316,O
highly,7316,O
overlapped,7316,O
pharmacophores,7316,O
.,7316,O
Dual,7317,O
antithrombotic,7317,O
agents,7317,O
acting,7317,O
as,7317,O
anticoagulants,7317,O
and,7317,O
aggregation,7317,O
inhibitors,7317,O
could,7317,O
have,7317,O
substantial,7317,O
advantages,7317,O
over,7317,O
currently,7317,O
prescribed,7317,O
combinations,7317,O
of,7317,O
antithrombotic,7317,O
drugs,7317,O
.,7317,O
Herein,7318,O
",",7318,O
we,7318,O
report,7318,O
compounds,7318,O
with,7318,O
moderate,7318,O
inhibitory,7318,O
activity,7318,O
for,7318,O
factor,7318,B-GENE-Y
Xa,7318,I-GENE-Y
and,7318,O
fibrinogen,7318,B-GENE-N
GPIIb/IIIa,7318,B-GENE-Y
binding,7318,O
(,7318,O
both,7318,O
in,7318,O
the,7318,O
micromolar,7318,O
range,7318,O
),7318,O
.,7318,O
These,7319,O
compounds,7319,O
resulted,7319,O
from,7319,O
our,7319,O
efforts,7319,O
to,7319,O
merge,7319,O
the,7319,O
pharmacophores,7319,O
of,7319,O
selective,7319,O
factor,7319,B-GENE-Y
Xa,7319,I-GENE-Y
inhibitor,7319,O
rivaroxaban,7319,B-CHEMICAL
with,7319,O
a,7319,O
mimic,7319,O
of,7319,O
the,7319,O
Arg-Gly-Asp,7319,B-GENE-N
(,7319,O
RGD,7319,B-GENE-N
),7319,O
sequence,7319,O
of,7319,O
fibrinogen,7319,B-GENE-N
to,7319,O
obtain,7319,O
designed,7319,O
multiple,7319,O
ligands,7319,O
with,7319,O
potential,7319,O
antithrombotic,7319,O
activity,7319,O
.,7319,O
Resulting,7320,O
from,7320,O
this,7320,O
study,7320,O
",",7320,O
a,7320,O
structurally,7320,O
novel,7320,O
class,7320,O
of,7320,O
submicromolar,7320,O
fibrinogen,7320,O
GPIIb/IIIa,7320,B-GENE-Y
binding,7320,O
inhibitor,7320,O
bearing,7320,O
"1,2,4-oxadiazol-5",7320,B-CHEMICAL
(,7320,I-CHEMICAL
4H,7320,I-CHEMICAL
),7320,I-CHEMICAL
-one,7320,I-CHEMICAL
moiety,7320,O
is,7320,O
also,7320,O
described,7320,O
.,7320,O
Role,7321,O
of,7321,O
quercetin,7321,B-CHEMICAL
in,7321,O
cadmium-induced,7321,B-CHEMICAL
oxidative,7321,O
stress,7321,O
",",7321,O
neuronal,7321,O
damage,7321,O
",",7321,O
and,7321,O
apoptosis,7321,O
in,7321,O
rats,7321,O
.,7321,O
The,7322,O
present,7322,O
study,7322,O
was,7322,O
carried,7322,O
out,7322,O
to,7322,O
evaluate,7322,O
the,7322,O
neuroprotective,7322,O
effect,7322,O
of,7322,O
quercetin,7322,B-CHEMICAL
(,7322,O
QE,7322,O
),7322,O
in,7322,O
protecting,7322,O
the,7322,O
cadmium,7322,B-CHEMICAL
(,7322,O
Cd,7322,B-CHEMICAL
),7322,O
-induced,7322,O
neuronal,7322,O
injury,7322,O
in,7322,O
frontal,7322,O
cortex,7322,O
of,7322,O
rats,7322,O
.,7322,O
A,7323,O
total,7323,O
of,7323,O
30,7323,O
adult,7323,O
male,7323,O
Sprague-Dawley,7323,O
rats,7323,O
were,7323,O
randomly,7323,O
divided,7323,O
into,7323,O
three,7323,O
groups,7323,O
of,7323,O
10,7323,O
animals,7323,O
each,7323,O
:,7323,O
control,7323,O
",",7323,O
Cd,7323,B-CHEMICAL
treated,7323,O
and,7323,O
Cd,7323,B-CHEMICAL
treated,7323,O
with,7323,O
QE,7323,O
.,7323,O
The,7324,O
Cd-treated,7324,B-CHEMICAL
group,7324,O
was,7324,O
injected,7324,O
subcutaneously,7324,O
with,7324,O
cadmium,7324,B-CHEMICAL
chloride,7324,I-CHEMICAL
(,7324,O
CdCl2,7324,B-CHEMICAL
),7324,O
dissolved,7324,O
in,7324,O
saline,7324,O
at,7324,O
a,7324,O
dose,7324,O
of,7324,O
2,7324,O
ml/kg/day,7324,O
for,7324,O
30,7324,O
days,7324,O
",",7324,O
resulting,7324,O
in,7324,O
a,7324,O
dosage,7324,O
of,7324,O
1,7324,O
mg/kg,7324,O
Cd,7324,B-CHEMICAL
.,7324,O
The,7325,O
rats,7325,O
in,7325,O
QE-treated,7325,O
groups,7325,O
were,7325,O
given,7325,O
QE,7325,O
(,7325,O
15,7325,O
mg/kg,7325,O
body,7325,O
weight,7325,O
),7325,O
once,7325,O
a,7325,O
day,7325,O
intraperitoneally,7325,O
starting,7325,O
2,7325,O
days,7325,O
prior,7325,O
to,7325,O
Cd,7325,B-CHEMICAL
injection,7325,O
",",7325,O
during,7325,O
the,7325,O
study,7325,O
period,7325,O
.,7325,O
Rats,7326,O
were,7326,O
sacrificed,7326,O
at,7326,O
the,7326,O
end,7326,O
of,7326,O
the,7326,O
study,7326,O
and,7326,O
the,7326,O
frontal,7326,O
cortex,7326,O
tissues,7326,O
were,7326,O
removed,7326,O
for,7326,O
biochemical,7326,O
and,7326,O
histopathological,7326,O
investigation,7326,O
.,7326,O
To,7327,O
date,7327,O
",",7327,O
there,7327,O
is,7327,O
no,7327,O
available,7327,O
information,7327,O
on,7327,O
the,7327,O
effect,7327,O
of,7327,O
QE,7327,O
on,7327,O
neuronal,7327,O
injury,7327,O
after,7327,O
Cd,7327,B-CHEMICAL
exposure,7327,O
.,7327,O
Rats,7328,O
intoxicated,7328,O
with,7328,O
Cd,7328,B-CHEMICAL
for,7328,O
30,7328,O
days,7328,O
",",7328,O
significantly,7328,O
increased,7328,O
tissue,7328,O
malondialdehyde,7328,B-CHEMICAL
(,7328,O
MDA,7328,B-CHEMICAL
),7328,O
levels,7328,O
and,7328,O
significantly,7328,O
decreased,7328,O
enzymatic,7328,O
antioxidants,7328,O
superoxide,7328,B-GENE-N
dismutase,7328,I-GENE-N
",",7328,O
glutathione,7328,B-CHEMICAL
peroxidase,7328,I-GENE-N
and,7328,O
catalase,7328,B-GENE-Y
in,7328,O
the,7328,O
frontal,7328,O
cortex,7328,O
tissue,7328,O
.,7328,O
Administration,7329,O
of,7329,O
QE,7329,O
with,7329,O
Cd,7329,B-CHEMICAL
significantly,7329,O
diminished,7329,O
the,7329,O
levels,7329,O
of,7329,O
MDA,7329,B-CHEMICAL
and,7329,O
significantly,7329,O
elevated,7329,O
the,7329,O
levels,7329,O
of,7329,O
enzymatic,7329,O
antioxidants,7329,O
in,7329,O
the,7329,O
frontal,7329,O
cortex,7329,O
tissue,7329,O
.,7329,O
The,7330,O
histopathological,7330,O
studies,7330,O
in,7330,O
the,7330,O
brain,7330,O
of,7330,O
rats,7330,O
also,7330,O
supported,7330,O
that,7330,O
QE,7330,O
markedly,7330,O
reduced,7330,O
the,7330,O
Cd-induced,7330,B-CHEMICAL
histopathological,7330,O
changes,7330,O
and,7330,O
well,7330,O
preserved,7330,O
the,7330,O
normal,7330,O
histological,7330,O
architecture,7330,O
of,7330,O
the,7330,O
frontal,7330,O
cortex,7330,O
tissue,7330,O
.,7330,O
The,7331,O
caspase-3,7331,B-GENE-Y
immunopositivity,7331,O
was,7331,O
increased,7331,O
in,7331,O
degenerating,7331,O
neurons,7331,O
of,7331,O
the,7331,O
Cd,7331,B-CHEMICAL
group,7331,O
.,7331,O
Treatment,7332,O
with,7332,O
QE,7332,O
markedly,7332,O
reduced,7332,O
the,7332,O
immunoreactivity,7332,O
of,7332,O
degenerating,7332,O
neurons,7332,O
.,7332,O
In,7333,O
conclusion,7333,O
",",7333,O
the,7333,O
results,7333,O
of,7333,O
the,7333,O
current,7333,O
study,7333,O
suggest,7333,O
that,7333,O
QE,7333,O
may,7333,O
be,7333,O
beneficial,7333,O
in,7333,O
combating,7333,O
the,7333,O
Cd-induced,7333,B-CHEMICAL
neurotoxicity,7333,O
in,7333,O
the,7333,O
brain,7333,O
of,7333,O
rats,7333,O
.,7333,O
We,7334,O
believe,7334,O
that,7334,O
further,7334,O
preclinical,7334,O
research,7334,O
into,7334,O
the,7334,O
utility,7334,O
of,7334,O
QE,7334,O
may,7334,O
indicate,7334,O
its,7334,O
usefulness,7334,O
as,7334,O
a,7334,O
potential,7334,O
treatment,7334,O
for,7334,O
neurodegeneration,7334,O
after,7334,O
Cd,7334,B-CHEMICAL
exposure,7334,O
in,7334,O
rats,7334,O
.,7334,O
Oestrogen,7335,B-CHEMICAL
action,7335,O
on,7335,O
thyroid,7335,O
progenitor,7335,O
cells,7335,O
:,7335,O
relevant,7335,O
for,7335,O
the,7335,O
pathogenesis,7335,O
of,7335,O
thyroid,7335,O
nodules,7335,O
?,7335,O
Benign,7336,O
and,7336,O
malignant,7336,O
thyroid,7336,O
nodules,7336,O
are,7336,O
more,7336,O
prevalent,7336,O
in,7336,O
females,7336,O
than,7336,O
in,7336,O
men,7336,O
.,7336,O
Experimental,7337,O
data,7337,O
suggest,7337,O
that,7337,O
the,7337,O
proliferative,7337,O
effect,7337,O
of,7337,O
oestrogen,7337,B-CHEMICAL
rather,7337,O
than,7337,O
polymorphisms,7337,O
is,7337,O
responsible,7337,O
for,7337,O
this,7337,O
gender,7337,O
difference,7337,O
.,7337,O
This,7338,O
study,7338,O
analysed,7338,O
whether,7338,O
both,7338,O
differentiated,7338,O
thyroid,7338,O
cells,7338,O
and,7338,O
thyroid,7338,O
stem,7338,O
and,7338,O
progenitor,7338,O
cells,7338,O
are,7338,O
a,7338,O
target,7338,O
of,7338,O
oestrogen,7338,B-CHEMICAL
action,7338,O
.,7338,O
In,7339,O
thyroid,7339,O
stem/progenitor,7339,O
cells,7339,O
derived,7339,O
from,7339,O
nodular,7339,O
goitres,7339,O
the,7339,O
ability,7339,O
of,7339,O
17beta-oestradiol,7339,B-CHEMICAL
to,7339,O
induce,7339,O
thyrosphere,7339,O
formation,7339,O
",",7339,O
the,7339,O
expression,7339,O
of,7339,O
oestrogen,7339,B-CHEMICAL
receptors,7339,I-GENE-Y
and,7339,O
the,7339,O
effect,7339,O
of,7339,O
17beta-oestradiol,7339,B-CHEMICAL
on,7339,O
growth,7339,O
",",7339,O
expression,7339,O
of,7339,O
marker,7339,O
of,7339,O
stem,7339,O
cells,7339,O
and,7339,O
thyroid,7339,O
differentiation,7339,O
(,7339,O
TSH,7339,B-GENE-Y
receptor,7339,I-GENE-Y
",",7339,O
thyroperoxidase,7339,B-GENE-Y
",",7339,O
thyroglobulin,7339,B-GENE-Y
",",7339,O
sodium,7339,B-GENE-Y
iodide,7339,I-GENE-Y
symporter,7339,I-GENE-Y
expression,7339,O
),7339,O
were,7339,O
analysed,7339,O
.,7339,O
17beta-oestradiol,7340,B-CHEMICAL
induced,7340,O
thyrosphere,7340,O
formation,7340,O
",",7340,O
albeit,7340,O
to,7340,O
lower,7340,O
extent,7340,O
than,7340,O
other,7340,O
growth,7340,O
factors,7340,O
.,7340,O
Thyroid,7341,O
stem,7341,O
and,7341,O
progenitor,7341,O
cells,7341,O
expressed,7341,O
oestrogen,7341,B-GENE-N
receptor,7341,I-GENE-N
alpha,7341,I-GENE-N
and,7341,I-GENE-N
beta,7341,I-GENE-N
with,7341,O
an,7341,O
8,7341,O
time,7341,O
higher,7341,O
expression,7341,O
level,7341,O
of,7341,O
oestrogen,7341,B-GENE-N
receptor,7341,I-GENE-N
alpha,7341,I-GENE-N
mRNA,7341,O
compared,7341,O
to,7341,O
differentiated,7341,O
thyrocytes,7341,O
.,7341,O
17beta-oestradiol,7342,B-CHEMICAL
was,7342,O
a,7342,O
potent,7342,O
stimulator,7342,O
of,7342,O
thyroid,7342,O
stem/,7342,O
progenitor,7342,O
cell,7342,O
growth,7342,O
.,7342,O
In,7343,O
contrast,7343,O
",",7343,O
TSH-induced,7343,O
differentiation,7343,O
of,7343,O
progenitor,7343,O
cells,7343,O
",",7343,O
in,7343,O
particular,7343,O
the,7343,O
expression,7343,O
of,7343,O
the,7343,O
sodium,7343,B-CHEMICAL
iodide,7343,I-CHEMICAL
symporter,7343,I-GENE-Y
",",7343,O
was,7343,O
significantly,7343,O
inhibited,7343,O
by,7343,O
17beta-oestradiol.In,7343,B-CHEMICAL
conclusion,7343,O
",",7343,O
oestrogen,7343,B-CHEMICAL
stimulated,7343,O
growth,7343,O
and,7343,O
simultaneously,7343,O
inhibited,7343,O
differentiation,7343,O
of,7343,O
thyroid,7343,O
nodules,7343,O
derived,7343,O
stem/progenitor,7343,O
cells,7343,O
.,7343,O
From,7344,O
these,7344,O
data,7344,O
and,7344,O
based,7344,O
on,7344,O
the,7344,O
concept,7344,O
of,7344,O
cellular,7344,O
heterogeneity,7344,O
",",7344,O
we,7344,O
hypothesize,7344,O
a,7344,O
supportive,7344,O
role,7344,O
of,7344,O
oestrogen,7344,B-CHEMICAL
in,7344,O
the,7344,O
propagation,7344,O
of,7344,O
thyroid,7344,O
stem/progenitor,7344,O
cells,7344,O
leading,7344,O
to,7344,O
a,7344,O
selection,7344,O
of,7344,O
a,7344,O
progeny,7344,O
of,7344,O
growth-prone,7344,O
cells,7344,O
with,7344,O
a,7344,O
decreased,7344,O
differentiation,7344,O
.,7344,O
These,7345,O
cells,7345,O
may,7345,O
be,7345,O
the,7345,O
origin,7345,O
of,7345,O
hypo-,7345,O
or,7345,O
non-functioning,7345,O
thyroid,7345,O
nodules,7345,O
in,7345,O
females,7345,O
.,7345,O
Differential,7346,O
regulation,7346,O
of,7346,O
Arabidopsis,7346,B-GENE-N
plastid,7346,I-GENE-N
gene,7346,O
expression,7346,O
and,7346,O
RNA,7346,O
editing,7346,O
in,7346,O
non-photosynthetic,7346,O
tissues,7346,O
.,7346,O
RNA,7347,O
editing,7347,O
is,7347,O
one,7347,O
of,7347,O
the,7347,O
post-transcriptional,7347,O
processes,7347,O
that,7347,O
commonly,7347,O
occur,7347,O
in,7347,O
plant,7347,B-GENE-N
plastids,7347,I-GENE-N
and,7347,O
mitochondria,7347,O
.,7347,O
In,7348,O
Arabidopsis,7348,O
",",7348,O
34,7348,O
C-to-U,7348,O
RNA,7348,O
editing,7348,O
events,7348,O
",",7348,O
affecting,7348,O
transcripts,7348,O
of,7348,O
18,7348,O
plastid,7348,B-GENE-N
genes,7348,O
",",7348,O
have,7348,O
been,7348,O
identified,7348,O
.,7348,O
Here,7349,O
",",7349,O
we,7349,O
examined,7349,O
the,7349,O
editing,7349,O
and,7349,O
expression,7349,O
of,7349,O
these,7349,O
transcripts,7349,O
in,7349,O
different,7349,O
organs,7349,O
",",7349,O
and,7349,O
in,7349,O
green,7349,O
and,7349,O
non-green,7349,O
seedlings,7349,O
(,7349,O
etiolated,7349,O
",",7349,O
cia5-2,7349,O
",",7349,O
ispF,7349,O
and,7349,O
ispG,7349,O
albino,7349,O
mutants,7349,O
",",7349,O
lincomycin-,7349,B-CHEMICAL
",",7349,O
and,7349,O
norflurazon-treated,7349,B-CHEMICAL
),7349,O
.,7349,O
The,7350,O
editing,7350,O
efficiency,7350,O
of,7350,O
Arabidopsis,7350,B-GENE-N
plastid,7350,I-GENE-N
transcripts,7350,O
varies,7350,O
from,7350,O
site,7350,O
to,7350,O
site,7350,O
",",7350,O
and,7350,O
may,7350,O
be,7350,O
specifically,7350,O
regulated,7350,O
in,7350,O
different,7350,O
tissues,7350,O
.,7350,O
Steady,7351,O
state,7351,O
levels,7351,O
of,7351,O
plastid,7351,B-GENE-N
transcripts,7351,O
are,7351,O
low,7351,O
or,7351,O
undetectable,7351,O
in,7351,O
etiolated,7351,O
seedlings,7351,O
",",7351,O
but,7351,O
most,7351,O
editing,7351,O
sites,7351,O
are,7351,O
edited,7351,O
with,7351,O
efficiencies,7351,O
similar,7351,O
to,7351,O
those,7351,O
observed,7351,O
in,7351,O
green,7351,O
seedlings,7351,O
.,7351,O
By,7352,O
contrast,7352,O
",",7352,O
the,7352,O
editing,7352,O
of,7352,O
some,7352,O
sites,7352,O
is,7352,O
completely,7352,O
lost,7352,O
or,7352,O
significantly,7352,O
reduced,7352,O
in,7352,O
other,7352,O
non-green,7352,O
tissues,7352,O
;,7352,O
for,7352,O
instance,7352,O
",",7352,O
the,7352,O
editing,7352,O
of,7352,O
ndhB-149,7352,B-GENE-N
",",7352,O
ndhB-1255,7352,B-GENE-N
",",7352,O
and,7352,O
ndhD-2,7352,B-GENE-N
is,7352,O
completely,7352,O
lost,7352,O
in,7352,O
roots,7352,O
and,7352,O
in,7352,O
lincomycin-treated,7352,B-CHEMICAL
seedlings,7352,O
.,7352,O
The,7353,O
editing,7353,O
of,7353,O
ndhD-2,7353,B-GENE-N
is,7353,O
also,7353,O
completely,7353,O
lost,7353,O
in,7353,O
albino,7353,O
mutants,7353,O
and,7353,O
norflurazon-treated,7353,B-CHEMICAL
seedlings,7353,O
.,7353,O
However,7354,O
",",7354,O
matK-640,7354,O
is,7354,O
completely,7354,O
edited,7354,O
",",7354,O
and,7354,O
accD-794,7354,B-GENE-N
",",7354,O
atpF-92,7354,B-GENE-N
",",7354,O
psbE-214,7354,B-GENE-N
",",7354,O
psbF-77,7354,B-GENE-N
",",7354,O
psbZ-50,7354,B-GENE-N
",",7354,O
and,7354,O
rps14-50,7354,B-GENE-N
are,7354,O
completely,7354,O
or,7354,O
highly,7354,O
edited,7354,O
in,7354,O
both,7354,O
green,7354,O
and,7354,O
non-green,7354,O
tissues,7354,O
.,7354,O
In,7355,O
addition,7355,O
",",7355,O
the,7355,O
expression,7355,O
of,7355,O
nucleus-encoded,7355,O
RNA,7355,B-GENE-N
polymerase,7355,I-GENE-N
dependent,7355,O
transcripts,7355,O
is,7355,O
specifically,7355,O
induced,7355,O
by,7355,O
lincomycin,7355,B-CHEMICAL
",",7355,O
and,7355,O
the,7355,O
splicing,7355,O
of,7355,O
ndhB,7355,B-GENE-N
transcripts,7355,O
is,7355,O
significantly,7355,O
reduced,7355,O
in,7355,O
the,7355,O
albino,7355,O
mutants,7355,O
and,7355,O
inhibitor-treated,7355,O
seedlings,7355,O
.,7355,O
Our,7356,O
results,7356,O
indicate,7356,O
that,7356,O
plastid,7356,B-GENE-N
gene,7356,O
expression,7356,O
",",7356,O
and,7356,O
the,7356,O
splicing,7356,O
and,7356,O
editing,7356,O
of,7356,O
plastid,7356,B-GENE-N
transcripts,7356,O
are,7356,O
specifically,7356,O
and,7356,O
differentially,7356,O
regulated,7356,O
in,7356,O
various,7356,O
types,7356,O
of,7356,O
non-green,7356,O
tissues,7356,O
.,7356,O
Drug-drug,7357,O
interactions,7357,O
between,7357,O
HMG-CoA,7357,B-GENE-Y
reductase,7357,I-GENE-Y
inhibitors,7357,O
(,7357,O
statins,7357,O
),7357,O
and,7357,O
antiviral,7357,O
protease,7357,B-GENE-N
inhibitors,7357,O
.,7357,O
The,7358,O
HMG-CoA,7358,B-GENE-Y
reductase,7358,I-GENE-Y
inhibitors,7358,O
are,7358,O
a,7358,O
class,7358,O
of,7358,O
drugs,7358,O
also,7358,O
known,7358,O
as,7358,O
statins,7358,O
.,7358,O
These,7359,O
drugs,7359,O
are,7359,O
effective,7359,O
and,7359,O
widely,7359,O
prescribed,7359,O
for,7359,O
the,7359,O
treatment,7359,O
of,7359,O
hypercholesterolemia,7359,O
and,7359,O
prevention,7359,O
of,7359,O
cardiovascular,7359,O
morbidity,7359,O
and,7359,O
mortality,7359,O
.,7359,O
Seven,7360,O
statins,7360,O
are,7360,O
currently,7360,O
available,7360,O
:,7360,O
atorvastatin,7360,B-CHEMICAL
",",7360,O
fluvastatin,7360,B-CHEMICAL
",",7360,O
lovastatin,7360,B-CHEMICAL
",",7360,O
pitavastatin,7360,B-CHEMICAL
",",7360,O
pravastatin,7360,B-CHEMICAL
",",7360,O
rosuvastatin,7360,B-CHEMICAL
and,7360,O
simvastatin,7360,B-CHEMICAL
.,7360,O
Although,7361,O
these,7361,O
drugs,7361,O
are,7361,O
generally,7361,O
well,7361,O
tolerated,7361,O
",",7361,O
skeletal,7361,O
muscle,7361,O
abnormalities,7361,O
from,7361,O
myalgia,7361,O
to,7361,O
severe,7361,O
lethal,7361,O
rhabdomyolysis,7361,O
can,7361,O
occur,7361,O
.,7361,O
Factors,7362,O
that,7362,O
increase,7362,O
statin,7362,O
concentrations,7362,O
such,7362,O
as,7362,O
drug-drug,7362,O
interactions,7362,O
can,7362,O
increase,7362,O
the,7362,O
risk,7362,O
of,7362,O
these,7362,O
adverse,7362,O
events,7362,O
.,7362,O
Drug-drug,7363,O
interactions,7363,O
are,7363,O
dependent,7363,O
on,7363,O
statins,7363,O
',7363,O
pharmacokinetic,7363,O
profile,7363,O
:,7363,O
simvastatin,7363,B-CHEMICAL
",",7363,O
lovastatin,7363,B-CHEMICAL
and,7363,O
atorvastatin,7363,B-CHEMICAL
are,7363,O
metabolized,7363,O
through,7363,O
cytochrome,7363,B-GENE-N
P450,7363,I-GENE-N
(,7363,I-GENE-N
CYP,7363,I-GENE-N
),7363,I-GENE-N
3A,7363,I-GENE-N
",",7363,O
while,7363,O
the,7363,O
metabolism,7363,O
of,7363,O
the,7363,O
other,7363,O
statins,7363,O
is,7363,O
independent,7363,O
of,7363,O
this,7363,O
CYP,7363,B-GENE-N
.,7363,O
All,7364,O
statins,7364,O
are,7364,O
substrate,7364,O
of,7364,O
organic,7364,B-GENE-Y
anion,7364,I-GENE-Y
transporter,7364,I-GENE-Y
polypeptide,7364,I-GENE-Y
1B1,7364,I-GENE-Y
",",7364,O
an,7364,O
uptake,7364,O
transporter,7364,O
expressed,7364,O
in,7364,O
hepatocyte,7364,O
membrane,7364,O
that,7364,O
may,7364,O
also,7364,O
explain,7364,O
some,7364,O
drug-drug,7364,O
interactions,7364,O
.,7364,O
Many,7365,O
HIV-infected,7365,O
patients,7365,O
have,7365,O
dyslipidemia,7365,O
and,7365,O
comorbidities,7365,O
that,7365,O
may,7365,O
require,7365,O
statin,7365,O
treatment,7365,O
.,7365,O
HIV-protease,7366,B-GENE-N
inhibitors,7366,O
(,7366,O
HIV,7366,O
PIs,7366,O
),7366,O
are,7366,O
part,7366,O
of,7366,O
recommended,7366,O
antiretroviral,7366,O
treatment,7366,O
in,7366,O
combination,7366,O
with,7366,O
two,7366,O
reverse,7366,B-GENE-N
transcriptase,7366,I-GENE-N
inhibitors,7366,O
.,7366,O
All,7367,O
HIV,7367,O
PIs,7367,O
except,7367,O
nelfinavir,7367,B-CHEMICAL
are,7367,O
coadministered,7367,O
with,7367,O
a,7367,O
low,7367,O
dose,7367,O
of,7367,O
ritonavir,7367,B-CHEMICAL
",",7367,O
a,7367,O
potent,7367,O
CYP3A,7367,B-GENE-N
inhibitor,7367,O
to,7367,O
improve,7367,O
their,7367,O
pharmacokinetic,7367,O
properties,7367,O
.,7367,O
Cobicistat,7368,O
is,7368,O
a,7368,O
new,7368,O
potent,7368,O
CYP3A,7368,B-GENE-N
inhibitor,7368,O
that,7368,O
is,7368,O
combined,7368,O
with,7368,O
elvitegravir,7368,O
and,7368,O
will,7368,O
be,7368,O
combined,7368,O
with,7368,O
HIV-PIs,7368,O
in,7368,O
the,7368,O
future,7368,O
.,7368,O
The,7369,O
HCV-PIs,7369,O
boceprevir,7369,B-CHEMICAL
and,7369,O
telaprevir,7369,B-CHEMICAL
are,7369,O
both,7369,O
",",7369,O
to,7369,O
different,7369,O
extents,7369,O
",",7369,O
inhibitors,7369,O
of,7369,O
CYP3A,7369,B-GENE-N
.,7369,O
This,7370,O
review,7370,O
summarizes,7370,O
the,7370,O
pharmacokinetic,7370,O
properties,7370,O
of,7370,O
statins,7370,O
and,7370,O
PIs,7370,O
with,7370,O
emphasis,7370,O
on,7370,O
their,7370,O
metabolic,7370,O
pathways,7370,O
explaining,7370,O
clinically,7370,O
important,7370,O
drug-drug,7370,O
interactions,7370,O
.,7370,O
Simvastatin,7371,B-CHEMICAL
and,7371,O
lovastatin,7371,B-CHEMICAL
metabolized,7371,O
through,7371,O
CYP3A,7371,B-GENE-N
have,7371,O
the,7371,O
highest,7371,O
potency,7371,O
for,7371,O
drug-drug,7371,O
interaction,7371,O
with,7371,O
potent,7371,O
CYP3A,7371,B-GENE-N
inhibitors,7371,O
such,7371,O
as,7371,O
ritonavir-,7371,B-CHEMICAL
or,7371,O
cobicistat-boosted,7371,B-CHEMICAL
HIV-PI,7371,O
or,7371,O
the,7371,O
hepatitis,7371,O
C,7371,O
virus,7371,O
(,7371,O
HCV,7371,O
),7371,O
PI,7371,O
",",7371,O
telaprevir,7371,B-CHEMICAL
or,7371,O
boceprevir,7371,B-CHEMICAL
",",7371,O
and,7371,O
therefore,7371,O
their,7371,O
coadministration,7371,O
is,7371,O
contraindicated,7371,O
.,7371,O
Atorvastatin,7372,B-CHEMICAL
is,7372,O
also,7372,O
a,7372,O
CYP3A,7372,B-GENE-N
substrate,7372,O
",",7372,O
but,7372,O
less,7372,O
potent,7372,O
drug-drug,7372,O
interactions,7372,O
have,7372,O
been,7372,O
reported,7372,O
with,7372,O
CYP3A,7372,B-GENE-N
inhibitors,7372,O
.,7372,O
Non-CYP3A-dependent,7373,O
statin,7373,O
concentrations,7373,O
are,7373,O
also,7373,O
affected,7373,O
although,7373,O
to,7373,O
a,7373,O
lesser,7373,O
extent,7373,O
when,7373,O
coadministered,7373,O
with,7373,O
HIV,7373,O
or,7373,O
HCV,7373,O
PIs,7373,O
",",7373,O
mainly,7373,O
through,7373,O
interaction,7373,O
with,7373,O
OATP1B1,7373,B-GENE-Y
",",7373,O
and,7373,O
treatment,7373,O
should,7373,O
start,7373,O
with,7373,O
the,7373,O
lowest,7373,O
available,7373,O
statin,7373,O
dose,7373,O
.,7373,O
Effectiveness,7374,O
and,7374,O
occurrence,7374,O
of,7374,O
adverse,7374,O
effects,7374,O
should,7374,O
be,7374,O
monitored,7374,O
at,7374,O
regular,7374,O
time,7374,O
intervals,7374,O
.,7374,O
Synthesis,7375,O
",",7375,O
structure-activity,7375,O
relationships,7375,O
",",7375,O
and,7375,O
in,7375,O
vivo,7375,O
efficacy,7375,O
of,7375,O
the,7375,O
novel,7375,O
potent,7375,O
and,7375,O
selective,7375,O
anaplastic,7375,B-GENE-Y
lymphoma,7375,I-GENE-Y
kinase,7375,I-GENE-Y
(,7375,O
ALK,7375,B-GENE-Y
),7375,O
inhibitor,7375,O
5-chloro-N2-,7375,B-CHEMICAL
(,7375,I-CHEMICAL
2-isopropoxy-5-methyl-4-,7375,I-CHEMICAL
(,7375,I-CHEMICAL
piperidin-4-yl,7375,I-CHEMICAL
),7375,I-CHEMICAL
phenyl,7375,I-CHEMICAL
),7375,I-CHEMICAL
-N4-,7375,I-CHEMICAL
(,7375,I-CHEMICAL
2-,7375,I-CHEMICAL
(,7375,I-CHEMICAL
isopropylsulf,7375,I-CHEMICAL
onyl,7375,I-CHEMICAL
),7375,I-CHEMICAL
phenyl,7375,I-CHEMICAL
),7375,I-CHEMICAL
"pyrimidine-2,4-diamine",7375,I-CHEMICAL
(,7375,O
LDK378,7375,B-CHEMICAL
),7375,O
currently,7375,O
in,7375,O
phase,7375,O
1,7375,O
and,7375,O
phase,7375,O
2,7375,O
clinical,7375,O
trials,7375,O
.,7375,O
The,7376,O
synthesis,7376,O
",",7376,O
preclinical,7376,O
profile,7376,O
",",7376,O
and,7376,O
in,7376,O
vivo,7376,O
efficacy,7376,O
in,7376,O
rat,7376,O
xenograft,7376,O
models,7376,O
of,7376,O
the,7376,O
novel,7376,O
and,7376,O
selective,7376,O
anaplastic,7376,B-GENE-Y
lymphoma,7376,I-GENE-Y
kinase,7376,I-GENE-Y
inhibitor,7376,O
15b,7376,O
(,7376,O
LDK378,7376,B-CHEMICAL
),7376,O
are,7376,O
described,7376,O
.,7376,O
In,7377,O
this,7377,O
initial,7377,O
report,7377,O
",",7377,O
preliminary,7377,O
structure-activity,7377,O
relationships,7377,O
(,7377,O
SARs,7377,O
),7377,O
are,7377,O
described,7377,O
as,7377,O
well,7377,O
as,7377,O
the,7377,O
rational,7377,O
design,7377,O
strategy,7377,O
employed,7377,O
to,7377,O
overcome,7377,O
the,7377,O
development,7377,O
deficiencies,7377,O
of,7377,O
the,7377,O
first,7377,O
generation,7377,O
ALK,7377,B-GENE-Y
inhibitor,7377,O
4,7377,O
(,7377,O
TAE684,7377,B-CHEMICAL
),7377,O
.,7377,O
Compound,7378,O
15b,7378,O
is,7378,O
currently,7378,O
in,7378,O
phase,7378,O
1,7378,O
and,7378,O
phase,7378,O
2,7378,O
clinical,7378,O
trials,7378,O
with,7378,O
substantial,7378,O
antitumor,7378,O
activity,7378,O
being,7378,O
observed,7378,O
in,7378,O
ALK-positive,7378,B-GENE-Y
cancer,7378,O
patients,7378,O
.,7378,O
Benzodiazepines,7379,B-CHEMICAL
",",7379,O
but,7379,O
not,7379,O
beta,7379,B-CHEMICAL
carbolines,7379,I-CHEMICAL
",",7379,O
limit,7379,O
high,7379,O
frequency,7379,O
repetitive,7379,O
firing,7379,O
of,7379,O
action,7379,O
potentials,7379,O
of,7379,O
spinal,7379,O
cord,7379,O
neurons,7379,O
in,7379,O
cell,7379,O
culture,7379,O
.,7379,O
Effects,7380,O
of,7380,O
benzodiazepines,7380,B-CHEMICAL
(,7380,O
BDZs,7380,B-CHEMICAL
),7380,O
and,7380,O
beta,7380,B-CHEMICAL
carbolines,7380,I-CHEMICAL
(,7380,O
beta,7380,B-CHEMICAL
CCs,7380,I-CHEMICAL
),7380,O
on,7380,O
sustained,7380,O
repetitive,7380,O
firing,7380,O
at,7380,O
high,7380,O
frequency,7380,O
(,7380,O
SRF,7380,O
),7380,O
of,7380,O
action,7380,O
potentials,7380,O
of,7380,O
mouse,7380,O
spinal,7380,O
cord,7380,O
neurons,7380,O
in,7380,O
cell,7380,O
culture,7380,O
were,7380,O
examined,7380,O
using,7380,O
intracellular,7380,O
recording,7380,O
techniques,7380,O
.,7380,O
In,7381,O
control,7381,O
medium,7381,O
neurons,7381,O
responded,7381,O
to,7381,O
depolarizing,7381,O
current,7381,O
pulses,7381,O
with,7381,O
SRF,7381,O
.,7381,O
Limitation,7382,O
of,7382,O
SRF,7382,O
was,7382,O
produced,7382,O
by,7382,O
the,7382,O
anticonvulsant,7382,O
BDZs,7382,B-CHEMICAL
(,7382,O
diazepam,7382,B-CHEMICAL
",",7382,O
clonazepam,7382,B-CHEMICAL
",",7382,O
nitrazepam,7382,B-CHEMICAL
and,7382,O
lorazepam,7382,B-CHEMICAL
),7382,O
at,7382,O
low,7382,O
to,7382,O
mid,7382,O
nanomolar,7382,O
concentrations,7382,O
",",7382,O
by,7382,O
a,7382,O
convulsant,7382,O
BDZ,7382,B-CHEMICAL
which,7382,O
does,7382,O
not,7382,O
bind,7382,O
to,7382,O
high,7382,O
affinity,7382,O
BDZ,7382,B-GENE-N
receptors,7382,I-GENE-N
(,7382,O
Ro,7382,B-CHEMICAL
5-4864,7382,I-CHEMICAL
),7382,O
at,7382,O
high,7382,O
nanomolar,7382,O
concentrations,7382,O
and,7382,O
by,7382,O
a,7382,O
BDZ,7382,B-GENE-N
receptor,7382,I-GENE-N
weak,7382,O
partial,7382,O
agonist,7382,O
(,7382,O
Ro,7382,B-CHEMICAL
15-1788,7382,I-CHEMICAL
),7382,O
at,7382,O
micromolar,7382,O
concentrations,7382,O
.,7382,O
The,7383,O
limitation,7383,O
of,7383,O
SRF,7383,O
was,7383,O
accompanied,7383,O
by,7383,O
use-,7383,O
and,7383,O
voltage-dependent,7383,O
reduction,7383,O
of,7383,O
maximal,7383,O
rate,7383,O
of,7383,O
rise,7383,O
(,7383,O
Vmax,7383,O
),7383,O
of,7383,O
sodium-dependent,7383,B-CHEMICAL
action,7383,O
potentials,7383,O
.,7383,O
Partial,7384,O
agonist,7384,O
and,7384,O
inverse,7384,O
agonist,7384,O
beta,7384,O
CCs,7384,O
did,7384,O
not,7384,O
limit,7384,O
SRF,7384,O
at,7384,O
concentrations,7384,O
up,7384,O
to,7384,O
200,7384,O
nM,7384,O
.,7384,O
The,7385,O
limitation,7385,O
of,7385,O
SRF,7385,O
by,7385,O
diazepam,7385,B-CHEMICAL
was,7385,O
not,7385,O
prevented,7385,O
by,7385,O
inverse,7385,O
or,7385,O
partial,7385,O
agonists,7385,O
at,7385,O
the,7385,O
BDZ,7385,B-GENE-N
receptor,7385,I-GENE-N
",",7385,O
including,7385,O
Ro,7385,B-CHEMICAL
15-1788,7385,I-CHEMICAL
and,7385,O
the,7385,O
beta,7385,B-CHEMICAL
CCs,7385,I-CHEMICAL
.,7385,O
These,7386,O
findings,7386,O
suggest,7386,O
that,7386,O
limitation,7386,O
of,7386,O
SRF,7386,O
was,7386,O
produced,7386,O
by,7386,O
binding,7386,O
of,7386,O
BDZs,7386,B-CHEMICAL
",",7386,O
but,7386,O
not,7386,O
beta,7386,B-CHEMICAL
CCs,7386,I-CHEMICAL
",",7386,O
to,7386,O
voltage-dependent,7386,B-GENE-N
sodium,7386,B-CHEMICAL
channels,7386,I-GENE-N
and,7386,O
not,7386,O
to,7386,O
high,7386,O
affinity,7386,O
central,7386,O
BDZ,7386,B-CHEMICAL
receptors,7386,I-GENE-N
",",7386,O
and,7386,O
that,7386,O
BDZs,7386,B-CHEMICAL
limit,7386,O
SRF,7386,O
by,7386,O
slowing,7386,O
recovery,7386,O
of,7386,O
sodium,7386,B-GENE-N
channels,7386,I-GENE-N
from,7386,O
inactivation,7386,O
.,7386,O
We,7387,O
propose,7387,O
that,7387,O
the,7387,O
limitation,7387,O
of,7387,O
SRF,7387,O
may,7387,O
contribute,7387,O
to,7387,O
the,7387,O
efficacy,7387,O
of,7387,O
BDZs,7387,B-CHEMICAL
against,7387,O
generalized,7387,O
tonic-clonic,7387,O
seizures,7387,O
and,7387,O
status,7387,O
epilepticus,7387,O
.,7387,O
Androgens,7388,B-CHEMICAL
directly,7388,O
stimulate,7388,O
proliferation,7388,O
of,7388,O
bone,7388,O
cells,7388,O
in,7388,O
vitro,7388,O
.,7388,O
This,7389,O
report,7389,O
describes,7389,O
the,7389,O
first,7389,O
observation,7389,O
of,7389,O
a,7389,O
direct,7389,O
mitogenic,7389,O
effect,7389,O
of,7389,O
androgens,7389,B-CHEMICAL
on,7389,O
isolated,7389,O
osteoblastic,7389,O
cells,7389,O
in,7389,O
serum-free,7389,O
culture,7389,O
.,7389,O
[,7390,B-CHEMICAL
3H,7390,I-CHEMICAL
],7390,I-CHEMICAL
thymidine,7390,I-CHEMICAL
incorporation,7390,O
into,7390,O
DNA,7390,O
and,7390,O
cell,7390,O
counts,7390,O
were,7390,O
used,7390,O
as,7390,O
measures,7390,O
of,7390,O
cell,7390,O
proliferation,7390,O
.,7390,O
The,7391,O
percentage,7391,O
of,7391,O
cells,7391,O
that,7391,O
stained,7391,O
for,7391,O
alkaline,7391,B-GENE-N
phosphatase,7391,I-GENE-N
was,7391,O
used,7391,O
as,7391,O
a,7391,O
measure,7391,O
of,7391,O
differentiation,7391,O
.,7391,O
Dihydrotestosterone,7392,B-CHEMICAL
(,7392,O
DHT,7392,B-CHEMICAL
),7392,O
enhanced,7392,O
mouse,7392,O
osteoblastic,7392,O
cell,7392,O
proliferation,7392,O
in,7392,O
a,7392,O
dose,7392,O
dependent,7392,O
manner,7392,O
over,7392,O
a,7392,O
wide,7392,O
range,7392,O
of,7392,O
doses,7392,O
(,7392,O
10,7392,O
(,7392,O
-8,7392,O
),7392,O
to,7392,O
10,7392,O
(,7392,O
-11,7392,O
),7392,O
molar,7392,O
),7392,O
",",7392,O
and,7392,O
was,7392,O
maximally,7392,O
active,7392,O
at,7392,O
10,7392,O
(,7392,O
-9,7392,O
),7392,O
M.,7392,O
DHT,7392,B-CHEMICAL
also,7392,O
stimulated,7392,O
proliferation,7392,O
in,7392,O
human,7392,O
osteoblast,7392,O
cell,7392,O
cultures,7392,O
and,7392,O
in,7392,O
cultures,7392,O
of,7392,O
the,7392,O
human,7392,O
osteosarcoma,7392,O
cell,7392,O
line,7392,O
",",7392,O
TE89,7392,O
.,7392,O
Testosterone,7393,B-CHEMICAL
",",7393,O
fluoxymesterone,7393,B-CHEMICAL
(,7393,O
a,7393,O
synthetic,7393,O
androgenic,7393,O
steroid,7393,B-CHEMICAL
),7393,O
and,7393,O
methenolone,7393,B-CHEMICAL
(,7393,O
an,7393,O
anabolic,7393,O
steroid,7393,B-CHEMICAL
),7393,O
were,7393,O
also,7393,O
mitogenic,7393,O
in,7393,O
the,7393,O
mouse,7393,O
bone,7393,O
cell,7393,O
system,7393,O
.,7393,O
The,7394,O
mitogenic,7394,O
effect,7394,O
of,7394,O
DHT,7394,B-CHEMICAL
on,7394,O
bone,7394,O
cells,7394,O
was,7394,O
inhibited,7394,O
by,7394,O
antiandrogens,7394,O
(,7394,O
hydroxyflutamide,7394,B-CHEMICAL
and,7394,O
cyproterone,7394,B-CHEMICAL
acetate,7394,I-CHEMICAL
),7394,O
which,7394,O
compete,7394,O
for,7394,O
binding,7394,O
to,7394,O
the,7394,O
androgen,7394,B-GENE-N
receptor,7394,I-GENE-N
.,7394,O
In,7395,O
addition,7395,O
to,7395,O
effects,7395,O
on,7395,O
cell,7395,O
proliferation,7395,O
",",7395,O
DHT,7395,B-CHEMICAL
increased,7395,O
the,7395,O
percentage,7395,O
of,7395,O
alkaline,7395,B-GENE-N
phosphatase,7395,I-GENE-N
(,7395,O
ALP,7395,B-GENE-N
),7395,O
positive,7395,O
cells,7395,O
in,7395,O
all,7395,O
three,7395,O
bone,7395,O
cell,7395,O
systems,7395,O
tested,7395,O
",",7395,O
and,7395,O
this,7395,O
effect,7395,O
was,7395,O
inhibited,7395,O
by,7395,O
antiandrogens,7395,O
.,7395,O
We,7396,O
conclude,7396,O
that,7396,O
androgens,7396,B-CHEMICAL
can,7396,O
stimulate,7396,O
human,7396,O
and,7396,O
murine,7396,O
osteoblastic,7396,O
cell,7396,O
proliferation,7396,O
in,7396,O
vitro,7396,O
",",7396,O
and,7396,O
induce,7396,O
expression,7396,O
of,7396,O
the,7396,O
osteoblast-line,7396,B-GENE-N
differentiation,7396,I-GENE-N
marker,7396,I-GENE-N
ALP,7396,B-GENE-N
",",7396,O
presumably,7396,O
by,7396,O
an,7396,O
androgen,7396,B-CHEMICAL
receptor,7396,I-GENE-N
mediated,7396,O
mechanism,7396,O
.,7396,O
The,7397,O
effect,7397,O
of,7397,O
histamine-H1,7397,B-GENE-Y
receptor,7397,I-GENE-Y
antagonism,7397,O
with,7397,O
terfenadine,7397,B-CHEMICAL
on,7397,O
concentration-related,7397,O
AMP-induced,7397,B-CHEMICAL
bronchoconstriction,7397,O
in,7397,O
asthma,7397,O
.,7397,O
Selective,7398,O
histamine-H1,7398,B-CHEMICAL
receptor,7398,I-GENE-Y
antagonists,7398,O
inhibit,7398,O
adenosine,7398,B-CHEMICAL
5'-monophosphate,7398,I-CHEMICAL
(,7398,O
AMP,7398,B-CHEMICAL
),7398,O
-induced,7398,O
bronchoconstriction,7398,O
by,7398,O
greater,7398,O
than,7398,O
80,7398,O
%,7398,O
when,7398,O
expressed,7398,O
as,7398,O
a,7398,O
percentage,7398,O
inhibition,7398,O
of,7398,O
the,7398,O
FEV1,7398,O
time-response,7398,O
curve,7398,O
following,7398,O
inhalation,7398,O
of,7398,O
the,7398,O
provocation,7398,O
concentration,7398,O
of,7398,O
AMP,7398,B-CHEMICAL
required,7398,O
to,7398,O
produce,7398,O
a,7398,O
20,7398,O
%,7398,O
decrease,7398,O
in,7398,O
FEV1,7398,O
from,7398,O
baseline,7398,O
(,7398,O
PC20,7398,O
),7398,O
.,7398,O
To,7399,O
investigate,7399,O
this,7399,O
further,7399,O
we,7399,O
have,7399,O
determined,7399,O
that,7399,O
",",7399,O
in,7399,O
eight,7399,O
mild,7399,O
atopic,7399,O
asthmatic,7399,O
subjects,7399,O
",",7399,O
terfenadine,7399,B-CHEMICAL
(,7399,O
180,7399,O
mg,7399,O
),7399,O
",",7399,O
administered,7399,O
3,7399,O
hr,7399,O
pre-challenge,7399,O
",",7399,O
increases,7399,O
the,7399,O
geometric,7399,O
mean,7399,O
PC20,7399,O
for,7399,O
histamine,7399,B-CHEMICAL
from,7399,O
0.4,7399,O
(,7399,O
range,7399,O
0.03-3,7399,O
),7399,O
mg/ml,7399,O
after,7399,O
placebo,7399,O
",",7399,O
to,7399,O
20.2,7399,O
(,7399,O
range,7399,O
0.6-64,7399,O
),7399,O
mg/ml,7399,O
following,7399,O
active,7399,O
treatment,7399,O
(,7399,O
P,7399,O
less,7399,O
than,7399,O
0.0001,7399,O
),7399,O
.,7399,O
For,7400,O
AMP,7400,B-CHEMICAL
",",7400,O
the,7400,O
PC20,7400,O
increased,7400,O
from,7400,O
9.3,7400,O
(,7400,O
range,7400,O
1.0-113.3,7400,O
),7400,O
mg/ml,7400,O
after,7400,O
placebo,7400,O
",",7400,O
to,7400,O
150.2,7400,O
(,7400,O
range,7400,O
32.1-1177.7,7400,O
),7400,O
mg/ml,7400,O
with,7400,O
terfenadine,7400,B-CHEMICAL
(,7400,O
P,7400,O
less,7400,O
than,7400,O
0.0001,7400,O
),7400,O
.,7400,O
This,7401,O
16.2-fold,7401,O
(,7401,O
range,7401,O
",",7401,O
5.5-47.9,7401,O
),7401,O
displacement,7401,O
to,7401,O
the,7401,O
right,7401,O
of,7401,O
the,7401,O
AMP,7401,B-CHEMICAL
concentration-response,7401,O
curve,7401,O
by,7401,O
a,7401,O
selective,7401,O
histamine-H1,7401,B-GENE-Y
receptor,7401,I-GENE-Y
antagonist,7401,O
emphasizes,7401,O
the,7401,O
central,7401,O
role,7401,O
of,7401,O
histamine,7401,B-CHEMICAL
in,7401,O
the,7401,O
airways,7401,O
response,7401,O
to,7401,O
this,7401,O
nucleotide,7401,O
.,7401,O
Ibrutinib,7402,B-CHEMICAL
:,7402,O
a,7402,O
review,7402,O
of,7402,O
its,7402,O
use,7402,O
in,7402,O
patients,7402,O
with,7402,O
mantle,7402,O
cell,7402,O
lymphoma,7402,O
or,7402,O
chronic,7402,O
lymphocytic,7402,O
leukaemia,7402,O
.,7402,O
Ibrutinib,7403,B-CHEMICAL
(,7403,O
Imbruvica,7403,B-CHEMICAL
(,7403,I-CHEMICAL
R,7403,I-CHEMICAL
),7403,I-CHEMICAL
),7403,O
is,7403,O
a,7403,O
first-in-class,7403,O
",",7403,O
potent,7403,O
",",7403,O
orally,7403,O
administered,7403,O
",",7403,O
covalent,7403,O
inhibitor,7403,O
of,7403,O
Bruton,7403,B-GENE-Y
's,7403,I-GENE-Y
tyrosine,7403,B-CHEMICAL
kinase,7403,I-GENE-Y
(,7403,O
BTK,7403,B-GENE-Y
),7403,O
that,7403,O
inhibits,7403,O
B-cell,7403,B-GENE-N
antigen,7403,I-GENE-N
receptor,7403,I-GENE-N
signalling,7403,O
downstream,7403,O
of,7403,O
BTK,7403,B-GENE-Y
.,7403,O
Oral,7404,O
ibrutinib,7404,B-CHEMICAL
is,7404,O
indicated,7404,O
for,7404,O
the,7404,O
treatment,7404,O
of,7404,O
patients,7404,O
with,7404,O
relapsed/refractory,7404,O
mantle,7404,O
cell,7404,O
lymphoma,7404,O
(,7404,O
MCL,7404,O
),7404,O
or,7404,O
chronic,7404,O
lymphocytic,7404,O
leukaemia,7404,O
(,7404,O
CLL,7404,O
),7404,O
and,7404,O
for,7404,O
the,7404,O
treatment,7404,O
of,7404,O
patients,7404,O
with,7404,O
CLL,7404,O
and,7404,O
a,7404,O
chromosome,7404,O
17,7404,O
deletion,7404,O
(,7404,O
del,7404,O
17p,7404,O
),7404,O
or,7404,O
TP53,7404,B-GENE-Y
mutation,7404,O
.,7404,O
This,7405,O
article,7405,O
summarizes,7405,O
pharmacological,7405,O
",",7405,O
efficacy,7405,O
and,7405,O
tolerability,7405,O
data,7405,O
relevant,7405,O
to,7405,O
the,7405,O
use,7405,O
of,7405,O
ibrutinib,7405,B-CHEMICAL
in,7405,O
these,7405,O
indications,7405,O
.,7405,O
In,7406,O
clinical,7406,O
studies,7406,O
",",7406,O
ibrutinib,7406,B-CHEMICAL
induced,7406,O
a,7406,O
high,7406,O
overall,7406,O
response,7406,O
rate,7406,O
in,7406,O
patients,7406,O
with,7406,O
relapsed/refractory,7406,O
MCL,7406,O
(,7406,O
phase,7406,O
II,7406,O
study,7406,O
),7406,O
.,7406,O
In,7407,O
addition,7407,O
",",7407,O
ibrutinib,7407,B-CHEMICAL
significantly,7407,O
prolonged,7407,O
progression-free,7407,O
survival,7407,O
and,7407,O
significantly,7407,O
improved,7407,O
the,7407,O
partial,7407,O
response,7407,O
rate,7407,O
and,7407,O
overall,7407,O
survival,7407,O
in,7407,O
patients,7407,O
with,7407,O
relapsed/refractory,7407,O
CLL,7407,O
(,7407,O
RESONATE,7407,O
study,7407,O
),7407,O
",",7407,O
including,7407,O
in,7407,O
those,7407,O
with,7407,O
del,7407,O
17p,7407,O
",",7407,O
a,7407,O
subgroup,7407,O
with,7407,O
a,7407,O
poor,7407,O
prognosis,7407,O
.,7407,O
Ibrutinib,7408,B-CHEMICAL
had,7408,O
an,7408,O
acceptable,7408,O
tolerability,7408,O
profile,7408,O
in,7408,O
these,7408,O
studies,7408,O
with,7408,O
<,7408,O
10,7408,O
%,7408,O
of,7408,O
patients,7408,O
discontinuing,7408,O
treatment,7408,O
because,7408,O
of,7408,O
adverse,7408,O
events,7408,O
.,7408,O
Given,7409,O
its,7409,O
efficacy,7409,O
and,7409,O
tolerability,7409,O
",",7409,O
once-daily,7409,O
",",7409,O
oral,7409,O
ibrutinib,7409,B-CHEMICAL
is,7409,O
an,7409,O
emerging,7409,O
treatment,7409,O
option,7409,O
for,7409,O
patients,7409,O
with,7409,O
relapsed/refractory,7409,O
MCL,7409,O
or,7409,O
CLL,7409,O
and,7409,O
CLL,7409,O
patients,7409,O
with,7409,O
del,7409,O
17p,7409,O
or,7409,O
TP53,7409,B-GENE-Y
mutation,7409,O
.,7409,O
Effects,7410,O
of,7410,O
beta-adrenoceptor,7410,B-GENE-N
antagonist,7410,O
administration,7410,O
on,7410,O
beta,7410,B-GENE-Y
2-adrenoceptor,7410,I-GENE-Y
density,7410,O
in,7410,O
human,7410,O
lymphocytes,7410,O
.,7410,O
The,7411,O
role,7411,O
of,7411,O
the,7411,O
``,7411,O
intrinsic,7411,O
sympathomimetic,7411,O
activity,7411,O
'',7411,O
.,7411,O
Abrupt,7412,O
withdrawal,7412,O
of,7412,O
beta-adrenoceptor,7412,B-GENE-N
antagonists,7412,O
may,7412,O
lead,7412,O
to,7412,O
``,7412,O
rebound-effects,7412,O
'',7412,O
.,7412,O
To,7413,O
study,7413,O
the,7413,O
mechanism,7413,O
underlying,7413,O
this,7413,O
phenomenon,7413,O
",",7413,O
the,7413,O
effects,7413,O
of,7413,O
the,7413,O
nonselective,7413,O
beta-adrenoceptor,7413,B-GENE-N
antagonists,7413,O
propranolol,7413,B-CHEMICAL
[,7413,O
no,7413,O
intrinsic,7413,O
sympathomimetic,7413,O
activity,7413,O
(,7413,O
ISA,7413,O
),7413,O
],7413,O
",",7413,O
alprenolol,7413,B-CHEMICAL
(,7413,O
weak,7413,O
ISA,7413,O
),7413,O
and,7413,O
mepindolol,7413,B-CHEMICAL
(,7413,O
strong,7413,O
ISA,7413,O
),7413,O
on,7413,O
lymphocyte,7413,O
beta,7413,B-GENE-Y
2-adrenoceptor,7413,I-GENE-Y
density,7413,O
--,7413,O
assessed,7413,O
by,7413,O
(,7413,B-CHEMICAL
+/-,7413,I-CHEMICAL
),7413,I-CHEMICAL
-,7413,I-CHEMICAL
[,7413,I-CHEMICAL
125I,7413,I-CHEMICAL
],7413,I-CHEMICAL
-iodocyanopindolol,7413,I-CHEMICAL
(,7413,O
ICYP,7413,B-CHEMICAL
),7413,O
binding,7413,O
--,7413,O
and,7413,O
plasma,7413,O
renin,7413,B-GENE-Y
activity,7413,O
(,7413,O
PRA,7413,O
),7413,O
were,7413,O
investigated,7413,O
in,7413,O
male,7413,O
healthy,7413,O
volunteers,7413,O
aged,7413,O
23-35,7413,O
years,7413,O
.,7413,O
Propranolol,7414,B-CHEMICAL
treatment,7414,O
(,7414,O
4,7414,O
X,7414,O
40,7414,O
mg/day,7414,O
),7414,O
increased,7414,O
the,7414,O
density,7414,O
of,7414,O
beta,7414,B-GENE-Y
2-adrenoceptors,7414,I-GENE-Y
by,7414,O
25,7414,O
%,7414,O
after,7414,O
2,7414,O
days,7414,O
;,7414,O
concomitantly,7414,O
PRA,7414,O
and,7414,O
heart,7414,O
rate,7414,O
were,7414,O
reduced,7414,O
.,7414,O
During,7415,O
treatment,7415,O
beta,7415,B-GENE-Y
2-adrenoceptor,7415,I-GENE-Y
density,7415,O
remained,7415,O
elevated,7415,O
.,7415,O
After,7416,O
withdrawal,7416,O
of,7416,O
propranolol,7416,B-CHEMICAL
PRA,7416,O
reached,7416,O
pre-drug,7416,O
levels,7416,O
rapidly,7416,O
",",7416,O
while,7416,O
heart,7416,O
rate,7416,O
was,7416,O
significantly,7416,O
enhanced,7416,O
.,7416,O
Beta,7417,B-GENE-Y
2-Adrenoceptor,7417,I-GENE-Y
density,7417,O
",",7417,O
however,7417,O
",",7417,O
declined,7417,O
slowly,7417,O
being,7417,O
still,7417,O
significantly,7417,O
increased,7417,O
after,7417,O
3,7417,O
days,7417,O
",",7417,O
although,7417,O
propranolol,7417,B-CHEMICAL
was,7417,O
not,7417,O
detectable,7417,O
in,7417,O
plasma,7417,O
after,7417,O
24,7417,O
h.,7417,O
The,7417,O
affinity,7417,O
of,7417,O
ICYP,7417,B-CHEMICAL
to,7417,O
beta,7417,B-GENE-Y
2-adrenoceptors,7417,I-GENE-Y
was,7417,O
not,7417,O
changed,7417,O
during,7417,O
or,7417,O
after,7417,O
treatment,7417,O
.,7417,O
Mepindolol,7418,B-CHEMICAL
treatment,7418,O
(,7418,O
2,7418,O
X,7418,O
5,7418,O
mg/day,7418,O
),7418,O
caused,7418,O
a,7418,O
30,7418,O
%,7418,O
decrease,7418,O
of,7418,O
beta,7418,B-GENE-Y
2-adrenoceptor,7418,I-GENE-Y
density,7418,O
and,7418,O
PRA,7418,O
after,7418,O
2,7418,O
days,7418,O
;,7418,O
both,7418,O
parameters,7418,O
remained,7418,O
reduced,7418,O
during,7418,O
treatment,7418,O
.,7418,O
After,7419,O
withdrawal,7419,O
",",7419,O
PRA,7419,O
reached,7419,O
rapidly,7419,O
pre-drug,7419,O
levels,7419,O
",",7419,O
whereas,7419,O
beta,7419,B-GENE-Y
2-adrenoceptor,7419,I-GENE-Y
density,7419,O
was,7419,O
still,7419,O
after,7419,O
4,7419,O
days,7419,O
significantly,7419,O
diminished,7419,O
.,7419,O
The,7420,O
KD-values,7420,O
for,7420,O
ICYP,7420,B-CHEMICAL
",",7420,O
however,7420,O
",",7420,O
were,7420,O
not,7420,O
changed,7420,O
.,7420,O
During,7421,O
and,7421,O
after,7421,O
treatment,7421,O
heart,7421,O
rate,7421,O
was,7421,O
not,7421,O
affected,7421,O
.,7421,O
Alprenolol,7422,B-CHEMICAL
treatment,7422,O
(,7422,O
4,7422,O
X,7422,O
100,7422,O
mg/day,7422,O
),7422,O
led,7422,O
to,7422,O
a,7422,O
rapid,7422,O
fall,7422,O
in,7422,O
PRA,7422,O
",",7422,O
but,7422,O
did,7422,O
not,7422,O
significantly,7422,O
affect,7422,O
beta,7422,B-GENE-Y
2-adrenoceptor,7422,I-GENE-Y
density,7422,O
.,7422,O
It,7423,O
is,7423,O
concluded,7423,O
",",7423,O
that,7423,O
the,7423,O
ISA,7423,O
may,7423,O
play,7423,O
an,7423,O
important,7423,O
role,7423,O
in,7423,O
modulating,7423,O
beta,7423,B-GENE-Y
2-adrenoceptor,7423,I-GENE-Y
density,7423,O
and,7423,O
hence,7423,O
tissue,7423,O
responsiveness,7423,O
to,7423,O
beta-adrenoceptor,7423,B-GENE-N
stimulation,7423,O
.,7423,O
(,7424,O
ABSTRACT,7424,O
TRUNCATED,7424,O
AT,7424,O
250,7424,O
WORDS,7424,O
),7424,O
Inhibition,7425,O
of,7425,O
5-lipoxygenase,7425,B-GENE-Y
pathway,7425,O
of,7425,O
arachidonic,7425,B-CHEMICAL
acid,7425,I-CHEMICAL
metabolism,7425,O
in,7425,O
human,7425,O
neutrophils,7425,O
by,7425,O
sulfasalazine,7425,B-CHEMICAL
and,7425,O
5-aminosalicylic,7425,B-CHEMICAL
acid,7425,I-CHEMICAL
.,7425,O
The,7426,O
possible,7426,O
effect,7426,O
of,7426,O
sulfasalazine,7426,B-CHEMICAL
",",7426,O
5-aminosalicylic,7426,B-CHEMICAL
acid,7426,I-CHEMICAL
",",7426,O
and,7426,O
acetyl-5-aminosalicylic,7426,B-CHEMICAL
acid,7426,I-CHEMICAL
on,7426,O
endogenous,7426,O
arachidonic,7426,B-CHEMICAL
acid,7426,I-CHEMICAL
release,7426,O
and,7426,O
metabolism,7426,O
was,7426,O
studied,7426,O
in,7426,O
human,7426,O
polymorphonuclear,7426,O
leukocytes,7426,O
(,7426,O
PMNs,7426,O
),7426,O
.,7426,O
A,7427,O
new,7427,O
in,7427,O
vitro,7427,O
assay,7427,O
was,7427,O
used,7427,O
by,7427,O
which,7427,O
[,7427,B-CHEMICAL
1-14C,7427,I-CHEMICAL
],7427,I-CHEMICAL
arachidonic,7427,I-CHEMICAL
acid,7427,I-CHEMICAL
is,7427,O
incorporated,7427,O
by,7427,O
purified,7427,O
peripheral,7427,O
PMNs,7427,O
until,7427,O
steady,7427,O
state,7427,O
was,7427,O
obtained,7427,O
(,7427,O
5,7427,O
hr,7427,O
),7427,O
.,7427,O
After,7428,O
preincubation,7428,O
with,7428,O
the,7428,O
test,7428,O
drugs,7428,O
prior,7428,O
to,7428,O
activation,7428,O
with,7428,O
calcium,7428,B-CHEMICAL
ionophore,7428,I-CHEMICAL
A23187,7428,I-CHEMICAL
",",7428,O
the,7428,O
released,7428,O
eicosanoids,7428,B-CHEMICAL
were,7428,O
isolated,7428,O
by,7428,O
extraction,7428,O
and,7428,O
thin-layer,7428,O
chromatography,7428,O
(,7428,O
TLC,7428,O
),7428,O
and,7428,O
quantitated,7428,O
by,7428,O
autoradiography,7428,O
and,7428,O
laser,7428,O
densitometry,7428,O
.,7428,O
Median,7429,O
drug,7429,O
concentrations,7429,O
needed,7429,O
for,7429,O
50,7429,O
%,7429,O
inhibition,7429,O
of,7429,O
leukotriene,7429,B-CHEMICAL
B4,7429,I-CHEMICAL
and,7429,O
5-hydroxyeicosatetraenoic,7429,B-CHEMICAL
acid,7429,I-CHEMICAL
(,7429,O
5-HETE,7429,B-CHEMICAL
),7429,O
release,7429,O
was,7429,O
4-5,7429,O
mM,7429,O
(,7429,O
range,7429,O
1-9,7429,O
mM,7429,O
),7429,O
for,7429,O
both,7429,O
sulfasalazine,7429,B-CHEMICAL
and,7429,O
5-aminosalicylic,7429,B-CHEMICAL
acid,7429,I-CHEMICAL
.,7429,O
The,7430,O
acetylated,7430,B-CHEMICAL
derivative,7430,I-CHEMICAL
of,7430,I-CHEMICAL
5-aminosalicylic,7430,I-CHEMICAL
acid,7430,I-CHEMICAL
was,7430,O
ineffective,7430,O
.,7430,O
The,7431,O
present,7431,O
data,7431,O
suggest,7431,O
that,7431,O
inhibition,7431,O
of,7431,O
arachidonic,7431,B-CHEMICAL
acid,7431,I-CHEMICAL
lipoxygenation,7431,O
may,7431,O
be,7431,O
an,7431,O
essential,7431,O
action,7431,O
of,7431,O
sulfasalazine,7431,B-CHEMICAL
and,7431,O
its,7431,O
active,7431,O
metabolite,7431,O
",",7431,O
5-aminosalicylic,7431,B-CHEMICAL
acid,7431,I-CHEMICAL
.,7431,O
Interference,7432,O
with,7432,O
lipoxygenase,7432,B-GENE-N
enzymes,7432,O
",",7432,O
rather,7432,O
than,7432,O
a,7432,O
steroid-like,7432,B-CHEMICAL
inhibition,7432,O
of,7432,O
arachidonic,7432,B-CHEMICAL
acid,7432,I-CHEMICAL
release,7432,O
from,7432,O
intracellular,7432,O
phospholipids,7432,O
",",7432,O
seems,7432,O
to,7432,O
be,7432,O
the,7432,O
mode,7432,O
of,7432,O
action,7432,O
.,7432,O
Bevantolol,7433,B-CHEMICAL
:,7433,O
a,7433,O
beta-1,7433,B-GENE-Y
adrenoceptor,7433,I-GENE-Y
antagonist,7433,O
with,7433,O
unique,7433,O
additional,7433,O
actions,7433,O
.,7433,O
UNLABELLED,7434,O
:,7434,O
Bevantolol,7434,B-CHEMICAL
is,7434,O
a,7434,O
beta-1,7434,B-GENE-Y
adrenoceptor,7434,I-GENE-Y
antagonist,7434,O
that,7434,O
has,7434,O
been,7434,O
shown,7434,O
to,7434,O
be,7434,O
as,7434,O
effective,7434,O
as,7434,O
other,7434,O
beta,7434,O
blockers,7434,O
for,7434,O
the,7434,O
treatment,7434,O
of,7434,O
angina,7434,O
pectoris,7434,O
and,7434,O
hypertension,7434,O
.,7434,O
Some,7435,O
interesting,7435,O
additional,7435,O
properties,7435,O
",",7435,O
such,7435,O
as,7435,O
the,7435,O
absence,7435,O
of,7435,O
the,7435,O
side,7435,O
effect,7435,O
of,7435,O
cold,7435,O
extremities,7435,O
",",7435,O
required,7435,O
investigation,7435,O
",",7435,O
and,7435,O
a,7435,O
great,7435,O
deal,7435,O
of,7435,O
new,7435,O
evidence,7435,O
has,7435,O
been,7435,O
accumulated,7435,O
during,7435,O
the,7435,O
last,7435,O
three,7435,O
years,7435,O
.,7435,O
This,7436,O
new,7436,O
data,7436,O
is,7436,O
consistent,7436,O
with,7436,O
the,7436,O
proposal,7436,O
put,7436,O
forward,7436,O
a,7436,O
couple,7436,O
of,7436,O
years,7436,O
ago,7436,O
that,7436,O
bevantolol,7436,O
interacts,7436,O
with,7436,O
alpha-adrenoceptors,7436,B-GENE-N
.,7436,O
All,7437,O
the,7437,O
available,7437,O
evidence,7437,O
",",7437,O
published,7437,O
and,7437,O
unpublished,7437,O
",",7437,O
has,7437,O
been,7437,O
reviewed,7437,O
and,7437,O
fits,7437,O
into,7437,O
a,7437,O
coherent,7437,O
pattern,7437,O
",",7437,O
here,7437,O
arranged,7437,O
into,7437,O
five,7437,O
sections,7437,O
.,7437,O
Chemistry,7438,O
:,7438,O
affinity,7438,O
for,7438,O
alpha-adrenoceptors,7438,B-GENE-N
.,7438,O
Animal,7439,O
experiments,7439,O
confirm,7439,O
both,7439,O
agonist,7439,O
and,7439,O
antagonist,7439,O
effects,7439,O
on,7439,O
alpha-receptors,7439,O
",",7439,O
in,7439,O
addition,7439,O
to,7439,O
antagonist,7439,O
activity,7439,O
at,7439,O
beta-1,7439,B-GENE-N
receptors,7439,I-GENE-N
.,7439,O
In,7440,O
addition,7440,O
",",7440,O
bevantolol,7440,B-CHEMICAL
has,7440,O
electrophysiologic,7440,O
effects,7440,O
",",7440,O
including,7440,O
bradycardia,7440,O
by,7440,O
a,7440,O
direct,7440,O
action,7440,O
on,7440,O
the,7440,O
sinus,7440,O
node,7440,O
and,7440,O
a,7440,O
class,7440,O
1,7440,O
antiarrhythmic,7440,O
action,7440,O
.,7440,O
Investigations,7441,O
in,7441,O
humans,7441,O
have,7441,O
shown,7441,O
that,7441,O
although,7441,O
bevantolol,7441,B-CHEMICAL
has,7441,O
a,7441,O
short,7441,O
half-life,7441,O
",",7441,O
good,7441,O
control,7441,O
of,7441,O
hypertension,7441,O
can,7441,O
be,7441,O
achieved,7441,O
on,7441,O
once-a-day,7441,O
dosing,7441,O
.,7441,O
SAFETY,7442,O
:,7442,O
bevantolol,7442,B-CHEMICAL
has,7442,O
remarkably,7442,O
few,7442,O
side,7442,O
effects,7442,O
",",7442,O
does,7442,O
not,7442,O
cause,7442,O
cold,7442,O
extremities,7442,O
",",7442,O
and,7442,O
does,7442,O
not,7442,O
significantly,7442,O
affect,7442,O
glomerular,7442,O
filtration,7442,O
rate,7442,O
in,7442,O
patients,7442,O
with,7442,O
renal,7442,O
impairment,7442,O
.,7442,O
Evidence,7443,O
has,7443,O
been,7443,O
obtained,7443,O
in,7443,O
man,7443,O
for,7443,O
interaction,7443,O
with,7443,O
alpha-adrenoceptors,7443,B-GENE-N
in,7443,O
the,7443,O
brain,7443,O
;,7443,O
and,7443,O
in,7443,O
the,7443,O
peripheral,7443,O
circulation,7443,O
bevantolol,7443,B-CHEMICAL
does,7443,O
not,7443,O
",",7443,O
as,7443,O
do,7443,O
other,7443,O
beta,7443,O
blockers,7443,O
",",7443,O
increase,7443,O
peripheral,7443,O
vascular,7443,O
resistance,7443,O
",",7443,O
but,7443,O
reduces,7443,O
it,7443,O
.,7443,O
It,7444,O
is,7444,O
suggested,7444,O
that,7444,O
all,7444,O
the,7444,O
additional,7444,O
actions,7444,O
of,7444,O
bevantolol,7444,B-CHEMICAL
can,7444,O
be,7444,O
attributed,7444,O
to,7444,O
a,7444,O
partial,7444,O
agonist,7444,O
action,7444,O
on,7444,O
alpha-adrenoceptors,7444,B-GENE-N
.,7444,O
Benzodiazepine,7445,B-GENE-N
receptor,7445,I-GENE-N
binding,7445,O
of,7445,O
triazolobenzodiazepines,7445,B-CHEMICAL
in,7445,O
vivo,7445,O
:,7445,O
increased,7445,O
receptor,7445,O
number,7445,O
with,7445,O
low-dose,7445,O
alprazolam,7445,B-CHEMICAL
.,7445,O
Triazolobenzodiazepines,7446,B-CHEMICAL
are,7446,O
in,7446,O
clinical,7446,O
use,7446,O
as,7446,O
hypnotics,7446,O
and,7446,O
anxiolytics,7446,O
.,7446,O
We,7447,O
analyzed,7447,O
in,7447,O
vivo,7447,O
receptor,7447,O
binding,7447,O
and,7447,O
brain,7447,O
concentrations,7447,O
of,7447,O
alprazolam,7447,B-CHEMICAL
",",7447,O
triazolam,7447,B-CHEMICAL
",",7447,O
and,7447,O
estazolam,7447,B-CHEMICAL
.,7447,O
Drug,7448,O
concentrations,7448,O
measured,7448,O
in,7448,O
the,7448,O
cerebral,7448,O
cortex,7448,O
1,7448,O
h,7448,O
after,7448,O
administration,7448,O
were,7448,O
directly,7448,O
proportional,7448,O
to,7448,O
dose,7448,O
for,7448,O
all,7448,O
three,7448,O
compounds,7448,O
.,7448,O
In,7449,O
vivo,7449,O
receptor,7449,O
binding,7449,O
",",7449,O
as,7449,O
defined,7449,O
by,7449,O
the,7449,O
specific,7449,O
uptake,7449,O
of,7449,O
[,7449,B-CHEMICAL
3H,7449,I-CHEMICAL
],7449,I-CHEMICAL
Ro15-1788,7449,I-CHEMICAL
",",7449,O
decreased,7449,O
with,7449,O
increasing,7449,O
doses,7449,O
of,7449,O
estazolam,7449,B-CHEMICAL
and,7449,O
triazolam,7449,B-CHEMICAL
",",7449,O
a,7449,O
finding,7449,O
indicating,7449,O
dose-related,7449,O
increases,7449,O
in,7449,O
receptor,7449,O
occupancy,7449,O
due,7449,O
to,7449,O
these,7449,O
compounds,7449,O
.,7449,O
Triazolam,7450,B-CHEMICAL
was,7450,O
substantially,7450,O
more,7450,O
potent,7450,O
",",7450,O
with,7450,O
an,7450,O
IC50,7450,O
value,7450,O
of,7450,O
16,7450,O
ng/g,7450,O
",",7450,O
compared,7450,O
with,7450,O
117,7450,O
ng/g,7450,O
for,7450,O
estazolam,7450,B-CHEMICAL
.,7450,O
At,7451,O
higher,7451,O
doses,7451,O
of,7451,O
alprazolam,7451,B-CHEMICAL
(,7451,O
greater,7451,O
than,7451,O
0.2,7451,O
mg/kg,7451,O
),7451,O
",",7451,O
receptor,7451,O
binding,7451,O
by,7451,O
[,7451,B-CHEMICAL
3H,7451,I-CHEMICAL
],7451,I-CHEMICAL
Ro15-1788,7451,I-CHEMICAL
",",7451,O
likewise,7451,O
decreased,7451,O
with,7451,O
increasing,7451,O
dose,7451,O
of,7451,O
the,7451,O
former,7451,O
drug,7451,O
.,7451,O
However,7452,O
",",7452,O
at,7452,O
lower,7452,O
doses,7452,O
of,7452,O
alprazolam,7452,B-CHEMICAL
(,7452,O
0.02-0.05,7452,O
mg/kg,7452,O
),7452,O
",",7452,O
which,7452,O
resulted,7452,O
in,7452,O
cortex,7452,O
concentrations,7452,O
of,7452,O
2-7,7452,O
ng/g,7452,O
",",7452,O
receptor,7452,O
binding,7452,O
was,7452,O
increased,7452,O
above,7452,O
control,7452,O
values,7452,O
in,7452,O
cortex,7452,O
",",7452,O
hypothalamus,7452,O
",",7452,O
and,7452,O
hippocampus,7452,O
but,7452,O
not,7452,O
in,7452,O
several,7452,O
other,7452,O
brain,7452,O
regions,7452,O
.,7452,O
Binding,7453,O
returned,7453,O
to,7453,O
control,7453,O
values,7453,O
at,7453,O
doses,7453,O
of,7453,O
greater,7453,O
than,7453,O
or,7453,O
equal,7453,O
to,7453,O
0.01,7453,O
mg/kg,7453,O
.,7453,O
Similar,7454,O
results,7454,O
were,7454,O
obtained,7454,O
in,7454,O
time,7454,O
course,7454,O
studies,7454,O
.,7454,O
At,7455,O
8,7455,O
and,7455,O
10,7455,O
h,7455,O
after,7455,O
a,7455,O
dose,7455,O
of,7455,O
1,7455,O
mg/kg,7455,O
i.p.,7455,O
",",7455,O
corresponding,7455,O
to,7455,O
cortex,7455,O
concentrations,7455,O
of,7455,O
2.7-7,7455,O
ng/g,7455,O
",",7455,O
receptor,7455,O
binding,7455,O
was,7455,O
increased,7455,O
compared,7455,O
with,7455,O
controls,7455,O
.,7455,O
Similarly,7456,O
",",7456,O
at,7456,O
1,7456,O
",",7456,O
2,7456,O
",",7456,O
and,7456,O
3,7456,O
h,7456,O
after,7456,O
a,7456,O
single,7456,O
dose,7456,O
of,7456,O
0.05,7456,O
mg/kg,7456,O
",",7456,O
corresponding,7456,O
to,7456,O
cortex,7456,O
concentrations,7456,O
of,7456,O
3.7-5.8,7456,O
ng/g,7456,O
",",7456,O
receptor,7456,O
binding,7456,O
was,7456,O
also,7456,O
increased,7456,O
.,7456,O
The,7457,O
apparent,7457,O
affinity,7457,O
of,7457,O
benzodiazepine,7457,B-CHEMICAL
receptors,7457,I-GENE-N
for,7457,O
clonazepam,7457,B-CHEMICAL
in,7457,O
mice,7457,O
receiving,7457,O
alprazolam,7457,B-CHEMICAL
(,7457,O
0.05,7457,O
mg/kg,7457,O
),7457,O
was,7457,O
unchanged,7457,O
from,7457,O
that,7457,O
in,7457,O
untreated,7457,O
control,7457,O
mice,7457,O
",",7457,O
an,7457,O
observation,7457,O
suggesting,7457,O
that,7457,O
low,7457,O
doses,7457,O
of,7457,O
alprazolam,7457,B-CHEMICAL
increased,7457,O
receptor,7457,O
number,7457,O
.,7457,O
(,7458,O
ABSTRACT,7458,O
TRUNCATED,7458,O
AT,7458,O
250,7458,O
WORDS,7458,O
),7458,O
Muscarinic,7459,O
cholinergic,7459,O
and,7459,O
histamine,7459,B-GENE-Y
H1,7459,I-GENE-Y
receptor,7459,I-GENE-Y
binding,7459,O
of,7459,O
phenothiazine,7459,B-CHEMICAL
drug,7459,O
metabolites,7459,O
.,7459,O
In,7460,O
vitro,7460,O
binding,7460,O
affinities,7460,O
of,7460,O
chlorpromazine,7460,B-CHEMICAL
",",7460,O
fluphenazine,7460,B-CHEMICAL
",",7460,O
levomepromazine,7460,B-CHEMICAL
",",7460,O
perphenazine,7460,B-CHEMICAL
and,7460,O
some,7460,O
of,7460,O
their,7460,O
metabolites,7460,O
for,7460,O
dopamine,7460,B-CHEMICAL
D2,7460,I-GENE-Y
receptors,7460,I-GENE-Y
",",7460,O
alpha,7460,B-GENE-N
1-,7460,I-GENE-N
and,7460,I-GENE-N
alpha,7460,I-GENE-N
2,7460,I-GENE-N
adrenoceptors,7460,I-GENE-N
in,7460,O
rat,7460,O
brain,7460,O
were,7460,O
previously,7460,O
reported,7460,O
from,7460,O
our,7460,O
laboratories,7460,O
.,7460,O
The,7461,O
present,7461,O
study,7461,O
reports,7461,O
the,7461,O
in,7461,O
vitro,7461,O
binding,7461,O
affinities,7461,O
of,7461,O
the,7461,O
same,7461,O
compounds,7461,O
for,7461,O
muscarinic,7461,B-GENE-N
cholinergic,7461,I-GENE-N
receptors,7461,I-GENE-N
and,7461,O
for,7461,O
histamine,7461,B-CHEMICAL
H1,7461,I-GENE-Y
receptors,7461,I-GENE-Y
in,7461,O
rat,7461,O
brain,7461,O
",",7461,O
using,7461,O
3H-quinuclidinyl,7461,B-CHEMICAL
benzilate,7461,I-CHEMICAL
and,7461,O
3H-mepyramine,7461,B-CHEMICAL
as,7461,O
radioligands,7461,O
.,7461,O
Chlorpromazine,7462,B-CHEMICAL
",",7462,O
levomepromazine,7462,B-CHEMICAL
",",7462,O
and,7462,O
their,7462,O
metabolites,7462,O
had,7462,O
5-30,7462,O
times,7462,O
higher,7462,O
binding,7462,O
affinities,7462,O
for,7462,O
muscarinic,7462,B-GENE-N
cholinergic,7462,I-GENE-N
receptors,7462,I-GENE-N
than,7462,O
fluphenazine,7462,B-CHEMICAL
",",7462,O
perphenazine,7462,B-CHEMICAL
and,7462,O
their,7462,O
metabolites,7462,O
.,7462,O
Levomepromazine,7463,B-CHEMICAL
was,7463,O
the,7463,O
most,7463,O
potent,7463,O
and,7463,O
fluphenazine,7463,B-CHEMICAL
the,7463,O
least,7463,O
potent,7463,O
of,7463,O
the,7463,O
four,7463,O
drugs,7463,O
in,7463,O
histamine,7463,B-GENE-Y
H1,7463,I-GENE-Y
receptor,7463,I-GENE-Y
binding,7463,O
.,7463,O
7-Hydroxy,7464,B-CHEMICAL
levomepromazine,7464,I-CHEMICAL
",",7464,O
3-hydroxy,7464,B-CHEMICAL
levomepromazine,7464,I-CHEMICAL
and,7464,O
7-hydroxy,7464,B-CHEMICAL
fluphenazine,7464,I-CHEMICAL
had,7464,O
only,7464,O
10,7464,O
%,7464,O
of,7464,O
the,7464,O
potency,7464,O
of,7464,O
the,7464,O
parent,7464,O
drug,7464,O
in,7464,O
histamine,7464,B-GENE-Y
H1,7464,I-GENE-Y
receptor,7464,I-GENE-Y
binding,7464,O
",",7464,O
while,7464,O
the,7464,O
7-hydroxy-metabolites,7464,B-CHEMICAL
of,7464,O
chlorpromazine,7464,B-CHEMICAL
and,7464,O
perphenazine,7464,B-CHEMICAL
had,7464,O
about,7464,O
75,7464,O
%,7464,O
of,7464,O
the,7464,O
potency,7464,O
of,7464,O
the,7464,O
parent,7464,O
drug,7464,O
in,7464,O
this,7464,O
binding,7464,O
system,7464,O
.,7464,O
Their,7465,O
histamine,7465,B-GENE-Y
H1,7465,I-GENE-Y
receptor,7465,I-GENE-Y
binding,7465,O
affinities,7465,O
indicate,7465,O
that,7465,O
metabolites,7465,O
may,7465,O
contribute,7465,O
to,7465,O
the,7465,O
sedative,7465,O
effects,7465,O
of,7465,O
chlorpromazine,7465,B-CHEMICAL
and,7465,O
levomepromazine,7465,B-CHEMICAL
.,7465,O
Retinoid-induced,7466,B-CHEMICAL
hemorrhaging,7466,O
and,7466,O
bone,7466,O
toxicity,7466,O
in,7466,O
rats,7466,O
fed,7466,O
diets,7466,O
deficient,7466,O
in,7466,O
vitamin,7466,B-CHEMICAL
K.,7466,O
The,7466,O
recent,7466,O
increase,7466,O
in,7466,O
the,7466,O
clinical,7466,O
use,7466,O
of,7466,O
synthetic,7466,O
vitamin,7466,B-CHEMICAL
A,7466,I-CHEMICAL
compounds,7466,O
has,7466,O
led,7466,O
to,7466,O
concern,7466,O
of,7466,O
possible,7466,O
side,7466,O
effects,7466,O
.,7466,O
Some,7467,O
of,7467,O
these,7467,O
effects,7467,O
are,7467,O
known,7467,O
to,7467,O
be,7467,O
influenced,7467,O
by,7467,O
dietary,7467,O
levels,7467,O
of,7467,O
vitamin,7467,B-CHEMICAL
K.,7467,O
We,7467,O
therefore,7467,O
compared,7467,O
the,7467,O
toxic,7467,O
effects,7467,O
of,7467,O
13-cis-retinoic,7467,B-CHEMICAL
acid,7467,I-CHEMICAL
(,7467,O
13cisRA,7467,B-CHEMICAL
),7467,O
",",7467,O
retinyl,7467,B-CHEMICAL
acetate,7467,I-CHEMICAL
(,7467,O
ROAc,7467,B-CHEMICAL
),7467,O
",",7467,O
and,7467,O
N-,7467,B-CHEMICAL
(,7467,I-CHEMICAL
4-hydroxyphenyl,7467,I-CHEMICAL
),7467,I-CHEMICAL
retinamide,7467,I-CHEMICAL
(,7467,O
4HPR,7467,B-CHEMICAL
),7467,O
in,7467,O
male,7467,O
Sprague-Dawley,7467,O
rats,7467,O
maintained,7467,O
on,7467,O
diets,7467,O
containing,7467,O
different,7467,O
levels,7467,O
of,7467,O
vitamin,7467,B-CHEMICAL
K.,7467,O
Animals,7467,O
were,7467,O
fed,7467,O
either,7467,O
an,7467,O
NIH-07,7467,O
diet,7467,O
supplemented,7467,O
with,7467,O
menadione,7467,B-CHEMICAL
(,7467,O
3.1,7467,O
ppm,7467,O
vitamin,7467,B-CHEMICAL
K3,7467,I-CHEMICAL
),7467,O
",",7467,O
an,7467,O
NIH-07,7467,O
diet,7467,O
not,7467,O
supplemented,7467,O
with,7467,O
menadione,7467,B-CHEMICAL
",",7467,O
or,7467,O
an,7467,O
AIN-076,7467,O
purified,7467,O
diet,7467,O
devoid,7467,O
of,7467,O
vitamin,7467,B-CHEMICAL
K.,7467,O
The,7467,O
retinoids,7467,B-CHEMICAL
had,7467,O
no,7467,O
effect,7467,O
on,7467,O
prothrombin,7467,B-GENE-Y
times,7467,O
of,7467,O
animals,7467,O
fed,7467,O
the,7467,O
supplemented,7467,O
diet,7467,O
.,7467,O
When,7468,O
menadione,7468,B-CHEMICAL
was,7468,O
omitted,7468,O
from,7468,O
the,7468,O
diet,7468,O
",",7468,O
however,7468,O
",",7468,O
4HPR-dosed,7468,B-CHEMICAL
animals,7468,O
had,7468,O
elevated,7468,O
prothrombin,7468,B-GENE-Y
times,7468,O
.,7468,O
This,7469,O
effect,7469,O
was,7469,O
observed,7469,O
as,7469,O
early,7469,O
as,7469,O
Day,7469,O
7,7469,O
and,7469,O
was,7469,O
accompanied,7469,O
by,7469,O
one,7469,O
confirmed,7469,O
hemorrhagic,7469,O
death,7469,O
.,7469,O
13cisRA-dosed,7470,B-CHEMICAL
animals,7470,O
showed,7470,O
no,7470,O
change,7470,O
in,7470,O
prothrombin,7470,B-GENE-Y
times,7470,O
.,7470,O
In,7471,O
the,7471,O
high-dose,7471,O
ROAc,7471,B-CHEMICAL
group,7471,O
",",7471,O
there,7471,O
was,7471,O
a,7471,O
twofold,7471,O
increase,7471,O
in,7471,O
prothrombin,7471,B-GENE-Y
times,7471,O
but,7471,O
only,7471,O
after,7471,O
prolonged,7471,O
dosing,7471,O
.,7471,O
In,7472,O
animals,7472,O
fed,7472,O
the,7472,O
NIH-07,7472,O
diets,7472,O
",",7472,O
13cisRA,7472,B-CHEMICAL
and,7472,O
ROAc,7472,B-CHEMICAL
induced,7472,O
multiple,7472,O
bone,7472,O
fractures,7472,O
at,7472,O
all,7472,O
dose,7472,O
levels,7472,O
.,7472,O
In,7473,O
contrast,7473,O
",",7473,O
4HPR,7473,B-CHEMICAL
administered,7473,O
at,7473,O
the,7473,O
highest,7473,O
dose,7473,O
induced,7473,O
only,7473,O
one,7473,O
fracture,7473,O
in,7473,O
one,7473,O
animal,7473,O
.,7473,O
Animals,7474,O
fed,7474,O
the,7474,O
purified,7474,O
diet,7474,O
lost,7474,O
weight,7474,O
faster,7474,O
and,7474,O
diet,7474,O
sooner,7474,O
than,7474,O
those,7474,O
maintained,7474,O
on,7474,O
the,7474,O
other,7474,O
diets,7474,O
.,7474,O
Bone,7475,O
fractures,7475,O
were,7475,O
not,7475,O
observed,7475,O
in,7475,O
these,7475,O
animals,7475,O
because,7475,O
of,7475,O
early,7475,O
deaths,7475,O
resulting,7475,O
from,7475,O
hemorrhaging,7475,O
.,7475,O
For,7476,O
all,7476,O
retinoid-dosed,7476,B-CHEMICAL
groups,7476,O
maintained,7476,O
on,7476,O
the,7476,O
purified,7476,O
diet,7476,O
",",7476,O
changes,7476,O
in,7476,O
prothrombin,7476,B-GENE-Y
times,7476,O
occured,7476,O
as,7476,O
early,7476,O
as,7476,O
1,7476,O
week,7476,O
.,7476,O
The,7477,O
order,7477,O
of,7477,O
effect,7477,O
was,7477,O
4HPR,7477,B-CHEMICAL
greater,7477,O
than,7477,O
ROAc,7477,B-CHEMICAL
greater,7477,O
than,7477,O
13cisRA,7477,B-CHEMICAL
",",7477,O
with,7477,O
increases,7477,O
in,7477,O
prothrombin,7477,B-GENE-Y
times,7477,O
correlating,7477,O
with,7477,O
increases,7477,O
in,7477,O
hemorrhagic,7477,O
deaths,7477,O
.,7477,O
Hence,7478,O
",",7478,O
the,7478,O
degree,7478,O
of,7478,O
retinoid-induced,7478,B-CHEMICAL
hemorrhage,7478,O
",",7478,O
but,7478,O
not,7478,O
the,7478,O
incidence,7478,O
of,7478,O
bone,7478,O
fractures,7478,O
",",7478,O
was,7478,O
inversely,7478,O
related,7478,O
to,7478,O
vitamin,7478,B-CHEMICAL
K,7478,I-CHEMICAL
levels,7478,O
in,7478,O
the,7478,O
diet,7478,O
.,7478,O
13cisRA,7479,B-CHEMICAL
and,7479,O
ROAc,7479,B-CHEMICAL
",",7479,O
but,7479,O
not,7479,O
4HPR,7479,B-CHEMICAL
",",7479,O
caused,7479,O
a,7479,O
dose-dependent,7479,O
reduction,7479,O
in,7479,O
plasma,7479,O
osteocalcin,7479,B-GENE-Y
",",7479,O
an,7479,O
effect,7479,O
that,7479,O
correlated,7479,O
with,7479,O
retinoid-induced,7479,B-CHEMICAL
bone,7479,O
effects,7479,O
.,7479,O
In,7480,O
contrast,7480,O
",",7480,O
serum,7480,O
alkaline,7480,B-GENE-N
phosphatase,7480,I-GENE-N
was,7480,O
elevated,7480,O
in,7480,O
animals,7480,O
dosed,7480,O
with,7480,O
13cisRA,7480,B-CHEMICAL
or,7480,O
4HPR,7480,B-CHEMICAL
but,7480,O
not,7480,O
in,7480,O
those,7480,O
dose,7480,O
with,7480,O
ROAc,7480,B-CHEMICAL
.,7480,O
For,7481,O
this,7481,O
enzyme,7481,O
",",7481,O
the,7481,O
electrophoretic,7481,O
pattern,7481,O
on,7481,O
agarose,7481,O
gel,7481,O
showed,7481,O
a,7481,O
decrease,7481,O
",",7481,O
compared,7481,O
to,7481,O
controls,7481,O
",",7481,O
in,7481,O
the,7481,O
major,7481,O
isozyme,7481,O
in,7481,O
serum,7481,O
of,7481,O
ROAc-dosed,7481,B-CHEMICAL
animals,7481,O
.,7481,O
Hence,7482,O
",",7482,O
plasma,7482,O
osteocalcin,7482,B-GENE-Y
is,7482,O
a,7482,O
better,7482,O
predictor,7482,O
of,7482,O
retinoid-induced,7482,B-CHEMICAL
bone,7482,O
effects,7482,O
than,7482,O
serum,7482,O
alkaline,7482,B-GENE-N
phosphatase,7482,I-GENE-N
.,7482,O
Multiple,7483,O
affinity,7483,O
states,7483,O
of,7483,O
opiate,7483,B-GENE-N
receptor,7483,I-GENE-N
in,7483,O
neuroblastoma,7483,O
x,7483,O
glioma,7483,O
NG108-15,7483,O
hybrid,7483,O
cells,7483,O
.,7483,O
Opiate,7484,O
agonist,7484,O
association,7484,O
rate,7484,O
is,7484,O
a,7484,O
function,7484,O
of,7484,O
receptor,7484,O
occupancy,7484,O
.,7484,O
The,7485,O
existence,7485,O
of,7485,O
multiple,7485,O
affinity,7485,O
states,7485,O
for,7485,O
the,7485,O
opiate,7485,O
receptor,7485,O
in,7485,O
neuroblastoma,7485,O
x,7485,O
glioma,7485,O
NG108-15,7485,O
hybrid,7485,O
cells,7485,O
has,7485,O
been,7485,O
demonstrated,7485,O
by,7485,O
competition,7485,O
binding,7485,O
studies,7485,O
with,7485,O
tritiated,7485,B-CHEMICAL
diprenorphine,7485,I-CHEMICAL
and,7485,O
[,7485,B-CHEMICAL
D-Ala2,7485,I-CHEMICAL
",",7485,I-CHEMICAL
D-Leu5,7485,I-CHEMICAL
],7485,I-CHEMICAL
enkephalin,7485,B-GENE-N
(,7485,O
DADLE,7485,B-CHEMICAL
),7485,O
.,7485,O
In,7486,O
the,7486,O
presence,7486,O
of,7486,O
10,7486,O
mM,7486,O
Mg2+,7486,B-CHEMICAL
",",7486,O
all,7486,O
receptors,7486,O
exist,7486,O
in,7486,O
a,7486,O
high,7486,O
affinity,7486,O
state,7486,O
with,7486,O
Kd,7486,O
=,7486,O
1.88,7486,O
+/-,7486,O
0.16,7486,O
nM,7486,O
.,7486,O
Addition,7487,O
of,7487,O
10,7487,O
microM,7487,O
guanyl-5'-yl,7487,B-CHEMICAL
imidodiphosphate,7487,I-CHEMICAL
(,7487,O
Gpp,7487,B-CHEMICAL
(,7487,I-CHEMICAL
NH,7487,I-CHEMICAL
),7487,I-CHEMICAL
p,7487,I-CHEMICAL
),7487,O
decreased,7487,O
the,7487,O
affinity,7487,O
of,7487,O
DADLE,7487,B-CHEMICAL
to,7487,O
Kd,7487,O
=,7487,O
8.08,7487,O
+/-,7487,O
0.93,7487,O
nM,7487,O
.,7487,O
However,7488,O
",",7488,O
in,7488,O
the,7488,O
presence,7488,O
of,7488,O
100,7488,O
mM,7488,O
Na+,7488,B-CHEMICAL
",",7488,O
which,7488,O
is,7488,O
required,7488,O
for,7488,O
opiate,7488,O
inhibition,7488,O
of,7488,O
adenylate,7488,B-GENE-N
cyclase,7488,I-GENE-N
activity,7488,O
",",7488,O
analysis,7488,O
of,7488,O
competition,7488,O
binding,7488,O
data,7488,O
revealed,7488,O
three,7488,O
sites,7488,O
:,7488,O
the,7488,O
first,7488,O
",",7488,O
consisting,7488,O
of,7488,O
17.5,7488,O
%,7488,O
of,7488,O
total,7488,O
receptor,7488,O
population,7488,O
has,7488,O
a,7488,O
Kd,7488,O
=,7488,O
0.38,7488,O
+/-,7488,O
0.18,7488,O
nM,7488,O
;,7488,O
the,7488,O
second,7488,O
",",7488,O
50.6,7488,O
%,7488,O
of,7488,O
the,7488,O
population,7488,O
",",7488,O
has,7488,O
a,7488,O
Kd,7488,O
=,7488,O
6.8,7488,O
+/-,7488,O
2.2,7488,O
nM,7488,O
;,7488,O
and,7488,O
the,7488,O
third,7488,O
",",7488,O
31.9,7488,O
%,7488,O
of,7488,O
the,7488,O
population,7488,O
",",7488,O
has,7488,O
a,7488,O
Kd,7488,O
of,7488,O
410,7488,O
+/-,7488,O
110,7488,O
nM,7488,O
.,7488,O
Thus,7489,O
",",7489,O
in,7489,O
the,7489,O
presence,7489,O
of,7489,O
sodium,7489,B-CHEMICAL
",",7489,O
a,7489,O
high,7489,O
affinity,7489,O
complex,7489,O
between,7489,O
receptor,7489,O
(,7489,O
R,7489,O
),7489,O
",",7489,O
GTP,7489,B-CHEMICAL
binding,7489,O
component,7489,O
(,7489,O
Ni,7489,O
),7489,O
",",7489,O
and,7489,O
ligand,7489,O
(,7489,O
L,7489,O
),7489,O
was,7489,O
formed,7489,O
which,7489,O
was,7489,O
different,7489,O
from,7489,O
that,7489,O
formed,7489,O
in,7489,O
the,7489,O
absence,7489,O
of,7489,O
sodium,7489,B-CHEMICAL
.,7489,O
These,7490,O
multiple,7490,O
affinity,7490,O
states,7490,O
of,7490,O
receptor,7490,O
in,7490,O
the,7490,O
hybrid,7490,O
cells,7490,O
are,7490,O
agonist-specific,7490,O
",",7490,O
and,7490,O
the,7490,O
percentage,7490,O
of,7490,O
total,7490,O
opiate,7490,B-GENE-N
receptor,7490,I-GENE-N
in,7490,O
high,7490,O
affinity,7490,O
state,7490,O
is,7490,O
relatively,7490,O
constant,7490,O
in,7490,O
various,7490,O
concentrations,7490,O
of,7490,O
Na+,7490,B-CHEMICAL
.,7490,O
Multiple,7491,O
affinity,7491,O
states,7491,O
of,7491,O
opiate,7491,B-GENE-N
receptor,7491,I-GENE-N
can,7491,O
be,7491,O
demonstrated,7491,O
further,7491,O
by,7491,O
Scatchard,7491,O
analysis,7491,O
of,7491,O
saturation,7491,O
binding,7491,O
studies,7491,O
with,7491,O
[,7491,B-CHEMICAL
3H,7491,I-CHEMICAL
],7491,I-CHEMICAL
DADLE,7491,I-CHEMICAL
.,7491,O
In,7492,O
the,7492,O
presence,7492,O
of,7492,O
Mg2+,7492,B-CHEMICAL
",",7492,O
or,7492,O
Gpp,7492,B-CHEMICAL
(,7492,I-CHEMICAL
NH,7492,I-CHEMICAL
),7492,I-CHEMICAL
p,7492,I-CHEMICAL
",",7492,O
analysis,7492,O
of,7492,O
[,7492,B-CHEMICAL
3H,7492,I-CHEMICAL
],7492,I-CHEMICAL
DADLE,7492,I-CHEMICAL
binding,7492,O
demonstrates,7492,O
that,7492,O
opiate,7492,O
receptor,7492,O
can,7492,O
exist,7492,O
in,7492,O
a,7492,O
single,7492,O
affinity,7492,O
state,7492,O
",",7492,O
with,7492,O
apparent,7492,O
Kd,7492,O
values,7492,O
of,7492,O
[,7492,B-CHEMICAL
3H,7492,I-CHEMICAL
],7492,I-CHEMICAL
DADLE,7492,I-CHEMICAL
in,7492,O
10,7492,O
mM,7492,O
Mg2+,7492,O
=,7492,O
1.75,7492,O
+/-,7492,O
0.28,7492,O
nM,7492,O
and,7492,O
in,7492,O
10,7492,O
microM,7492,O
Gpp,7492,B-CHEMICAL
(,7492,I-CHEMICAL
NH,7492,I-CHEMICAL
),7492,I-CHEMICAL
p,7492,I-CHEMICAL
=,7492,O
0.85,7492,O
+/-,7492,O
0.12,7492,O
nM,7492,O
.,7492,O
There,7493,O
is,7493,O
a,7493,O
reduction,7493,O
of,7493,O
Bmax,7493,O
value,7493,O
from,7493,O
0.19,7493,O
+/-,7493,O
0.02,7493,O
nM,7493,O
in,7493,O
the,7493,O
presence,7493,O
of,7493,O
Mg2+,7493,B-CHEMICAL
to,7493,O
0.14,7493,O
+/-,7493,O
0.03,7493,O
nM,7493,O
in,7493,O
the,7493,O
presence,7493,O
of,7493,O
Gpp,7493,B-CHEMICAL
(,7493,I-CHEMICAL
NH,7493,I-CHEMICAL
),7493,I-CHEMICAL
p.,7493,O
In,7493,O
the,7493,O
presence,7493,O
of,7493,O
100,7493,O
mM,7493,O
Na+,7493,B-CHEMICAL
",",7493,O
Scatchard,7493,O
analysis,7493,O
of,7493,O
saturation,7493,O
binding,7493,O
of,7493,O
[,7493,B-CHEMICAL
3H,7493,I-CHEMICAL
],7493,I-CHEMICAL
DADLE,7493,I-CHEMICAL
reveals,7493,O
nonlinear,7493,O
plots,7493,O
;,7493,O
two-site,7493,O
analysis,7493,O
of,7493,O
the,7493,O
curves,7493,O
yields,7493,O
Kd,7493,O
=,7493,O
0.43,7493,O
+/-,7493,O
0.09,7493,O
and,7493,O
7.9,7493,O
+/-,7493,O
3.2,7493,O
nM,7493,O
.,7493,O
These,7494,O
Kd,7494,O
values,7494,O
are,7494,O
analogous,7494,O
to,7494,O
that,7494,O
obtained,7494,O
with,7494,O
competition,7494,O
binding,7494,O
studies,7494,O
.,7494,O
Again,7495,O
",",7495,O
this,7495,O
conversion,7495,O
of,7495,O
single,7495,O
site,7495,O
binding,7495,O
Scatchard,7495,O
plots,7495,O
to,7495,O
multiple,7495,O
sites,7495,O
binding,7495,O
plots,7495,O
in,7495,O
the,7495,O
presence,7495,O
of,7495,O
Na+,7495,B-CHEMICAL
is,7495,O
restricted,7495,O
to,7495,O
3H-agonist,7495,B-CHEMICAL
binding,7495,O
only,7495,O
.,7495,O
(,7496,O
ABSTRACT,7496,O
TRUNCATED,7496,O
AT,7496,O
400,7496,O
WORDS,7496,O
),7496,O
Inhibition,7497,O
of,7497,O
the,7497,O
leukotriene,7497,B-GENE-N
synthetase,7497,I-GENE-N
of,7497,O
rat,7497,O
basophil,7497,O
leukemia,7497,O
cells,7497,O
by,7497,O
diethylcarbamazine,7497,B-CHEMICAL
",",7497,O
and,7497,O
synergism,7497,O
between,7497,O
diethylcarbamazine,7497,B-CHEMICAL
and,7497,O
piriprost,7497,B-CHEMICAL
",",7497,O
a,7497,O
5-lipoxygenase,7497,B-GENE-Y
inhibitor,7497,O
.,7497,O
Diethylcarbamazine,7498,B-CHEMICAL
inhibited,7498,O
the,7498,O
formation,7498,O
of,7498,O
sulfidopeptide,7498,B-CHEMICAL
leukotrienes,7498,I-CHEMICAL
in,7498,O
rat,7498,O
basophil,7498,O
leukemia,7498,O
(,7498,O
RBL,7498,O
),7498,O
cells,7498,O
(,7498,O
50,7498,O
%,7498,O
inhibitory,7498,O
concentration,7498,O
",",7498,O
EC50,7498,O
",",7498,O
3,7498,O
mM,7498,O
),7498,O
.,7498,O
Similar,7499,O
concentrations,7499,O
also,7499,O
inhibited,7499,O
the,7499,O
formation,7499,O
of,7499,O
leukotriene,7499,B-CHEMICAL
C4,7499,I-CHEMICAL
(,7499,O
LTC4,7499,B-CHEMICAL
),7499,O
by,7499,O
LTC,7499,B-GENE-Y
synthetase,7499,I-GENE-Y
",",7499,O
a,7499,O
detergent-solubilized,7499,O
cell,7499,O
free,7499,O
particulate,7499,O
enzyme,7499,O
from,7499,O
RBL,7499,O
cells,7499,O
which,7499,O
is,7499,O
capable,7499,O
of,7499,O
coupling,7499,O
LTA4,7499,B-CHEMICAL
to,7499,O
glutathione,7499,B-CHEMICAL
.,7499,O
By,7500,O
contrast,7500,O
",",7500,O
the,7500,O
conversion,7500,O
of,7500,O
LTA4,7500,B-CHEMICAL
to,7500,O
LTC4,7500,B-CHEMICAL
using,7500,O
enzymes,7500,O
from,7500,O
rat,7500,O
liver,7500,O
was,7500,O
at,7500,O
least,7500,O
ten,7500,O
times,7500,O
less,7500,O
sensitive,7500,O
to,7500,O
this,7500,O
inhibitor,7500,O
.,7500,O
The,7501,O
EC50,7501,O
for,7501,O
inhibition,7501,O
of,7501,O
the,7501,O
leukotriene,7501,B-GENE-Y
C,7501,I-GENE-Y
synthetase,7501,I-GENE-Y
of,7501,O
RBL,7501,O
cells,7501,O
was,7501,O
directly,7501,O
proportional,7501,O
to,7501,O
the,7501,O
LTA4,7501,B-CHEMICAL
concentration,7501,O
in,7501,O
the,7501,O
incubations,7501,O
",",7501,O
ranging,7501,O
from,7501,O
1.5,7501,O
mM,7501,O
at,7501,O
10,7501,O
microM,7501,O
LTA4,7501,B-CHEMICAL
to,7501,O
over,7501,O
40,7501,O
mM,7501,O
at,7501,O
500,7501,O
microM,7501,O
LTA4,7501,B-CHEMICAL
.,7501,O
Kinetic,7502,O
analysis,7502,O
revealed,7502,O
that,7502,O
the,7502,O
inhibition,7502,O
of,7502,O
the,7502,O
leukotriene,7502,B-GENE-Y
C,7502,I-GENE-Y
synthetase,7502,I-GENE-Y
reaction,7502,O
by,7502,O
diethylcarbamazine,7502,B-CHEMICAL
was,7502,O
competitive,7502,O
with,7502,O
respect,7502,O
to,7502,O
LTA4,7502,B-CHEMICAL
.,7502,O
In,7503,O
contrast,7503,O
to,7503,O
diethylcarbamazine,7503,B-CHEMICAL
",",7503,O
piriprost,7503,B-CHEMICAL
(,7503,O
"U-60,257",7503,B-CHEMICAL
;,7503,O
"6,9-deepoxy-6,9-",7503,B-CHEMICAL
(,7503,I-CHEMICAL
phenylimino,7503,I-CHEMICAL
),7503,I-CHEMICAL
-delta,7503,I-CHEMICAL
"6,8-prostaglandin",7503,I-CHEMICAL
I1,7503,I-CHEMICAL
),7503,O
",",7503,O
which,7503,O
inhibits,7503,O
the,7503,O
formation,7503,O
of,7503,O
sulfidopeptide,7503,B-CHEMICAL
leuktrienes,7503,I-CHEMICAL
in,7503,O
RBL,7503,O
cells,7503,O
at,7503,O
the,7503,O
5-lipoxygenase,7503,B-GENE-Y
step,7503,O
(,7503,O
EC50,7503,O
5,7503,O
microM,7503,O
),7503,O
",",7503,O
did,7503,O
not,7503,O
inhibit,7503,O
the,7503,O
leukotriene,7503,B-CHEMICAL
synthetase,7503,I-GENE-N
of,7503,O
these,7503,O
cells,7503,O
.,7503,O
On,7504,O
the,7504,O
other,7504,O
hand,7504,O
",",7504,O
low,7504,O
concentrations,7504,O
of,7504,O
piriprost,7504,B-CHEMICAL
",",7504,O
which,7504,O
had,7504,O
no,7504,O
demonstrable,7504,O
inhibitory,7504,O
activity,7504,O
on,7504,O
leukotriene,7504,B-CHEMICAL
formation,7504,O
by,7504,O
themselves,7504,O
",",7504,O
markedly,7504,O
synergized,7504,O
the,7504,O
inhibitory,7504,O
activity,7504,O
of,7504,O
diethylcarbamazine,7504,B-CHEMICAL
.,7504,O
These,7505,O
results,7505,O
are,7505,O
consistent,7505,O
with,7505,O
the,7505,O
interpretation,7505,O
that,7505,O
both,7505,O
piriprost,7505,B-CHEMICAL
and,7505,O
diethylcarbamazine,7505,B-CHEMICAL
inhibit,7505,O
leukotriene,7505,B-CHEMICAL
formation,7505,O
but,7505,O
that,7505,O
they,7505,O
act,7505,O
on,7505,O
sequential,7505,O
steps,7505,O
in,7505,O
the,7505,O
biosynthetic,7505,O
pathway,7505,O
in,7505,O
such,7505,O
a,7505,O
manner,7505,O
as,7505,O
to,7505,O
synergistically,7505,O
interfere,7505,O
with,7505,O
the,7505,O
availability,7505,O
or,7505,O
utilization,7505,O
of,7505,O
LTA4,7505,B-CHEMICAL
in,7505,O
the,7505,O
leukotriene,7505,B-GENE-Y
C,7505,I-GENE-Y
synthetase,7505,I-GENE-Y
reaction,7505,O
.,7505,O
Intestinal,7506,O
permeability,7506,O
and,7506,O
lactose,7506,B-CHEMICAL
hydrolysis,7506,O
in,7506,O
human,7506,O
rotaviral,7506,O
gastroenteritis,7506,O
assessed,7506,O
simultaneously,7506,O
by,7506,O
non-invasive,7506,O
differential,7506,O
sugar,7506,O
permeation,7506,O
.,7506,O
Changes,7507,O
in,7507,O
intestinal,7507,O
permeability,7507,O
and,7507,O
lactose,7507,B-CHEMICAL
hydrolysis,7507,O
have,7507,O
been,7507,O
investigated,7507,O
in,7507,O
three,7507,O
adults,7507,O
and,7507,O
fifteen,7507,O
infants,7507,O
with,7507,O
acute,7507,O
rotaviral,7507,O
gastroenteritis,7507,O
by,7507,O
differential,7507,O
sugar,7507,O
absorption,7507,O
.,7507,O
The,7508,O
method,7508,O
involves,7508,O
chromatographic,7508,O
measurement,7508,O
of,7508,O
urinary,7508,O
lactose,7508,B-CHEMICAL
",",7508,O
lactulose,7508,B-CHEMICAL
and,7508,O
L-rhamnose,7508,B-CHEMICAL
excretion,7508,O
following,7508,O
combined,7508,O
ingestion,7508,O
in,7508,O
an,7508,O
iso-osmolar,7508,O
test,7508,O
solution,7508,O
.,7508,O
All,7509,O
patients,7509,O
had,7509,O
abnormal,7509,O
intestinal,7509,O
permeability,7509,O
indicated,7509,O
by,7509,O
raised,7509,O
urine,7509,O
lactulose/L-rhamnose,7509,B-CHEMICAL
excretion,7509,O
",",7509,O
ratio,7509,O
of,7509,O
percentages,7509,O
recovered,7509,O
in,7509,O
5,7509,O
h,7509,O
",",7509,O
of,7509,O
0.462,7509,O
(,7509,O
0.100-1.227,7509,O
),7509,O
mean,7509,O
and,7509,O
range,7509,O
",",7509,O
compared,7509,O
with,7509,O
0.027,7509,O
(,7509,O
0.008-0.052,7509,O
),7509,O
for,7509,O
healthy,7509,O
controls,7509,O
(,7509,O
P,7509,O
less,7509,O
than,7509,O
0.001,7509,O
),7509,O
.,7509,O
Ten,7510,O
patients,7510,O
also,7510,O
had,7510,O
urinary,7510,O
lactose/lactulose,7510,B-CHEMICAL
excretion,7510,O
ratios,7510,O
raised,7510,O
above,7510,O
the,7510,O
normal,7510,O
range,7510,O
(,7510,O
0.014-0.41,7510,O
",",7510,O
mean,7510,O
0.258,7510,O
),7510,O
during,7510,O
their,7510,O
acute,7510,O
illness,7510,O
",",7510,O
indicating,7510,O
impaired,7510,O
intestinal,7510,O
lactose,7510,B-CHEMICAL
hydrolysis,7510,O
.,7510,O
Both,7511,O
indices,7511,O
had,7511,O
become,7511,O
normal,7511,O
4,7511,O
weeks,7511,O
after,7511,O
the,7511,O
acute,7511,O
illness,7511,O
",",7511,O
serial,7511,O
investigation,7511,O
of,7511,O
five,7511,O
patients,7511,O
showing,7511,O
that,7511,O
improvement,7511,O
was,7511,O
complete,7511,O
much,7511,O
earlier,7511,O
.,7511,O
Except,7512,O
for,7512,O
the,7512,O
short,7512,O
duration,7512,O
these,7512,O
changes,7512,O
are,7512,O
similar,7512,O
to,7512,O
those,7512,O
associated,7512,O
with,7512,O
villous,7512,O
atrophy,7512,O
in,7512,O
coeliac,7512,O
disease,7512,O
.,7512,O
The,7513,O
test,7513,O
procedure,7513,O
was,7513,O
verified,7513,O
with,7513,O
respect,7513,O
to,7513,O
intestinal,7513,O
lactose,7513,B-CHEMICAL
hydrolysis,7513,O
by,7513,O
demonstrating,7513,O
a,7513,O
linear,7513,O
relationship,7513,O
between,7513,O
lactose/lactulose,7513,B-CHEMICAL
excretion,7513,O
and,7513,O
log,7513,O
jejunal,7513,O
mucosal,7513,O
lactase,7513,B-GENE-Y
activity,7513,O
by,7513,O
in,7513,O
vitro,7513,O
assay,7513,O
(,7513,O
R2,7513,O
=,7513,O
0.95,7513,O
),7513,O
in,7513,O
a,7513,O
further,7513,O
group,7513,O
of,7513,O
subjects,7513,O
.,7513,O
Differential,7514,O
lactose/lactulose/L-rhamnose,7514,B-CHEMICAL
absorption,7514,O
provides,7514,O
a,7514,O
non-invasive,7514,O
and,7514,O
sensitive,7514,O
index,7514,O
of,7514,O
small,7514,O
intestinal,7514,O
integrity,7514,O
of,7514,O
value,7514,O
for,7514,O
the,7514,O
interpretation,7514,O
of,7514,O
prolonged,7514,O
or,7514,O
otherwise,7514,O
complicated,7514,O
enteritis,7514,O
and,7514,O
the,7514,O
distinction,7514,O
of,7514,O
primary,7514,O
secondary,7514,O
intestinal,7514,O
lactase,7514,B-GENE-Y
deficiency,7514,O
.,7514,O
Characteristics,7515,O
of,7515,O
the,7515,O
binding,7515,O
of,7515,O
phenoxybenzamine,7515,B-CHEMICAL
to,7515,O
calmodulin,7515,B-GENE-N
.,7515,O
To,7516,O
determine,7516,O
the,7516,O
factors,7516,O
that,7516,O
influence,7516,O
the,7516,O
interaction,7516,O
between,7516,O
phenoxybenzamine,7516,B-CHEMICAL
and,7516,O
calmodulin,7516,B-GENE-N
",",7516,O
the,7516,O
binding,7516,O
of,7516,O
phenoxybenzamine,7516,B-CHEMICAL
to,7516,O
calmodulin,7516,B-GENE-N
was,7516,O
determined,7516,O
by,7516,O
equilibrium,7516,O
dialysis,7516,O
under,7516,O
a,7516,O
variety,7516,O
of,7516,O
experimental,7516,O
conditions,7516,O
.,7516,O
This,7517,O
interaction,7517,O
was,7517,O
found,7517,O
to,7517,O
be,7517,O
similar,7517,O
in,7517,O
some,7517,O
respects,7517,O
to,7517,O
the,7517,O
interaction,7517,O
between,7517,O
phenothiazines,7517,B-CHEMICAL
and,7517,O
calmodulin,7517,B-GENE-N
.,7517,O
It,7518,O
was,7518,O
saturable,7518,O
",",7518,O
with,7518,O
between,7518,O
1,7518,O
and,7518,O
2,7518,O
mol,7518,O
of,7518,O
phenoxybenzamine,7518,B-CHEMICAL
bound,7518,O
to,7518,O
1,7518,O
mol,7518,O
of,7518,O
calmodulin,7518,B-GENE-N
.,7518,O
It,7519,O
was,7519,O
also,7519,O
dependent,7519,O
upon,7519,O
temperature,7519,O
",",7519,O
the,7519,O
presence,7519,O
of,7519,O
a,7519,O
divalent,7519,O
cation,7519,O
such,7519,O
as,7519,O
calcium,7519,B-CHEMICAL
",",7519,O
and,7519,O
on,7519,O
pH,7519,O
",",7519,O
showing,7519,O
maximum,7519,O
binding,7519,O
at,7519,O
pH,7519,O
6.5,7519,O
with,7519,O
little,7519,O
binding,7519,O
at,7519,O
pH,7519,O
values,7519,O
below,7519,O
4.2,7519,O
or,7519,O
above,7519,O
8.0,7519,O
.,7519,O
The,7520,O
site,7520,O
at,7520,O
which,7520,O
phenoxybenzamine,7520,B-CHEMICAL
bound,7520,O
to,7520,O
calmodulin,7520,B-GENE-N
appears,7520,O
to,7520,O
be,7520,O
similar,7520,O
to,7520,O
that,7520,O
at,7520,O
which,7520,O
certain,7520,O
antipsychotic,7520,O
agents,7520,O
bind,7520,O
",",7520,O
since,7520,O
several,7520,O
of,7520,O
them,7520,O
",",7520,O
including,7520,O
penfluridol,7520,B-CHEMICAL
",",7520,O
pimozide,7520,B-CHEMICAL
and,7520,O
spiroperidol,7520,B-CHEMICAL
",",7520,O
prevented,7520,O
the,7520,O
binding,7520,O
of,7520,O
phenoxybenzamine,7520,B-CHEMICAL
to,7520,O
calmodulin,7520,B-GENE-N
.,7520,O
However,7521,O
",",7521,O
in,7521,O
contrast,7521,O
to,7521,O
the,7521,O
reversible,7521,O
binding,7521,O
of,7521,O
most,7521,O
phenothiazines,7521,B-CHEMICAL
to,7521,O
calmodulin,7521,B-GENE-N
",",7521,O
phenoxybenzamine,7521,B-CHEMICAL
bound,7521,O
to,7521,O
calmodulin,7521,B-GENE-N
irreversibly,7521,O
.,7521,O
The,7522,O
binding,7522,O
of,7522,O
phenoxybenzamine,7522,B-CHEMICAL
to,7522,O
calmodulin,7522,B-GENE-N
was,7522,O
fairly,7522,O
selective,7522,O
in,7522,O
that,7522,O
other,7522,O
alpha-adrenergic,7522,B-GENE-N
agents,7522,O
such,7522,O
as,7522,O
prazosin,7522,B-CHEMICAL
",",7522,O
yohimbine,7522,B-CHEMICAL
and,7522,O
clonidine,7522,B-CHEMICAL
failed,7522,O
to,7522,O
bind,7522,O
to,7522,O
calmodulin,7522,B-GENE-N
when,7522,O
examined,7522,O
under,7522,O
the,7522,O
same,7522,O
experimental,7522,O
conditions,7522,O
.,7522,O
In,7523,O
addition,7523,O
",",7523,O
phenoxybenzamine,7523,B-CHEMICAL
showed,7523,O
little,7523,O
or,7523,O
no,7523,O
calcium-dependent,7523,B-CHEMICAL
binding,7523,O
to,7523,O
the,7523,O
S-100,7523,B-GENE-N
protein,7523,I-GENE-N
",",7523,O
bovine,7523,B-GENE-Y
serum,7523,I-GENE-Y
albumin,7523,I-GENE-Y
or,7523,O
cytochrome,7523,B-GENE-Y
c.,7523,O
The,7523,O
irreversible,7523,O
complex,7523,O
between,7523,O
phenoxybenzamine,7523,B-CHEMICAL
and,7523,O
calmodulin,7523,B-GENE-N
may,7523,O
be,7523,O
useful,7523,O
for,7523,O
inhibiting,7523,O
certain,7523,O
calmodulin-dependent,7523,B-GENE-N
reactions,7523,O
and,7523,O
for,7523,O
studying,7523,O
the,7523,O
various,7523,O
biological,7523,O
functions,7523,O
of,7523,O
calmodulin,7523,B-GENE-N
.,7523,O
Pharmacological,7524,O
and,7524,O
clinical,7524,O
studies,7524,O
of,7524,O
the,7524,O
antiandrogen,7524,O
Anandron,7524,B-CHEMICAL
.,7524,O
This,7525,O
paper,7525,O
summarizes,7525,O
the,7525,O
animal,7525,O
and,7525,O
human,7525,O
studies,7525,O
with,7525,O
Anandron,7525,B-CHEMICAL
available,7525,O
at,7525,O
the,7525,O
time,7525,O
of,7525,O
the,7525,O
meeting,7525,O
.,7525,O
The,7526,O
following,7526,O
was,7526,O
demonstrated,7526,O
in,7526,O
the,7526,O
rat,7526,O
and,7526,O
confirmed,7526,O
in,7526,O
man,7526,O
:,7526,O
interaction,7526,O
of,7526,O
Anandron,7526,B-CHEMICAL
with,7526,O
the,7526,O
prostatic,7526,B-GENE-N
androgen,7526,I-GENE-N
receptor,7526,I-GENE-N
",",7526,O
antiandrogen,7526,O
activity,7526,O
against,7526,O
testosterone,7526,B-CHEMICAL
(,7526,O
in,7526,O
particular,7526,O
against,7526,O
the,7526,O
early,7526,O
transient,7526,O
rise,7526,O
induced,7526,O
by,7526,O
LHRH,7526,B-GENE-N
analogs,7526,O
),7526,O
and,7526,O
adrenal,7526,O
androgens,7526,B-CHEMICAL
.,7526,O
Thus,7527,O
",",7527,O
as,7527,O
shown,7527,O
in,7527,O
4,7527,O
different,7527,O
double,7527,O
blind,7527,O
studies,7527,O
performed,7527,O
in,7527,O
stage,7527,O
D2,7527,O
prostrate,7527,O
cancer,7527,O
patients,7527,O
",",7527,O
the,7527,O
combination,7527,O
of,7527,O
Anandron,7527,B-CHEMICAL
with,7527,O
surgical,7527,O
or,7527,O
chemical,7527,O
castration,7527,O
enhanced,7527,O
the,7527,O
beneficial,7527,O
effects,7527,O
of,7527,O
castration,7527,O
alone,7527,O
and,7527,O
thus,7527,O
seems,7527,O
a,7527,O
step,7527,O
forward,7527,O
in,7527,O
the,7527,O
hormonal,7527,O
treatment,7527,O
of,7527,O
prostatic,7527,O
carcinoma,7527,O
.,7527,O
Adenosine,7528,B-GENE-N
receptors,7528,I-GENE-N
:,7528,O
development,7528,O
of,7528,O
selective,7528,O
agonists,7528,O
and,7528,O
antagonists,7528,O
.,7528,O
Adenosine,7529,B-CHEMICAL
modulates,7529,O
a,7529,O
variety,7529,O
of,7529,O
physiological,7529,O
functions,7529,O
through,7529,O
interaction,7529,O
with,7529,O
A1,7529,B-GENE-N
and,7529,I-GENE-N
A2,7529,I-GENE-N
adenosine,7529,I-GENE-N
receptors,7529,I-GENE-N
",",7529,O
where,7529,O
agonists,7529,O
mediate,7529,O
inhibition,7529,O
and,7529,O
stimulation,7529,O
",",7529,O
respectively,7529,O
",",7529,O
of,7529,O
adenylate,7529,B-GENE-N
cyclase,7529,I-GENE-N
.,7529,O
In,7530,O
the,7530,O
cardiovascular,7530,O
system,7530,O
",",7530,O
A2,7530,B-GENE-N
receptors,7530,I-GENE-N
mediate,7530,O
vasodilation,7530,O
and,7530,O
reduction,7530,O
in,7530,O
blood,7530,O
pressure,7530,O
",",7530,O
while,7530,O
A1,7530,B-GENE-Y
receptors,7530,I-GENE-Y
mediate,7530,O
cardiac,7530,O
depression,7530,O
.,7530,O
The,7531,O
involvement,7531,O
of,7531,O
adenylate,7531,B-GENE-N
cyclase,7531,I-GENE-N
in,7531,O
these,7531,O
responses,7531,O
remains,7531,O
unresolved,7531,O
.,7531,O
Adenosine,7532,B-CHEMICAL
analogs,7532,O
in,7532,O
particular,7532,O
the,7532,O
N6-substituted,7532,B-CHEMICAL
compounds,7532,O
are,7532,O
more,7532,O
potent,7532,O
at,7532,O
A1,7532,B-GENE-Y
receptors,7532,I-GENE-Y
than,7532,O
at,7532,O
A2,7532,B-GENE-N
receptors,7532,I-GENE-N
.,7532,O
The,7533,O
subregion,7533,O
of,7533,O
the,7533,O
adenosine,7533,B-GENE-N
receptor,7533,I-GENE-N
that,7533,O
interacts,7533,O
with,7533,O
the,7533,O
N6-substituent,7533,B-CHEMICAL
is,7533,O
different,7533,O
for,7533,O
A1,7533,B-GENE-N
and,7533,I-GENE-N
A2,7533,I-GENE-N
receptors,7533,I-GENE-N
",",7533,O
particularly,7533,O
with,7533,O
respect,7533,O
to,7533,O
phenyl,7533,B-CHEMICAL
interactions,7533,O
",",7533,O
bulk,7533,O
tolerance,7533,O
and,7533,O
stereoselectivity,7533,O
.,7533,O
A,7534,O
series,7534,O
of,7534,O
para-substituted,7534,O
N6-phenyladenosines,7534,B-CHEMICAL
have,7534,O
been,7534,O
synthesized,7534,O
based,7534,O
on,7534,O
a,7534,O
``,7534,O
functionalized,7534,O
congener,7534,O
'',7534,O
approach,7534,O
in,7534,O
which,7534,O
a,7534,O
chemically,7534,O
reactive,7534,O
group,7534,O
",",7534,O
such,7534,O
as,7534,O
an,7534,O
amine,7534,B-CHEMICAL
or,7534,O
carboxylic,7534,B-CHEMICAL
acid,7534,I-CHEMICAL
",",7534,O
is,7534,O
introduced,7534,O
at,7534,O
the,7534,O
terminus,7534,O
of,7534,O
a,7534,O
chain,7534,O
.,7534,O
From,7535,O
the,7535,O
``,7535,O
functionalized,7535,O
congener,7535,O
'',7535,O
are,7535,O
synthesized,7535,O
a,7535,O
variety,7535,O
of,7535,O
conjugates,7535,O
each,7535,O
containing,7535,O
a,7535,O
common,7535,O
pharmacophore,7535,O
.,7535,O
Certain,7536,O
of,7536,O
the,7536,O
adenosine,7536,B-CHEMICAL
conjugates,7536,O
are,7536,O
highly,7536,O
selective,7536,O
for,7536,O
A1,7536,B-GENE-Y
receptors,7536,I-GENE-Y
.,7536,O
Xanthines,7537,B-CHEMICAL
are,7537,O
classical,7537,O
antagonists,7537,O
for,7537,O
adenosine,7537,B-CHEMICAL
receptors,7537,I-GENE-N
for,7537,O
many,7537,O
of,7537,O
their,7537,O
pharmacological,7537,O
actions,7537,O
may,7537,O
be,7537,O
due,7537,O
to,7537,O
blockade,7537,O
of,7537,O
adenosine,7537,B-CHEMICAL
receptors,7537,I-GENE-N
.,7537,O
Caffeine,7538,B-CHEMICAL
and,7538,O
theophylline,7538,B-CHEMICAL
are,7538,O
virtually,7538,O
non-selective,7538,O
for,7538,O
A2,7538,B-GENE-N
and,7538,I-GENE-N
A2,7538,I-GENE-N
receptors,7538,I-GENE-N
.,7538,O
Replacement,7539,O
of,7539,O
the,7539,O
methyl,7539,B-CHEMICAL
groups,7539,O
of,7539,O
theophylline,7539,B-CHEMICAL
with,7539,O
n-propyl,7539,B-CHEMICAL
or,7539,O
larger,7539,O
alkyl,7539,B-CHEMICAL
groups,7539,O
yields,7539,O
xanthines,7539,B-CHEMICAL
with,7539,O
selectivity,7539,O
for,7539,O
A1,7539,B-GENE-Y
receptors,7539,I-GENE-Y
",",7539,O
particularly,7539,O
when,7539,O
combined,7539,O
with,7539,O
an,7539,O
8-phenyl,7539,B-CHEMICAL
moiety,7539,O
.,7539,O
Most,7540,O
"1,3-dialkyl-8-phenyl",7540,B-CHEMICAL
xanthines,7540,I-CHEMICAL
are,7540,O
very,7540,O
insoluble,7540,O
",",7540,O
but,7540,O
incorporation,7540,O
of,7540,O
polar,7540,O
aryl,7540,B-CHEMICAL
substituents,7540,O
",",7540,O
such,7540,O
as,7540,O
sulfo,7540,B-CHEMICAL
or,7540,O
carboxy,7540,B-CHEMICAL
to,7540,O
increase,7540,O
solubility,7540,O
",",7540,O
results,7540,O
in,7540,O
marked,7540,O
reduction,7540,O
in,7540,O
potency,7540,O
and,7540,O
selectivity,7540,O
.,7540,O
A,7541,O
new,7541,O
series,7541,O
of,7541,O
more,7541,O
hydrophilic,7541,O
"1,3-dipropyl-8-phenylxanthines",7541,B-CHEMICAL
has,7541,O
been,7541,O
synthesized,7541,O
using,7541,O
the,7541,O
``,7541,O
functionalized,7541,O
congener,7541,O
'',7541,O
approach,7541,O
.,7541,O
Certain,7542,O
conjugates,7542,O
of,7542,O
8-,7542,B-CHEMICAL
[,7542,I-CHEMICAL
4-,7542,I-CHEMICAL
(,7542,I-CHEMICAL
carboxymethyloxy,7542,I-CHEMICAL
),7542,I-CHEMICAL
phenyl,7542,I-CHEMICAL
1,7542,I-CHEMICAL
],7542,I-CHEMICAL
"1,3-dipropylxanthine",7542,I-CHEMICAL
display,7542,O
A1,7542,O
selectivity,7542,O
in,7542,O
biochemical,7542,O
and,7542,O
cardiovascular,7542,O
models,7542,O
.,7542,O
Certain,7543,O
analogs,7543,O
of,7543,O
caffeine,7543,B-CHEMICAL
in,7543,O
which,7543,O
the,7543,O
methyl,7543,B-CHEMICAL
group,7543,O
at,7543,O
the,7543,O
1-,7543,O
or,7543,O
7-position,7543,O
is,7543,O
replaced,7543,O
with,7543,O
a,7543,O
propargyl,7543,O
or,7543,O
propyl,7543,B-CHEMICAL
group,7543,O
display,7543,O
selectivity,7543,O
for,7543,O
A2,7543,B-GENE-N
receptors,7543,I-GENE-N
.,7543,O
The,7544,O
profile,7544,O
of,7544,O
a,7544,O
series,7544,O
of,7544,O
adenosine,7544,B-CHEMICAL
analogs,7544,O
or,7544,O
of,7544,O
xanthine,7544,B-CHEMICAL
antagonists,7544,O
can,7544,O
be,7544,O
used,7544,O
to,7544,O
define,7544,O
the,7544,O
nature,7544,O
of,7544,O
adenosine,7544,B-GENE-N
receptors,7544,I-GENE-N
.,7544,O
Inhibition,7545,O
of,7545,O
testicular,7545,O
LDH-X,7545,B-GENE-N
from,7545,O
laboratory,7545,O
animals,7545,O
and,7545,O
man,7545,O
by,7545,O
gossypol,7545,B-CHEMICAL
and,7545,O
its,7545,O
isomers,7545,O
.,7545,O
The,7546,O
inhibitory,7546,O
effect,7546,O
of,7546,O
(,7546,B-CHEMICAL
+,7546,I-CHEMICAL
),7546,I-CHEMICAL
-,7546,I-CHEMICAL
",",7546,I-CHEMICAL
(,7546,I-CHEMICAL
-,7546,I-CHEMICAL
),7546,I-CHEMICAL
-,7546,I-CHEMICAL
",",7546,I-CHEMICAL
(,7546,I-CHEMICAL
+/-,7546,I-CHEMICAL
),7546,I-CHEMICAL
-gossypol,7546,I-CHEMICAL
and,7546,O
(,7546,B-CHEMICAL
+/-,7546,I-CHEMICAL
),7546,I-CHEMICAL
-gossypol,7546,I-CHEMICAL
acetic,7546,I-CHEMICAL
acid,7546,I-CHEMICAL
upon,7546,O
testicular,7546,O
cytosolic,7546,O
LDH-X,7546,B-GENE-Y
was,7546,O
measured,7546,O
in,7546,O
vitro,7546,O
.,7546,O
Gossypol,7547,B-CHEMICAL
acetic,7547,I-CHEMICAL
acid,7547,I-CHEMICAL
(,7547,O
0-100,7547,O
mumol/l,7547,O
),7547,O
inhibited,7547,O
LDH-X,7547,B-GENE-N
prepared,7547,O
from,7547,O
the,7547,O
testes,7547,O
of,7547,O
the,7547,O
mouse,7547,O
greater,7547,O
than,7547,O
rabbit,7547,O
greater,7547,O
than,7547,O
human,7547,O
greater,7547,O
than,7547,O
rat,7547,O
greater,7547,O
than,7547,O
hamster,7547,O
.,7547,O
There,7548,O
was,7548,O
no,7548,O
relationship,7548,O
between,7548,O
inhibition,7548,O
and,7548,O
in-vivo,7548,O
antifertility,7548,O
activity,7548,O
.,7548,O
LDH,7549,B-GENE-N
activity,7549,O
measured,7549,O
in,7549,O
vitro,7549,O
in,7549,O
serum,7549,O
of,7549,O
men,7549,O
and,7549,O
hamsters,7549,O
was,7549,O
unaffected,7549,O
by,7549,O
gossypol,7549,B-CHEMICAL
.,7549,O
Gossypol,7550,B-CHEMICAL
and,7550,O
its,7550,O
isomers,7550,O
were,7550,O
non-competitive,7550,O
inhibitors,7550,O
of,7550,O
human,7550,B-GENE-N
and,7550,I-GENE-N
hamster,7550,I-GENE-N
LDH-X,7550,I-GENE-N
with,7550,O
respect,7550,O
to,7550,O
the,7550,O
coenzyme,7550,O
NADH,7550,B-CHEMICAL
",",7550,O
competitive,7550,O
inhibitors,7550,O
of,7550,O
human,7550,B-GENE-Y
LDH-X,7550,I-GENE-Y
and,7550,O
noncompetitive-competitive,7550,O
inhibitors,7550,O
of,7550,O
hamster,7550,B-GENE-Y
LDH-X,7550,I-GENE-Y
with,7550,O
respect,7550,O
to,7550,O
the,7550,O
substrate,7550,O
alpha-ketobutyrate,7550,B-CHEMICAL
.,7550,O
Co-incubation,7551,O
with,7551,O
human,7551,B-GENE-Y
serum,7551,I-GENE-Y
albumin,7551,I-GENE-Y
or,7551,O
poly-L-lysine,7551,B-CHEMICAL
but,7551,O
not,7551,O
lysine,7551,B-CHEMICAL
protected,7551,O
human,7551,B-GENE-N
and,7551,I-GENE-N
hamster,7551,I-GENE-N
LDH-X,7551,I-GENE-N
from,7551,O
gossypol,7551,B-CHEMICAL
.,7551,O
Inactivation,7552,O
of,7552,O
prostaglandin,7552,B-GENE-N
H,7552,I-GENE-N
synthase,7552,I-GENE-N
and,7552,O
prostacyclin,7552,B-GENE-Y
synthase,7552,I-GENE-Y
by,7552,O
phenylbutazone,7552,B-CHEMICAL
.,7552,O
Requirement,7553,O
for,7553,O
peroxidative,7553,O
metabolism,7553,O
.,7553,O
Phenylbutazone,7554,B-CHEMICAL
(,7554,O
PB,7554,B-CHEMICAL
),7554,O
",",7554,O
a,7554,O
nonsteroidal,7554,O
anti-inflammatory,7554,O
drug,7554,O
",",7554,O
is,7554,O
an,7554,O
efficient,7554,O
reducing,7554,O
cofactor,7554,O
for,7554,O
the,7554,O
peroxidase,7554,O
activity,7554,O
of,7554,O
prostaglandin,7554,B-CHEMICAL
H,7554,I-CHEMICAL
synthase,7554,I-GENE-N
(,7554,O
PHS,7554,B-GENE-N
),7554,O
.,7554,O
Most,7555,O
reducing,7555,O
cofactors,7555,O
for,7555,O
the,7555,O
peroxidase,7555,O
protect,7555,O
PHS,7555,B-GENE-N
and,7555,O
prostacyclin,7555,B-GENE-Y
synthase,7555,I-GENE-Y
from,7555,O
inactivation,7555,O
by,7555,O
hydroperoxides,7555,B-CHEMICAL
.,7555,O
PB,7556,B-CHEMICAL
",",7556,O
however,7556,O
",",7556,O
does,7556,O
not,7556,O
protect,7556,O
these,7556,O
enzymes,7556,O
",",7556,O
but,7556,O
rather,7556,O
augments,7556,O
their,7556,O
hydroperoxide-dependent,7556,B-CHEMICAL
inactivation,7556,O
.,7556,O
Using,7557,O
ram,7557,O
seminal,7557,O
vesicle,7557,O
microsomes,7557,O
as,7557,O
a,7557,O
source,7557,O
of,7557,O
PHS,7557,B-GENE-N
and,7557,O
prostacyclin,7557,B-GENE-Y
synthase,7557,I-GENE-Y
",",7557,O
we,7557,O
have,7557,O
examined,7557,O
the,7557,O
interaction,7557,O
of,7557,O
PB,7557,B-CHEMICAL
and,7557,O
exogenous,7557,O
hydroperoxides,7557,B-CHEMICAL
.,7557,O
Chromatographic,7558,O
analysis,7558,O
of,7558,O
the,7558,O
metabolism,7558,O
of,7558,O
14C-labeled,7558,B-CHEMICAL
arachidonic,7558,I-CHEMICAL
acid,7558,I-CHEMICAL
in,7558,O
this,7558,O
system,7558,O
revealed,7558,O
that,7558,O
PB-dependent,7558,B-CHEMICAL
inactivation,7558,O
of,7558,O
PHS,7558,B-GENE-N
is,7558,O
markedly,7558,O
increased,7558,O
in,7558,O
the,7558,O
presence,7558,O
of,7558,O
100,7558,O
microM,7558,O
H2O2,7558,B-CHEMICAL
.,7558,O
This,7559,O
inactivation,7559,O
is,7559,O
a,7559,O
linear,7559,O
function,7559,O
of,7559,O
PB,7559,B-CHEMICAL
concentration,7559,O
between,7559,O
10,7559,O
and,7559,O
250,7559,O
microM,7559,O
",",7559,O
with,7559,O
a,7559,O
half-maximal,7559,O
effect,7559,O
in,7559,O
this,7559,O
range,7559,O
at,7559,O
about,7559,O
100,7559,O
microM,7559,O
PB,7559,O
.,7559,O
Prostacyclin,7560,B-GENE-Y
synthase,7560,I-GENE-Y
is,7560,O
even,7560,O
more,7560,O
sensitive,7560,O
to,7560,O
inactivation,7560,O
by,7560,O
the,7560,O
combined,7560,O
PB,7560,B-CHEMICAL
and,7560,O
H2O2,7560,B-CHEMICAL
treatment,7560,O
",",7560,O
with,7560,O
a,7560,O
corresponding,7560,O
half-maximal,7560,O
effect,7560,O
at,7560,O
PB,7560,B-CHEMICAL
concentrations,7560,O
near,7560,O
25,7560,O
microM,7560,O
.,7560,O
This,7561,O
PB-,7561,B-CHEMICAL
and,7561,O
H2O2-dependent,7561,B-CHEMICAL
inactivation,7561,O
is,7561,O
demonstrable,7561,O
whether,7561,O
PGH2,7561,B-CHEMICAL
is,7561,O
generated,7561,O
in,7561,O
situ,7561,O
from,7561,O
arachidonic,7561,B-CHEMICAL
acid,7561,I-CHEMICAL
or,7561,O
is,7561,O
added,7561,O
exogenously,7561,O
",",7561,O
supporting,7561,O
a,7561,O
direct,7561,O
effect,7561,O
of,7561,O
the,7561,O
treatment,7561,O
on,7561,O
prostacyclin,7561,B-CHEMICAL
synthase,7561,I-GENE-Y
.,7561,O
As,7562,O
PB,7562,B-CHEMICAL
undergoes,7562,O
peroxide-dependent,7562,B-CHEMICAL
co-oxygenation,7562,O
catalyzed,7562,O
by,7562,O
PHS,7562,B-GENE-N
",",7562,O
we,7562,O
propose,7562,O
that,7562,O
it,7562,O
is,7562,O
an,7562,O
oxygenated,7562,O
derivative,7562,O
of,7562,O
PB,7562,B-CHEMICAL
",",7562,O
rather,7562,O
than,7562,O
the,7562,O
parent,7562,O
compound,7562,O
",",7562,O
which,7562,O
is,7562,O
responsible,7562,O
for,7562,O
the,7562,O
inactivation,7562,O
of,7562,O
PHS,7562,B-GENE-N
and,7562,O
prostacyclin,7562,B-GENE-Y
synthase,7562,I-GENE-Y
.,7562,O
Nafazatrom,7563,B-CHEMICAL
",",7563,O
a,7563,O
competitive,7563,O
inhibitor,7563,O
of,7563,O
PB,7563,B-CHEMICAL
co-oxygenation,7563,O
",",7563,O
blocks,7563,O
the,7563,O
effects,7563,O
of,7563,O
the,7563,O
PB,7563,B-CHEMICAL
and,7563,O
H2O2,7563,B-CHEMICAL
treatment,7563,O
",",7563,O
supporting,7563,O
our,7563,O
proposal,7563,O
.,7563,O
Drug-protein,7564,O
interactions,7564,O
:,7564,O
isolation,7564,O
and,7564,O
characterization,7564,O
of,7564,O
covalent,7564,O
adducts,7564,O
of,7564,O
phenoxybenzamine,7564,B-CHEMICAL
and,7564,O
calmodulin,7564,B-GENE-Y
.,7564,O
Phenoxybenzamine,7565,B-CHEMICAL
",",7565,O
an,7565,O
alpha-adrenergic,7565,O
antagonist,7565,O
containing,7565,O
a,7565,O
(,7565,B-CHEMICAL
chloroethyl,7565,I-CHEMICAL
),7565,I-CHEMICAL
amine,7565,I-CHEMICAL
group,7565,O
",",7565,O
labels,7565,O
calmodulin,7565,B-GENE-Y
in,7565,O
the,7565,O
presence,7565,O
of,7565,O
calcium,7565,B-CHEMICAL
.,7565,O
The,7566,O
covalent,7566,O
interaction,7566,O
is,7566,O
inhibited,7566,O
by,7566,O
chlorpromazine,7566,B-CHEMICAL
in,7566,O
a,7566,O
concentration-dependent,7566,O
manner,7566,O
.,7566,O
Adducts,7567,O
of,7567,O
calmodulin,7567,B-GENE-Y
and,7567,O
phenoxybenzamine,7567,B-CHEMICAL
were,7567,O
separated,7567,O
by,7567,O
high-performance,7567,O
liquid,7567,O
chromatography,7567,O
into,7567,O
four,7567,O
major,7567,O
fractions,7567,O
:,7567,O
two,7567,O
containing,7567,O
0.6,7567,O
and,7567,O
1.2,7567,O
mol,7567,O
of,7567,O
drug,7567,O
per,7567,O
mol,7567,O
of,7567,O
protein,7567,O
and,7567,O
two,7567,O
different,7567,O
fractions,7567,O
each,7567,O
containing,7567,O
2.0,7567,O
mol/mol,7567,O
.,7567,O
Each,7568,O
adduct,7568,O
had,7568,O
a,7568,O
reduced,7568,O
ability,7568,O
to,7568,O
activate,7568,O
cyclic,7568,B-CHEMICAL
nucleotide,7568,I-CHEMICAL
phosphodiesterase,7568,I-GENE-N
and,7568,O
myosin,7568,B-GENE-Y
light,7568,I-GENE-Y
chain,7568,I-GENE-Y
kinase,7568,I-GENE-Y
",",7568,O
and,7568,O
the,7568,O
chlorpromazine,7568,B-CHEMICAL
binding,7568,O
capacities,7568,O
of,7568,O
the,7568,O
phenoxybenzamine-calmodulin,7568,B-CHEMICAL
adducts,7568,O
were,7568,O
diminished,7568,O
to,7568,O
the,7568,O
extent,7568,O
of,7568,O
phenoxybenzamine,7568,B-CHEMICAL
incorporation,7568,O
into,7568,O
each,7568,O
adduct,7568,O
.,7568,O
Isolation,7569,O
and,7569,O
characterization,7569,O
of,7569,O
labeled,7569,O
peptides,7569,O
from,7569,O
phenoxybenzamine-modified,7569,B-CHEMICAL
calmodulins,7569,B-GENE-Y
indicated,7569,O
that,7569,O
peptides,7569,O
encompassing,7569,O
residues,7569,O
38-75,7569,O
",",7569,O
107-126,7569,O
",",7569,O
and,7569,O
127-148,7569,O
contained,7569,O
phenoxybenzamine,7569,B-CHEMICAL
label,7569,O
.,7569,O
These,7570,O
studies,7570,O
directly,7570,O
demonstrate,7570,O
the,7570,O
relatedness,7570,O
between,7570,O
the,7570,O
binding,7570,O
activities,7570,O
of,7570,O
two,7570,O
structurally,7570,O
dissimilar,7570,O
calmodulin,7570,B-GENE-Y
antagonists,7570,O
",",7570,O
demonstrate,7570,O
that,7570,O
covalent,7570,O
adducts,7570,O
of,7570,O
calmodulin,7570,B-GENE-Y
and,7570,O
drugs,7570,O
with,7570,O
equal,7570,O
stoichiometries,7570,O
of,7570,O
labeling,7570,O
can,7570,O
have,7570,O
quantitative,7570,O
differences,7570,O
in,7570,O
activity,7570,O
and,7570,O
sites,7570,O
of,7570,O
modification,7570,O
",",7570,O
and,7570,O
provide,7570,O
direct,7570,O
evidence,7570,O
of,7570,O
distinct,7570,O
drug,7570,O
binding,7570,O
regions,7570,O
in,7570,O
calmodulin,7570,B-GENE-Y
located,7570,O
in,7570,O
the,7570,O
amphipathic,7570,O
alpha-helical,7570,O
regions,7570,O
of,7570,O
the,7570,O
second,7570,O
and,7570,O
fourth,7570,O
domains,7570,O
.,7570,O
Amine,7571,B-GENE-N
oxidase,7571,I-GENE-N
activities,7571,O
in,7571,O
brown,7571,O
adipose,7571,O
tissue,7571,O
of,7571,O
the,7571,O
rat,7571,O
:,7571,O
identification,7571,O
of,7571,O
semicarbazide-sensitive,7571,B-CHEMICAL
(,7571,O
clorgyline-resistant,7571,B-CHEMICAL
),7571,O
activity,7571,O
at,7571,O
the,7571,O
fat,7571,O
cell,7571,O
membrane,7571,O
.,7571,O
Amine,7572,B-CHEMICAL
oxidase,7572,I-GENE-N
activity,7572,O
",",7572,O
previously,7572,O
described,7572,O
in,7572,O
homogenates,7572,O
of,7572,O
brown,7572,O
adipose,7572,O
tissue,7572,O
of,7572,O
the,7572,O
rat,7572,O
",",7572,O
has,7572,O
now,7572,O
been,7572,O
investigated,7572,O
in,7572,O
preparations,7572,O
of,7572,O
isolated,7572,O
fat,7572,O
cells,7572,O
.,7572,O
It,7573,O
was,7573,O
found,7573,O
that,7573,O
the,7573,O
specific,7573,O
activities,7573,O
of,7573,O
both,7573,O
monoamine,7573,B-CHEMICAL
oxidase,7573,I-GENE-Y
A,7573,I-GENE-Y
(,7573,O
MAO,7573,B-GENE-N
),7573,O
and,7573,O
of,7573,O
the,7573,O
semicarbazide-sensitive,7573,B-CHEMICAL
clorgyline-resistant,7573,B-CHEMICAL
amine,7573,I-GENE-Y
oxidase,7573,I-GENE-Y
(,7573,O
SSAO,7573,B-GENE-Y
),7573,O
were,7573,O
higher,7573,O
in,7573,O
isolated,7573,O
fat,7573,O
cells,7573,O
than,7573,O
in,7573,O
the,7573,O
original,7573,O
whole,7573,O
tissue,7573,O
.,7573,O
Brown,7574,O
adipocytes,7574,O
therefore,7574,O
represent,7574,O
a,7574,O
major,7574,O
source,7574,O
of,7574,O
both,7574,O
these,7574,O
enzymes,7574,O
.,7574,O
In,7575,O
plasma,7575,O
membranes,7575,O
prepared,7575,O
from,7575,O
these,7575,O
isolated,7575,O
brown,7575,O
fat,7575,O
cells,7575,O
by,7575,O
borate,7575,B-CHEMICAL
extraction,7575,O
there,7575,O
was,7575,O
a,7575,O
similar,7575,O
enrichment,7575,O
of,7575,O
activity,7575,O
of,7575,O
SSAO,7575,B-GENE-Y
and,7575,O
of,7575,O
the,7575,O
plasma,7575,O
membrane,7575,O
marker,7575,O
enzyme,7575,O
",",7575,O
phosphodiesterase,7575,B-GENE-N
I,7575,I-GENE-N
.,7575,O
However,7576,O
in,7576,O
preparations,7576,O
of,7576,O
cell,7576,O
membranes,7576,O
made,7576,O
by,7576,O
binding,7576,O
the,7576,O
cells,7576,O
to,7576,O
polycation-coated,7576,O
beads,7576,O
",",7576,O
enrichment,7576,O
of,7576,O
phosphodiesterase,7576,B-GENE-N
I,7576,I-GENE-N
activity,7576,O
was,7576,O
much,7576,O
greater,7576,O
than,7576,O
that,7576,O
of,7576,O
SSAO,7576,B-GENE-Y
.,7576,O
It,7577,O
is,7577,O
suggested,7577,O
that,7577,O
the,7577,O
disposition,7577,O
of,7577,O
the,7577,O
enzyme,7577,O
within,7577,O
the,7577,O
cell,7577,O
membrane,7577,O
may,7577,O
account,7577,O
for,7577,O
the,7577,O
discrepancy,7577,O
in,7577,O
these,7577,O
results,7577,O
",",7577,O
i.e,7577,O
.,7577,O
the,7578,O
sidedness,7578,O
of,7578,O
the,7578,O
membrane,7578,O
may,7578,O
be,7578,O
important,7578,O
.,7578,O
Histochemical,7579,O
visualization,7579,O
of,7579,O
enzyme,7579,O
activity,7579,O
in,7579,O
whole,7579,O
tissue,7579,O
at,7579,O
the,7579,O
ultrastructural,7579,O
level,7579,O
was,7579,O
undertaken,7579,O
.,7579,O
Positive,7580,O
staining,7580,O
of,7580,O
mitochondria,7580,O
was,7580,O
achieved,7580,O
in,7580,O
the,7580,O
presence,7580,O
of,7580,O
the,7580,O
MAO,7580,B-GENE-N
substrate,7580,O
",",7580,O
tryptamine,7580,B-CHEMICAL
.,7580,O
Staining,7581,O
around,7581,O
the,7581,O
edges,7581,O
of,7581,O
the,7581,O
brown,7581,O
fat,7581,O
cells,7581,O
was,7581,O
observed,7581,O
with,7581,O
the,7581,O
SSAO,7581,B-GENE-Y
substrates,7581,O
",",7581,O
tyramine,7581,B-CHEMICAL
and,7581,O
benzylamine,7581,B-CHEMICAL
.,7581,O
Staining,7582,O
was,7582,O
largely,7582,O
absent,7582,O
when,7582,O
substrate,7582,O
was,7582,O
omitted,7582,O
or,7582,O
after,7582,O
pretreatment,7582,O
with,7582,O
the,7582,O
irreversible,7582,O
SSAO,7582,B-GENE-Y
inhibitor,7582,O
",",7582,O
hydralazine,7582,B-CHEMICAL
and,7582,O
the,7582,O
slowly,7582,O
reversible,7582,O
inhibitor,7582,O
",",7582,O
semicarbazide,7582,B-CHEMICAL
.,7582,O
It,7583,O
is,7583,O
not,7583,O
definitely,7583,O
proven,7583,O
that,7583,O
this,7583,O
staining,7583,O
represents,7583,O
sites,7583,O
of,7583,O
enzyme,7583,O
activity,7583,O
but,7583,O
the,7583,O
results,7583,O
are,7583,O
consistent,7583,O
with,7583,O
evidence,7583,O
from,7583,O
other,7583,O
studies,7583,O
indicating,7583,O
that,7583,O
SSAO,7583,B-GENE-Y
in,7583,O
brown,7583,O
adipose,7583,O
tissue,7583,O
of,7583,O
the,7583,O
rat,7583,O
may,7583,O
be,7583,O
found,7583,O
predominantly,7583,O
at,7583,O
the,7583,O
fat,7583,O
cell,7583,O
surface,7583,O
.,7583,O
(,7584,O
ABSTRACT,7584,O
TRUNCATED,7584,O
AT,7584,O
250,7584,O
WORDS,7584,O
),7584,O
Penicillin-binding,7585,B-GENE-N
proteins,7585,I-GENE-N
and,7585,O
role,7585,O
of,7585,O
amdinocillin,7585,B-CHEMICAL
in,7585,O
causing,7585,O
bacterial,7585,O
cell,7585,O
death,7585,O
.,7585,O
The,7586,O
activity,7586,O
of,7586,O
penicillins,7586,B-CHEMICAL
against,7586,O
bacteria,7586,O
is,7586,O
in,7586,O
large,7586,O
part,7586,O
related,7586,O
to,7586,O
binding,7586,O
to,7586,O
specific,7586,O
receptor,7586,O
proteins,7586,O
involved,7586,O
in,7586,O
cell,7586,O
wall,7586,O
biosynthesis,7586,O
.,7586,O
These,7587,O
proteins,7587,O
have,7587,O
been,7587,O
designated,7587,O
penicillin-binding,7587,B-GENE-N
proteins,7587,I-GENE-N
.,7587,O
They,7588,O
can,7588,O
be,7588,O
separated,7588,O
into,7588,O
distinct,7588,O
entities,7588,O
through,7588,O
the,7588,O
use,7588,O
of,7588,O
acrylamide,7588,B-CHEMICAL
gel,7588,O
electrophoresis,7588,O
and,7588,O
binding,7588,O
of,7588,O
radioactive,7588,O
14C-labeled,7588,B-CHEMICAL
penicillin,7588,I-CHEMICAL
G.,7588,O
Six,7588,O
major,7588,O
proteins,7588,O
have,7588,O
been,7588,O
defined,7588,O
in,7588,O
the,7588,O
Enterobacteriaceae,7588,O
",",7588,O
penicillin-binding,7588,B-GENE-N
proteins,7588,I-GENE-N
1,7588,I-GENE-N
to,7588,I-GENE-N
6,7588,I-GENE-N
.,7588,O
Selection,7589,O
of,7589,O
mutants,7589,O
has,7589,O
shown,7589,O
that,7589,O
there,7589,O
are,7589,O
three,7589,O
essential,7589,O
proteins,7589,O
:,7589,O
penicillin-binding,7589,B-GENE-N
protein,7589,I-GENE-N
1,7589,I-GENE-N
",",7589,O
which,7589,O
is,7589,O
divided,7589,O
into,7589,O
penicillin-binding,7589,B-GENE-N
protein,7589,I-GENE-N
1Bs,7589,I-GENE-N
",",7589,O
a,7589,O
peptidoglycan,7589,B-GENE-N
transpeptidase,7589,I-GENE-N
",",7589,O
and,7589,O
penicillin-binding,7589,B-GENE-N
protein,7589,I-GENE-N
1A,7589,I-GENE-N
",",7589,O
which,7589,O
acts,7589,O
as,7589,O
a,7589,O
replacement,7589,O
for,7589,O
penicillin-binding,7589,B-GENE-N
protein,7589,I-GENE-N
1Bs,7589,I-GENE-N
.,7589,O
Penicillin-binding,7590,B-GENE-N
protein,7590,I-GENE-N
2,7590,I-GENE-N
is,7590,O
a,7590,O
murein-elongation,7590,B-GENE-N
initiating,7590,O
enzyme,7590,O
and,7590,O
penicillin-binding,7590,B-GENE-N
protein,7590,I-GENE-N
3,7590,I-GENE-N
is,7590,O
a,7590,O
septal,7590,O
murein-synthesizing,7590,B-GENE-N
enzyme,7590,O
.,7590,O
Penicillin-binding,7591,B-GENE-N
proteins,7591,I-GENE-N
4,7591,I-GENE-N
",",7591,I-GENE-N
5,7591,I-GENE-N
",",7591,I-GENE-N
and,7591,I-GENE-N
6,7591,I-GENE-N
are,7591,O
not,7591,O
essential,7591,O
for,7591,O
bacterial,7591,O
survival,7591,O
.,7591,O
Binding,7592,O
of,7592,O
penicillins,7592,B-CHEMICAL
to,7592,O
penicillin-binding,7592,B-GENE-N
protein,7592,I-GENE-N
1Bs,7592,I-GENE-N
produces,7592,O
lysis,7592,O
",",7592,O
binding,7592,O
to,7592,O
penicillin-binding,7592,B-GENE-N
protein,7592,I-GENE-N
2,7592,I-GENE-N
produces,7592,O
round,7592,O
cells,7592,O
",",7592,O
and,7592,O
binding,7592,O
to,7592,O
penicillin-binding,7592,B-GENE-N
protein,7592,I-GENE-N
3,7592,I-GENE-N
produces,7592,O
long,7592,O
filaments,7592,O
.,7592,O
Amdinocillin,7593,B-CHEMICAL
is,7593,O
a,7593,O
beta-amidino,7593,B-CHEMICAL
penicillanic,7593,I-CHEMICAL
acid,7593,I-CHEMICAL
derivative,7593,O
that,7593,O
binds,7593,O
specifically,7593,O
to,7593,O
penicillin-binding,7593,B-CHEMICAL
protein,7593,I-GENE-N
2,7593,I-GENE-N
.,7593,O
The,7594,O
compound,7594,O
is,7594,O
more,7594,O
beta-lactamase,7594,B-GENE-N
stable,7594,O
than,7594,O
ampicillin,7594,B-CHEMICAL
and,7594,O
has,7594,O
no,7594,O
major,7594,O
delay,7594,O
in,7594,O
entry,7594,O
into,7594,O
the,7594,O
periplasmic,7594,O
space,7594,O
as,7594,O
do,7594,O
some,7594,O
penicillins,7594,B-CHEMICAL
.,7594,O
Amdinocillin,7595,B-CHEMICAL
inhibits,7595,O
most,7595,O
of,7595,O
the,7595,O
Enterobacteriaceae,7595,O
",",7595,O
with,7595,O
the,7595,O
exception,7595,O
of,7595,O
some,7595,O
indole-positive,7595,B-CHEMICAL
Proteus,7595,O
species,7595,O
",",7595,O
but,7595,O
it,7595,O
does,7595,O
not,7595,O
inhibit,7595,O
gram-positive,7595,O
cocci,7595,O
or,7595,O
Pseudomonas,7595,O
aeruginosa,7595,O
.,7595,O
Amdinocillin,7596,B-CHEMICAL
produces,7596,O
spherical,7596,O
bacterial,7596,O
cells,7596,O
that,7596,O
eventually,7596,O
lyse,7596,O
.,7596,O
Its,7597,O
activity,7597,O
in,7597,O
vitro,7597,O
is,7597,O
markedly,7597,O
affected,7597,O
by,7597,O
ionic,7597,O
content,7597,O
of,7597,O
media,7597,O
.,7597,O
This,7598,O
agent,7598,O
acts,7598,O
synergistically,7598,O
with,7598,O
many,7598,O
penicillins,7598,B-CHEMICAL
",",7598,O
such,7598,O
as,7598,O
ampicillin,7598,B-CHEMICAL
",",7598,O
carbenicillin,7598,B-CHEMICAL
",",7598,O
and,7598,O
the,7598,O
like,7598,O
",",7598,O
and,7598,O
with,7598,O
cephalosporins,7598,B-CHEMICAL
",",7598,O
cefazolin,7598,B-CHEMICAL
",",7598,O
cefamandole,7598,B-CHEMICAL
",",7598,O
or,7598,O
cefoxitin,7598,B-CHEMICAL
to,7598,O
inhibit,7598,O
gram-negative,7598,O
bacilli,7598,O
",",7598,O
probably,7598,O
on,7598,O
the,7598,O
basis,7598,O
of,7598,O
binding,7598,O
to,7598,O
different,7598,O
proteins,7598,O
needed,7598,O
for,7598,O
the,7598,O
production,7598,O
of,7598,O
the,7598,O
peptidoglycan,7598,B-GENE-N
of,7598,O
the,7598,O
bacterial,7598,O
cell,7598,O
wall,7598,O
.,7598,O
Amdinocillin,7599,B-CHEMICAL
possesses,7599,O
a,7599,O
number,7599,O
of,7599,O
the,7599,O
essentials,7599,O
for,7599,O
effective,7599,O
antimicrobial,7599,O
activity,7599,O
and,7599,O
",",7599,O
by,7599,O
virtue,7599,O
of,7599,O
its,7599,O
enhancement,7599,O
of,7599,O
the,7599,O
activity,7599,O
of,7599,O
other,7599,O
beta-lactams,7599,B-CHEMICAL
",",7599,O
may,7599,O
prove,7599,O
to,7599,O
be,7599,O
a,7599,O
useful,7599,O
agent,7599,O
in,7599,O
the,7599,O
chemotherapy,7599,O
of,7599,O
certain,7599,O
infections,7599,O
.,7599,O
Loss,7600,O
of,7600,O
alpha,7600,B-GENE-Y
2-macroglobulin,7600,I-GENE-Y
and,7600,O
epidermal,7600,B-GENE-Y
growth,7600,I-GENE-Y
factor,7600,I-GENE-Y
surface,7600,O
binding,7600,O
induced,7600,O
by,7600,O
phenothiazines,7600,B-CHEMICAL
and,7600,O
naphthalene,7600,B-CHEMICAL
sulfonamides,7600,I-CHEMICAL
.,7600,O
We,7601,O
have,7601,O
found,7601,O
that,7601,O
certain,7601,O
naphthalenesulfonamides,7601,B-CHEMICAL
[,7601,O
e.g.,7601,O
",",7601,O
N-6,7601,B-CHEMICAL
(,7601,I-CHEMICAL
-aminohexyl,7601,I-CHEMICAL
),7601,I-CHEMICAL
-5-chloro-1-naphthalenesulfonamide,7601,I-CHEMICAL
(,7601,O
W-7,7601,B-CHEMICAL
),7601,O
],7601,O
and,7601,O
phenothiazines,7601,B-CHEMICAL
[,7601,O
e.g.,7601,O
",",7601,O
trifluoperazine,7601,B-CHEMICAL
(,7601,O
TFP,7601,B-CHEMICAL
),7601,O
],7601,O
induce,7601,O
a,7601,O
loss,7601,O
of,7601,O
cell-surface,7601,O
receptors,7601,O
for,7601,O
alpha,7601,B-GENE-Y
2-macroglobulin,7601,I-GENE-Y
",",7601,O
and,7601,O
epidermal,7601,B-GENE-Y
growth,7601,I-GENE-Y
factor,7601,I-GENE-Y
(,7601,O
EGF,7601,B-GENE-Y
),7601,O
in,7601,O
fibroblasts,7601,O
.,7601,O
The,7602,O
loss,7602,O
of,7602,O
alpha,7602,B-GENE-Y
2-macroglobulin,7602,I-GENE-Y
receptors,7602,I-GENE-Y
is,7602,O
independent,7602,O
of,7602,O
receptor,7602,O
occupancy,7602,O
and,7602,O
is,7602,O
rapidly,7602,O
reversed,7602,O
upon,7602,O
removal,7602,O
of,7602,O
these,7602,O
agents,7602,O
from,7602,O
the,7602,O
culture,7602,O
medium,7602,O
.,7602,O
The,7603,O
extent,7603,O
of,7603,O
EGF,7603,B-GENE-Y
receptor,7603,I-GENE-Y
loss,7603,O
is,7603,O
less,7603,O
than,7603,O
for,7603,O
alpha,7603,B-GENE-Y
2-macroglobulin,7603,I-GENE-Y
",",7603,O
and,7603,O
the,7603,O
EGF,7603,B-GENE-Y
receptors,7603,I-GENE-Y
do,7603,O
not,7603,O
reappear,7603,O
at,7603,O
the,7603,O
surface,7603,O
when,7603,O
W-7,7603,B-CHEMICAL
is,7603,O
removed,7603,O
.,7603,O
Receptor,7604,O
loss,7604,O
was,7604,O
measured,7604,O
as,7604,O
a,7604,O
change,7604,O
in,7604,O
the,7604,O
capacity,7604,O
for,7604,O
binding,7604,O
iodinated,7604,O
ligands,7604,O
;,7604,O
no,7604,O
change,7604,O
in,7604,O
affinity,7604,O
of,7604,O
binding,7604,O
was,7604,O
observed,7604,O
.,7604,O
This,7605,O
receptor,7605,O
loss,7605,O
could,7605,O
reflect,7605,O
inactivation,7605,O
of,7605,O
receptors,7605,O
or,7605,O
internalization,7605,O
.,7605,O
W-7,7606,B-CHEMICAL
did,7606,O
not,7606,O
induce,7606,O
a,7606,O
loss,7606,O
of,7606,O
cell,7606,O
surface,7606,O
beta,7606,B-GENE-Y
2-microglobulin,7606,I-GENE-Y
",",7606,O
a,7606,O
membrane,7606,O
protein,7606,O
which,7606,O
is,7606,O
excluded,7606,O
from,7606,O
coated,7606,O
pits,7606,O
and,7606,O
which,7606,O
is,7606,O
not,7606,O
internalized,7606,O
",",7606,O
indicating,7606,O
that,7606,O
the,7606,O
effect,7606,O
of,7606,O
W-7,7606,B-CHEMICAL
was,7606,O
specific,7606,O
for,7606,O
membrane,7606,O
receptors,7606,O
and,7606,O
not,7606,O
a,7606,O
result,7606,O
of,7606,O
bulk,7606,O
depletion,7606,O
of,7606,O
plasma,7606,O
membrane,7606,O
.,7606,O
The,7607,O
loss,7607,O
of,7607,O
alpha,7607,B-GENE-Y
2-macroglobulin,7607,I-GENE-Y
and,7607,O
EGF,7607,B-GENE-Y
receptors,7607,I-GENE-Y
occurs,7607,O
at,7607,O
concentrations,7607,O
which,7607,O
do,7607,O
not,7607,O
cause,7607,O
an,7607,O
increase,7607,O
in,7607,O
the,7607,O
pH,7607,O
of,7607,O
endocytic,7607,O
vesicles,7607,O
or,7607,O
the,7607,O
cytoplasm,7607,O
",",7607,O
indicating,7607,O
that,7607,O
these,7607,O
agents,7607,O
act,7607,O
by,7607,O
a,7607,O
mechanism,7607,O
distinct,7607,O
from,7607,O
the,7607,O
effect,7607,O
of,7607,O
other,7607,O
weak,7607,O
bases,7607,O
.,7607,O
Since,7608,O
both,7608,O
TFP,7608,B-CHEMICAL
and,7608,O
W-7,7608,B-CHEMICAL
are,7608,O
potent,7608,O
inhibitors,7608,O
of,7608,O
calmodulin,7608,B-GENE-N
",",7608,O
we,7608,O
investigated,7608,O
the,7608,O
possibility,7608,O
that,7608,O
inhibition,7608,O
of,7608,O
calmodulin,7608,B-GENE-N
was,7608,O
responsible,7608,O
for,7608,O
the,7608,O
loss,7608,O
of,7608,O
receptors,7608,O
.,7608,O
Three,7609,O
lines,7609,O
of,7609,O
evidence,7609,O
suggest,7609,O
that,7609,O
calmodulin,7609,B-GENE-N
inhibition,7609,O
is,7609,O
not,7609,O
responsible,7609,O
for,7609,O
the,7609,O
inhibition,7609,O
of,7609,O
binding,7609,O
and,7609,O
endocytosis,7609,O
:,7609,O
1,7609,O
),7609,O
Promethazine,7609,B-CHEMICAL
",",7609,O
a,7609,O
phenothiazine,7609,B-CHEMICAL
that,7609,O
is,7609,O
a,7609,O
poor,7609,O
inhibitor,7609,O
of,7609,O
calmodulin,7609,O
",",7609,O
is,7609,O
nearly,7609,O
as,7609,O
effective,7609,O
as,7609,O
TFP,7609,B-CHEMICAL
at,7609,O
inhibiting,7609,O
endocytosis,7609,O
;,7609,O
calmidazolium,7609,O
",",7609,O
a,7609,O
potent,7609,O
inhibitor,7609,O
of,7609,O
several,7609,O
calmodulin,7609,B-GENE-N
functions,7609,O
",",7609,O
did,7609,O
not,7609,O
cause,7609,O
a,7609,O
loss,7609,O
of,7609,O
binding,7609,O
;,7609,O
2,7609,O
),7609,O
the,7609,O
microinjection,7609,O
of,7609,O
calmodulin,7609,B-GENE-N
into,7609,O
cells,7609,O
did,7609,O
not,7609,O
reverse,7609,O
the,7609,O
effects,7609,O
of,7609,O
W-7,7609,B-CHEMICAL
;,7609,O
using,7609,O
pressure,7609,O
microinjection,7609,O
",",7609,O
we,7609,O
introduced,7609,O
up,7609,O
to,7609,O
a,7609,O
100-fold,7609,O
excess,7609,O
of,7609,O
calmodulin,7609,B-GENE-N
over,7609,O
native,7609,O
levels,7609,O
into,7609,O
individual,7609,O
gerbil,7609,O
fibroma,7609,O
cells,7609,O
;,7609,O
using,7609,O
rhodamine-labeled,7609,B-CHEMICAL
alpha,7609,B-GENE-Y
2-macroglobulin,7609,I-GENE-Y
",",7609,O
we,7609,O
saw,7609,O
that,7609,O
the,7609,O
W-7,7609,B-CHEMICAL
induced,7609,O
inhibition,7609,O
of,7609,O
receptor-mediated,7609,O
endocytosis,7609,O
was,7609,O
the,7609,O
same,7609,O
in,7609,O
injected,7609,O
and,7609,O
uninjected,7609,O
cells,7609,O
;,7609,O
3,7609,O
),7609,O
we,7609,O
injected,7609,O
calcineurin,7609,B-GENE-N
",",7609,O
a,7609,O
calmodulin-binding,7609,B-GENE-N
protein,7609,I-GENE-N
",",7609,O
into,7609,O
cells,7609,O
(,7609,O
1-3,7609,O
pg/cell,7609,O
),7609,O
and,7609,O
observed,7609,O
no,7609,O
effect,7609,O
on,7609,O
the,7609,O
receptor-mediated,7609,O
endocytosis,7609,O
of,7609,O
rhodamine-labeled,7609,B-CHEMICAL
alpha,7609,B-GENE-Y
2-macroglobulin,7609,I-GENE-Y
.,7609,O
These,7610,O
data,7610,O
indicated,7610,O
that,7610,O
cell,7610,O
surface,7610,O
receptor,7610,O
numbers,7610,O
can,7610,O
be,7610,O
regulated,7610,O
by,7610,O
a,7610,O
cellular,7610,O
component,7610,O
that,7610,O
is,7610,O
not,7610,O
cytoplasmic,7610,B-GENE-N
calmodulin,7610,I-GENE-N
but,7610,O
that,7610,O
shares,7610,O
some,7610,O
drug,7610,O
sensitivities,7610,O
with,7610,O
calmodulin,7610,B-GENE-N
.,7610,O
The,7611,O
effect,7611,O
of,7611,O
various,7611,O
amino,7611,B-CHEMICAL
acids,7611,I-CHEMICAL
and,7611,O
drugs,7611,O
on,7611,O
the,7611,O
para-,7611,B-CHEMICAL
and,7611,I-CHEMICAL
meta-hydroxyphenylacetic,7611,I-CHEMICAL
acid,7611,I-CHEMICAL
concentrations,7611,O
in,7611,O
the,7611,O
mouse,7611,O
caudate,7611,O
nucleus,7611,O
.,7611,O
Injection,7612,O
of,7612,O
L-p-tyrosine,7612,B-CHEMICAL
(,7612,O
800,7612,O
mg/kg,7612,O
",",7612,O
2,7612,O
h,7612,O
),7612,O
increased,7612,O
the,7612,O
mouse,7612,O
striatal,7612,O
para-hydroxyphenylacetic,7612,B-CHEMICAL
acid,7612,I-CHEMICAL
(,7612,O
p-HPAA,7612,B-CHEMICAL
),7612,O
concentrations,7612,O
.,7612,O
A,7613,O
smaller,7613,O
dose,7613,O
of,7613,O
D,7613,B-CHEMICAL
",",7613,I-CHEMICAL
L-m-tyrosine,7613,I-CHEMICAL
(,7613,O
20,7613,O
mg/kg,7613,O
",",7613,O
2,7613,O
h,7613,O
),7613,O
produced,7613,O
a,7613,O
larger,7613,O
increase,7613,O
in,7613,O
mouse,7613,O
striatal,7613,O
meta-hydroxyphenylacetic,7613,B-CHEMICAL
acid,7613,I-CHEMICAL
(,7613,O
m-HPAA,7613,B-CHEMICAL
),7613,O
concentrations,7613,O
.,7613,O
The,7614,O
administration,7614,O
of,7614,O
L-phenylalanine,7614,B-CHEMICAL
to,7614,O
mice,7614,O
caused,7614,O
a,7614,O
slight,7614,O
increase,7614,O
in,7614,O
the,7614,O
p-HPAA,7614,B-CHEMICAL
concentration,7614,O
in,7614,O
the,7614,O
corpus,7614,O
striatum,7614,O
after,7614,O
2,7614,O
h,7614,O
while,7614,O
a,7614,O
larger,7614,O
dose,7614,O
of,7614,O
L-phenylalanine,7614,B-CHEMICAL
(,7614,O
800,7614,O
mg/kg,7614,O
),7614,O
produced,7614,O
a,7614,O
greater,7614,O
increase,7614,O
.,7614,O
Eight,7615,O
hours,7615,O
following,7615,O
L-phenylalanine,7615,B-CHEMICAL
injection,7615,O
",",7615,O
p-HPAA,7615,B-CHEMICAL
concentrations,7615,O
were,7615,O
still,7615,O
elevated,7615,O
.,7615,O
With,7616,O
D-phenylalanine,7616,B-CHEMICAL
a,7616,O
significant,7616,O
increase,7616,O
was,7616,O
observed,7616,O
at,7616,O
eight,7616,O
hours,7616,O
after,7616,O
drug,7616,O
administration,7616,O
.,7616,O
Two,7617,O
drugs,7617,O
which,7617,O
reduce,7617,O
dopamine,7617,B-CHEMICAL
synthesis,7617,O
",",7617,O
alpha-methyl-para-tyrosine,7617,B-CHEMICAL
and,7617,O
apomorphine,7617,B-CHEMICAL
",",7617,O
decreased,7617,O
m-HPAA,7617,B-CHEMICAL
striatal,7617,O
concentrations,7617,O
without,7617,O
affecting,7617,O
p-HPAA,7617,B-CHEMICAL
concentrations,7617,O
.,7617,O
From,7618,O
these,7618,O
results,7618,O
",",7618,O
it,7618,O
is,7618,O
proposed,7618,O
that,7618,O
tyrosine,7618,B-GENE-Y
hydroxylase,7618,I-GENE-Y
activity,7618,O
determines,7618,O
p-HPAA,7618,B-CHEMICAL
concentrations,7618,O
by,7618,O
regulating,7618,O
p-tyrosine,7618,B-CHEMICAL
availability,7618,O
.,7618,O
This,7619,O
enzyme,7619,O
may,7619,O
also,7619,O
synthesize,7619,O
m-tyrosine,7619,B-CHEMICAL
which,7619,O
is,7619,O
subsequently,7619,O
decarboxylated,7619,O
to,7619,O
form,7619,O
m-tyramine,7619,B-CHEMICAL
and,7619,O
then,7619,O
oxidatively,7619,O
deaminated,7619,O
to,7619,O
form,7619,O
m-HPAA,7619,B-CHEMICAL
.,7619,O
Demonstration,7620,O
of,7620,O
histamine,7620,B-CHEMICAL
receptors,7620,I-GENE-N
on,7620,O
human,7620,O
platelets,7620,O
by,7620,O
flow,7620,O
cytometry,7620,O
.,7620,O
Fluoresceinated,7621,B-GENE-Y
human,7621,I-GENE-Y
albumin,7621,I-GENE-Y
conjugated,7621,O
with,7621,O
histamine,7621,B-CHEMICAL
(,7621,O
FHA-HIS,7621,B-GENE-Y
),7621,O
has,7621,O
been,7621,O
used,7621,O
for,7621,O
the,7621,O
demonstration,7621,O
of,7621,O
histamine,7621,B-CHEMICAL
receptors,7621,I-GENE-N
on,7621,O
human,7621,O
platelets,7621,O
.,7621,O
Such,7622,O
receptors,7622,O
were,7622,O
demonstrated,7622,O
on,7622,O
40-63,7622,O
%,7622,O
of,7622,O
peripheral,7622,O
blood,7622,O
platelets,7622,O
in,7622,O
4,7622,O
healthy,7622,O
donors,7622,O
.,7622,O
The,7623,O
binding,7623,O
of,7623,O
FHA-HIS,7623,B-GENE-Y
was,7623,O
inhibited,7623,O
on,7623,O
35-79,7623,O
%,7623,O
of,7623,O
the,7623,O
platelets,7623,O
by,7623,O
the,7623,O
histamine,7623,B-CHEMICAL
H1,7623,I-GENE-Y
receptor,7623,I-GENE-Y
antagonists,7623,O
diphenhydramine,7623,B-CHEMICAL
and,7623,O
clemastine,7623,B-CHEMICAL
.,7623,O
The,7624,O
histamine,7624,B-CHEMICAL
H2,7624,I-GENE-Y
receptor,7624,I-GENE-Y
antagonist,7624,O
cimetidine,7624,B-CHEMICAL
blocked,7624,O
the,7624,O
FHA-HIS,7624,B-GENE-Y
binding,7624,O
on,7624,O
14-37,7624,O
%,7624,O
of,7624,O
the,7624,O
platelets,7624,O
.,7624,O
It,7625,O
is,7625,O
concluded,7625,O
that,7625,O
histamine,7625,B-CHEMICAL
H1,7625,I-GENE-Y
as,7625,O
well,7625,O
as,7625,O
H2,7625,B-GENE-Y
receptors,7625,I-GENE-Y
occur,7625,O
on,7625,O
human,7625,O
platelets,7625,O
but,7625,O
the,7625,O
receptors,7625,O
are,7625,O
not,7625,O
equally,7625,O
distributed,7625,O
in,7625,O
the,7625,O
platelet,7625,O
population,7625,O
.,7625,O
The,7626,O
effect,7626,O
of,7626,O
vitamin,7626,B-CHEMICAL
B6,7626,I-CHEMICAL
deficiency,7626,O
on,7626,O
alanine,7626,B-GENE-N
:,7626,I-GENE-N
glyoxylate,7626,I-GENE-N
aminotransferase,7626,I-GENE-N
isoenzymes,7626,O
in,7626,O
rat,7626,O
liver,7626,O
.,7626,O
Endogenous,7627,O
synthesis,7627,O
of,7627,O
oxalate,7627,B-CHEMICAL
has,7627,O
been,7627,O
reported,7627,O
to,7627,O
increase,7627,O
in,7627,O
vitamin,7627,B-CHEMICAL
B6,7627,I-CHEMICAL
deficiency,7627,O
probably,7627,O
due,7627,O
to,7627,O
defective,7627,O
transamination,7627,O
of,7627,O
glyoxylate,7627,B-CHEMICAL
",",7627,O
the,7627,O
direct,7627,O
source,7627,O
of,7627,O
oxalate,7627,B-CHEMICAL
",",7627,O
to,7627,O
glycine,7627,B-CHEMICAL
.,7627,O
Alanine,7628,B-CHEMICAL
:,7628,I-GENE-N
glyoxylate,7628,B-CHEMICAL
aminotransferase,7628,I-GENE-N
(,7628,O
AGT,7628,B-GENE-N
),7628,O
in,7628,O
the,7628,O
liver,7628,O
catalyzes,7628,O
most,7628,O
of,7628,O
the,7628,O
glyoxylate,7628,B-CHEMICAL
transamination,7628,O
in,7628,O
mammalian,7628,O
tissues,7628,O
(,7628,O
E.,7628,O
V.,7628,O
Rowsell,7628,O
",",7628,O
K.,7628,O
Snell,7628,O
",",7628,O
J,7628,O
.,7628,O
A.,7629,O
Carnie,7629,O
",",7629,O
and,7629,O
K.,7629,O
V.,7629,O
Rowsell,7629,O
(,7629,O
1972,7629,O
),7629,O
Biochem,7629,O
.,7629,O
J,7630,O
.,7630,O
127,7631,O
",",7631,O
155-165,7631,O
),7631,O
.,7631,O
The,7632,O
effects,7632,O
of,7632,O
vitamin,7632,B-CHEMICAL
B6,7632,I-CHEMICAL
deficiency,7632,O
on,7632,O
hepatic,7632,O
AGT,7632,B-GENE-N
isoenzymes,7632,O
",",7632,O
designated,7632,O
AGT,7632,B-GENE-Y
1,7632,I-GENE-Y
and,7632,O
AGT,7632,B-GENE-Y
2,7632,I-GENE-Y
",",7632,O
respectively,7632,O
",",7632,O
were,7632,O
examined,7632,O
with,7632,O
male,7632,O
rats,7632,O
;,7632,O
AGT,7632,B-GENE-Y
1,7632,I-GENE-Y
is,7632,O
located,7632,O
both,7632,O
in,7632,O
the,7632,O
peroxisomes,7632,O
and,7632,O
in,7632,O
the,7632,O
mitochondria,7632,O
",",7632,O
and,7632,O
AGT,7632,B-GENE-Y
2,7632,I-GENE-Y
only,7632,O
in,7632,O
the,7632,O
mitochondria,7632,O
.,7632,O
The,7633,O
holo,7633,O
activity,7633,O
of,7633,O
combined,7633,O
peroxisomal,7633,O
and,7633,O
mitochondrial,7633,O
AGT,7633,B-GENE-Y
1,7633,I-GENE-Y
with,7633,O
a,7633,O
low,7633,O
Km,7633,O
for,7633,O
L-alanine,7633,B-CHEMICAL
rapidly,7633,O
decreased,7633,O
after,7633,O
a,7633,O
lag,7633,O
time,7633,O
of,7633,O
about,7633,O
2,7633,O
days,7633,O
during,7633,O
feeding,7633,O
of,7633,O
the,7633,O
vitamin,7633,B-CHEMICAL
B6-deficient,7633,O
diet,7633,O
(,7633,O
by,7633,O
50,7633,O
%,7633,O
in,7633,O
5,7633,O
days,7633,O
",",7633,O
by,7633,O
86,7633,O
%,7633,O
in,7633,O
14,7633,O
days,7633,O
),7633,O
.,7633,O
Peroxisomal,7634,O
AGT,7634,B-GENE-Y
1,7634,I-GENE-Y
activity,7634,O
was,7634,O
more,7634,O
affected,7634,O
than,7634,O
the,7634,O
mitochondrial,7634,O
.,7634,O
The,7635,O
holo,7635,O
activity,7635,O
of,7635,O
AGT,7635,B-GENE-Y
2,7635,I-GENE-Y
with,7635,O
a,7635,O
high,7635,O
Km,7635,O
for,7635,O
L-alanine,7635,B-CHEMICAL
decreased,7635,O
more,7635,O
slowly,7635,O
than,7635,O
AGT,7635,B-GENE-Y
1,7635,I-GENE-Y
(,7635,O
by,7635,O
33,7635,O
%,7635,O
in,7635,O
14,7635,O
days,7635,O
",",7635,O
by,7635,O
60,7635,O
%,7635,O
in,7635,O
28,7635,O
days,7635,O
),7635,O
.,7635,O
Urinary,7636,O
excretion,7636,O
of,7636,O
oxalate,7636,B-CHEMICAL
began,7636,O
to,7636,O
increase,7636,O
in,7636,O
8-9,7636,O
days,7636,O
",",7636,O
when,7636,O
AGT,7636,B-GENE-Y
2,7636,I-GENE-Y
remained,7636,O
intact,7636,O
but,7636,O
most,7636,O
of,7636,O
AGT,7636,B-GENE-Y
1,7636,I-GENE-Y
is,7636,O
depleted,7636,O
.,7636,O
When,7637,O
the,7637,O
defect,7637,O
in,7637,O
the,7637,O
glyoxylate,7637,B-CHEMICAL
transamination,7637,O
in,7637,O
vivo,7637,O
in,7637,O
vitamin,7637,B-CHEMICAL
B6,7637,I-CHEMICAL
deficiency,7637,O
is,7637,O
considered,7637,O
",",7637,O
these,7637,O
findings,7637,O
suggest,7637,O
that,7637,O
it,7637,O
is,7637,O
due,7637,O
to,7637,O
the,7637,O
deficiency,7637,O
of,7637,O
AGT,7637,B-GENE-Y
1,7637,I-GENE-Y
.,7637,O
The,7638,O
importance,7638,O
of,7638,O
peroxisomal,7638,O
AGT,7638,B-GENE-Y
1,7638,I-GENE-Y
is,7638,O
discussed,7638,O
",",7638,O
since,7638,O
peroxisomes,7638,O
have,7638,O
been,7638,O
described,7638,O
to,7638,O
be,7638,O
probably,7638,O
the,7638,O
major,7638,O
site,7638,O
of,7638,O
glyoxylate,7638,B-CHEMICAL
formation,7638,O
.,7638,O
How,7639,O
do,7639,O
volatile,7639,O
anesthetics,7639,O
inhibit,7639,O
Ca,7639,B-GENE-N
(,7639,I-GENE-N
2+,7639,I-GENE-N
),7639,I-GENE-N
-ATPases,7639,I-GENE-N
?,7639,O
Volatile,7640,O
anesthetics,7640,O
at,7640,O
concentrations,7640,O
that,7640,O
are,7640,O
used,7640,O
in,7640,O
clinical,7640,O
practice,7640,O
to,7640,O
induce,7640,O
anesthesia,7640,O
selectively,7640,O
inhibit,7640,O
activity,7640,O
of,7640,O
the,7640,O
plasma,7640,O
membrane,7640,O
Ca,7640,B-CHEMICAL
(,7640,I-CHEMICAL
2+,7640,I-CHEMICAL
),7640,I-CHEMICAL
-transport,7640,I-GENE-N
ATPase,7640,I-GENE-N
(,7640,O
Kosk-Kosicka,7640,O
",",7640,O
D.,7640,O
",",7640,O
and,7640,O
Roszczynska,7640,O
",",7640,O
G.,7640,O
(,7640,O
1993,7640,O
),7640,O
Anesthesiology,7640,O
79,7640,O
",",7640,O
774-780,7640,O
),7640,O
.,7640,O
We,7641,O
have,7641,O
investigated,7641,O
the,7641,O
mechanism,7641,O
of,7641,O
the,7641,O
inhibitory,7641,O
action,7641,O
of,7641,O
several,7641,O
anesthetics,7641,O
on,7641,O
the,7641,O
purified,7641,O
erythrocyte,7641,O
Ca,7641,B-CHEMICAL
(,7641,I-CHEMICAL
2+,7641,I-CHEMICAL
),7641,I-CHEMICAL
-ATPase,7641,I-GENE-N
by,7641,O
employing,7641,O
fluorescence,7641,O
spectroscopy,7641,O
measurements,7641,O
that,7641,O
report,7641,O
changes,7641,O
in,7641,O
the,7641,O
environment,7641,O
of,7641,O
intrinsic,7641,O
tryptophans,7641,B-CHEMICAL
and,7641,O
of,7641,O
an,7641,O
extrinsic,7641,O
probe,7641,O
attached,7641,O
in,7641,O
the,7641,O
active,7641,O
site,7641,O
of,7641,O
the,7641,O
enzyme,7641,O
.,7641,O
We,7642,O
have,7642,O
shown,7642,O
that,7642,O
the,7642,O
observed,7642,O
inhibition,7642,O
of,7642,O
the,7642,O
Ca,7642,B-CHEMICAL
(,7642,I-CHEMICAL
2+,7642,I-CHEMICAL
),7642,I-CHEMICAL
-dependent,7642,O
activation,7642,O
of,7642,O
the,7642,O
enzyme,7642,O
correlates,7642,O
well,7642,O
with,7642,O
the,7642,O
elimination,7642,O
of,7642,O
the,7642,O
Ca,7642,B-CHEMICAL
(,7642,I-CHEMICAL
2+,7642,I-CHEMICAL
),7642,I-CHEMICAL
-induced,7642,O
conformation,7642,O
change,7642,O
that,7642,O
is,7642,O
important,7642,O
for,7642,O
the,7642,O
proper,7642,O
function,7642,O
of,7642,O
the,7642,O
enzyme,7642,O
.,7642,O
Analysis,7643,O
of,7643,O
the,7643,O
anesthetics,7643,O
effects,7643,O
on,7643,O
the,7643,O
total,7643,O
tryptophan,7643,B-CHEMICAL
fluorescence,7643,O
indicates,7643,O
a,7643,O
significant,7643,O
effect,7643,O
on,7643,O
enzyme,7643,O
conformation,7643,O
.,7643,O
Similar,7644,O
changes,7644,O
have,7644,O
been,7644,O
observed,7644,O
in,7644,O
the,7644,O
sarcoplasmic,7644,B-GENE-N
reticulum,7644,I-GENE-N
Ca,7644,B-CHEMICAL
(,7644,I-CHEMICAL
2+,7644,I-CHEMICAL
),7644,I-CHEMICAL
-ATPase,7644,I-GENE-N
.,7644,O
We,7645,O
propose,7645,O
that,7645,O
volatile,7645,O
anesthetics,7645,O
inhibit,7645,O
Ca,7645,B-CHEMICAL
(,7645,I-CHEMICAL
2+,7645,I-CHEMICAL
),7645,I-CHEMICAL
-ATPase,7645,I-GENE-N
by,7645,O
interacting,7645,O
with,7645,O
nonpolar,7645,O
sites,7645,O
in,7645,O
protein,7645,O
interior,7645,O
",",7645,O
in,7645,O
analogy,7645,O
to,7645,O
the,7645,O
binding,7645,O
demonstrated,7645,O
for,7645,O
myoglobin,7645,B-GENE-Y
",",7645,O
hemoglobin,7645,B-GENE-N
",",7645,O
and,7645,O
adenylate,7645,B-CHEMICAL
kinase,7645,I-GENE-N
(,7645,O
Schoenborn,7645,O
",",7645,O
B.,7645,O
P.,7645,O
",",7645,O
and,7645,O
Featherstone,7645,O
",",7645,O
R.,7645,O
M.,7645,O
(,7645,O
1967,7645,O
),7645,O
Adv,7645,O
.,7645,O
Pharmacol,7646,O
.,7646,O
5,7647,O
",",7647,O
1-17,7647,O
;,7647,O
Tilton,7647,O
",",7647,O
R.,7647,O
F.,7647,O
",",7647,O
Kuntz,7647,O
",",7647,O
I.,7647,O
D.,7647,O
",",7647,O
and,7647,O
Petsko,7647,O
",",7647,O
G.,7647,O
A,7647,O
.,7647,O
(,7648,O
1984,7648,O
),7648,O
Biochemistry,7648,O
23,7648,O
",",7648,O
2849-2857,7648,O
),7648,O
.,7648,O
Such,7649,O
binding,7649,O
is,7649,O
expected,7649,O
to,7649,O
modify,7649,O
conformational,7649,O
substate,7649,O
(,7649,O
s,7649,O
),7649,O
of,7649,O
the,7649,O
enzyme,7649,O
and,7649,O
perturb,7649,O
its,7649,O
function,7649,O
.,7649,O
We,7650,O
view,7650,O
this,7650,O
process,7650,O
as,7650,O
an,7650,O
example,7650,O
of,7650,O
a,7650,O
general,7650,O
phenomena,7650,O
of,7650,O
interaction,7650,O
of,7650,O
small,7650,O
molecules,7650,O
with,7650,O
internal,7650,O
sites,7650,O
in,7650,O
proteins,7650,O
.,7650,O
The,7651,O
effect,7651,O
of,7651,O
triclosan,7651,B-CHEMICAL
on,7651,O
mediators,7651,O
of,7651,O
gingival,7651,O
inflammation,7651,O
.,7651,O
Triclosan,7652,B-CHEMICAL
(,7652,O
"2,4,4",7652,B-CHEMICAL
',7652,I-CHEMICAL
",",7652,I-CHEMICAL
-trichloro-2'-hydroxydiphenylether,7652,I-CHEMICAL
),7652,O
is,7652,O
a,7652,O
well-known,7652,O
and,7652,O
widely,7652,O
used,7652,O
nonionic,7652,O
antibacterial,7652,O
agent,7652,O
which,7652,O
has,7652,O
recently,7652,O
been,7652,O
introduced,7652,O
in,7652,O
toothpastes,7652,O
and,7652,O
mouthrinses,7652,O
.,7652,O
The,7653,O
efficacy,7653,O
of,7653,O
triclosan-containing,7653,B-CHEMICAL
toothpaste,7653,O
and,7653,O
mouthrinse,7653,O
to,7653,O
reduce,7653,O
both,7653,O
plaque,7653,O
and,7653,O
gingivitis,7653,O
in,7653,O
long-term,7653,O
clinical,7653,O
trials,7653,O
has,7653,O
been,7653,O
well,7653,O
documented,7653,O
.,7653,O
Until,7654,O
recently,7654,O
",",7654,O
it,7654,O
was,7654,O
generally,7654,O
assumed,7654,O
that,7654,O
triclosan,7654,O
's,7654,O
effect,7654,O
on,7654,O
gingival,7654,O
inflammation,7654,O
was,7654,O
due,7654,O
to,7654,O
its,7654,O
antimicrobial,7654,O
and,7654,O
anti-plaque,7654,O
effect,7654,O
.,7654,O
It,7655,O
has,7655,O
now,7655,O
become,7655,O
apparent,7655,O
that,7655,O
triclosan,7655,B-CHEMICAL
may,7655,O
have,7655,O
a,7655,O
direct,7655,O
anti-inflammatory,7655,O
effect,7655,O
on,7655,O
the,7655,O
gingival,7655,O
tissues,7655,O
.,7655,O
Several,7656,O
in,7656,O
vitro,7656,O
studies,7656,O
were,7656,O
conducted,7656,O
to,7656,O
evaluate,7656,O
the,7656,O
effect,7656,O
of,7656,O
triclosan,7656,B-CHEMICAL
on,7656,O
4,7656,O
primary,7656,O
enzymes,7656,O
of,7656,O
the,7656,O
pathways,7656,O
of,7656,O
arachidonic,7656,B-CHEMICAL
acid,7656,I-CHEMICAL
metabolism,7656,O
",",7656,O
cyclo-oxygenase,7656,B-GENE-Y
1,7656,I-GENE-Y
",",7656,O
cyclo-oxygenase,7656,B-GENE-Y
2,7656,I-GENE-Y
",",7656,O
5-lipoxygenase,7656,B-GENE-Y
and,7656,O
15-lipoxygenase,7656,B-GENE-Y
.,7656,O
These,7657,O
pathways,7657,O
lead,7657,O
to,7657,O
the,7657,O
production,7657,O
of,7657,O
known,7657,O
mediators,7657,O
of,7657,O
inflammation,7657,O
such,7657,O
as,7657,O
the,7657,O
prostaglandins,7657,B-CHEMICAL
",",7657,O
leukotrienes,7657,B-CHEMICAL
and,7657,O
lipoxins,7657,B-CHEMICAL
.,7657,O
Triclosan,7658,B-CHEMICAL
inhibited,7658,O
both,7658,O
cyclooxygenase,7658,B-GENE-Y
1,7658,I-GENE-Y
and,7658,O
cyclo-oxygenase,7658,B-GENE-Y
2,7658,I-GENE-Y
with,7658,O
IC-50,7658,O
values,7658,O
of,7658,O
43,7658,O
microM,7658,O
and,7658,O
227,7658,O
microM,7658,O
",",7658,O
respectively,7658,O
.,7658,O
Triclosan,7659,B-CHEMICAL
also,7659,O
inhibited,7659,O
5-lipoxygenase,7659,B-GENE-Y
with,7659,O
an,7659,O
IC-50,7659,O
of,7659,O
43,7659,O
microM,7659,O
.,7659,O
The,7660,O
15-lipoxygenase,7660,B-GENE-Y
was,7660,O
similarly,7660,O
inhibited,7660,O
by,7660,O
triclosan,7660,B-CHEMICAL
with,7660,O
an,7660,O
IC-50,7660,O
of,7660,O
61,7660,O
microM,7660,O
.,7660,O
Hence,7661,O
",",7661,O
triclosan,7661,B-CHEMICAL
has,7661,O
the,7661,O
ability,7661,O
to,7661,O
inhibit,7661,O
both,7661,O
the,7661,O
cyclo-oxygenase,7661,B-GENE-N
and,7661,O
lipoxygenase,7661,B-GENE-N
pathways,7661,O
of,7661,O
arachidonic,7661,B-CHEMICAL
acid,7661,I-CHEMICAL
metabolism,7661,O
with,7661,O
similar,7661,O
efficacy,7661,O
.,7661,O
In,7662,O
cell,7662,O
culture,7662,O
experiments,7662,O
",",7662,O
it,7662,O
was,7662,O
found,7662,O
that,7662,O
triclosan,7662,B-CHEMICAL
inhibited,7662,O
IL-1,7662,B-GENE-Y
beta,7662,I-GENE-Y
induced,7662,O
prostaglandin,7662,B-CHEMICAL
E2,7662,I-CHEMICAL
production,7662,O
by,7662,O
human,7662,O
gingival,7662,O
fibroblasts,7662,O
in,7662,O
a,7662,O
concentration,7662,O
dependent,7662,O
manner,7662,O
",",7662,O
and,7662,O
at,7662,O
relatively,7662,O
low,7662,O
concentrations,7662,O
.,7662,O
These,7663,O
data,7663,O
",",7663,O
taken,7663,O
together,7663,O
",",7663,O
indicate,7663,O
that,7663,O
triclosan,7663,B-CHEMICAL
can,7663,O
inhibit,7663,O
formation,7663,O
of,7663,O
several,7663,O
important,7663,O
mediators,7663,O
of,7663,O
gingival,7663,O
inflammation,7663,O
.,7663,O
(,7664,O
ABSTRACT,7664,O
TRUNCATED,7664,O
AT,7664,O
250,7664,O
WORDS,7664,O
),7664,O
The,7665,O
dynamics,7665,O
of,7665,O
cobalamin,7665,B-CHEMICAL
utilization,7665,O
in,7665,O
L-1210,7665,O
mouse,7665,O
leukemia,7665,O
cells,7665,O
:,7665,O
a,7665,O
model,7665,O
of,7665,O
cellular,7665,O
cobalamin,7665,B-CHEMICAL
metabolism,7665,O
.,7665,O
The,7666,O
uptake,7666,O
and,7666,O
metabolism,7666,O
of,7666,O
cobalamin,7666,B-CHEMICAL
(,7666,O
Cbl,7666,B-CHEMICAL
),7666,O
has,7666,O
been,7666,O
studied,7666,O
in,7666,O
L-1210,7666,O
murine,7666,O
leukemia,7666,O
cells,7666,O
propagating,7666,O
in,7666,O
vitro,7666,O
.,7666,O
Extracellular,7667,O
Cbl,7667,B-CHEMICAL
(,7667,O
protein,7667,O
bound,7667,O
and,7667,O
free,7667,O
),7667,O
and,7667,O
intracellular,7667,O
Cbl,7667,B-CHEMICAL
(,7667,O
protein,7667,O
bound,7667,O
and,7667,O
free,7667,O
),7667,O
were,7667,O
determined,7667,O
after,7667,O
culturing,7667,O
L-1210,7667,O
cells,7667,O
in,7667,O
the,7667,O
presence,7667,O
of,7667,O
[,7667,B-CHEMICAL
57Co,7667,I-CHEMICAL
],7667,I-CHEMICAL
cyanocobalamin,7667,I-CHEMICAL
(,7667,O
CN-Cbl,7667,B-CHEMICAL
),7667,O
bound,7667,O
to,7667,O
transcobalamin,7667,B-GENE-Y
II,7667,I-GENE-Y
(,7667,O
transcobalamin,7667,B-GENE-N
",",7667,O
TC,7667,B-GENE-N
),7667,O
.,7667,O
The,7668,O
intracellular,7668,O
pool,7668,O
of,7668,O
free,7668,O
[,7668,B-CHEMICAL
57Co,7668,I-CHEMICAL
],7668,I-CHEMICAL
Cbl,7668,I-CHEMICAL
increased,7668,O
during,7668,O
the,7668,O
first,7668,O
24,7668,O
h,7668,O
of,7668,O
culture,7668,O
and,7668,O
a,7668,O
substantial,7668,O
fraction,7668,O
of,7668,O
this,7668,O
free,7668,O
pool,7668,O
was,7668,O
effluxed,7668,O
from,7668,O
the,7668,O
cell,7668,O
to,7668,O
the,7668,O
medium,7668,O
.,7668,O
Upon,7669,O
depletion,7669,O
of,7669,O
extracellular,7669,O
TC-,7669,B-CHEMICAL
[,7669,I-CHEMICAL
57Co,7669,I-CHEMICAL
],7669,I-CHEMICAL
CN-Cbl,7669,I-CHEMICAL
",",7669,O
the,7669,O
intracellular,7669,O
concentration,7669,O
of,7669,O
free,7669,O
Cbl,7669,B-CHEMICAL
decreased,7669,O
as,7669,O
did,7669,O
the,7669,O
efflux,7669,O
of,7669,O
Cbl,7669,B-CHEMICAL
to,7669,O
the,7669,O
medium,7669,O
.,7669,O
Internalized,7670,O
[,7670,B-CHEMICAL
57Co,7670,I-CHEMICAL
],7670,I-CHEMICAL
CN-Cbl,7670,I-CHEMICAL
was,7670,O
converted,7670,O
to,7670,O
hydroxocobalamin,7670,B-CHEMICAL
(,7670,O
OH-Cbl,7670,B-CHEMICAL
),7670,O
",",7670,O
methylcobalamin,7670,B-CHEMICAL
(,7670,O
Me-Cbl,7670,B-CHEMICAL
),7670,O
and,7670,O
5'-deoxyadenosylcobalamin,7670,B-CHEMICAL
.,7670,O
These,7671,O
Cbl,7671,B-CHEMICAL
forms,7671,O
were,7671,O
found,7671,O
in,7671,O
both,7671,O
soluble,7671,O
(,7671,O
cytoplasmic,7671,O
),7671,O
and,7671,O
insoluble,7671,O
(,7671,O
membrane,7671,O
),7671,O
fractions,7671,O
.,7671,O
Intracellular,7672,O
protein-bound,7672,O
[,7672,B-CHEMICAL
57Co,7672,I-CHEMICAL
],7672,I-CHEMICAL
Cbl,7672,I-CHEMICAL
fractionated,7672,O
with,7672,O
methionine,7672,B-GENE-Y
synthase,7672,I-GENE-Y
(,7672,O
MS,7672,B-GENE-Y
),7672,O
and,7672,O
methylmalonyl-CoA,7672,B-GENE-Y
mutase,7672,I-GENE-Y
(,7672,O
MU,7672,B-GENE-Y
),7672,O
activity,7672,O
.,7672,O
The,7673,O
major,7673,O
form,7673,O
of,7673,O
Cbl,7673,B-CHEMICAL
associated,7673,O
with,7673,O
the,7673,O
two,7673,O
enzymes,7673,O
was,7673,O
OH-Cbl,7673,B-CHEMICAL
.,7673,O
Cells,7674,O
propagated,7674,O
in,7674,O
medium,7674,O
containing,7674,O
N5-methyltetrahydrofolate,7674,B-CHEMICAL
and,7674,O
homocysteine,7674,B-CHEMICAL
showed,7674,O
a,7674,O
substantial,7674,O
increase,7674,O
in,7674,O
MS,7674,B-GENE-Y
activity,7674,O
which,7674,O
paralleled,7674,O
the,7674,O
increase,7674,O
in,7674,O
the,7674,O
intracellular,7674,O
concentration,7674,O
of,7674,O
Me-Cbl,7674,B-CHEMICAL
and,7674,O
the,7674,O
Cbl,7674,B-CHEMICAL
bound,7674,O
to,7674,O
the,7674,O
enzyme,7674,O
.,7674,O
Ergovaline,7675,B-CHEMICAL
binding,7675,O
and,7675,O
activation,7675,O
of,7675,O
D2,7675,B-GENE-Y
dopamine,7675,I-GENE-Y
receptors,7675,I-GENE-Y
in,7675,O
GH4ZR7,7675,O
cells,7675,O
.,7675,O
Ergovaline,7676,B-CHEMICAL
inhibition,7676,O
of,7676,O
radioligand,7676,O
binding,7676,O
to,7676,O
the,7676,O
D2,7676,B-GENE-Y
dopamine,7676,I-GENE-Y
receptor,7676,I-GENE-Y
and,7676,O
ergot,7676,B-CHEMICAL
alkaloid,7676,I-CHEMICAL
inhibition,7676,O
of,7676,O
vasoactive,7676,B-GENE-Y
intestinal,7676,I-GENE-Y
peptide,7676,I-GENE-Y
(,7676,O
VIP,7676,B-GENE-Y
),7676,O
-stimulated,7676,O
cyclic,7676,B-CHEMICAL
AMP,7676,I-CHEMICAL
production,7676,O
in,7676,O
GH4ZR7,7676,O
cells,7676,O
",",7676,O
stably,7676,O
transfected,7676,O
with,7676,O
a,7676,O
rat,7676,B-GENE-Y
D2,7676,I-GENE-Y
dopamine,7676,B-CHEMICAL
receptor,7676,I-GENE-Y
",",7676,O
were,7676,O
evaluated,7676,O
.,7676,O
Ergovaline,7677,B-CHEMICAL
inhibition,7677,O
of,7677,O
the,7677,O
binding,7677,O
of,7677,O
the,7677,O
D2-specific,7677,B-GENE-Y
radioligand,7677,O
",",7677,O
[,7677,B-CHEMICAL
3H,7677,I-CHEMICAL
],7677,I-CHEMICAL
YM-09151-2,7677,I-CHEMICAL
",",7677,O
exhibited,7677,O
a,7677,O
KI,7677,O
(,7677,O
inhibition,7677,O
constant,7677,O
),7677,O
of,7677,O
6.9,7677,O
+/-,7677,O
2.6,7677,O
nM,7677,O
",",7677,O
whereas,7677,O
dopamine,7677,B-CHEMICAL
was,7677,O
much,7677,O
less,7677,O
potent,7677,O
(,7677,O
370,7677,O
+/-,7677,O
160,7677,O
nM,7677,O
),7677,O
.,7677,O
Ergot,7678,B-CHEMICAL
alkaloids,7678,I-CHEMICAL
were,7678,O
also,7678,O
effective,7678,O
in,7678,O
inhibiting,7678,O
VIP-stimulated,7678,B-GENE-Y
cyclic,7678,B-CHEMICAL
AMP,7678,I-CHEMICAL
production,7678,O
",",7678,O
with,7678,O
EC50,7678,O
values,7678,O
for,7678,O
ergovaline,7678,B-CHEMICAL
",",7678,O
ergonovine,7678,B-CHEMICAL
",",7678,O
alpha-ergocryptine,7678,B-CHEMICAL
",",7678,O
ergotamine,7678,B-CHEMICAL
",",7678,O
and,7678,O
dopamine,7678,B-CHEMICAL
of,7678,O
8,7678,O
+/-,7678,O
2,7678,O
",",7678,O
47,7678,O
+/-,7678,O
2,7678,O
",",7678,O
28,7678,O
+/-,7678,O
2,7678,O
",",7678,O
2,7678,O
+/-,7678,O
1,7678,O
",",7678,O
and,7678,O
8,7678,O
+/-,7678,O
1,7678,O
nM,7678,O
",",7678,O
respectively,7678,O
.,7678,O
Inhibition,7679,O
of,7679,O
cyclic,7679,B-CHEMICAL
AMP,7679,I-CHEMICAL
production,7679,O
by,7679,O
ergovaline,7679,B-CHEMICAL
was,7679,O
blocked,7679,O
by,7679,O
the,7679,O
dopamine,7679,B-GENE-N
receptor,7679,I-GENE-N
antagonist,7679,O
",",7679,O
(,7679,B-CHEMICAL
-,7679,I-CHEMICAL
),7679,I-CHEMICAL
-sulpiride,7679,I-CHEMICAL
(,7679,O
IC50,7679,O
",",7679,O
300,7679,O
+/-,7679,O
150,7679,O
nM,7679,O
),7679,O
.,7679,O
Our,7680,O
results,7680,O
indicate,7680,O
that,7680,O
ergot,7680,O
compounds,7680,O
",",7680,O
especially,7680,O
ergovaline,7680,B-CHEMICAL
",",7680,O
bind,7680,O
to,7680,O
D2,7680,B-GENE-Y
dopamine,7680,I-GENE-Y
receptors,7680,I-GENE-Y
and,7680,O
elicit,7680,O
second,7680,O
messenger,7680,O
responses,7680,O
similar,7680,O
to,7680,O
that,7680,O
of,7680,O
dopamine,7680,B-CHEMICAL
.,7680,O
These,7681,O
findings,7681,O
suggest,7681,O
that,7681,O
some,7681,O
of,7681,O
the,7681,O
deleterious,7681,O
effects,7681,O
of,7681,O
consumption,7681,O
of,7681,O
endophyte-infected,7681,O
tall,7681,O
fescue,7681,O
",",7681,O
which,7681,O
contains,7681,O
several,7681,O
ergot,7681,B-CHEMICAL
alkaloids,7681,I-CHEMICAL
including,7681,O
ergovaline,7681,B-CHEMICAL
",",7681,O
may,7681,O
be,7681,O
due,7681,O
to,7681,O
D2,7681,B-GENE-Y
dopamine,7681,B-CHEMICAL
receptor,7681,I-GENE-Y
activation,7681,O
.,7681,O
Binding,7682,O
of,7682,O
antipsychotic,7682,O
drugs,7682,O
at,7682,O
alpha,7682,B-GENE-N
1A-,7682,I-GENE-N
and,7682,I-GENE-N
alpha,7682,I-GENE-N
1B-adrenoceptors,7682,I-GENE-N
:,7682,O
risperidone,7682,B-CHEMICAL
is,7682,O
selective,7682,O
for,7682,O
the,7682,O
alpha,7682,B-GENE-Y
1B-adrenoceptors,7682,I-GENE-Y
.,7682,O
The,7683,O
binding,7683,O
of,7683,O
the,7683,O
antipsychotic,7683,O
drugs,7683,O
risperidone,7683,B-CHEMICAL
",",7683,O
(,7683,B-CHEMICAL
+,7683,I-CHEMICAL
),7683,I-CHEMICAL
-butaclamol,7683,I-CHEMICAL
",",7683,O
clozapine,7683,B-CHEMICAL
",",7683,O
haloperidol,7683,B-CHEMICAL
",",7683,O
spiperone,7683,B-CHEMICAL
",",7683,O
thioridazine,7683,B-CHEMICAL
and,7683,O
YM-09151-2,7683,B-CHEMICAL
was,7683,O
studied,7683,O
at,7683,O
the,7683,O
subtypes,7683,O
of,7683,O
the,7683,O
alpha,7683,B-GENE-N
1-adrenoceptor,7683,I-GENE-N
.,7683,O
Saturation,7684,O
experiments,7684,O
showed,7684,O
that,7684,O
[,7684,B-CHEMICAL
3H,7684,I-CHEMICAL
],7684,I-CHEMICAL
prazosin,7684,I-CHEMICAL
labelled,7684,O
a,7684,O
single,7684,O
population,7684,O
of,7684,O
binding,7684,O
sites,7684,O
in,7684,O
the,7684,O
spleen,7684,O
(,7684,O
alpha,7684,B-GENE-Y
1B,7684,I-GENE-Y
),7684,O
and,7684,O
hippocampus,7684,O
(,7684,O
alpha,7684,B-GENE-Y
1A,7684,I-GENE-Y
and,7684,O
alpha,7684,B-GENE-Y
1B,7684,I-GENE-Y
),7684,O
(,7684,O
dissociation,7684,O
constants,7684,O
(,7684,O
KD,7684,O
),7684,O
:,7684,O
0.26,7684,O
nM,7684,O
and,7684,O
0.14,7684,O
nM,7684,O
respectively,7684,O
),7684,O
.,7684,O
Prazosin,7685,B-CHEMICAL
displaced,7685,O
the,7685,O
radioligand,7685,O
in,7685,O
a,7685,O
monophasic,7685,O
manner,7685,O
in,7685,O
both,7685,O
the,7685,O
spleen,7685,O
and,7685,O
hippocampus,7685,O
whereas,7685,O
5-methyl-urapidil,7685,B-CHEMICAL
",",7685,O
phentolamine,7685,B-CHEMICAL
and,7685,O
WB,7685,B-CHEMICAL
4101,7685,I-CHEMICAL
displaced,7685,O
the,7685,O
radioligand,7685,O
in,7685,O
a,7685,O
monophasic,7685,O
manner,7685,O
in,7685,O
the,7685,O
spleen,7685,O
but,7685,O
in,7685,O
a,7685,O
biphasic,7685,O
manner,7685,O
in,7685,O
the,7685,O
hippocampus,7685,O
.,7685,O
The,7686,O
affinity,7686,O
of,7686,O
these,7686,O
three,7686,O
compounds,7686,O
for,7686,O
the,7686,O
low,7686,O
affinity,7686,O
site,7686,O
in,7686,O
the,7686,O
hippocampus,7686,O
was,7686,O
similar,7686,O
to,7686,O
that,7686,O
observed,7686,O
in,7686,O
the,7686,O
spleen,7686,O
",",7686,O
suggesting,7686,O
that,7686,O
all,7686,O
three,7686,O
were,7686,O
selective,7686,O
for,7686,O
the,7686,O
alpha,7686,B-GENE-Y
1A-adrenoceptor,7686,I-GENE-Y
.,7686,O
Furthermore,7687,O
",",7687,O
the,7687,O
affinities,7687,O
for,7687,O
the,7687,O
alpha,7687,B-GENE-N
1A-,7687,I-GENE-N
and,7687,I-GENE-N
alpha,7687,I-GENE-N
1B-adrenoceptors,7687,I-GENE-N
calculated,7687,O
in,7687,O
this,7687,O
manner,7687,O
were,7687,O
in,7687,O
agreement,7687,O
with,7687,O
literature,7687,O
values,7687,O
.,7687,O
With,7688,O
the,7688,O
exception,7688,O
of,7688,O
risperidone,7688,B-CHEMICAL
",",7688,O
all,7688,O
the,7688,O
antipsychotic,7688,O
drugs,7688,O
tested,7688,O
failed,7688,O
to,7688,O
show,7688,O
selectivity,7688,O
for,7688,O
either,7688,O
of,7688,O
the,7688,O
alpha,7688,B-GENE-N
1-adrenoceptor,7688,I-GENE-N
subtypes,7688,O
.,7688,O
Risperidone,7689,B-CHEMICAL
was,7689,O
120-fold,7689,O
more,7689,O
selective,7689,O
for,7689,O
the,7689,O
alpha,7689,B-GENE-Y
1B-adrenoceptor,7689,I-GENE-Y
with,7689,O
respect,7689,O
to,7689,O
the,7689,O
alpha,7689,B-GENE-Y
1A-adrenoceptor,7689,I-GENE-Y
(,7689,O
Ki,7689,O
values,7689,O
:,7689,O
2.3,7689,O
+/-,7689,O
1.2,7689,O
nM,7689,O
and,7689,O
283.6,7689,O
+/-,7689,O
174.1,7689,O
nM,7689,O
respectively,7689,O
),7689,O
.,7689,O
Mediation,7690,O
of,7690,O
noradrenaline-induced,7690,B-CHEMICAL
contractions,7690,O
of,7690,O
rat,7690,O
aorta,7690,O
by,7690,O
the,7690,O
alpha,7690,B-GENE-Y
1B-adrenoceptor,7690,I-GENE-Y
subtype,7690,O
.,7690,O
1,7691,O
.,7691,O
The,7692,O
subtypes,7692,O
of,7692,O
alpha,7692,B-GENE-N
1-adrenoceptor,7692,I-GENE-N
mediating,7692,O
contractions,7692,O
to,7692,O
exogenous,7692,O
noradrenaline,7692,B-CHEMICAL
(,7692,O
NA,7692,B-CHEMICAL
),7692,O
in,7692,O
rat,7692,O
aorta,7692,O
have,7692,O
been,7692,O
examined,7692,O
in,7692,O
both,7692,O
biochemical,7692,O
and,7692,O
functional,7692,O
studies,7692,O
.,7692,O
2,7693,O
.,7693,O
Incubation,7694,O
of,7694,O
rat,7694,O
aortic,7694,O
membranes,7694,O
with,7694,O
the,7694,O
irreversible,7694,O
alpha,7694,B-GENE-Y
1B-adrenoceptor,7694,I-GENE-Y
antagonist,7694,O
",",7694,O
chloroethylclonidine,7694,B-CHEMICAL
(,7694,O
CEC,7694,B-CHEMICAL
:,7694,O
10,7694,O
microM,7694,O
),7694,O
did,7694,O
not,7694,O
change,7694,O
the,7694,O
KD,7694,O
of,7694,O
[,7694,B-CHEMICAL
3H,7694,I-CHEMICAL
],7694,I-CHEMICAL
-prazosin,7694,I-CHEMICAL
binding,7694,O
in,7694,O
comparison,7694,O
to,7694,O
untreated,7694,O
membranes,7694,O
",",7694,O
but,7694,O
reduced,7694,O
by,7694,O
88,7694,O
%,7694,O
the,7694,O
total,7694,O
number,7694,O
of,7694,O
binding,7694,O
sites,7694,O
(,7694,O
Bmax,7694,O
),7694,O
.,7694,O
3,7695,O
.,7695,O
Contractions,7696,O
of,7696,O
rat,7696,O
aortic,7696,O
strips,7696,O
to,7696,O
NA,7696,B-CHEMICAL
after,7696,O
CEC,7696,B-CHEMICAL
(,7696,O
50,7696,O
microM,7696,O
for,7696,O
30,7696,O
min,7696,O
),7696,O
incubation,7696,O
followed,7696,O
by,7696,O
repetitive,7696,O
washing,7696,O
",",7696,O
showed,7696,O
a,7696,O
marked,7696,O
shift,7696,O
in,7696,O
the,7696,O
potency,7696,O
of,7696,O
NA,7696,B-CHEMICAL
and,7696,O
a,7696,O
partial,7696,O
reduction,7696,O
in,7696,O
the,7696,O
maximum,7696,O
response,7696,O
.,7696,O
The,7697,O
residual,7697,O
contractions,7697,O
to,7697,O
NA,7697,B-CHEMICAL
after,7697,O
CEC,7697,B-CHEMICAL
incubation,7697,O
were,7697,O
not,7697,O
affected,7697,O
by,7697,O
prazosin,7697,B-CHEMICAL
(,7697,O
10,7697,O
nM,7697,O
),7697,O
.,7697,O
4,7698,O
.,7698,O
The,7699,O
competitive,7699,O
antagonists,7699,O
prazosin,7699,B-CHEMICAL
",",7699,O
terazosin,7699,B-CHEMICAL
",",7699,O
(,7699,B-CHEMICAL
R,7699,I-CHEMICAL
),7699,I-CHEMICAL
-YM-12617,7699,I-CHEMICAL
",",7699,O
phentolamine,7699,B-CHEMICAL
",",7699,O
5-methylurapidil,7699,B-CHEMICAL
and,7699,O
spiperone,7699,B-CHEMICAL
inhibited,7699,O
contractions,7699,O
to,7699,O
NA,7699,B-CHEMICAL
with,7699,O
estimated,7699,O
pA2,7699,O
values,7699,O
of,7699,O
9.85,7699,O
",",7699,O
8.54,7699,O
",",7699,O
9.34,7699,O
",",7699,O
7.71,7699,O
",",7699,O
7.64,7699,O
and,7699,O
8.41,7699,O
",",7699,O
respectively,7699,O
.,7699,O
5,7700,O
.,7700,O
The,7701,O
affinity,7701,O
of,7701,O
the,7701,O
same,7701,O
antagonists,7701,O
for,7701,O
the,7701,O
alpha,7701,B-GENE-N
1A-,7701,I-GENE-N
and,7701,I-GENE-N
alpha,7701,I-GENE-N
1B-,7701,I-GENE-N
adrenoceptors,7701,I-GENE-N
was,7701,O
evaluated,7701,O
by,7701,O
utilizing,7701,O
membranes,7701,O
from,7701,O
rat,7701,O
hippocampus,7701,O
pretreated,7701,O
with,7701,O
CEC,7701,B-CHEMICAL
",",7701,O
and,7701,O
rat,7701,O
liver,7701,O
",",7701,O
respectively,7701,O
.,7701,O
5-Methylurapidil,7702,B-CHEMICAL
and,7702,O
phentolamine,7702,B-CHEMICAL
were,7702,O
confirmed,7702,O
as,7702,O
selective,7702,O
for,7702,O
the,7702,O
alpha,7702,B-GENE-Y
1A-adrenoceptors,7702,I-GENE-Y
",",7702,O
whereas,7702,O
spiperone,7702,B-CHEMICAL
was,7702,O
alpha,7702,O
1B-selective,7702,O
.,7702,O
6,7703,O
.,7703,O
A,7704,O
significant,7704,O
correlation,7704,O
was,7704,O
found,7704,O
between,7704,O
the,7704,O
pA2,7704,O
values,7704,O
of,7704,O
the,7704,O
alpha,7704,B-GENE-N
1-adrenoceptor,7704,I-GENE-N
antagonists,7704,O
tested,7704,O
and,7704,O
their,7704,O
affinity,7704,O
for,7704,O
the,7704,O
alpha,7704,B-GENE-Y
1B-adrenoceptor,7704,I-GENE-Y
subtype,7704,O
",",7704,O
but,7704,O
not,7704,O
for,7704,O
the,7704,O
alpha,7704,O
1A-subtype,7704,O
.,7704,O
7,7705,O
.,7705,O
In,7706,O
conclusion,7706,O
",",7706,O
these,7706,O
findings,7706,O
indicate,7706,O
that,7706,O
in,7706,O
rat,7706,O
aorta,7706,O
most,7706,O
of,7706,O
the,7706,O
contraction,7706,O
is,7706,O
mediated,7706,O
by,7706,O
alpha,7706,B-GENE-Y
1B-adrenoceptors,7706,I-GENE-Y
",",7706,O
and,7706,O
that,7706,O
the,7706,O
potency,7706,O
(,7706,O
pA2,7706,O
),7706,O
of,7706,O
an,7706,O
antagonist,7706,O
in,7706,O
this,7706,O
tissue,7706,O
should,7706,O
be,7706,O
related,7706,O
to,7706,O
its,7706,O
antagonistic,7706,O
effect,7706,O
on,7706,O
this,7706,O
subtype,7706,O
of,7706,O
the,7706,O
alpha,7706,B-GENE-N
1-adrenoceptor,7706,I-GENE-N
population,7706,O
.,7706,O
Beta,7707,O
2-,7707,O
but,7707,O
not,7707,O
beta,7707,B-GENE-Y
1-adrenoceptors,7707,I-GENE-Y
are,7707,O
involved,7707,O
in,7707,O
desipramine,7707,B-CHEMICAL
enhancement,7707,O
of,7707,O
aggressive,7707,O
behavior,7707,O
in,7707,O
long-term,7707,O
isolated,7707,O
mice,7707,O
.,7707,O
The,7708,O
effects,7708,O
of,7708,O
several,7708,O
beta-adrenoceptor,7708,B-GENE-N
antagonists,7708,O
on,7708,O
the,7708,O
desipramine-induced,7708,B-CHEMICAL
increase,7708,O
in,7708,O
aggressive,7708,O
behavior,7708,O
in,7708,O
long-term,7708,O
isolated,7708,O
mice,7708,O
were,7708,O
examined,7708,O
.,7708,O
Desipramine,7709,B-CHEMICAL
HCl,7709,I-CHEMICAL
(,7709,O
10,7709,O
mg/kg,7709,O
",",7709,O
IP,7709,O
),7709,O
significantly,7709,O
increased,7709,O
the,7709,O
duration,7709,O
of,7709,O
aggressive,7709,O
behavior,7709,O
in,7709,O
isolated,7709,O
mice,7709,O
but,7709,O
did,7709,O
not,7709,O
significantly,7709,O
change,7709,O
the,7709,O
latency,7709,O
to,7709,O
the,7709,O
first,7709,O
attack,7709,O
consistent,7709,O
with,7709,O
our,7709,O
previous,7709,O
reports,7709,O
.,7709,O
Intraperitoneal,7710,O
administration,7710,O
of,7710,O
(,7710,B-CHEMICAL
+/-,7710,I-CHEMICAL
),7710,I-CHEMICAL
propranolol,7710,I-CHEMICAL
HCl,7710,I-CHEMICAL
(,7710,O
2.5-10,7710,O
mg/kg,7710,O
),7710,O
",",7710,O
a,7710,O
nonselective,7710,O
beta-adrenoceptor,7710,B-GENE-N
antagonist,7710,O
",",7710,O
dose,7710,O
dependently,7710,O
attenuated,7710,O
the,7710,O
desipramine-induced,7710,B-CHEMICAL
enhancement,7710,O
of,7710,O
aggressive,7710,O
behavior,7710,O
without,7710,O
significantly,7710,O
affecting,7710,O
the,7710,O
basal,7710,O
aggressive,7710,O
responses,7710,O
.,7710,O
"ICI118,551",7711,B-CHEMICAL
HCl,7711,I-CHEMICAL
(,7711,O
1.25-5,7711,O
mg/kg,7711,O
",",7711,O
IP,7711,O
),7711,O
",",7711,O
a,7711,O
selective,7711,O
beta,7711,B-GENE-Y
2-adrenoceptor,7711,I-GENE-Y
antagonist,7711,O
",",7711,O
also,7711,O
blocked,7711,O
the,7711,O
desipramine-induced,7711,O
enhancement,7711,O
of,7711,O
aggressive,7711,O
behavior,7711,O
in,7711,O
a,7711,O
dose-dependent,7711,O
manner,7711,O
",",7711,O
whereas,7711,O
metoprolol,7711,B-CHEMICAL
tartrate,7711,I-CHEMICAL
(,7711,O
5-20,7711,O
mg/kg,7711,O
",",7711,O
IP,7711,O
),7711,O
",",7711,O
a,7711,O
selective,7711,O
beta,7711,B-GENE-Y
1-adrenoceptor,7711,I-GENE-Y
antagonist,7711,O
",",7711,O
did,7711,O
not,7711,O
affect,7711,O
it,7711,O
.,7711,O
Moreover,7712,O
",",7712,O
clenbuterol,7712,B-CHEMICAL
HCl,7712,I-CHEMICAL
(,7712,O
0.1-0.5,7712,O
mg/kg,7712,O
",",7712,O
IP,7712,O
),7712,O
",",7712,O
a,7712,O
lipophilic,7712,O
beta,7712,B-GENE-Y
2-adrenoceptor,7712,I-GENE-Y
agonist,7712,O
",",7712,O
significantly,7712,O
increased,7712,O
the,7712,O
duration,7712,O
of,7712,O
basal,7712,O
aggressive,7712,O
behavior,7712,O
.,7712,O
Taken,7713,O
together,7713,O
with,7713,O
our,7713,O
previous,7713,O
finding,7713,O
that,7713,O
the,7713,O
desipramine-induced,7713,B-CHEMICAL
enhancement,7713,O
of,7713,O
aggressive,7713,O
behavior,7713,O
can,7713,O
be,7713,O
blocked,7713,O
by,7713,O
yohimbine,7713,B-CHEMICAL
",",7713,O
an,7713,O
alpha,7713,B-GENE-N
2-adrenoceptor,7713,I-GENE-N
antagonist,7713,O
",",7713,O
the,7713,O
present,7713,O
results,7713,O
indicate,7713,O
that,7713,O
not,7713,O
only,7713,O
alpha,7713,O
2-,7713,O
but,7713,O
also,7713,O
beta,7713,B-GENE-Y
2-adrenoceptor,7713,I-GENE-Y
stimulation,7713,O
plays,7713,O
important,7713,O
roles,7713,O
in,7713,O
modulation,7713,O
of,7713,O
aggressive,7713,O
behavior,7713,O
in,7713,O
long-term,7713,O
isolated,7713,O
mice,7713,O
.,7713,O
Alpha,7714,B-GENE-N
1-adrenoceptor,7714,I-GENE-N
subtypes,7714,O
mediating,7714,O
the,7714,O
regulation,7714,O
and,7714,O
modulation,7714,O
of,7714,O
Ca2+,7714,B-CHEMICAL
sensitization,7714,O
in,7714,O
rabbit,7714,O
thoracic,7714,O
aorta,7714,O
.,7714,O
Norepinephrine,7715,B-CHEMICAL
(,7715,O
10,7715,O
microM,7715,O
),7715,O
",",7715,O
methoxamine,7715,B-CHEMICAL
(,7715,O
100,7715,O
microM,7715,O
),7715,O
and,7715,O
clonidine,7715,B-CHEMICAL
(,7715,O
100,7715,O
microM,7715,O
),7715,O
with,7715,O
guanosine,7715,B-CHEMICAL
5'-triphosphate,7715,I-CHEMICAL
(,7715,O
GTP,7715,O
",",7715,O
50,7715,O
microM,7715,O
),7715,O
or,7715,O
guanosine,7715,B-CHEMICAL
5'-O-,7715,I-CHEMICAL
(,7715,I-CHEMICAL
3-thiotriphosphate,7715,I-CHEMICAL
),7715,I-CHEMICAL
(,7715,O
GTP,7715,B-CHEMICAL
gamma-S,7715,I-CHEMICAL
",",7715,O
10,7715,O
microM,7715,O
),7715,O
all,7715,O
significantly,7715,O
enhanced,7715,O
the,7715,O
contraction,7715,O
induced,7715,O
by,7715,O
0.3,7715,O
microM,7715,O
Ca2+,7715,B-CHEMICAL
(,7715,O
pCa6.5,7715,O
),7715,O
in,7715,O
beta-escin-skinned,7715,O
smooth,7715,O
muscle,7715,O
of,7715,O
rabbit,7715,O
thoracic,7715,O
aorta,7715,O
.,7715,O
The,7716,O
enhancement,7716,O
of,7716,O
Ca2+,7716,B-CHEMICAL
contraction,7716,O
produced,7716,O
by,7716,O
norepinephrine,7716,B-CHEMICAL
was,7716,O
greater,7716,O
than,7716,O
that,7716,O
produced,7716,O
by,7716,O
methoxamine,7716,B-CHEMICAL
or,7716,O
clonidine,7716,B-CHEMICAL
.,7716,O
In,7717,O
beta-escin-skinned,7717,O
strips,7717,O
of,7717,O
chloroethylclonidine-pretreated,7717,B-CHEMICAL
smooth,7717,O
muscle,7717,O
",",7717,O
the,7717,O
enhancement,7717,O
of,7717,O
Ca2+,7717,B-CHEMICAL
contraction,7717,O
produced,7717,O
by,7717,O
norepinephrine,7717,B-CHEMICAL
was,7717,O
significantly,7717,O
decreased,7717,O
",",7717,O
whereas,7717,O
the,7717,O
amplitude,7717,O
was,7717,O
the,7717,O
same,7717,O
as,7717,O
that,7717,O
produced,7717,O
by,7717,O
methoxamine,7717,B-CHEMICAL
or,7717,O
clonidine,7717,B-CHEMICAL
;,7717,O
this,7717,O
enhancement,7717,O
was,7717,O
inhibited,7717,O
by,7717,O
the,7717,O
selective,7717,O
alpha,7717,B-GENE-Y
1A-adrenoceptor,7717,I-GENE-Y
antagonist,7717,O
WB,7717,B-CHEMICAL
4101,7717,I-CHEMICAL
(,7717,O
100,7717,O
nM,7717,O
),7717,O
.,7717,O
The,7718,O
enhancement,7718,O
of,7718,O
Ca2+,7718,B-CHEMICAL
contraction,7718,O
produced,7718,O
by,7718,O
methoxamine,7718,B-CHEMICAL
and,7718,O
clonidine,7718,B-CHEMICAL
was,7718,O
not,7718,O
affected,7718,O
by,7718,O
chloroethylclonidine,7718,B-CHEMICAL
pretreatment,7718,O
.,7718,O
The,7719,O
effects,7719,O
of,7719,O
methoxamine,7719,B-CHEMICAL
",",7719,O
clonidine,7719,B-CHEMICAL
and,7719,O
norepinephrine,7719,B-CHEMICAL
in,7719,O
the,7719,O
chloroethylclonidine-pretreated,7719,B-CHEMICAL
tissue,7719,O
were,7719,O
all,7719,O
inhibited,7719,O
by,7719,O
guanosine,7719,B-CHEMICAL
5'-O-,7719,I-CHEMICAL
(,7719,I-CHEMICAL
2-thiodiphosphate,7719,I-CHEMICAL
),7719,I-CHEMICAL
(,7719,O
GDP,7719,B-CHEMICAL
beta-S,7719,I-CHEMICAL
",",7719,O
1,7719,O
mM,7719,O
),7719,O
and,7719,O
1-,7719,B-CHEMICAL
(,7719,I-CHEMICAL
5-isoquinolinylsulfonyl,7719,I-CHEMICAL
),7719,I-CHEMICAL
-methylpiperazine,7719,I-CHEMICAL
(,7719,O
H-7,7719,O
",",7719,O
20,7719,O
microM,7719,O
),7719,O
.,7719,O
Furthermore,7720,O
",",7720,O
the,7720,O
phosphorylation,7720,O
of,7720,O
myosin,7720,B-GENE-N
light,7720,I-GENE-N
chain,7720,I-GENE-N
produced,7720,O
by,7720,O
norepinephrine,7720,B-CHEMICAL
was,7720,O
greater,7720,O
than,7720,O
that,7720,O
produced,7720,O
by,7720,O
clonidine,7720,B-CHEMICAL
.,7720,O
These,7721,O
results,7721,O
suggest,7721,O
that,7721,O
both,7721,O
alpha,7721,B-GENE-N
1-adrenoceptor,7721,I-GENE-N
subtypes,7721,I-GENE-N
(,7721,I-GENE-N
alpha,7721,I-GENE-N
1A,7721,I-GENE-N
and,7721,I-GENE-N
alpha,7721,I-GENE-N
1B,7721,I-GENE-N
),7721,O
increase,7721,O
the,7721,O
Ca2+,7721,B-CHEMICAL
sensitivity,7721,O
of,7721,O
contractile,7721,O
elements,7721,O
",",7721,O
and,7721,O
that,7721,O
the,7721,O
Ca2+,7721,B-CHEMICAL
sensitization,7721,O
produced,7721,O
by,7721,O
alpha,7721,B-GENE-Y
1A-subtype,7721,I-GENE-Y
receptors,7721,I-GENE-Y
is,7721,O
mediated,7721,O
through,7721,O
G-protein,7721,B-GENE-N
and,7721,O
protein,7721,B-GENE-N
kinase,7721,I-GENE-N
C,7721,I-GENE-N
",",7721,O
and,7721,O
plays,7721,O
an,7721,O
important,7721,O
role,7721,O
in,7721,O
contraction,7721,O
of,7721,O
smooth,7721,O
muscle,7721,O
of,7721,O
rabbit,7721,O
thoracic,7721,O
aorta,7721,O
.,7721,O
STZ,7722,O
transport,7722,O
and,7722,O
cytotoxicity,7722,O
.,7722,O
Specific,7723,O
enhancement,7723,O
in,7723,O
GLUT2-expressing,7723,B-GENE-Y
cells,7723,O
.,7723,O
The,7724,O
glucose,7724,B-CHEMICAL
analog,7724,O
streptozotocin,7724,B-CHEMICAL
(,7724,O
STZ,7724,B-CHEMICAL
),7724,O
has,7724,O
long,7724,O
been,7724,O
used,7724,O
as,7724,O
a,7724,O
tool,7724,O
for,7724,O
creating,7724,O
experimental,7724,O
diabetes,7724,O
because,7724,O
of,7724,O
its,7724,O
relatively,7724,O
specific,7724,O
beta-cell,7724,O
cytotoxic,7724,O
effect,7724,O
",",7724,O
but,7724,O
the,7724,O
mechanism,7724,O
by,7724,O
which,7724,O
systemic,7724,O
injection,7724,O
of,7724,O
STZ,7724,B-CHEMICAL
causes,7724,O
beta-cell,7724,O
destruction,7724,O
is,7724,O
not,7724,O
well,7724,O
understood,7724,O
.,7724,O
In,7725,O
the,7725,O
current,7725,O
study,7725,O
",",7725,O
we,7725,O
have,7725,O
used,7725,O
insulinoma,7725,O
(,7725,O
RIN,7725,O
),7725,O
and,7725,O
AtT-20ins,7725,O
cell,7725,O
lines,7725,O
engineered,7725,O
for,7725,O
overexpression,7725,O
of,7725,O
GLUT2,7725,B-GENE-Y
or,7725,O
GLUT1,7725,B-GENE-Y
to,7725,O
investigate,7725,O
the,7725,O
role,7725,O
of,7725,O
glucose,7725,B-CHEMICAL
transporter,7725,I-GENE-N
isoforms,7725,O
in,7725,O
mediating,7725,O
STZ,7725,B-CHEMICAL
cytotoxicity,7725,O
.,7725,O
The,7726,O
in,7726,O
vivo,7726,O
effects,7726,O
of,7726,O
STZ,7726,B-CHEMICAL
were,7726,O
evaluated,7726,O
by,7726,O
implantation,7726,O
of,7726,O
RIN,7726,O
cells,7726,O
expressing,7726,O
or,7726,O
lacking,7726,O
GLUT2,7726,B-GENE-Y
into,7726,O
athymic,7726,O
nude,7726,O
rats,7726,O
.,7726,O
The,7727,O
drug,7727,O
had,7727,O
a,7727,O
potent,7727,O
cytotoxic,7727,O
effect,7727,O
on,7727,O
RIN,7727,O
cells,7727,O
expressing,7727,O
GLUT2,7727,B-GENE-Y
",",7727,O
but,7727,O
had,7727,O
no,7727,O
effect,7727,O
on,7727,O
cells,7727,O
lacking,7727,O
GLUT2,7727,B-GENE-Y
expression,7727,O
",",7727,O
as,7727,O
indicated,7727,O
by,7727,O
histological,7727,O
analysis,7727,O
and,7727,O
measurement,7727,O
of,7727,O
the,7727,O
blood,7727,O
glucose,7727,B-CHEMICAL
levels,7727,O
of,7727,O
treated,7727,O
animals,7727,O
.,7727,O
The,7728,O
preferential,7728,O
cytotoxic,7728,O
effect,7728,O
of,7728,O
STZ,7728,B-CHEMICAL
on,7728,O
GLUT2-expressing,7728,B-GENE-Y
cell,7728,O
lines,7728,O
was,7728,O
confirmed,7728,O
by,7728,O
in,7728,O
vitro,7728,O
analysis,7728,O
of,7728,O
GLUT2-expressing,7728,B-GENE-Y
and,7728,O
untransfected,7728,O
RIN,7728,O
cells,7728,O
",",7728,O
as,7728,O
well,7728,O
as,7728,O
GLUT2-,7728,B-GENE-Y
and,7728,O
GLUT1-overexpressing,7728,B-GENE-Y
AtT-20ins,7728,O
cells,7728,O
.,7728,O
Consistent,7729,O
with,7729,O
these,7729,O
data,7729,O
",",7729,O
only,7729,O
GLUT2-expressing,7729,B-GENE-Y
RIN,7729,O
or,7729,O
AtT-20ins,7729,O
cells,7729,O
transported,7729,O
STZ,7729,B-CHEMICAL
efficiently,7729,O
.,7729,O
We,7730,O
conclude,7730,O
that,7730,O
expression,7730,O
of,7730,O
GLUT2,7730,B-GENE-Y
is,7730,O
required,7730,O
for,7730,O
efficient,7730,O
killing,7730,O
of,7730,O
neuroendocrine,7730,O
cells,7730,O
by,7730,O
STZ,7730,B-CHEMICAL
",",7730,O
and,7730,O
this,7730,O
effect,7730,O
is,7730,O
related,7730,O
to,7730,O
specific,7730,O
recognition,7730,O
of,7730,O
the,7730,O
drug,7730,O
as,7730,O
a,7730,O
transported,7730,O
substrate,7730,O
by,7730,O
GLUT2,7730,B-GENE-Y
but,7730,O
not,7730,O
GLUT1,7730,B-GENE-Y
.,7730,O
Annexin,7731,B-GENE-Y
1,7731,I-GENE-Y
regulation,7731,O
in,7731,O
human,7731,O
epidermal,7731,O
cells,7731,O
.,7731,O
Annexin,7732,B-GENE-Y
1,7732,I-GENE-Y
(,7732,O
named,7732,O
p35,7732,B-GENE-Y
",",7732,O
lipocortin,7732,B-GENE-Y
I,7732,I-GENE-Y
or,7732,O
calpactin,7732,B-GENE-Y
II,7732,I-GENE-Y
),7732,O
",",7732,O
initially,7732,O
described,7732,O
as,7732,O
a,7732,O
glucocorticoid,7732,O
induced,7732,O
protein,7732,O
",",7732,O
belongs,7732,O
to,7732,O
a,7732,O
new,7732,O
characterized,7732,O
family,7732,O
of,7732,O
intracellular,7732,O
proteins,7732,O
.,7732,O
In,7733,O
the,7733,O
skin,7733,O
",",7733,O
the,7733,O
role,7733,O
of,7733,O
annexins,7733,B-GENE-N
has,7733,O
still,7733,O
not,7733,O
been,7733,O
elucidated,7733,O
.,7733,O
In,7734,O
a,7734,O
previous,7734,O
study,7734,O
",",7734,O
we,7734,O
reported,7734,O
the,7734,O
localization,7734,O
of,7734,O
annexin,7734,B-GENE-Y
1,7734,I-GENE-Y
in,7734,O
both,7734,O
freshly,7734,O
isolated,7734,O
human,7734,O
epidermal,7734,O
cells,7734,O
and,7734,O
in,7734,O
cultured,7734,O
keratinocytes,7734,O
using,7734,O
immunofluorescence,7734,O
",",7734,O
FACS,7734,O
analysis,7734,O
and,7734,O
immunoblotting,7734,O
techniques,7734,O
.,7734,O
The,7735,O
protein,7735,O
was,7735,O
characterized,7735,O
by,7735,O
Western,7735,O
blot,7735,O
and,7735,O
immunoprecipitation,7735,O
as,7735,O
a,7735,O
35,7735,O
kDa,7735,O
protein,7735,O
.,7735,O
Results,7736,O
from,7736,O
in,7736,O
vivo,7736,O
studies,7736,O
confirmed,7736,O
the,7736,O
presence,7736,O
of,7736,O
annexin,7736,B-GENE-Y
1,7736,I-GENE-Y
in,7736,O
basal,7736,O
and,7736,O
suprabasal,7736,O
layers,7736,O
of,7736,O
normal,7736,O
human,7736,O
skin,7736,O
with,7736,O
modified,7736,O
reactivity,7736,O
patterns,7736,O
in,7736,O
hyperproliferative,7736,O
lesions,7736,O
.,7736,O
In,7737,O
the,7737,O
present,7737,O
study,7737,O
",",7737,O
the,7737,O
role,7737,O
of,7737,O
glucocorticoids,7737,O
in,7737,O
annexin,7737,B-GENE-Y
1,7737,I-GENE-Y
regulation,7737,O
was,7737,O
investigated,7737,O
in,7737,O
epidermal,7737,O
cells,7737,O
by,7737,O
Western,7737,O
blot,7737,O
and,7737,O
immunoprecipation,7737,O
assays,7737,O
.,7737,O
In,7738,O
contrast,7738,O
to,7738,O
other,7738,O
studies,7738,O
",",7738,O
we,7738,O
found,7738,O
that,7738,O
glucocorticoid,7738,O
treatment,7738,O
of,7738,O
epidermal,7738,O
cells,7738,O
led,7738,O
to,7738,O
a,7738,O
decrease,7738,O
in,7738,O
annexin,7738,B-GENE-Y
1,7738,I-GENE-Y
content,7738,O
in,7738,O
the,7738,O
cytoplasm,7738,O
and,7738,O
the,7738,O
membranes,7738,O
of,7738,O
cells,7738,O
.,7738,O
As,7739,O
annexin,7739,B-GENE-Y
1,7739,I-GENE-Y
was,7739,O
not,7739,O
detected,7739,O
in,7739,O
the,7739,O
nucleus,7739,O
of,7739,O
cells,7739,O
",",7739,O
we,7739,O
conclude,7739,O
that,7739,O
there,7739,O
was,7739,O
a,7739,O
down,7739,O
regulation,7739,O
of,7739,O
annexin,7739,B-GENE-Y
1,7739,I-GENE-Y
after,7739,O
glucocorticoid,7739,O
treatments,7739,O
rather,7739,O
than,7739,O
a,7739,O
translocation,7739,O
of,7739,O
the,7739,O
protein,7739,O
to,7739,O
the,7739,O
nucleus,7739,O
.,7739,O
Despite,7740,O
the,7740,O
absence,7740,O
of,7740,O
the,7740,O
signal,7740,O
peptide,7740,O
sequence,7740,O
necessary,7740,O
for,7740,O
protein,7740,O
secretion,7740,O
",",7740,O
annexin,7740,B-GENE-Y
1,7740,I-GENE-Y
was,7740,O
released,7740,O
in,7740,O
the,7740,O
keratinocyte,7740,O
culture,7740,O
medium,7740,O
.,7740,O
We,7741,O
found,7741,O
that,7741,O
the,7741,O
protein,7741,O
was,7741,O
secreted,7741,O
only,7741,O
in,7741,O
low,7741,O
Ca2+,7741,B-CHEMICAL
medium,7741,O
(,7741,O
0.15,7741,O
mM,7741,O
),7741,O
",",7741,O
this,7741,O
process,7741,O
required,7741,O
an,7741,O
active,7741,O
metabolism,7741,O
.,7741,O
Inhibitory,7742,O
effects,7742,O
of,7742,O
lysine,7742,B-CHEMICAL
analogues,7742,O
on,7742,O
t-PA,7742,B-GENE-Y
induced,7742,O
whole,7742,O
blood,7742,O
clot,7742,O
lysis,7742,O
.,7742,O
The,7743,O
lysine,7743,B-CHEMICAL
analogues,7743,O
epsilon-aminocaproic,7743,B-CHEMICAL
acid,7743,I-CHEMICAL
(,7743,O
EACA,7743,B-CHEMICAL
),7743,O
and,7743,O
trans-4-amino-methyl,7743,B-CHEMICAL
cyclohexane,7743,I-CHEMICAL
carboxylic,7743,I-CHEMICAL
acid,7743,I-CHEMICAL
(,7743,O
AMCA,7743,B-CHEMICAL
),7743,O
are,7743,O
used,7743,O
to,7743,O
prevent,7743,O
excessive,7743,O
bleeding,7743,O
in,7743,O
patients,7743,O
with,7743,O
coagulopathies,7743,O
",",7743,O
such,7743,O
as,7743,O
hemophilia,7743,O
and,7743,O
thrombocytopenia,7743,O
",",7743,O
or,7743,O
in,7743,O
those,7743,O
who,7743,O
have,7743,O
received,7743,O
tissue,7743,B-GENE-Y
plasminogen,7743,I-GENE-Y
activator,7743,I-GENE-Y
(,7743,O
t-PA,7743,B-GENE-Y
),7743,O
.,7743,O
However,7744,O
",",7744,O
their,7744,O
relative,7744,O
efficacy,7744,O
in,7744,O
inhibiting,7744,O
lysis,7744,O
of,7744,O
clots,7744,O
that,7744,O
have,7744,O
been,7744,O
formed,7744,O
in,7744,O
the,7744,O
presence,7744,O
of,7744,O
exogenous,7744,O
t-PA,7744,B-GENE-Y
or,7744,O
that,7744,O
have,7744,O
been,7744,O
formed,7744,O
and,7744,O
then,7744,O
exposed,7744,O
to,7744,O
exogenous,7744,O
t-PA,7744,B-GENE-Y
has,7744,O
not,7744,O
been,7744,O
well,7744,O
characterized,7744,O
.,7744,O
The,7745,O
present,7745,O
study,7745,O
utilized,7745,O
blood,7745,O
from,7745,O
normal,7745,O
volunteers,7745,O
and,7745,O
125I-fibrinogen,7745,B-CHEMICAL
in,7745,O
a,7745,O
dilute,7745,O
whole,7745,O
blood,7745,O
clot,7745,O
assay,7745,O
to,7745,O
determine,7745,O
the,7745,O
relative,7745,O
concentrations,7745,O
of,7745,O
lysine,7745,B-CHEMICAL
analogues,7745,O
required,7745,O
for,7745,O
inhibition,7745,O
of,7745,O
clot,7745,O
lysis,7745,O
induced,7745,O
by,7745,O
exogenous,7745,O
t-PA.,7745,B-GENE-Y
AMCA,7745,B-CHEMICAL
(,7745,O
0.06,7745,O
mM,7745,O
),7745,O
and,7745,O
EACA,7745,B-CHEMICAL
(,7745,O
0.6,7745,O
mM,7745,O
),7745,O
were,7745,O
effective,7745,O
in,7745,O
prolonging,7745,O
clot,7745,O
lysis,7745,O
if,7745,O
(,7745,O
1,7745,O
),7745,O
whole,7745,O
blood,7745,O
clots,7745,O
were,7745,O
formed,7745,O
and,7745,O
then,7745,O
exposed,7745,O
to,7745,O
a,7745,O
lysine,7745,B-CHEMICAL
analogue,7745,O
and,7745,O
exogenous,7745,O
t-PA,7745,B-GENE-Y
or,7745,O
if,7745,O
(,7745,O
2,7745,O
),7745,O
whole,7745,O
blood,7745,O
clots,7745,O
were,7745,O
formed,7745,O
in,7745,O
the,7745,O
presence,7745,O
of,7745,O
exogenous,7745,O
t-PA,7745,B-GENE-Y
and,7745,O
a,7745,O
lysine,7745,B-CHEMICAL
analogue,7745,O
.,7745,O
However,7746,O
",",7746,O
their,7746,O
inhibitory,7746,O
effect,7746,O
was,7746,O
markedly,7746,O
reduced,7746,O
if,7746,O
clots,7746,O
were,7746,O
formed,7746,O
in,7746,O
the,7746,O
presence,7746,O
of,7746,O
t-PA,7746,B-GENE-Y
and,7746,O
then,7746,O
exposed,7746,O
to,7746,O
either,7746,O
of,7746,O
the,7746,O
lysine,7746,B-CHEMICAL
analogues,7746,O
.,7746,O
The,7747,O
analogues,7747,O
did,7747,O
not,7747,O
inhibit,7747,O
the,7747,O
initial,7747,O
binding,7747,O
of,7747,O
t-PA,7747,B-GENE-Y
to,7747,O
fibrin,7747,B-GENE-N
.,7747,O
They,7748,O
did,7748,O
inhibit,7748,O
binding,7748,O
of,7748,O
plasminogen,7748,B-GENE-Y
to,7748,O
fibrin,7748,B-GENE-N
as,7748,O
well,7748,O
as,7748,O
the,7748,O
activation,7748,O
of,7748,O
plasminogen,7748,B-GENE-Y
by,7748,O
t-PA,7748,B-GENE-Y
in,7748,O
the,7748,O
absence,7748,O
of,7748,O
fibrin,7748,B-GENE-N
.,7748,O
The,7749,O
data,7749,O
suggest,7749,O
that,7749,O
lysine,7749,B-CHEMICAL
analogues,7749,O
",",7749,O
even,7749,O
at,7749,O
low,7749,O
concentrations,7749,O
",",7749,O
reduce,7749,O
the,7749,O
rate,7749,O
of,7749,O
t-PA,7749,B-GENE-Y
induced,7749,O
whole,7749,O
blood,7749,O
clot,7749,O
lysis,7749,O
by,7749,O
several,7749,O
mechanisms,7749,O
.,7749,O
Histamine,7750,B-CHEMICAL
enhances,7750,O
the,7750,O
depolarizing,7750,O
afterpotential,7750,O
of,7750,O
immunohistochemically,7750,O
identified,7750,O
vasopressin,7750,B-CHEMICAL
neurons,7750,O
in,7750,O
the,7750,O
rat,7750,O
supraoptic,7750,O
nucleus,7750,O
via,7750,O
H1-receptor,7750,B-GENE-Y
activation,7750,O
.,7750,O
Previous,7751,O
studies,7751,O
have,7751,O
demonstrated,7751,O
that,7751,O
histamine,7751,B-CHEMICAL
primarily,7751,O
excites,7751,O
unidentified,7751,O
neurons,7751,O
in,7751,O
the,7751,O
rat,7751,O
supraoptic,7751,O
nucleus,7751,O
.,7751,O
We,7752,O
investigated,7752,O
the,7752,O
neuromodulatory,7752,O
effects,7752,O
of,7752,O
histamine,7752,B-CHEMICAL
on,7752,O
immunohistochemically,7752,O
identified,7752,O
vasopressin,7752,B-CHEMICAL
neurons,7752,O
in,7752,O
the,7752,O
rat,7752,O
supraoptic,7752,O
nucleus,7752,O
using,7752,O
intracellular,7752,O
recording,7752,O
techniques,7752,O
from,7752,O
the,7752,O
hypothalamo-neurohypophysial,7752,O
explant,7752,O
.,7752,O
Exogenous,7753,O
application,7753,O
of,7753,O
histamine,7753,B-CHEMICAL
(,7753,O
0.1-100,7753,O
microM,7753,O
),7753,O
to,7753,O
vasopressinergic,7753,O
neurons,7753,O
produced,7753,O
a,7753,O
small,7753,O
membrane,7753,O
depolarization,7753,O
accompanied,7753,O
by,7753,O
an,7753,O
increase,7753,O
of,7753,O
up,7753,O
to,7753,O
100,7753,O
%,7753,O
in,7753,O
the,7753,O
amplitude,7753,O
of,7753,O
the,7753,O
depolarizing,7753,O
afterpotential,7753,O
that,7753,O
follows,7753,O
current-evoked,7753,O
trains,7753,O
of,7753,O
action,7753,O
potentials,7753,O
.,7753,O
The,7754,O
enhancement,7754,O
of,7754,O
the,7754,O
depolarizing,7754,O
afterpotential,7754,O
by,7754,O
histamine,7754,B-CHEMICAL
did,7754,O
not,7754,O
depend,7754,O
upon,7754,O
the,7754,O
depolarization,7754,O
.,7754,O
Further,7755,O
",",7755,O
histamine,7755,B-CHEMICAL
enhanced,7755,O
the,7755,O
amplitude,7755,O
of,7755,O
the,7755,O
depolarizing,7755,O
afterpotential,7755,O
when,7755,O
blocking,7755,O
the,7755,O
afterhyperpolarizing,7755,O
potential,7755,O
with,7755,O
d-tubocurarine,7755,B-CHEMICAL
or,7755,O
apamin,7755,O
",",7755,O
and,7755,O
in,7755,O
the,7755,O
presence,7755,O
of,7755,O
tetrodotoxin,7755,B-CHEMICAL
and,7755,O
d-tubocurarine,7755,B-CHEMICAL
or,7755,O
apamin,7755,O
",",7755,O
indicating,7755,O
a,7755,O
postsynaptic,7755,O
action,7755,O
of,7755,O
histamine,7755,B-CHEMICAL
on,7755,O
the,7755,O
depolarizing,7755,O
afterpotential,7755,O
that,7755,O
is,7755,O
not,7755,O
simply,7755,O
a,7755,O
reflection,7755,O
of,7755,O
a,7755,O
decrease,7755,O
in,7755,O
the,7755,O
afterhyperpolarizing,7755,O
potential,7755,O
.,7755,O
These,7756,O
toxins,7756,O
also,7756,O
had,7756,O
no,7756,O
effect,7756,O
on,7756,O
the,7756,O
histamine-induced,7756,B-CHEMICAL
depolarization,7756,O
.,7756,O
The,7757,O
enhancement,7757,O
of,7757,O
the,7757,O
depolarizing,7757,O
afterpotential,7757,O
by,7757,O
histamine,7757,B-CHEMICAL
was,7757,O
mimicked,7757,O
by,7757,O
the,7757,O
histamine,7757,B-CHEMICAL
H1-receptor,7757,I-GENE-Y
agonist,7757,O
2-thiazolylethylamine,7757,B-CHEMICAL
and,7757,O
was,7757,O
reduced,7757,O
or,7757,O
blocked,7757,O
by,7757,O
the,7757,O
H1-receptor,7757,B-GENE-Y
antagonist,7757,O
promethazine,7757,B-CHEMICAL
",",7757,O
but,7757,O
was,7757,O
not,7757,O
blocked,7757,O
or,7757,O
reduced,7757,O
in,7757,O
the,7757,O
presence,7757,O
of,7757,O
the,7757,O
histamine,7757,B-CHEMICAL
H2-receptor,7757,I-GENE-Y
antagonist,7757,O
",",7757,O
cimetidine,7757,B-CHEMICAL
.,7757,O
In,7758,O
summary,7758,O
",",7758,O
these,7758,O
results,7758,O
show,7758,O
that,7758,O
the,7758,O
excitatory,7758,O
effect,7758,O
of,7758,O
histamine,7758,B-CHEMICAL
on,7758,O
immunohistochemically,7758,O
identified,7758,O
vasopressin,7758,B-CHEMICAL
neurons,7758,O
in,7758,O
the,7758,O
supraoptic,7758,O
nucleus,7758,O
is,7758,O
due,7758,O
in,7758,O
part,7758,O
to,7758,O
the,7758,O
H1-receptor-mediated,7758,B-GENE-Y
enhancement,7758,O
of,7758,O
the,7758,O
depolarizing,7758,O
afterpotential,7758,O
independent,7758,O
of,7758,O
any,7758,O
change,7758,O
in,7758,O
the,7758,O
afterhyperpolarizing,7758,O
potential,7758,O
or,7758,O
membrane,7758,O
potential,7758,O
.,7758,O
Adapalene,7759,B-CHEMICAL
",",7759,O
a,7759,O
new,7759,O
chemical,7759,O
entity,7759,O
with,7759,O
retinoid,7759,B-CHEMICAL
activity,7759,O
.,7759,O
Adapalene,7760,B-CHEMICAL
is,7760,O
a,7760,O
novel,7760,O
chemical,7760,O
entity,7760,O
which,7760,O
",",7760,O
in,7760,O
terms,7760,O
of,7760,O
pharmacology,7760,O
",",7760,O
behaves,7760,O
similar,7760,O
to,7760,O
tretinoin,7760,B-CHEMICAL
",",7760,O
but,7760,O
is,7760,O
chemically,7760,O
and,7760,O
photochemically,7760,O
stable,7760,O
.,7760,O
It,7761,O
has,7761,O
a,7761,O
particular,7761,O
selectivity,7761,O
profile,7761,O
for,7761,O
the,7761,O
known,7761,O
nuclear,7761,O
retinoic,7761,B-CHEMICAL
acid,7761,I-CHEMICAL
receptors,7761,I-GENE-N
with,7761,O
low,7761,O
affinity,7761,O
for,7761,O
RAR,7761,B-GENE-Y
alpha,7761,I-GENE-Y
and,7761,O
no,7761,O
transactivating,7761,O
potential,7761,O
for,7761,O
RXR,7761,B-GENE-Y
alpha,7761,I-GENE-Y
.,7761,O
This,7762,O
receptor,7762,O
profile,7762,O
could,7762,O
imply,7762,O
that,7762,O
adapalene,7762,B-CHEMICAL
",",7762,O
in,7762,O
contrast,7762,O
to,7762,O
tretinoin,7762,B-CHEMICAL
",",7762,O
affects,7762,O
the,7762,O
terminal,7762,O
differentiation,7762,O
pathway,7762,O
of,7762,O
epidermal,7762,O
cells,7762,O
rather,7762,O
than,7762,O
their,7762,O
proliferation,7762,O
.,7762,O
Furthermore,7763,O
",",7763,O
adapalene,7763,B-CHEMICAL
does,7763,O
not,7763,O
bind,7763,O
to,7763,O
members,7763,O
of,7763,O
the,7763,O
cellular,7763,O
retinoic,7763,B-CHEMICAL
acid,7763,I-CHEMICAL
binding,7763,I-GENE-N
protein,7763,I-GENE-N
family,7763,O
.,7763,O
Adapalene,7764,B-CHEMICAL
has,7764,O
comedolytic,7764,O
activity,7764,O
in,7764,O
the,7764,O
topical,7764,O
rhino,7764,O
mouse,7764,O
model,7764,O
.,7764,O
It,7765,O
exerts,7765,O
a,7765,O
moderate-to-potent,7765,O
anti-inflammatory,7765,O
effect,7765,O
in,7765,O
a,7765,O
series,7765,O
of,7765,O
in,7765,O
vitro,7765,O
and,7765,O
in,7765,O
vivo,7765,O
models,7765,O
.,7765,O
In,7766,O
comparative,7766,O
clinical,7766,O
studies,7766,O
involving,7766,O
72,7766,O
acne,7766,O
patients,7766,O
",",7766,O
the,7766,O
efficacy,7766,O
of,7766,O
adapalene,7766,B-CHEMICAL
was,7766,O
comparable,7766,O
",",7766,O
if,7766,O
not,7766,O
superior,7766,O
",",7766,O
to,7766,O
tretinoin,7766,B-CHEMICAL
",",7766,O
but,7766,O
adapalene,7766,B-CHEMICAL
was,7766,O
better,7766,O
tolerated,7766,O
.,7766,O
The,7767,O
data,7767,O
reviewed,7767,O
in,7767,O
this,7767,O
paper,7767,O
indicate,7767,O
that,7767,O
adapalene,7767,B-CHEMICAL
should,7767,O
be,7767,O
particularly,7767,O
beneficial,7767,O
in,7767,O
the,7767,O
treatment,7767,O
of,7767,O
acne,7767,O
.,7767,O
Comparative,7768,O
effects,7768,O
of,7768,O
three,7768,O
different,7768,O
potent,7768,O
renin,7768,B-GENE-N
inhibitors,7768,O
in,7768,O
primates,7768,O
.,7768,O
The,7769,O
goal,7769,O
of,7769,O
the,7769,O
present,7769,O
study,7769,O
was,7769,O
to,7769,O
compare,7769,O
the,7769,O
effects,7769,O
of,7769,O
three,7769,O
potent,7769,O
reference,7769,O
renin,7769,B-GENE-Y
inhibitors,7769,O
(,7769,O
remikiren,7769,B-CHEMICAL
",",7769,O
CGP,7769,B-CHEMICAL
38560A,7769,I-CHEMICAL
",",7769,O
and,7769,O
enalkiren,7769,B-CHEMICAL
),7769,O
in,7769,O
sodium-depleted,7769,B-CHEMICAL
normotensive,7769,O
squirrel,7769,O
monkeys,7769,O
.,7769,O
In,7770,O
these,7770,O
monkeys,7770,O
",",7770,O
arterial,7770,O
pressure,7770,O
was,7770,O
measured,7770,O
in,7770,O
the,7770,O
conscious,7770,O
state,7770,O
with,7770,O
a,7770,O
telemetry,7770,O
system,7770,O
.,7770,O
Oral,7771,O
and,7771,O
intravenous,7771,O
maximal,7771,O
effective,7771,O
doses,7771,O
of,7771,O
the,7771,O
three,7771,O
renin,7771,B-GENE-Y
inhibitors,7771,O
were,7771,O
compared,7771,O
in,7771,O
parallel,7771,O
groups,7771,O
of,7771,O
monkeys,7771,O
.,7771,O
In,7772,O
additional,7772,O
experiments,7772,O
",",7772,O
remikiren,7772,O
was,7772,O
given,7772,O
on,7772,O
top,7772,O
of,7772,O
either,7772,O
CGP,7772,B-CHEMICAL
38560A,7772,I-CHEMICAL
or,7772,O
enalkiren,7772,B-CHEMICAL
in,7772,O
the,7772,O
same,7772,O
animals,7772,O
.,7772,O
Finally,7773,O
",",7773,O
the,7773,O
three,7773,O
drugs,7773,O
were,7773,O
compared,7773,O
with,7773,O
the,7773,O
angiotensin,7773,B-GENE-Y
converting,7773,I-GENE-Y
enzyme,7773,I-GENE-Y
inhibitor,7773,O
cilazapril,7773,B-CHEMICAL
.,7773,O
The,7774,O
effects,7774,O
of,7774,O
the,7774,O
three,7774,O
drugs,7774,O
on,7774,O
the,7774,O
plasma,7774,O
components,7774,O
of,7774,O
the,7774,O
renin-angiotensin,7774,B-GENE-Y
system,7774,O
(,7774,O
plasma,7774,O
renin,7774,B-GENE-Y
activity,7774,O
",",7774,O
immunoreactive,7774,O
renin,7774,B-GENE-Y
",",7774,O
and,7774,O
immunoreactive,7774,O
angiotensin,7774,B-GENE-Y
II,7774,I-GENE-Y
concentrations,7774,O
),7774,O
were,7774,O
also,7774,O
measured,7774,O
.,7774,O
Our,7775,O
results,7775,O
show,7775,O
that,7775,O
remikiren,7775,B-CHEMICAL
was,7775,O
as,7775,O
effective,7775,O
as,7775,O
cilazapril,7775,B-CHEMICAL
and,7775,O
markedly,7775,O
more,7775,O
effective,7775,O
than,7775,O
CGP,7775,B-CHEMICAL
38560A,7775,I-CHEMICAL
or,7775,O
enalkiren,7775,B-CHEMICAL
in,7775,O
reducing,7775,O
arterial,7775,O
pressure,7775,O
in,7775,O
our,7775,O
monkey,7775,O
model,7775,O
.,7775,O
Interestingly,7776,O
",",7776,O
these,7776,O
differences,7776,O
in,7776,O
arterial,7776,O
pressure,7776,O
could,7776,O
not,7776,O
be,7776,O
explained,7776,O
by,7776,O
differences,7776,O
of,7776,O
in,7776,O
vitro,7776,O
potency,7776,O
or,7776,O
different,7776,O
biochemical,7776,O
changes,7776,O
of,7776,O
the,7776,O
plasma,7776,O
components,7776,O
of,7776,O
the,7776,O
renin-angiotensin,7776,B-GENE-Y
system,7776,O
",",7776,O
because,7776,O
the,7776,O
inhibitors,7776,O
all,7776,O
reduced,7776,O
immunoreactive,7776,O
angiotensin,7776,B-GENE-Y
II,7776,I-GENE-Y
to,7776,O
similarly,7776,O
low,7776,O
levels,7776,O
.,7776,O
One,7777,O
possible,7777,O
explanation,7777,O
is,7777,O
that,7777,O
",",7777,O
in,7777,O
our,7777,O
model,7777,O
",",7777,O
remikiren,7777,B-CHEMICAL
in,7777,O
contrast,7777,O
to,7777,O
CGP,7777,B-CHEMICAL
38560A,7777,I-CHEMICAL
and,7777,O
enalkiren,7777,B-CHEMICAL
is,7777,O
able,7777,O
to,7777,O
inhibit,7777,O
renin,7777,B-GENE-Y
in,7777,O
a,7777,O
functionally,7777,O
important,7777,O
extraplasmatic,7777,O
compartment,7777,O
.,7777,O
Inhibition,7778,O
of,7778,O
cytokine-primed,7778,B-GENE-N
eosinophil,7778,O
chemotaxis,7778,O
by,7778,O
nedocromil,7778,B-CHEMICAL
sodium,7778,I-CHEMICAL
.,7778,O
BACKGROUND,7779,O
:,7779,O
Eosinophil,7779,O
influx,7779,O
into,7779,O
the,7779,O
lung,7779,O
tissue,7779,O
is,7779,O
considered,7779,O
to,7779,O
be,7779,O
relevant,7779,O
for,7779,O
the,7779,O
pathogenesis,7779,O
of,7779,O
asthma,7779,O
.,7779,O
Various,7780,O
chemotactic,7780,O
factors,7780,O
may,7780,O
be,7780,O
responsible,7780,O
for,7780,O
this,7780,O
influx,7780,O
.,7780,O
Recently,7781,O
it,7781,O
has,7781,O
been,7781,O
demonstrated,7781,O
that,7781,O
the,7781,O
cytokines,7781,B-GENE-N
granulocyte-macrophage,7781,B-GENE-Y
colony-stimulating,7781,I-GENE-Y
factor,7781,I-GENE-Y
(,7781,O
GM-CSF,7781,B-GENE-Y
),7781,O
",",7781,O
interleukin-3,7781,B-GENE-Y
(,7781,O
IL-3,7781,B-GENE-Y
),7781,O
",",7781,O
and,7781,O
interleukin-5,7781,B-GENE-Y
(,7781,O
IL-5,7781,B-GENE-Y
),7781,O
are,7781,O
present,7781,O
in,7781,O
the,7781,O
circulation,7781,O
of,7781,O
individuals,7781,O
with,7781,O
allergic,7781,O
asthma,7781,O
.,7781,O
These,7782,O
cytokines,7782,B-GENE-N
have,7782,O
the,7782,O
capacity,7782,O
to,7782,O
modulate,7782,O
chemotactic,7782,O
responses,7782,O
of,7782,O
eosinophils,7782,O
toward,7782,O
platelet-activating,7782,O
factor,7782,O
",",7782,O
formyl-methionyl-leucyl-phenylalanine,7782,B-CHEMICAL
",",7782,O
(,7782,O
FMLP,7782,B-CHEMICAL
),7782,O
and,7782,O
neutrophil-activating,7782,B-GENE-Y
factor,7782,I-GENE-Y
(,7782,O
NAF,7782,B-GENE-Y
),7782,O
/IL-8,7782,O
",",7782,O
but,7782,O
not,7782,O
toward,7782,O
complement,7782,B-GENE-Y
fragment,7782,I-GENE-Y
C5a,7782,I-GENE-Y
(,7782,O
C5a,7782,B-GENE-Y
),7782,O
.,7782,O
Here,7783,O
the,7783,O
effect,7783,O
of,7783,O
nedocromil,7783,B-CHEMICAL
sodium,7783,I-CHEMICAL
on,7783,O
the,7783,O
chemotactic,7783,O
response,7783,O
of,7783,O
eosinophils,7783,O
from,7783,O
allergic,7783,O
asthmatic,7783,O
individuals,7783,O
and,7783,O
from,7783,O
normal,7783,O
donors,7783,O
preincubated,7783,O
with,7783,O
GM-CSF,7783,B-GENE-Y
or,7783,O
IL-3,7783,B-GENE-N
toward,7783,O
FMLP,7783,O
",",7783,O
NAF/IL-8,7783,B-GENE-Y
was,7783,O
evaluated,7783,O
.,7783,O
RESULTS,7784,O
:,7784,O
Nedocromil,7784,B-CHEMICAL
sodium,7784,I-CHEMICAL
inhibited,7784,O
the,7784,O
chemotactic,7784,O
response,7784,O
toward,7784,O
FMLP,7784,B-CHEMICAL
and,7784,O
NAF/IL-8,7784,B-GENE-Y
of,7784,O
GM-CSF,7784,B-GENE-Y
primed,7784,O
eosinophils,7784,O
approximately,7784,O
60,7784,O
%,7784,O
(,7784,O
inhibitory,7784,O
concentration,7784,O
of,7784,O
50,7784,O
%,7784,O
[,7784,O
IC50,7784,O
],7784,O
approximately,7784,O
1,7784,O
to,7784,O
10,7784,O
nmol/L,7784,O
),7784,O
",",7784,O
whereas,7784,O
these,7784,O
responses,7784,O
of,7784,O
IL-3,7784,B-GENE-Y
primed,7784,O
eosinophils,7784,O
was,7784,O
completely,7784,O
inhibited,7784,O
(,7784,O
IC50,7784,O
approximately,7784,O
1,7784,O
nmol/L,7784,O
),7784,O
.,7784,O
CONCLUSIONS,7785,O
:,7785,O
The,7785,O
chemotactic,7785,O
responses,7785,O
toward,7785,O
C5a,7785,B-GENE-Y
were,7785,O
inhibited,7785,O
by,7785,O
nedocromil,7785,B-CHEMICAL
sodium,7785,I-CHEMICAL
at,7785,O
higher,7785,O
concentrations,7785,O
than,7785,O
were,7785,O
required,7785,O
in,7785,O
the,7785,O
priming,7785,O
studies,7785,O
(,7785,O
IC50,7785,O
approximately,7785,O
10,7785,O
to,7785,O
100,7785,O
nmol/L,7785,O
),7785,O
.,7785,O
Nedocromil,7786,B-CHEMICAL
sodium,7786,I-CHEMICAL
(,7786,O
0.1,7786,O
mumol/L,7786,O
),7786,O
was,7786,O
also,7786,O
effective,7786,O
in,7786,O
inhibiting,7786,O
the,7786,O
chemotactic,7786,O
response,7786,O
toward,7786,O
FMLP,7786,B-CHEMICAL
(,7786,O
10,7786,O
nmol/L,7786,O
),7786,O
of,7786,O
eosinophils,7786,O
isolated,7786,O
from,7786,O
the,7786,O
circulation,7786,O
of,7786,O
patients,7786,O
with,7786,O
allergic,7786,O
asthma,7786,O
3,7786,O
hours,7786,O
after,7786,O
allergen,7786,O
challenge,7786,O
.,7786,O
These,7787,O
findings,7787,O
might,7787,O
explain,7787,O
in,7787,O
part,7787,O
the,7787,O
antiinflammatory,7787,O
action,7787,O
of,7787,O
nedocromil,7787,B-CHEMICAL
sodium,7787,I-CHEMICAL
.,7787,O
Dominant,7788,O
expression,7788,O
of,7788,O
mRNA,7788,O
for,7788,O
prostaglandin,7788,B-CHEMICAL
D,7788,I-CHEMICAL
synthase,7788,I-GENE-Y
in,7788,O
leptomeninges,7788,O
",",7788,O
choroid,7788,O
plexus,7788,O
",",7788,O
and,7788,O
oligodendrocytes,7788,O
of,7788,O
the,7788,O
adult,7788,O
rat,7788,O
brain,7788,O
.,7788,O
Glutathione-independent,7789,B-CHEMICAL
prostaglandin,7789,B-GENE-Y
D,7789,I-GENE-Y
synthase,7789,I-GENE-Y
[,7789,O
prostaglandin-H2,7789,B-CHEMICAL
D-isomerase,7789,I-GENE-Y
;,7789,O
(,7789,B-CHEMICAL
"5Z,13E",7789,I-CHEMICAL
),7789,I-CHEMICAL
-,7789,I-CHEMICAL
(,7789,I-CHEMICAL
15S,7789,I-CHEMICAL
),7789,I-CHEMICAL
-9,7789,I-CHEMICAL
"alpha,11",7789,I-CHEMICAL
"alpha-epidioxy-15-hydroxyprosta-5,13-dienoate",7789,I-CHEMICAL
D-isomerase,7789,I-GENE-Y
",",7789,O
EC,7789,B-GENE-Y
5.3.99.2,7789,I-GENE-Y
],7789,O
is,7789,O
an,7789,O
enzyme,7789,O
responsible,7789,O
for,7789,O
biosynthesis,7789,O
of,7789,O
prostaglandin,7789,B-CHEMICAL
D2,7789,I-CHEMICAL
in,7789,O
the,7789,O
central,7789,O
nervous,7789,O
system,7789,O
.,7789,O
In,7790,O
situ,7790,O
hybridization,7790,O
with,7790,O
antisense,7790,O
RNA,7790,O
for,7790,O
the,7790,O
enzyme,7790,O
indicated,7790,O
that,7790,O
mRNA,7790,O
for,7790,O
the,7790,O
enzyme,7790,O
was,7790,O
predominantly,7790,O
expressed,7790,O
in,7790,O
the,7790,O
leptomeninges,7790,O
",",7790,O
choroid,7790,O
plexus,7790,O
",",7790,O
and,7790,O
oligodendrocytes,7790,O
of,7790,O
the,7790,O
adult,7790,O
rat,7790,O
brain,7790,O
.,7790,O
The,7791,O
findings,7791,O
agree,7791,O
with,7791,O
those,7791,O
obtained,7791,O
by,7791,O
immunohistochemical,7791,O
staining,7791,O
with,7791,O
antibodies,7791,O
against,7791,O
the,7791,O
enzyme,7791,O
.,7791,O
It,7792,O
was,7792,O
further,7792,O
revealed,7792,O
that,7792,O
prostaglandin,7792,B-CHEMICAL
D,7792,I-CHEMICAL
synthase,7792,I-GENE-Y
activity,7792,O
was,7792,O
considerably,7792,O
greater,7792,O
in,7792,O
the,7792,O
isolated,7792,O
leptomeninges,7792,O
(,7792,O
14.2,7792,O
nmol,7792,O
per,7792,O
min,7792,O
per,7792,O
mg,7792,O
of,7792,O
protein,7792,O
),7792,O
and,7792,O
choroid,7792,O
plexus,7792,O
(,7792,O
7.0,7792,O
nmol,7792,O
per,7792,O
min,7792,O
per,7792,O
mg,7792,O
of,7792,O
protein,7792,O
),7792,O
than,7792,O
the,7792,O
activity,7792,O
in,7792,O
the,7792,O
whole,7792,O
brain,7792,O
(,7792,O
2.0,7792,O
nmol,7792,O
per,7792,O
min,7792,O
per,7792,O
mg,7792,O
of,7792,O
protein,7792,O
),7792,O
.,7792,O
These,7793,O
results,7793,O
",",7793,O
taken,7793,O
together,7793,O
",",7793,O
indicate,7793,O
that,7793,O
the,7793,O
enzyme,7793,O
is,7793,O
mainly,7793,O
synthesized,7793,O
and,7793,O
located,7793,O
in,7793,O
the,7793,O
leptomeninges,7793,O
",",7793,O
choroid,7793,O
plexus,7793,O
",",7793,O
and,7793,O
oligodendrocytes,7793,O
in,7793,O
the,7793,O
brain,7793,O
.,7793,O
cDNA,7794,O
cloning,7794,O
and,7794,O
functional,7794,O
properties,7794,O
of,7794,O
human,7794,B-GENE-N
glutamate,7794,I-GENE-N
receptor,7794,I-GENE-N
EAA3,7794,B-GENE-Y
(,7794,O
GluR5,7794,B-GENE-Y
),7794,O
in,7794,O
homomeric,7794,O
and,7794,O
heteromeric,7794,O
configuration,7794,O
.,7794,O
We,7795,O
have,7795,O
isolated,7795,O
a,7795,O
new,7795,O
member,7795,O
of,7795,O
the,7795,O
human,7795,B-GENE-N
glutamate,7795,I-GENE-N
receptor,7795,I-GENE-N
family,7795,O
from,7795,O
a,7795,O
fetal,7795,O
brain,7795,O
cDNA,7795,O
library,7795,O
.,7795,O
This,7796,O
cDNA,7796,O
clone,7796,O
",",7796,O
designated,7796,O
EAA3a,7796,B-GENE-Y
",",7796,O
shares,7796,O
a,7796,O
90,7796,O
%,7796,O
nucleotide,7796,B-CHEMICAL
identity,7796,O
with,7796,O
the,7796,O
previously,7796,O
reported,7796,O
rat,7796,B-GENE-Y
GluR5-2b,7796,I-GENE-Y
cDNA,7796,O
splice,7796,O
variant,7796,O
and,7796,O
differed,7796,O
from,7796,O
human,7796,B-GENE-Y
GluR5-1d,7796,I-GENE-Y
in,7796,O
the,7796,O
amino,7796,B-CHEMICAL
and,7796,O
carboxy,7796,B-CHEMICAL
terminal,7796,O
regions,7796,O
.,7796,O
Cell,7797,O
lines,7797,O
stably,7797,O
expressing,7797,O
EAA3a,7797,B-GENE-Y
protein,7797,O
formed,7797,O
homomeric,7797,O
ligand-gated,7797,B-GENE-N
ion,7797,I-GENE-N
channels,7797,I-GENE-N
responsive,7797,O
",",7797,O
in,7797,O
order,7797,O
of,7797,O
decreasing,7797,O
affinity,7797,O
to,7797,O
domoate,7797,O
",",7797,O
kainate,7797,B-CHEMICAL
",",7797,O
L-glutamate,7797,B-CHEMICAL
and,7797,O
(,7797,B-CHEMICAL
RS,7797,I-CHEMICAL
),7797,I-CHEMICAL
-alpha-amino-3-hydroxy-5-,7797,I-CHEMICAL
methylisoxazole-propionate,7797,I-CHEMICAL
(,7797,O
AMPA,7797,B-CHEMICAL
),7797,O
.,7797,O
Kainate-evoked,7798,B-CHEMICAL
currents,7798,O
showed,7798,O
partial,7798,O
desensitization,7798,O
that,7798,O
was,7798,O
reduced,7798,O
on,7798,O
incubation,7798,O
with,7798,O
concanavalin,7798,B-GENE-N
A,7798,I-GENE-N
(,7798,O
conA,7798,B-GENE-N
),7798,O
but,7798,O
not,7798,O
cyclothiazide,7798,B-CHEMICAL
and,7798,O
were,7798,O
attenuated,7798,O
by,7798,O
the,7798,O
non-N-methyl-D-aspartate,7798,B-CHEMICAL
(,7798,I-GENE-N
NMDA,7798,I-GENE-N
),7798,I-GENE-N
receptor,7798,I-GENE-N
antagonist,7798,O
CNQX,7798,B-CHEMICAL
(,7798,O
6-cyano-7-nitro-quinoxalinedione,7798,B-CHEMICAL
),7798,O
.,7798,O
Coexpression,7799,O
of,7799,O
EAA3a,7799,B-GENE-Y
and,7799,O
human,7799,B-GENE-Y
EAA1,7799,I-GENE-Y
cDNAs,7799,O
in,7799,O
HEK,7799,O
293,7799,O
cells,7799,O
formed,7799,O
a,7799,O
heteromeric,7799,O
channel,7799,O
with,7799,O
unique,7799,O
properties,7799,O
.,7799,O
Kainate,7800,B-CHEMICAL
and,7800,O
AMPA,7800,B-CHEMICAL
activated,7800,O
the,7800,O
heteromeric,7800,O
channel,7800,O
with,7800,O
significantly,7800,O
higher,7800,O
affinities,7800,O
than,7800,O
observed,7800,O
for,7800,O
EAA3a,7800,B-GENE-Y
alone,7800,O
.,7800,O
Ligand,7801,O
binding,7801,O
studies,7801,O
with,7801,O
the,7801,O
recombinant,7801,O
EAA3a,7801,B-GENE-Y
receptor,7801,O
expressed,7801,O
in,7801,O
mammalian,7801,O
cells,7801,O
indicated,7801,O
a,7801,O
high,7801,O
affinity,7801,O
kainate,7801,B-CHEMICAL
binding,7801,O
site,7801,O
(,7801,O
Kd,7801,O
=,7801,O
120,7801,O
+/-,7801,O
15.0,7801,O
nM,7801,O
),7801,O
.,7801,O
The,7802,O
relative,7802,O
potency,7802,O
of,7802,O
compounds,7802,O
in,7802,O
displacing,7802,O
[,7802,B-CHEMICAL
3H,7802,I-CHEMICAL
],7802,I-CHEMICAL
-kainate,7802,I-CHEMICAL
binding,7802,O
to,7802,O
EAA3a,7802,B-GENE-Y
receptor,7802,O
was,7802,O
:,7802,O
domoate,7802,O
>,7802,O
kainate,7802,B-CHEMICAL
>,7802,O
L-glutamate,7802,B-CHEMICAL
=,7802,O
quisqualate,7802,B-CHEMICAL
>,7802,O
"6,7-dinitroquinoxaline-2,3-dione",7802,B-CHEMICAL
(,7802,O
DNQX,7802,B-CHEMICAL
),7802,O
=,7802,O
CNQX,7802,B-CHEMICAL
>,7802,O
AMPA,7802,B-CHEMICAL
>,7802,O
dihydrokainate,7802,B-CHEMICAL
>,7802,O
NMDA,7802,B-CHEMICAL
.,7802,O
Leukotrienes,7803,B-CHEMICAL
in,7803,O
the,7803,O
pathogenesis,7803,O
of,7803,O
pulmonary,7803,O
blast,7803,O
injury,7803,O
.,7803,O
Our,7804,O
previous,7804,O
studies,7804,O
demonstrate,7804,O
a,7804,O
significant,7804,O
increase,7804,O
of,7804,O
sulfidopeptide,7804,O
leukotriene,7804,B-CHEMICAL
concentrations,7804,O
in,7804,O
animals,7804,O
exposed,7804,O
to,7804,O
a,7804,O
free,7804,O
air,7804,O
blast,7804,O
.,7804,O
The,7805,O
aim,7805,O
of,7805,O
this,7805,O
study,7805,O
was,7805,O
to,7805,O
analyze,7805,O
the,7805,O
role,7805,O
of,7805,O
leukotrienes,7805,B-CHEMICAL
in,7805,O
the,7805,O
local,7805,O
response,7805,O
of,7805,O
lung,7805,O
tissue,7805,O
as,7805,O
well,7805,O
as,7805,O
in,7805,O
the,7805,O
general,7805,O
response,7805,O
of,7805,O
organisms,7805,O
to,7805,O
blast,7805,O
overpressure,7805,O
.,7805,O
The,7806,O
study,7806,O
was,7806,O
conducted,7806,O
on,7806,O
adult,7806,O
rabbits,7806,O
exposed,7806,O
to,7806,O
moderate,7806,O
blast,7806,O
overpressure,7806,O
(,7806,O
four,7806,O
pulmonary,7806,O
contusions,7806,O
characterized,7806,O
as,7806,O
confluent,7806,O
ecchymoses,7806,O
involving,7806,O
30,7806,O
to,7806,O
60,7806,O
%,7806,O
of,7806,O
the,7806,O
lungs,7806,O
),7806,O
",",7806,O
generated,7806,O
in,7806,O
laboratory,7806,O
conditions,7806,O
.,7806,O
One,7807,O
group,7807,O
of,7807,O
experimental,7807,O
animals,7807,O
was,7807,O
treated,7807,O
with,7807,O
5-lipoxygenase,7807,B-GENE-Y
(,7807,O
5-LO,7807,B-GENE-Y
),7807,O
inhibitor,7807,O
",",7807,O
diethylcarbamazine,7807,B-CHEMICAL
(,7807,O
DEC,7807,B-CHEMICAL
",",7807,O
Sigma,7807,O
",",7807,O
St.,7807,O
Louis,7807,O
",",7807,O
Missouri,7807,O
),7807,O
(,7807,O
50,7807,O
mg/kg,7807,O
",",7807,O
i.v,7807,O
.,7807,O
),7808,O
",",7808,O
immediately,7808,O
before,7808,O
blast,7808,O
.,7808,O
The,7809,O
early,7809,O
posttraumatic,7809,O
period,7809,O
was,7809,O
observed,7809,O
(,7809,O
30,7809,O
minutes,7809,O
after,7809,O
blast,7809,O
),7809,O
.,7809,O
Hemodynamic,7810,O
parameters,7810,O
(,7810,O
mean,7810,O
arterial,7810,O
pressure,7810,O
",",7810,O
heart,7810,O
rate,7810,O
",",7810,O
blood,7810,O
gases,7810,O
),7810,O
as,7810,O
well,7810,O
as,7810,O
arterial,7810,O
plasma,7810,O
levels,7810,O
of,7810,O
conjugated,7810,O
dienes,7810,O
were,7810,O
observed,7810,O
.,7810,O
The,7811,O
myeloperoxidase,7811,O
activity,7811,O
",",7811,O
lipid,7811,O
peroxidation,7811,O
products,7811,O
levels,7811,O
",",7811,O
and,7811,O
water,7811,O
contents,7811,O
were,7811,O
measured,7811,O
in,7811,O
the,7811,O
lung,7811,O
tissue,7811,O
of,7811,O
injured,7811,O
rabbits,7811,O
.,7811,O
We,7812,O
observed,7812,O
that,7812,O
5-LO,7812,O
inhibition,7812,O
reduced,7812,O
edema,7812,O
formation,7812,O
",",7812,O
accumulation,7812,O
of,7812,O
neutrophils,7812,O
",",7812,O
and,7812,O
generation,7812,O
of,7812,O
lipid,7812,O
peroxidation,7812,O
products,7812,O
in,7812,O
injured,7812,O
lungs,7812,O
.,7812,O
In,7813,O
this,7813,O
study,7813,O
",",7813,O
we,7813,O
demonstrated,7813,O
that,7813,O
treatment,7813,O
with,7813,O
DEC,7813,O
inhibits,7813,O
the,7813,O
increased,7813,O
systemic,7813,O
generation,7813,O
of,7813,O
conjugated,7813,O
dienes,7813,O
after,7813,O
blast,7813,O
injury,7813,O
.,7813,O
Although,7814,O
DEC,7814,O
exerts,7814,O
local,7814,O
antioxidant,7814,O
activity,7814,O
with,7814,O
beneficial,7814,O
effects,7814,O
on,7814,O
lung,7814,O
tissue,7814,O
",",7814,O
this,7814,O
5-LO,7814,O
inhibitor,7814,O
intensifies,7814,O
the,7814,O
blast,7814,O
overpressure,7814,O
caused,7814,O
hemodynamic,7814,O
insufficiency,7814,O
.,7814,O
Tamsulosin,7815,B-CHEMICAL
",",7815,O
the,7815,O
first,7815,O
prostate-selective,7815,O
alpha,7815,B-GENE-Y
1A-adrenoceptor,7815,I-GENE-Y
antagonist,7815,O
.,7815,O
A,7816,O
meta-analysis,7816,O
of,7816,O
two,7816,O
randomized,7816,O
",",7816,O
placebo-controlled,7816,O
",",7816,O
multicentre,7816,O
studies,7816,O
in,7816,O
patients,7816,O
with,7816,O
benign,7816,O
prostatic,7816,O
obstruction,7816,O
(,7816,O
symptomatic,7816,O
BPH,7816,O
),7816,O
.,7816,O
European,7817,O
Tamsulosin,7817,B-CHEMICAL
Study,7817,O
Group,7817,O
.,7817,O
OBJECTIVE,7818,O
:,7818,O
This,7818,O
meta-analysis,7818,O
of,7818,O
two,7818,O
European,7818,O
studies,7818,O
evaluated,7818,O
the,7818,O
efficacy,7818,O
and,7818,O
safety,7818,O
of,7818,O
modified-release,7818,O
tamsulosin,7818,B-CHEMICAL
0.4,7818,O
mg,7818,O
once,7818,O
daily,7818,O
compared,7818,O
with,7818,O
placebo,7818,O
in,7818,O
patients,7818,O
with,7818,O
benign,7818,O
prostatic,7818,O
enlargement,7818,O
",",7818,O
lower,7818,O
urinary,7818,O
tract,7818,O
symptoms,7818,O
and,7818,O
prostatic,7818,O
obstruction,7818,O
(,7818,O
symptomatic,7818,O
BPH,7818,O
),7818,O
.,7818,O
METHODS,7819,O
:,7819,O
Patients,7819,O
entered,7819,O
a,7819,O
2-week,7819,O
placebo,7819,O
run-in,7819,O
period,7819,O
",",7819,O
followed,7819,O
by,7819,O
randomization,7819,O
to,7819,O
treatment,7819,O
with,7819,O
tamsulosin,7819,B-CHEMICAL
(,7819,O
382,7819,O
patients,7819,O
),7819,O
or,7819,O
placebo,7819,O
(,7819,O
193,7819,O
patients,7819,O
),7819,O
once,7819,O
daily,7819,O
for,7819,O
12,7819,O
weeks,7819,O
.,7819,O
RESULTS,7820,O
:,7820,O
Maximum,7820,O
urinary,7820,O
flow,7820,O
rate,7820,O
improved,7820,O
to,7820,O
a,7820,O
greater,7820,O
extent,7820,O
in,7820,O
the,7820,O
tamsulosin,7820,B-CHEMICAL
group,7820,O
(,7820,O
1.6,7820,O
ml/s,7820,O
",",7820,O
16,7820,O
%,7820,O
),7820,O
than,7820,O
the,7820,O
placebo,7820,O
group,7820,O
(,7820,O
0.6,7820,O
ml/s,7820,O
",",7820,O
6,7820,O
%,7820,O
),7820,O
(,7820,O
p,7820,O
=,7820,O
0.002,7820,O
),7820,O
.,7820,O
Total,7821,O
Boyarsky,7821,O
symptom,7821,O
score,7821,O
also,7821,O
improved,7821,O
to,7821,O
a,7821,O
greater,7821,O
extent,7821,O
in,7821,O
the,7821,O
tamsulosin,7821,B-CHEMICAL
group,7821,O
(,7821,O
3.3,7821,O
points,7821,O
",",7821,O
35.1,7821,O
%,7821,O
reduction,7821,O
),7821,O
than,7821,O
the,7821,O
placebo,7821,O
group,7821,O
(,7821,O
2.4,7821,O
points,7821,O
",",7821,O
25.5,7821,O
%,7821,O
reduction,7821,O
),7821,O
(,7821,O
p,7821,O
=,7821,O
0.002,7821,O
),7821,O
.,7821,O
Significantly,7822,O
more,7822,O
tamsulosin,7822,B-CHEMICAL
patients,7822,O
(,7822,O
66,7822,O
%,7822,O
),7822,O
than,7822,O
placebo,7822,O
patients,7822,O
(,7822,O
49,7822,O
%,7822,O
),7822,O
had,7822,O
a,7822,O
>,7822,O
or,7822,O
=,7822,O
25,7822,O
%,7822,O
decrease,7822,O
in,7822,O
total,7822,O
symptom,7822,O
score,7822,O
at,7822,O
endpoint,7822,O
(,7822,O
p,7822,O
<,7822,O
0.001,7822,O
),7822,O
.,7822,O
Twelve,7823,O
weeks,7823,O
of,7823,O
treatment,7823,O
with,7823,O
tamsulosin,7823,B-CHEMICAL
also,7823,O
produced,7823,O
significant,7823,O
improvements,7823,O
in,7823,O
average,7823,O
urinary,7823,O
flow,7823,O
rate,7823,O
(,7823,O
p,7823,O
=,7823,O
0.005,7823,O
),7823,O
and,7823,O
voiding,7823,O
or,7823,O
``,7823,O
obstructive,7823,O
'',7823,O
(,7823,O
p,7823,O
=,7823,O
0.008,7823,O
),7823,O
and,7823,O
storage,7823,O
or,7823,O
``,7823,O
irritative,7823,O
',7823,O
(,7823,O
p,7823,O
=,7823,O
0.017,7823,O
),7823,O
symptom,7823,O
scores,7823,O
.,7823,O
The,7824,O
incidence,7824,O
of,7824,O
drug-related,7824,O
adverse,7824,O
events,7824,O
was,7824,O
comparable,7824,O
for,7824,O
the,7824,O
tamsulosin,7824,B-CHEMICAL
and,7824,O
placebo,7824,O
groups,7824,O
(,7824,O
13,7824,O
and,7824,O
12,7824,O
%,7824,O
respectively,7824,O
",",7824,O
p,7824,O
=,7824,O
0.802,7824,O
),7824,O
.,7824,O
The,7825,O
same,7825,O
applies,7825,O
to,7825,O
the,7825,O
incidence,7825,O
of,7825,O
adverse,7825,O
events,7825,O
commonly,7825,O
attributed,7825,O
to,7825,O
alpha,7825,B-GENE-Y
1-adrenoceptor,7825,I-GENE-Y
antagonists,7825,O
",",7825,O
such,7825,O
as,7825,O
dizziness,7825,O
",",7825,O
headache,7825,O
",",7825,O
postural,7825,O
hypotension,7825,O
",",7825,O
syncope,7825,O
",",7825,O
asthenia,7825,O
",",7825,O
somnolence,7825,O
and,7825,O
rhinitis,7825,O
.,7825,O
There,7826,O
were,7826,O
no,7826,O
clinically,7826,O
significant,7826,O
changes,7826,O
in,7826,O
blood,7826,O
pressure,7826,O
or,7826,O
pulse,7826,O
rate,7826,O
in,7826,O
tamsulosin,7826,B-CHEMICAL
patients,7826,O
compared,7826,O
with,7826,O
placebo,7826,O
patients,7826,O
both,7826,O
in,7826,O
hypertensive,7826,O
and,7826,O
normotensive,7826,O
BPH,7826,O
patients,7826,O
.,7826,O
CONCLUSION,7827,O
:,7827,O
Tamsulosin,7827,B-CHEMICAL
0.4,7827,O
mg,7827,O
once,7827,O
daily,7827,O
is,7827,O
safe,7827,O
",",7827,O
well-tolerated,7827,O
and,7827,O
improves,7827,O
both,7827,O
the,7827,O
symptoms,7827,O
and,7827,O
urinary,7827,O
flow,7827,O
rate,7827,O
in,7827,O
patients,7827,O
with,7827,O
benign,7827,O
prostatic,7827,O
obstruction,7827,O
(,7827,O
symptomatic,7827,O
BPH,7827,O
),7827,O
.,7827,O
Human,7828,B-GENE-Y
prohormone,7828,I-GENE-Y
convertase,7828,I-GENE-Y
3,7828,I-GENE-Y
gene,7828,O
:,7828,O
exon-intron,7828,O
organization,7828,O
and,7828,O
molecular,7828,O
scanning,7828,O
for,7828,O
mutations,7828,O
in,7828,O
Japanese,7828,O
subjects,7828,O
with,7828,O
NIDDM,7828,O
.,7828,O
Proinsulin,7829,B-GENE-Y
is,7829,O
converted,7829,O
to,7829,O
insulin,7829,B-GENE-Y
by,7829,O
the,7829,O
concerted,7829,O
action,7829,O
of,7829,O
two,7829,O
sequence-specific,7829,O
subtilisin-like,7829,B-GENE-N
proteases,7829,I-GENE-N
termed,7829,O
prohormone,7829,B-GENE-Y
convertase,7829,I-GENE-Y
2,7829,I-GENE-Y
(,7829,O
PC2,7829,B-GENE-Y
),7829,O
and,7829,O
prohormone,7829,B-GENE-Y
convertase,7829,I-GENE-Y
3,7829,I-GENE-Y
(,7829,O
PC3,7829,B-GENE-Y
),7829,O
.,7829,O
PC3,7830,B-GENE-Y
is,7830,O
a,7830,O
type,7830,B-GENE-N
I,7830,I-GENE-N
proinsulin-processing,7830,I-GENE-N
enzyme,7830,I-GENE-N
that,7830,O
initiates,7830,O
the,7830,O
sequential,7830,O
processing,7830,O
of,7830,O
proinsulin,7830,B-GENE-Y
to,7830,O
insulin,7830,B-GENE-Y
by,7830,O
cleaving,7830,O
the,7830,O
proinsulin,7830,B-GENE-Y
molecule,7830,O
on,7830,O
the,7830,O
COOH-terminal,7830,B-CHEMICAL
side,7830,O
of,7830,O
the,7830,O
dibasic,7830,O
peptide,7830,O
",",7830,O
Arg31-Arg32,7830,O
",",7830,O
joining,7830,O
the,7830,O
B-chain,7830,O
and,7830,O
C-peptide,7830,B-CHEMICAL
.,7830,O
Thus,7831,O
",",7831,O
PC3,7831,B-GENE-Y
plays,7831,O
a,7831,O
key,7831,O
role,7831,O
in,7831,O
regulating,7831,O
insulin,7831,B-GENE-Y
biosynthesis,7831,O
.,7831,O
Expressions,7832,O
of,7832,O
insulin,7832,B-GENE-Y
and,7832,O
PC3,7832,B-GENE-Y
",",7832,O
but,7832,O
not,7832,O
PC2,7832,B-GENE-Y
",",7832,O
are,7832,O
coordinately,7832,O
regulated,7832,O
by,7832,O
glucose,7832,B-CHEMICAL
",",7832,O
consistent,7832,O
with,7832,O
the,7832,O
important,7832,O
role,7832,O
of,7832,O
PC3,7832,B-GENE-Y
in,7832,O
regulating,7832,O
proinsulin,7832,B-GENE-Y
processing,7832,O
.,7832,O
NIDDM,7833,O
is,7833,O
associated,7833,O
with,7833,O
increased,7833,O
secretion,7833,O
of,7833,O
proinsulin,7833,B-GENE-Y
and,7833,O
proinsulin-like,7833,B-GENE-Y
molecules,7833,O
",",7833,O
suggesting,7833,O
that,7833,O
mutations,7833,O
in,7833,O
the,7833,O
PC3,7833,B-GENE-Y
gene,7833,O
may,7833,O
be,7833,O
involved,7833,O
in,7833,O
the,7833,O
development,7833,O
of,7833,O
this,7833,O
disorder,7833,O
.,7833,O
To,7834,O
examine,7834,O
this,7834,O
hypothesis,7834,O
",",7834,O
we,7834,O
have,7834,O
isolated,7834,O
and,7834,O
characterized,7834,O
the,7834,O
human,7834,B-GENE-Y
PC3,7834,I-GENE-Y
gene,7834,O
and,7834,O
screened,7834,O
it,7834,O
for,7834,O
mutations,7834,O
in,7834,O
a,7834,O
group,7834,O
of,7834,O
Japanese,7834,O
subjects,7834,O
with,7834,O
NIDDM,7834,O
.,7834,O
The,7835,O
PC3,7835,B-GENE-Y
gene,7835,O
consists,7835,O
of,7835,O
14,7835,O
exons,7835,O
spanning,7835,O
more,7835,O
than,7835,O
35,7835,O
kb,7835,O
.,7835,O
The,7836,O
exon-intron,7836,O
organization,7836,O
of,7836,O
PC2,7836,B-GENE-Y
and,7836,O
PC3,7836,B-GENE-Y
genes,7836,O
are,7836,O
conserved,7836,O
",",7836,O
consistent,7836,O
with,7836,O
a,7836,O
common,7836,O
evolutionary,7836,O
origin,7836,O
for,7836,O
the,7836,O
prohormone,7836,B-GENE-N
convertase,7836,I-GENE-N
gene,7836,O
family,7836,O
.,7836,O
Single-strand,7837,O
conformational,7837,O
analysis,7837,O
and,7837,O
nucleotide,7837,B-CHEMICAL
sequencing,7837,O
of,7837,O
the,7837,O
entire,7837,O
coding,7837,O
region,7837,O
of,7837,O
the,7837,O
PC3,7837,B-GENE-Y
gene,7837,O
in,7837,O
102,7837,O
Japanese,7837,O
subjects,7837,O
with,7837,O
NIDDM,7837,O
revealed,7837,O
missense,7837,O
mutations,7837,O
in,7837,O
exons,7837,O
2,7837,O
(,7837,O
Arg/Gln53,7837,B-GENE-N
),7837,O
and,7837,O
14,7837,O
(,7837,O
Gln/Glu638,7837,B-GENE-N
),7837,O
",",7837,O
neither,7837,O
of,7837,O
which,7837,O
was,7837,O
associated,7837,O
with,7837,O
NIDDM,7837,O
in,7837,O
this,7837,O
population,7837,O
.,7837,O
These,7838,O
data,7838,O
suggest,7838,O
that,7838,O
genetic,7838,O
variation,7838,O
in,7838,O
the,7838,O
PC3,7838,B-GENE-Y
gene,7838,O
is,7838,O
unlikely,7838,O
to,7838,O
be,7838,O
a,7838,O
major,7838,O
contributor,7838,O
to,7838,O
NIDDM,7838,O
susceptibility,7838,O
in,7838,O
Japanese,7838,O
.,7838,O
Desipramine,7839,B-CHEMICAL
administration,7839,O
in,7839,O
the,7839,O
olfactory,7839,O
bulbectomized,7839,O
rat,7839,O
:,7839,O
changes,7839,O
in,7839,O
brain,7839,O
beta-adrenoceptor,7839,B-GENE-N
and,7839,O
5-HT2A,7839,B-GENE-Y
binding,7839,O
sites,7839,O
and,7839,O
their,7839,O
relationship,7839,O
to,7839,O
behaviour,7839,O
.,7839,O
1,7840,O
.,7840,O
The,7841,O
effects,7841,O
of,7841,O
repeated,7841,O
administration,7841,O
of,7841,O
the,7841,O
tricyclic,7841,B-CHEMICAL
antidepressant,7841,O
drug,7841,O
",",7841,O
desipramine,7841,B-CHEMICAL
(,7841,O
DMI,7841,B-CHEMICAL
),7841,O
",",7841,O
on,7841,O
behaviour,7841,O
(,7841,O
locomotor,7841,O
activity,7841,O
and,7841,O
rearing,7841,O
),7841,O
and,7841,O
the,7841,O
number,7841,O
and,7841,O
affinity,7841,O
of,7841,O
brain,7841,O
beta-adrenoceptor,7841,B-GENE-N
and,7841,O
5-HT2A,7841,B-GENE-Y
receptor,7841,O
binding,7841,O
sites,7841,O
were,7841,O
examined,7841,O
in,7841,O
olfactory,7841,O
bulbectomized,7841,O
(,7841,O
OB,7841,O
),7841,O
and,7841,O
sham-operated,7841,O
control,7841,O
rats,7841,O
.,7841,O
2,7842,O
.,7842,O
Locomotor,7843,O
activity,7843,O
and,7843,O
rearing,7843,O
were,7843,O
increased,7843,O
in,7843,O
OB,7843,O
rats,7843,O
compared,7843,O
to,7843,O
sham-operated,7843,O
controls,7843,O
.,7843,O
The,7844,O
effect,7844,O
of,7844,O
various,7844,O
doses,7844,O
of,7844,O
DMI,7844,B-CHEMICAL
(,7844,O
administered,7844,O
orally,7844,O
twice,7844,O
daily,7844,O
for,7844,O
21,7844,O
days,7844,O
),7844,O
on,7844,O
these,7844,O
behavioural,7844,O
measures,7844,O
was,7844,O
examined,7844,O
.,7844,O
A,7845,O
dose,7845,O
of,7845,O
7.5,7845,O
mg,7845,O
kg-1,7845,O
provided,7845,O
optimal,7845,O
reversal,7845,O
of,7845,O
hyperlocomotion,7845,O
and,7845,O
increased,7845,O
rearing,7845,O
in,7845,O
OB,7845,O
rats,7845,O
",",7845,O
without,7845,O
changing,7845,O
these,7845,O
measures,7845,O
in,7845,O
sham-operated,7845,O
controls,7845,O
.,7845,O
3,7846,O
.,7846,O
The,7847,O
time,7847,O
course,7847,O
of,7847,O
DMI,7847,B-CHEMICAL
(,7847,O
7.5,7847,O
mg,7847,O
kg-1,7847,O
),7847,O
on,7847,O
behavioural,7847,O
and,7847,O
neurochemical,7847,O
measures,7847,O
was,7847,O
examined,7847,O
.,7847,O
locomotion,7848,O
and,7848,O
rearing,7848,O
in,7848,O
OB,7848,O
rats,7848,O
were,7848,O
not,7848,O
significantly,7848,O
altered,7848,O
after,7848,O
7,7848,O
days,7848,O
",",7848,O
were,7848,O
significantly,7848,O
attenuated,7848,O
after,7848,O
14,7848,O
days,7848,O
and,7848,O
were,7848,O
normalized,7848,O
after,7848,O
21,7848,O
days,7848,O
.,7848,O
4,7849,O
.,7849,O
After,7850,O
7,7850,O
days,7850,O
of,7850,O
DMI,7850,B-CHEMICAL
administration,7850,O
the,7850,O
number,7850,O
of,7850,O
beta-adrenoceptors,7850,B-GENE-N
was,7850,O
lower,7850,O
in,7850,O
frontal,7850,O
and,7850,O
occipital,7850,O
cortex,7850,O
and,7850,O
hippocampus,7850,O
.,7850,O
This,7851,O
reduction,7851,O
was,7851,O
largely,7851,O
restricted,7851,O
to,7851,O
the,7851,O
beta,7851,B-GENE-Y
1-adrenoceptor,7851,I-GENE-Y
subtype,7851,O
.,7851,O
Administration,7852,O
of,7852,O
DMI,7852,B-CHEMICAL
for,7852,O
14,7852,O
or,7852,O
21,7852,O
days,7852,O
did,7852,O
not,7852,O
further,7852,O
reduce,7852,O
the,7852,O
number,7852,O
of,7852,O
beta-adrenoceptors,7852,B-GENE-N
.,7852,O
The,7853,O
DMI,7853,B-CHEMICAL
induced,7853,O
reduction,7853,O
in,7853,O
beta-adrenoceptors,7853,B-GENE-N
did,7853,O
not,7853,O
differ,7853,O
in,7853,O
OB,7853,O
and,7853,O
sham-operated,7853,O
control,7853,O
rats,7853,O
.,7853,O
5,7854,O
.,7854,O
DMI,7855,B-CHEMICAL
administration,7855,O
for,7855,O
up,7855,O
to,7855,O
21,7855,O
days,7855,O
produced,7855,O
a,7855,O
progressive,7855,O
reduction,7855,O
in,7855,O
the,7855,O
number,7855,O
of,7855,O
5-HT2A,7855,B-GENE-Y
receptors,7855,O
in,7855,O
frontal,7855,O
cortex,7855,O
",",7855,O
without,7855,O
significant,7855,O
alterations,7855,O
in,7855,O
occipital,7855,O
cortex,7855,O
.,7855,O
6,7856,O
.,7856,O
The,7857,O
time,7857,O
course,7857,O
of,7857,O
the,7857,O
reduction,7857,O
in,7857,O
the,7857,O
number,7857,O
of,7857,O
5-HT2A,7857,B-GENE-Y
receptors,7857,O
was,7857,O
similar,7857,O
to,7857,O
that,7857,O
of,7857,O
the,7857,O
DMI-induced,7857,B-CHEMICAL
behavioural,7857,O
changes,7857,O
whereas,7857,O
that,7857,O
for,7857,O
the,7857,O
reduction,7857,O
in,7857,O
beta-adrenoceptors,7857,B-GENE-N
was,7857,O
clearly,7857,O
different,7857,O
.,7857,O
7,7858,O
.,7858,O
The,7859,O
present,7859,O
results,7859,O
suggest,7859,O
that,7859,O
the,7859,O
action,7859,O
of,7859,O
DMI,7859,B-CHEMICAL
in,7859,O
this,7859,O
animal,7859,O
model,7859,O
is,7859,O
unlikely,7859,O
to,7859,O
be,7859,O
directly,7859,O
related,7859,O
to,7859,O
a,7859,O
reduction,7859,O
in,7859,O
beta-adrenoceptors,7859,B-GENE-N
but,7859,O
may,7859,O
be,7859,O
related,7859,O
to,7859,O
a,7859,O
reduction,7859,O
in,7859,O
frontal,7859,O
cortical,7859,O
5-HT2A,7859,B-GENE-Y
receptors,7859,O
.,7859,O
Binding,7860,O
of,7860,O
thalidomide,7860,B-CHEMICAL
to,7860,O
alpha1-acid,7860,B-GENE-N
glycoprotein,7860,I-GENE-N
may,7860,O
be,7860,O
involved,7860,O
in,7860,O
its,7860,O
inhibition,7860,O
of,7860,O
tumor,7860,B-GENE-Y
necrosis,7860,I-GENE-Y
factor,7860,I-GENE-Y
alpha,7860,I-GENE-Y
production,7860,O
.,7860,O
In,7861,O
addition,7861,O
to,7861,O
its,7861,O
well,7861,O
known,7861,O
sedative,7861,O
and,7861,O
teratogenic,7861,O
effects,7861,O
",",7861,O
thalidomide,7861,O
also,7861,O
possesses,7861,O
potent,7861,O
immunomodulatory,7861,O
and,7861,O
antiinflammatory,7861,O
activities,7861,O
",",7861,O
being,7861,O
most,7861,O
effective,7861,O
against,7861,O
leprosy,7861,O
and,7861,O
chronic,7861,O
graft-versus-host,7861,O
disease,7861,O
.,7861,O
The,7862,O
immunomodulatory,7862,O
activity,7862,O
of,7862,O
thalidomide,7862,B-CHEMICAL
has,7862,O
been,7862,O
ascribed,7862,O
to,7862,O
the,7862,O
selective,7862,O
inhibition,7862,O
of,7862,O
tumor,7862,B-GENE-Y
necrosis,7862,I-GENE-Y
factor,7862,I-GENE-Y
alpha,7862,I-GENE-Y
from,7862,O
monocytes,7862,O
.,7862,O
The,7863,O
molecular,7863,O
mechanism,7863,O
for,7863,O
the,7863,O
immunomodulatory,7863,O
effect,7863,O
of,7863,O
thalidomide,7863,B-CHEMICAL
remains,7863,O
unknown,7863,O
.,7863,O
To,7864,O
elucidate,7864,O
this,7864,O
mechanism,7864,O
",",7864,O
we,7864,O
synthesized,7864,O
an,7864,O
active,7864,O
photoaffinity,7864,O
label,7864,O
of,7864,O
thalidomide,7864,B-CHEMICAL
as,7864,O
a,7864,O
probe,7864,O
to,7864,O
identify,7864,O
the,7864,O
molecular,7864,O
target,7864,O
of,7864,O
the,7864,O
drug,7864,O
.,7864,O
Using,7865,O
the,7865,O
probe,7865,O
",",7865,O
we,7865,O
specifically,7865,O
labeled,7865,O
a,7865,O
pair,7865,O
of,7865,O
proteins,7865,O
of,7865,O
43-45,7865,O
kDa,7865,O
with,7865,O
high,7865,O
acidity,7865,O
from,7865,O
bovine,7865,O
thymus,7865,O
extract,7865,O
.,7865,O
Purification,7866,O
of,7866,O
these,7866,O
proteins,7866,O
and,7866,O
partial,7866,O
peptide,7866,O
sequence,7866,O
determination,7866,O
revealed,7866,O
them,7866,O
to,7866,O
be,7866,O
alpha1-acid,7866,B-GENE-Y
glycoprotein,7866,I-GENE-Y
(,7866,O
AGP,7866,B-GENE-Y
),7866,O
.,7866,O
We,7867,O
show,7867,O
that,7867,O
the,7867,O
binding,7867,O
of,7867,O
thalidomide,7867,B-CHEMICAL
photoaffinity,7867,O
label,7867,O
to,7867,O
authentic,7867,O
human,7867,B-GENE-N
AGP,7867,I-GENE-N
is,7867,O
competed,7867,O
with,7867,O
both,7867,O
thalidomide,7867,B-CHEMICAL
and,7867,O
the,7867,O
nonradioactive,7867,O
photoaffinity,7867,O
label,7867,O
at,7867,O
concentrations,7867,O
comparable,7867,O
to,7867,O
those,7867,O
required,7867,O
for,7867,O
inhibition,7867,O
of,7867,O
production,7867,O
of,7867,O
tumor,7867,B-GENE-Y
necrosis,7867,I-GENE-Y
factor,7867,I-GENE-Y
alpha,7867,I-GENE-Y
from,7867,O
human,7867,O
monocytes,7867,O
",",7867,O
suggesting,7867,O
that,7867,O
AGP,7867,B-GENE-N
may,7867,O
be,7867,O
involved,7867,O
in,7867,O
the,7867,O
immunomodulatory,7867,O
activity,7867,O
of,7867,O
thalidomide,7867,B-CHEMICAL
.,7867,O
AMPA,7868,B-GENE-N
receptor,7868,I-GENE-N
heterogeneity,7868,O
in,7868,O
rat,7868,O
hippocampal,7868,O
neurons,7868,O
revealed,7868,O
by,7868,O
differential,7868,O
sensitivity,7868,O
to,7868,O
cyclothiazide,7868,B-CHEMICAL
.,7868,O
1,7869,O
.,7869,O
The,7870,O
kinetics,7870,O
of,7870,O
onset,7870,O
of,7870,O
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic,7870,B-CHEMICAL
acid,7870,I-CHEMICAL
(,7870,B-GENE-N
AMPA,7870,I-GENE-N
),7870,I-GENE-N
receptor,7870,I-GENE-N
desensitization,7870,O
by,7870,O
glutamate,7870,B-CHEMICAL
",",7870,O
and,7870,O
the,7870,O
extent,7870,O
of,7870,O
attenuation,7870,O
of,7870,O
AMPA,7870,B-CHEMICAL
receptor,7870,I-GENE-N
desensitization,7870,O
by,7870,O
cyclothiazide,7870,B-CHEMICAL
",",7870,O
showed,7870,O
pronounced,7870,O
cell-to-cell,7870,O
variation,7870,O
in,7870,O
cultures,7870,O
of,7870,O
rat,7870,O
hippocampal,7870,O
neurons,7870,O
.,7870,O
Cultures,7871,O
prepared,7871,O
from,7871,O
area,7871,O
CA1,7871,O
stratum,7871,O
radiatum,7871,O
tended,7871,O
to,7871,O
show,7871,O
weaker,7871,O
modulation,7871,O
by,7871,O
cyclothiazide,7871,B-CHEMICAL
than,7871,O
cultures,7871,O
prepared,7871,O
from,7871,O
the,7871,O
whole,7871,O
hippocampus,7871,O
.,7871,O
2,7872,O
.,7872,O
Kinetic,7873,O
analysis,7873,O
of,7873,O
concentration,7873,O
jump,7873,O
responses,7873,O
to,7873,O
glutamate,7873,B-CHEMICAL
revealed,7873,O
multiple,7873,O
populations,7873,O
of,7873,O
receptors,7873,O
with,7873,O
fast,7873,O
(,7873,O
approximately,7873,O
400,7873,O
ms,7873,O
),7873,O
",",7873,O
intermediate,7873,O
(,7873,O
approximately,7873,O
2-4,7873,O
s,7873,O
),7873,O
",",7873,O
and,7873,O
slow,7873,O
(,7873,O
>,7873,O
20,7873,O
s,7873,O
),7873,O
time,7873,O
constants,7873,O
for,7873,O
recovery,7873,O
from,7873,O
modulation,7873,O
by,7873,O
cyclothiazide,7873,B-CHEMICAL
.,7873,O
The,7874,O
amplitudes,7874,O
of,7874,O
these,7874,O
components,7874,O
varied,7874,O
widely,7874,O
between,7874,O
cells,7874,O
",",7874,O
suggesting,7874,O
the,7874,O
existence,7874,O
of,7874,O
at,7874,O
least,7874,O
three,7874,O
populations,7874,O
of,7874,O
AMPA,7874,B-GENE-N
receptor,7874,I-GENE-N
subtypes,7874,O
",",7874,O
the,7874,O
relative,7874,O
density,7874,O
of,7874,O
which,7874,O
varied,7874,O
from,7874,O
cell,7874,O
to,7874,O
cell,7874,O
.,7874,O
3,7875,O
.,7875,O
The,7876,O
complex,7876,O
patterns,7876,O
of,7876,O
sensitivity,7876,O
to,7876,O
cyclothiazide,7876,B-CHEMICAL
seen,7876,O
in,7876,O
hippocampal,7876,O
neurons,7876,O
could,7876,O
be,7876,O
reconstituted,7876,O
by,7876,O
assembly,7876,O
of,7876,O
recombinant,7876,O
AMPA,7876,B-GENE-N
receptor,7876,I-GENE-N
subunits,7876,O
generated,7876,O
from,7876,O
cDNAs,7876,O
encoding,7876,O
the,7876,O
flip,7876,O
(,7876,O
i,7876,O
),7876,O
and,7876,O
flop,7876,O
(,7876,O
o,7876,O
),7876,O
splice,7876,O
variants,7876,O
of,7876,O
the,7876,O
GluR-A,7876,B-GENE-Y
and,7876,O
GluR-B,7876,B-GENE-Y
subunits,7876,O
.,7876,O
Recovery,7877,O
from,7877,O
modulation,7877,O
by,7877,O
cyclothiazide,7877,B-CHEMICAL
was,7877,O
slower,7877,O
for,7877,O
GluR-AiBi,7877,B-GENE-N
and,7877,O
GluR-AoBi,7877,B-GENE-N
than,7877,O
for,7877,O
GluR-AiBo,7877,B-GENE-N
and,7877,O
GluR-AoBo,7877,B-GENE-N
.,7877,O
4,7878,O
.,7878,O
Coexpression,7879,O
of,7879,O
the,7879,O
flip,7879,O
and,7879,O
flop,7879,O
splice,7879,O
variants,7879,O
of,7879,O
GluR-A,7879,B-GENE-Y
",",7879,O
in,7879,O
the,7879,O
absence,7879,O
of,7879,O
GluR-B,7879,B-GENE-Y
",",7879,O
revealed,7879,O
that,7879,O
heteromeric,7879,O
AMPA,7879,B-CHEMICAL
receptors,7879,I-GENE-N
with,7879,O
intermediate,7879,O
sensitivity,7879,O
to,7879,O
cyclothiazide,7879,B-CHEMICAL
",",7879,O
similar,7879,O
to,7879,O
responses,7879,O
observed,7879,O
for,7879,O
the,7879,O
combinations,7879,O
GluR-AoBi,7879,B-GENE-N
or,7879,O
GluR-AiBo,7879,B-GENE-N
",",7879,O
could,7879,O
be,7879,O
generated,7879,O
independently,7879,O
of,7879,O
the,7879,O
presence,7879,O
of,7879,O
the,7879,O
GluR-B,7879,B-GENE-Y
subunit,7879,O
.,7879,O
However,7880,O
",",7880,O
recovery,7880,O
from,7880,O
modulation,7880,O
by,7880,O
cyclothiazide,7880,B-CHEMICAL
was,7880,O
twofold,7880,O
slower,7880,O
for,7880,O
GluR-AiBi,7880,B-GENE-N
than,7880,O
for,7880,O
homomeric,7880,O
GluR-Ai,7880,B-GENE-N
",",7880,O
indicating,7880,O
that,7880,O
the,7880,O
GluR-A,7880,B-GENE-Y
and,7880,O
GluR-B,7880,B-GENE-Y
subunits,7880,O
are,7880,O
not,7880,O
functionally,7880,O
equivalent,7880,O
in,7880,O
controlling,7880,O
sensitivity,7880,O
to,7880,O
cyclothiazide,7880,B-CHEMICAL
.,7880,O
5,7881,O
.,7881,O
These,7882,O
results,7882,O
demonstrate,7882,O
that,7882,O
AMPA,7882,B-CHEMICAL
receptors,7882,I-GENE-N
expressed,7882,O
in,7882,O
hippocampal,7882,O
neurons,7882,O
are,7882,O
assembled,7882,O
in,7882,O
a,7882,O
variety,7882,O
of,7882,O
subunit,7882,O
and,7882,O
splice,7882,O
variant,7882,O
combinations,7882,O
that,7882,O
might,7882,O
serve,7882,O
as,7882,O
a,7882,O
mechanism,7882,O
to,7882,O
fine-tune,7882,O
the,7882,O
kinetics,7882,O
of,7882,O
synaptic,7882,O
transmission,7882,O
.,7882,O
Striatal,7883,O
dopamine,7883,B-CHEMICAL
",",7883,O
dopamine,7883,B-GENE-Y
transporter,7883,I-GENE-Y
",",7883,O
and,7883,O
vesicular,7883,B-GENE-Y
monoamine,7883,I-GENE-Y
transporter,7883,I-GENE-Y
in,7883,O
chronic,7883,O
cocaine,7883,B-CHEMICAL
users,7883,O
.,7883,O
Depletion,7884,O
of,7884,O
striatal,7884,O
dopamine,7884,B-CHEMICAL
(,7884,O
DA,7884,B-CHEMICAL
),7884,O
has,7884,O
been,7884,O
hypothesized,7884,O
to,7884,O
explain,7884,O
some,7884,O
of,7884,O
the,7884,O
neurological,7884,O
and,7884,O
psychiatric,7884,O
complications,7884,O
of,7884,O
chronic,7884,O
use,7884,O
of,7884,O
cocaine,7884,B-CHEMICAL
",",7884,O
including,7884,O
increased,7884,O
risk,7884,O
for,7884,O
neuroleptic-precipitated,7884,O
movement,7884,O
disorders,7884,O
.,7884,O
We,7885,O
measured,7885,O
levels,7885,O
of,7885,O
DA,7885,B-CHEMICAL
",",7885,O
as,7885,O
well,7885,O
as,7885,O
two,7885,O
DA,7885,B-CHEMICAL
nerve,7885,O
terminal,7885,O
indices,7885,O
",",7885,O
namely,7885,O
",",7885,O
the,7885,O
DA,7885,B-CHEMICAL
transporter,7885,I-GENE-Y
(,7885,O
DAT,7885,B-GENE-Y
),7885,O
and,7885,O
the,7885,O
vesicular,7885,B-GENE-Y
monoamine,7885,B-CHEMICAL
transporter,7885,I-GENE-Y
(,7885,O
VMAT2,7885,B-GENE-Y
),7885,O
in,7885,O
autopsied,7885,O
brain,7885,O
of,7885,O
12,7885,O
chronic,7885,O
cocaine,7885,B-CHEMICAL
users,7885,O
.,7885,O
Mean,7886,O
DA,7886,B-CHEMICAL
levels,7886,O
were,7886,O
normal,7886,O
in,7886,O
the,7886,O
putamen,7886,O
",",7886,O
the,7886,O
motor,7886,O
component,7886,O
of,7886,O
the,7886,O
striatum,7886,O
;,7886,O
however,7886,O
4,7886,O
of,7886,O
the,7886,O
12,7886,O
subjects,7886,O
had,7886,O
DA,7886,B-CHEMICAL
values,7886,O
below,7886,O
the,7886,O
lower,7886,O
limit,7886,O
of,7886,O
the,7886,O
control,7886,O
range,7886,O
.,7886,O
DA,7887,B-CHEMICAL
concentrations,7887,O
were,7887,O
significantly,7887,O
reduced,7887,O
in,7887,O
the,7887,O
caudate,7887,O
head,7887,O
(,7887,O
head,7887,O
",",7887,O
-33,7887,O
%,7887,O
;,7887,O
tail,7887,O
",",7887,O
-39,7887,O
%,7887,O
),7887,O
with,7887,O
a,7887,O
trend,7887,O
for,7887,O
reduction,7887,O
in,7887,O
nucleus,7887,O
accumbens,7887,O
(,7887,O
-27,7887,O
%,7887,O
),7887,O
.,7887,O
Striatal,7888,O
DAT,7888,B-GENE-Y
protein,7888,O
(,7888,O
-25,7888,O
to,7888,O
-46,7888,O
%,7888,O
),7888,O
and,7888,O
VMAT2,7888,B-GENE-Y
(,7888,O
-17,7888,O
to,7888,O
-22,7888,O
%,7888,O
),7888,O
were,7888,O
reduced,7888,O
",",7888,O
whereas,7888,O
DAT,7888,B-GENE-Y
determined,7888,O
by,7888,O
[,7888,B-CHEMICAL
3H,7888,I-CHEMICAL
],7888,I-CHEMICAL
WIN,7888,I-CHEMICAL
"35,428",7888,I-CHEMICAL
binding,7888,O
was,7888,O
normal,7888,O
.,7888,O
In,7889,O
conclusion,7889,O
",",7889,O
our,7889,O
data,7889,O
suggest,7889,O
that,7889,O
chronic,7889,O
cocaine,7889,B-CHEMICAL
use,7889,O
is,7889,O
associated,7889,O
with,7889,O
modestly,7889,O
reduced,7889,O
levels,7889,O
of,7889,O
striatal,7889,O
DA,7889,B-CHEMICAL
and,7889,O
the,7889,O
DA,7889,B-GENE-Y
transporter,7889,I-GENE-Y
in,7889,O
some,7889,O
subjects,7889,O
and,7889,O
that,7889,O
these,7889,O
changes,7889,O
might,7889,O
contribute,7889,O
to,7889,O
the,7889,O
neurological,7889,O
and,7889,O
psychiatric,7889,O
effects,7889,O
of,7889,O
the,7889,O
drug,7889,O
.,7889,O
Purification,7890,O
and,7890,O
characterization,7890,O
of,7890,O
a,7890,O
novel,7890,O
hyaluronan-binding,7890,B-GENE-N
protein,7890,I-GENE-N
(,7890,O
PHBP,7890,B-GENE-Y
),7890,O
from,7890,O
human,7890,O
plasma,7890,O
:,7890,O
it,7890,O
has,7890,O
three,7890,O
EGF,7890,O
",",7890,O
a,7890,O
kringle,7890,O
and,7890,O
a,7890,O
serine,7890,B-CHEMICAL
protease,7890,I-GENE-N
domain,7890,I-GENE-N
",",7890,O
similar,7890,O
to,7890,O
hepatocyte,7890,O
growth,7890,O
factor,7890,O
activator,7890,O
.,7890,O
A,7891,O
novel,7891,O
hyaluronan-binding,7891,B-GENE-N
protein,7891,I-GENE-N
(,7891,O
PHBP,7891,B-GENE-Y
),7891,O
was,7891,O
purified,7891,O
from,7891,O
human,7891,O
plasma,7891,O
by,7891,O
affinity,7891,O
chromatography,7891,O
on,7891,O
hyaluronan-conjugated,7891,O
Sepharose,7891,O
.,7891,O
The,7892,O
contaminating,7892,O
IgM,7892,B-GENE-N
and,7892,O
albumin,7892,B-GENE-N
in,7892,O
the,7892,O
partially,7892,O
purified,7892,O
preparation,7892,O
were,7892,O
removed,7892,O
with,7892,O
anti-IgG,7892,O
antibody-conjugated,7892,O
Sepharose,7892,O
and,7892,O
anti-albumin,7892,O
antibody-conjugated,7892,O
Sepharose,7892,O
",",7892,O
respectively,7892,O
",",7892,O
and,7892,O
no,7892,O
other,7892,O
contaminant,7892,O
was,7892,O
observed,7892,O
.,7892,O
Finally,7893,O
",",7893,O
800,7893,O
micrograms,7893,O
of,7893,O
PHBP,7893,B-GENE-Y
was,7893,O
isolated,7893,O
from,7893,O
500,7893,O
ml,7893,O
of,7893,O
human,7893,O
plasma,7893,O
.,7893,O
PHBP,7894,B-GENE-Y
gave,7894,O
a,7894,O
single,7894,O
70-kDa,7894,O
band,7894,O
on,7894,O
SDS-PAGE,7894,O
under,7894,O
non-reducing,7894,O
conditions,7894,O
",",7894,O
and,7894,O
50-kDa,7894,O
and,7894,O
17-kDa,7894,O
bands,7894,O
under,7894,O
reducing,7894,O
conditions,7894,O
.,7894,O
Thus,7895,O
",",7895,O
PHBP,7895,B-GENE-Y
was,7895,O
a,7895,O
heterodimer,7895,O
composed,7895,O
of,7895,O
50-kDa,7895,O
and,7895,O
17-kDa,7895,O
subunits,7895,O
",",7895,O
bridged,7895,O
by,7895,O
a,7895,O
disulfide,7895,B-CHEMICAL
linkage,7895,O
.,7895,O
Both,7896,O
subunits,7896,O
had,7896,O
novel,7896,O
N-terminal,7896,B-CHEMICAL
amino,7896,I-CHEMICAL
acid,7896,I-CHEMICAL
sequences,7896,O
",",7896,O
indicating,7896,O
that,7896,O
PHBP,7896,B-GENE-Y
was,7896,O
a,7896,O
novel,7896,O
hyaluronan-binding,7896,O
protein,7896,O
in,7896,O
human,7896,O
plasma,7896,O
.,7896,O
The,7897,O
amino,7897,B-CHEMICAL
acid,7897,I-CHEMICAL
sequence,7897,O
deduced,7897,O
from,7897,O
the,7897,O
nucleotide,7897,B-CHEMICAL
sequence,7897,O
of,7897,O
the,7897,O
cloned,7897,O
PHBP,7897,B-GENE-Y
cDNA,7897,O
exhibited,7897,O
significant,7897,O
homology,7897,O
to,7897,O
that,7897,O
of,7897,O
hepatocyte,7897,B-GENE-Y
growth,7897,I-GENE-Y
factor,7897,I-GENE-Y
activator,7897,I-GENE-Y
(,7897,O
HGFA,7897,B-GENE-Y
),7897,O
.,7897,O
The,7898,O
results,7898,O
of,7898,O
Northern,7898,O
blot,7898,O
analysis,7898,O
indicated,7898,O
that,7898,O
liver,7898,O
",",7898,O
kidney,7898,O
",",7898,O
and,7898,O
pancreas,7898,O
expressed,7898,O
PHBP,7898,B-GENE-Y
mRNA,7898,O
.,7898,O
The,7899,O
predicted,7899,O
structure,7899,O
of,7899,O
PHBP,7899,B-GENE-Y
showed,7899,O
three,7899,O
epidermal,7899,B-GENE-N
growth,7899,I-GENE-N
factor,7899,I-GENE-N
(,7899,I-GENE-N
EGF,7899,I-GENE-N
),7899,I-GENE-N
domains,7899,I-GENE-N
",",7899,O
a,7899,O
kringle,7899,B-GENE-N
domain,7899,I-GENE-N
and,7899,O
a,7899,O
serine,7899,B-CHEMICAL
protease,7899,I-GENE-N
domain,7899,I-GENE-N
",",7899,O
from,7899,O
its,7899,O
N-terminus,7899,B-CHEMICAL
",",7899,O
although,7899,O
HGFA,7899,B-GENE-Y
has,7899,O
a,7899,O
fibronectin,7899,B-GENE-N
type,7899,I-GENE-N
II,7899,I-GENE-N
domain,7899,I-GENE-N
",",7899,O
an,7899,O
EGF,7899,B-GENE-N
domain,7899,I-GENE-N
",",7899,O
a,7899,O
fibronectin,7899,B-GENE-N
type,7899,I-GENE-N
I,7899,I-GENE-N
domain,7899,I-GENE-N
",",7899,O
an,7899,O
EGF,7899,B-GENE-N
domain,7899,I-GENE-N
",",7899,O
a,7899,O
kringle,7899,B-GENE-N
domain,7899,I-GENE-N
",",7899,O
and,7899,O
a,7899,O
serine,7899,B-CHEMICAL
protease,7899,I-GENE-N
domain,7899,I-GENE-N
",",7899,O
from,7899,O
its,7899,O
N-terminus,7899,B-CHEMICAL
.,7899,O
Hypoxemia,7900,O
associated,7900,O
with,7900,O
cimetidine,7900,B-CHEMICAL
therapy,7900,O
in,7900,O
a,7900,O
newborn,7900,O
infant,7900,O
.,7900,O
Cimetidine,7901,B-CHEMICAL
therapy,7901,O
used,7901,O
for,7901,O
the,7901,O
treatment,7901,O
of,7901,O
gastric,7901,O
bleeding,7901,O
due,7901,O
to,7901,O
tolazoline,7901,B-CHEMICAL
therapy,7901,O
in,7901,O
a,7901,O
newborn,7901,O
infant,7901,O
was,7901,O
temporally,7901,O
associated,7901,O
with,7901,O
episodes,7901,O
of,7901,O
severe,7901,O
hypoxemia,7901,O
.,7901,O
It,7902,O
appears,7902,O
likely,7902,O
that,7902,O
the,7902,O
histamine,7902,B-GENE-Y
H2,7902,I-GENE-Y
receptor,7902,I-GENE-Y
blocked,7902,O
by,7902,O
cimetidine,7902,B-CHEMICAL
obviated,7902,O
the,7902,O
pulmonary,7902,O
vasodilator,7902,O
effect,7902,O
of,7902,O
tolazoline,7902,B-CHEMICAL
therapy,7902,O
.,7902,O
Interactions,7903,O
of,7903,O
"2,3-benzodiazepines",7903,B-CHEMICAL
and,7903,O
cyclothiazide,7903,B-CHEMICAL
at,7903,O
AMPA,7903,B-GENE-N
receptors,7903,I-GENE-N
:,7903,O
patch,7903,O
clamp,7903,O
recordings,7903,O
in,7903,O
cultured,7903,O
neurones,7903,O
and,7903,O
area,7903,O
CA1,7903,O
in,7903,O
hippocampal,7903,O
slices,7903,O
.,7903,O
1,7904,O
.,7904,O
The,7905,O
"2,3-benzodiazepines",7905,B-CHEMICAL
GYKI,7905,B-CHEMICAL
52466,7905,I-CHEMICAL
",",7905,O
GYKI,7905,B-CHEMICAL
53405,7905,I-CHEMICAL
and,7905,O
GYKI,7905,B-CHEMICAL
53655,7905,I-CHEMICAL
antagonized,7905,O
AMPA-induced,7905,B-CHEMICAL
currents,7905,O
in,7905,O
cultured,7905,O
superior,7905,O
colliculus,7905,O
neurones,7905,O
in,7905,O
a,7905,O
non,7905,O
use-dependent,7905,O
manner,7905,O
(,7905,O
steady,7905,O
state,7905,O
IC50s,7905,O
:,7905,O
GYKI,7905,B-CHEMICAL
52466,7905,I-CHEMICAL
9.8,7905,O
+/-,7905,O
0.6,7905,O
microM,7905,O
;,7905,O
GYKI,7905,B-CHEMICAL
53405,7905,I-CHEMICAL
3.1,7905,O
+/-,7905,O
0.6,7905,O
microM,7905,O
;,7905,O
GYKI,7905,B-CHEMICAL
53655,7905,I-CHEMICAL
0.8,7905,O
+/-,7905,O
0.1,7905,O
microM,7905,O
),7905,O
.,7905,O
2,7906,O
.,7906,O
Higher,7907,O
concentrations,7907,O
of,7907,O
all,7907,O
three,7907,O
antagonists,7907,O
slowed,7907,O
the,7907,O
onset,7907,O
kinetics,7907,O
and,7907,O
quickened,7907,O
the,7907,O
offset,7907,O
kinetics,7907,O
of,7907,O
AMPA-induced,7907,B-CHEMICAL
currents,7907,O
indicative,7907,O
of,7907,O
an,7907,O
allosteric,7907,O
interaction,7907,O
with,7907,O
the,7907,O
AMPA,7907,B-CHEMICAL
recognition,7907,O
site,7907,O
.,7907,O
3,7908,O
.,7908,O
Cyclothiazide,7909,B-CHEMICAL
(,7909,O
3-300,7909,O
microM,7909,O
),7909,O
dramatically,7909,O
slowed,7909,O
desensitization,7909,O
of,7909,O
AMPA-induced,7909,B-CHEMICAL
currents,7909,O
and,7909,O
potentiated,7909,O
steady,7909,O
state,7909,O
currents,7909,O
(,7909,O
EC50,7909,O
10.0,7909,O
+/-,7909,O
2.5,7909,O
microM,7909,O
),7909,O
to,7909,O
a,7909,O
much,7909,O
greater,7909,O
degree,7909,O
than,7909,O
peak,7909,O
currents,7909,O
.,7909,O
Both,7910,O
tau,7910,O
on,7910,O
and,7910,O
tau,7910,O
off,7910,O
were,7910,O
also,7910,O
increased,7910,O
by,7910,O
cyclothiazide,7910,B-CHEMICAL
in,7910,O
a,7910,O
concentration-dependent,7910,O
manner,7910,O
(,7910,O
EC50,7910,O
:,7910,O
tau,7910,O
on,7910,O
42.1,7910,O
+/-,7910,O
4.5,7910,O
microM,7910,O
;,7910,O
tau,7910,O
off,7910,O
31.6,7910,O
+/-,7910,O
6.6,7910,O
microM,7910,O
),7910,O
.,7910,O
4,7911,O
.,7911,O
Cyclothiazide,7912,B-CHEMICAL
(,7912,O
10-100,7912,O
microM,7912,O
),7912,O
shifted,7912,O
the,7912,O
concentration-response,7912,O
curves,7912,O
of,7912,O
the,7912,O
"2,3-benzodiazepines",7912,B-CHEMICAL
to,7912,O
the,7912,O
right,7912,O
.,7912,O
For,7913,O
example,7913,O
",",7913,O
with,7913,O
10,7913,O
microM,7913,O
cyclothiazide,7913,B-CHEMICAL
the,7913,O
IC50s,7913,O
of,7913,O
GYKI,7913,B-CHEMICAL
52466,7913,I-CHEMICAL
and,7913,O
GYKI,7913,B-CHEMICAL
53405,7913,I-CHEMICAL
on,7913,O
steady-state,7913,O
AMPA-induced,7913,B-CHEMICAL
currents,7913,O
were,7913,O
57.9,7913,O
+/-,7913,O
9.5,7913,O
and,7913,O
41.6,7913,O
+/-,7913,O
1.5,7913,O
microM,7913,O
",",7913,O
respectively,7913,O
.,7913,O
5,7914,O
.,7914,O
GYKI,7915,B-CHEMICAL
53405,7915,I-CHEMICAL
and,7915,O
GYKI,7915,B-CHEMICAL
52466,7915,I-CHEMICAL
concentration-dependently,7915,O
reversed,7915,O
the,7915,O
effects,7915,O
of,7915,O
cyclothiazide,7915,B-CHEMICAL
(,7915,O
100,7915,O
microM,7915,O
),7915,O
on,7915,O
offset,7915,O
kinetics,7915,O
(,7915,O
GYKI,7915,B-CHEMICAL
53405,7915,I-CHEMICAL
IC50,7915,O
16.6,7915,O
+/-,7915,O
4.2,7915,O
microM,7915,O
),7915,O
.,7915,O
However,7916,O
",",7916,O
the,7916,O
"2,3-benzodiazepines",7916,B-CHEMICAL
were,7916,O
unable,7916,O
to,7916,O
reintroduce,7916,O
desensitization,7916,O
in,7916,O
the,7916,O
presence,7916,O
of,7916,O
cyclothiazide,7916,B-CHEMICAL
and,7916,O
even,7916,O
concentration-dependently,7916,O
slowed,7916,O
the,7916,O
onset,7916,O
kinetics,7916,O
of,7916,O
AMPA,7916,B-CHEMICAL
responses,7916,O
further,7916,O
(,7916,O
GYKI,7916,B-CHEMICAL
53405,7916,I-CHEMICAL
EC50,7916,O
8.0,7916,O
+/-,7916,O
2.8,7916,O
microM,7916,O
),7916,O
.,7916,O
6,7917,O
.,7917,O
GYKI,7918,B-CHEMICAL
52466,7918,I-CHEMICAL
decreased,7918,O
the,7918,O
peak,7918,O
amplitude,7918,O
of,7918,O
hippocampal,7918,O
area,7918,O
CA1,7918,O
AMPA,7918,B-GENE-N
receptor-mediated,7918,O
excitatory,7918,O
postsynaptic,7918,O
currents,7918,O
(,7918,O
e.p.s.cs,7918,O
),7918,O
(,7918,O
IC50,7918,O
10.8,7918,O
+/-,7918,O
0.8,7918,O
microM,7918,O
),7918,O
with,7918,O
no,7918,O
apparent,7918,O
effect,7918,O
on,7918,O
response,7918,O
kinetics,7918,O
.,7918,O
Cyclothiazide,7919,B-CHEMICAL
prolonged,7919,O
the,7919,O
decay,7919,O
time,7919,O
constant,7919,O
of,7919,O
AMPA,7919,B-GENE-N
receptor-mediated,7919,O
e.p.s.cs,7919,O
(,7919,O
EC50,7919,O
35.7,7919,O
+/-,7919,O
6.5,7919,O
microM,7919,O
),7919,O
with,7919,O
less,7919,O
pronounced,7919,O
effects,7919,O
in,7919,O
slowing,7919,O
e.p.s.c,7919,O
.,7919,O
onset,7920,O
kinetics,7920,O
and,7920,O
increasing,7920,O
e.p.s.c,7920,O
.,7920,O
amplitude,7921,O
.,7921,O
7,7922,O
.,7922,O
Cyclothiazide,7923,B-CHEMICAL
(,7923,O
330,7923,O
microM,7923,O
),7923,O
shifted,7923,O
the,7923,O
concentration-response,7923,O
curve,7923,O
for,7923,O
the,7923,O
effects,7923,O
of,7923,O
GYKI,7923,B-CHEMICAL
52466,7923,I-CHEMICAL
on,7923,O
AMPA,7923,B-GENE-N
receptor-mediated,7923,O
e.p.s.c,7923,O
.,7923,O
peak,7924,O
amplitude,7924,O
to,7924,O
the,7924,O
right,7924,O
(,7924,O
GYKI,7924,B-CHEMICAL
52466,7924,I-CHEMICAL
IC50,7924,O
26.9,7924,O
+/-,7924,O
9.4,7924,O
microM,7924,O
),7924,O
.,7924,O
Likewise,7925,O
",",7925,O
GYKI,7925,B-CHEMICAL
52466,7925,I-CHEMICAL
(,7925,O
30-100,7925,O
microM,7925,O
),7925,O
),7925,O
shifted,7925,O
the,7925,O
concentration-response,7925,O
curve,7925,O
for,7925,O
the,7925,O
effects,7925,O
of,7925,O
cyclothiazide,7925,B-CHEMICAL
on,7925,O
AMPA,7925,B-GENE-N
receptor-mediated,7925,O
e.p.s.c,7925,O
.,7925,O
decay,7926,O
time,7926,O
constants,7926,O
to,7926,O
the,7926,O
right,7926,O
.,7926,O
8,7927,O
.,7927,O
In,7928,O
conclusion,7928,O
",",7928,O
cyclothiazide,7928,B-CHEMICAL
and,7928,O
the,7928,O
"2,3-benzodiazepines",7928,B-CHEMICAL
seem,7928,O
to,7928,O
bind,7928,O
to,7928,O
different,7928,O
sites,7928,O
on,7928,O
AMPA,7928,B-GENE-N
receptors,7928,I-GENE-N
but,7928,O
exert,7928,O
strong,7928,O
allosteric,7928,O
interactions,7928,O
with,7928,O
one,7928,O
another,7928,O
and,7928,O
with,7928,O
other,7928,O
domains,7928,O
such,7928,O
as,7928,O
the,7928,O
agonist,7928,O
recognition,7928,O
site,7928,O
.,7928,O
The,7929,O
interactions,7929,O
of,7929,O
GYKI,7929,B-CHEMICAL
52466,7929,I-CHEMICAL
and,7929,O
cyclothiazide,7929,B-CHEMICAL
on,7929,O
AMPA,7929,B-GENE-N
receptor-mediated,7929,O
e.p.s.cs,7929,O
in,7929,O
area,7929,O
CA1,7929,O
of,7929,O
hippocampal,7929,O
slices,7929,O
provide,7929,O
evidence,7929,O
that,7929,O
the,7929,O
decay,7929,O
time,7929,O
constant,7929,O
of,7929,O
these,7929,O
synaptic,7929,O
events,7929,O
are,7929,O
not,7929,O
governed,7929,O
by,7929,O
desensitization,7929,O
.,7929,O
Comparison,7930,O
of,7930,O
ligand,7930,O
binding,7930,O
affinities,7930,O
at,7930,O
human,7930,B-GENE-N
I1-imidazoline,7930,I-GENE-N
binding,7930,I-GENE-N
sites,7930,I-GENE-N
and,7930,O
the,7930,O
high,7930,O
affinity,7930,O
state,7930,O
of,7930,O
alpha-2,7930,B-GENE-N
adrenoceptor,7930,I-GENE-N
subtypes,7930,O
.,7930,O
To,7931,O
identify,7931,O
selective,7931,O
compounds,7931,O
for,7931,O
nonadrenergic,7931,O
I1-imidazoline,7931,B-GENE-Y
receptors,7931,I-GENE-Y
(,7931,O
I1,7931,B-GENE-Y
),7931,O
",",7931,O
the,7931,O
affinities,7931,O
of,7931,O
22,7931,O
ligands,7931,O
for,7931,O
[,7931,B-CHEMICAL
125I,7931,I-CHEMICAL
],7931,I-CHEMICAL
p-iodoclonidine,7931,I-CHEMICAL
binding,7931,O
have,7931,O
been,7931,O
compared,7931,O
at,7931,O
human,7931,B-GENE-N
platelet,7931,I-GENE-N
I1-imidazoline,7931,I-GENE-N
binding,7931,I-GENE-N
sites,7931,I-GENE-N
(,7931,O
analyzed,7931,O
under,7931,O
norepinephrine,7931,B-CHEMICAL
mask,7931,O
of,7931,O
alpha-2,7931,B-GENE-N
AR,7931,I-GENE-N
),7931,O
and,7931,O
at,7931,O
human,7931,B-GENE-Y
alpha-2A,7931,I-GENE-Y
",",7931,O
alpha-2B,7931,B-GENE-Y
and,7931,O
alpha-2C,7931,B-GENE-Y
adrenoceptors,7931,I-GENE-Y
stably,7931,O
expressed,7931,O
on,7931,O
transfected,7931,O
Chinese,7931,O
hamster,7931,O
ovary,7931,O
cells,7931,O
.,7931,O
Competition,7932,O
curves,7932,O
at,7932,O
the,7932,O
platelet,7932,O
I1-imidazoline,7932,B-GENE-N
binding,7932,I-GENE-N
site,7932,I-GENE-N
were,7932,O
biphasic,7932,O
for,7932,O
most,7932,O
compounds,7932,O
.,7932,O
Only,7933,O
tizanidine,7933,B-CHEMICAL
and,7933,O
"BDF,6143",7933,B-CHEMICAL
displayed,7933,O
monophasic,7933,O
I1,7933,O
competition,7933,O
curves,7933,O
.,7933,O
Agmatine,7934,B-CHEMICAL
",",7934,O
an,7934,O
endogenous,7934,O
neurotransmitter,7934,O
candidate,7934,O
for,7934,O
the,7934,O
I1-imidazoline,7934,B-GENE-Y
receptor,7934,I-GENE-Y
",",7934,O
was,7934,O
identified,7934,O
as,7934,O
the,7934,O
most,7934,O
selective,7934,O
agent,7934,O
for,7934,O
a,7934,O
subcomponent,7934,O
of,7934,O
platelet,7934,O
I1,7934,B-GENE-N
sites,7934,I-GENE-N
.,7934,O
The,7935,O
affinity,7935,O
of,7935,O
agmatine,7935,B-CHEMICAL
at,7935,O
the,7935,O
high,7935,O
affinity,7935,O
component,7935,O
of,7935,O
platelet,7935,O
I1,7935,B-GENE-N
sites,7935,I-GENE-N
was,7935,O
1400-fold,7935,O
selective,7935,O
over,7935,O
alpha-2A,7935,B-GENE-Y
adrenoceptors,7935,I-GENE-Y
",",7935,O
5000-fold,7935,O
selective,7935,O
over,7935,O
alpha-2B,7935,B-GENE-Y
adrenoceptors,7935,I-GENE-Y
and,7935,O
800-fold,7935,O
selective,7935,O
over,7935,O
alpha-2C,7935,B-GENE-Y
adrenoceptors,7935,I-GENE-Y
.,7935,O
Moxonidine,7936,B-CHEMICAL
and,7936,O
tizanidine,7936,B-CHEMICAL
also,7936,O
displayed,7936,O
selectivities,7936,O
for,7936,O
a,7936,O
high,7936,O
affinity,7936,O
component,7936,O
of,7936,O
the,7936,O
platelet,7936,O
I1,7936,B-GENE-N
binding,7936,I-GENE-N
sites,7936,I-GENE-N
over,7936,O
alpha-2,7936,B-GENE-N
adrenoceptors,7936,I-GENE-N
.,7936,O
Naphazoline,7937,B-CHEMICAL
was,7937,O
the,7937,O
most,7937,O
selective,7937,O
compound,7937,O
for,7937,O
the,7937,O
high,7937,O
affinity,7937,O
state,7937,O
of,7937,O
the,7937,O
alpha-2A,7937,B-GENE-Y
adrenoceptor,7937,I-GENE-Y
",",7937,O
displaying,7937,O
7-,7937,O
",",7937,O
23-,7937,O
and,7937,O
9-fold,7937,O
higher,7937,O
affinity,7937,O
than,7937,O
alpha-2B,7937,B-GENE-Y
",",7937,O
alpha-2C,7937,B-GENE-Y
and,7937,O
platelet,7937,O
I1-midazoline,7937,B-GENE-N
binding,7937,I-GENE-N
sites,7937,I-GENE-N
",",7937,O
respectively,7937,O
.,7937,O
No,7938,O
single,7938,O
selective,7938,O
compound,7938,O
was,7938,O
identified,7938,O
for,7938,O
the,7938,O
alpha-2B,7938,B-GENE-Y
adrenoceptor,7938,I-GENE-Y
.,7938,O
Norepinephrine,7939,B-CHEMICAL
displayed,7939,O
",",7939,O
respectively,7939,O
",",7939,O
18-,7939,O
and,7939,O
31-fold,7939,O
selectivity,7939,O
for,7939,O
the,7939,O
high,7939,O
affinity,7939,O
state,7939,O
of,7939,O
the,7939,O
alpha-2C,7939,B-GENE-Y
adrenoceptor,7939,I-GENE-Y
as,7939,O
compared,7939,O
to,7939,O
alpha-2A-,7939,B-GENE-Y
or,7939,O
alpha-2B,7939,B-GENE-Y
adrenoceptors,7939,I-GENE-Y
",",7939,O
and,7939,O
was,7939,O
>,7939,O
"100,000-",7939,O
fold,7939,O
selective,7939,O
over,7939,O
platelet,7939,O
I1-imidazoline,7939,B-GENE-N
sites,7939,I-GENE-N
.,7939,O
Thus,7940,O
",",7940,O
human,7940,B-GENE-N
alpha-2,7940,I-GENE-N
adrenoceptors,7940,I-GENE-N
and,7940,O
the,7940,O
platelet,7940,O
I1-imidazoline,7940,B-GENE-N
binding,7940,I-GENE-N
site,7940,I-GENE-N
can,7940,O
be,7940,O
clearly,7940,O
discriminated,7940,O
based,7940,O
on,7940,O
their,7940,O
affinities,7940,O
for,7940,O
certain,7940,O
compounds,7940,O
.,7940,O
Activation,7941,O
of,7941,O
cytoprotective,7941,O
prostaglandin,7941,B-GENE-Y
synthase-1,7941,I-GENE-Y
by,7941,O
minoxidil,7941,B-CHEMICAL
as,7941,O
a,7941,O
possible,7941,O
explanation,7941,O
for,7941,O
its,7941,O
hair,7941,O
growth-stimulating,7941,O
effect,7941,O
.,7941,O
Data,7942,O
from,7942,O
the,7942,O
literature,7942,O
indicate,7942,O
that,7942,O
nonsteroidal,7942,O
anti-inflammatory,7942,O
drugs,7942,O
(,7942,O
NSAIDs,7942,O
),7942,O
",",7942,O
such,7942,O
as,7942,O
indomethacin,7942,B-CHEMICAL
",",7942,O
naproxen,7942,B-CHEMICAL
",",7942,O
piroxicam,7942,B-CHEMICAL
",",7942,O
or,7942,O
ibuprofen,7942,B-CHEMICAL
",",7942,O
induce,7942,O
hair,7942,O
loss,7942,O
in,7942,O
vivo,7942,O
.,7942,O
These,7943,O
NSAIDs,7943,O
are,7943,O
well-known,7943,O
inhibitors,7943,O
of,7943,O
both,7943,O
the,7943,O
cytoprotective,7943,O
isoform,7943,O
of,7943,O
prostaglandin,7943,B-CHEMICAL
endoperoxide,7943,I-GENE-Y
synthase-1,7943,I-GENE-Y
(,7943,O
PGHS-1,7943,B-GENE-Y
),7943,O
and,7943,O
of,7943,O
the,7943,O
inducible,7943,O
form,7943,O
(,7943,O
PGHS-2,7943,B-GENE-Y
),7943,O
.,7943,O
By,7944,O
immunohistochemical,7944,O
staining,7944,O
",",7944,O
we,7944,O
found,7944,O
that,7944,O
PGHS-1,7944,B-GENE-Y
is,7944,O
the,7944,O
main,7944,O
isoform,7944,O
present,7944,O
in,7944,O
the,7944,O
dermal,7944,O
papilla,7944,O
from,7944,O
normal,7944,O
human,7944,O
hair,7944,O
follicle,7944,O
(,7944,O
either,7944,O
anagen,7944,O
or,7944,O
catagen,7944,O
),7944,O
",",7944,O
whereas,7944,O
PGHS-2,7944,B-GENE-Y
was,7944,O
only,7944,O
faintly,7944,O
and,7944,O
exclusively,7944,O
expressed,7944,O
in,7944,O
anagen,7944,O
dermal,7944,O
papilla,7944,O
.,7944,O
Thus,7945,O
",",7945,O
PGHS-1,7945,B-GENE-Y
might,7945,O
be,7945,O
the,7945,O
primary,7945,O
target,7945,O
of,7945,O
the,7945,O
hair,7945,O
growth-inhibitory,7945,O
effects,7945,O
of,7945,O
NSAIDs,7945,O
.,7945,O
We,7946,O
thus,7946,O
speculated,7946,O
that,7946,O
activation,7946,O
of,7946,O
PGHS-1,7946,B-GENE-Y
might,7946,O
be,7946,O
a,7946,O
mechanism,7946,O
by,7946,O
which,7946,O
minoxidil,7946,B-CHEMICAL
(,7946,O
"2,4-diamino-6-piperidinopyrimidine-3-oxyde",7946,B-CHEMICAL
),7946,O
stimulates,7946,O
hair,7946,O
growth,7946,O
in,7946,O
vivo,7946,O
.,7946,O
We,7947,O
demonstrate,7947,O
here,7947,O
that,7947,O
minoxidil,7947,B-CHEMICAL
is,7947,O
a,7947,O
potent,7947,O
activator,7947,O
of,7947,O
purified,7947,O
PGHS-1,7947,B-GENE-Y
(,7947,O
AC50,7947,O
=,7947,O
80,7947,O
microM,7947,O
),7947,O
",",7947,O
as,7947,O
assayed,7947,O
by,7947,O
oxygen,7947,B-CHEMICAL
consumption,7947,O
and,7947,O
PGE2,7947,O
production,7947,O
.,7947,O
This,7948,O
activation,7948,O
was,7948,O
also,7948,O
evidenced,7948,O
by,7948,O
increased,7948,O
PGE2,7948,O
production,7948,O
by,7948,O
BALB/c,7948,O
3T3,7948,O
fibroblasts,7948,O
and,7948,O
by,7948,O
human,7948,O
dermal,7948,O
papilla,7948,O
fibroblasts,7948,O
in,7948,O
culture,7948,O
.,7948,O
Our,7949,O
findings,7949,O
suggest,7949,O
that,7949,O
minoxidil,7949,B-CHEMICAL
and,7949,O
its,7949,O
derivatives,7949,O
may,7949,O
have,7949,O
a,7949,O
cytoprotective,7949,O
activity,7949,O
in,7949,O
vivo,7949,O
and,7949,O
that,7949,O
more,7949,O
potent,7949,O
second-generation,7949,O
hair,7949,O
growth-promoting,7949,O
drugs,7949,O
might,7949,O
be,7949,O
designed,7949,O
",",7949,O
based,7949,O
on,7949,O
this,7949,O
mechanism,7949,O
.,7949,O
Clonal,7950,O
CD8+,7950,O
and,7950,O
CD52-,7950,O
T,7950,O
cells,7950,O
are,7950,O
induced,7950,O
in,7950,O
responding,7950,O
B,7950,O
cell,7950,O
lymphoma,7950,O
patients,7950,O
treated,7950,O
with,7950,O
Campath-1H,7950,O
(,7950,O
anti-CD52,7950,O
),7950,O
.,7950,O
Five,7951,O
patients,7951,O
with,7951,O
non-Hodgkin,7951,O
's,7951,O
lymphoma,7951,O
(,7951,O
NHL,7951,O
),7951,O
and,7951,O
4,7951,O
patients,7951,O
with,7951,O
chronic,7951,O
lymphocytic,7951,O
leukaemia,7951,O
(,7951,O
CLL,7951,O
),7951,O
were,7951,O
treated,7951,O
with,7951,O
the,7951,O
CDR-grafted,7951,O
(,7951,O
rat,7951,O
x,7951,O
human,7951,O
),7951,O
monoclonal,7951,O
antibody,7951,O
(,7951,O
mAb,7951,O
),7951,O
Campath-1H,7951,O
(,7951,O
anti-CD52,7951,O
),7951,O
.,7951,O
Tumour,7952,O
regression,7952,O
was,7952,O
noted,7952,O
preferentially,7952,O
in,7952,O
peripheral,7952,O
blood,7952,O
and,7952,O
in,7952,O
the,7952,O
bone,7952,O
marrow,7952,O
but,7952,O
lymph,7952,O
nodes,7952,O
were,7952,O
less,7952,O
affected,7952,O
.,7952,O
Normal,7953,O
blood,7953,O
B,7953,O
and,7953,O
T,7953,O
cells,7953,O
were,7953,O
profoundly,7953,O
reduced,7953,O
in,7953,O
all,7953,O
patients,7953,O
whereas,7953,O
CD16+,7953,O
NK,7953,O
cells,7953,O
and,7953,O
CD14+,7953,O
monocytes,7953,O
decreased,7953,O
marginally,7953,O
.,7953,O
In,7954,O
all,7954,O
responding,7954,O
CLL,7954,O
patients,7954,O
CD52-negative,7954,B-GENE-Y
T,7954,O
but,7954,O
not,7954,O
B,7954,O
cells,7954,O
appeared,7954,O
during,7954,O
treatment,7954,O
and,7954,O
persisted,7954,O
for,7954,O
several,7954,O
months,7954,O
(,7954,O
4-19+,7954,O
),7954,O
during,7954,O
unmaintained,7954,O
follow-up,7954,O
.,7954,O
Clonal,7955,O
T,7955,O
cells,7955,O
defined,7955,O
as,7955,O
a,7955,O
predominance,7955,O
of,7955,O
a,7955,O
single,7955,O
T,7955,B-GENE-N
cell,7955,I-GENE-N
receptor,7955,I-GENE-N
(,7955,I-GENE-N
TCR,7955,I-GENE-N
),7955,I-GENE-N
V,7955,I-GENE-N
gene,7955,O
usage,7955,O
",",7955,O
in,7955,O
one,7955,O
case,7955,O
verified,7955,O
by,7955,O
TCR,7955,B-GENE-N
CDR3,7955,O
fragment,7955,O
analysis,7955,O
and,7955,O
nucleotide,7955,B-CHEMICAL
sequencing,7955,O
",",7955,O
emerged,7955,O
within,7955,O
the,7955,O
CD52-/CD8+,7955,O
cell,7955,O
population,7955,O
during,7955,O
Campath-1H,7955,O
therapy,7955,O
in,7955,O
2,7955,O
CLL,7955,O
patients,7955,O
",",7955,O
both,7955,O
achieving,7955,O
a,7955,O
long-lasting,7955,O
remission,7955,O
.,7955,O
The,7956,O
increase,7956,O
in,7956,O
CD8+,7956,O
T,7956,O
cell,7956,O
expansions,7956,O
(,7956,O
up,7956,O
to,7956,O
23-fold,7956,O
),7956,O
during,7956,O
unmaintained,7956,O
remission,7956,O
and,7956,O
follow-up,7956,O
suggest,7956,O
that,7956,O
the,7956,O
clonal,7956,O
CD8+,7956,O
cells,7956,O
may,7956,O
represent,7956,O
regulatory,7956,O
T,7956,O
cells,7956,O
controlling,7956,O
the,7956,O
growth,7956,O
of,7956,O
the,7956,O
tumour,7956,O
B,7956,O
cell,7956,O
clone,7956,O
.,7956,O
Clonal,7957,O
T,7957,O
cells,7957,O
might,7957,O
thus,7957,O
be,7957,O
a,7957,O
target,7957,O
for,7957,O
an,7957,O
immune,7957,O
therapeutic,7957,O
intervention,7957,O
in,7957,O
B,7957,O
cell,7957,O
tumours,7957,O
.,7957,O
Clinical,7958,O
manifestations,7958,O
of,7958,O
genetic,7958,O
defects,7958,O
affecting,7958,O
gonadotrophins,7958,B-GENE-N
and,7958,O
their,7958,O
receptors,7958,O
.,7958,O
Raised,7959,O
activity,7959,O
of,7959,O
the,7959,O
LH,7959,B-GENE-N
axis,7959,O
caused,7959,O
by,7959,O
activating,7959,O
mutations,7959,O
of,7959,O
LH,7959,B-GENE-Y
receptor,7959,I-GENE-Y
gene,7959,O
presents,7959,O
with,7959,O
precocious,7959,O
puberty,7959,O
in,7959,O
boys,7959,O
",",7959,O
analogous,7959,O
to,7959,O
the,7959,O
presentation,7959,O
of,7959,O
LH,7959,B-GENE-N
secreting,7959,O
pituitary,7959,O
adenomas,7959,O
(,7959,O
Faggiano,7959,O
et,7959,O
al.,7959,O
",",7959,O
1983,7959,O
;,7959,O
Ambrosi,7959,O
et,7959,O
al.,7959,O
",",7959,O
1990,7959,O
),7959,O
.,7959,O
LH,7960,B-GENE-N
``,7960,O
hyperactivity,7960,O
',7960,O
in,7960,O
females,7960,O
appears,7960,O
to,7960,O
have,7960,O
no,7960,O
effect,7960,O
.,7960,O
Hyperactivity,7961,O
of,7961,O
the,7961,O
FSH,7961,B-GENE-N
axis,7961,O
caused,7961,O
by,7961,O
activating,7961,O
mutations,7961,O
of,7961,O
the,7961,O
FSH,7961,B-GENE-Y
receptor,7961,I-GENE-Y
gene,7961,O
might,7961,O
parallel,7961,O
the,7961,O
presentation,7961,O
of,7961,O
FSH,7961,B-GENE-N
secreting,7961,O
pituitary,7961,O
adenomas,7961,O
with,7961,O
Sertoli,7961,O
cell,7961,O
hypertrophy,7961,O
in,7961,O
men,7961,O
(,7961,O
Heseltine,7961,O
et,7961,O
al.,7961,O
",",7961,O
1989,7961,O
),7961,O
or,7961,O
reversible,7961,O
premature,7961,O
ovarian,7961,O
failure,7961,O
in,7961,O
women,7961,O
(,7961,O
Moses,7961,O
et,7961,O
al.,7961,O
",",7961,O
1986,7961,O
;,7961,O
Okuda,7961,O
et,7961,O
al.,7961,O
",",7961,O
1989,7961,O
),7961,O
.,7961,O
Indeed,7962,O
the,7962,O
first,7962,O
such,7962,O
case,7962,O
to,7962,O
be,7962,O
described,7962,O
is,7962,O
a,7962,O
male,7962,O
who,7962,O
maintained,7962,O
testicular,7962,O
volume,7962,O
and,7962,O
fertility,7962,O
in,7962,O
the,7962,O
absence,7962,O
of,7962,O
gonadotrophins,7962,B-GENE-N
(,7962,O
Gromoll,7962,O
et,7962,O
al.,7962,O
",",7962,O
1996,7962,O
),7962,O
.,7962,O
Female,7963,O
precocious,7963,O
puberty,7963,O
may,7963,O
require,7963,O
hyperactivity,7963,O
of,7963,O
both,7963,O
gonadotrophin,7963,B-GENE-N
axes,7963,O
because,7963,O
of,7963,O
the,7963,O
``,7963,O
two-cell,7963,O
',7963,O
arrangement,7963,O
required,7963,O
for,7963,O
ovarian,7963,O
oestrogen,7963,B-CHEMICAL
production,7963,O
.,7963,O
Mutations,7964,O
of,7964,O
the,7964,O
Gs,7964,B-GENE-N
alpha-subunit,7964,O
gene,7964,O
can,7964,O
mimic,7964,O
this,7964,O
situation,7964,O
in,7964,O
some,7964,O
women,7964,O
with,7964,O
the,7964,O
McCune-Albright,7964,O
syndrome,7964,O
(,7964,O
Malchoff,7964,O
et,7964,O
al.,7964,O
",",7964,O
1994,7964,O
),7964,O
.,7964,O
Lack,7965,O
of,7965,O
LH,7965,B-GENE-N
activity,7965,O
caused,7965,O
by,7965,O
defects,7965,O
in,7965,O
the,7965,O
LH,7965,B-GENE-Y
beta,7965,I-GENE-Y
molecule,7965,O
causes,7965,O
infertility,7965,O
in,7965,O
men,7965,O
and,7965,O
that,7965,O
resulting,7965,O
from,7965,O
inactivating,7965,O
mutations,7965,O
of,7965,O
the,7965,O
LH,7965,B-GENE-Y
receptor,7965,I-GENE-Y
gene,7965,O
causes,7965,O
Leydig,7965,O
cell,7965,O
agenesis,7965,O
in,7965,O
men,7965,O
while,7965,O
ovarian,7965,O
development,7965,O
in,7965,O
females,7965,O
is,7965,O
relatively,7965,O
normal,7965,O
.,7965,O
Lack,7966,O
of,7966,O
FSH,7966,B-GENE-N
activity,7966,O
caused,7966,O
by,7966,O
defects,7966,O
in,7966,O
the,7966,O
FSH,7966,B-GENE-Y
beta,7966,I-GENE-Y
caused,7966,O
infertility,7966,O
in,7966,O
a,7966,O
female,7966,O
",",7966,O
and,7966,O
that,7966,O
caused,7966,O
by,7966,O
inactivating,7966,O
mutations,7966,O
of,7966,O
the,7966,O
FSH,7966,B-GENE-Y
receptor,7966,I-GENE-Y
gene,7966,O
causes,7966,O
ovarian,7966,O
dysgenesis,7966,O
in,7966,O
women,7966,O
but,7966,O
only,7966,O
variable,7966,O
depression,7966,O
of,7966,O
spermatogenesis,7966,O
in,7966,O
men,7966,O
.,7966,O
Incidentally,7967,O
",",7967,O
this,7967,O
categorization,7967,O
of,7967,O
reproductive,7967,O
disorders,7967,O
may,7967,O
also,7967,O
be,7967,O
applied,7967,O
to,7967,O
the,7967,O
TSH,7967,B-GENE-N
axis,7967,O
.,7967,O
Pituitary,7968,O
adenomas,7968,O
and,7968,O
activating,7968,O
mutations,7968,O
of,7968,O
the,7968,O
TSH,7968,B-GENE-Y
receptor,7968,I-GENE-Y
gene,7968,O
(,7968,O
Parma,7968,O
et,7968,O
al.,7968,O
",",7968,O
1993,7968,O
),7968,O
cause,7968,O
hyperthyroidism,7968,O
and,7968,O
TSH,7968,B-GENE-Y
beta,7968,I-GENE-Y
gene,7968,O
defects,7968,O
(,7968,O
Hayashizaki,7968,O
et,7968,O
al.,7968,O
",",7968,O
1989,7968,O
),7968,O
and,7968,O
inactivating,7968,O
mutations,7968,O
of,7968,O
the,7968,O
TSH,7968,B-GENE-Y
receptor,7968,I-GENE-Y
gene,7968,O
(,7968,O
Sunthornthepvarakul,7968,O
et,7968,O
al.,7968,O
",",7968,O
1995,7968,O
),7968,O
cause,7968,O
hypothyroidism,7968,O
.,7968,O
To,7969,O
complete,7969,O
the,7969,O
analogy,7969,O
with,7969,O
thyroid,7969,O
disorders,7969,O
",",7969,O
it,7969,O
is,7969,O
curious,7969,O
that,7969,O
despite,7969,O
structural,7969,O
similarities,7969,O
with,7969,O
the,7969,O
TSH,7969,B-GENE-Y
receptor,7969,I-GENE-Y
",",7969,O
neither,7969,O
LH,7969,B-GENE-N
nor,7969,I-GENE-N
FSH,7969,I-GENE-N
receptor,7969,I-GENE-N
autoantibodies,7969,O
have,7969,O
a,7969,O
prominent,7969,O
role,7969,O
in,7969,O
ovarian,7969,O
pathophysiology,7969,O
(,7969,O
Moncayo,7969,O
et,7969,O
al.,7969,O
",",7969,O
1989,7969,O
;,7969,O
Van,7969,O
Weissenbruch,7969,O
et,7969,O
al.,7969,O
",",7969,O
1991,7969,O
;,7969,O
Simoni,7969,O
et,7969,O
al.,7969,O
",",7969,O
1993,7969,O
),7969,O
.,7969,O
Complete,7970,O
gonadotrophin,7970,B-GENE-N
resistance,7970,O
is,7970,O
likely,7970,O
to,7970,O
be,7970,O
very,7970,O
rare,7970,O
",",7970,O
however,7970,O
",",7970,O
so,7970,O
what,7970,O
are,7970,O
we,7970,O
likely,7970,O
to,7970,O
find,7970,O
in,7970,O
partial,7970,O
gonadotrophin,7970,B-GENE-N
resistance,7970,O
?,7970,O
Might,7971,O
the,7971,O
``,7971,O
resistant,7971,O
ovary,7971,O
syndrome,7971,O
',7971,O
come,7971,O
right,7971,O
in,7971,O
the,7971,O
end,7971,O
",",7971,O
with,7971,O
corresponding,7971,O
minor,7971,O
FSH,7971,B-GENE-Y
receptor,7971,I-GENE-Y
mutations,7971,O
?,7971,O
Experience,7972,O
with,7972,O
insulin,7972,B-GENE-Y
and,7972,O
androgen,7972,O
resistance,7972,O
syndromes,7972,O
suggests,7972,O
that,7972,O
such,7972,O
a,7972,O
scenario,7972,O
is,7972,O
unlikely,7972,O
.,7972,O
Insulin,7973,B-GENE-Y
receptor,7973,I-GENE-Y
gene,7973,O
mutations,7973,O
are,7973,O
found,7973,O
in,7973,O
extreme,7973,O
Type,7973,O
A,7973,O
insulin,7973,B-GENE-Y
resistance,7973,O
but,7973,O
not,7973,O
in,7973,O
moderate,7973,O
forms,7973,O
of,7973,O
insulin,7973,B-GENE-Y
resistance,7973,O
(,7973,O
O'Rahilly,7973,O
et,7973,O
al.,7973,O
",",7973,O
1991,7973,O
),7973,O
.,7973,O
Androgen,7974,B-GENE-Y
receptor,7974,I-GENE-Y
gene,7974,O
mutations,7974,O
are,7974,O
found,7974,O
in,7974,O
nearly,7974,O
all,7974,O
cases,7974,O
of,7974,O
complete,7974,O
androgen,7974,O
insensitivity,7974,O
but,7974,O
rarely,7974,O
in,7974,O
partial,7974,O
forms,7974,O
(,7974,O
Patterson,7974,O
et,7974,O
al.,7974,O
",",7974,O
1994,7974,O
),7974,O
.,7974,O
Mild,7975,O
resistance,7975,O
to,7975,O
hormone,7975,O
action,7975,O
is,7975,O
rarely,7975,O
detectable,7975,O
in,7975,O
relatives,7975,O
who,7975,O
are,7975,O
heterozygous,7975,O
for,7975,O
receptor,7975,O
mutations,7975,O
which,7975,O
are,7975,O
inherited,7975,O
in,7975,O
a,7975,O
recessive,7975,O
pattern,7975,O
.,7975,O
It,7976,O
seems,7976,O
unlikely,7976,O
therefore,7976,O
",",7976,O
that,7976,O
individuals,7976,O
heterozygous,7976,O
for,7976,O
inactivating,7976,O
receptor,7976,O
mutations,7976,O
will,7976,O
manifest,7976,O
symptoms,7976,O
of,7976,O
reproductive,7976,O
disorders,7976,O
and,7976,O
account,7976,O
for,7976,O
common,7976,O
conditions,7976,O
.,7976,O
Thus,7977,O
",",7977,O
while,7977,O
mutation,7977,O
analysis,7977,O
provides,7977,O
new,7977,O
insights,7977,O
into,7977,O
the,7977,O
gender,7977,O
specific,7977,O
role,7977,O
of,7977,O
the,7977,O
gonadotrophins,7977,B-GENE-N
the,7977,O
cause,7977,O
of,7977,O
early,7977,O
gonadal,7977,O
failure,7977,O
in,7977,O
the,7977,O
majority,7977,O
of,7977,O
individuals,7977,O
remains,7977,O
a,7977,O
mystery,7977,O
.,7977,O
Evolution,7978,O
of,7978,O
the,7978,O
aminoacyl-tRNA,7978,B-CHEMICAL
synthetase,7978,I-GENE-N
family,7978,O
and,7978,O
the,7978,O
organization,7978,O
of,7978,O
the,7978,O
Drosophila,7978,O
glutamyl-prolyl-tRNA,7978,B-CHEMICAL
synthetase,7978,I-GENE-Y
gene,7978,O
.,7978,O
Intron/exon,7979,O
structure,7979,O
of,7979,O
the,7979,O
gene,7979,O
",",7979,O
control,7979,O
of,7979,O
expression,7979,O
of,7979,O
the,7979,O
two,7979,O
mRNAs,7979,O
",",7979,O
selective,7979,O
advantage,7979,O
of,7979,O
the,7979,O
multienzyme,7979,O
complex,7979,O
.,7979,O
In,7980,O
Drosophila,7980,O
",",7980,O
glutamyl-prolyl-tRNA,7980,B-CHEMICAL
synthetase,7980,I-GENE-Y
is,7980,O
a,7980,O
multifunctional,7980,O
synthetase,7980,O
encoded,7980,O
by,7980,O
a,7980,O
unique,7980,O
gene,7980,O
and,7980,O
composed,7980,O
of,7980,O
three,7980,O
domains,7980,O
:,7980,O
the,7980,O
amino-,7980,B-CHEMICAL
and,7980,O
carboxy-terminal,7980,B-CHEMICAL
domains,7980,O
catalyze,7980,O
the,7980,O
aminoacylation,7980,O
of,7980,O
glutamic,7980,B-CHEMICAL
acid,7980,I-CHEMICAL
and,7980,O
proline,7980,O
tRNA,7980,O
species,7980,O
",",7980,O
respectively,7980,O
",",7980,O
and,7980,O
the,7980,O
central,7980,O
domain,7980,O
is,7980,O
made,7980,O
of,7980,O
75,7980,O
amino,7980,B-CHEMICAL
acids,7980,I-CHEMICAL
repeated,7980,O
six,7980,O
times,7980,O
amongst,7980,O
which,7980,O
46,7980,O
are,7980,O
highly,7980,O
conserved,7980,O
and,7980,O
constitute,7980,O
the,7980,O
repeated,7980,O
motifs,7980,O
[,7980,O
Cerini,7980,O
",",7980,O
C.,7980,O
",",7980,O
Kerjan,7980,O
",",7980,O
P.,7980,O
",",7980,O
Astier,7980,O
",",7980,O
M.,7980,O
",",7980,O
Gratecos,7980,O
",",7980,O
D.,7980,O
",",7980,O
Mirande,7980,O
",",7980,O
M.,7980,O
&,7980,O
Semeriva,7980,O
",",7980,O
M.,7980,O
(,7980,O
1991,7980,O
),7980,O
EMBO,7980,O
J,7980,O
.,7980,O
10,7981,O
",",7981,O
4267-4277,7981,O
],7981,O
.,7981,O
The,7982,O
intron/exon,7982,O
organization,7982,O
of,7982,O
the,7982,O
Drosophila,7982,O
gene,7982,O
reveals,7982,O
the,7982,O
presence,7982,O
of,7982,O
six,7982,O
exons,7982,O
among,7982,O
which,7982,O
four,7982,O
are,7982,O
in,7982,O
the,7982,O
5'-end,7982,O
encoding,7982,O
glutamic,7982,B-CHEMICAL
acid,7982,I-CHEMICAL
activity,7982,O
.,7982,O
Only,7983,O
one,7983,O
exon,7983,O
encodes,7983,O
the,7983,O
repeated,7983,O
motifs,7983,O
.,7983,O
A,7984,O
comparison,7984,O
of,7984,O
introns,7984,O
positions,7984,O
",",7984,O
intron,7984,O
classes,7984,O
and,7984,O
intron/exon,7984,O
boundaries,7984,O
in,7984,O
the,7984,O
Drosophila,7984,O
gene,7984,O
and,7984,O
in,7984,O
its,7984,O
human,7984,O
counterpart,7984,O
is,7984,O
compatible,7984,O
with,7984,O
the,7984,O
intron-early,7984,O
hypothesis,7984,O
presiding,7984,O
",",7984,O
at,7984,O
least,7984,O
in,7984,O
part,7984,O
",",7984,O
to,7984,O
the,7984,O
evolution,7984,O
of,7984,O
the,7984,O
synthetases,7984,B-GENE-N
.,7984,O
The,7985,O
full-length,7985,O
fly,7985,O
protein,7985,O
is,7985,O
encoded,7985,O
by,7985,O
a,7985,O
6.1-kb,7985,O
mRNA,7985,O
which,7985,O
is,7985,O
expressed,7985,O
throughout,7985,O
development,7985,O
.,7985,O
In,7986,O
addition,7986,O
",",7986,O
a,7986,O
shorter,7986,O
transcript,7986,O
encompasses,7986,O
the,7986,O
3'-end,7986,O
of,7986,O
the,7986,O
cDNA,7986,O
and,7986,O
it,7986,O
is,7986,O
especially,7986,O
abundant,7986,O
in,7986,O
5-10-h,7986,O
embryos,7986,O
until,7986,O
the,7986,O
first,7986,O
larval,7986,O
stage,7986,O
.,7986,O
Expression,7987,O
of,7987,O
these,7987,O
two,7987,O
mRNAs,7987,O
seems,7987,O
to,7987,O
be,7987,O
controlled,7987,O
by,7987,O
two,7987,O
independent,7987,O
promoters,7987,O
.,7987,O
The,7988,O
6.1-kb,7988,O
mRNA,7988,O
promoter,7988,O
is,7988,O
probably,7988,O
localized,7988,O
in,7988,O
the,7988,O
5'-end,7988,O
of,7988,O
the,7988,O
gene,7988,O
.,7988,O
The,7989,O
small,7989,O
mRNA,7989,O
promoter,7989,O
resides,7989,O
in,7989,O
the,7989,O
4th,7989,O
intron,7989,O
and,7989,O
evidence,7989,O
is,7989,O
provided,7989,O
that,7989,O
the,7989,O
mRNA,7989,O
encodes,7989,O
only,7989,O
the,7989,O
domain,7989,O
corresponding,7989,O
to,7989,O
prolyl-tRNA,7989,B-CHEMICAL
synthetase,7989,I-GENE-Y
and,7989,O
is,7989,O
functional,7989,O
in,7989,O
vivo,7989,O
.,7989,O
Finally,7990,O
",",7990,O
transgenic,7990,O
flies,7990,O
have,7990,O
been,7990,O
established,7990,O
by,7990,O
using,7990,O
constructs,7990,O
corresponding,7990,O
to,7990,O
the,7990,O
three,7990,O
domains,7990,O
of,7990,O
the,7990,O
protein,7990,O
.,7990,O
Overexpression,7991,O
of,7991,O
the,7991,O
repeated,7991,O
motifs,7991,O
leads,7991,O
to,7991,O
a,7991,O
sterility,7991,O
of,7991,O
the,7991,O
flies,7991,O
that,7991,O
suggests,7991,O
a,7991,O
role,7991,O
of,7991,O
these,7991,O
motifs,7991,O
in,7991,O
linking,7991,O
the,7991,O
multienzyme,7991,O
complex,7991,O
to,7991,O
an,7991,O
",",7991,O
as,7991,O
yet,7991,O
",",7991,O
unknown,7991,O
structure,7991,O
of,7991,O
the,7991,O
protein,7991,O
synthesis,7991,O
apparatus,7991,O
.,7991,O
Pharmacology,7992,O
and,7992,O
chemistry,7992,O
of,7992,O
adapalene,7992,B-CHEMICAL
.,7992,O
BACKGROUND,7993,O
:,7993,O
Retinoid,7993,B-CHEMICAL
research,7993,O
in,7993,O
the,7993,O
field,7993,O
of,7993,O
dermatology,7993,O
has,7993,O
been,7993,O
influenced,7993,O
by,7993,O
the,7993,O
clinical,7993,O
success,7993,O
of,7993,O
topical,7993,O
tretinoin,7993,B-CHEMICAL
and,7993,O
oral,7993,O
isotretinoin,7993,B-CHEMICAL
in,7993,O
the,7993,O
treatment,7993,O
of,7993,O
acne,7993,O
",",7993,O
and,7993,O
by,7993,O
the,7993,O
discovery,7993,O
of,7993,O
high-affinity,7993,O
binding,7993,O
proteins,7993,O
for,7993,O
retinoic,7993,B-CHEMICAL
acid,7993,I-CHEMICAL
mediating,7993,O
its,7993,O
action,7993,O
and,7993,O
interaction,7993,O
with,7993,O
other,7993,O
vitamins,7993,B-CHEMICAL
and,7993,O
hormones,7993,O
.,7993,O
OBJECTIVE,7994,O
:,7994,O
We,7994,O
sought,7994,O
molecules,7994,O
with,7994,O
an,7994,O
optimal,7994,O
balance,7994,O
between,7994,O
stability,7994,O
",",7994,O
efficacy,7994,O
",",7994,O
and,7994,O
local,7994,O
tolerance,7994,O
for,7994,O
topical,7994,O
acne,7994,O
therapy,7994,O
.,7994,O
METHODS,7995,O
:,7995,O
In,7995,O
vitro,7995,O
and,7995,O
in,7995,O
vivo,7995,O
bioassay,7995,O
systems,7995,O
were,7995,O
used,7995,O
to,7995,O
test,7995,O
the,7995,O
ability,7995,O
of,7995,O
retinoids,7995,B-CHEMICAL
to,7995,O
modulate,7995,O
cell,7995,O
proliferation,7995,O
and,7995,O
differentiation,7995,O
.,7995,O
In,7996,O
addition,7996,O
",",7996,O
antiinflammatory,7996,O
properties,7996,O
were,7996,O
assessed,7996,O
.,7996,O
Binding,7997,O
and,7997,O
transactivation,7997,O
assays,7997,O
were,7997,O
used,7997,O
to,7997,O
compare,7997,O
affinities,7997,O
and,7997,O
transcriptional,7997,O
activities,7997,O
of,7997,O
adapalene,7997,B-CHEMICAL
and,7997,O
tretinoin,7997,B-CHEMICAL
for,7997,O
the,7997,O
nuclear,7997,B-GENE-N
transcription,7997,I-GENE-N
factors,7997,I-GENE-N
",",7997,O
retinoic,7997,B-GENE-N
acid,7997,I-GENE-N
receptors,7997,I-GENE-N
(,7997,O
RARs,7997,B-GENE-N
),7997,O
.,7997,O
RESULTS,7998,O
AND,7998,O
CONCLUSION,7998,O
:,7998,O
Adapalene,7998,B-CHEMICAL
is,7998,O
a,7998,O
stable,7998,O
naphthoic,7998,B-CHEMICAL
acid,7998,I-CHEMICAL
derivative,7998,O
with,7998,O
potent,7998,O
retinoid,7998,B-CHEMICAL
pharmacology,7998,O
",",7998,O
controlling,7998,O
cell,7998,O
proliferation,7998,O
and,7998,O
differentiation,7998,O
.,7998,O
In,7999,O
addition,7999,O
it,7999,O
has,7999,O
significant,7999,O
antiinflammatory,7999,O
action,7999,O
.,7999,O
The,8000,O
nuclear,8000,B-GENE-N
gene,8000,I-GENE-N
transcription,8000,I-GENE-N
factors,8000,I-GENE-N
RAR,8000,B-GENE-Y
beta,8000,I-GENE-Y
and,8000,O
RAR,8000,B-GENE-Y
gamma,8000,I-GENE-Y
mediate,8000,O
the,8000,O
retinoid,8000,B-CHEMICAL
activity,8000,O
of,8000,O
adapalene,8000,B-CHEMICAL
.,8000,O
Cinitapride,8001,B-CHEMICAL
protects,8001,O
against,8001,O
ethanol-induced,8001,B-CHEMICAL
gastric,8001,O
mucosal,8001,O
injury,8001,O
in,8001,O
rats,8001,O
:,8001,O
role,8001,O
of,8001,O
5-hydroxytryptamine,8001,B-CHEMICAL
",",8001,O
prostaglandins,8001,B-CHEMICAL
and,8001,O
sulfhydryl,8001,B-CHEMICAL
compounds,8001,O
.,8001,O
This,8002,O
study,8002,O
was,8002,O
designed,8002,O
to,8002,O
determine,8002,O
the,8002,O
gastroprotective,8002,O
properties,8002,O
of,8002,O
cinitapride,8002,B-CHEMICAL
(,8002,O
CNT,8002,B-CHEMICAL
),8002,O
",",8002,O
a,8002,O
novel,8002,O
prokinetic,8002,O
benzamide,8002,B-CHEMICAL
derivative,8002,O
agonist,8002,O
of,8002,O
5-HT4,8002,B-GENE-Y
and,8002,O
5-HT1,8002,B-GENE-N
receptors,8002,O
and,8002,O
5-HT2,8002,B-GENE-N
antagonist,8002,O
",",8002,O
on,8002,O
mucosal,8002,O
injury,8002,O
produced,8002,O
by,8002,O
50,8002,O
%,8002,O
(,8002,O
v/v,8002,O
),8002,O
ethanol,8002,B-CHEMICAL
.,8002,O
Results,8003,O
were,8003,O
compared,8003,O
with,8003,O
those,8003,O
for,8003,O
5-hydroxytryptamine,8003,B-CHEMICAL
(,8003,O
5-HT,8003,B-CHEMICAL
:,8003,O
10,8003,O
mg,8003,O
kg-1,8003,O
),8003,O
.,8003,O
The,8004,O
possible,8004,O
involvements,8004,O
of,8004,O
gastric,8004,O
mucus,8004,O
secretion,8004,O
",",8004,O
endogenous,8004,O
prostaglandins,8004,B-CHEMICAL
(,8004,O
PGs,8004,B-CHEMICAL
),8004,O
and,8004,O
sulfhydryl,8004,B-CHEMICAL
compounds,8004,O
(,8004,O
SH,8004,B-CHEMICAL
),8004,O
in,8004,O
the,8004,O
protection,8004,O
mediated,8004,O
by,8004,O
CNT,8004,B-CHEMICAL
were,8004,O
also,8004,O
examined,8004,O
.,8004,O
Intraperitoneal,8005,O
administration,8005,O
of,8005,O
CNT,8005,B-CHEMICAL
(,8005,O
0.50,8005,O
and,8005,O
1,8005,O
mg,8005,O
kg-1,8005,O
),8005,O
",",8005,O
30,8005,O
min,8005,O
before,8005,O
ethanol,8005,B-CHEMICAL
",",8005,O
significantly,8005,O
prevented,8005,O
gastric,8005,O
ulceration,8005,O
and,8005,O
increased,8005,O
the,8005,O
hexosamine,8005,B-CHEMICAL
content,8005,O
of,8005,O
gastric,8005,O
mucus,8005,O
.,8005,O
CNT,8006,B-CHEMICAL
(,8006,O
1,8006,O
mg,8006,O
kg-1,8006,O
),8006,O
also,8006,O
produced,8006,O
a,8006,O
significant,8006,O
increase,8006,O
in,8006,O
gastric,8006,O
mucosal,8006,O
levels,8006,O
of,8006,O
PGE2,8006,B-CHEMICAL
",",8006,O
but,8006,O
did,8006,O
not,8006,O
induce,8006,O
any,8006,O
significant,8006,O
changes,8006,O
in,8006,O
SH,8006,B-CHEMICAL
values,8006,O
.,8006,O
On,8007,O
the,8007,O
contrary,8007,O
",",8007,O
pretreatment,8007,O
with,8007,O
5-HT,8007,B-CHEMICAL
worsened,8007,O
ethanol-induced,8007,B-CHEMICAL
erosions,8007,O
",",8007,O
however,8007,O
",",8007,O
did,8007,O
not,8007,O
affect,8007,O
gastric,8007,O
mucus,8007,O
secretion,8007,O
",",8007,O
glycoprotein,8007,B-GENE-N
content,8007,O
or,8007,O
PGE2,8007,B-CHEMICAL
levels,8007,O
",",8007,O
although,8007,O
the,8007,O
non-protein,8007,O
SH,8007,B-CHEMICAL
fraction,8007,O
was,8007,O
significantly,8007,O
decreased,8007,O
.,8007,O
The,8008,O
present,8008,O
results,8008,O
demonstrate,8008,O
that,8008,O
the,8008,O
gastroprotective,8008,O
effects,8008,O
of,8008,O
CNT,8008,B-CHEMICAL
could,8008,O
be,8008,O
partly,8008,O
explained,8008,O
by,8008,O
a,8008,O
complex,8008,O
PG,8008,B-CHEMICAL
dependent,8008,O
mechanism,8008,O
.,8008,O
We,8009,O
suggest,8009,O
that,8009,O
5-HT,8009,B-CHEMICAL
dependent,8009,O
mechanisms,8009,O
through,8009,O
5-HT2,8009,B-GENE-N
receptor,8009,O
blockade,8009,O
and,8009,O
5-HT1,8009,B-GENE-N
receptor,8009,O
activation,8009,O
could,8009,O
be,8009,O
also,8009,O
involved,8009,O
.,8009,O
Cloning,8010,O
",",8010,O
characterization,8010,O
",",8010,O
and,8010,O
expression,8010,O
of,8010,O
a,8010,O
calcitonin,8010,B-GENE-Y
receptor,8010,I-GENE-Y
from,8010,O
guinea,8010,O
pig,8010,O
brain,8010,O
.,8010,O
A,8011,O
calcitonin,8011,B-GENE-Y
receptor,8011,I-GENE-Y
was,8011,O
cloned,8011,O
from,8011,O
guinea,8011,O
pig,8011,O
brain,8011,O
by,8011,O
using,8011,O
a,8011,O
degenerate,8011,O
reverse,8011,O
transcription-polymerase,8011,O
chain,8011,O
reaction,8011,O
(,8011,O
RT-PCR,8011,O
),8011,O
strategy,8011,O
.,8011,O
When,8012,O
the,8012,O
cloned,8012,O
guinea,8012,B-GENE-Y
pig,8012,I-GENE-Y
calcitonin,8012,I-GENE-Y
receptor,8012,I-GENE-Y
was,8012,O
transfected,8012,O
into,8012,O
COS,8012,O
1,8012,O
cells,8012,O
",",8012,O
salmon,8012,B-GENE-N
calcitonin,8012,I-GENE-N
stimulated,8012,O
intracellular,8012,O
cyclic,8012,B-CHEMICAL
AMP,8012,I-CHEMICAL
accumulation,8012,O
with,8012,O
an,8012,O
EC50,8012,O
of,8012,O
0.1,8012,O
nM,8012,O
",",8012,O
whereas,8012,O
human,8012,B-GENE-Y
calcitonin,8012,I-GENE-Y
was,8012,O
>,8012,O
250-fold,8012,O
less,8012,O
potent,8012,O
(,8012,O
EC50,8012,O
27.6,8012,O
nM,8012,O
),8012,O
.,8012,O
Related,8013,O
neuropeptides,8013,O
rat,8013,B-GENE-Y
alphaCGRP,8013,I-GENE-Y
and,8013,O
rat,8013,B-GENE-Y
amylin,8013,I-GENE-Y
did,8013,O
not,8013,O
activate,8013,O
the,8013,O
guinea,8013,B-GENE-Y
pig,8013,I-GENE-Y
calcitonin,8013,I-GENE-Y
receptor,8013,I-GENE-Y
at,8013,O
physiologic,8013,O
concentrations,8013,O
.,8013,O
Stimulation,8014,O
of,8014,O
the,8014,O
transfected,8014,O
guinea,8014,B-GENE-Y
pig,8014,I-GENE-Y
calcitonin,8014,I-GENE-Y
receptor,8014,I-GENE-Y
by,8014,O
salmon,8014,O
calcitonin,8014,O
also,8014,O
resulted,8014,O
in,8014,O
phosphatidylinositol,8014,B-CHEMICAL
hydrolysis,8014,O
with,8014,O
an,8014,O
EC50,8014,O
of,8014,O
2.5,8014,O
nM,8014,O
.,8014,O
Expression,8015,O
of,8015,O
the,8015,O
calcitonin,8015,B-GENE-Y
receptor,8015,I-GENE-Y
was,8015,O
mapped,8015,O
by,8015,O
a,8015,O
combination,8015,O
of,8015,O
RT-PCR,8015,O
",",8015,O
northern,8015,O
analysis,8015,O
",",8015,O
and,8015,O
expression,8015,O
in,8015,O
Xenopus,8015,O
oocytes,8015,O
.,8015,O
The,8016,O
guinea,8016,B-GENE-Y
pig,8016,I-GENE-Y
calcitonin,8016,I-GENE-Y
receptor,8016,I-GENE-Y
was,8016,O
most,8016,O
highly,8016,O
expressed,8016,O
in,8016,O
diencephalon,8016,O
and,8016,O
a,8016,O
single,8016,O
subtype,8016,O
was,8016,O
detected,8016,O
.,8016,O
Adenosine,8017,B-CHEMICAL
deaminase,8017,I-GENE-Y
is,8017,O
a,8017,O
specific,8017,O
partner,8017,O
for,8017,O
the,8017,O
Grb2,8017,B-GENE-Y
isoform,8017,O
Grb3-3,8017,B-GENE-Y
.,8017,O
Grb3-3,8018,B-GENE-Y
is,8018,O
an,8018,O
isoform,8018,O
of,8018,O
Grb2,8018,B-GENE-Y
",",8018,O
thought,8018,O
to,8018,O
arise,8018,O
by,8018,O
alternative,8018,O
splicing,8018,O
",",8018,O
that,8018,O
lacks,8018,O
a,8018,O
functional,8018,O
SH2,8018,B-GENE-N
domain,8018,I-GENE-N
but,8018,O
retains,8018,O
functional,8018,O
SH3,8018,B-GENE-N
domains,8018,I-GENE-N
",",8018,O
which,8018,O
allow,8018,O
interaction,8018,O
with,8018,O
other,8018,O
proteins,8018,O
through,8018,O
binding,8018,O
to,8018,O
prolinerich,8018,O
sequences,8018,O
.,8018,O
Several,8019,O
evidences,8019,O
suggest,8019,O
that,8019,O
besides,8019,O
common,8019,O
partners,8019,O
for,8019,O
Grb2,8019,B-GENE-Y
and,8019,O
Grb3-3,8019,B-GENE-Y
",",8019,O
specific,8019,O
targets,8019,O
could,8019,O
exist,8019,O
.,8019,O
In,8020,O
order,8020,O
to,8020,O
find,8020,O
specific,8020,O
partners,8020,O
for,8020,O
Grb3-3,8020,B-GENE-Y
",",8020,O
we,8020,O
have,8020,O
screened,8020,O
a,8020,O
human,8020,O
cDNA,8020,O
library,8020,O
by,8020,O
the,8020,O
yeast,8020,O
two-hybrid,8020,O
system,8020,O
with,8020,O
Grb3-3,8020,B-GENE-Y
as,8020,O
a,8020,O
bait,8020,O
.,8020,O
We,8021,O
have,8021,O
identified,8021,O
adenosine,8021,B-CHEMICAL
deaminase,8021,I-GENE-Y
",",8021,O
an,8021,O
enzyme,8021,O
involved,8021,O
in,8021,O
purine,8021,B-CHEMICAL
metabolism,8021,O
whose,8021,O
deficiency,8021,O
is,8021,O
associated,8021,O
with,8021,O
severe,8021,O
combined,8021,O
immunodeficiency,8021,O
",",8021,O
as,8021,O
a,8021,O
Grb3-3,8021,B-GENE-Y
binding,8021,O
protein,8021,O
that,8021,O
is,8021,O
not,8021,O
able,8021,O
to,8021,O
bind,8021,O
to,8021,O
Grb2,8021,B-GENE-Y
.,8021,O
This,8022,O
interaction,8022,O
has,8022,O
been,8022,O
confirmed,8022,O
in,8022,O
vitro,8022,O
with,8022,O
GST,8022,B-GENE-N
fusion,8022,O
proteins,8022,O
and,8022,O
in,8022,O
vivo,8022,O
by,8022,O
coimmunoprecipitation,8022,O
experiments,8022,O
in,8022,O
NIH3T3,8022,O
cells,8022,O
stably,8022,O
transfected,8022,O
with,8022,O
Grb3-3,8022,B-GENE-Y
.,8022,O
The,8023,O
functional,8023,O
significance,8023,O
of,8023,O
this,8023,O
finding,8023,O
is,8023,O
discussed,8023,O
.,8023,O
Alendronate,8024,B-CHEMICAL
inhibition,8024,O
of,8024,O
protein-tyrosine-phosphatase-meg1,8024,B-GENE-Y
.,8024,O
Alendronate,8025,B-CHEMICAL
(,8025,O
"4-amino-1-hydroxybutylidene-1,1-bisphosphonate",8025,B-CHEMICAL
),8025,O
is,8025,O
a,8025,O
potent,8025,O
bisphosphonate,8025,B-CHEMICAL
that,8025,O
inhibits,8025,O
osteoclastic,8025,O
bone,8025,O
resorption,8025,O
and,8025,O
has,8025,O
proven,8025,O
effective,8025,O
for,8025,O
the,8025,O
treatment,8025,O
of,8025,O
osteoporosis,8025,O
.,8025,O
Its,8026,O
molecular,8026,O
mechanism,8026,O
of,8026,O
action,8026,O
",",8026,O
however,8026,O
",",8026,O
has,8026,O
not,8026,O
been,8026,O
defined,8026,O
precisely,8026,O
.,8026,O
Here,8027,O
we,8027,O
report,8027,O
that,8027,O
alendronate,8027,B-CHEMICAL
is,8027,O
a,8027,O
potent,8027,O
inhibitor,8027,O
of,8027,O
the,8027,O
protein-tyrosine-phosphatase-meg1,8027,B-GENE-Y
(,8027,O
PTPmeg1,8027,B-GENE-Y
),8027,O
.,8027,O
Two,8028,O
substrates,8028,O
were,8028,O
employed,8028,O
in,8028,O
this,8028,O
study,8028,O
:,8028,O
fluorescein,8028,O
diphosphate,8028,B-CHEMICAL
and,8028,O
the,8028,O
phosphotyrosyl,8028,O
peptide,8028,O
src-pY527,8028,B-GENE-Y
.,8028,O
With,8029,O
either,8029,O
substrate,8029,O
",",8029,O
alendronate,8029,B-CHEMICAL
was,8029,O
a,8029,O
slow,8029,O
binding,8029,O
inhibitor,8029,O
of,8029,O
PTPmeg1,8029,B-GENE-Y
.,8029,O
Among,8030,O
the,8030,O
other,8030,O
bisphosphonates,8030,B-CHEMICAL
studied,8030,O
",",8030,O
alendronate,8030,B-CHEMICAL
was,8030,O
more,8030,O
potent,8030,O
and,8030,O
selective,8030,O
for,8030,O
PTPmeg1,8030,B-GENE-Y
.,8030,O
The,8031,O
hydrolysis,8031,O
of,8031,O
fluorescein,8031,O
diphosphate,8031,B-CHEMICAL
by,8031,O
PTP,8031,B-GENE-Y
epsilon,8031,I-GENE-Y
and,8031,O
PTPmeg1,8031,B-GENE-Y
was,8031,O
sensitive,8031,O
to,8031,O
alendronate,8031,B-CHEMICAL
",",8031,O
with,8031,O
IC50,8031,O
values,8031,O
of,8031,O
less,8031,O
than,8031,O
1,8031,O
microM,8031,O
;,8031,O
PTPsigma,8031,B-GENE-Y
",",8031,O
however,8031,O
",",8031,O
under,8031,O
the,8031,O
same,8031,O
conditions,8031,O
",",8031,O
was,8031,O
inhibited,8031,O
by,8031,O
only,8031,O
50,8031,O
%,8031,O
with,8031,O
141,8031,O
microM,8031,O
alendronate,8031,B-CHEMICAL
.,8031,O
Similarly,8032,O
",",8032,O
with,8032,O
the,8032,O
src-pY527,8032,B-GENE-Y
substrate,8032,O
",",8032,O
alendronate,8032,B-CHEMICAL
inhibition,8032,O
was,8032,O
also,8032,O
PTP,8032,B-GENE-N
dependent,8032,O
.,8032,O
Alendronate,8033,B-CHEMICAL
inhibited,8033,O
PTPmeg1,8033,B-GENE-Y
with,8033,O
an,8033,O
IC50,8033,O
value,8033,O
of,8033,O
23,8033,O
microM,8033,O
",",8033,O
PTPsigma,8033,B-GENE-Y
with,8033,O
an,8033,O
IC50,8033,O
value,8033,O
of,8033,O
2,8033,O
microM,8033,O
",",8033,O
and,8033,O
did,8033,O
not,8033,O
inhibit,8033,O
PTP,8033,B-GENE-Y
epsilon,8033,I-GENE-Y
at,8033,O
concentrations,8033,O
up,8033,O
to,8033,O
1,8033,O
mM,8033,O
.,8033,O
The,8034,O
alendronate,8034,B-CHEMICAL
inhibition,8034,O
of,8034,O
these,8034,O
three,8034,O
PTPs,8034,B-GENE-N
and,8034,O
two,8034,O
substrates,8034,O
is,8034,O
consistent,8034,O
with,8034,O
the,8034,O
formation,8034,O
of,8034,O
a,8034,O
ternary,8034,O
complex,8034,O
comprised,8034,O
of,8034,O
enzyme,8034,O
",",8034,O
substrate,8034,O
",",8034,O
and,8034,O
inhibitor,8034,O
.,8034,O
PTP,8035,B-GENE-N
inhibition,8035,O
by,8035,O
hisphosphonates,8035,B-CHEMICAL
or,8035,O
vanadate,8035,B-CHEMICAL
was,8035,O
diminished,8035,O
by,8035,O
the,8035,O
metal,8035,O
chelating,8035,O
agent,8035,O
EDTA,8035,B-CHEMICAL
",",8035,O
or,8035,O
by,8035,O
the,8035,O
reducing,8035,O
agent,8035,O
dithiothreitol,8035,B-CHEMICAL
",",8035,O
suggesting,8035,O
that,8035,O
a,8035,O
metal,8035,O
ion,8035,O
and,8035,O
the,8035,O
oxidation,8035,O
of,8035,O
a,8035,O
cysteine,8035,B-CHEMICAL
residue,8035,O
are,8035,O
required,8035,O
for,8035,O
full,8035,O
inhibition,8035,O
.,8035,O
These,8036,O
observations,8036,O
show,8036,O
substrate-,8036,O
and,8036,O
enzyme-specific,8036,O
PTP,8036,B-GENE-N
inhibition,8036,O
by,8036,O
alendronate,8036,B-CHEMICAL
and,8036,O
support,8036,O
the,8036,O
possibility,8036,O
that,8036,O
a,8036,O
certain,8036,O
PTP,8036,B-GENE-N
(,8036,O
s,8036,O
),8036,O
may,8036,O
be,8036,O
the,8036,O
molecular,8036,O
target,8036,O
for,8036,O
alendronate,8036,B-CHEMICAL
action,8036,O
.,8036,O
Ligand,8037,O
binding,8037,O
specificities,8037,O
of,8037,O
the,8037,O
eight,8037,O
types,8037,O
and,8037,O
subtypes,8037,O
of,8037,O
the,8037,O
mouse,8037,B-GENE-N
prostanoid,8037,B-CHEMICAL
receptors,8037,I-GENE-N
expressed,8037,O
in,8037,O
Chinese,8037,O
hamster,8037,O
ovary,8037,O
cells,8037,O
.,8037,O
1,8038,O
.,8038,O
Eight,8039,O
types,8039,O
and,8039,O
subtypes,8039,O
of,8039,O
the,8039,O
mouse,8039,B-GENE-N
prostanoid,8039,B-CHEMICAL
receptor,8039,I-GENE-N
",",8039,O
the,8039,O
prostaglandin,8039,B-CHEMICAL
D,8039,I-CHEMICAL
(,8039,I-GENE-Y
DP,8039,B-CHEMICAL
),8039,I-GENE-Y
receptor,8039,I-GENE-Y
",",8039,O
the,8039,O
prostaglandin,8039,B-GENE-Y
F,8039,I-GENE-Y
(,8039,I-GENE-Y
FP,8039,I-GENE-Y
),8039,I-GENE-Y
receptor,8039,I-GENE-Y
",",8039,O
the,8039,O
prostaglandin,8039,B-GENE-Y
I,8039,I-GENE-Y
(,8039,I-GENE-Y
IP,8039,I-GENE-Y
),8039,I-GENE-Y
receptor,8039,I-GENE-Y
",",8039,O
the,8039,O
thromboxane,8039,B-GENE-Y
A,8039,I-GENE-Y
(,8039,I-GENE-Y
TP,8039,I-GENE-Y
),8039,I-GENE-Y
receptor,8039,I-GENE-Y
and,8039,O
the,8039,O
EP1,8039,B-GENE-Y
",",8039,O
EP2,8039,B-GENE-Y
",",8039,O
EP3,8039,B-GENE-Y
and,8039,O
EP4,8039,B-GENE-Y
subtypes,8039,O
of,8039,O
the,8039,O
prostaglandin,8039,B-CHEMICAL
E,8039,I-CHEMICAL
receptor,8039,I-GENE-N
",",8039,O
were,8039,O
stably,8039,O
expressed,8039,O
in,8039,O
Chinese,8039,O
hamster,8039,O
ovary,8039,O
cells,8039,O
.,8039,O
Their,8040,O
ligand,8040,O
binding,8040,O
characteristics,8040,O
were,8040,O
examined,8040,O
with,8040,O
thirty,8040,O
two,8040,O
prostanoids,8040,B-CHEMICAL
and,8040,O
their,8040,O
analogues,8040,O
by,8040,O
determining,8040,O
the,8040,O
Ki,8040,O
values,8040,O
from,8040,O
the,8040,O
displacement,8040,O
curves,8040,O
of,8040,O
radioligand,8040,O
binding,8040,O
to,8040,O
the,8040,O
respective,8040,O
receptors,8040,O
.,8040,O
2,8041,O
.,8041,O
The,8042,O
DP,8042,B-CHEMICAL
",",8042,O
IP,8042,B-CHEMICAL
and,8042,O
TP,8042,B-CHEMICAL
receptors,8042,I-GENE-Y
showed,8042,O
high,8042,O
ligand,8042,O
binding,8042,O
specificity,8042,O
and,8042,O
only,8042,O
bound,8042,O
their,8042,O
own,8042,O
putative,8042,O
ligands,8042,O
with,8042,O
high,8042,O
affinity,8042,O
such,8042,O
as,8042,O
PGD2,8042,B-CHEMICAL
",",8042,O
BW245C,8042,B-CHEMICAL
and,8042,O
BW868C,8042,B-CHEMICAL
for,8042,O
DP,8042,B-CHEMICAL
",",8042,O
cicaprost,8042,B-CHEMICAL
",",8042,O
iloprost,8042,B-CHEMICAL
and,8042,O
isocabacyclin,8042,B-CHEMICAL
for,8042,O
IP,8042,B-CHEMICAL
",",8042,O
and,8042,O
S-145,8042,B-CHEMICAL
",",8042,O
I-BOP,8042,B-CHEMICAL
and,8042,O
GR,8042,B-CHEMICAL
32191,8042,I-CHEMICAL
for,8042,O
TP,8042,B-CHEMICAL
.,8042,O
3,8043,O
.,8043,O
The,8044,O
FP,8044,B-CHEMICAL
receptor,8044,I-GENE-Y
bound,8044,O
PGF2,8044,B-CHEMICAL
alpha,8044,O
and,8044,O
fluprostenol,8044,B-CHEMICAL
with,8044,O
Ki,8044,O
values,8044,O
of,8044,O
3-4,8044,O
nM,8044,O
.,8044,O
In,8045,O
addition,8045,O
",",8045,O
PGD2,8045,B-CHEMICAL
",",8045,O
17-phenyl-PGE2,8045,B-CHEMICAL
",",8045,O
STA2,8045,B-CHEMICAL
",",8045,O
I-BOP,8045,B-CHEMICAL
",",8045,O
PGE2,8045,B-CHEMICAL
and,8045,O
M,8045,B-CHEMICAL
&,8045,I-CHEMICAL
B-28767,8045,I-CHEMICAL
bound,8045,O
to,8045,O
this,8045,O
receptor,8045,O
with,8045,O
Ki,8045,O
values,8045,O
less,8045,O
than,8045,O
100,8045,O
nM,8045,O
.,8045,O
4,8046,O
.,8046,O
The,8047,O
EP1,8047,B-GENE-Y
receptor,8047,O
bound,8047,O
17-phenyl-PGE2,8047,B-CHEMICAL
",",8047,O
sulprostone,8047,B-CHEMICAL
and,8047,O
iloprost,8047,B-CHEMICAL
in,8047,O
addition,8047,O
to,8047,O
PGE2,8047,B-CHEMICAL
and,8047,O
PGE1,8047,B-CHEMICAL
",",8047,O
with,8047,O
Ki,8047,O
values,8047,O
of,8047,O
14-36,8047,O
nM,8047,O
.,8047,O
"16,16-dimethyl-PGE2",8048,B-CHEMICAL
and,8048,O
two,8048,O
putative,8048,O
EP1,8048,B-GENE-Y
antagonists,8048,O
",",8048,O
AH6809,8048,B-CHEMICAL
and,8048,O
SC-19220,8048,B-CHEMICAL
",",8048,O
did,8048,O
not,8048,O
show,8048,O
any,8048,O
significant,8048,O
binding,8048,O
to,8048,O
this,8048,O
receptor,8048,O
.,8048,O
M,8049,B-CHEMICAL
&,8049,I-CHEMICAL
B-28767,8049,I-CHEMICAL
",",8049,O
a,8049,O
putative,8049,O
EP3,8049,B-GENE-Y
agonist,8049,O
",",8049,O
and,8049,O
misoprostol,8049,B-CHEMICAL
",",8049,O
a,8049,O
putative,8049,O
EP2/EP3,8049,B-GENE-Y
agonist,8049,O
",",8049,O
also,8049,O
bound,8049,O
to,8049,O
this,8049,O
receptor,8049,O
with,8049,O
Ki,8049,O
values,8049,O
of,8049,O
120,8049,O
nM,8049,O
.,8049,O
5,8050,O
.,8050,O
The,8051,O
EP2,8051,B-GENE-Y
and,8051,O
EP4,8051,B-GENE-Y
receptors,8051,O
showed,8051,O
similar,8051,O
binding,8051,O
profiles,8051,O
.,8051,O
They,8052,O
bound,8052,O
"16,16-dimethyl",8052,B-CHEMICAL
PGE2,8052,I-CHEMICAL
and,8052,O
11-deoxy-PGE1,8052,B-CHEMICAL
in,8052,O
addition,8052,O
to,8052,O
PGE2,8052,B-CHEMICAL
and,8052,O
PGE1,8052,B-CHEMICAL
.,8052,O
The,8053,O
two,8053,O
receptors,8053,O
were,8053,O
discriminated,8053,O
by,8053,O
butaprost,8053,B-CHEMICAL
",",8053,O
AH-13205,8053,B-CHEMICAL
and,8053,O
AH-6809,8053,B-CHEMICAL
that,8053,O
bound,8053,O
to,8053,O
the,8053,O
EP2,8053,B-GENE-Y
receptor,8053,O
but,8053,O
not,8053,O
to,8053,O
the,8053,O
EP4,8053,B-GENE-Y
receptor,8053,O
",",8053,O
and,8053,O
by,8053,O
1-OH-PGE1,8053,B-CHEMICAL
that,8053,O
bound,8053,O
to,8053,O
the,8053,O
EP4,8053,B-GENE-Y
but,8053,O
not,8053,O
to,8053,O
the,8053,O
EP2,8053,B-GENE-Y
receptor,8053,O
.,8053,O
6,8054,O
.,8054,O
The,8055,O
EP3,8055,B-GENE-Y
receptor,8055,O
showed,8055,O
the,8055,O
broadest,8055,O
binding,8055,O
profile,8055,O
",",8055,O
and,8055,O
bound,8055,O
sulprostone,8055,B-CHEMICAL
",",8055,O
M,8055,B-CHEMICAL
&,8055,I-CHEMICAL
B-28767,8055,I-CHEMICAL
",",8055,O
GR63799X,8055,B-CHEMICAL
",",8055,O
11-deoxy-PGE1,8055,B-CHEMICAL
",",8055,O
"16,16-dimethyl-PGE2",8055,B-CHEMICAL
and,8055,O
17-phenyl-PGE2,8055,B-CHEMICAL
",",8055,O
in,8055,O
addition,8055,O
to,8055,O
PGE2,8055,B-CHEMICAL
and,8055,O
PGE1,8055,B-CHEMICAL
",",8055,O
with,8055,O
Ki,8055,O
values,8055,O
of,8055,O
0.6-3.7,8055,O
nM,8055,O
.,8055,O
In,8056,O
addition,8056,O
",",8056,O
three,8056,O
IP,8056,B-GENE-Y
ligands,8056,O
",",8056,O
iloprost,8056,B-CHEMICAL
",",8056,O
carbacyclin,8056,B-CHEMICAL
and,8056,O
isocarbacyclin,8056,B-CHEMICAL
",",8056,O
and,8056,O
one,8056,O
TP,8056,B-GENE-Y
ligand,8056,O
",",8056,O
STA2,8056,B-CHEMICAL
",",8056,O
bound,8056,O
to,8056,O
this,8056,O
receptor,8056,O
with,8056,O
Ki,8056,O
values,8056,O
comparable,8056,O
to,8056,O
the,8056,O
Ki,8056,O
values,8056,O
of,8056,O
these,8056,O
compounds,8056,O
for,8056,O
the,8056,O
IP,8056,B-GENE-Y
and,8056,O
TP,8056,B-GENE-Y
receptors,8056,I-GENE-Y
",",8056,O
respectively,8056,O
.,8056,O
7,8057,O
.,8057,O
8-Epi-PGF2,8058,O
alpha,8058,O
showed,8058,O
only,8058,O
weak,8058,O
binding,8058,O
to,8058,O
the,8058,O
IP,8058,B-GENE-Y
",",8058,O
TP,8058,B-GENE-Y
",",8058,O
FP,8058,B-GENE-Y
",",8058,O
EP2,8058,B-GENE-Y
and,8058,O
EP3,8058,B-GENE-Y
receptor,8058,O
at,8058,O
10,8058,O
microM,8058,O
concentration,8058,O
.,8058,O
The,8059,O
structures,8059,O
of,8059,O
thymidine,8059,B-GENE-Y
kinase,8059,I-GENE-Y
from,8059,O
herpes,8059,O
simplex,8059,O
virus,8059,O
type,8059,O
1,8059,O
in,8059,O
complex,8059,O
with,8059,O
substrates,8059,O
and,8059,O
a,8059,O
substrate,8059,O
analogue,8059,O
.,8059,O
Thymidine,8060,B-GENE-Y
kinase,8060,I-GENE-Y
from,8060,O
Herpes,8060,O
simplex,8060,O
virus,8060,O
type,8060,O
1,8060,O
(,8060,O
TK,8060,B-GENE-Y
),8060,O
was,8060,O
crystallized,8060,O
in,8060,O
an,8060,O
N-terminally,8060,B-CHEMICAL
truncated,8060,O
but,8060,O
fully,8060,O
active,8060,O
form,8060,O
.,8060,O
The,8061,O
structures,8061,O
of,8061,O
TK,8061,B-GENE-Y
complexed,8061,O
with,8061,O
ADP,8061,B-CHEMICAL
at,8061,O
the,8061,O
ATP-site,8061,B-CHEMICAL
and,8061,O
deoxythymidine-5'-monophosphate,8061,B-CHEMICAL
(,8061,O
dTMP,8061,B-CHEMICAL
),8061,O
",",8061,O
deoxythymidine,8061,B-CHEMICAL
(,8061,O
dT,8061,B-CHEMICAL
),8061,O
",",8061,O
or,8061,O
idoxuridine-5'-phosphate,8061,B-CHEMICAL
(,8061,O
5-iodo-dUMP,8061,B-CHEMICAL
),8061,O
at,8061,O
the,8061,O
substrate-site,8061,O
were,8061,O
refined,8061,O
to,8061,O
2.75,8061,O
A,8061,O
",",8061,O
2.8,8061,O
A,8061,O
",",8061,O
and,8061,O
3.0,8061,O
A,8061,O
resolution,8061,O
",",8061,O
respectively,8061,O
.,8061,O
TK,8062,B-GENE-Y
catalyzes,8062,O
the,8062,O
phosphorylation,8062,O
of,8062,O
dT,8062,B-CHEMICAL
resulting,8062,O
in,8062,O
an,8062,O
ester,8062,B-CHEMICAL
",",8062,O
and,8062,O
the,8062,O
phosphorylation,8062,O
of,8062,O
dTMP,8062,B-CHEMICAL
giving,8062,O
rise,8062,O
to,8062,O
an,8062,O
anhydride,8062,B-CHEMICAL
.,8062,O
The,8063,O
presented,8063,O
TK,8063,B-GENE-Y
structures,8063,O
indicate,8063,O
that,8063,O
there,8063,O
are,8063,O
only,8063,O
small,8063,O
differences,8063,O
between,8063,O
these,8063,O
two,8063,O
modes,8063,O
of,8063,O
action,8063,O
.,8063,O
Glu83,8064,O
serves,8064,O
as,8064,O
a,8064,O
general,8064,O
base,8064,O
in,8064,O
the,8064,O
ester,8064,B-CHEMICAL
reaction,8064,O
.,8064,O
Arg163,8065,O
parks,8065,O
at,8065,O
an,8065,O
internal,8065,O
aspartate,8065,B-CHEMICAL
during,8065,O
ester,8065,B-CHEMICAL
formation,8065,O
and,8065,O
binds,8065,O
the,8065,O
alpha-phosphate,8065,B-CHEMICAL
of,8065,O
dTMP,8065,B-CHEMICAL
during,8065,O
anhydride,8065,B-CHEMICAL
formation,8065,O
.,8065,O
The,8066,O
bound,8066,O
deoxythymidine,8066,B-CHEMICAL
leaves,8066,O
a,8066,O
35,8066,O
A3,8066,O
cavity,8066,O
at,8066,O
position,8066,O
5,8066,O
of,8066,O
the,8066,O
base,8066,O
and,8066,O
two,8066,O
sequestered,8066,O
water,8066,O
molecules,8066,O
at,8066,O
position,8066,O
2,8066,O
.,8066,O
Cavity,8067,O
and,8067,O
water,8067,O
molecules,8067,O
reduce,8067,O
the,8067,O
substrate,8067,O
specificity,8067,O
to,8067,O
such,8067,O
an,8067,O
extent,8067,O
that,8067,O
TK,8067,B-GENE-Y
can,8067,O
phosphorylate,8067,B-CHEMICAL
various,8067,O
substrate,8067,O
analogues,8067,O
useful,8067,O
in,8067,O
pharmaceutical,8067,O
applications,8067,O
.,8067,O
TK,8068,B-CHEMICAL
is,8068,O
structurally,8068,O
homologous,8068,O
to,8068,O
the,8068,O
well-known,8068,O
nucleoside,8068,B-CHEMICAL
monophosphate,8068,I-CHEMICAL
kinases,8068,I-GENE-N
but,8068,O
contains,8068,O
large,8068,O
additional,8068,O
peptide,8068,O
segments,8068,O
.,8068,O
Blockage,8069,O
of,8069,O
the,8069,O
HERG,8069,B-GENE-Y
human,8069,I-GENE-Y
cardiac,8069,I-GENE-Y
K+,8069,I-GENE-Y
channel,8069,I-GENE-Y
by,8069,O
the,8069,O
gastrointestinal,8069,O
prokinetic,8069,O
agent,8069,O
cisapride,8069,B-CHEMICAL
.,8069,O
Cisapride,8070,B-CHEMICAL
",",8070,O
a,8070,O
gastrointestinal,8070,O
prokinetic,8070,O
agent,8070,O
",",8070,O
is,8070,O
known,8070,O
to,8070,O
cause,8070,O
long,8070,O
Q-T,8070,O
syndrome,8070,O
and,8070,O
ventricular,8070,O
arrhythmias,8070,O
.,8070,O
The,8071,O
cellular,8071,O
mechanism,8071,O
is,8071,O
not,8071,O
known,8071,O
.,8071,O
The,8072,O
human,8072,B-GENE-Y
ether-a-go-go-related,8072,I-GENE-Y
gene,8072,I-GENE-Y
(,8072,O
HERG,8072,B-GENE-Y
),8072,O
",",8072,O
which,8072,O
encodes,8072,O
the,8072,O
rapidly,8072,O
activating,8072,O
delayed,8072,O
rectifier,8072,O
K+,8072,B-CHEMICAL
current,8072,O
and,8072,O
is,8072,O
important,8072,O
in,8072,O
cardiac,8072,O
repolarization,8072,O
",",8072,O
may,8072,O
serve,8072,O
as,8072,O
a,8072,O
target,8072,O
for,8072,O
the,8072,O
action,8072,O
of,8072,O
cisapride,8072,B-CHEMICAL
.,8072,O
We,8073,O
tested,8073,O
the,8073,O
hypothesis,8073,O
that,8073,O
cisapride,8073,B-CHEMICAL
blocks,8073,O
HERG,8073,B-GENE-Y
.,8073,O
The,8074,O
whole,8074,O
cell,8074,O
patch-clamp,8074,O
recording,8074,O
technique,8074,O
was,8074,O
used,8074,O
to,8074,O
study,8074,O
HERG,8074,B-GENE-Y
channels,8074,O
stably,8074,O
expressed,8074,O
heterologously,8074,O
in,8074,O
HEK293,8074,O
cells,8074,O
.,8074,O
Under,8075,O
voltage-clamp,8075,O
conditions,8075,O
",",8075,O
cisapride,8075,B-CHEMICAL
block,8075,O
of,8075,O
HERG,8075,B-GENE-Y
is,8075,O
dose,8075,O
dependent,8075,O
with,8075,O
a,8075,O
half-maximal,8075,O
inhibitory,8075,O
concentration,8075,O
of,8075,O
6.5,8075,O
nM,8075,O
at,8075,O
22,8075,O
degrees,8075,O
C,8075,O
(,8075,O
n,8075,O
=,8075,O
25,8075,O
cells,8075,O
),8075,O
.,8075,O
Currents,8076,O
rapidly,8076,O
recovered,8076,O
with,8076,O
drug,8076,O
washout,8076,O
.,8076,O
The,8077,O
onset,8077,O
of,8077,O
block,8077,O
by,8077,O
cisapride,8077,B-CHEMICAL
required,8077,O
channel,8077,O
activation,8077,O
indicative,8077,O
of,8077,O
open,8077,O
or,8077,O
inactivated,8077,O
state,8077,O
blockage,8077,O
.,8077,O
Block,8078,O
of,8078,O
HERG,8078,B-GENE-Y
with,8078,O
cisapride,8078,B-CHEMICAL
after,8078,O
channel,8078,O
activation,8078,O
was,8078,O
voltage,8078,O
dependent,8078,O
.,8078,O
At,8079,O
-20,8079,O
mV,8079,O
",",8079,O
10,8079,O
nM,8079,O
cisapride,8079,B-CHEMICAL
reduced,8079,O
HERG,8079,B-GENE-Y
tail-current,8079,O
amplitude,8079,O
by,8079,O
5,8079,O
%,8079,O
",",8079,O
whereas,8079,O
",",8079,O
at,8079,O
+,8079,O
20,8079,O
mV,8079,O
",",8079,O
the,8079,O
tail-current,8079,O
amplitude,8079,O
was,8079,O
reduced,8079,O
by,8079,O
45,8079,O
%,8079,O
(,8079,O
n,8079,O
=,8079,O
4,8079,O
cells,8079,O
),8079,O
.,8079,O
At,8080,O
-20,8080,O
and,8080,O
+,8080,O
20,8080,O
mV,8080,O
",",8080,O
100,8080,O
nM,8080,O
cisapride,8080,B-CHEMICAL
reduced,8080,O
tail-current,8080,O
amplitude,8080,O
by,8080,O
66,8080,O
and,8080,O
90,8080,O
%,8080,O
",",8080,O
respectively,8080,O
.,8080,O
We,8081,O
conclude,8081,O
that,8081,O
cisapride,8081,B-CHEMICAL
is,8081,O
a,8081,O
potent,8081,O
blocker,8081,O
of,8081,O
HERG,8081,B-GENE-Y
channels,8081,O
expressed,8081,O
in,8081,O
HEK293,8081,O
cells,8081,O
.,8081,O
This,8082,O
effect,8082,O
may,8082,O
account,8082,O
for,8082,O
the,8082,O
clinical,8082,O
occurrence,8082,O
of,8082,O
Q-T,8082,O
prolongation,8082,O
and,8082,O
ventricular,8082,O
arrhythmias,8082,O
observed,8082,O
with,8082,O
cisapride,8082,B-CHEMICAL
.,8082,O
Analysis,8083,O
of,8083,O
NMDA,8083,B-GENE-N
receptors,8083,I-GENE-N
in,8083,O
the,8083,O
human,8083,O
spinal,8083,O
cord,8083,O
.,8083,O
NMDA,8084,B-CHEMICAL
receptors,8084,I-GENE-N
in,8084,O
postmortem,8084,O
human,8084,O
spinal,8084,O
cord,8084,O
were,8084,O
analyzed,8084,O
using,8084,O
[,8084,B-CHEMICAL
3H,8084,I-CHEMICAL
],8084,I-CHEMICAL
MK-801,8084,I-CHEMICAL
ligand,8084,O
binding,8084,O
and,8084,O
immunoblotting,8084,O
with,8084,O
NMDA,8084,B-CHEMICAL
receptor,8084,I-GENE-N
subunit-specific,8084,O
antibodies,8084,O
.,8084,O
The,8085,O
average,8085,O
KD,8085,O
for,8085,O
[,8085,B-CHEMICAL
3H,8085,I-CHEMICAL
],8085,I-CHEMICAL
MK-801,8085,I-CHEMICAL
binding,8085,O
was,8085,O
1.77,8085,O
nM,8085,O
with,8085,O
a,8085,O
Bmax,8085,O
of,8085,O
0.103,8085,O
pmol/mg,8085,O
.,8085,O
The,8086,O
EC50,8086,O
for,8086,O
stimulation,8086,O
of,8086,O
-3H-MK-801,8086,O
binding,8086,O
with,8086,O
L-glutamate,8086,B-CHEMICAL
was,8086,O
0.34,8086,O
microM,8086,O
.,8086,O
None,8087,O
of,8087,O
these,8087,O
parameters,8087,O
were,8087,O
affected,8087,O
by,8087,O
postmortem,8087,O
intervals,8087,O
up,8087,O
to,8087,O
72,8087,O
h.,8087,O
Immunoblotting,8087,O
of,8087,O
native,8087,O
NMDA,8087,B-CHEMICAL
receptors,8087,I-GENE-N
showed,8087,O
that,8087,O
NR1,8087,B-GENE-Y
",",8087,O
NR2A,8087,B-GENE-Y
",",8087,O
NR2C,8087,B-GENE-N
",",8087,O
and,8087,O
NR2D,8087,B-GENE-Y
subunits,8087,O
could,8087,O
all,8087,O
be,8087,O
found,8087,O
in,8087,O
the,8087,O
human,8087,O
spinal,8087,O
cord,8087,O
of,8087,O
which,8087,O
NR1,8087,B-GENE-Y
was,8087,O
preferentially,8087,O
located,8087,O
to,8087,O
the,8087,O
dorsal,8087,O
half,8087,O
.,8087,O
Immunoprecipitation,8088,O
of,8088,O
solubilized,8088,O
receptors,8088,O
revealed,8088,O
that,8088,O
NR1,8088,B-GENE-Y
",",8088,O
NR2C,8088,B-GENE-N
",",8088,O
and,8088,O
NR2D,8088,B-GENE-Y
subunits,8088,O
coprecipitated,8088,O
with,8088,O
the,8088,O
NR2A,8088,B-GENE-Y
subunit,8088,O
",",8088,O
indicating,8088,O
that,8088,O
native,8088,O
human,8088,O
spinal,8088,O
cord,8088,O
NMDA,8088,B-CHEMICAL
receptors,8088,I-GENE-N
are,8088,O
heteroligimeric,8088,B-CHEMICAL
receptors,8088,I-GENE-N
assembled,8088,O
by,8088,O
at,8088,O
least,8088,O
three,8088,O
different,8088,O
receptor,8088,O
subunits,8088,O
.,8088,O
These,8089,O
results,8089,O
provide,8089,O
a,8089,O
basis,8089,O
for,8089,O
the,8089,O
development,8089,O
of,8089,O
drugs,8089,O
selectively,8089,O
aimed,8089,O
at,8089,O
spinal,8089,O
cord,8089,O
NMDA,8089,B-GENE-N
receptors,8089,I-GENE-N
for,8089,O
the,8089,O
future,8089,O
treatment,8089,O
of,8089,O
spinal,8089,O
cord,8089,O
disorders,8089,O
.,8089,O
Monoamine,8090,B-GENE-N
transporter,8090,I-GENE-N
and,8090,O
sodium,8090,B-GENE-N
channel,8090,I-GENE-N
mechanisms,8090,O
in,8090,O
the,8090,O
rapid,8090,O
pressor,8090,O
response,8090,O
to,8090,O
cocaine,8090,B-CHEMICAL
.,8090,O
Intravenous,8091,O
(,8091,O
I.V,8091,O
.,8091,O
),8091,O
cocaine,8092,B-CHEMICAL
(,8092,O
0.03-3,8092,O
mg/kg,8092,O
),8092,O
produced,8092,O
dose-dependent,8092,O
",",8092,O
rapid,8092,O
",",8092,O
and,8092,O
brief,8092,O
increases,8092,O
in,8092,O
blood,8092,O
pressure,8092,O
(,8092,O
BP,8092,O
),8092,O
in,8092,O
conscious,8092,O
rats,8092,O
pretreated,8092,O
with,8092,O
the,8092,O
dopamine,8092,B-GENE-N
receptor,8092,I-GENE-N
antagonist,8092,O
",",8092,O
SCH,8092,B-CHEMICAL
23390,8092,I-CHEMICAL
.,8092,O
Monoamine,8093,B-CHEMICAL
uptake,8093,O
inhibitors,8093,O
structurally,8093,O
analogous,8093,O
to,8093,O
cocaine,8093,B-CHEMICAL
(,8093,O
cocaethylene,8093,B-CHEMICAL
",",8093,O
CFT,8093,B-CHEMICAL
",",8093,O
betaCIT,8093,B-CHEMICAL
",",8093,O
CPT,8093,B-CHEMICAL
",",8093,O
(,8093,B-CHEMICAL
+,8093,I-CHEMICAL
),8093,I-CHEMICAL
-cocaine,8093,I-CHEMICAL
",",8093,O
norcocaine,8093,B-CHEMICAL
",",8093,O
and,8093,O
benztropine,8093,B-CHEMICAL
),8093,O
also,8093,O
produced,8093,O
this,8093,O
rapid,8093,O
pressor,8093,O
response,8093,O
",",8093,O
whereas,8093,O
structurally,8093,O
unrelated,8093,O
uptake,8093,O
inhibitors,8093,O
with,8093,O
diverse,8093,O
monoamine,8093,B-GENE-N
transporter,8093,I-GENE-N
selectivities,8093,O
(,8093,O
BTCP,8093,B-CHEMICAL
",",8093,O
indatraline,8093,B-CHEMICAL
",",8093,O
GBR,8093,B-CHEMICAL
12935,8093,I-CHEMICAL
",",8093,O
mazindol,8093,B-CHEMICAL
",",8093,O
nomifensine,8093,B-CHEMICAL
",",8093,O
and,8093,O
zimeldine,8093,B-CHEMICAL
),8093,O
either,8093,O
did,8093,O
not,8093,O
produce,8093,O
a,8093,O
rapid,8093,O
pressor,8093,O
response,8093,O
or,8093,O
produced,8093,O
only,8093,O
a,8093,O
small,8093,O
pressor,8093,O
response,8093,O
.,8093,O
At,8094,O
nonconvulsant,8094,O
doses,8094,O
",",8094,O
the,8094,O
sodium,8094,B-GENE-N
channel,8094,I-GENE-N
blockers,8094,O
acetylprocainamide,8094,B-CHEMICAL
",",8094,O
dibucaine,8094,B-CHEMICAL
",",8094,O
dyclonine,8094,B-CHEMICAL
",",8094,O
prilocaine,8094,B-CHEMICAL
",",8094,O
proparacaine,8094,B-CHEMICAL
",",8094,O
quinidine,8094,B-CHEMICAL
",",8094,O
and,8094,O
tetracaine,8094,B-CHEMICAL
produced,8094,O
a,8094,O
small,8094,O
pressor,8094,O
response,8094,O
or,8094,O
no,8094,O
increase,8094,O
in,8094,O
BP,8094,O
.,8094,O
In,8095,O
rats,8095,O
implanted,8095,O
with,8095,O
telemetric,8095,O
devices,8095,O
",",8095,O
cocaine,8095,B-CHEMICAL
and,8095,O
its,8095,O
analog,8095,O
",",8095,O
CFT,8095,B-CHEMICAL
",",8095,O
produced,8095,O
a,8095,O
biphasic,8095,O
pharmacological,8095,O
response,8095,O
that,8095,O
consisted,8095,O
of,8095,O
an,8095,O
initial,8095,O
brief,8095,O
and,8095,O
abrupt,8095,O
behavioral,8095,O
arousal,8095,O
associated,8095,O
with,8095,O
a,8095,O
rapid,8095,O
",",8095,O
large,8095,O
increase,8095,O
in,8095,O
BP,8095,O
followed,8095,O
by,8095,O
prolonged,8095,O
",",8095,O
parallel,8095,O
increases,8095,O
in,8095,O
BP,8095,O
and,8095,O
locomotor,8095,O
activity,8095,O
.,8095,O
Pretreatment,8096,O
with,8096,O
SCH,8096,B-CHEMICAL
23390,8096,I-CHEMICAL
prevented,8096,O
the,8096,O
prolonged,8096,O
but,8096,O
not,8096,O
the,8096,O
initial,8096,O
rapid,8096,O
and,8096,O
brief,8096,O
pressor,8096,O
and,8096,O
activity,8096,O
responses,8096,O
to,8096,O
both,8096,O
cocaine,8096,B-CHEMICAL
and,8096,O
CFT,8096,B-CHEMICAL
administration,8096,O
.,8096,O
The,8097,O
present,8097,O
data,8097,O
suggest,8097,O
that,8097,O
the,8097,O
inhibition,8097,O
of,8097,O
dopamine,8097,B-CHEMICAL
",",8097,I-GENE-N
norepinephrine,8097,B-CHEMICAL
",",8097,I-GENE-N
or,8097,I-GENE-N
serotonin,8097,B-CHEMICAL
transporter,8097,I-GENE-N
functions,8097,O
",",8097,O
either,8097,O
alone,8097,O
or,8097,O
in,8097,O
combination,8097,O
",",8097,O
does,8097,O
not,8097,O
mediate,8097,O
the,8097,O
rapid,8097,O
pressor,8097,O
response,8097,O
to,8097,O
cocaine,8097,B-CHEMICAL
.,8097,O
The,8098,O
sodium,8098,B-CHEMICAL
channel-blocking,8098,O
action,8098,O
of,8098,O
cocaine,8098,B-CHEMICAL
per,8098,O
se,8098,O
does,8098,O
not,8098,O
appear,8098,O
to,8098,O
be,8098,O
involved,8098,O
in,8098,O
the,8098,O
rapid,8098,O
pressor,8098,O
response,8098,O
to,8098,O
cocaine,8098,B-CHEMICAL
.,8098,O
Finally,8099,O
",",8099,O
the,8099,O
present,8099,O
results,8099,O
confirm,8099,O
previous,8099,O
findings,8099,O
that,8099,O
dopaminergic,8099,O
mechanisms,8099,O
mediate,8099,O
the,8099,O
prolonged,8099,O
increases,8099,O
in,8099,O
BP,8099,O
and,8099,O
locomotor,8099,O
activity,8099,O
produced,8099,O
by,8099,O
cocaine,8099,B-CHEMICAL
.,8099,O
Identification,8100,O
of,8100,O
cDNAs,8100,O
encoding,8100,O
two,8100,O
human,8100,B-GENE-N
alpha,8100,I-GENE-N
class,8100,I-GENE-N
glutathione,8100,B-CHEMICAL
transferases,8100,I-GENE-N
(,8100,O
GSTA3,8100,B-GENE-Y
and,8100,O
GSTA4,8100,B-GENE-Y
),8100,O
and,8100,O
the,8100,O
heterologous,8100,O
expression,8100,O
of,8100,O
GSTA4-4,8100,B-GENE-Y
.,8100,O
The,8101,O
Expressed,8101,O
Sequence,8101,O
Tag,8101,O
database,8101,O
has,8101,O
been,8101,O
searched,8101,O
for,8101,O
examples,8101,O
of,8101,O
previously,8101,O
undescribed,8101,O
human,8101,B-GENE-N
Alpha,8101,I-GENE-N
class,8101,I-GENE-N
glutathione,8101,B-CHEMICAL
transferases,8101,I-GENE-N
.,8101,O
An,8102,O
incomplete,8102,O
transcript,8102,O
of,8102,O
the,8102,O
previously,8102,O
described,8102,O
GSTA3,8102,B-GENE-Y
gene,8102,O
was,8102,O
identified,8102,O
in,8102,O
a,8102,O
cDNA,8102,O
library,8102,O
derived,8102,O
from,8102,O
8-9,8102,O
week,8102,O
placenta,8102,O
.,8102,O
This,8103,O
indicates,8103,O
that,8103,O
the,8103,O
GSTA3,8103,B-GENE-Y
gene,8103,O
is,8103,O
functional,8103,O
and,8103,O
is,8103,O
possibly,8103,O
under,8103,O
specific,8103,O
developmental,8103,O
regulation,8103,O
.,8103,O
A,8104,O
second,8104,O
cDNA,8104,O
",",8104,O
termed,8104,O
GSTA4,8104,B-GENE-Y
",",8104,O
was,8104,O
identified,8104,O
in,8104,O
a,8104,O
brain,8104,O
cDNA,8104,O
library,8104,O
.,8104,O
The,8105,O
encoded,8105,O
GSTA4-4,8105,B-GENE-Y
enzyme,8105,O
was,8105,O
expressed,8105,O
in,8105,O
Escherichia,8105,O
coli,8105,O
and,8105,O
was,8105,O
found,8105,O
to,8105,O
be,8105,O
immunologically,8105,O
distinct,8105,O
from,8105,O
GSTA1-1,8105,B-GENE-Y
and,8105,O
to,8105,O
have,8105,O
high,8105,O
activity,8105,O
with,8105,O
alk-2-enals,8105,O
.,8105,O
Although,8106,O
GSTA4-4,8106,B-GENE-Y
appears,8106,O
to,8106,O
be,8106,O
functionally,8106,O
similar,8106,O
to,8106,O
the,8106,O
mouse,8106,B-GENE-Y
GST5.7,8106,I-GENE-Y
and,8106,O
rat,8106,B-GENE-Y
GST8-8,8106,I-GENE-Y
Alpha,8106,O
class,8106,O
enzymes,8106,O
",",8106,O
sequence,8106,O
comparisons,8106,O
and,8106,O
phylogenetic,8106,O
analysis,8106,O
suggest,8106,O
that,8106,O
GSTA4-4,8106,B-GENE-Y
may,8106,O
be,8106,O
a,8106,O
member,8106,O
of,8106,O
a,8106,O
distinct,8106,O
Alpha,8106,O
class,8106,O
subgroup,8106,O
.,8106,O
Characterization,8107,O
of,8107,O
binding,8107,O
sites,8107,O
of,8107,O
a,8107,O
new,8107,O
neurotensin,8107,B-GENE-N
receptor,8107,I-GENE-N
antagonist,8107,O
",",8107,O
[,8107,B-CHEMICAL
3H,8107,I-CHEMICAL
],8107,I-CHEMICAL
SR,8107,I-CHEMICAL
142948A,8107,I-CHEMICAL
",",8107,O
in,8107,O
the,8107,O
rat,8107,O
brain,8107,O
.,8107,O
The,8108,O
present,8108,O
study,8108,O
describes,8108,O
the,8108,O
characterization,8108,O
of,8108,O
the,8108,O
binding,8108,O
properties,8108,O
and,8108,O
autoradiographic,8108,O
distribution,8108,O
of,8108,O
a,8108,O
new,8108,O
nonpeptide,8108,O
antagonist,8108,O
of,8108,O
neurotensin,8108,B-CHEMICAL
receptors,8108,I-GENE-N
",",8108,O
[,8108,B-CHEMICAL
3H,8108,I-CHEMICAL
],8108,I-CHEMICAL
SR,8108,I-CHEMICAL
142948A,8108,I-CHEMICAL
(,8108,O
2-,8108,B-CHEMICAL
[,8108,I-CHEMICAL
[,8108,I-CHEMICAL
5-,8108,I-CHEMICAL
(,8108,I-CHEMICAL
"2,6-dimethoxyphenyl",8108,I-CHEMICAL
),8108,I-CHEMICAL
-1-,8108,I-CHEMICAL
(,8108,I-CHEMICAL
4-,8108,I-CHEMICAL
(,8108,I-CHEMICAL
N-,8108,I-CHEMICAL
(,8108,I-CHEMICAL
3-dimethylaminopropyl,8108,I-CHEMICAL
),8108,I-CHEMICAL
-N-methyl,8108,I-CHEMICAL
carbamoyl,8108,I-CHEMICAL
),8108,I-CHEMICAL
-2-isopropylphenyl,8108,I-CHEMICAL
),8108,I-CHEMICAL
-1H-pyrazole-3-carbonyl,8108,I-CHEMICAL
],8108,I-CHEMICAL
-amino,8108,I-CHEMICAL
],8108,I-CHEMICAL
-ad,8108,I-CHEMICAL
amantane-2-carboxylic,8108,I-CHEMICAL
acid,8108,I-CHEMICAL
",",8108,I-CHEMICAL
hydrochloride,8108,I-CHEMICAL
),8108,O
",",8108,O
in,8108,O
the,8108,O
rat,8108,O
brain,8108,O
.,8108,O
The,8109,O
binding,8109,O
of,8109,O
[,8109,B-CHEMICAL
3H,8109,I-CHEMICAL
],8109,I-CHEMICAL
SR,8109,I-CHEMICAL
142948A,8109,I-CHEMICAL
in,8109,O
brain,8109,O
membrane,8109,O
homogenates,8109,O
was,8109,O
specific,8109,O
",",8109,O
time-dependent,8109,O
",",8109,O
reversible,8109,O
and,8109,O
saturable,8109,O
.,8109,O
[,8110,B-CHEMICAL
3H,8110,I-CHEMICAL
],8110,I-CHEMICAL
SR,8110,I-CHEMICAL
142948A,8110,I-CHEMICAL
bound,8110,O
to,8110,O
an,8110,O
apparently,8110,O
homogeneous,8110,O
population,8110,O
of,8110,O
sites,8110,O
",",8110,O
with,8110,O
a,8110,O
Kd,8110,O
of,8110,O
3.5,8110,O
nM,8110,O
and,8110,O
a,8110,O
Bmax,8110,O
value,8110,O
of,8110,O
508,8110,O
fmol/mg,8110,O
of,8110,O
protein,8110,O
",",8110,O
which,8110,O
was,8110,O
80,8110,O
%,8110,O
higher,8110,O
than,8110,O
that,8110,O
observed,8110,O
in,8110,O
saturation,8110,O
experiments,8110,O
with,8110,O
[,8110,B-CHEMICAL
3H,8110,I-CHEMICAL
],8110,I-CHEMICAL
neurotensin,8110,I-CHEMICAL
.,8110,O
[,8111,B-CHEMICAL
3H,8111,I-CHEMICAL
],8111,I-CHEMICAL
SR,8111,I-CHEMICAL
142948A,8111,I-CHEMICAL
binding,8111,O
was,8111,O
inhibited,8111,O
by,8111,O
SR,8111,B-CHEMICAL
142948A,8111,I-CHEMICAL
",",8111,O
the,8111,O
related,8111,O
nonpeptide,8111,O
receptor,8111,O
antagonist,8111,O
",",8111,O
SR,8111,B-CHEMICAL
48692,8111,I-CHEMICAL
(,8111,O
2-,8111,B-CHEMICAL
[,8111,I-CHEMICAL
[,8111,I-CHEMICAL
1-,8111,I-CHEMICAL
(,8111,I-CHEMICAL
7-chloroquinolin-4-yl,8111,I-CHEMICAL
),8111,I-CHEMICAL
-5-,8111,I-CHEMICAL
(,8111,I-CHEMICAL
"2,6-dimethoxyphenyl",8111,I-CHEMICAL
),8111,I-CHEMICAL
-1H-pyrazole,8111,I-CHEMICAL
-3-carbonyl,8111,I-CHEMICAL
],8111,I-CHEMICAL
amino,8111,I-CHEMICAL
],8111,I-CHEMICAL
-adamantane-2-carboxylic,8111,I-CHEMICAL
acid,8111,I-CHEMICAL
),8111,O
and,8111,O
neurotensin,8111,B-GENE-Y
.,8111,O
Saturation,8112,O
and,8112,O
competition,8112,O
studies,8112,O
in,8112,O
the,8112,O
presence,8112,O
or,8112,O
absence,8112,O
of,8112,O
the,8112,O
histamine,8112,B-GENE-Y
H1,8112,I-GENE-Y
receptor,8112,I-GENE-Y
antagonist,8112,O
",",8112,O
levocabastine,8112,B-CHEMICAL
",",8112,O
revealed,8112,O
that,8112,O
[,8112,B-CHEMICAL
3H,8112,I-CHEMICAL
],8112,I-CHEMICAL
SR,8112,I-CHEMICAL
142948A,8112,I-CHEMICAL
bound,8112,O
with,8112,O
similar,8112,O
affinities,8112,O
to,8112,O
both,8112,O
the,8112,O
levocabastine-insensitive,8112,B-CHEMICAL
neurotensin,8112,B-CHEMICAL
NT1,8112,I-GENE-Y
receptors,8112,I-GENE-Y
(,8112,O
20,8112,O
%,8112,O
of,8112,O
the,8112,O
total,8112,O
binding,8112,O
population,8112,O
),8112,O
and,8112,O
the,8112,O
recently,8112,O
cloned,8112,O
levocabastine-sensitive,8112,B-CHEMICAL
neurotensin,8112,B-GENE-Y
NT2,8112,I-GENE-Y
receptors,8112,I-GENE-Y
(,8112,O
80,8112,O
%,8112,O
of,8112,O
the,8112,O
receptors,8112,O
),8112,O
(,8112,O
Kd,8112,O
=,8112,O
6.8,8112,O
and,8112,O
4.8,8112,O
nM,8112,O
",",8112,O
respectively,8112,O
),8112,O
.,8112,O
The,8113,O
regional,8113,O
distribution,8113,O
of,8113,O
[,8113,B-CHEMICAL
3H,8113,I-CHEMICAL
],8113,I-CHEMICAL
SR,8113,I-CHEMICAL
142948A,8113,I-CHEMICAL
binding,8113,O
in,8113,O
the,8113,O
rat,8113,O
brain,8113,O
closely,8113,O
matched,8113,O
the,8113,O
distribution,8113,O
of,8113,O
[,8113,B-CHEMICAL
125I,8113,I-CHEMICAL
],8113,I-CHEMICAL
neurotensin,8113,I-CHEMICAL
binding,8113,O
.,8113,O
In,8114,O
conclusion,8114,O
",",8114,O
these,8114,O
findings,8114,O
indicate,8114,O
that,8114,O
[,8114,B-CHEMICAL
3H,8114,I-CHEMICAL
],8114,I-CHEMICAL
SR,8114,I-CHEMICAL
142948A,8114,I-CHEMICAL
is,8114,O
a,8114,O
new,8114,O
potent,8114,O
antagonist,8114,O
radioligand,8114,O
which,8114,O
recognizes,8114,O
with,8114,O
high,8114,O
affinity,8114,O
both,8114,O
neurotensin,8114,B-GENE-Y
NT1,8114,I-GENE-Y
and,8114,O
NT2,8114,B-GENE-Y
receptors,8114,I-GENE-Y
and,8114,O
represents,8114,O
thus,8114,O
an,8114,O
excellent,8114,O
tool,8114,O
to,8114,O
study,8114,O
neurotensin,8114,B-GENE-N
receptors,8114,I-GENE-N
in,8114,O
the,8114,O
rat,8114,O
brain,8114,O
.,8114,O
A,8115,O
new,8115,O
concept,8115,O
of,8115,O
drug,8115,O
delivery,8115,O
for,8115,O
acne,8115,O
.,8115,O
Adapalene,8116,B-CHEMICAL
is,8116,O
a,8116,O
stable,8116,O
naphthoic,8116,B-CHEMICAL
acid,8116,I-CHEMICAL
derivative,8116,O
that,8116,O
displays,8116,O
a,8116,O
strong,8116,O
retinoid,8116,B-CHEMICAL
agonist,8116,O
pharmacology,8116,O
.,8116,O
This,8117,O
drug,8117,O
controls,8117,O
cell,8117,O
proliferation,8117,O
and,8117,O
differentiation,8117,O
",",8117,O
and,8117,O
possesses,8117,O
significant,8117,O
anti-inflammatory,8117,O
action,8117,O
.,8117,O
The,8118,O
retinoid,8118,B-CHEMICAL
action,8118,O
of,8118,O
adapalene,8118,B-CHEMICAL
are,8118,O
mediated,8118,O
by,8118,O
the,8118,O
ligand-activated,8118,B-GENE-N
gene,8118,I-GENE-N
transcription,8118,I-GENE-N
factors,8118,I-GENE-N
retinoic,8118,B-GENE-N
acid,8118,I-GENE-N
receptors,8118,I-GENE-N
RAR,8118,B-GENE-Y
beta,8118,I-GENE-Y
and,8118,O
RAR,8118,B-GENE-Y
gamma,8118,I-GENE-Y
.,8118,O
We,8119,O
describe,8119,O
here,8119,O
how,8119,O
an,8119,O
aqueous,8119,O
gel,8119,O
containing,8119,O
adapalene,8119,B-CHEMICAL
was,8119,O
selected,8119,O
for,8119,O
the,8119,O
topical,8119,O
treatment,8119,O
of,8119,O
acne,8119,O
.,8119,O
Isoform-specific,8120,O
inhibition,8120,O
of,8120,O
L-type,8120,B-GENE-N
calcium,8120,I-GENE-N
channels,8120,I-GENE-N
by,8120,O
dihydropyridines,8120,B-CHEMICAL
is,8120,O
independent,8120,O
of,8120,O
isoform-specific,8120,O
gating,8120,O
properties,8120,O
.,8120,O
Dihydropyridines,8121,B-CHEMICAL
(,8121,O
DHPs,8121,B-CHEMICAL
),8121,O
block,8121,O
L-type,8121,B-GENE-N
Ca2+,8121,B-CHEMICAL
channels,8121,I-GENE-N
more,8121,O
potently,8121,O
at,8121,O
depolarized,8121,O
membrane,8121,O
potentials,8121,O
",",8121,O
consistent,8121,O
with,8121,O
high,8121,O
affinity,8121,O
binding,8121,O
to,8121,O
the,8121,O
inactivated,8121,O
state,8121,O
.,8121,O
Nisoldipine,8122,B-CHEMICAL
(,8122,O
a,8122,O
DHP,8122,B-CHEMICAL
antagonist,8122,O
),8122,O
blocks,8122,O
the,8122,O
smooth,8122,B-GENE-N
muscle,8122,I-GENE-N
channel,8122,I-GENE-N
more,8122,O
potently,8122,O
than,8122,O
the,8122,O
cardiac,8122,O
one,8122,O
",",8122,O
a,8122,O
phenomenon,8122,O
observed,8122,O
not,8122,O
only,8122,O
in,8122,O
native,8122,O
channels,8122,O
but,8122,O
also,8122,O
in,8122,O
expressed,8122,O
channels,8122,O
.,8122,O
We,8123,O
examined,8123,O
whether,8123,O
this,8123,O
tissue,8123,O
specificity,8123,O
was,8123,O
attributable,8123,O
to,8123,O
differences,8123,O
of,8123,O
inactivation,8123,O
in,8123,O
the,8123,O
two,8123,O
channel,8123,O
types,8123,O
.,8123,O
We,8124,O
expressed,8124,O
cardiac,8124,O
or,8124,O
smooth,8124,B-GENE-Y
muscle,8124,I-GENE-Y
alpha1C,8124,I-GENE-Y
subunits,8124,O
in,8124,O
combination,8124,O
with,8124,O
beta2a,8124,O
and,8124,O
alpha2/delta,8124,O
subunits,8124,O
in,8124,O
human,8124,O
embryonic,8124,O
kidney,8124,O
cells,8124,O
",",8124,O
and,8124,O
used,8124,O
2,8124,O
mM,8124,O
Ca2+,8124,B-CHEMICAL
as,8124,O
the,8124,O
permeant,8124,O
ion,8124,O
.,8124,O
This,8125,O
system,8125,O
thus,8125,O
reproduces,8125,O
the,8125,O
in,8125,O
vivo,8125,O
topology,8125,O
and,8125,O
charge,8125,O
carrier,8125,O
of,8125,O
the,8125,O
channels,8125,O
while,8125,O
facilitating,8125,O
comparison,8125,O
of,8125,O
the,8125,O
two,8125,O
alpha1C,8125,O
splice,8125,O
variants,8125,O
.,8125,O
Both,8126,O
voltage-dependent,8126,O
and,8126,O
isoform-specific,8126,O
sensitivity,8126,O
of,8126,O
10,8126,O
nM,8126,O
nisoldipine,8126,B-CHEMICAL
inhibition,8126,O
of,8126,O
the,8126,O
channel,8126,O
were,8126,O
demonstrated,8126,O
",",8126,O
with,8126,O
the,8126,O
use,8126,O
of,8126,O
-100,8126,O
mV,8126,O
as,8126,O
the,8126,O
holding,8126,O
potential,8126,O
for,8126,O
fully,8126,O
reprimed,8126,O
channels,8126,O
and,8126,O
-65,8126,O
mV,8126,O
to,8126,O
populate,8126,O
the,8126,O
inactivated,8126,O
state,8126,O
.,8126,O
Under,8127,O
drug-free,8127,O
conditions,8127,O
",",8127,O
we,8127,O
characterized,8127,O
fast,8127,O
inactivation,8127,O
(,8127,O
1-sec,8127,O
prepulses,8127,O
),8127,O
and,8127,O
slow,8127,O
inactivation,8127,O
(,8127,O
3,8127,O
min,8127,O
prepulses,8127,O
),8127,O
in,8127,O
the,8127,O
two,8127,O
isoforms,8127,O
.,8127,O
Inactivation,8128,O
parameters,8128,O
were,8128,O
not,8128,O
statistically,8128,O
different,8128,O
in,8128,O
the,8128,O
two,8128,O
channel,8128,O
isoforms,8128,O
;,8128,O
if,8128,O
anything,8128,O
",",8128,O
cardiac,8128,B-GENE-N
channels,8128,I-GENE-N
tended,8128,O
to,8128,O
inactivate,8128,O
more,8128,O
than,8128,O
the,8128,O
smooth,8128,B-GENE-N
muscle,8128,I-GENE-N
channels,8128,I-GENE-N
at,8128,O
relevant,8128,O
voltages,8128,O
.,8128,O
Likewise,8129,O
",",8129,O
the,8129,O
voltage-dependent,8129,O
activation,8129,O
was,8129,O
identical,8129,O
in,8129,O
the,8129,O
two,8129,O
isoforms,8129,O
.,8129,O
We,8130,O
thus,8130,O
conclude,8130,O
that,8130,O
the,8130,O
more,8130,O
potent,8130,O
nisoldipine,8130,B-CHEMICAL
inhibition,8130,O
of,8130,O
smooth,8130,O
muscle,8130,O
versus,8130,O
cardiac,8130,B-GENE-N
L-type,8130,I-GENE-N
Ca2+,8130,B-CHEMICAL
channels,8130,I-GENE-N
is,8130,O
not,8130,O
attributable,8130,O
to,8130,O
differences,8130,O
in,8130,O
channel,8130,O
inactivation,8130,O
or,8130,O
activation,8130,O
.,8130,O
Intrinsic,8131,O
",",8131,O
gating-independent,8131,O
DHP,8131,B-CHEMICAL
receptor,8131,I-GENE-N
binding,8131,O
affinity,8131,O
differences,8131,O
must,8131,O
be,8131,O
invoked,8131,O
to,8131,O
explain,8131,O
the,8131,O
isoform-specific,8131,O
sensitivity,8131,O
of,8131,O
the,8131,O
DHP,8131,B-CHEMICAL
block,8131,O
.,8131,O
Remethylation,8132,O
defects,8132,O
:,8132,O
guidelines,8132,O
for,8132,O
clinical,8132,O
diagnosis,8132,O
and,8132,O
treatment,8132,O
.,8132,O
The,8133,O
main,8133,O
remethylation,8133,O
defects,8133,O
include,8133,O
disorders,8133,O
which,8133,O
all,8133,O
have,8133,O
defective,8133,O
methionine,8133,B-CHEMICAL
synthesis,8133,O
in,8133,O
common,8133,O
.,8133,O
Methylenetetrahydrofolate,8134,B-CHEMICAL
reductase,8134,I-GENE-Y
deficiency,8134,O
impairs,8134,O
methyltetrahydrofolate,8134,B-CHEMICAL
synthesis,8134,O
",",8134,O
defects,8134,O
in,8134,O
cytosolic,8134,O
reduction,8134,O
of,8134,O
hydroxocobalamin,8134,B-CHEMICAL
(,8134,O
CblC/D,8134,O
),8134,O
impair,8134,O
the,8134,O
synthesis,8134,O
of,8134,O
both,8134,O
methyl-,8134,B-CHEMICAL
and,8134,O
adenosyl,8134,B-CHEMICAL
cobalamin,8134,I-CHEMICAL
and,8134,O
deficiencies,8134,O
of,8134,O
methionine,8134,B-CHEMICAL
synthase,8134,I-GENE-Y
(,8134,O
CblE/G,8134,O
),8134,O
are,8134,O
associated,8134,O
with,8134,O
defective,8134,O
methyl,8134,B-CHEMICAL
cobalamin,8134,I-CHEMICAL
synthesis,8134,O
.,8134,O
The,8135,O
clinical,8135,O
presentation,8135,O
is,8135,O
characterized,8135,O
by,8135,O
acute,8135,O
neurological,8135,O
distress,8135,O
in,8135,O
early,8135,O
infancy,8135,O
.,8135,O
In,8136,O
childhood,8136,O
",",8136,O
patients,8136,O
present,8136,O
with,8136,O
progressive,8136,O
encephalopathy,8136,O
with,8136,O
an,8136,O
end-stage,8136,O
which,8136,O
has,8136,O
many,8136,O
signs,8136,O
in,8136,O
common,8136,O
with,8136,O
the,8136,O
adult,8136,O
onset,8136,O
form,8136,O
.,8136,O
In,8137,O
fact,8137,O
",",8137,O
both,8137,O
have,8137,O
more,8137,O
or,8137,O
less,8137,O
severe,8137,O
signs,8137,O
of,8137,O
subacute,8137,O
degeneration,8137,O
of,8137,O
the,8137,O
cord,8137,O
.,8137,O
Cobalamin,8138,B-CHEMICAL
defective,8138,O
patients,8138,O
must,8138,O
be,8138,O
treated,8138,O
with,8138,O
parenteral,8138,O
supplementation,8138,O
of,8138,O
hydroxocobalamin,8138,B-CHEMICAL
(,8138,O
1-2,8138,O
mg,8138,O
per,8138,O
dose,8138,O
),8138,O
.,8138,O
Some,8139,O
methylenetetrahydrofolate,8139,B-CHEMICAL
patients,8139,O
could,8139,O
be,8139,O
folate,8139,B-CHEMICAL
responsive,8139,O
and,8139,O
must,8139,O
have,8139,O
a,8139,O
high-dosage,8139,O
folate,8139,O
trial,8139,O
.,8139,O
In,8140,O
addition,8140,O
",",8140,O
oral,8140,O
betaine,8140,B-CHEMICAL
supplementation,8140,O
(,8140,O
2-9,8140,O
g,8140,O
per,8140,O
day,8140,O
depending,8140,O
on,8140,O
age,8140,O
),8140,O
appears,8140,O
an,8140,O
effective,8140,O
means,8140,O
to,8140,O
prevent,8140,O
further,8140,O
neurological,8140,O
deterioration,8140,O
.,8140,O
Increased,8141,O
Cat3-mediated,8141,B-GENE-Y
cationic,8141,O
amino,8141,B-CHEMICAL
acid,8141,I-CHEMICAL
transport,8141,O
functionally,8141,O
compensates,8141,O
in,8141,O
Cat1,8141,B-GENE-Y
knockout,8141,O
cell,8141,O
lines,8141,O
.,8141,O
Arginine,8142,B-CHEMICAL
transport,8142,O
is,8142,O
important,8142,O
for,8142,O
a,8142,O
number,8142,O
of,8142,O
biological,8142,O
processes,8142,O
in,8142,O
vertebrates,8142,O
",",8142,O
and,8142,O
its,8142,O
transport,8142,O
may,8142,O
be,8142,O
rate-limiting,8142,O
for,8142,O
the,8142,O
production,8142,O
of,8142,O
nitric,8142,B-CHEMICAL
oxide,8142,I-CHEMICAL
.,8142,O
The,8143,O
majority,8143,O
of,8143,O
L-Arg,8143,B-CHEMICAL
transport,8143,O
is,8143,O
mediated,8143,O
by,8143,O
System,8143,B-GENE-N
y+,8143,I-GENE-N
",",8143,O
although,8143,O
several,8143,O
other,8143,O
carriers,8143,O
have,8143,O
been,8143,O
kinetically,8143,O
defined,8143,O
.,8143,O
System,8144,B-GENE-N
y+,8144,I-GENE-N
cationic,8144,O
amino,8144,B-CHEMICAL
acid,8144,I-CHEMICAL
transport,8144,O
is,8144,O
mediated,8144,O
by,8144,O
proteins,8144,O
encoded,8144,O
by,8144,O
a,8144,O
family,8144,O
of,8144,O
genes,8144,O
",",8144,O
Cat1,8144,B-GENE-Y
",",8144,O
Cat2,8144,B-GENE-Y
",",8144,O
and,8144,O
Cat3,8144,B-GENE-Y
.,8144,O
High,8145,O
affinity,8145,O
L-arginine,8145,B-CHEMICAL
transport,8145,O
was,8145,O
investigated,8145,O
in,8145,O
embryonic,8145,O
fibroblast,8145,O
cells,8145,O
derived,8145,O
from,8145,O
Cat1,8145,B-GENE-Y
knockout,8145,O
mice,8145,O
that,8145,O
lack,8145,O
functional,8145,O
Cat1,8145,B-GENE-Y
.,8145,O
Both,8146,O
wild,8146,O
type,8146,O
and,8146,O
knockout,8146,O
cells,8146,O
transport,8146,O
arginine,8146,B-CHEMICAL
with,8146,O
comparable,8146,O
Km,8146,O
and,8146,O
Vmax,8146,O
.,8146,O
However,8147,O
",",8147,O
the,8147,O
apparent,8147,O
affinity,8147,O
for,8147,O
lysine,8147,B-CHEMICAL
transport,8147,O
was,8147,O
2.4,8147,O
times,8147,O
lower,8147,O
in,8147,O
Cat1,8147,B-GENE-Y
(,8147,O
-/-,8147,O
),8147,O
cells,8147,O
when,8147,O
compared,8147,O
with,8147,O
wild,8147,O
type,8147,O
cells,8147,O
",",8147,O
a,8147,O
property,8147,O
characteristic,8147,O
of,8147,O
Cat3-mediated,8147,B-GENE-Y
transport,8147,O
.,8147,O
Northern,8148,O
analysis-documented,8148,O
Cat2,8148,B-GENE-Y
mRNA,8148,O
increased,8148,O
2-fold,8148,O
",",8148,O
whereas,8148,O
Cat3,8148,B-GENE-Y
mRNA,8148,O
levels,8148,O
increased,8148,O
11-fold,8148,O
in,8148,O
Cat1,8148,B-GENE-Y
(,8148,O
-/-,8148,O
),8148,O
relative,8148,O
to,8148,O
Cat1,8148,B-GENE-Y
(,8148,O
+/+,8148,O
),8148,O
cells,8148,O
.,8148,O
The,8149,O
low,8149,O
affinity,8149,O
Cat2a,8149,B-GENE-N
mRNA,8149,O
was,8149,O
not,8149,O
detectably,8149,O
expressed,8149,O
in,8149,O
these,8149,O
cells,8149,O
.,8149,O
Even,8150,O
though,8150,O
Cat3,8150,B-GENE-Y
expression,8150,O
is,8150,O
normally,8150,O
limited,8150,O
to,8150,O
adult,8150,O
brain,8150,O
",",8150,O
there,8150,O
was,8150,O
a,8150,O
large,8150,O
increase,8150,O
in,8150,O
the,8150,O
amount,8150,O
of,8150,O
Cat3,8150,B-GENE-Y
protein,8150,O
present,8150,O
at,8150,O
the,8150,O
plasma,8150,O
membrane,8150,O
of,8150,O
Cat1,8150,B-GENE-Y
(,8150,O
-/-,8150,O
),8150,O
embryonic,8150,O
fibroblast,8150,O
cells,8150,O
.,8150,O
These,8151,O
results,8151,O
suggest,8151,O
that,8151,O
Cat3,8151,B-GENE-Y
compensates,8151,O
for,8151,O
the,8151,O
loss,8151,O
of,8151,O
functional,8151,O
Cat1,8151,B-GENE-Y
in,8151,O
cells,8151,O
derived,8151,O
from,8151,O
Cat1,8151,B-GENE-Y
knockout,8151,O
mice,8151,O
and,8151,O
mediates,8151,O
the,8151,O
majority,8151,O
of,8151,O
high,8151,O
affinity,8151,O
arginine,8151,B-CHEMICAL
transport,8151,O
.,8151,O
Effect,8152,O
of,8152,O
lintitript,8152,B-CHEMICAL
",",8152,O
a,8152,O
new,8152,O
CCK-A,8152,B-GENE-Y
receptor,8152,I-GENE-Y
antagonist,8152,O
",",8152,O
on,8152,O
gastric,8152,O
emptying,8152,O
of,8152,O
a,8152,O
solid-liquid,8152,O
meal,8152,O
in,8152,O
humans,8152,O
.,8152,O
The,8153,O
role,8153,O
of,8153,O
cholecystokinin,8153,B-GENE-Y
(,8153,O
CCK,8153,B-GENE-Y
),8153,O
in,8153,O
the,8153,O
regulation,8153,O
of,8153,O
gastric,8153,O
emptying,8153,O
of,8153,O
physiological,8153,O
meals,8153,O
containing,8153,O
solids,8153,O
and,8153,O
liquids,8153,O
in,8153,O
humans,8153,O
remains,8153,O
controversial,8153,O
.,8153,O
We,8154,O
studied,8154,O
the,8154,O
role,8154,O
of,8154,O
endogenous,8154,O
CCK,8154,B-GENE-Y
in,8154,O
the,8154,O
emptying,8154,O
of,8154,O
a,8154,O
solid/liquid,8154,O
meal,8154,O
administering,8154,O
the,8154,O
new,8154,O
",",8154,O
highly,8154,O
specific,8154,O
and,8154,O
potent,8154,O
CCK-A,8154,B-GENE-Y
receptor,8154,I-GENE-Y
antagonist,8154,O
lintitript,8154,B-CHEMICAL
.,8154,O
Gastric,8155,O
emptying,8155,O
was,8155,O
assessed,8155,O
in,8155,O
nine,8155,O
healthy,8155,O
male,8155,O
volunteers,8155,O
using,8155,O
a,8155,O
randomized,8155,O
",",8155,O
double,8155,O
blind,8155,O
",",8155,O
two-period,8155,O
crossover,8155,O
design,8155,O
with,8155,O
oral,8155,O
lintitript,8155,B-CHEMICAL
(,8155,O
15,8155,O
mg,8155,O
1,8155,O
h,8155,O
prior,8155,O
to,8155,O
meal,8155,O
intake,8155,O
),8155,O
or,8155,O
placebo,8155,O
on,8155,O
two,8155,O
different,8155,O
days,8155,O
.,8155,O
After,8156,O
ingestion,8156,O
of,8156,O
a,8156,O
pancake,8156,O
(,8156,O
570,8156,O
kcal,8156,O
),8156,O
labelled,8156,O
with,8156,O
500,8156,O
microCi,8156,O
of,8156,O
99mTc-sulfur,8156,B-CHEMICAL
colloid,8156,O
and,8156,O
500,8156,O
ml,8156,O
10,8156,O
%,8156,O
dextrose,8156,O
containing,8156,O
80,8156,O
microCi,8156,O
.,8156,O
111In-DTPA,8157,B-CHEMICAL
",",8157,O
subjects,8157,O
were,8157,O
studied,8157,O
in,8157,O
a,8157,O
sitting,8157,O
position,8157,O
",",8157,O
using,8157,O
a,8157,O
dual-headed,8157,O
gamma,8157,O
camera,8157,O
.,8157,O
Plasma,8158,O
CCK,8158,B-GENE-Y
and,8158,O
pancreatic,8158,B-GENE-Y
polypeptide,8158,I-GENE-Y
(,8158,O
PP,8158,B-GENE-Y
),8158,O
were,8158,O
measured,8158,O
by,8158,O
a,8158,O
specific,8158,O
RIA,8158,O
.,8158,O
Lintitript,8159,B-CHEMICAL
distinctly,8159,O
accelerated,8159,O
gastric,8159,O
emptying,8159,O
of,8159,O
solids,8159,O
",",8159,O
while,8159,O
gastric,8159,O
emptying,8159,O
of,8159,O
liquids,8159,O
was,8159,O
not,8159,O
significantly,8159,O
altered,8159,O
.,8159,O
The,8160,O
lag,8160,O
period,8160,O
was,8160,O
shortened,8160,O
by,8160,O
20,8160,O
%,8160,O
(,8160,O
P,8160,O
<,8160,O
0.05,8160,O
),8160,O
",",8160,O
AUC,8160,O
and,8160,O
half,8160,O
emptying,8160,O
time,8160,O
of,8160,O
solid,8160,O
emptying,8160,O
were,8160,O
lowered,8160,O
by,8160,O
12,8160,O
%,8160,O
and,8160,O
13,8160,O
%,8160,O
",",8160,O
respectively,8160,O
(,8160,O
P,8160,O
<,8160,O
0.03,8160,O
),8160,O
.,8160,O
Lintitript,8161,B-CHEMICAL
markedly,8161,O
increased,8161,O
postprandial,8161,O
plasma,8161,O
CCK,8161,B-GENE-Y
release,8161,O
(,8161,O
P,8161,O
<,8161,O
0.001,8161,O
),8161,O
while,8161,O
distinctly,8161,O
reducing,8161,O
postprandial,8161,O
PP,8161,B-GENE-Y
levels,8161,O
(,8161,O
P,8161,O
<,8161,O
0.01,8161,O
),8161,O
as,8161,O
compared,8161,O
to,8161,O
placebo,8161,O
.,8161,O
These,8162,O
data,8162,O
provide,8162,O
further,8162,O
evidence,8162,O
for,8162,O
a,8162,O
significant,8162,O
role,8162,O
of,8162,O
CCK,8162,B-GENE-Y
in,8162,O
the,8162,O
regulation,8162,O
of,8162,O
gastric,8162,O
emptying,8162,O
of,8162,O
solids,8162,O
.,8162,O
The,8163,O
study,8163,O
demonstrates,8163,O
for,8163,O
the,8163,O
first,8163,O
time,8163,O
the,8163,O
marked,8163,O
gastrokinetic,8163,O
properties,8163,O
of,8163,O
the,8163,O
new,8163,O
CCK-A,8163,B-GENE-Y
receptor,8163,I-GENE-Y
antagonist,8163,O
lintitript,8163,B-CHEMICAL
in,8163,O
humans,8163,O
.,8163,O
Beta-adrenoceptor-mediated,8164,B-GENE-N
inhibition,8164,O
of,8164,O
IFN-gamma,8164,B-GENE-Y
",",8164,O
IL-3,8164,B-GENE-Y
",",8164,O
and,8164,O
GM-CSF,8164,B-GENE-Y
mRNA,8164,O
accumulation,8164,O
in,8164,O
activated,8164,O
human,8164,O
T,8164,O
lymphocytes,8164,O
is,8164,O
solely,8164,O
mediated,8164,O
by,8164,O
the,8164,O
beta2-adrenoceptor,8164,B-GENE-Y
subtype,8164,O
.,8164,O
Cytokine,8165,B-GENE-N
gene,8165,O
expression,8165,O
in,8165,O
T,8165,O
lymphocytes,8165,O
is,8165,O
a,8165,O
strictly,8165,O
regulated,8165,O
process,8165,O
",",8165,O
involving,8165,O
both,8165,O
stimulatory,8165,O
and,8165,O
inhibitory,8165,O
signals,8165,O
.,8165,O
beta-Adrenoceptor,8166,B-GENE-N
(,8166,O
betaAR,8166,B-GENE-N
),8166,O
agonists,8166,O
are,8166,O
widely,8166,O
used,8166,O
in,8166,O
the,8166,O
treatment,8166,O
of,8166,O
asthma,8166,O
and,8166,O
are,8166,O
able,8166,O
to,8166,O
induce,8166,O
an,8166,O
inhibitory,8166,O
signal,8166,O
on,8166,O
immunological,8166,O
responses,8166,O
after,8166,O
binding,8166,O
to,8166,O
their,8166,O
specific,8166,O
receptors,8166,O
.,8166,O
In,8167,O
this,8167,O
study,8167,O
",",8167,O
the,8167,O
characterization,8167,O
of,8167,O
betaAR,8167,B-GENE-N
subtype,8167,O
(,8167,O
s,8167,O
),8167,O
(,8167,O
beta1,8167,O
",",8167,O
beta2,8167,O
",",8167,O
and,8167,O
beta3,8167,O
),8167,O
involved,8167,O
in,8167,O
the,8167,O
regulation,8167,O
of,8167,O
interleukin,8167,B-GENE-Y
(,8167,I-GENE-Y
IL,8167,I-GENE-Y
),8167,I-GENE-Y
-3,8167,I-GENE-Y
",",8167,O
IL-4,8167,B-GENE-Y
",",8167,O
granulocyte-macrophage,8167,B-GENE-Y
colony-stimulating,8167,I-GENE-Y
factor,8167,I-GENE-Y
(,8167,O
GM-CSF,8167,B-GENE-Y
),8167,O
",",8167,O
and,8167,O
interferon-gamma,8167,B-GENE-Y
(,8167,O
IFN-gamma,8167,B-GENE-Y
),8167,O
mRNA,8167,O
accumulation,8167,O
was,8167,O
studied,8167,O
by,8167,O
using,8167,O
various,8167,O
betaAR,8167,B-GENE-N
agonists,8167,O
and,8167,O
antagonists,8167,O
.,8167,O
Concanavalin,8168,B-GENE-N
A,8168,I-GENE-N
(,8168,O
Con,8168,B-GENE-N
A,8168,I-GENE-N
),8168,O
-induced,8168,O
IFN-gamma,8168,B-GENE-Y
",",8168,O
GM-CSF,8168,B-GENE-Y
",",8168,O
and,8168,O
IL-3,8168,B-GENE-Y
mRNAs,8168,O
are,8168,O
dose-dependently,8168,O
inhibited,8168,O
by,8168,O
the,8168,O
nonselective,8168,O
betaAR,8168,B-GENE-N
agonist,8168,O
isoproterenol,8168,B-CHEMICAL
and,8168,O
by,8168,O
the,8168,O
selective,8168,O
beta2AR,8168,B-GENE-Y
agonist,8168,O
fenoterol,8168,B-CHEMICAL
.,8168,O
IL-4,8169,B-GENE-Y
mRNA,8169,O
accumulation,8169,O
was,8169,O
not,8169,O
susceptible,8169,O
to,8169,O
betaAR,8169,B-GENE-N
stimulation,8169,O
.,8169,O
The,8170,O
observed,8170,O
inhibition,8170,O
on,8170,O
IFN-gamma,8170,B-GENE-Y
",",8170,O
GM-CSF,8170,B-GENE-Y
",",8170,O
and,8170,O
IL-3,8170,B-GENE-Y
mRNA,8170,O
was,8170,O
blocked,8170,O
by,8170,O
the,8170,O
selective,8170,O
beta2AR,8170,B-GENE-Y
antagonist,8170,O
ICI,8170,B-CHEMICAL
"118,551",8170,I-CHEMICAL
(,8170,O
10,8170,O
(,8170,O
-6,8170,O
),8170,O
M,8170,O
),8170,O
and,8170,O
by,8170,O
timolol,8170,B-CHEMICAL
(,8170,O
10,8170,O
(,8170,O
-6,8170,O
),8170,O
M,8170,O
),8170,O
",",8170,O
a,8170,O
nonselective,8170,O
antagonist,8170,O
.,8170,O
The,8171,O
selective,8171,O
beta1AR,8171,B-GENE-Y
antagonist,8171,O
atenolol,8171,B-CHEMICAL
(,8171,O
0.3,8171,O
x,8171,O
10,8171,O
(,8171,O
-6,8171,O
),8171,O
M,8171,O
),8171,O
did,8171,O
not,8171,O
have,8171,O
any,8171,O
effect,8171,O
.,8171,O
Secretion,8172,O
of,8172,O
GM-CSF,8172,B-GENE-Y
protein,8172,O
in,8172,O
the,8172,O
presence,8172,O
of,8172,O
increasing,8172,O
concentrations,8172,O
of,8172,O
isoproterenol,8172,B-CHEMICAL
followed,8172,O
a,8172,O
similar,8172,O
pattern,8172,O
as,8172,O
observed,8172,O
for,8172,O
GM-CSF,8172,B-GENE-Y
mRNA,8172,O
.,8172,O
In,8173,O
addition,8173,O
",",8173,O
the,8173,O
betaAR-mediated,8173,B-GENE-N
inhibition,8173,O
of,8173,O
IFN-gamma,8173,B-GENE-Y
",",8173,O
GM-CSF,8173,B-GENE-Y
",",8173,O
and,8173,O
IL-3,8173,B-GENE-Y
mRNA,8173,O
accumulation,8173,O
and,8173,O
GM-CSF,8173,B-GENE-Y
protein,8173,O
secretion,8173,O
were,8173,O
related,8173,O
to,8173,O
the,8173,O
accumulation,8173,O
of,8173,O
intracellular,8173,O
cyclic,8173,B-CHEMICAL
adenosine,8173,I-CHEMICAL
monophosphate,8173,I-CHEMICAL
(,8173,O
cAMP,8173,B-CHEMICAL
),8173,O
levels,8173,O
.,8173,O
Although,8174,O
beta3AR,8174,B-GENE-Y
mRNA,8174,O
was,8174,O
detectable,8174,O
in,8174,O
Con,8174,B-GENE-N
A-activated,8174,O
T,8174,O
lymphocytes,8174,O
",",8174,O
we,8174,O
could,8174,O
not,8174,O
demonstrate,8174,O
a,8174,O
functional,8174,O
activity,8174,O
in,8174,O
the,8174,O
regulation,8174,O
of,8174,O
cytokine,8174,B-GENE-N
expression,8174,O
:,8174,O
the,8174,O
beta3AR,8174,B-GENE-Y
agonist,8174,O
BRL,8174,B-CHEMICAL
37344,8174,I-CHEMICAL
had,8174,O
no,8174,O
effect,8174,O
on,8174,O
the,8174,O
accumulation,8174,O
of,8174,O
the,8174,O
studied,8174,O
cytokine,8174,B-GENE-N
mRNAs,8174,O
",",8174,O
and,8174,O
did,8174,O
not,8174,O
significantly,8174,O
affect,8174,O
cellular,8174,O
cAMP,8174,B-CHEMICAL
levels,8174,O
.,8174,O
These,8175,O
data,8175,O
demonstrate,8175,O
that,8175,O
beta-agonist-induced,8175,O
inhibition,8175,O
of,8175,O
IFN-gamma,8175,B-GENE-Y
",",8175,O
GM-CSF,8175,B-GENE-Y
",",8175,O
and,8175,O
IL-3,8175,B-GENE-Y
mRNA,8175,O
accumulation,8175,O
is,8175,O
solely,8175,O
mediated,8175,O
by,8175,O
beta2-adrenoceptors,8175,B-GENE-Y
.,8175,O
Oxytocin,8176,B-GENE-Y
receptor,8176,I-GENE-Y
binding,8176,O
and,8176,O
uterotonic,8176,O
activity,8176,O
of,8176,O
carbetocin,8176,B-CHEMICAL
and,8176,O
its,8176,O
metabolites,8176,O
following,8176,O
enzymatic,8176,O
degradation,8176,O
.,8176,O
Metabolites,8177,O
of,8177,O
the,8177,O
analogue,8177,O
1-deamino-1-carba-2-tyrosine,8177,B-CHEMICAL
(,8177,I-CHEMICAL
O-methyl,8177,I-CHEMICAL
),8177,I-CHEMICAL
-oxytocin,8177,I-CHEMICAL
(,8177,O
carbetocin,8177,B-CHEMICAL
),8177,O
following,8177,O
incubation,8177,O
with,8177,O
a,8177,O
rat,8177,O
kidney,8177,O
homogenate,8177,O
were,8177,O
isolated,8177,O
and,8177,O
their,8177,O
pharmacodynamic,8177,O
properties,8177,O
investigated,8177,O
.,8177,O
Apart,8178,O
from,8178,O
the,8178,O
parent,8178,O
compound,8178,O
two,8178,O
metabolites,8178,O
were,8178,O
identified,8178,O
namely,8178,O
desGlyNH2-carbetocin,8178,B-CHEMICAL
(,8178,O
carbetocin,8178,B-CHEMICAL
metabolite,8178,O
I,8178,O
),8178,O
and,8178,O
desLeuGlyNH2-carbetocin,8178,B-CHEMICAL
(,8178,O
carbetocin,8178,B-CHEMICAL
metabolite,8178,O
II,8178,O
),8178,O
.,8178,O
Both,8179,O
carbetocin,8179,B-CHEMICAL
",",8179,O
carbetocin,8179,B-CHEMICAL
metabolite,8179,O
I,8179,O
and,8179,O
carbetocin,8179,B-CHEMICAL
metabolite,8179,O
II,8179,O
displayed,8179,O
binding,8179,O
affinities,8179,O
to,8179,O
the,8179,O
myometrial,8179,O
oxytocin,8179,B-GENE-Y
receptor,8179,I-GENE-Y
of,8179,O
a,8179,O
similar,8179,O
magnitude,8179,O
as,8179,O
oxytocin,8179,B-GENE-Y
.,8179,O
Carbetocin,8180,B-CHEMICAL
was,8180,O
found,8180,O
to,8180,O
have,8180,O
agonistic,8180,O
properties,8180,O
on,8180,O
isolated,8180,O
myometrial,8180,O
strips,8180,O
and,8180,O
it,8180,O
was,8180,O
found,8180,O
to,8180,O
exert,8180,O
this,8180,O
effect,8180,O
through,8180,O
generation,8180,O
of,8180,O
inositol,8180,B-CHEMICAL
phosphates,8180,I-CHEMICAL
",",8180,O
as,8180,O
is,8180,O
the,8180,O
case,8180,O
for,8180,O
oxytocin,8180,B-GENE-Y
.,8180,O
However,8181,O
",",8181,O
maximal,8181,O
contractile,8181,O
effect,8181,O
of,8181,O
carbetocin,8181,B-CHEMICAL
was,8181,O
approximately,8181,O
50,8181,O
%,8181,O
lower,8181,O
than,8181,O
that,8181,O
of,8181,O
oxytocin,8181,B-GENE-Y
(,8181,O
2.70,8181,O
+/-,8181,O
0.12,8181,O
g,8181,O
compared,8181,O
to,8181,O
5.22,8181,O
+/-,8181,O
0.26,8181,O
g,8181,O
),8181,O
and,8181,O
EC50,8181,O
was,8181,O
approximately,8181,O
ten,8181,O
times,8181,O
higher,8181,O
(,8181,O
48.0,8181,O
+/-,8181,O
8.20,8181,O
nM,8181,O
compared,8181,O
to,8181,O
5.62,8181,O
+/-,8181,O
1.22,8181,O
nM,8181,O
),8181,O
.,8181,O
Neither,8182,O
carbetocin,8182,B-CHEMICAL
metabolite,8182,O
I,8182,O
nor,8182,O
carbetocin,8182,B-CHEMICAL
metabolite,8182,O
II,8182,O
were,8182,O
able,8182,O
to,8182,O
contract,8182,O
isolated,8182,O
myometrial,8182,O
tissue,8182,O
.,8182,O
All,8183,O
three,8183,O
compounds,8183,O
displayed,8183,O
antagonistic,8183,O
properties,8183,O
against,8183,O
oxytocin,8183,B-GENE-Y
in,8183,O
vitro,8183,O
",",8183,O
with,8183,O
carbetocin,8183,B-CHEMICAL
being,8183,O
the,8183,O
strongest,8183,O
inhibitor,8183,O
(,8183,O
pA2,8183,O
=,8183,O
8.21,8183,O
),8183,O
and,8183,O
carbetocin,8183,B-CHEMICAL
metabolite,8183,O
II,8183,O
(,8183,O
pA2,8183,O
=,8183,O
8.01,8183,O
),8183,O
being,8183,O
stronger,8183,O
than,8183,O
carbetocin,8183,B-CHEMICAL
metabolite,8183,O
I,8183,O
(,8183,O
pA2,8183,O
=,8183,O
7.81,8183,O
),8183,O
.,8183,O
These,8184,O
results,8184,O
indicate,8184,O
that,8184,O
carbetocin,8184,B-CHEMICAL
is,8184,O
a,8184,O
partial,8184,O
agonist/antagonist,8184,O
to,8184,O
the,8184,O
oxytocin,8184,B-CHEMICAL
receptor,8184,I-GENE-Y
while,8184,O
the,8184,O
two,8184,O
metabolites,8184,O
carbetocin,8184,B-CHEMICAL
metabolite,8184,O
I,8184,O
and,8184,O
carbetocin,8184,B-CHEMICAL
metabolite,8184,O
II,8184,O
are,8184,O
pure,8184,O
antagonists,8184,O
.,8184,O
All,8185,O
three,8185,O
analogues,8185,O
bound,8185,O
to,8185,O
the,8185,O
myometrial,8185,O
vasopressin,8185,B-GENE-N
V1,8185,I-GENE-N
receptor,8185,I-GENE-N
",",8185,O
albeit,8185,O
with,8185,O
much,8185,O
lower,8185,O
affinities,8185,O
than,8185,O
to,8185,O
the,8185,O
oxytocin,8185,B-GENE-Y
receptor,8185,I-GENE-Y
.,8185,O
Carbetocin,8186,B-CHEMICAL
metabolite,8186,O
II,8186,O
showed,8186,O
the,8186,O
weakest,8186,O
binding,8186,O
affinity,8186,O
of,8186,O
33.7,8186,O
+/-,8186,O
7.34,8186,O
nM,8186,O
compared,8186,O
to,8186,O
7.24,8186,O
+/-,8186,O
0.29,8186,O
nM,8186,O
for,8186,O
carbetocin,8186,B-CHEMICAL
and,8186,O
9.89,8186,O
+,8186,O
2.80,8186,O
nM,8186,O
for,8186,O
carbetocin,8186,B-CHEMICAL
metabolite,8186,O
I,8186,O
.,8186,O
Only,8187,O
carbetocin,8187,B-CHEMICAL
bound,8187,O
to,8187,O
the,8187,O
renal,8187,O
vasopressin,8187,B-GENE-Y
V2,8187,I-GENE-Y
receptor,8187,I-GENE-Y
though,8187,O
the,8187,O
binding,8187,O
affinity,8187,O
was,8187,O
very,8187,O
low,8187,O
(,8187,O
61.3,8187,O
+/-,8187,O
14.6,8187,O
nM,8187,O
),8187,O
.,8187,O
Crystallographic,8188,O
analysis,8188,O
of,8188,O
the,8188,O
human,8188,B-GENE-N
phenylalanine,8188,I-GENE-N
hydroxylase,8188,I-GENE-N
catalytic,8188,I-GENE-N
domain,8188,I-GENE-N
with,8188,O
bound,8188,O
catechol,8188,B-CHEMICAL
inhibitors,8188,O
at,8188,O
2.0,8188,O
A,8188,O
resolution,8188,O
.,8188,O
The,8189,O
aromatic,8189,B-GENE-N
amino,8189,I-GENE-N
acid,8189,I-GENE-N
hydroxylases,8189,I-GENE-N
represent,8189,O
a,8189,O
superfamily,8189,O
of,8189,O
structurally,8189,O
and,8189,O
functionally,8189,O
closely,8189,O
related,8189,O
enzymes,8189,O
",",8189,O
one,8189,O
of,8189,O
those,8189,O
functions,8189,O
being,8189,O
reversible,8189,O
inhibition,8189,O
by,8189,O
catechol,8189,B-CHEMICAL
derivatives,8189,O
.,8189,O
Here,8190,O
we,8190,O
present,8190,O
the,8190,O
crystal,8190,O
structure,8190,O
of,8190,O
the,8190,O
dimeric,8190,O
catalytic,8190,O
domain,8190,O
(,8190,O
residues,8190,O
117-424,8190,O
),8190,O
of,8190,O
human,8190,B-GENE-Y
phenylalanine,8190,B-CHEMICAL
hydroxylase,8190,I-GENE-Y
(,8190,O
hPheOH,8190,B-GENE-Y
),8190,O
",",8190,O
cocrystallized,8190,O
with,8190,O
various,8190,O
potent,8190,O
and,8190,O
well-known,8190,O
catechol,8190,B-CHEMICAL
inhibitors,8190,O
and,8190,O
refined,8190,O
at,8190,O
a,8190,O
resolution,8190,O
of,8190,O
2.0,8190,O
A,8190,O
.,8190,O
The,8191,O
catechols,8191,B-CHEMICAL
bind,8191,O
by,8191,O
bidentate,8191,O
coordination,8191,O
to,8191,O
each,8191,O
iron,8191,B-CHEMICAL
in,8191,O
both,8191,O
subunits,8191,O
of,8191,O
the,8191,O
dimer,8191,O
through,8191,O
the,8191,O
catechol,8191,B-CHEMICAL
hydroxyl,8191,I-CHEMICAL
groups,8191,O
",",8191,O
forming,8191,O
a,8191,O
blue-green,8191,O
colored,8191,O
ligand-to-metal,8191,O
charge-transfer,8191,O
complex,8191,O
.,8191,O
In,8192,O
addition,8192,O
",",8192,O
Glu330,8192,O
and,8192,O
Tyr325,8192,O
are,8192,O
identified,8192,O
as,8192,O
determinant,8192,O
residues,8192,O
in,8192,O
the,8192,O
recognition,8192,O
of,8192,O
the,8192,O
inhibitors,8192,O
.,8192,O
In,8193,O
particular,8193,O
",",8193,O
the,8193,O
interaction,8193,O
with,8193,O
Glu330,8193,O
conforms,8193,O
to,8193,O
the,8193,O
structural,8193,O
explanation,8193,O
for,8193,O
the,8193,O
pH,8193,O
dependence,8193,O
of,8193,O
catecholamine,8193,B-CHEMICAL
binding,8193,O
to,8193,O
PheOH,8193,B-CHEMICAL
",",8193,O
with,8193,O
a,8193,O
pKa,8193,O
value,8193,O
of,8193,O
5.1,8193,O
(,8193,O
20,8193,O
degreesC,8193,O
),8193,O
.,8193,O
The,8194,O
overall,8194,O
structure,8194,O
of,8194,O
the,8194,O
catechol-bound,8194,B-CHEMICAL
enzyme,8194,O
is,8194,O
very,8194,O
similar,8194,O
to,8194,O
that,8194,O
of,8194,O
the,8194,O
uncomplexed,8194,O
enzyme,8194,O
(,8194,O
rms,8194,O
difference,8194,O
of,8194,O
0.2,8194,O
A,8194,O
for,8194,O
the,8194,O
Calpha,8194,O
atoms,8194,O
),8194,O
.,8194,O
Most,8195,O
striking,8195,O
is,8195,O
the,8195,O
replacement,8195,O
of,8195,O
two,8195,O
iron-bound,8195,O
water,8195,O
molecules,8195,O
with,8195,O
catechol,8195,B-CHEMICAL
hydroxyl,8195,I-CHEMICAL
groups,8195,O
.,8195,O
This,8196,O
change,8196,O
is,8196,O
consistent,8196,O
with,8196,O
a,8196,O
change,8196,O
in,8196,O
the,8196,O
ligand,8196,O
field,8196,O
symmetry,8196,O
of,8196,O
the,8196,O
high-spin,8196,O
(,8196,O
S,8196,O
=,8196,O
5/2,8196,O
),8196,O
Fe,8196,O
(,8196,O
III,8196,O
),8196,O
from,8196,O
a,8196,O
rhombic,8196,O
to,8196,O
a,8196,O
nearly,8196,O
axial,8196,O
ligand,8196,O
field,8196,O
symmetry,8196,O
as,8196,O
seen,8196,O
upon,8196,O
noradrenaline,8196,B-CHEMICAL
binding,8196,O
using,8196,O
EPR,8196,O
spectroscopy,8196,O
[,8196,O
Martinez,8196,O
",",8196,O
A.,8196,O
",",8196,O
Andersson,8196,O
",",8196,O
K.,8196,O
K.,8196,O
",",8196,O
Haavik,8196,O
",",8196,O
J.,8196,O
",",8196,O
and,8196,O
Flatmark,8196,O
",",8196,O
T.,8196,O
(,8196,O
1991,8196,O
),8196,O
Eur,8196,O
.,8196,O
J.,8197,O
Biochem,8197,O
.,8197,O
198,8198,O
",",8198,O
675-682,8198,O
],8198,O
.,8198,O
Crystallographic,8199,O
comparison,8199,O
with,8199,O
the,8199,O
structurally,8199,O
related,8199,O
rat,8199,B-GENE-Y
tyrosine,8199,B-CHEMICAL
hydroxylase,8199,I-GENE-Y
binary,8199,O
complex,8199,O
with,8199,O
the,8199,O
oxidized,8199,O
cofactor,8199,O
"7,8-dihydrobiopterin",8199,B-CHEMICAL
revealed,8199,O
overlapping,8199,O
binding,8199,O
sites,8199,O
for,8199,O
the,8199,O
catechols,8199,B-CHEMICAL
and,8199,O
the,8199,O
cofactor,8199,O
",",8199,O
compatible,8199,O
with,8199,O
a,8199,O
competitive,8199,O
type,8199,O
of,8199,O
inhibition,8199,O
of,8199,O
the,8199,O
catechols,8199,B-CHEMICAL
versus,8199,O
BH4,8199,O
.,8199,O
The,8200,O
comparison,8200,O
demonstrates,8200,O
some,8200,O
structural,8200,O
differences,8200,O
at,8200,O
the,8200,O
active,8200,O
site,8200,O
as,8200,O
the,8200,O
potential,8200,O
basis,8200,O
for,8200,O
the,8200,O
different,8200,O
substrate,8200,O
specificity,8200,O
of,8200,O
the,8200,O
two,8200,O
enzymes,8200,O
.,8200,O
Various,8201,O
glucocorticoids,8201,O
differ,8201,O
in,8201,O
their,8201,O
ability,8201,O
to,8201,O
induce,8201,O
gene,8201,O
expression,8201,O
",",8201,O
apoptosis,8201,O
and,8201,O
to,8201,O
repress,8201,O
NF-kappaB-dependent,8201,B-GENE-N
transcription,8201,O
.,8201,O
Glucocorticoids,8202,O
(,8202,O
GCs,8202,O
),8202,O
influence,8202,O
a,8202,O
great,8202,O
variety,8202,O
of,8202,O
cellular,8202,O
functions,8202,O
by,8202,O
at,8202,O
least,8202,O
three,8202,O
important,8202,O
modes,8202,O
of,8202,O
action,8202,O
:,8202,O
the,8202,O
activation,8202,O
(,8202,O
or,8202,O
repression,8202,O
),8202,O
of,8202,O
genes,8202,O
controlled,8202,O
by,8202,O
binding,8202,O
sites,8202,O
for,8202,O
the,8202,O
glucocorticoid,8202,B-GENE-Y
receptor,8202,I-GENE-Y
(,8202,O
GR,8202,B-GENE-Y
),8202,O
",",8202,O
the,8202,O
induction,8202,O
of,8202,O
apoptosis,8202,O
in,8202,O
lymphocytes,8202,O
and,8202,O
the,8202,O
recently,8202,O
discovered,8202,O
cross-talk,8202,O
to,8202,O
other,8202,O
transcription,8202,O
factors,8202,O
such,8202,O
as,8202,O
NF-kappaB,8202,B-GENE-N
.,8202,O
In,8203,O
this,8203,O
study,8203,O
we,8203,O
systematically,8203,O
compared,8203,O
various,8203,O
natural,8203,O
and,8203,O
synthetic,8203,O
steroid,8203,B-CHEMICAL
hormones,8203,O
frequently,8203,O
used,8203,O
as,8203,O
therapeutic,8203,O
agents,8203,O
on,8203,O
their,8203,O
ability,8203,O
to,8203,O
mediate,8203,O
these,8203,O
three,8203,O
modes,8203,O
of,8203,O
action,8203,O
.,8203,O
Betamethasone,8204,B-CHEMICAL
",",8204,O
triamcinolone,8204,B-CHEMICAL
",",8204,O
dexamethasone,8204,B-CHEMICAL
and,8204,O
clobetasol,8204,B-CHEMICAL
turned,8204,O
out,8204,O
to,8204,O
be,8204,O
the,8204,O
best,8204,O
inducers,8204,O
of,8204,O
gene,8204,O
expression,8204,O
and,8204,O
apoptosis,8204,O
.,8204,O
All,8205,O
GCs,8205,O
including,8205,O
the,8205,O
antagonistic,8205,O
compound,8205,O
RU486,8205,B-CHEMICAL
efficiently,8205,O
reduced,8205,O
NF-kappaB-mediated,8205,B-GENE-N
transactivation,8205,O
to,8205,O
comparable,8205,O
extents,8205,O
",",8205,O
suggesting,8205,O
that,8205,O
ligand-induced,8205,O
nuclear,8205,O
localization,8205,O
of,8205,O
the,8205,O
GR,8205,B-GENE-Y
is,8205,O
sufficient,8205,O
for,8205,O
transrepression,8205,O
.,8205,O
Glucocorticoid,8206,O
treatment,8206,O
of,8206,O
cells,8206,O
did,8206,O
not,8206,O
result,8206,O
in,8206,O
elevated,8206,O
IkappaB-alpha,8206,B-GENE-Y
expression,8206,O
",",8206,O
but,8206,O
impaired,8206,O
the,8206,O
tumor,8206,B-GENE-Y
necrosis,8206,I-GENE-Y
factor,8206,I-GENE-Y
(,8206,I-GENE-Y
TNF,8206,I-GENE-Y
),8206,I-GENE-Y
-alpha-induced,8206,O
degradation,8206,O
of,8206,O
IkappaB-alpha,8206,B-GENE-Y
without,8206,O
affecting,8206,O
DNA,8206,O
binding,8206,O
of,8206,O
NF-kappaB,8206,B-GENE-N
.,8206,O
The,8207,O
structural,8207,O
requirements,8207,O
for,8207,O
the,8207,O
various,8207,O
functions,8207,O
of,8207,O
glucocorticoids,8207,O
are,8207,O
discussed,8207,O
.,8207,O
Cooperative,8208,O
binding,8208,O
of,8208,O
ATP,8208,B-CHEMICAL
and,8208,O
MgADP,8208,B-CHEMICAL
in,8208,O
the,8208,O
sulfonylurea,8208,B-GENE-N
receptor,8208,I-GENE-N
is,8208,O
modulated,8208,O
by,8208,O
glibenclamide,8208,B-CHEMICAL
.,8208,O
The,8209,O
ATP-sensitive,8209,B-GENE-N
potassium,8209,I-GENE-N
(,8209,I-GENE-N
KATP,8209,I-GENE-N
),8209,I-GENE-N
channels,8209,I-GENE-N
in,8209,O
pancreatic,8209,O
beta,8209,O
cells,8209,O
are,8209,O
critical,8209,O
in,8209,O
the,8209,O
regulation,8209,O
of,8209,O
glucose-induced,8209,B-CHEMICAL
insulin,8209,B-GENE-Y
secretion,8209,O
.,8209,O
Although,8210,O
electrophysiological,8210,O
studies,8210,O
provide,8210,O
clues,8210,O
to,8210,O
the,8210,O
complex,8210,O
control,8210,O
of,8210,O
KATP,8210,B-GENE-N
channels,8210,I-GENE-N
by,8210,O
ATP,8210,B-CHEMICAL
",",8210,O
MgADP,8210,B-CHEMICAL
",",8210,O
and,8210,O
pharmacological,8210,O
agents,8210,O
",",8210,O
the,8210,O
molecular,8210,O
mechanism,8210,O
of,8210,O
KATP-channel,8210,B-GENE-N
regulation,8210,O
remains,8210,O
unclear,8210,O
.,8210,O
The,8211,O
KATP,8211,B-GENE-N
channel,8211,I-GENE-N
is,8211,O
a,8211,O
heterooligomeric,8211,O
complex,8211,O
of,8211,O
SUR1,8211,B-GENE-Y
subunits,8211,O
of,8211,O
the,8211,O
ATP-binding-cassette,8211,B-CHEMICAL
superfamily,8211,O
with,8211,O
two,8211,O
nucleotide-binding,8211,B-GENE-N
folds,8211,I-GENE-N
(,8211,O
NBF1,8211,B-GENE-N
and,8211,O
NBF2,8211,B-GENE-N
),8211,O
and,8211,O
the,8211,O
pore-forming,8211,O
Kir6.2,8211,B-GENE-Y
subunits,8211,O
.,8211,O
Here,8212,O
",",8212,O
we,8212,O
report,8212,O
that,8212,O
MgATP,8212,B-CHEMICAL
and,8212,O
MgADP,8212,B-CHEMICAL
",",8212,O
but,8212,O
not,8212,O
the,8212,O
Mg,8212,B-CHEMICAL
salt,8212,O
of,8212,O
gamma-thio-ATP,8212,B-CHEMICAL
",",8212,O
stabilize,8212,O
the,8212,O
binding,8212,O
of,8212,O
prebound,8212,O
8-azido-,8212,B-CHEMICAL
[,8212,I-CHEMICAL
alpha-32P,8212,I-CHEMICAL
],8212,I-CHEMICAL
ATP,8212,I-CHEMICAL
to,8212,O
SUR1,8212,B-GENE-Y
.,8212,O
Mutation,8213,O
in,8213,O
the,8213,O
Walker,8213,B-GENE-N
A,8213,I-GENE-N
and,8213,I-GENE-N
B,8213,I-GENE-N
motifs,8213,I-GENE-N
of,8213,O
NBF2,8213,B-GENE-N
of,8213,O
SUR1,8213,B-GENE-Y
abolished,8213,O
this,8213,O
stabilizing,8213,O
effect,8213,O
of,8213,O
MgADP,8213,B-CHEMICAL
.,8213,O
These,8214,O
results,8214,O
suggest,8214,O
that,8214,O
SUR1,8214,B-GENE-Y
binds,8214,O
8-azido-ATP,8214,B-CHEMICAL
strongly,8214,O
at,8214,O
NBF1,8214,B-GENE-N
and,8214,O
that,8214,O
MgADP,8214,B-CHEMICAL
",",8214,O
either,8214,O
by,8214,O
direct,8214,O
binding,8214,O
to,8214,O
NBF2,8214,B-GENE-N
or,8214,O
by,8214,O
hydrolysis,8214,O
of,8214,O
bound,8214,O
MgATP,8214,B-CHEMICAL
at,8214,O
NBF2,8214,B-GENE-N
",",8214,O
stabilizes,8214,O
prebound,8214,O
8-azido-ATP,8214,B-CHEMICAL
binding,8214,O
at,8214,O
NBF1,8214,B-GENE-N
.,8214,O
The,8215,O
sulfonylurea,8215,B-CHEMICAL
glibenclamide,8215,I-CHEMICAL
caused,8215,O
release,8215,O
of,8215,O
prebound,8215,O
8-azido-,8215,B-CHEMICAL
[,8215,I-CHEMICAL
alpha-32P,8215,I-CHEMICAL
],8215,I-CHEMICAL
ATP,8215,I-CHEMICAL
from,8215,O
SUR1,8215,B-GENE-Y
in,8215,O
the,8215,O
presence,8215,O
of,8215,O
MgADP,8215,B-CHEMICAL
or,8215,O
MgATP,8215,B-CHEMICAL
in,8215,O
a,8215,O
concentration-dependent,8215,O
manner,8215,O
.,8215,O
This,8216,O
direct,8216,O
biochemical,8216,O
evidence,8216,O
of,8216,O
cooperative,8216,O
interaction,8216,O
in,8216,O
nucleotide,8216,B-CHEMICAL
binding,8216,O
of,8216,O
the,8216,O
two,8216,O
NBFs,8216,B-GENE-N
of,8216,O
SUR1,8216,B-GENE-Y
suggests,8216,O
that,8216,O
glibenclamide,8216,B-CHEMICAL
both,8216,O
blocks,8216,O
this,8216,O
cooperative,8216,O
binding,8216,O
of,8216,O
ATP,8216,B-CHEMICAL
and,8216,O
MgADP,8216,B-CHEMICAL
and,8216,O
",",8216,O
in,8216,O
cooperation,8216,O
with,8216,O
the,8216,O
MgADP,8216,B-CHEMICAL
bound,8216,O
at,8216,O
NBF2,8216,B-GENE-N
",",8216,O
causes,8216,O
ATP,8216,B-CHEMICAL
to,8216,O
be,8216,O
released,8216,O
from,8216,O
NBF1,8216,B-GENE-N
.,8216,O
